| HY-100001 | SKF-96365 (hydrochloride) | 130495-35-1 | Reference compound |
| HY-100002 | ML162 | 1035072-16-2 | Reference compound |
| HY-100003 | ML-210 | 1360705-96-9 | Reference compound |
| HY-100004 | Fumarate hydratase-IN-1 | 1644060-37-6 | Reference compound |
| HY-100005A | Fumarate hydratase-IN-2 (sodium salt) | 2070009-45-7 | Reference compound |
| HY-100006 | MRT68921 | 1190379-70-4 | Reference compound |
| HY-100006A | MRT68921 (dihydrochloride) | 2080306-21-2 | Reference compound |
| HY-100006B | MRT68921 (hydrochloride) | 2070014-87-6 | Reference compound |
| HY-100007 | Vonoprazan | 881681-00-1 | Reference compound |
| HY-100007A | Vonoprazan (hydrochloride) | 1957202-44-6 | Reference compound |
| HY-100007R | Vonoprazan (Standard) | 881681-00-1 | Reference Standards |
| HY-100008 | Peretinoin | 81485-25-8 | Reference compound |
| HY-100008R | Peretinoin (Standard) | 81485-25-8 | Reference Standards |
| HY-100009 | Ufenamate | 67330-25-0 | Reference compound |
| HY-10001 | Calcipotriol | 112965-21-6 | Reference compound |
| HY-100011 | SR-3029 | 1454585-06-8 | Reference compound |
| HY-100012 | CBR-5884 | 681159-27-3 | Reference compound |
| HY-100013A1 | (1R,2R)-2-PCCA (hydrochloride) | 1609563-71-4 | Reference compound |
| HY-100013B1 | (1S,2S)-2-PCCA (hydrochloride) | 1609563-70-3 | Reference compound |
| HY-100013C | 2-PCCA (hydrochloride) | | Reference compound |
| HY-100014 | KDM5A-IN-1 | 1905481-36-8 | Reference compound |
| HY-100015 | Mivebresib | 1445993-26-9 | Reference compound |
| HY-100015R | Mivebresib (Standard) | 1445993-26-9 | Reference Standards |
| HY-100016 | AZD0156 | 1821428-35-6 | Reference compound |
| HY-100017 | BAY-876 | 1799753-84-6 | Reference compound |
| HY-100018 | BAY1125976 | 1402608-02-9 | Reference compound |
| HY-100019 | Rogaratinib | 1443530-05-9 | Reference compound |
| HY-10001A | Calcipotriol (monohydrate) | 147657-22-5 | Reference compound |
| HY-10001AR | Calcipotriol (monohydrate) (Standard) | 147657-22-5 | Reference Standards |
| HY-10001R | Calcipotriol (Standard) | 112965-21-6 | Reference Standards |
| HY-10002 | Calcitriol | 32222-06-3 | Natural Products |
| HY-100020 | BAY-1436032 | 1803274-65-8 | Reference compound |
| HY-100022 | Tomivosertib | 1849590-01-7 | Reference compound |
| HY-100022A | Tomivosertib (hydrochloride) | 1849590-02-8 | Reference compound |
| HY-100023 | LY3177833 | 1627696-51-8 | Reference compound |
| HY-100023A | LY3177833 (monhydrate) | 1627696-53-0 | Reference compound |
| HY-100024 | NTRC 0066-0 | 1817791-73-3 | Reference compound |
| HY-100025 | HLCL-61 | 586395-74-6 | Reference compound |
| HY-100025A | HLCL-61 (hydrochloride) | 1158279-20-9 | Reference compound |
| HY-100026 | PQR620 | 1927857-56-4 | Reference compound |
| HY-100027A | Ro 41-1049 (hydrochloride) | 127917-66-2 | Reference compound |
| HY-100028 | AT-130 | 211364-06-6 | Reference compound |
| HY-100029 | Bay 41-4109 | 298708-81-3 | Reference compound |
| HY-100029A | Bay 41-4109 (racemate) | 298708-79-9 | Reference compound |
| HY-100029AR | Bay 41-4109 (racemate) (Standard) | 298708-79-9 | Reference Standards |
| HY-100029B | Bay 41-4109 (less active enantiomer) | 476617-51-3 | Reference compound |
| HY-10002A | (1S)-Calcitriol | 61476-45-7 | Reference compound |
| HY-10002B | (1R,5Z)-Calcitriol | 32511-63-0 | Reference compound |
| HY-10002R | Calcitriol (Standard) | 32222-06-3 | Reference Standards |
| HY-10002S | Calcitriol-13C3 | | Isotope-Labeled Compounds |
| HY-10002S1 | Calcitriol-d3 | 128723-16-0 | Isotope-Labeled Compounds |
| HY-10003 | Alfacalcidol | 41294-56-8 | Reference compound |
| HY-100032 | PD 117519 | 96392-15-3 | Reference compound |
| HY-100033 | NSC5844 | 140926-75-6 | Reference compound |
| HY-100034 | NSC 663284 | 383907-43-5 | Reference compound |
| HY-100035 | PT-262 | 86811-36-1 | Reference compound |
| HY-100036 | MK-4101 | 935273-79-3 | Reference compound |
| HY-100037 | NT157 | 1384426-12-3 | Reference compound |
| HY-100039 | YYA-021 | 144217-65-2 | Reference compound |
| HY-10003A | 1α-Hydroxy-3-epi-vitamin D3 | 58028-00-5 | Reference compound |
| HY-10003R | Alfacalcidol (Standard) | 41294-56-8 | Reference Standards |
| HY-10003S | Alfacalcidol-d7 | | Isotope-Labeled Compounds |
| HY-10004 | Faropenem daloxate | 141702-36-5 | Reference compound |
| HY-100040 | Ethyl 1H-pyrazole-4-carboxylate | 37622-90-5 | Biochemical Assay Reagents |
| HY-100041 | Bromobimane | 71418-44-5 | Dye Reagents |
| HY-100043S | 2-Ethyl-3,5-dimethylpyrazine-13C2 | | Isotope-Labeled Compounds |
| HY-100044 | SR 4330 | 20028-80-2 | Reference compound |
| HY-100045 | p-Nitrophenyl phosphorylcholine | 21064-69-7 | Reference compound |
| HY-100046 | Nordoxepin (hydrochloride) | 2887-91-4 | Reference compound |
| HY-100046R | Nordoxepin (hydrochloride) (Standard) | 2887-91-4 | Reference Standards |
| HY-100046S1 | Nordoxepin-d4 (hydrochloride) | 2249819-14-3 | Isotope-Labeled Compounds |
| HY-100047 | Nα,Nα-Bis(carboxymethyl)-L-lysine | 113231-05-3 | Peptides |
| HY-100048S | Acetylisoniazid-d4 | 1330169-81-7 | Isotope-Labeled Compounds |
| HY-10004R | Faropenem daloxate (Standard) | 141702-36-5 | Reference Standards |
| HY-10005 | Flavopiridol | 146426-40-6 | Reference compound |
| HY-100050 | 4-Hydroxymidazolam | 59468-85-8 | Reference compound |
| HY-100052 | 6-Hydroxybentazon | 60374-42-7 | Reference compound |
| HY-100052R | 6-Hydroxybentazon (Standard) | 60374-42-7 | Reference Standards |
| HY-100057 | BMY 28674 | 125481-61-0 | Reference compound |
| HY-100057S | BMY 28674-d8 | 1189644-16-3 | Isotope-Labeled Compounds |
| HY-10006 | Flavopiridol (Hydrochloride) | 131740-09-5 | Reference compound |
| HY-100061 | 2-(Dimethylamino)acetaldehyde | 52334-92-6 | Reference compound |
| HY-100061A | 2-(Dimethylamino)acetaldehyde (hydrochloride) | 125969-54-2 | Reference compound |
| HY-100064 | O-Desmethyl gefitinib | 847949-49-9 | Reference compound |
| HY-100064R | O-Desmethyl gefitinib (Standard) | 847949-49-9 | Reference Standards |
| HY-100064S | O-Desmethyl gefitinib-d8 | | Isotope-Labeled Compounds |
| HY-100064S1 | O-Desmethyl gefitinib-d6 | | Isotope-Labeled Compounds |
| HY-100069 | Fluazinam impurity 1 | 169327-87-1 | Reference compound |
| HY-100069R | Fluazinam impurity 1 (Standard) | 169327-87-1 | Reference Standards |
| HY-10007 | NPS-2143 | 284035-33-2 | Reference compound |
| HY-100072 | (2E,4E,6Z)-Methyl deca-2,4,6-trienoate | 51544-64-0 | Reference compound |
| HY-100079 | 9-Propenyladenine | 1446486-33-4 | Reference compound |
| HY-100079A | (Z)-9-Propenyladenine | 1464851-21-5 | Reference compound |
| HY-100079R | 9-Propenyladenine (Standard) | 1446486-33-4 | Reference Standards |
| HY-10008 | SNS-032 | 345627-80-7 | Reference compound |
| HY-100080 | A-887826 | 1266212-81-0 | Reference compound |
| HY-100083 | Dolutegravir intermediate-1 | 1335210-23-5 | Reference compound |
| HY-100084 | Methyl-3β-hydroxycholenate | 20231-57-6 | Reference compound |
| HY-100085 | 21-Desacetyldeflazacort | 13649-57-5 | Reference compound |
| HY-100085R | 21-Desacetyldeflazacort (Standard) | 13649-57-5 | Reference Standards |
| HY-100085S | 21-Desacetyldeflazacort-d5 | | Isotope-Labeled Compounds |
| HY-100087 | Budesonide impurity C | 1040085-99-1 | Reference compound |
| HY-10008R | SNS-032 (Standard) | 345627-80-7 | Reference Standards |
| HY-10009 | Semagacestat | 425386-60-3 | Reference compound |
| HY-100096 | Emtricitabine S-oxide | 152128-77-3 | Reference compound |
| HY-10009R | Semagacestat (Standard) | 425386-60-3 | Reference Standards |
| HY-10010 | Ko 143 | 461054-93-3 | Reference compound |
| HY-10011 | SCH 563705 | 473728-58-4 | Reference compound |
| HY-100110 | KNK437 | 218924-25-5 | Reference compound |
| HY-100111 | GLX351322 | 835598-94-2 | Reference compound |
| HY-100112 | WEHI-345 analog | 1354825-62-9 | Reference compound |
| HY-100113 | Buloxibutid | 477775-14-7 | Reference compound |
| HY-100114 | TA-01 | 1784751-18-3 | Reference compound |
| HY-100115 | TA-02 | 1784751-19-4 | Reference compound |
| HY-100116A | Mitoquinone (mesylate) | 845959-50-4 | Reference compound |
| HY-100118 | BW-A 78U | 101155-02-6 | Reference compound |
| HY-100119 | Enecadin | 259525-01-4 | Reference compound |
| HY-100119A | Enecadin (hydrochloride) | 178429-67-9 | Reference compound |
| HY-10011A | (S)-SCH 563705 | | Reference compound |
| HY-10011B | (Rac)-SCH 563705 | 2701435-64-3 | Reference compound |
| HY-10012 | AZD-5438 | 602306-29-6 | Reference compound |
| HY-100120 | Pparδ agonist 2 | 870884-12-1 | Reference compound |
| HY-100121 | Vibunazole | 80456-55-9 | Reference compound |
| HY-100122 | Bevenopran | 676500-67-7 | Reference compound |
| HY-100124 | Bamaluzole | 87034-87-5 | Reference compound |
| HY-100125 | Timegadine | 71079-19-1 | Reference compound |
| HY-100125A | Timegadine (hydrochloride) | 71080-06-3 | Reference compound |
| HY-100126 | Tubercidin | 69-33-0 | Natural Products |
| HY-100126R | Tubercidin (Standard) | 69-33-0 | Reference Standards |
| HY-100128 | DM1-SMe | 138148-68-2 | ADC Related |
| HY-100129 | JNJ-17203212 | 821768-06-3 | Reference compound |
| HY-10012R | AZD-5438 (Standard) | 602306-29-6 | Reference Standards |
| HY-10013 | Taranabant | 701977-09-5 | Reference compound |
| HY-100130 | N-[(4-Aminophenyl)methyl]adenosine | 95523-13-0 | Reference compound |
| HY-100131 | GSK481 | 1622849-58-4 | Reference compound |
| HY-100132 | CBP/p300-IN-5 | 1889284-33-6 | Reference compound |
| HY-100133A | DOTA-ADIBO (TFA) | | Biochemical Assay Reagents |
| HY-100138 | 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) | 173308-19-5 | ADC Related |
| HY-100139 | Diflumidone | 22736-85-2 | Reference compound |
| HY-10013A | Taranabant (racemate) | 701977-00-6 | Reference compound |
| HY-10013B | Taranabant ((1R,2R)stereoisomer) | 701977-08-4 | Reference compound |
| HY-10014 | R547 | 741713-40-6 | Reference compound |
| HY-100140 | Pipequaline | 77472-98-1 | Reference compound |
| HY-100140A | Pipequaline hydrochloride | 80221-58-5 | Reference compound |
| HY-100140R | Pipequaline (Standard) | 77472-98-1 | Reference Standards |
| HY-100141 | Ancarolol | 75748-50-4 | Reference compound |
| HY-100142 | Clozic | 22494-47-9 | Reference compound |
| HY-100143 | Pentiapine | 81382-51-6 | Reference compound |
| HY-100144 | Pirozadil | 54110-25-7 | Reference compound |
| HY-100144R | Pirozadil (Standard) | 54110-25-7 | Reference Standards |
| HY-100145 | Prifuroline | 70833-07-7 | Reference compound |
| HY-100146 | Pirazolac | 71002-09-0 | Reference compound |
| HY-100148 | ICI 211965 | 129424-08-4 | Reference compound |
| HY-10015 | PAP-1 | 870653-45-5 | Reference compound |
| HY-100150 | Mepixanox | 17854-59-0 | Reference compound |
| HY-100151 | RGH-5526 | 69579-13-1 | Reference compound |
| HY-100152 | Beperidium iodide | 86434-57-3 | Reference compound |
| HY-100153 | 48740 RP | 93363-11-2 | Reference compound |
| HY-100154 | Darenzepine | 84629-61-8 | Reference compound |
| HY-100155 | 4-IBP | 155798-08-6 | Reference compound |
| HY-100159 | Ipenoxazone | 104454-71-9 | Reference compound |
| HY-100159A | Ipenoxazone (hydrochloride) | 118635-68-0 | Reference compound |
| HY-10015R | PAP-1 (Standard) | 870653-45-5 | Reference Standards |
| HY-10016 | E 2012 | 870843-42-8 | Reference compound |
| HY-100160 | RP 54275 | 81364-78-5 | Reference compound |
| HY-100161 | CI-943 | 89239-35-0 | Reference compound |
| HY-100162 | TOK-8801 | 105963-46-0 | Reference compound |
| HY-100164 | SDZ-MKS 492 | 114606-56-3 | Reference compound |
| HY-100166 | AP521 | 151227-08-6 | Reference compound |
| HY-100167 | TAK-778 | 180185-61-9 | Reference compound |
| HY-100168 | BAPTA | 85233-19-8 | Biochemical Assay Reagents |
| HY-100168A | BAPTA (tetrasodium) | 126824-24-6 | Reference compound |
| HY-100168AR | BAPTA (tetrasodium) (Standard) | 126824-24-6 | Reference Standards |
| HY-100168B | BAPTA (tetrapotassium) | 73630-08-7 | Biochemical Assay Reagents |
| HY-100168R | BAPTA (Standard) | 85233-19-8 | Reference Standards |
| HY-10017 | SCH 546738 | 906805-42-3 | Reference compound |
| HY-100170 | 5-HT4 antagonist 1 | 261766-73-8 | Reference compound |
| HY-100171 | PRX933 hydrochloride | 639029-42-8 | Reference compound |
| HY-100171A | PRX933 | 313658-33-2 | Reference compound |
| HY-100172 | Proteasome-IN-1 | 374080-21-4 | Reference compound |
| HY-100173 | DW-1350 | 491577-61-8 | Reference compound |
| HY-100174 | W-2429 | 37795-69-0 | Reference compound |
| HY-100176 | PF-4878691 | 532959-63-0 | Reference compound |
| HY-100176R | PF-4878691 (Standard) | 532959-63-0 | Reference Standards |
| HY-100177 | L-Threonine derivative-1 | 852055-88-0 | Reference compound |
| HY-100178 | CX-157 | 205187-53-7 | Reference compound |
| HY-10017A | (R)-SCH 546738 | 2181148-54-7 | Reference compound |
| HY-10018 | Toll-like receptor modulator | 926927-42-6 | Reference compound |
| HY-100180 | Delpazolid | 1219707-39-7 | Reference compound |
| HY-100180R | Delpazolid (Standard) | 1219707-39-7 | Reference Standards |
| HY-100181 | PF-04991532 | 1215197-37-7 | Reference compound |
| HY-100181B | (R)-PF-04991532 | | Reference compound |
| HY-100182 | BACE1-IN-1 | 1310347-50-2 | Reference compound |
| HY-100183 | GSK2239633A | 1240516-71-5 | Reference compound |
| HY-100184 | DSM265 | 1282041-94-4 | Reference compound |
| HY-100186 | GSK-2881078 | 1539314-06-1 | Reference compound |
| HY-100189 | LS2265 | 72678-30-9 | Reference compound |
| HY-10019 | Varenicline | 249296-44-4 | Reference compound |
| HY-100190 | Amphethinile | 91531-98-5 | Reference compound |
| HY-100191 | BMY-25271 | 78441-82-4 | Reference compound |
| HY-100193 | FK-448 Free base | 85858-76-0 | Reference compound |
| HY-100194 | FKK | 78299-79-3 | Reference compound |
| HY-100195 | SAR-020106 | 1184843-57-9 | Reference compound |
| HY-100196 | Pyrroloquinoline quinone | 72909-34-3 | Natural Products |
| HY-100196A | Pyrroloquinoline quinone (disodium salt) | 122628-50-6 | Natural Products |
| HY-100196AR | Pyrroloquinoline quinone (disodium salt) (Standard) | 122628-50-6 | Reference Standards |
| HY-100196R | Pyrroloquinoline quinone (Standard) | 72909-34-3 | Reference Standards |
| HY-100196S1 | Pyrroloquinoline quinone-13C3 (sodium) | | Isotope-Labeled Compounds |
| HY-100197 | Synaptamide | 162758-94-3 | Reference compound |
| HY-100198 | PI4KIIIbeta-IN-10 | 1881233-39-1 | Reference compound |
| HY-100199 | HUHS015 | 1453097-13-6 | Reference compound |
| HY-10019A | Varenicline (dihydrochloride) | 866823-63-4 | Reference compound |
| HY-10019AR | Varenicline (dihydrochloride) (Standard) | 866823-63-4 | Reference Standards |
| HY-10019AS | Varenicline-d4 (dihydrochloride) | | Isotope-Labeled Compounds |
| HY-10019AS1 | Varenicline-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10019R | Varenicline (Standard) | 249296-44-4 | Reference Standards |
| HY-10019S | Varenicline-d4 | 2183239-01-0 | Isotope-Labeled Compounds |
| HY-10019S1 | Varenicline-15N,13C,d2 | | Isotope-Labeled Compounds |
| HY-10019S2 | Varenicline-13C15N | 2140265-12-7 | Isotope-Labeled Compounds |
| HY-10020 | Varenicline (Hydrochloride) | 230615-23-3 | Reference compound |
| HY-100200 | SMER28 | 307538-42-7 | Reference compound |
| HY-100201 | A-196 | 1982372-88-2 | Reference compound |
| HY-100202 | TPEN | 16858-02-9 | Reference compound |
| HY-100206 | 5α-Androstane-3β,5,6β-triol | 4725-51-3 | Reference compound |
| HY-100207 | CP21R7 | 125314-13-8 | Reference compound |
| HY-100208 | HC-067047 | 883031-03-6 | Reference compound |
| HY-100209 | Sufugolix | 308831-61-0 | Reference compound |
| HY-10020R | Varenicline (Hydrochloride) (Standard) | 230615-23-3 | Reference Standards |
| HY-10020S | Varenicline-15N3 (hydrochloride) | 1244134-80-2 | Isotope-Labeled Compounds |
| HY-10021 | Varenicline (Tartrate) | 375815-87-5 | Reference compound |
| HY-100210 | FN-439 | 124168-73-6 | Peptides |
| HY-100210A | FN-439 (TFA) | | Reference compound |
| HY-100211 | TAPI-2 | 187034-31-7 | Reference compound |
| HY-100211A | (R)-TAPI-2 | 689284-12-6 | Reference compound |
| HY-100212 | JE-2147 | 186538-00-1 | Reference compound |
| HY-100213 | EAI045 | 1942114-09-1 | Reference compound |
| HY-100214 | EAI001 | 892772-75-7 | Reference compound |
| HY-100215 | Biotin Hydrazide | 66640-86-6 | Biochemical Assay Reagents |
| HY-100216 | SPDP | 68181-17-9 | ADC Related |
| HY-100217 | DL-3-Indolylglycine | 6747-15-5 | Reference compound |
| HY-100218A | RSL3 | 1219810-16-8 | Reference compound |
| HY-100218B | (1R,3S)-RSL3 | 1219810-13-5 | Reference compound |
| HY-100218C | (1R,3R)-RSL3 | 1219810-15-7 | Reference compound |
| HY-100219 | CB1151 | 182369-28-4 | Reference compound |
| HY-10021R | Varenicline (Tartrate) (Standard) | 375815-87-5 | Reference Standards |
| HY-100220 | GSK6853 | 1910124-24-1 | Reference compound |
| HY-100221 | AM-2394 | 1442684-77-6 | Reference compound |
| HY-100222 | CZ415 | 1429639-50-8 | Reference compound |
| HY-100223 | Calpeptin | 117591-20-5 | Reference compound |
| HY-100223R | Calpeptin (Standard) | 117591-20-5 | Reference Standards |
| HY-100224 | SANT-1 | 304909-07-7 | Reference compound |
| HY-100224G | SANT-1 (GMP) | 304909-07-7 | GMP Small Molecules |
| HY-100225 | ME0328 | 1445251-22-8 | Reference compound |
| HY-100226 | A-205804 | 251992-66-2 | Reference compound |
| HY-100227 | E 64c | 76684-89-4 | Reference compound |
| HY-100228 | SKF 89976A | 85375-85-5 | Reference compound |
| HY-100228A | SKF89976A (hydrochloride) | 85375-15-1 | Reference compound |
| HY-100229 | Aloxistatin | 88321-09-9 | Reference compound |
| HY-100229R | Aloxistatin (Standard) | 88321-09-9 | Reference Standards |
| HY-100230A | ML133 (hydrochloride) | 1222781-70-5 | Reference compound |
| HY-100231 | Cathepsin inhibitor 1 | 225120-65-0 | Reference compound |
| HY-100233 | IQ-1S (free acid) | 23146-22-7 | Reference compound |
| HY-100233A | IQ-1S | 1421610-21-0 | Reference compound |
| HY-100234 | DREADD agonist 21 | 56296-18-5 | Reference compound |
| HY-100234A | DREADD agonist 21 (dihydrochloride) | 2250025-92-2 | Reference compound |
| HY-100235 | GSK591 | 1616391-87-7 | Reference compound |
| HY-100235A | GSK591 (hydrochloride) | 2320953-89-5 | Reference compound |
| HY-100236 | Madrasin | 374913-63-0 | Reference compound |
| HY-100237 | SZL P1-41 | 222716-34-9 | Reference compound |
| HY-100238 | Antihistamine-1 | 1186430-60-3 | Reference compound |
| HY-100239 | ICI 153110 | 87164-90-7 | Reference compound |
| HY-100240 | Lodelaben | 111149-90-7 | Reference compound |
| HY-100241 | Nafocare B1 | 93135-89-8 | Reference compound |
| HY-100242 | Mivotilate | 130112-42-4 | Reference compound |
| HY-100242R | Mivotilate (Standard) | 130112-42-4 | Reference Standards |
| HY-100243 | (+)-Norcisapride | 202590-69-0 | Reference compound |
| HY-100243A | Norcisapride | 83863-69-8 | Reference compound |
| HY-100244 | NS1652 | 1566-81-0 | Reference compound |
| HY-100245 | OM-189 | 55381-18-5 | Reference compound |
| HY-100246 | CI-1044 | 197894-84-1 | Reference compound |
| HY-100248 | Sarmazenil | 78771-13-8 | Reference compound |
| HY-100249 | XEN723 | 1072803-08-7 | Reference compound |
| HY-10025 | (S)-SW IV-52 (hydrochloride) | 845745-37-1 | Reference compound |
| HY-100250 | Spirofylline | 98204-48-9 | Reference compound |
| HY-100253 | TA-7552 | 104756-72-1 | Reference compound |
| HY-100254 | TAK-024 | 186971-69-7 | Reference compound |
| HY-100255 | Tiodazosin | 66969-81-1 | Reference compound |
| HY-100256 | Trifarotene | 895542-09-3 | Reference compound |
| HY-100256R | Trifarotene (Standard) | 895542-09-3 | Reference Standards |
| HY-100257 | Sodium Channel inhibitor 2 | 653573-60-5 | Reference compound |
| HY-100258 | Y-9738 | 59399-41-6 | Reference compound |
| HY-100260 | beta-L-D4A | 7057-48-9 | Reference compound |
| HY-100261 | CCR5 antagonist 1 | 716354-86-8 | Reference compound |
| HY-100262 | Sulfasymazine | 1984-94-7 | Reference compound |
| HY-100263 | Metofenazate | 388-51-2 | Reference compound |
| HY-100263B | Metofenazate (diethanesulfonate) | 1674-48-2 | Reference compound |
| HY-100264 | Uldazepam | 28546-58-9 | Reference compound |
| HY-100265 | Cinperene | 14796-24-8 | Reference compound |
| HY-100266 | Nitromifene | 10448-84-7 | Reference compound |
| HY-100267 | Chlordantoin | 5588-20-5 | Reference compound |
| HY-100268 | Xenalamine | 1174-11-4 | Reference compound |
| HY-100269 | Chymase-IN-1 | 862090-74-2 | Reference compound |
| HY-100270 | Rho-Kinase-IN-1 | 1035094-83-7 | Reference compound |
| HY-100271 | Org41841 | 301847-37-0 | Reference compound |
| HY-100272 | B220 | 112228-65-6 | Reference compound |
| HY-100273 | AGN 194078 | 321995-62-4 | Reference compound |
| HY-100274 | Adenosine antagonist-1 | 431040-19-6 | Reference compound |
| HY-100275 | MK-3328 | 1201323-97-8 | Reference compound |
| HY-100276 | Naminidil | 220641-11-2 | Reference compound |
| HY-100277 | Mifobate | 76541-72-5 | Reference compound |
| HY-100277R | Mifobate (Standard) | 76541-72-5 | Reference Standards |
| HY-100278 | AKP-001 | 897644-83-6 | Reference compound |
| HY-100279 | RMI 10874 | 38020-45-0 | Reference compound |
| HY-100280 | Pirolate | 55149-05-8 | Reference compound |
| HY-100283 | CGS 15435 | 95853-92-2 | Reference compound |
| HY-100284 | Thiazolidinone-Derivatives-1 | 136272-75-8 | Reference compound |
| HY-100285 | RD3-0028 | 3886-39-3 | Reference compound |
| HY-100286 | MDL 19301 | 89388-38-5 | Reference compound |
| HY-100287 | 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide | 137089-36-2 | Reference compound |
| HY-100288 | RP 73163 (Racemate) | 136609-53-5 | Reference compound |
| HY-100289 | MF 5137 | 148927-23-5 | Reference compound |
| HY-10029 | Nutlin-3a | 675576-98-4 | Reference compound |
| HY-100290 | 5-HT1A modulator 1 | 142477-34-7 | Reference compound |
| HY-100291 | SX-3228 | 156364-04-4 | Reference compound |
| HY-100292 | SL910102 | 144756-71-8 | Reference compound |
| HY-100294 | Ruzadolane | 115762-17-9 | Reference compound |
| HY-100295 | (4-Acetamidocyclohexyl) nitrate | 137213-91-3 | Reference compound |
| HY-100296 | Gastrofensin AN 5 free base | 89845-16-9 | Reference compound |
| HY-100297 | MK-447 | 58456-91-0 | Reference compound |
| HY-100298 | Caldaret | 133804-44-1 | Reference compound |
| HY-100299 | RPR107393 free base | 197576-78-6 | Reference compound |
| HY-10029A | (Rac)-Nutlin-3 | 890090-75-2 | Reference compound |
| HY-10030 | Mardepodect (succinate) | 1037309-45-7 | Reference compound |
| HY-100300 | AGN 192836 | 171102-29-7 | Reference compound |
| HY-100301 | FR167344 free base | 215258-13-2 | Reference compound |
| HY-100302 | FR183998 free base | 239440-20-1 | Reference compound |
| HY-100303 | FR194738 free base | 204067-45-8 | Reference compound |
| HY-100303A | FR194738 | 204067-52-7 | Reference compound |
| HY-100304 | KW-8232 free base | 170365-25-0 | Reference compound |
| HY-100304A | KW-8232 | 217813-15-5 | Reference compound |
| HY-100305 | Substituted piperidines-1 | 170842-46-3 | Reference compound |
| HY-100306 | PNU-176798 | 428861-91-0 | Reference compound |
| HY-100308 | SB-568849 | 395679-53-5 | Reference compound |
| HY-100309 | 9-Aminocamptothecin | 91421-43-1 | Natural Products |
| HY-100310 | N-type calcium channel blocker-1 | 241499-17-2 | Reference compound |
| HY-100312 | (±)-WS75624B | 188048-45-5 | Reference compound |
| HY-100313 | YM-53601 free base | 182959-28-0 | Reference compound |
| HY-100313A | YM-53601 | 182959-33-7 | Reference compound |
| HY-100314 | BCR-ABL-IN-1 | 188260-50-6 | Reference compound |
| HY-100315 | XL 999 | 705946-27-6 | Reference compound |
| HY-100316 | CP-96486 | 139401-45-9 | Reference compound |
| HY-100318 | NGD-4715 | 476322-70-0 | Reference compound |
| HY-100319 | UK-157147 | 162704-20-3 | Reference compound |
| HY-10032 | PF 477736 | 952021-60-2 | Reference compound |
| HY-100320 | AVE5688 | 613260-13-2 | Reference compound |
| HY-100321 | MCHR1 antagonist 2 | 863115-70-2 | Reference compound |
| HY-100322 | H100 | 643727-55-3 | Reference compound |
| HY-100325 | NHE3-IN-1 | 632355-68-1 | Reference compound |
| HY-100326 | PDE7-IN-3 | 908570-13-8 | Reference compound |
| HY-100327 | MK-6913 | 1398510-92-3 | Reference compound |
| HY-100328 | CB2R-IN-1 | 1257555-79-5 | Reference compound |
| HY-100329 | CGP 65015 | 189564-33-8 | Reference compound |
| HY-100330 | YM348 | 372163-84-3 | Reference compound |
| HY-100331 | MCH-1 antagonist 1 | 1039825-68-7 | Reference compound |
| HY-100332 | CP 375 | 752186-89-3 | Reference compound |
| HY-100333 | PF-02575799 | 863491-70-7 | Reference compound |
| HY-100334 | Pirinixil | 65089-17-0 | Reference compound |
| HY-100335 | PCI-33380 | 1022899-36-0 | Reference compound |
| HY-100336 | AC260584 | 560083-42-3 | Reference compound |
| HY-100337 | WWL70 | 947669-91-2 | Reference compound |
| HY-100338 | CNX-500 | 1202758-21-1 | Reference compound |
| HY-100339 | GSK583 | 1346547-00-9 | Reference compound |
| HY-100341 | M2I-1 | 312271-03-7 | Reference compound |
| HY-100342 | Ibrutinib-biotin | 1599432-18-4 | Reference compound |
| HY-100343 | GNE-495 | 1449277-10-4 | Reference compound |
| HY-100345 | AMTB (hydrochloride) | 926023-82-7 | Reference compound |
| HY-100346 | PK14105 | 107257-28-3 | Reference compound |
| HY-100347 | SRI-011381 | 1629138-41-5 | Reference compound |
| HY-100347A | SRI-011381 (hydrochloride) | 2070014-88-7 | Reference compound |
| HY-100347S | SRI-011381-d5 | | Isotope-Labeled Compounds |
| HY-100348 | EPI-001 | 227947-06-0 | Reference compound |
| HY-100348R | EPI-001 (Standard) | 227947-06-0 | Reference Standards |
| HY-100349 | SU4312 | 5812-07-7 | Reference compound |
| HY-100349A | cis-SU4312 | 90828-16-3 | Reference compound |
| HY-10035 | TTA-P2 | 1072018-68-8 | Reference compound |
| HY-100350 | CA-074 methyl ester | 147859-80-1 | Reference compound |
| HY-100351 | BI-7273 | 1883429-21-7 | Reference compound |
| HY-100352 | BI-9564 | 1883429-22-8 | Reference compound |
| HY-100353 | C12-Ceramide | 74713-60-3 | Reference compound |
| HY-100353R | C12-Ceramide (Standard) | 74713-60-3 | Reference Standards |
| HY-100354 | C16-Ceramide | 24696-26-2 | Reference compound |
| HY-100354S | C16-Ceramide-13C16 | | Isotope-Labeled Compounds |
| HY-100354S3 | C16-Ceramide-d9 | 2260669-51-8 | Isotope-Labeled Compounds |
| HY-100354S4 | C16-Ceramide-d31 | 852043-41-5 | Isotope-Labeled Compounds |
| HY-100355 | C18-Ceramide | 2304-81-6 | Reference compound |
| HY-100355R | C18-Ceramide (Standard) | 2304-81-6 | Reference Standards |
| HY-100355S | C18-Ceramide-d3 | 2011762-82-4 | Isotope-Labeled Compounds |
| HY-100355S1 | C18-Ceramide-d7 | 1840942-14-4 | Isotope-Labeled Compounds |
| HY-100356 | Aptiganel | 137159-92-3 | Reference compound |
| HY-100358 | AQ-13 dihydrochloride | 169815-40-1 | Reference compound |
| HY-100359 | CL-82198 | 307002-71-7 | Reference compound |
| HY-10035A | (R)-TTA-P2 | | Reference compound |
| HY-10036 | Glucagon receptor antagonist-1 | 503559-84-0 | Reference compound |
| HY-100360 | MS049 | 1502816-23-0 | Reference compound |
| HY-100360A | MS049 (dihydrochloride) | 2095432-59-8 | Reference compound |
| HY-100365 | Remetinostat | 946150-57-8 | Reference compound |
| HY-100366 | Lu AF21934 | 1445605-23-1 | Reference compound |
| HY-100367 | ES 936 | 192820-78-3 | Reference compound |
| HY-100368 | MELK-8a | 1922153-17-0 | Reference compound |
| HY-100368A | MELK-8a (hydrochloride) | 2096992-20-8 | Reference compound |
| HY-100369A | DMCM (hydrochloride) | 1215833-62-7 | Reference compound |
| HY-100369AR | DMCM (hydrochloride) (Standard) | 1215833-62-7 | Reference Standards |
| HY-10037 | Quiflapon | 136668-42-3 | Reference compound |
| HY-100370 | MRK-016 | 342652-67-9 | Reference compound |
| HY-100371 | (RS)-MCPG | 146669-29-6 | Reference compound |
| HY-100371R | (RS)-MCPG (Standard) | 146669-29-6 | Reference Standards |
| HY-100372 | E4CPG | 170846-89-6 | Reference compound |
| HY-100373 | Isavuconazonium (sulfate) | 946075-13-4 | Reference compound |
| HY-100374 | Val-Cit-PAB-MMAE | 644981-35-1 | ADC Related |
| HY-100374G | Val-Cit-PAB-MMAE (GMP) | 644981-35-1 | GMP Small Molecules |
| HY-100375 | Diroximel fumarate | 1577222-14-0 | Reference compound |
| HY-100376 | CPI-1189 | 183619-38-7 | Reference compound |
| HY-100377 | Lvguidingan | 82351-05-1 | Reference compound |
| HY-100379 | Valrocemide | 92262-58-3 | Reference compound |
| HY-10037R | Quiflapon (Standard) | 136668-42-3 | Reference Standards |
| HY-10038 | A 922500 | 959122-11-3 | Reference compound |
| HY-100380 | TPO agonist 1 | 1033040-23-1 | Reference compound |
| HY-100381 | Nigericin (sodium salt) | 28643-80-3 | Natural Products |
| HY-100381R | Nigericin (sodium salt) (Standard) | 28643-80-3 | Reference Standards |
| HY-100382 | FPTQ | 864863-72-9 | Reference compound |
| HY-100383 | BH3I-1 | 300817-68-9 | Reference compound |
| HY-100384 | NKL 22 | 537034-15-4 | Reference compound |
| HY-100385 | Brevianamide F | 38136-70-8 | Natural Products |
| HY-100385R | Brevianamide F (Standard) | 38136-70-8 | Reference Standards |
| HY-100386 | Ticlopidine | 55142-85-3 | Reference compound |
| HY-100386R | Ticlopidine (Standard) | 55142-85-3 | Reference Standards |
| HY-100386S | Ticlopidine-d4 | 1246817-49-1 | Isotope-Labeled Compounds |
| HY-100388 | SHP099 | 1801747-42-1 | Reference compound |
| HY-100388A | SHP099 (monohydrochloride) | 2200214-93-1 | Reference compound |
| HY-100388AR | SHP099 (monohydrochloride) (Standard) | 2200214-93-1 | Reference Standards |
| HY-100388R | SHP099 (Standard) | 1801747-42-1 | Reference Standards |
| HY-100390 | (S)-ML753286 | 1699720-85-8 | Reference compound |
| HY-100394 | NVP-BAW2881 | 861875-60-7 | Reference compound |
| HY-100395 | F16 | 36098-33-6 | Reference compound |
| HY-100396 | SQ22536 | 17318-31-9 | Reference compound |
| HY-100396R | SQ22536 (Standard) | 17318-31-9 | Reference Standards |
| HY-100397 | Elastatinal | 51798-45-9 | Reference compound |
| HY-100397R | Elastatinal (Standard) | 51798-45-9 | Reference Standards |
| HY-100398 | PF-04979064 | 1220699-06-8 | Reference compound |
| HY-100399 | Nevanimibe | 133825-80-6 | Reference compound |
| HY-100399A | Nevanimibe hydrochloride | 133825-81-7 | Reference compound |
| HY-100399AR | Nevanimibe hydrochloride (Standard) | 133825-81-7 | Reference Standards |
| HY-100400A | K-604 (dihydrochloride) | 217094-32-1 | Reference compound |
| HY-100400AR | K-604 (dihydrochloride) (Standard) | 217094-32-1 | Reference Standards |
| HY-100401 | Pactimibe | 189198-30-9 | Reference compound |
| HY-100401A | Pactimibe (sulfate) | 608510-47-0 | Reference compound |
| HY-100402 | CFMTI | 864864-17-5 | Reference compound |
| HY-100403 | Ro 67-7476 | 298690-60-5 | Reference compound |
| HY-100404 | DFMTI | 864864-86-8 | Reference compound |
| HY-100405 | FTIDC | 873551-53-2 | Reference compound |
| HY-100406 | (S)-MCPG | 150145-89-4 | Reference compound |
| HY-100407 | JNJ16259685 | 409345-29-5 | Reference compound |
| HY-100408 | GNF-6231 | 1243245-18-2 | Reference compound |
| HY-100409 | PHCCC | 179068-02-1 | Reference compound |
| HY-100410 | FCCP | 370-86-5 | Reference compound |
| HY-100410R | FCCP (Standard) | 370-86-5 | Reference Standards |
| HY-100411 | MLi-2 | 1627091-47-7 | Reference compound |
| HY-100412 | Linaprazan | 248919-64-4 | Reference compound |
| HY-100412A | Linaprazan (mesylate) | 855998-67-3 | Reference compound |
| HY-100412R | Linaprazan (Standard) | 248919-64-4 | Reference Standards |
| HY-100413 | CS-526 | 313272-12-7 | Reference compound |
| HY-100414 | Soraprazan | 261944-46-1 | Reference compound |
| HY-100415 | UKI-1 | 220355-63-5 | Reference compound |
| HY-100416 | LY2365109 | 868265-28-5 | Reference compound |
| HY-100416A | LY2365109 (hydrochloride) | 1779796-27-8 | Reference compound |
| HY-100418 | SKA-111 | 1369170-24-0 | Reference compound |
| HY-100419 | BFH772 | 890128-81-1 | Reference compound |
| HY-10042 | Odanacatib | 603139-19-1 | Reference compound |
| HY-100421 | CPI-455 | 1628208-23-0 | Reference compound |
| HY-100421A | CPI-455 (hydrochloride) | 2095432-28-1 | Reference compound |
| HY-100422 | KDM5-IN-1 | 1628210-26-3 | Reference compound |
| HY-100423 | Eltanexor | 1642300-52-4 | Reference compound |
| HY-100423A | Eltanexor Z-isomer | 1642300-78-4 | Reference compound |
| HY-100426 | Osemozotan | 137275-81-1 | Reference compound |
| HY-100426A | Osemozotan (hydrochloride) | 137275-80-0 | Reference compound |
| HY-100427 | Imazamox | 114311-32-9 | Reference compound |
| HY-100427R | Imazamox (Standard) | 114311-32-9 | Reference Standards |
| HY-100427S | Imazamox-13C,d3 | | Isotope-Labeled Compounds |
| HY-100428 | Netoglitazone | 161600-01-7 | Reference compound |
| HY-100428R | Netoglitazone (Standard) | 161600-01-7 | Reference Standards |
| HY-100429 | CAN508 | 140651-18-9 | Reference compound |
| HY-10042S | Odanacatib-d4 | | Isotope-Labeled Compounds |
| HY-10043 | gamma-secretase modulator 1 | 1172637-87-4 | Reference compound |
| HY-100430 | CCF642 | 346640-08-2 | Reference compound |
| HY-100431 | IMR-1 | 310456-65-6 | Reference compound |
| HY-100431A | IMR-1A | 331862-41-0 | Reference compound |
| HY-100431AR | IMR-1A (Standard) | 331862-41-0 | Reference Standards |
| HY-100432 | LOC14 | 877963-94-5 | Reference compound |
| HY-100433 | PACMA 31 | 1401089-31-3 | Reference compound |
| HY-100434 | PD-161570 | 192705-80-9 | Reference compound |
| HY-100435 | Oxaquin | 790704-50-6 | Reference compound |
| HY-100436 | Cadazolid | 1025097-10-2 | Reference compound |
| HY-100436R | Cadazolid (Standard) | 1025097-10-2 | Reference Standards |
| HY-100437 | HA15 | 1609402-14-3 | Reference compound |
| HY-100438 | Hydronidone | 851518-71-3 | Reference compound |
| HY-10043A | gamma-secretase modulator 1 (hydrochloride) | 2741571-83-3 | Reference compound |
| HY-10044 | WYE-132 | 1144068-46-1 | Reference compound |
| HY-100441 | Treprostinil | 81846-19-7 | Reference compound |
| HY-100441R | Treprostinil (Standard) | 81846-19-7 | Reference Standards |
| HY-100441S1 | Treprostinil-13C2,d1 | | Isotope-Labeled Compounds |
| HY-100441S2 | Treprostinil-d9 | 2747918-14-3 | Isotope-Labeled Compounds |
| HY-100441S3 | Treprostinil-d7 | | Isotope-Labeled Compounds |
| HY-100442 | Paquinimod | 248282-01-1 | Reference compound |
| HY-100442R | Paquinimod (Standard) | 248282-01-1 | Reference Standards |
| HY-100442S | Paquinimod-d5 | | Isotope-Labeled Compounds |
| HY-100442S1 | Paquinimod-d5-1 | | Isotope-Labeled Compounds |
| HY-100443 | PX20606 | 1268245-19-7 | Reference compound |
| HY-100443A | trans-PX20606 | 1268244-85-4 | Reference compound |
| HY-100443B | (R,R)-PX20606 | 1268244-88-7 | Reference compound |
| HY-100444 | SIS3 (free base) | 521985-36-4 | Reference compound |
| HY-100445 | αvβ1 integrin-IN-1 | 1689540-62-2 | Reference compound |
| HY-100445A | αvβ1 integrin-IN-1 (TFA) | | Reference compound |
| HY-100446 | NTU281 | 815619-12-6 | Reference compound |
| HY-100447 | TM5275 (sodium) | 1103926-82-4 | Reference compound |
| HY-100448A | Butaprost | 69685-22-9 | Reference compound |
| HY-100449 | AL-8810 | 246246-19-5 | Reference compound |
| HY-100449A | (S)-AL-8810 | 1224444-55-6 | Reference compound |
| HY-10045 | AEE788 | 497839-62-0 | Reference compound |
| HY-100450 | BML-111 | 78606-80-1 | Reference compound |
| HY-100452 | TCS-OX2-29 | 372523-75-6 | Reference compound |
| HY-100452A | TCS-OX2-29 (hydrochloride) | 1610882-30-8 | Reference compound |
| HY-100453 | HO-3867 | 1172133-28-6 | Reference compound |
| HY-100454 | CGP 25454A | 104391-26-6 | Reference compound |
| HY-100455 | RK-33 | 1070773-09-9 | Reference compound |
| HY-100456 | ZL006 | 1181226-02-7 | Reference compound |
| HY-100457 | IC87201 | 866927-10-8 | Reference compound |
| HY-100459 | GSK3179106 | 1627856-64-7 | Reference compound |
| HY-10046 | Plerixafor | 110078-46-1 | Reference compound |
| HY-100460 | BIPM | 1070424-33-7 | Reference compound |
| HY-100461 | C29 | 363600-92-4 | Reference compound |
| HY-100462 | PTP1B-IN-2 | 1919853-46-5 | Reference compound |
| HY-100463 | TPI-1 | 79756-69-7 | Reference compound |
| HY-100464 | tBID | 1639895-85-4 | Reference compound |
| HY-100468 | REV7/REV3L-IN-1 | 1979192-13-6 | Reference compound |
| HY-100469 | LXRβ agonist-2 | 1949801-52-8 | Reference compound |
| HY-10046R | Plerixafor (Standard) | 110078-46-1 | Reference Standards |
| HY-10046S | Plerixafor-d4 | 1246819-87-3 | Isotope-Labeled Compounds |
| HY-100470 | NSC781406 | 1676893-24-5 | Reference compound |
| HY-100471 | Esaxerenone | 1632006-28-0 | Reference compound |
| HY-100471R | Esaxerenone (Standard) | 1632006-28-0 | Reference Standards |
| HY-100472 | ZYZ-488 | 1470302-79-4 | Reference compound |
| HY-100474 | Visomitin | 934826-68-3 | Reference compound |
| HY-100475 | KYP-2047 | 796874-99-2 | Reference compound |
| HY-100476 | Mutant IDH1-IN-3 | 1648909-73-2 | Reference compound |
| HY-100481 | RP 72540 | 139088-45-2 | Reference compound |
| HY-100482 | CPI-637 | 1884712-47-3 | Reference compound |
| HY-100483 | A-804598 | 1125758-85-1 | Reference compound |
| HY-100486 | BTTAA | 1334179-85-9 | Reference compound |
| HY-100487 | TAK-243 | 1450833-55-2 | Reference compound |
| HY-100488 | Bay 59-3074 | 406205-74-1 | Reference compound |
| HY-100489 | TBHQ | 1948-33-0 | Reference compound |
| HY-100489R | TBHQ (Standard) | 1948-33-0 | Reference Standards |
| HY-100490 | Rilmenidine | 54187-04-1 | Reference compound |
| HY-100490A | Rilmenidine (hemifumarate) | 207572-68-7 | Reference compound |
| HY-100490AR | Rilmenidine (hemifumarate) (Standard) | 207572-68-7 | Reference Standards |
| HY-100490B | Rilmenidine (phosphate) | 85409-38-7 | Reference compound |
| HY-100490BR | Rilmenidine (phosphate) (Standard) | 85409-38-7 | Reference Standards |
| HY-100490R | Rilmenidine (Standard) | 54187-04-1 | Reference Standards |
| HY-100490S | Rilmenidine-d4 | 85047-14-9 | Isotope-Labeled Compounds |
| HY-100491 | H3B-6527 | 1702259-66-2 | Reference compound |
| HY-100492 | Fisogatinib | 1707289-21-1 | Reference compound |
| HY-100493 | BP-1-102 | 1334493-07-0 | Reference compound |
| HY-100494 | SH5-07 | 1456632-41-9 | Reference compound |
| HY-100495 | FT011 | 1001288-58-9 | Reference compound |
| HY-100496 | Nucleocidin | 24751-69-7 | Natural Products |
| HY-100498 | GSK2256098 | 1224887-10-8 | Reference compound |
| HY-100498A | GSK-2256098 (hydrochloride) | 1416771-10-2 | Reference compound |
| HY-100499 | Tyrphostin AG 528 | 133550-49-9 | Reference compound |
| HY-10049A | CP 122721 (hydrochloride) | 145877-52-7 | Reference compound |
| HY-100500 | Lenampicillin (hydrochloride) | 80734-02-7 | Reference compound |
| HY-100501 | M2698 | 1379545-95-5 | Reference compound |
| HY-100502 | CID5721353 | 301356-95-6 | Reference compound |
| HY-100503 | Maytansinoid DM4 | 799840-96-3 | ADC Related |
| HY-100504 | S-methyl DM1 | 912569-84-7 | ADC Related |
| HY-100506 | GLPG0187 | 1320346-97-1 | Reference compound |
| HY-100507 | Avadomide | 1015474-32-4 | Reference compound |
| HY-100507A | Avadomide (hydrochloride) | 1398053-45-6 | Reference compound |
| HY-100507R | Avadomide (Standard) | 1015474-32-4 | Reference Standards |
| HY-100508 | ITSA-1 | 200626-61-5 | Reference compound |
| HY-100509 | NPS-1034 | 1221713-92-3 | Reference compound |
| HY-10051 | GR203040 | 168398-02-5 | Reference compound |
| HY-100510 | RAF709 | 1628838-42-5 | Reference compound |
| HY-100511 | Benzophenonetetracarboxylic acid | 2479-49-4 | Reference compound |
| HY-100512 | Benzenepentacarboxylic Acid | 1585-40-6 | Dye Reagents |
| HY-100513A | Dehydroaltenusin | 31186-13-7 | Natural Products |
| HY-100514 | GSK484 (hydrochloride) | 1652591-81-5 | Reference compound |
| HY-100515 | Robotnikinin | 1132653-79-2 | Reference compound |
| HY-100516 | Cimicoxib | 265114-23-6 | Reference compound |
| HY-100516R | Cimicoxib (Standard) | 265114-23-6 | Reference Standards |
| HY-100517 | TP-472 | 2079895-62-6 | Reference compound |
| HY-100518 | T-26c | 869296-13-9 | Reference compound |
| HY-100518A | T 26c (sodium) | 869298-22-6 | Reference compound |
| HY-100519 | NVS-PAK1-1 | 1783816-74-9 | Reference compound |
| HY-10052 | Aprepitant | 170729-80-3 | Reference compound |
| HY-100520 | EGFR-IN-2 | 1643497-70-4 | Reference compound |
| HY-100521 | GKI-1 | 2444764-03-6 | Reference compound |
| HY-100522 | FMK 9a | 1955550-51-2 | Reference compound |
| HY-100523 | ML385 | 846557-71-9 | Reference compound |
| HY-100524 | LRE1 | 1252362-53-0 | Reference compound |
| HY-100526 | XMU-MP-1 | 2061980-01-4 | Reference compound |
| HY-100527 | AN2718 | 174672-06-1 | Reference compound |
| HY-100528 | Nanchangmycin | 65101-87-3 | Natural Products |
| HY-100528A | Dianemycin | 35865-33-9 | Natural Products |
| HY-100528AR | Dianemycin (Standard) | 35865-33-9 | Reference Standards |
| HY-100528R | Nanchangmycin (Standard) | 65101-87-3 | Reference Standards |
| HY-100529 | PD150606 | 179528-45-1 | Reference compound |
| HY-10052R | Aprepitant (Standard) | 170729-80-3 | Reference Standards |
| HY-10053 | Maropitant | 147116-67-4 | Reference compound |
| HY-100530 | Rp-cAMPS (triethylammonium salt) | 151837-09-1 | Reference compound |
| HY-100530A | Rp-cAMPS | 73208-40-9 | Reference compound |
| HY-100530B | Sp-cAMPS | 71774-13-5 | Reference compound |
| HY-100530C | Sp-cAMPS (sodium salt) | 142439-95-0 | Reference compound |
| HY-100530D | Rp-cAMPS (sodium salt) | 142439-94-9 | Reference compound |
| HY-100531 | DprE1-IN-2 | 1615713-87-5 | Reference compound |
| HY-100532 | CD437 | 125316-60-1 | Reference compound |
| HY-100532R | CD437 (Standard) | 125316-60-1 | Reference Standards |
| HY-100532S | CD437-13C6 | | Isotope-Labeled Compounds |
| HY-100533 | IDE1 | 1160927-48-9 | Reference compound |
| HY-100534 | IDE 2 | 1136466-93-7 | Reference compound |
| HY-100535 | KAAD-Cyclopamine | 306387-90-6 | Reference compound |
| HY-100536 | IWP-3 | 687561-60-0 | Reference compound |
| HY-100538 | DTP3 | 1809784-29-9 | Peptides |
| HY-100538A | DTP3 (TFA) | 2759216-46-9 | Peptides |
| HY-100539 | PD 128907 | 123594-64-9 | Reference compound |
| HY-100539A | PD 128907 (hydrochloride) | 112960-16-4 | Biochemical Assay Reagents |
| HY-10053B | Maropitant (citrate) | 862543-54-2 | Reference compound |
| HY-10053R | Maropitant (Standard) | 147116-67-4 | Reference Standards |
| HY-10053S | Maropitant-d3 | 2124295-52-7 | Isotope-Labeled Compounds |
| HY-10053S1 | Maropitant-13C,d3 | | Isotope-Labeled Compounds |
| HY-100540 | Golgicide A | 1139889-93-2 | Reference compound |
| HY-100540A | (Rac)-Golgicide A | 1005036-73-6 | Reference compound |
| HY-100540B | Golgicide A-2 | 1394285-50-7 | Reference compound |
| HY-100540C | Golgicide A-1 | 1394285-49-4 | Reference compound |
| HY-100541 | INH6 | 1001753-24-7 | Reference compound |
| HY-100542 | D-α-Hydroxyglutaric acid (disodium) | 103404-90-6 | Reference compound |
| HY-100542R | D-α-Hydroxyglutaric acid (disodium) (Standard) | 103404-90-6 | Reference Standards |
| HY-100543 | Zenidolol | 72795-26-7 | Reference compound |
| HY-100544 | FLLL32 | 1226895-15-3 | Reference compound |
| HY-100545 | BAPTA-AM | 126150-97-8 | Biochemical Assay Reagents |
| HY-100545R | BAPTA-AM (Standard) | 126150-97-8 | Reference Standards |
| HY-100546 | GSK-LSD1 | 1431368-48-7 | Reference compound |
| HY-100546A | GSK-LSD1 (dihydrochloride) | 2102933-95-7 | Reference compound |
| HY-100547 | IEM-1754 | 162831-31-4 | Reference compound |
| HY-100548 | GSK621 | 1346607-05-3 | Reference compound |
| HY-100549 | (S)-Crizotinib | 1374356-45-2 | Reference compound |
| HY-100550 | MSDC 0160 | 146062-49-9 | Reference compound |
| HY-100551 | meso-Erythritol | 149-32-6 | Natural Products |
| HY-100551R | meso-Erythritol (Standard) | 149-32-6 | Reference Standards |
| HY-100552 | VUF10166 | 155584-74-0 | Reference compound |
| HY-100554 | BMY 7378 | 21102-95-4 | Reference compound |
| HY-100555 | CH5138303 | 959763-06-5 | Reference compound |
| HY-100556 | Tie2 kinase inhibitor 1 | 948557-43-5 | Reference compound |
| HY-100557 | Hydroxypropyl Cellulose | 9004-64-2 | Reference compound |
| HY-100557A | Low-Substituted Hydroxypropyl Cellulose | 9004-64-2 | Reference compound |
| HY-100557B | HPC, Viscosity(1%):150-400mPa.s | 9004-64-2 | Biochemical Assay Reagents |
| HY-100557C | HPC, Viscosity(1%):4000-6500mPa.s | 9004-64-2 | Biochemical Assay Reagents |
| HY-100557D | HPC, Viscosity(5%):75-150mPa.s | 9004-64-2 | Biochemical Assay Reagents |
| HY-100557E | HPC, Viscosity(1%):1275-3500mPa.s | 9004-64-2 | Biochemical Assay Reagents |
| HY-100557H | HPC, Viscosity(2%):95000-105000mPa.s | 9004-64-2 | Biochemical Assay Reagents |
| HY-100558 | Bafilomycin A1 | 88899-55-2 | Natural Products |
| HY-100559 | SecinH3 | 853625-60-2 | Reference compound |
| HY-100560 | Abscisic acid | 21293-29-8 | Natural Products |
| HY-100560R | Abscisic acid (Standard) | 21293-29-8 | Reference Standards |
| HY-100560S | Abscisic acid-d6 | 721948-65-8 | Isotope-Labeled Compounds |
| HY-100561 | Tempol | 2226-96-2 | Reference compound |
| HY-100561R | Tempol (Standard) | 2226-96-2 | Reference Standards |
| HY-100561S | Tempol-d17,15N | 90429-66-6 | Isotope-Labeled Compounds |
| HY-100561S1 | Tempol-d17 | 100326-46-3 | Isotope-Labeled Compounds |
| HY-100562 | Flopropione | 2295-58-1 | Natural Products |
| HY-100563 | Cyclo(RGDyK) (trifluoroacetate) | 250612-42-1 | Peptides |
| HY-100563A | Cyclo(RGDyK) | 217099-14-4 | Peptides |
| HY-100564 | 2',3'-cGAMP | 1441190-66-4 | Reference compound |
| HY-100564A | 2',3'-cGAMP (sodium) | 2734858-36-5 | Reference compound |
| HY-100564BS | 2',3'-cGAMP-d8 (ammonium) | | Isotope-Labeled Compounds |
| HY-100565 | SGC2085 | 1821908-48-8 | Reference compound |
| HY-100565A | SGC2085 (hydrochloride) | 1821908-49-9 | Reference compound |
| HY-100566 | SuO-Val-Cit-PAB-MMAE | | ADC Related |
| HY-100567 | MAL-di-EG-Val-Cit-PAB-MMAE | 2746391-62-6 | ADC Related |
| HY-100568 | 3-O-Demethylfortimicin A | 74842-47-0 | Reference compound |
| HY-10057 | AT9283 (hydrochloride) | 896466-61-8 | Reference compound |
| HY-100570 | KF15766 | 124907-44-4 | Reference compound |
| HY-100571 | Cloprostenol isopropyl ester | 157283-66-4 | Reference compound |
| HY-100571A | (+)-5-trans Cloprostenol isopropyl ester | | Reference compound |
| HY-100572 | Nicainoprol | 76252-06-7 | Reference compound |
| HY-100573 | Necrosulfonamide | 1360614-48-7 | Reference compound |
| HY-100573A | (E/Z)-Necrosulfonamide | 432531-71-0 | Reference compound |
| HY-100573S | Necrosulfonamide-d4 | 1795144-22-7 | Isotope-Labeled Compounds |
| HY-100574 | Cl-amidine | 913723-61-2 | Reference compound |
| HY-100574A | Cl-amidine (hydrochloride) | 1373232-26-8 | Reference compound |
| HY-100574B | Cl-amidine (TFA) | 1043444-18-3 | Reference compound |
| HY-100574C | D-Cl-amidine | 1404060-15-6 | Reference compound |
| HY-100574D | D-Cl-amidine (hydrochloride) | 2985338-61-0 | Reference compound |
| HY-100575 | Acriflavine | 8048-52-0 | Dye Reagents |
| HY-100576 | NH125 | 278603-08-0 | Reference compound |
| HY-100577 | Ticarcillin (sodium) | 29457-07-6 | Reference compound |
| HY-100578 | AGK2 | 304896-28-4 | Reference compound |
| HY-100579 | Ferrostatin-1 | 347174-05-4 | Reference compound |
| HY-10058 | AT9283 (lactic acid) | 896466-76-5 | Reference compound |
| HY-100580 | Asaraldehyde | 4460-86-0 | Natural Products |
| HY-100580R | Asaraldehyde (Standard) | 4460-86-0 | Reference Standards |
| HY-100581 | CORM-3 | 475473-26-8 | Reference compound |
| HY-100582 | Ribitol | 488-81-3 | Natural Products |
| HY-100582R | Ribitol (Standard) | 488-81-3 | Reference Standards |
| HY-100582S | Ribitol-1-13C | | Isotope-Labeled Compounds |
| HY-100582S1 | Ribitol-2-13C | | Isotope-Labeled Compounds |
| HY-100582S2 | Ribitol-3-13C | | Isotope-Labeled Compounds |
| HY-100582S3 | Ribitol-5-13C | | Isotope-Labeled Compounds |
| HY-100583 | (-)-(S)-Equol | 531-95-3 | Natural Products |
| HY-100583A | (±)-Equol | 94105-90-5 | Natural Products |
| HY-100583AR | (±)-Equol (Standard) | 94105-90-5 | Reference Standards |
| HY-100583R | (-)-(S)-Equol (Standard) | 531-95-3 | Reference Standards |
| HY-100584 | Davercin | 55224-05-0 | Reference compound |
| HY-100584R | Davercin (Standard) | 55224-05-0 | Reference Standards |
| HY-100585 | Splitomicin | 5690-03-9 | Reference compound |
| HY-100585R | Splitomicin (Standard) | 5690-03-9 | Reference Standards |
| HY-100586 | Ibuprofen (L-lysine) | 57469-77-9 | Reference compound |
| HY-100586R | Ibuprofen (L-lysine) (Standard) | 57469-77-9 | Reference Standards |
| HY-100587 | D-Glutamine | 5959-95-5 | Natural Products |
| HY-100587R | D-Glutamine (Standard) | 5959-95-5 | Reference Standards |
| HY-100588 | VU0364770 | 61350-00-3 | Reference compound |
| HY-100588A | VU0364770 (hydrochloride) | 1414842-70-8 | Reference compound |
| HY-100589 | Isepamicin (sulfate) | 67814-76-0 | Reference compound |
| HY-100590 | FPH1 | 708219-39-0 | Reference compound |
| HY-100591 | SirReal2 | 709002-46-0 | Reference compound |
| HY-100592 | Nicaraven | 79455-30-4 | Reference compound |
| HY-100592R | Nicaraven (Standard) | 79455-30-4 | Reference Standards |
| HY-100593 | Spiramycin | 8025-81-8 | Natural Products |
| HY-100593A | Spiramycin (hexanedioate) | 11034-40-5 | Reference compound |
| HY-100593R | Spiramycin (Standard) | 8025-81-8 | Reference Standards |
| HY-100594 | EUK-134 | 81065-76-1 | Reference compound |
| HY-100595 | Sodium stibogluconate | 16037-91-5 | Reference compound |
| HY-100596 | AS1842856 | 836620-48-5 | Reference compound |
| HY-100597 | Saponins | 8047-15-2 | Natural Products |
| HY-100599 | Urolithin A | 1143-70-0 | Natural Products |
| HY-100599R | Urolithin A (Standard) | 1143-70-0 | Reference Standards |
| HY-100600 | BGG463 | 890129-26-7 | Reference compound |
| HY-100602 | HJC0152 | 1420290-99-8 | Reference compound |
| HY-100603 | GSK-F1 | 1402345-92-9 | Reference compound |
| HY-100603A | (S)-GSK-F1 | 1384097-27-1 | Reference compound |
| HY-100604 | JNJ-40418677 | 1146594-87-7 | Reference compound |
| HY-100604A | (R)-JNJ-40418677 | 1146594-85-5 | Reference compound |
| HY-100605 | VU0483605 | 1623101-11-0 | Reference compound |
| HY-100606 | l-Pindolol | 26328-11-0 | Reference compound |
| HY-100607 | Landiolol | 133242-30-5 | Reference compound |
| HY-100607A | Landiolol (hydrochloride) | 144481-98-1 | Reference compound |
| HY-100607AR | Landiolol (hydrochloride) (Standard) | 144481-98-1 | Reference Standards |
| HY-100608 | BMS453 | 166977-43-1 | Reference compound |
| HY-100609 | 4-P-PDOT | 134865-74-0 | Reference compound |
| HY-100609R | 4-P-PDOT (Standard) | 134865-74-0 | Reference Standards |
| HY-10061 | Lesogaberan | 344413-67-8 | Reference compound |
| HY-100611 | CaCCinh-A01 | 407587-33-1 | Reference compound |
| HY-100612 | T16Ainh-A01 | 552309-42-9 | Reference compound |
| HY-100613 | MONNA | 1572936-83-4 | Reference compound |
| HY-100614 | AS1517499 | 919486-40-1 | Reference compound |
| HY-100615 | Revizinone | 133718-29-3 | Reference compound |
| HY-100615A | R 80123 | 133718-30-6 | Reference compound |
| HY-100616 | cis-ACBD | 73550-55-7 | Reference compound |
| HY-100616A | trans-ACBD | 117488-23-0 | Reference compound |
| HY-100617 | (S)-4CPG | 134052-73-6 | Reference compound |
| HY-100617A | (RS)-4CPG | 7292-81-1 | Reference compound |
| HY-100617B | (R)-4CPG | 134052-68-9 | Reference compound |
| HY-100618 | Hispidin | 555-55-5 | Natural Products |
| HY-100618R | Hispidin (Standard) | 555-55-5 | Reference Standards |
| HY-100619 | BMS-986020 | 1257213-50-5 | Reference compound |
| HY-100619A | BMS-986020 (sodium) | 1380650-53-2 | Reference compound |
| HY-10061A | Lesogaberan (napadisylate) | 477956-38-0 | Reference compound |
| HY-10061B | Lesogaberan (hydrochloride) | 2925644-17-1 | Reference compound |
| HY-100620 | RPR121056 | 181467-56-1 | Reference compound |
| HY-100620R | RPR121056 (Standard) | 181467-56-1 | Reference Standards |
| HY-100621 | MDL 72527 | 93565-01-6 | Reference compound |
| HY-100622 | Ro 20-0657/000 | 29606-06-2 | Reference compound |
| HY-100623 | Dofetilide N-oxide | 144449-71-8 | Reference compound |
| HY-100624 | Ryuvidine | 265312-55-8 | Reference compound |
| HY-100625 | BVT948 | 39674-97-0 | Reference compound |
| HY-100626 | WNK463 | 2012607-27-9 | Reference compound |
| HY-100627 | APS-2-79 | 2002381-25-9 | Reference compound |
| HY-100627A | APS-2-79 (hydrochloride) | 2002381-31-7 | Reference compound |
| HY-10063 | Ispronicline | 252870-53-4 | Reference compound |
| HY-100631 | FGFR4-IN-1 | 1708971-72-5 | Reference compound |
| HY-100633S | N-Demethy Ivabradine-d6 (hydrochloride) | 1346600-74-5 | Isotope-Labeled Compounds |
| HY-100634 | 4-Hydroxypropranolol (hydrochloride) | 14133-90-5 | Reference compound |
| HY-100634R | 4-Hydroxypropranolol (hydrochloride) (Standard) | 14133-90-5 | Reference Standards |
| HY-100634S | 4-Hydroxypropranolol-d7 (hydrochloride) | 1219804-03-1 | Isotope-Labeled Compounds |
| HY-100634SA | 4-Hydroxypropranolol-d7 | 1219908-86-7 | Isotope-Labeled Compounds |
| HY-100635 | Diacetolol | 22568-64-5 | Reference compound |
| HY-100635R | Diacetolol (Standard) | 22568-64-5 | Reference Standards |
| HY-100635S | Diacetolol-d7 | 1346604-19-0 | Isotope-Labeled Compounds |
| HY-100636 | Gefitinib N-oxide | 847949-51-3 | Reference compound |
| HY-100636A | Gefitinib N-oxide (hydrochloride) | | Reference compound |
| HY-100637 | Hydroxybupropion | 92264-81-8 | Reference compound |
| HY-100638 | RPR132595A | 185304-42-1 | Reference compound |
| HY-100638A | RPR132595A (hydrochloride) | | Reference compound |
| HY-100639 | Roflumilast N-oxide | 292135-78-5 | Reference compound |
| HY-100639R | Roflumilast N-oxide (Standard) | 292135-78-5 | Reference Standards |
| HY-10064 | Ticagrelor | 274693-27-5 | Reference compound |
| HY-100640 | Roflumilast Impurity E | 1391052-76-8 | Reference compound |
| HY-100640R | Roflumilast Impurity E (Standard) | 1391052-76-8 | Reference Standards |
| HY-100641 | 4-Hydroxytolbutamide | 5719-85-7 | Reference compound |
| HY-100641S | 4-Hydroxytolbutamide-d9 | 1185112-19-9 | Isotope-Labeled Compounds |
| HY-100642 | 3-O-Methyltolcapone | 134612-80-9 | Reference compound |
| HY-100642R | 3-O-Methyltolcapone (Standard) | 134612-80-9 | Reference Standards |
| HY-100642S | 3-O-Methyltolcapone-d7 | | Isotope-Labeled Compounds |
| HY-100642S1 | 3-O-Methyltolcapone-d4 | 2469274-07-3 | Isotope-Labeled Compounds |
| HY-100644 | Trimethoprim N-oxide | 27653-68-5 | Reference compound |
| HY-100645 | Trimethoprim 3-oxide | 27653-67-4 | Reference compound |
| HY-100646 | (E)-10-Hydroxynortriptyline (maleate) | 74853-74-0 | Reference compound |
| HY-100646A | (Z)-10-Hydroxynortriptyline | 47132-19-4 | Reference compound |
| HY-100646AS | (Z)-10-Hydroxynortriptyline-d3 | | Isotope-Labeled Compounds |
| HY-100647S | N-Desmethyl Nefopam-d4 (hydrochloride) | 2747914-61-8 | Isotope-Labeled Compounds |
| HY-100648 | Keto Ziprasidone | 884305-07-1 | Reference compound |
| HY-100649 | Hydroxy ziprasidone | 884305-08-2 | Reference compound |
| HY-10064R | Ticagrelor (Standard) | 274693-27-5 | Reference Standards |
| HY-10064S | Ticagrelor-d7 | 1265911-55-4 | Isotope-Labeled Compounds |
| HY-10064S1 | Ticagrelor-d4 | 1265911-54-3 | Isotope-Labeled Compounds |
| HY-10065 | Axitinib | 319460-85-0 | Reference compound |
| HY-100650 | Carbodenafil | 944241-52-5 | Reference compound |
| HY-100651 | Desmethylnortriptyline | 4444-42-2 | Reference compound |
| HY-100651R | Desmethylnortriptyline (Standard) | 4444-42-2 | Reference Standards |
| HY-100652A | O-Desmethyl apixaban sulfate (sodium) | | Reference compound |
| HY-100653 | AZD5153 | 1869912-39-9 | Reference compound |
| HY-100653A | AZD5153 (6-Hydroxy-2-naphthoic acid) | 1869912-40-2 | Reference compound |
| HY-100654 | 10-DEBC (hydrochloride) | 925681-41-0 | Reference compound |
| HY-100655 | O-Desmethyl apixaban | 503612-76-8 | Reference compound |
| HY-100655R | O-Desmethyl apixaban (Standard) | 503612-76-8 | Reference Standards |
| HY-100656 | Desmethyl cariprazine | 839712-15-1 | Reference compound |
| HY-100657 | meta-Fexofenadine | 479035-75-1 | Reference compound |
| HY-100657R | meta-Fexofenadine (Standard) | 479035-75-1 | Reference Standards |
| HY-100657S | Meta-Fexofenadine-d6 | | Isotope-Labeled Compounds |
| HY-100658 | Didesmethyl cariprazine | 839712-25-3 | Reference compound |
| HY-100659 | Dihydrodiol-Ibrutinib | 1654820-87-7 | Reference compound |
| HY-100659S | Dihydrodiol-Ibrutinib-d5 | 2068022-09-1 | Isotope-Labeled Compounds |
| HY-10065R | Axitinib (Standard) | 319460-85-0 | Reference Standards |
| HY-10065S | Axitinib-13C,d3 | 1261432-00-1 | Isotope-Labeled Compounds |
| HY-10065S1 | Axitinib-d3 | 1126623-89-9 | Isotope-Labeled Compounds |
| HY-10066 | Nelivaptan | 439687-69-1 | Reference compound |
| HY-100660A | Cetirizine Impurity B (dihydrochloride) | 1000690-91-4 | Reference compound |
| HY-100661 | Cetirizine Impurity D | 346451-15-8 | Reference compound |
| HY-100661R | Cetirizine Impurity D (Standard) | 346451-15-8 | Reference Standards |
| HY-100662 | Didesethyl chloroquine | 4298-14-0 | Reference compound |
| HY-100662S | Didesethyl chloroquine-d4 | 1215797-41-3 | Isotope-Labeled Compounds |
| HY-100663 | Gefitinib impurity 2 | 246512-44-7 | Reference compound |
| HY-100664 | Zopiclone N-oxide | 43200-96-0 | Reference compound |
| HY-100665 | Dehydroaripiprazole | 129722-25-4 | Reference compound |
| HY-100665R | Dehydroaripiprazole (Standard) | 129722-25-4 | Reference Standards |
| HY-100665S | Dehydroaripiprazole-d8 | 2749328-53-6 | Isotope-Labeled Compounds |
| HY-100666 | Fosfluconazole | 194798-83-9 | Reference compound |
| HY-100666R | Fosfluconazole (Standard) | 194798-83-9 | Reference Standards |
| HY-100667 | UBP608 | 2199-87-3 | Reference compound |
| HY-100668 | JYL 1421 | 401907-26-4 | Reference compound |
| HY-100669 | Mycro 3 | 944547-46-0 | Reference compound |
| HY-10067 | Y-33075 | 199433-58-4 | Reference compound |
| HY-100670 | Olinone | 1770789-37-1 | Reference compound |
| HY-100671 | L002 | 321695-57-2 | Reference compound |
| HY-100672 | SR59230A | 174689-39-5 | Reference compound |
| HY-100672B | (2R)-SR59230A | 1932675-95-0 | Reference compound |
| HY-100673 | LM22A-4 | 37988-18-4 | Reference compound |
| HY-100675 | JTE-013 | 383150-41-2 | Reference compound |
| HY-100675R | JTE-013 (Standard) | 383150-41-2 | Reference Standards |
| HY-100676 | GRI977143 | 325850-81-5 | Reference compound |
| HY-100677 | VUF11207 | 1378524-41-4 | Reference compound |
| HY-100678 | CGS 15943 | 104615-18-1 | Reference compound |
| HY-100678R | CGS 15943 (Standard) | 104615-18-1 | Reference Standards |
| HY-100679 | Pirlindole | 60762-57-4 | Reference compound |
| HY-100679A | Pirlindole (mesylate) | 207572-66-5 | Reference compound |
| HY-100679R | Pirlindole (Standard) | 60762-57-4 | Reference Standards |
| HY-100679S | Pirlindole-d4 | 1801646-26-3 | Isotope-Labeled Compounds |
| HY-10068 | Y-33075 (hydrochloride) | 471843-75-1 | Reference compound |
| HY-100681 | GSK2837808A | 1445879-21-9 | Reference compound |
| HY-100682 | T-3256336 | 1266227-69-3 | Reference compound |
| HY-100683 | A12B4C3 | 1005129-80-5 | Reference compound |
| HY-100684 | UAMC-1110 | 1448440-52-5 | Reference compound |
| HY-100685 | MS-444 | 150045-18-4 | Reference compound |
| HY-100686 | U93631 | 152273-12-6 | Reference compound |
| HY-100687 | GNF-PF-3777 | 77603-42-0 | Reference compound |
| HY-100688 | ML390 | 2029049-79-2 | Reference compound |
| HY-100689 | Propyl pyrazole triol | 263717-53-9 | Reference compound |
| HY-100689R | Propyl pyrazole triol (Standard) | 263717-53-9 | Reference Standards |
| HY-10069 | Y-33075 (dihydrochloride) | 173897-44-4 | Reference compound |
| HY-100690 | NSC16168 | 6837-93-0 | Reference compound |
| HY-100691 | NOD-IN-1 | 132819-92-2 | Reference compound |
| HY-100692 | Lin28-let-7a antagonist 1 | 2024548-03-4 | Reference compound |
| HY-100693 | SYP-5 | 1384268-04-5 | Reference compound |
| HY-100694 | GS-9901 | 1640247-87-5 | Reference compound |
| HY-100695 | DDR-TRK-1 | 1934246-19-1 | Reference compound |
| HY-100696 | PNZ5 | 1629277-36-6 | Reference compound |
| HY-100697 | TPOP146 | 2018300-62-2 | Reference compound |
| HY-100699 | Clenproperol | 38339-11-6 | Reference compound |
| HY-100699S | Clenproperol-d7 | 1173021-09-4 | Isotope-Labeled Compounds |
| HY-100701 | Dutacatib | 501000-36-8 | Reference compound |
| HY-100702 | SH-5 | 701976-54-7 | Reference compound |
| HY-100703 | Pipamperone | 1893-33-0 | Reference compound |
| HY-100703A | Pipamperone (dihydrochloride) | 2448-68-2 | Reference compound |
| HY-100703R | Pipamperone (Standard) | 1893-33-0 | Reference Standards |
| HY-100704 | Procaterol (hydrochloride) | 62929-91-3 | Reference compound |
| HY-100704A | (Rac)-Procaterol (hydrochloride) | 59828-07-8 | Reference compound |
| HY-100705 | DMNB | 20357-25-9 | Reference compound |
| HY-100706 | AMA-37 | 404009-46-7 | Reference compound |
| HY-100707 | IC 86621 | 404009-40-1 | Reference compound |
| HY-100708 | NSC632839 | 157654-67-6 | Reference compound |
| HY-100709 | ZPCK | 26049-94-5 | Reference compound |
| HY-10071 | Y-27632 | 146986-50-7 | Reference compound |
| HY-100710 | Epothilone C | 186692-73-9 | Reference compound |
| HY-100711 | Prodigiosin | 82-89-3 | Natural Products |
| HY-100711A | Prodigiosin (hydrochloride) | 56144-17-3 | Natural Products |
| HY-100712 | DPO-1 | 43077-30-1 | Reference compound |
| HY-100713 | Temocapril | 111902-57-9 | Reference compound |
| HY-100713R | Temocapril (Standard) | 111902-57-9 | Reference Standards |
| HY-100713S | Temocapril-d5 | 1356840-03-3 | Isotope-Labeled Compounds |
| HY-100714 | DL-AP5 | 76326-31-3 | Reference compound |
| HY-100714A | D-AP5 | 79055-68-8 | Reference compound |
| HY-100714B | L-AP5 | 79055-67-7 | Reference compound |
| HY-100714C | DL-AP5 (sodium) | 1303993-72-7 | Reference compound |
| HY-100714CR | DL-AP5 (sodium) (Standard) | 1303993-72-7 | Reference Standards |
| HY-100714D | DL-AP5 (lithium) | 125229-62-1 | Reference compound |
| HY-100714R | DL-AP5 (Standard) | 76326-31-3 | Reference Standards |
| HY-100716 | Eganelisib | 1693758-51-8 | Reference compound |
| HY-100717 | HT-2157 | 303149-14-6 | Reference compound |
| HY-100718 | SCH00013 | 217963-18-3 | Reference compound |
| HY-100719 | BRD-6929 | 849234-64-6 | Reference compound |
| HY-10071A | Y-27632 (hydrochloride hydrate) | 331752-47-7 | Reference compound |
| HY-10072 | SPC 839 | 219773-55-4 | Reference compound |
| HY-100720 | GSK2193874 | 1336960-13-4 | Reference compound |
| HY-100721 | GC376 (sodium) | 1416992-39-6 | Reference compound |
| HY-100723 | THK-523 | 1573029-17-0 | Reference compound |
| HY-100724 | YM-17690 | 108806-41-3 | Reference compound |
| HY-100725 | BM212 | 146204-42-4 | Reference compound |
| HY-100725R | BM212 (Standard) | 146204-42-4 | Reference Standards |
| HY-100726 | GNE-272 | 1936428-93-1 | Reference compound |
| HY-100727 | AM-2099 | 1443373-17-8 | Reference compound |
| HY-100728 | BMT-145027 | 2018282-44-3 | Reference compound |
| HY-100729 | GSK9311 | 1923851-49-3 | Reference compound |
| HY-100729A | GSK9311 (hydrochloride) | 2253733-09-2 | Reference compound |
| HY-100731 | Cyclosporin | 79217-60-0 | Natural Products |
| HY-100732 | Cambinol | 14513-15-6 | Reference compound |
| HY-100732R | Cambinol (Standard) | 14513-15-6 | Reference Standards |
| HY-100733 | 4E2RCat | 432499-63-3 | Reference compound |
| HY-100734 | Histone Acetyltransferase Inhibitor II | 932749-62-7 | Reference compound |
| HY-100735 | C 87 | 332420-90-3 | Reference compound |
| HY-100736 | ML348 | 899713-86-1 | Reference compound |
| HY-100737 | ML349 | 890819-86-0 | Reference compound |
| HY-100738 | Ubiquitin Isopeptidase Inhibitor I, G5 | 108477-18-5 | Reference compound |
| HY-100739 | RA190 | 1617495-03-0 | Reference compound |
| HY-10074 | TPCA-1 | 507475-17-4 | Reference compound |
| HY-100740 | Lanabecestat | 1383982-64-6 | Reference compound |
| HY-100740A | Lanabecestat (hydrochloride) | 1383986-31-9 | Reference compound |
| HY-100740B | Lanabecestat (camsylate) | 1522418-41-2 | Reference compound |
| HY-100740C | (1α,1'S,4β)-Lanabecestat | 1384082-96-5 | Reference compound |
| HY-100740R | Lanabecestat (Standard) | 1383982-64-6 | Reference Standards |
| HY-100741 | S63845 | 1799633-27-4 | Reference compound |
| HY-100741A | (S,R)-S63845 | | Reference compound |
| HY-100741C | (R,R)-S63845 | | Reference compound |
| HY-100742 | GNE-140 (racemate) | 1802977-61-2 | Reference compound |
| HY-100742A | (R)-GNE-140 | 2003234-63-5 | Reference compound |
| HY-100742B | (S)-GNE-140 | 2003234-64-6 | Reference compound |
| HY-100743 | DL-AP4 | 6323-99-5 | Reference compound |
| HY-100743R | DL-AP4 (Standard) | 6323-99-5 | Reference Standards |
| HY-100744 | AS8351 | 796-42-9 | Reference compound |
| HY-100746 | STF-62247 | 315702-99-9 | Reference compound |
| HY-100747 | PSB-12379 | 1802226-78-3 | Reference compound |
| HY-100747A | PSB-12379 (disodium) | | Reference compound |
| HY-100748 | Zabadinostat | 934828-12-3 | Reference compound |
| HY-100749 | HeE1-2Tyr | 2245195-67-7 | Reference compound |
| HY-100750 | Norverapamil (hydrochloride) | 67812-42-4 | Reference compound |
| HY-100750R | Norverapamil (hydrochloride) (Standard) | 67812-42-4 | Reference Standards |
| HY-100751 | N-563 | 140686-92-6 | Reference compound |
| HY-100753 | STAT3-IN-1 | 2059952-75-7 | Reference compound |
| HY-100754 | Ritlecitinib | 1792180-81-4 | Reference compound |
| HY-100754A | Ritlecitinib (malonate) | 2140301-97-7 | Reference compound |
| HY-100754B | (2R,5S)-Ritlecitinib | 1792180-79-0 | Reference compound |
| HY-100754C | Ritlecitinib (tosylate) | 2192215-81-7 | Reference compound |
| HY-100755 | KR-33493 | 1021497-97-1 | Reference compound |
| HY-100756 | BAY-826 | 1448316-08-2 | Reference compound |
| HY-100757 | CPUY074020 | 902279-44-1 | Reference compound |
| HY-100758 | FUBP1-IN-1 | 883003-62-1 | Reference compound |
| HY-100759 | JAK2-IN-4 | 1438284-00-4 | Reference compound |
| HY-100760 | Toxoflavin | 84-82-2 | Reference compound |
| HY-100760R | Toxoflavin (Standard) | 84-82-2 | Reference Standards |
| HY-100760S | Toxoflavin-13C4 | 2300178-70-3 | Isotope-Labeled Compounds |
| HY-100761 | SS28 | 141172-08-9 | Reference compound |
| HY-100762 | Mcl1-IN-11 | 2042211-13-0 | Reference compound |
| HY-100763 | Mcl1-IN-12 | 2042211-12-9 | Reference compound |
| HY-100764 | YUKA1 | 708991-09-7 | Reference compound |
| HY-100765 | BI-0252 | 1818291-27-8 | Reference compound |
| HY-100767 | Guanylyl Imidodiphosphate (trisodium) | 148892-91-5 | Biochemical Assay Reagents |
| HY-100768 | HTHQ | 148081-72-5 | Reference compound |
| HY-100768R | HTHQ (Standard) | 148081-72-5 | Reference Standards |
| HY-100769 | Hypidone (hydrochloride) | 1339058-04-6 | Reference compound |
| HY-100771 | PCC0208009 | 1668565-74-9 | Reference compound |
| HY-100775 | Fezagepras (sodium) | 1254472-97-3 | Reference compound |
| HY-100775A | Fezagepras | 1002101-19-0 | Reference compound |
| HY-100775AR | Fezagepras (Standard) | 1002101-19-0 | Reference Standards |
| HY-100775R | Fezagepras (sodium) (Standard) | 1254472-97-3 | Reference Standards |
| HY-100777 | DACA | 89459-25-6 | Reference compound |
| HY-100777R | DACA (Standard) | 89459-25-6 | Reference Standards |
| HY-100778 | SMM-189 | 1054451-07-8 | Reference compound |
| HY-100779 | Rimacalib | 215174-50-8 | Reference compound |
| HY-100781 | D-AP4 | 78739-01-2 | Reference compound |
| HY-100781A | L-AP4 | 23052-81-5 | Reference compound |
| HY-100781B | L-AP4 (monohydrate) | 2247534-79-6 | Reference compound |
| HY-100782 | DL-AP7 | 85797-13-3 | Reference compound |
| HY-100783 | (-)-Bicuculline (methobromide) | 73604-30-5 | Reference compound |
| HY-100783A | (+)-Bicuculline (methochloride) | 53552-05-9 | Reference compound |
| HY-100783B | Bicuculline (methobromide) | 66016-70-4 | Reference compound |
| HY-100784 | Dihydrokainic acid | 52497-36-6 | Reference compound |
| HY-100784R | Dihydrokainic acid (Standard) | 52497-36-6 | Reference Standards |
| HY-100785 | gamma-DGG | 6729-55-1 | Reference compound |
| HY-100785A | gamma-DGG (acetate) | 2935387-13-4 | Reference compound |
| HY-100786 | DL-AP3 | 5652-28-8 | Reference compound |
| HY-100787 | L-Cysteine S-sulfate (sodium) | 7381-67-1 | Reference compound |
| HY-100788 | 2-PMPA | 173039-10-6 | Reference compound |
| HY-100788C | 2-PMPA (sodium) | 373645-42-2 | Reference compound |
| HY-100788R | 2-PMPA (Standard) | 173039-10-6 | Reference Standards |
| HY-100789 | ON1231320 | 1312471-39-8 | Reference compound |
| HY-10079 | CHS-828 | 200484-11-3 | Reference compound |
| HY-100790 | Ciliobrevin A | 302803-72-1 | Reference compound |
| HY-100791 | NSC23005 (sodium) | 1796596-46-7 | Reference compound |
| HY-100792 | URB602 | 565460-15-3 | Reference compound |
| HY-100792R | URB602 (Standard) | 565460-15-3 | Reference Standards |
| HY-100793 | SR12813 | 126411-39-0 | Reference compound |
| HY-100794 | GR127935 (hydrochloride) | 148642-42-6 | Reference compound |
| HY-100795 | Pirmenol | 68252-19-7 | Reference compound |
| HY-100795A | Pirmenol (hydrochloride) | 61477-94-9 | Reference compound |
| HY-100796 | Guanoclor | 5001-32-1 | Reference compound |
| HY-100797 | (RS)-CPP | 100828-16-8 | Reference compound |
| HY-100798 | Phaclofen | 114012-12-3 | Reference compound |
| HY-100799 | ZAPA (sulfate) | 371962-01-5 | Reference compound |
| HY-10079A | CHS-828 (nicotinate) | 1160589-73-0 | Reference compound |
| HY-10079R | CHS-828 (Standard) | 200484-11-3 | Reference Standards |
| HY-10080 | Teglarinad (chloride) | 432037-57-5 | Reference compound |
| HY-100800 | TACA | 38090-53-8 | Reference compound |
| HY-100801 | L-threo-3-Hydroxyaspartic acid | 7298-99-9 | Reference compound |
| HY-100801A | DL-threo-3-Hydroxyaspartic acid | 4294-45-5 | Peptides |
| HY-100801R | L-threo-3-Hydroxyaspartic acid (Standard) | 7298-99-9 | Reference Standards |
| HY-100802 | Homoquinolinic acid | 490-75-5 | Reference compound |
| HY-100803 | Hypotaurine | 300-84-5 | Natural Products |
| HY-100803R | Hypotaurine (Standard) | 300-84-5 | Reference Standards |
| HY-100804 | L-Cysteinesulfinic acid | 1115-65-7 | Natural Products |
| HY-100804R | L-Cysteinesulfinic acid (Standard) | 1115-65-7 | Reference Standards |
| HY-100805 | D-Glutamic acid | 6893-26-1 | Natural Products |
| HY-100805R | D-Glutamic acid (Standard) | 6893-26-1 | Reference Standards |
| HY-100805S | D-Glutamic acid-d5 | 14341-88-9 | Isotope-Labeled Compounds |
| HY-100805S1 | D-Glutamic acid-13C5,15N | 1202063-56-6 | Isotope-Labeled Compounds |
| HY-100805S2 | D-Glutamic acid-13C5 | 1202063-54-4 | Isotope-Labeled Compounds |
| HY-100806 | Kynurenic acid | 492-27-3 | Natural Products |
| HY-100806R | Kynurenic acid (Standard) | 492-27-3 | Reference Standards |
| HY-100806S | Kynurenic acid-d5 | 350820-13-2 | Isotope-Labeled Compounds |
| HY-100807 | Quinolinic acid | 89-00-9 | Natural Products |
| HY-100807R | Quinolinic acid (Standard) | 89-00-9 | Reference Standards |
| HY-100807S | Quinolinic acid-d3 | 138946-42-6 | Isotope-Labeled Compounds |
| HY-100807S1 | Quinolinic acid-13C7 | 1346642-91-8 | Isotope-Labeled Compounds |
| HY-100807S2 | Quinolinic acid-13C4,15N | | Isotope-Labeled Compounds |
| HY-100808 | D-Serine | 312-84-5 | Natural Products |
| HY-100808R | D-Serine (Standard) | 312-84-5 | Reference Standards |
| HY-100808S | D-Serine-d3 | 1414348-52-9 | Isotope-Labeled Compounds |
| HY-100809 | Guvacine hydrochloride | 6027-91-4 | Natural Products |
| HY-10081 | GS-6201 | 752222-83-6 | Reference compound |
| HY-100810 | Isoguvacine (hydrochloride) | 68547-97-7 | Reference compound |
| HY-100811 | 7-Chlorokynurenic acid | 18000-24-3 | Reference compound |
| HY-100811A | 7-Chlorokynurenic acid (sodium salt) | 1263094-00-3 | Reference compound |
| HY-100811AR | 7-Chlorokynurenic acid (sodium salt) (Standard) | 1263094-00-3 | Reference Standards |
| HY-100811R | 7-Chlorokynurenic acid (Standard) | 18000-24-3 | Reference Standards |
| HY-100812 | 2-Hydroxysaclofen | 117354-64-0 | Reference compound |
| HY-100813 | Saclofen | 125464-42-8 | Reference compound |
| HY-100813R | Saclofen (Standard) | 125464-42-8 | Reference Standards |
| HY-100814 | (R)-CPP | 126453-07-4 | Reference compound |
| HY-100815 | (R)-AMPA | 83654-13-1 | Reference compound |
| HY-100815A | (S)-AMPA | 83643-88-3 | Reference compound |
| HY-100815B | (RS)-AMPA | 77521-29-0 | Reference compound |
| HY-100815BR | (RS)-AMPA (Standard) | 77521-29-0 | Reference Standards |
| HY-100815C | (RS)-AMPA (hydrobromide) | 171259-81-7 | Reference compound |
| HY-100815D | (RS)-AMPA (monohydrate) | 76463-67-7 | Reference compound |
| HY-100815E | (RS)-AMPA (hydrochloride) | 2922283-04-1 | Reference compound |
| HY-100816 | Rbin-1 | 328023-11-6 | Reference compound |
| HY-100817 | Rbin-2 | 2032282-97-4 | Reference compound |
| HY-100818 | Futibatinib | 1448169-71-8 | Reference compound |
| HY-100818R | Futibatinib (Standard) | 1448169-71-8 | Reference Standards |
| HY-10082 | Triapine | 143621-35-6 | Reference compound |
| HY-100820 | Sarizotan | 351862-32-3 | Reference compound |
| HY-100820A | Sarizotan (hydrochloride) | 195068-07-6 | Reference compound |
| HY-100820B | Sarizotan (dihydrochloride) | 177976-12-4 | Reference compound |
| HY-100820R | Sarizotan (Standard) | 351862-32-3 | Reference Standards |
| HY-100821 | 2,4-Dihydroxyphenylacetylasparagine | 111872-98-1 | Natural Products |
| HY-100822 | (R)-(+)-HA-966 | 123931-04-4 | Reference compound |
| HY-100822A | (S)-(-)-HA 966 | 111821-58-0 | Reference compound |
| HY-100823 | (1S,3R)-ACPD | 111900-32-4 | Reference compound |
| HY-100824 | PP2 Analog | 309739-67-1 | Reference compound |
| HY-100825 | OABK (hydrochloride) | 1984862-48-7 | Reference compound |
| HY-100826 | TN1 | 289479-94-3 | Reference compound |
| HY-100827 | Safotibant | 633698-99-4 | Reference compound |
| HY-100828 | BGP-15 | 66611-37-8 | Reference compound |
| HY-10082A | (E)-3-AP | 200933-27-3 | Reference compound |
| HY-10082B | Triapine (hydrochloride) | 216240-62-9 | Reference compound |
| HY-10082S1 | Triapine-d3 | | Isotope-Labeled Compounds |
| HY-100830 | NCB-0846 | 1792999-26-8 | Reference compound |
| HY-100830A | NCB-0970 | 2749881-54-5 | Reference compound |
| HY-100831 | YM-58483 | 223499-30-7 | Reference compound |
| HY-100831R | YM-58483 (Standard) | 223499-30-7 | Reference Standards |
| HY-100832 | UNC3866 | 1872382-47-2 | Peptides |
| HY-100832A | UNC3866 (TFA) | 1872382-48-3 | Peptides |
| HY-100833 | Antibiotic-5d | 251349-54-9 | Reference compound |
| HY-100833R | Antibiotic-5d (Standard) | 251349-54-9 | Reference Standards |
| HY-100834 | 5,7-Dichlorokynurenic acid | 131123-76-7 | Reference compound |
| HY-100834A | 5,7-Dichlorokynurenic acid (sodium) | 1184986-70-6 | Reference compound |
| HY-100834R | 5,7-Dichlorokynurenic acid (Standard) | 131123-76-7 | Reference Standards |
| HY-100835 | N-(4-Hydroxyphenylacetyl)spermine | 130210-32-1 | Reference compound |
| HY-100836 | trans-4-Carboxy-L-proline | 64769-66-0 | Natural Products |
| HY-100837 | 5-Iodowillardiine | 140187-25-3 | Reference compound |
| HY-100838 | cis-α-(Carboxycyclopropyl)glycine | 117857-95-1 | Reference compound |
| HY-100838A | L-CCG-I | 117857-93-9 | Reference compound |
| HY-100839 | (RS)-(Tetrazol-5-yl)glycine | 138199-51-6 | Reference compound |
| HY-10084 | CK0106023 | 336115-72-1 | Reference compound |
| HY-100840 | (S)-4C3HPG | 85148-82-9 | Reference compound |
| HY-100840A | (RS)-4C3HPG | 134052-66-7 | Reference compound |
| HY-100841 | (Rac)-3-Hydroxyphenylglycine | 31932-87-3 | Reference compound |
| HY-100841A | (S)-3-Hydroxyphenylglycine | 71301-82-1 | Reference compound |
| HY-100842 | (R)-3C4HPG | 13861-03-5 | Reference compound |
| HY-100842A | (S)-3C4HPG | 55136-48-6 | Reference compound |
| HY-100843 | L-AP6 | 78944-89-5 | Reference compound |
| HY-100844 | GS-444217 | 1262041-49-5 | Reference compound |
| HY-100845 | Salvinorin A | 83729-01-5 | Reference compound |
| HY-100846 | JQEZ5 | 1913252-04-6 | Reference compound |
| HY-100847 | AZ0108 | 1825345-52-5 | Reference compound |
| HY-100848 | TX1-85-1 | 1603845-32-4 | Reference compound |
| HY-100849 | JAK 3i | 1918238-72-8 | Reference compound |
| HY-100850 | Piperoxan (hydrochloride) | 135-87-5 | Reference compound |
| HY-100851 | LY-272015 | 159730-07-1 | Reference compound |
| HY-100851A | LY-272015 (hydrochloride) | 172895-15-7 | Reference compound |
| HY-100852 | ER-000444793 | 792957-74-5 | Reference compound |
| HY-100853 | IWP-O1 | 2074607-48-8 | Reference compound |
| HY-100855 | DC_C66 | 108181-00-6 | Reference compound |
| HY-100856 | PCO371 | 1613373-33-3 | Reference compound |
| HY-100857 | PrPSc-IN-1 | 1315475-30-9 | Dye Reagents |
| HY-100858 | PP7 | 433238-84-7 | Reference compound |
| HY-100859 | LSD1-IN-5 | 2035912-55-9 | Reference compound |
| HY-100860 | LSD1-IN-6 | 2035912-43-5 | Reference compound |
| HY-100861 | C-11 | 2007965-97-9 | ADC Related |
| HY-100862 | BRCA1-IN-2 | 1622262-55-8 | Reference compound |
| HY-100863 | BRCA1-IN-1 | 1622262-74-1 | Reference compound |
| HY-100864 | mPGES1-IN-3 | 1469976-70-2 | Reference compound |
| HY-100865 | BPR1K871 | 2443767-35-7 | Reference compound |
| HY-100866 | F1324 | 2607975-44-8 | Peptides |
| HY-100866A | F1324 (TFA) | | Peptides |
| HY-100866B | F1324 (acetate) | | Peptides |
| HY-100867 | Mivavotinib | 1312691-33-0 | Reference compound |
| HY-100867A | Mivavotinib (monohydrochloride) | 1952251-28-3 | Reference compound |
| HY-100869 | MM-589 | 2097887-20-0 | Reference compound |
| HY-100869A | MM-589 (TFA) | 2253167-09-6 | Reference compound |
| HY-100869B | MM-589 (racemic mixture ) (TFA) | | Reference compound |
| HY-10087 | Navitoclax | 923564-51-6 | Reference compound |
| HY-100870 | Obefazimod | 1258453-75-6 | Reference compound |
| HY-100871 | WT-161 | 1206731-57-8 | Reference compound |
| HY-100872 | KRIBB11 | 342639-96-7 | Reference compound |
| HY-100873 | PF-1355 | 1435467-38-1 | Reference compound |
| HY-100874 | N3-PEG3-vc-PAB-MMAE | | ADC Related |
| HY-100875 | Bisantrene | 78186-34-2 | Reference compound |
| HY-100875A | Bisantrene (dihydrochloride) | 71439-68-4 | Reference compound |
| HY-100875R | Bisantrene (Standard) | 78186-34-2 | Reference Standards |
| HY-100876 | GGTI298 | 180977-44-0 | Reference compound |
| HY-100877 | GCN2-IN-1 | 1448693-69-3 | Reference compound |
| HY-10087A1 | Navitoclax (dihydrochloride) | 1093851-28-5 | Reference compound |
| HY-10087R | Navitoclax (Standard) | 923564-51-6 | Reference Standards |
| HY-10087S | Navitoclax-d8 | 1217620-38-6 | Isotope-Labeled Compounds |
| HY-10088 | Zibotentan | 186497-07-4 | Reference compound |
| HY-100881 | TUG-891 | 1374516-07-0 | Reference compound |
| HY-100881R | TUG-891 (Standard) | 1374516-07-0 | Reference Standards |
| HY-100882 | ONO-7300243 | 638132-34-0 | Reference compound |
| HY-100885 | Acelarin | 840506-29-8 | Reference compound |
| HY-100886 | BAY1082439 | 1375469-38-7 | Reference compound |
| HY-100887 | Piperazine Erastin | 1538593-71-3 | Reference compound |
| HY-100888 | Simurosertib | 1330782-76-7 | Reference compound |
| HY-100888A | (R)-Simurosertib | 1330782-69-8 | Reference compound |
| HY-10088R | Zibotentan (Standard) | 186497-07-4 | Reference Standards |
| HY-100891 | CD80-IN-3 | 486449-65-4 | Reference compound |
| HY-100892 | MX69 | 1005264-47-0 | Reference compound |
| HY-100894 | Biotin-VAD-FMK | 1135688-15-1 | Biochemical Assay Reagents |
| HY-100895 | SAR-20347 | 1450881-55-6 | Reference compound |
| HY-100897 | Sulodexide | 57821-29-1 | Reference compound |
| HY-100898 | OGT 2115 | 853929-59-6 | Reference compound |
| HY-100899 | Heparastatin | 153758-25-9 | Reference compound |
| HY-100900 | ML364 | 1991986-30-1 | Reference compound |
| HY-100901 | CDD3505 | 173865-33-3 | Reference compound |
| HY-100902 | CDD3506 | 197913-15-8 | Reference compound |
| HY-100903 | Norbinaltorphimine dihydrochloride | 113158-34-2 | Reference compound |
| HY-100904 | RX 801077 (hydrochloride) | 89196-95-2 | Reference compound |
| HY-100904A | RX 801077 | 72583-92-7 | Reference compound |
| HY-100906 | 1,1-Dimethyl-4-acetylpiperazinium (iodide) | 75667-84-4 | Reference compound |
| HY-100907 | (±)-Acetylcarnitine (chloride) | 2504-11-2 | Reference compound |
| HY-100908 | N-Acetyltryptamine | 1016-47-3 | Reference compound |
| HY-100908R | N-Acetyltryptamine (Standard) | 1016-47-3 | Reference Standards |
| HY-100910 | W-13 (hydrochloride) | 88519-57-7 | Reference compound |
| HY-100911 | W-5 (hydrochloride) | 61714-25-8 | Reference compound |
| HY-100912 | W-7 (hydrochloride) | 61714-27-0 | Reference compound |
| HY-100913 | W-7 (isomer hydrochloride) | 69762-85-2 | Reference compound |
| HY-100914 | A-7 (hydrochloride) | 79127-24-5 | Reference compound |
| HY-100915 | SKF 97541 | 127729-35-5 | Reference compound |
| HY-100916 | Arecaidine-propargyl ester (tosylate) | 147202-94-6 | Reference compound |
| HY-100919 | Ambenonium (chloride) | 115-79-7 | Reference compound |
| HY-100919R | Ambenonium (chloride) (Standard) | 115-79-7 | Reference Standards |
| HY-100920 | Arcaine (sulfate) | 14923-17-2 | Reference compound |
| HY-100921 | Spaglumic Acid | 3106-85-2 | Natural Products |
| HY-100921A | Spaglumic Acid (trisodium) | 57096-28-3 | Reference compound |
| HY-100921R | Spaglumic Acid (Standard) | 3106-85-2 | Reference Standards |
| HY-100922 | N-Acetylglycyl-D-glutamic acid | 135701-69-8 | Reference compound |
| HY-100923 | H-9 (Dihydrochloride) | 116700-36-8 | Reference compound |
| HY-100924 | β-CCB | 84454-35-3 | Reference compound |
| HY-100925 | Binospirone (hydrochloride) | 102908-60-1 | Reference compound |
| HY-100927 | Ro 20-1724 | 29925-17-5 | Reference compound |
| HY-100927R | Ro 20-1724 (Standard) | 29925-17-5 | Reference Standards |
| HY-100928 | YS 035 (hydrochloride) | 89805-39-0 | Reference compound |
| HY-100929 | GBR-12879 (dihydrochloride) | 67469-45-8 | Reference compound |
| HY-100930 | L-693403 (maleate) | 207455-21-8 | Reference compound |
| HY-100931 | SC-10 | 102649-79-6 | Reference compound |
| HY-100932 | ML-9 | 105637-50-1 | Reference compound |
| HY-100932A | ML-9 (Free Base) | 110448-31-2 | Reference compound |
| HY-100933 | MY-5445 | 78351-75-4 | Reference compound |
| HY-100934 | SC-9 | 102649-78-5 | Reference compound |
| HY-100935 | Cimaterol | 54239-37-1 | Reference compound |
| HY-100935R | Cimaterol (Standard) | 54239-37-1 | Reference Standards |
| HY-100935S | Cimaterol-d7 | 1228182-44-2 | Isotope-Labeled Compounds |
| HY-100936 | Etazolate (hydrochloride) | 35838-58-5 | Reference compound |
| HY-100936R | Etazolate (hydrochloride) (Standard) | 35838-58-5 | Reference Standards |
| HY-100937 | DPCPX | 102146-07-6 | Reference compound |
| HY-100937R | DPCPX (Standard) | 102146-07-6 | Reference Standards |
| HY-100937S | DPCPX-d4 | | Isotope-Labeled Compounds |
| HY-100938 | m-CPBG (hydrochloride) | 2113-05-5 | Reference compound |
| HY-100939 | 4-Chlorophenylguanidine (hydrochloride) | 14279-91-5 | Reference compound |
| HY-100940 | 6-Chloromelatonin | 63762-74-3 | Reference compound |
| HY-100941 | CCCP | 555-60-2 | Reference compound |
| HY-100941R | CCCP (Standard) | 555-60-2 | Reference Standards |
| HY-100942 | 5-Carboxamidotryptamine (maleate) | 74885-72-6 | Reference compound |
| HY-100943 | Cinanserin (hydrochloride) | 54-84-2 | Reference compound |
| HY-100944 | Conduritol B epoxide | 6090-95-5 | Reference compound |
| HY-100945 | Nitrocaramiphen (hydrochloride) | 98636-73-8 | Reference compound |
| HY-100946 | CEP-40783 | 1437321-24-8 | Reference compound |
| HY-100947 | VH-298 | 2097381-85-4 | Reference compound |
| HY-100947A | cis VH-298 | 2097381-86-5 | Reference compound |
| HY-100948 | ATM-3507 | 1861449-70-8 | Reference compound |
| HY-100948B | ATM-3507 (trihydrochloride) | 2438679-30-0 | Reference compound |
| HY-100949 | EC330 | 2016795-77-8 | Reference compound |
| HY-10095 | Olcegepant | 204697-65-4 | Reference compound |
| HY-100950 | ABC1183 | 1042735-18-1 | Reference compound |
| HY-100951 | Beaucage reagent | 66304-01-6 | Reference compound |
| HY-100952 | Nifenalol (hydrochloride) | 5704-60-9 | Reference compound |
| HY-100953 | CYM-5520 | 1449747-00-5 | Reference compound |
| HY-100954 | 2,4-Diamino-6-hydroxypyrimidine | 56-06-4 | Reference compound |
| HY-100954R | 2,4-Diamino-6-hydroxypyrimidine (Standard) | 56-06-4 | Reference Standards |
| HY-100955 | DL-Decanoylcarnitine (chloride) | 18822-87-2 | Reference compound |
| HY-100956 | Flurofamide | 70788-28-2 | Reference compound |
| HY-100957 | Dilazep (dihydrochloride) | 20153-98-4 | Reference compound |
| HY-100957R | Dilazep (dihydrochloride) (Standard) | 20153-98-4 | Reference Standards |
| HY-100958 | 4-DAMP | 1952-15-4 | Reference compound |
| HY-100959 | 3,5-Dinitrocatechol | 7659-29-2 | Reference compound |
| HY-100959R | 3,5-Dinitrocatechol (Standard) | 7659-29-2 | Reference Standards |
| HY-10095A | Olcegepant (hydrochloride) | 586368-06-1 | Reference compound |
| HY-10096 | TCS2002 | 1005201-24-0 | Reference compound |
| HY-100960 | Dioctanoylglycol | 627-86-1 | Reference compound |
| HY-100961 | NPC 200 | 85872-53-3 | Reference compound |
| HY-100962 | (E)-AG 99 | 122520-85-8 | Reference compound |
| HY-100962A | AG 99 | 118409-59-9 | Reference compound |
| HY-100963 | U-54494A | 112465-94-8 | Reference compound |
| HY-100964S | N(1),N(12)-Diethylspermine-d10 (tetrahydrochloride) | | Isotope-Labeled Compounds |
| HY-100965 | Diphenyleneiodonium chloride | 4673-26-1 | Reference compound |
| HY-100966 | BD-1008 (dihydrobromide) | 138356-09-9 | Reference compound |
| HY-100966S | BD-1008-d5 (dihydrobromide) | | Isotope-Labeled Compounds |
| HY-100967 | SKF 91488 (dihydrochloride) | 68941-21-9 | Reference compound |
| HY-100968 | GBR 12783 (dihydrochloride) | 67469-75-4 | Reference compound |
| HY-100969 | EBPC | 4450-98-0 | Reference compound |
| HY-100970 | 4F 4PP (oxalate) | 144734-36-1 | Reference compound |
| HY-100971 | Spiramide | 510-74-7 | Natural Products |
| HY-100972 | ARV-771 | 1949837-12-0 | Reference compound |
| HY-100973 | Adenosine 5′-diphosphoribose | 20762-30-5 | Reference compound |
| HY-100973A | Adenosine 5′-diphosphoribose (sodium) | 68414-18-6 | Reference compound |
| HY-100973AR | Adenosine 5′-diphosphoribose (sodium) (Standard) | 68414-18-6 | Reference Standards |
| HY-100973R | Adenosine 5′-diphosphoribose (Standard) | 20762-30-5 | Reference Standards |
| HY-100975 | TB5 | 948841-07-4 | Reference compound |
| HY-100976 | LUF6283 | 92933-48-7 | Reference compound |
| HY-100977 | Dimethoxycurcumin | 160096-59-3 | Reference compound |
| HY-100977S | Dimethoxycurcumin-d6 | 3006902-95-7 | Isotope-Labeled Compounds |
| HY-100978 | (±)-Hexanoylcarnitine (chloride) | 6920-35-0 | Reference compound |
| HY-100979 | W-84 (dibromide) | 21093-51-6 | Reference compound |
| HY-100980 | HEAT (hydrochloride) | 30007-39-7 | Reference compound |
| HY-100981 | MR-16728 (hydrochloride) | 207403-36-9 | Reference compound |
| HY-100982 | (E)-4-Hydroxycrotonic acid | 24587-49-3 | Reference compound |
| HY-100983 | Protein kinase inhibitor H-7 (dihydrochloride) | 108930-17-2 | Reference compound |
| HY-100983R | Protein kinase inhibitor H-7 (dihydrochloride) (Standard) | 108930-17-2 | Reference Standards |
| HY-100984 | HA-100 | 84468-24-6 | Reference compound |
| HY-100984A | HA-100 (hydrochloride) | 141543-63-7 | Reference compound |
| HY-100985 | IPAG | 193527-91-2 | Reference compound |
| HY-100986 | L-NIO (dihydrochloride) | 159190-44-0 | Reference compound |
| HY-100986B | L-NIO | 36889-13-1 | Reference compound |
| HY-100987 | Lauroylcarnitine (chloride) | 14919-37-0 | Reference compound |
| HY-100990 | MMPX | 78033-08-6 | Reference compound |
| HY-100991 | FG 7142 | 78538-74-6 | Reference compound |
| HY-100991R | FG 7142 (Standard) | 78538-74-6 | Reference Standards |
| HY-100993 | α-Methylserotonin (maleate) | 97469-12-0 | Reference compound |
| HY-100994 | N-Methylquipazine (maleate) | 171205-17-7 | Reference compound |
| HY-100996 | 10074-G5 | 413611-93-5 | Reference compound |
| HY-100997 | Chloroorienticin A | 118395-73-6 | Reference compound |
| HY-100998 | Metaphit | 96316-00-6 | Reference compound |
| HY-100998A | Metaphit (methylsulfate) | 99287-12-4 | Reference compound |
| HY-100999 | (R)-(-)-α-Methylhistamine (dihydrobromide) | 868698-49-1 | Reference compound |
| HY-101000 | Clazuril | 101831-36-1 | Reference compound |
| HY-101000R | Clazuril (Standard) | 101831-36-1 | Reference Standards |
| HY-101002 | Sarcosinamide chloroethylnitrosourea | 81965-43-7 | Reference compound |
| HY-101004 | PCA 4248 | 123875-01-4 | Reference compound |
| HY-101005 | N-Methylhistamine (dihydrochloride) | 16503-22-3 | Reference compound |
| HY-101006 | Methyl 2,5-dihydroxycinnamate | 63177-57-1 | Reference compound |
| HY-101006R | Methyl 2,5-dihydroxycinnamate (Standard) | 63177-57-1 | Reference Standards |
| HY-101007A | (+)-Tyrphostin B44 | 133550-37-5 | Reference compound |
| HY-101009 | Methiothepin (maleate) | 19728-88-2 | Reference compound |
| HY-101010 | Methylfurmethide (iodide) | 1197-60-0 | Reference compound |
| HY-101011 | Naloxonazine (dihydrochloride) | 880759-65-9 | Reference compound |
| HY-101012 | NPPB | 107254-86-4 | Reference compound |
| HY-101012R | NPPB (Standard) | 107254-86-4 | Reference Standards |
| HY-101013 | D-SNAP | 79032-48-7 | Dye Reagents |
| HY-101014 | Octanoylcarnitine (chloride) | 14919-35-8 | Reference compound |
| HY-101015 | (2E)-OBAA | 221632-26-4 | Reference compound |
| HY-101015A | OBAA | 134531-42-3 | Reference compound |
| HY-101016 | 17-ODYA | 34450-18-5 | Reference compound |
| HY-101016R | 17-ODYA (Standard) | 34450-18-5 | Reference Standards |
| HY-101017 | Palmitoylcarnitine (chloride) | 6865-14-1 | Reference compound |
| HY-101017A | D-Palmitoylcarnitine (chloride) | 28330-02-1 | Natural Products |
| HY-101017R | Palmitoylcarnitine (chloride) (Standard) | 6865-14-1 | Reference Standards |
| HY-101018 | Propionyl-DL-carnitine (chloride) | 18828-58-5 | Reference compound |
| HY-101018R | Propionyl-DL-carnitine (chloride) (Standard) | 18828-58-5 | Reference Standards |
| HY-101019 | Ossirene | 106566-58-9 | Reference compound |
| HY-101020 | Picolinamide | 1452-77-3 | Reference compound |
| HY-101020R | Picolinamide (Standard) | 1452-77-3 | Reference Standards |
| HY-101021 | Ascochlorin | 26166-39-2 | Natural Products |
| HY-101022 | CXCR2-IN-1 | 1873376-49-8 | Reference compound |
| HY-101023 | MK-8617 | 1187990-87-9 | Reference compound |
| HY-101024 | PF-06263276 | 1421502-62-6 | Reference compound |
| HY-101025 | Nrf2-IN-1 | 1610022-76-8 | Reference compound |
| HY-101026 | CCT251236 | 1693731-40-6 | Reference compound |
| HY-101027 | GSK 4027 | 2079896-25-4 | Reference compound |
| HY-101027A | GSK4028 | 2079886-19-2 | Reference compound |
| HY-101028 | ZINC13466751 | 117953-17-0 | Reference compound |
| HY-101029 | MBM-55 | 2083622-09-5 | Reference compound |
| HY-101029A | MBM-55S | 2083624-07-9 | Reference compound |
| HY-101030 | MBM-17 | 2083621-90-1 | Reference compound |
| HY-101030A | MBM-17S | 2083621-91-2 | Reference compound |
| HY-101031 | c-Met-IN-1 | 2084836-84-8 | Reference compound |
| HY-101032 | RIPA-56 | 1956370-21-0 | Reference compound |
| HY-101033 | GPR35 agonist 1 | 2079880-92-3 | Reference compound |
| HY-101034 | CHMFL-ABL/KIT-155 | 2081093-21-0 | Reference compound |
| HY-101035 | LOM612 | 2173232-79-4 | Reference compound |
| HY-101036 | Choline (bitartrate) | 87-67-2 | Natural Products |
| HY-101036R | Choline (bitartrate) (Standard) | 87-67-2 | Reference Standards |
| HY-101037 | Sarcosine | 107-97-1 | Natural Products |
| HY-101037R | Sarcosine (Standard) | 107-97-1 | Reference Standards |
| HY-101037S | Sarcosine-15N | | Isotope-Labeled Compounds |
| HY-101037S1 | Sarcosine-d3 | 118685-91-9 | Isotope-Labeled Compounds |
| HY-101038 | ZK 756326 | 874911-96-3 | Reference compound |
| HY-101038A | ZK756326 (dihydrochloride) | 1780259-94-0 | Reference compound |
| HY-101039 | AR-M 1000390 | 209808-01-5 | Reference compound |
| HY-101039A | AR-M 1000390 (hydrochloride) | 209808-47-9 | Reference compound |
| HY-101040 | Telacebec | 1334719-95-7 | Reference compound |
| HY-101040A | Telacebec (ditosylate) | 1566517-83-6 | Reference compound |
| HY-101040R | Telacebec (Standard) | 1334719-95-7 | Reference Standards |
| HY-101041 | (E)-AG 556 | 133550-41-1 | Reference compound |
| HY-101042 | AG-494 | 133550-35-3 | Reference compound |
| HY-101043 | 4-PPBP (maleate) | 201216-39-9 | Reference compound |
| HY-101044 | PPADS (tetrasodium) | 192575-19-2 | Reference compound |
| HY-101045 | AT-112 | 139047-55-5 | Reference compound |
| HY-101046 | Azaperone (dimaleate) | 150323-78-7 | Reference compound |
| HY-101047 | D-erythro-Sphingosine | 123-78-4 | Natural Products |
| HY-101047R | D-erythro-Sphingosine (Standard) | 123-78-4 | Reference Standards |
| HY-101047S | D-erythro-Sphingosine-d7 | 1246304-34-6 | Isotope-Labeled Compounds |
| HY-101047S1 | D-erythro-Sphingosine-13C2,d2 | 2692623-81-5 | Isotope-Labeled Compounds |
| HY-101048 | Synthalin A (sulfate) | 182285-12-7 | Reference compound |
| HY-101049 | CGS 12066 (dimaleate) | 109028-10-6 | Reference compound |
| HY-101050 | Tropanserin | 85181-40-4 | Reference compound |
| HY-101051 | 2-TEDC | 132465-10-2 | Reference compound |
| HY-101052 | HTMT (dimaleate) | 195867-54-0 | Reference compound |
| HY-101053 | Src Inhibitor 1 | 179248-59-0 | Reference compound |
| HY-101054 | NQ301 | 130089-98-4 | Reference compound |
| HY-101055 | Kinetin riboside | 4338-47-0 | Reference compound |
| HY-101055R | Kinetin riboside (Standard) | 4338-47-0 | Reference Standards |
| HY-101055S | Kinetin riboside-d5 | | Isotope-Labeled Compounds |
| HY-101056 | Brensocatib | 1802148-05-5 | Reference compound |
| HY-101058 | PD1-PDL1-IN 1 | 2005454-12-4 | Reference compound |
| HY-101058A | PD1-PDL1-IN 1 (TFA) | | Reference compound |
| HY-101059 | FGIN 1-27 | 142720-24-9 | Reference compound |
| HY-101059R | FGIN 1-27 (Standard) | 142720-24-9 | Reference Standards |
| HY-101060 | FGIN 1-43 | 145040-29-5 | Reference compound |
| HY-101061 | 2-MPMDQ | 149847-77-8 | Reference compound |
| HY-101062 | 3-AQC | 201216-42-4 | Reference compound |
| HY-101063 | Amthamine (dihydrobromide) | 142457-00-9 | Reference compound |
| HY-101064 | Fmoc-leucine | 35661-60-0 | Reference compound |
| HY-101064S | Fmoc-leucine-13C | 202114-53-2 | Isotope-Labeled Compounds |
| HY-101064S1 | Fmoc-leucine-13C6,15N | 1163133-36-5 | Isotope-Labeled Compounds |
| HY-101064S2 | Fmoc-leucine-d3 | 538372-74-6 | Isotope-Labeled Compounds |
| HY-101064S3 | Fmoc-leucine-d10 | 1190594-22-9 | Isotope-Labeled Compounds |
| HY-101064S4 | Fmoc-leucine-15N | 200937-57-1 | Isotope-Labeled Compounds |
| HY-101065 | AJ-76 (hydrochloride) | 85378-82-1 | Reference compound |
| HY-101068 | TOFA | 54857-86-2 | Reference compound |
| HY-101069 | Y-26763 | 127408-31-5 | Reference compound |
| HY-101070 | SMCC-DM1 | 1228105-51-8 | ADC Related |
| HY-101071 | (S)-Monastrol | 254753-54-3 | Reference compound |
| HY-101071A | Monastrol | 329689-23-8 | Reference compound |
| HY-101073 | Salermide | 1105698-15-4 | Reference compound |
| HY-101074 | UCM 608 | 151889-03-1 | Reference compound |
| HY-101075 | L-690330 | 142523-38-4 | Reference compound |
| HY-101075A | L-690330 (hydrate) | 2930564-26-2 | Reference compound |
| HY-101076 | L-690488 | 142523-14-6 | Reference compound |
| HY-101077 | Iso-PPADS (tetrasodium) | 207572-67-6 | Reference compound |
| HY-101078 | (±)-Epibatidine | 148152-66-3 | Reference compound |
| HY-101078A | (±)-Epibatidine (dihydrochloride) | 162885-01-0 | Natural Products |
| HY-101079 | BRL 52537 (hydrochloride) | 112282-24-3 | Reference compound |
| HY-10108 | LY294002 | 154447-36-6 | Reference compound |
| HY-101080 | 3'-Fluorobenzylspiperone (maleate) | 1135278-61-3 | Reference compound |
| HY-101082 | N6,2′-O-Dimethyladenosine | 57817-83-1 | Reference compound |
| HY-101083 | BDA-366 | 1909226-00-1 | Reference compound |
| HY-101083A | (Rac)-BDA-366 | 142645-19-0 | Reference compound |
| HY-101084 | NSC 228155 | 113104-25-9 | Reference compound |
| HY-101085 | SKL2001 | 909089-13-0 | Reference compound |
| HY-101085G | SKL2001 (GMP) | 909089-13-0 | GMP Small Molecules |
| HY-101086 | Acetylcholine (iodide) | 2260-50-6 | Natural Products |
| HY-101086R | Acetylcholine (iodide) (Standard) | 2260-50-6 | Reference Standards |
| HY-101087 | Benzenesulphonamide | 98-10-2 | Reference compound |
| HY-101087R | Benzenesulphonamide (Standard) | 98-10-2 | Reference Standards |
| HY-101088 | CeMMEC13 | 1790895-25-8 | Reference compound |
| HY-101089 | RHPS4 | 390362-78-4 | Reference compound |
| HY-10108A | LY294002 (hydrochloride) | 934389-88-5 | Reference compound |
| HY-10108AR | LY294002 (hydrochloride) (Standard) | 934389-88-5 | Reference Standards |
| HY-10108R | LY294002 (Standard) | 154447-36-6 | Reference Standards |
| HY-10109 | AS-605240 | 648450-29-7 | Reference compound |
| HY-101090 | KYA1797K | 1956356-56-1 | Reference compound |
| HY-101091 | Importazole | 662163-81-7 | Reference compound |
| HY-101092 | QS-21 | 141256-04-4 | Natural Products |
| HY-101093 | CA-170 | 1673534-76-3 | Reference compound |
| HY-101093B | PD-1-IN-20 | | Reference compound |
| HY-101094 | Ocaperidone | 129029-23-8 | Reference compound |
| HY-101096 | Suvecaltamide | 953778-58-0 | Reference compound |
| HY-101097 | PD-1-IN-17 | 1673560-66-1 | Reference compound |
| HY-101097A | PD-1-IN-17 (TFA) | | Reference compound |
| HY-101098 | PD-1-IN-18 | 1673534-97-8 | Reference compound |
| HY-10110 | IC-87114 | 371242-69-2 | Reference compound |
| HY-101100 | Anpirtoline (hydrochloride) | 99201-87-3 | Reference compound |
| HY-101100A | Anpirtoline | 98330-05-3 | Reference compound |
| HY-101101 | L-701252 | 151057-13-5 | Reference compound |
| HY-101102 | 7-Hydroxy-DPAT (hydrobromide) | 76135-30-3 | Reference compound |
| HY-101103 | HP-β-CD | 128446-35-5 | Biochemical Assay Reagents |
| HY-101105 | SB-224289 | 180083-23-2 | Reference compound |
| HY-101105A | SB-224289 (hydrochloride) | 180084-26-8 | Reference compound |
| HY-101106 | AR7 | 80306-38-3 | Reference compound |
| HY-101108 | Tazarotenic acid | 118292-41-4 | Reference compound |
| HY-101108R | Tazarotenic acid (Standard) | 118292-41-4 | Reference Standards |
| HY-101108S | Tazarotenic acid-d6 | 1794760-38-5 | Isotope-Labeled Compounds |
| HY-101108S1 | Tazarotenic acid-13C2,d2 | 1309935-88-3 | Isotope-Labeled Compounds |
| HY-101109 | Sodium ionophore III | 81686-22-8 | Reference compound |
| HY-10110R | IC-87114 (Standard) | 371242-69-2 | Reference Standards |
| HY-10111 | TG100-115 | 677297-51-7 | Reference compound |
| HY-101111 | PF-06840003 | 198474-05-4 | Reference compound |
| HY-101112 | Okicenone | 137018-54-3 | Natural Products |
| HY-101114 | LAS191954 | 1403947-26-1 | Reference compound |
| HY-101115 | PI3K-IN-6 | 1842380-77-1 | Reference compound |
| HY-101116 | GLP-1R Antagonist 1 | 488097-06-9 | Reference compound |
| HY-101117 | EED226 | 2083627-02-3 | Reference compound |
| HY-101119 | GLL398 | 2077980-80-2 | Reference compound |
| HY-101120 | 666-15 | 1433286-70-4 | Reference compound |
| HY-101121 | NI-42 | 1884640-99-6 | Reference compound |
| HY-101122 | LX2761 | 1610954-97-6 | Reference compound |
| HY-101124 | Rodatristat ethyl | 1673571-51-1 | Reference compound |
| HY-101125 | L-Moses | 2079885-05-3 | Reference compound |
| HY-101125A | L-Moses (dihydrochloride) | 2922480-38-2 | Reference compound |
| HY-101125B | D-Moses | 2084850-77-9 | Reference compound |
| HY-101126 | TP-3654 | 1361951-15-6 | Reference compound |
| HY-101127 | SGD-1882 | 1222490-34-7 | ADC Related |
| HY-101128 | Bicyclomycin benzoate | 37134-40-0 | Reference compound |
| HY-101128R | Bicyclomycin benzoate (Standard) | 37134-40-0 | Reference Standards |
| HY-101130 | PNU-74654 | 113906-27-7 | Reference compound |
| HY-101131 | Dansyl glutathione | 75017-02-6 | Reference compound |
| HY-101132 | VB-201 | 630112-41-3 | Reference compound |
| HY-101139 | Xanthine amine congener | 96865-92-8 | Reference compound |
| HY-101139A | Xanthine amine congener (hydrochloride) | 1783977-95-6 | Reference compound |
| HY-101139AR | Xanthine amine congener (hydrochloride) (Standard) | 1783977-95-6 | Reference Standards |
| HY-101139B | Xanthine amine congener (trihydrochloride) | 2459963-12-1 | Reference compound |
| HY-10114 | TGX-221 | 663619-89-4 | Reference compound |
| HY-101140 | KI696 | 1799974-70-1 | Reference compound |
| HY-101140A | KI696 isomer | 1799974-69-8 | Reference compound |
| HY-101141 | sulfo-SPDB-DM4 | 1626359-59-8 | ADC Related |
| HY-101143 | PGMI-004A | 1313738-90-7 | Reference compound |
| HY-101144 | RSM-932A | 850807-63-5 | Reference compound |
| HY-101146 | SF2523 | 1174428-47-7 | Reference compound |
| HY-101147 | YKL-05-099 | 1936529-65-5 | Reference compound |
| HY-10114R | TGX-221 (Standard) | 663619-89-4 | Reference Standards |
| HY-10115 | PI-103 | 371935-74-9 | Reference compound |
| HY-101150 | DGN462 | 1394079-41-4 | ADC Related |
| HY-101150A | sulfo-DGN462 (sodium) | 1401203-09-5 | ADC Related |
| HY-101151 | sulfo-SPDB | 1193111-39-5 | ADC Related |
| HY-101152 | SG3199-Val-Ala-PAB | 1595275-61-8 | ADC Related |
| HY-101153 | MC-Val-Ala-OH | 1342211-31-7 | ADC Related |
| HY-101157 | Propargyl-PEG5-acid | 1245823-51-1 | ADC Related |
| HY-101159 | Mal-amido-PEG8-C2-acid | 1334177-86-4 | ADC Related |
| HY-10115A | PI-103 (Hydrochloride) | 371935-79-4 | Reference compound |
| HY-10115AR | PI-103 (Hydrochloride) (Standard) | 371935-79-4 | Reference Standards |
| HY-10115R | PI-103 (Standard) | 371935-74-9 | Reference Standards |
| HY-10116 | PI-540 | 885616-78-4 | Reference compound |
| HY-101160 | SG2057 | 260417-62-7 | Reference compound |
| HY-101161 | SG3199 | 1595275-71-0 | ADC Related |
| HY-101162 | SGD-1910 | 1342820-51-2 | ADC Related |
| HY-101164 | MAP4 | 157381-42-5 | Reference compound |
| HY-101165 | Cyclothiazide | 2259-96-3 | Reference compound |
| HY-101165R | Cyclothiazide (Standard) | 2259-96-3 | Reference Standards |
| HY-101167 | Aminopotentidine | 140873-26-3 | Reference compound |
| HY-101169 | Tetrindole (mesylate) | 170964-68-8 | Reference compound |
| HY-101170 | BU224 (hydrochloride) | 205437-64-5 | Reference compound |
| HY-101170R | BU224 (hydrochloride) (Standard) | 205437-64-5 | Reference Standards |
| HY-101172 | RS 23597-190 | 149719-06-2 | Reference compound |
| HY-101173 | Imetit (dihydrobromide) | 32385-58-3 | Reference compound |
| HY-101175 | 3-Bromo-7-nitroindazole | 74209-34-0 | Reference compound |
| HY-101176 | 2-Iodomelatonin | 93515-00-5 | Reference compound |
| HY-101176R | 2-Iodomelatonin (Standard) | 93515-00-5 | Reference Standards |
| HY-101178 | L-689560 | 139051-78-8 | Reference compound |
| HY-101179 | Tesmilifene (fumarate) | 1185241-83-1 | Reference compound |
| HY-101179R | Tesmilifene (fumarate) (Standard) | 1185241-83-1 | Reference Standards |
| HY-10118 | Filibuvir | 877130-28-4 | Reference compound |
| HY-101180 | C2 Ceramide | 3102-57-6 | Reference compound |
| HY-101181 | THK-5105 | 1374107-46-6 | Reference compound |
| HY-101182 | THK-5117 | 1374107-54-6 | Reference compound |
| HY-101183 | THK5351 | 1707147-26-9 | Biochemical Assay Reagents |
| HY-101183A | THK5351 (R enantiomer) | 2101218-44-2 | Reference compound |
| HY-101184 | T807 | 1415379-56-4 | Reference compound |
| HY-101184R | T807 (Standard) | 1415379-56-4 | Reference Standards |
| HY-101185 | T808 | 1320211-61-7 | Reference compound |
| HY-101186 | MK-6240 | 1841078-87-2 | Reference compound |
| HY-101188 | INCB38579 | 1246207-65-7 | Reference compound |
| HY-101189 | JNJ-39758979 | 1046447-90-8 | Reference compound |
| HY-101189B | JNJ-39758979 (dihydrochloride) | | Reference compound |
| HY-10119 | Vorapaxar | 618385-01-6 | Reference compound |
| HY-101190 | Volixibat | 1025216-57-2 | Reference compound |
| HY-101191 | Ecteinascidin 770 | 114899-80-8 | Natural Products |
| HY-101192 | GSK682753A | 1334294-76-6 | Reference compound |
| HY-101193 | Zinc Protoporphyrin | 15442-64-5 | Reference compound |
| HY-101193R | Zinc Protoporphyrin (Standard) | 15442-64-5 | Reference Standards |
| HY-101194 | Tin protoporphyrin IX dichloride | 14325-05-4 | Reference compound |
| HY-101195 | DL-erythro-Dihydrosphingosine | 3102-56-5 | Reference compound |
| HY-101196 | PG 9 (maleate) | 155649-00-6 | Reference compound |
| HY-101197 | SM-21 (maleate) | 155059-42-0 | Reference compound |
| HY-101198 | Clobenpropit (dihydrobromide) | 145231-35-2 | Reference compound |
| HY-101199 | N-Benzylnaltrindole (hydrochloride) | 1206487-81-1 | Reference compound |
| HY-10119A | Vorapaxar (sulfate) | 705260-08-8 | Reference compound |
| HY-10119AR | Vorapaxar (sulfate) (Standard) | 705260-08-8 | Reference Standards |
| HY-10119R | Vorapaxar (Standard) | 618385-01-6 | Reference Standards |
| HY-10119S | Vorapaxar-d5 | | Isotope-Labeled Compounds |
| HY-101200 | Linsidomine (hydrochloride) | 16142-27-1 | Reference compound |
| HY-101200R | Linsidomine (hydrochloride) (Standard) | 16142-27-1 | Reference Standards |
| HY-101202 | SNC80 | 156727-74-1 | Reference compound |
| HY-101202A | (Rac)-SNC80 | 1217643-87-2 | Reference compound |
| HY-101203 | GJ103 | 1459687-89-8 | Reference compound |
| HY-101203A | GJ103 (sodium) | 1459687-96-7 | Reference compound |
| HY-101205 | ICI 199441 | 115199-84-3 | Reference compound |
| HY-101207 | NCS-382 | 520505-01-5 | Reference compound |
| HY-101208 | L694247 | 137403-12-4 | Reference compound |
| HY-10121 | Asenapine | 65576-45-6 | Reference compound |
| HY-101212 | Fadraciclib | 1070790-89-4 | Reference compound |
| HY-101213 | OSW-1 | 145075-81-6 | Natural Products |
| HY-101214 | UK-371804 | 256477-09-5 | Reference compound |
| HY-101214A | UK-371804 (hydrochloride) | 256476-36-5 | Reference compound |
| HY-101215 | Evobrutinib | 1415823-73-2 | Reference compound |
| HY-101216 | Org-26576 | 100044-96-0 | Reference compound |
| HY-101217 | BI 689648 | 1633009-87-6 | Reference compound |
| HY-101218 | N-Biotinyl-6-aminohexanoic acid | 72040-64-3 | Reference compound |
| HY-101219 | VEGFR-IN-1 | 269390-69-4 | Reference compound |
| HY-10121B | Asenapine (citrate) | 1411867-74-7 | Reference compound |
| HY-10121R | Asenapine (Standard) | 65576-45-6 | Reference Standards |
| HY-10121S2 | Asenapine-13C,d3 | 2747915-30-4 | Isotope-Labeled Compounds |
| HY-10121S4 | Asenapine-d3,13C | 1217729-73-1 | Isotope-Labeled Compounds |
| HY-10122 | Silodosin | 160970-54-7 | Reference compound |
| HY-101220 | RMI-61140 | 24140-98-5 | Reference compound |
| HY-101222 | SB-203186 (hydrochloride) | 207572-69-8 | Reference compound |
| HY-101223 | DIPPA (hydrochloride) | 155512-52-0 | Reference compound |
| HY-101225 | 8 Hydroxy PIPAT (oxalate) | 1451210-48-2 | Reference compound |
| HY-101226 | MSOP | 66515-29-5 | Reference compound |
| HY-101227 | (±)-threo-3-Methylglutamic acid | 63088-04-0 | Reference compound |
| HY-101229 | (2R,3S)-Chlorpheg | 140924-23-8 | Reference compound |
| HY-10122A | (Rac)-Silodosin | 160970-64-9 | Reference compound |
| HY-10122R | Silodosin (Standard) | 160970-54-7 | Reference Standards |
| HY-10122S | Silodosin-d4 | 1426173-86-5 | Isotope-Labeled Compounds |
| HY-101230 | ICI 174864 | 89352-67-0 | Reference compound |
| HY-101231 | ICI-204448 | 121264-04-8 | Reference compound |
| HY-101232 | Tiotidine | 69014-14-8 | Reference compound |
| HY-101232R | Tiotidine (Standard) | 69014-14-8 | Reference Standards |
| HY-101233 | ICI 154129 | 83420-94-4 | Reference compound |
| HY-101234 | ICI 162846 | 84545-30-2 | Reference compound |
| HY-101236 | ICI 192605 | 117621-64-4 | Reference compound |
| HY-101237 | DHBP (dibromide) | 6159-05-3 | Reference compound |
| HY-101238 | Agmatine (sulfate) | 2482-00-0 | Natural Products |
| HY-101238R | Agmatine (sulfate) (Standard) | 2482-00-0 | Reference Standards |
| HY-101239 | Oxotremorine (sesquifumarate) | 17360-35-9 | Reference compound |
| HY-101240 | Propranolol glycol | 36112-95-5 | Reference compound |
| HY-101240R | Propranolol glycol (Standard) | 36112-95-5 | Reference Standards |
| HY-101240S | Propranolol glycol-d5 | 69533-57-9 | Isotope-Labeled Compounds |
| HY-101241 | MPPG | 169209-65-8 | Reference compound |
| HY-101242 | (±)-α-Methyl-(4-sulfonophenyl)glycine | 169209-64-7 | Peptides |
| HY-101243 | XMD16-5 | 1345098-78-3 | Reference compound |
| HY-101244 | ZINC00881524 | 557782-81-7 | Reference compound |
| HY-101245 | Pilsicainide (hydrochloride) | 88069-49-2 | Reference compound |
| HY-101246 | RPI-1 | 269730-03-2 | Reference compound |
| HY-101247 | MTPG | 169209-66-9 | Reference compound |
| HY-101248 | GR-46611 | 185259-85-2 | Reference compound |
| HY-101249 | L-732138 | 148451-96-1 | Reference compound |
| HY-101250 | Glemanserin | 107703-78-6 | Reference compound |
| HY-101250R | Glemanserin (Standard) | 107703-78-6 | Reference Standards |
| HY-101251 | AMT (hydrochloride) | 21463-31-0 | Reference compound |
| HY-101251R | AMT (hydrochloride) (Standard) | 21463-31-0 | Reference Standards |
| HY-101252 | S-EIT (hydrobromide) | 1071-37-0 | Biochemical Assay Reagents |
| HY-101253 | AM-92016 (hydrochloride) | 133229-11-5 | Reference compound |
| HY-101254 | Luzindole | 117946-91-5 | Reference compound |
| HY-101254R | Luzindole (Standard) | 117946-91-5 | Reference Standards |
| HY-101255 | ODQ | 41443-28-1 | Reference compound |
| HY-101255R | ODQ (Standard) | 41443-28-1 | Reference Standards |
| HY-101256 | ZM226600 | 147695-92-9 | Reference compound |
| HY-101257 | YKL-5-124 | 1957203-01-8 | Reference compound |
| HY-101257A | CDK7-IN-1 | 1957203-02-9 | Reference compound |
| HY-101257B | YKL-5-124 (TFA) | 2748220-93-9 | Reference compound |
| HY-101258 | Cardol triene | 79473-24-8 | Reference compound |
| HY-101259 | BMS-195614 | 182135-66-6 | Reference compound |
| HY-10126 | Barasertib-HQPA | 722544-51-6 | Reference compound |
| HY-101260 | DORA-22 | 1088991-95-0 | Reference compound |
| HY-101261 | ATPA | 140158-50-5 | Reference compound |
| HY-101262 | SB234551 | 188257-69-4 | Reference compound |
| HY-101263 | 2-Thio-PAF | 96801-55-7 | Reference compound |
| HY-101264 | CCR2 antagonist 3 | 1380100-86-6 | Reference compound |
| HY-101265 | Icanbelimod | 1514888-56-2 | Reference compound |
| HY-101266 | Milademetan | 1398568-47-2 | Reference compound |
| HY-101266A | Milademetan (tosylate) | 1398569-75-9 | Reference compound |
| HY-101266B | Milademetan (tosylate hydrate) | 2095625-97-9 | Reference compound |
| HY-101267 | CHMFL-BMX-078 | 1808288-51-8 | Reference compound |
| HY-101268 | CHMFL-ABL-053 | 1808287-83-3 | Reference compound |
| HY-10127 | Barasertib | 722543-31-9 | Reference compound |
| HY-101270 | STK16-IN-1 | 1223001-53-3 | Reference compound |
| HY-101271 | WAY-200070 | 440122-66-7 | Reference compound |
| HY-101272 | GDC-0326 | 1282514-88-8 | Reference compound |
| HY-101273 | BAR502 | 1612191-86-2 | Reference compound |
| HY-101274 | BAR501 | 1632118-69-4 | Reference compound |
| HY-101274A | (3α,5β,6β,7α)-BAR501 | 1632118-70-7 | Reference compound |
| HY-101275 | EMT inhibitor-1 | 1638526-21-2 | Reference compound |
| HY-101277 | Vadadustat | 1000025-07-9 | Reference compound |
| HY-101277S1 | Vadadustat-13C6 | | Isotope-Labeled Compounds |
| HY-101278 | Thiomyristoyl | 1429749-41-6 | Reference compound |
| HY-101279 | ST034307 | 133406-29-8 | Reference compound |
| HY-10127A | Barasertib (dihydrochloride) | 722543-50-2 | Reference compound |
| HY-10127R | Barasertib (Standard) | 722543-31-9 | Reference Standards |
| HY-10128 | ZM-447439 | 331771-20-1 | Reference compound |
| HY-101280 | LB-60-OF61 | 794461-93-1 | Reference compound |
| HY-101280A | LB-60-OF61 (hydrochloride) | 742064-38-6 | Reference compound |
| HY-101281 | VU 6008667 | 2092923-21-0 | Reference compound |
| HY-101281A | (Rac)-VU 6008667 | 2092917-63-8 | Reference compound |
| HY-101281B | (R)-VU 6008667 | 2097818-14-7 | Reference compound |
| HY-101282 | Glutaminyl Cyclase Inhibitor 3 | 2092921-50-9 | Reference compound |
| HY-101283 | HCH6-1 | 1435265-06-7 | Reference compound |
| HY-101284 | DMU2105 | 1821143-79-6 | Reference compound |
| HY-101284A | (E/Z)-DMU2105 | 1031063-36-1 | Reference compound |
| HY-101285 | DMU2139 | 1821143-80-9 | Reference compound |
| HY-101287 | MPT0B392 | 1346169-92-3 | Reference compound |
| HY-10129 | Veliparib | 912444-00-9 | Reference compound |
| HY-101290 | BMT-090605 | 1551403-51-0 | Reference compound |
| HY-101290A | BMT-090605 (hydrochloride) | 2231664-45-0 | Reference compound |
| HY-101291 | Iberdomide | 1323403-33-3 | Reference compound |
| HY-101291R | Iberdomide (Standard) | 1323403-33-3 | Reference Standards |
| HY-101292 | FK614 | 193012-35-0 | Reference compound |
| HY-101293 | VU0359595 | 1246303-14-9 | Reference compound |
| HY-101294 | TPPU | 1222780-33-7 | Reference compound |
| HY-101295 | Pan-RAS-IN-1 | 1835283-94-7 | Reference compound |
| HY-101296 | PD-166866 | 192705-79-6 | Reference compound |
| HY-101297 | Z-IETD-FMK | 210344-98-2 | Reference compound |
| HY-101298 | Paprotrain | 57046-73-8 | Reference compound |
| HY-101299 | (+)-Dihydrexidine (hydrochloride) | 158704-02-0 | Reference compound |
| HY-101299A | Dihydrexidine | 123039-93-0 | Reference compound |
| HY-101299B | Dihydrexidine (hydrochloride) | 137417-08-4 | Reference compound |
| HY-10129R | Veliparib (Standard) | 912444-00-9 | Reference Standards |
| HY-10130 | Veliparib (dihydrochloride) | 912445-05-7 | Reference compound |
| HY-101300 | Cirazoline (hydrochloride) | 40600-13-3 | Reference compound |
| HY-101300R | Cirazoline (hydrochloride) (Standard) | 40600-13-3 | Reference Standards |
| HY-101301A | RS 45041-190 (hydrochloride) | 204274-74-8 | Reference compound |
| HY-101302 | Naltriben (mesylate) | 122517-78-6 | Reference compound |
| HY-101303 | 5-MCA-NAT | 190277-13-5 | Reference compound |
| HY-101304 | S-Isopropylisothiourea (hydrobromide) | 4269-97-0 | Reference compound |
| HY-101306 | Clocinnamox (mesylate) | 117332-69-1 | Reference compound |
| HY-101307 | BNTX (maleate) | 864461-31-4 | Reference compound |
| HY-101308 | MRS2179 (tetrasodium) | 1454889-37-2 | Reference compound |
| HY-101308A | MRS2179 (tetrasodium hydrate) | | Reference compound |
| HY-101309A | 5-(Nonyloxy)tryptamine (oxalate) | 157798-13-5 | Reference compound |
| HY-10131 | Procaspase-3/6 activator 1 | 1100353-03-4 | Reference compound |
| HY-101310 | SYM 2081 | 31137-74-3 | Reference compound |
| HY-101311 | UPF-523 | 168560-79-0 | Reference compound |
| HY-101312 | Cilostamide | 68550-75-4 | Reference compound |
| HY-101312R | Cilostamide (Standard) | 68550-75-4 | Reference Standards |
| HY-101313 | (S)-Remoxipride | 80125-14-0 | Reference compound |
| HY-101313A | (S)-Remoxipride (hydrochloride) | 73220-03-8 | Reference compound |
| HY-101314 | 3-CPMT | 14008-79-8 | Reference compound |
| HY-101315 | AHN 1-055 (hydrochloride) | 202646-03-5 | Reference compound |
| HY-101316 | TRIM | 25371-96-4 | Reference compound |
| HY-101317 | TAN-67 (dihydrobromide) | 1217628-73-3 | Reference compound |
| HY-101317A | TAN-67 | 148545-09-9 | Reference compound |
| HY-101318 | β-Funaltrexamine (hydrochloride) | 72786-10-8 | Reference compound |
| HY-101320 | ZD-7114 | 129689-30-1 | Reference compound |
| HY-101320A | ZD-7114 (hydrochloride) | 129689-28-7 | Reference compound |
| HY-101321 | Immepip | 151070-83-6 | Reference compound |
| HY-101321A | Immepip (dihydrobromide) | 164391-47-3 | Reference compound |
| HY-101321AR | Immepip (dihydrobromide) (Standard) | 164391-47-3 | Reference Standards |
| HY-101322A | MM 77 (dihydrochloride) | 159187-70-9 | Reference compound |
| HY-101323 | Olvanil | 58493-49-5 | Reference compound |
| HY-101323R | Olvanil (Standard) | 58493-49-5 | Reference Standards |
| HY-101324 | MK-212 | 64022-27-1 | Reference compound |
| HY-101324A | MK-212 (monohydrochloride) | 61655-58-1 | Reference compound |
| HY-101324AR | MK-212 (monohydrochloride) (Standard) | 61655-58-1 | Reference Standards |
| HY-101325 | BRL 37344 (sodium) | 127299-93-8 | Reference compound |
| HY-101325A | BRL-37344 | 90730-96-4 | Reference compound |
| HY-101327 | Xamoterol | 81801-12-9 | Reference compound |
| HY-101327A | Xamoterol (hemifumarate) | 73210-73-8 | Reference compound |
| HY-101329 | Anthracene-9-carboxylic acid | 723-62-6 | Reference compound |
| HY-101329R | Anthracene-9-carboxylic acid (Standard) | 723-62-6 | Reference Standards |
| HY-101329S | Anthracene-9-carboxylic acid-d9 | 1219803-78-7 | Isotope-Labeled Compounds |
| HY-10133 | β-Secretase Inhibitor IV | 797035-11-1 | Reference compound |
| HY-101331 | Phenylbiguanide | 102-02-3 | Reference compound |
| HY-101331A | Phenylbiguanide (hydrochloride) | 55-57-2 | Reference compound |
| HY-101331R | Phenylbiguanide (Standard) | 102-02-3 | Reference Standards |
| HY-101332 | EGLU | 170984-72-2 | Reference compound |
| HY-101333 | CPPG | 183364-82-1 | Reference compound |
| HY-101334 | MPDC | 159262-32-5 | Reference compound |
| HY-101334A | MPDC (hydrochloride) | | Reference compound |
| HY-101335 | DCG-IV | 147782-19-2 | Reference compound |
| HY-101336 | RS 17053 hydrochloride | 169505-93-5 | Reference compound |
| HY-101337 | Imiloxan | 81167-16-0 | Reference compound |
| HY-101337A | Imiloxan (hydrochloride) | 81167-22-8 | Reference compound |
| HY-101338 | RS-79948-197 | 186002-54-0 | Reference compound |
| HY-101339 | (R)-RS 56812 | 143137-37-5 | Reference compound |
| HY-101339A | (R)-RS 56812 (hydrochloride) | 143339-12-2 | Reference compound |
| HY-101340 | Luvixasertib | 1610759-22-2 | Reference compound |
| HY-101340A | Luvixasertib (hydrochloride) | 1610677-37-6 | Reference compound |
| HY-101341 | RS 67333 (hydrochloride) | 168986-60-5 | Reference compound |
| HY-101342 | RS 67506 (hydrochloride) | 168986-61-6 | Reference compound |
| HY-101343 | RS 39604 | 167710-87-4 | Reference compound |
| HY-101344 | Cyanopindolol (fumarate) | 69906-86-1 | Reference compound |
| HY-101345 | AH 11110A | 179388-65-9 | Reference compound |
| HY-101346 | ZD7288 | 133059-99-1 | Reference compound |
| HY-101347 | Chlorisondamine (diiodide) | 96750-66-2 | Reference compound |
| HY-101348 | L-741626 | 81226-60-0 | Reference compound |
| HY-101348R | L-741626 (Standard) | 81226-60-0 | Reference Standards |
| HY-101349 | L 741742 | 156337-32-5 | Reference compound |
| HY-101349A | L 741742 (hydrochloride) | 874882-93-6 | Reference compound |
| HY-101350 | QX-314 (bromide) | 24003-58-5 | Reference compound |
| HY-101352 | LY 225910 | 133040-77-4 | Reference compound |
| HY-101353 | LY 235959 | 137433-06-8 | Reference compound |
| HY-101354 | R-IMPP | 2133832-83-2 | Reference compound |
| HY-101355 | CGP 20712 | 137888-49-4 | Reference compound |
| HY-101355A | CGP 20712 (dihydrochloride) | 1216905-73-5 | Reference compound |
| HY-101355AR | CGP 20712 (dihydrochloride) (Standard) | 1216905-73-5 | Reference Standards |
| HY-101355B | CGP 20712 A | 105737-62-0 | Reference compound |
| HY-101355BR | CGP 20712 A (Standard) | 105737-62-0 | Reference Standards |
| HY-101356 | CPCCOEt | 179067-99-3 | Reference compound |
| HY-101357 | CP 93129 | 127792-75-0 | Reference compound |
| HY-101357A | CP 93129 (dihydrochloride) | 879089-64-2 | Reference compound |
| HY-101357AR | CP 93129 (dihydrochloride) (Standard) | 879089-64-2 | Reference Standards |
| HY-101358 | 8-M-PDOT | 134865-70-6 | Reference compound |
| HY-101359 | TPMPA | 182485-36-5 | Reference compound |
| HY-101360 | 1-EBIO | 10045-45-1 | Reference compound |
| HY-101361 | Lidocaine methiodide | 1462-71-1 | Reference compound |
| HY-101362 | QX-222 (chloride) | 5369-00-6 | Reference compound |
| HY-101363 | 1-BCP | 34023-62-6 | Reference compound |
| HY-101363R | 1-BCP (Standard) | 34023-62-6 | Reference Standards |
| HY-101364 | CHPG | 170846-74-9 | Reference compound |
| HY-101364A | CHPG (sodium salt) | 1303993-73-8 | Reference compound |
| HY-101364AR | CHPG (sodium salt) (Standard) | 1303993-73-8 | Reference Standards |
| HY-101365 | RS-102221 | 185376-97-0 | Reference compound |
| HY-101365A | RS-102221 (hydrochloride) | 187397-18-8 | Reference compound |
| HY-101365AR | RS-102221 (hydrochloride) (Standard) | 187397-18-8 | Reference Standards |
| HY-101366 | A-61603 | 107756-30-9 | Reference compound |
| HY-101367A | GR 55562 (dihydrochloride) | 159533-25-2 | Reference compound |
| HY-101368A | WIN 64338 (hydrochloride) | 163727-74-0 | Reference compound |
| HY-101369 | BW-723C86 | 160521-72-2 | Reference compound |
| HY-101370 | 2-Methylthio-ATP (tetrasodium) | 100020-57-3 | Reference compound |
| HY-101371 | Hesperin | 4430-35-7 | Reference compound |
| HY-101372A | Oxotremorine M (iodide) | 3854-04-4 | Reference compound |
| HY-101373A | Zolantidine (dimaleate) | 104076-39-3 | Reference compound |
| HY-101373AR | Zolantidine (dimaleate) (Standard) | 104076-39-3 | Reference Standards |
| HY-101374A | AGN 192403 (hydrochloride) | 1021868-90-5 | Reference compound |
| HY-101375 | (RS)-APICA | 170847-18-4 | Reference compound |
| HY-101376 | (+)-N-Allylnormetazocine (hydrochloride) | 133005-41-1 | Reference compound |
| HY-101377A | R(+)-8-OH-DPAT (hydrobromide) | 78095-19-9 | Reference compound |
| HY-101377B | S(-)-8-OH-DPAT (hydrobromide) | 78095-20-2 | Reference compound |
| HY-101378 | CGP 54626 (hydrochloride) | 149184-21-4 | Reference compound |
| HY-101379A | 8-Bromo-cGMP (sodium) | 51116-01-9 | Reference compound |
| HY-101380A | BU226 (hydrochloride) | 1186195-56-1 | Reference compound |
| HY-101381 | Otenzepad | 102394-31-0 | Reference compound |
| HY-101382 | GR 103691 | 162408-66-4 | Reference compound |
| HY-101383 | PF-01247324 | 875051-72-2 | Reference compound |
| HY-101384A | Ro 10-5824 (dihydrochloride) | 189744-94-3 | Reference compound |
| HY-101385 | L-765314 | 189349-50-6 | Reference compound |
| HY-101386 | PZM21 | 1997387-43-5 | Reference compound |
| HY-101387 | rel-ACPT-I | 194918-76-8 | Reference compound |
| HY-101387A | ACPT-II | 195209-04-2 | Reference compound |
| HY-101388 | AM404 | 183718-77-6 | Reference compound |
| HY-101389 | (R)-Methanandamide | 157182-49-5 | Reference compound |
| HY-101390 | (+)-Niguldipine (hydrochloride) | 113145-69-0 | Reference compound |
| HY-101390A | (-)-Niguldipine (hydrochloride) | 113145-70-3 | Reference compound |
| HY-101390B | Niguldipine (free base) | 102993-22-6 | Reference compound |
| HY-101392 | Harmane | 486-84-0 | Natural Products |
| HY-101392A | Harmane (hydrochloride) | 21655-84-5 | Natural Products |
| HY-101392R | Harmane (Standard) | 486-84-0 | Reference Standards |
| HY-101392S | Harmane-d1 | | Isotope-Labeled Compounds |
| HY-101392S1 | Harmane-d2 | | Isotope-Labeled Compounds |
| HY-101392S2 | Harmane-d4 | 2012598-89-7 | Isotope-Labeled Compounds |
| HY-101393A | CGP 12177 (hydrochloride) | 64208-32-8 | Reference compound |
| HY-101394 | Spermine NONOate | 136587-13-8 | Reference compound |
| HY-101395 | W146 | 909725-61-7 | Reference compound |
| HY-101395A | W146 (TFA) | 909725-62-8 | Reference compound |
| HY-101396 | ICA-069673 | 582323-16-8 | Reference compound |
| HY-101397 | Allopurinol riboside | 16220-07-8 | Natural Products |
| HY-101397R | Allopurinol riboside (Standard) | 16220-07-8 | Reference Standards |
| HY-101398 | Coproporphyrin III | 14643-66-4 | Natural Products |
| HY-101398R | Coproporphyrin III (Standard) | 14643-66-4 | Reference Standards |
| HY-101399 | γ-Glu-Phe | 7432-24-8 | Natural Products |
| HY-101399A | γ-Glu-Phe (TFA) | 2828432-42-2 | Natural Products |
| HY-101399R | γ-Glu-Phe (Standard) | 7432-24-8 | Reference Standards |
| HY-101399S | γ-Glu-(Phe-13C9,15N) | | Isotope-Labeled Compounds |
| HY-101400 | Deoxycytidine triphosphate | 2056-98-6 | Biochemical Assay Reagents |
| HY-101400A | Deoxycytidine triphosphate (trisodium) solution (100mM) | 109909-44-6 | Biochemical Assay Reagents |
| HY-101400S | Deoxycytidine triphosphate-d14 (dilithium) | 2687960-70-7 | Isotope-Labeled Compounds |
| HY-101400S1 | Deoxycytidine triphosphate-15N3,d14 (dilithium) | | Isotope-Labeled Compounds |
| HY-101400S2 | Deoxycytidine triphosphate-13C9,15N3 (dilithium) | | Isotope-Labeled Compounds |
| HY-101400S3 | Deoxycytidine triphosphate-15N3 (dilithium) | | Isotope-Labeled Compounds |
| HY-101400S4 | Deoxycytidine triphosphate-13C9 (dilithium) | | Isotope-Labeled Compounds |
| HY-101401 | 3-(Methylthio)propionic acid | 646-01-5 | Natural Products |
| HY-101401R | 3-(Methylthio)propionic acid (Standard) | 646-01-5 | Reference Standards |
| HY-101402 | Cyclo(his-pro) | 53109-32-3 | Natural Products |
| HY-101402A | Cyclo(his-pro) (TFA) | 936749-56-3 | Natural Products |
| HY-101402AR | Cyclo(his-pro) (TFA) (Standard) | 936749-56-3 | Reference Standards |
| HY-101403 | N-(5-Aminopentyl)acetamide | 32343-73-0 | Natural Products |
| HY-101403A | Monoacetylcadaverine (hydrochloride) | 102029-76-5 | Reference compound |
| HY-101403R | N-(5-Aminopentyl)acetamide (Standard) | 32343-73-0 | Reference Standards |
| HY-101404 | DL-Homocysteine thiolactone (hydrochloride) | 6038-19-3 | Natural Products |
| HY-101404A | L-Homocysteine thiolactone (hydrochloride) | 31828-68-9 | Reference compound |
| HY-101404R | DL-Homocysteine thiolactone (hydrochloride) (Standard) | 6038-19-3 | Reference Standards |
| HY-101404S | DL-Homocysteine thiolactone-d4 (hydrochloride) | 1219805-31-8 | Isotope-Labeled Compounds |
| HY-101405 | Gestrinone | 16320-04-0 | Reference compound |
| HY-101405R | Gestrinone (Standard) | 16320-04-0 | Reference Standards |
| HY-101406 | Thyroxine sulfate | 77074-49-8 | Natural Products |
| HY-101406R | Thyroxine sulfate (Standard) | 77074-49-8 | Reference Standards |
| HY-101407 | Nicotinamide N-oxide | 1986-81-8 | Natural Products |
| HY-101407R | Nicotinamide N-oxide (Standard) | 1986-81-8 | Reference Standards |
| HY-101408 | Docosatrienoic Acid | 28845-86-5 | Natural Products |
| HY-101409 | O-Acetylserine | 5147-00-2 | Natural Products |
| HY-101409A | O-Acetyl-L-serine (hydrochloride) | 66638-22-0 | Natural Products |
| HY-101409AR | O-Acetyl-L-serine (hydrochloride) (Standard) | 66638-22-0 | Reference Standards |
| HY-101409R | O-Acetylserine (Standard) | 5147-00-2 | Reference Standards |
| HY-101410 | SDMA | 30344-00-4 | Natural Products |
| HY-101410A | SDMA (p-hydroxyazobenzene-p′-sulfonate) | 1266235-58-8 | Reference compound |
| HY-101410R | SDMA (Standard) | 30344-00-4 | Reference Standards |
| HY-101410S | SDMA-d6 | 1331888-08-4 | Isotope-Labeled Compounds |
| HY-101411 | 4-Acetamidobutanoic acid | 3025-96-5 | Natural Products |
| HY-101411R | 4-Acetamidobutanoic acid (Standard) | 3025-96-5 | Reference Standards |
| HY-101411S | 4-Acetamidobutanoic acid-d3 | | Isotope-Labeled Compounds |
| HY-101412 | 2-(Methylamino)-1H-purin-6(7H)-one | 10030-78-1 | Natural Products |
| HY-101413 | Iberin | 505-44-2 | Natural Products |
| HY-101414 | L-DABA | 1758-80-1 | Natural Products |
| HY-101414A | L-DABA (hydrobromide) | 73143-97-2 | Reference compound |
| HY-101414R | L-DABA (Standard) | 1758-80-1 | Reference Standards |
| HY-101415 | Coenzyme Q9 | 303-97-9 | Natural Products |
| HY-101415R | Coenzyme Q9 (Standard) | 303-97-9 | Reference Standards |
| HY-101416 | Vanilpyruvic acid | 1081-71-6 | Reference compound |
| HY-101416R | Vanilpyruvic acid (Standard) | 1081-71-6 | Reference Standards |
| HY-101417 | Diethyl phosphate | 598-02-7 | Natural Products |
| HY-101417R | Diethyl phosphate (Standard) | 598-02-7 | Reference Standards |
| HY-101417S1 | Diethyl phosphate-d10-1 | 2483831-48-5 | Isotope-Labeled Compounds |
| HY-101418 | JNJ-47965567 | 1428327-31-4 | Reference compound |
| HY-101419 | CYM-5541 | 945128-26-7 | Reference compound |
| HY-101420 | VUF10460 | 1028327-66-3 | Reference compound |
| HY-101422 | GAL-021 | 1380341-99-0 | Reference compound |
| HY-101422A | GAL-021 (sulfate) | 1380342-00-6 | Reference compound |
| HY-101423 | NIH-12848 | 959551-10-1 | Reference compound |
| HY-101424 | 2-Chloro-N-(2-methyl-4-bromophenyl)acetamide | 96686-51-0 | Reference compound |
| HY-101425 | TCMTB | 21564-17-0 | Reference compound |
| HY-101426 | RG14620 | 136831-49-7 | Reference compound |
| HY-101427 | Bamaquimast | 135779-82-7 | Reference compound |
| HY-101428 | NS-638 | 150493-34-8 | Reference compound |
| HY-101429 | RG13022 | 136831-48-6 | Reference compound |
| HY-101430 | PGD2-IN-1 | 885066-67-1 | Reference compound |
| HY-101432 | Fenclozic acid | 17969-20-9 | Reference compound |
| HY-101433 | N-Acetylprocainamide (hydrochloride) | 34118-92-8 | Reference compound |
| HY-101433R | N-Acetylprocainamide (hydrochloride) (Standard) | 34118-92-8 | Reference Standards |
| HY-101434 | Cetamolol | 34919-98-7 | Reference compound |
| HY-101434A | Cetamolol (hydrochloride) | 77590-95-5 | Reference compound |
| HY-101435 | Centpropazine | 91315-34-3 | Reference compound |
| HY-101436 | Sematilide | 101526-83-4 | Reference compound |
| HY-101436A | Sematilide (hydrochloride) | 101526-62-9 | Reference compound |
| HY-101436AR | Sematilide (hydrochloride) (Standard) | 101526-62-9 | Reference Standards |
| HY-101437 | Ralfinamide | 133865-88-0 | Reference compound |
| HY-101437A | Ralfinamide (mesylate) | 202825-45-4 | Reference compound |
| HY-101437R | Ralfinamide (Standard) | 133865-88-0 | Reference Standards |
| HY-101438 | Darbufelone | 139226-28-1 | Reference compound |
| HY-101438A | Darbufelone (mesylate) | 139340-56-0 | Reference compound |
| HY-101439 | JTT-552 | 888730-46-9 | Reference compound |
| HY-101440A | Indantadol (hydrochloride) | 202914-18-9 | Reference compound |
| HY-101441 | ST-193 | 489416-12-8 | Reference compound |
| HY-101441A | ST-193 (hydrochloride) | 2320274-72-2 | Reference compound |
| HY-101442 | SR9238 | 1416153-62-2 | Reference compound |
| HY-101442R | SR9238 (Standard) | 1416153-62-2 | Reference Standards |
| HY-101443 | ISCK03 | 945526-43-2 | Reference compound |
| HY-101444A | PAβN (dihydrochloride) | 100929-99-5 | Reference compound |
| HY-101445 | Trolox | 53188-07-1 | Reference compound |
| HY-101445A | (R)-Trolox | 53101-49-8 | Reference compound |
| HY-101445AR | (R)-Trolox (Standard) | 53101-49-8 | Reference Standards |
| HY-101445B | (S)-Trolox | 53174-06-4 | Reference compound |
| HY-101445R | Trolox (Standard) | 53188-07-1 | Reference Standards |
| HY-101446 | HIOC | 314054-36-9 | Reference compound |
| HY-101447 | SI-2 | 223788-33-8 | Reference compound |
| HY-101447A | SI-2 (hydrochloride) | 1992052-49-9 | Reference compound |
| HY-101448 | TMI-1 | 287403-39-8 | Reference compound |
| HY-101449 | Adaptaquin | 385786-48-1 | Reference compound |
| HY-101450 | PF-6274484 | 1035638-91-5 | Reference compound |
| HY-101451 | PBIT | 2514-30-9 | Reference compound |
| HY-101453 | Ceefourin 1 | 315702-40-0 | Reference compound |
| HY-101454 | SR0987 | 303126-97-8 | Reference compound |
| HY-101455 | CDN1163 | 892711-75-0 | Reference compound |
| HY-101456 | PCPA methyl ester (hydrochloride) | 14173-40-1 | Reference compound |
| HY-101457 | JZP-430 | 1672691-74-5 | Reference compound |
| HY-101458 | IT1t | 864677-55-4 | Reference compound |
| HY-101458A | IT1t (dihydrochloride) | 1092776-63-0 | Reference compound |
| HY-101459 | RTC13 | 1359825-94-7 | Reference compound |
| HY-101460 | Tz-Thalidomide | 2087490-42-2 | Reference compound |
| HY-101461 | Methyl-β-cyclodextrin | 128446-36-6 | Biochemical Assay Reagents |
| HY-101462 | RAD51 Inhibitor B02 | 1290541-46-6 | Reference compound |
| HY-101464 | ML329 | 19992-50-8 | Reference compound |
| HY-101465 | AK-1 | 330461-64-8 | Reference compound |
| HY-101466 | E7090 | 1622204-21-0 | Reference compound |
| HY-101466A | E7090 (succinate) | 1879965-80-6 | Reference compound |
| HY-101467 | Trilaciclib | 1374743-00-6 | Reference compound |
| HY-101467A | Trilaciclib (hydrochloride) | 1977495-97-8 | Reference compound |
| HY-101467AR | Trilaciclib (hydrochloride) (Standard) | 1977495-97-8 | Reference Standards |
| HY-101472 | Closthioamide | 1227367-59-0 | Natural Products |
| HY-101473 | EMD527040 | 851333-14-7 | Reference compound |
| HY-101474 | (±)-Zanubrutinib | 1633350-06-7 | Reference compound |
| HY-101474A | Zanubrutinib | 1691249-45-2 | Reference compound |
| HY-101474AR | Zanubrutinib (Standard) | 1691249-45-2 | Reference Standards |
| HY-101474B | (R)-Zanubrutinib | 1691249-44-1 | Reference compound |
| HY-101474BS | (R)-Zanubrutinib-d5 | | Isotope-Labeled Compounds |
| HY-101474S | Zanubrutinib-d5 | | Isotope-Labeled Compounds |
| HY-101476 | Emodepside | 155030-63-0 | Reference compound |
| HY-101476R | Emodepside (Standard) | 155030-63-0 | Reference Standards |
| HY-101478 | Fenobam | 57653-26-6 | Reference compound |
| HY-101478A | Fenobam (hydrate) | 63540-28-3 | Reference compound |
| HY-101478R | Fenobam (Standard) | 57653-26-6 | Reference Standards |
| HY-101479 | Iclaprim | 192314-93-5 | Reference compound |
| HY-101479R | Iclaprim (Standard) | 192314-93-5 | Reference Standards |
| HY-101479S | Iclaprim-d6 | 1130072-57-9 | Isotope-Labeled Compounds |
| HY-101480 | Xylamidine | 6443-50-1 | Reference compound |
| HY-101480A | Xylamidine (tosylate) | 6443-40-9 | Reference compound |
| HY-101481 | Flurbiprofen axetil | 91503-79-6 | Reference compound |
| HY-101481R | Flurbiprofen axetil (Standard) | 91503-79-6 | Reference Standards |
| HY-101482 | Ibuprofen piconol | 64622-45-3 | Reference compound |
| HY-101482R | Ibuprofen piconol (Standard) | 64622-45-3 | Reference Standards |
| HY-101483 | Dihydromunduletone | 674786-20-0 | Reference compound |
| HY-101484A | NE-100 (hydrochloride) | 149409-57-4 | Reference compound |
| HY-101484AR | NE-100 (hydrochloride) (Standard) | 149409-57-4 | Reference Standards |
| HY-101485 | AUTEN-99 (hydrobromide) | 1049780-58-6 | Reference compound |
| HY-101486 | LF3 | 664969-54-4 | Reference compound |
| HY-101488 | CC-885 | 1010100-07-8 | Reference compound |
| HY-101489 | GZD856 | 1257628-64-0 | Reference compound |
| HY-101489A | GZD856 (formic) | 2804039-78-7 | Reference compound |
| HY-101490 | PDE1-IN-2 | 1904611-63-7 | Reference compound |
| HY-101491 | SR-18292 | 2095432-55-4 | Reference compound |
| HY-101491S | SR-18292-d9 | | Isotope-Labeled Compounds |
| HY-101492 | GPR120 Agonist 3 | 1599477-75-4 | Reference compound |
| HY-101493 | SUN11602 | 704869-38-5 | Reference compound |
| HY-101494 | Temuterkib | 1951483-29-6 | Reference compound |
| HY-101495 | 18-HEPE | 141110-17-0 | Natural Products |
| HY-101496 | MT-DADMe-ImmA | 653592-04-2 | Reference compound |
| HY-101499 | GKT136901 | 955272-06-7 | Reference compound |
| HY-101499A | GKT136901 (hydrochloride) | 1254507-01-1 | Reference compound |
| HY-101499AR | GKT136901 (hydrochloride) (Standard) | 1254507-01-1 | Reference Standards |
| HY-101499R | GKT136901 (Standard) | 955272-06-7 | Reference Standards |
| HY-101502A | SB290157 (trifluoroacetate) | 1140525-25-2 | Reference compound |
| HY-101503 | HTS01037 | 682741-29-3 | Reference compound |
| HY-101505 | Zinc dethyldithiocarbamate | 14324-55-1 | Biochemical Assay Reagents |
| HY-101506 | 2,4,6-Tribromophenyl caproate | 16732-09-5 | Reference compound |
| HY-101507 | Zerencotrep | 1628287-16-0 | Reference compound |
| HY-101508 | GNA002 | 1385035-79-9 | Reference compound |
| HY-101509 | HSL-IN-1 | 2095156-13-9 | Reference compound |
| HY-101510 | F1063-0967 | 613225-56-2 | Reference compound |
| HY-101511 | TTT-28 | 1609138-51-3 | Reference compound |
| HY-101512 | A-395 | 2089148-72-9 | Reference compound |
| HY-101513 | eIF4A3-IN-1 | 2095486-67-0 | Reference compound |
| HY-101514 | β3-AR agonist 1 | 1283125-73-4 | Reference compound |
| HY-101515 | MELK-IN-1 | 2095596-44-2 | Reference compound |
| HY-101516 | CYP17-IN-1 | 2093317-51-0 | Reference compound |
| HY-101517 | PI3K-IN-2 | 1403458-28-5 | Reference compound |
| HY-101518 | Alrizomadlin | 1818393-16-6 | Reference compound |
| HY-101519 | BETd-260 | 2093388-62-4 | Reference compound |
| HY-101520 | Dot1L-IN-1 | 2088518-50-5 | Reference compound |
| HY-101520A | Dot1L-IN-1 (TFA) | | Reference compound |
| HY-101521 | CHMFL-BTK-01 | 2095280-64-9 | Reference compound |
| HY-101522 | CHMFL-EGFR-202 | 2089381-40-6 | Reference compound |
| HY-101523 | Cdc7-IN-1 | 1402055-25-7 | Reference compound |
| HY-101524 | TC13172 | 2093393-05-4 | Reference compound |
| HY-101525 | MBP146-78 | 188343-77-3 | Reference compound |
| HY-101526 | GENZ-882706 | 2070864-35-4 | Reference compound |
| HY-101526R | GENZ-882706(Raceme) | 2070861-46-8 | Reference compound |
| HY-101527 | 20-HEDE | 240427-90-1 | Reference compound |
| HY-101528 | IDRA 21 | 22503-72-6 | Reference compound |
| HY-101529 | Imanixil | 75689-93-9 | Reference compound |
| HY-101530 | Polyoxyethylene stearate | 9004-99-3 | Reference compound |
| HY-101530A | Polyoxyl 8 stearate | 70802-40-3 | Reference compound |
| HY-101530B | Polyoxyl 40 stearate | 171286-89-8 | Reference compound |
| HY-101530C | Polyoxyl 100 stearate | 9004-99-3 | Reference compound |
| HY-101532 | 6A-Azido-6A-deoxy-β-cyclodextrin | 98169-85-8 | Reference compound |
| HY-101533 | AZD-5991 | 2143061-81-6 | Reference compound |
| HY-101533A | AZD-5991 (Racemate) | 2143010-83-5 | Reference compound |
| HY-101533B | AZD-5991 (S-enantiomer) | 2143061-82-7 | Reference compound |
| HY-101534 | GSK1059865 | 1191044-58-2 | Reference compound |
| HY-101535 | ARP101 | 849773-63-3 | Reference compound |
| HY-101536 | GPR4 antagonist 1 | 1197879-16-5 | Reference compound |
| HY-101540 | NMI 8739 | 129024-87-9 | Reference compound |
| HY-101541 | Docosahexaenoic acid methyl ester | 2566-90-7 | Reference compound |
| HY-101541R | Docosahexaenoic acid methyl ester (Standard) | 2566-90-7 | Reference Standards |
| HY-101541S | Docosahexaenoic acid-d5 methyl ester | 2687960-96-7 | Isotope-Labeled Compounds |
| HY-101541S1 | Docosahexaenoic acid-13C22 methyl ester | | Isotope-Labeled Compounds |
| HY-101542 | Milfasartan | 148564-47-0 | Reference compound |
| HY-101544 | ARQ 069 | 1314021-57-2 | Reference compound |
| HY-101546A | Cavidine | 32728-75-9 | Natural Products |
| HY-101547 | TRPC6-IN-1 | 901715-05-7 | Reference compound |
| HY-101548 | OGT-IN-1 | 371215-02-0 | Reference compound |
| HY-101549 | MRX-2843 | 1429882-07-4 | Reference compound |
| HY-101549A | MRX-2843 (hydrochloride) | 2498541-94-7 | Reference compound |
| HY-101550 | HI-TOPK-032 | 487020-03-1 | Reference compound |
| HY-101552A | L,L-Dityrosine | 63442-81-9 | Reference compound |
| HY-101552B | L,L-Dityrosine (hydrochloride) | 221308-01-6 | Reference compound |
| HY-101552C | Dityrosine (dihydrochloride) | 2716849-01-1 | Reference compound |
| HY-101553 | Triflubazam | 22365-40-8 | Reference compound |
| HY-101554 | Guancydine | 1113-10-6 | Reference compound |
| HY-101556 | Namirotene | 101506-83-6 | Reference compound |
| HY-101558B | Elzasonan (hydrochloride) | 220322-05-4 | Reference compound |
| HY-101559 | 10-Nitrooleic acid | 875685-46-4 | Reference compound |
| HY-101559S | 10-Nitrooleate-d17 (nitrate) | 2749984-40-3 | Isotope-Labeled Compounds |
| HY-101560 | Linrodostat | 1923833-60-6 | Reference compound |
| HY-101560A | Linrodostat (mesylate) | 2221034-29-1 | Reference compound |
| HY-101561 | Avapritinib | 1703793-34-3 | Reference compound |
| HY-101561R | Avapritinib (Standard) | 1703793-34-3 | Reference Standards |
| HY-101562 | Inavolisib | 2060571-02-8 | Reference compound |
| HY-101563 | GSK3326595 | 1616392-22-3 | Reference compound |
| HY-101564 | Onametostat | 2086772-26-9 | Reference compound |
| HY-101565 | Tapotoclax | 1883727-34-1 | Reference compound |
| HY-101566 | Elimusertib | 1876467-74-1 | Reference compound |
| HY-101566A | Elimusertib (hydrochloride) | | Reference compound |
| HY-101566S | Elimusertib-d3 | | Isotope-Labeled Compounds |
| HY-101567 | BMS-986158 | 1800340-40-2 | Reference compound |
| HY-101568 | Roblitinib | 1708971-55-4 | Reference compound |
| HY-101569 | Darovasertib | 1874276-76-2 | Reference compound |
| HY-101570 | Nedisertib | 1637542-33-6 | Reference compound |
| HY-101572 | MHP | 1104874-94-3 | Reference compound |
| HY-101573 | Bencianol | 85443-48-7 | Reference compound |
| HY-101574 | Pratosartan | 153804-05-8 | Reference compound |
| HY-101575 | Acetylazide | 3590-05-4 | Reference compound |
| HY-101576 | RP 70676 | 136609-26-2 | Reference compound |
| HY-101577 | NCX899 | 690655-41-5 | Reference compound |
| HY-101578 | 2614W94 | 205187-35-5 | Reference compound |
| HY-101579 | LY 178002 | 107889-32-7 | Reference compound |
| HY-10158 | Bosutinib | 380843-75-4 | Reference compound |
| HY-101580 | Paliroden | 188396-77-2 | Reference compound |
| HY-101581 | Bucloxic acid | 32808-51-8 | Reference compound |
| HY-101581A | Bucloxic acid (calcium) | 32808-53-0 | Reference compound |
| HY-101582 | ZT 52656A hydrochloride | 115730-24-0 | Reference compound |
| HY-101583 | NEO 376 | 496921-73-4 | Reference compound |
| HY-101585 | Imoxiterol | 88578-07-8 | Reference compound |
| HY-101586 | Alvameline | 120241-31-8 | Reference compound |
| HY-101586A | Alvameline (maleate) | 219581-36-9 | Reference compound |
| HY-101587 | (E)-KME-4 | 102271-49-8 | Reference compound |
| HY-101588 | Gefapixant | 1015787-98-0 | Reference compound |
| HY-101588A | Gefapixant (citrate) | 2310299-91-1 | Reference compound |
| HY-101588R | Gefapixant (Standard) | 1015787-98-0 | Reference Standards |
| HY-101589 | Sotirimod | 227318-75-4 | Reference compound |
| HY-10158A | Bosutinib (hydrate) | 918639-08-4 | Reference compound |
| HY-10158AR | Bosutinib (hydrate) (Standard) | 918639-08-4 | Reference Standards |
| HY-10158S | Bosutinib-d8 | | Isotope-Labeled Compounds |
| HY-10158S1 | Bosutinib-13C,d3 | | Isotope-Labeled Compounds |
| HY-10159 | Nilotinib | 641571-10-0 | Reference compound |
| HY-101590 | Symetine | 15599-45-8 | Reference compound |
| HY-101590A | Symetine (dihydrochloride) | 5585-62-6 | Reference compound |
| HY-101593 | Fibracillin | 51154-48-4 | Reference compound |
| HY-101594 | Tulopafant | 116289-53-3 | Reference compound |
| HY-101595 | RPH-2823 | 96558-24-6 | Reference compound |
| HY-101596 | Ethyl dirazepate | 23980-14-5 | Reference compound |
| HY-101597 | NVX-207 | 745020-66-0 | Reference compound |
| HY-101598 | PD-159020 | 177904-00-6 | Reference compound |
| HY-10159A | Nilotinib (monohydrochloride monohydrate) | 923288-90-8 | Reference compound |
| HY-10159AR | Nilotinib (monohydrochloride monohydrate) (Standard) | 923288-90-8 | Reference Standards |
| HY-10159B | Nilotinib (hydrochloride) | 923288-95-3 | Reference compound |
| HY-10159R | Nilotinib (Standard) | 641571-10-0 | Reference Standards |
| HY-10159S | Nilotinib-d6 | 1268356-17-7 | Isotope-Labeled Compounds |
| HY-10159S1 | Nilotinib-13C,d3 | 1261398-62-2 | Isotope-Labeled Compounds |
| HY-101600 | RPR104632 | 154106-92-0 | Reference compound |
| HY-101601 | Bamirastine | 215529-47-8 | Reference compound |
| HY-101602 | Aligeron | 70713-45-0 | Reference compound |
| HY-101603 | Manitimus | 202057-76-9 | Reference compound |
| HY-101604 | Atrimustine | 75219-46-4 | Reference compound |
| HY-101604R | Atrimustine (Standard) | 75219-46-4 | Reference Standards |
| HY-101605 | Prodipine hydrochloride | 31314-39-3 | Reference compound |
| HY-101606 | Etersalate | 62992-61-4 | Reference compound |
| HY-101607 | KT-362 | 105394-80-7 | Reference compound |
| HY-101607A | KT-362 (free acid) | 93392-97-3 | Reference compound |
| HY-101608 | Ambasilide | 83991-25-7 | Reference compound |
| HY-101609 | Lesopitron (dihydrochloride) | 132449-89-9 | Reference compound |
| HY-10161 | Tozasertib | 639089-54-6 | Reference compound |
| HY-101610 | OPC-28326 | 167626-17-7 | Reference compound |
| HY-101611 | MSC2530818 | 1883423-59-3 | Reference compound |
| HY-101612 | SPD-473 citrate | 161190-26-7 | Reference compound |
| HY-101616 | ABT-639 hydrochloride | 1235560-31-2 | Reference compound |
| HY-101617 | Droxicainide | 78289-26-6 | Reference compound |
| HY-101617A | Droxicainide (hydrochloride) | 149572-05-4 | Reference compound |
| HY-101618 | L162389 | 169281-53-2 | Reference compound |
| HY-101619 | Abaperidone | 183849-43-6 | Reference compound |
| HY-101619A | Abaperidone (hydrochloride) | 183849-45-8 | Reference compound |
| HY-10162 | Olaparib | 763113-22-0 | Reference compound |
| HY-101620 | MRZ 2-514 | 202808-11-5 | Reference compound |
| HY-101621 | Teludipine hydrochloride | 108700-03-4 | Reference compound |
| HY-101621S | Teludipine-d6 | 1246833-02-2 | Isotope-Labeled Compounds |
| HY-101622 | 5-HT6/7 antagonist 1 | 131999-28-5 | Reference compound |
| HY-101625 | Recilisib | 334969-03-8 | Reference compound |
| HY-101625A | Recilisib (sodium) | 922139-31-9 | Reference compound |
| HY-101626 | Sigma-LIGAND-1 | 139652-01-0 | Reference compound |
| HY-101626A | Sigma-LIGAND-1 (hydrochloride) | 139652-86-1 | Reference compound |
| HY-101627 | YM17E | 124900-72-7 | Reference compound |
| HY-101628 | VEGFR-2-IN-9 | 408502-06-7 | Reference compound |
| HY-101629 | (E)-Crotylbarbital | 28360-89-6 | Reference compound |
| HY-10162R | Olaparib (Standard) | 763113-22-0 | Reference Standards |
| HY-10162S | Olaparib-d5 | 2143107-56-4 | Isotope-Labeled Compounds |
| HY-10162S1 | Olaparib-d8 | | Isotope-Labeled Compounds |
| HY-10162S3 | Olaparib-d4-1 | 2143107-55-3 | Isotope-Labeled Compounds |
| HY-10163 | Dabigatran | 211914-51-1 | Reference compound |
| HY-101630 | Deramciclane | 120444-71-5 | Reference compound |
| HY-101630A | Deramciclane (fumarate) | 120444-72-6 | Reference compound |
| HY-101630R | Deramciclane (Standard) | 120444-71-5 | Reference Standards |
| HY-101631 | Levophacetoperane (hydrochloride) | 23257-56-9 | Reference compound |
| HY-101632 | Irindalone | 96478-43-2 | Reference compound |
| HY-101633 | GSK-1004723 | 955359-72-5 | Reference compound |
| HY-101634 | ABT-072 | 1132936-00-5 | Reference compound |
| HY-101634A | ABT-072 (potassium trihydrate) | 1132940-31-8 | Reference compound |
| HY-101635 | Proxibarbal | 2537-29-3 | Reference compound |
| HY-101637 | Reglitazar | 170861-63-9 | Reference compound |
| HY-101638 | (±)-Fabesetron (hydrochloride) | 129299-81-6 | Reference compound |
| HY-101638A | (±)-Fabesetron | 129299-72-5 | Reference compound |
| HY-101639 | CP-409092 | 194098-25-4 | Reference compound |
| HY-101639A | CP-409092 (hydrochloride) | 225240-86-8 | Reference compound |
| HY-10163AS | Dabigatran-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10163AS1 | Dabigatran-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10163R | Dabigatran (Standard) | 211914-51-1 | Reference Standards |
| HY-10163S | Dabigatran-d4 | 1618637-32-3 | Isotope-Labeled Compounds |
| HY-10163S1 | Dabigatran-d3 | 1246817-44-6 | Isotope-Labeled Compounds |
| HY-10163S2 | Dabigatran-13C6 | 1210608-88-0 | Isotope-Labeled Compounds |
| HY-10163S3 | Dabigatran-13C,d3 | | Isotope-Labeled Compounds |
| HY-10164 | E-6123 | 131614-02-3 | Reference compound |
| HY-101640 | TPA 023 | 252977-51-8 | Reference compound |
| HY-101641 | NRA-0160 | 204718-47-8 | Reference compound |
| HY-101642 | Losmiprofen | 74168-08-4 | Reference compound |
| HY-101644 | Saterinone | 102669-89-6 | Reference compound |
| HY-101644A | Saterinone hydrochloride | 102685-83-6 | Reference compound |
| HY-101646 | Saviprazole | 121617-11-6 | Reference compound |
| HY-101647 | Intoplicine | 125974-72-3 | Reference compound |
| HY-101647A | Intoplicine (dimesylate) | 133711-99-6 | Reference compound |
| HY-101648 | ACAT-IN-1 cis isomer | 145961-79-1 | Reference compound |
| HY-101649 | Imiglitazar | 250601-04-8 | Reference compound |
| HY-10165 | PSI-6130 | 817204-33-4 | Reference compound |
| HY-101651 | WQ 2743 | 189280-13-5 | Reference compound |
| HY-101653 | MHP 133 | 147340-43-0 | Reference compound |
| HY-101654 | Rocepafant | 132579-32-9 | Reference compound |
| HY-101655 | COX-2-IN-2 | 134729-13-8 | Reference compound |
| HY-101656 | Medroxalol | 56290-94-9 | Reference compound |
| HY-101656A | Medroxalol (hydrochloride) | 70161-10-3 | Reference compound |
| HY-101657 | Clocoumarol | 35838-63-2 | Reference compound |
| HY-101658 | Pargolol hydrochloride | 36902-82-6 | Reference compound |
| HY-101658A | Pargolol | 47082-97-3 | Reference compound |
| HY-101660 | Nifursemizone | 5579-89-5 | Reference compound |
| HY-101661 | Win 58237 | 158001-76-4 | Reference compound |
| HY-101662 | Pibrentasvir | 1353900-92-1 | Reference compound |
| HY-101663 | Ruzasvir | 1613081-64-3 | Reference compound |
| HY-101664 | Ilaprazole | 172152-36-2 | Reference compound |
| HY-101664R | Ilaprazole (Standard) | 172152-36-2 | Reference Standards |
| HY-101664S | Ilaprazole-d3 | 1070969-17-3 | Isotope-Labeled Compounds |
| HY-101665 | Pagoclone | 133737-32-3 | Reference compound |
| HY-101666 | HBX 41108 | 924296-39-9 | Reference compound |
| HY-101667 | LTURM34 | 1879887-96-3 | Reference compound |
| HY-101668 | Sulamserod | 219757-90-1 | Reference compound |
| HY-101668A | Sulamserod (hydrochloride) | 184159-40-8 | Reference compound |
| HY-101669 | TDN345 | 134069-68-4 | Reference compound |
| HY-10167 | Tecalcet | 148717-54-8 | Reference compound |
| HY-101670 | MTPPA | 70991-61-6 | Reference compound |
| HY-101671 | S-methyl-KE-298 | 143584-75-2 | Reference compound |
| HY-101671R | S-methyl-KE-298 (Standard) | 143584-75-2 | Reference Standards |
| HY-101672 | Deferitazole | 945635-15-4 | Reference compound |
| HY-101674 | Tiapamil hydrochloride | 57010-32-9 | Reference compound |
| HY-101675 | Setipafant | 132418-35-0 | Reference compound |
| HY-101676 | RG-12525 | 120128-20-3 | Reference compound |
| HY-101677 | cPrPMEDAP | 182798-83-0 | Reference compound |
| HY-101679 | YM-58790 | 214558-72-2 | Reference compound |
| HY-101679A | YM-58790 (free base) | 168830-70-4 | Reference compound |
| HY-10167A | Tecalcet (Hydrochloride) | 177172-49-5 | Reference compound |
| HY-101680 | Zolasartan | 145781-32-4 | Reference compound |
| HY-101681 | Utibapril | 109683-61-6 | Reference compound |
| HY-101682 | SCH 42495 | 136511-43-8 | Reference compound |
| HY-101682A | SCH 42495 (racemate) | 145841-10-7 | Reference compound |
| HY-101682B | (R)-SCH 42495 | 156792-25-5 | Reference compound |
| HY-101683 | Deriglidole | 122830-14-2 | Reference compound |
| HY-101684 | Nitroxazepine | 47439-36-1 | Reference compound |
| HY-101684A | Nitroxazepine (hydrochloride) | 16398-39-3 | Reference compound |
| HY-101685 | Iganidipine | 119687-33-1 | Reference compound |
| HY-101685A | Iganidipine di(hydrochloride) | 117241-46-0 | Reference compound |
| HY-101686 | LM-1484 | 197506-02-8 | Reference compound |
| HY-101687 | Nosantine (racemate) | 75166-67-5 | Reference compound |
| HY-101689 | Benzpiperylone | 53-89-4 | Reference compound |
| HY-101690 | QF0301B | 149247-12-1 | Reference compound |
| HY-101691 | Ecastolol | 77695-52-4 | Reference compound |
| HY-101692 | AZ-1355 | 75451-07-9 | Reference compound |
| HY-101693 | Senazodan | 98326-32-0 | Reference compound |
| HY-101693A | Senazodan (hydrochloride) | 98326-33-1 | Reference compound |
| HY-101694 | Siltenzepine | 98374-54-0 | Reference compound |
| HY-101695 | EP1-antagonist-1 | 851204-35-8 | Reference compound |
| HY-101696 | Fluproquazone | 40507-23-1 | Reference compound |
| HY-101698 | Alniditan | 152317-89-0 | Reference compound |
| HY-101698B | Alniditan (dihydrochloride) | 155428-00-5 | Reference compound |
| HY-101699 | AMG-076 (free base) | 693823-79-9 | Reference compound |
| HY-101699A | AMG-076 | 1001438-96-5 | Reference compound |
| HY-101700 | LCB-2853 | 141335-10-6 | Reference compound |
| HY-101701 | Hepronicate | 7237-81-2 | Reference compound |
| HY-101703 | Ro 31-9790 | 145337-55-9 | Reference compound |
| HY-101704 | Y1 receptor antagonist 1 | 221697-09-2 | Reference compound |
| HY-101704A | Y1 receptor antagonist 1 (formic) | | Reference compound |
| HY-101705 | Tibenelast sodium | 105102-18-9 | Reference compound |
| HY-101706 | CGP48369 | 135689-23-5 | Reference compound |
| HY-101707 | UK51656 | 88150-59-8 | Reference compound |
| HY-101708 | N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea | 97627-24-2 | Reference compound |
| HY-101709 | Ricasetron | 117086-68-7 | Reference compound |
| HY-10171 | NPS-2143 (hydrochloride) | 324523-20-8 | Reference compound |
| HY-101710 | Benzgalantamine | 224169-27-1 | Reference compound |
| HY-101712 | TRC051384 | 867164-40-7 | Reference compound |
| HY-101713 | Ilacirnon | 1100318-47-5 | Reference compound |
| HY-101713R | Ilacirnon (Standard) | 1100318-47-5 | Reference Standards |
| HY-101714 | Oxyphenisatin acetate | 115-33-3 | Reference compound |
| HY-101714R | Oxyphenisatin acetate (Standard) | 115-33-3 | Reference Standards |
| HY-101715 | Panidazole | 13752-33-5 | Reference compound |
| HY-101716 | RP-54745 | 135330-08-4 | Reference compound |
| HY-101717 | Indanidine | 85392-79-6 | Reference compound |
| HY-101718 | Aticaprant | 1174130-61-0 | Reference compound |
| HY-101719 | Ketocaine | 1092-46-2 | Reference compound |
| HY-10172 | IMD-0354 | 978-62-1 | Reference compound |
| HY-101720 | Fradafiban | 148396-36-5 | Reference compound |
| HY-101720A | Fradafiban (hydrochloride) | | Reference compound |
| HY-101721 | Ko-3290 | 79848-61-6 | Reference compound |
| HY-101722 | Melinamide | 14417-88-0 | Reference compound |
| HY-101722R | Melinamide (Standard) | 14417-88-0 | Reference Standards |
| HY-101723 | Modecainide | 81329-71-7 | Reference compound |
| HY-101723R | Modecainide (Standard) | 81329-71-7 | Reference Standards |
| HY-101724 | ReN-1869 hydrochloride | 170149-76-5 | Reference compound |
| HY-101725 | Meclonazepam | 58662-84-3 | Reference compound |
| HY-101725A | (R)-Meclonazepam | 86630-81-1 | Reference compound |
| HY-101726 | DuP 105 | 96800-41-8 | Reference compound |
| HY-101727 | Nexopamil (racemate) | 116759-35-4 | Reference compound |
| HY-101729 | Anti-Heart Failure Agent 1 | 142648-47-3 | Reference compound |
| HY-10172R | IMD-0354 (Standard) | 978-62-1 | Reference Standards |
| HY-101730 | Antibacterial compound 2 | 170104-58-2 | Reference compound |
| HY-101731 | CP-96021 (hydrochloride) | 167011-22-5 | Reference compound |
| HY-101733 | Zabicipril (hydrochloride) | 90130-77-1 | Reference compound |
| HY-101734 | Trestolone | 3764-87-2 | Reference compound |
| HY-101735 | (9Z,11E)-Prodlure | 50767-79-8 | Natural Products |
| HY-101735R | (9Z,11E)-Prodlure (Standard) | 50767-79-8 | Reference Standards |
| HY-101736 | AMG9810 | 545395-94-6 | Reference compound |
| HY-101737 | 24-Norursodeoxycholic acid | 99697-24-2 | Reference compound |
| HY-101737R | 24-Norursodeoxycholic acid (Standard) | 99697-24-2 | Reference Standards |
| HY-101738 | Peliglitazar | 331744-64-0 | Reference compound |
| HY-101738A | Peliglitazar (racemate) | 331744-72-0 | Reference compound |
| HY-101739 | Amcinafal | 3924-70-7 | Reference compound |
| HY-10174 | PD184161 | 212631-67-9 | Reference compound |
| HY-101740 | SQ-31765 | 138383-07-0 | Reference compound |
| HY-101743 | Elucaine | 25314-87-8 | Reference compound |
| HY-101744 | Ipsalazide | 82101-17-5 | Reference compound |
| HY-101745 | Rocastine | 91833-49-7 | Reference compound |
| HY-101746 | GSK376501A | 1010412-80-2 | Reference compound |
| HY-101747 | ADR 851 (free base) | 138559-56-5 | Reference compound |
| HY-101747A | ADR 851 | 123805-17-4 | Reference compound |
| HY-101748 | Tegadifur | 62987-05-7 | Reference compound |
| HY-101749 | WAY127093B (racemate) | 145743-63-1 | Reference compound |
| HY-101750 | Arrhythmias-Targeting Compound 1 | 335619-12-0 | Reference compound |
| HY-101751 | Chlorthenoxazine | 132-89-8 | Reference compound |
| HY-101752 | (±)-Befunolol | 39552-01-7 | Reference compound |
| HY-101752A | (±)-Befunolol (hydrochloride) | 39543-79-8 | Reference compound |
| HY-101753 | Cianopramine | 66834-24-0 | Reference compound |
| HY-101753A | Cianopramine (hydrochloride) | 66834-20-6 | Reference compound |
| HY-101754 | Oxyfenamate | 50-19-1 | Reference compound |
| HY-101755 | Tedatioxetine (hydrobromide) | 960151-65-9 | Reference compound |
| HY-101756 | SDZ281-977 | 150779-71-8 | Reference compound |
| HY-101757 | NO-prednisolone | 327610-87-7 | Reference compound |
| HY-101758 | BM-131246 | 103787-97-9 | Reference compound |
| HY-101759 | Isoxsuprine-monoester-1 | 67160-74-1 | Reference compound |
| HY-101760 | GSK2982772 | 1622848-92-3 | Reference compound |
| HY-101761 | TM5441 | 1190221-43-2 | Reference compound |
| HY-101761A | TM5441 (sodium) | 2319722-53-5 | Reference compound |
| HY-101762 | TyK2-IN-2 | 2098466-94-3 | Reference compound |
| HY-101763A | (S,R,S)-AHPC (monohydrochloride) | 1448189-80-7 | Reference compound |
| HY-101763B | (S,R,S)-AHPC (dihydrochloride) | 2137142-47-1 | Reference compound |
| HY-101764 | Lintitript | 136381-85-6 | Reference compound |
| HY-101765 | GW 833972A | 1092502-33-4 | Reference compound |
| HY-101766 | Btk inhibitor 2 | 1558036-85-3 | Reference compound |
| HY-101768 | PRN1371 | 1802929-43-6 | Reference compound |
| HY-101769 | UAMC00039 (dihydrochloride) | 697797-51-6 | Reference compound |
| HY-101770 | BTB-1 | 86030-08-2 | Reference compound |
| HY-101771A | (2-Chloropyridin-4-yl)methanamine hydrochloride | 916210-98-5 | Reference compound |
| HY-101772 | Ziritaxestat | 1628260-79-6 | Reference compound |
| HY-101772R | Ziritaxestat (Standard) | 1628260-79-6 | Reference Standards |
| HY-101773 | c-Met-IN-2 | 1635406-73-3 | Reference compound |
| HY-101774 | CSF1R-IN-1 | 2095849-04-8 | Reference compound |
| HY-101775 | 9-Hydroxyellipticin | 51131-85-2 | Reference compound |
| HY-101775A | 9-Hydroxyellipticine (hydrochloride) | 52238-35-4 | Reference compound |
| HY-101775AR | 9-Hydroxyellipticine (hydrochloride) (Standard) | 52238-35-4 | Reference Standards |
| HY-101776 | Desmethyl-VS-5584 | 1246535-95-4 | Reference compound |
| HY-101776A | Desmethyl-VS-5584 (hydrochloride) | | Reference compound |
| HY-101777 | TC-O 9311 | 444932-31-4 | Reference compound |
| HY-101778 | ML311 | 315698-17-0 | Reference compound |
| HY-101779 | DCG04 | 314263-42-8 | Reference compound |
| HY-101779A | DCG04 isomer-1 | | Reference compound |
| HY-10178 | PHA-680632 | 398493-79-3 | Reference compound |
| HY-101780 | Tinostamustine | 1236199-60-2 | Reference compound |
| HY-101780A | Tinostamustine (hydrochloride) | 1793059-58-1 | Reference compound |
| HY-101782 | HSK0935 | 1638851-44-1 | Reference compound |
| HY-101783 | GNE-955 | 1527523-39-2 | Reference compound |
| HY-101784 | NE 52-QQ57 | 1401728-56-0 | Reference compound |
| HY-101785 | eIF4A3-IN-2 | 2095677-20-4 | Reference compound |
| HY-101786 | KZR-504 | 1629052-78-3 | Reference compound |
| HY-101787 | TP-024 | 1358575-02-6 | Reference compound |
| HY-101788 | Glucokinase activator 1 | 1328987-85-4 | Reference compound |
| HY-101789 | Nav1.7-IN-3 | 1788872-06-9 | Reference compound |
| HY-10179 | Danusertib | 827318-97-8 | Reference compound |
| HY-101790 | ZM223 | 2031177-48-5 | Reference compound |
| HY-101790A | ZM223 (hydrochloride) | 2438679-27-5 | Reference compound |
| HY-101791 | P-gp inhibitor 1 | 2050747-49-2 | Reference compound |
| HY-101792 | RG7800 | 1449598-06-4 | Reference compound |
| HY-101792A | RG7800 (tetrahydrochloride) | | Reference compound |
| HY-101793 | BMS-935177 | 1231889-53-4 | Reference compound |
| HY-101794 | 2-(Pyridyldithio)ethylamine (hydrochloride) | 106139-15-5 | Biochemical Assay Reagents |
| HY-101795 | Larixyl acetate | 4608-49-5 | Natural Products |
| HY-101795R | Larixyl acetate (Standard) | 4608-49-5 | Reference Standards |
| HY-101796 | NSC-70220 | 4551-00-2 | Reference compound |
| HY-101797 | Veralipride | 66644-81-3 | Reference compound |
| HY-101797R | Veralipride (Standard) | 66644-81-3 | Reference Standards |
| HY-101798 | MDVN1003 | 2058116-52-0 | Reference compound |
| HY-101799 | NCGC00244536 | 2003260-55-5 | Reference compound |
| HY-10179R | Danusertib (Standard) | 827318-97-8 | Reference Standards |
| HY-10180 | MLN8054 | 869363-13-3 | Reference compound |
| HY-101800 | Senexin B | 1449228-40-3 | Reference compound |
| HY-101801 | Ac-Gly-BoroPro | 886992-99-0 | Reference compound |
| HY-101802 | Fluzinamide | 76263-13-3 | Reference compound |
| HY-101803 | CP671305 | 445295-04-5 | Reference compound |
| HY-101804 | (E)-Alprenoxime | 125720-84-5 | Reference compound |
| HY-101805 | SK1-IN-1 | 1218816-71-7 | Reference compound |
| HY-101807 | Ro-15-2041 | 77448-87-4 | Reference compound |
| HY-101808 | Doxefazepam | 40762-15-0 | Reference compound |
| HY-101809 | CNS-5161 hydrochloride | 160756-38-7 | Reference compound |
| HY-101809A | CNS 5161 | 160754-76-7 | Reference compound |
| HY-10180A | MLN8054 (sodium) | 869366-15-4 | Reference compound |
| HY-10180R | MLN8054 (Standard) | 869363-13-3 | Reference Standards |
| HY-10181 | Dasatinib | 302962-49-8 | Reference compound |
| HY-101810 | Tazanolast | 82989-25-1 | Reference compound |
| HY-101811 | LAS-31180 | 137338-43-3 | Reference compound |
| HY-101812 | Terbufibrol | 56488-59-6 | Reference compound |
| HY-101813 | Laflunimus | 147076-36-6 | Reference compound |
| HY-101813R | Laflunimus (Standard) | 147076-36-6 | Reference Standards |
| HY-101815 | Lidanserin | 73725-85-6 | Reference compound |
| HY-101817 | Spirendolol | 81840-58-6 | Reference compound |
| HY-101818 | PNU288034 | 383199-88-0 | Reference compound |
| HY-101819 | Antibacterial compound 1 | 232951-56-3 | Reference compound |
| HY-10181A | Dasatinib (hydrochloride) | 854001-07-3 | Reference compound |
| HY-10181AR | Dasatinib (hydrochloride) (Standard) | 854001-07-3 | Reference Standards |
| HY-10181B | Dasatinib (monohydrate) | 863127-77-9 | Reference compound |
| HY-10181BR | Dasatinib (monohydrate) (Standard) | 863127-77-9 | Reference Standards |
| HY-10181G | Dasatinib (GMP) | 302962-49-8 | GMP Small Molecules |
| HY-10181R | Dasatinib (Standard) | 302962-49-8 | Reference Standards |
| HY-10181S | Dasatinib-d8 | 1132093-70-9 | Isotope-Labeled Compounds |
| HY-10181S1 | Dasatinib-d4 | 1160297-08-4 | Isotope-Labeled Compounds |
| HY-10182 | Laduviglusib | 252917-06-9 | Reference compound |
| HY-101820 | Simotinib | 944258-89-3 | Reference compound |
| HY-101820A | Simotinib (hydrochloride) | 1538617-88-7 | Reference compound |
| HY-101820R | Simotinib (Standard) | 944258-89-3 | Reference Standards |
| HY-101822 | Naminterol | 93047-40-6 | Reference compound |
| HY-101823A | A-81282 | 141872-46-0 | Reference compound |
| HY-101826 | ER21355 | 150452-18-9 | Reference compound |
| HY-101826A | ER21355 (hydrochloride) | 150452-21-4 | Reference compound |
| HY-101827 | Citenamide | 10423-37-7 | Reference compound |
| HY-101828 | Guaiapate | 852-42-6 | Reference compound |
| HY-101829 | Sulfaproxiline | 116-42-7 | Reference compound |
| HY-10182A | Laduviglusib (monohydrochloride) | 1797989-42-4 | Reference compound |
| HY-10182AR | Laduviglusib (monohydrochloride) (Standard) | 1797989-42-4 | Reference Standards |
| HY-10182B | Laduviglusib (trihydrochloride) | 1782235-14-6 | Reference compound |
| HY-10182BR | Laduviglusib (trihydrochloride) (Standard) | 1782235-14-6 | Reference Standards |
| HY-10182C | Laduviglusib (dihydrochloride) | 2109414-84-6 | Reference compound |
| HY-10182G | Laduviglusib (GMP) | 252917-06-9 | GMP Small Molecules |
| HY-10182R | Laduviglusib (Standard) | 252917-06-9 | Reference Standards |
| HY-10183 | Go6976 | 136194-77-9 | Reference compound |
| HY-101830 | Wy 49051 | 113418-56-7 | Reference compound |
| HY-101831 | Heterocyclyl carbamate derivative 1 | 168830-01-1 | Reference compound |
| HY-101832 | SBC-110736 | 1629166-02-4 | Reference compound |
| HY-101833 | YM-264 | 131888-54-5 | Reference compound |
| HY-101834 | ACT-462206 | 1361321-96-1 | Reference compound |
| HY-101835 | Decoyinine | 2004-04-8 | Reference compound |
| HY-101836 | DKM 2-93 | 65836-72-8 | Reference compound |
| HY-101837 | CGP 53716 | 152459-94-4 | Reference compound |
| HY-101838 | dBET1 | 1799711-21-9 | Reference compound |
| HY-101839 | ML381 | 1623481-80-0 | Reference compound |
| HY-10184 | TG 100572 | 867334-05-2 | Reference compound |
| HY-101840 | EIPA | 1154-25-2 | Reference compound |
| HY-101840A | EIPA (hydrochloride) | 1345839-28-2 | Reference compound |
| HY-101840AR | EIPA (hydrochloride) (Standard) | 1345839-28-2 | Reference Standards |
| HY-101840R | EIPA (Standard) | 1154-25-2 | Reference Standards |
| HY-101841 | LY 2033298 | 886047-13-8 | Reference compound |
| HY-101842 | ND-646 | 1434639-57-2 | Reference compound |
| HY-101843 | ML213 | 489402-47-3 | Reference compound |
| HY-101844 | ML-18 | 1422269-30-4 | Reference compound |
| HY-101845 | FITM | 932737-65-0 | Reference compound |
| HY-101846 | AX-15836 | 2035509-96-5 | Reference compound |
| HY-101847 | DBHDA | 99584-96-0 | Reference compound |
| HY-101848 | Latrunculin B | 76343-94-7 | Natural Products |
| HY-101848A | 16-epi-Latrunculin B | 444911-05-1 | Reference compound |
| HY-101849 | Fasentin | 392721-37-8 | Reference compound |
| HY-101849R | Fasentin (Standard) | 392721-37-8 | Reference Standards |
| HY-10185 | TG 100572 (Hydrochloride) | 867331-64-4 | Reference compound |
| HY-101850 | MOPSO | 68399-77-9 | Biochemical Assay Reagents |
| HY-101853 | STAT5-IN-1 | 285986-31-4 | Reference compound |
| HY-101854 | N6-(2-Phenylethyl)adenosine | 20125-39-7 | Reference compound |
| HY-101855 | Emrusolmin | 882697-00-9 | Reference compound |
| HY-101856 | BMS-986142 | 1643368-58-4 | Reference compound |
| HY-101857 | TP-020 | 1800025-30-2 | Reference compound |
| HY-101858 | BQCA | 338747-41-4 | Reference compound |
| HY-101859 | NucPE1 | 1404091-23-1 | Dye Reagents |
| HY-10186 | TG 100801 | 867331-82-6 | Reference compound |
| HY-101860 | GIBH-130 | 1252608-59-5 | Reference compound |
| HY-101861 | Miridesap | 224624-80-0 | Reference compound |
| HY-101862 | CB-7921220 | 115453-99-1 | Reference compound |
| HY-101863 | CB-6673567 | 379218-90-3 | Reference compound |
| HY-101864 | Blarcamesine (hydrochloride) | 195615-84-0 | Reference compound |
| HY-101865 | KKL-10 | 952849-76-2 | Reference compound |
| HY-101866 | KKL-35 | 865285-29-6 | Reference compound |
| HY-101867 | AU1235 | 1338780-86-1 | Reference compound |
| HY-101868 | INF39 | 866028-26-4 | Reference compound |
| HY-101869 | MK-0343 | 233275-76-8 | Reference compound |
| HY-101869R | MK-0343 (Standard) | 233275-76-8 | Reference Standards |
| HY-10187 | TG 100801 (Hydrochloride) | 1018069-81-2 | Reference compound |
| HY-101870 | Uzansertib | 1620012-39-6 | Reference compound |
| HY-101870B | Uzansertib (phosphate) | 2088852-47-3 | Reference compound |
| HY-101871 | Trehalose 6-behenate | 66755-19-9 | Reference compound |
| HY-101872 | GSK-872 | 1346546-69-7 | Reference compound |
| HY-101872A | GSK-872 (hydrochloride) | 2703752-81-0 | Reference compound |
| HY-101873 | Atorvastatin lactone | 125995-03-1 | Reference compound |
| HY-101873R | Atorvastatin lactone (Standard) | 125995-03-1 | Reference Standards |
| HY-101873S | Atorvastatin lactone-d5 | | Isotope-Labeled Compounds |
| HY-101876 | Rhodamine 800 | 137993-41-0 | Dye Reagents |
| HY-101877 | Statine | 49642-07-1 | Reference compound |
| HY-101877R | Statine (Standard) | 49642-07-1 | Reference Standards |
| HY-101878 | Texas Red | 60311-02-6 | Dye Reagents |
| HY-101879 | Acridine Orange (hydrochloride) | 65-61-2 | Dye Reagents |
| HY-101880 | ADHP | 119171-73-2 | Dye Reagents |
| HY-101882 | BCECF | 85138-49-4 | Dye Reagents |
| HY-101883 | BCECF-AM | 117464-70-7 | Dye Reagents |
| HY-101884 | Biocytin | 576-19-2 | Reference compound |
| HY-101884A | Biotinylated-D-lysine (TFA) | | Reference compound |
| HY-101884R | Biocytin (Standard) | 576-19-2 | Reference Standards |
| HY-101885 | Biotin LC hydrazide | 109276-34-8 | Biochemical Assay Reagents |
| HY-101886 | 5-BrUTP sodium salt | 161848-60-8 | Biochemical Assay Reagents |
| HY-101887 | Calcein Blue | 54375-47-2 | Dye Reagents |
| HY-101888 | Cresyl Violet (acetate) | 10510-54-0 | Dye Reagents |
| HY-101889 | Cresyl Violet perchlorate | 41830-80-2 | Dye Reagents |
| HY-101890 | Dabsyl chloride | 56512-49-3 | Dye Reagents |
| HY-101891 | Di-8-ANEPPS | 157134-53-7 | Dye Reagents |
| HY-101892 | DiBAC4(3) | 70363-83-6 | Dye Reagents |
| HY-101893 | Dihydrofluorescein diacetate | 35340-49-9 | Dye Reagents |
| HY-101894 | Dihydrorhodamine 123 | 109244-58-8 | Dye Reagents |
| HY-101895 | Fluorescein di(β-D-galactopyranoside) | 17817-20-8 | Dye Reagents |
| HY-101896 | Fluo-4 AM | 273221-67-3 | Dye Reagents |
| HY-101897 | Fura-2 AM | 108964-32-5 | Dye Reagents |
| HY-101898 | Indo-1 AM | 112926-02-0 | Dye Reagents |
| HY-101899 | Monochlorobimane | 76421-73-3 | Dye Reagents |
| HY-101900 | Nile Blue A (sulfate) | 3625-57-8 | Dye Reagents |
| HY-101901 | Oxazine 1 perchlorate | 24796-94-9 | Dye Reagents |
| HY-101902 | Quin-2AM | 83104-85-2 | Dye Reagents |
| HY-101903 | BMS-309403 | 300657-03-8 | Reference compound |
| HY-101903A | BMS-309403 (sodium) | 2802523-05-1 | Reference compound |
| HY-101903AR | BMS-309403 (sodium) (Standard) | 2802523-05-1 | Reference Standards |
| HY-101903R | BMS-309403 (Standard) | 300657-03-8 | Reference Standards |
| HY-101904 | 2-Chloro-2'-deoxycytidine | 10212-19-8 | Reference compound |
| HY-101905 | Moniliformin (sodium salt) | 71376-34-6 | Natural Products |
| HY-101906 | DC260126 | 346692-04-4 | Reference compound |
| HY-101907 | ASP7663 | 1190217-35-6 | Reference compound |
| HY-101908 | BMS CCR2 22 | 445479-97-0 | Reference compound |
| HY-101909 | Val-Cit-PAB-MMAF | 863971-56-6 | ADC Related |
| HY-10191 | Linsitinib | 867160-71-2 | Reference compound |
| HY-101910 | PSB-12062 | 55476-47-6 | Reference compound |
| HY-101911 | 5-BDBD | 768404-03-1 | Reference compound |
| HY-101913 | IL-17A antagonist 1 | 2205034-18-8 | Reference compound |
| HY-101915 | IL-17A antagonist 3 | 2230780-65-9 | Reference compound |
| HY-101916 | Heparan Sulfate | 9050-30-0 | Natural Products |
| HY-101916R | Heparan Sulfate (Standard) | 9050-30-0 | Reference Standards |
| HY-101918 | DS-1040 (Tosylate) | 1335138-89-0 | Reference compound |
| HY-10191R | Linsitinib (Standard) | 867160-71-2 | Reference Standards |
| HY-10192 | NVP-TAE 684 | 761439-42-3 | Reference compound |
| HY-101920 | Autophinib | 1644443-47-9 | Reference compound |
| HY-101921 | PI3Kδ-IN-1 | 1911564-39-0 | Reference compound |
| HY-101922 | IRAK4-IN-1 | 1820787-94-7 | Reference compound |
| HY-101923 | LYN-1604 | 2088939-99-3 | Reference compound |
| HY-101923A | LYN-1604 (hydrochloride) | 2216753-86-3 | Reference compound |
| HY-101923B | LYN-1604 (dihydrochloride) | 2310109-38-5 | Reference compound |
| HY-101924 | AVN-492 | 1220646-23-0 | Reference compound |
| HY-101925 | CM-272 | 1846570-31-7 | Reference compound |
| HY-101928 | KDM4D-IN-1 | 2098902-68-0 | Reference compound |
| HY-101929 | CU-CPT17e | 2109805-75-4 | Reference compound |
| HY-10193 | AZD-1480 | 935666-88-9 | Reference compound |
| HY-101930 | BMS-816336 | 1009583-20-3 | Reference compound |
| HY-101930A | (Rac)-BMS-816336 | 1009365-98-3 | Reference compound |
| HY-101930B | (R)-BMS-816336 | 1009583-83-8 | Reference compound |
| HY-101931 | hVEGF-IN-1 | 1637443-98-1 | Reference compound |
| HY-101932 | TNP-470 | 129298-91-5 | Reference compound |
| HY-101933 | MARK-IN-1 | 1109283-93-3 | Reference compound |
| HY-101934 | MARK-IN-2 | 1314893-26-9 | Reference compound |
| HY-101937 | L-ANAP | 1313516-26-5 | Dye Reagents |
| HY-101937A | (±)-ANAP | 1185251-08-4 | Dye Reagents |
| HY-101937B | L-ANAP (hydrochloride) | | Dye Reagents |
| HY-101937C | (±)-ANAP (hydrochloride) | 2308035-47-2 | Dye Reagents |
| HY-101937D | L-ANAP (TFA) | 2287346-69-2 | Dye Reagents |
| HY-101938 | Sinefungin | 58944-73-3 | Reference compound |
| HY-101939 | RP-001 | 1306761-53-4 | Reference compound |
| HY-101939A | RP-001 (hydrochloride) | 1781880-34-9 | Reference compound |
| HY-10193A | (1R)-AZD-1480 | 935666-99-2 | Reference compound |
| HY-10194 | Sepantronium (bromide) | 781661-94-7 | Reference compound |
| HY-101941 | BTK IN-1 | 1270014-40-8 | Reference compound |
| HY-101942 | Zegocractin | 1713240-67-5 | Reference compound |
| HY-101943 | LY 345899 | 10538-99-5 | Reference compound |
| HY-101944 | Iralukast | 151581-24-7 | Reference compound |
| HY-101945 | A-69412 | 123606-23-5 | Reference compound |
| HY-101946 | AS-35 | 108427-72-1 | Reference compound |
| HY-101947 | SMI-16a | 587852-28-6 | Reference compound |
| HY-10194A | Sepantronium (hydrochloride) | 355406-09-6 | Reference compound |
| HY-10195 | Ruboxistaurin | 169939-94-0 | Reference compound |
| HY-101950 | KIN1148 | 1428729-56-9 | Reference compound |
| HY-101952 | Prostaglandin E2 | 363-24-6 | Natural Products |
| HY-101952G | Prostaglandin E2 (GMP) | 363-24-6 | GMP Small Molecules |
| HY-101952R | Prostaglandin E2 (Standard) | 363-24-6 | Reference Standards |
| HY-101952S | Prostaglandin E2-d4 | 34210-10-1 | Isotope-Labeled Compounds |
| HY-101952S1 | Prostaglandin E2-d9 | 1356347-42-6 | Isotope-Labeled Compounds |
| HY-101953 | β-Apo-13-carotenone | 17974-57-1 | Reference compound |
| HY-101954 | Inarigivir | 475650-36-3 | Reference compound |
| HY-101954A | Inarigivir (ammonium) | 2172788-92-8 | Reference compound |
| HY-101955 | (2S,6S)-Hydroxynorketamine (hydrochloride) | 1430202-70-2 | Reference compound |
| HY-101955A | (2R,6R)-Hydroxynorketamine (hydrochloride) | 1430202-69-9 | Reference compound |
| HY-101957 | AG 1295 | 71897-07-9 | Reference compound |
| HY-101957R | AG 1295 (Standard) | 71897-07-9 | Reference Standards |
| HY-101958 | Tyrphostin 25 | 118409-58-8 | Reference compound |
| HY-101958R | Tyrphostin 25 (Standard) | 118409-58-8 | Reference Standards |
| HY-101959 | Tyrphostin AG213 | 122520-86-9 | Reference compound |
| HY-101959A | Tyrphostin 47 | 118409-60-2 | Reference compound |
| HY-10195A | Ruboxistaurin (mesylate) | 192050-59-2 | Reference compound |
| HY-10195B | Ruboxistaurin (hydrochloride) | 169939-93-9 | Reference compound |
| HY-10195BS | Ruboxistaurin-d6 (hydrochloride) | 1794767-04-6 | Isotope-Labeled Compounds |
| HY-10195R | Ruboxistaurin (Standard) | 169939-94-0 | Reference Standards |
| HY-101960 | (Z)-Tyrphostin A51 | 122520-90-5 | Reference compound |
| HY-101960A | Tyrphostin A51 | 126433-07-6 | Reference compound |
| HY-101961 | Tyrphostin AG 1288 | 116313-73-6 | Reference compound |
| HY-101962 | HNMPA | 132541-52-7 | Reference compound |
| HY-101963 | AD80 | 1384071-99-1 | Reference compound |
| HY-101964 | SPI-112 | 1051387-90-6 | Reference compound |
| HY-101965 | SPI-112Me | 1243685-62-2 | Reference compound |
| HY-101966 | NCT-503 | 1916571-90-8 | Reference compound |
| HY-101967 | GSK299423 | 1352149-24-6 | Reference compound |
| HY-101968 | 2'-Deoxypseudoisocytidine | 65358-18-1 | Oligonucleotides |
| HY-101969 | Pseudothymidine | 65358-15-8 | Oligonucleotides |
| HY-10197 | Wortmannin | 19545-26-7 | Reference compound |
| HY-101970 | Deoxypseudouridine | 39967-60-7 | Oligonucleotides |
| HY-101971 | AZ PFKFB3 26 | 1704740-52-2 | Reference compound |
| HY-101972 | AZ-PFKFB3-67 | 1704741-11-6 | Reference compound |
| HY-101972A | AZ-PFKFB3-67 (quarterhydrate) | | Reference compound |
| HY-101973 | XL041 | 1256918-39-4 | Reference compound |
| HY-101974 | Biotin-PEG3-Bromide | 1041766-91-9 | Reference compound |
| HY-101976 | JAK3-IN-6 | 1443235-95-7 | Reference compound |
| HY-101977 | Selitrectinib | 2097002-61-2 | Reference compound |
| HY-101977B | (3aR)-Selitrectinib | 1350884-56-8 | Reference compound |
| HY-101977R | Selitrectinib (Standard) | 2097002-61-2 | Reference Standards |
| HY-101978 | Ciforadenant | 1202402-40-1 | Reference compound |
| HY-101979 | Numidargistat | 2095732-06-0 | Reference compound |
| HY-101979A | Numidargistat (dihydrochloride) | | Reference compound |
| HY-10197R | Wortmannin (Standard) | 19545-26-7 | Reference Standards |
| HY-10198 | Navarixin | 473727-83-2 | Reference compound |
| HY-101980 | Imaradenant | 1321514-06-0 | Reference compound |
| HY-101981 | Uridine 5'-monophosphate | 58-97-9 | Natural Products |
| HY-101981R | Uridine 5'-monophosphate (Standard) | 58-97-9 | Reference Standards |
| HY-101981S | Uridine 5'-monophosphate-15N2 | | Isotope-Labeled Compounds |
| HY-101981S1 | Uridine 5'-monophosphate-15N2,d11 (dilithium) | | Isotope-Labeled Compounds |
| HY-101981S2 | Uridine 5'-monophosphate-d11 (dilithium) | | Isotope-Labeled Compounds |
| HY-101981S3 | Uridine 5'-monophosphate-13C9,15N2 (dilithium) | 2483830-55-1 | Isotope-Labeled Compounds |
| HY-101981S4 | Uridine 5'-monophosphate-13C9 (dilithium) | | Isotope-Labeled Compounds |
| HY-101981S5 | Uridine 5'-monophosphate-15N2 (dilithium) | | Isotope-Labeled Compounds |
| HY-101982 | Lys-SMCC-DM1 | 1281816-04-3 | ADC Related |
| HY-101982A | (Rac)-Lys-SMCC-DM1 | | ADC Related |
| HY-101984 | N6,N6-Dimethyladenosine | 2620-62-4 | Reference compound |
| HY-101984R | N6,N6-Dimethyladenosine (Standard) | 2620-62-4 | Reference Standards |
| HY-101985 | BV02 | 292870-53-2 | Reference compound |
| HY-101986 | BIIE-0246 | 246146-55-4 | Reference compound |
| HY-101986A | BIIE-0246 (hydrochloride) | | Reference compound |
| HY-101986C | BIIE-0246 (dihydrochloride) | 246146-31-6 | Reference compound |
| HY-101987 | BW 245C | 72814-32-5 | Reference compound |
| HY-101988 | Prostaglandin D2 | 41598-07-6 | Natural Products |
| HY-101988R | Prostaglandin D2 (Standard) | 41598-07-6 | Reference Standards |
| HY-101988S | Prostaglandin D2-d4 | 211105-29-2 | Isotope-Labeled Compounds |
| HY-101988S1 | Prostaglandin D2-d9 | 2254642-52-7 | Isotope-Labeled Compounds |
| HY-101989 | Tubulin polymerization-IN-24 | 564468-51-5 | Reference compound |
| HY-101990 | IMS2186 | 1031206-36-6 | Reference compound |
| HY-101991 | ML291 | 1523437-16-2 | Reference compound |
| HY-101993 | Nap-FF | 946568-62-3 | Reference compound |
| HY-101996 | SMBA1 | 906440-37-7 | Reference compound |
| HY-101997 | BEPP (hydrochloride) | 455311-98-5 | Reference compound |
| HY-101998 | CTP inhibitor | 412940-35-3 | Reference compound |
| HY-101999 | EM20-25 | 141266-44-6 | Reference compound |
| HY-10199A | Ibutamoren | 159634-47-6 | Reference compound |
| HY-10200 | BMS-754807 | 1001350-96-4 | Reference compound |
| HY-102000 | IACS-9571 | 1800477-30-8 | Reference compound |
| HY-102000A | IACS-9571 (TFA) | 1883598-69-3 | Reference compound |
| HY-102000B | IACS-9571 (hydrochloride) | 2319611-93-1 | Reference compound |
| HY-102001 | Tomaymycin DM | 945490-09-5 | ADC Related |
| HY-102003 | Rucaparib (monocamsylate) | 1859053-21-6 | Reference compound |
| HY-102003A | Rucaparib (camsylate) | 1327258-57-0 | Reference compound |
| HY-102004 | Rilapladib | 412950-08-4 | Reference compound |
| HY-102007 | Gamitrinib TPP | 1131626-46-4 | Reference compound |
| HY-102007A | Gamitrinib TPP hexafluorophosphate | 1131626-47-5 | Reference compound |
| HY-102008 | LBM-415 | 478913-91-6 | Reference compound |
| HY-10201 | Sorafenib | 284461-73-0 | Reference compound |
| HY-102010 | Pancratistatin | 96203-70-2 | Natural Products |
| HY-102011 | BMS-1166 | 1818314-88-3 | Reference compound |
| HY-102011A | BMS-1166 (hydrochloride) | 2113650-05-6 | Reference compound |
| HY-102013 | Omilancor | 1912399-75-7 | Reference compound |
| HY-102013R | Omilancor (Standard) | 1912399-75-7 | Reference Standards |
| HY-102014 | RN-18 | 431980-38-0 | Reference compound |
| HY-102015 | 6-Biopterin | 22150-76-1 | Natural Products |
| HY-102015R | 6-Biopterin (Standard) | 22150-76-1 | Reference Standards |
| HY-102015S | 6-Biopterin-d3 | 1217838-71-5 | Isotope-Labeled Compounds |
| HY-102016 | SB756050 | 447410-57-3 | Reference compound |
| HY-102018 | 3'-Deoxy-3'-fluoroadenosine | 75059-22-2 | Reference compound |
| HY-102019 | NSC61610 | 500538-94-3 | Reference compound |
| HY-10201A | Sorafenib (tosylate) | 475207-59-1 | Reference compound |
| HY-10201AR | Sorafenib (tosylate) (Standard) | 475207-59-1 | Reference Standards |
| HY-10201R | Sorafenib (Standard) | 284461-73-0 | Reference Standards |
| HY-10201S | Sorafenib-d3 | 1130115-44-4 | Isotope-Labeled Compounds |
| HY-10201S1 | Sorafenib-d4 | 1207560-07-3 | Isotope-Labeled Compounds |
| HY-10201S2 | Sorafenib-13C,d3 | 1210608-86-8 | Isotope-Labeled Compounds |
| HY-10201S4 | Sorafenib-d3 (tosylate) | 1333386-17-6 | Isotope-Labeled Compounds |
| HY-10202 | Tandutinib | 387867-13-2 | Reference compound |
| HY-102020 | RG3039 | 1005504-62-0 | Reference compound |
| HY-102022 | α-Galactosylceramide | 158021-47-7 | Reference compound |
| HY-102023 | GNF351 | 1227634-69-6 | Reference compound |
| HY-102024 | A2A receptor antagonist 1 | 443103-97-7 | Reference compound |
| HY-102025 | Antifungal agent 1 | 1265166-14-0 | Reference compound |
| HY-102026 | Formycin A | 6742-12-7 | Reference compound |
| HY-102027 | FX1 | 1426138-42-2 | Reference compound |
| HY-102028 | KY1220 | 292168-79-7 | Reference compound |
| HY-102029 | Sarafotoxin S6c | 121695-87-2 | Peptides |
| HY-10202A | Tandutinib (hydrochloride) | 2438900-70-8 | Reference compound |
| HY-10202AR | Tandutinib (hydrochloride) (Standard) | 2438900-70-8 | Reference Standards |
| HY-10202B | Tandutinib (sulfate) | 387867-14-3 | Reference compound |
| HY-10202R | Tandutinib (Standard) | 387867-13-2 | Reference Standards |
| HY-10203 | Vatalanib | 212141-54-3 | Reference compound |
| HY-102031 | Linperlisib | 1702816-75-8 | Reference compound |
| HY-102032 | Butyryltimolol | 106351-79-5 | Reference compound |
| HY-102032A | (RS)-Butyryltimolol | 2320274-78-8 | Reference compound |
| HY-102032AR | (RS)-Butyryltimolol (Standard) | 2320274-78-8 | Reference Standards |
| HY-102033 | Oxamflatin | 151720-43-3 | Reference compound |
| HY-102034 | Complement factor D-IN-1 | 1386455-76-0 | Reference compound |
| HY-102035 | PARP-2-IN-1 | 2115698-83-2 | Reference compound |
| HY-102036 | G-744 | 1346669-54-2 | Reference compound |
| HY-102037 | SSTR5 antagonist 1 | 1628741-91-2 | Reference compound |
| HY-102038 | PC786 | 1902114-15-1 | Reference compound |
| HY-102039 | CDK9-IN-8 | 2105956-51-0 | Reference compound |
| HY-10204 | OSI-930 | 728033-96-3 | Reference compound |
| HY-102040 | Hispidol | 5786-54-9 | Reference compound |
| HY-102040R | Hispidol (Standard) | 5786-54-9 | Reference Standards |
| HY-102041 | SMS2-IN-1 | 2098890-15-2 | Reference compound |
| HY-102044 | BET-IN-2 | 2104688-91-5 | Reference compound |
| HY-102045 | T-3764518 | 1809151-56-1 | Reference compound |
| HY-102046 | FM-381 | 2226521-65-7 | Reference compound |
| HY-102047 | KDOAM-25 | 2230731-99-2 | Reference compound |
| HY-102047A | KDOAM-25 (trihydrochloride) | | Reference compound |
| HY-102047B | KDOAM-25 (citrate) | 2448475-08-7 | Reference compound |
| HY-102048 | STAT5-IN-2 | 2111834-61-6 | Reference compound |
| HY-102049 | IL-15-IN-1 | 1831830-20-6 | Reference compound |
| HY-10205 | Cediranib | 288383-20-0 | Reference compound |
| HY-102050 | PF-05085727 | 1415637-72-7 | Reference compound |
| HY-102051 | XIAP/cIAP1 antagonist-1 | 1403898-55-4 | Reference compound |
| HY-102052 | DCEBIO | 60563-36-2 | Reference compound |
| HY-102053 | Apimostinel | 1421866-48-9 | Reference compound |
| HY-102054 | Acetylhydrolase-IN-1 | 79637-91-5 | Reference compound |
| HY-102055 | JAK2 JH2 Tracer | 2101955-00-2 | Dye Reagents |
| HY-102056 | BAY 59-9435 | 654059-21-9 | Reference compound |
| HY-102057 | Felcisetrag | 916075-84-8 | Reference compound |
| HY-102058 | WM-1119 | 2055397-28-7 | Reference compound |
| HY-102059 | MOZ-IN-2 | 2055397-88-9 | Reference compound |
| HY-10205R | Cediranib (Standard) | 288383-20-0 | Reference Standards |
| HY-10206 | Amuvatinib | 850879-09-3 | Reference compound |
| HY-102060 | WM-8014 | 2055397-18-5 | Reference compound |
| HY-102061 | Naronapride (dihydrochloride) | 860169-57-9 | Reference compound |
| HY-102062 | Nω-Propyl-L-arginine | 137361-05-8 | Reference compound |
| HY-102062A | Nω-Propyl-L-arginine (hydrochloride) | 2321366-46-3 | Reference compound |
| HY-102063 | MRS 2219 | 14141-47-0 | Reference compound |
| HY-102064 | SR 57227A | 77145-61-0 | Reference compound |
| HY-102065 | SC-19220 | 19395-87-0 | Reference compound |
| HY-102066 | Utatrectinib | 1079274-94-4 | Reference compound |
| HY-102067 | 3289-8625 | 294891-81-9 | Reference compound |
| HY-102068 | Clathrin-IN-1 | 1332879-52-3 | Reference compound |
| HY-102069 | 3MB-PP1 | 956025-83-5 | Reference compound |
| HY-10206A | Amuvatinib hydrochloride | 1055986-67-8 | Reference compound |
| HY-10206R | Amuvatinib (Standard) | 850879-09-3 | Reference Standards |
| HY-10207 | Dovitinib (lactate) | 692737-80-7 | Reference compound |
| HY-102070 | NS13001 | 1063331-94-1 | Reference compound |
| HY-102071 | KIN59 | 4152-77-6 | Reference compound |
| HY-102073 | TG53 | 946369-04-6 | Reference compound |
| HY-102074 | ERDRP-0519 | 1374006-96-8 | Reference compound |
| HY-102075A | TMP778 | 1422053-04-0 | Reference compound |
| HY-102075B | TMP780 | 1422053-03-9 | Reference compound |
| HY-102076 | 0990CL | 511514-03-7 | Reference compound |
| HY-102077 | SAMT-247 | 850715-59-2 | Reference compound |
| HY-102078 | ZINC69391 | 303094-67-9 | Reference compound |
| HY-102079 | SAFit1 | 1643125-32-9 | Reference compound |
| HY-10207R | Dovitinib (lactate) (Standard) | 692737-80-7 | Reference Standards |
| HY-10208 | Pazopanib | 444731-52-6 | Reference compound |
| HY-102080 | SAFit2 | 1643125-33-0 | Reference compound |
| HY-102081 | 2OH-BNPP1 | 833481-73-5 | Reference compound |
| HY-102082 | Adenosine N1-oxide | 146-92-9 | Natural Products |
| HY-102083 | BRD4884 | 1404559-91-6 | Reference compound |
| HY-102084 | LMT-28 | 1239600-18-0 | Reference compound |
| HY-102085 | 11-Deoxyglycyrrhetinic acid (sodium) | 1148013-87-9 | Reference compound |
| HY-102086 | MSX3 | 261717-23-1 | Reference compound |
| HY-102087 | JPM-OEt | 262381-84-0 | Reference compound |
| HY-102089 | Fluoroclebopride | 154540-49-5 | Reference compound |
| HY-10208R | Pazopanib (Standard) | 444731-52-6 | Reference Standards |
| HY-10208S | Pazopanib-d6 | 1219592-01-4 | Isotope-Labeled Compounds |
| HY-10208S1 | Pazopanib-13C,d3 | 1261734-88-6 | Isotope-Labeled Compounds |
| HY-10208S2 | Pazopanib-d3 | 1219591-97-5 | Isotope-Labeled Compounds |
| HY-10209 | Masitinib | 790299-79-5 | Reference compound |
| HY-102090 | B7/CD28 interaction inhibitor 1 | 635324-72-0 | Reference compound |
| HY-102091 | (2R,4R)-APDC | 169209-63-6 | Reference compound |
| HY-102091A | (2R,4R)-APDC (hydrate) | | Reference compound |
| HY-102092 | FR139317 | 142375-60-8 | Reference compound |
| HY-102093 | ZD 7155(hydrochloride) | 146709-78-6 | Reference compound |
| HY-102093A | ZD 7155 | 151801-76-2 | Reference compound |
| HY-102093R | ZD 7155(hydrochloride) (Standard) | 146709-78-6 | Reference Standards |
| HY-102094 | (E/Z)-SIB-1893 | 6266-99-5 | Reference compound |
| HY-102095 | SIB-1757 | 31993-01-8 | Reference compound |
| HY-10209A | Masitinib (mesylate) | 1048007-93-7 | Reference compound |
| HY-10209AR | Masitinib (mesylate) (Standard) | 1048007-93-7 | Reference Standards |
| HY-10209R | Masitinib (Standard) | 790299-79-5 | Reference Standards |
| HY-10210 | Retaspimycin (Hydrochloride) | 857402-63-2 | Reference compound |
| HY-10211 | Tanespimycin | 75747-14-7 | Reference compound |
| HY-10211R | Tanespimycin (Standard) | 75747-14-7 | Reference Standards |
| HY-10212 | BIIB021 | 848695-25-0 | Reference compound |
| HY-10212R | BIIB021 (Standard) | 848695-25-0 | Reference Standards |
| HY-10213 | SNX-5422 | 908115-27-5 | Reference compound |
| HY-10213A | SNX-5422 (mesylate) | 1173111-67-5 | Reference compound |
| HY-10214 | SNX-2112 | 908112-43-6 | Reference compound |
| HY-10215 | Luminespib | 747412-49-3 | Reference compound |
| HY-10215R | Luminespib (Standard) | 747412-49-3 | Reference Standards |
| HY-10216 | Refametinib (R enantiomer) | 923032-38-6 | Reference compound |
| HY-10217 | Thrombin Inhibitor 2 | 312904-62-4 | Reference compound |
| HY-10218 | Everolimus | 159351-69-6 | Reference compound |
| HY-10218R | Everolimus (Standard) | 159351-69-6 | Reference Standards |
| HY-10218S | Everolimus-d4 | 1338452-54-2 | Isotope-Labeled Compounds |
| HY-10218S1 | Everolimus-13C2,d4 | 1661009-29-5 | Isotope-Labeled Compounds |
| HY-10219 | Rapamycin | 53123-88-9 | Natural Products |
| HY-10219G | Rapamycin (GMP) | 53123-88-9 | GMP Small Molecules |
| HY-10219GL | Rapamycin (GMP Like) | 53123-88-9 | GMP Small Molecules |
| HY-10219R | Rapamycin (Standard) | 53123-88-9 | Reference Standards |
| HY-10219S | Rapamycin-d3 | 392711-19-2 | Isotope-Labeled Compounds |
| HY-10219S1 | Rapamycin-13C,d3 | | Isotope-Labeled Compounds |
| HY-10220 | SF1126 | 936487-67-1 | Reference compound |
| HY-10221 | Vorinostat | 149647-78-9 | Reference compound |
| HY-10221G | Vorinostat (GMP) | 149647-78-9 | GMP Small Molecules |
| HY-10221R | Vorinostat (Standard) | 149647-78-9 | Reference Standards |
| HY-10222 | Ixabepilone | 219989-84-1 | Reference compound |
| HY-10222R | Ixabepilone (Standard) | 219989-84-1 | Reference Standards |
| HY-10223 | CUDC-101 | 1012054-59-9 | Reference compound |
| HY-10224 | Panobinostat | 404950-80-7 | Reference compound |
| HY-10224A | Panobinostat (lactate) | 960055-56-5 | Reference compound |
| HY-10224R | Panobinostat (Standard) | 404950-80-7 | Reference Standards |
| HY-10224S | Panobinostat-d4 | 1185237-51-7 | Isotope-Labeled Compounds |
| HY-10224S1 | Panobinostat-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10225 | Belinostat | 866323-14-0 | Reference compound |
| HY-10226 | JNJ-16241199 | 604769-01-9 | Reference compound |
| HY-10227 | Bortezomib | 179324-69-7 | Reference compound |
| HY-10227R | Bortezomib (Standard) | 179324-69-7 | Reference Standards |
| HY-10227S | Bortezomib-d8 | | Isotope-Labeled Compounds |
| HY-10228 | Motesanib | 453562-69-1 | Reference compound |
| HY-10228R | Motesanib (Standard) | 453562-69-1 | Reference Standards |
| HY-10229 | Motesanib (Diphosphate) | 857876-30-3 | Reference compound |
| HY-10229R | Motesanib (Diphosphate) (Standard) | 857876-30-3 | Reference Standards |
| HY-10230 | Midostaurin | 120685-11-2 | Reference compound |
| HY-10230R | Midostaurin (Standard) | 120685-11-2 | Reference Standards |
| HY-10230S | Midostaurin-d5 | | Isotope-Labeled Compounds |
| HY-10231 | PX-478 | 685898-44-6 | Reference compound |
| HY-10232 | THIP | 64603-91-4 | Reference compound |
| HY-10232R | THIP (Standard) | 64603-91-4 | Reference Standards |
| HY-10232S | THIP-d4 | 2748778-97-2 | Isotope-Labeled Compounds |
| HY-10233 | Gaboxadol (hydrochloride) | 85118-33-8 | Reference compound |
| HY-10233R | Gaboxadol (hydrochloride) (Standard) | 85118-33-8 | Reference Standards |
| HY-10234 | Saracatinib | 379231-04-6 | Reference compound |
| HY-10234A | Saracatinib (difumarate) | 893428-72-3 | Reference compound |
| HY-10234AR | Saracatinib (difumarate) (Standard) | 893428-72-3 | Reference Standards |
| HY-10234R | Saracatinib (Standard) | 379231-04-6 | Reference Standards |
| HY-10234S | Saracatinib-d3 | 2200301-36-4 | Isotope-Labeled Compounds |
| HY-10235 | Telaprevir | 402957-28-2 | Reference compound |
| HY-10235R | Telaprevir (Standard) | 402957-28-2 | Reference Standards |
| HY-10235S | Telaprevir-d4 | | Isotope-Labeled Compounds |
| HY-10237 | Boceprevir | 394730-60-0 | Reference compound |
| HY-10237R | Boceprevir (Standard) | 394730-60-0 | Reference Standards |
| HY-10237S | Boceprevir-d9 | 1256751-11-7 | Isotope-Labeled Compounds |
| HY-10238 | Danoprevir | 850876-88-9 | Reference compound |
| HY-10239 | Danoprevir (sodium) | 916826-48-7 | Reference compound |
| HY-10240 | Mericitabine | 940908-79-2 | Reference compound |
| HY-10240R | Mericitabine (Standard) | 940908-79-2 | Reference Standards |
| HY-10241 | Simeprevir | 923604-59-5 | Reference compound |
| HY-10241A | Simeprevir (sodium) | 1241946-89-3 | Reference compound |
| HY-10241S | Simeprevir-13C,d3 | | Isotope-Labeled Compounds |
| HY-10242 | Ciluprevir | 300832-84-2 | Reference compound |
| HY-10243 | Vaniprevir | 923590-37-8 | Reference compound |
| HY-10244 | MK-0608 | 443642-29-3 | Reference compound |
| HY-10247 | BRAF inhibitor | 918505-61-0 | Reference compound |
| HY-10248 | RAF265 | 927880-90-8 | Reference compound |
| HY-10249 | GSK-690693 | 937174-76-0 | Reference compound |
| HY-10249A | AKT Kinase Inhibitor | 842148-40-7 | Reference compound |
| HY-10249D | AKT Kinase Inhibitor (hydrochloride) | 3026697-00-4 | Reference compound |
| HY-10250 | Triciribine phosphate | 61966-08-3 | Reference compound |
| HY-10250A | Triciribine phosphate (sodium) | | Reference compound |
| HY-10250S | Triciribine phosphate-13C,d3 | | Isotope-Labeled Compounds |
| HY-10250S1 | Triciribine phosphate-d3 | | Isotope-Labeled Compounds |
| HY-10251 | BMS-599626 | 714971-09-2 | Reference compound |
| HY-10252 | NVP-ADW742 | 475488-23-4 | Reference compound |
| HY-10253 | AG1024 | 65678-07-1 | Reference compound |
| HY-10254 | Mirdametinib | 391210-10-9 | Reference compound |
| HY-10254G | Mirdametinib (GMP) | 391210-10-9 | GMP Small Molecules |
| HY-10255 | Sunitinib (Malate) | 341031-54-7 | Reference compound |
| HY-10255A | Sunitinib | 557795-19-4 | Reference compound |
| HY-10255AR | Sunitinib (Standard) | 557795-19-4 | Reference Standards |
| HY-10255AS | Sunitinib-d10 | 1126721-82-1 | Isotope-Labeled Compounds |
| HY-10255AS1 | Sunitinib-d4 | 1126721-79-6 | Isotope-Labeled Compounds |
| HY-10255R | Sunitinib (Malate) (Standard) | 341031-54-7 | Reference Standards |
| HY-10256 | Adezmapimod | 152121-47-6 | Reference compound |
| HY-10256A | Adezmapimod (hydrochloride) | 869185-85-3 | Reference compound |
| HY-10256AR | Adezmapimod (hydrochloride) (Standard) | 869185-85-3 | Reference Standards |
| HY-10256R | Adezmapimod (Standard) | 152121-47-6 | Reference Standards |
| HY-10257 | BAY 11-7085 | 196309-76-9 | Reference compound |
| HY-10259 | PD 123319 | 130663-39-7 | Reference compound |
| HY-10259A | PD 123319 (ditrifluoroacetate) | 136676-91-0 | Reference compound |
| HY-10260 | Vandetanib | 443913-73-3 | Reference compound |
| HY-10260A | Vandetanib (trifluoroacetate) | 338992-53-3 | Reference compound |
| HY-10260B | Vandetanib (hydrochloride) | 524722-52-9 | Reference compound |
| HY-10260R | Vandetanib (Standard) | 443913-73-3 | Reference Standards |
| HY-10260S | Vandetanib-d6 | 1174683-49-8 | Isotope-Labeled Compounds |
| HY-10260S1 | Vandetanib-d4 | 1215100-18-7 | Isotope-Labeled Compounds |
| HY-10260S2 | Vandetanib-13C6 | 1261397-03-8 | Isotope-Labeled Compounds |
| HY-10261 | Afatinib | 850140-72-6 | Reference compound |
| HY-10261A | Afatinib (dimaleate) | 850140-73-7 | Reference compound |
| HY-10261AR | Afatinib (dimaleate) (Standard) | 850140-73-7 | Reference Standards |
| HY-10261AS | Afatinib-d6 (dimaleate) | | Isotope-Labeled Compounds |
| HY-10261B | (E/Z)-Afatinib | 439081-18-2 | Reference compound |
| HY-10261BR | (E/Z)-Afatinib (Standard) | 439081-18-2 | Reference Standards |
| HY-10261D | Afatinib (oxalate) | 1398312-64-5 | Reference compound |
| HY-10261E | (R)-Afatinib | 439081-17-1 | Reference compound |
| HY-10261R | Afatinib (Standard) | 850140-72-6 | Reference Standards |
| HY-10261S | Afatinib-d6 | 1313874-96-2 | Isotope-Labeled Compounds |
| HY-10261S1 | Afatinib-d4 | | Isotope-Labeled Compounds |
| HY-10262 | BMS-536924 | 468740-43-4 | Reference compound |
| HY-10264 | Edoxaban | 480449-70-5 | Reference compound |
| HY-10264A | Edoxaban (tosylate) | 480449-71-6 | Reference compound |
| HY-10264B | Edoxaban (tosylate monohydrate) | 1229194-11-9 | Reference compound |
| HY-10264C | Edoxaban (hydrochloride) | 480448-29-1 | Reference compound |
| HY-10264R | Edoxaban (Standard) | 480449-70-5 | Reference Standards |
| HY-10264S | Edoxaban-d6 | 1304701-57-2 | Isotope-Labeled Compounds |
| HY-10267 | Eribaxaban | 536748-46-6 | Reference compound |
| HY-10268 | Betrixaban | 330942-05-7 | Reference compound |
| HY-10268A | Betrixaban (maleate) | 936539-80-9 | Reference compound |
| HY-10268B | Betrixaban (hydrochloride) | 2099719-47-6 | Reference compound |
| HY-10268R | Betrixaban (Standard) | 330942-05-7 | Reference Standards |
| HY-10268S | Betrixaban-d6 | 2098655-51-5 | Isotope-Labeled Compounds |
| HY-10268S1 | Betrixaban-d4 | 2098655-55-9 | Isotope-Labeled Compounds |
| HY-10268S2 | Betrixaban-13C6 | | Isotope-Labeled Compounds |
| HY-10269 | LY-517717 | 313489-71-3 | Reference compound |
| HY-10270 | Flovagatran | 871576-03-3 | Reference compound |
| HY-10271 | Flovagatran (sodium) | 871575-98-3 | Reference compound |
| HY-10273 | Atecegatran metoxil | 433937-93-0 | Reference compound |
| HY-10274 | Dabigatran etexilate | 211915-06-9 | Reference compound |
| HY-10274A | Dabigatran etexilate (mesylate) | 872728-81-9 | Reference compound |
| HY-10274AR | Dabigatran etexilate (mesylate) (Standard) | 872728-81-9 | Reference Standards |
| HY-10274R | Dabigatran etexilate (Standard) | 211915-06-9 | Reference Standards |
| HY-10274S | Dabigatran etexilate-d13 | 2749293-92-1 | Isotope-Labeled Compounds |
| HY-10275 | Atecegatran | 433937-74-7 | Reference compound |
| HY-10275A | Atecegatran (TFA) | 433937-75-8 | Reference compound |
| HY-10276 | GW813893 | 478644-12-1 | Reference compound |
| HY-10277 | Odiparcil | 137215-12-4 | Reference compound |
| HY-10278 | Razaxaban | 218298-21-6 | Reference compound |
| HY-10280S | YM-60828-d3 | 1794812-00-2 | Isotope-Labeled Compounds |
| HY-10281 | YM-60828 (methanesulfonate) | 209187-02-0 | Reference compound |
| HY-10282 | Daglutril | 182821-27-8 | Reference compound |
| HY-10284 | Linagliptin | 668270-12-0 | Reference compound |
| HY-10284R | Linagliptin (Standard) | 668270-12-0 | Reference Standards |
| HY-10284S | Linagliptin-d4 | 2140263-92-7 | Isotope-Labeled Compounds |
| HY-10284S1 | Linagliptin-13C,d3 | 1398044-43-3 | Isotope-Labeled Compounds |
| HY-10284S3 | Linagliptin-d3-1 | 1398044-48-8 | Isotope-Labeled Compounds |
| HY-10284S4 | Linagliptin-d5 | | Isotope-Labeled Compounds |
| HY-10284S5 | Linagliptin-d6 | | Isotope-Labeled Compounds |
| HY-10285 | Saxagliptin | 361442-04-8 | Reference compound |
| HY-10285A | Saxagliptin (hydrate) | 945667-22-1 | Reference compound |
| HY-10285AR | Saxagliptin (hydrate) (Standard) | 945667-22-1 | Reference Standards |
| HY-10285R | Saxagliptin (Standard) | 361442-04-8 | Reference Standards |
| HY-10285S | Saxagliptin-15N,d2 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10285S1 | (rel)-Saxagliptin-13C,d2 (TFA) | 2012595-09-2 | Isotope-Labeled Compounds |
| HY-10285S2 | Saxagliptin-13C2 | | Isotope-Labeled Compounds |
| HY-10286 | Dutogliptin | 852329-66-9 | Reference compound |
| HY-10286A | Dutogliptin (tartrate) | 890402-81-0 | Reference compound |
| HY-10287 | Gosogliptin | 869490-23-3 | Reference compound |
| HY-10289 | Carmegliptin | 813452-18-5 | Reference compound |
| HY-10290 | MK-0674 | 887781-62-6 | Reference compound |
| HY-10291 | Tarenflurbil | 51543-40-9 | Reference compound |
| HY-10291R | Tarenflurbil (Standard) | 51543-40-9 | Reference Standards |
| HY-10293 | Aderbasib | 791828-58-5 | Reference compound |
| HY-10294 | Relacatib | 362505-84-8 | Reference compound |
| HY-10295 | SB 202190 | 152121-30-7 | Reference compound |
| HY-10295A | SB 202190 (hydrochloride) | 350228-36-3 | Reference compound |
| HY-10295AR | SB 202190 (hydrochloride) (Standard) | 350228-36-3 | Reference Standards |
| HY-10295R | SB 202190 (Standard) | 152121-30-7 | Reference Standards |
| HY-10297 | Omipalisib | 1086062-66-9 | Reference compound |
| HY-10299 | GSK-923295 | 1088965-37-0 | Reference compound |
| HY-102998 | Nav1.7-IN-6 | 1788066-71-6 | Reference compound |
| HY-10300 | Narlaprevir | 865466-24-6 | Reference compound |
| HY-103000 | HSF1A | 1196723-93-9 | Reference compound |
| HY-103001 | HMN-154 | 173528-92-2 | Reference compound |
| HY-103002 | SU5408 | 15966-93-5 | Reference compound |
| HY-103005 | Ramelteon metabolite M-II | 896736-21-3 | Reference compound |
| HY-103005R | Ramelteon metabolite M-II (Standard) | 896736-21-3 | Reference Standards |
| HY-103005S | Ramelteon metabolite M-II-d3 | 1246812-22-5 | Isotope-Labeled Compounds |
| HY-103006 | NAI-N3 | 1612756-29-2 | Reference compound |
| HY-103007 | TC-G-1008 | 1621175-65-2 | Reference compound |
| HY-103009 | MSX-127 | 6616-56-4 | Reference compound |
| HY-10300R | Narlaprevir (Standard) | 865466-24-6 | Reference Standards |
| HY-10301 | MK-3207 | 957118-49-9 | Reference compound |
| HY-103010 | MSX-130 | 4051-59-6 | Reference compound |
| HY-103015 | WZ4141 | 1222776-76-2 | Reference compound |
| HY-103016 | WZ4141R | 2319589-98-3 | Reference compound |
| HY-103017 | JH-X-119-01 (hydrochloride) | 2591344-30-6 | Reference compound |
| HY-103017A | JH-X-119-01 | 2227368-54-7 | Reference compound |
| HY-103018 | Gusacitinib | 1425381-60-7 | Reference compound |
| HY-103018A | Gusacitinib (hydrochloride) | 2228989-14-6 | Reference compound |
| HY-103019 | (+)-Enitociclib | 1610358-56-9 | Reference compound |
| HY-103019A | (±)-Enitociclib | 1610358-53-6 | Reference compound |
| HY-103019B | (-)-Enitociclib | 1610358-59-2 | Reference compound |
| HY-103019E | Enitociclib | 1610408-97-3 | Reference compound |
| HY-10302 | MK-3207 (Hydrochloride) | 957116-20-0 | Reference compound |
| HY-103020 | BAY-1816032 | 1891087-61-8 | Reference compound |
| HY-103021 | LY3200882 | 1898283-02-7 | Reference compound |
| HY-103022 | Repotrectinib | 1802220-02-5 | Reference compound |
| HY-103023 | CLP290 | 1181083-81-7 | Reference compound |
| HY-103024 | ICI-63197 | 27277-00-5 | Reference compound |
| HY-103025 | Methylprednisolone aceponate | 86401-95-8 | Reference compound |
| HY-103025R | Methylprednisolone aceponate (Standard) | 86401-95-8 | Reference Standards |
| HY-103028 | GSK962 | 2049872-86-6 | Reference compound |
| HY-103028A | GSK963 | 2049868-46-2 | Reference compound |
| HY-103029 | Bosutinib isomer | 1391063-17-4 | Reference compound |
| HY-10303 | PIK-294 | 900185-02-6 | Reference compound |
| HY-103030 | PI3K-IN-32 | 371934-59-7 | Reference compound |
| HY-103032 | Multi-kinase inhibitor 1 | 778274-97-8 | Reference compound |
| HY-103033 | T.cruzi-IN-1 | 1350920-22-7 | Reference compound |
| HY-103034 | Sipoglitazar | 342026-92-0 | Reference compound |
| HY-103035 | BIO-32546 | 1548743-66-3 | Reference compound |
| HY-103036 | BET bromodomain inhibitor | 1505453-59-7 | Reference compound |
| HY-103038 | ML327 | 1883510-31-3 | Reference compound |
| HY-103039 | TLR7 agonist 2 | 1642857-69-9 | Reference compound |
| HY-10304 | Orbofiban | 163250-90-6 | Reference compound |
| HY-103041 | Brr2-IN-2 | | Reference compound |
| HY-103045 | CMPD101 | 865608-11-3 | Reference compound |
| HY-103045A | CMPD101 (hydrochloride) | 1941168-71-3 | Reference compound |
| HY-103046 | UbcH5c-IN-1 | 2123480-72-6 | Reference compound |
| HY-103048 | PD-1/PD-L1-IN 3 | 1629654-95-0 | Peptides |
| HY-103048A | PD-1/PD-L1-IN 3 (TFA) | | Peptides |
| HY-10304A | Orbofiban (acetate) | 163250-91-7 | Reference compound |
| HY-103050 | ML-030 | 1013750-77-0 | Reference compound |
| HY-103053 | PS121912 | 1529814-60-5 | Reference compound |
| HY-103054 | RO5203648 | 1043491-54-8 | Reference compound |
| HY-103055 | PPTN (mesylate) | 1160271-31-7 | Reference compound |
| HY-103056 | DDD85646 | 1215010-55-1 | Reference compound |
| HY-103058 | GSK199 | 1549811-53-1 | Reference compound |
| HY-103059 | SOICR-IN-1 | 1479049-35-8 | Reference compound |
| HY-10306 | Gantofiban | 183547-57-1 | Reference compound |
| HY-103060 | KLH45 | 1632236-44-2 | Reference compound |
| HY-103061 | Dehydro-ZINC39395747 | 433248-87-4 | Reference compound |
| HY-103064 | 2-Methylthio-AMP (sodium) | 81921-45-1 | Reference compound |
| HY-103066 | Br-PBTC | 1839519-57-1 | Reference compound |
| HY-103067 | A1899 | 498577-46-1 | Reference compound |
| HY-103068 | Diethyl-pythiDC | 1821370-70-0 | Reference compound |
| HY-10307 | Roxifiban | 170902-47-3 | Reference compound |
| HY-103070 | PythiDC | 1821370-71-1 | Reference compound |
| HY-103071 | GSK-5503A | 1253186-46-7 | Reference compound |
| HY-103073 | Mesendogen | 864716-85-8 | Reference compound |
| HY-103074 | GSK2226649A | 1848232-20-1 | Reference compound |
| HY-103076 | EZ-482 | 1016456-76-0 | Reference compound |
| HY-103078 | I-XW-053 | 5496-35-5 | Reference compound |
| HY-103078A | I-XW-053 (sodium) | 1644644-89-2 | Reference compound |
| HY-103079 | PRL-3 Inhibitor 2 | 577962-95-9 | Reference compound |
| HY-10307A | Roxifiban (acetate) | 176022-59-6 | Reference compound |
| HY-10308 | Lefradafiban | 149503-79-7 | Reference compound |
| HY-103080 | CMF019 | 1586787-08-7 | Reference compound |
| HY-103081 | β-Glucuronidase-IN-1 | 484006-66-8 | Reference compound |
| HY-103082 | CLK1-IN-1 | 2123491-32-5 | Reference compound |
| HY-103083 | GPR40 agonist 4 | 2102196-57-4 | Reference compound |
| HY-103085 | T-3775440 hydrochloride | 1422535-52-1 | Reference compound |
| HY-103086 | INU-152 | 1380228-30-7 | Reference compound |
| HY-103087 | FIN56 | 1083162-61-1 | Reference compound |
| HY-103088 | Palupiprant | 1369489-71-3 | Reference compound |
| HY-103089 | LY393558 | 271780-64-4 | Reference compound |
| HY-10309 | Sibrafiban | 172927-65-0 | Reference compound |
| HY-103090 | NPS ALX Compound 4a | 299433-10-6 | Reference compound |
| HY-103090A | NPS ALX Compound 4a (dihydrochloride) | 1781934-44-8 | Reference compound |
| HY-103091 | Donitriptan (hydrochloride) | 170911-68-9 | Reference compound |
| HY-103092 | CP-135807 | 151272-90-1 | Reference compound |
| HY-103093 | Zotepine | 26615-21-4 | Reference compound |
| HY-103093R | Zotepine (Standard) | 26615-21-4 | Reference Standards |
| HY-103094 | LY266097 (hydrochloride) | 172895-39-5 | Reference compound |
| HY-103095 | Enmetazobactam | 1001404-83-6 | Reference compound |
| HY-103095A | Enmetazobactam (iodide) | 1379594-98-5 | Reference compound |
| HY-103096 | R162 | 64302-87-0 | Reference compound |
| HY-103097 | ST271 | 106392-48-7 | Reference compound |
| HY-103098 | EMDT oxalate | 263744-72-5 | Reference compound |
| HY-103099 | SB-399885 hydrochloride | 402713-81-9 | Reference compound |
| HY-10309R | Sibrafiban (Standard) | 172927-65-0 | Reference Standards |
| HY-103100 | SB-699551 | 864741-95-7 | Reference compound |
| HY-103101 | LP44 (hydrochloride) | 824958-12-5 | Reference compound |
| HY-103102 | TCB2 | 912342-28-0 | Reference compound |
| HY-103104 | Fananserin | 127625-29-0 | Reference compound |
| HY-103105 | LP 12 (hydrochloride) | 1185136-22-4 | Reference compound |
| HY-103105A | LP 12 (hydrochloride hydrate) | | Reference compound |
| HY-103106 | 1-Methylpsilocin | 1465-16-3 | Biochemical Assay Reagents |
| HY-103107 | LY334370 | 182563-08-2 | Reference compound |
| HY-103107A | LY334370 (hydrochloride) | 199673-74-0 | Reference compound |
| HY-103107R | LY334370 (Standard) | 182563-08-2 | Reference Standards |
| HY-103108 | CJ033466 | 519148-48-2 | Reference compound |
| HY-103109 | Melperone (hydrochloride) | 1622-79-3 | Reference compound |
| HY-103110 | ST1936 | 1210-81-7 | Reference compound |
| HY-103110A | ST1936 (oxalate) | 1782228-83-4 | Reference compound |
| HY-103111 | MMPIP (hydrochloride) | 1215566-78-1 | Reference compound |
| HY-103112 | SB 243213 (hydrochloride) | 200940-23-4 | Reference compound |
| HY-103112A | SB 243213 (dihydrochloride) | 1780372-25-9 | Reference compound |
| HY-103112B | SB 243213 | 200940-22-3 | Reference compound |
| HY-103113 | MS 245 (oxalate) | 275363-58-1 | Reference compound |
| HY-103114 | AT1015 (hydrochloride) | 190508-50-0 | Reference compound |
| HY-103115 | Pruvanserin (hydrochloride) | 443144-27-2 | Reference compound |
| HY-103116 | DV-7028 (hydrochloride) | 133364-62-2 | Reference compound |
| HY-103117 | S 32212 hydrochloride | 847871-78-7 | Reference compound |
| HY-103118 | PU02 | 313984-77-9 | Reference compound |
| HY-103119 | LP-20 (hydrochloride) | 1386928-34-2 | Reference compound |
| HY-103120 | Org37684 | 213007-95-5 | Reference compound |
| HY-103123 | SB 258719 (hydrochloride) | 1217674-10-6 | Reference compound |
| HY-103124 | DOI (hydrochloride) | 42203-78-1 | Reference compound |
| HY-103126 | DR4485 (hydrochloride) | 402942-53-4 | Reference compound |
| HY-103128 | inS3-54A18 | 328998-53-4 | Reference compound |
| HY-103129 | SB-200646A | 143797-62-0 | Reference compound |
| HY-103129A | SB-200646 | 143797-63-1 | Reference compound |
| HY-103130 | EMD386088 | 1171123-46-8 | Reference compound |
| HY-103131 | PNU-142633 | 187665-65-2 | Reference compound |
| HY-103132 | PNU109291 | 187665-60-7 | Reference compound |
| HY-103133 | WAY208466 (dihydrochloride) | 1207064-61-6 | Reference compound |
| HY-103134 | SB 204070A | 148688-01-1 | Reference compound |
| HY-103135 | SB 206553 (hydrochloride) | 1197334-04-5 | Reference compound |
| HY-103136 | R-96544 | 167144-80-1 | Reference compound |
| HY-103137 | Zacopride (hydrochloride) | 101303-98-4 | Reference compound |
| HY-103137R | Zacopride (hydrochloride) (Standard) | 101303-98-4 | Reference Standards |
| HY-103138 | (Rac)-WAY-161503 (hydrochloride) | 276695-22-8 | Reference compound |
| HY-103138A | (Rac)-WAY-161503 | 75704-24-4 | Reference compound |
| HY-103139 | Altanserin (hydrochloride) | 1135280-78-2 | Reference compound |
| HY-10314 | Lotrafiban | 171049-14-2 | Reference compound |
| HY-103140 | Ro60-0175 (fumarate) | 169675-09-6 | Reference compound |
| HY-103141 | SB-258585 (hydrochloride) | 1216468-02-8 | Reference compound |
| HY-103142 | AS19 | 1000578-26-6 | Reference compound |
| HY-103143 | SDZ 205-557 (hydrochloride) | 1197334-02-3 | Reference compound |
| HY-103143A | SDZ 205-557 | 137196-67-9 | Reference compound |
| HY-103144 | WAY 629 (hydrochloride) | 57756-44-2 | Reference compound |
| HY-103144A | WAY 629 | 57756-45-3 | Reference compound |
| HY-103145 | PNU-22394 (hydrochloride) | 15923-42-9 | Reference compound |
| HY-103146 | GR125487 (sulfamate) | 859502-43-5 | Reference compound |
| HY-103147 | Mesulergine (hydrochloride) | 72786-12-0 | Reference compound |
| HY-103148 | LY215840 | 137328-52-0 | Reference compound |
| HY-103149 | SB-216641A | 193611-67-5 | Reference compound |
| HY-10314A | Lotrafiban (hydrochloride) | 179599-82-7 | Reference compound |
| HY-10315 | Elarofiban | 198958-88-2 | Reference compound |
| HY-103151 | CP94253 (hydrochloride) | 845861-39-4 | Reference compound |
| HY-103151A | CP94253 | 131084-35-0 | Reference compound |
| HY-103152 | GR 113808 | 144625-51-4 | Reference compound |
| HY-103152R | GR 113808 (Standard) | 144625-51-4 | Reference Standards |
| HY-103153 | SB 204741 | 152239-46-8 | Reference compound |
| HY-103153R | SB 204741 (Standard) | 152239-46-8 | Reference Standards |
| HY-103154 | SB228357 | 181629-93-6 | Reference compound |
| HY-103155 | SB-221284 | 196965-14-7 | Reference compound |
| HY-103156 | NAS-181 (dimesylate) | 1217474-40-2 | Reference compound |
| HY-103157 | PD146176 | 4079-26-9 | Reference compound |
| HY-103157R | PD146176 (Standard) | 4079-26-9 | Reference Standards |
| HY-103158 | BW B70C | 134470-38-5 | Reference compound |
| HY-103159 | 1-Deazaadenosine | 14432-09-8 | Reference compound |
| HY-10315A | Elarofiban (diTFA) | 198958-89-3 | Reference compound |
| HY-103160A | EHNA (hydrochloride) | 58337-38-5 | Reference compound |
| HY-103160B | EHNA | 51350-19-7 | Reference compound |
| HY-103161 | ABT-702 dihydrochloride | 1188890-28-9 | Reference compound |
| HY-103162 | ANR94 | 634924-89-3 | Reference compound |
| HY-103163 | (±)-5'-Chloro-5'-deoxy-ENBA | 103626-26-2 | Reference compound |
| HY-103164 | (E)-8-(3-Chlorostyryl)caffeine | 147700-11-6 | Reference compound |
| HY-103164A | 8-(3-Chlorostyryl)caffeine | 148589-13-3 | Reference compound |
| HY-103165 | PSB-0788 | 1027513-54-7 | Reference compound |
| HY-103166 | PSB-603 | 1092351-10-4 | Reference compound |
| HY-103167 | CGH2466 (dihydrochloride) | 1177618-54-0 | Reference compound |
| HY-103168 | XCC | 96865-83-7 | Reference compound |
| HY-103169 | SCH442416 | 316173-57-6 | Reference compound |
| HY-103169R | SCH442416 (Standard) | 316173-57-6 | Reference Standards |
| HY-103170 | LUF5834 | 333962-91-7 | Reference compound |
| HY-103171 | BAY 60-6583 | 910487-58-0 | Reference compound |
| HY-103171R | BAY 60-6583 (Standard) | 910487-58-0 | Reference Standards |
| HY-103172 | 8-Aminoadenine | 28128-33-8 | Reference compound |
| HY-103173 | 5'-N-Ethylcarboxamidoadenosine | 35920-39-9 | Reference compound |
| HY-103173R | 5'-N-Ethylcarboxamidoadenosine (Standard) | 35920-39-9 | Reference Standards |
| HY-103174 | MRS1334 | 192053-05-7 | Reference compound |
| HY-103175 | PSB36 | 524944-72-7 | Reference compound |
| HY-103176 | PSB11 (hydrochloride) | 453591-58-7 | Reference compound |
| HY-103177 | PSB-10 (hydrochloride) | 591771-91-4 | Reference compound |
| HY-103178 | MRE3008F20 | 252979-43-4 | Reference compound |
| HY-103179 | SDZ-WAG994 | 130714-47-5 | Reference compound |
| HY-103180 | 2'-MeCCPA | 205171-12-6 | Reference compound |
| HY-103181 | N6-Cyclopentyladenosine | 41552-82-3 | Reference compound |
| HY-103182 | PSB-1115 | 152529-79-8 | Reference compound |
| HY-103182A | PSB-1115 (potassium salt) | 409344-71-4 | Reference compound |
| HY-103182R | PSB-1115 (Standard) | 152529-79-8 | Reference Standards |
| HY-103183 | CV1808 | 53296-10-9 | Reference compound |
| HY-103183R | CV1808 (Standard) | 53296-10-9 | Reference Standards |
| HY-103185 | CCPA | 37739-05-2 | Reference compound |
| HY-103185A | CCPA (hemihydrate) | 1217443-91-8 | Reference compound |
| HY-103185R | CCPA (Standard) | 37739-05-2 | Reference Standards |
| HY-103186 | MRS-1706 | 264622-53-9 | Reference compound |
| HY-103186R | MRS-1706 (Standard) | 264622-53-9 | Reference Standards |
| HY-103187 | HEMADO | 403842-38-6 | Reference compound |
| HY-103188 | PD81723 | 132861-87-1 | Reference compound |
| HY-103189 | VUF-5574 | 280570-45-8 | Reference compound |
| HY-10319 | BAY-549 | 867017-68-3 | Reference compound |
| HY-103190 | MRS1220 | 183721-15-5 | Reference compound |
| HY-103191 | 1,9-Dideoxyforskolin | 64657-18-7 | Natural Products |
| HY-103192 | MDL12330A | 40297-09-4 | Reference compound |
| HY-103193 | NKH477 | 138605-00-2 | Reference compound |
| HY-103194 | KH7 | 330676-02-3 | Reference compound |
| HY-103195 | NKY80 | 299442-43-6 | Reference compound |
| HY-103196 | Sotalol | 3930-20-9 | Reference compound |
| HY-103197 | 2-Methoxyidazoxan (monohydrochloride) | 109544-45-8 | Reference compound |
| HY-103197R | 2-Methoxyidazoxan (monohydrochloride) (Standard) | 109544-45-8 | Reference Standards |
| HY-103199 | Carpindolol | 39731-05-0 | Reference compound |
| HY-10320 | Doramapimod | 285983-48-4 | Reference compound |
| HY-103200 | SR59230A (hydrochloride) | 1135278-41-9 | Reference compound |
| HY-103201 | A 80426 (mesylate) | 152148-64-6 | Reference compound |
| HY-103202A | SNAP5089 (Free base) | 157066-76-7 | Reference compound |
| HY-103203 | ST91 | 4749-61-5 | Reference compound |
| HY-103204 | RS100329 (hydrochloride) | 1215654-26-4 | Reference compound |
| HY-103207 | Amibegron hydrochloride | 121524-09-2 | Reference compound |
| HY-103208 | Benalfocin (hydrochloride) | 86129-54-6 | Reference compound |
| HY-103209 | Rec 15/2615 (hydrochloride) | 173059-17-1 | Reference compound |
| HY-10320A | Doramapimod (hydrochloride) | 1283526-53-3 | Reference compound |
| HY-10320G | Doramapimod (GMP) | 285983-48-4 | GMP Small Molecules |
| HY-10320R | Doramapimod (Standard) | 285983-48-4 | Reference Standards |
| HY-10321 | PD173074 | 219580-11-7 | Reference compound |
| HY-103210 | DSP-4 (hydrochloride) | 40616-75-9 | Reference compound |
| HY-103211 | L748337 | 244192-94-7 | Reference compound |
| HY-103212 | Azepexole (dihydrochloride) | 36067-72-8 | Reference compound |
| HY-103212A | Azepexole (hydrochloride) | 147663-20-5 | Reference compound |
| HY-103212B | Azepexole | 36067-73-9 | Reference compound |
| HY-103213 | JP1302 dihydrochloride | 1259314-65-2 | Reference compound |
| HY-103213A | JP1302 | 80259-18-3 | Reference compound |
| HY-103213R | JP1302 dihydrochloride (Standard) | 1259314-65-2 | Reference Standards |
| HY-103214 | Bucindolol | 71119-11-4 | Reference compound |
| HY-103214A | Bucindolol (hydrochloride) | 70369-47-0 | Reference compound |
| HY-103214R | Bucindolol (Standard) | 71119-11-4 | Reference Standards |
| HY-103216 | RWJ52353 | 245744-10-9 | Reference compound |
| HY-103216A | RWJ52353 (hydrochloride) | 245744-13-2 | Reference compound |
| HY-103217 | Talopram (hydrochloride) | 7013-41-4 | Reference compound |
| HY-103218 | Talsupram (hydrochloride) | 25487-28-9 | Reference compound |
| HY-10321R | PD173074 (Standard) | 219580-11-7 | Reference Standards |
| HY-10322 | Falnidamol | 196612-93-8 | Reference compound |
| HY-103220 | 6,2',4'-Trimethoxyflavone | 720675-74-1 | Reference compound |
| HY-103221 | MeBIO | 667463-95-8 | Reference compound |
| HY-103222 | DiMNF | 14756-24-2 | Reference compound |
| HY-103223 | Phortress | 328087-38-3 | Reference compound |
| HY-103224 | PIT-1 | 53501-41-0 | Reference compound |
| HY-103224R | PIT-1 (Standard) | 53501-41-0 | Reference Standards |
| HY-103225 | S-8510 (phosphate) | 151466-23-8 | Reference compound |
| HY-103226 | SC-57461A | 423169-68-0 | Reference compound |
| HY-103227 | Desidustat | 1616690-16-4 | Reference compound |
| HY-103227R | Desidustat (Standard) | 1616690-16-4 | Reference Standards |
| HY-103228 | GYKI 53655 (hydrochloride) | 143692-48-2 | Reference compound |
| HY-103229 | Cl-HIBO | 909400-43-7 | Reference compound |
| HY-10322R | Falnidamol (Standard) | 196612-93-8 | Reference Standards |
| HY-103230 | IEM-1460 | 121034-89-7 | Reference compound |
| HY-103232 | IEM-1925 (bromide) | 258282-23-4 | Reference compound |
| HY-103233 | DNQX (disodium salt) | 1312992-24-7 | Reference compound |
| HY-103234 | GYKI 52466 | 102771-26-6 | Reference compound |
| HY-103234A | GYKI 52466 (dihydrochloride) | 2319722-40-0 | Reference compound |
| HY-103234AR | GYKI 52466 (dihydrochloride) (Standard) | 2319722-40-0 | Reference Standards |
| HY-103234B | GYKI 52466 (hydrochloride) | 192065-56-8 | Reference compound |
| HY-103235 | NPEC-caged-(S)-AMPA | 1257323-84-4 | Reference compound |
| HY-103236 | NSC232003 | 1905453-18-0 | Reference compound |
| HY-103237 | L-Adenosine | 3080-29-3 | Oligonucleotides |
| HY-103238 | RSVA405 | 140405-36-3 | Reference compound |
| HY-103239 | PT1 | 331002-70-1 | Reference compound |
| HY-10324 | D4476 | 301836-43-1 | Reference compound |
| HY-103240 | Methoxy-X04 | 863918-78-9 | Dye Reagents |
| HY-103241 | Ro 90-7501 | 293762-45-5 | Reference compound |
| HY-103242 | CRANAD-2 | 1193447-34-5 | Reference compound |
| HY-103243 | TCPOBOP | 76150-91-9 | Reference compound |
| HY-103243R | TCPOBOP (Standard) | 76150-91-9 | Reference Standards |
| HY-103244 | CITCO | 338404-52-7 | Reference compound |
| HY-103245 | Cl-4AS-1 | 188589-66-4 | Reference compound |
| HY-103246 | TFM-4AS-1 | 188589-61-9 | Reference compound |
| HY-103247 | EMD 66684 | 1216884-39-7 | Reference compound |
| HY-103247B | EMD-66684 (potassium salt) | 187683-79-0 | Reference compound |
| HY-103248 | Toyocamycin | 606-58-6 | Natural Products |
| HY-103248R | Toyocamycin (Standard) | 606-58-6 | Reference Standards |
| HY-103249 | Reutericyclin | 303957-69-9 | Natural Products |
| HY-10325 | CL-387785 | 194423-06-8 | Reference compound |
| HY-103250 | PF-945863 | 893556-85-9 | Reference compound |
| HY-103251 | PF-5081090 | 1312473-63-4 | Reference compound |
| HY-103251R | PF-5081090 (Standard) | 1312473-63-4 | Reference Standards |
| HY-103252 | Monomethyl fumarate | 2756-87-8 | Reference compound |
| HY-103252R | Monomethyl fumarate (Standard) | 2756-87-8 | Reference Standards |
| HY-103252S | Monomethyl fumarate-d3 | 1616345-41-5 | Isotope-Labeled Compounds |
| HY-103252S1 | Monomethyl fumarate-d5 | 1616345-45-9 | Isotope-Labeled Compounds |
| HY-103253 | LY231617 | 141545-89-3 | Reference compound |
| HY-103254 | ML221 | 877636-42-5 | Reference compound |
| HY-103255 | CFM-4 | 331458-02-7 | Reference compound |
| HY-103256 | 2,3-DCPE | 418788-90-6 | Reference compound |
| HY-103257 | CHM-1 | 154554-41-3 | Reference compound |
| HY-103258 | TC ASK 10 | 1005775-56-3 | Reference compound |
| HY-103259 | Sodium metatungstate | 12141-67-2 | Reference compound |
| HY-103259A | Sodium metatungstate (hydrate) | 314075-43-9 | Reference compound |
| HY-10326 | GW788388 | 452342-67-5 | Reference compound |
| HY-103261 | SCH28080 | 76081-98-6 | Reference compound |
| HY-103261R | SCH28080 (Standard) | 76081-98-6 | Reference Standards |
| HY-103262 | PSB069 | 78510-31-3 | Reference compound |
| HY-103263 | PSB-06126 | 1052089-16-3 | Reference compound |
| HY-103265 | ARL67156 (trisodium) | 1021868-83-6 | Reference compound |
| HY-103265A | ARL67156 | 160928-38-1 | Reference compound |
| HY-103265B | ARL67156 (trisodium hydrate) | | Reference compound |
| HY-103265D | ARL67156 (triethylamine) | | Reference compound |
| HY-103266 | TC-A 2317 (hydrochloride) | 1245907-03-2 | Reference compound |
| HY-103267 | S32826 (disodium) | 1103672-43-0 | Reference compound |
| HY-103267A | S32826 | 1096770-84-1 | Reference compound |
| HY-103267R | S32826 (disodium) (Standard) | 1103672-43-0 | Reference Standards |
| HY-103268 | (Rac)-AZD3839 | 1227163-56-5 | Reference compound |
| HY-103269 | BAI1 | 335165-68-9 | Reference compound |
| HY-10327 | GW-6604 | 452342-37-9 | Reference compound |
| HY-103271 | Bax inhibitor peptide, negative control | 1315378-74-5 | Reference compound |
| HY-103272 | iMAC2 | 335166-36-4 | Reference compound |
| HY-103273 | Muristerone A | 38778-30-2 | Natural Products |
| HY-103274 | PD180970 | 287204-45-9 | Reference compound |
| HY-103275 | Adaphostin | 241127-58-2 | Reference compound |
| HY-103275R | Adaphostin (Standard) | 241127-58-2 | Reference Standards |
| HY-103276 | Alytesin | 31078-12-3 | Peptides |
| HY-103277 | BIM 23042 | 111857-96-6 | Peptides |
| HY-103277A | BIM 23042 (TFA) | | Peptides |
| HY-10328 | Neflamapimod | 209410-46-8 | Reference compound |
| HY-103280 | LysRs-IN-1 | 281676-77-5 | Reference compound |
| HY-103281 | Litorin | 55749-97-8 | Natural Products |
| HY-103282 | [D-Phe12]-Bombesin | 108437-87-2 | Reference compound |
| HY-103283 | Neuromedin C (porcine) | 81608-30-2 | Peptides |
| HY-103285 | GRP (porcine) | 74815-57-9 | Peptides |
| HY-103286 | PD176252 | 204067-01-6 | Reference compound |
| HY-103287 | [D-Phe12,Leu14]-Bombesin | 108437-88-3 | Reference compound |
| HY-103289 | MEN 11270 | 235082-52-7 | Reference compound |
| HY-10329 | JNJ-7706621 | 443797-96-4 | Reference compound |
| HY-103290 | R715 | 185052-09-9 | Peptides |
| HY-103291 | Sar-[D-Phe8]-des-Arg9-Bradykinin | 126959-88-4 | Reference compound |
| HY-103292 | [Phe8Ψ(CH-NH)Arg9]-Bradykinin | 118122-39-7 | Peptides |
| HY-103293 | Lys-Bradykinin | 342-10-9 | Reference compound |
| HY-103293A | Lys-Bradykinin (TFA) | | Reference compound |
| HY-103293B | Lys-Bradykinin (tetraacetate) | 84640-50-6 | Peptides |
| HY-103294 | R892 | 229030-05-1 | Reference compound |
| HY-103295 | Lys-[Des-Arg9]Bradykinin | 71800-36-7 | Peptides |
| HY-103295A | Lys-[Des-Arg9]Bradykinin (TFA) | 2763588-90-3 | Peptides |
| HY-103296 | Bombinakinin M | 509151-65-9 | Reference compound |
| HY-103297 | OXFBD02 | 1429129-68-9 | Reference compound |
| HY-103298 | MNI-caged kainate | 1315378-75-6 | Reference compound |
| HY-103299 | KG-501 | 18228-17-6 | Reference compound |
| HY-10330 | Toceranib | 356068-94-5 | Reference compound |
| HY-103300 | NPE-caged-proton | 1186195-63-0 | Reference compound |
| HY-103302 | SUN B8155 | 345893-91-6 | Reference compound |
| HY-103303 | CRSP-1 | 697327-12-1 | Peptides |
| HY-103304 | CGRP antagonist 4 | 217438-17-0 | Reference compound |
| HY-103305 | cis-Ned19 | 1137264-00-6 | Reference compound |
| HY-103306 | Ryanodine | 15662-33-6 | Natural Products |
| HY-103307 | FPL64176 | 120934-96-5 | Reference compound |
| HY-103307R | FPL64176 (Standard) | 120934-96-5 | Reference Standards |
| HY-103308 | TRAM-39 | 197525-99-8 | Reference compound |
| HY-103309 | ML218 | 1346233-68-8 | Reference compound |
| HY-103309A | ML218 (hydrochloride) | 2319922-08-0 | Reference compound |
| HY-103309S | ML218-d9 | | Isotope-Labeled Compounds |
| HY-10330A | Toceranib (phosphate) | 874819-74-6 | Reference compound |
| HY-10330S | Toceranib-d8 | 1795134-78-9 | Isotope-Labeled Compounds |
| HY-10331 | Regorafenib | 755037-03-7 | Reference compound |
| HY-103310 | MRS1845 | 544478-19-5 | Reference compound |
| HY-103311 | Ruthenium red | 11103-72-3 | Dye Reagents |
| HY-103312 | Xestospongin C | 88903-69-9 | Natural Products |
| HY-103313 | SR33805 (oxalate) | 121346-33-6 | Reference compound |
| HY-103314 | Gadolinium chloride | 10138-52-0 | Reference compound |
| HY-103315 | Bepridil hydrochloride | 68099-86-5 | Reference compound |
| HY-103315R | Bepridil hydrochloride (Standard) | 68099-86-5 | Reference Standards |
| HY-103315S | Bepridil-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-103316 | trans-Ned 19 | 1354235-96-3 | Reference compound |
| HY-103316A | Ned 19 | 874374-25-1 | Reference compound |
| HY-103317 | NAADP | 5502-96-5 | Reference compound |
| HY-103318 | PD173212 | 217171-01-2 | Reference compound |
| HY-103319 | Calmidazolium (chloride) | 57265-65-3 | Reference compound |
| HY-10331A | Regorafenib (monohydrate) | 1019206-88-2 | Reference compound |
| HY-10331AR | Regorafenib (monohydrate) (Standard) | 1019206-88-2 | Reference Standards |
| HY-10331B | Regorafenib (mesylate) | 835621-08-4 | Reference compound |
| HY-10331R | Regorafenib (Standard) | 755037-03-7 | Reference Standards |
| HY-10331S | Regorafenib-d3 | 1255386-16-3 | Isotope-Labeled Compounds |
| HY-10331S1 | Regorafenib-13C,d3 | | Isotope-Labeled Compounds |
| HY-10332 | (Z)-Semaxanib | 194413-58-6 | Reference compound |
| HY-103320 | Calhex 231 | 652973-93-8 | Reference compound |
| HY-103320A | Calhex 231 (hydrochloride) | 2387505-78-2 | Reference compound |
| HY-103320B | (1R,2R)-Calhex 231 (hydrochloride) | | Reference compound |
| HY-103322 | 6-Bnz-cAMP (sodium salt) | 1135306-29-4 | Reference compound |
| HY-103323 | Fas C-Terminal Tripeptide | 189109-90-8 | Peptides |
| HY-103324 | Palmitoylisopropylamide | 189939-61-5 | Reference compound |
| HY-103325 | JTE-907 | 282089-49-0 | Reference compound |
| HY-103326 | NIDA-41020 | 502486-89-7 | Reference compound |
| HY-103327 | MJ15 | 944154-76-1 | Reference compound |
| HY-103329 | b-AEA | 956605-71-3 | Reference compound |
| HY-10333 | BMS-690514 | 859853-30-8 | Reference compound |
| HY-103330 | TC-C 14G | 656804-72-7 | Reference compound |
| HY-103331 | COR170 | 1048039-15-1 | Reference compound |
| HY-103332 | N-Arachidonylglycine | 179113-91-8 | Reference compound |
| HY-103332R | N-Arachidonylglycine (Standard) | 179113-91-8 | Reference Standards |
| HY-103332S | N-Arachidonylglycine-d8 | 1159908-44-7 | Isotope-Labeled Compounds |
| HY-103333 | Arvanil | 128007-31-8 | Reference compound |
| HY-103334 | MAFP | 188404-10-6 | Reference compound |
| HY-103335 | O1918 | 536697-79-7 | Reference compound |
| HY-103336 | Tocrifluor 1117 | 1186195-59-4 | Reference compound |
| HY-103337 | N-Arachidonoylserotonin | 187947-37-1 | Reference compound |
| HY-103338 | AM1172 | 251908-92-6 | Reference compound |
| HY-103339 | VDM11 | 313998-81-1 | Reference compound |
| HY-103340 | O-2093 | 439080-01-0 | Reference compound |
| HY-103341 | UCM707 | 390824-20-1 | Reference compound |
| HY-103342 | OMDM-2 | 616884-63-0 | Reference compound |
| HY-103344 | ZJ43 | 723331-20-2 | Reference compound |
| HY-103345 | 2-MPPA | 254737-29-6 | Reference compound |
| HY-103345R | 2-MPPA (Standard) | 254737-29-6 | Reference Standards |
| HY-103346 | MMPSI | 220509-74-0 | Reference compound |
| HY-103347 | M50054 | 54135-60-3 | Reference compound |
| HY-103347R | M50054 (Standard) | 54135-60-3 | Reference Standards |
| HY-103348 | Boc-Asp(OMe)-fluoromethyl ketone | 187389-53-3 | Reference compound |
| HY-103349 | PETCM | 10129-56-3 | Reference compound |
| HY-103350 | CA-074 | 134448-10-5 | Reference compound |
| HY-103351 | Cathepsin G Inhibitor I | 429676-93-7 | Reference compound |
| HY-103352 | L-006235 | 294623-49-7 | Reference compound |
| HY-103352R | L-006235 (Standard) | 294623-49-7 | Reference Standards |
| HY-103353 | SID 26681509 | 958772-66-2 | Reference compound |
| HY-103353A | SID 26681509 (quarterhydrate) | | Reference compound |
| HY-103354 | Proglumide (sodium) | 99247-33-3 | Reference compound |
| HY-103354A | Proglumide (hemicalcium) | 85068-56-0 | Reference compound |
| HY-103354R | Proglumide (sodium) (Standard) | 99247-33-3 | Reference Standards |
| HY-103355 | YM022 | 145084-28-2 | Reference compound |
| HY-103357 | LY288513 | 147523-65-7 | Reference compound |
| HY-103357A | LY262691 | 138932-35-1 | Reference compound |
| HY-103358 | KF38789 | 257292-29-8 | Reference compound |
| HY-103359 | Ceranib1 | 328076-61-5 | Reference compound |
| HY-10336 | Brivanib (alaninate) | 649735-63-7 | Reference compound |
| HY-103360 | J-113863 | 353791-85-2 | Reference compound |
| HY-103360A | cis-J-113863 | 202796-41-6 | Reference compound |
| HY-103360B | trans-J-113863 | 202796-42-7 | Reference compound |
| HY-103361 | SB297006 | 58816-69-6 | Reference compound |
| HY-103362 | CCR2 antagonist 4 (hydrochloride) | 1313730-14-1 | Reference compound |
| HY-103363 | SB-328437 | 247580-43-4 | Reference compound |
| HY-103364 | C-021 | 864289-85-0 | Reference compound |
| HY-103364A | C-021 (dihydrochloride) | 1784252-84-1 | Reference compound |
| HY-103364AR | C-021 (dihydrochloride) (Standard) | 1784252-84-1 | Reference Standards |
| HY-103364R | C-021 (Standard) | 864289-85-0 | Reference Standards |
| HY-103365 | BX-513 (hydrochloride) | 1216540-18-9 | Reference compound |
| HY-103366 | NSC 109555 (ditosylate) | 66748-43-4 | Reference compound |
| HY-103367 | CHK1-IN-7 | 838823-31-7 | Reference compound |
| HY-103368 | Eact | 461000-66-8 | Reference compound |
| HY-103369 | PG01 | 853138-65-5 | Reference compound |
| HY-10336R | Brivanib (alaninate) (Standard) | 649735-63-7 | Reference Standards |
| HY-10337 | Brivanib | 649735-46-6 | Reference compound |
| HY-103370 | Talniflumate | 66898-62-2 | Reference compound |
| HY-103370R | Talniflumate (Standard) | 66898-62-2 | Reference Standards |
| HY-103371 | DCPIB | 82749-70-0 | Reference compound |
| HY-103372 | GSK264220A | 685506-42-7 | Reference compound |
| HY-103373 | PE154 | 1192750-33-6 | Dye Reagents |
| HY-103374 | Phenserine | 101246-66-6 | Reference compound |
| HY-103374A | Phenserine (tartrate) | 156910-61-1 | Reference compound |
| HY-103375 | SN003 | 197801-88-0 | Reference compound |
| HY-103376 | NBI-27914 (hydrochloride) | 1215766-76-9 | Reference compound |
| HY-103377 | Antalarmin (hydrochloride) | 220953-69-5 | Reference compound |
| HY-103377R | Antalarmin (hydrochloride) (Standard) | 220953-69-5 | Reference Standards |
| HY-103378 | NBI 35965 (methanesulfonate) | 603151-83-3 | Reference compound |
| HY-103379 | CP 376395 (hydrochloride) | 1013933-37-3 | Reference compound |
| HY-10337R | Brivanib (Standard) | 649735-46-6 | Reference Standards |
| HY-10338 | Foretinib | 849217-64-7 | Reference compound |
| HY-103380 | NSC 625987 | 141992-47-4 | Reference compound |
| HY-103381 | NSC693868 | 40254-90-8 | Reference compound |
| HY-103382 | Arcyriaflavin A | 118458-54-1 | Natural Products |
| HY-103382R | Arcyriaflavin A (Standard) | 118458-54-1 | Reference Standards |
| HY-103383 | (R)-DRF053 (dihydrochloride) | 1241675-76-2 | Reference compound |
| HY-103384 | TMCB | 905105-89-7 | Reference compound |
| HY-103385 | NCX4040 | 287118-97-2 | Reference compound |
| HY-103385R | NCX4040 (Standard) | 287118-97-2 | Reference Standards |
| HY-103386 | FR122047 | 130717-51-0 | Reference compound |
| HY-103387 | DuP-697 | 88149-94-4 | Reference compound |
| HY-103388 | NCX 466 | 1262956-64-8 | Reference compound |
| HY-103389 | 1-Aminobenzotriazole | 1614-12-6 | Reference compound |
| HY-103389R | 1-Aminobenzotriazole (Standard) | 1614-12-6 | Reference Standards |
| HY-10338A | Foretinib (phosphate) | 1226999-07-0 | Reference compound |
| HY-10338R | Foretinib (Standard) | 849217-64-7 | Reference Standards |
| HY-10339 | KW-2449 | 1000669-72-6 | Reference compound |
| HY-103390 | Ro26-4550 (TFA) | 1217448-66-2 | Reference compound |
| HY-103391 | Qc1 | 403718-45-6 | Reference compound |
| HY-103392 | Stiripentol | 49763-96-4 | Reference compound |
| HY-103392S | Stiripentol-d9 | 1185239-64-8 | Isotope-Labeled Compounds |
| HY-103394 | TC HSD 21 | 330203-01-5 | Reference compound |
| HY-103395 | Methylmalonic acid | 516-05-2 | Natural Products |
| HY-103395R | Methylmalonic acid (Standard) | 516-05-2 | Reference Standards |
| HY-103395S | Methylmalonic acid-d3 | 42522-59-8 | Isotope-Labeled Compounds |
| HY-103395S1 | Methylmalonic acid-13C4 | 1173019-21-0 | Isotope-Labeled Compounds |
| HY-103396 | Trimetrexate (glucuronate) | 82952-64-5 | Reference compound |
| HY-103396R | Trimetrexate (glucuronate) (Standard) | 82952-64-5 | Reference Standards |
| HY-103397 | Nanaomycin A | 52934-83-5 | Reference compound |
| HY-103397A | Dihydrokalafungin | 98392-26-8 | Reference compound |
| HY-103397R | Nanaomycin A (Standard) | 52934-83-5 | Reference Standards |
| HY-103398 | Nanaomycin C | 58286-55-8 | Natural Products |
| HY-103399 | Trovafloxacin (mesylate) | 147059-75-4 | Reference compound |
| HY-103399R | Trovafloxacin (mesylate) (Standard) | 147059-75-4 | Reference Standards |
| HY-10340 | Tirbanibulin | 897016-82-9 | Reference compound |
| HY-103400 | 8-Chloroadenosine | 34408-14-5 | Reference compound |
| HY-103400R | 8-Chloroadenosine (Standard) | 34408-14-5 | Reference Standards |
| HY-103403 | (-)-OSU6162 (hydrochloride) | 156907-84-5 | Reference compound |
| HY-103404 | PNU-96415E | 170856-41-4 | Reference compound |
| HY-103405 | NGD94-1 | 178928-68-2 | Reference compound |
| HY-103406 | PNU-177864 | 250266-51-4 | Reference compound |
| HY-103406A | PNU-177864 (hydrochloride) | 1783978-03-9 | Reference compound |
| HY-103407 | PD 168568 | 210688-56-5 | Reference compound |
| HY-103407A | PD 168568 (dihydrochloride) | 1782532-06-2 | Reference compound |
| HY-103408 | PG01037 (dihydrochloride) | 675599-62-9 | Reference compound |
| HY-103409 | ABT-724 (trihydrochloride) | 587870-77-7 | Reference compound |
| HY-10340A | Tirbanibulin (dihydrochloride) | 1038395-65-1 | Reference compound |
| HY-10340AR | Tirbanibulin (dihydrochloride) (Standard) | 1038395-65-1 | Reference Standards |
| HY-10340B | Tirbanibulin (Mesylate) | 1080645-95-9 | Reference compound |
| HY-10340BR | Tirbanibulin (Mesylate) (Standard) | 1080645-95-9 | Reference Standards |
| HY-10340R | Tirbanibulin (Standard) | 897016-82-9 | Reference Standards |
| HY-10341 | Fasudil (Hydrochloride) | 105628-07-7 | Reference compound |
| HY-103410 | Carmoxirole (hydrochloride) | 115092-85-8 | Reference compound |
| HY-103410R | Carmoxirole (hydrochloride) (Standard) | 115092-85-8 | Reference Standards |
| HY-103411 | SKF83822 (hydrobromide) | 74115-10-9 | Reference compound |
| HY-103412 | SKF 83959 (hydrobromide) | 67287-95-0 | Reference compound |
| HY-103413 | Eticlopride (hydrochloride) | 97612-24-3 | Reference compound |
| HY-103414 | Raclopride | 84225-95-6 | Reference compound |
| HY-103414R | Raclopride (Standard) | 84225-95-6 | Reference Standards |
| HY-103414S | Raclopride-d5 (hydrochloride) | 1217623-85-2 | Isotope-Labeled Compounds |
| HY-103415 | Nemonapride | 75272-39-8 | Reference compound |
| HY-103416 | A-77636 (hydrochloride) | 145307-34-2 | Reference compound |
| HY-103417 | SKF 77434 (hydrobromide) | 300561-58-4 | Reference compound |
| HY-103418 | Dopamine D2 receptor agonist-3 | 1257326-24-1 | Reference compound |
| HY-10341A | Fasudil | 103745-39-7 | Reference compound |
| HY-10341B | Fasudil (hydrochloride semihydrate) | 186694-02-0 | Reference compound |
| HY-10341C | Fasudil (dihydrochloride) | 203911-27-7 | Reference compound |
| HY-10341D | Fasudil (mesylate) | 1001206-62-7 | Reference compound |
| HY-10341R | Fasudil (Hydrochloride) (Standard) | 105628-07-7 | Reference Standards |
| HY-10342 | Enzastaurin | 170364-57-5 | Reference compound |
| HY-103423 | PAOPA | 114200-31-6 | Reference compound |
| HY-103424 | A-412997 (dihydrochloride) | 1347744-96-0 | Reference compound |
| HY-103425 | JHW007 (hydrochloride) | 202645-74-7 | Reference compound |
| HY-103427 | NPEC-caged-dopamine | 1257326-23-0 | Reference compound |
| HY-103428 | LE 300 | 274694-98-3 | Reference compound |
| HY-103429 | Quinelorane (dihydrochloride) | 97548-97-5 | Reference compound |
| HY-10342R | Enzastaurin (Standard) | 170364-57-5 | Reference Standards |
| HY-10343 | Sotrastaurin | 425637-18-9 | Reference compound |
| HY-103430 | SKF-83566 (hydrobromide) | 108179-91-5 | Reference compound |
| HY-103430A | SKF-83566 | 99295-33-7 | Reference compound |
| HY-103431 | A68930 (hydrochloride) | 130465-39-3 | Reference compound |
| HY-103432 | DPP4-In | 866396-34-1 | Reference compound |
| HY-103433 | K579 | 440100-64-1 | Reference compound |
| HY-103434 | PK44 | 1017682-65-3 | Reference compound |
| HY-103435 | Vialinin A | 858134-23-3 | Reference compound |
| HY-103436 | NSC624206 | 13116-77-3 | Reference compound |
| HY-103437 | EGFR-IN-80 | 171745-13-4 | Reference compound |
| HY-103438 | BIBU1361 | 793726-84-8 | Reference compound |
| HY-103438A | BIBU1361 (dihydrochloride) | 1643609-75-9 | Reference compound |
| HY-103439 | GW583340 (dihydrochloride) | 1173023-85-2 | Reference compound |
| HY-10343R | Sotrastaurin (Standard) | 425637-18-9 | Reference Standards |
| HY-10344 | AZD 6482 | 1173900-33-8 | Reference compound |
| HY-103440 | EGFR/ErbB-2/ErbB-4 inhibitor-3 | 881001-19-0 | Reference compound |
| HY-103441 | JNJ28871063 (hydrochloride) | 944342-90-9 | Reference compound |
| HY-103442 | CGP52411 | 145915-58-8 | Reference compound |
| HY-103443 | HKI-357 | 848133-17-5 | Reference compound |
| HY-103443A | HKI-357 (dimaleate) | 915942-25-5 | Reference compound |
| HY-103444 | ARP-100 | 704888-90-4 | Reference compound |
| HY-103444R | ARP-100 (Standard) | 704888-90-4 | Reference Standards |
| HY-103445 | SSR69071 | 344930-95-6 | Reference compound |
| HY-103446 | FERb 033 | 1111084-78-6 | Reference compound |
| HY-103447 | Zearalenone | 17924-92-4 | Natural Products |
| HY-103447R | Zearalenone (Standard) | 17924-92-4 | Reference Standards |
| HY-103447S | (Rac)-Zearalenone-d6 | 1185236-04-7 | Isotope-Labeled Compounds |
| HY-103447S1 | Zearalenone-13C18 | 911392-43-3 | Isotope-Labeled Compounds |
| HY-103447S2 | Zearalenone-13C7 | | Isotope-Labeled Compounds |
| HY-103449 | G15 | 1161002-05-6 | Reference compound |
| HY-103450 | G36 | 1392487-51-2 | Reference compound |
| HY-103451 | (R,R)-THC | 221368-54-3 | Reference compound |
| HY-103451A | rel-(R,R)-THC | 138090-06-9 | Reference compound |
| HY-103452 | RU58668 | 151555-47-4 | Reference compound |
| HY-103453 | (R)-DPN | 524047-78-7 | Reference compound |
| HY-103454 | MPP (dihydrochloride) | 911295-24-4 | Reference compound |
| HY-103454B | MPP (hydrochloride) | 2863676-89-3 | Reference compound |
| HY-103455 | ZK164015 | 177583-70-9 | Reference compound |
| HY-103456 | PHTPP | 805239-56-9 | Reference compound |
| HY-103456R | PHTPP (Standard) | 805239-56-9 | Reference Standards |
| HY-103457 | Y134 | 849662-80-2 | Reference compound |
| HY-103458 | BMS 182874 (hydrochloride) | 1215703-04-0 | Reference compound |
| HY-103459 | CI-1020 | 162256-50-0 | Reference compound |
| HY-10346 | AV-412 | 451493-31-5 | Reference compound |
| HY-103460 | IRL 2500 | 169545-27-1 | Reference compound |
| HY-103461 | FAAH-IN-6 | 1143578-94-2 | Reference compound |
| HY-103462 | TC-F2 | 1304778-15-1 | Reference compound |
| HY-103463 | SA57 | 1346169-63-8 | Reference compound |
| HY-103464 | 5'-Fluoroindirubinoxime | 861214-33-7 | Reference compound |
| HY-103465 | FFN511 | 1004548-96-2 | Reference compound |
| HY-103465B | FFN511 (hydrochloride) | 2596358-28-8 | Reference compound |
| HY-103466 | FM4-64 | 162112-35-8 | Dye Reagents |
| HY-103467 | NPE-caged-HPTS (sodium) | 223759-19-1 | Dye Reagents |
| HY-103469 | Peroxy Orange 1 | 1199576-10-7 | Dye Reagents |
| HY-10346A | AV-412 (free base) | 451492-95-8 | Reference compound |
| HY-103470 | K114 | 872201-12-2 | Dye Reagents |
| HY-103471 | Y11 | 1086639-59-9 | Reference compound |
| HY-103472 | FPR-A14 | 329691-12-5 | Reference compound |
| HY-103473 | Boc-MLF | 67247-12-5 | Reference compound |
| HY-103473A | Boc-MLF (TFA) | | Reference compound |
| HY-103474 | Bicuculline methiodide | 40709-69-1 | Reference compound |
| HY-103475 | GS39783 | 39069-52-8 | Reference compound |
| HY-103476 | Ro15-4513 | 91917-65-6 | Reference compound |
| HY-103476R | Ro15-4513 (Standard) | 91917-65-6 | Reference Standards |
| HY-103478 | KHK-IN-2 | 2135304-43-5 | Reference compound |
| HY-103479 | GOAT-IN-1 | 1452473-54-9 | Reference compound |
| HY-103482 | JNJ0966 | 315705-75-0 | Reference compound |
| HY-103483 | MD2-IN-1 | 111797-22-9 | Reference compound |
| HY-103484 | GATA4-NKX2-5-IN-1 | 544681-96-1 | Reference compound |
| HY-103487 | Uprifosbuvir | 1496551-77-9 | Reference compound |
| HY-103489 | PI-273 | 925069-34-7 | Reference compound |
| HY-10349 | WAY-100635 | 162760-96-5 | Reference compound |
| HY-103490 | Takinib | 1111556-37-6 | Reference compound |
| HY-103490R | Takinib (Standard) | 1111556-37-6 | Reference Standards |
| HY-103491 | PF-06462894 | 1622291-66-0 | Reference compound |
| HY-103492 | CDK8-IN-1 | 1629633-48-2 | Reference compound |
| HY-103493 | TAK-915 | 1476727-50-0 | Reference compound |
| HY-103495 | 17-PA | 694438-95-4 | Reference compound |
| HY-103496 | U-90042 | 134516-99-7 | Reference compound |
| HY-103497 | U-89843A (hydrochloride) | 157013-85-9 | Reference compound |
| HY-103498 | Org20599 | 156685-94-8 | Reference compound |
| HY-103499 | ZK 93426 (hydrochloride) | 1216792-30-1 | Reference compound |
| HY-10349A | WAY-100635 (maleate) | 1092679-51-0 | Reference compound |
| HY-10349AR | WAY-100635 (maleate) (Standard) | 1092679-51-0 | Reference Standards |
| HY-10349R | WAY-100635 (Standard) | 162760-96-5 | Reference Standards |
| HY-103500 | Ro19-4603 | 99632-94-7 | Reference compound |
| HY-103501 | SB-205384 | 160296-13-9 | Reference compound |
| HY-103502 | CGP7930 | 57717-80-3 | Reference compound |
| HY-103503 | CGP13501 | 56189-68-5 | Reference compound |
| HY-103504 | (S)-SNAP5114 | 157604-55-2 | Reference compound |
| HY-103505 | CL 218872 | 66548-69-4 | Reference compound |
| HY-103506 | NNC-711 | 145645-62-1 | Reference compound |
| HY-103507 | N-Arachidonyl-GABA | 128201-89-8 | Reference compound |
| HY-103509 | NNC 05-2090 (hydrochloride) | 184845-18-9 | Reference compound |
| HY-10351 | Robalzotan | 169758-66-1 | Reference compound |
| HY-103510 | TB-21007 | 207306-50-1 | Reference compound |
| HY-103511 | TCS1105 | 185391-33-7 | Reference compound |
| HY-103512 | TP003 | 628690-75-5 | Reference compound |
| HY-103513 | GABAA receptor agent 2 | 1236105-75-1 | Reference compound |
| HY-103516 | CGP55845 (hydrochloride) | 149184-22-5 | Reference compound |
| HY-103518 | CGP36216 | 123691-29-2 | Reference compound |
| HY-103518A | CGP36216 (hydrochloride) | 1781834-71-6 | Reference compound |
| HY-103519 | rac-BHFF | 123557-91-5 | Reference compound |
| HY-10351A | Robalzotan (hydrochloride) | 184674-99-5 | Reference compound |
| HY-103520 | DS2 | 374084-31-8 | Reference compound |
| HY-103521 | Anxiolytic/nonsedative agent-1 | 355022-97-8 | Reference compound |
| HY-103522 | AA29504 | 945828-50-2 | Reference compound |
| HY-103524 | Valerenic acid | 3569-10-6 | Reference compound |
| HY-103524R | Valerenic acid (Standard) | 3569-10-6 | Reference Standards |
| HY-103526 | DPNI-GABA | 927866-58-8 | Reference compound |
| HY-103527 | RuBi-GABA | 1028141-88-9 | Reference compound |
| HY-103528 | SCS | 3232-36-8 | Reference compound |
| HY-10353 | Raltegravir | 518048-05-0 | Reference compound |
| HY-103530 | CGP35348 | 123690-79-9 | Reference compound |
| HY-103530R | CGP35348 (Standard) | 123690-79-9 | Reference Standards |
| HY-103531 | CGP52432 | 139667-74-6 | Reference compound |
| HY-103532 | CGP46381 | 123691-14-5 | Reference compound |
| HY-103533 | Gabazine | 104104-50-9 | Reference compound |
| HY-103533R | Gabazine (Standard) | 104104-50-9 | Reference Standards |
| HY-103534 | CI-966 (hydrochloride) | 110283-66-4 | Reference compound |
| HY-103535 | GBLD345 | 122479-08-7 | Reference compound |
| HY-103536 | Galnon | 475115-35-6 | Reference compound |
| HY-103536A | Galnon (TFA) | 1217448-19-5 | Reference compound |
| HY-103537 | (Rac)-BIIB042 | 1257395-14-4 | Reference compound |
| HY-103538 | JLK-6 | 62252-26-0 | Reference compound |
| HY-103539 | 3,5-Bis(4-nitrophenoxy)benzoic acid | 173550-33-9 | Reference compound |
| HY-10353A | Raltegravir (potassium) | 871038-72-1 | Reference compound |
| HY-10353AR | Raltegravir (potassium) (Standard) | 871038-72-1 | Reference Standards |
| HY-10353AS | Raltegravir-d3 (potassium) | 1246816-98-7 | Isotope-Labeled Compounds |
| HY-10353AS1 | Raltegravir-13C,d3 (potassium) | | Isotope-Labeled Compounds |
| HY-10353AS2 | Raltegravir-d4 (potassium) | | Isotope-Labeled Compounds |
| HY-10353B | Raltegravir (sodium) | 1292804-07-9 | Reference compound |
| HY-10353S | Raltegravir-d4 | 2712343-38-7 | Isotope-Labeled Compounds |
| HY-10353S1 | Raltegravir-d6 | 1100750-98-8 | Isotope-Labeled Compounds |
| HY-103540 | Tabimorelin (hemifumarate) | 242143-80-2 | Reference compound |
| HY-103544 | [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P | 96736-12-8 | Peptides |
| HY-103545 | GIP (1-39) | 725474-97-5 | Peptides |
| HY-103546 | BETP | 1371569-69-5 | Reference compound |
| HY-103547 | L-168049 | 191034-25-0 | Reference compound |
| HY-103548 | GSK9027 | 1229096-88-1 | Reference compound |
| HY-103549 | Z-Cyclopentyl-AP4 | 103439-17-4 | Reference compound |
| HY-10355 | AKT inhibitor VIII | 612847-09-3 | Reference compound |
| HY-103550 | A-841720 | 869802-58-4 | Reference compound |
| HY-103551 | (±)-LY395756 | 852679-66-4 | Reference compound |
| HY-103551A | LY 541850 | 852679-76-6 | Reference compound |
| HY-103552 | LY487379 (hydrochloride) | 353229-59-1 | Reference compound |
| HY-103555 | NPEC-caged-(1S,3R)-ACPD | 1315379-60-2 | Reference compound |
| HY-103556 | YM-202074 (fumarate) | 299900-84-8 | Reference compound |
| HY-103557 | Ro 64-5229 | 246852-46-0 | Reference compound |
| HY-103558 | LY379268 | 191471-52-0 | Reference compound |
| HY-103559 | HexylHIBO | 334887-43-3 | Reference compound |
| HY-103560 | (S)-HexylHIBO | 334887-48-8 | Reference compound |
| HY-103561 | DCB | 6971-97-7 | Reference compound |
| HY-103562 | DMeOB | 40252-74-2 | Reference compound |
| HY-103563 | 3-MATIDA | 518357-51-2 | Reference compound |
| HY-103564 | ACDPP | 37804-11-8 | Reference compound |
| HY-103565 | AMN082 | 97075-46-2 | Reference compound |
| HY-103565A | AMN082 (free base) | 83027-13-8 | Reference compound |
| HY-103565AR | AMN082 (free base) (Standard) | 83027-13-8 | Reference Standards |
| HY-103565R | AMN082 (Standard) | 97075-46-2 | Reference Standards |
| HY-103566 | LY456236 | 338736-46-2 | Reference compound |
| HY-103567 | Desmethyl-YM-298198 (hydrochloride) | 1177767-57-5 | Reference compound |
| HY-103567A | Desmethyl-YM-298198 | 299901-57-8 | Reference compound |
| HY-103568 | YM-298198 (hydrochloride) | 1216398-09-2 | Reference compound |
| HY-10357 | MK-2206 (free base) | 1032349-93-1 | Reference compound |
| HY-103570 | MCPG (sodium) | 1303994-09-3 | Reference compound |
| HY-103571 | VU0285683 | 327056-22-4 | Reference compound |
| HY-103572 | MNI137 | 946619-21-2 | Reference compound |
| HY-103573 | VU 0360223 | 1274859-33-4 | Reference compound |
| HY-103574 | Raseglurant (hydrochloride) | 757949-98-7 | Reference compound |
| HY-103575 | MFZ 10-7 | 1224431-15-5 | Reference compound |
| HY-103575A | MFZ 10-7 (hydrochloride) | 1779796-36-9 | Reference compound |
| HY-103576 | LGD-3303 | 917891-35-1 | Reference compound |
| HY-103577 | LG-121071 | 179897-70-2 | Reference compound |
| HY-103578 | S-40503 | 404920-28-1 | Reference compound |
| HY-10358 | MK-2206 (dihydrochloride) | 1032350-13-2 | Reference compound |
| HY-103583 | KDU731 | 1610610-48-4 | Reference compound |
| HY-103586 | GS-441524 | 1191237-69-0 | Reference compound |
| HY-103586A | GS-441524 (hydrochloride) | 2378280-82-9 | Reference compound |
| HY-103591 | DUPA(OtBu)-OH | 1026987-94-9 | Reference compound |
| HY-103592 | ARN14974 | 1644158-57-5 | Reference compound |
| HY-103593 | LCL521 | 1226851-11-1 | Reference compound |
| HY-103593A | LCL521 dihydrochloride | 1226759-47-2 | Reference compound |
| HY-103594 | 2-Aminoacridone | 27918-14-5 | Dye Reagents |
| HY-103595 | Epirizole | 18694-40-1 | Reference compound |
| HY-103595R | Epirizole (Standard) | 18694-40-1 | Reference Standards |
| HY-103596 | Thalidomide-4-OH | 5054-59-1 | Reference compound |
| HY-103597 | Thalidomide-O-COOH | 1061605-21-7 | Reference compound |
| HY-103598 | (S,R,S)-AHPC-PEG3-N3 | 1797406-80-4 | Reference compound |
| HY-103599 | (S,R,S)-AHPC-PEG2-N3 | 2010159-45-0 | Reference compound |
| HY-103600 | (S,R,S)-AHPC-PEG1-N3 | 2101200-09-1 | Reference compound |
| HY-103601 | (S,R,S)-AHPC-PEG4-N3 | 1797406-81-5 | Reference compound |
| HY-103602 | (S,R,S)-AHPC-PEG3-NH2 (hydrochloride) | 2097971-11-2 | Reference compound |
| HY-103602A | (S,R,S)-AHPC-PEG3-NH2 | 2010159-56-3 | Reference compound |
| HY-103602B | (S,R,S)-AHPC-PEG3-NH2 (dihydrochloride) | 2376990-24-6 | Reference compound |
| HY-103603 | (S,R,S)-AHPC-PEG2-NH2 (hydrochloride) | 2097973-72-1 | Reference compound |
| HY-103603A | (S,R,S)-AHPC-PEG2-NH2 | 2010159-60-9 | Reference compound |
| HY-103603B | (S,R,S)-AHPC-PEG2-NH2 (dihydrochloride) | 2341796-76-5 | Reference compound |
| HY-103604 | (S,R,S)-AHPC-PEG4-NH2 (hydrochloride) | 2064292-52-8 | Reference compound |
| HY-103604A | (S,R,S)-AHPC-PEG4-NH2 | 2010159-57-4 | Reference compound |
| HY-103605 | (S,R,S)-AHPC-C6-PEG3-C4-Cl | 1835705-55-9 | Reference compound |
| HY-103606 | (S,R,S)-AHPC-PEG6-C4-Cl | 1835705-59-3 | Reference compound |
| HY-103607 | (S,R,S)-AHPC-PEG2-C4-Cl | 1835705-57-1 | Reference compound |
| HY-103608 | (S,R,S)-AHPC-(C3-PEG)2-C6-Cl | 1835705-61-7 | Reference compound |
| HY-103609 | Pyrene | 129-00-0 | Dye Reagents |
| HY-103609R | Pyrene (Standard) | 129-00-0 | Reference Standards |
| HY-103610 | 4,4'-Dimethoxybenzil | 1226-42-2 | Reference compound |
| HY-103611 | Thalidomide-O-amido-PEG3-C2-NH2 (TFA) | 1957236-21-3 | Reference compound |
| HY-103612 | Thalidomide-O-amido-C3-COOH | 2308035-51-8 | Reference compound |
| HY-103613 | Thalidomide-O-amido-C4-NH2 (TFA) | 1799711-25-3 | Reference compound |
| HY-103614 | Thalidomide-O-amido-C8-NH2 (TFA) | 1950635-16-1 | Reference compound |
| HY-103615 | Thalidomide-O-amido-C4-N3 | 2098488-36-7 | Reference compound |
| HY-103617 | PKM2-IN-1 | 94164-88-2 | Reference compound |
| HY-103618 | THZ531 | 1702809-17-3 | Reference compound |
| HY-103620 | ROCK2-IN-2 | 1995065-79-6 | Reference compound |
| HY-103623 | PF-05241328 | 1387633-03-5 | Reference compound |
| HY-103628 | PROTAC CDK9 Degrader-1 | 2118356-96-8 | Reference compound |
| HY-10363 | AP 24149 | 926922-29-4 | Reference compound |
| HY-103632 | PROTAC BRD9 Degrader-1 | 2097971-01-0 | Reference compound |
| HY-103633 | PROTAC BET Degrader-1 | 2093386-22-0 | Reference compound |
| HY-103634 | dFKBP-1 | 1799711-22-0 | Reference compound |
| HY-103636 | PROTAC Sirt2 Degrader-1 | 2098487-75-1 | Reference compound |
| HY-103637 | Vimirogant | 1802706-04-2 | Reference compound |
| HY-103637A | Vimirogant (hydrochloride) | 1802678-42-7 | Reference compound |
| HY-103638 | 3-Methoxytyramine (hydrochloride) | 1477-68-5 | Natural Products |
| HY-103638A | 3-Methoxytyramine | 554-52-9 | Natural Products |
| HY-103638AR | 3-Methoxytyramine (Standard) | 554-52-9 | Reference Standards |
| HY-103638R | 3-Methoxytyramine (hydrochloride) (Standard) | 1477-68-5 | Reference Standards |
| HY-103638S | 3-Methoxytyramine-d4 (hydrochloride) | 1216788-76-9 | Isotope-Labeled Compounds |
| HY-103639 | M62812 (free base) | 613262-61-6 | Reference compound |
| HY-103639A | M62812 | 613263-00-6 | Reference compound |
| HY-103640 | Amifostine thiol (dihydrochloride) | 14653-77-1 | Reference compound |
| HY-103640R | Amifostine thiol (dihydrochloride) (Standard) | 14653-77-1 | Reference Standards |
| HY-103641 | (2R)-Octyl-α-hydroxyglutarate | 1391194-67-4 | Reference compound |
| HY-103641A | (2S)-Octyl-α-hydroxyglutarate | 1391194-64-1 | Reference compound |
| HY-103641AR | (2S)-Octyl-α-hydroxyglutarate (Standard) | 1391194-64-1 | Reference Standards |
| HY-103641AS1 | (2R)-Octyl-α-hydroxyglutarate-d17 | 2748638-78-8 | Isotope-Labeled Compounds |
| HY-103641B | (2R)-Octyl-α-hydroxyglutarate (sodium) | 1391068-16-8 | Reference compound |
| HY-103641C | Octyl-α-hydroxyglutarate | 2097068-39-6 | Reference compound |
| HY-103641R | (2R)-Octyl-α-hydroxyglutarate (Standard) | 1391194-67-4 | Reference Standards |
| HY-103642 | D-myo-Inositol 1,4,5-trisphosphate (hexapotassium salt) | 103476-24-0 | Reference compound |
| HY-103642A | D-myo-Inositol-1,4,5-triphosphate (trisodium) | 141611-10-1 | Reference compound |
| HY-103643 | Fumagillol | 108102-51-8 | Natural Products |
| HY-103643R | Fumagillol (Standard) | 108102-51-8 | Reference Standards |
| HY-103645 | GW779439X | 551919-98-3 | Reference compound |
| HY-103646 | CK7 | 507487-89-0 | Reference compound |
| HY-103647 | K00546 | 443798-47-8 | Reference compound |
| HY-103649 | OT antagonist 3 | 925703-75-9 | Reference compound |
| HY-103650 | OT antagonist 1 | 479080-38-1 | Reference compound |
| HY-103651 | OT antagonist 1 demethyl derivative | 2763705-17-3 | Reference compound |
| HY-103652 | OT antagonist 3 analog | 2444044-37-3 | Reference compound |
| HY-103656 | Tetraphenylporphyrin | 917-23-7 | Reference compound |
| HY-103658 | Myramistin | 15809-19-5 | Reference compound |
| HY-10366 | BI-78D3 | 883065-90-5 | Reference compound |
| HY-103660 | 18:0 LYSO-PE | 69747-55-3 | Reference compound |
| HY-103661 | BI-6C9 | 791835-21-7 | Reference compound |
| HY-103662 | GW-870086 | 827319-43-7 | Reference compound |
| HY-103663 | MAK683 | 1951408-58-4 | Reference compound |
| HY-103663A | MAK683 (hydrochloride) | 2170606-94-5 | Reference compound |
| HY-103664 | Fmoc-1,6-diaminohexane | 166410-37-3 | Reference compound |
| HY-103664A | Fmoc-1,6-diaminohexane (hydrochloride) | 945923-91-1 | Reference compound |
| HY-103665 | STING agonist-3 | 2138299-29-1 | Reference compound |
| HY-103665A | STING agonist-3 (trihydrochloride) | | Reference compound |
| HY-103666 | CY-09 | 1073612-91-5 | Reference compound |
| HY-103667 | 2-HBA | 131359-24-5 | Reference compound |
| HY-103668A | SSD114 (hydrochloride) | 2319790-02-6 | Reference compound |
| HY-103669 | HAT-IN-1 | 1889281-94-0 | Reference compound |
| HY-10367 | Canertinib | 267243-28-7 | Reference compound |
| HY-103671 | IPN60090 | 1853164-83-6 | Reference compound |
| HY-103671A | IPN60090 (dihydrochloride) | 2102101-72-2 | Reference compound |
| HY-103672 | AZD7624 | 1095004-78-6 | Reference compound |
| HY-103673 | AMPD2 inhibitor 1 | 2139356-35-5 | Reference compound |
| HY-10367A | Canertinib (dihydrochloride) | 289499-45-2 | Reference compound |
| HY-10367AR | Canertinib (dihydrochloride) (Standard) | 289499-45-2 | Reference Standards |
| HY-10367R | Canertinib (Standard) | 267243-28-7 | Reference Standards |
| HY-10368 | EGFR/VEGFR2-IN-4 | 870962-74-6 | Reference compound |
| HY-103682 | PF-06726304 | 1616287-82-1 | Reference compound |
| HY-103682A | PF-06726304 (acetate) | 2080306-28-9 | Reference compound |
| HY-103683 | PF-06409577 | 1467057-23-3 | Reference compound |
| HY-103683R | PF-06409577 (Standard) | 1467057-23-3 | Reference Standards |
| HY-103684 | RT-NH2 | 2321343-06-8 | Dye Reagents |
| HY-103687 | Abiraterone metabolite 1 | 1940176-03-3 | Reference compound |
| HY-103688 | N-Ac-γ-Calicheamicin-AcBut-NHS ester | 174885-02-0 | Reference compound |
| HY-103689 | Cucurbit[8]uril | 259886-51-6 | Reference compound |
| HY-103691 | ARN5187 | 1287451-26-6 | Reference compound |
| HY-103691A | ARN5187 (trihydrochloride) | 1700693-96-4 | Reference compound |
| HY-103692 | STX-0119 | 851095-32-4 | Reference compound |
| HY-103693 | NAZ2329 | 2809469-05-2 | Reference compound |
| HY-103694 | Nebularine | 550-33-4 | Natural Products |
| HY-103695 | CD73-IN-1 | 2132396-40-6 | Reference compound |
| HY-103696 | PTC-028 | 1782970-28-8 | Reference compound |
| HY-103697 | Gardiquimod | 1020412-43-4 | Reference compound |
| HY-103697A | Gardiquimod (diTFA) | 1159840-61-5 | Reference compound |
| HY-103697AR | Gardiquimod (diTFA) (Standard) | 1159840-61-5 | Reference Standards |
| HY-103697B | Gardiquimod (hydrochloride) | 2956183-81-4 | Reference compound |
| HY-103697R | Gardiquimod (Standard) | 1020412-43-4 | Reference Standards |
| HY-103698 | TLR7/8 agonist 1 | 1258457-59-8 | Reference compound |
| HY-103698A | TLR7/8 agonist 1 (dihydrochloride) | 1620278-72-9 | Reference compound |
| HY-103700A | Azide-phenylalanine (hydrochloride) | 1409940-46-0 | Reference compound |
| HY-103700B | (Rac)-Azide-phenylalanine | 1822572-56-4 | Reference compound |
| HY-103701 | L-Ascorbic acid 2-phosphate | 23313-12-4 | Reference compound |
| HY-103701A | L-Ascorbic acid 2-phosphate (magnesium) | 113170-55-1 | Reference compound |
| HY-103701AR | L-Ascorbic acid 2-phosphate (magnesium) (Standard) | 113170-55-1 | Reference Standards |
| HY-103701B | L-Ascorbic acid 2-phosphate (magnesium hydrate) | 1713265-25-8 | Biochemical Assay Reagents |
| HY-103702 | TIP48/49-IN-1 | 1807337-58-1 | Reference compound |
| HY-103703 | DEAE Cross-linked dextran A 25 | 12609-80-2 | Reference compound |
| HY-103704 | LY2562175 | 1103500-20-4 | Reference compound |
| HY-103705 | iCRT3 | 901751-47-1 | Reference compound |
| HY-103706 | ROC-325 | 1859141-26-6 | Reference compound |
| HY-103708 | Nezukone | 13656-81-0 | Reference compound |
| HY-10371 | Pim1/AKK1-IN-1 | 1093222-27-5 | Reference compound |
| HY-103710 | IBR2 | 313526-24-8 | Reference compound |
| HY-103710A | (R)-IBR2 | 952739-54-7 | Reference compound |
| HY-103711 | Estramustine | 2998-57-4 | Reference compound |
| HY-103711R | Estramustine (Standard) | 2998-57-4 | Reference Standards |
| HY-103712 | Samuraciclib | 1805833-75-3 | Reference compound |
| HY-103712A | Samuraciclib (hydrochloride) | 1805789-54-1 | Reference compound |
| HY-103712B | Samuraciclib (hydrochloride dihydrate) | | Reference compound |
| HY-103712C | Samuraciclib (hydrochloride hydrate) | | Reference compound |
| HY-103713 | Seclidemstat | 1423715-37-0 | Reference compound |
| HY-103713A | Seclidemstat (mesylate) | 2044953-70-8 | Reference compound |
| HY-103714 | Ensartinib | 1370651-20-9 | Reference compound |
| HY-103714A | Ensartinib (dihydrochloride) | 2137030-98-7 | Reference compound |
| HY-103715 | NLRP3 modulators 1 | 2143015-87-4 | Reference compound |
| HY-10372 | PP121 | 1092788-83-4 | Reference compound |
| HY-103721 | SIRT6-IN-2 | 891002-11-2 | Reference compound |
| HY-10373 | Trimetrexate | 52128-35-5 | Reference compound |
| HY-10373A | Trimetrexate (trihydrochloride) | 1658520-97-8 | Reference compound |
| HY-10373B | Trimetrexate (isethionate) | 82935-04-4 | Reference compound |
| HY-10374 | Semaxinib | 204005-46-9 | Reference compound |
| HY-10388 | TTA-Q6 | 910484-28-5 | Reference compound |
| HY-10388A | TTA-Q6(isomer) | 910484-32-1 | Reference compound |
| HY-10389 | Alvespimycin | 467214-20-6 | Reference compound |
| HY-10392 | Sutezolid | 168828-58-8 | Reference compound |
| HY-10392R | Sutezolid (Standard) | 168828-58-8 | Reference Standards |
| HY-10392S | Sutezolid-13C4 | | Isotope-Labeled Compounds |
| HY-10393 | Eperezolid | 165800-04-4 | Reference compound |
| HY-10393R | Eperezolid (Standard) | 165800-04-4 | Reference Standards |
| HY-10394 | Linezolid | 165800-03-3 | Reference compound |
| HY-10394R | Linezolid (Standard) | 165800-03-3 | Reference Standards |
| HY-10394S | Linezolid-d3 | 1127120-38-0 | Isotope-Labeled Compounds |
| HY-10394S1 | PNU-100766-d8 | 1032182-14-1 | Isotope-Labeled Compounds |
| HY-10395 | PD173955 | 260415-63-2 | Reference compound |
| HY-10396 | Emricasan | 254750-02-2 | Reference compound |
| HY-10396A | (2R,3S)-Emricasan | 409369-54-6 | Reference compound |
| HY-10396R | Emricasan (Standard) | 254750-02-2 | Reference Standards |
| HY-10397 | EP1013 | 223568-55-6 | Reference compound |
| HY-10397A | MX1013 | 582316-00-5 | Reference compound |
| HY-10398 | CTS-1027 | 193022-04-7 | Reference compound |
| HY-10399 | Ladostigil | 209394-27-4 | Reference compound |
| HY-10399A | Ladostigil (hydrochloride) | 209394-18-3 | Reference compound |
| HY-10399B | (S)-Ladostigil | 209394-29-6 | Reference compound |
| HY-10400 | Ladostigil (hemitartrate) | 209394-46-7 | Reference compound |
| HY-104000 | BAY-320 | 1445830-50-1 | Reference compound |
| HY-104001 | BAY-524 | 1445830-39-6 | Reference compound |
| HY-104003 | S 38093 | 862896-30-8 | Reference compound |
| HY-104003A | S 38093 (hydrochloride) | 1222097-72-4 | Reference compound |
| HY-104004 | Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH | 120173-57-1 | Reference compound |
| HY-104004A | Fmoc-Ser(O-β-D-GalNAc(OAc)3)-OH | 160067-63-0 | Peptides |
| HY-104005 | ML335 | 825658-06-8 | Reference compound |
| HY-104006 | CYM51010 | 1069498-96-9 | Reference compound |
| HY-104008 | ACY-957 | 1609389-52-7 | Reference compound |
| HY-104009 | GSK2807 | 2245255-65-4 | Reference compound |
| HY-104009A | GSK2807 (Trifluoroacetate) | 2245255-66-5 | Reference compound |
| HY-10401 | VX-702 | 745833-23-2 | Reference compound |
| HY-104010 | Asciminib | 1492952-76-7 | Reference compound |
| HY-104010A | Asciminib (hydrochloride) | 2119669-71-3 | Reference compound |
| HY-104010R | Asciminib (Standard) | 1492952-76-7 | Reference Standards |
| HY-104012 | Islatravir | 865363-93-5 | Reference compound |
| HY-104013 | Aminopurvalanol A | 220792-57-4 | Reference compound |
| HY-104014 | DMT-2'O-MOE-rG(ib) Phosphoramidite | 251647-55-9 | Reference compound |
| HY-104015 | NecroX-5 | 1383718-29-3 | Reference compound |
| HY-104016 | 2'-O-MOE-5MeU-3'-phosphoramidite | 163878-63-5 | Reference compound |
| HY-104017 | DMT-2'-O-MOE-rA(Bz) phosphoramidite | 251647-53-7 | Reference compound |
| HY-10401R | VX-702 (Standard) | 745833-23-2 | Reference Standards |
| HY-10402 | Losmapimod | 585543-15-3 | Reference compound |
| HY-104020A | Philanthotoxin 74 dihydrochloride | 1227301-51-0 | Reference compound |
| HY-104020B | Philanthotoxin 74 (diTFA) | 401601-12-5 | Reference compound |
| HY-104021 | GSK840 | 2361146-30-5 | Reference compound |
| HY-104025 | SPB | 858128-57-1 | ADC Related |
| HY-104026 | L-Kynurenine | 2922-83-0 | Natural Products |
| HY-104026B | L-Kynurenine (sulfate) | 16055-80-4 | Reference compound |
| HY-104026BS | L-Kynurenine-13C10 (sulfate) | | Isotope-Labeled Compounds |
| HY-104026CS | L-Kynurenine-13C10 (sulfate hemihydrate) | | Isotope-Labeled Compounds |
| HY-104026R | L-Kynurenine (Standard) | 2922-83-0 | Reference Standards |
| HY-104026S | L-Kynurenine-d4 | 2672568-86-2 | Isotope-Labeled Compounds |
| HY-104026S1 | L-Kynurenine-d4-1 | 194546-33-3 | Isotope-Labeled Compounds |
| HY-104026S2 | L-Kynurenine-d4-1 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-104026S3 | L-Kynurenine-13C4,15N-1 | | Isotope-Labeled Compounds |
| HY-104026S5 | L-Kynurenine-13C10 (sulfate hydrate) | | Isotope-Labeled Compounds |
| HY-104027 | ML402 | 298684-44-3 | Reference compound |
| HY-104028 | BAY 73-6691 | 794568-92-6 | Reference compound |
| HY-104028A | BAY 73-6691 (racemate) | 794568-90-4 | Reference compound |
| HY-104028B | (S)-BAY 73-6691 | 794568-91-5 | Reference compound |
| HY-104029 | Olorofim | 1928707-56-5 | Reference compound |
| HY-10402R | Losmapimod (Standard) | 585543-15-3 | Reference Standards |
| HY-10403 | PH-797804 | 586379-66-0 | Reference compound |
| HY-104031 | tCFA15 | 220757-88-0 | Reference compound |
| HY-104031R | tCFA15 (Standard) | 220757-88-0 | Reference Standards |
| HY-104032 | Ac-CoA Synthase Inhibitor1 | 508186-14-9 | Reference compound |
| HY-104035E | Dimethyl silicone oil, viscosity 100 cSt (25 °C) | 63148-62-9 | Biochemical Assay Reagents |
| HY-104035H | Dimethyl silicone oil, viscosity 10 cSt (25 °C) | 63148-62-9 | Biochemical Assay Reagents |
| HY-104036 | IDH-305 | 1628805-46-8 | Reference compound |
| HY-104037 | Cintirorgon | 2055536-64-4 | Reference compound |
| HY-104037A | Cintirorgon (sodium) | 2055538-47-9 | Reference compound |
| HY-104038 | Pariceract | 1919820-28-2 | Reference compound |
| HY-104039 | 2'-Deoxy-5'-O-DMT-5-methylcytidine | 176755-83-2 | Reference compound |
| HY-10403A | (aS)-PH-797804 | 1358027-80-1 | Reference compound |
| HY-10404 | Dilmapimod | 444606-18-2 | Reference compound |
| HY-104040 | MKC8866 | 1338934-59-0 | Reference compound |
| HY-104042 | Vorasidenib | 1644545-52-7 | Reference compound |
| HY-104044 | Pamiparib | 1446261-44-4 | Reference compound |
| HY-104044A | Pamiparib (maleate) | 2086689-94-1 | Reference compound |
| HY-104044R | Pamiparib (Standard) | 1446261-44-4 | Reference Standards |
| HY-104046 | Octaaminocryptand 1 | 135469-17-9 | Reference compound |
| HY-104047 | LM22B-10 | 342777-54-2 | Reference compound |
| HY-104048 | QC6352 | 1851373-36-8 | Reference compound |
| HY-10404A | Dilmapimod (tosylate) | 937169-00-1 | Reference compound |
| HY-10404R | Dilmapimod (Standard) | 444606-18-2 | Reference Standards |
| HY-10405 | Pamapimod | 449811-01-2 | Reference compound |
| HY-104050 | M-31850 | 281224-40-6 | Reference compound |
| HY-104051 | Monacolin J | 79952-42-4 | Reference compound |
| HY-104056 | Fura Red | 149732-62-7 | Dye Reagents |
| HY-104058 | Oregon-BAPTA Green 1AM | 244167-57-5 | Dye Reagents |
| HY-104059 | AMG2850 | 1470018-52-0 | Reference compound |
| HY-10405R | Pamapimod (Standard) | 449811-01-2 | Reference Standards |
| HY-10405S | Pamapimod-d4 | 1246814-57-2 | Isotope-Labeled Compounds |
| HY-10406 | Talmapimod | 309913-83-5 | Reference compound |
| HY-104061 | AMG8788 | 1159996-43-6 | Reference compound |
| HY-104062 | AMG9678 | 1159997-27-9 | Reference compound |
| HY-104064 | 1A-116 | 1430208-73-3 | Reference compound |
| HY-104065 | Pyrotinib | 1269662-73-8 | Reference compound |
| HY-104065A | (Rac)-Pyrotinib | 1246089-97-3 | Reference compound |
| HY-104065B | Pyrotinib dimaleate | 1397922-61-0 | Reference compound |
| HY-104065BR | Pyrotinib dimaleate (Standard) | 1397922-61-0 | Reference Standards |
| HY-104066 | Theliatinib | 1353644-70-8 | Reference compound |
| HY-104066A | Theliatinib (tartrate) | 2413487-72-4 | Reference compound |
| HY-104067 | Naphthol AS-MX phosphate | 1596-56-1 | Reference compound |
| HY-104068 | Naphthol AS-E | 92-78-4 | Reference compound |
| HY-104069 | S1P1 agonist 1 | 1220973-37-4 | Reference compound |
| HY-10406A | Talmapimod (hydrochloride ) | 2387505-88-4 | Reference compound |
| HY-10407 | SU 5402 | 215543-92-3 | Reference compound |
| HY-104070 | LG-100064 | 153559-46-7 | Reference compound |
| HY-104071 | Succinaldehydic acid | 692-29-5 | Natural Products |
| HY-104072 | BRD4-IN-3 | 1380087-86-4 | Reference compound |
| HY-104073 | CAY10602 | 374922-43-7 | Reference compound |
| HY-104074 | Pocapavir | 146949-21-5 | Reference compound |
| HY-104074S | Pocapavir-d3 | | Isotope-Labeled Compounds |
| HY-104075 | R916562 | 1037798-41-6 | Reference compound |
| HY-104076 | β-L-Glucose pentaacetate | 66966-07-2 | Biochemical Assay Reagents |
| HY-104076A | α-L-Glucose pentaacetate | 147648-81-5 | Biochemical Assay Reagents |
| HY-104077 | Remdesivir | 1809249-37-3 | Reference compound |
| HY-104077A | Remdesivir (maleate) | 2250110-53-1 | Reference compound |
| HY-104077R | Remdesivir (Standard) | 1809249-37-3 | Reference Standards |
| HY-104077S | Remdesivir-d5 | | Isotope-Labeled Compounds |
| HY-104077S1 | Remdesivir-d4 | | Isotope-Labeled Compounds |
| HY-104077S2 | Remdesivir impurity 9-d4 | | Isotope-Labeled Compounds |
| HY-10407G | SU 5402 (GMP) | 215543-92-3 | GMP Small Molecules |
| HY-10408 | Ki20227 | 623142-96-1 | Reference compound |
| HY-104081 | Cholestyramine | 11041-12-6 | Reference compound |
| HY-104086 | Cucurbit[7]uril | 259886-50-5 | Biochemical Assay Reagents |
| HY-10409 | Fedratinib | 936091-26-8 | Reference compound |
| HY-10409A | Fedratinib (hydrochloride hydrate) | 1374744-69-0 | Reference compound |
| HY-10409AR | Fedratinib (hydrochloride hydrate) (Standard) | 1374744-69-0 | Reference Standards |
| HY-10409R | Fedratinib (Standard) | 936091-26-8 | Reference Standards |
| HY-10409S | Fedratinib-d9 | | Isotope-Labeled Compounds |
| HY-10410 | TG101209 | 936091-14-4 | Reference compound |
| HY-10411 | AZ960 | 905586-69-8 | Reference compound |
| HY-10412 | CEP-1347 | 156177-65-0 | Reference compound |
| HY-10413 | MK-2894 | 1006036-87-8 | Reference compound |
| HY-10414 | MK-2894 (sodium salt) | 1006036-88-9 | Reference compound |
| HY-10416 | Oxamniquine | 21738-42-1 | Reference compound |
| HY-10418 | AH 6809 | 33458-93-4 | Reference compound |
| HY-10418R | AH 6809 (Standard) | 33458-93-4 | Reference Standards |
| HY-10419A | AH23848 (hemicalcium salt) | 81496-19-7 | Reference compound |
| HY-10421 | Tyrosine kinase inhibitor | 1021950-26-4 | Reference compound |
| HY-10422 | AZD-8055 | 1009298-09-2 | Reference compound |
| HY-10423 | OSI-027 | 936890-98-1 | Reference compound |
| HY-10424 | Milciclib | 802539-81-7 | Reference compound |
| HY-10424A | Milciclib (maleate) | 1253645-38-3 | Reference compound |
| HY-10424R | Milciclib (Standard) | 802539-81-7 | Reference Standards |
| HY-10425 | Rizavasertib | 552325-16-3 | Reference compound |
| HY-10426 | XCT790 | 725247-18-7 | Reference compound |
| HY-10427 | WAY-260022 | 850692-43-2 | Reference compound |
| HY-10431 | SB-431542 | 301836-41-9 | Reference compound |
| HY-10431G | SB-431542 (GMP) | 301836-41-9 | GMP Small Molecules |
| HY-10431R | SB-431542 (Standard) | 301836-41-9 | Reference Standards |
| HY-10432 | A 83-01 | 909910-43-6 | Reference compound |
| HY-10432A | A 83-01 (sodium) | 2828431-89-4 | Reference compound |
| HY-10432G | A 83-01 (GMP) | 909910-43-6 | GMP Small Molecules |
| HY-10432R | A 83-01 (Standard) | 909910-43-6 | Reference Standards |
| HY-10435 | SKF-82958 | 80751-65-1 | Reference compound |
| HY-10435A | SKF-82958 (hydrobromide) | 74115-01-8 | Reference compound |
| HY-10435AR | SKF-82958 (hydrobromide) (Standard) | 74115-01-8 | Reference Standards |
| HY-10437 | Setileuton | 910656-27-8 | Reference compound |
| HY-10437A | Setileuton (tosylate) | 1137737-87-1 | Reference compound |
| HY-10439 | HPGDS inhibitor 1 | 1033836-12-2 | Reference compound |
| HY-10440 | Vismodegib | 879085-55-9 | Reference compound |
| HY-10440R | Vismodegib (Standard) | 879085-55-9 | Reference Standards |
| HY-10442 | 3-Deazaneplanocin A | 102052-95-9 | Reference compound |
| HY-10443 | Balapiravir | 690270-29-2 | Reference compound |
| HY-10443A | Balapiravir (hydrochloride) | 690270-65-6 | Reference compound |
| HY-10443R | Balapiravir (Standard) | 690270-29-2 | Reference Standards |
| HY-10444 | R-1479 | 478182-28-4 | Reference compound |
| HY-10445 | Pramiconazole | 219923-85-0 | Reference compound |
| HY-10446 | Pralatrexate | 146464-95-1 | Reference compound |
| HY-10446R | Pralatrexate (Standard) | 146464-95-1 | Reference Standards |
| HY-10447 | Terameprocol | 24150-24-1 | Reference compound |
| HY-10448 | Capsaicin | 404-86-4 | Natural Products |
| HY-10448A | Capsaicin (Purity 65%) | 404-86-4 | Natural Products |
| HY-10448AR | Capsaicin (Purity 65%) (Standard) | 404-86-4 | Reference Standards |
| HY-10448R | Capsaicin (Standard) | 404-86-4 | Reference Standards |
| HY-10448S | (E/Z)-Capsaicin-d3 | 1185237-43-7 | Isotope-Labeled Compounds |
| HY-10448S1 | Capsaicin-d3 | 1217899-52-9 | Isotope-Labeled Compounds |
| HY-10448S4 | Capsaicin-d7 | | Isotope-Labeled Compounds |
| HY-10449 | Luseogliflozin | 898537-18-3 | Reference compound |
| HY-10449A | Luseogliflozin (hydrate) | 1152425-66-5 | Reference compound |
| HY-10450 | Dapagliflozin | 461432-26-8 | Reference compound |
| HY-10450A | Dapagliflozin ((2S)-1,2-propanediol, hydrate) | 960404-48-2 | Reference compound |
| HY-10450AR | Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) | 960404-48-2 | Reference Standards |
| HY-10450R | Dapagliflozin (Standard) | 461432-26-8 | Reference Standards |
| HY-10450S | Dapagliflozin-d5 | 1204219-80-6 | Isotope-Labeled Compounds |
| HY-10450S2 | Dapagliflozin-d4 | 1224234-25-6 | Isotope-Labeled Compounds |
| HY-10450S3 | Dapagliflozin-13C6 | | Isotope-Labeled Compounds |
| HY-10450S5 | Dapagliflozin-13C6-1 | | Isotope-Labeled Compounds |
| HY-10451 | Canagliflozin | 842133-18-0 | Reference compound |
| HY-10451R | Canagliflozin (Standard) | 842133-18-0 | Reference Standards |
| HY-10451S | Canagliflozin-d4 | 1997338-61-0 | Isotope-Labeled Compounds |
| HY-10451S2 | Canagliflozin-d6 | | Isotope-Labeled Compounds |
| HY-10452 | Ixazomib citrate | 1239908-20-3 | Reference compound |
| HY-10453 | Ixazomib | 1072833-77-2 | Reference compound |
| HY-10453R | Ixazomib (Standard) | 1072833-77-2 | Reference Standards |
| HY-10454 | Delanzomib | 847499-27-8 | Reference compound |
| HY-10455 | Carfilzomib | 868540-17-4 | Reference compound |
| HY-10455R | Carfilzomib (Standard) | 868540-17-4 | Reference Standards |
| HY-10455S | Carfilzomib-d8 | 1537187-53-3 | Isotope-Labeled Compounds |
| HY-10456 | TAK-715 | 303162-79-0 | Reference compound |
| HY-10457 | Velusetrag | 866933-46-2 | Reference compound |
| HY-10457A | Velusetrag (hydrochloride) | 866933-51-9 | Reference compound |
| HY-10458 | PF-562271 (besylate) | 939791-38-5 | Reference compound |
| HY-10459 | PF-562271 | 717907-75-0 | Reference compound |
| HY-10460 | PF-431396 | 717906-29-1 | Reference compound |
| HY-10461 | PF-573228 | 869288-64-2 | Reference compound |
| HY-10461R | PF-573228 (Standard) | 869288-64-2 | Reference Standards |
| HY-10465 | Daclatasvir (dihydrochloride) | 1009119-65-6 | Reference compound |
| HY-10465R | Daclatasvir (dihydrochloride) (Standard) | 1009119-65-6 | Reference Standards |
| HY-10466 | Daclatasvir | 1009119-64-5 | Reference compound |
| HY-10466BS | Daclatasvir-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10466R | Daclatasvir (Standard) | 1009119-64-5 | Reference Standards |
| HY-10466S | Daclatasvir-d6 | 1801709-41-0 | Isotope-Labeled Compounds |
| HY-10466S1 | Daclatasvir-13C2,d6 | | Isotope-Labeled Compounds |
| HY-10466S2 | Daclatasvir-d16 | | Isotope-Labeled Compounds |
| HY-10467 | HCV-796 analog | 691852-36-5 | Reference compound |
| HY-10468 | NM107 | 20724-73-6 | Reference compound |
| HY-10468R | NM107 (Standard) | 20724-73-6 | Reference Standards |
| HY-10469 | GSK256066 | 801312-28-7 | Reference compound |
| HY-10469R | GSK256066 (Standard) | 801312-28-7 | Reference Standards |
| HY-10472 | LY2811376 | 1194044-20-6 | Reference compound |
| HY-10473 | Eprotirome | 355129-15-6 | Reference compound |
| HY-10474 | Torkinib | 1092351-67-1 | Reference compound |
| HY-10474R | Torkinib (Standard) | 1092351-67-1 | Reference Standards |
| HY-10475 | AM580 | 102121-60-8 | Reference compound |
| HY-10475G | AM580 (GMP) | 102121-60-8 | GMP Small Molecules |
| HY-10475R | AM580 (Standard) | 102121-60-8 | Reference Standards |
| HY-10480 | Fasiglifam | 1000413-72-8 | Reference compound |
| HY-10480A | (R)-Fasiglifam | 1234474-57-7 | Reference compound |
| HY-10482 | SCH-1473759 | 1094069-99-4 | Reference compound |
| HY-10483 | SCH-1473759 (hydrochloride) | 1094067-13-6 | Reference compound |
| HY-10484 | Pevonedistat hydrochloride | 1160295-21-5 | Reference compound |
| HY-10486 | JDTic | 361444-66-8 | Reference compound |
| HY-10487 | JDTic (dihydrochloride) | 785835-79-2 | Reference compound |
| HY-10492 | Dinaciclib | 779353-01-4 | Reference compound |
| HY-10493 | Cobicistat | 1004316-88-4 | Reference compound |
| HY-10493R | Cobicistat (Standard) | 1004316-88-4 | Reference Standards |
| HY-10493S | Cobicistat-d8 | 2699607-48-0 | Isotope-Labeled Compounds |
| HY-10496 | SC75741 | 913822-46-5 | Reference compound |
| HY-10497 | BMS-794833 | 1174046-72-0 | Reference compound |
| HY-10498 | Lexibulin | 917111-44-5 | Reference compound |
| HY-10498A | Lexibulin (dihydrochloride) | 917111-49-0 | Reference compound |
| HY-10498R | Lexibulin (Standard) | 917111-44-5 | Reference Standards |
| HY-10499 | PH-064 | 892546-37-1 | Reference compound |
| HY-10499A | PH-064 (tetra(hydrochloride)) | 2489449-03-6 | Reference compound |
| HY-105000S1 | trans-Dihydro Tetrabenazine-d7 | 1217744-19-8 | Isotope-Labeled Compounds |
| HY-105003 | ST 1535 | 496955-42-1 | Reference compound |
| HY-105005 | Crisdesalazine | 927685-43-6 | Reference compound |
| HY-105006 | Spongosine | 24723-77-1 | Reference compound |
| HY-105008 | Secoisolariciresinol diglucoside | 257930-74-8 | Natural Products |
| HY-105008R | Secoisolariciresinol diglucoside (Standard) | 257930-74-8 | Reference Standards |
| HY-10501 | SU14813 | 627908-92-3 | Reference compound |
| HY-105010 | FK-739 (free base) | 133052-30-9 | Reference compound |
| HY-105014 | Tecastemizole | 75970-99-9 | Reference compound |
| HY-105014R | Tecastemizole (Standard) | 75970-99-9 | Reference Standards |
| HY-105017 | Evodenoson | 844873-47-8 | Reference compound |
| HY-105018 | Epelsiban | 872599-83-2 | Reference compound |
| HY-105018A | Epelsiban besylate | 1159097-48-9 | Reference compound |
| HY-105019 | Melflufen | 380449-51-4 | Reference compound |
| HY-105019A | Melflufen (hydrochloride) | 380449-54-7 | Reference compound |
| HY-10501A | SU14813 (maleate) | 849643-15-8 | Reference compound |
| HY-10502 | Tipifarnib | 192185-72-1 | Reference compound |
| HY-105022 | Sabeluzole | 104383-17-7 | Reference compound |
| HY-105022R | Sabeluzole (Standard) | 104383-17-7 | Reference Standards |
| HY-105023 | Cyclosporin G | 74436-00-3 | Reference compound |
| HY-105024 | FPL 62064 | 103141-09-9 | Reference compound |
| HY-105025 | Thymocartin | 85466-18-8 | Peptides |
| HY-105025A | Thymocartin (TFA) | | Reference compound |
| HY-105025B | Thymocartin (acetate) | 85503-03-3 | Reference compound |
| HY-105027 | Sufotidine | 80343-63-1 | Reference compound |
| HY-105028 | Tenidap | 120210-48-2 | Reference compound |
| HY-105028A | Tenidap (sodium) | 119784-94-0 | Reference compound |
| HY-105028R | Tenidap (Standard) | 120210-48-2 | Reference Standards |
| HY-105028S | Tenidap-d3 | 142741-60-4 | Isotope-Labeled Compounds |
| HY-10502A | Tipifarnib (S enantiomer) | 192185-71-0 | Reference compound |
| HY-105033 | Irloxacin | 91524-15-1 | Reference compound |
| HY-105034 | Tiospirone | 87691-91-6 | Reference compound |
| HY-105034A | Tiospirone (hydrochloride) | 87691-92-7 | Reference compound |
| HY-105035 | Rodorubicin | 96497-67-5 | Reference compound |
| HY-105037 | Forigerimod | 497156-60-2 | Peptides |
| HY-105037A | Forigerimod (TFA) | | Peptides |
| HY-105039 | Disomotide | 181477-43-0 | Peptides |
| HY-105040 | Pomaglumetad methionil | 956385-05-0 | Reference compound |
| HY-105040C | Pomaglumetad methionil (hydrochloride) | 635318-26-2 | Reference compound |
| HY-105041 | Tedizolid phosphate (sodium) | 856867-39-5 | Reference compound |
| HY-105042 | Selank | 129954-34-3 | Peptides |
| HY-105042A | Selank (diacetate) | | Peptides |
| HY-105047 | Fluorescein lisicol | 140616-46-2 | Reference compound |
| HY-105048 | Omiganan | 204248-78-2 | Peptides |
| HY-105048A | Omiganan (pentahydrochloride) | 269062-93-3 | Peptides |
| HY-105049 | T-91825 | 189345-04-8 | Reference compound |
| HY-10505 | Orteronel | 566939-85-3 | Reference compound |
| HY-105052 | SC 34301 | 81026-63-3 | Reference compound |
| HY-105055 | Didemnin B | 77327-05-0 | Natural Products |
| HY-105056 | Bretazenil | 84379-13-5 | Reference compound |
| HY-105058A | 14α/β-Vindeburnol | | Reference compound |
| HY-105059 | Denzimol | 73931-96-1 | Reference compound |
| HY-105059A | Denzimol (hydrochloride) | 77234-90-3 | Reference compound |
| HY-105061 | Misonidazole | 13551-87-6 | Reference compound |
| HY-105063 | DiaPep277 | 179822-83-4 | Peptides |
| HY-105064 | Zoniporide | 241800-98-6 | Reference compound |
| HY-105064B | Zoniporide (hydrochloride) | 241800-97-5 | Reference compound |
| HY-105064C | Zoniporide (dihydrochloride) | 241799-10-0 | Reference compound |
| HY-105064D | Zoniporide (hydrochloride hydrate) | 863406-85-3 | Reference compound |
| HY-105064DR | Zoniporide (hydrochloride hydrate) (Standard) | 863406-85-3 | Reference Standards |
| HY-105064R | Zoniporide (Standard) | 241800-98-6 | Reference Standards |
| HY-105066 | Davunetide | 211439-12-2 | Peptides |
| HY-105067A | Tertomotide (hydrochloride) | 922174-60-5 | Peptides |
| HY-105068 | Apadenoson | 250386-15-3 | Reference compound |
| HY-105069A | Rusalatide (acetate) | 875455-82-6 | Peptides |
| HY-105070A | Eritoran (tetrasodium) | 185954-98-7 | Reference compound |
| HY-105074 | Farglitazar | 196808-45-4 | Reference compound |
| HY-105077A | Nemifitide (diTFA) | 204992-09-6 | Peptides |
| HY-10508 | (R)-PD 0325901CL | 1003216-77-0 | Reference compound |
| HY-105082 | Avitriptan | 151140-96-4 | Reference compound |
| HY-105083A | Pumosetrag | 153062-94-3 | Reference compound |
| HY-105084 | Lubeluzole | 144665-07-6 | Reference compound |
| HY-105084A | Lubeluzole (dihydrochloride) | 144665-09-8 | Reference compound |
| HY-105086 | Pamaqueside | 150332-35-7 | Reference compound |
| HY-105088 | Pexiganan | 147664-63-9 | Peptides |
| HY-105088A | Pexiganan (acetate) | 172820-23-4 | Peptides |
| HY-105090 | Lerisetron | 143257-98-1 | Reference compound |
| HY-105090R | Lerisetron (Standard) | 143257-98-1 | Reference Standards |
| HY-105092 | Tetomilast | 145739-56-6 | Reference compound |
| HY-105093 | N 0861 | 141696-90-4 | Reference compound |
| HY-105094 | Leminoprazole | 104340-86-5 | Reference compound |
| HY-105096 | Arofylline | 136145-07-8 | Reference compound |
| HY-105098 | Lobucavir | 127759-89-1 | Reference compound |
| HY-105098B | (±)-Lobucavir | 126062-18-8 | Reference compound |
| HY-105099 | Rifalazil | 129791-92-0 | Reference compound |
| HY-105099R | Rifalazil (Standard) | 129791-92-0 | Reference Standards |
| HY-10510 | BI-D1870 | 501437-28-1 | Reference compound |
| HY-105102 | Netivudine | 84558-93-0 | Reference compound |
| HY-105108 | Cilansetron (hydrochloride hydrate) | 209859-87-0 | Reference compound |
| HY-105109 | Cilansetron | 120635-74-7 | Reference compound |
| HY-105109B | (S)-Cilansetron | 120635-77-0 | Reference compound |
| HY-105110 | SCH 39304 | 120924-80-3 | Reference compound |
| HY-105112 | Carmoxirole | 98323-83-2 | Reference compound |
| HY-105113 | Cefluprenam | 116853-25-9 | Reference compound |
| HY-105114 | Imitrodast | 114686-12-3 | Reference compound |
| HY-105115 | Abecarnil | 111841-85-1 | Reference compound |
| HY-105117 | Fantofarone | 114432-13-2 | Reference compound |
| HY-105117R | Fantofarone (Standard) | 114432-13-2 | Reference Standards |
| HY-105118 | Zaldaride | 109826-26-8 | Reference compound |
| HY-105118A | Zaldaride maleate | 109826-27-9 | Reference compound |
| HY-10512 | AR-A014418 | 487021-52-3 | Reference compound |
| HY-105120 | Vapiprost | 85505-64-2 | Reference compound |
| HY-105120A | Vapiprost (hydrochloride) | 87248-13-3 | Reference compound |
| HY-105122 | Zanoterone | 107000-34-0 | Reference compound |
| HY-105124 | Bufuralol | 54340-62-4 | Reference compound |
| HY-105124A | Bufuralol (hydrochloride) | 60398-91-6 | Reference compound |
| HY-105124AR | Bufuralol (hydrochloride) (Standard) | 60398-91-6 | Reference Standards |
| HY-105124S | Bufuralol-d9 (hydrochloride) | 1173023-51-2 | Isotope-Labeled Compounds |
| HY-105126 | Rioprostil | 77287-05-9 | Reference compound |
| HY-105127 | Brofaromine (hydrochloride) | 63638-90-4 | Reference compound |
| HY-105128 | Epostane | 80471-63-2 | Reference compound |
| HY-105129 | Pimonidazole (hydrochloride) | 70132-51-3 | Reference compound |
| HY-105129A | Pimonidazole | 70132-50-2 | Reference compound |
| HY-105129AR | Pimonidazole (Standard) | 70132-50-2 | Reference Standards |
| HY-105129AS | Pimonidazole-d10 | 2468639-37-2 | Isotope-Labeled Compounds |
| HY-105129R | Pimonidazole (hydrochloride) (Standard) | 70132-51-3 | Reference Standards |
| HY-10512R | AR-A014418 (Standard) | 487021-52-3 | Reference Standards |
| HY-10512S | AR-A014418-d3 | 1216908-63-2 | Isotope-Labeled Compounds |
| HY-105132 | Binodaline | 60662-16-0 | Reference compound |
| HY-105135 | 15-Deoxy-16-hydroxy-16-vinyl-PGE2 Me ester | 73621-92-8 | Reference compound |
| HY-105137 | Lanepitant (dihydrochloride) | 170508-05-1 | Reference compound |
| HY-105138 | Adentri | 166374-48-7 | Reference compound |
| HY-10514 | BX795 | 702675-74-9 | Reference compound |
| HY-105142 | M-5011 | 76604-64-3 | Reference compound |
| HY-10515 | BX-320 | 702676-93-5 | Reference compound |
| HY-105154A | Proxodolol | 152289-59-3 | Reference compound |
| HY-105155 | Lobradimil | 159768-75-9 | Peptides |
| HY-105157 | Icopezil | 145508-78-7 | Reference compound |
| HY-105161 | AP-521 (free base) | 151227-58-6 | Reference compound |
| HY-105163 | Finrozole | 160146-17-8 | Reference compound |
| HY-105164 | Topixantrone | 156090-18-5 | Reference compound |
| HY-105164A | Topixantrone (dihydrochloride) | 2514569-86-7 | Reference compound |
| HY-105165 | Nortopixantrone | 156090-17-4 | Reference compound |
| HY-105165A | Nortopixantrone (dihydrochloride) | 438244-41-8 | Reference compound |
| HY-105168 | TAK 044 | 157380-72-8 | Peptides |
| HY-10517 | Orantinib | 252916-29-3 | Reference compound |
| HY-105170B | ABT-418 (hydrochloride) | 147388-83-8 | Reference compound |
| HY-105172 | TT-232 | 147159-51-1 | Peptides |
| HY-105172A | TT-232 (TFA) | 2703745-48-4 | Reference compound |
| HY-105173 | Teverelix | 151272-78-5 | Peptides |
| HY-105174 | BPC 157 | 137525-51-0 | Peptides |
| HY-105174A | BPC 157 (acetate) | 1628202-19-6 | Peptides |
| HY-105176 | Ontazolast | 147432-77-7 | Reference compound |
| HY-105176A | (R)-Ontazolast | 149106-77-4 | Reference compound |
| HY-105177 | ORG 33628 | 155768-17-5 | Reference compound |
| HY-10517A | (Z)-Orantinib | 210644-62-5 | Reference compound |
| HY-10518 | BMS-345541 (hydrochloride) | 547757-23-3 | Reference compound |
| HY-105180 | Lenapenem | 149951-16-6 | Reference compound |
| HY-105182 | Xanomeline | 131986-45-3 | Reference compound |
| HY-105182A | Xanomeline (tartrate) | 152854-19-8 | Reference compound |
| HY-105182AR | Xanomeline (tartrate) (Standard) | 152854-19-8 | Reference Standards |
| HY-105182R | Xanomeline (Standard) | 131986-45-3 | Reference Standards |
| HY-105182S1 | Xanomeline-d3 | 175615-28-8 | Isotope-Labeled Compounds |
| HY-105183 | PD 145065 | 153049-49-1 | Peptides |
| HY-105184 | YM511 | 148869-05-0 | Reference compound |
| HY-105185 | Fidarestat | 136087-85-9 | Reference compound |
| HY-105185B | (Rac)-Fidarestat | 105300-43-4 | Reference compound |
| HY-10519 | BMS-345541 | 445430-58-0 | Reference compound |
| HY-105191 | Azalanstat | 143393-27-5 | Reference compound |
| HY-105192 | CP-122288 | 143321-74-8 | Reference compound |
| HY-105196 | DAT-582 | 141034-42-6 | Reference compound |
| HY-105198 | Lexipafant | 139133-26-9 | Reference compound |
| HY-10520 | CGP 57380 | 522629-08-9 | Reference compound |
| HY-105201 | Fabesetron | 129300-27-2 | Reference compound |
| HY-105201A | Fabesetron (hydrochloride) | 129299-90-7 | Reference compound |
| HY-105205 | Terlakiren | 119625-78-4 | Reference compound |
| HY-105207 | L 696229 | 135525-71-2 | Reference compound |
| HY-10521 | Darapladib | 356057-34-6 | Reference compound |
| HY-105215 | FK888 | 138449-07-7 | Reference compound |
| HY-105216 | L 697661 | 135525-78-9 | Reference compound |
| HY-105217 | Turosteride | 137099-09-3 | Reference compound |
| HY-105218 | Ifetroban | 143443-90-7 | Reference compound |
| HY-105218A | Ifetroban (sodium) | 156715-37-6 | Reference compound |
| HY-10521R | Darapladib (Standard) | 356057-34-6 | Reference Standards |
| HY-10522 | LEDGIN6 | 957890-42-5 | Reference compound |
| HY-105220 | WY-47766 | 134217-27-9 | Reference compound |
| HY-105221 | Masilukast | 136564-68-6 | Reference compound |
| HY-105226 | CI-988 | 130332-27-3 | Reference compound |
| HY-105226B | CI-988 (hemihydrate) | | Reference compound |
| HY-105231 | Bryostatin 1 | 83314-01-6 | Natural Products |
| HY-105235 | Enadoline | 124378-77-4 | Reference compound |
| HY-105235A | Enadoline (hydrochloride) | 124439-07-2 | Reference compound |
| HY-105236 | (Rac)-Enadoline | 107431-28-7 | Reference compound |
| HY-105237 | Eesperamicin A1 | 99674-26-7 | Reference compound |
| HY-105238 | JHU-75528 | 947696-17-5 | Reference compound |
| HY-105239 | Selepressin | 876296-47-8 | Peptides |
| HY-105239A | Selepressin (acetate) | | Peptides |
| HY-10524 | GSK1904529A | 1089283-49-7 | Reference compound |
| HY-105240 | Delparantag | 872454-31-4 | Peptides |
| HY-105246 | Pracinostat (dihydrochloride) | 929016-98-8 | Reference compound |
| HY-105249 | RDEA 806 | 878670-61-2 | Reference compound |
| HY-105252A | BF 227 | 845647-80-5 | Reference compound |
| HY-105253 | PARP-2/1-IN-2 | 912444-01-0 | Reference compound |
| HY-105257 | Pranazepide | 150408-73-4 | Reference compound |
| HY-105259 | SR 43845 | 114037-60-4 | Reference compound |
| HY-105262 | Galocitabine | 124012-42-6 | Reference compound |
| HY-105263 | EM574 | 110480-13-2 | Reference compound |
| HY-105264 | FK224 | 125787-94-2 | Reference compound |
| HY-105266 | Zabicipril | 83059-56-7 | Reference compound |
| HY-105267 | LY 121019 | 79404-91-4 | Reference compound |
| HY-105268 | AzddMeC | 87190-79-2 | Reference compound |
| HY-10527 | Telatinib | 332012-40-5 | Reference compound |
| HY-105270 | Tallimustine | 115308-98-0 | Reference compound |
| HY-105270A | Tallimustine (hydrochloride) | 118438-45-2 | Reference compound |
| HY-105271 | S-312-d | 120056-57-7 | Reference compound |
| HY-105272 | Loreclezole | 117857-45-1 | Reference compound |
| HY-105272A | Loreclezole (hydrochloride) | 2227372-56-5 | Reference compound |
| HY-105272R | Loreclezole (Standard) | 117857-45-1 | Reference Standards |
| HY-105273 | Erbulozole | 124784-31-2 | Reference compound |
| HY-105275A | FK 453 | 121524-18-3 | Reference compound |
| HY-105279 | α-Trinositol | 28841-62-5 | Reference compound |
| HY-10527C | Telatinib (mesylate) | 332013-26-0 | Reference compound |
| HY-10527CR | Telatinib (mesylate) (Standard) | 332013-26-0 | Reference Standards |
| HY-10527R | Telatinib (Standard) | 332012-40-5 | Reference Standards |
| HY-10528 | Tasquinimod | 254964-60-8 | Reference compound |
| HY-105282 | Eremomycin | 110865-90-2 | Natural Products |
| HY-105283 | PF 04531083 | 1079400-07-9 | Reference compound |
| HY-105284 | Sulopenem | 120788-07-0 | Reference compound |
| HY-105284A | Sulopenem (sodium) | 112294-81-2 | Reference compound |
| HY-105284R | Sulopenem (Standard) | 120788-07-0 | Reference Standards |
| HY-105285 | Piromelatine | 946846-83-9 | Reference compound |
| HY-105285R | Piromelatine (Standard) | 946846-83-9 | Reference Standards |
| HY-105286 | BI-135585 | 1114561-85-1 | Reference compound |
| HY-10528R | Tasquinimod (Standard) | 254964-60-8 | Reference Standards |
| HY-10528S | Tasquinimod-d3 | 1416701-99-9 | Isotope-Labeled Compounds |
| HY-10529 | Betulinic acid | 472-15-1 | Natural Products |
| HY-105294 | FR 64822 | 102671-35-2 | Reference compound |
| HY-105296 | Blarcamesine | 195615-83-9 | Reference compound |
| HY-10529R | Betulinic acid (Standard) | 472-15-1 | Reference Standards |
| HY-10530 | Varlitinib | 845272-21-1 | Reference compound |
| HY-105303 | CEP-9722 | 916574-83-9 | Reference compound |
| HY-105304 | COX-2-IN-36 | 189954-93-6 | Reference compound |
| HY-105309 | GSK-626616 | 1025821-33-3 | Reference compound |
| HY-10530A | Varlitinib (tosylate) | 1146629-86-8 | Reference compound |
| HY-10531 | ARRY-380 (analog) | 937265-83-3 | Reference compound |
| HY-105315 | AFP-07 | 171232-82-9 | Reference compound |
| HY-105318 | LGD-2226 | 328947-93-9 | Biochemical Assay Reagents |
| HY-10532 | SRT 1720 | 925434-55-5 | Reference compound |
| HY-105321 | PBT 1033 | 747408-78-2 | Reference compound |
| HY-105321A | PBT 1033 (hydrochloride) | 648896-70-2 | Reference compound |
| HY-105321R | PBT 1033 (Standard) | 747408-78-2 | Reference Standards |
| HY-105323 | YM758 (phosphate) | 312752-86-6 | Reference compound |
| HY-105327 | P11149 | 164724-79-2 | Reference compound |
| HY-10532A | SRT 1720 (hydrochloride) | 1001645-58-4 | Biochemical Assay Reagents |
| HY-10532R | SRT 1720 (Standard) | 925434-55-5 | Reference Standards |
| HY-10533 | Eniluracil | 59989-18-3 | Reference compound |
| HY-105332 | CRA1000 | 226948-11-4 | Reference compound |
| HY-105336 | 3-Deazauridine | 23205-42-7 | Reference compound |
| HY-10533R | Eniluracil (Standard) | 59989-18-3 | Reference Standards |
| HY-10534 | Voreloxin | 175414-77-4 | Reference compound |
| HY-105343 | BW-180C | 63631-40-3 | Peptides |
| HY-105346 | WIN 51708 | 144177-30-0 | Reference compound |
| HY-105349 | T-0156 | 324572-93-2 | Reference compound |
| HY-10535 | Evofosfamide | 918633-87-1 | Reference compound |
| HY-105350 | Pristinamycin IB | 57206-54-9 | Reference compound |
| HY-105351 | CGS25155 | 150126-87-7 | Reference compound |
| HY-10537 | Laromustine | 173424-77-6 | Reference compound |
| HY-105375 | FR 901537 | 161162-21-6 | Reference compound |
| HY-105387 | Heliquinomycin | 178182-49-5 | Natural Products |
| HY-10539 | Enzastaurin di(hydrochloride) | 365253-37-8 | Reference compound |
| HY-105392 | LB30057 | 184770-78-3 | Reference compound |
| HY-105393 | LB 10517 (sodium) | 175553-22-7 | Reference compound |
| HY-105395 | BCX-1898 | 345267-14-3 | Reference compound |
| HY-105396 | L 670630 | 133174-26-2 | Reference compound |
| HY-10539B | Enzastaurin (hydrochloride) | 359017-79-1 | Reference compound |
| HY-105412A | RU 52583 | 123829-33-4 | Reference compound |
| HY-105414 | Esterbut-3 | 125161-47-9 | Reference compound |
| HY-105416 | Calphostin C | 121263-19-2 | Reference compound |
| HY-10542 | GW 5074 | 220904-83-6 | Reference compound |
| HY-10542A | (Z)-GW 5074 | 1233748-60-1 | Reference compound |
| HY-105435 | FR121196 | 133920-65-7 | Reference compound |
| HY-105436 | FR 113680 | 126088-92-4 | Reference compound |
| HY-10544 | Tegobuvir | 1000787-75-6 | Reference compound |
| HY-105440 | LY 301875 | 154668-27-6 | Reference compound |
| HY-105445 | CP-113818 | 135025-12-6 | Reference compound |
| HY-10545 | Taribavirin | 119567-79-2 | Reference compound |
| HY-105454 | Recainam | 74738-24-2 | Reference compound |
| HY-105454A | Recainam (hydrochloride) | 74752-07-1 | Reference compound |
| HY-105454R | Recainam (Standard) | 74738-24-2 | Reference Standards |
| HY-10545A | Taribavirin (hydrochloride) | 40372-00-7 | Reference compound |
| HY-105460 | TEI-6472 | 151379-49-6 | Reference compound |
| HY-105463 | Saptomycin D | 137714-91-1 | Natural Products |
| HY-10547 | OSU-03012 | 742112-33-0 | Reference compound |
| HY-105477 | Maniwamycin A | 122566-70-5 | Reference compound |
| HY-105484 | U-75302 | 119477-85-9 | Reference compound |
| HY-105485 | FR-62765 | 105346-34-7 | Reference compound |
| HY-10549 | PI3Kγ inhibitor 1 | 1172118-03-4 | Reference compound |
| HY-105495 | Iliparcil | 137214-72-3 | Reference compound |
| HY-10550 | Tariquidar | 206873-63-4 | Reference compound |
| HY-105507 | PF-10040 | 132928-46-2 | Reference compound |
| HY-10550A | Tariquidar (methanesulfonate, hydrate) | 625375-83-9 | Reference compound |
| HY-10550AR | Tariquidar (methanesulfonate, hydrate) (Standard) | 625375-83-9 | Reference Standards |
| HY-10550B | Tariquidar (dimesylate) | 625375-84-0 | Reference compound |
| HY-10550R | Tariquidar (Standard) | 206873-63-4 | Reference Standards |
| HY-105516 | E5090 | 131420-91-2 | Reference compound |
| HY-105521A | Dexnafenodone (hydrochloride) | 94096-42-1 | Reference compound |
| HY-105525A | Sameridine (hydrochloride) | 136483-84-6 | Reference compound |
| HY-105529 | Indicine N-oxide | 41708-76-3 | Natural Products |
| HY-105530 | Zeniplatin | 111490-36-9 | Reference compound |
| HY-105534 | TAK-637 | 217185-75-6 | Reference compound |
| HY-105537 | Ro 70‐0004 | 186386-21-0 | Reference compound |
| HY-105541 | Octotiamine | 137-86-0 | Reference compound |
| HY-105542 | Niaprazine | 27367-90-4 | Reference compound |
| HY-105542R | Niaprazine (Standard) | 27367-90-4 | Reference Standards |
| HY-105544 | Tribehenin | 18641-57-1 | Biochemical Assay Reagents |
| HY-105545 | Dexetimide | 21888-98-2 | Reference compound |
| HY-105545A | Levetimide | 21888-99-3 | Reference compound |
| HY-105545C | Dexetimide (hydrochloride) | 21888-96-0 | Reference compound |
| HY-105549 | Quinacillin | 1596-63-0 | Reference compound |
| HY-10555 | AMG-221 | 1095565-81-3 | Reference compound |
| HY-105556 | Amphetaminil | 17590-01-1 | Reference compound |
| HY-105559 | Viquidil | 84-55-9 | Reference compound |
| HY-105559A | Viquidil (hydrochloride) | 52211-63-9 | Reference compound |
| HY-105562 | Nadoxolol | 54063-51-3 | Reference compound |
| HY-105567A | Carbiphene (hydrochloride) | 467-22-1 | Reference compound |
| HY-105569 | Amphotalide | 1673-06-9 | Reference compound |
| HY-105572 | Moveltipril (calcium) | 85921-53-5 | Reference compound |
| HY-105577 | Picilorex | 62510-56-9 | Reference compound |
| HY-105578A | Letimide (hydrochloride) | 21791-39-9 | Reference compound |
| HY-105579 | Isonixin | 57021-61-1 | Reference compound |
| HY-10558 | CYC-116 | 693228-63-6 | Reference compound |
| HY-105583 | Cloforex | 14261-75-7 | Reference compound |
| HY-105584 | Tolycaine | 3686-58-6 | Reference compound |
| HY-105589 | Liroldine | 105102-20-3 | Reference compound |
| HY-10559 | Nelotanserin | 839713-36-9 | Reference compound |
| HY-10560 | Temanogrel | 887936-68-7 | Reference compound |
| HY-105604 | Anilopam | 53716-46-4 | Reference compound |
| HY-105608 | Narceine | 131-28-2 | Natural Products |
| HY-10560A | Temanogrel (hydrochloride) | 957466-27-2 | Reference compound |
| HY-10560R | Temanogrel (Standard) | 887936-68-7 | Reference Standards |
| HY-10561 | RU 58841 | 154992-24-2 | Reference compound |
| HY-105613 | Metabutoxycaine | 3624-87-1 | Reference compound |
| HY-105616 | Roflurane | 679-90-3 | Reference compound |
| HY-10562 | Ketanserin | 74050-98-9 | Reference compound |
| HY-105627A | Profadol (hydrochloride) | 2324-94-9 | Reference compound |
| HY-105628A | Prodilidine (hydrochloride) | 3734-16-5 | Reference compound |
| HY-10562A | Ketanserin (tartrate) | 83846-83-7 | Reference compound |
| HY-10562AR | Ketanserin (tartrate) (Standard) | 83846-83-7 | Reference Standards |
| HY-10562R | Ketanserin (Standard) | 74050-98-9 | Reference Standards |
| HY-10563 | Sarpogrelate | 125926-17-2 | Reference compound |
| HY-105630 | Pipebuzone | 27315-91-9 | Reference compound |
| HY-105631 | Hydroxytetracaine | 490-98-2 | Reference compound |
| HY-105634 | Nomegestrol | 58691-88-6 | Reference compound |
| HY-105634A | Nomegestrol acetate | 58652-20-3 | Reference compound |
| HY-105634AR | Nomegestrol acetate (Standard) | 58652-20-3 | Reference Standards |
| HY-105637 | Cropropamide | 633-47-6 | Reference compound |
| HY-10564 | Sarpogrelate (hydrochloride) | 135159-51-2 | Reference compound |
| HY-105641 | Morazone | 6536-18-1 | Reference compound |
| HY-105647 | Ambuphylline | 5634-34-4 | Reference compound |
| HY-10564R | Sarpogrelate (hydrochloride) (Standard) | 135159-51-2 | Reference Standards |
| HY-10564S | Sarpogrelate-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10564S1 | Sarpogrelate-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-105651 | Butalamine | 22131-35-7 | Reference compound |
| HY-105651A | Butalamine (hydrochloride) | 56974-46-0 | Reference compound |
| HY-105651AR | Butalamine (hydrochloride) (Standard) | 56974-46-0 | Reference Standards |
| HY-105652 | Ambucetamide | 519-88-0 | Reference compound |
| HY-105656 | Hydrocortisone phosphate (sodium) | 6000-74-4 | Reference compound |
| HY-105661 | IMD-0560 | 439144-66-8 | Reference compound |
| HY-105666 | TGX-155 | 351071-90-4 | Reference compound |
| HY-105668 | Cathepsin S-IN-1 | 537706-31-3 | Reference compound |
| HY-105670 | PHA-543613 | 478149-53-0 | Reference compound |
| HY-105670A | PHA-543613 (hydrochloride) | 1586767-92-1 | Reference compound |
| HY-105670B | PHA-543613 (dihydrochloride) | 478148-58-2 | Reference compound |
| HY-105672 | Cafaminol | 30924-31-3 | Reference compound |
| HY-105674 | Azidamfenicol | 13838-08-9 | Reference compound |
| HY-10568 | TC-E 5005 | 959705-64-7 | Reference compound |
| HY-105685 | SRX246 | 512784-93-9 | Reference compound |
| HY-105686 | FR-229934 | 799841-02-4 | Reference compound |
| HY-105689 | AGN 192870 | 166977-57-7 | Reference compound |
| HY-10569 | Ponesimod | 854107-55-4 | Reference compound |
| HY-105692 | DR2313 | 284028-90-6 | Reference compound |
| HY-105697 | Protoveratrine A | 143-57-7 | Natural Products |
| HY-105698 | Clofexamide | 1223-36-5 | Reference compound |
| HY-105699 | Napamezole | 91524-14-0 | Reference compound |
| HY-10569R | Ponesimod (Standard) | 854107-55-4 | Reference Standards |
| HY-10569S | Ponesimod-d4 | | Isotope-Labeled Compounds |
| HY-10569S1 | Ponesimod-d7 | | Isotope-Labeled Compounds |
| HY-10570 | Nevirapine | 129618-40-2 | Reference compound |
| HY-10570R | Nevirapine (Standard) | 129618-40-2 | Reference Standards |
| HY-10570S | Nevirapine-d4 | 1051418-95-1 | Isotope-Labeled Compounds |
| HY-10570S1 | Nevirapine-d3 | 1051419-24-9 | Isotope-Labeled Compounds |
| HY-10570S2 | Nevirapine-d8 | 1051418-86-0 | Isotope-Labeled Compounds |
| HY-10570S3 | Nevirapine-d5 | 1189717-29-0 | Isotope-Labeled Compounds |
| HY-10571 | Delavirdine | 136817-59-9 | Reference compound |
| HY-105710 | Tropatepine | 27574-24-9 | Reference compound |
| HY-105713 | Sulochrin | 519-57-3 | Natural Products |
| HY-105717 | Meralein (sodium) | 4386-35-0 | Reference compound |
| HY-105718 | Olmidine | 31105-14-3 | Reference compound |
| HY-10571A | Delavirdine (mesylate) | 147221-93-0 | Reference compound |
| HY-10571AR | Delavirdine (mesylate) (Standard) | 147221-93-0 | Reference Standards |
| HY-10571R | Delavirdine (Standard) | 136817-59-9 | Reference Standards |
| HY-10572 | Efavirenz | 154598-52-4 | Reference compound |
| HY-105721 | Aranotin | 19885-51-9 | Reference compound |
| HY-105723 | Duazomycin | 2508-89-6 | Reference compound |
| HY-10572A | (R)-Efavirenz | 154801-74-8 | Reference compound |
| HY-10572B | (Rac)-Efavirenz | 177530-93-7 | Reference compound |
| HY-10572BR | (Rac)-Efavirenz (Standard) | 177530-93-7 | Reference Standards |
| HY-10572BS | (Rac)-Efavirenz-d4 | 1246812-58-7 | Isotope-Labeled Compounds |
| HY-10572BS1 | (Rac)-Efavirenz-d5 | 2749807-27-8 | Isotope-Labeled Compounds |
| HY-10572R | Efavirenz (Standard) | 154598-52-4 | Reference Standards |
| HY-10572S | Efavirenz-d5 | 1132642-95-5 | Isotope-Labeled Compounds |
| HY-10572S1 | Efavirenz-13C6 | 1261394-62-0 | Isotope-Labeled Compounds |
| HY-105733A | Suxemerid (disulfate) | 34144-82-6 | Reference compound |
| HY-105738 | Butaverine | 55837-14-4 | Reference compound |
| HY-10574 | Rilpivirine | 500287-72-9 | Reference compound |
| HY-105740 | Trenimon | 68-76-8 | Reference compound |
| HY-105744 | Leiopyrrole | 5633-16-9 | Reference compound |
| HY-105747A | Guanoxyfen (nitrate) | 860385-36-0 | Reference compound |
| HY-105749 | Pentamethonium (bromide) | 541-20-8 | Reference compound |
| HY-10574A | Rilpivirine (hydrochloride) | 700361-47-3 | Reference compound |
| HY-10574AR | Rilpivirine (hydrochloride) (Standard) | 700361-47-3 | Reference Standards |
| HY-10574AS | Rilpivirine-d6 (hydrochloride) | 2714324-67-9 | Isotope-Labeled Compounds |
| HY-10574R | Rilpivirine (Standard) | 500287-72-9 | Reference Standards |
| HY-10574S | Rilpivirine-d6 | 1312424-26-2 | Isotope-Labeled Compounds |
| HY-10574S1 | Rilpivirine-13C6 | | Isotope-Labeled Compounds |
| HY-105751 | Kalafungin | 11048-15-0 | Natural Products |
| HY-105752 | Loflucarban | 790-69-2 | Reference compound |
| HY-105762 | Etamiphyllin | 314-35-2 | Reference compound |
| HY-105762A | Etamiphyllin (camsylate) | 19326-29-5 | Reference compound |
| HY-105771 | Parapenzolate (bromide) | 5634-41-3 | Reference compound |
| HY-105772A | Lometraline (hydrochloride) | 30060-91-4 | Reference compound |
| HY-10578 | PD 169316 | 152121-53-4 | Reference compound |
| HY-105785 | Clomacran | 5310-55-4 | Reference compound |
| HY-10578R | PD 169316 (Standard) | 152121-53-4 | Reference Standards |
| HY-10579 | Pluripotin | 839707-37-8 | Reference compound |
| HY-105790 | Piperilate | 4546-39-8 | Reference compound |
| HY-105790A | Piperilate (hydrochloride) | 4544-15-4 | Reference compound |
| HY-105791 | Sulazepam | 2898-13-7 | Reference compound |
| HY-105791S | Sulazepam-d5 | | Isotope-Labeled Compounds |
| HY-105793 | Mazaticol | 42024-98-6 | Reference compound |
| HY-105797 | Apoatropine | 500-55-0 | Natural Products |
| HY-105797A | Apoatropine (hydrochloride) | 5978-81-4 | Natural Products |
| HY-105798 | Butanserin | 87051-46-5 | Reference compound |
| HY-10580 | GSK 3 Inhibitor IX | 667463-62-9 | Reference compound |
| HY-105808 | Furobufen | 38873-55-1 | Reference compound |
| HY-105808R | Furobufen (Standard) | 38873-55-1 | Reference Standards |
| HY-10581 | Gatifloxacin | 112811-59-3 | Reference compound |
| HY-105815 | Chlornaphazine | 494-03-1 | Reference compound |
| HY-105818 | Cloticasone propionate | 80486-69-7 | Reference compound |
| HY-10581A | Gatifloxacin (hydrochloride) | 121577-32-0 | Reference compound |
| HY-10581AR | Gatifloxacin (hydrochloride) (Standard) | 121577-32-0 | Reference Standards |
| HY-10581AS | Gatifloxacin-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-10581AS1 | Gatifloxacin-d4 (hydrochloride) | 1189946-71-1 | Isotope-Labeled Compounds |
| HY-10581B | Gatifloxacin (mesylate) | 316819-28-0 | Reference compound |
| HY-10581C | Gatifloxacin (sesquihydrate) | 180200-66-2 | Reference compound |
| HY-10581CR | Gatifloxacin (sesquihydrate) (Standard) | 180200-66-2 | Reference Standards |
| HY-10581R | Gatifloxacin (Standard) | 112811-59-3 | Reference Standards |
| HY-10582 | Flurbiprofen | 5104-49-4 | Reference compound |
| HY-105820 | Algestone | 595-77-7 | Reference compound |
| HY-105825 | Sermetacin | 57645-05-3 | Reference compound |
| HY-105829 | Sulfatroxazole | 23256-23-7 | Reference compound |
| HY-105829S | Sulfatroxazole-d4 | | Isotope-Labeled Compounds |
| HY-10582R | Flurbiprofen (Standard) | 5104-49-4 | Reference Standards |
| HY-10582S | Flurbiprofen-d3 | 1185133-81-6 | Isotope-Labeled Compounds |
| HY-10582S1 | Flurbiprofen-d5 | 215175-76-1 | Isotope-Labeled Compounds |
| HY-10582S2 | Flurbiprofen-13C,d3 | 2747917-55-9 | Isotope-Labeled Compounds |
| HY-10582S3 | Flurbiprofen-d4 | | Isotope-Labeled Compounds |
| HY-10583 | Y-27632 (dihydrochloride) | 129830-38-2 | Reference compound |
| HY-105832 | Fenbenicillin (potassium) | 1177-30-6 | Reference compound |
| HY-105838 | Sulfamethomidine | 3772-76-7 | Reference compound |
| HY-10583G | Y-27632 (dihydrochloride) (GMP) | 129830-38-2 | GMP Small Molecules |
| HY-10583R | Y-27632 (dihydrochloride) (Standard) | 129830-38-2 | Reference Standards |
| HY-105840 | Dichloramine-T | 473-34-7 | Reference compound |
| HY-105841A | Tetronasin (sodium) | 75139-05-8 | Reference compound |
| HY-105844 | Albutoin | 830-89-7 | Reference compound |
| HY-105845 | Phenaglycodol | 79-93-6 | Reference compound |
| HY-105846 | Nogalamycin | 1404-15-5 | Reference compound |
| HY-10585 | Valproic acid | 99-66-1 | Reference compound |
| HY-105852 | Proxazole | 5696-09-3 | Reference compound |
| HY-105853 | Pitofenone | 54063-52-4 | Reference compound |
| HY-105853S | Pitofenone-d4 | | Isotope-Labeled Compounds |
| HY-105855 | Tisocromide | 35423-51-9 | Reference compound |
| HY-105856 | Thozalinone | 655-05-0 | Reference compound |
| HY-105857A | Thiazesim (hydrochloride) | 3122-01-8 | Reference compound |
| HY-105858 | H-Ile-Trp-OH | 13589-06-5 | Reference compound |
| HY-10585A | Valproic acid (sodium) | 1069-66-5 | Reference compound |
| HY-10585AG | Valproic acid (sodium) (GMP) | 1069-66-5 | GMP Small Molecules |
| HY-10585AR | Valproic acid (sodium) (Standard) | 1069-66-5 | Reference Standards |
| HY-10585AS | Valproic acid-d7 (sodium) | 1189994-89-5 | Isotope-Labeled Compounds |
| HY-10585AS1 | Valproic acid-d14 (sodium) | | Isotope-Labeled Compounds |
| HY-10585B | Valproic acid (sodium)(2:1) | 76584-70-8 | Reference compound |
| HY-10585R | Valproic acid (Standard) | 99-66-1 | Reference Standards |
| HY-10585S | Valproic acid-d4 | 87745-17-3 | Isotope-Labeled Compounds |
| HY-10585S1 | Valproic acid-d6 | 87745-18-4 | Isotope-Labeled Compounds |
| HY-10585S2 | Valproic acid-d15 | 362049-65-8 | Isotope-Labeled Compounds |
| HY-10585S3 | Valproic acid-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-10585S4 | Valproic acid-d4-1 | 345909-03-7 | Isotope-Labeled Compounds |
| HY-10586 | 5-Azacytidine | 320-67-2 | Reference compound |
| HY-105860 | Selurampanel | 912574-69-7 | Reference compound |
| HY-10586R | 5-Azacytidine (Standard) | 320-67-2 | Reference Standards |
| HY-10587 | BIX-01294 | 935693-62-2 | Reference compound |
| HY-105872 | Trifenagrel | 84203-09-8 | Reference compound |
| HY-10587A | BIX-01294 (hydrochloride hydrate) | 1808255-64-2 | Reference compound |
| HY-10588 | Bay K 8644 | 71145-03-4 | Reference compound |
| HY-10588R | Bay K 8644 (Standard) | 71145-03-4 | Reference Standards |
| HY-105890 | Spiroplatin | 74790-08-2 | Reference compound |
| HY-105896 | SB399885 | 402713-80-8 | Reference compound |
| HY-10590 | TWS119 | 601514-19-6 | Reference compound |
| HY-105900 | Ro 22-0654 | 81741-99-3 | Reference compound |
| HY-10590R | TWS119 (Standard) | 601514-19-6 | Reference Standards |
| HY-10591 | Neuropathiazol | 880090-88-0 | Reference compound |
| HY-105912 | ONO 1082 | 111111-04-7 | Reference compound |
| HY-105917 | Emidurdar | 265646-85-3 | Reference compound |
| HY-105919 | Naroparcil | 120819-70-7 | Reference compound |
| HY-105925 | Mefenidil | 58261-91-9 | Reference compound |
| HY-105927 | Lycetamine | 60209-20-3 | Reference compound |
| HY-105929 | Lorajmine | 47562-08-3 | Reference compound |
| HY-10593 | IQ 1 | 331001-62-8 | Reference compound |
| HY-105930 | Lobaplatin | 135558-11-1 | Reference compound |
| HY-105932 | Lexithromycin | 53066-26-5 | Reference compound |
| HY-105932R | Lexithromycin (Standard) | 53066-26-5 | Reference Standards |
| HY-105934A | Ketotrexate (sodium) | 52386-42-2 | Reference compound |
| HY-105935 | Keracyanin (chloride) | 18719-76-1 | Natural Products |
| HY-105935R | Keracyanin (chloride) (Standard) | 18719-76-1 | Reference Standards |
| HY-105939 | Isofezolac | 50270-33-2 | Reference compound |
| HY-10594 | Letaxaban | 870262-90-1 | Reference compound |
| HY-105940 | IQB-782 | 40454-21-5 | Reference compound |
| HY-105946 | Hidrosmin | 115960-14-0 | Natural Products |
| HY-105946A | Hidrosmin (mixture) | 115960-14-0 | Reference compound |
| HY-10595 | RO-28-1675 | 300353-13-3 | Reference compound |
| HY-105953 | Froxiprost | 62559-74-4 | Reference compound |
| HY-105955 | FPL 14294 | 154132-95-3 | Reference compound |
| HY-10596 | BMS-688521 | 893397-44-9 | Reference compound |
| HY-105960 | Fenmetozole | 41473-09-0 | Reference compound |
| HY-105960A | Fenmetozole (hydrochloride) | 23712-05-2 | Reference compound |
| HY-105962 | Erizepine | 96645-87-3 | Reference compound |
| HY-105967A | Dicresulene (diammonium) | | Reference compound |
| HY-105969 | Dichloromethotrexate | 528-74-5 | Reference compound |
| HY-105981 | Cefempidone | 103238-57-9 | Reference compound |
| HY-105983A | CBS-1114 (hydrochloride) | 33244-00-7 | Oligonucleotides |
| HY-105997 | AZD 6703 | 851845-37-9 | Reference compound |
| HY-105999 | APC 366 | 158921-85-8 | Reference compound |
| HY-105999A | APC 366 (hydrochloride) | 178925-65-0 | Reference compound |
| HY-105999B | APC 366 (TFA) | 2421110-28-1 | Reference compound |
| HY-106000 | GSK239512 | 720691-69-0 | Reference compound |
| HY-106003 | GSK356278 | 720704-34-7 | Reference compound |
| HY-106004 | Zamicastat | 1080028-80-3 | Reference compound |
| HY-106005 | MMV390048 | 1314883-11-8 | Reference compound |
| HY-106006 | RV-1729 | 1293915-42-0 | Reference compound |
| HY-106007 | Trabodenoson | 871108-05-3 | Reference compound |
| HY-106008 | Avanbulin | 798577-91-0 | Reference compound |
| HY-106009 | VRX0466617 | 926906-64-1 | Reference compound |
| HY-106010 | LBP1 | 1050478-18-6 | Reference compound |
| HY-106011 | SLX-4090 | 913541-47-6 | Reference compound |
| HY-106012 | PI4K-IN-1 | 1800017-49-5 | Reference compound |
| HY-106014 | Tezacitabine | 130306-02-4 | Reference compound |
| HY-106016 | HP 184 | 119229-64-0 | Reference compound |
| HY-106017 | Nerispirdine | 119229-65-1 | Reference compound |
| HY-106018 | Mitemcinal | 154738-42-8 | Reference compound |
| HY-106018A | Mitemcinal (fumarate) | 154802-96-7 | Reference compound |
| HY-106019 | Liarozole | 115575-11-6 | Reference compound |
| HY-106019A | Liarozole (hydrochloride) | 145858-50-0 | Reference compound |
| HY-106019B | Liarozole (fumarate) | 145858-52-2 | Reference compound |
| HY-106019C | Liarozole (dihydrochloride) | 1883548-96-6 | Reference compound |
| HY-106019CR | Liarozole (dihydrochloride) (Standard) | 1883548-96-6 | Reference Standards |
| HY-106019R | Liarozole (Standard) | 115575-11-6 | Reference Standards |
| HY-106024A | Alagebrium (bromide) | 181069-80-7 | Reference compound |
| HY-106024B | Alagebrium chloride | 341028-37-3 | Reference compound |
| HY-106025 | Radequinil | 219846-31-8 | Reference compound |
| HY-106027 | Romazarit | 109543-76-2 | Reference compound |
| HY-106029 | 4α-TPA | 63597-44-4 | Reference compound |
| HY-106031 | F-14512 | 866874-63-7 | Reference compound |
| HY-106033 | Edotreotide | 204318-14-9 | Peptides |
| HY-106035 | Tyroservatide | 154039-16-4 | Reference compound |
| HY-106037 | PGF2α-isopropyl ester | 53764-90-2 | Reference compound |
| HY-106038 | Acopafant | 125372-33-0 | Reference compound |
| HY-106039 | LY 215490 | 150010-68-7 | Reference compound |
| HY-106043 | Lutrelin | 66866-63-5 | Reference compound |
| HY-106045 | Imazodan | 84243-58-3 | Reference compound |
| HY-106045A | Imazodan (hydrochloride) | 89198-09-4 | Reference compound |
| HY-106048 | Bredinin aglycone | 56973-26-3 | Reference compound |
| HY-106048R | Bredinin aglycone (Standard) | 56973-26-3 | Reference Standards |
| HY-106049 | Acrihellin | 67696-82-6 | Reference compound |
| HY-106050 | Tilomisole | 58433-11-7 | Reference compound |
| HY-106052 | Bofumustine | 55102-44-8 | Reference compound |
| HY-106054 | Nocloprost | 79360-43-3 | Reference compound |
| HY-106055 | Murabutide | 74817-61-1 | Reference compound |
| HY-106056 | Zindoxifene | 86111-26-4 | Reference compound |
| HY-106062 | CV 3988 | 85703-73-7 | Reference compound |
| HY-106064A | Piriprost (potassium) | 88851-62-1 | Reference compound |
| HY-106066 | Dazmegrel | 76894-77-4 | Reference compound |
| HY-106067 | Dazoxiben | 78218-09-4 | Reference compound |
| HY-106067A | Dazoxiben (hydrochloride) | 74226-22-5 | Reference compound |
| HY-106067AR | Dazoxiben (hydrochloride) (Standard) | 74226-22-5 | Reference Standards |
| HY-106072 | Vinzolidine | 67699-40-5 | Reference compound |
| HY-106075 | Bromerguride | 83455-48-5 | Reference compound |
| HY-106076 | REV 2871 | 80263-73-6 | Reference compound |
| HY-106077 | Meteneprost | 61263-35-2 | Reference compound |
| HY-106077A | Meteneprost (potassium) | 122576-55-0 | Reference compound |
| HY-106078 | Oxmetidine | 72830-39-8 | Reference compound |
| HY-106079 | Fezolamine | 80410-36-2 | Reference compound |
| HY-106080 | Furegrelate | 85666-24-6 | Reference compound |
| HY-106080A | Furegrelate (sodium) | 85666-17-7 | Reference compound |
| HY-106080AR | Furegrelate (sodium) (Standard) | 85666-17-7 | Reference Standards |
| HY-106083 | Quazolast | 86048-40-0 | Reference compound |
| HY-106084 | Cefteram | 82547-58-8 | Reference compound |
| HY-106087 | IX 207-887 | 98320-39-9 | Reference compound |
| HY-106088 | Tibenelast (free acid) | 97852-72-7 | Reference compound |
| HY-106090A | Teloxantrone (hydrochloride hydrate) | 132937-88-3 | Reference compound |
| HY-106093 | Eltenac | 72895-88-6 | Reference compound |
| HY-106094 | CY 208-243 | 100999-26-6 | Reference compound |
| HY-106098 | Adibendan | 100510-33-6 | Reference compound |
| HY-106100 | Roxindole | 112192-04-8 | Reference compound |
| HY-106100A | Roxindole (hydrochloride) | 108050-82-4 | Reference compound |
| HY-106100AR | Roxindole (hydrochloride) (Standard) | 108050-82-4 | Reference Standards |
| HY-106101 | Echinomycin | 512-64-1 | Reference compound |
| HY-106102 | [Deglycinamide9, Arginine8]-Vasopressin | 37552-33-3 | Peptides |
| HY-106103 | Seglitide | 81377-02-8 | Peptides |
| HY-106103A | Seglitide (acetate) | 99248-33-6 | Peptides |
| HY-106104 | Inocoterone acetate | 83646-86-0 | Reference compound |
| HY-106105 | ONO 3708 | 102191-05-9 | Reference compound |
| HY-106110 | OP-2507 | 101758-79-6 | Reference compound |
| HY-106113 | Ditekiren | 103336-05-6 | Reference compound |
| HY-106115 | Vintoperol | 106498-99-1 | Reference compound |
| HY-106119 | Camonagrel | 105920-77-2 | Reference compound |
| HY-106120 | Adolezesin | 110314-48-2 | Reference compound |
| HY-106123 | Pomisartan | 144702-17-0 | Reference compound |
| HY-106124 | IS-159 | 133790-13-3 | Reference compound |
| HY-106128 | Lagatide | 157476-77-2 | Peptides |
| HY-106129 | Izonsteride | 176975-26-1 | Reference compound |
| HY-106130 | Implitapide | 177469-96-4 | Reference compound |
| HY-106136 | TIK-301 | 118702-11-7 | Reference compound |
| HY-106137 | Tofimilast | 185954-27-2 | Reference compound |
| HY-106138 | Avorelin | 140703-49-7 | Reference compound |
| HY-106139 | Bimosiamose | 187269-40-5 | Reference compound |
| HY-106139A | Bimosiamose (disodium) | 187269-60-9 | Reference compound |
| HY-106139R | Bimosiamose (Standard) | 187269-40-5 | Reference Standards |
| HY-10614 | A-966492 | 934162-61-5 | Reference compound |
| HY-106140A | Asoprisnil ecamate | 222732-94-7 | Reference compound |
| HY-106141 | Albaconazole | 187949-02-6 | Reference compound |
| HY-106141S | Albaconazole-d3 | 1217825-34-7 | Isotope-Labeled Compounds |
| HY-106143 | Belaperidone | 208661-17-0 | Reference compound |
| HY-106146 | Paclitaxel ceribate | 186040-50-6 | Reference compound |
| HY-106147 | Frakefamide | 188196-22-7 | Reference compound |
| HY-106147B | Frakefamide (TFA) | | Reference compound |
| HY-106150 | Eniporide | 176644-21-6 | Biochemical Assay Reagents |
| HY-106150B | Eniporide hydrochloride | 211813-86-4 | Reference compound |
| HY-106155 | Amdoxovir | 145514-04-1 | Reference compound |
| HY-106157 | Donitriptan | 170912-52-4 | Reference compound |
| HY-106157A | Donitriptan (mesylate) | 200615-15-2 | Reference compound |
| HY-106158 | T-1095 | 209746-59-8 | Reference compound |
| HY-106161 | Rupintrivir | 223537-30-2 | Reference compound |
| HY-106161S1 | Rupintrivir-d7 | | Isotope-Labeled Compounds |
| HY-106168 | Thymectacin | 232925-18-7 | Reference compound |
| HY-10617 | Rucaparib (phosphate) | 459868-92-9 | Reference compound |
| HY-106171 | NBI-6024 | 239480-61-6 | Peptides |
| HY-106174 | Lapisteride | 142139-60-4 | Reference compound |
| HY-106175 | Detiviciclovir | 220984-26-9 | Reference compound |
| HY-106178 | PMX-53 | 219639-75-5 | Reference compound |
| HY-106178D | PMX 53 (monoacetate) | 852629-88-0 | Reference compound |
| HY-10617A | Rucaparib | 283173-50-2 | Reference compound |
| HY-10617AR | Rucaparib (Standard) | 283173-50-2 | Reference Standards |
| HY-10617AS | Rucaparib-d8 | | Isotope-Labeled Compounds |
| HY-10617B | Rucaparib (hydrochloride) | 773059-19-1 | Reference compound |
| HY-10617C | Rucaparib (tartrate) | 773059-22-6 | Reference compound |
| HY-10617D | Rucaparib (acetate) | 773059-23-7 | Reference compound |
| HY-10617R | Rucaparib (phosphate) (Standard) | 459868-92-9 | Reference Standards |
| HY-106180 | DTI 0009 | 110299-05-3 | Reference compound |
| HY-106181 | Rivoglitazone | 185428-18-6 | Reference compound |
| HY-106181A | Rivoglitazone (hydrochloride) | 299176-11-7 | Reference compound |
| HY-106182 | TBC3711 | 349453-49-2 | Reference compound |
| HY-106186 | GW-493838 | 253124-46-8 | Reference compound |
| HY-106187 | MART-1 (27-35) (human) | 156251-11-5 | Peptides |
| HY-106188 | L 756423 | 216863-66-0 | Reference compound |
| HY-10619 | Niraparib | 1038915-60-4 | Reference compound |
| HY-106194 | SLV310 | 264869-71-8 | Reference compound |
| HY-106198 | Lidorestat | 245116-90-9 | Reference compound |
| HY-106199 | Adenosine A1 receptor activator T62 | 40312-34-3 | Reference compound |
| HY-10619A | Niraparib (hydrochloride) | 1038915-64-8 | Reference compound |
| HY-10619B | Niraparib (tosylate) | 1038915-73-9 | Reference compound |
| HY-10619D | Niraparib (R-enantiomer) | 1038915-58-0 | Reference compound |
| HY-10619E | Niraparib (tosylate hydrate) | 1613220-15-7 | Reference compound |
| HY-10619R | Niraparib (Standard) | 1038915-60-4 | Reference Standards |
| HY-10620 | PI3K-IN-22 | 1202884-94-3 | Reference compound |
| HY-106200 | CJ-13,610 | 179420-17-8 | Reference compound |
| HY-106200A | CJ-13,610 (hydrochloride) | 179420-27-0 | Reference compound |
| HY-106203 | Crinecerfont | 752253-39-7 | Reference compound |
| HY-106203A | Crinecerfont (hydrochloride) | 321839-75-2 | Reference compound |
| HY-106203B | (R)-Crinecerfont | 2649012-21-3 | Reference compound |
| HY-106203C | Crinecerfont (tosylate) | 2649012-17-7 | Reference compound |
| HY-106204 | Nelipepimut-S | 160212-35-1 | Peptides |
| HY-106206 | AL-6598 | 170291-06-2 | Reference compound |
| HY-106207 | Celivarone | 401925-43-7 | Reference compound |
| HY-106215 | Etiprednol dicloacetate | 199331-40-3 | Reference compound |
| HY-106216 | Tiprelestat | 820211-82-3 | Peptides |
| HY-106218 | Flurocitabine | 37717-21-8 | Reference compound |
| HY-106218A | Flurocitabine (hydrochloride) | 40505-45-1 | Reference compound |
| HY-10622 | PF-00446687 (free base) | 862281-92-3 | Reference compound |
| HY-106224 | Orexin A (human, rat, mouse) | 205640-90-0 | Peptides |
| HY-106224A | Orexin A (human, rat, mouse) (TFA) | | Peptides |
| HY-106224B | Orexin A (human, rat, mouse) (acetate) | | Peptides |
| HY-106225 | Rotigaptide | 355151-12-1 | Reference compound |
| HY-106225R | Rotigaptide (Standard) | 355151-12-1 | Reference Standards |
| HY-106228 | HLF1-11 | 183623-03-2 | Peptides |
| HY-106230A | Dasantafil | 569351-91-3 | Reference compound |
| HY-106231 | Gastrazole (free acid) | 174610-98-1 | Reference compound |
| HY-106233 | Tiviciclovir | 103024-93-7 | Reference compound |
| HY-106233B | Tiviciclovir (hydrochloride) | | Reference compound |
| HY-106234 | ZP 120C | 383123-18-0 | Peptides |
| HY-106235 | LB80317 | 441785-24-6 | Reference compound |
| HY-106239 | Fostedil | 75889-62-2 | Reference compound |
| HY-10624 | THIQ | 312637-48-2 | Reference compound |
| HY-106244 | DOTATATE | 177943-88-3 | Peptides |
| HY-106244A | DOTATATE (acetate) | 177943-89-4 | Peptides |
| HY-106245 | HT-0712 | 617720-02-2 | Reference compound |
| HY-106246 | Pruvanserin | 443144-26-1 | Reference compound |
| HY-106253 | Efipladib | 381683-94-9 | Reference compound |
| HY-106254 | Vapendavir | 439085-51-5 | Reference compound |
| HY-106254A | Vapendavir (diphosphate) | 1198151-75-5 | Reference compound |
| HY-106254S | Vapendavir-d5 | 2738376-73-1 | Isotope-Labeled Compounds |
| HY-106254S1 | Vapendavir-d6 | 2012598-53-5 | Isotope-Labeled Compounds |
| HY-106257A | Ceftolozane (TFA) | 1628046-32-1 | Reference compound |
| HY-106257S | Ceftolozane-d6 (TFA) | | Isotope-Labeled Compounds |
| HY-106258 | Atilmotin | 533927-56-9 | Peptides |
| HY-10626 | T0901317 | 293754-55-9 | Reference compound |
| HY-106262 | Delcasertib | 949100-39-4 | Reference compound |
| HY-106262B | Delcasertib (hydrochloride) | | Peptides |
| HY-106263 | Tyroserleutide | 138168-48-6 | Peptides |
| HY-106263A | Tyroserleutide (TFA) | | Peptides |
| HY-106263B | Tyroserleutide (hydrochloride) | 852982-42-4 | Peptides |
| HY-106265 | 9,10-trans-Dehydroepothilone D | 350493-61-7 | Reference compound |
| HY-106266 | Chiglitazar | 743438-45-1 | Reference compound |
| HY-106266B | Chiglitazar (sodium) | 2390374-10-2 | Reference compound |
| HY-106268 | Larazotide | 258818-34-7 | Peptides |
| HY-106268A | Larazotide (acetate) | 881851-50-9 | Peptides |
| HY-10626R | T0901317 (Standard) | 293754-55-9 | Reference Standards |
| HY-10627 | GW3965 | 405911-09-3 | Reference compound |
| HY-106275 | FX-06 | 88650-17-3 | Peptides |
| HY-106277 | Fasitibant (free base) | 869939-83-3 | Reference compound |
| HY-106277A | Fasitibant (chloride hydrochloride) | 869880-33-1 | Reference compound |
| HY-106278 | GW 590735 | 343321-96-0 | Reference compound |
| HY-106278A | GW 590735 (sodium) | 343322-50-9 | Reference compound |
| HY-106279 | EA-230 | 503844-09-5 | Peptides |
| HY-10627A | GW3965 (hydrochloride) | 405911-17-3 | Reference compound |
| HY-10627AR | GW3965 (hydrochloride) (Standard) | 405911-17-3 | Reference Standards |
| HY-106281 | Bemfivastatin | 805241-79-6 | Reference compound |
| HY-106281A | Bemfivastatin (hemicalcium) | 805241-64-9 | Reference compound |
| HY-106282 | BIT-225 | 917909-71-8 | Reference compound |
| HY-106288 | Human PTHrP-(1-36) | 172867-62-8 | Peptides |
| HY-10629 | LXR-623 | 875787-07-8 | Reference compound |
| HY-106291 | Cefclidin | 105239-91-6 | Reference compound |
| HY-106296 | WIN 54954 | 107355-45-3 | Reference compound |
| HY-106296R | WIN 54954 (Standard) | 107355-45-3 | Reference Standards |
| HY-106297 | Tosagestin | 110072-15-6 | Reference compound |
| HY-106299 | Lilopristone | 97747-88-1 | Reference compound |
| HY-10629R | LXR-623 (Standard) | 875787-07-8 | Reference Standards |
| HY-106300 | AA 193 | 107804-48-8 | Reference compound |
| HY-106301 | Devazepide | 103420-77-5 | Reference compound |
| HY-106301R | Devazepide (Standard) | 103420-77-5 | Reference Standards |
| HY-106302 | Duramycin | 1391-36-2 | Natural Products |
| HY-106303 | YT 146 | 90596-75-1 | Reference compound |
| HY-106305A | Ledoxantrone (trihydrochloride) | 119221-49-7 | Reference compound |
| HY-106306 | Laprafylline | 90749-32-9 | Reference compound |
| HY-106307 | Retelliptine | 72238-02-9 | Reference compound |
| HY-106312 | Viroxime | 63198-97-0 | Reference compound |
| HY-106312A | Enviroxime | 72301-79-2 | Reference compound |
| HY-106316 | CGS 20625 | 111205-55-1 | Reference compound |
| HY-106323 | [Leu13]-Motilin | 59530-69-7 | Peptides |
| HY-106325 | AA 2379 | 103446-98-6 | Reference compound |
| HY-106328 | Fluasterone | 112859-71-9 | Reference compound |
| HY-106328R | Fluasterone (Standard) | 112859-71-9 | Reference Standards |
| HY-10633 | SB-705498 | 501951-42-4 | Reference compound |
| HY-106332A | Sezolamide (hydrochloride) | 119271-78-2 | Reference compound |
| HY-106333 | Irtemazole | 129369-64-8 | Reference compound |
| HY-106334 | Noberastine | 110588-56-2 | Reference compound |
| HY-106338 | Polyketomycin | 200625-47-4 | Natural Products |
| HY-106339 | Lymecycline | 992-21-2 | Reference compound |
| HY-106339R | Lymecycline (Standard) | 992-21-2 | Reference Standards |
| HY-106339S | Lymecycline-d8 | | Isotope-Labeled Compounds |
| HY-10634 | AMG 517 | 659730-32-2 | Reference compound |
| HY-106345 | ILS-920 | 892494-07-4 | Reference compound |
| HY-106347 | Itriglumide | 201605-51-8 | Reference compound |
| HY-106349 | Fosteabine | 73532-83-9 | Reference compound |
| HY-10634R | AMG 517 (Standard) | 659730-32-2 | Reference Standards |
| HY-10635 | ABT-102 | 808756-71-0 | Reference compound |
| HY-106350 | Cefpimizole | 84880-03-5 | Reference compound |
| HY-106350A | Cefpimizole (sodium) | 85287-61-2 | Reference compound |
| HY-106353 | Smilagenin | 126-18-1 | Natural Products |
| HY-106353R | Smilagenin (Standard) | 126-18-1 | Reference Standards |
| HY-106356 | GV-150013 | 167355-22-8 | Reference compound |
| HY-106358 | Andolast (free base) | 132640-22-3 | Reference compound |
| HY-106358A | Andolast | 143330-46-5 | Reference compound |
| HY-106358R | Andolast (free base) (Standard) | 132640-22-3 | Reference Standards |
| HY-106359 | Delmitide | 287096-87-1 | Peptides |
| HY-106359A | Delmitide (acetate) | 501019-16-5 | Peptides |
| HY-10635A | (S)-ABT-102 | 808756-70-9 | Reference compound |
| HY-106361 | Flerobuterol | 82101-10-8 | Reference compound |
| HY-106361A | Flerobuterol (hydrochloride) | 82101-08-4 | Reference compound |
| HY-106364 | Peplomycin | 68247-85-8 | Reference compound |
| HY-106365 | Rofleponide | 144459-70-1 | Reference compound |
| HY-106365A | Rofleponide epimer | 144459-71-2 | Reference compound |
| HY-106368 | Dexamethasone cipecilate | 132245-57-9 | Reference compound |
| HY-106369 | HMR 1556 | 223749-46-0 | Reference compound |
| HY-106371 | Siccanin | 22733-60-4 | Reference compound |
| HY-106372A | Carcainium (chloride) | 1042-42-8 | Reference compound |
| HY-106373 | Adrenocorticotropic hormone | 9002-60-2 | Reference compound |
| HY-106373A | Adrenocorticotropic hormone (TFA) | | Reference compound |
| HY-106374 | Elpamotide | 673478-49-4 | Peptides |
| HY-106376 | DL-Buthionine-(S,R)-sulfoximine | 5072-26-4 | Reference compound |
| HY-106376A | L-Buthionine-(S,R)-sulfoximine | 83730-53-4 | Reference compound |
| HY-106376B | DL-Buthionine-(S,R)-sulfoximine (hydrochloride) | | Reference compound |
| HY-106376BR | DL-Buthionine-(S,R)-sulfoximine (hydrochloride) (Standard) | | Reference Standards |
| HY-106376C | L-Buthionine-(S,R)-sulfoximine (hydrochloride) | | Reference compound |
| HY-106376R | DL-Buthionine-(S,R)-sulfoximine (Standard) | 5072-26-4 | Reference Standards |
| HY-106377A | BIO-11006 (acetate) | | Peptides |
| HY-106379 | Lurosetron | 128486-54-4 | Reference compound |
| HY-10638 | AP23464 | 845895-51-4 | Reference compound |
| HY-106381 | Aurothiomalate (sodium) | 12244-57-4 | Reference compound |
| HY-106381A | Aurothiomalate tetramer (sodium) | | Reference compound |
| HY-106382 | PMEDAP | 113852-41-8 | Reference compound |
| HY-106389 | Onapristone | 96346-61-1 | Reference compound |
| HY-106392 | Lucerastat | 141206-42-0 | Reference compound |
| HY-106392R | Lucerastat (Standard) | 141206-42-0 | Reference Standards |
| HY-106395 | Telinavir | 143224-34-4 | Reference compound |
| HY-106395A | (Rac)-Telinavir | 162679-88-1 | Reference compound |
| HY-106397 | Delucemine | 186495-49-8 | Reference compound |
| HY-106397A | Delucemine (hydrochloride) | 186495-99-8 | Reference compound |
| HY-106399 | Acodazole | 79152-85-5 | Reference compound |
| HY-106399A | Acodazole (hydrochloride) | 55435-65-9 | Reference compound |
| HY-106400 | EGIS 11150 | 494861-87-9 | Reference compound |
| HY-106405 | Nebicapone | 274925-86-9 | Reference compound |
| HY-106405R | Nebicapone (Standard) | 274925-86-9 | Reference Standards |
| HY-106406 | Benzylacyclouridine | 82857-69-0 | Reference compound |
| HY-106406R | Benzylacyclouridine (Standard) | 82857-69-0 | Reference Standards |
| HY-106407 | Beloxepin | 135928-30-2 | Reference compound |
| HY-106408 | Nelonemdaz | 640290-67-1 | Reference compound |
| HY-106408A | Nelonemdaz (potassium) | 916214-57-8 | Reference compound |
| HY-106409 | Tefinostat | 914382-60-8 | Reference compound |
| HY-106410 | Zabofloxacin | 219680-11-2 | Reference compound |
| HY-106410A | Zabofloxacin (hydrochloride) | 623574-00-5 | Reference compound |
| HY-106412 | Stacofylline | 98833-92-2 | Reference compound |
| HY-106415 | Terflavoxate | 86433-40-1 | Reference compound |
| HY-106416 | Neldazosin | 109713-79-3 | Reference compound |
| HY-106420 | 16,16-Dimethyl prostaglandin E2 | 39746-25-3 | Reference compound |
| HY-106424 | Soretolide | 130403-08-6 | Reference compound |
| HY-106425 | Omzotirome | 1092551-88-6 | Reference compound |
| HY-106426 | Gallium maltolate | 108560-70-9 | Reference compound |
| HY-106428 | Icrocaptide | 169543-49-1 | Reference compound |
| HY-106429 | OT-551 (free base) | 627085-11-4 | Reference compound |
| HY-106430 | Piclozotan | 182415-09-4 | Reference compound |
| HY-106431 | Olpadronic acid | 63132-39-8 | Reference compound |
| HY-106431R | Olpadronic acid (Standard) | 63132-39-8 | Reference Standards |
| HY-106432 | Sabcomeline | 159912-53-5 | Reference compound |
| HY-106432A | Sabcomeline (hydrochloride) | 159912-58-0 | Reference compound |
| HY-106434 | Piritrexim | 72732-56-0 | Reference compound |
| HY-106437 | ELB-139 | 188116-08-7 | Reference compound |
| HY-106439 | BTG 1640 | 152538-59-5 | Reference compound |
| HY-10644 | Lck inhibitor 2 | 944795-06-6 | Reference compound |
| HY-106441A | Rislenemdaz | 808732-98-1 | Reference compound |
| HY-106443 | Arimoclomol | 289893-25-0 | Reference compound |
| HY-106443A | Arimoclomol (maleate) | 289893-26-1 | Reference compound |
| HY-106443B | Arimoclomol (citrate) | 368860-21-3 | Reference compound |
| HY-106444 | Fipamezole | 150586-58-6 | Reference compound |
| HY-106444A | Fipamezole (hydrochloride) | 150586-72-4 | Reference compound |
| HY-106445 | Ciamexon | 75985-31-8 | Reference compound |
| HY-106446 | Rentiapril | 80830-42-8 | Reference compound |
| HY-106446R | Rentiapril (Standard) | 80830-42-8 | Reference Standards |
| HY-106447 | Losulazine | 72141-57-2 | Reference compound |
| HY-106448 | Midesteine | 94149-41-4 | Reference compound |
| HY-106449 | Recoflavone | 203191-10-0 | Reference compound |
| HY-106450 | Binodenoson | 144348-08-3 | Reference compound |
| HY-106454 | N-Desalkylflurazepam | 2886-65-9 | Reference compound |
| HY-106454R | N-Desalkylflurazepam (Standard) | 2886-65-9 | Reference Standards |
| HY-106456 | Depramine | 303-54-8 | Reference compound |
| HY-106467 | Caroverine | 23465-76-1 | Reference compound |
| HY-106467B | Caroverine (hydrochloride) | 55750-05-5 | Reference compound |
| HY-106467BR | Caroverine (hydrochloride) (Standard) | 55750-05-5 | Reference Standards |
| HY-106469 | Taltrimide | 81428-04-8 | Reference compound |
| HY-106471 | Pildralazine | 64000-73-3 | Reference compound |
| HY-106472 | Tioxaprofen | 40198-53-6 | Reference compound |
| HY-106473 | Delmetacin | 16401-80-2 | Reference compound |
| HY-106474 | Meribendan | 119322-27-9 | Reference compound |
| HY-106476 | Primidolol | 67227-55-8 | Reference compound |
| HY-106477 | Quazinone | 70018-51-8 | Reference compound |
| HY-106479 | Verofylline | 66172-75-6 | Reference compound |
| HY-106481 | Bufrolin | 54867-56-0 | Reference compound |
| HY-106484 | Tiflucarbine | 89875-86-5 | Reference compound |
| HY-106486A | Butoprozine (hydrochloride) | 62134-34-3 | Reference compound |
| HY-106487 | Pridefine | 5370-41-2 | Reference compound |
| HY-106495 | Vadocaine | 72005-58-4 | Reference compound |
| HY-106499 | Sulfinalol | 66264-77-5 | Reference compound |
| HY-106499A | Sulfinalol (hydrochloride) | 63251-39-8 | Reference compound |
| HY-106504 | Aganodine | 86696-87-9 | Reference compound |
| HY-106506 | Desciclovir | 84408-37-7 | Reference compound |
| HY-106506R | Desciclovir (Standard) | 84408-37-7 | Reference Standards |
| HY-106508 | Fendosal | 53597-27-6 | Reference compound |
| HY-106509 | Velaresol | 77858-21-0 | Reference compound |
| HY-106509R | Velaresol (Standard) | 77858-21-0 | Reference Standards |
| HY-106512 | Cianergoline | 74627-35-3 | Reference compound |
| HY-106514 | Prifelone | 69425-13-4 | Reference compound |
| HY-106515 | Tebuquine | 74129-03-6 | Reference compound |
| HY-106516 | Napactadine (free base) | 76631-45-3 | Reference compound |
| HY-106518 | Adimolol (free base) | 78459-19-5 | Reference compound |
| HY-10652 | JAK-2/3-IN-1 | 1036241-36-7 | Reference compound |
| HY-106523 | Nipradolol | 81486-22-8 | Reference compound |
| HY-106526 | Xibornol | 13741-18-9 | Reference compound |
| HY-106530 | Gitoformate | 10176-39-3 | Reference compound |
| HY-106534 | Gemeprost | 64318-79-2 | Reference compound |
| HY-106535 | Valbilan | 3102-00-9 | Reference compound |
| HY-106537 | W 3699 | 17243-64-0 | Reference compound |
| HY-106538 | Cadralazine | 64241-34-5 | Reference compound |
| HY-106538R | Cadralazine (Standard) | 64241-34-5 | Reference Standards |
| HY-106539 | Colesevelam (hydrochloride) | 182815-44-7 | Reference compound |
| HY-106541 | Neticonazole | 130726-68-0 | Reference compound |
| HY-106541R | Neticonazole (Standard) | 130726-68-0 | Reference Standards |
| HY-106542 | Eberconazole | 128326-82-9 | Reference compound |
| HY-106542A | Eberconazole nitrate | 130104-32-4 | Reference compound |
| HY-106542AR | Eberconazole nitrate (Standard) | 130104-32-4 | Reference Standards |
| HY-106546 | Tolciclate | 50838-36-3 | Reference compound |
| HY-106547 | Rilmazafone | 99593-25-6 | Reference compound |
| HY-10655 | Palosuran | 540769-28-6 | Reference compound |
| HY-106550 | Enprostil | 73121-56-9 | Reference compound |
| HY-106554 | Trimazosin | 35795-16-5 | Reference compound |
| HY-106554A | Trimazosin (hydrochloride hydrate) | 53746-46-6 | Reference compound |
| HY-106555 | Protizinic acid | 13799-03-6 | Reference compound |
| HY-106556 | Zorubicin | 54083-22-6 | Reference compound |
| HY-106559 | Sorbinicate | 6184-06-1 | Reference compound |
| HY-10655A | Palosuran (hydrochloride) | 2469274-58-4 | Reference compound |
| HY-10655AR | Palosuran (hydrochloride) (Standard) | 2469274-58-4 | Reference Standards |
| HY-10655R | Palosuran (Standard) | 540769-28-6 | Reference Standards |
| HY-10656 | SB-657510 | 474960-44-6 | Reference compound |
| HY-106560 | Proglumetacin | 57132-53-3 | Reference compound |
| HY-106561 | Tioclomarol | 22619-35-8 | Reference compound |
| HY-106562 | Dopexamine | 86197-47-9 | Reference compound |
| HY-106564A | Flutropium (bromide) | 63516-07-4 | Reference compound |
| HY-106565 | Meproscillarin | 33396-37-1 | Reference compound |
| HY-106566 | Alclometasone dipropionate | 66734-13-2 | Reference compound |
| HY-106566R | Alclometasone dipropionate (Standard) | 66734-13-2 | Reference Standards |
| HY-106567 | Fluocortin butyl ester | 41767-29-7 | Reference compound |
| HY-10657 | SB-706375 | 733734-61-7 | Reference compound |
| HY-106570 | Tripamide | 73803-48-2 | Reference compound |
| HY-106571 | Cefteram pivoxil | 82547-81-7 | Reference compound |
| HY-106571R | Cefteram pivoxil (Standard) | 82547-81-7 | Reference Standards |
| HY-106572 | Cefbuperazone | 76610-84-9 | Reference compound |
| HY-106572A | Cefbuperazone (sodium) | 76648-01-6 | Reference compound |
| HY-106574 | Ceftobiprole medocaril | 376653-43-9 | Reference compound |
| HY-106574A | Ceftobiprole medocaril (sodium) | 252188-71-9 | Reference compound |
| HY-106575 | Nifurzide | 39978-42-2 | Reference compound |
| HY-106577 | Cibenzoline | 53267-01-9 | Reference compound |
| HY-106577A | (-)-(S)-Cibenzoline | 103419-18-7 | Reference compound |
| HY-106577AS | (-)-(S)-Cibenzoline-d4 | | Isotope-Labeled Compounds |
| HY-106577R | Cibenzoline (Standard) | 53267-01-9 | Reference Standards |
| HY-106577S | Cibenzoline-d4 | | Isotope-Labeled Compounds |
| HY-106577S1 | Cibenzoline-d5 | | Isotope-Labeled Compounds |
| HY-106578 | Quinupramine | 31721-17-2 | Reference compound |
| HY-106579 | Tiaprofenic acid | 33005-95-7 | Reference compound |
| HY-106579R | Tiaprofenic acid (Standard) | 33005-95-7 | Reference Standards |
| HY-106579S | Tiaprofenic acid-d3 | 2740831-64-3 | Isotope-Labeled Compounds |
| HY-10658 | AC-7954 | 477313-09-0 | Reference compound |
| HY-106580 | Plafibride | 63394-05-8 | Reference compound |
| HY-106581 | Pirifibrate | 55285-45-5 | Reference compound |
| HY-106582 | Sobuzoxane | 98631-95-9 | Reference compound |
| HY-106583 | Piroxicam cinnamate | 87234-24-0 | Reference compound |
| HY-106584 | Mosapramine | 89419-40-9 | Reference compound |
| HY-106585 | Cyclobendazole | 31431-43-3 | Reference compound |
| HY-106586 | Ioxaglic acid | 59017-64-0 | Reference compound |
| HY-106586A | Ioxaglate (sodium) | 67992-58-9 | Reference compound |
| HY-106587A | Octoclothepin (maleate salt) | 4789-68-8 | Reference compound |
| HY-106588 | Heptaplatin | 146665-77-2 | Reference compound |
| HY-106590 | Saccharocin | 86630-31-1 | Reference compound |
| HY-106591A | 4-Vinylcyclohexene dioxide | 106-87-6 | Reference compound |
| HY-106592A | U-74389G | 153190-29-5 | Reference compound |
| HY-106594A | Prussian blue insoluble | 14038-43-8 | Reference compound |
| HY-106594B | Prussian blue soluble | 12240-15-2 | Reference compound |
| HY-106597 | Pirlimycin | 79548-73-5 | Reference compound |
| HY-106597A | Pirlimycin (hydrochloride) | 78822-40-9 | Reference compound |
| HY-106597AR | Pirlimycin (hydrochloride) (Standard) | 78822-40-9 | Reference Standards |
| HY-106601 | Picenadol | 79201-85-7 | Reference compound |
| HY-106602 | Gevotroline | 107266-06-8 | Reference compound |
| HY-106605S | Flumezapine-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-106608 | Glutaurine | 56488-60-9 | Reference compound |
| HY-106608A | Glutaurine (TFA) | | Reference compound |
| HY-10661 | FL104 | 885672-81-1 | Reference compound |
| HY-106611 | Brinazarone | 89622-90-2 | Reference compound |
| HY-106612 | Abanoquil | 90402-40-7 | Reference compound |
| HY-106616 | Muzolimine | 55294-15-0 | Reference compound |
| HY-106616R | Muzolimine (Standard) | 55294-15-0 | Reference Standards |
| HY-106617 | Etoperidone | 52942-31-1 | Reference compound |
| HY-106617A | Etoperidone (hydrochloride) | 57775-22-1 | Reference compound |
| HY-106617AS | Etoperidone-d8 (hydrochloride) | 1329796-60-2 | Isotope-Labeled Compounds |
| HY-106618 | Mopidamol | 13665-88-8 | Reference compound |
| HY-106619 | Seprilose | 133692-55-4 | Reference compound |
| HY-106628 | Sudoxicam | 34042-85-8 | Reference compound |
| HY-106628R | Sudoxicam (Standard) | 34042-85-8 | Reference Standards |
| HY-106634 | Mitoguazone | 459-86-9 | Reference compound |
| HY-106634R | Mitoguazone (Standard) | 459-86-9 | Reference Standards |
| HY-106635 | Suriclone | 53813-83-5 | Reference compound |
| HY-106638 | Voclosporin | 515814-01-4 | Reference compound |
| HY-106638R | Voclosporin (Standard) | 515814-01-4 | Reference Standards |
| HY-106638S | Voclosporin-d4 | | Isotope-Labeled Compounds |
| HY-10664 | SB-611812 | 345892-71-9 | Reference compound |
| HY-106644 | Femoxetine | 59859-58-4 | Reference compound |
| HY-106644A | Femoxetine (hydrochloride) | 56222-04-9 | Reference compound |
| HY-106645 | Cloxacepride | 65569-29-1 | Reference compound |
| HY-106647 | Abacavir hydroxyacetate | 1446418-48-9 | Reference compound |
| HY-10664R | SB-611812 (Standard) | 345892-71-9 | Reference Standards |
| HY-106659 | SCH 900978 | 873947-10-5 | Reference compound |
| HY-10666 | SB-436811 | 346729-66-6 | Reference compound |
| HY-106660 | BP 897 (hydrochloride) | 314776-92-6 | Reference compound |
| HY-106662 | Chloroquinoxaline sulfonamide | 97919-22-7 | Reference compound |
| HY-106667 | DL 071IT | 55104-39-7 | Reference compound |
| HY-106668 | Isepamicin | 58152-03-7 | Reference compound |
| HY-106670 | Dulozafone | 75616-02-3 | Reference compound |
| HY-106671 | Spirogermanium | 41992-23-8 | Reference compound |
| HY-106673 | Hydrocortisone buteprate | 72590-77-3 | Reference compound |
| HY-106673R | Hydrocortisone buteprate (Standard) | 72590-77-3 | Reference Standards |
| HY-106681 | Lagosin | 6834-98-6 | Natural Products |
| HY-106682 | Falipamil | 77862-92-1 | Reference compound |
| HY-106684 | Ridazolol | 83395-21-5 | Reference compound |
| HY-106684A | Ridazolol (hydrochloride) | 83394-57-4 | Reference compound |
| HY-106685 | Selenazofurin | 83705-13-9 | Reference compound |
| HY-106688 | Alinidine | 33178-86-8 | Reference compound |
| HY-106688A | Alinidine (hydrobromide) | 71306-36-0 | Reference compound |
| HY-106689 | Dihydro-5-azacytidine | 62488-57-7 | Reference compound |
| HY-106689A | Dihydro-5-azacytidine (acetate) | 2470972-18-8 | Oligonucleotides |
| HY-106690 | Centhaquin | 57961-90-7 | Reference compound |
| HY-106691 | Pirmagrel | 85691-74-3 | Reference compound |
| HY-106697 | Ponalrestat | 72702-95-5 | Reference compound |
| HY-106699 | Taprostene (sodium) | 87440-45-7 | Reference compound |
| HY-106700 | Pentisomide | 78833-03-1 | Reference compound |
| HY-106702 | Fostriecin (sodium) | 87860-39-7 | Natural Products |
| HY-106702A | Fostriecin | 87810-56-8 | Reference compound |
| HY-106714 | Clocortolone pivalate | 34097-16-0 | Reference compound |
| HY-106714R | Clocortolone pivalate (Standard) | 34097-16-0 | Reference Standards |
| HY-106716 | SR 41378 | 93181-85-2 | Reference compound |
| HY-10672 | Urotensin-II receptor antagonist-1 | 1034708-07-0 | Reference compound |
| HY-106720 | Amosulalol | 85320-68-9 | Reference compound |
| HY-106720A | Amosulalol (hydrochloride) | 70958-86-0 | Reference compound |
| HY-106720B | (-)-Amosulalol | 94666-15-6 | Reference compound |
| HY-106720C | (+)-Amosulalol | 94666-17-8 | Reference compound |
| HY-106723 | AMP-PCP | 3469-78-1 | Reference compound |
| HY-106723A | AMP-PCP (disodium) | 7414-56-4 | Reference compound |
| HY-106732 | AT-076 | 1657028-64-2 | Reference compound |
| HY-106735 | Arotinoid | 71441-09-3 | Reference compound |
| HY-106736 | Etilefrine pivalate (hydrochloride) | 42145-91-5 | Reference compound |
| HY-106739 | Motapizone | 90697-57-7 | Reference compound |
| HY-106741 | Bazinaprine | 94011-82-2 | Reference compound |
| HY-106745 | Elziverine | 95520-81-3 | Reference compound |
| HY-106747 | Ralitoline | 93738-40-0 | Reference compound |
| HY-106749 | E-0747 | 99599-78-7 | Reference compound |
| HY-106753 | Tolnapersine | 70312-00-4 | Reference compound |
| HY-106755 | Tucaresol | 84290-27-7 | Reference compound |
| HY-106756 | Spiradoline | 87151-85-7 | Reference compound |
| HY-106758 | Cefuzonam (sodium) | 82219-81-6 | Reference compound |
| HY-106761 | Oxodipine | 90729-41-2 | Reference compound |
| HY-106765 | Thymotrinan | 85465-82-3 | Reference compound |
| HY-106765A | Thymotrinan (TFA) | | Reference compound |
| HY-106766 | DHP-218 | 102097-78-9 | Reference compound |
| HY-106769 | Fluparoxan | 105182-45-4 | Reference compound |
| HY-106769A | (3aR,9aR)-Fluparoxan (hydrochloride) | 105226-30-0 | Reference compound |
| HY-106769B | (3aR,9aR)-Fluparoxan | 105182-47-6 | Reference compound |
| HY-106769C | Fluparoxan (hydrochloride) | 105227-44-9 | Reference compound |
| HY-106770 | Esuprone | 91406-11-0 | Reference compound |
| HY-106774 | R-61837 | 100241-46-1 | Reference compound |
| HY-106777 | Cyclopentenylcytosine | 90597-22-1 | Reference compound |
| HY-106779 | Tamolarizine (hydrochloride) | 93035-33-7 | Reference compound |
| HY-10678 | BMS-687453 | 1000998-59-3 | Reference compound |
| HY-106781A | OPC 4392 (hydrochloride) | 1329509-60-5 | Reference compound |
| HY-106782 | Titanocene dichloride | 1271-19-8 | Biochemical Assay Reagents |
| HY-106783 | Polymyxin B nonapeptide | 86408-36-8 | Peptides |
| HY-106783A | Polymyxin B nonapeptide (TFA) | 2220175-42-6 | Peptides |
| HY-106783AR | Polymyxin B nonapeptide (TFA) (Standard) | 2220175-42-6 | Reference Standards |
| HY-106783R | Polymyxin B nonapeptide (Standard) | 86408-36-8 | Reference Standards |
| HY-106784 | Ajoene | 92285-01-3 | Natural Products |
| HY-106784A | (E)-Ajoene | 92284-99-6 | Natural Products |
| HY-106785 | Pobilukast | 107023-41-6 | Reference compound |
| HY-106789 | Plaunotol | 64218-02-6 | Reference compound |
| HY-10679 | PF-03049423 (free base) | 954138-07-9 | Reference compound |
| HY-10679A | PF-03049423 | 402955-58-2 | Reference compound |
| HY-10680 | MK-6892 | 917910-45-3 | Reference compound |
| HY-106801 | Girolline | 110883-46-0 | Reference compound |
| HY-106805 | ICI 169369 | 85273-96-7 | Reference compound |
| HY-106807 | Litoxetine | 86811-09-8 | Reference compound |
| HY-106808 | Cerebrocrast | 118790-71-9 | Reference compound |
| HY-106809 | BMY-21502 | 123259-91-6 | Reference compound |
| HY-10681 | Gedatolisib | 1197160-78-3 | Reference compound |
| HY-106810 | Naltiazem | 108383-95-5 | Reference compound |
| HY-106810A | Naltiazem (hydrochloride) | 108383-96-6 | Reference compound |
| HY-106816 | Ceronapril | 111223-26-8 | Reference compound |
| HY-106817 | Amitivir | 111393-84-1 | Reference compound |
| HY-106818A | Monatepil (maleate) | 103379-03-9 | Reference compound |
| HY-106822 | Losigamone | 112856-44-7 | Reference compound |
| HY-106823 | Tebufelone | 112018-00-5 | Reference compound |
| HY-106825 | Clanfenur | 51213-99-1 | Reference compound |
| HY-106827 | Trimegestone | 74513-62-5 | Reference compound |
| HY-106827S1 | Trimegestone-13C,d3 | | Isotope-Labeled Compounds |
| HY-106828 | E2-CDS | 103562-82-9 | Reference compound |
| HY-10683 | PKI-402 | 1173204-81-3 | Reference compound |
| HY-106831 | R 56865 | 104606-13-5 | Reference compound |
| HY-106832 | Vatanidipine | 116308-55-5 | Reference compound |
| HY-106832A | Vatanidipine (hydrochloride) | 133743-71-2 | Reference compound |
| HY-106833A | SDZ-62-434 | 115621-95-9 | Reference compound |
| HY-106835 | Flobufen | 112344-52-2 | Reference compound |
| HY-106837 | Israpafant | 117279-73-9 | Reference compound |
| HY-106838A | Org 6906 | 67384-25-2 | Reference compound |
| HY-10684 | Pridopidine | 346688-38-8 | Reference compound |
| HY-106840 | L-365260 | 118101-09-0 | Reference compound |
| HY-106840A | L-365260 (hemihydrate) | | Reference compound |
| HY-106841 | Draflazine | 120770-34-5 | Reference compound |
| HY-106841A | (S)-Draflazine | 138681-29-5 | Reference compound |
| HY-106842 | Nitecapone | 116313-94-1 | Reference compound |
| HY-106844 | EMD 53998 | 120223-04-3 | Reference compound |
| HY-106844A | (+)-EMD 57033 | 147527-31-9 | Reference compound |
| HY-106848 | Arteflene | 123407-36-3 | Reference compound |
| HY-106850 | 3′-Azido-2′,3′-dideoxyuridine | 84472-85-5 | Reference compound |
| HY-106851 | Panadiplon | 124423-84-3 | Reference compound |
| HY-106855 | Almokalant | 123955-10-2 | Reference compound |
| HY-106856 | Dimiracetam | 126100-97-8 | Reference compound |
| HY-106859 | Letrazuril | 103337-74-2 | Reference compound |
| HY-106860 | Gedocarnil | 109623-97-4 | Reference compound |
| HY-106866 | Bulaquine | 79781-00-3 | Reference compound |
| HY-106872 | R82913 | 126347-69-1 | Reference compound |
| HY-106873 | Nepinalone | 22443-11-4 | Reference compound |
| HY-106873A | Nepinalone (hydrochloride) | 22443-55-6 | Reference compound |
| HY-106874 | Delequamine | 119905-05-4 | Reference compound |
| HY-106874A | Delequamine (hydrochloride) | 119942-75-5 | Reference compound |
| HY-106874B | rel-Delequamine | 119813-87-5 | Reference compound |
| HY-106875 | Saripidem | 103844-86-6 | Reference compound |
| HY-106877 | Minalrestat | 129688-50-2 | Reference compound |
| HY-106882 | GE 2270A | 134861-34-0 | Peptides |
| HY-106887 | SCH 32615 | 83861-02-3 | Reference compound |
| HY-106888 | CS-722 (Free base) | 749179-13-3 | Reference compound |
| HY-106888A | CS-722 | 144886-17-9 | Reference compound |
| HY-106889 | Zelandopam (free base) | 139233-53-7 | Reference compound |
| HY-106890 | E4177 | 135070-05-2 | Reference compound |
| HY-106892 | BW 348U87 | 127142-14-7 | Reference compound |
| HY-106895 | Antiarrhythmic agent-1 | 136081-07-7 | Reference compound |
| HY-106897 | BF389 | 127245-22-1 | Reference compound |
| HY-106899A | (rel)-MK 287 | 143445-03-8 | Reference compound |
| HY-106900 | Lifarizine | 119514-66-8 | Reference compound |
| HY-106901A | Asoxime (dichloride) | 34433-31-3 | Reference compound |
| HY-106901AS | Asoxime-d4 (dichloride) | | Isotope-Labeled Compounds |
| HY-106902 | F-1394 | 162490-89-3 | Reference compound |
| HY-106904 | Nexopamil | 136033-49-3 | Reference compound |
| HY-106907 | Furprofen | 66318-17-0 | Reference compound |
| HY-106908 | Filaminast | 141184-34-1 | Reference compound |
| HY-106909A | YM114 | 153608-99-2 | Reference compound |
| HY-106910 | Saredutant | 142001-63-6 | Reference compound |
| HY-106912A | L-706000 (free base) | 161799-18-4 | Reference compound |
| HY-106914 | Sinitrodil | 143248-63-9 | Reference compound |
| HY-106916 | Unoprostone | 120373-36-6 | Reference compound |
| HY-106917 | Lirequinil | 143943-73-1 | Reference compound |
| HY-106918 | Tivirapine | 137332-54-8 | Reference compound |
| HY-106920 | Kynostatin 272 | 147318-81-8 | Reference compound |
| HY-106921 | Bisnafide | 144849-63-8 | Reference compound |
| HY-106921A | Bisnafide (mesylate) | 145124-30-7 | Reference compound |
| HY-106922 | Sanfetrinem | 156769-21-0 | Reference compound |
| HY-106922A | Sanfetrinem (sodium) | 141611-76-9 | Reference compound |
| HY-106924A | Antiallergic agent-3 | 160665-99-6 | Reference compound |
| HY-106925 | Cetefloxacin | 141725-88-4 | Reference compound |
| HY-106927 | Bay Y5959 | 146136-94-9 | Reference compound |
| HY-106929 | Moxilubant | 146978-48-5 | Reference compound |
| HY-106929B | Moxilubant (hydrochloride) | 146957-32-6 | Reference compound |
| HY-106932 | L-734217 | 146144-48-1 | Reference compound |
| HY-106933 | Dabelotine | 118976-38-8 | Reference compound |
| HY-106933A | Dabelotine (methanesulfonate) | 153049-48-0 | Reference compound |
| HY-106934 | Peldesine | 133432-71-0 | Reference compound |
| HY-106934A | Peldesine (dihydrochloride) | 2772702-10-8 | Reference compound |
| HY-106938 | Eldacimibe | 141993-70-6 | Reference compound |
| HY-106945 | Prezatide copper | 130120-56-8 | Peptides |
| HY-106947 | SY-640 | 168705-70-2 | Reference compound |
| HY-106949 | Tazomeline | 131987-54-7 | Reference compound |
| HY-106950 | Fosfructose | 488-69-7 | Natural Products |
| HY-106950A | Fosfructose (trisodium) | 38099-82-0 | Natural Products |
| HY-106950B | D-Fructose 1,6-bisphosphate (tetracyclohexylammonium) | 56594-87-7 | Biochemical Assay Reagents |
| HY-106950CS | Fosfructose-1-13C (sodium) | | Isotope-Labeled Compounds |
| HY-106950CS1 | Fosfructose-2-13C (sodium) | | Isotope-Labeled Compounds |
| HY-106950CS3 | Fosfructose-6-13C (sodium) | | Isotope-Labeled Compounds |
| HY-106950S1 | Fosfructose-13C6 (tetrasodium hydrate) | | Isotope-Labeled Compounds |
| HY-106951 | MK 386 | 158493-17-5 | Reference compound |
| HY-106954 | Upidosin | 152735-23-4 | Reference compound |
| HY-106956 | Lubazodone | 161178-07-0 | Reference compound |
| HY-106957 | Efletirizine | 150756-35-7 | Reference compound |
| HY-106958 | Talviraline | 163451-80-7 | Reference compound |
| HY-106959 | Flurithromycin | 82664-20-8 | Reference compound |
| HY-106961 | ONO 1301 | 176391-41-6 | Reference compound |
| HY-106961A | (Z)-ONO 1301 | 153814-74-5 | Reference compound |
| HY-106963 | ALRT1550 | 178600-20-9 | Reference compound |
| HY-106964A | (Rac)-S 16924 | 734513-52-1 | Reference compound |
| HY-106965 | Org 21465 | 167946-96-5 | Reference compound |
| HY-106968 | ZD-9379 | 170142-20-8 | Reference compound |
| HY-106973A | Nolomirole (hydrochloride) | 138531-51-8 | Reference compound |
| HY-106975 | SCH-42354 | 144505-58-8 | Reference compound |
| HY-106982 | Ezlopitant | 147116-64-1 | Reference compound |
| HY-106991A | Amustaline (dihydrochloride) | 210584-54-6 | Reference compound |
| HY-106992 | S 3304 | 203640-27-1 | Reference compound |
| HY-106993 | Cipralisant | 213027-19-1 | Reference compound |
| HY-106993A | Cipralisant (maleate) | 223420-20-0 | Reference compound |
| HY-106993B | Cipralisant (enantiomer) | 223420-11-9 | Reference compound |
| HY-106994 | Nebentan | 403604-85-3 | Reference compound |
| HY-106994A | Nebentan (potassium) | 342005-82-7 | Reference compound |
| HY-106996 | AWD 12-281 | 257892-33-4 | Reference compound |
| HY-106997 | Icofungipen | 198022-65-0 | Reference compound |
| HY-107001 | DPC 961 | 214287-88-4 | Reference compound |
| HY-107002A | Lergotrile (mesylate) | 51473-23-5 | Reference compound |
| HY-107003 | Opaviraline | 178040-94-3 | Reference compound |
| HY-107004 | Amotosalen | 161262-29-9 | Reference compound |
| HY-107004A | Amotosalen (hydrochloride) | 161262-45-9 | Reference compound |
| HY-107008 | SW 71425 | 155990-20-8 | Reference compound |
| HY-107010 | Esprolol | 396654-09-4 | Reference compound |
| HY-107010A | Esprolol (hydrochloride) | 112805-65-9 | Reference compound |
| HY-107013 | CP-544439 | 230954-09-3 | Reference compound |
| HY-107015A | Prednisolone metazoate (sodium) | 630-67-1 | Reference compound |
| HY-107018 | AR-A 2 | 220051-79-6 | Reference compound |
| HY-107019 | Surinabant | 288104-79-0 | Reference compound |
| HY-107020 | BMS 310705 | 280578-49-6 | Reference compound |
| HY-107022A | BMS-341400 (mesylate) | 296250-54-9 | Reference compound |
| HY-107023 | AZD 9684 | 775274-06-1 | Reference compound |
| HY-107024 | Osteogenic Growth Peptide (10-14) | 105250-85-9 | Peptides |
| HY-107025 | Cf1743 | 319425-66-6 | Reference compound |
| HY-107026 | Lagociclovir valactate | 1001670-19-4 | Reference compound |
| HY-107027 | Polymyxin E2 (sulfate) | 1338055-88-1 | Reference compound |
| HY-107030 | Nitrefazole | 21721-92-6 | Reference compound |
| HY-107031 | Metapramine | 21730-16-5 | Reference compound |
| HY-107032 | Amitriptylinoxide | 4317-14-0 | Reference compound |
| HY-107033 | Tetroxoprim | 53808-87-0 | Reference compound |
| HY-107033R | Tetroxoprim (Standard) | 53808-87-0 | Reference Standards |
| HY-107034 | Moxipraquine | 23790-08-1 | Reference compound |
| HY-107036 | BMS-394136 | 343246-73-1 | Reference compound |
| HY-107037 | Tolmesoxide | 38452-29-8 | Reference compound |
| HY-10704 | PTP1B-IN-1 | 612530-44-6 | Reference compound |
| HY-107040 | Etoxadrol | 28189-85-7 | Reference compound |
| HY-107043 | 7β-Hydroxy-epi-androsterone | 25848-69-5 | Reference compound |
| HY-107045 | CHF 4227 (free base) | 444643-64-5 | Reference compound |
| HY-107046 | UK-432097 | 380221-63-6 | Reference compound |
| HY-107051 | GW 766994 | 408303-43-5 | Reference compound |
| HY-107055 | RTI 336 | 204069-50-1 | Reference compound |
| HY-107063 | AHR-1911 | 22584-04-9 | Reference compound |
| HY-107064 | Cefroxadine | 51762-05-1 | Reference compound |
| HY-107072A | Trantinterol (hydrochloride) | 611234-02-7 | Reference compound |
| HY-107074 | Levovirin valinate (hydrochloride) | 705930-02-5 | Reference compound |
| HY-107085 | Talmetacin | 67489-39-8 | Reference compound |
| HY-107091 | Aspartyl-alanyl-diketopiperazine | 110954-19-3 | Reference compound |
| HY-107093 | MBC-11 | 332863-86-2 | Reference compound |
| HY-107093A | MBC-11 (trisodium) | 387877-45-4 | Reference compound |
| HY-107093B | MBC-11 (triethylamine) | | Reference compound |
| HY-107094 | MT-7716 hydrochloride | 1215859-93-0 | Reference compound |
| HY-107094A | MT-7716 (free base) | 610323-32-5 | Reference compound |
| HY-107095 | JNJ19567470 | 724471-26-5 | Reference compound |
| HY-107096 | CH-0793076 | 534605-78-2 | Reference compound |
| HY-107096B | CH-0793076 (TFA) | 2740278-76-4 | Reference compound |
| HY-107098 | PPL-100 (free acid) | 874339-65-8 | Reference compound |
| HY-107101 | (5R)-5-Hydroxytriptolide | 583028-68-6 | Reference compound |
| HY-107111 | GSK1034702 | 932373-87-0 | Reference compound |
| HY-107111A | GSK1034702 (hydrochloride) | 932373-86-9 | Reference compound |
| HY-107116 | MAP4343 | 511-26-2 | Reference compound |
| HY-107116S | MAP4343-d4 | | Isotope-Labeled Compounds |
| HY-10711A | ALX-5407 (hydrochloride) | 200006-08-2 | Reference compound |
| HY-10712 | Org-24598 | 372198-97-5 | Reference compound |
| HY-107123 | TMC310911 | 1000287-05-7 | Reference compound |
| HY-107124 | BMS-770767 | 1875067-34-7 | Reference compound |
| HY-107125 | AVN-322 | 1194574-68-9 | Reference compound |
| HY-107125A | AVN-322 (free base) | 1194574-33-8 | Reference compound |
| HY-107126 | Ibrexafungerp | 1207753-03-4 | Reference compound |
| HY-107126A | Ibrexafungerp (citrate) | 1965291-08-0 | Reference compound |
| HY-107126B | Ibrexafungerp (phosphate) | 1965291-14-8 | Reference compound |
| HY-107128 | Ampreloxetine (hydrochloride) | 1227056-87-2 | Reference compound |
| HY-107129 | MK-3577 | 1019112-29-8 | Reference compound |
| HY-10713 | Org-24598 (lithium) | 722456-08-8 | Reference compound |
| HY-107130 | Alirinetide | 725715-18-4 | Peptides |
| HY-107133 | Simmitecan (hydrochloride) | 1247847-78-4 | Reference compound |
| HY-107139 | JNJ-10229570 | 524923-88-4 | Reference compound |
| HY-107145 | Ningetinib Tosylate | 1394820-77-9 | Reference compound |
| HY-107145A | Ningetinib | 1394820-69-9 | Reference compound |
| HY-107146 | PZ-128 | 371131-16-7 | Reference compound |
| HY-10715 | SSR504734 | 615571-23-8 | Reference compound |
| HY-107150 | Reproxalap | 916056-79-6 | Reference compound |
| HY-107151 | ABP-700 | 1446482-29-6 | Reference compound |
| HY-10716 | PF-03463275 (hydrochloride) | 1173177-11-1 | Reference compound |
| HY-107164 | Thiomarinol A | 146697-04-3 | Natural Products |
| HY-10716A | PF-03463275 | 1173239-39-8 | Reference compound |
| HY-107176A | Hyzetimibe | 1266548-74-6 | Reference compound |
| HY-107186 | EO-122 | 23581-62-6 | Reference compound |
| HY-107191 | Sildenafil (Mesylate) | 1308285-21-3 | Reference compound |
| HY-107193 | Bacitracin | 1405-87-4 | Natural Products |
| HY-107194 | NSC12 | 102586-30-1 | Reference compound |
| HY-107197 | 8-Prenylchrysin | 34125-75-2 | Reference compound |
| HY-107198 | (2S)-6-Prenylnaringenin | 68236-13-5 | Natural Products |
| HY-107199 | N-Butylthiophosphoric triamide | 94317-64-3 | Reference compound |
| HY-107201 | β-Cyclodextrin | 7585-39-9 | Natural Products |
| HY-107201A | β-Cyclodextrin (hydrate) | 68168-23-0 | Reference compound |
| HY-107202 | Polyinosinic-polycytidylic acid | 24939-03-5 | Reference compound |
| HY-107202A | Poly (I:C):Kanamycin (1:1) | | Reference compound |
| HY-107203 | Propentofylline | 55242-55-2 | Reference compound |
| HY-107204 | Furafylline | 80288-49-9 | Reference compound |
| HY-107204R | Furafylline (Standard) | 80288-49-9 | Reference Standards |
| HY-107205 | Propargyl methacrylate | 13861-22-8 | Reference compound |
| HY-107207 | Kaempferol 3-neohesperidoside | 32602-81-6 | Natural Products |
| HY-107207R | Kaempferol 3-neohesperidoside (Standard) | 32602-81-6 | Reference Standards |
| HY-107208 | Procyanidol B4 | 29106-51-2 | Natural Products |
| HY-107208R | Procyanidol B4 (Standard) | 29106-51-2 | Reference Standards |
| HY-107209 | RKI-1313 | 1342276-76-9 | Reference compound |
| HY-10721 | PF-AKT400 | 1004990-28-6 | Reference compound |
| HY-107210 | Avenasterol | 23290-26-8 | Natural Products |
| HY-107211 | Echinocandin B nucleus | 79411-15-7 | Natural Products |
| HY-107212 | Selamectin | 220119-17-5 | Reference compound |
| HY-107212R | Selamectin (Standard) | 220119-17-5 | Reference Standards |
| HY-107213 | Tulathromycin B | 280755-12-6 | Reference compound |
| HY-107216 | G-1 | 881639-98-1 | Reference compound |
| HY-107217 | Apo-12'-lycopenal | 1071-52-9 | Natural Products |
| HY-107218 | 11-Hydroxysugiol | 88664-08-8 | Natural Products |
| HY-107219 | Jatropholone B | 71386-38-4 | Reference compound |
| HY-10722 | DX-9065a | 155204-81-2 | Reference compound |
| HY-107224 | Levatin | 140670-84-4 | Natural Products |
| HY-107225 | Croverin | 76475-17-7 | Natural Products |
| HY-107226 | Crovatin | 142409-09-4 | Natural Products |
| HY-107227 | 12-O-Tiglylphorbol-13-isobutyrate | 92214-54-5 | Natural Products |
| HY-107231 | Xanthiside | 866366-86-1 | Natural Products |
| HY-107232 | Xanthiazone | 212701-97-8 | Natural Products |
| HY-107233 | Saponin CP4 | 75799-18-7 | Natural Products |
| HY-107235 | Saponin CP6 | 72629-76-6 | Natural Products |
| HY-107236 | Huzhangoside D | 96315-53-6 | Natural Products |
| HY-107237 | Broussonetine A | 173220-07-0 | Natural Products |
| HY-107238 | (3β,24R)-3-(Acetyloxy)eupha-7,25-dien-24-ol | 1352001-09-2 | Natural Products |
| HY-10724 | Fidexaban | 183305-24-0 | Reference compound |
| HY-107242 | Raddeanoside R8 | 124961-61-1 | Natural Products |
| HY-107245 | Segetalin B | 164991-89-3 | Natural Products |
| HY-107246 | Segetalin A | 161875-97-4 | Natural Products |
| HY-107247 | Escin IIb | 158800-83-0 | Natural Products |
| HY-107248 | Escin IIa | 158732-55-9 | Natural Products |
| HY-10725 | Tanogitran | 637328-69-9 | Reference compound |
| HY-107256 | Eupalinilide D | 757202-14-5 | Natural Products |
| HY-107257 | Eupalinilide C | 757202-11-2 | Natural Products |
| HY-107259 | 23S-Hydroxyl-11,15-dioxo-ganoderic acid DM | 1085273-49-9 | Natural Products |
| HY-107260 | Lucidenic acid D | 98665-16-8 | Natural Products |
| HY-107265 | Lucidenic acid E | 98665-17-9 | Natural Products |
| HY-107271 | Imperialine 3-β-D-glucoside | 67968-40-5 | Natural Products |
| HY-107273 | Delavinone | 96997-98-7 | Natural Products |
| HY-107275 | Ebeiedinone | 25650-68-4 | Natural Products |
| HY-107276 | Yubeinine | 157478-01-8 | Natural Products |
| HY-107277 | Hapepunine | 68422-01-5 | Natural Products |
| HY-107284 | Officinalisinin I | 57944-18-0 | Natural Products |
| HY-107295 | Trichilinin B | 117842-13-4 | Natural Products |
| HY-107296 | 1-Acetyltrichilinin | 117842-14-5 | Natural Products |
| HY-107300 | Dehydrosoyasaponin I methyl ester | 117210-13-6 | Natural Products |
| HY-107301 | Dehydrosoyasaponin I | 117210-14-7 | Natural Products |
| HY-107302 | Sandosaponin A | 135272-91-2 | Natural Products |
| HY-107305 | Isosalvianolic acid B | 930573-88-9 | Natural Products |
| HY-107306 | Glycoside O-4 | 94898-61-0 | Natural Products |
| HY-107307 | Ophiopojaponin A | 313054-32-9 | Natural Products |
| HY-107309 | Scabioside C | 17233-22-6 | Natural Products |
| HY-107310 | Cussosaponin C | 366814-42-8 | Natural Products |
| HY-107311 | Hederacholchiside E | 33783-82-3 | Natural Products |
| HY-107313 | Macranthoside A | 128730-82-5 | Natural Products |
| HY-107314 | Pulchinenoside B | 135247-95-9 | Natural Products |
| HY-107315 | Alisol F 24-acetate | 443683-76-9 | Natural Products |
| HY-107318 | Alacepril | 74258-86-9 | Reference compound |
| HY-107319 | Almitrine mesylate | 29608-49-9 | Reference compound |
| HY-107320 | Amtolmetin guacil | 87344-06-7 | Reference compound |
| HY-107321 | Azosemide | 27589-33-9 | Reference compound |
| HY-107322 | Barnidipine (hydrochloride) | 104757-53-1 | Reference compound |
| HY-107322A | Barnidipine | 104713-75-9 | Reference compound |
| HY-107322AS1 | Barnidipine-d5 | 2771469-19-1 | Isotope-Labeled Compounds |
| HY-107322S | Barnidipine-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-107323 | Bentazepam | 29462-18-8 | Reference compound |
| HY-107323A | Bentazepam (hydrochloride) | 29462-19-9 | Reference compound |
| HY-107324 | β-Elemene | 515-13-9 | Natural Products |
| HY-107324R | β-Elemene (Standard) | 515-13-9 | Reference Standards |
| HY-107326 | Bunazosin | 80755-51-7 | Reference compound |
| HY-107326A | Bunazosin (hydrochloride) | 52712-76-2 | Reference compound |
| HY-107327 | Carazolol | 57775-29-8 | Reference compound |
| HY-107327R | Carazolol (Standard) | 57775-29-8 | Reference Standards |
| HY-107327S | Carazolol-d7 | 1173021-02-7 | Isotope-Labeled Compounds |
| HY-107327S1 | Carazolol-d7 (hydrochloride) | 1276197-44-4 | Isotope-Labeled Compounds |
| HY-107328 | Carumonam (disodium) | 86832-68-0 | Reference compound |
| HY-107329 | Cefathiamidine | 33075-00-2 | Reference compound |
| HY-107329R | Cefathiamidine (Standard) | 33075-00-2 | Reference Standards |
| HY-107330 | (6R,7S)-Cefminox (sodium heptahydrate) | 92636-39-0 | Reference compound |
| HY-107330R | (6R,7S)-Cefminox (sodium heptahydrate) (Standard) | 92636-39-0 | Reference Standards |
| HY-107333 | Cinoxate | 104-28-9 | Reference compound |
| HY-107333S | Cinoxate-d3 | | Isotope-Labeled Compounds |
| HY-107335 | Aplodan | 6903-79-3 | Reference compound |
| HY-107336 | Cyclovalone | 579-23-7 | Reference compound |
| HY-107337 | Delapril (hydrochloride) | 83435-67-0 | Reference compound |
| HY-107337S | Delapril-d3 (hydrochloride) | 2714473-25-1 | Isotope-Labeled Compounds |
| HY-107338 | Denotivir | 51287-57-1 | Reference compound |
| HY-107339 | Deserpidine | 131-01-1 | Natural Products |
| HY-107339A | Deserpidine (hydrochloride) | 6033-69-8 | Reference compound |
| HY-107339R | Deserpidine (Standard) | 131-01-1 | Reference Standards |
| HY-107340 | Diftalone | 21626-89-1 | Reference compound |
| HY-107343 | Docosahexaenoic acid ethyl ester | 81926-94-5 | Reference compound |
| HY-107343R | Docosahexaenoic acid ethyl ester (Standard) | 81926-94-5 | Reference Standards |
| HY-107343S | Docosahexaenoic acid ethyl ester-d5 | 2692624-15-8 | Isotope-Labeled Compounds |
| HY-107343S1 | Docosahexaenoic acid ethyl ester-d5-1 | 159146-01-7 | Isotope-Labeled Compounds |
| HY-107345 | Droxicam | 90101-16-9 | Reference compound |
| HY-107346 | Enbucrilate | 6606-65-1 | Biochemical Assay Reagents |
| HY-107348 | Etofylline clofibrate | 54504-70-0 | Reference compound |
| HY-107349 | Fenoverine | 37561-27-6 | Reference compound |
| HY-107349R | Fenoverine (Standard) | 37561-27-6 | Reference Standards |
| HY-107349S | Fenoverine-d8 | | Isotope-Labeled Compounds |
| HY-107351 | Fluorocholine (chloride) | 459424-38-5 | Biochemical Assay Reagents |
| HY-107352 | Fosfenopril | 95399-71-6 | Reference compound |
| HY-107352R | Fosfenopril (Standard) | 95399-71-6 | Reference Standards |
| HY-107352S | Fosfenopril-d7 | 1279220-43-7 | Isotope-Labeled Compounds |
| HY-107353 | Gadopentetic acid | 80529-93-7 | Reference compound |
| HY-107353R | Gadopentetic acid (Standard) | 80529-93-7 | Reference Standards |
| HY-107354 | Gepefrine | 18840-47-6 | Reference compound |
| HY-107355 | Letosteine | 53943-88-7 | Reference compound |
| HY-107358 | Lidamidine | 66871-56-5 | Reference compound |
| HY-107358A | Lidamidine (hydrochloride) | 65009-35-0 | Reference compound |
| HY-107360 | Lobenzarit (disodium) | 64808-48-6 | Reference compound |
| HY-107361 | Golidocitinib | 2091134-68-6 | Reference compound |
| HY-107362 | CH7057288 | 2095616-82-1 | Reference compound |
| HY-107363 | FT-1518 | 1313026-58-2 | Reference compound |
| HY-107364 | MTX-211 | 1952236-05-3 | Reference compound |
| HY-107365 | PQR530 | 1927857-61-1 | Reference compound |
| HY-107366 | SGN-2FF | 2089647-47-0 | Reference compound |
| HY-107367 | Epertinib | 908305-13-5 | Reference compound |
| HY-107367A | Epertinib (hydrochloride) | 2071195-74-7 | Reference compound |
| HY-107368 | Sulcotrione | 99105-77-8 | Reference compound |
| HY-107368R | Sulcotrione (Standard) | 99105-77-8 | Reference Standards |
| HY-107369 | 4-Butylresorcinol | 18979-61-8 | Reference compound |
| HY-107369R | 4-Butylresorcinol (Standard) | 18979-61-8 | Reference Standards |
| HY-107370 | Atomoxetine | 83015-26-3 | Reference compound |
| HY-107370AS | (Rac)-Atomoxetine-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-107370AS1 | (Rac)-Atomoxetine-d5 (hydrochloride) | 1398065-95-6 | Isotope-Labeled Compounds |
| HY-107370S | Atomoxetine-d7 | 919104-07-7 | Isotope-Labeled Compounds |
| HY-107370S1 | Atomoxetine-d5 | 1129478-03-0 | Isotope-Labeled Compounds |
| HY-107371 | 6-Bromo-2-hydroxy-3-methoxybenzaldehyde | 20035-41-0 | Reference compound |
| HY-107372 | Uridine triphosphate | 63-39-8 | Natural Products |
| HY-107372A | Uridine triphosphate (trisodium dihydrate) | 116295-90-0 | Biochemical Assay Reagents |
| HY-107372S | Uridine triphosphate-13C9,15N2 (sodium) | 285978-18-9 | Isotope-Labeled Compounds |
| HY-107372S2 | Uridine triphosphate-13C9 (dilithium) | | Isotope-Labeled Compounds |
| HY-107372S3 | Uridine triphosphate-d13 (dilithium) | | Isotope-Labeled Compounds |
| HY-107372S4 | Uridine triphosphate-15N2 (dilithium) | | Isotope-Labeled Compounds |
| HY-107373 | β-Chloro-L-alanine | 2731-73-9 | Reference compound |
| HY-107373A | 3-Chloro-L-alanine Hydrochloride | 51887-89-9 | Reference compound |
| HY-107377 | Benzo[a]pyrene | 50-32-8 | Natural Products |
| HY-107377R | Benzo[a]pyrene (Standard) | 50-32-8 | Reference Standards |
| HY-107377S | Benzo[a]pyrene-d12 | 63466-71-7 | Isotope-Labeled Compounds |
| HY-107378 | L-Valyl-L-phenylalanine | 3918-92-1 | Reference compound |
| HY-107379 | AKR1C3-IN-1 | 327092-81-9 | Reference compound |
| HY-107380A | PGlu-3-methyl-His-Pro-NH2 (TFA) | | Peptides |
| HY-107381 | (+)-Cloprostenol | 54276-21-0 | Reference compound |
| HY-107381A | (+)-Cloprostenol (sodium) | 62561-03-9 | Reference compound |
| HY-107381R | (+)-Cloprostenol (Standard) | 54276-21-0 | Reference Standards |
| HY-107382 | RF9 | 876310-60-0 | Reference compound |
| HY-107382A | RF9 (hydrochloride) | | Reference compound |
| HY-107383 | Tetrahydrobiopterin | 17528-72-2 | Natural Products |
| HY-107384 | Asimadoline | 153205-46-0 | Reference compound |
| HY-107384A | Asimadoline (hydrochloride) | 185951-07-9 | Reference compound |
| HY-107385 | Epristeride | 119169-78-7 | Reference compound |
| HY-107385R | Epristeride (Standard) | 119169-78-7 | Reference Standards |
| HY-107390 | AX-024 | 1370544-73-2 | Reference compound |
| HY-107390A | AX-024 (hydrochloride) | 1704801-24-0 | Reference compound |
| HY-107393 | LY-311727 | 164083-84-5 | Reference compound |
| HY-107394 | UK 356618 | 230961-08-7 | Reference compound |
| HY-107395 | BMS 753 | 215307-86-1 | Reference compound |
| HY-107396 | YM-750 | 138046-43-2 | Reference compound |
| HY-107397 | Ch55 | 110368-33-7 | Reference compound |
| HY-107398 | 1-(2,3-Dichlorophenyl)ethanamine (hydrochloride) | 39959-66-5 | Reference compound |
| HY-107399 | CD3254 | 196961-43-0 | Reference compound |
| HY-107400 | B I09 | 1607803-67-7 | Reference compound |
| HY-107404 | SID 7969543 | 868224-64-0 | Reference compound |
| HY-107405 | TC-N 1752 | 1211866-85-1 | Reference compound |
| HY-107405S | TC-N 1752-d5 | | Isotope-Labeled Compounds |
| HY-107407 | SB-218078 | 135897-06-2 | Reference compound |
| HY-107408 | SANT 2 | 329196-48-7 | Reference compound |
| HY-107409 | GNE 5729 | 2026635-66-3 | Reference compound |
| HY-107409B | (S,S)-GNE 5729 | 2026636-06-4 | Reference compound |
| HY-107410 | SC-26196 | 218136-59-5 | Reference compound |
| HY-107411 | Bromoenol lactone | 88070-98-8 | Reference compound |
| HY-107412 | Proteasome inhibitor IX | 856849-35-9 | Reference compound |
| HY-107413 | SR11237 | 146670-40-8 | Reference compound |
| HY-107414 | SKA-121 | 1820708-73-3 | Reference compound |
| HY-107415 | PLX7922 | 1638772-61-8 | Reference compound |
| HY-107416 | RHC 80267 | 83654-05-1 | Reference compound |
| HY-107417 | Hypothemycin | 76958-67-3 | Natural Products |
| HY-107418 | Tropifexor | 1383816-29-2 | Reference compound |
| HY-107419 | NU6140 | 444723-13-1 | Reference compound |
| HY-107420 | AY 9944 | 366-93-8 | Reference compound |
| HY-107421 | Prostratin | 60857-08-1 | Natural Products |
| HY-107422 | Lenumlostat | 2007885-39-2 | Reference compound |
| HY-107422A | Lenumlostat (hydrochloride) | 2098884-53-6 | Reference compound |
| HY-107423 | GNE 6901 | 1698900-69-4 | Reference compound |
| HY-107424 | BAY-299 | 2080306-23-4 | Reference compound |
| HY-107425 | MZ 1 | 1797406-69-9 | Reference compound |
| HY-107425A | cis-MZ 1 | 1797406-72-4 | Reference compound |
| HY-107425B | cis-MZ 1 (hydrate) | | Reference compound |
| HY-107426 | Verrucarin A | 3148-09-2 | Reference compound |
| HY-107427 | PF-3644022 | 1276121-88-0 | Reference compound |
| HY-107428 | PD-166793 | 199850-67-4 | Reference compound |
| HY-107429 | Abrocitinib | 1622902-68-4 | Reference compound |
| HY-107429R | Abrocitinib (Standard) | 1622902-68-4 | Reference Standards |
| HY-107430 | Oxythiamine | 136-16-3 | Reference compound |
| HY-107430A | Oxythiamine (chloride hydrochloride) | 614-05-1 | Reference compound |
| HY-107430B | Oxythiamine (chloride) | 582-36-5 | Reference compound |
| HY-107430R | Oxythiamine (Standard) | 136-16-3 | Reference Standards |
| HY-107431 | Diphenylpyraline | 147-20-6 | Reference compound |
| HY-107431R | Diphenylpyraline (Standard) | 147-20-6 | Reference Standards |
| HY-107433 | U18666A | 3039-71-2 | Reference compound |
| HY-107434 | Molindone | 7416-34-4 | Reference compound |
| HY-107434S | Molindone-d8 | 1189805-13-7 | Isotope-Labeled Compounds |
| HY-107436 | LE135 | 155877-83-1 | Reference compound |
| HY-107437 | CD2665 | 170355-78-9 | Reference compound |
| HY-107438 | Thalidomide-O-amido-C4-NH2 | 1799711-24-2 | Reference compound |
| HY-107438A | Thalidomide-O-amido-C4-NH2 (hydrochloride) | 2245697-86-1 | Reference compound |
| HY-107439 | Thalidomide-O-amido-C8-NH2 | 1950635-15-0 | Reference compound |
| HY-107439A | Thalidomide-O-amido-C8-NH2 (hydrochloride) | 2415263-07-7 | Reference compound |
| HY-107440 | Thalidomide-O-amido-PEG3-C2-NH2 | 1957236-20-2 | Reference compound |
| HY-107440A | Thalidomide-O-amido-PEG3-C2-NH2 (hydrochloride) | 2245697-84-9 | Reference compound |
| HY-107442 | PROTAC BRD4-binding moiety 1 | 2101200-10-4 | Reference compound |
| HY-107443 | I-BET762 carboxylic acid | 1300019-38-8 | Reference compound |
| HY-107443A | (R)-I-BET762 carboxylic acid | 1786401-70-4 | Reference compound |
| HY-107444 | PROTAC Her3-binding moiety 1 | 1603845-36-8 | Reference compound |
| HY-107445 | PROTAC BRD9-binding moiety 1 | 2097512-23-5 | Reference compound |
| HY-107445A | PROTAC BRD9-binding moiety 1 (hydrochloride) | 2448414-41-1 | Reference compound |
| HY-107447 | N-Deshydroxyethyl Dasatinib | 910297-51-7 | Reference compound |
| HY-107447R | N-Deshydroxyethyl Dasatinib (Standard) | 910297-51-7 | Reference Standards |
| HY-107447S | N-Deshydroxyethyl Dasatinib-d8 | 1189998-96-6 | Isotope-Labeled Compounds |
| HY-107451 | PROTAC BET-binding moiety 1 | 2093387-77-8 | Reference compound |
| HY-107452 | SLF-amido-C2-COOH | 1092369-24-8 | Reference compound |
| HY-107453 | SirReal1-O-propargyl | 1862237-99-7 | Reference compound |
| HY-107454 | OSS_128167 | 887686-02-4 | Reference compound |
| HY-107455 | A-485 | 1889279-16-6 | Reference compound |
| HY-107456 | E6130 | 1427058-33-0 | Reference compound |
| HY-107457 | AZD-8529 | 1092453-15-0 | Reference compound |
| HY-107457A | AZD-8529 (mesylate) | 1314217-69-0 | Reference compound |
| HY-107458 | AP23848 | 834894-21-2 | Reference compound |
| HY-107459 | (E/Z)-AG490 | 134036-52-5 | Reference compound |
| HY-107460 | LDN-211904 (oxalate) | 1198408-78-4 | Reference compound |
| HY-107461 | LY2623091 | 1162264-07-4 | Reference compound |
| HY-107462 | 17α-Hydroxydigitoxigenin | 26629-41-4 | Reference compound |
| HY-107466 | WK298 | 1067654-70-9 | Reference compound |
| HY-107468 | PL-100 | 612547-11-2 | Reference compound |
| HY-107469 | Pyridoxal | 66-72-8 | Natural Products |
| HY-107469R | Pyridoxal (Standard) | 66-72-8 | Reference Standards |
| HY-107469S | Pyridoxal-d3 (hydrochloride) | 1173023-49-8 | Isotope-Labeled Compounds |
| HY-107469S1 | Pyridoxal-d3 | 1173148-04-3 | Isotope-Labeled Compounds |
| HY-107470 | Antitumor agent-21 | 1256037-58-7 | Reference compound |
| HY-107471 | CB2 receptor agonist 3 | 919077-81-9 | Reference compound |
| HY-107477 | GSK8573 | 1693766-04-9 | Reference compound |
| HY-107479 | (R)-JNJ-31020028 | 1094873-17-2 | Reference compound |
| HY-107480 | YK11 | 1370003-76-1 | Reference compound |
| HY-107480R | YK11 (Standard) | 1370003-76-1 | Reference Standards |
| HY-107481 | Fasoracetam | 110958-19-5 | Reference compound |
| HY-107482 | Picamilon | 34562-97-5 | Reference compound |
| HY-107482A | Picamilon (sodium) | 62936-56-5 | Reference compound |
| HY-107483 | Cambendazole | 26097-80-3 | Reference compound |
| HY-107483R | Cambendazole (Standard) | 26097-80-3 | Reference Standards |
| HY-107483S | Cambendazole-d7 | 1228182-48-6 | Isotope-Labeled Compounds |
| HY-107485 | HIV-1 integrase inhibitor 8 | 1568-80-5 | Reference compound |
| HY-107486 | Nosiheptide | 56377-79-8 | Natural Products |
| HY-107486R | Nosiheptide (Standard) | 56377-79-8 | Reference Standards |
| HY-107489 | RO 4938581 | 883093-10-5 | Reference compound |
| HY-107492 | Ethaboxam | 162650-77-3 | Reference compound |
| HY-107494 | 13-cis-4-Oxoretinoic acid | 71748-58-8 | Reference compound |
| HY-107494A | all-trans-4-Oxoretinoic acid | 38030-57-8 | Natural Products |
| HY-107494AR | all-trans-4-Oxoretinoic acid (Standard) | 38030-57-8 | Reference Standards |
| HY-107494S2 | 4-Oxoretinoic acid-d3 | 1346606-26-5 | Isotope-Labeled Compounds |
| HY-107495 | Betahistine EP Impurity C | 5452-87-9 | Reference compound |
| HY-107496 | Imidocarb (dipropionate) | 55750-06-6 | Reference compound |
| HY-107496R | Imidocarb (dipropionate) (Standard) | 55750-06-6 | Reference Standards |
| HY-107497 | 1-Methyl-3-amino-4-cyanopyrazole | 21230-50-2 | Reference compound |
| HY-107498 | GNE-8324 | 1698901-76-6 | Reference compound |
| HY-107500 | UVI 3003 | 847239-17-2 | Reference compound |
| HY-107501 | (Rac)-1-Oleoyl lysophosphatidic acid (sodium) | 22556-62-3 | Reference compound |
| HY-107502 | Cryptophycin analog 1 | 1260431-28-4 | Reference compound |
| HY-107503 | MMPIP | 479077-02-6 | Reference compound |
| HY-107504 | VU0360172 (hydrochloride) | 1309976-62-2 | Reference compound |
| HY-107505 | CBiPES (hydrochloride) | 856702-40-4 | Reference compound |
| HY-107505A | CBiPES | 353235-01-5 | Reference compound |
| HY-107506 | Ro 67-4853 | 302841-89-0 | Reference compound |
| HY-107507 | Ro 01-6128 | 302841-86-7 | Reference compound |
| HY-107508 | VU-29 | 890764-36-0 | Reference compound |
| HY-107509 | LY2389575 (hydrochloride) | 885104-09-6 | Reference compound |
| HY-107510 | YM-230888 | 446257-23-4 | Reference compound |
| HY-107512 | Kynurenic acid (sodium) | 2439-02-3 | Reference compound |
| HY-107513 | BAY 36-7620 | 232605-26-4 | Reference compound |
| HY-107514 | (RS)-PPG | 120667-15-4 | Reference compound |
| HY-107515 | LY367385 | 198419-91-9 | Reference compound |
| HY-107515A | LY367385 (hydrochloride) | 2829282-00-8 | Reference compound |
| HY-107516 | (S)-3,4-DCPG | 201730-11-2 | Reference compound |
| HY-107517 | UBP 1112 | 339526-74-8 | Reference compound |
| HY-107518 | (R,S)-3,4-Dicarboxyphenylglycine | 176796-64-8 | Reference compound |
| HY-107519 | (R)-3,4-DCPG | 201730-10-1 | Reference compound |
| HY-107520 | MNI-caged-L-glutamate | 295325-62-1 | Reference compound |
| HY-107520A | MNI-caged-L-glutamate (TFA) | 2226362-29-2 | Reference compound |
| HY-107521 | TFB-TBOA | 480439-73-4 | Reference compound |
| HY-107522 | DL-TBOA | 205309-81-5 | Reference compound |
| HY-107522B | DL-TBOA (ammonium) | 2093503-71-8 | Reference compound |
| HY-107523 | WAY-213613 | 868359-05-1 | Reference compound |
| HY-107523A | WAY-213613 (hydrochloride) | 2450268-84-3 | Reference compound |
| HY-107524 | (±)-HIP-B | 227619-65-0 | Reference compound |
| HY-107525 | (±)-HIP-A | 227619-64-9 | Reference compound |
| HY-107526 | (Rac)-ALX 5407 | 405225-21-0 | Reference compound |
| HY-107527 | Org 25543 (hydrochloride) | 495076-64-7 | Reference compound |
| HY-107527A | Org 25543 | 363628-88-0 | Reference compound |
| HY-107528 | FRATtide | 251087-38-4 | Reference compound |
| HY-107529 | TC-G 24 | 1257256-44-2 | Reference compound |
| HY-107530 | 3F8 | 159109-11-2 | Reference compound |
| HY-107531 | A 1070722 | 1384424-80-9 | Reference compound |
| HY-107532 | N-Nonyldeoxynojirimycin | 81117-35-3 | Peptides |
| HY-107533 | T-98475 | 199119-18-1 | Reference compound |
| HY-107534 | AG-045572 | 263847-55-8 | Reference compound |
| HY-107535 | AS1269574 | 330981-72-1 | Reference compound |
| HY-107536 | ML 145 | 1164500-72-4 | Reference compound |
| HY-107537 | CID 2745687 | 264233-05-8 | Reference compound |
| HY-107538 | YE120 | 383124-82-1 | Reference compound |
| HY-107539 | GPR35 agonist 4 | 871085-49-3 | Reference compound |
| HY-107541 | O-1602 | 317321-41-8 | Reference compound |
| HY-107541R | O-1602 (Standard) | 317321-41-8 | Reference Standards |
| HY-107542 | Oleoylethanolamide | 111-58-0 | Natural Products |
| HY-107542R | Oleoylethanolamide (Standard) | 111-58-0 | Reference Standards |
| HY-107542S | Oleoylethanolamide-d4 | 946524-36-3 | Isotope-Labeled Compounds |
| HY-107542S2 | Oleoylethanolamide-d2 | 1245477-09-1 | Isotope-Labeled Compounds |
| HY-107543 | 8-CPT-2Me-cAMP (sodium) | 634207-53-7 | Reference compound |
| HY-107544 | 8-pCPT-2'-O-Me-cAMP-AM | 1152197-23-3 | Reference compound |
| HY-107545 | Dynole 34-2 | 1128165-88-7 | Reference compound |
| HY-107546 | CFM 1571 (hydrochloride) | 1215548-30-3 | Reference compound |
| HY-107547 | BPIPP | 325746-94-9 | Reference compound |
| HY-107548 | A-350619 (hydrochloride) | 1217201-17-6 | Reference compound |
| HY-107549 | KD 5170 | 940943-37-3 | Reference compound |
| HY-107550 | HDAC6-IN-7 | 956154-63-5 | Reference compound |
| HY-107551 | GLI antagonist-1 | 599150-20-6 | Reference compound |
| HY-107553 | Chetomin | 1403-36-7 | Reference compound |
| HY-107554 | Methimepip (dihydrobromide) | 817636-54-7 | Reference compound |
| HY-107555 | VUF 8430 (dihydrobromide) | 100130-32-3 | Reference compound |
| HY-107556 | VUF 5681 (dihydrobromide) | 639089-06-8 | Reference compound |
| HY-107557 | Proxyfan | 177708-09-7 | Reference compound |
| HY-107557A | Proxyfan (Oxalate) | 1620017-81-3 | Reference compound |
| HY-107558 | JNJ10191584 (maleate) | 869497-75-6 | Reference compound |
| HY-107559 | GT-2016 | 152241-24-2 | Reference compound |
| HY-10756 | BMS-740808 | 280118-23-2 | Reference compound |
| HY-107560 | 4-Methylhistamine (dihydrochloride) | 36376-47-3 | Reference compound |
| HY-107561 | A-943931 (hydrochloride) | 1227675-50-4 | Reference compound |
| HY-107562 | JNJ 10181457 dihydrochloride | 544707-20-2 | Reference compound |
| HY-107562A | JNJ-10181457 | 544707-19-9 | Reference compound |
| HY-107563 | ROS 234 | 184576-87-2 | Reference compound |
| HY-107563A | ROS 234 (dioxalate) | 1781941-93-2 | Reference compound |
| HY-107564 | Impentamine (dihydrobromide) | 149629-70-9 | Reference compound |
| HY-107565 | 2-Pyridylethylamine (hydrochloride) | 3343-39-3 | Reference compound |
| HY-107566 | Conessine | 546-06-5 | Natural Products |
| HY-107566A | Conessine (dihydrobromide) | 5913-82-6 | Natural Products |
| HY-107567 | Carcinine | 56897-53-1 | Reference compound |
| HY-107567B | Carcinine (dihydrochloride) | 57022-38-5 | Reference compound |
| HY-107568 | Iodophenpropit (dihydrobromide) | 145196-87-8 | Reference compound |
| HY-107569 | Garcinol | 78824-30-3 | Natural Products |
| HY-107570 | IWP-12 | 688353-45-9 | Reference compound |
| HY-107571 | VULM 1457 | 228544-65-8 | Reference compound |
| HY-107572 | PD 128042 | 114289-47-3 | Reference compound |
| HY-107573 | KDM2/7-IN-1 | 1453071-47-0 | Reference compound |
| HY-107574 | TC-E 5003 | 17328-16-4 | Reference compound |
| HY-107575 | TLR4-IN-C34 | 40592-88-9 | Reference compound |
| HY-107577 | Gedunin | 2753-30-2 | Natural Products |
| HY-107578 | Macbecin | 73341-72-7 | Reference compound |
| HY-107579 | Acifran | 72420-38-3 | Reference compound |
| HY-107579R | Acifran (Standard) | 72420-38-3 | Reference Standards |
| HY-10758 | FXa-IN-1 | 441328-10-5 | Reference compound |
| HY-107580 | GPR109 receptor agonist-1 | 306935-41-1 | Reference compound |
| HY-107581 | MK-1903 | 1268882-43-4 | Reference compound |
| HY-107582 | JW480 | 1354359-53-7 | Reference compound |
| HY-107584 | BYK 191023 (dihydrochloride) | 1216722-25-6 | Reference compound |
| HY-107586 | Demethylasterriquinone B1 | 78860-34-1 | Natural Products |
| HY-107587 | A-286982 | 280749-17-9 | Reference compound |
| HY-107588 | TC-I 15 | 916734-43-5 | Reference compound |
| HY-107589 | BIO5192 | 327613-57-0 | Reference compound |
| HY-107589A | BIO5192 (hydrate) | | Reference compound |
| HY-107590 | GR144053 (trihydrochloride) | 1215333-48-4 | Reference compound |
| HY-107591 | (Rac)-PF-184 | 1187460-81-6 | Reference compound |
| HY-107591A | (Rac)-PF-184 (hydrate) | | Reference compound |
| HY-107591B | PF-184 | | Reference compound |
| HY-107592 | ACHP | 406208-42-2 | Reference compound |
| HY-107593 | PS-1145 (dihydrochloride) | 1049743-58-9 | Reference compound |
| HY-107594 | Benzene hexabromide | 1837-91-8 | Reference compound |
| HY-107595 | SD-1008 | 960201-81-4 | Reference compound |
| HY-107596 | SR-3576 | 1164153-22-3 | Reference compound |
| HY-107597 | Halicin | 40045-50-9 | Reference compound |
| HY-107598 | JNK Inhibitor VIII | 894804-07-0 | Reference compound |
| HY-107599 | AEG3482 | 63735-71-7 | Reference compound |
| HY-107600 | IQ-3 | 312538-03-7 | Reference compound |
| HY-107601 | UBP316 | 936095-50-0 | Reference compound |
| HY-107602 | UBP310 | 902464-46-4 | Reference compound |
| HY-107603 | NS3763 | 70553-45-6 | Reference compound |
| HY-107604 | UBP 302 | 745055-91-8 | Reference compound |
| HY-107605 | UBP296 | 745055-86-1 | Reference compound |
| HY-107606 | UBP301 | 569371-10-4 | Reference compound |
| HY-107606A | UBP301 (hydrochloride) | | Reference compound |
| HY-107607 | FPL-55712 (free base) | 40785-97-5 | Reference compound |
| HY-107607A | FPL-55712 | 40786-08-1 | Reference compound |
| HY-107608 | Leukotriene B4 | 71160-24-2 | Natural Products |
| HY-107608A | 5(S),12(S)-Leukotriene B4 | 79056-01-2 | Reference compound |
| HY-107608R | Leukotriene B4 (Standard) | 71160-24-2 | Reference Standards |
| HY-107608S | Leukotriene B4-d4 | 124629-74-9 | Isotope-Labeled Compounds |
| HY-107608S1 | Leukotriene B4-d5 | | Isotope-Labeled Compounds |
| HY-107609 | BAY-u 9773 | 154978-38-8 | Reference compound |
| HY-107610 | SR2640 (hydrochloride) | 146662-42-2 | Reference compound |
| HY-107611 | Ro 24-5913 | 128312-51-6 | Reference compound |
| HY-107612 | GPBAR-A | 877052-79-4 | Reference compound |
| HY-107613 | R 59-022 | 93076-89-2 | Reference compound |
| HY-107613A | R 59-022 (hydrochloride) | 93076-98-3 | Reference compound |
| HY-107614 | 1-Oleoyl lysophosphatidic acid (sodium) | 325465-93-8 | Reference compound |
| HY-107614G | 1-Oleoyl lysophosphatidic acid (sodium) (GMP) | 325465-93-8 | GMP Small Molecules |
| HY-107615 | TC LPA5 4 | 1393814-38-4 | Reference compound |
| HY-107616 | H2L5186303 | 139262-76-3 | Reference compound |
| HY-107617 | PTIQ | 1032822-42-6 | Reference compound |
| HY-107619 | PD-334581 | 548756-68-9 | Reference compound |
| HY-107620 | PD 198306 | 212631-61-3 | Reference compound |
| HY-107621 | U0124 | 108923-79-1 | Reference compound |
| HY-107622 | (E/Z)-BIX02188 | 1094614-84-2 | Reference compound |
| HY-107623 | TC-MCH 7c | 864756-35-4 | Reference compound |
| HY-107624 | ATC0175 | 510733-97-8 | Reference compound |
| HY-107625 | SNAP 94847 | 487051-12-7 | Reference compound |
| HY-107625A | SNAP 94847 (hydrochloride) | 1781934-47-1 | Reference compound |
| HY-107626 | ATC0065 | 510732-84-0 | Reference compound |
| HY-107626A | ATC0065 (free base) | 509145-82-8 | Reference compound |
| HY-107627 | MCL0020 | 475498-26-1 | Peptides |
| HY-107628 | N-Pentanoyl 2-benzyltryptamine | 220339-00-4 | Reference compound |
| HY-107629 | Flutax 1 | 191930-58-2 | Biochemical Assay Reagents |
| HY-107630 | RU 26752 | 76676-33-0 | Reference compound |
| HY-107631 | Oxprenoate (potassium) | 76676-34-1 | Reference compound |
| HY-107632 | GYY4137 | 106740-09-4 | Reference compound |
| HY-107632G | GYY4137 (GMP) | 106740-09-4 | GMP Small Molecules |
| HY-107633 | A 1120 | 1152782-19-8 | Reference compound |
| HY-107634 | CP-20961 | 35607-20-6 | Reference compound |
| HY-107635 | TMN355 | 1186372-20-2 | Reference compound |
| HY-107636 | DC_AC50 | 497061-48-0 | Reference compound |
| HY-107637 | ONO-4817 | 223472-31-9 | Reference compound |
| HY-107639 | UK-370106 | 230961-21-4 | Reference compound |
| HY-107640 | WAY-170523 | 307002-73-9 | Reference compound |
| HY-107641 | α-Cyano-4-hydroxycinnamic acid | 28166-41-8 | Reference compound |
| HY-107642 | MA-2029 | 287206-61-5 | Reference compound |
| HY-107643 | Reversan | 313397-13-6 | Reference compound |
| HY-107644 | AQ-RA 741 | 123548-16-3 | Reference compound |
| HY-107645 | DAU 5884 (hydrochloride) | 131780-48-8 | Reference compound |
| HY-107646 | PD 102807 | 23062-91-1 | Reference compound |
| HY-107647 | (S)-(+)-Dimethindene (maleate) | 136152-65-3 | Reference compound |
| HY-107647A | (R)-(+)-Dimethindene (maleate) | 136152-64-2 | Reference compound |
| HY-107648 | McN-A-343 | 55-45-8 | Reference compound |
| HY-107649 | Zamifenacin (fumarate) | 127308-98-9 | Reference compound |
| HY-107650 | Milameline (hydrochloride) | 139886-04-7 | Reference compound |
| HY-107650A | Milameline (hydroiodide) | | Reference compound |
| HY-107651 | VU 0365114 | 1208222-39-2 | Reference compound |
| HY-107652 | AF-DX 384 | 118290-26-9 | Reference compound |
| HY-107653 | J 104129 (fumarate) | 257603-40-0 | Reference compound |
| HY-107654 | Muscarine (iodide) | 24570-49-8 | Reference compound |
| HY-107654S | Muscarine-d9 (iodide) | | Isotope-Labeled Compounds |
| HY-107655 | Arecaidine but-2-ynyl ester (tosylate) | 119630-77-2 | Reference compound |
| HY-107656 | PTAC (oxalate) | 201939-40-4 | Reference compound |
| HY-107657 | (+)-Blebbistatin | 1177356-70-5 | Reference compound |
| HY-107658 | SN 6 | 415697-08-4 | Reference compound |
| HY-107659 | YM-244769 (hydrochloride) | 837424-39-2 | Reference compound |
| HY-107660 | SIRT2-IN-8 | 115687-05-3 | Reference compound |
| HY-107661 | Arundic Acid | 185517-21-9 | Reference compound |
| HY-107661A | S-(+)-Arundic Acid | 807363-10-6 | Reference compound |
| HY-107661R | Arundic Acid (Standard) | 185517-21-9 | Reference Standards |
| HY-107662 | TCS PrP Inhibitor 13 | 34320-83-7 | Reference compound |
| HY-107663 | MIF-1 | 2002-44-0 | Peptides |
| HY-107663A | MIF-1 (TFA) | 35240-69-8 | Peptides |
| HY-107664 | SR 142948 | 184162-64-9 | Reference compound |
| HY-107664A | SR 142948 (dihydrochloride) | | Reference compound |
| HY-107665 | Ro 106-9920 | 62645-28-7 | Peptides |
| HY-107666 | PHA 568487 | 527680-57-5 | Reference compound |
| HY-107667 | TC-2559 (fumarate) | 212332-35-9 | Reference compound |
| HY-107668 | TC-1698 (dihydrochloride) | 787587-06-8 | Reference compound |
| HY-107668A | TC-1698 | 700834-58-8 | Reference compound |
| HY-107669 | nAChR-IN-1 (hydrochloride) | 849461-91-2 | Reference compound |
| HY-107670 | Dihydro-β-erythroidine (hydrobromide) | 29734-68-7 | Natural Products |
| HY-107671 | DMAB-anabaseine (dihydrochloride) | 154149-38-9 | Reference compound |
| HY-107672 | MG624 | 77257-42-2 | Reference compound |
| HY-107673 | RJR-2429 (dihydrochloride) | 1021418-53-0 | Reference compound |
| HY-107674 | bPiDDB | 525596-66-1 | Reference compound |
| HY-107675 | Desformylflustrabromine hydrochloride | 951322-11-5 | Reference compound |
| HY-107676 | SIB-1553A | 191611-89-9 | Reference compound |
| HY-107676A | SIB-1553A (free base) | 191611-76-4 | Reference compound |
| HY-107677 | A 844606 | 861119-08-6 | Reference compound |
| HY-107678 | SEN12333 | 874450-44-9 | Reference compound |
| HY-107679 | SR 16584 | 1150153-86-8 | Reference compound |
| HY-107680 | 3-Pyr-Cytisine | 948027-43-8 | Reference compound |
| HY-107681 | SIB-1508Y | 192231-16-6 | Reference compound |
| HY-107682 | TQS | 353483-92-8 | Reference compound |
| HY-107683 | LY-2087101 | 913186-74-0 | Reference compound |
| HY-107684 | 3-Bromocytisine | 207390-14-5 | Reference compound |
| HY-107686 | 5-Iodo-A-85380 (dihydrochloride) | 1217837-17-6 | Reference compound |
| HY-107689 | RuBiNic | 1256362-30-7 | Reference compound |
| HY-107690 | DMPO | 3317-61-1 | Reference compound |
| HY-107691 | GR 159897 | 158848-32-9 | Reference compound |
| HY-107692 | SB 218795 | 174635-53-1 | Reference compound |
| HY-107693 | SSR 146977 (hydrochloride) | 264618-38-4 | Reference compound |
| HY-107694 | (Rac)-Dizocilpine | 70449-94-4 | Reference compound |
| HY-107695 | Remacemide (hydrochloride) | 111686-79-4 | Reference compound |
| HY-107696 | Ro 04-5595 (hydrochloride) | 64047-73-0 | Reference compound |
| HY-107697 | N20C (hydrochloride) | 1177583-87-7 | Reference compound |
| HY-107698 | PMPA (NMDA antagonist) | 113919-36-1 | Reference compound |
| HY-107699 | PPPA | 113190-92-4 | Reference compound |
| HY-107700 | Gavestinel (sodium salt) | 153436-38-5 | Reference compound |
| HY-107701 | CGP 78608 (hydrochloride) | 1135278-54-4 | Reference compound |
| HY-107701A | CGP-78608 | 206648-13-7 | Reference compound |
| HY-107702 | CGP 37849 | 127910-31-0 | Reference compound |
| HY-107703 | CGP 39551 | 127910-32-1 | Reference compound |
| HY-107704 | SDZ 220-040 | 174575-40-7 | Reference compound |
| HY-107705 | NMDAR antagonist 4 | 132623-44-0 | Reference compound |
| HY-107706 | Co 101244 (hydrochloride) | 193356-17-1 | Reference compound |
| HY-107707 | TCS 46b | 302799-86-6 | Reference compound |
| HY-107708 | threo-Ifenprodil (hemitartrate) | 1312991-83-5 | Reference compound |
| HY-107709 | MK-4074 | 1039758-22-9 | Reference compound |
| HY-107710 | LY 233053 | 125546-04-5 | Reference compound |
| HY-107711 | DQP-1105 | 380560-89-4 | Reference compound |
| HY-107712 | TCN 213 | 556803-08-8 | Reference compound |
| HY-107713 | PPDA | 684283-16-7 | Reference compound |
| HY-107714 | MNI-D-aspartate | 845555-94-4 | Reference compound |
| HY-107716 | Ro 8-4304 (hydrochloride) | 1312991-77-7 | Reference compound |
| HY-107717 | MNI-caged-NMDA | 1227675-52-6 | Reference compound |
| HY-107718 | Midafotel | 117414-74-1 | Reference compound |
| HY-107719 | D-AP7 | 81338-23-0 | Reference compound |
| HY-107720 | ARL 17477 | 866914-87-6 | Reference compound |
| HY-107721 | (±)-J-113397 | 217461-40-0 | Reference compound |
| HY-107722 | SCH 221510 | 322473-89-2 | Reference compound |
| HY-107723 | CGP71683 hydrochloride | 192322-50-2 | Reference compound |
| HY-107723A | CGP71683 | 192321-23-6 | Reference compound |
| HY-107724 | PD 160170 | 181468-88-2 | Reference compound |
| HY-107725 | BIBO3304 | 191868-14-1 | Reference compound |
| HY-107725A | BIBO3304 (diTFA) | 2310085-85-7 | Reference compound |
| HY-107726 | BIBP3226 (TFA) | 1068148-47-9 | Reference compound |
| HY-107726A | BIBP3226 | 159013-54-4 | Reference compound |
| HY-107727 | BMS-193885 (L-Lactic acid) | 679839-66-8 | Reference compound |
| HY-107728 | S 25585 | 263849-50-9 | Reference compound |
| HY-107729 | Lu AA33810 | 304008-29-5 | Reference compound |
| HY-107730 | NPY5RA-972 | 439861-56-0 | Reference compound |
| HY-107731 | SF 11 | 443292-81-7 | Reference compound |
| HY-107732 | JNJ-5207787 | 683746-68-1 | Reference compound |
| HY-107733 | NTNCB (hydrochloride) | 191931-56-3 | Reference compound |
| HY-107734 | L 152804 | 6508-43-6 | Reference compound |
| HY-107735 | CYM 9484 | 1383478-94-1 | Reference compound |
| HY-107736 | AI-3 | 882288-28-0 | Reference compound |
| HY-107737 | 1,2-DLPC | 18194-25-7 | Reference compound |
| HY-107738 | Guggulsterone | 95975-55-6 | Natural Products |
| HY-107739 | Penciclovir (sodium) | 97845-62-0 | Reference compound |
| HY-107740 | Pseudoisocyanine (iodide) | 977-96-8 | Reference compound |
| HY-107741 | SNC162 | 178803-51-5 | Reference compound |
| HY-107743 | Naloxone benzoylhydrazone | 119630-94-3 | Reference compound |
| HY-107744 | Nalmefene | 55096-26-9 | Reference compound |
| HY-107745 | SDM25N (hydrochloride) | 342884-71-3 | Reference compound |
| HY-107747 | GR 89696 | 126766-32-3 | Reference compound |
| HY-107747A | GR 89696 (free base) | 126766-31-2 | Reference compound |
| HY-107748 | 5'-Guanidinonaltrindole (hydrochloride) | 351183-88-5 | Reference compound |
| HY-107748A | 5'-Guanidinonaltrindole (TFA) | 219655-57-9 | Reference compound |
| HY-107749 | ML 190 | 1355244-02-8 | Reference compound |
| HY-107750 | Cyprodime | 118111-54-9 | Reference compound |
| HY-107750A | Cyprodime (hydrochloride) | 2387505-50-0 | Reference compound |
| HY-107751 | BW373U86 | 155836-50-3 | Reference compound |
| HY-107753 | XRP44X | 729605-21-4 | Reference compound |
| HY-107754 | Cesium chloride | 7647-17-8 | Biochemical Assay Reagents |
| HY-107755 | 3-Azaspiro[5.5]undecane (hydrochloride) | 1125-01-5 | Reference compound |
| HY-107756 | LOE 908 (hydrochloride) | 143482-60-4 | Reference compound |
| HY-107757 | GMQ | 5361-15-9 | Reference compound |
| HY-107758 | Y-29794 (oxalate) | 146794-84-5 | Reference compound |
| HY-107759 | Butabindide (oxalate) | 185213-03-0 | Reference compound |
| HY-107760 | Decanoyl-RVKR-CMK | 150113-99-8 | Peptides |
| HY-107760A | Decanoyl-RVKR-CMK (TFA) | 2098497-25-5 | Peptides |
| HY-107761 | JMV 390-1 | 148473-36-3 | Reference compound |
| HY-107762 | CGS35066 | 261619-50-5 | Reference compound |
| HY-107765 | LY2955303 | 1433497-19-8 | Reference compound |
| HY-107767 | Antibiotic DC 81 | 81307-24-6 | Reference compound |
| HY-107769 | Duocarmycin TM | 157922-77-5 | ADC Related |
| HY-10777 | EMD 495235 | 811811-33-3 | Reference compound |
| HY-107770 | Duocarmycin MB | 1613286-58-0 | ADC Related |
| HY-107771 | Fluensulfone | 318290-98-1 | Reference compound |
| HY-107771R | Fluensulfone (Standard) | 318290-98-1 | Reference Standards |
| HY-107773 | GSK3004774 | 2138814-32-9 | Reference compound |
| HY-107774 | BMS-986163 | 1801151-09-6 | Reference compound |
| HY-107775 | Ganfeborole (hydrochloride) | 2131798-13-3 | Reference compound |
| HY-107777 | LLY-283 | 2040291-27-6 | Reference compound |
| HY-107777A | LLY-284 | 2226515-75-7 | Reference compound |
| HY-107778 | PF-9366 | 72882-78-1 | Reference compound |
| HY-107779 | BI-882370 | 1392429-79-6 | Reference compound |
| HY-107780 | Cyclic-di-GMP | 61093-23-0 | Natural Products |
| HY-107780A | Cyclic-di-GMP (sodium) | | Natural Products |
| HY-107780B | Cyclic-di-GMP (diammonium) | 609343-82-0 | Natural Products |
| HY-107781 | PAT-505 | 1782070-22-7 | Reference compound |
| HY-107782 | Picrotin | 21416-53-5 | Natural Products |
| HY-107782R | Picrotin (Standard) | 21416-53-5 | Reference Standards |
| HY-107783 | Sulfo-GMBS | 185332-92-7 | Reference compound |
| HY-107784 | Ectoine | 96702-03-3 | Natural Products |
| HY-107784R | Ectoine (Standard) | 96702-03-3 | Reference Standards |
| HY-107787 | Dioxopromethazine | 13754-56-8 | Reference compound |
| HY-107787A | Dioxopromethazine hydrochloride | 15374-15-9 | Reference compound |
| HY-107787AR | Dioxopromethazine hydrochloride (Standard) | 15374-15-9 | Reference Standards |
| HY-107789 | Sodium lauryl sulfoacetate | 1847-58-1 | Natural Products |
| HY-107790 | 5-Methoxyflavone | 42079-78-7 | Reference compound |
| HY-107792 | Benurestat | 38274-54-3 | Reference compound |
| HY-107793 | Picosulfate (sodium salt hydrate) | 1307301-38-7 | Reference compound |
| HY-107794 | Clodronate (disodium tetrahydrate) | 88416-50-6 | Reference compound |
| HY-107794R | Clodronate (disodium tetrahydrate) (Standard) | 88416-50-6 | Reference Standards |
| HY-107795 | Benorilate | 5003-48-5 | Reference compound |
| HY-107795R | Benorilate (Standard) | 5003-48-5 | Reference Standards |
| HY-107796 | Metamizole (magnesium) | 63372-86-1 | Reference compound |
| HY-107798 | Potassium guaiacolsulfonate (hemihydrate) | 78247-49-1 | Reference compound |
| HY-107798R | Potassium guaiacolsulfonate (hemihydrate) (Standard) | 78247-49-1 | Reference Standards |
| HY-107799 | Castor oil | 8001-79-4 | Biochemical Assay Reagents |
| HY-10780 | JTV-803 (mesylate) | 247131-79-9 | Reference compound |
| HY-107801 | Inosine pranobex | 36703-88-5 | Reference compound |
| HY-107801R | Inosine pranobex (Standard) | 36703-88-5 | Reference Standards |
| HY-107802 | Breviscapine | 116122-36-2 | Natural Products |
| HY-107803 | Geranium oil | 8000-46-2 | Natural Products |
| HY-107805 | Dihydroactinidiolide | 17092-92-1 | Natural Products |
| HY-107811 | Harmol | 487-03-6 | Natural Products |
| HY-107811A | Harmol (hydrochloride) | 40580-83-4 | Reference compound |
| HY-107811R | Harmol (Standard) | 487-03-6 | Reference Standards |
| HY-107813 | Amikacin (sulfate) | 149022-22-0 | Reference compound |
| HY-107813R | Amikacin (sulfate) (Standard) | 149022-22-0 | Reference Standards |
| HY-107814 | Nicarbazin | 330-95-0 | Reference compound |
| HY-107814R | Nicarbazin (Standard) | 330-95-0 | Reference Standards |
| HY-107814S | Nicarbazin-d8 | | Isotope-Labeled Compounds |
| HY-107815 | CHIR 98024 | 556813-39-9 | Reference compound |
| HY-107818 | 4-Hydroxychalcone | 20426-12-4 | Natural Products |
| HY-107819 | 5α-Cholestan-3β-ol | 80-97-7 | Natural Products |
| HY-107819R | 5α-Cholestan-3β-ol (Standard) | 80-97-7 | Reference Standards |
| HY-107819S | 5α-Cholestan-3β-ol-d5 | 2260669-14-3 | Isotope-Labeled Compounds |
| HY-107820 | Ethylvanillin acetate | 72207-94-4 | Reference compound |
| HY-107823 | Cholesteryl acetate | 604-35-3 | Natural Products |
| HY-107824 | D-Melibiose | 585-99-9 | Natural Products |
| HY-107824A | Allolactose | 28447-39-4 | Natural Products |
| HY-107825 | Flavonol | 577-85-5 | Natural Products |
| HY-107826 | 5α-Cholestan-3-one | 566-88-1 | Natural Products |
| HY-107829 | 3-Aminopropionitrile fumarate (2:1) | 2079-89-2 | Reference compound |
| HY-107830 | Methyl cholate | 1448-36-8 | Natural Products |
| HY-107830R | Methyl cholate (Standard) | 1448-36-8 | Reference Standards |
| HY-107831 | 5-Acetylsalicylic acid | 13110-96-8 | Reference compound |
| HY-107832 | Ketoisophorone | 1125-21-9 | Natural Products |
| HY-107833 | A40926 | 102961-72-8 | Reference compound |
| HY-107834 | PIK-75 | 372196-67-3 | Reference compound |
| HY-107835 | Flumethrin | 69770-45-2 | Reference compound |
| HY-107835R | Flumethrin (Standard) | 69770-45-2 | Reference Standards |
| HY-107836 | Methiothepin (mesylate) | 74611-28-2 | Reference compound |
| HY-107837 | L-Ascorbic acid 2-phosphate (trisodium) | 66170-10-3 | Natural Products |
| HY-107837R | L-Ascorbic acid 2-phosphate (trisodium) (Standard) | 66170-10-3 | Reference Standards |
| HY-107840 | RGW-611 | 6497-78-5 | Reference compound |
| HY-107841 | K-Ras(G12C) inhibitor 6 | 2060530-16-5 | Reference compound |
| HY-107842 | (Z)-JIB-04 | 199596-24-2 | Reference compound |
| HY-107843 | 3',4',5',5,7-Pentamethoxyflavanone | 479672-30-5 | Natural Products |
| HY-107845 | SCR7 pyrazine | 14892-97-8 | Reference compound |
| HY-107846 | Xylan | 9014-63-5 | Natural Products |
| HY-107848 | DL-O-Tyrosine | 2370-61-8 | Peptides |
| HY-107849 | 2-Amino-3,5-dibromobenzaldehyde | 50910-55-9 | Biochemical Assay Reagents |
| HY-107850 | Pregnanediol | 80-92-2 | Natural Products |
| HY-107850A | 5α-Pregnane-3α,20α-diol | 566-58-5 | Reference compound |
| HY-107850S | Pregnanediol-d5 | | Isotope-Labeled Compounds |
| HY-107854 | N-Acetyl-5-hydroxytryptamine | 1210-83-9 | Natural Products |
| HY-107854R | N-Acetyl-5-hydroxytryptamine (Standard) | 1210-83-9 | Reference Standards |
| HY-107854S | N-Acetyl-5-hydroxytryptamine-d3 | 2001098-07-1 | Isotope-Labeled Compounds |
| HY-107855 | DL-Mevalonolactone | 674-26-0 | Reference compound |
| HY-107855S | DL-Mevalonolactone-d7 | 347840-19-1 | Isotope-Labeled Compounds |
| HY-107855S1 | DL-Mevalonolactone-d3 | 61219-76-9 | Isotope-Labeled Compounds |
| HY-107856 | 5-Fluorouridine | 316-46-1 | Reference compound |
| HY-107856R | 5-Fluorouridine (Standard) | 316-46-1 | Reference Standards |
| HY-107857 | 3-Chloropropiophenone | 936-59-4 | Biochemical Assay Reagents |
| HY-107858 | Veratryl alcohol | 93-03-8 | Natural Products |
| HY-107859 | Tris(2-chloroethyl) phosphate | 115-96-8 | Reference compound |
| HY-107859S | Tris(2-chloroethyl)phosphate-d12 | 1276500-47-0 | Isotope-Labeled Compounds |
| HY-107863 | Fructooligosaccharides | 308066-66-2 | Biochemical Assay Reagents |
| HY-107864 | Erythrosine B (free acid) | 15905-32-5 | Dye Reagents |
| HY-107864A | Erythrosine B (aluminum) | 12227-78-0 | Dye Reagents |
| HY-107867 | (±)-Clopidogrel (bisulfate) | 135046-48-9 | Reference compound |
| HY-107867S | Clopidogrel-d4 (sulfate) | 1219274-96-0 | Isotope-Labeled Compounds |
| HY-107867S3 | (Rac)-Clopidogrel-d3 (sulfate) | 2468372-74-7 | Isotope-Labeled Compounds |
| HY-107869 | Isoindigo | 476-34-6 | Natural Products |
| HY-10787 | Ximelagatran | 192939-46-1 | Reference compound |
| HY-107870 | 1,2,4-Triazole-3-carboxylic acid, 97% | 4928-87-4 | Biochemical Assay Reagents |
| HY-10790 | Cilomilast | 153259-65-5 | Reference compound |
| HY-107901 | Pparδ agonist 1 | 1902161-12-9 | Reference compound |
| HY-107902 | RIG-1 modulator 1 | 1428729-63-8 | Reference compound |
| HY-107903 | Thyroglobulin | 9010-34-8 | Biochemical Assay Reagents |
| HY-107906 | Conjugated estrogen (sodium) | 12126-59-9 | Reference compound |
| HY-107909 | Theophylline (sodium glycinate) | 8000-10-0 | Reference compound |
| HY-10791 | Ritanserin | 87051-43-2 | Reference compound |
| HY-107910 | Hyaluronidase, Bovine testes | 37326-33-3 | Reference compound |
| HY-107911 | Protamine sulfate | 9009-65-8 | Biochemical Assay Reagents |
| HY-107915 | Levonordefrin | 829-74-3 | Reference compound |
| HY-107915R | Levonordefrin (Standard) | 829-74-3 | Reference Standards |
| HY-107916 | Thyrotropin | 9002-71-5 | Reference compound |
| HY-107917 | Desoxycorticosterone pivalate | 808-48-0 | Reference compound |
| HY-107917R | Desoxycorticosterone pivalate (Standard) | 808-48-0 | Reference Standards |
| HY-107918 | Alkaloids, Rauwolfia | 8063-17-0 | Reference compound |
| HY-10792 | Eplivanserin | 130579-75-8 | Reference compound |
| HY-107921 | EDTA Calcium disodium,98% | 62-33-9 | Biochemical Assay Reagents |
| HY-107921R | EDTA Calcium disodium,98% (Standard) | 62-33-9 | Reference Standards |
| HY-107922 | Ethopropazine (hydrochloride) | 1094-08-2 | Reference compound |
| HY-107922R | Ethopropazine (hydrochloride) (Standard) | 1094-08-2 | Reference Standards |
| HY-107923 | Sulfisoxazole acetyl | 80-74-0 | Reference compound |
| HY-107925 | Propyliodone | 587-61-1 | Reference compound |
| HY-107928 | Iron dextran | 9004-66-4 | Reference compound |
| HY-107928A | Iron–Dextran(Fe 25-35% w/w) | 9004-66-4 | Biochemical Assay Reagents |
| HY-107928B | Iron–Dextran(Fe 35-40% w/w) | 9004-66-4 | Biochemical Assay Reagents |
| HY-107929 | Calcium polystyrene sulfonate | 37286-92-3 | Reference compound |
| HY-10792A | Eplivanserin (mixture) | 130581-13-4 | Reference compound |
| HY-107931 | Propiolactone | 57-57-8 | Reference compound |
| HY-107935 | 6α-Fluoroprednisolone | 53-34-9 | Reference compound |
| HY-107937 | Acrisorcin | 7527-91-5 | Reference compound |
| HY-107939 | Paramethasone Acetate | 1597-82-6 | Reference compound |
| HY-107939R | Paramethasone Acetate (Standard) | 1597-82-6 | Reference Standards |
| HY-10794 | MF498 | 915191-42-3 | Reference compound |
| HY-107940 | Sutilains | 12211-28-8 | Enzyme |
| HY-107944 | Chlorphenesin carbamate | 886-74-8 | Reference compound |
| HY-107944R | Chlorphenesin carbamate (Standard) | 886-74-8 | Reference Standards |
| HY-107947 | Fluphenazine enanthate | 2746-81-8 | Reference compound |
| HY-107949 | Flumethasone pivalate | 2002-29-1 | Reference compound |
| HY-107949R | Flumethasone pivalate (Standard) | 2002-29-1 | Reference Standards |
| HY-107953 | Chorionic gonadotrophin | 9002-61-3 | Reference compound |
| HY-107956 | Imipramine (pamoate) | 10075-24-8 | Reference compound |
| HY-107957 | Cholebrine | 16034-77-8 | Reference compound |
| HY-107959 | Colestipol (hydrochloride) | 37296-80-3 | Reference compound |
| HY-107961 | Diflorasone diacetate | 33564-31-7 | Reference compound |
| HY-107961R | Diflorasone diacetate (Standard) | 33564-31-7 | Reference Standards |
| HY-107965 | Safflower oil (from Carthamus tinctorius seed) | 8001-23-8 | Biochemical Assay Reagents |
| HY-107966 | Heparin calcium (MW 15000-19000) | 37270-89-6 | Biochemical Assay Reagents |
| HY-107966A | Heparin calcium (MW 3600-5000) | 37270-89-6 | Biochemical Assay Reagents |
| HY-107967 | Isosulfan blue | 68238-36-8 | Dye Reagents |
| HY-107967R | Isosulfan blue (Standard) | 68238-36-8 | Dye Reagents |
| HY-107969 | Haloperidol decanoate | 74050-97-8 | Reference compound |
| HY-107969R | Haloperidol decanoate (Standard) | 74050-97-8 | Reference Standards |
| HY-10797 | CJ-42794 | 847728-01-2 | Reference compound |
| HY-107977 | IDH1 Inhibitor 3 | 2171081-24-4 | Reference compound |
| HY-107978 | RIPK-IN-4 | 2141969-56-2 | Reference compound |
| HY-107980 | DS28120313 | 2146177-09-3 | Reference compound |
| HY-107981 | LSN 3213128 | 1941211-99-9 | Reference compound |
| HY-107982 | VU6005649 | 2137047-43-7 | Reference compound |
| HY-107986 | GNE-6776 | 2009273-71-4 | Reference compound |
| HY-107987 | CXCR7 modulator 1 | 2231812-31-8 | Reference compound |
| HY-107988 | MK-3903 | 1219737-12-8 | Reference compound |
| HY-107989 | Urofollitropin | 97048-13-0 | Peptides |
| HY-10799 | EG00229 (trifluoroacetate) | 1210945-69-9 | Reference compound |
| HY-107992 | Iotrolan | 79770-24-4 | Reference compound |
| HY-107994 | Aminooxyacetic acid (hemihydrochloride) | 2921-14-4 | Reference compound |
| HY-107994A | Aminoxyacetic acid | 645-88-5 | Reference compound |
| HY-107996 | Lapyrium (chloride) | 6272-74-8 | Reference compound |
| HY-107997 | TAP311 | 1149362-88-8 | Reference compound |
| HY-107999 | CADD522 | 199735-88-1 | Reference compound |
| HY-108003 | MM 07 | 1876450-21-3 | Reference compound |
| HY-108004 | Decamethoxine | 38146-42-8 | Reference compound |
| HY-108006 | Mirogabalin besylate | 1138245-21-2 | Reference compound |
| HY-108009 | Rezafungin | 1396640-59-7 | Reference compound |
| HY-108009A | Rezafungin (acetate) | 1631754-41-0 | Reference compound |
| HY-10801 | CAY10650 | 1233706-88-1 | Reference compound |
| HY-108011 | Naftazone | 15687-37-3 | Reference compound |
| HY-108011R | Naftazone (Standard) | 15687-37-3 | Reference Standards |
| HY-108012 | ME1111 | 1391758-52-3 | Reference compound |
| HY-108013 | Armillarisin A | 53696-74-5 | Natural Products |
| HY-108014 | (+)-KDT501 | 1374259-84-3 | Reference compound |
| HY-108015 | RO5263397 | 1357266-05-7 | Reference compound |
| HY-108016 | Peruvoside | 1182-87-2 | Natural Products |
| HY-108017 | Ferric maltol | 33725-54-1 | Reference compound |
| HY-108020 | LY2881835 | 1292290-38-0 | Reference compound |
| HY-108022 | Azemiglitazone | 1133819-87-0 | Reference compound |
| HY-108022A | Azemiglitazone (potassium) | 1314533-27-1 | Reference compound |
| HY-108024 | Ganaplacide | 1261113-96-5 | Reference compound |
| HY-108024A | Ganaplacide (hydrochloride) | 2751586-94-2 | Reference compound |
| HY-108026 | Hapten C | 90579-19-4 | Reference compound |
| HY-108030 | Bencycloquidium bromide | 860804-18-8 | Reference compound |
| HY-108032 | Hydroxyectoin | 165542-15-4 | Natural Products |
| HY-108034 | GET73 | 202402-01-5 | Reference compound |
| HY-108035 | (-)-JM-1232 | 1013427-48-9 | Reference compound |
| HY-108036 | Pro-xylane (30% in water) | 439685-79-7 | Reference compound |
| HY-108036A | (S)-Pro-xylane | 868156-46-1 | Reference compound |
| HY-108038 | ABT-107 | 855291-54-2 | Reference compound |
| HY-108039 | Bezisterim | 1001100-69-1 | Reference compound |
| HY-10804 | CCT 137690 | 1095382-05-0 | Reference compound |
| HY-108040 | NCX-6560 | 803728-45-2 | Reference compound |
| HY-108044 | ONO-5334 | 868273-90-9 | Reference compound |
| HY-108045 | Lodenafil carbonate | 398507-55-6 | Reference compound |
| HY-108045R | Lodenafil carbonate (Standard) | 398507-55-6 | Reference Standards |
| HY-108047 | MK-0873 | 500355-52-2 | Reference compound |
| HY-108048 | Desoxypeganine | 495-59-0 | Natural Products |
| HY-108048A | Desoxypeganine (hydrochloride) | 61939-05-7 | Reference compound |
| HY-10805 | Almorexant | 871224-64-5 | Reference compound |
| HY-108050 | 4-Hydroxyoxyphenbutazone | 55648-39-0 | Reference compound |
| HY-108052 | Delphinidin 3-glucoside (chloride) | 6906-38-3 | Natural Products |
| HY-108052R | Delphinidin 3-glucoside (chloride) (Standard) | 6906-38-3 | Reference Standards |
| HY-108054 | Cindunistat | 364067-22-1 | Reference compound |
| HY-108054A | Cindunistat ((hydrochloride) maleate) | 753491-31-5 | Reference compound |
| HY-108055 | Urantide | 669089-53-6 | Peptides |
| HY-108056 | PF 219061 | 547770-05-8 | Reference compound |
| HY-108057 | Facinicline | 677306-35-3 | Reference compound |
| HY-108057A | Facinicline (hydrochloride) | 677305-02-1 | Reference compound |
| HY-108058A | Immethridine (dihydrobromide) | 699020-93-4 | Reference compound |
| HY-108059 | β-Cryptoxanthin | 472-70-8 | Natural Products |
| HY-10805A | Almorexant (hydrochloride) | 913358-93-7 | Reference compound |
| HY-10805S | Almorexant-13C,d3 | | Isotope-Labeled Compounds |
| HY-10806 | SB-649868 | 380899-24-1 | Reference compound |
| HY-108060 | Valopicitabine | 640281-90-9 | Reference compound |
| HY-108060A | Valopicitabine (dihydrochloride) | 640725-71-9 | Reference compound |
| HY-108062 | BLI-489 | 623564-40-9 | Reference compound |
| HY-108062A | BLI-489 (hydrate) | 2580120-08-5 | Reference compound |
| HY-108065 | 3'-Sialyllactose | 35890-38-1 | Natural Products |
| HY-108065A | 3'-Sialyllactose (sodium) | 128596-80-5 | Natural Products |
| HY-108067 | SAD448 | 581106-09-4 | Reference compound |
| HY-108068 | Alphadolone acetate | 23930-37-2 | Reference compound |
| HY-108069 | Iptakalim (hydrochloride) | 642407-63-4 | Reference compound |
| HY-10809 | Bitopertin | 845614-11-1 | Reference compound |
| HY-10809A | Bitopertin (R enantiomer) | 845614-12-2 | Reference compound |
| HY-10811 | GNE-493 | 1033735-94-2 | Reference compound |
| HY-10812 | GNE-490 | 1033739-92-2 | Reference compound |
| HY-108132 | Ro 23-9358 | 153125-17-8 | Reference compound |
| HY-108136A | Bisindolylmaleimide X (hydrochloride) | 145317-11-9 | Reference compound |
| HY-108137 | Z-LVG-CHN2 | 119670-30-3 | Reference compound |
| HY-108137A | Z-L(D-Val)G-CHN2 | | Reference compound |
| HY-10814 | CP-810123 | 439608-12-5 | Reference compound |
| HY-10815 | σ1 Receptor antagonist-1 | 1204401-49-9 | Reference compound |
| HY-108161 | LF 1695 | 86187-86-2 | Reference compound |
| HY-108162 | Ataquimast (free base) | 586348-21-2 | Reference compound |
| HY-108162A | Ataquimast | 182316-31-0 | Reference compound |
| HY-108163 | SB-237376 (free base) | 179258-59-4 | Reference compound |
| HY-108163A | SB-237376 | 179258-62-9 | Reference compound |
| HY-108164 | Aspidin BB | 584-28-1 | Natural Products |
| HY-108166 | Hydroxystilbamidine | 495-99-8 | Dye Reagents |
| HY-108166A | Hydroxystilbamidine bis(methanesulfonate) | 223769-64-0 | Dye Reagents |
| HY-108170 | Pyrethrin II | 121-29-9 | Natural Products |
| HY-108171A | Hexocyclium (methylsulfate) | 115-63-9 | Reference compound |
| HY-10818 | LY309887 | 127228-54-0 | Reference compound |
| HY-10819 | AG2034 | 177575-17-6 | Reference compound |
| HY-108191 | Paldimycin A | 101411-70-5 | Reference compound |
| HY-108193 | GW 328267 | 210237-78-8 | Reference compound |
| HY-108194 | CGP 46700 | 115900-75-9 | Reference compound |
| HY-108195S | 2,2′,4,5,5′-Pentachlorobiphenyl-3′,4′,6′-d3 | 1219794-68-9 | Isotope-Labeled Compounds |
| HY-108196 | PTP1B-IN-15 | 765317-71-3 | Reference compound |
| HY-10820 | Pemetrexed | 137281-23-3 | Reference compound |
| HY-108204 | AZD 3043 | 579494-66-9 | Reference compound |
| HY-10820A | Pemetrexed (disodium) | 150399-23-8 | Reference compound |
| HY-10820AS | Pemetrexed-d5 (disodium) | | Isotope-Labeled Compounds |
| HY-10820B | Pemetrexed (disodium heptahydrate) | 357166-29-1 | Reference compound |
| HY-10820BR | Pemetrexed (disodium heptahydrate) (Standard) | 357166-29-1 | Reference Standards |
| HY-10820R | Pemetrexed (Standard) | 137281-23-3 | Reference Standards |
| HY-10820S | Pemetrexed-d5 | 1129408-57-6 | Isotope-Labeled Compounds |
| HY-10821 | Raltitrexed | 112887-68-0 | Reference compound |
| HY-108213 | Inosinic acid | 131-99-7 | Natural Products |
| HY-108213A | Inosinic acid (disodium)(hydrate)(1:2:X) | 352195-40-5 | Natural Products |
| HY-108213AR | Inosinic acid (disodium)(hydrate)(1:2:X) (Standard) | 352195-40-5 | Reference Standards |
| HY-108213R | Inosinic acid (Standard) | 131-99-7 | Reference Standards |
| HY-108213S | Inosinic acid-13C10,15N4 (dilithium) | | Isotope-Labeled Compounds |
| HY-108213S1 | Inosinic acid-15N4 (dilithium) | | Isotope-Labeled Compounds |
| HY-10822 | Idetrexed | 501332-69-0 | Reference compound |
| HY-108226 | Regorafenib N-oxide and N-desmethyl (M5) | 835621-12-0 | Reference compound |
| HY-108226S | Regorafenib N-oxide and N-desmethyl (M5)-d3 | | Isotope-Labeled Compounds |
| HY-108226S1 | Regorafenib N-oxide and N-desmethyl (M5)-13C6 | | Isotope-Labeled Compounds |
| HY-108227 | Quetiapine sulfone | 329216-65-1 | Reference compound |
| HY-108228 | Zolpidic acid | 189005-44-5 | Reference compound |
| HY-108229 | 6β-Naltrexol | 49625-89-0 | Reference compound |
| HY-108229S | 6β-Naltrexol-d3 | 1435727-11-9 | Isotope-Labeled Compounds |
| HY-10822A | ONX 0801 (trisodium) | 1097638-00-0 | Reference compound |
| HY-10823 | OSI-7904L | 139987-54-5 | Reference compound |
| HY-108230 | ALK-IN-12 | 1197958-53-4 | Reference compound |
| HY-108232 | MK-2206 | 1032349-77-1 | Reference compound |
| HY-108234 | VU 0255035 | 1135243-19-4 | Reference compound |
| HY-108235 | Lanicemine | 153322-05-5 | Reference compound |
| HY-108235A | Lanicemine (dihydrochloride) | 153322-06-6 | Reference compound |
| HY-108235B | (Rac)-Lanicemine | 61890-25-3 | Reference compound |
| HY-108235C | (R)-Lanicemine | 190581-71-6 | Reference compound |
| HY-108236 | Naxagolide (hydrochloride) | 99705-65-4 | Reference compound |
| HY-108237 | Naxagolide | 88058-88-2 | Reference compound |
| HY-108238 | BSI-401 | 142404-10-2 | Reference compound |
| HY-108239 | BIX-01294 (trihydrochloride) | 1392399-03-9 | Reference compound |
| HY-10824 | Talotrexin | 113857-87-7 | Reference compound |
| HY-108241 | (Z)-PUGNAc | 132489-69-1 | Reference compound |
| HY-108242 | Apomorphine (hydrochloride) | 314-19-2 | Reference compound |
| HY-108243 | AZD5423 | 1034148-04-3 | Reference compound |
| HY-108244 | Balsalazide (disodium) | 213594-60-6 | Reference compound |
| HY-108246 | GlcNAcstatin | 922163-64-2 | Reference compound |
| HY-108247 | Guanethidine (sesquisulfate) | 60-02-6 | Reference compound |
| HY-108248 | KU-32 | 956498-70-7 | Reference compound |
| HY-108249 | Tribenoside | 10310-32-4 | Reference compound |
| HY-108249R | Tribenoside (Standard) | 10310-32-4 | Reference Standards |
| HY-10824A | Talotrexin (monoammonium) | 648420-92-2 | Reference compound |
| HY-10824B | Talotrexin (ammonium) | 678991-55-4 | Reference compound |
| HY-10825 | DG051 | 929915-58-2 | Reference compound |
| HY-108250 | (R)-Bicalutamide | 113299-40-4 | Reference compound |
| HY-108251 | Methotrexate metabolite | 19741-14-1 | Reference compound |
| HY-108251R | Methotrexate metabolite (Standard) | 19741-14-1 | Reference Standards |
| HY-108251S | Methotrexate metabolite-d3 | 1794780-00-9 | Isotope-Labeled Compounds |
| HY-108252 | SB-649915 | 420785-70-2 | Reference compound |
| HY-108254 | Bisindolylmaleimide IV | 119139-23-0 | Reference compound |
| HY-108255 | HIV-1 inhibitor-60 | 1443461-21-9 | Reference compound |
| HY-108256 | Melitracen (hydrochloride) | 10563-70-9 | Reference compound |
| HY-108256R | Melitracen (hydrochloride) (Standard) | 10563-70-9 | Reference Standards |
| HY-108256S | Melitracen-d6 (hydrochloride) | 1189648-08-5 | Isotope-Labeled Compounds |
| HY-108257 | Atorvastatin (sodium) | 134523-01-6 | Reference compound |
| HY-108258 | PSN 375963 | 388575-52-8 | Reference compound |
| HY-108258A | PSN 375963 (hydrochloride) | 1781834-82-9 | Reference compound |
| HY-108259 | HQL-79 | 162641-16-9 | Reference compound |
| HY-10826 | DG051 (free acid) | 929916-05-2 | Reference compound |
| HY-108260 | Deferitrin | 239101-33-8 | Reference compound |
| HY-108261 | Tomeglovir | 233254-24-5 | Reference compound |
| HY-108262 | UCN-02 | 121569-61-7 | Natural Products |
| HY-108263 | 3-Hydroxy Midostaurin | 179237-49-1 | Reference compound |
| HY-108263A | (S)-3-Hydroxy Midostaurin | 945260-14-0 | Reference compound |
| HY-108263B | (R)-3-Hydroxy Midostaurin | 155848-20-7 | Reference compound |
| HY-108263S | 3-Hydroxy Midostaurin-d5 | | Isotope-Labeled Compounds |
| HY-108264 | TCS 21311 | 1260181-14-3 | Reference compound |
| HY-108268 | Cyclocephaloside II | 215776-78-6 | Natural Products |
| HY-10827 | Kelatorphan | 92175-57-0 | Reference compound |
| HY-108271 | Mogroside III-A1 | 88901-42-2 | Natural Products |
| HY-108272 | Mogroside II-A2 | 88901-45-5 | Natural Products |
| HY-108275 | Mogroside VI | 189307-15-1 | Natural Products |
| HY-108277 | Ginsenoside F5 | 189513-26-6 | Natural Products |
| HY-108278 | Zolimidine | 1222-57-7 | Reference compound |
| HY-108279 | Ulifloxacin | 112984-60-8 | Reference compound |
| HY-108279R | Ulifloxacin (Standard) | 112984-60-8 | Reference Standards |
| HY-108279S | Ulifloxacin-d8 | 1246820-95-0 | Isotope-Labeled Compounds |
| HY-108280 | Tropesin | 65189-78-8 | Reference compound |
| HY-108281 | Enfenamic acid | 23049-93-6 | Reference compound |
| HY-108283 | Trepibutone | 41826-92-0 | Reference compound |
| HY-108283R | Trepibutone (Standard) | 41826-92-0 | Reference Standards |
| HY-108285 | (Rac)-Telmesteine | 127657-29-8 | Reference compound |
| HY-108286 | Talinolol | 57460-41-0 | Reference compound |
| HY-108286S | (Rac)-Talinolol-d5 | 1215343-94-4 | Isotope-Labeled Compounds |
| HY-108287 | Trithiozine | 35619-65-9 | Reference compound |
| HY-108288 | Sulbactam pivoxil | 69388-79-0 | Reference compound |
| HY-108288R | Sulbactam pivoxil (Standard) | 69388-79-0 | Reference Standards |
| HY-108290 | Riodoxol | 19403-92-0 | Reference compound |
| HY-108292 | Propacetamol (hydrochloride) | 66532-86-3 | Reference compound |
| HY-108292R | Propacetamol (hydrochloride) (Standard) | 66532-86-3 | Reference Standards |
| HY-108293 | Promestriene | 39219-28-8 | Reference compound |
| HY-108293R | Promestriene (Standard) | 39219-28-8 | Reference Standards |
| HY-108294 | Nonaethylene glycol monododecyl ether | 3055-99-0 | Reference compound |
| HY-108295 | Pivagabine | 69542-93-4 | Reference compound |
| HY-108296 | Pirenoxine | 1043-21-6 | Reference compound |
| HY-108297 | Piketoprofen | 60576-13-8 | Reference compound |
| HY-108297R | Piketoprofen (Standard) | 60576-13-8 | Reference Standards |
| HY-108298 | Perfluorodecalin | 306-94-5 | Reference compound |
| HY-108299 | Perfluamine | 338-83-0 | Biochemical Assay Reagents |
| HY-108300 | Oxyfedrine (hydrochloride) | 16777-42-7 | Reference compound |
| HY-108302 | Nifenalol | 7413-36-7 | Reference compound |
| HY-108304 | Prajmalium (bitartrate) | 2589-47-1 | Reference compound |
| HY-108306 | Moprolol | 5741-22-0 | Reference compound |
| HY-108307 | Micronomicin (sulfate) | 66803-19-8 | Natural Products |
| HY-108308 | Ibuprofen guaiacol ester | 66332-77-2 | Reference compound |
| HY-108309 | Medronic acid | 1984-15-2 | Reference compound |
| HY-108309R | Medronic acid (Standard) | 1984-15-2 | Reference Standards |
| HY-10830A | PBPE (hydrochloride) | 262425-59-2 | Reference compound |
| HY-108312 | AC-VEID-CHO | 319494-39-8 | Peptides |
| HY-108312A | AC-VEID-CHO (TFA) | | Peptides |
| HY-108313 | T-00127_HEV1 | 900874-91-1 | Reference compound |
| HY-108314 | GC-7 | 150333-69-0 | Reference compound |
| HY-108314A | GC7 Sulfate | 150417-90-6 | Reference compound |
| HY-108315 | 6-Aminochrysene | 2642-98-0 | Reference compound |
| HY-108316 | Sultiame | 61-56-3 | Reference compound |
| HY-108316R | Sultiame (Standard) | 61-56-3 | Reference Standards |
| HY-108316S | Sulthiame-d4 | 1795021-05-4 | Isotope-Labeled Compounds |
| HY-108317 | ABL127 | 1073529-41-5 | Reference compound |
| HY-108318 | RK-24466 | 213743-31-8 | Reference compound |
| HY-108319 | DPP-IV-IN-2 | 136259-18-2 | Reference compound |
| HY-108321 | Zofenopril | 81872-10-8 | Reference compound |
| HY-108321S | Zofenopril-d5 | | Isotope-Labeled Compounds |
| HY-108322 | NBTGR | 13153-27-0 | Reference compound |
| HY-108323 | CCR2 antagonist 4 | 226226-39-7 | Reference compound |
| HY-108324 | (Z)-Thiothixene | 3313-26-6 | Reference compound |
| HY-108324A | Thiothixene (hydrochloride) | 49746-04-5 | Reference compound |
| HY-108324R | (Z)-Thiothixene (Standard) | 3313-26-6 | Reference Standards |
| HY-108325 | Brequinar | 96187-53-0 | Reference compound |
| HY-108325A | Brequinar (sodium) | 96201-88-6 | Biochemical Assay Reagents |
| HY-108325S | Brequinar-d3 | | Isotope-Labeled Compounds |
| HY-108327 | PF-05020182 | 1354712-92-7 | Reference compound |
| HY-108328 | Nerigliatin | 1245603-92-2 | Reference compound |
| HY-108329 | AM-0902 | 1883711-97-4 | Reference compound |
| HY-10833 | ROCK-IN-10 | 1038549-25-5 | Reference compound |
| HY-108330 | AG126 | 118409-62-4 | Reference compound |
| HY-108331 | 3-TYP | 120241-79-4 | Reference compound |
| HY-108333 | SB-633825 | 956613-01-7 | Reference compound |
| HY-108335 | Sipatrigine | 130800-90-7 | Reference compound |
| HY-108337 | GNE-0723 | 1883518-31-7 | Reference compound |
| HY-108339 | PF-06471553 | 1808094-07-6 | Reference compound |
| HY-10834 | β-catenin-IN-6 | 1039731-99-1 | Reference compound |
| HY-108340 | PF-06767832 | 1859081-58-5 | Reference compound |
| HY-108341 | PF-06424439 | 1469284-78-3 | Reference compound |
| HY-108341A | PF-06424439 (methanesulfonate) | 1469284-79-4 | Reference compound |
| HY-108342 | PF-00956980 | 1262832-74-5 | Reference compound |
| HY-108343 | WEE1-IN-4 | 622855-37-2 | Reference compound |
| HY-108344 | SNS-314 | 1057249-41-8 | Reference compound |
| HY-108345 | Bleomycin | 11056-06-7 | Reference compound |
| HY-108346 | JX401 | 349087-34-9 | Reference compound |
| HY-108347 | CP-100356 (hydrochloride) | 142715-48-8 | Reference compound |
| HY-108348 | BML-259 | 267654-00-2 | Reference compound |
| HY-10835 | DG-041 | 861238-35-9 | Reference compound |
| HY-108350 | MI-2-2 | 1454920-20-7 | Reference compound |
| HY-108351 | IM-54 | 861891-50-1 | Reference compound |
| HY-108352 | HU 331 | 137252-25-6 | Reference compound |
| HY-108353 | Isoprenaline | 7683-59-2 | Reference compound |
| HY-108353A | Isoprenaline (hemisulfate) | 299-95-6 | Reference compound |
| HY-108353S | Isoprenaline-d7 (acetate) | | Isotope-Labeled Compounds |
| HY-108355 | R59949 | 120166-69-0 | Reference compound |
| HY-108356 | NS3694 | 426834-38-0 | Reference compound |
| HY-108357 | 6-Diazo-5-oxo-L-nor-Leucine | 157-03-9 | Reference compound |
| HY-108357R | 6-Diazo-5-oxo-L-nor-Leucine (Standard) | 157-03-9 | Reference Standards |
| HY-108359 | Alsterpaullone | 237430-03-4 | Reference compound |
| HY-10836 | Cruzain-IN-1 | 1199523-24-4 | Reference compound |
| HY-108360 | PDD 00017273 | 1945950-21-9 | Reference compound |
| HY-108361 | CCG-203971 | 1443437-74-8 | Reference compound |
| HY-108365 | Gamithromycin | 145435-72-9 | Reference compound |
| HY-108368 | Azido-PEG2-CH2COOH | 882518-90-3 | Reference compound |
| HY-108368A | Azido-PEG2-CH2COOH (CHA) | 2098500-94-6 | Reference compound |
| HY-108369 | Azido-PEG1-CH2CO2H | 79598-48-4 | Reference compound |
| HY-108370 | N33-TEG-COOH | 201467-81-4 | Reference compound |
| HY-108371 | Boc-C1-PEG2-C4-Cl | 1835705-53-7 | Reference compound |
| HY-108372 | Boc-C5-O-C5-O-C6-Cl | 1835705-52-6 | Reference compound |
| HY-108374 | 4-Azidobutylamine | 88192-20-5 | Reference compound |
| HY-108379 | Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid | 1610413-97-2 | ADC Related |
| HY-10838 | GW 501516 | 317318-70-0 | Reference compound |
| HY-108381 | Idrocilamide | 6961-46-2 | Reference compound |
| HY-108385 | Ochratoxin A-D4 | 1448049-50-0 | Isotope-Labeled Compounds |
| HY-108387 | Morantel (citrate) | 69525-81-1 | Reference compound |
| HY-108388 | Cloethocarb | 51487-69-5 | Reference compound |
| HY-10838R | GW 501516 (Standard) | 317318-70-0 | Reference Standards |
| HY-108391 | C8-Ceramide | 74713-59-0 | Reference compound |
| HY-108396 | γ-Linolenic acid ethyl ester | 31450-14-3 | Reference compound |
| HY-108398A | Mead acid | 20590-32-3 | Natural Products |
| HY-108398AS | Mead acid-d6 | 2692624-12-5 | Isotope-Labeled Compounds |
| HY-108398B | 11(Z),14(Z),17(Z)-Eicosatrienoic acid | 17046-59-2 | Natural Products |
| HY-108398BR | 11(Z),14(Z),17(Z)-Eicosatrienoic acid (Standard) | 17046-59-2 | Reference Standards |
| HY-108400 | SCH-23390 (maleate) | 87134-87-0 | Reference compound |
| HY-108402 | Cefodizime | 69739-16-8 | Reference compound |
| HY-108402A | Cefodizime (sodium) | 86329-79-5 | Reference compound |
| HY-108402AR | Cefodizime (sodium) (Standard) | 86329-79-5 | Reference Standards |
| HY-108402R | Cefodizime (Standard) | 69739-16-8 | Reference Standards |
| HY-108403 | Phenibut | 1078-21-3 | Reference compound |
| HY-108411 | Emedastine | 87233-61-2 | Reference compound |
| HY-108411R | Emedastine (Standard) | 87233-61-2 | Reference Standards |
| HY-108411S | Emedastine-13C,d3 (fumarate) | | Isotope-Labeled Compounds |
| HY-108413 | Talazoparib tosylate | 1373431-65-2 | Reference compound |
| HY-108414 | (R)-Equol | 221054-79-1 | Reference compound |
| HY-108415 | Cloprostenol sodium salt | 55028-72-3 | Reference compound |
| HY-108415R | Cloprostenol sodium salt (Standard) | 55028-72-3 | Reference Standards |
| HY-108416 | 5,7-Dihydroxy-4-methylphthalide | 27979-57-3 | Reference compound |
| HY-108417 | Debio 0617B | 1332329-27-7 | Reference compound |
| HY-108418 | PI3Kδ-IN-15 | 870281-17-7 | Reference compound |
| HY-108418A | (R)-PI3Kδ-IN-15 | 1707193-37-0 | Reference compound |
| HY-108419 | WHI-P258 | 21561-09-1 | Reference compound |
| HY-108420 | INK4C-IN-2 | 6314-70-1 | Reference compound |
| HY-108421 | Xinjiachalcone A | 151410-32-1 | Natural Products |
| HY-108422 | Benodanil | 15310-01-7 | Reference compound |
| HY-108422R | Benodanil (Standard) | 15310-01-7 | Reference Standards |
| HY-108425 | AMG8379 | 1642112-31-9 | Reference compound |
| HY-108425A | AMG8380 | 1642112-32-0 | Reference compound |
| HY-108425B | (Rac)-AMG8379 | 1641574-26-6 | Reference compound |
| HY-108431 | MN58b | 203192-01-2 | Reference compound |
| HY-108432 | BMS-741672 | 1004757-96-3 | Reference compound |
| HY-108433 | CPT2 | 1670277-66-3 | Enzyme |
| HY-108434 | Ceapin-A7 | 2323027-38-7 | Reference compound |
| HY-108435 | GNE-049 | 1936421-41-8 | Reference compound |
| HY-108436 | Deltazinone 1 | 894554-89-3 | Reference compound |
| HY-108437 | exo-IWR-1 | 1127442-87-8 | Reference compound |
| HY-108438 | TCS 2210 | 1201916-31-5 | Reference compound |
| HY-108439 | Neurodazine | 937807-66-4 | Reference compound |
| HY-10844 | Pretomanid | 187235-37-6 | Reference compound |
| HY-108440 | Shz-1 | 326886-05-9 | Reference compound |
| HY-108441 | CCT031374 (hydrobromide) | 1219184-91-4 | Reference compound |
| HY-108442 | JW67 | 442644-28-2 | Reference compound |
| HY-108443 | DMH4 | 515880-75-8 | Reference compound |
| HY-108444 | (Z)-FeCP-oxindole | 1137967-28-2 | Reference compound |
| HY-108444A | (E)-FeCP-oxindole | 884338-18-5 | Reference compound |
| HY-108446 | GSK 1562590 (hydrochloride) | 1003878-07-6 | Reference compound |
| HY-108447 | BC-11 (hydrobromide) | 443776-49-6 | Reference compound |
| HY-108448 | N-Oleoyldopamine | 105955-11-1 | Reference compound |
| HY-108449 | Acoltremon | 68489-09-8 | Reference compound |
| HY-10844R | Pretomanid (Standard) | 187235-37-6 | Reference Standards |
| HY-10844S | Pretomanid-d4 | 1346617-34-2 | Isotope-Labeled Compounds |
| HY-10844S1 | Pretomanid-d5 | | Isotope-Labeled Compounds |
| HY-10845 | CGI-17341 | 127692-13-1 | Reference compound |
| HY-108450 | Polygodial | 6754-20-7 | Natural Products |
| HY-108451 | Ononetin | 487-49-0 | Natural Products |
| HY-108455 | N-Palmitoyl dopamine | 136181-87-8 | Reference compound |
| HY-108456 | N-Stearoyldopamine | 105955-10-0 | Reference compound |
| HY-108457 | 9-Phenanthrol | 484-17-3 | Reference compound |
| HY-108458 | SB 452533 | 459429-39-1 | Reference compound |
| HY-10846 | Delamanid | 681492-22-8 | Reference compound |
| HY-108460 | A-784168 | 824982-41-4 | Reference compound |
| HY-108461 | TRPM8-IN-1 | 1159996-20-9 | Reference compound |
| HY-108462 | ML-SA1 | 332382-54-4 | Reference compound |
| HY-108463 | A-967079 | 1170613-55-4 | Reference compound |
| HY-108464 | Phenamil | 2038-35-9 | Reference compound |
| HY-108464A | Phenamil (methanesulfonate) | 1161-94-0 | Reference compound |
| HY-108465 | Pyr3 | 1160514-60-2 | Reference compound |
| HY-108466 | Ro 08-2750 | 37854-59-4 | Reference compound |
| HY-108467 | GGsTop | 926281-37-0 | Reference compound |
| HY-108468 | KL001 | 309928-48-1 | Reference compound |
| HY-108469 | BI-6015 | 93987-29-2 | Reference compound |
| HY-10846R | Delamanid (Standard) | 681492-22-8 | Reference Standards |
| HY-10846S | Delamanid-d4 | | Isotope-Labeled Compounds |
| HY-10846S1 | Delamanid-d4-1 | 2673270-27-2 | Isotope-Labeled Compounds |
| HY-10847 | SB-277011 | 215803-78-4 | Reference compound |
| HY-108470 | Ro5-3335 | 30195-30-3 | Reference compound |
| HY-108471 | CU-CPT22 | 1416324-85-0 | Reference compound |
| HY-108472 | Loxoribine | 121288-39-9 | Reference compound |
| HY-108473 | CU-CPT 4a | 1279713-77-7 | Reference compound |
| HY-108474 | Nolatrexed dihydrochloride | 152946-68-4 | Reference compound |
| HY-108475 | ProINDY | 719277-30-2 | Reference compound |
| HY-108476 | INDY | 1169755-45-6 | Reference compound |
| HY-108477 | TMPyP4 tosylate | 36951-72-1 | Reference compound |
| HY-108479 | Nolpitantium | 153050-21-6 | Reference compound |
| HY-10847A | SB-277011 (dihydrochloride) | 1226917-67-4 | Reference compound |
| HY-10847B | SB-277011 (hydrochloride) | 215804-67-4 | Reference compound |
| HY-108480 | SDZ NKT 343 | 180046-99-5 | Reference compound |
| HY-108481 | L-760735 | 188923-01-5 | Reference compound |
| HY-108482 | CP-96,345 | 132746-60-2 | Reference compound |
| HY-108483 | RP 67580 | 135911-02-3 | Reference compound |
| HY-108484 | PP 3 | 5334-30-5 | Reference compound |
| HY-108485 | Damnacanthal | 477-84-9 | Natural Products |
| HY-108486 | Herbimycin A | 70563-58-5 | Natural Products |
| HY-108488 | KB SRC 4 | 1380088-03-8 | Reference compound |
| HY-108489 | ER-27319 (maleate) | 1204480-26-1 | Reference compound |
| HY-108490 | VPC 23019 | 449173-19-7 | Reference compound |
| HY-108491 | N,N-Dimethylsphingosine | 119567-63-4 | Reference compound |
| HY-108492 | TC-SP 14 | 1257093-40-5 | Reference compound |
| HY-108493 | CS-2100 | 913827-99-3 | Reference compound |
| HY-108494 | CYM50260 | 1355026-60-6 | Reference compound |
| HY-108495 | CYM50308 | 1345858-76-5 | Reference compound |
| HY-108496 | Sphingosine-1-phosphate | 26993-30-6 | Natural Products |
| HY-108496S | Sphingosine-1-phosphate-d7 | 2260670-15-1 | Isotope-Labeled Compounds |
| HY-108497 | L-803087 | 217480-26-7 | Reference compound |
| HY-108497A | L-803087 (TFA) | 1786412-46-1 | Reference compound |
| HY-108498 | L-817818 | 217480-27-8 | Reference compound |
| HY-108499 | NNC 26-9100 | 199522-35-5 | Reference compound |
| HY-108501 | (1R,1'S,3'R/1R,1'R,3'S)-L-054,264 | 208706-12-1 | Reference compound |
| HY-108502 | KC 12291 (hydrochloride) | 181936-98-1 | Reference compound |
| HY-108504 | Co 102862 | 181144-66-1 | Reference compound |
| HY-108505 | QX-314 (chloride) | 5369-03-9 | Reference compound |
| HY-108506 | Licarbazepine | 29331-92-8 | Reference compound |
| HY-108506R | Licarbazepine (Standard) | 29331-92-8 | Reference Standards |
| HY-108506S | Licarbazepine-d3 | 1189917-36-9 | Isotope-Labeled Compounds |
| HY-108506S1 | Licarbazepine-d4 | 1020719-39-4 | Isotope-Labeled Compounds |
| HY-108506S2 | Licarbazepine-d4-1 | 1188265-49-7 | Isotope-Labeled Compounds |
| HY-108506S4 | Licarbazepine-d8 | 1261393-17-2 | Isotope-Labeled Compounds |
| HY-108507 | MRT-10 | 330829-30-6 | Reference compound |
| HY-108508 | SMANT (hydrochloride) | 1177600-74-6 | Reference compound |
| HY-108509 | BMY-14802 (hydrochloride) | 105565-55-7 | Reference compound |
| HY-108510 | Rimcazole (dihydrochloride) | 75859-03-9 | Reference compound |
| HY-108511 | PB28 (dihydrochloride) | 172907-03-8 | Reference compound |
| HY-108511A | PB28 | 172906-90-0 | Reference compound |
| HY-108512 | PD 144418 | 154130-99-1 | Reference compound |
| HY-108512A | PD 144418 (oxalate) | 1794760-28-3 | Reference compound |
| HY-108513 | σ1 Receptor antagonist 4 | 362512-81-0 | Reference compound |
| HY-108514 | (±)-PPCC (hemioxalate) | 932736-91-9 | Reference compound |
| HY-108515 | (+)-Igmesine (hydrochloride) | | Reference compound |
| HY-108516 | TC-E 5001 | 865565-29-3 | Reference compound |
| HY-108518 | SB-772077B (dihydrochloride) | 607373-46-6 | Reference compound |
| HY-108519 | AS1892802 | 928320-12-1 | Reference compound |
| HY-10852 | Arterolane | 664338-39-0 | Reference compound |
| HY-108520 | HX630 | 188844-52-2 | Reference compound |
| HY-108521 | HX531 | 188844-34-0 | Reference compound |
| HY-108522 | PA452 | 457657-34-0 | Reference compound |
| HY-108523 | LG100754 | 180713-37-5 | Reference compound |
| HY-108524 | LG101506 | 331248-11-4 | Reference compound |
| HY-108525 | Fluorobexarotene | 1190848-23-7 | Reference compound |
| HY-108526 | AC-55649 | 59662-49-6 | Reference compound |
| HY-108527 | CD1530 | 107430-66-0 | Reference compound |
| HY-108528 | BMS961 | 185629-22-5 | Reference compound |
| HY-108529 | BMS493 | 215030-90-3 | Reference compound |
| HY-10852A | Arterolane (maleate) | 959520-73-1 | Reference compound |
| HY-108530 | MM11253 | 345952-44-5 | Reference compound |
| HY-108531 | ER 50891 | 187400-85-7 | Reference compound |
| HY-108531A | ER 50891 (quarterhydrate) | | Reference compound |
| HY-108532 | AC-261066 | 870773-76-5 | Reference compound |
| HY-108533 | CD2314 | 170355-37-0 | Reference compound |
| HY-108534 | PMX464 | 485842-97-5 | Reference compound |
| HY-108535 | HEPES (sodium) | 75277-39-3 | Biochemical Assay Reagents |
| HY-108536D | Calcium chloride dihydrate, for cell culture, 99% | 10035-04-8 | Biochemical Assay Reagents |
| HY-108537 | L 012 (sodium salt) | 143556-24-5 | Dye Reagents |
| HY-108538 | Ethacrynic acid D5 | 1330052-59-9 | Reference compound |
| HY-108539 | CE3F4 | 143703-25-7 | Reference compound |
| HY-108539A | (R)-CE3F4 | 1593478-56-8 | Reference compound |
| HY-108540 | BCH | 20448-79-7 | Reference compound |
| HY-108541 | N2-Methyl-L-arginine | 2480-28-6 | Reference compound |
| HY-108543 | NSC 95397 | 93718-83-3 | Reference compound |
| HY-108544 | INCA-6 | 3519-82-2 | Reference compound |
| HY-108546 | L-AP3 | 23052-80-4 | Reference compound |
| HY-108547 | Alexidine (dihydrochloride) | 1715-30-6 | Reference compound |
| HY-108548 | Rp-8-Br-PET-cGMPS (sodium) | 185246-32-6 | Reference compound |
| HY-108549 | clasto-Lactacystin β-lactone | 154226-60-5 | Natural Products |
| HY-108551 | MG-262 | 179324-22-2 | Reference compound |
| HY-108552 | MG-115 | 133407-86-0 | Reference compound |
| HY-108553 | Dihydroeponemycin | 126463-64-7 | Reference compound |
| HY-108554 | Q94 (hydrochloride) | 1052076-77-3 | Reference compound |
| HY-108555 | FR-171113 | 173904-50-2 | Reference compound |
| HY-108556 | RWJ-56110 | 252889-88-6 | Reference compound |
| HY-108556A | RWJ-56110 (dihydrochloride) | 2387505-58-8 | Reference compound |
| HY-108557 | TCS 2510 | 346673-06-1 | Reference compound |
| HY-108559 | L-161982 | 147776-06-5 | Reference compound |
| HY-108560 | (+)-Fluprostenol | 54276-17-4 | Reference compound |
| HY-108560A | 15(S)-Fluprostenol | 54276-24-3 | Reference compound |
| HY-108560R | (+)-Fluprostenol (Standard) | 54276-17-4 | Reference Standards |
| HY-108561 | L-670596 | 121083-05-4 | Reference compound |
| HY-108562 | SC-51322 | 146032-79-3 | Reference compound |
| HY-108563 | SC 51089 | 146033-02-5 | Reference compound |
| HY-108563A | SC 51089 (free base) | 146033-03-6 | Reference compound |
| HY-108564 | L 655240 | 103253-15-2 | Reference compound |
| HY-108565 | BMY 45778 | 152575-66-1 | Reference compound |
| HY-108566 | U-46619 | 56985-40-1 | Reference compound |
| HY-108567 | Bisphenol A diglycidyl ether | 1675-54-3 | Biochemical Assay Reagents |
| HY-108567R | Bisphenol A diglycidyl ether (Standard) | 1675-54-3 | Reference Standards |
| HY-108567S1 | 2,2-Bis(4-glycidyloxyphenyl)propane-d6 | 1346600-09-6 | Isotope-Labeled Compounds |
| HY-108568 | 15-Deoxy-Δ-12,14-prostaglandin J2 | 87893-55-8 | Natural Products |
| HY-108568R | 15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) | 87893-55-8 | Reference Standards |
| HY-108568S | 15-Deoxy-Δ-12,14-prostaglandin J2-d4 | 1542166-82-4 | Isotope-Labeled Compounds |
| HY-108569 | nTZDpa | 118414-59-8 | Reference compound |
| HY-10857 | Vipadenant | 442908-10-3 | Reference compound |
| HY-108570 | AUDA | 479413-70-2 | Reference compound |
| HY-108571 | CP-775146 | 702680-17-9 | Reference compound |
| HY-108572 | S26948 | 353280-43-0 | Reference compound |
| HY-108573 | P-1075 | 60559-98-0 | Reference compound |
| HY-108574 | CP 339818 (hydrochloride) | 478341-55-8 | Reference compound |
| HY-108575 | Chromanol 293B | 163163-23-3 | Reference compound |
| HY-108576 | Linopirdine (dihydrochloride) | 113168-57-3 | Reference compound |
| HY-108577 | XE991 dihydrochloride | 122955-13-9 | Reference compound |
| HY-108577A | XE991 | 122955-42-4 | Reference compound |
| HY-108578 | RuBi-4AP | 851956-02-0 | Reference compound |
| HY-108579 | UCL 1684 (dibromide) | 199934-16-2 | Reference compound |
| HY-10858 | WAY 316606 | 915759-45-4 | Reference compound |
| HY-108582 | Y-27152 | 127408-30-4 | Reference compound |
| HY-108583 | Psora-4 | 724709-68-6 | Reference compound |
| HY-108584 | Flindokalner | 187523-35-9 | Reference compound |
| HY-108585 | VU591 hydrochloride | 1315380-70-1 | Reference compound |
| HY-108585A | VU591 | 1222810-74-3 | Reference compound |
| HY-108586 | NS3623 | 343630-41-1 | Reference compound |
| HY-108587 | ICA 110381 | 325457-99-6 | Reference compound |
| HY-108588 | NS5806 | 426834-69-7 | Reference compound |
| HY-108589 | PNU 37883 (hydrochloride) | 57568-80-6 | Reference compound |
| HY-10858A | WAY 316606 (hydrochloride) | 1781835-02-6 | Reference compound |
| HY-108590 | DMP-543 | 160588-45-4 | Reference compound |
| HY-108591 | L-364,373 | 103342-82-1 | Reference compound |
| HY-108592 | UCL 2077 | 918311-87-2 | Reference compound |
| HY-108593 | BMS-191011 | 202821-81-6 | Reference compound |
| HY-108594 | PD-118057 | 313674-97-4 | Reference compound |
| HY-108595 | VU590 | 313505-85-0 | Reference compound |
| HY-108596 | BL-1249 | 18200-13-0 | Reference compound |
| HY-108597 | TC-S 7005 | 1082739-92-1 | Reference compound |
| HY-108599 | DCP-LA | 28399-31-7 | Reference compound |
| HY-108599A | DCPLA-ME | 56687-67-3 | Reference compound |
| HY-108599R | DCP-LA (Standard) | 28399-31-7 | Reference Standards |
| HY-108600 | CGP-53353 | 145915-60-2 | Reference compound |
| HY-108601 | (S)-Ro 32-0432 (free base) | 151342-35-7 | Reference compound |
| HY-108601A | (S)-Ro 32-0432 | 1781828-85-0 | Reference compound |
| HY-108602 | Bryostatin 3 | 143370-84-7 | Reference compound |
| HY-108603 | Bryostatin 2 | 87745-28-6 | Natural Products |
| HY-108604 | Bisindolylmaleimide II | 137592-45-1 | Reference compound |
| HY-108605 | PIM1-IN-2 | 477845-12-8 | Reference compound |
| HY-108606 | PI-828 | 942289-87-4 | Reference compound |
| HY-108607 | PACOCF3 | 141022-99-3 | Reference compound |
| HY-108608 | o-3M3FBS | 313981-55-4 | Reference compound |
| HY-108609 | YM-26734 | 144337-18-8 | Reference compound |
| HY-10861 | D3/5-HT receptor modulator-1 | 898532-85-9 | Reference compound |
| HY-108610 | (R)-Edelfosine | 77286-66-9 | Reference compound |
| HY-108610A | Edelfosine | 70641-51-9 | Reference compound |
| HY-108611 | AACOCF3 | 149301-79-1 | Reference compound |
| HY-108612 | VU0155069 | 1130067-06-9 | Reference compound |
| HY-108612A | VU0155069 (hydrochloride) | 1781834-89-6 | Reference compound |
| HY-108613 | JJKK 048 | 1515855-97-6 | Reference compound |
| HY-108614 | GPi688 | 918902-32-6 | Reference compound |
| HY-108615 | CP-316819 | 186392-43-8 | Reference compound |
| HY-108616 | VU 0364739 (hydrochloride) | 1244640-48-9 | Reference compound |
| HY-108617 | YM976 | 191219-80-4 | Reference compound |
| HY-108618 | BC11-38 | 686770-80-9 | Reference compound |
| HY-108619 | Gisadenafil (besylate) | 334827-98-4 | Reference compound |
| HY-10862 | FAAH inhibitor 1 | 326866-17-5 | Reference compound |
| HY-108620 | CDP-840 | 162542-90-7 | Reference compound |
| HY-108621 | RS-25344 (hydrochloride) | 152815-28-6 | Reference compound |
| HY-108622 | Mesopram | 189940-24-7 | Reference compound |
| HY-108623 | Atizoram | 135637-46-6 | Reference compound |
| HY-108624 | CYM 50769 | 1421365-63-0 | Reference compound |
| HY-108625 | SHA 68 | 847553-89-3 | Reference compound |
| HY-108626 | ML154 | 1345964-89-7 | Reference compound |
| HY-108627 | DMPQ (dihydrochloride) | 1123491-15-5 | Reference compound |
| HY-108628 | SU16f | 251356-45-3 | Reference compound |
| HY-10863 | Anandamide | 94421-68-8 | Natural Products |
| HY-108630 | U-73343 | 142878-12-4 | Reference compound |
| HY-108631 | EB-47 (dihydrochloride) | 1190332-25-2 | Reference compound |
| HY-108632 | BYK204165 | 1104546-89-5 | Reference compound |
| HY-108633 | BYK 49187 | 163120-31-8 | Reference compound |
| HY-108634 | Apafant | 105219-56-5 | Reference compound |
| HY-108635 | C16-PAF | 74389-68-7 | Reference compound |
| HY-108636 | RETRA | 1036069-26-7 | Reference compound |
| HY-108637 | PhiKan 083 | 880813-36-5 | Reference compound |
| HY-108637A | PhiKan 083 hydrochloride | 1050480-30-2 | Reference compound |
| HY-108638 | NSC 146109 (hydrochloride) | 59474-01-0 | Reference compound |
| HY-108639 | MIRA-1 | 72835-26-8 | Reference compound |
| HY-10863S | Anandamide-d8 | 924894-98-4 | Isotope-Labeled Compounds |
| HY-10863S1 | Anandamide-d11 | 2260669-86-9 | Isotope-Labeled Compounds |
| HY-10864 | URB-597 | 546141-08-6 | Reference compound |
| HY-108640 | HLI373 | 502137-98-6 | Reference compound |
| HY-108640A | HLI373 (dihydrochloride) | 1782531-99-0 | Reference compound |
| HY-108641 | SKF-86002 (dihydrochloride) | 116339-68-5 | Reference compound |
| HY-108642 | AMG-548 | 864249-60-5 | Reference compound |
| HY-108642A | AMG-548 (hydrochloride) | 2437438-16-7 | Reference compound |
| HY-108642B | AMG-548 (dihydrochloride) | 2518299-32-4 | Reference compound |
| HY-108643 | CMPD1 | 41179-33-3 | Reference compound |
| HY-108644 | SB 706504 | 911110-38-8 | Reference compound |
| HY-108645 | AL 8697 | 1057394-06-5 | Reference compound |
| HY-108646 | SX 011 | 309913-42-6 | Reference compound |
| HY-108647 | EO 1428 | 321351-00-2 | Reference compound |
| HY-108648 | 2-MeS-ADP (trisodium) | 475193-31-8 | Reference compound |
| HY-108648A | 2-MeSADP | 34983-48-7 | Reference compound |
| HY-108649A | MRS2768 (tetrasodium salt) | 2567869-47-8 | Reference compound |
| HY-10865 | LY2183240 | 874902-19-9 | Reference compound |
| HY-108650 | 2-Thio-UTP (tetrasodium) | 1343364-70-4 | Reference compound |
| HY-108651 | Uridine-5'-O-(3-thiotriphosphate) (trisodium) | 1266569-94-1 | Reference compound |
| HY-108652 | α,β-Methylene-ATP (trisodium) | 1343364-54-4 | Reference compound |
| HY-108654 | PSB 0474 | 917567-60-3 | Reference compound |
| HY-108656 | MRS2365 | 436847-09-5 | Reference compound |
| HY-108656A | MRS2365 (trisodium) | | Reference compound |
| HY-108657 | MRS2279 | 367909-40-8 | Reference compound |
| HY-108657A | MRS2279 (diammonium) | 2387505-47-5 | Reference compound |
| HY-108658 | MRS2500 (tetraammonium) | 630103-23-0 | Reference compound |
| HY-108659 | NF340 | 202982-98-7 | Reference compound |
| HY-108660 | PSB-0739 | 1052087-90-7 | Reference compound |
| HY-108661 | NF546 | 1006028-37-0 | Reference compound |
| HY-108661A | NF546 (hydrate) | | Reference compound |
| HY-108662 | PIT | 56583-49-4 | Reference compound |
| HY-108663 | 5-OMe-UDP | 1207530-98-0 | Reference compound |
| HY-108664 | MRS2957 | 1228271-30-4 | Reference compound |
| HY-108665 | AR-C66096 (tetrasodium) | 145782-74-7 | Reference compound |
| HY-108666 | ATPγS (tetralithium salt) | 93839-89-5 | Reference compound |
| HY-108667 | TNP-ATP (triethylammonium) | 61368-63-6 | Reference compound |
| HY-108668 | TC-P 262 | 873398-67-5 | Reference compound |
| HY-108669 | AZ10606120 (dihydrochloride) | 607378-18-7 | Reference compound |
| HY-10867 | PF-622 | 898235-65-9 | Reference compound |
| HY-108670 | AZ 11645373 | 227088-94-0 | Reference compound |
| HY-108671 | NF110 | 111150-22-2 | Reference compound |
| HY-108672 | NF157 | 104869-26-3 | Reference compound |
| HY-108673 | Ro 0437626 | 134362-79-1 | Reference compound |
| HY-108675 | PPNDS (tetrasodium) | 1021868-77-8 | Reference compound |
| HY-108676 | NF023 (hexasodium) | 104869-31-0 | Reference compound |
| HY-108677 | L-368,899 hydrochloride | 160312-62-9 | Reference compound |
| HY-108678 | TC OT 39 | 479232-57-0 | Reference compound |
| HY-108679 | WAY-267464 (hydrochloride) | 1432043-31-6 | Reference compound |
| HY-108680 | Carbazeran (citrate) | 153473-94-0 | Reference compound |
| HY-108681 | 680C91 | 163239-22-3 | Reference compound |
| HY-108682 | EMPA | 680590-49-2 | Reference compound |
| HY-108683 | ACT-335827 | 1354039-86-3 | Reference compound |
| HY-108685 | Alendronate sodium | 129318-43-0 | Reference compound |
| HY-108685S | Alendronate-d4 (sodium) | 1309283-09-7 | Isotope-Labeled Compounds |
| HY-108688 | GSK2033 | 1221277-90-2 | Reference compound |
| HY-108689 | Broflanilide | 1207727-04-5 | Reference compound |
| HY-108689R | Broflanilide (Standard) | 1207727-04-5 | Reference Standards |
| HY-10869 | OL-135 | 681135-77-3 | Reference compound |
| HY-108690 | Fluxametamide | 928783-29-3 | Reference compound |
| HY-108691 | PF-06465469 | 1407966-77-1 | Reference compound |
| HY-108692 | Enterolactone | 78473-71-9 | Natural Products |
| HY-108692R | Enterolactone (Standard) | 78473-71-9 | Reference Standards |
| HY-108692S | Enterolactone-d6 | 104411-11-2 | Isotope-Labeled Compounds |
| HY-108693 | β-Tocotrienol | 490-23-3 | Reference compound |
| HY-108693R | β-Tocotrienol (Standard) | 490-23-3 | Reference Standards |
| HY-108694 | γ-Tocotrienol | 14101-61-2 | Natural Products |
| HY-108694R | γ-Tocotrienol (Standard) | 14101-61-2 | Reference Standards |
| HY-108695 | Enterodiol | 80226-00-2 | Reference compound |
| HY-108695B | (±)-Enterodiol | 77756-22-0 | Natural Products |
| HY-108695BR | (±)-Enterodiol (Standard) | 77756-22-0 | Reference Standards |
| HY-108696 | GNE-781 | 1936422-33-1 | Reference compound |
| HY-108697 | PT2399 | 1672662-14-4 | Reference compound |
| HY-108697A | (Rac)-PT2399 | 1672662-07-5 | Reference compound |
| HY-108698 | Preclamol (hydrochloride) | 88768-67-6 | Reference compound |
| HY-108698A | (R)-Preclamol (hydrochloride) | 89874-80-6 | Reference compound |
| HY-108699 | TM-N1324 | 1144477-35-9 | Reference compound |
| HY-10870 | RO-9187 | 876708-03-1 | Reference compound |
| HY-108700 | N-3-Oxo-octanoyl-L-homoserine lactone | 147795-39-9 | Reference compound |
| HY-108701 | Nampt-IN-3 | 2121591-52-2 | Reference compound |
| HY-108702 | ML-792 | 1644342-14-2 | Reference compound |
| HY-108703 | Foliglurax | 1883329-51-8 | Reference compound |
| HY-108703A | Foliglurax (monohydrochloride) | 2133294-96-7 | Reference compound |
| HY-108704 | CT-721 | 1388710-60-8 | Reference compound |
| HY-108705 | BI-3802 | 2166387-65-9 | Reference compound |
| HY-108706 | KDM2A/7A-IN-1 | 2169272-46-0 | Reference compound |
| HY-108707 | LY3130481 | 1610802-47-5 | Reference compound |
| HY-108708 | GeA-69 | 2143475-98-1 | Reference compound |
| HY-108709 | CC-671 | 1618658-88-0 | Reference compound |
| HY-10871 | Otenabant | 686344-29-6 | Reference compound |
| HY-108710 | VU0650786 | 1809085-30-0 | Reference compound |
| HY-108711 | GPR120 Agonist 1 | 1628448-77-0 | Reference compound |
| HY-108712 | TDCPP | 13674-87-8 | Reference compound |
| HY-108712R | TDCPP (Standard) | 13674-87-8 | Reference Standards |
| HY-108713 | Famitinib | 1044040-56-3 | Reference compound |
| HY-108713A | Famitinib (malate) | 1256377-67-9 | Reference compound |
| HY-108713R | Famitinib (Standard) | 1044040-56-3 | Reference Standards |
| HY-108714 | NGP555 | 1304630-27-0 | Reference compound |
| HY-108715 | Real Thiol | 2280796-90-7 | Dye Reagents |
| HY-108715A | RT-AM | 2280796-94-1 | Dye Reagents |
| HY-108716 | Felezonexor | 1076235-04-5 | Reference compound |
| HY-108717 | Proteinase K | 39450-01-6 | Reference compound |
| HY-108717A | Recombinant Proteinase K (DNase & RNase free, animal free) | 39450-01-6 | Enzyme |
| HY-108717B | Proteinase K (NGS grade) | 39450-01-6 | Enzyme |
| HY-108718 | G-418 | 49863-47-0 | Reference compound |
| HY-108719 | Insulin glargine | 160337-95-1 | Peptides |
| HY-10871A | Otenabant (Hydrochloride) | 686347-12-6 | Reference compound |
| HY-10873 | N-Desethyl Sunitinib | 356068-97-8 | Reference compound |
| HY-108730 | Avelumab | 1537032-82-8 | Inhibitory Antibodies |
| HY-108730A | Avelumab (anti-PD-L1) | 1537032-82-8 | Inhibitory Antibodies |
| HY-108738 | Daclizumab | 152923-56-3 | Inhibitory Antibodies |
| HY-108739 | Idarucizumab | 1362509-93-0 | Inhibitory Antibodies |
| HY-10873R | N-Desethyl Sunitinib (Standard) | 356068-97-8 | Reference Standards |
| HY-10873S | N-Desethyl Sunitinib-d5 | 1217247-62-5 | Isotope-Labeled Compounds |
| HY-10873S1 | N-Desethyl Sunitinib-d4 (TFA) | 2012601-57-7 | Isotope-Labeled Compounds |
| HY-10873S2 | N-Desethyl Sunitinib-d5 (hydrochloride) | 1261432-14-7 | Isotope-Labeled Compounds |
| HY-108741 | Plecanatide | 467426-54-6 | Peptides |
| HY-108741A | Plecanatide (acetate) | 1075732-84-1 | Peptides |
| HY-108742 | Abaloparatide | 247062-33-5 | Peptides |
| HY-108742A | Abaloparatide (TFA) | | Peptides |
| HY-108743 | Insulin degludec | 844439-96-9 | Peptides |
| HY-108746 | Defibrotide (sodium) | 83712-60-1 | Oligonucleotides |
| HY-108749 | Olive oil | 8001-25-0 | Biochemical Assay Reagents |
| HY-10875 | LRRK2-IN-1 | 1234480-84-2 | Reference compound |
| HY-108750 | Soybean oil | 8001-22-7 | Biochemical Assay Reagents |
| HY-108751 | Aripiprazole Lauroxil | 1259305-29-7 | Reference compound |
| HY-108753 | Eteplirsen | 1173755-55-9 | Oligonucleotides |
| HY-108753A | Eteplirsen (sodium) | | Oligonucleotides |
| HY-108760 | Gadoterate meglumine | 92943-93-6 | Reference compound |
| HY-108764 | Mipomersen (sodium) | 629167-92-6 | Oligonucleotides |
| HY-108765 | Ferric carboxymaltose | 53858-86-9 | Biochemical Assay Reagents |
| HY-108766 | Ponatinib (hydrochloride) | 1114544-31-8 | Reference compound |
| HY-108767 | Insulin aspart | 116094-23-6 | Peptides |
| HY-108768 | Pasireotide (pamoate) | 396091-79-5 | Peptides |
| HY-108772 | Crofelemer | 148465-45-6 | Reference compound |
| HY-108774 | Rosuvastatin zinc salt | 953412-08-3 | Reference compound |
| HY-108775A | Sodium thiosulfate (99%, water≤1.0%) | 7772-98-7 | Biochemical Assay Reagents |
| HY-108776 | (Rac)-sn-Glycerol 3-phosphate (sodium) | 1555-56-2 | Natural Products |
| HY-108786 | Asfotase alfa | 1174277-80-5 | Inhibitory Antibodies |
| HY-108790 | Peginterferon beta-1a | 1211327-92-2 | Reference compound |
| HY-108795 | Albiglutide fragment | 224638-84-0 | Peptides |
| HY-108795A | Albiglutide fragment (TFA) | | Peptides |
| HY-108798 | Ziv-aflibercept | 1609655-49-3 | Inhibitory Antibodies |
| HY-108801 | Aflibercept | 862111-32-8 | Inhibitory Antibodies |
| HY-108801A | Aflibercept (VEGF Trap) | 862111-32-8 | Inhibitory Antibodies |
| HY-108807 | Glucarpidase | 1622456-55-6 | Enzyme |
| HY-108810 | Canakinumab | 914613-48-2 | Inhibitory Antibodies |
| HY-108813 | Belatacept | 706808-37-9 | Inhibitory Antibodies |
| HY-108814 | Ecallantide | 460738-38-9 | Peptides |
| HY-108814A | Ecallantide (TFA) | | Peptides |
| HY-108817 | HIV-1 integrase inhibitor 3 | 1638504-56-9 | Reference compound |
| HY-108818 | XZ426 | 1638504-52-5 | Reference compound |
| HY-10882 | Clotrimazole | 23593-75-1 | Reference compound |
| HY-108820 | HIV-1 integrase inhibitor 4 | 1638504-66-1 | Reference compound |
| HY-108822 | Rilonacept | 501081-76-1 | Inhibitory Antibodies |
| HY-108826 | Iduronate sulfatase | 50936-59-9 | Enzyme |
| HY-108829 | Abatacept | 332348-12-6 | Inhibitory Antibodies |
| HY-108829A | Abatacept (powder) | 332348-12-6 | Inhibitory Antibodies |
| HY-10882R | Clotrimazole (Standard) | 23593-75-1 | Reference Standards |
| HY-10882S | Clotrimazole-d5 | 1185076-41-8 | Isotope-Labeled Compounds |
| HY-10882S1 | Clotrimazole-d10 | | Isotope-Labeled Compounds |
| HY-108830 | Galsulfase | 552858-79-4 | Biochemical Assay Reagents |
| HY-108831 | Natalizumab | 189261-10-7 | Inhibitory Antibodies |
| HY-108831A | Natalizumab (Solution) | 189261-10-7 | Inhibitory Antibodies |
| HY-108841 | Raleukin | 143090-92-0 | Inhibitory Antibodies |
| HY-108844 | Rasburicase | 134774-45-1 | Reference compound |
| HY-108845 | Tenecteplase | 191588-94-0 | Enzyme |
| HY-108847 | Etanercept | 185243-69-0 | Inhibitory Antibodies |
| HY-10885 | A-620223 (succinate) | 943650-25-7 | Reference compound |
| HY-108852 | Basiliximab | 179045-86-4 | Inhibitory Antibodies |
| HY-108858 | Dornase alfa | 143831-71-4 | Enzyme |
| HY-10886 | MCOPPB | 1028969-49-4 | Reference compound |
| HY-108860 | Oncaspar | 130167-69-0 | Inhibitory Antibodies |
| HY-108865 | Alteplase | 105857-23-6 | Enzyme |
| HY-108868 | Mersalyl | 492-18-2 | Reference compound |
| HY-108869 | Fodipir | 118248-91-2 | Reference compound |
| HY-108869R | Fodipir (Standard) | 118248-91-2 | Reference Standards |
| HY-108872S | Water-18O | 14314-42-2 | Isotope-Labeled Compounds |
| HY-108872S1 | Water-17O | 13768-40-6 | Isotope-Labeled Compounds |
| HY-108874 | Candicidin | 1403-17-4 | Natural Products |
| HY-108875 | Erythromycin stearate | 643-22-1 | Reference compound |
| HY-108876 | Daunorubicin (citrate) | 1884557-85-0 | ADC Related |
| HY-108877 | Cefepime (hydrochloride) | 107648-80-6 | Reference compound |
| HY-108879 | Cefotetan (disodium) | 74356-00-6 | Reference compound |
| HY-10888 | Istradefylline | 155270-99-8 | Reference compound |
| HY-108880 | Carindacillin (sodium) | 26605-69-6 | Reference compound |
| HY-108881 | Troleandomycin | 2751-09-9 | Reference compound |
| HY-108881R | Troleandomycin (Standard) | 2751-09-9 | Reference Standards |
| HY-108882 | DNase I, Bovine pancreas | 9003-98-9 | Enzyme |
| HY-108882A | Recombinant DNase I (RNase-free) | 9003-98-9 | Enzyme |
| HY-108882B | DNase I (RNase & Protease free) | 9003-98-9 | Enzyme |
| HY-108882C | DNase I (filtered) | 9003-98-9 | Enzyme |
| HY-108882D | Recombinant DNase I (Protease & RNase free, animal free) | 9003-98-9 | Enzyme |
| HY-108883 | Plasmin, Human plasma | 9001-90-5 | Enzyme |
| HY-108886 | JWG-071 | 2250323-50-1 | Reference compound |
| HY-108887 | Anticancer agent 124 | 1884226-20-3 | Reference compound |
| HY-10888R | Istradefylline (Standard) | 155270-99-8 | Reference Standards |
| HY-10888S | Istradefylline-13C,d3 | 2749234-46-4 | Isotope-Labeled Compounds |
| HY-10889 | Preladenant | 377727-87-2 | Reference compound |
| HY-108896 | Icatibant (acetate) | 138614-30-9 | Peptides |
| HY-108900 | Leu-AMS | 288591-93-5 | Reference compound |
| HY-108900A | Leu-AMS R enantiomer | | Reference compound |
| HY-108901 | Formoterol (hemifumarate hydrate) | 183814-30-4 | Reference compound |
| HY-108901R | Formoterol (hemifumarate hydrate) (Standard) | 183814-30-4 | Reference Standards |
| HY-108903 | Hyaluronidase (human recombinant) | 37326-33-3 | Enzyme |
| HY-108903A | Hyaluronidase, Ovine testes | 37326-33-3 | Enzyme |
| HY-108904 | Urokinase, Human urine | 9039-53-6 | Enzyme |
| HY-108905 | Mecasermin | 68562-41-4 | Peptides |
| HY-108907 | SR-1277 | 1446715-47-4 | Reference compound |
| HY-108908 | (Rac)-Modipafant | 122956-68-7 | Reference compound |
| HY-108908A | Modipafant | 122957-06-6 | Reference compound |
| HY-108909 | Chymopapain | 9001-09-6 | Enzyme |
| HY-10891 | HIV-1 inhibitor-61 | 1114507-62-8 | Reference compound |
| HY-108910 | Chymotrypsin | 9004-07-3 | Enzyme |
| HY-108910A | Chymotrypsin (MS grade) | 9004-07-3 | Enzyme |
| HY-108910B | TLCK-treated Chymotrypsin | 9004-07-3 | Enzyme |
| HY-108910C | Chymotrypsin, Human Pancreas | 9004-07-3 | Enzyme |
| HY-108912 | RO1138452 | 221529-58-4 | Reference compound |
| HY-108913 | Nitrocefin | 41906-86-9 | Reference compound |
| HY-108913R | Nitrocefin (Standard) | 41906-86-9 | Reference Standards |
| HY-108915 | Trimethylamine N-oxide (dihydrate) | 62637-93-8 | Natural Products |
| HY-108917 | Morphothiadin | 1092970-12-1 | Reference compound |
| HY-108917A | Morphothiadin (mesylate) | 1646361-04-7 | Reference compound |
| HY-10892 | HEPT | 123027-56-5 | Reference compound |
| HY-108920 | 4-Chlorokynurenine | 153152-32-0 | Reference compound |
| HY-108922 | Probucol disuccinate | 216168-45-5 | Reference compound |
| HY-108931 | AG 1406 | 71308-34-4 | Reference compound |
| HY-108932 | Gemcitabine monophosphate | 116371-67-6 | Reference compound |
| HY-108932A | Gemcitabine monophosphate (disodium) | 1638288-31-9 | Reference compound |
| HY-108933 | JK-P3 | 942655-44-9 | Reference compound |
| HY-108935 | Lavendustin B | 125697-91-8 | Reference compound |
| HY-108936 | QCC374 | 1356331-63-9 | Reference compound |
| HY-108937 | NSC 15364 | 4550-72-5 | Reference compound |
| HY-108938 | SDZ285428 | 174262-13-6 | Reference compound |
| HY-108939 | Aminoacyl tRNA synthetase-IN-1 | 219931-45-0 | Reference compound |
| HY-108940 | GlyRS-IN-1 | 112921-11-6 | Reference compound |
| HY-108941 | Salicyl-AMS | 863238-55-5 | Reference compound |
| HY-108943 | Sabinene | 3387-41-5 | Natural Products |
| HY-108944 | LYP-IN-1 | 1404436-51-6 | Reference compound |
| HY-10895 | SB-334867 | 249889-64-3 | Reference compound |
| HY-108952 | 17,17-(Ethylenedioxy)androst-4-en-3-one | 1044-89-9 | Reference compound |
| HY-108953 | (S)-Quinolactacine A | 319917-25-4 | Natural Products |
| HY-108954 | A-30912A nucleus (hydrochloride) | 1029890-89-8 | Peptides |
| HY-108958 | (Rac)-AZD8186 | 1296270-45-5 | Reference compound |
| HY-108959 | D-87503 | 800394-83-6 | Reference compound |
| HY-10895A | SB-334867 (free base) | 792173-99-0 | Reference compound |
| HY-10896 | JNJ-10397049 | 708275-58-5 | Reference compound |
| HY-108960 | PPADS | 149017-66-3 | Reference compound |
| HY-108963 | LY 170198 | 99682-33-4 | Reference compound |
| HY-108964 | Carvone | 99-49-0 | Natural Products |
| HY-108964R | Carvone (Standard) | 99-49-0 | Reference Standards |
| HY-108966 | Kushenol C | 99119-73-0 | Natural Products |
| HY-108968 | Alitame (hydrate) | 99016-42-9 | Reference compound |
| HY-108968R | Alitame (hydrate) (Standard) | 99016-42-9 | Reference Standards |
| HY-108969 | Pyrazoloacridine | 99009-20-8 | Reference compound |
| HY-108970 | Bafilomycin D | 98813-13-9 | Natural Products |
| HY-108971 | Demecycline | 987-02-0 | Reference compound |
| HY-108971R | Demecycline (Standard) | 987-02-0 | Reference Standards |
| HY-108972 | SQ 29548 | 98672-91-4 | Reference compound |
| HY-108973 | CGP 15210G | 98518-48-0 | Reference compound |
| HY-108974 | Drotaverine (hydrochloride) | 985-12-6 | Reference compound |
| HY-108974S | Drotaverine-d10 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-108976 | Raclopride (tartrate) | 98185-20-7 | Reference compound |
| HY-108977 | VUF 8430 | 98021-17-1 | Reference compound |
| HY-10898 | SB-674042 | 483313-22-0 | Reference compound |
| HY-108981 | CERM11956 | 97631-49-7 | Reference compound |
| HY-108984 | BBMP | 97120-13-3 | Reference compound |
| HY-108985 | Trazium esilate | 97110-59-3 | Reference compound |
| HY-108986 | JFD00244 | 96969-83-4 | Reference compound |
| HY-108987 | 1-O-hexadecyl-2-O-methyl-sn-glycerol | 96960-92-8 | Biochemical Assay Reagents |
| HY-108988 | Albicidin | 1622253-00-2 | Reference compound |
| HY-108989 | FMDP | 96920-07-9 | Reference compound |
| HY-108991 | T-0509 | 96843-99-1 | Reference compound |
| HY-108992 | Deoxynyboquinone | 96748-86-6 | Reference compound |
| HY-108993 | Fujianmycin B | 130548-09-3 | Reference compound |
| HY-108996 | PD 118879 | 96568-33-1 | Reference compound |
| HY-108997 | Palonidipine | 96515-73-0 | Reference compound |
| HY-108997A | Palonidipine (hydrochloride) | 96515-74-1 | Reference compound |
| HY-108998 | Bisaramil (hydrochloride) | 96480-44-3 | Reference compound |
| HY-108999 | Crisnatol (mesylate) | 96389-69-4 | Reference compound |
| HY-108999A | Crisnatol | 96389-68-3 | Reference compound |
| HY-10900 | TCS 1102 | 916141-36-1 | Reference compound |
| HY-109000 | Afabicin | 1518800-35-5 | Reference compound |
| HY-109000A | Afabicin (disodium) | 1518800-29-7 | Reference compound |
| HY-109001 | Alicapistat | 1254698-46-8 | Reference compound |
| HY-109001A | (1S,2R)-Alicapistat | 2221010-57-5 | Reference compound |
| HY-109002 | Apararenone | 945966-46-1 | Reference compound |
| HY-109004 | Enzaplatovir | 1323077-89-9 | Reference compound |
| HY-109004A | (S)-Enzaplatovir | 1323077-88-8 | Reference compound |
| HY-109006 | Ilmetropium (iodide) | 129109-88-2 | Reference compound |
| HY-109008 | Nacubactam | 1452458-86-4 | Reference compound |
| HY-109009 | Padsevonil | 1294000-61-5 | Reference compound |
| HY-109010 | Poseltinib | 1353552-97-2 | Reference compound |
| HY-109011 | Rosiptor | 782487-28-9 | Reference compound |
| HY-109011A | Rosiptor (acetate) | 782487-29-0 | Reference compound |
| HY-109012 | Seltorexant | 1293281-49-8 | Reference compound |
| HY-109012A | Seltorexant (hydrochloride) | 1293284-49-7 | Reference compound |
| HY-109013 | Sofpironium (bromide) | 1628106-94-4 | Reference compound |
| HY-109014 | Tenofovir exalidex | 911208-73-6 | Reference compound |
| HY-109015 | Tucidinostat | 1616493-44-7 | Reference compound |
| HY-109015S | Tucidinostat-d4 | | Isotope-Labeled Compounds |
| HY-109016 | Valnivudine | 956483-02-6 | Reference compound |
| HY-109017 | Vamorolone | 13209-41-1 | Reference compound |
| HY-109018 | Velagliflozin | 946525-65-1 | Reference compound |
| HY-109018A | Velagliflozin (proline) | 1539295-26-5 | Reference compound |
| HY-109018B | Velagliflozin (proline hydrate) | 1661838-94-3 | Reference compound |
| HY-109019 | Vorolanib | 1013920-15-4 | Reference compound |
| HY-109020 | Acrizanib | 1229453-99-9 | Reference compound |
| HY-109022 | Atogepant | 1374248-81-3 | Reference compound |
| HY-109022A | (3R,5R,6S)-Atogepant | | Reference compound |
| HY-109023 | Azeloprazole | 955095-45-1 | Reference compound |
| HY-109024 | Balovaptan | 1228088-30-9 | Reference compound |
| HY-109025 | Baloxavir marboxil | 1985606-14-1 | Reference compound |
| HY-109025A | Baloxavir | 1985605-59-1 | Reference compound |
| HY-109025AR | Baloxavir (Standard) | 1985605-59-1 | Reference Standards |
| HY-109025AS | Baloxavir-d5 | | Isotope-Labeled Compounds |
| HY-109025R | Baloxavir marboxil (Standard) | 1985606-14-1 | Reference Standards |
| HY-109027 | Cavosonstat | 1371587-51-7 | Reference compound |
| HY-109029 | Dezapelisib | 1262440-25-4 | Reference compound |
| HY-109030 | Dorzagliatin | 1191995-00-2 | Reference compound |
| HY-109030R | Dorzagliatin (Standard) | 1191995-00-2 | Reference Standards |
| HY-109032 | Firuglipel | 1371591-51-3 | Reference compound |
| HY-109033 | Fosmetpantotenate | 1858268-66-2 | Reference compound |
| HY-109035 | Inarigivir soproxil | 942123-43-5 | Reference compound |
| HY-109036 | Landipirdine | 1000308-25-7 | Reference compound |
| HY-109036A | (S)-Landipirdine | 1000308-09-7 | Reference compound |
| HY-109037 | Mavacamten | 1642288-47-8 | Reference compound |
| HY-109037R | Mavacamten (Standard) | 1642288-47-8 | Reference Standards |
| HY-109037S | Mavacamten-d6 | 2453251-18-6 | Isotope-Labeled Compounds |
| HY-109037S2 | Mavacamten-d1 | 2453251-02-8 | Isotope-Labeled Compounds |
| HY-109037S3 | Mavacamten-d5 | 2453251-00-6 | Isotope-Labeled Compounds |
| HY-109037S4 | Mavacamten-d7 | | Isotope-Labeled Compounds |
| HY-109038 | Mocravimod | 509092-16-4 | Reference compound |
| HY-109039 | Praliciguat | 1628730-49-3 | Reference compound |
| HY-109040 | Quilseconazole | 1340593-70-5 | Reference compound |
| HY-109041 | Razuprotafib | 1008510-37-9 | Reference compound |
| HY-109042 | Relacorilant | 1496510-51-0 | Reference compound |
| HY-109044 | Tapinarof | 79338-84-4 | Reference compound |
| HY-109044R | Tapinarof (Standard) | 79338-84-4 | Reference Standards |
| HY-109044S | Tapinarof-d5 | 2748997-80-8 | Isotope-Labeled Compounds |
| HY-109045 | Teslexivir | 1075798-37-6 | Reference compound |
| HY-109045A | Teslexivir (hydrochloride) | 1075281-70-7 | Reference compound |
| HY-109046 | Tulrampator | 1038984-31-4 | Reference compound |
| HY-109047 | Adafosbuvir | 1613589-09-5 | Reference compound |
| HY-109049 | Adavivint | 1467093-03-3 | Reference compound |
| HY-109050 | Alobresib | 1637771-14-2 | Reference compound |
| HY-109051 | Arfolitixorin | 31690-11-6 | Natural Products |
| HY-109051A | Arfolitixorin (calcium) | 1148151-21-6 | Reference compound |
| HY-109051C | Arfolitixorin (sulfate) | 149930-93-8 | Reference compound |
| HY-109052 | Atabecestat | 1200493-78-2 | Reference compound |
| HY-109053 | Delgocitinib | 1263774-59-9 | Reference compound |
| HY-109053A | Delgocitinib (ethanolate) | 2064338-33-4 | Reference compound |
| HY-109054 | O-Demethyltramadol | 80456-81-1 | Reference compound |
| HY-109054A | O-Desmethyltramadol (hydrochloride) | 185453-02-5 | Reference compound |
| HY-109054AS | O-Desmethyltramadol-d6 (hydrochloride) | 1261393-87-6 | Isotope-Labeled Compounds |
| HY-109055 | Elenbecestat | 1388651-30-6 | Reference compound |
| HY-109056 | Elsulfavirine | 868046-19-9 | Reference compound |
| HY-109057 | Enarodustat | 1262132-81-9 | Reference compound |
| HY-109057A | Enarodustat (hydrochloride) | 1262131-60-1 | Reference compound |
| HY-109058 | Firibastat | 648927-86-0 | Reference compound |
| HY-109059 | Fulacimstat | 1488354-15-9 | Reference compound |
| HY-109060 | Garvagliptin | 1601479-87-1 | Reference compound |
| HY-109061 | Lazertinib | 1903008-80-9 | Reference compound |
| HY-109064 | Loxicodegol | 1211231-76-3 | Reference compound |
| HY-109065 | Minesapride | 1184662-54-1 | Reference compound |
| HY-109066 | Olinciguat | 1628732-62-6 | Reference compound |
| HY-109067 | Opiranserin | 1441000-45-8 | Reference compound |
| HY-109067A | Opiranserin (hydrochloride) | 1440796-75-7 | Reference compound |
| HY-109068 | Parsaclisib | 1426698-88-5 | Reference compound |
| HY-109068A | Parsaclisib (hydrochloride) | 1995889-48-9 | Reference compound |
| HY-109069 | Petesicatib | 1252637-35-6 | Reference compound |
| HY-109070 | Ralaniten | 1203490-23-6 | Reference compound |
| HY-109071 | Relmapirazin | 1313706-17-0 | Reference compound |
| HY-109072 | Riamilovir | 123606-06-4 | Reference compound |
| HY-109073 | Rovazolac | 1454288-88-0 | Reference compound |
| HY-109074 | Seliforant | 1164115-89-2 | Reference compound |
| HY-109075 | Tasipimidine | 1465908-70-6 | Reference compound |
| HY-109075A | Tasipimidine (sulfate) | 1465908-73-9 | Reference compound |
| HY-109076 | Tigilanol tiglate | 943001-56-7 | Natural Products |
| HY-109077 | Tigolaner | 1621436-41-6 | Reference compound |
| HY-109077S | Tigolaner-d4 | | Isotope-Labeled Compounds |
| HY-109078 | Vecabrutinib | 1510829-06-7 | Reference compound |
| HY-109079 | Abeprazan | 1902954-60-2 | Reference compound |
| HY-109079A | Abeprazan (hydrochloride) | 1902954-87-3 | Reference compound |
| HY-109080 | Belvarafenib | 1446113-23-0 | Reference compound |
| HY-109080A | Belvarafenib (TFA) | 2443966-84-3 | Reference compound |
| HY-109081 | Cedazuridine | 1141397-80-9 | Reference compound |
| HY-109081A | Cedazuridine (hydrochloride) | | Reference compound |
| HY-109082 | Cevidoplenib | 1703788-21-9 | Reference compound |
| HY-109082A | Cevidoplenib (dimesylate) | 2043659-93-2 | Reference compound |
| HY-109083 | Cilofexor | 1418274-28-8 | Reference compound |
| HY-109083A | Cilofexor (tromethamine) | 2253764-93-9 | Reference compound |
| HY-109084 | Conteltinib | 1384860-29-0 | Reference compound |
| HY-109084A | Conteltinib (tetrahydrochloride) | | Reference compound |
| HY-109085 | Difamilast | 937782-05-3 | Reference compound |
| HY-109085R | Difamilast (Standard) | 937782-05-3 | Reference Standards |
| HY-109086 | Edicotinib | 1142363-52-7 | Reference compound |
| HY-109086A | Edicotinib (hydrochloride) | 1559069-92-9 | Reference compound |
| HY-109087 | Elismetrep | 1400699-64-0 | Reference compound |
| HY-109089 | Epeleuton | 1667760-39-5 | Reference compound |
| HY-109089S | Epeleuton-d5 | | Isotope-Labeled Compounds |
| HY-109091 | Lanraplenib | 1800046-95-0 | Reference compound |
| HY-109091A | Lanraplenib (monosuccinate) | 1800046-97-2 | Reference compound |
| HY-109091B | Lanraplenib (succinate) | 1800047-00-0 | Reference compound |
| HY-109092 | Licogliflozin | 1291094-73-9 | Reference compound |
| HY-109092A | rel-Licogliflozin | 2730989-98-5 | Reference compound |
| HY-109093 | Linzagolix | 935283-04-8 | Reference compound |
| HY-109094 | Mosedipimod | 221139-79-3 | Reference compound |
| HY-109096 | Nidufexor | 1773489-72-7 | Reference compound |
| HY-109097 | Otaplimastat | 1176758-04-5 | Reference compound |
| HY-109098 | Parimifasor | 1796641-10-5 | Reference compound |
| HY-109099 | Pemigatinib | 1513857-77-6 | Reference compound |
| HY-109099R | Pemigatinib (Standard) | 1513857-77-6 | Reference Standards |
| HY-109101 | Risdiplam | 1825352-65-5 | Reference compound |
| HY-109101AS1 | Risdiplam-hydroxylate-d3 | | Isotope-Labeled Compounds |
| HY-109101AS2 | Risdiplam-hydroxylate-d6 | | Isotope-Labeled Compounds |
| HY-109101R | Risdiplam (Standard) | 1825352-65-5 | Reference Standards |
| HY-109101S | Risdiplam-d4 | | Isotope-Labeled Compounds |
| HY-109102 | Setafrastat | 1399715-48-0 | Natural Products |
| HY-109103 | Tegatrabetan | 1227637-23-1 | Reference compound |
| HY-109104 | Telratolimod | 1359993-59-1 | Reference compound |
| HY-109105 | Tepilamide fumarate | 1208229-58-6 | Reference compound |
| HY-109106 | Upacicalcet | 1333218-50-0 | Reference compound |
| HY-109106A | Upacicalcet (sodium) | 2052969-18-1 | Reference compound |
| HY-109106B | (Rac)-Upacicalcet | 2649575-19-7 | Reference compound |
| HY-109108 | Valemetostat | 1809336-39-7 | Reference compound |
| HY-109108A | Valemetostat (tosylate) | 1809336-93-3 | Reference compound |
| HY-109109 | Alteminostat | 1246374-97-9 | Reference compound |
| HY-109110 | Avasopasem manganese | 435327-40-5 | Reference compound |
| HY-109111 | Azelaprag | 2049980-18-7 | Reference compound |
| HY-109112 | Brilaroxazine | 1239729-06-6 | Reference compound |
| HY-109112R | Brilaroxazine (Standard) | 1239729-06-6 | Reference Standards |
| HY-109114 | Dersimelagon | 1835256-48-8 | Reference compound |
| HY-109114A | Dersimelagon (phosphate) | 2490660-87-0 | Reference compound |
| HY-109115 | Fosifloxuridine nafalbenamide | 1332837-31-6 | Reference compound |
| HY-109116 | Hydromethylthionine | 613-11-6 | Reference compound |
| HY-109116A | Hydromethylthionine (dihydrobromide) | 951131-15-0 | Reference compound |
| HY-109117 | Iadademstat | 1431304-21-0 | Reference compound |
| HY-109118 | Masupirdine (free base) | 701205-60-9 | Reference compound |
| HY-109118A | Masupirdine (mesylate) | 1791396-46-7 | Reference compound |
| HY-10912 | Fexaramine | 574013-66-4 | Reference compound |
| HY-109120 | Odevixibat | 501692-44-0 | Reference compound |
| HY-109120S | Odevixibat-d5 | | Isotope-Labeled Compounds |
| HY-109120S1 | Odevixibat-13C6 | | Isotope-Labeled Compounds |
| HY-109121 | Reldesemtiv | 1345410-31-2 | Reference compound |
| HY-109122 | Selatogrel | 1159500-34-1 | Reference compound |
| HY-109123 | Soticlestat | 1429505-03-2 | Reference compound |
| HY-109124 | Taniborbactam | 1613267-49-4 | Reference compound |
| HY-109124A | Taniborbactam (hydrochloride) | 2244235-49-0 | Reference compound |
| HY-109125A | Amcipatricin (L-aspartate) | 143563-20-6 | Reference compound |
| HY-109127 | Berotralstat | 1809010-50-1 | Reference compound |
| HY-109127A | Berotralstat (dihydrochloride) | 1809010-52-3 | Reference compound |
| HY-109127R | Berotralstat (Standard) | 1809010-50-1 | Reference Standards |
| HY-109128 | Danicamtiv | 1970972-74-7 | Reference compound |
| HY-10913 | Danegaptide | 943134-39-2 | Reference compound |
| HY-109131 | Foscarbidopa | 1907685-81-7 | Reference compound |
| HY-109133 | Pecavaptan | 1914998-56-3 | Reference compound |
| HY-109134 | Pizuglanstat | 1244967-98-3 | Reference compound |
| HY-109134A | Pizuglanstat (hydrate) | 1584160-52-0 | Reference compound |
| HY-109136 | Runcaciguat | 1402936-61-1 | Reference compound |
| HY-109137 | Selgantolimod | 2004677-13-6 | Reference compound |
| HY-109139 | Taminadenant | 1337962-47-6 | Reference compound |
| HY-109139A | Taminadenant (mesylate) | 2253894-81-2 | Reference compound |
| HY-10913A | Danegaptide Hydrochloride | 943133-81-1 | Reference compound |
| HY-10913S | Danegaptide-d5 | | Isotope-Labeled Compounds |
| HY-10914 | UCPH-101 | 1118460-77-7 | Reference compound |
| HY-109140 | Tuvatexib | 2055404-90-3 | Reference compound |
| HY-109142 | Ziresovir | 1422500-60-4 | Reference compound |
| HY-109143 | Elsubrutinib | 1643570-24-4 | Reference compound |
| HY-109143B | (R)-Elsubrutinib | 1643570-23-3 | Reference compound |
| HY-109144 | Enavogliflozin | 1415472-28-4 | Reference compound |
| HY-109146 | Imifoplatin | 1339960-28-9 | Reference compound |
| HY-109147 | Imnopitant | 290297-57-3 | Reference compound |
| HY-109147A | Imnopitant (dihydrochloride) | 290296-52-5 | Reference compound |
| HY-109148 | Izencitinib | 2051918-33-1 | Reference compound |
| HY-109149 | Lomardexamfetamine | 1032291-80-7 | Reference compound |
| HY-10915 | LUF6096 | 1116652-18-6 | Reference compound |
| HY-109150 | Mesdopetam | 1403894-72-3 | Reference compound |
| HY-109150A | Mesdopetam (hemitartrate) | 2562346-14-7 | Reference compound |
| HY-109151 | Milategrast | 859217-52-0 | Reference compound |
| HY-109152 | Navocaftor | 2159103-66-7 | Reference compound |
| HY-109153 | Nerindocianine | 748120-01-6 | Reference compound |
| HY-109154 | Obafistat | 2160582-57-8 | Reference compound |
| HY-109156 | Pregabalin arenacarbil | 1174748-30-1 | Reference compound |
| HY-109157 | Ralmitaront | 2133417-13-5 | Reference compound |
| HY-109158 | Rebamipide mofetil | 1527495-76-6 | Reference compound |
| HY-109160 | Rimtuzalcap | 2167246-24-2 | Reference compound |
| HY-109162 | Trazpiroben | 1352993-39-5 | Reference compound |
| HY-109163 | Treprostinil palmitil | 1706528-83-7 | Reference compound |
| HY-109164 | Zelquistinel | 2151842-64-5 | Reference compound |
| HY-109165 | Acoramidis | 1446711-81-4 | Reference compound |
| HY-109165A | Acoramidis (hydrochloride) | 2242751-53-5 | Reference compound |
| HY-109167 | Aramisulpride | 71675-90-6 | Reference compound |
| HY-109168 | Bersacapavir | 1638266-40-6 | Reference compound |
| HY-109169 | Bomedemstat | 1990504-34-1 | Reference compound |
| HY-109169A | Bomedemstat (ditosylate) | 1990504-72-7 | Reference compound |
| HY-109169B | Bomedemstat (hydrochloride) | | Reference compound |
| HY-109169C | Bomedemstat (dihydrochloride) | | Reference compound |
| HY-10917 | GW2580 | 870483-87-7 | Reference compound |
| HY-109170 | Eliapixant | 1948229-21-7 | Reference compound |
| HY-109171 | Elinzanetant | 929046-33-3 | Reference compound |
| HY-109171R | Elinzanetant (Standard) | 929046-33-3 | Reference Standards |
| HY-109171S | Elinzanetant-d3 | | Isotope-Labeled Compounds |
| HY-109173 | Filapixant | 1948232-63-0 | Reference compound |
| HY-109174 | Fosciclopirox | 1380539-06-9 | Reference compound |
| HY-109174A | Fosciclopirox (disodium) | 1380539-08-1 | Reference compound |
| HY-109175 | Fosifidancitinib | 1237168-58-9 | Reference compound |
| HY-109176 | Giredestrant | 1953133-47-5 | Reference compound |
| HY-109177 | Icenticaftor | 1334546-77-8 | Reference compound |
| HY-109178 | Ifidancitinib | 1236667-40-5 | Reference compound |
| HY-109179 | Itacnosertib | 1628870-27-8 | Reference compound |
| HY-109179A | Itacnosertib (hydrocholide) | 2409543-84-4 | Reference compound |
| HY-10917S | GW2580-d6 | 2733770-48-2 | Isotope-Labeled Compounds |
| HY-109181 | Lazuvapagon | 2379889-71-9 | Reference compound |
| HY-109182 | Lorpucitinib | 2230282-02-5 | Reference compound |
| HY-109183 | Luvadaxistat | 1425511-32-5 | Reference compound |
| HY-109184 | Murizatoclax | 2245848-05-7 | Reference compound |
| HY-109185 | Pelcitoclax | 1619923-36-2 | Reference compound |
| HY-109186 | Pexopiprant | 932708-14-0 | Reference compound |
| HY-109187 | Posenacaftor | 2095064-05-2 | Reference compound |
| HY-109187A | Posenacaftor (sodium) | 2095064-06-3 | Reference compound |
| HY-109187B | (R)-Posenacaftor (sodium) | 2095064-09-6 | Reference compound |
| HY-109188 | Relzomostat | 2081078-92-2 | Reference compound |
| HY-109189 | Rezivertinib | 1835667-12-3 | Reference compound |
| HY-10919 | C-1311 | 138154-39-9 | Reference compound |
| HY-109190 | Seralutinib | 1619931-27-9 | Reference compound |
| HY-109191 | Sovesudil | 1333400-14-8 | Reference compound |
| HY-109191A | Sovesudil (hydrochloride) | 2984963-50-8 | Reference compound |
| HY-109192 | Tolebrutinib | 1971920-73-6 | Reference compound |
| HY-109193 | Tovinontrine | 2062661-53-2 | Reference compound |
| HY-109194 | Udonitrectag | 1458063-04-1 | Reference compound |
| HY-109195 | Vebicorvir | 2090064-66-5 | Reference compound |
| HY-109196 | Velufenacin | 1648737-78-3 | Reference compound |
| HY-109197 | Vonafexor | 1192171-69-9 | Reference compound |
| HY-109198 | Zandelisib | 1401436-95-0 | Reference compound |
| HY-10920 | Axitinib analogue 1 | 319463-51-9 | Reference compound |
| HY-10929 | UNC0224 | 1197196-48-7 | Reference compound |
| HY-10930 | UNC0321 | 1238673-32-9 | Reference compound |
| HY-10932 | Aniracetam | 72432-10-1 | Reference compound |
| HY-10932R | Aniracetam (Standard) | 72432-10-1 | Reference Standards |
| HY-10933 | CX516 | 154235-83-3 | Reference compound |
| HY-10933S | CX516-d10 | 1286653-21-1 | Isotope-Labeled Compounds |
| HY-10934 | Mibampator | 375345-95-2 | Reference compound |
| HY-10935 | LY450108 | 376594-67-1 | Reference compound |
| HY-10936 | S 18986 | 175340-20-2 | Reference compound |
| HY-10937 | Farampator | 211735-76-1 | Reference compound |
| HY-10939 | (-)-15-Deoxyspergualin | 89149-10-0 | Reference compound |
| HY-10939A | (-)-15-Deoxyspergualin (trihydrochloride) | 84937-45-1 | Biochemical Assay Reagents |
| HY-10940 | Pifithrin-μ | 64984-31-2 | Reference compound |
| HY-10941 | VER-155008 | 1134156-31-2 | Reference compound |
| HY-10942 | VER-82576 | 847559-80-2 | Reference compound |
| HY-10943 | GNF-7 | 839706-07-9 | Reference compound |
| HY-10949 | SMER3 | 67200-34-4 | Reference compound |
| HY-109500 | Masoprocol | 27686-84-6 | Natural Products |
| HY-109502S | 10-OH-NBP-d4 | | Isotope-Labeled Compounds |
| HY-109506 | DPPC | 63-89-8 | Natural Products |
| HY-109506R | DPPC (Standard) | 63-89-8 | Reference Standards |
| HY-109506S | DPPC-d62 | 25582-63-2 | Isotope-Labeled Compounds |
| HY-109506S1 | DPPC-d9 | | Isotope-Labeled Compounds |
| HY-109506S2 | (Rac)-DPPC-d6 | 82765-17-1 | Isotope-Labeled Compounds |
| HY-109506S3 | DPPC-d9-1 | 77165-56-1 | Isotope-Labeled Compounds |
| HY-109506S4 | DPPC-d4 | 326495-33-4 | Isotope-Labeled Compounds |
| HY-109506S5 | DPPC-d13 | 86531-55-7 | Isotope-Labeled Compounds |
| HY-109506S6 | DPPC-d66 | 326495-34-5 | Isotope-Labeled Compounds |
| HY-109506S7 | DPPC-d71 | 474943-49-2 | Isotope-Labeled Compounds |
| HY-109506S8 | DPPC-d75 | 181041-62-3 | Isotope-Labeled Compounds |
| HY-109506S9 | DPPC-13C2 | 65277-91-0 | Isotope-Labeled Compounds |
| HY-109509 | Enoxaparin | 679809-58-6 | Reference compound |
| HY-109511 | AZD-1678 | 942137-41-9 | Reference compound |
| HY-109513 | Ioxilan | 107793-72-6 | Reference compound |
| HY-109513R | Ioxilan (Standard) | 107793-72-6 | Reference Standards |
| HY-109517 | Calf thymus DNA | 91080-16-9 | Natural Products |
| HY-109519 | Simethicone | 8050-81-5 | Reference compound |
| HY-109520 | Glatiramer (acetate) | 147245-92-9 | Reference compound |
| HY-109521A | Manganese chloride (tetrahydrate), molecular biology grade,≥99.0% (KT) | 13446-34-9 | Biochemical Assay Reagents |
| HY-109523 | Cerivastatin (sodium) | 143201-11-0 | Reference compound |
| HY-109523S | Cerivastatin-d3 (sodium) | 916314-45-9 | Isotope-Labeled Compounds |
| HY-109525 | Sacrosidase | 85897-35-4 | Enzyme |
| HY-109527 | 5-HT7 agonist 1 | 334974-31-1 | Reference compound |
| HY-109528 | Fomivirsen (sodium) | 160369-77-7 | Oligonucleotides |
| HY-109530 | Insulin lispro | 133107-64-9 | Reference compound |
| HY-109532 | Ganirelix (acetate) | 129311-55-3 | Reference compound |
| HY-109534 | Poly(tetrafluoroethylene) | 9002-84-0 | Biochemical Assay Reagents |
| HY-109536B | Ammonium polyphosphate, n90g/100ml | 68333-79-9 | Biochemical Assay Reagents |
| HY-109538 | Secretin (swine) | 17034-35-4 | Peptides |
| HY-109538R | Secretin (swine) (Standard) | 17034-35-4 | Reference Standards |
| HY-109539 | Gemtuzumab ozogamicin | 220578-59-6 | ADC Related |
| HY-109540 | Perfluorohexane | 355-42-0 | Reference compound |
| HY-109541 | Colfosceril miristate | 18194-24-6 | Oligonucleotides |
| HY-109541S | Colfosceril miristate-d58 | 326495-29-8 | Isotope-Labeled Compounds |
| HY-109541S1 | Colfosceril miristate-d4 | 185906-01-8 | Isotope-Labeled Compounds |
| HY-109541S2 | Colfosceril miristate-d9 | 71479-88-4 | Isotope-Labeled Compounds |
| HY-109541S3 | Colfosceril miristate-d13 | 326495-28-7 | Isotope-Labeled Compounds |
| HY-109541S4 | Colfosceril miristate-d63 | 326495-30-1 | Isotope-Labeled Compounds |
| HY-109541S5 | Colfosceril miristate-d67 | 326495-32-3 | Isotope-Labeled Compounds |
| HY-109541S6 | (Rac)-Colfosceril miristate-d72 | 100483-63-4 | Isotope-Labeled Compounds |
| HY-109542 | Cyclopenthiazide | 742-20-1 | Reference compound |
| HY-109542R | Cyclopenthiazide (Standard) | 742-20-1 | Reference Standards |
| HY-109543 | Indisetron | 141549-75-9 | Reference compound |
| HY-109543A | Indisetron (dihydrochloride) | 160472-97-9 | Reference compound |
| HY-109544 | Repirinast | 73080-51-0 | Reference compound |
| HY-109545 | Isopropyl unoprostone | 120373-24-2 | Reference compound |
| HY-109546 | Omeprazole magnesium | 95382-33-5 | Reference compound |
| HY-109547 | Diclofenac epolamine | 119623-66-4 | Reference compound |
| HY-109549 | Desirudin | 120993-53-5 | Inhibitory Antibodies |
| HY-10955 | TTA-P1 | 918333-06-9 | Reference compound |
| HY-109555 | Insulin glulisine | 207748-29-6 | Peptides |
| HY-109556 | Insulin Detemir | 169148-63-4 | Peptides |
| HY-109561 | Pegaptanib (sodium) | 222716-86-1 | Oligonucleotides |
| HY-109562 | CCG258208 | 2055990-90-2 | Reference compound |
| HY-109562A | CCG258208 (hydrochloride) | | Reference compound |
| HY-109564 | 5α-Pregnane-3β,6α-diol-20-one | 21853-11-2 | Natural Products |
| HY-109564R | 5α-Pregnane-3β,6α-diol-20-one (Standard) | 21853-11-2 | Reference Standards |
| HY-109565 | Tolinapant | 1799328-86-1 | Reference compound |
| HY-109566 | AZD1390 | 2089288-03-7 | Reference compound |
| HY-109567 | Gemcabene | 183293-82-5 | Reference compound |
| HY-109567A | Gemcabene (calcium) | 209789-08-2 | Reference compound |
| HY-109568 | Lynestrenol | 52-76-6 | Reference compound |
| HY-109568R | Lynestrenol (Standard) | 52-76-6 | Reference Standards |
| HY-109569 | Vitamin K2 | 11032-49-8 | Natural Products |
| HY-10957 | L-692429 | 145455-23-8 | Reference compound |
| HY-109571 | HZ-1157 | 1009734-33-1 | Reference compound |
| HY-109572 | GABAA receptor modulator-1 | 951654-29-8 | Reference compound |
| HY-109573 | hnps-PLA-IN-1 | 185298-58-2 | Reference compound |
| HY-109574 | Raf inhibitor 2 | 220904-99-4 | Reference compound |
| HY-10957A | L-692429 (hydrochloride) | 169188-19-6 | Reference compound |
| HY-109582 | ADT-OH | 18274-81-2 | Reference compound |
| HY-109583 | 4-Oxofenretinide | 865536-65-8 | Reference compound |
| HY-109583S | 4-Oxofenretinide-d4 | 2991099-34-2 | Isotope-Labeled Compounds |
| HY-109585 | IRAK4-IN-7 | 1801343-74-7 | Reference compound |
| HY-109586 | BRL-50481 | 433695-36-4 | Reference compound |
| HY-109587 | BM635 | 1493762-74-5 | Reference compound |
| HY-109587A | BM635 (hydrochloride) | 2748337-90-6 | Reference compound |
| HY-109587B | BM635 (mesylate) | 2703867-74-5 | Reference compound |
| HY-109588 | NITD-349 | 1473450-62-2 | Reference compound |
| HY-109589A | trans-11-Eicosenoic acid | 62322-84-3 | Biochemical Assay Reagents |
| HY-10959 | RG7112 | 939981-39-2 | Reference compound |
| HY-109590 | Arachidonic acid | 506-32-1 | Natural Products |
| HY-109590A | Arachidonic acid (sodium salt) | 6610-25-9 | Reference compound |
| HY-109590R | Arachidonic acid (Standard) | 506-32-1 | Reference Standards |
| HY-109590S | Arachidonic acid-d8 | 69254-37-1 | Isotope-Labeled Compounds |
| HY-109590S1 | Arachidonic acid-d5 | 123167-26-0 | Isotope-Labeled Compounds |
| HY-109590S2 | Arachidonic acid-d11 | 2692624-11-4 | Isotope-Labeled Compounds |
| HY-109590S3 | Arachidonic acid-13C4 | 2692624-40-9 | Isotope-Labeled Compounds |
| HY-109591 | Oleoyl coenzyme A | 1716-06-9 | Biochemical Assay Reagents |
| HY-109591A | Oleoyl coenzyme A (lithium) | 188824-37-5 | Biochemical Assay Reagents |
| HY-109591B | Oleoyl Coenzyme A (triammonium) | 799812-89-8 | Enzyme |
| HY-109591C | 9(Z)-Octadecenoyl coenzyme A (potassium) | 369657-01-2 | Natural Products |
| HY-109591S | Oleoyl coenzyme A-13C18 (lithium) | | Isotope-Labeled Compounds |
| HY-109592 | Imidaprilate | 89371-44-8 | Reference compound |
| HY-109592S | Imidaprilate-d5 | | Isotope-Labeled Compounds |
| HY-109593 | BMS-813160 | 1286279-29-5 | Reference compound |
| HY-10961 | Momelotinib | 1056634-68-4 | Reference compound |
| HY-109617 | 4-(4-Fluorophenyl)benzoic acid | 5731-10-2 | Reference compound |
| HY-109619 | D4-abiraterone | 154229-21-7 | Reference compound |
| HY-10962 | Momelotinib (sulfate) | 1056636-06-6 | Reference compound |
| HY-10963 | Momelotinib (mesylate) | 1056636-07-7 | Reference compound |
| HY-109633 | PI3K-IN-18 | 371943-05-4 | Reference compound |
| HY-109633A | PI3K-IN-18 (dihydrochloride) | 1188890-32-5 | Reference compound |
| HY-10964 | Vadimezan | 117570-53-3 | Reference compound |
| HY-10965 | Rolofylline | 136199-02-5 | Reference compound |
| HY-109654 | Ensulizole | 27503-81-7 | Reference compound |
| HY-109654R | Ensulizole (Standard) | 27503-81-7 | Reference Standards |
| HY-109655 | Ethylhexyl triazone | 88122-99-0 | Reference compound |
| HY-109655R | Ethylhexyl triazone (Standard) | 88122-99-0 | Reference Standards |
| HY-109656 | Diethylamino hydroxybenzoyl hexyl benzoate | 302776-68-7 | Reference compound |
| HY-109656R | Diethylamino hydroxybenzoyl hexyl benzoate (Standard) | 302776-68-7 | Reference Standards |
| HY-10966 | SB-590885 | 405554-55-4 | Reference compound |
| HY-10966R | SB-590885 (Standard) | 405554-55-4 | Reference Standards |
| HY-10968 | CYM5442 | 1094042-01-9 | Reference compound |
| HY-10968A | CYM5442 (hydrochloride) | 1783987-80-3 | Reference compound |
| HY-10969 | Obatoclax (Mesylate) | 803712-79-0 | Reference compound |
| HY-109690 | 1-(2-Amino-3-hydroxyphenyl)ethanone | 4502-10-7 | Reference compound |
| HY-109692 | GPR120 Agonist 5 | 1079821-35-4 | Reference compound |
| HY-10969A | Obatoclax | 803712-67-6 | Reference compound |
| HY-109706 | (Rac)-CPI-098 | 3967-01-9 | Reference compound |
| HY-10971 | Alisertib | 1028486-01-2 | Reference compound |
| HY-109714 | 3,4-Benzocoumarin | 2005-10-9 | Reference compound |
| HY-109718 | ATL-801 | 1000005-71-9 | Reference compound |
| HY-10971A | Alisertib (sodium) | 1028486-06-7 | Reference compound |
| HY-10974 | MK-0752 | 471905-41-6 | Reference compound |
| HY-109743 | BP14979 | 1000036-77-0 | Reference compound |
| HY-109748 | Mn(III)TMPyP (pentachloride) | 125565-45-9 | Biochemical Assay Reagents |
| HY-10975 | MK-0752 (sodium) | 656810-87-6 | Reference compound |
| HY-109754 | Sulopenem etzadroxil | 1000296-70-7 | Reference compound |
| HY-109755 | PF-04064900 | 1000296-71-8 | Reference compound |
| HY-10976 | Luminespib analog | 747412-64-2 | Reference compound |
| HY-10977 | Tivozanib | 475108-18-0 | Reference compound |
| HY-10977A | Tivozanib (hydrochloride hydrate) | 682745-41-1 | Reference compound |
| HY-10977S | Tivozanib-d6 | 1714998-87-4 | Isotope-Labeled Compounds |
| HY-10978 | Crisaborole | 906673-24-3 | Reference compound |
| HY-109785A | (R)-Gyramide A (hydrochloride) | 1793050-70-0 | Reference compound |
| HY-10978R | Crisaborole (Standard) | 906673-24-3 | Reference Standards |
| HY-10978S | Crisaborole-d4 | 2268785-42-6 | Isotope-Labeled Compounds |
| HY-10979 | AN0128 | 872044-70-7 | Reference compound |
| HY-109796 | NIK250 | 1000817-20-8 | Reference compound |
| HY-10980 | Tavaborole | 174671-46-6 | Reference compound |
| HY-109804 | CORM-401 | 1001015-18-4 | Reference compound |
| HY-10980R | Tavaborole (Standard) | 174671-46-6 | Reference Standards |
| HY-10981 | Lenvatinib | 417716-92-8 | Reference compound |
| HY-10981A | Lenvatinib (mesylate) | 857890-39-2 | Reference compound |
| HY-10981AR | Lenvatinib (mesylate) (Standard) | 857890-39-2 | Reference Standards |
| HY-10981R | Lenvatinib (Standard) | 417716-92-8 | Reference Standards |
| HY-10981S | Lenvatinib-d4 | 2264050-65-7 | Isotope-Labeled Compounds |
| HY-10981S1 | Lenvatinib-d5 | | Isotope-Labeled Compounds |
| HY-10981S2 | Lenvatinib-15N,d4 | | Isotope-Labeled Compounds |
| HY-10982 | Amonafide | 69408-81-7 | Reference compound |
| HY-10982A | Amonafide (dihydrochloride) | 150091-68-2 | Reference compound |
| HY-10984 | Pomalidomide | 19171-19-8 | Reference compound |
| HY-109841 | Oleoyl serotonin | 1002100-44-8 | Reference compound |
| HY-109841S | Oleoyl Serotonin-d17 | 2749980-90-1 | Isotope-Labeled Compounds |
| HY-10984A | (S)-Pomalidomide | 202271-89-4 | Reference compound |
| HY-10984R | Pomalidomide (Standard) | 19171-19-8 | Reference Standards |
| HY-10984S | Pomalidomide-d5 | 1377838-49-7 | Isotope-Labeled Compounds |
| HY-10984S1 | Pomalidomide-d3 | 2093128-28-8 | Isotope-Labeled Compounds |
| HY-10984S2 | Pomalidomide-d4 | 1416575-78-4 | Isotope-Labeled Compounds |
| HY-10984S3 | Pomalidomide-15N,13C5 | | Isotope-Labeled Compounds |
| HY-10984S4 | Pomalidomide-13C5 | 1416575-79-5 | Isotope-Labeled Compounds |
| HY-10985 | Marizomib | 437742-34-2 | Reference compound |
| HY-109854 | (S)-Lisofylline | 100324-80-9 | Reference compound |
| HY-109854A | (R)-Lisofylline | 100324-81-0 | Reference compound |
| HY-109855 | CP-67015 | 100325-51-7 | Reference compound |
| HY-109869 | Photoregulin1 | 1003736-23-9 | Reference compound |
| HY-10987 | ENMD-2076 (Tartrate) | 1453868-32-0 | Reference compound |
| HY-109877 | Ro 22-3581 | 10041-06-2 | Reference compound |
| HY-10987A | ENMD-2076 | 934353-76-1 | Reference compound |
| HY-109887 | 3-Bromoimidazo[1,2-a]pyridine-6-carbaldehyde | 1004550-20-2 | Reference compound |
| HY-109897 | CV-6209 | 100488-87-7 | Reference compound |
| HY-10990 | Abexinostat | 783355-60-2 | Reference compound |
| HY-10991 | MGCD-265 analog | 875337-44-3 | Reference compound |
| HY-10992 | AZD-7762 | 860352-01-8 | Reference compound |
| HY-10992A | AZD-7762 (hydrochloride) | 1246094-78-9 | Reference compound |
| HY-10993 | Adavosertib | 955365-80-7 | Reference compound |
| HY-10993R | Adavosertib (Standard) | 955365-80-7 | Reference Standards |
| HY-10995 | Tozadenant | 870070-55-6 | Reference compound |
| HY-10996 | KHS101 | 1262770-73-9 | Reference compound |
| HY-109963 | PR5-LL-CM01 | 1005307-86-7 | Reference compound |
| HY-109968 | Irdabisant | 1005402-19-6 | Reference compound |
| HY-109968A | Irdabisant (hydrochloride) | 1005398-61-7 | Reference compound |
| HY-109969 | Z060228 | 1005459-82-4 | Reference compound |
| HY-10996A | KHS101 hydrochloride | 1784282-12-7 | Reference compound |
| HY-10997 | Ibrutinib | 936563-96-1 | Reference compound |
| HY-10997A | Ibrutinib (Racemate) | 936563-87-0 | Reference compound |
| HY-10997R | Ibrutinib (Standard) | 936563-96-1 | Reference Standards |
| HY-10997S | Ibrutinib-d5 | 1553977-17-5 | Isotope-Labeled Compounds |
| HY-10998 | Salmefamol | 18910-65-1 | Reference compound |
| HY-109987 | ISPA-28 | 1006335-39-2 | Reference compound |
| HY-10999 | Trametinib | 871700-17-3 | Reference compound |
| HY-109992 | LY 186126 | 100644-00-6 | Reference compound |
| HY-10999A | Trametinib (DMSO solvate) | 1187431-43-1 | Reference compound |
| HY-10999R | Trametinib (Standard) | 871700-17-3 | Reference Standards |
| HY-10999S | Trametinib-d4 | | Isotope-Labeled Compounds |
| HY-10999S1 | Trametinib-13C6 | | Isotope-Labeled Compounds |
| HY-10999S2 | Trametinib-13C,d3 | 2712126-59-3 | Isotope-Labeled Compounds |
| HY-11000 | GSK429286A | 864082-47-3 | Reference compound |
| HY-110000 | (+)-PD 128907 hydrochloride | 300576-59-4 | Reference compound |
| HY-110001 | (S)-WAY 100135 (dihydrochloride) | 149007-54-5 | Reference compound |
| HY-110002 | LFM-A13 | 62004-35-7 | Biochemical Assay Reagents |
| HY-110003 | Arachidonylcyclopropylamide | 229021-64-1 | Reference compound |
| HY-110004 | ACEA | 220556-69-4 | Biochemical Assay Reagents |
| HY-110005 | Sp-cAMPS (triethylamine) | 93602-66-5 | Reference compound |
| HY-11000A | CaMKP inhibitor (sodium) | 52789-62-5 | Reference compound |
| HY-11001 | PHA-793887 | 718630-59-2 | Reference compound |
| HY-110010 | Nafadotride | 149649-22-9 | Reference compound |
| HY-110011 | Cromakalim | 94470-67-4 | Reference compound |
| HY-110012 | SCH-202676 (hydrobromide) | 265980-25-4 | Reference compound |
| HY-110013 | Terreic acid | 121-40-4 | Reference compound |
| HY-110013A | (Rac)-Terreic acid | 15255-24-0 | Reference compound |
| HY-110014 | Noladin ether | 222723-55-9 | Reference compound |
| HY-110015 | (-)-Chromanol 293B | 163163-24-4 | Reference compound |
| HY-110016 | Docosatetraenylethanolamide | 150314-35-5 | Natural Products |
| HY-110018 | N-Arachidonyldopamine | 199875-69-9 | Reference compound |
| HY-110018S | N-Arachidonyldopamine-d8 | 1159908-42-5 | Isotope-Labeled Compounds |
| HY-110019 | Indatraline (hydrochloride) | 96850-13-4 | Reference compound |
| HY-110019A | cis-Indatraline (hydrochloride) | 86939-08-4 | Reference compound |
| HY-11002 | CP-466722 | 1080622-86-1 | Reference compound |
| HY-110020 | rel-O-2050 | 851320-29-1 | Reference compound |
| HY-110021 | Fenoldopam (hydrochloride) | 181217-39-0 | Reference compound |
| HY-110022 | GW1929 (hydrochloride) | 1217466-21-1 | Reference compound |
| HY-110023 | Zimelidine (dihydrochloride) | 60525-15-7 | Reference compound |
| HY-110023R | Zimelidine (dihydrochloride) (Standard) | 60525-15-7 | Reference Standards |
| HY-110024 | S-14506 (hydrochloride) | 286369-38-8 | Reference compound |
| HY-110024A | S-14506 | 135722-25-7 | Reference compound |
| HY-110026 | GTP-14564 | 34823-86-4 | Reference compound |
| HY-110027 | 2,3-DCPE (hydrochloride) | 1009555-55-8 | Reference compound |
| HY-110028 | Leelamine (hydrochloride) | 16496-99-4 | Natural Products |
| HY-110029 | Paroxetine (maleate) | 64006-44-6 | Reference compound |
| HY-11003 | GW843682X | 660868-91-7 | Reference compound |
| HY-110031 | BAI1 (hydrochloride) | 329349-20-4 | Reference compound |
| HY-110032 | Lamotrigine (isethionate) | 113170-86-8 | Reference compound |
| HY-110033 | Ecopipam (hydrobromide) | 2587360-22-1 | Reference compound |
| HY-110034 | Didesmethylsibutramine (hydrochloride) | 84484-78-6 | Reference compound |
| HY-110034R | Didesmethylsibutramine (hydrochloride) (Standard) | 84484-78-6 | Reference Standards |
| HY-110034S | Didesmethylsibutramine-d7 (hydrochloride) | 1188263-87-7 | Isotope-Labeled Compounds |
| HY-110036 | GW-405833 | 180002-83-9 | Reference compound |
| HY-110036A | GW405833 (hydrochloride) | 1202865-22-2 | Reference compound |
| HY-110037 | MRS-3777 (hemioxalate) | 1186195-57-2 | Reference compound |
| HY-110038 | FTI-277 (TFA) | 1217447-06-7 | Reference compound |
| HY-110039 | BIBX 1382 (dihydrochloride) | 1216920-18-1 | Reference compound |
| HY-11004 | AZ 628 | 878739-06-1 | Reference compound |
| HY-110040 | L759633 | 174627-50-0 | Reference compound |
| HY-110042 | CCT018159 | 171009-07-7 | Reference compound |
| HY-110043 | (±)-Clopidogrel (hydrochloride) | 130209-90-4 | Reference compound |
| HY-110044 | MNITMT | 177653-76-8 | Reference compound |
| HY-110045 | ZM-306416 (hydrochloride) | 196603-47-1 | Reference compound |
| HY-110046 | CL-82198 (hydrochloride) | 1188890-36-9 | Reference compound |
| HY-110047 | CB65 | 913534-05-1 | Reference compound |
| HY-110048 | O-2545 (hydrochloride) | 874745-43-4 | Reference compound |
| HY-11005 | BX-912 | 702674-56-4 | Reference compound |
| HY-110050 | GP1a | 511532-96-0 | Reference compound |
| HY-110051 | DPP4-In (hydrochloride) | 866396-70-5 | Reference compound |
| HY-110052 | TBCA | 934358-00-6 | Reference compound |
| HY-110053 | Tandospirone (hydrochloride) | 99095-10-0 | Reference compound |
| HY-110054 | CCG-2046 | 13017-69-1 | Reference compound |
| HY-110056 | NBI 35965 (hydrochloride) | 1782228-59-4 | Reference compound |
| HY-110057 | FR 409 | 138472-01-2 | Reference compound |
| HY-11006 | KU-57788 | 503468-95-9 | Reference compound |
| HY-110060 | NDT 9513727 | 439571-48-9 | Reference compound |
| HY-110063 | 4-IPP | 41270-96-6 | Reference compound |
| HY-110065 | SER-601 | 1048038-90-9 | Reference compound |
| HY-110066 | (Z)-Guggulsterone | 39025-23-5 | Natural Products |
| HY-110066R | (Z)-Guggulsterone (Standard) | 39025-23-5 | Reference Standards |
| HY-110067 | VO-OHPic | 675848-25-6 | Reference compound |
| HY-11007 | GNF-2 | 778270-11-4 | Reference compound |
| HY-110070 | DL-AP4 (sodium) | 1263093-79-3 | Reference compound |
| HY-110071 | APcK110 | 1001083-74-4 | Reference compound |
| HY-110073 | iMAC2 (hydrochloride) | 335166-00-2 | Reference compound |
| HY-110074 | TWS119 (TFA) | 1507095-58-0 | Reference compound |
| HY-110075 | Dexrazoxane (monohydrochloride) | 1263283-43-7 | Reference compound |
| HY-110076 | VU590 (dihydrochloride) | 1783987-83-6 | Reference compound |
| HY-110077 | API-1 | 36707-00-3 | Reference compound |
| HY-110078 | Eeyarestatin I | 412960-54-4 | Reference compound |
| HY-110079 | TNP | 519178-28-0 | Reference compound |
| HY-110080 | Lisuride (maleate) | 19875-60-6 | Reference compound |
| HY-110081S | Doxycycline hyclate-d5 | | Isotope-Labeled Compounds |
| HY-110082 | Quinine (hydrochloride) | 130-89-2 | Reference compound |
| HY-110083 | PK44 (phosphate) | 1017682-66-4 | Reference compound |
| HY-110084 | BTZO-1 | 99420-15-2 | Reference compound |
| HY-110085 | 2,2′-Dihydroxy-6,6′-dinaphthyl disulfide | 6088-51-3 | Reference compound |
| HY-110086 | RWJ 50271 | 162112-37-0 | Reference compound |
| HY-110087 | 4BP-TQS | 360791-49-7 | Reference compound |
| HY-110088 | SCH529074 | 922150-11-6 | Reference compound |
| HY-11009 | CGP60474 | 164658-13-3 | Reference compound |
| HY-110090 | UA62784 | 313367-92-9 | Reference compound |
| HY-110091 | TRPV1 antagonist 9 | 939040-79-6 | Reference compound |
| HY-110092 | PSB-1114 (tetrasodium) | 1657025-60-9 | Reference compound |
| HY-110092A | PSB-1114 (triethylamine) | | Reference compound |
| HY-110093 | UNC0638 (hydrate) | 1255517-77-1 | Reference compound |
| HY-110094 | BIMU 8 | 134296-40-5 | Reference compound |
| HY-110095 | (±)-CPSI-1306 | 1309793-47-2 | Reference compound |
| HY-110096 | A-484954 | 142557-61-7 | Reference compound |
| HY-110097 | Aptiganel (hydrochloride) | 137160-11-3 | Reference compound |
| HY-110098 | Ro 5212773 | 1110781-88-8 | Reference compound |
| HY-110099 | (±)-NBI-74330 | 473722-68-8 | Reference compound |
| HY-11010 | AS601245 | 345987-15-7 | Reference compound |
| HY-110100 | CPYPP | 310460-39-0 | Reference compound |
| HY-110101 | ARN272 | 488793-85-7 | Reference compound |
| HY-110102 | Atiprimod (hydrochloride) | 130065-61-1 | Reference compound |
| HY-110103 | ML3403 | 549505-65-9 | Reference compound |
| HY-110104 | 8MDP | 29491-75-6 | Reference compound |
| HY-110105 | NS8593 (hydrochloride) | 875755-24-1 | Reference compound |
| HY-110106 | I-BET151 (dihydrochloride) | 1883545-47-8 | Reference compound |
| HY-110107 | GW438014A | 469861-49-2 | Reference compound |
| HY-110109 | ETP-45658 | 1198357-79-7 | Reference compound |
| HY-11010A | AS601245 (TFA) | 345987-16-8 | Reference compound |
| HY-11011 | A-770041 | 869748-10-7 | Reference compound |
| HY-110110 | VU0463271 | 1391737-01-1 | Reference compound |
| HY-110110A | VU0463271 (quarterhydrate) | | Reference compound |
| HY-110111 | T2AA | 1380782-27-3 | Reference compound |
| HY-110111A | T2AA (hydrochloride) | 2138331-07-2 | Reference compound |
| HY-110112 | BTT-3033 | 1259028-99-3 | Reference compound |
| HY-110113 | CTA056 | 1265822-30-7 | Reference compound |
| HY-110114 | Gue1654 | 397290-30-1 | Reference compound |
| HY-110115 | TC-Mps1-12 | 1206170-62-8 | Reference compound |
| HY-110116 | SD-2590 (hydrochloride) | 226395-93-3 | Reference compound |
| HY-110117 | BIRT 377 | 213211-10-0 | Reference compound |
| HY-110118 | Edaglitazone | 213411-83-7 | Reference compound |
| HY-110119 | Galloflavin (potassium) | 1780260-20-9 | Reference compound |
| HY-11012 | TDZD-8 | 327036-89-5 | Reference compound |
| HY-110120 | DSR-6434 | 1059070-10-8 | Reference compound |
| HY-110121 | NS3861 (fumarate) | 216853-60-0 | Reference compound |
| HY-110121A | NS3861 | 216853-59-7 | Reference compound |
| HY-110122 | AZ 12216052 | 1290628-31-7 | Reference compound |
| HY-110123 | ML-00253764 (hydrochloride) | 1706524-94-8 | Reference compound |
| HY-110124 | ML202 | 1221186-52-2 | Reference compound |
| HY-110125 | ML-193 | 713121-80-3 | Reference compound |
| HY-110126 | AR-C118925XX | 216657-60-2 | Reference compound |
| HY-110127 | NU9056 | 1450644-28-6 | Reference compound |
| HY-110128 | Sulfidefluor 7-AM | 1416872-50-8 | Dye Reagents |
| HY-110129 | Eplivanserin (hemifumarate) | 130580-02-8 | Reference compound |
| HY-11013 | ZSET1446 | 887603-94-3 | Reference compound |
| HY-110130 | RN-1 (dihydrochloride) | 1781835-13-9 | Reference compound |
| HY-110131 | A 85380 (hydrochloride) | 174740-86-4 | Reference compound |
| HY-110132 | JNJ-27141491 | 871313-59-6 | Reference compound |
| HY-110133 | JTE-607 | 188791-09-5 | Reference compound |
| HY-110133A | JTE-607 (free base) | 188791-71-1 | Reference compound |
| HY-110134 | S07662 | 883226-64-0 | Reference compound |
| HY-110135 | NBI-31772 | 374620-70-9 | Reference compound |
| HY-110135A | NBI-31772 (hydrate) | | Reference compound |
| HY-110136 | PMX 205 | 514814-49-4 | Reference compound |
| HY-110136A | PMX 205 (Trifluoroacetate) | | Reference compound |
| HY-110137 | Furamidine (dihydrochloride) | 55368-40-6 | Reference compound |
| HY-110137A | Furamidine | 73819-26-8 | Reference compound |
| HY-110138 | PDP-EA | 861891-72-7 | Reference compound |
| HY-110139 | Procaspase-IN-5 | 1489285-17-7 | Reference compound |
| HY-110140 | (E)-KN-93 (phosphate) | 1188890-41-6 | Reference compound |
| HY-110141 | ABP688 | 924298-51-1 | Reference compound |
| HY-110142 | Thermopsidine | 492-02-4 | Reference compound |
| HY-110143 | CLP257 | 1181081-71-9 | Reference compound |
| HY-110144 | TC-E 5008 | 50405-58-8 | Reference compound |
| HY-110145 | MRS 1477 | 212200-21-0 | Reference compound |
| HY-110146 | XAP044 | 196928-50-4 | Reference compound |
| HY-110147A | SSM3 (tetraTFA) | 2320930-10-5 | Reference compound |
| HY-110147B | SSM3 (tetraTFA hydrate) | | Reference compound |
| HY-110148 | WWL113 | 947669-86-5 | Reference compound |
| HY-110150 | UNC3230 | 1031602-63-7 | Reference compound |
| HY-110151 | Bengamide B | 104947-69-5 | Natural Products |
| HY-110152 | LSN2463359 | 1401031-52-4 | Reference compound |
| HY-110153 | NS19504 | 327062-46-4 | Reference compound |
| HY-110154 | NSC636819 | 1618672-71-1 | Reference compound |
| HY-110155 | LM11A-31 (dihydrochloride) | 1243259-19-9 | Reference compound |
| HY-110155A | (Rac)-LM11A-31 (dihydrochloride) | 1214672-15-7 | Reference compound |
| HY-110156 | YZ9 | 6093-71-6 | Reference compound |
| HY-110157 | AC-186 | 1421854-16-1 | Reference compound |
| HY-110158 | UNC2327 | 1426152-53-5 | Reference compound |
| HY-110159 | (E/Z)-Teriflunomide | 108605-62-5 | Reference compound |
| HY-110159S | Teriflunomide-d4 | 1185240-22-5 | Isotope-Labeled Compounds |
| HY-110160 | Pozanicline (dihydrochloride) | 161416-61-1 | Reference compound |
| HY-110161 | sst2 Receptor agonist-1 | 1021912-42-4 | Reference compound |
| HY-110162 | QO 58 | 1259536-62-3 | Reference compound |
| HY-110164 | AdipoRon hydrochloride | 1781835-20-8 | Reference compound |
| HY-110165 | hENT4-IN-1 | 949467-71-4 | Reference compound |
| HY-110166 | PD 90780 | 77422-99-2 | Reference compound |
| HY-110167 | TFC 007 | 927878-49-7 | Reference compound |
| HY-110168 | NS 9283 | 913830-15-6 | Reference compound |
| HY-110169 | (E/Z)-3PO | 13309-08-5 | Reference compound |
| HY-11017 | Rivastigmine (tartrate) | 129101-54-8 | Reference compound |
| HY-110170 | Dansyl-NECA | 219982-12-4 | Reference compound |
| HY-110171 | iMDK | 881970-80-5 | Reference compound |
| HY-110171A | iMDK (quarterhydrate) | | Reference compound |
| HY-110172 | PDI-IN-1 | 1461648-55-4 | Reference compound |
| HY-110173 | TC-G 1005 | 1415407-60-1 | Reference compound |
| HY-110174 | NAB2 | 1504588-00-4 | Reference compound |
| HY-110175 | CX614 | 191744-13-5 | Reference compound |
| HY-110176 | ASP2535 | 374886-51-8 | Reference compound |
| HY-110177 | SP-100030 | 154563-54-9 | Reference compound |
| HY-110178 | WWL123 | 1338574-83-6 | Reference compound |
| HY-110179 | PSNCBAM-1 | 877202-74-9 | Reference compound |
| HY-11017AS | (S)-Rivastigmine-d6 (tartrate) | 194930-00-2 | Isotope-Labeled Compounds |
| HY-11017R | Rivastigmine (tartrate) (Standard) | 129101-54-8 | Reference Standards |
| HY-11018 | Risperidone | 106266-06-2 | Reference compound |
| HY-110180 | VU0409106 | 1276617-62-9 | Reference compound |
| HY-110181 | M8-B | 883976-12-3 | Reference compound |
| HY-110182 | SP-141 | 1253491-42-7 | Reference compound |
| HY-110183 | Angiotensin A | 51833-76-2 | Peptides |
| HY-110184 | PK-THPP | 1332454-07-5 | Reference compound |
| HY-110185 | NSC 617145 | 203115-63-3 | Reference compound |
| HY-110186 | PQ-69 | 910045-32-8 | Reference compound |
| HY-110188 | BiP inducer X | 101714-41-4 | Reference compound |
| HY-110189 | Pregnenolone monosulfate (sodium) | 1852-38-6 | Natural Products |
| HY-110189S | Pregnenolone monosulfate (sodium)-13C2,d2 | 2483824-22-0 | Isotope-Labeled Compounds |
| HY-110189S1 | Pregnenolone monosulfate-d4 (sodium) | 1485492-21-4 | Isotope-Labeled Compounds |
| HY-11018A | Risperidone (hydrochloride) | 666179-74-4 | Reference compound |
| HY-11018B | Risperidone (mesylate) | 666179-96-0 | Reference compound |
| HY-11018R | Risperidone (Standard) | 106266-06-2 | Reference Standards |
| HY-11018S1 | Risperidone-d4-1 | | Isotope-Labeled Compounds |
| HY-11018S2 | Risperidone-d6 | 1225444-65-4 | Isotope-Labeled Compounds |
| HY-110190 | VU0422288 | 1630936-95-6 | Reference compound |
| HY-110191 | VU0469650 | 1443748-47-7 | Reference compound |
| HY-110192 | ML 297 | 1443246-62-5 | Reference compound |
| HY-110193 | SPP-86 | 1357349-91-7 | Reference compound |
| HY-110194 | Virodhamine (TFA) | 1415264-56-0 | Reference compound |
| HY-110195 | Smurf1-IN-A01 | 1007647-73-5 | Reference compound |
| HY-110196 | (S)-PFI-2 (hydrochloride) | 1627607-88-8 | Reference compound |
| HY-110197 | 6bK (TFA) | 1774353-12-6 | Reference compound |
| HY-110198 | ONO-8130 | 459841-96-4 | Reference compound |
| HY-110199 | TC-I 2014 | 1221349-53-6 | Reference compound |
| HY-110200 | TC AQP1 1 | 37710-81-9 | Reference compound |
| HY-110201 | Estrogen receptor modulator 1 | 63676-22-2 | Reference compound |
| HY-110202 | MRS5698 | 1377273-00-1 | Reference compound |
| HY-110203 | R-7050 | 303997-35-5 | Reference compound |
| HY-110204 | Heclin | 890605-54-6 | Reference compound |
| HY-110206 | AM6545 | 1245626-05-4 | Reference compound |
| HY-110207 | SM-324405 | 677773-91-0 | Reference compound |
| HY-110208 | BRD9876 | 32703-82-5 | Reference compound |
| HY-110209 | AC4 | 1459809-09-6 | Reference compound |
| HY-11021 | Elinogrel | 936500-94-6 | Reference compound |
| HY-110210 | BODIPY-FL NHS ester | 146616-66-2 | Dye Reagents |
| HY-110211 | BODIPY TMR-X SE | 217190-15-3 | Dye Reagents |
| HY-110212 | BODIPY TR-X | 197306-80-2 | Dye Reagents |
| HY-110213 | BODIPY 630/650X | 380367-48-6 | Dye Reagents |
| HY-110215 | XD14 | 1370888-71-3 | Reference compound |
| HY-110216 | 5J-4 | 827001-82-1 | Reference compound |
| HY-110217 | BMS-566419 | 566161-24-8 | Reference compound |
| HY-110218 | CW 008 | 1134613-19-6 | Reference compound |
| HY-110220 | CIM0216 | 1031496-06-6 | Reference compound |
| HY-110221 | Rp-8-pCPT-cGMPS (sodium) | 208445-07-2 | Reference compound |
| HY-110223 | Atomoxetine-d3 (hydrochloride) | 1217776-38-9 | Reference compound |
| HY-110225 | Levetiracetam-d6 (ring-d6) | 1133229-30-7 | Reference compound |
| HY-110228 | Metformin-d6 (hydrochloride) | 1185166-01-1 | Isotope-Labeled Compounds |
| HY-110230 | Flupirtine-d4 (hydrochloride) | 1324717-75-0 | Reference compound |
| HY-110231 | Simvastatin-d6 | 1002347-71-8 | Isotope-Labeled Compounds |
| HY-110232 | Risperidone-d4 | 1020719-76-9 | Isotope-Labeled Compounds |
| HY-110233S | Acamprosate-d6 (calcium) | 1225580-91-5 | Isotope-Labeled Compounds |
| HY-110234 | Topiramate D12 | 1279037-95-4 | Reference compound |
| HY-110234R | Topiramate D12 (Standard) | 1279037-95-4 | Reference Standards |
| HY-110237 | BX430 | 688309-70-8 | Reference compound |
| HY-110238 | MK6-83 | 1062271-24-2 | Reference compound |
| HY-110239 | Perlapine | 1977-11-3 | Reference compound |
| HY-110240 | IHR-1 | 548779-60-8 | Reference compound |
| HY-110241 | Dianicline (dihydrochloride) | 292634-27-6 | Reference compound |
| HY-110242 | Mps-BAY2a | 1382477-96-4 | Reference compound |
| HY-110243 | CAIX Inhibitor S4 | 1330061-67-0 | Reference compound |
| HY-110244 | Tilfrinib | 1600515-49-8 | Reference compound |
| HY-110245 | DMH2 | 1206711-14-9 | Reference compound |
| HY-110246 | Quin C1 | 786706-21-6 | Reference compound |
| HY-110247 | TRAF-STOP inhibitor 6877002 | 433249-94-6 | Reference compound |
| HY-110248 | MI 14 | 1715934-43-2 | Reference compound |
| HY-110249 | CINPA1 | 102636-74-8 | Reference compound |
| HY-110250 | DFHBI | 1241390-29-3 | Dye Reagents |
| HY-110251 | DFHBI-1T | 1539318-36-9 | Dye Reagents |
| HY-110251A | DFHBI-2T | 1539318-40-5 | Dye Reagents |
| HY-110252 | Salvinorin B | 92545-30-7 | Natural Products |
| HY-110253 | 18A | 331261-50-8 | Reference compound |
| HY-110254 | AZD 9272 | 327056-26-8 | Reference compound |
| HY-110255 | AZD 2066 | 934282-55-0 | Reference compound |
| HY-110255A | AZD 2066 (hydrate) | | Reference compound |
| HY-110255B | AZD-2066 (hydrochloride) | 934338-70-2 | Reference compound |
| HY-110256 | N-Acetylcysteine amide | 38520-57-9 | Reference compound |
| HY-110257 | BDY FL-X, SE | 217190-09-5 | Dye Reagents |
| HY-110258 | ML334 | 1432500-66-7 | Reference compound |
| HY-110258B | (R,S,R)-ML334 | 1432065-33-2 | Reference compound |
| HY-110259 | HFI-142 | 332164-34-8 | Reference compound |
| HY-110260 | LDN-193188 | 1267610-30-9 | Reference compound |
| HY-110261 | GS143 | 916232-21-8 | Reference compound |
| HY-110262 | MSC 2032964A | 1124381-43-6 | Reference compound |
| HY-110263 | EML 425 | 1675821-32-5 | Reference compound |
| HY-110264 | MI-192 | 1415340-63-4 | Reference compound |
| HY-110265 | SAR216471 (hydrochloride) | 1279829-64-9 | Reference compound |
| HY-110266 | GN44028 | 1421448-26-1 | Reference compound |
| HY-110267 | DY268 | 1609564-75-1 | Reference compound |
| HY-110269 | VUF 11222 | 1414376-84-3 | Reference compound |
| HY-11027 | MK-0773 | 606101-58-0 | Reference compound |
| HY-110270 | RN-9893 | 1803003-68-0 | Reference compound |
| HY-110270A | RN-9893 (hydrochloride) | 2109450-40-8 | Reference compound |
| HY-110271 | N-Acetylpuromycin | 22852-13-7 | Reference compound |
| HY-110272 | Vatalanib (succinate) | 212142-18-2 | Reference compound |
| HY-110273 | N106 | 862974-25-2 | Reference compound |
| HY-110274 | IP7e | 500164-74-9 | Reference compound |
| HY-110275 | RA839 | 1832713-02-6 | Reference compound |
| HY-110277 | S2101 | 1239262-36-2 | Reference compound |
| HY-110278 | ADX71743 | 1431641-29-0 | Reference compound |
| HY-110279 | Ogerin | 1309198-71-7 | Reference compound |
| HY-11028 | PF-02413873 | 936345-35-6 | Reference compound |
| HY-110280 | MC1742 | 1776116-74-5 | Reference compound |
| HY-110281 | Dehydroascorbic acid | 490-83-5 | Natural Products |
| HY-110281R | Dehydroascorbic acid (Standard) | 490-83-5 | Reference Standards |
| HY-110282 | S3QEL-2 | 890888-12-7 | Reference compound |
| HY-110284 | BAM 15 | 210302-17-3 | Reference compound |
| HY-110285 | ML382 | 1646499-97-9 | Reference compound |
| HY-110286 | 6-Hydroxy-DOPA | 21373-30-8 | Reference compound |
| HY-110287 | Apcin | 300815-04-7 | Reference compound |
| HY-110288 | 3FAx-Neu5Ac | 117405-58-0 | Reference compound |
| HY-110289 | (R)-Citalopram (oxalate) | 219861-53-7 | Reference compound |
| HY-110289R | (R)-Citalopram (oxalate) (Standard) | 219861-53-7 | Reference Standards |
| HY-110289S1 | (R)-Citalopram-d4 (oxalate) | | Isotope-Labeled Compounds |
| HY-11029 | SNT-207707 | 1064662-40-3 | Reference compound |
| HY-110291 | A-971432 | 1240308-45-5 | Reference compound |
| HY-110292 | A-425619 | 581809-67-8 | Reference compound |
| HY-110293 | CHMFL-FLT3-122 | 1839150-56-9 | Reference compound |
| HY-110294 | CM037 | 896795-60-1 | Reference compound |
| HY-110295 | SPL-334 | 688347-51-5 | Reference compound |
| HY-110296 | EC19 | 1010694-08-2 | Reference compound |
| HY-11030 | SNT-207858 | 1104080-42-3 | Reference compound |
| HY-110302 | 6'-GNTI (dihydrochloride) | 2410327-94-3 | Reference compound |
| HY-110303 | Xanthine amine congener (dihydrochloride) | 1962928-23-9 | Reference compound |
| HY-110304 | NPEC-caged-LY379268 | 1315379-62-4 | Reference compound |
| HY-11030A | SNT-207858 (free base) | 1104662-66-9 | Reference compound |
| HY-110312 | JTV-519 (fumarate) | 1883549-36-7 | Reference compound |
| HY-110313 | SB-747651A (dihydrochloride) | 1781882-72-1 | Reference compound |
| HY-110314 | CYM50358 (hydrochloride) | 1781750-72-8 | Reference compound |
| HY-110315 | Ischemin (sodium) | | Reference compound |
| HY-110318 | VUF11207 (fumarate) | 1785665-61-3 | Reference compound |
| HY-110319 | (E/Z)-Daporinad (hydrochloride) | 1785666-54-7 | Reference compound |
| HY-110320 | LDN-209929 (dihydrochloride) | 1784281-97-5 | Reference compound |
| HY-110322 | PPTN (hydrochloride) | 1992047-65-0 | Reference compound |
| HY-110322A | PPTN | 1160271-30-6 | Reference compound |
| HY-110325 | PF-04885614 | 1480833-70-2 | Reference compound |
| HY-110328 | PKI-166 (hydrochloride) | 2230253-82-2 | Reference compound |
| HY-110329 | ML179 | 1883548-87-5 | Reference compound |
| HY-110331 | CCT241533 (dihydrochloride) | 1962925-28-5 | Reference compound |
| HY-110333 | BMS-599626 (dihydrochloride) | 1781932-33-9 | Reference compound |
| HY-110334 | FFN 206 (dihydrochloride) | 1883548-88-6 | Dye Reagents |
| HY-110335 | OXA-06 (hydrochloride) | 1825455-91-1 | Reference compound |
| HY-110335A | OXA-06 | 944955-32-2 | Reference compound |
| HY-110336 | ETP-45835 (dihydrochloride) | 2136571-30-5 | Reference compound |
| HY-110337 | FFN 102 (mesylate) | 1883548-92-2 | Dye Reagents |
| HY-110339 | RKI-1447 (dihydrochloride) | 1782109-09-4 | Reference compound |
| HY-11034 | CVT-12012 | 1018675-35-8 | Reference compound |
| HY-110341 | MRT 68601 (hydrochloride) | 1962928-25-1 | Reference compound |
| HY-110343 | DBM 1285 (dihydrochloride) | 1782532-29-9 | Reference compound |
| HY-110346 | AZD5582 (dihydrochloride) | 1883545-51-4 | Reference compound |
| HY-110347 | Mps1-IN-1 (dihydrochloride) | 1883548-93-3 | Reference compound |
| HY-11035 | WAY-262611 | 1123231-07-1 | Reference compound |
| HY-110350 | CHR-6494 (TFA) | 1458630-17-5 | Reference compound |
| HY-110351 | BGC-20-1531 (hydrochloride) | 1962928-26-2 | Reference compound |
| HY-110353 | CU-T12-9 | 1821387-73-8 | Reference compound |
| HY-110354 | UCM05 | 1094451-90-7 | Reference compound |
| HY-110354R | UCM05 (Standard) | 1094451-90-7 | Reference Standards |
| HY-110358 | QAQ (dichloride) | | Reference compound |
| HY-110358A | QAQ | 1204416-85-2 | Reference compound |
| HY-110360 | Fenretinide-d4 | 2118244-64-5 | Reference compound |
| HY-110363 | Miglustat-d9 (hydrochloride) | 1883545-57-0 | Isotope-Labeled Compounds |
| HY-110365 | Icerguastat (Carbonate) | 1883549-35-6 | Reference compound |
| HY-110366 | WAY-181187 (oxalate) | 1883548-85-3 | Peptides |
| HY-110367 | LCB 03-0110 (dihydrochloride) | 1962928-28-4 | Reference compound |
| HY-110367A | LCB 03-0110 | 1228102-01-9 | Reference compound |
| HY-110368 | BS-181 (dihydrochloride) | 1883548-83-1 | Reference compound |
| HY-110369 | MRS2905 (trisodium) | 3033550-04-5 | Reference compound |
| HY-110374 | NVS-CECR2-1 | 1992047-61-6 | Reference compound |
| HY-110377 | Tariquidar (dihydrochloride) | 1992047-62-7 | Reference compound |
| HY-110378 | ISOX-DUAL | 1962928-22-8 | Reference compound |
| HY-110379 | M084 (hydrochloride) | 1992047-63-8 | Reference compound |
| HY-11038 | Zelavespib | 873436-91-0 | Reference compound |
| HY-110381 | JNJ-DGAT2-A | 1962931-71-0 | Reference compound |
| HY-110382 | Cyclic-di-GMP (disodium) | 2222132-40-1 | Reference compound |
| HY-110382S | 13C20,15N10-Cyclic di-GMP (sodium) | | Isotope-Labeled Compounds |
| HY-110385 | cGAMP (disodium) | 2407516-83-8 | Natural Products |
| HY-110385A | cGAMP (diammonium) | | Natural Products |
| HY-110387 | IDO-IN-9 | 1888378-12-8 | Reference compound |
| HY-110389 | Pitofenone hydrochloride | 1248-42-6 | Reference compound |
| HY-11038B | Zelavespib (hydrochloride) | 2095432-24-7 | Reference compound |
| HY-11038D | Zelavespib (formic) | | Reference compound |
| HY-11039 | PU24FCl | 422508-46-1 | Reference compound |
| HY-110390 | GR148672X | 263890-70-6 | Reference compound |
| HY-110392 | CMP8 | 851107-28-3 | Reference compound |
| HY-110393 | CLR1501 | 1250963-36-0 | Dye Reagents |
| HY-110397 | KP-457 | 1365803-52-6 | Reference compound |
| HY-110397G | KP-457 (GMP) | 1365803-52-6 | GMP Small Molecules |
| HY-110398 | 5,6,7-Trimethoxyflavone | 973-67-1 | Natural Products |
| HY-110399 | Cirsiliol | 34334-69-5 | Natural Products |
| HY-110402 | (S,R,S)-AHPC (TFA) | 1631137-51-3 | Reference compound |
| HY-110404 | Capzimin | 2084868-04-0 | Reference compound |
| HY-110406 | 13(S)-HPODE | 33964-75-9 | Natural Products |
| HY-110406A | (±)13-HpODE | 23017-93-8 | Reference compound |
| HY-110407 | 2'-O,4'-C-Methyleneadenosine | 206055-70-1 | Oligonucleotides |
| HY-110408 | Flurandrenolone Acetate | 2802-11-1 | Reference compound |
| HY-11041 | LSP1-2111 | 936234-43-4 | Reference compound |
| HY-11042 | GNE-477 | 1032754-81-6 | Reference compound |
| HY-11044 | PF-03654746 (Tosylate) | 1039399-17-1 | Reference compound |
| HY-11045 | PF-03654746 | 935840-31-6 | Reference compound |
| HY-11046A | KRP-109 | 1275996-50-3 | Reference compound |
| HY-11048 | NS11394 | 951650-22-9 | Reference compound |
| HY-11051 | JNJ-20788560 | 825649-28-3 | Reference compound |
| HY-11052A | Trap-101 (hydrochloride) | 1216621-00-9 | Reference compound |
| HY-11053 | S 24795 | 304679-75-2 | Reference compound |
| HY-11054 | TH-237A | 935467-97-3 | Reference compound |
| HY-11055 | KP 544 | 393856-87-6 | Reference compound |
| HY-11058 | BHF177 | 917896-43-6 | Reference compound |
| HY-11059 | KH064 | 393569-31-8 | Reference compound |
| HY-11062 | Icilin | 36945-98-9 | Reference compound |
| HY-11063 | Fingolimod | 162359-55-9 | Reference compound |
| HY-11063R | Fingolimod (Standard) | 162359-55-9 | Reference Standards |
| HY-11063S | Fingolimod-d4 | 1346747-38-3 | Isotope-Labeled Compounds |
| HY-11063S1 | Fingolimod-d4 (hydrochloride) | 1346604-90-7 | Isotope-Labeled Compounds |
| HY-11065A | (iodo-125)-CGP 71872 | 200402-51-3 | Reference compound |
| HY-11067 | WHI-P97 | 211555-05-4 | Reference compound |
| HY-11068 | SB 239063 | 193551-21-2 | Reference compound |
| HY-11070 | MK-0952 | 934995-87-6 | Reference compound |
| HY-11071 | MK-0952 (sodium) | 934995-88-7 | Reference compound |
| HY-11072 | MK-0359 | 346629-30-9 | Reference compound |
| HY-11076 | GI 181771 | 305366-98-7 | Reference compound |
| HY-11077 | SR 146131 | 221671-61-0 | Reference compound |
| HY-11079 | A-803467 | 944261-79-4 | Reference compound |
| HY-11080 | PKI-179 | 1197160-28-3 | Reference compound |
| HY-11080A | PKI-179 (hydrochloride) | 1463510-35-1 | Reference compound |
| HY-11083 | GW-803430 | 515141-51-2 | Reference compound |
| HY-11084 | SNAP-7941 | 387825-78-7 | Reference compound |
| HY-11085 | T-226296 | 331758-35-1 | Reference compound |
| HY-11087 | SD 0006 | 271576-80-8 | Reference compound |
| HY-11090A | DPC423 | 292135-59-2 | Reference compound |
| HY-11091 | Razaxaban (hydrochloride) | 405940-76-3 | Reference compound |
| HY-11092 | BMS-509744 | 439575-02-7 | Reference compound |
| HY-11095 | NPS 2390 | 226878-01-9 | Reference compound |
| HY-11097 | TMC353121 | 857066-90-1 | Reference compound |
| HY-11098 | JNJ 2408068 | 317846-22-3 | Reference compound |
| HY-11100 | Asenapine (maleate) | 85650-56-2 | Reference compound |
| HY-111000 | BNC-1 | 96335-59-0 | Reference compound |
| HY-111002 | Displurigen | 96156-26-2 | Reference compound |
| HY-111003 | Isothiafludine | 960527-22-4 | Reference compound |
| HY-111006 | (+)-UH 232 | 95999-12-5 | Reference compound |
| HY-111007 | CH5015765 | 959766-47-3 | Reference compound |
| HY-111008 | Trimidox | 95933-74-7 | Reference compound |
| HY-111008A | Trimidox (hydrochloride) | 95933-75-8 | Reference compound |
| HY-111009 | Swinholide A | 95927-67-6 | Natural Products |
| HY-11101 | Alendronate (sodium hydrate) | 121268-17-5 | Reference compound |
| HY-111011 | CR 665 (acetate) | 958873-83-1 | Reference compound |
| HY-111012 | DBCO-(PEG)3-VC-PAB-MMAE | 2754384-60-4 | ADC Related |
| HY-111013 | VK-II-86 | 955371-84-3 | Reference compound |
| HY-111014 | VK-II-36 | 955371-66-1 | Reference compound |
| HY-111016 | LJP 1586 | 955037-42-0 | Reference compound |
| HY-111018 | FPL 62129 | 95445-79-7 | Reference compound |
| HY-111019A | SCH 34343 (sodium) | 94392-35-5 | Reference compound |
| HY-11101R | Alendronate (sodium hydrate) (Standard) | 121268-17-5 | Reference Standards |
| HY-11101S | Alendronate-d6 (sodium hydrate) | | Isotope-Labeled Compounds |
| HY-11102 | RO4929097 | 847925-91-1 | Reference compound |
| HY-111021 | ASP-4058 | 952565-91-2 | Reference compound |
| HY-111021A | ASP-4058 (hydrochloride) | 952510-14-4 | Reference compound |
| HY-111022 | Icerguastat | 951441-04-6 | Reference compound |
| HY-111023 | Nemonoxacin (malate) | 951163-60-3 | Reference compound |
| HY-111024 | 2,2,5,7,8-Pentamethyl-6-Chromanol | 950-99-2 | Reference compound |
| HY-111024R | 2,2,5,7,8-Pentamethyl-6-Chromanol (Standard) | 950-99-2 | Reference Standards |
| HY-111025 | Ectylurea | 95-04-5 | Reference compound |
| HY-111026 | PPQ-581 | 950381-32-5 | Reference compound |
| HY-111027 | HDAC8-IN-13 | 949792-00-1 | Reference compound |
| HY-111028 | J1038 | 949727-86-0 | Reference compound |
| HY-111029 | ALX-1393 | 949164-09-4 | Reference compound |
| HY-111029A | ALX-1393 (TFA) | | Reference compound |
| HY-11103 | Sitaxsentan (sodium) | 210421-74-2 | Reference compound |
| HY-111030 | PRMT1-IN-2 | 947508-41-0 | Reference compound |
| HY-111036 | AMG0347 | 946615-43-6 | Reference compound |
| HY-111037 | BMS-457 | 946594-19-0 | Reference compound |
| HY-111038 | Capsiconiate | 946572-73-2 | Natural Products |
| HY-111040 | Hedgehog agonist 1 | 946002-48-8 | Reference compound |
| HY-111044 | (+)-JNJ-37654032 | 944919-15-7 | Reference compound |
| HY-111048 | Corin | 1808113-09-8 | Reference compound |
| HY-111049 | GSK8062 | 943549-47-1 | Reference compound |
| HY-11105 | Pilaralisib analogue | 956958-53-5 | Reference compound |
| HY-111050 | JNJ-38877618 | 943540-74-7 | Reference compound |
| HY-111051 | JN403 | 942606-12-4 | Reference compound |
| HY-111052 | AZD7325 | 942437-37-8 | Reference compound |
| HY-111053 | P11 | 942285-55-4 | Reference compound |
| HY-111054 | N-methyl-N-dithiocarboxyglucamine | 94161-07-6 | Reference compound |
| HY-111054A | N-methyl-N-dithiocarboxyglucamine (sodium) | 91840-27-6 | Reference compound |
| HY-111055 | BIP-135 | 941575-71-9 | Reference compound |
| HY-111056 | UK122 | 940290-58-4 | Reference compound |
| HY-111058 | D-106669 | 938444-93-0 | Reference compound |
| HY-11106 | Nintedanib esylate | 656247-18-6 | Reference compound |
| HY-111061 | GTX-758 | 938067-78-8 | Reference compound |
| HY-111063 | BX048 | 937395-09-0 | Reference compound |
| HY-111064 | BX 667 | 937395-08-9 | Reference compound |
| HY-111065 | OXA-01 | 936889-68-8 | Reference compound |
| HY-111066 | JNJ-37822681 | 935776-74-2 | Reference compound |
| HY-111066A | JNJ-37822681 (dihydrochloride) | 2108806-02-4 | Reference compound |
| HY-111067 | (4S)-(+)-Ascochin | 935699-58-4 | Natural Products |
| HY-111068 | KD-3010 | 934760-92-6 | Reference compound |
| HY-111069 | Nifeviroc | 934740-33-7 | Reference compound |
| HY-11106R | Nintedanib esylate (Standard) | 656247-18-6 | Reference Standards |
| HY-11107 | PHA-665752 | 477575-56-7 | Reference compound |
| HY-111070 | Karavilagenin D | 934739-29-4 | Natural Products |
| HY-111071 | Nilofabicin | 934628-27-0 | Reference compound |
| HY-111071R | Nilofabicin (Standard) | 934628-27-0 | Reference Standards |
| HY-111073 | Bentysrepinine | 934264-38-7 | Reference compound |
| HY-111074 | DB12055 | 934017-32-0 | Reference compound |
| HY-111077 | INCB16562 | 933768-63-9 | Reference compound |
| HY-111079 | HIV-1 inhibitor-70 | 933452-76-7 | Reference compound |
| HY-11108 | R406 (free base) | 841290-80-0 | Reference compound |
| HY-111081 | (±)-PPCC | 932736-90-8 | Reference compound |
| HY-111081C | (±)-PPCC (oxalate) | 1781628-91-8 | Reference compound |
| HY-111082 | ISAM-140 | 932191-62-3 | Reference compound |
| HY-111083 | ML191 | 931695-79-3 | Reference compound |
| HY-111084 | UK 52831 | 93118-77-5 | Reference compound |
| HY-111085 | CPI-905 | 931078-17-0 | Reference compound |
| HY-111086 | DG70 | 930470-97-6 | Reference compound |
| HY-111087 | AZD-7295 | 929890-64-2 | Reference compound |
| HY-111088 | LUF5981 | 929641-63-4 | Reference compound |
| HY-11109 | Resatorvid | 243984-11-4 | Reference compound |
| HY-111093 | Protein kinase inhibitor 8 | 926319-75-7 | Reference compound |
| HY-111094 | NPD7155 | 924764-38-5 | Reference compound |
| HY-111095B | D-(-)-Lactic acid (sodium) | 920-49-0 | Natural Products |
| HY-111095BR | D-(-)-Lactic acid (sodium) (Standard) | 920-49-0 | Reference Standards |
| HY-111095S1 | D-(-)-Lactic acid-13C | 2102426-04-8 | Isotope-Labeled Compounds |
| HY-111095S2 | D-(-)-Lactic acid-13C-1 | 1224440-85-0 | Isotope-Labeled Compounds |
| HY-111095S3A | D-(-)-Lactic acid-13C-2 (sodium) | 1217621-81-2 | Isotope-Labeled Compounds |
| HY-111098 | GSK1702934A | 924377-85-5 | Reference compound |
| HY-111099 | GLPG1837 | 1654725-02-6 | Reference compound |
| HY-111101 | AZ1495 | 2196204-23-4 | Reference compound |
| HY-111102 | FL-411 | 2118944-88-8 | Reference compound |
| HY-111108 | LDH-IN-1 | 1964515-43-2 | Reference compound |
| HY-111109 | EZM 2302 | 1628830-21-6 | Reference compound |
| HY-111110 | Olorinab | 1268881-20-4 | Reference compound |
| HY-111111 | Galicaftor | 1918143-53-9 | Reference compound |
| HY-111112S | ZHC-116-d8 (trihydrochloride) | | Isotope-Labeled Compounds |
| HY-111116 | LY3104607 | 1795232-22-2 | Reference compound |
| HY-111117 | 3-Methyltoxoflavin | 32502-62-8 | Reference compound |
| HY-111121 | cBu-Cit-OH | 1799663-03-8 | Reference compound |
| HY-111125 | AMRI-59 | 923515-92-8 | Reference compound |
| HY-111126 | K67 | 2046250-48-8 | Reference compound |
| HY-111129 | CP-66713 | 91896-57-0 | Reference compound |
| HY-111130 | Methapyrilene | 91-80-5 | Reference compound |
| HY-111131 | RY764 | 491845-95-5 | Reference compound |
| HY-111132 | JT010 | 917562-33-5 | Reference compound |
| HY-111133 | LY 154045 | 91706-86-4 | Reference compound |
| HY-111134 | TAN 420C | 91700-91-3 | Reference compound |
| HY-111135 | IKK2-IN-3 | 916985-21-2 | Reference compound |
| HY-111136 | BL-1020 (mesylate) | 916898-61-8 | Reference compound |
| HY-111137 | Puquitinib | 916890-10-3 | Reference compound |
| HY-111138 | CZC-8004 | 916603-07-1 | Reference compound |
| HY-111139 | MS417 | 916489-36-6 | Reference compound |
| HY-111140 | YS121 | 916482-17-2 | Reference compound |
| HY-111142 | COR 32-24 | 91595-86-7 | Reference compound |
| HY-111143 | SCH-900271 | 915210-50-3 | Reference compound |
| HY-111144 | Abediterol | 915133-65-2 | Reference compound |
| HY-111145 | RD162 | 915087-27-3 | Reference compound |
| HY-111149 | PS372424 | 914291-61-5 | Reference compound |
| HY-111149A | PS372424 (hydrochloride) | 1596362-29-6 | Reference compound |
| HY-111150 | AMG-222 | 913978-37-7 | Reference compound |
| HY-111151 | AR-9281 | 913548-29-5 | Reference compound |
| HY-111152 | ML115 | 912798-42-6 | Reference compound |
| HY-111154 | BPH-608 | 911783-02-3 | Reference compound |
| HY-111155 | RBI-257 (maleate) | 911378-38-6 | Reference compound |
| HY-111156 | NW-1172 (free base) | 911290-20-5 | Reference compound |
| HY-111157 | Dezinamide | 91077-32-6 | Biochemical Assay Reagents |
| HY-111158 | BMS-748730 | 910297-57-3 | Reference compound |
| HY-111160 | SKF 83509 | 90955-43-4 | Reference compound |
| HY-111161 | GSK575594A | 909418-68-4 | Reference compound |
| HY-111162 | GSK494581A | 909416-67-7 | Reference compound |
| HY-111163 | NSC49652 | 908563-68-8 | Reference compound |
| HY-111164 | CBS-3595 | 908380-97-2 | Reference compound |
| HY-111166 | USP7/USP47 inhibitor 1 | 90680-28-7 | Reference compound |
| HY-111172 | Inotilone | 906366-79-8 | Reference compound |
| HY-111173 | Diprotin B | 90614-49-6 | Reference compound |
| HY-111174 | Diprotin A | 90614-48-5 | Peptides |
| HY-111174A | Diprotin A (TFA) | 209248-71-5 | Peptides |
| HY-111174R | Diprotin A (Standard) | 90614-48-5 | Reference Standards |
| HY-111176 | PD 145305 | 90536-15-5 | Reference compound |
| HY-111177 | Pheneturide | 90-49-3 | Reference compound |
| HY-111177R | Pheneturide (Standard) | 90-49-3 | Reference Standards |
| HY-111178 | Lauflumide | 90280-13-0 | Reference compound |
| HY-111179 | ML261 | 902523-58-4 | Reference compound |
| HY-111180 | ML262 | 902502-82-3 | Reference compound |
| HY-111182 | Estrone acetate | 901-93-9 | Reference compound |
| HY-111183 | Neocarzinostatin | 9014-02-2 | Reference compound |
| HY-111184 | PIK-108 | 901398-68-3 | Reference compound |
| HY-111186 | Flocoumafen | 90035-08-8 | Reference compound |
| HY-111186R | Flocoumafen (Standard) | 90035-08-8 | Reference Standards |
| HY-111187 | KX2-361 | 897016-26-1 | Reference compound |
| HY-111188 | A55453 | 89687-06-9 | Reference compound |
| HY-111189 | GSK931145 | 896117-64-9 | Reference compound |
| HY-111190 | Thiotropocin | 89550-93-6 | Natural Products |
| HY-111191 | ONO-2952 | 895169-20-7 | Reference compound |
| HY-111191A | (R)-ONO-2952 | 2988224-39-9 | Reference compound |
| HY-111192 | IPR-803 | 892243-35-5 | Reference compound |
| HY-111193 | Declopramide | 891-60-1 | Reference compound |
| HY-111194 | Ro 22-8515 | 89052-67-5 | Reference compound |
| HY-111197 | LY-2300559 | 889116-06-7 | Reference compound |
| HY-111198 | YM-355179 (fumarate) | 887647-69-0 | Reference compound |
| HY-111199 | JP83 | 887264-44-0 | Reference compound |
| HY-111200 | Vabicaserin hydrochloride | 887258-94-8 | Reference compound |
| HY-111201 | Iodiconazole | 887138-63-8 | Reference compound |
| HY-111202 | Pyributicarb | 88678-67-5 | Reference compound |
| HY-111202R | Pyributicarb (Standard) | 88678-67-5 | Reference Standards |
| HY-111203 | TT-301 | 886208-76-0 | Reference compound |
| HY-111204 | MK3281 | 886041-60-7 | Reference compound |
| HY-111205 | γ-Secretase modulator 16 | 884599-96-6 | Reference compound |
| HY-111206 | β3-AR agonist 3 | 883724-08-1 | Reference compound |
| HY-111207 | CA224 | 883561-04-4 | Reference compound |
| HY-111208 | CCT129957 | 883098-58-6 | Reference compound |
| HY-111209 | Pichromene | 883046-50-2 | Reference compound |
| HY-111210 | Pridopidine (hydrochloride) | 882737-42-0 | Reference compound |
| HY-111212 | Tomelukast | 88107-10-2 | Reference compound |
| HY-111213 | PRMT5-IN-20 | 880813-30-9 | Reference compound |
| HY-111214 | K-14585 | 880546-17-8 | Reference compound |
| HY-111216 | CGP52608 | 87958-67-6 | Reference compound |
| HY-111217 | AKOS-22 | 878983-38-1 | Reference compound |
| HY-111218 | TRPV1 antagonist 5 | 878811-00-8 | Reference compound |
| HY-111219 | Parogrelil (hydrochloride) | 139145-84-9 | Reference compound |
| HY-111220 | AP23846 | 878654-51-4 | Reference compound |
| HY-111221 | PD 113271 | 87860-38-6 | Reference compound |
| HY-111222 | PD 113270 | 87860-37-5 | Reference compound |
| HY-111223 | Tralkoxydim | 87820-88-0 | Reference compound |
| HY-111223R | Tralkoxydim (Standard) | 87820-88-0 | Reference Standards |
| HY-111224 | GSK812397 | 878197-98-9 | Reference compound |
| HY-111226 | GSK5182 | 877387-37-6 | Reference compound |
| HY-111226A | (E/Z)-GSK5182 | 2699724-40-6 | Reference compound |
| HY-111232 | GSK894281 | 874958-63-1 | Reference compound |
| HY-111233 | Disoxaril | 87495-31-6 | Reference compound |
| HY-111234 | IDO-IN-11 | 1888378-32-2 | Reference compound |
| HY-111237 | Butyrolactone I | 87414-49-1 | Reference compound |
| HY-111238 | Butyrolactone II | 87414-44-6 | Natural Products |
| HY-111239 | GSK317354A | 874119-13-8 | Reference compound |
| HY-111241 | SV 293 | 873445-73-9 | Reference compound |
| HY-111242 | SV 156 | 873445-60-4 | Reference compound |
| HY-111243 | Ganoderone A | 873061-79-1 | Natural Products |
| HY-111244 | DCB-3503 | 87302-58-7 | Reference compound |
| HY-111245 | AZD-1305 | 872045-91-5 | Reference compound |
| HY-111246 | MK-3984 | 871325-55-2 | Reference compound |
| HY-111247 | Ro 09-0680 | 87112-49-0 | Natural Products |
| HY-111248 | ABD-295 | 871113-99-4 | Reference compound |
| HY-111249 | TTT 3002 | 871037-95-5 | Reference compound |
| HY-111253 | CYM-5478 | 870762-83-7 | Reference compound |
| HY-111254 | GQ-16 | 870554-67-9 | Reference compound |
| HY-111255 | SPD304 | 869998-49-2 | Reference compound |
| HY-111255A | SPD304 (dihydrochloride) | 1049741-03-8 | Reference compound |
| HY-111256 | A-850002 | 869802-73-3 | Reference compound |
| HY-111258 | GSK345931A | 869499-38-7 | Reference compound |
| HY-111259 | Ro 31-1118 (free base) | 81228-35-5 | Reference compound |
| HY-111260 | R547 (mesylate) | 869369-26-6 | Reference compound |
| HY-111262 | ABT-384 | 868623-40-9 | Reference compound |
| HY-111263 | NIAD-4 | 868592-56-7 | Dye Reagents |
| HY-111264 | Naphthomycin B | 86825-88-9 | Natural Products |
| HY-111266 | Halenaquinone | 86690-14-4 | Natural Products |
| HY-111267 | Aftin-4 | 866893-90-5 | Reference compound |
| HY-111269 | AZD8848 | 866269-28-5 | Reference compound |
| HY-111271 | L 888607 | 860033-06-3 | Reference compound |
| HY-111271A | L 888607 (Racemate) | 1030017-51-6 | Reference compound |
| HY-111271B | (R)-L 888607 | 2446042-90-4 | Reference compound |
| HY-111273 | AR244555 | 858350-62-6 | Reference compound |
| HY-111274 | Indomethacin farnesil | 85801-02-1 | Reference compound |
| HY-111278 | Pyocyanin | 85-66-5 | Reference compound |
| HY-111278R | Pyocyanin (Standard) | 85-66-5 | Reference Standards |
| HY-111279 | Sisapronil | 856225-89-3 | Reference compound |
| HY-111280 | ST 198 | 854924-64-4 | Reference compound |
| HY-111283 | AJ-76 | 85379-09-5 | Reference compound |
| HY-111284 | Kebuzone | 853-34-9 | Reference compound |
| HY-111285 | HAMNO | 138736-73-9 | Reference compound |
| HY-111287 | Autophagonizer | 853136-76-2 | Reference compound |
| HY-111288 | MB-07811 | 852948-13-1 | Reference compound |
| HY-111291 | ICI 169369 (free base) | 85273-95-6 | Reference compound |
| HY-111292 | CYM-5482 | 852230-33-2 | Reference compound |
| HY-111293 | Arachidonamide | 85146-53-8 | Reference compound |
| HY-111295 | LAS38096 | 851371-22-7 | Reference compound |
| HY-111296 | YM 53403 | 851331-05-0 | Reference compound |
| HY-111297 | BMVC4 | 868843-84-9 | Reference compound |
| HY-111298 | TG 41 | 850339-33-2 | Reference compound |
| HY-111299 | Psammaplysene A | 850013-02-4 | Reference compound |
| HY-111301 | FR217840 | 848444-16-6 | Reference compound |
| HY-111302 | Norgestrienone | 848-21-5 | Reference compound |
| HY-111303 | CHIC35 | 848193-72-6 | Reference compound |
| HY-111304 | MF266-1 | 848188-18-1 | Reference compound |
| HY-111306 | ATL-802 | 847612-12-8 | Reference compound |
| HY-111308 | RTI-118 | 847554-50-1 | Reference compound |
| HY-111309 | LGD-2941 | 847235-85-2 | Reference compound |
| HY-111310 | ML351 | 847163-28-4 | Reference compound |
| HY-111313 | JNJ-26070109 | 844645-08-5 | Reference compound |
| HY-111314 | NZ 419 | 84210-26-4 | Reference compound |
| HY-111315 | XEN103 | 840489-44-3 | Reference compound |
| HY-111317 | SIRT1 activator 3 | 839699-72-8 | Reference compound |
| HY-111320 | Chrysomycin B | 83852-56-6 | Reference compound |
| HY-111321 | Fuscin | 83-85-2 | Natural Products |
| HY-111323 | ASN06917370 | 837404-68-9 | Reference compound |
| HY-111325 | Synta66 | 835904-51-3 | Reference compound |
| HY-111326 | Naphazoline | 835-31-4 | Reference compound |
| HY-111326A | Naphazoline (nitrate) | 5144-52-5 | Reference compound |
| HY-111326AR | Naphazoline (nitrate) (Standard) | 5144-52-5 | Reference Standards |
| HY-111326S | Naphazoline-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-111327 | Valibose | 83470-79-5 | Reference compound |
| HY-111329 | JGB1741 | 1256375-38-8 | Reference compound |
| HY-111330 | Hydroxyphenyl Fluorescein | 359010-69-8 | Dye Reagents |
| HY-111331 | Germicidin B | 150973-78-7 | Natural Products |
| HY-111332 | (E)-PHCCC | 177610-87-6 | Reference compound |
| HY-111333 | Pyrroxamycin | 105888-54-8 | Natural Products |
| HY-111334 | Brassinin | 105748-59-2 | Natural Products |
| HY-111335 | Methoxybrassinin | 105748-60-5 | Natural Products |
| HY-111338 | Tacrine | 321-64-2 | Reference compound |
| HY-111341 | AZD5904 | 618913-30-7 | Reference compound |
| HY-111342 | HDAC8-IN-1 | 1417997-93-3 | Reference compound |
| HY-111343 | ONC212 | 1807861-48-8 | Reference compound |
| HY-111345 | Epaminurad | 1198153-15-9 | Reference compound |
| HY-111345A | Epaminurad (hydrochloride) | 1198153-46-6 | Reference compound |
| HY-111346 | 1-Linoleoyl Glycerol | 2277-28-3 | Natural Products |
| HY-111347 | BB-Cl-Amidine | 1802637-39-3 | Reference compound |
| HY-111347A | BB-Cl-Amidine (hydrochloride) | 2436747-41-8 | Reference compound |
| HY-111348 | Lamifiban | 144412-49-7 | Reference compound |
| HY-111348A | Lamifiban (TFA) | 144412-50-0 | Reference compound |
| HY-111351 | MLK-IN-1 | 1627729-62-7 | Reference compound |
| HY-111353 | GPR120 Agonist 2 | 1234844-11-1 | Reference compound |
| HY-111354 | Tinoridine (hydrochloride) | 25913-34-2 | Reference compound |
| HY-111355 | Cholesterol sulfate | 1256-86-6 | Natural Products |
| HY-111355B | Cholesteryl sulfate (sodium) | 2864-50-8 | Natural Products |
| HY-111355S | Cholesterol sulfate-d7 (sodium) | 2687961-01-7 | Isotope-Labeled Compounds |
| HY-111356 | IIIM-290 | 2213468-64-3 | Reference compound |
| HY-111357 | Antifungal agent 2 | 2211060-61-4 | Reference compound |
| HY-111358 | TLR7 agonist 1 | 2178156-33-5 | Reference compound |
| HY-111359 | GPR40 agonist 1 | 1853982-41-8 | Reference compound |
| HY-111360 | SPL-707 | 2195361-33-0 | Reference compound |
| HY-111361 | FN-1501 | 1429515-59-2 | Reference compound |
| HY-111363 | MK8722 | 1394371-71-1 | Reference compound |
| HY-111365 | TES-1025 | 1883602-21-8 | Reference compound |
| HY-111366 | CD12681 | 1952239-59-6 | Reference compound |
| HY-111368 | EBI-1051 | 1801896-05-8 | Reference compound |
| HY-111369 | CHK1-IN-2 | 912367-45-4 | Reference compound |
| HY-111370 | mTOR inhibitor-2 | 2219323-96-1 | Reference compound |
| HY-111371 | PF-05180999 | 1394033-54-5 | Reference compound |
| HY-111372 | Finerenone | 1050477-31-0 | Reference compound |
| HY-111372A | (Rac)-Finerenone | 1050477-27-4 | Reference compound |
| HY-111372R | Finerenone (Standard) | 1050477-31-0 | Reference Standards |
| HY-111372S | Finerenone-d3 | 2917530-37-9 | Isotope-Labeled Compounds |
| HY-111372S1 | Finerenone-d5 | | Isotope-Labeled Compounds |
| HY-111373 | RapaLink-1 | 1887095-82-0 | Reference compound |
| HY-111374 | NMDI14 | 307519-88-6 | Reference compound |
| HY-111375 | Azoxymethane | 25843-45-2 | Reference compound |
| HY-111376 | Pyrrophenone | 341973-06-6 | Reference compound |
| HY-111377 | Amine-PEG3-Biotin | 359860-27-8 | Dye Reagents |
| HY-111378 | Casein Kinase II Inhibitor IV | 863598-09-8 | Reference compound |
| HY-111378A | Casein Kinase II Inhibitor IV (hydrochloride) | 2320347-54-2 | Reference compound |
| HY-111379 | EHT 5372 | 1425945-63-6 | Reference compound |
| HY-111380 | EHT 1610 | 1425945-60-3 | Reference compound |
| HY-111381 | BI-3812 | 2166387-64-8 | Reference compound |
| HY-111382 | Diphenylterazine | 344940-63-2 | Dye Reagents |
| HY-111383 | LX2343 | 333745-53-2 | Reference compound |
| HY-111385 | UNC9994 (hydrochloride) | 2108826-33-9 | Reference compound |
| HY-111386 | E-7386 | 1799824-08-0 | Reference compound |
| HY-111387 | IDF-11774 | 1429054-28-3 | Reference compound |
| HY-111388 | Romaciclib | 1609522-33-9 | Reference compound |
| HY-111388A | Romaciclib (monohydrochloride) | 2443816-41-7 | Reference compound |
| HY-111388B | Romaciclib (hydrochloride) | 1609452-30-3 | Reference compound |
| HY-111389 | FAAH-IN-1 | 1242441-47-9 | Reference compound |
| HY-111390 | Dot1L-IN-2 | 1940206-71-2 | Reference compound |
| HY-111391 | Resazurin (sodium) | 62758-13-8 | Dye Reagents |
| HY-111391A | Resazurin (sodium), indicator | 62758-13-8 | Biochemical Assay Reagents |
| HY-111391R | Resazurin (sodium) (Standard) | 62758-13-8 | Reference Standards |
| HY-111392 | Glucametacine | 52443-21-7 | Reference compound |
| HY-111396 | PC58538 | 434910-94-8 | Reference compound |
| HY-111397 | Bizelesin | 129655-21-6 | Reference compound |
| HY-111398 | ALB-127158(a) | 1173154-32-9 | Reference compound |
| HY-111400 | SR-4370 | 1816294-67-3 | Reference compound |
| HY-111402 | Pyridomycin | 18791-21-4 | Reference compound |
| HY-111405 | Antimicrobial Compound 1 | 15237-83-9 | Reference compound |
| HY-111406 | Omidenepag isopropyl | 1187451-19-9 | Reference compound |
| HY-111407 | MK-8353 | 1184173-73-6 | Reference compound |
| HY-111408 | EOAI3402143 | 1699750-95-2 | Reference compound |
| HY-111409 | RIP1 kinase inhibitor 1 | 2095515-38-9 | Reference compound |
| HY-111410 | ATX inhibitor 1 | 2225892-70-4 | Reference compound |
| HY-111411 | IZCZ-3 | 2223019-53-0 | Reference compound |
| HY-111412 | DAAO inhibitor-1 | 2065250-25-9 | Reference compound |
| HY-111413 | c(phg-isoDGR-(NMe)k) | 1844830-65-4 | Biochemical Assay Reagents |
| HY-111413A | c(phg-isoDGR-(NMe)k) (TFA) | | Biochemical Assay Reagents |
| HY-111414 | Hsp90-Cdc37-IN-1 | 2227303-22-0 | Reference compound |
| HY-111415 | EGFR-IN-5 | 2225887-26-1 | Reference compound |
| HY-111416 | WY-135 | 2163060-83-9 | Reference compound |
| HY-111417 | GSK2973980A | 2219321-25-0 | Reference compound |
| HY-111418 | EBI-2511 | 2098546-05-3 | Reference compound |
| HY-111419 | DSP-1053 | 1176326-76-3 | Reference compound |
| HY-111419A | DSP-1053 (benzenesulfonate) | 1176326-78-5 | Reference compound |
| HY-111420 | CBP/p300-IN-1 | 2443789-32-8 | Reference compound |
| HY-111421 | ODM-204 | 1642818-64-1 | Reference compound |
| HY-111422 | PLX51107 | 1627929-55-8 | Reference compound |
| HY-111423 | BDP8900 | 2226507-05-5 | Reference compound |
| HY-111424 | BDP9066 | 2226507-04-4 | Reference compound |
| HY-111424A | (R)-BDP9066 | 2284549-25-1 | Reference compound |
| HY-111425 | SSE15206 | 1370046-40-4 | Reference compound |
| HY-111427 | CDK8/19-IN-1 | 1818427-07-4 | Reference compound |
| HY-111428 | Phleomycin D1 | 11031-11-1 | Reference compound |
| HY-111429 | YAP/TAZ inhibitor-1 | 2093565-23-0 | Reference compound |
| HY-111430 | 1-Ethynylnaphthalene | 15727-65-8 | Reference compound |
| HY-111431 | p-Cresyl sulfate | 3233-58-7 | Natural Products |
| HY-111431A | p-Cresyl sulfate (potassium) | 91978-69-7 | Reference compound |
| HY-111431AS | p-Cresol sulfate-d7 (potassium) | 2469278-96-2 | Isotope-Labeled Compounds |
| HY-111431R | p-Cresyl sulfate (Standard) | 3233-58-7 | Reference Standards |
| HY-111432 | CCG-232601 | 1922099-21-5 | Reference compound |
| HY-111433 | BRD4 degrader AT1 | 2098836-45-2 | Reference compound |
| HY-111434 | UAA crosslinker 1 | 1167421-25-1 | Reference compound |
| HY-111434A | UAA crosslinker 1 (hydrochloride) | 1994331-17-7 | Reference compound |
| HY-111441 | 1,4-Chrysenequinone | 100900-16-1 | Reference compound |
| HY-111442 | GC 14 | 447415-34-1 | Reference compound |
| HY-111443 | TR antagonist 1 | 500794-88-7 | Reference compound |
| HY-111444 | Auxinole | 86445-22-9 | Reference compound |
| HY-111445 | CeMMEC1 | 440662-09-9 | Reference compound |
| HY-111446 | EPAC 5376753 | 302826-61-5 | Reference compound |
| HY-111447 | VAS 3947 | 869853-70-3 | Reference compound |
| HY-111449 | BAY-218 | 2162982-11-6 | Reference compound |
| HY-111450 | CB7993113 | 819827-50-4 | Reference compound |
| HY-111451 | Tuvusertib | 1613200-51-3 | Reference compound |
| HY-111452 | EGFR-IN-85 | 1956378-29-2 | Reference compound |
| HY-111453 | Velsecorat | 1196509-60-0 | Reference compound |
| HY-111454 | SR17018 | 2134602-45-0 | Reference compound |
| HY-111455 | LP-211 | 1052147-86-0 | Reference compound |
| HY-111456 | DBCO-NHCO-PEG4-NHS ester | 2100306-58-7 | ADC Related |
| HY-111457 | BAY-677 | 2117404-84-7 | Reference compound |
| HY-111457A | BAY-678 | 675103-36-3 | Reference compound |
| HY-111458 | GSK2643943A | 2449301-27-1 | Reference compound |
| HY-111460 | 15-Oxospiramilactone | 1053172-87-4 | Reference compound |
| HY-111463 | CDK8-IN-3 | 1884500-15-5 | Reference compound |
| HY-111465 | CDK8-IN-4 | 1613638-82-6 | Reference compound |
| HY-111467 | Mcl1-IN-4 | 1580484-04-3 | Reference compound |
| HY-111468 | Mcl1-IN-3 | 1814891-79-6 | Reference compound |
| HY-111469 | CPT-157633 | 888213-72-7 | Reference compound |
| HY-111471 | JAK-IN-5 | 2096999-92-5 | Reference compound |
| HY-111471A | JAK-IN-5 (hydrochloride) | 2751323-21-2 | Reference compound |
| HY-111472 | Porcn-IN-1 | 2036044-77-4 | Reference compound |
| HY-111473 | Anti-inflammatory agent 82 | 178408-16-7 | Reference compound |
| HY-111474 | Para-aminoblebbistatin | 2097734-03-5 | Reference compound |
| HY-111475 | Mitochondrial fusion promoter M1 | 219315-22-7 | Reference compound |
| HY-111477 | (E/Z)-Ensifentrine | 298680-25-8 | Reference compound |
| HY-111478 | Tiaprost | 71116-82-0 | Reference compound |
| HY-111479 | Amibegron | 121524-08-1 | Reference compound |
| HY-111480 | Propionylpromazine | 3568-24-9 | Reference compound |
| HY-111481 | Flutazolam | 27060-91-9 | Reference compound |
| HY-111482 | SM 16 | 614749-78-9 | Reference compound |
| HY-111483 | Tizaterkib | 2097416-76-5 | Reference compound |
| HY-111483A | Tizaterkib (hexanedioic acid) | 2097416-93-6 | Reference compound |
| HY-111484 | GDC-0927 | 1642297-01-5 | Reference compound |
| HY-111484A | GDC-0927 (Racemate) | 1443983-36-5 | Reference compound |
| HY-111485 | INCB-057643 | 1820889-23-3 | Reference compound |
| HY-111486 | LSZ-102 | 2135600-76-7 | Reference compound |
| HY-111487 | α-Methylacyl-CoA racemase 1 | | Enzyme |
| HY-111488 | ML 400 | 1908414-42-5 | Reference compound |
| HY-111489 | LMPTP inhibitor 1 | 1908414-82-3 | Reference compound |
| HY-111489A | LMPTP inhibitor 1 (hydrochloride) | 2310135-38-5 | Reference compound |
| HY-111489B | LMPTP inhibitor 1 (dihydrochloride) | 2310135-46-5 | Reference compound |
| HY-111490 | Desisobutyryl-ciclesonide | 161115-59-9 | Reference compound |
| HY-111490R | Desisobutyryl-ciclesonide (Standard) | 161115-59-9 | Reference Standards |
| HY-111491 | Methiothepin | 20229-30-5 | Reference compound |
| HY-111492 | DIM-C-pPhOCH3 | 33985-68-1 | Reference compound |
| HY-111493 | LRRK2 inhibitor 1 | 1802525-61-6 | Reference compound |
| HY-111494 | TRPA1 Antagonist 1 | 1984825-08-2 | Reference compound |
| HY-111496 | Sulfo-NHS-SS-Biotin (sodium) | 325143-98-4 | Dye Reagents |
| HY-111498 | RGX-104 (hydrochloride) | 610318-03-1 | Reference compound |
| HY-111498A | RGX-104 | 610318-54-2 | Reference compound |
| HY-111499 | Emopamil | 78370-13-5 | Reference compound |
| HY-111500 | (Rac)-NMDAR antagonist 1 | 2435557-99-4 | Reference compound |
| HY-111500A | NMDAR antagonist 1 | 2220162-06-9 | Reference compound |
| HY-111501 | H4R antagonist 1 | 1429375-54-1 | Reference compound |
| HY-111502 | Y06036 | 1832671-96-1 | Reference compound |
| HY-111503 | Y06137 | 2226534-49-0 | Reference compound |
| HY-111505 | NAcM-OPT | 2089293-61-6 | Reference compound |
| HY-111505A | NAcM-OPT (hydrochloride) | 2416146-10-4 | Reference compound |
| HY-111506 | Aurora inhibitor 1 | 2227019-45-4 | Reference compound |
| HY-111507 | PDGFRα kinase inhibitor 1 | 2209053-93-8 | Reference compound |
| HY-111508 | PI3K/mTOR Inhibitor-2 | 1848242-58-9 | Reference compound |
| HY-111509 | TAK-828F | 1854901-94-2 | Reference compound |
| HY-111510 | IPI-3063 | 1425043-73-7 | Reference compound |
| HY-111512 | PF-06795071 | 2075629-81-9 | Reference compound |
| HY-111513 | 4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine | 566169-98-0 | Reference compound |
| HY-111514 | 4-(6-Bromo-2-benzothiazolyl)benzenamine | 566169-97-9 | Reference compound |
| HY-111515 | BAY-678 (racemate) | 675103-35-2 | Reference compound |
| HY-111516 | MGV354 | | Reference compound |
| HY-111517 | H3B-8800 | 1825302-42-8 | Reference compound |
| HY-111518 | JH-XI-10-02 | 2209085-22-1 | Reference compound |
| HY-111519 | dTRIM24 | 2170695-14-2 | Reference compound |
| HY-111520 | NVS-SM2 | 1562333-92-9 | Reference compound |
| HY-111521 | Meropenem-vaborbactam | 2031124-72-6 | Reference compound |
| HY-111522 | RK-9123016 | 955900-27-3 | Reference compound |
| HY-111523 | Isomahanine | 144606-95-1 | Natural Products |
| HY-111524 | CPUY201112 | 1860793-58-3 | Reference compound |
| HY-111525 | Monactin | 7182-54-9 | Natural Products |
| HY-111527 | PPZ2 | 896203-18-2 | Reference compound |
| HY-111529 | Tafenoquine | 106635-80-7 | Reference compound |
| HY-111529A | Tafenoquine (Succinate) | 106635-81-8 | Reference compound |
| HY-111530 | GSTO1-IN-1 | 568544-03-6 | Reference compound |
| HY-111531 | DMTr-LNA-5MeU-3-CED-phosphoramidite | 206055-75-6 | Oligonucleotides |
| HY-111532 | (3R,4R)-A2-32-01 | 1359752-95-6 | Reference compound |
| HY-111532B | (3S,4S)-A2-32-01 | | Reference compound |
| HY-111533 | Ingenol 3-Hexanoate | 83036-61-7 | Reference compound |
| HY-111534 | SBI-115 | 882366-16-7 | Reference compound |
| HY-111535 | BoNT-IN-2 | 354784-03-5 | Reference compound |
| HY-111536 | Mitochonic acid 5 | 1354707-41-7 | Reference compound |
| HY-111537 | rel-AZ5576 | 1333468-05-5 | Reference compound |
| HY-111538 | MAGL-IN-1 | 2324160-91-8 | Reference compound |
| HY-111539 | BAY-1316957 | 1613264-40-6 | Reference compound |
| HY-111540 | LY-3381916 | 2166616-75-5 | Reference compound |
| HY-111540A | (Rac)-LY-3381916 | 2166616-74-4 | Reference compound |
| HY-111540B | (S)-LY-3381916 | 2166616-76-6 | Reference compound |
| HY-111543 | AN11251 | 2130750-59-1 | Reference compound |
| HY-111544 | EML741 | 2328074-38-8 | Reference compound |
| HY-111545 | BSc5371 | 2286419-03-0 | Reference compound |
| HY-111546 | BI-3663 | 2341740-84-7 | Reference compound |
| HY-111547 | M1001 | 874590-32-6 | Reference compound |
| HY-111548 | Spastazoline | 2351882-11-4 | Reference compound |
| HY-111549 | Bragsin1 | 369631-68-5 | Reference compound |
| HY-111550 | Bragsin2 | 342795-08-8 | Reference compound |
| HY-111551 | FT113 | 1630808-89-7 | Reference compound |
| HY-111552 | PIM1-IN-1 | 1417630-95-5 | Reference compound |
| HY-111553 | TAS0728 | 2088323-16-2 | Reference compound |
| HY-111554 | AcLys-PABC-VC-Aur0101 | 1438851-17-2 | ADC Related |
| HY-111555 | AmPEG6C2-Aur0131 | 1650569-94-0 | ADC Related |
| HY-111556 | BSJ-03-123 | 2361493-16-3 | Reference compound |
| HY-111557 | YM-254890 | 568580-02-9 | Natural Products |
| HY-111558 | Bobcat339 | 2280037-51-4 | Reference compound |
| HY-111558A | Bobcat339 (hydrochloride) | 2436747-44-1 | Reference compound |
| HY-111570 | PI3Kγ inhibitor AZ2 | 2231760-33-9 | Reference compound |
| HY-111573 | KCL-286 | 1952276-71-9 | Reference compound |
| HY-111578 | BDP-13176 | 2290660-61-4 | Reference compound |
| HY-111582 | BBIQ | 1229024-57-0 | Reference compound |
| HY-111582G | BBIQ (GMP) | 1229024-57-0 | GMP Small Molecules |
| HY-111583 | RXFP3/4 agonist 1 | 2351104-40-8 | Reference compound |
| HY-111587 | Ifenprodil glucuronide | 66516-92-5 | Reference compound |
| HY-111588 | Xanthoangelol | 62949-76-2 | Natural Products |
| HY-111589 | EPZ-4777 | 1381761-52-9 | Reference compound |
| HY-111592 | S-(5′-Adenosyl)-L-cysteine | 35899-53-7 | Peptides |
| HY-111593 | Homo-PROTAC pVHL30 degrader 1 | 2244684-49-7 | Reference compound |
| HY-111594 | Homo-PROTAC cereblon degrader 1 | 2244520-98-5 | Reference compound |
| HY-111595 | SAHA chloroalkane T1 | 1613617-05-2 | Reference compound |
| HY-111603 | Calcium dobesilate | 20123-80-2 | Reference compound |
| HY-111603R | Calcium dobesilate (Standard) | 20123-80-2 | Reference Standards |
| HY-111603S | Dobesilate-d6 (calcium) | | Isotope-Labeled Compounds |
| HY-111604 | Turbinaric acid | 56882-00-9 | Natural Products |
| HY-111606 | DUPA | 302941-52-2 | Reference compound |
| HY-111613 | Pinaverium bromide | 53251-94-8 | Reference compound |
| HY-111613R | Pinaverium bromide (Standard) | 53251-94-8 | Reference Standards |
| HY-111613S | Pinaverium bromide-d4 | | Isotope-Labeled Compounds |
| HY-111613S1 | Pinaverium bromide-d4-1 | | Isotope-Labeled Compounds |
| HY-111614 | Melengestrol acetate | 2919-66-6 | Reference compound |
| HY-111614R | Melengestrol acetate (Standard) | 2919-66-6 | Reference Standards |
| HY-111614S | Melengestrol acetate-d6 | | Isotope-Labeled Compounds |
| HY-111614S1 | Melengestrol acetate-d2 | | Isotope-Labeled Compounds |
| HY-111614S2 | Melengestrol acetate-d3 | | Isotope-Labeled Compounds |
| HY-111615 | J-2156 | 848647-56-3 | Peptides |
| HY-111615A | J-2156 (TFA) | 2387505-73-7 | Peptides |
| HY-111616 | GSK1820795A | 2650253-86-2 | Reference compound |
| HY-111617 | BTR-1 | 18331-34-5 | Reference compound |
| HY-111621 | DC661 | 1872387-43-3 | Reference compound |
| HY-111623 | USP30 inhibitor 11 | 2067332-64-1 | Reference compound |
| HY-111627 | 5-Aza-7-deazaguanine | 67410-64-4 | Reference compound |
| HY-111630 | PluriSIn #2 | 56563-17-8 | Reference compound |
| HY-111634 | Epsilon-momfluorothrin | 1065124-65-3 | Reference compound |
| HY-111636 | VSW1198 | | Reference compound |
| HY-111638 | 1-(2'-O-4-C-Methylene-beta-D-ribofuranosyl)thymine | 206055-67-6 | Oligonucleotides |
| HY-111639 | 2’-O,4’-C-Methyleneuridine | 200435-92-3 | Reference compound |
| HY-111640 | 3'-Azido-3'-deoxy-5-methylcytidine | 1282040-14-5 | Reference compound |
| HY-111641 | 3'-Azido-3'-deoxy-5-fluorocytidine | 2095417-18-6 | Reference compound |
| HY-111642 | 3'-Azido-3'-deoxy-beta-L-uridine | 2095417-28-8 | Reference compound |
| HY-111643 | 6-Amino-5-azacytidine | 105331-00-8 | Reference compound |
| HY-111644 | 6-Methyl-5-azacytidine | 105330-94-7 | Reference compound |
| HY-111645 | 3-Methylcytidine | 2140-64-9 | Reference compound |
| HY-111646 | N6-Etheno 2'-deoxyadenosine | 68498-25-9 | Reference compound |
| HY-111647 | N2-Methylguanosine | 2140-77-4 | Natural Products |
| HY-111647R | N2-Methylguanosine (Standard) | 2140-77-4 | Reference Standards |
| HY-111647S1 | N2-Methylguanosine-d3 | | Isotope-Labeled Compounds |
| HY-111648 | 6-O-Methyl Guanosine | 7803-88-5 | Reference compound |
| HY-111651 | Gboxin | 2101315-36-8 | Reference compound |
| HY-111652 | S-Gboxin | 2101317-21-7 | Reference compound |
| HY-111653 | CycLuc1 | 1247879-16-8 | Dye Reagents |
| HY-111655 | SKA-31 | 40172-65-4 | Reference compound |
| HY-111659 | His-Pro | 20930-58-9 | Peptides |
| HY-111659A | His-Pro (hydrochloride) | 2415727-78-3 | Peptides |
| HY-111660S | 3-Methoxytyramine sulfate-d4 | | Isotope-Labeled Compounds |
| HY-111660S1 | 3-Methoxytyramine sulfate-13C,d3 | | Isotope-Labeled Compounds |
| HY-111661 | 6,7-Dimethyl-8-ribityllumazine | 2535-20-8 | Reference compound |
| HY-111662 | Fc 11a-2 | 960119-75-9 | Reference compound |
| HY-111663 | VL285 | 1448188-57-5 | Reference compound |
| HY-111664 | (R)-(+)-Citronellal | 2385-77-5 | Natural Products |
| HY-111664A | (S)-(-)-Citronellal | 5949-05-3 | Natural Products |
| HY-111669 | CT1812 | 1802632-22-9 | Reference compound |
| HY-111671 | SOS1 activator 1 | 2245237-53-8 | Reference compound |
| HY-111673 | 8-CPT-Cyclic AMP (sodium) | 93882-12-3 | Reference compound |
| HY-111674 | LDC7559 | 2407782-01-6 | Reference compound |
| HY-111675 | Ac-FLTD-CMK | 2376255-48-8 | Reference compound |
| HY-111678 | ML230 | 1776055-05-0 | Reference compound |
| HY-111680 | Nesolicaftor | 1953130-87-4 | Reference compound |
| HY-111741 | M700F048 | 2056235-51-7 | Natural Products |
| HY-111742 | Bifenazate-diazene | 149878-40-0 | Reference compound |
| HY-111744 | Deacetylanisomycin | 27958-06-1 | Reference compound |
| HY-111745 | Tyk2-IN-5 | 1797432-62-2 | Reference compound |
| HY-111746 | CWHM-1008 | 2362539-97-5 | Reference compound |
| HY-111747 | TBAJ-587 | 2252316-16-6 | Reference compound |
| HY-111748 | RORγt Inverse agonist 2 | 1801197-92-1 | Reference compound |
| HY-111749 | JAK-IN-4 | 1400877-37-3 | Reference compound |
| HY-111750 | JAK-IN-3 | 1400876-94-9 | Reference compound |
| HY-111751 | JNJ-61432059 | 2035814-50-5 | Reference compound |
| HY-111752 | EML4-ALK kinase inhibitor 1 | 1373409-08-5 | Reference compound |
| HY-111753 | WDR5-IN-4 | 2407457-36-5 | Reference compound |
| HY-111753A | WDR5-IN-4 (TFA) | 2749300-35-2 | Reference compound |
| HY-111754 | DMX-5804 | 2306178-56-1 | Reference compound |
| HY-111755 | Oral antiplatelet agent 1 | 2299200-91-0 | Reference compound |
| HY-111756 | BLM-IN-1 | 2056014-40-3 | Reference compound |
| HY-111757 | ABBV-4083 | 1809266-03-2 | Reference compound |
| HY-111758 | PROTAC B-Raf degrader 1 | 2364367-27-9 | Reference compound |
| HY-111759 | Jaspamycin | 22242-96-2 | Reference compound |
| HY-111760 | NRX-252262 | 2438637-61-5 | Reference compound |
| HY-111761 | DIQ3 | 2258636-02-9 | Reference compound |
| HY-111763 | GPR40/FFAR1 modulator 1 | 874755-26-7 | Reference compound |
| HY-111766 | YD-3 | 170632-41-4 | Reference compound |
| HY-111767 | BAY-545 | 1699717-32-2 | Reference compound |
| HY-111769 | Taurochenodeoxycholate-3-sulfate | 67030-59-5 | Natural Products |
| HY-111770 | 2-Bromohexadecanoic acid | 18263-25-7 | Reference compound |
| HY-111772 | Elexacaftor | 2216712-66-0 | Reference compound |
| HY-111772A | (R)-Elexacaftor | 2229860-99-3 | Reference compound |
| HY-111772S | Elexacaftor-13C,d3 | | Isotope-Labeled Compounds |
| HY-111772S1 | Elexacaftor-d3 | | Isotope-Labeled Compounds |
| HY-111775 | LJ570 | 2252488-69-8 | Reference compound |
| HY-111777 | FASN-IN-1 | 1808260-84-5 | Reference compound |
| HY-111778 | EHMT2-IN-1 | 2230849-55-3 | Reference compound |
| HY-111781 | Civorebrutinib | 2155853-43-1 | Reference compound |
| HY-111782 | 8-Mercaptoguanosine | 26001-38-7 | Reference compound |
| HY-111783 | AZD-7648 | 2230820-11-6 | Reference compound |
| HY-111784 | Inobrodib | 2222941-37-7 | Reference compound |
| HY-111786 | LHC-165 | 1258595-14-0 | Reference compound |
| HY-111787 | Elzovantinib | 2271119-26-5 | Reference compound |
| HY-111789 | Subasumstat | 1858276-04-6 | Reference compound |
| HY-111789A | (S)-Subasumstat | 1858282-76-4 | Reference compound |
| HY-111790 | M3258 | 2285330-15-4 | Reference compound |
| HY-111791 | ACY-1083 | 1708113-43-2 | Reference compound |
| HY-111792 | GSK1795091 | 1233589-81-5 | Reference compound |
| HY-111793 | NUCC-390 | 1060524-97-1 | Reference compound |
| HY-111793A | NUCC-390 (dihydrochloride) | 2749281-71-6 | Reference compound |
| HY-111798 | Heme Oxygenase-1-IN-1 | 1093058-52-6 | Reference compound |
| HY-111798A | Heme Oxygenase-1-IN-1 (hydrochloride) | 1092851-70-1 | Reference compound |
| HY-111801 | Woodorien | 155112-92-8 | Natural Products |
| HY-111802 | 3,4'-Dihydroxyflavone | 14919-49-4 | Reference compound |
| HY-111803 | 4'-Methoxyflavonol | 6889-78-7 | Reference compound |
| HY-111804 | 3',4'-Dihydroxyflavonol | 6068-78-6 | Reference compound |
| HY-111806 | 3,7,4'-Trihydroxyflavone | 2034-65-3 | Natural Products |
| HY-111807 | Locked nucleic acid 1 | 206055-71-2 | Oligonucleotides |
| HY-111809 | N6-Ethyladenosine | 14357-08-5 | Reference compound |
| HY-111810 | SMYD2-IN-1 | 2023788-96-5 | Reference compound |
| HY-111811 | Homomangiferin | 21794-66-1 | Natural Products |
| HY-111812 | Tricin 7-O-glucuronide | 32769-02-1 | Natural Products |
| HY-111815 | N4-Acetylcytidine triphosphate | 1428903-57-4 | Natural Products |
| HY-111815A | N4-Acetylcytidine triphosphate (sodium) | 2803886-33-9 | Natural Products |
| HY-111815B | N4-Acetylcytidine triphosphate (sodium) (solution) | 2803886-33-9 | Natural Products |
| HY-111817 | ACT-451840 | 1984890-99-4 | Reference compound |
| HY-111817A | (Rac)-ACT-451840 | 1839508-99-4 | Reference compound |
| HY-111818 | TH34 | 2196203-96-8 | Reference compound |
| HY-111820 | CK1-IN-1 | 1784751-20-7 | Reference compound |
| HY-111823 | VH032 thiol | 2098836-54-3 | Reference compound |
| HY-111824 | VH032-thiol-C6-NH2 | 2098836-63-4 | Reference compound |
| HY-111825A | (R)-1-PeCSO | 16718-23-3 | Natural Products |
| HY-111826 | γ-Glutamyl-S-1-propenyl cysteine | 91216-96-5 | Natural Products |
| HY-111827 | S-1-Propenyl-L-cysteine | 52438-09-2 | Natural Products |
| HY-111828 | TTA-A2 | 953778-63-7 | Reference compound |
| HY-111830 | Lignin | 9005-53-2 | Natural Products |
| HY-111832 | 1,2,3,6-Tetragalloylglucose | 79886-50-3 | Natural Products |
| HY-111836 | NRX-252114 | 2763260-39-3 | Reference compound |
| HY-111838 | ZZW-115 | 801991-87-7 | Reference compound |
| HY-111838A | ZZW-115 (hydrochloride) | 10122-45-9 | Reference compound |
| HY-111839 | ATRA-hydroxyimino | 135325-47-2 | Reference compound |
| HY-111840 | PROTAC CRABP-II Degrader-1 | 1225383-40-3 | Reference compound |
| HY-111841 | PROTAC CRABP-II Degrader-2 | 1225383-38-9 | Reference compound |
| HY-111842 | PROTAC CRABP-II Degrader-3 | 1225383-41-4 | Reference compound |
| HY-111843 | Ch55-O-C3-NH2 | 144298-98-6 | Reference compound |
| HY-111844 | PROTAC RAR Degrader-1 | 1351169-27-1 | Reference compound |
| HY-111845 | Estrone-N-O-C1-amido | 138219-84-8 | Reference compound |
| HY-111846 | PROTAC ERα Degrader-2 | 1351169-29-3 | Reference compound |
| HY-111848 | PROTAC AR Degrader-4 | 1351169-31-7 | Reference compound |
| HY-111848A | PROTAC AR Degrader-4 (TFA) | | Reference compound |
| HY-111849 | Imatinib carbaldehyde | 1436868-85-7 | Reference compound |
| HY-111850 | Bestatin-amido-Me | 339186-54-8 | Reference compound |
| HY-111851 | SNIPER(ABL)-049 | | Reference compound |
| HY-111852 | GNF5-amido-Me | 778277-37-5 | Reference compound |
| HY-111853 | MV-1-NH-Me | 2095244-62-3 | Reference compound |
| HY-111854 | SNIPER(ABL)-015 | | Reference compound |
| HY-111855 | HG-7-85-01-Decyclopropane | 2444044-44-2 | Reference compound |
| HY-111857 | Dasatinib carbaldehyde | 2112837-79-1 | Reference compound |
| HY-111858 | SNIPER(ABL)-050 | | Reference compound |
| HY-111859 | SNIPER(ABL)-058 | 2222354-61-0 | Reference compound |
| HY-111860 | SNIPER(ABL)-013 | | Reference compound |
| HY-111861 | SNIPER(ABL)-024 | 2222355-77-1 | Reference compound |
| HY-111862 | SNIPER(ABL)-044 | | Reference compound |
| HY-111863 | SNIPER(ABL)-047 | | Reference compound |
| HY-111866 | PROTAC RIPK degrader-2 | 1801547-16-9 | Reference compound |
| HY-111870 | PROTAC RIPK degrader-6 | 2089205-64-9 | Reference compound |
| HY-111871 | SNIPER(ABL)-033 | 2222354-18-7 | Reference compound |
| HY-111872 | SNIPER(ABL)-020 | | Reference compound |
| HY-111873 | SNIPER(ABL)-019 | | Reference compound |
| HY-111874 | SNIPER(ABL)-039 | 2222354-29-0 | Reference compound |
| HY-111875 | SNIPER(BRD)-1 | 2095244-54-3 | Reference compound |
| HY-111876 | SNIPER(TACC3)-1 | | Reference compound |
| HY-111876A | SNIPER(TACC3)-1 (hydrochloride) | | Reference compound |
| HY-111877 | SNIPER(TACC3)-2 | | Reference compound |
| HY-111877A | SNIPER(TACC3)-2 (hydrochloride) | | Reference compound |
| HY-111878 | BzNH-BS | 2443928-42-3 | Reference compound |
| HY-111879 | Biotin-BS | | Reference compound |
| HY-111880 | γ-Sanshool | 78886-65-4 | Natural Products |
| HY-111887 | Emzadirib | 2301085-04-9 | Reference compound |
| HY-111894 | BACE-IN-3 | 1388149-39-0 | Reference compound |
| HY-111895A | Macropa-NH2 (hydrochloride) | 2443966-86-5 | Reference compound |
| HY-111895B | Macropa-NH2 (TFA) | 2705054-08-4 | Reference compound |
| HY-111896 | 7-Methoxyrosmanol | 113085-62-4 | Natural Products |
| HY-111896A | (-)-7-Methoxyrosmanol | 24703-38-6 | Natural Products |
| HY-111898 | Epirosmanol | 93380-12-2 | Natural Products |
| HY-111899 | 7-Ethoxyrosmanol | 111200-01-2 | Natural Products |
| HY-111900 | Rosmaquinone | 121927-71-7 | Natural Products |
| HY-111902 | MCB-3681 | 790704-42-6 | Reference compound |
| HY-111903 | Levomecol | 118573-58-3 | Natural Products |
| HY-111904 | EHMT2-IN-2 | 2230850-47-0 | Reference compound |
| HY-111905 | BRD7-IN-1 | 2448414-48-8 | Reference compound |
| HY-111905A | BRD7-IN-1 free base | 2305379-66-0 | Reference compound |
| HY-111911 | Xanthocillin X permethyl ether | 4464-33-9 | Natural Products |
| HY-111912 | Tribenuron-methyl | 101200-48-0 | Reference compound |
| HY-111912R | Tribenuron-methyl (Standard) | 101200-48-0 | Reference Standards |
| HY-111914A | Ferroheme | 14875-96-8 | Natural Products |
| HY-111915 | 1,2-Dioleoyl-sn-glycero-3-phosphate, sodium salt | 108392-02-5 | Natural Products |
| HY-111916 | ODM-207 | 1801503-93-4 | Reference compound |
| HY-111918 | A71378 | 127902-33-4 | Reference compound |
| HY-111919 | 3-Nitrocoumarin | 28448-04-6 | Reference compound |
| HY-111922 | H-Gly-Gly-Pro-OH | 14379-76-1 | Peptides |
| HY-111925 | BI-749327 | 2361241-23-6 | Reference compound |
| HY-111926 | N6-Methyladenosine 5'-monophosphate (disodium salt) | 81921-35-9 | Reference compound |
| HY-111927 | Pilloin | 32174-62-2 | Natural Products |
| HY-111928 | 5,7-Dimethoxyluteolin | 90363-40-9 | Natural Products |
| HY-111930 | 5-Iodo-indirubin-3'-monoxime | 331467-03-9 | Reference compound |
| HY-111931 | Indirubin-3'-monoxime-5-sulphonic acid | 331467-05-1 | Reference compound |
| HY-111932 | Indirubin-5-sulfonate | 244021-67-8 | Reference compound |
| HY-111934 | Cymarin | 508-77-0 | Natural Products |
| HY-111935 | 3,3'-Diethyl-9-methylthiacarbocyanine (iodide) | 3065-79-0 | Reference compound |
| HY-111937 | MI-1 | 433311-07-0 | Reference compound |
| HY-111939 | Amiprofos methyl | 36001-88-4 | Reference compound |
| HY-111939R | Amiprofos methyl (Standard) | 36001-88-4 | Reference Standards |
| HY-111940 | LUT014 | 2274819-46-2 | Reference compound |
| HY-111941 | GSK8612 | 2361659-62-1 | Reference compound |
| HY-111945 | Cys modifier 1 | 2374314-08-4 | Reference compound |
| HY-111946 | GSK3145095 | 1622849-43-7 | Reference compound |
| HY-111947 | c-Fms-IN-6 | 1628574-81-1 | Reference compound |
| HY-111948 | c-Fms-IN-7 | 1313408-89-7 | Reference compound |
| HY-111950 | (-)-Ibuprofenamide | 121839-78-9 | Reference compound |
| HY-111951 | D-Panose | 33401-87-5 | Reference compound |
| HY-111951R | D-Panose (Standard) | 33401-87-5 | Reference Standards |
| HY-111952 | SR-4995 | 891509-95-8 | Reference compound |
| HY-111954 | (+)-Erinacin A | 156101-08-5 | Reference compound |
| HY-111956 | D-Ala-Lys-AMCA | 375822-19-8 | Dye Reagents |
| HY-111956A | D-Ala-Lys-AMCA (TFA) | | Dye Reagents |
| HY-111956B | D-Ala-Lys-AMCA (hydrochloride) | 2703746-41-0 | Dye Reagents |
| HY-111957 | Fenquinotrione | 1342891-70-6 | Reference compound |
| HY-111959 | 2-Selenouracil | 16724-03-1 | Reference compound |
| HY-111961 | Epitizide | 1764-85-8 | Reference compound |
| HY-111964 | Lenacapavir | 2189684-44-2 | Reference compound |
| HY-111964A | Lenacapavir (sodium) | 2283356-12-5 | Reference compound |
| HY-111965 | PF-06647263 | 1822383-65-2 | Reference compound |
| HY-111968 | Orysastrobin | 248593-16-0 | Reference compound |
| HY-111968R | Orysastrobin (Standard) | 248593-16-0 | Reference Standards |
| HY-111969 | BT18 | 924811-53-0 | Reference compound |
| HY-111973 | Phaseic acid | 24394-14-7 | Reference compound |
| HY-111973S3 | Phaseic acid-d4 | 721948-57-8 | Isotope-Labeled Compounds |
| HY-111974 | β-D-Glucopyranosyl abscisate | 21414-42-6 | Natural Products |
| HY-111975S1 | 7'-Hydroxy ABA-d2 | 865875-19-0 | Isotope-Labeled Compounds |
| HY-111975S5 | 7'-Hydroxy ABA-d7 | | Isotope-Labeled Compounds |
| HY-111976 | MT1 | 2060573-82-0 | Reference compound |
| HY-111977 | ZEN-3219 | 1952264-34-4 | Reference compound |
| HY-111978 | ZEN-3862 | 1952264-33-3 | Reference compound |
| HY-111979 | ZEN-3411 | 1952264-36-6 | Reference compound |
| HY-111983 | Etiroxate | 17365-01-4 | Reference compound |
| HY-111984A | Quinazosin (dihydrochloride) | 7262-00-2 | Reference compound |
| HY-111985 | Revospirone | 95847-87-3 | Reference compound |
| HY-111986 | Trixolane | 47420-28-0 | Reference compound |
| HY-111988 | Penamecillin | 983-85-7 | Reference compound |
| HY-111990 | Tetrofosmin | 127502-06-1 | Reference compound |
| HY-111991S | Cyhalothrin-d5 | 2411870-79-4 | Isotope-Labeled Compounds |
| HY-111996 | Kv3 modulator 1 | 1380696-64-9 | Reference compound |
| HY-111997 | VH285-PEG4-C4-Cl | 1799506-07-2 | Reference compound |
| HY-111999A | E7766 (diammonium salt) | 2242635-03-4 | Reference compound |
| HY-111999B | E7766 (disodium) | 2242636-28-6 | Reference compound |
| HY-112005 | DOPE | 4004-05-1 | Oligonucleotides |
| HY-112005A | DOPE (Excipient) | 4004-05-1 | Natural Products |
| HY-112006 | (S)-ar-Curcumene | 4176-06-1 | Natural Products |
| HY-112009S | Methiocarb sulfoxide-d3 | | Isotope-Labeled Compounds |
| HY-112015 | Deschlorohaloperidol | 3109-12-4 | Reference compound |
| HY-112016 | C20 Ceramide | 7344-02-7 | Natural Products |
| HY-112016A | Sphingomyelin C20:2 | 123482-93-9 | Natural Products |
| HY-112019 | L-Methionine-34S | 1006386-95-3 | Isotope-Labeled Compounds |
| HY-112023 | Lumisterol 3 (>90%) | 5226-01-7 | Reference compound |
| HY-112026 | 1-Adamantaneethanol | 6240-11-5 | Reference compound |
| HY-112030 | Dipotassium tetrachloroplatinate | 10025-99-7 | Biochemical Assay Reagents |
| HY-112037 | IACS-010759 | 1570496-34-2 | Reference compound |
| HY-112037A | IACS-010759 (hydrochloride) | 1807523-99-4 | Reference compound |
| HY-112038 | GSK2983559 (free acid) | 1579965-12-0 | Reference compound |
| HY-112038A | GSK2983559 | | Reference compound |
| HY-112041 | Unesbulin | 1610964-64-1 | Reference compound |
| HY-112045 | Foscenvivint | 1422253-38-0 | Reference compound |
| HY-112047 | GSK8175 | 1423007-82-2 | Reference compound |
| HY-112050 | CU-CPT-8m | 125079-83-6 | Reference compound |
| HY-112051 | CU-CPT9b | 2162962-69-6 | Reference compound |
| HY-112052 | Aminomalonic acid | 1068-84-4 | Natural Products |
| HY-112052R | Aminomalonic acid (Standard) | 1068-84-4 | Reference Standards |
| HY-112053 | DPPH | 1898-66-4 | Reference compound |
| HY-112053R | DPPH (Standard) | 1898-66-4 | Reference Standards |
| HY-112055 | DIM-C-pPhOH | 151358-47-3 | Reference compound |
| HY-112056 | DIM-C-pPhCO2Me | 151358-48-4 | Reference compound |
| HY-112057 | Pseudoerythromycin A enol ether | 105882-69-7 | Reference compound |
| HY-112060 | Saccharin 1-methylimidazole | 482333-74-4 | Reference compound |
| HY-112061 | 8-OH-DPAT | 78950-78-4 | Reference compound |
| HY-112062 | POL1-IN-1 | 1822358-25-7 | Reference compound |
| HY-112063 | CIL56 | 300802-28-2 | Reference compound |
| HY-112065 | PF-06869206 | 2227425-05-8 | Reference compound |
| HY-112066 | SHIN1 | 2146095-85-2 | Reference compound |
| HY-112066A | (+)-SHIN1 | 2443966-90-1 | Reference compound |
| HY-112066B | (-)-SHIN1 | 2444764-09-2 | Reference compound |
| HY-112067 | Chlorcyclizine | 82-93-9 | Reference compound |
| HY-112067A | Chlorcyclizine (hydrochloride) | 14362-31-3 | Reference compound |
| HY-112068 | DM-NOFD | 865488-53-5 | Reference compound |
| HY-112070 | Oxyfedrine | 15687-41-9 | Reference compound |
| HY-112071 | Prenalterol | 57526-81-5 | Reference compound |
| HY-112071A | Prenalterol (hydrochloride) | 61260-05-7 | Reference compound |
| HY-112074 | Tiamenidine | 31428-61-2 | Reference compound |
| HY-112074A | Tiamenidine (hydrochloride) | 51274-83-0 | Reference compound |
| HY-112075 | Lidoflazine | 3416-26-0 | Reference compound |
| HY-112076 | Atropine methyl (bromide) | 2870-71-5 | Reference compound |
| HY-112076A | Atropine methyl (nitrate) | 52-88-0 | Reference compound |
| HY-112076R | Atropine methyl (bromide) (Standard) | 2870-71-5 | Reference Standards |
| HY-112077 | (Z)-Viaminate | 251441-94-8 | Reference compound |
| HY-112077A | Viaminate | 53839-71-7 | Reference compound |
| HY-112077AR | Viaminate (Standard) | 53839-71-7 | Reference Standards |
| HY-112078 | (S,R,S)-AHPC-Me | 1948273-02-6 | Reference compound |
| HY-112078A | (S,R,S,R)-AHPC-Me | 2055344-67-5 | Reference compound |
| HY-112080 | BAY-6035 | 2247890-13-5 | Reference compound |
| HY-112080A | (R)-BAY-6035 | 2283389-29-5 | Reference compound |
| HY-112081 | BAY-707 | 2109805-96-9 | Reference compound |
| HY-112081A | BAY-707 (acetate) | 2223023-19-4 | Reference compound |
| HY-112082 | BAY885 | 2307249-33-6 | Reference compound |
| HY-112083 | BAY-3827 | 2377576-35-5 | Reference compound |
| HY-112085 | N-Bis(2-hydroxypropyl)nitrosamine | 53609-64-6 | Reference compound |
| HY-112088 | AZD4573 | 2057509-72-3 | Reference compound |
| HY-112089 | Naporafenib | 1800398-38-2 | Reference compound |
| HY-112090 | ABBV-744 | 2138861-99-9 | Reference compound |
| HY-112091 | GSK2200150A | 1443138-53-1 | Reference compound |
| HY-112094 | WNK-IN-11 | 2123489-30-3 | Reference compound |
| HY-112094S | WNK-IN-11-d3 | 2123483-49-6 | Isotope-Labeled Compounds |
| HY-112096 | eCF506 | 1914078-41-3 | Reference compound |
| HY-112096S | eCF506-d5 | | Isotope-Labeled Compounds |
| HY-112097 | E260 | 1241537-79-0 | Reference compound |
| HY-112098 | PROTAC ERα Degrader-1 | 2417369-94-7 | Reference compound |
| HY-112099 | Mc-Val-Cit-PAB-Cl | 1639351-92-0 | ADC Related |
| HY-112100 | PROTAC ERα Degrader-5 | 2158322-33-7 | ADC Related |
| HY-112101 | Prohydrojasmon (racemate) | 158474-72-7 | Reference compound |
| HY-112101R | Prohydrojasmon (racemate) (Standard) | 158474-72-7 | Reference Standards |
| HY-112102 | (22S,23S)-Homobrassinolide | 80483-89-2 | Reference compound |
| HY-112102R | (22S,23S)-Homobrassinolide (Standard) | 80483-89-2 | Reference Standards |
| HY-112103 | 6-(γ,γ-Dimethylallylamino)purine | 2365-40-4 | Natural Products |
| HY-112103R | 6-(γ,γ-Dimethylallylamino)purine (Standard) | 2365-40-4 | Reference Standards |
| HY-112103S | 6-(γ,γ-Dimethylallylamino)purine-d6 | 175733-28-5 | Isotope-Labeled Compounds |
| HY-112104 | Meta-topolin | 75737-38-1 | Reference compound |
| HY-112105 | Prohexadione (calcium) | 127277-53-6 | Reference compound |
| HY-112105A | Prohexadione | 88805-35-0 | Reference compound |
| HY-112105R | Prohexadione (calcium) (Standard) | 127277-53-6 | Reference Standards |
| HY-112106A | Diethyl aminoethyl hexanoate citrate | 220439-24-7 | Reference compound |
| HY-112107 | Folcisteine | 5025-82-1 | Reference compound |
| HY-112108 | Chitosan oligosaccharide | 148411-57-8 | Reference compound |
| HY-112111 | Poly-L-Glutamic acid (MW 700000) | 25513-46-6 | Natural Products |
| HY-112111A | Poly-L-Glutamic acid (MW 100000) | 25513-46-6 | Biochemical Assay Reagents |
| HY-112113 | SLV-2436 | 2095704-43-9 | Reference compound |
| HY-112114 | DTPA-DAB2 | 2437438-20-3 | Reference compound |
| HY-112120 | 2-Amino-6-chloro-9-(3-deoxy-3-fluoro-beta-D-ribofuranosyl)-9H-purine | 1612192-05-8 | Reference compound |
| HY-112125 | KRN2 | 248260-75-5 | Reference compound |
| HY-112125A | KRN2 (bromide) | 1390654-28-0 | Reference compound |
| HY-112126 | KRN5 | 1800465-47-7 | Reference compound |
| HY-112128 | USP7-IN-3 | 2202738-42-7 | Reference compound |
| HY-112129 | AGI-25696 | 2201066-35-3 | Reference compound |
| HY-112130 | AGI-24512 | 2201066-53-5 | Reference compound |
| HY-112131 | MAT2A inhibitor 1 | 2201057-10-3 | Reference compound |
| HY-112132 | Palmitodiolein | 2190-30-9 | Reference compound |
| HY-112134 | CSN5i-3 | 2375740-98-8 | Reference compound |
| HY-112134A | (R)-CSN5i-3 | 2863607-74-1 | Reference compound |
| HY-112136 | TAO Kinase inhibitor 1 | 850467-66-2 | Reference compound |
| HY-112137 | Trehalose-6,6'-dibehenate | 66758-35-8 | Reference compound |
| HY-112139 | 4-(Bromoacetyl)phenoxyacetic acid | 29936-81-0 | Reference compound |
| HY-112140 | JH-VIII-157-02 | 1639422-97-1 | Reference compound |
| HY-112142 | AB-423 | 1572510-80-5 | Reference compound |
| HY-112142A | (Rac)-AB-423 | 422547-55-5 | Reference compound |
| HY-112143 | STOCK2S-26016 | 332922-63-1 | Reference compound |
| HY-112144 | TP0463518 | 1558021-37-6 | Reference compound |
| HY-112145 | FLT3-IN-3 | 2229050-90-0 | Reference compound |
| HY-112146 | MMG-11 | 313254-94-3 | Reference compound |
| HY-112146A | MMG-11 (quarterhydrate) | | Reference compound |
| HY-112147 | IDO1 and HDAC1 Inhibitor | 2227044-16-6 | Reference compound |
| HY-112148 | AKT-IN-2 | 1295514-91-8 | Reference compound |
| HY-112149 | ZL0420 | 2230496-80-5 | Reference compound |
| HY-112149A | (E/Z)-ZL0420 | 2229039-45-4 | Reference compound |
| HY-112150 | ZL0454 | 2229042-77-5 | Reference compound |
| HY-112151 | EG01377 | 2227996-00-9 | Reference compound |
| HY-112151A | EG01377 (dihydrochloride) | 2749438-61-5 | Reference compound |
| HY-112152 | GSK726701A | 945721-87-9 | Reference compound |
| HY-112154 | CXCR7 modulator 2 | 2227426-37-9 | Reference compound |
| HY-112155 | MS4078 | 2229036-62-6 | Reference compound |
| HY-112156 | MS4077 | 2230077-10-6 | Reference compound |
| HY-112157 | PF-06751979 | 1818339-66-0 | Reference compound |
| HY-112158 | NSC139021 | 1147-56-4 | Reference compound |
| HY-112160 | XL-784 (free base) | 1356992-21-6 | Reference compound |
| HY-112161 | Branebrutinib | 1912445-55-6 | Reference compound |
| HY-112162 | BOS-172722 | 1578245-44-9 | Reference compound |
| HY-112163 | Zotatifin | 2098191-53-6 | Reference compound |
| HY-112163A | rel-Zotatifin | 2098191-54-7 | Reference compound |
| HY-112164 | IACS-8968 | 2144425-14-7 | Reference compound |
| HY-112164A | IACS-8968 (R-enantiomer) | 2239305-67-8 | Reference compound |
| HY-112164B | IACS-8968 (S-enantiomer) | 2239305-70-3 | Reference compound |
| HY-112165 | PRMT5-IN-2 | 1989620-04-3 | Reference compound |
| HY-112166 | (E)-Rilzabrutinib | 1575596-29-0 | Reference compound |
| HY-112167 | GDC-0575 | 1196541-47-5 | Reference compound |
| HY-112167A | GDC-0575 (dihydrochloride) | 1657014-42-0 | Reference compound |
| HY-112167B | GDC0575 (hydrochloride) | 1196504-54-7 | Reference compound |
| HY-112169 | 10-Formyltetrahydrofolic acid | 2800-34-2 | Reference compound |
| HY-112169A | 10-Formyltetrahydrofolic acid (disodium) | 914800-65-0 | Reference compound |
| HY-112171 | γ-L-Glutamyl-L-alanine | 5875-41-2 | Reference compound |
| HY-112172 | Tenalisib R Enantiomer | 1639417-54-1 | Reference compound |
| HY-112173 | Prolylleucine | 61596-47-2 | Peptides |
| HY-112174 | UDP-GlcNAc (disodium) | 91183-98-1 | Reference compound |
| HY-112174S | UDP-GlcNAc-13C (disodium) | | Isotope-Labeled Compounds |
| HY-112175 | N-Acetylhistamine | 673-49-4 | Natural Products |
| HY-112175R | N-Acetylhistamine (Standard) | 673-49-4 | Reference Standards |
| HY-112176 | Kanosamine hydrochloride | 57649-10-2 | Reference compound |
| HY-112176R | Kanosamine hydrochloride (Standard) | 57649-10-2 | Reference Standards |
| HY-112177 | Myxothiazol | 76706-55-3 | Natural Products |
| HY-112179 | GSK180 | 1799725-26-0 | Reference compound |
| HY-112180 | Rilematovir | 1383450-81-4 | Reference compound |
| HY-112181 | KO-947 | 1695533-89-1 | Reference compound |
| HY-112182 | UM-164 | 903564-48-7 | Reference compound |
| HY-112185 | Orforglipron | 2212020-52-3 | Reference compound |
| HY-112185A | Orforglipron (hemicalcium hydrate) | 3008544-96-2 | Reference compound |
| HY-112189 | Interferon receptor inducer-1 | 2215120-36-6 | Reference compound |
| HY-112191 | PI3K-IN-10 | 2211922-64-2 | Reference compound |
| HY-112197 | PKG drug G1 | 374703-78-3 | Reference compound |
| HY-112198 | AZ31 | 2088113-98-6 | Reference compound |
| HY-112199 | CP-447697 | 1092847-21-6 | Reference compound |
| HY-112202 | GSK3395879 | 2215852-91-6 | Reference compound |
| HY-112205 | RR-11a | 1361390-56-8 | Reference compound |
| HY-112205A | RR-11a analog | 685543-66-2 | Reference compound |
| HY-112209 | VU0467154 | 1451993-15-9 | Reference compound |
| HY-112210 | Shield-1 | 914805-33-7 | Reference compound |
| HY-112215 | Nemtabrutinib | 2095393-15-8 | Reference compound |
| HY-112217A | PSEM 89S (TFA) | 1336913-03-1 | Reference compound |
| HY-112218 | MIK665 | 1799631-75-6 | Reference compound |
| HY-112218A | (R)-MIK665 | 1799831-02-9 | Reference compound |
| HY-112219 | H3R antagonist 1 | 1448422-61-4 | Reference compound |
| HY-112219A | H3R antagonist 1 (hydrochloride) | 2319790-07-1 | Reference compound |
| HY-112220 | VIT-2763 | 2095668-10-1 | Reference compound |
| HY-112225 | Narasin (sodium) | 58331-17-2 | Reference compound |
| HY-112226 | VRT-043198 | 244133-31-1 | Reference compound |
| HY-112226R | VRT-043198 (Standard) | 244133-31-1 | Reference Standards |
| HY-112233 | O-304 | 1261289-04-6 | Reference compound |
| HY-112234 | L-Sepiapterin | 17094-01-8 | Natural Products |
| HY-112240 | Antibacterial agent 104 | 2095612-29-4 | Reference compound |
| HY-112243 | Cimpuciclib | 2202767-78-8 | Reference compound |
| HY-112243A | Cimpuciclib (tosylate) | 2408872-84-2 | Reference compound |
| HY-112247 | SR 16832 | 2088135-12-8 | Reference compound |
| HY-112248 | (Rac)-HAMI 3379 | 712313-35-4 | Reference compound |
| HY-112248A | HAMI 3379 | 1245653-57-9 | Reference compound |
| HY-112251 | D-Lin-MC3-DMA | 1224606-06-7 | Oligonucleotides |
| HY-112251A | D-Lin-MC3-DMA (Excipient) | 1224606-06-7 | Reference compound |
| HY-112251S | D-Lin-MC3-DMA-13C3 | | Isotope-Labeled Compounds |
| HY-112253 | Fructose 1-phosphate | 15978-08-2 | Natural Products |
| HY-112253A | D-Fructose 1-phosphate (disodium) | 71662-09-4 | Reference compound |
| HY-112254 | ZINC03129319 | 1777807-64-3 | Reference compound |
| HY-112255 | J9 | 947018-15-7 | Reference compound |
| HY-112256 | ACP-105 | 899821-23-9 | Reference compound |
| HY-112257 | S-23 | 1010396-29-8 | Reference compound |
| HY-112258 | IMP-1088 | 2059148-82-0 | Reference compound |
| HY-112261 | CDK12-IN-3 | 2220184-50-7 | Reference compound |
| HY-112262 | CGRP antagonist 1 | 1123757-49-2 | Reference compound |
| HY-112263 | ORL1 antagonist 1 | 1174985-59-1 | Reference compound |
| HY-112264 | ETA antagonist 1 | 161801-60-1 | Reference compound |
| HY-112265 | CRTh2 antagonist 1 | 1379445-54-1 | Reference compound |
| HY-112266 | MARK-IN-4 | 1990492-86-8 | Reference compound |
| HY-112267 | Olacaftor | 1897384-89-2 | Reference compound |
| HY-112267A | (R)-Olacaftor | 1899111-41-1 | Reference compound |
| HY-112269 | Glutaminyl Cyclase Inhibitor 1 | 2110449-60-8 | Reference compound |
| HY-112270 | Glutaminyl Cyclase Inhibitor 2 | 1884546-29-5 | Reference compound |
| HY-112272 | Lerociclib | 1628256-23-4 | Reference compound |
| HY-112272A | Lerociclib (dihydrochloride) | 2097938-59-3 | Reference compound |
| HY-112273 | CD532 | 1639009-81-6 | Reference compound |
| HY-112273A | CD532 (hydrochloride) | 2926498-81-7 | Reference compound |
| HY-112274 | M443 | 1820684-31-8 | Reference compound |
| HY-112275 | TNF-α-IN-1 | 444287-49-4 | Reference compound |
| HY-112276 | Beryllon II | 51550-25-5 | Dye Reagents |
| HY-112277 | NCT-505 | 2231079-74-4 | Reference compound |
| HY-112278 | NCT-506 | 2231098-99-8 | Reference compound |
| HY-112279 | GNE-131 | 1629063-81-5 | Reference compound |
| HY-112280 | Crozbaciclib | 2099128-41-1 | Reference compound |
| HY-112280A | Crozbaciclib (fumarate) | 2567494-39-5 | Reference compound |
| HY-112282 | BI-1408 | 2231075-94-6 | Reference compound |
| HY-112284 | Ebopiprant | 2005486-31-5 | Reference compound |
| HY-112284A | Ebopiprant (hydrochloride) | 2005486-32-6 | Reference compound |
| HY-112285 | FT895 | 2225728-57-2 | Reference compound |
| HY-112286 | PI3Kγ inhibitor 2 | 1315538-79-4 | Reference compound |
| HY-112287 | ERK1/2 inhibitor 1 | 2095719-90-5 | Reference compound |
| HY-112288 | C188-9 | 432001-19-9 | Reference compound |
| HY-112289 | IDH889 | 1429179-07-6 | Reference compound |
| HY-112289B | (1R)-IDH889 | 1429179-08-7 | Reference compound |
| HY-112290 | MK-0736 | 719272-79-4 | Reference compound |
| HY-112290A | MK-0736 (hydrochloride) | 719274-77-8 | Reference compound |
| HY-112291 | SB 220025 | 165806-53-1 | Reference compound |
| HY-112291A | SB 220025 (tri(hydrochloride)) | 197446-75-6 | Reference compound |
| HY-112292 | GW806742X | 579515-63-2 | Reference compound |
| HY-112292A | GW806742X (hydrochloride) | | Reference compound |
| HY-112293 | GW2974 | 202272-68-2 | Reference compound |
| HY-112294 | TIE-2/VEGFR-2 kinase-IN-1 | 453590-24-4 | Reference compound |
| HY-112295 | AzKTB | | Reference compound |
| HY-112296 | T025 | 2407433-00-3 | Reference compound |
| HY-112297 | BACE-1 inhibitor 1 | 1262858-14-9 | Reference compound |
| HY-112298 | DS88790512 | 2231089-95-3 | Reference compound |
| HY-112299 | Zipalertinib | 1661854-97-2 | Reference compound |
| HY-112300 | ERK2 IN-1 | 1093061-47-2 | Reference compound |
| HY-112301 | Pralsetinib | 2097132-94-8 | Reference compound |
| HY-112301A | trans-Pralsetinib | 2097132-93-7 | Reference compound |
| HY-112301R | Pralsetinib (Standard) | 2097132-94-8 | Reference Standards |
| HY-112302 | HC-070 | 1628291-95-1 | Reference compound |
| HY-112304 | NCD38 (TFA) | | Reference compound |
| HY-112304A | (1R,2S)-NCD38 (TFA) | 2078047-42-2 | Reference compound |
| HY-112305 | AZ32 | 2288709-96-4 | Reference compound |
| HY-112306 | Ripretinib | 1442472-39-0 | Reference compound |
| HY-112307A | (Rac)-1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol (sodium) | 124011-52-5 | Reference compound |
| HY-112308 | NCGC00247743 | 1435192-04-3 | Reference compound |
| HY-112314 | AZD0424 | 692054-06-1 | Reference compound |
| HY-112316 | BAY1238097 | 1564268-08-1 | Reference compound |
| HY-112316A | (R)-BAY1238097 | 1564269-85-7 | Reference compound |
| HY-112316B | (Rac)-BAY1238097 | 1564268-19-4 | Reference compound |
| HY-112318 | GSK-2793660 (free base) | 1613458-70-0 | Reference compound |
| HY-112318A | GSK-2793660 | 1613458-78-8 | Reference compound |
| HY-112319 | MK-8457 | 1312518-84-5 | Reference compound |
| HY-112322 | Carbacyclin | 69552-46-1 | Reference compound |
| HY-112324 | Terizidone | 25683-71-0 | Reference compound |
| HY-112328 | Fascaplysin | 114719-57-2 | Natural Products |
| HY-112330 | 4-Cyano-3-methylisoquinoline | 161468-32-2 | Reference compound |
| HY-112331 | SJ000291942 | 425613-09-8 | Reference compound |
| HY-112333 | SC-68376 | 318480-82-9 | Reference compound |
| HY-112335 | Lck Inhibitor III | 1188890-30-3 | Reference compound |
| HY-112336 | Aloisine RP106 | 496864-15-4 | Reference compound |
| HY-112337 | VEGFR-2-IN-44 | 288144-20-7 | Reference compound |
| HY-112338 | C188 | 823828-18-8 | Reference compound |
| HY-112340 | CB1 antagonist 4 | 1253641-65-4 | Reference compound |
| HY-112345 | PD-089828 | 179343-17-0 | Reference compound |
| HY-112346 | RGB-286147 | 784211-09-2 | Reference compound |
| HY-112348 | HA-1004 (hydrochloride) | 92564-34-6 | Reference compound |
| HY-112349 | SB 203580 sulfone | 152121-46-5 | Reference compound |
| HY-112350 | AGL 2043 | 226717-28-8 | Reference compound |
| HY-112352 | SU9518 | 251356-32-8 | Reference compound |
| HY-112353 | NP603 | 949164-80-1 | Reference compound |
| HY-112355 | Aurora kinase inhibitor-2 | 331770-21-9 | Reference compound |
| HY-112356 | Scytonemin | 152075-98-4 | Natural Products |
| HY-112358 | GW8510 | 222036-17-1 | Reference compound |
| HY-112359 | C-82 | 1422253-37-9 | Reference compound |
| HY-112362 | 3-(4-Pyridyl)indole | 7272-84-6 | Reference compound |
| HY-112363 | Aloisine A | 496864-16-5 | Reference compound |
| HY-112367 | SB 202474 | 172747-50-1 | Reference compound |
| HY-112368 | PHPS1 | 314291-83-3 | Reference compound |
| HY-112371 | (S)-CR8 | 1084893-56-0 | Reference compound |
| HY-112373 | Aurora kinase inhibitor-3 | 879127-16-9 | Reference compound |
| HY-112374 | NPAS3-IN-1 | 2207-44-5 | Reference compound |
| HY-112375 | AT6 | 2098836-50-9 | Reference compound |
| HY-112376 | MZP-54 | 2010159-47-2 | Reference compound |
| HY-112377 | MZP-55 | 2010159-48-3 | Reference compound |
| HY-112378 | D-65476 | 249762-74-1 | Reference compound |
| HY-112382 | Iso-Olomoucine | 101622-50-8 | Reference compound |
| HY-112384 | Safingol | 15639-50-6 | Reference compound |
| HY-112384A | Safingol (hydrochloride) | 139755-79-6 | Reference compound |
| HY-112384B | DL-threo-Dihydrosphingosine | 2304-75-8 | Reference compound |
| HY-112386 | OXSI-2 | 622387-85-3 | Reference compound |
| HY-112388 | GSK-3b Inhibitor XI | 626604-39-5 | Reference compound |
| HY-112389 | p38 MAP Kinase Inhibitor III | 581098-48-8 | Reference compound |
| HY-112390 | Syk Inhibitor II (dihydrochloride) | 227449-73-2 | Reference compound |
| HY-112390A | Syk Inhibitor II | 726695-51-8 | Reference compound |
| HY-112390B | Syk Inhibitor II (dihydrochloride dihydrate) | 1965323-05-0 | Reference compound |
| HY-112390C | Syk Inhibitor II (hydrochloride) | 2490508-82-0 | Reference compound |
| HY-112391 | SD-1029 | 118372-34-2 | Reference compound |
| HY-112392 | GSK-3 Inhibitor XIII | 404828-14-4 | Reference compound |
| HY-112393 | TX-1918 | 503473-32-3 | Reference compound |
| HY-112394 | 2-Cyanoethylalsterpaullone | 852527-97-0 | Reference compound |
| HY-112395 | BTO-1 | 40647-02-7 | Reference compound |
| HY-112398 | GSK1379725A | 1802251-00-8 | Reference compound |
| HY-112400 | Bisindolylmaleimide V | 113963-68-1 | Reference compound |
| HY-112401 | p38 MAP Kinase Inhibitor IV | 1638-41-1 | Reference compound |
| HY-112402 | SP 600125, negative control | 54642-23-8 | Reference compound |
| HY-112403 | (S)-Roscovitine | 186692-45-5 | Reference compound |
| HY-112405 | BPIQ-I | 174709-30-9 | Reference compound |
| HY-112409 | WEE1-IN-2 | 622855-50-9 | Reference compound |
| HY-112411 | PD 174265 | 216163-53-0 | Reference compound |
| HY-112412 | PDGFR Tyrosine Kinase Inhibitor III | 205254-94-0 | Reference compound |
| HY-112415 | Lith-O-Asp | 881179-02-8 | Reference compound |
| HY-112416 | AZD4320 | 1357576-48-7 | Reference compound |
| HY-112417 | Ki11502 | 347155-76-4 | Reference compound |
| HY-112418 | CDK4/6-IN-18 | 546102-60-7 | Reference compound |
| HY-112420 | EGFR/ErbB-2/ErbB-4 inhibitor-2 | 179248-61-4 | Reference compound |
| HY-112423 | CE-245677 | 717899-97-3 | Reference compound |
| HY-112424 | Tinodasertib | 1464151-33-4 | Reference compound |
| HY-112426 | LAU159 | 2055050-87-6 | Reference compound |
| HY-112427 | Sirt2-IN-1 | 1862238-00-3 | Reference compound |
| HY-112428 | Sirt2-IN-2 | 1862238-01-4 | Reference compound |
| HY-112429 | HJB97 | 2093391-24-1 | Reference compound |
| HY-112430 | TRPM8 antagonist 2 | 259674-19-6 | Reference compound |
| HY-112431 | Carnostatine | | Reference compound |
| HY-112431A | Carnostatine (hydrochloride) | | Reference compound |
| HY-112432 | GlyT1 Inhibitor 1 | 1820934-93-7 | Reference compound |
| HY-112433 | NIK SMI1 | 1660114-31-7 | Reference compound |
| HY-112433A | (S)-NIK SMI1 | 2984765-48-0 | Reference compound |
| HY-112434 | PF-06733804 | 1873373-33-1 | Reference compound |
| HY-112435 | UCT943 | 1450666-80-4 | Reference compound |
| HY-112436 | PF-6683324 | 1799788-94-5 | Reference compound |
| HY-112436A | (3S,4R)-PF-6683324 | 1799789-00-6 | Reference compound |
| HY-112437 | PF-06737007 | 1863905-38-7 | Reference compound |
| HY-112438 | MF-094 | 2241025-68-1 | Reference compound |
| HY-112438A | rac-MF-094 | 2758431-95-5 | Reference compound |
| HY-112439 | PI3Kdelta inhibitor 1 | 2242109-74-4 | Reference compound |
| HY-112440 | HZX-02-059 | 2240205-30-3 | Reference compound |
| HY-112441 | Prolyl Hydroxylase inhibitor 1 | 2205125-60-4 | Reference compound |
| HY-112442 | AZ-3 | 2228908-91-4 | Reference compound |
| HY-112443 | AZD3458 | 2132961-46-5 | Reference compound |
| HY-112444 | BACE1-IN-2 | 1352416-78-4 | Reference compound |
| HY-112445 | SGC3027 | 2624313-13-7 | Reference compound |
| HY-112446 | ST638 | 107761-24-0 | Reference compound |
| HY-112447 | STAT3-IN-5 | 1041438-68-9 | Reference compound |
| HY-112450 | Olomoucine II | 500735-47-7 | Reference compound |
| HY-112451 | cFMS Receptor Inhibitor II | 959860-85-6 | Reference compound |
| HY-112452 | SU11652 | 326914-10-7 | Reference compound |
| HY-112455 | cFMS Receptor Inhibitor IV | 959626-45-0 | Reference compound |
| HY-112456 | IKK2-IN-4 | 354811-10-2 | Reference compound |
| HY-112457 | MK2-IN-3 (hydrate) | 1186648-22-5 | Reference compound |
| HY-112460 | CDK2-IN-3 | 222035-13-4 | Reference compound |
| HY-112461 | NF449 | 389142-38-5 | Reference compound |
| HY-112461A | NF449 (octasodium) | 627034-85-9 | Reference compound |
| HY-112462 | Cdk1/2 Inhibitor III | 443798-55-8 | Reference compound |
| HY-112463 | CDK1-IN-2 | 220749-41-7 | Reference compound |
| HY-112464 | PKR Inhibitor, negative control | 852547-30-9 | Reference compound |
| HY-112465 | H-8 (dihydrochloride) | 113276-94-1 | Reference compound |
| HY-112466 | p38 MAPK-IN-4 | 219138-24-6 | Reference compound |
| HY-112467 | Tivozanib (hydrate) | 682745-40-0 | Reference compound |
| HY-112468 | PNU112455A (hydrochloride) | 21886-12-4 | Reference compound |
| HY-112469 | ERK Inhibitor II (Negative control) | 1177970-73-8 | Reference compound |
| HY-112472 | S3969 | 1027997-01-8 | Reference compound |
| HY-112473 | NAV-2729 | 419547-11-8 | Reference compound |
| HY-112474 | Tyrphostin AG 112 | 144978-82-5 | Reference compound |
| HY-112475 | Flt-3 Inhibitor III | 852045-46-6 | Reference compound |
| HY-112476 | PRL-3 Inhibitor I | 893449-38-2 | Reference compound |
| HY-112477 | Chk2-IN-1 | 724708-21-8 | Reference compound |
| HY-112478 | PTP Inhibitor IV | 329317-98-8 | Reference compound |
| HY-112482A | ABT-702 (hydrochloride) | 2624336-92-9 | Reference compound |
| HY-112483 | QX77 | 1798331-92-6 | Reference compound |
| HY-112484 | RS-246204 | 878451-87-7 | Reference compound |
| HY-112486 | TA-316 | 1429321-13-0 | Reference compound |
| HY-112486G | TA-316 (GMP) | 1429321-13-0 | GMP Small Molecules |
| HY-112487 | Sandoz 58-035 | 78934-83-5 | Reference compound |
| HY-112489 | FSG67 | 1158383-34-6 | Reference compound |
| HY-112490 | Atorvastatin (calcium hydrate) | 344423-98-9 | Biochemical Assay Reagents |
| HY-112491 | KRas G12C inhibitor 1 | 2158297-28-8 | Reference compound |
| HY-112492 | KRas G12C inhibitor 2 | 2206735-61-5 | Reference compound |
| HY-112493 | KRas G12C inhibitor 3 | 2206735-75-1 | Reference compound |
| HY-112494 | KRas G12C inhibitor 4 | 2206736-07-2 | Reference compound |
| HY-112495 | VH032-PEG5-C6-Cl | 1799506-06-1 | Reference compound |
| HY-112496 | Cl-C6-PEG4-O-CH2COOH | 1799506-30-1 | Reference compound |
| HY-112498 | Cy3 NHS ester | 1393363-07-9 | Dye Reagents |
| HY-112498A | Cy3 NHS ester (bromide) | 2892098-34-7 | Dye Reagents |
| HY-112499 | Menaquinone-7 | 2124-57-4 | Reference compound |
| HY-112499R | Menaquinone-7 (Standard) | 2124-57-4 | Reference Standards |
| HY-112499S | Menaquinone-7-d7 | 1233937-31-9 | Isotope-Labeled Compounds |
| HY-112499S1 | Menaquinone-7-13C6 | | Isotope-Labeled Compounds |
| HY-112501 | Codon readthrough inducer 1 | 1338233-09-2 | Reference compound |
| HY-112502 | MethADP | 3768-14-7 | Reference compound |
| HY-112502A | MethADP (disodium) | 104835-70-3 | Reference compound |
| HY-112502B | MethADP (sodium) | 89016-30-8 | Reference compound |
| HY-112502C | MethADP (triammonium) | | Reference compound |
| HY-112502D | MethADP (trisodium) | 2659222-76-9 | Reference compound |
| HY-112504 | INCB054329 | 1628607-64-6 | Reference compound |
| HY-112504A | INCB054329 (Racemate) | 1628607-62-4 | Reference compound |
| HY-112504D | (R)-INCB054329 | 1628607-63-5 | Reference compound |
| HY-112505 | Efflux inhibitor-1 | 1776055-29-8 | Reference compound |
| HY-112509 | STL427944 | 292028-62-7 | Reference compound |
| HY-112514 | 1,3,6,8-Tetrahydroxynaphthalene | 18512-30-6 | Reference compound |
| HY-112516 | Fmoc-Lys(amino aldehyde)-Boc | 146803-44-3 | Reference compound |
| HY-112522 | HS79 | 2138838-56-7 | Reference compound |
| HY-112522A | HS80 | 2138838-57-8 | Reference compound |
| HY-112523A | DMTAP | 197974-74-6 | Biochemical Assay Reagents |
| HY-112526 | Thiofluor 623 | 1004324-99-5 | Dye Reagents |
| HY-112527 | 7(Z),11(Z)-Heptacosadiene | 100462-58-6 | Natural Products |
| HY-112528 | Glycerophospho-N-palmitoyl ethanolamine | 100575-09-5 | Reference compound |
| HY-112530 | 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine | 1069-79-0 | Natural Products |
| HY-112530S | 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine-d70 | 326495-43-6 | Isotope-Labeled Compounds |
| HY-112531 | Poly(2-hydroxyethyl methacrylate) (Mv 20000) | 25249-16-5 | Reference compound |
| HY-112531A | Poly(2-hydroxyethyl methacrylate) (Mv 1000000) | 25249-16-5 | Reference compound |
| HY-112531B | Poly(2-hydroxyethyl methacrylate) (Mv 300000) | 25249-16-5 | Reference compound |
| HY-112532 | REV 5901 | 101910-24-1 | Reference compound |
| HY-112532A | REV 5901 (hydrochloride) | 92532-23-5 | Reference compound |
| HY-112533 | 11-Deoxy-11-methylene PGD2 | 100648-29-1 | Reference compound |
| HY-112534 | GSTO-IN-2 | 1202710-57-3 | Reference compound |
| HY-112535 | α-2,3-sialyltransferase-IN-1 | 881179-06-2 | Reference compound |
| HY-112537 | D-Glucose 6-phosphate | 56-73-5 | Natural Products |
| HY-112537A | Dipotassium glucose-6-phosphate, 98% | 5996-17-8 | Biochemical Assay Reagents |
| HY-112537B | D-Glucose 6-phosphate (sodium) | 54010-71-8 | Natural Products |
| HY-112537S1 | D-Glucose 6-Phosphate-13C6 (disodium xhydrate) | | Isotope-Labeled Compounds |
| HY-112537S2 | D-Glucose 6-phosphate-13C | | Isotope-Labeled Compounds |
| HY-112538 | 1-(1-Naphthyl)piperazine (hydrochloride) | 104113-71-5 | Reference compound |
| HY-112540 | Acetoacetic acid | 541-50-4 | Natural Products |
| HY-112540A | Acetoacetic acid (lithium) | 3483-11-2 | Natural Products |
| HY-112540B | Acetoacetic acid (sodium) | 623-58-5 | Reference compound |
| HY-112541 | 21-Hydroxyoligomycin A | 102042-09-1 | Natural Products |
| HY-112542 | Nemadectin | 102130-84-7 | Natural Products |
| HY-112542R | Nemadectin (Standard) | 102130-84-7 | Reference Standards |
| HY-112543 | S119-8 | 443639-96-1 | Reference compound |
| HY-112544 | IK1 inhibitor PA-6 | 500715-03-7 | Reference compound |
| HY-112545 | DDR2-IN-1 | 1573053-23-2 | Reference compound |
| HY-112546 | MMP-2 Inhibitor I | 10335-69-0 | Reference compound |
| HY-112547 | CRT5 | 1034297-58-9 | Reference compound |
| HY-112549 | 5-oxo-ETE | 106154-18-1 | Reference compound |
| HY-112549S | 5-OxoETE-d7 | 1881277-29-7 | Isotope-Labeled Compounds |
| HY-112551 | 2′,3′,5′-Triacetyl-5-azacytidine | 10302-78-0 | Reference compound |
| HY-112552 | 1,2-Distearoyl-sn-glycerol | 10567-21-2 | Reference compound |
| HY-112553 | HZ52 | 1077626-51-7 | Reference compound |
| HY-112554 | PDM11 | 1032508-03-4 | Reference compound |
| HY-112555 | PDE7-IN-2 | 107522-19-0 | Reference compound |
| HY-112557 | PROTAC TBK1 degrader-2 | 2052306-13-3 | Reference compound |
| HY-112558 | AZ3451 | 2100284-59-9 | Reference compound |
| HY-112559 | Bis-PEG2-acid | 19364-66-0 | Reference compound |
| HY-112560 | Bis-PEG2-PFP ester | 1314378-18-1 | ADC Related |
| HY-112561 | Bis-PEG1-PFP ester | 1807539-02-1 | ADC Related |
| HY-112562 | GPR84 antagonist 8 | 1445846-30-9 | Reference compound |
| HY-112564 | JNJ-632 | 1572510-42-9 | Reference compound |
| HY-112565 | MBX-4132 | 2286411-30-9 | Reference compound |
| HY-112569 | MAT2A inhibitor 2 | 13299-99-5 | Reference compound |
| HY-112570 | CC-90003 | 1621999-82-3 | Reference compound |
| HY-112573A | Azapentacene (sodium) | 3863-80-7 | Reference compound |
| HY-112575 | Tiazotic acid | 64679-65-8 | Reference compound |
| HY-112579 | Ceftobiprole | 209467-52-7 | Reference compound |
| HY-112580 | SRI-31040 | 1928715-72-3 | Reference compound |
| HY-112581 | 5-Methoxyuridine | 35542-01-9 | Reference compound |
| HY-112581B | 5-Methoxyuridine 5'-triphosphate (trisodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-112582 | N1-Methylpseudouridine | 13860-38-3 | Oligonucleotides |
| HY-112582A | N1-Methylpseudouridine-5′-triphosphate | 1428903-59-6 | Oligonucleotides |
| HY-112582B | N1-Methylpseudouridine-5′-triphosphate (tetralithium) | | Reference compound |
| HY-112582C | N1-Methylpseudouridine-5′-triphosphate (trisodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-112582S | N1-Methylpseudouridine-d3 | | Isotope-Labeled Compounds |
| HY-112583 | MIV-247 | 1352817-76-5 | Reference compound |
| HY-112584 | JBSNF-000088 | 7150-23-4 | Reference compound |
| HY-112585 | Darunavir-d9 | 1133378-37-6 | Reference compound |
| HY-112586 | Sulfaethoxypyridazine | 963-14-4 | Reference compound |
| HY-112586R | Sulfaethoxypyridazine (Standard) | 963-14-4 | Reference Standards |
| HY-112586S1 | Sulfaethoxypyridazine-13C6 | | Isotope-Labeled Compounds |
| HY-112587 | MC3482 | 2922280-86-0 | Reference compound |
| HY-112588 | dBET6 | 1950634-92-0 | Reference compound |
| HY-112589 | BRITE-338733 | 503105-88-2 | Reference compound |
| HY-112591 | NSC260594 | 906718-66-9 | Reference compound |
| HY-112596 | H3B-6545 | 2052130-80-8 | Reference compound |
| HY-112596A | H3B-6545 (hydrochloride) | 2052132-51-9 | Reference compound |
| HY-112597 | Mavodelpar (free acid) | 942594-93-6 | Reference compound |
| HY-112597A | Mavodelpar | 1604815-32-8 | Reference compound |
| HY-112598 | PF-06815345 | 1900686-46-5 | Reference compound |
| HY-112598A | PF-06815345 (hydrochloride) | 2334434-49-8 | Reference compound |
| HY-112599 | Pomalidomide-PEG4-C2-NH2 | 2225940-52-1 | Reference compound |
| HY-112599B | Pomalidomide-PEG4-C2-NH2 (hydrochloride) | 2357105-92-9 | Reference compound |
| HY-112600 | Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 | 2435572-48-6 | Reference compound |
| HY-112600A | Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 (TFA) | 2435572-49-7 | Reference compound |
| HY-112601 | IDH1 Inhibitor 1 | 2234285-81-3 | Reference compound |
| HY-112602 | PI3K/mTOR Inhibitor-1 | 1949802-49-6 | Reference compound |
| HY-112603 | AP5 | 1623194-37-5 | Reference compound |
| HY-112603A | AP5 (sodium) | 1623143-67-8 | Reference compound |
| HY-112604 | MK-8318 | 1416581-40-2 | Reference compound |
| HY-112605 | sPLA2-X Inhibitor 31 | 2241025-50-1 | Reference compound |
| HY-112606 | ML-290 | 1482500-76-4 | Reference compound |
| HY-112607 | Tubulin inhibitor 1 | 2237054-53-2 | Reference compound |
| HY-112608 | CHMFL-PI3KD-317 | 2244992-76-3 | Reference compound |
| HY-112609 | QCA570 | 2207569-08-0 | Reference compound |
| HY-112610 | CF53 | 1808160-52-2 | Reference compound |
| HY-112611 | H3B-5942 | 2052128-15-9 | Reference compound |
| HY-112612 | RTI-13951-33 | 2244884-08-8 | Reference compound |
| HY-112612A | RTI-13951-33 hydrochloride | | Reference compound |
| HY-112613 | UCB9608 | 1616413-96-7 | Reference compound |
| HY-112614 | ATM Inhibitor-1 | 2135639-94-8 | Reference compound |
| HY-112615 | NAMPT inhibitor-linker 1 | 2241019-57-6 | ADC Related |
| HY-112616 | NAMPT inhibitor-linker 2 | 2241014-82-2 | ADC Related |
| HY-112617 | Thalidomide-O-amido-PEG2-C2-NH2 | 1957235-74-3 | Reference compound |
| HY-112617A | Thalidomide-O-amido-PEG2-C2-NH2 (TFA) | 1957235-75-4 | Reference compound |
| HY-112617B | Thalidomide-O-amido-PEG2-C2-NH2 (hydrochloride) | 2376990-30-4 | Reference compound |
| HY-112618 | Thalidomide-O-amido-C6-NH2 | 1950635-13-8 | Reference compound |
| HY-112618A | Thalidomide-O-amido-C6-NH2 (TFA) | 1950635-14-9 | Reference compound |
| HY-112618B | Thalidomide-O-amido-C6-NH2 (hydrochloride) | 2376990-31-5 | Reference compound |
| HY-112619 | TES-991 | 1883602-20-7 | Reference compound |
| HY-112620 | MS21570 | 65373-29-7 | Reference compound |
| HY-112621 | Leukotriene A4 methyl ester | 73466-12-3 | Reference compound |
| HY-112622 | GSK3186899 | 1972617-87-0 | Reference compound |
| HY-112623 | Vafidemstat | 1357362-02-7 | Reference compound |
| HY-112624 | Dextran | 9004-54-0 | Oligonucleotides |
| HY-112624A | Dextran T1 (MW 1,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624B | Dextran T70 (MW 70,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624C | Dextran (MW 40000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624D | Dextran T60 (MW 60,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624E | Dextran T0.8 (MW 800) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624F | CY7-Dextran (MW 4000) | | Dye Reagents |
| HY-112624F1 | CY5-Dextran (MW 4000) | | Dye Reagents |
| HY-112624H | Dextran T2 (MW 2,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624I | Dextran T3 (MW 3,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624J | Dextran T4 (MW 4,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624K | Dextran T5 (MW 5,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624L | Dextran T10 (MW 10,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624M | Dextran T150 (MW 150,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624N | Dextran T200 (MW 200,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624O | Dextran T100 (MW 100,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624P | Dextran T500 (MW 500,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624Q | Dextran T800 (MW 800,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624T | Dextran T7 (MW 7,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112624U | Dextran T20 (MW 20,000) | 9004-54-0 | Biochemical Assay Reagents |
| HY-112626 | CDK12-IN-2 | 2244987-03-7 | Reference compound |
| HY-112627 | CAY 10465 | 688348-33-6 | Reference compound |
| HY-112628 | CAY10464 | 688348-37-0 | Reference compound |
| HY-112629 | PDM2 | 688348-25-6 | Reference compound |
| HY-112633 | SMN-C3 | 1449597-34-5 | Reference compound |
| HY-112634 | SIRT5 inhibitor 1 | 2166487-21-2 | Reference compound |
| HY-112636 | Astrophloxine | 14696-39-0 | Reference compound |
| HY-112639 | Aristeromycin | 19186-33-5 | Natural Products |
| HY-112641 | AkaLumine | 1176235-08-7 | Dye Reagents |
| HY-112641A | AkaLumine (hydrochloride) | 2558205-28-8 | Dye Reagents |
| HY-112642 | 9-Methoxycanthin-6-one | 74991-91-6 | Natural Products |
| HY-112645 | BAY-2402234 | 2225819-06-5 | Reference compound |
| HY-112647 | Stafib-1 | 1688703-26-5 | Reference compound |
| HY-112648 | Stafib-2 | 2097938-74-2 | Reference compound |
| HY-112649 | Pomstafib-2 | 2332841-83-3 | Reference compound |
| HY-112650 | 12-OxoETE | 108437-64-5 | Natural Products |
| HY-112652 | ACS-67 | 1088434-86-9 | Reference compound |
| HY-112653 | 8(S)-HETE | 98462-03-4 | Natural Products |
| HY-112653A | (±)8-HETE | 70968-93-3 | Natural Products |
| HY-112654 | GCN2iB | 2183470-12-2 | Reference compound |
| HY-112654A | GCN2iB (acetate) | 2183470-13-3 | Reference compound |
| HY-112657 | Xanthorrhizol | 30199-26-9 | Natural Products |
| HY-112658 | p-Iodoclonidine (hydrochloride) | 108294-57-1 | Reference compound |
| HY-112659 | Lin28-let-7 antagonist 1 | 108825-65-6 | Reference compound |
| HY-112661 | PC-766B | 108375-77-5 | Reference compound |
| HY-112663 | Monazomycin | 11006-31-8 | Natural Products |
| HY-112665 | Virginiamycin Complex | 11006-76-1 | Reference compound |
| HY-112665R | Virginiamycin Complex (Standard) | 11006-76-1 | Reference Standards |
| HY-112666 | Farnesyl thiosalicylic acid amide | 1092521-74-8 | Reference compound |
| HY-112667 | CU-CPT-9a | 2165340-32-7 | Reference compound |
| HY-112668 | Retagliptin (phosphate) | 1256756-88-3 | Reference compound |
| HY-112668A | Retagliptin | 1174122-54-3 | Reference compound |
| HY-112668B | Retagliptin (hydrochloride) | 1174038-86-8 | Reference compound |
| HY-112669 | 5-Chloro-2'-deoxyuridine | 50-90-8 | Reference compound |
| HY-112670 | Exo1 | 75541-83-2 | Reference compound |
| HY-112671 | CDDO-dhTFEA | 1191265-33-4 | Reference compound |
| HY-112673 | RSV-IN-1 | 861139-16-4 | Reference compound |
| HY-112675 | 4-Octyl itaconate | 3133-16-2 | Reference compound |
| HY-112675R | 4-Octyl itaconate (Standard) | 3133-16-2 | Reference Standards |
| HY-112675S | 4-Octyl itaconate-13C5-1 | | Isotope-Labeled Compounds |
| HY-112678 | TM6008 | 945008-17-3 | Reference compound |
| HY-112679 | GLP-1 receptor agonist 2 | 2230197-64-3 | Reference compound |
| HY-112680 | Carboxypyridostatin | 1417638-60-8 | Reference compound |
| HY-112680A | Carboxy pyridostatin (trifluoroacetate salt) | 2444713-88-4 | Reference compound |
| HY-112681 | PKC-theta inhibitor 2 | 736048-65-0 | Reference compound |
| HY-112681B | PKC-theta inhibitor 2 (hydrochloride) | 2253640-49-0 | Reference compound |
| HY-112683 | V-9302 | 1855871-76-9 | Reference compound |
| HY-112683A | V-9302 (hydrochloride) | 2416138-42-4 | Reference compound |
| HY-112684 | RO-7 | 1370241-45-4 | Reference compound |
| HY-112688 | H-Arg-4MβNA | 60285-94-1 | Reference compound |
| HY-112689 | Androgen receptor antagonist 9 | 915086-32-7 | Reference compound |
| HY-112690 | Pradefovir | 625095-60-5 | Reference compound |
| HY-112690A | Pradefovir mesylate | 625095-61-6 | Reference compound |
| HY-112692 | AT-121 | 2099681-31-7 | Reference compound |
| HY-112692A | AT-121 (hydrochloride) | 2099681-71-5 | Reference compound |
| HY-112693 | H-151 | 941987-60-6 | Reference compound |
| HY-112697 | Rhodamine B isothiocyanate | 36877-69-7 | Dye Reagents |
| HY-112698 | CA-5f | 1370032-19-1 | Reference compound |
| HY-112699 | AMPA receptor modulator-1 | 2036074-41-4 | Reference compound |
| HY-112700 | SHIP2-IN-1 | 2252247-80-4 | Reference compound |
| HY-112701 | CCR6 inhibitor 1 | 2437547-04-9 | Reference compound |
| HY-112702 | CRS400393 | 2253175-64-1 | Reference compound |
| HY-112703 | AMG 333 | 1416799-28-4 | Reference compound |
| HY-112704 | PDE5-IN-2 | 2244517-61-9 | Reference compound |
| HY-112705 | VU0529331 | 1286725-49-2 | Reference compound |
| HY-112706 | PF-06747711 | 1892576-58-7 | Reference compound |
| HY-112707 | AM9405 | 3032946-55-4 | Reference compound |
| HY-112708 | Brepocitinib | 1883299-62-4 | Reference compound |
| HY-112708A | Brepocitinib (P-Tosylate) | 2140301-96-6 | Reference compound |
| HY-112709 | LIT-927 | 2172879-52-4 | Reference compound |
| HY-112710 | ORIC-101 | 2222344-98-9 | Reference compound |
| HY-112711 | LV-320 | 2449093-46-1 | Reference compound |
| HY-112712 | Cyclophilin inhibitor 1 | 1509904-96-4 | Reference compound |
| HY-112713 | SMS2-IN-2 | 2241838-28-6 | Reference compound |
| HY-112714 | GSK3532795 | 1392312-45-6 | Reference compound |
| HY-112714A | GSK3532795 (oxalate) | 2097784-79-5 | Reference compound |
| HY-112714B | GSK3532795 (hydrochloride) | 2023808-13-9 | Reference compound |
| HY-112715 | ATP synthase inhibitor 1 | 1023043-30-2 | Reference compound |
| HY-112716 | N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride | 4272-74-6 | Reference compound |
| HY-112718 | PROTAC BET Degrader-10 | 1957234-97-7 | Reference compound |
| HY-112719 | BRD 4354 | 315698-07-8 | Reference compound |
| HY-112719B | BRD 4354 (ditrifluoroacetate) | | Reference compound |
| HY-112720 | AGL-2263 | 638213-98-6 | Reference compound |
| HY-112721 | FDI-6 | 313380-27-7 | Reference compound |
| HY-112722 | Neurotoxin Inhibitor | 951571-70-3 | Reference compound |
| HY-112723 | Apinocaltamide | 1838651-58-3 | Reference compound |
| HY-112724 | Ivarmacitinib | 1445987-21-2 | Reference compound |
| HY-112724A | Ivarmacitinib (sulfate) | 1639419-51-4 | Reference compound |
| HY-112726 | PXS-4728A | 1478364-68-9 | Reference compound |
| HY-112728 | MMV024101 | 1092565-44-0 | Reference compound |
| HY-112729 | HC-056456 | 7733-96-2 | Reference compound |
| HY-112730 | PEO-IAA | 6266-66-6 | Reference compound |
| HY-112731 | TFAP | 1011244-68-0 | Natural Products |
| HY-112732 | Sparfosic acid | 51321-79-0 | Reference compound |
| HY-112732B | Sparfosic acid (trisodium) | 70962-66-2 | Reference compound |
| HY-112734 | 4'-Methylchrysoeriol | 4712-12-3 | Reference compound |
| HY-112735 | Hexadimethrine bromide | 28728-55-4 | Oligonucleotides |
| HY-112736 | RG 14893 | 141835-49-6 | Reference compound |
| HY-112737 | LY223982 | 117423-74-2 | Reference compound |
| HY-112738 | AX048 | 873079-69-7 | Reference compound |
| HY-112739 | SC-41930 | 120072-59-5 | Reference compound |
| HY-112741 | SB-209247 | 154413-61-3 | Reference compound |
| HY-112742 | CP-195543 | 204981-48-6 | Reference compound |
| HY-112746 | Etacstil | 155701-61-4 | Reference compound |
| HY-112747 | Soy PE | 97281-51-1 | Reference compound |
| HY-112749 | ME-344 | 1374524-68-1 | Reference compound |
| HY-112752 | Gal-C4-Chol | 219850-70-1 | Biochemical Assay Reagents |
| HY-112754A | DOTAP (chloride) | 132172-61-3 | Oligonucleotides |
| HY-112754A1 | DOTAP (chloride) (Excipient) | 132172-61-3 | Reference compound |
| HY-112755 | DODMA | 104162-47-2 | Oligonucleotides |
| HY-112755A | 1,2(R)-Dioleyloxy-3-dimethylamino-propane | 666234-78-2 | Reference compound |
| HY-112756 | PEG2000-DGG | | Biochemical Assay Reagents |
| HY-112757 | DLinDMA | 871258-12-7 | Oligonucleotides |
| HY-112758 | DLin-KC2-DMA | 1190197-97-7 | Oligonucleotides |
| HY-112760 | 18:0 mPEG2000 PE (sodium) | 247925-28-6 | Oligonucleotides |
| HY-112762 | LHF-535 | 1450929-77-7 | Reference compound |
| HY-112762A | (E)-LHF-535 | | Reference compound |
| HY-112763 | CLinDMA | 908860-82-2 | Reference compound |
| HY-112764 | DMG-PEG 2000 | 160743-62-4 | Oligonucleotides |
| HY-112764A | DMG-PEG (Excipient) | 160743-62-4 | Reference compound |
| HY-112766 | DPyPE | 201036-16-0 | Reference compound |
| HY-112768 | PEG2000-DMPE | | Reference compound |
| HY-112769 | EX229 | 1219739-36-2 | Reference compound |
| HY-112772A | 98N12-5 | 917572-74-8 | Oligonucleotides |
| HY-112773 | 1,1′,1′′,1′′′-[1,4-Piperazinediylbis(2,1-ethanediylnitrilo)]tetrakis[2-dodecanol] | 1265904-26-4 | Reference compound |
| HY-112776 | BN82002 | 396073-89-5 | Reference compound |
| HY-112776A | BN82002 (hydrochloride) | 1049740-43-3 | Reference compound |
| HY-112777 | Kinesore | 363571-83-9 | Reference compound |
| HY-112778 | NFAT Transcription Factor Regulator-1 | 245747-71-1 | Reference compound |
| HY-112779 | Pertussis Toxin | 70323-44-3 | Reference compound |
| HY-112780 | UC2288 | 1394011-91-6 | Reference compound |
| HY-112781 | Pesampator | 1258963-59-5 | Reference compound |
| HY-112782 | VTX-27 | 1321924-70-2 | Reference compound |
| HY-112785 | Pyriftalid | 135186-78-6 | Reference compound |
| HY-112785R | Pyriftalid (Standard) | 135186-78-6 | Reference Standards |
| HY-112786 | MC-Val-Cit-PAB-MMAF | 863971-17-9 | ADC Related |
| HY-112788 | ONO-8590580 | 1802661-73-9 | Reference compound |
| HY-112789 | (+)-JQ1 PA | 2115701-93-2 | Reference compound |
| HY-112790 | Adenosylcobalamin | 13870-90-1 | Natural Products |
| HY-112790R | Adenosylcobalamin (Standard) | 13870-90-1 | Reference Standards |
| HY-112792 | CCR2 antagonist 1 | 1683534-96-4 | Reference compound |
| HY-112792A | (1S)-CCR2 antagonist 1 | 1683534-97-5 | Reference compound |
| HY-112793 | 3-O-Benzyl-1,2-O-isopropylidene-α-D-glucofuranose | 22529-61-9 | Biochemical Assay Reagents |
| HY-112794 | Topanol CA | 1843-03-4 | Reference compound |
| HY-112796 | Ethyl 2,3,4,6-tetra-O-benzyl-β-D-thiogalactopyranoside | 125411-99-6 | Biochemical Assay Reagents |
| HY-112797 | Ds-HAPP | 330163-26-3 | Dye Reagents |
| HY-112798 | PH-002 | 1311174-68-1 | Reference compound |
| HY-112799 | DK419 | 2102672-22-8 | Reference compound |
| HY-112800 | cyt-PTPε Inhibitor-1 | 428478-94-8 | Reference compound |
| HY-112801 | F-1 | 2244775-31-1 | Reference compound |
| HY-112802 | Ubavitinib | 2248003-60-1 | Reference compound |
| HY-112802A | Ubavitinib (tosylate) | 2248003-71-4 | Reference compound |
| HY-112803 | GNE-371 | 1926986-36-8 | Dye Reagents |
| HY-112804 | SGC-iMLLT | 2255338-25-9 | Reference compound |
| HY-112805 | ST8154AA1 | 2247025-59-6 | ADC Related |
| HY-112806 | ST8155AA1 | 2247025-63-2 | ADC Related |
| HY-112807 | SGLT inhibitor-1 | 2247314-23-2 | Reference compound |
| HY-112808 | KAN0438757 | 1451255-59-6 | Reference compound |
| HY-112809 | GSK2646264 | 1398695-47-0 | Reference compound |
| HY-112811 | PROTAC CDK9 degrader-2 | 2435721-30-3 | Reference compound |
| HY-112812 | SCD1 inhibitor-1 | 1069094-65-0 | Reference compound |
| HY-112813 | TUG-1375 | 2247372-59-2 | Reference compound |
| HY-112814 | VU6001376 | 1968546-34-0 | Reference compound |
| HY-112815 | ALK2-IN-2 | 2254409-25-9 | Reference compound |
| HY-112816 | MA242 | 1049704-18-8 | Reference compound |
| HY-112816A | MA242 (free base) | 1049704-17-7 | Reference compound |
| HY-112818 | S130 | 1160852-22-1 | Reference compound |
| HY-112819 | Insulin levels modulator | 1019254-94-4 | Reference compound |
| HY-112820 | Chlorantraniliprole | 500008-45-7 | Reference compound |
| HY-112820R | Chlorantraniliprole (Standard) | 500008-45-7 | Reference Standards |
| HY-112821 | IBS008738 | 385425-03-6 | Reference compound |
| HY-112822 | ON-013100 | 865783-95-5 | Reference compound |
| HY-112823 | Almonertinib | 1899921-05-1 | Reference compound |
| HY-112823A | Almonertinib (mesylate) | 2134096-06-1 | Reference compound |
| HY-112823B | Almonertinib (hydrochloride) | 2134096-03-8 | Reference compound |
| HY-112823R | Almonertinib (Standard) | 1899921-05-1 | Reference Standards |
| HY-112824 | L-162313 | 151488-11-8 | Reference compound |
| HY-112825 | TSI-01 | 704878-75-1 | Reference compound |
| HY-112828 | LEI105 | 1800327-36-9 | Reference compound |
| HY-112829 | Denifanstat | 1399177-37-7 | Reference compound |
| HY-112830 | BF-168 | 634911-47-0 | Reference compound |
| HY-112831 | Osoresnontrine | 1189767-28-9 | Reference compound |
| HY-112832 | Lumigen APS-5 | 193884-53-6 | Biochemical Assay Reagents |
| HY-112835 | Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside | 96597-16-9 | Biochemical Assay Reagents |
| HY-112839 | 1-Myristoyl-2-(4-nitrophenylsuccinyl)-sn-glycero-3-phosphocholine | 273931-53-6 | Reference compound |
| HY-112840 | ST3932 | 1246018-21-2 | Reference compound |
| HY-112841 | PTZ-343 | 101199-38-6 | Reference compound |
| HY-112842 | MBQ-167 | 2097938-73-1 | Reference compound |
| HY-112843 | CNT2 inhibitor-1 | 880155-70-4 | Reference compound |
| HY-112847 | Sulfosuccinimidyl oleate | 135661-44-8 | Reference compound |
| HY-112847A | Sulfosuccinimidyl oleate (sodium) | | Reference compound |
| HY-112847B | (E/Z)-Sulfosuccinimidyl oleate (sodium) | 1212012-37-7 | Reference compound |
| HY-112851 | Diacylglycerol acyltransferase inhibitor-1 | 1610800-25-3 | Reference compound |
| HY-112852 | TL02-59 | 1315330-17-6 | Reference compound |
| HY-112852A | TL02-59 (dihydrochloride) | 2415263-06-6 | Reference compound |
| HY-112853 | Fosmidomycin sodium salt | 66508-37-0 | Reference compound |
| HY-112855 | PF-06454589 | 1527473-30-8 | Reference compound |
| HY-112858 | dSPACER | 129821-76-7 | Reference compound |
| HY-112859 | VU0661013 | 2131184-57-9 | Reference compound |
| HY-112860 | Asp-AMS | 828288-98-8 | Reference compound |
| HY-112861 | Gln-AMS | 209543-57-7 | Reference compound |
| HY-112861A | Gln-AMS (TFA) | | Reference compound |
| HY-112862 | Arg-AMS | 301351-95-1 | Reference compound |
| HY-112863 | RORγt inhibitor 3 | 1361413-10-6 | Reference compound |
| HY-112864 | TGFβRI-IN-6 | 2072051-04-6 | Reference compound |
| HY-112865 | Octocog alfa | 139076-62-3 | Reference compound |
| HY-112868B | ABH (hydrochloride) | 194656-75-2 | Reference compound |
| HY-112870 | Firmonertinib | 1869057-83-9 | Reference compound |
| HY-112870A | Firmonertinib (mesylate) | 2130958-55-1 | Reference compound |
| HY-112874 | BMS-681 | 847998-92-9 | Reference compound |
| HY-112877 | ALK-5-IN-1 | 1018953-58-6 | Reference compound |
| HY-112879 | Mito-TEMPO | 1334850-99-5 | Reference compound |
| HY-112885 | nor-NOHA | 189302-40-7 | Reference compound |
| HY-112885A | nor-NOHA (acetate) | 1140844-63-8 | Reference compound |
| HY-112885B | nor-NOHA (monoacetate) | 2250019-93-1 | Reference compound |
| HY-112885C | nor-NOHA (dihydrochloride) | 291758-32-2 | Reference compound |
| HY-112889 | Oxythiamine diphosphate | 10497-04-8 | Reference compound |
| HY-112889B | Oxythiamine diphosphate (ammonium) | | Reference compound |
| HY-112894 | ZG-10 | 1408077-04-2 | Reference compound |
| HY-112895 | UT-155 | 2031161-35-8 | Reference compound |
| HY-112895A | (R)-UT-155 | 2031161-54-1 | Reference compound |
| HY-112897 | IITZ-01 | 1807988-47-1 | Reference compound |
| HY-112898 | DC1SMe | 501666-85-9 | ADC Related |
| HY-112899 | DC1 | 169901-27-3 | ADC Related |
| HY-112900 | DC41SMe | 1354787-71-5 | ADC Related |
| HY-112901 | DC41 | 1354787-69-1 | ADC Related |
| HY-112902 | OGG1-IN-08 | 350997-39-6 | Reference compound |
| HY-112903A | YW3-56 (hydrochloride) | 2309756-20-3 | Reference compound |
| HY-112904 | XRK3F2 | 2375193-43-2 | Reference compound |
| HY-112906 | C-176 | 314054-00-7 | Reference compound |
| HY-112907 | RIP2 Kinase Inhibitor 3 | 1398053-50-3 | Reference compound |
| HY-112908 | RTS-V5 | 2285346-31-6 | Reference compound |
| HY-112909 | UAMC-3203 | 2271358-64-4 | Reference compound |
| HY-112909A | UAMC-3203 hydrochloride | 2271358-65-5 | Reference compound |
| HY-112910 | Grp94 Inhibitor-1 | 2234897-35-7 | Reference compound |
| HY-112911 | Endothelial lipase inhibitor-1 | 1466427-02-0 | Reference compound |
| HY-112912 | P-gp modulator 1 | 2249749-39-9 | Reference compound |
| HY-112913 | SOCE inhibitor 1 | 2169316-15-6 | Reference compound |
| HY-112914 | mTOR inhibitor-1 | 468747-17-3 | Reference compound |
| HY-112915 | Eg5 Inhibitor V, trans-24 | 869304-55-2 | Reference compound |
| HY-112920 | TM-25659 | 260553-97-7 | Reference compound |
| HY-112921 | diABZI STING agonist-1 (tautomerism) | 2138498-18-5 | Reference compound |
| HY-112921A | diABZI STING agonist-1 | 2138299-33-7 | Reference compound |
| HY-112921B | diABZI STING agonist-1 (trihydrochloride) | 2138299-34-8 | Reference compound |
| HY-112927 | MU380 | 2109805-78-7 | Reference compound |
| HY-112929 | DT-061 | 1809427-19-7 | Reference compound |
| HY-112929B | (1S,2S,3R)-DT-061 | 1809427-20-0 | Reference compound |
| HY-112935 | Nonacog alfa | 181054-95-5 | Inhibitory Antibodies |
| HY-112937 | GNE-6640 | 2009273-67-8 | Reference compound |
| HY-112939 | Colestilan | 95522-45-5 | Reference compound |
| HY-112942 | CMP-Sialic acid | 3063-71-6 | Reference compound |
| HY-112942A | CMP-Sialic acid (sodium salt) | 1007117-62-5 | Reference compound |
| HY-112945 | MLS0315771 | 727664-91-7 | Reference compound |
| HY-112948 | 2-Methylbutyrylcarnitine | 256928-75-3 | Reference compound |
| HY-112950 | RET-IN-1 | 2222755-14-6 | Reference compound |
| HY-112951 | ChX710 | 2438721-44-7 | Reference compound |
| HY-112958 | Fomivirsen | 144245-52-3 | Reference compound |
| HY-112959 | Telavancin | 372151-71-8 | Reference compound |
| HY-112961 | Patiromer | 1208912-84-8 | Reference compound |
| HY-112968 | Human protein C | 925910-74-3 | Enzyme |
| HY-112968A | Bovine Protein C | | Enzyme |
| HY-112974 | Inotersen | 1492984-65-2 | Reference compound |
| HY-112980 | Nusinersen | 1258984-36-9 | Oligonucleotides |
| HY-112980A | Nusinersen (sodium) | | Oligonucleotides |
| HY-112988 | Perfluoropentane | 678-26-2 | Reference compound |
| HY-112998 | Efmoroctocog alfa | 1270012-79-7 | Inhibitory Antibodies |
| HY-113000 | Cetoleic acid | 1002-96-6 | Natural Products |
| HY-113002A | alpha-D-Glucose 1,6-bisphosphate (cyclohexanamine) | 71662-13-0 | Biochemical Assay Reagents |
| HY-113003 | H-γ-Glu-Gln-OH | 10148-81-9 | Natural Products |
| HY-113004 | 3-Hydroxyvaleric acid | 10237-77-1 | Natural Products |
| HY-113005 | Glutarylcarnitine | 102636-82-8 | Natural Products |
| HY-113005A | Glutarylcarnitine (lithium) | | Reference compound |
| HY-113005S | Glutarylcarnitine-d9 (chloride) | | Isotope-Labeled Compounds |
| HY-113008 | Urocanic acid | 104-98-3 | Natural Products |
| HY-113008A | cis-Urocanic acid | 7699-35-6 | Reference compound |
| HY-113008AS | cis-Urocanic acid-13C3 | | Isotope-Labeled Compounds |
| HY-113008B | trans-Urocanic acid | 3465-72-3 | Reference compound |
| HY-113008R | Urocanic acid (Standard) | 104-98-3 | Reference Standards |
| HY-113008S1 | Urocanic acid-13C3 | 1173097-34-1 | Isotope-Labeled Compounds |
| HY-113010 | 1-Arachidoyl-sn-glycero-3-phosphocholine | 108341-80-6 | Natural Products |
| HY-113010S1 | 1-Arachidoyl-sn-glycero-3-phosphocholine-d4 | 2483831-16-7 | Isotope-Labeled Compounds |
| HY-113011 | Maltotriose | 1109-28-0 | Natural Products |
| HY-113011R | Maltotriose (Standard) | 1109-28-0 | Reference Standards |
| HY-113013 | Hydroxypyruvic acid | 1113-60-6 | Natural Products |
| HY-113013A | Hydroxypyruvic acid (lithium hydrate) | 209728-15-4 | Reference compound |
| HY-113013C | Hydroxypyruvic acid (lithium) | 3369-79-7 | Biochemical Assay Reagents |
| HY-113014 | O-Phospho-L-threonine | 1114-81-4 | Natural Products |
| HY-113015 | Stearoylethanolamide | 111-57-9 | Natural Products |
| HY-113015R | Stearoylethanolamide (Standard) | 111-57-9 | Reference Standards |
| HY-113015S | Stearoylethanolamide-d3 | 2749393-37-9 | Isotope-Labeled Compounds |
| HY-113016 | Elaidic acid | 112-79-8 | Natural Products |
| HY-113016R | Elaidic acid (Standard) | 112-79-8 | Reference Standards |
| HY-113016S | Elaidic acid-d9 | 1809227-37-9 | Isotope-Labeled Compounds |
| HY-113016S1 | Elaidic acid-d17 | | Isotope-Labeled Compounds |
| HY-113018 | Ibuprofen acyl-β-D-glucuronide | 115075-59-7 | Natural Products |
| HY-113018A | (S)-Ibuprofen acyl-β-D-glucuronide | 98649-76-4 | Reference compound |
| HY-113018S | Ibuprofen acyl-β-D-glucuronide-d3 | | Isotope-Labeled Compounds |
| HY-113019 | 3β,7α-Dihydroxycholest-5-enoic acid | 115538-84-6 | Natural Products |
| HY-113019S | 3β,7α-Dihydroxycholest-5-enoic acid-d3 | 2342573-95-7 | Isotope-Labeled Compounds |
| HY-113020 | 21-Hydroxypregnenolone | 1164-98-3 | Natural Products |
| HY-113024 | Pristanic acid | 1189-37-3 | Natural Products |
| HY-113024R | Pristanic acid (Standard) | 1189-37-3 | Reference Standards |
| HY-113024S | Pristanic acid-d3 | 1383920-14-6 | Isotope-Labeled Compounds |
| HY-113025A | L-hydroxylysine (dihydrochloride) | 172213-74-0 | Natural Products |
| HY-113026 | Delta-Tocopherol | 119-13-1 | Natural Products |
| HY-113026R | Delta-Tocopherol (Standard) | 119-13-1 | Reference Standards |
| HY-113026S | (2RS,4R,8R)-δ-Tocopherol-d4 (Mixture of Diastereomers) | 1292815-80-5 | Isotope-Labeled Compounds |
| HY-113027 | p-Hydroxymandelic acid | 1198-84-1 | Natural Products |
| HY-113027R | p-Hydroxymandelic acid (Standard) | 1198-84-1 | Reference Standards |
| HY-113031 | 16a-Hydroxydehydroisoandrosterone | 1232-73-1 | Reference compound |
| HY-113031S | 16α-Hydroxydehydroepiandrosterone-d6 | 97453-29-7 | Isotope-Labeled Compounds |
| HY-113031S1 | 16α-Hydroxydehydroepiandrosterone-d5 | | Isotope-Labeled Compounds |
| HY-113033 | Pentosidine | 124505-87-9 | Natural Products |
| HY-113033A | Pentosidine (TFA) | 225784-09-8 | Reference compound |
| HY-113037 | (E/Z)-Farnesyl pyrophosphate | 13058-04-3 | Reference compound |
| HY-113037B | Farnesyl pyrophosphate | 372-97-4 | Reference compound |
| HY-113037C | Farnesyl pyrophosphate (ammonium) | 116057-57-9 | Reference compound |
| HY-113037S1 | Farnesyl pyrophosphate-d3 | | Isotope-Labeled Compounds |
| HY-113038 | D-α-Hydroxyglutaric acid | 13095-47-1 | Natural Products |
| HY-113038A | α-Hydroxyglutaric acid (disodium) | 40951-21-1 | Natural Products |
| HY-113038AR | α-Hydroxyglutaric acid (disodium) (Standard) | 40951-21-1 | Reference Standards |
| HY-113038AS | α-Hydroxyglutaric acid-13C5 (disodium) | 2482467-23-0 | Isotope-Labeled Compounds |
| HY-113038AS1 | α-Hydroxyglutaric acid-d4 (disodium) | 2483831-91-8 | Isotope-Labeled Compounds |
| HY-113038B | α-Hydroxyglutaric acid | 2889-31-8 | Reference compound |
| HY-113039 | L-2-Hydroxyglutaric acid | 13095-48-2 | Natural Products |
| HY-113039R | L-2-Hydroxyglutaric acid (Standard) | 13095-48-2 | Reference Standards |
| HY-113040A | (17R,18S)-Epoxyeicosatetraenoic acid | 725246-18-4 | Reference compound |
| HY-113041 | Prostaglandin A2 | 13345-50-1 | Reference compound |
| HY-113041S | Prostaglandin A2-d4 | 201608-18-6 | Isotope-Labeled Compounds |
| HY-113042 | Prostaglandin B2 | 13367-85-6 | Natural Products |
| HY-113042S | Prostaglandin B2-d4 | 211105-23-6 | Isotope-Labeled Compounds |
| HY-113043 | Galactonic acid | 13382-27-9 | Reference compound |
| HY-113044 | Uridine diphosphate glucose | 133-89-1 | Natural Products |
| HY-113044R | Uridine diphosphate glucose (Standard) | 133-89-1 | Reference Standards |
| HY-113045 | Aquacobalamin | 13422-52-1 | Reference compound |
| HY-113046 | 5-Methyltetrahydrofolic acid | 134-35-0 | Natural Products |
| HY-113046R | 5-Methyltetrahydrofolic acid (Standard) | 134-35-0 | Reference Standards |
| HY-113046S | 5-Methyltetrahydrofolic acid-13C5 | | Isotope-Labeled Compounds |
| HY-113046S1 | 5-Methyltetrahydrofolic acid-13C6 | 212248-92-5 | Isotope-Labeled Compounds |
| HY-113047 | 5,6-Dihydrouridine | 5627-05-4 | Natural Products |
| HY-113048 | Erythronic acid | 13752-84-6 | Reference compound |
| HY-113048A | Erythronic acid (potassium) | | Reference compound |
| HY-113049 | Phosphoenolpyruvic acid | 138-08-9 | Reference compound |
| HY-113049A | Phosphoenolpyruvic acid (trisodium) | 5541-93-5 | Biochemical Assay Reagents |
| HY-113050 | 2,3-Diphosphoglyceric acid | 138-81-8 | Reference compound |
| HY-113050A | 2,3-Diphosphoglyceric acid (pentasodium) | 1287756-01-7 | Natural Products |
| HY-113050B | 2,3-Diphosphoglyceric acid (pentacyclohexylamine) | 62868-79-5 | Biochemical Assay Reagents |
| HY-113050SA | 2,3-Diphosphoglyceric acid-d3 (ammonium) | 2712139-19-8 | Isotope-Labeled Compounds |
| HY-113053 | Prostaglandin A1 | 14152-28-4 | Natural Products |
| HY-113054 | DL-Glyceraldehyde 3-phosphate | 591-59-3 | Reference compound |
| HY-113056A | N1-Acetylspermidine (hydrochloride) | 34450-16-3 | Reference compound |
| HY-113056AS | N1-Acetylspermidine-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-113057 | 3-Hydroxycapric acid | 14292-26-3 | Natural Products |
| HY-113057R | 3-Hydroxycapric acid (Standard) | 14292-26-3 | Reference Standards |
| HY-113058 | 3-Hydroxyoctanoic acid | 14292-27-4 | Biochemical Assay Reagents |
| HY-113061 | Pseudouridine | 1445-07-4 | Natural Products |
| HY-113061R | Pseudouridine (Standard) | 1445-07-4 | Reference Standards |
| HY-113061S | Pseudouridine-O18 | | Isotope-Labeled Compounds |
| HY-113062 | 20α-Dihydroprogesterone | 145-14-2 | Natural Products |
| HY-113062S | 20α-Dihydroprogesterone-13C5 | | Isotope-Labeled Compounds |
| HY-113063 | 3-Methyl-2-oxovaleric acid | 1460-34-0 | Natural Products |
| HY-113063R | 3-Methyl-2-oxovaleric acid (Standard) | 1460-34-0 | Reference Standards |
| HY-113064 | Selenocystine | 2897-21-4 | Peptides |
| HY-113066 | Guanosine 5'-diphosphate | 146-91-8 | Oligonucleotides |
| HY-113066A | Guanosine 5'-diphosphate (disodium salt) | 7415-69-2 | Oligonucleotides |
| HY-113066B | Guanosine 5'-diphosphate (ditromethamine) | 103192-39-8 | Reference compound |
| HY-113066C | Guanosine 5'-diphosphate (sodium), 96% (HPLC) | 43139-22-6 | Biochemical Assay Reagents |
| HY-113066S1 | Guanosine 5'-diphosphate-13C10 (dilithium) | | Isotope-Labeled Compounds |
| HY-113066S2 | Guanosine 5'-diphosphate-d13 (dilithium) | | Isotope-Labeled Compounds |
| HY-113066S3 | Guanosine 5'-diphosphate-13C10,15N5 (dilithium) | | Isotope-Labeled Compounds |
| HY-113067 | Phytanic acid | 14721-66-5 | Reference compound |
| HY-113067S | Phytanic acid-d3 | 1383920-40-8 | Isotope-Labeled Compounds |
| HY-113068 | (rel)-β-Tocopherol | 148-03-8 | Natural Products |
| HY-113068R | (rel)-β-Tocopherol (Standard) | 148-03-8 | Reference Standards |
| HY-113068S | β-Tocopherol-d3 | 936230-75-0 | Isotope-Labeled Compounds |
| HY-113069 | Decanoylcarnitine | 1492-27-9 | Natural Products |
| HY-113070 | Dihomo-γ-Linolenoyl Ethanolamide | 150314-34-4 | Reference compound |
| HY-113071 | Mevalonic acid | 150-97-0 | Natural Products |
| HY-113071A | Mevalonic acid (lithium salt) | 2618458-93-6 | Natural Products |
| HY-113071AR | Mevalonic acid (lithium salt) (Standard) | 2618458-93-6 | Reference Standards |
| HY-113071C | (S)-Mevalonic acid | 32451-23-3 | Reference compound |
| HY-113073 | 2,4-Dihydroxybutanoic acid | 1518-62-3 | Reference compound |
| HY-113074 | Glycolithocholic acid 3-sulfate | 15324-64-8 | Reference compound |
| HY-113074R | Glycolithocholic acid 3-sulfate (Standard) | 15324-64-8 | Reference Standards |
| HY-113075 | 1,5-Anhydrosorbitol | 154-58-5 | Natural Products |
| HY-113075S | 1,5-Anhydrosorbitol-13C | 2709705-29-1 | Isotope-Labeled Compounds |
| HY-113076 | Thiamine pyrophosphate | 154-87-0 | Natural Products |
| HY-113076R | Thiamine pyrophosphate (Standard) | 154-87-0 | Reference Standards |
| HY-113076S | Thiamine pyrophosphate-d3 | 2483831-79-2 | Isotope-Labeled Compounds |
| HY-113077 | 9-Hydroxy-10(E),12(E)-octadecadienoic acid | 115185-06-3 | Natural Products |
| HY-113079 | Argininic acid | 157-07-3 | Natural Products |
| HY-113080 | N-Acetylornithine | 6205-08-9 | Natural Products |
| HY-113080R | N-Acetylornithine (Standard) | 6205-08-9 | Reference Standards |
| HY-113080S | N-Acetylornithine-d2 | | Isotope-Labeled Compounds |
| HY-113081 | 1-Methyladenosine | 15763-06-1 | Natural Products |
| HY-113081AS | 1-Methyladenosine-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-113081R | 1-Methyladenosine (Standard) | 15763-06-1 | Reference Standards |
| HY-113081S | 1-Methyladenosine-d3 | | Isotope-Labeled Compounds |
| HY-113081S1 | 1-Methyladenosine-d3 (hydriodide) | | Isotope-Labeled Compounds |
| HY-113082 | L-Thyronine | 1596-67-4 | Reference compound |
| HY-113083 | Acetaminophen glucuronide | 16110-10-4 | Reference compound |
| HY-113083R | Acetaminophen glucuronide (Standard) | 16110-10-4 | Reference Standards |
| HY-113084 | L-Cysteine S-sulfate | 1637-71-4 | Peptides |
| HY-113085 | 3-Hydroxyhippuric acid | 1637-75-8 | Natural Products |
| HY-113085R | 3-Hydroxyhippuric acid (Standard) | 1637-75-8 | Reference Standards |
| HY-113086 | CE(16:1(9Z)) | 16711-66-3 | Reference compound |
| HY-113089 | Epsilon-(gamma-glutamyl)-lysine | 17105-15-6 | Natural Products |
| HY-113089A | Epsilon-(gamma-glutamyl)-lysine (TFA) | | Natural Products |
| HY-113091 | Alpha-Tocotrienol | 1721-51-3 | Natural Products |
| HY-113092 | Propionylcarnitine | 17298-37-2 | Natural Products |
| HY-113093 | Ethyl glucuronide | 17685-04-0 | Natural Products |
| HY-113093S | Ethyl glucuronide-d5 | 1135070-98-2 | Isotope-Labeled Compounds |
| HY-113094 | Paullinic acid | 17735-94-3 | Natural Products |
| HY-113094R | Paullinic acid (Standard) | 17735-94-3 | Reference Standards |
| HY-113095 | γ-CEHC | 178167-75-4 | Natural Products |
| HY-113095R | γ-CEHC (Standard) | 178167-75-4 | Reference Standards |
| HY-113095S | γ-CEHC-d5 | | Isotope-Labeled Compounds |
| HY-113096 | Prostaglandin D1 | 17968-82-0 | Reference compound |
| HY-113096S | Prostaglandin D1-d4 | | Isotope-Labeled Compounds |
| HY-113097 | 3α,7α-Dihydroxycoprostanic acid | 17974-66-2 | Natural Products |
| HY-113097S | 3α,7α-Dihydroxycoprostanic acid-d3 | 338976-76-4 | Isotope-Labeled Compounds |
| HY-113097S1 | 3α,7α-Dihydroxycoprostanic acid-d5 | | Isotope-Labeled Compounds |
| HY-113098 | 2-Oxovaleric acid | 1821-02-9 | Natural Products |
| HY-113098R | 2-Oxovaleric acid (Standard) | 1821-02-9 | Reference Standards |
| HY-113099 | Indolelactic acid | 1821-52-9 | Natural Products |
| HY-113099R | Indolelactic acid (Standard) | 1821-52-9 | Reference Standards |
| HY-113099S | Indolelactic acid-d5 | 2470130-19-7 | Isotope-Labeled Compounds |
| HY-113100 | N-Acetylputrescine hydrochloride | 18233-70-0 | Natural Products |
| HY-113100R | N-Acetylputrescine hydrochloride (Standard) | 18233-70-0 | Reference Standards |
| HY-113101 | 2-Hydroxyadipic acid | 18294-85-4 | Natural Products |
| HY-113101R | 2-Hydroxyadipic acid (Standard) | 18294-85-4 | Reference Standards |
| HY-113102A | 9(E),11(E)-Octadecadienoic acid | 544-71-8 | Reference compound |
| HY-113102B | 9(Z),11(Z)-Octadecadienoic acid | 544-70-7 | Reference compound |
| HY-113104S | Androsterone glucuronide-d4 (sodium) | 2687960-88-7 | Isotope-Labeled Compounds |
| HY-113105 | Estriol 16α-(β-D-glucuronide) | 1852-50-2 | Reference compound |
| HY-113107 | 3-Hydroxydodecanoic acid | 1883-13-2 | Natural Products |
| HY-113107R | 3-Hydroxydodecanoic acid (Standard) | 1883-13-2 | Reference Standards |
| HY-113110 | Cysteinylglycine | 19246-18-5 | Natural Products |
| HY-113110A | Cysteinylglycine (TFA) | 1100364-95-1 | Reference compound |
| HY-113111 | 11,12-DiHETrE | 192461-95-3 | Reference compound |
| HY-113111S | 11,12-DiHETrE-d11 | | Isotope-Labeled Compounds |
| HY-113112 | 8,9-DiHETrE | 192461-96-4 | Natural Products |
| HY-113113 | 13,14-Dihydro PGE1 | 19313-28-1 | Reference compound |
| HY-113113S | 13,14-Dihydro PGE1-d4 | 2705226-66-8 | Isotope-Labeled Compounds |
| HY-113114 | Tetrahydrocortisone | 53-05-4 | Natural Products |
| HY-113114S | Tetrahydrocortisone-d5 | | Isotope-Labeled Compounds |
| HY-113114S1 | Tetrahydrocortisone-d6 | | Isotope-Labeled Compounds |
| HY-113116 | Sphinganine 1-phosphate | 19794-97-9 | Reference compound |
| HY-113116S | Sphinganine 1-phosphate-d7 | 2315262-23-6 | Isotope-Labeled Compounds |
| HY-113118 | AAMU | 19893-78-8 | Natural Products |
| HY-113118S | Acetylamino-6-amino-3-methyluracil-13C4,15N3 | | Isotope-Labeled Compounds |
| HY-113119 | N-Butyrylglycine | 20208-73-5 | Peptides |
| HY-113119S | N-Butyrylglycine-d7 | | Isotope-Labeled Compounds |
| HY-113119S1 | N-Butyrylglycine-d2 | 1219799-10-6 | Isotope-Labeled Compounds |
| HY-113120 | Stearidonic acid | 20290-75-9 | Natural Products |
| HY-113121 | Vanillylmandelic acid | 55-10-7 | Natural Products |
| HY-113121R | Vanillylmandelic acid (Standard) | 55-10-7 | Reference Standards |
| HY-113121S | Vanillylmandelic acid-d3 | 74495-70-8 | Isotope-Labeled Compounds |
| HY-113121S1 | Vanillylmandelic acid-d1 | 53587-34-1 | Isotope-Labeled Compounds |
| HY-113123 | LysoPC(14:0/0:0) | 20559-16-4 | Natural Products |
| HY-113123S1 | LysoPC(14:0/0:0)-d7 | | Isotope-Labeled Compounds |
| HY-113125 | Dolichol-20 | 2067-66-5 | Natural Products |
| HY-113126 | 3-Hydroxyisobutyric acid | 2068-83-9 | Natural Products |
| HY-113126A | 3-Hydroxyisobutyric acid (sodium) | 1219589-99-7 | Reference compound |
| HY-113126B | (R)-3-Hydroxyisobutyric acid (sodium) | 1228078-57-6 | Reference compound |
| HY-113127 | L-Tryptophanamide | 20696-57-5 | Reference compound |
| HY-113128 | sn-Glycerol 3-phosphate | 17989-41-2 | Natural Products |
| HY-113128A | sn-Glycerol 3-phosphate (lithium) | | Reference compound |
| HY-113128B | sn-Glycerol 3-phosphate (biscyclohexylammonium salt) | 29849-82-9 | Natural Products |
| HY-113128C | (Rac)-sn-Glycerol 3-phosphate | 57-03-4 | Reference compound |
| HY-113128S | sn-Glycerol 3-phosphate-13C3 (disodium) | | Isotope-Labeled Compounds |
| HY-113130 | Eicosadienoic acid | 2091-39-6 | Natural Products |
| HY-113131 | Dihydroxyacetone phosphate | 57-04-5 | Natural Products |
| HY-113131A | Dihydroxyacetone phosphate (hemimagnesium hydrate) | | Natural Products |
| HY-113132 | 5,6-DHET | 213382-49-1 | Natural Products |
| HY-113133 | Kojibiose | 2140-29-6 | Reference compound |
| HY-113133R | Kojibiose (Standard) | 2140-29-6 | Reference Standards |
| HY-113134 | 25-Hydroxycholesterol | 2140-46-7 | Natural Products |
| HY-113134S | 25-Hydroxycholesterol-d6 | 88247-69-2 | Isotope-Labeled Compounds |
| HY-113135 | 5-Methylcytidine | 2140-61-6 | Natural Products |
| HY-113135R | 5-Methylcytidine (Standard) | 2140-61-6 | Reference Standards |
| HY-113136 | 1-Methylguanosine | 2140-65-0 | Natural Products |
| HY-113136S | 1-Methylguanosine-d3 | | Isotope-Labeled Compounds |
| HY-113137 | N2,N2-Dimethylguanosine | 2140-67-2 | Natural Products |
| HY-113137R | N2,N2-Dimethylguanosine (Standard) | 2140-67-2 | Reference Standards |
| HY-113138 | 3-Methyluridine | 2140-69-4 | Natural Products |
| HY-113139 | 1-Methylinosine | 2140-73-0 | Natural Products |
| HY-113139S | 1-Methylinosine-d3 | | Isotope-Labeled Compounds |
| HY-113143 | Galactose 1-phosphate | 2255-14-3 | Natural Products |
| HY-113143A | Galactose 1-phosphate Potassium salt | 19046-60-7 | Natural Products |
| HY-113143AS | Galactose 1-phosphate-13C (potassium) | 478518-78-4 | Isotope-Labeled Compounds |
| HY-113143AS1 | Galactose 1-phosphate-13C-1 (potassium) | 478518-80-8 | Isotope-Labeled Compounds |
| HY-113144 | L-Hexanoylcarnitine | 22671-29-0 | Natural Products |
| HY-113144AS | L-Hexanoylcarnitine-d3 (chloride) | 2483831-95-2 | Isotope-Labeled Compounds |
| HY-113144R | L-Hexanoylcarnitine (Standard) | 22671-29-0 | Reference Standards |
| HY-113144S | L-Hexanoylcarnitine-d9 | 2847775-84-0 | Isotope-Labeled Compounds |
| HY-113145 | (Rac)-Salvianic acid A | 23028-17-3 | Natural Products |
| HY-113146 | 2-Octenal | 2363-89-5 | Biochemical Assay Reagents |
| HY-113147 | L-Palmitoylcarnitine | 2364-67-2 | Natural Products |
| HY-113147A | L-Palmitoylcarnitine (chloride) | 18877-64-0 | Reference compound |
| HY-113147AR | L-Palmitoylcarnitine (chloride) (Standard) | 18877-64-0 | Reference Standards |
| HY-113147AS | L-Palmitoylcarnitine-d3 (hydrochloride) | 1334532-26-1 | Isotope-Labeled Compounds |
| HY-113147B | L-Palmitoylcarnitine (TFA) | | Natural Products |
| HY-113147S1 | L-Palmitoylcarnitine-d9 | 2847775-90-8 | Isotope-Labeled Compounds |
| HY-113149 | Argininosuccinic acid | 2387-71-5 | Reference compound |
| HY-113149A | Argininosuccinic acid (disodium) | 918149-29-8 | Reference compound |
| HY-113150 | Hexanoylglycine | 24003-67-6 | Reference compound |
| HY-113150S | Hexanoylglycine-d11 | | Isotope-Labeled Compounds |
| HY-113150S1 | Hexanoylglycine-d2 | 1256842-52-0 | Isotope-Labeled Compounds |
| HY-113151 | 18-Oxocortisol | 2410-60-8 | Natural Products |
| HY-113152 | Hypogeic acid (50mg/ml in ethanol) | 2416-19-5 | Natural Products |
| HY-113157 | Estrone 3-glucuronide | 2479-90-5 | Reference compound |
| HY-113158 | 4-Hydroxyhippuric acid | 2482-25-9 | Reference compound |
| HY-113158R | 4-Hydroxyhippuric acid (Standard) | 2482-25-9 | Reference Standards |
| HY-113159 | Docosapentaenoic acid (22n-3) | 24880-45-3 | Natural Products |
| HY-113159A | Docosapentaenoic acid (22n-3) (sodium) | 2983837-44-9 | Reference compound |
| HY-113161 | L-Octanoylcarnitine | 25243-95-2 | Natural Products |
| HY-113161R | L-Octanoylcarnitine (Standard) | 25243-95-2 | Reference Standards |
| HY-113161S | L-Octanoylcarnitine-d3 | 204259-56-3 | Isotope-Labeled Compounds |
| HY-113161S1 | L-Octanoylcarnitine-d9 | 2847775-88-4 | Isotope-Labeled Compounds |
| HY-113162 | Bovinic acid | 2540-56-9 | Natural Products |
| HY-113162A | Bovinic acid (sodium) | 756499-04-4 | Reference compound |
| HY-113162R | Bovinic acid (Standard) | 2540-56-9 | Reference Standards |
| HY-113164 | Vitamin K1 2,3-epoxide | 25486-55-9 | Reference compound |
| HY-113164S | Vitamin K1 2,3-epoxide-d7 | | Isotope-Labeled Compounds |
| HY-113165 | Isobutyryl-L-carnitine | 25518-49-4 | Natural Products |
| HY-113165A | Isobutyryl-L-carnitine (chloride) | 6920-31-6 | Reference compound |
| HY-113165AS | Isobutyryl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-113166 | Dodecanoylcarnitine | 25518-54-1 | Natural Products |
| HY-113166R | Dodecanoylcarnitine (Standard) | 25518-54-1 | Reference Standards |
| HY-113167 | 2-Phosphoglyceric acid | 2553-59-5 | Reference compound |
| HY-113168 | Butyrylcarnitine | 25576-40-3 | Natural Products |
| HY-113168AS | (±)-Butyrylcarnitine-d9 | 2936622-23-8 | Isotope-Labeled Compounds |
| HY-113168R | Butyrylcarnitine (Standard) | 25576-40-3 | Reference Standards |
| HY-113169 | Estriol 3-glucuronide | 2479-91-6 | Natural Products |
| HY-113170 | CE(20:0) | 2573-03-7 | Natural Products |
| HY-113200 | N1-Acetylspermine | 25593-72-0 | Natural Products |
| HY-113200A | N1-Acetylspermine (trihydrochloride) | 77928-70-2 | Reference compound |
| HY-113201 | Tetradecanoylcarnitine | 25597-07-3 | Natural Products |
| HY-113201R | Tetradecanoylcarnitine (Standard) | 25597-07-3 | Reference Standards |
| HY-113201S | Tetradecanoylcarnitine-d9 | 2245713-18-0 | Isotope-Labeled Compounds |
| HY-113202 | Stearoylcarnitine | 25597-09-5 | Natural Products |
| HY-113202A | DL-Stearoylcarnitine | 1976-27-8 | Reference compound |
| HY-113202S | Stearoyl-L-carnitine-d3 | 1021439-31-5 | Isotope-Labeled Compounds |
| HY-113202S1 | Stearoyl-L-carnitine-d9 (chloride) | 2936622-19-2 | Isotope-Labeled Compounds |
| HY-113204 | N-Oleoyl glycine | 2601-90-3 | Natural Products |
| HY-113204R | N-Oleoyl glycine (Standard) | 2601-90-3 | Reference Standards |
| HY-113205 | 15-keto-Prostaglandin E2 | 26441-05-4 | Natural Products |
| HY-113205S | 15-Keto-prostaglandin E2-d9 | | Isotope-Labeled Compounds |
| HY-113205S1 | 15-Keto-prostaglandin E2-d4 | | Isotope-Labeled Compounds |
| HY-113206 | D-Sedoheptulose 7-phosphate | 2646-35-7 | Natural Products |
| HY-113206A | D-Sedoheptulose-7-phosphate (barium) | 17187-72-3 | Reference compound |
| HY-113208 | 13,14-Dihydro-15-keto Prostaglandin F2α | 27376-76-7 | Natural Products |
| HY-113208A | 11β-13,14-Dihydro-15-keto Prostaglandin F2α | 107615-77-0 | Reference compound |
| HY-113208AS1 | 11β-13,14-Dihydro-15-keto Prostaglandin F2α-d4 | | Isotope-Labeled Compounds |
| HY-113209 | 8-Isoprostaglandin F2α | 27415-26-5 | Natural Products |
| HY-113209A | ent-8-Iso-15(S)-prostaglandin F2α | 214748-66-0 | Reference compound |
| HY-113209R | 8-Isoprostaglandin F2α (Standard) | 27415-26-5 | Reference Standards |
| HY-113209S | 8-Iso-PGF2a-d4 | 211105-40-7 | Isotope-Labeled Compounds |
| HY-113209S1 | 8-iso Prostaglandin F2α-d9 | | Isotope-Labeled Compounds |
| HY-113209S2 | 8-Isoprostaglandin F2α-13C5 | | Isotope-Labeled Compounds |
| HY-113210 | Hydroxyphenylacetylglycine | 28116-23-6 | Natural Products |
| HY-113212 | Ursocholic acid | 2955-27-3 | Natural Products |
| HY-113212R | Ursocholic acid (Standard) | 2955-27-3 | Reference Standards |
| HY-113212S | Ursocholic acid-d4 | | Isotope-Labeled Compounds |
| HY-113214 | 3,5-Diiodo-L-tyrosine | 300-39-0 | Natural Products |
| HY-113214R | 3,5-Diiodo-L-tyrosine (Standard) | 300-39-0 | Reference Standards |
| HY-113215 | Allotetrahydrocortisol | 302-91-0 | Natural Products |
| HY-113215S | Allotetrahydrocortisol-d5 | 2687961-06-2 | Isotope-Labeled Compounds |
| HY-113216 | Asymmetric dimethylarginine | 30315-93-6 | Natural Products |
| HY-113216AS | Asymmetric dimethylarginine-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-113216B | Asymmetric dimethylarginine (dihydrochloride) | 220805-22-1 | Reference compound |
| HY-113216BS | Asymmetric-dimethylarginine-d6 (dihydrochloride) | 1313730-20-9 | Isotope-Labeled Compounds |
| HY-113216R | Asymmetric dimethylarginine (Standard) | 30315-93-6 | Reference Standards |
| HY-113216S | Asymmetric dimethylarginine-d7 (hydrochloride hydrate) | | Isotope-Labeled Compounds |
| HY-113217 | Cholesteryl oleate | 303-43-5 | Natural Products |
| HY-113217S | Cholesteryl oleate-d7 | 1416275-35-8 | Isotope-Labeled Compounds |
| HY-113217S1 | Cholesteryl oleate-d7-1 | 2260669-48-3 | Isotope-Labeled Compounds |
| HY-113218 | Acetyl-L-carnitine | 3040-38-8 | Natural Products |
| HY-113218S | Acetyl-L-carnitine-d9 | 203805-90-7 | Isotope-Labeled Compounds |
| HY-113219 | Hydroxyphenyllactic acid | 306-23-0 | Natural Products |
| HY-113219R | Hydroxyphenyllactic acid (Standard) | 306-23-0 | Reference Standards |
| HY-113220 | Monoisobutyl phthalic acid | 30833-53-5 | Natural Products |
| HY-113220S | Monoisobutyl phthalic acid-d4 | 1219802-26-2 | Isotope-Labeled Compounds |
| HY-113221 | Isovalerylcarnitine | 31023-24-2 | Natural Products |
| HY-113221AS | Isovalerylcarnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-113221R | Isovalerylcarnitine (Standard) | 31023-24-2 | Reference Standards |
| HY-113224 | Desmosterol | 313-04-2 | Natural Products |
| HY-113224R | Desmosterol (Standard) | 313-04-2 | Reference Standards |
| HY-113224S | Desmosterol-d6 | 1246298-67-8 | Isotope-Labeled Compounds |
| HY-113225 | Guanosine triphosphate | 86-01-1 | Oligonucleotides |
| HY-113225B | Guanosine triphosphate (tritris) | 103192-46-7 | Reference compound |
| HY-113225S1 | Guanosine triphosphate-13C10,15N5 (tetraammonium) | | Isotope-Labeled Compounds |
| HY-113225S2 | Guanosine triphosphate-13C (dilithium) | | Isotope-Labeled Compounds |
| HY-113225S3 | Guanosine triphosphate-15N5 (dilithium) | | Isotope-Labeled Compounds |
| HY-113225S4 | Guanosine triphosphate-15N5,d14 (dilithium) | | Isotope-Labeled Compounds |
| HY-113225S5 | Guanosine triphosphate-13C10 (dilithium) | | Isotope-Labeled Compounds |
| HY-113226 | Orotidine | 314-50-1 | Natural Products |
| HY-113227 | Oxoadipic acid | 3184-35-8 | Natural Products |
| HY-113227R | Oxoadipic acid (Standard) | 3184-35-8 | Reference Standards |
| HY-113228 | Isocitric acid | 320-77-4 | Natural Products |
| HY-113228R | Isocitric acid (Standard) | 320-77-4 | Reference Standards |
| HY-113230 | Galactosylhydroxylysine | 32448-36-5 | Reference compound |
| HY-113230B | Galactosylhydroxylysine (hydrochloride) | | Natural Products |
| HY-113231 | 3-(3-Hydroxyphenyl)-3-hydroxypropanoic acid | 3247-75-4 | Natural Products |
| HY-113232 | 3-Methylcrotonylglycine | 33008-07-0 | Natural Products |
| HY-113232S | 3-Methylcrotonylglycine-d2 | 1276197-31-9 | Isotope-Labeled Compounds |
| HY-113233 | 19-Noretiocholanolone | 33036-33-8 | Natural Products |
| HY-113236 | p-Synephrine | 614-35-7 | Natural Products |
| HY-113238A | Lithocholic acid 3-sulfate (disodium) | 64936-81-8 | Biochemical Assay Reagents |
| HY-113238AS | Lithocholic acid 3-sulfate-d4 (disodium) | | Isotope-Labeled Compounds |
| HY-113238F | FITC-Lithocholic acid 3-sulfate | | Dye Reagents |
| HY-113238S1 | Lithocholic acid 3-sulfate-d4（ sodium salt） | | Isotope-Labeled Compounds |
| HY-113239 | Hydroxycotinine | 34834-67-8 | Natural Products |
| HY-113239S | Hydroxycotinine-d3 | 1311275-10-1 | Isotope-Labeled Compounds |
| HY-113239S1 | rel-Hydroxycotinine-d3 | 159956-78-2 | Isotope-Labeled Compounds |
| HY-113239S2 | (Rac)-Hydroxycotinine-d3 | | Isotope-Labeled Compounds |
| HY-113242 | 5-Nonadecylresorcinol | 35176-46-6 | Natural Products |
| HY-113245 | 3-Indolyl-β-D-glucuronide | 35804-66-1 | Reference compound |
| HY-113246 | 15-keto-Prostaglandin F2a | 35850-13-6 | Reference compound |
| HY-113247 | trans-trans-Muconic acid | 3588-17-8 | Natural Products |
| HY-113247R | trans-trans-Muconic acid (Standard) | 3588-17-8 | Reference Standards |
| HY-113247S | trans-trans-Muconic acid-d4 | 1955496-83-9 | Isotope-Labeled Compounds |
| HY-113247S1 | Muconic acid-d4 | 1185239-59-1 | Isotope-Labeled Compounds |
| HY-113248 | 3-Nitro-L-tyrosine | 621-44-3 | Natural Products |
| HY-113248S | 3-Nitro-L-tyrosine-d3 | 213386-10-8 | Isotope-Labeled Compounds |
| HY-113248S1 | 3-Nitro-L-tyrosine-13C6 | | Isotope-Labeled Compounds |
| HY-113251 | 2-Hydroxyestrone | 362-06-1 | Reference compound |
| HY-113251S | 2-Hydroxyestrone-d4 | 81586-97-2 | Isotope-Labeled Compounds |
| HY-113251S1 | 2-Hydroxyestrone-13C6 | | Isotope-Labeled Compounds |
| HY-113252 | 2-Methoxyestrone | 362-08-3 | Natural Products |
| HY-113252R | 2-Methoxyestrone (Standard) | 362-08-3 | Reference Standards |
| HY-113252S | 2-Methoxyestrone-13C,d3 | 1217460-84-8 | Isotope-Labeled Compounds |
| HY-113252S1 | 2-Methoxyestrone-13C6 | | Isotope-Labeled Compounds |
| HY-113252S2 | 2-Methoxyestrone-d4 | 949885-90-9 | Isotope-Labeled Compounds |
| HY-113253A | N8-Acetylspermidine dihydrochloride | 34450-15-2 | Natural Products |
| HY-113254 | 13,14-Dihydro-15-keto-PGE2 | 363-23-5 | Reference compound |
| HY-113254S | 13,14-Dihydro-15-keto-PGE2-d4 | | Isotope-Labeled Compounds |
| HY-113254S1 | 13,14-Dihydro-15-keto-PGE2-d9 | 2750534-81-5 | Isotope-Labeled Compounds |
| HY-113256 | Linoleyl carnitine | 36816-10-1 | Natural Products |
| HY-113257 | Dopamine 4-sulfate | 38339-02-5 | Natural Products |
| HY-113259 | 7α-Hydroxy-4-cholesten-3-one | 3862-25-7 | Natural Products |
| HY-113259AS | 7β-Hydroxy-4-cholesten-3-one-d7 | 1262046-74-1 | Isotope-Labeled Compounds |
| HY-113259R | 7α-Hydroxy-4-cholesten-3-one (Standard) | 3862-25-7 | Reference Standards |
| HY-113259S | 7α-Hydroxy-4-cholesten-3-one-d7 | 2260669-17-6 | Isotope-Labeled Compounds |
| HY-113261 | Oleoylcarnitine | 38677-66-6 | Natural Products |
| HY-113261A | (Rac)-Oleoylcarnitine | 13962-05-5 | Natural Products |
| HY-113261R | Oleoylcarnitine (Standard) | 38677-66-6 | Reference Standards |
| HY-113261S | Oleoylcarnitine-d9 | 2847775-85-1 | Isotope-Labeled Compounds |
| HY-113262 | 8-Hydroxyguanosine | 3868-31-3 | Natural Products |
| HY-113263 | 17a-Hydroxypregnenolone | 387-79-1 | Natural Products |
| HY-113263R | 17a-Hydroxypregnenolone (Standard) | 387-79-1 | Reference Standards |
| HY-113263S | 17a-Hydroxypregnenolone-d3 | 105078-92-0 | Isotope-Labeled Compounds |
| HY-113263S1 | 17α-Hydroxypregnenolone-13C2,d2 | 2483824-29-7 | Isotope-Labeled Compounds |
| HY-113264 | PGD2 ethanolamide | 398138-28-8 | Reference compound |
| HY-113264S | PGD2 ethanolamide-d4 | 2714417-74-8 | Isotope-Labeled Compounds |
| HY-113266 | Valerylcarnitine | 40225-14-7 | Natural Products |
| HY-113266R | Valerylcarnitine (Standard) | 40225-14-7 | Reference Standards |
| HY-113266S | Valerylcarnitine-d9 | 2847775-89-5 | Isotope-Labeled Compounds |
| HY-113268 | Biotin sulfone | 40720-05-6 | Natural Products |
| HY-113268R | Biotin sulfone (Standard) | 40720-05-6 | Reference Standards |
| HY-113269 | alpha-CEHC | 4072-32-6 | Reference compound |
| HY-113269R | alpha-CEHC (Standard) | 4072-32-6 | Reference Standards |
| HY-113270 | Actinine | 407-64-7 | Natural Products |
| HY-113270A | Actinine (chloride) | 6249-56-5 | Natural Products |
| HY-113270AS | Actinine-d9 (chloride) | 85806-17-3 | Isotope-Labeled Compounds |
| HY-113271 | 5-Androstenetriol | 4150-30-5 | Reference compound |
| HY-113273A | Diadenosine pentaphosphate (pentasodium) | 4097-04-5 | Reference compound |
| HY-113273B | Diadenosine pentaphosphate (pentaammonium) | 102783-61-9 | Reference compound |
| HY-113273C | Diadenosine pentaphosphate (pentalithium) | 94108-02-8 | Reference compound |
| HY-113274 | Pi-Methylimidazoleacetic acid | 4200-48-0 | Natural Products |
| HY-113274A | Pi-Methylimidazoleacetic acid (hydrochloride) | 1071661-55-6 | Reference compound |
| HY-113277 | 3-Methyladipic acid | 3058-01-3 | Natural Products |
| HY-113277R | 3-Methyladipic acid (Standard) | 3058-01-3 | Reference Standards |
| HY-113278 | Leucyl-phenylalanine | 3063-05-6 | Natural Products |
| HY-113279 | 7-Dehydrocholesterol | 434-16-2 | Natural Products |
| HY-113279R | 7-Dehydrocholesterol (Standard) | 434-16-2 | Reference Standards |
| HY-113279S | 7-Dehydrocholesterol-d7 | 388622-58-0 | Isotope-Labeled Compounds |
| HY-113280S | Pyridoxol 5'-phosphate-d3 | | Isotope-Labeled Compounds |
| HY-113283 | Homogentisic acid | 451-13-8 | Natural Products |
| HY-113283R | Homogentisic acid (Standard) | 451-13-8 | Reference Standards |
| HY-113284 | Succinyladenosine | 4542-23-8 | Natural Products |
| HY-113285 | Ureidopropionic acid | 462-88-4 | Natural Products |
| HY-113285F | FITC-Ureidopropionic acid | | Dye Reagents |
| HY-113285R | Ureidopropionic acid (Standard) | 462-88-4 | Reference Standards |
| HY-113286 | 4-Guanidinobutanoic acid | 463-00-3 | Natural Products |
| HY-113286R | 4-Guanidinobutanoic acid (Standard) | 463-00-3 | Reference Standards |
| HY-113288 | Campestanol | 474-60-2 | Natural Products |
| HY-113289 | Brassicasterol | 474-67-9 | Reference compound |
| HY-113289R | Brassicasterol (Standard) | 474-67-9 | Reference Standards |
| HY-113291 | 5'-Deoxyadenosine | 4754-39-6 | Natural Products |
| HY-113291R | 5'-Deoxyadenosine (Standard) | 4754-39-6 | Reference Standards |
| HY-113293 | Estrone sulfate | 481-97-0 | Reference compound |
| HY-113293A | Estrone sulfate (potassium) | 1240-04-6 | Natural Products |
| HY-113293B | Estrone sulfate (sodium) | 438-67-5 | Natural Products |
| HY-113293BS | Estrone sulfate-d5 (sodium) | 2734919-86-7 | Isotope-Labeled Compounds |
| HY-113293BS1 | Estrone sulfate-d4 (sodium) | 285979-80-8 | Isotope-Labeled Compounds |
| HY-113294 | 3-Hydroxykynurenine | 484-78-6 | Reference compound |
| HY-113294R | 3-Hydroxykynurenine (Standard) | 484-78-6 | Reference Standards |
| HY-113294S | 3-Hydroxykynurenine-13C3,15N | 2267306-16-9 | Isotope-Labeled Compounds |
| HY-113295 | Salicyluric acid | 487-54-7 | Natural Products |
| HY-113295R | Salicyluric acid (Standard) | 487-54-7 | Reference Standards |
| HY-113295S | Salicyluric acid-13C2,15N | 1286521-95-6 | Isotope-Labeled Compounds |
| HY-113295S3 | Salicyluric acid-d4 | | Isotope-Labeled Compounds |
| HY-113296S | Indoxyl sulfate-13C6 (potassium) | | Isotope-Labeled Compounds |
| HY-113298 | Citraconic acid | 498-23-7 | Natural Products |
| HY-113298R | Citraconic acid (Standard) | 498-23-7 | Reference Standards |
| HY-113299 | Metanephrine | 5001-33-2 | Reference compound |
| HY-113301 | Hexacosanoic acid | 506-46-7 | Natural Products |
| HY-113301R | Hexacosanoic acid (Standard) | 506-46-7 | Reference Standards |
| HY-113301S | Hexacosanoic acid-d4 | 1208837-79-9 | Isotope-Labeled Compounds |
| HY-113301S1 | Hexacosanoic acid-d4-1 | 1194984-85-4 | Isotope-Labeled Compounds |
| HY-113301S2 | Hexacosanoic acid-d3 | 2692624-17-0 | Isotope-Labeled Compounds |
| HY-113302 | 19-Hydroxyandrost-4-ene-3,17-dione | 510-64-5 | Natural Products |
| HY-113303 | FAPy-adenine | 5122-36-1 | Natural Products |
| HY-113304 | (S)-3,4-Dihydroxybutyric acid | 51267-44-8 | Natural Products |
| HY-113304A | (S)-3,4-Dihydroxybutyric acid (lithium hydrate) | | Reference compound |
| HY-113305 | Dopamine 3-O-sulfate | 51317-41-0 | Natural Products |
| HY-113306 | 1-Methyladenine | 5142-22-3 | Natural Products |
| HY-113308 | Taurolithocholic acid | 516-90-5 | Natural Products |
| HY-113308A | Taurolithocholic acid (sodium salt) | 6042-32-6 | Natural Products |
| HY-113308AS | Taurolithocholic acid-d4 (sodium) | 2410279-97-7 | Isotope-Labeled Compounds |
| HY-113308AS1 | Taurolithocholic Acid-d5 (sodium salt) | 1265476-97-8 | Isotope-Labeled Compounds |
| HY-113308AS2 | Taurolithocholic acid-d4-1 (sodium) | | Isotope-Labeled Compounds |
| HY-113308S | Taurolithocholic acid-d5 | 1265681-64-8 | Isotope-Labeled Compounds |
| HY-113308S1 | Taurolithocholic acid-d4 | 2410279-96-6 | Isotope-Labeled Compounds |
| HY-113313 | Aldosterone | 52-39-1 | Natural Products |
| HY-113313R | Aldosterone (Standard) | 52-39-1 | Reference Standards |
| HY-113313S | Aldosterone-d8 | 1261254-31-2 | Isotope-Labeled Compounds |
| HY-113313S1 | Aldosterone-d7 | | Isotope-Labeled Compounds |
| HY-113313S2 | Aldosterone-d4 | | Isotope-Labeled Compounds |
| HY-113314 | AFMK | 52450-38-1 | Reference compound |
| HY-113315 | 3b-Hydroxy-5-cholenoic acid | 5255-17-4 | Natural Products |
| HY-113315R | 3b-Hydroxy-5-cholenoic acid (Standard) | 5255-17-4 | Reference Standards |
| HY-113315S | 3b-Hydroxy-5-cholenoic acid-d4 | 2770684-32-5 | Isotope-Labeled Compounds |
| HY-113316A | (±)-Salsolinol (hydrochloride) | 79923-51-6 | Natural Products |
| HY-113316B | (S)-Salsolinol | 27740-96-1 | Natural Products |
| HY-113317 | L-Xylulose | 527-50-4 | Reference compound |
| HY-113318 | Coproporphyrin I | 531-14-6 | Reference compound |
| HY-113319 | β-D-Fructose,98%(mixtures) | 53188-23-1 | Biochemical Assay Reagents |
| HY-113320 | Etiocholanolone | 53-42-9 | Natural Products |
| HY-113320R | Etiocholanolone (Standard) | 53-42-9 | Reference Standards |
| HY-113320S | Etiocholanolone-d5 | 1620102-33-1 | Isotope-Labeled Compounds |
| HY-113320S1 | Etiocholanolone-d2 | 2687960-82-1 | Isotope-Labeled Compounds |
| HY-113322 | 3-Hydroxyquinine | 53467-23-5 | Reference compound |
| HY-113322S | (3S)-3-Hydroxy quinidine-vinyl-d3 | | Isotope-Labeled Compounds |
| HY-113323 | 3-Methoxy-4-hydroxyphenylglycol | 534-82-7 | Reference compound |
| HY-113323S | 3-Methoxy-4-hydroxyphenylglycol-d3 | 74495-72-0 | Isotope-Labeled Compounds |
| HY-113324 | NADPH | 53-57-6 | Natural Products |
| HY-113325 | NADP | 53-59-8 | Natural Products |
| HY-113325A | NADP (sodium hydrate) | 698999-85-8 | Reference compound |
| HY-113327 | 1,3,7-Trimethyluric acid | 5415-44-1 | Natural Products |
| HY-113327R | 1,3,7-Trimethyluric acid (Standard) | 5415-44-1 | Reference Standards |
| HY-113327S | 1,3,7-Trimethyluric acid-d9 | 117490-42-3 | Isotope-Labeled Compounds |
| HY-113328 | Aminoadipic acid | 542-32-5 | Natural Products |
| HY-113328R | Aminoadipic acid (Standard) | 542-32-5 | Reference Standards |
| HY-113328S | Aminoadipic acid-d3 | 2483832-01-3 | Isotope-Labeled Compounds |
| HY-113328S1 | Aminoadipic acid-d6 | 2509058-79-9 | Isotope-Labeled Compounds |
| HY-113329 | Guanidinoethyl sulfonate | 543-18-0 | Reference compound |
| HY-113330 | 12S-HHT | 54397-84-1 | Reference compound |
| HY-113331 | Thromboxane B2 | 54397-85-2 | Reference compound |
| HY-113331S | Thromboxane B2-d4 | 1346112-79-5 | Isotope-Labeled Compounds |
| HY-113331S1 | Thromboxane B2-d9 | | Isotope-Labeled Compounds |
| HY-113332 | Myristoleic acid | 544-64-9 | Natural Products |
| HY-113332R | Myristoleic acid (Standard) | 544-64-9 | Reference Standards |
| HY-113334 | Turanose | 547-25-1 | Natural Products |
| HY-113334R | Turanose (Standard) | 547-25-1 | Reference Standards |
| HY-113335 | Trihydroxycholestanoic acid | 547-98-8 | Reference compound |
| HY-113335S | Trihydroxycholestanoic acid-d3 | 338976-79-7 | Isotope-Labeled Compounds |
| HY-113335S1 | Trihydroxycholestanoic acid-d5 | 2936622-49-8 | Isotope-Labeled Compounds |
| HY-113336 | 15(S)-HETE | 54845-95-3 | Natural Products |
| HY-113336A | 15(R)-HETE | 83603-31-0 | Reference compound |
| HY-113336B | (±)15-HETE | 71030-36-9 | Reference compound |
| HY-113336S | 15(S)-HETE-d8 | 84807-87-4 | Isotope-Labeled Compounds |
| HY-113337 | Ap4A | 5542-28-9 | Reference compound |
| HY-113337A | Ap4A (tetraammonium) | 102783-36-8 | Reference compound |
| HY-113338 | 8-Hydroxyguanine | 5614-64-2 | Natural Products |
| HY-113338A | 8-Hydroxyguanine (hydrochloride) | 1246818-54-1 | Reference compound |
| HY-113340 | 2-Furoylglycine | 5657-19-2 | Natural Products |
| HY-113341 | 7β-Hydroxycholesterol | 566-27-8 | Reference compound |
| HY-113341S | 7ß-Hydroxycholesterol-d7 | 349553-97-5 | Isotope-Labeled Compounds |
| HY-113342 | 7-Ketocholesterol | 566-28-9 | Natural Products |
| HY-113342S | 7-Keto Cholesterol-d7 | 127684-08-6 | Isotope-Labeled Compounds |
| HY-113344 | 16α-Hydroxyestrone | 566-76-7 | Reference compound |
| HY-113345 | Zymostenol | 566-97-2 | Reference compound |
| HY-113345R | Zymostenol (Standard) | 566-97-2 | Reference Standards |
| HY-113345S | Zymostenol-d7 | 2260669-19-8 | Isotope-Labeled Compounds |
| HY-113346 | Tetrahydrodeoxycorticosterone | 567-03-3 | Reference compound |
| HY-113346S | Tetrahydrodeoxycorticosterone-d3 | 72205-58-4 | Isotope-Labeled Compounds |
| HY-113347 | cis-5-Tetradecenoic acid | 5684-70-8 | Reference compound |
| HY-113350 | Thromboxane A2 | 57576-52-0 | Reference compound |
| HY-113351 | 11β-Hydroxyandrosterone | 57-61-4 | Natural Products |
| HY-113352 | 7-Methylguanine | 578-76-7 | Natural Products |
| HY-113352R | 7-Methylguanine (Standard) | 578-76-7 | Reference Standards |
| HY-113352S | 7-Methylguanine-d3 | 17829-03-7 | Isotope-Labeled Compounds |
| HY-113353 | Nicotinuric acid | 583-08-4 | Natural Products |
| HY-113353R | Nicotinuric acid (Standard) | 583-08-4 | Reference Standards |
| HY-113353S | Nicotinuric acid-d4 | 1216737-36-8 | Isotope-Labeled Compounds |
| HY-113354 | Anserine | 584-85-0 | Natural Products |
| HY-113354R | Anserine (Standard) | 584-85-0 | Reference Standards |
| HY-113354S | Anserine-d4 | 1201658-81-2 | Isotope-Labeled Compounds |
| HY-113354S1 | Anserine-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-113355 | NADH | 58-68-4 | Reference compound |
| HY-113356 | m-Tyramine | 588-05-6 | Natural Products |
| HY-113357 | m-Coumaric acid | 588-30-7 | Natural Products |
| HY-113357R | m-Coumaric acid (Standard) | 588-30-7 | Reference Standards |
| HY-113357S | m-Coumaric acid-13C3 | 1261170-79-9 | Isotope-Labeled Compounds |
| HY-113358 | 6-keto Prostaglandin F1α | 58962-34-8 | Natural Products |
| HY-113358S | 6-keto Prostaglandin F1α-d4 | 82414-64-0 | Isotope-Labeled Compounds |
| HY-113359 | Uridine 5'-diphosphate | 58-98-0 | Reference compound |
| HY-113359AS | Uridine 5'-diphosphate-d12 (dilithium) | | Isotope-Labeled Compounds |
| HY-113359AS1 | Uridine 5'-diphosphate-13C9 (dilithium) | | Isotope-Labeled Compounds |
| HY-113359AS2 | Uridine 5'-diphosphate-13C9,15N2 (dilithium) | | Isotope-Labeled Compounds |
| HY-113359AS3 | Uridine 5'-diphosphate-15N2 (dilithium) | | Isotope-Labeled Compounds |
| HY-113360 | Chenodeoxycholic acid 3-sulfate | 59132-32-0 | Reference compound |
| HY-113362 | Petroselinic acid | 593-39-5 | Natural Products |
| HY-113362R | Petroselinic acid (Standard) | 593-39-5 | Reference Standards |
| HY-113365 | Cholestenone | 601-57-0 | Natural Products |
| HY-113365R | Cholestenone (Standard) | 601-57-0 | Reference Standards |
| HY-113365S | Cholestenone-d5 | 72560-60-2 | Isotope-Labeled Compounds |
| HY-113365S1 | Cholestenone-13C | 68165-57-1 | Isotope-Labeled Compounds |
| HY-113365S2 | Cholestenone-13C2 | 82938-09-8 | Isotope-Labeled Compounds |
| HY-113365S3 | Cholestenone-d7 | 2389048-48-8 | Isotope-Labeled Compounds |
| HY-113366 | Prostaglandin J2 | 60203-57-8 | Reference compound |
| HY-113366S | Prostaglandin J2-d4 | 2738376-80-0 | Isotope-Labeled Compounds |
| HY-113367 | Suberylglycine | 60317-54-6 | Natural Products |
| HY-113367S | Suberylglycine-d4 | 2469259-73-0 | Isotope-Labeled Compounds |
| HY-113367S1 | Suberylglycine-d2 | 1219799-02-6 | Isotope-Labeled Compounds |
| HY-113369 | Cholesteryl arachidonate | 604-34-2 | Natural Products |
| HY-113369S | Cholesteryl arachidonate-d8 | | Isotope-Labeled Compounds |
| HY-113371 | 2-Methylcitric acid | 6061-96-7 | Natural Products |
| HY-113371A | 2-Methylcitric acid (trisodium) | 117041-96-0 | Reference compound |
| HY-113371AS | 2-Methylcitric acid-d3 (trisodium) | 2483831-23-6 | Isotope-Labeled Compounds |
| HY-113371R | 2-Methylcitric acid (Standard) | 6061-96-7 | Reference Standards |
| HY-113371S | 2-Methylcitric acid-d3 | 146764-58-1 | Isotope-Labeled Compounds |
| HY-113373 | Guanidinosuccinic acid | 6133-30-8 | Natural Products |
| HY-113374A | N1,N12-Diacetylspermine (dihydrochloride) | 77928-71-3 | Reference compound |
| HY-113375 | D-Ribofuranose | 613-83-2 | Natural Products |
| HY-113376 | Etiocholanolone glucuronide | 3602-09-3 | Reference compound |
| HY-113377 | L-Glyceric acid | 28305-26-2 | Natural Products |
| HY-113377A | L-Glyceric acid (sodium) | 146298-95-5 | Natural Products |
| HY-113378 | 3-Hydroxybutyric acid | 300-85-6 | Natural Products |
| HY-113378R | 3-Hydroxybutyric acid (Standard) | 300-85-6 | Reference Standards |
| HY-113378S | 3-Hydroxybutyric acid-d4 (sodium) | 1219804-68-8 | Isotope-Labeled Compounds |
| HY-113379 | 2,3-Diaminopropionic acid | 4033-39-0 | Natural Products |
| HY-113380 | (S)-b-aminoisobutyric acid | 4249-19-8 | Natural Products |
| HY-113380R | (S)-b-aminoisobutyric acid (Standard) | 4249-19-8 | Reference Standards |
| HY-113381 | 2-Hydroxybutyric acid | 600-15-7 | Reference compound |
| HY-113381A | (R)-2-Hydroxybutanoic acid | 20016-85-7 | Reference compound |
| HY-113381B | (R)-2-Hydroxybutanoic acid (sodium) | 2307465-23-0 | Reference compound |
| HY-113382 | N-Methylhydantoin | 616-04-6 | Natural Products |
| HY-113382R | N-Methylhydantoin (Standard) | 616-04-6 | Reference Standards |
| HY-113400 | Cytidine 5'-diphosphate | 63-38-7 | Natural Products |
| HY-113400S | Cytidine diphosphate-15N3 (dilithium) | | Isotope-Labeled Compounds |
| HY-113400S1 | Cytidine diphosphate-13C9 (dilithium) | | Isotope-Labeled Compounds |
| HY-113400S2 | Cytidine diphosphate-13C9,15N3 (dilithium) | | Isotope-Labeled Compounds |
| HY-113400S3 | Cytidine diphosphate-d13 (dilithium) | | Isotope-Labeled Compounds |
| HY-113401 | Adenosine 2',3'-cyclic phosphate | 634-01-5 | Natural Products |
| HY-113402 | Gamma-glutamylcysteine | 636-58-8 | Natural Products |
| HY-113402A | Gamma-glutamylcysteine (TFA) | 283159-88-6 | Reference compound |
| HY-113402R | Gamma-glutamylcysteine (Standard) | 636-58-8 | Reference Standards |
| HY-113403 | Pyridinoline | 63800-01-1 | Natural Products |
| HY-113404 | DL-Dopa | 63-84-3 | Natural Products |
| HY-113404S | DL-Dopa-d6 | | Isotope-Labeled Compounds |
| HY-113404S1 | L-Dopa-d3 | 157929-66-3 | Isotope-Labeled Compounds |
| HY-113405 | 21-Deoxycortisol | 641-77-0 | Natural Products |
| HY-113405R | 21-Deoxycortisol (Standard) | 641-77-0 | Reference Standards |
| HY-113405S | 21-Desoxycortisol-d4 | | Isotope-Labeled Compounds |
| HY-113405S1 | 21-Deoxycortisol-d8 | 2479914-04-8 | Isotope-Labeled Compounds |
| HY-113406 | (±)-Hexanoylcarnitine | 6418-78-6 | Natural Products |
| HY-113407 | D-Fructose-6-phosphate | 643-13-0 | Natural Products |
| HY-113407A | D-Fructose-6-phosphate (disodium) | 26177-86-6 | Natural Products |
| HY-113407C | D-Fructose-6-phosphate (disodium monohydrate) | | Natural Products |
| HY-113407CR | D-Fructose-6-phosphate (disodium monohydrate) (Standard) | | Reference Standards |
| HY-113408 | Tiglyl carnitine | 64681-36-3 | Natural Products |
| HY-113408R | Tiglyl carnitine (Standard) | 64681-36-3 | Reference Standards |
| HY-113409 | 3-Hydroxyisovaleric acid | 625-08-1 | Natural Products |
| HY-113409R | 3-Hydroxyisovaleric acid (Standard) | 625-08-1 | Reference Standards |
| HY-113410 | 3-Methylglutaric acid | 626-51-7 | Natural Products |
| HY-113410R | 3-Methylglutaric acid (Standard) | 626-51-7 | Reference Standards |
| HY-113410S | 3-Methylglutaric acid-d4 | 1219798-68-1 | Isotope-Labeled Compounds |
| HY-113411 | 3-Hydroxyglutaric acid | 638-18-6 | Natural Products |
| HY-113411S | 3-Hydroxyglutaric acid-d5 | 1219805-72-7 | Isotope-Labeled Compounds |
| HY-113412A | 3-Methylhistamine (dihydrochloride) | 36475-47-5 | Natural Products |
| HY-113412AR | 3-Methylhistamine (dihydrochloride) (Standard) | 36475-47-5 | Reference Standards |
| HY-113413 | Imidazoleacetic acid | 645-65-8 | Natural Products |
| HY-113413R | Imidazoleacetic acid (Standard) | 645-65-8 | Reference Standards |
| HY-113414 | Deoxycorticosterone | 64-85-7 | Natural Products |
| HY-113414R | Deoxycorticosterone (Standard) | 64-85-7 | Reference Standards |
| HY-113414S | Deoxycorticosterone-d8 | 55487-63-3 | Isotope-Labeled Compounds |
| HY-113415 | Testosterone sulfate | 651-45-6 | Reference compound |
| HY-113415A | Testosterone sulfate (pyridinium) | 34991-10-1 | Reference compound |
| HY-113416 | Dehydroepiandrosterone sulfate | 651-48-9 | Reference compound |
| HY-113416AS | Dehydroepiandrosterone sulfate-d6 (sodium dihydrate) | | Isotope-Labeled Compounds |
| HY-113416R | Dehydroepiandrosterone sulfate (Standard) | 651-48-9 | Reference Standards |
| HY-113418 | Beta-Cortol | 667-65-2 | Reference compound |
| HY-113420 | 11-Dehydro-thromboxane B2 | 67910-12-7 | Natural Products |
| HY-113420S | 11-Dehydro-thromboxane B2-d4 | 1240398-15-5 | Isotope-Labeled Compounds |
| HY-113420S2 | 11-Dehydro-thromboxane B2-13C5 | | Isotope-Labeled Compounds |
| HY-113421 | Linoleoyl ethanolamide | 68171-52-8 | Reference compound |
| HY-113421S | Linoleoyl ethanolamide-d4 | 1451194-69-6 | Isotope-Labeled Compounds |
| HY-113422S | Tetrahydrocorticosterone-d5 | | Isotope-Labeled Compounds |
| HY-113422S1 | Tetrahydrocorticosterone-d3 | | Isotope-Labeled Compounds |
| HY-113423 | Tetrahydro-11-deoxycortisol | 68-60-0 | Reference compound |
| HY-113424A | 1,2-Dioleoyl-sn-glycero-3-phosphocholine | 4235-95-4 | Oligonucleotides |
| HY-113424AS | 1,2-Dioleoyl-sn-glycero-3-phosphocholine-d9 | | Isotope-Labeled Compounds |
| HY-113426 | Nepsilon-Acetyl-L-lysine | 692-04-6 | Natural Products |
| HY-113426S | Nepsilon-acetyl-L-lysine-d8 | | Isotope-Labeled Compounds |
| HY-113427 | trans-Vaccenic acid | 693-72-1 | Natural Products |
| HY-113427A | cis-Vaccenic acid | 506-17-2 | Natural Products |
| HY-113427AR | cis-Vaccenic acid (Standard) | 506-17-2 | Reference Standards |
| HY-113427AS | cis-Vaccenic acid-d13 | | Isotope-Labeled Compounds |
| HY-113427R | trans-Vaccenic acid (Standard) | 693-72-1 | Reference Standards |
| HY-113427S | trans-Vaccenic acid-d13 | | Isotope-Labeled Compounds |
| HY-113430 | 5-n-Heneicosylresorcinol | 70110-59-7 | Natural Products |
| HY-113431 | Arabinosylhypoxanthine | 7013-16-3 | Reference compound |
| HY-113432 | Nudifloramide | 701-44-0 | Natural Products |
| HY-113432R | Nudifloramide (Standard) | 701-44-0 | Reference Standards |
| HY-113432S | Nudifloramide-d3 | 1207384-48-2 | Isotope-Labeled Compounds |
| HY-113432S1 | Nudifloramide-d6 | 2012598-72-8 | Isotope-Labeled Compounds |
| HY-113434 | 5(S)-HETE | 70608-72-9 | Reference compound |
| HY-113434A | 5(R)-HETE | 61641-47-2 | Reference compound |
| HY-113434B | 5-HETE | 71030-39-2 | Reference compound |
| HY-113434S | 5(S)-HETE-d8 | 330796-62-8 | Isotope-Labeled Compounds |
| HY-113435 | 8-Dehydrocholesterol | 70741-38-7 | Natural Products |
| HY-113436 | Cholesteryl 11-eicosenoate | 70832-37-0 | Natural Products |
| HY-113437 | 1,2-Dipalmitoyl-sn-glycerol 3-phosphate | 7091-44-3 | Reference compound |
| HY-113437A | 1,2-Dipalmitoyl-sn-glycerol 3-phosphate (sodium) | 169051-60-9 | Natural Products |
| HY-113437AS | 1,2-Dipalmitoyl-sn-glycerol 3-phosphate-d62 (sodium) | 327179-00-0 | Isotope-Labeled Compounds |
| HY-113438 | 15(S)-HPETE | 70981-96-3 | Reference compound |
| HY-113439 | 12-HETE | 71030-37-0 | Reference compound |
| HY-113439S | 12-HETE-d8 | 2525175-25-9 | Isotope-Labeled Compounds |
| HY-113440 | 5-Methoxytryptophol | 712-09-4 | Natural Products |
| HY-113441 | 4-Hydroxy-3-methoxyphenylglycol sulfate (potassium) | 71324-20-4 | Reference compound |
| HY-113441S | 3-Methoxy-4-Hydroxyphenylglycol sulfate-d3 (potassium) | 474909-54-1 | Isotope-Labeled Compounds |
| HY-113442 | 6-trans-12-epi-Leukotriene B4 | 71548-19-1 | Reference compound |
| HY-113442A | 6-trans-Leukotriene B4 | 71652-82-9 | Reference compound |
| HY-113443 | 12(S)-HPETE | 71774-10-2 | Reference compound |
| HY-113444 | Prostaglandin D3 | 71902-47-1 | Reference compound |
| HY-113445 | Thromboxane B3 | 71953-80-5 | Reference compound |
| HY-113446 | Leukotriene C4 | 72025-60-6 | Reference compound |
| HY-113446R | Leukotriene C4 (Standard) | 72025-60-6 | Reference Standards |
| HY-113446S | Leukotriene C4-d5 | 1441421-73-3 | Isotope-Labeled Compounds |
| HY-113447 | 11-Dehydrocorticosterone | 72-23-1 | Reference compound |
| HY-113448 | CE(20:3(8Z,11Z,14Z)) | 7274-08-0 | Reference compound |
| HY-113449 | Ubiquinone-1 | 727-81-1 | Natural Products |
| HY-113450 | 10Z-Nonadecenoic acid | 73033-09-7 | Natural Products |
| HY-113451 | 3-Hydroxysebacic acid | 73141-46-5 | Reference compound |
| HY-113451R | 3-Hydroxysebacic acid (Standard) | 73141-46-5 | Reference Standards |
| HY-113453 | 11(R)-HETE | 73347-43-0 | Reference compound |
| HY-113453A | 11-S-Hydroxyeicosatetraenoic acid | 54886-50-9 | Natural Products |
| HY-113455 | 9S-HODE | 73543-67-6 | Reference compound |
| HY-113455S | 9S-HODE-d4 | 890955-25-6 | Isotope-Labeled Compounds |
| HY-113455S1 | 9(S)-HODE-13C18 | | Isotope-Labeled Compounds |
| HY-113456 | Leukotriene D4 | 73836-78-9 | Reference compound |
| HY-113456S | Leukotriene D4-d5 | 1240398-17-7 | Isotope-Labeled Compounds |
| HY-113457 | 11-Oxo etiocholanolone | 739-27-5 | Natural Products |
| HY-113457S | 11-Oxo etiocholanolone-d5 | | Isotope-Labeled Compounds |
| HY-113459 | Prostaglandin F1a | 745-62-0 | Reference compound |
| HY-113459S | Prostaglandin F1a-d9 | 1542166-81-3 | Isotope-Labeled Compounds |
| HY-113459S1 | 13,14-Dihydro-15-keto Prostaglandin F2α-d4 | 42932-59-2 | Isotope-Labeled Compounds |
| HY-113460 | 11-trans-Leukotriene C4 | 74841-69-3 | Reference compound |
| HY-113461 | 13,14-Dihydro-15-keto-prostaglandin A2 | 74872-89-2 | Reference compound |
| HY-113462 | α-Carotene | 7488-99-5 | Natural Products |
| HY-113462R | α-Carotene (Standard) | 7488-99-5 | Reference Standards |
| HY-113463 | CE(20:5(5Z,8Z,11Z,14Z,17Z) | 74892-97-0 | Natural Products |
| HY-113465 | Leukotriene E4 | 75715-89-8 | Reference compound |
| HY-113465A | 11-trans Leukotriene E4 | 75715-88-7 | Reference compound |
| HY-113465S | Leukotriene E4-d5 | 1240398-14-4 | Isotope-Labeled Compounds |
| HY-113466 | 4-Hydroxynonenal | 75899-68-2 | Reference compound |
| HY-113466S | 4-Hydroxynonenal-d3 | 148706-06-3 | Isotope-Labeled Compounds |
| HY-113468 | 3-O-Methyl-DL-DOPA | 7636-26-2 | Reference compound |
| HY-113468A | 3-O-Methyldopa | 300-48-1 | Natural Products |
| HY-113468AS | 3-O-Methyldopa-d3 | 586954-09-8 | Isotope-Labeled Compounds |
| HY-113468AS1 | 3-O-Methyldopa-d3 (hydrate) | | Isotope-Labeled Compounds |
| HY-113468R | 3-O-Methyl-DL-DOPA (Standard) | 7636-26-2 | Reference Standards |
| HY-113469 | Cyclic GMP | 7665-99-8 | Natural Products |
| HY-113469A | Cyclic GMP (sodium) | 40732-48-7 | Natural Products |
| HY-113469B | Cyclic GMP (TBAOH) | | Oligonucleotides |
| HY-113469R | Cyclic GMP (Standard) | 7665-99-8 | Reference Standards |
| HY-113470 | LysoPC(16:1(9Z)) | 76790-27-7 | Reference compound |
| HY-113471 | Perillic acid | 7694-45-3 | Reference compound |
| HY-113471A | (S)-(-)-Perillic acid | 23635-14-5 | Natural Products |
| HY-113472 | N-Methyl-4-pyridone-3-carboxamide | 769-49-3 | Natural Products |
| HY-113472R | N-Methyl-4-pyridone-3-carboxamide (Standard) | 769-49-3 | Reference Standards |
| HY-113472S | N-Methyl-4-pyridone-3-carboxamide-d3 | 1207384-47-1 | Isotope-Labeled Compounds |
| HY-113473 | 10-Nitrolinoleic acid | 774603-04-2 | Reference compound |
| HY-113474 | 3,4-Dihydroxymandelic acid | 775-01-9 | Natural Products |
| HY-113474R | 3,4-Dihydroxymandelic acid (Standard) | 775-01-9 | Reference Standards |
| HY-113475A | 8(S),15(S)-DiHETE | 80234-65-7 | Natural Products |
| HY-113477 | CE(20:2(6Z,9Z)) | 77715-45-8 | Natural Products |
| HY-113478 | 3β-Ursodeoxycholic acid | 78919-26-3 | Reference compound |
| HY-113478R | 3β-Ursodeoxycholic acid (Standard) | 78919-26-3 | Reference Standards |
| HY-113478S | Ursodeoxycholic acid-2,2,4,4-d4 | 347841-46-7 | Isotope-Labeled Compounds |
| HY-113479 | 20-Hydroxy-leukotriene B4 | 79516-82-8 | Reference compound |
| HY-113481 | Prostaglandin E3 | 802-31-3 | Natural Products |
| HY-113481A | 17-trans Prostaglandin E3 | 210979-33-2 | Reference compound |
| HY-113482 | 1β-Hydroxydeoxycholic acid | 80434-32-8 | Reference compound |
| HY-113482S | 1β-Hydroxydeoxycholic acid-d5 | | Isotope-Labeled Compounds |
| HY-113483 | 20-Carboxy-Leukotriene B4 | 80434-82-8 | Reference compound |
| HY-113484 | Leukotriene B5 | 80445-66-5 | Reference compound |
| HY-113485 | Melanin | 8049-97-6 | Natural Products |
| HY-113486 | Lathosterol | 80-99-9 | Natural Products |
| HY-113486R | Lathosterol (Standard) | 80-99-9 | Reference Standards |
| HY-113486S | (S)-Lathosterol-d4 | 1182005-25-9 | Isotope-Labeled Compounds |
| HY-113486S1 | lathosterol-d7 | 2260669-10-9 | Isotope-Labeled Compounds |
| HY-113488 | 8,9-Epoxyeicosatrienoic acid | 81246-85-7 | Reference compound |
| HY-113489 | 14,15-Epoxyeicosatrienoic acid | 81276-03-1 | Natural Products |
| HY-113490 | 15-KETE | 81416-72-0 | Natural Products |
| HY-113491 | 3-Phosphoglyceric acid | 820-11-1 | Reference compound |
| HY-113492 | 5(S)15(S)-DiHETE | 82200-87-1 | Reference compound |
| HY-113493 | 4-Pyridoxic acid | 82-82-6 | Natural Products |
| HY-113493R | 4-Pyridoxic acid (Standard) | 82-82-6 | Reference Standards |
| HY-113493S1 | 4-Pyridoxic acid-d3 | 1435934-03-4 | Isotope-Labeled Compounds |
| HY-113494 | Stigmastanol | 83-45-4 | Natural Products |
| HY-113494R | Stigmastanol (Standard) | 83-45-4 | Reference Standards |
| HY-113495 | Deoxypyridinoline | 83462-55-9 | Reference compound |
| HY-113498 | Sphingomyelin | 85187-10-6 | Natural Products |
| HY-113499A | cis-Malonylcarnitine | 910825-21-7 | Natural Products |
| HY-113505 | Delta-12-Prostaglandin J2 | 87893-54-7 | Reference compound |
| HY-113509 | Lipoxin A4 | 89663-86-5 | Natural Products |
| HY-113509A | 6-epi-Lipoxin A4 | 94292-80-5 | Reference compound |
| HY-113509B | 15(R)-Lipoxin A4 | 171030-11-8 | Natural Products |
| HY-113509S | Lipoxin A4-d5 | 1622429-53-1 | Isotope-Labeled Compounds |
| HY-113510 | 9(S)-HOTrE | 89886-42-0 | Natural Products |
| HY-113511 | Glycogen, Mussel | 9005-79-2 | Natural Products |
| HY-113511A | Glycogen, Oysters | 9005-79-2 | Natural Products |
| HY-113511B | Glycogen, from rabbit liver, ≥85% | 9005-79-2 | Biochemical Assay Reagents |
| HY-113511C | Glycogen, from bovine liver, ≥85% | 9005-79-2 | Biochemical Assay Reagents |
| HY-113512 | 17-HDHA | 90780-52-2 | Reference compound |
| HY-113513 | 5-HEPE | 92008-51-0 | Reference compound |
| HY-113514 | 6-Phosphogluconic acid | 921-62-0 | Reference compound |
| HY-113516 | 20-HETE Ethanolamide | 942069-11-6 | Natural Products |
| HY-113517 | Normetanephrine | 97-31-4 | Reference compound |
| HY-113517R | Normetanephrine (Standard) | 97-31-4 | Reference Standards |
| HY-113517S | (Rac)-Normetanephrine-d3 | 1073244-89-9 | Isotope-Labeled Compounds |
| HY-113519 | 14R(15S)-EET | 98103-48-1 | Reference compound |
| HY-113524 | N-Acetyl-L-aspartic acid | 997-55-7 | Natural Products |
| HY-113524R | N-Acetyl-L-aspartic acid (Standard) | 997-55-7 | Reference Standards |
| HY-113524S | N-Acetyl-L-aspartic acid-d3 | 284665-15-2 | Isotope-Labeled Compounds |
| HY-113527 | TRIA-662 | 1005-24-9 | Natural Products |
| HY-113527R | TRIA-662 (Standard) | 1005-24-9 | Reference Standards |
| HY-113527S | TRIA-662-d3 | 1218993-18-0 | Isotope-Labeled Compounds |
| HY-113529 | Stachyose (tetrahydrate) | 10094-58-3 | Natural Products |
| HY-113531 | ZK 95962 | 101071-43-6 | Reference compound |
| HY-113533 | Resolvin D4 | 1025684-60-9 | Reference compound |
| HY-113533A | 17(R)-Resolvin D4 | 528583-89-3 | Reference compound |
| HY-113534 | MV1 | 1001600-54-9 | Reference compound |
| HY-113537 | Demegestone | 10116-22-0 | Reference compound |
| HY-113542 | Blasticidin A | 100513-53-9 | Natural Products |
| HY-113543S | Desmetryn-d3 | | Isotope-Labeled Compounds |
| HY-113545 | 9(R)-HODE | 10075-11-3 | Natural Products |
| HY-113545A | (±)9-HODE | 98524-19-7 | Reference compound |
| HY-113547 | Nanterinone | 102791-47-9 | Reference compound |
| HY-113549 | Erbstatin | 100827-28-9 | Reference compound |
| HY-113553 | 4-Aminophenylphosphorylcholine | 102185-28-4 | Reference compound |
| HY-113555 | DORA 42 | 1030377-48-0 | Reference compound |
| HY-113556 | Sappanone A | 102067-84-5 | Natural Products |
| HY-113557 | DNAC-1 | 1006021-30-2 | Reference compound |
| HY-113560 | Plipastatin B1 | 103955-73-3 | Peptides |
| HY-113561 | Biphenomycin A | 100296-21-7 | Natural Products |
| HY-113562 | Laidlomycin phenylcarbamate | 101191-83-7 | Reference compound |
| HY-113567 | GSK2324 | 1020567-30-9 | Reference compound |
| HY-113568 | CAY10581 | 1018340-07-2 | Reference compound |
| HY-113569 | Armentomycin | 10139-00-1 | Reference compound |
| HY-113571 | Tie2 kinase inhibitor 2 | 1020412-97-8 | Reference compound |
| HY-113572 | PX-866-17OH | 1012327-63-7 | Reference compound |
| HY-113573 | Protosappanin A | 102036-28-2 | Natural Products |
| HY-113574 | HSP90-IN-29 | 1012788-65-6 | Reference compound |
| HY-113575 | Dehydroaripiprazole (hydrochloride) | 1008531-60-9 | Reference compound |
| HY-113575S | Dehydro Aripiprazole-d8 (hydrochloride) | 1215383-78-0 | Isotope-Labeled Compounds |
| HY-113578 | PD 116152 | 101708-64-9 | Reference compound |
| HY-113582 | Albothricin | 103867-06-7 | Natural Products |
| HY-113585 | 1,4-Dideoxy-1,4-imino-D-arabinitol (hydrochloride) | 100991-92-2 | Reference compound |
| HY-113586 | Besifovir Dipivoxil | 441785-26-8 | Reference compound |
| HY-113587 | Nicoclonate (hydrochloride) | 10400-20-1 | Reference compound |
| HY-113590 | FR295389 | 1019207-72-7 | Reference compound |
| HY-113591 | CB2 receptor agonist 10 | 1046140-32-2 | Reference compound |
| HY-113592 | ERK-IN-4 | 1049738-54-6 | Reference compound |
| HY-113593 | GSK1360707 | 1013098-04-8 | Reference compound |
| HY-113594 | ICI 200355 | 105080-32-8 | Reference compound |
| HY-113595 | Temafloxacin (hydrochloride) | 105784-61-0 | Reference compound |
| HY-113596 | Acetyl Coenzyme A (trisodium) | 102029-73-2 | Reference compound |
| HY-113596A | Acetyl coenzyme A (lithium) | 32140-51-5 | Biochemical Assay Reagents |
| HY-113596R | Acetyl Coenzyme A (trisodium) (Standard) | 102029-73-2 | Reference Standards |
| HY-113599 | Isoprocurcumenol | 102130-90-5 | Natural Products |
| HY-113600 | H-0106 (dihydrochloride) | 1011465-90-9 | Reference compound |
| HY-113601 | Linatine | 10139-06-7 | Reference compound |
| HY-113602 | Paldimycin B | 101411-71-6 | Reference compound |
| HY-113603 | Tildacerfont | 1014983-00-6 | Reference compound |
| HY-113604 | Pentabromopseudilin | 10245-81-5 | Natural Products |
| HY-113605 | Runanine | 100485-12-9 | Natural Products |
| HY-113606 | Adenosine 5'-phosphosulfate (disodium) | 102029-95-8 | Reference compound |
| HY-113608 | VCP171 | 1018830-99-3 | Reference compound |
| HY-113612 | Cytostatin | 682329-63-1 | Natural Products |
| HY-113612A | Cytostatin (sodium) | 457070-06-3 | Reference compound |
| HY-113613 | ETB067 | 1000995-79-8 | Reference compound |
| HY-113614 | Tetrahydrobostrycin | 1072119-07-3 | Natural Products |
| HY-113616 | VU0364572 | 1240514-87-7 | Reference compound |
| HY-113616A | VU0364572 (TFA) | 1240514-89-9 | Reference compound |
| HY-113618A | RO2959 (hydrochloride) | 1219927-22-6 | Reference compound |
| HY-113618B | RO2959 (monohydrochloride) | 2309172-44-7 | Reference compound |
| HY-113621B | Ageladine A (dihydrochloride) | 2757574-06-2 | Natural Products |
| HY-113622 | Cladospirone bisepoxide | 152607-03-9 | Natural Products |
| HY-113623 | Pyrenophorol | 22248-41-5 | Natural Products |
| HY-113626 | (-)-Cyclopenin | 20007-87-8 | Natural Products |
| HY-113626A | Cyclopenin | 19553-26-5 | Reference compound |
| HY-113627 | Undecylprodigiosin | 52340-48-4 | Natural Products |
| HY-113627A | Undecylprodigiosin (hydrochloride) | 56247-02-0 | Reference compound |
| HY-113628 | ABT-080 | 189498-57-5 | Reference compound |
| HY-113629 | 2-Keto-D-Glucose | 1854-25-7 | Natural Products |
| HY-113629R | 2-Keto-D-Glucose (Standard) | 1854-25-7 | Reference Standards |
| HY-113630A | 20β-22-Azacholesterol | 40521-33-3 | Natural Products |
| HY-113631 | Amorfrutin B | 78916-42-4 | Natural Products |
| HY-113632 | Debromohymenialdisine | 75593-17-8 | Natural Products |
| HY-113635 | ONO-6240 | 99659-62-8 | Reference compound |
| HY-113636 | Kazinol A | 99624-28-9 | Natural Products |
| HY-113637 | Galbonolide A | 100227-57-4 | Reference compound |
| HY-113638 | CVT-11127 | 1018674-83-3 | Peptides |
| HY-113639 | A-933548 | 1037826-43-9 | Reference compound |
| HY-113640 | BC-7013 | 1028291-66-8 | Reference compound |
| HY-113641 | ROCK-IN-32 | 1013117-40-2 | Reference compound |
| HY-113642 | CP-67804 | 103978-08-1 | Reference compound |
| HY-113643 | Levemopamil (hydrochloride) | 101238-54-4 | Reference compound |
| HY-113646 | Shield-2 | 1013621-70-9 | Reference compound |
| HY-113648 | LP10 | 1025400-45-6 | Reference compound |
| HY-113649 | AKB-6899 | 1007377-55-0 | Reference compound |
| HY-113653 | GSK2041706A | 1032824-43-3 | Reference compound |
| HY-113654 | AMG 7905 | 1026876-55-0 | Reference compound |
| HY-113655 | AD-5075 | 103788-05-2 | Reference compound |
| HY-113658 | ts-SA | 100715-13-7 | Reference compound |
| HY-113659 | 3',5'-O-Bis(isobutiryl)-4'-azido-2'-β-C-methyl-2'-deoxycytidine | 1019639-33-8 | Reference compound |
| HY-113662 | CLB-016 | 1005636-29-2 | Reference compound |
| HY-113667 | ASN04885796 | 1032892-26-4 | Reference compound |
| HY-113669 | A-940894 | 1027330-82-0 | Reference compound |
| HY-113670 | CLK1/2-IN-2 | 1005776-20-4 | Reference compound |
| HY-113671 | Belfosdil | 103486-79-9 | Reference compound |
| HY-113673 | A-935142 | 1031335-85-9 | Reference compound |
| HY-113678 | Colistin | 1066-17-7 | Reference compound |
| HY-113679 | Ceramides Mixture | 100403-19-8 | Reference compound |
| HY-113680 | KY1022 | 1029721-36-5 | Reference compound |
| HY-113681 | REV 5975 | 101820-46-6 | Reference compound |
| HY-113683 | AZ 12488024 | 1018988-00-5 | Reference compound |
| HY-113687 | T145 | 1021186-98-0 | Reference compound |
| HY-113689 | GAT211 | 102704-40-5 | Reference compound |
| HY-113690 | AHN 086 | 103625-22-5 | Reference compound |
| HY-113691 | (E)-L-652343 | 102565-09-3 | Reference compound |
| HY-113692 | AZD-9164 (bromide) | 1034916-72-7 | Reference compound |
| HY-113693 | ONO-RS-347 | 103176-67-6 | Reference compound |
| HY-113695 | BW A575C | 103221-88-1 | Reference compound |
| HY-113697 | Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD | 1037589-69-7 | Reference compound |
| HY-113700 | PD 116779 | 102674-89-5 | Reference compound |
| HY-113702 | PD 113413 | 103733-50-2 | Reference compound |
| HY-113703 | PD117588 | 99734-97-1 | Reference compound |
| HY-113704 | BKM1740 | 1070966-97-0 | Reference compound |
| HY-113711 | 15-OxoEDE | 105835-44-7 | Natural Products |
| HY-113713 | CH-38083 | 104786-63-2 | Reference compound |
| HY-113714 | C562-1101 | 1094693-07-8 | Reference compound |
| HY-113715 | Niclofolan | 10331-57-4 | Reference compound |
| HY-113716 | Adecypenol | 104493-13-2 | Reference compound |
| HY-113717 | ICL-SIRT078 | 1060430-64-9 | Reference compound |
| HY-113719 | VM4-037 | 1071470-72-8 | Reference compound |
| HY-113721 | BML-244 | 104062-70-6 | Reference compound |
| HY-113722 | DAT1 | 107401-70-7 | Reference compound |
| HY-113723 | MRS2298 | 491611-43-9 | Reference compound |
| HY-113725 | L 668411 | 112965-15-8 | Reference compound |
| HY-113726 | Nerisopam | 102771-12-0 | Reference compound |
| HY-113729 | B 746 | 103051-26-9 | Reference compound |
| HY-113730 | VUF5834 | 860002-95-5 | Reference compound |
| HY-113732 | Kazinol F | 104494-35-1 | Reference compound |
| HY-113733 | ICI-195739 | 103961-78-0 | Reference compound |
| HY-113734 | CM026 | 851941-94-1 | Reference compound |
| HY-113735 | Cephapirin Benzathine | 97468-37-6 | Reference compound |
| HY-113736 | Glycyllysine | 997-62-6 | Peptides |
| HY-113739 | Desmethylcitalopram (hydrochloride) | 97743-99-2 | Reference compound |
| HY-113739A | (S)-Desmethylcitalopram | 144025-14-9 | Reference compound |
| HY-113739S | Desmethylcitalopram-d3 (hydrochloride) | 1189650-18-7 | Isotope-Labeled Compounds |
| HY-113739S1 | Desmethylcitalopram-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-113743 | Ecomustine | 98383-18-7 | Reference compound |
| HY-113745 | LX-6171 | 914808-66-5 | Reference compound |
| HY-113748 | Rev 6207 (free base) | 98056-23-6 | Reference compound |
| HY-113749 | L-Mabuterol (hydrochloride) | 95656-55-6 | Reference compound |
| HY-113751 | JNJ-39393406 | 953428-73-4 | Reference compound |
| HY-113752 | MMV019313 | 902630-14-2 | Reference compound |
| HY-113753 | PDF-IN-1 | 900783-19-9 | Reference compound |
| HY-113755 | AA-1777 | 90316-11-3 | Reference compound |
| HY-113756 | trans-Latanoprost acid | 903549-49-5 | Reference compound |
| HY-113756A | Latanoprost acid | 41639-83-2 | Reference compound |
| HY-113756AR | Latanoprost acid (Standard) | 41639-83-2 | Reference Standards |
| HY-113757 | Picrasidine M | 99964-79-1 | Natural Products |
| HY-113758 | LY 163443 | 97581-70-9 | Reference compound |
| HY-113759 | Saquayamycin A | 99260-65-8 | Reference compound |
| HY-113761 | ASN03576800 | 957513-35-8 | Reference compound |
| HY-113763 | TWEAK-Fn14-IN-1 | 951612-19-4 | Reference compound |
| HY-113764 | N-Butanoyl-DL-homoserine lactone | 98426-48-3 | Reference compound |
| HY-113767 | Momordin II | 95851-41-5 | Natural Products |
| HY-113771 | Saquayamycin C | 99260-70-5 | Reference compound |
| HY-113772 | Inflachromene | 908568-01-4 | Reference compound |
| HY-113775 | Octadecanoyl-L-threo-sphingosine | 95037-06-2 | Natural Products |
| HY-113776 | 15(S)-HETRE | 92693-02-2 | Natural Products |
| HY-113777 | 22-HDHA | 90780-46-4 | Reference compound |
| HY-113778 | 15-keto-17-phenyl trinor Prostaglandin F2α | 949564-89-0 | Reference compound |
| HY-113781 | Ractopamine | 97825-25-7 | Reference compound |
| HY-113783 | Halobetasol | 98651-66-2 | Reference compound |
| HY-113783R | Halobetasol (Standard) | 98651-66-2 | Reference Standards |
| HY-113784 | Thiocarlide | 910-86-1 | Reference compound |
| HY-113784R | Thiocarlide (Standard) | 910-86-1 | Reference Standards |
| HY-113786 | EZH2-IN-21 | 923894-97-7 | Reference compound |
| HY-113787 | (R)-9b | 1655527-68-6 | Reference compound |
| HY-113790 | ISX-1 | 909207-35-8 | Reference compound |
| HY-113791 | Decuroside I | 96638-79-8 | Natural Products |
| HY-113793 | BPH-742 | 1059677-12-1 | Reference compound |
| HY-113794 | DSHS00884 | 675104-49-1 | Reference compound |
| HY-113795 | Aldgamycin E | 11011-06-6 | Natural Products |
| HY-113796 | Kopsoffinol | 96935-25-0 | Natural Products |
| HY-113797 | RS-52367 | 62435-92-1 | Reference compound |
| HY-113799 | Echinosporin | 79127-35-8 | Reference compound |
| HY-113801 | N-(3-Oxooctanoyl)-DL-homoserine lactone | 106983-27-1 | Natural Products |
| HY-113801R | N-(3-Oxooctanoyl)-DL-homoserine lactone (Standard) | 106983-27-1 | Reference Standards |
| HY-113802 | VUF 8328 | 102203-17-8 | Reference compound |
| HY-113803 | 4-Hydroxynonenal alkyne | 1011268-23-7 | Reference compound |
| HY-113805 | MC70 | 1031367-64-2 | Reference compound |
| HY-113806 | (±)-Trolline | 1021950-79-7 | Natural Products |
| HY-113807 | ZLJ-6 | 1051931-39-5 | Reference compound |
| HY-113811 | Diisopropyl xanthogen disulfide | 105-65-7 | Reference compound |
| HY-113812 | ZK110841 | 105595-17-3 | Reference compound |
| HY-113813 | SQ 28853 | 107550-68-5 | Reference compound |
| HY-113816 | Radicinin | 10088-95-6 | Natural Products |
| HY-113817 | SHIP1 activator 1 | 1000010-33-2 | Reference compound |
| HY-113818 | Kadsuracoccinic acid A | 1016260-22-2 | Natural Products |
| HY-113820 | AZD4619 | 1067247-60-2 | Reference compound |
| HY-113821 | 1-Naphthyl phosphate (potassium salt) | 100929-85-9 | Reference compound |
| HY-113823 | Naphthol AS-G | 91-96-3 | Reference compound |
| HY-113824 | RID-F | 1020853-03-5 | Reference compound |
| HY-113825 | CLK1/2-IN-1 | 1005784-23-5 | Reference compound |
| HY-113826 | L-656224 | 102612-16-8 | Reference compound |
| HY-113827 | THPN | 100079-26-3 | Reference compound |
| HY-113828 | Biotin-PEG2-C4-alkyne | 1011268-28-2 | Reference compound |
| HY-113829 | Valnemulin | 101312-92-9 | Reference compound |
| HY-113831 | CLK1/2-IN-3 | 1005784-60-0 | Reference compound |
| HY-113833 | N-Methylindan-2-amine (hydrochloride) | 10408-85-2 | Reference compound |
| HY-113834 | (R,R)-Ethambutol | 10054-05-4 | Reference compound |
| HY-113836 | 3-Hydroxyhexanoic acid | 10191-24-9 | Natural Products |
| HY-113840 | Sumarotene | 105687-93-2 | Reference compound |
| HY-113841 | RS-87337 | 107707-38-0 | Reference compound |
| HY-113843 | RETRA (hydrobromide) | 1035875-01-4 | Reference compound |
| HY-113844 | Ac-Gly-Lys-OMe | 10236-44-9 | Peptides |
| HY-113844A | Ac-Gly-Lys-OMe (acetate) | 14752-92-2 | Reference compound |
| HY-113845 | (+)-Intermedine | 10285-06-0 | Natural Products |
| HY-113845R | (+)-Intermedine (Standard) | 10285-06-0 | Reference Standards |
| HY-113846 | CMP-5 (hydrochloride) | 1030021-40-9 | Reference compound |
| HY-113846A | CMP-5 (dihydrochloride) | 2309409-79-6 | Reference compound |
| HY-113847 | Nanterinone (mesylate) | 102791-74-2 | Reference compound |
| HY-113848 | AEM1 | 1030123-90-0 | Reference compound |
| HY-113849 | MLS-573151 | 10179-57-4 | Reference compound |
| HY-113850 | CPSA | 1038713-54-0 | Reference compound |
| HY-113851 | BH-IAA | 1020201-82-4 | Reference compound |
| HY-113852 | K-259-2 | 102819-46-5 | Natural Products |
| HY-113853 | WF-10129 | 109075-64-1 | Natural Products |
| HY-113854 | AZD2906 | 1034148-15-6 | Reference compound |
| HY-113857 | RAD-243 | 103825-20-3 | Reference compound |
| HY-113858 | Brefonalol | 103880-26-8 | Reference compound |
| HY-113860 | Antiviral agent 52 | 101784-44-5 | Reference compound |
| HY-113861 | Propioxatin A | 102962-94-7 | Natural Products |
| HY-113862 | PHOME | 1028430-42-3 | Dye Reagents |
| HY-113863 | Rilopirox | 104153-37-9 | Reference compound |
| HY-113864 | Diisobutyl carbinol | 108-82-7 | Reference compound |
| HY-113866 | E-55888 | 1034142-33-0 | Reference compound |
| HY-113869 | BPH-628 | 1059677-40-5 | Reference compound |
| HY-113870 | 6-NBDG | 108708-22-1 | Dye Reagents |
| HY-113871 | R-PEP-27 | 103122-78-7 | Reference compound |
| HY-113873 | 10-Thiastearic acid | 105099-89-6 | Reference compound |
| HY-113874 | Picrasidine N | 101219-62-9 | Natural Products |
| HY-113876 | 2-Methyl-3-phenylquinoxaline | 10130-23-1 | Reference compound |
| HY-113877 | 3-Amino benzamidoxime | 100524-07-0 | Reference compound |
| HY-113878 | 12-OAHSA | 101901-73-9 | Reference compound |
| HY-113878S | 12-OAHSA-d17 | | Isotope-Labeled Compounds |
| HY-113879 | 18-Carboxy dinor Leukotriene B4 | 102674-12-4 | Reference compound |
| HY-113884 | (R)-Coriolic acid | 10219-69-9 | Reference compound |
| HY-113884A | (±)-Coriolic acid | 18104-45-5 | Reference compound |
| HY-113884B | (S)-Coriolic acid | 29623-28-7 | Reference compound |
| HY-113885 | MDA77 | 1103774-21-5 | Reference compound |
| HY-113887 | Prostaglandin F1β | 10164-73-5 | Reference compound |
| HY-113887A | 11β-Prostaglandin F1β | 37785-86-7 | Reference compound |
| HY-113887S | Prostaglandin F1β-d9 | 2389048-37-5 | Isotope-Labeled Compounds |
| HY-113889 | ZK112993 | 105114-63-4 | Reference compound |
| HY-113890 | Halofenozide | 112226-61-6 | Reference compound |
| HY-113891 | JX040 | 1089596-75-7 | Reference compound |
| HY-113892 | Leniquinsin | 10351-50-5 | Reference compound |
| HY-113893 | β-Interleukin I (163-171), human | 106021-96-9 | Peptides |
| HY-113894 | Retreversine | 1028332-91-3 | Reference compound |
| HY-113896 | U-67827E | 103494-23-1 | Reference compound |
| HY-113897 | Chloramphenicol 3-acetate | 10318-16-8 | Reference compound |
| HY-113898 | Ganoderic acid K | 104700-95-0 | Natural Products |
| HY-113899 | Biotin 4-amidobenzoic acid (sodium) | 102418-74-6 | Biochemical Assay Reagents |
| HY-113903 | (+)-Isopulegol | 104870-56-6 | Natural Products |
| HY-113904S | (Rac)-Tenofovir-d6 | 1020719-94-1 | Isotope-Labeled Compounds |
| HY-113904S1 | (Rac)-Tenofovir-d7 | 2747914-59-4 | Isotope-Labeled Compounds |
| HY-113906 | GSK1614343 | 1092076-04-4 | Reference compound |
| HY-113906A | (αR,8aS)-GSK1614343 | 1092476-84-0 | Reference compound |
| HY-113907 | SDZ-285604 | 1033846-45-5 | Reference compound |
| HY-113908 | (1S,3S)-3-Aminomethyl-cyclopentanol | 1007306-62-8 | Reference compound |
| HY-113909 | Dinoprost (methoxyamine) | 101913-98-8 | Reference compound |
| HY-113913 | 12(S)-HPEPE | 103239-14-1 | Reference compound |
| HY-113914 | 9-ING-41 | 1034895-42-5 | Reference compound |
| HY-113915 | Kuguaglycoside C | 1041631-93-9 | Natural Products |
| HY-113916 | Onalespib (lactate) | 1019889-35-0 | Reference compound |
| HY-113919 | Nothofagin | 11023-94-2 | Natural Products |
| HY-113920 | Azumolene (sodium) | 105336-14-9 | Reference compound |
| HY-113920A | Azumolene | 64748-79-4 | Reference compound |
| HY-113921 | m-PEG4-propargyl | 1101668-39-6 | Reference compound |
| HY-113924 | Tri(t-butoxycarbonylethoxymethyl) ethanol | 1027581-61-8 | Reference compound |
| HY-113925 | 1,2-Dilauroyl-sn-glycero-3-phosphate (sodium) | 108321-06-8 | Biochemical Assay Reagents |
| HY-113926 | BAY 60-2770 | 1027642-43-8 | Reference compound |
| HY-113929 | Loperamide oxide | 106900-12-3 | Reference compound |
| HY-113929R | Loperamide oxide (Standard) | 106900-12-3 | Reference Standards |
| HY-113930 | 3-[2-N-(Biotinyl)aminoethyldithio]propanoic acid | 104582-29-8 | Reference compound |
| HY-113931 | Aminooxy-PEG2-azide | 1043426-13-6 | ADC Related |
| HY-113932 | Trolamine salicylate ester | 10377-95-4 | Reference compound |
| HY-113933 | NE11808 | 105462-22-4 | Reference compound |
| HY-113934 | L-threo Lysosphingomyelin (d18:1) | 105615-55-2 | Reference compound |
| HY-113936 | A-943931 | 1027330-97-7 | Reference compound |
| HY-113938 | AZD4694 | 1054629-49-0 | Reference compound |
| HY-113942 | Cycloate | 1134-23-2 | Reference compound |
| HY-113942R | Cycloate (Standard) | 1134-23-2 | Reference Standards |
| HY-113943 | 9(S)-HETE | 107656-13-3 | Reference compound |
| HY-113943A | 9-HETE | 70968-92-2 | Reference compound |
| HY-113943AS | 9-HETE-d8 | | Isotope-Labeled Compounds |
| HY-113943S | 9(S)-HETE-d8 | | Isotope-Labeled Compounds |
| HY-113945 | Abbeymycin | 108073-64-9 | Natural Products |
| HY-113948 | 2-Deoxy-3,5-di-O-p-toluoyl-α-L-ribofuranosyl chloride | 141846-57-3 | Biochemical Assay Reagents |
| HY-113949 | Methyl 2,3-O-Isopropylidene-β-D-ribofuranoside | 4099-85-8 | Reference compound |
| HY-113949A | Methyl 2,3-O-Isopropylidene-β-L-ribofuranoside | 20672-63-3 | Reference compound |
| HY-113950 | Dichlorophenyl-ABA | 18201-65-5 | Reference compound |
| HY-113951 | Prolyl Endopeptidase Inhibitor 1 | 86925-97-5 | Reference compound |
| HY-113952 | Actinonin | 13434-13-4 | Natural Products |
| HY-113952R | Actinonin (Standard) | 13434-13-4 | Reference Standards |
| HY-113953 | Z-Asp-CH2-DCB | 153088-73-4 | Reference compound |
| HY-113955 | CP-346086 | 186390-48-7 | Reference compound |
| HY-113955A | CP-346086 (dihydrate) | 1262769-98-1 | Reference compound |
| HY-113957 | MPI_5a | 1259296-46-2 | Reference compound |
| HY-113958 | Difethialone | 104653-34-1 | Reference compound |
| HY-113958R | Difethialone (Standard) | 104653-34-1 | Reference Standards |
| HY-113960 | ERRα antagonist-1 | 1072145-33-5 | Reference compound |
| HY-113962 | 7α,25-Dihydroxycholesterol | 64907-22-8 | Natural Products |
| HY-113962S | 7α,25-Dihydroxycholesterol-d6 | 2260669-11-0 | Isotope-Labeled Compounds |
| HY-113963 | Ac-IETD-CHO | 191338-86-0 | Peptides |
| HY-113965 | CUR61414 | 334998-36-6 | Reference compound |
| HY-113967 | PF-04859989 | 34783-48-7 | Reference compound |
| HY-113969 | 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | 61563-24-4 | Reference compound |
| HY-113970A | Nebracetam (hydrochloride) | 1177279-49-0 | Reference compound |
| HY-113972 | Methyl mycophenolate | 31858-66-9 | Natural Products |
| HY-113972A | (E/Z)-Methyl mycophenolate | 24243-40-1 | Reference compound |
| HY-113972R | Methyl mycophenolate (Standard) | 31858-66-9 | Reference Standards |
| HY-113973 | LPA2 antagonist 2 | 36840-10-5 | Reference compound |
| HY-113974 | trans-AUCB | 885012-33-9 | Reference compound |
| HY-113976A | Endothall | 145-73-3 | Reference compound |
| HY-113976AR | Endothall (Standard) | 145-73-3 | Reference Standards |
| HY-113978 | 6-Formylpterin | 712-30-1 | Reference compound |
| HY-113985 | Cirazoline | 59939-16-1 | Reference compound |
| HY-113986 | Dexfadrostat | 102676-87-9 | Reference compound |
| HY-113986B | (S)-Dexfadrostat | 102676-86-8 | Reference compound |
| HY-113995 | (-)-Vesamicol | 112709-59-8 | Reference compound |
| HY-114002 | Anticancer agent 129 | 135882-37-0 | Reference compound |
| HY-114005 | SB-734117 | 607368-97-8 | Reference compound |
| HY-114009 | AKR1C1-IN-1 | 4906-68-7 | Reference compound |
| HY-114011 | AMG7703 | 1103523-24-5 | Reference compound |
| HY-114015 | APC-6860 | 154628-42-9 | Reference compound |
| HY-114017 | Libvatrep | 871814-52-7 | Reference compound |
| HY-114023 | BML-288 | 851681-89-5 | Reference compound |
| HY-114025 | H4 Receptor antagonist 1 | 848217-00-5 | Reference compound |
| HY-114029 | Ep vinyl quinidine | 101143-87-7 | Reference compound |
| HY-114038 | SB-747651A | 607372-46-3 | Reference compound |
| HY-114040 | NO-711 | 159094-94-7 | Reference compound |
| HY-114041 | Resolvin E1 | 552830-51-0 | Natural Products |
| HY-114041S | Resolvin E1-d4 | | Isotope-Labeled Compounds |
| HY-114041S1 | Resolvin E1-d4-1 | 2714040-94-3 | Isotope-Labeled Compounds |
| HY-114043 | NCGC00092410 | 442898-34-2 | Reference compound |
| HY-114056 | AS115 | 926657-43-4 | Reference compound |
| HY-114060 | CFMB | 1208552-99-1 | Reference compound |
| HY-114061 | (R)-FTY 720P | 402616-23-3 | Reference compound |
| HY-114071 | BMS270394 | 262433-54-5 | Reference compound |
| HY-114072 | J-113397 | 256640-45-6 | Reference compound |
| HY-114072A | (S,S)-J-113397 | 256640-46-7 | Reference compound |
| HY-114076 | CGP55845 | 150175-54-5 | Reference compound |
| HY-114080 | Patamostat | 114568-26-2 | Reference compound |
| HY-114080A | Patamostat (mesylate) | 114568-32-0 | Reference compound |
| HY-114080B | Patamostat (hydrochloride) | 3031765-17-7 | Reference compound |
| HY-114081A | Hemicholinium (chloride) | 18997-39-2 | Reference compound |
| HY-114085 | BP 897 | 192384-87-5 | Reference compound |
| HY-114086 | ML359 | 1069858-99-6 | Reference compound |
| HY-114091 | PF-00356231 (hydrochloride) | 820223-77-6 | Reference compound |
| HY-114091A | PF-00356231 | 766536-21-4 | Reference compound |
| HY-114095 | BML-280 | 1158347-73-9 | Reference compound |
| HY-114097A | CCR1 antagonist 11 (hydrochloride) | | Reference compound |
| HY-114100 | Metesind | 138384-68-6 | Reference compound |
| HY-114116 | ML-109 | 1186649-91-1 | Reference compound |
| HY-114117 | Tyclopyrazoflor | 1477919-27-9 | Reference compound |
| HY-114118 | Semaglutide | 910463-68-2 | Reference compound |
| HY-114118A | Semaglutide (TFA) | | Reference compound |
| HY-114118B | Semaglutide (acetate) | 1997361-85-9 | Reference compound |
| HY-114118F | Semaglutide, FITC labeled | | Dye Reagents |
| HY-114118S3 | Semaglutide-13C6,15N (TFA) | | Isotope-Labeled Compounds |
| HY-114128 | Turoctocog alfa | 1192451-26-5 | Reference compound |
| HY-114133 | Depreotide | 161982-62-3 | Peptides |
| HY-114134 | Epoetin beta | 122312-54-3 | Inhibitory Antibodies |
| HY-114141 | BI-671800 | 1093108-50-9 | Reference compound |
| HY-114146 | CID 1375606 | 313493-80-0 | Reference compound |
| HY-114147 | Tuberculosis inhibitor 3 | 2219325-28-5 | Reference compound |
| HY-114150 | D-Val-Leu-Arg-pNA | 64816-14-4 | Peptides |
| HY-114150D | D-Val-Leu-Arg-pNA (acetate) | 162303-66-4 | Peptides |
| HY-114153 | PLX5622 | 1303420-67-8 | Reference compound |
| HY-114153A | PLX5622 (hemifumarate) | | Reference compound |
| HY-114154 | AL-438 | 239066-73-0 | Reference compound |
| HY-114157 | DO-264 | 2301866-59-9 | Reference compound |
| HY-114158 | Pronase E (Activity ≥ 7000 U/g) | 9036-06-0 | Natural Products |
| HY-114158A | Pronase E (Activity ≥ 4000 U/mg) | 9036-06-0 | Natural Products |
| HY-114161 | H-Val-Pro-Pro-OH | 58872-39-2 | Peptides |
| HY-114161A | H-Val-Pro-Pro-OH (TFA) | 2828433-08-3 | Peptides |
| HY-114162 | VTP50469 | 2169916-18-9 | Reference compound |
| HY-114162A | VTP50469 (fumarate) | 2169919-29-1 | Reference compound |
| HY-114162B | VTP50469 (mesylate) | 2169919-27-9 | Reference compound |
| HY-114164 | Thrombin (MW 37kDa) | 9002-04-4 | Reference compound |
| HY-114164A | Human α-Thrombin | 9002-04-4 | Enzyme |
| HY-114164B | Human γ-Thrombin | 9002-04-4 | Enzyme |
| HY-114164C | Thrombin, Pig blood | 9002-04-4 | Enzyme |
| HY-114164D | Rat Thrombin | 9002-04-4 | Enzyme |
| HY-114164E | Rabbit Thrombin | 9002-04-4 | Enzyme |
| HY-114164F | Canine Thrombin | 9002-04-4 | Enzyme |
| HY-114164G | Murine Thrombin | 9002-04-4 | Enzyme |
| HY-114165 | DJ-V-159 | 2253744-53-3 | Reference compound |
| HY-114166 | 2-D08 | 144707-18-6 | Reference compound |
| HY-114168 | KRAS G12C inhibitor 5 | 2158297-63-1 | Reference compound |
| HY-114169 | WRG-28 | 1913291-02-7 | Reference compound |
| HY-114169S | WRG-28-d5 | | Isotope-Labeled Compounds |
| HY-114170 | ML604440 | 1140517-08-3 | Reference compound |
| HY-114173 | DDR1-IN-4 | 2125676-13-1 | Reference compound |
| HY-114174 | Fmoc-Ala-Glu-Asn-Lys-NH2 | 220701-06-4 | Peptides |
| HY-114175 | Adenosine deaminase, microorganism | 9026-93-1 | Enzyme |
| HY-114175A | Adenosine deaminase, Calf Spleen | 9026-93-1 | Enzyme |
| HY-114176 | (S,R,S)-AHPC-C4-NH2 (hydrochloride) | 2245697-83-8 | Reference compound |
| HY-114176A | (S,R,S)-AHPC-C4-NH2 | 2138439-53-7 | Reference compound |
| HY-114176B | (S,R,S)-AHPC-C4-NH2 (dihydrochloride) | 2341796-78-7 | Reference compound |
| HY-114177 | Ebvaciclib | 2185857-97-8 | Reference compound |
| HY-114177A | (S)-Ebvaciclib | 2185859-59-8 | Reference compound |
| HY-114180 | RU.521 | 2262452-06-0 | Reference compound |
| HY-114181 | IRAK4-IN-4 | 1850276-58-2 | Reference compound |
| HY-114182 | PF-06928215 | 2378173-15-8 | Reference compound |
| HY-114184 | MK-8245 analog | 1030612-87-3 | Reference compound |
| HY-114189 | GW284543 | 790186-68-4 | Reference compound |
| HY-114189A | GW284543 (hydrochloride) | 179246-08-3 | Reference compound |
| HY-114191 | SSTR5 antagonist 2 | 1254730-81-8 | Reference compound |
| HY-114191A | SSTR5 antagonist 2 (TFA) | 1254733-98-6 | Reference compound |
| HY-114191B | SSTR5 antagonist 2 (hydrochloride) | 2988224-31-1 | Reference compound |
| HY-114192 | TGFβRI-IN-1 | 1950628-94-0 | Reference compound |
| HY-114193 | CCR1 antagonist 6 | 2436773-01-0 | Reference compound |
| HY-114194 | CCR1 antagonist 7 | 2446154-74-9 | Reference compound |
| HY-114196 | Aclimostat | 2082752-83-6 | Reference compound |
| HY-114197 | Antimalarial agent 14 | 1150-59-0 | Reference compound |
| HY-114198 | Tenovin-2 | 666211-30-9 | Reference compound |
| HY-114199 | Eph inhibitor 1 | 861249-77-6 | Reference compound |
| HY-114200 | Imrecoxib | 395683-14-4 | Reference compound |
| HY-114200R | Imrecoxib (Standard) | 395683-14-4 | Reference Standards |
| HY-114202 | delta-Valerobetaine | 6778-33-2 | Natural Products |
| HY-114202S | delta-Valerobetaine-d9 (chloride) | 85806-18-4 | Isotope-Labeled Compounds |
| HY-114203 | Eckol | 88798-74-7 | Natural Products |
| HY-114204 | GSK8814 | 1997369-78-4 | Reference compound |
| HY-114205 | TP-238 | 2415263-04-4 | Reference compound |
| HY-114205A | TP-238 (hydrochloride) | 2415263-05-5 | Reference compound |
| HY-114206 | SKI-73 | 2206744-61-6 | Reference compound |
| HY-114207 | VinSpinIn | 2380021-98-5 | Reference compound |
| HY-114208 | BI-9321 | 2387510-86-1 | Reference compound |
| HY-114208A | BI-9321 (trihydrochloride) | 2387510-87-2 | Reference compound |
| HY-114209 | MRK-740 | 2387510-80-5 | Reference compound |
| HY-114211 | SGC8158 | | Reference compound |
| HY-114214 | CKD-712 | 626252-75-3 | Reference compound |
| HY-114215 | DSM-421 | 2011769-21-2 | Reference compound |
| HY-114216 | DBPR110 | 1310694-75-7 | Reference compound |
| HY-114220 | T-2307 | 873546-31-7 | Reference compound |
| HY-114221 | Org 48762-0 | 755753-89-0 | Reference compound |
| HY-114224 | TP-271 | 1207284-17-0 | Reference compound |
| HY-114226 | Olutasidenib | 1887014-12-1 | Reference compound |
| HY-114227 | Hexidium (iodide) | 211566-66-4 | Reference compound |
| HY-114228 | PROTAC BET degrader-2 | 2093388-33-9 | Reference compound |
| HY-114229 | PROTAC BET degrader-3 | 3031993-61-7 | Reference compound |
| HY-114231 | Exaluren | 1375073-93-0 | Reference compound |
| HY-114231B | Exaluren (disulfate) | 2244622-33-9 | Reference compound |
| HY-114231C | Exaluren (sulfate) | 1375073-94-1 | Reference compound |
| HY-114233 | MC-GGFG-Exatecan | 1600418-29-8 | ADC Related |
| HY-114234A | TAK-070 (Free base) | 212571-56-7 | Reference compound |
| HY-114237 | GDC-0276 | 1494581-70-2 | Reference compound |
| HY-114240 | 5'-Cholesteryl-TEG phosphoramidite | 1325147-19-0 | Reference compound |
| HY-114243 | DpC | 1382469-39-7 | Reference compound |
| HY-114244 | USL311 | 1373268-67-7 | Reference compound |
| HY-114245 | Se-Methylselenocysteine | 26046-90-2 | Natural Products |
| HY-114245B | Se-Methylselenocysteine (hydrochloride) | 863394-07-4 | Reference compound |
| HY-114245R | Se-Methylselenocysteine (Standard) | 26046-90-2 | Reference Standards |
| HY-114246 | ONC1-13B | 1351185-54-0 | Reference compound |
| HY-114247 | FMAU | 69256-17-3 | Reference compound |
| HY-114250 | Cantrixil | 2135511-22-5 | Reference compound |
| HY-114252 | Strophanthidin | 66-28-4 | Natural Products |
| HY-114252R | Strophanthidin (Standard) | 66-28-4 | Reference Standards |
| HY-114256 | EC1169 | 1610413-96-1 | Reference compound |
| HY-114258 | LY3295668 | 1919888-06-4 | Reference compound |
| HY-114263 | NXT629 | 1454925-59-7 | Reference compound |
| HY-114266 | UC-1728 | 948304-40-3 | Reference compound |
| HY-114267 | Cbz-B3A | 1884710-81-9 | Reference compound |
| HY-114268 | BRD-K98645985 | 1357647-78-9 | Reference compound |
| HY-114269 | (-)-(S)-B-973B | 2244989-34-0 | Reference compound |
| HY-114271A | T3-ATA (S-isomer) | 2438721-48-1 | Reference compound |
| HY-114272A | T4-ATA (S-isomer) | 2448470-97-9 | Reference compound |
| HY-114275 | Justicidin B | 17951-19-8 | Natural Products |
| HY-114277 | Sotorasib | 2296729-00-3 | Reference compound |
| HY-114277A | Sotorasib (racemate) | 2252403-56-6 | Reference compound |
| HY-114277B | Sotorasib isomer | | Reference compound |
| HY-114277S | Sotorasib-d7 | | Isotope-Labeled Compounds |
| HY-114277S2 | Sotorasib-d3 | | Isotope-Labeled Compounds |
| HY-114286 | PXS-5153A | 2125956-82-1 | Reference compound |
| HY-114286A | PXS-5153A (monohydrochloride) | | Reference compound |
| HY-114289 | 6-HEX | 155911-16-3 | Dye Reagents |
| HY-114292A | (E)-tri-Pcoumaroylspermidine | 131086-78-7 | Natural Products |
| HY-114293 | Acetyl coenzyme A | 72-89-9 | Reference compound |
| HY-114293A | Acetyl coenzyme A (trilithium) | 75520-41-1 | Biochemical Assay Reagents |
| HY-114293S | Acetyl coenzyme A-13C2 (lithium) | | Isotope-Labeled Compounds |
| HY-114294A | DL-3-Hydroxy-3-methylglutaryl coenzyme A (disodium hydrate) | 103476-21-7 | Biochemical Assay Reagents |
| HY-114295 | Geranyl diphosphate | 763-10-0 | Reference compound |
| HY-114295A | Geranyl diphosphate (triammonium) | 116057-55-7 | Reference compound |
| HY-114296 | 2,3-Oxidosqualene | 7200-26-2 | Reference compound |
| HY-114297 | Zymosterol | 128-33-6 | Natural Products |
| HY-114297S | Zymosterol-d5 | 1246298-29-2 | Isotope-Labeled Compounds |
| HY-114299 | Salcaprozate (sodium) | 203787-91-1 | Reference compound |
| HY-114299R | Salcaprozate (sodium) (Standard) | 203787-91-1 | Reference Standards |
| HY-114299S | Salcaprozate-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-114300 | DSP-0565 | 1226855-28-2 | Reference compound |
| HY-114301 | PF-06305591 | 1449473-97-5 | Reference compound |
| HY-114301A | PF-06305591 (dihydrate) | 2703582-76-5 | Reference compound |
| HY-114302 | CCB02 | 2100864-57-9 | Reference compound |
| HY-114303 | CM-675 | 1872466-47-1 | Reference compound |
| HY-114304 | COH000 | 1534358-79-6 | Reference compound |
| HY-114305 | A1874 | 2064292-12-0 | Reference compound |
| HY-114306 | EC0489 | 1096702-14-5 | Reference compound |
| HY-114307 | Ly93 | 1883528-69-5 | Reference compound |
| HY-114308 | SGL5213 | 1240305-17-2 | Reference compound |
| HY-114309 | URAT1 inhibitor 1 | 2268720-62-1 | Reference compound |
| HY-114310 | VDR agonist 1 | 2269494-43-9 | Reference compound |
| HY-114311 | FGFR1/DDR2 inhibitor 1 | 2308497-58-5 | Reference compound |
| HY-114312 | MD-224 | 2136247-12-4 | Reference compound |
| HY-114313 | Microtubule inhibitor 1 | 2305668-80-6 | Reference compound |
| HY-114314 | BA-53038B | 2306195-65-1 | Reference compound |
| HY-114315 | NQO1 substrate | 2304503-05-5 | Reference compound |
| HY-114316 | HMG499 | 2416941-68-7 | Reference compound |
| HY-114317 | MARK4 inhibitor 1 | 2271081-58-2 | Reference compound |
| HY-114318 | Bz-DL-Arg-βNA (hydrochloride) | 913-04-2 | Reference compound |
| HY-114319 | β-Cembrenediol | 57605-81-9 | Natural Products |
| HY-114320 | BuChE-IN-TM-10 | 2313524-95-5 | Reference compound |
| HY-114321 | Wnt/β-catenin agonist 1 | 2305372-67-0 | Reference compound |
| HY-114322 | VZ185 | 2306193-61-1 | Reference compound |
| HY-114322A | cis-VZ185 | 2306193-98-4 | Reference compound |
| HY-114323 | PROTAC FLT-3 degrader 1 | 2230826-81-8 | Reference compound |
| HY-114324 | PROTAC PARP1 degrader | 2369022-68-2 | Reference compound |
| HY-114324A | rel-PROTAC PARP1 degrader | | Reference compound |
| HY-114325 | AcLysValCit-PABC-DMAE-SW-163D | 2411007-69-5 | ADC Related |
| HY-114327 | D-Ribose 1,5-diphosphate | 14689-84-0 | Reference compound |
| HY-114330 | ZK824859 | 2271122-53-1 | Reference compound |
| HY-114330A | ZK824859 (hydrochloride) | 2436760-76-6 | Reference compound |
| HY-114331 | DLK-IN-1 | 1620574-24-4 | Reference compound |
| HY-114332 | GNE-8505 | 1620573-48-9 | Reference compound |
| HY-114333 | Octyl-α-ketoglutarate | 876150-14-0 | Reference compound |
| HY-114334 | Glutaminase-IN-1 | 2247127-79-1 | Reference compound |
| HY-114335 | Triphala | 857906-76-4 | Natural Products |
| HY-114336 | Enocyanin | 11029-12-2 | Natural Products |
| HY-114338 | Dalpiciclib | 1637781-04-4 | Reference compound |
| HY-114338A | Dalpiciclib (hydrochloride) | 2891598-76-6 | Reference compound |
| HY-114339 | CDK4/6-IN-2 | 1800506-48-2 | Reference compound |
| HY-114340 | LEM-14 | 1814881-70-3 | Reference compound |
| HY-114346A | BODIPY FL EDA (free base) | 220524-70-9 | Dye Reagents |
| HY-114347 | 6,3'-Dimethoxyflavone | 79786-40-6 | Reference compound |
| HY-114348 | N,N'-Diacetyl-L-cystine | 5545-17-5 | Reference compound |
| HY-114348R | N,N'-Diacetyl-L-cystine (Standard) | 5545-17-5 | Reference Standards |
| HY-114349 | HS-1371 | 2158197-70-5 | Reference compound |
| HY-114350 | BDP FL maleimide | 773859-49-7 | Dye Reagents |
| HY-114351 | BODIPY FL hydrazide | 178388-71-1 | Dye Reagents |
| HY-114352 | BODIPY FL-X | 217190-07-3 | Dye Reagents |
| HY-114353 | BDP FL azide | 1379771-95-5 | Dye Reagents |
| HY-114354 | BODIPY FL alkyne | 302795-84-2 | Dye Reagents |
| HY-114356 | BPI-9016M | 1528546-94-2 | Reference compound |
| HY-114357A | DS-1205b (free base) | 1855860-24-0 | Reference compound |
| HY-114358 | Tamnorzatinib | 1646839-59-9 | Reference compound |
| HY-114360 | Taurohyodeoxycholic acid | 2958-04-5 | Natural Products |
| HY-114360A | Taurohyodeoxycholic acid (sodium) | 38411-85-7 | Biochemical Assay Reagents |
| HY-114360AS1 | Taurohyodeoxycholic acid-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-114361 | OSMI-4 | 2260791-14-6 | Reference compound |
| HY-114362 | DL-alpha-Tocopherol methoxypolyethylene glycol succinate | 1309573-60-1 | Reference compound |
| HY-114363A | SRI 31215 (TFA) | 1832686-44-8 | Reference compound |
| HY-114364 | UDP-Galactose (disodium) | 137868-52-1 | Biochemical Assay Reagents |
| HY-114364S | UDP-α-D-Galactose-13C (disodium) | | Isotope-Labeled Compounds |
| HY-114365 | UDP-GalNAc (disodium) | 108320-87-2 | Biochemical Assay Reagents |
| HY-114366 | BC-1485 | 2035085-19-7 | Reference compound |
| HY-114367 | Delphinidin 3-rutinoside (chloride) | 15674-58-5 | Natural Products |
| HY-114368 | Kira8 | 1630086-20-2 | Reference compound |
| HY-114368A | Kira8 (Hydrochloride) | 2250019-92-0 | Reference compound |
| HY-114370 | Selpercatinib | 2152628-33-4 | Reference compound |
| HY-114370R | Selpercatinib (Standard) | 2152628-33-4 | Reference Standards |
| HY-114370S | Selpercatinib-13C,d3 | | Isotope-Labeled Compounds |
| HY-114371 | Eclitasertib | 2125450-76-0 | Reference compound |
| HY-114372 | Lycopodine | 466-61-5 | Reference compound |
| HY-114373 | Calarene | 17334-55-3 | Natural Products |
| HY-114374 | RO5461111 | 1252637-46-9 | Reference compound |
| HY-114377 | p-SCN-Bn-DOTA | 127985-74-4 | Reference compound |
| HY-114379 | AS2717638 | 2148339-28-8 | Reference compound |
| HY-114380 | Radioprotectin-1 | 1622006-09-0 | Reference compound |
| HY-114381 | GT 949 | 460330-27-2 | Reference compound |
| HY-114383 | ST-539 | 1040754-67-3 | Reference compound |
| HY-114384 | NV-5138 | 2095886-80-7 | Reference compound |
| HY-114384B | NV-5138 (hydrochloride) | 2639392-70-2 | Reference compound |
| HY-114385 | 13,14-epoxy Travoprost | 2557327-99-6 | Reference compound |
| HY-114388 | QM385 | 2093421-02-2 | Reference compound |
| HY-114392 | Gly-β-MCA | 66225-78-3 | Reference compound |
| HY-114392R | Gly-β-MCA (Standard) | 66225-78-3 | Reference Standards |
| HY-114395 | NVS-ZP7-4 | 2349367-89-9 | Reference compound |
| HY-114395A | (R)-NVS-ZP7-4 | 2517682-14-1 | Reference compound |
| HY-114396 | BR351 | 960113-85-3 | Reference compound |
| HY-114397 | SHP394 | 2055757-40-7 | Reference compound |
| HY-114398 | BAY-293 | 2244904-70-7 | Reference compound |
| HY-114398A | (S)-BAY-293 | 2244904-69-4 | Reference compound |
| HY-114399 | STING ligand-1 | 2365039-41-2 | Reference compound |
| HY-114400 | TRPV4 agonist-1 (free base) | 2314467-59-7 | Reference compound |
| HY-114400A | TRPV4 agonist-1 | 2314467-60-0 | Reference compound |
| HY-114402 | ARD-69 | 2316837-10-0 | Reference compound |
| HY-114403 | VU6012962 | 2313526-86-0 | Reference compound |
| HY-114404 | SJFα | 2254609-27-1 | Reference compound |
| HY-114405 | SJFδ | 2254609-23-7 | Reference compound |
| HY-114406 | TD-106 | 2250288-69-6 | Reference compound |
| HY-114407 | TD-428 | 2334525-50-5 | Reference compound |
| HY-114409 | GB1107 | 1978336-61-6 | Reference compound |
| HY-114410 | CCI-006 | 292053-42-0 | Reference compound |
| HY-114411 | ERRγ inverse agonist 1 | 2316832-86-5 | Reference compound |
| HY-114412 | TD-0212 | 1073549-10-6 | Reference compound |
| HY-114412A | TD-0212 (TFA) | 1073549-11-7 | Reference compound |
| HY-114413 | YZ129 | 1643120-60-8 | Reference compound |
| HY-114414 | HDACs/mTOR Inhibitor 1 | 2271413-06-8 | Reference compound |
| HY-114415 | AWZ1066S | 2239272-16-1 | Reference compound |
| HY-114416 | GS-626510 | 1637770-13-8 | Reference compound |
| HY-114418 | MMP3 inhibitor 1 | 312930-75-9 | Reference compound |
| HY-114419 | Zetomipzomib | 1629677-75-3 | Reference compound |
| HY-114419A | Zetomipzomib (maleate) | 2170983-62-5 | Reference compound |
| HY-114420 | AP1867-2-(carboxymethoxy) | 2230613-03-1 | Reference compound |
| HY-114421 | FKBP12 PROTAC dTAG-13 | 2064175-41-1 | Reference compound |
| HY-114423 | p38α inhibitor 1 | 1034189-82-6 | Reference compound |
| HY-114424 | H-Ile-Pro-Pro-OH | 26001-32-1 | Peptides |
| HY-114424A | H-Ile-Pro-Pro-OH (hydrochloride) | 1208862-61-6 | Peptides |
| HY-114426 | AT-1002 | 835872-35-0 | Reference compound |
| HY-114426A | AT-1002 (TFA) | | Reference compound |
| HY-114427 | NS-102 | 136623-01-3 | Reference compound |
| HY-114428 | P110δ-IN-1 | 1595129-71-7 | Reference compound |
| HY-114429 | CB-6644 | 2316817-88-4 | Reference compound |
| HY-114430 | Fmoc-Phe-Lys(Boc)-PAB-PNP | 1646299-50-4 | ADC Related |
| HY-114434 | AP1867 | 195514-23-9 | Reference compound |
| HY-114436 | MRTX-1257 | 2206736-04-9 | Reference compound |
| HY-114436S | MRTX-1257-d6 | 2639608-44-7 | Isotope-Labeled Compounds |
| HY-114437 | Fusion Inhibitory Peptide | 75539-79-6 | Peptides |
| HY-114439 | MtbHU-IN-1 | 59736-84-4 | Reference compound |
| HY-114440 | Belapectin | 1980787-47-0 | Reference compound |
| HY-114452 | LY2940094 | 1307245-86-8 | Reference compound |
| HY-114452A | LY2940094 (tartrate) | 1307245-87-9 | Reference compound |
| HY-114453 | SHP389 | 2235394-90-6 | Reference compound |
| HY-114454 | INH14 | 200134-22-1 | Reference compound |
| HY-114456 | Ganglioside GM3 | 124579-05-1 | Reference compound |
| HY-114456AS | Ganglioside GM3-d5 (Bovine Milk ammonium salt) | 2260669-91-6 | Isotope-Labeled Compounds |
| HY-114456S | Ganglioside GM3-d7 | | Isotope-Labeled Compounds |
| HY-114457 | Phosphatidylinositol 4,5-bisphosphate | 245126-95-8 | Natural Products |
| HY-114458 | Monooctyl succinate | 74295-86-6 | Reference compound |
| HY-114459 | Mutant IDH1-IN-4 | 1416270-18-2 | Reference compound |
| HY-114460 | SHP2-IN-1 | 1801764-90-8 | Reference compound |
| HY-114461B | (3S,17S)-FD-895 | 2598242-04-5 | Reference compound |
| HY-114464 | 11-Beta-hydroxyandrostenedione | 382-44-5 | Natural Products |
| HY-114464S | 11-Beta-hydroxyandrostenedione-d4 | 2687960-98-9 | Isotope-Labeled Compounds |
| HY-114464S1 | 11-Beta-hydroxyandrostenedione-d7 | 2331287-27-3 | Isotope-Labeled Compounds |
| HY-114481 | Imidazole ketone erastin | 1801530-11-9 | Reference compound |
| HY-114483 | AES-135 | 2361659-61-0 | Reference compound |
| HY-114489A | Haemanthamine | 466-75-1 | Natural Products |
| HY-114489B | Haemanthamine (hydrochloride) | | Natural Products |
| HY-114490 | ULK-101 | 2443816-45-1 | Reference compound |
| HY-114491 | Rineterkib | 1715025-32-3 | Dye Reagents |
| HY-114491A | Rineterkib (hydrochloride) | 1715025-34-5 | Reference compound |
| HY-114492 | GSK547 | 2226735-55-1 | Reference compound |
| HY-114492A | (Rac)-GSK547 | | Reference compound |
| HY-114495 | Caerulomycin A | 21802-37-9 | Natural Products |
| HY-114501 | Z3-Dodecenyl E2-butenoate | 104086-73-9 | Reference compound |
| HY-114502 | Chrysanthemic acid | 10453-89-1 | Reference compound |
| HY-114503 | NSAH | 1099592-35-4 | Reference compound |
| HY-114503A | (E/Z)-NSAH | 54009-54-0 | Reference compound |
| HY-114504 | RVX-297 | 1044871-04-6 | Reference compound |
| HY-114505 | 3-Hydroxypentadecane-4-one | 1046789-93-8 | Reference compound |
| HY-114507 | Flumioxazin | 103361-09-7 | Reference compound |
| HY-114507R | Flumioxazin (Standard) | 103361-09-7 | Reference Standards |
| HY-114508 | Dihydrochalcone | 1083-30-3 | Reference compound |
| HY-114509 | Anilazine | 101-05-3 | Reference compound |
| HY-114509R | Anilazine (Standard) | 101-05-3 | Reference Standards |
| HY-114509S | Anilazine-d4 | 1219802-20-6 | Isotope-Labeled Compounds |
| HY-114511 | BMS-593214 | 1004551-40-9 | Reference compound |
| HY-114512 | m-PEG1-NHS ester | 1027371-75-0 | Reference compound |
| HY-114514 | R 47 243 | 104383-18-8 | Reference compound |
| HY-114516 | Fructosylvaline | 10003-64-2 | Reference compound |
| HY-114517 | 3-Acetyl-2,5-dimethylfuran | 10599-70-9 | Reference compound |
| HY-114518 | Butenafine | 101828-21-1 | Reference compound |
| HY-114518S2 | Butenafine-d4 | 1653964-70-5 | Isotope-Labeled Compounds |
| HY-114519 | Helenalin acetate | 10180-86-6 | Reference compound |
| HY-114520 | TT01001 | 1022367-69-6 | Reference compound |
| HY-114521 | 5-(4-Methoxyphenyl)oxazole | 1011-51-4 | Reference compound |
| HY-114522 | X-alpha-Gal | 107021-38-5 | Reference compound |
| HY-114524 | (E)-4-Oxo-2-nonenal | 103560-62-9 | Reference compound |
| HY-114524S | (E)-4-Oxo-2-nonenal-d3 | 1313400-91-7 | Isotope-Labeled Compounds |
| HY-114525 | Chlorbenside | 103-17-3 | Reference compound |
| HY-114525R | Chlorbenside (Standard) | 103-17-3 | Reference Standards |
| HY-114527 | TPMP-I-2 | 102660-13-9 | Reference compound |
| HY-114529 | Yuanhunine | 104387-15-7 | Natural Products |
| HY-114530 | LY2452473 | 1029692-15-6 | Reference compound |
| HY-114531 | Lomifylline | 10226-54-7 | Reference compound |
| HY-114535 | Jaceidin | 10173-01-0 | Natural Products |
| HY-114536 | Mitolactol | 10318-26-0 | Reference compound |
| HY-114538 | Asobamast | 104777-03-9 | Reference compound |
| HY-114539 | L-750667 (triHydrochloride) | 1021868-80-3 | Reference compound |
| HY-114540 | CP-339818 | 185855-91-8 | Reference compound |
| HY-114541 | Coumarin-7-pinacolboronate | 190788-61-5 | Dye Reagents |
| HY-114542 | LY 201409 | 109306-94-7 | Reference compound |
| HY-114544A | N-3-oxo-dodecanoyl-L-homoserine lactone | 168982-69-2 | Reference compound |
| HY-114545 | 5HPP-33 | 105624-86-0 | Reference compound |
| HY-114547 | PD 109488 | 103733-49-9 | Reference compound |
| HY-114547R | PD 109488 (Standard) | 103733-49-9 | Reference Standards |
| HY-114548 | Ebselen oxide | 104473-83-8 | Reference compound |
| HY-114550 | LY339434 | 219566-62-8 | Reference compound |
| HY-114551 | Streptothricin E | 3776-38-3 | Reference compound |
| HY-114552 | (S)-Dabelotine | 152985-35-8 | Reference compound |
| HY-114553 | 5-Fluoro PB-22 3-carboxyindole metabolite | 1432794-98-3 | Reference compound |
| HY-114553S | 1-(5-Fluoropentyl)-1H-indole-3-carboxylic acid-d5 | 2703812-55-7 | Isotope-Labeled Compounds |
| HY-114557 | NSC 90469 | 1041-01-6 | Natural Products |
| HY-114557R | NSC 90469 (Standard) | 1041-01-6 | Reference Standards |
| HY-114558 | Resmethrin | 10453-86-8 | Reference compound |
| HY-114559 | DNJNAc | 105265-96-1 | Reference compound |
| HY-114561 | LY 97119 | 72456-59-8 | Reference compound |
| HY-114564 | Satigrel | 111753-73-2 | Reference compound |
| HY-114565 | LY221068 | 132392-39-3 | Reference compound |
| HY-114566 | SPV106 | 1036939-38-4 | Reference compound |
| HY-114568 | AMC-01 | 1047978-71-1 | Reference compound |
| HY-114569 | 6-CEPN | 1054549-73-3 | Reference compound |
| HY-114569A | DH-8P-DB | 1054549-71-1 | Reference compound |
| HY-114570 | Tiazofurin | 60084-10-8 | Reference compound |
| HY-114571 | cis-Lomibuvir | 1026785-59-0 | Reference compound |
| HY-114573 | TNF-α-IN-19 | 338773-13-0 | Reference compound |
| HY-114575 | Cycloxydim | 101205-02-1 | Reference compound |
| HY-114577 | Palifosfamide (tromethamine) | 1070409-31-2 | Reference compound |
| HY-114578 | PD 118717 | 104229-37-0 | Reference compound |
| HY-114581 | U27391 | 106314-87-8 | Reference compound |
| HY-114582 | Lexitropsin | 110124-49-7 | Reference compound |
| HY-114584 | A-953227 | 1037826-77-9 | Reference compound |
| HY-114585 | Sperabillin A | 111337-86-1 | Natural Products |
| HY-114585A | Sperabillin A (dihydrochloride) | 111337-87-2 | Reference compound |
| HY-114586 | L-158809 | 133240-46-7 | Reference compound |
| HY-114588 | Tafetinib analogue 1 | 1032265-67-0 | Reference compound |
| HY-114589 | VU0240382 | 1092550-36-1 | Reference compound |
| HY-114591 | Spiromesifen | 283594-90-1 | Reference compound |
| HY-114591R | Spiromesifen (Standard) | 283594-90-1 | Reference Standards |
| HY-114591S | Spiromesifen-d9 | 2470126-90-8 | Isotope-Labeled Compounds |
| HY-114592 | M199 | 1051933-86-8 | Reference compound |
| HY-114593 | ent-8-iso Prostaglandin F2α | 159812-83-6 | Reference compound |
| HY-114594 | Khusimol | 16223-63-5 | Natural Products |
| HY-114595 | Hemigossypol | 40817-07-0 | Natural Products |
| HY-114597 | PKF050-638 | 528893-52-9 | Reference compound |
| HY-114599 | 8-iso Prostaglandin A1 | 211186-29-7 | Reference compound |
| HY-114602 | AR-C117977 | 216685-07-3 | Reference compound |
| HY-114603 | Efegatran | 105806-65-3 | Reference compound |
| HY-114603A | Efegatran (sulfate) | 126721-07-1 | Reference compound |
| HY-114603B | Efegatran di(hydrochloride) | 173006-83-2 | Reference compound |
| HY-114604 | Propioxatin B | 102962-95-8 | Natural Products |
| HY-114608 | RY785 | 1393748-80-5 | Reference compound |
| HY-114610 | 13Z,16Z-Docosadienoic acid | 17735-98-7 | Reference compound |
| HY-114611 | BDM44768 | 2011754-00-8 | Reference compound |
| HY-114612 | 11-Ketotestosterone | 564-35-2 | Reference compound |
| HY-114614 | Clenpirin | 27050-41-5 | Reference compound |
| HY-114615 | AMP-Deoxynojirimycin | 216758-20-2 | Reference compound |
| HY-114616 | PBB3 | 1565796-97-5 | Reference compound |
| HY-114618 | S33084 | 273203-30-8 | Reference compound |
| HY-114619 | Oleyl anilide | 5429-85-6 | Reference compound |
| HY-114621 | DB772 | 1451058-50-6 | Reference compound |
| HY-114621A | DB772 (hydrate) | | Reference compound |
| HY-114621B | DB772 (free base) | 433735-90-1 | Reference compound |
| HY-114622 | AFN-1252 (tosylate) | 1047981-31-6 | Reference compound |
| HY-114623 | Prostaglandin D2 methyl ester | 49852-81-5 | Reference compound |
| HY-114626 | L-Lysine thioctate | 20902-53-8 | Reference compound |
| HY-114627 | Valone | 83-28-3 | Reference compound |
| HY-114628 | MS012 | 2089617-83-2 | Reference compound |
| HY-114630 | Protokylol | 136-70-9 | Reference compound |
| HY-114631 | EM-800 | 182167-03-9 | Reference compound |
| HY-114632 | Oxeglitazar | 280585-34-4 | Reference compound |
| HY-114633 | VU625 | 901008-62-6 | Reference compound |
| HY-114634 | Mesoxalate | 473-90-5 | Reference compound |
| HY-114635 | Dexecadotril | 112573-72-5 | Reference compound |
| HY-114636 | RG-102240 | 162326-49-0 | Reference compound |
| HY-114638 | Diproteverine | 69373-95-1 | Reference compound |
| HY-114638A | Diproteverine (hydrochloride) | 69373-88-2 | Reference compound |
| HY-114639 | Maritinone | 33927-59-2 | Natural Products |
| HY-114641 | BIIL-260 | 204974-93-6 | Reference compound |
| HY-114641A | BIIL-260 (hydrochloride) | 192581-24-1 | Reference compound |
| HY-114643 | (Rac)-Tovinontrine | 1430840-90-6 | Reference compound |
| HY-114644 | Galangal acetate | 52946-22-2 | Natural Products |
| HY-114645 | PDK1-IN-RS2 | 1643958-89-7 | Reference compound |
| HY-114646 | TMC-205 | 403646-00-4 | Natural Products |
| HY-114649 | 19-Hydroxy cholesterol | 561-63-7 | Natural Products |
| HY-114651 | Phenazoviridin | 155233-15-1 | Natural Products |
| HY-114652 | AalphaC | 26148-68-5 | Reference compound |
| HY-114653 | SRPIN803 | 380572-02-1 | Reference compound |
| HY-114656 | Dihydro-PGF1α | 20592-20-5 | Reference compound |
| HY-114657 | Benproperine | 2156-27-6 | Reference compound |
| HY-114657A | Benproperine (phosphate) | 19428-14-9 | Reference compound |
| HY-114658 | Daunomycinone | 21794-55-8 | Reference compound |
| HY-114658R | Daunomycinone (Standard) | 21794-55-8 | Reference Standards |
| HY-114661 | m-PEG4-Tos | 62921-76-0 | Reference compound |
| HY-114662 | Methyl 13-methylpentadecanoate | 5487-50-3 | Natural Products |
| HY-114663 | FDU-PB-22 | 1883284-94-3 | Reference compound |
| HY-114664 | KNK423 | 1859-42-3 | Reference compound |
| HY-114666 | Trimoxamine (hydrochloride) | 7082-27-1 | Reference compound |
| HY-114667 | Lavendustin C6 | 144676-04-0 | Reference compound |
| HY-114668 | Camptothecin-20(S)-O-propionate | 194414-69-2 | Reference compound |
| HY-114668A | Camptothecin-20(S)-O-propionate (hydrate) | 1147090-70-7 | Reference compound |
| HY-114670 | Propargyl-PEG4-amine | 1013921-36-2 | Reference compound |
| HY-114671 | Taprostene | 108945-35-3 | Reference compound |
| HY-114672 | MBCQ | 150450-53-6 | Reference compound |
| HY-114673 | Benzomalvin B | 157047-97-7 | Natural Products |
| HY-114674 | A-127722 | 195704-72-4 | Reference compound |
| HY-114674A | Atrasentan (sodium) | 178738-96-0 | Reference compound |
| HY-114678 | LY302148 | 182564-47-2 | Reference compound |
| HY-114680 | ACD-10284 | 16231-76-8 | Reference compound |
| HY-114682 | Lenperone | 24678-13-5 | Reference compound |
| HY-114682A | Lenperone (hydrochloride) | 24677-86-9 | Reference compound |
| HY-114683 | KS370G | 105955-01-9 | Reference compound |
| HY-114684 | A20832 | 40526-96-3 | Reference compound |
| HY-114685 | S-8510 (free base) | 151224-83-8 | Reference compound |
| HY-114686 | (R)-γ-Valerolactone | 58917-25-2 | Reference compound |
| HY-114687 | 5,7-Dihydroxy-11-ketotetranorprostanoic acid | 24379-94-0 | Reference compound |
| HY-114688 | BITC-SG | 62959-30-2 | Reference compound |
| HY-114689 | Diclofenac methyl ester | 15307-78-5 | Reference compound |
| HY-114690 | PNU-140975 | 179474-69-2 | Reference compound |
| HY-114691 | R 59494 | 104588-44-5 | Reference compound |
| HY-114692 | Eterobarb | 27511-99-5 | Reference compound |
| HY-114695 | Prostaglandin F2α-1-glyceryl ester | 43042-79-1 | Reference compound |
| HY-114695S | Prostaglandin F2α-1-glyceryl ester-d5 | | Isotope-Labeled Compounds |
| HY-114696 | Prehispanolone | 132922-55-5 | Natural Products |
| HY-114697 | DSG Crosslinker | 79642-50-5 | ADC Related |
| HY-114697S | DSG Crosslinker-d4 | 2242802-40-8 | Isotope-Labeled Compounds |
| HY-114698 | Retro-2 cycl | 1429192-00-6 | Reference compound |
| HY-114699 | DC_YM21 | 2001072-35-9 | Reference compound |
| HY-114700 | ZINC08438472 | 443872-20-6 | Reference compound |
| HY-114702 | M77976 | 394237-61-7 | Reference compound |
| HY-114703 | Eslicarbazepine | 104746-04-5 | Reference compound |
| HY-114703S1 | Eslicarbazepine-d4 | | Isotope-Labeled Compounds |
| HY-114705 | Ameltolide | 787-93-9 | Reference compound |
| HY-114706 | Suritozole | 110623-33-1 | Reference compound |
| HY-114707 | Threonyl-seryl-lysine | 71730-64-8 | Peptides |
| HY-114711 | Barbigerone | 75425-27-3 | Natural Products |
| HY-114712 | SJ572403 | 19970-45-7 | Reference compound |
| HY-114713 | POBN | 66893-81-0 | Reference compound |
| HY-114716 | Jacareubin | 3811-29-8 | Natural Products |
| HY-114717 | Pterophyllin 2 | 210231-09-7 | Reference compound |
| HY-114719 | A 854777 | 117009-82-2 | Reference compound |
| HY-114720 | Laureatin | 18762-30-6 | Natural Products |
| HY-114721 | BTA-9881 | 1646857-24-0 | Reference compound |
| HY-114723 | NPD9948 | 59856-85-8 | Reference compound |
| HY-114724 | HSR-609 | 161522-25-4 | Reference compound |
| HY-114725 | VRT-532 | 38214-71-0 | Reference compound |
| HY-114727 | PDE7-IN-4 | 18741-24-7 | Reference compound |
| HY-114729 | Leucylproline | 6403-35-6 | Reference compound |
| HY-114730 | CGA-JK3 | 1621626-06-9 | Reference compound |
| HY-114731 | Adenallene | 114987-18-7 | Reference compound |
| HY-114732 | Procaterol | 72332-33-3 | Reference compound |
| HY-114735 | Mandelonitrile benzoate | 4242-46-0 | Reference compound |
| HY-114736 | Hydroxy Varenicline | 357424-21-6 | Reference compound |
| HY-114737 | L-573655 | 112507-21-8 | Reference compound |
| HY-114738 | Rubilactone | 142182-54-5 | Natural Products |
| HY-114739 | MA-0204 | 2095128-17-7 | Reference compound |
| HY-114740 | β-Naphthoflavone | 6051-87-2 | Reference compound |
| HY-114743 | GS 283 | 149440-36-8 | Reference compound |
| HY-114744 | 6α-Hydroxy metandienone | 55720-48-4 | Reference compound |
| HY-114745 | MoTP | 57055-82-0 | Reference compound |
| HY-114746 | 25H-NBOMe imine analog | 1566571-78-5 | Reference compound |
| HY-114747 | 1-(Adamantan-1-yl)-3-propylthiourea | 25444-85-3 | Reference compound |
| HY-114748 | AHU1 | 216774-38-8 | Reference compound |
| HY-114749 | LL-C 10037α | 93752-54-6 | Natural Products |
| HY-114750 | Mebendazole-amine | 52329-60-9 | Reference compound |
| HY-114750R | Mebendazole-amine (Standard) | 52329-60-9 | Reference Standards |
| HY-114750S | Mebendazole-amine-13C6 | | Isotope-Labeled Compounds |
| HY-114751 | 16,16-Dimethylprostaglandin E1 | 41692-15-3 | Reference compound |
| HY-114753 | Neboglamine | 163000-63-3 | Reference compound |
| HY-114753A | Neboglamine (hydrochloride) | 2759182-59-5 | Reference compound |
| HY-114754 | BemPPOX | 1998101-23-7 | Reference compound |
| HY-114756 | 2-(2-Pyridyl)-4-methyl-thiazole-5-carboxylic acid | 34418-48-9 | Reference compound |
| HY-114757 | 2-Hydroxydecanoic acid | 5393-81-7 | Biochemical Assay Reagents |
| HY-114758 | Pyridoxal isonicotinoyl hydrazone | 737-86-0 | Reference compound |
| HY-114759 | MS-PPOH | 206052-02-0 | Reference compound |
| HY-114760 | Vanillic acid glucoside | 32142-31-7 | Natural Products |
| HY-114761 | Prostaglandin F2α dimethyl amine | 67508-09-2 | Reference compound |
| HY-114763 | LP8 | 327042-42-2 | Reference compound |
| HY-114766 | Pumafentrine | 207993-12-2 | Reference compound |
| HY-114769 | Beflubutamid | 113614-08-7 | Reference compound |
| HY-114769R | Beflubutamid (Standard) | 113614-08-7 | Reference Standards |
| HY-114770 | (E,E)-GLL398 | 2077980-83-5 | Reference compound |
| HY-114771 | α-Truxillic acid | 490-20-0 | Reference compound |
| HY-114772 | Methyl reserpate | 2901-66-8 | Natural Products |
| HY-114773 | N-Undecanoyl-L-homoserine lactone | 216596-71-3 | Biochemical Assay Reagents |
| HY-114775 | RCGD423 | 108237-91-8 | Reference compound |
| HY-114776 | Biotin-olefin | 92924-45-3 | Dye Reagents |
| HY-114778 | Fluzoparib | 1358715-18-0 | Reference compound |
| HY-114779 | N9-Isopropylolomoucine | 158982-15-1 | Reference compound |
| HY-114780 | Lactivicin | 107167-31-7 | Reference compound |
| HY-114782 | H-Tyr-Tyr-OH | 1050-28-8 | Reference compound |
| HY-114784 | Ingavirin | 219694-63-0 | Reference compound |
| HY-114784S | Ingavirin-d6 | | Isotope-Labeled Compounds |
| HY-114785 | BPHA | 193807-60-2 | Reference compound |
| HY-114788 | Lysylcysteine | 106325-92-2 | Peptides |
| HY-114791 | Lobelanidine | 552-72-7 | Natural Products |
| HY-114792 | 15-Methylprostaglandin E1 | 35700-26-6 | Reference compound |
| HY-114794 | Desglymidodrine | 3600-87-1 | Reference compound |
| HY-114794R | Desglymidodrine (Standard) | 3600-87-1 | Reference Standards |
| HY-114795 | Indomethacin heptyl ester | 282728-47-6 | Reference compound |
| HY-114796 | tHGA | 43230-43-9 | Reference compound |
| HY-114798 | Rabelomycin | 28399-50-0 | Natural Products |
| HY-114799 | 2-(4-Pyridyl)-4-methyl-thiazole-5-carboxylic acid | 144060-98-0 | Reference compound |
| HY-114800 | Soporidine | 1060376-43-3 | Reference compound |
| HY-114803 | Kokusaginine | 484-08-2 | Natural Products |
| HY-114805 | Formothion | 2540-82-1 | Reference compound |
| HY-114806 | Fenclofenac | 34645-84-6 | Reference compound |
| HY-114806R | Fenclofenac (Standard) | 34645-84-6 | Reference Standards |
| HY-114810 | Prostaglandin F2α serinol amide | 1135226-99-1 | Reference compound |
| HY-114812 | Anthrarobin | 577-33-3 | Reference compound |
| HY-114813 | KHG26693 | 1497249-95-2 | Reference compound |
| HY-114814 | ORM-10921 (free base) | 610782-82-6 | Reference compound |
| HY-114814A | (+)-ORM-10921 (free base) | 610782-83-7 | Reference compound |
| HY-114816 | N-Butanoyl-L-homoserine lactone | 67605-85-0 | ADC Related |
| HY-114816R | N-Butanoyl-L-homoserine lactone (Standard) | 67605-85-0 | Reference Standards |
| HY-114816S | N-butyryl-L-Homoserine lactone-d5 | 2701379-46-4 | Isotope-Labeled Compounds |
| HY-114818 | 4-(tert-Butyl)-benzhydroxamic Acid | 62034-73-5 | Reference compound |
| HY-114822 | Prostaglandin A3 | 36614-31-0 | Reference compound |
| HY-114824 | Streptovitacin A | 523-86-4 | Natural Products |
| HY-114826 | Prostaglandin E2-1-glyceryl ester | 37497-47-5 | Reference compound |
| HY-114826S | Prostaglandin E2-1-glyceryl ester-d5 | | Isotope-Labeled Compounds |
| HY-114830 | Fenleuton | 141579-54-6 | Reference compound |
| HY-114832 | OS 1808 | 5675-57-0 | Reference compound |
| HY-114837 | HBED | 35998-29-9 | Reference compound |
| HY-114840 | L 731734 | 149786-89-0 | Reference compound |
| HY-114841 | ONO 207 | 27376-74-5 | Reference compound |
| HY-114842 | TDRL-551 | 1644626-43-6 | Reference compound |
| HY-114843 | Benzyl-PEG1-Tos | 4981-83-3 | Reference compound |
| HY-114846 | Ro 22-9194 | 106134-33-2 | Reference compound |
| HY-114848 | Amiprilose (hydrochloride) | 60414-06-4 | Reference compound |
| HY-114849 | Norflurazon | 27314-13-2 | Reference compound |
| HY-114849R | Norflurazon (Standard) | 27314-13-2 | Reference Standards |
| HY-114850 | 5-trans Prostaglandin F2β | 36150-02-4 | Reference compound |
| HY-114850A | (5R)-Dinoprost (tromethamine) | 89847-02-9 | Reference compound |
| HY-114852 | Pheleuin | 169195-23-7 | Reference compound |
| HY-114853 | BVT.13 | 756813-87-3 | Reference compound |
| HY-114855 | BT2 | 34576-94-8 | Reference compound |
| HY-114856 | DTBT | 165190-76-1 | Reference compound |
| HY-114857 | Clofencet | 129025-54-3 | Reference compound |
| HY-114858 | Epiblastin A | 16470-02-3 | Reference compound |
| HY-114859 | 4-CAB (hydrochloride) | 23292-08-2 | Reference compound |
| HY-114860 | LY 215891 | 68403-79-2 | Reference compound |
| HY-114861 | Nor-6α-Oxycodol | 116499-16-2 | Reference compound |
| HY-114862 | 13,14-dihydro-15(R)-Prostaglandin E1 | 201848-10-4 | Reference compound |
| HY-114863 | PHCCC(4Me) | 1259532-01-8 | Reference compound |
| HY-114865 | BMS-192364 | 202822-21-7 | Reference compound |
| HY-114866 | Eritadenine | 23918-98-1 | Natural Products |
| HY-114867 | (15R)-Bimatoprost | 1163135-92-9 | Reference compound |
| HY-114869 | DPQ | 129075-73-6 | Reference compound |
| HY-114870 | 2-Methyl benzamideoxime | 40312-14-9 | Reference compound |
| HY-114871 | SL651498 | 205881-86-3 | Reference compound |
| HY-114872 | SLF | 195513-96-3 | Reference compound |
| HY-114872A | SLF (TFA) | 2378802-47-0 | Reference compound |
| HY-114873 | LY256548 | 107889-31-6 | Reference compound |
| HY-114876 | Desmethylflunitrazepam | 2558-30-7 | Reference compound |
| HY-114877 | CG-707 | 1443442-61-2 | Reference compound |
| HY-114879 | DDAO | 118290-05-4 | Dye Reagents |
| HY-114880 | AB-FUBINACA 3-fluorobenzyl isomer | 1185282-19-2 | Reference compound |
| HY-114881 | Frequentin | 29119-03-7 | Natural Products |
| HY-114883 | Homocarnosine | 3650-73-5 | Reference compound |
| HY-114883A | Homocarnosine (TFA) | 2991254-59-0 | Reference compound |
| HY-114886 | IGP-5 | 351978-83-1 | Reference compound |
| HY-114887 | Lodenosine | 110143-10-7 | Reference compound |
| HY-114892 | 15-A2t-Isoprostane | 474391-66-7 | Reference compound |
| HY-114895 | SSR504734 (free base) | 742693-38-5 | Reference compound |
| HY-114897 | L-167307 | 188352-45-6 | Reference compound |
| HY-114898 | ML404 | 1826026-00-9 | Reference compound |
| HY-114899 | Azamethiphos | 35575-96-3 | Reference compound |
| HY-114899R | Azamethiphos (Standard) | 35575-96-3 | Reference Standards |
| HY-114899S | Azamethiphos-d6 | 1189894-02-7 | Isotope-Labeled Compounds |
| HY-114902 | Y02224 | 1853988-48-3 | Reference compound |
| HY-114903 | (E/Z)-BIO-acetoxime | 740841-15-0 | Reference compound |
| HY-114906 | SIRT1/2/3-IN-2 | 388086-13-3 | Reference compound |
| HY-114907 | 4',5'-Dibromofluorescein | 596-03-2 | Dye Reagents |
| HY-114909 | TachypleginA | 331839-29-3 | Reference compound |
| HY-114910 | 11-Deoxy Prostaglandin E2 | 35536-53-9 | Reference compound |
| HY-114911 | Feprazone | 30748-29-9 | Reference compound |
| HY-114911R | Feprazone (Standard) | 30748-29-9 | Reference Standards |
| HY-114912 | Benzoadenosine | 60189-62-0 | Reference compound |
| HY-114913 | Fenarimol | 60168-88-9 | Reference compound |
| HY-114914 | 3-Hydroxylidocaine | 34604-55-2 | Reference compound |
| HY-114915 | PSB-1434 | 1619884-65-9 | Reference compound |
| HY-114918 | MS438 | 512840-45-8 | Reference compound |
| HY-114920 | Piprofurol | 40680-87-3 | Reference compound |
| HY-114923 | SU-11752 | 688036-19-3 | Reference compound |
| HY-114924 | LY465608 | 328918-26-9 | Reference compound |
| HY-114925 | AB-BICA | 1969264-37-6 | Reference compound |
| HY-114926 | KT185 | 1472640-86-0 | Reference compound |
| HY-114927 | (±)-Dunnione | 521-49-3 | Reference compound |
| HY-114928 | Deiodoamiodarone | 23551-25-9 | Reference compound |
| HY-114929 | THDP17 | 104741-27-7 | Reference compound |
| HY-114930 | Endopeptidase-IN-1 | 182821-29-0 | Reference compound |
| HY-114932 | Linoleoyl phenylalanine | 2441-64-7 | Peptides |
| HY-114933 | VU0119498 | 79183-37-2 | Reference compound |
| HY-114936 | Piericidin A | 2738-64-9 | Natural Products |
| HY-114937 | (R)-Eslicarbazepine acetate | 186694-45-1 | Reference compound |
| HY-114938 | Fumaramidmycin | 57687-92-0 | Natural Products |
| HY-114939 | Phelorphan | 110871-16-4 | Reference compound |
| HY-114941 | Aladotril | 173429-64-6 | Reference compound |
| HY-114942 | Prostaglandin E1 ethyl ester | 35900-16-4 | Reference compound |
| HY-114945 | CGRP antagonist 2 | 866086-05-7 | Reference compound |
| HY-114946 | N-methyl-4,4-difluoro Modafinil | 1613222-54-0 | Reference compound |
| HY-114947 | 9-deoxy-9-methylene Prostaglandin E2 | 61263-32-9 | Reference compound |
| HY-114950 | EXP3179 | 114798-36-6 | Reference compound |
| HY-114950R | EXP3179 (Standard) | 114798-36-6 | Reference Standards |
| HY-114952 | SM-32504 | 185539-34-8 | Reference compound |
| HY-114953 | BMS-248360 | 254737-87-6 | Reference compound |
| HY-114954 | CID1792197 | 1164479-69-9 | Reference compound |
| HY-114955 | MTTC | 152467-47-5 | Reference compound |
| HY-114958 | RH 421 | 107610-19-5 | Dye Reagents |
| HY-114961 | 15-epi Prostaglandin A1 | 20897-92-1 | Reference compound |
| HY-114962 | S-22153 | 180304-07-8 | Reference compound |
| HY-114965 | TP-064 | 2080306-20-1 | Reference compound |
| HY-114966 | RP73870 | 197012-43-4 | Reference compound |
| HY-114968 | p38 MAPK-IN-5 | 344457-87-0 | Reference compound |
| HY-114969 | Clioxanide | 14437-41-3 | Natural Products |
| HY-114971 | CREBBP-IN-1 | 1801324-41-3 | Reference compound |
| HY-114974 | Rivenprost | 256382-08-8 | Reference compound |
| HY-114976 | S-Allylmercapturic acid | 23127-41-5 | Natural Products |
| HY-114976S | N-Acetyl-S-allyl-L-cysteine-d3 | 1331907-55-1 | Isotope-Labeled Compounds |
| HY-114977 | Avenanthramide A | 108605-70-5 | Natural Products |
| HY-114977R | Avenanthramide A (Standard) | 108605-70-5 | Reference Standards |
| HY-114978 | VU0424465 | 1428630-85-6 | Reference compound |
| HY-114979 | Pyoluteorin | 25683-07-2 | Reference compound |
| HY-114981 | SRTCX1002 | 1203479-63-3 | Reference compound |
| HY-114982 | KEA1-97 | 2138882-71-8 | Reference compound |
| HY-114983 | Chimmitecan | 185425-25-6 | Reference compound |
| HY-114986 | 6-Keto-PGE1 | 67786-53-2 | Reference compound |
| HY-114987 | EMD 21657 | 61711-37-3 | Reference compound |
| HY-114988 | PGE-M | 24769-56-0 | Reference compound |
| HY-114988S | tetranor-PGEM-d6 | 1240398-16-6 | Isotope-Labeled Compounds |
| HY-114989 | Fluorizoline | 1362243-70-6 | Reference compound |
| HY-114990 | EMD 57439 | 148714-88-9 | Reference compound |
| HY-114991 | Leptospermone | 567-75-9 | Natural Products |
| HY-114992 | 2-Propyl-2-pentenoic acid | 60218-41-9 | Reference compound |
| HY-114994 | MS437 | 541535-31-3 | Reference compound |
| HY-114995 | Tr-PEG2-OH | 105589-77-3 | ADC Related |
| HY-114996 | ADAMTS-5 Inhibitor | 929634-33-3 | Reference compound |
| HY-114998 | α-D-Glucosamine pentaacetate | 7784-54-5 | Biochemical Assay Reagents |
| HY-114999 | Methyl-2,3,4,6-tetra-O-benzyl-α-D-galactopyranoside | 53008-63-2 | Biochemical Assay Reagents |
| HY-115004 | MM-433593 | 1006604-91-6 | Reference compound |
| HY-115014 | Cibenzoline (succinate) | 100678-32-8 | Reference compound |
| HY-115038 | ELN484228 | 312-63-0 | Reference compound |
| HY-115051 | 2-Hydroxymethyltetrahydropyran | 100-72-1 | Natural Products |
| HY-115062 | MJ33 (lithium salt) | 1007476-63-2 | Reference compound |
| HY-115066 | GSK1521498 (free base) | 1007573-18-3 | Reference compound |
| HY-115066A | GSK1521498 (free base) (hydrochloride) | 1007578-24-6 | Reference compound |
| HY-115122 | IDO-IN-12 | 1888341-29-4 | Reference compound |
| HY-115127 | 3-Methylanisole | 100-84-5 | Reference compound |
| HY-115127S | 3-Methylanisole-d3 | 20369-34-0 | Isotope-Labeled Compounds |
| HY-115139 | Fenadiazole | 1008-65-7 | Reference compound |
| HY-115159 | Ro 14-9578 | 100891-41-6 | Reference compound |
| HY-115192 | ent-Naxagolide (hydrochloride) | 100935-99-7 | Reference compound |
| HY-115194 | Amastatin (hydrochloride) | 100938-10-1 | Reference compound |
| HY-115213 | SORT-PGRN interaction inhibitor 1 | 100957-85-5 | Reference compound |
| HY-115231 | ci-IP3/PM | 1009832-82-9 | Reference compound |
| HY-115243 | 2-Chloro-1,4-naphthoquinone | 1010-60-2 | Reference compound |
| HY-115249 | Metronidazole acetic acid | 1010-93-1 | Reference compound |
| HY-115249R | Metronidazole acetic acid (Standard) | 1010-93-1 | Reference Standards |
| HY-115272 | GSK894490A | 1012035-06-1 | Reference compound |
| HY-115273 | MRS-2179 | 101204-49-3 | Reference compound |
| HY-115282 | JNJ-63576253 (free base) | 2110426-27-0 | Reference compound |
| HY-115282A | JNJ-63576253 | 2110428-64-1 | Reference compound |
| HY-115292 | Simvastatin hydroxy acid (sodium) | 101314-97-0 | Reference compound |
| HY-115312 | Ro 18-5364 | 101387-98-8 | Reference compound |
| HY-115314 | Mequitamium (iodide) | 101396-42-3 | Reference compound |
| HY-115319 | CP-24879 (hydrochloride) | 10141-51-2 | Reference compound |
| HY-115340 | Decanoic acid (sodium) | 1002-62-6 | Biochemical Assay Reagents |
| HY-115340S | Decanoic acid-d19 (sodium) | 1086096-26-5 | Isotope-Labeled Compounds |
| HY-115349 | Neamine (tetrahydrochloride) | 15446-43-2 | Reference compound |
| HY-115351 | GW-3333 | 212609-68-2 | Reference compound |
| HY-115354 | 4-Hydroxy alprazolam | 30896-57-2 | Reference compound |
| HY-115354S | 4-Hydroxy Alprazolam-d5 | 2747915-82-6 | Isotope-Labeled Compounds |
| HY-115356 | Eoxin E4 | 1000852-57-2 | Reference compound |
| HY-115357 | BMS711939 | 1000998-62-8 | Reference compound |
| HY-115358 | Lignoceroyl Ethanolamide | 10015-68-6 | Reference compound |
| HY-115360 | IND45193 | 10024-04-1 | Reference compound |
| HY-115362 | Methyl palmitelaidate | 10030-74-7 | Biochemical Assay Reagents |
| HY-115363 | Curcumenone | 100347-96-4 | Natural Products |
| HY-115364 | Parbendazole | 14255-87-9 | Reference compound |
| HY-115364R | Parbendazole (Standard) | 14255-87-9 | Reference Standards |
| HY-115364S | Parbendazole-d3 | 1613439-58-9 | Isotope-Labeled Compounds |
| HY-115365 | (3β,20E)-24-Norchola-5,20(22)-diene-3,23-diol | 53495-21-9 | Reference compound |
| HY-115366 | Soluflazine | 112415-83-5 | Reference compound |
| HY-115367 | Aldgamycin G | 107745-56-2 | Natural Products |
| HY-115369 | Methyl (13Z,16Z,19Z)-docosatrienoate | 108698-01-7 | Biochemical Assay Reagents |
| HY-115371 | Butaperazine (dimaleate) | 1063-55-4 | Reference compound |
| HY-115374 | m-PEG6-azide | 1043884-49-6 | ADC Related |
| HY-115375 | R 50595 (hydrochloride) | 104860-61-9 | Reference compound |
| HY-115376 | Z62954982 | 1090893-12-1 | Reference compound |
| HY-115378 | 1-(3,5-Dimethylphenyl)piperazine | 105907-65-1 | Reference compound |
| HY-115379 | Latromotide | 1049674-65-8 | Peptides |
| HY-115381 | Lipoxin A5 | 110657-98-2 | Reference compound |
| HY-115382 | Guanoctine (hydrochloride) | 1070-95-7 | Reference compound |
| HY-115383 | Roflupram | 1093412-18-0 | Reference compound |
| HY-115384 | Amino-PEG5-C2-acid | 1191078-74-6 | ADC Related |
| HY-115385 | Lumichrome | 1086-80-2 | Reference compound |
| HY-115385R | Lumichrome (Standard) | 1086-80-2 | Reference Standards |
| HY-115386 | MitoTEMPOL | 1101113-39-6 | Reference compound |
| HY-115387 | Oleoyl proline | 107432-37-1 | Peptides |
| HY-115390 | 14,15-Dehydro Leukotriene B4 | 114616-11-4 | Reference compound |
| HY-115391 | Boc-LRR-AMC | 109358-46-5 | Peptides |
| HY-115392 | Ms-PEG12-m | 1059604-93-1 | Reference compound |
| HY-115393 | N-Heptanoyl-DL-homoserine lactone | 106983-26-0 | Peptides |
| HY-115393A | N-Heptanoyl-L-homoserine lactone | 177158-20-2 | Reference compound |
| HY-115394 | Soyasaponin IV | 108906-97-4 | Natural Products |
| HY-115397 | Aprepitant-d4 | 1133387-60-6 | Isotope-Labeled Compounds |
| HY-115399A | N-3-Oxo-hexadecanoyl-L-Homoserine lactone | 925448-37-9 | Reference compound |
| HY-115400 | 1V209 | 1062444-54-5 | Reference compound |
| HY-115402 | DAz-1 | 1112977-84-0 | Dye Reagents |
| HY-115403 | FKGK18 | 1071001-09-6 | Reference compound |
| HY-115406A | CPTH6 (hydrobromide) | 2321332-57-2 | Reference compound |
| HY-115407 | Cochliodone A | 1072931-48-6 | Natural Products |
| HY-115408 | 9(R)-HETE | 107656-14-4 | Reference compound |
| HY-115410 | NG-Amino-L-arginine (hydrochloride) | 1031799-40-2 | Reference compound |
| HY-115411 | L-Hydroxy arginine (acetate) | 1140844-61-6 | Peptides |
| HY-115411A | L-Hydroxy arginine (dihydrochloride) | 133565-48-7 | Reference compound |
| HY-115412 | Vorinostat-d5 | 1132749-48-4 | Reference compound |
| HY-115413 | LG50643 | 111372-42-0 | Reference compound |
| HY-115414 | Bis-propargyl-PEG8 | 1092554-87-4 | Reference compound |
| HY-115415 | 1,2-Distearoyl-sn-glycero-3-phosphate (sodium) | 108321-18-2 | Biochemical Assay Reagents |
| HY-115415S | 1,2-Distearoyl-sn-glycero-3-phosphate-d70 (sodium) | 327179-02-2 | Isotope-Labeled Compounds |
| HY-115416 | Pigment Red 49:1 | 1103-38-4 | Dye Reagents |
| HY-115417 | Bosentan-d4 | 1065472-77-6 | Reference compound |
| HY-115419 | 1-Thio-β-D-glucose (sodium) | 10593-29-0 | Reference compound |
| HY-115420 | 1-β-D-Glucosylsphingadienine (d18:2 (4E8E)) | 114200-59-8 | Reference compound |
| HY-115421 | 11(R)-HEPE | 109430-11-7 | Reference compound |
| HY-115421A | 11-HEPE | 99217-78-4 | Reference compound |
| HY-115421B | 11(S)-HEPE | 156473-26-6 | Reference compound |
| HY-115428 | (R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide | 220556-74-1 | Reference compound |
| HY-115429 | Calcium dextrofolinate | 115940-48-2 | Reference compound |
| HY-115430 | Tenofovir disoproxil aspartate | 1571075-19-8 | Reference compound |
| HY-115431 | Antho-rwamide I | 114056-25-6 | Peptides |
| HY-115433 | α-Muricholic acid | 2393-58-0 | Natural Products |
| HY-115433R | α-Muricholic acid (Standard) | 2393-58-0 | Reference Standards |
| HY-115433S | α-Muricholic acid-d5 | | Isotope-Labeled Compounds |
| HY-115433S1 | α-Muricholic acid-d4 | | Isotope-Labeled Compounds |
| HY-115434 | 3,5-Diiodothyroacetic acid | 1155-40-4 | Reference compound |
| HY-115435 | 1,2-Dimyristoyl-sn-glycero-3-phospho-L-serine (sodium) | 105405-50-3 | Biochemical Assay Reagents |
| HY-115435S | 1,2-Dimyristoyl-sn-glycero-3-phospho-L-serine-d54 (sodium) | 327178-93-8 | Isotope-Labeled Compounds |
| HY-115436 | LYG-202 | 1175077-25-4 | Reference compound |
| HY-115437 | Methyl all-cis-7,10,13,16,19-docosapentaenoate | 108698-02-8 | Biochemical Assay Reagents |
| HY-115440 | CRS3123 (dihydrochloride) | 1013915-99-5 | Reference compound |
| HY-115440R | CRS3123 (dihydrochloride) (Standard) | 1013915-99-5 | Reference Standards |
| HY-115441 | (Rac)-Luliconazole | 101530-21-6 | Reference compound |
| HY-115445 | LCS-1 | 41931-13-9 | Reference compound |
| HY-115446A | Lenalidomide-C4-NH2 (hydrochloride) | 2435715-90-3 | Reference compound |
| HY-115447 | Clobenpropit | 145231-45-4 | Reference compound |
| HY-115448 | Bio-AMS | 1393881-52-1 | Reference compound |
| HY-115448A | Bio-AMS (TFA) | | Reference compound |
| HY-115449 | Chromeceptin | 331859-86-0 | Reference compound |
| HY-115450 | ONO-0300302 | 856689-51-5 | Reference compound |
| HY-115451 | Photoregulin 3 | 785708-33-0 | Reference compound |
| HY-115452 | G5-7 | 939681-36-4 | Reference compound |
| HY-115453 | UBCS039 | 358721-70-7 | Reference compound |
| HY-115454 | GB111-NH2 | 956479-18-8 | Reference compound |
| HY-115454A | GB111-NH2 (hydrochloride) | | Reference compound |
| HY-115460 | AER-271 | 634913-39-6 | Reference compound |
| HY-115461 | MID-1 | 312608-54-1 | Reference compound |
| HY-115462 | PGN-9856 | 863704-91-0 | Reference compound |
| HY-115463 | EB-3D | 1839150-63-8 | Reference compound |
| HY-115464 | NC1153 | 150661-91-9 | Reference compound |
| HY-115466 | MLT-748 | 1832578-30-9 | Reference compound |
| HY-115467 | MitoBloCK-10 | 394694-98-5 | Reference compound |
| HY-115470 | CLK-IN-T3 | 2109805-56-1 | Reference compound |
| HY-115474 | Cardionogen-2 | 578755-52-9 | Reference compound |
| HY-115475 | SW-100 | 2126744-35-0 | Reference compound |
| HY-115477 | Brilaroxazine (hydrochloride) | 1708960-04-6 | Reference compound |
| HY-115480 | 1,3,5-Trihydroxyxanthone | 6732-85-0 | Natural Products |
| HY-115481 | EphB1-IN-1 | 1980036-18-7 | Reference compound |
| HY-115486 | MPO-IN-28 | 37836-90-1 | Reference compound |
| HY-115487 | MF-766 | 1050656-06-8 | Reference compound |
| HY-115488A | BNM-III-170 | 1859189-55-1 | Reference compound |
| HY-115489 | GGTI-286 | 171744-11-9 | Reference compound |
| HY-115489A | GGTI-286 (TFA) | | Reference compound |
| HY-115492 | NSC668394 | 382605-72-3 | Reference compound |
| HY-115493 | TIQ-15 | 1380336-17-3 | Reference compound |
| HY-115494 | Neladenoson dalanate (hydrochloride) | 1239235-25-6 | Reference compound |
| HY-115495 | 6-Alkynyl fucose | 935658-91-6 | Reference compound |
| HY-115496 | 7-BIA | 1313403-49-4 | Reference compound |
| HY-115497 | BRD5529 | 1358488-78-4 | Reference compound |
| HY-115498 | ARN14494 | 1037837-27-6 | Reference compound |
| HY-115499 | MPC-0767 | 1310540-32-9 | Reference compound |
| HY-115502 | BCI | 1245792-51-1 | Reference compound |
| HY-115502A | BCI (hydrochloride) | 95130-23-7 | Reference compound |
| HY-115506 | PF-05105679 | 1398583-31-7 | Reference compound |
| HY-115510 | SPR inhibitor 3 | 1292285-54-1 | Reference compound |
| HY-115513 | Pitstop 1 | 1332879-51-2 | Reference compound |
| HY-115514A | BRK inhibitor P21d (hydrochloride) | 2250025-98-8 | Reference compound |
| HY-115519 | (E/Z)-GO289 | 694522-87-7 | Reference compound |
| HY-115521 | Jarin-1 | 1212704-51-2 | Reference compound |
| HY-115524 | DBCO-NHS ester 2 | 1384870-47-6 | ADC Related |
| HY-115528 | FF-10502 | 184302-49-6 | Reference compound |
| HY-115529 | (-)BI97D6 | 1430067-36-9 | Reference compound |
| HY-115531 | UNC-2170 | 1648707-58-7 | Reference compound |
| HY-115532 | BCL6-IN-7 | 2097518-46-0 | Reference compound |
| HY-115533 | LBL1 | 1605301-58-3 | Reference compound |
| HY-115537 | NAE-IN-M22 | 864420-54-2 | Reference compound |
| HY-115539 | Windorphen | 19881-70-0 | Reference compound |
| HY-115543 | β-catenin-IN-37 | 1783856-40-5 | Reference compound |
| HY-115545 | DBCO-NHS ester 3 | 1393350-27-0 | ADC Related |
| HY-115550 | Chalcone 4 (hydrate) | 1202866-96-3 | Reference compound |
| HY-115551 | BzDANP | 1994258-88-6 | Reference compound |
| HY-115552 | Simmiparib | 1551355-46-4 | Reference compound |
| HY-115553 | DETQ | 1638667-81-8 | Reference compound |
| HY-115555 | K-Ras-PDEδ-IN-1 | 1841464-21-8 | Reference compound |
| HY-115560 | Thalidomide-O-amido-C3-NH2 | 2022182-57-4 | Reference compound |
| HY-115560A | Thalidomide-O-amido-C3-NH2 (TFA) | 2022182-58-5 | Reference compound |
| HY-115562 | Dorrigocin A | 158446-29-8 | Reference compound |
| HY-115566 | S1PL-IN-1 | 1538574-95-6 | Reference compound |
| HY-115567 | 5-NIdR | 191421-10-0 | Reference compound |
| HY-115568 | BETd-246 | 2140289-17-2 | Reference compound |
| HY-115570 | GW406108X | 1644443-92-4 | Reference compound |
| HY-115570A | (Z/E)-GW406108X | 265098-01-9 | Reference compound |
| HY-115574 | RSV L-protein-IN-1 | 851658-10-1 | Reference compound |
| HY-115575 | tBPC | 1942-71-8 | Reference compound |
| HY-115576 | P62-mediated mitophagy inducer | 1809031-84-2 | Reference compound |
| HY-115577 | Mitochonic acid 35 | 1611470-23-5 | Reference compound |
| HY-115579 | MALAT1-IN-1 | 827327-28-6 | Reference compound |
| HY-115581 | Thymidine 3',5'-disphosphate | 2863-04-9 | Reference compound |
| HY-115581A | Thymidine 3',5'-diphosphate (tetrasodium) | 118675-87-9 | Reference compound |
| HY-115582 | 3,4-DMMA (hydrochloride) | 70932-18-2 | Reference compound |
| HY-115584 | Lufenuron | 103055-07-8 | Reference compound |
| HY-115584B | Lufenuron, (-)- | 130841-26-8 | Reference compound |
| HY-115584R | Lufenuron (Standard) | 103055-07-8 | Reference Standards |
| HY-115584S | Lufenuron-13C6 | | Isotope-Labeled Compounds |
| HY-115589 | YLT-11 | | Reference compound |
| HY-115594 | Erasin | | Reference compound |
| HY-115597 | BTT-266 | 2413939-89-4 | Reference compound |
| HY-115604 | Pitstop 2 | 1419320-73-2 | Reference compound |
| HY-115608 | cis-4P-PDOT | 620170-78-7 | Reference compound |
| HY-115613 | ML-180 | 863588-32-3 | Reference compound |
| HY-115615 | VUF11207 (TFA) | 1492153-74-8 | Reference compound |
| HY-115620 | AQX-016A | 849669-54-1 | Reference compound |
| HY-115625 | AG-205 | 1375078-57-1 | Reference compound |
| HY-115627 | PKUMDL-LC-101-D04 | 2143896-83-5 | Reference compound |
| HY-115630 | cRIPGBM (chloride) | 2361988-77-2 | Reference compound |
| HY-115635 | ABO (hydrochloride) | 2309172-24-3 | Reference compound |
| HY-115640 | TRFS-green | 1513848-14-0 | Reference compound |
| HY-115642 | preQ1 (dihydrochloride) | 86694-45-3 | Reference compound |
| HY-115644 | BMS-470539 (dihydrochloride) | 2341796-82-3 | Reference compound |
| HY-115645 | R121919 (hydrochloride) | 195055-66-4 | Reference compound |
| HY-115650 | TAE-1 | 1414469-59-2 | Reference compound |
| HY-115658 | VU0420373 | 38376-29-3 | Reference compound |
| HY-115661 | Bisdionin C | 74857-22-0 | Reference compound |
| HY-115666 | COH34 analog 1 | 314248-24-3 | Reference compound |
| HY-115669 | Pentachloropseudilin | 69640-38-6 | Reference compound |
| HY-115670 | GW280264X | 866924-39-2 | Reference compound |
| HY-115671 | KLH45b | | Reference compound |
| HY-115672 | KS15 | 1033781-20-2 | Reference compound |
| HY-115673 | LAS17 | 2362527-67-9 | Reference compound |
| HY-115676 | GSK199 analog (hydrochloride) | 2048226-46-4 | Reference compound |
| HY-115677 | ILK-IN-3 | 6975-75-3 | Reference compound |
| HY-115681 | (2R/S)-6-PNG | 68682-01-9 | Reference compound |
| HY-115681R | (2R/S)-6-PNG (Standard) | 68682-01-9 | Reference Standards |
| HY-115682 | (S)-ZINC-3573 | 2095596-11-3 | Reference compound |
| HY-115683 | NUN82647 | 16082-64-7 | Reference compound |
| HY-115684 | 2-Undecanol | 1653-30-1 | Natural Products |
| HY-115684R | 2-Undecanol (Standard) | 1653-30-1 | Reference Standards |
| HY-115685 | 3-Methyl-GABA | 1216629-00-3 | Reference compound |
| HY-115686 | 8-Azaadenosine | 10299-44-2 | Reference compound |
| HY-115687 | PDE4B-IN-2 | 915082-52-9 | Reference compound |
| HY-115688 | TXNIP-IN-1 | 1268955-50-5 | Reference compound |
| HY-115688A | (S)-TXNIP-IN-1 | 1212421-96-9 | Reference compound |
| HY-115689 | Maohuoside B | 849834-04-4 | Natural Products |
| HY-115690 | K-TMZ | 2269482-26-8 | Reference compound |
| HY-115691 | STY-BODIPY | 2383063-37-2 | Dye Reagents |
| HY-115692 | 2-Coumaranone-1-L | 1887057-34-2 | Reference compound |
| HY-115693 | CAP 3 | 2292123-03-4 | Reference compound |
| HY-115701 | 1-Stearoyl-2-15(S)-Hpete-Sn-Glycero-3-Pe | 154436-49-4 | Reference compound |
| HY-115702S | 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine-d4 | 211106-54-6 | Isotope-Labeled Compounds |
| HY-115703 | C17 Ceramide (d18:1/17:0) | 67492-16-4 | Natural Products |
| HY-115704 | Butyryl-L-carnitine (chloride) | 162067-50-7 | Reference compound |
| HY-115704S | Butyryl-L-carnitine-d7 (chloride) | | Isotope-Labeled Compounds |
| HY-115704S1 | Butyryl-L-carnitine-d3 (chloride) | 1334532-21-6 | Isotope-Labeled Compounds |
| HY-115705 | 1,2,3-Tri-10(Z)-heptadecenoyl glycerol | 1094209-16-1 | Isotope-Labeled Compounds |
| HY-115705S | 1,2,3-Tri-10(Z)-Heptadecenoyl Glycerol-d5 | | Isotope-Labeled Compounds |
| HY-115706 | 13-Dilignoceroyl glycerol | 120639-92-1 | Isotope-Labeled Compounds |
| HY-115707 | 1-Palmitoyl-3-Linolenoyl-rac-glycerol | 126281-90-1 | Reference compound |
| HY-115708 | C22 Phytoceramide (t18:0/22:0) | 164576-03-8 | Reference compound |
| HY-115708S | C22 Phytoceramide-d3 (t18:0/22:0) | 2011762-87-9 | Isotope-Labeled Compounds |
| HY-115709 | 4,6-O-Benzylidene-D-glucose | 30688-66-5 | Reference compound |
| HY-115711 | Dicrotalic anhydride | 34695-32-4 | Reference compound |
| HY-115712 | DHPS-IN-1 | 2643300-54-1 | Reference compound |
| HY-115713 | Heme Oxygenase-1-IN-2 | 2839158-50-6 | Reference compound |
| HY-115714 | CDK9-IN-12 | 1942843-54-0 | Reference compound |
| HY-115715 | EN219 | 380351-29-1 | Reference compound |
| HY-115715A | EN219-alkyne | | Reference compound |
| HY-115716 | EGFR-IN-17 | 2817679-31-3 | Reference compound |
| HY-115717 | UZH2 | 2756566-45-5 | Reference compound |
| HY-115718 | PZ703b | 2471970-56-4 | Reference compound |
| HY-115718A | PZ703b (TFA) | | Reference compound |
| HY-115718B | PZ703b (hydrochloride) | | Reference compound |
| HY-115719 | CASK-IN-1 | 2755241-73-5 | Reference compound |
| HY-115720 | Betulinic acid derivative-1 | 2708127-92-6 | Reference compound |
| HY-115721 | Antimalarial agent 2 | 2829950-49-2 | Reference compound |
| HY-115722 | (S)-(-)-MRJF22 | 2757301-90-7 | Reference compound |
| HY-115723 | Antiallergic agent-1 | 2839159-12-3 | Reference compound |
| HY-115724 | FPPQ | 1648745-46-3 | Reference compound |
| HY-115725 | Antileishmanial agent-1 | 2454115-43-4 | Reference compound |
| HY-115726 | FRM-024 | 2085780-87-4 | Reference compound |
| HY-115726A | (-)-FRM-024 | 2085780-85-2 | Reference compound |
| HY-115727 | BET-IN-1 | 2727161-43-3 | Reference compound |
| HY-115728 | PROTAC CDK9 degrader-4 | 2411021-01-5 | Reference compound |
| HY-115729 | PROTAC CDK9 ligand-1 | 3031327-95-1 | Reference compound |
| HY-115729A | (R)-PROTAC CDK9 ligand-1 | 2411021-95-7 | Reference compound |
| HY-115730 | RdRP-IN-3 | 2641299-75-2 | Reference compound |
| HY-115731 | Tocol | 119-98-2 | Reference compound |
| HY-115732 | PKA-IN-1 | 179985-52-5 | Reference compound |
| HY-115733 | Cathepsin L-IN-2 | 108005-94-3 | Reference compound |
| HY-115734 | Phenylpyropene C | 419532-92-6 | Reference compound |
| HY-115735 | SKI-I | 306301-68-8 | Reference compound |
| HY-115736 | Xanthosine-5'-Triphosphate | 6253-56-1 | Reference compound |
| HY-115736A | Xanthosine-5'-Triphosphate (trisodium) | 105931-36-0 | Reference compound |
| HY-115737 | L-threo-PPMP | 207278-87-3 | Reference compound |
| HY-115738 | 2-Acetamido-2,4-dideoxy-4-fluoro-α-D-glucopyranose | 129728-87-6 | Reference compound |
| HY-115739 | RTIL 13 | 1009376-10-6 | Reference compound |
| HY-115740 | Cytarabine triphosphate | 13191-15-6 | Reference compound |
| HY-115740A | Cytarabine triphosphate (trisodium) | 1179343-17-9 | Oligonucleotides |
| HY-115741 | 3BrB-PP1 | 956025-99-3 | Reference compound |
| HY-115742 | (Rac)-γ-Tocopherol | 73980-80-0 | Reference compound |
| HY-115743 | TAK1-IN-3 | 494772-87-1 | Reference compound |
| HY-115744 | Mercaptoethylguanidine (MEG) (dihydrobromide) | 32665-11-5 | Reference compound |
| HY-115745 | Calmodulin antagonist-1 | 78957-84-3 | Reference compound |
| HY-115746 | Dimethyl-bisphenol A | 1568-83-8 | Reference compound |
| HY-115747 | Namoline | 342795-11-3 | Reference compound |
| HY-115748 | Mant-GTPγS | 136749-24-1 | Reference compound |
| HY-115748A | Mant-GTPγS (triammonium) | | Reference compound |
| HY-115749 | D-Luciferin 6′-methyl ether | 24404-90-8 | Reference compound |
| HY-115749A | (Rac)-Luciferin 6′-methyl ether (sodium) | 646450-23-9 | Dye Reagents |
| HY-115750 | Nω-allyl-L-arginine | 139461-37-3 | Reference compound |
| HY-115753 | Calpain Inhibitor-1 | 1448429-06-8 | Reference compound |
| HY-115754 | S-(N-PhenethylthiocarbaMoyl)-L-cysteine | 53330-02-2 | Reference compound |
| HY-115755 | Thio-ITP | 27652-34-2 | Reference compound |
| HY-115756 | 4-Maleimidosalicylic acid | 19232-43-0 | Reference compound |
| HY-115758 | PRMT1-IN-1 | 1025948-98-4 | Reference compound |
| HY-115759 | N-Octylmaleimide | 4080-76-6 | Reference compound |
| HY-115760 | Okadaic acid (ammonium salt) | 175522-42-6 | Reference compound |
| HY-115761 | Dihydrochlamydocin | 52574-64-8 | Reference compound |
| HY-115762 | 4-Hydroxytryptamine creatinine sulfate | 55206-11-6 | Reference compound |
| HY-115763 | 3-Aminopropylphosphinic acid | 103680-47-3 | Reference compound |
| HY-115764 | nAChR agonist 2 | 252870-46-5 | Reference compound |
| HY-115765 | N6-Benzyl-5'-ethylcarboxamido adenosine | 152918-32-6 | Reference compound |
| HY-115766 | Anabaseine | 3471-05-4 | Reference compound |
| HY-115767 | (±)-1,2-Diolein | 2442-61-7 | Reference compound |
| HY-115767S | (±)-1,2-Diolein-13C3 | 2692624-38-5 | Isotope-Labeled Compounds |
| HY-115768 | Compound 48/80 | 94724-12-6 | Reference compound |
| HY-115768A | Compound 48/80 (trimer) | | Reference compound |
| HY-115769 | 1,2-Didecanoylglycerol | 17863-69-3 | Reference compound |
| HY-115770 | 8-Methylsulfinyloctyl isothiocyanate | 75272-81-0 | Natural Products |
| HY-115771 | 3-Phenylpropyl isothiocyanate | 2627-27-2 | Reference compound |
| HY-115772 | 4′-Bromoflavone | 20525-20-6 | Reference compound |
| HY-115773 | NMTCA | 103659-08-1 | Reference compound |
| HY-115774 | 5-HT4R agonist-1 | 2231302-46-6 | Reference compound |
| HY-115777 | ARN-6039 | 1675206-11-7 | Reference compound |
| HY-115781 | DN401 | 2135749-60-7 | Reference compound |
| HY-115796 | VU0477886 | 1926222-30-1 | Reference compound |
| HY-115805 | YKL-04-085 | 2120356-29-6 | Reference compound |
| HY-115820 | Cyclo(Pro-Pro) | 6708-06-1 | Natural Products |
| HY-115821 | Ascorutin | 8067-12-7 | Reference compound |
| HY-115822 | α-Fluoromethylhistidine (dihydrochloride) | 81839-27-2 | Reference compound |
| HY-115823 | ztz240 | 325457-98-5 | Reference compound |
| HY-115824 | 7ETMC | 1370702-83-2 | Reference compound |
| HY-115826 | AB-163 | 14984-65-7 | Reference compound |
| HY-115827 | AH22921 | 74480-23-2 | Reference compound |
| HY-115828 | APA-APA-MPO (dihydrochloride) | 1610362-98-5 | Reference compound |
| HY-115829 | APA-H-MPO (hydrochloride) | 1610362-93-0 | Reference compound |
| HY-115831 | SAR247799 | 1315311-14-8 | Reference compound |
| HY-115832 | Ap44mSe | 79514-49-1 | Reference compound |
| HY-115833 | Histamine H4 receptor antagonist-2 | 379247-14-0 | Reference compound |
| HY-115836 | DDPO | 118675-83-5 | Reference compound |
| HY-115837 | DHPCC-9 | 1192248-37-5 | Reference compound |
| HY-115839 | Detajmium | 47719-70-0 | Reference compound |
| HY-115839A | Detajmium (L-tartrate) | 33774-52-6 | Reference compound |
| HY-115840 | ICL-CCIC-0019 | 936498-64-5 | Reference compound |
| HY-115843 | LL-D05139β | 95153-19-8 | Natural Products |
| HY-115844 | LY-99335 | 78738-97-3 | Reference compound |
| HY-115845 | ML366 | 851094-56-9 | Reference compound |
| HY-115848 | Antiviral agent 12 | 314030-54-1 | Reference compound |
| HY-115849 | Nrf2-Activator-12G | 1554271-18-9 | Reference compound |
| HY-115850 | Ornithine-methotrexate | 80407-73-4 | Reference compound |
| HY-115851 | Demethyl PL265 | 1206514-62-6 | Reference compound |
| HY-115853 | Pyclen | 78668-34-5 | Reference compound |
| HY-115854 | Ro 15-1310 | 78756-33-9 | Reference compound |
| HY-115855 | Ro 31-4639 | 125131-65-9 | Reference compound |
| HY-115856 | Sch 50910 | 790633-59-9 | Reference compound |
| HY-115857 | SH-053-S-CH3-2'F | 872874-00-5 | Reference compound |
| HY-115858 | SU-13197 | 12379-49-6 | Reference compound |
| HY-115859 | SCH 25393 | 73212-54-1 | Reference compound |
| HY-115860 | TAS-4 | 794544-99-3 | Reference compound |
| HY-115861 | UCM765 | 944284-77-9 | Reference compound |
| HY-115862 | Benzo[c][1,8]naphthyridin-6(5H)-one | 53439-81-9 | Reference compound |
| HY-115864 | Osavampator | 1358751-06-0 | Reference compound |
| HY-115865 | XIAP degrader-1 | 2803617-91-4 | Reference compound |
| HY-115866 | COX-2-IN-6 | 2756347-91-6 | Reference compound |
| HY-115867 | GSK852 | 2305842-30-0 | Reference compound |
| HY-115867A | (S)-GSK852 | 2305919-51-9 | Reference compound |
| HY-115868 | BMS-911172 | 1644248-18-9 | Reference compound |
| HY-115869 | RMC-4529 | 2250059-27-7 | Reference compound |
| HY-115870 | AZD8154 | 2215022-45-8 | Reference compound |
| HY-115871 | PDE4-IN-4 | 1793069-00-7 | Reference compound |
| HY-115871A | (Rac)-PDE4-IN-4 | | Reference compound |
| HY-115872 | β-Lactamase-IN-6 | 2326468-84-0 | Reference compound |
| HY-115873 | Folate-MS432 | 2769735-56-8 | Reference compound |
| HY-115874 | BMS-753426 | 1004536-52-0 | Reference compound |
| HY-115875 | LDHA-IN-5 | 2776148-90-2 | Reference compound |
| HY-115876 | BTK-IN-5 | 2145152-06-1 | Reference compound |
| HY-115877 | GDC-0334 | 1984824-54-5 | Reference compound |
| HY-115878 | NJH-2-057 | 2858812-70-9 | Reference compound |
| HY-115879 | SHR168442 | 2382961-86-4 | Reference compound |
| HY-115880 | KRAS G12D inhibitor 3 | 2757095-11-5 | Reference compound |
| HY-115880A | KRAS G12D inhibitor 3 (TFA) | 2757095-12-6 | Reference compound |
| HY-115881 | SR-1114 | 2769141-82-2 | Reference compound |
| HY-115882 | PptT-IN-1 | | Reference compound |
| HY-115883 | PptT-IN-2 | 3035894-73-3 | Reference compound |
| HY-115884 | PptT-IN-3 | 3035894-87-9 | Reference compound |
| HY-115885 | XP5 | 2760511-91-7 | Reference compound |
| HY-115887 | R110 | 1985622-33-0 | Reference compound |
| HY-115888 | MIF2-IN-1 | 2917525-79-0 | Reference compound |
| HY-115889 | L-NAPNA | 85697-89-8 | Reference compound |
| HY-115892 | 1,3,9-Trimethyluric acid | 7464-93-9 | Natural Products |
| HY-115893A | P18IN005 (hydrochloride) | 7403-44-3 | Reference compound |
| HY-115894 | DapL-IN-1 | 423732-11-0 | Reference compound |
| HY-115895 | Trebenzomine | 23915-73-3 | Reference compound |
| HY-115896 | Zuclopenthixol decanoate | 64053-00-5 | Reference compound |
| HY-115898 | Decachlorobiphenyl | 2051-24-3 | Reference compound |
| HY-115899 | Malonyl CoA | 524-14-1 | Reference compound |
| HY-115900 | Tuberculosis inhibitor 4 | | Reference compound |
| HY-115901 | 4-PQBH | 2243355-51-1 | Reference compound |
| HY-115902 | FGFR4-IN-7 | 2765046-07-7 | Reference compound |
| HY-115903 | HIF-1α-IN-2 | 2762315-06-8 | Reference compound |
| HY-115903A | HIF-1α-IN-2 (hydrochloride) | | Reference compound |
| HY-115904 | FLT3/CDK4-IN-1 | 2762296-44-4 | Reference compound |
| HY-115905 | Antimalarial agent 9 | 2914224-54-5 | Reference compound |
| HY-115906 | K783-0308 | 422554-29-8 | Reference compound |
| HY-115907 | K20 | | Reference compound |
| HY-115908 | ZDLD13 | 2762278-95-3 | Reference compound |
| HY-115909 | ZDLD20 | 2762279-02-5 | Reference compound |
| HY-115910 | Y13g | 2766380-73-6 | Reference compound |
| HY-115910A | Y13g (dihydrochloride) | | Reference compound |
| HY-115911 | GPVI antagonist 2 | 880399-00-8 | Reference compound |
| HY-115912 | GPVI antagonist 3 | 901654-94-2 | Reference compound |
| HY-115913 | PDE4-IN-6 | | Reference compound |
| HY-115914 | Lipid-lowering agent-1 | 2304859-34-3 | Reference compound |
| HY-115915 | TS010 | | Reference compound |
| HY-115916 | NOS-IN-2 | 2766146-79-4 | Reference compound |
| HY-115917 | NOS-IN-3 | 2761725-68-0 | Reference compound |
| HY-115918 | XA-E | 132998-84-6 | Reference compound |
| HY-115919 | AChE-IN-8 | 2919335-82-1 | Reference compound |
| HY-115920 | Anti-inflammatory agent 8 | 1103920-19-9 | Reference compound |
| HY-115921 | Anti-inflammatory agent 9 | 2910876-54-7 | Reference compound |
| HY-115922 | Anti-inflammatory agent 10 | 2910876-55-8 | Reference compound |
| HY-115923 | Nur77 modulator 2 | 2055829-03-1 | Reference compound |
| HY-115924 | CDK1-IN-1 | 2761858-59-5 | Reference compound |
| HY-115925 | SHP2-IN-9 | 2987135-92-0 | Reference compound |
| HY-115926 | BRD4 Inhibitor-16 | | Reference compound |
| HY-115927 | 8A8 | 2766594-12-9 | Reference compound |
| HY-115928 | M24 | 2761947-05-9 | Reference compound |
| HY-115929 | DENV-IN-4 | 2762302-75-8 | Reference compound |
| HY-115930 | Bim-IN-1 | 2909483-36-7 | Reference compound |
| HY-115932 | Aurora kinase-IN-1 | | Reference compound |
| HY-115933 | EGFR/BRAF-IN-1 | 2906174-89-6 | Reference compound |
| HY-115934 | COX-2-IN-7 | | Reference compound |
| HY-115935 | COX-2-IN-8 | | Reference compound |
| HY-115936 | COX-2-IN-9 | | Reference compound |
| HY-115937 | c-Met-IN-9 | 2760326-29-0 | Reference compound |
| HY-115938 | BEC2 | 1429614-99-2 | Reference compound |
| HY-115939 | Urease-IN-2 | | Reference compound |
| HY-115940 | Aldose reductase-IN-2 | 1687735-82-5 | Reference compound |
| HY-115941 | HDAC-IN-9 | | Reference compound |
| HY-115942 | Anticancer agent 29 | 2907774-89-2 | Reference compound |
| HY-115943 | Anticancer agent 30 | 2907774-88-1 | Reference compound |
| HY-115944 | BTK-IN-9 | 2361192-21-2 | Reference compound |
| HY-115945 | Complex III-IN-1 | | Reference compound |
| HY-115946 | Complex III-IN-2 | | Reference compound |
| HY-115947 | Anticancer agent 33 | | Reference compound |
| HY-115948 | Antitumor agent-46 | 2917547-18-1 | Reference compound |
| HY-115949 | Antitumor agent-47 | 2917547-24-9 | Reference compound |
| HY-115950 | Antitumor agent-48 | 2917547-29-4 | Reference compound |
| HY-115951 | EGFR/HER2-IN-2 | 1215571-02-0 | Reference compound |
| HY-115952 | EGFR/HER2-IN-3 | 1031620-09-3 | Reference compound |
| HY-115953 | Dopamine D3 receptor ligand-1 | 2882828-93-3 | Reference compound |
| HY-115954 | Dopamine D3 receptor ligand-2 | 2882828-95-5 | Reference compound |
| HY-115955 | Dopamine D3 receptor ligand-3 | 2891605-81-3 | Reference compound |
| HY-115956 | Tubulin inhibitor 18 | 2762382-51-2 | Reference compound |
| HY-115957 | Tubulin inhibitor 19 | | Reference compound |
| HY-115958 | Tubulin inhibitor 20 | 860356-56-5 | Reference compound |
| HY-115959 | Anticancer agent 34 | 2379335-06-3 | Reference compound |
| HY-115960 | Anticancer agent 35 | 2902563-75-9 | Reference compound |
| HY-115961 | Anticancer agent 36 | 2902563-76-0 | Reference compound |
| HY-115962 | Anticancer agent 37 | 905783-28-0 | Reference compound |
| HY-115963 | Anticancer agent 38 | 69123-54-2 | Reference compound |
| HY-115964 | VP-4556 | 654633-67-7 | Reference compound |
| HY-115965 | VP-4604 | 64268-93-5 | Reference compound |
| HY-115965R | VP-4604 (Standard) | 64268-93-5 | Reference Standards |
| HY-115966 | COX-1/2-IN-1 | 2358849-47-3 | Reference compound |
| HY-115967 | COX-1/2-IN-2 | 2882832-86-0 | Reference compound |
| HY-115968 | Dopamine D3 receptor ligand-4 | 2376333-77-4 | Reference compound |
| HY-115969 | F-17 | 1572464-22-2 | Reference compound |
| HY-115970 | Tubulin inhibitor 21 | | Reference compound |
| HY-115971 | Anti-Trypanosoma cruzi agent-1 | 2854299-38-8 | Reference compound |
| HY-115972 | Anti-Trypanosoma cruzi agent-2 | 2863602-85-9 | Reference compound |
| HY-115973 | AChE-IN-11 | | Reference compound |
| HY-115974 | GRPR antagonist-1 | 3052544-28-9 | Reference compound |
| HY-115975 | GRPR antagonist-2 | 3052544-42-7 | Reference compound |
| HY-115976 | COX-2-IN-10 | | Reference compound |
| HY-115977 | Aldose reductase-IN-3 | 1390616-76-8 | Reference compound |
| HY-115978 | α-Glucosidase-IN-2 | 2699784-18-2 | Reference compound |
| HY-115979 | Sirt2-IN-5 | 902456-47-7 | Reference compound |
| HY-115981 | NS5A-IN-2 | 2764786-74-3 | Reference compound |
| HY-115982 | NS5A-IN-3 | 2764786-56-1 | Reference compound |
| HY-115983 | DMUP | 2364350-07-0 | Reference compound |
| HY-115986 | MAO-B-IN-5 | 849909-77-9 | Reference compound |
| HY-115987 | MAO-B-IN-6 | 2376198-66-0 | Reference compound |
| HY-115988 | IMB-26 | 1001426-49-8 | Reference compound |
| HY-115989 | HCV-IN-38 | 3035807-39-4 | Reference compound |
| HY-115990 | Topoisomerase IV inhibitor 1 | 2883403-42-5 | Reference compound |
| HY-115991 | Topoisomerase IV inhibitor 2 | 2883403-36-7 | Reference compound |
| HY-115992 | CDK4/6-IN-9 | 2688098-02-2 | Reference compound |
| HY-115993 | CDK4/6-IN-10 | 2688098-11-3 | Reference compound |
| HY-115994 | Carbonic anhydrase inhibitor 10 | 2883453-30-1 | Reference compound |
| HY-115995 | Antitumor agent-50 | 2891985-53-6 | Reference compound |
| HY-115996 | Antitumor agent-51 | 3035774-65-0 | Reference compound |
| HY-115997 | PROTAC HSP90 degrader BP3 | 2669072-88-0 | Reference compound |
| HY-115998 | Carbonic anhydrase inhibitor 11 | 2411059-71-5 | Reference compound |
| HY-115999 | Carbonic anhydrase inhibitor 12 | 2883451-38-3 | Reference compound |
| HY-116000 | Glumetinib | 1642581-63-2 | Reference compound |
| HY-116001 | (+)-Carbovir | 124915-24-8 | Reference compound |
| HY-116001B | (-)-Carbovir | 120443-30-3 | Reference compound |
| HY-116003 | 12,13-DiHOME | 263399-35-5 | Reference compound |
| HY-116004 | Anti-Trypanosoma cruzi agent-5 | 205381-53-9 | Reference compound |
| HY-116005 | A-286501 | 483341-15-7 | Reference compound |
| HY-116006 | Bis-PEG5-acid | 439114-13-3 | Reference compound |
| HY-116007 | Gaxilose | 14087-31-1 | Natural Products |
| HY-116008 | 8-iso Prostaglandin F3α | 7045-31-0 | Reference compound |
| HY-116009 | RMC-4550 | 2172651-73-7 | Reference compound |
| HY-116010 | Oleandomycin | 3922-90-5 | Reference compound |
| HY-116010A | Oleandomycin (phosphate) | 7060-74-4 | Reference compound |
| HY-116010R | Oleandomycin (Standard) | 3922-90-5 | Reference Standards |
| HY-116011 | N,N’-bis-Cbz-β-Alethine | 104071-84-3 | Reference compound |
| HY-116013 | Dodecylphosphocholine | 29557-51-5 | Reference compound |
| HY-116013S | Dodecylphosphocholine-d38 | 130890-78-7 | Isotope-Labeled Compounds |
| HY-116013S1 | Dodecylphosphocholine-d25 | 861924-55-2 | Isotope-Labeled Compounds |
| HY-116015 | Dihomo-γ-Linolenic acid methyl ester | 21061-10-9 | Reference compound |
| HY-116016 | Etilevodopa | 37178-37-3 | Reference compound |
| HY-116016A | Etilevodopa (hydrochloride) | 39740-30-2 | Reference compound |
| HY-116016AR | Etilevodopa (hydrochloride) (Standard) | 39740-30-2 | Reference Standards |
| HY-116016R | Etilevodopa (Standard) | 37178-37-3 | Reference Standards |
| HY-116017 | C10 Ceramide | 111122-57-7 | Natural Products |
| HY-116018 | FKGK11 | 1071000-98-0 | Reference compound |
| HY-116020 | FAUC 365 | 474432-66-1 | Reference compound |
| HY-116021 | Buquinolate | 5486-03-3 | Reference compound |
| HY-116021S | Buquinolate-13C3 | | Isotope-Labeled Compounds |
| HY-116022 | 4-Nitrophenyl phosphate | 330-13-2 | Reference compound |
| HY-116022A | 4-Nitrophenyl phosphate (disodium hexahydrate) | 333338-18-4 | Biochemical Assay Reagents |
| HY-116022B | 4-Nitrophenyl phosphate (ditromethamine) | 68189-42-4 | Biochemical Assay Reagents |
| HY-116022C | 4-Nitrophenyl phosphate (cyclohexylammonium) | 52483-84-8 | Biochemical Assay Reagents |
| HY-116023 | Moveltipril | 85856-54-8 | Reference compound |
| HY-116024 | Dimefuron | 34205-21-5 | Reference compound |
| HY-116025 | APN-C3-PEG4-alkyne | 2183440-36-8 | Reference compound |
| HY-116026 | 3-Hydroxycarbofuran | 16655-82-6 | Reference compound |
| HY-116026R | 3-Hydroxycarbofuran (Standard) | 16655-82-6 | Reference Standards |
| HY-116026S | 3-Hydroxycarbofuran-d3 | 1794759-59-3 | Isotope-Labeled Compounds |
| HY-116027 | Biotin-PEG3-acid | 252881-76-8 | Reference compound |
| HY-116028 | 15-deoxy-Δ12,14-Prostaglandin D2 | 85235-11-6 | Reference compound |
| HY-116028S1 | 15-deoxy-Δ12,14-Prostaglandin D2-d4 | | Isotope-Labeled Compounds |
| HY-116029 | Tolmetin β-D-Glucuronide | 71595-19-2 | Reference compound |
| HY-116030 | JNJ-26076713 | 669076-03-3 | Reference compound |
| HY-116031 | ATC0175 (free base) | 509118-03-0 | Reference compound |
| HY-116033 | BMS-363131 | 384829-65-6 | Reference compound |
| HY-116034 | Arasertaconazole | 583057-48-1 | Reference compound |
| HY-116035 | Nimbolide | 25990-37-8 | Natural Products |
| HY-116037 | cis-10-Heptadecenoic acid | 29743-97-3 | Biochemical Assay Reagents |
| HY-116037A | trans-10-Heptadecenoic acid | 126761-43-1 | Natural Products |
| HY-116038 | Kulinone | 21688-61-9 | Natural Products |
| HY-116039 | Epiroprim | 73090-70-7 | Reference compound |
| HY-116042 | FSCPX | 156547-56-7 | Reference compound |
| HY-116043 | Prodiamine | 29091-21-2 | Reference compound |
| HY-116044 | BCATc Inhibitor 2 | 406191-34-2 | Reference compound |
| HY-116045 | PDEB1-IN-1 | 1622300-88-2 | Reference compound |
| HY-116046 | GR 196429 | 170729-12-1 | Reference compound |
| HY-116047 | Anisylacetone | 104-20-1 | Natural Products |
| HY-116047R | Anisylacetone (Standard) | 104-20-1 | Reference Standards |
| HY-116047S | Anisylacetone-d5 | 2676886-20-5 | Isotope-Labeled Compounds |
| HY-116050 | 17(S)-HETE | 183509-25-3 | Reference compound |
| HY-116050A | 17(R)-HETE | 183509-24-2 | Reference compound |
| HY-116051 | 16,16-Dimethylprostaglandin F2α | 39746-23-1 | Reference compound |
| HY-116051A | 16,16-Dimethylprostaglandin F2β | 59769-89-0 | Reference compound |
| HY-116052 | p53-MDM2-IN-2 | 1542066-69-2 | Reference compound |
| HY-116055 | (2R)-Glycerol-O-β-D-galactopyranoside | 16232-91-0 | Reference compound |
| HY-116056 | 16-O-Methylcafestol | 108214-28-4 | Natural Products |
| HY-116057 | Stemazole | 317337-07-8 | Reference compound |
| HY-116060 | RK-286D | 140429-37-4 | Reference compound |
| HY-116062 | JNJ-7925476 (hydrochloride) | 109085-56-5 | Reference compound |
| HY-116062A | JNJ-7925476 | 129540-12-1 | Reference compound |
| HY-116063 | Doxorubicin-SMCC | 400647-59-8 | ADC Related |
| HY-116065 | CUMI-101 | 179756-61-7 | Reference compound |
| HY-116066 | YM471 (free base) | 183173-00-4 | Reference compound |
| HY-116067 | VU0404251 | 1276013-77-4 | Reference compound |
| HY-116069 | Propargyl-PEG1-NH2 | 122116-12-5 | Reference compound |
| HY-116070 | Iodoantipyrine | 129-81-7 | Reference compound |
| HY-116071 | Autophagy-IN-3 | 1227476-98-3 | Reference compound |
| HY-116072 | Antiarrhythmic agent-2 | 105919-73-1 | Reference compound |
| HY-116073 | L-Penicillamine | 1113-41-3 | Peptides |
| HY-116074 | FUB-PB-22 3-carboxyindole metabolite | 226883-79-0 | Reference compound |
| HY-116076 | S-15535 | 146998-34-7 | Reference compound |
| HY-116077 | AB 5046B | 154037-63-5 | Natural Products |
| HY-116078 | CKD-519 | 1402796-27-3 | Reference compound |
| HY-116080 | SB 210661 | 162750-10-9 | Reference compound |
| HY-116081 | LY 221501 | 145512-35-2 | Reference compound |
| HY-116082 | CP 226269 | 220941-93-5 | Reference compound |
| HY-116083 | 13,14-Dihydro-15-keto-tetranor prostaglandin D2 | 1204116-69-7 | Reference compound |
| HY-116084 | Trimethylamine N-oxide | 1184-78-7 | Natural Products |
| HY-116084S | Trimethylamine N-oxide-d9 | 1161070-49-0 | Isotope-Labeled Compounds |
| HY-116084S1 | Trimethylamine-N-oxide-13C3 | | Isotope-Labeled Compounds |
| HY-116087 | SRS11-92 | 1467047-25-1 | Reference compound |
| HY-116088 | W123 | 1345982-24-2 | Reference compound |
| HY-116090 | Conoidin A | 18080-67-6 | Reference compound |
| HY-116095 | CypD-IN-5 | 1572646-93-5 | Reference compound |
| HY-116096 | 15-epi-PGE1 | 20897-91-0 | Reference compound |
| HY-116097 | PSB-1491 | 1619884-67-1 | Reference compound |
| HY-116098 | Anecortave desacetate | 10184-70-0 | Reference compound |
| HY-116099 | ER-819762 | 1155773-15-1 | Reference compound |
| HY-116100 | (E/Z)-HA155 | 1229652-22-5 | Reference compound |
| HY-116100A | HA155 | 1312201-00-5 | Reference compound |
| HY-116102 | Laurinterol | 10539-87-4 | Reference compound |
| HY-116104 | Americanol A | 133838-65-0 | Natural Products |
| HY-116105 | Cyclazodone | 14461-91-7 | Reference compound |
| HY-116105S | Cyclazodone-d5 | 1246817-86-6 | Isotope-Labeled Compounds |
| HY-116107 | AG311 | 1126602-42-3 | Reference compound |
| HY-116108 | Musk tibetene | 145-39-1 | Natural Products |
| HY-116109 | LAS 30538 | 145067-04-5 | Reference compound |
| HY-116111 | AG 370 | 134036-53-6 | Reference compound |
| HY-116114 | 7(Z),11(Z)-Pentacosadiene | 127599-39-7 | Biochemical Assay Reagents |
| HY-116115 | 17-Oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid | 1233715-33-7 | Natural Products |
| HY-116116 | Tafetinib | 1032265-57-8 | Reference compound |
| HY-116117 | Salicylcurcumin | 1236545-54-2 | Natural Products |
| HY-116119 | BDF 9148 | 120838-62-2 | Reference compound |
| HY-116120 | N-Acetyldesloratadine | 117796-52-8 | Reference compound |
| HY-116121 | S-Nitrosohomocysteine | 139427-42-2 | Reference compound |
| HY-116124 | 17(S)-HpDHA | 123673-33-6 | Reference compound |
| HY-116126 | Leuhistin | 129085-76-3 | Natural Products |
| HY-116128 | Brassilexin | 119752-76-0 | Natural Products |
| HY-116129 | BPR1J-340 | 1395051-72-5 | Reference compound |
| HY-116131 | DAC-2-25 | 1675245-09-6 | Reference compound |
| HY-116132 | Kotanin | 27909-08-6 | Natural Products |
| HY-116133 | 3-Hydroxystearic acid | 17773-30-7 | Natural Products |
| HY-116136 | Acanthoic acid | 119290-87-8 | Natural Products |
| HY-116137 | Nav1.7-IN-17 | 1235403-87-8 | Reference compound |
| HY-116138 | RG-14467 | 137515-05-0 | Reference compound |
| HY-116139 | Isoxaflutole | 141112-29-0 | Reference compound |
| HY-116139R | Isoxaflutole (Standard) | 141112-29-0 | Reference Standards |
| HY-116141 | 7-Hydroxycoumarinyl arachidonate | 161180-11-6 | Reference compound |
| HY-116143 | MAGL-IN-12 | 1352011-38-1 | Reference compound |
| HY-116144 | Picaridin | 119515-38-7 | Reference compound |
| HY-116144R | Picaridin (Standard) | 119515-38-7 | Reference Standards |
| HY-116145 | MHY884 | 1393371-35-1 | Reference compound |
| HY-116146 | CYM50179 | 1355026-47-9 | Reference compound |
| HY-116147 | Ceranib-2 | 1402830-75-4 | Reference compound |
| HY-116148 | AHR-11797 | 125992-09-8 | Reference compound |
| HY-116149 | A-424274 | 1335145-56-6 | Reference compound |
| HY-116150 | Xymedon | 14716-32-6 | Reference compound |
| HY-116151B | Phloxine B | 18472-87-2 | Dye Reagents |
| HY-116152 | Cipepofol | 1637741-58-2 | Reference compound |
| HY-116152A | (S)-Cipepofol | 1637741-59-3 | Reference compound |
| HY-116152S | Cipepofol-d6 | 2677052-88-7 | Isotope-Labeled Compounds |
| HY-116152S2 | Cipepofol-d6-2 | 2677052-87-6 | Isotope-Labeled Compounds |
| HY-116153 | HUHS2002 | 1393102-59-4 | Reference compound |
| HY-116154 | Metacavir | 120503-45-9 | Reference compound |
| HY-116157 | Pyranthrone | 128-70-1 | Dye Reagents |
| HY-116158 | Oosponol | 146-04-3 | Natural Products |
| HY-116161 | Bimatoprost isopropyl ester | 130273-87-9 | Reference compound |
| HY-116161A | 17-Phenyl trinor PGF2α isopropyl ester | 130209-76-6 | Reference compound |
| HY-116163 | ML350 | | Reference compound |
| HY-116164 | A-79175 | 141579-87-5 | Reference compound |
| HY-116165 | ML-298 | 1426916-02-0 | Reference compound |
| HY-116166 | Methyl 3-hydroxyundecanoate | 129758-71-0 | Natural Products |
| HY-116167 | RY 024 | 173990-15-3 | Reference compound |
| HY-116168 | Aldecalmycin | 139953-58-5 | Natural Products |
| HY-116169 | KUC-7322 | 255734-04-4 | Reference compound |
| HY-116170 | SN34037 | 1548116-54-6 | Reference compound |
| HY-116171 | (Rac)-Calpain Inhibitor XII | 181769-57-3 | Reference compound |
| HY-116174 | Omaciclovir | 124265-89-0 | Reference compound |
| HY-116175 | BIBB 515 | 156635-05-1 | Reference compound |
| HY-116181 | YQA14 | 1221408-42-9 | Reference compound |
| HY-116182 | RO5487624 | 1399103-28-6 | Reference compound |
| HY-116183 | ITX 4520 | 1392116-37-8 | Reference compound |
| HY-116184 | PF-05387252 | 1604034-71-0 | Reference compound |
| HY-116185 | N-Acetyl-3,4-methylenedioxymethcathinone | 1227293-15-3 | Reference compound |
| HY-116186 | m-PEG5-MS | 130955-38-3 | ADC Related |
| HY-116188 | HX1 | 1520083-61-7 | Reference compound |
| HY-116189 | Julibrine I | 142628-28-2 | Natural Products |
| HY-116191 | WJD008 | 1309087-83-9 | Reference compound |
| HY-116193 | 5-PAHSA | 1481636-41-2 | Reference compound |
| HY-116193S | 5-PAHSA-d31 | 2749807-01-8 | Isotope-Labeled Compounds |
| HY-116194 | NaV1.7 blocker-801 | 1235403-75-4 | Reference compound |
| HY-116195 | L-Linalool | 126-91-0 | Natural Products |
| HY-116195R | L-Linalool (Standard) | 126-91-0 | Reference Standards |
| HY-116196 | 17-HETE | 128914-47-6 | Reference compound |
| HY-116197 | CGP44532 | 133345-68-3 | Reference compound |
| HY-116198 | 15-PGDH-IN-2 | 1221413-57-5 | Reference compound |
| HY-116201 | 1-Methyl-3-BZP | 137539-25-4 | Reference compound |
| HY-116202 | PACA | 1431724-30-9 | Reference compound |
| HY-116203 | BN 50739 | 128672-07-1 | Reference compound |
| HY-116204 | SKLB70326 | 1257317-77-3 | Reference compound |
| HY-116205 | UBP684 | 1357838-47-1 | Reference compound |
| HY-116208 | Dalcotidine | 120958-90-9 | Reference compound |
| HY-116209 | Pyrogallol triacetate | 525-52-0 | Reference compound |
| HY-116210 | Phenylphosphinic acid | 1779-48-2 | Reference compound |
| HY-116211 | Amfonelic acid | 15180-02-6 | Reference compound |
| HY-116212 | JCP-170 | 120218-98-6 | Reference compound |
| HY-116213 | Sparstolonin B | 1259330-61-4 | Reference compound |
| HY-116214 | Cyprodinil | 121552-61-2 | Reference compound |
| HY-116214R | Cyprodinil (Standard) | 121552-61-2 | Reference Standards |
| HY-116214S | Cyprodinil-d5 | 1773496-67-5 | Isotope-Labeled Compounds |
| HY-116214S1 | Cyprodinil-13C6 | 1773496-63-1 | Isotope-Labeled Compounds |
| HY-116215 | 2-NBDG | 186689-07-6 | Dye Reagents |
| HY-116216 | PD 168368 | 204066-82-0 | Reference compound |
| HY-116217 | 5-Fluoro-2'-deoxycytidine | 10356-76-0 | Reference compound |
| HY-116218 | Amelparib | 1227156-72-0 | Reference compound |
| HY-116218C | Amelparib (hydrochloride) | | Reference compound |
| HY-116220 | Mcl1-IN-14 | 2012563-29-8 | Reference compound |
| HY-116222 | A 53693 | 115103-48-5 | Reference compound |
| HY-116223 | Tianagliflozin | 1461750-27-5 | Reference compound |
| HY-116227 | (2S,3R)-LP99 | 1808948-28-8 | Reference compound |
| HY-116228 | Cadrofloxacin | 153808-85-6 | Reference compound |
| HY-116229 | Gemifloxacin | 175463-14-6 | Reference compound |
| HY-116230 | BI-L-45 XX | 111317-77-2 | Reference compound |
| HY-116231 | (S)-Gyramide A | 1000592-48-2 | Reference compound |
| HY-116232 | 2-(3-Pyridyl)-benzimidazole | 1137-67-3 | Reference compound |
| HY-116236 | THIIC | 1204737-09-6 | Reference compound |
| HY-116237 | CREBBP-IN-9 | 1219576-50-7 | Reference compound |
| HY-116238 | ROCK-IN-D2 | 1219721-78-4 | Reference compound |
| HY-116239 | Zenarestat | 112733-06-9 | Reference compound |
| HY-116240 | 2′,3′-Dideoxy-5-ethyluridine | 108895-49-4 | Reference compound |
| HY-116241 | L-157012 | 114801-28-4 | Reference compound |
| HY-116242 | Dioctyl adipate | 123-79-5 | Reference compound |
| HY-116245 | Octanophenone | 1674-37-9 | Reference compound |
| HY-116246 | 5(S)-HETE lactone | 127708-42-3 | Reference compound |
| HY-116247 | ST247 | 1356497-91-0 | Reference compound |
| HY-116248 | Ro 41-5253 | 144092-31-9 | Reference compound |
| HY-116250 | Prostaglandin D2-1-glyceryl ester | 309260-52-4 | Reference compound |
| HY-116251 | CID21480113 | 1648-34-6 | Reference compound |
| HY-116252 | (±)-trans-Lamivudine | 131086-22-1 | Reference compound |
| HY-116254 | L-739750 | 160141-08-2 | Reference compound |
| HY-116255 | MS453 | 2059892-29-2 | Reference compound |
| HY-116257 | GSK-7227 | 1067214-81-6 | Reference compound |
| HY-116258 | C16 Ceramide (d16:1,C16:0) | 123065-37-2 | Reference compound |
| HY-116258S | C16 Ceramide-d7 (d16:1,C16:0) | 1840942-13-3 | Isotope-Labeled Compounds |
| HY-116259 | PT-S58 | 1356497-92-1 | Reference compound |
| HY-116262 | SCH 51866 | 167298-74-0 | Reference compound |
| HY-116263 | CATPB | 1322598-09-3 | Reference compound |
| HY-116264 | CatB-IN-1 | 1417737-67-7 | Reference compound |
| HY-116266 | RS 67333 | 160845-95-4 | Reference compound |
| HY-116269 | AZA197 | 1249398-09-1 | Reference compound |
| HY-116270 | DBCO-Maleimide | 1395786-30-7 | ADC Related |
| HY-116271 | Sperabillin C | 111337-84-9 | Natural Products |
| HY-116272 | A51493A | 121245-06-5 | Reference compound |
| HY-116273 | ML299 | 1426916-00-8 | Reference compound |
| HY-116274 | BMS-8 | 1675201-90-7 | Reference compound |
| HY-116277 | Z118332870 | 1223377-83-0 | Reference compound |
| HY-116278 | HJC0149 | 1430330-65-6 | Reference compound |
| HY-116279 | JG-48 | 1627122-26-2 | Reference compound |
| HY-116280 | Aceratioside | 133084-09-0 | Natural Products |
| HY-116281 | ICI D1542 | 147332-48-7 | Reference compound |
| HY-116282 | Dextran sulfate sodium salt (MW 5000) | 9011-18-1 | Biochemical Assay Reagents |
| HY-116282A | Dextran sulfate sodium salt (MW 4500-5500) | 9011-18-1 | Reference compound |
| HY-116282B | Dextran sulfate sodium salt (MW 16000-24000) | 9011-18-1 | Reference compound |
| HY-116282C | Dextran sulfate sodium salt (MW 35000-45000) | 9011-18-1 | Reference compound |
| HY-116282D | Dextran sulfate sodium salt (MW 450000-550000) | 9011-18-1 | Reference compound |
| HY-116282H | Dextran sulfate sodium salt (MW 9000-20000) | 9011-18-1 | Biochemical Assay Reagents |
| HY-116282I | Dextran sulfate sodium salt (MW>500000) | 9011-18-1 | Biochemical Assay Reagents |
| HY-116282J | Dextran sulfate, low sulfate (MW 5000) | 9011-18-1 | Biochemical Assay Reagents |
| HY-116282M | Dextran sulfate, low sulfate (MW 40000) | 9011-18-1 | Biochemical Assay Reagents |
| HY-116282P | Dextran sulfate, high sulfate (MW 5000) | 9011-18-1 | Biochemical Assay Reagents |
| HY-116282W | Dextran sulfate sodium salt (MW 6500-10000) | 9011-18-1 | Biochemical Assay Reagents |
| HY-116283 | 2,3:5,6-Di-O-isopropylidene-L-gulono-1,4-lactone | 7306-64-1 | Biochemical Assay Reagents |
| HY-116284 | Methyl β-D-glucopyranoside | 709-50-2 | Reference compound |
| HY-116284A | Methyl β-D-glucopyranoside (hemihydrate) | 7000-27-3 | Natural Products |
| HY-116285 | n-Octyl β-D-glucopyranoside | 29836-26-8 | Biochemical Assay Reagents |
| HY-116285S | n-Octyl β-D-glucopyranoside-d24 | 869666-57-9 | Isotope-Labeled Compounds |
| HY-116285S1 | 1-O-n-Octyl-β-D-glucopyranoside-d17 | 129522-81-2 | Isotope-Labeled Compounds |
| HY-116290 | Zaragozic acid A | 142561-96-4 | Natural Products |
| HY-116290A | Zaragozic acid A (trisodium) | 144541-82-2 | Reference compound |
| HY-116291 | 4α-Phorbol 12,13-didecanoate | 27536-56-7 | Reference compound |
| HY-116294A | Methoctramine (tetrahydrochloride) | 104807-46-7 | Reference compound |
| HY-116298 | MRS 2500 | 779323-43-2 | Reference compound |
| HY-116301 | CAY10502 | 888320-29-4 | Reference compound |
| HY-116302 | MMP-9-IN-9 | 206549-55-5 | Reference compound |
| HY-116304 | 1G244 | 847928-32-9 | Reference compound |
| HY-116306 | Probestin | 123652-87-9 | Reference compound |
| HY-116307 | 2-Thio-UTP | 35763-29-2 | Reference compound |
| HY-116309 | SDZ 216-525 | 141533-35-9 | Reference compound |
| HY-116312 | 8-CPT-2'-O-Me-cAMP | 510774-50-2 | Reference compound |
| HY-116325 | 3,5,3'-Triiodo-D-thyronine | 5714-08-9 | Reference compound |
| HY-116326 | BayCysLT2 | 712313-33-2 | Reference compound |
| HY-116330 | Hyperforin | 11079-53-1 | Natural Products |
| HY-116330A | Hyperforin (dicyclohexylammonium salt) | 238074-03-8 | Natural Products |
| HY-116330AR | Hyperforin (dicyclohexylammonium salt) (Standard) | 238074-03-8 | Reference Standards |
| HY-116349 | Bromodomain IN-1 | 1914120-48-1 | Reference compound |
| HY-116364 | AZT triphosphate | 92586-35-1 | Reference compound |
| HY-116364A | AZT triphosphate (TEA) | | Reference compound |
| HY-116364B | AZT triphosphate (tetraammonium) | 106060-92-8 | Reference compound |
| HY-116364C | AZT triphosphate (sodium) | 149022-21-9 | Biochemical Assay Reagents |
| HY-116374 | Glycolithocholic acid | 474-74-8 | Reference compound |
| HY-116374A | Glycolithocholic acid (sodium) | 24404-83-9 | Reference compound |
| HY-116374S | Glycolithocholic acid-d4 | 2044276-16-4 | Isotope-Labeled Compounds |
| HY-116377 | DU-14 | 186303-55-9 | Reference compound |
| HY-116379 | RS-100329 | 232953-52-5 | Reference compound |
| HY-116380 | CB2 receptor antagonist 5 | 1314230-69-7 | Reference compound |
| HY-116386 | GSK334429 | 799557-57-6 | Reference compound |
| HY-116387 | WR99210 | 47326-86-3 | Reference compound |
| HY-116387A | WR99210 (hydrochloride) | 30711-93-4 | Reference compound |
| HY-116392A | (−)-L-threo-PDMP (hydrochloride) | 161491-04-9 | Reference compound |
| HY-116392B | DL-threo-PDMP (hydrochloride) | 80938-69-8 | Reference compound |
| HY-116392D | PDMP (hydrochloride) | 73257-80-4 | Reference compound |
| HY-116392E | D-threo-PDMP | 109836-82-0 | Reference compound |
| HY-116392F | D-threo-PDMP (hydrochloride) | 139889-62-6 | Reference compound |
| HY-116392G | D,L-erythro-PDMP | 109760-77-2 | Reference compound |
| HY-116392H | D,L-erythro-PDMP (hydrochloride) | 80943-40-4 | Reference compound |
| HY-116399 | MMP-2/MMP-9-IN-1 | 193807-58-8 | Reference compound |
| HY-116400 | BN 50341 | 107550-66-3 | Reference compound |
| HY-116408 | Propiverine | 60569-19-9 | Reference compound |
| HY-116408A | Propiverine (hydrochloride) | 54556-98-8 | Reference compound |
| HY-116408AR | Propiverine (hydrochloride) (Standard) | 54556-98-8 | Reference Standards |
| HY-116408AS | Propiverine-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-116418 | Virodhamine | 287937-12-6 | Reference compound |
| HY-116420 | ROCK2-IN-8 | 681173-76-2 | Reference compound |
| HY-116422 | N,N-Dimethyl sphinganine | 17267-46-8 | Natural Products |
| HY-116423 | JH295 | 1311143-71-1 | Reference compound |
| HY-116423A | JH295 (hydrate) | 2714087-26-8 | Reference compound |
| HY-116424 | DYn-2 | 1354630-46-8 | Reference compound |
| HY-116425 | N-1-Naphthylphthalamic acid | 132-66-1 | Reference compound |
| HY-116425R | N-1-Naphthylphthalamic acid (Standard) | 132-66-1 | Reference Standards |
| HY-116426 | IDT | 18138-19-7 | Reference compound |
| HY-116427 | Propargyl-PEG4-thiol | 1347750-80-4 | ADC Related |
| HY-116429 | Maresin 1 | 1268720-28-0 | Reference compound |
| HY-116429A | 7(S)-Maresin 1 | 1268720-66-6 | Reference compound |
| HY-116429S | Maresin 1-d5 | | Isotope-Labeled Compounds |
| HY-116431 | I-BOP | 128719-90-4 | Reference compound |
| HY-116432 | Hancolupenone | 132746-04-4 | Natural Products |
| HY-116433 | Nequinate | 13997-19-8 | Reference compound |
| HY-116433R | Nequinate (Standard) | 13997-19-8 | Reference Standards |
| HY-116434 | LY 189332 | 123215-05-4 | Reference compound |
| HY-116436 | Clathrodin | 135383-64-1 | Reference compound |
| HY-116437 | Selatinib | 1275595-86-2 | Reference compound |
| HY-116439 | Diisononyl phthalate | 28553-12-0 | Reference compound |
| HY-116441 | 4-Hydroxy-3-methoxyamphetamine (hydrochloride) | 13062-61-8 | Reference compound |
| HY-116442 | Azapropazone | 13539-59-8 | Reference compound |
| HY-116442R | Azapropazone (Standard) | 13539-59-8 | Reference Standards |
| HY-116443 | 2-Amino-1-phenylbutane (hydrochloride) | 20735-15-3 | Reference compound |
| HY-116444 | 16(S)-HETE | 183509-23-1 | Reference compound |
| HY-116444A | 16-HETE | 128914-46-5 | Reference compound |
| HY-116445 | UNC9975 | 1354030-19-5 | Reference compound |
| HY-116446 | Pironetin | 151519-02-7 | Reference compound |
| HY-116447 | Antitumor agent-159 | 1611446-66-2 | Reference compound |
| HY-116448 | Metaflumizone | 139968-49-3 | Reference compound |
| HY-116448R | Metaflumizone (Standard) | 139968-49-3 | Reference Standards |
| HY-116448S | Metaflumizone-d4 | | Isotope-Labeled Compounds |
| HY-116450 | TISCH | 131615-52-6 | Reference compound |
| HY-116451 | PF-04859989 (hydrochloride) | 177943-33-8 | Reference compound |
| HY-116452 | YLT192 | 1246566-47-1 | Reference compound |
| HY-116453 | RO5527239 | 1354812-99-9 | Reference compound |
| HY-116454 | GSK5750 | 1312345-89-3 | Reference compound |
| HY-116455 | BRD-9526 | 1446352-30-2 | Reference compound |
| HY-116456 | 25T2-NBOMe (hydrochloride) | 1539266-51-7 | Reference compound |
| HY-116457 | Propanidid | 1421-14-3 | Reference compound |
| HY-116459 | trans-Cevimeline (hydrochloride) | 107220-29-1 | Reference compound |
| HY-116460 | N'-(5-Chloro-2-hydroxyphenyl)-N-octylpropanediamide | 1298023-69-4 | Reference compound |
| HY-116461 | ML-184 | 794572-10-4 | Reference compound |
| HY-116462 | ONO-EI-601 | 155023-59-9 | Reference compound |
| HY-116463 | E1R | 1301211-78-8 | Reference compound |
| HY-116463A | (2R,3S)-E1R | 1424832-60-9 | Reference compound |
| HY-116463B | (2S,3S)-E1R | 1424832-57-4 | Reference compound |
| HY-116463C | (2R,3R)-E1R | 1400888-63-2 | Reference compound |
| HY-116463D | (Rac)-E1R | 787623-60-3 | Reference compound |
| HY-116464 | 4-APB (hydrochloride) | 286834-82-0 | Reference compound |
| HY-116468 | PPARγ agonist 11 | 1143573-33-4 | Reference compound |
| HY-116469 | ZP7 | 1188890-60-9 | Reference compound |
| HY-116472 | alpha-RA-F | 1260239-23-3 | Reference compound |
| HY-116473 | CFM-1 | 1380448-60-1 | Reference compound |
| HY-116474 | Viridicatol | 14484-44-7 | Natural Products |
| HY-116474R | Viridicatol (Standard) | 14484-44-7 | Reference Standards |
| HY-116476 | Risotilide | 120688-08-6 | Reference compound |
| HY-116477 | URB937 | 1357160-72-5 | Reference compound |
| HY-116478 | L-3373 | 1951-26-4 | Reference compound |
| HY-116479 | Citromycetin | 478-60-4 | Natural Products |
| HY-116480 | LY593093 | 1108748-12-4 | Reference compound |
| HY-116482 | Desmedipham | 13684-56-5 | Reference compound |
| HY-116482R | Desmedipham (Standard) | 13684-56-5 | Reference Standards |
| HY-116483 | MPX-007 | 1688685-29-1 | Reference compound |
| HY-116486 | Aureusimine B | 170713-71-0 | Natural Products |
| HY-116487 | R-18893 | 147362-54-7 | Reference compound |
| HY-116489 | Pyribenzoxim | 168088-61-7 | Reference compound |
| HY-116490 | Guvacoline (hydrobromide) | 17210-51-4 | Natural Products |
| HY-116494 | ML753286 | 1699720-89-2 | Reference compound |
| HY-116494A | (6R)-ML753286 | | Reference compound |
| HY-116495 | (-)-OSU6162 | 146798-66-5 | Reference compound |
| HY-116496 | 7-Methyladenine | 935-69-3 | Reference compound |
| HY-116497 | PH11 | 1627843-95-1 | Reference compound |
| HY-116498 | Penigequinolone A | 180045-91-4 | Reference compound |
| HY-116500A | AH-1058 | 228123-15-7 | Reference compound |
| HY-116501 | VPC-14449 | 1621375-32-3 | Reference compound |
| HY-116503 | Methyl 3-hydroxytridecanoate | 150024-70-7 | Natural Products |
| HY-116504 | WB-308 | 1373764-87-4 | Reference compound |
| HY-116505 | JAK1-IN-4 | 2091134-35-7 | Reference compound |
| HY-116506 | Bigelovin | 3668-14-2 | Natural Products |
| HY-116507 | AZD0328 | 220099-91-2 | Reference compound |
| HY-116508 | MK 319 | 1462383-00-1 | Reference compound |
| HY-116511 | Benzoximate | 29104-30-1 | Reference compound |
| HY-116512 | Linalyl cinnamate | 78-37-5 | Reference compound |
| HY-116513 | Adrenochrome | 54-06-8 | Reference compound |
| HY-116514 | (S)-(−)-Perillyl alcohol | 18457-55-1 | Natural Products |
| HY-116514R | (S)-(?)-Perillyl alcohol (Standard) | 18457-55-1 | Reference Standards |
| HY-116518 | Piperafizine A | 130603-59-7 | Reference compound |
| HY-116519 | LY173013 | 126165-78-4 | Reference compound |
| HY-116521 | SR2595 | 1415252-61-7 | Reference compound |
| HY-116522 | AR420626 | 1798310-55-0 | Reference compound |
| HY-116524 | PF-04781340 | 1648726-56-0 | Reference compound |
| HY-116525 | Octaethylporphyrin | 2683-82-1 | Reference compound |
| HY-116528 | GCA-186 | 149950-61-8 | Reference compound |
| HY-116529 | Lamellarin E | 115982-19-9 | Natural Products |
| HY-116530 | 9-Cyclopentyladenine (monomethanesulfonate) | 189639-09-6 | Reference compound |
| HY-116532 | YCW-E11 | 1519043-97-0 | Reference compound |
| HY-116533 | RMM-46 | 1307896-46-3 | Reference compound |
| HY-116535 | D-threo-PPMP (hydrochloride) | 139889-65-9 | Reference compound |
| HY-116535A | DL-threo-PPMP (hydrochloride) | 139974-41-7 | Reference compound |
| HY-116535B | DL-threo-PPMP | 149022-18-4 | Reference compound |
| HY-116535C | D-threo-PPMP | 139889-53-5 | Reference compound |
| HY-116536 | N-3-Oxo-tetradecanoyl-L-homoserine lactone | 177158-19-9 | Reference compound |
| HY-116537 | A76889 | 134805-77-9 | Reference compound |
| HY-116538 | (10E,12Z)-Octadeca-10,12-dienoic acid | 2420-56-6 | Biochemical Assay Reagents |
| HY-116540 | L 858051 | 110452-75-0 | Reference compound |
| HY-116541 | Acibenzolar-S-methyl | 135158-54-2 | Reference compound |
| HY-116541R | Acibenzolar-S-methyl (Standard) | 135158-54-2 | Reference Standards |
| HY-116543 | ST362 | 1323359-80-3 | Reference compound |
| HY-116544 | Octan-2-yl 2-cyanoacrylate | 133978-15-1 | Reference compound |
| HY-116546 | Sch 40853 | 129672-23-7 | Reference compound |
| HY-116546S | Sch 40853-d4 | | Isotope-Labeled Compounds |
| HY-116547 | Methylenephenanthrene | 203-64-5 | Reference compound |
| HY-116548 | Nitracaine | 1648893-21-3 | Reference compound |
| HY-116549 | Prostaglandin F2α alcohol | 13261-27-3 | Reference compound |
| HY-116550 | Piroheptine (hydrochloride) | 16378-22-6 | Reference compound |
| HY-116552 | KAR425 | 1809050-49-4 | Reference compound |
| HY-116553 | FzM1 | 1680196-54-6 | Reference compound |
| HY-116554 | GYKI-46903 | 142999-59-5 | Reference compound |
| HY-116556 | Rilmakalim | 132014-21-2 | Reference compound |
| HY-116557 | JCP-265 | 140652-99-9 | Reference compound |
| HY-116559 | TIBI | 1196457-06-3 | Reference compound |
| HY-116560 | ONO-8809 | 123288-47-1 | Reference compound |
| HY-116561 | Adamantylmethamphetamine (hydrochloride) | 19835-42-8 | Reference compound |
| HY-116563 | PI3Kα-IN-24 | 1350960-66-5 | Reference compound |
| HY-116564 | Lotilaner | 1369852-71-0 | Reference compound |
| HY-116565 | Usmarapride | 1428862-33-2 | Reference compound |
| HY-116565A | Usmarapride (free base) | 1428862-32-1 | Reference compound |
| HY-116567 | OPC-51803 | 192514-54-8 | Reference compound |
| HY-116567A | (S)-OPC-51803 | 192514-57-1 | Reference compound |
| HY-116568 | Prothioconazole | 178928-70-6 | Reference compound |
| HY-116568R | Prothioconazole (Standard) | 178928-70-6 | Reference Standards |
| HY-116569 | VU0455691 | 1392443-41-2 | Reference compound |
| HY-116571 | RU44790 | 110012-78-7 | Reference compound |
| HY-116572 | TASIN-1 (hydrochloride) | 1678515-13-3 | Reference compound |
| HY-116572A | TASIN-1 | 792927-06-1 | Reference compound |
| HY-116574 | Leiokinine A | 132587-63-4 | Natural Products |
| HY-116576 | LY219057 | 150351-93-2 | Reference compound |
| HY-116578 | Metopimazine | 14008-44-7 | Reference compound |
| HY-116578S | Metopimazine-d6 | 1215315-86-8 | Isotope-Labeled Compounds |
| HY-116579 | BMS-212122 | 194213-64-4 | Reference compound |
| HY-116580 | AZD-3289 | 1227163-49-6 | Reference compound |
| HY-116582 | 8-Nitroguanine | 168701-80-2 | Reference compound |
| HY-116583 | Resorufin butyrate | 15585-42-9 | Dye Reagents |
| HY-116585 | C6 D-Threo Ceramide (d18:1/6:0) | 189894-79-9 | Reference compound |
| HY-116586 | AF710B | | Reference compound |
| HY-116586A | (Rac)-AF710B | 1235733-73-9 | Reference compound |
| HY-116587 | Halocarban | 369-77-7 | Reference compound |
| HY-116588 | FT001 | 1778655-51-8 | Reference compound |
| HY-116590 | (±)-Glaziovine | 17127-48-9 | Natural Products |
| HY-116591 | 8-Iso-15-keto prostaglandin F2β | 1621482-36-7 | Reference compound |
| HY-116592 | SOMCL-863 | 1452310-87-0 | Reference compound |
| HY-116594 | OPC-14523 (free base) | 145969-30-8 | Reference compound |
| HY-116594A | OPC-14523 (hydrochloride) | 145969-31-9 | Reference compound |
| HY-116597 | L-783483 | 194608-77-0 | Reference compound |
| HY-116598 | Lanopepden (mesylate) | 1441390-17-5 | Reference compound |
| HY-116600 | AL-4114 | 139911-05-0 | Reference compound |
| HY-116601 | 6-Hydroxywarfarin | 17834-02-5 | Reference compound |
| HY-116603 | SB-236057 | 180083-49-2 | Reference compound |
| HY-116604 | RLX | 4425-23-4 | Reference compound |
| HY-116605 | GSK926 | 1346704-13-9 | Reference compound |
| HY-116606 | LY108742 | 150196-69-3 | Reference compound |
| HY-116607 | BAY38-7690 | 246872-58-2 | Reference compound |
| HY-116609 | C6 L-threo Ceramide | 189894-80-2 | Reference compound |
| HY-116610 | L 748780 | 168086-64-4 | Reference compound |
| HY-116613 | FR-181877 | 172936-99-1 | Reference compound |
| HY-116615 | Methyl 2-hydroxytetracosanoate | 2433-95-6 | Biochemical Assay Reagents |
| HY-116617 | 15-Keto Travoprost | 404830-45-1 | Reference compound |
| HY-116617R | 15-Keto Travoprost (Standard) | 404830-45-1 | Reference Standards |
| HY-116619 | (E/Z)-Dacinostat | 591207-53-3 | Reference compound |
| HY-116620 | Benzomalvin C | 157047-98-8 | Reference compound |
| HY-116621 | NU-7163 | 503468-03-9 | Reference compound |
| HY-116622 | α5IA | 215874-86-5 | Reference compound |
| HY-116623 | A-123189 | 255713-53-2 | Reference compound |
| HY-116624 | MAZ51 | 163655-37-6 | Reference compound |
| HY-116625 | PF-04628935 | 1383719-97-8 | Reference compound |
| HY-116626 | SM-7368 | 380623-76-7 | Reference compound |
| HY-116628 | (R)-ADR 882 | 138559-57-6 | Reference compound |
| HY-116629 | Dactylyne | 55306-12-2 | Reference compound |
| HY-116632 | Methyl 3-hydroxyhexanoate | 21188-58-9 | Natural Products |
| HY-116633 | BCM-599 | 1820763-99-2 | Reference compound |
| HY-116637 | Tetrahydromagnolol | 20601-85-8 | Natural Products |
| HY-116638 | AHR-5333 | 60284-71-1 | Reference compound |
| HY-116638A | AHR-5333 (mandelate) | 128766-12-1 | Reference compound |
| HY-116639 | Javanicin | 476-45-9 | Natural Products |
| HY-116643 | SU 10603 | 786-97-0 | Reference compound |
| HY-116649 | CB1 antagonist 2 | 614726-85-1 | Reference compound |
| HY-116653 | Flurtamone | 96525-23-4 | Reference compound |
| HY-116653R | Flurtamone (Standard) | 96525-23-4 | Reference Standards |
| HY-116654 | 2-Methyl-4'-(methylthio)-2-morpholinopropiophenone | 71868-10-5 | Reference compound |
| HY-116655 | Hydroxy-PEG1-acid | 89211-34-7 | ADC Related |
| HY-116655A | Hydroxy-PEG1-acid (sodium salt) | 2855229-28-4 | Reference compound |
| HY-116656 | Oximino oxamyl | 30558-43-1 | Reference compound |
| HY-116658 | Leontine | 6783-60-4 | Natural Products |
| HY-116661 | Cannabigerovarin | 55824-11-8 | Reference compound |
| HY-116662 | CL 232468 | 96555-65-6 | Reference compound |
| HY-116663 | (±)20-HDHA | 90906-41-5 | Natural Products |
| HY-116664 | DPQZ | 1431362-93-4 | Reference compound |
| HY-116666S | (Rac)-Etomidate acid-d5 | | Isotope-Labeled Compounds |
| HY-116671 | Folipastatin | 139959-71-0 | Natural Products |
| HY-116673 | TTK21 | 709676-56-2 | Reference compound |
| HY-116675 | Sulmazole | 73384-60-8 | Reference compound |
| HY-116677 | Tris(benzyltriazolylmethyl)amine | 510758-28-8 | Reference compound |
| HY-116678 | Cloricromen | 68206-94-0 | Reference compound |
| HY-116678A | Cloricromen (hydrochloride) | 74697-28-2 | Reference compound |
| HY-116679 | 17-trifluoromethylphenyl trinor Prostaglandin F2α | 221246-34-0 | Reference compound |
| HY-116680 | LY53857 | 60634-51-7 | Reference compound |
| HY-116681 | Aflavarin | 144429-67-4 | Natural Products |
| HY-116682 | GKA-71 | 863504-35-2 | Reference compound |
| HY-116683 | 116-9e | 831217-43-7 | Reference compound |
| HY-116685 | AF-CX 1325 | 88708-96-7 | Reference compound |
| HY-116686 | Inz-1 | 897776-15-7 | Reference compound |
| HY-116687 | 7-Aminoflunitrazepam | 34084-50-9 | Reference compound |
| HY-116687S | 7-Aminoflunitrazepam-d7 | | Isotope-Labeled Compounds |
| HY-116688 | 2-Hydroxy-4-(methylthio)butyric acid | 583-91-5 | Natural Products |
| HY-116690 | Daimuron | 42609-52-9 | Reference compound |
| HY-116690R | Daimuron (Standard) | 42609-52-9 | Reference Standards |
| HY-116691 | Hydrocortisone aceponate | 74050-20-7 | Reference compound |
| HY-116691R | Hydrocortisone aceponate (Standard) | 74050-20-7 | Reference Standards |
| HY-116692 | Apoptosis inducer 34 | 582314-48-5 | Reference compound |
| HY-116693 | DprE1-IN-12 | 634167-64-9 | Reference compound |
| HY-116694 | Digallic acid | 536-08-3 | Natural Products |
| HY-116699 | CP-868388 (free base) | 702681-67-2 | Reference compound |
| HY-116700 | Hinnuliquinone | 78860-37-4 | Natural Products |
| HY-116701 | A 274 | 77273-75-7 | Reference compound |
| HY-116702 | Flufiprole | 704886-18-0 | Reference compound |
| HY-116703 | L-erythro-Dihydrosphingosine | 6036-76-6 | Natural Products |
| HY-116704 | 11-Deoxyprostaglandin F2α | 37786-06-4 | Reference compound |
| HY-116705 | 2-Deoxy-2-fluoro-L-fucose | 70763-62-1 | Reference compound |
| HY-116706 | Lenacil | 2164-08-1 | Reference compound |
| HY-116706R | Lenacil (Standard) | 2164-08-1 | Reference Standards |
| HY-116708 | DCE_254 | 673443-80-6 | Reference compound |
| HY-116710 | 3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone | 875014-22-5 | Reference compound |
| HY-116711 | 11-cis-Retinal | 564-87-4 | Natural Products |
| HY-116713 | PfDHODH-IN-3 | 92872-51-0 | Reference compound |
| HY-116714 | Cannabigerorcinic acid | 69734-83-4 | Reference compound |
| HY-116716 | PIN1 inhibitor API-1 | 680622-70-2 | Reference compound |
| HY-116722 | (2E)-4-Hydroperoxy-2-nonenal | 7439-43-2 | Reference compound |
| HY-116723 | CFMMC | 1190598-60-7 | Reference compound |
| HY-116724 | Robenidine | 25875-51-8 | Reference compound |
| HY-116726 | Crambene | 6071-81-4 | Reference compound |
| HY-116727 | RU 24926 | 65934-61-4 | Reference compound |
| HY-116730 | CHS-111 | 886755-63-1 | Reference compound |
| HY-116731 | 2-Hydroxydodecanoic acid | 2984-55-6 | Biochemical Assay Reagents |
| HY-116732 | GW-678248 | 329939-64-2 | Reference compound |
| HY-116733 | Tafluprost ethyl ester | 209860-89-9 | Reference compound |
| HY-116736 | BRD7539 | 2057420-00-3 | Reference compound |
| HY-116738 | Trimecaine | 616-68-2 | Reference compound |
| HY-116739 | 13(E)-Docosenoic acid | 506-33-2 | Natural Products |
| HY-116739R | 13(E)-Docosenoic acid (Standard) | 506-33-2 | Reference Standards |
| HY-116741 | Benzofenap | 82692-44-2 | Reference compound |
| HY-116741R | Benzofenap (Standard) | 82692-44-2 | Reference Standards |
| HY-116746 | Clopimozide | 53179-12-7 | Reference compound |
| HY-116748 | (±)-trans-1,2-Bis(2-mercaptoacetamido)cyclohexane | 257641-01-3 | Reference compound |
| HY-116749 | Ethaselen | 217798-39-5 | Reference compound |
| HY-116750 | 6-Hydroxykaempferol | 4324-55-4 | Natural Products |
| HY-116752 | Dinor-12-oxo phytodienoic acid | 197247-23-7 | Natural Products |
| HY-116752S | Dinor-12-oxo phytodienoic acid-d5 | | Isotope-Labeled Compounds |
| HY-116753 | (-)Clausenamide | 201529-58-0 | Natural Products |
| HY-116754 | Methyl 2-hydroxydecanoate | 71271-24-4 | Biochemical Assay Reagents |
| HY-116755 | Tiropramide | 55837-29-1 | Reference compound |
| HY-116755S | Tiropramide-d5 | | Isotope-Labeled Compounds |
| HY-116757 | (±)-α-CMBHC | 7083-09-2 | Reference compound |
| HY-116758 | 16,16-Dimethyl prostaglandin A1 | 41692-24-4 | Reference compound |
| HY-116759 | VU0405601 | 712325-30-9 | Reference compound |
| HY-116761 | GSK467 | 1628332-52-4 | Reference compound |
| HY-116762 | N-butyryl-L-Homocysteine thiolactone | 202284-85-3 | Biochemical Assay Reagents |
| HY-116763 | COX-2/5-LOX-IN-4 | 443919-96-8 | Reference compound |
| HY-116765 | MAO-B-IN-35 | 1619884-75-1 | Reference compound |
| HY-116766 | ACEA1011 | 153504-72-4 | Reference compound |
| HY-116767 | BLT-1 | 321673-30-7 | Reference compound |
| HY-116768 | 10(E),12(Z)-Conjugated linoleic acid methyl ester | 21870-97-3 | Reference compound |
| HY-116770 | PFM01 | 1558598-41-6 | Reference compound |
| HY-116771 | CL 316243 (free acid) | 183720-02-7 | Reference compound |
| HY-116771A | CL 316243 | 138908-40-4 | Reference compound |
| HY-116772 | Cyanox CY 1790 | 40601-76-1 | Reference compound |
| HY-116773 | A-69024 | 58939-37-0 | Reference compound |
| HY-116776 | Hexadecatetraenoic acid | 29259-52-7 | Reference compound |
| HY-116776S | Hexadecatetraenoic acid-d5 | 2408811-79-8 | Isotope-Labeled Compounds |
| HY-116777 | Impromidine | 55273-05-7 | Reference compound |
| HY-116777A | Impromidine (hydrochloride) | 65573-02-6 | Reference compound |
| HY-116778 | Prostaglandin G2 | 51982-36-6 | Natural Products |
| HY-116780A | Prothipendyl (hydrochloride) | 1225-65-6 | Reference compound |
| HY-116780S | Prothipendyl-d6 (hydrochloride) | 1346604-67-8 | Isotope-Labeled Compounds |
| HY-116781 | PD 114595 | 94636-28-9 | Reference compound |
| HY-116785 | BRD32048 | 433694-46-3 | Reference compound |
| HY-116786 | 11-Hydroxycanthin-6-one | 75969-83-4 | Natural Products |
| HY-116787 | 5-Hydroxythiabendazole | 948-71-0 | Reference compound |
| HY-116787R | 5-Hydroxythiabendazole (Standard) | 948-71-0 | Reference Standards |
| HY-116788 | Lipofermata | 297180-15-5 | Reference compound |
| HY-116790 | (-)-Penbutolol | 38363-40-5 | Reference compound |
| HY-116790A | (+)-Penbutolol | 38363-41-6 | Reference compound |
| HY-116790B | (±)-Penbutolol | 36507-48-9 | Reference compound |
| HY-116790BS | (±)-Penbutolol-d9 | 1346747-40-7 | Isotope-Labeled Compounds |
| HY-116790BSA | (±)-Penbutolol-d9 (hydrochloride) | 1346605-01-3 | Isotope-Labeled Compounds |
| HY-116791 | Calanolide A | 142632-32-4 | Natural Products |
| HY-116792 | Phenoxyacetone | 621-87-4 | Natural Products |
| HY-116793 | Dimepiperate | 61432-55-1 | Reference compound |
| HY-116793R | Dimepiperate (Standard) | 61432-55-1 | Reference Standards |
| HY-116794 | SF5 | 34634-22-5 | Reference compound |
| HY-116795 | 5-Methoxy-α-ethyltryptamine | 4765-10-0 | Reference compound |
| HY-116797 | MS15203 | 73912-52-4 | Reference compound |
| HY-116799 | NSC 145669 | 31785-60-1 | Reference compound |
| HY-116800 | FR194921 | 202646-80-8 | Reference compound |
| HY-116802 | Bromobutide | 74712-19-9 | Reference compound |
| HY-116804 | ZLD1039 | 1826865-46-6 | Reference compound |
| HY-116806 | AF-2785 | 252025-48-2 | Reference compound |
| HY-116807 | Dihydrolipoic Acid | 462-20-4 | Reference compound |
| HY-116807R | Dihydrolipoic Acid (Standard) | 462-20-4 | Reference Standards |
| HY-116808 | TPN729 | 936951-20-1 | Reference compound |
| HY-116808B | TPN729MA | 1422955-52-9 | Reference compound |
| HY-116809 | Lopirazepam | 42863-81-0 | Reference compound |
| HY-116812 | Sclerotigenin | 65641-84-1 | Reference compound |
| HY-116813 | ZK 93423 | 83910-44-5 | Reference compound |
| HY-116814 | ML401 | 1597489-14-9 | Reference compound |
| HY-116815 | Lalistat 1 | 501104-16-1 | Reference compound |
| HY-116818 | Crebinostat | 1092061-61-4 | Reference compound |
| HY-116819 | VU0453379 | 1638646-27-1 | Reference compound |
| HY-116819A | VU0453379 (hydrochloride) | | Reference compound |
| HY-116820 | OS-3-106 | 1580000-17-4 | Reference compound |
| HY-116822 | SSR 146977 | 264618-44-2 | Reference compound |
| HY-116825 | Jalapinolic acid | 502-75-0 | Reference compound |
| HY-116826 | Buramate | 4663-83-6 | Reference compound |
| HY-116828 | ARI-3531 | 1432499-51-8 | Reference compound |
| HY-116830 | BRD0705 | 2056261-41-5 | Reference compound |
| HY-116830A | (Rac)-BRD0705 | 1597440-03-3 | Reference compound |
| HY-116830B | BRD5648 | 2056261-42-6 | Reference compound |
| HY-116831 | 4′-Dihydrophaseic acid | 41756-77-8 | Natural Products |
| HY-116832 | Retrorsine N-oxide | 15503-86-3 | Natural Products |
| HY-116833 | 4-Chloro-3,5-dimethylphenoxyacetic acid | 19545-95-0 | Reference compound |
| HY-116834 | Vat Blue 4B | 2475-31-2 | Biochemical Assay Reagents |
| HY-116835 | BI-6901 | 2040401-92-9 | Reference compound |
| HY-116836 | p38α inhibitor 7 | 668981-02-0 | Reference compound |
| HY-116837 | LUF5831 | 333963-57-8 | Reference compound |
| HY-116838 | TAM-16 | 2030241-59-7 | Reference compound |
| HY-116843 | (15S)-15-Methylprostaglandin E2 | 35700-27-7 | Reference compound |
| HY-116844 | Glymidine | 339-44-6 | Reference compound |
| HY-116845 | TG3-95-1 | 301322-12-3 | Reference compound |
| HY-116849 | LY 181984 | 3955-50-8 | Reference compound |
| HY-116850 | Oxagrelate | 56611-65-5 | Reference compound |
| HY-116852 | Thiocolchicine | 2730-71-4 | Reference compound |
| HY-116852S | Thiocolchicine-d3 | 1314417-95-2 | Isotope-Labeled Compounds |
| HY-116854 | NNC 92-1687 | 22903-37-3 | Reference compound |
| HY-116855 | TASP0433864 | 1431980-60-7 | Reference compound |
| HY-116856 | SRPKIN-1 | 2089226-94-6 | Reference compound |
| HY-116857 | Ditalimfos | 5131-24-8 | Reference compound |
| HY-116857R | Ditalimfos (Standard) | 5131-24-8 | Reference Standards |
| HY-116859 | Ro 14-7437 | 78756-03-3 | Reference compound |
| HY-116862 | Dibenzylfluorescein | 97744-44-0 | Dye Reagents |
| HY-116863 | KKL-40 | 865285-47-8 | Reference compound |
| HY-116863R | KKL-40 (Standard) | 865285-47-8 | Reference Standards |
| HY-116865 | Equilenin | 517-09-9 | Natural Products |
| HY-116865S | Equilenin-4,16,16-d3 | 56588-54-6 | Isotope-Labeled Compounds |
| HY-116866 | Sclerotiorin | 549-23-5 | Natural Products |
| HY-116868 | Anecortave acetate | 7753-60-8 | Reference compound |
| HY-116870 | Vamidothion | 2275-23-2 | Reference compound |
| HY-116871 | YKL-1-116 | 1957202-71-9 | Reference compound |
| HY-116872 | MAC13772 | 4871-40-3 | Reference compound |
| HY-116874 | SKF 83822 | 74115-08-5 | Reference compound |
| HY-116877 | C2 Ceramide (d14:1/2:0) | 2097561-20-9 | Reference compound |
| HY-116878 | 25B-NBOH (hydrochloride) | 1539266-16-4 | Reference compound |
| HY-116879 | 4-Oxo-2-Nonenal Alkyne | 1680193-58-1 | Reference compound |
| HY-116881 | SCH 57790 | 221660-80-6 | Reference compound |
| HY-116883 | Endothion | 2778-04-3 | Reference compound |
| HY-116885 | Thunalbene | 220862-05-5 | Natural Products |
| HY-116887 | N6-Methyladenine | 443-72-1 | Reference compound |
| HY-116888 | BFE-55 | 21151-91-7 | Reference compound |
| HY-116889 | 15-Keto latanoprost acid | 369585-22-8 | Reference compound |
| HY-116890 | CRTh2 antagonist 4 | 916046-55-4 | Reference compound |
| HY-116893 | Diethyl bipy55'DC | 1762-46-5 | Reference compound |
| HY-116894 | Rotundifuran | 50656-65-0 | Natural Products |
| HY-116895 | JJH260 | 1831135-30-8 | Reference compound |
| HY-116896 | LY117018 | 63676-25-5 | Reference compound |
| HY-116896A | LY117018 (TFA) | 2390041-98-0 | Reference compound |
| HY-116897 | G202-0362 | 868883-12-9 | Reference compound |
| HY-116899 | Nonaethylene glycol | 3386-18-3 | Reference compound |
| HY-116900 | Karsil | 2533-89-3 | Reference compound |
| HY-116903 | Pfn1-IN-2 | 919010-22-3 | Reference compound |
| HY-116904 | Anticancer agent 253 | 1983924-33-9 | Reference compound |
| HY-116908 | SB-272183 | 216058-27-4 | Reference compound |
| HY-116909 | O-Methylsterigmatocystin | 17878-69-2 | Natural Products |
| HY-116910 | CPP-115 | 640897-20-7 | Reference compound |
| HY-116913 | Moxicoumone | 17692-56-7 | Reference compound |
| HY-116915 | Synstab A | 257612-36-5 | Reference compound |
| HY-116916 | Acetophenazine | 2751-68-0 | Reference compound |
| HY-116916S | Acetophenazine-d4 (dimaleate) | | Isotope-Labeled Compounds |
| HY-116917 | G-9791 | 1926204-95-6 | Reference compound |
| HY-116918 | N,N-Diphenylacetamide | 519-87-9 | Reference compound |
| HY-116919 | MLS000536924 | 511306-37-9 | Reference compound |
| HY-116920 | Alyssin | 646-23-1 | Natural Products |
| HY-116920A | (R)-Alyssin | 167963-06-6 | Reference compound |
| HY-116920B | (S)-Alyssin | 167963-04-4 | Reference compound |
| HY-116923 | p18SMI-21 | 20535-76-6 | Reference compound |
| HY-116924 | 1,3-Bis-aminooxy propane | 98627-69-1 | Reference compound |
| HY-116925 | L-767679 | 182198-53-4 | Reference compound |
| HY-116926 | Deoxynybomycin | 27259-98-9 | Reference compound |
| HY-116927 | KW-7158 | 214764-26-8 | Reference compound |
| HY-116930 | S-20928 | 152302-33-5 | Reference compound |
| HY-116931 | Kelletinin I | 87697-99-2 | Natural Products |
| HY-116933 | Murrayanol | 144525-81-5 | Natural Products |
| HY-116934 | 5-Pentadecylresorcinol | 3158-56-3 | Natural Products |
| HY-116934R | 5-Pentadecylresorcinol (Standard) | 3158-56-3 | Reference Standards |
| HY-116938 | Farnesiferol C | 512-17-4 | Reference compound |
| HY-116939 | (E)-Broparestrol | 22393-62-0 | Reference compound |
| HY-116940 | Sm4 | 365542-77-4 | Reference compound |
| HY-116941 | A-381393 | 726174-00-1 | Reference compound |
| HY-116942 | 2002-H20 | 351520-91-7 | Reference compound |
| HY-116943 | MTC420 | 2088930-66-7 | Reference compound |
| HY-116945 | Diphenamid | 957-51-7 | Reference compound |
| HY-116946 | Glucokinase activator 6 | 480463-02-3 | Reference compound |
| HY-116947 | COX-2-IN-5 | 416901-58-1 | Reference compound |
| HY-116948 | Azo-mustard | 4213-40-5 | Reference compound |
| HY-116952 | Xylosucrose | 512-66-3 | Biochemical Assay Reagents |
| HY-116953 | Lipoxin B4 | 98049-69-5 | Reference compound |
| HY-116954 | Metribuzin | 21087-64-9 | Reference compound |
| HY-116954R | Metribuzin (Standard) | 21087-64-9 | Reference Standards |
| HY-116955 | Palmitoleoyl chloride | 40426-22-0 | Reference compound |
| HY-116956 | D-Erythrose | 583-50-6 | Biochemical Assay Reagents |
| HY-116956A | L-Erythrose (solution) (70% in water) | 533-49-3 | Biochemical Assay Reagents |
| HY-116956S | D-Erythrose-1-13C | 70849-19-3 | Isotope-Labeled Compounds |
| HY-116956S1 | D-Erythrose-2-13C | 83434-88-2 | Isotope-Labeled Compounds |
| HY-116956S2 | D-Erythrose-3-13C | | Isotope-Labeled Compounds |
| HY-116956S3 | D-Erythrose-4-13C | 90913-08-9 | Isotope-Labeled Compounds |
| HY-116957 | Bunitrolol (hydrochloride) | 29876-08-2 | Reference compound |
| HY-116958 | SCH 206272 | 226915-43-1 | Reference compound |
| HY-116959 | SM-130686 | 259667-25-9 | Reference compound |
| HY-116960 | FR 76830 | 113243-75-7 | Reference compound |
| HY-116961 | TH1020 | 1841460-82-9 | Reference compound |
| HY-116965 | Tyvelose | 5658-12-8 | Biochemical Assay Reagents |
| HY-116969 | 22(R)-Hydroxycholesterol | 17954-98-2 | Reference compound |
| HY-116969S | 22(R)-Hydroxycholesterol-d7 | 1246302-93-1 | Isotope-Labeled Compounds |
| HY-116970 | L-749372 | 159183-70-7 | Reference compound |
| HY-116971 | DCG066 | 494786-13-9 | Reference compound |
| HY-116972 | Etanidazole | 22668-01-5 | Reference compound |
| HY-116973 | L 738372 | 159565-60-3 | Reference compound |
| HY-116974 | ent-Thiamphenicol | 19934-71-5 | Reference compound |
| HY-116975 | Enoxastrobin | 238410-11-2 | Reference compound |
| HY-116976 | NSC-57969 | 6632-09-3 | Reference compound |
| HY-116977 | Binifibrate | 69047-39-8 | Reference compound |
| HY-116982 | BMY 7378 (free base) | 21102-94-3 | Reference compound |
| HY-116992 | Chloroneb | 2675-77-6 | Reference compound |
| HY-116992R | Chloroneb (Standard) | 2675-77-6 | Reference Standards |
| HY-116993 | N-(Hydroxymethyl)nicotinamide | 3569-99-1 | Reference compound |
| HY-116999 | IR415 | 452967-14-5 | Reference compound |
| HY-117002 | SRI 37892 | 1030769-75-5 | Reference compound |
| HY-117005 | C450-0730 | 1036730-46-7 | Reference compound |
| HY-117006 | E1231 | 1031195-19-3 | Reference compound |
| HY-117008 | CAY10589 | 1077626-52-8 | Reference compound |
| HY-117009 | Bis-PEG9-NHS ester | 1008402-79-6 | ADC Related |
| HY-117010 | Kushenol K | 101236-49-1 | Natural Products |
| HY-117012 | NE58018 | 105462-23-5 | Reference compound |
| HY-117015 | Purfalcamine | 1038620-68-6 | Reference compound |
| HY-117016 | Nonacosadiene | 104410-91-5 | Reference compound |
| HY-117019 | LY150310 (free base) | 103294-47-9 | Reference compound |
| HY-117020 | Methyl (S)-(-)-N-Z-aziridine-2-carboxylate | 104597-98-0 | Reference compound |
| HY-117023 | m-PEG2-4-nitrophenyl carbonate | 105108-59-6 | Reference compound |
| HY-117024 | Abediterol (napadisylate) | 1044516-17-7 | Reference compound |
| HY-117025 | Manzamine A | 104196-68-1 | Natural Products |
| HY-117025A | Manzamine A (hydrochloride) | 104264-80-4 | Natural Products |
| HY-117026 | LKY-047 | 1954681-29-8 | Reference compound |
| HY-117028 | Tos-PEG7-OH | 1028089-05-5 | Reference compound |
| HY-117029 | NAAD (sodium) | 104809-30-5 | Reference compound |
| HY-117031 | m-PEG8-MS | 1059588-19-0 | ADC Related |
| HY-117034 | Rankinidine | 106466-66-4 | Natural Products |
| HY-117037 | FR900359 | 107530-18-7 | Natural Products |
| HY-117038 | Anordiol | 1045-29-0 | Reference compound |
| HY-117040 | nor-Binaltorphimine | 105618-26-6 | Reference compound |
| HY-117041 | m-PEG4-CH2-aldehyde | 1059189-65-9 | Reference compound |
| HY-117042 | Biotin-PEG2-C6-azide | 1011268-29-3 | Reference compound |
| HY-117043 | GRL0617 | 1093070-16-6 | Reference compound |
| HY-117044 | 12(R)-HEPE | 109430-12-8 | Reference compound |
| HY-117044A | (±)12-HEPE | 81187-21-5 | Reference compound |
| HY-117045 | Propargyl-PEG12-OH | 1036204-61-1 | Reference compound |
| HY-117046 | AVN-101 | 1025725-91-0 | Reference compound |
| HY-117046A | AVN-101 (hydrochloride) | 1061354-48-0 | Reference compound |
| HY-117047 | ALC67 | 1044255-57-3 | Reference compound |
| HY-117048 | PF-4191834 | 1029317-21-2 | Reference compound |
| HY-117049 | Leucettine L41 | 1112978-84-3 | Reference compound |
| HY-117050 | PEG12-Tos | 1050500-41-8 | ADC Related |
| HY-117051 | STA-2842 | 1046490-67-8 | Reference compound |
| HY-117052 | Thiophene-2-amidoxime | 108443-93-2 | Reference compound |
| HY-117053 | ZM 253270 | 169340-04-9 | Reference compound |
| HY-117055 | Ro 18-3981 | 103295-92-7 | Reference compound |
| HY-117057 | Hexaenoic acid | 105528-06-1 | Reference compound |
| HY-117057S | Hexaenoic acid-d6 | 2692624-21-6 | Isotope-Labeled Compounds |
| HY-117058 | LY243246 | 106400-18-4 | Reference compound |
| HY-117059 | SK609 (hydrochloride) | 1092797-77-7 | Reference compound |
| HY-117061 | Prostaglandin F2α alcohol methyl ether | 143656-18-2 | Reference compound |
| HY-117063 | LEK 8841 (methanesulfonate) | 145204-80-4 | Reference compound |
| HY-117065 | MAC173979 | 41501-64-8 | Reference compound |
| HY-117066 | CL075 | 256922-53-9 | Reference compound |
| HY-117068 | (R)-Bromoenol lactone | 478288-90-3 | Reference compound |
| HY-117068S | (R)-Bromoenol lactone-d7 | | Isotope-Labeled Compounds |
| HY-117070 | TO-PRO-3 (iodide) | 157199-63-8 | Dye Reagents |
| HY-117071 | Dabuzalgron | 219311-44-1 | Reference compound |
| HY-117071A | Dabuzalgron (hydrochloride) | 219311-43-0 | Reference compound |
| HY-117072 | (E)-2-Hexadecenal alkyne | 1778692-99-1 | Reference compound |
| HY-117073 | ITH12575 | 1802013-08-6 | Reference compound |
| HY-117074 | BMS-247243 | 307316-55-8 | Reference compound |
| HY-117077 | A70450 | 142928-23-2 | Reference compound |
| HY-117078 | Justicidin A | 25001-57-4 | Natural Products |
| HY-117079 | N-Boc-N-bis(PEG2-OH) | 275385-03-0 | ADC Related |
| HY-117080 | Sulfo-EGS | 167410-92-6 | Reference compound |
| HY-117081 | C30(ω-hydroxy) Ceramide (d18:1/30:0) | 457100-08-2 | Natural Products |
| HY-117082 | UTL-5g | 646530-37-2 | Reference compound |
| HY-117083 | Clothiapine | 2058-52-8 | Reference compound |
| HY-117085 | Lobaric acid | 522-53-2 | Reference compound |
| HY-117087 | K103 | 1071544-43-8 | Reference compound |
| HY-117088 | LM11A-31 | 102562-74-3 | Reference compound |
| HY-117089 | Tetraconazole | 112281-77-3 | Reference compound |
| HY-117089R | Tetraconazole (Standard) | 112281-77-3 | Reference Standards |
| HY-117090 | (rac)-AL-37350A | 362603-40-5 | Reference compound |
| HY-117091 | DDD-028 | 1538586-09-2 | Reference compound |
| HY-117093 | H8-A5 | 423731-10-6 | Reference compound |
| HY-117095 | 4-Methylumbelliferyl oleate | 18323-58-5 | Dye Reagents |
| HY-117096 | Piperophos | 24151-93-7 | Reference compound |
| HY-117096R | Piperophos (Standard) | 24151-93-7 | Reference Standards |
| HY-117097 | Bayer 16574 | 3568-51-2 | Reference compound |
| HY-117099 | TMB-8 | 53464-72-5 | Reference compound |
| HY-117100 | Propargyl-PEG14-OH | | Reference compound |
| HY-117102 | ANI-7 | 931417-26-4 | Reference compound |
| HY-117103 | AMG131 | 315224-26-1 | Reference compound |
| HY-117103A | AMG131 (benzenesulfonate) | 849738-78-9 | Reference compound |
| HY-117104 | Hydroxy-PEG4-acid | 937188-59-5 | ADC Related |
| HY-117105 | DAPD-NHc-pr | 280138-71-8 | Reference compound |
| HY-117106 | PNU-107484A | 200266-76-8 | Reference compound |
| HY-117107 | Cheirolin | 505-34-0 | Biochemical Assay Reagents |
| HY-117108 | Nocardicin A | 39391-39-4 | Natural Products |
| HY-117109 | Amino Tadalafil | 385769-84-6 | Reference compound |
| HY-117109R | Amino Tadalafil (Standard) | 385769-84-6 | Reference Standards |
| HY-117110 | Arginylproline | 2418-69-1 | Reference compound |
| HY-117112 | Hexamethoxymethylmelamine | 3089-11-0 | Reference compound |
| HY-117113 | JI051 | 2234281-75-3 | Reference compound |
| HY-117115 | 1,2-Dihexanoyl-sn-glycerol | 30403-47-5 | Biochemical Assay Reagents |
| HY-117118A | AC-90179 | 359878-19-6 | Reference compound |
| HY-117119 | VER-3323 | 259857-99-3 | Reference compound |
| HY-117124 | BMS-337197 | 267645-83-0 | Reference compound |
| HY-117125 | Longifolin | 39007-94-8 | Natural Products |
| HY-117126 | BTZ-N3 | 1839081-05-8 | Reference compound |
| HY-117129 | MK 436 | 33450-08-7 | Reference compound |
| HY-117131 | ZINC17167211 | 592539-21-4 | Reference compound |
| HY-117133 | Nesvategrast | 1621332-91-9 | Reference compound |
| HY-117134 | 2-Ethylhexyl palmitate | 29806-73-3 | Biochemical Assay Reagents |
| HY-117135 | HNS-32 | 186086-10-2 | Reference compound |
| HY-117136 | AN-7 | 213262-83-0 | Reference compound |
| HY-117139 | NESS 0327 | 494844-07-4 | Reference compound |
| HY-117141 | N-Arachidonoyl-3-hydroxy-γ-aminobutyric acid | 959761-62-7 | Peptides |
| HY-117142 | Quizalofop-P | 94051-08-8 | Reference compound |
| HY-117142R | Quizalofop-P (Standard) | 94051-08-8 | Reference Standards |
| HY-117143 | TK05 | 1245734-61-5 | Reference compound |
| HY-117145 | Thiophene-2 | 420089-51-6 | Reference compound |
| HY-117146 | Indoxacarb | 173584-44-6 | Reference compound |
| HY-117147 | GSK2945 | 1438071-12-5 | Reference compound |
| HY-117147A | GSK2945 (hydrochloride) | | Reference compound |
| HY-117149 | MLS000532223 | 16616-39-0 | Reference compound |
| HY-117151 | A-315675 | 335679-69-1 | Reference compound |
| HY-117152 | L-threo-Sphingosine | 25695-95-8 | Reference compound |
| HY-117153 | GW7604 | 361203-06-7 | Reference compound |
| HY-117154 | INH154 | 1587705-63-2 | Reference compound |
| HY-117155 | PKI-166 | 187724-61-4 | Reference compound |
| HY-117158 | SKF 89748 | 81998-18-7 | Reference compound |
| HY-117160 | 4-trans-Hydroxy-glibenclamide | 23155-00-2 | Reference compound |
| HY-117160S1 | 4-trans-Hydroxy glibenclamide-d5 | | Isotope-Labeled Compounds |
| HY-117160S2 | 4-trans-Hydroxy glibenclamide-13C,d4 | | Isotope-Labeled Compounds |
| HY-117161 | ZINC05626394 | 189057-68-9 | Reference compound |
| HY-117162 | S 1432 | 24932-86-3 | Reference compound |
| HY-117163 | FzM1.8 | 2204290-85-5 | Reference compound |
| HY-117164 | Longicautadine | 85335-06-4 | Natural Products |
| HY-117166 | Naftoxate | 28820-28-2 | Reference compound |
| HY-117167 | KB-141 | 219691-94-8 | Reference compound |
| HY-117168 | 1,2-Dilinoleoyl-sn-glycerol | 24529-89-3 | Reference compound |
| HY-117170 | B1912 | 24028-59-9 | Reference compound |
| HY-117171S | Proquinazid-(propoxy-d7) | 2140327-37-1 | Isotope-Labeled Compounds |
| HY-117172 | CP320626 | 186430-23-9 | Reference compound |
| HY-117173 | (Rac)-Rasagiline | 1875-50-9 | Reference compound |
| HY-117175 | Pandamarilactonine A | 303008-80-2 | Natural Products |
| HY-117176 | KRP-199 | 221164-28-9 | Reference compound |
| HY-117178 | TA 0910 acid-type | 103300-77-2 | Reference compound |
| HY-117179 | Endosulfan sulfate | 1031-07-8 | Reference compound |
| HY-117179R | Endosulfan sulfate (Standard) | 1031-07-8 | Reference Standards |
| HY-117180 | Diastovaricin I | 102281-52-7 | Natural Products |
| HY-117181 | UK-1745 | 170684-14-7 | Reference compound |
| HY-117182 | LG190178 | 233268-81-0 | Reference compound |
| HY-117183 | Lankacidinol | 23498-37-5 | Natural Products |
| HY-117184 | MSX-2 | 261717-18-4 | Reference compound |
| HY-117186 | Bis-propargyl-PEG6 | 400775-35-1 | Reference compound |
| HY-117187 | Corr4A | 421580-53-2 | Reference compound |
| HY-117190 | Pseudolycorine | 29429-03-6 | Natural Products |
| HY-117191 | m-PEG3-CH2-alcohol | 100688-48-0 | Reference compound |
| HY-117194 | 18BIOder | 275374-93-1 | Reference compound |
| HY-117195 | Lauroyl lysine | 52315-75-0 | Reference compound |
| HY-117196 | GW 9578 | 247923-29-1 | Reference compound |
| HY-117199 | MCPA-thioethyl | 25319-90-8 | Reference compound |
| HY-117200 | Necrostatin-7 | 351062-08-3 | Reference compound |
| HY-117201 | Methyl 3-hydroxyoctanoate | 7367-87-5 | Natural Products |
| HY-117203A | CDK12-IN-E9 | 2020052-55-3 | Reference compound |
| HY-117204 | AA-57 | 68026-87-9 | Natural Products |
| HY-117209 | Cannabivarin | 33745-21-0 | Natural Products |
| HY-117213 | Ex26 | 1233332-37-0 | Reference compound |
| HY-117215 | β-Ocimene | 13877-91-3 | Biochemical Assay Reagents |
| HY-117215A | trans-β-Ocimene | 3779-61-1 | Natural Products |
| HY-117216 | L-703606 | 144425-84-3 | Reference compound |
| HY-117216A | L-703606 (oxalate) | 351351-06-9 | Reference compound |
| HY-117216B | L-703606 (oxalate hydrate) | | Reference compound |
| HY-117218 | KY-04045 | 1223284-75-0 | Reference compound |
| HY-117219 | SKF 104976 | 136209-43-3 | Reference compound |
| HY-117220 | Aspochalasin M | 1173040-34-0 | Natural Products |
| HY-117223 | GEA 857 | 120493-42-7 | Reference compound |
| HY-117224 | Rhizopterin | 119-20-0 | Natural Products |
| HY-117225 | Pantoprazole sulfone | 127780-16-9 | Reference compound |
| HY-117226 | GSK 690 | 2101305-84-2 | Reference compound |
| HY-117226A | GSK 690 (Hydrochloride) | 2436760-79-9 | Reference compound |
| HY-117229 | Sonidegib metabolite M48 | 1221722-10-6 | Reference compound |
| HY-117230 | Triflusulfuron-methyl | 126535-15-7 | Reference compound |
| HY-117230R | Triflusulfuron-methyl (Standard) | 126535-15-7 | Reference Standards |
| HY-117231 | RM 06 | 126869-52-1 | Reference compound |
| HY-117233 | UU-T02 | 1500080-17-0 | Reference compound |
| HY-117235 | Diallyl Trisulfide | 2050-87-5 | Natural Products |
| HY-117235R | Diallyl Trisulfide (Standard) | 2050-87-5 | Reference Standards |
| HY-117237 | Hisphen | 2764-56-9 | Reference compound |
| HY-117238 | Ketomethylenebestatin | 137028-97-8 | Reference compound |
| HY-117239 | SB-206606 | 116049-78-6 | Reference compound |
| HY-117240 | NCT-502 | 1542213-00-2 | Reference compound |
| HY-117241 | AB 3217-B | 139159-00-5 | Reference compound |
| HY-117243 | GSK329 | 1268490-12-5 | Reference compound |
| HY-117244 | AZD7507 | 1041852-85-0 | Reference compound |
| HY-117245 | Pallidol | 1622292-61-8 | Natural Products |
| HY-117247 | 5,6,7,8-Tetrahydro-8-deazahomofolic acid | 111113-75-8 | Reference compound |
| HY-117248 | SR-3737 | 1164153-37-0 | Reference compound |
| HY-117249 | Sanazole | 104958-90-9 | Reference compound |
| HY-117250 | EcDsbB-IN-10 | 112749-52-7 | Reference compound |
| HY-117251 | LP-403812 | 1142050-84-7 | Reference compound |
| HY-117253 | PHA-782584 | 1126899-61-3 | Reference compound |
| HY-117254 | BAS00127538 | 110673-34-2 | Reference compound |
| HY-117255 | ZM260384 | 161229-62-5 | Reference compound |
| HY-117256 | Gabazine (free base) | 105538-73-6 | Reference compound |
| HY-117257 | PF-0713 | 1083093-47-3 | Reference compound |
| HY-117259 | Valiltramiprosate | 1034190-08-3 | Reference compound |
| HY-117259S | Valiltramiprosate-d6 | | Isotope-Labeled Compounds |
| HY-117260 | Coformycin | 11033-22-0 | Natural Products |
| HY-117262 | Propaquizafop | 111479-05-1 | Reference compound |
| HY-117262R | Propaquizafop (Standard) | 111479-05-1 | Reference Standards |
| HY-117264 | (-)-6-Aminocarbovir | 109881-25-6 | Reference compound |
| HY-117266 | β-D-Galactopyranoside, 98% | 56245-60-4 | Biochemical Assay Reagents |
| HY-117268 | 1,3,4,6-Tetra-O-acetyl-β-D-mannopyranose | 18968-05-3 | Biochemical Assay Reagents |
| HY-117269 | Methyl-D-galactoside | 93302-26-2 | Biochemical Assay Reagents |
| HY-117271 | D-Galactosamine pentaacetate | 76375-60-5 | Biochemical Assay Reagents |
| HY-117272A | (2R,3R)-2,3,4-Trihydroxybutanoic acid | 488-16-4 | Reference compound |
| HY-117273 | AZ304 | 942507-42-8 | Reference compound |
| HY-117275 | Meclofenamic acid | 644-62-2 | Reference compound |
| HY-117275A | Meclofenamic acid (sodium hydrate) | 67254-91-5 | Reference compound |
| HY-117275R | Meclofenamic acid (Standard) | 644-62-2 | Reference Standards |
| HY-117275S | Meclofenamic acid-d4 | 1185072-18-7 | Isotope-Labeled Compounds |
| HY-117275S1 | Meclofenamic acid-13C6 | | Isotope-Labeled Compounds |
| HY-117279 | (S)-Metolachor | 87392-12-9 | Reference compound |
| HY-117279R | (S)-Metolachor (Standard) | 87392-12-9 | Reference Standards |
| HY-117280 | GN25 | 1227401-27-5 | Reference compound |
| HY-117281 | Moexipril | 103775-10-6 | Reference compound |
| HY-117281S | Moexipril-d5 | 1356929-49-1 | Isotope-Labeled Compounds |
| HY-117281S1 | Moexipril-d3 | | Isotope-Labeled Compounds |
| HY-117282 | JG-98 | 1456551-16-8 | Reference compound |
| HY-117283 | rel-Aprikalim | 89544-10-5 | Reference compound |
| HY-117284 | Eucatropine | 100-91-4 | Reference compound |
| HY-117285 | Medermycin | 60227-09-0 | Reference compound |
| HY-117286 | (S)-JQ-35 | 1349719-98-7 | Reference compound |
| HY-117287 | Deucravacitinib | 1609392-27-9 | Isotope-Labeled Compounds |
| HY-117287A | Deucravacitinib (hydrochloride) | 1609392-28-0 | Isotope-Labeled Compounds |
| HY-117288 | S55746 | 1448584-12-0 | Reference compound |
| HY-117288A | S55746 (hydrochloride) | 1448525-91-4 | Reference compound |
| HY-117289 | AKOS B018304 | 6308-22-1 | Reference compound |
| HY-117290 | BMS-962212 | 1430114-34-3 | Reference compound |
| HY-117291 | XMD-17-51 | 1628614-50-5 | Reference compound |
| HY-117291A | XMD-17-51 (TFA) | 2436579-93-8 | Reference compound |
| HY-117292 | DAO-IN-2 | 39793-31-2 | Reference compound |
| HY-117293 | Phenyl sulfamate | 19792-91-7 | Reference compound |
| HY-117295A | 7-Fluorotryptamine (hydrochloride) | 159730-09-3 | Reference compound |
| HY-117311 | Spirotryprostatin A | 182234-25-9 | Natural Products |
| HY-117313 | Fumitremorgin B | 12626-17-4 | Natural Products |
| HY-117314 | CyMe4BTBP | 886970-80-5 | Reference compound |
| HY-117318 | PDE12-IN-1 | 2259620-80-7 | Reference compound |
| HY-117319 | Indolmycin | 21200-24-8 | Reference compound |
| HY-117332 | IQA | 391670-48-7 | Reference compound |
| HY-117348 | NCC-149 | 1316652-41-1 | Reference compound |
| HY-117356A | MRS2693 (ammonium) | 911391-37-2 | Reference compound |
| HY-117356B | MRS2693 (trisodium) | 1448858-83-0 | Reference compound |
| HY-117357 | SI-113 | 1392816-46-4 | Reference compound |
| HY-117358 | KW-5805 | 113302-01-5 | Reference compound |
| HY-117359 | UCD38B (hydrochloride) | 1115177-19-9 | Reference compound |
| HY-117361 | LY207702 | 103828-81-5 | Reference compound |
| HY-117364 | HS148 | 1892595-16-2 | Reference compound |
| HY-117365 | MI-1481 | 1887178-64-4 | Reference compound |
| HY-117366 | PS432 | 2083630-26-4 | Reference compound |
| HY-117368 | AL-8417 | 180472-20-2 | Reference compound |
| HY-117370 | USP25/28 inhibitor AZ1 | 2165322-94-9 | Reference compound |
| HY-117371 | Hemiasterlin | 157207-90-4 | Natural Products |
| HY-117373 | Pelargonidin-3-rutinosid | 33978-17-5 | Reference compound |
| HY-117374 | HDAC3-IN-1 | 2044701-99-5 | Reference compound |
| HY-117375 | Brotianide | 23233-88-7 | Reference compound |
| HY-117376 | (all-E)-UAB30 | 205252-59-1 | Reference compound |
| HY-117378 | N-5984 | 220475-76-3 | Reference compound |
| HY-117378A | N-5984 (hydrochloride) | 185035-23-8 | Reference compound |
| HY-117379 | CHIR-2279 | 158198-45-9 | Reference compound |
| HY-117380 | SB 235375 | 224961-34-6 | Reference compound |
| HY-117381 | γ-secretase-IN-2 | 564462-36-8 | Reference compound |
| HY-117383 | NGI-1 | 790702-57-7 | Reference compound |
| HY-117386 | Methoxyfenozide | 161050-58-4 | Reference compound |
| HY-117386R | Methoxyfenozide (Standard) | 161050-58-4 | Reference Standards |
| HY-117386S | Methoxyfenozide-d9 | 2469014-53-5 | Isotope-Labeled Compounds |
| HY-117387 | BFE-37 | 107572-73-6 | Reference compound |
| HY-117389 | Homocarbonyltopsentin | 172286-77-0 | Reference compound |
| HY-117391 | AZ-Dyrk1B-33 | 1679330-37-0 | Reference compound |
| HY-117393 | Bisindolylmaleimide III | 137592-43-9 | Reference compound |
| HY-117394 | MD 85 | 193551-00-7 | Reference compound |
| HY-117395 | PU-H54 | 1454619-13-6 | Reference compound |
| HY-117396 | Isomahanimbine | 26871-46-5 | Natural Products |
| HY-117397 | Fenazaquin | 120928-09-8 | Reference compound |
| HY-117397R | Fenazaquin (Standard) | 120928-09-8 | Reference Standards |
| HY-117398 | HCI-2184 | 1341200-61-0 | Reference compound |
| HY-117401 | 5-Dodecanoylaminofluorescein | 107827-77-0 | Dye Reagents |
| HY-117403 | AB-FUBICA | 1801338-22-6 | Reference compound |
| HY-117406 | Clencyclohexerol | 157877-79-7 | Reference compound |
| HY-117406R | Clencyclohexerol (Standard) | 157877-79-7 | Reference Standards |
| HY-117407 | ALLO-2 | 1357350-60-7 | Reference compound |
| HY-117408 | VU6004256 | 2011034-33-4 | Reference compound |
| HY-117409 | Aminoethyl-SS-ethylalcohol | 15579-01-8 | ADC Related |
| HY-117410 | Vipivotide tetraxetan | 1702967-37-0 | ADC Related |
| HY-117411 | Coblopasvir | 1312608-46-0 | Reference compound |
| HY-117411A | Coblopasvir (dihydrochloride) | 1966138-53-3 | Reference compound |
| HY-117412 | KCG 1 | 139036-51-4 | Reference compound |
| HY-117413 | SR-17398 | 1496088-76-6 | Reference compound |
| HY-117419 | (-)-Lavandulyl acetate | 20777-39-3 | Natural Products |
| HY-117419A | (±)-Lavandulyl acetate | 25905-14-0 | Natural Products |
| HY-117419AR | (±)-Lavandulyl acetate (Standard) | 25905-14-0 | Reference Standards |
| HY-117420 | CM764 | 1350296-29-5 | Reference compound |
| HY-117421 | CM-579 | 1846570-40-8 | Reference compound |
| HY-117421A | CM-579 trihydrochloride | 2448471-08-5 | Reference compound |
| HY-117422 | CAY10410 | 596104-94-8 | Reference compound |
| HY-117423 | ST7710AA1 | 1542067-20-8 | Reference compound |
| HY-117424 | Inz-4 | 1585213-98-4 | Reference compound |
| HY-117425 | Kigelinone | 149471-08-9 | Natural Products |
| HY-117426 | MO-I-500 | 1585219-04-0 | Reference compound |
| HY-117427 | D5D-IN-326 | 1236767-85-3 | Reference compound |
| HY-117429 | Se-Aspirin | 1850293-95-6 | Reference compound |
| HY-117430 | Hymeglusin | 29066-42-0 | Reference compound |
| HY-117431 | Prostaglandin B3 | 36614-32-1 | Reference compound |
| HY-117432 | JC-171 | 2112809-98-8 | Reference compound |
| HY-117433 | 4-Hydroperoxy cyclophosphamide | 39800-16-3 | Reference compound |
| HY-117433S | 4-Hydroperoxy Cyclophosphamide-d4 | 1246816-71-6 | Isotope-Labeled Compounds |
| HY-117434 | Suberosol | 151368-42-2 | Reference compound |
| HY-117436 | R(+)-6-Bromo-APB (hydrobromide) | 139689-19-3 | Reference compound |
| HY-117437 | Azintamide | 1830-32-6 | Reference compound |
| HY-117439 | (R)-Norverapamil | 123932-43-4 | Reference compound |
| HY-117440 | 4'-Methoxy-S-trityl-L-cysteinol | 1338701-15-7 | Reference compound |
| HY-117441 | 5(S)-HPEPE | 143292-98-2 | Natural Products |
| HY-117442 | A2B57 | 1602733-73-2 | Reference compound |
| HY-117443 | IWP-051 | 1354041-91-0 | Reference compound |
| HY-117444 | ONO-9780307 | 856691-44-6 | Reference compound |
| HY-117445 | Oxazole yellow | 143413-86-9 | Dye Reagents |
| HY-117446 | AS-1669058 | 1395553-32-8 | Reference compound |
| HY-117446A | AS-1669058 (free base) | 1395553-31-7 | Reference compound |
| HY-117447 | LY303336 | 157187-00-3 | Reference compound |
| HY-117450 | VU0415374 | 1266338-03-7 | Reference compound |
| HY-117451 | Dodine | 2439-10-3 | Reference compound |
| HY-117452 | LY-402913 | 334970-65-9 | Reference compound |
| HY-117453 | BMS-901715 | 1699861-37-4 | Reference compound |
| HY-117457 | BPIC | 1444382-92-6 | Reference compound |
| HY-117459 | E-3030 (free acid) | 478926-45-3 | Reference compound |
| HY-117460 | Indanorex | 16112-96-2 | Reference compound |
| HY-117463 | Dexamethasone beloxil | 150587-07-8 | Reference compound |
| HY-117464 | CM-352 | 1664361-37-8 | Reference compound |
| HY-117465 | HAC-Y6 | 1331959-78-4 | Reference compound |
| HY-117466 | FR186054 | 179053-90-8 | Reference compound |
| HY-117467 | BMT-108908 | 1801151-15-4 | Reference compound |
| HY-117468 | Lissamine rhodamine B | 2609-88-3 | Dye Reagents |
| HY-117469 | Triptohypol C | 193957-88-9 | Natural Products |
| HY-117471 | Antiarrhythmic agent-3 | 21236-52-2 | Reference compound |
| HY-117472 | DLC27-14 | 1360869-92-6 | Reference compound |
| HY-117473 | DAT-230 | 1504583-00-9 | Reference compound |
| HY-117474 | MJN110 | 1438416-21-7 | Reference compound |
| HY-117475 | N-Acetylthyroxine | 26041-51-0 | Reference compound |
| HY-117477 | DPC 963 | 214287-90-8 | Reference compound |
| HY-117479 | CL67 | 1401242-86-1 | Reference compound |
| HY-117481 | NSC-639829 | 134742-19-1 | Reference compound |
| HY-117482 | BPN-15606 | 1914989-49-3 | Reference compound |
| HY-117482A | BPN-15606 (besylate) | 2436239-00-6 | Reference compound |
| HY-117483 | Gly-Pro-Glu | 32302-76-4 | Peptides |
| HY-117484 | Rubrosterone | 19466-41-2 | Natural Products |
| HY-117486 | RU 56187 | 143782-25-6 | Reference compound |
| HY-117488 | (S)-Grepafloxacin | 146761-69-5 | Reference compound |
| HY-117489 | Julibrine II | 142628-29-3 | Reference compound |
| HY-117491 | BRD4 Inhibitor-10 | 1660117-38-3 | Reference compound |
| HY-117492 | Aconiazide | 13410-86-1 | Reference compound |
| HY-117496 | Ampelopsin A | 130608-11-6 | Natural Products |
| HY-117497 | Simetride | 154-82-5 | Reference compound |
| HY-117500 | Aplysamine-1 | 159026-30-9 | Natural Products |
| HY-117501 | Dexchlorpheniramine | 25523-97-1 | Reference compound |
| HY-117502 | SL-25.1188 | 185835-97-6 | Reference compound |
| HY-117507 | U92016A (hydrochloride) | 149654-41-1 | Reference compound |
| HY-117508 | JNJ-54175446 | 1627902-21-9 | Reference compound |
| HY-117511 | HJC0123 | 1430420-02-2 | Reference compound |
| HY-117512 | UWA-101 (hydrochloride) | 1431520-52-3 | Reference compound |
| HY-117513 | CEP1612 | 189036-01-9 | Reference compound |
| HY-117514 | 5-LOX-IN-7 | 1272519-89-7 | Reference compound |
| HY-117515 | YLT205 | 1316196-63-0 | Reference compound |
| HY-117516 | SR10067 | 1380548-02-6 | Reference compound |
| HY-117517 | NG-012 | 141731-76-2 | Natural Products |
| HY-117518 | Paranyline | 1729-61-9 | Reference compound |
| HY-117518A | Paranyline (hydrochloride) | 5585-60-4 | Reference compound |
| HY-117519 | Amino-Tri-(carboxyethoxymethyl)-methane | 174362-95-9 | ADC Related |
| HY-117519A | Amino-Tri-(carboxyethoxymethyl)-methane (hydrochloride) | 1416771-72-6 | ADC Related |
| HY-117522 | Sepin-1 | 163126-81-6 | Reference compound |
| HY-117523 | (Z)-RG-13022 | 149286-90-8 | Reference compound |
| HY-117526 | (-)-Mesembrine | 24880-43-1 | Natural Products |
| HY-117528 | WAY-123398 | 138490-53-6 | Reference compound |
| HY-117529 | BMS-351 | 1370001-71-0 | Reference compound |
| HY-117532 | PenCB | 31508-00-6 | Reference compound |
| HY-117533 | UNC0006 | 1354030-14-0 | Reference compound |
| HY-117535 | CDK2-IN-4 | 2079895-42-2 | Reference compound |
| HY-117540 | ZLD10A | 1782064-91-8 | Reference compound |
| HY-117541 | Glycyl-glutamine | 13115-71-4 | Reference compound |
| HY-117542 | D595 | 16740-29-7 | Reference compound |
| HY-117543 | Ethonafide | 160554-87-0 | Reference compound |
| HY-117544 | Porphyrin precursor | 149365-62-8 | Reference compound |
| HY-117547 | Licostinel | 153504-81-5 | Reference compound |
| HY-117548 | UNC1062 | 1350549-36-8 | Reference compound |
| HY-117549 | Ibrolipim | 133208-93-2 | Reference compound |
| HY-117554 | BRD9757 | 1423058-85-8 | Reference compound |
| HY-117556 | U-104489 | 177577-60-5 | Reference compound |
| HY-117557 | LY306669 | 153227-04-4 | Reference compound |
| HY-117558 | (Rac)-L-826141 | 491869-01-3 | Reference compound |
| HY-117561 | DuP 714 | 130982-43-3 | Reference compound |
| HY-117562 | a-FABP-IN-1 | 1310361-52-4 | Reference compound |
| HY-117563 | CAY10621 | 120005-55-2 | Reference compound |
| HY-117566 | RPR 102341 | 149105-53-3 | Reference compound |
| HY-117568 | A-80b | 135561-94-3 | Reference compound |
| HY-117569 | KF24345 (free base) | 178750-21-5 | Reference compound |
| HY-117570 | KSC-34 | 2226201-97-2 | Reference compound |
| HY-117571 | Zatolmilast | 1606974-33-7 | Reference compound |
| HY-117572 | MRS2567 | 15398-83-1 | Reference compound |
| HY-117573 | 1Z105 | 1438280-73-9 | Reference compound |
| HY-117574 | SB 207710 | 148703-08-6 | Reference compound |
| HY-117575 | WAY-100135 | 133025-23-7 | Reference compound |
| HY-117575A | WAY-100135 (dihydrochloride) | 149055-79-8 | Reference compound |
| HY-117578 | KB 5666 | 131916-69-3 | Reference compound |
| HY-117580 | 16α-Hydroxyprednisolone | 13951-70-7 | Reference compound |
| HY-117580R | 16α-Hydroxyprednisolone (Standard) | 13951-70-7 | Reference Standards |
| HY-117580S | 16α-Hydroxyprednisolone-d3 | | Isotope-Labeled Compounds |
| HY-117581 | L-669,262 | 130468-11-0 | Reference compound |
| HY-117582 | Elvucitabine | 181785-84-2 | Oligonucleotides |
| HY-117583 | cis-BG47 | | Reference compound |
| HY-117583A | BG47 | 1628784-54-2 | Reference compound |
| HY-117584 | L-163255 (free base) | 159634-54-5 | Reference compound |
| HY-117585 | Caylin-2 | 1392830-09-9 | Reference compound |
| HY-117586 | 9-PAHPA | 1636134-70-7 | Natural Products |
| HY-117591 | L 684248 | 156728-18-6 | Reference compound |
| HY-117595 | PHM16 | 1448791-29-4 | Reference compound |
| HY-117596 | UNC569 | 1350547-65-7 | Reference compound |
| HY-117597 | YM440 | 163300-58-1 | Reference compound |
| HY-117598 | OXFBD03 | 1429129-71-4 | Reference compound |
| HY-117600 | Tributyl phosphate | 126-73-8 | Natural Products |
| HY-117600S | Tributyl phosphate-D27 | 61196-26-7 | Isotope-Labeled Compounds |
| HY-117601 | 11-Deoxyalisol B | 155073-73-7 | Natural Products |
| HY-117602 | TLR7 agonist 3 | 1229024-78-5 | Reference compound |
| HY-117603 | CM-10-18 | 1159614-57-9 | Reference compound |
| HY-117604 | THPP-1 | 1257051-63-0 | Reference compound |
| HY-117605 | N-Desmethyl Sildenafil | 139755-82-1 | Reference compound |
| HY-117605R | N-Desmethyl Sildenafil (Standard) | 139755-82-1 | Reference Standards |
| HY-117605S | N-Desmethyl Sildenafil-d8 | 1185168-06-2 | Isotope-Labeled Compounds |
| HY-117606 | LY3027788 | 1377615-76-3 | Reference compound |
| HY-117606A | LY3027788 (hydrochloride) | 1377615-55-8 | Reference compound |
| HY-117607 | Alatrioprilat | 135038-59-4 | Reference compound |
| HY-117608 | ML 315 | 1440251-53-5 | Reference compound |
| HY-117608A | ML 315 (hydrochloride) | 2172559-91-8 | Reference compound |
| HY-117609 | UE2343 | 1346013-80-6 | Reference compound |
| HY-117610 | Ro 31-8830 | 131848-98-1 | Reference compound |
| HY-117610A | Bisindolylmaleimide XI (hydrochloride) | 145333-02-4 | Reference compound |
| HY-117611 | GAT107 | 1476807-74-5 | Reference compound |
| HY-117614 | WF-210 | 1242279-00-0 | Reference compound |
| HY-117615 | Rhapontisterone | 137476-71-2 | Natural Products |
| HY-117616 | Laurotetanine | 128-76-7 | Natural Products |
| HY-117617 | CAY10669 | 1243583-88-1 | Reference compound |
| HY-117618 | KF-14124 | 134186-26-8 | Reference compound |
| HY-117621 | PF-04634817 | 1228111-63-4 | Reference compound |
| HY-117621A | PF-04634817 (succinate) | 2140301-98-8 | Reference compound |
| HY-117622 | ND-2110 | 1388894-17-4 | Reference compound |
| HY-117623 | PF-06685249 | 1467059-70-6 | Reference compound |
| HY-117626 | LP-935509 | 1454555-29-3 | Reference compound |
| HY-117627 | L 158338 | 133240-38-7 | Reference compound |
| HY-117630 | RB-6145 | 129448-97-1 | Reference compound |
| HY-117632 | Elcubragistat | 1446817-84-0 | Reference compound |
| HY-117633 | Sultroponium | 15130-91-3 | Reference compound |
| HY-117634 | WS009B | 136286-50-5 | Reference compound |
| HY-117636 | (Rac)-L-659989 | 129314-27-8 | Reference compound |
| HY-117637 | ALS-I-41 | 1369357-99-2 | Reference compound |
| HY-117639 | AUT1 | 1311136-84-1 | Reference compound |
| HY-117644 | L-749329 | 159590-37-1 | Reference compound |
| HY-117646 | FG-5893 | 150527-23-4 | Reference compound |
| HY-117647 | CRA-19156 | 579511-43-6 | Reference compound |
| HY-117649 | RU-39411 | 120382-04-9 | Reference compound |
| HY-117650A | RG7834 | 2072057-17-9 | Reference compound |
| HY-117651 | 2-Fluoropalmitic acid | 16518-94-8 | Reference compound |
| HY-117651R | 2-Fluoropalmitic acid (Standard) | 16518-94-8 | Reference Standards |
| HY-117652 | Lobetyol | 136171-87-4 | Natural Products |
| HY-117656 | ESI-05 | 5184-64-5 | Reference compound |
| HY-117657 | (-)-BO 2367 | 145902-81-4 | Reference compound |
| HY-117658 | GSK-114 | 1301761-96-5 | Reference compound |
| HY-117659 | PGDM | 133161-96-3 | Reference compound |
| HY-117660 | Lincomycin | 154-21-2 | Natural Products |
| HY-117660R | Lincomycin (Standard) | 154-21-2 | Reference Standards |
| HY-117660S | Lincomycin-d3 | | Isotope-Labeled Compounds |
| HY-117661 | SPHINX31 | 1818389-84-2 | Reference compound |
| HY-117664 | PNR-7-02 | 1633660-76-0 | Reference compound |
| HY-117665 | Fimaporfin | 1443547-43-0 | Dye Reagents |
| HY-117666 | NSC668036 | 144678-63-7 | Reference compound |
| HY-117668 | MDL 101146 | 149859-17-6 | Reference compound |
| HY-117669 | VPC-14228 | 19983-28-9 | Reference compound |
| HY-117672 | L-671776 | 134313-74-9 | Natural Products |
| HY-117677 | Cdc7-IN-21 | 1330781-04-8 | Reference compound |
| HY-117678 | TG-2-IN-1 | 135273-74-4 | Reference compound |
| HY-117679 | LY 135114 (free base) | 126254-82-8 | Reference compound |
| HY-117682 | L-(+)-threo-Chloramphenicol | 134-90-7 | Reference compound |
| HY-117683 | BCTP | 464152-46-3 | Reference compound |
| HY-117684 | Cabamiquine | 1469439-69-7 | Reference compound |
| HY-117684A | Cabamiquine (succinate) | 2444781-71-7 | Reference compound |
| HY-117685 | Cefovecin (sodium) | 141195-77-9 | Reference compound |
| HY-117688 | WJ35435 | 1620054-84-3 | Reference compound |
| HY-117690 | dBRD9 | 2170679-45-3 | Reference compound |
| HY-117690A | dBRD9 (dihydrochloride) | 2341840-98-8 | Reference compound |
| HY-117693 | (E/Z)-Mirin | 299953-00-7 | Reference compound |
| HY-117694 | MK-8825 | 1380887-60-4 | Reference compound |
| HY-117695 | AQC | 148757-94-2 | Dye Reagents |
| HY-117697 | Lu AF11205 | 1290133-16-2 | Reference compound |
| HY-117699 | Fluanisone | 1480-19-9 | Reference compound |
| HY-117699R | Fluanisone (Standard) | 1480-19-9 | Reference Standards |
| HY-117700 | TNKS-IN-2 | 1584646-59-2 | Reference compound |
| HY-117702 | RB 101 | 135949-60-9 | Reference compound |
| HY-117703 | CVS 738 | 151275-15-9 | Reference compound |
| HY-117705 | G244-LM | 1563007-08-8 | Reference compound |
| HY-117706 | LY 292728 | 153034-77-6 | Reference compound |
| HY-117707 | EBI-907 | 1581764-31-9 | Reference compound |
| HY-117708 | Antitumor agent-144 | 137346-42-0 | Reference compound |
| HY-117709 | BRD6688 | 1404562-17-9 | Reference compound |
| HY-117712 | LG 6-101 | 132798-26-6 | Reference compound |
| HY-117713 | Cycloechinulin | 143086-29-7 | Natural Products |
| HY-117714 | AZD-3161 | 1369501-46-1 | Reference compound |
| HY-117715 | CK-3197 | 132523-92-3 | Reference compound |
| HY-117717 | (Rac)-SC-31391 | 144730-93-8 | Reference compound |
| HY-117718 | AG957 | 140674-76-6 | Reference compound |
| HY-117720 | OSU-2S | 1351056-65-9 | Reference compound |
| HY-117721 | IHVR-11029 | 1383152-30-4 | Reference compound |
| HY-117722 | JW 618 | 1416133-88-4 | Reference compound |
| HY-117723 | MF-PGDH-008 | 452077-89-3 | Reference compound |
| HY-117724 | AZ3976 | 1418747-15-5 | Reference compound |
| HY-117725 | S-2720 | 146739-86-8 | Reference compound |
| HY-117726 | WAY-169916 | 669764-18-5 | Reference compound |
| HY-117727 | Leriglitazone | 146062-44-4 | Reference compound |
| HY-117727A | Leriglitazone (hydrochloride) | 146062-46-6 | Reference compound |
| HY-117727S | Leriglitazone-d4 | 1188263-49-1 | Isotope-Labeled Compounds |
| HY-117731 | UKH-1114 | 2113664-14-3 | Reference compound |
| HY-117732 | Xanthorin | 17526-15-7 | Natural Products |
| HY-117734 | PYD-106 | 1560894-05-4 | Reference compound |
| HY-117736 | Ro 09-1428 | 134452-47-4 | Reference compound |
| HY-117737A | RRD-251 | 72214-67-6 | Reference compound |
| HY-117738 | Benarthin | 143651-45-0 | Natural Products |
| HY-117739 | BRD1652 | 1597438-92-0 | Reference compound |
| HY-117740 | Heronamide C | 1257083-94-5 | Natural Products |
| HY-117741 | GSK951A | 1403602-33-4 | Reference compound |
| HY-117742 | DA-7867 | 380382-38-7 | Reference compound |
| HY-117743 | Eprosartan | 133040-01-4 | Reference compound |
| HY-117743AS1 | Eprosartan-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-117743R | Eprosartan (Standard) | 133040-01-4 | Reference Standards |
| HY-117743S | Eprosartan-d3 | 1185243-70-2 | Isotope-Labeled Compounds |
| HY-117743S1 | Eprosartan-d6 | | Isotope-Labeled Compounds |
| HY-117746 | KSK120 | 1638100-63-6 | Reference compound |
| HY-117747 | DMP 323 | 151867-81-1 | Reference compound |
| HY-117749 | Bisoxatin (acetate) | 14008-48-1 | Reference compound |
| HY-117754 | PSB-SB1202 | 1399049-60-5 | Reference compound |
| HY-117755 | PF-739 | 1852452-14-2 | Reference compound |
| HY-117756 | Piflufolastat | 1423758-00-2 | Reference compound |
| HY-117757 | Ninopterin | 2179-16-0 | Reference compound |
| HY-117760 | Spirolaxine | 126382-01-2 | Natural Products |
| HY-117761 | MHY908 | 1393371-39-5 | Reference compound |
| HY-117762 | U-83836E | 137018-55-4 | Reference compound |
| HY-117763 | A-39355 | 144092-66-0 | Reference compound |
| HY-117764 | LSP4-2022 | 1413405-33-0 | Reference compound |
| HY-117765 | RS-5773 | 129173-57-5 | Reference compound |
| HY-117766 | PC945 | 1931946-73-4 | Reference compound |
| HY-117769 | GSK837149A | 13616-29-0 | Reference compound |
| HY-117770 | STAT3-IN-30 | 1803281-30-2 | Reference compound |
| HY-117771 | DO34 | 1848233-58-8 | Reference compound |
| HY-117771A | DO34 analog | 2098969-71-0 | Reference compound |
| HY-117772 | FSC231 | 1215849-96-9 | Reference compound |
| HY-117774 | AHR-2244 (hydrochloride) | 24677-84-7 | Reference compound |
| HY-117776 | CAY10677 | 1443253-20-0 | Reference compound |
| HY-117777 | GSK121 | 1652591-80-4 | Reference compound |
| HY-117778 | SF2312 | 107729-45-3 | Reference compound |
| HY-117778B | SF2312 (ammonium) | | Reference compound |
| HY-117779 | DBIBB | 1569309-92-7 | Reference compound |
| HY-117780 | Rawsonol | 125111-69-5 | Natural Products |
| HY-117782 | Anticancer agent 236 | 1356340-69-6 | Reference compound |
| HY-117784 | BI-L-357 | 149539-02-6 | Reference compound |
| HY-117785 | 4’-Methoxy-α-ethylaminovalerophenone (hydrochloride) | 17837-89-7 | Reference compound |
| HY-117786 | Go 7874 | 153207-86-4 | Reference compound |
| HY-117787 | TUG-905 | 1390641-90-3 | Reference compound |
| HY-117789 | Keto-itraconazole | 112560-33-5 | Reference compound |
| HY-117791 | (R)-Pralatrexate | 1320211-70-8 | Reference compound |
| HY-117792 | LY314228 | 182633-54-1 | Reference compound |
| HY-117793 | I-191 | 1690172-25-8 | Reference compound |
| HY-117798 | LY 806303 | 149725-15-5 | Reference compound |
| HY-117799 | LY-426965 | 228418-82-4 | Reference compound |
| HY-117799A | LY-426965 (hydrochloride) | 326821-27-6 | Reference compound |
| HY-117799C | (±)-LY-426965 (dihydrochloride) | 228418-81-3 | Reference compound |
| HY-117800 | BJE6-106 | 1564249-38-2 | Reference compound |
| HY-117803 | CP 461 (free base) | 227619-92-3 | Reference compound |
| HY-117804 | 8-Br-cADPR | 151898-26-9 | Reference compound |
| HY-117805 | UR-7247 | 177847-28-8 | Reference compound |
| HY-117807 | A-176120 | 185049-54-1 | Reference compound |
| HY-117809 | PDK1-IN-2 | 1643958-85-3 | Reference compound |
| HY-117810 | JAK2-IN-1 | 1361415-84-0 | Reference compound |
| HY-117811 | (R,R)-MK 287 | 143490-81-7 | Reference compound |
| HY-117813 | 2-Thiouridine | 20235-78-3 | Biochemical Assay Reagents |
| HY-117817 | Ranelic acid | 135459-90-4 | Reference compound |
| HY-117818 | Sapurimycin | 132609-35-9 | Natural Products |
| HY-117819 | TMP920 | 1421837-45-7 | Reference compound |
| HY-117820 | TASP0390325 | 1642187-96-9 | Reference compound |
| HY-117822 | BRD0209 | 1597439-87-6 | Reference compound |
| HY-117823 | VUF11418 | 1414376-85-4 | Reference compound |
| HY-117824 | L-703014 | 142638-79-7 | Reference compound |
| HY-117825 | RU-TRAAK-2 | 1210538-56-9 | Reference compound |
| HY-117826 | JNJ 28610244 | 1251462-28-8 | Reference compound |
| HY-117829 | UNC9994 | 1354030-51-5 | Reference compound |
| HY-117830 | CX08005 | 1256341-22-6 | Reference compound |
| HY-117831 | NSC-79887 | 19056-78-1 | Reference compound |
| HY-117832 | Pyripyropene A | 147444-03-9 | Natural Products |
| HY-117833 | PXS-4681A | 1478364-87-2 | Reference compound |
| HY-117836 | FAK-IN-16 | 1257994-15-2 | Reference compound |
| HY-117837 | GSK1829820A | 1443138-52-0 | Reference compound |
| HY-117838 | Phosphodiesterase 10-IN-2 | 1257051-56-1 | Reference compound |
| HY-117839 | PD-135666 | 134557-41-8 | Reference compound |
| HY-117840 | Altromycin F | 134887-78-8 | Natural Products |
| HY-117841 | T900607 | 261944-52-9 | Reference compound |
| HY-117842 | KY 234 | 172544-75-1 | Reference compound |
| HY-117843 | Ppc-1 | 1245818-17-0 | Reference compound |
| HY-117845 | Citreamicin alpha | 122535-63-1 | Natural Products |
| HY-117846 | MLAF50 | 1417653-96-3 | Reference compound |
| HY-117848 | PDE8B-IN-1 (hydrochloride) | 1305116-67-9 | Reference compound |
| HY-117849 | Neutramycin | 1404-08-6 | Reference compound |
| HY-117850 | TAK 187 | 155432-64-7 | Reference compound |
| HY-117851 | AC-265347 | 1253901-26-6 | Reference compound |
| HY-117853 | Atreleuton | 154355-76-7 | Reference compound |
| HY-117853S | Atreleuton-d4 | 2012598-86-4 | Isotope-Labeled Compounds |
| HY-117854 | SB 201146 | 141311-11-7 | Reference compound |
| HY-117856 | IND24 | 1426047-44-0 | Reference compound |
| HY-117857 | MRT00033659 | 1401731-54-1 | Reference compound |
| HY-117858 | CL-329167 | 143945-39-5 | Reference compound |
| HY-117860 | Vat Yellow 4 | 128-66-5 | Dye Reagents |
| HY-117861 | ML198 | 1380716-06-2 | Reference compound |
| HY-117862 | TASP0412098 | 1233248-29-7 | Reference compound |
| HY-117865 | GNE-886 | 2101957-05-3 | Reference compound |
| HY-117867A | AVE-8063 (hydrochloride) | 162705-22-8 | Reference compound |
| HY-117868 | NC-174 | 138460-25-0 | Reference compound |
| HY-117869 | AFK-108 | 135330-85-7 | Reference compound |
| HY-117870 | Ro 24-4383 | 135312-05-9 | Reference compound |
| HY-117872 | Sartorypyrone A | 1452396-10-9 | Natural Products |
| HY-117873 | KBP-7018 | 1613437-66-3 | Reference compound |
| HY-117873A | KBP-7018 (hydrochloride) | 1613437-67-4 | Reference compound |
| HY-117878 | ML345 | 1632125-79-1 | Reference compound |
| HY-117880 | Exicorilant | 1781244-77-6 | Reference compound |
| HY-117881 | CJ-15208 | 210236-47-8 | Reference compound |
| HY-117882 | Piperiacetildenafil | 147676-50-4 | Reference compound |
| HY-117883 | GZ-793A | 1356447-90-9 | Reference compound |
| HY-117884 | (Rac)-CCT 250863 | 1364269-06-6 | Reference compound |
| HY-117885 | PF-5177624 | 1350821-45-2 | Reference compound |
| HY-117887 | Fidrisertib | 2141955-96-4 | Reference compound |
| HY-117889 | PARP14 inhibitor H10 | 2084811-68-5 | Reference compound |
| HY-117891 | Davasaicin | 147497-64-1 | Reference compound |
| HY-117896 | SC-50605 | 138828-39-4 | Reference compound |
| HY-117897 | CK-2-68 | 1361004-87-6 | Reference compound |
| HY-117900 | PF-06250112 | 1609465-89-5 | Reference compound |
| HY-117900A | (Rac)-PF-06250112 | 1609465-88-4 | Reference compound |
| HY-117901 | Sandoricin | 133585-55-4 | Natural Products |
| HY-117902 | SRI-31142 | 1940118-04-6 | Reference compound |
| HY-117903A | MRT-92 | 1428315-82-5 | Reference compound |
| HY-117906 | GV196771 | 166974-22-7 | Reference compound |
| HY-117909 | CEP-40125 | 1456608-94-8 | Reference compound |
| HY-117910 | (-)-Lentiginosine | 125279-72-3 | Reference compound |
| HY-117912 | TRC210258 | 1431553-15-9 | Reference compound |
| HY-117913 | ES-8891 | 129445-88-1 | Reference compound |
| HY-117917 | (Rac)-MGV354 | 1852495-86-3 | Reference compound |
| HY-117918 | ST-1892 | 1409411-32-0 | Reference compound |
| HY-117921 | DA-E 5090 | 131420-84-3 | Reference compound |
| HY-117922 | JYL-79 | 289902-64-3 | Reference compound |
| HY-117923 | PF-06465603 | 1431626-44-6 | Reference compound |
| HY-117924 | AUTEN-67 | 1783800-77-0 | Reference compound |
| HY-117925 | Personalised postprandial-targeting | 1529779-90-5 | Reference compound |
| HY-117926 | AGN 191701 | 156691-84-8 | Reference compound |
| HY-117927 | EPZ0025654 | 1888328-89-9 | Reference compound |
| HY-117928 | BRL 55834 | 131899-25-7 | Reference compound |
| HY-117930 | Danicopan | 1903768-17-1 | Reference compound |
| HY-117931 | NS004 | 141797-92-4 | Reference compound |
| HY-117934 | Isokotanin B | 154160-09-5 | Natural Products |
| HY-117935 | GGTI-286 (hydrochloride) | 181141-66-2 | Reference compound |
| HY-117936 | Muscarinic agonist 1 | 168818-83-5 | Reference compound |
| HY-117937 | BC-1215 | 1507370-20-8 | Reference compound |
| HY-117938 | T-3861174 | 2209057-94-1 | Reference compound |
| HY-117939 | GM1489 | 171347-75-4 | Reference compound |
| HY-117943 | (rac)-ONO-2050297 | 1637756-67-2 | Reference compound |
| HY-117947 | (R)-OR-S1 | 1809336-19-3 | Reference compound |
| HY-117948 | ML399 | 1560968-49-1 | Reference compound |
| HY-117951 | ANT431 | 1639972-90-9 | Reference compound |
| HY-117952 | L 743310 | 187724-86-3 | Reference compound |
| HY-117953 | RU 59063 | 155180-53-3 | Reference compound |
| HY-117955 | GMA-839 | 162882-76-0 | Reference compound |
| HY-117957 | BMS-932481 | 1263871-36-8 | Reference compound |
| HY-117958 | HJC0197 | 1383539-73-8 | Reference compound |
| HY-117959 | TAK-615 | 1664335-55-0 | Reference compound |
| HY-117960 | Orismilast | 1353546-86-7 | Reference compound |
| HY-117961 | Candoxatrilat | 123122-54-3 | Reference compound |
| HY-117962 | (Rac)-BI 703704 | 1423067-48-4 | Reference compound |
| HY-117962A | BI 703704 | 2740807-77-4 | Reference compound |
| HY-117963 | Lincosamine | 13006-69-4 | Reference compound |
| HY-117964 | Pigment Red 53 | 2092-56-0 | Reference compound |
| HY-117965 | Miricorilant | 1400902-13-7 | Reference compound |
| HY-117966 | Bibn 140 | 145301-79-7 | Reference compound |
| HY-117967 | MK-6169 | 1620479-63-1 | Reference compound |
| HY-117970 | MMPI-1154 | 1382722-47-5 | Reference compound |
| HY-117971 | BVT173187 | 1374984-75-4 | Reference compound |
| HY-117973 | L 691816 | 150461-07-7 | Reference compound |
| HY-117974 | Durlobactam (sodium) | 1467157-21-6 | Reference compound |
| HY-117977 | FCPR03 | 1917347-65-9 | Reference compound |
| HY-117978 | LY2922083 | 1309435-78-6 | Reference compound |
| HY-117979 | Alphadolone | 14107-37-0 | Reference compound |
| HY-117980 | Meturedepa | 1661-29-6 | Reference compound |
| HY-117981 | OUP-186 | 1480830-24-7 | Reference compound |
| HY-117982 | SKI2496 | 1308378-95-1 | Reference compound |
| HY-117983 | RU-505 | 1314206-29-5 | Reference compound |
| HY-117984 | RU 35929 | 111711-47-8 | Reference compound |
| HY-117985 | Evogliptin | 1222102-29-5 | Reference compound |
| HY-117985A | Evogliptin (hydrochloride) | 1246960-27-9 | Reference compound |
| HY-117985B | Evogliptin (tartrate) | 1222102-51-3 | Reference compound |
| HY-117985S | Evogliptin-d9 | | Isotope-Labeled Compounds |
| HY-117986 | AB 3217-A | 139158-99-9 | Natural Products |
| HY-117987 | CPS-11 | 145945-21-7 | Reference compound |
| HY-117988 | SNX2-1-108 | 1366002-73-4 | Reference compound |
| HY-117990 | GSK572A | 1403602-32-3 | Reference compound |
| HY-117991 | DW10075 | 1804982-31-7 | Reference compound |
| HY-117992 | BR103 | 1434873-26-3 | Reference compound |
| HY-117993 | MIND4 | 1639965-26-6 | Reference compound |
| HY-117996 | KPT-251 | 1388841-50-6 | Reference compound |
| HY-117997 | UMB-32 | 1635437-39-6 | Reference compound |
| HY-117999 | BAY39-5493 | 247037-81-6 | Reference compound |
| HY-118008 | Lesopitron | 132449-46-8 | Reference compound |
| HY-118008A | Lesopitron (hydrochloride) | 132449-88-8 | Reference compound |
| HY-118009 | Azotochelin | 23369-85-9 | Natural Products |
| HY-118010 | Norfenfluramine | 1886-26-6 | Reference compound |
| HY-118010A | (+)-Norfenfluramine (hydrochloride) | 37936-89-3 | Reference compound |
| HY-118012 | Flaviviruses-IN-1 | 392237-10-4 | Reference compound |
| HY-118013 | NDM-1 inhibitor-2 | 665013-76-3 | Reference compound |
| HY-118014 | CAY10535 | 945716-28-9 | Reference compound |
| HY-118019 | Scandenolide | 23758-16-9 | Natural Products |
| HY-118020A | Loliolid | 5989-02-6 | Natural Products |
| HY-118021 | Hatomamicin | 116290-93-8 | Natural Products |
| HY-118022 | VU0361747 | 1309976-66-6 | Reference compound |
| HY-118024 | Littorine | 21956-47-8 | Natural Products |
| HY-118025 | (±)-2-Oxo clopidogrel | 109904-27-0 | Reference compound |
| HY-118025R | (±)-2-Oxo clopidogrel (Standard) | 109904-27-0 | Reference Standards |
| HY-118028 | Leyk | 1950-36-3 | Reference compound |
| HY-118029 | Saroaspidin A | 112663-69-1 | Natural Products |
| HY-118030 | RQ-00311651 | 1257116-00-9 | Reference compound |
| HY-118032 | Bozepinib | 1207993-83-6 | Reference compound |
| HY-118033 | SQ 30774 | 121995-36-6 | Reference compound |
| HY-118034 | MTBT | 1110905-26-4 | Reference compound |
| HY-118036 | ACT-387042 | 1229514-11-7 | Reference compound |
| HY-118037 | VUF10132 | 1037732-88-9 | Reference compound |
| HY-118040 | 3-Oxo-C16:1 | 1269663-80-0 | Reference compound |
| HY-118041 | PMPMEase-IN-1 | 1190196-76-9 | Reference compound |
| HY-118043 | RK-1441B | 132138-94-4 | Reference compound |
| HY-118044 | I-SAP | 133538-58-6 | Reference compound |
| HY-118046 | GSK2163632A | 1123163-20-1 | Reference compound |
| HY-118047 | CI 972 (anhydrous) | 115787-68-3 | Reference compound |
| HY-118048 | NAV 26 | 1198160-14-3 | Reference compound |
| HY-118050 | L589420-0-2 | 1431-30-7 | Reference compound |
| HY-118051 | LY 186826 | 126165-79-5 | Reference compound |
| HY-118052 | BPKDi | 1201673-28-0 | Reference compound |
| HY-118054 | LRH-1 Inhibitor-3 | 1185410-60-9 | Reference compound |
| HY-118055 | 15-Deoxy-Δ12,14-prostaglandin A2 | 112839-31-3 | Reference compound |
| HY-118056 | ABD459 | 1047670-51-8 | Reference compound |
| HY-118057 | L-739594 | 156879-13-9 | Reference compound |
| HY-118060 | Dipeptide 2 | 24587-37-9 | Peptides |
| HY-118061 | VCC234718 | 1278553-16-4 | Reference compound |
| HY-118063 | Fluoroclorgyline | 135062-18-9 | Reference compound |
| HY-118064 | (R)-Thionisoxetine | 163059-33-4 | Reference compound |
| HY-118064A | (R)-Thionisoxetine (hydrochloride) | 222961-65-1 | Reference compound |
| HY-118065 | Fenhexamid | 126833-17-8 | Reference compound |
| HY-118065R | Fenhexamid (Standard) | 126833-17-8 | Reference Standards |
| HY-118068 | Methyl 3-hydroxyoctadecanoate | 2420-36-2 | Natural Products |
| HY-118069 | (R)-ZINC-3573 | 2089389-15-9 | Reference compound |
| HY-118072 | Aspalatone | 147249-33-0 | Reference compound |
| HY-118075 | Coenzyme Q2 | 606-06-4 | Enzyme |
| HY-118077 | RE 11775 | 25474-41-3 | Reference compound |
| HY-118078 | Robenacoxib | 220991-32-2 | Reference compound |
| HY-118078R | Robenacoxib (Standard) | 220991-32-2 | Reference Standards |
| HY-118078S | Robenacoxib-d5 | 2012598-81-9 | Isotope-Labeled Compounds |
| HY-118079 | Drimentine B | 204398-91-4 | Reference compound |
| HY-118081 | inS3-54-A26 | 328998-77-2 | Reference compound |
| HY-118084 | LS-104 | 368836-72-0 | Reference compound |
| HY-118085 | Fluazolate | 174514-07-9 | Reference compound |
| HY-118086 | MRS1067 | 70460-45-6 | Reference compound |
| HY-118090 | L-γ-Glutamyl-L-glutamic acid | 1116-22-9 | Peptides |
| HY-118090A | D-γ-Glutamyl-D-glutamic acid | 4553-17-7 | Peptides |
| HY-118091 | LY191704 | 146117-78-4 | Reference compound |
| HY-118091A | Bexlosteride | 148905-78-6 | Reference compound |
| HY-118091B | LY300503 | 148905-79-7 | Reference compound |
| HY-118093 | N-benzoyl-L-aspartic acid | 4631-12-3 | Reference compound |
| HY-118094 | 8-iso Prostaglandin E1 | 21003-46-3 | Reference compound |
| HY-118095 | A60586 | 146667-75-6 | Reference compound |
| HY-118097 | GW0072 | 321557-86-2 | Reference compound |
| HY-118098 | LY3202626 | 1628690-73-2 | Reference compound |
| HY-118099 | Florfenicol amine (hydrochloride) | 108656-33-3 | Reference compound |
| HY-118099R | Florfenicol amine (hydrochloride) (Standard) | 108656-33-3 | Reference Standards |
| HY-118100 | Cyclo(Tyr-Val) | 21754-25-6 | Reference compound |
| HY-118101 | 15-Deoxy-Δ12,14-prostaglandin A1 | 573951-20-9 | Reference compound |
| HY-118103 | Coprostanol | 360-68-9 | Reference compound |
| HY-118103R | Coprostanol (Standard) | 360-68-9 | Reference Standards |
| HY-118103S | Coprostanol-d5 | | Isotope-Labeled Compounds |
| HY-118105 | RK-20448 | 479501-40-1 | Reference compound |
| HY-118109 | SIRT3-IN-2 | 848688-62-0 | Reference compound |
| HY-118110 | MLS000545091 | 322666-76-2 | Reference compound |
| HY-118112 | 4-N-Maleimidobenzoicacid-NHS | 64191-06-6 | Reference compound |
| HY-118113 | BVT-116429 | 870710-02-4 | Reference compound |
| HY-118115 | Pyrabactin | 419538-69-5 | Reference compound |
| HY-118116 | bicyclo-PGE2 | 109826-53-1 | Reference compound |
| HY-118117 | Rovatirelin | 204386-76-5 | Reference compound |
| HY-118118 | Phlebiakauranol aldehyde | 57743-92-7 | Natural Products |
| HY-118119 | CAY10526 | 938069-71-7 | Reference compound |
| HY-118120 | GEMSA | 77482-44-1 | Reference compound |
| HY-118122 | Fialuridine | 69123-98-4 | Reference compound |
| HY-118124 | 2-Iodoestradiol | 24381-12-2 | Reference compound |
| HY-118126 | Mecoprop | 93-65-2 | Reference compound |
| HY-118126R | Mecoprop (Standard) | 93-65-2 | Reference Standards |
| HY-118126S | Mecoprop-d3 | 352431-15-3 | Isotope-Labeled Compounds |
| HY-118127 | Rilapine | 79781-95-6 | Reference compound |
| HY-118129 | Schisandronic acid | 55511-14-3 | Natural Products |
| HY-118131 | PKR-IN-C51 | 1314594-23-4 | Reference compound |
| HY-118132 | LL-Z1220 | 36431-52-4 | Reference compound |
| HY-118133 | 4'-Hydroxy flurbiprofen | 52807-12-2 | Reference compound |
| HY-118134 | Hepln-13 | 64369-13-7 | Reference compound |
| HY-118135 | 4-Methylumbelliferyl-α-D-galactopyranoside | 38597-12-5 | Dye Reagents |
| HY-118136 | CGP 28392 | 89289-93-0 | Reference compound |
| HY-118138 | NC-182 | 106224-67-3 | Reference compound |
| HY-118139 | Desmethyl Celecoxib | 170569-87-6 | Reference compound |
| HY-118139S | Celecoxib-d4 | 544686-20-6 | Isotope-Labeled Compounds |
| HY-118140 | ZCZ011 | 1998197-39-9 | Reference compound |
| HY-118141 | BMS-194449 | 170686-12-1 | Reference compound |
| HY-118142 | 4-Nitrobenzofuroxan | 18771-85-2 | Reference compound |
| HY-118144 | PD166326 | 185039-91-2 | Reference compound |
| HY-118146 | Cicrotoic acid | 25229-42-9 | Reference compound |
| HY-118147 | ML356 | 1808260-45-8 | Reference compound |
| HY-118148 | UK-66914 | 113049-11-9 | Reference compound |
| HY-118149 | 9(S)-HpODE | 29774-12-7 | Reference compound |
| HY-118149A | (±)9-HpODE | 5502-91-0 | Natural Products |
| HY-118151 | Rho-Kinase-IN-3 | 864082-23-5 | Reference compound |
| HY-118152 | Org-12962 | 132834-56-1 | Reference compound |
| HY-118155 | 9-Amino-6-chloro-2-methoxyacridine | 3548-09-2 | Dye Reagents |
| HY-118156 | L-699333 | 155238-60-1 | Reference compound |
| HY-118157 | 3,5,7-Trimethoxyflavone | 26964-29-4 | Reference compound |
| HY-118158 | FAAH/MAGL-IN-4 | 256383-45-6 | Reference compound |
| HY-118159 | Diphenyl-1-pyrenylphosphine | 110231-30-6 | Dye Reagents |
| HY-118160 | PPM-18 | 65240-86-0 | Reference compound |
| HY-118161 | 1-Adamantylaspartate | 115545-59-0 | Reference compound |
| HY-118163 | tetranor-PGFM | 23109-94-6 | Reference compound |
| HY-118164 | Ro 31-8472 | 144284-57-1 | Reference compound |
| HY-118165 | Phenthoate | 2597-03-7 | Reference compound |
| HY-118165R | Phenthoate (Standard) | 2597-03-7 | Reference Standards |
| HY-118165S | Phenthoate-d6 | | Isotope-Labeled Compounds |
| HY-118166 | Gentisein | 529-49-7 | Natural Products |
| HY-118167 | Monoethylglycinexylidide | 7728-40-7 | Reference compound |
| HY-118167R | Monoethylglycinexylidide (Standard) | 7728-40-7 | Reference Standards |
| HY-118167S | Monoethylglycinexylidide-d6 | 1216698-89-3 | Isotope-Labeled Compounds |
| HY-118167S1 | Monoethylglycinexylidide-d6 (hydrochloride) | 2748541-96-8 | Isotope-Labeled Compounds |
| HY-118168 | A 9387 | 3161-15-7 | Reference compound |
| HY-118169 | A-Factor | 60866-47-9 | Reference compound |
| HY-118170 | T16A(inh)-C01 | 171506-87-9 | Reference compound |
| HY-118172 | PD-307243 | 313533-41-4 | Reference compound |
| HY-118174 | N-(2,4-Dinitrophenyl)glycine | 1084-76-0 | Peptides |
| HY-118175 | RG 14921 | 144909-21-7 | Reference compound |
| HY-118177 | Neutrophil elastase inhibitor 1 | 1448314-31-5 | Reference compound |
| HY-118178 | LY43578 | 26766-35-8 | Reference compound |
| HY-118179 | VU0486321 | 1816301-67-3 | Reference compound |
| HY-118180 | CAY10595 | 916047-16-0 | Reference compound |
| HY-118182 | Tidembersat | 175013-73-7 | Reference compound |
| HY-118184 | AF3485 | 1195786-61-8 | Reference compound |
| HY-118185 | SQ 31844 | 115766-42-2 | Reference compound |
| HY-118189 | Misoprostol acid | 112137-89-0 | Reference compound |
| HY-118189S | Misoprostol acid-d5 | 1337917-44-8 | Isotope-Labeled Compounds |
| HY-118190 | AL 8810 methyl ester | 1176541-11-9 | Reference compound |
| HY-118192 | Kmeriol | 54306-10-4 | Natural Products |
| HY-118194 | A-65186 | 119295-94-2 | Reference compound |
| HY-118196 | L 365031 | 111035-59-7 | Reference compound |
| HY-118197 | L-669083 | 130007-52-2 | Reference compound |
| HY-118198 | NPY Y2 antagonist 1 | 1185845-15-1 | Reference compound |
| HY-118202 | (-)-Gallopamil | 36622-40-9 | Reference compound |
| HY-118202A | (-)-Gallopamil (hydrochloride) | 36622-39-6 | Reference compound |
| HY-118203 | SU4984 | 186610-89-9 | Reference compound |
| HY-118205 | SCH-538415 | 637772-75-9 | Reference compound |
| HY-118207 | LU-32-176B | 770688-66-9 | Reference compound |
| HY-118208 | ML-097 | 743456-83-9 | Reference compound |
| HY-118209 | L 646462 | 89149-85-9 | Reference compound |
| HY-118210 | PHOP | 288862-83-9 | Reference compound |
| HY-118211 | EcDsbB-IN-9 | 41933-33-9 | Reference compound |
| HY-118213 | N-(2-Hydroxyethyl)-1,8-naphthalimide | 5450-40-8 | Dye Reagents |
| HY-118216 | Bitertanol | 55179-31-2 | Reference compound |
| HY-118216R | Bitertanol (Standard) | 55179-31-2 | Reference Standards |
| HY-118217 | Cyclanilide | 113136-77-9 | Reference compound |
| HY-118217R | Cyclanilide (Standard) | 113136-77-9 | Reference Standards |
| HY-118220 | EP 171 | 122089-44-5 | Reference compound |
| HY-118221 | Arizonin A1 | 108890-87-5 | Reference compound |
| HY-118222 | KBR 2822 | 126988-60-1 | Reference compound |
| HY-118224 | BPH-715 | 1059677-23-4 | Reference compound |
| HY-118226 | 5,6,7,8-Tetrahydro-2-naphthoic acid | 1131-63-1 | Reference compound |
| HY-118230 | Kidamycin | 11072-82-5 | Reference compound |
| HY-118232 | VUF8504 | 112575-50-5 | Reference compound |
| HY-118233 | Alilusem (potassium) | 114417-20-8 | Reference compound |
| HY-118234 | (Rac)-PD 138312 | 107334-06-5 | Reference compound |
| HY-118236 | (S)-AZD 6482 | 1173900-37-2 | Reference compound |
| HY-118238 | Remeglurant | 1309783-00-3 | Reference compound |
| HY-118239 | Re 80 | 116193-60-3 | Reference compound |
| HY-118242 | RU 45144 | 119286-92-9 | Reference compound |
| HY-118243 | KMS88009 | 1089681-42-4 | Reference compound |
| HY-118244 | Clathrin-IN-3 | 1419321-16-6 | Reference compound |
| HY-118245 | APP-FUBINACA | 1185282-03-4 | Reference compound |
| HY-118247 | Ro 14-6113 | 110675-48-4 | Reference compound |
| HY-118248 | HW 173 | 110270-70-7 | Reference compound |
| HY-118250 | GSK2245035 | 1207629-49-9 | Reference compound |
| HY-118250A | GSK2245035 (maleate) | 1325212-97-2 | Reference compound |
| HY-118251 | PD130883 | 123685-36-9 | Reference compound |
| HY-118256 | LSN2814617 | 1313498-17-7 | Reference compound |
| HY-118256A | (Rac)-LSN2814617 | 1313498-08-6 | Reference compound |
| HY-118259 | L-663581 | 122384-14-9 | Reference compound |
| HY-118260 | Phendioxan | 130905-04-3 | Reference compound |
| HY-118261 | L 659286 | 119742-06-2 | Reference compound |
| HY-118262 | Resorufin acetate | 1152-14-3 | Dye Reagents |
| HY-118263 | Dacomitinib (hydrate) | 1042385-75-0 | Reference compound |
| HY-118264 | MDL-100240 | 142695-08-7 | Reference compound |
| HY-118265 | N-Acetylglutaminylglutamine amide | 123199-99-5 | Reference compound |
| HY-118266 | BTdCPU | 1257423-87-2 | Reference compound |
| HY-118267 | Lentinellic acid | 115219-90-4 | Natural Products |
| HY-118268 | RG 6866 | 120602-97-3 | Reference compound |
| HY-118269 | OSI-296 | 1175296-94-2 | Reference compound |
| HY-118271 | GNF-8625 | 1196546-33-4 | Reference compound |
| HY-118274 | ADDA | 126456-06-2 | Reference compound |
| HY-118275 | FK960 | 133920-70-4 | Reference compound |
| HY-118276 | Lithocholenic acid | 1053-37-8 | Reference compound |
| HY-118279 | KSCM-1 | 1415247-17-4 | Reference compound |
| HY-118281 | ATD-3169 | 1788105-63-4 | Reference compound |
| HY-118282 | mPGES1-IN-7 | 1268709-57-4 | Reference compound |
| HY-118283 | 5-Hydroxylansoprazole | 131926-98-2 | Reference compound |
| HY-118284 | Vicagrel | 1314081-53-2 | Reference compound |
| HY-118285 | Ro4491533 | 579482-31-8 | Reference compound |
| HY-118288 | Aurachin B | 108354-12-7 | Natural Products |
| HY-118292 | Hydroquinone diacetate | 1205-91-0 | Reference compound |
| HY-118294 | 15-OH Tafluprost | 130209-78-8 | Reference compound |
| HY-118295 | Pyrimidine-indole hybrid | 441742-93-4 | Reference compound |
| HY-118297 | Ac4ManNAz (80% α isomer) | 361154-30-5 | Reference compound |
| HY-118299 | JYL 1511 | 623166-14-3 | Reference compound |
| HY-118300 | Abitesartan | 137882-98-5 | Reference compound |
| HY-118301 | ADX71441 | 1207440-88-7 | Reference compound |
| HY-118304 | AKN-028 | 1175017-90-9 | Reference compound |
| HY-118304A | AKN-028 (TFA) | 1175017-91-0 | Reference compound |
| HY-118304B | AKN-028 (acetate) | | Reference compound |
| HY-118306 | Amphidinolide F | 139594-87-9 | Reference compound |
| HY-118308 | AHN-683 | 143934-15-0 | Reference compound |
| HY-118310 | Xylocydine | 685901-63-7 | Reference compound |
| HY-118311 | (Z)-W 3699 | 63250-48-6 | Reference compound |
| HY-118312 | CAY10657 | 494772-86-0 | Reference compound |
| HY-118314 | CI-1015 | 156672-01-4 | Reference compound |
| HY-118315 | L-012 | 143323-55-1 | Reference compound |
| HY-118316 | GSK223 | 899758-61-3 | Reference compound |
| HY-118317 | Zacopride | 90182-92-6 | Reference compound |
| HY-118319 | MJN228 | 459168-97-9 | Reference compound |
| HY-118320 | Alizarine Yellow R | 2243-76-7 | Dye Reagents |
| HY-118322 | Bayer 30468 | 3186-12-7 | Reference compound |
| HY-118324 | 10-Propoxydecanoic acid | 119290-12-9 | Reference compound |
| HY-118325 | Epibatidine (dihydrochloride) | 166374-43-2 | Reference compound |
| HY-118326 | MRT 68601 | 1190379-37-3 | Reference compound |
| HY-118327 | Maleuric acid | 105-61-3 | Reference compound |
| HY-118328 | Hymenidin | 107019-95-4 | Natural Products |
| HY-118329 | S 135 | 104679-67-6 | Reference compound |
| HY-118330 | Apigeninidin (chloride) | 1151-98-0 | Dye Reagents |
| HY-118331 | Kazusamycin B | 107140-30-7 | Reference compound |
| HY-118332 | 19(R)-HETE | 115461-39-7 | Reference compound |
| HY-118334 | Armillaramide | 111149-09-8 | Natural Products |
| HY-118335 | Prazobind | 107021-36-3 | Reference compound |
| HY-118336 | VUF10497 | 1080623-12-6 | Reference compound |
| HY-118338 | WRR-483 | 1076088-50-0 | Reference compound |
| HY-118339 | PF-4479745 | 1065110-43-1 | Reference compound |
| HY-118341 | Clitocine | 105798-74-1 | Natural Products |
| HY-118341R | Clitocine (Standard) | 105798-74-1 | Reference Standards |
| HY-118342 | PQCA | 1144504-35-7 | Reference compound |
| HY-118343 | AC-93253 | 108527-83-9 | Reference compound |
| HY-118347 | Aspartame acesulfame | 106372-55-8 | Peptides |
| HY-118349 | Dansylphenylalanine | 1104-36-5 | Peptides |
| HY-118350 | FR 75513 | 127975-78-4 | Reference compound |
| HY-118351 | N-Tridecanoyl-L-homserine lactone | 878627-21-5 | Biochemical Assay Reagents |
| HY-118352 | LB-205 | 1113025-86-7 | Reference compound |
| HY-118354 | A 80556 | 114676-82-3 | Reference compound |
| HY-118355 | ALLM | 110115-07-6 | Reference compound |
| HY-118356 | WIN 62,577 | 144177-32-2 | Reference compound |
| HY-118357 | Milbemycin A3 Oxime | 114177-14-9 | Reference compound |
| HY-118358 | C8 L-threo ceramide (d18:1/8:0) | 175892-44-1 | Natural Products |
| HY-118362 | Netzahualcoyonol | 113579-07-0 | Reference compound |
| HY-118364 | AGN 190727 | 115503-91-8 | Reference compound |
| HY-118365 | NSC 140873 | 106410-13-3 | Reference compound |
| HY-118367 | A 80915A | 127875-60-9 | Natural Products |
| HY-118368 | L-742001 (hydrochloride) | 174605-64-2 | Reference compound |
| HY-118370 | MF-592 | 1064195-48-7 | Reference compound |
| HY-118371 | Arginase inhibitor 2 | 1345810-21-0 | Reference compound |
| HY-118374 | AM-9635 | 1338483-10-5 | Reference compound |
| HY-118375 | Phenylbutyl isoselenocyanate | 1072807-15-8 | Reference compound |
| HY-118376 | Nestifylline | 116763-36-1 | Reference compound |
| HY-118378 | ZD6021 | 255049-08-2 | Reference compound |
| HY-118379 | NU/ICRF 500 | 156074-08-7 | Reference compound |
| HY-118380 | p-Nitrobenzyl mesylate | 39628-94-9 | Reference compound |
| HY-118382 | SCH-451659 | 502628-66-2 | Reference compound |
| HY-118383 | Agathisflavone | 28441-98-7 | Reference compound |
| HY-118384 | Sangivamycin | 18417-89-5 | Natural Products |
| HY-118384R | Sangivamycin (Standard) | 18417-89-5 | Reference Standards |
| HY-118386 | H2-005 | 1060478-12-7 | Reference compound |
| HY-118387 | AVE-0118 | 498577-53-0 | Reference compound |
| HY-118388 | AS604872 | 612532-48-6 | Reference compound |
| HY-118391 | Benzoyl-L-phenylalanine | 2566-22-5 | Reference compound |
| HY-118397 | RB394 | 1830320-32-5 | Reference compound |
| HY-118399 | PNU-200579 | 194482-44-5 | Reference compound |
| HY-118402 | PD 119819 | 105277-43-8 | Reference compound |
| HY-118403 | CK2-IN-12 | 300675-28-9 | Reference compound |
| HY-118406 | Ethybenztropine | 524-83-4 | Reference compound |
| HY-118406A | Ethybenztropine (hydrochloride) | 26598-44-7 | Reference compound |
| HY-118406B | Ethybenztropine (hydrobromide) | 24815-25-6 | Reference compound |
| HY-118407 | LY56110 | 26766-37-0 | Reference compound |
| HY-118408 | D-4418 | 257892-34-5 | Reference compound |
| HY-118409 | VPC-3033 | 110763-24-1 | Reference compound |
| HY-118410 | L-738167 | 163212-43-9 | Reference compound |
| HY-118411 | 5-Ethynyl-2'-deoxyuridine | 61135-33-9 | Reference compound |
| HY-118412 | Terallethrin | 15589-31-8 | Reference compound |
| HY-118414 | 20-Ethyl prostaglandin E2 | 37492-24-3 | Reference compound |
| HY-118416 | BMS-986124 | 1447968-71-9 | Reference compound |
| HY-118420 | BMS-185411 | 166977-24-8 | Reference compound |
| HY-118421 | Nullscript | 300816-11-9 | Reference compound |
| HY-118423 | SJ-3366 | 195720-26-4 | Reference compound |
| HY-118424 | JNJ-55511118 | 2036081-86-2 | Reference compound |
| HY-118426 | (Rac)-Tipifarnib | 192185-68-5 | Reference compound |
| HY-118427 | Asterriquinol D dimethyl ether | 287117-66-2 | Natural Products |
| HY-118428 | Fluenetil | 4301-50-2 | Reference compound |
| HY-118431 | DMABA NHS ester | 58068-85-2 | Reference compound |
| HY-118431S | DMABA-d4 NHS ester | 1175002-03-5 | Isotope-Labeled Compounds |
| HY-118431S2 | DMABA-d6 NHS ester | 1175002-04-6 | Isotope-Labeled Compounds |
| HY-118431S3 | DMABA-d10 NHS ester | 1175002-05-7 | Isotope-Labeled Compounds |
| HY-118436 | 3-Methyl-2-quinoxalinone | 14003-34-0 | Reference compound |
| HY-118438 | 10-Cl-BBQ | 23982-76-5 | Reference compound |
| HY-118441 | 25T-NBOMe (hydrochloride) | 1539266-47-1 | Reference compound |
| HY-118442 | Sphingosine (d14:1) | 24558-60-9 | Natural Products |
| HY-118444 | (Rac)-WRC-0571 | 501667-77-2 | Reference compound |
| HY-118448 | 2,4-Diacetylphloroglucinol | 2161-86-6 | Reference compound |
| HY-118448R | 2,4-Diacetylphloroglucinol (Standard) | 2161-86-6 | Reference Standards |
| HY-118450 | FR260010 (free base) | 374555-75-6 | Reference compound |
| HY-118451 | Lanomycin | 141363-91-9 | Reference compound |
| HY-118452 | cis-3,4',5-Trimethoxy-3'-hydroxystilbene | 586410-08-4 | Reference compound |
| HY-118455 | MRS1097 | 185259-16-9 | Reference compound |
| HY-118459 | L 658758 | 116507-04-1 | Reference compound |
| HY-118461 | PD 120697 | 108351-91-3 | Reference compound |
| HY-118462 | Coelenteramine 400a | 70217-82-2 | Dye Reagents |
| HY-118462A | Coelenteramine 400a (hydrochloride) | 2320429-05-6 | Reference compound |
| HY-118463 | Benzomalvin A | 157047-96-6 | Natural Products |
| HY-118464 | AC915 | 259729-84-5 | Reference compound |
| HY-118465 | ent-Prostaglandin E2 | 65085-69-0 | Reference compound |
| HY-118466 | Xanthumin | 580-49-4 | Natural Products |
| HY-118467 | Benzolamide | 3368-13-6 | Reference compound |
| HY-118468 | Azothoate | 5834-96-8 | Reference compound |
| HY-118469 | Phanquinone | 84-12-8 | Reference compound |
| HY-118470 | Butaxamine (hydrochloride) | 5696-15-1 | Reference compound |
| HY-118472 | Benazeprilat | 86541-78-8 | Reference compound |
| HY-118472R | Benazeprilat (Standard) | 86541-78-8 | Reference Standards |
| HY-118472S | Benazeprilat-d5 | 1279033-05-4 | Isotope-Labeled Compounds |
| HY-118473 | AZD6370 | 752239-85-3 | Reference compound |
| HY-118474 | GW 610 | 872726-44-8 | Reference compound |
| HY-118475 | 6-Piperazin-1-yl-isoquinoline (hydrochloride) | 936643-77-5 | Reference compound |
| HY-118478 | Ajugasterone B | 21490-21-1 | Natural Products |
| HY-118480 | 4-MMPB | 928853-86-5 | Reference compound |
| HY-118481 | H-Pro-Glu-OH | 67644-00-2 | Reference compound |
| HY-118482 | Sauristolactam | 128533-02-8 | Natural Products |
| HY-118484 | (RS)-Sakuranetin | 520-29-6 | Reference compound |
| HY-118486 | LDL-IN-1 | 615264-52-3 | Reference compound |
| HY-118487 | OB-24 | 939825-12-4 | Reference compound |
| HY-118487A | OB-24 (free base) | 940061-39-2 | Reference compound |
| HY-118488 | L 640035 | 77167-93-2 | Reference compound |
| HY-118489 | L644711 | 81997-33-3 | Reference compound |
| HY-118490 | T-2000 | 97846-21-4 | Reference compound |
| HY-118492 | Riodipine | 71653-63-9 | Reference compound |
| HY-118494 | Ascaridole | 512-85-6 | Natural Products |
| HY-118495 | Cardol diene | 79473-25-9 | Natural Products |
| HY-118497 | BMS 182874 | 153042-42-3 | Reference compound |
| HY-118499 | Alpiropride | 81982-32-3 | Reference compound |
| HY-118503 | Fexaramate | 592524-75-9 | Reference compound |
| HY-118504 | Sulfoxaflor | 946578-00-3 | Reference compound |
| HY-118504R | Sulfoxaflor (Standard) | 946578-00-3 | Reference Standards |
| HY-118512 | Platencin | 869898-86-2 | Reference compound |
| HY-118514 | CAY10514 | 868526-38-9 | Reference compound |
| HY-118515 | ATM4 4-Acetoxy analog | 91295-74-8 | Reference compound |
| HY-118517 | α-Hydroxytamoxifen | 97151-02-5 | Reference compound |
| HY-118518 | Ronipamil | 85247-77-4 | Reference compound |
| HY-118520 | 16-Phenoxy tetranor prostaglandin F2α methyl ester | 51638-90-5 | Reference compound |
| HY-118521 | AS-041164 | 6318-41-8 | Reference compound |
| HY-118524 | Dipiproverine | 117-30-6 | Reference compound |
| HY-118524A | Dipiproverine (hydrochloride) | 2404-18-4 | Reference compound |
| HY-118525 | AL-9 | 869218-90-6 | Reference compound |
| HY-118527 | Fenirofibrate | 54419-31-7 | Reference compound |
| HY-118527S | Fenirofibrate-d6 | 1189423-29-7 | Isotope-Labeled Compounds |
| HY-118528 | TP0427736 | 864374-00-5 | Reference compound |
| HY-118528A | TP0427736 (hydrochloride) | 2459963-17-6 | Reference compound |
| HY-118529 | JUN-1111 | 874351-38-9 | Reference compound |
| HY-118530 | Bucillamine | 65002-17-7 | Reference compound |
| HY-118530R | Bucillamine (Standard) | 65002-17-7 | Reference Standards |
| HY-118532 | Tyrphostin AG30 | 122520-79-0 | Reference compound |
| HY-118533A | Ambenonium (dichloride tetrahydrate) | 52022-31-8 | Reference compound |
| HY-118534 | Cyclobutyrol | 512-16-3 | Reference compound |
| HY-118534A | Cyclobutyrol (sodium) | 1130-23-0 | Reference compound |
| HY-118535 | N-Oleoyl valine | 60374-41-6 | Peptides |
| HY-118537 | ICI 56780 | 28130-28-1 | Reference compound |
| HY-118538 | Noreximide | 3647-74-3 | Reference compound |
| HY-118539 | NSC12404 | 5411-64-3 | Reference compound |
| HY-118540 | Resazurin | 550-82-3 | Dye Reagents |
| HY-118541 | RH-5849 | 112225-87-3 | Reference compound |
| HY-118542 | Nutlin 1 | 548472-58-8 | Reference compound |
| HY-118543 | TM6089 | 863421-32-3 | Reference compound |
| HY-118544 | Sch 24937 | 75696-17-2 | Reference compound |
| HY-118545 | Butamirate | 18109-80-3 | Reference compound |
| HY-118545A | Butamirate (citrate) | 18109-81-4 | Reference compound |
| HY-118545AR | Butamirate (citrate) (Standard) | 18109-81-4 | Reference Standards |
| HY-118546 | JNJ-17156516 | 649551-06-4 | Reference compound |
| HY-118547 | Clorofene | 120-32-1 | Reference compound |
| HY-118548 | Tetranor-PGAM | 52510-53-9 | Reference compound |
| HY-118551 | Bromperidol decanoate | 75067-66-2 | Reference compound |
| HY-118551R | Bromperidol decanoate (Standard) | 75067-66-2 | Reference Standards |
| HY-118553 | Saframycin D | 66082-30-2 | Reference compound |
| HY-118555 | Vascular disrupting agent 1 | 875468-82-9 | Reference compound |
| HY-118556 | Prostaglandin E2 serinol amide | 951209-67-9 | Reference compound |
| HY-118557 | Iferanserin | 58754-46-4 | Reference compound |
| HY-118557A | Iferanserin (hydrochloride) | 210350-29-1 | Reference compound |
| HY-118560S | Tricyclodecenyl acetate-13C2 | | Isotope-Labeled Compounds |
| HY-118561 | Bermoprofen | 78499-27-1 | Reference compound |
| HY-118562 | Dansylamide | 1431-39-6 | Dye Reagents |
| HY-118563 | Farnesylthioacetic acid | 135784-48-4 | Biochemical Assay Reagents |
| HY-118564 | SB209995 | 146574-41-6 | Reference compound |
| HY-118566 | 5α-Androstenone | 18339-16-7 | Natural Products |
| HY-118566S | 5α-Androstenone-d4 | | Isotope-Labeled Compounds |
| HY-118567 | Bis(maltolato)oxovanadium(IV) | 38213-69-3 | Reference compound |
| HY-118570 | 5-Oxoprolyltryptophan | 35937-24-7 | Reference compound |
| HY-118571 | Benzoin methyl ether | 3524-62-7 | Reference compound |
| HY-118574 | UBP141 | 344768-30-5 | Reference compound |
| HY-118575 | DR-4004 | 201608-41-5 | Reference compound |
| HY-118576 | Histidylprolineamide | 33605-69-5 | Peptides |
| HY-118578 | Furalaxyl | 57646-30-7 | Reference compound |
| HY-118578R | Furalaxyl (Standard) | 57646-30-7 | Reference Standards |
| HY-118580 | RO-09-4609 | 279230-20-5 | Reference compound |
| HY-118581 | Coralyne (chloride) | 38989-38-7 | Reference compound |
| HY-118582 | Jacaranone | 60263-07-2 | Natural Products |
| HY-118583A | 4-Fluoro phenibut (hydrochloride) | 1858241-03-8 | Reference compound |
| HY-118584 | Ro 12-7310 | 65316-65-6 | Reference compound |
| HY-118588 | Diminutol | 361431-33-6 | Reference compound |
| HY-118590 | ICRF-193 | 21416-88-6 | Reference compound |
| HY-118590A | ICRF-196 | 21416-68-2 | Reference compound |
| HY-118593 | A2315A | 58717-24-1 | Reference compound |
| HY-118594 | Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate | 632-93-9 | Reference compound |
| HY-118599 | Prostaglandin F2α ethyl amide | 54130-36-8 | Reference compound |
| HY-118601S | N-Desmethyl Pirenzepine-d8 | 1189860-05-6 | Isotope-Labeled Compounds |
| HY-118607 | VU041 | 332943-64-3 | Reference compound |
| HY-118608 | 2α-Methyl androsterone | 6961-54-2 | Reference compound |
| HY-118609 | EP4 receptor agonist 2 | 493035-81-7 | Reference compound |
| HY-118612 | RO3201195 | 249937-52-8 | Reference compound |
| HY-118614 | β-Nicotyrine | 487-19-4 | Reference compound |
| HY-118614R | β-Nicotyrine (Standard) | 487-19-4 | Reference Standards |
| HY-118615 | LY2048978 | 676495-11-7 | Reference compound |
| HY-118618 | Eucannabinolide | 38458-58-1 | Natural Products |
| HY-118620 | Nortriptyline | 72-69-5 | Natural Products |
| HY-118620R | Nortriptyline (Standard) | 72-69-5 | Reference Standards |
| HY-118621 | JCP174 | 126062-19-9 | Reference compound |
| HY-118622 | Isogentisin | 491-64-5 | Natural Products |
| HY-118624 | Fluprostenol methyl ester | 73275-76-0 | Reference compound |
| HY-118628 | (E/Z)-BML264 | 110683-10-8 | Reference compound |
| HY-118628A | BML264 | 99196-74-4 | Reference compound |
| HY-118630 | Vacuolin-1 | 351986-85-1 | Reference compound |
| HY-118632 | BILR 355 | 380378-81-4 | Reference compound |
| HY-118633 | Ethamoxytriphetol | 67-98-1 | Reference compound |
| HY-118634 | trans-Resveratrol-4'-O-D-Glucuronide | 387372-20-5 | Reference compound |
| HY-118634S | trans-Resveratrol-4'-O-D-Glucuronide-d4 | 1420291-58-2 | Isotope-Labeled Compounds |
| HY-118635 | Cyprodenate | 15585-86-1 | Reference compound |
| HY-118638 | Corynanthine | 483-10-3 | Natural Products |
| HY-118639 | CP-74006 | 4943-86-6 | Reference compound |
| HY-118641 | Cannabinodiol | 39624-81-2 | Natural Products |
| HY-118642 | D-Ribose-L-cysteine | 232617-15-1 | Reference compound |
| HY-118643 | Cimlanod | 1620330-72-4 | Reference compound |
| HY-118645S | 1'-Hydroxymidazolam-d4 | 1781843-10-4 | Isotope-Labeled Compounds |
| HY-118645S1 | 1'-Hydroxymidazolam-13C3 | 1189677-14-2 | Isotope-Labeled Compounds |
| HY-118648 | Prostaglandin F2α methyl ester | 33854-16-9 | Reference compound |
| HY-118651 | Griseoluteic acid | 489-76-9 | Natural Products |
| HY-118652 | Δ17-6-keto Prostaglandin F1α | 68324-95-8 | Reference compound |
| HY-118653 | SAR629 | 1221418-42-3 | Reference compound |
| HY-118656 | Cannabicitran | 31508-71-1 | Natural Products |
| HY-118657 | Ripazepam | 26308-28-1 | Reference compound |
| HY-118659 | Benzalphthalide | 575-61-1 | Reference compound |
| HY-118660 | Anhydrotetracycline (hydrochloride) | 13803-65-1 | Reference compound |
| HY-118660R | Anhydrotetracycline (hydrochloride) (Standard) | 13803-65-1 | Reference Standards |
| HY-118661 | BDM14471 | 934618-96-9 | Reference compound |
| HY-118665 | L-736380 | 152885-49-9 | Reference compound |
| HY-118667 | Dehydroergosterol | 516-85-8 | Biochemical Assay Reagents |
| HY-118668 | ABD-350 | 1117772-52-7 | Reference compound |
| HY-118670 | 16(S)-Iloprost | 74843-14-4 | Reference compound |
| HY-118670A | 16(R)-Iloprost | 74843-13-3 | Reference compound |
| HY-118672 | HNHA | 926908-04-5 | Reference compound |
| HY-118674 | AK-2-38 | 122508-12-7 | Reference compound |
| HY-118675 | L-erythro-Chloramphenicol | 7384-89-6 | Reference compound |
| HY-118676 | Niceritrol | 5868-05-3 | Biochemical Assay Reagents |
| HY-118678 | MRS1186 | 183721-03-1 | Reference compound |
| HY-118681 | 8-Iso-16-cyclohexyl-tetranor prostaglandin E2 | 53319-30-5 | Reference compound |
| HY-118683 | KR-31378 | 335381-68-5 | Reference compound |
| HY-118687 | 4-Bromoethcathinone (hydrochloride) | 135333-26-5 | Reference compound |
| HY-118689 | RA-2 | 1867107-62-7 | Reference compound |
| HY-118694 | TAPI-0 | 163958-73-4 | Reference compound |
| HY-118695 | IRL-3630 | 173189-01-0 | Reference compound |
| HY-118696 | MGAT2-IN-5 | 1426208-69-6 | Reference compound |
| HY-118697 | N-dodecanoyl-L-Homoserine lactone | 137173-46-7 | Reference compound |
| HY-118697R | N-Dodecanoyl-L-homoserine lactone (Standard) | 137173-46-7 | Reference Standards |
| HY-118699 | Indole-3-thio carboxamide | 59108-90-6 | Reference compound |
| HY-118700 | 2-Iminobiotin | 13395-35-2 | Reference compound |
| HY-118700A | 2-Iminobiotin (hydrobromide) | 76985-52-9 | Reference compound |
| HY-118700AR | 2-Iminobiotin (hydrobromide) (Standard) | 76985-52-9 | Reference Standards |
| HY-118703 | L-Ristosamine nucleoside | 136035-11-5 | Reference compound |
| HY-118704 | P-2281 | 1112994-35-0 | Reference compound |
| HY-118705 | Lagochiline | 23554-81-6 | Natural Products |
| HY-118706 | PD 118440 | 108351-90-2 | Reference compound |
| HY-118708 | WEB2347 | 114800-19-0 | Reference compound |
| HY-118709 | Ro 23-7637 | 107071-66-9 | Reference compound |
| HY-118710 | α-Isopropylaminopentiophenone (hydrochloride) | 18268-14-9 | Reference compound |
| HY-118712 | mTOR inhibitor WYE-23 | 1062169-46-3 | Reference compound |
| HY-118714 | α-Hydroxy alprazolam | 37115-43-8 | Reference compound |
| HY-118714S | α-Hydroxy alprazolam-d5 | 136765-24-7 | Isotope-Labeled Compounds |
| HY-118715 | Setin-1 | 1313802-67-3 | Reference compound |
| HY-118716 | PhIP | 105650-23-5 | Reference compound |
| HY-118717 | mTOR inhibitor WYE-28 | 1062172-60-4 | Reference compound |
| HY-118719 | Esterbut-6 | 125161-48-0 | Reference compound |
| HY-118723 | BMH-22 | 309726-06-5 | Reference compound |
| HY-118724 | Laetrile | 1332-94-1 | Natural Products |
| HY-118725 | Luffariellolide | 111149-87-2 | Natural Products |
| HY-118726 | Luotonin F | 244616-85-1 | Natural Products |
| HY-118727 | 6-APDB (hydrochloride) | 1281872-58-9 | Reference compound |
| HY-118728 | Prostaglandin A2 methyl ester | 31753-19-2 | Reference compound |
| HY-118730 | Flucycloxuron | 113036-88-7 | Reference compound |
| HY-118730R | Flucycloxuron (Standard) | 113036-88-7 | Reference Standards |
| HY-118731 | TNK-6123 | 251481-69-3 | Reference compound |
| HY-118734 | IK-862 | 478911-60-3 | Reference compound |
| HY-118736 | Ganodermic acid S | 112430-63-4 | Natural Products |
| HY-118737 | Isamfazone | 55902-02-8 | Reference compound |
| HY-118740 | L-708906 | 251963-74-3 | Reference compound |
| HY-118742 | Benzobicyclon | 156963-66-5 | Reference compound |
| HY-118742R | Benzobicyclon (Standard) | 156963-66-5 | Reference Standards |
| HY-118745 | A-73209 | 136451-98-4 | Reference compound |
| HY-118747 | Scirpusin A | 69297-51-4 | Natural Products |
| HY-118748 | Suprafenacine | 1477482-50-0 | Reference compound |
| HY-118751 | Bensultap | 17606-31-4 | Reference compound |
| HY-118752 | Fentiazac | 18046-21-4 | Reference compound |
| HY-118754 | 13,14-Dihydro-15-keto PGF1α | 29044-75-5 | Reference compound |
| HY-118755 | Acid violet 43 | 4430-18-6 | Biochemical Assay Reagents |
| HY-118756 | Anirolac | 66635-85-6 | Reference compound |
| HY-118758 | γ-Kainylglutamic acid | 98394-38-8 | Reference compound |
| HY-118759 | DSP Crosslinker | 57757-57-0 | ADC Related |
| HY-118759S | DSP Crosslinker-d8 | 1639836-65-9 | Isotope-Labeled Compounds |
| HY-118761 | 5,6-Epoxyretinoic acid | 13100-69-1 | Reference compound |
| HY-118762 | KGP94 | 1131456-28-4 | Reference compound |
| HY-118764 | Propargyl-PEG2-acid | 1859379-85-3 | ADC Related |
| HY-118765 | Ro 23-3423 | 110996-51-5 | Reference compound |
| HY-118768 | FMS586 (free base) | 302556-51-0 | Reference compound |
| HY-118769 | Japonilure | 64726-91-6 | Reference compound |
| HY-118770 | Nafetolol | 42050-23-7 | Reference compound |
| HY-118772 | 17-Phenyl trinor prostaglandin A2 | 38315-51-4 | Reference compound |
| HY-118773 | MreB Perturbing Compound A22 (hydrochloride) | 22816-60-0 | Reference compound |
| HY-118773R | MreB Perturbing Compound A22 (hydrochloride) (Standard) | 22816-60-0 | Reference Standards |
| HY-118774 | Propofol β-D-glucuronide | 114991-26-3 | Reference compound |
| HY-118774R | Propofol β-D-glucuronide (Standard) | 114991-26-3 | Reference Standards |
| HY-118774S | Propofol-d17 β-D-glucuronide | 1683581-05-6 | Isotope-Labeled Compounds |
| HY-118775 | LEK 8804 | 153415-44-2 | Reference compound |
| HY-118778 | KR-32568 | 852146-73-7 | Reference compound |
| HY-118779 | Rhazimine | 93772-08-8 | Natural Products |
| HY-118780 | CHD-5 | 289494-16-2 | Reference compound |
| HY-118781 | Propargyl-PEG3-azide | 932741-18-9 | Reference compound |
| HY-118782 | Ibuprofen diethylaminoethyl ester | 64622-41-9 | Reference compound |
| HY-118783 | 2-Hexyl-4-pentynoic acid | 96017-59-3 | Reference compound |
| HY-118785 | MSP-3 | 1820968-63-5 | Reference compound |
| HY-118788 | N-Desmethyl rosiglitazone | 257892-31-2 | Reference compound |
| HY-118788S | N-Desmethyl rosiglitazone-d4 | 1215407-67-2 | Isotope-Labeled Compounds |
| HY-118790 | BB-223-carboxyindole metabolite | 858515-71-6 | Reference compound |
| HY-118792 | AHR activator 1 | 352346-46-4 | Reference compound |
| HY-118793 | Inosine oxime | 3414-62-8 | Reference compound |
| HY-118795 | SC-22716 | 262451-89-8 | Reference compound |
| HY-118796 | 4-Hydroxy MET | 77872-41-4 | Reference compound |
| HY-118797 | Malioxamycin | 73020-27-6 | Reference compound |
| HY-118798 | DA 3003-2 | 383907-47-9 | Reference compound |
| HY-118802 | 4-Hydroxy DPT | 63065-88-3 | Reference compound |
| HY-118803 | AS1468240 | 365462-61-9 | Reference compound |
| HY-118806 | AC-42 | 244291-63-2 | Reference compound |
| HY-118806A | AC-42 (hydrochloride) | 447407-36-5 | Reference compound |
| HY-118808 | Propargyl-PEG2-NHBoc | 869310-84-9 | ADC Related |
| HY-118809 | J 2931 | 86071-23-0 | Reference compound |
| HY-118810 | BIO-013077-01 | 746667-48-1 | Reference compound |
| HY-118811 | Napropamide-M | 41643-35-0 | Reference compound |
| HY-118813 | 3-Deoxy-galactosone | 4134-97-8 | Natural Products |
| HY-118814 | YM928 | 190842-36-5 | Reference compound |
| HY-118816 | 11β-Prostaglandin F2α | 714966-38-8 | Reference compound |
| HY-118819 | 5-Bromo-3-phenyl salicylic acid | 99514-99-5 | Reference compound |
| HY-118820 | MB-28767 | 80558-61-8 | Reference compound |
| HY-118821 | JTC-017 | 357330-77-9 | Reference compound |
| HY-118824 | Moschamine | 193224-22-5 | Natural Products |
| HY-118824A | N-Feruloylserotonin | 68573-23-9 | Natural Products |
| HY-118825 | N-butyl Amphetamine (hydrochloride) | 35892-11-6 | Reference compound |
| HY-118827 | Vedaprofen | 71109-09-6 | Reference compound |
| HY-118827R | Vedaprofen (Standard) | 71109-09-6 | Reference Standards |
| HY-118827S | Vedaprofen-d3 | 1185054-34-5 | Isotope-Labeled Compounds |
| HY-118828 | 12-Oxo phytodienoic acid | 85551-10-6 | Reference compound |
| HY-118828A | (9S,13R)-12-Oxo phytodienoic acid | 71606-07-0 | Natural Products |
| HY-118828AS | (9S,13R)-12-Oxo phytodienoic acid-d5 | 2692624-08-9 | Isotope-Labeled Compounds |
| HY-118828B | 12-Oxo phytodienoic acid (≥90%) | 85551-10-6 | Natural Products |
| HY-118829 | 3,4-Methylenedioxy PV9 (hydrochloride) | 24646-40-0 | Reference compound |
| HY-118830 | 13,14-Dihydro-15-keto prostaglandin D2 | 59894-07-4 | Reference compound |
| HY-118830S | 13,14-Dihydro-15-keto prostaglandin D2-d4 | | Isotope-Labeled Compounds |
| HY-118830S1 | 13,14-Dihydro-15-keto prostaglandin D2-d9 | 2738376-77-5 | Isotope-Labeled Compounds |
| HY-118833 | RAC 109 | 25360-99-0 | Reference compound |
| HY-118834 | Teleocidin A1 | 70497-14-2 | Natural Products |
| HY-118835 | Zimelidine | 56775-88-3 | Reference compound |
| HY-118836 | GSK215083 | 607742-80-3 | Reference compound |
| HY-118837 | WF-536 | 539857-64-2 | Reference compound |
| HY-118839 | trans-Phenothrin | 66036-31-5 | Reference compound |
| HY-118840 | 1,4-D-Gulonolactone | 6322-07-2 | Natural Products |
| HY-118842 | Sunepitron (hydrochloride) | 148408-65-5 | Reference compound |
| HY-118843 | Lombazole | 60628-98-0 | Reference compound |
| HY-118844 | Flumazenil acid | 84378-44-9 | Reference compound |
| HY-118844R | Flumazenil acid (Standard) | 84378-44-9 | Reference Standards |
| HY-118847 | Antifungal agent 86 | 327077-97-4 | Reference compound |
| HY-118848 | A63162 | 111525-11-2 | Reference compound |
| HY-118851 | NSC-77053 | 77308-57-7 | Reference compound |
| HY-118852 | Isoxaben | 82558-50-7 | Reference compound |
| HY-118852R | Isoxaben (Standard) | 82558-50-7 | Reference Standards |
| HY-118853 | Dichlofenthion | 97-17-6 | Reference compound |
| HY-118854 | Fepradinol | 36981-91-6 | Reference compound |
| HY-118858 | UCPH-102 | 1229591-56-3 | Reference compound |
| HY-118860 | Corifollitropin alfa | 195962-23-3 | Inhibitory Antibodies |
| HY-118861 | Enclomiphene | 15690-57-0 | Reference compound |
| HY-118861A | Enclomiphene (citrate) | 7599-79-3 | Reference compound |
| HY-118861AS1 | Clomiphene-d5 (citrate) | 1217200-17-3 | Isotope-Labeled Compounds |
| HY-118861B | Enclomiphene (hydrochloride) | 14158-65-7 | Reference compound |
| HY-118861S | Enclomiphene-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-118861S1 | Enclomiphene-d4 | | Isotope-Labeled Compounds |
| HY-118865 | Piperaquine (tetraphosphate) | 911061-10-4 | Reference compound |
| HY-118865S | Piperaquine-d6 (tetraphosphate) | | Isotope-Labeled Compounds |
| HY-118870 | γ-Globulins from human blood | 9007-83-4 | Natural Products |
| HY-118874 | Oblimersen | 190977-41-4 | Oligonucleotides |
| HY-118874A | Oblimersen (sodium) | | Oligonucleotides |
| HY-118877 | Urea-13C | 58069-82-2 | Isotope-Labeled Compounds |
| HY-118893 | Asukamycin | 61116-33-4 | Reference compound |
| HY-118894 | AB182 | 54805-58-2 | Reference compound |
| HY-118895 | L-641953 | 89825-69-4 | Reference compound |
| HY-118896 | Acequinocyl | 57960-19-7 | Reference compound |
| HY-118896R | Acequinocyl (Standard) | 57960-19-7 | Reference Standards |
| HY-118896S | Acequinocyl-d25 | 2469735-25-7 | Isotope-Labeled Compounds |
| HY-118897 | UNC-2170 (maleate) | 2173992-60-2 | Reference compound |
| HY-118899 | XR5944 | 343247-32-5 | Reference compound |
| HY-118901 | Opipramol | 315-72-0 | Reference compound |
| HY-118901A | Opipramol (dihydrochloride) | 909-39-7 | Reference compound |
| HY-118901R | Opipramol (Standard) | 315-72-0 | Reference Standards |
| HY-118901S | Opipramol-d4 | 1215716-70-3 | Isotope-Labeled Compounds |
| HY-118902 | Aloisine B | 496864-14-3 | Reference compound |
| HY-118904 | VL-0395 | 620167-11-5 | Reference compound |
| HY-118906 | BO-1165 | 89426-64-2 | Reference compound |
| HY-118907 | Methyl Orange | 547-58-0 | Dye Reagents |
| HY-118907R | Methyl Orange (Standard) | 547-58-0 | Dye Reagents |
| HY-118910 | AHR-14310C | 119810-68-3 | Reference compound |
| HY-118911 | ATM Inhibitor-10 | 1941214-06-7 | Reference compound |
| HY-118912 | BMH-9 | 457937-39-2 | Reference compound |
| HY-118914 | Glucagon receptor antagonist inactive control | 362482-00-6 | Reference compound |
| HY-118915 | FR 106969 | 50655-20-4 | Natural Products |
| HY-118916 | FTI-2148 | 251577-09-0 | Reference compound |
| HY-118916A | FTI-2148 (diTFA) | 817586-01-9 | Reference compound |
| HY-118918 | YM218 (free base) | 387816-81-1 | Reference compound |
| HY-118919 | CYM5181 | 695155-81-8 | Reference compound |
| HY-118920 | SQ 26655 | 82337-14-2 | Reference compound |
| HY-118921 | Ovatodiolide | 3484-37-5 | Natural Products |
| HY-118922 | IW927 | 389142-48-7 | Reference compound |
| HY-118923 | Saflufenacil | 372137-35-4 | Reference compound |
| HY-118923R | Saflufenacil (Standard) | 372137-35-4 | Reference Standards |
| HY-118924 | IR-825 | 1558079-49-4 | Reference compound |
| HY-118925 | Holothurin A | 38-26-6 | Natural Products |
| HY-118926 | Bioresmethrin | 28434-01-7 | Reference compound |
| HY-118930 | MK-0493 | 455956-93-1 | Reference compound |
| HY-118930A | MK-0493 (hydrochloride) | 455957-71-8 | Reference compound |
| HY-118931 | EF-1502 | 684645-54-3 | Reference compound |
| HY-118932 | HCV-IN-45 | 301211-35-8 | Reference compound |
| HY-118933 | Calpain Inhibitor VI | 190274-53-4 | Reference compound |
| HY-118934 | Novocebrin | 36702-84-8 | Reference compound |
| HY-118935 | NGD9002 (free base) | 666256-06-0 | Reference compound |
| HY-118938 | Hoquizil (hydrochloride) | 23256-28-2 | Reference compound |
| HY-118939 | Acantholide | 72548-16-4 | Natural Products |
| HY-118941 | BAY 73-1449 | 693790-96-4 | Reference compound |
| HY-118942 | Topovale | 500214-53-9 | Reference compound |
| HY-118944 | L-748328 | 244192-93-6 | Reference compound |
| HY-118946 | BPH-1358 | 5352-53-4 | Reference compound |
| HY-118946A | BPH-1358 (free base) | 801985-13-7 | Reference compound |
| HY-118946B | BPH-1358 (mesylate) | | Reference compound |
| HY-118948 | MSN-50 | 1592908-75-2 | Reference compound |
| HY-118949 | LY255582 | 119193-09-8 | Reference compound |
| HY-118950 | J 628 | 65323-80-0 | Reference compound |
| HY-118951 | VU0038882 | 429653-28-1 | Reference compound |
| HY-118952 | PF-06456384 | 1834610-73-9 | Reference compound |
| HY-118952A | PF-06456384 (trihydrochloride) | 1834610-75-1 | Reference compound |
| HY-118955 | Acid red 88 | 1658-56-6 | Biochemical Assay Reagents |
| HY-118956 | Adrogolide (hydrochloride) | 166591-11-3 | Reference compound |
| HY-118958 | Ablukast | 96566-25-5 | Reference compound |
| HY-118959 | S2160 | 54799-93-8 | Reference compound |
| HY-118960 | BMS-199264 (hydrochloride) | 186180-83-6 | Reference compound |
| HY-118961 | SR31527 (chloride) | 311814-78-5 | Reference compound |
| HY-118964 | Tyrphostin AG 568 | 151013-48-8 | Reference compound |
| HY-118965 | Alazopeptin | 1397-84-8 | Reference compound |
| HY-118967 | VUANT1 | 663212-40-6 | Reference compound |
| HY-118969 | BMS-262084 | 253174-92-4 | Reference compound |
| HY-118974 | PD-151307 | 225925-12-2 | Reference compound |
| HY-118978 | PF-00277343 | 332926-04-2 | Reference compound |
| HY-118979 | L-691678 | 144210-49-1 | Reference compound |
| HY-118980 | Sorbitol dehydrogenase-IN-1 | 300551-49-9 | Reference compound |
| HY-118982 | CT-2584 | 166981-13-1 | Reference compound |
| HY-118983 | Pivampicillin (hydrochloride) | 26309-95-5 | Reference compound |
| HY-118984 | CRX-526 | 245515-64-4 | Reference compound |
| HY-118985 | Acifluorfen (sodium) | 62476-59-9 | Reference compound |
| HY-118987 | AT-127 | 2099680-72-3 | Reference compound |
| HY-118988 | CAY10506 | 292615-75-9 | Reference compound |
| HY-118990 | Lobelane (hydrochloride) | 246244-19-9 | Reference compound |
| HY-118992 | Aurodox | 12704-90-4 | Reference compound |
| HY-118994 | ARN19874 | 2190502-57-7 | Reference compound |
| HY-118996A | Isometamidium (chloride) | 34301-55-8 | Reference compound |
| HY-118996B | Isometamidium (chloride hydrochloride) | 6798-24-9 | Reference compound |
| HY-118997 | PD-89211 | 444725-49-9 | Reference compound |
| HY-118998 | TX2-121-1 | 1603845-42-6 | Reference compound |
| HY-119001 | BKM1644 | 1070966-96-9 | Reference compound |
| HY-119002 | BO-1236 | 105358-77-8 | Reference compound |
| HY-119005A | YM-49598 (iodide) | 476494-44-7 | Reference compound |
| HY-119006 | L-640,033 | 115326-36-8 | Reference compound |
| HY-119009 | TM-233 | 1103745-28-3 | Reference compound |
| HY-119010 | UCM 549 | 753502-19-1 | Reference compound |
| HY-119011 | Pivampicillin | 33817-20-8 | Reference compound |
| HY-119012 | L 681217 | 93522-10-2 | Reference compound |
| HY-119013 | VPC32183 | 717110-61-7 | Reference compound |
| HY-119016 | SK1-I | 1072443-89-0 | Reference compound |
| HY-119017 | SB-429201 | 1027971-34-1 | Reference compound |
| HY-119018 | AHR-6293 | 61941-63-7 | Reference compound |
| HY-119019 | ASB14780 | 1069046-00-9 | Reference compound |
| HY-119022 | MAC-0547630 | 950386-41-1 | Reference compound |
| HY-119023 | JNJ-26993135 | 841202-16-2 | Reference compound |
| HY-119024 | BCI-137 | 112170-24-8 | Reference compound |
| HY-119025 | L 681176 | 91386-17-3 | Reference compound |
| HY-119030 | Rubradirin | 11031-38-2 | Reference compound |
| HY-119033 | MGL-IN-1 | 1881244-28-5 | Reference compound |
| HY-119034 | AD-20 | 111542-07-5 | Reference compound |
| HY-119035 | R-75317 | 115406-25-2 | Reference compound |
| HY-119037 | UK-101 | 1000313-40-5 | Reference compound |
| HY-119038 | ML-7 | 109376-83-2 | Reference compound |
| HY-119039 | RU-301 | 1110873-99-8 | Reference compound |
| HY-119046 | SNX-0723 | 1073969-18-2 | Reference compound |
| HY-119053 | MS7972 | 352553-42-5 | Reference compound |
| HY-119054 | DNMT1-IN-4 | 889797-65-3 | Reference compound |
| HY-119055 | Sch 33303 | 89108-58-7 | Reference compound |
| HY-119057 | DSM74 | 898743-92-5 | Reference compound |
| HY-119060 | FP0429 | 870860-41-6 | Reference compound |
| HY-119061 | SB357134 | 219963-52-7 | Reference compound |
| HY-119062 | A-800141 | 681245-85-2 | Reference compound |
| HY-119063 | L-645151 | 86394-94-7 | Reference compound |
| HY-119064 | L-645164 | 85493-98-7 | Reference compound |
| HY-119067 | Aspirochlorine | 59978-04-0 | Natural Products |
| HY-119069 | FAUC 3019 | 387360-48-7 | Reference compound |
| HY-119076 | A31472 | 69319-52-4 | Reference compound |
| HY-119078 | VU0080241 | 393845-24-4 | Reference compound |
| HY-119082 | (E/Z)-VU0029767 | 326001-01-8 | Reference compound |
| HY-119082A | VU0029767 | 1134973-88-8 | Reference compound |
| HY-119086 | L-651392 | 93211-49-5 | Reference compound |
| HY-119087 | JNJ-28583867 | 892407-39-5 | Reference compound |
| HY-119088 | Estrogen receptor modulator 12 | 554431-74-2 | Reference compound |
| HY-119092 | Bisaramil | 89194-77-4 | Reference compound |
| HY-119093 | Halopemide | 59831-65-1 | Reference compound |
| HY-119095 | L-741671 | 187724-85-2 | Reference compound |
| HY-119097 | LY456066 | 338738-66-2 | Reference compound |
| HY-119098 | GSK983 | 827591-02-6 | Reference compound |
| HY-119101 | AZD-5672 | 780750-65-4 | Reference compound |
| HY-119102 | BPU-11 | 909664-41-1 | Reference compound |
| HY-119103 | PF-03246799 | 1065110-62-4 | Reference compound |
| HY-119104 | AZD1940 | 881413-29-2 | Reference compound |
| HY-119105 | LY81067 | 87186-60-5 | Reference compound |
| HY-119108 | Emitefur | 110690-43-2 | Reference compound |
| HY-119109 | Laminaran | 9008-22-4 | Natural Products |
| HY-119110 | LY52 | 769970-91-4 | Reference compound |
| HY-119112A | LY 379196 | | Reference compound |
| HY-119113 | C 175 | 6237-31-6 | Reference compound |
| HY-119120 | JTK-101 | 503048-34-8 | Reference compound |
| HY-119123 | Voxvoganan | 1166254-80-3 | Reference compound |
| HY-119123A | Voxvoganan (trihydrochloride) | | Reference compound |
| HY-119124 | Edoxaban M4 | 834919-19-6 | Reference compound |
| HY-119127 | TP-680 | 176915-07-4 | Reference compound |
| HY-119130 | SQ 28516 | 92121-46-5 | Reference compound |
| HY-119131 | AK 275 | 158798-83-5 | Reference compound |
| HY-119136 | BFF-122 | 1152314-49-2 | Reference compound |
| HY-119137 | AMDE-1 | 478043-30-0 | Reference compound |
| HY-119140 | LY 116467 | 57202-76-3 | Reference compound |
| HY-119141 | RH 3421 | 99832-61-8 | Reference compound |
| HY-119145 | MRS2496 | 491611-67-7 | Reference compound |
| HY-119146 | Zolazepam | 31352-82-6 | Reference compound |
| HY-119148 | SQ 28517 | 92131-67-4 | Reference compound |
| HY-119151 | GS-9191 | 859209-84-0 | Reference compound |
| HY-119152 | CMX-2043 | 910627-26-8 | Peptides |
| HY-119156 | Altanserin | 76330-71-7 | Reference compound |
| HY-119158 | VU0652925 | 1476847-58-1 | Reference compound |
| HY-119160 | TM5007 | 342595-05-5 | Reference compound |
| HY-119163 | L-902688 | 634193-54-7 | Reference compound |
| HY-119165 | GSM-1 | 884600-68-4 | Reference compound |
| HY-119166 | 3,5,4'-Tribromosalicylanilide | 87-10-5 | Reference compound |
| HY-119168 | LP-471756 | 413605-11-5 | Reference compound |
| HY-119169 | Tubulozole | 84697-22-3 | Reference compound |
| HY-119171 | GSK 366 | 1953157-39-5 | Reference compound |
| HY-119172 | NSC-60339 | 70-09-7 | Reference compound |
| HY-119173 | PBD-150 | 790663-33-1 | Reference compound |
| HY-119174 | MK771 | 66537-55-1 | Reference compound |
| HY-119176 | Oxyfluorfen | 42874-03-3 | Reference compound |
| HY-119176R | Oxyfluorfen (Standard) | 42874-03-3 | Reference Standards |
| HY-119177 | PD173956 | 305820-76-2 | Reference compound |
| HY-119179 | UCCF-853 | 625458-06-2 | Reference compound |
| HY-119182 | Mitonafide | 54824-17-8 | Reference compound |
| HY-119183 | A 23887 | 61955-05-3 | Reference compound |
| HY-119185 | AZD-6605 | 893556-15-5 | Reference compound |
| HY-119186 | Axillarin | 5188-73-8 | Natural Products |
| HY-119188 | Saframycin A | 66082-27-7 | Reference compound |
| HY-119190 | PF-06445974 | 2055776-17-3 | Reference compound |
| HY-119191 | KF26777 (free base) | 206129-88-6 | Reference compound |
| HY-119195 | I5B2 | 93768-49-1 | Natural Products |
| HY-119196 | Caprospinol | 4952-56-1 | Reference compound |
| HY-119197 | PPARα/γ/δ agonist 1 | 853652-40-1 | Reference compound |
| HY-119198 | NSC745885 | 4219-52-7 | Reference compound |
| HY-119200 | LY-195448 (hydrochloride) | 111112-18-6 | Reference compound |
| HY-119202 | (S)-BMS-378806 | 357263-14-0 | Reference compound |
| HY-119203 | NNC 38-1049 | 757183-18-9 | Reference compound |
| HY-119206 | Sulbenicillin | 41744-40-5 | Reference compound |
| HY-119208 | VUF11211 | 906556-51-2 | Reference compound |
| HY-119209 | Nefazodone | 83366-66-9 | Reference compound |
| HY-119210 | ZINC04177596 | 364052-84-6 | Reference compound |
| HY-119211 | LY 97241 | 72456-63-4 | Reference compound |
| HY-119213 | BMY-27709 | 99390-76-8 | Reference compound |
| HY-119215 | Antioquine | 93767-27-2 | Reference compound |
| HY-119217 | AZ084 | 929300-19-6 | Reference compound |
| HY-119218 | LH 1 | 67190-52-7 | Reference compound |
| HY-119219 | Detoxin C1 | 74717-53-6 | Natural Products |
| HY-119220 | Granotapide | 594842-13-4 | Reference compound |
| HY-119221 | AUY954 | 820240-77-5 | Reference compound |
| HY-119221A | AUY 954 (hydrochloride) | 820240-78-6 | Reference compound |
| HY-119222 | GSK256073 | 862892-90-8 | Reference compound |
| HY-119222A | GSK256073 (tris) | 1228650-42-7 | Reference compound |
| HY-119223 | Desmethylmirtazapine | 61337-68-6 | Reference compound |
| HY-119223R | Desmethylmirtazapine (Standard) | 61337-68-6 | Reference Standards |
| HY-119224 | BIA 3-335 | 359783-06-5 | Reference compound |
| HY-119226 | VU0152099 | 612514-42-8 | Reference compound |
| HY-119229 | VRT-325 | 815592-21-3 | Reference compound |
| HY-119230 | Kobe2601 | 316151-68-5 | Reference compound |
| HY-119232 | GSK466317A | 864082-48-4 | Reference compound |
| HY-119234 | CX4338 | 41609-06-7 | Reference compound |
| HY-119238 | CRL-42872 | 256385-24-7 | Reference compound |
| HY-119239 | R 28935 | 55806-43-4 | Reference compound |
| HY-119240 | CCT020312 | 324759-76-4 | Reference compound |
| HY-119242 | BTI-A-404 | 537679-57-5 | Reference compound |
| HY-119243 | LY2794193 | 2173037-97-1 | Reference compound |
| HY-119244 | Gly-Pro-pNA (hydrochloride) | 103213-34-9 | Reference compound |
| HY-119245 | Udifitimod | 1883345-06-9 | Reference compound |
| HY-119246 | A-269A | 38621-52-2 | Natural Products |
| HY-119248 | KRP-297 | 213252-19-8 | Reference compound |
| HY-119254 | BAY-850 | 2099142-76-2 | Reference compound |
| HY-119254A | trans-BAY-850 | | Reference compound |
| HY-119256 | COR627 | 329221-34-3 | Reference compound |
| HY-119257 | ABT-100 | 450839-40-4 | Reference compound |
| HY-119259 | AZD8309 | 333742-48-6 | Reference compound |
| HY-119261 | Ruboxyl | 80214-88-6 | Reference compound |
| HY-119264 | PRLX-93936 | 903499-49-0 | Reference compound |
| HY-119264A | PRLX-93936 (dihydrochloride) | 1094210-96-4 | Reference compound |
| HY-119265 | LDL-IN-4 | 615264-62-5 | Reference compound |
| HY-119266 | HTS13517 | 91533-02-7 | Reference compound |
| HY-119268 | Thiosildenafil | 479073-79-5 | Reference compound |
| HY-119268R | Thiosildenafil (Standard) | 479073-79-5 | Reference Standards |
| HY-119270 | PD 130908 | 131505-02-7 | Reference compound |
| HY-119271 | CMLD010509 | 256497-58-2 | Reference compound |
| HY-119271A | (-)-CMLD010509 | 2240186-24-5 | Reference compound |
| HY-119272 | EF24 | 342808-40-6 | Reference compound |
| HY-119274 | BN-82451 (dihydrochloride) | 663172-95-0 | Reference compound |
| HY-119277 | CJB-090 (dihydrochloride) | 595584-40-0 | Reference compound |
| HY-119279 | VUF 10214 | 848837-33-2 | Reference compound |
| HY-119280 | Sch 29482 | 77646-83-4 | Reference compound |
| HY-119282 | AZD6538 | 453566-30-8 | Reference compound |
| HY-119283 | CAY10499 | 359714-55-9 | Reference compound |
| HY-119287 | TSQ | 109628-27-5 | Dye Reagents |
| HY-119288 | BC-23 | 6298-15-3 | Reference compound |
| HY-119291 | RA642 | 54093-30-0 | Reference compound |
| HY-119293 | K777 | 233277-99-1 | Reference compound |
| HY-119293A | K777 (tosylate) | 502960-91-0 | Oligonucleotides |
| HY-119296 | Cloprednol | 5251-34-3 | Reference compound |
| HY-119296R | Cloprednol (Standard) | 5251-34-3 | Reference Standards |
| HY-119304 | GW-406381 | 221148-46-5 | Reference compound |
| HY-119306 | MCC-134 | 181238-67-5 | Reference compound |
| HY-119307 | Apratastat | 287405-51-0 | Reference compound |
| HY-119309 | Sucrose octaacetate | 126-14-7 | Reference compound |
| HY-119309R | Sucrose octaacetate (Standard) | 126-14-7 | Reference Standards |
| HY-119311 | Ketopioglitazone | 146062-45-5 | Reference compound |
| HY-119311S | Ketopioglitazone-d4 | 1215370-26-5 | Isotope-Labeled Compounds |
| HY-119312 | C8 Dihydroceramide | 145774-33-0 | Reference compound |
| HY-119315 | Flucloronide | 3693-39-8 | Reference compound |
| HY-119316A | CM-545 | 1624792-70-6 | Reference compound |
| HY-119319 | LLP6 | 254902-10-8 | Reference compound |
| HY-119320 | Ethimidine | 2482-80-6 | Reference compound |
| HY-119322 | Tifenazoxide | 279215-43-9 | Reference compound |
| HY-119323 | 7-Azido-4-methylcoumarin | 95633-27-5 | Reference compound |
| HY-119324 | Anticancer agent 254 | 1841421-67-7 | Reference compound |
| HY-119325A | Lanperisone (hydrochloride) | 116287-13-9 | Reference compound |
| HY-119326 | N-Formylmethamphetamine | 42932-20-7 | Reference compound |
| HY-119327 | Butylate | 2008-41-5 | Reference compound |
| HY-119327R | Butylate (Standard) | 2008-41-5 | Reference Standards |
| HY-119328 | Pestalotin | 34565-32-7 | Natural Products |
| HY-119329 | Glycidamide | 5694-00-8 | Reference compound |
| HY-119331 | CFM-5 | 639507-03-2 | Reference compound |
| HY-119332 | 3-Keto petromyzonol | 359436-56-9 | Natural Products |
| HY-119333 | NNC 11-1607 | 250649-13-9 | Reference compound |
| HY-119335 | Cyphenothrin | 39515-40-7 | Reference compound |
| HY-119335R | Cyphenothrin (Standard) | 39515-40-7 | Reference Standards |
| HY-119336 | Mebroqualone | 4260-20-2 | Reference compound |
| HY-119337 | CE-2072 | 208840-22-6 | Reference compound |
| HY-119339 | SX-682 | 1648843-04-2 | Reference compound |
| HY-119343 | Biotin-PFP ester | 120550-35-8 | Reference compound |
| HY-119344 | MS37452 | 423748-02-1 | Reference compound |
| HY-119347 | Cirsilineol | 41365-32-6 | Natural Products |
| HY-119347R | Cirsilineol (Standard) | 41365-32-6 | Reference Standards |
| HY-119349 | (±)-Dihydrozeatin | 23599-75-9 | Reference compound |
| HY-119350 | Zalunfiban | 1448313-27-6 | Reference compound |
| HY-119350B | Zalunfiban (dihydrochloride) | 2815778-41-5 | Reference compound |
| HY-119350C | Zalunfiban (acetate) | 2376629-15-9 | Reference compound |
| HY-119351 | BNS | 1417440-37-9 | Reference compound |
| HY-119352 | S-2 Methanandamide | 157182-48-4 | Reference compound |
| HY-119353 | Repromicin | 56689-42-0 | Reference compound |
| HY-119357 | TN-16 | 33016-12-5 | Reference compound |
| HY-119358 | Traumatic Acid | 6402-36-4 | Natural Products |
| HY-119358R | Traumatic Acid (Standard) | 6402-36-4 | Reference Standards |
| HY-119359 | 5,6-Epoxy-13-cis retinoic acid | 81444-57-7 | Reference compound |
| HY-119360 | Lilly 18947 (free base) | 2600-77-3 | Reference compound |
| HY-119361 | (Rac)-Deox B 7,4 | 674786-37-9 | Reference compound |
| HY-119366 | S18-000003 | 2068119-11-7 | Reference compound |
| HY-119367 | ODM-203 | 1430723-35-5 | Reference compound |
| HY-119368 | NPB | 2247491-97-8 | Reference compound |
| HY-119369 | FadD32 Inhibitor-1 | 2081969-24-4 | Reference compound |
| HY-119370 | CHMFL-ABL-121 | 2270879-07-5 | Reference compound |
| HY-119372 | TDP1 Inhibitor-1 | 2248702-80-7 | Reference compound |
| HY-119373 | Cav 2.2 blocker 1 | 1567335-29-8 | Reference compound |
| HY-119374 | BRM/BRG1 ATP Inhibitor-1 | 2270879-17-7 | Reference compound |
| HY-119375 | Syncytial Virus Inhibitor-1 | 1422496-79-4 | Reference compound |
| HY-119377 | UPGL00004 | 1890169-95-5 | Reference compound |
| HY-119378 | AK 295 | 160399-35-9 | Reference compound |
| HY-119379 | Fonsartan (free acid) | 144628-52-4 | Reference compound |
| HY-119381 | Iodofenphos | 18181-70-9 | Reference compound |
| HY-119381R | Iodofenphos (Standard) | 18181-70-9 | Reference Standards |
| HY-119383 | iCRT-5 | 18623-44-4 | Reference compound |
| HY-119384 | Promegestone | 34184-77-5 | Reference compound |
| HY-119385 | Savoxepin (mesylate) | 79262-47-8 | Reference compound |
| HY-119387 | Chevalone B | 1318025-75-0 | Natural Products |
| HY-119389 | RGH-1756 | 207277-37-0 | Reference compound |
| HY-119390 | AA-CW236 | 1869921-96-9 | Reference compound |
| HY-119392 | 16-Hexadecanolide | 109-29-5 | Natural Products |
| HY-119393 | Olanzapine N-oxide | 174794-02-6 | Reference compound |
| HY-119393S | Olanzapine N-Oxide-d3 | 1189732-75-9 | Isotope-Labeled Compounds |
| HY-119395A | Kynuramine (dihydrobromide) | 304-47-2 | Reference compound |
| HY-119395B | Kynuramine (dihydrochloride) | 36681-58-0 | Reference compound |
| HY-119396 | DY3002 | 2020015-37-4 | Reference compound |
| HY-119397 | KDM5-C49 | 1596348-16-1 | Reference compound |
| HY-119397A | KDM5-C49 (hydrochloride) | 3026728-26-4 | Reference compound |
| HY-119398 | Lanuginosine | 23740-25-2 | Reference compound |
| HY-119401 | CAY10444 | 298186-80-8 | Reference compound |
| HY-119402 | TP-021 | 2130878-25-8 | Reference compound |
| HY-119403 | 4-Phenyl-1,2,3-thiadiazole | 25445-77-6 | Reference compound |
| HY-119404 | Diproqualone | 36518-02-2 | Reference compound |
| HY-119405 | Niddamycin | 20283-69-6 | Reference compound |
| HY-119407 | Terpendole E | 167427-23-8 | Natural Products |
| HY-119409 | Levophacetoperane | 24558-01-8 | Reference compound |
| HY-119410 | Linotroban | 120824-08-0 | Reference compound |
| HY-119412 | Biliatresone | 1801433-90-8 | Natural Products |
| HY-119413 | 9-Ethyladenine | 2715-68-6 | Natural Products |
| HY-119413R | 9-Ethyladenine (Standard) | 2715-68-6 | Reference Standards |
| HY-119414 | N,N-Dimethyl-L-valine | 2812-32-0 | Reference compound |
| HY-119415 | Levovirin | 206269-27-4 | Reference compound |
| HY-119417 | Chloramben | 133-90-4 | Reference compound |
| HY-119417A | Chloramben (sodium) | 1954-81-0 | Reference compound |
| HY-119417R | Chloramben (Standard) | 133-90-4 | Reference Standards |
| HY-119418 | Desketoraloxifene | 216570-81-9 | Reference compound |
| HY-119419 | Pirimicarb | 23103-98-2 | Reference compound |
| HY-119419R | Pirimicarb (Standard) | 23103-98-2 | Reference Standards |
| HY-119419S | Pirimicarb-d6 | 1015854-66-6 | Isotope-Labeled Compounds |
| HY-119422 | Melianodiol | 32764-64-0 | Natural Products |
| HY-119423 | MMP Inhibitor II | 203915-59-7 | Reference compound |
| HY-119424 | SP4206 | 515846-21-6 | Reference compound |
| HY-119425 | Razoxane | 21416-67-1 | Reference compound |
| HY-119426 | Dexamisole | 14769-74-5 | Reference compound |
| HY-119427 | Anti-melanoma agent 3 | 1253697-49-2 | Reference compound |
| HY-119429 | Bis-PEG4-acid | 31127-85-2 | Reference compound |
| HY-119433 | Asoprisnil | 199396-76-4 | Reference compound |
| HY-119435 | Triallate | 2303-17-5 | Reference compound |
| HY-119435R | Triallate (Standard) | 2303-17-5 | Reference Standards |
| HY-119437 | FLTX1 | 1481401-71-1 | Reference compound |
| HY-119438 | Aspon | 3244-90-4 | Reference compound |
| HY-119439 | Lignan J1 | 27041-98-1 | Natural Products |
| HY-119440 | Xanthinol | 2530-97-4 | Reference compound |
| HY-119442 | Quininib | 143816-42-6 | Reference compound |
| HY-119443 | Neridronate | 79778-41-9 | Reference compound |
| HY-119445 | Sophorose | 534-46-3 | Biochemical Assay Reagents |
| HY-119445A | Sophorose (monohydrate) | 140686-17-5 | Biochemical Assay Reagents |
| HY-119447 | Mavacoxib | 170569-88-7 | Reference compound |
| HY-119447S | Mavacoxib-d4 | | Isotope-Labeled Compounds |
| HY-119451 | (Z)-8-Dodecenyl acetate | 28079-04-1 | Reference compound |
| HY-119453 | Oxycinchophen | 485-89-2 | Reference compound |
| HY-119454S | Chlomethoxyfen-d3 | | Isotope-Labeled Compounds |
| HY-119456 | Romifidine | 65896-16-4 | Reference compound |
| HY-119456A | Romifidine (hydrochloride) | 65896-14-2 | Reference compound |
| HY-119456AS | Romifidine-d4 (hydrochloride) | 1329834-57-2 | Isotope-Labeled Compounds |
| HY-119458 | Luotonin A | 205989-12-4 | Natural Products |
| HY-119459 | Fluopyram | 658066-35-4 | Reference compound |
| HY-119459R | Fluopyram (Standard) | 658066-35-4 | Reference Standards |
| HY-119460 | Cuspin-1 | 337932-29-3 | Reference compound |
| HY-119461 | Capuride | 5579-13-5 | Reference compound |
| HY-119464 | MRL-871 | 1392809-08-3 | Reference compound |
| HY-119465 | Restricticin | 135357-96-9 | Natural Products |
| HY-119466 | Broperamole | 33144-79-5 | Reference compound |
| HY-119467 | MDK0734 | 1366240-73-4 | Reference compound |
| HY-119468 | Medifoxamine | 32359-34-5 | Reference compound |
| HY-119469 | Aceclofenac ethyl ester | 139272-67-6 | Reference compound |
| HY-119478 | Lophophorine | 17627-78-0 | Natural Products |
| HY-119480 | Megazol | 19622-55-0 | Reference compound |
| HY-119482 | Cymipristone | 329971-40-6 | Reference compound |
| HY-119485 | Dilevalol | 75659-07-3 | Reference compound |
| HY-119485AS | Dilevalol-d3 (hydrochloride) | 2734920-41-1 | Isotope-Labeled Compounds |
| HY-119486 | Tavapadon | 1643489-24-0 | Reference compound |
| HY-119486A | (Rac)-Tavapadon | 1643462-64-9 | Reference compound |
| HY-119487 | MMPP | 1895957-18-2 | Reference compound |
| HY-119490 | UMB-136 | 2109805-83-4 | Reference compound |
| HY-119491 | Ethyl tricosanoate | 18281-07-7 | Biochemical Assay Reagents |
| HY-119493 | MSBN | 135980-66-4 | Reference compound |
| HY-119494 | Commendamide | 193825-78-4 | Reference compound |
| HY-119497 | SB251023 | 208842-53-9 | Reference compound |
| HY-119499 | 6-Thioguanosine | 85-31-4 | Reference compound |
| HY-119500 | Ilimaquinone | 71678-03-0 | Natural Products |
| HY-119502 | Camalexin | 135531-86-1 | Natural Products |
| HY-119502R | Camalexin (Standard) | 135531-86-1 | Reference Standards |
| HY-119505 | Curcuphenol | 69301-27-5 | Reference compound |
| HY-119506 | KL044 | 1801856-93-8 | Reference compound |
| HY-119508 | Propaphos | 7292-16-2 | Reference compound |
| HY-119509 | Cismethrin | 35764-59-1 | Reference compound |
| HY-119513 | Nizofenone | 54533-85-6 | Reference compound |
| HY-119515 | Denopamine | 71771-90-9 | Reference compound |
| HY-119516 | Naftalofos | 1491-41-4 | Reference compound |
| HY-119517 | Seclazone | 29050-11-1 | Reference compound |
| HY-119518 | BMS641 | 369364-50-1 | Reference compound |
| HY-119519 | OB-2 | 300689-25-2 | Reference compound |
| HY-119521 | Mexiletine | 31828-71-4 | Reference compound |
| HY-119521S | Mexiletine-d3 | | Isotope-Labeled Compounds |
| HY-119521S1 | Mexiletine-d6 | 1330267-50-9 | Isotope-Labeled Compounds |
| HY-119523 | Disuccinimidyl sebacate | 23024-29-5 | Reference compound |
| HY-119524 | Clofibride | 26717-47-5 | Reference compound |
| HY-119525 | Propetamphos | 31218-83-4 | Reference compound |
| HY-119525R | Propetamphos (Standard) | 31218-83-4 | Reference Standards |
| HY-119526 | Bismaleimide | 13676-54-5 | Reference compound |
| HY-119527 | Conagenin | 134381-30-9 | Natural Products |
| HY-119528 | Mansonone F | 5090-88-0 | Natural Products |
| HY-119529 | Jineol | 178762-28-2 | Natural Products |
| HY-119530 | Thiamiprine | 5581-52-2 | Reference compound |
| HY-119530R | Thiamiprine (Standard) | 5581-52-2 | Reference Standards |
| HY-119532 | Nordeprenyl | 18913-84-3 | Reference compound |
| HY-119532R | Nordeprenyl (Standard) | 18913-84-3 | Reference Standards |
| HY-119536 | Norsufentanil | 61086-18-8 | Reference compound |
| HY-119536S | Norsufentanil-d3 | 1204688-16-3 | Isotope-Labeled Compounds |
| HY-119537 | Alstonidine | 25394-75-6 | Natural Products |
| HY-119539 | Limocitrin | 489-33-8 | Natural Products |
| HY-119540 | Furametpyr | 123572-88-3 | Reference compound |
| HY-119541 | Ampreloxetine | 1227056-84-9 | Reference compound |
| HY-119541A | Ampreloxetine (TFA) | 1227056-85-0 | Reference compound |
| HY-119543 | O-Succinyl-L-homoserine | 1492-23-5 | Peptides |
| HY-119544 | Ripisartan | 148504-51-2 | Reference compound |
| HY-119545 | PD159790 | 179598-53-9 | Reference compound |
| HY-119546 | Pinolenic acid | 16833-54-8 | Natural Products |
| HY-119548 | Bifidenone | 2078008-57-6 | Reference compound |
| HY-119550 | J1075 | 383892-69-1 | Reference compound |
| HY-119552 | Acetylaszonalenin | 42230-55-7 | Natural Products |
| HY-119554 | Perfluorodecyl bromide | 307-43-7 | Reference compound |
| HY-119556 | Butonate | 126-22-7 | Reference compound |
| HY-119557 | Buthiazide | 2043-38-1 | Reference compound |
| HY-119558 | Bromacil | 314-40-9 | Reference compound |
| HY-119558R | Bromacil (Standard) | 314-40-9 | Reference Standards |
| HY-119560 | Spirgetine | 144-45-6 | Reference compound |
| HY-119572 | Sodium zirconium cyclosilicate | 17141-74-1 | Reference compound |
| HY-119575 | Tetramethyluric acid | 2309-49-1 | Biochemical Assay Reagents |
| HY-119576 | Phox-I2 | 353495-22-4 | Reference compound |
| HY-119577 | Ubretid | 15876-67-2 | Reference compound |
| HY-119577R | Ubretid (Standard) | 15876-67-2 | Reference Standards |
| HY-119580 | Leucocyanidin | 480-17-1 | Natural Products |
| HY-119580B | (+)-Leucocyanidin | 69256-15-1 | Natural Products |
| HY-119580R | Leucocyanidin (Standard) | 480-17-1 | Reference Standards |
| HY-119581 | MBED | 123363-40-6 | Reference compound |
| HY-119582 | Safironil | 134377-69-8 | Reference compound |
| HY-119583 | Furanomycin | 18455-25-9 | Reference compound |
| HY-119586 | LG190119 | 233268-77-4 | Reference compound |
| HY-119587 | Alestramustine | 139402-18-9 | Reference compound |
| HY-119589 | Altersolanol B | 22350-90-9 | Reference compound |
| HY-119591 | BPDBA | 312281-74-6 | Reference compound |
| HY-119592 | Cyclophostin | | Natural Products |
| HY-119593 | α-Homonojirimycin | 119557-99-2 | Natural Products |
| HY-119594 | Melarsoprol | 494-79-1 | Reference compound |
| HY-119595 | Haloperidide | 2924-46-1 | Reference compound |
| HY-119596 | Eupatoriochromene | 19013-03-7 | Natural Products |
| HY-119599 | Linearolactone | 113973-98-1 | Natural Products |
| HY-119602 | Rolziracetam | 18356-28-0 | Reference compound |
| HY-119603 | Regelinol | 109974-22-3 | Natural Products |
| HY-119604 | Cafamycin | 112303-17-0 | Natural Products |
| HY-119605 | DAA-1097 | 220551-79-1 | Reference compound |
| HY-119606 | Bacimethrin | 3690-12-8 | Biochemical Assay Reagents |
| HY-119607 | DYRKi | 1640364-04-0 | Reference compound |
| HY-119608 | GSK854 | 1316059-00-3 | Reference compound |
| HY-119609 | Ilicicolin C | 22562-67-0 | Natural Products |
| HY-119611 | Thioquinapiperifil | 220060-39-9 | Reference compound |
| HY-119611A | Thioquinapiperifil (dihydrochloride) | 204077-66-7 | Reference compound |
| HY-119613 | Clociguanil | 3378-93-6 | Reference compound |
| HY-119614 | Niridazole | 61-57-4 | Reference compound |
| HY-119615 | Mezilamine | 50335-55-2 | Reference compound |
| HY-119616 | Phenamet | 3819-34-9 | Reference compound |
| HY-119617 | 2-(3-Hydroxypicolinamido)acetic acid | 3458-69-3 | Reference compound |
| HY-119618 | R1498 | 303196-31-8 | Reference compound |
| HY-119621 | Aceglatone | 642-83-1 | Reference compound |
| HY-119624 | MOMIPP | 1363421-46-8 | Reference compound |
| HY-119627 | Cajucarinolide | 147742-03-8 | Natural Products |
| HY-119630 | Propineb | 12071-83-9 | Reference compound |
| HY-119630R | Propineb (Standard) | 12071-83-9 | Reference Standards |
| HY-119631 | Nornidulin | 33403-37-1 | Reference compound |
| HY-119632 | Anisopirol | 857-62-5 | Reference compound |
| HY-119635 | Albicanol | 54632-04-1 | Natural Products |
| HY-119637 | Frangufoline | 19526-09-1 | Natural Products |
| HY-119638 | Oxiperomide | 5322-53-2 | Reference compound |
| HY-119640 | Aspercolorin | 29123-52-2 | Natural Products |
| HY-119641 | Apholate | 52-46-0 | Reference compound |
| HY-119642 | Kopsinine | 559-51-3 | Natural Products |
| HY-119646 | Aviglycine | 49669-74-1 | Reference compound |
| HY-119647 | PPOH | 206052-01-9 | Reference compound |
| HY-119648 | CCR-11 | 1287652-03-2 | Reference compound |
| HY-119648A | (E/Z)-CCR-11 | 301687-87-6 | Reference compound |
| HY-119649 | Flonicamid | 158062-67-0 | Reference compound |
| HY-119649R | Flonicamid (Standard) | 158062-67-0 | Reference Standards |
| HY-119649S | Flonicamid-15N,18O | 2483830-60-8 | Isotope-Labeled Compounds |
| HY-119651 | Perthane | 72-56-0 | Reference compound |
| HY-119653 | AZ9482 | 1825345-33-2 | Reference compound |
| HY-119657 | Cellocidin | 543-21-5 | Natural Products |
| HY-119658 | PF-4178903 | 1310796-72-5 | Reference compound |
| HY-119660 | Surgumycin | 51938-50-2 | Reference compound |
| HY-119663 | Averantin | 5803-62-3 | Natural Products |
| HY-119666 | Rooperol | 83644-00-2 | Reference compound |
| HY-119667 | Enrasentan | 167256-08-8 | Reference compound |
| HY-119669 | Furylfuramide | 3688-53-7 | Reference compound |
| HY-119671 | BW 755C | 66000-40-6 | Reference compound |
| HY-119672 | Oct4 inducer-1 | 182564-41-6 | Reference compound |
| HY-119673 | Lincophenicol | 148077-13-8 | Reference compound |
| HY-119674 | Xanthopterin | 119-44-8 | Reference compound |
| HY-119674A | Xanthopterin (hydrate) | 5979-01-1 | Natural Products |
| HY-119675 | Albonoursin | 1222-90-8 | Reference compound |
| HY-119677 | Oxypertine | 153-87-7 | Reference compound |
| HY-119678 | Fortunellin | 20633-93-6 | Natural Products |
| HY-119682 | Bax agonist 1 | 18304-79-5 | Reference compound |
| HY-119683 | Epoxiconazole | 133855-98-8 | Reference compound |
| HY-119683A | (Rac)-Epoxiconazole | 135319-73-2 | Reference compound |
| HY-119683R | Epoxiconazole (Standard) | 133855-98-8 | Reference Standards |
| HY-119683S1 | Epoxiconazole-d4 | 2699607-18-4 | Isotope-Labeled Compounds |
| HY-119684 | Maresin 2 | 1639809-46-3 | Reference compound |
| HY-119684S | Maresin 2-d5 | | Isotope-Labeled Compounds |
| HY-119686 | Miloxacin | 37065-29-5 | Reference compound |
| HY-119686S | Miloxacin-d3 | 1228182-43-1 | Isotope-Labeled Compounds |
| HY-119687 | Bifenazate | 149877-41-8 | Reference compound |
| HY-119687R | Bifenazate (Standard) | 149877-41-8 | Reference Standards |
| HY-119688 | Amabiline | 17958-43-9 | Natural Products |
| HY-119689 | Umibecestat | 1387560-01-1 | Reference compound |
| HY-119690 | T326 | 1451042-19-5 | Reference compound |
| HY-119691 | Alamifovir | 193681-12-8 | Reference compound |
| HY-119692 | Curvulin | 19054-27-4 | Natural Products |
| HY-119694 | Rotenolone | 509-96-6 | Natural Products |
| HY-119695 | Simvastatin acid | 121009-77-6 | Reference compound |
| HY-119695A | Simvastatin acid (ammonium) | 139893-43-9 | Natural Products |
| HY-119695AR | Simvastatin acid (ammonium) (Standard) | 139893-43-9 | Reference Standards |
| HY-119695AS | Simvastatin acid-d6 (ammonium) | | Isotope-Labeled Compounds |
| HY-119695AS1 | Simvastatin acid-d9 (ammonium) | | Isotope-Labeled Compounds |
| HY-119695AS2 | Simvastatin acid-d3 (ammonium) | | Isotope-Labeled Compounds |
| HY-119695B | Simvastatin acid (calcium hydrate) | 530112-57-3 | Reference compound |
| HY-119695S | Simvastatin acid-d6 | 2747915-75-7 | Isotope-Labeled Compounds |
| HY-119696 | MTIC | 3413-72-7 | Reference compound |
| HY-119696R | MTIC (Standard) | 3413-72-7 | Reference Standards |
| HY-119696S | MTIC-d3 | 1185242-69-6 | Isotope-Labeled Compounds |
| HY-119697 | Setosusin | 182926-45-0 | Natural Products |
| HY-119698 | BAP9THP | 2312-73-4 | Reference compound |
| HY-119699 | PV1115 | 1093793-10-2 | Reference compound |
| HY-119700 | Isocil | 314-42-1 | Reference compound |
| HY-119702 | YZ51 | 1835652-66-8 | Reference compound |
| HY-119706 | Barbadin | 356568-70-2 | Reference compound |
| HY-119707 | TDR 32750 | 1428183-45-2 | Reference compound |
| HY-119708 | Ensifentrine | 1884461-72-6 | Reference compound |
| HY-119708S | Ensifentrine-d6 | | Isotope-Labeled Compounds |
| HY-119711 | NNGH | 161314-17-6 | Reference compound |
| HY-119712A | L-Primapterin | 2636-52-4 | Reference compound |
| HY-119713 | Khellinol | 478-42-2 | Natural Products |
| HY-119714 | Ambelline | 3660-62-6 | Reference compound |
| HY-119715 | AG-012986 | 486414-35-1 | Reference compound |
| HY-119720 | Neocryptotanshinone | 109664-02-0 | Natural Products |
| HY-119721 | CP-424174 | 210825-31-3 | Reference compound |
| HY-119722 | Butafosfan | 17316-67-5 | Reference compound |
| HY-119723 | Myristoyl ethanolamide | 142-58-5 | Reference compound |
| HY-119724 | ABCG2-IN-3 | 1942919-63-2 | Reference compound |
| HY-119725 | Tetradifon | 116-29-0 | Reference compound |
| HY-119725R | Tetradifon (Standard) | 116-29-0 | Reference Standards |
| HY-119726 | Fosmanogepix | 2091769-17-2 | Reference compound |
| HY-119726A | Fosmanogepix (tautomerism) | 1169701-00-1 | Reference compound |
| HY-119727 | WNK-IN-1 | 2125724-72-1 | Reference compound |
| HY-119728 | FR198248 | 197316-54-4 | Natural Products |
| HY-119729 | Axinysterol | 151606-24-5 | Natural Products |
| HY-119730 | Tripartin | 1428962-73-5 | Reference compound |
| HY-119731 | Antidesmone | 222629-77-8 | Natural Products |
| HY-119733 | BU09059 | 1541206-05-6 | Reference compound |
| HY-119734 | Gossypolone | 4547-72-2 | Reference compound |
| HY-119735 | Curcolone | 17015-43-9 | Natural Products |
| HY-119736 | Leptolstatin | 149633-91-0 | Natural Products |
| HY-119737 | Chlorsulfuron | 64902-72-3 | Reference compound |
| HY-119737R | Chlorsulfuron (Standard) | 64902-72-3 | Reference Standards |
| HY-119738 | OSMI-1 | 1681056-61-0 | Reference compound |
| HY-119738A | (Rac)-OSMI-1 | 2748153-92-4 | Reference compound |
| HY-119739 | Skyrin | 602-06-2 | Natural Products |
| HY-119741 | Salacinol | 200399-47-9 | Natural Products |
| HY-119744 | BAY 38-7271 | 212188-60-8 | Reference compound |
| HY-119748 | Sageone | 142546-15-4 | Natural Products |
| HY-119749 | Diazaborine | 22959-81-5 | Reference compound |
| HY-119750 | Budralazine | 36798-79-5 | Reference compound |
| HY-119751 | Hematein | 475-25-2 | Reference compound |
| HY-119753 | Disobutamide | 68284-69-5 | Reference compound |
| HY-119755 | Quadrosilan | 4657-20-9 | Reference compound |
| HY-119757 | Tyrphostin AG1433 | 168835-90-3 | Reference compound |
| HY-119757A | Tyrphostin AG1433 (hydrochloride) | 168836-03-1 | Reference compound |
| HY-119759 | Lipoxamycin | 32886-15-0 | Natural Products |
| HY-119759A | Lipoxamycin (hemisulfate) | 11075-87-9 | Reference compound |
| HY-119759AR | Lipoxamycin (hemisulfate) (Standard) | 11075-87-9 | Reference Standards |
| HY-119761 | L-670,548 | 121564-89-4 | Reference compound |
| HY-119762 | Spizofurone | 72492-12-7 | Reference compound |
| HY-119764 | Ikarugamycin | 36531-78-9 | Natural Products |
| HY-119765 | VU0366248 | 1243310-20-4 | Reference compound |
| HY-119766 | Aramite | 140-57-8 | Reference compound |
| HY-119766R | Aramite (Standard) | 140-57-8 | Reference Standards |
| HY-119767 | Jolkinolide A | 37905-07-0 | Natural Products |
| HY-119768 | (±)-BAK2-66 | 1301178-83-5 | Reference compound |
| HY-119769 | XX-650-23 | 117739-40-9 | Reference compound |
| HY-119770 | HDL376 | 147751-31-3 | Reference compound |
| HY-119772 | VU0366369 | 1222834-53-8 | Reference compound |
| HY-119774 | Caroxazone | 18464-39-6 | Reference compound |
| HY-119775 | U92016A | 136924-88-4 | Reference compound |
| HY-119776 | UBP618 | 1333110-86-3 | Reference compound |
| HY-119779 | Pyridalyl | 179101-81-6 | Reference compound |
| HY-119779R | Pyridalyl (Standard) | 179101-81-6 | Reference Standards |
| HY-119780 | BW1370U87 | 134476-36-1 | Reference compound |
| HY-119782 | L-Argininamide | 2788-83-2 | Peptides |
| HY-119784 | Eupenifeldin | 151803-45-1 | Natural Products |
| HY-119788S | Fenitrothion oxon-d6 | 1185155-54-7 | Isotope-Labeled Compounds |
| HY-119789 | Albofungin | 37895-35-5 | Reference compound |
| HY-119790 | Palmitoyllactic acid | 7795-58-6 | Reference compound |
| HY-119791 | NBD-amine | 10199-91-4 | Reference compound |
| HY-119792A | Neostigmine (hydroxide) | 588-17-0 | Reference compound |
| HY-119793 | Tolnidamine | 50454-68-7 | Reference compound |
| HY-119799 | UK-500001 | 582332-31-8 | Reference compound |
| HY-119802 | Practolol | 6673-35-4 | Reference compound |
| HY-119802R | Practolol (Standard) | 6673-35-4 | Reference Standards |
| HY-119802S | Practolol-d7 | 2714414-11-4 | Isotope-Labeled Compounds |
| HY-119804 | Licopyranocoumarin | 117038-80-9 | Natural Products |
| HY-119806 | TMPPAA | 844900-50-1 | Reference compound |
| HY-119807 | Prosultiamine | 59-58-5 | Reference compound |
| HY-119808 | Terrein | 582-46-7 | Reference compound |
| HY-119809 | Violacein | 548-54-9 | Natural Products |
| HY-119810 | Seletracetam | 357336-74-4 | Reference compound |
| HY-119810A | Seletracetam (lithium) | | Inhibitory Antibodies |
| HY-119810B | Seletracetam (lithium bromide) | 2024584-38-9 | Reference compound |
| HY-119812 | Eugenone | 480-27-3 | Natural Products |
| HY-119813 | (S,S)-Sinogliatin | 1191996-10-7 | Reference compound |
| HY-119815 | Tenonitrozole | 3810-35-3 | Reference compound |
| HY-119816 | Piretanide | 55837-27-9 | Reference compound |
| HY-119816R | Piretanide (Standard) | 55837-27-9 | Reference Standards |
| HY-119817 | Flosequinan | 76568-02-0 | Reference compound |
| HY-119818 | Farnesylthiotriazole | 156604-45-4 | Reference compound |
| HY-119819 | Psicofuranine | 1874-54-0 | Reference compound |
| HY-119820 | Xaliproden (free base) | 135354-02-8 | Reference compound |
| HY-119821 | Terphenyllin | 52452-60-5 | Natural Products |
| HY-119821R | Terphenyllin (Standard) | 52452-60-5 | Reference Standards |
| HY-119822 | Texasin | 897-46-1 | Reference compound |
| HY-119823 | PGP-4008 | 365565-02-2 | Reference compound |
| HY-119824 | Trofosfamide | 22089-22-1 | Reference compound |
| HY-119825 | Sarracine | 2492-09-3 | Natural Products |
| HY-119826 | Quinfamide | 62265-68-3 | Reference compound |
| HY-119827 | Moflomycin | 107430-03-5 | Reference compound |
| HY-119830 | Azaconazole | 60207-31-0 | Reference compound |
| HY-119831 | Rohitukine | 71294-60-5 | Reference compound |
| HY-119832 | Setastine | 64294-95-7 | Reference compound |
| HY-119832B | (S)-Setastine | | Reference compound |
| HY-119833 | Rubone | 73694-15-2 | Reference compound |
| HY-119839 | Acediasulfone | 80-03-5 | Reference compound |
| HY-119840 | Anthragallol | 602-64-2 | Reference compound |
| HY-119842 | ALO1567 | 97677-19-5 | Reference compound |
| HY-119843 | Asterric Acid | 577-64-0 | Reference compound |
| HY-119844 | Anidoxime | 34297-34-2 | Reference compound |
| HY-119844A | Anidoxime (hydrochloride) | 31729-11-0 | Reference compound |
| HY-119845 | Agamanone | 143381-59-3 | Natural Products |
| HY-119846 | Afromosin | 550-79-8 | Natural Products |
| HY-119847 | Abafungin | 129639-79-8 | Reference compound |
| HY-119850 | Aladorian | 865433-00-7 | Reference compound |
| HY-119850A | Aladorian (sodium) | 1233219-11-8 | Reference compound |
| HY-119853 | Bayer A 139 | 800-24-8 | Reference compound |
| HY-119855 | Aildenafil | 496835-35-9 | Reference compound |
| HY-119857 | AGK7 | 304896-21-7 | Reference compound |
| HY-119858 | Acetiromate | 2260-08-4 | Reference compound |
| HY-119859 | Cytochlor | 32387-56-7 | Reference compound |
| HY-119860 | Ataprost | 83997-19-7 | Reference compound |
| HY-119862 | Bupicomide | 22632-06-0 | Reference compound |
| HY-119863 | Barthrin | 70-43-9 | Reference compound |
| HY-119864 | Drinidene | 53394-92-6 | Reference compound |
| HY-119866 | β-Alethine | 646-08-2 | Reference compound |
| HY-119868 | Butaxamine | 2922-20-5 | Reference compound |
| HY-119873 | Celiprolol | 56980-93-9 | Reference compound |
| HY-119873S | Celiprolol-d9 (hydrochloride) | 1215535-20-8 | Isotope-Labeled Compounds |
| HY-119874 | Alkannin | 23444-65-7 | Natural Products |
| HY-119878 | Lobuprofen | 98207-12-6 | Reference compound |
| HY-119881 | Alafosfalin | 60668-24-8 | Reference compound |
| HY-119881R | Alafosfalin (Standard) | 60668-24-8 | Reference Standards |
| HY-119883 | A-61603 (free base） | 750531-54-5 | Reference compound |
| HY-119885 | Amiflamine | 77518-07-1 | Reference compound |
| HY-119885A | (±)-Amiflamine | 77502-96-6 | Reference compound |
| HY-119886 | BMS-986169 | 1801151-08-5 | Reference compound |
| HY-119889 | A1B11 | 1602731-56-5 | Reference compound |
| HY-119890 | Isbogrel | 89667-40-3 | Reference compound |
| HY-119892 | Batracylin | 67199-66-0 | Reference compound |
| HY-119893 | Diamfenetide | 36141-82-9 | Reference compound |
| HY-119893R | Diamfenetide (Standard) | 36141-82-9 | Reference Standards |
| HY-119894 | Althiomycin | 12656-40-5 | Reference compound |
| HY-119896 | Clethodim | 99129-21-2 | Reference compound |
| HY-119896R | Clethodim (Standard) | 99129-21-2 | Reference Standards |
| HY-119898 | Alloocimene | 673-84-7 | Natural Products |
| HY-119899 | BO-0742 | 774234-08-1 | Reference compound |
| HY-119900 | Carnidazole | 42116-76-7 | Reference compound |
| HY-119900R | Carnidazole (Standard) | 42116-76-7 | Reference Standards |
| HY-119900S | Carnidazole-d3 | | Isotope-Labeled Compounds |
| HY-119901 | Eupatarone | 17249-61-5 | Natural Products |
| HY-119902 | Bistrifluron | 201593-84-2 | Reference compound |
| HY-119902R | Bistrifluron (Standard) | 201593-84-2 | Reference Standards |
| HY-119904 | Malaoxon | 1634-78-2 | Reference compound |
| HY-119904R | Malaoxon (Standard) | 1634-78-2 | Reference Standards |
| HY-119906 | Conglobatin | 72263-05-9 | Natural Products |
| HY-119908 | Hetramine | 531-08-8 | Reference compound |
| HY-119909 | GNX-865 | 1223568-82-8 | Reference compound |
| HY-119910 | (E)-Aminoquinol | 529507-84-4 | Reference compound |
| HY-119910B | Aminoquinol (phosphate) | 7195-12-2 | Reference compound |
| HY-119910C | Aminoquinol (triphosphate) | 3653-53-0 | Reference compound |
| HY-119913A | Dacemazine (hydrochloride) | 25384-29-6 | Reference compound |
| HY-119914 | Bromadol | 77239-98-6 | Reference compound |
| HY-119915 | Atrolactamide | 2019-68-3 | Reference compound |
| HY-119917 | Gossypetin | 489-35-0 | Natural Products |
| HY-119918 | Cycrimine | 77-39-4 | Reference compound |
| HY-119919 | Clofenamide | 671-95-4 | Reference compound |
| HY-119921 | Indatraline | 86939-10-8 | Reference compound |
| HY-119926 | 13-Hydroxylupanine | 15358-48-2 | Natural Products |
| HY-119926A | 13-Hydroxylupanine (hydrochloride) | 6809-89-8 | Natural Products |
| HY-119929 | B 669 | 78182-92-0 | Reference compound |
| HY-119931 | 2-Hydroxychalcone | 644-78-0 | Natural Products |
| HY-119932 | PROTAC FAK degrader 1 | 2301916-69-6 | Reference compound |
| HY-119933 | RIPK1-IN-7 | 2300982-44-7 | Reference compound |
| HY-119934 | NaV1.7 inhibitor-1 | 1494585-79-3 | Reference compound |
| HY-119935 | JAK3 covalent inhibitor-1 | 2300106-50-5 | Reference compound |
| HY-119936 | GLPG2451 | 2055015-61-5 | Reference compound |
| HY-119937 | ROCK inhibitor-2 | 1127308-52-4 | Reference compound |
| HY-119938 | Tuberculosis inhibitor 1 | 2230810-28-1 | Reference compound |
| HY-119939 | CHDI-390576 | 1629729-98-1 | Reference compound |
| HY-119940 | MC180295 | 2237942-08-2 | Reference compound |
| HY-119941 | VU0652835 | 1848252-81-2 | Reference compound |
| HY-119942 | c-Fms-IN-8 | 1255303-58-2 | Reference compound |
| HY-119943 | PF-06256142 | 1609583-14-3 | Reference compound |
| HY-119943A | (Rac)-PF-06256142 | 1609580-97-3 | Reference compound |
| HY-119943B | (R)-PF-06256142 | 1609583-15-4 | Reference compound |
| HY-119944 | JND3229 | 2260886-64-2 | Reference compound |
| HY-119945 | Brobactam | 26631-90-3 | Reference compound |
| HY-119945A | Brobactam (sodium) | 73335-78-1 | Reference compound |
| HY-119946 | BF-1 | 518980-66-0 | Reference compound |
| HY-119948 | AKCI | 669750-88-3 | Reference compound |
| HY-119950 | ADCI | 124070-15-1 | Reference compound |
| HY-119953 | BIBN-99 | 145301-48-0 | Reference compound |
| HY-119955 | Amflutizole | 82114-19-0 | Reference compound |
| HY-119956 | Biflorin | 89701-85-9 | Natural Products |
| HY-119960 | AHR-10037 | 78281-73-9 | Reference compound |
| HY-119961 | (+)-Mepivacaine | 24358-84-7 | Reference compound |
| HY-119963A | trans-β-Terpineol | 7299-41-4 | Reference compound |
| HY-119964 | Cetaben | 55986-43-1 | Reference compound |
| HY-119966 | CCT036477 | 305372-78-5 | Reference compound |
| HY-119968 | Granaticin | 19879-06-2 | Reference compound |
| HY-119969 | Diaziquone | 57998-68-2 | Reference compound |
| HY-119970 | Helenalin | 6754-13-8 | Natural Products |
| HY-119971 | BIM5078 | 337506-43-1 | Reference compound |
| HY-119972 | Diloxanide | 579-38-4 | Reference compound |
| HY-119973 | CAY10397 | 78028-01-0 | Reference compound |
| HY-119974 | Caracemide | 81424-67-1 | Reference compound |
| HY-119975 | Carazostatin | 126168-32-9 | Reference compound |
| HY-119976 | Boscalid | 188425-85-6 | Biochemical Assay Reagents |
| HY-119976R | Boscalid (Standard) | 188425-85-6 | Reference Standards |
| HY-119976S | Boscalid-d4 | 2468796-76-9 | Isotope-Labeled Compounds |
| HY-119977 | APF | 359010-70-1 | Reference compound |
| HY-119979 | Cardanol monoene | 501-26-8 | Natural Products |
| HY-119980 | Fluphenazine | 69-23-8 | Reference compound |
| HY-119980A | Fluphenazine (dimaleate) | 3093-66-1 | Reference compound |
| HY-119980B | Fluphenazine (hydrochloride) | 1254-47-3 | Reference compound |
| HY-119980BS | Fluphenazine-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-119980S | Fluphenazine-d8 | 1323633-98-2 | Isotope-Labeled Compounds |
| HY-119981 | Ani9 | 356102-14-2 | Reference compound |
| HY-119982 | Cyclamide | 664-95-9 | Natural Products |
| HY-119983 | 7H-Dibenzo[c,g]carbazole | 194-59-2 | Reference compound |
| HY-119984 | DNP-INT | 69311-70-2 | Reference compound |
| HY-119985 | Broxaterol | 76596-57-1 | Reference compound |
| HY-119987 | Sudan orange G | 2051-85-6 | Dye Reagents |
| HY-119987R | Sudan orange G (Standard) | 2051-85-6 | Dye Reagents |
| HY-119987S | Sudan Orange G-d5 | | Isotope-Labeled Compounds |
| HY-119989 | Cyclopyrimorate | 499231-24-2 | Reference compound |
| HY-11999 | CGI-1746 | 910232-84-7 | Reference compound |
| HY-119990 | Fotocaine | 1612189-10-2 | Reference compound |
| HY-119991 | AHR-9294 | 84023-64-3 | Reference compound |
| HY-119993 | AR03 | 510721-85-4 | Reference compound |
| HY-119994 | DFPM | 301338-95-4 | Reference compound |
| HY-119995 | Chloropyramine | 59-32-5 | Reference compound |
| HY-119996 | AR-C141990 | 873327-59-4 | Reference compound |
| HY-119996A | AR-C141990 (hydrochloride) | 2250019-94-2 | Reference compound |
| HY-119997 | Disulergine | 59032-40-5 | Reference compound |
| HY-12000 | AG490 | 133550-30-8 | Reference compound |
| HY-120000 | MS402 | 1672684-68-2 | Reference compound |
| HY-120002 | Proclonol | 14088-71-2 | Reference compound |
| HY-120004 | PF-06827443 | 2115022-67-6 | Reference compound |
| HY-120006A | (rel)-AR234960 | 1408311-94-3 | Reference compound |
| HY-120007 | JC124 | 1638611-48-9 | Reference compound |
| HY-120009 | Showdomycin | 16755-07-0 | Natural Products |
| HY-12001 | WZ-3146 | 1214265-56-1 | Reference compound |
| HY-120011 | Ro 24-6392 | 131149-63-8 | Reference compound |
| HY-120012 | Mizacorat | 1893415-00-3 | Reference compound |
| HY-120016 | RU 43044 | 136959-96-1 | Reference compound |
| HY-120017 | Befloxatone | 134564-82-2 | Reference compound |
| HY-120018 | VPC-13566 | 218464-59-6 | Reference compound |
| HY-120019 | Ac-YVAD-CHO | 143313-51-3 | Peptides |
| HY-120019A | Ac-YVAD-CHO (acetate) | | Reference compound |
| HY-120020 | LY-395153 | 211313-51-8 | Reference compound |
| HY-120021 | tert-Butyl 4-(1H-indol-4-yl)piperazine-1-carboxylate | 252978-89-5 | Reference compound |
| HY-120023 | VU0453595 | 1432436-13-9 | Reference compound |
| HY-120024 | BMS-986188 | 1776115-10-6 | Reference compound |
| HY-120025 | CRT0105950 | 1661845-86-8 | Reference compound |
| HY-120026 | KB130015 | 147030-48-6 | Reference compound |
| HY-120027 | Kribb3 | 129414-88-6 | Reference compound |
| HY-120028 | GNE-207 | 2158266-58-9 | Reference compound |
| HY-12003 | SNS-314 (mesylate) | 1146618-41-8 | Reference compound |
| HY-120033 | RY796 | 1393441-53-6 | Reference compound |
| HY-120034 | NCGC 607 | 1462267-07-7 | Reference compound |
| HY-120035 | DD1 | 187585-11-1 | Reference compound |
| HY-120036 | Tyrphostin AG1112 | 153150-84-6 | Reference compound |
| HY-120039 | (R)-MDL-101146 | 163660-53-5 | Reference compound |
| HY-120039A | (S)-MDL-101146 | 163660-59-1 | Reference compound |
| HY-120040 | HS94 | 1892594-93-2 | Reference compound |
| HY-120041 | ND-2158 | 1388896-07-8 | Reference compound |
| HY-120043 | KCO912 | 185695-83-4 | Reference compound |
| HY-120044 | L-739749 | 156511-34-1 | Reference compound |
| HY-120045 | DuP 747 | 142515-44-4 | Reference compound |
| HY-120045A | DuP 747 (hydrochloride) | 115904-74-0 | Reference compound |
| HY-120046 | YF479 | 1803281-22-2 | Reference compound |
| HY-120047 | Rutamarin | 13164-05-1 | Natural Products |
| HY-120048 | NBC19 | 2068818-75-5 | Reference compound |
| HY-120049 | TAK-603 | 158146-85-1 | Reference compound |
| HY-12005 | Fingolimod (hydrochloride) | 162359-56-0 | Reference compound |
| HY-120050 | GK470 | 1621517-53-0 | Reference compound |
| HY-120051 | Afizagabar | 1398496-82-6 | Reference compound |
| HY-120056 | YKL-06-061 | 2172617-15-9 | Reference compound |
| HY-120059 | NS4591 | 273930-52-2 | Reference compound |
| HY-12005R | Fingolimod (hydrochloride) (Standard) | 162359-56-0 | Reference Standards |
| HY-120060 | GNF6702 | 1799329-72-8 | Reference compound |
| HY-120062 | TVB-3664 | 2097262-58-1 | Reference compound |
| HY-120066 | Seriniquinone | 22200-69-7 | Reference compound |
| HY-120068 | VU0418506 | 1330624-42-4 | Reference compound |
| HY-120069 | APX2009 | 1415030-15-7 | Reference compound |
| HY-120072 | PF-3450074 | 1352879-65-2 | Reference compound |
| HY-120074 | UBP512 | 1333112-78-9 | Reference compound |
| HY-120075 | TJ191 | 1522415-97-9 | Reference compound |
| HY-120076 | CP-293019 | 179089-90-8 | Reference compound |
| HY-120077 | LY307452 | 174393-13-6 | Reference compound |
| HY-120078 | AZD2716 | 1845753-81-2 | Reference compound |
| HY-120079 | MSN-125 | 1592908-16-1 | Reference compound |
| HY-12008 | Erlotinib (Hydrochloride) | 183319-69-9 | Reference compound |
| HY-120080 | UR-2922 | 220386-56-1 | Reference compound |
| HY-120081 | Metixene | 4969-02-2 | Reference compound |
| HY-120081A | Metixene (hydrochloride hydrate) | 7081-40-5 | Reference compound |
| HY-120081AR | Metixene (hydrochloride hydrate) (Standard) | 7081-40-5 | Reference Standards |
| HY-120081B | Metixene (hydrochloride) | 1553-34-0 | Reference compound |
| HY-120083 | Rodatristat | 1673568-73-4 | Reference compound |
| HY-120084 | BTX161 | 2052301-24-1 | Reference compound |
| HY-120085 | PFE-360 | 1527475-61-1 | Reference compound |
| HY-120086 | RO-5963 | 1416663-77-8 | Reference compound |
| HY-120087 | KG-548 | 175205-09-1 | Reference compound |
| HY-120088 | PF-06446846 | 1632250-49-7 | Reference compound |
| HY-120088A | PF-06446846 (hydrochloride) | 1632250-50-0 | Reference compound |
| HY-12008A | Erlotinib (mesylate) | 248594-19-6 | Reference compound |
| HY-12008R | Erlotinib (Hydrochloride) (Standard) | 183319-69-9 | Reference Standards |
| HY-12008S | Erlotinib-d6 (hydrochloride) | 1189953-78-3 | Isotope-Labeled Compounds |
| HY-12008S1 | Erlotinib-13C6 (hydrochloride) | 1210610-07-3 | Isotope-Labeled Compounds |
| HY-12009 | Pazopanib (Hydrochloride) | 635702-64-6 | Reference compound |
| HY-120090 | MRS1177 | 183721-13-3 | Reference compound |
| HY-120092 | BMT-046091 | 1551401-20-7 | Reference compound |
| HY-120096 | BIBO3304 (free base) | 191868-13-0 | Reference compound |
| HY-120097 | R-10015 | 2097938-51-5 | Reference compound |
| HY-120098 | Vinleurosine | 23360-92-1 | Natural Products |
| HY-120098A | Vinleurosine (sulfate) | 54081-68-4 | Reference compound |
| HY-12009R | Pazopanib (Hydrochloride) (Standard) | 635702-64-6 | Reference Standards |
| HY-12009S | Pazopanib-13C,d3 (hydrochloride) | 1261398-44-0 | Isotope-Labeled Compounds |
| HY-12010 | BMS-599626 (Hydrochloride) | 873837-23-1 | Reference compound |
| HY-120102 | Emicoron | 1422423-23-1 | Reference compound |
| HY-120103 | PF-06649298 | 1854061-16-7 | Reference compound |
| HY-120104 | Nitidanin | 171674-89-8 | Natural Products |
| HY-120105 | NSC666715 | 170747-33-8 | Reference compound |
| HY-120106 | BG14 | 1628784-50-8 | Reference compound |
| HY-120109 | 13-HODE methyl ester | 109837-85-6 | Natural Products |
| HY-12011 | HA14-1 | 65673-63-4 | Reference compound |
| HY-120110 | IOX4 | 1154097-71-8 | Reference compound |
| HY-120111 | MW-150 | 1628502-91-9 | Reference compound |
| HY-120111A | MW-150 hydrochloride | 1923773-01-6 | Reference compound |
| HY-120111B | MW-150 dihydrochloride dihydrate | 1661020-92-3 | Reference compound |
| HY-120113 | SC-2001 | 1383727-17-0 | Reference compound |
| HY-120115 | PARPi-FL | 1380359-84-1 | Dye Reagents |
| HY-120117 | Rumbrin | 148528-19-2 | Reference compound |
| HY-120118 | Metarrestin | 1443414-10-5 | Reference compound |
| HY-12011A | (Rac)-HA14-1 | 927635-64-1 | Reference compound |
| HY-12012 | SB 216763 | 280744-09-4 | Reference compound |
| HY-120122 | PK7088 | 1446352-67-5 | Reference compound |
| HY-120123 | FR181157 | 171046-15-4 | Reference compound |
| HY-120124 | Samelisant | 1394808-20-8 | Reference compound |
| HY-120128 | MTSEA (hydrobromide) | 16599-33-0 | Reference compound |
| HY-12013 | PD153035 (Hydrochloride) | 183322-45-4 | Reference compound |
| HY-120132 | KNI-102 | 139694-65-8 | Reference compound |
| HY-120135 | LTURM 36 | 1879887-94-1 | Reference compound |
| HY-120137 | CMP-5 | 880813-42-3 | Reference compound |
| HY-120138 | BDM31827 | 1388658-04-5 | Reference compound |
| HY-120139 | KMH-233 | 1941174-13-5 | Reference compound |
| HY-120139A | (R)-KMH-233 | 2994330-89-9 | Reference compound |
| HY-12014 | SU11274 | 658084-23-2 | Reference compound |
| HY-120140 | Ganoderic acid DM | 173075-45-1 | Natural Products |
| HY-120142 | EC359 | 2012591-09-0 | Reference compound |
| HY-120144 | SR-8993 | 1594121-16-0 | Reference compound |
| HY-120145 | MST-312 | 368449-04-1 | Reference compound |
| HY-120146 | NNC 05-2090 | 184845-43-0 | Reference compound |
| HY-120147 | Ethiazide | 1824-58-4 | Reference compound |
| HY-120148 | SM19712 (free acid) | 194542-49-9 | Reference compound |
| HY-120148A | SM19712 | 194542-56-8 | Reference compound |
| HY-120149 | Inotodiol | 35963-37-2 | Natural Products |
| HY-12015 | Iniparib | 160003-66-7 | Reference compound |
| HY-120151 | 3,5-Dinitro-p-toluic acid | 16533-71-4 | Reference compound |
| HY-120152A | SLP7111228 (hydrochloride) | 1449768-48-2 | Reference compound |
| HY-120154 | Palitantin | 15265-28-8 | Natural Products |
| HY-120157 | Vif-ElonginC interaction inhibitor 1 | 374679-27-3 | Reference compound |
| HY-120158 | ZD0947 | 172649-40-0 | Reference compound |
| HY-120159 | GS-493 | 1710337-31-7 | Reference compound |
| HY-12016 | KU-55933 | 587871-26-9 | Reference compound |
| HY-120160 | Darglitazone | 141200-24-0 | Reference compound |
| HY-120160A | Darglitazone (Sodium) | 149904-87-0 | Reference compound |
| HY-120161 | AS6 | 1609660-14-1 | Reference compound |
| HY-120164 | Glycerophospho-N-oleoyl ethanolamine | 201738-24-1 | Reference compound |
| HY-120166 | DiFMUP | 214491-43-7 | Reference compound |
| HY-120167 | YM-44778 | 173941-74-7 | Reference compound |
| HY-12017 | PF-04217903 | 956905-27-4 | Reference compound |
| HY-120170 | BMS-466442 | 1598424-76-0 | Reference compound |
| HY-120171 | DH-376 | 1848233-57-7 | Reference compound |
| HY-120173 | Ro 47-3359 | 155144-64-2 | Reference compound |
| HY-120174 | SU200 | 184003-14-3 | Reference compound |
| HY-120175 | Nonaethylene glycol monomethyl ether | 6048-68-6 | Reference compound |
| HY-120177 | KT182 | 1402612-62-7 | Reference compound |
| HY-120178 | (±)7(8)-DiHDPA | 168111-93-1 | Natural Products |
| HY-120179 | LP-922761 | 1454808-95-7 | Reference compound |
| HY-120179A | LP-922761 (hydrate) | | Reference compound |
| HY-12017A | PF-04217903 (mesylate) | 956906-93-7 | Reference compound |
| HY-12017B | PF-04217903 (phenolsulfonate) | 1159490-85-3 | Reference compound |
| HY-12018 | Vatalanib (dihydrochloride) | 212141-51-0 | Reference compound |
| HY-120180 | BMS-188107 | 139232-80-7 | Reference compound |
| HY-120181 | AGI-14100 | 1448346-43-7 | Reference compound |
| HY-120182 | GR 128107 | 190328-44-0 | Reference compound |
| HY-120183 | Harzianopyridone | 137813-88-8 | Natural Products |
| HY-120184 | VU0467485 | 1451994-10-7 | Reference compound |
| HY-120185 | Saintopin | 131190-63-1 | Reference compound |
| HY-120187 | DDCPPB-Glu | 149325-95-1 | Reference compound |
| HY-120188 | CC618 | 1680204-90-3 | Reference compound |
| HY-120189 | LY 233536 | 136845-59-5 | Reference compound |
| HY-12018A | Vatalanib (hydrochloride) | 212141-52-1 | Reference compound |
| HY-12019 | SGX-523 | 1022150-57-7 | Reference compound |
| HY-120190 | Citreoindole | 138655-14-8 | Reference compound |
| HY-120192 | CGP 62349 | 187608-26-0 | Reference compound |
| HY-120196 | CPI703 | 1904649-00-8 | Reference compound |
| HY-120197 | 17-Phenyl trinor prostaglandin F2α methyl amide | 155206-01-2 | Reference compound |
| HY-120198 | Naftypramide | 1505-95-9 | Reference compound |
| HY-12020 | TW-37 | 877877-35-5 | Reference compound |
| HY-120200 | YF-452 | 1951466-83-3 | Reference compound |
| HY-120201 | 7-Hydroxy coumarin glucuronide (sodium) | 168286-98-4 | Reference compound |
| HY-120201S | 7-Hydroxy Coumarin-d5 β-D-glucuronide (sodium) | | Isotope-Labeled Compounds |
| HY-120203 | DA 1131 | 169285-98-7 | Reference compound |
| HY-120204 | BI8626 | 1875036-75-1 | Reference compound |
| HY-120205 | A-119637 | 255713-47-4 | Reference compound |
| HY-120206 | Brasofensine | 171655-91-7 | Reference compound |
| HY-120206A | Brasofensine (maleate) | 173830-14-3 | Reference compound |
| HY-120206B | Brasofensine (sulfate) | 171655-92-8 | Reference compound |
| HY-120207 | (R)-GDC-0927 | 1642297-53-7 | Reference compound |
| HY-120208 | MK204 | 1959605-73-2 | Reference compound |
| HY-120209 | Pigment Yellow 13 | 5102-83-0 | Reference compound |
| HY-120210 | XY018 | 1873358-87-2 | Reference compound |
| HY-120213 | YH-306 | 1373764-75-0 | Reference compound |
| HY-120214 | TAS05567 | 1429038-15-2 | Reference compound |
| HY-120215 | KT203 | 1402612-64-9 | Reference compound |
| HY-120217 | VH032 | 1448188-62-2 | Reference compound |
| HY-120219 | TU-2100 | 207972-39-2 | Reference compound |
| HY-12022 | 3-Aminobenzamide | 3544-24-9 | Reference compound |
| HY-120220 | Piposulfan | 2608-24-4 | Reference compound |
| HY-120221 | SE 175 | 258278-64-7 | Reference compound |
| HY-120223 | BMS-196085 | 170686-10-9 | Reference compound |
| HY-120225 | NJK14047 | 1800576-41-3 | Reference compound |
| HY-120226A | VU714 (oxalate) | 474625-52-0 | Reference compound |
| HY-120229 | GGTI-2147 | 191102-87-1 | Reference compound |
| HY-12023 | GTx-007 | 401900-40-1 | Reference compound |
| HY-120231 | Z-VRPR-FMK | 1381885-28-4 | Reference compound |
| HY-120232 | ABT-963 | 266320-83-6 | Reference compound |
| HY-120233 | MK-8876 | 1426960-33-9 | Reference compound |
| HY-120234 | Z-LLNle-CHO | 133407-83-7 | Peptides |
| HY-120236 | KSCM-5 | 1415247-18-5 | Reference compound |
| HY-120237 | m-PEG7-Amine | 170572-38-0 | ADC Related |
| HY-120238 | RG 13647 | 145543-03-9 | Reference compound |
| HY-120239 | Ro 63-0563 | 202466-77-1 | Reference compound |
| HY-12024 | Alvespimycin (hydrochloride) | 467214-21-7 | Reference compound |
| HY-120240 | AND-302 | 1380201-88-6 | Reference compound |
| HY-120241 | Reticulol | 26246-41-3 | Natural Products |
| HY-120242 | N-(3-Oxobutanoyl)-L-homoserine lactone | 148433-27-6 | Reference compound |
| HY-120243 | L-Ibotenic acid | 25690-45-3 | Reference compound |
| HY-120245 | GSK-340 | 2222509-79-5 | Reference compound |
| HY-120248 | FR221647 | 256461-28-6 | Reference compound |
| HY-12025 | Serdemetan | 881202-45-5 | Reference compound |
| HY-120251 | Leteprinim | 138117-50-7 | Reference compound |
| HY-120251A | Leteprinim (potassium) | 192564-13-9 | Reference compound |
| HY-120252 | ABC44 | 1831135-46-6 | Reference compound |
| HY-120253 | Spirotetramat | 203313-25-1 | Reference compound |
| HY-120253R | Spirotetramat (Standard) | 203313-25-1 | Reference Standards |
| HY-120255 | 17(R)-HDHA | 155976-53-7 | Reference compound |
| HY-120255A | 17(S)-HDHA | 92693-03-3 | Reference compound |
| HY-120255AS | 17(S)-HDHA-d5 | 2738376-87-7 | Isotope-Labeled Compounds |
| HY-120256 | Corynecin II | 35098-52-3 | Biochemical Assay Reagents |
| HY-120258 | Tr-PEG3-OH | 133699-09-9 | ADC Related |
| HY-12026 | WZ4002 | 1213269-23-8 | Reference compound |
| HY-120261 | GB-88 | 1416435-96-5 | Reference compound |
| HY-120264 | YPC-22026 | 1964457-41-7 | Reference compound |
| HY-120265 | MIPS-9922 | 1416956-33-6 | Reference compound |
| HY-120267 | TID43 | 19231-60-8 | Reference compound |
| HY-120268 | SLM6031434 | 1897379-33-7 | Reference compound |
| HY-120268A | SLM6031434 (hydrochloride) | 1897379-34-8 | Reference compound |
| HY-120269 | CAY10512 | 139141-12-1 | Reference compound |
| HY-120270 | PF-06679142 | 1467059-66-0 | Reference compound |
| HY-120271 | GGTI-297 | 181045-83-0 | Reference compound |
| HY-120272 | SMAP-2 | 1809068-70-9 | Reference compound |
| HY-120273 | Glucocorticoids receptor agonist 3 | 305821-96-9 | Reference compound |
| HY-120274 | Balcinrenone | 1850385-64-6 | Reference compound |
| HY-120275 | CYD-2-11 | 1425944-22-4 | Reference compound |
| HY-120276 | Golexanolone | 2089238-18-4 | Reference compound |
| HY-120277 | TIPP | 146369-65-5 | Reference compound |
| HY-120278 | 4-Ethoxyquinazoline | 16347-96-9 | Reference compound |
| HY-120279A | CFI-400437 | 1169211-37-3 | Reference compound |
| HY-12028 | PD98059 | 167869-21-8 | Reference compound |
| HY-120284 | CCCI-01 | 215778-97-5 | Reference compound |
| HY-120285 | M-0002 (hydrochloride) | 285559-03-7 | Reference compound |
| HY-120286 | K-13 | 108890-90-0 | Natural Products |
| HY-120287 | L-054522 | 214348-67-1 | Reference compound |
| HY-120288 | AM4299B | 160825-49-0 | Reference compound |
| HY-12029 | WZ8040 | 1214265-57-2 | Reference compound |
| HY-120290 | PU141 | 168334-34-7 | Reference compound |
| HY-120293 | CB30900 | 145788-82-5 | Reference compound |
| HY-120294 | Chrysin 6-C-glucoside 8-C-arabinoside | 185145-34-0 | Reference compound |
| HY-120295 | A-192621 | 195529-54-5 | Reference compound |
| HY-120296 | 5-Methylurapidil | 34661-85-3 | Reference compound |
| HY-120297 | S 9788 | 140945-01-3 | Reference compound |
| HY-120298 | LY-510929 | 401789-93-3 | Reference compound |
| HY-120299 | KC01 | 1646795-59-6 | Reference compound |
| HY-12030 | PIK-90 | 677338-12-4 | Reference compound |
| HY-120300 | UCM710 | 213738-77-3 | Reference compound |
| HY-120301 | L-366682 | 127819-96-9 | Reference compound |
| HY-120302 | PD 140376 | 149027-97-4 | Reference compound |
| HY-120303 | LY269415 | 132392-65-5 | Reference compound |
| HY-120306 | HHL-6 | 1215093-76-7 | Reference compound |
| HY-120308 | (R)-Nolpitantium | 154728-59-3 | Reference compound |
| HY-120309 | BMY 42393 | 136451-58-6 | Reference compound |
| HY-12031 | U0126-EtOH | 1173097-76-1 | Reference compound |
| HY-120311 | Benadrostin | 117241-60-8 | Natural Products |
| HY-120312 | PCTR3 | 1810710-69-0 | Reference compound |
| HY-120313 | SN23862 | 142439-61-0 | Reference compound |
| HY-120314 | GEA 3162 | 144576-10-3 | Reference compound |
| HY-120315 | Nyssoside | 182138-70-1 | Natural Products |
| HY-120316 | AB3127-C | 139159-01-6 | Reference compound |
| HY-120317 | CPTH2-Alkyne | 1613116-16-7 | Reference compound |
| HY-120318 | Zeaxanthin | 144-68-3 | Natural Products |
| HY-12031A | U0126 | 109511-58-2 | Reference compound |
| HY-12031B | (2Z,3Z)-U0126 | 218601-62-8 | Reference compound |
| HY-12032 | AG14361 | 328543-09-5 | Reference compound |
| HY-120322 | MK-0969 | 203321-88-4 | Reference compound |
| HY-120323 | DRI-C21045 | 2101765-81-3 | Reference compound |
| HY-120325 | DHMPA | 18684-28-1 | Reference compound |
| HY-120327 | KY-226 | 1621673-53-7 | Reference compound |
| HY-120329 | Lu 26-046 | 143756-51-8 | Reference compound |
| HY-12033 | 2-Methoxyestradiol | 362-07-2 | Natural Products |
| HY-120330 | Nek2-IN-5 | 1507367-00-1 | Reference compound |
| HY-120331 | U-89360E | 161897-65-0 | Reference compound |
| HY-120332 | Sonlicromanol (hydrochloride) | 2162149-24-6 | Reference compound |
| HY-120333 | Antibiotic PF 1052 | 147317-15-5 | Natural Products |
| HY-120337 | V-11-0711 | 1428339-47-2 | Reference compound |
| HY-120338 | RYL-552 | 1801444-56-3 | Reference compound |
| HY-12033S | 2-Methoxyestradiol-13C,d3 | 1217470-09-1 | Isotope-Labeled Compounds |
| HY-12033S1 | 2-Methoxyestradiol-13C6 | | Isotope-Labeled Compounds |
| HY-12033S2 | 2-Methoxyestradiol-d5 | 358731-34-7 | Isotope-Labeled Compounds |
| HY-12034 | WYE-354 | 1062169-56-5 | Reference compound |
| HY-120343 | GSK106 | 1652591-82-6 | Reference compound |
| HY-120346 | PBK-IN-9 | 1338540-55-8 | Reference compound |
| HY-120348 | ML67-33 | 1443290-89-8 | Reference compound |
| HY-120349 | LL-Z1640-4 | 66018-41-5 | Reference compound |
| HY-12035 | AMG-208 | 1002304-34-8 | Reference compound |
| HY-120350 | BI-1347 | 2163056-91-3 | Reference compound |
| HY-120354 | YU142670 | 133847-06-0 | Reference compound |
| HY-120355 | AP14145 | 1446770-54-2 | Reference compound |
| HY-120355A | AP14145 (hydrochloride) | 2387505-59-9 | Reference compound |
| HY-120356 | T-1101 | 1438638-83-5 | Reference compound |
| HY-120356A | T-1101 (tosylate) | 2250404-95-4 | Reference compound |
| HY-120356S1 | T-1101-d7 | | Isotope-Labeled Compounds |
| HY-120357 | Ascrolimus | 148147-65-3 | Reference compound |
| HY-120358 | L-6424 | 147030-50-0 | Reference compound |
| HY-12036 | GSK1059615 | 958852-01-2 | Reference compound |
| HY-120360 | CB-64D | 157752-20-0 | Reference compound |
| HY-120366 | WCK-5153 | 1452460-79-5 | Reference compound |
| HY-120367 | DTP348 | 1383370-92-0 | Reference compound |
| HY-120368 | Fluorescein-PEG4-acid | 1807518-76-8 | Reference compound |
| HY-120369 | URB532 | 195140-79-5 | Reference compound |
| HY-12037 | Rigosertib (sodium) | 592542-60-4 | Reference compound |
| HY-120371 | CPUY192018 | 1567836-15-0 | Reference compound |
| HY-120373 | MB710 | 2230044-57-0 | Reference compound |
| HY-120374 | V-PYRRO/NO | 179344-98-0 | Reference compound |
| HY-120375 | LUF7346 | 1821638-40-7 | Reference compound |
| HY-120376 | XZH-5 | 1360562-98-6 | Reference compound |
| HY-120377 | CYP1A1 inhibitor 8a | 1821136-07-5 | Reference compound |
| HY-12037A | Rigosertib | 592542-59-1 | Reference compound |
| HY-12038 | Ki8751 | 228559-41-9 | Reference compound |
| HY-120380 | FeTMPyP | 133314-07-5 | Reference compound |
| HY-120381 | PD 136450 | 139067-52-0 | Reference compound |
| HY-120382 | LY 215890 | 153502-35-3 | Reference compound |
| HY-120383 | Amicetin | 17650-86-1 | Natural Products |
| HY-120384 | AZD-0284 | 2101291-07-8 | Reference compound |
| HY-120386 | LY382884 | 211566-75-5 | Reference compound |
| HY-120387 | SMU-B | 1253286-90-6 | Reference compound |
| HY-120388 | Irganox 1330 | 1709-70-2 | Reference compound |
| HY-120388R | Irganox 1330 (Standard) | 1709-70-2 | Reference Standards |
| HY-12039 | Lyn-IN-1 | 887650-05-7 | Reference compound |
| HY-120390 | L 694746 | 139934-80-8 | Reference compound |
| HY-120391 | LiLo | 134439-56-8 | Reference compound |
| HY-120394 | TVB-3166 | 1533438-83-3 | Reference compound |
| HY-120395 | UC-514321 | 299420-83-0 | Reference compound |
| HY-120396 | LY 293284 | 141318-62-9 | Reference compound |
| HY-120397 | Bis-propargyl-PEG4 | 159428-42-9 | Reference compound |
| HY-120398 | CH5447240 | 1253919-92-4 | Reference compound |
| HY-12040 | Elesclomol | 488832-69-5 | Reference compound |
| HY-120400 | KDM5-C70 | 1596348-32-1 | Reference compound |
| HY-120401 | Glybuzole | 1492-02-0 | Reference compound |
| HY-120402 | BMS-200 | 1675203-82-3 | Reference compound |
| HY-120405 | RS-12254 | 137550-79-9 | Reference compound |
| HY-120407 | Looplure | 14959-86-5 | Reference compound |
| HY-120408 | (±)-Scopolamine | 138-12-5 | Natural Products |
| HY-12041 | SP600125 | 129-56-6 | Reference compound |
| HY-120411 | Sadopine | 111127-62-9 | Reference compound |
| HY-120415 | RK 397 | 154396-73-3 | Reference compound |
| HY-120417 | JP-153 | 1802937-26-3 | Reference compound |
| HY-120418 | L-687306 | 133444-98-1 | Reference compound |
| HY-120419 | PF9601N | 133845-63-3 | Reference compound |
| HY-12042 | Pimasertib | 1236699-92-5 | Reference compound |
| HY-120420 | N4Py | 167695-87-6 | Reference compound |
| HY-120421 | SW116 (free base) | 1036759-00-8 | Reference compound |
| HY-120422S | N-Desmethyl Regorafenib-d3 | | Isotope-Labeled Compounds |
| HY-120423 | AM-6538 | 1245626-00-9 | Reference compound |
| HY-120425 | Ethiprole | 181587-01-9 | Reference compound |
| HY-120425R | Ethiprole (Standard) | 181587-01-9 | Reference Standards |
| HY-120426 | MMDPPO | 146322-08-9 | Reference compound |
| HY-120427 | Cosalane | 154212-56-3 | Reference compound |
| HY-120428 | VU0410425 | 1341167-72-3 | Reference compound |
| HY-120429 | SKLB-163 | 1255099-06-9 | Reference compound |
| HY-12042A | Pimasertib (hydrochloride) | 1236361-78-6 | Reference compound |
| HY-12043 | SB 525334 | 356559-20-1 | Reference compound |
| HY-120430 | HO-PEG14-OH | 1189112-05-7 | Reference compound |
| HY-120431 | RE 1492 | 112169-14-9 | Reference compound |
| HY-120432 | CaMdr1p-IN-1 | 1257542-38-3 | Reference compound |
| HY-120435 | Tyrothricin | 1404-88-2 | Natural Products |
| HY-120436 | RM 49 | 113785-48-1 | Reference compound |
| HY-120438 | TASP0415914 | 1292300-75-4 | Reference compound |
| HY-12044 | Cabozantinib (S-malate) | 1140909-48-3 | Reference compound |
| HY-120441 | CAY10590 | 1101136-50-8 | Reference compound |
| HY-120442 | (±)16(17)-DiHDPA | 1345275-27-5 | Reference compound |
| HY-120444 | MS0124 | 1197196-63-6 | Reference compound |
| HY-120446 | Thiocystine | 14172-54-4 | Reference compound |
| HY-120448 | QTX125 | 1279698-31-5 | Reference compound |
| HY-120448A | QTX125 (TFA) | 2989537-78-0 | Reference compound |
| HY-120449 | AZ4800 | 1226886-78-7 | Reference compound |
| HY-12044R | Cabozantinib (S-malate) (Standard) | 1140909-48-3 | Reference Standards |
| HY-12045 | HMN-214 | 173529-46-9 | Reference compound |
| HY-120450 | CL-55 | 1370706-59-4 | Reference compound |
| HY-120451 | Salvinone | 124681-15-8 | Natural Products |
| HY-120454 | G-479 | 1168092-22-5 | Reference compound |
| HY-120455 | PD 125967 | 128139-14-0 | Reference compound |
| HY-120456 | SR16835 | 1207195-45-6 | Reference compound |
| HY-120458 | LCAHA | 117094-40-3 | Reference compound |
| HY-120459 | Rs-029 | 110230-95-0 | Reference compound |
| HY-12046 | PIK-93 | 593960-11-3 | Reference compound |
| HY-120460 | 8(R)-HETE | 105500-09-2 | Reference compound |
| HY-120462 | Genz-669178 | 1254834-91-7 | Reference compound |
| HY-120463 | R8605 | 119306-51-3 | Reference compound |
| HY-120464 | PF-05212377 | 1226793-34-5 | Reference compound |
| HY-120465 | ZINC36617540 | 1174905-91-9 | Reference compound |
| HY-120467 | Bima SA | 1175838-84-2 | Reference compound |
| HY-120468 | GSK2263167 | 1165924-28-6 | Reference compound |
| HY-120469 | 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide | 1258292-64-6 | Reference compound |
| HY-12047 | Ponatinib | 943319-70-8 | Reference compound |
| HY-120471 | AM-0687 | 1259522-94-5 | Reference compound |
| HY-120474 | Ro 23-0364 | 98601-60-6 | Reference compound |
| HY-120475 | PBT434 | 1232841-78-9 | Reference compound |
| HY-120475A | PBT434 (mesylate) | 2387898-69-1 | Reference compound |
| HY-120476 | JNJ-39729209 | 1160606-90-5 | Reference compound |
| HY-120478 | ASP6432 | 1282549-08-9 | Reference compound |
| HY-120479 | Cythioate | 115-93-5 | Reference compound |
| HY-12047R | Ponatinib (Standard) | 943319-70-8 | Reference Standards |
| HY-12047S | Ponatinib-d8 | 1562993-37-6 | Isotope-Labeled Compounds |
| HY-12048 | Chelerythrine (chloride) | 3895-92-9 | Natural Products |
| HY-120481 | JNJ-40413269 | 1184847-16-2 | Reference compound |
| HY-120482 | CHM-1-P-Na | 1207854-61-2 | Reference compound |
| HY-120485 | Raxofelast | 128232-14-4 | Reference compound |
| HY-120486 | LY203647 | 122009-61-4 | Reference compound |
| HY-120487 | VUF8507 | 112575-48-1 | Reference compound |
| HY-120489 | A110 | 1185388-35-5 | Reference compound |
| HY-12048R | Chelerythrine (chloride) (Standard) | 3895-92-9 | Reference Standards |
| HY-12049 | CCT129202 | 942947-93-5 | Reference compound |
| HY-120490 | NMK-TD-100 | 1252802-38-2 | Reference compound |
| HY-120491 | L 722151 | 122841-09-2 | Reference compound |
| HY-120492 | RS-21314 | 125709-03-7 | Reference compound |
| HY-120494 | sEH inhibitor-1 | 1208549-68-1 | Reference compound |
| HY-120495 | EP6 | 1353567-32-4 | Reference compound |
| HY-120496 | Clofutriben | 1204178-50-6 | Reference compound |
| HY-120497 | PKCζ-IN-1 | 1132609-87-0 | Reference compound |
| HY-120498 | RS-64459-193 | 123882-89-3 | Reference compound |
| HY-120499 | AZD8542 | 1126366-36-6 | Reference compound |
| HY-12050 | CP-673451 | 343787-29-1 | Reference compound |
| HY-120500 | 16-[[2-(Methylamino)-2-oxoacetyl]amino]-11Z-hexadecenoic acid | 1235543-17-5 | Reference compound |
| HY-120501 | B022 | 1202764-53-1 | Reference compound |
| HY-120502 | 5-LOX-IN-6 | 1159576-98-3 | Reference compound |
| HY-120504 | N-Acetyltyramine | 1202-66-0 | Reference compound |
| HY-120506 | L-366811 | 127819-95-8 | Reference compound |
| HY-120508 | Pivanex | 122110-53-6 | Reference compound |
| HY-120511 | KNT-127 | 1256921-89-7 | Reference compound |
| HY-120512 | 5-Phenyl-4E-pentenol | 13159-16-5 | Dye Reagents |
| HY-120514 | JNc-440 | 1119503-63-7 | Reference compound |
| HY-120515 | 7-Oxostaurosporine | 125035-83-8 | Reference compound |
| HY-120516 | CDE-096 | 1228357-04-7 | Reference compound |
| HY-120519 | L-665871 | 123788-05-6 | Reference compound |
| HY-120520 | Caylin-1 | 1207480-88-3 | Reference compound |
| HY-120521 | Urodilatin | 115966-23-9 | Peptides |
| HY-120522 | L-659877 | 125989-12-0 | Reference compound |
| HY-120523 | UBP646 | 1333213-35-6 | Reference compound |
| HY-120524 | CGP 31358 | 125652-47-3 | Reference compound |
| HY-120527 | VU0463841 | 1439095-16-5 | Reference compound |
| HY-120528 | GB-110 | 1252806-70-4 | Reference compound |
| HY-120528A | GB-110 (hydrochloride) | | Reference compound |
| HY-120529 | Aciculatin | 134044-97-6 | Natural Products |
| HY-12053 | Vinorelbine | 71486-22-1 | Natural Products |
| HY-120530 | JNJ-46281222 | 1254980-38-5 | Reference compound |
| HY-120531 | UR-PI376 | 1192559-94-6 | Reference compound |
| HY-120533 | Syk-IN-11 | 1194954-83-0 | Reference compound |
| HY-120535 | RS 30026 | 127683-04-9 | Reference compound |
| HY-120536 | HPi1 | 13080-21-2 | Reference compound |
| HY-120537 | m-PEG5-CH2COOH | 16142-03-3 | ADC Related |
| HY-120538 | CPG-52364 | 1093135-60-4 | Reference compound |
| HY-120539 | Enofelast | 125722-16-9 | Reference compound |
| HY-12053A | Vinorelbine (ditartrate) | 125317-39-7 | Natural Products |
| HY-12053AR | Vinorelbine (ditartrate) (Standard) | 125317-39-7 | Reference Standards |
| HY-12053AS | Vinorelbine-d3 (ditartrate) | | Isotope-Labeled Compounds |
| HY-12054 | Hesperadin | 422513-13-1 | Reference compound |
| HY-120541 | ST-1006 | 1196994-11-2 | Reference compound |
| HY-120541A | ST-1006 (Maleate) | 1196994-12-3 | Reference compound |
| HY-120542 | SR 1824 | 1338259-06-5 | Reference compound |
| HY-120544 | BAY-386 | 1256941-06-6 | Reference compound |
| HY-120546 | Ulixacaltamide | 1199236-64-0 | Reference compound |
| HY-120546S | Ulixacaltamide-d9 (hydrochloride) | 1346604-21-4 | Isotope-Labeled Compounds |
| HY-120547 | UCB-11056 | 127390-77-6 | Reference compound |
| HY-120548 | KBU2046 | 1143863-69-7 | Reference compound |
| HY-12054A | Hesperadin (hydrochloride) | | Reference compound |
| HY-12055 | BIX02188 | 334949-59-6 | Reference compound |
| HY-120550 | RS 49676 | 111962-89-1 | Reference compound |
| HY-120551 | Fructigenine A | 144606-96-2 | Natural Products |
| HY-120553 | B-355252 | 1261576-81-1 | Reference compound |
| HY-120555 | Texaline | 115070-72-9 | Reference compound |
| HY-120556 | tetranor-12(R)-HETE | 135271-51-1 | Reference compound |
| HY-120559 | GSK-2250665A | 1246030-96-5 | Reference compound |
| HY-12056 | BIX02189 | 1265916-41-3 | Reference compound |
| HY-120560 | OMDM169 | 130193-44-1 | Reference compound |
| HY-120561 | PC-046 | 1202401-59-9 | Reference compound |
| HY-120563 | LY135305 | 123199-75-7 | Reference compound |
| HY-120564 | BMS-763534 | 1188407-40-0 | Reference compound |
| HY-120565 | WB403 | 1594041-84-5 | Reference compound |
| HY-120566 | PSB-16131 | 1213268-80-4 | Reference compound |
| HY-120567 | VU0400195 | 1309434-83-0 | Reference compound |
| HY-120568 | M4284 | 1373346-85-0 | Reference compound |
| HY-12056A | (E/Z)-BIX02189 | 1094614-85-3 | Biochemical Assay Reagents |
| HY-12057 | Vemurafenib | 918504-65-1 | Reference compound |
| HY-120570 | WN1316 | 1356959-71-1 | Reference compound |
| HY-120571 | L-674573 | 127481-29-2 | Reference compound |
| HY-120572 | PI-091 | 129051-63-4 | Natural Products |
| HY-120574 | TH1338 | 1258494-60-8 | Reference compound |
| HY-120576 | ML169 | 1222878-02-5 | Reference compound |
| HY-120577 | BA 41899 | 166020-57-1 | Reference compound |
| HY-120579 | A 53868A | 116198-48-2 | Reference compound |
| HY-12057R | Vemurafenib (Standard) | 918504-65-1 | Reference Standards |
| HY-12057S | Vemurafenib-d5 | 1365986-90-8 | Isotope-Labeled Compounds |
| HY-12057S1 | Vemurafenib-d7 | 1365986-73-7 | Isotope-Labeled Compounds |
| HY-12058 | AZD8330 | 869357-68-6 | Reference compound |
| HY-120581 | ML388 | 1537192-31-6 | Reference compound |
| HY-120583 | (Rac)-LY 255262 | 106892-82-4 | Reference compound |
| HY-120585 | L-365209 | 122211-30-7 | Reference compound |
| HY-120586 | SC-46944 | 120729-15-9 | Reference compound |
| HY-120587 | Bis-PEG6-acid | 119189-70-7 | Reference compound |
| HY-120588 | BI 639667 | 1295298-26-8 | Reference compound |
| HY-120589 | VU0360172 | 1310012-12-4 | Reference compound |
| HY-12059 | AT7867 | 857531-00-1 | Reference compound |
| HY-120590 | Ruserontinib | 1350544-93-2 | Reference compound |
| HY-120594 | R78206 | 124436-97-1 | Reference compound |
| HY-120595 | JNJ-49095397 | 1220626-82-3 | Reference compound |
| HY-120596 | PPARδ/γ agonist 1 (sodium) | 1258076-66-2 | Reference compound |
| HY-120597 | SAK3 | 1256269-87-0 | Reference compound |
| HY-120598 | ASP7657 (free base) | 1196045-28-9 | Reference compound |
| HY-120599 | Sabizabulin | 1332881-26-1 | Reference compound |
| HY-120599A | Sabizabulin (hydrochloride) | 2635953-17-0 | Reference compound |
| HY-12059A | AT7867 (dihydrochloride) | 1431697-86-7 | Reference compound |
| HY-12059B | AT7867 (hydrochloride) | 2624336-89-4 | Reference compound |
| HY-12060 | KRN-633 | 286370-15-8 | Reference compound |
| HY-120600 | Sibiriline | 1346526-26-8 | Reference compound |
| HY-120601 | Alizarin Red S (sodium) | 130-22-3 | Dye Reagents |
| HY-120601A | Alizarin Red S | 83-61-4 | Reference compound |
| HY-120602 | WWL229 | 1338575-28-2 | Reference compound |
| HY-120604 | BVB808 | 1414587-22-6 | Reference compound |
| HY-120606 | A-78773 | 141579-67-1 | Reference compound |
| HY-120607 | Chevalone C | 1318025-77-2 | Natural Products |
| HY-120608 | BMS-814580 | 1197420-11-3 | Reference compound |
| HY-120609 | BMS-902483 | 1192810-88-0 | Reference compound |
| HY-12061 | KU-60019 | 925701-46-8 | Reference compound |
| HY-120611 | BMS-960 (free base) | 1265321-86-5 | Reference compound |
| HY-120611A | BMS-960 | 1265323-40-7 | Reference compound |
| HY-120613 | BMS-986187 | 684238-37-7 | Reference compound |
| HY-120614 | BMS-186511 | 167467-53-0 | Reference compound |
| HY-120619 | BMS-193885 | 186185-03-5 | Reference compound |
| HY-12062 | PD318088 | 391210-00-7 | Reference compound |
| HY-120620 | BMS-195270 | 202822-23-9 | Reference compound |
| HY-120622 | BMS-243117 | 225521-80-2 | Reference compound |
| HY-120623 | BMS-284640 | 230640-88-7 | Reference compound |
| HY-120625 | BMS-358233 | 601519-75-9 | Reference compound |
| HY-120628 | BMS-587101 | 509083-77-6 | Reference compound |
| HY-120629 | BMS-639623 | 675122-44-8 | Reference compound |
| HY-12063 | PHT-427 | 1191951-57-1 | Reference compound |
| HY-120631A | BMS-538305 (hydrochloride) | 841302-51-0 | Reference compound |
| HY-120632 | BMS-433771 | 543700-68-1 | Reference compound |
| HY-120632A | BMS-433771 (dihydrochloride hydrate) | 543700-67-0 | Reference compound |
| HY-120633 | BMS-986104 | 1622180-31-7 | Reference compound |
| HY-120633A | BMS-986104 (hydrochloride) | 1622180-39-5 | Reference compound |
| HY-120634 | BMS-929075 | 1217338-97-0 | Reference compound |
| HY-120635 | BMS-1001 (hydrochloride) | 2113650-04-5 | Reference compound |
| HY-120636 | P2Y1 antagonist 1 | 1555697-67-0 | Reference compound |
| HY-120637 | BMS-986034 | 1492631-88-5 | Reference compound |
| HY-120638 | BMS-250749 | 406913-72-2 | Reference compound |
| HY-120639 | BMS-663749 lysine | 864953-34-4 | Reference compound |
| HY-120640 | BMS-605541 | 639858-32-5 | Reference compound |
| HY-120643 | BMS-823778 (hydrochloride) | 1140898-87-8 | Reference compound |
| HY-120643A | BMS-823778 | 1140897-32-0 | Reference compound |
| HY-120644 | BMS-919373 | 1272353-82-8 | Reference compound |
| HY-120645 | BMS-986122 | 313669-88-4 | Reference compound |
| HY-120646 | BMS-242 | 1675204-51-9 | Reference compound |
| HY-120647 | BMS-1001 | 2113650-03-4 | Reference compound |
| HY-120648 | CAY 10434 | 769917-29-5 | Reference compound |
| HY-120648A | CAY 10462 (dihydrochloride) | 502656-68-0 | Reference compound |
| HY-120649 | SKM 4-45-1 | 290374-09-3 | Reference compound |
| HY-120650 | CAY10435 | 288862-73-7 | Reference compound |
| HY-120651 | LDL-IN-2 | 778624-05-8 | Reference compound |
| HY-120652 | A3AR antagonist 3 | 863202-33-9 | Reference compound |
| HY-120653 | CB1 antagonist 5 | 878533-35-8 | Reference compound |
| HY-120654 | [1,1′:4′,1′′-Terphenyl]-3,4′′,5-triol | 890854-82-7 | Reference compound |
| HY-120656 | Prostaglandin K2 | 275816-51-8 | Reference compound |
| HY-120657 | 9-PAHSA | 1481636-31-0 | Reference compound |
| HY-120657R | 9-PAHSA (Standard) | 1481636-31-0 | Reference Standards |
| HY-120657S | 9-PAHSA-d4 | 2704278-85-1 | Isotope-Labeled Compounds |
| HY-120657S1 | 9-PAHSA-d31 | | Isotope-Labeled Compounds |
| HY-120658 | (Rac)-LY193239 | 122548-63-4 | Reference compound |
| HY-120659 | Gly-Gly-AMC | 208645-74-3 | Dye Reagents |
| HY-12066 | GSK1292263 | 1032823-75-8 | Reference compound |
| HY-120661 | T-1840383 | 1195779-24-8 | Reference compound |
| HY-120662 | GSK1331268 | 1207197-70-3 | Reference compound |
| HY-120663 | KRCA-0713 | 1884321-89-4 | Reference compound |
| HY-120664 | BRD50837 | 1314295-24-3 | Reference compound |
| HY-120665 | Prostaglandin B1 | 13345-51-2 | Natural Products |
| HY-120666 | TAMRA-PEG4-Alkyne | 1225057-68-0 | Dye Reagents |
| HY-120667 | DS-5272 | 1235575-97-9 | Reference compound |
| HY-120669 | PF-06761281 | 1854061-19-0 | Reference compound |
| HY-12067 | R406 | 841290-81-1 | Reference compound |
| HY-120672 | LG 83-6-05 | 131602-24-9 | Reference compound |
| HY-120673 | SQ 32970 | 122280-12-0 | Reference compound |
| HY-120675 | SSTC3 | 1242422-09-8 | Reference compound |
| HY-120676 | B-Raf IN 18 | 1244644-50-5 | Reference compound |
| HY-120677 | AHR-15010 | 132031-90-4 | Reference compound |
| HY-120678 | DBCO-PEG4-acid | 2110448-99-0 | Reference compound |
| HY-120679 | XK469 | 157435-10-4 | Reference compound |
| HY-12068 | PI3K-IN-1 | 1349796-36-6 | Reference compound |
| HY-120682 | UH-AH 37 | 120382-14-1 | Reference compound |
| HY-120684 | PDE10-IN-6 | 1207549-69-6 | Reference compound |
| HY-120685 | WAY-125971 | 139047-48-6 | Reference compound |
| HY-120686 | S-14671 | 135722-27-9 | Reference compound |
| HY-120687 | A68930 | 130465-45-1 | Reference compound |
| HY-120688 | L-772405 | 177947-03-4 | Reference compound |
| HY-120689 | PF-04745637 | 1917294-46-2 | Reference compound |
| HY-12069 | SB-743921 (hydrochloride) | 940929-33-9 | Reference compound |
| HY-120690 | RO5464466 | 1399767-47-5 | Reference compound |
| HY-120691A | GSK205 | 1263068-83-2 | Reference compound |
| HY-120692 | Cyclanoline (chloride) | 17472-50-3 | Natural Products |
| HY-120695 | Nafiverine | 5061-22-3 | Reference compound |
| HY-120696 | SR9186 | 1361414-26-7 | Reference compound |
| HY-120697 | MSAB | 173436-66-3 | Reference compound |
| HY-120699 | RO5488608 | 1337920-46-3 | Reference compound |
| HY-12070 | DPH | 484049-04-9 | Reference compound |
| HY-120700 | L-682,679 | 126409-24-3 | Reference compound |
| HY-120702 | N-Boc-PEG5-bromide | 1392499-32-9 | ADC Related |
| HY-120703 | RU 58642 | 143782-63-2 | Reference compound |
| HY-120704 | Mps-BAY2b | 1263420-68-3 | Reference compound |
| HY-120709 | GSK2793660 (hydrochloride) | 1613458-79-9 | Reference compound |
| HY-12071 | LDN193189 | 1062368-24-4 | Reference compound |
| HY-120710 | DNS-8254 | 1821107-98-5 | Reference compound |
| HY-120711 | BRD0476 | 1314958-91-2 | Reference compound |
| HY-120712 | Ro 31-8588 | 141979-04-6 | Reference compound |
| HY-120713 | MK-8325 (dihydrochloride) | 1334314-19-0 | Reference compound |
| HY-120714 | Metiazinic acid | 13993-65-2 | Reference compound |
| HY-120715 | 4-Epianhydrochlortetracycline (hydrochloride) | 158018-53-2 | Reference compound |
| HY-120717 | VU6001966 | 2009052-76-8 | Reference compound |
| HY-120719 | SB 201823-A | 141429-64-3 | Reference compound |
| HY-12071A | LDN193189 (Tetrahydrochloride) | 2310134-98-4 | Reference compound |
| HY-12071B | LDN-193189 (dihydrochloride) | 1435934-00-1 | Reference compound |
| HY-12071C | LDN193189 (hydrochloride) | 1062368-62-0 | Biochemical Assay Reagents |
| HY-12071G | LDN193189 (GMP) | 1062368-24-4 | GMP Small Molecules |
| HY-12072 | Lck Inhibitor | 847950-09-8 | Reference compound |
| HY-120720 | Isomitraphylline | 4963-01-3 | Natural Products |
| HY-120721 | Lagunamycin | 150693-65-5 | Natural Products |
| HY-120722 | TCH-165 | 1446350-60-2 | Reference compound |
| HY-120723 | (Rac)-Phox-I1 | 1388151-90-3 | Reference compound |
| HY-120724 | HO-PEG15-OH | 28821-35-4 | Reference compound |
| HY-120726 | BF844 | 1404506-35-9 | Reference compound |
| HY-120727 | VU0364289 | 1242443-29-3 | Reference compound |
| HY-120729 | Pyrazophos | 13457-18-6 | Reference compound |
| HY-120729R | Pyrazophos (Standard) | 13457-18-6 | Reference Standards |
| HY-120730 | DA 1686 | 13071-27-7 | Reference compound |
| HY-120731 | N-Oleoyl leucine | 136560-76-4 | Peptides |
| HY-120733 | Calpinactam | 1205538-83-5 | Natural Products |
| HY-120734 | Quinoxyfen | 124495-18-7 | Reference compound |
| HY-120734R | Quinoxyfen (Standard) | 124495-18-7 | Reference Standards |
| HY-120734S | Quinoxyfen-d4 | | Isotope-Labeled Compounds |
| HY-120735 | Lascivol | 129421-88-1 | Natural Products |
| HY-120736 | MEB55 | 1323359-63-2 | Reference compound |
| HY-120737 | L-702007 | 139547-89-0 | Reference compound |
| HY-120738 | p-MPPI (hydrochloride) | 220643-77-6 | Reference compound |
| HY-12074 | Cazpaullone | 914088-64-5 | Reference compound |
| HY-120740 | 4-Amino-PPHT | 129298-03-9 | Reference compound |
| HY-120741 | PF-04822163 | 1798334-07-2 | Reference compound |
| HY-120742 | MMG-0358 | 1378976-02-3 | Reference compound |
| HY-120743 | Triplin | 1421584-86-2 | Reference compound |
| HY-120744 | LDN-193665 | 1289638-16-9 | Reference compound |
| HY-120747 | A-65282 | 135906-72-8 | Reference compound |
| HY-12075 | LY2109761 | 700874-71-1 | Reference compound |
| HY-120750 | A 62176 (hydrochloride) | 111783-54-1 | Reference compound |
| HY-120751 | TROX-1 | 1309601-26-0 | Reference compound |
| HY-120752 | CAY10509 | 1245699-47-1 | Reference compound |
| HY-120753 | Rimocidin | 1393-12-0 | Reference compound |
| HY-120755 | LY290324 | 146554-87-2 | Reference compound |
| HY-120756 | PD125754 | 124339-32-8 | Reference compound |
| HY-120757 | LP-130 | 153314-49-9 | Reference compound |
| HY-120758 | SEL24-B489 | 1616359-00-2 | Reference compound |
| HY-120759 | 3-Hydroxy carvedilol | 146574-43-8 | Reference compound |
| HY-12076 | BMS 777607 | 1025720-94-8 | Reference compound |
| HY-120760 | L-691831 | 136668-70-7 | Reference compound |
| HY-120761 | Amino-PEG10-OH | 129449-09-8 | ADC Related |
| HY-120763 | LB42908 | 226927-89-5 | Reference compound |
| HY-120764 | PF-46396 | 1207481-21-7 | Reference compound |
| HY-120765 | BRD2879 | 1304750-47-7 | Reference compound |
| HY-120766 | NCDM-32B | 1239468-48-4 | Reference compound |
| HY-120767 | Linzagolix (choline) | 1321816-57-2 | Reference compound |
| HY-120768 | A-30312 | 144092-65-9 | Reference compound |
| HY-120769 | Pimprinine | 13640-26-1 | Reference compound |
| HY-120770 | DBCO-PEG4-Maleimide | 1480516-75-3 | ADC Related |
| HY-120773 | Fmoc-PEG3-C2-NHS ester | 1352827-47-4 | Reference compound |
| HY-120774 | GS-462808 | 1354198-41-6 | Reference compound |
| HY-120775 | Boc-NH-PEG1-CH2CH2COOH | 1260092-44-1 | ADC Related |
| HY-120776 | SC-51316 | 133690-62-7 | Reference compound |
| HY-120777 | GSK729 | 1403602-92-5 | Reference compound |
| HY-120781 | Fluorescein-thiourea-PEG4-azide | 1454662-54-4 | Reference compound |
| HY-120782 | Yhhu-3792 | 2097826-24-7 | Reference compound |
| HY-120782A | Yhhu-3792 (hydrochloride) | 2624336-93-0 | Reference compound |
| HY-120783 | Lu AF58801 | 1531592-40-1 | Reference compound |
| HY-120784 | Hexafluoro-diallylhexaflurobisphenol | 128481-73-2 | Reference compound |
| HY-120785 | SR1555 | 1386439-51-5 | Reference compound |
| HY-120785A | SR1555 (hydrochloride) | 2309312-90-9 | Reference compound |
| HY-120786 | MPT0B014 | 1215208-59-5 | Reference compound |
| HY-120788 | VMAT2-IN-4 | 1436695-49-6 | Reference compound |
| HY-120789 | PF-06648671 | 1587727-31-8 | Reference compound |
| HY-12079 | CP-481715 | 212790-31-3 | Reference compound |
| HY-120791A | L-Lysyl-L-lysine (trihydrochloride) | 73343-51-8 | Reference compound |
| HY-120792 | DAU 5884 | 131780-47-7 | Reference compound |
| HY-120793 | CMC2.24 | 1255639-43-0 | Reference compound |
| HY-120794 | SC-67655 | 182134-00-5 | Reference compound |
| HY-120796 | MW108 (hydrochloride) | 1454658-89-9 | Reference compound |
| HY-120797 | CRT0273750 | 1979939-16-6 | Reference compound |
| HY-120798 | 4-Nitrophenyl phenylphosphonate | 57072-35-2 | Reference compound |
| HY-12080 | BX471 | 217645-70-0 | Reference compound |
| HY-120801 | APX-115 | 1395946-75-4 | Reference compound |
| HY-120801A | APX-115 (free base) | 1270084-92-8 | Reference compound |
| HY-120802 | Navafenterol | 1435519-06-4 | Reference compound |
| HY-120802A | Navafenterol (saccharinate) | 1648550-37-1 | Reference compound |
| HY-120803 | Mefluidide | 53780-34-0 | Reference compound |
| HY-120803R | Mefluidide (Standard) | 53780-34-0 | Reference Standards |
| HY-120805 | Aurofusarin | 13191-64-5 | Natural Products |
| HY-120809 | Spiramycin III | 24916-52-7 | Reference compound |
| HY-12080A | BX471 (hydrochloride) | 288262-96-4 | Reference compound |
| HY-120811 | PF-04701475 | 1488407-52-8 | Reference compound |
| HY-120812 | HIV-IN-11 | 160729-91-9 | Reference compound |
| HY-120813 | ARN 077 | 1373625-34-3 | Reference compound |
| HY-120813A | ARN 077 (enantiomer) | 1439366-88-7 | Reference compound |
| HY-120816 | WU-07047 | 1702378-78-6 | Reference compound |
| HY-120818 | TRPC3/6-IN-3 | 1366234-01-6 | Reference compound |
| HY-120820 | LY320954 | 182633-59-6 | Reference compound |
| HY-120821 | Endosidin-2 | 1839524-44-5 | Reference compound |
| HY-120823 | PF-05381941 | 1474022-02-0 | Reference compound |
| HY-120824 | Mofezolac | 78967-07-4 | Reference compound |
| HY-120826 | A2AAR/hMAO-B-IN-1 | 1439488-21-7 | Reference compound |
| HY-120827 | Allosamidin | 103782-08-7 | Reference compound |
| HY-120828 | Albenatide | 1031700-39-6 | Reference compound |
| HY-120829 | Bisoprolol (fumarate) | 105878-43-1 | Reference compound |
| HY-120829S | Bisoprolol-d5 (hemifumarate) | | Isotope-Labeled Compounds |
| HY-12082A | GSK369796 Dihydrochloride | 1010411-21-8 | Reference compound |
| HY-12083 | PPY-A | 875634-01-8 | Reference compound |
| HY-120831 | Pyridoxylideneglutamic acid | 13934-03-7 | Biochemical Assay Reagents |
| HY-120832 | Azt-pmap | 142629-81-0 | Reference compound |
| HY-120833 | Ac-Ile-Glu-Thr-Asp-pNA | 219138-21-3 | Peptides |
| HY-120835 | SB-202742 | 124576-72-3 | Natural Products |
| HY-120836 | AOH1160 | 2089314-57-6 | Reference compound |
| HY-120837 | PZ-II-029 | 164025-44-9 | Reference compound |
| HY-120838 | Heptelidic acid | 57710-57-3 | Reference compound |
| HY-120840 | GR 100679 | 150351-87-4 | Reference compound |
| HY-120842 | RLH-033 | 157097-10-4 | Reference compound |
| HY-120843 | WS009A | 136286-49-2 | Natural Products |
| HY-120845 | Tr-PEG5-OH | 141282-24-8 | ADC Related |
| HY-120846 | CHIR 4531 | 158198-48-2 | Reference compound |
| HY-12085 | Apremilast | 608141-41-9 | Reference compound |
| HY-120851 | O-7460 | 1572051-31-0 | Reference compound |
| HY-120852 | JG26 | 1464910-32-4 | Reference compound |
| HY-120853 | SR-4326 | 1164153-25-6 | Reference compound |
| HY-120855 | CCG-100602 | 1207113-88-9 | Reference compound |
| HY-120856 | ARN-3236 | 1613710-01-2 | Reference compound |
| HY-120857 | BPIQ-II (hydrochloride) | 171179-37-6 | Reference compound |
| HY-120858 | 25T4-NBOMe (hydrochloride) | 1566571-73-0 | Reference compound |
| HY-120859 | Zidebactam | 1436861-97-0 | Reference compound |
| HY-120859A | Zidebactam sodium salt | 1706777-46-9 | Reference compound |
| HY-12085R | Apremilast (Standard) | 608141-41-9 | Reference Standards |
| HY-12085S | Apremilast-d5 | 1258597-47-5 | Isotope-Labeled Compounds |
| HY-12085S1 | Apremilast-d8 | 1258597-45-3 | Isotope-Labeled Compounds |
| HY-12085S2 | (Rac)-Apremilast-d5 | 1258597-61-3 | Isotope-Labeled Compounds |
| HY-12085S3 | Apremilast-d3 | 1258597-46-4 | Isotope-Labeled Compounds |
| HY-120860 | Sporidesmolide I | 2900-38-1 | Natural Products |
| HY-120861 | Acerinol | 19902-53-5 | Natural Products |
| HY-120862 | L 368935 | 145878-31-5 | Reference compound |
| HY-120863 | (Rac)-PD 135390 | 150351-31-8 | Reference compound |
| HY-120864 | SEN461 | 1287727-28-9 | Reference compound |
| HY-120865 | 1,3-PBIT (dihydrobromide) | 200716-66-1 | Reference compound |
| HY-120867 | TASP0376377 | 1233246-60-0 | Reference compound |
| HY-120868 | TP-004 | 1454299-21-8 | Reference compound |
| HY-120870 | para-Nitroblebbistatin | 1621326-32-6 | Reference compound |
| HY-120872 | AJS1669 (free acid) | 1853130-05-8 | Reference compound |
| HY-120874 | PF-06372865 | 1614245-70-3 | Reference compound |
| HY-120875 | HX600 | 172705-89-4 | Reference compound |
| HY-120876 | L-680833 | 127063-08-5 | Reference compound |
| HY-120877 | MRT199665 | 1456858-57-3 | Reference compound |
| HY-120877A | (R)-MRT199665 | | Reference compound |
| HY-120878 | CXCR2-IN-2 | 1838123-21-9 | Reference compound |
| HY-120878A | (R,R)-CXCR2-IN-2 | 1838123-22-0 | Reference compound |
| HY-120879 | PF2562 | 1609258-91-4 | Reference compound |
| HY-120880 | SKF107457 | 126333-28-6 | Peptides |
| HY-120882 | BM-1197 | 1391107-89-3 | Reference compound |
| HY-120883 | Rhizopodin | 150346-23-9 | Natural Products |
| HY-120884 | InhA-IN-5 | 1854095-63-8 | Reference compound |
| HY-120885 | (+)-Oxanthromicin | 1616622-08-2 | Natural Products |
| HY-120886 | GW 2433 | 227941-61-9 | Reference compound |
| HY-12089 | Torcetrapib | 262352-17-0 | Reference compound |
| HY-120890 | 3,4',5-Trismethoxybenzophenone | 94709-12-3 | Reference compound |
| HY-120891 | trans-EKODE-(E)-Ib | 478931-82-7 | Reference compound |
| HY-120892 | Fluprostenol serinol amide | 1176658-85-7 | Reference compound |
| HY-120893 | trans-4,5-Epoxy-(E)-2-decenal | 134454-31-2 | Reference compound |
| HY-120894 | 16(R)-HETE | 183509-22-0 | Reference compound |
| HY-120896B | Imipramine Blue (chloride) | | Reference compound |
| HY-120897 | NS-3-008 (hydrochloride) | 1172854-54-4 | Reference compound |
| HY-12090 | Anacetrapib | 875446-37-0 | Reference compound |
| HY-120900 | AN-12-H5 | 1193340-31-6 | Reference compound |
| HY-120901 | II-B08 | 1143579-78-5 | Reference compound |
| HY-120902 | GSK-3β inhibitor 8 | 1139875-74-3 | Reference compound |
| HY-120903 | DBCO-C3-Acid | 1207355-31-4 | ADC Related |
| HY-120904 | AMPK-IN-1 | 1219739-95-3 | Reference compound |
| HY-120908 | c-Met-IN-16 | 1208248-23-0 | Reference compound |
| HY-120909 | YK5 | 1268273-23-9 | Reference compound |
| HY-120912 | Gingerenone A | 128700-97-0 | Natural Products |
| HY-120914 | TrxR1-IN-B19 | 170950-29-5 | Reference compound |
| HY-120918 | NH2-PEG7 | 1425973-14-3 | Reference compound |
| HY-120920 | UNC9995 | 1354030-52-6 | Reference compound |
| HY-120921 | Zoxamide | 156052-68-5 | Reference compound |
| HY-120921R | Zoxamide (Standard) | 156052-68-5 | Reference Standards |
| HY-120922 | Spiroakyroside | 139390-87-7 | Natural Products |
| HY-120924 | BRD9185 | 2057420-29-6 | Reference compound |
| HY-120926 | BBR 2160 | 118587-22-7 | Reference compound |
| HY-120927 | Alvimopan metabolite | 156130-41-5 | Reference compound |
| HY-120927A | Alvimopan metabolite (hydrochloride) | 170098-43-8 | Reference compound |
| HY-120927S | Alvimopan metabolite-d5 | 2124272-23-5 | Isotope-Labeled Compounds |
| HY-120928 | S 16474 | 149250-10-2 | Reference compound |
| HY-120929 | BI8622 | 1875036-74-0 | Reference compound |
| HY-12093 | MMP408 | 1025716-81-7 | Reference compound |
| HY-120931 | LY329146 | 191043-78-4 | Reference compound |
| HY-120934 | C25-140 | 1358099-18-9 | Reference compound |
| HY-120935 | (R)-Dabelotine | 152886-02-7 | Reference compound |
| HY-120936 | IACS-4759 | 1884209-99-7 | Reference compound |
| HY-120937 | DC4 Crosslinker | 1374647-94-5 | Reference compound |
| HY-120939 | S14063 | 137289-83-9 | Reference compound |
| HY-120940 | AZ13705339 | 2016806-57-6 | Reference compound |
| HY-120940A | AZ13705339 (hemihydrate) | | Reference compound |
| HY-120941 | LASSBio-1359 | 1396397-19-5 | Reference compound |
| HY-120942 | XIE18-6 | 1286862-52-9 | Reference compound |
| HY-120943 | K-111 | 221564-97-2 | Reference compound |
| HY-120944 | BAY-7598 | 1816257-74-5 | Reference compound |
| HY-120946 | VMY-2-95 | 1434047-61-6 | Reference compound |
| HY-120947 | AV-105 | 1205550-99-7 | Reference compound |
| HY-120948 | RU 45196 | 121548-81-0 | Reference compound |
| HY-120949 | (1R,2R)-U-50488 (hydrochloride) | 109620-49-7 | Reference compound |
| HY-12095 | CB1 inverse agonist 2 | 1019839-52-1 | Reference compound |
| HY-120950 | S-tram,tram-Farnesylated cysteine methyl ester | 125741-64-2 | Reference compound |
| HY-120951 | PFM39 | 1310744-67-2 | Reference compound |
| HY-120953 | GAT228 | 1446648-15-2 | Reference compound |
| HY-120954 | 14,15-EE-5(Z)-E | 519038-92-7 | Reference compound |
| HY-120955 | (+)-5-trans Cloprostenol | 57968-81-7 | Reference compound |
| HY-120956 | Methyl stearidonate | 73097-00-4 | Natural Products |
| HY-120957 | AMC Arachidonoyl Amide | 862913-13-1 | Reference compound |
| HY-120958 | Nisinic acid | 68378-49-4 | Reference compound |
| HY-120959 | DAUDA | 73025-02-2 | Dye Reagents |
| HY-120961 | Oleoyl ethyl amide | 85075-82-7 | Reference compound |
| HY-120962 | N-Arachidonoyl Taurine | 119959-65-8 | Reference compound |
| HY-120962S | N-Arachidonoyl Taurine-d4 | | Isotope-Labeled Compounds |
| HY-120963 | N-Oleoyl Taurine | 52514-04-2 | Natural Products |
| HY-120964 | N-Stearoyl Taurine | 63155-80-6 | Reference compound |
| HY-120965 | N-Palmitoyl Taurine | 83982-06-3 | Reference compound |
| HY-120966 | NCX 2121 | 301838-28-8 | Reference compound |
| HY-120967 | (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% | 1217471-69-6 | Biochemical Assay Reagents |
| HY-120967A | (2S)-OMPT | 645408-61-3 | Biochemical Assay Reagents |
| HY-120968 | Arachidoyl ethanolamide | 94421-69-9 | Natural Products |
| HY-120969 | Docosanoyl ethanolamide | 94109-05-4 | Natural Products |
| HY-12096A | WAY-207024 (dihydrochloride) | 872002-73-8 | Reference compound |
| HY-120970 | Bis(7)-tacrine (dihydrochloride) | 224445-12-9 | Reference compound |
| HY-120971 | N-Decanoyl p-Nitroaniline | 72298-63-6 | Reference compound |
| HY-120972 | Pentafluorobenzenesulfonyl fluorescein | 728912-45-6 | Dye Reagents |
| HY-120973 | Butaprost (free acid) | 215168-33-5 | Biochemical Assay Reagents |
| HY-120973A | (S)-Butaprost (free acid) | 433219-55-7 | Reference compound |
| HY-120974 | α-lipoic acid derivative 1 | 691410-93-2 | Reference compound |
| HY-120975 | 2,3-Dinor thromboxane b1 | 196493-76-2 | Reference compound |
| HY-120976 | DEPMPO | 157230-67-6 | Reference compound |
| HY-120977 | Methyl pentacosanoate | 55373-89-2 | Natural Products |
| HY-120978 | Omega-3 arachidonic acid methyl ester | 132712-70-0 | Biochemical Assay Reagents |
| HY-120979 | NO-Losartan A | 791122-48-0 | Reference compound |
| HY-12098 | Verubulin (hydrochloride) | 917369-31-4 | Reference compound |
| HY-120980 | Thromboxane B1 | 64626-32-0 | Reference compound |
| HY-120981S | (±)5-iPF2α-VI-d11 | 936565-17-2 | Isotope-Labeled Compounds |
| HY-120982 | (+)-15-epi Cloprostenol | 54276-22-1 | Reference compound |
| HY-120983 | 2-Hexadecanoylthio-1-ethylphosphorylcholine | 60793-01-3 | Biochemical Assay Reagents |
| HY-120984 | Oleic Acid-2,6-diisopropylanilide | 140112-65-8 | Reference compound |
| HY-120985 | Araguspongin B | 123000-02-2 | Reference compound |
| HY-120986 | (S)-Bromoenol lactone | 478288-94-7 | Reference compound |
| HY-120986S | (S)-Bromoenol lactone-d7 | | Isotope-Labeled Compounds |
| HY-120987 | Ethyl stearidonate | 119798-44-6 | Biochemical Assay Reagents |
| HY-120989 | Methyl 7(Z)-hexadecenoate | 56875-67-3 | Natural Products |
| HY-12099 | A3AR antagonist 2 | 1144161-05-6 | Reference compound |
| HY-120990 | Piloty's acid | 599-71-3 | Reference compound |
| HY-120991 | 1-Palmitoyl-2-linoleoyl-sn-glycero-3-PE | 26662-95-3 | Biochemical Assay Reagents |
| HY-120993 | 1,N6-Ethenoadenosine 5'-monophosphate (sodium) | 885597-18-2 | Dye Reagents |
| HY-120994 | Rp-8-CPT-cAMPS (sodium) | 221905-35-7 | Reference compound |
| HY-120994A | Rp-8-CPT-cAMPS | 129735-01-9 | Reference compound |
| HY-120994B | Sp-8-CPT-cAMPS | 129693-13-6 | Reference compound |
| HY-120996 | 10(E)-Pentadecenoic acid | 321744-58-5 | Reference compound |
| HY-120996B | 10(Z)-Pentadecenoic acid | 84743-29-3 | Reference compound |
| HY-120997 | E6 Berbamine | 114784-59-7 | Reference compound |
| HY-120999 | DL-erythro/threo Sphinganine (d16:0) | 50731-08-3 | Natural Products |
| HY-12100 | Umeclidinium (bromide) | 869113-09-7 | Reference compound |
| HY-121000 | Albocycline | 25129-91-3 | Natural Products |
| HY-121002 | Alstonine | 642-18-2 | Natural Products |
| HY-121003 | Aspyrone | 17398-00-4 | Reference compound |
| HY-121004 | Bikaverin | 33390-21-5 | Natural Products |
| HY-121005 | Bufetolol | 53684-49-4 | Reference compound |
| HY-121006 | Biguanide | 56-03-1 | Reference compound |
| HY-121007 | Bepafant | 114776-28-2 | Reference compound |
| HY-121008 | Brl 20596 | 69082-47-9 | Reference compound |
| HY-12100R | Umeclidinium (bromide) (Standard) | 869113-09-7 | Reference Standards |
| HY-12100S | Umeclidinium-d5 (bromide) | | Isotope-Labeled Compounds |
| HY-12100S1 | Umeclidinium-d10 (bromide) | | Isotope-Labeled Compounds |
| HY-121011 | Cannabigerorcin | 38106-51-3 | Reference compound |
| HY-121012 | (rac)-AG-205 | 442656-02-2 | Reference compound |
| HY-121013 | Bryononic acid | 24480-44-2 | Natural Products |
| HY-121014 | Amphimedine | 86047-14-5 | Natural Products |
| HY-121018 | Daltroban | 79094-20-5 | Reference compound |
| HY-121019 | Flordipine | 77590-96-6 | Reference compound |
| HY-121020 | Arcapillin | 83162-82-7 | Natural Products |
| HY-121021 | BB-78485 | 207732-11-4 | Reference compound |
| HY-121025 | BUR1 | 23000-46-6 | Reference compound |
| HY-121026 | DMNQ | 6956-96-3 | Reference compound |
| HY-121027 | Anagyrine | 486-89-5 | Natural Products |
| HY-121027A | Anagyrine (hydrochloride) | 74195-83-8 | Natural Products |
| HY-121029 | Bisegliptin | 862501-61-9 | Reference compound |
| HY-121030 | DACM | 55145-14-7 | Dye Reagents |
| HY-121034 | Acaterin | 144398-20-9 | Natural Products |
| HY-121035 | 7BIO | 916440-85-2 | Reference compound |
| HY-121037 | Eggmanone | 505068-32-6 | Reference compound |
| HY-121038 | Chamazulene | 529-05-5 | Natural Products |
| HY-121039 | Avenin | 6309-98-4 | Reference compound |
| HY-12104 | PF-514273 | 851728-60-4 | Reference compound |
| HY-121042 | BSBM6 | 1186629-63-9 | Reference compound |
| HY-121043 | AA 497 (free base) | 59605-49-1 | Reference compound |
| HY-121043A | AA 497 | 65860-38-0 | Reference compound |
| HY-121045 | Bunitrolol | 34915-68-9 | Reference compound |
| HY-121046 | Flunixin | 38677-85-9 | Reference compound |
| HY-121046S | Flunixin-d3 | 1015856-60-6 | Isotope-Labeled Compounds |
| HY-121048 | AH 7725 | 33459-28-8 | Reference compound |
| HY-121050 | Ambruticin | 58857-02-6 | Natural Products |
| HY-121051 | Aleurodiscal | 122535-46-0 | Natural Products |
| HY-121053 | Adatanserin | 127266-56-2 | Reference compound |
| HY-121053A | Adatanserin (hydrochloride) | 144966-96-1 | Reference compound |
| HY-121054 | Chalcone | 94-41-7 | Natural Products |
| HY-121057 | 3-Hydroxyflunitrazepam | 67739-71-3 | Reference compound |
| HY-121058 | AD 4743 | 87858-57-9 | Reference compound |
| HY-121060 | Gloxazone | 2507-91-7 | Reference compound |
| HY-121061 | Abikoviromycin | 31774-33-1 | Natural Products |
| HY-121062 | Betamethasone acibutate | 5534-05-4 | Reference compound |
| HY-121065 | BN-82685 | 477603-18-2 | Reference compound |
| HY-121066 | Dehydrorotenone | 3466-09-9 | Natural Products |
| HY-121067 | Carbarsone | 121-59-5 | Reference compound |
| HY-121068 | Bisoxatin | 17692-24-9 | Reference compound |
| HY-121068R | Bisoxatin (Standard) | 17692-24-9 | Reference Standards |
| HY-121069 | Elubiol | 67914-69-6 | Reference compound |
| HY-121070 | AZD1092 | 871656-65-4 | Reference compound |
| HY-121071 | Ascamycin | 91432-48-3 | Natural Products |
| HY-121072 | ASS234 | 1334106-34-1 | Reference compound |
| HY-121075 | Alizarin complexone | 3952-78-1 | Reference compound |
| HY-121076 | Berteroin | 4430-42-6 | Reference compound |
| HY-121079 | Azimsulfuron | 120162-55-2 | Reference compound |
| HY-121079R | Azimsulfuron (Standard) | 120162-55-2 | Reference Standards |
| HY-12108 | S 1360 | 280571-30-4 | Reference compound |
| HY-121080 | AMG8163 | 659731-59-6 | Reference compound |
| HY-121081 | BAY-958 | 1335490-39-5 | Reference compound |
| HY-121082 | (-)-Dihydroalprenolol | 59624-90-7 | Reference compound |
| HY-121083 | Aerugidiol | 116425-35-5 | Natural Products |
| HY-121085 | CID-663143 | 578723-96-3 | Reference compound |
| HY-121086 | BAY-588 | 1799759-24-2 | Reference compound |
| HY-121087 | BCI-215 | 1245792-67-9 | Reference compound |
| HY-121088 | Ceefourin 2 | 348148-51-6 | Reference compound |
| HY-121089 | P300-IN-5 | 163107-37-7 | Reference compound |
| HY-12109 | L-870810 | 410544-95-5 | Reference compound |
| HY-121090 | FAAH-IN-9 | 288862-89-5 | Reference compound |
| HY-121091 | EP2 receptor agonist 4 | 212310-16-2 | Reference compound |
| HY-121092 | CAY10701 | 1616967-52-2 | Reference compound |
| HY-121093 | DC-S239 | 303141-21-1 | Reference compound |
| HY-121094 | Androgen receptor allosteric antagonist 1 | 927819-39-4 | Reference compound |
| HY-121095 | Bizine | 1591932-50-1 | Reference compound |
| HY-121095A | Bizine di(hydrochloride) | 1808112-57-3 | Reference compound |
| HY-121096 | Funalenone | 259728-61-5 | Reference compound |
| HY-121097 | Diapocynin | 29799-22-2 | Natural Products |
| HY-121099 | Cgp 8065 | 62939-04-2 | Reference compound |
| HY-121100 | BZAD-01 | 305339-41-7 | Reference compound |
| HY-121103 | Aclantate | 39633-62-0 | Reference compound |
| HY-121104 | Bactobolin | 72615-20-4 | Natural Products |
| HY-121104A | Bactobolin (hydrochloride) | 73543-68-7 | Natural Products |
| HY-121106 | 9-Deazaguanine | 65996-58-9 | Reference compound |
| HY-121107 | Chrysene | 218-01-9 | Natural Products |
| HY-121107R | Chrysene (Standard) | 218-01-9 | Reference Standards |
| HY-121107S | Chrysene-d12 | 1719-03-5 | Isotope-Labeled Compounds |
| HY-121109 | Benalaxyl | 71626-11-4 | Reference compound |
| HY-121109R | Benalaxyl (Standard) | 71626-11-4 | Reference Standards |
| HY-121109S | Benalaxyl-d5 | 2714421-66-4 | Isotope-Labeled Compounds |
| HY-12111 | BMS-564929 | 627530-84-1 | Reference compound |
| HY-121110 | Fexarene | 574013-68-6 | Reference compound |
| HY-121111 | Agaritine | 2757-90-6 | Natural Products |
| HY-121116 | CGS 8216 | 77779-60-3 | Natural Products |
| HY-121117 | Chloracetophos | 5952-41-0 | Reference compound |
| HY-121118 | Coronaridine | 467-77-6 | Natural Products |
| HY-121119 | MRS 1523 | 212329-37-8 | Reference compound |
| HY-121120 | Isosulfazecin | 77900-75-5 | Natural Products |
| HY-121122 | A778317 | 808756-64-1 | Reference compound |
| HY-121123 | Adamantanine | 42381-05-5 | Reference compound |
| HY-121124 | Fluindione | 957-56-2 | Reference compound |
| HY-121124S | Fluindione-d4 | 1246820-41-6 | Isotope-Labeled Compounds |
| HY-121125 | Aucubigenin | 64274-28-8 | Natural Products |
| HY-121129 | Eticlopride | 84226-12-0 | Reference compound |
| HY-12113 | Oprozomib | 935888-69-0 | Reference compound |
| HY-121130 | Dacuronium | 43021-45-0 | Reference compound |
| HY-121131 | Deacylcortivazol | 4906-84-7 | Reference compound |
| HY-121132 | Butibufen | 55837-18-8 | Reference compound |
| HY-121133 | (-)-Cyclopenol | 20007-85-6 | Natural Products |
| HY-121134 | Decylubiquinone | 55486-00-5 | Reference compound |
| HY-121136 | Chartreusin | 6377-18-0 | Reference compound |
| HY-121136A | Chartreusin (sodium) | 1393-72-2 | Natural Products |
| HY-121137 | BMPO | 387334-31-8 | Reference compound |
| HY-121138 | 1,8-Dihydroxy-4,5-dinitroanthraquinone | 81-55-0 | Reference compound |
| HY-12114 | Serlopitant | 860642-69-9 | Reference compound |
| HY-121140 | AZ1729 | 2016864-46-1 | Reference compound |
| HY-121141 | Adiphenine | 64-95-9 | Reference compound |
| HY-121143 | Bis-Q | 73711-18-9 | Reference compound |
| HY-121144 | Cefazedone | 56187-47-4 | Natural Products |
| HY-121144R | Cefazedone (Standard) | 56187-47-4 | Reference Standards |
| HY-121145 | Abruquinone A | 71593-10-7 | Natural Products |
| HY-121146 | Chinotilin (iodide) | 56583-56-3 | Reference compound |
| HY-121148 | Mutalomycin | 62618-08-0 | Reference compound |
| HY-121149 | Droloxifene | 82413-20-5 | Reference compound |
| HY-121149B | (E/Z)-Droloxifene | 165813-01-4 | Reference compound |
| HY-12115 | NG-nitro-L-arginine | 2149-70-4 | Reference compound |
| HY-121151 | (±)-Methotrexate | 60388-53-6 | Reference compound |
| HY-121151S | Amethopterin-d3 | | Isotope-Labeled Compounds |
| HY-121153 | Altenusin | 31186-12-6 | Natural Products |
| HY-121154 | Hexachloroparaxylene | 68-36-0 | Reference compound |
| HY-121156 | Anatibant | 209733-45-9 | Reference compound |
| HY-121156A | Anatibant (hydrochloride) | 209788-45-4 | Reference compound |
| HY-121157 | Chlorfenson | 80-33-1 | Reference compound |
| HY-121157R | Chlorfenson (Standard) | 80-33-1 | Reference Standards |
| HY-121158 | Butamifos | 36335-67-8 | Reference compound |
| HY-121158R | Butamifos (Standard) | 36335-67-8 | Reference Standards |
| HY-121159 | Alanopine | 19149-54-3 | Reference compound |
| HY-12116 | L-NIL | 53774-63-3 | Reference compound |
| HY-121160 | Amiprilose | 56824-20-5 | Reference compound |
| HY-121161 | (Rac)-Brassinazole | 224047-41-0 | Reference compound |
| HY-121161A | Brassinazole | 280129-83-1 | Reference compound |
| HY-121161B | (2S,3R)-Brassinazole | 259200-31-2 | Reference compound |
| HY-121161C | (2R,3S)-Brassinazole | 259200-30-1 | Reference compound |
| HY-121162 | Mesembrine | 468-53-1 | Natural Products |
| HY-121163 | PF-184563 | 748806-39-5 | Reference compound |
| HY-121165 | Cymiazole | 61676-87-7 | Reference compound |
| HY-121165R | Cymiazole (Standard) | 61676-87-7 | Reference Standards |
| HY-121166 | Levobetaxolol | 93221-48-8 | Reference compound |
| HY-121167 | L-Albizziin | 1483-07-4 | Reference compound |
| HY-121168 | Aprophen | 3563-01-7 | Reference compound |
| HY-121169 | Amorolfine | 78613-35-1 | Reference compound |
| HY-12117 | L-NIL (hydrochloride) | 150403-89-7 | Reference compound |
| HY-121172 | 1,4-DPCA | 331830-20-7 | Reference compound |
| HY-121174 | Alaternin | 39723-40-5 | Natural Products |
| HY-121176 | Asalin | 13425-94-0 | Reference compound |
| HY-121178 | Deoxyviolacein | 5839-61-2 | Reference compound |
| HY-12118 | L-NIL (dihydrochloride) | 159190-45-1 | Reference compound |
| HY-121180 | A-58365B | 87896-53-5 | Reference compound |
| HY-121182 | Chalcomycin | 20283-48-1 | Natural Products |
| HY-121183 | Aprikalim | 132562-26-6 | Reference compound |
| HY-121184 | Epicoccamide | 606139-26-8 | Natural Products |
| HY-121185 | Hexoprenaline | 3215-70-1 | Reference compound |
| HY-121186 | Bevantolol (hydrochloride) | 42864-78-8 | Reference compound |
| HY-121186R | Bevantolol (hydrochloride) (Standard) | 42864-78-8 | Reference Standards |
| HY-121187 | BiPNQ | 313513-16-5 | Reference compound |
| HY-121188 | DDMS | 206052-03-1 | Reference compound |
| HY-12119 | GW274150 | 210354-22-6 | Reference compound |
| HY-121191 | Bisnorcymserine | 219920-81-7 | Reference compound |
| HY-121192 | Capillarisin | 56365-38-9 | Natural Products |
| HY-121195 | Apalcillin | 63469-19-2 | Reference compound |
| HY-121197 | Balanol | 63590-19-2 | Natural Products |
| HY-121198 | Dimestrol | 130-79-0 | Reference compound |
| HY-121199 | Germanicol | 465-02-1 | Natural Products |
| HY-12119A | GW274150 (phosphate) | 438542-15-5 | Reference compound |
| HY-12119B | GW274150 (dihydrochloride) | 438542-17-7 | Reference compound |
| HY-121200 | Azadirone | 30002-86-9 | Reference compound |
| HY-121201 | Amicarbalide | 3459-96-9 | Reference compound |
| HY-121202 | Leucopterin | 492-11-5 | Natural Products |
| HY-121203 | Citalopram | 59729-33-8 | Reference compound |
| HY-121203A | Citalopram (oxalate) | 207559-01-1 | Reference compound |
| HY-121203R | Citalopram (Standard) | 59729-33-8 | Reference Standards |
| HY-121203S | Citalopram-d4 (hydrobromide) | 1219803-58-3 | Isotope-Labeled Compounds |
| HY-121203S1 | Citalopram-d6 (oxalate) | 1246819-94-2 | Isotope-Labeled Compounds |
| HY-121203S3 | Citalopram-d6 | 1190003-26-9 | Isotope-Labeled Compounds |
| HY-121203S4 | Citalopram-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-121204 | Iberverin | 505-79-3 | Natural Products |
| HY-121204R | Iberverin (Standard) | 505-79-3 | Reference Standards |
| HY-121205 | Guineesine | 55038-30-7 | Natural Products |
| HY-121206 | (-)-Isopulegol | 89-79-2 | Reference compound |
| HY-121206R | (-)-Isopulegol (Standard) | 89-79-2 | Reference Standards |
| HY-121207 | Denopterin | 22006-84-4 | Reference compound |
| HY-121208 | Ketanserinol | 76330-73-9 | Reference compound |
| HY-121208R | Ketanserinol (Standard) | 76330-73-9 | Reference Standards |
| HY-121211 | Digitolutein | 477-86-1 | Natural Products |
| HY-121212 | Icosabutate | 1253909-57-7 | Reference compound |
| HY-121212R | Icosabutate (Standard) | 1253909-57-7 | Reference Standards |
| HY-121213 | Erysolin | 504-84-7 | Reference compound |
| HY-121214 | Amisulbrom | 348635-87-0 | Reference compound |
| HY-121214R | Amisulbrom (Standard) | 348635-87-0 | Reference Standards |
| HY-121215 | Chloracyzine | 800-22-6 | Reference compound |
| HY-121219 | (-)-Lupinine | 486-70-4 | Natural Products |
| HY-12122 | AR-C102222 | 253771-21-0 | Reference compound |
| HY-121220 | Carbetamide | 16118-49-3 | Reference compound |
| HY-121220R | Carbetamide (Standard) | 16118-49-3 | Reference Standards |
| HY-121221 | Justiciresinol | 136051-41-7 | Natural Products |
| HY-121222 | alpha-Bisabolol | 515-69-5 | Natural Products |
| HY-121225 | Faradiol | 20554-95-4 | Natural Products |
| HY-121226 | Karakin | 1400-11-9 | Natural Products |
| HY-121227 | Cylindrin | 17904-55-1 | Natural Products |
| HY-121229A | (±)-Coniine | 3238-60-6 | Natural Products |
| HY-12122A | AR-C102222 (hydrochloride) | 1781934-50-6 | Reference compound |
| HY-121231 | trans-Caffeic acid | 501-16-6 | Natural Products |
| HY-121231R | trans-Caffeic acid (Standard) | 501-16-6 | Reference Standards |
| HY-121232 | Delapril | 83435-66-9 | Reference compound |
| HY-121233 | Chloropropylate | 5836-10-2 | Reference compound |
| HY-121234 | Botryodiplodin | 27098-03-9 | Reference compound |
| HY-121235 | Clonixin | 17737-65-4 | Reference compound |
| HY-121235R | Clonixin (Standard) | 17737-65-4 | Reference Standards |
| HY-121236 | Bavachromene | 41743-38-8 | Natural Products |
| HY-121238 | Hyocholic Acid | 547-75-1 | Reference compound |
| HY-121238R | Hyocholic Acid (Standard) | 547-75-1 | Reference Standards |
| HY-121238S | Hyocholic Acid-d4 | | Isotope-Labeled Compounds |
| HY-121238S1 | Hyocholic Acid-d5 | | Isotope-Labeled Compounds |
| HY-121239 | Lemnalol | 82570-34-1 | Natural Products |
| HY-12124 | BBS-4 | 402934-09-2 | Reference compound |
| HY-121240 | Brecanavir | 313682-08-5 | Reference compound |
| HY-121241 | Dehydroemetine | 4914-30-1 | Reference compound |
| HY-121242 | Buthidazole | 55511-98-3 | Reference compound |
| HY-121243 | Halauxifen | 943832-60-8 | Reference compound |
| HY-121244 | Coumafuryl | 117-52-2 | Reference compound |
| HY-121245 | Capoamycin | 97937-29-6 | Natural Products |
| HY-121246 | Fluorofenidone | 848353-85-5 | Reference compound |
| HY-121246S | Fluorofenidone-d3 | | Isotope-Labeled Compounds |
| HY-121247 | Bromotetrandrine | 62067-29-2 | Reference compound |
| HY-121248 | Hydramethylnon | 67485-29-4 | Reference compound |
| HY-121249 | Capeserod (hydrochloride) | 191023-43-5 | Reference compound |
| HY-121250 | Fasnall | 929978-58-5 | Reference compound |
| HY-121251 | BI-167107 | 1202235-68-4 | Reference compound |
| HY-121252 | Dopal | 5707-55-1 | Natural Products |
| HY-121252A | Dopal (purity>80%) | 5707-55-1 | Reference compound |
| HY-121252S | Dopal-d5 | | Isotope-Labeled Compounds |
| HY-121254 | GERI-BP002-A | 119-47-1 | Natural Products |
| HY-121255 | (-)-Cryptopleurine | 482-22-4 | Reference compound |
| HY-121256 | Chlorasquin | 18921-73-8 | Reference compound |
| HY-121259 | Doxorubicinol | 54193-28-1 | Reference compound |
| HY-121259S | Doxorubicinol-13C,d3 (TFA) | | Isotope-Labeled Compounds |
| HY-121261 | Antineoplastic agent-1 | 738-99-8 | Reference compound |
| HY-121262 | Bisabolene | 495-62-5 | Natural Products |
| HY-121263 | Dicyclanil | 112636-83-6 | Reference compound |
| HY-121263R | Dicyclanil (Standard) | 112636-83-6 | Reference Standards |
| HY-121265 | Bendiocarb | 22781-23-3 | Reference compound |
| HY-121265R | Bendiocarb (Standard) | 22781-23-3 | Reference Standards |
| HY-121267 | Dicamba | 1918-00-9 | Biochemical Assay Reagents |
| HY-121267R | Dicamba (Standard) | 1918-00-9 | Reference Standards |
| HY-121267S | Dicamba-13C6 | | Isotope-Labeled Compounds |
| HY-121267S1 | Dicamba-d3 | 349553-95-3 | Isotope-Labeled Compounds |
| HY-121268 | Demeclocycline | 127-33-3 | Reference compound |
| HY-121268A | Demeclocycline (calcium) | 17146-81-5 | Reference compound |
| HY-121268R | Demeclocycline (Standard) | 127-33-3 | Reference Standards |
| HY-12127 | Pexacerfont | 459856-18-9 | Reference compound |
| HY-121271 | Kadsurin | 51670-40-7 | Natural Products |
| HY-121272 | Difloxacin | 98106-17-3 | Reference compound |
| HY-121272AS | Difloxacin-d3 (hydrochloride trihydrate) | | Isotope-Labeled Compounds |
| HY-121272AS1 | Difloxacin-d3 (hydrochloride) | 1173021-89-0 | Isotope-Labeled Compounds |
| HY-121272AS2 | Difloxacin-d3 | 1173147-93-7 | Isotope-Labeled Compounds |
| HY-121272R | Difloxacin (Standard) | 98106-17-3 | Reference Standards |
| HY-121274 | Dicyclonon | 79260-71-2 | Reference compound |
| HY-121275 | Benserazide | 322-35-0 | Reference compound |
| HY-121276 | Benperidol | 2062-84-2 | Reference compound |
| HY-121276R | Benperidol (Standard) | 2062-84-2 | Reference Standards |
| HY-121276S1 | Benperidol-d4 | | Isotope-Labeled Compounds |
| HY-121278 | Benzotript | 39544-74-6 | Reference compound |
| HY-121280 | ERK2-IN-4 | 933786-58-4 | Reference compound |
| HY-121282 | Mepazine | 60-89-9 | Reference compound |
| HY-121282A | Mepazine (hydrochloride) | 2975-36-2 | Reference compound |
| HY-121282B | Mepazine (acetate) | 24360-97-2 | Reference compound |
| HY-121284 | Triazamate | 112143-82-5 | Reference compound |
| HY-121286 | Echinatine | 480-83-1 | Natural Products |
| HY-121287 | Ioxynil | 1689-83-4 | Reference compound |
| HY-121288 | Diisoamylamine | 544-00-3 | Reference compound |
| HY-121289 | Drazoxolon | 5707-69-7 | Reference compound |
| HY-12129 | CP 154526 (hydrochloride) | 257639-98-8 | Reference compound |
| HY-121290 | BPH-651 | 149537-49-5 | Reference compound |
| HY-121291 | Aureothin | 2825-00-5 | Natural Products |
| HY-121292 | Clidanac | 34148-01-1 | Reference compound |
| HY-121294 | Indanomycin | 66513-28-8 | Reference compound |
| HY-121295 | Roseoflavin | 51093-55-1 | Reference compound |
| HY-121299 | m-Chlorophenylbiguanide | 48144-44-1 | Reference compound |
| HY-12130 | CP 154526 | 157286-86-7 | Reference compound |
| HY-121300 | Kendomycin | 183202-73-5 | Reference compound |
| HY-121301 | Amperozide | 75558-90-6 | Reference compound |
| HY-121305 | D-Ribulose | 488-84-6 | Biochemical Assay Reagents |
| HY-121305A | L-Ribulose | 2042-27-5 | Reference compound |
| HY-121306 | Indecainide | 74517-78-5 | Reference compound |
| HY-121307 | Gliamilide | 51876-98-3 | Reference compound |
| HY-121309 | Doxorubicinone | 24385-10-2 | Reference compound |
| HY-121309R | Doxorubicinone (Standard) | 24385-10-2 | Reference Standards |
| HY-121309S | Doxorubicinone-d3 | | Isotope-Labeled Compounds |
| HY-121309S1 | Doxorubicinone-13C,d3 | | Isotope-Labeled Compounds |
| HY-12131 | DMP 696 | 202578-52-7 | Reference compound |
| HY-121310 | Phthalocyanine | 574-93-6 | Biochemical Assay Reagents |
| HY-121311 | Metrenperone | 81043-56-3 | Reference compound |
| HY-121312 | Flutonidine | 28125-87-3 | Reference compound |
| HY-121313 | Embusartan | 156001-18-2 | Reference compound |
| HY-121314 | Cloprostenol | 40665-92-7 | Reference compound |
| HY-121315 | BRD4097 | 1550053-19-4 | Reference compound |
| HY-121317 | Leucinocaine | 92-23-9 | Reference compound |
| HY-121318 | LK 11 | 74143-01-4 | Reference compound |
| HY-121319 | Chloranocryl | 2164-09-2 | Reference compound |
| HY-121320 | Raptinal | 1176-09-6 | Reference compound |
| HY-121322 | Neoagarobiose | 484-58-2 | Natural Products |
| HY-121323 | Erucin | 4430-36-8 | Reference compound |
| HY-121323R | Erucin (Standard) | 4430-36-8 | Reference Standards |
| HY-121324 | Prometryn | 7287-19-6 | Reference compound |
| HY-121324R | Prometryn (Standard) | 7287-19-6 | Reference Standards |
| HY-121324S | Prometryn-d14 | 1202864-57-0 | Isotope-Labeled Compounds |
| HY-121325 | Fervenulin | 483-57-8 | Reference compound |
| HY-121328 | Empenthrin | 54406-48-3 | Reference compound |
| HY-121329 | Carumonam | 87638-04-8 | Reference compound |
| HY-121330 | Convolvine | 537-30-4 | Natural Products |
| HY-121331 | Butralin | 33629-47-9 | Reference compound |
| HY-121331R | Butralin (Standard) | 33629-47-9 | Reference Standards |
| HY-121332 | Cyclopeptine | 50886-63-0 | Reference compound |
| HY-121333 | Dinactin | 20261-85-2 | Natural Products |
| HY-121335 | Chlorthal | 2136-79-0 | Reference compound |
| HY-121337 | Flurochloridone | 61213-25-0 | Reference compound |
| HY-121337R | Flurochloridone (Standard) | 61213-25-0 | Reference Standards |
| HY-121338 | Karbutilate | 4849-32-5 | Reference compound |
| HY-121338R | Karbutilate (Standard) | 4849-32-5 | Reference Standards |
| HY-12134 | Poloxin | 321688-88-4 | Reference compound |
| HY-121340 | Emylcamate | 78-28-4 | Reference compound |
| HY-121341 | Brodimoprim | 56518-41-3 | Reference compound |
| HY-121341R | Brodimoprim (Standard) | 56518-41-3 | Reference Standards |
| HY-121345 | Homobaldrinal | 67910-07-0 | Natural Products |
| HY-121347 | Enterocin | 59678-46-5 | Natural Products |
| HY-121348 | Ficellomycin | 59458-27-4 | Natural Products |
| HY-121349 | Aerothionin | 28714-26-3 | Natural Products |
| HY-12135 | Poloxipan | 1239513-63-3 | Reference compound |
| HY-121350 | Merodantoin | 143413-73-4 | Reference compound |
| HY-121351 | Inokosterone | 15130-85-5 | Natural Products |
| HY-121352 | Kibdelone C | 934464-79-6 | Reference compound |
| HY-121354 | Hydracarbazine | 3614-47-9 | Reference compound |
| HY-121356 | Carebastine | 90729-42-3 | Reference compound |
| HY-121356S | Carebastine-d5 | 1189661-02-6 | Isotope-Labeled Compounds |
| HY-121356S1 | Carebastine-d5 Methyl Ester | 1190019-51-2 | Isotope-Labeled Compounds |
| HY-121358 | Lactiflorasyne | 107259-45-0 | Natural Products |
| HY-12136 | Purpurogallin | 569-77-7 | Natural Products |
| HY-121360 | Cylindrospermopsin | 143545-90-8 | Natural Products |
| HY-121362 | Evernic Acid | 537-09-7 | Natural Products |
| HY-121362R | Evernic Acid (Standard) | 537-09-7 | Reference Standards |
| HY-121364 | Bodilisant | 1416130-06-7 | Dye Reagents |
| HY-121365 | Forphenicinol | 71522-58-2 | Reference compound |
| HY-121366 | Kadethrin | 58769-20-3 | Reference compound |
| HY-121367 | Lythrine | 5286-10-2 | Reference compound |
| HY-121368 | Mahanine | 28360-49-8 | Natural Products |
| HY-12137 | Volasertib | 755038-65-4 | Reference compound |
| HY-121370 | a-D-Galactose | 3646-73-9 | Natural Products |
| HY-121372 | Lactandrate | 43000-65-3 | Reference compound |
| HY-121374 | Cardanol diene | 51546-63-5 | Reference compound |
| HY-121376 | Neoamygdalin | 29883-16-7 | Natural Products |
| HY-121377 | Epiyangambin | 24192-64-1 | Natural Products |
| HY-12137A | Volasertib (trihydrochloride) | 946161-17-7 | Reference compound |
| HY-121380 | Secologanate | 22864-93-3 | Natural Products |
| HY-121381 | Kuraridine | 34981-25-4 | Natural Products |
| HY-121382 | Gypsogenin | 639-14-5 | Natural Products |
| HY-121382R | Gypsogenin (Standard) | 639-14-5 | Reference Standards |
| HY-121383 | Labetalol | 36894-69-6 | Reference compound |
| HY-121383R | Labetalol (Standard) | 36894-69-6 | Reference Standards |
| HY-121385 | Hydroxy bosentan | 253688-60-7 | Reference compound |
| HY-121385S | Hydroxy Bosentan-d6 | 1246817-57-1 | Isotope-Labeled Compounds |
| HY-121385S1 | Hydroxy Bosentan-d4 | 1065472-91-4 | Isotope-Labeled Compounds |
| HY-121386 | Yuanhuanin | 83133-14-6 | Natural Products |
| HY-121387 | Furmecyclox | 60568-05-0 | Reference compound |
| HY-121388 | Ledol | 577-27-5 | Natural Products |
| HY-121389 | Hexadecanamide | 629-54-9 | Natural Products |
| HY-121390 | Lasiocarpine | 303-34-4 | Natural Products |
| HY-121390A | Lasiocarpine (hydrochloride) | 1976-49-4 | Reference compound |
| HY-121391 | Hedonal | 541-95-7 | Reference compound |
| HY-121392 | GR 125743 | 148547-33-5 | Reference compound |
| HY-121393 | Imidazenil | 151271-08-8 | Reference compound |
| HY-121394 | L-659,989 | 113787-28-3 | Reference compound |
| HY-121395 | Lepiochlorin | 71339-41-8 | Natural Products |
| HY-121397 | Phyltetralin | 123048-17-9 | Natural Products |
| HY-121398 | Dipivefrin | 52365-63-6 | Reference compound |
| HY-121399 | Gizzerosine | 89238-78-8 | Reference compound |
| HY-12140 | Vestipitant | 334476-46-9 | Reference compound |
| HY-121400 | Hepaxanthin | 512-39-0 | Reference compound |
| HY-121401 | Myrtenal | 564-94-3 | Natural Products |
| HY-121401A | (−)-Myrtenal | 18486-69-6 | Natural Products |
| HY-121404 | Muscarine | 300-54-9 | Reference compound |
| HY-121404A | Muscarine (chloride) | 2303-35-7 | Reference compound |
| HY-121404B | Muscarine (tosylate) | 82083-43-0 | Reference compound |
| HY-121405 | Malonomicin | 38249-71-7 | Reference compound |
| HY-121406 | (Z)-Lafutidine | 206449-93-6 | Reference compound |
| HY-121407 | Lateritin | 172721-98-1 | Natural Products |
| HY-121408 | Hymexelsin | 117842-09-8 | Natural Products |
| HY-121410 | Narasin | 55134-13-9 | Reference compound |
| HY-121411 | Disparlure | 29804-22-6 | Natural Products |
| HY-121412 | Lankacidin C | 23623-31-6 | Natural Products |
| HY-121413 | Clinolamide | 3207-50-9 | Reference compound |
| HY-121414 | Phenazine oxide | 304-81-4 | Reference compound |
| HY-121415 | Herkinorin | 862073-77-6 | Reference compound |
| HY-121416 | Jurubidine | 6084-44-2 | Natural Products |
| HY-121417 | Laserpitin | 7067-12-1 | Reference compound |
| HY-121418 | Lusianthridin | 87530-30-1 | Natural Products |
| HY-12142 | Vofopitant | 168266-90-8 | Reference compound |
| HY-121421 | Diniprofylline | 17692-30-7 | Reference compound |
| HY-121422 | JZP-361 | 1680193-80-9 | Reference compound |
| HY-121423 | Dimethachlor | 50563-36-5 | Reference compound |
| HY-121423R | Dimethachlor (Standard) | 50563-36-5 | Reference Standards |
| HY-121425 | Dunnione | 33404-57-8 | Natural Products |
| HY-121426 | BPP | 73671-44-0 | Reference compound |
| HY-121427 | Fluazifop | 69335-91-7 | Reference compound |
| HY-121427R | Fluazifop (Standard) | 69335-91-7 | Reference Standards |
| HY-121428 | Fagaramide | 60045-88-7 | Reference compound |
| HY-121429 | Dymanthine | 124-28-7 | Reference compound |
| HY-12142S | rac-Vofopitant-d3 | | Isotope-Labeled Compounds |
| HY-12143 | Vofopitant (dihydrochloride) | 168266-51-1 | Reference compound |
| HY-121430 | Lamellarin H | 115982-22-4 | Natural Products |
| HY-121431 | FR-901235 | 124190-19-8 | Natural Products |
| HY-121432 | Kitol | 4626-00-0 | Reference compound |
| HY-121434 | N-Deacetylcolchicine | 3476-50-4 | Reference compound |
| HY-121435 | K-8012 | 1346513-17-4 | Reference compound |
| HY-121436 | Levoxadrol | 4792-18-1 | Reference compound |
| HY-121441 | Fispemifene | 341524-89-8 | Reference compound |
| HY-121442 | Enpiperate | 3608-67-1 | Reference compound |
| HY-121444 | MYRA-A | 3900-43-4 | Reference compound |
| HY-121447 | Heneicosanoic acid | 2363-71-5 | Natural Products |
| HY-121447R | Heneicosanoic acid (Standard) | 2363-71-5 | Reference Standards |
| HY-121448 | GW409544 | 258345-41-4 | Reference compound |
| HY-12145 | CP-99994 (hydrochloride) | 145148-39-6 | Reference compound |
| HY-121450 | Lavoltidine | 76956-02-0 | Reference compound |
| HY-121451 | Dibenzyl phthalate | 523-31-9 | Reference compound |
| HY-121451S | Dibenzyl Phthalate-d4 | 1015854-62-2 | Isotope-Labeled Compounds |
| HY-121452 | Migrastatin | 314245-65-3 | Natural Products |
| HY-121453 | Bamifylline (hydrochloride) | 20684-06-4 | Reference compound |
| HY-121453R | Bamifylline (hydrochloride) (Standard) | 20684-06-4 | Reference Standards |
| HY-121456 | Salnacedin | 87573-01-1 | Reference compound |
| HY-121457 | 9-Nitrooleate | 875685-44-2 | Reference compound |
| HY-121457S | 9-Nitrooleate-d17 | 2714117-50-5 | Isotope-Labeled Compounds |
| HY-121458 | Nemorosone | 351416-47-2 | Natural Products |
| HY-121459 | Neoantimycin | 22862-63-1 | Reference compound |
| HY-12146 | ELOVL6-IN-2 | 1067647-43-1 | Reference compound |
| HY-121460 | Spiraprilat | 83602-05-5 | Reference compound |
| HY-121461 | A25822B | 50686-98-1 | Reference compound |
| HY-121462 | Cyanine | 523-42-2 | Biochemical Assay Reagents |
| HY-121465 | Stearoyl Serotonin | 67964-87-8 | Reference compound |
| HY-121466 | Ormetoprim | 6981-18-6 | Reference compound |
| HY-121466R | Ormetoprim (Standard) | 6981-18-6 | Reference Standards |
| HY-121467 | Acotiamide | 185106-16-5 | Reference compound |
| HY-121467A | Acotiamide (hydrochloride) | 185104-11-4 | Reference compound |
| HY-121467AS | Acotiamide-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-121467S | Acotiamide-d6 | 2749427-97-0 | Isotope-Labeled Compounds |
| HY-121467S1 | Acotiamide-d4 | | Isotope-Labeled Compounds |
| HY-121469 | Dioxone | 702-54-5 | Reference compound |
| HY-121470 | Vesamicol | 22232-64-0 | Reference compound |
| HY-121471 | Chrysoeriol | 491-71-4 | Natural Products |
| HY-121471R | Chrysoeriol (Standard) | 491-71-4 | Reference Standards |
| HY-121473 | Aklavin | 60504-57-6 | Reference compound |
| HY-121474 | Dactimicin | 73196-97-1 | Natural Products |
| HY-121476 | Arachidonoyl Serinol | 183718-70-9 | Reference compound |
| HY-121477 | Resorantel | 20788-07-2 | Reference compound |
| HY-121477R | Resorantel (Standard) | 20788-07-2 | Reference Standards |
| HY-121478 | Nifoxipam | 74723-10-7 | Reference compound |
| HY-121481 | Cucurbitadienol | 35012-08-9 | Natural Products |
| HY-121482 | (+)-Ochromycinone | 28882-53-3 | Natural Products |
| HY-121483 | Leucinal | 82473-52-7 | Reference compound |
| HY-121488 | GP130 receptor agonist-1 | 339303-87-6 | Reference compound |
| HY-12149 | A-867744 | 1000279-69-5 | Reference compound |
| HY-121490 | IMM-02 | 218929-99-8 | Reference compound |
| HY-121491 | ONO-6126 | 401519-28-6 | Reference compound |
| HY-121493 | TM2-115 | 1197196-47-6 | Reference compound |
| HY-121495 | BKI-1369 | 1951431-22-3 | Reference compound |
| HY-121496 | 3M-011 | 642473-62-9 | Reference compound |
| HY-121497 | 3-Methoxybenzamide | 5813-86-5 | Reference compound |
| HY-12150 | CCMI | 917837-54-8 | Reference compound |
| HY-121503 | FD44 | 68207-21-6 | Reference compound |
| HY-121504A | 4-Methylcathinone (hydrochloride) | 6941-17-9 | Reference compound |
| HY-121507 | Hydroxy-PEG2-C2-sulfonic acid | 112724-27-3 | Reference compound |
| HY-121508 | (E/Z)-IT-603 | 292168-90-2 | Reference compound |
| HY-12151 | NS 1738 | 501684-93-1 | Reference compound |
| HY-121512 | SK-7041 | 617690-98-9 | Reference compound |
| HY-121513 | Torcitabine | 40093-94-5 | Oligonucleotides |
| HY-121514 | Talopeptin | 84235-60-9 | Reference compound |
| HY-121515 | DPM-1001 | 1471172-27-6 | Reference compound |
| HY-121515A | DPM-1001 (trihydrochloride) | | Reference compound |
| HY-121516 | CM-TPMF | 477865-59-1 | Reference compound |
| HY-121517 | URB754 | 86672-58-4 | Reference compound |
| HY-121519 | GSK2332255B | 1366233-41-1 | Reference compound |
| HY-12152 | PNU-120596 | 501925-31-1 | Reference compound |
| HY-121520 | Docosahexaenoyl glycine | 132850-40-9 | Peptides |
| HY-121522 | SD-70 | 332173-89-4 | Reference compound |
| HY-121523 | MIND4-17 | 345989-24-4 | Reference compound |
| HY-121524 | DJ101 | 1803242-21-8 | Reference compound |
| HY-121525 | Biebrich scarlet | 4196-99-0 | Dye Reagents |
| HY-121526 | S-Nitroso-N-acetyl-DL-penicillamine | 67776-06-1 | Reference compound |
| HY-121527 | Amylmetacresol | 1300-94-3 | Reference compound |
| HY-121527R | Amylmetacresol (Standard) | 1300-94-3 | Reference Standards |
| HY-121528 | Nilestriol | 39791-20-3 | Reference compound |
| HY-12153 | JNJ-1930942 | 929562-28-7 | Reference compound |
| HY-121532 | (-)-Rasfonin | 303156-68-5 | Natural Products |
| HY-121535 | Levosemotiadil | 116476-16-5 | Reference compound |
| HY-121537 | CAY10404 | 340267-36-9 | Reference compound |
| HY-121538 | CUDA | 479413-68-8 | Reference compound |
| HY-121538A | CUDA (disodium) | | Reference compound |
| HY-121538S | CUDA-d11 | | Isotope-Labeled Compounds |
| HY-121539 | Supercinnamaldehyde | 70351-51-8 | Reference compound |
| HY-121540 | IWP-2-V2 | 877618-79-6 | Reference compound |
| HY-121541 | CB-25 | 869376-63-6 | Reference compound |
| HY-121542 | PPARδ agonist 10 | 685139-10-0 | Reference compound |
| HY-121543 | Sch 38548 | 107811-54-1 | Reference compound |
| HY-121544 | Methicillin | 61-32-5 | Reference compound |
| HY-121544A | Methicillin (sodium hydrate) | 7246-14-2 | Reference compound |
| HY-121544AR | Methicillin (sodium hydrate) (Standard) | 7246-14-2 | Reference Standards |
| HY-121545 | CB-52 | 869376-90-9 | Reference compound |
| HY-121546 | ALLO-1 | 37468-32-9 | Reference compound |
| HY-121548 | Drimentine A | 204398-90-3 | Reference compound |
| HY-121549 | S-NEPC | 147349-28-8 | Reference compound |
| HY-12155 | JNJ-26990990 | 877316-38-6 | Reference compound |
| HY-121550 | ME3221 | 139958-16-0 | Reference compound |
| HY-121553 | Prenisteine | 5287-46-7 | Reference compound |
| HY-121556 | Rufigallol | 82-12-2 | Reference compound |
| HY-121557 | OMDM-1 | 616884-62-9 | Reference compound |
| HY-121558 | JP104 | 887264-45-1 | Reference compound |
| HY-121560 | L-leucyldoxorubicin | 70774-25-3 | Reference compound |
| HY-121562 | SB 714786 | 584555-10-2 | Reference compound |
| HY-121564 | Radermachol | 95378-00-0 | Dye Reagents |
| HY-121565 | SaRI 59-801 | 80565-58-8 | Reference compound |
| HY-121567 | Metipranolol | 22664-55-7 | Reference compound |
| HY-121567R | Metipranolol (Standard) | 22664-55-7 | Reference Standards |
| HY-121569 | Syntelin | 438481-33-5 | Reference compound |
| HY-12157 | VU 0238429 | 1160247-92-6 | Reference compound |
| HY-121570 | Noxytiolin | 15599-39-0 | Reference compound |
| HY-121573 | α-Acetyldigoxin | 5511-98-8 | Reference compound |
| HY-121575 | Lythridine | 15299-77-1 | Reference compound |
| HY-121576 | Butenachlor | 87310-56-3 | Reference compound |
| HY-121577 | Sonlicromanol | 1541170-75-5 | Reference compound |
| HY-121578 | Agaridoxin | 58298-77-4 | Reference compound |
| HY-121579 | L-764406 | 227002-04-2 | Reference compound |
| HY-12158 | VU0238441 | 85511-68-8 | Reference compound |
| HY-121580 | Tabimorelin | 193079-69-5 | Reference compound |
| HY-121582 | (E)-SI-2 | 380537-35-9 | Reference compound |
| HY-121583 | Gemcadiol | 35449-36-6 | Reference compound |
| HY-121584 | Lycoperodine-1 | 42438-90-4 | Natural Products |
| HY-121585 | CAY10698 | 684236-01-9 | Reference compound |
| HY-121586 | Nafazatrom | 59040-30-1 | Reference compound |
| HY-121587 | Etisazole | 7716-60-1 | Reference compound |
| HY-121588 | IMTPPE | 851688-13-6 | Reference compound |
| HY-12159 | MK-0668 | 865110-07-2 | Reference compound |
| HY-121591 | A-28086B | 58439-94-4 | Natural Products |
| HY-121592 | Yokonoside | 53823-12-4 | Natural Products |
| HY-121593 | Ruizgenin | 41743-71-9 | Reference compound |
| HY-121594 | GSK-269984B | 892664-17-4 | Reference compound |
| HY-121595 | 5,5-Diphenylbarbituric acid | 21914-07-8 | Reference compound |
| HY-121596 | Styramate | 94-35-9 | Reference compound |
| HY-121597 | Yuankanin | 77099-20-8 | Natural Products |
| HY-121598 | Actisomide | 96914-39-5 | Reference compound |
| HY-121599 | CGP 36742 | 123690-78-8 | Reference compound |
| HY-12159A | MK-0668 (mesylate) | 865111-04-2 | Reference compound |
| HY-121600 | GAT229 | 889860-85-9 | Reference compound |
| HY-121601 | Lichesterol | 50657-31-3 | Natural Products |
| HY-121602 | DSP 4 (free base) | 62078-98-2 | Reference compound |
| HY-121603 | Bornaprine | 20448-86-6 | Reference compound |
| HY-121604 | (Rac)-MEM 1003 | 165187-25-7 | Reference compound |
| HY-121605 | RL71 | 1195795-93-7 | Reference compound |
| HY-121607 | INI-43 | 881046-01-1 | Reference compound |
| HY-121608 | Lumiflavin | 1088-56-8 | Dye Reagents |
| HY-121609 | Pholedrine | 370-14-9 | Reference compound |
| HY-121609A | Pholedrine (hydrochloride) | 877-86-1 | Reference compound |
| HY-121610 | FR-202306 | 342785-41-5 | Reference compound |
| HY-121611 | HI-236 | 233271-65-3 | Reference compound |
| HY-121613 | Resistoflavine | 29706-96-5 | Reference compound |
| HY-121614 | Ribocitrin | 77752-20-6 | Reference compound |
| HY-121615 | α-Phellandrene | 99-83-2 | Natural Products |
| HY-121616 | (R)-SLV 319 | 656827-86-0 | Reference compound |
| HY-121617 | Bucainide | 51481-62-0 | Reference compound |
| HY-121618 | α-Thujone | 546-80-5 | Natural Products |
| HY-121619 | Jacaric acid | 28872-28-8 | Natural Products |
| HY-121620 | Monolaurin | 142-18-7 | Reference compound |
| HY-121620S | Monolaurin-d23 | | Isotope-Labeled Compounds |
| HY-121621 | RO5101576 | 1123155-95-2 | Reference compound |
| HY-121623 | VU0359516 | 1220513-59-6 | Reference compound |
| HY-121624 | Anthglutin | 69168-09-8 | Natural Products |
| HY-121626 | SKF 83692 | 99234-87-4 | Reference compound |
| HY-121629 | PS210 | 1221962-86-2 | Reference compound |
| HY-12163 | Entinostat | 209783-80-2 | Reference compound |
| HY-121631 | Yibeissine | 143502-51-6 | Natural Products |
| HY-121632 | Quinoclamine | 2797-51-5 | Reference compound |
| HY-121632R | Quinoclamine (Standard) | 2797-51-5 | Reference Standards |
| HY-121633 | Kayahope | 49828-25-3 | Reference compound |
| HY-121634 | DAP-81 | 794466-17-4 | Reference compound |
| HY-121635 | FOX-7 | 145250-81-3 | Reference compound |
| HY-121636 | Resolvin D2 | 810668-37-2 | Reference compound |
| HY-121636S | Resolvin D2-d5 | 1881277-33-3 | Isotope-Labeled Compounds |
| HY-121637 | IDFP | 615250-02-7 | Reference compound |
| HY-121638 | CU-3 | 2983265-35-4 | Reference compound |
| HY-121638A | (5Z,2E)-CU-3 | 1815598-71-0 | Reference compound |
| HY-121638B | (E/Z)-CU-3 | 861123-84-4 | Reference compound |
| HY-12163S | Entinostat-d4 | | Isotope-Labeled Compounds |
| HY-12164 | Mocetinostat | 726169-73-9 | Reference compound |
| HY-121641 | Nitrosobenzene | 586-96-9 | Reference compound |
| HY-121642 | SL-017 | 1169831-01-9 | Reference compound |
| HY-121644 | Viminol | 21363-18-8 | Reference compound |
| HY-121645 | 2,4-Dibromoestradiol | 19590-55-7 | Reference compound |
| HY-121647 | Nopol | 128-50-7 | Reference compound |
| HY-121648 | PK 130 | 140448-29-9 | Reference compound |
| HY-121649 | AQ4 | 70476-63-0 | Reference compound |
| HY-121650 | ADTN | 53463-78-8 | Reference compound |
| HY-121650A | ADTN (hydrobromide) | 13575-86-5 | Biochemical Assay Reagents |
| HY-121652 | Mefox | 79573-48-1 | Reference compound |
| HY-121653 | Flesinoxan | 98206-10-1 | Reference compound |
| HY-121653B | Flesinoxan (hydrochloride) | 98205-89-1 | Reference compound |
| HY-121654 | L-Iditol | 488-45-9 | Biochemical Assay Reagents |
| HY-121655 | Dansyllysine | 1101-84-4 | Dye Reagents |
| HY-121656 | AKR1C2/3-IN-2 | 56600-73-8 | Reference compound |
| HY-121657 | Ornidazole diol | 62580-80-7 | Reference compound |
| HY-121657R | Ornidazole diol (Standard) | 62580-80-7 | Reference Standards |
| HY-121659 | DCFBC | 564482-79-7 | Reference compound |
| HY-121660 | Hexyl nicotinate | 23597-82-2 | Reference compound |
| HY-121661 | Antibacterial agent 201 | 1666171-29-4 | Reference compound |
| HY-121662 | Lenaldekar | 418800-15-4 | Reference compound |
| HY-121663 | ST-148 | 400863-77-6 | Reference compound |
| HY-121665 | Rosaprostol | 56695-65-9 | Reference compound |
| HY-121667 | Scaff10-8 | 777857-56-4 | Reference compound |
| HY-121670 | Ambenoxan | 2455-84-7 | Reference compound |
| HY-121670A | Ambenoxan (hydrochloride) | 1617-99-8 | Reference compound |
| HY-121671 | TBTC | 213192-26-8 | Reference compound |
| HY-121672 | PI3K-IN-7 | 1502813-63-9 | Reference compound |
| HY-121675 | 2-Bromo-LSD | 478-84-2 | Reference compound |
| HY-121677 | Norgestomet | 25092-41-5 | Reference compound |
| HY-121678 | Tetridamine | 17289-49-5 | Reference compound |
| HY-121679 | COX-2-IN-50 | 1242169-24-9 | Reference compound |
| HY-12168 | Tanomastat | 179545-77-8 | Reference compound |
| HY-121681 | K 308 | 36774-74-0 | Reference compound |
| HY-121683 | (E)-2-Hexadecenal | 22644-96-8 | Reference compound |
| HY-121684 | Ramentaceone | 14787-38-3 | Natural Products |
| HY-121685 | Tipepidine | 5169-78-8 | Reference compound |
| HY-121685A | Tipepidine (hydrochloride) | 1449686-84-3 | Reference compound |
| HY-121687 | HIPP | 3682-17-5 | Natural Products |
| HY-121688 | Sulphenone | 80-00-2 | Reference compound |
| HY-12168B | (Rac)-Tanomastat | 179545-76-7 | Reference compound |
| HY-12169 | Marimastat | 154039-60-8 | Reference compound |
| HY-121690 | Semotiadil | 116476-13-2 | Reference compound |
| HY-121691 | Sugereoside | 41743-57-1 | Natural Products |
| HY-121692 | (S)-Alprenolol | 23846-71-1 | Reference compound |
| HY-121692A | (S)-Alprenolol (L-tartrate) | 16768-36-8 | Reference compound |
| HY-121692B | (S)-Alprenolol (hydrochloride) | 15132-12-4 | Reference compound |
| HY-121693 | DIDS | 53005-05-3 | Reference compound |
| HY-121694 | CENTA | 80072-86-2 | Reference compound |
| HY-121696 | Penicillin N | 525-94-0 | Reference compound |
| HY-121699 | Kibdelone B | 934464-78-5 | Reference compound |
| HY-12170 | Prinomastat | 192329-42-3 | Reference compound |
| HY-121700 | L-751788 | 166174-54-5 | Reference compound |
| HY-121701 | SR33805 (analog) | 121346-32-5 | Reference compound |
| HY-121702 | Dihydrohomofolic acid | 14866-11-6 | Reference compound |
| HY-121703 | Rutacridone | 17948-33-3 | Natural Products |
| HY-121704 | SR 57227A (free base) | 77145-51-8 | Reference compound |
| HY-121705 | Propionyl-L-carnitine | 20064-19-1 | Peptides |
| HY-121708 | KI-328 | 930089-25-1 | Reference compound |
| HY-121709 | 4-Aminopteroylaspartic acid | 25312-31-6 | Reference compound |
| HY-12170A | Prinomastat (hydrochloride) | 1435779-45-5 | Reference compound |
| HY-12170B | (R)-Prinomastat | 207795-16-2 | Reference compound |
| HY-121710 | MonoHER | 23869-24-1 | Reference compound |
| HY-121711 | 5-OH-HxMF | 1176-88-1 | Natural Products |
| HY-121713 | Aniline mustard | 553-27-5 | Reference compound |
| HY-121716 | Pelagiomicin A | 173485-80-8 | Natural Products |
| HY-121718 | DQBS | 372087-80-4 | Reference compound |
| HY-121719 | TIQ-A | 420849-22-5 | Reference compound |
| HY-12172 | MK-8141 | 903579-36-2 | Reference compound |
| HY-121720 | L 657925 | 122757-59-9 | Reference compound |
| HY-121721 | Inz-5 | 1585214-21-6 | Reference compound |
| HY-121722 | Deoxyhypusine | 82543-85-9 | Reference compound |
| HY-121725 | MM-206 | 1809581-87-0 | Reference compound |
| HY-121726 | 3HOI-BA-01 | 355428-84-1 | Reference compound |
| HY-121727 | Triafamone | 874195-61-6 | Reference compound |
| HY-121728 | Langkamide | 1370510-16-9 | Reference compound |
| HY-121731 | Nimbocinone | 105532-11-4 | Natural Products |
| HY-121733 | PHGDH-inactive | 1914971-16-6 | Reference compound |
| HY-121735 | 2α-Mannobiose | 15548-39-7 | Reference compound |
| HY-121736 | AGI-12026 | 1446501-77-4 | Reference compound |
| HY-121738 | TC AC 28 | 1809296-92-1 | Reference compound |
| HY-12174 | Zankiren | 138742-43-5 | Reference compound |
| HY-121740 | FAUC-312 | 562104-72-7 | Reference compound |
| HY-121743 | Ro26-4550 | 193744-04-6 | Reference compound |
| HY-121744 | PS10 | 1564265-82-2 | Reference compound |
| HY-121745 | Phosmet oxon | 3735-33-9 | Reference compound |
| HY-121745R | Phosmet oxon (Standard) | 3735-33-9 | Reference Standards |
| HY-121746 | GW7845 | 196809-22-0 | Reference compound |
| HY-121748 | Erycibelline | 107633-95-4 | Natural Products |
| HY-121750 | CCG-222740 | 1922098-69-8 | Reference compound |
| HY-121751 | A 643C | 65822-42-6 | Reference compound |
| HY-121754 | Daphnecinnamte B | 325148-07-0 | Natural Products |
| HY-121755 | Tibric acid | 37087-94-8 | Reference compound |
| HY-121758 | 2-Hydroxyicosanoic acid | 16742-48-6 | Natural Products |
| HY-12176 | Aliskiren | 173334-57-1 | Reference compound |
| HY-121760 | Liconeolignan | 82209-75-4 | Natural Products |
| HY-121761 | Pyrazolate | 58011-68-0 | Reference compound |
| HY-121762 | NTE-122 (dihydrochloride) | 166967-84-6 | Reference compound |
| HY-121763 | SCH-43478 | 112446-99-8 | Reference compound |
| HY-121764 | MPCI | 884538-31-2 | Reference compound |
| HY-121765 | Dacisteine | 18725-37-6 | Reference compound |
| HY-121765R | Dacisteine (Standard) | 18725-37-6 | Reference Standards |
| HY-121766 | Iprovalicarb | 140923-17-7 | Reference compound |
| HY-121767 | PD 123177 | 114785-12-5 | Reference compound |
| HY-121768 | Trimethacarb | 2686-99-9 | Reference compound |
| HY-121769 | BFE-61 | 39543-80-1 | Reference compound |
| HY-12176A | Aliskiren (hydrochloride) | 173399-03-6 | Reference compound |
| HY-12176AS | Aliskiren-d6 (hydrochloride) | 1246815-96-2 | Isotope-Labeled Compounds |
| HY-12176B | Aliskiren (fumarate) | 1196835-68-3 | Reference compound |
| HY-12176R | Aliskiren (Standard) | 173334-57-1 | Reference Standards |
| HY-12177 | Aliskiren (hemifumarate) | 173334-58-2 | Reference compound |
| HY-121770 | Rutarin | 20320-81-4 | Natural Products |
| HY-121771 | Fenothiocarb | 62850-32-2 | Reference compound |
| HY-121773 | Metoquizine | 7125-67-9 | Reference compound |
| HY-121775 | PF-00217830 | 846032-02-8 | Reference compound |
| HY-121776 | Nicomol | 27959-26-8 | Reference compound |
| HY-121777 | SFOM-0046 | 1383607-61-1 | Reference compound |
| HY-121778 | Melitracen | 5118-29-6 | Reference compound |
| HY-121779 | o,p'-DDE | 3424-82-6 | Reference compound |
| HY-121779S | 2,4’-DDE-d8 | 1402834-57-4 | Isotope-Labeled Compounds |
| HY-12177S | Aliskiren-d6 (hemifumarate) | | Isotope-Labeled Compounds |
| HY-121780 | Aranorosin | 117184-53-9 | Natural Products |
| HY-121782 | A 65281 | 111279-49-3 | Reference compound |
| HY-121783 | BE2254 | 40077-13-2 | Reference compound |
| HY-121784 | Maridomycin | 35775-82-7 | Natural Products |
| HY-121785 | 10-Thiofolic acid | 54931-98-5 | Reference compound |
| HY-121787 | OX1a | 136340-88-0 | Reference compound |
| HY-121789 | Proadifen | 302-33-0 | Reference compound |
| HY-121789S | Proadifen-d2 | 151412-33-8 | Isotope-Labeled Compounds |
| HY-121791S | Fluometuron-d6 | 2030182-29-5 | Isotope-Labeled Compounds |
| HY-121792 | CK2-IN-1 | 51726-83-1 | Reference compound |
| HY-121793 | Roemerine | 548-08-3 | Natural Products |
| HY-121794 | Avarol | 55303-98-5 | Natural Products |
| HY-121795 | Pravastatin lactone | 85956-22-5 | Reference compound |
| HY-121795S | Pravastatin lactone-d3 | 1217769-04-4 | Isotope-Labeled Compounds |
| HY-121796 | Mixanpril | 156039-69-9 | Reference compound |
| HY-121798 | TZD18 | 228577-00-2 | Reference compound |
| HY-121799 | Taurohyocholic acid | 32747-07-2 | Reference compound |
| HY-121799A | Taurohyocholic acid (sodium salt) | 117997-17-8 | Reference compound |
| HY-121799S | Taurohyocholic acid-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-121800 | ML138 | 1355243-24-1 | Reference compound |
| HY-121801 | Zarilamid | 84527-51-5 | Reference compound |
| HY-121802 | Dynarrestin | 2222768-84-3 | Reference compound |
| HY-121804 | SSJ-183 | 1187533-34-1 | Reference compound |
| HY-121805 | DBCO-C6-acid | 1425485-72-8 | ADC Related |
| HY-121806 | VU0486846 | 1788055-11-7 | Reference compound |
| HY-121809S | DL-Methyldopa-d3 | | Isotope-Labeled Compounds |
| HY-121810 | LBT-999 | 877467-20-4 | Reference compound |
| HY-121811 | Pongamol | 484-33-3 | Reference compound |
| HY-121813 | Rimcazole | 75859-04-0 | Reference compound |
| HY-121814 | (S)-Acenocoumarol | 66556-78-3 | Reference compound |
| HY-121814A | (R)-Acenocoumarol | 66556-77-2 | Reference compound |
| HY-121817 | Sulfiram | 95-05-6 | Reference compound |
| HY-121817R | Sulfiram (Standard) | 95-05-6 | Reference Standards |
| HY-121818 | (-)-Tremetone | 4976-25-4 | Natural Products |
| HY-12182 | ONO-8711 | 216158-34-8 | Reference compound |
| HY-121820 | DMJ-I-228 | 1374035-59-2 | Reference compound |
| HY-121825 | U-44069 | 56985-32-1 | Reference compound |
| HY-121826 | Naronapride | 860174-12-5 | Reference compound |
| HY-121827 | LH21 | 611207-11-5 | Reference compound |
| HY-121828 | TX-1123 | 157397-06-3 | Reference compound |
| HY-12182A | ONO-8711 (dicyclohexylamine) | | Reference compound |
| HY-121830 | 5Z,8Z,11Z,14Z-Eicosatetraenoic acid, 3-thienylmethyl ester | 390824-17-6 | Reference compound |
| HY-121832 | DDX3-IN-1 | 1919828-83-3 | Reference compound |
| HY-121833 | Gambogic amide | 286935-60-2 | Reference compound |
| HY-121834 | RNase L-IN-2 | 357618-26-9 | Reference compound |
| HY-121835 | GLP-1R agonist 2 | 281209-71-0 | Reference compound |
| HY-121839 | Manoyl oxide | 596-84-9 | Reference compound |
| HY-12184 | ONO-AE 248 | 211230-67-0 | Reference compound |
| HY-121841 | Cannabidiorcol | 35482-50-9 | Reference compound |
| HY-121843 | Ronactolol | 90895-85-5 | Reference compound |
| HY-121845 | 4-Br-Bnlm | 1654775-71-9 | Reference compound |
| HY-121848 | VU0155094 | 731006-86-3 | Reference compound |
| HY-121849 | KL-1156 | 819868-62-7 | Reference compound |
| HY-12185 | BRD7389 | 376382-11-5 | Reference compound |
| HY-121850 | Rolicyprine | 2829-19-8 | Reference compound |
| HY-121851 | Revaprazan | 199463-33-7 | Reference compound |
| HY-121852 | SCH 336 | 447459-51-0 | Reference compound |
| HY-121854 | Bromadoline | 67579-24-2 | Reference compound |
| HY-121854A | Bromadoline (maleate) | 81447-81-6 | Reference compound |
| HY-121855 | 1-Monoelaidin | 2716-53-2 | Biochemical Assay Reagents |
| HY-121856 | Flumizole | 36740-73-5 | Reference compound |
| HY-121858 | Nicotianamine | 34441-14-0 | Natural Products |
| HY-121859 | RU28362 | 74915-64-3 | Reference compound |
| HY-12186 | 3-Deazaneplanocin A (hydrochloride) | 120964-45-6 | Reference compound |
| HY-121860 | L-Ascorbyl myristate | 33425-76-2 | Reference compound |
| HY-121862 | CM03 | 2101208-44-8 | Reference compound |
| HY-121866 | CP-84364 | 114457-62-4 | Reference compound |
| HY-121867 | KSCM-11 | 1415247-16-3 | Reference compound |
| HY-12186G | 3-Deazaneplanocin A (hydrochloride) (GMP) | 120964-45-6 | GMP Small Molecules |
| HY-121870 | Dimethocaine | 94-15-5 | Reference compound |
| HY-121870A | Dimethocaine (hydrochloride) | 553-63-9 | Reference compound |
| HY-121872 | DP-b99 | 222315-88-0 | Reference compound |
| HY-121873 | Lavendamycin | 81645-09-2 | Natural Products |
| HY-121874 | EP009 | 1462951-30-9 | Reference compound |
| HY-121877 | Valnoctamide | 4171-13-5 | Reference compound |
| HY-121877S | Valnoctamide-d5 | 1190015-82-7 | Isotope-Labeled Compounds |
| HY-121879 | SHP836 | 1957276-35-5 | Reference compound |
| HY-121880 | Difenoxuron | 14214-32-5 | Reference compound |
| HY-121881 | PU3 | 352519-21-2 | Reference compound |
| HY-121883 | Lignoceric acid | 557-59-5 | Natural Products |
| HY-121883R | Lignoceric acid (Standard) | 557-59-5 | Reference Standards |
| HY-121883S | Lignoceric acid-d47 | 68060-00-4 | Isotope-Labeled Compounds |
| HY-121883S1 | Lignoceric acid-d3 | 851073-55-7 | Isotope-Labeled Compounds |
| HY-121883S2 | Lignoceric acid-d4 | 61389-26-2 | Isotope-Labeled Compounds |
| HY-121883S3 | Lignoceric acid-d4-1 | 1219794-59-8 | Isotope-Labeled Compounds |
| HY-121883S4 | Lignoceric acid-d4-2 | 1219794-61-2 | Isotope-Labeled Compounds |
| HY-121883SS5 | Lignoceric acid-d9 | 2415226-90-1 | Isotope-Labeled Compounds |
| HY-121884 | Spiroxamine | 118134-30-8 | Reference compound |
| HY-121884R | Spiroxamine (Standard) | 118134-30-8 | Reference Standards |
| HY-121885 | LMD-009 | 950195-51-4 | Reference compound |
| HY-121886 | Bucricaine | 316-15-4 | Reference compound |
| HY-121888 | 20-HEPE | 116477-57-7 | Reference compound |
| HY-121889 | FQ | 190838-76-7 | Reference compound |
| HY-121890 | Etoxybamide | 66857-17-8 | Reference compound |
| HY-121891 | Rhinocaine | 32066-26-5 | Reference compound |
| HY-121892 | (Z)-KC02 | 1646795-60-9 | Reference compound |
| HY-121893 | p53-MDM2-IN-3 | 1542066-74-9 | Reference compound |
| HY-121895 | BI 831266 | 958227-46-8 | Reference compound |
| HY-121896 | DSHN | 313952-63-5 | Reference compound |
| HY-121898 | Milenperone | 59831-64-0 | Reference compound |
| HY-121899 | 1-Oxo Ibuprofen | 65813-55-0 | Reference compound |
| HY-121899R | 1-Oxo Ibuprofen (Standard) | 65813-55-0 | Reference Standards |
| HY-12190 | JNJ-5207852 | 398473-34-2 | Reference compound |
| HY-121900 | LT175 | 862901-87-9 | Reference compound |
| HY-121902 | Butidrine | 7433-10-5 | Reference compound |
| HY-121906 | DOAM | 63779-90-8 | Reference compound |
| HY-121907 | N-Palmitoyl L-alanine | 56255-31-3 | Reference compound |
| HY-121908 | FCPT | 862250-23-5 | Reference compound |
| HY-121909 | Piperic acid | 5285-18-7 | Reference compound |
| HY-12190A | JNJ-5207852 (dihydrochloride) | 1782228-76-5 | Reference compound |
| HY-12191 | A-331440 | 392338-13-5 | Reference compound |
| HY-121910 | Methyl 2-hydroxytetradecanoate | 56009-40-6 | Natural Products |
| HY-121914 | (2-Chlorophenyl)diphenylmethanol | 66774-02-5 | Reference compound |
| HY-121914R | (2-Chlorophenyl)diphenylmethanol (Standard) | 66774-02-5 | Reference Standards |
| HY-121914S | (2-Chlorophenyl)diphenyl-methanol-d5 | 1219802-30-8 | Isotope-Labeled Compounds |
| HY-121915 | 3-Hydroxyundecanoic acid | 40165-88-6 | Natural Products |
| HY-121917 | Ro 31-7837 | 120280-33-3 | Reference compound |
| HY-121918 | RU 41656 | 134377-22-3 | Reference compound |
| HY-12191A | A 331440 (hydrochloride) | 1049740-32-0 | Reference compound |
| HY-121920 | 25C-NBOH (hydrochloride) | 1539266-20-0 | Reference compound |
| HY-121922 | Dienone B | 17194-81-9 | Natural Products |
| HY-121924 | L-689065 | 146775-25-9 | Reference compound |
| HY-121927 | Mobiletrex | 238074-89-0 | Reference compound |
| HY-12193 | A-349821 | 556835-30-4 | Reference compound |
| HY-121930 | Coumarin 6H | 58336-35-9 | Dye Reagents |
| HY-121931 | AA863 | 80809-95-6 | Reference compound |
| HY-121932 | Naphthol AS-BR | 91-92-9 | Reference compound |
| HY-121933 | IDD388 | 314297-26-2 | Reference compound |
| HY-121934 | BH3I-2' | 315195-18-7 | Reference compound |
| HY-121935 | Tecnazene | 117-18-0 | Reference compound |
| HY-121935R | Tecnazene (Standard) | 117-18-0 | Reference Standards |
| HY-121936 | Yohimbic acid | 522-87-2 | Natural Products |
| HY-121936A | Yohimbic acid (hydrate) | 207801-27-2 | Reference compound |
| HY-121936R | Yohimbic acid (Standard) | 522-87-2 | Reference Standards |
| HY-121939 | 6-Hydroxy-L-DOPA | 27244-64-0 | Reference compound |
| HY-121939R | 6-Hydroxy-L-DOPA (Standard) | 27244-64-0 | Reference Standards |
| HY-121940 | 14-Methylhexadecanoic acid | 5918-29-6 | Biochemical Assay Reagents |
| HY-121941 | Epoxy Fluor 7 | 863223-43-2 | Dye Reagents |
| HY-121943 | 12-Methyltetradecanoic acid | 5502-94-3 | Biochemical Assay Reagents |
| HY-121944 | Ricinine | 524-40-3 | Natural Products |
| HY-121944R | Ricinine (Standard) | 524-40-3 | Reference Standards |
| HY-121944S | Ricinine-d3 | 1313734-77-8 | Isotope-Labeled Compounds |
| HY-121947 | 1'-Naphthoyl-2-methylindole | 80749-33-3 | Reference compound |
| HY-121948 | Sesamex | 51-14-9 | Reference compound |
| HY-121949 | U-0521 | 5466-89-7 | Reference compound |
| HY-12195 | ABT-239 | 460746-46-7 | Reference compound |
| HY-121950 | 18-Methyleicosanoic acid | 36332-93-1 | Reference compound |
| HY-121950S | 18-Methyleicosanoic acid-d3 | 2708278-14-0 | Isotope-Labeled Compounds |
| HY-121951 | N-Methylquipazine | 28614-26-8 | Reference compound |
| HY-121952 | (9E,11E)-9,11-Octadecadienoic acid methyl ester | 13038-47-6 | Reference compound |
| HY-121954 | Necrostatin-1 (inactive control) | 64419-92-7 | Reference compound |
| HY-121955 | FW1256 | 117089-08-4 | Reference compound |
| HY-121957 | BnO-PEG1-CH2COOH | 93206-09-8 | Reference compound |
| HY-121962 | neo-Inositol | 488-54-0 | Natural Products |
| HY-121964 | cis-Piperidine-2,3-dicarboxylic acid | 46026-75-9 | Reference compound |
| HY-121965 | β-D-Glucose | 492-61-5 | Biochemical Assay Reagents |
| HY-121966 | Riparin | 112356-54-4 | Reference compound |
| HY-121969 | DDX3-IN-2 | 1919828-81-1 | Reference compound |
| HY-121970 | iGP-1 | 27031-00-1 | Reference compound |
| HY-121971 | PMPMEase-IN-2 | 1190196-77-0 | Reference compound |
| HY-121973 | Juvocimene II | 75539-63-8 | Natural Products |
| HY-121974 | SR14150 | 709024-69-1 | Reference compound |
| HY-121975 | N-Cyclohexanecarbonylpentadecylamine | 702638-84-4 | Natural Products |
| HY-121977 | IKs124 | 199335-15-4 | Reference compound |
| HY-121978 | Laxifloran | 27973-50-8 | Natural Products |
| HY-121982 | Cyclo(L-Phe-L-Val) | 35590-86-4 | Reference compound |
| HY-121983 | CAY10594 | 1130067-34-3 | Reference compound |
| HY-121985 | Protheobromine | 50-39-5 | Reference compound |
| HY-121986 | Yellow AB | 85-84-7 | Dye Reagents |
| HY-121987 | 15(S)-HEDE | 92693-04-4 | Reference compound |
| HY-121987A | (±)15-HEDE | 77159-57-0 | Reference compound |
| HY-121988 | INF4E | 88039-46-7 | Reference compound |
| HY-121989 | cis-Trismethoxy resveratrol | 94608-23-8 | Reference compound |
| HY-12199 | Pitolisant | 362665-56-3 | Reference compound |
| HY-121991 | N-5-Carboxypentyl-1-deoxynojirimycin | 79206-51-2 | Reference compound |
| HY-121993 | Combretastatin A-1 | 109971-63-3 | Reference compound |
| HY-121995 | (14Z)-14-Eicosenoic acid | 17735-95-4 | Natural Products |
| HY-121996 | Prostaglandin E2 Ethanolamide | 194935-38-1 | Reference compound |
| HY-121996S | Prostaglandin E2 ethanolamide-d4 | 2389048-36-4 | Isotope-Labeled Compounds |
| HY-121998 | Binucleine 2 | 220088-42-6 | Reference compound |
| HY-121999 | (+)-cis-Abienol | 17990-16-8 | Reference compound |
| HY-12199A | Pitolisant (oxalate) | 362665-57-4 | Reference compound |
| HY-12199B | Pitolisant (hydrochloride) | 903576-44-3 | Reference compound |
| HY-12199BS | Pitolisant-d5 (hydrochloride) | 2740634-42-6 | Isotope-Labeled Compounds |
| HY-12199S | Pitolisant-d10 | | Isotope-Labeled Compounds |
| HY-12199S1 | Pitolisant-d6 | 2416991-77-8 | Isotope-Labeled Compounds |
| HY-12200 | GSK189254A (hydrochloride) | 945493-87-8 | Reference compound |
| HY-122001 | PF-05186462 | 1235406-03-7 | Reference compound |
| HY-122005 | AVE-9488 | 291756-32-6 | Reference compound |
| HY-122006 | NPD926 | 384361-79-9 | Reference compound |
| HY-122008 | ORM-3819 | 360794-85-0 | Reference compound |
| HY-122009 | Indican | 487-60-5 | Dye Reagents |
| HY-12201 | TAK-901 | 934541-31-8 | Reference compound |
| HY-122010 | NVP-AAD777 | 300842-59-5 | Reference compound |
| HY-122011 | PF-4950834 | 1256264-62-6 | Reference compound |
| HY-122014 | S 39625 | 536711-20-3 | Reference compound |
| HY-122015 | ASP2905 | 792184-90-8 | Reference compound |
| HY-122016A | BRD-4592 | 2119598-24-0 | Reference compound |
| HY-122017 | Methoxy-SANT-2 | 496793-78-3 | Reference compound |
| HY-122018 | GS-9148 | 875608-25-6 | Reference compound |
| HY-122019 | ABD56 | 521294-19-9 | Reference compound |
| HY-12201A | TAK-901 (hydrochloride) | 934542-50-4 | Reference compound |
| HY-12202 | MEK inhibitor | 334951-92-7 | Reference compound |
| HY-122021 | J-115814 | 329716-61-2 | Reference compound |
| HY-122022 | JR-AB2-011 | 2411853-34-2 | Reference compound |
| HY-122024 | AZSMO-23 | 496793-75-0 | Reference compound |
| HY-122025 | AC-262536 | 870888-46-3 | Reference compound |
| HY-122026 | PF-04802367 | 1962178-27-3 | Reference compound |
| HY-122028 | HSD-016 | 946396-92-5 | Reference compound |
| HY-122029 | BRD6897 | 618395-82-7 | Reference compound |
| HY-12203 | PFK-158 | 1462249-75-7 | Reference compound |
| HY-122030 | Lithooxazoline | 80724-92-1 | Natural Products |
| HY-122032 | A 58365A | 87896-52-4 | Natural Products |
| HY-122035 | Flambalactone | 55729-17-4 | Reference compound |
| HY-122036 | Flumedroxone acetate | 987-18-8 | Reference compound |
| HY-122038 | NU-8165 | 849723-20-2 | Reference compound |
| HY-122039 | Hypusine (dihydrochloride) | 82310-93-8 | Reference compound |
| HY-12204 | PFK-015 | 4382-63-2 | Reference compound |
| HY-122040 | 5-Chloro hydrochlorothiazide | 5233-42-1 | Reference compound |
| HY-122041 | Ethacridine | 442-16-0 | Reference compound |
| HY-122043 | Nimolinone | 106533-51-1 | Reference compound |
| HY-122046 | Amb123203 | 956571-77-0 | Reference compound |
| HY-122047 | SW063058 | 533876-30-1 | Reference compound |
| HY-122048 | AR-C67085 | 164992-25-0 | Reference compound |
| HY-122049 | ENMD-1068 (hydrobromide) | 644961-61-5 | Reference compound |
| HY-122050 | Oe-9000 | 675132-92-0 | Reference compound |
| HY-122051 | AC1903 | 831234-13-0 | Reference compound |
| HY-122052 | UK‑396082 | 400044-47-5 | Reference compound |
| HY-122053 | Amidephrine (hydrochloride) | 58921-07-6 | Reference compound |
| HY-122054 | BPK-29 | 2143467-62-1 | Reference compound |
| HY-122054A | BPK-29 (hydrochloride) | 2444815-73-8 | Reference compound |
| HY-122056 | 1,2-Diheptanoyl-SN-glycero-3-phosphocholine | 39036-04-9 | Biochemical Assay Reagents |
| HY-122057 | Bisdionin F | 917877-86-2 | Reference compound |
| HY-122058 | KRH-3955 | 1097732-62-1 | Reference compound |
| HY-122058A | KRH-3955 (hydrochloride) | 2253744-59-9 | Reference compound |
| HY-12206 | Thioperamide | 106243-16-7 | Reference compound |
| HY-122060 | BYK 191023 | 608880-48-4 | Reference compound |
| HY-122062 | Fenoxycarb | 72490-01-8 | Natural Products |
| HY-122062R | Fenoxycarb (Standard) | 72490-01-8 | Reference Standards |
| HY-122062S | Fenoxycarb-13C6 | | Isotope-Labeled Compounds |
| HY-122063 | FR260330 | 442198-67-6 | Reference compound |
| HY-122064 | FR20 | 570373-45-4 | Reference compound |
| HY-122066 | NSC47924 | 6638-24-0 | Reference compound |
| HY-12206A | Thioperamide (maleate) | 148440-81-7 | Reference compound |
| HY-122070 | Tirilazad (mesylate) | 110101-67-2 | Reference compound |
| HY-122070A | Tirilazad (mesylate hydrate) | 111793-42-1 | Reference compound |
| HY-122071 | Bicyclomycin | 38129-37-2 | Natural Products |
| HY-122073 | Furalazine | 556-12-7 | Reference compound |
| HY-122075 | FR 78844 | 112856-39-0 | Reference compound |
| HY-122076 | A-26771B | 56448-20-5 | Reference compound |
| HY-122077 | NS5818 | 674299-39-9 | Reference compound |
| HY-122078 | FR-190809 | 215589-63-2 | Reference compound |
| HY-122079 | NSC1011 | 5335-97-7 | Reference compound |
| HY-122080 | Memoquin | 616885-87-1 | Reference compound |
| HY-122082 | Methopterin | 2410-93-7 | Reference compound |
| HY-122082R | Methopterin (Standard) | 2410-93-7 | Reference Standards |
| HY-122083 | T2384 | 315222-83-4 | Reference compound |
| HY-122084 | (3β,5α)-Androstan-3-amine (hydrochloride) | 54156-23-9 | Reference compound |
| HY-122086 | Prifinium (bromide) | 4630-95-9 | Reference compound |
| HY-122089 | Lapyrium | 109260-82-4 | Natural Products |
| HY-122094 | Steppogenin | 56486-94-3 | Natural Products |
| HY-122096 | DCLX069 | 792946-69-1 | Reference compound |
| HY-122097 | M7594_0037 | 774551-07-4 | Reference compound |
| HY-122098 | Diaplasinin | 481631-45-2 | Reference compound |
| HY-122099 | Riddelline | 23246-96-0 | Natural Products |
| HY-12210 | (S)-BI-1001 | 957889-73-5 | Reference compound |
| HY-122101 | NSC114792 | 17392-79-9 | Reference compound |
| HY-122104 | UCL-1848 (TFA) | 201147-53-7 | Reference compound |
| HY-122105 | JNJ-40255293 | 1147271-25-7 | Reference compound |
| HY-122106 | RS-104966 | 193022-38-7 | Reference compound |
| HY-122108 | Ilicicolin A | 22581-06-2 | Natural Products |
| HY-122109A | Levonantradol (hydrochloride) | 70222-86-5 | Reference compound |
| HY-122111 | (±)7-HDHA | 90780-55-5 | Natural Products |
| HY-122112 | CM572 | 1121932-91-9 | Reference compound |
| HY-122113 | PD173952 | 305820-75-1 | Reference compound |
| HY-122114 | ICA-27243 | 325457-89-4 | Reference compound |
| HY-122115 | DCE_42 | 669749-45-5 | Reference compound |
| HY-122117 | Haptamide B | 546124-87-2 | Reference compound |
| HY-122118 | Lambast | 845-52-3 | Reference compound |
| HY-12212 | Omaveloxolone | 1474034-05-3 | Reference compound |
| HY-122120 | Rafabegron | 244081-42-3 | Reference compound |
| HY-122122 | ML-60218 | 577784-91-9 | Reference compound |
| HY-122123 | S-6123 | 87508-45-0 | Reference compound |
| HY-122124 | CAY10583 | 862891-27-8 | Reference compound |
| HY-122126 | BN 52111 | 120889-14-7 | Reference compound |
| HY-122127 | Acetobixan | 380201-24-1 | Reference compound |
| HY-122128 | Lilly 51641 | 5388-85-2 | Reference compound |
| HY-122129 | Dotriaconta-14,17,20,23,26,29-hexaenoic acid | 105517-82-6 | Reference compound |
| HY-122129S | Dotriaconta-14,17,20,23,26,29-hexaenoic acid-d6 | 2692624-20-5 | Isotope-Labeled Compounds |
| HY-12213 | CDDO-EA | 932730-51-3 | Reference compound |
| HY-122131 | XTT (sodium) | 111072-31-2 | Reference compound |
| HY-122133 | CI 750 | 47739-68-4 | Reference compound |
| HY-122134 | SC-58272 | 164931-25-3 | Reference compound |
| HY-122135 | A-317567 | 371217-32-2 | Reference compound |
| HY-122136 | S26131 | 296280-56-3 | Reference compound |
| HY-122138 | VU6010572 | 2126784-39-0 | Reference compound |
| HY-122139 | Desethylene Ciprofloxacin (hydrochloride) | 528851-31-2 | Reference compound |
| HY-122139R | Desethylene Ciprofloxacin (hydrochloride) (Standard) | 528851-31-2 | Reference Standards |
| HY-122140 | ACG548B | 795316-16-4 | Reference compound |
| HY-122141 | Glycohyocholic acid | 32747-08-3 | Reference compound |
| HY-122141R | Glycohyocholic acid (Standard) | 32747-08-3 | Reference Standards |
| HY-122141S | Glycohyocholic acid-d4 | | Isotope-Labeled Compounds |
| HY-122142 | Pyr-Pro-Arg-pNA | 72194-57-1 | Peptides |
| HY-122143 | V-06-018 | 299927-26-7 | Reference compound |
| HY-122144 | α-Triglycidyl isocyanurate | 59653-73-5 | Reference compound |
| HY-122146 | Bactobolin B | 74141-68-7 | Reference compound |
| HY-122147 | L-644698 | 72313-41-8 | Reference compound |
| HY-122148 | DA 4626 | 83184-14-9 | Reference compound |
| HY-122149 | L-648051 | 91541-18-3 | Reference compound |
| HY-12214A | NVP-2 | 1263373-43-8 | Reference compound |
| HY-12215 | Lorlatinib | 1454846-35-5 | Reference compound |
| HY-122150 | AMPA receptor modulator-3 | 211311-39-6 | Reference compound |
| HY-122151 | MPT0B002 | 946077-08-3 | Reference compound |
| HY-122152 | Spiclomazine (hydrochloride) | 27007-85-8 | Reference compound |
| HY-122153 | VSN-16 | 863713-78-4 | Reference compound |
| HY-122154 | FR234938 | 256461-79-7 | Reference compound |
| HY-122156 | IMB-301 | 64009-84-3 | Reference compound |
| HY-122158 | CRAC channel inhibitor-1 | 903591-53-7 | Reference compound |
| HY-122159 | MDPD | 693265-89-3 | Reference compound |
| HY-12215R | Lorlatinib (Standard) | 1454846-35-5 | Reference Standards |
| HY-12215S2 | Deulorlatinib | 2131126-33-3 | Isotope-Labeled Compounds |
| HY-12216 | Resmetirom | 920509-32-6 | Reference compound |
| HY-122161 | JNJ-10311795 | 518062-14-1 | Reference compound |
| HY-122164 | LY-503430 | 625820-83-9 | Reference compound |
| HY-122165A | LY-79771 (hydrochloride) | 74248-92-3 | Reference compound |
| HY-122166 | Histamine receptors inhibitor 1 | 744270-00-6 | Reference compound |
| HY-122167 | L-869298 | 362718-73-8 | Reference compound |
| HY-122168 | AAT-008 | 847727-81-5 | Reference compound |
| HY-122170 | RU5135 | 78774-26-2 | Reference compound |
| HY-122171 | A-317920 | 360551-59-3 | Reference compound |
| HY-122172 | GSK3-IN-6 | 681432-85-9 | Reference compound |
| HY-122175 | ZK-158252 | 162362-36-9 | Reference compound |
| HY-122177 | MK181 | 314297-32-0 | Reference compound |
| HY-122178 | 5-trans U-44069 | 330796-57-1 | Reference compound |
| HY-122179 | NUCC-555 | 1060469-90-0 | Reference compound |
| HY-122181 | OTS186935 | 2093400-18-9 | Reference compound |
| HY-122181A | OTS186935 (trihydrochloride) | 2093401-85-3 | Reference compound |
| HY-122181B | OTS186935 (hydrochloride) | | Reference compound |
| HY-122182 | OTS193320 | 2093401-33-1 | Reference compound |
| HY-122184 | PET-16 | 34387-64-9 | Reference compound |
| HY-122185 | Anticancer agent 211 | 314022-97-4 | Reference compound |
| HY-122186 | SGC-GAK-1 | 2226517-76-4 | Reference compound |
| HY-122189 | Akuammine | 3512-87-6 | Reference compound |
| HY-12219 | MSI-1436 | 186139-09-3 | Reference compound |
| HY-122190 | TAK-071 | 1820812-16-5 | Reference compound |
| HY-122191 | AK-Toxin II | 85146-10-7 | Reference compound |
| HY-122192 | ICAM-1988 | 444169-80-6 | Reference compound |
| HY-122196 | TYT-1 | 64803-10-7 | Reference compound |
| HY-122197 | ML339 | 2579689-83-9 | Reference compound |
| HY-122198 | ML367 | 381168-77-0 | Reference compound |
| HY-12219A | MSI-1436 lactate | 1309370-86-2 | Reference compound |
| HY-12219B | MSI-1701 | 390808-64-7 | Reference compound |
| HY-12220 | MM-102 | 1417329-24-8 | Reference compound |
| HY-122200 | Phenamacril | 39491-78-6 | Reference compound |
| HY-122200R | Phenamacril (Standard) | 39491-78-6 | Reference Standards |
| HY-122201 | NSC156529 | 41134-88-7 | Reference compound |
| HY-122203 | PCS1055 (dihydrochloride) | 361979-40-0 | Reference compound |
| HY-122203A | PCS1055 | 357173-55-8 | Reference compound |
| HY-122204 | 5M038 | 338962-32-6 | Reference compound |
| HY-122207 | Erythromycin A enol ether | 33396-29-1 | Reference compound |
| HY-122207R | Erythromycin A enol ether (Standard) | 33396-29-1 | Reference Standards |
| HY-122208 | SGA360 | 680611-86-3 | Reference compound |
| HY-122209 | DVR-01 | 330461-34-2 | Reference compound |
| HY-12220A | MM-102 (TFA) | 1883545-52-5 | Reference compound |
| HY-122210 | T521 | 891020-54-5 | Reference compound |
| HY-122211 | MRS2802 | 1047980-53-9 | Reference compound |
| HY-122212 | PF-9404C | 780825-97-0 | Reference compound |
| HY-122213 | RU-25055 | 67983-56-6 | Reference compound |
| HY-122214 | AC-73 | 775294-71-8 | Reference compound |
| HY-122215 | Tilisolol (hydrochloride) | 62774-96-3 | Reference compound |
| HY-122216 | LY 88329 | 78693-86-4 | Reference compound |
| HY-122217 | Pyridate | 55512-33-9 | Reference compound |
| HY-122217R | Pyridate (Standard) | 55512-33-9 | Reference Standards |
| HY-122217S | Pyridate-d5 | | Isotope-Labeled Compounds |
| HY-122218 | JHU-083 | 1998725-11-3 | Reference compound |
| HY-122219 | R243 | 688352-84-3 | Reference compound |
| HY-12222 | Obeticholic acid | 459789-99-2 | Reference compound |
| HY-122221 | KUM 32 | 28717-34-2 | Reference compound |
| HY-122223 | EPZ030456 | 1808011-23-5 | Reference compound |
| HY-122227 | SMP-797 (hydrochloride) | 259224-95-8 | Reference compound |
| HY-122228 | Cestrin | 671181-94-5 | Reference compound |
| HY-122229 | GS-9822 | 2219362-41-9 | Reference compound |
| HY-12222R | Obeticholic acid (Standard) | 459789-99-2 | Reference Standards |
| HY-12222S | Obeticholic acid-d5 | 1992000-80-2 | Isotope-Labeled Compounds |
| HY-12222S1 | Obeticholic Acid-d4 | | Isotope-Labeled Compounds |
| HY-122230 | UR-3216 | 220386-65-2 | Reference compound |
| HY-122231 | MRS3558 | 793695-40-6 | Reference compound |
| HY-122232 | SW083688 | 422281-45-6 | Reference compound |
| HY-122233 | Dimethrin | 70-38-2 | Reference compound |
| HY-122234 | VPC-18005 | 2242480-48-2 | Reference compound |
| HY-122235 | MRL-24 | 393794-17-7 | Reference compound |
| HY-122236 | UMK57 | 342595-74-8 | Reference compound |
| HY-122237 | ATZ-1993 | 219705-77-8 | Reference compound |
| HY-122240 | AAE871 | 289479-07-8 | Reference compound |
| HY-122241 | MT477 | 328069-91-6 | Reference compound |
| HY-122243 | IU1-47 | 670270-31-2 | Reference compound |
| HY-122245 | Sortin2 | 372972-39-9 | Reference compound |
| HY-122246 | ML192 | 460331-61-7 | Reference compound |
| HY-122247 | PVZB1194 | 1141768-04-8 | Reference compound |
| HY-122248 | Phebestin | 187402-73-9 | Reference compound |
| HY-122249 | MT-7 | 946507-08-0 | Reference compound |
| HY-122250 | LY 288601 | 152920-47-3 | Reference compound |
| HY-122251 | CCG-4986 | 7134-19-2 | Reference compound |
| HY-122255 | LY487379 | 353231-17-1 | Reference compound |
| HY-122258 | NSC-370284 | 116409-29-1 | Reference compound |
| HY-122259 | AMPte-Glu-γ-Glu | 41600-13-9 | Reference compound |
| HY-122260 | S-25932 | 92358-02-6 | Reference compound |
| HY-122261 | Spiroamantadine | 34522-38-8 | Reference compound |
| HY-122266 | Orcein | 1400-62-0 | Dye Reagents |
| HY-122267 | Clovamide | 53755-02-5 | Natural Products |
| HY-122267A | cis-Clovamide | 53755-03-6 | Natural Products |
| HY-122268 | QYL-685 | 210355-14-9 | Reference compound |
| HY-122270 | Kahweol stearate | 108214-31-9 | Natural Products |
| HY-122271 | Safrazine (hydrochloride) | 7296-30-2 | Reference compound |
| HY-122272 | Paroxetine | 61869-08-7 | Reference compound |
| HY-122272S | Paroxetine-d4 | 923932-45-0 | Isotope-Labeled Compounds |
| HY-122272S2 | Paroxetine-d6-1 | 1435728-63-4 | Isotope-Labeled Compounds |
| HY-122273 | Pyrithiamine (hydrobromide) | 534-64-5 | Reference compound |
| HY-122274 | MMV666693 | 312527-99-4 | Reference compound |
| HY-122277 | 1'-Hydroxy bufuralol | 57704-16-2 | Reference compound |
| HY-122277S | 1'-Hydroxy bufuralol-d9 | 1185069-74-2 | Isotope-Labeled Compounds |
| HY-122278 | Melevodopa | 7101-51-1 | Reference compound |
| HY-122280 | Aerobactin | 26198-65-2 | Natural Products |
| HY-122280R | Aerobactin (Standard) | 26198-65-2 | Reference Standards |
| HY-122281 | JTE 7-31 | 194358-72-0 | Reference compound |
| HY-122282 | AZ11657312 | 804561-22-6 | Reference compound |
| HY-122285 | A-25794 | 22198-93-2 | Reference compound |
| HY-122288 | SC 28538 | 64444-68-4 | Reference compound |
| HY-122289 | Metioprim | 68902-57-8 | Reference compound |
| HY-122292 | Celastramycin A | 188988-62-7 | Reference compound |
| HY-122294 | Rociverine | 53716-44-2 | Reference compound |
| HY-122295 | Dehydroleucodine | 36150-07-9 | Natural Products |
| HY-122297 | H-Arg-Phe-OH | 2047-13-4 | Reference compound |
| HY-122298 | Fenpicoxamid | 517875-34-2 | Reference compound |
| HY-122299 | Motretinide | 56281-36-8 | Reference compound |
| HY-122300 | R-(-)-Oxaprotiline (hydrochloride) | 76496-69-0 | Reference compound |
| HY-122300A | Oxaprotiline | 56433-44-4 | Reference compound |
| HY-122300B | R-(-)-Oxaprotiline | 76496-68-9 | Reference compound |
| HY-122300C | Oxaprotiline (hydrochloride) | 39022-39-4 | Reference compound |
| HY-122302 | BU-2313 A | 69774-86-3 | Natural Products |
| HY-122303 | 4-hydroxy DiPT (hydrochloride) | 63065-90-7 | Reference compound |
| HY-122306 | Ansatrienin B | 82189-04-6 | Reference compound |
| HY-122307 | Sulisatin | 54935-03-4 | Reference compound |
| HY-122307A | Sulisatin (disodium) | 54935-04-5 | Reference compound |
| HY-122308 | Militarine | 58139-23-4 | Natural Products |
| HY-122308R | Militarine (Standard) | 58139-23-4 | Reference Standards |
| HY-122309 | A-71497 | 134762-03-1 | Reference compound |
| HY-122311 | Orniplabin | 733805-92-0 | Reference compound |
| HY-122312 | BAY-8002 | 724440-27-1 | Reference compound |
| HY-122315 | Oncrasin-60 | 92407-91-5 | Reference compound |
| HY-122317 | Menthol glucuronide | 79466-08-3 | Reference compound |
| HY-122319 | Oxadiargyl | 39807-15-3 | Reference compound |
| HY-122319R | Oxadiargyl (Standard) | 39807-15-3 | Reference Standards |
| HY-122320 | Phytosterols | 949109-75-5 | Reference compound |
| HY-122323 | L-Leucyl-L-arginine | 26607-15-8 | Reference compound |
| HY-122324 | Tylophorine | 482-20-2 | Natural Products |
| HY-122324A | (-)-Tylophorine | 111408-21-0 | Natural Products |
| HY-122326 | Ioglycamic acid | 2618-25-9 | Reference compound |
| HY-122327 | Nodusmicin | 76265-48-0 | Reference compound |
| HY-122328 | Flambamycin | 42617-24-3 | Natural Products |
| HY-122330 | Dicobalt edetate | 36499-65-7 | Reference compound |
| HY-122331 | Norbormide | 991-42-4 | Reference compound |
| HY-122332 | 2'-Fluoroaminopterin | 85803-29-8 | Reference compound |
| HY-122334 | Myxopyronin A | 88192-98-7 | Natural Products |
| HY-122336 | Asperlicin D | 93413-07-1 | Reference compound |
| HY-122338 | Fexarine | 574013-67-5 | Reference compound |
| HY-122341 | Thrazarine | 120128-14-5 | Natural Products |
| HY-122347 | Orvepitant | 579475-18-6 | Reference compound |
| HY-122347A | Orvepitant (maleate) | 579475-24-4 | Reference compound |
| HY-122349 | Lotrifen | 66535-86-2 | Reference compound |
| HY-12235 | PI-3065 | 955977-50-1 | Reference compound |
| HY-122350 | Dactimicin (sulfate) | 73245-91-7 | Reference compound |
| HY-122351 | Advantame (free acid) | 245650-17-3 | Reference compound |
| HY-122351A | Advantame | 714229-20-6 | Reference compound |
| HY-122351AR | Advantame (Standard) | 714229-20-6 | Reference Standards |
| HY-122353 | Orotirelin | 62305-86-6 | Reference compound |
| HY-122356 | Ambazone (monohydrate) | 6011-12-7 | Reference compound |
| HY-122356A | Ambazone | 539-21-9 | Reference compound |
| HY-122357 | Bestim | 66471-20-3 | Peptides |
| HY-122358 | Neoarsphenamine | 457-60-3 | Reference compound |
| HY-122359 | Levormeloxifene | 78994-23-7 | Reference compound |
| HY-122359A | rel-Levormeloxifene | 31477-60-8 | Reference compound |
| HY-122359B | Levormeloxifene (fumarate) | 199583-01-2 | Reference compound |
| HY-12236 | SKF 81297 (hydrobromide) | 67287-39-2 | Reference compound |
| HY-122364 | Bucumolol (hydrochloride) | 36556-75-9 | Reference compound |
| HY-122365 | Inositol nicotinate | 6556-11-2 | Reference compound |
| HY-122365R | Inositol nicotinate (Standard) | 6556-11-2 | Reference Standards |
| HY-122366 | L-Chlorozotocin | 69839-80-1 | Reference compound |
| HY-122367 | Neoxaline | 909900-78-3 | Natural Products |
| HY-122369 | Histargin | 93361-66-1 | Natural Products |
| HY-12236A | SKF 81297 | 71636-61-8 | Reference compound |
| HY-12236B | (R)-SKF-81297 (hydrobromide) | 253446-15-0 | Reference compound |
| HY-12237 | SKF 38393 (hydrobromide) | 20012-10-6 | Reference compound |
| HY-122370A | Tripolin B | 186611-44-9 | Reference compound |
| HY-122373 | Coprine | 58919-61-2 | Reference compound |
| HY-122375 | Palustrol | 5986-49-2 | Natural Products |
| HY-122376 | S-Bioallethrin | 28434-00-6 | Reference compound |
| HY-122378 | Diopterin | 6807-82-5 | Reference compound |
| HY-122379 | 8-Hydroxypinoresinol | 81426-17-7 | Natural Products |
| HY-12238 | IWR-1 | 1127442-82-3 | Reference compound |
| HY-122380 | Alteconazole | 93479-96-0 | Reference compound |
| HY-122381 | Kyotorphin | 70904-56-2 | Peptides |
| HY-122382 | Levofuraltadone | 3795-88-8 | Reference compound |
| HY-122384 | Alcindoromycin | 72586-21-1 | Natural Products |
| HY-122385 | Dabequin (phosphate) | 56548-51-7 | Reference compound |
| HY-122386 | Kirromycin | 50935-71-2 | Natural Products |
| HY-122389 | Difenzoquat methyl sulfate | 43222-48-6 | Reference compound |
| HY-122389R | Difenzoquat methyl sulfate (Standard) | 43222-48-6 | Reference Standards |
| HY-12239 | CID755673 | 521937-07-5 | Reference compound |
| HY-122394 | Thiolactomycin | 82079-32-1 | Reference compound |
| HY-122395 | Triornicin | 77165-75-4 | Natural Products |
| HY-122397 | Rubrolone | 65445-21-8 | Natural Products |
| HY-122399 | Luprostiol | 67110-79-6 | Reference compound |
| HY-12240 | B32B3 | 294193-86-5 | Reference compound |
| HY-122401 | Daigremontianin | 98205-50-6 | Reference compound |
| HY-122402 | Umirolimus | 851536-75-9 | Reference compound |
| HY-122404 | Xantocillin | 580-74-5 | Natural Products |
| HY-122406 | Thiacetarsamide | 531-72-6 | Reference compound |
| HY-122407 | Hexadecyltrimethylammonium (hydroxide),25% in methanol | 505-86-2 | Biochemical Assay Reagents |
| HY-122409 | Cularine | 479-39-0 | Reference compound |
| HY-12241 | AZ82 | 1449578-65-7 | Reference compound |
| HY-122410 | Dihydrolanosterol | 79-62-9 | Natural Products |
| HY-122410R | Dihydrolanosterol (Standard) | 79-62-9 | Reference Standards |
| HY-122410S | Dihydrolanosterol-d7 | 2260669-12-1 | Isotope-Labeled Compounds |
| HY-122411 | Panomifene | 77599-17-8 | Reference compound |
| HY-122412 | Lenampicillin | 86273-18-9 | Reference compound |
| HY-122413 | m-PEG7-NHS ester | 874208-92-1 | Reference compound |
| HY-122414 | Phosalacine | 92567-89-0 | Natural Products |
| HY-122415 | Tunicamine | 66054-53-3 | Reference compound |
| HY-122416 | 6,8-Diprenylnaringenin | 68236-11-3 | Natural Products |
| HY-12242 | GBR 12935 (dihydrochloride) | 67469-81-2 | Reference compound |
| HY-122422 | Gepirone | 83928-76-1 | Reference compound |
| HY-122422A | Gepirone (hydrochloride) | 83928-66-9 | Reference compound |
| HY-122422R | Gepirone (Standard) | 83928-76-1 | Reference Standards |
| HY-122422S | Gepirone-d8 | 2749331-28-8 | Isotope-Labeled Compounds |
| HY-122423 | Desethylamiodarone | 83409-32-9 | Reference compound |
| HY-122425 | Nylidrin | 447-41-6 | Reference compound |
| HY-122426 | 1-Bromoundecane | 693-67-4 | Reference compound |
| HY-122426S | 1-Bromoundecane-d23 | 349553-92-0 | Isotope-Labeled Compounds |
| HY-122426S1 | 1-Bromoundecane-d3 | 1219805-63-6 | Isotope-Labeled Compounds |
| HY-122426S2 | 1-Bromoundecane-d4 | 1219802-82-0 | Isotope-Labeled Compounds |
| HY-122427 | Xylocytidine | 3530-56-1 | Reference compound |
| HY-122428 | Samandarone | 467-52-7 | Natural Products |
| HY-12242A | GBR 12935 | 76778-22-8 | Reference compound |
| HY-12242B | GBR 12935 (fumarate) | 1349767-56-1 | Reference compound |
| HY-12243 | CID-797718 | 370586-05-3 | Reference compound |
| HY-122430 | Rosaramicin | 35834-26-5 | Reference compound |
| HY-122437 | Quinuronium (disulfate) | 135-14-8 | Reference compound |
| HY-122439 | Lovastatin acid | 75225-51-3 | Reference compound |
| HY-12244 | BB-22 | 1400742-42-8 | Reference compound |
| HY-122440 | Scopoline | 487-27-4 | Natural Products |
| HY-122445 | Resorcinolnaphthalein | 41307-63-5 | Reference compound |
| HY-122447 | Saroaspidin C | 112663-70-4 | Natural Products |
| HY-122448 | (-)-Sativan | 41743-86-6 | Natural Products |
| HY-122448A | (Rac)-Sativan | 71831-00-0 | Natural Products |
| HY-12245 | SB-366791 | 472981-92-3 | Reference compound |
| HY-122451 | Ofurace | 58810-48-3 | Reference compound |
| HY-122451R | Ofurace (Standard) | 58810-48-3 | Reference Standards |
| HY-122453 | Palinavir | 154612-39-2 | Reference compound |
| HY-122456 | Fmoc-PEG4-NHS ester | 1314378-14-7 | Reference compound |
| HY-122457 | Δ2,3-Doramectin | 1987882-63-2 | Reference compound |
| HY-122459 | Fmoc-PEG5-NHS ester | 1402080-11-8 | Reference compound |
| HY-12246 | XEN445 | 1515856-92-4 | Reference compound |
| HY-122461 | Glycobiarsol | 116-49-4 | Reference compound |
| HY-122462 | Ladirubicin | 171047-47-5 | Reference compound |
| HY-122464 | (±)-Jasmonic acid | 77026-92-7 | Reference compound |
| HY-122464A | Jasmonic acid | 6894-38-8 | Natural Products |
| HY-122464B | 7-epi Jasmonic acid | 62653-85-4 | Reference compound |
| HY-122464S1 | Jasmonic acid-d5 | 1821807-88-8 | Isotope-Labeled Compounds |
| HY-122464S2 | (±)-Jasmonic acid-d5 | 2750534-78-0 | Isotope-Labeled Compounds |
| HY-122466 | Lonomycin A | 58785-63-0 | Reference compound |
| HY-122467 | Kumbicin C | 1878151-58-6 | Natural Products |
| HY-122469 | Kurasoin B | 193696-42-3 | Reference compound |
| HY-122470 | Stampidine | 217178-62-6 | Reference compound |
| HY-122471A | Laudexium (methylsulfate) | 3253-60-9 | Reference compound |
| HY-122473 | fluoro-Dapagliflozin | 1181681-43-5 | Reference compound |
| HY-122474 | Acetylaranotin | 20485-01-2 | Natural Products |
| HY-122477 | Zylofuramine | 3563-92-6 | Reference compound |
| HY-12248 | Telaglenastat | 1439399-58-2 | Reference compound |
| HY-122481 | Thaspine (acetate) | 74578-01-1 | Natural Products |
| HY-122482 | β-Rubromycin | 27267-70-5 | Reference compound |
| HY-122483 | Diethyl pyimDC | 1821370-64-2 | Reference compound |
| HY-122485 | α-Copaene | 3856-25-5 | Natural Products |
| HY-122486 | Lophirachalcone | 122585-40-4 | Reference compound |
| HY-122487 | Troriluzole | 1926203-09-9 | Reference compound |
| HY-122487A | Troriluzole (hydrochloride) | 1926204-76-3 | Reference compound |
| HY-122488 | Rinderine | 6029-84-1 | Natural Products |
| HY-122489 | DL-Laudanosine | 1699-51-0 | Natural Products |
| HY-122489A | (S)-Laudanosine | 2688-77-9 | Natural Products |
| HY-122489R | DL-Laudanosine (Standard) | 1699-51-0 | Reference Standards |
| HY-12248A | Telaglenastat (hydrochloride) | 1874231-60-3 | Reference compound |
| HY-122490 | Laidlomycin | 56283-74-0 | Natural Products |
| HY-122491 | Dimethyl-W84 (dibromide) | 402475-33-6 | Reference compound |
| HY-122493 | Illudin M | 1146-04-9 | Natural Products |
| HY-122494 | Bilanafos | 35597-43-4 | Peptides |
| HY-122494A | Bialaphos (sodium) | 71048-99-2 | Reference compound |
| HY-122494AR | Bialaphos (sodium) (Standard) | 71048-99-2 | Reference Standards |
| HY-122495 | rel-Quinpirole (dihydrochloride) | 73625-62-4 | Reference compound |
| HY-122496 | Malvidin (chloride) | 643-84-5 | Natural Products |
| HY-122496R | Malvidin (chloride) (Standard) | 643-84-5 | Reference Standards |
| HY-122499 | Ciprostene (calcium) | 81703-55-1 | Reference compound |
| HY-122500 | Kahukuene A | 146293-93-8 | Natural Products |
| HY-122502 | Pyrazofurin | 30868-30-5 | Reference compound |
| HY-122503 | Guamecycline | 16545-11-2 | Reference compound |
| HY-122504 | Linoleoyl glycine | 2764-03-6 | Reference compound |
| HY-122505 | Cephamycin C | 38429-35-5 | Reference compound |
| HY-122506 | Salviolone | 119400-86-1 | Natural Products |
| HY-122507 | Septamycin | 54927-63-8 | Reference compound |
| HY-122508 | Hydroxyebastine | 210686-41-2 | Reference compound |
| HY-122508S | Hydroxy Ebastine-d5 | 1189954-07-1 | Isotope-Labeled Compounds |
| HY-122509 | Senkirkin | 2318-18-5 | Natural Products |
| HY-122509R | Senkirkin (Standard) | 2318-18-5 | Reference Standards |
| HY-122510 | Atropine oxide | 4438-22-6 | Reference compound |
| HY-122510A | Atropine oxide (hydrochloride) | 4574-60-1 | Reference compound |
| HY-122511 | Darcanolide | 33909-56-7 | Reference compound |
| HY-122515 | Fulvic Acid | 479-66-3 | Natural Products |
| HY-122515R | Fulvic Acid (Standard) | 479-66-3 | Reference Standards |
| HY-122517 | Mirincamycin (hydrochloride) | 8063-91-0 | Reference compound |
| HY-122518 | 8-Deazafolic acid | 51989-25-4 | Reference compound |
| HY-122519 | Trixylyl phosphate | 25155-23-1 | Reference compound |
| HY-122520 | Fentonium (bromide) | 5868-06-4 | Reference compound |
| HY-122521 | Sootepin D | 1154518-97-4 | Natural Products |
| HY-122522 | 2-Methylcardol triene | 50423-15-9 | Reference compound |
| HY-122523 | Tetromycin A | 180027-83-2 | Reference compound |
| HY-122524 | 7-Methylguanosine | 20244-86-4 | Natural Products |
| HY-122524S | 7-Methylguanosine-d3 | | Isotope-Labeled Compounds |
| HY-122525A | Sabiporide (hydrochloride) | 324758-66-9 | Reference compound |
| HY-122525B | Sabiporide (mesylate) | 261505-81-1 | Reference compound |
| HY-122526 | Thialysine (hydrochloride) | 4099-35-8 | Peptides |
| HY-122529 | Almurtide | 61136-12-7 | Reference compound |
| HY-122530 | Juvocimene I | 75539-64-9 | Natural Products |
| HY-122531 | Oleyl myristate | 22393-93-7 | Natural Products |
| HY-122532 | Fagaronine (chloride) | 52259-64-0 | Reference compound |
| HY-122534 | Mensacarcin | 808750-39-2 | ADC Related |
| HY-122536 | Ricinelaidic acid | 540-12-5 | Reference compound |
| HY-122537 | Arotinolol (hydrochloride) | 68377-91-3 | Reference compound |
| HY-122537A | Arotinolol | 68377-92-4 | Reference compound |
| HY-122542 | PPACK | 71142-71-7 | Peptides |
| HY-122542A | PPACK (dihydrochloride) | 82188-90-7 | Peptides |
| HY-122542B | PPACK (TFA) | 157379-44-7 | Peptides |
| HY-122543 | PPACK II (diTFA) | 649748-23-2 | Reference compound |
| HY-122543A | PPACK II | 74392-49-7 | Reference compound |
| HY-122550 | Artemisitene | 101020-89-7 | Natural Products |
| HY-122551 | Chlorfenethol | 80-06-8 | Reference compound |
| HY-122552 | Chrysotobibenzyl | 108853-09-4 | Natural Products |
| HY-122559 | BMS-984923 | 1375752-78-5 | Reference compound |
| HY-122560 | VU0134992 | 755002-90-5 | Reference compound |
| HY-122560A | VU0134992 (hydrochloride) | 1052515-91-9 | Reference compound |
| HY-122562 | MT-802 | 2231744-29-7 | Reference compound |
| HY-122564 | Pyrimidyn 7 | 1440126-94-2 | Reference compound |
| HY-122566 | SMU127 | 903864-87-9 | Reference compound |
| HY-122568 | STING agonist-15 | 875863-22-2 | Reference compound |
| HY-122571 | Retro-2 | 1201652-50-7 | Reference compound |
| HY-122573 | Bromodomain inhibitor-13 | 1914047-59-8 | Reference compound |
| HY-122575 | Aurintricarboxylic acid | 4431-00-9 | Reference compound |
| HY-122577 | EN40 | 2094547-67-6 | Reference compound |
| HY-122578 | P53R3 | 922150-12-7 | Reference compound |
| HY-122579 | IGS-1.76 | 313480-47-6 | Reference compound |
| HY-122582 | TL13-12 | 2229037-04-9 | Reference compound |
| HY-122583 | D-G23 | 1225141-73-0 | Reference compound |
| HY-122585 | proMMP-9 inhibitor-3c | 2138321-18-1 | Reference compound |
| HY-122586 | BRD6989 | 642008-81-9 | Reference compound |
| HY-122587 | AVG-233 | 2151937-80-1 | Reference compound |
| HY-122588 | Negamycin | 33404-78-3 | Natural Products |
| HY-122590 | Glabrescione B | 65893-94-9 | Reference compound |
| HY-122591 | PTUPB | 1287761-01-6 | Reference compound |
| HY-122592 | Zifaxaban | 1378266-98-8 | Reference compound |
| HY-122593 | PI3Kδ-IN-5 | 2088525-31-7 | Reference compound |
| HY-122594 | BNS-22 | 1151668-24-4 | Reference compound |
| HY-122595 | EZH2-IN-1 | 1377997-28-8 | Reference compound |
| HY-122604 | PF-DcpSi | 2092917-19-4 | Reference compound |
| HY-122605 | TRPM4-IN-1 | 351424-20-9 | Reference compound |
| HY-122607 | DPA-714 | 958233-07-3 | Reference compound |
| HY-122608 | Samelisant (free base) | 1394808-82-2 | Reference compound |
| HY-122609 | XO44 | 2088112-70-1 | Reference compound |
| HY-122610 | VUT-MK142 | 1313491-22-3 | Reference compound |
| HY-122611 | CSRM617 | 787504-88-5 | Reference compound |
| HY-122611A | CSRM617 (hydrochloride) | 1353749-74-2 | Reference compound |
| HY-122611R | CSRM617 (Standard) | 787504-88-5 | Reference Standards |
| HY-122612 | SB-258585 | 209480-63-7 | Reference compound |
| HY-122613 | YM543 (free base) | 655237-16-4 | Reference compound |
| HY-122614 | S29434 | 874484-20-5 | Reference compound |
| HY-122615 | SPOP-IN-6b | 2136270-20-5 | Reference compound |
| HY-122615A | SPOP-IN-6b (hydrochloride) | 2136270-68-1 | Reference compound |
| HY-122615B | SPOP-IN-6b (dihydrochloride) | | Reference compound |
| HY-122616 | PF-06273340 | 1402438-74-7 | Reference compound |
| HY-122620 | Rafutrombopag (tautomerism) | 2114365-78-3 | Reference compound |
| HY-122622 | PF-04471141 (hydrochloride) | 1655498-17-1 | Reference compound |
| HY-122623 | DB818 | 790241-43-9 | Reference compound |
| HY-122623A | DB818 (dihydrochloride) | | Reference compound |
| HY-122624 | MMP13-IN-2 | 935759-55-0 | Reference compound |
| HY-122626 | BRPF1B/TRIM24-IN-1 | 1242907-48-7 | Reference compound |
| HY-122627 | CLZ-8 | 678158-55-9 | Reference compound |
| HY-122629 | DRAK2-IN-1 | 871837-60-4 | Reference compound |
| HY-122630 | TH-257 | 2244678-29-1 | Reference compound |
| HY-122631 | TG693 | 885272-55-9 | Reference compound |
| HY-122632 | Ciliobrevin D | 1370554-01-0 | Reference compound |
| HY-122635 | T-448 (free base) | 1597426-52-2 | Reference compound |
| HY-122635A | T-448 | 1597426-53-3 | Reference compound |
| HY-122639 | ZINC05007751 | 591239-68-8 | Reference compound |
| HY-122641 | Deltasonamide 1 | 2088485-33-8 | Reference compound |
| HY-122641A | Deltasonamide 2 | 2088485-34-9 | Reference compound |
| HY-122641B | Deltasonamide 2 (TFA) | 2235358-74-2 | Reference compound |
| HY-122641C | Deltasonamide 2 (hydrochloride) | 2448341-55-5 | Reference compound |
| HY-122641D | Deltasonamide 1 (TFA) | 2235358-73-1 | Reference compound |
| HY-122642 | TAK1-IN-4 | 1570374-32-1 | Reference compound |
| HY-122643 | NITD-916 | 1614262-83-7 | Reference compound |
| HY-122645 | SMARCA2-IN-4 | 1915012-19-9 | Reference compound |
| HY-122646 | USP7-IN-2 | 2196243-57-7 | Reference compound |
| HY-122647 | Valiglurax | 1976050-09-5 | Reference compound |
| HY-122649 | UU-T01 | 1417162-83-4 | Reference compound |
| HY-122650 | PHY34 | 2130033-55-3 | Reference compound |
| HY-122652 | MitoBloCK-6 | 303215-67-0 | Reference compound |
| HY-122653 | CCT367766 | 2229856-58-8 | Reference compound |
| HY-122653A | CCT367766 (formic) | | Reference compound |
| HY-122655 | HMCEF | 2002363-68-8 | Reference compound |
| HY-122657 | AI-10-104 | 1881276-00-1 | Reference compound |
| HY-122661 | Mefuparib (hydrochloride) | 1449746-00-2 | Reference compound |
| HY-122663 | (Rac)-BIO8898 | 402564-79-8 | Reference compound |
| HY-122663A | BIO8898 | | Reference compound |
| HY-122664 | XMU-MP-2 | 2031152-10-8 | Reference compound |
| HY-122665 | HTH-01-091 | 2000209-42-5 | Reference compound |
| HY-122665A | HTH-01-091 (TFA) | | Reference compound |
| HY-122666 | Org 25935 | 949588-40-3 | Reference compound |
| HY-122668 | K22 | 2141978-86-9 | Reference compound |
| HY-122671 | OB-1 | 300803-69-4 | Reference compound |
| HY-122671S | OB-1-d3 | | Isotope-Labeled Compounds |
| HY-122672 | Adhesamine | 462605-73-8 | Reference compound |
| HY-122672A | Adhesamine (diTFA) | 1201698-09-0 | Reference compound |
| HY-122675 | ACG416B | 795316-15-3 | Reference compound |
| HY-122678 | LQZ-7F | 354543-09-2 | Reference compound |
| HY-122681 | SR-16435 | 857262-16-9 | Reference compound |
| HY-122682 | SBI-993 | 2073059-82-0 | Reference compound |
| HY-122683 | sAJM589 | 2089-82-9 | Reference compound |
| HY-122694 | Thalidomide-O-amido-PEG-C2-NH2 | 2022182-59-6 | Reference compound |
| HY-122694A | Thalidomide-O-amido-PEG-C2-NH2 (hydrochloride) | 2204226-02-6 | Reference compound |
| HY-122695 | FEN1-IN-2 | 824983-94-0 | Reference compound |
| HY-122696 | CH2COOH-PEG3-CH2COOH | 32775-08-9 | Reference compound |
| HY-122697 | ML418 | 1928763-08-9 | Reference compound |
| HY-122698 | CCI-007 | 939228-52-1 | Reference compound |
| HY-12270 | T-5224 | 530141-72-1 | Reference compound |
| HY-122700 | Factor D inhibitor 6 | 1386455-51-1 | Reference compound |
| HY-122702 | PEG6-(CH2CO2H)2 | 77855-76-6 | Reference compound |
| HY-122703 | BETi-211 | 1995867-02-1 | Reference compound |
| HY-122704 | Surfen | 3811-56-1 | Reference compound |
| HY-122704A | Surfen (dihydrochloride) | 5424-37-3 | Reference compound |
| HY-122705 | RAD51-IN-1 | 2101739-18-6 | Reference compound |
| HY-122706A | IP6K2-IN-2 | 2967648-66-2 | Reference compound |
| HY-122709 | hTG2 inhibitor VA4 | 2088001-23-2 | Reference compound |
| HY-122710 | Thalidomide-O-amido-PEG4-C2-NH2 | 1957236-22-4 | Reference compound |
| HY-122710A | Thalidomide-O-amido-PEG4-C2-NH2 (hydrochloride) | 2245697-85-0 | Reference compound |
| HY-122714 | SK-216 | 654080-03-2 | Reference compound |
| HY-122716 | PTGR2-IN-1 | 349093-44-3 | Reference compound |
| HY-122720 | SEC inhibitor KL-1 | 900308-84-1 | Reference compound |
| HY-122721 | Mcl1-IN-5 | 2056238-04-9 | Reference compound |
| HY-122723 | GOT1 inhibitor-1 | 732973-87-4 | Reference compound |
| HY-122724 | IQDMA | 401463-02-3 | Reference compound |
| HY-122725A | Lenalidomide-C5-NH2 (TFA) | 2550398-71-3 | Reference compound |
| HY-122725B | Lenalidomide-C5-NH2 (hydrochloride) | 2595367-27-2 | Reference compound |
| HY-122727 | STL127705 | 1326852-06-5 | Reference compound |
| HY-12273 | DMH-1 | 1206711-16-1 | Reference compound |
| HY-122732 | OADS | 5970-15-0 | Reference compound |
| HY-122737 | RORγt Inverse agonist 8 | 2079892-79-6 | Reference compound |
| HY-12273G | DMH-1 (GMP) | 1206711-16-1 | GMP Small Molecules |
| HY-12273R | DMH-1 (Standard) | 1206711-16-1 | Reference Standards |
| HY-12274 | ML347 | 1062368-49-3 | Reference compound |
| HY-122742 | HBT1 | 489408-02-8 | Reference compound |
| HY-122743 | Iperoxo | 247079-84-1 | Reference compound |
| HY-122746 | E67-2 | 1364914-62-4 | Reference compound |
| HY-12275 | FR 180204 | 865362-74-9 | Reference compound |
| HY-122751 | (R)-DNMDP | 1630760-60-9 | Reference compound |
| HY-122753 | SLMP53-1 | 1643469-17-3 | Reference compound |
| HY-12276 | MALT1 inhibitor MI-2 | 1047953-91-2 | Reference compound |
| HY-122760 | Bax activator-1 | 1638526-94-9 | Reference compound |
| HY-122761 | Quifenadine | 10447-39-9 | Reference compound |
| HY-122762 | Cetraxate (hydrochloride) | 27724-96-5 | Reference compound |
| HY-122764 | Acalyphin | 81861-72-5 | Natural Products |
| HY-122765 | Luxabendazole | 90509-02-7 | Reference compound |
| HY-122765S | Luxabendazole-d3 | 1448346-27-7 | Isotope-Labeled Compounds |
| HY-122767 | Romurtide | 78113-36-7 | Peptides |
| HY-122769 | Adapiprazine | 57942-72-0 | Reference compound |
| HY-12277 | AZ191 | 1594092-37-1 | Reference compound |
| HY-122772 | (-)-Integerrimine | 480-79-5 | Natural Products |
| HY-122776 | Deacetylmatricarin | 10180-88-8 | Natural Products |
| HY-122777 | γ-Rubromycin | 27267-71-6 | Natural Products |
| HY-122778 | δ-Tocotrienol | 25612-59-3 | Reference compound |
| HY-122778R | δ-Tocotrienol (Standard) | 25612-59-3 | Reference Standards |
| HY-12278 | K02288 | 1431985-92-0 | Reference compound |
| HY-122782 | Lucidal | 252351-96-5 | Natural Products |
| HY-122783 | Isogambogic acid | 149655-52-7 | Natural Products |
| HY-122785 | Fusapyrone | 156856-31-4 | Reference compound |
| HY-122786 | 3-O-Methylviridicatin | 6152-57-4 | Reference compound |
| HY-122787 | Tylocrebrine | 6879-02-3 | Reference compound |
| HY-122788 | N-Oleoyl serinol | 72809-08-6 | Reference compound |
| HY-12279 | Umbralisib | 1532533-67-7 | Reference compound |
| HY-122790 | 2-Hydroxydocosanoic acid | 13980-14-8 | Natural Products |
| HY-122792 | Phenyramidol (Hydrochloride) | 326-43-2 | Reference compound |
| HY-122792R | Phenyramidol (Hydrochloride) (Standard) | 326-43-2 | Reference Standards |
| HY-122794 | Tyrosylleucine | 17355-10-1 | Peptides |
| HY-122794A | Tyrosylleucine (TFA) | 66852-01-5 | Peptides |
| HY-122795 | Vanoxonin | 86933-99-5 | Natural Products |
| HY-122797 | Oleic anhydride | 24909-72-6 | Biochemical Assay Reagents |
| HY-122798 | Verdantiol | 91-51-0 | Reference compound |
| HY-122799 | Cannabigerovarinic acid | 64924-07-8 | Reference compound |
| HY-12279A | Umbralisib (tosylate) | 1532533-72-4 | Reference compound |
| HY-12279B | Umbralisib (sulfate) | 1532533-75-7 | Reference compound |
| HY-12279C | Umbralisib (hydrochloride) | 1532533-78-0 | Reference compound |
| HY-12279F | Umbralisib R-enantiomer | 1532533-69-9 | Reference compound |
| HY-12280 | THZ2 | 1604810-84-5 | Reference compound |
| HY-122808 | (-)-Camphoric acid | 560-09-8 | Natural Products |
| HY-12281 | FPH2 | 957485-64-2 | Reference compound |
| HY-122811 | Dansyl-L-leucine | 1100-22-7 | Peptides |
| HY-122812 | Maesopsin | 5989-16-2 | Reference compound |
| HY-122813S1 | Dabigatran acyl-β-D-glucuronide-d3 (TFA) | | Isotope-Labeled Compounds |
| HY-122814 | Hedgehog IN-1 | 330796-24-2 | Reference compound |
| HY-122815 | Fusicoccin | 20108-30-9 | Natural Products |
| HY-122816 | HLY78 | 854847-61-3 | Reference compound |
| HY-122817 | FR900098 (sodium) | 73226-73-0 | Reference compound |
| HY-122818 | BpV(phen) (trihydrate) | 171202-16-7 | Reference compound |
| HY-122819 | Calindol (hydrochloride) | 729610-18-8 | Reference compound |
| HY-12282 | GNE-9605 | 1536200-31-3 | Reference compound |
| HY-122825 | SNIPER(ER)-110 | 2241690-03-7 | Reference compound |
| HY-122826 | ZXH-3-26 | 2243076-67-5 | Reference compound |
| HY-122828 | PROTAC BTK Degrader-2 | 2250382-66-0 | Reference compound |
| HY-122829 | BCL6 PROTAC 1 | 2257479-54-0 | Reference compound |
| HY-12283 | Rostafuroxin | 156722-18-8 | Reference compound |
| HY-122830 | DD-03-171 | 2366132-45-6 | Reference compound |
| HY-122832 | ABC99 | 2331255-53-7 | Reference compound |
| HY-12284 | NVP-QAV680 | 872365-16-7 | Reference compound |
| HY-122844 | Ifebemtinib | 1227948-82-4 | Reference compound |
| HY-122844A | Ifebemtinib (hydrochloride) | | Reference compound |
| HY-122848 | DDR1/2 inhibitor-3 | 2241813-33-0 | Reference compound |
| HY-12285 | Serabelisib | 1268454-23-4 | Reference compound |
| HY-122856 | AZ12601011 | 2748337-86-0 | Reference compound |
| HY-122857 | PKCiota-IN-1 | 2230052-97-6 | Reference compound |
| HY-122858 | PKCiota-IN-2 | 2230055-52-2 | Reference compound |
| HY-122858A | PKCiota-IN-2 (formic) | | Reference compound |
| HY-12286 | PI-1840 | 1401223-22-0 | Reference compound |
| HY-122862 | RAS inhibitor Abd-7 | 2351843-48-4 | Reference compound |
| HY-122866 | ZT-12-037-01 | 2328073-61-4 | Reference compound |
| HY-12287 | YH239-EE | 1364488-67-4 | Reference compound |
| HY-122872 | MKK7-COV-9 | 2283355-59-7 | Reference compound |
| HY-122874 | DI-404 | 2187412-79-7 | Reference compound |
| HY-122876 | KUNB31 | 2220263-80-7 | Reference compound |
| HY-122878 | HS-131 | 2084850-40-6 | Dye Reagents |
| HY-12288 | Ozanimod | 1306760-87-1 | Reference compound |
| HY-122881 | HOIPIN-1 | | Reference compound |
| HY-122881A | (E/Z)-HOIPIN-1 | 2470242-33-0 | Reference compound |
| HY-122882 | HOIPIN-8 | 2519537-70-1 | Reference compound |
| HY-122883 | BC-1471 | 896683-84-4 | Reference compound |
| HY-122885 | IU1-248 | 2307472-03-1 | Reference compound |
| HY-122886 | XL 188 | 2305045-76-3 | Reference compound |
| HY-12288A | Ozanimod (hydrochloride) | 1618636-37-5 | Reference compound |
| HY-12288R | Ozanimod (Standard) | 1306760-87-1 | Reference Standards |
| HY-12289 | Defactinib | 1073154-85-4 | Reference compound |
| HY-122891 | SB02024 | 2126737-28-6 | Reference compound |
| HY-122895 | E64FC26 | 2285446-62-8 | Reference compound |
| HY-122895A | (E/Z)-E64FC26 | 2285446-67-3 | Reference compound |
| HY-12289A | Defactinib (hydrochloride) | 1073160-26-5 | Reference compound |
| HY-12289S | Defactinib-d6 | 2384121-03-1 | Isotope-Labeled Compounds |
| HY-12290 | Arg-Gly-Asp-Ser | 91037-65-9 | Peptides |
| HY-122903 | TK216 | 1903783-48-1 | Reference compound |
| HY-122903A | (-)-TK216 | 1903783-78-7 | Reference compound |
| HY-122903B | (+)-TK216 | 1903783-77-6 | Reference compound |
| HY-122906 | JTE-952 | 1255303-54-8 | Reference compound |
| HY-122907 | JNJ4796 | 2241664-16-2 | Reference compound |
| HY-122908 | Atuliflapon | 2041075-86-7 | Reference compound |
| HY-122909 | GSK2593074A | 1337531-06-2 | Reference compound |
| HY-12290A | Arg-Gly-Asp-Ser (TFA) | | Peptides |
| HY-12291 | HG6-64-1 | 1315329-43-1 | Reference compound |
| HY-122910 | RIPGBM | 355406-76-7 | Reference compound |
| HY-122912 | ALDH1A inhibitor 673A | 109437-62-9 | Reference compound |
| HY-122913 | Borussertib | 1800070-77-2 | Reference compound |
| HY-122914 | KRAS inhibitor-3 | 900897-56-5 | Reference compound |
| HY-122915 | Zedoarondiol | 98644-24-7 | Natural Products |
| HY-122916 | 7-Acetyllycopsamine | 73544-48-6 | Natural Products |
| HY-122917 | Danshenol A | 189308-08-5 | Natural Products |
| HY-122918 | Moracin T | 1146113-27-0 | Natural Products |
| HY-122919 | Momordicoside L | 81348-83-6 | Natural Products |
| HY-12292 | IM-12 | 1129669-05-1 | Reference compound |
| HY-122920 | Soyasaponin II | 55319-36-3 | Natural Products |
| HY-122921 | 5-Galloylquinic acid | 53584-43-3 | Natural Products |
| HY-122922 | Valtropine | 495-82-9 | Natural Products |
| HY-122924 | Theogallin | 17365-11-6 | Natural Products |
| HY-122924R | Theogallin (Standard) | 17365-11-6 | Reference Standards |
| HY-122927 | Symphytine | 22571-95-5 | Reference compound |
| HY-12293 | LY2857785 | 1619903-54-6 | Reference compound |
| HY-122930 | Lysicamine | 15444-20-9 | Natural Products |
| HY-122931 | Supinine | 551-58-6 | Natural Products |
| HY-122932 | Neoquassin | 76-77-7 | Natural Products |
| HY-122932R | Neoquassin (Standard) | 76-77-7 | Reference Standards |
| HY-122933 | Kurarinol | 855746-98-4 | Natural Products |
| HY-122934 | 11-Methoxyangonin | 56070-89-4 | Natural Products |
| HY-122935 | Nigranoic acid | 39111-07-4 | Natural Products |
| HY-122936 | Tanshindiol C | 97465-71-9 | Reference compound |
| HY-122938 | Ceplignan | 185244-78-4 | Natural Products |
| HY-122939 | MAIPGG | 161876-61-5 | Reference compound |
| HY-12294 | PEAQX | 459836-30-7 | Reference compound |
| HY-122940 | Precocene II | 644-06-4 | Natural Products |
| HY-122941 | Viscidulin II | 92519-93-2 | Natural Products |
| HY-122942 | Moracin M | 56317-21-6 | Natural Products |
| HY-122943 | Moracin D | 69120-07-6 | Natural Products |
| HY-122944 | 20-Deoxocarnosol | 94529-97-2 | Natural Products |
| HY-122945 | Villosin C | 160927-81-1 | Natural Products |
| HY-122946 | Pterisolic acid B | 1401419-86-0 | Natural Products |
| HY-122948 | Isogambogenic acid | 887923-47-9 | Natural Products |
| HY-122949 | Momordicine I | 91590-76-0 | Natural Products |
| HY-12294A | PEAQX (tetrasodium hydrate) | | Reference compound |
| HY-12294B | (Rac)-PEAQX | 2514919-70-9 | Reference compound |
| HY-122950 | Harzianic acid | 157148-06-6 | Reference compound |
| HY-122951 | Eburicoic acid | 560-66-7 | Natural Products |
| HY-122953 | Daturaolone | 41498-80-0 | Natural Products |
| HY-122954 | Momordicoside K | 81348-84-7 | Natural Products |
| HY-122955 | Xanthobaccin A | 227596-81-8 | Natural Products |
| HY-122957 | Huperzine C | 163089-71-2 | Natural Products |
| HY-122958 | Peucedanocoumarin III | 130464-57-2 | Natural Products |
| HY-122959 | Kihadanin B | 73793-68-7 | Natural Products |
| HY-12296 | Navtemadlin | 1352066-68-2 | Reference compound |
| HY-122960 | Epifriedelanol acetate | 2259-07-6 | Natural Products |
| HY-122961 | Dehydromiltirone | 116064-77-8 | Natural Products |
| HY-122963 | Danshenol B | 189308-09-6 | Natural Products |
| HY-122964 | URB447 | 1132922-57-6 | Reference compound |
| HY-122965 | Batatasin III | 56684-87-8 | Natural Products |
| HY-122966 | Desmethylxanthohumol | 115063-39-3 | Natural Products |
| HY-122967 | Isosalvianolic acid C | 142115-17-1 | Natural Products |
| HY-122968 | Brocresine | 555-65-7 | Reference compound |
| HY-122969 | Anwuweizonic acid | 117020-59-4 | Natural Products |
| HY-12296A | (3S,5S,6R)-Navtemadlin | 2459946-14-4 | Reference compound |
| HY-12296S | Navtemadlin-d7 | | Isotope-Labeled Compounds |
| HY-12297 | Sulfatinib | 1308672-74-3 | Reference compound |
| HY-122970 | 1,2-Dihydrotanshinone | 77769-21-2 | Natural Products |
| HY-122974 | VA-K-14 (hydrochloride) | 1171341-19-7 | Reference compound |
| HY-122975 | Metronidazole Benzoate | 13182-89-3 | Reference compound |
| HY-122975R | Metronidazole Benzoate (Standard) | 13182-89-3 | Reference Standards |
| HY-122979 | (+)-Butaclamol (hydrochloride) | 55528-07-9 | Reference compound |
| HY-12297R | Sulfatinib (Standard) | 1308672-74-3 | Reference Standards |
| HY-12298 | Setanaxib | 1218942-37-0 | Reference compound |
| HY-122980 | Myxochelin A | 120243-02-9 | Reference compound |
| HY-122983 | Diisobutyl adipate | 141-04-8 | Reference compound |
| HY-122984 | Diquat (dibromide) | 85-00-7 | Reference compound |
| HY-122984R | Diquat (dibromide) (Standard) | 85-00-7 | Reference Standards |
| HY-122984S | Diquat-d4 (dibromide) | | Isotope-Labeled Compounds |
| HY-122985 | Graphislactone A | 52179-44-9 | Reference compound |
| HY-122988 | Xenbucin | 959-10-4 | Reference compound |
| HY-122988A | Namoxyrate | 1234-71-5 | Reference compound |
| HY-122989 | Aristolactam BIII | 53948-10-0 | Natural Products |
| HY-12299 | WH-4-023 | 837422-57-8 | Reference compound |
| HY-122991 | Prospasmine (hydrochloride) | 132-45-6 | Reference compound |
| HY-122996 | Nikkomycin M | 77368-62-8 | Reference compound |
| HY-122997 | Acetylaleuritolic acid | 28937-85-1 | Natural Products |
| HY-122998 | Iodoalphionic acid | 577-91-3 | Reference compound |
| HY-12300 | Ocifisertib | 1338806-73-7 | Reference compound |
| HY-123000 | 4-Methylumbelliferyl 2-acetamido-2-deoxy-α-D-galactopyranoside | 124223-99-0 | Biochemical Assay Reagents |
| HY-123001 | Nomelidine | 60324-59-6 | Reference compound |
| HY-123002 | Pyrifenox | 88283-41-4 | Reference compound |
| HY-123002R | Pyrifenox (Standard) | 88283-41-4 | Reference Standards |
| HY-123006 | Aszonalenin | 81797-27-5 | Natural Products |
| HY-123007S | 13(S)-HODE-d4 | 139408-39-2 | Isotope-Labeled Compounds |
| HY-123008 | Reproterol (hydrochloride) | 13055-82-8 | Reference compound |
| HY-123008R | Reproterol (hydrochloride) (Standard) | 13055-82-8 | Reference Standards |
| HY-123009 | KCN1 | 927823-01-6 | Reference compound |
| HY-12300A | Ocifisertib (hydrochloride) | 1338799-83-9 | Reference compound |
| HY-12300B | Ocifisertib (fumarate) | 1616420-30-4 | Reference compound |
| HY-12301 | MK-3697 | 1224846-01-8 | Reference compound |
| HY-123011 | Henagliflozin | 1623804-44-3 | Reference compound |
| HY-123012 | Lubabegron | 391920-32-4 | Reference compound |
| HY-123012A | Lubabegron (fumarate) | 391926-19-5 | Reference compound |
| HY-123013 | Y 9000 | 53944-40-4 | Reference compound |
| HY-123014 | (Rac)-SC-45694 | 120772-66-9 | Reference compound |
| HY-123015 | Tamolarizine | 93035-32-6 | Reference compound |
| HY-123016 | 9(S)-HODE cholesteryl ester | 143442-54-0 | Reference compound |
| HY-123016A | (±)9-HODE cholesteryl ester | 33783-76-5 | Reference compound |
| HY-123019 | RA-263 | 82205-95-6 | Reference compound |
| HY-12302 | Kenpaullone | 142273-20-9 | Reference compound |
| HY-123020 | CYD-2-88 | 1821496-27-8 | Reference compound |
| HY-123022 | Tomopenem | 222400-20-6 | Reference compound |
| HY-123023 | 12(S)-HETE-d8 | 84807-90-9 | Isotope-Labeled Compounds |
| HY-123024 | Cefatrizine | 51627-14-6 | Reference compound |
| HY-123025 | Schizozygine | 2047-63-4 | Natural Products |
| HY-123026 | Salannin | 992-20-1 | Natural Products |
| HY-123028 | RFamide | 34388-59-5 | Reference compound |
| HY-123029 | 5,6,7,8-Tetrahydro-2-quinolone | 54802-19-6 | Reference compound |
| HY-12303 | OAC1 | 300586-90-7 | Reference compound |
| HY-123032 | Sorivudine | 77181-69-2 | Reference compound |
| HY-123033 | Nicotinamide riboside | 1341-23-7 | Natural Products |
| HY-123033A | Nicotinamide riboside (chloride) | 23111-00-4 | Natural Products |
| HY-123033AR | Nicotinamide riboside (chloride) (Standard) | 23111-00-4 | Reference Standards |
| HY-123033B | Nicotinamide riboside (tartrate) | 2415657-86-0 | Reference compound |
| HY-123033C | Nicotinamide riboside (malate) | 2415659-01-5 | Reference compound |
| HY-123033D | Nicotinamide riboside (triflate) | 445489-49-6 | Reference compound |
| HY-123034 | CDKI-83 | 1189558-88-0 | Reference compound |
| HY-123035 | Gamendazole | 877773-32-5 | Reference compound |
| HY-123036 | Renierone | 73777-65-8 | Reference compound |
| HY-123037 | Triadimefon | 43121-43-3 | Reference compound |
| HY-123037R | Triadimefon (Standard) | 43121-43-3 | Reference Standards |
| HY-123038 | CVT-5440 | 531506-64-6 | Reference compound |
| HY-123039 | CP-532623 | 261947-38-0 | Reference compound |
| HY-12304 | IOX1 | 5852-78-8 | Reference compound |
| HY-123040 | ACAT Inhibitor 1 | 142642-31-7 | Reference compound |
| HY-123043 | Afeletecan | 215604-75-4 | Reference compound |
| HY-123044 | Tedatioxetine | 508233-95-2 | Reference compound |
| HY-123045 | PNU-292137 | 326823-27-2 | Reference compound |
| HY-123046 | AS1708727 | 1253226-93-5 | Reference compound |
| HY-123047 | Tibolone | 5630-53-5 | Natural Products |
| HY-123047R | Tibolone (Standard) | 5630-53-5 | Reference Standards |
| HY-123047S | Tibolone-d5 | | Isotope-Labeled Compounds |
| HY-12305 | Q-VD-OPh | 1135695-98-5 | Reference compound |
| HY-123050 | (Rac)-SAR131675 | 1092539-44-0 | Reference compound |
| HY-123051 | Ac-WLA-AMC | 1104011-59-7 | Dye Reagents |
| HY-123052 | Ac-PAL-AMC | 1431362-79-6 | Reference compound |
| HY-123053 | Z-Leu-Leu-Glu-AMC | 348086-66-8 | Peptides |
| HY-123054 | BTSA1 | 314761-14-3 | Reference compound |
| HY-123055 | Adenosine dialdehyde | 34240-05-6 | Reference compound |
| HY-123056 | EAD1 | 1644388-26-0 | Reference compound |
| HY-123056A | EAD1 (TFA) | 2320427-95-8 | Reference compound |
| HY-123058 | Vps34-IN-4 | 1383716-46-8 | Reference compound |
| HY-123059 | (Rac)-ICI-118551 (hydrochloride) | 1217094-53-5 | Reference compound |
| HY-12305A | (R)-Q-VD-OPh | | Reference compound |
| HY-12306 | 8-Bromo-cAMP sodium salt | 76939-46-3 | Reference compound |
| HY-123063 | Petromyzonol | 28979-29-5 | Natural Products |
| HY-123065 | Chromotropic acid (disodium dihydrate) | 5808-22-0 | Biochemical Assay Reagents |
| HY-123067 | NBD-Fructose | 940961-04-6 | Dye Reagents |
| HY-123068 | Captopril disulfide | 64806-05-9 | Reference compound |
| HY-123068R | Captopril disulfide (Standard) | 64806-05-9 | Reference Standards |
| HY-12306A | 8-Bromo-cAMP | 23583-48-4 | Reference compound |
| HY-12307 | (-)-Indolactam V | 90365-57-4 | Reference compound |
| HY-123070 | ONO-RS-082 | 99754-06-0 | Reference compound |
| HY-123071 | Box5 | 1206604-29-6 | Peptides |
| HY-123071A | Box5 (TFA) | | Peptides |
| HY-123075 | Odoroside H | 18810-25-8 | Natural Products |
| HY-123076 | Pifithrin-α, p-Nitro, Cyclic | 60477-38-5 | Reference compound |
| HY-123077 | Norsanguinarine | 522-30-5 | Natural Products |
| HY-12308 | TCS 2314 | 317353-73-4 | Reference compound |
| HY-123080 | Tanshinol B | 189290-30-0 | Natural Products |
| HY-123081 | Eburicol | 6890-88-6 | Natural Products |
| HY-123083 | Javanicin C | 126149-71-1 | Natural Products |
| HY-123085 | Alloxazine | 490-59-5 | Reference compound |
| HY-123087 | N-(3-Hydroxytetradecanoyl)-DL-homoserine lactone | 172670-99-4 | Reference compound |
| HY-12309 | EC23 | 104561-41-3 | Reference compound |
| HY-123090 | 11β-HSD1-IN-12 | 872506-67-7 | Reference compound |
| HY-123091 | Ivangustin | 14164-59-1 | Natural Products |
| HY-123095 | TS 155-2 | 1314486-37-7 | Natural Products |
| HY-123096 | Silthiofam | 175217-20-6 | Reference compound |
| HY-123096R | Silthiofam (Standard) | 175217-20-6 | Reference Standards |
| HY-123098 | Tetrahydromethotrexate | 4299-28-9 | Reference compound |
| HY-123099 | MS-1020 | 1255516-86-9 | Reference compound |
| HY-12310 | RSC133 | 1418131-46-0 | Reference compound |
| HY-123100 | Ganoderic acid N | 110241-19-5 | Natural Products |
| HY-123100R | Ganoderic acid N (Standard) | 110241-19-5 | Reference Standards |
| HY-123103 | Linetastine | 159776-68-8 | Reference compound |
| HY-123106 | MCL-0129 | 768357-45-5 | Reference compound |
| HY-123109 | (S,R,S)-AHPC-Boc | 1448189-98-7 | Reference compound |
| HY-123109A | (S,S,S)-AHPC-Boc | 1797406-74-6 | Reference compound |
| HY-123112 | Hoe 892 | 75111-35-2 | Reference compound |
| HY-123114 | Linamarin | 554-35-8 | Natural Products |
| HY-123115 | Leucrose | 7158-70-5 | Reference compound |
| HY-123117 | VA5 | 2088001-24-3 | Reference compound |
| HY-12312 | TCS 401 | 243966-09-8 | Reference compound |
| HY-123120 | SA-152 | 142450-99-5 | Reference compound |
| HY-123121 | Nargenicin A1 | 70695-02-2 | Reference compound |
| HY-123123 | RS-61756-007 | 121571-14-0 | Reference compound |
| HY-123126 | Cevine | 124-98-1 | Reference compound |
| HY-123127 | CVT-2759 analog | 342419-10-7 | Reference compound |
| HY-123128 | Raphanatin | 38165-56-9 | Reference compound |
| HY-12312A | TCS 401 (free base) | 243967-42-2 | Reference compound |
| HY-123130 | ABT-770 | 220614-50-6 | Reference compound |
| HY-123133 | PKSI-527 | 128837-71-8 | Reference compound |
| HY-123134 | FIIN-4 | 2093088-81-2 | Reference compound |
| HY-123135 | Scirpusin B | 69297-49-0 | Natural Products |
| HY-123137 | Ro 24-6778 | 130838-10-7 | Reference compound |
| HY-123138 | LY206130 (free base) | 127414-58-8 | Reference compound |
| HY-123139 | Flutroline | 70801-02-4 | Reference compound |
| HY-123141 | K00135 | 869650-21-5 | Reference compound |
| HY-123142 | RX809055AX | 122566-12-5 | Reference compound |
| HY-123143 | XR11576 | 346689-77-8 | Reference compound |
| HY-123144 | N-Hydroxymethylsorafenib | 1380310-94-0 | Reference compound |
| HY-123145 | JNJ-10258859 | 374927-03-4 | Reference compound |
| HY-123148 | IMB-808 | 870768-70-0 | Reference compound |
| HY-12315 | N-Oxalylglycine | 5262-39-5 | Reference compound |
| HY-123154 | PDE10A-IN-4 | 898563-49-0 | Reference compound |
| HY-123155 | Pyrimorph | 868390-90-3 | Reference compound |
| HY-123156 | SC-23110 | 60149-28-2 | Reference compound |
| HY-123157 | Methoserpidine | 865-04-3 | Reference compound |
| HY-123158 | Diflufenzopyr | 109293-97-2 | Reference compound |
| HY-123158R | Diflufenzopyr (Standard) | 109293-97-2 | Reference Standards |
| HY-123159 | AKI603 | 1432515-73-5 | Reference compound |
| HY-12316 | 20(S)-Hydroxycholesterol | 516-72-3 | Natural Products |
| HY-123161 | JBIR-15 | 1198588-57-6 | Natural Products |
| HY-123162A | Astromicin (disulfate) | 72275-67-3 | Reference compound |
| HY-123163 | JNJ-1250132 | 240805-96-3 | Reference compound |
| HY-123168 | ZIMET 124/73 | 61930-46-9 | Reference compound |
| HY-12316R | 20(S)-Hydroxycholesterol (Standard) | 516-72-3 | Reference Standards |
| HY-12317 | GSA-10 | 300833-95-8 | Reference compound |
| HY-123170 | PD 099560 | 155758-74-0 | Reference compound |
| HY-123171 | ASP8497 | 651055-26-4 | Reference compound |
| HY-123172 | CEP-2563 | 183488-70-2 | Reference compound |
| HY-123174 | Demethoxyrapamycin | 83482-58-0 | Reference compound |
| HY-123175 | Chinfloxacin | 868208-92-8 | Reference compound |
| HY-123176 | GYKI-13380 | 75614-09-4 | Reference compound |
| HY-123177 | Ratjadone | 163564-92-9 | Reference compound |
| HY-123178 | Fenpropathrin | 39515-41-8 | Reference compound |
| HY-123178R | Fenpropathrin (Standard) | 39515-41-8 | Reference Standards |
| HY-123178S | Fenpropathrin-d5 | | Isotope-Labeled Compounds |
| HY-123179 | Mefruside | 7195-27-9 | Reference compound |
| HY-123179S | Mefruside-d3 | 2468638-25-5 | Isotope-Labeled Compounds |
| HY-12318 | IBMX | 28822-58-4 | Reference compound |
| HY-123180 | Ro 31-2201 | 88851-65-4 | Reference compound |
| HY-123182 | PD-140548 | 140677-01-6 | Reference compound |
| HY-123184 | S 1924 | 111371-30-3 | Reference compound |
| HY-123187 | AS2553627 | 1251906-10-1 | Reference compound |
| HY-123189 | LY 171859 | 89139-28-6 | Reference compound |
| HY-12318G | IBMX (GMP) | 28822-58-4 | GMP Small Molecules |
| HY-12318R | IBMX (Standard) | 28822-58-4 | Reference Standards |
| HY-12319 | Cardiogenol C | 671225-39-1 | Reference compound |
| HY-123190 | Safracin A | 87578-98-1 | Natural Products |
| HY-123191 | CJ-463 | 600142-19-6 | Reference compound |
| HY-123192 | Uredofos | 52406-01-6 | Reference compound |
| HY-123193S | Avizafone-d5 (dihydrobromide) | | Isotope-Labeled Compounds |
| HY-123194 | SIRT2/6-IN-1 | 1214468-35-5 | Reference compound |
| HY-123195 | CK-119 | 197917-10-5 | Reference compound |
| HY-123196 | CVT-2759 | 342419-09-4 | Reference compound |
| HY-123197 | FR-193879 | 194928-82-0 | Reference compound |
| HY-123198 | 4-Hydroxybufuralol | 61470-08-4 | Reference compound |
| HY-123199 | Serotonin azidobenzamidine | 98409-42-8 | Reference compound |
| HY-12319A | Cardiogenol C (hydrochloride) | 1049741-55-0 | Reference compound |
| HY-123201 | KRN383 analog | 919767-02-5 | Reference compound |
| HY-123202 | MRS2603 | 860623-35-4 | Reference compound |
| HY-123203 | CP-608039 | 331727-55-0 | Reference compound |
| HY-123204 | FR182024 | 179034-83-4 | Reference compound |
| HY-123205 | Oxatomide | 60607-34-3 | Reference compound |
| HY-123205R | Oxatomide (Standard) | 60607-34-3 | Reference Standards |
| HY-123206 | R-96544 (free base) | 167144-79-8 | Reference compound |
| HY-123208 | Sulfonterol | 42461-79-0 | Reference compound |
| HY-123210 | Lodenafil | 139755-85-4 | Reference compound |
| HY-123210R | Lodenafil (Standard) | 139755-85-4 | Reference Standards |
| HY-123211 | WAY-150138 | 273388-09-3 | Reference compound |
| HY-123214 | Rifametane | 94168-98-6 | Reference compound |
| HY-123215 | CC-17369 | 1547162-46-8 | Reference compound |
| HY-123216 | Cefmatilen | 140128-74-1 | Reference compound |
| HY-123219 | Salifluor | 78417-90-0 | Reference compound |
| HY-123220 | S 1592 | 25552-58-3 | Reference compound |
| HY-123222 | CGP 56999 | 153994-97-9 | Reference compound |
| HY-123225 | LCRF-0004 | 1229611-73-7 | Reference compound |
| HY-123226 | TA-606 | 190602-72-3 | Reference compound |
| HY-123227 | SQ 27786 | 89813-31-0 | Reference compound |
| HY-123228 | CHF5022 | 749269-77-0 | Reference compound |
| HY-123229 | Ropizine | 3601-19-2 | Reference compound |
| HY-12323 | ISX-9 | 832115-62-5 | Reference compound |
| HY-123230 | Trifloxystrobin | 141517-21-7 | Reference compound |
| HY-123230R | Trifloxystrobin (Standard) | 141517-21-7 | Reference Standards |
| HY-123230S | Trifloxystrobin-d6 | 2470226-50-5 | Isotope-Labeled Compounds |
| HY-123230S1 | Trifloxystrobin-d3 | | Isotope-Labeled Compounds |
| HY-123232 | KU-0058684 | 623578-11-0 | Reference compound |
| HY-123234 | Kolanone | 81827-55-6 | Natural Products |
| HY-123237 | KRC-108 | 1146944-35-5 | Reference compound |
| HY-123239 | KLS-13019 | 1801243-39-9 | Reference compound |
| HY-12323G | ISX-9 (GMP) | 832115-62-5 | GMP Small Molecules |
| HY-12324 | SB269652 | 215802-15-6 | Reference compound |
| HY-123240 | CI-966 | 110283-79-9 | Reference compound |
| HY-123241 | ZINC08792229 | 904514-73-4 | Reference compound |
| HY-123242 | FTI-2153 | 344900-92-1 | Reference compound |
| HY-123242A | FTI-2153 (TFA) | 2820151-01-5 | Reference compound |
| HY-123244 | YC137 | 810659-53-1 | Reference compound |
| HY-123247 | LY113174 | 112959-07-6 | Reference compound |
| HY-123249 | HZ166 | 612527-56-7 | Reference compound |
| HY-12325 | GSK2194069 | 1332331-08-4 | Reference compound |
| HY-123251 | DB-766 | 423165-22-4 | Reference compound |
| HY-123252 | Kurchessine | 6869-45-0 | Natural Products |
| HY-123253 | cis-LY393053 | 394735-81-0 | Reference compound |
| HY-123254 | CCG-224406 | 1870843-22-3 | Reference compound |
| HY-123259 | CB3731 | 80015-07-2 | Reference compound |
| HY-12326 | c-di-AMP | 54447-84-6 | Reference compound |
| HY-123260 | S12340 | 144754-35-8 | Reference compound |
| HY-123264 | RL648_81 | 1919050-87-5 | Reference compound |
| HY-123265 | Luteoreticulin | 22388-89-2 | Reference compound |
| HY-123266 | D011-2120 | 620931-39-7 | Reference compound |
| HY-123268 | Ro 363 | 74513-77-2 | Reference compound |
| HY-123268A | Ro 363 (hydrochloride) | 250580-70-2 | Reference compound |
| HY-123269 | PKUMDL-WQ-2101 | 304481-72-9 | Reference compound |
| HY-12326A | c-di-AMP (disodium) | 2734909-87-4 | Reference compound |
| HY-12326B | c-di-AMP (diammonium) | | Reference compound |
| HY-12327 | Trk-IN-1 | 1402438-37-2 | Reference compound |
| HY-123270 | RP23618 | 207991-30-8 | Reference compound |
| HY-123271 | Ro 23-9424 | 115622-58-7 | Reference compound |
| HY-123272 | E6801 | 528859-04-3 | Reference compound |
| HY-123275 | H-D-Phe-Pip-Arg-pNA | 64815-81-2 | Peptides |
| HY-123275A | H-D-Phe-Pip-Arg-pNA (hydrochloride) | 160192-34-7 | Peptides |
| HY-123275B | H-D-Phe-Pip-Arg-pNA (acetate) | 115388-96-0 | Peptides |
| HY-123275C | H-D-Phe-Pip-Arg-pNA (dihydrochloride) | 62354-65-8 | Peptides |
| HY-123277 | IMB-10 | 307525-40-2 | Reference compound |
| HY-123279 | OM137 | 292170-13-9 | Reference compound |
| HY-123283 | OXi8007 | 288847-41-6 | Reference compound |
| HY-123284 | LY137150 | 86315-69-7 | Reference compound |
| HY-123286 | (E)-Triandrin | 132294-76-9 | Natural Products |
| HY-123287 | Soquinolol | 61563-18-6 | Reference compound |
| HY-123289 | CP-690550A | 1243290-37-0 | Reference compound |
| HY-123290 | KCC009 | 744198-19-4 | Reference compound |
| HY-123291 | SM-276001 | 473930-22-2 | Reference compound |
| HY-123292 | RSU 1164 | 88876-94-2 | Reference compound |
| HY-123293 | UK 34787 | 72818-36-1 | Reference compound |
| HY-123294 | Fentrazamide | 158237-07-1 | Reference compound |
| HY-123294R | Fentrazamide (Standard) | 158237-07-1 | Reference Standards |
| HY-123295 | HDAC3-IN-T247 | 1451042-18-4 | Reference compound |
| HY-123297 | TUG-469 | 1236109-67-3 | Reference compound |
| HY-123298 | Chrysotoxine | 156951-82-5 | Natural Products |
| HY-12330 | AZD8186 | 1627494-13-6 | Reference compound |
| HY-123301 | GABAB receptor antagonist 2 | 200402-50-2 | Reference compound |
| HY-123302 | CID1172084 | 459848-10-3 | Reference compound |
| HY-123304 | MBX2546 | 695160-12-4 | Reference compound |
| HY-123305 | 5-Hydroxymebendazole | 60254-95-7 | Reference compound |
| HY-123305R | 5-Hydroxymebendazole (Standard) | 60254-95-7 | Reference Standards |
| HY-123305S | 5-Hydroxymebendazole-d3 | 1173020-86-4 | Isotope-Labeled Compounds |
| HY-123307 | Quizalofop | 76578-12-6 | Reference compound |
| HY-123308 | VPC13163 | 6637-10-1 | Reference compound |
| HY-12331 | KRCA-0008 | 1472795-20-2 | Reference compound |
| HY-123310 | JNJ-26146900 | 868691-50-3 | Reference compound |
| HY-123311 | CP59430 | 86329-06-8 | Reference compound |
| HY-123312 | CK-548 | 388604-55-5 | Reference compound |
| HY-123314 | Floxacrine | 53966-34-0 | Reference compound |
| HY-123315 | Sulfaperin | 599-88-2 | Reference compound |
| HY-123316 | Iobitridol | 136949-58-1 | Reference compound |
| HY-123319 | Antofloxacin (hydrochloride) | 873888-67-6 | Reference compound |
| HY-123319A | Antofloxacin | 119354-43-7 | Reference compound |
| HY-12332 | JW 642 | 1416133-89-5 | Reference compound |
| HY-123320S | Fluvalinate-d5 | | Isotope-Labeled Compounds |
| HY-123321 | Sakyomicin A | 86413-75-4 | Natural Products |
| HY-123322 | PF-184298 | 813447-40-4 | Reference compound |
| HY-123323 | MK-0434 | 134067-56-4 | Reference compound |
| HY-123324 | Pomalidomide-5-OH | 1547162-41-3 | Reference compound |
| HY-123325 | Kapurimycin A1 | 132412-65-8 | Natural Products |
| HY-123327 | FAUC-113 | 221470-50-4 | Reference compound |
| HY-123328 | AGN 191976 | 159359-94-1 | Reference compound |
| HY-12332R | JW 642 (Standard) | 1416133-89-5 | Reference Standards |
| HY-12333 | Denfivontinib | 1457983-28-6 | Reference compound |
| HY-123330 | GW695634 | 457635-65-3 | Reference compound |
| HY-123331 | S 82-5455 | 90832-34-1 | Reference compound |
| HY-123334 | GNF-1331 | 603101-22-0 | Reference compound |
| HY-123335 | L-796778 | 217480-25-6 | Reference compound |
| HY-123335A | L-796778 (acetate) | 2922280-21-3 | Reference compound |
| HY-123336 | Schisantherin C | 64938-51-8 | Natural Products |
| HY-123337 | Zamifenacin | 127308-82-1 | Reference compound |
| HY-123338 | Dihydroguaiaretic acid | 36469-60-0 | Natural Products |
| HY-123339 | Sannamycin G | 73522-72-2 | Reference compound |
| HY-12334 | HTH-01-015 | 1613724-42-7 | Reference compound |
| HY-123340 | Ozolinone | 56784-39-5 | Reference compound |
| HY-123341 | 9-OxoODE | 54232-59-6 | Reference compound |
| HY-123341S | 9-OxoODE-d3 | 2714198-70-4 | Isotope-Labeled Compounds |
| HY-123345 | CRT 0105446 | 1661846-05-4 | Reference compound |
| HY-123346 | SW155246 | 420092-79-1 | Reference compound |
| HY-123347 | TPU-0037C | 485815-61-0 | Reference compound |
| HY-123348 | Sampatrilat | 129981-36-8 | Reference compound |
| HY-123349 | 5α-Hydroxy-6-keto cholesterol | 13027-33-3 | Reference compound |
| HY-12335 | UNC0379 | 1620401-82-2 | Reference compound |
| HY-123350 | Saroaspidin B | 112663-68-0 | Natural Products |
| HY-123351 | Kievitone | 40105-60-0 | Natural Products |
| HY-123352 | ZK 216348 | 669073-68-1 | Reference compound |
| HY-123352A | (-)-ZK 216348 | | Reference compound |
| HY-123353 | Neladenoson dalanate | 1239309-58-0 | Reference compound |
| HY-123354 | SC 44914 | 115812-74-3 | Reference compound |
| HY-123356 | EMD-503982 | 768370-75-8 | Reference compound |
| HY-123357 | IMM-H004 | 1456807-80-9 | Reference compound |
| HY-123358 | AR-H049020XX | 251454-45-2 | Reference compound |
| HY-123359 | RTC14 | 414909-09-4 | Reference compound |
| HY-12335A | UNC0379 (TFA) | 1620401-83-3 | Reference compound |
| HY-12336 | NIBR189 | 1599432-08-2 | Reference compound |
| HY-123360 | BIBW 22 | 137694-16-7 | Reference compound |
| HY-123361 | LY326325 | 177314-99-7 | Reference compound |
| HY-123363 | Tafluposide | 179067-42-6 | Reference compound |
| HY-123365 | GV2-20 | 346411-65-2 | Reference compound |
| HY-123367 | Rubraxanthone | 65411-01-0 | Reference compound |
| HY-123368 | Zolertine (hydrochloride) | 7241-94-3 | Reference compound |
| HY-123369 | BMI-1026 | 477726-77-5 | Reference compound |
| HY-12337 | GK921 | 1025015-40-0 | Reference compound |
| HY-123370 | FR-167356 | 174185-16-1 | Reference compound |
| HY-123371 | Ro 07-1902 | 68160-71-4 | Reference compound |
| HY-123374 | (Rac)-AMG 628 | 862269-73-6 | Reference compound |
| HY-123375 | Fenethazine | 522-24-7 | Reference compound |
| HY-123376 | FR-190997 | 193344-25-1 | Reference compound |
| HY-123377 | Fotagliptin | 1312954-58-7 | Reference compound |
| HY-123377A | Fotagliptin (benzoate) | 1403496-40-1 | Reference compound |
| HY-123379 | Relomycin | 1404-48-4 | Natural Products |
| HY-12338 | ON 146040 | 1404231-34-0 | Reference compound |
| HY-123380 | Methyl streptonigrin | 3398-48-9 | Reference compound |
| HY-123381 | Gemopatrilat | 160135-92-2 | Reference compound |
| HY-123382 | GSK-1482160 (isomer) | 1695551-19-9 | Reference compound |
| HY-123383 | Renierol | 16795-96-3 | Reference compound |
| HY-123386 | Yakuchinone A | 78954-23-1 | Natural Products |
| HY-123387 | Suksdorfin | 53023-17-9 | Natural Products |
| HY-123388 | SCH 12223 (free base) | 89109-20-6 | Reference compound |
| HY-123389 | MR2034 | 57236-85-8 | Reference compound |
| HY-12339 | NVS-CRF38 | 1207258-55-6 | Reference compound |
| HY-123390 | DB07107 | 552332-71-5 | Reference compound |
| HY-123391 | PD 127443 | 121502-05-4 | Reference compound |
| HY-123392 | Sch 13835 | 150519-34-9 | Reference compound |
| HY-123395 | NSC-84096 | 908813-78-5 | Reference compound |
| HY-123396 | 8-Chloro-cAMP | 41941-56-4 | Reference compound |
| HY-123396A | 8-Chloro-cAMP (sodium) | 124705-03-9 | Reference compound |
| HY-123397 | SCH-44643 | 133330-43-5 | Reference compound |
| HY-123398 | RS-51324 | 69811-30-9 | Reference compound |
| HY-123399 | Ro 19-1400 | 122937-55-7 | Reference compound |
| HY-12340 | ETP-46321 | 1252594-99-2 | Reference compound |
| HY-123400A | iso-Samixogrel | 133276-52-5 | Reference compound |
| HY-123401 | DDRI-18 | 4402-18-0 | Reference compound |
| HY-123402 | GSK3987 | 264206-85-1 | Reference compound |
| HY-123405 | YM-75440 | 780736-74-5 | Reference compound |
| HY-123408 | Umespirone | 107736-98-1 | Reference compound |
| HY-123409 | Nicousamide | 704881-43-6 | Reference compound |
| HY-12341 | ML355 | 1532593-30-8 | Reference compound |
| HY-123410 | KM-233 | 628263-22-9 | Reference compound |
| HY-123411 | MGS0039 | 569686-87-9 | Reference compound |
| HY-123412 | FOL7185 | 5441-46-3 | Reference compound |
| HY-123414 | GX-936 | 1235406-09-3 | Reference compound |
| HY-123415 | PD 134922 | 150351-30-7 | Reference compound |
| HY-123417 | IRC-083864 | 1142057-18-8 | Reference compound |
| HY-123418 | PKUMDL-WQ-2201 | 592474-91-4 | Reference compound |
| HY-123419 | CPI-4203 | 1628214-07-2 | Reference compound |
| HY-12342 | ML216 | 1430213-30-1 | Reference compound |
| HY-123420 | Dinordrin | 64675-08-7 | Reference compound |
| HY-123421 | UK-9040 | 47453-14-5 | Reference compound |
| HY-123422 | GSK360A | 931399-19-8 | Reference compound |
| HY-123424 | Roseofungin | 12687-98-8 | Reference compound |
| HY-123426 | JY-XHe-053 | 612526-36-0 | Reference compound |
| HY-123427 | Transcainide | 88296-62-2 | Reference compound |
| HY-123428 | MSK-195 | 289902-82-5 | Reference compound |
| HY-123429 | CK0683A | 83539-21-3 | Reference compound |
| HY-12343 | ML277 | 1401242-74-7 | Reference compound |
| HY-123432 | AHR-13268D | 130838-11-8 | Reference compound |
| HY-123433 | JNJ-40068782 | 950196-50-6 | Reference compound |
| HY-123434 | PD-149164 | 181941-32-2 | Reference compound |
| HY-123435 | RWJ 22108 | 112769-37-6 | Reference compound |
| HY-123436 | Sarubicin B | 84745-01-7 | Natural Products |
| HY-123437 | WAY-120744 | 127810-07-5 | Reference compound |
| HY-123438 | WAY-151693 | 206551-25-9 | Reference compound |
| HY-123439 | FTY720-C2 | 249289-10-9 | Reference compound |
| HY-12344 | UNC2025 | 1429881-91-3 | Reference compound |
| HY-123440 | S3608 | 57359-17-8 | Reference compound |
| HY-123442 | L 775,606 | 188400-51-3 | Reference compound |
| HY-123444 | Kijimicin | 129297-22-9 | Reference compound |
| HY-123445 | AZD7009 | 864368-79-6 | Reference compound |
| HY-123446 | JNJ-42259152 | 1301167-87-2 | Reference compound |
| HY-123449 | MK-761 (free base) | 65321-41-7 | Reference compound |
| HY-123449A | MK-761 (TFA) | | Reference compound |
| HY-12344A | UNC2025 (hydrochloride) | 2070015-17-5 | Reference compound |
| HY-12345 | ML365 | 947914-18-3 | Reference compound |
| HY-123450 | S116836 | 1257628-57-1 | Reference compound |
| HY-123451 | ACH-702 | 922491-46-1 | Reference compound |
| HY-123452 | SCH 30497 | 83674-78-6 | Reference compound |
| HY-123453 | SM27 | 6266-54-2 | Reference compound |
| HY-123454 | SKF1 | 678997-25-6 | Reference compound |
| HY-123457 | PF-1163A | 258871-59-9 | Reference compound |
| HY-123459 | Garomefrine (hydrochlorid) | 137431-04-0 | Reference compound |
| HY-12346 | FH1 | 2719-05-3 | Reference compound |
| HY-123460 | BN-81674 | 252278-73-2 | Reference compound |
| HY-123461 | Sul-121 (hydrochloride) | 1541170-25-5 | Reference compound |
| HY-123464 | RBC10 | 362503-73-9 | Reference compound |
| HY-123467 | Lasiokaurin | 28957-08-6 | Natural Products |
| HY-123468 | HA-1004 | 91742-10-8 | Reference compound |
| HY-123468A | HA-1004 di(hydrochloride) | 92564-08-4 | Reference compound |
| HY-123469 | RS-0466 | 536993-37-0 | Reference compound |
| HY-12347 | Ro 61-8048 | 199666-03-0 | Reference compound |
| HY-123473 | SB-414796 | 264262-71-7 | Reference compound |
| HY-123474 | PF-1163B | 258871-60-2 | Natural Products |
| HY-123475 | Sisunatovir | 1903763-82-5 | Reference compound |
| HY-123475A | Sisunatovir (hydrochloride) | 1903763-83-6 | Reference compound |
| HY-123478 | Fengabine | 80018-06-0 | Reference compound |
| HY-123479 | CK0492B | 64169-11-5 | Reference compound |
| HY-12348 | LEO 29102 | 1035572-38-3 | Reference compound |
| HY-123480 | EGIS-7625 | 755040-97-2 | Reference compound |
| HY-123481 | JNJ-42253432 | 1428327-35-8 | Reference compound |
| HY-123484 | ROCK-IN-D1 | 1219721-73-9 | Reference compound |
| HY-123485 | PPI-1019 | 290828-45-4 | Reference compound |
| HY-123486 | HS-438 | 1430720-10-7 | Reference compound |
| HY-123487 | Sapintoxin A | 79083-69-5 | Natural Products |
| HY-123489 | 3α,21-Dihydroxy-5α-pregnan-20-one | 567-02-2 | Reference compound |
| HY-123489S | 3α,21-Dihydroxy-5α-pregnan-20-one-d3 | 203805-98-5 | Isotope-Labeled Compounds |
| HY-12349 | H1PVAT | 351438-49-8 | Reference compound |
| HY-123490 | Regrelor (disodium) | 676251-22-2 | Reference compound |
| HY-123492 | Kentsin | 56767-30-7 | Peptides |
| HY-123493 | P552-02 (mesylate) | 587879-54-7 | Reference compound |
| HY-123494 | BRD0418 | 1565827-99-7 | Reference compound |
| HY-123495 | CRANAD-28 | 1623747-97-6 | Dye Reagents |
| HY-123498 | MCI-225 (dehydratase) | 99487-26-0 | Reference compound |
| HY-123499 | SRA880 | 573984-99-3 | Reference compound |
| HY-123501 | MitoE10 | 1810703-64-0 | Reference compound |
| HY-123502 | Ceralasertib (formate) | 1352280-98-8 | Reference compound |
| HY-123503 | Salicortin | 1887055-63-1 | Natural Products |
| HY-123504 | ML344 | 894856-92-9 | Reference compound |
| HY-123505 | Dersalazine (sodium) | 367249-56-7 | Reference compound |
| HY-123506 | Fenlean | 863193-70-8 | Reference compound |
| HY-123510 | NSC-670224 | 1374648-47-1 | Reference compound |
| HY-123512 | OUL35 | 6336-34-1 | Reference compound |
| HY-123515 | Clorobiocin | 39868-96-7 | Reference compound |
| HY-123517 | DC07090 (dihydrochloride) | 1158264-37-9 | Reference compound |
| HY-123517A | DC07090 | 879070-72-1 | Reference compound |
| HY-123519 | 14α-Hydroxy Paspalinine | 151341-77-4 | Natural Products |
| HY-12352 | HJC0416 | 1617518-22-5 | Reference compound |
| HY-123520 | GSK299115A | 864082-35-9 | Reference compound |
| HY-123522 | PAT-048 | 1359983-15-5 | Reference compound |
| HY-123523 | Enocitabine | 55726-47-1 | Reference compound |
| HY-123524 | STAT3-IN-4 | 825611-06-1 | Reference compound |
| HY-123525 | COR628 | 550310-04-8 | Reference compound |
| HY-123526 | NSC265473 | 61786-74-1 | Reference compound |
| HY-123528 | Kahweol oleate | 108214-30-8 | Reference compound |
| HY-123529 | LY389795 | 222529-89-7 | Reference compound |
| HY-12352A | HJC0416 (hydrochloride) | 2415263-08-8 | Reference compound |
| HY-123531 | JNJ 10329670 | 400797-24-2 | Reference compound |
| HY-123532 | JNJ10191584 | 73903-17-0 | Reference compound |
| HY-123533 | Resorufin | 635-78-9 | Dye Reagents |
| HY-123533A | Resorufin sodium salt | 34994-50-8 | Dye Reagents |
| HY-123533S | Resorufin-d6 | 1196157-65-9 | Isotope-Labeled Compounds |
| HY-123534 | CYT-1010 | 213769-33-6 | Reference compound |
| HY-123534A | CYT-1010 (hydrochloride) | 1161517-81-2 | Reference compound |
| HY-123535 | P18IN003 | 71727-40-7 | Reference compound |
| HY-123538 | GRK2 Inhibitor 1 | 24269-96-3 | Reference compound |
| HY-12353A | Pimodivir | 1629869-44-8 | Reference compound |
| HY-12353B | Pimodivir (hydrochlorid hemihydrate) | 1777721-70-6 | Reference compound |
| HY-12354 | SB-3CT | 292605-14-2 | Reference compound |
| HY-123541 | Tec-IN-6 | 923762-87-2 | Reference compound |
| HY-123542 | ONO-3403 | 181586-07-2 | Reference compound |
| HY-123544 | RDR03871 | 286008-51-3 | Reference compound |
| HY-123547 | TLK19781 | 309932-60-3 | Reference compound |
| HY-123548 | ML148 | 451496-96-1 | Reference compound |
| HY-123549 | PSB-6426 | 958459-33-1 | Reference compound |
| HY-12355 | Siponimod | 1230487-00-9 | Reference compound |
| HY-123550 | Rosenonolactone | 508-71-4 | Natural Products |
| HY-123552 | RK-1441A | 132035-29-1 | Natural Products |
| HY-123554 | Flavagline FL3 | 1186012-80-5 | Reference compound |
| HY-123555 | PD 142505-0028 | 161774-09-0 | Reference compound |
| HY-123556 | SZV-558 | 1648929-13-8 | Reference compound |
| HY-123557 | Dasolampanel etibutil | 503291-52-9 | Reference compound |
| HY-123558 | Bactobolin C | 74141-69-8 | Natural Products |
| HY-12355A | Siponimod (hemifumarate) | 1234627-85-0 | Reference compound |
| HY-12355R | Siponimod (Standard) | 1230487-00-9 | Reference Standards |
| HY-12355S | Siponimod-d11 | 2104759-32-0 | Isotope-Labeled Compounds |
| HY-123560 | BKM-570 | 259885-54-6 | Reference compound |
| HY-123561 | MMV008138 | 1679333-73-3 | Reference compound |
| HY-123562 | GNF7686 | 442567-43-3 | Reference compound |
| HY-123563 | Metazosin | 95549-92-1 | Reference compound |
| HY-123564 | Mcl1-IN-7 | 2012563-34-5 | Reference compound |
| HY-123567 | LY86057 | 148966-66-9 | Reference compound |
| HY-123568 | PBI-1393 | 175072-12-5 | Reference compound |
| HY-123569 | ISQ-1 (hydrochloride) | 405165-77-7 | Reference compound |
| HY-12357 | Bempedoic acid | 738606-46-7 | Reference compound |
| HY-123571 | CP-199330 | 158102-92-2 | Reference compound |
| HY-123572 | Bis-T-23 | 171674-76-3 | Reference compound |
| HY-123575 | LY 245769 | 127345-02-2 | Reference compound |
| HY-123578 | NSC689857 | 241127-79-7 | Reference compound |
| HY-12357S | Bempedoic acid-d5 | 2408131-71-3 | Isotope-Labeled Compounds |
| HY-12357S2 | Bempedoic acid-d4 | 2408131-70-2 | Isotope-Labeled Compounds |
| HY-12358 | Tpl2 Kinase Inhibitor 1 | 871307-18-5 | Reference compound |
| HY-123580 | RU26988 | 74915-58-5 | Reference compound |
| HY-123581 | Quinocetone | 81810-66-4 | Reference compound |
| HY-123581R | Quinocetone (Standard) | 81810-66-4 | Reference Standards |
| HY-123582 | CP-866,087 | 519052-02-9 | Reference compound |
| HY-123583 | MitoBADY | 1644119-76-5 | Dye Reagents |
| HY-123587 | PR-924 | 1416709-79-9 | Reference compound |
| HY-123587A | (R)-PR-924 | | Reference compound |
| HY-123589 | Gyramide A | 913509-94-1 | Natural Products |
| HY-12359 | TPPB | 497259-23-1 | Reference compound |
| HY-123590 | BC12-4 | 94212-33-6 | Reference compound |
| HY-123593 | Mozavaptan (hydrochloride) | 138470-70-9 | Reference compound |
| HY-123594 | R-2 Methanandamide | 157182-47-3 | Reference compound |
| HY-123596 | LAS191859 | 1420071-13-1 | Reference compound |
| HY-123597 | NSC 109555 | 15427-93-7 | Reference compound |
| HY-123598 | Corynecin III | 18048-95-8 | Natural Products |
| HY-123600 | SRI-29329 | 2086809-58-5 | Reference compound |
| HY-123601 | DHQZ 36 | 1542098-94-1 | Reference compound |
| HY-123602 | CGP 55802A | 152564-63-1 | Reference compound |
| HY-123604 | TH1834 | 2108830-08-4 | Reference compound |
| HY-123604A | TH1834 (dihydrochloride) | 2108830-09-5 | Reference compound |
| HY-123605 | CAY10406 | 2108603-03-6 | Reference compound |
| HY-123607 | UniPR129 | 1639159-47-9 | Reference compound |
| HY-123608 | JE-2178 | 210181-19-4 | Reference compound |
| HY-123609 | Pyrene-amido-PEG4-azide | 1817735-36-6 | Reference compound |
| HY-12361 | PF 1022A | 133413-70-4 | Natural Products |
| HY-123610 | BRD-7880 | 1456542-69-0 | Reference compound |
| HY-123611 | Supinoxin | 888478-45-3 | Reference compound |
| HY-123614 | PD 140248 (hydrochloride) | 147208-55-7 | Reference compound |
| HY-123615 | SPD-2 | 1643781-40-1 | Reference compound |
| HY-123617 | AZ8838 | 2100285-41-2 | Reference compound |
| HY-12361R | PF 1022A (Standard) | 133413-70-4 | Reference Standards |
| HY-12362 | Val-cit-PAB-OH | 159857-79-1 | ADC Related |
| HY-123621 | GNE-375 | 1926989-06-1 | Reference compound |
| HY-123622 | CYMAL-5, 98% (TLC) | 250692-65-0 | Biochemical Assay Reagents |
| HY-123625 | R-348 (choline) | 1620142-65-5 | Reference compound |
| HY-123626 | BiBET | 2059110-46-0 | Reference compound |
| HY-123628 | 3,4,6-Tri-O-benzyl-β-D-mannopyranose 1,2-(methyl orthoacetate) | 16697-49-7 | Reference compound |
| HY-123629 | TAMRA-PEG3-Azide | 1228100-59-1 | Dye Reagents |
| HY-12362G | Val-cit-PAB-OH (GMP) | 159857-79-1 | GMP Small Molecules |
| HY-12363 | U-69593 | 96744-75-1 | Reference compound |
| HY-123630 | Allura Red AC | 25956-17-6 | Dye Reagents |
| HY-123630R | Allura Red AC (Standard) | 25956-17-6 | Dye Reagents |
| HY-123631 | Phenylbutazone trimethylgallate | 16006-74-9 | Reference compound |
| HY-123632 | (3S,5S)-Atorvastatin (sodium salt) | 1428118-38-0 | Reference compound |
| HY-123633 | 4-Methylumbelliferyl β-D-Glucopyranoside | 18997-57-4 | Reference compound |
| HY-123634 | (S)-3'-Aminoblebbistatin | 2097141-18-7 | Reference compound |
| HY-123635 | Nybomycin | 30408-30-1 | Natural Products |
| HY-123636 | UPCDC-30245 | 1883351-01-6 | Reference compound |
| HY-123637 | Autotaxin-IN-1 | 1619971-30-0 | Reference compound |
| HY-123638 | 6-Hydroxykaempferol 3,6,7-tri-O-β-D-glucoside | 145134-62-9 | Natural Products |
| HY-123639 | LM-4108 | 261766-32-9 | Reference compound |
| HY-12364 | C75 | 218137-86-1 | Reference compound |
| HY-123642 | BLXA-4-ME | 362516-29-8 | Reference compound |
| HY-123643 | Brilliant sulfaflavine | 2391-30-2 | Dye Reagents |
| HY-123645 | Rhodamine B hydrazide | 74317-53-6 | Dye Reagents |
| HY-123646 | RS 2135 | 133775-36-7 | Reference compound |
| HY-123647 | Satratoxin H | 53126-64-0 | Natural Products |
| HY-123648 | Rhizoferrin | 138846-62-5 | Natural Products |
| HY-123649 | MK-4882 | 1246470-32-5 | Reference compound |
| HY-12364A | trans-C75 | 191282-48-1 | Reference compound |
| HY-12364B | (−)-C75 | 1234694-22-4 | Reference compound |
| HY-12364C | (+)-trans-C75 | 1234694-20-2 | Reference compound |
| HY-12365 | Namodenoson | 163042-96-4 | Reference compound |
| HY-123650 | FSBA (hydrochloride) | 78859-42-4 | Reference compound |
| HY-123652 | Etofamide | 25287-60-9 | Reference compound |
| HY-123653 | SirReal-1 | 801227-82-7 | Reference compound |
| HY-123654 | L-796449 | 194608-80-5 | Reference compound |
| HY-123655 | Fenazinel (dihydrochloride) | 685138-02-7 | Reference compound |
| HY-123656 | Antiproliferative agent-61 | 1613078-24-2 | Reference compound |
| HY-123657 | RXP 407 | 237770-41-1 | Reference compound |
| HY-12365R | Namodenoson (Standard) | 163042-96-4 | Reference Standards |
| HY-12365S2 | Namodenoson-d5 | | Isotope-Labeled Compounds |
| HY-12366 | Ubrogepant | 1374248-77-7 | Reference compound |
| HY-123661 | MIPS1455 | 1627580-82-8 | Reference compound |
| HY-123662 | AGN-201904Z | 651728-41-5 | Reference compound |
| HY-123663 | U-101958 (maleate) | 224170-09-6 | Reference compound |
| HY-123664 | Trioxifene (mesylate) | 68307-81-3 | Reference compound |
| HY-123665 | PSB-1410 | 1494477-03-0 | Reference compound |
| HY-123667 | NCFP | 774548-65-1 | Reference compound |
| HY-123668 | KM05382 | 882291-64-7 | Reference compound |
| HY-123669 | R-138727 | 204204-73-9 | Reference compound |
| HY-123669A | trans-R-138727 | 239466-74-1 | Reference compound |
| HY-123669AS | (R)-trans-138727-d4 | 1217222-86-0 | Isotope-Labeled Compounds |
| HY-12366R | Ubrogepant (Standard) | 1374248-77-7 | Reference Standards |
| HY-12366S | Ubrogepant-d5 | | Isotope-Labeled Compounds |
| HY-123671 | CYM2503 | 1308833-36-4 | Reference compound |
| HY-123672 | Lovastatin hydroxy acid (sodium) | 75225-50-2 | Reference compound |
| HY-123672R | Lovastatin hydroxy acid (sodium) (Standard) | 75225-50-2 | Reference Standards |
| HY-123672S | Lovastatin-d3 hydroxy acid (sodium) | 1217528-38-5 | Isotope-Labeled Compounds |
| HY-123673 | MCP110 | 521310-51-0 | Reference compound |
| HY-123675 | CFI-400936 | 1338793-07-9 | Reference compound |
| HY-123676 | Sonepiprazole (mesylate) | 170858-34-1 | Reference compound |
| HY-123677 | E2508 | 685886-34-4 | Reference compound |
| HY-123679 | FR168888 | 168620-46-0 | Reference compound |
| HY-123681 | R 57720 | 98164-11-5 | Reference compound |
| HY-123686 | Ivermectin B1a monosaccharide | 71837-27-9 | Natural Products |
| HY-123687 | DBCO-Sulfo-NHS ester (sodium) | 1400191-52-7 | Dye Reagents |
| HY-123689 | Samidorphan | 852626-89-2 | Reference compound |
| HY-123689A | Samidorphan (hydrochloride) | 2328045-02-7 | Reference compound |
| HY-123689S | Samidorphan-d4 | | Isotope-Labeled Compounds |
| HY-123689S1 | Samidorphan-d5 | | Isotope-Labeled Compounds |
| HY-12369 | GGTI-2133 | 191102-79-1 | Reference compound |
| HY-123690 | Etoposide toniribate | 433304-61-1 | Reference compound |
| HY-123691 | 7-O-Demethyl rapamycin | 151519-50-5 | Reference compound |
| HY-123692 | RHI002-Me | 314261-66-0 | Reference compound |
| HY-123693 | ML358 | 1158607-44-3 | Reference compound |
| HY-123695 | 5-HT4 antagonist 3 | 148702-58-3 | Reference compound |
| HY-123696 | CDy9 | 1800205-57-5 | Dye Reagents |
| HY-123697 | VE-465 | 639089-73-9 | Reference compound |
| HY-123698 | Mebolazine | 3625-07-8 | Reference compound |
| HY-12369A | GGTI-2133 (TFA) | 1217480-14-2 | Reference compound |
| HY-12370 | TY-51469 | 603987-59-3 | Reference compound |
| HY-123700 | Kaikasaponin III | 115330-90-0 | Natural Products |
| HY-123702 | CAP-53194 | 660817-08-3 | Reference compound |
| HY-123704 | CGS-12066 (maleate) | 1350965-83-1 | Reference compound |
| HY-123706 | Salinosporamide C | 863126-96-9 | Natural Products |
| HY-123707 | KPU-300 | 1620692-60-5 | Reference compound |
| HY-123708 | SNAP 398299 | 903878-06-8 | Reference compound |
| HY-12371 | VU0431316 | 1620203-63-5 | Reference compound |
| HY-123710 | GYKI-16084 | 185739-21-3 | Reference compound |
| HY-123711 | PC170942 | 867207-49-6 | Reference compound |
| HY-123712 | 2α,17α-Diethynyl-A-nor-5α-androstane-2β,17β-diol diacetate | 70226-89-0 | Reference compound |
| HY-123714 | TL4-12 | 1620820-12-3 | Reference compound |
| HY-123715 | Anticancer agent 255 | 1983924-20-4 | Reference compound |
| HY-123716 | Rubradirin B | 68833-11-4 | Natural Products |
| HY-123718 | 6-Benzylthioinosine | 6165-03-3 | Reference compound |
| HY-12372 | Sanggenon G | 85698-31-3 | Natural Products |
| HY-123720 | Sch 31828 | 115216-83-6 | Natural Products |
| HY-123721 | Tiracizine (hydrochloride) | 78816-67-8 | Reference compound |
| HY-123723 | Hydroxystreptomycin | 6835-00-3 | Natural Products |
| HY-123724 | Ravidomycin | 74622-75-6 | Natural Products |
| HY-123727 | Acid blue 120 | 3529-01-9 | Dye Reagents |
| HY-123728 | FR-A-19 | 141099-46-9 | Reference compound |
| HY-123733 | MIP-1095 | 949575-22-8 | Reference compound |
| HY-123733A | MIP-1095 (TFA) | | Reference compound |
| HY-123734 | S-75 | 37764-44-6 | Reference compound |
| HY-123736 | Ro 32-7315 | 219613-02-2 | Reference compound |
| HY-123737 | MK-8133 | 1431472-56-8 | Reference compound |
| HY-12374 | KBP-5493 | 1314944-07-4 | Reference compound |
| HY-123740 | Disuccinimidyl sulfoxide | 1351828-03-9 | Reference compound |
| HY-123742 | Estradiol 3-sulfate 17-glucuronide (potassium) | 10392-35-5 | Reference compound |
| HY-123743 | JNJ-42314415 | 1334165-90-0 | Reference compound |
| HY-123744 | PD-156707 | 162412-70-6 | Reference compound |
| HY-123747 | SC-53116 | 141196-99-8 | Reference compound |
| HY-123747A | SC-53116 (hydrochloride) | 879208-42-1 | Reference compound |
| HY-123749 | Tetramethylrhodamine-5-iodoacetamide | 114458-99-0 | Dye Reagents |
| HY-12375 | BMS-903452 | 1339944-47-6 | Reference compound |
| HY-123750 | Zimet 38/74 | 61930-49-2 | Reference compound |
| HY-123751 | Antifolate C1 | 136784-51-5 | Reference compound |
| HY-123752 | MS-0022 | 691392-89-9 | Reference compound |
| HY-123753 | MDL 27399 | 131374-22-6 | Reference compound |
| HY-123754 | AGN-201904 | 651729-53-2 | Reference compound |
| HY-123756 | NBD-10007 | 1375736-65-4 | Reference compound |
| HY-123757 | (Rac)-GR218231 | 175442-95-2 | Reference compound |
| HY-123758 | XDM-CBP | 2138461-99-9 | Reference compound |
| HY-123759 | sEH-IN-12 | 1883803-09-5 | Reference compound |
| HY-12376 | BAY 41-2272 | 256376-24-6 | Reference compound |
| HY-123763 | MLN3126 | 628300-71-0 | Reference compound |
| HY-123766 | EGFR-IN-99 | 2068806-31-3 | Reference compound |
| HY-123767 | HEC72702 | 1793063-59-8 | Reference compound |
| HY-12377 | GSK0660 | 1014691-61-2 | Reference compound |
| HY-123772 | CDK5 inhibitor 20-223 | 865317-30-2 | Reference compound |
| HY-123777 | VT-1598 | 2089320-99-8 | Reference compound |
| HY-123777A | VT-1598 (tosylate) | 2089321-00-4 | Reference compound |
| HY-12378 | BQ-123 | 136553-81-6 | Reference compound |
| HY-123781 | RUSKI-201 | 1458031-48-5 | Reference compound |
| HY-123781A | RUSKI-201 (dihydrochloride) | 2320262-09-5 | Reference compound |
| HY-123782 | (Rac)-UK-414495 | 337962-93-3 | Reference compound |
| HY-123785 | ORM-10962 | 763926-98-3 | Reference compound |
| HY-123786 | NSC745887 | 54490-26-5 | Reference compound |
| HY-123788 | BRD5814 | 1953181-29-7 | Reference compound |
| HY-123789 | T5342126 | 956507-49-6 | Reference compound |
| HY-12378A | BQ-123 (TFA) | | Reference compound |
| HY-12379 | NS-2028 | 204326-43-2 | Reference compound |
| HY-123790 | AS2541019 | 2098906-98-8 | Reference compound |
| HY-123794 | MP07-66 | 1938056-90-6 | Reference compound |
| HY-123797 | KGA-2727 | 666842-36-0 | Reference compound |
| HY-123798 | N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane | 25561-30-2 | Biochemical Assay Reagents |
| HY-123798R | N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane (Standard) | 25561-30-2 | Reference Standards |
| HY-12380 | Atipamezole (hydrochloride) | 104075-48-1 | Reference compound |
| HY-123800 | BI 187004 | 1303515-32-3 | Reference compound |
| HY-123801 | MIDD0301 | 2187489-08-1 | Reference compound |
| HY-123801A | MIDD0301 (sodium) | 2593569-36-7 | Reference compound |
| HY-123802 | BIO7662 | 327613-10-5 | Reference compound |
| HY-123805 | KIN1400 | 446826-86-4 | Reference compound |
| HY-12380A | Atipamezole | 104054-27-5 | Reference compound |
| HY-12381 | ML224 | 1338824-21-7 | Reference compound |
| HY-123812 | PF-03654764 | 935840-35-0 | Reference compound |
| HY-123813 | CCX-777 | 1226686-36-7 | Reference compound |
| HY-123814 | 4-CPPC | 29553-70-6 | Reference compound |
| HY-123815 | BRD5459 | 612037-58-8 | Reference compound |
| HY-123819 | KRH-1636 | 568526-77-2 | Reference compound |
| HY-12382 | NMS-P715 | 1202055-32-0 | Reference compound |
| HY-123820 | LY3020371 (hydrochloride) | 1377615-44-5 | Reference compound |
| HY-123823 | Nitroaspirin | 175033-36-0 | Reference compound |
| HY-123824 | GNE-0439 | 1241902-40-8 | Reference compound |
| HY-123825 | GX-674 | 1432913-36-4 | Reference compound |
| HY-123826 | CCT68127 | 660822-23-1 | Reference compound |
| HY-123829 | LY2624803 | 879409-35-5 | Reference compound |
| HY-12383 | Pelubiprofen | 69956-77-0 | Reference compound |
| HY-123833 | PF-05661014 | 2153474-85-0 | Reference compound |
| HY-123834 | FEN1-IN-1 | 824983-91-7 | Reference compound |
| HY-123837 | MLS1082 | 883958-36-9 | Reference compound |
| HY-123838 | Ro60-0175 | 169675-08-5 | Reference compound |
| HY-12383S | Pelubiprofen-13C,d3 | | Isotope-Labeled Compounds |
| HY-12384 | Tenosal | 95232-68-1 | Reference compound |
| HY-123840 | MRK-623 | 461449-78-5 | Reference compound |
| HY-123844 | dBET57 | 1883863-52-2 | Reference compound |
| HY-123846 | MLS-0437605 | 862975-18-6 | Reference compound |
| HY-123847 | KPT-6566 | 881487-77-0 | Reference compound |
| HY-123849 | SN32976 | 1246202-11-8 | Reference compound |
| HY-12385 | Ximoprofen | 56187-89-4 | Reference compound |
| HY-123851 | MSC2504877 | 1460286-21-8 | Reference compound |
| HY-123854 | PF-06426779 | 1817628-40-2 | Reference compound |
| HY-123856 | MY10 | 2204270-73-3 | Reference compound |
| HY-123857 | JNJ-55308942 | 2166558-11-6 | Reference compound |
| HY-123862 | LAS195319 | 1605328-04-8 | Reference compound |
| HY-123863 | SSR411298 | 666860-59-9 | Reference compound |
| HY-123869 | GR127935 | 148672-13-3 | Reference compound |
| HY-123870 | MX107 | 2170102-50-6 | Reference compound |
| HY-123872 | MSC1094308 | 2219320-08-6 | Reference compound |
| HY-123875A | Ralaniten triacetate | 1637573-04-6 | Reference compound |
| HY-123879 | BAA473 | 27240-87-5 | Reference compound |
| HY-12388 | N-Desmethyl clomipramine | 303-48-0 | Natural Products |
| HY-123882 | IRAK4-IN-29 | 1604034-78-7 | Reference compound |
| HY-123885 | NSC243928 (mesylate) | 59988-01-1 | Reference compound |
| HY-123886 | Aranciamycin | 72389-06-1 | Natural Products |
| HY-123887 | Manumycin B | 139023-58-8 | Natural Products |
| HY-123888 | Viomellein | 55625-78-0 | Natural Products |
| HY-12388A | N-Desmethyl clomipramine (hydrochloride) | 29854-14-6 | Reference compound |
| HY-12388AR | N-Desmethyl clomipramine (hydrochloride) (Standard) | 29854-14-6 | Reference Standards |
| HY-12388AS | N-Desmethyl clomipramine-d3 (hydrochloride) | 1189971-04-7 | Isotope-Labeled Compounds |
| HY-12388S | N-Desmethyl clomipramine-d7 | | Isotope-Labeled Compounds |
| HY-12388S1 | N-Desmethyl clomipramine-d6 | | Isotope-Labeled Compounds |
| HY-12389 | 8-Hydroxyamoxapine | 61443-78-5 | Reference compound |
| HY-123891 | NS-062 | 2226257-92-5 | Reference compound |
| HY-123892 | RK-287107 | 2171386-10-8 | Reference compound |
| HY-123894 | Pelargonidin 3,5-diglucoside (chloride) | 17334-58-6 | Natural Products |
| HY-123895 | Tanshindiol A | 97411-46-6 | Natural Products |
| HY-123896 | Calceolarioside A | 84744-28-5 | Natural Products |
| HY-123897 | Chamaejasmenin C | 89595-70-0 | Natural Products |
| HY-123898 | Cepharadione B | 55610-02-1 | Natural Products |
| HY-123899 | Cleomiscosin B | 76985-93-8 | Natural Products |
| HY-12389S | 8-Hydroxy amoxapine-d8 | 1189505-24-5 | Isotope-Labeled Compounds |
| HY-12390 | Lofepramine | 23047-25-8 | Reference compound |
| HY-123900 | AZ12799734 | 1117684-36-2 | Reference compound |
| HY-123901 | Garcinone E | 112649-21-5 | Natural Products |
| HY-123902 | Ophiobolin C | 19022-51-6 | Reference compound |
| HY-123903 | Tanshindiol B | 97465-70-8 | Natural Products |
| HY-123904 | UoS12258 | 875927-64-3 | Reference compound |
| HY-123905 | LIN28 inhibitor LI71 | 1357248-83-9 | Reference compound |
| HY-123905A | LIN28 inhibitor LI71 enantiomer | 956189-58-5 | Reference compound |
| HY-12390A | Lofepramine (hydrochloride) | 26786-32-3 | Reference compound |
| HY-12390S | Lofepramine-d3 | 1185083-78-6 | Isotope-Labeled Compounds |
| HY-123911 | dBET23 | 1957234-83-1 | Reference compound |
| HY-123914 | P516-0475 | 1359627-33-0 | Reference compound |
| HY-123915 | Antimalarial agent 20 | 1422207-75-7 | Reference compound |
| HY-123916 | DBCO-Biotin | 1418217-95-4 | Reference compound |
| HY-123918 | JMS-17-2 | 1380392-05-1 | Reference compound |
| HY-123918A | JMS-17-2 (hydrochloride) | 2341841-07-2 | Reference compound |
| HY-123919 | TL13-112 | 2229037-19-6 | Reference compound |
| HY-12392 | Iprindole | 5560-72-5 | Reference compound |
| HY-123921 | Gefitinib-based PROTAC 3 | 2230821-27-7 | Reference compound |
| HY-123922 | NOSO-502 | 1894081-09-4 | Reference compound |
| HY-123924 | CSLP37 | 2244984-64-1 | Reference compound |
| HY-123927 | UniPR1331 | 1809170-59-9 | Reference compound |
| HY-123929 | PAWI-2 | 1448427-02-8 | Reference compound |
| HY-123931 | ZLDI-8 | 667880-38-8 | Reference compound |
| HY-123934 | VU6007477 | 2220141-46-6 | Reference compound |
| HY-123936 | SR12343 | 2055101-86-3 | Reference compound |
| HY-123937 | THAL-SNS-032 | 2139287-33-3 | Reference compound |
| HY-12394 | Dothiepin | 113-53-1 | Reference compound |
| HY-123940 | SGC-AAK1-1 | 2247894-32-0 | Reference compound |
| HY-123941 | FKBP12 PROTAC dTAG-7 | 2064175-32-0 | Reference compound |
| HY-123942 | Diprovocim | 2170867-89-5 | Reference compound |
| HY-123943 | STING agonist-4 | 2138300-40-8 | Reference compound |
| HY-12394S | Dothiepin-d3 | 136765-31-6 | Isotope-Labeled Compounds |
| HY-12394S1 | Dothiepin-d6 (hydrochloride) | 1276545-35-7 | Isotope-Labeled Compounds |
| HY-12395 | Ecteinascidin-Analog-1 | 874758-58-4 | Reference compound |
| HY-123950 | MMRi64 | 430458-66-5 | Reference compound |
| HY-123952 | RTC-5 | 1423077-49-9 | Reference compound |
| HY-123954 | BTX-A51 | 2079068-74-7 | Reference compound |
| HY-123955 | Casein Kinase inhibitor A86 | 2079069-01-3 | Reference compound |
| HY-123956 | HG-12-6 | 2222354-57-4 | Reference compound |
| HY-12396 | Aminothiazole | 96-50-4 | Reference compound |
| HY-123960 | Raphin1 | 2022961-17-5 | Reference compound |
| HY-123960A | Raphin1 (acetate) | 2242616-04-0 | Reference compound |
| HY-123960B | (E/Z)-Raphin1 | 94023-67-3 | Reference compound |
| HY-123961 | SJF-8240 | 2230821-68-6 | Reference compound |
| HY-123962 | G6PD activator AG1 | 421581-52-4 | Reference compound |
| HY-123963 | C-178 | 329198-87-0 | Reference compound |
| HY-123966 | MY33-3 | 2204280-41-9 | Reference compound |
| HY-123966A | MY33-3 (hydrochloride) | 2204280-42-0 | Reference compound |
| HY-123967 | RNF5 inhibitor inh-02 | 324579-65-9 | Reference compound |
| HY-12397 | ZK159222 | 156965-15-0 | Reference compound |
| HY-123971 | HDAC6 degrader-4 | 2235382-05-3 | Reference compound |
| HY-123972 | SEC inhibitor KL-2 | 900308-51-2 | Reference compound |
| HY-123976 | MPT0G211 | 2151853-97-1 | Reference compound |
| HY-123976A | MPT0G211 (mesylate) | 2151854-33-8 | Reference compound |
| HY-123977 | RasGRP3 ligand 1 | 2229068-13-5 | Reference compound |
| HY-123979 | ζ-Stat | 3316-02-7 | Reference compound |
| HY-123979A | ζ-Stat (trisodium) | 31894-34-5 | Reference compound |
| HY-12398 | TEI-9647 | 173388-20-0 | Reference compound |
| HY-123981 | 5MPN | 47208-82-2 | Reference compound |
| HY-123982 | SOD1-Derlin-1 inhibitor-2 | 2170170-27-9 | Reference compound |
| HY-123983 | HS56 | 922050-57-5 | Reference compound |
| HY-123984 | LTβR-IN-1 | 2189366-77-4 | Reference compound |
| HY-123985 | MFN2 agonist-1 | 2230047-87-5 | Reference compound |
| HY-123986 | CTPI-2 | 68003-38-3 | Reference compound |
| HY-12398A | TEI-9648 | 173388-21-1 | Reference compound |
| HY-12399 | MKC9989 | 1338934-20-5 | Reference compound |
| HY-123994 | Tenovin-D3 (hydrochloride) | 1258283-70-3 | Reference compound |
| HY-123999 | CD38 inhibitor 1 | 1700637-55-3 | Reference compound |
| HY-12400 | GSK3182571 | 2135595-04-7 | Reference compound |
| HY-124001 | N-Docosanoyl taurine | 783284-48-0 | Natural Products |
| HY-124002 | 4-Hydroxyalternariol | 959417-21-1 | Reference compound |
| HY-124003 | Phytomonic acid | 503-06-0 | Natural Products |
| HY-124004 | Acetyl-6-formylpterin | 29769-49-1 | Reference compound |
| HY-124005 | Prolylisoleucine | 51926-51-3 | Reference compound |
| HY-124007 | 4-Iodo-SAHA | 1219807-87-0 | Reference compound |
| HY-124008 | Uniconazole-P | 83657-17-4 | Reference compound |
| HY-124009 | L-Cysteic acid | 498-40-8 | Reference compound |
| HY-124009A | L-Cysteic acid (monohydrate) | 23537-25-9 | Natural Products |
| HY-124009R | L-Cysteic acid (Standard) | 498-40-8 | Reference Standards |
| HY-12401 | Mps1-IN-3 | 1609584-72-6 | Reference compound |
| HY-124011 | m-PEG3-aldehyde | 356066-46-1 | Reference compound |
| HY-124012 | PCNA-I1 | 444930-42-1 | Reference compound |
| HY-124013 | NBDA | 64917-85-7 | Dye Reagents |
| HY-124014 | Methyl 2-hydroxyhexadecanoate | 16742-51-1 | Natural Products |
| HY-124015 | 1,1,1-Trifluoro-10(Z)-nonadecen-2-one | 177987-23-4 | Reference compound |
| HY-124018 | MMV665852 | 4300-43-0 | Reference compound |
| HY-124019 | 4,5-DiHDPA lactone | 845673-68-9 | Reference compound |
| HY-12401A | Mps1-IN-3 (hydrochloride) | 2989453-29-2 | Reference compound |
| HY-12402 | SBC-115076 | 489415-96-5 | Reference compound |
| HY-124020 | ß-pBrPh-Glc | 30572-42-0 | Reference compound |
| HY-124021 | Benzyl 2-naphthyl ether | 613-62-7 | Reference compound |
| HY-124022 | HDAC-IN-69 | 676599-90-9 | Reference compound |
| HY-124029 | BI-4394 | 1222173-37-6 | Reference compound |
| HY-12403 | Talfirastide | 51833-78-4 | Peptides |
| HY-124030 | 3-Hydroxyphenazepam | 70030-11-4 | Reference compound |
| HY-124031 | Lobetyolinin | 142451-48-7 | Natural Products |
| HY-124033 | Aspinonene | 157676-96-5 | Biochemical Assay Reagents |
| HY-124035 | Streptochlorin | 120191-51-7 | Reference compound |
| HY-124036 | DS-7423 | 1222104-37-1 | Reference compound |
| HY-124037 | SRT 1460 | 925432-73-1 | Reference compound |
| HY-12403A | Talfirastide (acetate) | 2855063-75-9 | Peptides |
| HY-12404 | Diminazene (aceturate) | 908-54-3 | Reference compound |
| HY-124040 | BI-1950 | 1159724-42-1 | Reference compound |
| HY-124041 | p-Hydroxybestatin | 70267-76-4 | Reference compound |
| HY-124042 | K6PC-5 | 756875-51-1 | Reference compound |
| HY-124045 | Butyrospermol | 472-28-6 | Natural Products |
| HY-124047 | RX 67668 | 40709-76-0 | Reference compound |
| HY-124049 | Ethyl 4-methyl-2-(2-thienyl)-thiazole-5 carboxylate | 56421-62-6 | Reference compound |
| HY-12404R | Diminazene (aceturate) (Standard) | 908-54-3 | Reference Standards |
| HY-12405 | CGP-42112 | 127060-75-7 | Reference compound |
| HY-124050 | Echimidine | 520-68-3 | Reference compound |
| HY-124051 | BAY-8040 | 1194453-23-0 | Reference compound |
| HY-124052 | AZ-27 | 1516772-44-3 | Reference compound |
| HY-124053 | BRD2492 | 1821669-43-5 | Reference compound |
| HY-124056 | AZ10397767 | 333742-63-5 | Reference compound |
| HY-124058 | Jacobine | 6870-67-3 | Natural Products |
| HY-124059 | SW-034538 | 412919-82-5 | Reference compound |
| HY-12406 | VLX600 | 327031-55-0 | Reference compound |
| HY-124060 | PS423 | 1221964-37-9 | Reference compound |
| HY-124061 | GB83 | 1252806-86-2 | Reference compound |
| HY-124062 | TAS-114 | 1198221-21-4 | Reference compound |
| HY-124063 | BI-1935 | 940954-41-6 | Reference compound |
| HY-124064 | TMP-153 | 128831-46-9 | Reference compound |
| HY-124066 | RU-302 | 1182129-77-6 | Reference compound |
| HY-124068 | LQB-118 | 1219104-20-7 | Reference compound |
| HY-124069 | M-525 | 2173582-08-4 | Reference compound |
| HY-12407 | ZK168281 | 186371-96-0 | Reference compound |
| HY-124071 | ACT-389949 | 1258417-54-7 | Reference compound |
| HY-124072 | HL001 | 1186371-31-2 | Reference compound |
| HY-124073 | Dihydrocapsiate | 205687-03-2 | Natural Products |
| HY-124073R | Dihydrocapsiate (Standard) | 205687-03-2 | Reference Standards |
| HY-124076 | Triphenylbismuth | 603-33-8 | Reference compound |
| HY-124078 | NIC | 114773-20-5 | Reference compound |
| HY-124079 | HIF-1/2α-IN-3 | 1085450-53-8 | Reference compound |
| HY-12408 | 6H05 | 1469338-01-9 | Reference compound |
| HY-124081 | N-Oleoyl-L-serine | 107743-37-3 | Peptides |
| HY-124082 | Dodecyl gallate | 1166-52-5 | Reference compound |
| HY-124082R | Dodecyl gallate (Standard) | 1166-52-5 | Reference Standards |
| HY-124083 | MPT0B214 | 1215208-65-3 | Reference compound |
| HY-124084 | SW203668 | 1673556-40-5 | Reference compound |
| HY-124084A | SW203668 (TFA) | 2117405-48-6 | Reference compound |
| HY-124085 | Prostaglandin F1α alcohol | 13487-47-3 | Reference compound |
| HY-124086 | BHQ-O-5HT | 1417436-52-2 | Reference compound |
| HY-124087 | (±)-2-Propyl-4-pentenoic acid | 1575-72-0 | Reference compound |
| HY-124087R | (±)-2-Propyl-4-pentenoic acid (Standard) | 1575-72-0 | Reference Standards |
| HY-124089 | Eicosapentaenoyl ethanolamide | 109001-03-8 | Reference compound |
| HY-124089S | Eicosapentaenoyl ethanolamide-d4 | 946524-41-0 | Isotope-Labeled Compounds |
| HY-12408A | 6H05 (TFA) | 2061344-88-3 | Reference compound |
| HY-12409 | PFI-3 | 1819363-80-8 | Reference compound |
| HY-124091 | Methyl 2-hydroxytricosanoate | 118745-41-8 | Natural Products |
| HY-124092 | Raluridine | 119644-22-3 | Reference compound |
| HY-124093 | 8-Deazahomofolic acid | 111113-73-6 | Reference compound |
| HY-124095 | Mannosan,95% | 14168-65-1 | Biochemical Assay Reagents |
| HY-124097 | HNMPA-(AM)3 | 120944-03-8 | Reference compound |
| HY-124098 | Lignocaine N-oxide | 2903-45-9 | Reference compound |
| HY-124099 | SCH 40120 | 110545-79-4 | Reference compound |
| HY-12410 | GNE-9822 | 1557232-32-2 | Reference compound |
| HY-124100 | LTB4 antagonist 4 | 117423-95-7 | Reference compound |
| HY-124101 | PDAT | 1226213-83-7 | Reference compound |
| HY-124104 | Aldicarb sulfoxide | 1646-87-3 | Reference compound |
| HY-124104S | Aldicarb sulfoxide-d3 | 1795136-36-5 | Isotope-Labeled Compounds |
| HY-124108 | Eicosatetraynoic acid | 1191-85-1 | Reference compound |
| HY-124109 | TRC051384 (hydrochloride) | 1333327-56-2 | Reference compound |
| HY-12411 | AMG-3969 | 1361224-53-4 | Reference compound |
| HY-124110 | TC299423 | 1975146-56-5 | Reference compound |
| HY-124111 | 10-Deoxymethymycin | 36826-66-1 | Reference compound |
| HY-124112 | PAM 1392 | 13794-65-5 | Reference compound |
| HY-124113 | 4'-Bromo-resveratrol | 1224713-90-9 | Reference compound |
| HY-124114 | 4-Hydroxytoremifene | 110503-62-3 | Reference compound |
| HY-124116 | PD 121373 | 113457-06-0 | Reference compound |
| HY-124117 | LY 278584 | 119193-37-2 | Reference compound |
| HY-124118 | (all-Z)-6,9,12,15,18-Heneicosapentaenoic acid ethyl ester | 131775-86-5 | Natural Products |
| HY-12412 | ML132 | 1230628-71-3 | Reference compound |
| HY-124122 | BPTQ | 1802665-43-5 | Reference compound |
| HY-124123 | Aminooxy-PEG4-alcohol | 106492-60-8 | ADC Related |
| HY-124124 | N-Methylnicotinamide | 114-33-0 | Natural Products |
| HY-124124R | N-Methylnicotinamide (Standard) | 114-33-0 | Reference Standards |
| HY-124124S | N-Methylnicotinamide-d4 | 2708278-64-0 | Isotope-Labeled Compounds |
| HY-124127 | Allylpyrocatechol | 1125-74-2 | Reference compound |
| HY-124129 | 10074-A4 | 312631-87-1 | Reference compound |
| HY-124131 | DS-437 | 1674364-87-4 | Reference compound |
| HY-124132 | Autophagy-IN-4 | 1411646-44-0 | Reference compound |
| HY-124134 | AD-2646 | 366487-89-0 | Reference compound |
| HY-124135 | SB-656104 | 446020-51-5 | Reference compound |
| HY-124136 | WYC-209 | 2131803-90-0 | Reference compound |
| HY-124137 | Runx1-CBFβ interaction inhibitor 1 | 493028-20-9 | Reference compound |
| HY-124138 | Pikromycin | 19721-56-3 | Reference compound |
| HY-12413A | BMS-986118 | 1610562-74-7 | Reference compound |
| HY-124140 | Heliosupine | 32728-78-2 | Natural Products |
| HY-124140R | Heliosupine (Standard) | 32728-78-2 | Reference Standards |
| HY-124141 | Myristelaidic acid | 50286-30-1 | Natural Products |
| HY-124143 | Isoguanine | 3373-53-3 | Natural Products |
| HY-124144 | MMV667492 | 380877-02-1 | Reference compound |
| HY-124145 | Metfendrazine | 3734-26-7 | Reference compound |
| HY-124146 | BI1002494 | 1319738-39-0 | Reference compound |
| HY-124150 | BM567 | 284464-77-3 | Reference compound |
| HY-124151 | Adenosine-2'-monophosphate | 130-49-4 | Natural Products |
| HY-124151R | Adenosine-2'-monophosphate (Standard) | 130-49-4 | Reference Standards |
| HY-124152 | 3,4-Dephostatin | 173043-84-0 | Reference compound |
| HY-124153 | GNE-431 | 1433820-83-7 | Reference compound |
| HY-124154 | Jaconine | 480-75-1 | Natural Products |
| HY-124154A | Jaconine (hydrochloride) | 7251-11-8 | Reference compound |
| HY-124156 | KY-02327 | 2093407-25-9 | Reference compound |
| HY-124156A | KY-02327 (acetate) | 2989396-34-9 | Reference compound |
| HY-124157 | AA41612 | 433690-62-1 | Reference compound |
| HY-124158 | KR-60436 | 220853-65-6 | Reference compound |
| HY-124160 | JNJ-56022486 | 2036082-79-6 | Reference compound |
| HY-124161 | SCH54292 | 188480-51-5 | Reference compound |
| HY-124163 | Epostatin | 181372-99-6 | Reference compound |
| HY-124168 | PF-244 | 33979-27-0 | Reference compound |
| HY-124171 | Zinquin ethyl ester | 181530-09-6 | Dye Reagents |
| HY-124173 | PF-06815189 | 2218484-75-2 | Reference compound |
| HY-124175 | 16-Phenoxy prostaglandin F2α ethyl amide | 951319-59-8 | Reference compound |
| HY-124176 | L-6355 | 85642-08-6 | Reference compound |
| HY-124177 | C14 Ceramide | 34227-72-0 | Natural Products |
| HY-124177A | C14 Ceramide (d18:1/14:0) | 123408-74-2 | Natural Products |
| HY-124178 | (R)-Levrazoxane | 24613-06-7 | Reference compound |
| HY-124179 | IT-901 | 1584121-99-2 | Reference compound |
| HY-12418 | Stenoparib | 1140964-99-3 | Reference compound |
| HY-124181 | SM-1295 | 1562375-46-5 | Reference compound |
| HY-124185 | LC 6 | 66818-22-2 | Reference compound |
| HY-124187 | Pinolenic acid ethyl ester | 493015-74-0 | Biochemical Assay Reagents |
| HY-12419 | BMS-983970 | 1584713-87-0 | Reference compound |
| HY-124190 | Isopropyl myristate | 110-27-0 | Reference compound |
| HY-124190R | Isopropyl myristate (Standard) | 110-27-0 | Reference Standards |
| HY-124191 | Ravidasvir (hydrochloride) | 1303533-81-4 | Reference compound |
| HY-124192 | Amogastrin | 16870-37-4 | Reference compound |
| HY-124197 | Coumarin hydrazine | 113707-87-2 | Dye Reagents |
| HY-124198 | 2,1,3-Benzoselenadiazole | 273-15-4 | Reference compound |
| HY-124199 | Cephalochromin | 25908-26-3 | Natural Products |
| HY-12420 | JNJ-47117096 hydrochloride | 1610536-69-0 | Reference compound |
| HY-124200 | AL 8810 isopropyl ester | 208114-93-6 | Reference compound |
| HY-124202 | SQ 32602 | 169529-81-1 | Reference compound |
| HY-124204 | LY 274614 | 136109-04-1 | Reference compound |
| HY-124205 | Pepticinnamin E | 147317-36-0 | Reference compound |
| HY-124208 | L-770644 | 173901-95-6 | Reference compound |
| HY-124208A | L-770644 (dihydrochloride) | 182251-68-9 | Reference compound |
| HY-124209 | 9-keto Fluprostenol | 156406-33-6 | Reference compound |
| HY-12420A | JNJ-47117096 | 1610586-62-3 | Reference compound |
| HY-12421 | BET-BAY 002 | 1588521-78-1 | Reference compound |
| HY-124210 | Formycin B | 13877-76-4 | Natural Products |
| HY-124211 | Dibenzo(a,i)pyrene | 189-55-9 | Reference compound |
| HY-124211S | Dibenzo(a,i)pyrene-d14 | 158776-07-9 | Isotope-Labeled Compounds |
| HY-124212 | Thaxtomin A | 122380-18-1 | Natural Products |
| HY-124215 | Fenchone | 1195-79-5 | Natural Products |
| HY-124215S1 | Fenchone-d3 | | Isotope-Labeled Compounds |
| HY-124216 | Penasterol | 116424-94-3 | Natural Products |
| HY-124217 | Prolintane (hydrochloride) | 1211-28-5 | Reference compound |
| HY-124218 | S 863390 | 130024-92-9 | Reference compound |
| HY-124219 | 17-Phenoxy trinor prostaglandin F2α ethyl amide | 1421369-12-1 | Reference compound |
| HY-12421B | BET-BAY 002 (S enantiomer) | 2070009-49-1 | Reference compound |
| HY-12422 | Voruciclib | 1000023-04-0 | Reference compound |
| HY-124220 | Karounidiol | 118117-31-0 | Natural Products |
| HY-124221 | Radamide | 1166398-85-1 | Reference compound |
| HY-124223 | AF-DX 384 (methanesulfonate) | 118290-27-0 | Reference compound |
| HY-124225 | RU 33965 | 122321-05-5 | Reference compound |
| HY-124228 | Ethyl glutamate | 1119-33-1 | Reference compound |
| HY-124229 | PD 122860 | 122576-86-7 | Reference compound |
| HY-12422A | Voruciclib (hydrochloride) | 1000023-05-1 | Reference compound |
| HY-12422B | (2S,3R)-Voruciclib (hydrochloride) | 2920469-94-7 | Reference compound |
| HY-12422C | rel-(2S,3R)-Voruciclib | 1253731-24-6 | Reference compound |
| HY-12422E | rel-(2S,3R)-Voruciclib (hydrochloride) | 1253647-46-9 | Reference compound |
| HY-12423 | Pamufetinib | 1190836-34-0 | Reference compound |
| HY-124230 | 15-PGDH-IN-3 | 355827-05-3 | Reference compound |
| HY-124232 | BTG 502 | 99083-11-1 | Reference compound |
| HY-124235 | SK&F 97574 (hydrochloride) | 144453-77-0 | Reference compound |
| HY-124236 | Chrysobactin | 120124-51-8 | Natural Products |
| HY-124237 | N-Octanoyl-DL-homoserine lactone | 106983-30-6 | Peptides |
| HY-124237A | N-Octanoyl-L-homoserine lactone | 147852-84-4 | Reference compound |
| HY-124237AR | N-Octanoyl-L-homoserine lactone (Standard) | 147852-84-4 | Reference Standards |
| HY-12423A | Pamufetinib (mesylate) | 1688673-09-7 | Reference compound |
| HY-12424 | Zotarolimus | 221877-54-9 | Reference compound |
| HY-124240 | SRTCX1003 | 1203480-86-7 | Reference compound |
| HY-124241 | N-Cyclopropyl bimatoprost | 1138395-12-6 | Reference compound |
| HY-124242 | (S)-α-Methylbenzyl ricinoleamide | 1246776-22-6 | Reference compound |
| HY-124243 | N-Cyclopropyl methyl bimatoprost | 1138395-10-4 | Reference compound |
| HY-124244 | DB-959 | 1257641-15-8 | Reference compound |
| HY-124245 | 3-Hydroxy desloratadine | 119410-08-1 | Reference compound |
| HY-124245R | 3-Hydroxy desloratadine (Standard) | 119410-08-1 | Reference Standards |
| HY-124245S | 3-Hydroxy desloratadine-d4 | 1246819-99-7 | Isotope-Labeled Compounds |
| HY-124245S1 | 3-Hydroxy desloratadine-d4 (hydrobromide) | | Isotope-Labeled Compounds |
| HY-124245S2 | 3-Hydroxy desloratadine-d6 | | Isotope-Labeled Compounds |
| HY-12424A | 42-(2-Tetrazolyl)rapamycin | 221877-56-1 | Reference compound |
| HY-12425 | DGAT1-IN-1 | 1449779-49-0 | Reference compound |
| HY-124250 | 9-OxoOTrE | 125559-74-2 | Reference compound |
| HY-124251 | 3-Thiopheneacrylic acid | 1195-52-4 | Reference compound |
| HY-124252 | 5,8,11-Eicosatriynoic acid | 13488-22-7 | Reference compound |
| HY-124254 | C.I. Vat Yellow 2 | 129-09-9 | Dye Reagents |
| HY-124257 | (R)-Citronellol | 1117-61-9 | Natural Products |
| HY-124258 | Valilactone | 113276-96-3 | Natural Products |
| HY-124259 | I-AB-MECA | 152918-27-9 | Reference compound |
| HY-12426 | mAChR-IN-1 | 119391-56-9 | Reference compound |
| HY-124260 | SB-204900 | 173220-67-2 | Natural Products |
| HY-124261 | Sampangine | 116664-93-8 | Natural Products |
| HY-124262 | Saptomycin E | 137714-92-2 | Natural Products |
| HY-124264 | UBP710 | 1333111-40-2 | Reference compound |
| HY-124265 | 4β-Hydroxycholesterol | 17320-10-4 | Reference compound |
| HY-124265S | 4β-Hydroxycholesterol-d7 | 1246302-80-6 | Isotope-Labeled Compounds |
| HY-124265S1 | 4β-Hydroxycholesterol-d5 | | Isotope-Labeled Compounds |
| HY-124265S2 | 4β-Hydroxycholesterol-d4 | 1363529-44-5 | Isotope-Labeled Compounds |
| HY-124267 | Zgwatinib | 1268264-10-3 | Reference compound |
| HY-12426A | mAChR-IN-1 (hydrochloride) | 119391-73-0 | Reference compound |
| HY-124270 | Sibenadet (hydrochloride) | 154189-24-9 | Reference compound |
| HY-124273 | C2 L-threo Ceramide (d18:1/2:0) | 143615-69-4 | Reference compound |
| HY-124279 | 14-Pentadecenoic acid | 17351-34-7 | Natural Products |
| HY-12428 | A-1165442 | 1221443-94-2 | Reference compound |
| HY-124281 | 9(R)-PAHSA | 2097130-84-0 | Reference compound |
| HY-124281A | 9(S)-PAHSA | 2097130-87-3 | Reference compound |
| HY-124282 | 17-Hydroxyheptadecanoic acid | 13099-34-8 | Natural Products |
| HY-124283 | LEI-101 (free base) | 1228660-00-1 | Reference compound |
| HY-124283A | LEI-101 | 2250025-91-1 | Reference compound |
| HY-124284 | Hexamethylene bisacetamide | 3073-59-4 | Reference compound |
| HY-124285 | ATPCA (hydrochloride) | 185444-92-2 | Reference compound |
| HY-124286 | N-cis-Tetradec-9Z-enoyl-L-homoserine lactone | 1675245-06-3 | Reference compound |
| HY-124288 | PDK1/AurA-IN-1 | 1919884-11-9 | Reference compound |
| HY-12429 | Beclabuvir | 958002-33-0 | Reference compound |
| HY-124290 | Carotegrast methyl | 401905-67-7 | Reference compound |
| HY-124290A | Carotegrast methyl (hydrochloride) | 1338380-52-1 | Reference compound |
| HY-124292 | Honokiol DCA | 1620160-42-0 | Reference compound |
| HY-124293 | AA147 | 393121-74-9 | Reference compound |
| HY-124295 | Imofinostat | 1338320-94-7 | Reference compound |
| HY-124296 | 2C-TFM (hydrochloride) | 159277-13-1 | Reference compound |
| HY-124298 | Calcein Blue AM | 168482-84-6 | Dye Reagents |
| HY-12429A | Beclabuvir (hydrochloride) | 958002-36-3 | Reference compound |
| HY-124300 | JNJ-54166060 | 1627900-41-7 | Reference compound |
| HY-124300A | (S)-JNJ-54166060 | 1627900-42-8 | Reference compound |
| HY-124301 | Penicolinate A | 1418291-68-5 | Natural Products |
| HY-124303 | 4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid | 136156-13-3 | Reference compound |
| HY-124303S | 4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid-d5 | 2749975-45-7 | Isotope-Labeled Compounds |
| HY-124304 | Pinokalant | 149759-26-2 | Reference compound |
| HY-124305 | ML395 | 1638957-17-1 | Reference compound |
| HY-124306 | ML-099 | 496775-95-2 | Reference compound |
| HY-124308 | PS315 | 1221964-50-6 | Reference compound |
| HY-124309 | NHI-2 | 1269802-97-2 | Reference compound |
| HY-124310 | PDE5-IN-6c | 1448419-13-3 | Reference compound |
| HY-124311 | 20-Hydroxyeicosanoic acid | 62643-46-3 | Natural Products |
| HY-124313 | 1-Methyl-1,4-dihydronicotinamide | 17750-23-1 | Reference compound |
| HY-124314 | LEI-106 | 1620582-23-1 | Reference compound |
| HY-124315 | Ro24-5098 | 127682-75-1 | Reference compound |
| HY-124317 | PF-06649283 | 1621585-17-8 | Reference compound |
| HY-124318 | SMPH Crosslinker | 367927-39-7 | Reference compound |
| HY-12432 | Gilteritinib | 1254053-43-4 | Reference compound |
| HY-124320 | Desmethylene paroxetine (hydrochloride) | 1394861-12-1 | Reference compound |
| HY-124321 | Metralindole (hydrochloride) | 53734-79-5 | Reference compound |
| HY-124322 | NB-360 | 1262857-73-7 | Reference compound |
| HY-124323 | m-PEG4-NHS ester | 622405-78-1 | Reference compound |
| HY-124324 | 4-Nitrophenyl β-D-cellotrioside | 106927-48-4 | Dye Reagents |
| HY-124325 | PIP-199 | 622795-76-0 | Reference compound |
| HY-124329 | BS3 Crosslinker | 82436-77-9 | ADC Related |
| HY-124329A | BS3 Crosslinker (disodium) | 127634-19-9 | ADC Related |
| HY-124329AS | BS3 Crosslinker-d4 (disodium) | 910292-87-4 | Isotope-Labeled Compounds |
| HY-12432A | Gilteritinib hemifumarate | 1254053-84-3 | Reference compound |
| HY-12432R | Gilteritinib (Standard) | 1254053-43-4 | Reference Standards |
| HY-12432S1 | Gilteritinib-d8 | 2377109-74-3 | Isotope-Labeled Compounds |
| HY-12433 | BMS-819881 | 1197420-05-5 | Reference compound |
| HY-124330 | Tripolin A | 1148118-92-6 | Reference compound |
| HY-124332 | 25T7-NBOMe (hydrochloride) | 1539266-55-1 | Reference compound |
| HY-124334 | L-161240 | 183298-68-2 | Reference compound |
| HY-124337 | BG48 | 1628784-53-1 | Reference compound |
| HY-124339 | JNJ525 | 2092913-64-7 | Reference compound |
| HY-12434 | INT-767 | 1000403-03-1 | Reference compound |
| HY-124341 | ND-378 | 1807453-72-0 | Reference compound |
| HY-124343 | Diethylhomospermine | 119422-08-1 | Reference compound |
| HY-124344 | Avenanthramide C | 116764-15-9 | Natural Products |
| HY-124345 | 2-Trifluoromethyl-2'-methoxychalcone | 1309371-03-6 | Reference compound |
| HY-124346 | T-3364366 | 1356354-09-0 | Reference compound |
| HY-124348 | DM-PIT-1 | 701947-53-7 | Reference compound |
| HY-124350 | 10-Formylfolic acid | 134-05-4 | Reference compound |
| HY-124350R | 10-Formylfolic acid (Standard) | 134-05-4 | Reference Standards |
| HY-124350S | 10-Formylfolic acid-d4 | 461426-41-5 | Isotope-Labeled Compounds |
| HY-124351 | 5'-Hydroxy meloxicam | 130262-92-9 | Reference compound |
| HY-124352 | 2-Nonyl-3-hydroxy-4-quinolone | 1259944-03-0 | Reference compound |
| HY-124352S | 2-Nonyl-3-hydroxy-4-quinolone-d4 | | Isotope-Labeled Compounds |
| HY-124353 | 11-Dehydro thromboxane B3 | 129228-55-3 | Reference compound |
| HY-124355 | 4-Hydroxy hexenal | 17427-21-3 | Reference compound |
| HY-124355S | 4-Hydroxy hexenal-d3 | 148706-05-2 | Isotope-Labeled Compounds |
| HY-124356 | Alcaftadine carboxylic acid | 147083-93-0 | Reference compound |
| HY-124356AS | Alcaftadine carboxylic acid-d3 (sodium) | | Isotope-Labeled Compounds |
| HY-124357 | Seproxetine (hydrochloride) | 127685-30-7 | Reference compound |
| HY-12436 | NTRC-824 | 1623002-61-8 | Reference compound |
| HY-124360 | NIT | 299922-10-4 | Reference compound |
| HY-124363 | 5-cis Carbaprostacyclin | 69609-77-4 | Reference compound |
| HY-124364 | RO6889678 | 1578153-27-1 | Reference compound |
| HY-124365 | Rhamnetin tetraacetate | 16280-26-5 | Reference compound |
| HY-124366 | Slingshot inhibitor D3 | 1715076-35-9 | Reference compound |
| HY-124367 | 25B-NBF (hydrochloride) | 1539266-17-5 | Reference compound |
| HY-12437 | BDP5290 | 1817698-21-7 | Reference compound |
| HY-124370 | 9(Z),11(E)-Conjugated linoleic acid methyl ester | 13058-52-1 | Natural Products |
| HY-124371 | Amentoflavone hexaacetate | 17482-37-0 | Natural Products |
| HY-124372 | JNJ-46356479 | 1254979-66-2 | Reference compound |
| HY-124373 | ND-336 | 1807453-83-3 | Reference compound |
| HY-124373A | (R)-ND-336 | 2252493-33-5 | Reference compound |
| HY-124375 | IND81 | 1426047-52-0 | Reference compound |
| HY-124377 | SPDP-C6-NHS ester | 158913-22-5 | Reference compound |
| HY-124378 | MAGL-IN-17 | 1643657-35-5 | Reference compound |
| HY-124379 | TPCK | 402-71-1 | Reference compound |
| HY-12438 | G007-LK | 1380672-07-0 | Reference compound |
| HY-124380 | Hydroxy-PEG2-acid | 1334286-77-9 | Reference compound |
| HY-124381 | ML10375 | 174008-52-7 | Reference compound |
| HY-124382 | AS1928370 | 1345614-89-2 | Reference compound |
| HY-124386 | DBCO-NHCO-PEG4-amine | 1255942-08-5 | ADC Related |
| HY-124388 | PDE4-IN-20 | 1396397-03-7 | Reference compound |
| HY-12439 | ML380 | 1627138-52-6 | Reference compound |
| HY-124391 | L 156373 | 122211-29-4 | Reference compound |
| HY-124392 | AMG580 | 1227067-71-1 | Reference compound |
| HY-124393 | GRN-529 | 1253291-12-1 | Reference compound |
| HY-124395 | MS2126 | 16078-42-5 | Reference compound |
| HY-124396 | Lanceotoxin A | 93771-82-5 | Reference compound |
| HY-124399 | N-Octadecyl-N'-propyl-sulfamide | 925891-74-3 | Reference compound |
| HY-124401 | BT-13 | 924537-98-4 | Reference compound |
| HY-124403 | D 15413 | 83364-03-8 | Reference compound |
| HY-124404 | 12(R)-HETE | 82337-46-0 | Reference compound |
| HY-124404A | 12(S)-HETE | 54397-83-0 | Reference compound |
| HY-124406 | A-794282 | 869802-44-8 | Reference compound |
| HY-124408 | Mepronil | 55814-41-0 | Reference compound |
| HY-124408R | Mepronil (Standard) | 55814-41-0 | Reference Standards |
| HY-124409 | WSP-1 | 1352750-34-5 | Dye Reagents |
| HY-124410 | Mitoquinol | 845959-55-9 | Reference compound |
| HY-124410S | Mitoquinol-d15 | | Isotope-Labeled Compounds |
| HY-124411 | Lobenzarit | 63329-53-3 | Reference compound |
| HY-124412 | Paynantheine | 4697-66-9 | Natural Products |
| HY-124412S | Paynantheine-d3 | | Isotope-Labeled Compounds |
| HY-124413 | Otosenine | 16958-29-5 | Natural Products |
| HY-124414 | 4'-Hydroxytamoxifen | 82413-23-8 | Reference compound |
| HY-124414A | 4'-Hydroxytamoxifen (TFA) | | Reference compound |
| HY-124414AR | 4'-Hydroxytamoxifen (TFA) (Standard) | | Reference Standards |
| HY-124414R | 4'-Hydroxytamoxifen (Standard) | 82413-23-8 | Reference Standards |
| HY-124414S | 4'-Hydroxytamoxifen-d6 (contains up to 10% E isomer) | 1346606-80-1 | Isotope-Labeled Compounds |
| HY-124416 | ML604086 | 850330-18-6 | Reference compound |
| HY-124417 | SBI-477 analog | 2073059-56-8 | Reference compound |
| HY-124418 | SBI-477 | 781628-99-7 | Reference compound |
| HY-124419 | RO0711401 | 714971-87-6 | Reference compound |
| HY-12442 | LY5 | 1436382-03-4 | Reference compound |
| HY-124421 | 5F-203 | 260443-89-8 | Reference compound |
| HY-124422 | Pentacosanoic acid | 506-38-7 | Natural Products |
| HY-124422R | Pentacosanoic acid (Standard) | 506-38-7 | Reference Standards |
| HY-124423 | ReN 1869 | 170149-99-2 | Reference compound |
| HY-124424 | VU0071063 | 333415-38-6 | Reference compound |
| HY-124425 | 5′-Deoxythymidine | 3458-14-8 | Natural Products |
| HY-124425R | 5′-Deoxythymidine (Standard) | 3458-14-8 | Reference Standards |
| HY-124427 | Lithospermidin B | 83415-79-6 | Natural Products |
| HY-124428 | ASP6537 | 524699-72-7 | Reference compound |
| HY-124429 | FQI1 | 599151-35-6 | Reference compound |
| HY-12443 | PF-5006739 | 1293395-67-1 | Reference compound |
| HY-124431 | Kikumycin A | 37913-77-2 | Reference compound |
| HY-124433 | Methyl 11-methyldodecanoate | 5129-57-7 | Biochemical Assay Reagents |
| HY-124434 | Mesembrenone | 468-54-2 | Natural Products |
| HY-124438 | Herbicidin A | 55353-31-6 | Reference compound |
| HY-124439 | Setomimycin | 69431-87-4 | Reference compound |
| HY-12444 | Y15 | 4506-66-5 | Reference compound |
| HY-124445 | APC0576 | 318967-58-7 | Reference compound |
| HY-124447 | BTYNB | 304456-62-0 | Reference compound |
| HY-124448 | Lofemizole | 65571-68-8 | Reference compound |
| HY-124449 | Afidopyropen | 915972-17-7 | Reference compound |
| HY-12445 | Asnuciclib | 1421693-22-2 | Reference compound |
| HY-124451 | 2-Chloronaphthalene | 91-58-7 | Reference compound |
| HY-124451S | 2-Chloronaphthalene-d7 | 93951-84-9 | Isotope-Labeled Compounds |
| HY-124452 | Nocardamine | 26605-16-3 | Biochemical Assay Reagents |
| HY-124454 | JCC76 | 1021926-22-6 | Reference compound |
| HY-124455 | Lunine | 518-60-5 | Natural Products |
| HY-124456 | Unguinol | 36587-59-4 | Reference compound |
| HY-124458 | Morocromen | 35843-07-3 | Reference compound |
| HY-12446 | K-Ras(G12C) inhibitor 9 | 1469337-91-4 | Reference compound |
| HY-124462 | Trifluperidol (hydrochloride) | 2062-77-3 | Reference compound |
| HY-124463 | Epiallopregnanolone | 567-01-1 | Reference compound |
| HY-124463S1 | Epiallopregnanolone-d5 | | Isotope-Labeled Compounds |
| HY-124464 | MD 770222 | 70133-35-6 | Reference compound |
| HY-124466 | Codlemone | 33956-49-9 | Natural Products |
| HY-124467 | Difludiazepam | 39080-67-6 | Reference compound |
| HY-124469 | UM-C162 | 1799734-10-3 | Reference compound |
| HY-12447 | SMK-17 | 765958-29-0 | Reference compound |
| HY-124472 | 2,4-Difluororesorcinol | 195136-71-1 | Reference compound |
| HY-124473 | Naphthofluorescein | 61419-02-1 | Reference compound |
| HY-124474 | Procurcumenol | 21698-40-8 | Natural Products |
| HY-124475 | Antalarmin | 157284-96-3 | Reference compound |
| HY-124476 | Cystamine | 51-85-4 | Reference compound |
| HY-124477 | Stachybotrylactam | 163391-76-2 | Natural Products |
| HY-124478 | Ethyl gentisate | 3943-91-7 | Reference compound |
| HY-124479A | γ-Lumicolchicine | 6901-14-0 | Reference compound |
| HY-12448 | SPDB | 115088-06-7 | ADC Related |
| HY-124480 | Tetrazine-Ph-acid | 1380500-92-4 | Reference compound |
| HY-124481 | Oleocanthal | 289030-99-5 | Natural Products |
| HY-124482 | Mesembrenol | 25516-15-8 | Reference compound |
| HY-124484 | JI130 | 2234271-86-2 | Reference compound |
| HY-124485 | Nitroscanate | 19881-18-6 | Reference compound |
| HY-124489 | 2-Hydroxyestradiol | 362-05-0 | Reference compound |
| HY-124489S | 2-Hydroxyestradiol-13C6 | | Isotope-Labeled Compounds |
| HY-124489S1 | 2-Hydroxyestradiol-d5 | 221093-33-0 | Isotope-Labeled Compounds |
| HY-12449 | Crenigacestat | 1421438-81-4 | Reference compound |
| HY-124491 | Moquizone | 19395-58-5 | Reference compound |
| HY-124493 | Aluminon | 569-58-4 | Biochemical Assay Reagents |
| HY-124495 | Butocarboxim | 34681-10-2 | Reference compound |
| HY-124496 | Piperitenone | 491-09-8 | Natural Products |
| HY-124498 | Oxantel | 36531-26-7 | Reference compound |
| HY-124499 | RUC-1 | 796886-30-1 | Reference compound |
| HY-12450 | Lomofungin | 26786-84-5 | Natural Products |
| HY-124500 | AC-4-130 | 1834571-82-2 | Reference compound |
| HY-124501 | LY 165163 | 1814-64-8 | Reference compound |
| HY-124502 | UNC4203 | 1818234-19-3 | Reference compound |
| HY-124503 | Longanlactone | 1438721-51-7 | Natural Products |
| HY-124504 | Lunularic acid | 23255-59-6 | Natural Products |
| HY-124508 | Lambertellin | 28980-51-0 | Natural Products |
| HY-124509 | Pyrocoll | 484-73-1 | Reference compound |
| HY-12451 | FICZ | 172922-91-7 | Reference compound |
| HY-124512 | Quercetin pentaacetate | 1064-06-8 | Reference compound |
| HY-124514 | UC-857993 | 487001-04-7 | Reference compound |
| HY-124517 | Burimamide | 34970-69-9 | Reference compound |
| HY-124519 | Centmitor-1 | 331749-88-3 | Reference compound |
| HY-12452 | DPN | 1428-67-7 | Reference compound |
| HY-124521 | Quinelorane | 97466-90-5 | Reference compound |
| HY-124526 | Chiauranib | 1256349-48-0 | Reference compound |
| HY-124527 | HET0016 | 339068-25-6 | Reference compound |
| HY-12453 | TBK1/IKKε-IN-2 | 1292310-49-6 | Reference compound |
| HY-124531 | Tetra(cyanoethoxymethyl) methane | 2465-91-0 | Reference compound |
| HY-124533 | Trimethylolmelamine | 1017-56-7 | Reference compound |
| HY-124534 | (1S,3R)-3-Aminocyclopentane carboxylic acid | 71830-07-4 | Reference compound |
| HY-124535 | TGX-115 | 351071-62-0 | Reference compound |
| HY-124537 | (+)-Volkensiflavone | 27542-37-6 | Natural Products |
| HY-124539 | ZK 187638 | 397298-63-4 | Reference compound |
| HY-12454 | DM4 | 796073-69-3 | ADC Related |
| HY-124540 | ABT-202 | 309959-34-0 | Reference compound |
| HY-124540B | (Rac)-ABT-202 (dihydrochloride) | 1258641-38-1 | Reference compound |
| HY-124542 | 5-Hydroxydiclofenac | 69002-84-2 | Reference compound |
| HY-124543 | MRS-1191 | 185222-90-6 | Reference compound |
| HY-124546 | Necrostatin-5 | 337349-54-9 | Reference compound |
| HY-124547 | 2,4-D methyl ester | 1928-38-7 | Reference compound |
| HY-124547R | 2,4-D methyl ester (Standard) | 1928-38-7 | Reference Standards |
| HY-124547S | 2,4-D methyl ester-d3 | 2732917-35-8 | Isotope-Labeled Compounds |
| HY-124547S1 | 2,4-D Methyl ester-d3-1 | 358731-20-1 | Isotope-Labeled Compounds |
| HY-12454S | DM4-d6 | | Isotope-Labeled Compounds |
| HY-12455 | Duocarmycin A | 118292-34-5 | ADC Related |
| HY-124550 | Sarcophine | 55038-27-2 | Natural Products |
| HY-124551 | Viridiol | 23820-80-6 | Natural Products |
| HY-124552 | Epolactaene | 167782-17-4 | Natural Products |
| HY-124555 | Hexamide | 3653-39-2 | Reference compound |
| HY-124556 | Elasnin | 68112-21-0 | Reference compound |
| HY-124557 | Mahanimbine | 21104-28-9 | Natural Products |
| HY-124559 | (Rac)-Nanatinostat | 914937-68-1 | Reference compound |
| HY-12456 | Duocarmycin SA | 130288-24-3 | ADC Related |
| HY-124560 | Lifibrol | 96609-16-4 | Reference compound |
| HY-124564 | Methisazone | 1910-68-5 | Reference compound |
| HY-124569 | NAB-14 | 1237541-73-9 | Reference compound |
| HY-12457 | Rachelmycin | 69866-21-3 | Natural Products |
| HY-124571 | ZQ-16 | 376616-73-8 | Reference compound |
| HY-124573 | OBI-3424 | 2097713-68-1 | Reference compound |
| HY-124576 | ABD-1970 | 2010154-82-0 | Reference compound |
| HY-124577 | MDI-2268 | 1609176-50-2 | Reference compound |
| HY-12458 | Pyrindamycin A | 118292-36-7 | Reference compound |
| HY-124581 | DS-6930 | 1242328-82-0 | Reference compound |
| HY-124582 | NEO214 | 1361198-80-2 | Reference compound |
| HY-124583 | PF-4363467 | 2040055-84-1 | Reference compound |
| HY-124584 | Minnelide | 1254702-87-8 | Reference compound |
| HY-124584A | Minnelide (free base) | 1254885-39-6 | Reference compound |
| HY-124586 | Streptonigrin | 3930-19-6 | Natural Products |
| HY-124587 | MLT-747 | 2097853-86-4 | Reference compound |
| HY-124588 | MC3343 | 1535187-91-7 | Reference compound |
| HY-12459 | Pyrindamycin B | 118292-35-6 | Reference compound |
| HY-124591 | TC-2153 | 1381769-23-8 | Reference compound |
| HY-124592 | BMT-052 | 1628720-84-2 | Isotope-Labeled Compounds |
| HY-124593 | PTC299 | 1256565-36-2 | Reference compound |
| HY-124594 | CA inhibitor 1 | 2189684-45-3 | Reference compound |
| HY-124596 | CD161 | 1627716-22-6 | Reference compound |
| HY-124597 | ARN726 | 1628343-77-0 | Reference compound |
| HY-12460 | SPDB-DM4 | 1626359-62-3 | ADC Related |
| HY-124600 | NVR 3-778 | 1445790-55-5 | Reference compound |
| HY-124602 | DI-591 | 2245887-38-9 | Reference compound |
| HY-124603 | AT791 | 1219962-49-8 | Reference compound |
| HY-124607 | (R)-BRD3731 | 2056262-08-7 | Reference compound |
| HY-124607B | BRD3731 | 2056262-07-6 | Reference compound |
| HY-124609 | CAD031 | 2071209-49-7 | Reference compound |
| HY-12461 | WS6 | 1421227-53-3 | Reference compound |
| HY-124611 | JG-231 | 1627126-59-3 | Reference compound |
| HY-124613 | Pyrazinib | 200417-97-6 | Reference compound |
| HY-124614 | GLP-26 | 2133017-36-2 | Reference compound |
| HY-124617 | AMXT-1501 | 441022-64-6 | Reference compound |
| HY-124617A | AMXT-1501 tetrahydrochloride | 2444815-84-1 | Reference compound |
| HY-124618 | FGI-106 | 501081-38-5 | Reference compound |
| HY-124618A | FGI-106 (tetrahydrochloride) | 1149348-10-6 | Reference compound |
| HY-124619 | GPI-1046 | 186452-09-5 | Reference compound |
| HY-12462 | WS3 | 1421227-52-2 | Reference compound |
| HY-124622 | NNC-0640 | 307986-98-7 | Reference compound |
| HY-124623 | DNDI-8219 | 2222660-40-2 | Reference compound |
| HY-124624 | PBOX-15 | 354759-10-7 | Reference compound |
| HY-124625 | BI-4464 | 1227948-02-8 | Reference compound |
| HY-124626 | (R)-(+)-Mequitazine | 147780-50-5 | Reference compound |
| HY-124628 | IPI-9119 | 1346564-56-4 | Reference compound |
| HY-124629 | DB2313 | 2170606-74-1 | Reference compound |
| HY-124629A | DB2313 (tetrahydrochloride) | 2170606-75-2 | Reference compound |
| HY-12463 | Carmoterol (hydrochloride) | 137888-11-0 | Reference compound |
| HY-124632 | WJ460 | 1415251-36-3 | Reference compound |
| HY-124634 | PZ-2891 | 2170608-82-7 | Reference compound |
| HY-124637 | ALE-0540 | 234779-34-1 | Reference compound |
| HY-124638 | MNK inhibitor 9 | 1889336-59-7 | Reference compound |
| HY-124639 | CDK9 inhibitor HH1 | 204188-41-0 | Reference compound |
| HY-12463A | Carmoterol | 147568-66-9 | Reference compound |
| HY-12464 | Butafenacil | 134605-64-4 | Reference compound |
| HY-124643 | RIPK2-IN-3 | 1290490-78-6 | Reference compound |
| HY-124644 | 1E7-03 | 1565845-92-2 | Reference compound |
| HY-124645 | QL-X-138 | 1469988-63-3 | Reference compound |
| HY-124646 | KIRA-7 | 1937235-76-1 | Reference compound |
| HY-124647 | PI3Kα-IN-1 | 2100855-80-7 | Reference compound |
| HY-124648 | SMN-C2 | 1446311-56-3 | Reference compound |
| HY-12464R | Butafenacil (Standard) | 134605-64-4 | Reference Standards |
| HY-12465 | Z-Ile-Leu-aldehyde | 161710-10-7 | Reference compound |
| HY-124651 | SEMBL | 1443448-82-5 | Reference compound |
| HY-124652 | TBK1/IKKε-IN-4 | 1381930-17-1 | Reference compound |
| HY-124653 | HSP27 inhibitor J2 | 2133499-85-9 | Reference compound |
| HY-124654 | SS148 | 1985669-27-9 | Reference compound |
| HY-124658 | G0507 | 1223998-29-5 | Reference compound |
| HY-12466 | Z-DEVD-FMK | 210344-95-9 | Reference compound |
| HY-124660A | A-395N | 2089056-09-5 | Reference compound |
| HY-124662 | IHVR-19029 | 1447464-73-4 | Reference compound |
| HY-124663 | CBK289001 | 1212663-24-5 | Reference compound |
| HY-124664 | TP0438836 | 957772-01-9 | Reference compound |
| HY-124668 | CCR1 antagonist 12 | 921208-19-7 | Reference compound |
| HY-124669 | RTC-30 | 1423077-95-5 | Reference compound |
| HY-12467 | OTS964 (hydrochloride) | 1338545-07-5 | Reference compound |
| HY-124670 | 1beta-Hydroxyalantolactone | 68776-47-6 | Natural Products |
| HY-124673 | AF40431 | 181125-92-8 | Reference compound |
| HY-124674 | CCT365623 | 2126134-01-6 | Reference compound |
| HY-124674A | CCT365623 (hydrochloride) | 2126136-98-7 | Reference compound |
| HY-124675 | MYCMI-6 | 681282-09-7 | Reference compound |
| HY-124676A | DB2115 (tertahydrochloride) | 1366126-19-3 | Reference compound |
| HY-124679 | DS86760016 | 1853176-89-2 | Reference compound |
| HY-12468 | A-1210477 | 1668553-26-1 | Reference compound |
| HY-124680 | AC-263093 (free base) | 849459-86-5 | Reference compound |
| HY-124681 | NY0116 | 1003000-59-6 | Reference compound |
| HY-124687 | ROMK-IN-32 | 1914944-54-9 | Reference compound |
| HY-124689 | TR-100 | 1128165-86-5 | Reference compound |
| HY-12469 | Decernotinib | 944842-54-0 | Reference compound |
| HY-124691 | D-I03 | 688342-78-1 | Reference compound |
| HY-124696 | PU139 | 158093-65-3 | Reference compound |
| HY-124697 | BMP signaling agonist sb4 | 100874-08-6 | Reference compound |
| HY-124699 | MMSET-IN-1 | 1998139-29-9 | Reference compound |
| HY-12470 | PF-4800567 | 1188296-52-7 | Reference compound |
| HY-124700 | LYPLAL1-IN-1 | 1966129-74-7 | Reference compound |
| HY-124701 | Filastatin | 431996-53-1 | Reference compound |
| HY-124702 | ICA-105574 | 316146-57-3 | Reference compound |
| HY-124703 | Pyrimidinone 8 | 65004-42-4 | Reference compound |
| HY-124704 | Chst15-IN-1 | 2158198-77-5 | Reference compound |
| HY-12470A | PF-4800567 (hydrochloride) | 1391052-28-0 | Reference compound |
| HY-12471 | VLX1570 | 1431280-51-1 | Reference compound |
| HY-124711 | TBOPP | 1996629-79-8 | Reference compound |
| HY-124712 | Divin | 1443321-11-6 | Reference compound |
| HY-124713 | ML372 | 1331745-61-9 | Reference compound |
| HY-124717 | YC-001 | 748778-73-6 | Reference compound |
| HY-124718 | p32 Inhibitor M36 | 802555-85-7 | Reference compound |
| HY-124719 | hSMG-1 inhibitor 11j | 1402452-15-6 | Reference compound |
| HY-12472 | Balipodect | 1238697-26-1 | Reference compound |
| HY-124722 | OHM1 | 1450995-09-1 | Reference compound |
| HY-124723 | Gerfelin | 627545-07-7 | Reference compound |
| HY-124726 | Aumitin | 946293-78-3 | Reference compound |
| HY-124727 | ZT55 | 2138488-38-5 | Reference compound |
| HY-124729 | BL-918 | 2101517-69-3 | Reference compound |
| HY-124729A | (Rac)-BL-918 | 2435589-07-2 | Reference compound |
| HY-12473 | Vps34-IN-2 | 1523404-29-6 | Reference compound |
| HY-124731 | PD-321852 | 622856-21-7 | Reference compound |
| HY-124733 | LIT-001 (free base) | 2245072-20-0 | Reference compound |
| HY-124733A | LIT-001 | 2245072-21-1 | Reference compound |
| HY-124735 | RH01687 | 302901-13-9 | Reference compound |
| HY-124738 | BI 01383298 | 2227549-00-8 | Reference compound |
| HY-124739 | HBX 28258 | 1426544-54-8 | Reference compound |
| HY-124740 | ML00253764 | 681847-92-7 | Reference compound |
| HY-124741 | Jamaicin | 24211-36-7 | Natural Products |
| HY-124744 | ASP 8477 | 906737-25-5 | Reference compound |
| HY-124745 | KY-05009 | 1228280-29-2 | Reference compound |
| HY-124748 | ENMD-1068 | 789488-77-3 | Reference compound |
| HY-124748A | ENMD-1068 (hydrochloride) | 2703451-51-6 | Reference compound |
| HY-12475 | Mutant IDH1-IN-1 | 1355326-21-4 | Reference compound |
| HY-124750 | NecroX-7 | 1120332-55-9 | Reference compound |
| HY-124751 | YTX-465 | 2225824-53-1 | Reference compound |
| HY-124754 | Navacaprant | 2244614-14-8 | Reference compound |
| HY-124756 | SBI-425 | 1451272-71-1 | Reference compound |
| HY-124757 | FiVe1 | 932359-76-7 | Reference compound |
| HY-124758 | SH-BC-893 | 1841409-92-4 | Reference compound |
| HY-124759 | CCR1 antagonist 9 | 1220026-26-5 | Reference compound |
| HY-12476 | SAR156497 | 1256137-14-0 | Reference compound |
| HY-124760 | hSMG-1 inhibitor 11e | 1402452-10-1 | Reference compound |
| HY-124761 | Poloppin | 683808-78-8 | Reference compound |
| HY-124762 | TNIK-IN-1 | 933886-36-3 | Reference compound |
| HY-124764 | KY-04031 | 468056-29-3 | Reference compound |
| HY-124767 | SR 142948A | 184162-21-8 | Reference compound |
| HY-124768 | PDE12-IN-3 | 1803357-22-3 | Reference compound |
| HY-12477 | PF-06447475 | 1527473-33-1 | Reference compound |
| HY-124771 | RH01386 | 301177-36-6 | Reference compound |
| HY-124772 | BI-2545 | 2162961-71-7 | Reference compound |
| HY-124775 | (S)-C33 | 2066488-39-7 | Reference compound |
| HY-124776 | NPD8733 | 696655-62-6 | Reference compound |
| HY-124777 | NPD4456 | 859668-98-7 | Reference compound |
| HY-124778 | SW106065 | 62289-81-0 | Reference compound |
| HY-124779 | (S)-Alaproclate | 66171-75-3 | Reference compound |
| HY-124779A | (S)-Alaproclate (hydrochloride) | 57469-92-8 | Reference compound |
| HY-124780 | HOOCCH2O-PEG4-CH2COOH | 77855-75-5 | Reference compound |
| HY-124781 | ML406 | 774589-47-8 | Reference compound |
| HY-124781R | ML406 (Standard) | 774589-47-8 | Reference Standards |
| HY-124782 | HDAC8-IN-8 | 1884231-52-0 | Reference compound |
| HY-124789 | TBT1 | 52535-76-9 | Reference compound |
| HY-124789R | TBT1 (Standard) | 52535-76-9 | Reference Standards |
| HY-12479 | Epetraborole | 1093643-37-8 | Reference compound |
| HY-124790 | KSP-IA | 639074-49-0 | Reference compound |
| HY-124793 | GAK inhibitor 49 | 319492-82-5 | Reference compound |
| HY-124793A | GAK inhibitor 49 (hydrochloride) | 2930378-91-7 | Reference compound |
| HY-124795 | FPMINT | 924866-33-1 | Reference compound |
| HY-124796 | Qstatin | 902688-24-8 | Reference compound |
| HY-124798 | Rheb inhibitor NR1 | 2216763-38-9 | Reference compound |
| HY-12479A | Epetraborole (hydrochloride) | 1234563-16-6 | Reference compound |
| HY-12479B | Epetraborole (R-mandelate) | 1234563-15-5 | Reference compound |
| HY-12480 | Lanopepden | 1152107-25-9 | Reference compound |
| HY-124801 | ABMA | 332108-65-3 | Reference compound |
| HY-124803 | GPCR modulator-1 | 1407592-99-7 | Reference compound |
| HY-124805 | MAL3-101 | 831217-40-4 | Reference compound |
| HY-124806 | TTP-8307 | 950225-08-8 | Reference compound |
| HY-124808 | IMM-01 | 218795-74-5 | Reference compound |
| HY-12481 | SAR405 | 1523406-39-4 | Reference compound |
| HY-124811 | IRES-C11 | 342416-30-2 | Reference compound |
| HY-124813 | PDZ1i | 2083618-79-3 | Reference compound |
| HY-124814 | C215 | 912780-51-9 | Reference compound |
| HY-124815 | CP-312 | 895470-67-4 | Reference compound |
| HY-124817 | Col003 | 328565-16-8 | Reference compound |
| HY-124819 | D13-9001 | 957471-96-4 | Reference compound |
| HY-12481A | SAR405 R enantiomer | 1946010-79-2 | Reference compound |
| HY-124821 | VA012 | 885898-58-8 | Reference compound |
| HY-124822 | COH-SR4 | 73439-19-7 | Reference compound |
| HY-124823 | Monastroline | 462630-41-7 | Reference compound |
| HY-124824 | Methyl gerfelin | 700870-56-0 | Reference compound |
| HY-124825 | iGOT1-01 | 882256-55-5 | Reference compound |
| HY-124826 | BC21 | 691005-38-6 | Reference compound |
| HY-124827 | Tec-IN-1 | 931664-41-4 | Reference compound |
| HY-124828 | CMLD-2 | 958843-91-9 | Reference compound |
| HY-12483 | SR1664 | 1338259-05-4 | Reference compound |
| HY-124830 | SPA70 | 931314-31-7 | Reference compound |
| HY-124831 | NTRC-844 | 1811503-67-9 | Reference compound |
| HY-124832 | δ-Secretase inhibitor 11 | 842964-18-5 | Reference compound |
| HY-124833 | Quinalizarin | 81-61-8 | Reference compound |
| HY-124834 | Nrf2 activator-10 | 75483-04-4 | Reference compound |
| HY-124838 | EG1 | 693241-54-2 | Reference compound |
| HY-12484 | BMH-21 | 896705-16-1 | Reference compound |
| HY-124843 | LLL3 | 63972-38-3 | Reference compound |
| HY-124844 | Azaphilone-9 | 1448460-87-4 | Reference compound |
| HY-124848 | CMPD167 | 313994-79-5 | Reference compound |
| HY-12485 | TBA-354 | 1257426-19-9 | Reference compound |
| HY-124855 | STD1T | 893075-58-6 | Reference compound |
| HY-124857 | 7DG | 26927-01-5 | Reference compound |
| HY-124858 | SC99 | 882290-02-0 | Reference compound |
| HY-124859 | CeMMEC2 | 902955-25-3 | Reference compound |
| HY-12485R | TBA-354 (Standard) | 1257426-19-9 | Reference Standards |
| HY-12486 | FL118 | 135415-73-5 | Reference compound |
| HY-124861 | Malic enzyme inhibitor ME1 | 522649-59-8 | Reference compound |
| HY-124863A | (R)-AAL | 241476-71-1 | Reference compound |
| HY-124866 | PDI-IN-3 | 922507-80-0 | Reference compound |
| HY-124867 | D3-βArr | 662164-09-2 | Reference compound |
| HY-12487 | NL-103 | 1788896-33-2 | Reference compound |
| HY-124870 | N.41 | 357441-99-7 | Reference compound |
| HY-124871 | LASV inhibitor 3.3 | 554438-52-7 | Reference compound |
| HY-124873 | SERCA2a activator 1 | 2139330-34-8 | Reference compound |
| HY-124874 | (rel)-Asperparaline A | 195966-93-9 | Natural Products |
| HY-124875 | Arylsulfonamide 64B | 1342890-83-8 | Reference compound |
| HY-124876 | SynuClean-D | 685121-45-3 | Reference compound |
| HY-124878S | LY 227942-d5 | | Isotope-Labeled Compounds |
| HY-124879 | MF 961 | 138372-62-0 | Reference compound |
| HY-12488 | LY2510924 | 1088715-84-7 | Reference compound |
| HY-124880 | JNJ-28330835 | 888072-47-7 | Reference compound |
| HY-124881 | Scandoside | 18842-99-4 | Natural Products |
| HY-124882 | Dienestrol diacetate | 84-19-5 | Reference compound |
| HY-124883 | R-(–)-Flecainide | 99495-90-6 | Reference compound |
| HY-124887 | L 651142 | 99046-40-9 | Reference compound |
| HY-124889 | Dimethenamid | 87674-68-8 | Reference compound |
| HY-12489 | Ponceau S | 6226-79-5 | Dye Reagents |
| HY-124890 | Thr101 | 727664-79-1 | Reference compound |
| HY-124891 | 1-Phenylpyrrole | 635-90-5 | Reference compound |
| HY-124891S | 1-Phenylpyrrole-d9 | | Isotope-Labeled Compounds |
| HY-124892A | Acetylethylcholine mustard (hydrochloride) | 103994-00-9 | Reference compound |
| HY-124894 | (+)-Benalaxyl | 97716-85-3 | Reference compound |
| HY-124896 | Bonannione A | 97126-57-3 | Natural Products |
| HY-124899 | Hh-Ag1.5 | 612542-14-0 | Reference compound |
| HY-12489A | Ponceau S, BS | 6226-79-5 | Dye Reagents |
| HY-124901 | Tetrasul | 2227-13-6 | Reference compound |
| HY-124901R | Tetrasul (Standard) | 2227-13-6 | Reference Standards |
| HY-124902 | Valclavam | 98359-78-5 | Natural Products |
| HY-124905 | MCI-176 | 103315-31-7 | Reference compound |
| HY-124906 | JAMI1001A | 1001019-46-0 | Reference compound |
| HY-124908 | HT1042 | 23589-77-7 | Reference compound |
| HY-124909 | (6R)-FR054 | 10378-06-0 | Reference compound |
| HY-124909A | FR054 | 35954-65-5 | Reference compound |
| HY-12491 | PIK-C98 | 691388-62-2 | Reference compound |
| HY-124910 | BU-E-75 | 114667-74-2 | Reference compound |
| HY-124911 | LY53857 (free base) | 32896-53-0 | Reference compound |
| HY-124915 | Netzahualcoyondiol | 113579-08-1 | Natural Products |
| HY-124916 | Lycopsamine | 10285-07-1 | Natural Products |
| HY-124916R | Lycopsamine (Standard) | 10285-07-1 | Reference Standards |
| HY-124918 | Cremastranone | 107585-69-3 | Reference compound |
| HY-124919 | JJO-1 | 16722-44-4 | Reference compound |
| HY-12492 | VER-246608 | 1684386-71-7 | Reference compound |
| HY-124920S | Methiocarb-d3 | 1581694-94-1 | Isotope-Labeled Compounds |
| HY-124923 | Lupulone | 468-28-0 | Natural Products |
| HY-124923R | Lupulone (Standard) | 468-28-0 | Reference Standards |
| HY-124925 | Vincanol | 19877-89-5 | Reference compound |
| HY-124926 | S23757 | 208718-14-3 | Reference compound |
| HY-124927 | ARN14988 | 1502027-70-4 | Reference compound |
| HY-124929 | Mimocin | 76177-28-1 | Reference compound |
| HY-12493 | LY-2584702 (free base) | 1082949-67-4 | Reference compound |
| HY-124938 | ABC-1 | 309735-05-5 | Reference compound |
| HY-124939 | ND-322 (hydrochloride) | 1333379-23-9 | Reference compound |
| HY-12493A | LY-2584702 (tosylate salt) | 1082949-68-5 | Reference compound |
| HY-12493B | LY-2584702 (hydrochloride) | 1082948-81-9 | Reference compound |
| HY-12494 | LDC1267 | 1361030-48-9 | Reference compound |
| HY-124941 | 7-Deacetylgedunin | 10314-90-6 | Reference compound |
| HY-124944 | APS6-45 | 2188236-41-9 | Reference compound |
| HY-124946 | C1A | 1021463-02-4 | Reference compound |
| HY-124947 | PF-4522654 | 1065109-28-5 | Reference compound |
| HY-12495 | ISRIB (trans-isomer) | 1597403-47-8 | Reference compound |
| HY-124950 | Picumeterol | 130641-36-0 | Reference compound |
| HY-124950A | (+)-Picumeterol | 139423-79-3 | Reference compound |
| HY-124951 | Arctiol | 36061-11-7 | Natural Products |
| HY-124952 | iKIX1 | 656222-54-7 | Reference compound |
| HY-124953 | 7,3',4'-Trihydroxyisoflavone | 485-63-2 | Reference compound |
| HY-124954 | MN-25 | 501926-82-5 | Reference compound |
| HY-124955 | proTAME | 1362911-19-0 | Reference compound |
| HY-124956 | GIV3727 | 957136-80-0 | Reference compound |
| HY-124957 | β-NETA | 31059-54-8 | Reference compound |
| HY-124958 | NDMC101 | 1308631-40-4 | Reference compound |
| HY-124959 | Spiradoline (mesylate) | 87173-97-5 | Reference compound |
| HY-12495A | ISRIB | 548470-11-7 | Biochemical Assay Reagents |
| HY-12496 | NS-1619 | 153587-01-0 | Reference compound |
| HY-124960 | CTPB | 586976-24-1 | Reference compound |
| HY-124962 | D-NMAPPD | 35922-06-6 | Reference compound |
| HY-12497 | ANA-12 | 219766-25-3 | Reference compound |
| HY-12498 | GV-58 | 1402821-41-3 | Reference compound |
| HY-124984 | ML353 | 2990506-75-5 | Reference compound |
| HY-124987 | MRS4458 | 2225834-49-9 | Reference compound |
| HY-12499 | (S)-Willardiine | 21416-43-3 | Reference compound |
| HY-124996 | (Rac)-ZLc-002 | | Reference compound |
| HY-125001 | JH-VIII-49 | 2209084-73-9 | Reference compound |
| HY-125006 | TRi-1 | 246020-68-8 | Reference compound |
| HY-12501 | ITI-214 (free base) | 1160521-50-5 | Reference compound |
| HY-125010 | Dicycloplatin | 287402-09-9 | Reference compound |
| HY-125012 | MAP4K4-IN-3 | 1811510-58-3 | Reference compound |
| HY-125016 | TT-10 | 2230640-94-3 | Reference compound |
| HY-125017 | Bozitinib | 1440964-89-5 | Reference compound |
| HY-125018 | QM31 | 937735-00-7 | Reference compound |
| HY-125019 | iJak-381 | 1831144-46-7 | Reference compound |
| HY-12501A | ITI-214 | 1642303-38-5 | Reference compound |
| HY-12502 | Efonidipine | 111011-63-3 | Reference compound |
| HY-125020 | NCGC00135472 | 862811-76-5 | Reference compound |
| HY-125021 | 2BAct | 2143542-28-1 | Reference compound |
| HY-125025 | SMI 6860766 | 433234-16-3 | Reference compound |
| HY-125026 | MyomiRs-IN-1 | 1392224-59-7 | Reference compound |
| HY-125027 | Isobutyl-deoxynyboquinone | 1430798-22-3 | Reference compound |
| HY-125028 | Hck-IN-1 | 1473404-51-1 | Reference compound |
| HY-12502A | Efonidipine (hydrochloride monoethanolate) | 111011-76-8 | Reference compound |
| HY-12502B | Efonidipine (hydrochloride) | 111011-53-1 | Reference compound |
| HY-12503 | CFM-2 | 178616-26-7 | Reference compound |
| HY-125033 | EIDD-1931 | 3258-02-4 | Reference compound |
| HY-125033S1 | EIDD-1931-d2 | 1955549-12-8 | Isotope-Labeled Compounds |
| HY-125035 | LCH-7749944 | 796888-12-5 | Reference compound |
| HY-125036 | MitoBloCK-11 | 413606-16-3 | Reference compound |
| HY-125039 | N-Acetyl lysyltyrosylcysteine amide | 1287585-40-3 | Reference compound |
| HY-12504 | Pyr6 | 245747-08-4 | Reference compound |
| HY-125040 | Isariin C | 80111-96-2 | Reference compound |
| HY-125042 | Sarothralin G | 130756-15-9 | Natural Products |
| HY-125043 | SKF-75670 (hydrobromide) | 62717-63-9 | Reference compound |
| HY-125045 | Kahweol eicosanoate | 108214-32-0 | Natural Products |
| HY-125046 | CYM50374 | 1314212-81-1 | Reference compound |
| HY-125047 | Daledalin tosylate | 23226-37-1 | Reference compound |
| HY-125048 | Racemomycin B | 3776-37-2 | Natural Products |
| HY-125049 | Kijanimicin | 78798-08-0 | Reference compound |
| HY-12505 | CX546 | 215923-54-9 | Reference compound |
| HY-125050 | KCA-1490 | 909719-71-7 | Reference compound |
| HY-125051 | SG3-179 | 1877286-78-6 | Reference compound |
| HY-125053 | Batifiban | 710312-77-9 | Peptides |
| HY-125053A | Batifiban (TFA) | | Peptides |
| HY-125054 | Kelletinin A | 112727-22-7 | Reference compound |
| HY-125058 | Kinamycin C | 35303-08-3 | Natural Products |
| HY-125059 | PTC-510 (free base) | 865531-74-4 | Reference compound |
| HY-12506 | Naspm | 122306-11-0 | Reference compound |
| HY-125060 | Viridicatin | 129-24-8 | Natural Products |
| HY-125061 | Hydroxythiohomosildenafil | 479073-82-0 | Reference compound |
| HY-125062 | Steviolmonoside | 60129-60-4 | Reference compound |
| HY-125064 | AP22408 | 268741-43-1 | Reference compound |
| HY-125065 | MK-4541 | 796885-38-6 | Reference compound |
| HY-125066 | Reveromycin B | 144860-68-4 | Reference compound |
| HY-125067 | Yadanzioside P | 79439-84-2 | Natural Products |
| HY-125068 | RPR203494 | 218160-26-0 | Reference compound |
| HY-12506A | Naspm (trihydrochloride) | 1049731-36-3 | Reference compound |
| HY-12507 | GSK-7975A | 1253186-56-9 | Reference compound |
| HY-125070 | Saframycin C | 66082-29-9 | Natural Products |
| HY-125072 | Arabinose 1,5-diphosphate | 93132-85-5 | Reference compound |
| HY-125074 | PNU 142300 | 368891-69-4 | Reference compound |
| HY-125075 | PD 165929 | 185215-75-2 | Reference compound |
| HY-125079 | DSP-2230 | 1233231-30-5 | Reference compound |
| HY-12508 | CMPDA | 380607-77-2 | Reference compound |
| HY-125080 | BIBS-222 | 142023-57-2 | Reference compound |
| HY-125083 | Lys-D-Pro-Thr | 117027-34-6 | Peptides |
| HY-125084 | NEU617 | 1432450-82-2 | Reference compound |
| HY-125085 | ALDH3A1-IN-3 | 315239-63-5 | Reference compound |
| HY-125086 | Leustroducsin B | 145142-82-1 | Natural Products |
| HY-125087 | A-304121 | 360551-71-9 | Reference compound |
| HY-125088 | Oleoylestrone | 180003-17-2 | Reference compound |
| HY-125088S | Oleoylestrone-d4 | 443791-75-1 | Isotope-Labeled Compounds |
| HY-12509 | PEPA | 141286-78-4 | Reference compound |
| HY-125090 | PHA-680626 | 398493-74-8 | Reference compound |
| HY-125091 | LY2066948 | 648904-56-7 | Reference compound |
| HY-125092 | Drimentine C | 204398-92-5 | Reference compound |
| HY-125095 | Yonkenafil (hydrochloride) | 804519-64-0 | Reference compound |
| HY-125096 | C108297 | 864972-30-5 | Reference compound |
| HY-125097 | 5'-Hydroxy-staurosporine | 308847-74-7 | Reference compound |
| HY-125098 | Illudin S | 1149-99-1 | Natural Products |
| HY-125099 | AFM-30a | 2095107-57-4 | Reference compound |
| HY-125099A | AFM-30a (hydrochloride) | | Reference compound |
| HY-12510 | Methoxy-PEPy | 524924-76-3 | Reference compound |
| HY-125100 | Loroglossin | 58139-22-3 | Natural Products |
| HY-125101A | Rafutrombopag (diolamine) | 1257792-42-9 | Reference compound |
| HY-125102 | AZ12253801 | 851432-37-6 | Reference compound |
| HY-125104 | Mirosamicin | 73684-69-2 | Natural Products |
| HY-125108 | PHPS1 (sodium) | 1177131-02-0 | Reference compound |
| HY-12511 | SKF-86002 | 72873-74-6 | Reference compound |
| HY-125111 | PSB-SB-487 | 1399049-81-0 | Reference compound |
| HY-125112 | Vicenin-1 | 35927-38-9 | Natural Products |
| HY-125114 | Jatrophane 4 | 210108-88-6 | Natural Products |
| HY-125115 | Jatrophane 3 | 210108-87-5 | Natural Products |
| HY-125116 | Jatrophane 2 | 210108-86-4 | Natural Products |
| HY-125117 | Simocyclinone D8 | 301845-97-6 | Natural Products |
| HY-125118 | GSK-A1 | 1416334-69-4 | Reference compound |
| HY-12512 | cGAMP | 849214-04-6 | Reference compound |
| HY-125120 | Kansuiphorin C | 133898-77-8 | Natural Products |
| HY-125121 | Esculentoside C | 65931-92-2 | Natural Products |
| HY-125122 | Mulberrofuran A | 68978-04-1 | Natural Products |
| HY-125123 | Euchrestaflavanone A | 80510-05-0 | Natural Products |
| HY-125124 | Chamaejasmenin D | 865852-47-7 | Natural Products |
| HY-125125 | Danshenxinkun D | 98873-76-8 | Natural Products |
| HY-125127 | Danshenxinkun C | 65907-77-9 | Natural Products |
| HY-125128 | Glp-Pro-Val-pNA | 83329-36-6 | Peptides |
| HY-125129 | Carlinoside | 59952-97-5 | Natural Products |
| HY-12513 | Samotolisib | 1386874-06-1 | Reference compound |
| HY-125130 | Hesperetin 7-O-glucoside | 31712-49-9 | Natural Products |
| HY-125131 | Buddlejasaponin IV | 139523-30-1 | Natural Products |
| HY-125132 | Agelastatin A | 152406-28-5 | Reference compound |
| HY-125134 | Alloaromadendrene | 25246-27-9 | Natural Products |
| HY-125135 | (-)-β-Peltatin | 518-29-6 | Natural Products |
| HY-125138 | ω-Muricholic Acid | 6830-03-1 | Natural Products |
| HY-125138S | ω-Muricholic Acid-d5 | 2725726-64-5 | Isotope-Labeled Compounds |
| HY-125138S1 | ω-Muricholic acid-d4 | | Isotope-Labeled Compounds |
| HY-125139 | omega-3 Arachidonic acid ethyl ester, in ethanol, 98% | 123940-93-2 | Biochemical Assay Reagents |
| HY-12514 | NK3201 | 204460-24-2 | Reference compound |
| HY-125140 | ω-3 Arachidonic acid | 24880-40-8 | Natural Products |
| HY-125140S | ω-3 Arachidonic Acid-d8 | 2692624-30-7 | Isotope-Labeled Compounds |
| HY-125141 | δ-CEHC | 84599-16-6 | Reference compound |
| HY-125143 | ABC34 | 1831135-56-8 | Reference compound |
| HY-125144 | BIIB 513 | 265986-98-9 | Reference compound |
| HY-125145 | AA92593 | 457961-34-1 | Reference compound |
| HY-125146 | BMD4503-2 | 301357-87-9 | Reference compound |
| HY-125147 | A-1293201 | 1375557-33-7 | Reference compound |
| HY-125148 | AQ148 | 178820-70-7 | Reference compound |
| HY-12515 | Nicardipine | 55985-32-5 | Reference compound |
| HY-125150 | AL-3138 | 64603-03-8 | Reference compound |
| HY-125151 | BP-1-108 | 1334492-85-1 | Reference compound |
| HY-125152 | Candicidin D | 39372-30-0 | Reference compound |
| HY-125153 | Bursin | 60267-34-7 | Peptides |
| HY-125153A | Bursin (triacetate) | 136994-55-3 | Reference compound |
| HY-125156 | Dapagliflozin-3-O-β-D-glucuronide | 1351438-75-9 | Reference compound |
| HY-125157 | Me-Indoxam | 172732-62-6 | Reference compound |
| HY-125158 | HOI-07 | 1451013-67-4 | Reference compound |
| HY-125158A | (E/Z)-HOI-07 | 1606160-40-0 | Reference compound |
| HY-125159 | Derquantel | 187865-22-1 | Reference compound |
| HY-12515A | Nicardipine (hydrochloride) | 54527-84-3 | Reference compound |
| HY-12515AR | Nicardipine (hydrochloride) (Standard) | 54527-84-3 | Reference Standards |
| HY-12515AS | Nicardipine-d3 (hydrochloride) | 1432061-50-1 | Isotope-Labeled Compounds |
| HY-12515AS2 | Nicardipine-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-12515B | (S)-Nicardipine | 76093-36-2 | Reference compound |
| HY-12515C | (R)-Nicardipine | 76093-35-1 | Reference compound |
| HY-12515CS1 | (R)-Nicardipine-d3 | | Isotope-Labeled Compounds |
| HY-12516 | Desogestrel | 54024-22-5 | Reference compound |
| HY-125161 | MT0703 | 108353-14-6 | Reference compound |
| HY-125163 | MM 47755 | 117620-87-8 | Natural Products |
| HY-125165 | SLC5111312 (hydrochloride) | 1870811-01-0 | Reference compound |
| HY-125166 | DB04760 | 544678-85-5 | Reference compound |
| HY-125167 | WOBE437 | 2108100-73-6 | Reference compound |
| HY-125168 | EGA | 415687-81-9 | Reference compound |
| HY-125169 | NSC 185058 | 39122-38-8 | Reference compound |
| HY-12516R | Desogestrel (Standard) | 54024-22-5 | Reference Standards |
| HY-12517 | GNE-293 | 1354955-67-1 | Reference compound |
| HY-125170 | Galiellalactone | 133613-71-5 | Natural Products |
| HY-125171 | IAXO-102 | 1115270-63-7 | Reference compound |
| HY-125172 | PolyQ aggregation inhibitor C2-8 | 300670-16-0 | Reference compound |
| HY-125176 | G907 | 2244035-16-1 | Reference compound |
| HY-12518 | OF-1 | 919973-83-4 | Reference compound |
| HY-125182 | SMCypI C31 | 2649904-85-6 | Reference compound |
| HY-125183 | BMS-818251 | 2974489-09-1 | Reference compound |
| HY-12519 | Oltipraz | 64224-21-1 | Reference compound |
| HY-125191 | BRD1991 | 2235468-02-5 | Reference compound |
| HY-125197 | BRD5631 | 2446154-91-0 | Reference compound |
| HY-12519G | Oltipraz (GMP) | 64224-21-1 | GMP Small Molecules |
| HY-12519S | Oltipraz-d3 | 2012598-51-3 | Isotope-Labeled Compounds |
| HY-125202 | KuWal151 | 2341841-06-1 | Reference compound |
| HY-125203 | PV-1019 | 1093793-05-5 | Reference compound |
| HY-125209 | TH5427 | 2253744-56-6 | Reference compound |
| HY-125209A | TH5427 (hydrochloride) | 2253744-57-7 | Reference compound |
| HY-12520A | SKF 38393 (hydrochloride) | 62717-42-4 | Reference compound |
| HY-12520B | (R)-SKF 38393 (hydrochloride) | 81702-42-3 | Reference compound |
| HY-12521 | GSK-5498A | 1253186-49-0 | Reference compound |
| HY-125218 | PARP11 inhibitor ITK7 | 2411890-36-1 | Reference compound |
| HY-12522 | PF-06380101 | 1436391-86-4 | ADC Related |
| HY-125221 | DJ4 | 1681020-24-5 | Reference compound |
| HY-125222 | Drp1-IN-1 | 2247733-08-8 | Reference compound |
| HY-12522S | PF-06380101-d8 | | Isotope-Labeled Compounds |
| HY-12523 | Peptide M | 110652-62-5 | Peptides |
| HY-125232 | MS645 | 2250091-96-2 | Reference compound |
| HY-125236 | BET-IN-19 | 1643947-30-1 | Reference compound |
| HY-12524 | Bikinin | 188011-69-0 | Reference compound |
| HY-125244 | LEM-14-1189 | 2987501-17-5 | Reference compound |
| HY-12525 | LGD-6972 | 1207989-09-0 | Reference compound |
| HY-125254 | LEI110 | 2313525-90-3 | Reference compound |
| HY-125257 | SHP2 inhibitor LY6 | 2296718-09-5 | Reference compound |
| HY-125259 | SHP504 | 2222280-83-1 | Reference compound |
| HY-12525A | LGD-6972 (sodium) | 1207989-22-7 | Reference compound |
| HY-125260 | SHP844 | 2222280-82-0 | Reference compound |
| HY-125263 | OP-1074 | 1443752-76-8 | Reference compound |
| HY-125263B | (R)-OP-1074 | 1443752-77-9 | Reference compound |
| HY-125265 | JTP-117968 | 2250132-99-9 | Reference compound |
| HY-125269 | TED-347 | 2378626-29-8 | Reference compound |
| HY-12527 | Pyridoclax | 1651890-44-6 | Reference compound |
| HY-125273 | DNS-pE | 2196245-98-2 | Reference compound |
| HY-125276 | TH5487 | 2304947-71-3 | Reference compound |
| HY-125278 | OGT-IN-4 | 2411972-44-4 | Reference compound |
| HY-125279 | OAT-2068 | 2221950-65-6 | Reference compound |
| HY-12528 | DBPR108 | 1186426-66-3 | Reference compound |
| HY-125283 | IM176OUT05 | 1643659-96-4 | Reference compound |
| HY-125284 | Sphynolactone-7 | 2305752-57-0 | Reference compound |
| HY-125286 | AB-680 | 2105904-82-1 | Reference compound |
| HY-125286A | AB-680 (ammonium) | | Reference compound |
| HY-125287 | (Rac)-Minzasolmin | 1802518-63-3 | Reference compound |
| HY-12529 | Ro-3306 | 872573-93-8 | Reference compound |
| HY-125290 | MU1210 | 2275601-87-9 | Reference compound |
| HY-125292 | NV03 | 2448341-58-8 | Reference compound |
| HY-125295 | Leucokinin I | 104600-89-7 | Peptides |
| HY-125296 | Fipronil sulfone | 120068-36-2 | Reference compound |
| HY-125296R | Fipronil sulfone (Standard) | 120068-36-2 | Reference Standards |
| HY-125296S | Fipronil sulfone-13C6 | | Isotope-Labeled Compounds |
| HY-125298 | Cycloaspeptide A | 109171-13-3 | Natural Products |
| HY-12530 | Velpatasvir | 1377049-84-7 | Reference compound |
| HY-125300 | Oligomycin E | 110231-34-0 | Reference compound |
| HY-125301 | Thymoctonan | 107489-37-2 | Reference compound |
| HY-125304 | L 363851 | 100807-53-2 | Reference compound |
| HY-125305 | Z-AEVD-FMK | 1135688-47-9 | Reference compound |
| HY-125306 | Rotihibin A | 142689-34-7 | Natural Products |
| HY-125309 | ABT-299 | 161395-35-3 | Reference compound |
| HY-12530R | Velpatasvir (Standard) | 1377049-84-7 | Reference Standards |
| HY-12530S1 | Velpatasvir-d3 | | Isotope-Labeled Compounds |
| HY-12530S3 | Velpatasvir-13C,d3 | | Isotope-Labeled Compounds |
| HY-12531 | Encainide (hydrochloride) | 66794-74-9 | Reference compound |
| HY-125311 | Zaragozic acid D | 155179-14-9 | Natural Products |
| HY-125314 | AG-041R | 159883-95-1 | Reference compound |
| HY-125316 | AMG-151 | 1138669-65-4 | Reference compound |
| HY-125319 | Amidepsine A | 169181-28-6 | Natural Products |
| HY-12532 | Astemizole | 68844-77-9 | Reference compound |
| HY-125321 | Lychnostatin 2 | 128700-84-5 | Natural Products |
| HY-125322 | Reveromycin C | 144860-69-5 | Reference compound |
| HY-125323 | 6-Hydroxykaempferol 3,6-diglucoside | 142674-16-6 | Natural Products |
| HY-125324 | Squalestatin 3 | 142505-92-8 | Natural Products |
| HY-125325 | Deoxymulundocandin | 138626-63-8 | Natural Products |
| HY-125326 | Spinosyn D | 131929-63-0 | Reference compound |
| HY-125327 | YM-543 | 1610007-47-0 | Reference compound |
| HY-12532R | Astemizole (Standard) | 68844-77-9 | Reference Standards |
| HY-12533 | Disopyramide | 3737-09-5 | Reference compound |
| HY-125330 | Denagliptin (tosylate) | 811432-66-3 | Reference compound |
| HY-125331 | DRF-1042 | 200619-13-2 | ADC Related |
| HY-125335 | Oligomycin D | 1404-59-7 | Reference compound |
| HY-125338 | Psammaplysene B | 865722-85-6 | Reference compound |
| HY-125339 | Ro 41-0960 | 125628-97-9 | Reference compound |
| HY-12533A | Disopyramide (phosphate) | 22059-60-5 | Reference compound |
| HY-12533B | Disopyramide (hydrochloride) | 54687-36-4 | Reference compound |
| HY-12533R | Disopyramide (Standard) | 3737-09-5 | Reference Standards |
| HY-12534 | Wiskostatin | 253449-04-6 | Reference compound |
| HY-125340 | Sarcinapterin | 89157-12-0 | Natural Products |
| HY-125341 | Microginin 527 | 1135249-50-1 | Reference compound |
| HY-125344 | Fusarisetin A | 1300041-53-5 | Natural Products |
| HY-125346 | Lactoferroxin A | 117667-25-1 | Reference compound |
| HY-125347 | TA-993 | 150591-06-3 | Reference compound |
| HY-125348 | 6α-Hydroxy paclitaxel | 153212-75-0 | Reference compound |
| HY-125348S | 6α-Hydroxy Paclitaxel-d5 | 1315376-90-9 | Isotope-Labeled Compounds |
| HY-125349 | A-83016F | 142435-72-1 | Reference compound |
| HY-12535 | Trichodesmine | 548-90-3 | Natural Products |
| HY-125350 | Entacapone acid | 160391-70-8 | Reference compound |
| HY-125351 | SPT-IN-1 | 1933533-18-6 | Reference compound |
| HY-125354 | Limonin glucoside | 123564-61-4 | Natural Products |
| HY-125355 | SEC | 1802997-81-4 | Reference compound |
| HY-125357 | Ternatin | 148619-41-4 | Reference compound |
| HY-125358 | Dactylfungin B | 146935-36-6 | Natural Products |
| HY-125360 | Mazipredone (free base) | 13085-08-0 | Reference compound |
| HY-125361 | Ganosporeric acid A | 135357-25-4 | Natural Products |
| HY-125365 | Rifamycin S | 13553-79-2 | Natural Products |
| HY-125365R | Rifamycin S (Standard) | 13553-79-2 | Reference Standards |
| HY-125366 | ARI-3099 | 1432499-49-4 | Reference compound |
| HY-125368 | LB30870 | 1583240-63-4 | Reference compound |
| HY-12537 | Peptide 401 | 32908-73-9 | Peptides |
| HY-125370S | Phenylephrine glucuronide-d3 | | Isotope-Labeled Compounds |
| HY-125371 | 2'-C-Methyladenosine | 15397-12-3 | Reference compound |
| HY-125372 | 2-Amino benzamidoxime | 16348-49-5 | Reference compound |
| HY-125374 | Larotaxel | 156294-36-9 | Reference compound |
| HY-125374A | Larotaxel (dihydrate) | 192573-38-9 | Reference compound |
| HY-125375 | L-662583 | 119731-75-8 | Reference compound |
| HY-125376 | PI3Kδ-IN-3 | 1431540-99-6 | Reference compound |
| HY-125377 | Leustroducsin C | 145142-83-2 | Natural Products |
| HY-125378 | SBP-0636457 | 1422180-49-1 | Reference compound |
| HY-125378A | (7R)-SBP-0636457 | 1422180-61-7 | Reference compound |
| HY-12538 | Graveoline | 485-61-0 | Reference compound |
| HY-125381 | CFTR corrector 2 | 1628416-28-3 | Reference compound |
| HY-125382 | L-797591 | 217480-24-5 | Reference compound |
| HY-125383 | ZK118182 Isopropyl ester | 154927-31-8 | Reference compound |
| HY-125384 | ARN14686 | 1628345-10-7 | Reference compound |
| HY-125385 | Sulforhodamine 101 DHPE | 187099-99-6 | Dye Reagents |
| HY-125386 | SQ 32056 | 139113-49-8 | Reference compound |
| HY-125387 | TOP1210 | 1628439-59-7 | Reference compound |
| HY-125388 | Martinomycin | 160791-16-2 | Natural Products |
| HY-12539 | Fluorocurarine (chloride) | 22273-09-2 | Reference compound |
| HY-125390 | SM-360320 | 226907-52-4 | Reference compound |
| HY-125392 | 2-(Biotin-amido)-1,3-bis-(C1-PEG1-acid) | 2086689-02-1 | Reference compound |
| HY-125393 | Leustroducsin A | 145142-81-0 | Natural Products |
| HY-125394 | 9(R)-HODE cholesteryl ester | 330800-93-6 | Reference compound |
| HY-125395 | Altromycin G | 134887-79-9 | Natural Products |
| HY-125396 | 11-Deoxyprostaglandin F2β | 37786-07-5 | Reference compound |
| HY-125399 | PSMA-11 | 1366302-52-4 | Reference compound |
| HY-125400 | Zaragozic acid C | 146389-62-0 | Natural Products |
| HY-125402 | GSK-843 | 1601496-05-2 | Reference compound |
| HY-125407 | Palmitoyl serinol | 126127-31-9 | Reference compound |
| HY-125407S | Palmitoyl serinol-d5 | 946524-35-2 | Isotope-Labeled Compounds |
| HY-125408 | Maresin conjugates in tissue regeneration 1 | 1784701-61-6 | Reference compound |
| HY-125409 | Lysinoalanine | 18810-04-3 | Reference compound |
| HY-125409A | (S,R)-Lysinoalanine | 63121-95-9 | Reference compound |
| HY-125410 | Promothiocin A | 156737-05-2 | Natural Products |
| HY-125411 | Berninamycin D | 161263-50-9 | Natural Products |
| HY-125412 | Fasciculic acid B | 126882-55-1 | Natural Products |
| HY-125414 | Lydicamycin | 133352-27-9 | Natural Products |
| HY-125415 | PF-4693627 | 1312815-93-2 | Reference compound |
| HY-125416 | Streptothricin F | 3808-42-2 | Reference compound |
| HY-125419 | Amythiamicin B | 156620-48-3 | Natural Products |
| HY-12542 | Dantrolene | 7261-97-4 | Reference compound |
| HY-125420 | 5-Deazaisofolic acid | 130327-67-2 | Reference compound |
| HY-125422 | Matlystatin A | 140626-94-4 | Natural Products |
| HY-125424 | AM8191 (hydrochloride) | 1417548-17-4 | Reference compound |
| HY-125427 | SKOG102 | 21062-28-2 | Reference compound |
| HY-125429 | Lokysterolamine B | 159934-15-3 | Natural Products |
| HY-12542A | Dantrolene (sodium hemiheptahydrate) | 24868-20-0 | Reference compound |
| HY-12542AR | Dantrolene (sodium hemiheptahydrate) (Standard) | 24868-20-0 | Reference Standards |
| HY-12542R | Dantrolene (Standard) | 7261-97-4 | Reference Standards |
| HY-12542S | Dantrolene-13C3 | 1185234-99-4 | Isotope-Labeled Compounds |
| HY-125430 | Padanamide A | 1314881-80-5 | Reference compound |
| HY-125432 | Poststatin | 135219-43-1 | Reference compound |
| HY-125433 | A-75925 | 129467-48-7 | Reference compound |
| HY-125434 | Laccaic acid B | 17249-00-2 | Natural Products |
| HY-125437 | 3-Epidehydrotumulosic acid | 167775-54-4 | Natural Products |
| HY-125439 | Squalestatin 2 | 142505-91-7 | Reference compound |
| HY-125441 | L-732531 | 148365-48-4 | Reference compound |
| HY-125443 | Lucialdehyde A | 420781-84-6 | Natural Products |
| HY-125445 | PCTR1 | 1810710-59-8 | Reference compound |
| HY-125446S | 2-Hydroxymethyl olanzapine-d3 | 1190006-36-0 | Isotope-Labeled Compounds |
| HY-125449 | Fasciculic acid C | 126882-56-2 | Reference compound |
| HY-12545 | Brevetoxin-3 | 85079-48-7 | Natural Products |
| HY-125452 | DiSBAC10 | 169211-45-4 | Dye Reagents |
| HY-125453 | Symplostatin 1 | 212007-18-6 | Natural Products |
| HY-125455 | Ro 41-1879 | 141916-35-0 | Reference compound |
| HY-125457 | α-Naphtholbenzein | 145-50-6 | Dye Reagents |
| HY-125458 | Iromycin A | 213137-53-2 | Natural Products |
| HY-12546 | Brevetoxin B | 79580-28-2 | Natural Products |
| HY-125461 | Altersolanol A | 22268-16-2 | Natural Products |
| HY-125463 | ANQ9040 | 142021-80-5 | Reference compound |
| HY-125465 | SLLN-15 | 2403650-93-9 | Reference compound |
| HY-125466 | cRIPGBM | 2361988-76-1 | Reference compound |
| HY-125469 | ICA-105665 | 2694728-63-5 | Reference compound |
| HY-12547 | Betonicine | 515-25-3 | Natural Products |
| HY-125471 | VK-1727 | | Reference compound |
| HY-125473 | IDX375 | 1162665-52-2 | Reference compound |
| HY-125474 | Carrageenan | 9000-07-1 | Biochemical Assay Reagents |
| HY-125475 | Rivipansel | 927881-99-0 | Reference compound |
| HY-125486 | Reversin 121 | 174630-04-7 | Peptides |
| HY-125487 | Appenolide A | 148077-10-5 | Reference compound |
| HY-125488 | Unguisin B | 226956-07-6 | Peptides |
| HY-125490 | Shermilamine B | 122271-41-4 | Natural Products |
| HY-125494 | Droxinavir (hydrochloride) | 155662-50-3 | Reference compound |
| HY-125495 | Telmesteine | 122946-43-4 | Reference compound |
| HY-125496 | A201A | 37305-78-5 | Natural Products |
| HY-12550 | GW542573X | 660846-41-3 | Reference compound |
| HY-125501 | Biotin-XX hydrazide | 211237-33-1 | Biochemical Assay Reagents |
| HY-125505 | BI-11634 | 1622159-00-5 | Reference compound |
| HY-125506 | NP-G2-044 | 1807454-59-6 | Reference compound |
| HY-125508 | CCD-3693 | 162883-07-0 | Reference compound |
| HY-125510 | UNC2541 | 1612782-86-1 | Reference compound |
| HY-125511 | Chaetoviridin A | 128252-98-2 | Natural Products |
| HY-125512 | Saccharocarcin B | 158475-33-3 | Reference compound |
| HY-125515 | Tetrahydroharmine | 17019-01-1 | Natural Products |
| HY-125516 | MCTR3 | 1784701-63-8 | Reference compound |
| HY-125518 | Xanthomegnin | 1685-91-2 | Natural Products |
| HY-125522 | Methyl helicterate | 102637-02-5 | Natural Products |
| HY-125523 | Fumiquinazoline D | 140715-86-2 | Natural Products |
| HY-125524 | Antibacterial agent 199 | 1629166-56-8 | Natural Products |
| HY-125527 | Resolvin D1 | 872993-05-0 | Natural Products |
| HY-125527A | 17(R)-Resolvin D1 | 528583-91-7 | Reference compound |
| HY-125527AS | 17(R)-Resolvin D1-d5 | | Isotope-Labeled Compounds |
| HY-125527S | Resolvin D1-d5 | 1881277-32-2 | Isotope-Labeled Compounds |
| HY-125528 | Ro 09-1679 | 141426-89-3 | Reference compound |
| HY-125529 | DMPAC-Chol | 184582-91-0 | Biochemical Assay Reagents |
| HY-125530 | Platycoside A | 209404-00-2 | Natural Products |
| HY-125531 | Dactylorhin A | 256459-34-4 | Natural Products |
| HY-125532 | 3-O-cis-p-Coumaroyltormentic acid | 121072-40-0 | Natural Products |
| HY-125534 | Tos-PEG9-Boc | 1345337-28-1 | Reference compound |
| HY-125535 | OSU-53 | 1290069-19-0 | Reference compound |
| HY-125538 | Deoxybrevianamide E | 34610-68-9 | Natural Products |
| HY-125539 | Roridin E | 16891-85-3 | Natural Products |
| HY-12554 | Terlipressin | 14636-12-5 | Reference compound |
| HY-125540 | Saussureamine C | 148245-83-4 | Natural Products |
| HY-125541 | DBCO-NHCO-PEG4-acid | 1870899-46-9 | ADC Related |
| HY-125542 | DCZ3301 | 2136278-38-9 | Reference compound |
| HY-125543 | Karsoside | 149155-50-0 | Natural Products |
| HY-125544 | LY 295427 | 152755-31-2 | Reference compound |
| HY-125545 | Cynanester A | 143502-52-7 | Natural Products |
| HY-125546 | Erythromycin C | 1675-02-1 | Natural Products |
| HY-125546R | Erythromycin C (Standard) | 1675-02-1 | Reference Standards |
| HY-125548 | Antradion | 19854-90-1 | Reference compound |
| HY-12554A | Terlipressin (diacetate) | 1884420-36-3 | Reference compound |
| HY-12554B | Terlipressin (acetate) | 914453-96-6 | Reference compound |
| HY-125550 | Doramectin aglycone | 1987883-26-0 | Reference compound |
| HY-125551 | L-687908 | 132565-33-4 | Reference compound |
| HY-125552 | Chlorothricin | 34707-92-1 | Reference compound |
| HY-125553 | Hexapeptide-10 | 146439-94-3 | Peptides |
| HY-125554 | KDdiA-PC | 439904-34-4 | Reference compound |
| HY-125555 | Azosulfamide | 133-60-8 | Reference compound |
| HY-125556 | Tetragastrin | 1947-37-1 | Peptides |
| HY-125557 | Lauroguadine (hydrochloride) | 135-42-2 | Reference compound |
| HY-125558 | PT150 | 189035-07-2 | Reference compound |
| HY-125559 | Jesaconitine | 16298-90-1 | Natural Products |
| HY-125560 | Leucomycin A1 | 16846-34-7 | Reference compound |
| HY-125561 | Josamycin propionate | 31674-19-8 | Reference compound |
| HY-125561R | Josamycin propionate (Standard) | 31674-19-8 | Reference Standards |
| HY-125563 | 13,14-Dehydro-15-cyclohexyl carbaprostacyclin | 145375-81-1 | Reference compound |
| HY-125564 | Acetyltrialanine | 19245-85-3 | Natural Products |
| HY-125567 | Antileukinate | 138559-60-1 | Peptides |
| HY-125568 | Pyridoxatin | 135529-30-5 | Natural Products |
| HY-125569 | Leucomycin A5 | 18361-45-0 | Biochemical Assay Reagents |
| HY-12557 | γ-Glutamylvaline | 2746-34-1 | Natural Products |
| HY-125570 | Ginsenoside Rs3 | 194861-70-6 | Natural Products |
| HY-125571 | A 74704 | 129467-45-4 | Reference compound |
| HY-125572 | Gibberellin A7 | 510-75-8 | Natural Products |
| HY-125575 | FC11409B | 1380411-57-3 | Reference compound |
| HY-125576 | Griselimycin | 26034-16-2 | Reference compound |
| HY-125579 | Ro 25-0534 | 143488-32-8 | Reference compound |
| HY-12558 | LY3009120 | 1454682-72-4 | Reference compound |
| HY-125580 | Makaluvamine A | 146555-78-4 | Reference compound |
| HY-125582 | Enmenol | 28957-06-4 | Natural Products |
| HY-125583 | Ketodieldrin | 21038-31-3 | Reference compound |
| HY-125586 | β-Amanitin | 21150-22-1 | ADC Related |
| HY-125587 | 25-Desacetyl rifampicin | 16783-99-6 | Reference compound |
| HY-125587S | 25-Desacetyl Rifampicin-d3 | 2714485-01-3 | Isotope-Labeled Compounds |
| HY-125587S1 | 25-Desacetyl rifampicin-d4 | 2747918-77-8 | Isotope-Labeled Compounds |
| HY-125588 | Chromium picolinate | 14639-25-9 | Reference compound |
| HY-125588R | Chromium picolinate (Standard) | 14639-25-9 | Reference Standards |
| HY-12559 | Alisporivir | 254435-95-5 | Reference compound |
| HY-125592 | Calyxin H | 202596-22-3 | Natural Products |
| HY-125593 | Dasminapant | 1570231-89-8 | Reference compound |
| HY-125594 | T-1095A | 209746-56-5 | Reference compound |
| HY-125596 | Lachnumon | 150671-02-6 | Reference compound |
| HY-125597 | Glabrocoumarone A | 178330-48-8 | Natural Products |
| HY-125598 | Secologanin | 19351-63-4 | Natural Products |
| HY-12560 | PNU-282987 (free base) | 711085-63-1 | Reference compound |
| HY-125600 | LY219703 | 156281-08-2 | Reference compound |
| HY-125602 | MNI-444 | 1974301-94-4 | Reference compound |
| HY-125603 | Termitomycamide B | 1254277-89-8 | Natural Products |
| HY-125604 | WCK-4234 | 1804915-68-1 | Reference compound |
| HY-125605 | Nannochelin A | 133705-25-6 | Reference compound |
| HY-125606 | Amphocil | 120895-52-5 | Reference compound |
| HY-125608 | Tiacumicin C | 106008-70-2 | Natural Products |
| HY-12560A | PNU-282987 | 123464-89-1 | Reference compound |
| HY-12560C | (S)-PNU-282987 (hydrochloride) | 128311-08-0 | Reference compound |
| HY-12560D | PNU-282987 (S enantiomer free base) | 737727-12-7 | Reference compound |
| HY-125610 | DA-3934 | 183176-50-3 | Reference compound |
| HY-125611 | Fluorogestone acetate | 2529-45-5 | Reference compound |
| HY-125612 | Artonin E | 129683-93-8 | Natural Products |
| HY-125615 | DMP 728 (methanesulfonate) | 155158-97-7 | Reference compound |
| HY-125616 | Biotinoyl tripeptide-1 | 299157-54-3 | Peptides |
| HY-125617 | α-Lipomycin | 51053-40-8 | Natural Products |
| HY-125618 | Lankacidinol A | 23498-36-4 | Reference compound |
| HY-125619 | 1,2-Dioctanoyl-sn-glycero-3-phosphocholine | 19191-91-4 | Biochemical Assay Reagents |
| HY-125620 | Rubiginone D2 | 274913-71-2 | Natural Products |
| HY-125623 | MitoPerOx | 1392820-50-6 | Dye Reagents |
| HY-125625 | ES 6864 | 116326-39-7 | Reference compound |
| HY-125626 | 8-iso-15-keto Prostaglandin F2α | 191919-01-4 | Reference compound |
| HY-125628 | Kahalalide A | 179733-11-0 | Reference compound |
| HY-125629 | Primordazine B | 339337-07-4 | Reference compound |
| HY-125630 | Decacyclene | 191-48-0 | Reference compound |
| HY-125631 | Cyclothialidine | 147214-63-9 | Reference compound |
| HY-125632 | Ro 19-9638 | 116370-29-7 | Reference compound |
| HY-125633 | Kapurimycin A3 | 129966-45-6 | Natural Products |
| HY-125636 | Mycro1 | 313987-85-8 | Reference compound |
| HY-125637 | Venturicidin B | 33538-72-6 | Reference compound |
| HY-125639 | (rac)-AR-13503 | 1254032-16-0 | Reference compound |
| HY-12564 | Phthalazinone pyrazole | 880487-62-7 | Reference compound |
| HY-125641 | AL-34662 | 210580-75-9 | Reference compound |
| HY-125643 | Pitavastatin lactone | 141750-63-2 | Reference compound |
| HY-125643R | Pitavastatin lactone (Standard) | 141750-63-2 | Reference Standards |
| HY-125644 | L-Lombricine | 18416-85-8 | Reference compound |
| HY-125645 | M122 | 2127411-50-9 | Reference compound |
| HY-125647 | 10-Deazaaminopterin | 52454-37-2 | Reference compound |
| HY-125648 | Euphorbadienol | 566-14-3 | Natural Products |
| HY-125649 | Delphinidin 3,5-diglucoside | 17670-06-3 | Natural Products |
| HY-125650 | Pseudouridimycin | 1566586-52-4 | Natural Products |
| HY-125650A | Pseudouridimycin (TFA) | 2760807-99-4 | Reference compound |
| HY-125652 | Macrosphelide A | 172923-77-2 | Natural Products |
| HY-125653 | Kapurimycin A2 | 132412-64-7 | Natural Products |
| HY-125654 | Olanexidine | 146510-36-3 | Reference compound |
| HY-125654A | Olanexidine (hydrochloride) | 146509-94-6 | Reference compound |
| HY-125654B | Olanexidine (hydrochloride semihydrate) | 218282-71-4 | Reference compound |
| HY-125654C | Olanexidine (gluconate) | 799787-53-4 | Reference compound |
| HY-125655 | UNC-4219 (TFA) | 1872382-50-7 | Reference compound |
| HY-125656 | Bostrycin | 21879-81-2 | Natural Products |
| HY-125658 | Biotinyl tyramide | 41994-02-9 | Dye Reagents |
| HY-125658S | Biotinyl tyramide-d4 | | Isotope-Labeled Compounds |
| HY-125660 | Leucettamol A | 151124-32-2 | Reference compound |
| HY-125662A | BMX-001 | 1379783-91-1 | Reference compound |
| HY-125664 | Lucialdehyde B | 480439-84-7 | Natural Products |
| HY-125665 | Pheophorbide A | 15664-29-6 | Natural Products |
| HY-125665R | Pheophorbide A (Standard) | 15664-29-6 | Reference Standards |
| HY-125666 | Agistatin B | 144096-46-8 | Natural Products |
| HY-125667 | PA1 | 1620951-72-5 | Reference compound |
| HY-125668 | Ro 43-5054 | 138107-58-1 | Reference compound |
| HY-125669 | XR 3054 | 247090-97-7 | Reference compound |
| HY-12567 | ML375 | 1488362-55-5 | Reference compound |
| HY-125670 | Lanceolarin | 15914-68-8 | Natural Products |
| HY-125671 | Triarachidin | 620-64-4 | Natural Products |
| HY-125673 | AC-178335 | 212966-15-9 | Reference compound |
| HY-125676 | Thermopterin | 135745-46-9 | Natural Products |
| HY-125677 | SHetA2 | 361483-66-1 | Reference compound |
| HY-125678 | Jasmine lactone | 25524-95-2 | Natural Products |
| HY-125678S | Jasmine lactone-d2 | | Isotope-Labeled Compounds |
| HY-12567A | (R)-ML375 | 1488362-56-6 | Reference compound |
| HY-125682 | Amphotericin A | 1405-32-9 | Reference compound |
| HY-125684 | Trichodecenin I | 141024-74-0 | Natural Products |
| HY-125685 | Germacrene D | 23986-74-5 | Natural Products |
| HY-125686 | Beesioside Q | 261767-91-3 | Natural Products |
| HY-125687 | N,N'-suberoyldiglycylglycine | 143673-93-2 | Reference compound |
| HY-125690 | Thielocin B1 | 144118-26-3 | Reference compound |
| HY-125691 | LY-338979 | 193281-00-4 | Reference compound |
| HY-125692 | L-740093 | 154967-59-6 | Reference compound |
| HY-125693 | L685818 | 143839-74-1 | Reference compound |
| HY-125694 | MFB-1041 | 151856-47-2 | Reference compound |
| HY-125695 | Loxitalamic acid | 28179-44-4 | Reference compound |
| HY-125698 | 3-Deoxyaphidicolin | 85483-00-7 | Natural Products |
| HY-125699 | Ochratoxin C | 4865-85-4 | Natural Products |
| HY-12570 | CK2-IN-9 | 1461658-58-1 | Reference compound |
| HY-125700 | Baogongteng A | 74239-84-2 | Natural Products |
| HY-125701 | A-76154 | 136989-30-5 | Reference compound |
| HY-125702 | Pulsatilloside E | 366814-43-9 | Natural Products |
| HY-125703 | Ferutinin | 41743-44-6 | Natural Products |
| HY-125705 | Herquline A | 71812-08-3 | Natural Products |
| HY-125706 | 1233B | 34668-61-6 | Natural Products |
| HY-125707 | Concanamycin B | 81552-33-2 | Natural Products |
| HY-125712 | CGP 53820 | 149267-24-3 | Reference compound |
| HY-125713 | Ganoderic acid Y | 86377-52-8 | Natural Products |
| HY-125715 | Trigalacturonic acid | 6037-45-2 | Biochemical Assay Reagents |
| HY-125716 | DRF-2519 (free base) | 194713-46-7 | Reference compound |
| HY-125717 | VU0029251 | 330819-85-7 | Reference compound |
| HY-125719 | Clevudine triphosphate | 174625-00-4 | Reference compound |
| HY-12572 | TIE-2/VEGFR-2 kinase-IN-2 | 501693-48-7 | Reference compound |
| HY-125720 | A-39183A | 79426-51-0 | Natural Products |
| HY-125721 | Tetranactin | 33956-61-5 | Natural Products |
| HY-125723 | Echinocandin B | 54651-05-7 | Reference compound |
| HY-125726 | Sulfo galactosylceramide | 151057-28-2 | Reference compound |
| HY-125727 | Globosuxanthone A | 917091-74-8 | Natural Products |
| HY-125728 | Micrococcin P1 | 67401-56-3 | Reference compound |
| HY-125729 | Ivermectin B1b | 70209-81-3 | Natural Products |
| HY-125730 | Kibdelone A | 934464-77-4 | Natural Products |
| HY-125731 | Glycodeoxycholic Acid | 360-65-6 | Natural Products |
| HY-125731R | Glycodeoxycholic Acid (Standard) | 360-65-6 | Reference Standards |
| HY-125731S | Glycodeoxycholic acid-d4 | 1069132-37-1 | Isotope-Labeled Compounds |
| HY-125731S1 | Glycodeoxycholic acid-d6 | 2483831-98-5 | Isotope-Labeled Compounds |
| HY-125732 | Decarestrictine D | 127393-89-9 | Natural Products |
| HY-125733 | Thiocillin I | 59979-01-0 | Reference compound |
| HY-125734 | DMHAPC-Chol | 774598-29-7 | Biochemical Assay Reagents |
| HY-125735 | Sch725674 | 877061-66-0 | Natural Products |
| HY-125737 | 15-deoxy-Δ12,14-Prostaglandin J2 Glutathione | 537695-15-1 | Reference compound |
| HY-125738 | Obscurolide A1 | 144397-99-9 | Reference compound |
| HY-125740 | Malvidin-3-glucoside (chloride) | 7228-78-6 | Natural Products |
| HY-125740R | Malvidin-3-glucoside (chloride) (Standard) | 7228-78-6 | Reference Standards |
| HY-125741 | GW768505A (free base) | 501693-25-0 | Reference compound |
| HY-125743 | S-1 Methanandamide | 157182-50-8 | Reference compound |
| HY-125744 | Palmitoyl thio-PC | 113881-60-0 | Reference compound |
| HY-125745 | Loloatin B 10 | 182422-45-3 | Peptides |
| HY-125746 | BODIPY-Cholesterol | 878557-19-8 | Dye Reagents |
| HY-125747 | Actinomycin X2 | 18865-48-0 | Peptides |
| HY-125748 | CBM-301940 | 902146-11-6 | Reference compound |
| HY-125750 | Coumarin 7 | 27425-55-4 | Dye Reagents |
| HY-125751 | UCSF924 | 1434515-70-4 | Reference compound |
| HY-125759 | 3-Phenyltoxoflavin | 32502-63-9 | Reference compound |
| HY-125762 | Tyrosinase-IN-16 | 126651-85-2 | Reference compound |
| HY-12577 | TNKS1/2-IN-1 | 1498300-31-4 | Reference compound |
| HY-125770 | 5(S)-HPETE | 71774-08-8 | Reference compound |
| HY-125771 | 1-Stearoyl-sn-glycero-3-phosphocholine | 19420-57-6 | Biochemical Assay Reagents |
| HY-125771S | 1-Stearoyl-sn-glycero-3-phosphocholine-d35 | 327178-92-7 | Isotope-Labeled Compounds |
| HY-125772 | Acetyl podocarpic acid anhydride | 344327-48-6 | Reference compound |
| HY-125773 | β-cyano-L-Alanine | 6232-19-5 | Reference compound |
| HY-125774 | Bimatoprost acid | 38344-08-0 | Reference compound |
| HY-125774S | Bimatoprost acid-d4 | 58976-50-4 | Isotope-Labeled Compounds |
| HY-125775 | 12(S)-Hydroxy-16-heptadecynoic acid | 148019-74-3 | Reference compound |
| HY-125776 | Kresoxim-methyl | 143390-89-0 | Reference compound |
| HY-125776R | Kresoxim-methyl (Standard) | 143390-89-0 | Reference Standards |
| HY-125777A | α-Conotoxin Vc1.1 (TFA) | | Peptides |
| HY-125778 | Cochlioquinone B | 32450-26-3 | Reference compound |
| HY-125780 | 5-Phenylhydantoin | 89-24-7 | Reference compound |
| HY-125780R | 5-Phenylhydantoin (Standard) | 89-24-7 | Reference Standards |
| HY-125782 | 15(R)-15-Methyl prostaglandin D2 | 210978-26-0 | Reference compound |
| HY-125783 | 1-Palmitoyl-sn-glycero-3-phosphocholine | 17364-16-8 | Reference compound |
| HY-125783S | 1-Palmitoyl-sn-glycero-3-phosphocholine-d9 | 1872379-72-0 | Isotope-Labeled Compounds |
| HY-125783S1 | 1-Palmitoyl-sn-glycero-3-phosphocholine-d31 | 327178-91-6 | Isotope-Labeled Compounds |
| HY-125783S2 | 1-Palmitoyl-sn-glycero-3-phosphocholine-d49 | 2315262-40-7 | Isotope-Labeled Compounds |
| HY-125783S3 | 1-Palmitoyl-sn-glycero-3-phosphocholine-d9-1 | 182257-09-6 | Isotope-Labeled Compounds |
| HY-125784 | Viloxazine (hydrochloride) | 35604-67-2 | Reference compound |
| HY-125784A | (R)-Viloxazine (hydrochloride) | 56287-63-9 | Reference compound |
| HY-125784AS | (R)-Viloxazine-d5 (hydrochloride) | 1246815-04-2 | Isotope-Labeled Compounds |
| HY-125784B | (S)-Viloxazine (hydrochloride) | 56287-61-7 | Reference compound |
| HY-125784BS | (S)-Viloxazine-d5 (hydrochloride) | 1246816-39-6 | Isotope-Labeled Compounds |
| HY-125784S | (rac)-Viloxazine-d5 (hydrochloride) | 1276483-10-3 | Isotope-Labeled Compounds |
| HY-125785A | 2-Mercaptopyridine N-oxide (sodium) | 3811-73-2 | Reference compound |
| HY-125786 | Solvent violet 9 | 467-63-0 | Reference compound |
| HY-125787 | MLS000389544 | 573965-48-7 | Reference compound |
| HY-125789 | PF-04753299 | 1289620-49-0 | Reference compound |
| HY-12579 | RO 2468 | 1360821-21-1 | Reference compound |
| HY-125791 | cis-Epoxysuccinic acid | 16533-72-5 | Reference compound |
| HY-125792 | Nexinhib20 | 331949-35-0 | Reference compound |
| HY-125796 | U-14624 | 14901-16-7 | Reference compound |
| HY-125798 | 2,3-Dehydro-2-deoxy-N-acetylneuraminic acid | 24967-27-9 | Reference compound |
| HY-12580 | RO5353 | 1360821-61-9 | Reference compound |
| HY-125801 | 3-Oxo-5β-cholanoic acid | 1553-56-6 | Reference compound |
| HY-125801R | 3-Oxo-5β-cholanoic acid (Standard) | 1553-56-6 | Reference Standards |
| HY-125802 | Monolauryl phosphate | 2627-35-2 | Biochemical Assay Reagents |
| HY-125809 | 4-(1-Phenylethyl)resorcinol | 85-27-8 | Biochemical Assay Reagents |
| HY-125810 | 4'-Ethynyl-2'-deoxyadenosine | 306305-07-7 | Reference compound |
| HY-125814 | 2-Chloro-N6-furfuryladenine | 101862-47-9 | Reference compound |
| HY-125815 | Reactive Blue 4 | 13324-20-4 | Dye Reagents |
| HY-125817 | BI-3406 | 2230836-55-0 | Reference compound |
| HY-125818 | Cytidine-5'-triphosphate | 65-47-4 | Oligonucleotides |
| HY-125818B | Cytidine-5'-triphosphate (sodium hydrate) | 123334-07-6 | Biochemical Assay Reagents |
| HY-125818C | Cytidine-5'-triphosphate (disodium hydrate) | 652154-13-7 | Reference compound |
| HY-125818S1 | Cytidine-5′-triphosphate-d14 (disodium) | | Isotope-Labeled Compounds |
| HY-125818S2 | Cytidine-5'-triphosphate-13C,d1 (dilithium) | | Isotope-Labeled Compounds |
| HY-125818S3 | Cytidine-5'-triphosphate-13C9 (dilithium) | | Isotope-Labeled Compounds |
| HY-125818S4 | Cytidine-5'-triphosphate-d14 (dilithium) | | Isotope-Labeled Compounds |
| HY-125818S5 | Cytidine-5'-triphosphate-15N3,d14 (dilithium) | | Isotope-Labeled Compounds |
| HY-125818S6 | Cytidine-5'-triphosphate-15N3 (dilithium) | | Isotope-Labeled Compounds |
| HY-125819 | Sigma-1 receptor antagonist 2 | 1639220-15-7 | Reference compound |
| HY-125820 | Sigma-1 receptor antagonist 3 | 1639220-17-9 | Reference compound |
| HY-125821 | Sigma-1 receptor antagonist 1 | 1639220-19-1 | Reference compound |
| HY-125824 | Danuglipron | 2230198-02-2 | Reference compound |
| HY-125824A | Danuglipron (tromethamine) | 2230198-03-3 | Reference compound |
| HY-125825 | Pseudoginsenoside Rh2 | 1370264-16-6 | Reference compound |
| HY-125825A | (Z)-Pseudoginsenoside Rh2 | 1636114-55-0 | Natural Products |
| HY-125826 | Heptasaccharide Glc4Xyl3 | 121591-98-8 | Natural Products |
| HY-125827 | 13-Methylberberine (chloride) | 54260-72-9 | Natural Products |
| HY-125828 | 1-(3,4-Dimethoxycinnamoyl)piperidine | 128261-84-7 | Reference compound |
| HY-12583 | A-366 | 1527503-11-2 | Reference compound |
| HY-125830 | ITIC | 1664293-06-4 | Reference compound |
| HY-125831 | ITIC-4F | 2097998-59-7 | Reference compound |
| HY-125832 | PBDB-T | 1415929-80-4 | Reference compound |
| HY-125833 | Alpha-Naphthoflavone | 604-59-1 | Natural Products |
| HY-125834 | GMB-475 | 2490599-18-1 | Reference compound |
| HY-125835 | CP-10 | 2366268-80-4 | Reference compound |
| HY-125836 | CCR4 antagonist 2 | 2206788-99-8 | Reference compound |
| HY-125837 | MS31 | 2366264-12-0 | Reference compound |
| HY-125837A | MS31 (trihydrochloride) | 2748239-18-9 | Reference compound |
| HY-125838 | J30-8 | 2366255-71-0 | Reference compound |
| HY-125839 | OP-3633 | 2102494-14-2 | Reference compound |
| HY-12584 | PF-5190457 | 1334782-79-4 | Reference compound |
| HY-125840 | Belzutifan | 1672668-24-4 | Reference compound |
| HY-125841 | EGFR mutant-IN-1 | | Reference compound |
| HY-125843 | Pomalidomide-PEG1-C2-N3 | 2271036-44-1 | Reference compound |
| HY-125844 | Tos-PEG1-O-CH2COOH | | Reference compound |
| HY-125845 | (S,R,S)-AHPC | 1448297-52-6 | Reference compound |
| HY-125845A | (S,S,S)-AHPC (hydrochloride) | 2115897-23-7 | Reference compound |
| HY-125846 | (S,R,S)-AHPC-PEG1-OTs | | Reference compound |
| HY-125847 | Salvianolic acid F | 158732-59-3 | Natural Products |
| HY-125848 | Ginsenoside F2 | 62025-49-4 | Natural Products |
| HY-125848R | Ginsenoside F2 (Standard) | 62025-49-4 | Reference Standards |
| HY-125849 | Chrysin 7-O-beta-gentiobioside | 88640-89-5 | Natural Products |
| HY-12585 | AM-4668 | 1011531-27-3 | Reference compound |
| HY-125850 | Berberrubine (chloride) | 15401-69-1 | Natural Products |
| HY-125850R | Berberrubine (chloride) (Standard) | 15401-69-1 | Reference Standards |
| HY-125851 | TP-008 | 1976038-41-1 | Reference compound |
| HY-125853 | Phosphatidylcholines,soya | 97281-47-5 | Oligonucleotides |
| HY-125854 | Phosphatidylcholines, egg | 97281-44-2 | Natural Products |
| HY-125856 | Milvexian | 1802425-99-5 | Reference compound |
| HY-125856A | Milvexian (TFA) | 1802426-00-1 | Reference compound |
| HY-125857 | Cytochrome C | 9007-43-6 | Biochemical Assay Reagents |
| HY-125857A | Cytochrome C (equine heart) | 9007-43-6 | Biochemical Assay Reagents |
| HY-125857B | Cytochrome C (Saccharomyces cerevisiae) | 9007-43-6 | Biochemical Assay Reagents |
| HY-125857C | Cytochrome C (bovine heart) | 9007-43-6 | Biochemical Assay Reagents |
| HY-125858 | MI-1061 | 1410737-34-6 | Reference compound |
| HY-125858A | MI-1061 (TFA) | 1410737-35-7 | Reference compound |
| HY-125858B | (S,R,S)-MI-1061 | 1410738-90-7 | ADC Related |
| HY-125859 | Peroxidase, Horseradish | 9003-99-0 | Enzyme |
| HY-125859A | Myeloperoxidase, human white blood cells | 9003-99-0 | Enzyme |
| HY-125859B | Lactoperoxidase, bovine milk | 9003-99-0 | Enzyme |
| HY-12586 | AZD6564 | 1251841-50-5 | Reference compound |
| HY-125860 | Tyrosinase, Mushroom | 9002-10-2 | Enzyme |
| HY-125861 | Methyl cellulose | 9004-67-5 | Biochemical Assay Reagents |
| HY-125861A | Methyl cellulose(Viscosity:15mPa.s) | 9004-67-5 | Biochemical Assay Reagents |
| HY-125861B | Methyl cellulose(Viscosity:400mPa.s) | 9004-67-5 | Biochemical Assay Reagents |
| HY-125861C | Methyl cellulose(Viscosity:1500mPa.s) | 9004-67-5 | Biochemical Assay Reagents |
| HY-125861D | Methyl cellulose(Viscosity:40000mPa.s) | 9004-67-5 | Reference compound |
| HY-125861E | Methyl cellulose(Viscosity:4000mPa.s) | 9004-67-5 | Biochemical Assay Reagents |
| HY-125861H | Methyl cellulose(Viscosity:25mPa.s) | 9004-67-5 | Biochemical Assay Reagents |
| HY-125862 | Glutathione Reductase, baker's yeast | 9001-48-3 | Enzyme |
| HY-125863 | Glucose-6-phosphate dehydrogenase, Microorganism | 9001-40-5 | Enzyme |
| HY-125863A | Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) | 9001-40-5 | Enzyme |
| HY-125863B | Glucose 6-phosphate dehydrogenase (yeast, recombinant) | 9001-40-5 | Enzyme |
| HY-125863C | Glucose-6-phosphate dehydrogenase, Bacillus sp. | 9001-40-5 | Enzyme |
| HY-125864 | Fibrinogen (Bovine) | 9001-32-5 | Biochemical Assay Reagents |
| HY-125864A | Canine Fibrinogen | 9001-32-5 | Enzyme |
| HY-125864B | Murine Fibrinogen | 9001-32-5 | Enzyme |
| HY-125864C | Porcine Fibrinogen | 9001-32-5 | Enzyme |
| HY-125864D | Rabbit Fibrinogen | 9001-32-5 | Enzyme |
| HY-125865 | Casein | 9000-71-9 | Biochemical Assay Reagents |
| HY-125868 | Penethamate (hydriodide) | 808-71-9 | Reference compound |
| HY-125870 | Gellan gum, for cell culture | 71010-52-1 | Biochemical Assay Reagents |
| HY-125872 | KRAS G12C inhibitor 14 | 2349393-95-7 | Reference compound |
| HY-125873 | KRAS G12C inhibitor 15 | 2349393-21-9 | Reference compound |
| HY-125874 | KRAS G12C inhibitor 16 | 2349392-79-4 | Reference compound |
| HY-125875 | KRAS G12C inhibitor 17 | 2349393-04-8 | Reference compound |
| HY-125876 | PROTAC Bcl2 degrader-1 | 2378801-85-3 | Reference compound |
| HY-125877 | PROTAC Mcl1 degrader-1 | 2163793-38-0 | Reference compound |
| HY-125878 | PROTAC SGK3 degrader-1 | 2381320-35-8 | Reference compound |
| HY-125879 | DS08210767 | 2376334-75-5 | Reference compound |
| HY-12588 | Thiamet G | 1009816-48-1 | Reference compound |
| HY-125880 | SBI-553 | 1849603-72-0 | Reference compound |
| HY-125881 | ASP1126 | 1228580-11-7 | Reference compound |
| HY-125883 | Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc | 2435720-04-8 | Reference compound |
| HY-125884 | Pomalidomide-amido-C4-amido-C6-NH-Boc | 2435808-02-7 | Reference compound |
| HY-125887 | Boc-NH-PEG2-C2-amido-C4-acid | 1310327-20-8 | Reference compound |
| HY-125888 | Boc-NH-C6-amido-C4-acid | 10436-21-2 | Reference compound |
| HY-12589 | ZM39923 (hydrochloride) | 1021868-92-7 | Reference compound |
| HY-12589A | ZM39923 | 273727-89-2 | Reference compound |
| HY-12590 | Glutathione oxidized (disodium) | 103239-24-3 | Peptides |
| HY-125900 | Neocarzilin A | 124958-29-8 | Natural Products |
| HY-125904 | 4-Hydroxyretinoic acid | 66592-72-1 | Reference compound |
| HY-125905 | VH032-cyclopropane-F | 2306193-99-5 | Reference compound |
| HY-125906 | VHL Ligand-Linker Conjugates 15 | 2375564-62-6 | Reference compound |
| HY-125907 | Dox-Ph-PEG1-Cl | 773095-86-6 | Reference compound |
| HY-125908 | A-1210477-piperazinyl | 2351218-72-7 | Reference compound |
| HY-125909 | Phenolic acid | 29656-58-4 | Reference compound |
| HY-12591 | D-Luciferin (sodium) | 103404-75-7 | Dye Reagents |
| HY-125910 | Cholesteryl Linolenate | 2545-22-4 | Reference compound |
| HY-125911 | Gossypin | 652-78-8 | Natural Products |
| HY-125911R | Gossypin (Standard) | 652-78-8 | Reference Standards |
| HY-125913 | Benzamidine | 618-39-3 | Reference compound |
| HY-125916 | Pseurotin A | 58523-30-1 | Natural Products |
| HY-125918 | Bleomycin A5 (hydrochloride) | 55658-47-4 | Natural Products |
| HY-125919 | Vulpinic acid | 521-52-8 | Natural Products |
| HY-12591A | D-Luciferin | 2591-17-5 | Dye Reagents |
| HY-12591B | D-Luciferin (potassium) | 115144-35-9 | Dye Reagents |
| HY-125920 | Lauroylsarcosine (sodium) | 137-16-6 | Biochemical Assay Reagents |
| HY-125920R | Lauroylsarcosine (sodium) (Standard) | 137-16-6 | Reference Standards |
| HY-125921 | WST-3 | 515111-36-1 | Dye Reagents |
| HY-125922 | (22R)-Budesonide | 51372-29-3 | Reference compound |
| HY-125922S | (22R)-Budesonide-d6 | | Isotope-Labeled Compounds |
| HY-125923 | Djenkolic acid | 498-59-9 | Natural Products |
| HY-125924 | DSPE-PEG-Amine, MW 2000 (ammonium) | 474922-26-4 | Biochemical Assay Reagents |
| HY-125926S | 2-Ketodoxapram-d5 | 2407353-31-3 | Isotope-Labeled Compounds |
| HY-125926S1 | 2-Ketodoxapram-d4 | | Isotope-Labeled Compounds |
| HY-125927 | 8-Aminoadenosine | 3868-33-5 | Reference compound |
| HY-125928 | AA43279 | 354812-16-1 | Reference compound |
| HY-125929 | Murexide | 3051-09-0 | Biochemical Assay Reagents |
| HY-12593 | GS967 | 1262618-39-2 | Reference compound |
| HY-125930 | T-2513 | 288247-87-0 | Reference compound |
| HY-125930A | T-2513 (hydrochloride) | 187793-52-8 | Reference compound |
| HY-125931 | Unifiram | 272786-64-8 | Reference compound |
| HY-125932 | Debilon | 26808-51-5 | Natural Products |
| HY-125932A | 9β-Debilon | | Natural Products |
| HY-125933 | Val-Ala-PAB | 1343476-44-7 | Biochemical Assay Reagents |
| HY-125934 | Allocholic acid | 2464-18-8 | Natural Products |
| HY-125938 | Cycloartenyl ferulate | 21238-33-5 | Natural Products |
| HY-125939 | Bortezomib-pinanediol | 205393-22-2 | Reference compound |
| HY-12594 | Paritaprevir | 1216941-48-8 | Reference compound |
| HY-125940 | DPPG | 200880-41-7 | Oligonucleotides |
| HY-125940S | DPPG-d62 | 326495-46-9 | Isotope-Labeled Compounds |
| HY-125941 | PNU-101603 | 168828-60-2 | Reference compound |
| HY-125944 | MitoTEMPO (hydrate) | 1569257-94-8 | Reference compound |
| HY-125945 | Monosulfuron | 155860-63-2 | Reference compound |
| HY-125945R | Monosulfuron (Standard) | 155860-63-2 | Reference Standards |
| HY-125946 | Latanoprost lactone diol | 145667-75-0 | Reference compound |
| HY-125947 | 4-Epioxytetracycline | 14206-58-7 | Reference compound |
| HY-125947R | 4-Epioxytetracycline (Standard) | 14206-58-7 | Reference Standards |
| HY-125949 | Kanshone H | 1445952-33-9 | Natural Products |
| HY-12594A | Paritaprevir (dihydrate) | 1456607-71-8 | Reference compound |
| HY-125954 | Uridine diphosphate glucuronic acid | 2616-64-0 | Biochemical Assay Reagents |
| HY-125954A | Uridine diphosphate glucuronic acid (ammonium) | 43195-60-4 | Biochemical Assay Reagents |
| HY-125954B | UDP-galacturonic acid (trisodium) | 148407-07-2 | Biochemical Assay Reagents |
| HY-125956 | Aurkin A | 1534060-58-6 | Reference compound |
| HY-125957 | A-3 (hydrochloride) | 78957-85-4 | Reference compound |
| HY-125958 | AA9 | 2134114-20-6 | Reference compound |
| HY-125959 | Ucf-101 | 313649-08-0 | Reference compound |
| HY-12596 | JNJ-26489112 | 871824-55-4 | Reference compound |
| HY-125961 | T3Inh-1 | 50440-30-7 | Reference compound |
| HY-125962 | X-34 | 215294-98-7 | Dye Reagents |
| HY-125964 | LLP-3 | 1453835-43-2 | Reference compound |
| HY-125965 | BioA-IN-13 | 1164475-61-9 | Reference compound |
| HY-125966 | AI-4-57 | 63053-14-5 | Reference compound |
| HY-125967 | AM 374 | 86855-26-7 | Reference compound |
| HY-125969 | Rtt109 inhibitor 1 | 852935-07-0 | Reference compound |
| HY-12597 | Quisqualic acid | 52809-07-1 | Natural Products |
| HY-125970 | CRTh2 antagonist 2 | 780763-95-3 | Reference compound |
| HY-125971 | Xylopropamine (hydrobromide) | 861007-60-5 | Reference compound |
| HY-125972 | zr17-2 | 1263893-98-6 | Reference compound |
| HY-125974 | HM03 | 500565-15-1 | Reference compound |
| HY-125974A | HM03 (trihydrochloride) | 1082532-95-3 | Reference compound |
| HY-125975 | 1-Naphthyl 3,5-dinitrobenzoate | 93261-39-3 | Reference compound |
| HY-125976 | ML233 | 2080311-92-6 | Reference compound |
| HY-125978 | JY-3-094 | 389076-27-1 | Reference compound |
| HY-125979 | TSPC | 882286-32-0 | Reference compound |
| HY-12598 | (S)-3,5-DHPG | 162870-29-3 | Reference compound |
| HY-125980 | LX-3 | 380645-50-1 | Reference compound |
| HY-125982 | VUAA1 | 525582-84-7 | Reference compound |
| HY-125986 | GK187 | 1071001-50-7 | Reference compound |
| HY-125987 | RBC6 | 381186-64-7 | Reference compound |
| HY-125989 | 2-Methylthio-AMP | 22140-20-1 | Reference compound |
| HY-125989B | 2-Methylthio-AMP (diTEA) | 1227193-98-7 | Reference compound |
| HY-12598A | DHPG | 146255-66-5 | Reference compound |
| HY-12599 | URMC-099 | 1229582-33-5 | Reference compound |
| HY-125990 | SLC13A5-IN-1 | 2227548-95-8 | Reference compound |
| HY-125996 | NR1H4 activator 1 | 2242855-68-9 | Reference compound |
| HY-125997 | BTK inhibitor 10 | 2241732-30-7 | Reference compound |
| HY-125999 | EPI-589 | 1147883-03-1 | Reference compound |
| HY-12600 | AZD5582 | 1258392-53-8 | Reference compound |
| HY-126003 | ALDH1A1-IN-2 | 2231081-18-6 | Reference compound |
| HY-126005 | VGSC blocker-1 | 2230472-55-4 | Reference compound |
| HY-12601 | TNKS 22 | 1507362-00-6 | Reference compound |
| HY-126010 | Dooku1 | 2253744-54-4 | Reference compound |
| HY-126015 | P053 | 2748196-63-4 | Reference compound |
| HY-126020 | Bractoppin | 2290527-07-8 | Reference compound |
| HY-126021 | Mobam | 1079-33-0 | Reference compound |
| HY-126025 | α-Phthalimidopropiophenone | 19437-20-8 | Reference compound |
| HY-126026 | NF-κB-IN-17 | 786721-94-6 | Reference compound |
| HY-126027 | (+)-3-Carene | 498-15-7 | Natural Products |
| HY-126028 | (-)-Sotalol | 30236-31-8 | Reference compound |
| HY-126028A | (+)-Sotalol | 30236-32-9 | Reference compound |
| HY-12603 | CCT251455 | 1400284-80-1 | Reference compound |
| HY-126030 | (+)-Syringaresinol | 21453-69-0 | Natural Products |
| HY-126031 | (R)-KT109 | 2055172-60-4 | Reference compound |
| HY-126031A | (S)-KT109 | 2055172-61-5 | Reference compound |
| HY-126032 | Morantel | 20574-50-9 | Reference compound |
| HY-126033 | Sophoranol | 3411-37-8 | Natural Products |
| HY-126034 | 3,4-Dichloroisocoumarin | 51050-59-0 | Reference compound |
| HY-126036 | CH-141 | 78279-88-6 | Reference compound |
| HY-126037 | (±)-ML 209 | 1334526-14-5 | Reference compound |
| HY-126038 | BTS 39542 | 57410-31-8 | Reference compound |
| HY-126039 | L-739758 | 168157-33-3 | Reference compound |
| HY-126041A | (±)10(11)-EpDPA | 895127-65-8 | Natural Products |
| HY-126042 | (±)-Lisofylline | 6493-06-7 | Reference compound |
| HY-126042R | (±)-Lisofylline (Standard) | 6493-06-7 | Reference Standards |
| HY-126042S | (±)-Lisofylline-d6 | 1185995-26-9 | Isotope-Labeled Compounds |
| HY-126042S4 | (±)-Lisofylline-d4 | 1185879-05-3 | Isotope-Labeled Compounds |
| HY-126043 | (R)-Mephenytoin | 71140-51-7 | Reference compound |
| HY-126044 | 6-Hydroxy bexarotene | 368451-07-4 | Reference compound |
| HY-126046 | ACP1b | 1371635-84-5 | Reference compound |
| HY-126047 | (S)-(-)-Anatabine | 581-49-7 | Reference compound |
| HY-126047A | (R,S)-Anatabine | 2743-90-0 | Reference compound |
| HY-126047AR | (R,S)-Anatabine (Standard) | 2743-90-0 | Reference Standards |
| HY-126047AS | (R,S)-Anatabine-d4 | 1020719-11-2 | Isotope-Labeled Compounds |
| HY-126047B | (R)-(+)-Anatabine | 126454-22-6 | Reference compound |
| HY-126048 | JTP-70902 | 871696-49-0 | Reference compound |
| HY-126049 | (S)-Oxiracetam | 88929-35-5 | Reference compound |
| HY-12605 | SAR107375 | 1184300-63-7 | Reference compound |
| HY-126050 | (R)-Pantetheine | 496-65-1 | Reference compound |
| HY-126050R | (R)-Pantetheine (Standard) | 496-65-1 | Reference Standards |
| HY-126050S | (R)-Pantetheine-15N | | Isotope-Labeled Compounds |
| HY-126052 | Gnetol | 86361-55-9 | Natural Products |
| HY-126054 | A1062 | 1821-13-2 | Reference compound |
| HY-126055 | Hadacidin | 689-13-4 | Natural Products |
| HY-126055A | Hadacidin (sodium) | 2618-22-6 | Reference compound |
| HY-126057 | (R)-Praziquantel | 57452-98-9 | Reference compound |
| HY-126057A | (S)-Praziquantel | 57452-97-8 | Reference compound |
| HY-126057AS | (S)-Praziquantel-d11 | | Isotope-Labeled Compounds |
| HY-126057S | (R)-Praziquantel-d11 | 1399880-38-6 | Isotope-Labeled Compounds |
| HY-12605S | SAR107375-d11 (Tartrate) | | Isotope-Labeled Compounds |
| HY-126060 | 9-Ethylguanine | 879-08-3 | Reference compound |
| HY-126061 | 1,7-Dimethyluric acid | 33868-03-0 | Reference compound |
| HY-126061S | 1,7-Dimethyluric acid-d3 | 1189713-08-3 | Isotope-Labeled Compounds |
| HY-126063 | ICI-204448 (free acid) | 125190-72-9 | Reference compound |
| HY-126066 | (-)-Syringaresinol | 6216-81-5 | Natural Products |
| HY-126067 | (-)-Pinoresinol | 81446-29-9 | Natural Products |
| HY-126068 | (S)-Amisulpride | 71675-92-8 | Reference compound |
| HY-126069 | 15(R)-Iloprost | 85026-51-3 | Reference compound |
| HY-12607 | ML251 | 1486482-16-9 | Reference compound |
| HY-126070 | N-Butyl cinnamate | 538-65-8 | Biochemical Assay Reagents |
| HY-126073 | DFP00173 | 672286-03-2 | Reference compound |
| HY-126074 | Z433927330 | 1005883-72-6 | Reference compound |
| HY-126075 | WS-383 (free base) | 2247543-65-1 | Reference compound |
| HY-126075A | WS-383 | 2247544-02-9 | Reference compound |
| HY-126076 | VPC-80051 (racemate) | 877969-69-2 | Reference compound |
| HY-126076A | VPC-80051 | 2410979-04-1 | Reference compound |
| HY-126077 | MTI-31 | 1567915-38-1 | Reference compound |
| HY-12608 | TA-1887 | 1003005-29-5 | Reference compound |
| HY-126081 | (8-epi)-BW 245C | 65705-83-1 | Reference compound |
| HY-126082 | (+)-Carbovir triphosphate | 144606-93-9 | Reference compound |
| HY-126083 | 17β-Hydroxywortmannin | 58053-83-1 | Reference compound |
| HY-126084 | Carbaprostacyclin methyl ester | 69552-55-2 | Reference compound |
| HY-126085 | (±)-Alliin | 17795-26-5 | Natural Products |
| HY-126085R | (±)-Alliin (Standard) | 17795-26-5 | Reference Standards |
| HY-12610 | Carbonic anhydrase inhibitor 27 | 167098-81-9 | Reference compound |
| HY-126106 | (BrMT)2 | 622011-16-9 | Reference compound |
| HY-126107 | (±)-4-Hydroxy propranolol β-D-glucuronide | 94731-13-2 | Reference compound |
| HY-126108 | (±)8-HEPE | 99217-77-3 | Reference compound |
| HY-126108A | 8(S)-HEPE | 118492-81-2 | Reference compound |
| HY-126109 | (±)-8-Prenylnaringenin | 68682-02-0 | Natural Products |
| HY-12611 | Sergliflozin etabonate | 408504-26-7 | Reference compound |
| HY-126110 | (±)11-HDoHE | 87018-59-5 | Natural Products |
| HY-126112 | Mephenoxalone | 70-07-5 | Reference compound |
| HY-126112R | Mephenoxalone (Standard) | 70-07-5 | Reference Standards |
| HY-126113 | KIN101 | 610753-87-2 | Reference compound |
| HY-126114 | Lupeol acetate | 1617-68-1 | Natural Products |
| HY-126115 | 15(S)-Latanoprost | 145773-22-4 | Reference compound |
| HY-126115R | 15(S)-Latanoprost (Standard) | 145773-22-4 | Reference Standards |
| HY-126117 | (+)-Xylariamide A | 852690-88-1 | Reference compound |
| HY-126118 | Dienochlor | 2227-17-0 | Reference compound |
| HY-126119 | 5,10-Dideazafolic acid | 85597-18-8 | Reference compound |
| HY-126121 | 2-Hydroxy Ibuprofen | 51146-55-5 | Natural Products |
| HY-126121R | 2-Hydroxy Ibuprofen (Standard) | 51146-55-5 | Reference Standards |
| HY-126121S | 2-Hydroxy Ibuprofen-d6 | 1217055-71-4 | Isotope-Labeled Compounds |
| HY-126123 | NR2B-selective NMDA receptor antagonist 1 | 457897-92-6 | Reference compound |
| HY-126124 | AP39 | 1429061-80-2 | Reference compound |
| HY-126125 | CHIR-98023 | 252916-76-0 | Reference compound |
| HY-126126 | S-Adenosyl-DL-methionine | 17176-17-9 | Natural Products |
| HY-126127 | BRL 22321 (free base) | 72364-91-1 | Reference compound |
| HY-126128 | Heliotrine | 303-33-3 | Reference compound |
| HY-126129 | Desacetylcefotaxime | 66340-28-1 | Reference compound |
| HY-126129R | Desacetylcefotaxime (Standard) | 66340-28-1 | Reference Standards |
| HY-12613 | 2-C-methylene-myo-inositol oxide | 4068-87-5 | Reference compound |
| HY-126130 | LysRs-IN-2 | 2170696-76-9 | Reference compound |
| HY-126131 | anti-TB agent 1 | 2294013-78-6 | Reference compound |
| HY-126133 | AM-001 | 340817-81-4 | Reference compound |
| HY-126134 | HPGDS inhibitor 2 | 2101626-26-8 | Reference compound |
| HY-126136 | ML303 | 1638211-04-7 | Reference compound |
| HY-126137 | PDE9-IN-1 | 2305087-92-5 | Reference compound |
| HY-12614 | AMG-1694 | 1361217-07-3 | Reference compound |
| HY-126140 | MDRTB-IN-1 | 1973401-05-6 | Reference compound |
| HY-126142 | Top1 inhibitor 1 | 2302772-05-8 | ADC Related |
| HY-126143 | CHMFL-ABL-039 | 2304344-56-5 | Reference compound |
| HY-126144 | GSK-3β inhibitor 1 | 187325-53-7 | Reference compound |
| HY-126144A | (E/Z)-GSK-3β inhibitor 1 | 3367-88-2 | Reference compound |
| HY-126145 | S1PR1 modulator 1 | 2328109-05-1 | Reference compound |
| HY-126146 | PKC-iota inhibitor 1 | 2328094-11-5 | Reference compound |
| HY-126147 | J22352 | 2252395-44-9 | Reference compound |
| HY-126150 | Flucetosulfuron | 412928-75-7 | Reference compound |
| HY-126151 | Heneicomycin | 66170-37-4 | Reference compound |
| HY-126152 | Chlorthiamid | 1918-13-4 | Reference compound |
| HY-126152R | Chlorthiamid (Standard) | 1918-13-4 | Reference Standards |
| HY-126154 | L48H37 | 343307-76-6 | Reference compound |
| HY-126156 | Leucodin | 17946-87-1 | Natural Products |
| HY-126157 | Linearol | 37720-82-4 | Reference compound |
| HY-126158 | SRI-29574 | 1928712-46-2 | Reference compound |
| HY-12616 | ACT-209905 | 1062670-13-6 | Reference compound |
| HY-126160 | CB10-277 | 7203-91-0 | Reference compound |
| HY-126161 | Nonabine | 16985-03-8 | Reference compound |
| HY-126164 | LK 614 | 82461-57-2 | Reference compound |
| HY-126166 | NOC-5 | 146724-82-5 | Reference compound |
| HY-126167 | Deacetylsclerotiorin | 34696-50-9 | Reference compound |
| HY-126169 | L-Glutamine amide | 2013-17-4 | Reference compound |
| HY-126170 | Valanimycin | 101961-60-8 | Natural Products |
| HY-126171 | Hypusine | 34994-11-1 | Reference compound |
| HY-126172 | 9-Anthryldiazomethane | 10401-59-9 | Dye Reagents |
| HY-126175 | Neostigmine (iodide) | 1212-37-9 | Reference compound |
| HY-126176 | Cloransulam-methyl | 147150-35-4 | Reference compound |
| HY-126176R | Cloransulam-methyl (Standard) | 147150-35-4 | Reference Standards |
| HY-126179 | Fenquizone | 20287-37-0 | Reference compound |
| HY-126181 | 5-Formylcytosine | 4425-59-6 | Reference compound |
| HY-126182 | Deacetyldiltiazem | 42399-40-6 | Reference compound |
| HY-126182S | Deacetyldiltiazem-d4 | 112259-40-2 | Isotope-Labeled Compounds |
| HY-126182S3 | Deacetyldiltiazem-d6 (hydrochloride) | 1309283-22-4 | Isotope-Labeled Compounds |
| HY-126182S4 | Desacetyl Diltiazem-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-126184 | Revatropate | 149926-91-0 | Reference compound |
| HY-126185 | Nibroxane | 53983-00-9 | Reference compound |
| HY-12619 | DMT003096 | 912361-26-3 | Reference compound |
| HY-126192 | Pittsburgh Compound B | 566169-93-5 | Reference compound |
| HY-126193 | JS-K | 205432-12-8 | Reference compound |
| HY-126194 | Tolcapone 3-β-D-glucuronide | 204853-33-8 | Natural Products |
| HY-126195 | Fluoflavine | 531-46-4 | Reference compound |
| HY-126198 | Linogliride | 75358-37-1 | Reference compound |
| HY-126198A | Linogliride (fumarate) | 78782-47-5 | Reference compound |
| HY-126199 | Tetrachlorvinphos | 22248-79-9 | Reference compound |
| HY-126199R | Tetrachlorvinphos (Standard) | 22248-79-9 | Reference Standards |
| HY-126200 | Fenpropidin | 67306-00-7 | Reference compound |
| HY-126200R | Fenpropidin (Standard) | 67306-00-7 | Reference Standards |
| HY-126201 | GSK-3 inhibitor 7 | 405221-09-2 | Reference compound |
| HY-126202 | Lachnone A | 903892-99-9 | Natural Products |
| HY-126205 | Deacetyleupaserrin | 38456-39-2 | Natural Products |
| HY-126206 | Quazodine | 4015-32-1 | Reference compound |
| HY-126209 | Isomaltol | 3420-59-5 | Reference compound |
| HY-126210 | GJ072 | 943092-47-5 | Reference compound |
| HY-126211 | KBH-A42 | 798543-50-7 | Reference compound |
| HY-126212 | Isorutarin | 53846-51-8 | Natural Products |
| HY-126213 | 1-Oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine (sodium) | 326589-90-6 | Reference compound |
| HY-126214 | JH-RE-06 | 1361227-90-8 | Reference compound |
| HY-126214S | JH-RE-06-d6 | | Isotope-Labeled Compounds |
| HY-126216 | TAM-IN-2 | 2135642-56-5 | Reference compound |
| HY-126217 | hGPR91 antagonist 1 | 1314796-00-3 | Reference compound |
| HY-126218 | HSV-TK substrate | 111687-37-7 | Reference compound |
| HY-12622 | HSP70-IN-1 | 1268273-90-0 | Reference compound |
| HY-126220 | KMG-301AM | 1372642-77-7 | Dye Reagents |
| HY-126220A | KMG-301AM (TFA) | 1372642-78-8 | Dye Reagents |
| HY-126221A | (R)-Aminocarnitine | 98063-21-9 | Reference compound |
| HY-126221B | (R)-Aminocarnitine (TFA) | | Reference compound |
| HY-126222 | MitoTam (bromide, hydrobromide) | 1634624-73-9 | Reference compound |
| HY-126222A | MitoTam (iodide, hydriodide) | 1634624-74-0 | Reference compound |
| HY-126224 | Driselase, Basidiomycetes sp | 85186-71-6 | Enzyme |
| HY-126225 | SJA710-6 | 1397255-09-2 | Reference compound |
| HY-126226 | MK-6240 Precursor | 1841444-11-8 | Reference compound |
| HY-126230 | PAT-494 | 1781233-84-8 | Reference compound |
| HY-126230A | (Rac)-PAT-494 | 1781233-72-4 | Reference compound |
| HY-126232 | Verproside | 50932-20-2 | Natural Products |
| HY-126233 | PAT-347 | 1689554-51-5 | Reference compound |
| HY-126236 | 3,5-Diiodothyropropionic acid | 1158-10-7 | Reference compound |
| HY-126237 | Acetyllovastatin | 81189-92-6 | Reference compound |
| HY-12624 | Narazaciclib | 1357470-29-1 | Reference compound |
| HY-126241 | RV01 | 1016897-10-1 | Reference compound |
| HY-126242S | Tyk2-IN-7 | 1609391-90-3 | Isotope-Labeled Compounds |
| HY-126244 | CDK4/6-IN-3 | 2366237-37-6 | Reference compound |
| HY-126246 | CDC25B-IN-1 | 2374831-10-2 | Reference compound |
| HY-126247 | BI-2852 | 2375482-51-0 | Reference compound |
| HY-126247B | (R)-BI-2852 | 2375482-49-6 | Reference compound |
| HY-126248 | Tankyrase-IN-2 | 1588870-36-3 | Reference compound |
| HY-126249 | AAPK-25 | 2247919-28-2 | Reference compound |
| HY-12625 | MIV-6 | 1560968-27-5 | Reference compound |
| HY-126250 | NPD-1335 | 2376326-31-5 | Reference compound |
| HY-126251 | CDK9-IN-7 | 2369981-71-3 | Reference compound |
| HY-126252 | A-9758 | 2055271-22-0 | Reference compound |
| HY-126253 | BI-4916 | 2244451-48-5 | Reference compound |
| HY-126254 | BI-4924 | 2244452-09-1 | Reference compound |
| HY-126255 | SBI-797812 | 2237268-08-3 | Reference compound |
| HY-126256 | PRMT5-IN-1 | 2366149-83-7 | Reference compound |
| HY-126256A | PRMT5-IN-1 (hydrochloride) | | Reference compound |
| HY-126257 | AKT-IN-3 | 2374740-21-1 | Reference compound |
| HY-12625A | MIV-6R | 1560968-55-9 | Reference compound |
| HY-126271 | PYCR1-IN-1 | 709-85-3 | Reference compound |
| HY-126275 | HSD1590 | 2379279-96-4 | Reference compound |
| HY-12628 | GNE-618 | 1362151-42-5 | Reference compound |
| HY-126287 | JND4135 | 2366216-76-2 | Reference compound |
| HY-126288 | ASTX029 | 2095719-92-7 | Reference compound |
| HY-12629 | PF470 | 1539296-45-1 | Reference compound |
| HY-126291 | GNE-616 | 2349371-81-7 | Reference compound |
| HY-126292 | KRAS G12C inhibitor 13 | 2241719-75-3 | Reference compound |
| HY-126293 | Apelin agonist 1 | 2227512-85-6 | Reference compound |
| HY-126294 | Londamocitinib | 2241039-81-4 | Reference compound |
| HY-126295 | Anti-parasitic agent 3 | 2366983-10-8 | Reference compound |
| HY-126296 | RIPK1-IN-3 | 2242677-36-5 | Reference compound |
| HY-126297 | c-Fms-IN-10 | 1527517-50-5 | Reference compound |
| HY-126298 | RAF mutant-IN-1 | 2340020-82-6 | Reference compound |
| HY-126299 | NVS-BPTF-1 | 2662454-54-6 | Reference compound |
| HY-126300 | SGC6870 | 2561471-27-8 | Reference compound |
| HY-126300A | SGC6870N | 2561471-15-4 | Reference compound |
| HY-126301 | DMT1 blocker 1 | 1354790-56-9 | Reference compound |
| HY-126302 | DMT1 blocker 2 | 1062648-63-8 | Reference compound |
| HY-126303 | GS-443902 | 1355149-45-9 | Reference compound |
| HY-126303C | GS-443902 (trisodium) | 1355050-21-3 | Reference compound |
| HY-126304 | β-Glycerophosphate (disodium salt hydrate) | 154804-51-0 | Natural Products |
| HY-126304A | Glycerophosphoric acid (disodium salt hydrate) (α and β mixture) | | Reference compound |
| HY-126306 | Deoxyfuconojirimycin (hydrochloride) | 210174-73-5 | Biochemical Assay Reagents |
| HY-126307 | Urolithin B | 1139-83-9 | Natural Products |
| HY-126308 | (E/Z)-DMU2139 | 104890-70-2 | Reference compound |
| HY-12631 | BMS-654457 | 1004551-41-0 | Reference compound |
| HY-126311 | 4-Hydroxyresveratrol | 331443-00-6 | Reference compound |
| HY-126313 | BnOH-NH-bis-(C2-S)-propane-O-isoprene ester | 2448704-23-0 | Reference compound |
| HY-126316 | Zapalog | 1708091-24-0 | Reference compound |
| HY-126319 | SU5204 | 186611-11-0 | Reference compound |
| HY-12632 | GNE 2861 | 1394121-05-1 | Reference compound |
| HY-126320 | EGFR-IN-8 | 2407957-87-1 | Reference compound |
| HY-126321 | RORγt agonist 1 | 2377378-89-5 | Reference compound |
| HY-126322 | DVD-445 | 2375846-41-4 | Reference compound |
| HY-126323 | TCMDC-135051 | 2413716-15-9 | Reference compound |
| HY-126323A | TCMDC-135051 (TFA) | 2571578-55-5 | Reference compound |
| HY-126323B | TCMDC-135051 (hydrochloride) | 2705545-47-5 | Reference compound |
| HY-126324 | IV-23 | 2326007-49-0 | Reference compound |
| HY-126325 | BY27 | 2247236-59-3 | Reference compound |
| HY-126326 | SWE101 | 2376322-12-0 | Reference compound |
| HY-126327 | UNC4976 | 2920299-34-7 | Reference compound |
| HY-126327A | UNC4976 (TFA) | | Reference compound |
| HY-126328 | PKC-theta inhibitor 1 | 1160501-81-4 | Reference compound |
| HY-126329 | AZD9898 | 2042347-69-1 | Reference compound |
| HY-12633 | GS-6620 | 1350735-70-4 | Reference compound |
| HY-126330 | SS-208 | 2245942-72-5 | Reference compound |
| HY-126332 | NED-3238 | 2389062-09-1 | Reference compound |
| HY-126333 | Topoisomerase II inhibitor 1 | 2375613-31-1 | Reference compound |
| HY-12634 | Deleobuvir | 863884-77-9 | Reference compound |
| HY-126346 | DL-175 | 2487253-25-6 | Reference compound |
| HY-126349 | DTSSP Crosslinker | 81069-02-5 | ADC Related |
| HY-12635 | SP2509 | 1423715-09-6 | Reference compound |
| HY-126350 | CL2-SN-38 | 1036969-20-6 | ADC Related |
| HY-126351 | PROTAC ERRα ligand 2 | 2306388-57-6 | Reference compound |
| HY-126353 | Fmoc-Val-Ala-PAB-OH | 1394238-91-5 | ADC Related |
| HY-126354 | Palmitoyldocosahexaenoyl phosphatidylcholine | 59403-54-2 | Reference compound |
| HY-126355 | 4,7,10,13,16-Docosapentaenoic acid | 2313-14-6 | Reference compound |
| HY-126356 | 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine | 35418-59-8 | Reference compound |
| HY-126356S | 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d11 | | Isotope-Labeled Compounds |
| HY-126357 | Palmitoylcarnitine | 1935-18-8 | Reference compound |
| HY-126358 | Acetylcarnitine | 14992-62-2 | Reference compound |
| HY-126359 | 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine | 27098-24-4 | Reference compound |
| HY-12636 | INCB3619 | 791826-72-7 | Reference compound |
| HY-126360 | Oxazolone | 15646-46-5 | Reference compound |
| HY-126361 | ZK824190 | 2254001-81-3 | Reference compound |
| HY-126361A | ZK824190 (hydrochloride) | 2629177-12-2 | Reference compound |
| HY-126362 | ML266 | 1462267-08-8 | Reference compound |
| HY-126363 | Ditiocarb | 147-84-2 | Reference compound |
| HY-126363S | Ditiocarb-d10 | 1261734-83-1 | Isotope-Labeled Compounds |
| HY-126364 | Mc-Val-Ala-PAB | 1870916-87-2 | ADC Related |
| HY-126365 | Alisol B acetate | 19865-76-0 | Natural Products |
| HY-126367 | Light green SF yellowish | 5141-20-8 | Dye Reagents |
| HY-126370 | Geranylgeranyl pyrophosphate | 6699-20-3 | Reference compound |
| HY-126370A | Geranylgeranyl pyrophosphate (triammonium) | 313263-08-0 | Reference compound |
| HY-126373 | SN-38 glucuronide | 121080-63-5 | Reference compound |
| HY-126373S1 | SN-38 glucuronide-13C6 | | Isotope-Labeled Compounds |
| HY-126375 | Cbz-Valaciclovir | 124832-31-1 | Reference compound |
| HY-126375R | Cbz-?Valaciclovir (Standard) | 124832-31-1 | Reference Standards |
| HY-126376 | Iso-H7 (dihydrochloride) | 140663-38-3 | Reference compound |
| HY-126377 | Sulfobetaine 10 | 15163-36-7 | Biochemical Assay Reagents |
| HY-126378 | LSP-249 | 1801253-04-2 | Reference compound |
| HY-126379 | CDDO-2P-Im | 1883650-96-1 | Reference compound |
| HY-12638 | Dichlorophen | 97-23-4 | Reference compound |
| HY-126380 | Nardosinonediol | 20489-11-6 | Natural Products |
| HY-126381 | Boc-N-PEG5-C2-NHS ester | 2055040-78-1 | Reference compound |
| HY-126382 | Hesperidin methylchalcone | 24292-52-2 | Natural Products |
| HY-126383 | Spilanthol | 25394-57-4 | Natural Products |
| HY-126386 | Pectinase, aspergillus niger | 9032-75-1 | Enzyme |
| HY-126386A | Pectinase, aspergillus acne | 9032-75-1 | Enzyme |
| HY-126386B | Pectinase, rhizobia | 9032-75-1 | Enzyme |
| HY-126387 | Moenomycin complex | 11015-37-5 | Reference compound |
| HY-126388 | Trypsin Inhibitor, soybean | 9035-81-8 | Biochemical Assay Reagents |
| HY-126389 | Chitin, from crab carapace (powder) | 1398-61-4 | Biochemical Assay Reagents |
| HY-126389A | Chitin, from shrimp shells (powder) | 1398-61-4 | Biochemical Assay Reagents |
| HY-126389B | Chitin, from shrimp shells (chitinase substrate) | 1398-61-4 | Biochemical Assay Reagents |
| HY-12638R | Dichlorophen (Standard) | 97-23-4 | Reference Standards |
| HY-12639 | Bephenium | 7181-73-9 | Reference compound |
| HY-126390 | (E/Z)-BCI | 15982-84-0 | Reference compound |
| HY-126392 | Isonardoperoxide | 205248-65-3 | Natural Products |
| HY-126393 | Carboxymethyl-β-cyclodextrin, 99% | 218269-34-2 | Biochemical Assay Reagents |
| HY-126394 | Bamocaftor | 2204245-48-5 | Reference compound |
| HY-126394B | Bamocaftor (potassium) | 2204245-47-4 | Reference compound |
| HY-126395 | Patent Blue V (calcium salt) | 3536-49-0 | Dye Reagents |
| HY-126395R | Patent Blue V (calcium salt) (Standard) | 3536-49-0 | Dye Reagents |
| HY-126396 | Sordarin (sodium) | 463356-00-5 | Reference compound |
| HY-126397 | MnTBAP (chloride) | 55266-18-7 | Reference compound |
| HY-126399 | Bis-tris propane | 64431-96-5 | Biochemical Assay Reagents |
| HY-12639A | Bephenium (hydroxynaphthoate) | 3818-50-6 | Reference compound |
| HY-12639AR | Bephenium (hydroxynaphthoate) (Standard) | 3818-50-6 | Reference Standards |
| HY-12640 | Pyrantel (pamoate) | 22204-24-6 | Reference compound |
| HY-126400 | Tocopherols | 1406-66-2 | Natural Products |
| HY-126401 | Elgodipine | 119413-55-7 | Reference compound |
| HY-126402 | Arg-Gly-Asp (TFA) | 120103-89-1 | Reference compound |
| HY-126403 | Ethoxylated hydrogenated castor oil | 61788-85-0 | Biochemical Assay Reagents |
| HY-126404 | Casein hydrolysate | 65072-00-6 | Reference compound |
| HY-126405 | SMPT | 112241-19-7 | ADC Related |
| HY-126406 | Tirandamycin A | 34429-70-4 | Natural Products |
| HY-126407 | Secologanin dimethyl acetal | 77988-07-9 | Natural Products |
| HY-126409 | Petunidin-3-O-arabinoside (chloride) | 28500-03-0 | Natural Products |
| HY-12640R | Pyrantel (pamoate) (Standard) | 22204-24-6 | Reference Standards |
| HY-12641 | Pyrantel (tartrate) | 33401-94-4 | Reference compound |
| HY-126410 | Petunidin (chloride) | 1429-30-7 | Natural Products |
| HY-126410R | Petunidin (chloride) (Standard) | 1429-30-7 | Reference Standards |
| HY-126411 | Peonidin-3-O-galactoside (chloride) | 28148-89-2 | Natural Products |
| HY-126412 | Neochamaejasmine A | 90411-13-5 | Natural Products |
| HY-126413 | Peonidin-3-O-arabinoside (chloride) | 524943-91-7 | Natural Products |
| HY-126414 | Methylenedihydrotanshinquinone | 126979-81-5 | Natural Products |
| HY-126415 | Magnesium Lithospermate B | 122021-74-3 | Natural Products |
| HY-126416 | Methyl tanshinonate | 18887-19-9 | Natural Products |
| HY-126417 | Methylenetanshinquinone | 67656-29-5 | Natural Products |
| HY-126418 | Methyl 3-O-feruloylquinate | 154418-15-2 | Natural Products |
| HY-126419 | Kobophenol A | 124027-58-3 | Natural Products |
| HY-12641A | Pyrantel | 15686-83-6 | Reference compound |
| HY-12641R | Pyrantel (tartrate) (Standard) | 33401-94-4 | Reference Standards |
| HY-12642 | Diethylcarbamazine (citrate) | 1642-54-2 | Reference compound |
| HY-126420 | Kansuinine B | 57685-46-8 | Natural Products |
| HY-126421 | Kansuinine A | 57701-86-7 | Natural Products |
| HY-126422 | cis-Tiliroside | 163956-16-9 | Natural Products |
| HY-126423 | Isorhamnetin 3-glucuronide | 36687-76-0 | Natural Products |
| HY-126424 | OptoDArG | 2230617-93-1 | Reference compound |
| HY-126425 | NCGC00262650 | 344359-25-7 | Reference compound |
| HY-126426 | CBHcy | 88096-02-0 | Reference compound |
| HY-126428 | ZL0580 | 2377151-10-3 | Reference compound |
| HY-126429 | Nav1.1 activator 1 | 2332897-85-3 | Reference compound |
| HY-12642A | Diethylcarbamazine | 90-89-1 | Reference compound |
| HY-12642R | Diethylcarbamazine (citrate) (Standard) | 1642-54-2 | Reference Standards |
| HY-12643 | Eprinomectin | 123997-26-2 | Reference compound |
| HY-126432S | (Rac)-BA-1049-d5 | | Isotope-Labeled Compounds |
| HY-126436A | Poly-L-ornithine (hydrobromide) (MW 30000-70000) | 27378-49-0 | Biochemical Assay Reagents |
| HY-126436B | Poly-L-ornithine (hydrobromide) (MW>100000) | 27378-49-0 | Biochemical Assay Reagents |
| HY-126436C | Poly-L-ornithine (hydrobromide) (MW 5000-15000) | 27378-49-0 | Biochemical Assay Reagents |
| HY-126436D | Poly-L-ornithine (hydrochloride) (MW 15000-30000) | 26982-21-8 | Biochemical Assay Reagents |
| HY-126437 | Poly-L-lysine (hydrobromide) (MW 30000-70000) | 25988-63-0 | Oligonucleotides |
| HY-126437A | Poly-L-lysine (hydrochloride) | 26124-78-7 | Oligonucleotides |
| HY-126437B | Poly-L-lysine (hydrobromide) (MW 70000-150000) | 25988-63-0 | Peptides |
| HY-126437C | Poly-L-lysine (hydrobromide) (MW 150000-300000) | 25988-63-0 | Reference compound |
| HY-126437D | Poly-L-lysine (hydrobromide) (MW ＞300000) | 25988-63-0 | Peptides |
| HY-126437E | Poly-L-lysine (hydrobromide) (MW 15000-30000) | 25988-63-0 | Biochemical Assay Reagents |
| HY-126437H | Poly-L-lysine (hydrobromide) (MW 4000-15000) | 25988-63-0 | Biochemical Assay Reagents |
| HY-126437I | Poly-L-lysine (hydrobromide) (MW 1000-5000) | 25988-63-0 | Biochemical Assay Reagents |
| HY-126437J | Poly-L-lysine solution (0.01%, sterile-filtered, MW 150000-300000) | 25988-63-0 | Biochemical Assay Reagents |
| HY-126437K | Poly-L-lysine solution (0.01%, sterile-filtered, MW 70000-150000) | 25988-63-0 | Biochemical Assay Reagents |
| HY-12643R | Eprinomectin (Standard) | 123997-26-2 | Reference Standards |
| HY-12643S | Eprinomectin-d3 | | Isotope-Labeled Compounds |
| HY-12644 | Acalisib | 870281-34-8 | Reference compound |
| HY-12645 | NCL1 | 1196119-03-5 | Reference compound |
| HY-126455 | Penicillide | 55303-92-9 | Natural Products |
| HY-126456 | (S,R,S)-AHPC-propargyl | 2098799-78-9 | Reference compound |
| HY-126457 | Thalidomide-propargyl | 2098487-39-7 | Reference compound |
| HY-126458 | Thalidomide-O-PEG2-propargyl | 2098487-52-4 | Reference compound |
| HY-12646 | Rhosin (hydrochloride) | 1281870-42-5 | Reference compound |
| HY-126460 | Myristoyl glutamic acid | 53576-52-6 | Reference compound |
| HY-126460A | Myristoyl glutamic acid (sodium) | 38517-37-2 | Reference compound |
| HY-126461 | Salazinic acid | 521-39-1 | Natural Products |
| HY-126462 | Lantic acid | 22626-26-2 | Natural Products |
| HY-126463 | LolCDE-IN-4 | 1859918-13-0 | Reference compound |
| HY-126464 | Estromustine | 62899-40-5 | Reference compound |
| HY-126467 | TA-270 | 194037-25-7 | Reference compound |
| HY-126468 | Abieslactone | 33869-93-1 | Natural Products |
| HY-126469 | Janthinocin B | 131086-53-8 | Reference compound |
| HY-12646A | Rhosin | 1173671-63-0 | Reference compound |
| HY-12647 | GPR40 Activator 2 | 1312787-30-6 | Reference compound |
| HY-126474 | MitoB (bromide) | 1247025-84-8 | Reference compound |
| HY-126474S | MitoB-d15 (bromide) | | Isotope-Labeled Compounds |
| HY-126475 | KSK213 | 1876429-73-0 | Reference compound |
| HY-126476 | Justicisaponin I | 79162-16-6 | Natural Products |
| HY-126477 | NNK | 64091-91-4 | Reference compound |
| HY-126477R | NNK (Standard) | 64091-91-4 | Reference Standards |
| HY-126477S | NNK-d4 | 764661-24-7 | Isotope-Labeled Compounds |
| HY-126477S1 | NNK-d3 | 86270-92-0 | Isotope-Labeled Compounds |
| HY-126478 | Quinabactin | 946270-26-4 | Reference compound |
| HY-126479 | Carbomycin B | 21238-30-2 | Natural Products |
| HY-12648 | FASN-IN-4 | 1375105-96-6 | Reference compound |
| HY-126482 | Telomerase-IN-2 | 1610878-54-0 | Reference compound |
| HY-126483 | Telomerase-IN-3 | 150096-77-8 | Reference compound |
| HY-126484 | Eremofortin B | 60048-73-9 | Natural Products |
| HY-126486 | AVE1231 | 767334-89-4 | Reference compound |
| HY-126487 | H-Arg-Lys-OH | 40968-46-5 | Reference compound |
| HY-126487A | H-Arg-Lys-OH (TFA) | | Reference compound |
| HY-126488 | H-Ser-His-OH | 67726-09-4 | Reference compound |
| HY-126489 | Tetromycin B | 180027-84-3 | Reference compound |
| HY-12648A | FASN-IN-4 (tosylate) | 2095432-57-6 | Reference compound |
| HY-12649 | Y16 | 429653-73-6 | Reference compound |
| HY-126490 | Phleomycin | 11006-33-0 | Natural Products |
| HY-126491 | SPP-DM1 | 452072-20-7 | ADC Related |
| HY-126492 | Vat-Cit-PAB-Monomethyl Dolastatin 10 | 1415329-13-3 | ADC Related |
| HY-126493 | DM4-SPDP | | ADC Related |
| HY-126493A | (R)-DM4-SPDP | 2245698-48-8 | Reference compound |
| HY-126494 | DM4-SMCC | 1228105-52-9 | ADC Related |
| HY-126495 | Sulfo-LC-SPDP | 150244-18-1 | ADC Related |
| HY-126495A | Sulfo-LC-SPDP (sodium) | 169751-10-4 | ADC Related |
| HY-126496 | PEG4-SPDP | 1305053-43-3 | ADC Related |
| HY-126497 | LC-PEG8-SPDP | 1252257-56-9 | ADC Related |
| HY-126498 | PDEC-NB | 874302-76-8 | ADC Related |
| HY-12650 | Mirogabalin | 1138245-13-2 | Reference compound |
| HY-126502 | Mal-C2-NHS ester | 103750-03-4 | ADC Related |
| HY-126503 | trans-Sulfo-SMCC | 1286837-77-1 | ADC Related |
| HY-126504 | Mal-PEG2-NHS ester | 1433997-01-3 | ADC Related |
| HY-126505 | Mal-PEG4-NHS ester | 1325208-25-0 | ADC Related |
| HY-126506 | Mal-PEG4-PFP ester | 1415800-42-8 | ADC Related |
| HY-126507 | Mal-amido-PEG1-C2-NHS ester | 1260092-50-9 | ADC Related |
| HY-126508 | Mal-amido-PEG5-C2-NHS ester | 1315355-92-0 | ADC Related |
| HY-126509 | Mal-amido-PEG10-C2-NHS ester | 1137109-22-8 | ADC Related |
| HY-12650A | (rel)-Mirogabalin | 1138244-97-9 | Reference compound |
| HY-12650R | Mirogabalin (Standard) | 1138245-13-2 | Reference Standards |
| HY-12650S | Mirogabalin-13C2,d1 (Mixture of Diastereomers) | | Isotope-Labeled Compounds |
| HY-12650S1 | Mirogabalin-d4 | | Isotope-Labeled Compounds |
| HY-12651 | Primaquine (diphosphate) | 63-45-6 | Reference compound |
| HY-126510 | MC-PEG2-C2-NHS ester | 1263044-56-9 | ADC Related |
| HY-126511 | Propargyl-C1-NHS ester | 132178-37-1 | ADC Related |
| HY-126512 | Propargyl-C2-NHS ester | 906564-59-8 | ADC Related |
| HY-126513 | Propargyl-PEG1-NHS ester | 1174157-65-3 | ADC Related |
| HY-126514 | Propargyl-O-C1-amido-PEG2-C2-NHS ester | 2101206-30-6 | ADC Related |
| HY-126515 | Propargyl-O-C1-amido-PEG4-C2-NHS ester | 2101206-92-0 | ADC Related |
| HY-126516 | Propargyl-PEG4-NHS ester | 1428629-70-2 | ADC Related |
| HY-126517 | Cyclooctyne-O-NHS ester | 1425803-45-7 | ADC Related |
| HY-126518 | Cyclooctyne-O-PFP ester | 886209-60-5 | ADC Related |
| HY-126519 | PDdEC-NB | 1956318-90-3 | ADC Related |
| HY-12651A | Primaquine | 90-34-6 | Reference compound |
| HY-12651AS | Primaquine-13C,d3 | | Isotope-Labeled Compounds |
| HY-12651B | l-Primaquine | 57152-58-6 | Reference compound |
| HY-12651R | Primaquine (diphosphate) (Standard) | 63-45-6 | Reference Standards |
| HY-12651S | Primaquine-d3 (diphosphate) | | Isotope-Labeled Compounds |
| HY-12652 | AZD3147 | 1101810-02-9 | Reference compound |
| HY-126520 | N3-C2-NHS ester | 850180-76-6 | ADC Related |
| HY-126521 | N3-C3-NHS ester | 943858-70-6 | ADC Related |
| HY-126522 | N3-C4-NHS ester | 478801-48-8 | ADC Related |
| HY-126523 | N3-C5-NHS ester | 866363-70-4 | ADC Related |
| HY-126524 | N3-Ph-NHS ester | 53053-08-0 | ADC Related |
| HY-126525 | 4-N3Pfp-NHS ester | 126695-58-7 | ADC Related |
| HY-126526 | N3-PEG2-C2-NHS ester | 1312309-64-0 | ADC Related |
| HY-126527 | N3-PEG2-C2-PFP ester | 1393330-37-4 | ADC Related |
| HY-126528 | N3-PEG3-C2-NHS ester | 1245718-89-1 | ADC Related |
| HY-126529 | N3-PEG3-C2-PFP ester | 1807530-07-9 | ADC Related |
| HY-12653 | LDC4297 | 1453834-21-3 | Reference compound |
| HY-126530 | PPC-NB | 1887040-81-4 | ADC Related |
| HY-126531 | DMAC-PDB | 663599-04-0 | ADC Related |
| HY-126532 | Fmoc-Val-Cit-PAB-Duocarmycin TM | | ADC Related |
| HY-126533 | PDP-C1-Ph-Val-Cit | 1610769-13-5 | ADC Related |
| HY-126534 | Abemaciclib metabolite M18 | 2704316-81-2 | Reference compound |
| HY-126534A | Abemaciclib metabolite M18 (hydrochloride) | 2704316-82-3 | Reference compound |
| HY-126534S | Abemaciclib metabolite M18-d8 | | Isotope-Labeled Compounds |
| HY-126535 | Magnoloside B | 116872-05-0 | Natural Products |
| HY-126536 | ChemR23-IN-1 | 2378640-10-7 | Reference compound |
| HY-126539 | UBE2T/FANCL-IN-1 | 1359415-02-3 | Reference compound |
| HY-12653A | LDC4297 (hydrochloride) | 2319747-14-1 | Reference compound |
| HY-12654 | Molidustat | 1154028-82-6 | Reference compound |
| HY-126542 | VRK-IN-1 | 2378855-09-3 | Reference compound |
| HY-126548 | β-Secretase Inhibitor I | 1818239-19-8 | Reference compound |
| HY-12655 | IDE-IN-1 | 1417537-93-9 | Reference compound |
| HY-126550 | Azidoindolene 1 | 1364933-69-6 | Reference compound |
| HY-126551 | Butenoyl-PAF | 474944-25-7 | Reference compound |
| HY-126555 | OX3a | 329939-05-1 | Reference compound |
| HY-126556 | Cytochalasin J | 53760-20-6 | Natural Products |
| HY-126558 | GA3-AM | 1373154-68-7 | Reference compound |
| HY-126558R | GA3-AM (Standard) | 1373154-68-7 | Reference Standards |
| HY-126559 | Ansatrienin A | 82189-03-5 | Natural Products |
| HY-12656 | SCH 51344 | 171927-40-5 | Reference compound |
| HY-126560 | F-Amidine | 877617-45-3 | Reference compound |
| HY-126560A | F-Amidine (TFA) | 877617-46-4 | Reference compound |
| HY-126561 | Green CMFDA | 136832-63-8 | Dye Reagents |
| HY-126562 | Piperlonguminine | 5950-12-9 | Natural Products |
| HY-126562R | Piperlonguminine (Standard) | 5950-12-9 | Reference Standards |
| HY-126564 | Ebelactone A | 76808-16-7 | Natural Products |
| HY-126565 | Licam-C | 75956-68-2 | Reference compound |
| HY-126566 | Trichostatin C | 68676-88-0 | Reference compound |
| HY-126568 | Naftidrofuryl | 31329-57-4 | Reference compound |
| HY-126568S | Naftidrofuryl-d4 | 1215649-28-7 | Isotope-Labeled Compounds |
| HY-126568S1 | Nafronyl-d4 (oxalate) | | Isotope-Labeled Compounds |
| HY-126569 | Efrotomycin | 56592-32-6 | Reference compound |
| HY-12657 | Syk-IN-1 | 1491150-77-6 | Reference compound |
| HY-126571 | Virustomycin A | 84777-85-5 | Reference compound |
| HY-126573 | Trilaurin | 538-24-9 | Natural Products |
| HY-126573R | Trilaurin (Standard) | 538-24-9 | Reference Standards |
| HY-126573S | Trilaurin-d15 | 1219805-25-0 | Isotope-Labeled Compounds |
| HY-126574 | Pantothenoylcysteine | 13147-34-7 | Reference compound |
| HY-126576 | Dactylocycline A | 125622-12-0 | Natural Products |
| HY-126577 | Dactylocycline B | 125622-13-1 | Natural Products |
| HY-126578 | Dactylocycline D | 146064-00-8 | Reference compound |
| HY-126579 | Dactylocycline E | 146064-01-9 | Reference compound |
| HY-12658 | Mps1-IN-4 | 1263423-94-4 | Reference compound |
| HY-126582 | Reprimun | 41776-67-4 | Reference compound |
| HY-126583 | Nemadipine-A | 54280-71-6 | Reference compound |
| HY-126584 | H-Val-Val-OH | 3918-94-3 | Reference compound |
| HY-126585 | SAICAR | 3031-95-6 | Natural Products |
| HY-126585S | SAICAR-d1 | | Isotope-Labeled Compounds |
| HY-12659 | LX7101 | 1192189-69-7 | Reference compound |
| HY-126591 | Junceellin | 92508-09-3 | Natural Products |
| HY-126593 | Cryosim-3 | 1507344-37-7 | Reference compound |
| HY-126594 | Echinoside B | 75410-52-5 | Natural Products |
| HY-126596 | Angelylalkannin | 69175-72-0 | Natural Products |
| HY-126597 | Chaetoglobosin C | 50645-76-6 | Natural Products |
| HY-126598 | Chaetoglobosin F | 55945-75-0 | Natural Products |
| HY-126599 | Cochlioquinone A | 32450-25-2 | Natural Products |
| HY-12659B | LX7101 (monohydrochloride) | 2319882-48-7 | Reference compound |
| HY-12660 | MPI-0479605 | 1246529-32-7 | Reference compound |
| HY-126601 | Malonganenone A | 882403-69-2 | Natural Products |
| HY-126602 | Kinamycin B | 35303-13-0 | Natural Products |
| HY-126603 | Asperlactone | 76375-62-7 | Natural Products |
| HY-126604 | Pyranonigrin A | 773855-65-5 | Natural Products |
| HY-126605 | Trinactin | 7561-71-9 | Natural Products |
| HY-126606 | Isochlortetracycline | 514-53-4 | Reference compound |
| HY-126607 | Sericic acid | 55306-03-1 | Natural Products |
| HY-126609 | Emorfazone | 38957-41-4 | Reference compound |
| HY-126610 | Dactylfungin A | 146935-35-5 | Natural Products |
| HY-126613 | Laurycolactone A | 85643-76-1 | Natural Products |
| HY-126617 | Duclauxin | 1732-37-2 | Reference compound |
| HY-126618 | Aspochalasin I | 670225-69-1 | Natural Products |
| HY-126619 | Aspochalasin D | 71968-02-0 | Reference compound |
| HY-12661A | AMG PERK 44 | 1883548-84-2 | Reference compound |
| HY-12662 | PE859 | 1402727-29-0 | Reference compound |
| HY-126621 | DC-TEADin02 | 2380228-45-3 | Reference compound |
| HY-126629 | Antibacterial agent 12 | 2382921-99-3 | Reference compound |
| HY-12663 | AS2521780 | 1214726-89-2 | Reference compound |
| HY-126634 | Lyngbyatoxin B | 133084-52-3 | Natural Products |
| HY-126635 | Mafoprazine | 80428-29-1 | Reference compound |
| HY-126635R | Mafoprazine (Standard) | 80428-29-1 | Reference Standards |
| HY-126637 | Marasmic acid | 2212-99-9 | Natural Products |
| HY-126638 | Marcfortine A | 75731-43-0 | Reference compound |
| HY-12664 | AF64394 | 1637300-25-4 | Reference compound |
| HY-126640 | Phomoxanthone A | 359844-69-2 | Natural Products |
| HY-126643 | Wedeloside | 74686-30-9 | Natural Products |
| HY-126644 | Halocyamine B | 122548-04-3 | Natural Products |
| HY-126645 | Atelopidtoxin | 9061-57-8 | Natural Products |
| HY-126646 | Sporeamicin A | 131418-65-0 | Natural Products |
| HY-126649 | Bacillosporin C | 76706-63-3 | Reference compound |
| HY-126651 | Azotomycin | 7644-67-9 | Reference compound |
| HY-126653 | Atpenin A5 | 119509-24-9 | Reference compound |
| HY-126655 | Yunnanxane | 139713-81-8 | Natural Products |
| HY-126657 | Fumigaclavine A | 6879-59-0 | Natural Products |
| HY-126658 | Lycophlegmine | 82841-97-2 | Natural Products |
| HY-126660 | Cinerubin A | 34044-10-5 | Reference compound |
| HY-126662 | Netzahualcoyone | 87686-36-0 | Natural Products |
| HY-126663 | N-Me-L-Ala-maytansinol | 77668-69-0 | ADC Related |
| HY-126664 | Azonafide-PEABA | 2752193-52-3 | ADC Related |
| HY-126665 | DMEA-PNU-159682 | 1799421-48-9 | ADC Related |
| HY-126665A | DMEA-PNU-159682 (dichloroacetate) | 1799421-49-0 | Reference compound |
| HY-126666 | PNU-159682 carboxylic acid | 1204819-92-0 | ADC Related |
| HY-126667 | SC-Val-Cit-PAB | | ADC Related |
| HY-126668 | Mal-PEG4-VC-PAB-DMEA | 1569261-93-3 | ADC Related |
| HY-126668A | Mal-PEG4-VC-PAB-DMEA (TFA) | | ADC Related |
| HY-126669 | Mal-PEG4-VA | 1800456-31-8 | ADC Related |
| HY-126670 | mDPR(Boc)-Val-Cit-PAB | 2281797-55-3 | ADC Related |
| HY-126671 | Mal-Phe-C4-Val-Cit-PAB | | ADC Related |
| HY-126672 | Mal-PEG4-Val-Cit-PAB | 1949793-41-2 | ADC Related |
| HY-126673 | Mal-C2-Gly3-EDA | | ADC Related |
| HY-126674 | Mal-Phe-C4-Val-Cit-PAB-DMEA | | ADC Related |
| HY-126675 | AS2863619 (free base) | 2241300-50-3 | Reference compound |
| HY-126675A | AS2863619 | 2241300-51-4 | Reference compound |
| HY-126676 | DBCO-(PEG2-Val-Cit-PAB)2 | | ADC Related |
| HY-126677 | Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA | | ADC Related |
| HY-126678 | Dimethyl-SGD-1882 | 3026416-27-0 | ADC Related |
| HY-126679 | Apoptolidin | 194874-06-1 | Natural Products |
| HY-126681 | SC-VC-PAB-MMAE | 2259318-46-0 | ADC Related |
| HY-126682 | Mal-VC-PAB-DM1 | 1464051-44-2 | ADC Related |
| HY-126683 | Mal-C6-α-Amanitin | 1578249-76-9 | ADC Related |
| HY-126684 | Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA | 2259318-49-3 | ADC Related |
| HY-126685 | Mal-PEG4-VA-PBD | 1342820-68-1 | ADC Related |
| HY-126686 | Mal-Phe-C4-VC-PAB-MMAE | 2259318-51-7 | ADC Related |
| HY-126687 | Mal-PEG4-VC-PAB-DMEA-PNU-159682 | 2259318-52-8 | ADC Related |
| HY-126688 | Mal-C2-Gly3-EDA-PNU-159682 | 2259318-53-9 | ADC Related |
| HY-126689 | Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 | 2259318-54-0 | ADC Related |
| HY-126690 | DBCO-(PEG2-VC-PAB-MMAE)2 | 2259318-55-1 | ADC Related |
| HY-126691 | DBCO-PEG4-VC-PAB-DMEA-PNU-159682 | 2259318-56-2 | ADC Related |
| HY-126692 | Mal-VC-PAB-ABAEP-Azonafide | 2259318-48-2 | ADC Related |
| HY-126693 | SC-VC-PAB-DM1 | 2259318-47-1 | ADC Related |
| HY-126695 | Altromycin B | 128461-00-7 | Natural Products |
| HY-126696 | Altromycin D | 128461-01-8 | Natural Products |
| HY-126697 | Eremofortin A | 62445-06-1 | Natural Products |
| HY-126699 | Herbimycin C | 91700-92-4 | Reference compound |
| HY-126703 | Lantanose A | 145204-38-2 | Natural Products |
| HY-126704 | Tedisamil | 90961-53-8 | Reference compound |
| HY-126707 | Aldoifosfamide | 120144-70-9 | Reference compound |
| HY-126708 | Luisol A | 225110-59-8 | Natural Products |
| HY-126710 | OU749 | 519170-13-9 | Reference compound |
| HY-126712 | ROS tracer precursor | 2153480-20-5 | Reference compound |
| HY-126715 | Pimelautide | 78512-63-7 | Reference compound |
| HY-126716 | Leukotriene C4 methyl ester | 73958-10-8 | Reference compound |
| HY-126716S | Leukotriene C4-d5 methyl ester | | Isotope-Labeled Compounds |
| HY-126717 | SPDP-PEG6-NHS ester | 1818294-32-4 | Reference compound |
| HY-126718 | Methylenecyclopropylpyruvate | 5746-24-7 | Reference compound |
| HY-126719 | R-1 Methanandamide Phosphate | 649569-33-5 | Reference compound |
| HY-126720 | N-Lignoceroyl Taurine | 807370-75-8 | Reference compound |
| HY-126721 | Tetralysine | 997-20-6 | Peptides |
| HY-126722 | Lipoxin A4 methyl ester | 97643-35-1 | Reference compound |
| HY-126723 | Proline cetyl ester | 97010-18-9 | Reference compound |
| HY-126724 | Flutianil | 958647-10-4 | Reference compound |
| HY-126724R | Flutianil (Standard) | 958647-10-4 | Reference Standards |
| HY-126725 | Chitinovorin B | 95722-76-2 | Natural Products |
| HY-126726 | KOdiA-PC | 439904-33-3 | Biochemical Assay Reagents |
| HY-126730 | Rubratoxin A | 22467-31-8 | Reference compound |
| HY-126732 | L-640876 | 77527-71-0 | Reference compound |
| HY-126733 | (6R)-Leucovorin | 73951-54-9 | Natural Products |
| HY-126735 | Saquayamycin D | 99260-71-6 | Reference compound |
| HY-126738 | Anacardic acid triene | 103904-73-0 | Natural Products |
| HY-126740 | Anguinomycin A | 111278-01-4 | Reference compound |
| HY-126741 | Azadirachtin | 11141-17-6 | Natural Products |
| HY-126741R | Azadirachtin (Standard) | 11141-17-6 | Reference Standards |
| HY-126742 | MBX-1162 | 1225332-95-5 | Reference compound |
| HY-126743 | JBIR-22 | 1219095-76-7 | Reference compound |
| HY-126744 | Juncin E | 129602-22-8 | Natural Products |
| HY-126745 | Corynecin V | 40958-12-1 | Reference compound |
| HY-126746 | Corynecin I | 4423-58-9 | Natural Products |
| HY-126747 | Corynecin IV | 40958-11-0 | Reference compound |
| HY-126748 | VUF14862 | 2223023-78-5 | Reference compound |
| HY-126749 | VUF14738 | 2223027-70-9 | Reference compound |
| HY-126750 | GNF362 | 1003019-41-7 | Reference compound |
| HY-126752 | Ophthalmic acid | 495-27-2 | Natural Products |
| HY-126753 | Kujimycin A | 33955-27-0 | Natural Products |
| HY-126754 | Archangelicin | 2607-56-9 | Natural Products |
| HY-126758 | Ludartin | 36149-87-8 | Natural Products |
| HY-126760 | Retroisosenine | 62018-78-4 | Natural Products |
| HY-126762 | Fenprostalene | 69381-94-8 | Reference compound |
| HY-126763 | ATI22-107 | 681816-57-9 | Reference compound |
| HY-126765 | Territrem B | 70407-20-4 | Natural Products |
| HY-126770 | Rhizocticin A | 114301-25-6 | Natural Products |
| HY-126771 | Chrysomycin A | 82196-88-1 | Reference compound |
| HY-126772 | Tralomethrin | 66841-25-6 | Reference compound |
| HY-126774 | DAF-FM | 254109-20-1 | Dye Reagents |
| HY-126775 | Xenoclauxin | 7599-61-3 | Natural Products |
| HY-126779 | Stictic acid | 549-06-4 | Reference compound |
| HY-12678 | Entrectinib | 1108743-60-7 | Reference compound |
| HY-126780 | Nikkomycin N | 77368-58-2 | Natural Products |
| HY-126781 | Fozivudine tidoxil | 141790-23-0 | Reference compound |
| HY-126782 | Lexitropsin 1 | 123725-00-8 | Reference compound |
| HY-126783 | Levorin A0 | 77215-53-3 | Natural Products |
| HY-126785 | Suc-AAP-Abu-pNA | 108392-27-4 | Peptides |
| HY-126787 | 17-Hydroxyventuricidin A | 113204-43-6 | Natural Products |
| HY-126788 | Antibiotic DC 102 | 115722-50-4 | Natural Products |
| HY-126789 | DM-Nitrophen | 117367-86-9 | Reference compound |
| HY-126789A | DM-Nitrophen (tertasodium) | 291517-40-3 | Reference compound |
| HY-12678R | Entrectinib (Standard) | 1108743-60-7 | Reference Standards |
| HY-12678S | Entrectinib-d4 | | Isotope-Labeled Compounds |
| HY-12678S1 | Entrectinib-d8 | 2251773-94-9 | Isotope-Labeled Compounds |
| HY-126791 | Methylmalonyl-CoA | 1264-45-5 | Enzyme |
| HY-126791A | Methylmalonyl-CoA (tetralithium) | 104809-02-1 | Enzyme |
| HY-126791B | (2R)-Methylmalonyl-CoA | 73173-92-9 | Enzyme |
| HY-126793 | 2′,7′-Dichlorofluorescein diacetate | 2044-85-1 | Dye Reagents |
| HY-126795 | Aspergillin PZ | 483305-08-4 | Natural Products |
| HY-12680 | PRN694 | 1575818-46-0 | Reference compound |
| HY-126800 | Glycotriosyl glutamine | 83235-86-3 | Reference compound |
| HY-126801 | Sannamycin A | 72503-79-8 | Natural Products |
| HY-126802 | Saquayamycin B1 | 99260-68-1 | Reference compound |
| HY-126803 | Saquayamycin B | 99260-67-0 | Natural Products |
| HY-126804 | Safracin B | 87578-99-2 | Natural Products |
| HY-126806 | Pyrrofolic acid | 88912-57-6 | Reference compound |
| HY-126807 | AS1907417 | 885038-66-4 | Reference compound |
| HY-126809 | Chromozym PK | 58840-30-5 | Peptides |
| HY-12681 | CCT251545 | 1661839-45-7 | Reference compound |
| HY-126810 | NP213 | 942577-31-3 | Peptides |
| HY-126810A | NP213 (TFA) | | Peptides |
| HY-126812 | Longestin | 131774-53-3 | Natural Products |
| HY-126813 | Concanamycin C | 81552-34-3 | Natural Products |
| HY-126816 | Atrazine mercapturate | 138722-96-0 | Reference compound |
| HY-126818 | Desfuroylceftiofur | 120882-22-6 | Reference compound |
| HY-12682 | Glutaminase C-IN-1 | 311795-38-7 | Reference compound |
| HY-126820 | Tolypomycin R | 33889-22-4 | Reference compound |
| HY-126821 | Fluo-3 | 123632-39-3 | Dye Reagents |
| HY-126821A | Fluo-3 (pentaammonium) | 339221-91-9 | Dye Reagents |
| HY-126822 | MDL27324 | 123285-50-7 | Reference compound |
| HY-126823 | Phen Green SK diacetate (5/6-mixture) | 234075-45-7 | Dye Reagents |
| HY-126824 | 5,10-Dideazaaminopterin | 95674-53-6 | Reference compound |
| HY-126825 | NE21650 | 427899-21-6 | Reference compound |
| HY-126826 | Antibiotic K 4 | 84890-90-4 | Reference compound |
| HY-126829 | Coumarin-SAHA | 1260635-77-5 | Reference compound |
| HY-12683 | BPTES | 314045-39-1 | Reference compound |
| HY-126830 | Antifolate C2 | 1286279-90-0 | Reference compound |
| HY-126831 | SBFI-AM | 129423-53-6 | Dye Reagents |
| HY-126833 | Myristoyl coenzyme A | 3130-72-1 | Biochemical Assay Reagents |
| HY-126833A | Myristoyl coenzyme A (lithium) | 187100-75-0 | Reference compound |
| HY-126833B | Myristoyl coenzyme A (triammonium) | 799812-85-4 | Enzyme |
| HY-126835 | A924 | 65132-74-3 | Reference compound |
| HY-126837 | SPM VIII | 133397-76-9 | Reference compound |
| HY-126838 | Lavendofuseomycin | 134965-82-5 | Reference compound |
| HY-126839 | C12FDG | 138777-25-0 | Dye Reagents |
| HY-12684 | CH-223191 | 301326-22-7 | Reference compound |
| HY-126841 | 5-Methoxysterigmatocystin | 22897-08-1 | Natural Products |
| HY-126843 | Chromozym U | 112283-16-6 | Reference compound |
| HY-126845 | 3-cis-Hydroxyglibenclamide | 23074-02-4 | Reference compound |
| HY-126847 | N-Acylkansosamine | 92355-88-9 | Reference compound |
| HY-126848 | Diclofenac acyl glucuronide | 64118-81-6 | Reference compound |
| HY-126849 | 3-Morpholinosydnonimine | 33876-97-0 | Biochemical Assay Reagents |
| HY-12685 | Ceralifimod | 891859-12-4 | Reference compound |
| HY-126850 | 4-Epidoxycycline | 6543-77-7 | Reference compound |
| HY-126851 | Fluorescein-DBCO | 2054339-00-1 | Dye Reagents |
| HY-126852 | 4-Hydroxy Atorvastatin lactone | 163217-70-7 | Reference compound |
| HY-126852S | 4-Hydroxy Atorvastatin lactone-d5 | 265989-49-9 | Isotope-Labeled Compounds |
| HY-126854 | N-Acetyllactosamine | 32181-59-2 | Natural Products |
| HY-126854R | N-Acetyllactosamine (Standard) | 32181-59-2 | Reference Standards |
| HY-126855 | Cholic acid 7-sulfate | 60320-05-0 | Reference compound |
| HY-126856 | HC-Toxin | 83209-65-8 | Natural Products |
| HY-126857 | 5-Hydroxyomeprazole | 92340-57-3 | Reference compound |
| HY-126857A | 5-Hydroxyomeprazole (sodium) | 1215629-45-0 | Reference compound |
| HY-126857AS1 | 5-Hydroxyomeprazole-13C,d2 (sodium) | | Isotope-Labeled Compounds |
| HY-126857R | 5-Hydroxyomeprazole (Standard) | 92340-57-3 | Reference Standards |
| HY-126857S | 5-Hydroxy Omeprazole-d3 | 2748479-83-4 | Isotope-Labeled Compounds |
| HY-126857S3 | 5-Hydroxyomeprazole-d3-1 | 1216667-13-8 | Isotope-Labeled Compounds |
| HY-126858 | Ambuic acid | 340774-69-8 | Natural Products |
| HY-12686 | 5Z-7-Oxozeaenol | 253863-19-3 | Natural Products |
| HY-126861 | 2'-Deoxy-5-formylcytidine | 137017-45-9 | Reference compound |
| HY-126862 | AQ-RA 721 | 139051-89-1 | Reference compound |
| HY-126864 | 11-Oxahomofolic acid | 72254-43-4 | Reference compound |
| HY-126866 | Lankacidin C 8-acetate | 23812-97-7 | Reference compound |
| HY-126867 | Neohydroxyaspergillic acid | 72598-34-6 | Natural Products |
| HY-126869 | Pseudomonic acid D | 85248-93-7 | Natural Products |
| HY-12687 | Tizoxanide | 173903-47-4 | Reference compound |
| HY-126871 | Zaragozic acid D2 | 155179-15-0 | Natural Products |
| HY-126873 | Nikkomycin J | 77368-59-3 | Reference compound |
| HY-126874 | Tyropeptin A-4 | 688737-89-5 | Reference compound |
| HY-126876 | GL-V9 | 1178583-19-1 | Reference compound |
| HY-126877 | 3-Deaza-2'-deoxyadenosine | 78582-17-9 | Reference compound |
| HY-126878 | 11-Oxahomoaminopterin | 78520-72-6 | Reference compound |
| HY-12687R | Tizoxanide (Standard) | 173903-47-4 | Reference Standards |
| HY-12687S | Tizoxanide-d4 | 1246817-56-0 | Isotope-Labeled Compounds |
| HY-12688 | Succinyl phosphonate | 26647-82-5 | Reference compound |
| HY-126880 | Fmoc-NH-PEG8-NHS ester | 1334170-03-4 | Reference compound |
| HY-126881 | Fmoc-PEG2-C2-NHS ester | 1807534-85-5 | Reference compound |
| HY-126882 | Fmoc-PEG6-NHS ester | 1818294-31-3 | Reference compound |
| HY-126883 | Tr-PEG4-OH | 125274-16-0 | Reference compound |
| HY-126884 | DBCO-NHCO-PEG4-NH-Boc | 1255942-12-1 | ADC Related |
| HY-126885 | DBCO-PEG5-NHS ester | 2144395-59-3 | ADC Related |
| HY-126886 | Mal-PEG1-NHS ester | 1807518-72-4 | ADC Related |
| HY-126887 | Mal-PEG8-NHS ester | 2055033-05-9 | Reference compound |
| HY-126888 | Mal-PEG5-NHS ester | 1807537-42-3 | Reference compound |
| HY-126889 | Bis-PEG5-NHS ester | 756526-03-1 | ADC Related |
| HY-12688A | Succinyl phosphonate (trisodium salt) | 864167-45-3 | Reference compound |
| HY-12689 | Mitapivat | 1260075-17-9 | Reference compound |
| HY-126890 | Bis-PEG7-NHS ester | 1334170-02-3 | ADC Related |
| HY-126891 | Bis-PEG3-acid | 96517-92-9 | Reference compound |
| HY-126892 | Bis-PEG7-acid | 94376-75-7 | ADC Related |
| HY-126893 | Bis-PEG8-acid | 1246189-43-4 | ADC Related |
| HY-126894 | Bis-PEG9-acid | 1268488-70-5 | ADC Related |
| HY-126897 | N-Acetylloline | 4914-36-7 | Natural Products |
| HY-126898 | 5-LO/mPGES1-IN-1 | 1492060-44-2 | Reference compound |
| HY-126899 | TPI-287 | 849213-15-6 | Reference compound |
| HY-12689A | Mitapivat (hemisulfate sesquihydrate) | 2151847-10-6 | Reference compound |
| HY-12689B | Mitapivat (hemisulfate) | 2329710-91-8 | Reference compound |
| HY-12689C | Mitapivat (hydrochloride) | 2559738-69-9 | Reference compound |
| HY-12690 | DOTA derivative | 153777-70-9 | Reference compound |
| HY-126900 | HI-253 | 149486-73-7 | Reference compound |
| HY-126904 | ZINC08792355 | 904513-52-6 | Reference compound |
| HY-126905 | ZMC3 | 79514-41-3 | Reference compound |
| HY-126906 | Milbemycin A4 | 51596-11-3 | Reference compound |
| HY-126906R | Milbemycin A4 (Standard) | 51596-11-3 | Reference Standards |
| HY-126907 | A32390A | 61241-59-6 | Reference compound |
| HY-126908 | Tetrazine-Ph-NHS ester | 1616668-55-3 | Reference compound |
| HY-12691 | BFCAs-1 | 585531-74-4 | Reference compound |
| HY-126910 | Mesyl Salvinorin B | 862073-79-8 | Reference compound |
| HY-126911 | 11-keto Fluprostenol | 62145-07-7 | Reference compound |
| HY-126912 | Lauroyl coenzyme A | 6244-92-4 | Natural Products |
| HY-126912A | Lauroyl coenzyme A (lithium) | 190063-12-8 | Biochemical Assay Reagents |
| HY-126913 | Rhodblock 6 | 886625-06-5 | Reference compound |
| HY-126914 | Diacetylcercosporin | 62574-06-5 | Reference compound |
| HY-126915 | CNK-6004 | 96626-42-5 | Reference compound |
| HY-126916 | Tetrahydropyranyldiethyleneglycol | 2163-11-3 | Reference compound |
| HY-126917 | THP-PEG5-OH | 146395-14-4 | Reference compound |
| HY-126918 | THP-PEG6-OH | 42607-87-4 | ADC Related |
| HY-126919 | THP-PEG8-OH | 658858-65-2 | Reference compound |
| HY-12692 | DO3A tert-Butyl ester | 122555-91-3 | Reference compound |
| HY-126920 | AFG206 | 630122-37-1 | Reference compound |
| HY-126921 | Lab 170250F | 88630-25-5 | Reference compound |
| HY-126922 | Pyraflufen-ethyl | 129630-19-9 | Reference compound |
| HY-126922R | Pyraflufen-ethyl (Standard) | 129630-19-9 | Reference Standards |
| HY-126923 | 2,3-Dinor thromboxane B2 | 63250-09-9 | Reference compound |
| HY-126924 | (Rac)-Saphenamycin | 634600-55-8 | Reference compound |
| HY-126927 | TTR stabilizer L6 | 881290-53-5 | Reference compound |
| HY-12693 | R(+)-Methylindazone | 54197-31-8 | Reference compound |
| HY-126931 | Dinophysistoxin 1 | 81720-10-7 | Natural Products |
| HY-126932 | TTC-352 | 1607819-68-0 | Reference compound |
| HY-126935 | Ansatrienin A3 | 85819-31-4 | Natural Products |
| HY-126936 | MSD-D | 182504-18-3 | Reference compound |
| HY-126937 | Ivermectin B1a | 71827-03-7 | Reference compound |
| HY-126938 | 4-Methylumbelliferyl heptanoate | 18319-92-1 | Reference compound |
| HY-12693A | (Rac)-Methylindazone | 53108-00-2 | Reference compound |
| HY-12694 | Prucalopride (succinate) | 179474-85-2 | Reference compound |
| HY-126940 | Furanodiene | 19912-61-9 | Natural Products |
| HY-126941 | Hecogenin acetate | 915-35-5 | Natural Products |
| HY-126942 | Amino-PEG6-alcohol | 39160-70-8 | ADC Related |
| HY-126943 | SAHA-BPyne | 930772-88-6 | Reference compound |
| HY-126944 | 2-Aminobenzanilide | 4424-17-3 | Biochemical Assay Reagents |
| HY-126948 | Aminooxy-PEG1-azide | 2100306-70-3 | Reference compound |
| HY-126949 | Aminooxy-PEG3-azide | 1306615-51-9 | ADC Related |
| HY-12695 | Guanosine 5'-triphosphate (trisodium salt) | 36051-31-7 | Natural Products |
| HY-126950 | Aminooxy-PEG4-azide | 2100306-61-2 | Reference compound |
| HY-126951 | Aminooxy-PEG2-alcohol | 185022-12-2 | ADC Related |
| HY-126954 | 13-Deoxycarminomycin | 76034-18-9 | Reference compound |
| HY-126956 | Porphyra 334 | 70579-26-9 | Natural Products |
| HY-126957 | Biotin-PEG2-azide | 1910803-72-3 | Reference compound |
| HY-126958 | Biotin-PEG2-acid | 1365655-89-5 | ADC Related |
| HY-126959 | Biotin-PEG4-acid | 721431-18-1 | Reference compound |
| HY-12695B | Guanosine 5'-triphosphate (trisodium salt hydrate) | 207300-85-4 | Oligonucleotides |
| HY-126960 | Mal-PEG1-acid | 760952-64-5 | ADC Related |
| HY-126961 | Mal-PEG4-acid | 518044-41-2 | Reference compound |
| HY-126962 | Mal-PEG5-acid | 1286755-26-7 | Reference compound |
| HY-126963 | Mal-PEG6-acid | 518044-42-3 | Reference compound |
| HY-126965 | Lipid Y | 88090-57-7 | Reference compound |
| HY-126967A | 1-Palmitoyl-sn-glycerol 3-phosphate | 7220-34-0 | Reference compound |
| HY-126969 | C333H | 870095-15-1 | Reference compound |
| HY-12697 | NGB 2904 | 189060-98-8 | Reference compound |
| HY-126970 | HBF-0259 | 957011-15-3 | Reference compound |
| HY-126972 | RI(dl)-2 | 1902146-75-1 | Reference compound |
| HY-126972A | RI(dl)-2 (TFA) | | Reference compound |
| HY-126973 | BI-1230 | 849022-32-8 | Reference compound |
| HY-126974 | Propargyl-PEG3-NHS ester | 1428629-71-3 | ADC Related |
| HY-126975 | Propargyl-PEG3-acid | 1347760-82-0 | ADC Related |
| HY-126976 | Propargyl-PEG5-amine | 1589522-46-2 | ADC Related |
| HY-126977 | Propargyl-PEG9-OH | 2055022-35-8 | Reference compound |
| HY-126978 | Lepidimoide | 145039-76-5 | Natural Products |
| HY-126979 | Mycro2 | 314049-21-3 | Reference compound |
| HY-12697A | NGB 2904 (hydrochloride) | 189061-11-8 | Reference compound |
| HY-12698 | NNC 63-0532 | 250685-44-0 | Reference compound |
| HY-126981 | Sarasinoside B1 | 114066-50-1 | Natural Products |
| HY-126982 | ThioD | 2206682-00-8 | Reference compound |
| HY-126983 | 6',7'-Epoxybergamottin | 206978-14-5 | Natural Products |
| HY-126984 | Fanetizole (mesylate) | 79069-95-7 | Reference compound |
| HY-126985 | 4,9-Anhydrotetrodotoxin | 13072-89-4 | Reference compound |
| HY-126986 | Tetranor-PGDM | 70803-91-7 | Reference compound |
| HY-126986S | Tetranor-PGDM-d6 | 1314905-92-4 | Isotope-Labeled Compounds |
| HY-126987 | Mesosulfuron-methyl | 208465-21-8 | Reference compound |
| HY-126987R | Mesosulfuron-methyl (Standard) | 208465-21-8 | Reference Standards |
| HY-126988 | SP-Chymostatin B | 70857-49-7 | Reference compound |
| HY-126989 | 19-O-Acetylchaetoglobosin A | 50939-69-0 | Natural Products |
| HY-12699 | RO5166017 | 1048346-74-2 | Reference compound |
| HY-126991 | Leu-thiorphan | 80970-04-3 | Reference compound |
| HY-126994 | 6′-Amino-D-luciferin | 161055-47-6 | Dye Reagents |
| HY-126995 | Glycohyodeoxycholic acid | 13042-33-6 | Natural Products |
| HY-126995R | Glycohyodeoxycholic acid (Standard) | 13042-33-6 | Reference Standards |
| HY-126996 | Triiodothyronine sulfate | 31135-55-4 | Reference compound |
| HY-126997 | Bis-PEG3-PFP ester | 1314378-13-6 | Reference compound |
| HY-126998 | Bis-PEG4-PFP ester | 1314378-12-5 | Reference compound |
| HY-126999 | Bis-PEG5-PFP ester | 1334177-78-4 | Reference compound |
| HY-12700 | RO5256390 | 1043495-96-0 | Reference compound |
| HY-127000 | Julifloricine | 66771-80-0 | Natural Products |
| HY-127001 | Lycodine | 20316-18-1 | Natural Products |
| HY-127002 | Squarunkin A | 2101958-02-3 | Reference compound |
| HY-127002A | Squarunkin A (hydrochloride) | 2253744-55-5 | Reference compound |
| HY-127004 | Silperisone (hydrochloride) | 140944-30-5 | Reference compound |
| HY-127005 | Ritrosulfan | 4148-16-7 | Reference compound |
| HY-127007 | Okilactomycin | 111367-04-5 | Natural Products |
| HY-127008 | N-Butylfluorescein | 335193-91-4 | Dye Reagents |
| HY-127009 | Levoleucovorin | 68538-85-2 | Natural Products |
| HY-12701 | U-99194 | 82668-33-5 | Reference compound |
| HY-127010 | Arnolol | 87129-71-3 | Reference compound |
| HY-127011 | 7-Acetylintermedine | 74243-01-9 | Natural Products |
| HY-127012 | H-0104 (dihydrochloride) | 913636-88-1 | Reference compound |
| HY-127014 | Julimycin B2 | 18126-05-1 | Reference compound |
| HY-127016 | Manninotrionate (potassium) | 122871-01-6 | Reference compound |
| HY-127017 | Histidinomethylalanine | 88495-09-4 | Reference compound |
| HY-127018 | Maltoheptaose | 34620-78-5 | Reference compound |
| HY-127018A | Maltoheptaose (hydrate) | 331748-09-5 | Reference compound |
| HY-127019 | Nigericin | 28380-24-7 | Reference compound |
| HY-127019R | Nigericin (Standard) | 28380-24-7 | Reference Standards |
| HY-12701A | U-99194 (maleate) | 234757-41-6 | Reference compound |
| HY-12702 | 10058-F4 | 403811-55-2 | Reference compound |
| HY-127020 | Deoxyenterocin | 108605-51-2 | Reference compound |
| HY-127022A | Anisodine (hydrobromide) | 76822-34-9 | Natural Products |
| HY-127023 | Eicosapentaenoyl serotonin | 199875-71-3 | Reference compound |
| HY-127024 | Thyroid hormone receptor antagonist (1-850) | 251310-57-3 | Reference compound |
| HY-127025 | 8-Hydroxy loxapine | 61443-77-4 | Reference compound |
| HY-127026 | Quinaprilat | 82768-85-2 | Reference compound |
| HY-127026A | Quinaprilat (hydrate) | 1435786-09-6 | Reference compound |
| HY-127026B | Quinaprilat (hydrochloride) | 82586-58-1 | Reference compound |
| HY-127026R | Quinaprilat (Standard) | 82768-85-2 | Reference Standards |
| HY-127026S | Quinaprilat-d5 | 1279034-23-9 | Isotope-Labeled Compounds |
| HY-127027 | Acetaldophosphamide | 113341-60-9 | Reference compound |
| HY-127028 | Tripynadine | 81849-98-1 | Reference compound |
| HY-127029A | Umbelliprenin | 23838-17-7 | Natural Products |
| HY-12703 | KSI-3716 | 1151813-61-4 | Reference compound |
| HY-127030 | Zatosetron | 123482-22-4 | Reference compound |
| HY-127032 | Polyquaternium-1 | 75345-27-6 | Reference compound |
| HY-127033 | Santalene | 512-61-8 | Natural Products |
| HY-127034 | Antipain (dihydrochloride) | 37682-72-7 | Reference compound |
| HY-127035 | Tristearin | 555-43-1 | Natural Products |
| HY-127035R | Tristearin (Standard) | 555-43-1 | Reference Standards |
| HY-127035S | Tristearin-d105 | 125941-88-0 | Isotope-Labeled Compounds |
| HY-127035S1 | Tristearin-13C3 | 287100-84-9 | Isotope-Labeled Compounds |
| HY-127035S2 | Tristearin-d40 | 33048-69-0 | Isotope-Labeled Compounds |
| HY-127035S3 | Tristearin-d5 | 55256-03-6 | Isotope-Labeled Compounds |
| HY-127035S4 | Tristearin-d9 | 285979-76-2 | Isotope-Labeled Compounds |
| HY-127036 | Tocamphyl | 5634-42-4 | Reference compound |
| HY-127038 | Diflumidone (sodium) | 22737-01-5 | Reference compound |
| HY-127039 | Antipain | 37691-11-5 | Reference compound |
| HY-12703S | KSI-3716-d4 | | Isotope-Labeled Compounds |
| HY-12704 | ITD-1 | 1099644-42-4 | Reference compound |
| HY-127040 | Talastine (hydrochloride) | 16188-76-4 | Reference compound |
| HY-127041 | Virstatin | 88909-96-0 | Reference compound |
| HY-127042 | 6,7-Epoxy-latrunculin A | 122876-48-6 | Natural Products |
| HY-127043 | Pirbenicillin | 63975-62-2 | Reference compound |
| HY-127048 | Trichodermol | 2198-93-8 | Reference compound |
| HY-127049 | Arachidonic acid-biotin | 1217901-28-4 | Dye Reagents |
| HY-12705 | Bromocriptine | 25614-03-3 | Natural Products |
| HY-127052 | Stearonitrile | 638-65-3 | Natural Products |
| HY-127054 | Netilmicin | 56391-56-1 | Reference compound |
| HY-127056 | Sulfo DBCO-amine | 2028284-70-8 | Reference compound |
| HY-127059 | Clindamycin Sulfoxide | 22431-46-5 | Reference compound |
| HY-12705A | Bromocriptine (mesylate) | 22260-51-1 | Reference compound |
| HY-12705AR | Bromocriptine (mesylate) (Standard) | 22260-51-1 | Reference Standards |
| HY-12705S | Bromocriptine-13C,d3 | | Isotope-Labeled Compounds |
| HY-12706 | Spiroxatrine | 1054-88-2 | Reference compound |
| HY-127061 | Palmitoleoyl ethanolamide | 94421-67-7 | Reference compound |
| HY-127063 | Pseudojervine | 36069-05-3 | Natural Products |
| HY-127067 | Yuanhuadin | 76402-66-9 | Natural Products |
| HY-127069 | Methiomeprazine | 7009-43-0 | Reference compound |
| HY-12707 | Piribedil | 3605-01-4 | Reference compound |
| HY-127072 | Amicoumacin A | 78654-44-1 | Natural Products |
| HY-127074 | Chlorendic acid | 115-28-6 | Reference compound |
| HY-127075 | Alahopcin | 82576-50-9 | Reference compound |
| HY-127078 | Salaspermic acid | 71247-78-4 | Natural Products |
| HY-127079 | Epothilone F | 208518-52-9 | Natural Products |
| HY-12707A | Piribedil (dihydrochloride) | 1451048-94-4 | Reference compound |
| HY-12707B | Piribedil (maleate) | 937719-94-3 | Reference compound |
| HY-12707C | Piribedil (hydrochloride) | 78213-63-5 | Reference compound |
| HY-12707R | Piribedil (Standard) | 3605-01-4 | Reference Standards |
| HY-12707S | Piribedil-d8 | 1398044-45-5 | Isotope-Labeled Compounds |
| HY-12708 | Chlorpromazine | 50-53-3 | Reference compound |
| HY-127085 | Acanthifolicin | 77739-71-0 | Natural Products |
| HY-127086 | Dicarbine | 17411-19-7 | Reference compound |
| HY-127086A | Dicarbine (dihydrochloride) | 33162-17-3 | Reference compound |
| HY-127087 | Isogarcinol | 71117-97-0 | Natural Products |
| HY-12709 | ARC 239 | 67339-62-2 | Reference compound |
| HY-127090 | Muramyl dipeptide | 53678-77-6 | Reference compound |
| HY-127093 | Sedecamycin | 23477-98-7 | Reference compound |
| HY-127098 | Kahweol linoleate | 108214-29-5 | Reference compound |
| HY-12709A | ARC 239 (dihydrochloride) | 55974-42-0 | Reference compound |
| HY-12710 | Rauwolscine | 131-03-3 | Natural Products |
| HY-127102 | GSK3494245 | 2080410-41-7 | Reference compound |
| HY-127103 | FB23-2 | 2243736-45-8 | Reference compound |
| HY-127104 | FMF-04-159-2 | 2364489-81-4 | Reference compound |
| HY-127105 | Iptacopan | 1644670-37-0 | Reference compound |
| HY-127105A | Iptacopan (hydrochloride) | 1646321-63-2 | Reference compound |
| HY-127106 | VU0810464 | 2126040-21-7 | Reference compound |
| HY-127109 | Tisolagiline | 1894207-44-3 | Reference compound |
| HY-127109A | Tisolagiline (methylsulfate) | 1894207-45-4 | Reference compound |
| HY-12710A | Rauwolscine (hydrochloride) | 6211-32-1 | Natural Products |
| HY-12711 | 2-Methoxyidazoxan | 102575-24-6 | Reference compound |
| HY-127110 | AK106-001616 | 590416-75-4 | Reference compound |
| HY-127111 | NDI-091143 | 2375840-87-0 | Reference compound |
| HY-127112 | Oleic acid alkyne | 151333-45-8 | Reference compound |
| HY-127113 | Q8 | 1541762-55-3 | Reference compound |
| HY-127118 | Pteropterin | 89-38-3 | Reference compound |
| HY-127118A | Pteropterin (monohydrate) | 6164-84-7 | Reference compound |
| HY-127119 | Benanserin (hydrochloride) | 525-02-0 | Reference compound |
| HY-127120 | Timiperone | 57648-21-2 | Reference compound |
| HY-127122 | Valtorcitabine (dihydrochloride) | 359689-54-6 | Reference compound |
| HY-127125 | Diclofenac ethyl ester | 15307-77-4 | Reference compound |
| HY-127127 | Deamino-NAD | 1851-07-6 | Reference compound |
| HY-127127A | Deamino-NAD (sodium) | 104809-38-3 | Reference compound |
| HY-127128 | Flestolol (sulfate) | 88844-73-9 | Reference compound |
| HY-12713 | Lisuride | 18016-80-3 | Reference compound |
| HY-127130 | Spicamycin | 87099-85-2 | Reference compound |
| HY-127131 | Leucanicidin | 91021-66-8 | Reference compound |
| HY-127133 | Methylpiperidino pyrazole | 289726-02-9 | Reference compound |
| HY-127135 | B07 | 1260629-43-3 | Reference compound |
| HY-127137 | Adenylosuccinic acid | 19046-78-7 | Natural Products |
| HY-127137A | Adenylosuccinic acid (tetraammonium) | | Oligonucleotides |
| HY-127138 | Arctigenin mustard | 26788-57-8 | Natural Products |
| HY-127139 | Eicosapentaenoyl Chloride | 98770-65-1 | Reference compound |
| HY-12714 | TDHL | 37686-84-3 | Reference compound |
| HY-127140 | Cardanol triene | 79353-39-2 | Reference compound |
| HY-127142 | Cephapirin lactone | 60517-75-1 | Reference compound |
| HY-127143 | Sterculic acid | 738-87-4 | Natural Products |
| HY-127144 | α-Saxitoxinol | 75420-34-7 | Reference compound |
| HY-127146 | Platensimycin | 835876-32-9 | Natural Products |
| HY-127147 | Fazadinium (bromide) | 49564-56-9 | Reference compound |
| HY-127149 | Mofarotene | 125533-88-2 | Reference compound |
| HY-127150 | Clofezone | 17449-96-6 | Reference compound |
| HY-127151 | R-(-)-Phencynonate (hydrochloride) | 861655-73-4 | Reference compound |
| HY-127152 | Hippadine | 52886-06-3 | Natural Products |
| HY-127154 | Carmine (lithium) | 12772-56-4 | Dye Reagents |
| HY-127155 | Kigamicin C | 680571-51-1 | Natural Products |
| HY-127156 | Hikizimycin | 12706-94-4 | Reference compound |
| HY-127157 | Aspterric acid | 67309-95-9 | Natural Products |
| HY-127159 | Laurencin | 3442-58-8 | Reference compound |
| HY-12715S | Yohimbine-13C,d3 | 1261254-59-4 | Isotope-Labeled Compounds |
| HY-12715S1 | Yohimbine-d3 | 133146-00-6 | Isotope-Labeled Compounds |
| HY-12716 | BRL-44408 | 118343-19-4 | Reference compound |
| HY-127160 | Benzoxonium (chloride) | 19379-90-9 | Reference compound |
| HY-127160R | Benzoxonium (chloride) (Standard) | 19379-90-9 | Reference Standards |
| HY-127162 | Prostaglandin K1 | 69413-73-6 | Reference compound |
| HY-127165 | Velnacrine | 124027-47-0 | Reference compound |
| HY-127165S | Velnacrine-d3 | 1219806-47-9 | Isotope-Labeled Compounds |
| HY-127165S1 | Velnacrine-d3 (maleate) | | Isotope-Labeled Compounds |
| HY-127165S2 | Velnacrine-d4 (hydrochloride) | 1246816-08-9 | Isotope-Labeled Compounds |
| HY-127165S3 | Velnacrine-d4 | 1246911-78-3 | Isotope-Labeled Compounds |
| HY-127166 | Colchiceine | 477-27-0 | Natural Products |
| HY-127166R | Colchiceine (Standard) | 477-27-0 | Reference Standards |
| HY-127167 | 3',4'-Dihydroxyflavone | 4143-64-0 | Reference compound |
| HY-127168 | 6,7-Dihydroxyflavone | 38183-04-9 | Natural Products |
| HY-12716A | BRL-44408 (maleate) | 681806-46-2 | Reference compound |
| HY-12717 | Phentolamine | 50-60-2 | Reference compound |
| HY-127170 | 3-Hydroxycoumarin | 939-19-5 | Natural Products |
| HY-127178 | ML120 analog 1 | 445426-74-4 | Reference compound |
| HY-12717A | Phentolamine (hydrochloride) | 73-05-2 | Reference compound |
| HY-12717AS | Phentolamine-d4 (hydrochloride) | 1346599-65-2 | Isotope-Labeled Compounds |
| HY-12717R | Phentolamine (Standard) | 50-60-2 | Reference Standards |
| HY-12718A | (±)-WB 4101 (hydrochloride) | 2170-58-3 | Reference compound |
| HY-12719 | Dexmedetomidine | 113775-47-6 | Reference compound |
| HY-12719R | Dexmedetomidine (Standard) | 113775-47-6 | Reference Standards |
| HY-12720 | Apraclonidine | 66711-21-5 | Reference compound |
| HY-12720A | Apraclonidine (hydrochloride) | 73218-79-8 | Reference compound |
| HY-12720AR | Apraclonidine (hydrochloride) (Standard) | 73218-79-8 | Reference Standards |
| HY-12720B | Apraclonidine (dihydrochloride) | 73217-88-6 | Reference compound |
| HY-12721 | Clonidine | 4205-90-7 | Reference compound |
| HY-12721R | Clonidine (Standard) | 4205-90-7 | Reference Standards |
| HY-12721S | Clonidine-d4 (hydrochloride) | 67151-02-4 | Isotope-Labeled Compounds |
| HY-12723 | Apomorphine | 58-00-4 | Reference compound |
| HY-12724 | Guanabenz | 5051-62-7 | Reference compound |
| HY-12724A | Guanabenz (hydrochloride) | 23113-43-1 | Reference compound |
| HY-12725 | ML324 | 1222800-79-4 | Reference compound |
| HY-12726 | Liproxstatin-1 | 950455-15-9 | Reference compound |
| HY-12726A | Liproxstatin-1 (hydrochloride) | 2250025-95-5 | Reference compound |
| HY-12726S | Liproxstatin-1-13C6 | | Isotope-Labeled Compounds |
| HY-12726S1 | Liproxstatin-1-15N | | Isotope-Labeled Compounds |
| HY-12727 | EPZ015666 | 1616391-65-1 | Reference compound |
| HY-12731 | GSK2236805 | 1256390-53-0 | Reference compound |
| HY-12732 | PTC 725 | 1248581-07-8 | Reference compound |
| HY-12733 | AZD5248 | 1254318-44-9 | Reference compound |
| HY-12734 | AM-8735 | 1429386-01-5 | Reference compound |
| HY-12735 | SCH 900822 | 1220894-09-6 | Reference compound |
| HY-12736 | GSK143 | 1240390-27-5 | Reference compound |
| HY-12736A | GSK143 (dihydrochloride) | 2341796-81-2 | Reference compound |
| HY-12738 | PF-3882845 | 1023650-66-9 | Reference compound |
| HY-12740 | Lotamilast | 947620-48-6 | Reference compound |
| HY-12741 | LDN-212320 | 894002-50-7 | Reference compound |
| HY-12742 | SCR7 | 1533426-72-0 | Reference compound |
| HY-12743 | K-7174 | 191089-59-5 | Reference compound |
| HY-12743A | K-7174 (dihydrochloride) | 191089-60-8 | Reference compound |
| HY-12744 | Genz-123346 (free base) | 491833-30-8 | Reference compound |
| HY-12744A | Genz-123346 | 943344-58-9 | Reference compound |
| HY-12746 | DC-05 | 890643-16-0 | Reference compound |
| HY-12747 | DC_517 | 500017-70-9 | Reference compound |
| HY-12749 | Midodrine | 42794-76-3 | Reference compound |
| HY-12749A | Midodrine (hydrochloride) | 43218-56-0 | Reference compound |
| HY-12749AS | Midodrine-d6 (hydrochloride) | 1188265-43-1 | Isotope-Labeled Compounds |
| HY-12749B | (R)-Midodrine (hydrochloride) | 133163-28-7 | Reference compound |
| HY-12750 | AZD3965 | 1448671-31-5 | Reference compound |
| HY-12751 | Trimethobenzamide | 138-56-7 | Reference compound |
| HY-12751A | Trimethobenzamide (hydrochloride) | 554-92-7 | Reference compound |
| HY-12751AR | Trimethobenzamide (hydrochloride) (Standard) | 554-92-7 | Reference Standards |
| HY-12751S | Trimethobenzamide-d6 | | Isotope-Labeled Compounds |
| HY-12752 | Alimemazine | 84-96-8 | Reference compound |
| HY-12752A | Alimemazine hemitartrate | 4330-99-8 | Reference compound |
| HY-12752AR | Alimemazine hemitartrate (Standard) | 4330-99-8 | Reference Standards |
| HY-12752BS | Alimemazine-d6 (hydrochloride) | 1352792-16-5 | Isotope-Labeled Compounds |
| HY-12752S | Alimemazine-d6 | 1346603-88-0 | Isotope-Labeled Compounds |
| HY-12753A | Debutyldronedarone (hydrochloride) | 197431-02-0 | Reference compound |
| HY-12753AR | Debutyldronedarone (hydrochloride) (Standard) | 197431-02-0 | Reference Standards |
| HY-12753AS | Debutyldronedarone-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-12753S | Debutyldronedarone-d7 | | Isotope-Labeled Compounds |
| HY-12753S1 | Debutyldronedarone-d6 (hydrochloride) | 1346598-70-6 | Isotope-Labeled Compounds |
| HY-12754 | ML228 | 1357171-62-0 | Reference compound |
| HY-12755 | ML141 | 71203-35-5 | Reference compound |
| HY-12756 | E6446 | 1219925-73-1 | Reference compound |
| HY-12756A | E6446 (dihydrochloride) | 1345675-25-3 | Reference compound |
| HY-12757 | YHO-13177 | 912287-56-0 | Reference compound |
| HY-12758 | YHO-13351 | 1346753-00-1 | Reference compound |
| HY-12758A | YHO-13351 (free base) | 912288-64-3 | Reference compound |
| HY-12759 | CARM1-IN-1 | 1020399-49-8 | Reference compound |
| HY-12759A | CARM1-IN-1 (hydrochloride) | 2070018-31-2 | Reference compound |
| HY-12760 | Indoramin | 26844-12-2 | Reference compound |
| HY-12760S | Indoramin-d5 | 57165-41-0 | Isotope-Labeled Compounds |
| HY-12761 | A-836339 | 959746-77-1 | Reference compound |
| HY-12761R | A-836339 (Standard) | 959746-77-1 | Reference Standards |
| HY-12762 | QS11 | 944328-88-5 | Reference compound |
| HY-12763 | GNE-317 | 1394076-92-6 | Reference compound |
| HY-12764 | 6-OAU | 83797-69-7 | Reference compound |
| HY-12764R | 6-OAU (Standard) | 83797-69-7 | Reference Standards |
| HY-12765 | Losartan Carboxylic Acid | 124750-92-1 | Reference compound |
| HY-12765R | Losartan Carboxylic Acid (Standard) | 124750-92-1 | Reference Standards |
| HY-12765S | Losartan-d4 (carboxylic acid) | 1246820-62-1 | Isotope-Labeled Compounds |
| HY-12765S1 | Losartan carboxylic acid-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-12766 | Bupropion morpholinol | 357399-43-0 | Reference compound |
| HY-12766S | Bupropion morpholinol-d6 | 1216893-18-3 | Isotope-Labeled Compounds |
| HY-12767 | Carvedilol metabolite 4-Hydroxyphenyl Carvedilol | 142227-49-4 | Reference compound |
| HY-12767S | 4-Hydroxyphenyl Carvedilol-d5 | 1261395-96-3 | Isotope-Labeled Compounds |
| HY-12767S1 | Carvedilol metabolite 4-Hydroxyphenyl Carvedilol-d4 | | Isotope-Labeled Compounds |
| HY-12767S2 | Carvedilol metabolite 4-Hydroxyphenyl Carvedilol-13C6 | | Isotope-Labeled Compounds |
| HY-12768 | Sotuletinib | 953769-46-5 | Reference compound |
| HY-12768A | Sotuletinib (hydrochloride) | 2222138-31-8 | Reference compound |
| HY-12768B | Sotuletinib (dihydrochloride) | 2222138-40-9 | Reference compound |
| HY-12769 | Mebeverine acid | 475203-77-1 | Reference compound |
| HY-12769R | Mebeverine acid (Standard) | 475203-77-1 | Reference Standards |
| HY-12769S | Mebeverine acid-d5 | 2070015-30-2 | Isotope-Labeled Compounds |
| HY-12769S1 | Mebeverine acid-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-12769S2 | Mebeverine acid-d3 | | Isotope-Labeled Compounds |
| HY-12770 | Mebeverine alcohol | 14367-47-6 | Reference compound |
| HY-12770R | Mebeverine alcohol (Standard) | 14367-47-6 | Reference Standards |
| HY-12770S | Mebeverine alcohol-d5 | 2070015-15-3 | Isotope-Labeled Compounds |
| HY-12770S1 | Mebeverine alcohol-d3 | | Isotope-Labeled Compounds |
| HY-12771 | O-desmethyl Mebeverine acid | 586357-02-0 | Reference compound |
| HY-12771S | O-Desmethyl Mebeverine acid-d5 | 1329488-46-1 | Isotope-Labeled Compounds |
| HY-12771S1 | O-desmethyl Mebeverine acid D5 hydrochloride | | Isotope-Labeled Compounds |
| HY-12771S2 | O-Desmethyl Mebeverine acid-d6 | 1630732-39-6 | Isotope-Labeled Compounds |
| HY-12772 | Hydroxy Itraconazole | 112559-91-8 | Reference compound |
| HY-12772A | rel-Hydroxy Itraconazole | 207970-87-4 | Reference compound |
| HY-12772R | Hydroxy Itraconazole (Standard) | 112559-91-8 | Reference Standards |
| HY-12772S | Hydroxy Itraconazole-d8 | | Isotope-Labeled Compounds |
| HY-12772S1 | (2R,4S)-Hydroxy Itraconazole-d8 | 1217516-26-1 | Isotope-Labeled Compounds |
| HY-12772S2 | (2R,4S)-Hydroxy Itraconazole-d5 | 1217524-77-0 | Isotope-Labeled Compounds |
| HY-12772S3 | Hydroxy Itraconazole-d6 | | Isotope-Labeled Compounds |
| HY-12773AS | 5-Hydroxy Propafenone-d5 (hydrochloride) | 1215370-87-8 | Isotope-Labeled Compounds |
| HY-12773AS1 | 5-Hydroxy Propafenone-d5-1 (hydrochloride) | 1188265-48-6 | Isotope-Labeled Compounds |
| HY-12773AS2 | 5-Hydroxy Propafenone-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-12774 | IC261 | 186611-52-9 | Reference compound |
| HY-12776 | GSK805 | 1426802-50-7 | Reference compound |
| HY-12777 | Asivatrep | 1005168-10-4 | Reference compound |
| HY-12778 | Ivabradine metabolite N-Demethyl Ivabradine (hydrochloride) | 1246638-08-3 | Reference compound |
| HY-12778R | Ivabradine metabolite N-Demethyl Ivabradine (hydrochloride) (Standard) | 1246638-08-3 | Reference Standards |
| HY-12778S | N-Demethyl Ivabradine-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-12779 | Cyantraniliprole | 736994-63-1 | Reference compound |
| HY-12779R | Cyantraniliprole (Standard) | 736994-63-1 | Reference Standards |
| HY-12779S | Cyantraniliprole-d3 | 1392493-34-3 | Isotope-Labeled Compounds |
| HY-12781 | Desbutyl Lumefantrine | 355841-11-1 | Reference compound |
| HY-12781S | Desbutyl Lumefantrine-d9 | 1346606-35-6 | Isotope-Labeled Compounds |
| HY-12782T | Iadademstat (dihydrochloride) | 1431303-72-8 | Reference compound |
| HY-12783 | SCH 50911 (hydrochloride) | 160415-07-6 | Reference compound |
| HY-12783A | SCH 50911 | 733717-87-8 | Reference compound |
| HY-12784 | Cycloguanil | 516-21-2 | Reference compound |
| HY-12784A | Cycloguanil (hydrochloride) | 152-53-4 | Reference compound |
| HY-12784AR | Cycloguanil (hydrochloride) (Standard) | 152-53-4 | Reference Standards |
| HY-12784AS | Cycloguanil-d4 (hydrochloride) | 1189427-23-3 | Isotope-Labeled Compounds |
| HY-12784AS1 | Cycloguanil-d6 (hydrochloride) | 2712364-69-5 | Isotope-Labeled Compounds |
| HY-12784S | Cycloguanil-d6 | | Isotope-Labeled Compounds |
| HY-12784S1 | Cycloguanil-d6(nitrate) | | Isotope-Labeled Compounds |
| HY-12785 | Albendazole sulfoxide | 54029-12-8 | Reference compound |
| HY-12785R | Albendazole sulfoxide (Standard) | 54029-12-8 | Reference Standards |
| HY-12785S | Albendazole sulfoxide-d3 | 1448346-38-0 | Isotope-Labeled Compounds |
| HY-12785S1 | Albendazole sulfoxide-d7 | 2469575-37-7 | Isotope-Labeled Compounds |
| HY-12787 | L-779450 | 303727-31-3 | Reference compound |
| HY-12788 | PF-04449613 | 1236858-52-8 | Reference compound |
| HY-12788A | (S)-PF-04449613 | | Reference compound |
| HY-12789 | Etrasimod | 1206123-37-6 | Reference compound |
| HY-12790 | CB1-IN-1 | 1429239-98-4 | Reference compound |
| HY-12791 | hPGDS-IN-1 | 1234708-04-3 | Reference compound |
| HY-12793 | Padnarsertib | 1643913-93-2 | Reference compound |
| HY-12794 | Vps34-PIK-III | 1383716-40-2 | Reference compound |
| HY-12795 | Vps34-IN-1 | 1383716-33-3 | Reference compound |
| HY-12796 | Raxatrigine | 934240-30-9 | Reference compound |
| HY-12796A | Raxatrigine (hydrochloride) | 934240-31-0 | Reference compound |
| HY-12797 | GF 15 | 888042-13-5 | Reference compound |
| HY-12798 | Netarsudil | 1254032-66-0 | Reference compound |
| HY-12798A | Netarsudil (dimesylate) | 1422144-42-0 | Reference compound |
| HY-12798B | Netarsudil (hydrochloride) | 1253952-02-1 | Reference compound |
| HY-12798C | AR-13503 | 2309668-15-1 | Reference compound |
| HY-12798CR | AR-13503 (Standard) | 2309668-15-1 | Reference Standards |
| HY-12798E | (R)-AR-13503 | 2377238-62-3 | Reference compound |
| HY-128000 | ML095 | 1135318-57-8 | Reference compound |
| HY-128004 | ML171 analog 1 | 1730-44-5 | Reference compound |
| HY-12801 | DiZPK | 1337883-32-5 | Reference compound |
| HY-12801A | DiZPK (hydrochloride) | 2349295-23-2 | Reference compound |
| HY-12802 | AF38469 | 1531634-31-7 | Reference compound |
| HY-128024 | VHR-IN-1 | 956189-91-6 | Reference compound |
| HY-128026 | MMP-9/MMP-13 Inhibitor I | 204140-01-2 | Reference compound |
| HY-128027 | eCF309 | 2001571-40-8 | Reference compound |
| HY-128029 | Glycogen phosphorylase-IN-1 | 648926-15-2 | Reference compound |
| HY-128030 | Makisterone A | 20137-14-8 | Natural Products |
| HY-128031 | Resolvin D1 methyl ester | 937738-63-1 | Reference compound |
| HY-128033 | Fenpropimorph | 67564-91-4 | Reference compound |
| HY-128033R | Fenpropimorph (Standard) | 67564-91-4 | Reference Standards |
| HY-128034 | PPIase-Parvulin inhibitor | 64005-90-9 | Reference compound |
| HY-128035 | ML-211 | 2205032-89-7 | Reference compound |
| HY-128036B | ddATP (trisodium) | 72029-21-1 | Reference compound |
| HY-128036C | ddATP (tetrasodium) | | Reference compound |
| HY-128038 | N-Desmethyl-loperamide | 66164-07-6 | Reference compound |
| HY-128038S | N-Desmethyl-loperamide-d3 | 1189488-17-2 | Isotope-Labeled Compounds |
| HY-128039 | 17-Phenyl-ω-trinor-PGE2 | 38315-43-4 | Reference compound |
| HY-12804 | VAS2870 | 722456-31-7 | Reference compound |
| HY-128040 | Virodhamine (hydrochloride) | 443129-35-9 | Reference compound |
| HY-128041 | alpha-Hydroxy farnesyl phosphonic acid | 148796-53-6 | Reference compound |
| HY-128043 | 11-Deoxy prostaglandin E1 | 37786-00-8 | Reference compound |
| HY-128044 | Ftase inhibitor I | 149759-96-6 | Reference compound |
| HY-128045 | Fenoxazoline | 4846-91-7 | Reference compound |
| HY-128047 | GALK1-IN-1 | 669718-48-3 | Reference compound |
| HY-12805 | ML171 | 6631-94-3 | Reference compound |
| HY-128057 | NCRW0005-F05 | 342779-66-2 | Reference compound |
| HY-12806 | AG1557 | 189290-58-2 | Reference compound |
| HY-128060 | PDE5-IN-42 | 936449-28-4 | Reference compound |
| HY-128062 | LIMK1 inhibitor BMS-4 | 905298-84-2 | Reference compound |
| HY-128063 | CXCR3 antagonist 1 | 870998-13-3 | Reference compound |
| HY-128064 | Adenosine amine congener | 96760-69-9 | Reference compound |
| HY-128067 | 5-(N,N-Hexamethylene)-amiloride | 1428-95-1 | Reference compound |
| HY-128068 | DHODH-IN-17 | 16344-26-6 | Reference compound |
| HY-12807 | FIPI | 939055-18-2 | Reference compound |
| HY-128075 | Acifluorfen | 50594-66-6 | Reference compound |
| HY-128075R | Acifluorfen (Standard) | 50594-66-6 | Reference Standards |
| HY-12807A | FIPI (hydrochloride) | 1781834-93-2 | Reference compound |
| HY-12808 | STF-118804 | 894187-61-2 | Reference compound |
| HY-12809 | Optovin | 348575-88-2 | Reference compound |
| HY-128090 | Apstatin | 160470-73-5 | Reference compound |
| HY-128090A | Apstatin (TFA) | | Reference compound |
| HY-12810 | EHop-016 | 1380432-32-5 | Reference compound |
| HY-128103 | Glucagon receptor antagonist-7 | 438618-32-7 | Reference compound |
| HY-128105 | 1,2-Dihydroxynaphthalene | 574-00-5 | Natural Products |
| HY-12811 | PF-04856264 | 1235397-05-3 | Reference compound |
| HY-128111 | ASN02563583 | 483283-39-2 | Reference compound |
| HY-128113 | AG-09/1 | 356776-32-4 | Reference compound |
| HY-12812 | Autotaxin modulator 1 | 1548743-69-6 | Reference compound |
| HY-128121 | MLS1547 | 315698-36-3 | Reference compound |
| HY-128126 | B-TPMF | 477865-65-9 | Reference compound |
| HY-128127 | NAEPA | 24435-25-4 | Reference compound |
| HY-128128 | ASN04421891 | 570365-12-7 | Reference compound |
| HY-128129 | UT-B-IN-1 | 892742-76-6 | Reference compound |
| HY-12813 | PDE10-IN-1 | 1516896-09-5 | Reference compound |
| HY-128131 | UCCF-029 (free base) | 2110-25-0 | Reference compound |
| HY-128132 | C3a receptor agonist 1 | 944997-60-8 | Reference compound |
| HY-128133 | MMP-8 inhibitor-1 | 236403-25-1 | Reference compound |
| HY-128135 | MHY 553 | 6265-56-1 | Reference compound |
| HY-128139 | 2'-C-Methylguanosine | 374750-30-8 | Reference compound |
| HY-12813A | PDE10-IN-2 | 1516895-53-6 | Reference compound |
| HY-12814 | TH588 | 1609960-31-7 | Reference compound |
| HY-128140 | Z-FY-CHO | 167498-29-5 | Reference compound |
| HY-128142 | PKC/PKD-IN-1 | 1071135-06-2 | Reference compound |
| HY-128144 | Lalistat 2 | 1234569-09-5 | Reference compound |
| HY-128145 | HSD17B13-IN-41 | 1122660-25-6 | Reference compound |
| HY-128146 | 2-Nitrophenanthraquinone | 604-95-5 | Reference compound |
| HY-128147 | MetAP-2-IN-6 | 5301-98-4 | Reference compound |
| HY-12814A | TH588 (hydrochloride) | 1640282-30-9 | Reference compound |
| HY-12815 | MCC950 | 210826-40-7 | Reference compound |
| HY-128153 | Thienopyridone | 1018454-97-1 | Reference compound |
| HY-12815A | MCC950 (sodium) | 256373-96-3 | Reference compound |
| HY-128170 | Ebsulfur | 2527-03-9 | Reference compound |
| HY-128171 | Diflapolin | 724453-98-9 | Reference compound |
| HY-128172 | TRPM4-IN-2 | 667411-04-3 | Reference compound |
| HY-128174 | β-CCM | 69954-48-9 | Reference compound |
| HY-128189 | Aminoacyl tRNA synthetase-IN-4 | 342017-94-1 | Reference compound |
| HY-12819 | MK-1421 | 1235995-16-0 | Reference compound |
| HY-12820 | Sibofimloc | 1616113-45-1 | Reference compound |
| HY-128200 | Pseudomonas quinolone signal | 108985-27-9 | Reference compound |
| HY-128204 | AN3661 | 1268335-33-6 | Reference compound |
| HY-128205 | BTD | 896684-04-1 | Reference compound |
| HY-128206 | I3MT-3 | 459420-09-8 | Reference compound |
| HY-128207 | SID7970631 | 868224-75-3 | Reference compound |
| HY-12820R | Sibofimloc (Standard) | 1616113-45-1 | Reference Standards |
| HY-12821 | AEBSF (hydrochloride) | 30827-99-7 | Reference compound |
| HY-128221 | SGK1-IN-5 | 1426214-51-8 | Reference compound |
| HY-128222 | Selenosemicarbazide | 21198-79-8 | Reference compound |
| HY-128224 | Antiproliferative agent-13 | 663214-48-0 | Reference compound |
| HY-128229 | AHR antagonist 6 | 378223-81-5 | Reference compound |
| HY-12823 | BLU9931 | 1538604-68-0 | Reference compound |
| HY-128231 | GRK6-IN-4 | 300731-73-1 | Reference compound |
| HY-128234 | PDE11-IN-1 | 522652-41-1 | Reference compound |
| HY-12824 | RNPA1000 | 359600-10-5 | Reference compound |
| HY-12824R | RNPA1000 (Standard) | 359600-10-5 | Reference Standards |
| HY-12825 | BHPI | 56632-39-4 | Reference compound |
| HY-12826 | IMB-XH1 | 292057-76-2 | Reference compound |
| HY-128268 | PFK-IN-1 | 735303-62-5 | Reference compound |
| HY-12827 | Sortin1 | 503837-98-7 | Reference compound |
| HY-12828 | KH-CB19 | 1354037-26-5 | Reference compound |
| HY-12828A | KH-CB20 | 1354448-60-4 | Reference compound |
| HY-12829 | SR-3306 | 1128096-91-2 | Reference compound |
| HY-12830 | M-110 | 1395048-49-3 | Reference compound |
| HY-12831 | Ampkinone | 1233082-79-5 | Reference compound |
| HY-128311 | GRK6-IN-3 | 499231-87-7 | Reference compound |
| HY-12832 | JNJ-42041935 | 1193383-09-3 | Reference compound |
| HY-12833 | AMZ30 | 1313613-09-0 | Reference compound |
| HY-128333 | PI3K/mTOR Inhibitor-4 | 2361215-32-7 | Reference compound |
| HY-128334 | PCSK9 modulator-2 | 2365416-53-9 | Reference compound |
| HY-128337 | AN7973 | 1620899-32-2 | Reference compound |
| HY-128338 | CETP-IN-3 | 939391-31-8 | Reference compound |
| HY-128339 | Autogramin-1 | 2375541-73-2 | Reference compound |
| HY-12834 | MK2-IN-1 | 1314118-92-7 | Reference compound |
| HY-128340 | Autogramin-2 | 2375541-45-8 | Reference compound |
| HY-128341 | ERK5-IN-2 | 1888305-96-1 | Reference compound |
| HY-128342 | Complement C5-IN-1 | 2365402-67-9 | Reference compound |
| HY-128343 | KDM4-IN-2 | 2369607-62-3 | Reference compound |
| HY-128344 | BR102375 | 2366255-59-4 | Reference compound |
| HY-128345 | UDM-001651 | 1477497-01-0 | Reference compound |
| HY-128346 | PQM130 | 2089415-51-8 | Reference compound |
| HY-128347 | M‑89 | 2363165-42-6 | Reference compound |
| HY-128348 | PK68 | 2173556-69-7 | Reference compound |
| HY-128349 | MT-3014 | 1332727-40-8 | Reference compound |
| HY-12834A | MK2-IN-1 (hydrochloride) | 1314118-94-9 | Reference compound |
| HY-12835 | S1P1 agonist III | 1324003-64-6 | Reference compound |
| HY-128350 | FGTI-2734 | 1247018-19-4 | Reference compound |
| HY-128350A | FGTI-2734 (mesylate) | 2702297-24-1 | Reference compound |
| HY-128351 | SHR1653 | 2231770-73-1 | Reference compound |
| HY-128352 | SMYD3-IN-1 | 2095160-79-3 | Reference compound |
| HY-128353 | ROR agonist-1 | 2361528-74-5 | Reference compound |
| HY-128354 | CWHM-1552 | 2368253-58-9 | Reference compound |
| HY-128355 | IDO/TDO-IN-1 | 2033173-01-0 | Reference compound |
| HY-128355A | (R)-IDO/TDO-IN-1 | 2033173-00-9 | Reference compound |
| HY-128356 | SPL-410 | 2351886-00-3 | Reference compound |
| HY-128357 | Ibezapolstat | 1275582-97-2 | Reference compound |
| HY-128357A | Ibezapolstat (hydrochloride) | 1275582-98-3 | Reference compound |
| HY-128358 | MR-L2 | 2374703-19-0 | Reference compound |
| HY-128359 | ACBI1 | 2375564-55-7 | Reference compound |
| HY-12836 | IFN alpha-IFNAR-IN-1 | 844882-93-5 | Reference compound |
| HY-128360 | dMCL1-2 | 2351218-88-5 | Reference compound |
| HY-128361 | SLC26A3-IN-3 | 2369983-43-5 | Reference compound |
| HY-128362 | Ep300/CREBBP-IN-8 | 2259641-24-0 | Reference compound |
| HY-128363 | Ep300/CREBBP-IN-2 | 2259641-59-1 | Reference compound |
| HY-128364 | Ep300/CREBBP-IN-3 | 2259641-47-7 | Reference compound |
| HY-128365 | Neticonazole (hydrochloride) | 130773-02-3 | Reference compound |
| HY-128366 | Waltonitone | 1252676-55-3 | Natural Products |
| HY-128367 | Ep300/CREBBP-IN-4 | 2259641-42-2 | Reference compound |
| HY-128369 | Acid Yellow 36 | 587-98-4 | Dye Reagents |
| HY-12836A | IFN alpha-IFNAR-IN-1 (hydrochloride) | 2070014-98-9 | Reference compound |
| HY-12837 | EN460 | 496807-64-8 | Reference compound |
| HY-128370 | Calcium trinatrium diethylenetriaminepentaacetic acid (hydrate) | 207226-35-5 | Reference compound |
| HY-128371 | 2-Methylhexanoic acid | 4536-23-6 | Reference compound |
| HY-128371R | 2-?Methylhexanoic acid (Standard) | 4536-23-6 | Reference Standards |
| HY-128374 | D-Glucose 6-phosphate (disodium salt) | 3671-99-6 | Natural Products |
| HY-128374R | D-Glucose 6-phosphate (disodium salt) (Standard) | 3671-99-6 | Reference Standards |
| HY-128378 | 16-Dehydroprogesterone | 1096-38-4 | Natural Products |
| HY-128379 | Labetalone (hydrochloride) | 96441-14-4 | Reference compound |
| HY-128379R | Labetalone (hydrochloride) (Standard) | 96441-14-4 | Reference Standards |
| HY-12838 | RO5454948 | 1386979-55-0 | Reference compound |
| HY-128380 | Dibenamine (hydrochloride) | 55-43-6 | Reference compound |
| HY-128382 | Brilliant Black BN | 2519-30-4 | Dye Reagents |
| HY-128383 | 1-Methylpyrrolidine | 120-94-5 | Reference compound |
| HY-128383S | 1-Methylpyrrolidine-d8 | 131857-29-9 | Isotope-Labeled Compounds |
| HY-128383S1 | 1-Methylpyrrolidine-d3 | 77422-30-1 | Isotope-Labeled Compounds |
| HY-128384 | Benzyldodecyldimethylammonium (chloride dihydrate) | 147228-80-6 | Reference compound |
| HY-128386 | Cinitapride (monotartrate) | 1207859-16-2 | Reference compound |
| HY-128387 | 2,3-Butanediol | 513-85-9 | Natural Products |
| HY-128387R | 2,3-Butanediol (Standard) | 513-85-9 | Reference Standards |
| HY-128387S | 2,3-Butanediol-d6 | | Isotope-Labeled Compounds |
| HY-128387S1 | 2,3-Butanediol-d8 | 347841-77-4 | Isotope-Labeled Compounds |
| HY-128389 | 1-Furfurylpyrrole | 1438-94-4 | Reference compound |
| HY-128389R | 1-?Furfurylpyrrole (Standard) | 1438-94-4 | Reference Standards |
| HY-12839 | p38 MAPK-IN-1 | 1006378-90-0 | Reference compound |
| HY-128393 | Trilinolein | 537-40-6 | Natural Products |
| HY-128393R | Trilinolein (Standard) | 537-40-6 | Reference Standards |
| HY-128393S1 | Trilinolein-13C54 | | Isotope-Labeled Compounds |
| HY-128394 | L-Gulose | 6027-89-0 | Reference compound |
| HY-128394R | L-Gulose (Standard) | 6027-89-0 | Reference Standards |
| HY-128397 | CpCDPK1/TgCDPK1-IN-1 | 1092788-23-2 | Reference compound |
| HY-128398 | CpCDPK1/TgCDPK1-IN-2 | 1236038-23-5 | Reference compound |
| HY-128399 | CpCDPK1/TgCDPK1-IN-3 | 1092788-87-8 | Reference compound |
| HY-12840 | OBA-09 | 856095-68-6 | Reference compound |
| HY-128400 | 4'-Methoxychalcone | 959-23-9 | Natural Products |
| HY-128402 | P2X3-IN-1 | 2823331-49-1 | Reference compound |
| HY-128403 | BTK inhibitor 8 | 2230724-66-8 | Reference compound |
| HY-128407 | 2,2-Dihydroxy-1-phenylethan-1-one | 1075-06-5 | Reference compound |
| HY-12841 | KHK-IN-1 | 1303469-70-6 | Reference compound |
| HY-128410 | 4-Phenyl-7,8-dihydroxycoumarin | 842-01-3 | Reference compound |
| HY-128416 | 6-Chloro-7-hydroxy-4-methylcoumarin | 19492-02-5 | Reference compound |
| HY-128417 | alpha-D-glucose | 492-62-6 | Natural Products |
| HY-128417A | alpha-D-glucose (hydrate) | 14431-43-7 | Biochemical Assay Reagents |
| HY-128417AR | alpha-D-glucose (hydrate) (Standard) | 14431-43-7 | Reference Standards |
| HY-128417R | alpha-D-glucose (Standard) | 492-62-6 | Reference Standards |
| HY-128417S | alpha-D-glucose-d12 | 1379594-94-1 | Isotope-Labeled Compounds |
| HY-128417S1 | Alpha-D-glucose-13C | 287100-64-5 | Isotope-Labeled Compounds |
| HY-128417S3 | alpha-D-glucose-d7 | 23403-54-5 | Isotope-Labeled Compounds |
| HY-128417S4 | alpha-D-glucose-13C6 | 40010-60-4 | Isotope-Labeled Compounds |
| HY-128417S5 | alpha-D-glucose-13C6,d7 | | Isotope-Labeled Compounds |
| HY-128418 | Benzonatate (PEGn) | 32760-16-0 | Reference compound |
| HY-128419 | Biguanidinium-porphyrin | 1014978-87-0 | Reference compound |
| HY-12841A | KHK-IN-1 (hydrochloride) | 1303470-48-5 | Reference compound |
| HY-12842 | UC-112 | 383392-66-3 | Reference compound |
| HY-128420 | Lobeline (sulfate) | 134-64-5 | Natural Products |
| HY-128421 | Tridecanedioic acid | 505-52-2 | Natural Products |
| HY-128421R | Tridecanedioic acid (Standard) | 505-52-2 | Reference Standards |
| HY-128423 | Tylvalosin (tartrate) | 63428-13-7 | Reference compound |
| HY-128423A | Tylvalosin | 63409-12-1 | Reference compound |
| HY-128423AS | Tylvalosin-d9 | | Isotope-Labeled Compounds |
| HY-128423R | Tylvalosin (tartrate) (Standard) | 63428-13-7 | Reference Standards |
| HY-128424 | 4'-Deoxyphlorizin | 4319-68-0 | Reference compound |
| HY-128425 | N-Carbamoyl-DL-aspartic acid | 923-37-5 | Natural Products |
| HY-128425A | N-Carbamoyl-L-aspartic acid | 13184-27-5 | Natural Products |
| HY-128425R | N-?Carbamoyl-?DL-?aspartic acid (Standard) | 923-37-5 | Reference Standards |
| HY-128426 | Trans-2-butene-1,4-dicarboxylic acid | 4436-74-2 | Natural Products |
| HY-128426R | Trans-?2-?butene-?1,?4-?dicarboxylic acid (Standard) | 4436-74-2 | Reference Standards |
| HY-128427 | PLpro-IN-1 | 1093070-10-0 | Reference compound |
| HY-128428 | Carboprost | 35700-23-3 | Reference compound |
| HY-128428R | Carboprost (Standard) | 35700-23-3 | Reference Standards |
| HY-128429 | trans-2-Hexenal | 6728-26-3 | Natural Products |
| HY-128429S | trans-2-Hexenal-d2-1 | 164791-70-2 | Isotope-Labeled Compounds |
| HY-12843 | Bohemine | 189232-42-6 | Reference compound |
| HY-128430 | Farnesyl acetate | 29548-30-9 | Natural Products |
| HY-128431 | Arochlor 1254 | 11097-69-1 | Reference compound |
| HY-128433 | CK1-IN-3 | 349438-74-0 | Reference compound |
| HY-128434 | L-Leucyl-L-alanine | 7298-84-2 | Natural Products |
| HY-128434R | L-?Leucyl-?L-?alanine (Standard) | 7298-84-2 | Reference Standards |
| HY-128435 | 2,4'-Dihydroxybenzophenone-1 | 606-12-2 | Natural Products |
| HY-128436 | KT-531 | 2490284-18-7 | Reference compound |
| HY-128437 | TGFβ-IN-5 | 259870-32-1 | Reference compound |
| HY-128439 | BT173 | 2232180-74-2 | Reference compound |
| HY-12844 | Ro 64-6198 | 280783-56-4 | Reference compound |
| HY-128442 | Phenyl sulfate | 937-34-8 | Reference compound |
| HY-128443 | Benzyldimethylstearylammonium (chloride) | 122-19-0 | Reference compound |
| HY-128443R | Benzyldimethylstearylammonium (chloride) (Standard) | 122-19-0 | Reference Standards |
| HY-128446 | CAY10781 | 1210360-87-4 | Reference compound |
| HY-128447 | Allyl methyl sulfide | 10152-76-8 | Natural Products |
| HY-128447R | Allyl methyl sulfide (Standard) | 10152-76-8 | Reference Standards |
| HY-128448 | Carmoisine | 3567-69-9 | Dye Reagents |
| HY-128448R | Carmoisine (Standard) | 3567-69-9 | Dye Reagents |
| HY-128449 | Cephradine (monohydrate) | 75975-70-1 | Reference compound |
| HY-12845 | UNC2400 | 1433200-49-7 | Reference compound |
| HY-128450 | JAK-STAT-IN-1 | 1236666-76-4 | Reference compound |
| HY-128452 | 2'-Hydroxy-2-methoxychalcone | 42220-77-9 | Reference compound |
| HY-128454 | Dimethyl trisulfide | 3658-80-8 | Natural Products |
| HY-128454R | Dimethyl trisulfide (Standard) | 3658-80-8 | Reference Standards |
| HY-128454S | Dimethyl trisulfide-d6 | 58069-93-5 | Isotope-Labeled Compounds |
| HY-128459 | N-Demethylerythromycin A | 992-62-1 | Reference compound |
| HY-128459R | N-Demethylerythromycin A (Standard) | 992-62-1 | Reference Standards |
| HY-12846 | CCT196969 | 1163719-56-9 | Reference compound |
| HY-128463 | N-tert-Butyl-α-phenylnitrone | 3376-24-7 | Reference compound |
| HY-128463S | N-tert-Butyl-α-phenylnitrone-d14 | 119391-92-3 | Isotope-Labeled Compounds |
| HY-128464 | LL320 | 2672496-32-9 | Reference compound |
| HY-128465 | 1,2-Dilauroyl-sn-glycerol | 60562-15-4 | Reference compound |
| HY-128466 | N-Biotinyl-L-cysteine | 151009-85-7 | Biochemical Assay Reagents |
| HY-128467 | Dehydroacetic acid (sodium) | 4418-26-2 | Reference compound |
| HY-128467R | Dehydroacetic acid (sodium) (Standard) | 4418-26-2 | Reference Standards |
| HY-128468 | 1,2-Dimyristoyl-sn-glycerol | 60562-16-5 | Oligonucleotides |
| HY-128469 | Inaperisone | 99323-21-4 | Reference compound |
| HY-12847 | CCT241161 | 1163719-91-2 | Reference compound |
| HY-128470 | Mitoquidone | 91753-07-0 | Reference compound |
| HY-128473 | Valeryl salicylate | 64206-54-8 | Reference compound |
| HY-128476 | Sodium Tartrate | 868-18-8 | Reference compound |
| HY-128476R | Sodium Tartrate (Standard) | 868-18-8 | Reference Standards |
| HY-128479 | JYL-273 | 1391826-17-7 | Reference compound |
| HY-12848 | SAG | 912545-86-9 | Reference compound |
| HY-128480 | Sulfamidopyrine (sodium salt) | 129-89-5 | Reference compound |
| HY-128481 | SB24011 | 1497415-41-4 | Reference compound |
| HY-128482 | Diazobenzenesulfonic acid | 2154-66-7 | Reference compound |
| HY-128483 | Fusaric acid | 536-69-6 | Natural Products |
| HY-128483R | Fusaric acid (Standard) | 536-69-6 | Reference Standards |
| HY-128487 | H-Trp-Glu-OH | 36099-95-3 | Reference compound |
| HY-128488 | Antibiotic TAN-592B | 99685-75-3 | Natural Products |
| HY-12848A | (Rac)-SAG | 364590-63-6 | Reference compound |
| HY-12848B | SAG (hydrochloride) | 2095432-58-7 | Reference compound |
| HY-12848C | SAG (dihydrochloride) | 2702366-44-5 | Reference compound |
| HY-12848R | SAG (Standard) | 912545-86-9 | Reference Standards |
| HY-12848S | SAG-d3 | | Isotope-Labeled Compounds |
| HY-128490 | 4'-Acetyl-chrysomycin B | 2673269-86-6 | Reference compound |
| HY-128493 | PLK4-IN-4 | 2923999-01-1 | Reference compound |
| HY-128498 | Anticancer agent 182 | 133342-90-2 | Natural Products |
| HY-12850 | Dasotraline | 675126-05-3 | Reference compound |
| HY-128502 | Nifurtoinol | 1088-92-2 | Reference compound |
| HY-128509 | Dioxidine | 17311-31-8 | Reference compound |
| HY-12850A | Dasotraline (hydrochloride) | 675126-08-6 | Reference compound |
| HY-128510 | Colterol | 18866-78-9 | Reference compound |
| HY-128510A | Colterol (hydrochloride) | 52872-37-4 | Reference compound |
| HY-128511 | Piridoxilate | 24340-35-0 | Reference compound |
| HY-128514 | Minimycin | 32388-21-9 | Reference compound |
| HY-128515 | Metaterol | 3571-71-9 | Reference compound |
| HY-12852 | Diclosulam | 145701-21-9 | Reference compound |
| HY-128522 | ARS-1323-alkyne | 2436544-27-1 | Reference compound |
| HY-128523 | Kgp-IN-1 | 2097865-36-4 | Reference compound |
| HY-128523A | Kgp-IN-1 (hydrochloride) | 2097865-47-7 | Reference compound |
| HY-128525 | Enterobactin | 28384-96-5 | Reference compound |
| HY-128525R | Enterobactin (Standard) | 28384-96-5 | Reference Standards |
| HY-128527 | PROTAC ER Degrader-3 | 2158322-29-1 | Reference compound |
| HY-128528 | PROTAC ER Degrader-2 | | Reference compound |
| HY-12853 | Mesotrione | 104206-82-8 | Reference compound |
| HY-128530 | Tetrathiomolybdate | 16330-92-0 | Reference compound |
| HY-128532 | Formononetin 7-O-β-D-glucuronide | 18524-03-3 | Reference compound |
| HY-128536 | KMG-104AM | 2436544-28-2 | Dye Reagents |
| HY-12853R | Mesotrione (Standard) | 104206-82-8 | Reference Standards |
| HY-12854 | Imetelstat | 868169-64-6 | Oligonucleotides |
| HY-128544A | Proroxan (hydrochloride) | 33025-33-1 | Reference compound |
| HY-128545 | Nitrazine yellow | 5423-07-4 | Biochemical Assay Reagents |
| HY-128546 | Flupranone | 21686-10-2 | Reference compound |
| HY-12855 | Lys01 | 1391426-22-4 | Reference compound |
| HY-128550 | Carboprost methyl | 35700-21-1 | Reference compound |
| HY-128551 | Droprenilamine | 57653-27-7 | Reference compound |
| HY-128553 | Antineoplaston A10 | 91531-30-5 | Natural Products |
| HY-128553A | (Rac)-Antineoplaston A10 | 77658-84-5 | Reference compound |
| HY-128554 | N-Desethyl amodiaquine | 79352-78-6 | Reference compound |
| HY-128554A | N-Desethyl amodiaquine dihydrochloride | 79049-30-2 | Reference compound |
| HY-128554AR | N-Desethyl amodiaquine dihydrochloride (Standard) | 79049-30-2 | Reference Standards |
| HY-128554S | N-Desethyl amodiaquine-d5 | 1173023-19-2 | Isotope-Labeled Compounds |
| HY-128554S1 | N-Desethyl amodiaquine-d5 (dihydrochloride) | 1216894-33-5 | Isotope-Labeled Compounds |
| HY-12855A | Lys05 | 1391426-24-6 | Reference compound |
| HY-12856 | GSK503 | 1346572-63-1 | Reference compound |
| HY-128561 | AM12 | 2387510-84-9 | Reference compound |
| HY-128569 | ALK-IN-5 | 2351929-66-1 | Reference compound |
| HY-12857 | Brigatinib | 1197953-54-0 | Reference compound |
| HY-128570 | FD-IN-1 | 1646682-14-5 | Reference compound |
| HY-128571 | FLT3-IN-4 | 2304799-09-3 | Reference compound |
| HY-128572 | FLT3-IN-6 | 2377141-31-4 | Reference compound |
| HY-128573 | RORγt Inverse agonist 3 | 2364429-77-4 | Reference compound |
| HY-128574 | GLUT4 activator 1 | 2253733-37-6 | Reference compound |
| HY-128575 | BNC375 | 1557240-80-8 | Reference compound |
| HY-128576 | DS21360717 | 2304654-43-9 | Reference compound |
| HY-128577 | NIC3 | 494830-67-0 | Reference compound |
| HY-128578 | KPLH1130 | 906669-07-6 | Reference compound |
| HY-128579 | DW14800 | 2243709-60-4 | Reference compound |
| HY-12857S | Brigatinib-13C6 | | Isotope-Labeled Compounds |
| HY-12857S2 | Brigatinib-d11 | 2055306-76-6 | Isotope-Labeled Compounds |
| HY-12858 | Empesertib | 1443763-60-7 | Reference compound |
| HY-128580 | FAK inhibitor 2 | 2354405-14-2 | Reference compound |
| HY-128581 | γ-Secretase modulator 4 | 1420200-82-3 | Reference compound |
| HY-128582 | PI3K/HDAC-IN-1 | 2361418-52-0 | Reference compound |
| HY-128583 | G150 | 2369751-30-2 | Reference compound |
| HY-128584 | VU6005806 | 2180914-37-6 | Reference compound |
| HY-128585 | GNE684 | 2438637-64-8 | Reference compound |
| HY-128586 | TAS4464 | 1848959-10-3 | Reference compound |
| HY-128586A | TAS4464 (hydrochloride) | 1848959-11-4 | Reference compound |
| HY-128587 | Mevociclib | 1816989-16-8 | Reference compound |
| HY-128588 | STAT3-IN-3 | 2361304-26-7 | Reference compound |
| HY-128589 | CHMFL-KIT-033 | 2351801-41-5 | Reference compound |
| HY-12859 | BAY1217389 | 1554458-53-5 | Reference compound |
| HY-128590 | PHT-7.3 | 1614225-93-2 | Reference compound |
| HY-128591 | DIPQUO | 1269365-82-3 | Reference compound |
| HY-128592 | TAB29 | 2361144-71-8 | Reference compound |
| HY-128593 | TPN171 | 1229018-87-4 | Reference compound |
| HY-128594 | BACE1-IN-4 | 2361157-92-6 | Reference compound |
| HY-128595 | MT-4 | 2327925-35-7 | Reference compound |
| HY-128596 | ALK-IN-6 | 2055821-33-3 | Reference compound |
| HY-128597 | BRD-IN-3 | 2351938-32-2 | Reference compound |
| HY-128598 | MD2-TLR4-IN-1 | 2249801-12-3 | Reference compound |
| HY-128599 | NMS-P515 | 1262395-13-0 | Reference compound |
| HY-12860 | BMS-986115 | 1584647-27-7 | Reference compound |
| HY-128600 | ERD-308 | 2320561-35-9 | Reference compound |
| HY-128601 | CHK1-IN-3 | 2097252-39-4 | Reference compound |
| HY-128602 | c-Kit-IN-2 | 2121515-37-3 | Reference compound |
| HY-128604 | XY101 | 2349368-16-5 | Reference compound |
| HY-128605 | PD-1-IN-22 | 2349372-98-9 | Reference compound |
| HY-128606 | Thiamine diphosphate analog 1 | 2606-90-8 | Reference compound |
| HY-128607 | Mcl1-IN-9 | 1810769-31-3 | Reference compound |
| HY-12861 | CB-5083 | 1542705-92-9 | Reference compound |
| HY-128612 | Methylnitronitrosoguanidine | 70-25-7 | Reference compound |
| HY-128617 | Legumain inhibitor 1 | 2361157-34-6 | Reference compound |
| HY-12862 | Mps1-IN-7 | 1578244-34-4 | Reference compound |
| HY-12863 | Pelabresib | 1380087-89-7 | Reference compound |
| HY-128634 | Anticancer agent 164 | 2235393-30-1 | Reference compound |
| HY-12863B | CPI-0610 carboxylic acid | 1380089-81-5 | Reference compound |
| HY-12864 | Brilanestrant | 1365888-06-7 | Reference compound |
| HY-128642 | FAPI-2 | 2370952-98-8 | Reference compound |
| HY-128642A | FAPI-2 (TFA) | | Reference compound |
| HY-128643 | FAPI-4 | 2374782-02-0 | Reference compound |
| HY-128656 | LML134 | 1542135-76-1 | Reference compound |
| HY-12866 | Larotrectinib | 1223403-58-4 | Reference compound |
| HY-128661 | IDH1 Inhibitor 2 | 2244895-42-7 | Reference compound |
| HY-128669 | Abemaciclib metabolite M2 | 1231930-57-6 | Reference compound |
| HY-128669R | Abemaciclib metabolite M2 (Standard) | 1231930-57-6 | Reference Standards |
| HY-128669S | Abemaciclib metabolite M2-d6 | | Isotope-Labeled Compounds |
| HY-12866A | Larotrectinib sulfate | 1223405-08-0 | Reference compound |
| HY-12866B | (R)-Larotrectinib | 1223404-68-9 | Reference compound |
| HY-12866R | Larotrectinib (Standard) | 1223403-58-4 | Reference Standards |
| HY-12867 | PT-2385 | 1672665-49-4 | Reference compound |
| HY-128671 | 6-Thioinosine | 574-25-4 | Reference compound |
| HY-128675 | γ-D-Glutamylaminomethylsulfonic acid | 90237-02-8 | Peptides |
| HY-128676 | N-ε-propargyloxycarbonyl-L-lysine (hydrochloride) | 1428330-91-9 | Reference compound |
| HY-128677 | NCC007 | 2342583-66-6 | Reference compound |
| HY-128678 | ORM-10103 | 488847-28-5 | Reference compound |
| HY-128679 | TBK1/IKKε-IN-5 | 1893397-65-3 | Reference compound |
| HY-12868 | Bimiralisib | 1225037-39-7 | Reference compound |
| HY-128680 | c-Fms-IN-9 | 1628574-50-4 | Reference compound |
| HY-128681 | PGAM1-IN-1 | 2438637-65-9 | Reference compound |
| HY-128682 | PGAM1-IN-2 | 2438637-66-0 | Reference compound |
| HY-128683 | Cycloposine | 23185-94-6 | Natural Products |
| HY-128685 | FD 12-9 | 1451741-22-2 | Reference compound |
| HY-128686 | KAG-308 | 1215192-68-9 | Reference compound |
| HY-128689 | Anticancer agent 3 | 146537-05-5 | Reference compound |
| HY-12869 | AZD-8835 | 1620576-64-8 | Reference compound |
| HY-128692 | Lucifer Yellow CH (dilithium salt) | 67769-47-5 | Dye Reagents |
| HY-128693 | BpV(HOpic) | 722494-26-0 | Reference compound |
| HY-128694 | Foropafant | 136468-36-5 | Reference compound |
| HY-128695 | Oleanolic acid hemiphthalate disodium salt | 168770-31-8 | Reference compound |
| HY-128696 | Amlodipine aspartic acid impurity | 400602-35-9 | Peptides |
| HY-128696R | Amlodipine aspartic acid impurity (Standard) | 400602-35-9 | Reference Standards |
| HY-128699 | D-Desthiobiotin | 533-48-2 | Natural Products |
| HY-12870 | AZD9496 | 1639042-08-2 | Reference compound |
| HY-128700 | Nicotinic acid mononucleotide | 321-02-8 | Natural Products |
| HY-128700A | Nicotinic acid mononucleotide (triethylamine) | | Reference compound |
| HY-128701 | cis-9,trans-12-Tetradecadienyl acetate | 31654-77-0 | Biochemical Assay Reagents |
| HY-128703 | Bromodomain inhibitor-8 | 1300031-70-2 | Reference compound |
| HY-128706 | (+)-Menthofuran | 17957-94-7 | Natural Products |
| HY-128706R | (+)-Menthofuran (Standard) | 17957-94-7 | Reference Standards |
| HY-128707 | Z-LEVD-FMK | 1135688-25-3 | Reference compound |
| HY-128708 | ACPK | 1304056-21-0 | Reference compound |
| HY-12870A | AZD9496 (maleate) | 1639042-28-6 | Reference compound |
| HY-12871 | Atuveciclib (Racemate) | 1414943-88-6 | Reference compound |
| HY-128710 | 2'-Fluorothymidine | 122799-38-6 | Reference compound |
| HY-128711 | MAL-di-EG-Val-Cit-PAB-MMAF | | ADC Related |
| HY-128712 | NCGC00029283 | 714240-31-0 | Reference compound |
| HY-128715 | Fluperlapine | 67121-76-0 | Reference compound |
| HY-128716 | Pomalidomide-PEG3-C2-NH2 | 2093416-31-8 | Reference compound |
| HY-128716A | Pomalidomide-PEG3-C2-NH2 (TFA) | 2414913-97-4 | Reference compound |
| HY-128716B | Pomalidomide-PEG3-C2-NH2 (hydrochloride) | 2446474-09-3 | Reference compound |
| HY-128717 | GSK3368715 | 1629013-22-4 | Reference compound |
| HY-128717A | GSK3368715 (dihydrochloride) | 1628925-77-8 | Reference compound |
| HY-128717B | GSK3368715 (trihydrochloride) | 2227587-26-8 | Reference compound |
| HY-128717C | GSK3368715 (hydrochloride) | 2227587-25-7 | Reference compound |
| HY-128718 | Carbodine | 71184-20-8 | Reference compound |
| HY-12871A | (+)-Atuveciclib | 1414943-94-4 | Reference compound |
| HY-12871B | Atuveciclib | 2923012-24-0 | Reference compound |
| HY-12871C | Atuveciclib S-Enantiomer | 2250279-81-1 | Reference compound |
| HY-12872 | Nazartinib | 1508250-71-2 | Reference compound |
| HY-128720 | Diethyl oxalpropionate | 759-65-9 | Natural Products |
| HY-128721 | KX-01-191 | 2211903-84-1 | Reference compound |
| HY-128722 | HIV-1 inhibitor-3 | 1612841-22-1 | Reference compound |
| HY-128723 | Dapagliflozin impurity | 960404-86-8 | Reference compound |
| HY-128724 | CB-5339 | 1863952-15-1 | Reference compound |
| HY-128726 | ITK inhibitor 2 | 1309784-09-5 | Reference compound |
| HY-128729 | DNA2 inhibitor C5 | 35973-25-2 | Reference compound |
| HY-12872A | Nazartinib mesylate | 1508250-72-3 | Reference compound |
| HY-12872B | Nazartinib S-enantiomer | 1508256-20-9 | Reference compound |
| HY-12873 | RBC8 | 361185-42-4 | Reference compound |
| HY-128730 | Acetyl phosphate (lithium potassium) | 94249-01-1 | Natural Products |
| HY-128731 | 5-Methoxy-DL-tryptophan | 28052-84-8 | Natural Products |
| HY-128732 | rel-(2R,3S)-2,3-Dihydroxysuccinic acid (hydrate) | 5990-63-6 | Natural Products |
| HY-128733 | Phenyl acetate | 122-79-2 | Natural Products |
| HY-128733R | Phenyl acetate (Standard) | 122-79-2 | Reference Standards |
| HY-128733S | Phenyl acetate-d5 | 22705-26-6 | Isotope-Labeled Compounds |
| HY-128734 | Dihydroxyfumaric acid (hydrate) | 199926-38-0 | Natural Products |
| HY-128735 | N-Formylglycine | 2491-15-8 | Natural Products |
| HY-128735S | N-Formylglycine-d2 | | Isotope-Labeled Compounds |
| HY-128736 | L-2-Phosphoglyceric acid | 23295-92-3 | Natural Products |
| HY-128736B | D-2-Phosphoglyceric acid | 3443-57-0 | Reference compound |
| HY-128736C | L-2-Phosphoglyceric acid (sodium hydrate) | | Reference compound |
| HY-128737 | Methyl β-D-Galactopyranoside | 1824-94-8 | Natural Products |
| HY-128738 | Thymidine-5'-monophosphate (disodium) salt | 33430-62-5 | Natural Products |
| HY-128738R | Thymidine-5'-monophosphate (disodium) salt (Standard) | 33430-62-5 | Reference Standards |
| HY-128738S | Thymidine-5'-monophosphate-13C10,15N2 (disodium) | 1485539-28-3 | Isotope-Labeled Compounds |
| HY-128739 | Isomaltulose (hydrate) | 343336-76-5 | Natural Products |
| HY-128739R | Isomaltulose (hydrate) (Standard) | 343336-76-5 | Reference Standards |
| HY-12874 | CASIN | 425399-05-9 | Reference compound |
| HY-128740 | Mesoxalate (sodium) (monohydrate) | 31635-99-1 | Natural Products |
| HY-128741 | D-Allose | 2595-97-3 | Natural Products |
| HY-128741R | D-Allose (Standard) | 2595-97-3 | Reference Standards |
| HY-128741S | D-Allose-13C | 70849-28-4 | Isotope-Labeled Compounds |
| HY-128741S1 | D-Allose-13C-1 | | Isotope-Labeled Compounds |
| HY-128741S2 | D-Allose-13C-2 | | Isotope-Labeled Compounds |
| HY-128742 | Thiamine monophosphate (chloride) (dihydrate) | 273724-21-3 | Natural Products |
| HY-128742R | Thiamine monophosphate (chloride) (dihydrate) (Standard) | 273724-21-3 | Reference Standards |
| HY-128743 | 12-Hydroxydodecanoic acid | 505-95-3 | Natural Products |
| HY-128743R | 12-Hydroxydodecanoic acid (Standard) | 505-95-3 | Reference Standards |
| HY-128744 | Phosphonoacetic acid | 4408-78-0 | Natural Products |
| HY-128744R | Phosphonoacetic acid (Standard) | 4408-78-0 | Reference Standards |
| HY-128745 | D-Glucosamic acid | 3646-68-2 | Natural Products |
| HY-128746 | 2,6-Diaminoheptanedioic acid | 583-93-7 | Natural Products |
| HY-128746R | 2,6-Diaminoheptanedioic acid (Standard) | 583-93-7 | Reference Standards |
| HY-128746S | 2,6-Diaminoheptanedioic acid-13C7,15N2 | | Isotope-Labeled Compounds |
| HY-128746S1 | 2,6-Diaminoheptanedioic acid-15N2 | | Isotope-Labeled Compounds |
| HY-128747 | α-D-Glucose-1-phosphate (disodium) | 56401-20-8 | Natural Products |
| HY-128747A | α-D-Glucose-1-phosphate (disodium hydrate) | 230954-92-4 | Natural Products |
| HY-128747R | α-D-Glucose-1-phosphate (disodium) (Standard) | 56401-20-8 | Reference Standards |
| HY-128748 | DL-Glyceraldehyde | 56-82-6 | Natural Products |
| HY-128748S | DL-Glyceraldehyde-1-13C | 70849-18-2 | Isotope-Labeled Compounds |
| HY-128748S1 | DL-Glyceraldehyde-2-13C | 71122-43-5 | Isotope-Labeled Compounds |
| HY-128748S2 | DL-Glyceraldehyde-13C,d | 72599-69-0 | Isotope-Labeled Compounds |
| HY-128748S4 | DL-Glyceraldehyde-13C3 | 478529-56-5 | Isotope-Labeled Compounds |
| HY-128749 | D-Glucaric acid (potassium) | 576-42-1 | Natural Products |
| HY-128749A | D-Glucaric acid (tetrahydrate) | 5793-89-5 | Reference compound |
| HY-128749AR | D-Glucaric acid (tetrahydrate) (Standard) | 5793-89-5 | Reference Standards |
| HY-12875 | BQU57 | 1637739-82-2 | Reference compound |
| HY-128750 | (Z)-4-Amino-4-oxobut-2-enoic acid | 557-24-4 | Natural Products |
| HY-128752 | Uridine 5'-triphosphate (tris) salt | 108321-53-5 | Natural Products |
| HY-128753 | D-Lyxose | 1114-34-7 | Natural Products |
| HY-128753R | D-Lyxose (Standard) | 1114-34-7 | Reference Standards |
| HY-128753S3 | D-Lyxose-13C-2 | 70849-22-8 | Isotope-Labeled Compounds |
| HY-128753S4 | D-Lyxose-13C-3 | 83379-39-9 | Isotope-Labeled Compounds |
| HY-128753S5 | D-Lyxose-13C-4 | 139657-61-7 | Isotope-Labeled Compounds |
| HY-128753S6 | D-Lyxose-d | 288846-88-8 | Isotope-Labeled Compounds |
| HY-128753S7 | D-Lyxose-d-1 | | Isotope-Labeled Compounds |
| HY-128754 | Monoolein | 111-03-5 | Natural Products |
| HY-128754R | Monoolein (Standard) | 111-03-5 | Reference Standards |
| HY-128754S | Monoolein-d5 | 565183-24-6 | Isotope-Labeled Compounds |
| HY-128754S1 | Monoolein-d7 | 2260669-49-4 | Isotope-Labeled Compounds |
| HY-128756 | SIAIS178 | 2376047-73-1 | Reference compound |
| HY-128757 | Remibrutinib | 1787294-07-8 | Reference compound |
| HY-128758 | DYRKs-IN-1 | 1387090-01-8 | Reference compound |
| HY-128758A | DYRKs-IN-1 (hydrochloride) | 1386980-55-7 | Reference compound |
| HY-128759 | DYRKs-IN-2 | 1386980-04-6 | Reference compound |
| HY-128760 | COH34 | 906439-72-3 | Reference compound |
| HY-128761 | CBP/p300-IN-2 | 2158265-96-2 | Reference compound |
| HY-128763 | HDAC-IN-4 | 1252003-13-6 | Reference compound |
| HY-128766 | CHK1-IN-4 | 2120398-41-4 | Reference compound |
| HY-128766A | CHK1-IN-4 (hydrochloride) | | Reference compound |
| HY-128767 | VH032-PEG3-acetylene | 2098799-80-3 | Reference compound |
| HY-128769 | M2N12 | 2376577-06-7 | Reference compound |
| HY-128770 | LY3154207 | 1638667-79-4 | Reference compound |
| HY-128771 | K-Ras G12C-IN-4 | 2376328-55-9 | Reference compound |
| HY-128772 | XPC-6444 | 2230144-21-3 | Reference compound |
| HY-128773 | MRL-494 | 2434898-43-6 | Reference compound |
| HY-128773A | MRL-494 (hydrochloride) | 2699937-04-5 | Reference compound |
| HY-128774 | AM-6494 | 1874232-80-0 | Reference compound |
| HY-128775 | JHU395 | 2079938-92-2 | Reference compound |
| HY-128776 | Antitumor agent-19 | 2379727-90-7 | Reference compound |
| HY-128777 | WEHI-9625 | 2595314-46-6 | Reference compound |
| HY-128778 | Gozanertinib | 1226549-49-0 | Reference compound |
| HY-128780 | Upleganan | 2407717-17-1 | Reference compound |
| HY-128780B | SPR206 (acetate) | 2408422-41-1 | Reference compound |
| HY-128781 | Glucagon receptor antagonist-5 | 2200274-63-9 | Reference compound |
| HY-128783 | VU0090157 | 312622-77-8 | Reference compound |
| HY-128784 | PK11007 | 874146-69-7 | Reference compound |
| HY-128787 | hDHODH-IN-4 | 1644156-56-8 | Reference compound |
| HY-128788 | ddhCTP | 2279171-34-3 | Reference compound |
| HY-12879 | IWP-4 | 686772-17-8 | Reference compound |
| HY-128790 | 4-Methoxyestrone | 58562-33-7 | Reference compound |
| HY-128790S | 4-Methoxyestrone-13C,d3 | 1217437-34-7 | Isotope-Labeled Compounds |
| HY-128790S1 | 4-Methoxyestrone-13C6 | | Isotope-Labeled Compounds |
| HY-128792 | 1,3-Dipalmitin | 502-52-3 | Natural Products |
| HY-128792S | 1,3-Dipalmitin-d6 | 2692624-34-1 | Isotope-Labeled Compounds |
| HY-128793 | trans-Stilbene | 103-30-0 | Dye Reagents |
| HY-128793S | trans-Stilbene-13C2 | 153610-50-5 | Isotope-Labeled Compounds |
| HY-128793S1 | trans-Stilbene-d12 | 16341-52-9 | Isotope-Labeled Compounds |
| HY-128793S2 | trans-Stilbene-d10 | 20748-24-7 | Isotope-Labeled Compounds |
| HY-128793S3 | trans-Stilbene-d2 | 5284-44-6 | Isotope-Labeled Compounds |
| HY-128794 | PF-05150122 | 1235406-00-4 | Reference compound |
| HY-128798 | Menin-MLL inhibitor 20 | 2448173-47-3 | Reference compound |
| HY-128799 | CL097 | 1026249-18-2 | Reference compound |
| HY-128799A | CL097 (hydrochloride) | 2990770-48-2 | Reference compound |
| HY-12880 | HA-100 (dihydrochloride) | 210297-47-5 | Reference compound |
| HY-128801 | NH2-PEG3-C1-Boc | 189808-70-6 | Reference compound |
| HY-128802 | Tos-PEG3-O-C1-CH3COO | 855120-17-1 | Reference compound |
| HY-128803 | Tos-PEG4-NH-Boc | 1246999-33-6 | Reference compound |
| HY-128804 | PEG3-O-CH2COOH | 51951-05-4 | Reference compound |
| HY-128805 | Tos-PEG3-NH-Boc | 206265-94-3 | Reference compound |
| HY-128806 | E3 ligase Ligand 9 | 87304-15-2 | Reference compound |
| HY-128807 | E3 ligase Ligand 10 | 1073560-68-5 | Reference compound |
| HY-128808 | cIAP1 ligand 1 | 2095244-42-9 | Reference compound |
| HY-128809 | cIAP1 ligand 2 | 2357114-70-4 | Reference compound |
| HY-12881 | Eliprodil | 119431-25-3 | Reference compound |
| HY-128810 | E3 ligase Ligand 13 | 2701565-75-3 | Reference compound |
| HY-128811 | E3 ligase Ligand 14 | 2241489-43-8 | Reference compound |
| HY-128812 | cIAP1 Ligand-Linker Conjugates 11 | 1239943-19-1 | Reference compound |
| HY-128812A | cIAP1 Ligand-Linker Conjugates 11 (Hydrochloride) | 1239866-59-1 | Reference compound |
| HY-128813 | cIAP1 Ligand-Linker Conjugates 15 | 1225433-96-4 | Reference compound |
| HY-128813A | cIAP1 Ligand-Linker Conjugates 15 (hydrochloride) | 1225383-36-7 | Reference compound |
| HY-128814 | cIAP1 Ligand-Linker Conjugates 6 (hydrochloride) | | Reference compound |
| HY-128815 | cIAP1 Ligand-Linker Conjugates 14 | 1351169-40-8 | Reference compound |
| HY-128816 | cIAP1 Ligand-Linker Conjugates 2 | 1312302-14-9 | Reference compound |
| HY-128816A | cIAP1 Ligand-Linker Conjugates 2 (Hydrochloride) | | Reference compound |
| HY-128817 | cIAP1 Ligand-Linker Conjugates 12 | 2095244-52-1 | Reference compound |
| HY-128818 | cIAP1 Ligand-Linker Conjugates 5 | 2113688-20-1 | Reference compound |
| HY-128819 | cIAP1 Ligand-Linker Conjugates 3 | 2222354-20-1 | Reference compound |
| HY-12882 | Ifenprodil | 23210-56-2 | Reference compound |
| HY-128820 | cIAP1 Ligand-Linker Conjugates 1 | 2357114-75-9 | Reference compound |
| HY-128821 | cIAP1 Ligand-Linker Conjugates 4 | | Reference compound |
| HY-128822 | cIAP1 Ligand-Linker Conjugates 13 | | Reference compound |
| HY-128823 | cIAP1 Ligand-Linker Conjugates 7 | | Reference compound |
| HY-128824 | cIAP1 Ligand-Linker Conjugates 9 | | Reference compound |
| HY-128825 | cIAP1 Ligand-Linker Conjugates 8 | | Reference compound |
| HY-128826 | cIAP1 Ligand-Linker Conjugates 10 | | Reference compound |
| HY-128828 | 2-Hydroxy atorvastatin (calcium salt) | 265989-46-6 | Reference compound |
| HY-128829 | Kv3 modulator 2 | 2101321-76-8 | Reference compound |
| HY-12882A | Ifenprodil (tartrate) | 23210-58-4 | Natural Products |
| HY-12883 | PF 05089771 | 1235403-62-9 | Reference compound |
| HY-128830 | Kv3 modulator 3 | 1498186-01-8 | Reference compound |
| HY-128831 | Kv3 modulator 4 | 2173375-10-3 | Reference compound |
| HY-128832 | Nutlin-C1-amido-PEG4-C2-N3 | | Reference compound |
| HY-128833 | Bis-NH2-PEG2 | 929-59-9 | Reference compound |
| HY-128834 | N3-PEG4-C2-NH2 | 951671-92-4 | Reference compound |
| HY-128835 | Phenol-amido-C1-PEG3-N3 | 1096439-18-7 | Reference compound |
| HY-128836 | (4R,5S)-Nutlin carboxylic acid | 2306390-08-7 | Reference compound |
| HY-128837 | Nutlin carboxylic acid | 2249750-27-2 | Reference compound |
| HY-128838 | PROTAC ERRα Degrader-1 | 2306388-84-9 | Reference compound |
| HY-128838A | (rel)-PROTAC ERRα Degrader-1 | | Reference compound |
| HY-128839 | PROTAC ERRα Degrader-2 | 2306388-85-0 | Reference compound |
| HY-12883A | PF-05198007 | 1235406-19-5 | Reference compound |
| HY-12883B | PF 05089771 (tosylate) | 1430806-04-4 | Reference compound |
| HY-12884 | OAC2 | 6019-39-2 | Reference compound |
| HY-128840 | PROTAC MDM2 Degrader-1 | 2249944-98-5 | Reference compound |
| HY-128841 | PROTAC MDM2 Degrader-2 | 2249944-99-6 | Reference compound |
| HY-128842 | PROTAC MDM2 Degrader-3 | 2249750-23-8 | Reference compound |
| HY-128843 | PROTAC MDM2 Degrader-4 | 2249750-24-9 | Reference compound |
| HY-128844 | Bis-NH2-C1-PEG3 | 4246-51-9 | Reference compound |
| HY-128845 | PROTAC CRBN Degrader-1 | 2358775-70-7 | Reference compound |
| HY-128846 | Pomalidomide-C2-NH2 | 1957235-66-3 | Reference compound |
| HY-128846A | Pomalidomide-C2-NH2 (hydrochloride) | 2305369-00-8 | Reference compound |
| HY-128847 | Bis-PEG1-C-PEG1-CH2COOH | 2358775-67-2 | Reference compound |
| HY-128848 | Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH | 2351103-63-2 | Reference compound |
| HY-128849 | Eprodisate | 21668-77-9 | Reference compound |
| HY-12885 | 2’3’-c-di-AM(PS)2 (Rp,Rp) | 1638241-89-0 | Reference compound |
| HY-128850 | N-Acetyl-D-mannosamine | 3615-17-6 | Reference compound |
| HY-128850R | N-Acetyl-D-mannosamine (Standard) | 3615-17-6 | Reference Standards |
| HY-128850S1 | N-Acetyl-D-mannosamine-13C | | Isotope-Labeled Compounds |
| HY-128850S2 | N-Acetyl-D-mannosamine-13C-1 | | Isotope-Labeled Compounds |
| HY-128850S5 | N-Acetyl-D-mannosamine-15N | | Isotope-Labeled Compounds |
| HY-128851 | Coenzyme A | 85-61-0 | Natural Products |
| HY-128851A | Coenzyme A (trilithium) | 18439-24-2 | Biochemical Assay Reagents |
| HY-128851B | Coenzyme A (sodium) | 55672-92-9 | Biochemical Assay Reagents |
| HY-128851R | Coenzyme A (Standard) | 85-61-0 | Reference Standards |
| HY-128852 | N-Acetyl-D-galactosamine, 98% | 14215-68-0 | Biochemical Assay Reagents |
| HY-128853 | Taurodeoxycholate (sodium salt) | 1180-95-6 | Natural Products |
| HY-128853R | Taurodeoxycholate (sodium salt) (Standard) | 1180-95-6 | Reference Standards |
| HY-128853S | Taurodeoxycholate-d6 (sodium salt) | 2687960-92-3 | Isotope-Labeled Compounds |
| HY-128854 | Dimethyl biphenyl-4,4'-dicarboxylate | 792-74-5 | Reference compound |
| HY-128854S | Dimethyl biphenyl-4,4'-dicarboxylate-d8 | 1219803-50-5 | Isotope-Labeled Compounds |
| HY-128855 | Talsaclidine | 147025-53-4 | Reference compound |
| HY-128856 | P7C3-OMe | 313268-18-7 | Reference compound |
| HY-128859 | EMT inhibitor-2 | 2232228-60-1 | Reference compound |
| HY-12885A | 2’3’-c-di-AM(PS)2 (Rp,Rp) (disodium salt) | 1638750-95-4 | Reference compound |
| HY-12885B | 2’3’-c-di-AM(PS)2 (Rp,Rp) (ammonium salt) | 1638750-96-5 | Reference compound |
| HY-12885C | 2’3’-c-di-AM(PS)2 (Rp,Rp) enantiomer (ammonium salt) | | Reference compound |
| HY-12886 | Docebenone | 80809-81-0 | Reference compound |
| HY-128860 | Mutated EGFR-IN-2 | 2050906-97-1 | Reference compound |
| HY-128862 | EGFR-IN-7 | 2267329-76-8 | Reference compound |
| HY-128865 | BPR1M97 | 2059904-66-2 | Reference compound |
| HY-128866 | TBAJ-876 | 2332841-25-3 | Reference compound |
| HY-128866A | (Rac)-TBAJ-876 | 2131784-39-7 | Reference compound |
| HY-128867 | bio-THZ1 | 1604811-14-4 | Reference compound |
| HY-128868 | FITC-Dextran (MW 10000) | 60842-46-8 | Dye Reagents |
| HY-128868A | FITC-Dextran (MW 4000) | 60842-46-8 | Dye Reagents |
| HY-128868B | FITC-Dextran (MW 3000-5000) | 60842-46-8 | Dye Reagents |
| HY-128868C | FITC-Dextran (MW 20000) | 60842-46-8 | Dye Reagents |
| HY-128868D | FITC-Dextran (MW 40000) | 60842-46-8 | Dye Reagents |
| HY-128868E | FITC-Dextran (MW 70000) | 60842-46-8 | Dye Reagents |
| HY-128868F | FITC-Dextran (MW 110000) | 60842-46-8 | Dye Reagents |
| HY-128868G | FITC-Dextran (MW 150000) | 60842-46-8 | Dye Reagents |
| HY-128868H | FITC-Dextran (MW 500000) | 60842-46-8 | Dye Reagents |
| HY-128868I | FITC-Dextran (MW 2000000) | 60842-46-8 | Dye Reagents |
| HY-12887 | Piclamilast | 144035-83-6 | Reference compound |
| HY-128870 | Mal-PEG2-VCP-Eribulin | 2130869-18-8 | ADC Related |
| HY-128871 | VCP-Eribulin | 2130869-17-7 | ADC Related |
| HY-128872 | Etrinabdione | 1818428-24-8 | Reference compound |
| HY-128873 | Duocarmycin GA | 1613286-59-1 | ADC Related |
| HY-128875 | CBP/p300-IN-10 | 2259641-71-7 | Reference compound |
| HY-128876 | CBP/p300-IN-3 | 2299226-01-8 | Reference compound |
| HY-128878 | Dexloxiglumide | 119817-90-2 | Reference compound |
| HY-128879 | VP3.15 | 1281681-54-6 | Reference compound |
| HY-128879A | VP3.15 (dihydrobromide) | 1281681-33-1 | Reference compound |
| HY-12887R | Piclamilast (Standard) | 144035-83-6 | Reference Standards |
| HY-12888 | AZD5099 | 907543-25-3 | Reference compound |
| HY-128880 | (+)-CBI-CDPI1 | 128300-14-1 | ADC Related |
| HY-128881 | (+)-CBI-CDPI2 | 128300-15-2 | ADC Related |
| HY-128888 | (R,R)-GSK321 | 1816272-19-1 | Reference compound |
| HY-128888A | (S,S)-GSK321 | 1816272-20-4 | Reference compound |
| HY-128888B | (S,R)-GSK321 | 1816272-18-0 | Reference compound |
| HY-128889 | FXIa-IN-1 | 1803271-50-2 | Reference compound |
| HY-128890 | DOTA-NHS-ester | 170908-81-3 | ADC Related |
| HY-128890A | DOTA-NHS-ester (hexafluorophosphate TFA) | 1823122-52-6 | Biochemical Assay Reagents |
| HY-128890B | DOTA-NHS-ester (TFA) | | Reference compound |
| HY-128891 | Eperisone | 64840-90-0 | Reference compound |
| HY-128892 | EN6 | 1808714-73-9 | Reference compound |
| HY-128893 | MC-Sq-Cit-PAB-Gefitinib | 1941168-63-3 | ADC Related |
| HY-128894 | MC-Sq-Cit-PAB-Dolastatin10 | 1941168-65-5 | ADC Related |
| HY-128895 | KL1333 | 1800405-30-4 | Reference compound |
| HY-128896 | Nitro-PDS-Tubulysin M | 1941168-69-9 | ADC Related |
| HY-128897 | MC-VC-PABC-DNA31 | 1639352-03-6 | ADC Related |
| HY-128899 | MC-Val-Cit-PAB-Auristatin E | 2055896-77-8 | ADC Related |
| HY-128900 | 11-cis-Vaccenyl acetate | 6186-98-7 | Reference compound |
| HY-128901 | F 13714 (fumarate) | 208109-39-1 | Reference compound |
| HY-128902 | MC-Val-Cit-PAB-vinblastine | 2055896-92-7 | ADC Related |
| HY-128903 | MC-Val-Cit-PAB-carfilzomib (iodide) | 2055896-83-6 | ADC Related |
| HY-128904 | MC-Val-Cit-PAB-duocarmycin (chloride) | 2055896-98-3 | ADC Related |
| HY-128905 | MC-Val-Cit-PAB-dimethylDNA31 | 1639352-06-9 | ADC Related |
| HY-128906 | MC-Val-Cit-PAB-Retapamulin | 1639793-15-9 | ADC Related |
| HY-128907 | MC-Val-Cit-PAB-clindamycin | 1639793-13-7 | ADC Related |
| HY-128908 | MC-Val-Cit-PAB-Indibulin | 2055896-95-0 | ADC Related |
| HY-128909 | MC-Val-Cit-PAB-rifabutin | 2055900-34-8 | ADC Related |
| HY-128910 | MC-VC(S)-PABQ-Tubulysin M | 2055896-86-9 | ADC Related |
| HY-128912 | Arborinine | 5489-57-6 | Natural Products |
| HY-128913 | 1,3-Dihydroxy-4-methoxy-10-methylacridin-9(10H)-one | 1189362-86-4 | Natural Products |
| HY-128914 | Tubulysin | 1943604-24-7 | Reference compound |
| HY-128915 | Duocarmycin DM (free base) | 1116745-06-2 | ADC Related |
| HY-128916 | dmDNA31 | 845625-44-7 | Reference compound |
| HY-128917 | DNA31 | 845626-57-5 | Reference compound |
| HY-128918 | SIS17 | 2374313-54-7 | Reference compound |
| HY-128919 | Ac-Lys-AMC | 156661-42-6 | Reference compound |
| HY-12892 | SKI-178 | 1259484-97-3 | Reference compound |
| HY-128920 | Phortress (free base) | 741241-36-1 | Reference compound |
| HY-128921 | Bz-Lys-OMe | 17039-40-6 | Reference compound |
| HY-128922 | Dexamethasone palmitate | 14899-36-6 | Reference compound |
| HY-128922S | Dexamethasone palmitate-d31 | | Isotope-Labeled Compounds |
| HY-128923 | SKF-34288 (hydrochloride) | 320386-54-7 | Reference compound |
| HY-128925 | AMAS | 55750-61-3 | ADC Related |
| HY-128926 | SPP | 341498-08-6 | ADC Related |
| HY-128927 | Mc-Leu-Gly-Arg | "2639874-49-8
" | ADC Related |
| HY-128929 | Fmoc-PEA | 329223-23-6 | ADC Related |
| HY-128930 | 6-O-2-Propyn-1-yl-D-galactose | 881895-59-6 | ADC Related |
| HY-128931 | NH2-Ph-C4-acid-NH2-Me | 1263819-48-2 | Reference compound |
| HY-128932 | Cefminox (sodium) | 75498-96-3 | Reference compound |
| HY-128932R | Cefminox (sodium) (Standard) | 75498-96-3 | Reference Standards |
| HY-128933 | AMP-PNP (tetralithium) | 72957-42-7 | Reference compound |
| HY-128934 | Antitumor agent-2 | 1351163-57-9 | Reference compound |
| HY-128937 | EC1454 | 1602487-15-9 | Reference compound |
| HY-128938 | EC1167 | 1610414-00-0 | ADC Related |
| HY-128938A | EC1167 (hydrochloride) | | ADC Related |
| HY-128939 | EC0488 | 1059477-92-7 | Reference compound |
| HY-128940 | EC089 | 625827-91-0 | ADC Related |
| HY-128941 | CCK2R Ligand-Linker Conjugates 1 | 1452145-13-9 | ADC Related |
| HY-128942 | MAC glucuronide α-hydroxy lactone-linked SN-38 | 2246380-70-9 | ADC Related |
| HY-128943 | MAC glucuronide phenol-linked SN-38 | 2246380-69-6 | ADC Related |
| HY-128945 | CL2A | 2616704-22-2 | ADC Related |
| HY-128945A | CL2A (TFA) | | ADC Related |
| HY-128946 | CL2A-SN-38 | 1279680-68-0 | ADC Related |
| HY-128947 | CL2 Linker | 2270986-66-6 | ADC Related |
| HY-12895 | SKI V | 24418-86-8 | Reference compound |
| HY-128951 | AMCC-DM1 | 1228105-53-0 | ADC Related |
| HY-128952 | Tesirine | 1595275-62-9 | ADC Related |
| HY-128954 | Sulfo-PDBA-DM4 | 1461704-01-7 | ADC Related |
| HY-128955 | MC-VC-PABC-Aur0101 | 1438849-92-3 | ADC Related |
| HY-128957 | Vc-seco-DUBA | 1345681-58-4 | ADC Related |
| HY-128959 | MCC-Modified Daunorubicinol | 721945-30-8 | ADC Related |
| HY-128960 | DBA-DM4 | 905449-84-5 | ADC Related |
| HY-128961 | MC-Alkyl-Hydrazine Modified MMAF | 1404071-64-2 | ADC Related |
| HY-128965 | N-Glycolylneuraminic acid | 1113-83-3 | Reference compound |
| HY-128965R | N-Glycolylneuraminic acid (Standard) | 1113-83-3 | Reference Standards |
| HY-128968 | PEG4-aminooxy-MMAF | 1415246-35-3 | ADC Related |
| HY-128970 | Mp-polymer ester | | ADC Related |
| HY-128971 | LHVS | 170111-28-1 | Reference compound |
| HY-128972 | Purpurin 18 | 25465-77-4 | Reference compound |
| HY-128973 | Pyropheophorbide-a | 24533-72-0 | Reference compound |
| HY-128974 | N-Dodecyl-β-D-maltoside | 69227-93-6 | Reference compound |
| HY-128974S | N-Dodecyl-β-D-maltoside-d25 | 849110-74-3 | Isotope-Labeled Compounds |
| HY-128975 | m-Tyramine (hydrobromide) | 38449-59-1 | Reference compound |
| HY-128976 | 10β,17β-dihydroxyestra-1,4-dien-3-one | 549-02-0 | Reference compound |
| HY-128977 | CD235 | 1627716-57-7 | Reference compound |
| HY-128978 | (E,E)-RAMB4 | 919091-61-5 | Reference compound |
| HY-128979 | Deruxtecan analog 2 | 1599440-10-4 | ADC Related |
| HY-128979B | Deruxtecan analog 2 (monoTFA) | 2758874-59-6 | ADC Related |
| HY-128995AS | Glycyl-Exatecan-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-12900 | RB-005 | 1425049-20-2 | Reference compound |
| HY-129027 | Ac-Leu-Gly-Lys(Ac)MCA | 660847-06-3 | Reference compound |
| HY-129028 | H-Ala-Ala-Tyr-OH | 67131-52-6 | Peptides |
| HY-129028A | H-Ala-Ala-Tyr-OH (TFA) | | Peptides |
| HY-129029 | Bisoprolol | 66722-44-9 | Reference compound |
| HY-129029R | Bisoprolol (Standard) | 66722-44-9 | Reference Standards |
| HY-129029S | Bisoprolol-d5 | 1189881-87-5 | Isotope-Labeled Compounds |
| HY-12903 | Macozinone | 1377239-83-2 | Reference compound |
| HY-129030 | BDZ-g | 732278-52-3 | Reference compound |
| HY-129034 | Ramoplanin | 76168-82-6 | Natural Products |
| HY-129035 | PFI-653 | 2173134-00-2 | Reference compound |
| HY-129037 | BCRP-IN-1 | 765899-28-3 | Reference compound |
| HY-129038 | GR24 | 76974-79-3 | Biochemical Assay Reagents |
| HY-129039 | Butyrolactone 3 | 778649-18-6 | Reference compound |
| HY-12903R | Macozinone (Standard) | 1377239-83-2 | Reference Standards |
| HY-12904 | TCA1 | 864941-32-2 | Reference compound |
| HY-129040A | Iobenguane (sulfate) | 87862-25-7 | Reference compound |
| HY-129040AR | Iobenguane (sulfate) (Standard) | 87862-25-7 | Reference Standards |
| HY-129041 | Procaterol (hydrochloride hemihydrate) | 81262-93-3 | Reference compound |
| HY-129042 | Cibacron Blue 3G-A | 84166-13-2 | Dye Reagents |
| HY-129043 | 3-Formyl rifamycin | 13292-22-3 | Reference compound |
| HY-129043R | 3-Formyl rifamycin (Standard) | 13292-22-3 | Reference Standards |
| HY-129046 | RNase A, Bovine pancreas | 9001-99-4 | Enzyme |
| HY-129046A | RNase A (10mg/mL, DNase free) | | Enzyme |
| HY-129046B | RNase A, Bovine Pancreas (DNase & Protease Free) | 9001-99-4 | Enzyme |
| HY-129046C | RNase B, Bovine Pancreas | | Enzyme |
| HY-129046D | RNase A, Recombinant | 9001-99-4 | Enzyme |
| HY-129046E | RNase A (DNase & Protease Free), Recombinant | 9001-99-4 | Enzyme |
| HY-129046H | RNase A, Recombinant (Protease & DNase free, animal free) | 9001-99-4 | Enzyme |
| HY-129046I | RNase A, Recombinant (animal free) | 9001-99-4 | Enzyme |
| HY-129047 | Trypsin | 9002-07-7 | Reference compound |
| HY-129047A | Trypsin (MS grade) | 9002-07-7 | Enzyme |
| HY-129047B | Recombinant Trypsin Solution | 9002-07-7 | Enzyme |
| HY-129047C | TPCK-treated Trypsin | 9002-07-7 | Enzyme |
| HY-129047D | Trypsin, Human Pancreas | 9002-07-7 | Enzyme |
| HY-129048 | Fladrafinil | 90212-80-9 | Reference compound |
| HY-129051 | Amoscanate | 26328-53-0 | Reference compound |
| HY-129055 | Isoeleutherin | 1078723-14-4 | Natural Products |
| HY-129056 | Melagatran | 159776-70-2 | Reference compound |
| HY-129057 | 2',5-Difluoro-2'-deoxycytidine | 581772-30-7 | Reference compound |
| HY-129059 | Odapipam | 131796-63-9 | Reference compound |
| HY-129060 | Flutrimazole | 119006-77-8 | Reference compound |
| HY-129060R | Flutrimazole (Standard) | 119006-77-8 | Reference Standards |
| HY-129064 | Superoxide dismutase, Porcine erythrocytes | 9054-89-1 | Enzyme |
| HY-129064A | Superoxide Dismutase, Human Erythrocyte | | Enzyme |
| HY-129065 | Nourseothricin (sulfate) | 96736-11-7 | Reference compound |
| HY-129067 | Brain natriuretic peptide | 114471-18-0 | Reference compound |
| HY-129071 | Vindesine (sulfate) | 59917-39-4 | Natural Products |
| HY-129071R | Vindesine (sulfate) (Standard) | 59917-39-4 | Reference Standards |
| HY-129072 | Isocyclosporin A | 59865-16-6 | Reference compound |
| HY-129077 | FR179642 | 168110-44-9 | Natural Products |
| HY-129077R | FR179642 (Standard) | 168110-44-9 | Reference Standards |
| HY-129079 | TFMB-(R)-2-HG | 1445700-01-5 | Reference compound |
| HY-129079A | TFMB-(S)-2-HG | 1445703-64-9 | Reference compound |
| HY-12908 | Bcl-xL antagonist 2 | 1235032-75-3 | Reference compound |
| HY-129084 | Propargylcholine (bromide) | 111755-76-1 | Reference compound |
| HY-129086 | BPAM344 | 1204572-55-3 | Reference compound |
| HY-129087 | BC-1258 | 1507370-40-2 | Reference compound |
| HY-129088 | HUP30 | 312747-21-0 | Reference compound |
| HY-12909 | MK-4409 | 1207745-58-1 | Reference compound |
| HY-129090 | CGS-9895 | 77779-50-1 | Reference compound |
| HY-129094 | ICT5040 | 215655-21-3 | Reference compound |
| HY-129096 | IDT307 | 1141-41-9 | Dye Reagents |
| HY-129097 | FFN-102 (trifluoroacetate) | 1234064-11-9 | Dye Reagents |
| HY-129098 | DMHCA | 79066-03-8 | Reference compound |
| HY-129099 | N-Desmethyltamoxifen | 31750-48-8 | Reference compound |
| HY-129099A | N-Desmethyltamoxifen (hydrochloride) | 15917-65-4 | Reference compound |
| HY-129099AR | N-Desmethyltamoxifen (hydrochloride) (Standard) | 15917-65-4 | Reference Standards |
| HY-129101 | (-)-Eseroline (fumarate) | 70310-73-5 | Reference compound |
| HY-129103 | A-412997 | 630116-49-3 | Reference compound |
| HY-129105 | Clomethiazole | 533-45-9 | Reference compound |
| HY-129105A | Chlormethiazole (edisylate) | 1867-58-9 | Reference compound |
| HY-129109 | NBD-Pen | 1955505-54-0 | Dye Reagents |
| HY-129111 | EACC | 864941-31-1 | Reference compound |
| HY-129113 | α-Chaconine | 20562-03-2 | Natural Products |
| HY-129113R | α-?Chaconine (Standard) | 20562-03-2 | Reference Standards |
| HY-129115 | S1QEL1.1 | 897613-29-5 | Reference compound |
| HY-129116 | SSAA09E1 | 433212-75-0 | Reference compound |
| HY-129117 | Arteannuin L | 207446-89-7 | Natural Products |
| HY-129118 | Takeda103A | 865609-72-9 | Reference compound |
| HY-129119 | Akt1/Akt2-IN-2 | 612847-42-4 | Reference compound |
| HY-12912 | KDU691 | 1513879-19-0 | Reference compound |
| HY-129121 | ML-226 | 2055172-43-3 | Reference compound |
| HY-129122 | VBIT-4 | 2086257-77-2 | Reference compound |
| HY-129123 | ML318 | 1610516-67-0 | Reference compound |
| HY-129123R | ML318 (Standard) | 1610516-67-0 | Reference Standards |
| HY-129124 | β-Solamarine | 3671-38-3 | Natural Products |
| HY-129125 | YMU1 | 902589-96-2 | Reference compound |
| HY-129126 | NC9 | 1352090-52-8 | Reference compound |
| HY-12913 | AMG 579 | 1227067-61-9 | Reference compound |
| HY-129130 | Canthin-6-one N-oxide | 60755-87-5 | Natural Products |
| HY-129131 | Chrysin 6-C-arabinoside 8-C-glucoside | 185145-33-9 | Natural Products |
| HY-129133 | cis-Miyabenol C | 168037-22-7 | Natural Products |
| HY-129136 | TUG-1387 | 6319-64-8 | Reference compound |
| HY-129137 | Cyanidin 3-sophoroside (chloride) | 18376-31-3 | Reference compound |
| HY-129138 | Cyanidin 3,5-diglucoside (chloride) | 2611-67-8 | Natural Products |
| HY-129138R | Cyanidin 3,5-diglucoside (chloride) (Standard) | 2611-67-8 | Reference Standards |
| HY-129139 | Cyanidin-3-O-arabinoside | 111613-04-8 | Natural Products |
| HY-12914 | V116517 | 1073616-61-1 | Reference compound |
| HY-129140 | Delphinidin-3-O-arabinoside (chloride) | 171370-55-1 | Natural Products |
| HY-129141 | YKL-06-062 | 2172617-16-0 | Reference compound |
| HY-129143 | Delphinidin-3-sambubioside (chloride) | 53158-73-9 | Natural Products |
| HY-129143R | Delphinidin-3-sambubioside (chloride) (Standard) | 53158-73-9 | Reference Standards |
| HY-129144 | Dihydrodehydrodiconiferyl alcohol | 28199-69-1 | Natural Products |
| HY-129146S | Doxapram-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-129148 | Ganoderic acid AM1 | 149507-55-1 | Natural Products |
| HY-129149 | Ganoderic acid SZ | 865543-37-9 | Natural Products |
| HY-129150 | Ganoderic acid TR | 862893-75-2 | Natural Products |
| HY-129151 | Ganoderic acid C1 | 95311-97-0 | Natural Products |
| HY-129152 | Ganoderic acid T-N | 112430-64-5 | Natural Products |
| HY-129153 | Ganoderic acid ζ | 294674-09-2 | Natural Products |
| HY-129154 | Ganolucidic acid A | 98665-21-5 | Natural Products |
| HY-129155 | (Rac)-Germacrene D | 37839-63-7 | Natural Products |
| HY-129156 | HS-1793 | 927885-00-5 | Reference compound |
| HY-129159 | (-)-Clerosterol | 2364-23-0 | Natural Products |
| HY-129159R | (-)-Clerosterol (Standard) | 2364-23-0 | Reference Standards |
| HY-129160 | Ganoderenic acid H | 120462-48-8 | Natural Products |
| HY-129161 | Alisol O | 928148-51-0 | Natural Products |
| HY-129162 | Alisol A 23-acetate | 19865-75-9 | Natural Products |
| HY-129163 | HJ-PI01 | 6192-43-4 | Reference compound |
| HY-129166 | UCM53 | 2468847-23-4 | Reference compound |
| HY-129167 | Menin-MLL inhibitor 4 | 2169916-13-4 | Reference compound |
| HY-129169 | USP7-IN-6 | 2166586-47-4 | Reference compound |
| HY-129171 | TGFBR1-IN-1 | 2170830-26-7 | Reference compound |
| HY-129172 | PD-1/PD-L1-IN 5 (TFA) | 2170209-52-4 | Reference compound |
| HY-129172A | PD-1/PD-L1-IN 5 | 2170209-51-3 | Reference compound |
| HY-129179 | Lisaftoclax | 2180923-05-9 | Reference compound |
| HY-129179B | (Rac)-Lisaftoclax | 2651980-10-6 | Reference compound |
| HY-129180 | XY028-133 | 2229974-73-4 | Reference compound |
| HY-129181 | FGFR4-IN-4 | 2230973-67-6 | Reference compound |
| HY-129188 | CCT369260 | 2647503-57-7 | Reference compound |
| HY-129189 | RAS GTPase inhibitor 1 | 2252242-32-1 | Reference compound |
| HY-129197 | Stearyldiethanolamine | 10213-78-2 | Reference compound |
| HY-129199 | U-51605 | 64192-56-9 | Reference compound |
| HY-129200 | Aspergillomarasmine A | 3484-65-9 | Reference compound |
| HY-129201 | ZEN-2759 | 1616400-50-0 | Reference compound |
| HY-129206 | Locicortolone | 65049-45-8 | Reference compound |
| HY-129207 | JMV 3002 | 925239-03-8 | Reference compound |
| HY-129208 | Viridicatumtoxin | 39277-41-3 | Natural Products |
| HY-129209 | Myrotoxin B | 99486-49-4 | Natural Products |
| HY-129210 | KMUP-4 | 864873-81-4 | Reference compound |
| HY-129213 | CL-242817 | 86709-48-0 | Reference compound |
| HY-129214 | (2S,3R)-DEPMPO-Biotin | 936224-52-1 | Reference compound |
| HY-129217 | Naringinase | 9068-31-9 | Natural Products |
| HY-129225 | WRR139 | 2138924-36-2 | Reference compound |
| HY-129226 | SHMT-IN-2 | 2102681-49-0 | Reference compound |
| HY-129228 | Lychnopholide | 77448-64-7 | Natural Products |
| HY-129230 | Triletide | 62087-96-1 | Reference compound |
| HY-129231 | Levomoprolol | 77164-20-6 | Reference compound |
| HY-129234 | Mazethramycin | 68373-96-6 | Natural Products |
| HY-129236 | Hellebrin | 13289-18-4 | Reference compound |
| HY-129237 | Azo-enkephalin | 76995-89-6 | Reference compound |
| HY-129239 | Farudodstat | 1035688-66-4 | Reference compound |
| HY-129240S | 13-cis Acitretin-d3 | 1185241-03-5 | Isotope-Labeled Compounds |
| HY-129241 | AGX51 | 330834-54-3 | Reference compound |
| HY-129242 | Tempone | 2896-70-0 | Reference compound |
| HY-129242S | Tempone-15N,d16 | 80404-14-4 | Isotope-Labeled Compounds |
| HY-129242S1 | Tempone-d16 | 36763-53-8 | Isotope-Labeled Compounds |
| HY-129243 | Uredepa | 302-49-8 | Reference compound |
| HY-129244 | Levamlodipine (gentisate) | 856256-16-1 | Reference compound |
| HY-129245 | Razobazam | 78466-98-5 | Reference compound |
| HY-129246 | Cytembena | 21739-91-3 | Reference compound |
| HY-129247 | Versicolorin A | 6807-96-1 | Natural Products |
| HY-129250 | AZD5213 | 1119807-02-1 | Reference compound |
| HY-129252 | Prothracarcin | 81542-99-6 | Natural Products |
| HY-129253 | GSK984 | 827591-04-8 | Reference compound |
| HY-129254 | 5-Hydroxy propranolol | 81907-82-6 | Reference compound |
| HY-129257 | Esfenvalerate | 66230-04-4 | Reference compound |
| HY-129257R | Esfenvalerate (Standard) | 66230-04-4 | Reference Standards |
| HY-129258 | Lycoctonine | 26000-17-9 | Natural Products |
| HY-12926 | ST7612AA1 | 1428535-92-5 | Reference compound |
| HY-129260 | Kanosamine | 576-44-3 | Reference compound |
| HY-129262 | Deoxypheganomycin D | 69280-94-0 | Reference compound |
| HY-129263 | L-Isoleucyl-L-valine | 41017-96-3 | Reference compound |
| HY-129265 | Poloxin-2 | 321695-37-8 | Reference compound |
| HY-129269 | Pacidamycin I | 121264-05-9 | Natural Products |
| HY-12927 | SX-517 | 1240494-13-6 | Reference compound |
| HY-129271 | Deltorphin | 119975-64-3 | Peptides |
| HY-129273 | L-731735 | 149756-20-7 | Reference compound |
| HY-129274 | RO4988546 | 911114-85-7 | Reference compound |
| HY-129276 | N-Retinoyl phenylalanine | 97885-88-6 | Reference compound |
| HY-129278 | Lunarine | 24185-51-1 | Natural Products |
| HY-129279 | Andrastin A | 174232-42-9 | Natural Products |
| HY-12928 | ML336 | 1613465-33-0 | Reference compound |
| HY-129280 | Janthinocin A | 131086-52-7 | Reference compound |
| HY-129281 | Benzedrone (hydrochloride) | 1797979-43-1 | Reference compound |
| HY-129283 | Goralatide | 120081-14-3 | Natural Products |
| HY-129283A | Goralatide (TFA) | 1796568-94-9 | Natural Products |
| HY-129283B | Goralatide (acetate) | | Natural Products |
| HY-129284 | APHS | 209125-28-0 | Reference compound |
| HY-129285 | A83016A | 142383-42-4 | Reference compound |
| HY-129288 | GW837016X | 833473-68-0 | Reference compound |
| HY-12929 | NSC756093 | 1629908-92-4 | Reference compound |
| HY-129290 | Flamprop-methyl | 52756-25-9 | Reference compound |
| HY-129290R | Flamprop-methyl (Standard) | 52756-25-9 | Reference Standards |
| HY-129291 | Reductiomycin | 68748-55-0 | Natural Products |
| HY-129292 | Quinocarcin | 84573-33-1 | Reference compound |
| HY-129293 | AFP-07 (free acid) | 788799-13-3 | Reference compound |
| HY-129295 | Amidepsine D | 79786-34-8 | Reference compound |
| HY-129296 | YM-44781 (free acid) | 173943-29-8 | Reference compound |
| HY-129297 | CMPF | 86879-39-2 | Reference compound |
| HY-129297S | CMPF-d5 | 2749807-07-4 | Isotope-Labeled Compounds |
| HY-129298 | Amastatin | 67655-94-1 | Reference compound |
| HY-12930 | SPR719 | 1384984-18-2 | Reference compound |
| HY-129300 | Prosulfocarb | 52888-80-9 | Reference compound |
| HY-129300R | Prosulfocarb (Standard) | 52888-80-9 | Reference Standards |
| HY-129300S | Prosulfocarb-d7 | | Isotope-Labeled Compounds |
| HY-129301 | CCTA-1523 | 1616271-41-0 | Reference compound |
| HY-129303 | AP219 | 779282-36-9 | Reference compound |
| HY-129304 | (±)-Cannabichromeorcin | 55824-09-4 | Reference compound |
| HY-129305 | Tampramine (fumarate) | 83166-18-1 | Reference compound |
| HY-129306 | Gilvocarcin M | 77879-89-1 | Natural Products |
| HY-129307 | Gilvocarcin V | 77879-90-4 | Natural Products |
| HY-129308 | LS 82-556 | 92751-45-6 | Reference compound |
| HY-129310 | PIN1 inhibitor 5 | 884033-66-3 | Reference compound |
| HY-129311 | Tr-PEG6-OH | 127999-16-0 | ADC Related |
| HY-129312 | Awamycin | 87913-35-7 | Natural Products |
| HY-129313 | LG 6-102 | 132798-30-2 | Reference compound |
| HY-129314 | CM-39 | 361156-54-9 | Reference compound |
| HY-129315 | Deacylketoconazole | 67914-61-8 | Reference compound |
| HY-129316 | Dihydroaeruginoic Acid | 143209-04-5 | Reference compound |
| HY-129317 | A457 | 1233923-95-9 | Reference compound |
| HY-129318 | MBX-1066 | 868971-24-8 | Reference compound |
| HY-129319 | Valinotricin | 94899-85-1 | Natural Products |
| HY-129325 | Cytochalasin H | 53760-19-3 | Natural Products |
| HY-129327 | Isoadiantone | 54352-47-5 | Natural Products |
| HY-129328 | Magnesium glycinate | 14783-68-7 | Reference compound |
| HY-129329 | Lankamycin | 30042-37-6 | Natural Products |
| HY-12933 | BIIB-028 | 911398-13-5 | Reference compound |
| HY-129330 | Sapintoxin D | 80998-07-8 | Natural Products |
| HY-129331 | Neothramycin A | 59593-16-7 | Natural Products |
| HY-129333 | L-364918 | 122211-31-8 | Reference compound |
| HY-129334 | Macrocalin B | 93781-75-0 | Natural Products |
| HY-129336 | Abemaciclib metabolite M20 | 2138499-06-4 | Reference compound |
| HY-129336S | Abemaciclib metabolite M20-d8 | | Isotope-Labeled Compounds |
| HY-129337 | Reveromycin A | 134615-37-5 | Natural Products |
| HY-129338 | CID 7309015 | 1164457-99-1 | Reference compound |
| HY-129339 | Akrobomycin | 89156-94-5 | Natural Products |
| HY-129340 | AS-183 | 147317-12-2 | Natural Products |
| HY-129342 | Lincomycin B | 2520-24-3 | Reference compound |
| HY-129346 | STF-038533 | 423744-59-6 | Reference compound |
| HY-129347 | Lankacyclinol A | 52212-91-6 | Natural Products |
| HY-129348 | IRE1α kinase-IN-10 | 1415050-59-7 | Reference compound |
| HY-129349 | Phe-Lys(Trt)-PAB | 1116085-99-4 | ADC Related |
| HY-129350 | Fmoc-Phe-Lys(Trt)-PAB-PNP | 1116086-09-9 | ADC Related |
| HY-129351 | Aloc-D-Ala-Phe-Lys(Aloc)-PAB-PNP | 253863-34-2 | ADC Related |
| HY-129352 | Cbz-Phe-(Alloc)Lys-PAB-PNP | 159857-90-6 | ADC Related |
| HY-129353 | Boc-Phe-(Alloc)Lys-PAB-PNP | 1160844-44-9 | ADC Related |
| HY-129355 | Duocarmycin Analog | 372954-15-9 | ADC Related |
| HY-129356 | Seco-Duocarmycin SA | 144667-38-9 | ADC Related |
| HY-129356A | (S)-Seco-Duocarmycin SA | 152785-82-5 | ADC Related |
| HY-129357 | CCK-B Receptor Antagonist 2 | 155412-88-7 | Reference compound |
| HY-129359 | PDP-Pfp | 160580-70-1 | ADC Related |
| HY-12936 | DDD100097 | 1215012-74-0 | Reference compound |
| HY-129360 | Ala-Ala-Asn-PAB | 2149584-00-7 | ADC Related |
| HY-129360A | Ala-Ala-Asn-PAB (TFA) | | Peptides |
| HY-129361 | Fmoc-Ala-Ala-Asn-PABC-PNP | 1834516-06-1 | ADC Related |
| HY-129362 | Phe-Lys(Fmoc)-PAB | 2149584-03-0 | ADC Related |
| HY-129363 | AP1867-3-(aminoethoxy) | 2127390-15-0 | Reference compound |
| HY-129365 | SNPB | 663598-85-4 | ADC Related |
| HY-129366 | PDB-Pfp | 2088570-81-2 | ADC Related |
| HY-129367 | NO2-SPP | 663598-61-6 | ADC Related |
| HY-129368 | SPDMV | 890409-85-5 | ADC Related |
| HY-129369 | SPDMB | 2101206-29-3 | ADC Related |
| HY-129370 | SPDB-sulfo | 1628113-16-5 | ADC Related |
| HY-129371 | SPDV | 317331-86-5 | ADC Related |
| HY-129372 | PDdB-Pfp | 2101206-44-2 | ADC Related |
| HY-129373 | SPDMV-sulfo | 2101206-86-2 | ADC Related |
| HY-129374 | SPDH | 1824718-79-7 | ADC Related |
| HY-129375 | SNPB-sulfo-Me | 890409-86-6 | ADC Related |
| HY-129376 | Sulfo-SNPB | 1193111-37-3 | ADC Related |
| HY-129377 | Sulfo-SPP | 452072-27-4 | ADC Related |
| HY-129377A | Sulfo-SPP (sodium) | 452072-24-1 | ADC Related |
| HY-129378 | NO2-SPP-sulfo-Me | 890409-87-7 | ADC Related |
| HY-129379 | DC0-NH2 | 615538-51-7 | ADC Related |
| HY-12938 | AMG-8718 | 1215868-94-2 | Reference compound |
| HY-129380 | Fructosyl-lysine | 21291-40-7 | Natural Products |
| HY-129380A | Fructosyl-lysine (dihydrochloride) | 96192-35-7 | Reference compound |
| HY-129380R | Fructosyl-lysine (Standard) | 21291-40-7 | Reference Standards |
| HY-129384 | Rubratoxin B | 21794-01-4 | Reference compound |
| HY-129385 | Linustatin | 72229-40-4 | Natural Products |
| HY-129388 | Pulrodemstat (Methylbenzenesulfonate) | 2097523-57-2 | Reference compound |
| HY-129388A | Pulrodemstat | 1821307-10-1 | Reference compound |
| HY-129388B | Pulrodemstat (benzenesulfonate) | 2097523-60-7 | Reference compound |
| HY-129389 | Benzyl-α-GalNAc | 3554-93-6 | Reference compound |
| HY-129390 | Orelabrutinib | 1655504-04-3 | Reference compound |
| HY-129393 | Etrumadenant | 2239273-34-6 | Reference compound |
| HY-129395 | Mezigdomide | 2259648-80-9 | Reference compound |
| HY-129397 | 2,3-Dinor-11beta-prostaglandin F2alpha | 240405-20-3 | Reference compound |
| HY-129397S | 2,3-Dinor-11β-prostaglandin F2α-d9 | 851030-08-5 | Isotope-Labeled Compounds |
| HY-129398 | Formiminoglutamic acid | 816-90-0 | Reference compound |
| HY-12940 | GLPG0974 | 1391076-61-1 | Reference compound |
| HY-129405 | N-(Ketocaproyl)-DL-homoserine lactone | 76924-95-3 | Reference compound |
| HY-129405R | N-(Ketocaproyl)-DL-homoserine lactone (Standard) | 76924-95-3 | Reference Standards |
| HY-129406 | AF 698 | 82958-11-0 | Reference compound |
| HY-129407 | AAF-CMK (TFA) | 184901-82-4 | Peptides |
| HY-129407A | AAF-CMK | 102129-66-8 | Peptides |
| HY-129408 | SGE-516 | 1430064-74-6 | Reference compound |
| HY-129409 | 7,8-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one | 75187-63-2 | Natural Products |
| HY-12940A | (S)-GLPG0974 | 2326220-69-1 | Reference compound |
| HY-12941 | AM-7209 | 1623432-51-8 | Reference compound |
| HY-129410 | ADR-925 | 75459-34-6 | Reference compound |
| HY-129411 | Sinbaglustat | 441061-33-2 | Reference compound |
| HY-129412 | A-74273 | 130316-95-9 | Reference compound |
| HY-129415 | Esaprazole | 64204-55-3 | Reference compound |
| HY-12942 | PF-05175157 | 1301214-47-0 | Reference compound |
| HY-129420 | WSP-5 | 1593024-78-2 | Dye Reagents |
| HY-129421 | PA-9 | 1436004-46-4 | Reference compound |
| HY-129422 | Diallyl G | 127808-81-5 | Reference compound |
| HY-129424 | Mezolidon | 82697-73-2 | Reference compound |
| HY-129426 | PDK1/Akt/Flt dual pathway inhibitor | 331253-86-2 | Reference compound |
| HY-129428 | Fructosyl-methionine | 80860-78-2 | Reference compound |
| HY-129430 | N-Methylprotoporphyrin IX | 79236-56-9 | Reference compound |
| HY-129431 | U-89843A | 157013-32-6 | Reference compound |
| HY-129432 | (-)-Deacetylsclerotiorin | 61248-35-9 | Reference compound |
| HY-129433 | 17β-HSD1-IN-2 | 1318265-18-7 | Reference compound |
| HY-129434 | Nepetalactone | 490-10-8 | Reference compound |
| HY-129434A | 4aα,7α,7aα-Nepetalactone | 21651-62-7 | Natural Products |
| HY-129435 | Altromycin E | 134887-77-7 | Natural Products |
| HY-129436 | (S)-Bucindolol | 91548-61-7 | Reference compound |
| HY-12944 | GSK163929 | 716354-04-0 | Reference compound |
| HY-129440 | N-(p-Coumaroyl) Serotonin | 68573-24-0 | Natural Products |
| HY-129441 | Metoprine | 7761-45-7 | Reference compound |
| HY-129443 | Deacetylcephaloglycin | 3890-34-4 | Reference compound |
| HY-129444 | MD 780236 (free base) | 73423-36-6 | Reference compound |
| HY-129445 | SG-209 | 83440-03-3 | Reference compound |
| HY-129449 | AnnH31 | 241809-12-1 | Reference compound |
| HY-129450 | Ethyl-L-NIO (hydrochloride) | 150403-97-7 | Reference compound |
| HY-129451 | HIE-124 | 805326-00-5 | Reference compound |
| HY-129452 | (S)-3'-Hydroxy blebbistatin | 2097136-42-8 | Reference compound |
| HY-129453 | BOP (sodium) | 1947348-42-6 | Reference compound |
| HY-129454 | TPU-0037A | 485815-59-6 | Reference compound |
| HY-129457 | FINO2 | 869298-31-7 | Reference compound |
| HY-129458 | Cerivastatin | 145599-86-6 | Reference compound |
| HY-129459 | α-Tocotrienol | 58864-81-6 | Reference compound |
| HY-129459R | α-Tocotrienol (Standard) | 58864-81-6 | Reference Standards |
| HY-12946 | BI 653048 | 1198784-72-3 | Reference compound |
| HY-129460 | XJB-5-131 | 866404-31-1 | Reference compound |
| HY-129461 | Dibenzyl trisulfide | 6493-73-8 | Natural Products |
| HY-129462 | O-Isopropyl ethylthiocarbamate | 141-98-0 | Reference compound |
| HY-129464 | NO-711ME | 127586-66-7 | Reference compound |
| HY-129466 | PCTR2 | 1810710-63-4 | Reference compound |
| HY-129467 | (Rac)-Idroxioleic acid | 56472-29-8 | Reference compound |
| HY-129467A | (Rac)-Idroxioleic acid (sodium) | 1229114-68-4 | Reference compound |
| HY-129467R | (Rac)-Idroxioleic acid (Standard) | 56472-29-8 | Reference Standards |
| HY-129468 | Pirimiphos ethyl | 23505-41-1 | Reference compound |
| HY-129468R | Pirimiphos ethyl (Standard) | 23505-41-1 | Reference Standards |
| HY-129469 | Saframycin S | 75425-66-0 | Natural Products |
| HY-12946A | BI 653048 (phosphate) | 1198784-97-2 | Reference compound |
| HY-12947 | GNE-3511 | 1496581-76-0 | Reference compound |
| HY-129471 | Arbaprostil | 55028-70-1 | Reference compound |
| HY-129474 | MP 518 | 122432-93-3 | Reference compound |
| HY-129475 | Mycinamicin I | 73665-15-3 | Reference compound |
| HY-129476 | L-Canaline | 496-93-5 | Natural Products |
| HY-129478 | TC11 | 100823-03-8 | Reference compound |
| HY-129479 | Almoxatone | 84145-89-1 | Reference compound |
| HY-12948 | AMG319 | 1608125-21-8 | Reference compound |
| HY-129480 | Vertilmicin sulfate | 857468-21-4 | Reference compound |
| HY-129482 | Detoxin D1 | 37878-19-6 | Natural Products |
| HY-129484 | Sporidesmolide III | 1803-67-4 | Reference compound |
| HY-129485 | CM304 | 1417742-48-3 | Reference compound |
| HY-129487 | (E/Z)-MC4 | 219140-31-5 | Reference compound |
| HY-12949 | ML204 | 5465-86-1 | Reference compound |
| HY-129490 | Enpp-1-IN-1 | 2289728-58-9 | Reference compound |
| HY-129491 | O-Desmethyl Midostaurin | 740816-86-8 | Reference compound |
| HY-129491S | O-Desmethyl Midostaurin-d5 | 2699608-28-9 | Isotope-Labeled Compounds |
| HY-129492 | GNF4877 | 2041073-22-5 | Reference compound |
| HY-129493 | Lateropyrone | 93752-78-4 | Natural Products |
| HY-129496 | NP-313 | 5397-78-4 | Reference compound |
| HY-12949A | ML204 (hydrochloride) | 2070015-10-8 | Reference compound |
| HY-129500 | Zofenoprilat (arginine) | 81872-09-5 | Reference compound |
| HY-129502 | Fibrostatin C | 91776-47-5 | Natural Products |
| HY-129503 | 2-Heptyl-4-quinolone | 40522-46-1 | Natural Products |
| HY-129503S | 2-Heptyl-4-quinolone-13C6 | | Isotope-Labeled Compounds |
| HY-129503S1 | 2-Heptyl-4-quinolone-15N | | Isotope-Labeled Compounds |
| HY-129507 | Aplindore (fumarate) | 189681-71-8 | Reference compound |
| HY-129508 | Amthamine | 142437-67-0 | Reference compound |
| HY-129509 | Alterporriol B | 88901-69-3 | Natural Products |
| HY-129510 | 4-Methyl erlotinib | 1346601-52-2 | Reference compound |
| HY-129510R | 4-Methyl erlotinib (Standard) | 1346601-52-2 | Reference Standards |
| HY-129511 | Conivaptan-d4 | 1129433-63-1 | Reference compound |
| HY-129513 | SIB-1893 | 7370-21-0 | Reference compound |
| HY-129515 | Trichodecenin II | 140939-04-4 | Natural Products |
| HY-129516 | A-70874 | 131449-37-1 | Reference compound |
| HY-129517 | UBP714 | 773109-55-0 | Reference compound |
| HY-129522 | Sulfo-ara-F-NMN | 1374663-29-2 | Reference compound |
| HY-129523 | PROTAC K-Ras Degrader-1 | 2378258-52-5 | Reference compound |
| HY-129524 | Ethylene dimethanesulfonate | 4672-49-5 | Reference compound |
| HY-129525A | Sulfo-SIAB (sodium) | 144650-93-1 | ADC Related |
| HY-129526 | Mal-PEG3-NHS ester | 1537892-36-6 | ADC Related |
| HY-129527 | GNE-9278 | 2315311-83-0 | Reference compound |
| HY-129529 | 6-Hydroxyluteolin 7-glucoside | 54300-65-1 | Natural Products |
| HY-12953 | R-268712 | 879487-87-3 | Reference compound |
| HY-129531 | MuRF1-IN-1 | 445222-91-3 | Reference compound |
| HY-12954 | PTACH | 848354-66-5 | Reference compound |
| HY-129545 | DS-1001b | 1898207-64-1 | Reference compound |
| HY-129546 | Eprozinol (hydrochloride) | 27588-43-8 | Reference compound |
| HY-129547 | Fluo-3 (pentapotassium) | 853400-67-6 | Dye Reagents |
| HY-129548 | Prumycin | 38819-28-2 | Reference compound |
| HY-129548A | Prumycin di(hydrochloride) | 57420-47-0 | Reference compound |
| HY-129549 | Thiopropamine (hydrochloride) | 53632-92-1 | Reference compound |
| HY-129550 | BI-4020 | 2664214-60-0 | Reference compound |
| HY-129552 | WAY-855 | 482373-29-5 | Reference compound |
| HY-129554 | cis-9,10-Epoxystearic acid | 24560-98-3 | Natural Products |
| HY-129554R | cis-?9,?10-?Epoxystearic acid (Standard) | 24560-98-3 | Reference Standards |
| HY-129555 | Surfactin | 252023-70-4 | Natural Products |
| HY-129556 | Pepstanone A | 38752-31-7 | Natural Products |
| HY-129557 | A-49816 | 78235-72-0 | Reference compound |
| HY-129558 | UK-1 | 151271-53-3 | Reference compound |
| HY-12956 | Dinoprost | 551-11-1 | Natural Products |
| HY-129560 | DNDS (disodium) | 3709-43-1 | Reference compound |
| HY-129562 | Cucumechinoside D | 125640-33-7 | Natural Products |
| HY-129563 | CGP 57813 | 150608-41-6 | Reference compound |
| HY-129564 | Acetomycin | 510-18-9 | Reference compound |
| HY-129566 | Withanolide B | 56973-41-2 | Natural Products |
| HY-129566R | Withanolide B (Standard) | 56973-41-2 | Reference Standards |
| HY-129568 | Tetraphyllicine | 509-38-6 | Natural Products |
| HY-12956A | Dinoprost (tromethamine salt) | 38562-01-5 | Reference compound |
| HY-12956AR | Dinoprost (tromethamine salt) (Standard) | 38562-01-5 | Reference Standards |
| HY-12956B | (5R)-Dinoprost | 4510-16-1 | Reference compound |
| HY-12956R | Dinoprost (Standard) | 551-11-1 | Reference Standards |
| HY-12956S | Dinoprost-d4 | 34210-11-2 | Isotope-Labeled Compounds |
| HY-12956S1 | Dinoprost-d9 | | Isotope-Labeled Compounds |
| HY-12956S2 | Dinoprost-13C5 | | Isotope-Labeled Compounds |
| HY-12957 | NITD008 | 1044589-82-3 | Reference compound |
| HY-129571 | BioE-1115 | 1268863-35-9 | Reference compound |
| HY-129576 | PSB-16133 (sodium) | 2089035-40-3 | Reference compound |
| HY-129577 | Aplysin | 6790-63-2 | Natural Products |
| HY-129578 | Asperphenamate | 63631-36-7 | Natural Products |
| HY-129578R | Asperphenamate (Standard) | 63631-36-7 | Reference Standards |
| HY-129579 | Linadryl | 5928-69-8 | Reference compound |
| HY-129580 | Nannochelin B | 133705-27-8 | Natural Products |
| HY-129581 | Org 27759 | 868273-09-0 | Reference compound |
| HY-129582 | Ribasine | 87099-54-5 | Natural Products |
| HY-129583 | Lepidiline A | 596093-98-0 | Natural Products |
| HY-129584 | Lepidiline B | 596093-97-9 | Natural Products |
| HY-129585 | SM-4470 | 89433-57-8 | Reference compound |
| HY-129586 | Govorestat | 2170729-29-8 | Reference compound |
| HY-129589 | Thailanstatin A | 1426953-21-0 | ADC Related |
| HY-12959 | Repinotan | 144980-29-0 | Reference compound |
| HY-129591 | Paraherquamide A | 77392-58-6 | Natural Products |
| HY-129592 | p-Tolylmaleimide | 1631-28-3 | Reference compound |
| HY-129594 | DANP | 761401-89-2 | Reference compound |
| HY-129594A | DANP (dihydrochloride) | | Reference compound |
| HY-12959A | Repinotan (hydrochloride) | 144980-77-8 | Reference compound |
| HY-12960 | SKLB4771 | 1370256-78-2 | Reference compound |
| HY-129600 | MYCi361 | 2289690-31-7 | Reference compound |
| HY-129602 | SD-36 | 2429877-44-9 | Reference compound |
| HY-129603 | SI-109 | 2429877-30-3 | Reference compound |
| HY-129605 | Ferulenol | 6805-34-1 | Natural Products |
| HY-129607 | A-65317 | 122224-84-4 | Reference compound |
| HY-129608 | Lenalidomide-acetylene-C5-COOH | 2429878-72-6 | Reference compound |
| HY-129610 | KB02-SLF | 2384184-40-9 | Reference compound |
| HY-129611 | Bromelain | 9001-00-7 | Reference compound |
| HY-129613 | Rhizonin A | 85803-92-5 | Peptides |
| HY-129614 | LG 82-4-01 | 91505-19-0 | Reference compound |
| HY-129615 | MIP-1072 | 949575-20-6 | Reference compound |
| HY-129616 | TachypleginA-2 | 296798-88-4 | Reference compound |
| HY-129619 | SNIPER(ER)-87 | 2222354-91-6 | Reference compound |
| HY-12961A | Bretylium (tosylate) | 61-75-6 | Reference compound |
| HY-12961AR | Bretylium (tosylate) (Standard) | 61-75-6 | Reference Standards |
| HY-12962 | NMDA-IN-1 | 700878-19-9 | Reference compound |
| HY-129622 | NH2-PEG5-C6-Cl | 1261238-22-5 | Reference compound |
| HY-129622A | NH2-PEG5-C6-Cl (hydrochloride) | 2241669-16-7 | Reference compound |
| HY-129623 | Ethyl nonanoate | 123-29-5 | Natural Products |
| HY-129623R | Ethyl nonanoate (Standard) | 123-29-5 | Reference Standards |
| HY-129624 | Bisindolylmaleimide VIII | 125313-65-7 | Reference compound |
| HY-129624A | Bisindolylmaleimide VIII (acetate) | 138516-31-1 | Reference compound |
| HY-129629 | Thiomandelic acid | 4695-09-4 | Reference compound |
| HY-12963 | Dubermatinib | 1341200-45-0 | Reference compound |
| HY-129630 | Tetrahydrocortisol | 53-02-1 | Natural Products |
| HY-129630S | Tetrahydrocortisol-d5 | | Isotope-Labeled Compounds |
| HY-129634 | TrkA-IN-1 | 1680179-43-4 | Reference compound |
| HY-129636 | CLH304a | 1611483-29-4 | Reference compound |
| HY-129636A | (E/Z)-CLH304a | 797-17-1 | Reference compound |
| HY-129637 | NH2-PEG5-OH | 34188-11-9 | ADC Related |
| HY-129638 | L-10503 | 55308-37-7 | Reference compound |
| HY-129639 | L11204 | 55308-64-0 | Reference compound |
| HY-12964 | SGI-7079 | 1239875-86-5 | Reference compound |
| HY-129640 | A-130C | 73522-76-6 | Natural Products |
| HY-129641 | KF-392 | 60671-62-7 | Reference compound |
| HY-129642 | Hirsutide | 865368-30-5 | Natural Products |
| HY-129645 | L-647318 | 87770-13-6 | Reference compound |
| HY-129648 | AC-7954 (free base) | 734528-95-1 | Reference compound |
| HY-129649 | Hydro-UCB35625 | 301648-08-8 | Reference compound |
| HY-12965 | S49076 | 1265965-22-7 | Reference compound |
| HY-129650 | Flobetapir | 938435-69-9 | Reference compound |
| HY-129650R | Flobetapir (Standard) | 938435-69-9 | Reference Standards |
| HY-129651 | SHMT-IN-1 | 1508286-18-7 | Reference compound |
| HY-129652 | HaloAUTAC tt15 | 2241668-45-9 | Reference compound |
| HY-129653 | E3 ligase Ligand 18 | 2241669-88-3 | Reference compound |
| HY-129654 | MTSES (sodium) | 184644-83-5 | Reference compound |
| HY-129655 | Sulfo-SMPB (sodium) | 92921-26-1 | ADC Related |
| HY-129656 | GLP-1 receptor agonist 3 | 2230200-09-4 | Reference compound |
| HY-129657 | GLP-1 receptor agonist 4 | 1187061-62-6 | Reference compound |
| HY-129658 | TT-OAD2 (free base) | 1246826-07-2 | Reference compound |
| HY-129658A | TT-OAD2 | 2382719-60-8 | Reference compound |
| HY-12965A | S49076 (hydrochloride) | 1265966-31-1 | Reference compound |
| HY-12965B | (Z)-S49076 (hydrochloride) | 1265965-19-2 | Reference compound |
| HY-12966 | Cetirizine methyl ester | 83881-46-3 | Reference compound |
| HY-129660 | LK 204-545 | 83068-69-3 | Natural Products |
| HY-129661 | AH 7959 | 763023-14-9 | Reference compound |
| HY-129662 | Ro 31-0052 | 82381-67-7 | Reference compound |
| HY-129663 | L-687384 | 95417-67-7 | Reference compound |
| HY-129664 | L 683519 | 132172-14-6 | Reference compound |
| HY-129665 | GS-389 | 41498-37-7 | Natural Products |
| HY-129666 | NSC-65847 | 6949-15-1 | Reference compound |
| HY-129667 | BM 21.1298 | 5218-08-6 | Reference compound |
| HY-129668 | Bremazocine | 75684-07-0 | Reference compound |
| HY-129669 | Landomycin A | 130432-93-8 | Reference compound |
| HY-129670 | KMUP-1 | 81996-46-5 | Reference compound |
| HY-129671 | Polypodine B | 18069-14-2 | Natural Products |
| HY-129672 | Thelenotoside B | 72175-95-2 | Natural Products |
| HY-129673 | Sarubicin A | 75533-14-1 | Natural Products |
| HY-129674 | PHA 568487 (free base) | 527680-56-4 | Reference compound |
| HY-129677 | ORC-13661 (hydrochloride) | 1979935-34-6 | Reference compound |
| HY-129678 | UK-88947 (hydrochloride) | 137015-76-0 | Reference compound |
| HY-129679 | NMS-P953 | 1403679-33-3 | Reference compound |
| HY-129681 | MCL-1/BCL-2-IN-1 | 2493256-46-3 | Reference compound |
| HY-129682 | LY125180 | 74515-39-2 | Reference compound |
| HY-129683 | AM3102 | 213182-22-0 | Reference compound |
| HY-129685 | M79175 | 82319-87-7 | Reference compound |
| HY-129688 | Sut-8701 | 123577-73-1 | Reference compound |
| HY-129691 | Ro 14-1761 | 82502-19-0 | Reference compound |
| HY-129692 | Withanone | 27570-38-3 | Natural Products |
| HY-129692R | Withanone (Standard) | 27570-38-3 | Reference Standards |
| HY-129693 | PBI 51 | 130694-74-5 | Reference compound |
| HY-129694 | Lenoremycin | 51257-84-2 | Natural Products |
| HY-129695 | PD 132002 | 134452-04-3 | Reference compound |
| HY-129697 | 3-Hydroxy Medetomidine | 128366-50-7 | Reference compound |
| HY-129698 | MS-073 | 129716-45-6 | Reference compound |
| HY-129699 | RH01617 | 302333-18-2 | Reference compound |
| HY-12970 | EPZ020411 | 1700663-41-7 | Reference compound |
| HY-129700 | MCL-1/BCL-2-IN-2 | 2163793-44-8 | Reference compound |
| HY-129701 | MCL-1/BCL-2-IN-3 | 2163793-55-1 | Reference compound |
| HY-129702 | MCL-1/BCL-2-IN-4 | 2163793-56-2 | Reference compound |
| HY-129703 | Thalidomide-PEG2-C2-NH2 | 2093416-32-9 | Reference compound |
| HY-129703A | Thalidomide-PEG2-C2-NH2 (TFA) | 2097509-36-7 | Reference compound |
| HY-129703B | Thalidomide-PEG2-C2-NH2 (hydrochloride) | 2245697-87-2 | Reference compound |
| HY-129704 | Thalidomide-NH-C6-NH2 | 2093386-50-4 | Reference compound |
| HY-129704A | Thalidomide-NH-C6-NH2 (TFA) | 2093386-51-5 | Reference compound |
| HY-129704B | Thalidomide-NH-C6-NH2 (hydrochloride) | 2375194-37-7 | Reference compound |
| HY-129706 | LY127210 (free base) | 57184-68-6 | Reference compound |
| HY-129707 | AMG 837 (hemicalcium) | 1291087-14-3 | Reference compound |
| HY-129708 | LU 2443 | 19703-86-7 | Reference compound |
| HY-129709 | DAC 5945 | 124065-13-0 | Reference compound |
| HY-12970A | EPZ020411 (hydrochloride) | 2070015-25-5 | Reference compound |
| HY-12971 | Nampt-IN-1 | 1698878-14-6 | Reference compound |
| HY-129710 | CGP47656 | 133345-73-0 | Reference compound |
| HY-129711 | Pyrolan | 87-47-8 | Reference compound |
| HY-129714 | EMD 52297 | 129049-51-0 | Reference compound |
| HY-129715 | MPI-0441138 | 827030-33-1 | Reference compound |
| HY-129716 | L-693989 | 138661-20-8 | Reference compound |
| HY-129718 | Nafimidone alcohol | 71009-17-1 | Reference compound |
| HY-12972 | Mavelertinib | 1776112-90-3 | Reference compound |
| HY-129721 | Acid Red 26 | 3761-53-3 | Dye Reagents |
| HY-129724 | α-MSH(11-13) | 67727-97-3 | Reference compound |
| HY-129726 | FR-900137 | 73706-58-8 | Reference compound |
| HY-129727 | (E)-MS0019266 | 21945-37-9 | Reference compound |
| HY-129728 | Lienomycin | 12710-02-0 | Natural Products |
| HY-12973 | ALK-IN-13 | 1197953-88-0 | Reference compound |
| HY-129731 | Lappaconine | 23943-93-3 | Natural Products |
| HY-129733 | LND 623 | 90520-42-6 | Reference compound |
| HY-129734 | Aeruginosin B | 6508-65-2 | Natural Products |
| HY-129736 | P32/98 (hemifumarate) | 251572-86-8 | Reference compound |
| HY-129736A | P32/98 | 136259-20-6 | Reference compound |
| HY-129737 | A-62198 | 117978-26-4 | Reference compound |
| HY-129738 | I942 | 868145-09-9 | Reference compound |
| HY-12974 | PRT-060318 | 1194961-19-7 | Reference compound |
| HY-129742 | JTT-010 | 872422-30-5 | Reference compound |
| HY-129746 | Arylquin 1 | 1630743-73-5 | Reference compound |
| HY-129748 | SQ-24798 | 70873-80-2 | Reference compound |
| HY-129749 | IDO-IN-13 | 2291164-02-6 | Reference compound |
| HY-12975 | AZ6102 | 1645286-75-4 | Reference compound |
| HY-129751 | Nitrovin (hydrochloride) | 2315-20-0 | Reference compound |
| HY-129752 | Piperafizine B | 74720-33-5 | Natural Products |
| HY-129754 | Leuseramycin | 73537-10-7 | Natural Products |
| HY-129755 | CK-17 | 86727-00-6 | Reference compound |
| HY-129756 | Thioacetanilide | 637-53-6 | Reference compound |
| HY-129757 | 5-trans-Fluprostenol | 57968-83-9 | Reference compound |
| HY-129759 | KSG-504 (anhydrous) | 137005-17-5 | Reference compound |
| HY-12976 | DS-1558 | 1202575-67-4 | Reference compound |
| HY-129761 | AR 17048 | 65792-35-0 | Reference compound |
| HY-129762 | Yoshi-864 | 3458-22-8 | Reference compound |
| HY-129763 | Di-4-ANEPPS | 90134-00-2 | Dye Reagents |
| HY-129764 | Prostaglandin F3α | 745-64-2 | Reference compound |
| HY-129764A | (17E)-Prostaglandin F3α | 211100-24-2 | Reference compound |
| HY-129765 | Thiobenzanilide 63T | 1270966-08-9 | Reference compound |
| HY-129767 | CMLD012612 | 2368900-35-8 | Reference compound |
| HY-129768 | CMLD012072 | 2368900-33-6 | Reference compound |
| HY-129769 | CMLD012073 | 2368900-32-5 | Reference compound |
| HY-129770 | D-Methionine sulfoxide | 21056-56-4 | Reference compound |
| HY-129770A | D-Methionine sulfoxide (hydrochloride) | | Reference compound |
| HY-129771 | 3-Bromomethcathinone (hydrochloride) | 676487-42-6 | Reference compound |
| HY-129772 | Phthalimide-PEG3-C2-OTs | 382162-12-1 | Reference compound |
| HY-129773 | Phthalimide-PEG4-PDM-OTBS | | Reference compound |
| HY-129774 | Phthalimide-PEG4-MPDM-OH | | Reference compound |
| HY-129775 | K-Ras ligand-Linker Conjugate 1 | 2749492-84-8 | Reference compound |
| HY-129776 | K-Ras ligand-Linker Conjugate 2 | 2741300-61-6 | Reference compound |
| HY-129779 | BTL-104 | 753451-66-0 | Reference compound |
| HY-129780 | BTL-105 | 945007-11-4 | Reference compound |
| HY-129782 | SC-55858 | 179464-49-4 | Reference compound |
| HY-129783 | Phenindamine (tartrate) | 569-59-5 | Reference compound |
| HY-129785 | CP-220629 | 162141-96-0 | Reference compound |
| HY-129786 | LG 82-4-00 | 91505-18-9 | Reference compound |
| HY-129787 | PF-03550096 | 910376-39-5 | Reference compound |
| HY-129788 | Deltamycin A1 | 58880-22-1 | Natural Products |
| HY-129792 | Thiobencarb | 28249-77-6 | Reference compound |
| HY-129792R | Thiobencarb (Standard) | 28249-77-6 | Reference Standards |
| HY-129792S | Thiobencarb-d10 | 1219804-12-2 | Isotope-Labeled Compounds |
| HY-129793 | L-156903 | 116740-51-3 | Reference compound |
| HY-129794 | YM-298198 | 748758-45-4 | Reference compound |
| HY-129796 | 3'-Fluoroaminopterin | 85803-34-5 | Reference compound |
| HY-12980 | Batefenterol | 743461-65-6 | Reference compound |
| HY-129800 | CGP78850 | 258326-83-9 | Reference compound |
| HY-129801 | N-Ethyl Hexylone (hydrochloride) | 27912-41-0 | Reference compound |
| HY-129804 | Ceforanide (lysine) | 63767-79-3 | Reference compound |
| HY-129806 | Rugulosin | 23537-16-8 | Natural Products |
| HY-129808 | VPC12249 | 403520-23-0 | Reference compound |
| HY-12980A | Batefenterol (Succinate) | 945905-37-3 | Reference compound |
| HY-12981 | RG7713 | 920022-47-5 | Reference compound |
| HY-129810 | PD 135158 | 130325-35-8 | Reference compound |
| HY-129811 | Bis-ANS (dipotassium) | 65664-81-5 | Dye Reagents |
| HY-129812 | Borofalan | 80994-59-8 | Isotope-Labeled Compounds |
| HY-129813 | Aspochracin | 22029-09-0 | Natural Products |
| HY-129814 | MM 42842 (free acid) | 113784-28-4 | Reference compound |
| HY-129819 | (Rac)-DNDI-8219 | 1333170-15-2 | Reference compound |
| HY-129821 | PTI-1 | 1400742-46-2 | Reference compound |
| HY-129822 | 5-EAPB (hydrochloride) | 1823776-22-2 | Reference compound |
| HY-129824 | 3-Methyl orsellinic acid | 4707-46-4 | Reference compound |
| HY-129826 | J-104129 | 244277-89-2 | Reference compound |
| HY-12983 | ALS-8112 | 1445379-92-9 | Reference compound |
| HY-129831 | Prostaglandin I3 (sodium) | 68324-96-9 | Reference compound |
| HY-129832 | Biotin-azide | 908007-17-0 | Biochemical Assay Reagents |
| HY-129834 | Bilirubin Conjugate (disodium) | 68683-34-1 | Reference compound |
| HY-129836 | L-Amoxicillin | 26889-93-0 | Reference compound |
| HY-129836R | L-Amoxicillin (Standard) | 26889-93-0 | Reference Standards |
| HY-12983A | Lumicitabine | 1445385-02-3 | Reference compound |
| HY-129841 | Niguldipine (monohydrochloride) | 119934-51-9 | Reference compound |
| HY-129844 | Biphenyl-4-amidoxime | 40019-44-1 | Reference compound |
| HY-129846 | IBTP (iodide) | 159085-21-9 | Reference compound |
| HY-129847 | Alitame | 80863-62-3 | Reference compound |
| HY-129848 | Cucumarioside G1 | 81296-42-6 | Natural Products |
| HY-129850 | 4-Chloromethamphetamine (hydrochloride) | 30572-91-9 | Reference compound |
| HY-129851 | NTP42 | 2055599-51-2 | Reference compound |
| HY-129852 | 5-(4,6-Dichloro-s-triazin-2-ylamino)fluorescein hydrochloride | 21811-74-5 | Biochemical Assay Reagents |
| HY-129853A | Doxpicomine | 62904-71-6 | Reference compound |
| HY-129855 | DL-Tryptophan octyl ester (hydrochloride) | 6278-90-6 | Reference compound |
| HY-129858 | 5'-(N-Cyclopropyl)carboxamidoadenosine | 50908-62-8 | Reference compound |
| HY-129861 | 5'-Ethynyl-2'-deoxycytidine | 69075-47-4 | Reference compound |
| HY-129862 | Eclanamine (maleate) | 67450-45-7 | Reference compound |
| HY-129864A | 4-APDB (hydrochloride) | 1203342-42-0 | Reference compound |
| HY-129865 | MET (oxalate) | 5599-47-3 | Reference compound |
| HY-129867 | Z-Leu-Leu-Leu-AMC | 152015-61-7 | Peptides |
| HY-12987 | Pimozide | 2062-78-4 | Reference compound |
| HY-129870 | Diazoketone methotrexate | 82972-54-1 | Reference compound |
| HY-129876 | D-NAME (hydrochloride) | 50912-92-0 | Reference compound |
| HY-129878 | N-Trifluoroacetyladriamycin | 26295-56-7 | Reference compound |
| HY-12987R | Pimozide (Standard) | 2062-78-4 | Reference Standards |
| HY-12987S | Pimozide-d4 | 1803193-57-8 | Isotope-Labeled Compounds |
| HY-12987S1 | Pimozide-d5 N-Oxide | 1794795-40-6 | Isotope-Labeled Compounds |
| HY-12987S2 | Pimozide-d4-1 | | Isotope-Labeled Compounds |
| HY-12988 | C527 | 192718-06-2 | Reference compound |
| HY-129880 | Desacetylvinblastine hydrazide | 55383-37-4 | Reference compound |
| HY-129881 | 2-Thiothinone (hydrochloride) | 54817-67-3 | Reference compound |
| HY-129883 | (3R)-Hydroxyquinidine | 60761-51-5 | Reference compound |
| HY-129885 | Ephenidine (hydrochloride) | 6272-97-5 | Reference compound |
| HY-129886 | PKUMDL-LTQ-301 | 728886-01-9 | Reference compound |
| HY-129887 | Fluorescein diphosphate (tetraammonium) | 217305-49-2 | Dye Reagents |
| HY-129889 | Febuxostat acyl glucuronide | 1351692-92-6 | Reference compound |
| HY-12989 | LDN-91946 | 439946-22-2 | Reference compound |
| HY-129890 | 7-Hydroxy-PIPAT | 159559-71-4 | Reference compound |
| HY-129899 | (±)-Equol 4'-sulfate (sodium) | 1189685-28-6 | Reference compound |
| HY-12990 | Spautin-1 | 1262888-28-7 | Reference compound |
| HY-129900 | (-)-Luteoskyrin | 21884-44-6 | Reference compound |
| HY-129901 | 1-Demethyl phenazolam | 919973-69-6 | Reference compound |
| HY-129902 | L-Acosamine nucleoside | 136035-09-1 | Reference compound |
| HY-129903 | N-Desethyl vardenafil | 448184-46-1 | Reference compound |
| HY-129903R | N-Desethyl vardenafil (Standard) | 448184-46-1 | Reference Standards |
| HY-129903S | N-Desethyl Vardenafil-d8 | 1184985-26-9 | Isotope-Labeled Compounds |
| HY-129905 | L-Leucyl-L-Leucine methyl ester (hydrochloride) | 6491-83-4 | Reference compound |
| HY-129905A | L-Leucyl-L-Leucine methyl ester (hydrobromide) | 16689-14-8 | Reference compound |
| HY-129907 | 2-AEMP | 321882-95-5 | Reference compound |
| HY-129909 | Anticancer agent 173 | 177951-34-7 | Reference compound |
| HY-129912 | N1,N8-Diacetylspermidine | 82414-35-5 | Reference compound |
| HY-129912A | N1,N8-Diacetylspermidine (hydrochloride) | 178244-42-3 | Reference compound |
| HY-129914 | Cefcanel daloxate | 97275-40-6 | Reference compound |
| HY-129917 | KB02-JQ1 | 2384184-44-3 | Reference compound |
| HY-12991A | BIX-01338 (hydrate) | 1228184-65-3 | Reference compound |
| HY-129920 | Prostaglandin E2 methyl ester | 31753-17-0 | Reference compound |
| HY-129922 | 16(R)-AFP 07 (free acid) | 773825-80-2 | Reference compound |
| HY-129923 | (R)-Omeprazole (sodium) | 161796-77-6 | Reference compound |
| HY-129923R | (R)-Omeprazole (sodium) (Standard) | 161796-77-6 | Reference Standards |
| HY-129927 | Thiomuscimol | 62020-54-6 | Reference compound |
| HY-12993 | RSV604 | 676128-63-5 | Reference compound |
| HY-129932 | Pyrrolidine ricinoleamide | 1246776-23-7 | Reference compound |
| HY-129933 | (+)-Norpropoxyphene (maleate) | 159208-83-0 | Reference compound |
| HY-129934 | Latanoprost ethyl amide | 607351-44-0 | Reference compound |
| HY-129934S | Latanoprost ethyl amide-d4 | | Isotope-Labeled Compounds |
| HY-129937 | (S)-GNE-987 | 2738533-33-8 | Reference compound |
| HY-129937A | GNE-987 | 2417371-71-0 | Reference compound |
| HY-129938 | PROTAC BRD4 Degrader-24 | 2417370-39-7 | Reference compound |
| HY-129939 | PROTAC BRD4 ligand-1 | 2313230-51-0 | Reference compound |
| HY-12993A | RSV604 (racemate) | 676128-62-4 | Reference compound |
| HY-12993B | RSV604 (R enantiomer) | 932108-20-8 | Reference compound |
| HY-12994 | VP-14637 | 235106-62-4 | Reference compound |
| HY-129941 | (S,R,S)-AHPC-C10-NH2 | 2341796-74-3 | Reference compound |
| HY-129941A | (S,R,S)-AHPC-C10-NH2 (dihydrochloride) | 2341796-75-4 | Reference compound |
| HY-129942 | S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate | 2127875-65-2 | ADC Related |
| HY-129943 | Benzothiohydrazide | 20605-40-7 | Reference compound |
| HY-129944 | MJ33-OH | 199106-13-3 | Reference compound |
| HY-129944A | MJ33-OH (lithium) | 1135306-36-3 | Reference compound |
| HY-129946 | Dopamine D2 receptor antagonist-1 | 1055411-77-2 | Reference compound |
| HY-129947 | (-)-Carveol | 1253216-40-8 | Reference compound |
| HY-129948S | Ipratropium-d3 (iodide) | | Isotope-Labeled Compounds |
| HY-129949 | Aztreonam (lysine) | 827611-49-4 | Reference compound |
| HY-12995 | BI 665915 | 1360550-04-4 | Reference compound |
| HY-129951S | 7-Aminoclonazepam-d4 | 1215070-96-4 | Isotope-Labeled Compounds |
| HY-129952 | Dihydropleuromutilin | 42302-24-9 | Reference compound |
| HY-129953 | 9α,11β-Prostaglandin F2α | 38432-87-0 | Reference compound |
| HY-129953A | 5-trans Prostaglandin F2α | 36150-01-3 | Reference compound |
| HY-129953B | 15(R)-Prostaglandin F2α | 37658-84-7 | Reference compound |
| HY-129953C | 5-trans Prostaglandin F2α (tromethamine) | 330796-56-0 | Reference compound |
| HY-129953S | 9α,11β-Prostaglandin F2α-d4 | | Isotope-Labeled Compounds |
| HY-129953S1 | 9α,11β-Prostaglandin F2α-d9 | 2738376-79-7 | Isotope-Labeled Compounds |
| HY-129954 | 6-EAPB (hydrochloride) | 1823318-37-1 | Reference compound |
| HY-129955 | Carbazochrome (salicylate) | 13051-01-9 | Reference compound |
| HY-129959 | Aluminum phthalocyanine chloride | 14154-42-8 | Reference compound |
| HY-12995A | (S)-BI 665915 | 1360550-05-5 | Reference compound |
| HY-129960 | L-Selenocystine | 29621-88-3 | Peptides |
| HY-129963 | 3'-UMP (disodium) | 35170-03-7 | Reference compound |
| HY-129966 | PROTAC IRAK4 degrader-1 | 2360533-90-8 | Reference compound |
| HY-129967 | PROTAC IRAK4 ligand-1 | 2357108-39-3 | Reference compound |
| HY-129968 | AM-Imidazole-PA-Boc | 2357108-99-5 | Reference compound |
| HY-129969 | AG-1909 | 131927-00-9 | Reference compound |
| HY-129972 | Ribavirin 5'-monophosphate (dilithium) | 66983-94-6 | Reference compound |
| HY-129973 | 4-Chlorophenylurea | 140-38-5 | Reference compound |
| HY-129974 | 3,3'-Diiodo-L-thyronine | 4604-41-5 | Reference compound |
| HY-129974S | 3,3'-Diiodo-L-thyronine-13C6 | 1217459-13-6 | Isotope-Labeled Compounds |
| HY-129976 | Pemetrexed tromethamine (dihydrochloric) (dihydrate) | 1851348-04-3 | Reference compound |
| HY-129977 | 7-Hydroxy coumarin sulfate (potassium) | 1135316-80-1 | Reference compound |
| HY-129980 | NPC-15437 (dihydrochloride) | 141774-20-1 | Reference compound |
| HY-129982 | SC-435 | 289037-67-8 | Reference compound |
| HY-129983 | 5-Hydroxymethyl-2'-deoxyuridine | 5116-24-5 | Reference compound |
| HY-129985 | Clovoxamine | 54739-19-4 | Reference compound |
| HY-129986 | hCAI/II-IN-9 | 175014-68-3 | Reference compound |
| HY-129987 | Estradiol 17-(β-D-Glucuronide) (sodium) | 15087-02-2 | Reference compound |
| HY-129989 | A-130B | 73492-07-6 | Natural Products |
| HY-129990 | Dios-Arg (diTFA) | 1807353-31-6 | Biochemical Assay Reagents |
| HY-129993 | Gemfibrozil 1-O-β-glucuronide | 91683-38-4 | Reference compound |
| HY-129995 | TSHR antagonist S37b | 2143452-22-4 | Reference compound |
| HY-129995A | TSHR antagonist S37a | 2143452-20-2 | Reference compound |
| HY-129997 | Luteolinidin (chloride) | 1154-78-5 | Natural Products |
| HY-130000 | Pirmitegravir | 2245231-10-9 | Reference compound |
| HY-130001 | CDK9-IN-9 | 2246956-84-1 | Reference compound |
| HY-130003 | Hypoglycemic agent 1 | 2253733-57-0 | Reference compound |
| HY-130004 | MsbA-IN-6 | 2909443-13-4 | Reference compound |
| HY-13001 | Quizartinib | 950769-58-1 | Reference compound |
| HY-130011 | CCG-232964 | 2349373-70-0 | Reference compound |
| HY-130012 | CO23 | 1370363-74-8 | Reference compound |
| HY-130013 | HKYellow-AM (6/12-mixture) | 1448821-89-3 | Dye Reagents |
| HY-130015 | HKSOX-1 (5/6-mixture) | | Dye Reagents |
| HY-130017 | HKSOX-1r (5/6-mixture) | | Dye Reagents |
| HY-13001R | Quizartinib (Standard) | 950769-58-1 | Reference Standards |
| HY-13001S | Quizartinib-d8 | 1300734-19-3 | Isotope-Labeled Compounds |
| HY-13002 | Torin 2 | 1223001-51-1 | Reference compound |
| HY-130022 | HKPerox-1 | 2240163-05-5 | Dye Reagents |
| HY-130025 | HKOCl-3 | 2031170-80-4 | Dye Reagents |
| HY-130027 | HKOCl-4 | 2031170-85-9 | Dye Reagents |
| HY-13003 | Torin 1 | 1222998-36-8 | Reference compound |
| HY-13004 | Maraviroc | 376348-65-1 | Reference compound |
| HY-130043 | 11-O-Methylpseurotin A | 956904-34-0 | Natural Products |
| HY-130046 | 16-Epiestriol | 547-81-9 | Reference compound |
| HY-130046R | 16-Epiestriol (Standard) | 547-81-9 | Reference Standards |
| HY-130046S1 | 16β-Hydroxy-17β-estradiol-2,4-d2 | 366495-94-5 | Isotope-Labeled Compounds |
| HY-130047 | Bivittoside A | 77394-03-7 | Natural Products |
| HY-130049 | Lucidin ω-ethyl ether | 17526-17-9 | Natural Products |
| HY-13004R | Maraviroc (Standard) | 376348-65-1 | Reference Standards |
| HY-13004S | Maraviroc-d6 | 1033699-22-7 | Isotope-Labeled Compounds |
| HY-13005 | Fagomine | 53185-12-9 | Natural Products |
| HY-130050 | Luzopeptin A | 75580-37-9 | Natural Products |
| HY-130053 | Nafenopin | 3771-19-5 | Reference compound |
| HY-130055 | HQNO | 341-88-8 | Natural Products |
| HY-130055R | HQNO (Standard) | 341-88-8 | Reference Standards |
| HY-130059 | Guanine-7-oxide | 5227-68-9 | Reference compound |
| HY-130060 | 12(S)-HETrE | 72710-10-2 | Reference compound |
| HY-130061 | Cyclopentyluracil | 59967-83-8 | Reference compound |
| HY-130066 | Fortimicin C | 62874-51-5 | Natural Products |
| HY-130069 | Teicoplanin A2-5 | 91032-38-1 | Natural Products |
| HY-13007 | PF-3758309 | 898044-15-0 | Reference compound |
| HY-130070 | QO-40 | 1259536-70-3 | Reference compound |
| HY-130071 | Iproplatin | 62928-11-4 | Reference compound |
| HY-130072 | Bivittoside B | 77394-04-8 | Natural Products |
| HY-130073 | Amorfrutin A | 80489-90-3 | Natural Products |
| HY-130074 | FEMA 4809 | 1374760-95-8 | Reference compound |
| HY-130076 | MMP-2 Inhibitor II | 869577-51-5 | Reference compound |
| HY-130077 | Fmoc-PEG1-CH2CH2-NHS ester | 1807521-05-6 | Reference compound |
| HY-130078 | Ferrous bisglycinate | 20150-34-9 | Reference compound |
| HY-130079 | Procaine benzylpenicillin | 54-35-3 | Reference compound |
| HY-13007A | PF-3758309 (hydrochloride) | 1279034-84-2 | Reference compound |
| HY-13007B | PF-3758309 (dihydrochloride) | | Reference compound |
| HY-13008 | MK-0354 | 851776-28-8 | Reference compound |
| HY-130080 | DM3 | 796073-54-6 | ADC Related |
| HY-130081 | DM3-SMe | 796073-70-6 | ADC Related |
| HY-130082 | DM4-SMe | 796073-68-2 | ADC Related |
| HY-130083 | Seco-Duocarmycin TM | 236102-87-7 | ADC Related |
| HY-130084 | Mal-PEG2-VCP-NB | 2395887-69-9 | ADC Related |
| HY-130085 | Mal-PEG6-NHS ester | 1599472-25-9 | ADC Related |
| HY-130086 | Bis-PEG4-NHS ester | 1314378-11-4 | ADC Related |
| HY-130087 | Bis-PEG3-NHS ester | 1314378-16-9 | ADC Related |
| HY-130088 | Bis-PEG2-NHS ester | 65869-63-8 | ADC Related |
| HY-130089 | Bis-PEG1-NHS ester | 65869-64-9 | ADC Related |
| HY-13009 | PF-04620110 | 1109276-89-2 | Reference compound |
| HY-130090 | NHPI-PEG4-C2-Pfp ester | 2101206-46-4 | ADC Related |
| HY-130091 | NHPI-PEG4-C2-NHS ester | 1415328-95-8 | ADC Related |
| HY-130092 | NHPI-PEG3-C2-Pfp ester | 2101206-87-3 | ADC Related |
| HY-130093 | NHPI-PEG3-C2-NHS ester | 2101206-14-6 | ADC Related |
| HY-130094 | NHPI-PEG2-C2-Pfp ester | 2101206-47-5 | ADC Related |
| HY-130095 | NHPI-PEG2-C2-NHS ester | 2101206-31-7 | ADC Related |
| HY-130096 | Ald-Ph-amido-C2-nitrate | 141534-26-1 | ADC Related |
| HY-130097 | Ald-Ph-amido-PEG4-C2-acid | 1309460-27-2 | ADC Related |
| HY-130098 | Ald-Ph-amido-PEG3-C-COOH | 1007215-91-9 | ADC Related |
| HY-130099 | Ald-Ph-amido-PEG2 | 1061569-06-9 | ADC Related |
| HY-13010 | Laquinimod | 248281-84-7 | Reference compound |
| HY-130100 | Ald-Ph-amido-PEG3-C1-Boc | 1007215-94-2 | ADC Related |
| HY-130101 | Ald-Ph-amido-PEG4-C2-NHS ester | 1353011-74-1 | ADC Related |
| HY-130102 | Ald-Ph-amido-PEG3-C2-Pfp ester | 2101206-21-5 | ADC Related |
| HY-130103 | Ald-Ph-amido-PEG2-C2-Pfp ester | 2101206-60-2 | ADC Related |
| HY-130104 | Ald-Ph-amido-PEG2-C2-NHS ester | 1807521-07-8 | ADC Related |
| HY-130105 | Ald-Ph-amido-PEG1-C2-Pfp ester | 2101206-67-9 | ADC Related |
| HY-130106 | Ald-Ph-amido-PEG1-C2-NHS ester | 2101206-80-6 | ADC Related |
| HY-130107 | Ald-Ph-NHS ester | 60444-78-2 | ADC Related |
| HY-130108 | N3-PEG4-C2-Pfp ester | 1353012-00-6 | ADC Related |
| HY-130109 | N3-PEG4-C2-NHS ester | 944251-24-5 | ADC Related |
| HY-13010R | Laquinimod (Standard) | 248281-84-7 | Reference Standards |
| HY-13010S | Laquinimod-d5 | 1214267-09-0 | Isotope-Labeled Compounds |
| HY-13011 | Alectinib | 1256580-46-7 | Reference compound |
| HY-130110 | Sulfo-DMAC-SPP | 663599-11-9 | ADC Related |
| HY-130111 | DMAC-SPP | 663599-10-8 | ADC Related |
| HY-130112 | N-Succinimidyloxycarbonylpropyl methanethiosulfonate | 690632-55-4 | ADC Related |
| HY-130115 | IACS-8803 | 2095690-70-1 | Reference compound |
| HY-130115A | IACS-8803 (disodium) | 2243079-36-7 | Reference compound |
| HY-130115B | IACS-8803 (diammonium) | | Reference compound |
| HY-130116 | IACS-8779 | 2243079-26-5 | Reference compound |
| HY-130116A | IACS-8779 (disodium) | 2243079-27-6 | Reference compound |
| HY-130117 | AlbA-DCA | 2413716-79-5 | Reference compound |
| HY-130118 | MRGPRX1 agonist 1 | 2377379-39-8 | Reference compound |
| HY-130119 | Integrin-IN-2 | 2378617-67-3 | Reference compound |
| HY-13011A | Alectinib (Hydrochloride) | 1256589-74-8 | Reference compound |
| HY-13011R | Alectinib (Standard) | 1256580-46-7 | Reference Standards |
| HY-13011S | Alectinib-d8 | 1256585-15-5 | Isotope-Labeled Compounds |
| HY-13011S1 | Alectinib-d6 | 1616374-19-6 | Isotope-Labeled Compounds |
| HY-13012 | RepSox | 446859-33-2 | Reference compound |
| HY-130120 | HWL-088 | 2378617-96-8 | Reference compound |
| HY-130121 | MK-8719 | 1382799-40-7 | Reference compound |
| HY-130122 | MG-277 | 2411085-89-5 | Reference compound |
| HY-130126 | Sucunamostat (hydrate) | | Reference compound |
| HY-13012G | RepSox (GMP) | 446859-33-2 | GMP Small Molecules |
| HY-13013 | SIS3 | 521984-48-5 | Reference compound |
| HY-130136 | TMPRSS6-IN-1 | 2088415-78-3 | Reference compound |
| HY-130136A | TMPRSS6-IN-1 (TFA) | | Reference compound |
| HY-130137 | m-PEG8-C10-phosphonic acid | 2093153-86-5 | Reference compound |
| HY-130138 | (5S,6S)-DiHETE | 82948-87-6 | Reference compound |
| HY-130138A | (5S,6R)-DiHETE | 82948-88-7 | Reference compound |
| HY-130138B | (5S,6R)-DiHETEs | 129263-59-8 | Reference compound |
| HY-130138C | 5,6-DiHETE | 845673-97-4 | Reference compound |
| HY-130139 | 11,12-DiHETE | 867350-92-3 | Reference compound |
| HY-130140 | 8,9-DiHETE | 867350-87-6 | Natural Products |
| HY-130141 | m-PEG6-amino-Mal | 1644231-07-1 | Reference compound |
| HY-130142 | Biotinyl-NH-PEG3-C3-amido-C3-COOH (DIPEA) | 1205744-09-7 | Reference compound |
| HY-130142A | Biotinyl-NH-PEG3-C3-amido-C3-COOH | 1202761-21-4 | Reference compound |
| HY-130143 | Biotin-PEG3-azide | 875770-34-6 | Reference compound |
| HY-130144 | Ald-CH2-PEG3-azide | 1002342-83-7 | ADC Related |
| HY-130145 | m-PEG8-CH2COOH | 102013-72-9 | Reference compound |
| HY-130146 | Propargyl-PEG3-phosphonic acid diethyl ester | 1052678-30-4 | Reference compound |
| HY-130147 | Propargyl-PEG5-OH | 1036204-60-0 | Reference compound |
| HY-130148 | m-PEG8-Br | 1056881-04-9 | Reference compound |
| HY-130149 | Adagrasib | 2326521-71-3 | Reference compound |
| HY-130150 | m-PEG5-succinimidyl carbonate | 1058691-00-1 | ADC Related |
| HY-130151 | m-PEG7-CH2CH2COOH | 1093647-41-6 | ADC Related |
| HY-130152 | Ms-PEG7-MS | 109789-41-5 | Reference compound |
| HY-130154 | Ald-Ph-amido-PEG2-C2-acid | 1807534-84-4 | Reference compound |
| HY-130155 | AMPK activator C2 | 1428422-55-2 | Reference compound |
| HY-130157 | 3-(2-Pyridyldithio)propanoic Acid | 68617-64-1 | Reference compound |
| HY-130158 | Tos-PEG1-CH2-Boc | 1643957-24-7 | Reference compound |
| HY-130159 | Hydroxy-PEG12-t-butyl ester | 1186025-29-5 | Reference compound |
| HY-13016 | Cabozantinib | 849217-68-1 | Reference compound |
| HY-130160 | Fluorescein-thiourea-PEG2-azide | 1146195-72-3 | Reference compound |
| HY-130161 | m-PEG4-Br | 110429-45-3 | ADC Related |
| HY-130162 | Tos-PEG2-O-Propargyl | 1119249-30-7 | Reference compound |
| HY-130163 | Bromo-PEG1-CH2COOH | 1135131-50-8 | Reference compound |
| HY-130164 | Bromo-PEG3-C2-phosphonic acid | 1148026-99-6 | Reference compound |
| HY-130165 | Tr-PEG8-OH | 1144113-16-5 | ADC Related |
| HY-130166 | Amino-PEG9-acid | 1191079-83-0 | ADC Related |
| HY-130167 | Fmoc-NH-PEG9-CH2CH2COOH | 1191064-81-9 | ADC Related |
| HY-130168 | m-PEG5-azide | 1202681-04-6 | Reference compound |
| HY-130169 | Azido-PEG9-amine | 1207714-69-9 | ADC Related |
| HY-13016A | Cabozantinib (hydrochloride) | 1817759-42-4 | Reference compound |
| HY-13016R | Cabozantinib (Standard) | 849217-68-1 | Reference Standards |
| HY-13016S | Cabozantinib-d6 | 1802168-46-2 | Isotope-Labeled Compounds |
| HY-13016S1 | Cabozantinib-d4 | 1802168-53-1 | Isotope-Labeled Compounds |
| HY-13017 | Ivacaftor | 873054-44-5 | Reference compound |
| HY-130170 | Disuccinimidyl tartrate | 62069-75-4 | Reference compound |
| HY-130172 | Benzyl-PEG2-CH2-Boc | 1643957-26-9 | Reference compound |
| HY-130173 | Bafilomycin C1 | 88979-61-7 | Natural Products |
| HY-130174 | Ald-Ph-amido-PEG3-C2-NH2 | 1404111-56-3 | Reference compound |
| HY-130175 | Fmoc-NH-PEG4-CH2COOH | 437655-95-3 | ADC Related |
| HY-130176 | UFP-512 | 480446-44-4 | Reference compound |
| HY-130178 | CL-385319 | 1210501-46-4 | Reference compound |
| HY-130179 | RC-33 (hydrochloride) | 1346016-43-0 | Reference compound |
| HY-13017A | Ivacaftor (benzenesulfonate) | 1134822-09-5 | Reference compound |
| HY-13017B | Ivacaftor (hydrate) | 1134822-07-3 | Reference compound |
| HY-13017S | Ivacaftor-d9 | 1413431-07-8 | Isotope-Labeled Compounds |
| HY-13017S1 | Ivacaftor-d19 | 1413431-22-7 | Isotope-Labeled Compounds |
| HY-13017S2 | Ivacaftor-d18 | 1413431-05-6 | Isotope-Labeled Compounds |
| HY-13017S3 | Ivacaftor-d4 | | Isotope-Labeled Compounds |
| HY-13017S4 | Ivacaftor-13C6 | | Isotope-Labeled Compounds |
| HY-13018 | MRT67307 | 1190378-57-4 | Reference compound |
| HY-130180 | Propargyl-PEG6-NH2 | 1198080-04-4 | Reference compound |
| HY-130181 | m-PEG4-amino-Mal | 1263044-81-0 | Reference compound |
| HY-130182 | Propargyl-PEG8-NH2 | 1196732-52-1 | ADC Related |
| HY-130183 | Propargyl-PEG6-N3 | 1198080-03-3 | Reference compound |
| HY-130184 | Azido-PEG8-NHS ester | 1204834-00-3 | ADC Related |
| HY-130185 | m-PEG7-CH2CH2CHO | 1234369-95-9 | ADC Related |
| HY-130186 | Methyl propionate-PEG12 | 1239588-11-4 | Reference compound |
| HY-130187 | Sapienic acid | 17004-51-2 | Reference compound |
| HY-130187A | Sapienic acid (sodium) | 217477-25-3 | Reference compound |
| HY-130187S | Sapienic acid-d19 | 2692623-89-3 | Isotope-Labeled Compounds |
| HY-130188 | Benzyl-PEG2-azide | 1260001-87-3 | Reference compound |
| HY-130189 | S-Phenylmercapturic acid | 4775-80-8 | Peptides |
| HY-130189R | S-Phenylmercapturic acid (Standard) | 4775-80-8 | Reference Standards |
| HY-13018A | MRT67307 (hydrochloride) | 2095432-39-4 | Reference compound |
| HY-13018B | MRT67307 (dihydrochloride) | 1781882-89-0 | Reference compound |
| HY-13019 | BI605906 | 960293-88-3 | Reference compound |
| HY-130192 | Cbz-NH-PEG8-C2-acid | 1334177-87-5 | Reference compound |
| HY-130193 | Mal-PEG2-NH-Boc | 660843-21-0 | Reference compound |
| HY-130194 | Azido-PEG5-CH2CO2H | 217180-81-9 | ADC Related |
| HY-130195 | SPDP-PEG4-NHS ester | 1334177-95-5 | Reference compound |
| HY-130197 | Lipoamido-PEG4-azide | 890016-39-4 | Reference compound |
| HY-130198 | DNP-PEG4-acid | 858126-76-8 | Reference compound |
| HY-130199 | Psoromic acid | 7299-11-8 | Natural Products |
| HY-13020 | GSK1838705A | 1116235-97-2 | Reference compound |
| HY-130200 | NH2-PEG8-OH | 352439-37-3 | Reference compound |
| HY-130201 | Deacetylsaptomycin D | 138370-82-8 | Reference compound |
| HY-130202 | Ald-Ph-amido-PEG2-C2-Boc | 1807521-09-0 | Reference compound |
| HY-130204 | m-PEG8-azide | 869718-80-9 | Reference compound |
| HY-130205 | Milacemide (hydrochloride) | 76990-85-7 | Reference compound |
| HY-130207 | Oncrasin-72 | 92407-90-4 | Reference compound |
| HY-130208 | Thiodigalactoside | 51555-87-4 | Reference compound |
| HY-130209 | S-Acetyl-PEG8-OH | 1334177-81-9 | Reference compound |
| HY-13021 | SRT3190 | 1204707-73-2 | Reference compound |
| HY-130210 | Oxonol V | 61389-30-8 | Dye Reagents |
| HY-130211 | Azido-PEG5-alcohol | 86770-68-5 | ADC Related |
| HY-130212 | Amobam | 3566-10-7 | Reference compound |
| HY-130212R | Amobam (Standard) | 3566-10-7 | Reference Standards |
| HY-130213 | Thiol-PEG4-acid | 749247-06-1 | Reference compound |
| HY-130214 | 7-Hydroxypestalotin | 41164-59-4 | Natural Products |
| HY-130216 | THP-PEG3-OH | 60221-37-6 | Reference compound |
| HY-130219 | 18-HETE | 133268-58-3 | Reference compound |
| HY-13022 | CC-401 (hydrochloride) | 1438391-30-0 | Reference compound |
| HY-130220 | (±)5-HETE lactone | 81517-87-5 | Reference compound |
| HY-130221 | (25S)-Δ7-Dafachronic acid | 949004-12-0 | Reference compound |
| HY-130222 | Mal-PEG2-Val-Cit-PAB-OH | 2055041-38-6 | ADC Related |
| HY-130223 | 11β-Prostaglandin E2 | 38310-90-6 | Reference compound |
| HY-130224 | Altromycin C | 128439-48-5 | Natural Products |
| HY-130225 | Cannabichromevarin | 41408-19-9 | Natural Products |
| HY-130226 | 11-epi-PGE1 | 24570-01-2 | Reference compound |
| HY-130228 | N3-PEG8-CH2COOH | 1343472-07-0 | Reference compound |
| HY-130229 | (±)5,6-DHET lactone | 213126-92-2 | Reference compound |
| HY-13022A | CC-401 | 395104-30-0 | Reference compound |
| HY-13022B | CC-401 (dihydrochloride) | 2319601-04-0 | Reference compound |
| HY-13023 | AMG-Tie2-1 | 870223-96-4 | Reference compound |
| HY-130230 | THP-PEG4-OH | 128660-97-9 | Reference compound |
| HY-130231 | m-PEG2-acid | 149577-05-9 | Reference compound |
| HY-130232 | Mal-amido-PEG2-TFP ester | 1431291-44-9 | Reference compound |
| HY-130233 | S516 | 1016543-77-3 | Reference compound |
| HY-130235 | Naprodoxime (hydrochloride) | 58033-22-0 | Reference compound |
| HY-130237 | Cinnamtannin B-1 | 88082-60-4 | Natural Products |
| HY-130237R | Cinnamtannin B-1 (Standard) | 88082-60-4 | Reference Standards |
| HY-130238 | (±)8-HDHA | 90780-54-4 | Reference compound |
| HY-130239 | 14(S)-HDHA | 119433-37-3 | Reference compound |
| HY-130239A | (±)14-HDHA | 87042-40-8 | Reference compound |
| HY-130239S | 14(S)-HDHA-d5 | | Isotope-Labeled Compounds |
| HY-13024 | Rebastinib | 1020172-07-9 | Reference compound |
| HY-130240 | GCN2-IN-6 | 2183470-09-7 | Reference compound |
| HY-130241 | Reverse transcriptase-IN-1 | 2380001-43-2 | Reference compound |
| HY-130242 | PXS-5120A | 2125955-70-4 | Reference compound |
| HY-130243 | RORγt Inverse agonist 6 | 1887161-80-9 | Reference compound |
| HY-130244 | BACE1-IN-5 | 2581114-83-0 | Reference compound |
| HY-130245 | PCSK9 degrader 1 | | Reference compound |
| HY-130245A | (R,R)-PCSK9 degrader 1 | 2216703-12-5 | Reference compound |
| HY-130246 | NF-56-EJ40 | 2380230-73-7 | Reference compound |
| HY-130246A | NF-56-EJ40 (hydrochloride) | 2728500-80-7 | Reference compound |
| HY-130247 | Flonoltinib | 2387765-27-5 | Reference compound |
| HY-130247A | Flonoltinib (TFA) | 2928093-29-0 | Reference compound |
| HY-130247B | Flonoltinib (monomaleate) | | Reference compound |
| HY-130247C | Flonoltinib (sulfate) | 2568842-57-7 | Reference compound |
| HY-130248 | BAY-899 | 2471967-92-5 | Reference compound |
| HY-130248B | (R)-BAY-899 | 2988191-40-6 | Reference compound |
| HY-130249 | BAY-298 | 2471978-97-7 | Reference compound |
| HY-13025 | HIV-1 integrase inhibitor | 544467-07-4 | Reference compound |
| HY-130250 | SR-4835 | 2387704-62-1 | Reference compound |
| HY-130251 | DS18561882 | 2227149-22-4 | Reference compound |
| HY-130252 | YQ128 | 2454246-18-3 | Reference compound |
| HY-130253 | IRAK4-IN-6 | 2454244-02-9 | Reference compound |
| HY-130254 | CSK-IN-1 | 2380027-49-4 | Reference compound |
| HY-130255 | BTK inhibitor 13 | 2376726-26-8 | Reference compound |
| HY-130256 | β-NF-JQ1 | 2380000-55-3 | Reference compound |
| HY-130257 | CP5V | 2509359-75-3 | Reference compound |
| HY-130258 | LC3-mHTT-IN-AN1 | 486443-73-6 | Reference compound |
| HY-130259 | LC3-mHTT-IN-AN2 | 7758-73-8 | Natural Products |
| HY-13026 | Idelalisib | 870281-82-6 | Reference compound |
| HY-130260 | KRAS inhibitor-4 | 2374152-69-7 | Reference compound |
| HY-130261 | Mcl-1 antagonist 1 | 2376775-05-0 | Reference compound |
| HY-130262 | PDE1-IN-3 | 2370966-46-2 | Reference compound |
| HY-130264 | HIF-2α-IN-2 | 1672666-82-8 | Reference compound |
| HY-130269 | β-Naphthoflavone-CH2-OH | 2752755-32-9 | Reference compound |
| HY-13026S | Idelalisib-d5 | 1830330-31-8 | Isotope-Labeled Compounds |
| HY-13027 | DAPT | 208255-80-5 | Reference compound |
| HY-130270 | AhR Ligand-Linker Conjugates 1 | 2380012-98-4 | Reference compound |
| HY-130271 | (S,R,S)-AHPC-PEG5-COOH | 2172820-14-1 | Reference compound |
| HY-130272 | Anti-MI/R injury agent 1 | 2387506-35-4 | Reference compound |
| HY-130278 | MitoPQ | 1821370-28-8 | Reference compound |
| HY-13027G | DAPT (GMP) | 208255-80-5 | GMP Small Molecules |
| HY-130280 | Ianthelliformisamine A (TFA) | 1643593-28-5 | Reference compound |
| HY-130281 | Ianthelliformisamine B (diTFA) | 1643593-29-6 | Natural Products |
| HY-130282 | Ianthelliformisamine C (ditrifluoroacetate) | 1643593-30-9 | Reference compound |
| HY-130283 | Methyltetrazine-Ph-NHS ester | 1644644-96-1 | Reference compound |
| HY-130284 | NF864 | 69606-09-3 | Reference compound |
| HY-130285 | 10(S),17(S)-DiHDHA | 871826-47-0 | Reference compound |
| HY-130286 | 10-Hydroxy-4(Z),7(Z),11(E),13(Z),16(Z),19(Z)-docosahexaenoic acid | 90780-50-0 | Natural Products |
| HY-130287 | (±)16-HDHA | 90780-51-1 | Natural Products |
| HY-130288 | (±)13-HDHA | 90780-53-3 | Reference compound |
| HY-130289 | (±)4-HDHA | 90906-40-4 | Reference compound |
| HY-130290 | Biotin-PEG4-OH | 1217609-84-1 | Reference compound |
| HY-130291 | Biotin-PEG3-NHS ester | 1253286-56-4 | Reference compound |
| HY-130292 | m-PEG-acid | 125220-94-2 | Reference compound |
| HY-130293 | Propargyl-PEG4-CH2CH2-Boc | 1245823-50-0 | ADC Related |
| HY-130294 | Pyracrenic acid | 80832-44-6 | Natural Products |
| HY-130295 | Pomalidomide-PEG2-Tos | 2599846-07-6 | Reference compound |
| HY-130296 | Palbociclib-propargyl | 2366269-23-8 | Reference compound |
| HY-130297 | PROTAC BCR-ABL1 ligand 1 | 2489876-34-6 | Reference compound |
| HY-130298 | Amino-PEG11-OH | 15332-94-2 | ADC Related |
| HY-13030 | (+)-JQ-1 | 1268524-70-4 | Reference compound |
| HY-130302 | Integracin A | 224186-03-2 | Natural Products |
| HY-130304 | 8-Isoprostaglandin E2 | 27415-25-4 | Reference compound |
| HY-130304S | 8-Isoprostaglandin E2-d4 | | Isotope-Labeled Compounds |
| HY-130307 | Rubrofusarin | 3567-00-8 | Natural Products |
| HY-130309 | (±)8(9)-EpETE | 851378-93-3 | Reference compound |
| HY-13030A | (R)-(-)-JQ1 Enantiomer | 1268524-71-5 | Reference compound |
| HY-13031 | GW 841819X | 146135-18-4 | Reference compound |
| HY-130310 | 11(R)-HEDE | 330800-88-9 | Reference compound |
| HY-130310A | 11(S)-HEDE | 330800-90-3 | Reference compound |
| HY-130310B | (±)11-HEDE | 5598-37-8 | Reference compound |
| HY-130311 | 2-Linoleoyl glycerol | 3443-82-1 | Reference compound |
| HY-130312 | N-(Azido-PEG4)-N-Boc-PEG4-NHS ester | 2112731-96-9 | Reference compound |
| HY-130313 | Sodium lauroyl glutamate | 29923-31-7 | Reference compound |
| HY-130313R | Sodium lauroyl glutamate (Standard) | 29923-31-7 | Reference Standards |
| HY-130314 | PPHP | 87864-20-8 | Reference compound |
| HY-130315 | Br-PEG4-C2-Boc | 564476-32-0 | ADC Related |
| HY-130317 | trans-11-Methyl-2-dodecenic acid | 677354-24-4 | Reference compound |
| HY-130318 | Quinidine N-oxide | 70116-00-6 | Reference compound |
| HY-130319 | 9(S)-HEPE | 141545-44-0 | Reference compound |
| HY-130319A | 9-HEPE | 286390-03-2 | Reference compound |
| HY-13032 | Molibresib | 1260907-17-2 | Reference compound |
| HY-130320 | Monophosphoryl lipid A | 1246298-63-4 | Reference compound |
| HY-130320A | Monophosphoryl lipid A (free acid) | 960324-04-3 | Reference compound |
| HY-130320B | Monophosphoryl lipid A (Triethylamine) | | Reference compound |
| HY-130321 | Lauroyl-L-carnitine (chloride) | 6919-91-1 | Reference compound |
| HY-130321S | Lauroyl-L-carnitine-d3 (chloride) | 2687960-76-3 | Isotope-Labeled Compounds |
| HY-130321S1 | Lauroyl-L-carnitine-d9 (chloride) | 2245711-25-3 | Isotope-Labeled Compounds |
| HY-130322 | Maresin Conjugates in Tissue Regeneration 2 | 1784701-62-7 | Reference compound |
| HY-130323 | 13-HPOT | 67597-26-6 | Reference compound |
| HY-130324 | Azido-PEG7-amine | 1333154-77-0 | ADC Related |
| HY-130325 | α-Guanidinoglutaric acid | 73477-53-9 | Reference compound |
| HY-130326 | RAPTA-C | 372948-28-2 | Reference compound |
| HY-130328 | NH-bis-PEG2 | 54384-47-3 | ADC Related |
| HY-13032A | GSK 525768A | 1260530-25-3 | Reference compound |
| HY-13032B | Molibresib (besylate) | 1895049-20-3 | Reference compound |
| HY-13033 | CDK-IN-2 | 1269815-17-9 | Reference compound |
| HY-130330 | Ald-CH2-PEG5-Boc | 1446282-23-0 | Reference compound |
| HY-130332 | Mitomycin A | 4055-39-4 | Reference compound |
| HY-130333 | Tetrahydrohomofolic acid | 5786-82-3 | Reference compound |
| HY-130334 | Mal-PEG8-acid | 1818294-46-0 | Reference compound |
| HY-130335 | Encainide | 66778-36-7 | Reference compound |
| HY-130336 | m-PEG6-Tos | 155887-96-0 | Reference compound |
| HY-130337 | Teicoplanin A2-2 | 91032-26-7 | Reference compound |
| HY-130338 | Teicoplanin A2-3 | 91032-36-9 | Reference compound |
| HY-130339 | Teicoplanin A2-4 | 91032-37-0 | Reference compound |
| HY-13034 | Gandotinib | 1229236-86-5 | Reference compound |
| HY-130340 | Teicoplanin A3-1 | 93616-27-4 | Reference compound |
| HY-130342 | HO-PEG11-OH | 6809-70-7 | Reference compound |
| HY-130343 | 5-Methylmellein | 7734-92-1 | Biochemical Assay Reagents |
| HY-130344 | SKF 83959 | 80751-85-5 | Reference compound |
| HY-130345 | PAF (C18) | 74389-69-8 | Biochemical Assay Reagents |
| HY-130345S | C18-PAF-d4 | | Isotope-Labeled Compounds |
| HY-130346 | DBCO-PEG4-DBCO | 2182601-68-7 | ADC Related |
| HY-130347 | H2S Donor 5a | 134861-13-5 | Reference compound |
| HY-130348 | OPSS-PEG8-COOH | 1334177-96-6 | Reference compound |
| HY-130349 | Emamectin B1a | 121124-29-6 | Reference compound |
| HY-130350 | DNP-PEG3-DNP | 1365655-92-0 | Reference compound |
| HY-130351 | 25H-NBOMe (hydrochloride) | 1566571-52-5 | Reference compound |
| HY-130352 | 9-SAHSA | 1895916-79-6 | Reference compound |
| HY-130353 | Desethylamiodarone (hydrochloride) | 96027-74-6 | Reference compound |
| HY-130353R | Desethylamiodarone (hydrochloride) (Standard) | 96027-74-6 | Reference Standards |
| HY-130353S | Desethyl Amiodarone-d4 (hydrochloride) | 1189960-80-2 | Isotope-Labeled Compounds |
| HY-130354 | Dibutyryl-cGMP (sodium) | 51116-00-8 | Reference compound |
| HY-130356 | 5-trans U-46619 | 330796-58-2 | Reference compound |
| HY-130357 | 15(S)-HETE Ethanolamide | 161744-53-2 | Reference compound |
| HY-130358 | PDDHV | 179469-40-0 | Reference compound |
| HY-13036 | (Rac)-IBT6A | 1412418-47-3 | Reference compound |
| HY-130361 | Isoxadifen-ethyl | 163520-33-0 | Reference compound |
| HY-130361R | Isoxadifen-ethyl (Standard) | 163520-33-0 | Reference Standards |
| HY-130364 | Fmoc-NH-PEG6-CH2COOH | 437655-96-4 | ADC Related |
| HY-130365 | Tixocortol pivalate | 55560-96-8 | Reference compound |
| HY-130366 | JG-365 | 132748-20-0 | Reference compound |
| HY-130367 | U-48520 | 67579-11-7 | Reference compound |
| HY-130368 | W-7 | 65595-90-6 | Reference compound |
| HY-130369 | NSC10010 (hydrochloride) | 6286-09-5 | Reference compound |
| HY-13036A | IBT6A | 1022150-12-4 | Reference compound |
| HY-13036B | IBT6A (hydrochloride) | 1553977-42-6 | Reference compound |
| HY-13036C | (Rac)-IBT6A (hydrochloride) | 1807619-60-8 | Reference compound |
| HY-130372 | Propargyl-PEG9-bromide | 2055042-83-4 | ADC Related |
| HY-130373 | Propargyl-PEG9-amine | 2093153-98-9 | Reference compound |
| HY-130374 | Propargyl-PEG8-OH | 1351556-81-4 | Reference compound |
| HY-130375 | Propargyl-PEG8-Boc | 2055014-96-3 | Reference compound |
| HY-130376 | Propargyl-PEG8-NHS ester | 2182601-74-5 | ADC Related |
| HY-130377 | Propargyl-PEG8-bromide | 2055046-25-6 | ADC Related |
| HY-130378 | Propargyl-PEG7-alcohol | 1422023-54-8 | Reference compound |
| HY-130379 | Propargyl-PEG8-acid | 2055014-94-1 | ADC Related |
| HY-13038 | Fostamatinib Disodium | 1025687-58-4 | Reference compound |
| HY-130380 | Propargyl-PEG7-Boc | 1818294-29-9 | Reference compound |
| HY-130381 | Propargyl-PEG7-NHS ester | 2093152-77-1 | ADC Related |
| HY-130382 | Propargyl-PEG6-alcohol | 944560-99-0 | Reference compound |
| HY-130383 | Propargyl-PEG7-acid | 2093154-00-6 | ADC Related |
| HY-130384 | Propargyl-PEG6-Boc | 1355197-95-3 | Reference compound |
| HY-130385 | Propargyl-PEG6-NHS ester | 2093153-99-0 | ADC Related |
| HY-130386 | Propargyl-PEG6-acid | 1951438-84-8 | ADC Related |
| HY-130387 | Propargyl-PEG4-Tos | 875770-32-4 | ADC Related |
| HY-130388 | Propargyl-PEG5-NHS ester | 1393330-40-9 | ADC Related |
| HY-130389 | Propargyl-PEG4-O-C1-Boc | 2098489-63-3 | Reference compound |
| HY-13038A | Fostamatinib | 901119-35-5 | Reference compound |
| HY-13038AR | Fostamatinib (Standard) | 901119-35-5 | Reference Standards |
| HY-13038B | Fostamatinib (disodium hexahydrate) | 914295-16-2 | Reference compound |
| HY-13039 | (2S,3R,4R)-2,3,5-Tris(benzyloxy)-4-hydroxypentanal | 7597-81-1 | Biochemical Assay Reagents |
| HY-130390 | Propargyl-PEG4-O-C1-NHS ester | 1161883-51-7 | Reference compound |
| HY-130391 | MMP12-IN-3 | 208663-26-7 | Reference compound |
| HY-130392 | Wofapyrin | 8066-94-2 | Reference compound |
| HY-130393 | 3C-B-FLY (hydrochloride) | 178557-19-2 | Reference compound |
| HY-130394 | 2C-B-FLY (hydrochloride) | 178557-21-6 | Reference compound |
| HY-130395 | 15-Keto latanoprost | 135646-98-9 | Reference compound |
| HY-130396 | DBCO-PEG4-C2-acid | 1537170-85-6 | Reference compound |
| HY-130397 | Pyrene-amido-PEG4-CH2CH2COOH | 1817735-34-4 | Reference compound |
| HY-130398 | Aerophobin-2 | 87075-23-8 | Natural Products |
| HY-130399 | Mal-amido-PEG6-acid | 1334177-79-5 | Reference compound |
| HY-13040 | N-Benzoyl-5'-O-dmtr-2'-O-(2-methoxyethyl)-adenosine | 251647-48-0 | Reference compound |
| HY-130402A | Propamidine (isethionate) | 140-63-6 | Reference compound |
| HY-130402B | Propamidine | 104-32-5 | Reference compound |
| HY-130403 | Leptocarpin acetate | 73522-57-3 | Natural Products |
| HY-130404 | m-PEG3-Boc | 1778219-81-0 | Reference compound |
| HY-130405 | PtdIns-(1,2-dipalmitoyl) (ammonium) | 34290-57-8 | Reference compound |
| HY-130406 | Benthiavalicarb isopropyl | 177406-68-7 | Reference compound |
| HY-130407 | Lipoamido-PEG3-OH | 1342764-64-0 | Reference compound |
| HY-130408 | m-PEG6-Amine | 184357-46-8 | ADC Related |
| HY-130409 | Kelevan | 4234-79-1 | Reference compound |
| HY-13041 | LX-1031 | 945976-76-1 | Reference compound |
| HY-130410 | Bis-PEG6-NHS ester | 1526718-98-8 | ADC Related |
| HY-130411 | Amino-PEG11-amine | 479200-82-3 | Reference compound |
| HY-130412 | FlAsH-EDT2 | 212118-77-9 | Dye Reagents |
| HY-130413 | Protectin D1 | 660430-03-5 | Reference compound |
| HY-130414 | Mal-amido-PEG4-acid | 1263045-16-4 | Reference compound |
| HY-130415 | Tos-PEG2-CH2COOH | 1807537-35-4 | Reference compound |
| HY-130416 | Mal-PEG2-PFP ester | 1807512-47-5 | Reference compound |
| HY-130417 | Tos-PEG4-acid | 1453117-42-4 | Reference compound |
| HY-130418 | (-)-Domesticine | 54325-07-4 | Reference compound |
| HY-130419 | (±)13(14)-EpDPA | 895127-64-7 | Reference compound |
| HY-130420 | Azido-PEG5-PFP ester | 1818294-48-2 | Reference compound |
| HY-130422 | Tos-PEG4-t-butyl ester | 217817-01-1 | Reference compound |
| HY-130423 | Milbemycin A3 | 51596-10-2 | Reference compound |
| HY-130423R | Milbemycin A3 (Standard) | 51596-10-2 | Reference Standards |
| HY-130424 | m-PEG10-azide | 2112738-12-0 | Reference compound |
| HY-130425 | Bromo-PEG1-acid | 1393330-33-0 | Reference compound |
| HY-130426 | Maleimido-tri(ethylene glycol)-propionic acid | 518044-40-1 | ADC Related |
| HY-130429 | 14,15-Leukotriene C4 | 75290-60-7 | Natural Products |
| HY-130430 | Neplanocin A | 72877-50-0 | Natural Products |
| HY-130431 | Vinclozolin M2 | 83792-61-4 | Reference compound |
| HY-130432 | DBO-83 (dihydrochloride) | 195211-53-1 | Reference compound |
| HY-130433 | NBD Sphingosine | 1449370-25-5 | Dye Reagents |
| HY-130434 | 12-SAHSA | 51350-61-9 | Reference compound |
| HY-130435 | DBCO-PEG4-amine | 1840886-10-3 | ADC Related |
| HY-130436 | Acid-C2-PEG4-C2-NHS ester | 1343476-41-4 | Reference compound |
| HY-130437 | p-nitro-Pifithrin-α | 389850-21-9 | Reference compound |
| HY-130438 | EUK-118 | 186299-34-3 | Reference compound |
| HY-130439 | EUK-124 | 186299-35-4 | Reference compound |
| HY-13044 | ADL-5859 (hydrochloride) | 850173-95-4 | Reference compound |
| HY-130440 | Leukotriene F4 | 83851-42-7 | Reference compound |
| HY-130441 | Leukotriene B3 | 88099-35-8 | Natural Products |
| HY-130442 | Mal-PEG2-acid | 1374666-32-6 | ADC Related |
| HY-130443 | Cbz-NH-PEG6-C2-acid | 1334177-80-8 | Reference compound |
| HY-130444 | PTA2 | 71111-01-8 | Biochemical Assay Reagents |
| HY-130445 | m-PEG3-CH2COOH | 16024-60-5 | Reference compound |
| HY-130446 | m-PEG9-NHS ester | 1316189-13-5 | Reference compound |
| HY-130447 | Amino-PEG5-amine | 72236-26-1 | Reference compound |
| HY-130448 | 8-iso Prostaglandin F1β | 26771-95-9 | Reference compound |
| HY-130449 | N-Boc-N-bis(PEG4-OH) | 2093154-01-7 | ADC Related |
| HY-130452 | NOS1-IN-1 | 357965-99-2 | Reference compound |
| HY-130454 | Mal-PEG6-PFP ester | 1599486-33-5 | Reference compound |
| HY-130456 | AHR 10718 | 96436-73-6 | Reference compound |
| HY-130457 | m-PEG4-MS | 130955-37-2 | ADC Related |
| HY-130458 | EGNHS | 70539-42-3 | Reference compound |
| HY-130462 | 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC | 26853-31-6 | Natural Products |
| HY-130462R | 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC (Standard) | 26853-31-6 | Reference Standards |
| HY-130462S | 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC-d31 | 179093-76-6 | Isotope-Labeled Compounds |
| HY-130462S1 | 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC-d82 | 2260669-94-9 | Isotope-Labeled Compounds |
| HY-130462S2 | 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC-13C16 | 2692624-41-0 | Isotope-Labeled Compounds |
| HY-130462S3 | 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC-d64 | 2921921-66-4 | Isotope-Labeled Compounds |
| HY-130463 | POPG (sodium salt) | 268550-95-4 | Reference compound |
| HY-130465 | 7α-Thiospironolactone | 38753-76-3 | Reference compound |
| HY-130466 | Stearoyl-L-carnitine (chloride) | 32350-57-5 | Reference compound |
| HY-130466S | Stearoyl-L-carnitine-d3 (chloride) | 2245711-27-5 | Isotope-Labeled Compounds |
| HY-130467 | DNP-NH-PEG2-C2-acid | 1353011-89-8 | Reference compound |
| HY-130468 | Leptosin J | 160550-15-2 | Reference compound |
| HY-130469 | Mal-PEG4-Boc | 518044-36-5 | Reference compound |
| HY-13047 | S-(+)-Mecamylamine (hydrochloride) | 107596-30-5 | Reference compound |
| HY-130470 | Chloroacetamido-PEG4-C2-Boc | 1365655-90-8 | Reference compound |
| HY-130471 | Sannamycin C | 73522-71-1 | Reference compound |
| HY-130473 | Tos-PEG4-CH2COOH | 2028284-73-1 | Reference compound |
| HY-130474 | Azido-PEG6-NHS ester | 2055014-64-5 | ADC Related |
| HY-130475 | Azido-PEG9-acid | 1670249-37-2 | ADC Related |
| HY-130476 | Satratoxin G | 53126-63-9 | Natural Products |
| HY-130477 | Fmoc-Lys (biotin-PEG4)-OH | 1334172-64-3 | Reference compound |
| HY-130478 | m-PEG4-CH2COOH | 16024-66-1 | Reference compound |
| HY-130479 | AdipoR agonist 1 | 949745-75-9 | Reference compound |
| HY-13047A | rel-S-(+)-Mecamylamine (hydrochloride) | 110691-49-1 | Reference compound |
| HY-130480 | Fructose-arginine | 25020-14-8 | Reference compound |
| HY-130481 | Propargyl-PEG4-acid | 1415800-32-6 | Reference compound |
| HY-130482 | Salvinorin A carbamate | 858345-57-0 | Reference compound |
| HY-130483 | Br-PEG3-C2-Boc | 782475-37-0 | Reference compound |
| HY-130484 | 2,3-Dehydro-3,4-dihydro ivermectin | 1135339-49-9 | Reference compound |
| HY-130485 | Bromo-PEG2-C2-azide | 530151-56-5 | ADC Related |
| HY-130486 | NH2-PEG6-Boc | 1286281-32-0 | ADC Related |
| HY-130487 | miR-21-IN-2 | 304880-74-8 | Reference compound |
| HY-130488 | Hydroxy-PEG2-C2-PFP ester | 1820673-42-4 | Reference compound |
| HY-130489 | Bromo-PEG5-C2-acid | 1817735-27-5 | Reference compound |
| HY-13049 | Cediranib (maleate) | 857036-77-2 | Reference compound |
| HY-130490 | Biotin-bis-amido-SS-NHS | 142439-92-7 | Reference compound |
| HY-130491 | DNP-NH-PEG4-C2-Boc | 1817735-31-1 | Reference compound |
| HY-130492 | ARCC-4 | 1973403-00-7 | Reference compound |
| HY-130493 | HPB | 1800066-24-3 | Reference compound |
| HY-130494 | (±)11(12)-EET | 87173-81-7 | Reference compound |
| HY-130494S | (±)11(12)-EET-d11 | 2699607-19-5 | Isotope-Labeled Compounds |
| HY-130495 | CDDO-TFEA | 932730-52-4 | Reference compound |
| HY-130496 | Ald-Ph-PEG6-acid | 2055013-55-1 | Reference compound |
| HY-130497 | 12-Oxo-leukotriene B4 | 136696-10-1 | Reference compound |
| HY-130499 | ERRα Ligand-Linker Conjugates 1 | | Reference compound |
| HY-13050 | Sapitinib | 848942-61-0 | Reference compound |
| HY-130500 | Br-PEG3-CH2COOH | 1346502-15-5 | Reference compound |
| HY-130502 | 5β,6β-epoxycholestanol | 4025-59-6 | Biochemical Assay Reagents |
| HY-130503 | N-Boc-PEG1-bromide | 164332-88-1 | ADC Related |
| HY-130504 | Propargyl-PEG1-acid | 55683-37-9 | Reference compound |
| HY-130505 | N-Boc-PEG7-alcohol | 1292268-13-3 | ADC Related |
| HY-130506 | Glutamic acid diethyl ester | 16450-41-2 | Reference compound |
| HY-130507 | Aminooxy-PEG5-azide | 1919045-02-5 | Reference compound |
| HY-130508 | Methyltetrazine-Ph-PEG4-azide | 1802908-04-8 | Reference compound |
| HY-130509 | MTSSL | 81213-52-7 | Reference compound |
| HY-13050A | Sapitinib (fumarate) | 1196531-39-1 | Reference compound |
| HY-130511 | FCE 22250 | 86737-06-6 | Reference compound |
| HY-130512 | Br-PEG4-OH | 85141-94-2 | Reference compound |
| HY-130513 | m-PEG7-Boc | 874208-90-9 | Reference compound |
| HY-130514 | SMAPP1 | 327081-00-5 | Reference compound |
| HY-130515 | Cdc7-IN-3 | 1402057-87-7 | Reference compound |
| HY-130516 | Cdc7-IN-4 | 1402059-21-5 | Reference compound |
| HY-130517 | Cdc7-IN-5 | 1402057-86-6 | Reference compound |
| HY-130519 | Cdc7-IN-7 | 1402059-17-9 | Reference compound |
| HY-13052 | SB-737050A | 583045-76-5 | Reference compound |
| HY-130520 | Bromoacetamido-PEG4-C2-Boc | 1807521-00-1 | Reference compound |
| HY-130521 | Pomalidomide-amido-PEG3-C2-NH2 | 2328070-52-4 | Reference compound |
| HY-130522 | 6β-Prostaglandin I1 | 62770-50-7 | Reference compound |
| HY-130523 | Tos-PEG5-Boc | 581065-94-3 | Reference compound |
| HY-130524 | Amino-PEG4-CH2COOH | 195071-49-9 | ADC Related |
| HY-130525 | Iodo-PEG3-N3 | 936917-36-1 | Reference compound |
| HY-130526 | Tos-PEG6-CH2-Boc | 1530777-90-2 | Reference compound |
| HY-130527 | Ald-Ph-PEG4-NH-Boc | 2110449-01-7 | Reference compound |
| HY-130528 | m-PEG7-MS | 477775-57-8 | ADC Related |
| HY-130529 | OH-α-PVP (TFA) | 1797986-63-0 | Reference compound |
| HY-13053 | Depulfavirine | 867365-76-2 | Reference compound |
| HY-130530 | AP-C5 | 2234272-10-5 | Reference compound |
| HY-130531 | NH-bis(C2-PEG2-NH-Boc) | 2182601-69-8 | Reference compound |
| HY-130532 | Tos-PEG2-CH2-Boc | 882518-89-0 | Reference compound |
| HY-130533 | ReAsH-EDT2 | 438226-89-2 | Dye Reagents |
| HY-130534 | Tos-PEG2-Boc | 1309666-78-1 | Reference compound |
| HY-130536 | Br-PEG4-CH2-Boc | 1807505-29-8 | Reference compound |
| HY-130537 | Azido-PEG6-alcohol | 86770-69-6 | ADC Related |
| HY-130538 | 1-Naphthohydroxamic acid | 6953-61-3 | Reference compound |
| HY-130541 | Propargyl-PEG2-OH | 7218-43-1 | Reference compound |
| HY-130542 | Thiol-PEG8-acid | 866889-02-3 | Reference compound |
| HY-130543 | 1,1,1-Trifluoroethyl-PEG4-azide | 1817735-35-5 | Reference compound |
| HY-130544 | 5-Azidopentanoic acid | 79583-98-5 | Reference compound |
| HY-130545 | 3-(Pyridin-2-yldisulfanyl)propanehydrazide | 115616-51-8 | Reference compound |
| HY-130546 | Hydroxy-PEG3-SS-PEG3-alcohol | 5662-81-7 | ADC Related |
| HY-130547 | BS2G Crosslinker (disodium) | 881415-72-1 | ADC Related |
| HY-130547A | BS2G Crosslinker | 215597-83-4 | Reference compound |
| HY-130547S | BS2G Crosslinker-d4 (disodium) | 910292-86-3 | Isotope-Labeled Compounds |
| HY-130548 | m-PEG6-2-methylacrylate | 90784-86-4 | Reference compound |
| HY-130549 | Acid-PEG3-C2-Boc | 1807539-06-5 | Reference compound |
| HY-13055 | Telotristat etiprate | 1137608-69-5 | Reference compound |
| HY-130550 | (±)7(8)-EpDPA | 895127-66-9 | Natural Products |
| HY-130551 | Tetrazine-Ph-PEG5-NHS ester | 1682653-80-0 | Reference compound |
| HY-130553 | β-Spaglumic acid | 4910-46-7 | Reference compound |
| HY-130554 | m-PEG9-phosphonic acid | 2055016-25-4 | Reference compound |
| HY-130555 | PEG8-Tos | 886469-23-4 | Reference compound |
| HY-130557 | endo-BCN-PEG2-acid | 1993134-72-7 | Reference compound |
| HY-13055A | Telotristat ethyl | 1033805-22-9 | Reference compound |
| HY-13055B | Telotristat | 1033805-28-5 | Reference compound |
| HY-13055BR | Telotristat (Standard) | 1033805-28-5 | Reference Standards |
| HY-13055E | Telotristat (besilate) | 1374745-52-4 | Reference compound |
| HY-13056 | SMND-309 | 1065559-56-9 | Reference compound |
| HY-130560 | Biotin-PEG3-propionic hydrazide | 1381861-94-4 | Reference compound |
| HY-130561 | m-PEG7-azide | 208987-04-6 | Reference compound |
| HY-130563 | Propargyl-PEG3-CH2COOH | 1694731-93-5 | Reference compound |
| HY-130564 | Didemnin C | 77327-06-1 | Reference compound |
| HY-130567 | 1-Monoarachidin | 35474-99-8 | Reference compound |
| HY-130567S | 1-Arachidonoylglycerol-d8 | 2692624-29-4 | Isotope-Labeled Compounds |
| HY-130568 | Mal-PEG1-PFP ester | 1807530-08-0 | Reference compound |
| HY-130569 | 7-Hydroxymethotrexate | 5939-37-7 | Reference compound |
| HY-130569S | 7-Hydroxymethotrexate-d3 (sodium) | | Isotope-Labeled Compounds |
| HY-130569S1 | 7-Hydroxymethotrexate-d3 | 432545-62-5 | Isotope-Labeled Compounds |
| HY-130569S2 | 7-Hydroxymethotrexate-d3 (ammonium) | | Isotope-Labeled Compounds |
| HY-13056R | SMND-309 (Standard) | 1065559-56-9 | Reference Standards |
| HY-13057 | O6BTG-octylglucoside | 382607-78-5 | Reference compound |
| HY-130570 | β-Gal-NONOate | 357192-77-9 | Reference compound |
| HY-130571 | m-PEG9-Amine | 211859-73-3 | ADC Related |
| HY-130572 | Azido-PEG5-acid | 1425973-16-5 | ADC Related |
| HY-130573 | DMAPP | 358-72-5 | Natural Products |
| HY-130573A | DMAPP (triammonium) | 1186-30-7 | Reference compound |
| HY-130574 | MnTE-2-PyP (chloride) | 219818-60-7 | Reference compound |
| HY-130575 | Fura-FF AM | 348079-12-9 | Dye Reagents |
| HY-130576 | POVPC | 121324-31-0 | Reference compound |
| HY-130577 | Amino-PEG5-CH2COOH | 141282-35-1 | Reference compound |
| HY-130578 | m-PEG2-azide | 215181-61-6 | Reference compound |
| HY-130579 | Vinyl-L-NIO (hydrochloride) | 728944-69-2 | Reference compound |
| HY-13058 | ADX-47273 | 851881-60-2 | Reference compound |
| HY-130580 | Thiol-PEG6-alcohol | 194425-46-2 | Reference compound |
| HY-130581 | Lipid X | 86559-73-1 | Reference compound |
| HY-130584 | Propargyl-PEG2-MS | 943726-01-0 | Reference compound |
| HY-130585S | Estradiol undecylate-13C3 | 2482467-27-4 | Isotope-Labeled Compounds |
| HY-130586 | Mal-PEG3-PFP ester | 1807534-78-6 | Reference compound |
| HY-130587 | Sultosilic acid (piperazine salt) | 57775-27-6 | Reference compound |
| HY-130588 | Glutathione arsenoxide | 1271726-51-2 | Reference compound |
| HY-130588A | Glutathione arsenoxide (TFA) | | Reference compound |
| HY-130589 | Bromo-PEG2-bromide | 31255-10-4 | Reference compound |
| HY-13058B | (R)-ADX-47273 | 851881-59-9 | Reference compound |
| HY-13059 | SDZ 220-581 | 174575-17-8 | Reference compound |
| HY-130591 | Propargyl-PEG4-Br | 1308299-09-3 | ADC Related |
| HY-130592 | Compound 48/80 (trihydrochloride) | 848035-21-2 | Reference compound |
| HY-130594 | 6α-Prostaglandin I1 | 62777-90-6 | Reference compound |
| HY-130595 | Benzyl-PEG4-acid | 127457-64-1 | Reference compound |
| HY-130596 | DC-86-M | 94448-15-4 | Natural Products |
| HY-130597 | Propargyl-PEG2-Boc | 1807503-80-5 | Reference compound |
| HY-130598 | N-(Azido-PEG3)-N-Boc-PEG4-acid | 2112731-95-8 | Reference compound |
| HY-130599 | Hydroxy-PEG2-CH2-Boc | 149299-82-1 | Reference compound |
| HY-13059A | SDZ 220-581 (Ammonium salt) | 179411-94-0 | Reference compound |
| HY-13059B | SDZ 220-581 (hydrochloride) | 179411-93-9 | Reference compound |
| HY-13060 | ACHP (Hydrochloride) | 406209-26-5 | Reference compound |
| HY-130600 | HO-PEG17-OH | 351342-04-6 | Reference compound |
| HY-130601 | Thiol-PEG5-thiol | 89141-22-0 | Biochemical Assay Reagents |
| HY-130602 | MS432 | 2672512-44-4 | Reference compound |
| HY-130603 | DCZ0415 | 2242470-43-3 | Reference compound |
| HY-130604 | DT2216 | 2365172-42-3 | Reference compound |
| HY-130605 | BAY-1797 | 2055602-83-8 | Reference compound |
| HY-130606 | Nampt-IN-5 | 2380013-17-0 | Reference compound |
| HY-130607 | IDO1-IN-2 | 2346614-58-0 | Reference compound |
| HY-130608 | Mutated EGFR-IN-3 | 2375107-27-8 | Reference compound |
| HY-130609 | Aβ42-IN-1 | 2582757-69-3 | Reference compound |
| HY-130609A | Aβ42-IN-1 (free base) | 2434633-17-5 | Reference compound |
| HY-13061 | Daun02 | 290304-24-4 | ADC Related |
| HY-130612 | PROTAC BRD2/BRD4 degrader-1 | 2570470-42-5 | Reference compound |
| HY-130613 | MAC-545496 | 838810-96-1 | Reference compound |
| HY-130614 | PROTAC EED degrader-1 | 2639882-72-5 | Reference compound |
| HY-130615 | PROTAC EED degrader-2 | 2639882-69-0 | Reference compound |
| HY-130616 | EGFR-IN-11 | 2463200-44-2 | Reference compound |
| HY-130617 | Pomalidomide-amido-C1-Br | 2351106-38-0 | Reference compound |
| HY-130618 | Boc-C1-PEG3-C4-OH | 2376724-97-7 | Reference compound |
| HY-130619 | Boc-C1-PEG3-C4-OBn | 2381196-81-0 | Reference compound |
| HY-13062 | Daunorubicin (hydrochloride) | 23541-50-6 | Natural Products |
| HY-130620 | PEG3-C4-OBn | 2381196-79-6 | Reference compound |
| HY-130621 | OTs-C6-OBn | 126519-80-0 | Reference compound |
| HY-130622 | LT052 | 2543545-44-2 | Reference compound |
| HY-130624 | Hsp90-Cdc37-IN-2 | 2413849-81-5 | Reference compound |
| HY-130625 | PD-1/PD-L1-IN 6 | 2393983-76-9 | Reference compound |
| HY-130626 | RSV/IAV-IN-1 | 2395007-77-7 | Reference compound |
| HY-130627 | RSV/IAV-IN-2 | 2395007-75-5 | Reference compound |
| HY-130628 | PAK4-IN-1 | 2396529-58-9 | Reference compound |
| HY-13062A | Daunorubicin | 20830-81-3 | Natural Products |
| HY-13062R | Daunorubicin (hydrochloride) (Standard) | 23541-50-6 | Reference Standards |
| HY-13063 | Sodium formononetin-3'-sulfonate | 949021-68-5 | Reference compound |
| HY-130630 | mGluR2 modulator 1 | 2671063-84-4 | Reference compound |
| HY-130631 | SHP2-IN-5 | 54755-93-0 | Reference compound |
| HY-130637 | Boc-NH-PEG1-Ph-O-CH2COOH | 2361117-22-6 | Reference compound |
| HY-130638 | (S,R,S)-AHPC-O-Ph-PEG1-NH-Boc | 2409007-40-3 | Reference compound |
| HY-130639 | Thalidomide-NH-C4-NH-Boc | 2093388-52-2 | Reference compound |
| HY-13064 | Cobimetinib | 934660-93-2 | Reference compound |
| HY-130640 | (S,R,S)-AHPC-Me-C7 ester | 2639528-48-4 | Reference compound |
| HY-130641 | Br-C10-methyl ester | 6287-90-7 | Reference compound |
| HY-130642 | (S,R,S)-AHPC-Me-C10-Br | 2836297-55-1 | Reference compound |
| HY-130643 | PERK-IN-3 | 1337532-08-7 | Reference compound |
| HY-130644 | iRucaparib-AP6 | 2410557-00-3 | Reference compound |
| HY-130648 | Thalidomide-NH-PEG7 | 2641838-98-2 | ADC Related |
| HY-13064A | Cobimetinib (hemifumarate) | 1369665-02-0 | Reference compound |
| HY-13064S1 | Cobimetinib-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13065 | Isobavachalcone | 20784-50-3 | Natural Products |
| HY-130651 | 5-Hexynal | 29329-03-1 | Reference compound |
| HY-130652 | Pomalidomide 4'-PEG3-azide | 2271036-46-3 | Reference compound |
| HY-130653 | Azido-PEG4-C2-acid | 1257063-35-6 | ADC Related |
| HY-130654 | (S,R,S)-AHPC-C2-PEG4-N3 | 2597167-24-1 | Reference compound |
| HY-130656 | 8(Z)-Eicosenoic acid | 76261-96-6 | Natural Products |
| HY-130656A | 8(E)-Eicosenoic acid | 82683-14-5 | Reference compound |
| HY-130657 | m-PEG5-nitrile | 81836-41-1 | Reference compound |
| HY-130658 | D-NMMA (acetate) | 137694-75-8 | Reference compound |
| HY-130659 | Amino-PEG8-amine | 82209-36-7 | Reference compound |
| HY-13065R | Isobavachalcone (Standard) | 20784-50-3 | Reference Standards |
| HY-130660 | Prostaglandin F2α ethanolamide | 353787-70-9 | Reference compound |
| HY-130662 | Hydroxy-PEG8-Boc | 1334177-84-2 | Reference compound |
| HY-130665 | TL12-186 | 2250025-88-6 | Reference compound |
| HY-130666 | Chlorambucyl-proline | 81050-71-7 | Reference compound |
| HY-130667 | Ald-Ph-amido-C2-PEG3-azide | 1807540-88-0 | Reference compound |
| HY-130668 | Cyanidin arabinoside | 792868-19-0 | Natural Products |
| HY-130669 | Ald-Ph-amido-C2-PEG3-NH-Boc | 1807540-87-9 | Reference compound |
| HY-13067 | Celastrol | 34157-83-0 | Natural Products |
| HY-130670 | CGP 54626A (free base) | 149936-58-3 | Reference compound |
| HY-130671A | L-DPPG | 1190099-61-6 | Reference compound |
| HY-130671B | (S,S)-DPPG | | Reference compound |
| HY-130671S | L-DPPG-d9 (free base) | | Isotope-Labeled Compounds |
| HY-130672 | Hydroxy-PEG3-NHS | 1807518-71-3 | Reference compound |
| HY-130673 | L-NABE | 7672-27-7 | Reference compound |
| HY-130674 | Tos-PEG3-CH2COOH | 1581248-63-6 | Reference compound |
| HY-130675 | (±)15-HEPE | 88852-33-9 | Natural Products |
| HY-130675A | 15(S)-HEPE | 86282-92-0 | Reference compound |
| HY-130675AS | 15(S)-HEPE-d5 | | Isotope-Labeled Compounds |
| HY-130676 | CLK-IN-T3N | 2561494-73-1 | Reference compound |
| HY-13067R | Celastrol (Standard) | 34157-83-0 | Reference Standards |
| HY-13068 | Golvatinib | 928037-13-2 | Reference compound |
| HY-130680 | Syk-IN-3 | 1312534-69-2 | Reference compound |
| HY-130682 | Lenalidomide-propargyl-C2-amido-Ph-NH2 (hydrochloride) | 2748150-20-9 | Reference compound |
| HY-130683 | Lenalidomide-propargyl-C2-NH2 (hydrochloride) | 2489242-23-9 | Reference compound |
| HY-130684 | MDM2-IN-1 | 1410737-09-5 | Reference compound |
| HY-130687 | L-Psicose | 16354-64-6 | Biochemical Assay Reagents |
| HY-130689 | Pinoxepin (hydrochloride) | 14008-46-9 | Reference compound |
| HY-130690 | Propargyl-PEG1-SS-PEG1-C2-Boc | 1807518-78-0 | ADC Related |
| HY-130691 | MitoP (bromide) | 74597-01-6 | Reference compound |
| HY-130691S | MitoP-d15 (bromide) | | Isotope-Labeled Compounds |
| HY-130693 | Azido-PEG5-CH2CO2-PFP | 2144777-92-2 | Reference compound |
| HY-130694 | 15(R)-Prostaglandin E2 | 38873-82-4 | Reference compound |
| HY-130695 | N-(Amino-PEG5)-N-bis(PEG4-acid) | 2093152-86-2 | Reference compound |
| HY-130696 | (+)-U-50488 | 67198-17-8 | Reference compound |
| HY-13070 | MK-8245 | 1030612-90-8 | Reference compound |
| HY-130702 | 24(28)-Dehydroergosterol | 29560-24-5 | Reference compound |
| HY-130703 | 5-Dehydroepisterol | 23582-83-4 | Reference compound |
| HY-130704 | Isotachysterol 3 | 22350-43-2 | Reference compound |
| HY-130705 | Previtamin D3 | 1173-13-3 | Reference compound |
| HY-130705A | Tachysterol 3 | 17592-07-3 | Reference compound |
| HY-130707 | K-Ras ligand-Linker Conjugate 3 | 2378261-87-9 | Reference compound |
| HY-130708 | UNC6852 | 2688842-08-0 | Reference compound |
| HY-130709 | PROTAC CDK2/9 Degrader-1 | 2408641-24-5 | Reference compound |
| HY-13071 | Nestoron | 7759-35-5 | Reference compound |
| HY-130711 | (S,R,S)-AHPC-C3-NH2 | 2361119-88-0 | Reference compound |
| HY-130711A | (S,R,S)-AHPC-C3-NH2 (TFA) | 2688842-02-4 | Reference compound |
| HY-130711B | (S,R,S)-AHPC-C3-NH2 (hydrochloride) | 2940858-65-9 | Reference compound |
| HY-130711C | (S,R,S)-AHPC-C3-NH2 (dihydrochloride) | 2564467-25-8 | Reference compound |
| HY-130712 | NH2-C2-amido-C2-Boc | 1692613-62-9 | Reference compound |
| HY-130713 | Thalidomide-C2-amido-C2-COOH | 2353496-84-9 | Reference compound |
| HY-130714 | TD-165 | 2305936-56-3 | Reference compound |
| HY-130715 | tert-Butyl 11-aminoundecanoate | 220851-29-6 | Reference compound |
| HY-130716 | Thalidomide-NH-C10-COOH | 2428400-33-1 | Reference compound |
| HY-130718 | ThrRS-IN-1 | 2408626-64-0 | Reference compound |
| HY-13072 | Cenisertib | 871357-89-0 | Reference compound |
| HY-130723 | AMPK activator 2 | 2410961-69-0 | Reference compound |
| HY-130723A | AMPK activator 2 (hydrochloride) | | Reference compound |
| HY-13072B | Cenisertib (benzoate) | 1145859-64-8 | Reference compound |
| HY-130735 | Janelia Fluor® 646, SE | 1811539-59-9 | Dye Reagents |
| HY-130736 | Janelia Fluor® 549, SE | 1811539-32-8 | Dye Reagents |
| HY-130737 | Pomalidomide 4'-alkylC5-acid | 2225940-49-6 | Reference compound |
| HY-130738 | Benzyl-PEG3-CH2-Boc | 1443467-88-6 | Reference compound |
| HY-13074 | VO-Ohpic (trihydrate) | 476310-60-8 | Reference compound |
| HY-130742 | Azido-PEG8-Boc | 1623791-99-0 | Reference compound |
| HY-130743 | Dieugenol | 4433-08-3 | Reference compound |
| HY-130748 | K-252d | 105114-22-5 | Natural Products |
| HY-13075 | c-Fms-IN-3 | 885704-21-2 | Reference compound |
| HY-130750 | Phycocyanobilin | 20298-86-6 | Reference compound |
| HY-130751 | DODAP | 127512-29-2 | Oligonucleotides |
| HY-130752 | VNI | 1246770-52-4 | Reference compound |
| HY-130753 | JM 1397 | 121043-78-5 | Reference compound |
| HY-130755 | Cyclohexanoyl coenzyme A | 5960-12-3 | Reference compound |
| HY-130757 | Remisporine B | 571194-06-4 | Natural Products |
| HY-130758 | Ald-PEG1-C2-Boc | 2100306-48-5 | Reference compound |
| HY-13076 | CHIR-98014 | 252935-94-7 | Reference compound |
| HY-130760 | HIV-1 integrase inhibitor 7 | 204268-03-1 | Reference compound |
| HY-130762 | Cinnamic acid (sodium) | 538-42-1 | Reference compound |
| HY-130765 | Ferbam | 14484-64-1 | Reference compound |
| HY-130767 | Naphthol AS-TR phosphate | 2616-72-0 | Biochemical Assay Reagents |
| HY-130767A | Naphthol AS-TR phosphate (disodium) | 4264-93-1 | Biochemical Assay Reagents |
| HY-130768 | N-(Azido-PEG3)-N-Fluorescein-PEG3-acid | 2100306-50-9 | Dye Reagents |
| HY-13077 | MK-8245 (Trifluoroacetate) | 1415559-41-9 | Reference compound |
| HY-130770 | Ald-CH2-PEG3-CH2-Boc | 2100306-54-3 | Reference compound |
| HY-130772 | Filipin II | 38620-77-8 | Natural Products |
| HY-130774 | Ponceau 3R | 3564-09-8 | Dye Reagents |
| HY-130777 | AMP-PNP | 25612-73-1 | Biochemical Assay Reagents |
| HY-130777A | AMP-PNP (lithium hydrate) | | Biochemical Assay Reagents |
| HY-130778 | N,N'-Diacetylchitobiose | 35061-50-8 | Natural Products |
| HY-130778R | N,N'-Diacetylchitobiose (Standard) | 35061-50-8 | Reference Standards |
| HY-13078 | Cobimetinib (racemate) | 934662-91-6 | Reference compound |
| HY-130783 | LysoFP-NO2 | 69408-75-9 | Dye Reagents |
| HY-130784 | Dihydro montelukast | 142147-67-9 | Reference compound |
| HY-130785 | LysoFP-NH2 | 69408-85-1 | Reference compound |
| HY-130786 | Denbufylline | 57076-71-8 | Reference compound |
| HY-130787 | Apterin | 53947-89-0 | Natural Products |
| HY-130789 | Cimigenol-3-one | 31222-32-9 | Natural Products |
| HY-13078S | Cobimetinib-13C6 (racemate) | | Isotope-Labeled Compounds |
| HY-13079 | Cobimetinib (R-enantiomer) | 934660-94-3 | Reference compound |
| HY-130790 | Euparone | 53947-86-7 | Natural Products |
| HY-130791 | Dioctanoin | 36354-80-0 | Reference compound |
| HY-130794 | ALK/ROS1-IN-1 | 2365497-07-8 | Reference compound |
| HY-130795 | GSK-3β inhibitor 2 | 1702428-31-6 | Reference compound |
| HY-130797 | TLR7/8 agonist 3 | 642473-95-8 | Reference compound |
| HY-130798 | (S,R,S)-AHPC-amido-C5-acid | 2162120-87-6 | Reference compound |
| HY-130800 | Eragidomide | 1860875-51-9 | Reference compound |
| HY-130801 | 5-Hydroxy-2'-deoxyuridine | 5168-36-5 | Reference compound |
| HY-130802 | 5-Aminouridine | 2149-76-0 | Reference compound |
| HY-130803 | 5-Methyl-5,6-dihydrouridine | 23067-10-9 | Natural Products |
| HY-130805 | 5-Hydroxyuridine | 957-77-7 | Reference compound |
| HY-130806 | Dihydrodeoxyuridine | 5626-99-3 | Reference compound |
| HY-130807 | 5,6-Dihydrothymidine | 5627-00-9 | Reference compound |
| HY-130809 | DBCO-PEG4-Biotin | 1255942-07-4 | Reference compound |
| HY-130810 | DBCO-Sulfo-Link-biotin | 1363444-70-5 | ADC Related |
| HY-130812 | Gemcitabine-O-Si(di-iso)-O-Mc | | ADC Related |
| HY-130813 | BET-IN-6 | 2570470-39-0 | Reference compound |
| HY-130814 | Thalidomide-NH-C4-NH2 (TFA) | 2093387-50-7 | Reference compound |
| HY-130815 | MAK683-CH2CH2COOH | 2639882-68-9 | Reference compound |
| HY-130815A | MAK683-CH2CH2COOH (hydrochloride) | | Reference compound |
| HY-130816 | (S,R,S)-AHPC-O-Ph-PEG1-NH2 | 2361117-24-8 | Reference compound |
| HY-130818 | N-(5-Hydroxypentyl)maleimide | 180608-78-0 | ADC Related |
| HY-130819 | Tos-PEG4-THP | 86259-89-4 | Reference compound |
| HY-130820 | THP-PEG4-Pyrrolidine(N-Boc)-CH2OH | 2378261-80-2 | Reference compound |
| HY-130821 | THP-PEG4-Pyrrolidine(N-Me)-CH2OH | 2378261-81-3 | Reference compound |
| HY-130822 | K-Ras ligand-Linker Conjugate 4 | 2378261-83-5 | Reference compound |
| HY-130823 | K-Ras ligand-Linker Conjugate 5 | 2378261-85-7 | Reference compound |
| HY-130824 | Bis-PEG10-NHS ester | 2221949-02-4 | ADC Related |
| HY-130825 | Bis-PEG13-NHS ester | 2221949-00-2 | ADC Related |
| HY-130826 | Bis-PEG17-NHS ester | 2221948-93-0 | ADC Related |
| HY-130827 | Bis-PEG21-NHS ester | 2221948-98-5 | ADC Related |
| HY-130828 | Bis-PEG25-NHS ester | 2221948-96-3 | ADC Related |
| HY-130829 | m-PEG15-NHS ester | | Reference compound |
| HY-130830 | m-PEG24-NHS ester | 2395839-96-8 | Reference compound |
| HY-130831 | Hydroxy-PEG12-Boc | 2388521-20-6 | Reference compound |
| HY-130832 | Hydroxy-PEG13-Boc | | Reference compound |
| HY-130833 | Hydroxy-PEG16-Boc | 2592433-80-0 | Reference compound |
| HY-130834 | Hydroxy-PEG24-Boc | 2490419-62-8 | Reference compound |
| HY-130835 | FKBP12 PROTAC RC32 | 2375555-66-9 | Reference compound |
| HY-130836 | LpxH-IN-AZ1 | 901260-40-0 | Reference compound |
| HY-130837 | JH-LPH-28 | 2414592-36-0 | Reference compound |
| HY-130837R | JH-LPH-28 (Standard) | 2414592-36-0 | Reference Standards |
| HY-130838 | JH-LPH-33 | 2414590-04-6 | Reference compound |
| HY-130838R | JH-LPH-33 (Standard) | 2414590-04-6 | Reference Standards |
| HY-130839 | LolCDE-IN-1 | 1639933-78-0 | Reference compound |
| HY-130840 | LolCDE-IN-2 | 2748443-01-6 | Reference compound |
| HY-130841 | Apcin-A | 1683617-62-0 | Reference compound |
| HY-130842 | β-Naphthoflavone-CH2-Br | 1282513-77-2 | Reference compound |
| HY-130845 | AR antagonist 1 | 1818885-54-9 | Reference compound |
| HY-130845A | AR antagonist 1 (hydrochloride) | 1818885-55-0 | Reference compound |
| HY-130846 | Pip-alkyne-Ph-COOCH3 | 2308496-47-9 | Reference compound |
| HY-130847 | (S,R,S)-AHPC-Me-C10-NH2 | 2376139-52-3 | Reference compound |
| HY-130849 | (S,R,S)-AHPC-Me-C5-COOH | 2229976-21-8 | Reference compound |
| HY-130850 | CDK9-IN-10 | 3542-63-0 | Reference compound |
| HY-130851 | HS-27 | 1562024-11-6 | Reference compound |
| HY-130852 | CDK9-IN-11 | 2748368-15-0 | Reference compound |
| HY-130853 | Thalidomide-NH-PEG2-C2-NH-Boc | 2097509-40-3 | Reference compound |
| HY-130854 | Thalidomide-NH-C6-NH-Boc | 2093536-13-9 | Reference compound |
| HY-130855 | Mal-amido-PEG7-acid | 2112731-42-5 | Reference compound |
| HY-130856 | Mal-amido-PEG9-acid | 2112731-43-6 | Reference compound |
| HY-130857 | Mal-PEG24-acid | | Reference compound |
| HY-130858 | Mal-amido-PEG16-acid | | Reference compound |
| HY-130860 | Mal-NH-PEG2-CH2CH2COOPFP ester | 1347750-81-5 | Reference compound |
| HY-130861 | Mal-NH-PEG4-CH2CH2COOPFP ester | 1347750-84-8 | Reference compound |
| HY-130862 | Mal-NH-PEG6-CH2CH2COOPFP ester | 1599432-34-4 | Reference compound |
| HY-130863 | Mal-NH-PEG8-CH2CH2COOPFP ester | 2055023-14-6 | Reference compound |
| HY-130864 | Mal-NH-PEG12-CH2CH2COOPFP ester | 2136296-33-6 | Reference compound |
| HY-130865 | Mal-NH-PEG10-CH2CH2COOPFP ester | | Reference compound |
| HY-130866 | Mal-NH-PEG14-CH2CH2COOPFP ester | | Reference compound |
| HY-130867 | Mal-NH-PEG16-CH2CH2COOPFP ester | | Reference compound |
| HY-130868 | Mal-NH-PEG24-CH2CH2COOPFP ester | | Reference compound |
| HY-130870 | Fmoc-NH-PEG11-CH2CH2COOH | 3076038-46-2 | Reference compound |
| HY-130871 | HS-PEG3-CH2CH2NH2 | 1189760-69-7 | Reference compound |
| HY-130871A | HS-PEG3-CH2CH2NH2 (hydrochloride) | | Reference compound |
| HY-130872 | HS-PEG5-CH2CH2NH2 | 1347750-20-2 | Reference compound |
| HY-130872A | HS-PEG5-CH2CH2NH2 (hydrochloride) | 1446256-16-1 | Reference compound |
| HY-130873 | HS-PEG7-CH2CH2NH2 | | Reference compound |
| HY-130874 | HS-PEG7-CH2CH2COOH | | Reference compound |
| HY-130875 | HS-PEG9-CH2CH2COOH | | Reference compound |
| HY-130876 | HS-PEG10-CH2CH2COOH | | Reference compound |
| HY-130878 | HS-PEG24-CH2CH2COOH | | Reference compound |
| HY-130879 | HS-PEG5-CH2CH2N3 | 1449390-11-7 | Reference compound |
| HY-130880 | HS-PEG11-CH2CH2N3 | 2148986-08-5 | Reference compound |
| HY-130881 | HS-PEG6-CH2CH2-Boc | 1818294-40-4 | Reference compound |
| HY-130882 | HS-PEG7-CH2CH2N3 | 2148986-06-3 | Reference compound |
| HY-130883 | N3-PEG3-Propanehydrazide | | Reference compound |
| HY-130885 | N3-PEG6-Propanehydrazide | | Reference compound |
| HY-130886 | N3-PEG12-Hydrazide | | Reference compound |
| HY-130887 | (+)-Biotin-SLC | 1864003-57-5 | Reference compound |
| HY-130888 | (+)-Biotin-ONP | 33755-53-2 | Reference compound |
| HY-130889 | (+)-Biotin-PEG10-OH | | Reference compound |
| HY-130890 | (+)-Biotin-PEG12-OH | | Reference compound |
| HY-130891 | (+)-Biotin-PEG6-hydrazide | 2601437-70-9 | Reference compound |
| HY-130892 | (+)-Biotin-PEG2-hydrazide | 2413847-26-2 | Reference compound |
| HY-130893 | Biotin-EDA | 111790-37-5 | Reference compound |
| HY-130894 | Propargyl-PEG12-methane | | Reference compound |
| HY-130895 | Bis-Mal-PEG5 | | Reference compound |
| HY-130896 | Bis-Mal-PEG7 | | Reference compound |
| HY-130897 | Boc-NH-PEG11-CH2CH2N3 | 2395004-21-2 | Reference compound |
| HY-130898 | BM-PEG3 | 86099-06-1 | Reference compound |
| HY-130899 | Boc-NH-PEG23-CH2CH2N3 | | Reference compound |
| HY-130900 | Propargyl-PEG3-SH | 1412905-18-0 | Reference compound |
| HY-130901 | m-PEG25-Propargyl | | Reference compound |
| HY-130902 | m-PEG37-Propargyl | | Reference compound |
| HY-130903 | m-PEG49-NHS ester | | Reference compound |
| HY-130904 | DSPE-PEG47-acid | | Reference compound |
| HY-130905 | DSPE-PEG46-NH2 | | Reference compound |
| HY-130906 | DSPE-PEG46-N3 | | Reference compound |
| HY-130907 | Fmoc-N-PEG24-acid | 2170484-59-8 | Reference compound |
| HY-130908 | 11-Maleimidoundecanoic acid | 57079-01-3 | Reference compound |
| HY-130909 | Propargyl-PEG25-acid | | Reference compound |
| HY-130910 | Propargyl-PEG8-SH | 1422540-92-8 | Reference compound |
| HY-130911 | Propargyl-PEG12-SH | | Reference compound |
| HY-130912 | DBCO-NH-(CH2)4COOH | 2375193-74-9 | Reference compound |
| HY-130913 | 5-FAM-Alkyne | 510758-19-7 | Reference compound |
| HY-130922 | BCN-PEG1-Val-Cit-OH | | ADC Related |
| HY-130923 | BCN-PEG1-Val-Cit-PABC-OH | | ADC Related |
| HY-130924 | BCN-PEG3-Biotin | 1263166-92-2 | ADC Related |
| HY-130925 | BCN-PEG4-OH | | ADC Related |
| HY-130926 | BCN-PEG3-oxyamine | | ADC Related |
| HY-130927 | BCN-PEG4-Ts | | ADC Related |
| HY-130928 | Tetrazine-Ph-OPSS | | ADC Related |
| HY-130929 | β-Estradiol-6-CMO-PEG3-biotin | | ADC Related |
| HY-130930 | Acid-propionylamino-Val-Cit-OH | 2098907-84-5 | ADC Related |
| HY-130931 | Propargyl-NH-PEG3-C2-NHS ester | 1214319-94-4 | ADC Related |
| HY-130932 | Boc-Val-Ala-PAB-PNP | 1884578-00-0 | ADC Related |
| HY-130933 | Fmoc-Ala-Ala-Asn(Trt)-OH | 1951424-92-2 | ADC Related |
| HY-130934 | TCO-PEG1-Val-Cit-OH | | ADC Related |
| HY-130935 | DBCO-Val-Cit-OH | | ADC Related |
| HY-130936 | DBCO-Val-Cit-PABC-OH | | ADC Related |
| HY-130937 | DBCO-Val-Cit-PABC-PNP | 2994332-18-0 | ADC Related |
| HY-130938 | m-PEG25-acid | | Reference compound |
| HY-130939 | APN-PEG4-Amine (hydrochloride) | | ADC Related |
| HY-130940 | PTDA-PEG4-azide | 2639395-40-5 | ADC Related |
| HY-130941 | Fmoc-N-bis-PEG3-NH-Boc | | ADC Related |
| HY-130942 | Bromoacetamide-PEG3-propargyl | 932741-11-2 | Reference compound |
| HY-130943 | Methyltetrazine-PEG4-SS-PEG4-methyltetrazine | | ADC Related |
| HY-130944 | Mal-PEG1-Val-Cit-PABC-OH | 2055041-37-5 | ADC Related |
| HY-130945 | Tetrazine-PEG5-SS-amine | | ADC Related |
| HY-130946 | NH2-C5-PEG4-N3-L-Lysine-PEG3-N3 | | ADC Related |
| HY-130947 | Tetrazine-PEG4-SS-Py | | ADC Related |
| HY-130948 | Thalidomide-O-C4-NH2 | 1957235-96-9 | Reference compound |
| HY-130948B | Thalidomide-4-O-C4-NH2 (hydrochloride) | 2376990-29-1 | Reference compound |
| HY-130949 | Thalidomide-4-O-C7-NH2 | 2093536-11-7 | Reference compound |
| HY-130949B | Thalidomide-4-O-C7-NH2 (hydrochloride) | | Reference compound |
| HY-130950 | Thalidomide-O-C4-COOH | 2169266-67-3 | Reference compound |
| HY-130951 | Thalidomide-O-C6-COOH | 2169266-69-5 | Reference compound |
| HY-130952 | Thalidomide-O-C8-COOH | 2225148-51-4 | Reference compound |
| HY-130953 | Mal-PEG4-bis-PEG3-methyltetrazine | | ADC Related |
| HY-130954 | Hynic-PEG3-N3 | | ADC Related |
| HY-130955 | Amino-bis-PEG3-TCO | | ADC Related |
| HY-130956 | Boc-NMe-Val-Val-Dil-Dap-OH | | ADC Related |
| HY-130957 | Amino-PEG6-amido-bis-PEG5-N3 | | ADC Related |
| HY-130958 | Tubulysin IM-1 | | ADC Related |
| HY-130959 | Tubulysin IM-2 | 1032072-50-6 | ADC Related |
| HY-130960 | Tubulysin IM-3 | 1639986-05-2 | ADC Related |
| HY-130961 | Boc-Val-Dil-Dap-OH | 1415246-54-6 | ADC Related |
| HY-130962 | Ald-Ph-amido-PEG23-OPSS | | ADC Related |
| HY-130963 | Thalidomide-4-O-C10-NH2 | 1957236-08-6 | Reference compound |
| HY-130963B | Thalidomide-4-O-C10-NH2 (hydrochloride) | | Reference compound |
| HY-130964B | Thalidomide-PEG4-NH2 (hydrochloride) | 2387510-82-7 | Reference compound |
| HY-130965 | Thalidomide-PEG3-NH2 | 1957236-10-0 | Reference compound |
| HY-130965B | Thalidomide-PEG3-NH2 (hydrochloride) | 2983036-20-8 | Reference compound |
| HY-130966 | TCO-PEG1-Val-Cit-PABC-OH | | ADC Related |
| HY-130967 | Ald-Ph-PEG4-bis-PEG4-propargyl | | ADC Related |
| HY-130968 | Amino-PEG4-bis-PEG3-propargyl | | ADC Related |
| HY-130969 | Ald-Ph-PEG4-bis-PEG3-N3 | | ADC Related |
| HY-130970 | Amino-PEG4-bis-PEG3-methyltetrazine | | ADC Related |
| HY-130971 | Mal-PEG4-bis-PEG3-DBCO | | ADC Related |
| HY-130972 | Amino-bis-PEG3-DBCO | | ADC Related |
| HY-130973 | Mal-PEG4-bis-PEG4-propargyl | | ADC Related |
| HY-130974 | Ald-Ph-PEG4-bis-PEG3-methyltetrazine | | ADC Related |
| HY-130975 | Boc-Val-Dil-Dap-Phe-OMe | 1415246-55-7 | ADC Related |
| HY-130976 | N-Boc-Val-Dil-Dap-Doe | 135383-62-9 | ADC Related |
| HY-130977 | Tetrazine-PEG4-amine (hydrochloride) | 2752945-36-9 | ADC Related |
| HY-130978 | Duocarmycin DM | | ADC Related |
| HY-130979 | EED226-COOH | 2467965-71-3 | Reference compound |
| HY-130981 | FN-1501-propionic acid | 2408642-48-6 | Reference compound |
| HY-130982 | Lenalidomide-PEG3-iodine | 2738934-13-7 | Reference compound |
| HY-130983 | N-piperidine Ibrutinib (hydrochloride) | 2231747-18-3 | Reference compound |
| HY-130984 | Azido-PEG1-CH2COO-Cl | 79598-49-5 | Reference compound |
| HY-130985 | 9-Decyn-1-ol | 17643-36-6 | Reference compound |
| HY-130988 | Ipatasertib-NH2 | 1001382-14-4 | Reference compound |
| HY-130988A | Ipatasertib-NH2 (dihydrochloride) | 1001264-73-8 | Reference compound |
| HY-130989 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 | ADC Related |
| HY-130990 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 | ADC Related |
| HY-130991 | K-Ras ligand-Linker Conjugate 6 | 2378261-89-1 | Reference compound |
| HY-130992 | Androgen receptor antagonist 1 | 1338812-36-4 | Reference compound |
| HY-130993 | Isatropolone A | 2097813-40-4 | Natural Products |
| HY-130995 | Agrochelin | 247115-74-8 | Natural Products |
| HY-130996 | Diacetyl Agrochelin | 247115-75-9 | Natural Products |
| HY-130997 | 17-GMB-APA-GA | 256337-10-7 | ADC Related |
| HY-130999 | Microcolin B | 141205-32-5 | Natural Products |
| HY-13100 | PF 03716556 | 928774-43-0 | Reference compound |
| HY-131001 | DPNB-ABT594 | | Reference compound |
| HY-131002 | DPTIP | 351353-48-5 | Reference compound |
| HY-131002A | DPTIP (hydrochloride) | 2361799-64-4 | Reference compound |
| HY-131003 | Taletrectinib | 1505515-69-4 | Reference compound |
| HY-131003A | Taletrectinib (free base) | 1505514-27-1 | Reference compound |
| HY-131004 | CB2R PAM | 2244579-87-9 | Reference compound |
| HY-131005 | Eph inhibitor 2 | 861249-59-4 | Reference compound |
| HY-131006 | FFN200 (dihydrochloride) | 2080306-27-8 | Reference compound |
| HY-131007 | FFN270 (hydrochloride) | 2341841-05-0 | Reference compound |
| HY-131008 | Fluorescein tyramide | 210236-90-1 | Dye Reagents |
| HY-131009 | Fluorescein-NAD+ | | Reference compound |
| HY-13100A | (S)-PF 03716556 | 928774-44-1 | Reference compound |
| HY-13101 | MCOPPB (trihydrochloride) | 1108147-88-1 | Reference compound |
| HY-131010 | Flutax-2 (5/6-mixture) | | Dye Reagents |
| HY-131011 | Furanone C-30 | 247167-54-0 | Reference compound |
| HY-131012 | GoSlo-SR-5-69 | 1363419-31-1 | Reference compound |
| HY-131013 | GSHtracer | 1479071-34-5 | Reference compound |
| HY-131014 | FM-479 | 2226521-64-6 | Reference compound |
| HY-131015 | HaXS8 | 2080306-25-6 | Reference compound |
| HY-131016 | IHR-Cy3 | | Reference compound |
| HY-131018 | Jedi2 | 651005-90-2 | Reference compound |
| HY-131019 | JF-NP-26 | 2341841-03-8 | Reference compound |
| HY-13101B | (S)-MCOPPB | 1108147-70-1 | Reference compound |
| HY-13102 | UK-383367 | 348622-88-8 | Reference compound |
| HY-131020 | Janelia Fluor® 525, SE | 2975167-21-4 | Dye Reagents |
| HY-131021 | Janelia Fluor® 549, Azide | | Dye Reagents |
| HY-131022 | Janelia Fluor® 549 (TFA) | 2245946-45-4 | Dye Reagents |
| HY-131023 | Janelia Fluor® 549, Maleimide (TFA) | | Dye Reagents |
| HY-131024 | Janelia Fluor® 549, Tetrazine | | Dye Reagents |
| HY-131025 | Janelia Fluor® 585, SE | 1811539-88-4 | Dye Reagents |
| HY-131026 | Janelia Fluor® 635, SE | | Dye Reagents |
| HY-131027 | Janelia Fluor® 646, Azide | | Dye Reagents |
| HY-131028 | Janelia Fluor® 646 (TFA) | | Dye Reagents |
| HY-131029 | Janelia Fluor® 646, Maleimide | | Dye Reagents |
| HY-13103 | NS 11021 | 956014-19-0 | Reference compound |
| HY-131030 | Janelia Fluor® 669, SE | 2127150-20-1 | Dye Reagents |
| HY-131031 | KCC-07 | 315702-75-1 | Reference compound |
| HY-131032 | KI-7 | 1489263-00-4 | Reference compound |
| HY-131033 | L-Azidonorleucine (hydrochloride) | 1454334-76-9 | Reference compound |
| HY-131034 | LP-922056 | 1365060-22-5 | Reference compound |
| HY-131035 | Lys-CoA (TFA) | | Reference compound |
| HY-131036 | MAO-IN-M30 (dihydrochloride) | 64821-19-8 | Reference compound |
| HY-131037 | MB-0223 | 2247732-89-2 | Reference compound |
| HY-131039 | MDNI-caged-L-glutamate | 864085-92-7 | Reference compound |
| HY-13104 | MRS 2578 | 711019-86-2 | Reference compound |
| HY-131040 | NLRP3-IN-NBC6 | 2068818-02-8 | Reference compound |
| HY-131041 | Ned-K | 2250019-90-8 | Reference compound |
| HY-131042 | NNMTi | 42464-96-0 | Reference compound |
| HY-131043 | NVS-PAK1-C | 2250019-95-3 | Reference compound |
| HY-131044 | 5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione | 36140-65-5 | Reference compound |
| HY-131045 | HADA (hydrochloride) | 2253733-10-5 | Dye Reagents |
| HY-131048 | Antimicrobial agent-33 | 51244-45-2 | Reference compound |
| HY-131049 | Antimicrobial agent-30 | 24138-83-8 | Reference compound |
| HY-131050 | Aspergillus niger-IN-1 | 6325-94-6 | Reference compound |
| HY-131053 | 4-Chloro-N,N-diisopropylbenzamide | 79606-45-4 | Reference compound |
| HY-131054 | Cinerubin B | 35906-51-5 | Natural Products |
| HY-131055 | Mytoxin B | 105049-15-8 | Natural Products |
| HY-131056 | Gly3-VC-PAB-MMAE | 2684216-48-4 | ADC Related |
| HY-131057 | Mc-VC-PAB-SN38 | 1801838-28-7 | ADC Related |
| HY-131058 | Muscotoxin A | 1653999-47-3 | ADC Related |
| HY-131059 | CBS1117 | 959245-08-0 | Reference compound |
| HY-13106 | Olodanrigan | 1316755-16-4 | Reference compound |
| HY-131060 | CN128 (hydrochloride) | 1335282-05-7 | Reference compound |
| HY-131061 | BET bromodomain inhibitor 1 | 2411226-02-1 | Reference compound |
| HY-131062 | yGsy2p-IN-1 | 2415003-97-1 | Reference compound |
| HY-131063 | CDK6/9-IN-1 | 2414373-55-8 | Reference compound |
| HY-131064 | RIPK3-IN-1 | 2361139-70-8 | Reference compound |
| HY-131065 | MET kinase-IN-2 | 2101241-90-9 | Reference compound |
| HY-131066 | EMI48 | 34564-13-1 | Reference compound |
| HY-131067 | EMI56 | 2414374-41-5 | Reference compound |
| HY-131068 | BACE-1 inhibitor 2 | 2563970-92-1 | Reference compound |
| HY-131069A | MBX2329 | 1438272-42-4 | Reference compound |
| HY-13106A | Olodanrigan (sodium) | 1316755-17-5 | Reference compound |
| HY-13108 | Bz 423 | 216691-95-1 | Reference compound |
| HY-131081 | γ-Amanitin | 21150-23-2 | ADC Related |
| HY-131082 | (R)-8-Azido-2-(Fmoc-amino)octanoic acid | 1191429-18-1 | ADC Related |
| HY-131083 | ε-Amanitin | 21705-02-2 | Natural Products |
| HY-131084 | DMAC-SPDB-sulfo | 663599-07-3 | ADC Related |
| HY-131085 | Desmethyl Vc-seco-DUBA | | ADC Related |
| HY-131086 | Me-triacetyl-β-D-glucopyranuronate-Ph-ald-NO2 | 148579-93-5 | ADC Related |
| HY-131087 | Me-triacetyl-β-D-glucopyranuronate-Ph-CH2OH-Fmoc | 894096-02-7 | ADC Related |
| HY-131088 | N3-PEG8-Phe-Lys-PABC-Gefitinib | | ADC Related |
| HY-131089 | MC-VC-PABC-C6-α-Amanitin | 2922514-69-8 | ADC Related |
| HY-131091 | Boc-Glu(OBzl)-OSu | 32886-40-1 | Reference compound |
| HY-131092 | H-Asn-Arg-OH | 2478-01-5 | Reference compound |
| HY-131093 | Enduracidin | 11115-82-5 | Reference compound |
| HY-131094 | H-Gly-D-Tyr-OH | 133706-65-7 | Reference compound |
| HY-131095 | Z-Glu-Tyr-OH | 988-75-0 | Peptides |
| HY-131096 | L-Proline 4-methoxy-β-naphthylamide (hydrochloride) | 100930-07-2 | Reference compound |
| HY-131097 | Malachite green isothiocyanate | 147492-82-8 | Biochemical Assay Reagents |
| HY-131098 | Enduracidin A | 34438-27-2 | Reference compound |
| HY-131099 | Enduracidin B | 34304-21-7 | Reference compound |
| HY-131100 | Homo Sildenafil | 642928-07-2 | Reference compound |
| HY-131100R | Homo Sildenafil (Standard) | 642928-07-2 | Reference Standards |
| HY-131100S | Homo Sildenafil-d5 | 1216711-61-3 | Isotope-Labeled Compounds |
| HY-131101 | Nor-Acetildenafil | 949091-38-7 | Reference compound |
| HY-131101R | Nor-Acetildenafil (Standard) | 949091-38-7 | Reference Standards |
| HY-131102 | Mequindox | 13297-17-1 | Reference compound |
| HY-131102R | Mequindox (Standard) | 13297-17-1 | Reference Standards |
| HY-131103 | Phenylethanolamine A | 1346746-81-3 | Reference compound |
| HY-131103R | Phenylethanolamine A (Standard) | 1346746-81-3 | Reference Standards |
| HY-131103S | Phenylethanolamine A-d3 | 2507994-61-6 | Isotope-Labeled Compounds |
| HY-131104AS | Brombuterol-d9 (hydrochloride) | 1353867-94-3 | Isotope-Labeled Compounds |
| HY-131104S | Brombuterol-d9 | 1353940-55-2 | Isotope-Labeled Compounds |
| HY-131105 | Cimbuterol | 54239-39-3 | Reference compound |
| HY-131105R | Cimbuterol (Standard) | 54239-39-3 | Reference Standards |
| HY-131105S | Cimbuterol-d9 | 1246819-04-4 | Isotope-Labeled Compounds |
| HY-131106S | Clorprenaline-d7 | 2748354-86-9 | Isotope-Labeled Compounds |
| HY-131107 | Cefpodoxime proxetil impurity B | 947692-14-0 | Reference compound |
| HY-131108 | β-Aspartylaspartic acid | 60079-22-3 | Natural Products |
| HY-131108R | β-Aspartylaspartic acid (Standard) | 60079-22-3 | Reference Standards |
| HY-131109 | Cyclo(Gly-Tyr) | 5845-66-9 | Peptides |
| HY-131110 | Cyclo(Ala-Glu) | 16364-36-6 | Peptides |
| HY-131111 | Cyclo(Gly-Gln) | 52662-00-7 | Peptides |
| HY-131112 | N-Pivaloyl-L-tyrosine | 33019-85-1 | Reference compound |
| HY-131113 | N-Nitrosodibutylamine | 924-16-3 | Reference compound |
| HY-131113R | N-Nitrosodibutylamine (Standard) | 924-16-3 | Reference Standards |
| HY-131113S | N-Nitrosodibutylamine-d18 | 1219798-82-9 | Isotope-Labeled Compounds |
| HY-131113S1 | N-Nitrosodibutylamine-d9 | | Isotope-Labeled Compounds |
| HY-131114 | Valiolamine | 83465-22-9 | Reference compound |
| HY-131115 | Cyclo(Tyr-Leu) | 82863-65-8 | Natural Products |
| HY-131116 | Dihydrojasmonic acid | 3572-64-3 | Natural Products |
| HY-131118 | Desmethyl Ketoprofen | 22071-22-3 | Reference compound |
| HY-131119 | Dimethyldioctadecylammonium (bromide) | 3700-67-2 | Biochemical Assay Reagents |
| HY-131119S | Dimethyldioctadecylammonium-d74(bromide) | 1111808-79-7 | Isotope-Labeled Compounds |
| HY-131120 | Bromonitromethane | 563-70-2 | Reference compound |
| HY-131121 | 4-Isobutylbenzoic acid | 38861-88-0 | Reference compound |
| HY-131121R | 4-Isobutylbenzoic acid (Standard) | 38861-88-0 | Reference Standards |
| HY-131122S | 4-Nonylphenol-d5 | 358730-95-7 | Isotope-Labeled Compounds |
| HY-131123 | N-Nitrosomorpholine | 59-89-2 | Reference compound |
| HY-131123R | N-Nitrosomorpholine (Standard) | 59-89-2 | Reference Standards |
| HY-131123S | N-Nitrosomorpholine-d4 | 61578-30-1 | Isotope-Labeled Compounds |
| HY-131123S1 | N-Nitrosomorpholine-d8 | 1219805-76-1 | Isotope-Labeled Compounds |
| HY-131124 | 7-Amino-3-chloro cephalosporanic acid | 53994-69-7 | Reference compound |
| HY-131125 | trans-4-Nitrocinnamoyl chloride | 61921-33-3 | Reference compound |
| HY-131126 | Metolcarb | 1129-41-5 | Reference compound |
| HY-131126R | Metolcarb (Standard) | 1129-41-5 | Reference Standards |
| HY-131126S | Metolcarb-d3 | 1777782-68-9 | Isotope-Labeled Compounds |
| HY-131127 | 7-Acetoxy-1-methylquinolinium (iodide) | 7270-83-9 | Reference compound |
| HY-131130 | Neomycin C | 66-86-4 | Reference compound |
| HY-131131 | 5-CFDA-AM | 124412-00-6 | Dye Reagents |
| HY-131132 | JAB-3068 | 2169223-48-5 | Reference compound |
| HY-131132A | JAB-3068 (hydrochloride) | 2169223-49-6 | Reference compound |
| HY-131134S | Fosetyl-aluminum-d15 | | Isotope-Labeled Compounds |
| HY-131139 | Ganglioside GD3 (disodium salt) | 497932-19-1 | Reference compound |
| HY-131139A | Ganglioside GD3 (diammonium) | | Reference compound |
| HY-131140 | BD750 | 892686-59-8 | Reference compound |
| HY-131142 | Monensin methyl ester | 28636-21-7 | Reference compound |
| HY-131143 | Cadein1 | | Reference compound |
| HY-131144S | AMOZ-d5 | 1017793-94-0 | Isotope-Labeled Compounds |
| HY-131145 | Brombuterol (hydrochloride) | 21912-49-2 | Reference compound |
| HY-131145R | Brombuterol (hydrochloride) (Standard) | 21912-49-2 | Reference Standards |
| HY-131146 | AMOZ | 43056-63-9 | Reference compound |
| HY-131146R | AMOZ (Standard) | 43056-63-9 | Reference Standards |
| HY-131150 | Ristomycin (sulfate) | 11140-99-1 | Natural Products |
| HY-131150R | Ristomycin (sulfate) (Standard) | 11140-99-1 | Reference Standards |
| HY-131152 | Leucinostatin (mixture of A&B) | | Natural Products |
| HY-131156 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | ADC Related |
| HY-131157 | Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 | 1224601-12-0 | ADC Related |
| HY-131159 | Thalidomide-O-C8-Boc | 2225148-52-5 | Reference compound |
| HY-131160 | Nuclease, Serratia marcescens | 9025-65-4 | Enzyme |
| HY-131161 | M-MLV Reverse transcriptase | 9068-38-6 | Enzyme |
| HY-131162 | Chymase | 97501-92-3 | Enzyme |
| HY-131164 | Potassium clavulanate mixture with silicon dioxide (1:1) | | Reference compound |
| HY-131165 | Amoxicillin (trihydrate) mixture with potassium clavulanate (4:1) | | Reference compound |
| HY-131166 | Curdlan | 54724-00-4 | Reference compound |
| HY-131168 | (S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH | 2086301-47-3 | Reference compound |
| HY-131171 | 3β,5α-Tetrahydronorethisterone | 6424-05-1 | Reference compound |
| HY-131173 | N-Decanoylglycine | 14305-32-9 | Peptides |
| HY-131174 | 8-Ethyl Irinotecan | 947687-02-7 | Reference compound |
| HY-131177 | yGsy2p-IN-H23 | 1269190-98-8 | Reference compound |
| HY-131178 | HG-7-85-01-NH2 | 1258391-29-5 | Reference compound |
| HY-131179 | Influenza A virus-IN-1 | 2250313-14-3 | Reference compound |
| HY-131180 | BMS-986235 | 2253947-47-4 | Reference compound |
| HY-131181 | LEI-401 | 2393840-15-6 | Reference compound |
| HY-131182 | DS-1971a | 1450595-86-4 | Reference compound |
| HY-131183 | PROTAC PD-1/PD-L1 degrader-1 | 2447066-37-5 | Reference compound |
| HY-131184 | N-Boc-piperazine-C3-COOH | 959053-53-3 | Reference compound |
| HY-131185 | Pomalidomide-amido-C3-COOH | 2162120-77-4 | Reference compound |
| HY-131186 | Pomalidomide-amido-C3-piperazine-N-Boc | | Reference compound |
| HY-131187 | BMS-1166-N-piperidine-COOH | 2447066-00-2 | Reference compound |
| HY-131188 | PROTAC Bcl-xL degrader-1 | 2450351-07-0 | Reference compound |
| HY-131189 | N-Boc-SBP-0636457-OH | 2450350-79-3 | Reference compound |
| HY-131190 | N-Boc-SBP-0636457-O-C3-COOH | 2450350-91-9 | Reference compound |
| HY-131194 | JAK2/STAT3-IN-1 | 2485758-50-5 | Reference compound |
| HY-131203 | PROTAC BRD4 Degrader-6 | 2410947-56-5 | Reference compound |
| HY-131204 | CZL80 | 313482-91-6 | Reference compound |
| HY-131220 | aPKC-IN-1 | 15854-12-3 | Reference compound |
| HY-131223 | NDSB-211 | 38880-58-9 | Biochemical Assay Reagents |
| HY-131230 | Desmorpholinyl Quizartinib-PEG2-COOH | 2292116-14-2 | Reference compound |
| HY-131232 | Desmorpholinyl Navitoclax-NH-Me | 2365172-82-1 | Reference compound |
| HY-131233 | Anti-virus agent 1 | 1911578-83-0 | Reference compound |
| HY-131233R | Anti-virus agent 1 (Standard) | 1911578-83-0 | Reference Standards |
| HY-131236 | EBNA1-IN-SC7 | 324022-08-4 | Reference compound |
| HY-131244 | ALK-IN-9 | 2359662-39-6 | Reference compound |
| HY-131246 | DM-01 | 2355280-00-9 | Reference compound |
| HY-131247 | Bcl-2-IN-2 | 2383085-86-5 | Reference compound |
| HY-131249 | MK2-IN-3 | 724711-21-1 | Reference compound |
| HY-131250 | N-Boc-Sitagliptin | 486460-23-5 | Reference compound |
| HY-131251 | Cetirizine 3-chloro impurity | 1232460-31-9 | Reference compound |
| HY-131252 | Dihydro Donepezil | 120012-04-6 | Reference compound |
| HY-131253 | Febuxostat isopropyl isomer | 144060-52-6 | Reference compound |
| HY-131254 | (S)-O-Desmethyl Venlafaxine N-Oxide | 1021934-03-1 | Reference compound |
| HY-131255 | Ziprasidone amino acid | 1159977-64-6 | Reference compound |
| HY-131256 | Cetirizine Impurity C | 83881-59-8 | Reference compound |
| HY-131256A | Cetirizine Impurity C (dihydrochloride) | 2702511-37-1 | Reference compound |
| HY-131257 | Gefitinib impurity 1 | 675126-26-8 | Reference compound |
| HY-131257R | Gefitinib impurity 1 (Standard) | 675126-26-8 | Reference Standards |
| HY-131258 | Ibuprofen impurity 1 | 3585-47-5 | Reference compound |
| HY-131259 | Ibuprofen Impurity F | 65322-85-2 | Reference compound |
| HY-131259R | Ibuprofen Impurity F (Standard) | 65322-85-2 | Reference Standards |
| HY-131260 | Ibuprofen Impurity K | 43153-07-7 | Reference compound |
| HY-131260R | Ibuprofen Impurity K (Standard) | 43153-07-7 | Reference Standards |
| HY-131261 | Ibuprofen alcohol | 36039-36-8 | Reference compound |
| HY-131261R | Ibuprofen alcohol (Standard) | 36039-36-8 | Reference Standards |
| HY-131262 | Hydroxychloroquine Impurity E | 10500-64-8 | Reference compound |
| HY-131263 | Hydroxychloroquine Impurity F | 6281-58-9 | Reference compound |
| HY-131264 | Olmesartan medoxomil impurity C | 879562-26-2 | Reference compound |
| HY-131265 | Mesalamine impurity P | 887256-40-8 | Reference compound |
| HY-131266 | Febuxostat n-butyl isomer | 1657014-33-9 | Reference compound |
| HY-131266R | Febuxostat n-butyl isomer (Standard) | 1657014-33-9 | Reference Standards |
| HY-131267 | Febuxostat sec-butoxy acid | 1335202-59-9 | Reference compound |
| HY-131268 | O-Desisobutyl-O-n-propyl Febuxostat | 1530308-87-2 | Reference compound |
| HY-131269 | Febuxostat impurity 7 | 1350352-70-3 | Reference compound |
| HY-131269R | Febuxostat impurity 7 (Standard) | 1350352-70-3 | Reference Standards |
| HY-131270 | Febuxostat impurity 8 | 144060-62-8 | Reference compound |
| HY-131270R | Febuxostat impurity 8 (Standard) | 144060-62-8 | Reference Standards |
| HY-131271 | Febuxostat impurity 6 | 1271738-74-9 | Reference compound |
| HY-131272 | Febuxostat dicarboxylic acid impurity | 1239233-87-4 | Reference compound |
| HY-131272R | Febuxostat dicarboxylic acid impurity (Standard) | 1239233-87-4 | Reference Standards |
| HY-131273 | Febuxostat amide impurity | 1239233-86-3 | Reference compound |
| HY-131273R | Febuxostat amide impurity (Standard) | 1239233-86-3 | Reference Standards |
| HY-131274 | Fexofenadine Impurity F | 185066-33-5 | Reference compound |
| HY-131275 | Imatinib Impurity E | 1365802-18-1 | Reference compound |
| HY-131275R | Imatinib Impurity E (Standard) | 1365802-18-1 | Reference Standards |
| HY-131276 | Olmesartan lactone impurity | 849206-43-5 | Reference compound |
| HY-131276R | Olmesartan lactone impurity (Standard) | 849206-43-5 | Reference Standards |
| HY-131277 | Dehydro Olmesartan | 172875-98-8 | Reference compound |
| HY-131278 | Olmesartan methyl ester | 1347262-29-6 | Reference compound |
| HY-131279 | Olmesartan ethyl ester | 144689-23-6 | Reference compound |
| HY-131280 | Devaleryl Valsartan Impurity | 676129-92-3 | Reference compound |
| HY-131280R | Devaleryl Valsartan Impurity (Standard) | 676129-92-3 | Reference Standards |
| HY-131281 | Ivabradine impurity 1 | 1428869-91-3 | Reference compound |
| HY-131282 | Ivabradine impurity 2 | 73954-34-4 | Reference compound |
| HY-131283 | 8-Demethyl Ivabradine | 304464-97-9 | Reference compound |
| HY-131284 | (S)-Dehydro Venlafaxine | 2742899-98-3 | Reference compound |
| HY-131286A | Talaglumetad (hydrochloride) | 441765-97-5 | Reference compound |
| HY-131287 | MGS0028 | 321963-33-1 | Reference compound |
| HY-131289 | LY3020371 | 1377615-75-2 | Reference compound |
| HY-131295 | PD0325901-O-C2-dioxolane | 2581116-22-3 | Reference compound |
| HY-131296 | 5-A-RU-PABC-Val-Cit-Fmoc | 2677841-58-4 | Reference compound |
| HY-131298 | 1-Naphthyl butyrate | 3121-70-8 | Biochemical Assay Reagents |
| HY-131300 | Colchicoside | 477-29-2 | Natural Products |
| HY-131303 | Heptadecanoyl Coenzyme A | 3546-17-6 | Biochemical Assay Reagents |
| HY-131305 | HBDDE | 154675-18-0 | Reference compound |
| HY-131306 | Δ2-cis-Hexadecenoic acid | 2825-68-5 | Reference compound |
| HY-131306A | Δ2-trans-Hexadecenoic acid | 929-79-3 | Natural Products |
| HY-131306B | 2-Hexadecenoic acid | 629-56-1 | Biochemical Assay Reagents |
| HY-131307 | Tigloside | 216590-44-2 | Natural Products |
| HY-131308 | Thalidomide-NH-C2-PEG3-OH | 2140807-23-2 | Reference compound |
| HY-131309 | 12-Doxylstearic acid | 29545-47-9 | Reference compound |
| HY-131310 | 9(S)-HpOTrE | 111004-08-1 | Reference compound |
| HY-131312 | Crelosidenib | 2230263-60-0 | Reference compound |
| HY-131312A | Crelosidenib (gentisate) | 2759438-85-0 | Reference compound |
| HY-131314 | Ibuprofen carboxylic acid | 15935-54-3 | Reference compound |
| HY-131314S | Ibuprofen carboxylic acid-d3 | 1216505-29-1 | Isotope-Labeled Compounds |
| HY-131318 | Lenalidomide-I | 2207541-30-6 | Reference compound |
| HY-131325S | Simeton-d3 | | Isotope-Labeled Compounds |
| HY-131326 | DOTA-tris(tBu)ester NHS ester | 819869-77-7 | Reference compound |
| HY-131327 | Azo-resveratrol | 1393556-48-3 | Reference compound |
| HY-131328 | Pirtobrutinib | 2101700-15-4 | Reference compound |
| HY-131328A | (R)-Pirtobrutinib | 2101700-14-3 | Reference compound |
| HY-131332S1 | N-Desmethyl ulipristal acetate-d3 | | Isotope-Labeled Compounds |
| HY-131334 | AMPK activator 4 | 2493239-46-4 | Reference compound |
| HY-131335 | p38α inhibitor 2 | 1095003-80-7 | Reference compound |
| HY-131336 | MGS0274 | 1501974-69-1 | Reference compound |
| HY-131337 | RhlR antagonist 1 | 2614320-29-3 | Reference compound |
| HY-131338 | RORγt inverse agonist 13 | 2170477-75-3 | Reference compound |
| HY-131339 | SP-96 | 2682114-54-9 | Reference compound |
| HY-131340 | LASSBio-1632 | 3029936-02-2 | Reference compound |
| HY-131341 | Syk-IN-4 | 2932264-95-2 | Reference compound |
| HY-131342 | BIIB068 | 1798787-27-5 | Reference compound |
| HY-131343 | HBV-IN-4 | 2305897-84-9 | Reference compound |
| HY-131344 | mTOR inhibitor-8 | 2489196-70-3 | Reference compound |
| HY-131345 | PI3Kα-IN-4 | 2322293-83-2 | Reference compound |
| HY-131345A | (S)-PI3Kα-IN-4 | 2322293-84-3 | Reference compound |
| HY-131346 | HIF-PHD-IN-1 | 1567657-46-8 | Reference compound |
| HY-131347 | PD-1/PD-L1-IN-NP19 | 2377916-66-8 | Reference compound |
| HY-131349 | CCR4-351 | 2174938-70-4 | Reference compound |
| HY-131349A | CCR4-351 (hydrochloride) | 2174938-71-5 | Reference compound |
| HY-131350 | LXE408 | 1799330-15-6 | Reference compound |
| HY-131364 | Nur77 modulator 1 | 2469975-55-9 | Reference compound |
| HY-131368 | α,α-Trehalose 6-phosphate (potassium) | 136632-28-5 | Reference compound |
| HY-131368A | α,α-Trehalose 6-phosphate | 4484-88-2 | Reference compound |
| HY-131370B | Intralipid 20% | 68890-65-3 | Reference compound |
| HY-131371 | Glucoiberin (potassium) | 15592-34-4 | Reference compound |
| HY-131374 | TN14003 | 368874-31-1 | Peptides |
| HY-131376 | 13-Oxo-ODE | 54739-30-9 | Natural Products |
| HY-131376S | 13-Oxo-ODE-d3 | | Isotope-Labeled Compounds |
| HY-131382 | UTA1inh-C1 | 332144-37-3 | Reference compound |
| HY-131383 | Propoxyphenyl Aildenafil | 1391053-82-9 | Reference compound |
| HY-131384 | 8,11,14-Eicosatriynoic acid | 34262-64-1 | Biochemical Assay Reagents |
| HY-131385 | KB02-COOH | 2375196-30-6 | Reference compound |
| HY-131386 | BMS-1166-N-piperidine-CO-N-piperazine | 2447066-14-8 | Reference compound |
| HY-131386A | BMS-1166-N-piperidine-CO-N-piperazine (dihydrochloride) | 2691796-83-3 | Reference compound |
| HY-131387 | (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 | 2409538-69-6 | Reference compound |
| HY-131388 | ABM-14 | 1973408-76-2 | Reference compound |
| HY-131389 | Cholesteryl heptadecanoate | 24365-37-5 | Reference compound |
| HY-131390 | S-Ethylglutathione | 24425-52-3 | Reference compound |
| HY-131391 | m-Isobutyl Ibuprofen | 66622-47-7 | Reference compound |
| HY-131394 | 5-Hydroxymethyl-2’-deoxycytidine | 7226-77-9 | Natural Products |
| HY-131395 | N-Acetyl-Leukotriene E4 | 80115-95-3 | Reference compound |
| HY-131396 | α-Hydroxy Montelukast | 2045402-27-3 | Reference compound |
| HY-131397 | Docosahexaenoyl serotonin | 283601-58-1 | Reference compound |
| HY-131404 | TPBM | 6466-43-9 | Reference compound |
| HY-131405 | β-Eleostearic acid | 544-73-0 | Reference compound |
| HY-131408 | L-Allooctopine | 63358-47-4 | Reference compound |
| HY-131409 | D-Val-Leu-Lys-pNA (dihydrochloride) | 62354-43-2 | Dye Reagents |
| HY-131413 | O-Desmethyl Galanthamine | 60755-80-8 | Natural Products |
| HY-131416 | DD-3305 | 55690-47-6 | Reference compound |
| HY-131417 | cis-ACCP | 777075-44-2 | Reference compound |
| HY-131420 | 12-Methyltridecanoic acid | 2724-57-4 | Biochemical Assay Reagents |
| HY-131421 | 8-PIP-cAMP | 31357-06-9 | Reference compound |
| HY-131422 | (Rac)-8-Hydroxy-efavirenz | 205754-32-1 | Reference compound |
| HY-131422S | (Rac)-8-Hydroxy-efavirenz-d4 | 1246812-30-5 | Isotope-Labeled Compounds |
| HY-131423 | Triarachidonin | 23314-57-0 | Biochemical Assay Reagents |
| HY-131424 | Glycidyl linoleate | 24305-63-3 | Natural Products |
| HY-131433 | Teroxalene (hydrochloride) | 3845-22-5 | Reference compound |
| HY-131435 | CD73-IN-2 | 2452209-05-9 | Reference compound |
| HY-131442 | Alkyne-phenol | 1694495-59-4 | Reference compound |
| HY-131443 | TRC-766 | 1810734-44-1 | Reference compound |
| HY-131445 | RJW100 | 1276664-20-0 | Reference compound |
| HY-131445A | SS-RJW100 | | Reference compound |
| HY-131445B | RR-RJW100 | | Reference compound |
| HY-131446 | Chk1-IN-5 | 2120398-39-0 | Reference compound |
| HY-131447 | KY19382 | 2226664-93-1 | Reference compound |
| HY-131448 | A3334 | 854171-31-6 | Reference compound |
| HY-131449 | Terazosin dimer impurity (dihydrochloride) | 1486464-41-8 | Reference compound |
| HY-131450 | 1α,25-Dihydroxyprevitamin D3 | 57102-09-7 | Reference compound |
| HY-131450A | (E)-1α,25-Dihydroxyprevitamin D3 | 96862-25-8 | Reference compound |
| HY-131451 | Mc-Phe-Lys-PAB-MMAE | 646502-54-7 | Reference compound |
| HY-131452 | 1-Ethynylpyrene | 34993-56-1 | Reference compound |
| HY-131453A | Mitochondrial respiration-IN-1 (hydrobromide) | | Reference compound |
| HY-131454 | SR-717 | 2375421-09-1 | Reference compound |
| HY-131454A | SR-717 (free acid) | 2375420-34-9 | Reference compound |
| HY-131455A | Biotin-C1-PEG3-C3-amido-C5-Gly-Arg-Gly-N3 (TFA) | | Biochemical Assay Reagents |
| HY-131459S | N-Methyl Metribuzin-d3 | 1794754-27-0 | Isotope-Labeled Compounds |
| HY-131459S1 | N-Methyl Metribuzin-d3-1 | | Isotope-Labeled Compounds |
| HY-131461 | 6-TET Dipivaloate | 314734-87-7 | Reference compound |
| HY-131466 | N-Methyl Palbociclib | 571189-51-0 | Reference compound |
| HY-131466R | N-Methyl Palbociclib (Standard) | 571189-51-0 | Reference Standards |
| HY-131468 | Picoplatin | 181630-15-9 | Reference compound |
| HY-131471 | Zafirlukast metabolite M1 | 219583-10-5 | Reference compound |
| HY-131473 | Desmethyl thiosildenafil | 479073-86-4 | Reference compound |
| HY-131474 | Naphthol AS-D chloroacetate，98% (TLC) | 35245-26-2 | Biochemical Assay Reagents |
| HY-131475 | Naphthol AS-BI phosphate | 1919-91-1 | Biochemical Assay Reagents |
| HY-131475A | Naphthol AS-BI phosphate (disodium hydrate) | 207569-04-8 | Biochemical Assay Reagents |
| HY-131477A | Sinafloxacin (free base) | 156215-70-2 | Reference compound |
| HY-131479 | Threo-dihydrobupropion (hydrochloride) | 357637-18-4 | Reference compound |
| HY-131479A | Threo-dihydrobupropion | 153365-82-3 | Reference compound |
| HY-131481 | Mnm5s2U | 32860-54-1 | Reference compound |
| HY-131482 | PtdIns-(3)-P1(1,2-dioctanoyl) (sodium) | 299216-98-1 | Biochemical Assay Reagents |
| HY-131485 | 3-Acetylpyridine adenine dinucleotide, 90% | 86-08-8 | Biochemical Assay Reagents |
| HY-131485A | 3-Acetylpyridine adenine dinucleotide, 95% | 86-08-8 | Biochemical Assay Reagents |
| HY-131486 | Digoxigenin bisdigitoxoside | 5297-05-2 | Reference compound |
| HY-131488 | 8-Debenzoylpaeoniflorin | 23532-11-8 | Natural Products |
| HY-131490 | Tetrazolium violet | 1719-71-7 | Biochemical Assay Reagents |
| HY-131492 | Δ4-Dafachronic acid | 23017-97-2 | Reference compound |
| HY-131492S | Δ4-Dafachronic Acid-d3 | | Isotope-Labeled Compounds |
| HY-131493 | PF-06939999 | 2159123-14-3 | Reference compound |
| HY-131495 | (S)-6-O-Desmethylnaproxen | 52079-10-4 | Reference compound |
| HY-131495R | (S)-6-O-Desmethylnaproxen (Standard) | 52079-10-4 | Reference Standards |
| HY-131495S | (Rac)-O-Desmethylnaproxen-d3 | 1122399-99-8 | Isotope-Labeled Compounds |
| HY-131496S | ortho-Topolin riboside-d4 | 74511-48-1 | Isotope-Labeled Compounds |
| HY-131498 | MOCAc-PLGL(Dpa)AR | 140430-53-1 | Dye Reagents |
| HY-131499 | Thyroxine methyl ester | 32180-11-3 | Reference compound |
| HY-131500 | SU-9055 | 653-56-5 | Reference compound |
| HY-131501 | Menaquinone 9 | 523-39-7 | Reference compound |
| HY-131501R | Menaquinone 9 (Standard) | 523-39-7 | Reference Standards |
| HY-131501S | Menaquinone-9-d7 | | Isotope-Labeled Compounds |
| HY-131501S1 | Menaquinone-9-13C6 | | Isotope-Labeled Compounds |
| HY-131502 | Taspine | 602-07-3 | Natural Products |
| HY-131503 | 13-Methyltetradecanoic acid | 2485-71-4 | Natural Products |
| HY-131503S | 13-Methyltetradecanoic acid-d6 | | Isotope-Labeled Compounds |
| HY-131504A | Valienamine | 38231-86-6 | Reference compound |
| HY-131508 | M&B 5124 | 15382-90-8 | Reference compound |
| HY-131510 | Chromoionophore XIII | 135656-96-1 | Dye Reagents |
| HY-131511 | Rovicurt | 55830-67-6 | Reference compound |
| HY-131514 | L-Ornithine 2-oxoglutarate | 5191-97-9 | Reference compound |
| HY-131515 | Tri-Salicylic acid | 85531-17-5 | Reference compound |
| HY-131515R | Tri-Salicylic acid (Standard) | 85531-17-5 | Reference Standards |
| HY-131516 | Tiopronin-cysteine disulfide | 77591-18-5 | Reference compound |
| HY-131520 | (E,E,E)-Farnesyl alcohol azide | 851667-96-4 | Reference compound |
| HY-131521 | Oxalomalic acid (trisodium) | 89304-26-7 | Reference compound |
| HY-131524S | Taurocholic acid 3-sulfate-d4 (disodium) | | Isotope-Labeled Compounds |
| HY-131527 | Wy-45494 (hydrochloride) | 93413-90-2 | Reference compound |
| HY-131527R | Wy-45494 (hydrochloride) (Standard) | 93413-90-2 | Reference Standards |
| HY-131528 | Tenilsetam | 86696-86-8 | Reference compound |
| HY-131542 | APPA | 100750-39-8 | Reference compound |
| HY-131543 | 22-Hydroxy mifepristone | 105012-15-5 | Reference compound |
| HY-131543S | 22-Hydroxy Mifepristone-d6 | | Isotope-Labeled Compounds |
| HY-131545 | Parogrelil | 139145-27-0 | Reference compound |
| HY-131547 | Org OD 02-0 | 13258-85-0 | Reference compound |
| HY-131549A | bpV(bipy) (hydrate) | 1173697-60-3 | Reference compound |
| HY-131551 | Drometrizole | 2440-22-4 | Reference compound |
| HY-131551R | Drometrizole (Standard) | 2440-22-4 | Reference Standards |
| HY-131553 | D-α-Tocopherol Succinate | 4345-03-3 | Biochemical Assay Reagents |
| HY-131553R | D-α-Tocopherol Succinate (Standard) | 4345-03-3 | Reference Standards |
| HY-131554 | Tibezonium (iodide) | 54663-47-7 | Reference compound |
| HY-131555 | p-Decylaminophenol | 23227-12-5 | Reference compound |
| HY-131556 | 4-Iodoamphetamine (hydrochloride) | 21894-58-6 | Reference compound |
| HY-131557 | O-Deacetylravidomycin | 88580-27-2 | Biochemical Assay Reagents |
| HY-131566 | Amiquinsin (hydrochloride monohydrate) | 7125-70-4 | Reference compound |
| HY-131574 | Heliosupine N-oxide | 31701-88-9 | Natural Products |
| HY-131576 | Thymidine 5′-diphosphate | 491-97-4 | Reference compound |
| HY-131576A | Thymidine 5′-diphosphate (sodium) | 108322-12-9 | Reference compound |
| HY-131577 | Neutral protease, Paenibacillus polymyxa | 42613-33-2 | Enzyme |
| HY-131577A | Neutral protease I | 42613-33-2 | Enzyme |
| HY-131578 | Rinderine N-oxide | 137821-16-0 | Natural Products |
| HY-131579 | Deschloro Cetirizine (dihydrochloride) | 83881-54-3 | Reference compound |
| HY-131579R | Deschloro Cetirizine (dihydrochloride) (Standard) | 83881-54-3 | Reference Standards |
| HY-131583 | MP265 | 544-47-8 | Reference compound |
| HY-131586 | 3,7-Dihydroxyflavone | 492-00-2 | Natural Products |
| HY-131587 | Integerrimine N-oxide | 85955-28-8 | Natural Products |
| HY-131589 | Metoprolol acid | 56392-14-4 | Reference compound |
| HY-131589R | Metoprolol acid (Standard) | 56392-14-4 | Reference Standards |
| HY-131591 | Digalacturonic acid | 5894-59-7 | Reference compound |
| HY-131592 | Tricetin | 520-31-0 | Natural Products |
| HY-131596 | Emtricitabine triphosphate | 145819-92-7 | Reference compound |
| HY-131596B | Emtricitabine triphosphate (tetrasodium salt) | 1188407-46-6 | Reference compound |
| HY-131598 | 6-Thio-GTP | 17670-19-8 | Reference compound |
| HY-131603 | Lamivudine triphosphate | 143188-53-8 | Reference compound |
| HY-131605 | Ganciclovir triphosphate | 86761-38-8 | Reference compound |
| HY-131606 | Cidofovir diphosphate | 142276-31-1 | Reference compound |
| HY-131606B | Cidofovir diphosphate tri(triethylamine) | | Reference compound |
| HY-131607 | Carbovir triphosphate | 129941-14-6 | Reference compound |
| HY-131611 | 6-Azuridine | 54-25-1 | Reference compound |
| HY-131614 | TPC2-A1-N | 136186-07-7 | Reference compound |
| HY-131615 | TPC2-A1-P | 2804595-86-4 | Reference compound |
| HY-131616 | Ethyl α-eleostearate | 42021-86-3 | Natural Products |
| HY-131617 | Prostaglandin F2α 1,11-lactone | 62410-84-8 | Reference compound |
| HY-131618 | Hippuryl-Arg | 744-46-7 | Reference compound |
| HY-131619S | 3-Methyl Hippuric acid-d7 | 1216551-07-3 | Isotope-Labeled Compounds |
| HY-131620S | 4-Methylhippuric acid-d7 | 1216588-60-1 | Isotope-Labeled Compounds |
| HY-131622 | 7-Aminoclonazepam | 4959-17-5 | Reference compound |
| HY-131622S | 7-Aminoclonazepam-13C6 | 1538556-05-6 | Isotope-Labeled Compounds |
| HY-131624 | LON 954 | 63504-15-4 | Reference compound |
| HY-131626 | 1a,1b-Dihomo prostaglandin E2 | 26198-80-1 | Reference compound |
| HY-131629 | N-Desmethyl-U-47700 | 67579-73-1 | Reference compound |
| HY-131630 | O-Desmethylmetoprolol | 62572-94-5 | Reference compound |
| HY-131630S | O-Desmethylmetoprolol-d5 | 1189981-81-4 | Isotope-Labeled Compounds |
| HY-131631S | Desmethylcyclobenzaprine-d3 (hydrochloride) | 1784139-98-5 | Isotope-Labeled Compounds |
| HY-131632 | 1a,1b-Dihomo prostaglandin F2α | 57944-39-5 | Reference compound |
| HY-131633A | (+)-JQ-1-aldehyde | 2634778-37-1 | Reference compound |
| HY-131636S | Pergolide sulfoxide-d7 | | Isotope-Labeled Compounds |
| HY-131637 | Desacetyl bisacodyl | 603-41-8 | Reference compound |
| HY-131637R | Desacetyl bisacodyl (Standard) | 603-41-8 | Reference Standards |
| HY-131640 | 1,2-Didecanoyl PC | 3436-44-0 | Reference compound |
| HY-131643 | 3-Hydroxyhexadecanoic acid | 2398-34-7 | Natural Products |
| HY-131646 | Thalidomide-O-amido-C3-PEG3-C1-NH2 | 1799711-29-7 | Reference compound |
| HY-131647 | Pomalidomide 4'-PEG5-acid | 2139348-63-1 | Reference compound |
| HY-131648 | 1-Oleoyl-2-acetyl-sn-glycerol | 86390-77-4 | Reference compound |
| HY-131649 | Compound C108 | 15533-09-2 | Reference compound |
| HY-131651 | Leukotriene B4 ethanolamide | 877459-63-7 | Reference compound |
| HY-131652 | 1,2-Di-O-hexadecyl-sn-glycero-3-phosphocholine | 36314-47-3 | Biochemical Assay Reagents |
| HY-131654 | 16α-Hydroxy progesterone | 438-07-3 | Biochemical Assay Reagents |
| HY-131658 | VEGFR-2-IN-6 | 444731-47-9 | Reference compound |
| HY-131663 | L-Lysinamide | 32388-19-5 | Natural Products |
| HY-131664 | EP3 antagonist 2 | 1952261-87-8 | Reference compound |
| HY-131667 | Hdm2 E3 ligase inhibitor 1 | 414905-09-2 | Reference compound |
| HY-131668 | 9-POHSA | 1481636-43-4 | Reference compound |
| HY-131669 | Dasatinib metabolite M6 | 910297-53-9 | Reference compound |
| HY-131670 | (±)9,10-DiHOME | 263399-34-4 | Reference compound |
| HY-131673 | p-SCN-Bn-TCMC (tetrahydrochloride) | 2153478-57-8 | Reference compound |
| HY-131673A | (S)-p-SCN-Bn-TCMC (hydrochloride) | | Biochemical Assay Reagents |
| HY-131676 | C17 Sphingomyelin (d18:1/17:0) | 121999-64-2 | Reference compound |
| HY-131678 | Palmitoyl serotonin | 212707-51-2 | Reference compound |
| HY-131682 | 3-C6-NBD-cholesterol | 201731-19-3 | Dye Reagents |
| HY-131683 | ES9-17 | 55854-43-8 | Reference compound |
| HY-131688 | 2-Chlorohexadecanoic acid | 19117-92-1 | Reference compound |
| HY-131688R | 2-Chlorohexadecanoic acid (Standard) | 19117-92-1 | Reference Standards |
| HY-131693 | γ-Acetylenic GABA | 57659-38-8 | Reference compound |
| HY-131693A | γ-Acetylenic GABA (hydrochloride) | 103451-26-9 | Reference compound |
| HY-131694 | N-Dodecyllactobionamide | 69313-68-4 | Reference compound |
| HY-131696 | 11-deoxy Prostaglandin F1α | 37785-98-1 | Reference compound |
| HY-131697 | FeTPPS | 90384-82-0 | Reference compound |
| HY-131699 | t-Butyl ester-PEG4-CH2COOH | 929087-83-2 | Reference compound |
| HY-131701 | Lactosyl-C18-sphingosine | 109785-20-8 | Reference compound |
| HY-131701S | Lactosyl-C18-sphingosine-d7 | 2315262-32-7 | Isotope-Labeled Compounds |
| HY-131703 | UGT8-IN-1 | 2414349-93-0 | Reference compound |
| HY-131704 | FGFR4-IN-5 | 1628793-01-0 | Reference compound |
| HY-131705 | BTK inhibitor 17 | 1858206-76-4 | Reference compound |
| HY-131706A | GNF-8625 monopyridin-N-piperazine (hydrochloride) | 2412055-62-8 | Reference compound |
| HY-131707 | LEO 39652 | 1445656-91-6 | Reference compound |
| HY-131708 | FNDR-20123 (free base) | 1267502-34-0 | Reference compound |
| HY-131708A | FNDR-20123 | 2641930-61-0 | Reference compound |
| HY-131710 | PDE5-IN-3 | 2538149-57-2 | Reference compound |
| HY-131717 | Thalidomide-NH-CH2-COOH | 927670-97-1 | Reference compound |
| HY-131717A | Thalidomide-NH-CH2-COOH (TFA) | 2377032-39-6 | Reference compound |
| HY-131718 | (1-Isothiocyanatoethyl)benzene | 4478-92-6 | Reference compound |
| HY-131721 | 14,15-EET-SI | 218461-97-3 | Reference compound |
| HY-131722 | EA4 | 389614-94-2 | Reference compound |
| HY-131723 | Pregnenolone 16α-carbonitrile | 1434-54-4 | Reference compound |
| HY-131724 | 4-(Dodecylamino)phenol | 25848-37-7 | Reference compound |
| HY-131728 | GPR35 agonist 3 | 123021-85-2 | Reference compound |
| HY-131729 | 16-Phenoxy tetranor Prostaglandin A2 | 51639-10-2 | Reference compound |
| HY-131736 | 3'-O-Bn-GTP | 1610778-75-0 | Reference compound |
| HY-131737 | 1-NH2-cGMP | 78033-42-8 | Reference compound |
| HY-131740 | 2'-Deoxytubercidin 5'-triphosphate | 67460-15-5 | Reference compound |
| HY-131740A | 2'-Deoxytubercidin 5'-triphosphate (sodium) | | Reference compound |
| HY-131755 | 2'-Deoxyadenosine 3':5'-cyclic monophosphate (sodium) | 93839-95-3 | Biochemical Assay Reagents |
| HY-131760 | 2'-NH2-ATP | 61468-88-0 | Reference compound |
| HY-131763 | 2'-O-MB-cAMP (sodium) | 55443-13-5 | Reference compound |
| HY-131764 | 2'-O-MB-cGMP (sodium) | 58329-72-9 | Reference compound |
| HY-131766 | 2'-O-Me-cAMP | 40269-29-2 | Reference compound |
| HY-131768 | 2'-O-Succinyl-cAMP | 36940-87-1 | Reference compound |
| HY-131772 | 2-AHA-cAMP | 214276-80-9 | Reference compound |
| HY-131773 | 2-Cl-5'-AMP | 21466-01-3 | Reference compound |
| HY-131776 | 2-Chloro-ADP | 16506-88-0 | Reference compound |
| HY-131776A | 2-Chloro-ADP (sodium) | 82927-78-4 | Reference compound |
| HY-131777 | 2-Cl-cAMP | 39023-65-9 | Reference compound |
| HY-131787A | 2-Amino-ATP (tetrasodium) | | Biochemical Assay Reagents |
| HY-131790 | 3'-Amino-3'-deoxyadenosine | 2504-55-4 | Reference compound |
| HY-131792 | 2-Chloroinosine | 13276-43-2 | Reference compound |
| HY-131795 | 2-Methylthioadenosine | 4105-39-9 | Reference compound |
| HY-131796 | 3'-CMP | 84-52-6 | Reference compound |
| HY-131800 | 3'-Deoxy-3'-amino-ATP | 4209-30-7 | Reference compound |
| HY-131800A | 3'-Deoxy-3'-amino-ATP (tetrasodium) | | Biochemical Assay Reagents |
| HY-131801A | 3'-Amino-3'-dGTP (tetrasodium) | | Biochemical Assay Reagents |
| HY-131802 | 3'-Azido-3'-deoxyadenosine | 58699-62-0 | Reference compound |
| HY-131803 | 3'-Azido-3'-deoxyguanosine | 98870-11-2 | Reference compound |
| HY-131810 | 5'-AMPS | 19341-57-2 | Reference compound |
| HY-131811 | 5'-CMPS | 47151-76-8 | Reference compound |
| HY-131812 | 5'-dAMPS | 64145-26-2 | Reference compound |
| HY-131813 | 5'-dCMPS | 64145-27-3 | Reference compound |
| HY-131814 | 5'-dGMPS | 87358-26-7 | Reference compound |
| HY-131815 | 5'-dIMPS | 771477-45-3 | Reference compound |
| HY-131816 | 5'-dUMPS | 205379-91-5 | Reference compound |
| HY-131817 | 5'-GMPS | 76310-16-2 | Reference compound |
| HY-131818 | 5'-Amino-5'-deoxyadenosine | 14365-44-7 | Reference compound |
| HY-131821 | 5'-TMPS | 15548-51-3 | Reference compound |
| HY-131822 | 5'-UMPS | 15548-52-4 | Reference compound |
| HY-131823 | 5,6-DCl-cBIMP | 129693-10-3 | Reference compound |
| HY-131824 | 5,6-DM-cBIMP | 142754-31-2 | Reference compound |
| HY-131829 | N6-(2-Aminoethyl)-NAD+ | 59587-50-7 | Reference compound |
| HY-131833 | Fmoc-Gly-Gly-Phe-OH | 160036-44-2 | ADC Related |
| HY-131833A | Fmoc-Gly-Gly-D-Phe-OH | 2982232-04-0 | ADC Related |
| HY-131833G | Fmoc-Gly-Gly-Phe-OH (GMP) | 160036-44-2 | GMP Small Molecules |
| HY-131842 | 6-Bn-cAMP | 32115-08-5 | Reference compound |
| HY-131844 | 6-Bnz-5'-AMP | 40871-55-4 | Reference compound |
| HY-131846 | 6-Cl-5'-PuMP | 5843-59-4 | Reference compound |
| HY-131847 | 2,6-Dichloro-2',3',5'-triacetyl-purine riboside | 3056-18-6 | Reference compound |
| HY-131863 | Pomalidomide 4'-alkylC8-acid | 2305936-70-1 | Reference compound |
| HY-131864 | SJF-1528 | 2230821-38-0 | Reference compound |
| HY-131864A | SJF-1528 (hemihydrate) | | Reference compound |
| HY-131865 | SJF-1521 | 2230821-40-4 | Reference compound |
| HY-131866 | (S,R,S)-CO-C2-acid | 2172819-72-4 | Reference compound |
| HY-131867 | Thalidomide-NH-PEG1-NH2 (hydrochloride) | 2154342-56-8 | Reference compound |
| HY-131868 | TRPV3 antagonist 74a | 1432051-63-2 | Reference compound |
| HY-131870 | GX-201 | 1788071-27-1 | Reference compound |
| HY-131871 | Ethyl LipotF | 1808089-27-1 | Reference compound |
| HY-131872 | Pomalidomide-PEG2-COOH | 2140807-17-4 | Reference compound |
| HY-131873 | Dynapyrazole-A | 2226517-75-3 | Reference compound |
| HY-131874 | Thalidomide-O-C7-acid | 2169266-70-8 | Reference compound |
| HY-131875 | Pomalidomide 4'-alkylC3-acid | 2225940-47-4 | Reference compound |
| HY-131876 | Thalidomide-O-C3-acid | 2169266-64-0 | Reference compound |
| HY-131878 | Pomalidomide-C7-NH2 (hydrochloride) | 2446474-05-9 | Reference compound |
| HY-131879 | NS383 | 309711-59-9 | Reference compound |
| HY-131880 | Thalidomide-O-C2-acid | 2369068-42-6 | Reference compound |
| HY-131881 | JHU37160 | 2369979-68-8 | Reference compound |
| HY-131885 | RuBi-Glutamate (hexafluorophosphate sodium) | 2417096-44-5 | Reference compound |
| HY-131886 | Pomalidomide 4'-alkylC4-acid | 2225940-48-5 | Reference compound |
| HY-131887 | Pomalidomide-C6-COOH | 2225940-50-9 | Reference compound |
| HY-131888 | Pomalidomide-C3-NH2 (hydrochloride) | 2154342-45-5 | Reference compound |
| HY-131888A | Pomalidomide-C3-NH2 | 2093388-20-4 | Reference compound |
| HY-131889 | Thalidomide-O-C5-acid | 2087490-48-8 | Reference compound |
| HY-131890 | VH032 amide-PEG1-acid | 2172820-07-2 | Reference compound |
| HY-131891 | JHU37152 | 2369979-67-7 | Reference compound |
| HY-131892 | 2-Deoxy-D-galactose | 1949-89-9 | Reference compound |
| HY-131894 | DL-Serine hydroxamate | 55779-32-3 | Peptides |
| HY-131895 | 5,6-Dehydroarachidonic acid | 58688-54-3 | Reference compound |
| HY-131897 | 1-Stearoyl-2-arachidonoyl-sn-glycerol | 65914-84-3 | Reference compound |
| HY-131897S | 1-Stearoyl-2-Arachidonoyl-d8-sn-Glycerol | 2692624-31-8 | Isotope-Labeled Compounds |
| HY-131898 | PTIO | 18390-00-6 | Reference compound |
| HY-131899 | N-Bromoacetamide | 79-15-2 | Reference compound |
| HY-131900 | Protein kinase inhibitor H-7 | 84477-87-2 | Reference compound |
| HY-131901 | Phenylarsine oxide | 637-03-6 | Reference compound |
| HY-131902 | MLT-231 | 2682102-10-7 | Reference compound |
| HY-131903 | HS271 | 2410393-15-4 | Reference compound |
| HY-131904 | POMHEX | 2004714-34-3 | Reference compound |
| HY-131904A | Hex | 2004714-32-1 | Reference compound |
| HY-131906 | JAK2-IN-7 | 2593402-36-7 | Reference compound |
| HY-131907 | LpxC-IN-5 | 2253951-38-9 | Reference compound |
| HY-131908 | CPL304110 | 1627826-19-0 | Reference compound |
| HY-131909 | CJ-2360 | 2226742-61-4 | Reference compound |
| HY-131910 | IHMT-PI3Kδ-372 | 2429889-61-0 | Reference compound |
| HY-131910A | (R)-IHMT-PI3Kδ-372 | 2429889-62-1 | Reference compound |
| HY-131911 | PROTAC IDO1 Degrader-1 | 2488851-89-2 | Reference compound |
| HY-131912 | Thalidomide-NH-PEG8-Ts | 2488761-07-3 | Reference compound |
| HY-131914 | EST64454 | 1351438-26-0 | Reference compound |
| HY-131914A | EST64454 (hydrochloride) | 1950569-11-5 | Reference compound |
| HY-131914B | EST64454 (maleate) | 2088272-67-5 | Reference compound |
| HY-131920A | Polyuridylic acid (potassium) | | Biochemical Assay Reagents |
| HY-131921 | DL-Glyceraldehyde 3-phosphate diethyl acetal (barium) | 93965-35-6 | Biochemical Assay Reagents |
| HY-131922 | Iso-OMPA | 513-00-8 | Reference compound |
| HY-131923 | DAPM | 208255-51-0 | Peptides |
| HY-131924 | Thionicotinamide adenine dinucleotide | 4090-29-3 | Biochemical Assay Reagents |
| HY-131925 | Diethylamine NONOate (diethylammonium salt) | 372965-00-9 | Reference compound |
| HY-131926 | EDTA (iron sodium) | 15708-41-5 | Biochemical Assay Reagents |
| HY-131926R | EDTA (iron sodium) (Standard) | 15708-41-5 | Reference Standards |
| HY-131927 | 2-Naphthyl acetate | 1523-11-1 | Biochemical Assay Reagents |
| HY-131929 | AE-ITU (dihydrobromide) | 56-10-0 | Reference compound |
| HY-131930 | AH-8533 | 759397-79-0 | Reference compound |
| HY-131931 | Lysoganglioside-GM1 (potassium) | 171483-40-2 | Natural Products |
| HY-131932S | N-Desethyl-dorzolamide-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-131933 | DCP-Bio3 | 1001575-95-6 | Reference compound |
| HY-131934 | 9-OAHSA | 154086-90-5 | Reference compound |
| HY-131940 | 3-O-Methyl-N-acetyl-D-glucosamine | 94825-74-8 | Reference compound |
| HY-131941 | SJM-3 | 1234977-97-9 | Reference compound |
| HY-131942 | sFTX-3.3 | 141997-14-0 | Reference compound |
| HY-131943 | DS44960156 | 2361327-08-2 | Reference compound |
| HY-131944 | S-Acetylglutathione | 3054-47-5 | Reference compound |
| HY-131945 | CU-115 | 2471982-20-2 | Reference compound |
| HY-131946 | Menotropin | 61489-71-2 | Biochemical Assay Reagents |
| HY-131947 | DH97-7 | 343263-95-6 | Reference compound |
| HY-131948 | 3-Chlorodiphenylamine | 101-17-7 | Reference compound |
| HY-131952 | TLR7/8/9-IN-1 | 2180127-82-4 | Reference compound |
| HY-131953 | Androgen receptor-IN-3 | 926228-58-2 | Reference compound |
| HY-131954 | 5-HT3 antagonist 4 | 930478-88-9 | Reference compound |
| HY-131955 | Fmoc-aminooxy-PEG2-NH2 | 190249-87-7 | ADC Related |
| HY-131958 | D942 | 849727-81-7 | Reference compound |
| HY-131959 | (S,R,S)-AHPC-PEG5-Boc | 2923734-82-9 | Reference compound |
| HY-131960 | Sucrose-epichlorohydrin copolymer | 26873-85-8 | Biochemical Assay Reagents |
| HY-131960A | Sucrose-epichlorohydrin copolymer 70 | 26873-85-8 | Biochemical Assay Reagents |
| HY-131961 | Triciferol | 957214-00-5 | Reference compound |
| HY-131962 | PKD-IN-1 | 956121-30-5 | Reference compound |
| HY-131962A | PKD-IN-1 (dihydrochloride) | 2308510-39-4 | Reference compound |
| HY-131964 | Imidacloprid-urea | 120868-66-8 | Reference compound |
| HY-131964R | Imidacloprid-urea (Standard) | 120868-66-8 | Reference Standards |
| HY-131965 | Imidacloprid impurity 1 | 105828-41-9 | Reference compound |
| HY-131967 | CD73-IN-4 | 2216764-29-1 | Reference compound |
| HY-131968 | BMS-986202 | 1771691-34-9 | Isotope-Labeled Compounds |
| HY-131969 | ASK1-IN-2 | 2541792-70-3 | Reference compound |
| HY-131970 | LSD1/HDAC6-IN-1 | 2738306-38-0 | Reference compound |
| HY-131971 | AChE/BChE-IN-1 | 2720624-42-8 | Reference compound |
| HY-131972 | PF-06843195 | 2067281-51-8 | Reference compound |
| HY-131973 | PDE10A-IN-2 (hydrochloride) | | Reference compound |
| HY-131974 | Glucocorticoid receptor agonist-1 | 2166375-82-0 | Reference compound |
| HY-131976 | BVDV-IN-1 | 345651-04-9 | Reference compound |
| HY-131978 | DB18 | 2587177-94-2 | Reference compound |
| HY-131979 | TP-040 | 2757254-99-0 | Reference compound |
| HY-131981 | TP0586532 | 2427584-96-9 | Reference compound |
| HY-131983 | Neuraminidase-IN-2 | 2599015-44-6 | Reference compound |
| HY-131986 | LASSBio-1135 | 852453-71-5 | Reference compound |
| HY-131987S | Ethacizine-d5 | | Isotope-Labeled Compounds |
| HY-131989 | Desacetylcephapirin (sodium) | 104557-24-6 | Reference compound |
| HY-131990 | MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH | 1599440-25-1 | ADC Related |
| HY-131990A | MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH | 1802520-40-6 | Reference compound |
| HY-131990G | MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (GMP) | 1599440-25-1 | GMP Small Molecules |
| HY-131990S | MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH-d5 | | Isotope-Labeled Compounds |
| HY-131991 | Benzyl selenocyanate | 4671-93-6 | Reference compound |
| HY-131992 | N-Acetylpsychosine | 35823-61-1 | Reference compound |
| HY-131993 | Resolvin E4 | 1781227-87-9 | Reference compound |
| HY-131994 | STING agonist-16 | 652142-94-4 | Reference compound |
| HY-131995 | O-Arachidonoyl glycidol | 439146-24-4 | Reference compound |
| HY-131996S | N-Despropyl macitentan-d4 | | Isotope-Labeled Compounds |
| HY-131997 | 2'MeO6MF | 89112-85-6 | Reference compound |
| HY-131998 | Thalidomide-NH-PEG4-MS | 2140807-24-3 | Reference compound |
| HY-131999 | 3,4,5-Trihydroxycinnamic acid decyl ester | 1770778-45-4 | Reference compound |
| HY-13200 | BRL-15572 (dihydrochloride) | 193611-72-2 | Reference compound |
| HY-132001 | Ziftomenib | 2134675-36-6 | Reference compound |
| HY-132002 | Dimethylsildenafil | 1416130-63-6 | Reference compound |
| HY-132003 | Wortmannin-Rapamycin Conjugate 1 | 1067892-47-0 | Reference compound |
| HY-132004 | Tos-O-C4-NH-Boc | 180851-50-7 | Reference compound |
| HY-132007 | Propargyl-PEG3-PFP ester | 2148295-91-2 | Reference compound |
| HY-132008 | Benzyl-PEG4-THP | 1027926-86-8 | Reference compound |
| HY-132009 | Benzyl-PEG7-bromide | | Reference compound |
| HY-13200A | BRL-15572 (hydrochloride) | 1173022-77-9 | Reference compound |
| HY-13200B | BRL-15572 | 734517-40-9 | Reference compound |
| HY-13201 | CGS 21680 | 120225-54-9 | Reference compound |
| HY-132010 | Benzyl-PEG8-azide | | Reference compound |
| HY-132011 | Benzyl-PEG13-THP | | Reference compound |
| HY-132012 | Benzyl-PEG9-acid | | Reference compound |
| HY-132013 | Benzyl-PEG8-amine | | Reference compound |
| HY-132014 | THP-PEG11-THP | | Reference compound |
| HY-132015 | Benzyl-PEG8-acid | | Reference compound |
| HY-132016 | Benzyl-PEG8-NHS ester | | Reference compound |
| HY-132017 | Bromo-PEG4-NHS ester | 2148295-98-9 | Reference compound |
| HY-132018 | Bromo-PEG2-NHS ester | 2148295-96-7 | Reference compound |
| HY-132019 | Methylamino-PEG7-benzyl | | Reference compound |
| HY-13201A | CGS 21680 (Hydrochloride) | 124431-80-7 | Reference compound |
| HY-13201C | CGS 21680 (sodium) | 120225-64-1 | Biochemical Assay Reagents |
| HY-13202 | T0070907 | 313516-66-4 | Reference compound |
| HY-132020 | Tos-PEG2-THP | 69502-32-5 | Reference compound |
| HY-132021 | Benzyl-PEG7-NHBoc | | Reference compound |
| HY-132022 | Bis-PEG7-t-butyl ester | 2702251-39-4 | Reference compound |
| HY-132023 | Benzyl-PEG11-MS | | Reference compound |
| HY-132024 | Bromo-PEG4-MS | 2167807-41-0 | Reference compound |
| HY-132025 | Benzyl-PEG7-t-butyl ester | | Reference compound |
| HY-132026 | Benzyl-PEG6-MS | 1262681-32-2 | Reference compound |
| HY-132027 | Benzyl-PEG7-acid | | Reference compound |
| HY-132028 | Benzyl-PEG6-bromide | 1449202-44-1 | Reference compound |
| HY-132029 | Benzyl-PEG6-amine | 86770-78-7 | Reference compound |
| HY-13202S | T0070907-d4 | | Isotope-Labeled Compounds |
| HY-13203 | NVP-TAE 226 | 761437-28-9 | Reference compound |
| HY-132030 | Benzyl-PEG6-NHBoc | 2148295-93-4 | Reference compound |
| HY-132031 | Mal-Val-Ala-PAB(C2-glucuronic acid)-DMEA-PNU-159682 | 2682939-53-1 | Reference compound |
| HY-132033 | Bromo-PEG3-THP | 220568-33-2 | Reference compound |
| HY-132034 | Benzyl-PEG6-t-butyl ester | 2148296-00-6 | Reference compound |
| HY-132035 | Benzyl-PEG13-alcohol | | Reference compound |
| HY-13204 | Biperiden (hydrochloride) | 1235-82-1 | Reference compound |
| HY-132042 | Bromo-PEG2-MS | 1935075-34-5 | Reference compound |
| HY-132043 | Propargyl-PEG5-PFP ester | 2148295-92-3 | Reference compound |
| HY-132044 | Benzyl-PEG8-t-butyl ester | | Reference compound |
| HY-132048 | Benzyl-PEG7-MS | | Reference compound |
| HY-132049 | Benzyl-PEG7-azide | 868594-42-7 | Reference compound |
| HY-13204A | Biperiden | 514-65-8 | Reference compound |
| HY-13204AR | Biperiden (Standard) | 514-65-8 | Reference Standards |
| HY-13204AS | Biperiden-d5 | 2938691-75-7 | Isotope-Labeled Compounds |
| HY-13204B | Biperiden (lactate) | 7085-45-2 | Reference compound |
| HY-13204R | Biperiden (hydrochloride) (Standard) | 1235-82-1 | Reference Standards |
| HY-13204S | Biperiden-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13204S1 | rel-Biperiden-d5 | | Isotope-Labeled Compounds |
| HY-13204S2 | rel-Biperiden EP impurity A-d5 | | Isotope-Labeled Compounds |
| HY-13204S3 | rel-Biperiden EP impurity B-d5 | | Isotope-Labeled Compounds |
| HY-13205 | Belnacasan | 273404-37-8 | Reference compound |
| HY-132050 | Azido-PEG4-propargyl | 1192590-91-2 | Reference compound |
| HY-132051 | Benzyl-PEG14-alcohol | | Reference compound |
| HY-132052 | Benzyl-PEG12-alcohol | 2218463-17-1 | Reference compound |
| HY-132053 | Benzyl-PEG16-alcohol | | Reference compound |
| HY-132054 | Benzyl-PEG17-t-butyl ester | | Reference compound |
| HY-132055 | Azido-PEG8-THP | | Reference compound |
| HY-132056 | Hydroxy-PEG14-t-butyl ester | | Reference compound |
| HY-132057 | Bis-PEG10-t-butyl ester | | Reference compound |
| HY-132058 | THP-PEG16-alcohol | | Reference compound |
| HY-132059 | Azido-PEG13-azide | | Reference compound |
| HY-13206 | MTEP (hydrochloride) | 1186195-60-7 | Reference compound |
| HY-132060 | Azido-PEG7-t-butyl ester | 2596867-40-0 | Reference compound |
| HY-132061 | Azido-PEG14-t-butyl ester | | Reference compound |
| HY-132062 | Azido-PEG11-t-butyl ester | | Reference compound |
| HY-132063 | MS-PEG3-dodecyl | 2148295-99-0 | Reference compound |
| HY-132064 | FmocNH-PEG4-t-butyl ester | 2148295-94-5 | Reference compound |
| HY-132065 | Decaethylene glycol dodecyl ether | 618113-48-7 | Reference compound |
| HY-132066 | Bis-PEG3-t-butyl ester | 1611468-29-1 | Reference compound |
| HY-132067 | Bis-PEG4-t-butyl ester | 2100306-53-2 | Reference compound |
| HY-132068 | THP-PEG7-alcohol | 873110-21-5 | Reference compound |
| HY-13206A | MTEP | 329205-68-7 | Reference compound |
| HY-13207 | ONX-0914 | 960374-59-8 | Reference compound |
| HY-132070 | FA-PEG5-Mal | | Reference compound |
| HY-132071 | Methylamino-PEG3-t-butyl ester | 217817-03-3 | Reference compound |
| HY-132072 | THP-PEG8-THP | | Reference compound |
| HY-132073 | Benzyl-PEG14-t-butyl-ester | | Reference compound |
| HY-132074 | Benzyl-PEG11-alcohol | | Reference compound |
| HY-132075 | Methylamino-PEG3-acid | 2148295-95-6 | Reference compound |
| HY-132076 | Azido-PEG10-azide | 1421783-42-7 | Reference compound |
| HY-132077 | THP-PEG16-THP | | Reference compound |
| HY-132078 | Azido-PEG7-acid | | Reference compound |
| HY-132079 | FmocNH-PEG4-t-butyl acetate | 894427-95-3 | Reference compound |
| HY-13207A | ONX-0914 (TFA) | | Reference compound |
| HY-13208 | Xevinapant (hydrochloride) | 1071992-57-8 | Reference compound |
| HY-132080 | Bis-PEG8-t-butyl ester | | Reference compound |
| HY-132081 | Benzyl-PEG10-t-butyl ester | | Reference compound |
| HY-132082 | Benzyl-PEG13-azide | | Reference compound |
| HY-132083 | Hydroxy-PEG2-CH2CH2COO-PEG2-propionic acid | | Reference compound |
| HY-132084 | Bromoacetamido-PEG8-t-butyl acetate | | Reference compound |
| HY-132085 | Azido-PEG3-chloroacetamide | 604766-23-6 | Reference compound |
| HY-132086 | (2-Pyridyldithio)-PEG6 acid | | ADC Related |
| HY-132087 | Bromo-PEG7-alcohol | 86220-35-1 | Reference compound |
| HY-132088 | N-Boc-PEG-t-butyl ester | 145119-18-2 | Reference compound |
| HY-132089 | N-Boc-PEG3-t-butyl ester | | Reference compound |
| HY-13209 | Ambrisentan | 177036-94-1 | Reference compound |
| HY-132090 | Acid-PEG3-SSPy | 2088570-69-6 | Reference compound |
| HY-132091 | Propargyl-PEG9-acid | 1613752-50-3 | Reference compound |
| HY-132092 | Methyl-PEG3-Ald | 141981-62-6 | Reference compound |
| HY-132093 | Azido-PEG5-S-methyl ethanethioate | 1352221-64-7 | Reference compound |
| HY-132094 | Azido-PEG9-S-methyl ethanethioate | 2148986-33-6 | Reference compound |
| HY-132095 | Methyl-PEG4-acyl chloride | 62124-69-0 | Reference compound |
| HY-132096 | Azido-PEG4-acyl chloride | | Reference compound |
| HY-132097 | Bromo-PEG4-PFP ester | | Reference compound |
| HY-132098 | Bis-propargyl-PEG10 | 1351373-48-2 | Reference compound |
| HY-132099 | Fmoc-N-amido-PEG2-azide | | Reference compound |
| HY-13209BS | (Rac)-Ambrisentan-d3 | 1189479-60-4 | Isotope-Labeled Compounds |
| HY-13209BS1 | (Rac)-Ambrisentan-d5 | 1392210-85-3 | Isotope-Labeled Compounds |
| HY-13209C | Ambrisentan (sodium) | 1386915-48-5 | Reference compound |
| HY-13209R | Ambrisentan (Standard) | 177036-94-1 | Reference Standards |
| HY-13209S | Ambrisentan-d10 | 1046116-27-1 | Isotope-Labeled Compounds |
| HY-13210 | Zanamivir | 139110-80-8 | Reference compound |
| HY-132100 | Thiol-PEG2-t-butyl ester | 1398044-50-2 | Reference compound |
| HY-132101 | Amino-PEG7-t-butyl ester | 2428400-07-9 | Reference compound |
| HY-132102 | Bis-CH2-PEG2-acid | 2250056-38-1 | Reference compound |
| HY-132103 | NHS ester-PEG3-S-methyl ethanethioate | | Reference compound |
| HY-132104 | THP-PEG12-alcohol | | Reference compound |
| HY-132105 | Benzyl-PEG6-THP | 230620-73-2 | Reference compound |
| HY-132106 | Benzyl-PEG7-THP | 230620-75-4 | Reference compound |
| HY-132107 | MS-PEG3-THP | 357204-84-3 | Reference compound |
| HY-132108 | Benzyl-PEG3-MS | 702701-70-0 | Reference compound |
| HY-132109 | MS-PEG4-t-butyl ester | 1024602-74-1 | Reference compound |
| HY-13210A | Zanamivir (hydrate)(5:1) | 171094-50-1 | Reference compound |
| HY-13210R | Zanamivir (Standard) | 139110-80-8 | Reference Standards |
| HY-13211 | (E)-2-Decenoic acid | 334-49-6 | Reference compound |
| HY-132110 | Fmoc-N-amido-PEG3-azide | 1172605-58-1 | Reference compound |
| HY-132111 | Fmoc-N-amido-PEG5-azide | 2924480-17-9 | Reference compound |
| HY-132113 | CH2COOH-PEG12-CH2COOH | 2669737-17-9 | Reference compound |
| HY-132114 | Biotin-PEG3-pyridinrthiol | | Reference compound |
| HY-132115 | Biotin-PEG3-SH | 1244028-52-1 | Reference compound |
| HY-132116 | Biotin-PEG3-methyl ethanethioate | | Reference compound |
| HY-132117 | Bromo-PEG12-t-butyl ester | | Reference compound |
| HY-132118 | Bromo-PEG10-t-butyl ester | | Reference compound |
| HY-132119 | Boc-NHCH2CH2-PEG1-azide | 176220-30-7 | Reference compound |
| HY-13211R | (E)-2-Decenoic acid (Standard) | 334-49-6 | Reference Standards |
| HY-13212 | (Z)-2-Decenoic acid | 15790-91-7 | Natural Products |
| HY-132120 | Amino-PEG2-CH2CH2-SH (hydrochloride) | 3037676-58-4 | Reference compound |
| HY-132126 | SPHINX | 848057-98-7 | Reference compound |
| HY-132127 | Cicloprofen | 36950-96-6 | Reference compound |
| HY-132128 | BRD4 Inhibitor-12 | 328956-24-7 | Reference compound |
| HY-132129 | SOS1-IN-2 | 2359690-13-2 | Reference compound |
| HY-13212R | (Z)-2-Decenoic acid (Standard) | 15790-91-7 | Reference Standards |
| HY-13213 | AM211 | 1175526-27-8 | Reference compound |
| HY-132130 | BRD4 Inhibitor-13 | 218934-50-0 | Reference compound |
| HY-132132 | Neutrophil elastase inhibitor 3 | 1234707-32-4 | Reference compound |
| HY-132133 | Nav1.8-IN-1 | 1026822-49-0 | Reference compound |
| HY-132135 | (1E)-CFI-400437 (dihydrochloride) | 1247000-76-5 | Reference compound |
| HY-132136 | DMT-dU-CE Phosphoramidite | 109389-30-2 | Biochemical Assay Reagents |
| HY-132137 | 5-Propargylamino-3'-azidomethyl-dUTP | 666847-57-0 | Biochemical Assay Reagents |
| HY-132137A | 5-Propargylamino-3'-azidomethyl-dUTP (sodium) | | Biochemical Assay Reagents |
| HY-132137B | 5-Propargylamino-3'-azidomethyl-dUTP (tristriethylamine) | | Oligonucleotides |
| HY-132138 | 5-Propargylamino-3'-azidomethyl-dCTP | 666847-71-8 | Biochemical Assay Reagents |
| HY-132138A | 5-Propargylamino-3'-azidomethyl-dCTP (TEA) | | Oligonucleotides |
| HY-132139 | 7-Deaza-7-propargylamino-3'-azidomethyl-dATP | 666847-93-4 | Biochemical Assay Reagents |
| HY-132139A | 7-Deaza-7-propargylamino-3'-azidomethyl-dATP (triethylamine) | | Oligonucleotides |
| HY-13213A | AM211 (sodium) | 1263077-74-2 | Reference compound |
| HY-132140 | 7-Deaza-7-propargylamino-3'-azidomethyl-dGTP | 666847-81-0 | Biochemical Assay Reagents |
| HY-132140A | 7-Deaza-7-propargylamino-3'-azidomethyl-dGTP (triethylamine) | | Oligonucleotides |
| HY-132141 | 5-PA-dUTP | 179101-49-6 | Biochemical Assay Reagents |
| HY-132142 | 5-Propargylamino-dCTP | 115899-39-3 | Biochemical Assay Reagents |
| HY-132143 | 7-Deaza-7-propargylamino-dATP | 587848-72-4 | Biochemical Assay Reagents |
| HY-132143A | 7-Deaza-7-propargylamino-dATP (tetralithium) | | Reference compound |
| HY-132144 | 7-Deaza-7-propargylamino-dGTP | 587848-73-5 | Biochemical Assay Reagents |
| HY-132144A | 7-Deaza-7-propargylamino-dGTP (sodium) | | Biochemical Assay Reagents |
| HY-132145 | 5-Propargylamino-ddUTP | 114748-59-3 | Biochemical Assay Reagents |
| HY-132145A | 5-Propargylamino-ddUTP (triethylamine) (100mM in water) | | Biochemical Assay Reagents |
| HY-132145B | 5-Propargylamino-ddUTP (sodium) (100mM in water) | | Biochemical Assay Reagents |
| HY-132146 | 5-Propargylamino-ddCTP | 114748-56-0 | Biochemical Assay Reagents |
| HY-132146A | 5-Propargylamino-ddCTP (trisodium) solution (25mM) | | Biochemical Assay Reagents |
| HY-132147 | 7-Deaza-7-propargylamino-ddATP | 114748-69-5 | Biochemical Assay Reagents |
| HY-132148 | 7-Deaza-7-propargylamino-ddGTP | 114748-61-7 | Biochemical Assay Reagents |
| HY-13215 | Avasimibe | 166518-60-1 | Reference compound |
| HY-132150A | HPK1-IN-2 (dihydrochloride) | 2375595-72-3 | Reference compound |
| HY-132155 | Indan-5-sulphonamide | 35203-93-1 | Reference compound |
| HY-132156 | Carbonic anhydrase inhibitor 22 | 146533-50-8 | Reference compound |
| HY-132157 | 8-Chloroquinazolin-4-ol | 101494-95-5 | Reference compound |
| HY-132158 | MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin | 2414594-29-7 | ADC Related |
| HY-132159 | MC-AAA-NHCH2OCH2COOH | 2414594-28-6 | ADC Related |
| HY-13216 | Pyroxamide | 382180-17-8 | Reference compound |
| HY-132160 | 7-Aminomethyl-10-methyl-11-fluoro camptothecin | 2378616-23-8 | ADC Related |
| HY-132160A | 7-Aminomethyl-10-methyl-11-fluoro camptothecin (TFA) | | Reference compound |
| HY-132161 | MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT | 2378428-19-2 | ADC Related |
| HY-132162 | 7-MAD-MDCPT | 765871-81-6 | ADC Related |
| HY-132163 | MP-PEG4-VK(Boc)G-OSu | 2378428-21-6 | ADC Related |
| HY-132164 | Gly-7-MAD-MDCPT | 2378427-68-8 | Reference compound |
| HY-132166 | M4205 | 2590556-80-0 | Reference compound |
| HY-132167 | Saruparib | 2589531-76-8 | Reference compound |
| HY-132168 | RMC-5552 | 2382768-62-7 | Reference compound |
| HY-132169 | HCoV-229E-IN-1 | 2639757-13-2 | Reference compound |
| HY-13217 | Vanoxerine (dihydrochloride) | 67469-78-7 | Reference compound |
| HY-132170 | DSM502 | 2426616-55-7 | Reference compound |
| HY-132171 | DSM705 | 2653225-38-6 | Reference compound |
| HY-132171A | DSM705 (hydrochloride) | 2989908-08-7 | Reference compound |
| HY-132172 | TAK1-IN-2 | 2763213-98-3 | Reference compound |
| HY-132173 | GL0388 | 2886772-68-3 | Reference compound |
| HY-132174 | CHIKV-IN-2 | 2361289-44-1 | Reference compound |
| HY-132175 | CK2 inhibitor 2 | 2641079-92-5 | Reference compound |
| HY-132177 | α-L-Fucosidase, Microorganism | 9037-65-4 | Enzyme |
| HY-132177A | α-1-2 Fucosidase, bifidobacterium longum | 9037-65-4 | Enzyme |
| HY-132177B | α1-2,4,6 Fucosidase O, Omnitrophica bacterium | 9037-65-4 | Enzyme |
| HY-132177C | α1-3,4 Fucosidase, Bifidobacterium bifidum | 9037-65-4 | Enzyme |
| HY-132178 | Cytochrome P450 | 9035-51-2 | Enzyme |
| HY-132179 | Fucoidan | 9072-19-9 | Reference compound |
| HY-13217A | Vanoxerine | 67469-69-6 | Reference compound |
| HY-13218 | Acitazanolast | 114607-46-4 | Reference compound |
| HY-132180 | Seco-DUBA (hydrochloride) | 1795733-93-5 | ADC Related |
| HY-132180A | Seco-DUBA | 1227961-59-2 | ADC Related |
| HY-132181 | Dimethylamiloride (hydrochloride) | 2235-97-4 | Reference compound |
| HY-132182 | HPA-12 | 383418-30-2 | Reference compound |
| HY-132183 | Chloride peroxidase | 9055-20-3 | Enzyme |
| HY-132184 | 5,6-Epoxyeicosatrienoic acid | 87173-80-6 | Reference compound |
| HY-132184S | 5,6-Epoxyeicosatrienoic acid-d11 | 1881277-30-0 | Isotope-Labeled Compounds |
| HY-132186 | Abacavir carboxylate | 384380-52-3 | Reference compound |
| HY-132187 | Sphingosylphosphorylcholine | 1670-26-4 | Natural Products |
| HY-132187S | Sphingosylphosphorylcholine-d9 | 2315262-28-1 | Isotope-Labeled Compounds |
| HY-132187S1 | Sphingosylphosphorylcholine-d7 | 2260670-14-0 | Isotope-Labeled Compounds |
| HY-132188 | Manganese peroxidase | 114995-15-2 | Enzyme |
| HY-132189 | Laniquidar | 197509-46-9 | Reference compound |
| HY-13219 | Tepoxalin | 103475-41-8 | Reference compound |
| HY-132190 | Hexanolamino PAF C-16 | 137566-83-7 | Reference compound |
| HY-132191 | Pradimicin A | 117704-65-1 | Natural Products |
| HY-132192 | PD-1/PD-L1-IN-9 | 2628506-54-5 | Reference compound |
| HY-132192A | PD-1/PD-L1-IN-9 (hydrochloride) | | Reference compound |
| HY-132193 | RET-IN-4 | 2436473-55-9 | Reference compound |
| HY-132194 | ERα degrader-2 | 2235396-63-9 | Reference compound |
| HY-132195 | RORγt inverse agonist 14 | 2672496-70-5 | Reference compound |
| HY-132196 | BTK inhibitor 18 | | Reference compound |
| HY-132197 | CBP/p300-IN-12 | 2738688-57-6 | Reference compound |
| HY-132198 | JMJD7-IN-1 | 311316-96-8 | Reference compound |
| HY-132199 | SJ6986 | 2765625-93-0 | Reference compound |
| HY-132200 | UNC5293 | 2226789-82-6 | Reference compound |
| HY-132201 | MK-8153 | 1548286-45-8 | Reference compound |
| HY-132202 | PD-1/PD-L1-IN-10 | 2487550-41-2 | Reference compound |
| HY-132203 | Necrostatin-34 | 375835-43-1 | Reference compound |
| HY-132205 | DS45500853 | 2735803-28-6 | Reference compound |
| HY-132208 | Pomalidomide 4'-PEG2-azide | 2271036-45-2 | Reference compound |
| HY-13221 | BRL 54443 | 57477-39-1 | Reference compound |
| HY-132210 | rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane | 116673-45-1 | Reference compound |
| HY-132211 | 3-Thiatetradecanoic acid | 116296-31-2 | Reference compound |
| HY-132212 | LH1307 | 2375720-38-8 | Reference compound |
| HY-132215 | PF-06284674 | 1434288-24-0 | Reference compound |
| HY-132217 | CB2 receptor agonist 2 | 1314230-75-5 | Reference compound |
| HY-132219 | N,N-Dipropyldopamine (hydrobromide) | 65273-66-7 | Reference compound |
| HY-13221A | BRL 54443 (maleate) | 1197333-54-2 | Reference compound |
| HY-13222 | BAN ORL 24 | 1401463-54-4 | Reference compound |
| HY-132221 | CU-32 | 2400954-16-5 | Reference compound |
| HY-132222 | SET2 | 2313525-20-9 | Reference compound |
| HY-132223 | LH1306 | 2182653-84-3 | Reference compound |
| HY-132225 | SB 206553 | 158942-04-2 | Reference compound |
| HY-132228 | Zelatriazin | 1929519-13-0 | Reference compound |
| HY-132229 | LPM4870108 | 2803679-07-2 | Reference compound |
| HY-13222A | BAN ORL 24 (free base) | 475150-69-7 | Reference compound |
| HY-13223 | Crenolanib | 670220-88-9 | Reference compound |
| HY-132230 | GSK040 | 2752331-09-0 | Reference compound |
| HY-132231 | FD223 | 2050524-24-6 | Reference compound |
| HY-132232 | GSK097 | 2159137-02-5 | Reference compound |
| HY-132233 | DDO-2093 | 2250024-74-7 | Reference compound |
| HY-132233A | DDO-2093 (dihydrochloride) | | Reference compound |
| HY-132234 | M-1211 | 2377337-93-2 | Reference compound |
| HY-132237 | Methyl 3-hydroxyhexadecanoate | 51883-36-4 | Biochemical Assay Reagents |
| HY-132238 | Tetradecylphosphonic acid | 4671-75-4 | Biochemical Assay Reagents |
| HY-132239 | 5-Bromo-6-chloro-3-indolyl β-D-Galactopyranoside (contains ca. 10% Ethyl Acetate) | 93863-88-8 | Biochemical Assay Reagents |
| HY-13223A | Crenolanib (benzenesulfonate) | 670220-93-6 | Reference compound |
| HY-13224 | AZD4877 | 758722-49-5 | Reference compound |
| HY-132240 | SF-22 | 824981-55-7 | Reference compound |
| HY-132242 | DL-Sulforaphane N-acetyl-L-cysteine | 334829-66-2 | Reference compound |
| HY-132242R | DL-Sulforaphane N-acetyl-L-cysteine (Standard) | 334829-66-2 | Reference Standards |
| HY-132243 | NFAT Inhibitor-3 | 841210-82-0 | Reference compound |
| HY-132246 | WWL123 analogue-1 | 1338575-41-9 | Reference compound |
| HY-132247 | ErSO | 2407860-35-7 | Reference compound |
| HY-132247A | (±)-ErSO | 2407860-40-4 | Reference compound |
| HY-132247B | (S)-ErSO | 2407860-34-6 | Reference compound |
| HY-132248 | C5 Lenalidomide | 191732-70-4 | Reference compound |
| HY-13224A | AZD4877 (hydrochloride) | 758722-12-2 | Reference compound |
| HY-13225 | Rivanicline oxalate | 220662-95-3 | Reference compound |
| HY-132250 | MCC-DM1 | 1100692-14-5 | ADC Related |
| HY-132251 | MCC | 104676-09-7 | ADC Related |
| HY-132252 | Mal-PEG8-Val-Ala-PABC | | ADC Related |
| HY-132253 | Polatuzumab vedotin | 1313206-42-6 | ADC Related |
| HY-132253A | Polatuzumab vedotin (solution) | 1313206-42-6 | ADC Related |
| HY-132254 | Sacituzumab govitecan | 1491917-83-9 | ADC Related |
| HY-132254A | Sacituzumab govitecan (solution) | 1491917-83-9 | ADC Related |
| HY-132257 | Rovalpituzumab tesirine | 1613313-09-9 | Reference compound |
| HY-132258A | Mirvetuximab soravtansine (solution) | 1453084-37-1 | Reference compound |
| HY-132259 | Depatuxizumab mafodotin | 1585973-65-4 | Reference compound |
| HY-13225A | Rivanicline | 15585-43-0 | Reference compound |
| HY-13225B | Rivanicline hemioxalate | | Reference compound |
| HY-13225D | Rivanicline (fumarate) | 183288-99-5 | Reference compound |
| HY-13226 | Galunisertib | 700874-72-2 | Reference compound |
| HY-132260 | Naratuximab emtansine | 1607824-64-5 | Reference compound |
| HY-132261 | AcBut | 65623-82-7 | ADC Related |
| HY-132262 | Lorvotuzumab mertansine | 1008106-64-6 | Reference compound |
| HY-132263 | FAM hydrazide,5-isomer | 2183440-64-2 | Reference compound |
| HY-132264 | FAM hydrazide, 6-isomer (hydrochloride) | 2183440-65-3 | Dye Reagents |
| HY-132265 | SCO-267 | 1656261-09-4 | Reference compound |
| HY-132266 | BDP TR carboxylic acid | 150152-64-0 | Dye Reagents |
| HY-132267S | N-Nitrosodibenzylamine-d4 | 20002-23-7 | Isotope-Labeled Compounds |
| HY-132268 | Cav 2.2 blocker 2 | 1204535-44-3 | Reference compound |
| HY-132269 | Isoflupredone | 338-95-4 | Reference compound |
| HY-132269R | Isoflupredone (Standard) | 338-95-4 | Reference Standards |
| HY-132269S | Isoflupredone-d5 | | Isotope-Labeled Compounds |
| HY-13226A | Galunisertib (monohydrate) | 924898-09-9 | Reference compound |
| HY-13227 | SD-208 | 627536-09-8 | Reference compound |
| HY-132270 | FAM amine, 5-isomer | 2183440-41-5 | Reference compound |
| HY-132272 | Alkyne amidite, hydroxyprolinol | 1357289-02-1 | Reference compound |
| HY-132273 | Alkyne Phosphoramidite, 5'-terminal | 1417539-32-2 | Reference compound |
| HY-132274 | DMS(O)MT aminolink C6 | 1173109-53-9 | Reference compound |
| HY-132275 | Long trebler phosphoramidite | 1516489-83-0 | Reference compound |
| HY-132276 | PtdIns-(3,4,5)-P3-biotin (sodium) | 1415684-80-8 | Reference compound |
| HY-132277 | 15-Keto Bimatoprost | 1163135-96-3 | Reference compound |
| HY-132277S | 15-Keto Bimatoprost-d5 | | Isotope-Labeled Compounds |
| HY-132278 | DAz-2 | 1176905-54-6 | Dye Reagents |
| HY-13228 | YM-201636 | 371942-69-7 | Reference compound |
| HY-132280 | Tirilazad | 110101-66-1 | Reference compound |
| HY-132280R | Tirilazad (Standard) | 110101-66-1 | Reference Standards |
| HY-132281 | 16-Oxokahweol | 108664-99-9 | Reference compound |
| HY-132282 | Thiamphenicol glycinate (hydrochloride) | 2611-61-2 | Reference compound |
| HY-132283 | PF-9363 | 2569009-58-9 | Reference compound |
| HY-132286 | 2-PADQZ | 60547-97-9 | Reference compound |
| HY-132288 | Pom-8PEG | 2488761-03-9 | Reference compound |
| HY-132289 | Lipid M | 2089251-57-8 | Biochemical Assay Reagents |
| HY-13229 | BOC-D-FMK | 634911-80-1 | Reference compound |
| HY-132290 | TGFβRI-IN-3 | 2763602-67-9 | Reference compound |
| HY-132291 | HIV-1 inhibitor-8 | 2826996-78-3 | Reference compound |
| HY-132292 | ARD-2128 | 2222111-87-5 | Reference compound |
| HY-132293 | BAY-8400 | 2763602-59-9 | Reference compound |
| HY-132294 | GNE-502 | 1953134-16-1 | Reference compound |
| HY-132294A | (1S,3R)-GNE-502 | 1953134-15-0 | Reference compound |
| HY-132295 | Azenosertib | 2376146-48-2 | Reference compound |
| HY-132296 | GSK215 | 2743427-26-9 | Reference compound |
| HY-132297 | PARP1-IN-5 | 2735645-53-9 | Reference compound |
| HY-132297A | PARP1-IN-5 (dihydrochloride) | 2823308-89-8 | Reference compound |
| HY-132298 | TDI-10229 | 2810887-45-5 | Reference compound |
| HY-132299 | PI3Kγ inhibitor 4 | 1821038-80-5 | Reference compound |
| HY-132300 | ZW4864 | 2632259-93-7 | Reference compound |
| HY-132300A | ZW4864 (free base) | 2632259-92-6 | Reference compound |
| HY-132301 | MSC-4381 | 2445185-57-7 | Reference compound |
| HY-132302 | Hu7691 | 2360523-76-6 | Reference compound |
| HY-132302A | Hu7691 (free base) | 2241232-43-7 | Reference compound |
| HY-132303 | MK-8262 | 1432054-03-9 | Reference compound |
| HY-132304 | CC-90005 | 1799574-70-1 | Reference compound |
| HY-132305 | VEGFR-3-IN-1 | 2756668-73-0 | Reference compound |
| HY-132306 | CCF0058981 | 2708934-53-4 | Reference compound |
| HY-132307 | Mcl-1 inhibitor 6 | 2598978-56-2 | Reference compound |
| HY-132308 | DYRK1-IN-1 | 2814486-79-6 | Reference compound |
| HY-132309 | BRD0639 | 2760881-74-9 | Reference compound |
| HY-13231 | CDK9-IN-1 | 1415559-43-1 | Reference compound |
| HY-132310 | MAGL-IN-4 | 2135785-20-3 | Reference compound |
| HY-132313S | 2-(1-Hydroxyethyl) promazine-d4 Sulfoxide | 1346605-30-8 | Isotope-Labeled Compounds |
| HY-132316S | (rac)-2,4-O-Dimethylzearalenone-d6 | 1246833-55-5 | Isotope-Labeled Compounds |
| HY-13232 | ITK antagonist | 1149753-56-9 | Reference compound |
| HY-132326S | N,N-Didesmethyl trimebutine-d5 (hydrochloride) | 1286624-16-5 | Isotope-Labeled Compounds |
| HY-132329S | 2-Hydroxy imipramine-d6 | 1189880-70-3 | Isotope-Labeled Compounds |
| HY-13233 | Talabostat | 149682-77-9 | Reference compound |
| HY-132330S1 | 4-Hydroxy alverine-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-132332S | cis-Hydroxy perhexiline-d11 | 1276018-05-3 | Isotope-Labeled Compounds |
| HY-132334S | 9-cis-Retinoic acid-d5 | | Isotope-Labeled Compounds |
| HY-13233A | Talabostat (mesylate) | 150080-09-4 | Reference compound |
| HY-13233B | Talabostat isomer mesylate | | Reference compound |
| HY-13234 | Rifaximin | 80621-81-4 | Reference compound |
| HY-132344S | N-Desmethyl asenapine-d4 (hydrochloride) | 1246820-54-1 | Isotope-Labeled Compounds |
| HY-132348S | Granisetron-d3 | 1224925-64-7 | Isotope-Labeled Compounds |
| HY-132348S1 | Granisetron-d3 (1-methyl-d3) | 1224925-76-1 | Isotope-Labeled Compounds |
| HY-13234R | Rifaximin (Standard) | 80621-81-4 | Reference Standards |
| HY-13234S | Rifaximin-d6 | 1262992-43-7 | Isotope-Labeled Compounds |
| HY-13235 | I-BET151 | 1300031-49-5 | Reference compound |
| HY-132350S | iso-Nadolol (tert-Butyl-d9) | 1246820-10-9 | Isotope-Labeled Compounds |
| HY-132352S1 | (Rac)-4-Hydroxy Duloxetine-d3 | | Isotope-Labeled Compounds |
| HY-132355S | (E)-Fluvoxamine-d3 (maleate) | 1185245-56-0 | Isotope-Labeled Compounds |
| HY-13236 | LUF6000 | 890087-21-5 | Reference compound |
| HY-132362S | 1-(6-Hydroxy-2-propylheptyl) hydrogen 1,2-benzenedicarboxylate-d4 | 1412411-11-0 | Isotope-Labeled Compounds |
| HY-13237 | GSK2578215A | 1285515-21-0 | Reference compound |
| HY-132370S | 5-Hydroxy dantrolene-d4 | 1217225-15-4 | Isotope-Labeled Compounds |
| HY-132372S | 7-Hydroxy amoxapine-d8 | 1216833-74-7 | Isotope-Labeled Compounds |
| HY-132373S | N-Hydroxy Mexiletine-d6 Oxalate | 1330264-84-0 | Isotope-Labeled Compounds |
| HY-132379S | Hydroxy Pioglitazone-d5 (M-IV) (Mixture of-diastereomers) | 1189445-29-1 | Isotope-Labeled Compounds |
| HY-13238 | Dolutegravir | 1051375-16-6 | Reference compound |
| HY-132380S | 3-epi-Ochratoxin A-d5 | 1177316-02-7 | Isotope-Labeled Compounds |
| HY-132382S | β-Sitosterol-d7 (mixture of diasteromers) | 2260669-28-9 | Isotope-Labeled Compounds |
| HY-132383S | 24,25-Dihydroxy Vitamin D2-d3 | 118584-50-2 | Isotope-Labeled Compounds |
| HY-132384S | 5-(Methyl-d3)tetrahydrofolic Acid | 1356019-97-0 | Isotope-Labeled Compounds |
| HY-132386S | Imatinib-d8 (mesylate) | 1092942-83-0 | Isotope-Labeled Compounds |
| HY-132389S | Vitamin K3-d8 | 478171-80-1 | Isotope-Labeled Compounds |
| HY-13238A | Dolutegravir (sodium) | 1051375-19-9 | Reference compound |
| HY-13238R | Dolutegravir (Standard) | 1051375-16-6 | Reference Standards |
| HY-13238S1 | Dolutegravir-d3 | | Isotope-Labeled Compounds |
| HY-13238S2 | Dolutegravir-d5 | 2249814-82-0 | Isotope-Labeled Compounds |
| HY-13239 | LY2979165 | 1311385-32-6 | Reference compound |
| HY-132390S | Normesuximide-d5 | 1185130-51-1 | Isotope-Labeled Compounds |
| HY-132392S | L-DOPA-2,5,6-d3 | 53587-29-4 | Isotope-Labeled Compounds |
| HY-132394S | Hydroxy Atrazine-d5 | 1276197-25-1 | Isotope-Labeled Compounds |
| HY-132395S | 2-Phenanthrol-d9 | 922510-19-8 | Isotope-Labeled Compounds |
| HY-132397S | Phenylephrone-d3 (hydrochloride) | 1246819-29-3 | Isotope-Labeled Compounds |
| HY-132399S | Methsuximide-d5 | 1189980-63-9 | Isotope-Labeled Compounds |
| HY-13239A | LY2979165 (free base) | 1311385-35-9 | Reference compound |
| HY-13240 | LY2886721 | 1262036-50-9 | Reference compound |
| HY-132402S | N-Propionyl Mesalazine-d3 | 1330265-97-8 | Isotope-Labeled Compounds |
| HY-132404S | (rac)-3-O-Methyl DOPA-d3 | 1219173-95-1 | Isotope-Labeled Compounds |
| HY-132405S | Desmethyl Naproxen-d3 | 1189427-82-4 | Isotope-Labeled Compounds |
| HY-132409S | Monocrotophos-d6 | 1795136-77-4 | Isotope-Labeled Compounds |
| HY-13240A | LY2886721 (hydrochloride) | 1262036-49-6 | Reference compound |
| HY-13241 | Ralimetinib dimesylate | 862507-23-1 | Reference compound |
| HY-132412S | D-erythro-Ritalinic acid-d10 | 1330166-48-7 | Isotope-Labeled Compounds |
| HY-132413S | Octhilinone-d17 | 1185109-79-8 | Isotope-Labeled Compounds |
| HY-132417S | (rac)-N,O-Didesmethyl Tramadol-d3 | 1261398-22-4 | Isotope-Labeled Compounds |
| HY-13241A | Ralimetinib | 862505-00-8 | Reference compound |
| HY-13242 | Taladegib | 1258861-20-9 | Reference compound |
| HY-132421S | (±)-Equol-d4 | 1216469-13-4 | Isotope-Labeled Compounds |
| HY-132422S | Nor Lidocaine-d5 (hydrochloride) | 1329497-00-8 | Isotope-Labeled Compounds |
| HY-132423S | 4-Hydroxy Clonidine-d4 | 1189988-05-3 | Isotope-Labeled Compounds |
| HY-132425S | 6-Hydroxy Melatonin-d4 | 69533-61-5 | Isotope-Labeled Compounds |
| HY-132426S | Thiram-d12 | 69193-86-8 | Isotope-Labeled Compounds |
| HY-132427S | 3-Hydroxy Lidocaine-d5 | 1286482-71-0 | Isotope-Labeled Compounds |
| HY-132428S | O-Desmethyl Tramadol-d6 | 873928-73-5 | Isotope-Labeled Compounds |
| HY-132429S | 3-Indoxyl Sulfate-d5 (potassium) | 1644451-34-2 | Isotope-Labeled Compounds |
| HY-13243 | Alvimopan | 156053-89-3 | Reference compound |
| HY-132431S | Didesmethyl Sibutramine-d6 | 1189727-93-2 | Isotope-Labeled Compounds |
| HY-132436S | 4’-Hydroxy Flurbiprofen-d3 | 1189694-02-7 | Isotope-Labeled Compounds |
| HY-132439S | 4-Hydroxy Mepivacaine-d3 | 1323251-06-4 | Isotope-Labeled Compounds |
| HY-13243S1 | Alvimopan-d7 | 1261396-48-8 | Isotope-Labeled Compounds |
| HY-13244 | Disufenton sodium | 168021-79-2 | Reference compound |
| HY-132440S | Iso Rizatriptan-d6 | 1329834-30-1 | Isotope-Labeled Compounds |
| HY-132441S | (rac)-Mepindolol-d7 | 1794970-97-0 | Isotope-Labeled Compounds |
| HY-132442S | ∆8,9-Dehydro Estrone-d2 | 1219799-27-5 | Isotope-Labeled Compounds |
| HY-132444S | 5-Methoxytryptophol-benzene-d4 | 75238-47-0 | Isotope-Labeled Compounds |
| HY-132446S | Metoprolol Acid-d5 | 1215404-47-9 | Isotope-Labeled Compounds |
| HY-132447S | Nefopam-d3 N-Oxide | 1346603-50-6 | Isotope-Labeled Compounds |
| HY-13245 | PF-4136309 | 1341224-83-6 | Reference compound |
| HY-132451S | (R,S)-4-Hydroxy Cyclophosphamide-d4 Preparation Kit | 1329838-09-6 | Isotope-Labeled Compounds |
| HY-132457S | Fenthion-d6 | 1189662-83-6 | Isotope-Labeled Compounds |
| HY-13245A | (s)-PF-4136309 | 1372407-07-2 | Reference compound |
| HY-13245B | (Rac)-PF-4136309 | 857679-55-1 | Reference compound |
| HY-13246 | Apitolisib | 1032754-93-0 | Reference compound |
| HY-132461S | 2-Hydroxy Desipramine-d3 | 1189998-63-7 | Isotope-Labeled Compounds |
| HY-132461S1 | 2-Hydroxy Desipramine-d6 | 2733014-95-2 | Isotope-Labeled Compounds |
| HY-132464S1 | Esmolol acid-d7 (sodium) | | Isotope-Labeled Compounds |
| HY-132466S | Hydroxy Torsemide-d7 | 1329613-35-5 | Isotope-Labeled Compounds |
| HY-132468S | Keto Pioglitazone-d4 (M-III-d4) | 1185033-84-4 | Isotope-Labeled Compounds |
| HY-13247 | Setrobuvir | 1071517-39-9 | Reference compound |
| HY-132473S | rac Felodipine-(Methoxy-d3) | 1189970-31-7 | Isotope-Labeled Compounds |
| HY-132475S | rac-Duloxetine-d3 (oxalate) | 1346599-22-1 | Isotope-Labeled Compounds |
| HY-132476S | N-Methyl Gatifloxacin-d3 | 1216721-34-4 | Isotope-Labeled Compounds |
| HY-132477S | (Z)-4-Hydroxy Tamoxifen-d5 | 164365-20-2 | Isotope-Labeled Compounds |
| HY-13248 | AR-C155858 | 496791-37-8 | Reference compound |
| HY-132480S | Ciclopirox-d11 β-D-Glucuronide | 1279033-13-4 | Isotope-Labeled Compounds |
| HY-132483S | 7-Hydroxy Prochlorperazine-d8 | 1246819-57-7 | Isotope-Labeled Compounds |
| HY-132484S | 4-Hydroxy Propafenone-d5 (hydrochloride) | 1189863-32-8 | Isotope-Labeled Compounds |
| HY-132486S | Cetalkonium Chloride-d7 | 1998128-85-0 | Isotope-Labeled Compounds |
| HY-13249 | 1alpha-Hydroxy VD4 | 143032-85-3 | Reference compound |
| HY-132490S | 5-Hydroxy Buspirone-d8 | 1330164-16-3 | Isotope-Labeled Compounds |
| HY-132493S | Tiagabine-methyl-d6 (hydrochloride) | 1217808-68-8 | Isotope-Labeled Compounds |
| HY-132494S | Perazine-d8 | 1246815-57-5 | Isotope-Labeled Compounds |
| HY-132496S | 4’-Hydroxyphenyl Carvedilol-d3 | 1189675-28-2 | Isotope-Labeled Compounds |
| HY-13250 | Silvestrol aglycone | 960365-65-5 | Reference compound |
| HY-132504S | Tianeptine Metabolite MC5-d4 (sodium salt) | 1330171-36-2 | Isotope-Labeled Compounds |
| HY-132508S | Etravirine-d8 | 1142096-06-7 | Isotope-Labeled Compounds |
| HY-13250B | Silvestrol aglycone (enantiomer) | 1112993-18-6 | Reference compound |
| HY-13251 | Silvestrol | 697235-38-4 | Natural Products |
| HY-132518S | Pyrazole N-Demethyl Sildenafil-d3 | 1185044-03-4 | Isotope-Labeled Compounds |
| HY-13252 | MK-5108 | 1010085-13-8 | Reference compound |
| HY-132523S | Menaquinone 4-d7 2,3-Epoxide | 1233937-43-3 | Isotope-Labeled Compounds |
| HY-13253 | AMG 900 | 945595-80-2 | Reference compound |
| HY-132530S | NVP-BEZ 235-d3 | 1133206-74-2 | Isotope-Labeled Compounds |
| HY-13254 | A-674563 | 552325-73-2 | Reference compound |
| HY-132549S | Nilotinib-d3 | 1215678-43-5 | Isotope-Labeled Compounds |
| HY-13254A | A-674563 (hydrochloride) | 2070009-66-2 | Reference compound |
| HY-13255 | TAME | 901-47-3 | Reference compound |
| HY-132559S | PD-166285-d4 | 1246814-59-4 | Isotope-Labeled Compounds |
| HY-13255A | TAME hydrochloride | 1784-03-8 | Reference compound |
| HY-13256 | Desmethyl Erlotinib (hydrochloride) | 183320-51-6 | Reference compound |
| HY-13256A | Desmethyl Erlotinib | 183321-86-0 | Reference compound |
| HY-13256AR | Desmethyl Erlotinib (Standard) | 183321-86-0 | Reference Standards |
| HY-13256AS | Desmethyl Erlotinib-d4 | 1216420-11-9 | Isotope-Labeled Compounds |
| HY-13256AS1 | Desmethyl Erlotinib-d4-1 | 2012598-45-5 | Isotope-Labeled Compounds |
| HY-13256R | Desmethyl Erlotinib (hydrochloride) (Standard) | 183320-51-6 | Reference Standards |
| HY-13257 | Thiazovivin | 1226056-71-8 | Reference compound |
| HY-132572 | HIV-1 integrase inhibitor 9 | 2709085-95-8 | Reference compound |
| HY-132578 | M5N36 | 2832887-40-6 | Reference compound |
| HY-132579 | Tominersen | 1709886-74-7 | Oligonucleotides |
| HY-132579A | Tominersen (sodium) | | Oligonucleotides |
| HY-13257G | Thiazovivin (GMP) | 1226056-71-8 | GMP Small Molecules |
| HY-13258 | NVP-BHG712 isomer | 2245892-85-5 | Reference compound |
| HY-132580 | Tofersen | 2088232-70-4 | Oligonucleotides |
| HY-132580A | Tofersen (sodium) | 1898254-60-8 | Oligonucleotides |
| HY-132581 | Tadnersen | 2170507-65-8 | Oligonucleotides |
| HY-132581A | Tadnersen (sodium) | | Oligonucleotides |
| HY-132582 | IONIS-MAPTRx | 2857842-32-9 | Oligonucleotides |
| HY-132582A | Tau ASO-12 (murine) (sodium) | | Oligonucleotides |
| HY-132582C | IONIS-MAPTRx (sodium) | | Oligonucleotides |
| HY-132583 | IONIS-DNM2-2.5Rx | 2857839-05-3 | Oligonucleotides |
| HY-132583A | IONIS-DNM2-2.5Rx (sodium) | | Oligonucleotides |
| HY-132584 | Casimersen | 1422958-19-7 | Oligonucleotides |
| HY-132584A | Casimersen (sodium) | | Oligonucleotides |
| HY-132585A | SRP-5051 (sodium) | | Oligonucleotides |
| HY-132586 | Viltolarsen | 2055732-84-6 | Oligonucleotides |
| HY-132586A | Viltolarsen (sodium) | | Oligonucleotides |
| HY-132587 | Fitusiran | 1499251-18-1 | Oligonucleotides |
| HY-132587A | Fitusiran (sodium) | | Oligonucleotides |
| HY-132588 | Lumasiran | 1834610-13-7 | Oligonucleotides |
| HY-132589 | Vutrisiran | 1867157-35-4 | Oligonucleotides |
| HY-132589A | Vutrisiran (sodium) | | Oligonucleotides |
| HY-13258A | NVP-BHG712 | 940310-85-0 | Reference compound |
| HY-13259 | MG-132 | 133407-82-6 | Reference compound |
| HY-132590 | Revusiran | 1438322-82-7 | Oligonucleotides |
| HY-132590A | Revusiran (sodium) | | Oligonucleotides |
| HY-132591 | Inclisiran | 1639324-58-5 | Oligonucleotides |
| HY-132591A | Inclisiran (sodium) | | Oligonucleotides |
| HY-132592 | Suvodirsen | 2095270-67-8 | Oligonucleotides |
| HY-132592A | Suvodirsen (sodium) | 2142024-01-7 | Oligonucleotides |
| HY-132593 | Rovanersen | 2072901-32-5 | Oligonucleotides |
| HY-132593A | Rovanersen (sodium) | 2231347-41-2 | Oligonucleotides |
| HY-132595 | Teprasiran | 1231737-88-4 | Oligonucleotides |
| HY-132595A | Teprasiran (sodium) | 2169310-72-7 | Oligonucleotides |
| HY-132596 | Tivanisiran | 1848224-71-4 | Oligonucleotides |
| HY-132596A | Tivanisiran (sodium) | 1848239-71-3 | Oligonucleotides |
| HY-132598 | Miravirsen | 1072874-90-8 | Oligonucleotides |
| HY-132598A | Miravirsen (sodium) | | Oligonucleotides |
| HY-13259C | (R)-MG-132 | 1211877-36-9 | Reference compound |
| HY-13259D | MG-132 (negative control) | | Reference compound |
| HY-13260 | CCT128930 | 885499-61-6 | Reference compound |
| HY-132600 | RG-101 | 1929655-04-8 | Oligonucleotides |
| HY-132600A | RG-101 (sodium) | | Oligonucleotides |
| HY-132601 | Cobomarsen | 1848257-52-2 | Oligonucleotides |
| HY-132601A | Cobomarsen (sodium) | 1848257-85-1 | Oligonucleotides |
| HY-132602 | Remlarsen | 1848266-71-6 | Oligonucleotides |
| HY-132602A | Remlarsen (sodium) | | Oligonucleotides |
| HY-132604 | Fazirsiran | 2175009-08-0 | Oligonucleotides |
| HY-132604A | Fazirsiran (sodium) | 2175009-09-1 | Oligonucleotides |
| HY-132606 | Nedosiran | 2266591-83-5 | Oligonucleotides |
| HY-132606A | Nedosiran (sodium) | 2247026-22-6 | Oligonucleotides |
| HY-132607 | MTL-CEBPA | 2862057-05-2 | Oligonucleotides |
| HY-132607A | MTL-CEBPA (sodium) | | Oligonucleotides |
| HY-132608 | Inotersen (sodium) | 1432726-13-0 | Oligonucleotides |
| HY-132609 | Patisiran (sodium) | 1386913-72-9 | Oligonucleotides |
| HY-13260A | CCT128930 (hydrochloride) | 2453324-32-6 | Reference compound |
| HY-13261 | A66 | 1166227-08-2 | Reference compound |
| HY-132610 | Givosiran | 1639325-43-1 | Oligonucleotides |
| HY-132610A | Givosiran (sodium) | 1639325-44-2 | Oligonucleotides |
| HY-132611 | Golodirsen | 1422959-91-8 | Oligonucleotides |
| HY-132611A | Golodirsen (sodium) | | Oligonucleotides |
| HY-132613 | Lumasiran (sodium) | 1834612-06-4 | Oligonucleotides |
| HY-132617S | Carboxy Gliclazide-d4 | 1346602-90-1 | Isotope-Labeled Compounds |
| HY-132618S | N-Acetyltyramine Glucuronide-d3 | 1429623-59-5 | Isotope-Labeled Compounds |
| HY-13262 | Lumacaftor | 936727-05-8 | Reference compound |
| HY-132626S | N-Desmethyl Tamoxifen-d5 | 164365-16-6 | Isotope-Labeled Compounds |
| HY-132628S | (Rac)-trans-N-Methyl Sertraline-d6 (hydrochloride) | 2124272-18-8 | Isotope-Labeled Compounds |
| HY-13262S | Lumacaftor-d4 | 2733561-44-7 | Isotope-Labeled Compounds |
| HY-13263 | CHIR-124 | 405168-58-3 | Reference compound |
| HY-132636S | (Rac)-5-Carboxy Tolterodine-d14 | 1189681-84-2 | Isotope-Labeled Compounds |
| HY-132637S | Chlorfenvinphos-d10(Mixture of cis-trans isomers) | 1346606-54-9 | Isotope-Labeled Compounds |
| HY-13264 | Degrasyn | 856243-80-6 | Reference compound |
| HY-132641S | Equilin 3-Sulfate-d4 (sodium salt) | 285979-81-9 | Isotope-Labeled Compounds |
| HY-132643S | Benzyldimethyltetradecylammonium-d7 (chloride) | 1219178-72-9 | Isotope-Labeled Compounds |
| HY-132644S1 | 3-Demethyl Thiocolchicine--13C2,d6 | | Isotope-Labeled Compounds |
| HY-132645S | (Rac)-Tolterodine-d14 (hydrochloride) | 1246816-99-8 | Isotope-Labeled Compounds |
| HY-132649S | α-Cholestane-d4 | 205529-74-4 | Isotope-Labeled Compounds |
| HY-13265 | AR-42 | 935881-37-1 | Reference compound |
| HY-132651S | Dehydro Mefloquine-d5 | 1246819-32-8 | Isotope-Labeled Compounds |
| HY-132657S | Dehydro Felodipine-d3 | 1189916-52-6 | Isotope-Labeled Compounds |
| HY-13266 | BS-181 | 1092443-52-1 | Reference compound |
| HY-132665S | (R)-(+)-Celiprolol-d9 (hydrochloride) | 1330045-90-3 | Isotope-Labeled Compounds |
| HY-13266A | BS-181 (hydrochloride) | 1397219-81-6 | Reference compound |
| HY-13267 | Droxinostat | 99873-43-5 | Reference compound |
| HY-132670S | (R)-(-)-Felodipine-d5 | 1217744-87-0 | Isotope-Labeled Compounds |
| HY-132674S | Benzylhydrochlorothiazide-d5 | 1185024-05-8 | Isotope-Labeled Compounds |
| HY-132675S | Prochlorperazine Sulfoxide-d3 | 1189943-37-0 | Isotope-Labeled Compounds |
| HY-132676S | Ramiprilat-d5 (Mixture of Diastereomers) | 1356837-92-7 | Isotope-Labeled Compounds |
| HY-132681S | (Rac)-Cinacalcet-d3 (hydrochloride) | 1185097-33-9 | Isotope-Labeled Compounds |
| HY-132685AS | N-Desmethyl Topotecan-d3 (hydrochloride) | 2701830-42-2 | Isotope-Labeled Compounds |
| HY-13269 | BMS-707035 | 729607-74-3 | Reference compound |
| HY-132690S | N-Demethyl Trimebutine-d5 (hydrochloride) | 1286632-72-1 | Isotope-Labeled Compounds |
| HY-132690S1 | N-Demethyl Trimebutine-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-132692S | N-Acetyl Norgestimate-d6 | 1263195-02-3 | Isotope-Labeled Compounds |
| HY-13270 | ABT-751 | 141430-65-1 | Reference compound |
| HY-132706S | N-Deformyl Formoterol-d6 Fumarate (Mixture of Diastereomers) | 1795142-59-4 | Isotope-Labeled Compounds |
| HY-132709S | N-Desmethyl-diltiazem-d4 (hydrochloride) | 1217650-51-5 | Isotope-Labeled Compounds |
| HY-13270A | ABT-751 (hydrochloride) | 141450-48-8 | Reference compound |
| HY-13271 | Tubastatin A (Hydrochloride) | 1310693-92-5 | Reference compound |
| HY-132710S | Tris(1,3-dichloro-2-propyl) Phosphate-d15 | 1447569-77-8 | Isotope-Labeled Compounds |
| HY-13271A | Tubastatin A | 1252003-15-8 | Reference compound |
| HY-13271B | Tubastatin A (TFA) | 1239262-52-2 | Reference compound |
| HY-13272 | Dacomitinib | 1110813-31-4 | Reference compound |
| HY-132723AS | 17β-Estradiol-3-β-D-glucuronide-d3 (sodium) | | Isotope-Labeled Compounds |
| HY-132723S | 17β-Estradiol-3-β-D-glucuronide-d3 | 1260231-06-8 | Isotope-Labeled Compounds |
| HY-13272R | Dacomitinib (Standard) | 1110813-31-4 | Reference Standards |
| HY-13272S2 | Dacomitinib-d10 (dihydrochloride) | | Isotope-Labeled Compounds |
| HY-13272S3 | Dacomitinib-d10 | | Isotope-Labeled Compounds |
| HY-13273 | Ostarine | 841205-47-8 | Reference compound |
| HY-13273S | Ostarine-d4 | 1202044-20-9 | Isotope-Labeled Compounds |
| HY-13274 | JTC-801 | 244218-51-7 | Reference compound |
| HY-13274A | JTC-801 (free base) | 244218-93-7 | Reference compound |
| HY-13275 | IRAK inhibitor 1 | 1042224-63-4 | Reference compound |
| HY-13276 | IRAK inhibitor 2 | 928333-30-6 | Reference compound |
| HY-13277 | IRAK inhibitor 3 | 1012343-93-9 | Reference compound |
| HY-13278 | IRAK inhibitor 4 | 1012104-68-5 | Reference compound |
| HY-132787S | N-Nitrosodiethanolamine-d8 | 1173019-53-8 | Isotope-Labeled Compounds |
| HY-13278A | IRAK inhibitor 4 (trans) | 2070014-89-8 | Reference compound |
| HY-132795S | Des(1-cyclohexanol) Venlafaxine-d6 | 1330046-00-8 | Isotope-Labeled Compounds |
| HY-132798S | Desethylatrazine-d7 | 1216649-31-8 | Isotope-Labeled Compounds |
| HY-13280 | IRAK inhibitor 6 | 1042672-97-8 | Reference compound |
| HY-132800S | 7-Methyl-3-methyluric acid-d3 | 383160-11-0 | Isotope-Labeled Compounds |
| HY-132804S | 2-Ethyl-2-phenylmalonamide-d5 | 1215398-95-0 | Isotope-Labeled Compounds |
| HY-132805S | N-Acetyl-S-(2-hydroxyethyl)-L-cysteine-d4 (dicyclohexylamine salt) | 1331894-57-5 | Isotope-Labeled Compounds |
| HY-132806 | Alogabat | 2230009-48-8 | Reference compound |
| HY-132807 | Amdizalisib | 1894229-05-0 | Reference compound |
| HY-132808 | Atuzabrutinib | 1581714-49-9 | Reference compound |
| HY-132809 | Baxdrostat | 1428652-17-8 | Reference compound |
| HY-132809A | (S)-Baxdrostat | 1428652-16-7 | Reference compound |
| HY-132809B | (Rac)-Baxdrostat | 1428652-15-6 | Reference compound |
| HY-13281 | PIK-75 (hydrochloride) | 372196-77-5 | Reference compound |
| HY-132810 | Bevurogant | 1817773-66-2 | Reference compound |
| HY-132811 | Dazucorilant | 1496508-34-9 | Reference compound |
| HY-132812 | Emraclidine | 2170722-84-4 | Reference compound |
| HY-132813 | Evifacotrep | 2413739-88-3 | Reference compound |
| HY-132814 | Fosgonimeton | 2093305-05-4 | Reference compound |
| HY-132815 | Fostroxacitabine bralpamide | 2129993-56-0 | Reference compound |
| HY-132817 | Gunagratinib | 2211082-53-8 | Reference compound |
| HY-132818 | Idrevloride | 1416973-63-1 | Reference compound |
| HY-132819 | Ilunocitinib | 1187594-14-4 | Reference compound |
| HY-13282 | GANT 58 | 64048-12-0 | Reference compound |
| HY-132820 | Inaxaplin | 2446816-88-0 | Reference compound |
| HY-132821 | Irsenontrine | 1429509-82-9 | Reference compound |
| HY-132821A | Irsenontrine (maleate) | 1630083-70-3 | Reference compound |
| HY-132821B | (R)-Irsenontrine | 1429509-81-8 | Reference compound |
| HY-132822 | Ivospemin | 748119-79-1 | Reference compound |
| HY-132823 | Ledaborbactam | 1842397-36-7 | Reference compound |
| HY-132824 | Ledaborbactam etzadroxil | 1842399-68-1 | Reference compound |
| HY-132825 | Mivorilaner | 1414642-93-5 | Reference compound |
| HY-132827 | Ocedurenone | 1359969-24-6 | Reference compound |
| HY-132828 | Odatroltide | 1639303-73-3 | Reference compound |
| HY-132829 | Rucosopasem manganese | 2248030-85-3 | Reference compound |
| HY-13283 | MF63 | 892549-43-8 | Reference compound |
| HY-132830 | Sebetralstat | 1933514-13-6 | Reference compound |
| HY-132831 | Selnoflast | 2260969-36-4 | Reference compound |
| HY-132831A | Selnoflast (calcium) | 2887416-19-3 | Reference compound |
| HY-132831B | Selnoflast (potassium) | | Reference compound |
| HY-132832 | Sirpiglenastat | 2079939-05-0 | Reference compound |
| HY-132833S | 1,7-Dimethyl-1H-imidazo[4,5-g]quinoxalin-2-amine-d3 | | Isotope-Labeled Compounds |
| HY-132834S | 5-Carboxy-N-phenyl-2-1H-pyridone-d5 | 1020719-24-7 | Isotope-Labeled Compounds |
| HY-132836S | N2-Lauroyl-L-glutamine-d23 | 1795786-88-7 | Isotope-Labeled Compounds |
| HY-132840 | Sovilnesib | 2410796-79-9 | Reference compound |
| HY-132841 | Sucunamostat | 1802888-04-5 | Reference compound |
| HY-132841A | Sucunamostat (hydrochloride) | | Reference compound |
| HY-132842 | Sunvozertinib | 2370013-12-8 | Reference compound |
| HY-132842A | (S)-Sunvozertinib | 2370013-49-1 | Reference compound |
| HY-132844 | Tunlametinib | 1801756-06-8 | Reference compound |
| HY-132845 | Utreloxastat | 1213269-96-5 | Reference compound |
| HY-132846 | Vepafestinib | 2129515-96-2 | Reference compound |
| HY-132847 | Vibozilimod | 1403232-33-6 | Reference compound |
| HY-132848 | Polyvinylimidazole | 25232-42-2 | Biochemical Assay Reagents |
| HY-132849 | Nezulcitinib | 2412496-23-0 | Reference compound |
| HY-13284S | 7-α-Methylthio Spironolactone-d3 | | Isotope-Labeled Compounds |
| HY-13285 | Ki16425 | 355025-24-0 | Reference compound |
| HY-132850 | Dazcapistat | 2221010-42-8 | Reference compound |
| HY-132851 | Corixetan | 1952359-26-0 | ADC Related |
| HY-132853S | Bis(2-ethoxyethyl) phthalate-3,4,5,6-d4 | 1398066-12-0 | Isotope-Labeled Compounds |
| HY-132854S | Bis(2-butoxyethyl) phthalate-d4 | 1398065-96-7 | Isotope-Labeled Compounds |
| HY-132855S | Bis(4-methyl-2-pentyl) phthalate-d4 | 1398066-13-1 | Isotope-Labeled Compounds |
| HY-132856 | Lenalidomide-C5-amido-Boc | 2138441-25-3 | Reference compound |
| HY-132857 | ZXH-4-130 | 2711006-66-3 | Reference compound |
| HY-132857A | ZXH-4-130 (TFA) | 2711006-67-4 | Reference compound |
| HY-132858 | Thalidomide-4-O-C10-COOH | 2379870-45-6 | Reference compound |
| HY-132859 | Bromo-C10-OBn | 78277-30-2 | Reference compound |
| HY-132860S | Benzo[e]pyrene-d12 | 205440-82-0 | Isotope-Labeled Compounds |
| HY-132862 | ZXH-4-137 | 2711006-74-3 | Reference compound |
| HY-132863 | FTO-IN-2 | 2585198-85-0 | Reference compound |
| HY-132865 | FTO-IN-3 | 2585198-87-2 | Reference compound |
| HY-132866 | YS-370 | 2470908-79-1 | Reference compound |
| HY-132867 | MNK/PIM-IN-1 | 2430792-91-7 | Reference compound |
| HY-132868 | SLK/STK10-IN-1 | 264210-49-3 | Reference compound |
| HY-132869 | MEIS-IN-1 | 2761326-82-1 | Reference compound |
| HY-13286S | N-Hydroxy (E)-2-(4-methoxybenzoxy)-4-methoxy-3-prenylcinnamamide-d6 | | Isotope-Labeled Compounds |
| HY-13287 | SGI-1776 (free base) | 1025065-69-3 | Reference compound |
| HY-132870 | MEIS-IN-2 | 2761326-86-5 | Reference compound |
| HY-132871 | MEIS-IN-3 | 2761326-88-7 | Reference compound |
| HY-132878 | FgGpmk1-IN-1 | 319490-29-4 | Reference compound |
| HY-132879 | TAK-020 | 1627603-21-7 | Reference compound |
| HY-13287A | SGI-1776 | 1173928-26-1 | Reference compound |
| HY-13288 | Org 27569 | 868273-06-7 | Reference compound |
| HY-132880 | GSK251 | 2125968-05-8 | Reference compound |
| HY-132882 | ARN19689 | 2320521-34-2 | Reference compound |
| HY-132883 | EGFR/CSC-IN-1 | 2820447-02-5 | Reference compound |
| HY-132884 | TTK inhibitor 3 | 2820453-41-4 | Reference compound |
| HY-132885 | PARP/EZH2-IN-1 | 2687273-52-3 | Reference compound |
| HY-132886 | SARS-CoV-2-IN-6 | 2725749-22-2 | Reference compound |
| HY-132887 | PDE4-IN-3 | 2755687-49-9 | Reference compound |
| HY-132888 | NCATS-SM4487 | 2733617-81-5 | Reference compound |
| HY-132889 | BPTF-IN-BZ1 | 2766623-38-3 | Reference compound |
| HY-13289 | Nepicastat | 173997-05-2 | Reference compound |
| HY-132891 | RSK4-IN-1 | 2755819-10-2 | Reference compound |
| HY-132891A | RSK4-IN-1 (TFA) | | Reference compound |
| HY-132892 | NLRP3-IN-4 | 2758595-77-4 | Reference compound |
| HY-132893 | AZ14145845 | 2830555-70-7 | Reference compound |
| HY-132894 | Pixavir marboxilo | 2365473-17-0 | Reference compound |
| HY-132895 | JNJ-67569762 | 2380313-26-6 | Reference compound |
| HY-132896 | KDM4-IN-3 | 1068515-53-6 | Reference compound |
| HY-132897 | PCSK9-IN-2 | 2099167-44-7 | Reference compound |
| HY-132898 | PI3K-IN-23 | 2755651-17-1 | Reference compound |
| HY-13289A | Nepicastat (hydrochloride) | 170151-24-3 | Reference compound |
| HY-13289B | (R)-Nepicastat (hydrochloride) | 195881-94-8 | Reference compound |
| HY-13290 | KN-62 | 127191-97-3 | Reference compound |
| HY-132900 | RORγ agonist 1 | 2260631-91-0 | Reference compound |
| HY-132901 | IACS-15414 | 2411321-29-2 | Reference compound |
| HY-132902 | DEPTOR-IN-1 | 2615911-12-9 | Reference compound |
| HY-132903 | eeAChE-IN-1 | 2763366-27-2 | Reference compound |
| HY-132904 | eeAChE-IN-2 | 2763366-33-0 | Reference compound |
| HY-132905 | Antileishmanial agent-2 | 2863687-18-5 | Reference compound |
| HY-132906 | Antimalarial agent 3 | 3033386-12-5 | Reference compound |
| HY-132907 | MAO-B-IN-2 | 1253978-24-3 | Reference compound |
| HY-132908 | Anti-ToCV agent 1 | 2848583-24-2 | Reference compound |
| HY-132909 | Nurr1 inverse agonist-1 | 2758673-07-1 | Reference compound |
| HY-132910 | Antitubercular agent-9 | 2722634-44-6 | Reference compound |
| HY-132911 | Antiviral agent 6 | 2847129-11-5 | Reference compound |
| HY-132912 | Antifungal agent 15 | 2639531-53-4 | Reference compound |
| HY-132913 | Cyclopropenone probe 1 | 2771119-22-1 | Reference compound |
| HY-132914 | CDK/HDAC-IN-1 | 2762181-73-5 | Reference compound |
| HY-132915 | Anti gram-positive/negative bacteria agent 1 | 3031404-92-6 | Reference compound |
| HY-132916 | Antiviral agent 7 | | Reference compound |
| HY-132917 | ADAM8-IN-1 | 2758892-64-5 | Reference compound |
| HY-132918 | Antibacterial agent 30 | 2694867-40-6 | Reference compound |
| HY-13292 | Impurity B of Calcitriol | 66791-71-7 | Reference compound |
| HY-132920 | KRAS mutant protein inhibitor 1 | 2642630-16-6 | Reference compound |
| HY-132922 | EEDi-5273 | 2585648-55-9 | Reference compound |
| HY-132923 | NBTIs-IN-4 | 2758890-16-1 | Reference compound |
| HY-132924 | BMS-963272 | 1441057-15-3 | Reference compound |
| HY-132925 | Antifungal agent 16 | 2762034-41-1 | Reference compound |
| HY-132926 | HPK1-IN-8 | 1214561-09-7 | Reference compound |
| HY-132927 | Salpyran | 2719737-44-5 | Reference compound |
| HY-132927A | Salpyran (hydrochloride) | | Reference compound |
| HY-132927B | Salpyran (dihydrochloride) | | Reference compound |
| HY-132928 | Antitubercular agent-10 | 2679830-78-3 | Reference compound |
| HY-132929 | TCMDC-125431 | 3015474-50-4 | Reference compound |
| HY-13293 | Impurity C of Calcitriol | 86307-44-0 | Reference compound |
| HY-132930 | TCMDC-136230 | 3015474-48-0 | Reference compound |
| HY-132931 | TCMDC-125457 | 872113-12-7 | Reference compound |
| HY-132932 | Cavα2δ-IN-1 | 2416957-09-8 | Reference compound |
| HY-132933 | Fungicide4 | 7412-05-7 | Reference compound |
| HY-132934 | Ac32Az19 | 2760674-72-2 | Reference compound |
| HY-132935 | BPR1R024 | 2503015-75-4 | Reference compound |
| HY-132935A | BPR1R024 (mesylate) | 2763365-40-6 | Reference compound |
| HY-132936 | CXCR4 antagonist 2 | 2243636-57-7 | Reference compound |
| HY-132937 | PRMT5-IN-9 | 2691869-52-8 | Reference compound |
| HY-132938 | (S,R,S)-AHPC-Me-decanedioic acid | 2380273-45-8 | Reference compound |
| HY-132939 | 2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br | 2411022-24-5 | Reference compound |
| HY-13294 | Impurity C of Alfacalcidol | 82266-85-1 | Reference compound |
| HY-132940 | (+)-Pileamartine A | 2230306-50-8 | Reference compound |
| HY-132941 | CFT-2718 | | Reference compound |
| HY-132942 | PROTAC BRD4 ligand-2 | 2154358-11-7 | Reference compound |
| HY-132942A | PROTAC BRD4 ligand-2 (hydrochloride) | | Reference compound |
| HY-132943 | BRD4 ligand-Linker Conjugate 1 | 2154358-89-9 | Reference compound |
| HY-132943A | BRD4 ligand-Linker Conjugate 1 (TFA) | | Reference compound |
| HY-132944 | (R)-Pomalidomide-pyrrolidine | 2418618-52-5 | Reference compound |
| HY-132947S | Heptadecanoyl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-132948S | 5-(4-Hydroxyphenyl)-5-phenyl hydantoin-15N2,d5 | 369656-71-3 | Isotope-Labeled Compounds |
| HY-132949S | Decanoyl-L-carnitine-d3 (chloride) | 2483831-87-2 | Isotope-Labeled Compounds |
| HY-13295 | Vinpocetine | 42971-09-5 | Natural Products |
| HY-132950S | Acetone 2,4-dinitrophenylhydrazone-d3 | 259824-57-2 | Isotope-Labeled Compounds |
| HY-132951S | D-Glycero-D-guloheptonate-d7 | | Isotope-Labeled Compounds |
| HY-132952S | 3-Methylcrotonyl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-132953S | Formaldehyde 2,4-dinitrophenylhydrazone-d3 | 259824-50-5 | Isotope-Labeled Compounds |
| HY-132954S | 4-Fluorobenzaldehyde 2,4-dinitrophenylhydrazone-d3 | 2734379-03-2 | Isotope-Labeled Compounds |
| HY-132955S | Oleoyl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-132956S | Tigloyl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-132957S | Nonadecanoyl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-132958S | 2-Methylbutyryl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-132959S | 3-Methylbutyryl-DL-carnitine-d9 (hydrochloride) | 2608872-54-2 | Isotope-Labeled Compounds |
| HY-13295R | Vinpocetine (Standard) | 42971-09-5 | Reference Standards |
| HY-13295S | Vinpocetine-d5 | 2734920-39-7 | Isotope-Labeled Compounds |
| HY-13296 | PYR-41 | 418805-02-4 | Reference compound |
| HY-132960S | N-Propionylglycine-2,2-d2 | 1256842-51-9 | Isotope-Labeled Compounds |
| HY-132961S | N-Propionyl-d5-glycine | | Isotope-Labeled Compounds |
| HY-132962S | Pseudooxynicotine-d4 (hydrochloride) | 764661-23-6 | Isotope-Labeled Compounds |
| HY-132963S | 3-Fluorobenzaldehyde 2,4-dinitrophenylhydrazone-d3 | 2734701-43-8 | Isotope-Labeled Compounds |
| HY-132964S | 2,2-Dimethylpropionyl-L-carnitine-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-132966 | ASP2453 | 2241719-73-1 | Reference compound |
| HY-132967 | Anti-TSWV agent 1 | 2763371-23-7 | Reference compound |
| HY-132968 | Antifungal agent 20 | 2460281-94-9 | Reference compound |
| HY-132969 | SBP-3264 | 2869148-13-8 | Reference compound |
| HY-13297 | PYZD-4409 | 423148-78-1 | Reference compound |
| HY-132970 | EED ligand 1 | 2762275-20-5 | Reference compound |
| HY-132971 | Thalidomide-piperazine (hydrochloride) | 2228029-82-9 | Reference compound |
| HY-132972 | TrxR-IN-2 | 2866261-50-7 | Reference compound |
| HY-132973 | MC-Val-Cit-PAB-NH-C2-NH-Boc | 1616727-22-0 | ADC Related |
| HY-132975 | PrDiAzK | 2231405-64-2 | Reference compound |
| HY-132977 | BTTAA-OH | 1257633-69-4 | Reference compound |
| HY-132978 | SulfoxFluor | 2143892-50-4 | Reference compound |
| HY-132979 | KRAS G12C inhibitor 18 | 2649788-45-2 | Reference compound |
| HY-13298 | Mps1-IN-1 | 1125593-20-5 | Reference compound |
| HY-132980 | Olomorasib | 2771246-13-8 | Reference compound |
| HY-132981 | Lu AF27139 | 2097117-06-9 | Reference compound |
| HY-132987 | Avibactam tomilopil | 2245880-46-8 | Reference compound |
| HY-132988 | Fmoc-Tyr(3-F,tBu)-OH | 2254698-84-3 | Reference compound |
| HY-132989 | Mal-Deferoxamine | 1638156-31-6 | Reference compound |
| HY-13299 | MK-8033 | 1001917-37-8 | Reference compound |
| HY-132991 | ML 2-14 | | Reference compound |
| HY-132992 | EN219-O-C4-NH2 (TFA) | | Reference compound |
| HY-132993 | Hcyb1 | 2988566-71-6 | Reference compound |
| HY-132994 | TVD-0003510 | 2355276-51-4 | Reference compound |
| HY-132995 | DP-1 | 1472616-61-7 | Reference compound |
| HY-132995A | DP-1 (hydrochloride) | 1472616-35-5 | Reference compound |
| HY-132996 | 4-Isothiocyanatophenyl α-D-Mannopyranoside | 96345-79-8 | Reference compound |
| HY-132997 | PROTAC Bcl-xL degrader-3 | 2471970-60-0 | Reference compound |
| HY-132998 | HDAC6 degrader-1 | 2439058-23-6 | Reference compound |
| HY-13299A | MK-8033 (hydrochloride) | 1283000-43-0 | Reference compound |
| HY-13300 | SR-3677 | 1072959-67-1 | Reference compound |
| HY-133000 | Bis-PEG7-PFP ester | 1334170-01-2 | Reference compound |
| HY-133001 | Dehydrocyclopeptine | 31965-37-4 | Reference compound |
| HY-133002 | Methyl sterculate | 3220-60-8 | Natural Products |
| HY-133003 | L662,025 | 122328-38-5 | Reference compound |
| HY-133004 | Fenbutatin oxide | 13356-08-6 | Reference compound |
| HY-133004R | Fenbutatin oxide (Standard) | 13356-08-6 | Reference Standards |
| HY-133004S | Fenbutatin oxide-d30 | | Isotope-Labeled Compounds |
| HY-133005 | Desacetylvinblastine | 3352-69-0 | Reference compound |
| HY-133006 | Fluorescein-PEG5-acid | 2183440-40-4 | Reference compound |
| HY-133007 | Algestone acetophenide | 24356-94-3 | Reference compound |
| HY-133007R | Algestone acetophenide (Standard) | 24356-94-3 | Reference Standards |
| HY-133008 | endo-BCN-PEG3-acid | 1807501-82-1 | Reference compound |
| HY-133009 | BCN-PEG4-acid | 2226472-38-2 | Reference compound |
| HY-13300A | SR-3677 (dihydrochloride) | 1781628-88-3 | Reference compound |
| HY-13301 | MPC-3100 | 958025-66-6 | Reference compound |
| HY-133010 | Tamoxifen N-oxide | 75504-34-6 | Reference compound |
| HY-133010R | Tamoxifen N-oxide (Standard) | 75504-34-6 | Reference Standards |
| HY-133011 | nAChR agonist 1 | 1394371-75-5 | Reference compound |
| HY-133012 | GFB-8438 | 2304549-73-1 | Reference compound |
| HY-133013 | GLPG-3221 | 2222264-64-2 | Reference compound |
| HY-133014 | RIP2 kinase inhibitor 1 | 2380028-10-2 | Reference compound |
| HY-133015 | Mcl-1 inhibitor 3 | 2376774-73-9 | Reference compound |
| HY-133016 | M8891 | 1464842-09-8 | Reference compound |
| HY-133016A | (R)-M8891 | 2575547-29-2 | Reference compound |
| HY-133017 | Amcenestrant | 2114339-57-8 | Reference compound |
| HY-133018 | HCV-IN-7 | 1449756-86-8 | Reference compound |
| HY-133018A | HCV-IN-7 (hydrochloride) | 1449756-87-9 | Reference compound |
| HY-133019 | ATX inhibitor 5 | 2402772-45-4 | Reference compound |
| HY-13302 | CP-547632 | 252003-65-9 | Reference compound |
| HY-133020 | ARD-266 | 2666951-70-6 | Reference compound |
| HY-133021 | Arazine | 135304-07-3 | Reference compound |
| HY-133022 | trans-2-Undecenoic acid | 15790-94-0 | Reference compound |
| HY-133022R | trans-2-Undecenoic acid (Standard) | 15790-94-0 | Reference Standards |
| HY-133023 | Indium(III) isopropoxide | 38218-24-5 | Reference compound |
| HY-133024 | Flumexadol | 30914-89-7 | Reference compound |
| HY-133025 | FK962 | 283167-06-6 | Reference compound |
| HY-133026 | N-Acetylcarnosine | 56353-15-2 | Peptides |
| HY-133027 | Myristyl nicotinate | 273203-62-6 | Reference compound |
| HY-133028 | CKI-7 (free base) | 120615-25-0 | Reference compound |
| HY-133029 | PI3K-IN-9 | 2360875-63-2 | Reference compound |
| HY-13302B | CP-547632 (hydrochloride) | 252003-71-7 | Reference compound |
| HY-13302C | CP-547632 (TFA) | 2805804-54-8 | Reference compound |
| HY-13303 | RO 4927350 | 876755-27-0 | Reference compound |
| HY-133030 | DNMT-IN-1 | 2396691-28-2 | Reference compound |
| HY-133031 | CSV0C018875 | 442150-41-6 | Reference compound |
| HY-133031A | CSV0C018875 (hydrochloride) | 474084-56-5 | Reference compound |
| HY-133033 | COQ7-IN-1 | 2579696-72-1 | Reference compound |
| HY-133034 | NRP1 antagonist 1 | 2569598-01-0 | Reference compound |
| HY-133036 | APJ receptor agonist 1 | 2287153-38-0 | Reference compound |
| HY-13304 | LY2874455 | 1254473-64-7 | Reference compound |
| HY-133044 | Boc-Pip-alkyne-Ph-COOH | 2581824-70-4 | Reference compound |
| HY-133045 | VHL Ligand 8 | 2701565-76-4 | Reference compound |
| HY-133046 | VHL Ligand-Linker Conjugates 17 | | Reference compound |
| HY-133049 | Propargyl-PEG3-phosphonic acid | 1714139-62-4 | Reference compound |
| HY-13305 | MK-2048 | 869901-69-9 | Reference compound |
| HY-133050 | Hydroxy-PEG6-acid | 1347750-85-9 | Reference compound |
| HY-133051 | Hydroxy-PEG5-acid | 2079768-50-4 | Reference compound |
| HY-133052 | Hydroxy-PEG3-acid | 518044-49-0 | Reference compound |
| HY-133053 | HO-PEG8-CH2CH2COOH | 937188-60-8 | Reference compound |
| HY-133054 | PEG4-sulfonic acid | 173459-90-0 | Reference compound |
| HY-133056 | Pseudomonic acid C | 71980-98-8 | Reference compound |
| HY-133056R | Pseudomonic acid C (Standard) | 71980-98-8 | Reference Standards |
| HY-133057 | m-PEG4-CH2-alcohol | 145526-76-7 | Reference compound |
| HY-133058 | m-PEG7-CH2-OH | 1807512-35-1 | Reference compound |
| HY-133059 | MRZ-8676 | 872122-36-6 | Reference compound |
| HY-13306 | Pyrintegrin | 1228445-38-2 | Reference compound |
| HY-133060 | Sannamycin B | 72503-80-1 | Reference compound |
| HY-133061 | Fluorescein-thiourea-PEG6-acid | 2055014-69-0 | Reference compound |
| HY-133062 | Fmoc-NH-PEG5-CH2COOH | 635287-26-2 | ADC Related |
| HY-133063 | Fmoc-NH-PEG8-CH2COOH | 868594-52-9 | ADC Related |
| HY-133064 | m-PEG3-NHS ester | 876746-59-7 | Reference compound |
| HY-133065 | m-PEG5-NHS ester | 874208-94-3 | Reference compound |
| HY-133066 | m-PEG6-NHS ester | 1449390-12-8 | ADC Related |
| HY-133068 | 5-Hydroxyferulic acid | 1782-55-4 | Natural Products |
| HY-133068A | (E)-5-Hydroxyferulic acid | 110642-42-7 | Reference compound |
| HY-133069 | Tos-PEG2-C2-Boc | 850090-13-0 | Reference compound |
| HY-13307 | JK184 | 315703-52-7 | Reference compound |
| HY-133070 | Tos-PEG5-C2-Boc | 850090-10-7 | Reference compound |
| HY-133071 | Tos-PEG6-C2-Boc | 406213-75-0 | Reference compound |
| HY-133073 | CCR7 Ligand 1 | 681514-83-0 | Reference compound |
| HY-133078 | Thienyldecyl Isothiocyanate | 288323-41-1 | Reference compound |
| HY-133079 | Ascorbyl tetra-2-hexyldecanoate | 183476-82-6 | Reference compound |
| HY-13308 | Regorafenib (Hydrochloride) | 835621-07-3 | Reference compound |
| HY-133080 | BAY-784 | 1631164-24-3 | Reference compound |
| HY-133083 | BAY-474 | 1033767-86-0 | Reference compound |
| HY-133084 | ERK-IN-2 | 2743576-56-7 | Reference compound |
| HY-133084A | ERK-IN-2 (free base) | 2743576-55-6 | Reference compound |
| HY-133085 | Rimsulfuron | 122931-48-0 | Reference compound |
| HY-133085R | Rimsulfuron (Standard) | 122931-48-0 | Reference Standards |
| HY-133085S | Rimsulfuron-d6 | | Isotope-Labeled Compounds |
| HY-133086 | Hydrodolasetron | 127951-99-9 | Reference compound |
| HY-133086S | Hydrodolasetron-d4 | | Isotope-Labeled Compounds |
| HY-133086S1 | Hydrodolasetron-d5 | | Isotope-Labeled Compounds |
| HY-133088 | Curcumaromin A | 1810034-38-8 | Natural Products |
| HY-133089 | Curcumaromin B | 1810034-39-9 | Natural Products |
| HY-133090 | Erythbidin A | 210050-83-2 | Natural Products |
| HY-133091 | 7-Ethoxycoumarin | 31005-02-4 | Natural Products |
| HY-133091S | 7-Ethoxycoumarin-d5 | 1189956-39-5 | Isotope-Labeled Compounds |
| HY-133092 | Perphenazine sulfoxide | 10078-25-8 | Reference compound |
| HY-133092R | Perphenazine sulfoxide (Standard) | 10078-25-8 | Reference Standards |
| HY-133095 | BML-260 | 101439-76-3 | Reference compound |
| HY-133096 | Yadanzioside K | 101559-98-2 | Natural Products |
| HY-133097 | Yadanzioside M | 101559-99-3 | Natural Products |
| HY-133098 | Juncutol | 1021950-14-0 | Natural Products |
| HY-133100 | 5-ALA benzyl ester (hydrochloride) | 163271-32-7 | Reference compound |
| HY-133101 | 14-Norpseurotin | 1031727-34-0 | Natural Products |
| HY-133102 | Dihydronarwedine | 21041-10-1 | Natural Products |
| HY-133103 | Virosine B | 1052228-70-2 | Natural Products |
| HY-133104 | Neocaesalpin O | 1053189-53-9 | Natural Products |
| HY-133105 | Procysteine | 19771-63-2 | Reference compound |
| HY-133108 | Azadirachtin B | 106500-25-8 | Natural Products |
| HY-133109 | Trachelosiaside | 106647-12-5 | Natural Products |
| HY-13311 | Infigratinib | 872511-34-7 | Reference compound |
| HY-133110 | Afatinib N-Oxide | 2413212-11-8 | Reference compound |
| HY-133111 | 3-Hydroxy agomelatine | 166526-99-4 | Reference compound |
| HY-133111S | 3-Hydroxy agomelatine-d3 | 1079774-23-4 | Isotope-Labeled Compounds |
| HY-133112 | 7-Desmethyl-3-hydroxyagomelatine | 166527-00-0 | Reference compound |
| HY-133113 | 7-Desmethyl-agomelatine | 152302-45-9 | Reference compound |
| HY-133113S | 7-Desmethyl-agomelatine-d3 | 2749427-92-5 | Isotope-Labeled Compounds |
| HY-133114 | Ezetimibe ketone | 191330-56-0 | Reference compound |
| HY-133115 | N-Desmethylnefopam | 46868-19-3 | Reference compound |
| HY-133115AS | N-Desmethylnefopam-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-133116 | 4-Hydroxyatomoxetine | 435293-66-6 | Reference compound |
| HY-133116S | 4-Hydroxyatomoxetine-d3 | 1217686-14-0 | Isotope-Labeled Compounds |
| HY-133117 | BAY-985 | 2409479-29-2 | Reference compound |
| HY-133117A | (Rac)-BAY-985 | 2101925-20-4 | Reference compound |
| HY-133118 | 6RK73 | 1895050-66-4 | Reference compound |
| HY-133119 | PK150 | 2165324-62-7 | Reference compound |
| HY-13311A | Infigratinib phosphate | 1310746-10-1 | Reference compound |
| HY-13311S | Infigratinib-d3 | | Isotope-Labeled Compounds |
| HY-133120 | INY-03-041 | 2503017-97-6 | Reference compound |
| HY-133120A | INY-03-041 (trihydrochloride) | | Reference compound |
| HY-133121 | WDR5-IN-1 | 2408842-51-1 | Reference compound |
| HY-133122 | UCB-9260 | 1515888-53-5 | Reference compound |
| HY-133123 | EP4 receptor antagonist 1 | 2287259-07-6 | Reference compound |
| HY-133124 | PARP/PI3K-IN-1 | 2337386-47-5 | Reference compound |
| HY-133125 | ERAP1-IN-1 | 865273-97-8 | Reference compound |
| HY-133126 | hDDAH-1-IN-1 | 1229238-69-0 | Reference compound |
| HY-133126A | hDDAH-1-IN-1 (TFA) | 1229238-70-3 | Reference compound |
| HY-133127 | AR453588 | 1065609-00-8 | Reference compound |
| HY-133127A | AR453588 (hydrochloride) | 1065606-97-4 | Reference compound |
| HY-133128 | FM26 | 2407981-35-3 | Reference compound |
| HY-133129 | MS1943 | 2225938-17-8 | Reference compound |
| HY-13313 | XL888 | 1149705-71-4 | Reference compound |
| HY-133130 | JNJ-42226314 | 1252765-13-1 | Reference compound |
| HY-133131 | PROTAC BRD4 Degrader-1 | 2133360-00-4 | Reference compound |
| HY-133136 | PROTAC BRD4 Degrader-2 | 2185795-53-1 | Reference compound |
| HY-133137 | SJF620 | 2376187-16-3 | Reference compound |
| HY-133137A | SJF620 (hydrochloride) | 2821938-05-8 | Reference compound |
| HY-133138 | Pomalidomide-PEG1-azide | 2133360-04-8 | Reference compound |
| HY-133139 | Lenalidomide-PEG1-azide | 2185795-67-7 | Reference compound |
| HY-13314 | Tesevatinib | 781613-23-8 | Reference compound |
| HY-133141 | DI-87 | 2107280-55-5 | Reference compound |
| HY-133143 | 1,2-Bis(2-iodoethoxy)ethane | 36839-55-1 | Reference compound |
| HY-133144 | Lenalidomide-OH | 1416990-08-3 | Reference compound |
| HY-133145 | hDDAH-1-IN-2 | 2408834-77-3 | Reference compound |
| HY-133145A | hDDAH-1-IN-2 (sulfate) | 2747921-54-4 | Reference compound |
| HY-133146 | DJ001 | 2161305-12-8 | Reference compound |
| HY-133147 | HDAC3/6-IN-2 | 2417510-17-7 | Reference compound |
| HY-133148 | Lp-PLA2-IN-2 | 2071636-15-0 | Reference compound |
| HY-133149 | Lp-PLA2-IN-3 | 2196245-16-4 | Reference compound |
| HY-13314A | Tesevatinib (tosylate) | 1000599-06-3 | Reference compound |
| HY-13315 | Montelukast (sodium) | 151767-02-1 | Reference compound |
| HY-133152 | Brexpiprazole S-oxide | 1191900-51-2 | Reference compound |
| HY-133152S | Brexpiprazole S-oxide-d8 | 2748605-29-8 | Isotope-Labeled Compounds |
| HY-133153S | Fenpiverinium-d3 (bromide) | | Isotope-Labeled Compounds |
| HY-133154 | Carboxyaminoimidazole ribotide | 6001-14-5 | Reference compound |
| HY-133155 | 5-Aminoimidazole ribonucleotide | 25635-88-5 | Reference compound |
| HY-133157 | FAICAR | 13018-54-7 | Reference compound |
| HY-133158S | (S)-Adenosylmethionine decarboxylated-d3 (sulfuric) | | Isotope-Labeled Compounds |
| HY-133159 | Resolvin E2 | 865532-70-3 | Reference compound |
| HY-13315A | Montelukast | 158966-92-8 | Reference compound |
| HY-13315AR | Montelukast (Standard) | 158966-92-8 | Reference Standards |
| HY-13315B | Montelukast (dicyclohexylamine) | 577953-88-9 | Reference compound |
| HY-13315BR | Montelukast (dicyclohexylamine) (Standard) | 577953-88-9 | Reference Standards |
| HY-13315R | Montelukast (sodium) (Standard) | 151767-02-1 | Reference Standards |
| HY-13315S | Montelukast-d6 | 1093746-29-2 | Isotope-Labeled Compounds |
| HY-13315S1 | Montelukast-d6 (sodium) | 2673270-26-1 | Isotope-Labeled Compounds |
| HY-133160 | Valproic acid hydroxamate | 106132-78-9 | Reference compound |
| HY-133162 | Mal-PEG1-Boc | 810677-16-8 | Reference compound |
| HY-133164 | Asebotin | 11075-15-3 | Natural Products |
| HY-133166 | A-889425 | 1072921-02-8 | Reference compound |
| HY-133167 | Clothianidin | 210880-92-5 | Reference compound |
| HY-133167R | Clothianidin (Standard) | 210880-92-5 | Reference Standards |
| HY-133167S | Clothianidin-d3 | 1262776-24-8 | Isotope-Labeled Compounds |
| HY-133168 | Englerin A | 1094250-15-3 | Natural Products |
| HY-133168R | Englerin A (Standard) | 1094250-15-3 | Reference Standards |
| HY-133169 | Topazolin | 109605-79-0 | Natural Products |
| HY-13317 | Oseltamivir | 196618-13-0 | Reference compound |
| HY-133171 | (R)-Norfluoxetine | 130194-43-3 | Reference compound |
| HY-133171A | (S)-Norfluoxetine | 126924-38-7 | Reference compound |
| HY-133171AS3 | (R)-Norfluoxetine-d5 | 1217648-64-0 | Isotope-Labeled Compounds |
| HY-133172 | Zanamivir amine | 130525-62-1 | Biochemical Assay Reagents |
| HY-133174 | Biotin-PEG5-azide | 1163732-89-5 | Reference compound |
| HY-133175 | Biotin-PEG7-azide | 1334172-75-6 | Reference compound |
| HY-133176 | Biotin-PEG6-acid | 1352814-10-8 | Reference compound |
| HY-133178 | Urolithin D | 131086-98-1 | Natural Products |
| HY-133178R | Urolithin D (Standard) | 131086-98-1 | Reference Standards |
| HY-133179 | Wnt/β-catenin-IN-4 | 2131223-69-1 | Reference compound |
| HY-13317R | Oseltamivir (Standard) | 196618-13-0 | Reference Standards |
| HY-13317S | Oseltamivir-d3 | 1093851-61-6 | Isotope-Labeled Compounds |
| HY-13317S1 | Oseltamivir-d3-1 | | Isotope-Labeled Compounds |
| HY-13317S3 | Oseltamivir-d5 | 1093851-63-8 | Isotope-Labeled Compounds |
| HY-13317S4 | Oseltamivir-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13318 | Oseltamivir acid | 187227-45-8 | Reference compound |
| HY-133180 | YW1128 | 2131223-64-6 | Reference compound |
| HY-133181 | Triumbelletin | 131559-54-1 | Natural Products |
| HY-133182 | Chloculol | 131652-35-2 | Natural Products |
| HY-133183 | Urolignoside | 131723-83-6 | Natural Products |
| HY-133185 | Megastigmatrienone (mixed isomers) | 13215-88-8 | Natural Products |
| HY-133186 | Fenamidone | 161326-34-7 | Reference compound |
| HY-133186R | Fenamidone (Standard) | 161326-34-7 | Reference Standards |
| HY-133187S | Blonanserin C-d8 | | Isotope-Labeled Compounds |
| HY-133188 | Imazethapyr | 81335-77-5 | Reference compound |
| HY-133188R | Imazethapyr (Standard) | 81335-77-5 | Reference Standards |
| HY-133189 | Bis-propargyl-PEG9 | 1351373-47-1 | Reference compound |
| HY-13318A | Oseltamivir acid (hydrochloride) | 1415963-60-8 | Reference compound |
| HY-13318R | Oseltamivir acid (Standard) | 187227-45-8 | Reference Standards |
| HY-13318S | Oseltamivir acid-d3 | 1242184-43-5 | Isotope-Labeled Compounds |
| HY-13318S1 | Oseltamivir acid-13C,d3 | | Isotope-Labeled Compounds |
| HY-13319 | JNK-IN-8 | 1410880-22-6 | Reference compound |
| HY-133190 | Bis-propargyl-PEG7 | 1351373-46-0 | Reference compound |
| HY-133191 | Bis-propargyl-PEG2 | 126422-57-9 | Reference compound |
| HY-133192 | Bis-propargyl-PEG3 | 126422-58-0 | Reference compound |
| HY-133193 | Bis-propargyl-PEG5 | 185378-83-0 | Reference compound |
| HY-133194 | Taxinine M | 135730-55-1 | Natural Products |
| HY-133195 | Nefopam | 13669-70-0 | Reference compound |
| HY-133196 | Ustusolate A | 1136611-58-9 | Natural Products |
| HY-133198 | Valeriandoid B | 1380399-57-4 | Natural Products |
| HY-133199 | Benastatin A | 138968-85-1 | Natural Products |
| HY-13319G | JNK-IN-8 (GMP) | 1410880-22-6 | GMP Small Molecules |
| HY-13320 | 2-Keto Crizotinib | 1415558-82-5 | Reference compound |
| HY-133200 | A-85783 | 161395-33-1 | Biochemical Assay Reagents |
| HY-133203 | Minaxin C | 1418150-06-7 | Reference compound |
| HY-133204 | Chlorfluazuron | 71422-67-8 | Reference compound |
| HY-133204R | Chlorfluazuron (Standard) | 71422-67-8 | Reference Standards |
| HY-133205 | Taxumairol B | 142203-64-3 | Natural Products |
| HY-133206A | Fosnetupitant (chloride monohydrochloride ) | 1643757-72-5 | Reference compound |
| HY-133207 | Myoseverin B | 361431-27-8 | Reference compound |
| HY-133209 | Fischeria A | 221456-63-9 | Natural Products |
| HY-13321 | Anguizole | 442666-98-0 | Reference compound |
| HY-133210 | Mal-PEG5-PFP ester | 1807512-46-4 | Reference compound |
| HY-133211 | Mal-PEG6-Boc | 518044-37-6 | Reference compound |
| HY-133212 | Mal-PEG8-Boc | 2055048-43-4 | Reference compound |
| HY-133214 | Cyclazosin (hydrochloride) | 146929-33-1 | Reference compound |
| HY-133215 | Zileuton sulfoxide | 1147524-83-1 | Reference compound |
| HY-133216 | Bupirimate | 41483-43-6 | Reference compound |
| HY-133216R | Bupirimate (Standard) | 41483-43-6 | Reference Standards |
| HY-133219 | Guajadial C | 1529775-02-7 | Natural Products |
| HY-133219A | Guajadial D | 1529775-04-9 | Natural Products |
| HY-13322 | Pracinostat | 929016-96-6 | Reference compound |
| HY-133220 | Guajadial E | 1529775-06-1 | Natural Products |
| HY-133220A | Guajadial F | 1529775-08-3 | Natural Products |
| HY-133221 | Abiesadine N | 1159913-80-0 | Natural Products |
| HY-133222 | STX140 | 401600-86-0 | Reference compound |
| HY-133223 | Hispidanin B | 1616080-84-2 | Natural Products |
| HY-133224 | Caesalpine B | 1616757-60-8 | Natural Products |
| HY-133225 | Caesalpine A | 1616757-59-5 | Natural Products |
| HY-133226 | Erythrinin F | 1616592-60-9 | Natural Products |
| HY-133227 | Erythrinin D | 1616592-59-6 | Natural Products |
| HY-133228 | Erythrinin G | 1616592-61-0 | Natural Products |
| HY-133229 | Propargyl-PEG4-alcohol | 87450-10-0 | Reference compound |
| HY-13323 | CX-5461 | 1138549-36-6 | Reference compound |
| HY-133230 | Propargyl-PEG10-amine | 2112737-25-2 | Reference compound |
| HY-133231 | Bis-PEG10-acid | 2055023-26-0 | Reference compound |
| HY-133232 | Sonnerphenolic B | 1627516-10-2 | Natural Products |
| HY-133233 | Thioetheramide-PC | 116457-99-9 | Reference compound |
| HY-133235 | Baccatin IX | 1623410-12-7 | Natural Products |
| HY-133236 | Baccatin VIII | 1623410-10-5 | Natural Products |
| HY-133237 | Anemarrhenasaponin III | 163047-23-2 | Natural Products |
| HY-13323A | CX-5461 (dihydrochloride) | | Reference compound |
| HY-13323R | CX-5461 (Standard) | 1138549-36-6 | Reference Standards |
| HY-13324 | Bardoxolone methyl | 218600-53-4 | Reference compound |
| HY-133246 | Monodes(N-carboxymethyl)valine Daclatasvir | 1007884-60-7 | Reference compound |
| HY-133246A | Monodes(N-carboxymethyl)valine Daclatasvir (TFA) | | Reference compound |
| HY-133247 | Daclatasvir Impurity B | 2226541-13-3 | Reference compound |
| HY-133248 | Daclatasvir Impurity C | 1256385-55-3 | Reference compound |
| HY-13325 | Aβ42-IN-6 | 71939-12-3 | Reference compound |
| HY-13326 | ASP3026 | 1097917-15-1 | Reference compound |
| HY-133269 | m-PEG11-SH | | Reference compound |
| HY-13327 | Evacetrapib | 1186486-62-3 | Reference compound |
| HY-133270 | m-PEG10-SH | 651042-85-2 | Reference compound |
| HY-133271 | m-PEG4-SH | 52190-55-3 | Reference compound |
| HY-133272 | m-PEG5-SH | 524030-00-0 | Reference compound |
| HY-133273 | m-PEG3-SH | 31521-83-2 | Reference compound |
| HY-133274 | m-PEG16-SH | 874820-38-9 | Reference compound |
| HY-133275 | m-PEG24-SH | | Reference compound |
| HY-133276 | m-PEG7-Br | 104518-25-4 | Reference compound |
| HY-133277 | m-PEG2-Br,98%(stabilized with Na2CO3) | 54149-17-6 | Reference compound |
| HY-133278 | m-PEG10-Br | | Reference compound |
| HY-133279 | m-PEG11-Br | 1258596-39-2 | Reference compound |
| HY-13328 | Sapanisertib | 1224844-38-5 | Reference compound |
| HY-133280 | m-PEG9-SH | 651042-84-1 | Reference compound |
| HY-133281 | m-PEG16-Br | 1238189-11-1 | Reference compound |
| HY-133282 | m-PEG24-Br | | Reference compound |
| HY-133283 | m-PEG36-Br | | Reference compound |
| HY-133284 | m-PEG48-Br | | Reference compound |
| HY-133285 | m-PEG10-CH2COOH | 908258-58-2 | Reference compound |
| HY-133286 | m-PEG9-CH2COOH | 405518-55-0 | Reference compound |
| HY-133287 | m-PEG36-OH | | Reference compound |
| HY-133288 | m-PEG16-NH2 | 907577-50-8 | Reference compound |
| HY-133289 | m-PEG48-OH | | Reference compound |
| HY-13329 | IRAK-1-4 Inhibitor I | 509093-47-4 | Reference compound |
| HY-133290 | Thiol-PEG5-acid | 1449390-67-3 | Reference compound |
| HY-133291 | Thiol-PEG6-acid | 1347750-77-9 | Reference compound |
| HY-133292 | Thiol-PEG4-alcohol | 90952-27-5 | Reference compound |
| HY-133293 | Thiol-PEG5-alcohol | 248582-03-8 | Reference compound |
| HY-133294 | Thiol-PEG8-alcohol | 791620-96-7 | Reference compound |
| HY-133295 | Thiol-PEG10-alcohol | | Reference compound |
| HY-133296 | Thiol-PEG9-alcohol | | Reference compound |
| HY-133297 | Thiol-PEG12-alcohol | | Reference compound |
| HY-133298 | Amino-PEG14-alcohol | 34214-89-6 | Reference compound |
| HY-133299 | Br-PEG7-Br | 177987-04-1 | Reference compound |
| HY-13330 | Fexagratinib | 1035270-39-3 | Reference compound |
| HY-133300 | HO-PEG22-OH | | Reference compound |
| HY-133301 | HO-PEG8-CH2COOH | 780006-30-6 | Reference compound |
| HY-133302 | HO-PEG6-CH2COOH | 120394-66-3 | Reference compound |
| HY-133303 | HO-PEG12-CH2COOH | | Reference compound |
| HY-133304 | HO-PEG10-CH2COOH | 2250056-53-0 | Reference compound |
| HY-133305 | HO-PEG24-CH2COOH | | Reference compound |
| HY-133306 | Hydroxy-PEG12-acid | | Reference compound |
| HY-133307 | Hydroxy-PEG10-acid | 2375611-66-6 | ADC Related |
| HY-133308 | Hydroxy-PEG16-acid | | Reference compound |
| HY-133309 | HO-PEG24-CH2CH2COOH | | Reference compound |
| HY-13330R | Fexagratinib (Standard) | 1035270-39-3 | Reference Standards |
| HY-13331 | Clascoterone | 19608-29-8 | Reference compound |
| HY-133310 | Hydroxy-PEG7-CH2-Boc | 2378049-28-4 | Reference compound |
| HY-133311 | Hydroxy-PEG8-CH2-Boc | 2869101-36-8 | Reference compound |
| HY-133312 | Hydroxy-PEG10-CH2-Boc | | Reference compound |
| HY-133313 | Hydroxy-PEG12-CH2-Boc | | Reference compound |
| HY-133314 | Hydroxy-PEG24-CH2-Boc | | Reference compound |
| HY-133315 | HO-PEG1-benzyl ester | | Reference compound |
| HY-133316 | HO-PEG4-benzyl ester | | Reference compound |
| HY-133317 | Azido-PEG11-acid | | Reference compound |
| HY-133318 | Azido-PEG16-acid | | Reference compound |
| HY-133319 | Azido-PEG24-Boc | | Reference compound |
| HY-13331S1 | Clascoterone-d6 | | Isotope-Labeled Compounds |
| HY-13331S2 | Clascoterone-d5-1 | | Isotope-Labeled Compounds |
| HY-13332 | Calcifediol-d6 | 78782-98-6 | Isotope-Labeled Compounds |
| HY-133320 | N3-PEG16-Hydrazide | | Reference compound |
| HY-133321 | N3-PEG24-Hydrazide | | Reference compound |
| HY-133322 | m-PEG21-acid | | Reference compound |
| HY-133323 | m-PEG24-acid | 2248203-61-2 | Reference compound |
| HY-133324 | m-PEG37-acid | 2924199-92-6 | Reference compound |
| HY-133325 | m-PEG49-acid | | Reference compound |
| HY-133326 | m-PEG16-Mal | | Reference compound |
| HY-133327 | Amino-PEG12-amine | 361543-12-6 | Reference compound |
| HY-133328 | Amino-PEG13-amine | 1228119-65-0 | Reference compound |
| HY-133329 | Amino-PEG15-amine | | Reference compound |
| HY-13333 | NVP-BAG956 | 853910-02-8 | Reference compound |
| HY-133330 | Amino-PEG27-amine | 2252208-09-4 | Reference compound |
| HY-133332 | Amino-PEG11-CH2COOH | | Reference compound |
| HY-133333 | Amino-PEG12-CH2COOH | | Reference compound |
| HY-133334 | Amino-PEG7-acid | 2376111-92-9 | Reference compound |
| HY-133335 | Amino-PEG10-CH2-Boc | | Reference compound |
| HY-133336 | Amino-PEG12-CH2-Boc | | Reference compound |
| HY-133337 | Amino-PEG24-CH2-Boc | | Reference compound |
| HY-133338 | Amino-PEG36-CH2-Boc | | Reference compound |
| HY-133339 | H2N-PEG4-Hydrazide | 1425973-15-4 | Reference compound |
| HY-13334 | BGT226 (maleate) | 1245537-68-1 | Reference compound |
| HY-133340 | H2N-PEG5-Hydrazide | | Reference compound |
| HY-133341 | H2N-PEG6-Hydrazide | | Reference compound |
| HY-133342 | H2N-PEG8-Hydrazide | | Reference compound |
| HY-133343 | H2N-PEG12-Hydrazide | | Reference compound |
| HY-133344 | m-PEG3-Hydrazide | 1442104-10-0 | Reference compound |
| HY-133345 | m-PEG7-Hydrazide | | Reference compound |
| HY-133346 | m-PEG9-Hydrazide | | Reference compound |
| HY-133347 | m-PEG11-Hydrazide | | Reference compound |
| HY-133348 | m-PEG12-Hydrazide | | Reference compound |
| HY-133349 | m-PEG13-Hydrazide | | Reference compound |
| HY-13334A | BGT226 | 915020-55-2 | Reference compound |
| HY-13335 | PKCβ inhibitor 1 | 257879-35-9 | Reference compound |
| HY-133350 | m-PEG17-Hydrazide | | Reference compound |
| HY-133351 | m-PEG25-Hydrazide | | Reference compound |
| HY-133352 | Mal-PEG5-mal | 113387-03-4 | Reference compound |
| HY-133353 | Mal-PEG6-mal | | Reference compound |
| HY-133354 | Mal-PEG11-mal | | Reference compound |
| HY-133355 | Boc-NH-PEG12-NH2 | 1642551-09-4 | Reference compound |
| HY-133356 | Boc-NH-PEG15-azide | | Reference compound |
| HY-133357 | Cbz-NH-PEG10-CH2COOH | | Reference compound |
| HY-133358 | Cbz-NH-PEG12-C2-acid | 1334177-88-6 | Reference compound |
| HY-133359 | Cbz-NH-PEG24-C2-acid | | Reference compound |
| HY-13336 | Imisopasem manganese | 218791-21-0 | Reference compound |
| HY-133360 | Cbz-NH-PEG36-C2-acid | | Reference compound |
| HY-133361 | Fmoc-NH-PEG15-CH2CH2COOH | 2378590-46-4 | Reference compound |
| HY-133362 | Fmoc-NH-PEG16-CH2CH2COOH | | Reference compound |
| HY-133363 | Fmoc-NH-PEG19-CH2CH2COOH | | Reference compound |
| HY-133364 | Fmoc-NH-PEG25-CH2CH2COOH | 1257223-69-0 | Reference compound |
| HY-133365 | Fmoc-NH-PEG30-CH2CH2COOH | | Reference compound |
| HY-133366 | DBCO-NHCO-PEG2-amine | | Reference compound |
| HY-133367 | DBCO-NHCO-PEG6-amine | | Reference compound |
| HY-133368 | DBCO-NHCO-PEG12-amine | | Reference compound |
| HY-133369 | DBCO-NHCO-PEG3-acid | | Reference compound |
| HY-13337 | BMS-986094 | 1234490-83-5 | Reference compound |
| HY-133370 | DBCO-NHCO-PEG7-acid | | Reference compound |
| HY-133371 | DBCO-NHCO-C4-NHS ester | | Reference compound |
| HY-133372 | DBCO-NHCO-PEG2-maleimide | 2698339-31-8 | Reference compound |
| HY-133373 | DBCO-NHCO-PEG6-maleimide | | Reference compound |
| HY-133374 | DBCO-NHCO-PEG12-maleimide | | Reference compound |
| HY-133375 | DBCO-NHCO-PEG2-NHS ester | | Reference compound |
| HY-133376 | DBCO-NHCO-PEG12-biotin | 2621391-31-7 | Dye Reagents |
| HY-133377 | Biotin-PEG24-acid | | Reference compound |
| HY-133378 | Biotin-PEG24-NHS ester | | Reference compound |
| HY-133379 | Biotin-PEG12-Mal | | Reference compound |
| HY-13338 | Mabuterol | 56341-08-3 | Reference compound |
| HY-133380 | DSPE-PEG36-mal | | Reference compound |
| HY-133381 | DSPE-PEG36-DBCO | | Reference compound |
| HY-133382 | DSPE-PEG46-DBCO | | Reference compound |
| HY-133383 | DSPE-PEG46-Folate | | Reference compound |
| HY-133384 | SPDP-PEG5-acid | | Reference compound |
| HY-133385 | SPDP-PEG7-acid | | Reference compound |
| HY-133386 | SPDP-PEG9-acid | | Reference compound |
| HY-133387 | HS-C6-PEG9-acid | | Reference compound |
| HY-133388 | Boc-NH-C12-NH2 | 109792-60-1 | Reference compound |
| HY-133389 | Mal-PEG36-NHS ester | | Reference compound |
| HY-13338A | (S)-Mabuterol | 56707-25-6 | Reference compound |
| HY-13338S | Mabuterol-d9 | 1246819-58-8 | Isotope-Labeled Compounds |
| HY-13339 | Brofaromine | 63638-91-5 | Reference compound |
| HY-133390 | Azido-PEG1-azide | 24345-74-2 | Reference compound |
| HY-133391 | Azido-PEG3-azide | 101187-39-7 | Reference compound |
| HY-133392 | Azido-PEG5-azide | 356046-26-9 | Reference compound |
| HY-133393 | Azido-PEG6-azide | 1243536-56-2 | Reference compound |
| HY-133394 | Azido-PEG7-azide | 225523-86-4 | Reference compound |
| HY-133395 | Azido-PEG9-azide | 1171122-72-7 | Reference compound |
| HY-133396 | Azido-PEG11-azide | 1392284-57-9 | Reference compound |
| HY-133397 | Azido-PEG15-azide | | Reference compound |
| HY-133399 | Alkyne-PEG4-maleimide | 1609651-90-2 | Reference compound |
| HY-13340 | VU0152100 | 409351-28-6 | Reference compound |
| HY-133400 | endo-BCN-PEG3-mal | 2141976-33-0 | Reference compound |
| HY-133401 | endo-BCN-PEG3-NH2 | 1883512-27-3 | Reference compound |
| HY-133402 | BCN-exo-PEG3-NH2 | 1841134-72-2 | Reference compound |
| HY-133403A | Biotin-C1-PEG3-C3-amine (TFA) | 1334172-59-6 | Reference compound |
| HY-133404 | Fmoc-aminooxy-PFP ester | | Reference compound |
| HY-133405 | Boc-NH-O-C1-NHS ester | 80366-85-4 | Reference compound |
| HY-133406 | exo BCN-O-PNB | 1380006-72-3 | Reference compound |
| HY-133407 | β-Estradiol-6-one 6-(O-carboxymethyloxime) | 35048-47-6 | Reference compound |
| HY-133408 | 4-Methyl-4-(methyldisulfanyl)pentanoic acid | 796073-55-7 | ADC Related |
| HY-133409 | 4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid | 1537891-69-2 | ADC Related |
| HY-133410 | Mal-C2-cyclohexylcarboxyl-hydrazide (TFA) | 359436-59-2 | Reference compound |
| HY-133410A | Mal-C2-cyclohexylcarboxyl-hydrazide (hydrochloride) | 174422-72-1 | Reference compound |
| HY-133411A | NH2-O-C5-COOH (hydrobromide) | 448954-98-1 | Reference compound |
| HY-133412 | DBCO-NHCO-S-S-NHS ester | | ADC Related |
| HY-133413 | DBCO-CONH-S-S-NHS ester | 1435934-53-4 | ADC Related |
| HY-133424A | Trisulfo-Cy3-acid (disodium) | | Dye Reagents |
| HY-133425 | 2-Phthalimidehydroxy-acetic acid | 134724-87-1 | Reference compound |
| HY-133426 | Ald-Ph-amido-PEG4-propargyl | 1969299-27-1 | ADC Related |
| HY-133427 | Propargyl-PEG4-hydrazide | | ADC Related |
| HY-133428 | DBCO-PEG3-TCO | | ADC Related |
| HY-133429 | DBCO-PEG3-oxyamine | 2748394-67-2 | ADC Related |
| HY-13342AS | Apatinib-d8 (free base) | 2468771-43-7 | Isotope-Labeled Compounds |
| HY-13342S | Apatinib-d8 (hydrochloride) | 2468771-44-8 | Isotope-Labeled Compounds |
| HY-13343 | ZM 336372 | 208260-29-1 | Reference compound |
| HY-133430 | DBCO-PEG4-alkyne | 2741418-16-4 | ADC Related |
| HY-133431 | DBCO-PEG3-SS-NHS ester | | ADC Related |
| HY-133432 | DBCO-PEG4-SS-TCO | | ADC Related |
| HY-133433 | DBCO-PEG4-VA-PBD | 2241644-09-5 | ADC Related |
| HY-133434 | Aminoxyacetamide-PEG3-azide | 1379761-16-6 | ADC Related |
| HY-133435 | Aminooxy-amido-PEG4-propargyl | 2253965-03-4 | ADC Related |
| HY-133436 | Boc-aminooxy-amide-PEG4-propargyl | 2253965-01-2 | ADC Related |
| HY-133437 | BCN-PEG4-alkyne | | Reference compound |
| HY-133438 | BCN-PEG4-hydrazide | | Reference compound |
| HY-133439 | BCN-PEG4-NHS ester | | Reference compound |
| HY-13344 | PF-8380 | 1144035-53-9 | Reference compound |
| HY-13344A | PF-8380 (hydrochloride) | 2070015-01-7 | Reference compound |
| HY-133454 | Mal-PEG2-oxyamine | 1146245-73-9 | Reference compound |
| HY-133454A | Mal-PEG2-oxyamine (TFA) | | Isotope-Labeled Compounds |
| HY-133455 | Benzaldehyde-PEG4-azide | 1151451-77-2 | Reference compound |
| HY-133456 | Biotin-PEG2-aldehyde | | Reference compound |
| HY-133457 | Biotin-PEG2-C1-aldehyde | 2408505-11-1 | Reference compound |
| HY-133458 | Biotin-PEG3-amido-SS-amido-azide | 2866429-93-6 | Reference compound |
| HY-133459 | Mal-PEG1-Val-Cit-OH | | ADC Related |
| HY-133460 | Tetrazine-Ph-NHCO-PEG3-alcohol | | Reference compound |
| HY-133461 | Tetrazine-Ph-NHCO-PEG6-NH-Boc | | Reference compound |
| HY-133462 | Tetrazine-Ph-NHCO-PEG4-NH-Boc | | Reference compound |
| HY-133463 | Tetrazine-Ph-PEG5-Ph-tetrazine | | Reference compound |
| HY-133464 | Tetrazine-Ph-NHCO-PEG4-alkyne | | Reference compound |
| HY-133465 | Tetrazine-Ph-PEG4-Ph-aldehyde | | Reference compound |
| HY-133466 | Methyltetrazine-PEG4-SS-NHS ester | | ADC Related |
| HY-133467 | Methyltetrazine-PEG5-methyltetrazine | | Reference compound |
| HY-133468 | Methyltetrazine-PEG6-maleimide | | Reference compound |
| HY-133469 | Methyltetrazine-PEG8-N3 | | Reference compound |
| HY-133470 | Fmoc-NH-PEG4-alcohol | 868594-41-6 | Reference compound |
| HY-133471 | Fmoc-NH-PEG3-C2-NH2 | 906126-25-8 | Reference compound |
| HY-133472 | DBCO-NHCO-PEG3-Fmoc | | Reference compound |
| HY-133473 | S-acetyl-PEG6-Tos | 1818294-25-5 | Reference compound |
| HY-133474 | TCO-PEG3-oxyamine | | Reference compound |
| HY-133475 | TCO-PEG5-maleimide | | Reference compound |
| HY-133476 | TCO-PEG3-alcohol | 1955497-82-1 | Reference compound |
| HY-133477 | (S)-TCO-PEG3-maleimide | | Reference compound |
| HY-133478 | TCO-PEG11-TCO | | Reference compound |
| HY-133479 | Tetrazine-Ph-NHCO-C3-NHS ester | 1244040-64-9 | Reference compound |
| HY-133480 | Bromoacetyl-PEG3-DBCO | | Reference compound |
| HY-133481 | Iodo-PEG12-acid | | Reference compound |
| HY-133482 | Iodo-PEG12-NHS ester | | Reference compound |
| HY-133484 | Thalidomide-PEG2-NH2 | 1957235-94-7 | Reference compound |
| HY-133484B | Thalidomide-PEG2-NH2 (hydrochloride) | 2891597-17-2 | Reference compound |
| HY-133485 | Thalidomide-4-O-C8-NH2 | 1957235-91-4 | Reference compound |
| HY-133485B | Thalidomide-4-O-C8-NH2 (hydrochloride) | 2636798-38-2 | Reference compound |
| HY-133486 | GABAA receptor agent 1 | 1571-87-5 | Reference compound |
| HY-133487 | (S,R,S)-AHPC-C8-NH2 (dihydrochloride) | 2341796-80-1 | Reference compound |
| HY-133487A | (S,R,S)-AHPC-C8-NH2 (hydrochloride) | 2376139-49-8 | Reference compound |
| HY-133487B | (S,R,S)-AHPC-C8-NH2 | 2341796-79-8 | Reference compound |
| HY-133490A | ST1074 | 1402703-29-0 | Reference compound |
| HY-133492 | DBCO-PEG4-MMAF | 2360411-65-8 | ADC Related |
| HY-133493 | Folate-PEG3-NHS ester | | Reference compound |
| HY-133494 | Folate-PEG1-mal | 2743004-48-8 | Reference compound |
| HY-133495 | Folate-PEG2-amine | 1099829-15-8 | Reference compound |
| HY-133496 | Folate-PEG3-alkyne | 1245285-73-7 | Reference compound |
| HY-133497 | HyNic-PEG2-TCO | | Reference compound |
| HY-133498 | HyNic-PEG2-DBCO | 2741281-12-7 | Reference compound |
| HY-133499 | Boc-HyNic-PEG1-mal | 2743657-82-9 | Reference compound |
| HY-133500 | Boc-HyNic-PEG2-alkyne | | Reference compound |
| HY-133501 | Boc-HyNic-PEG2-N3 | | Reference compound |
| HY-133502 | Boc-HyNic-PEG2-DBCO | | Reference compound |
| HY-133503 | Mal-amide-PEG2-oxyamine-Boc | 2253965-15-8 | Reference compound |
| HY-133504 | Tetrazine-Ph-SS-amine | | ADC Related |
| HY-133505 | Me-Tet-PEG4-NH2 (hydrochloride) | 2656478-51-0 | Reference compound |
| HY-133506 | Bromoacetamide-PEG3-C1-acid | 173323-22-3 | Reference compound |
| HY-133507 | Mal-amide-PEG2-oxyamine | 2253965-09-0 | Reference compound |
| HY-133508 | Methyltetrazine-PEG4-SSPy | | Reference compound |
| HY-133509 | DBCO-C2-SulfoNHS ester | 1803279-86-8 | Reference compound |
| HY-133510 | Bis-BCN-PEG1-diamide | | Reference compound |
| HY-133511 | MLS000544460 | 352336-36-8 | Reference compound |
| HY-133512 | NCGC00249987 | 1384864-80-5 | Reference compound |
| HY-133513 | (±)-H3RESCA-TFP | 1919794-40-3 | Reference compound |
| HY-133527 | OG 488, SE | 198139-51-4 | Dye Reagents |
| HY-133528 | OptoBI-1 | 2415272-11-4 | Reference compound |
| HY-133529 | PA-8 | 878437-15-1 | Reference compound |
| HY-133530 | PDD00017238 | 1952247-05-0 | Reference compound |
| HY-133531 | PDD00017272 | 1945950-20-8 | Reference compound |
| HY-133532 | PB succiniMidyl ester | 215868-33-0 | Dye Reagents |
| HY-133533 | O-2050 | 1883545-42-3 | Reference compound |
| HY-133534 | PA-Nic (TFA) | | Reference compound |
| HY-133535 | PA Janelia Fluor® 646, SE | 2093120-32-0 | Dye Reagents |
| HY-133536 | PA Janelia Fluor® 549, SE | 1811539-42-0 | Dye Reagents |
| HY-133537 | Hygrolidin | 83329-73-1 | Natural Products |
| HY-133538 | 4-Succinimidyl-oxycarbonyl-α-(2-pyridyldithio)toluene | 160854-54-6 | ADC Related |
| HY-133539 | Propargyl-C8-amido-PEG2-NHS ester | 1006592-59-1 | ADC Related |
| HY-133540 | Maleimide-DOTA | 1006711-90-5 | ADC Related |
| HY-133540G | Maleimide-DOTA (GMP) | 1006711-90-5 | GMP Small Molecules |
| HY-133541 | Glucopiericidin A | 108073-65-0 | Natural Products |
| HY-133542 | Dimethylamine-SPDB | 1193111-73-7 | ADC Related |
| HY-133543 | SPDP-sulfo | 121115-30-8 | ADC Related |
| HY-133544 | Mal-CO-PEG5-NHS ester | 1232769-29-7 | ADC Related |
| HY-133545 | Mal-Ph-CONH-PEG4-NHS ester | 1263044-88-7 | ADC Related |
| HY-133546 | Ald-Ph-amido-PEG11-C2-NH2 | 1337889-01-6 | ADC Related |
| HY-133547 | NO2-SPP-sulfo | 663598-66-1 | ADC Related |
| HY-133548 | NO2-SPDB-sulfo | 663598-89-8 | ADC Related |
| HY-133549 | NO2-SPDMV-sulfo | 663599-00-6 | ADC Related |
| HY-133550 | DMAC-SPDB | 663599-05-1 | ADC Related |
| HY-133551 | WF-47-JS03 | 2561413-77-0 | Reference compound |
| HY-133552 | RORγt Inverse agonist 10 | 2413986-35-1 | Reference compound |
| HY-133553 | RET-IN-3 | 2414374-53-9 | Reference compound |
| HY-133554 | ASK1-IN-1 | 2411382-24-4 | Reference compound |
| HY-133555 | mGluR2 antagonist 1 | 1432728-49-8 | Reference compound |
| HY-133556 | IQZ23 | 2415643-79-5 | Reference compound |
| HY-133557 | XZ739 | 2365172-19-4 | Reference compound |
| HY-133558 | VII-31 | 2305757-96-2 | Reference compound |
| HY-133569 | ARN23765 | 2244458-40-8 | Reference compound |
| HY-133570 | 17-AEP-GA | 75747-23-8 | ADC Related |
| HY-133571 | Aminohexylgeldanamycin | 485395-71-9 | ADC Related |
| HY-133571A | Aminohexylgeldanamycin (hydrochloride) | 1146534-45-3 | ADC Related |
| HY-133572 | Ald-Ph-amido-PEG11-NH-Boc | 1245813-70-0 | ADC Related |
| HY-133573 | Cyclooctyne-O-amido-PEG2-PFP ester | 2101206-61-3 | ADC Related |
| HY-133574 | Mal-amido-PEG3-C1-PFP ester | 2101206-13-5 | ADC Related |
| HY-133575 | Cyclooctyne-O-amido-PEG3-PFP ester | 2101206-33-9 | ADC Related |
| HY-133576 | Cyclooctyne-O-amido-PEG4-PFP ester | | ADC Related |
| HY-133579 | Ald-Ph-amido-PEG3-NHS ester | 2101206-32-8 | ADC Related |
| HY-133581 | Mal-PEG3-C1-NHS ester | 2230016-26-7 | ADC Related |
| HY-133582 | Mal-amido-PEG3-C1-NHS ester | 2101206-45-3 | ADC Related |
| HY-133583 | Propargyl-O-C1-amido-PEG3-C2-NHS ester | 2101206-78-2 | ADC Related |
| HY-133584 | Bis-SS-C3-NHS ester | 98604-88-7 | ADC Related |
| HY-133585 | Bis-SS-C3-sulfo-NHS ester | 98604-89-8 | ADC Related |
| HY-133587 | 1,1,1,3,10,11-Hexachloroundecane | 601523-28-8 | Reference compound |
| HY-133588 | 4-Formylaminoantipyrine | 1672-58-8 | Reference compound |
| HY-133588R | 4-Formylaminoantipyrine (Standard) | 1672-58-8 | Reference Standards |
| HY-133588S | 4-Formylaminoantipyrine-d3 | | Isotope-Labeled Compounds |
| HY-133589 | Fulvine | 6029-87-4 | Reference compound |
| HY-133590 | Heliotrine N-oxide | 6209-65-0 | Reference compound |
| HY-133591 | Senecivernine | 72755-25-0 | Natural Products |
| HY-133592 | Neoabietic acid | 471-77-2 | Reference compound |
| HY-133592R | Neoabietic acid (Standard) | 471-77-2 | Reference Standards |
| HY-133593 | Palustric acid | 1945-53-5 | Natural Products |
| HY-133593R | Palustric acid (Standard) | 1945-53-5 | Reference Standards |
| HY-133594 | Sandaracopimaric acid | 471-74-9 | Natural Products |
| HY-133596 | 12,14-Dichlorodehydroabietic acid | 65281-77-8 | Reference compound |
| HY-133597 | 4-Chlorocatechol | 2138-22-9 | Reference compound |
| HY-133598 | 3,4,5-Trichlorocatechol | 56961-20-7 | Reference compound |
| HY-133599 | 4,5-Dichloroguaiacol | 2460-49-3 | Reference compound |
| HY-133600 | 4,5,6-Trichloroguaiacol | 2668-24-8 | Reference compound |
| HY-133601 | 3,4,5-Trichloroguaiacol | 57057-83-7 | Reference compound |
| HY-133602 | Tetrachloroguaiacol | 2539-17-5 | Reference compound |
| HY-133603 | 4,5-Dichloroveratrole | 2772-46-5 | Reference compound |
| HY-133604 | 3,4,5-Trichloroveratrole | 16766-29-3 | Reference compound |
| HY-133605 | Tetrachloroveratrole | 944-61-6 | Reference compound |
| HY-133606 | 3,4,5-Trichlorosyringol | 2539-26-6 | Reference compound |
| HY-133607 | 5,6-Dichlorovanillin | 18268-69-4 | Reference compound |
| HY-133608 | 4,6-Dichloroguaiacol | 16766-31-7 | Reference compound |
| HY-133609 | 3,5-Dichlorocatechol | 13673-92-2 | Reference compound |
| HY-133610 | 3,4,6-Trichlorocatechol | 32139-72-3 | Reference compound |
| HY-133611 | 3,4-Dichlorocatechol | 3978-67-4 | Reference compound |
| HY-133612 | 3,6-Dichlorocatechol | 3938-16-7 | Reference compound |
| HY-133614 | Dihydroisopimaric acid | 5673-36-9 | Reference compound |
| HY-133618 | Pomalidomide-C3-adavosertib | 2414418-49-6 | Reference compound |
| HY-133620 | 7-Oxodehydroabietic acid | 18684-55-4 | Reference compound |
| HY-133621 | 9,10-Dichlorostearic acid | 5829-48-1 | Reference compound |
| HY-133622 | 1,1-Dibromoacetone | 867-54-9 | Reference compound |
| HY-133623 | 1,1,1-Tribromoacetone | 3770-98-7 | Reference compound |
| HY-133624 | 1,1,3-Tribromoacetone | 3475-39-6 | Reference compound |
| HY-133624R | 1,1,3-Tribromoacetone (Standard) | 3475-39-6 | Reference Standards |
| HY-133625 | 1,1-Dibromo-3-chloroacetone | 1578-18-3 | Reference compound |
| HY-133626 | 1,1-Dibromo-3,3-dichloroacetone | 62874-83-3 | Reference compound |
| HY-133627 | 1,3-Dibromo-1,3-dichloroacetone | 62874-84-4 | Reference compound |
| HY-133628 | 1,1,3-Tribromo-3-chloroacetone | 55716-01-3 | Reference compound |
| HY-133629 | 1,1,1,3-Tetrachloroacetone | 16995-35-0 | Reference compound |
| HY-133630 | 1-Bromo-1,1-dichloroacetone | 1751-16-2 | Reference compound |
| HY-133631 | Chloronitromethane | 1794-84-9 | Reference compound |
| HY-133633 | Bromodichloronitromethane | 918-01-4 | Reference compound |
| HY-133634 | Dibromochloronitromethane | 1184-89-0 | Reference compound |
| HY-133635 | Tribromonitromethane | 464-10-8 | Reference compound |
| HY-133636 | Bromochloronitromethane | 135531-25-8 | Reference compound |
| HY-133641 | Dibromoiodomethane | 593-94-2 | Reference compound |
| HY-133642 | Dichloroiodomethane | 594-04-7 | Reference compound |
| HY-133643 | Bromodichloroacetonitrile | 60523-73-1 | Reference compound |
| HY-133644 | Tribromoacetonitrile | 75519-19-6 | Reference compound |
| HY-133646 | Bromochloroacetonitrile | 83463-62-1 | Reference compound |
| HY-133647 | Dibromoacetaldehyde | 3039-13-2 | Reference compound |
| HY-133649 | Dibromochloroacetaldehyde | 64316-11-6 | Reference compound |
| HY-133651 | 2,2-Dibromopropanoic acid | 594-48-9 | Reference compound |
| HY-133652 | 2,3-Dibromoacrylic acid | 24767-86-0 | Reference compound |
| HY-133653 | 3,3-Dibromopropenoic acid | 1578-21-8 | Reference compound |
| HY-133654 | 2,3,3-Tribromopropenoic acid | 71815-46-8 | Reference compound |
| HY-133655 | (E)-2,3-Dibromo-2-butenedioic acid | 608-38-8 | Reference compound |
| HY-133656 | (Z)-2-Bromo-3-methyl-2-butenedioic acid | 23366-89-4 | Reference compound |
| HY-133657 | Bromoiodoacetic acid | 71815-43-5 | Reference compound |
| HY-133658 | Chloroiodoacetic acid | 53715-09-6 | Reference compound |
| HY-133659 | Diiodoacetic acid | 598-89-0 | Reference compound |
| HY-133664 | Dibromochloroacetamide | 855878-13-6 | Reference compound |
| HY-133665 | 2,2-Dibromoacetamide | 598-70-9 | Reference compound |
| HY-133666 | Diiodoacetamide | 5875-23-0 | Reference compound |
| HY-133667 | Bromoiodoacetamide | 62872-36-0 | Reference compound |
| HY-133668 | Monoethyl phthalate | 2306-33-4 | Reference compound |
| HY-133668R | Monoethyl phthalate (Standard) | 2306-33-4 | Reference Standards |
| HY-133668S | Monoethyl phthalate-d4 | 1219806-03-7 | Isotope-Labeled Compounds |
| HY-133669 | DDR1-IN-5 | 2416022-90-5 | Reference compound |
| HY-133670 | DDR1-IN-6 | 2416021-47-9 | Reference compound |
| HY-133671S | Monooctyl phthalate-d4 | 1398065-74-1 | Isotope-Labeled Compounds |
| HY-133672 | (Rac)-Mono(3,5,5-trimethylhexyl) phthalate | 297182-83-3 | Reference compound |
| HY-133673S | Mono(3-carboxypropyl) phthalate-d4 | 1346600-69-8 | Isotope-Labeled Compounds |
| HY-133675 | Mono(5-carboxy-2-ethylpentyl) phthalate | 40809-41-4 | Reference compound |
| HY-133675S | Mono(5-carboxy-2-ethylpentyl) phthalate-d4 | 866864-06-4 | Isotope-Labeled Compounds |
| HY-133676S | Mono(2-ethyl-5-oxohexyl) phthalate-d4 | 679789-44-7 | Isotope-Labeled Compounds |
| HY-133677 | Mono(2-ethyl-5-hydroxyhexyl) phthalate | 40321-99-1 | Reference compound |
| HY-133677S | Mono(2-ethyl-5-hydroxyhexyl) phthalate-d4 | 679789-43-6 | Isotope-Labeled Compounds |
| HY-133680 | β-Tocopherol | 16698-35-4 | Natural Products |
| HY-133680R | β-Tocopherol (Standard) | 16698-35-4 | Reference Standards |
| HY-133680S | β-Tocopherol-d4 | 2241864-46-8 | Isotope-Labeled Compounds |
| HY-133681 | (±)-2,3-Dibromosuccinic acid | 1114-00-7 | Reference compound |
| HY-133681A | 2,3-Dibromosuccinic acid | 526-78-3 | Reference compound |
| HY-133683 | N-(3-Oxotetradecanoyl)-DL-homoserine lactone | 503610-29-5 | Natural Products |
| HY-133683R | N-(3-Oxotetradecanoyl)-DL-homoserine lactone (Standard) | 503610-29-5 | Reference Standards |
| HY-133684 | N-Tetradecanoyl-L-homoserine lactone | 202284-87-5 | Reference compound |
| HY-133684R | N-Tetradecanoyl-L-homoserine lactone (Standard) | 202284-87-5 | Reference Standards |
| HY-133685 | N-Hexanoyl-L-homoserine lactone | 147852-83-3 | Reference compound |
| HY-133685R | N-Hexanoyl-L-homoserine lactone (Standard) | 147852-83-3 | Reference Standards |
| HY-133685S | N-Hexanoyl-L-Homoserine lactone-d3 | 2705226-73-7 | Isotope-Labeled Compounds |
| HY-133689AS | 3-Nitrophenylhydrazine-13C6 (hydrochloride) | 1977535-33-3 | Isotope-Labeled Compounds |
| HY-133690 | D-myo-Inositol-1,3,4,5-tetraphosphate (sodium) | 210488-61-2 | Reference compound |
| HY-133694 | 2-Aminoflubendazole | 82050-13-3 | Reference compound |
| HY-133694R | 2-Aminoflubendazole (Standard) | 82050-13-3 | Reference Standards |
| HY-133694S | 2-Aminoflubendazole-13C6 | | Isotope-Labeled Compounds |
| HY-133695 | Florfenicol amine | 76639-93-5 | Reference compound |
| HY-133695R | Florfenicol amine (Standard) | 76639-93-5 | Reference Standards |
| HY-133695S | ent-Florfenicol Amine-d3 | 1217625-88-1 | Isotope-Labeled Compounds |
| HY-133699 | Pomalidomide-PEG4-COOH | 2138440-81-8 | Reference compound |
| HY-133702 | Aniline-piperazine-C3-NH-Boc | 643087-19-8 | Reference compound |
| HY-133704 | Pyrrolnitrin | 1018-71-9 | Reference compound |
| HY-133705 | Geldanamycin-FITC | 2969156-01-0 | Dye Reagents |
| HY-133706S | 2-Nitrobenzaldehyde semicarbazone-13C,15N2 | 760179-80-4 | Isotope-Labeled Compounds |
| HY-133707 | β-Muricholic acid | 2393-59-1 | Reference compound |
| HY-133707R | β-Muricholic acid (Standard) | 2393-59-1 | Reference Standards |
| HY-133707S | β-Muricholic acid-d5 | 2725726-62-3 | Isotope-Labeled Compounds |
| HY-133707S1 | β-Muricholic acid-d4 | | Isotope-Labeled Compounds |
| HY-133708 | β-Glucogallin | 13405-60-2 | Natural Products |
| HY-133709 | β-Aflatrem | 144446-23-1 | Natural Products |
| HY-133712 | Yonkenafil | 804518-63-6 | Reference compound |
| HY-133712S | Yonkenafil-d8 | | Isotope-Labeled Compounds |
| HY-133712S1 | Yonkenafil-d7 | | Isotope-Labeled Compounds |
| HY-133715 | Pilsicainide | 88069-67-4 | Reference compound |
| HY-133716 | Pantoprazole N-oxide | 953787-60-5 | Reference compound |
| HY-133717 | Naltriben | 111555-58-9 | Reference compound |
| HY-133718 | Acarviosin | 80943-41-5 | Reference compound |
| HY-133719 | Fenfuram | 24691-80-3 | Reference compound |
| HY-133720 | 4-Demethyltraxillaside | 1691201-82-7 | Natural Products |
| HY-133721 | Chamaechromone | 93413-00-4 | Natural Products |
| HY-133724 | Vardenafil N-oxide | 448184-48-3 | Reference compound |
| HY-133724R | Vardenafil N-oxide (Standard) | 448184-48-3 | Reference Standards |
| HY-133726 | Bixafen | 581809-46-3 | Reference compound |
| HY-133726R | Bixafen (Standard) | 581809-46-3 | Reference Standards |
| HY-133728 | Piribedil N-oxide | 53954-71-5 | Reference compound |
| HY-133732 | Alaproclate (hydrochloride) | 60719-83-7 | Reference compound |
| HY-133735 | GRP-60367 | 1309241-34-6 | Reference compound |
| HY-133735A | GRP-60367 (hydrochloride) | 2803211-60-9 | Reference compound |
| HY-133736 | PROTAC BRD4 Degrader-5-CO-PEG3-N3 | 2704602-92-4 | ADC Related |
| HY-133737 | PROTAC BRD4 Degrader-5 | 2409538-70-9 | Reference compound |
| HY-133738 | M-808 | 2377335-74-3 | Reference compound |
| HY-133739 | NBD-125 | 2367641-24-3 | Reference compound |
| HY-133740 | MS117 | 2702280-86-0 | Reference compound |
| HY-133747 | JAK3-IN-9 | 1430095-30-9 | Reference compound |
| HY-133754 | MI-1063 | 1410737-39-1 | Reference compound |
| HY-133760 | MI-888 | 1303607-59-1 | Reference compound |
| HY-133770 | Seco Rapamycin ethyl ester | | Reference compound |
| HY-133771AS | Nordoxepin-d3 (hydrochloride) | 1331665-54-3 | Isotope-Labeled Compounds |
| HY-133772 | Venetoclax N-oxide | 2469279-00-1 | Reference compound |
| HY-133773 | Desoxochlordiazepoxide | 4393-72-0 | Reference compound |
| HY-133774 | Trityl olmesartan medoxomil impurity III | 1227626-51-8 | Reference compound |
| HY-133775 | Olmesartan impurity | 154709-18-9 | Reference compound |
| HY-133776 | Rivastigmine carbamate impurity | 1346242-31-6 | Reference compound |
| HY-133777 | Ciprofibrate impurity A | 1474058-89-3 | Reference compound |
| HY-133778 | O-Desmethyl mycophenolic acid methyl ester | 33431-38-8 | Reference compound |
| HY-133779 | Gefitinib impurity 5 | 199327-61-2 | Reference compound |
| HY-133779R | Gefitinib impurity 5 (Standard) | 199327-61-2 | Reference Standards |
| HY-133780 | Afatinib impurity 11 | 1402086-20-7 | Reference compound |
| HY-133781 | cis-Clopidogrel-MP derivative | 1122047-98-6 | Reference compound |
| HY-133782 | Fluphenazine-N-2-chloroethane (hydrochloride) | 3892-78-2 | Reference compound |
| HY-133787 | Levofloxacin N-oxide | 117678-38-3 | Reference compound |
| HY-133787R | Levofloxacin N-oxide (Standard) | 117678-38-3 | Reference Standards |
| HY-133790 | Palonosetron N-oxide | 813425-83-1 | Reference compound |
| HY-133794 | Dasatinib N-oxide | 910297-52-8 | Reference compound |
| HY-133794R | Dasatinib N-oxide (Standard) | 910297-52-8 | Reference Standards |
| HY-133794S | Dasatinib N-oxide-d8 | 1189988-36-0 | Isotope-Labeled Compounds |
| HY-133795 | Lucanthone N-oxide | 5615-06-5 | Reference compound |
| HY-133797 | Cyclobenzaprine N-oxide | 6682-26-4 | Reference compound |
| HY-133797S | Cyclobenzaprine N-oxide-d3 | 1189877-07-3 | Isotope-Labeled Compounds |
| HY-133798 | Sorafenib N-oxide | 583840-03-3 | Reference compound |
| HY-133799 | Pomalidomide-C7-COOH | 2225940-51-0 | Reference compound |
| HY-133800 | Volvaltrate B | 1181224-13-4 | Natural Products |
| HY-133801 | Unguisin A | 226956-06-5 | Peptides |
| HY-133803 | Z-Ala-Ala-OH | 16012-70-7 | Reference compound |
| HY-133804 | Arteanoflavone | 68710-17-8 | Natural Products |
| HY-133807 | Benpyrine | 2550398-89-3 | Reference compound |
| HY-133807A | (Rac)-Benpyrine | 1333714-43-4 | Reference compound |
| HY-133807B | (R)-Benpyrine | 2637243-08-2 | Reference compound |
| HY-133813A | Apovincaminic acid (hydrochloride salt) | 72296-47-0 | Reference compound |
| HY-133813AR | Apovincaminic acid (hydrochloride salt) (Standard) | 72296-47-0 | Reference Standards |
| HY-133813S | Apovincaminic acid-d4 | | Isotope-Labeled Compounds |
| HY-133816 | Pomalidomide-amino-PEG5-NH2 (hydrochloride) | 2421217-05-0 | Reference compound |
| HY-133816A | Pomalidomide-amino-PEG5-NH2 | 2421217-04-9 | Reference compound |
| HY-133817 | Pomalidomide-amino-PEG3-NH2 (hydrochloride) | 2380273-75-4 | Reference compound |
| HY-133817A | Pomalidomide-amino-PEG3-NH2 | 2380273-74-3 | Reference compound |
| HY-133821 | N-Methylmesoporphyrin IX | 142234-85-3 | Dye Reagents |
| HY-133823 | 11-Hexadecenoic acid | 2271-34-3 | Natural Products |
| HY-133825 | Cyazofamid | 120116-88-3 | Reference compound |
| HY-133828 | Cinanserin | 1166-34-3 | Reference compound |
| HY-133829 | Zofenoprilat | 75176-37-3 | Reference compound |
| HY-133830 | 7α,24(S)-Dihydroxycholesterol | 245523-67-5 | Reference compound |
| HY-133832 | Elopiprazole | 115464-77-2 | Reference compound |
| HY-133838 | Ilmofosine | 83519-04-4 | Reference compound |
| HY-133839 | Kethoxal | 27762-78-3 | Reference compound |
| HY-133845 | CIL-102 | 479077-76-4 | Reference compound |
| HY-133846 | Iodothiouracil | 5984-97-4 | Reference compound |
| HY-133847 | LAPAO | 61792-31-2 | Reference compound |
| HY-133850 | 10-DEBC | 201788-90-1 | Reference compound |
| HY-133852 | FD-1080 | 1151666-58-8 | Dye Reagents |
| HY-133852A | FD-1080 (free acid) | 1151888-25-3 | Dye Reagents |
| HY-133854 | L 8412 | 50602-48-7 | Reference compound |
| HY-133858 | 25N-NBOMe (hydrochloride) | 1566571-65-0 | Reference compound |
| HY-133859 | M084 | 51314-51-3 | Reference compound |
| HY-133860 | Chrysoobtusin | 70588-06-6 | Natural Products |
| HY-133862 | SCH-202676 | 70375-43-8 | Reference compound |
| HY-133865 | Diacetoxy-6-gingerdiol | 143615-75-2 | Natural Products |
| HY-133869 | cGMP-HTL | | Reference compound |
| HY-133870 | Itaconate-alkyne | 2454181-83-8 | Reference compound |
| HY-133871 | trans-2-Hexadecenoyl-L-carnitine | 26145-55-1 | Reference compound |
| HY-133872 | [(3R)-3-Hydroxydodecanoyl]-L-carnitine | 1469900-99-9 | Reference compound |
| HY-133875 | CE3F4 analog 1 | 2141967-43-1 | Reference compound |
| HY-133876 | 4-Di-16-ASP | 114041-00-8 | Dye Reagents |
| HY-133878 | Octadeca-9,12-dienamide | 3072-13-7 | Reference compound |
| HY-133879 | Calcitriol lactone | 81203-50-1 | Reference compound |
| HY-133883 | Cyanine7.5 amine | 2104005-17-4 | Reference compound |
| HY-133884 | ICG-amine | 1686147-55-6 | Dye Reagents |
| HY-133885 | S-(-)-7-Desmethyl-8-nitro blebbistatin | 856925-75-2 | Reference compound |
| HY-133885A | R-(-)-7-Desmethyl-8-nitro blebbistatin | 1217619-62-9 | Reference compound |
| HY-133887 | Methotrexate α-tert-butyl ester | 79640-70-3 | Reference compound |
| HY-133890 | Tauro-α-muricholic acid | 25613-05-2 | Natural Products |
| HY-133890A | Tauro-α-muricholic acid (sodium) | 2260905-08-4 | Reference compound |
| HY-133890AS | Tauro-α-muricholic acid-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-133894 | Bofutrelvir | 2103278-86-8 | Reference compound |
| HY-133897 | (Rac)-Indoximod | 26988-72-7 | Reference compound |
| HY-133898 | Danavorexton | 2114324-48-8 | Reference compound |
| HY-133900 | Deoxyharringtonine | 36804-95-2 | Natural Products |
| HY-133902 | Neoglucobrassicin | 5187-84-8 | Natural Products |
| HY-133905 | Pandamine | 10233-81-5 | Natural Products |
| HY-133907 | NVS-PI3-4 | 941580-60-5 | Reference compound |
| HY-133910 | Lu AE98134 | 849000-18-6 | Reference compound |
| HY-133916 | G140 | 2369751-07-3 | Reference compound |
| HY-133924 | 18-Deoxyherboxidiene | 1200128-66-0 | Reference compound |
| HY-133925 | 6-O-Desmethyl donepezil | 120013-56-1 | Reference compound |
| HY-133925S | 6-O-Desmethyl donepezil-d5 | 1189443-74-0 | Isotope-Labeled Compounds |
| HY-133925S1 | 6-O-Desmethyl donepezil-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-133925S2 | 6-O-Desmethyl donepezil-d7 | 1261396-76-2 | Isotope-Labeled Compounds |
| HY-133926 | 5-O-Desmethyl donepezil | 120013-57-2 | Reference compound |
| HY-133926S | 5-O-Desmethyl donepezil-d5 | 1189929-21-2 | Isotope-Labeled Compounds |
| HY-133927 | (2E,6E)-3,7-Dimethyltrideca-2,6-dien-12-yn-1-ol | 2361137-98-4 | Reference compound |
| HY-133933 | Maleylsulfathiazole | 515-57-1 | Reference compound |
| HY-133935 | Benaxibine | 27661-27-4 | Reference compound |
| HY-133937 | Sulfametrole | 32909-92-5 | Reference compound |
| HY-133948 | 1-Monopalmitolein | 37515-61-0 | Biochemical Assay Reagents |
| HY-133949 | 8,11-Eicosadiynoic acid | 82073-91-4 | Reference compound |
| HY-133950 | N-Monoacetylcystine | 25779-79-7 | Reference compound |
| HY-133951 | 4',6,7-Trimethoxyisoflavone | 798-61-8 | Natural Products |
| HY-133952 | 7-Oxotridecanedioic acid | 101171-43-1 | Biochemical Assay Reagents |
| HY-133953 | 9-Oxoheptadecanedioic acid | 1502-36-9 | Reference compound |
| HY-133954 | 19-Heptatriacontanol | 872307-34-1 | Reference compound |
| HY-133956 | 3-ATA | 129821-08-5 | Reference compound |
| HY-133957 | Fluoromevalonate | 2822-77-7 | Biochemical Assay Reagents |
| HY-133961 | Cholesterol β-D-glucoside | 7073-61-2 | Reference compound |
| HY-133962 | Cholesteryl erucate | 24516-39-0 | Biochemical Assay Reagents |
| HY-133963 | Cholesteryl lignocerate | 73024-96-1 | Natural Products |
| HY-133965 | Cinchonain IIa | 85081-23-8 | Natural Products |
| HY-133966 | 6α-Hydroxy-5α-cholestane | 41083-73-2 | Reference compound |
| HY-133966S | 6α-Hydroxy-5α-cholestane-d7 | 1246302-83-9 | Isotope-Labeled Compounds |
| HY-133967 | (25R)-26-Hydroxycholest-4-en-3-one | 56792-59-7 | Reference compound |
| HY-133968 | 24-Methylenecholesterol | 474-63-5 | Natural Products |
| HY-133968R | 24-Methylenecholesterol (Standard) | 474-63-5 | Reference Standards |
| HY-133968S1 | 24-Methylenecholesterol-13C | | Isotope-Labeled Compounds |
| HY-133969 | 5β-Cholane | 80373-86-0 | Reference compound |
| HY-133970 | 5α-Cholestane | 481-21-0 | Biochemical Assay Reagents |
| HY-133970R | 5α-Cholestane (Standard) | 481-21-0 | Reference Standards |
| HY-133970S | 5α-Cholestane-d6 | 358731-18-7 | Isotope-Labeled Compounds |
| HY-133970S1 | 5α-Cholestane-d2 | 122241-86-5 | Isotope-Labeled Compounds |
| HY-133971 | Cholesterol 5α,6α-epoxide | 1250-95-9 | Biochemical Assay Reagents |
| HY-133971S | Cholesterol-5α,6α-epoxide-d7 | 127685-38-5 | Isotope-Labeled Compounds |
| HY-133972 | 3β-Hydroxy-5-cholestenoic acid | 6561-58-6 | Biochemical Assay Reagents |
| HY-133972S | 3β-Hydroxy-5-cholestenoic acid-d5 | 1620239-03-3 | Isotope-Labeled Compounds |
| HY-133974 | 7-keto-25-Hydroxycholesterol | 64907-23-9 | Reference compound |
| HY-133975 | Isoleucylcysteine | 117525-90-3 | Reference compound |
| HY-133976 | Aceclofenac methyl ester | 139272-66-5 | Reference compound |
| HY-133980 | O-Demethyl Lenvatinib | 417717-04-5 | Reference compound |
| HY-133980A | O-Demethyl Lenvatinib (hydrochloride) | | Reference compound |
| HY-133980AR | O-Demethyl Lenvatinib (hydrochloride) (Standard) | | Reference Standards |
| HY-133984 | (7Z)-7-Tricosene | 52078-42-9 | Natural Products |
| HY-133985 | 7(Z)-Pentacosene | 63623-49-4 | Natural Products |
| HY-133986 | 6-Methylchrysene | 1705-85-7 | Reference compound |
| HY-133987 | AP-1/NF-κB activation inhibitor 1 | 188936-12-1 | Reference compound |
| HY-133991 | Desethyl sildenafil | 139755-91-2 | Reference compound |
| HY-133994 | Octakis-(6-bromo-6-deoxy)-γ-cyclodextrin | 53784-84-2 | Reference compound |
| HY-133998 | SIRT-IN-3 | 1211-19-4 | Reference compound |
| HY-134000 | Emodic acid | 478-45-5 | Natural Products |
| HY-134001 | CBR-470-2 | 2416095-00-4 | Reference compound |
| HY-134004 | Pentoxyverine | 77-23-6 | Reference compound |
| HY-134004R | Pentoxyverine (Standard) | 77-23-6 | Reference Standards |
| HY-134005 | ISIS 416858 | 1223657-78-0 | Oligonucleotides |
| HY-134006 | Stemoninine | 69772-72-1 | Natural Products |
| HY-134008 | Protoapigenone | 862884-32-0 | Natural Products |
| HY-134009 | (+)-Cloprostenol methyl ester | 56687-85-5 | Reference compound |
| HY-13401 | Sovaprevir | 1001667-23-7 | Reference compound |
| HY-134013 | Piperitenone oxide | 3564-96-3 | Reference compound |
| HY-134017 | Acetyl dipeptide-1 cetyl ester | 196604-48-5 | Peptides |
| HY-134019 | Arachidonoyl p-nitroaniline | 119520-58-0 | Reference compound |
| HY-13402 | Varespladib | 172732-68-2 | Reference compound |
| HY-134021 | Prednisolone valerate acetate | 72064-79-0 | Reference compound |
| HY-13402A | Varespladib (sodium) | 172733-42-5 | Reference compound |
| HY-134031 | Ara-ATP | 3714-60-1 | Reference compound |
| HY-134036 | α-Obscurine | 596-55-4 | Natural Products |
| HY-134038 | Cannabinol methyl ether | 41935-92-6 | Reference compound |
| HY-134039 | 5-Hydroxy-8-methoxypsoralen | 7471-73-0 | Natural Products |
| HY-13404 | Capmatinib | 1029712-80-8 | Reference compound |
| HY-134041 | Phloroglucide | 491-45-2 | Natural Products |
| HY-134043 | Chlorthalidone Impurity G | 16289-13-7 | Reference compound |
| HY-134046 | (-)-Isodocarpin | 10391-08-9 | Natural Products |
| HY-134048 | Erucoylcarnitine | 51267-35-7 | Reference compound |
| HY-13404A | Capmatinib (dihydrochloride) | 1197376-85-4 | Reference compound |
| HY-13404B | Capmatinib (hydrochloride) | 1029714-89-3 | Reference compound |
| HY-13404C | Capmatinib (dihydrochloride hydrate) | 1865733-40-9 | Reference compound |
| HY-13404R | Capmatinib (Standard) | 1029712-80-8 | Reference Standards |
| HY-13405 | Tiaramide (hydrochloride) | 35941-71-0 | Reference compound |
| HY-134050 | Apostatin-1 | 2559703-06-7 | Reference compound |
| HY-134052 | Biliverdin dimethyl ester | 10035-62-8 | Biochemical Assay Reagents |
| HY-134054 | N-Acetylstepharine | 4880-87-9 | Natural Products |
| HY-134055 | Arachidonoyl-N,N-dimethyl amide | 45280-17-9 | Reference compound |
| HY-134056 | cis-13,16-Docosadienoic acid methyl ester | 61012-47-3 | Biochemical Assay Reagents |
| HY-13406 | TAK-779 | 229005-80-5 | Reference compound |
| HY-134061 | Arecaidine propargyl ester (hydrobromide) | 116511-28-5 | Reference compound |
| HY-134062 | 7-Methyl-6-mercaptopurine | 3324-79-6 | Reference compound |
| HY-134068 | Methyl 17-hydroxyheptadecanoate | 94036-00-7 | Natural Products |
| HY-13407 | Gossypol | 303-45-7 | Natural Products |
| HY-134070 | 2-O-Methyl PAF C-16 | 78858-44-3 | Reference compound |
| HY-13407R | Gossypol (Standard) | 303-45-7 | Reference Standards |
| HY-13407S | Gossypol-13C2 | | Isotope-Labeled Compounds |
| HY-13408 | (+)-Apogossypol | 66389-74-0 | Reference compound |
| HY-134080 | 1-O-Hexadecyl-2-O-methylglycerol | 84337-41-7 | Biochemical Assay Reagents |
| HY-134082A | (Z)-Oleyloxyethyl phosphorylcholine | 84601-19-4 | Reference compound |
| HY-134086 | NSD-IN-2 | 2351225-46-0 | Reference compound |
| HY-13409 | SB 242084 | 181632-25-7 | Reference compound |
| HY-134090 | 9-Methylstreptimidone | 51867-94-8 | Reference compound |
| HY-134092 | N-Methyl Leukotriene C4 | 131391-65-6 | Reference compound |
| HY-134094 | Fluridone | 59756-60-4 | Reference compound |
| HY-134094R | Fluridone (Standard) | 59756-60-4 | Reference Standards |
| HY-134095 | Erythromycin A N-oxide | 992-65-4 | Reference compound |
| HY-134098 | Diisopropyl adipate | 6938-94-9 | Reference compound |
| HY-134098R | Diisopropyl adipate (Standard) | 6938-94-9 | Reference Standards |
| HY-13409A | SB 242084 (dihydrochloride) | 1049747-87-6 | Reference compound |
| HY-13409B | SB 242084 (monohydrochloride) | 1260505-34-7 | Reference compound |
| HY-13410 | Xanomeline (oxalate) | 141064-23-5 | Reference compound |
| HY-134101 | 2-O-Ethyl PAF C-16 | 78858-42-1 | Reference compound |
| HY-134103A | ddGTP (trisodium) | | Oligonucleotides |
| HY-134104 | C20-Sphingosine | 6918-49-6 | Natural Products |
| HY-134106 | N-Boc-erythro-sphingosine | 116467-63-1 | Reference compound |
| HY-134107 | Azido-erythro-sphingosine | 103348-49-8 | Reference compound |
| HY-134108 | (3E,13Z)-Octadecadien-1-ol | 66410-28-4 | Natural Products |
| HY-134110 | N-Methylarachidonamide | 156910-29-1 | Reference compound |
| HY-134113 | Z-Gly-Pro-Arg-pNA | 66648-35-9 | Peptides |
| HY-134115 | Flumethasone 21-acetate | 2823-42-9 | Reference compound |
| HY-134116 | Isoflupredone acetate | 338-98-7 | Reference compound |
| HY-134116R | Isoflupredone acetate (Standard) | 338-98-7 | Reference Standards |
| HY-134119 | Ethyl palmitoleate | 56219-10-4 | Biochemical Assay Reagents |
| HY-13412 | Cariporide (mesilate) | 159138-81-5 | Reference compound |
| HY-134120 | 2-Hydroxystearic acid | 629-22-1 | Biochemical Assay Reagents |
| HY-134123 | Lipoxin B4 methyl ester | 97589-07-6 | Reference compound |
| HY-134124 | Glutathione ethyl ester | 92614-59-0 | Peptides |
| HY-134125 | Yohimbic acid ethyl ester | 73840-32-1 | Reference compound |
| HY-134126 | Methyl heneicosanoate | 6064-90-0 | Biochemical Assay Reagents |
| HY-134127 | Methyl hexacosanoate | 5802-82-4 | Biochemical Assay Reagents |
| HY-134127S1 | Methyl hexacosanoate-d4 | 2692624-18-1 | Isotope-Labeled Compounds |
| HY-134127S2 | Hexacosanoic acid methyl ester-d3 | 2743078-84-2 | Isotope-Labeled Compounds |
| HY-134129 | Benzoyl coenzyme A | 6756-74-7 | Reference compound |
| HY-134129A | Benzoyl coenzyme A (trilithium) | 102185-37-5 | Biochemical Assay Reagents |
| HY-13413 | Tofogliflozin (hydrate) | 1201913-82-7 | Reference compound |
| HY-134130 | Integrin modulator 1 | 2023788-32-9 | Reference compound |
| HY-134132 | 15(S)-HETE methyl ester | 70946-44-0 | Reference compound |
| HY-134135 | Prostaglandin A1 methyl ester | 26771-94-8 | Reference compound |
| HY-134136 | Octanoyl Coenzyme A | 1264-52-4 | Biochemical Assay Reagents |
| HY-134136A | Octanoyl coenzyme A (lithium) | 324518-20-9 | Biochemical Assay Reagents |
| HY-134136B | Octanoyl coenzyme A (triammonium) | 799812-82-1 | Enzyme |
| HY-134137 | Donepezil N-oxide | 120013-84-5 | Reference compound |
| HY-134137S | Donepezil N-oxide-d5 | | Isotope-Labeled Compounds |
| HY-134138 | Indomethacin N-octyl amide | 282728-65-8 | Reference compound |
| HY-13414 | Remogliflozin | 329045-45-6 | Reference compound |
| HY-134141 | 5-Octyl hydrogen L-glutamate | 4852-91-9 | Peptides |
| HY-134145 | 1-(Anilinocarbonyl)proline | 73096-22-7 | Reference compound |
| HY-134149 | N-Formyl desloratadine | 117810-61-4 | Reference compound |
| HY-134154 | PAz-PC | 117746-89-1 | Reference compound |
| HY-134156 | Methyl cis-11-octadecenoate | 1937-63-9 | Biochemical Assay Reagents |
| HY-134156A | Methyl vaccenate | 6198-58-9 | Biochemical Assay Reagents |
| HY-134160 | 5,6-Dihydro-5-Fluorouracil | 696-06-0 | Reference compound |
| HY-134161 | DL-α-(Difluoromethyl)arginine | 69955-43-7 | Reference compound |
| HY-134163 | 4-Methylumbelliferyl α-L-arabinopyranoside | 69414-26-2 | Biochemical Assay Reagents |
| HY-134164 | 4-Nitrophenyl α-L-arabinofuranoside | 6892-58-6 | Biochemical Assay Reagents |
| HY-13417 | AICAR | 2627-69-2 | Reference compound |
| HY-134173 | Arachidonoyl ethanolamide phosphate | 183323-26-4 | Natural Products |
| HY-134174 | 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphate | 62600-81-1 | Biochemical Assay Reagents |
| HY-134174A | 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphate (sodium) | 169437-35-8 | Biochemical Assay Reagents |
| HY-134177 | 2,5-Anhydro-D-glucitol-1,6-diphosphate | 4429-47-4 | Reference compound |
| HY-134178S | 5-Fluorouridine 5'-triphosphate-19F | | Isotope-Labeled Compounds |
| HY-134178S1 | 5-Fluorouridine 5'-triphosphate-13C,19F,d1 | | Isotope-Labeled Compounds |
| HY-13417A | AICAR (phosphate) | 681006-28-0 | Natural Products |
| HY-13417R | AICAR (Standard) | 2627-69-2 | Reference Standards |
| HY-13417S | AICAR-13C2,15N | 1609374-70-0 | Isotope-Labeled Compounds |
| HY-13418 | Dorsomorphin (dihydrochloride) | 1219168-18-9 | Reference compound |
| HY-134180 | rel-Carbovir monophosphate | 144490-73-3 | Reference compound |
| HY-134181 | Tremella polysaccharide, MW>1000000, cosmetic grade | 9075-53-0 | Biochemical Assay Reagents |
| HY-134181A | Tremella polysaccharide, MW<1000000, cosmetic grade | 9075-53-0 | Biochemical Assay Reagents |
| HY-134183 | AUTAC1 | 2241669-09-8 | Reference compound |
| HY-134184 | AUTAC2 | 2241669-08-7 | Reference compound |
| HY-134188 | JNJ-54717793 | 1628843-99-1 | Reference compound |
| HY-134189 | EST73502 | 1838622-25-5 | Reference compound |
| HY-134189A | EST73502 (monohydrochloride) | 2535970-65-9 | Reference compound |
| HY-13418A | Dorsomorphin | 866405-64-3 | Reference compound |
| HY-13418G | Dorsomorphin (dihydrochloride) (GMP) | 1219168-18-9 | GMP Small Molecules |
| HY-13419 | U-73122 | 112648-68-7 | Reference compound |
| HY-134194 | KL201 | 302939-48-6 | Reference compound |
| HY-13420 | Zebularine | 3690-10-6 | Reference compound |
| HY-134200 | 1-Palmitoyl-2-oleoyl-sn-glycerol | 29541-66-0 | Reference compound |
| HY-134205A | CBR-470-1 | 2416095-06-0 | Reference compound |
| HY-13421 | SR1001 | 1335106-03-0 | Reference compound |
| HY-134211 | (Z)-2-Octenoic acid | 1577-96-4 | Reference compound |
| HY-134215 | cis-11-Methyl-2-dodecenoic acid | 677354-23-3 | Reference compound |
| HY-134216 | MAHMA NONOate | 146724-86-9 | Reference compound |
| HY-134217 | KYN-101 | 2247950-73-6 | Reference compound |
| HY-134218 | 4-Nitrophenyl-α-D-maltopyranoside | 17400-77-0 | Biochemical Assay Reagents |
| HY-13422 | Zatebradine (hydrochloride) | 91940-87-3 | Reference compound |
| HY-134220 | Doramectin monosaccharide | 165108-44-1 | Reference compound |
| HY-134221 | S-Nitroso-N-acetylcysteine | 56577-02-7 | Reference compound |
| HY-134222A | N-Acetylserine | 16354-58-8 | Reference compound |
| HY-134222AS | Acetylserine-d3 | 2230887-17-7 | Isotope-Labeled Compounds |
| HY-134223 | 1,3-Diarachidoyl glycerol | 59925-28-9 | Reference compound |
| HY-134224 | Arachidonoyl 2'-fluoroethylamide | 166100-37-4 | Reference compound |
| HY-134225 | 1-O-Hexadecyl-2-arachidonoyl-sn-glycero-3-PC | 86288-11-1 | Reference compound |
| HY-134226 | Defluoro Levofloxacin | 117620-85-6 | Biochemical Assay Reagents |
| HY-134226R | Defluoro Levofloxacin (Standard) | 117620-85-6 | Reference Standards |
| HY-134228 | 4-Hydroperoxyifosfamide | 39800-28-7 | Reference compound |
| HY-13422A | Zatebradine | 85175-67-3 | Reference compound |
| HY-13423 | Tenovin-1 | 380315-80-0 | Reference compound |
| HY-134230 | L-2-Aminooxy-3-phenylpropanoic acid | 42990-62-5 | Reference compound |
| HY-134230A | L-2-Aminooxy-3-phenylpropanoic acid (hydrobromide) | 73086-97-2 | Reference compound |
| HY-134234 | Celecoxib carboxylic acid | 170571-01-4 | Reference compound |
| HY-134235 | PAF C-16 carboxylic acid | 129879-41-0 | Reference compound |
| HY-134238 | Cardiolipin (Heart, Bovine) (sodium) | 383907-10-6 | Natural Products |
| HY-13424 | RITA | 213261-59-7 | Reference compound |
| HY-134240 | L-Threonic acid (magnesium) | 778571-57-6 | Reference compound |
| HY-134241 | Altechromone A | 38412-47-4 | Natural Products |
| HY-134242 | 6-T-5'-GMP (disodium) | 74686-78-5 | Reference compound |
| HY-134242A | 6-T-5'-GMP | 15867-02-4 | Reference compound |
| HY-134243 | 6-T-GDP | 16541-19-8 | Reference compound |
| HY-134245 | 7-Deazaadenosine 5'-phosphate | 16719-46-3 | Reference compound |
| HY-134246 | 7-CH-5'-dAMP | 103078-56-4 | Reference compound |
| HY-13425 | Deguelin | 522-17-8 | Natural Products |
| HY-134254 | 8-AHA-cAMP | 39824-30-1 | Reference compound |
| HY-134256 | 8-APT-cGMP | 144509-87-5 | Biochemical Assay Reagents |
| HY-134258 | MEISi-1 | 446306-43-0 | Reference compound |
| HY-134259 | MEISi-2 | 2250156-71-7 | Reference compound |
| HY-13426 | Roxadustat | 808118-40-3 | Reference compound |
| HY-134261 | 8-Br-ADPR | 59259-77-7 | Reference compound |
| HY-134262 | 8-Bromo-ATP | 23567-97-7 | Reference compound |
| HY-134263 | 8-Br-cAMP-AM | 190522-24-8 | Reference compound |
| HY-134264 | 8-Br-2'-O-Me-cAMP | 612513-13-0 | Reference compound |
| HY-134266 | 8-Bromo-AMP | 23567-96-6 | Reference compound |
| HY-134268 | 8-Br-7-CH-ADPR | 1011457-95-6 | Reference compound |
| HY-134269 | 8-Br-7-CH-cADPR | 189876-06-0 | Reference compound |
| HY-13426R | Roxadustat (Standard) | 808118-40-3 | Reference Standards |
| HY-13426S | Roxadustat-d5 | 2043026-13-5 | Isotope-Labeled Compounds |
| HY-13427 | Allitinib tosylate | 1050500-29-2 | Reference compound |
| HY-134271 | 8-Br-cGMP-AM | 272445-71-3 | Reference compound |
| HY-134272A | 8-Bromo-2'-deoxy-ATP (tetrasodium) | 1188369-62-1 | Reference compound |
| HY-134274 | 8-Br-GTP | 23197-98-0 | Reference compound |
| HY-134279 | 8-Br-NAD+ (sodium) | 2022926-16-3 | Reference compound |
| HY-13428 | Tubacin | 537049-40-4 | Reference compound |
| HY-134280 | 8-Br-NHD+ | 477782-33-5 | Reference compound |
| HY-134283 | 8-Benzylthio-cAMP | 50655-17-9 | Reference compound |
| HY-134290 | 8-Chloro-ATP | 185341-71-3 | Reference compound |
| HY-134290A | 8-Chloro-ATP (tetrasodium) | 793671-47-3 | Reference compound |
| HY-134291 | 8-Chloro-2'-deoxyadenosine | 85562-55-6 | Reference compound |
| HY-134294 | 8-Chloroguanosine | 2104-68-9 | Reference compound |
| HY-134295 | 8-Chloroinosine | 116285-77-9 | Reference compound |
| HY-134298 | 8-CPT-6-Phe-cAMP | 72549-36-1 | Reference compound |
| HY-134299 | 8-CPT-cAMP-AM | 663941-66-0 | Reference compound |
| HY-134302 | 8-HA-cAMP | 59212-44-1 | Reference compound |
| HY-134308 | 8-NBD-cAMP (sodium) | 221905-51-7 | Dye Reagents |
| HY-134309 | NSC 288387 | 61369-43-5 | Reference compound |
| HY-13431 | KU-0060648 | 881375-00-4 | Reference compound |
| HY-134311 | 8-NBD-cGMP | 115993-88-9 | Dye Reagents |
| HY-134313 | 8-NH2-ATP | 35874-49-8 | Reference compound |
| HY-134313A | 8-NH2-ATP (tetrasodium) | 35892-97-8 | Reference compound |
| HY-134314 | 8-Nitro-cGMP | 913645-39-3 | Reference compound |
| HY-134315 | 8-Nitroguanosine | 337536-53-5 | Reference compound |
| HY-134317 | 8-Azidoadenosine | 4372-67-2 | Reference compound |
| HY-134318B | 8-Azido-ADP (disodium) | 102185-14-8 | Reference compound |
| HY-13432 | Nanatinostat | 1256448-47-1 | Reference compound |
| HY-134320 | 8-Azido-ATP | 53696-59-6 | Reference compound |
| HY-134320B | 8-Azido-ATP (trisodium) | | Reference compound |
| HY-134321 | 8-Azido-cAMP | 31966-52-6 | Dye Reagents |
| HY-134324 | 8-Hydroxyadenosine | 29851-57-8 | Reference compound |
| HY-134325 | 8-OH-cAMP | 31356-95-3 | Reference compound |
| HY-13432A | Nanatinostat (TFA) | 1256448-48-2 | Reference compound |
| HY-13433 | Thapsigargin | 67526-95-8 | Natural Products |
| HY-134332 | 8-pCPT-5'-AMP | 78710-84-6 | Reference compound |
| HY-134333 | ICCB280 | 2041072-41-5 | Reference compound |
| HY-134334 | C/EBPα inducer 1 | 2374285-52-4 | Reference compound |
| HY-134337 | 5'-O-DMTr-3'-O-methyl uridine-3'-CED-phosphoramidite | 179479-05-1 | Reference compound |
| HY-134338 | Ipflufenoquin | 1314008-27-9 | Reference compound |
| HY-134338R | Ipflufenoquin (Standard) | 1314008-27-9 | Reference Standards |
| HY-13434 | Ionomycin | 56092-81-0 | Natural Products |
| HY-134340 | 8-pMeOPT-2'-O-Me-cAMP | 612513-16-3 | Reference compound |
| HY-134345 | 8-pCPT-cGMP-AM | 272445-72-4 | Reference compound |
| HY-134348 | 8-pHPT-2'-O-Me-cAMP | 612513-15-2 | Reference compound |
| HY-13434A | Ionomycin (calcium) | 56092-82-1 | Natural Products |
| HY-13434AR | Ionomycin (calcium) (Standard) | 56092-82-1 | Reference Standards |
| HY-134351 | AA-dUTP (tetrasodium) | 85280-65-5 | Reference compound |
| HY-134352 | AA-UTP (tetrasodium) | 85280-66-6 | Reference compound |
| HY-134353B | ADP-β-S (trilithium) | 73536-95-5 | Reference compound |
| HY-134354 | pNP-ADPr | 939028-75-8 | Reference compound |
| HY-134354A | pNP-ADPr (disodium) | | Reference compound |
| HY-134355 | ADPRP | 53595-18-9 | Reference compound |
| HY-134356 | AICA-riboside, 5′-phosphate | 3031-94-5 | Reference compound |
| HY-134358 | Ara-F-NAD+ | 133575-27-6 | Reference compound |
| HY-134358A | Ara-F-NAD+ (sodium) | | Reference compound |
| HY-134361 | ATP-γ-S (tetrasodium) | 88453-52-5 | Reference compound |
| HY-134367 | Ap2A (disodium) | 85065-24-3 | Reference compound |
| HY-134368 | Ap3A | 5959-90-0 | Reference compound |
| HY-134369 | Ap4C (tetrasodium) | 1352921-13-1 | Reference compound |
| HY-134370 | Ap4G | 10527-46-5 | Reference compound |
| HY-134371 | IL-17 modulator 2 | 1449208-36-9 | Reference compound |
| HY-134375 | cAIMP | 1507367-51-2 | Reference compound |
| HY-134377 | Bocidelpar | 2095128-20-2 | Reference compound |
| HY-13438 | AZD3839 (free base) | 1227163-84-9 | Reference compound |
| HY-134382 | 7-CH-dADP | 187478-96-2 | Reference compound |
| HY-134385 | 6-PhEt-dATP | 1239610-11-7 | Reference compound |
| HY-134389 | 6-Phe-cAMP | 34051-30-4 | Reference compound |
| HY-13439 | SR144528 | 192703-06-3 | Reference compound |
| HY-134391 | 6-Phe-ADP | 105701-92-6 | Reference compound |
| HY-134393 | 6-Me-ATP | 3130-39-0 | Reference compound |
| HY-134393B | 6-Me-ATP (trisodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-134395 | 6-MB-cAMP | 70253-67-7 | Reference compound |
| HY-134398 | Kinetin triphosphate | 1450894-16-2 | Reference compound |
| HY-134398A | Kinetin triphosphate (tetrasodium) | | Reference compound |
| HY-13440 | AMG 511 | 1253573-53-3 | Reference compound |
| HY-134404 | 6-Cl-PuTP | 55673-61-5 | Reference compound |
| HY-134406 | 6-Cl-cPuMP (sodium) | 94200-58-5 | Reference compound |
| HY-13441 | (-)-Blebbistatin | 856925-71-8 | Reference compound |
| HY-134417 | NSC2805 | 4371-34-0 | Reference compound |
| HY-134418 | NOTA | 56491-86-2 | Reference compound |
| HY-134418A | NOTA (trihydrochloride) | 133256-65-2 | Biochemical Assay Reagents |
| HY-13441G | (-)-Blebbistatin (GMP) | 856925-71-8 | GMP Small Molecules |
| HY-13442 | Eribulin | 253128-41-5 | ADC Related |
| HY-134420 | p-Nitrophenyl α-L-fucoside | 10231-84-2 | Biochemical Assay Reagents |
| HY-134421 | 2-Butenoyl coenzyme A (lithium) | 102680-35-3 | Biochemical Assay Reagents |
| HY-134422 | Isobutyryl coenzyme A (lithium) | 103404-95-1 | Biochemical Assay Reagents |
| HY-134423 | Stearoyl coenzyme A (lithium) | 193402-48-1 | Biochemical Assay Reagents |
| HY-134423S | Stearoyl coenzyme A-13C18 (lithium) | | Isotope-Labeled Compounds |
| HY-134424 | Propionyl coenzyme A (lithium) | 108321-21-7 | Biochemical Assay Reagents |
| HY-134425 | β-Methylcrotonyl coenzyme A (lithium) | 108347-83-7 | Biochemical Assay Reagents |
| HY-134426 | DL-β-Hydroxybutyryl coenzyme A (lithium) | 103404-51-9 | Biochemical Assay Reagents |
| HY-134427 | Palmitoyl coenzyme A (lithium) | 188174-64-3 | Biochemical Assay Reagents |
| HY-134428 | Arachidonoyl coenzyme A (lithium) | 188174-63-2 | Biochemical Assay Reagents |
| HY-134429 | p-Nitrophenyl α-L-arabinopyranoside | 1223-07-0 | Biochemical Assay Reagents |
| HY-13442A | Eribulin (mesylate) | 441045-17-6 | Reference compound |
| HY-13442AS | Eribulin-d3 (mesylate) | | Isotope-Labeled Compounds |
| HY-13442C | Eribulin (mesylate) (purity>99%, single impurity ≤ 0.15%) | 441045-17-6 | Reference compound |
| HY-13443 | Exendin-4 | 141758-74-9 | Peptides |
| HY-134430 | p-Nitrophenyl myristate | 14617-85-7 | Biochemical Assay Reagents |
| HY-134432A | Boc-Gln-Ala-Arg-AMC (hydrochloride) | 201849-55-0 | Reference compound |
| HY-134432B | Boc-Gln-Ala-Arg-AMC (acetate) | | Dye Reagents |
| HY-134433 | GDP-L-fucose | 15839-70-0 | Reference compound |
| HY-134433A | GDP-L-fucose (disodium) | 148296-47-3 | Biochemical Assay Reagents |
| HY-134434 | Z-Arg-Arg-AMC (hydrochloride) | 136132-67-7 | Peptides |
| HY-134435 | Z-Arg-AMC (hydrochloride) | 70375-22-3 | Dye Reagents |
| HY-134438 | Hexanoyl coenzyme A (trilithium) | 103476-19-3 | Biochemical Assay Reagents |
| HY-134439 | 8-Octanoyloxypyrene-1,3,6-trisulfonic acid (trisodium) | 115787-84-3 | Reference compound |
| HY-13443A | Exendin-4 (acetate) | 914454-01-6 | Peptides |
| HY-13443B | Exendin-4-Lys-azide (TFA) | | Peptides |
| HY-13443F | Exendin 4, biotin labeled | | Peptides |
| HY-134440 | α,β-Methylene-ATP (dilithium) | 104809-20-3 | Reference compound |
| HY-134440A | α,β-Methylene-ATP | 7292-42-4 | Reference compound |
| HY-134442 | L-α-Phosphatidylinositol (liver, bovine) (sodium) | 383907-33-3 | Biochemical Assay Reagents |
| HY-134445 | N-Benzoyl-L-tyrosine p-nitroanilide | 6154-45-6 | Peptides |
| HY-134448 | 5-Bromo-4-chloro-3-indolyl β-D-fucopyranoside | 17016-46-5 | Biochemical Assay Reagents |
| HY-134449 | Z-Lys-ONp (hydrochloride) | 2179-15-9 | Peptides |
| HY-134450 | L-Aspartic acid β-hydroxamate | 1955-68-6 | Peptides |
| HY-134451 | Diethylumbelliferyl phosphate | 897-83-6 | Reference compound |
| HY-134452 | MeAIB | 2566-34-9 | Reference compound |
| HY-134453 | L-Idaric acid,1,4-lactone | 80876-59-1 | Biochemical Assay Reagents |
| HY-134453A | D-Saccharic acid 1,4-lactone (hydrate) | 61278-30-6 | Reference compound |
| HY-134454 | Z-Pro-Pro-CHO | 108708-25-4 | Peptides |
| HY-134454A | Z-Pro-prolinal | 88795-32-8 | Reference compound |
| HY-134455 | 4-Nitrophenyl β-D-fucopyranoside | 1226-39-7 | Biochemical Assay Reagents |
| HY-134458A | H-Lys-Tyr-OH (TFA) | | Reference compound |
| HY-134459 | 4-Nitrophenyl Laurate | 1956-11-2 | Reference compound |
| HY-134460 | 4-Methylumbelliferyl α-L-fucopyranoside | 54322-38-2 | Reference compound |
| HY-134463 | NHWD-870 | 2115742-03-3 | Reference compound |
| HY-134467 | Phylloflavan | 98570-83-3 | Natural Products |
| HY-13447 | PF-429242 | 947303-87-9 | Reference compound |
| HY-134471 | TNF-α-IN-2 | 2074702-04-6 | Reference compound |
| HY-134472 | PI3Kδ-IN-8 | 2101518-75-4 | Reference compound |
| HY-134476 | NF-κΒ activator 1 | 2387524-59-4 | Reference compound |
| HY-134477 | NF-κΒ activator 2 | 2375281-44-8 | Reference compound |
| HY-13447A | PF429242 (dihydrochloride) | 2248666-66-0 | Reference compound |
| HY-13448 | Nedocromil | 69049-73-6 | Reference compound |
| HY-134481 | FLT3-IN-10 | 2088735-51-5 | Reference compound |
| HY-134482 | PCSK9-IN-1 | 2730022-10-1 | Reference compound |
| HY-13448R | Nedocromil (Standard) | 69049-73-6 | Reference Standards |
| HY-13449 | TAK-733 | 1035555-63-5 | Reference compound |
| HY-134493 | Butyrate-Vitamin D3 | 31316-20-8 | Natural Products |
| HY-134494 | MS48107 | 2375070-79-2 | Reference compound |
| HY-134495 | N-Acetyl-L-cysteine ethyl ester | 59587-09-6 | Reference compound |
| HY-13450 | ZM 449829 | 4452-06-6 | Reference compound |
| HY-134508 | C24-Ceramide | 34435-05-7 | Reference compound |
| HY-134508A | C24-Ceramide (d18:1/24:0) | 102917-80-6 | Reference compound |
| HY-134508S | C24-Ceramide-d7 | 1840942-15-5 | Isotope-Labeled Compounds |
| HY-13451 | Finafloxacin | 209342-40-5 | Reference compound |
| HY-134511 | 15(S)-HpEPE | 125992-60-1 | Reference compound |
| HY-134512 | Aminooxy-PEG3-C2-thiol | 1200365-63-4 | Reference compound |
| HY-134517 | Fmoc-HoCys(ACM)-OH | 150281-21-3 | Reference compound |
| HY-134518 | Erythromycin oxime | 13127-18-9 | Reference compound |
| HY-13451A | Finafloxacin (hydrochloride) | 209342-41-6 | Reference compound |
| HY-13451AS | Finafloxacin-d4 (hydrochloride) | 2012598-36-4 | Isotope-Labeled Compounds |
| HY-13451R | Finafloxacin (Standard) | 209342-40-5 | Reference Standards |
| HY-13452 | CID-1067700 | 314042-01-8 | Reference compound |
| HY-134520 | 21-Deacetoxy deflazacort | 13649-88-2 | Reference compound |
| HY-134520R | 21-Deacetoxy deflazacort (Standard) | 13649-88-2 | Reference Standards |
| HY-134521 | Diclofenac amide | 15362-40-0 | Reference compound |
| HY-134524 | Isosorbide dimethyl ether | 5306-85-4 | Reference compound |
| HY-134525 | Ro 8-4304 | 195988-65-9 | Reference compound |
| HY-134529 | D-Ribofuranose1-dihydrogenphosphate | 14075-00-4 | Reference compound |
| HY-134529A | D-Ribofuranose1-dihydrogenphosphate (dicyclohexanamine) | 58459-37-3 | Reference compound |
| HY-13453 | BAY 11-7082 | 19542-67-7 | Reference compound |
| HY-134539 | IMT1 | 2304621-31-4 | Reference compound |
| HY-13454 | CID 2011756 | 638156-11-3 | Reference compound |
| HY-134541 | SM-102 | 2089251-47-6 | Oligonucleotides |
| HY-134541A | SM-102 (Excipient) | 2089251-47-6 | Reference compound |
| HY-134542 | CaV1.3 antagonist-1 | 1391385-57-1 | Reference compound |
| HY-134544 | Calendic acid | 5204-87-5 | Natural Products |
| HY-134545 | N-Arachidonoyl-L-alanine | 401941-73-9 | Peptides |
| HY-13455 | LDN-192960 | 184582-62-5 | Reference compound |
| HY-134554 | 5′-Deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine | 162204-30-0 | Reference compound |
| HY-134555 | A3AR antagonist 4 | 109740-09-2 | Reference compound |
| HY-134556 | 2'-Hydroxyflavanone | 17348-76-4 | Natural Products |
| HY-134557 | GS87 | 919936-70-2 | Reference compound |
| HY-134558 | 5-Methoxyflavanone | 55947-36-9 | Natural Products |
| HY-134559 | TKIM | 326921-25-9 | Reference compound |
| HY-13455A | LDN-192960 (hydrochloride) | 2309172-48-1 | Reference compound |
| HY-13456 | LY-404187 | 211311-95-4 | Reference compound |
| HY-134560 | N-(3-Oxodecanoyl)-L-homoserine lactone | 147795-40-2 | Natural Products |
| HY-134561 | 6-Amino-8-trifluoromethylphenanthridine | 651055-83-3 | Reference compound |
| HY-134562 | PF-06371900 | 1622291-81-9 | Reference compound |
| HY-134563 | Z-Asp(OMe)-Gln-Met-Asp(OMe)-FMK | 767287-99-0 | Reference compound |
| HY-134564 | Fluorescein octadecyl ester | 138833-46-2 | Dye Reagents |
| HY-134566 | NBD-X, SE | 145195-58-0 | Dye Reagents |
| HY-134567 | Ac-VDVAD-CHO | 194022-51-0 | Peptides |
| HY-134567A | Ac-VDVAD-CHO (TFA) | | Reference compound |
| HY-13457 | TCN 201 | 852918-02-6 | Reference compound |
| HY-134570 | ZINC40099027 | 1211825-25-0 | Reference compound |
| HY-134572 | (2S,3S)-Pterosin C | 35938-43-3 | Natural Products |
| HY-134573 | Dihydropashanone | 41997-41-5 | Natural Products |
| HY-134575 | C24:1-Ceramide | 54164-50-0 | Reference compound |
| HY-134575S | C24:1-Ceramide-d7 | 1840942-16-6 | Isotope-Labeled Compounds |
| HY-134577 | Clorprenaline | 3811-25-4 | Reference compound |
| HY-134577R | Clorprenaline (Standard) | 3811-25-4 | Reference Standards |
| HY-134577S | Clorprenaline-d6 | 1648796-40-0 | Isotope-Labeled Compounds |
| HY-134578 | H-Arg-Ser-Arg-OH | 115035-42-2 | Peptides |
| HY-134579 | Chaetomellic acid A | 148796-51-4 | Natural Products |
| HY-13458 | Droxidopa | 23651-95-8 | Reference compound |
| HY-134581 | Enpatoran | 2101938-42-3 | Reference compound |
| HY-134581A | Enpatoran (hydrochloride) | 2101945-93-9 | Reference compound |
| HY-134582 | dCBP-1 | 2484739-25-3 | Reference compound |
| HY-134583 | IDO1-IN-7 | 2351199-98-7 | Reference compound |
| HY-13458A | Droxidopa (hydrochloride) | 1260173-94-1 | Reference compound |
| HY-13458R | Droxidopa (Standard) | 23651-95-8 | Reference Standards |
| HY-13458S1 | Droxidopa-13C2,15N (hydrochloride) | 1329556-63-9 | Isotope-Labeled Compounds |
| HY-13458S2 | Droxidopa-13C6 | 1261397-37-8 | Isotope-Labeled Compounds |
| HY-13459 | PF-5274857 | 1373615-35-0 | Reference compound |
| HY-134591 | Thalidomide-NH-PEG4-COOH | 2412056-48-3 | Reference compound |
| HY-134592 | Piperidine-GNE-049-N-Boc | 1936431-36-5 | Reference compound |
| HY-134594 | SENP1-IN-1 | 2416910-69-3 | Reference compound |
| HY-134595 | SENP1-IN-2 | 2416910-70-6 | Reference compound |
| HY-134596 | SENP1-IN-3 | 2416910-59-1 | Reference compound |
| HY-134597 | SENP1-IN-4 | 2416910-64-8 | Reference compound |
| HY-134598 | 653-47 | 1224678-75-4 | Reference compound |
| HY-134598A | 653-47 (hydrochloride) | 1224567-46-7 | Reference compound |
| HY-134599 | (2E)-TCO-PNB ester | 1580501-97-8 | Reference compound |
| HY-13459A | PF-5274857 (hydrochloride) | 1613439-62-5 | Reference compound |
| HY-134601 | KH-3 | 1215115-03-9 | Reference compound |
| HY-134602 | 5'-Methoxynobiletin | 6965-36-2 | Natural Products |
| HY-134607 | (E)-Benzyl ferulate | 132335-97-8 | Natural Products |
| HY-134608 | Cobalt protoporphyrin IX | 14325-03-2 | Reference compound |
| HY-13461 | PHA-767491 | 845714-00-3 | Reference compound |
| HY-134611 | (2-Hydroxyethoxy)acetic acid | 13382-47-3 | Reference compound |
| HY-134615 | Mead ethanolamide | 169232-04-6 | Reference compound |
| HY-134616 | Ulinastatin | 80449-31-6 | Reference compound |
| HY-13461A | PHA-767491 (hydrochloride) | 942425-68-5 | Reference compound |
| HY-13462 | LY-364947 | 396129-53-6 | Reference compound |
| HY-134620 | Cyanine 5 NHS ester (tetrafluoroborate) | 1263093-76-0 | Dye Reagents |
| HY-134621 | P300-IN-1 | 2488868-36-4 | Reference compound |
| HY-134622 | GSK-3/CDK5/CDK2-IN-1 | 395074-72-3 | Reference compound |
| HY-134628S | (Rac)-8,14-Dihydroxy Efavirenz-d4 | 1189859-26-4 | Isotope-Labeled Compounds |
| HY-13463 | Avatrombopag | 570406-98-3 | Reference compound |
| HY-134633 | Alpha-lipoic acid choline ester (chloride) | 1808266-58-1 | Reference compound |
| HY-134635 | Dehydrozingerone | 1080-12-2 | Reference compound |
| HY-134636 | PAPA NONOate | 146672-58-4 | Reference compound |
| HY-13463A | Avatrombopag (maleate) | 677007-74-8 | Reference compound |
| HY-13463B | Avatrombopag (hydrochloride) | 570403-17-7 | Reference compound |
| HY-13463BS | Avatrombopag-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13463R | Avatrombopag (Standard) | 570406-98-3 | Reference Standards |
| HY-13464 | ALK-IN-1 | 1197958-12-5 | Reference compound |
| HY-134640 | AUTAC4 | 2267315-04-6 | Reference compound |
| HY-134645 | 1-Heneicosanol | 15594-90-8 | Biochemical Assay Reagents |
| HY-134648 | Ganfeborole | 2131798-12-2 | Reference compound |
| HY-13465 | VCH-916 | 1200133-34-1 | Reference compound |
| HY-134650 | (4E)-7-(4-Hydroxyphenyl)-1-phenylhept-4-en-3-one | 100667-52-5 | Natural Products |
| HY-134653 | 5-Ph-IAA | 168649-23-8 | Reference compound |
| HY-134654 | MRTX849 analog 24 | 2490716-96-4 | Reference compound |
| HY-134655 | D75-4590 | 384376-42-5 | Reference compound |
| HY-134656 | BC1618 | 2222094-18-8 | Reference compound |
| HY-134658 | Hentriacontanoic acid | 38232-01-8 | Biochemical Assay Reagents |
| HY-13465A | VCH-916 (free base) | 914778-92-0 | Reference compound |
| HY-13466 | MK-4256 | 1104599-69-0 | Reference compound |
| HY-134661 | (S)-Solangepras | 1799968-74-3 | Reference compound |
| HY-134661A | Solangepras | 2254706-21-1 | Reference compound |
| HY-134663 | 2-O-β-D-Glucosyloxy-4-methoxybenzene propanoic acid | 477873-63-5 | Natural Products |
| HY-134664 | 8α-(2-Methylacryloyloxy)-hirsutinolide-13-O-acetate | 67667-71-4 | Natural Products |
| HY-134665 | NITD-2 | 1197896-79-9 | Reference compound |
| HY-134669 | CypK | 1610703-09-7 | Reference compound |
| HY-13467 | AM-1638 | 1142214-62-7 | Reference compound |
| HY-134670 | a-Hydroxymetoprolol | 56392-16-6 | Reference compound |
| HY-134670R | a-Hydroxymetoprolol (Standard) | 56392-16-6 | Reference Standards |
| HY-134670S | α-Hydroxy Metoprolol-d5 (Mixture of Diastereomers) | 1189934-03-9 | Isotope-Labeled Compounds |
| HY-134670S1 | α-Hydroxymetoprolol-d7 | 1276197-39-7 | Isotope-Labeled Compounds |
| HY-134673 | UZH1 | 2925713-02-4 | Reference compound |
| HY-134673A | UZH1a | 2813577-78-3 | Reference compound |
| HY-134673B | UZH1b | 2814392-17-9 | Reference compound |
| HY-134675 | THP-PEG4-C1-OH | | Reference compound |
| HY-134676 | Propenyl-PEG3-Propenyl | 90736-68-8 | Reference compound |
| HY-134677 | Bromo-PEG7-Boc | 2766000-37-5 | Reference compound |
| HY-134678 | Propanol-PEG5-CH2OH | | Reference compound |
| HY-134679 | N-Boc-C1-PEG5-C3-NH2 | 956472-77-8 | Reference compound |
| HY-13468 | KW-2478 | 819812-04-9 | Reference compound |
| HY-134680 | Ms-PEG3-CH2CH2COOH | 2306832-21-1 | Reference compound |
| HY-134681 | Fmoc-NH-PEG5-NH-Boc | | Reference compound |
| HY-134682 | Fmoc-NH-PEG5-C2-NH2 | 2093277-71-3 | Reference compound |
| HY-134683 | Ms-PEG3-NHS ester | | Reference compound |
| HY-134684 | Mal-PEG3-O-Ac | | Reference compound |
| HY-134685 | Edoxaban impurity 6 | 480452-37-7 | Reference compound |
| HY-134686 | Edoxaban impurity 4 | 480452-36-6 | Reference compound |
| HY-134687 | Iodoacetamide-PEG5-azide | | Reference compound |
| HY-134688 | Iodoacetamide-PEG5-NH2 | | Reference compound |
| HY-134689 | Propanol-PEG3-CH2OH | 112935-57-6 | Reference compound |
| HY-13469 | Debio 0932 | 1061318-81-7 | Reference compound |
| HY-134690 | Propanol-PEG4-CH2OH | 156868-17-6 | Reference compound |
| HY-134691 | Propanol-PEG6-CH2OH | | Reference compound |
| HY-134692 | Azido-C1-PEG3-C3-NH2 | 1162336-72-2 | Reference compound |
| HY-134693 | Azido-C1-PEG4-C3-NH2 | | Reference compound |
| HY-134694 | Bromo-PEG2-NH2 (hydrobromide) | | Reference compound |
| HY-134695 | 5-(Biotinamido)pentylazide | 1349190-76-6 | Reference compound |
| HY-134696 | Azido-PEG6-CH2COOH | 880129-82-8 | Reference compound |
| HY-134697 | Benzyl-PEG15-alcohol | | Reference compound |
| HY-134698 | THP-PEG9-THP | 1809333-14-9 | Reference compound |
| HY-134699 | THP-PEG12-THP | | Reference compound |
| HY-13470 | GSK126 | 1346574-57-9 | Reference compound |
| HY-134700 | DSPE-PEG14-COOH | | Reference compound |
| HY-134701 | Acetamido-PEG2-Br | | Reference compound |
| HY-134702 | Mal-PEG12-CHO | | Reference compound |
| HY-134703 | Acid-PEG12-CHO | | Reference compound |
| HY-134704 | Biotin-PEG4-SH | 2762393-22-4 | Reference compound |
| HY-134705 | m-PEG2-amido-Ph-NH2 | 1284417-66-8 | Reference compound |
| HY-134706 | Acetamido-PEG3-Br | | Reference compound |
| HY-134707 | CHO-PEG12-Boc | | Reference compound |
| HY-134708 | Bromo-PEG3-CO-NH2 | | Reference compound |
| HY-134709 | Boc-NH-PEG5-Cl | | Reference compound |
| HY-134710 | Benzyl-PEG24-alcohol | 2218463-19-3 | Reference compound |
| HY-134711 | Amine-PEG6-thiol | | Reference compound |
| HY-134711A | Amine-PEG6-thiol (hydrochloride) | | Reference compound |
| HY-134712 | Methylacetamide-PEG3-NH2 | | Reference compound |
| HY-134713 | Tos-PEG14-OH | | Reference compound |
| HY-134714 | DBCO-PEG3-amine | 2093409-57-3 | Reference compound |
| HY-134715 | Fmoc-N-amido-PEG4-amine | | Reference compound |
| HY-134716 | Methyl acetate-PEG1-methyl acetate | 54665-51-9 | Reference compound |
| HY-134717 | Benzyl-PEG24-azide | | Reference compound |
| HY-134718 | Glycocholic acid-PEG10-iodoacetamide | | Reference compound |
| HY-134719 | ICG-Sulfo-OSu (sodium) | 190714-28-4 | Reference compound |
| HY-134720 | Amine-PEG4-Desthiobiotin | 2306109-91-9 | Reference compound |
| HY-134721 | Amine-PEG3-Desthiobiotin | 2237234-71-6 | Reference compound |
| HY-134722 | Hydrazide-PEG4-Desthiobiotin | | Reference compound |
| HY-134723 | DBCO-PEG4-GGFG-Dxd | 2694856-51-2 | ADC Related |
| HY-134724 | MTH1 ligand 1 | 2412986-35-5 | Reference compound |
| HY-134725 | MTH1 degrader-1 | 2412987-06-3 | Reference compound |
| HY-134730 | N-Acetylpyrrolidine-PEG2-Br | | Reference compound |
| HY-134731 | N-Ethylacetamide-PEG2-Br | | Reference compound |
| HY-134732 | N-Ethylpropionamide-PEG1-Br | 1539080-27-7 | Reference compound |
| HY-134733 | N-Ethyl-N-methylpropionamide-PEG1-Br | 1695856-63-3 | Reference compound |
| HY-134734 | BCN-exo-PEG7-maleimide | 2143965-47-1 | Reference compound |
| HY-134735 | N-Ethylacetamide-PEG1-Br | | Reference compound |
| HY-134736 | Bromo-PEG1-NH2 (hydrobromide) | 2287287-20-9 | Reference compound |
| HY-134737 | Boc-NH-PEG1-C5-OH | | Reference compound |
| HY-134738 | Iodoacetamide-PEG5-NH-Boc | | Reference compound |
| HY-134739 | N-Ethyl-3,3,3-trifluoro-N-methylpropanamide-PEG2-Br | | Reference compound |
| HY-134740 | Br-PEG2-oxazolidin-2-one | | Reference compound |
| HY-134741 | Benzyl-PEG8-MS | 1330059-91-0 | Reference compound |
| HY-134742 | 3-Aminophenol-PEG4-methyl | 1429340-32-8 | Reference compound |
| HY-134743 | m-PEG21-OH | | Reference compound |
| HY-134744 | Boc-Pyrrolidine-PEG2-COOH | | Reference compound |
| HY-134745 | DSPE-PEG2-mal | 1915739-87-5 | Reference compound |
| HY-134746 | Hexaethylene glycol dimethyl ether | 1072-40-8 | Reference compound |
| HY-134747 | THP-PEG10-THP | 42749-29-1 | Reference compound |
| HY-134748 | HO-PEG7-CH2COOH | 2250056-27-8 | Reference compound |
| HY-134749 | Propargyl-PEG2-urea-C3-triethoxysilane | 1637329-79-3 | Reference compound |
| HY-13475 | mPGES1-IN-8 | 1381846-21-4 | Reference compound |
| HY-134750 | HO-PEG5-CH2COOH | 52026-48-9 | Reference compound |
| HY-134751 | VES-POFP | | Reference compound |
| HY-134752 | Benzyl-PEG9-Boc | | Reference compound |
| HY-134753 | Teriflunomide impurity 3 | 1011244-72-6 | Reference compound |
| HY-134754 | Bromo-PEG12-acid | | Reference compound |
| HY-134755 | Bromo-PEG9-Boc | | Reference compound |
| HY-134757 | Lactate oxidase, Microorganism | 9028-72-2 | Enzyme |
| HY-134761 | EN4 | 1197824-15-9 | Reference compound |
| HY-134769 | OPC-163493 | 1644467-84-4 | Reference compound |
| HY-134771 | YM-341619 | 643082-52-4 | Reference compound |
| HY-134772 | AS1810722 | 909561-15-5 | Reference compound |
| HY-134775 | PLK4-IN-1 | 1247001-12-2 | Reference compound |
| HY-134775A | PLK4-IN-3 | 1247001-86-0 | Reference compound |
| HY-134780 | L-369 | 1443522-24-4 | Reference compound |
| HY-134781 | CKK-E12 | 1432494-65-9 | Oligonucleotides |
| HY-134782 | OF-Deg-Lin | 1853202-95-5 | Oligonucleotides |
| HY-134783 | 1,19-Bis(2-butyloctyl) 10-[[3-(dimethylamino)propyl](1-oxononyl)amino]nonadecanedioate | 2036272-50-9 | Reference compound |
| HY-13479 | EC144 | 911397-80-3 | Reference compound |
| HY-134795 | 5-Carboxymethylaminomethyluridine | 69181-26-6 | Reference compound |
| HY-134797 | p-SCN-Bn-deferoxamine | 1222468-90-7 | Reference compound |
| HY-134801 | CID1231538 | 354126-20-8 | Reference compound |
| HY-134807 | Indophagolin | 1207660-00-1 | Reference compound |
| HY-134809 | Cyclotriazadisulfonamide | 182316-44-5 | Reference compound |
| HY-134809A | Cyclotriazadisulfonamide (hydrochloride) | 392287-03-5 | Reference compound |
| HY-134811 | KRAS G12D inhibitor 1 | 2621928-43-4 | Reference compound |
| HY-134813 | MRTX1133 | 2621928-55-8 | Reference compound |
| HY-134813A | MRTX1133 (formic) | | Reference compound |
| HY-134816 | D-Glucan | 9012-72-0 | Biochemical Assay Reagents |
| HY-134817 | USP7-IN-8 | 2009273-60-1 | Reference compound |
| HY-134818 | ML-SI1 | | Reference compound |
| HY-134819 | (1S,2S)-ML-SI3 | 2563870-87-9 | Reference compound |
| HY-134819A | (1R,2R)-ML-SI3 | 2418594-00-8 | Reference compound |
| HY-134820 | MLT-943 | 1832576-04-1 | Reference compound |
| HY-134823 | MD-222 | 2136246-72-3 | Reference compound |
| HY-134828 | AZ506 | 2043321-54-4 | Reference compound |
| HY-134829 | BMS-986176 | 1815613-42-3 | Reference compound |
| HY-134832 | Mito-LND | 2361564-49-8 | Reference compound |
| HY-134836 | STM2457 | 2499663-01-1 | Reference compound |
| HY-134850 | QC-01–175 | 2267290-96-8 | Reference compound |
| HY-134851 | HIV-1 inhibitor-6 | 1821309-39-0 | Reference compound |
| HY-134852 | Fmoc-Cys(STmp)-OH | 1403834-74-1 | Peptides |
| HY-134853 | 2-(Boc-amino)ethanethiol | 67385-09-5 | Reference compound |
| HY-134858 | A1AT modulator 1 | 2406205-61-4 | Reference compound |
| HY-13486 | TAU-IN-1 | 1383373-65-6 | Reference compound |
| HY-134860 | Prostaglandin D1 alcohol | 1176470-37-3 | Reference compound |
| HY-134863 | A1AT modulator 2 | 2555004-05-0 | Reference compound |
| HY-134864 | GnRH antagonist 2 | 1709823-61-9 | Reference compound |
| HY-13487 | USP7/USP47 inhibitor | 1247825-37-1 | Reference compound |
| HY-134877 | BAY 2476568 | 2311901-93-4 | Reference compound |
| HY-134879 | Tau tracer 1 | 2173353-53-0 | Reference compound |
| HY-13488 | HG-10-102-01 | 1351758-81-0 | Reference compound |
| HY-134880 | Tau tracer 2 | 2173361-80-1 | Reference compound |
| HY-134883 | PRMT5-IN-4 | 152615-84-4 | Reference compound |
| HY-134884 | INCB086550 | 2230911-59-6 | Reference compound |
| HY-134885 | RMC-0331 | 2488788-52-7 | Reference compound |
| HY-134886 | PD-1-IN-24 | 2360909-50-6 | Reference compound |
| HY-134891 | HMBPP (lithium) | 396726-03-7 | Natural Products |
| HY-134894A | Glycerophosphorylethanolamine (sodium) | 883288-78-6 | Reference compound |
| HY-134895 | Gadoleic acid | 29204-02-2 | Biochemical Assay Reagents |
| HY-134899 | CPI-1328 | 2390367-27-6 | Reference compound |
| HY-134900 | Allyl methyl trisulfide | 34135-85-8 | Natural Products |
| HY-134900R | Allyl methyl trisulfide (Standard) | 34135-85-8 | Reference Standards |
| HY-134901 | WM-3835 | 2229025-70-9 | Reference compound |
| HY-134903 | (32-Carbonyl)-RMC-5552 | 2382768-55-8 | Reference compound |
| HY-134904 | RMC-6272 | 2382769-46-0 | Reference compound |
| HY-134909 | AS-136A | 949898-66-2 | Reference compound |
| HY-13491 | GNF-5837 | 1033769-28-6 | Reference compound |
| HY-134910 | SID-852843 | 909859-19-4 | Reference compound |
| HY-134911 | HS-243 | 848249-10-5 | Reference compound |
| HY-134912 | CMPPE | 841253-81-4 | Reference compound |
| HY-134913 | Rhodblock 1a | 701226-08-6 | Reference compound |
| HY-134914 | Fosmidomycin | 66508-53-0 | Natural Products |
| HY-134917 | Aldi-2 | 499997-25-0 | Reference compound |
| HY-134919 | CU-76 | 2400954-58-5 | Reference compound |
| HY-134921 | MI-nc (dihydrochloride) | 1934302-23-4 | Reference compound |
| HY-134922 | NS1-IN-1 | 181373-35-3 | Reference compound |
| HY-134923 | CA77.1 | 2412270-22-3 | Reference compound |
| HY-134924 | Succinyl-β-cycloaltrin | 957494-34-7 | Biochemical Assay Reagents |
| HY-134928 | Pyridinium bisretinoid A2E | 173449-96-2 | Reference compound |
| HY-134928A | Pyridinium bisretinoid A2E (TFA) | 1821308-73-9 | Reference compound |
| HY-134928AS | Pyridinium bisretinoid A2E-d4 (TFA) | | Isotope-Labeled Compounds |
| HY-134929 | Benitrobenrazide | 2454676-05-0 | Reference compound |
| HY-13493 | AC710 | 1351522-04-7 | Reference compound |
| HY-134931 | M090 | 1599466-63-3 | Reference compound |
| HY-134932 | AA74-1 | 1361532-00-4 | Reference compound |
| HY-134935 | L-Proline β-naphthylamide (hydrochloride) | 97216-16-5 | Peptides |
| HY-134937 | BC8-15 | 950385-77-0 | Reference compound |
| HY-134938S | 7-Hydroxywarfarin-d5 | 94820-65-2 | Isotope-Labeled Compounds |
| HY-134939 | thio-Miltefosine | 943022-11-5 | Reference compound |
| HY-13493A | AC710 (Mesylate) | 1351522-05-8 | Reference compound |
| HY-134940 | Quabodepistat | 1883747-71-4 | Reference compound |
| HY-134940S | Quabodepistat-d7 | | Isotope-Labeled Compounds |
| HY-13495 | ML281 | 1404437-62-2 | Reference compound |
| HY-134950 | (E)-C-HDMAPP (ammonium) | 933030-60-5 | Reference compound |
| HY-134952 | Acetylcholine (perchlorate) | 927-86-6 | Biochemical Assay Reagents |
| HY-134953 | Mephetyl tetrazole | 916923-10-9 | Reference compound |
| HY-134954 | Palmitoleoyl 3-carbacyclic phosphatidic acid | 910228-13-6 | Reference compound |
| HY-134955 | VT103 | 2290608-13-6 | Reference compound |
| HY-134956 | VT104 | 2417718-25-1 | Reference compound |
| HY-134956B | (R)-VT104 | 2417718-26-2 | Reference compound |
| HY-134957 | VT107 | 2417718-63-7 | Reference compound |
| HY-134958 | Polyinosinic-polycytidylic acid (potassium) | 31852-29-6 | Reference compound |
| HY-13496 | JNJ-28312141 | 885692-52-4 | Reference compound |
| HY-134960 | 2,3-Indolobetulonic acid | 905837-93-6 | Reference compound |
| HY-134961 | Z-Ala-Arg-Arg-AMC | 90468-18-1 | Peptides |
| HY-134963 | SBI-0087702 | 864431-36-7 | Reference compound |
| HY-134964 | CTB | 451491-47-7 | Reference compound |
| HY-134968 | TTBK1-IN-1 | 2735015-60-6 | Reference compound |
| HY-134968A | (R)-TTBK1-IN-1 | 2735015-59-3 | Reference compound |
| HY-13497 | STK33-IN-1 | 1404437-49-5 | Reference compound |
| HY-134971 | AE9C90CB | 893426-98-7 | Reference compound |
| HY-134975 | NY2267 | 886053-73-2 | Reference compound |
| HY-134976 | Azido-FTY720 | 881914-35-8 | Reference compound |
| HY-134977 | Atrovastatin-PEG3-FITC | 1440755-31-6 | Reference compound |
| HY-134978 | (Rac)-SHIN2 | 2204289-53-0 | Reference compound |
| HY-134978A | (+)SHIN2 | | Reference compound |
| HY-134978B | (-)SHIN2 | | Reference compound |
| HY-13498 | BRD-8899 | 1404437-50-8 | Reference compound |
| HY-134982 | Thalidomide-piperazine-Boc | 2222114-64-7 | Reference compound |
| HY-134983 | Thalidomide-Piperazine 5-fluoride | 2222114-22-7 | Reference compound |
| HY-134984 | Thalidomide-NH-amido-C4-NH2 | 2093388-67-9 | Reference compound |
| HY-134984A | Thalidomide-NH-amido-C4-NH2 (hydrochloride) | | Reference compound |
| HY-134985 | Thalidomide-NH-PEG1-NH2 | 2138439-12-8 | Reference compound |
| HY-134985A | Thalidomide-NH-PEG1-NH2 (diTFA) | 2768514-19-6 | Reference compound |
| HY-134986 | Thalidomide-NH-C5-NH2 | 2093386-39-9 | Reference compound |
| HY-134988 | EDP-305 | 1933507-63-1 | Reference compound |
| HY-13499 | JNJ-41443532 | 1228650-83-6 | Reference compound |
| HY-134990 | Hematoporphyrin monomethyl ether | 148471-91-4 | Reference compound |
| HY-134992 | Vazegepant | 1337918-83-8 | Reference compound |
| HY-134992S | (Rac)-Vazegepant-13C,d3 | | Isotope-Labeled Compounds |
| HY-134996 | N-Acetyl-2-carboxybenzenesulfonamide | 849067-18-1 | Reference compound |
| HY-134997 | 4-Oxo Docosahexaenoic Acid | 845673-74-7 | Reference compound |
| HY-134999 | 10-Hydroxywarfarin | 83219-99-2 | Reference compound |
| HY-13500 | GSK343 | 1346704-33-3 | Reference compound |
| HY-135000 | Decarbamoylsaxitoxin | 58911-04-9 | Natural Products |
| HY-135002 | LDN-209929 | 1233355-57-1 | Reference compound |
| HY-135004 | SU-4029 (dihydrochloride) | 3194-36-3 | Reference compound |
| HY-135005 | Biliverdin (hydrochloride) | 856699-18-8 | Natural Products |
| HY-135005A | Biliverdin | 114-25-0 | Natural Products |
| HY-135006 | Octahydroaminoacridine (succinate) | 866245-79-6 | Reference compound |
| HY-135006A | Octahydroaminoacridine | 13415-07-1 | Reference compound |
| HY-135008 | J14 | 1043854-13-2 | Reference compound |
| HY-135009 | 2-Di-1-ASP | 2156-29-8 | Dye Reagents |
| HY-13501 | Mubritinib | 366017-09-6 | Reference compound |
| HY-135013 | Umbellulone | 546-78-1 | Natural Products |
| HY-135014 | Undecylenoyl phenylalanine | 175357-18-3 | Reference compound |
| HY-135016 | Oleic acid (triethanolamine) | 2717-15-9 | Reference compound |
| HY-135018 | 6-Methoxy DiPT (hydrochloride) | 2426-76-8 | Reference compound |
| HY-13502 | Mitoxantrone | 65271-80-9 | Reference compound |
| HY-135020 | AC-24,055 | 1933-50-2 | Reference compound |
| HY-135021 | 3,4-Dihydro Naratriptan | 121679-20-7 | Reference compound |
| HY-135022 | 3-Bromoamphetamine (hydrochloride) | 1210708-61-4 | Reference compound |
| HY-135023 | 5-trans-PGE2 | 36150-00-2 | Reference compound |
| HY-135023R | 5-trans-PGE2 (Standard) | 36150-00-2 | Reference Standards |
| HY-135024 | Phenylacetyl CoA | 7532-39-0 | Enzyme |
| HY-135024A | Phenylacetyl CoA (lithium) | 108321-26-2 | Enzyme |
| HY-135025 | 5-Fluoro-3,5-ADB-PFUPPYCA | 1969261-68-4 | Reference compound |
| HY-135026 | DL-Norepinephrine (tartrate) | 3414-63-9 | Reference compound |
| HY-135029 | Fmoc-N-PEG3-CH2-NHS ester | 2128735-25-9 | Reference compound |
| HY-13502A | Mitoxantrone (dihydrochloride) | 70476-82-3 | Reference compound |
| HY-13502AR | Mitoxantrone (dihydrochloride) (Standard) | 70476-82-3 | Reference Standards |
| HY-13502AS | Mitoxantrone-d8 (dihydrochloride) | | Isotope-Labeled Compounds |
| HY-13502AS1 | Mitoxantrone-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13502B | Mitoxantrone (diacetate) | 70711-41-0 | Reference compound |
| HY-13502R | Mitoxantrone (Standard) | 65271-80-9 | Reference Standards |
| HY-13502S | Mitoxantrone-d8 | 1189974-82-0 | Isotope-Labeled Compounds |
| HY-13503 | Epothilone A | 152044-53-6 | Natural Products |
| HY-135030 | 4-Fluoro BZP (hydrochloride) | 199672-06-5 | Reference compound |
| HY-135032 | Norcarfentanil (hydrochloride) | 61085-87-8 | Reference compound |
| HY-135034 | UMB68 (sodium) | 581099-89-0 | Reference compound |
| HY-135035 | Decanoyl-L-carnitine | 3992-45-8 | Reference compound |
| HY-135035R | Decanoyl-L-carnitine (Standard) | 3992-45-8 | Reference Standards |
| HY-135035S | Decanoyl-L-carnitine-d3 | 1297655-08-3 | Isotope-Labeled Compounds |
| HY-135036 | 4-Methylumbelliferyl butyrate | 17695-46-4 | Dye Reagents |
| HY-135037 | Sempervirine methochloride | 6484-78-2 | Reference compound |
| HY-13503R | Epothilone A (Standard) | 152044-53-6 | Reference Standards |
| HY-13504 | PIK-293 | 900185-01-5 | Reference compound |
| HY-135041 | Totrombopag (choline) | 851606-62-7 | Reference compound |
| HY-135042 | CAY10614 | 1202208-36-3 | Reference compound |
| HY-135043 | S-Aristeromycinyl-L-homocysteine | 57884-84-1 | Reference compound |
| HY-135045 | (S,R,S)-AHPC-C4-COOH | 2172819-74-6 | Reference compound |
| HY-135046 | MTOB (sodium) | 51828-97-8 | Reference compound |
| HY-135048 | Mal-PEG4-OH | 1421933-37-0 | Reference compound |
| HY-135049 | Bromo-PEG6-bromide | 72713-23-6 | Reference compound |
| HY-13505 | AM281 | 202463-68-1 | Reference compound |
| HY-135053 | Autotaxin-IN-3 | 2156655-68-2 | Reference compound |
| HY-135055 | Magnesium lactate | 18917-93-6 | Reference compound |
| HY-135056 | MitoTracker Green FM | 201860-17-5 | Dye Reagents |
| HY-135057 | Lauroylamide propylbetaine (35% in water) | 4292-10-8 | Reference compound |
| HY-13506 | M344 | 251456-60-7 | Reference compound |
| HY-135060 | 3,4-Dichloromethcathinone (hydrochloride) | 15861-85-5 | Reference compound |
| HY-135061 | 20α-Dihydro prednisolone | 15847-24-2 | Reference compound |
| HY-135065 | 3-Iodothyronamine (hydrochloride) | 788824-64-6 | Reference compound |
| HY-135065S | 3-Iodothyronamine-d4 (hydrochloride) | 884320-54-1 | Isotope-Labeled Compounds |
| HY-135066 | Triallyl pentaerythritol | 1471-17-6 | Reference compound |
| HY-13506G | M344 (GMP) | 251456-60-7 | GMP Small Molecules |
| HY-13507 | Lumiracoxib | 220991-20-8 | Reference compound |
| HY-135070 | Ac-RLR-AMC | 929903-87-7 | Peptides |
| HY-135070B | Ac-RLR-AMC (TFA) | | Peptides |
| HY-135072 | N,N',N''-Triacetylchitotriose | 38864-21-0 | Natural Products |
| HY-135072R | N,N',N''-Triacetylchitotriose (Standard) | 38864-21-0 | Reference Standards |
| HY-135073 | PCMPA (hydrochloride) | 1934-63-0 | Reference compound |
| HY-135076 | 2,3-Dimethylmethcathinone (hydrochloride) | 1797981-99-7 | Reference compound |
| HY-135077 | Prostaglandin A1 ethyl ester | 93464-24-5 | Reference compound |
| HY-135078 | 2,5-Deoxyfructosazine | 17460-13-8 | Reference compound |
| HY-13507R | Lumiracoxib (Standard) | 220991-20-8 | Reference Standards |
| HY-13508 | JNJ-7777120 | 459168-41-3 | Reference compound |
| HY-135081 | N-(4-acetamidophenyl)-Indomethacin amide | 261766-23-8 | Reference compound |
| HY-135083 | BDP FL-PEG4-amine | 2183473-14-3 | Reference compound |
| HY-135085 | Thiol-C2-PEG2-OH | 56282-36-1 | Reference compound |
| HY-135087 | Caprylic/Capric Triglyceride | 65381-09-1 | Biochemical Assay Reagents |
| HY-135088 | Autotaxin-IN-4 | 2156655-86-4 | Reference compound |
| HY-135089 | Autotaxin-IN-5 | 2156655-99-9 | Reference compound |
| HY-13509 | CCG-50014 | 883050-24-6 | Reference compound |
| HY-135090 | m-PEG8-Tos | 82217-01-4 | Reference compound |
| HY-135094 | Palmitoyl glutamic acid | 38079-66-2 | Reference compound |
| HY-135094R | Palmitoyl glutamic acid (Standard) | 38079-66-2 | Reference Standards |
| HY-135096 | Amitriptyline-d3 (hydrochloride) | 342611-00-1 | Reference compound |
| HY-13510 | Cutamesine dihydrochloride | 165377-44-6 | Reference compound |
| HY-135101 | Methotrexate γ-Methyl Ester | 67022-39-3 | Reference compound |
| HY-135102 | Laidlomycin propionate (potassium) | 84799-02-0 | Reference compound |
| HY-135103 | Tauro-β-muricholic acid (sodium) | 145022-92-0 | Reference compound |
| HY-135103S | Tauro-β-muricholic acid-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-135107 | (S)-Ademetionine | 78548-84-2 | Reference compound |
| HY-135108 | QWF Peptide | 126088-82-2 | Peptides |
| HY-13511 | Rupatadine | 158876-82-5 | Reference compound |
| HY-135110 | Rp-8-Br-cGMPS (sodium) | 208445-06-1 | Reference compound |
| HY-135110A | Rp-8-Br-cGMPS | 150418-07-8 | Reference compound |
| HY-135111 | 4-Desmethoxy Omeprazole | 110374-16-8 | Reference compound |
| HY-135111R | 4-Desmethoxy Omeprazole (Standard) | 110374-16-8 | Reference Standards |
| HY-135113 | Lanthionine | 922-55-4 | Peptides |
| HY-135114 | Hydroxypropyl-beta-cyclodextrin | 107745-73-3 | Reference compound |
| HY-135115 | Oleuropein Aglycone | 31773-95-2 | Reference compound |
| HY-135119 | Salmeterol-d3 | 497063-94-2 | Isotope-Labeled Compounds |
| HY-13511A | Rupatadine (Fumarate) | 182349-12-8 | Reference compound |
| HY-13511AR | Rupatadine (Fumarate) (Standard) | 182349-12-8 | Reference Standards |
| HY-13511AS | Rupatadine-d4 (fumarate) | 1795153-63-7 | Isotope-Labeled Compounds |
| HY-13511R | Rupatadine (Standard) | 158876-82-5 | Reference Standards |
| HY-13511S | Rupatadine-d6 (D-tartrate) | | Isotope-Labeled Compounds |
| HY-13512 | Camostat (mesylate) | 59721-29-8 | Reference compound |
| HY-135121 | Ethacizine (hydrochloride) | 57530-40-2 | Reference compound |
| HY-135122 | DC10SMe | 2649727-40-0 | ADC Related |
| HY-135123 | DC4SMe | 615538-47-1 | ADC Related |
| HY-135124 | DC44SMe | 1354787-76-0 | ADC Related |
| HY-135125 | DC4 | 615538-48-2 | ADC Related |
| HY-135127 | Dot1L-IN-4 | 2565705-02-2 | Reference compound |
| HY-135128 | Dot1L-IN-5 | 2565705-03-3 | Reference compound |
| HY-135129 | Dot1L-IN-6 | 2565705-01-1 | Reference compound |
| HY-13512R | Camostat (mesylate) (Standard) | 59721-29-8 | Reference Standards |
| HY-13513 | U-104 | 178606-66-1 | Reference compound |
| HY-135130 | Bischloroanthrabenzoxocinone | 866022-28-8 | Natural Products |
| HY-135131 | Synthalin (hydrochloride) | 301-15-5 | Reference compound |
| HY-135133 | S-Phenylsulfonylcysteine | 97512-83-9 | Reference compound |
| HY-135136 | Aldehyde reactive probe (TFA) | 627090-10-2 | Reference compound |
| HY-135137 | Leptosin I | 160472-96-8 | Reference compound |
| HY-135139 | Methylbenzethonium (chloride hydrate) | 1320-44-1 | Reference compound |
| HY-13514 | TG 100713 | 925705-73-3 | Reference compound |
| HY-135140 | Methyltetrazine-amine | 1345955-28-3 | Reference compound |
| HY-135140A | Methyltetrazine-amine (hydrochloride) | 1596117-29-1 | Reference compound |
| HY-135142 | Br-PEG3-OH | 57641-67-5 | Reference compound |
| HY-135145 | Limantrafin | 218457-67-1 | Reference compound |
| HY-135146 | GSK-3484862 | 2170136-65-7 | Reference compound |
| HY-135146A | (Rac)-GSK-3484862 | 2170136-02-2 | Reference compound |
| HY-13515 | Sirtinol | 410536-97-9 | Reference compound |
| HY-135151 | Difluoro atorvastatin | 693794-20-6 | Reference compound |
| HY-135152 | CYPMPO | 934182-09-9 | Reference compound |
| HY-135153 | Methylamino-PEG4-acid | 1283658-71-8 | Reference compound |
| HY-135154 | epi-Aszonalenin A | 908853-14-5 | Natural Products |
| HY-135158 | Prolylvaline | 20488-27-1 | Peptides |
| HY-13516 | Aloperine | 56293-29-9 | Natural Products |
| HY-135161 | EDDP (perchlorate) | 31161-17-8 | Reference compound |
| HY-135163 | trans-Latanoprost | 913258-34-1 | Reference compound |
| HY-135164 | Lonchocarpic acid | 5490-47-1 | Natural Products |
| HY-135165 | Hydrobenzole (hydrochloride) | 37975-24-9 | Reference compound |
| HY-135166 | 2-(1-Hydroxypentyl)benzoic acid | 380905-48-6 | Reference compound |
| HY-135167 | HOCPCA | 867178-11-8 | Reference compound |
| HY-135169 | Mal-PEG3-Boc | 518044-35-4 | Reference compound |
| HY-135170 | Myristoyl-L-carnitine (chloride) | 173686-73-2 | Reference compound |
| HY-135170R | Myristoyl-L-carnitine (chloride) (Standard) | 173686-73-2 | Reference Standards |
| HY-135170S | Myristoyl-L-carnitine-d3 (chloride) | 1334532-25-0 | Isotope-Labeled Compounds |
| HY-135172 | Suc-Leu-Tyr-AMC | 94367-20-1 | Dye Reagents |
| HY-135174 | L-Cysteine-glutathione disulfide | 13081-14-6 | Reference compound |
| HY-135175 | Phenoprolamine (hydrochloride) | 93933-71-2 | Reference compound |
| HY-135176 | 13-Dihydrocarminomycin | 62182-86-9 | Natural Products |
| HY-135179 | Biotin-PEG3-alcohol | 289714-02-9 | Reference compound |
| HY-13518 | Piceatannol | 10083-24-6 | Natural Products |
| HY-135180 | 1H-1-Ethyl Candesartan Cilexetil | 914613-35-7 | Reference compound |
| HY-135180R | 1H-1-Ethyl Candesartan Cilexetil (Standard) | 914613-35-7 | Reference Standards |
| HY-135181 | Daunosamnyl-daunorubicin | 28008-54-0 | Reference compound |
| HY-135184 | Rifaquizinone | 922717-97-3 | Reference compound |
| HY-135186 | L-Monomenthyl glutarate | 220621-22-7 | Reference compound |
| HY-135187 | 8-Isoquinoline methanamine (hydrochloride) | 850734-84-8 | Reference compound |
| HY-135189 | 6-Aminophenanthridine | 832-68-8 | Reference compound |
| HY-13518R | Piceatannol (Standard) | 10083-24-6 | Reference Standards |
| HY-13519 | TRAM-34 | 289905-88-0 | Reference compound |
| HY-135190 | (-)-Cedrene | 469-61-4 | Natural Products |
| HY-135194 | Risperidone E-oxime | 691007-09-7 | Reference compound |
| HY-135194R | Risperidone E-oxime (Standard) | 691007-09-7 | Reference Standards |
| HY-135197 | L-Iduronic acid (sodium salt) | 61199-83-5 | Reference compound |
| HY-135199 | Ubiquitination-IN-1 | 1819330-15-8 | Reference compound |
| HY-13520 | Nocodazole | 31430-18-9 | Reference compound |
| HY-135200 | 4-Amino benzamidoxime | 277319-62-7 | Reference compound |
| HY-135201 | 3,4-Methylenedioxy PV8 (hydrochloride) | 24646-39-7 | Reference compound |
| HY-135202 | Chloromethylketone methotrexate | 83160-47-8 | Reference compound |
| HY-135203 | Cysteinylcysteine | 18048-87-8 | Reference compound |
| HY-135204 | Deschloronorketamine (hydrochloride) | 7015-20-5 | Reference compound |
| HY-135208 | tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate | 916048-02-7 | Reference compound |
| HY-13521 | SB-505124 | 694433-59-5 | Reference compound |
| HY-135211 | Rubomycin H | 38942-79-9 | Natural Products |
| HY-135212 | Hydroxy ipronidazole | 35175-14-5 | Reference compound |
| HY-135212R | Hydroxy ipronidazole (Standard) | 35175-14-5 | Reference Standards |
| HY-135212S | Hydroxy ipronidazole-d3 | 1156508-86-9 | Isotope-Labeled Compounds |
| HY-135214 | GA11 | 851053-64-0 | Reference compound |
| HY-135216 | Antiproliferative agent-54 | 1240322-54-6 | Reference compound |
| HY-135217 | Apiole | 523-80-8 | Natural Products |
| HY-135217R | Apiole (Standard) | 523-80-8 | Reference Standards |
| HY-135218 | AV-153 | 27296-05-5 | Reference compound |
| HY-135218A | AV-153 (free base) | 19350-66-4 | Reference compound |
| HY-13521A | SB-505124 (hydrochloride) | 356559-13-2 | Reference compound |
| HY-13522 | Fimepinostat | 1339928-25-4 | Reference compound |
| HY-135220 | PERK-IN-2 | 1337531-83-5 | Reference compound |
| HY-135221 | Cefcapene pivoxil (hydrochloride) | 147816-23-7 | Reference compound |
| HY-135221A | Cefcapene pivoxil | 105889-45-0 | Reference compound |
| HY-135221R | Cefcapene pivoxil (hydrochloride) (Standard) | 147816-23-7 | Reference Standards |
| HY-135222 | MMAI (hydrochloride) | 132980-17-7 | Reference compound |
| HY-135224 | 1,4-PBIT (dihydrobromide) | 157254-60-9 | Reference compound |
| HY-135226 | PROLI NONOate | 178948-42-0 | Reference compound |
| HY-135228 | GZ4 | 68312-88-9 | Reference compound |
| HY-13523 | PAC-1 | 315183-21-2 | Reference compound |
| HY-135230 | LY2444296 | 1346133-11-6 | Reference compound |
| HY-135231 | NL-1 | 188532-26-5 | Reference compound |
| HY-135232 | MMP-9-IN-1 | 502887-71-0 | Reference compound |
| HY-135233 | N-Succinimidyl-S-acetylthioacetate | 76931-93-6 | Biochemical Assay Reagents |
| HY-135235 | Cysteine thiol probe | 1947408-74-3 | Reference compound |
| HY-135236 | OXFBD04 | 2231747-03-6 | Reference compound |
| HY-135237 | DB04760 analog 1 | 2728373-94-0 | Reference compound |
| HY-135238 | (rel)-RSD 921 | 111728-01-9 | Reference compound |
| HY-135239 | Fura-FF (pentapotassium) | 192140-58-2 | Dye Reagents |
| HY-13524 | AG-1478 | 153436-53-4 | Reference compound |
| HY-135241 | 25I-NBF (hydrochloride) | 1539266-13-1 | Reference compound |
| HY-135242 | LY87130 (free base) | 72877-72-6 | Reference compound |
| HY-135244 | Imazamethabenz-methyl | 81405-85-8 | Reference compound |
| HY-135244R | Imazamethabenz-methyl (Standard) | 81405-85-8 | Reference Standards |
| HY-135245 | Ezetimibe hydroxy glucuronide | 536709-33-8 | Reference compound |
| HY-13524A | AG-1478 (hydrochloride) | 170449-18-0 | Reference compound |
| HY-13525 | CP-91149 | 186392-40-5 | Reference compound |
| HY-135250 | Thalidomide-4-O-C6-NH2 | 1957235-98-1 | Reference compound |
| HY-135250A | Thalidomide-4-O-C6-NH2 (TFA) | 1957235-99-2 | Reference compound |
| HY-135250B | Thalidomide-4-O-C6-NH2 (hydrochloride) | 2245697-88-3 | Reference compound |
| HY-135252 | N-Desbutyroyl acebutolol | 57898-80-3 | Reference compound |
| HY-135253 | GR122222X | 161161-54-2 | Reference compound |
| HY-135254 | CP-46665 (dihydrochloride) | 72618-10-1 | Reference compound |
| HY-135256 | Naphthol yellow S, 98% | 846-70-8 | Biochemical Assay Reagents |
| HY-135258 | Galactinol (dihydrate) | 1217474-91-3 | Reference compound |
| HY-135259 | CAY10580 | 64054-40-6 | Reference compound |
| HY-13526 | YO-01027 | 209984-56-5 | Reference compound |
| HY-135265 | Moclobemide N-Oxide | 64544-24-7 | Reference compound |
| HY-135266 | N-Ethyl Tadalafil | 1609405-34-6 | Reference compound |
| HY-135267 | 5-Fluoropentylindole | 1859218-30-6 | Reference compound |
| HY-135269 | Quin II (potassium) | 73630-23-6 | Dye Reagents |
| HY-13526G | YO-01027 (GMP) | 209984-56-5 | GMP Small Molecules |
| HY-13527 | LY310762 | 192927-92-7 | Reference compound |
| HY-135270 | ADRA1D receptor antagonist 1 | 1191908-14-1 | Reference compound |
| HY-135273 | A-1211212 | 1257044-75-9 | Reference compound |
| HY-135276 | Targaprimir-96 | 1655508-14-7 | Reference compound |
| HY-135276A | Targaprimir-96 (TFA) | | Reference compound |
| HY-135279 | CFTR corrector 4 | 1918142-34-3 | Reference compound |
| HY-13528 | Clinofibrate | 30299-08-2 | Reference compound |
| HY-135280 | MRL-650 | 852315-00-5 | Reference compound |
| HY-135281 | CYP11B2-IN-1 | 1356479-78-1 | Reference compound |
| HY-135282 | DHODH-IN-1 | 1800296-63-2 | Reference compound |
| HY-135283 | ABT-546 | 212481-66-8 | Reference compound |
| HY-135284 | FTY720-Mitoxy | 1604816-11-6 | Reference compound |
| HY-135285 | Rifamexil | 113102-19-5 | Reference compound |
| HY-135286A | (+)-Neomenthol | 2216-52-6 | Natural Products |
| HY-135286AR | (+)-Neomenthol (Standard) | 2216-52-6 | Reference Standards |
| HY-13529 | Globalagliatin | 1234703-40-2 | Reference compound |
| HY-135297 | Mono-and diglycerides | | Reference compound |
| HY-135298 | Soya fatty acids | 68308-53-2 | Reference compound |
| HY-135299 | CH6953755 | 2055918-71-1 | Reference compound |
| HY-13530 | CAY10505 | 1218777-13-9 | Reference compound |
| HY-135301 | Flavanone hydrazone | 1692-46-2 | Reference compound |
| HY-135303 | GLPG1205 | 1445847-37-9 | Reference compound |
| HY-135304 | PAD-IN-2 | 2304852-21-7 | Reference compound |
| HY-135306 | Cl-C6-PEG4-C3-COOH | 2127391-58-4 | Reference compound |
| HY-135307 | SSF-109 | 129586-32-9 | Reference compound |
| HY-135309 | PROTAC ER Degrader-4 | 2361114-15-8 | Reference compound |
| HY-13531 | AS-604850 | 648449-76-7 | Reference compound |
| HY-135312 | AZ'6421 | 2361115-35-5 | Reference compound |
| HY-135317 | Emavusertib | 1801344-14-8 | Reference compound |
| HY-135317B | Emavusertib (hydrochloride) | 2376399-42-5 | Reference compound |
| HY-135317C | Emavusertib (tosylate) | 2376399-41-4 | Reference compound |
| HY-135317D | Emavusertib (mesylate) | 2376399-40-3 | Reference compound |
| HY-135317E | Emavusertib (maleate) | 2376399-39-0 | Reference compound |
| HY-135317F | Emavusertib (phosphate) | 2376399-38-9 | Reference compound |
| HY-135318 | NBDHEX | 787634-60-0 | Reference compound |
| HY-135319 | Strictinin | 517-46-4 | Natural Products |
| HY-13532 | AS-252424 | 900515-16-4 | Reference compound |
| HY-135324 | 4,4'-Iminodiphenol | 1752-24-5 | Reference compound |
| HY-135325 | 4-Hydroxyacetophenone oxime | 34523-34-7 | Reference compound |
| HY-135325R | 4-Hydroxyacetophenone oxime (Standard) | 34523-34-7 | Reference Standards |
| HY-135326 | 4-Propionamidophenol | 1693-37-4 | Reference compound |
| HY-135326R | 4-Propionamidophenol (Standard) | 1693-37-4 | Reference Standards |
| HY-135327 | Amphotericin B methyl ester | 36148-89-7 | Reference compound |
| HY-135327A | Amphotericin B methyl ester (hydrochloride) | 35375-29-2 | Reference compound |
| HY-135328 | Norverapamil | 67018-85-3 | Reference compound |
| HY-135328AS | Norverapamil-d7 (hydrochloride) | 1216413-74-9 | Isotope-Labeled Compounds |
| HY-135328S | Norverapamil-d7 | 263175-44-6 | Isotope-Labeled Compounds |
| HY-135329 | Solifenacin D5 (hydrochloride) | 1426174-05-1 | Reference compound |
| HY-135329S | (1R,3S-)Solifenacin-d5 (hydrochloride) | 1217810-85-9 | Isotope-Labeled Compounds |
| HY-135330 | Lamivudine-13C,15N2 | 1391052-30-4 | Isotope-Labeled Compounds |
| HY-135331 | N-Desmethyl-Apalutamide | 1332391-11-3 | Reference compound |
| HY-135331S | N-Desmethyl-Apalutamide-15N,d4 | | Isotope-Labeled Compounds |
| HY-135334 | ACP-5862 | 2230757-47-6 | Reference compound |
| HY-135334S | ACP-5862-d4 | | Isotope-Labeled Compounds |
| HY-135335 | 3'-Hydroxy Repaglinide | 874908-14-2 | Reference compound |
| HY-135335S | 3'-Hydroxy Repaglinide-d5 | 1352792-15-4 | Isotope-Labeled Compounds |
| HY-135336 | (R)-Verapamil (hydrochloride) | 38176-02-2 | Reference compound |
| HY-135336A | (S)-Verapamil (hydrochloride) | 36622-28-3 | Reference compound |
| HY-135336AS | (S)-Verapamil-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-135336BS | (Rac)-Verapamil-d7 (hydrochloride) | 1188265-55-5 | Isotope-Labeled Compounds |
| HY-135336S | (R)-Verapamil-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-135337 | Ethyl tosylcarbamate | 5577-13-9 | Reference compound |
| HY-135339 | Benzyl-PEG2-CH2COOH | 91842-53-4 | Reference compound |
| HY-13534 | Abarelix | 183552-38-7 | Peptides |
| HY-135345 | PROTAC FKBP Degrader-3 | 2079056-43-0 | Reference compound |
| HY-13534A | Abarelix (Acetate) | 547741-72-0 | Peptides |
| HY-13535 | ATN-161 | 262438-43-7 | Reference compound |
| HY-135356 | m-Nifedipine | 21881-77-6 | Reference compound |
| HY-135356R | m-Nifedipine (Standard) | 21881-77-6 | Reference Standards |
| HY-135357 | Diisohexyl phthalate | 71850-09-4 | Reference compound |
| HY-135358 | (Rac)-5-Keto Fluvastatin | 1160169-39-0 | Reference compound |
| HY-135359 | RP 48497 | 148891-53-6 | Reference compound |
| HY-135359R | RP 48497 (Standard) | 148891-53-6 | Reference Standards |
| HY-13535A | ATN-161 (trifluoroacetate salt) | 904763-27-5 | Reference compound |
| HY-13536 | AZD-2461 | 1174043-16-3 | Reference compound |
| HY-135363 | Valsartan Ethyl Ester | 1111177-30-0 | Reference compound |
| HY-135366 | HPN-01 | 928655-63-4 | Reference compound |
| HY-135367 | pyCTZ | 2125486-34-0 | Dye Reagents |
| HY-135367A | pyCTZ (TFA) | | Dye Reagents |
| HY-135367B | pyCTZ (hydrochloride) | | Dye Reagents |
| HY-135368 | 8pyDTZ | 2351898-91-2 | Dye Reagents |
| HY-13537 | BPR1J-097 | 1327167-19-0 | Reference compound |
| HY-135372 | Descarbamoyl cefuroxime | 56271-94-4 | Reference compound |
| HY-135373 | Desfluoro-atorvastatin | 433289-84-0 | Reference compound |
| HY-135374 | (3R,5S)-Atorvastatin (sodium) | 131275-93-9 | Reference compound |
| HY-135375 | O-Methyl Atorvastatin (calcium) | 887196-29-4 | Reference compound |
| HY-135376 | Atorvastatin methyl ester | 345891-62-5 | Reference compound |
| HY-135377 | Atorvastatin 3-Deoxyhept-2E-Enoic Acid | 1105067-93-3 | Reference compound |
| HY-135378 | Atorvastatin ethyl ester | 1146977-93-6 | Reference compound |
| HY-135379 | Atorvastatin acetonide | 581772-29-4 | Reference compound |
| HY-13537A | BPR1J-097 Hydrochloride | | Reference compound |
| HY-13538 | Gemcitabine elaidate | 210829-30-4 | Reference compound |
| HY-135380 | Atorvastatin acetonide tert-butyl ester | 125971-95-1 | Reference compound |
| HY-135380R | Atorvastatin acetonide tert-butyl ester (Standard) | 125971-95-1 | Reference Standards |
| HY-135381 | 3-Oxo Atorvastatin | 887196-30-7 | Reference compound |
| HY-135382 | PROTAC IRAK4 degrader-2 | 2374122-27-5 | Reference compound |
| HY-135382A | PROTAC IRAK4 degrader-3 | 2374122-43-5 | Reference compound |
| HY-135383 | (3S,5S)-Pitavastatin (calcium) | 254452-92-1 | Reference compound |
| HY-135383A | (3S,5R)-Pitavastatin (calcium) | 254452-88-5 | Reference compound |
| HY-135383B | (Z)-Pitavastatin (calcium) | 1159588-21-2 | Reference compound |
| HY-135384 | tert-Buthyl Pitavastatin | 586966-54-3 | Reference compound |
| HY-135384R | tert-Buthyl Pitavastatin (Standard) | 586966-54-3 | Reference Standards |
| HY-135385 | Dihydro Dutasteride | 164656-22-8 | Reference compound |
| HY-135386 | 5β-Dutasteride | 957229-52-6 | Reference compound |
| HY-135387 | 4-Desmethyl Istradefylline | 160434-48-0 | Reference compound |
| HY-135388 | ent-Ezetimibe | 1376614-99-1 | Reference compound |
| HY-135389 | Desmethyl Levofloxacin | 117707-40-1 | Reference compound |
| HY-135389R | Desmethyl Levofloxacin (Standard) | 117707-40-1 | Reference Standards |
| HY-135389S | Desmethyl Levofloxacin-d8 (hydrochloride) | 1217677-38-7 | Isotope-Labeled Compounds |
| HY-135389S1 | Desmethyl Levofloxacin-d8 | 1217976-18-5 | Isotope-Labeled Compounds |
| HY-13538A | Gemcitabine elaidate (hydrochloride) | 2918768-08-6 | Reference compound |
| HY-135390 | Hydroxy desmethyl Bosentan | 253688-62-9 | Reference compound |
| HY-135391 | Ezetimibe phenoxy glucuronide | 190448-57-8 | Reference compound |
| HY-135391S | Ezetimibe phenoxy glucuronide-d4 | 1426174-41-5 | Isotope-Labeled Compounds |
| HY-135392 | N-Desmethyl Pimavanserin | 639863-77-7 | Reference compound |
| HY-135392R | N-Desmethyl Pimavanserin (Standard) | 639863-77-7 | Reference Standards |
| HY-135392S | N-Desmethyl Pimavanserin-d9 (hydrochloride) | 2712363-60-3 | Isotope-Labeled Compounds |
| HY-135393S | Sulfadimethoxypyrimidine-d4 | 1392211-88-9 | Isotope-Labeled Compounds |
| HY-135394 | 3-Desacetyl Cefotaxime lactone | 66340-33-8 | Reference compound |
| HY-135394R | 3-Desacetyl Cefotaxime lactone (Standard) | 66340-33-8 | Reference Standards |
| HY-135396 | (1S,2S)-Bortezomib | 1132709-14-8 | Reference compound |
| HY-135397 | (R)-Linezolid | 872992-20-6 | Reference compound |
| HY-135397R | (R)-?Linezolid (Standard) | 872992-20-6 | Reference Standards |
| HY-135398 | Decarboxy Moxifloxacin | 1322062-57-6 | Reference compound |
| HY-135399 | Tauro-obeticholic acid | 863239-61-6 | Reference compound |
| HY-135399A | Tauro-obeticholic acid (sodium) | 2278141-79-8 | Reference compound |
| HY-135399S | Tauro-obeticholic acid-d5 (sodium) | | Isotope-Labeled Compounds |
| HY-13540 | E7016 | 902128-92-1 | Reference compound |
| HY-135400 | Glyco-Obeticholic acid | 863239-60-5 | Reference compound |
| HY-135400S | Glyco-obeticholic acid-d5 | | Isotope-Labeled Compounds |
| HY-135401 | VU6015929 | 2442597-56-8 | Reference compound |
| HY-135402 | 2'-Ethyl Simvastatin | 79902-42-4 | Reference compound |
| HY-135404 | Anhydrosimvastatin | 210980-68-0 | Reference compound |
| HY-135404R | Anhydrosimvastatin (Standard) | 210980-68-0 | Reference Standards |
| HY-135405 | 4-Acetylsimvastatin | 145576-25-6 | Reference compound |
| HY-135405R | 4-Acetylsimvastatin (Standard) | 145576-25-6 | Reference Standards |
| HY-135406 | (3R,5R)-Rosuvastatin Lactone | 1422954-11-7 | Reference compound |
| HY-135407S | N-Desethyl Oxybutynin-d5 (hydrochloride) | 1173018-49-9 | Isotope-Labeled Compounds |
| HY-135408 | Trimetazidine-N-oxide | 1644530-89-1 | Reference compound |
| HY-13541 | ADH-1 | 229971-81-7 | Peptides |
| HY-135410 | ABZ-amine | 80983-36-4 | Reference compound |
| HY-135410R | ABZ-amine (Standard) | 80983-36-4 | Reference Standards |
| HY-135412 | N-Methyl Duloxetine (hydrochloride) | 916135-70-1 | Reference compound |
| HY-135413 | MeCY5-NHS ester | 937739-58-7 | Reference compound |
| HY-135413A | Sulfo-CY5-NHS ester (potassium) | 2230212-27-6 | Reference compound |
| HY-135413B | MeCY5-NHS ester (triethylamine) | | Reference compound |
| HY-135414 | Cyanine5 NHS ester (chloride) | 1032678-42-4 | Dye Reagents |
| HY-135414A | Cyanine5 NHS ester (bromide) | 1653991-59-3 | Dye Reagents |
| HY-135414B | Cyanine5 NHS ester (iodide) | | Dye Reagents |
| HY-135415 | Cyanine5.5 NHS ester (chloride) | 1469277-96-0 | Dye Reagents |
| HY-135415A | Cyanine5.5 NHS ester (chloride) (TEA) | | Dye Reagents |
| HY-135416 | Streptolysin O | 98072-47-0 | Natural Products |
| HY-135416A | Streptolysin O (≥1000000 units/mg) | 98072-47-0 | Reference compound |
| HY-135418 | Fmoc-Asp-NH2 | 200335-40-6 | ADC Related |
| HY-135419 | CB2 modulator 1 | 666261-80-9 | Reference compound |
| HY-13541A | ADH-1 (trifluoroacetate) | 1135237-88-5 | Peptides |
| HY-13542 | Guadecitabine | 929901-49-5 | Reference compound |
| HY-135421 | Dehydrobruceantinol | 99132-99-7 | Natural Products |
| HY-135422 | Nidulin | 10089-10-8 | Natural Products |
| HY-135423 | Sprodiamide | 128470-17-7 | Reference compound |
| HY-135425 | 10,12-Tricosadiynoic acid | 66990-30-5 | Reference compound |
| HY-135425R | 10,12-Tricosadiynoic acid (Standard) | 66990-30-5 | Reference Standards |
| HY-13543 | Tretazicar | 21919-05-1 | Reference compound |
| HY-135430 | SRS16-86 | 1793052-96-6 | Reference compound |
| HY-135432 | Etrasimod (arginine) | 1206123-97-8 | Reference compound |
| HY-135433 | MAPTAM | 147504-94-7 | Reference compound |
| HY-135434 | Prerubialatin | 1667718-89-9 | Reference compound |
| HY-135436 | AG 538 | 133550-18-2 | Reference compound |
| HY-135437 | Dodovisone B | 1616683-51-2 | Natural Products |
| HY-135438 | Mollugogenol A | 22550-76-1 | Reference compound |
| HY-135441 | PF-06422913 | 1539296-46-2 | Reference compound |
| HY-135444 | Heliangin | 13323-48-3 | Natural Products |
| HY-135445 | Prolylrapamycin | 156223-31-3 | Natural Products |
| HY-135447 | BM-531 | 284464-46-6 | Biochemical Assay Reagents |
| HY-135448 | 25G-NBOMe (hydrochloride) | 1797132-54-7 | Reference compound |
| HY-13545 | ABT-510 | 251579-55-2 | Peptides |
| HY-135453 | (-)-Pinocembrin | 206660-42-6 | Natural Products |
| HY-135456 | Ro4368554 | 478082-99-4 | Reference compound |
| HY-135457 | JMS-053 | 1954650-11-3 | Reference compound |
| HY-13545B | ABT-510 (acetate) | 442526-87-6 | Peptides |
| HY-13546 | ABT-518 | 286845-00-9 | Reference compound |
| HY-135460 | Milameline | 139886-32-1 | Reference compound |
| HY-135463 | NDSB-221 | 160788-56-7 | Biochemical Assay Reagents |
| HY-135464 | (±)-LY367385 | 198419-90-8 | Reference compound |
| HY-135466 | Profluralin | 26399-36-0 | Reference compound |
| HY-135466R | Profluralin (Standard) | 26399-36-0 | Reference Standards |
| HY-135468 | Boromycin | 34524-20-4 | Natural Products |
| HY-13547 | ADPM06 | 490035-90-0 | Reference compound |
| HY-135470 | Nifurpirinol | 13411-16-0 | Reference compound |
| HY-135470R | Nifurpirinol (Standard) | 13411-16-0 | Reference Standards |
| HY-135472 | Spinosyn A 17-pseudoaglycone | 131929-68-5 | Reference compound |
| HY-135473 | Chlormadinone | 1961-77-9 | Reference compound |
| HY-135473R | Chlormadinone (Standard) | 1961-77-9 | Reference Standards |
| HY-135473S | Chlormadinone-d6 | | Isotope-Labeled Compounds |
| HY-135474 | KM91104 | 304481-60-5 | Reference compound |
| HY-135475 | (R)-Meclizine | 189298-48-4 | Reference compound |
| HY-135476 | Depudecin | 139508-73-9 | Natural Products |
| HY-135478 | LY393615 | 325819-97-4 | Reference compound |
| HY-135478A | LY393615 (free base) | 774528-12-0 | Reference compound |
| HY-135479 | A28695B | 42617-35-6 | Reference compound |
| HY-13548 | DL-Alanosine | 5854-95-5 | Reference compound |
| HY-135480 | Geninthiocin | 158792-27-9 | Natural Products |
| HY-135482 | GABAA receptor agent 2 (TFA) | 1781880-44-1 | Reference compound |
| HY-135483A | AR-R17779 (hydrochloride) | 178419-42-6 | Reference compound |
| HY-135484 | NDSB-195 | 160255-06-1 | Biochemical Assay Reagents |
| HY-135489 | (±)-Reticuline | 1699-46-3 | Reference compound |
| HY-135490 | Reproterol | 54063-54-6 | Reference compound |
| HY-135492 | O-Methylmoschatoline | 5140-38-5 | Natural Products |
| HY-135495 | AM-0466 | 1642113-59-4 | Reference compound |
| HY-135496 | Fluclotizolam | 54123-15-8 | Reference compound |
| HY-135497 | Fallypride | 166173-78-0 | Reference compound |
| HY-135498 | Ferrioxamine E | 20008-20-2 | Reference compound |
| HY-13550 | Ametantrone | 64862-96-0 | Reference compound |
| HY-135500 | ACT-373898 | 1433875-14-9 | Reference compound |
| HY-135501 | Bamifylline | 2016-63-9 | Reference compound |
| HY-135505 | JTP-103237 | 1883864-16-1 | Reference compound |
| HY-135507 | NAS-181 | 205242-62-2 | Reference compound |
| HY-135507A | NAS-181 (free base) | 205242-61-1 | Reference compound |
| HY-135509 | Lorlatinib (acetate) | 1924207-18-0 | Reference compound |
| HY-13550A | Ametantrone (acetate) | 70711-40-9 | Reference compound |
| HY-13551 | Amsacrine | 51264-14-3 | Reference compound |
| HY-135511 | Nor-Cerpegin | 145887-88-3 | Reference compound |
| HY-135514 | Lys-Phe | 6235-35-4 | Reference compound |
| HY-135516 | Dalosirvat | 1360540-81-3 | Reference compound |
| HY-135517 | RXP470.1 | 891198-31-5 | Reference compound |
| HY-135517A | (2R)-RXP470.1 | | Reference compound |
| HY-13551A | Amsacrine (hydrochloride) | 54301-15-4 | Reference compound |
| HY-13551B | Amsacrine (gluconate) | 80277-07-2 | Reference compound |
| HY-13551R | Amsacrine (Standard) | 51264-14-3 | Reference Standards |
| HY-135520 | Trimannosyldilysine | 79390-81-1 | Reference compound |
| HY-135521 | U-49900 | 67579-76-4 | Reference compound |
| HY-135522 | Securinol A | 5008-48-0 | Natural Products |
| HY-135525 | Agroclavine | 548-42-5 | Natural Products |
| HY-135526 | Demethoxyviridiol | 56617-66-4 | Reference compound |
| HY-13553 | Anidulafungin | 166663-25-8 | Reference compound |
| HY-135530 | Chinese gallotannin | 5424-20-4 | Natural Products |
| HY-135531 | Cefuzonam | 82219-78-1 | Reference compound |
| HY-135532 | Amoxicillin-clavulanate (potassium) | 74469-00-4 | Reference compound |
| HY-135533 | Chromomycin A2 | 6992-70-7 | Natural Products |
| HY-135534 | Lysine 4-nitroanilide | 6184-11-8 | Reference compound |
| HY-13553R | Anidulafungin (Standard) | 166663-25-8 | Reference Standards |
| HY-13553S1 | Anidulafungin-13C6 | | Isotope-Labeled Compounds |
| HY-13554 | Annamycin | 92689-49-1 | Reference compound |
| HY-135541 | Darexaban (maleate) | 365462-24-4 | Reference compound |
| HY-135542 | NBI-27914 | 184241-44-9 | Reference compound |
| HY-135543 | Levophencynonate | 230313-75-4 | Reference compound |
| HY-135549 | Fluxapyroxad | 907204-31-3 | Reference compound |
| HY-135549R | Fluxapyroxad (Standard) | 907204-31-3 | Reference Standards |
| HY-13555 | β-Lapachone | 4707-32-8 | Natural Products |
| HY-135551 | Delbonine | 95066-33-4 | Natural Products |
| HY-135552 | Benoxathian (hydrochloride) | 92642-97-2 | Reference compound |
| HY-135555 | 5-Carboxamidotryptamine | 74885-09-9 | Reference compound |
| HY-135556 | Norfluoxetine | 83891-03-6 | Natural Products |
| HY-135556A | Norfluoxetine (oxalate) | 107674-50-0 | Reference compound |
| HY-135556AS | Norfluoxetine-d5 | 1185132-92-6 | Isotope-Labeled Compounds |
| HY-135558 | PROTAC BRD4 Degrader-3 | 2313234-00-1 | Reference compound |
| HY-13556 | Arzoxifene | 182133-25-1 | Reference compound |
| HY-135560 | Nicotelline | 494-04-2 | Reference compound |
| HY-135560S | Nicotelline-d9 | 2469258-18-0 | Isotope-Labeled Compounds |
| HY-135562 | Ascofuranone | 38462-04-3 | Reference compound |
| HY-135563 | Oxoprolintane | 35259-27-9 | Reference compound |
| HY-135564 | RK-682 (hemicalcium) | 332131-32-5 | Reference compound |
| HY-135564A | RK-682 | 150627-37-5 | Reference compound |
| HY-135564B | (Rac)-RK-682 | 154639-24-4 | Reference compound |
| HY-135566S | Clenpenterol-d5 (hydrochloride) | 1794793-20-6 | Isotope-Labeled Compounds |
| HY-135568 | CRL42872 (free base) | 256344-23-7 | Reference compound |
| HY-13556A | Arzoxifene (hydrochloride) | 182133-27-3 | Reference compound |
| HY-13557 | Ascomycin | 104987-12-4 | Natural Products |
| HY-135570 | hDHODH-IN-3 | 1644156-80-8 | Reference compound |
| HY-135571 | VBIT-3 | 2088463-66-3 | Reference compound |
| HY-135572 | TLX agonist 1 | 958323-31-4 | Reference compound |
| HY-135577 | β-Apooxytetracycline | 18751-99-0 | Reference compound |
| HY-135577R | β-Apooxytetracycline (Standard) | 18751-99-0 | Reference Standards |
| HY-135578 | Artelinic acid | 120020-26-0 | Reference compound |
| HY-13557R | Ascomycin (Standard) | 104987-12-4 | Reference Standards |
| HY-135580 | Raloxifene Bismethyl Ether | 84541-38-8 | Reference compound |
| HY-135580A | Raloxifene Bismethyl Ether (hydrochloride) | 84541-36-6 | Reference compound |
| HY-135581 | Raloxifene 6-glucuronide | 174264-50-7 | Reference compound |
| HY-135581S1 | Raloxifene 6-glucuronide-d4 (lithium) | | Isotope-Labeled Compounds |
| HY-135582 | Raloxifene 4'-glucuronide | 182507-22-8 | Reference compound |
| HY-135582S | Raloxifene 4'-glucuronide-d4 | 1279033-52-1 | Isotope-Labeled Compounds |
| HY-135582S1 | Raloxifene 4'-glucuronide-d4 (lithium) | | Isotope-Labeled Compounds |
| HY-135583 | LY88074 Trimethyl ether | 63675-87-6 | Reference compound |
| HY-135584 | Raloxifene 6-Monomethyl Ether | 178451-13-3 | Reference compound |
| HY-135585 | LY88074 | 177744-96-6 | Reference compound |
| HY-135586 | Raloxifene N-Oxide | 195454-31-0 | Reference compound |
| HY-135586R | Raloxifene N-Oxide (Standard) | 195454-31-0 | Reference Standards |
| HY-135587 | 4'-tert-Butyldimethylsilyl-6-hydroxy Raloxifene | 174264-46-1 | Reference compound |
| HY-135588 | Raloxifene 6,4'-Bis-β-D-glucuronide | 182507-20-6 | Reference compound |
| HY-135589 | 7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene | 1159977-58-8 | Reference compound |
| HY-13559 | Atiprimod | 123018-47-3 | Reference compound |
| HY-135590 | Raloxifene 4-Monomethyl Ether | 185415-07-0 | Reference compound |
| HY-135591 | Methyl Raloxifene 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate) | 174264-51-8 | Reference compound |
| HY-135592 | LY88074 Methyl ether | 63675-88-7 | Reference compound |
| HY-135593 | LY88074 analog 1 | 183060-99-3 | Reference compound |
| HY-135594 | 4'-Raloxifene-β-D-glucopyranoside | 334758-19-9 | Reference compound |
| HY-135595 | 6-Raloxifene-β-D-glucopyranoside | 334758-18-8 | Reference compound |
| HY-135596 | Raloxifene dimethyl ester (hydrochloride) | 84449-82-1 | Reference compound |
| HY-135597 | N-Acetyl-5-methyl-L-tryptophan | 114872-77-4 | Reference compound |
| HY-135599 | Lysine hydroxamate | 25125-92-2 | Reference compound |
| HY-13559A | Atiprimod (dimaleate) | 183063-72-1 | Reference compound |
| HY-13560 | AVN-944 | 297730-17-7 | Reference compound |
| HY-135601 | Cinacalcet metabolite M4 | 104774-87-0 | Reference compound |
| HY-135604S | Dibutyl phosphate-d18 | 156213-21-7 | Isotope-Labeled Compounds |
| HY-135605 | PNU-145156E | 154788-16-6 | Reference compound |
| HY-135606 | LW479 | 1688677-89-5 | Reference compound |
| HY-135608 | BD-1008 | 138356-08-8 | Reference compound |
| HY-13561 | AZM475271 | 476159-98-5 | Reference compound |
| HY-135611 | Imidocarb | 27885-92-3 | Reference compound |
| HY-135611A | Imidocarb (dihydrochloride monohydrate) | | Reference compound |
| HY-135611R | Imidocarb (Standard) | 27885-92-3 | Reference Standards |
| HY-135613 | LY280748 | 153226-99-4 | Reference compound |
| HY-135614 | (+)-Lunacrine | 204686-65-7 | Natural Products |
| HY-135615 | Desmethyl Sibutramine | 168835-59-4 | Reference compound |
| HY-135615A | Desmethyl Sibutramine (hydrochloride) | 84467-94-7 | Reference compound |
| HY-135615AR | Desmethyl Sibutramine (hydrochloride) (Standard) | 84467-94-7 | Reference Standards |
| HY-135615AS | DesMethyl Sibutramine-d7 (hydrochloride) | 1188265-54-4 | Isotope-Labeled Compounds |
| HY-135618 | DHODH-IN-3 | 1148126-04-8 | Reference compound |
| HY-135619 | DHODH-IN-4 | 1148125-93-2 | Reference compound |
| HY-13562 | Banoxantrone | 136470-65-0 | Reference compound |
| HY-135624 | Neogen | 182295-87-0 | Reference compound |
| HY-135625 | BPH-1218 | 1426824-36-3 | Reference compound |
| HY-135627 | JBP485 | 211868-63-2 | Natural Products |
| HY-135628 | PD-85639 | 149838-21-1 | Reference compound |
| HY-13562A | Banoxantrone (dihydrochloride) | 252979-56-9 | Reference compound |
| HY-13562AS | Banoxantrone-d12 (dihydrochloride) | 1562066-98-1 | Isotope-Labeled Compounds |
| HY-13562S | Banoxantrone-d12 | 1562067-05-3 | Isotope-Labeled Compounds |
| HY-13563 | Batabulin | 195533-53-0 | Reference compound |
| HY-135632 | Hydroxychlorodenafil | 1391054-00-4 | Reference compound |
| HY-135634 | GNF-2-PEG-acid | 2749287-69-0 | Dye Reagents |
| HY-135635 | ABL-001-Amide-PEG3-acid | | Dye Reagents |
| HY-135636 | Ponatinib Acid | 2748500-17-4 | Dye Reagents |
| HY-135637 | Nilotinib Acid | 2748500-05-0 | Dye Reagents |
| HY-135638 | Imatinib Acid | 2741007-77-0 | Dye Reagents |
| HY-135639 | Alkyne-probe 1 | 2752193-03-4 | Dye Reagents |
| HY-13563A | Batabulin (sodium) | 195533-98-3 | Reference compound |
| HY-13564 | Batimastat | 130370-60-4 | Reference compound |
| HY-135640 | TAMRA-probe 1 | | Dye Reagents |
| HY-135641 | Biotin-probe 1 | | Dye Reagents |
| HY-135642 | SMS1-IN-1 | 1807943-38-9 | Reference compound |
| HY-135643 | Sanglifehrin A | 187148-13-6 | Reference compound |
| HY-135644 | Rencofilstat | 1383420-08-3 | Reference compound |
| HY-135646 | Eleutheroside B1 | 16845-16-2 | Natural Products |
| HY-135648 | PfDHODH-IN-1 | 183945-55-3 | Reference compound |
| HY-135649 | Tremorine | 51-73-0 | Reference compound |
| HY-13564A | Batimastat (sodium salt) | 130464-84-5 | Reference compound |
| HY-13565 | Becatecarin | 119673-08-4 | Reference compound |
| HY-135652 | Hexyl gallate | 1087-26-9 | Reference compound |
| HY-135653 | EC5026 | 1809885-32-2 | Reference compound |
| HY-135653A | (Rac)-EC5026 | 1809885-55-9 | Reference compound |
| HY-135654 | hDHODH-IN-2 | 183946-00-1 | Reference compound |
| HY-135655 | Fobrepodacin (disodium) | 1384984-20-6 | Reference compound |
| HY-135655A | Fobrepodacin | 1384984-31-9 | Reference compound |
| HY-135658 | hDHODH-IN-1 | 1173715-42-8 | Reference compound |
| HY-135659 | BSH-IN-1 | 2553217-91-5 | Reference compound |
| HY-13566 | Belotecan | 256411-32-2 | Reference compound |
| HY-135660 | MMAE-SMCC | 2021179-11-1 | ADC Related |
| HY-135663 | Methyl jasmonate | 1211-29-6 | Natural Products |
| HY-135664 | hDHODH-IN-5 | 2029049-77-0 | Reference compound |
| HY-135666 | DHODH-IN-8 | 1148126-03-7 | Reference compound |
| HY-135667 | hDHODH-IN-7 | 1644156-41-1 | Reference compound |
| HY-13566A | Belotecan (hydrochloride) | 213819-48-8 | Reference compound |
| HY-13566AS | Belotecan-d7 (hydrochloride) | 1346598-22-8 | Isotope-Labeled Compounds |
| HY-13567 | Bendamustine | 16506-27-7 | Reference compound |
| HY-135670 | Glycosidase-IN-1 | 170376-12-2 | Reference compound |
| HY-135670A | β-glycosidase-IN-1 | 176485-27-1 | Reference compound |
| HY-135670B | Glycosidase-IN-2 | 476310-39-1 | Reference compound |
| HY-135671 | AhR modulator-1 | 118174-38-2 | Reference compound |
| HY-135674 | SR-318 | 2413286-32-3 | Reference compound |
| HY-135675 | DHODH-IN-11 | 1263303-95-2 | Reference compound |
| HY-135676 | DHODH-IN-12 | 1263303-93-0 | Reference compound |
| HY-135677 | DHODH-IN-13 | 1364791-86-5 | Reference compound |
| HY-135678 | DHODH-IN-14 | 1364791-93-4 | Reference compound |
| HY-135679 | DHODH-IN-15 | 1364791-88-7 | Reference compound |
| HY-13567S | Bendamustine-d4 | | Isotope-Labeled Compounds |
| HY-13567S1 | Bendamustine-d8 | 1134803-33-0 | Isotope-Labeled Compounds |
| HY-13568 | Benoxaprofen | 51234-28-7 | Reference compound |
| HY-135680 | I-OMe-Tyrphostin AG 538 | 1094048-77-7 | Reference compound |
| HY-135682 | Nitrosobiotin | 56859-26-8 | Reference compound |
| HY-13568R | Benoxaprofen (Standard) | 51234-28-7 | Reference Standards |
| HY-135691 | hnRNPK-IN-1 | 2313528-04-8 | Reference compound |
| HY-135699 | TD52 | 1798328-24-1 | Reference compound |
| HY-135699A | TD52 (dihydrochloride) | | Reference compound |
| HY-13569A | Beraprost (sodium) | 496807-11-5 | Reference compound |
| HY-13569AR | Beraprost (sodium) (Standard) | 496807-11-5 | Reference Standards |
| HY-13570 | Betamethasone | 378-44-9 | Reference compound |
| HY-135700 | Mevalonolactone | 19115-49-2 | Natural Products |
| HY-135702 | UBS109 | 1258513-40-4 | Reference compound |
| HY-13570A | Betamethasone (hydrochloride) | 956901-32-9 | Reference compound |
| HY-13570B | Betamethasone acetate | 987-24-6 | Reference compound |
| HY-13570BR | Betamethasone acetate (Standard) | 987-24-6 | Reference Standards |
| HY-13570BS1 | Betamethasone acetate-d5 | | Isotope-Labeled Compounds |
| HY-13570C | Betamethasone disodium phosphate | 151-73-5 | Reference compound |
| HY-13570CR | Betamethasone disodium phosphate (Standard) | 151-73-5 | Reference Standards |
| HY-13570CS | Betamethasone 21-phosphate-d5 | | Isotope-Labeled Compounds |
| HY-13570R | Betamethasone (Standard) | 378-44-9 | Reference Standards |
| HY-13570S | Betamethasone-d5 | | Isotope-Labeled Compounds |
| HY-13570S1 | Betamethasone-d5-1 | 2244574-92-1 | Isotope-Labeled Compounds |
| HY-13571 | Betamethasone dipropionate | 5593-20-4 | Reference compound |
| HY-135710 | ADAMTS-5-IN-2 | 294648-66-1 | Reference compound |
| HY-135711 | PDE8B-IN-1 | 1305116-69-1 | Reference compound |
| HY-135712 | Orange G | 1936-15-8 | Dye Reagents |
| HY-135714 | Bavarostat | 2134109-20-7 | Reference compound |
| HY-135715 | (E)-UK122 (TFA) | 1186653-73-5 | Reference compound |
| HY-135717 | Norbiotinamine | 173401-47-3 | Reference compound |
| HY-135717A | Norbiotinamine (hydrochloride) | 160385-86-4 | Reference compound |
| HY-13571A | Beclometasone dipropionate | 5534-09-8 | Reference compound |
| HY-13571AR | Beclometasone dipropionate (Standard) | 5534-09-8 | Reference Standards |
| HY-13571AS | Beclometasone dipropionate-d6 | | Isotope-Labeled Compounds |
| HY-13571AS1 | Beclometasone dipropionate-d10 | | Isotope-Labeled Compounds |
| HY-13571B | Beclometasone dipropionate (monohydrate) | 77011-63-3 | Reference compound |
| HY-13571R | Betamethasone dipropionate (Standard) | 5593-20-4 | Reference Standards |
| HY-13571S | Betamethasone dipropionate-d10 | 2280940-19-2 | Isotope-Labeled Compounds |
| HY-13571S1 | Betamethasone dipropionate-d5 | | Isotope-Labeled Compounds |
| HY-135725 | D-69491 (hydrochloride) | 346599-65-3 | Reference compound |
| HY-135727 | PF-6422899 | 1621002-23-0 | Reference compound |
| HY-13573 | Biapenem | 120410-24-4 | Reference compound |
| HY-135730 | Aglepristone | 124478-60-0 | Reference compound |
| HY-135731 | 4-Methylamino antipyrine | 519-98-2 | Reference compound |
| HY-135731A | 4-Methylamino antipyrine (hydrochloride) | 856307-27-2 | Reference compound |
| HY-135731AR | 4-Methylamino antipyrine (hydrochloride) (Standard) | 856307-27-2 | Reference Standards |
| HY-135731AS | 4-Methylamino antipyrine-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-135731R | 4-Methylamino antipyrine (Standard) | 519-98-2 | Reference Standards |
| HY-135732 | SK33 | 1928724-23-5 | Reference compound |
| HY-135735A | Levomedetomidine (hydrochloride) | 190000-46-5 | Reference compound |
| HY-135735S1 | Levomedetomidine-d8 | | Isotope-Labeled Compounds |
| HY-135737 | Dicaprylyl carbonate | 1680-31-5 | Natural Products |
| HY-135738 | Convicine | 19286-37-4 | Natural Products |
| HY-13573R | Biapenem (Standard) | 120410-24-4 | Reference Standards |
| HY-13574 | Biricodar (dicitrate) | 174254-13-8 | Reference compound |
| HY-135740 | Diphenhydramine N-oxide | 3922-74-5 | Reference compound |
| HY-135741 | NYX-2925 | 2012536-16-0 | Reference compound |
| HY-135742 | Lenvatinib N-oxide | 1788901-86-9 | Reference compound |
| HY-135743 | Apovincamine | 4880-92-6 | Natural Products |
| HY-135745 | Sulfentrazone | 122836-35-5 | Reference compound |
| HY-135745R | Sulfentrazone (Standard) | 122836-35-5 | Reference Standards |
| HY-135746 | OR-1896 | 220246-81-1 | Reference compound |
| HY-135746R | OR-1896 (Standard) | 220246-81-1 | Reference Standards |
| HY-135747 | Gut restricted-7 | 2553218-46-3 | Reference compound |
| HY-135748 | Polyinosinic-polycytidylic acid (sodium) | 42424-50-0 | Reference compound |
| HY-135748A | Poly (I:C):Kanamycin (1:1) (sodium) | | Reference compound |
| HY-135749 | BN201 | 1361200-34-1 | Reference compound |
| HY-13574A | Biricodar | 159997-94-1 | Reference compound |
| HY-13575 | Blonanserin | 132810-10-7 | Reference compound |
| HY-135750 | VAF347 | 574759-62-9 | Reference compound |
| HY-135751 | Holomycin | 488-04-0 | Reference compound |
| HY-135752 | Carbendazim mixture with flusilazole | 99827-19-7 | Reference compound |
| HY-135753 | Sethoxydim | 74051-80-2 | Reference compound |
| HY-135753R | Sethoxydim (Standard) | 74051-80-2 | Reference Standards |
| HY-135759 | Cetraxate | 34675-84-8 | Reference compound |
| HY-13575A | Blonanserin (dihydrochloride) | 132812-45-4 | Reference compound |
| HY-13575R | Blonanserin (Standard) | 132810-10-7 | Reference Standards |
| HY-13575S | Blonanserin-d8 | | Isotope-Labeled Compounds |
| HY-13575S1 | Blonanserin-d5 | 1346599-86-7 | Isotope-Labeled Compounds |
| HY-135761 | Penconazole | 66246-88-6 | Reference compound |
| HY-135761R | Penconazole (Standard) | 66246-88-6 | Reference Standards |
| HY-135761S | Penconazole-d7 | 1628110-84-8 | Isotope-Labeled Compounds |
| HY-135762 | Allylescaline (hydrochloride) | 39201-76-8 | Reference compound |
| HY-135763 | Metabolex-36 | 1224102-50-4 | Reference compound |
| HY-135765 | Micordilin | 61701-92-6 | Natural Products |
| HY-135766 | Colletodiol | 21142-67-6 | Natural Products |
| HY-135767 | Bicyclopyrone | 352010-68-5 | Reference compound |
| HY-135767R | Bicyclopyrone (Standard) | 352010-68-5 | Reference Standards |
| HY-13577 | Oclacitinib | 1208319-26-9 | Reference compound |
| HY-135770 | 9-Dehydroxyeurotinone | 1360606-85-4 | Natural Products |
| HY-135771 | Avarone | 55303-99-6 | Natural Products |
| HY-135772 | 12-Ketodeoxycholic acid | 5130-29-0 | Natural Products |
| HY-135772R | 12-Ketodeoxycholic acid (Standard) | 5130-29-0 | Reference Standards |
| HY-135773 | CRTh2 antagonist 3 | 312928-72-6 | Reference compound |
| HY-135774 | 6-Hydroxybenzbromarone | 152831-00-0 | Reference compound |
| HY-135774R | 6-Hydroxybenzbromarone (Standard) | 152831-00-0 | Reference Standards |
| HY-135775 | BMVC | 627810-06-4 | Reference compound |
| HY-135776 | BMVC2 | 850559-51-2 | Reference compound |
| HY-13577A | Oclacitinib (monomaleate) | 1640292-55-2 | Reference compound |
| HY-13577S | Oclacitinib-13C-d3 | | Isotope-Labeled Compounds |
| HY-13578 | Brivudine | 69304-47-8 | Reference compound |
| HY-135780 | 3'-Deoxyuridine-5'-triphosphate | 69199-40-2 | Reference compound |
| HY-135780A | 3'-Deoxyuridine-5'-triphosphate (trisodium) | | Reference compound |
| HY-135781 | H-Arg(Pbf)-OMe (hydrochloride) | 257288-19-0 | Reference compound |
| HY-135782 | iso-ADP ribose | 15720-01-1 | Dye Reagents |
| HY-135783 | AT 1001 | 1314801-63-2 | Reference compound |
| HY-135784 | OSMI-2 | 2260542-60-5 | Reference compound |
| HY-135785 | OSMI-3 | 2260791-13-5 | Reference compound |
| HY-13578R | Brivudine (Standard) | 69304-47-8 | Reference Standards |
| HY-13578S | Brivudine-13C, 15N2 | | Isotope-Labeled Compounds |
| HY-13579 | BTZ043 | 1161233-85-7 | Reference compound |
| HY-135793 | Macropa-NH2 diester | 2146091-22-5 | Reference compound |
| HY-135794 | 11-Ketodihydrotestosterone | 32694-37-4 | Reference compound |
| HY-135794R | 11-Ketodihydrotestosterone (Standard) | 32694-37-4 | Reference Standards |
| HY-135794S | 11-Ketodihydrotestosterone-d3 | 2479914-02-6 | Isotope-Labeled Compounds |
| HY-135795 | 1-Cyclohexyl-3-dodecyl urea | 402939-18-8 | Reference compound |
| HY-135796 | m-PEG3-OH | 112-35-6 | Reference compound |
| HY-135797 | DB1976 | 1557397-51-9 | Reference compound |
| HY-135797A | DB1976 (dihydrochloride) | 2369663-93-2 | Reference compound |
| HY-135798 | Tos-PEG2-NH-Boc | 192132-77-7 | Reference compound |
| HY-135799 | WH-15 | 1264748-47-1 | Dye Reagents |
| HY-13579A | BTZ043 (Racemate) | 957217-65-1 | Reference compound |
| HY-13579R | BTZ043 (Standard) | 1161233-85-7 | Reference Standards |
| HY-13580 | Budesonide | 51333-22-3 | Reference compound |
| HY-135801 | Arachidonyl alcohol | 13487-46-2 | Reference compound |
| HY-135804 | NH2-PEG3-C2-Boc | 252881-74-6 | Reference compound |
| HY-135805 | JBJ-04-125-02 | 2060610-53-7 | Reference compound |
| HY-135805A | (Rac)-JBJ-04-125-02 | 2140807-05-0 | Reference compound |
| HY-135805B | (Rac)-JBJ-04-125-02 (acetate) | | Reference compound |
| HY-135808 | BIZ 114 | 2099120-74-6 | Reference compound |
| HY-135809 | A2764 (dihydrochloride) | 861038-72-4 | Reference compound |
| HY-13580R | Budesonide (Standard) | 51333-22-3 | Reference Standards |
| HY-13580S | Budesonide-d8 | 1105542-94-6 | Isotope-Labeled Compounds |
| HY-135810 | Cletoquine | 4298-15-1 | Reference compound |
| HY-135810A | Cletoquine (oxalate) | 14142-64-4 | Reference compound |
| HY-135810S | Cletoquine-d4 | 1854126-47-8 | Isotope-Labeled Compounds |
| HY-135810S1 | Cletoquine-d4-1 | 1216461-56-1 | Isotope-Labeled Compounds |
| HY-135811 | Desethyl chloroquine | 1476-52-4 | Reference compound |
| HY-135811A | Desethyl chloroquine (diphosphate) | 247912-76-1 | Reference compound |
| HY-135811R | Desethyl chloroquine (Standard) | 1476-52-4 | Reference Standards |
| HY-135811S | Desethyl chloroquine-d4 | 1189971-72-9 | Isotope-Labeled Compounds |
| HY-135811S1 | Desethyl chloroquine-d5 | 1261392-69-1 | Isotope-Labeled Compounds |
| HY-135813 | LtaS-IN-1 | 877950-01-1 | Reference compound |
| HY-135815 | Mobocertinib | 1847461-43-1 | Reference compound |
| HY-135815A | Mobocertinib (succinate) | 2389149-74-8 | Reference compound |
| HY-135815B | Mobocertinib (mesylate) | 2389149-85-1 | Reference compound |
| HY-135816 | CK2/PIM1-IN-1 | 292640-28-9 | Reference compound |
| HY-135818 | XM462 | 1045857-53-1 | Reference compound |
| HY-135819 | Mal-PEG24-NHS ester | 2226733-37-3 | Reference compound |
| HY-13582 | Carbendazim | 10605-21-7 | Reference compound |
| HY-135820 | m-PEG12-acid | 2135793-73-4 | Reference compound |
| HY-135821 | Fmoc-NH-PEG12-CH2CH2COOH | 1952360-91-6 | Reference compound |
| HY-135823 | Propargyl-PEG12-bromide | 2410937-34-5 | Reference compound |
| HY-135824 | m-PEG12-2-methylacrylate | 2867-46-1 | Reference compound |
| HY-135825 | TFEB activator 1 | 39777-61-2 | Reference compound |
| HY-135826 | Necroptosis-IN-1 | 1391980-92-9 | Reference compound |
| HY-135827 | Roginolisib | 1305267-37-1 | Reference compound |
| HY-135827A | Roginolisib (hemifumarate) | 1621688-31-0 | Reference compound |
| HY-135829 | BAY 2416964 | 2242464-44-2 | Reference compound |
| HY-13582A | Carbendazim (hydrochloride) | 37574-18-8 | Reference compound |
| HY-13582R | Carbendazim (Standard) | 10605-21-7 | Reference Standards |
| HY-13582S | Carbendazim-d4 | 291765-95-2 | Isotope-Labeled Compounds |
| HY-13582S1 | Carbendazimb-d3 | 1255507-88-0 | Isotope-Labeled Compounds |
| HY-135830 | AHR antagonist 4 | 2242465-58-1 | Reference compound |
| HY-135831 | AHR antagonist 2 | 2338747-54-7 | Reference compound |
| HY-135832 | Demethyl-RSL3 | 2375354-13-3 | Reference compound |
| HY-135835 | 6-FAM-PEG3-Azide | 412319-45-0 | Dye Reagents |
| HY-135837 | Fluorescein-diisobutyrate-6-amide | 2375357-99-4 | Reference compound |
| HY-135841 | CM010 | 692269-09-3 | Reference compound |
| HY-135842 | Aspoxicillin | 63358-49-6 | Reference compound |
| HY-135842R | Aspoxicillin (Standard) | 63358-49-6 | Reference Standards |
| HY-135843 | TH-263 | 313520-94-4 | Reference compound |
| HY-135844 | LS-102 | 1456891-34-1 | Reference compound |
| HY-135845 | TP3011 | 534605-74-8 | Reference compound |
| HY-135846 | PDD00031705 | 2032096-45-8 | Reference compound |
| HY-135847 | Desmethyl ferroquine | 903546-18-9 | Reference compound |
| HY-135848 | N-Methylbenzamide | 613-93-4 | Reference compound |
| HY-135849 | Catalase, Aspergillus niger | 9001-05-2 | Enzyme |
| HY-135849A | Catalase, Bovine Liver | 9001-05-2 | Enzyme |
| HY-135849B | Catalase, Human Erythrocyte | | Enzyme |
| HY-135849C | Catalase, trichoderma reesei | 9001-05-2 | Enzyme |
| HY-13585 | Carmustine | 154-93-8 | Reference compound |
| HY-135853 | Molnupiravir | 2492423-29-5 | Reference compound |
| HY-135853R | Molnupiravir (Standard) | 2492423-29-5 | Reference Standards |
| HY-135853S | Molnupiravir-d7 | | Isotope-Labeled Compounds |
| HY-135855 | SARS-CoV-IN-1 | 888958-25-6 | Reference compound |
| HY-135856 | SARS-CoV-IN-2 | 888958-26-7 | Reference compound |
| HY-135858 | SARS-CoV-IN-3 | 888958-27-8 | Reference compound |
| HY-135859 | NH2-MPAA-NODA | | ADC Related |
| HY-13585R | Carmustine (Standard) | 154-93-8 | Reference Standards |
| HY-13585S | Carmustine-d8 | | Isotope-Labeled Compounds |
| HY-135860 | SARS-CoV-2-IN-1 | 2412965-59-2 | Reference compound |
| HY-135862 | Tetraniliprole | 1229654-66-3 | Reference compound |
| HY-135864 | KRAS inhibitor-6 | 2022986-61-2 | Reference compound |
| HY-135865 | KRAS inhibitor-7 | 2022986-68-9 | Reference compound |
| HY-135866 | KRAS inhibitor-8 | 2022986-70-3 | Reference compound |
| HY-135867 | NHC-triphosphate | 34973-27-8 | Reference compound |
| HY-135867A | NHC-triphosphate (tetrasodium) | | Reference compound |
| HY-135867D | NHC-diphosphate | 39023-73-9 | Reference compound |
| HY-135867E | NHC-triphosphate (tetraammonium) | | Reference compound |
| HY-135867F | NHC-diphosphate (triammonium) | | Reference compound |
| HY-135868 | Mito-apocynin (C2) | 1254044-41-1 | Reference compound |
| HY-135869 | Mito-apocynin (C11) | 1254044-38-6 | Reference compound |
| HY-135871 | BMT-124110 | 1679371-59-5 | Reference compound |
| HY-135871A | BMT-124110 (formic) | | Reference compound |
| HY-135878 | 2',5'-Dideoxyadenosine | 6698-26-6 | Reference compound |
| HY-13588 | Cefsulodin (sodium) | 52152-93-9 | Reference compound |
| HY-135880 | OMDM-3 | 616884-64-1 | Reference compound |
| HY-135880A | OMDM-4 | 616884-65-2 | Reference compound |
| HY-135881 | OMDM-5 | 616884-66-3 | Reference compound |
| HY-135882 | OMDM-6 | 616884-67-4 | Reference compound |
| HY-135883 | PKR activator 1 | 2283420-62-0 | Reference compound |
| HY-135884 | Tebapivat | 2283422-04-6 | Reference compound |
| HY-135885 | VBIT-12 | 2089227-65-4 | Reference compound |
| HY-135886 | 2-Nitrophenyl α-D-galactopyranoside | 19887-85-5 | Biochemical Assay Reagents |
| HY-135887 | ZX-29 | 2254805-62-2 | Reference compound |
| HY-135888 | TP748 | 951698-15-0 | Reference compound |
| HY-135889 | CPFX2090 | 1429439-25-7 | Reference compound |
| HY-13588A | Cefsulodin | 62587-73-9 | Reference compound |
| HY-13588B | Cefsulodin (sodium hydrate) | 1426397-23-0 | Reference compound |
| HY-13588R | Cefsulodin (sodium) (Standard) | 52152-93-9 | Reference Standards |
| HY-13589 | Cemadotin | 159776-69-9 | Peptides |
| HY-135890 | CG347B | 1598426-03-9 | Reference compound |
| HY-135891 | AZD2423 | 1229603-37-5 | Reference compound |
| HY-135892 | GNE-1858 | 2680616-96-8 | Reference compound |
| HY-135893 | SGK1-IN-2 | 1426214-64-3 | Reference compound |
| HY-135895 | Detomidine carboxylic acid | 115664-39-6 | Reference compound |
| HY-135897 | Urolithin C | 165393-06-6 | Natural Products |
| HY-135898 | DGK-IN-1 | 2407892-34-4 | Reference compound |
| HY-135899 | SIRT7 inhibitor 97491 | 1807758-81-1 | Reference compound |
| HY-13589A | Cemadotin (hydrochloride) | 172837-41-1 | Reference compound |
| HY-13590 | CEP-7055 | 402857-58-3 | Reference compound |
| HY-135900 | Aniline-MPB-amino-C3-PBD | 2412923-79-4 | ADC Related |
| HY-135901 | Py-MPB-amino-C3-PBD | 2412924-07-1 | ADC Related |
| HY-135902 | Synucleozid | 502139-01-7 | Reference compound |
| HY-135902A | Synucleozid (hydrochloride) | 2741856-68-6 | Reference compound |
| HY-135903 | Giredestrant (tartrate) | 2407529-33-1 | Reference compound |
| HY-135905 | CL264 | 1510712-69-2 | Reference compound |
| HY-135906 | CK2/ERK8-IN-1 | 1085822-09-8 | Reference compound |
| HY-135909 | TH1217 | 1862212-48-3 | Reference compound |
| HY-13591 | Piclidenoson | 152918-18-8 | Reference compound |
| HY-135910 | 3,4-Dehydro Cilostazol | 73963-62-9 | Reference compound |
| HY-135910R | 3,4-Dehydro Cilostazol (Standard) | 73963-62-9 | Reference Standards |
| HY-135910S | 3,4-Dehydro Cilostazol-d11 | 1073608-13-5 | Isotope-Labeled Compounds |
| HY-135911 | Biotin-PEG2-OH | 717119-80-7 | Reference compound |
| HY-135912 | Biotin-PEG2-CH2CH2N3 | 945633-30-7 | Reference compound |
| HY-135913 | Cbz-NH-PEG3-CH2COOH | 462100-05-6 | Reference compound |
| HY-135914 | JBJ-02-112-05 | 2748162-29-8 | Reference compound |
| HY-135915 | Biotin-C5-NHS Ester | 72040-63-2 | Reference compound |
| HY-135916 | Biotin-C5-amino-C5-amino | 89889-51-0 | Reference compound |
| HY-135917 | Propargyl-PEG6-SH | 1422540-91-7 | Reference compound |
| HY-135918 | NH2-PEG6-C1-Boc | 297162-50-6 | Reference compound |
| HY-135919 | Cbz-NH-PEG5-CH2COOH | 1449390-66-2 | Reference compound |
| HY-13592 | HDAC-IN-7 | 743420-02-2 | Reference compound |
| HY-135920 | Biotin-C10-NHS Ester | 887628-40-2 | Reference compound |
| HY-135921 | m-PEG5-Hydrazide | 1449390-65-1 | Reference compound |
| HY-135922 | m-PEG6-Hydrazide | 1449390-64-0 | Reference compound |
| HY-135923 | Cbz-NH-PEG2-CH2COOH | 165454-06-8 | Reference compound |
| HY-135924 | Biotin-PEG3-OH | 1263044-40-1 | Reference compound |
| HY-135925 | Cbz-NH-PEG1-CH2COOH | 1260092-43-0 | Reference compound |
| HY-135926 | Cbz-NH-PEG1-CH2CH2COOH | 1205751-19-4 | Reference compound |
| HY-135927 | H2N-PEG2-CH2COOtBu | 1122484-77-8 | Reference compound |
| HY-135928 | Biotin-C2-S-S-pyridine | 112247-65-1 | Biochemical Assay Reagents |
| HY-13593 | Chlorambucil | 305-03-3 | Reference compound |
| HY-135930 | Boc-NH-PEG10-CH2CH2NH2 | 1347704-59-9 | Reference compound |
| HY-135931 | m-PEG11-C2-NHS Ester | | Reference compound |
| HY-135932 | m-PEG8-O-alkyne | 880081-81-2 | Reference compound |
| HY-135933 | Boc-NH-PEG8-CH2CH2NH2 | 1052207-59-6 | Reference compound |
| HY-135935 | DBCO-NHCO-PEG2-CH2COOH | | Reference compound |
| HY-135936 | m-PEG9-C4-SH | | Reference compound |
| HY-135937 | Biotin-PEG9-CH2CH2COOH | | Reference compound |
| HY-135938 | NH2-PEG5-C1-Boc | 2231845-67-1 | Reference compound |
| HY-135939 | DBCO-NHCO-PEG2-Biotin | | Reference compound |
| HY-13593R | Chlorambucil (Standard) | 305-03-3 | Reference Standards |
| HY-13593S | Chlorambucil-d8 | | Isotope-Labeled Compounds |
| HY-13593S1 | Chlorambucil-d8-1 | | Isotope-Labeled Compounds |
| HY-13594 | Chlorin e6 | 19660-77-6 | Dye Reagents |
| HY-135940 | m-PEG3-Mal | | Reference compound |
| HY-135941 | Biotin-PEG9-NHS Ester | | Reference compound |
| HY-135942 | Cbz-NH-PEG8-CH2COOH | | Reference compound |
| HY-135943 | NH2-PEG8-C1-Boc | | Reference compound |
| HY-135947 | Boc-NH-PEG11-OH | 1556847-53-0 | Reference compound |
| HY-13595 | Chrysophanol | 481-74-3 | Natural Products |
| HY-135953 | CDDO-3P-Im | 1883650-95-0 | Reference compound |
| HY-135954 | PDK4-IN-1 | 2310262-10-1 | Reference compound |
| HY-135954A | PDK4-IN-1 (hydrochloride) | 2310262-11-2 | Reference compound |
| HY-135956 | T3 Acyl glucuronide | 910907-23-2 | Natural Products |
| HY-135957 | 2'-Azido-2'-deoxyuridine | 26929-65-7 | Reference compound |
| HY-135958 | DBCO-NHCO-PEG6-Biotin | | Reference compound |
| HY-135959 | DBCO-NH-PEG7-C2-NHS ester | | Reference compound |
| HY-13595R | Chrysophanol (Standard) | 481-74-3 | Reference Standards |
| HY-13596 | Cisatracurium (besylate) | 96946-42-8 | Reference compound |
| HY-135960 | BO-264 | 2408648-20-2 | Reference compound |
| HY-135961 | PTAD-PEG4-amine | | ADC Related |
| HY-135962 | Boc-Aminooxy-PEG2-bromide | 252378-67-9 | ADC Related |
| HY-135963 | Thiol-PEG3-thiol | 2781-02-4 | Biochemical Assay Reagents |
| HY-135964 | (2-pyridyldithio)-PEG4 acid | 581065-93-2 | ADC Related |
| HY-135966 | Azido-PEG3-SS-NHS | | ADC Related |
| HY-135967 | MTH1-IN-2 | 901044-91-5 | Reference compound |
| HY-135969 | Glycol chitosan | 123938-86-3 | Oligonucleotides |
| HY-13596R | Cisatracurium (besylate) (Standard) | 96946-42-8 | Reference Standards |
| HY-135970 | Alkyne-PEG4-SS-PEG4-alkyne | | ADC Related |
| HY-135971 | endo-BCN-PEG4-acid | 1881221-47-1 | ADC Related |
| HY-135973 | BCN-SS-NHS | | ADC Related |
| HY-135974 | Amino-PEG3-SS-acid | | ADC Related |
| HY-135975 | MC-Val-Ala-PAB-PNP | 1639939-40-4 | ADC Related |
| HY-135976 | P2X3 antagonist 34 | 2417288-67-4 | Reference compound |
| HY-135977 | DBCO-SS-aldehyde | | ADC Related |
| HY-135979 | DBCO-SS-PEG4-Biotin | | ADC Related |
| HY-13598 | Valecobulin | 1188371-47-2 | Reference compound |
| HY-135981 | CMS-121 | 1353224-53-9 | Reference compound |
| HY-135982 | GPR81 agonist 1 | 1620992-67-7 | Reference compound |
| HY-135985 | DCLK1-IN-1 | 2222635-15-4 | Reference compound |
| HY-13598A | Valecobulin (hydrochloride) | 1240321-53-2 | Reference compound |
| HY-13599 | Cladribine | 4291-63-8 | Reference compound |
| HY-135996 | Dilaurylglycerosulfate | 99387-94-7 | Reference compound |
| HY-135996A | Dilaurylglycerosulfate (sodium) | 99388-09-7 | Reference compound |
| HY-13599R | Cladribine (Standard) | 4291-63-8 | Reference Standards |
| HY-13599S | Cladribine-d4 | | Isotope-Labeled Compounds |
| HY-13599S1 | Cladribine-13C5,15N2 | | Isotope-Labeled Compounds |
| HY-13599S2 | Cladribine-15N | 1360874-38-9 | Isotope-Labeled Compounds |
| HY-13600 | Clobetasol propionate | 25122-46-7 | Reference compound |
| HY-136001 | PROTAC α-synuclein degrader 3 | 2412273-77-7 | Reference compound |
| HY-136005 | VH032-C7-COOH | 2172819-77-9 | Reference compound |
| HY-136006 | (S,R,S)-AHPC-C6-NH2 (dihydrochloride) | 2341796-77-6 | Reference compound |
| HY-136006A | (S,R,S)-AHPC-C6-NH2 (hydrochloride) | 2360522-76-3 | Reference compound |
| HY-136006B | (S,R,S)-AHPC-C6-NH2 | 2306389-03-5 | Reference compound |
| HY-136008 | (S,R,S)-AHPC-PEG1-NH2 | 2241641-57-4 | Reference compound |
| HY-136008A | (S,R,S)-AHPC-PEG1-NH2 (dihydrochloride) | 2341796-83-4 | Reference compound |
| HY-13600R | Clobetasol propionate (Standard) | 25122-46-7 | Reference Standards |
| HY-13600S1 | Clobetasol propionate-d5 | 2280940-18-1 | Isotope-Labeled Compounds |
| HY-136010 | RIP2 Kinase Inhibitor 4 | 2126803-41-4 | Reference compound |
| HY-136026 | Camlipixant | 1621164-74-6 | Reference compound |
| HY-13603 | Crolibulin | 1000852-17-4 | Reference compound |
| HY-136030 | APN-PEG4-PFP | | Reference compound |
| HY-136031 | Tetrazine-SS-Biotin | 2123482-78-8 | ADC Related |
| HY-136032 | Tetrazine-SS-NHS | | ADC Related |
| HY-136033 | Methyltetrazine-SS-NHS | | ADC Related |
| HY-136034 | Azido-PEG1-Val-Cit-OH | | ADC Related |
| HY-136035 | Methyltetrazine-SS-PEG4-Biotin | | ADC Related |
| HY-136036 | Tetrazine-SS-PEG4-Biotin | | ADC Related |
| HY-136037 | Boc-amino-PEG3-SS-acid | | ADC Related |
| HY-136038 | Azido-PEG3-SSPy | | ADC Related |
| HY-136039 | TCO-SS-amine | | ADC Related |
| HY-13604 | Cyproterone acetate | 427-51-0 | Reference compound |
| HY-136040 | Tetrazine-PEG4-SS-NHS | | ADC Related |
| HY-136041 | Boc-amino-PEG3-SSPy | | ADC Related |
| HY-136044 | APN-PEG4-BCN | | ADC Related |
| HY-136045 | APN-PEG4-tetrazine | | ADC Related |
| HY-136046 | PTAD-PEG4-alkyne | | ADC Related |
| HY-136047 | Methylcyclopropene-PEG3-amine | | ADC Related |
| HY-136048 | Methylcyclopropene-PEG4-NHS | | ADC Related |
| HY-136049 | APN-PEG4-DBCO | | ADC Related |
| HY-13604R | Cyproterone acetate (Standard) | 427-51-0 | Reference Standards |
| HY-13604S | Cyproterone acetate-d3 | 2376035-90-2 | Isotope-Labeled Compounds |
| HY-13605 | Cytarabine | 147-94-4 | Natural Products |
| HY-136050 | TCO-PEG3-Biotin | | ADC Related |
| HY-136051 | Biotin-PEG3-aldehyde | 889443-90-7 | ADC Related |
| HY-136052 | Tetrazine-PEG4-oxyamine (hydrochloride) | | ADC Related |
| HY-136053 | Tetrazine-PEG4-biotin | | ADC Related |
| HY-136054 | N3-PEG5-aldehyde | 2566404-73-5 | ADC Related |
| HY-136055 | (S,R,S)-AHPC-C5-COOH | 2267282-19-7 | Reference compound |
| HY-136056 | Methyltetrazine-PEG4-oxyamine | | ADC Related |
| HY-136057 | iFSP1 | 150651-39-1 | Reference compound |
| HY-136058 | N3-PEG4-amido-Lys(Fmoc)-acid | | ADC Related |
| HY-136059 | Desfluoro-ezetimibe | 302781-98-2 | Reference compound |
| HY-13605A | Cytarabine (hydrochloride) | 69-74-9 | Reference compound |
| HY-13605R | Cytarabine (Standard) | 147-94-4 | Reference Standards |
| HY-13605S | Cytarabine-d2 | 40632-26-6 | Isotope-Labeled Compounds |
| HY-13606 | Dacinostat | 404951-53-7 | Reference compound |
| HY-136060 | Mal-PEG2-bis-PEG3-BCN | | ADC Related |
| HY-136061 | BCN-PEG4-HyNic | 1507370-54-8 | ADC Related |
| HY-136063 | Mefentrifluconazole | 1417782-03-6 | Reference compound |
| HY-136063R | Mefentrifluconazole (Standard) | 1417782-03-6 | Reference Standards |
| HY-136064 | 4,4'-Dimethoxychalcone | 2373-89-9 | Natural Products |
| HY-136065 | bpV(phen) | 42494-73-5 | Reference compound |
| HY-136066 | Tauro-ω-muricholic acid (sodium) | 2456348-84-6 | Reference compound |
| HY-136067 | DBCO-PEG4-HyNic | | ADC Related |
| HY-136068 | DCAP | 500015-20-3 | Reference compound |
| HY-136068R | DCAP (Standard) | 500015-20-3 | Reference Standards |
| HY-136069 | Xeruborbactam | 2170834-63-4 | Reference compound |
| HY-13607 | BMS-641988 | 1093276-09-5 | Reference compound |
| HY-136070 | QPX7728 bis-acetoxy methyl ester | 2170834-56-5 | Reference compound |
| HY-136071 | QPX7728 methoxy acetoxy methy ester | 2170834-57-6 | Reference compound |
| HY-136072 | Xeruborbactam (disodium) | 2170848-99-2 | Reference compound |
| HY-136072A | (1R,2S)-Xeruborbactam (disodium) | 2170836-14-1 | Reference compound |
| HY-136073 | Wnt pathway activator 2 | 1360540-82-4 | Reference compound |
| HY-136074 | Methyltetrazine-PEG4-aldehyde | | ADC Related |
| HY-136075 | HyNic-PEG4-alkyne | | ADC Related |
| HY-136076 | TCO-PEG3-CH2-aldehyde | | ADC Related |
| HY-136077 | TCO-PEG3-aldehyde | | ADC Related |
| HY-136078 | Tetrazine-diazo-PEG4-biotin | | ADC Related |
| HY-136079 | Methyltetrazine-PEG4-hydrazone-DBCO | | ADC Related |
| HY-13607A | (rel)-BMS-641988 | 573738-99-5 | Reference compound |
| HY-136081 | Hexamidine | 3811-75-4 | Reference compound |
| HY-136081A | Hexamidine (diisethionate) | 659-40-5 | Reference compound |
| HY-136081AS | Hexamidine-d12 (dihydrochloride) | | Isotope-Labeled Compounds |
| HY-136084 | Mal-PEG4-(PEG3-DBCO)-(PEG3-TCO) | | ADC Related |
| HY-136085 | Amino-bis-PEG3-BCN | | ADC Related |
| HY-136086 | Tetrazine-PEG6-amine (hydrochloride) | | ADC Related |
| HY-136087 | Mal-bis-PEG3-DBCO | | ADC Related |
| HY-136088 | Acid-PEG1-bis-PEG3-BCN | | ADC Related |
| HY-136089 | Aminooxy-PEG2-bis-PEG3-BCN | | ADC Related |
| HY-13609 | Deflazacort | 14484-47-0 | Reference compound |
| HY-136090 | Amino-PEG4-bis-PEG3-N3 | | ADC Related |
| HY-136092 | Androsta-1,4,6-triene-3,17-dione | 633-35-2 | Reference compound |
| HY-136093 | Lixumistat (hydrochloride) | 1422365-52-3 | Reference compound |
| HY-136093A | Lixumistat (acetate) | 1422365-94-3 | Reference compound |
| HY-136093B | Lixumistat | 1422365-93-2 | Reference compound |
| HY-136094 | SRT3657 | 1383551-17-4 | Reference compound |
| HY-136095 | Tetrazine-biotin | 1714123-51-9 | ADC Related |
| HY-136096 | DBCO-PEG3 acetic-EVCit-PAB | 2253947-17-8 | ADC Related |
| HY-136097 | Maleimide-PEG2-hydrazide (TFA) | | ADC Related |
| HY-136098 | DBCO-PEG4-acetic-Val-Cit-PAB | | ADC Related |
| HY-136099 | Bocaminooxyacetamide-PEG2-Azido | | ADC Related |
| HY-13609R | Deflazacort (Standard) | 14484-47-0 | Reference Standards |
| HY-13609S | Deflazacort-d5 | | Isotope-Labeled Compounds |
| HY-13609S1 | Deflazacort-d7 | | Isotope-Labeled Compounds |
| HY-13610 | N1,N11-Diethylnorspermine | 121749-39-1 | Reference compound |
| HY-136100 | TCO-PEG1-Val-Cit-PABC-PNP | | ADC Related |
| HY-136101 | Bocaminooxyacetamide-PEG3-alkyne | | ADC Related |
| HY-136103 | DBCO-PEG4-Propionic-Val-Cit-PAB | | ADC Related |
| HY-136104 | Methyltetrazine-Maleimide | | ADC Related |
| HY-136105 | Azido-PEG1-Val-Cit-PABC-PNP | | ADC Related |
| HY-136106 | Fmoc-Gly3-Val-Cit-PAB | 2647914-09-6 | ADC Related |
| HY-136107 | Fmoc-Phe-Lys(Trt)-PAB | 1116085-98-3 | ADC Related |
| HY-136108 | Fmoc-Gly3-Val-Cit-PAB-PNP | 2647914-16-5 | ADC Related |
| HY-136109 | SEP-363856 (hydrochloride) | 1310422-41-3 | Reference compound |
| HY-136109A | SEP-363856 | 1310426-33-5 | Reference compound |
| HY-136109B | (Rac)-SEP-363856 | 1310426-29-9 | Reference compound |
| HY-136109E | SEP-363856 (mesylate) | 2375116-27-9 | Reference compound |
| HY-13610A | N1,N11-Diethylnorspermine (tetrahydrochloride) | 156886-85-0 | Reference compound |
| HY-13610B | N1,N11-Diethylnorspermine (hydrobromide) | 1384898-58-1 | Reference compound |
| HY-13611 | Diflomotecan | 220997-97-7 | Reference compound |
| HY-136110 | 2-Keto-D-galactose | 54142-77-7 | Reference compound |
| HY-136113 | Ibrutinib dimer | 2031255-23-7 | Reference compound |
| HY-136121 | Tubulin inhibitor 6 | 105925-39-1 | Reference compound |
| HY-136122 | Tubulin inhibitor 7 | 1309925-41-4 | Reference compound |
| HY-136123 | Tubulin inhibitor 8 | 1309925-39-0 | Reference compound |
| HY-136124 | Cetilistat impurity 1 | 890655-08-0 | Reference compound |
| HY-136125 | BCOT-PEF3-OPFP | 2101206-48-6 | ADC Related |
| HY-136127 | ALD-PEG4-OPFP | 1324007-10-4 | ADC Related |
| HY-136128 | H3B-120 | 2194903-42-7 | Reference compound |
| HY-136129 | N,N-Bis(PEG2-N3)-N-amido-PEG2-thiol | | ADC Related |
| HY-13613 | Dutasteride | 164656-23-9 | Reference compound |
| HY-136130 | N,N-Bis(PEG2-alkyne)-N-amido-PEG2-thiol | | ADC Related |
| HY-136131 | NH2-PEG4-hydrazone-DBCO | | ADC Related |
| HY-136132 | MC-VC-PAB-NH2 | 1616727-20-8 | ADC Related |
| HY-136132A | MC-VC-PAB-NH2 (TFA) | 1616727-21-9 | Reference compound |
| HY-136133 | NHS-PEG2-SS-PEG2-NHS | | ADC Related |
| HY-136134 | SS-bis-amino-PEG4-NHS ester | | ADC Related |
| HY-136135 | (2-pyridyldithio)-PEG1-hydrazine | 111625-28-6 | ADC Related |
| HY-136136 | Fmoc-Val-Ala-PAB-PNP | 1394238-92-6 | ADC Related |
| HY-136137 | Azide-PEG1-Val-Cit-PABC-OH | 2055041-40-0 | ADC Related |
| HY-13613R | Dutasteride (Standard) | 164656-23-9 | Reference Standards |
| HY-13613S | Dutasteride-13C6 | 1217685-27-2 | Isotope-Labeled Compounds |
| HY-13613S2 | Dutasteride-13C,15N,d | | Isotope-Labeled Compounds |
| HY-136140 | Aldehyde-benzyl-PEG5-alkyne | 1378928-83-6 | Reference compound |
| HY-136141 | DBCO-PEG3-propionic EVCit-PAB | | ADC Related |
| HY-136142 | Prasugrel chloride impurity | 1056459-37-0 | Reference compound |
| HY-136143 | (BHQ-3)-OSu (hexafluorophosphate) | 871240-95-8 | Reference compound |
| HY-136144 | FIDAS-5 | 1391934-98-7 | Reference compound |
| HY-136145 | FIDAS-3 | 1266684-01-8 | Reference compound |
| HY-136146 | SUVN-911 | 2414674-71-6 | Reference compound |
| HY-136149 | Mpro inhibitor N3 | 884650-98-0 | Reference compound |
| HY-136149A | Mpro inhibitor N3 (hemihydrate) | | Reference compound |
| HY-13615 | Folate-FITC | 583037-91-6 | Dye Reagents |
| HY-136150 | Methyl carnosate | 82684-06-8 | Natural Products |
| HY-136151 | UNC10217938A | 1347749-97-6 | Reference compound |
| HY-136152 | MCHR1 antagonist 3 | 1069622-60-1 | Reference compound |
| HY-136153 | Amphotericin X1 | 136135-57-4 | Reference compound |
| HY-136154 | Fmoc-Glu-(Boc)-Val-Cit-PAB-PNP | | ADC Related |
| HY-136155 | Fmoc-NH-Azide-PEG4-L-Lysine-PFP ester | | ADC Related |
| HY-136156 | Pomalidomide-PEG6-butyl iodide | 1835705-74-2 | Reference compound |
| HY-136157 | Py-ds-dmBut-amido-PEG4-NHS ester | | ADC Related |
| HY-136158 | 6-Maleimidocaproic acid sulfo-NHS | 103848-61-9 | Reference compound |
| HY-136158A | 6-Maleimidocaproic acid sulfo-NHS (sodium) | 215312-86-0 | Biochemical Assay Reagents |
| HY-136159 | 3-Mercaptopropionic acid NHS ester | 117235-10-6 | Reference compound |
| HY-13615A | EC-17 (disodium salt) | 910661-33-5 | Dye Reagents |
| HY-136160 | Thalidomide 4'-oxyacetamide-alkyl-C2-amine (hydrochloride) | 2341841-02-7 | Reference compound |
| HY-136161 | Pomalidomide-PEG6-NH2 (hydrochloride) | 2341841-01-6 | Reference compound |
| HY-136162 | Thalidomide-4-O-C2-NH2 (hydrochloride) | 2341840-99-9 | Reference compound |
| HY-136162A | Thalidomide-4-O-C2-NH2 | 390367-50-7 | Reference compound |
| HY-136163 | (S,R,S)-AHPC-C2-NH2 (dihydrochloride) | 2341796-73-2 | Reference compound |
| HY-136163A | (S,R,S)-AHPC-C2-NH2 | 2241643-69-4 | Reference compound |
| HY-136164 | VH032-OH | 2244684-42-0 | Reference compound |
| HY-136165 | (S,R,S)-AHPC-PEG3-propionic acid | 2140807-42-5 | Reference compound |
| HY-136166 | Thalidomide-NH-PEG3-propionic acid | 2138440-82-9 | Reference compound |
| HY-136168 | Mal-amino-sulfo | 158018-81-6 | Reference compound |
| HY-13617 | Edatrexate | 80576-83-6 | Reference compound |
| HY-136170 | MC-SN38 | 1473403-87-0 | ADC Related |
| HY-136171 | Antidepressant agent 1 | 67411-41-0 | Reference compound |
| HY-136172 | ESI-08 | 301177-43-5 | Reference compound |
| HY-136173 | Batoprotafib | 1801765-04-7 | Reference compound |
| HY-136174 | RBN-2397 | 2381037-82-5 | Reference compound |
| HY-136175 | Revumenib | 2169919-21-3 | Reference compound |
| HY-136177 | Tris(2,4-di-tert-butylphenyl)phosphate | 95906-11-9 | Natural Products |
| HY-136177R | Tris(2,4-di-tert-butylphenyl)phosphate (Standard) | 95906-11-9 | Reference Standards |
| HY-136179 | ZAP-180013 | 873080-25-2 | Reference compound |
| HY-13618 | Edotecarin | 174402-32-5 | Reference compound |
| HY-136181 | YNT-185 (dihydrochloride) | 1804978-82-2 | Reference compound |
| HY-136181A | YNT-185 | 1804978-81-1 | Reference compound |
| HY-136182 | YM-244769 (dihydrochloride) | 1780390-65-9 | Reference compound |
| HY-136182A | YM-244769 | 838819-70-8 | Reference compound |
| HY-136183 | (S,R,S)-AHPC-phenol-alkylC6-amine (dihydrochloride) | 2376990-28-0 | Reference compound |
| HY-136184 | (S,R,S)-AHPC-phenol-C4-NH2 (dihydrochloride) | 2376990-26-8 | Reference compound |
| HY-136185 | Atorvastatin Epoxy Tetrahydrofuran Impurity | 873950-19-7 | Reference compound |
| HY-136186 | (S,R,S)-AHPC-C7-amine | 2306389-04-6 | Reference compound |
| HY-136186A | (S,R,S)-AHPC-C7-amine (dihydrochloride) | 2415256-17-4 | Reference compound |
| HY-136186B | (S,R,S)-AHPC-C7-amine (hydrochloride) | 2502189-41-3 | Reference compound |
| HY-136187 | (S,R,S)-AHPC-C5-NH2 | 2170695-19-7 | Reference compound |
| HY-136187A | (S,R,S)-AHPC-C5-NH2 (dihydrochloride) | 2415256-20-9 | Reference compound |
| HY-136188 | UNC2399 | 2412791-72-9 | Reference compound |
| HY-136189 | UK-59811 (hydrochloride) | 2250025-89-7 | Reference compound |
| HY-13619 | Efaproxiral | 131179-95-8 | Reference compound |
| HY-136190 | TRPC6-PAM-C20 | 667427-75-0 | Reference compound |
| HY-136192 | TP-472N | 2080306-24-5 | Reference compound |
| HY-136194 | TL13-22 | 2229036-65-9 | Reference compound |
| HY-136195 | TL13-110 | 2229037-09-4 | Reference compound |
| HY-136197 | StRIP16 | 2761279-63-2 | Reference compound |
| HY-136198 | SRX3207 | 2254693-15-5 | Reference compound |
| HY-136199 | SIRT1-IN-1 | 352554-02-0 | Reference compound |
| HY-13619A | Efaproxiral (sodium) | 170787-99-2 | Reference compound |
| HY-13619S | Efaproxiral-d6 | 1246815-16-6 | Isotope-Labeled Compounds |
| HY-13620 | Elinafide | 162706-37-8 | Reference compound |
| HY-136200 | Antitrypanosomal agent 2 | 475626-30-3 | Reference compound |
| HY-136201 | Sodium Glucoheptonate | 31138-65-5 | Reference compound |
| HY-136201R | Sodium Glucoheptonate (Standard) | 31138-65-5 | Reference Standards |
| HY-136203 | Resveratrol analog 1 | 861446-16-4 | Reference compound |
| HY-136204 | Resveratrol analog 2 | 915378-82-4 | Reference compound |
| HY-136205 | IA-Alkyne | 930800-38-7 | Reference compound |
| HY-136207 | TC-2559 (difumarate) | 2454492-41-0 | Reference compound |
| HY-136208 | TAN-452 | 892039-23-5 | Reference compound |
| HY-136209 | SU5208 | 62540-08-3 | Reference compound |
| HY-136211 | Cystathionine-γ-lyase-IN-1 | 2165706-30-7 | Reference compound |
| HY-136213 | Endoplasmic reticulum dye 1 | 1404104-40-0 | Dye Reagents |
| HY-136214 | R-BC154 (acetate) | | Reference compound |
| HY-136217 | PU 23 | 817635-93-1 | Reference compound |
| HY-136219 | Protein kinase affinity probe 1 | 2098621-90-8 | Reference compound |
| HY-13622 | Elomotecan (hydrochloride) | 220997-99-9 | Reference compound |
| HY-136220 | AHR antagonist 5 | 2247953-39-3 | Reference compound |
| HY-136220A | AHR antagonist 5 (hemimaleate) | | Reference compound |
| HY-13622A | Elomotecan | 220998-10-7 | Reference compound |
| HY-13622B | Elomotecan (TFA) | | Reference compound |
| HY-13623 | Entecavir | 142217-69-4 | Reference compound |
| HY-136232 | PSEM 308 (hydrochloride) | | Reference compound |
| HY-136233 | PSB 0777 (ammonium) | 2122196-16-9 | Reference compound |
| HY-136233A | PSB 0777 (ammonium hydrate) | | Reference compound |
| HY-136234 | 9-cis-β-Carotene | 13312-52-2 | Natural Products |
| HY-136237 | Thalidomide-NH-C5-NH2 (hydrochloride) | 2375194-03-7 | Reference compound |
| HY-136238 | PM226 | 1949726-13-9 | Reference compound |
| HY-136239 | Beclomethasone 17-propionate | 5534-18-9 | Reference compound |
| HY-136239R | Beclomethasone 17-propionate (Standard) | 5534-18-9 | Reference Standards |
| HY-13623A | Entecavir (monohydrate) | 209216-23-9 | Reference compound |
| HY-13623AR | Entecavir (monohydrate) (Standard) | 209216-23-9 | Reference Standards |
| HY-13623C | (1R,3S,4R)-ent-Entecavir | 188399-46-4 | Reference compound |
| HY-13623CS | (1R,3S,4R)-ent-Entecavir-13C2,15N | | Isotope-Labeled Compounds |
| HY-13623S | Entecavir-d2 | | Isotope-Labeled Compounds |
| HY-13623S1 | Entecavir-13C2,15N | | Isotope-Labeled Compounds |
| HY-13624 | Epirubicin | 56420-45-2 | Reference compound |
| HY-136240 | Tioxazafen | 330459-31-9 | Reference compound |
| HY-136241 | OT-82 | 1800487-55-1 | Reference compound |
| HY-136242 | UT-34 | 2168525-92-4 | Reference compound |
| HY-136244 | PF-06952229 | 1801333-55-0 | Reference compound |
| HY-136247 | Cyanine 5 Tyramide | 1431148-26-3 | Dye Reagents |
| HY-136247A | Cyanine 5 Tyramide methyl indole | | Reference compound |
| HY-136248 | Cyanine 3 Tyramide | 174961-75-2 | Dye Reagents |
| HY-136248A | Cyanine 3 Tyramide methyl indole | | Dye Reagents |
| HY-13624A | Epirubicin (hydrochloride) | 56390-09-1 | Reference compound |
| HY-13624AR | Epirubicin (hydrochloride) (Standard) | 56390-09-1 | Reference Standards |
| HY-13625 | Ertapenem sodium | 153773-82-1 | Reference compound |
| HY-136250 | BSJ-03-204 | 2349356-09-6 | Reference compound |
| HY-136250A | BSJ-03-204 (triTFA) | | Reference compound |
| HY-136251 | BRD0539 | 1403838-79-8 | Reference compound |
| HY-136252 | BSJ-04-132 | 2349356-39-2 | Reference compound |
| HY-136254 | BzATP (triethylammonium salt) | | Reference compound |
| HY-136255 | Camizestrant | 2222844-89-3 | Reference compound |
| HY-136256 | Vimseltinib | 1628606-05-2 | Reference compound |
| HY-136257 | CMP98 | 2244684-50-0 | Reference compound |
| HY-136258 | nAChR agonist CMPI (hydrochloride) | 2250025-94-4 | Reference compound |
| HY-136259 | ML188 | 1417700-13-0 | Reference compound |
| HY-13625R | Ertapenem sodium (Standard) | 153773-82-1 | Reference Standards |
| HY-13626 | Spisulosine | 196497-48-0 | Natural Products |
| HY-136260 | DBCO-PEG4-Ahx-DM1 | 2479378-44-2 | ADC Related |
| HY-136261 | DM1-PEG4-DBCO | | ADC Related |
| HY-136262 | CRBN-6-5-5-VHL | 2362575-45-7 | Reference compound |
| HY-136265 | BC-LI-0186 | 695207-56-8 | Reference compound |
| HY-136266 | HCV-IN-29 | 1009119-83-8 | Reference compound |
| HY-136267 | HCV-IN-30 | 1007882-23-6 | Reference compound |
| HY-136268 | AQX-435 | 1619983-52-6 | Reference compound |
| HY-136269 | A 410099.1, amine-Boc (hydrochloride) | 2374122-37-7 | Reference compound |
| HY-136269A | A 410099.1, amine-Boc | 1613552-03-6 | Reference compound |
| HY-13626S | Spisulosine-d3 | 1246298-31-6 | Isotope-Labeled Compounds |
| HY-13627 | Estramustine (phosphate sodium) | 52205-73-9 | Reference compound |
| HY-136270 | Gartisertib | 1613191-99-3 | Reference compound |
| HY-136272 | A 410099.1 amide-PEG3-amine-Boc | 2415256-19-6 | Reference compound |
| HY-136273 | A 410099.1 amide-PEG2-amine-Boc | 2415256-16-3 | Reference compound |
| HY-136274 | Boc-A 410099.1 amide-alkylC4-amine | 2415256-18-5 | Reference compound |
| HY-136275 | AMPA receptor modulator-2 | 2034181-36-5 | Reference compound |
| HY-136276 | DMNB-caged-Serine | 780009-55-4 | Reference compound |
| HY-136277 | DFHO | 1420815-34-4 | Dye Reagents |
| HY-136278 | DETA NONOate | 146724-94-9 | Reference compound |
| HY-136279 | TrxR inhibitor D9 | 1527513-89-8 | Reference compound |
| HY-13627A | Estramustine phosphate | 4891-15-0 | Reference compound |
| HY-13628 | Etalocib | 161172-51-6 | Reference compound |
| HY-136280 | Panamesine | 139225-22-2 | Reference compound |
| HY-136281 | DuP 734 | 135135-87-4 | Reference compound |
| HY-136282 | OGT-IN-2 | 442665-87-4 | Reference compound |
| HY-136283 | DMNPE-4 AM-caged-calcium | 2253744-58-8 | Reference compound |
| HY-136284 | XP-59 | 890402-73-0 | Reference compound |
| HY-136285 | CPI-1612 | 2374971-81-8 | Reference compound |
| HY-136285A | (R,R)-CPI-1612 | 2374972-35-5 | Reference compound |
| HY-136286 | MC-DM1 | 1375089-56-7 | ADC Related |
| HY-136287 | DBM-MMAF | 1810001-93-4 | ADC Related |
| HY-136288 | Azide-PEG4-VC-PAB-Doxorubicin | | ADC Related |
| HY-136289 | MB-VC-MGBA | 932744-62-2 | ADC Related |
| HY-13628A | Etalocib (sodium) | 152608-41-8 | Reference compound |
| HY-13629 | Etoposide | 33419-42-0 | Natural Products |
| HY-136291 | Sulfo-SPDB-DGN462 | | ADC Related |
| HY-136293 | Mechercharmycin A | 822520-96-7 | Natural Products |
| HY-136295 | Quinaldopeptin | 130743-07-6 | Reference compound |
| HY-136298 | (Rac)-X77 | 2144491-78-9 | Reference compound |
| HY-136298A | X77 | 2455518-33-7 | Reference compound |
| HY-136299 | Sepimostat | 103926-64-3 | Reference compound |
| HY-136299A | Sepimostat (dimethanesulfonate) | 103926-82-5 | Reference compound |
| HY-13629R | Etoposide (Standard) | 33419-42-0 | Reference Standards |
| HY-13629S | Etoposide-d3 | | Isotope-Labeled Compounds |
| HY-13629S1 | Etoposide-13C,d3 | | Isotope-Labeled Compounds |
| HY-13630 | Etoposide phosphate | 117091-64-2 | Reference compound |
| HY-136300 | PHD-1-IN-1 | 2009343-14-8 | Reference compound |
| HY-136301 | Acid secretion-IN-1 | 161958-62-9 | Reference compound |
| HY-136302 | Karrikinolide | 857054-02-5 | Reference compound |
| HY-136303 | GS-704277 | 1911579-04-8 | Reference compound |
| HY-136304 | NHS-PEG1-SS-PEG1-NHS | 1688598-83-5 | Reference compound |
| HY-136306 | Metallo β-lactamase ligand 1 | 1087784-71-1 | Reference compound |
| HY-136307S | Tizoxanide-d4 glucuronide | | Isotope-Labeled Compounds |
| HY-136309 | Ald-PEG23-SPDP | | ADC Related |
| HY-13630A | Etoposide phosphate (disodium) | 122405-33-8 | Reference compound |
| HY-13630R | Etoposide phosphate (Standard) | 117091-64-2 | Reference Standards |
| HY-13631 | Exatecan | 171335-80-1 | Reference compound |
| HY-136310 | PIP4K-IN-a131 | 2055405-95-1 | Reference compound |
| HY-136311 | NCT-504 | 1222765-97-0 | Reference compound |
| HY-136312 | 17-DMAP-GA | 169521-68-0 | Reference compound |
| HY-136313 | MC-VC-PAB-Tubulysin M | 1639939-56-2 | ADC Related |
| HY-136314 | DBCO-PEG4-VC-PAB-MMAE | 2129164-91-4 | ADC Related |
| HY-136315 | OSu-Glu-VC-PAB-MMAD | | ADC Related |
| HY-136317 | MC-betaglucuronide-MMAE-1 | 1703778-92-0 | ADC Related |
| HY-136318 | β-D-tetraacetylgalactopyranoside-PEG1-N3 | 153252-36-9 | ADC Related |
| HY-13631A | Exatecan (mesylate) | 169869-90-3 | Reference compound |
| HY-13631AG | Exatecan (mesylate) (GMP) | 169869-90-3 | GMP Small Molecules |
| HY-13631AS | Exatecan-d5 (mesylate) | 2819276-88-3 | Isotope-Labeled Compounds |
| HY-13631AS1 | Exatecan-d3 (mesylate) | | Isotope-Labeled Compounds |
| HY-13631D | Dxd | 1599440-33-1 | ADC Related |
| HY-13631DS | Dxd-d5 | | Isotope-Labeled Compounds |
| HY-13631E | Deruxtecan | 1599440-13-7 | ADC Related |
| HY-13631ES | Deruxtecan-d4 | 2760715-91-9 | Isotope-Labeled Compounds |
| HY-13631ES1 | Deruxtecan-d6 | 2760715-89-5 | Isotope-Labeled Compounds |
| HY-13631ES2 | Deruxtecan-d4-1 | 2760715-88-4 | Isotope-Labeled Compounds |
| HY-13631ES3 | Deruxtecan-d2 | 2760715-87-3 | Isotope-Labeled Compounds |
| HY-13631ES4 | Deruxtecan-d5 | | Isotope-Labeled Compounds |
| HY-13631F | Gly-Gly-Phe-Gly-NH-O-CO-Exatecan (hydrochloride) | 3053688-78-8 | ADC Related |
| HY-13631I | (1S,9R)-Exatecan (mesylate) | 2938875-54-6 | Reference compound |
| HY-13631J | (1R,9R)-Exatecan (mesylate) | 2938875-39-7 | Reference compound |
| HY-13631M | Gly-Gly-Phe-Gly-NH-O-CO-Exatecan | 1599440-12-6 | Reference compound |
| HY-13631O | (1R)-Deruxtecan | 2270986-87-1 | Reference compound |
| HY-13631P | Exatecan (mesylate dihydrate) | 197720-53-9 | Reference compound |
| HY-13631R | Exatecan (Standard) | 171335-80-1 | Reference Standards |
| HY-13632 | Exemestane | 107868-30-4 | Reference compound |
| HY-136321 | MC-betaglucuronide-MMAE-2 | 1703778-81-7 | ADC Related |
| HY-136327 | Phenylacetic acid mustard | 10477-72-2 | Reference compound |
| HY-136328 | EZM0414 (TFA) | 2411759-92-5 | Reference compound |
| HY-136329 | β-D-glucuronide-pNP-carbonate | 894095-98-8 | ADC Related |
| HY-13632R | Exemestane (Standard) | 107868-30-4 | Reference Standards |
| HY-13632S | Exemestane-d2 | | Isotope-Labeled Compounds |
| HY-13632S1 | Exemestane-13C3 | | Isotope-Labeled Compounds |
| HY-13632S2 | Exemestane-d3 | | Isotope-Labeled Compounds |
| HY-13632S5 | Exemestane-13C,d2 | | Isotope-Labeled Compounds |
| HY-13632S6 | Exemestane-d4 | | Isotope-Labeled Compounds |
| HY-13633 | Exisulind | 59864-04-9 | Reference compound |
| HY-136330 | Oxazosulfyl | 1616678-32-0 | Reference compound |
| HY-136336 | Tofacitinib metabolite-1 | 1640971-51-2 | Reference compound |
| HY-136338 | Cimetidine sulfoxide | 54237-72-8 | Reference compound |
| HY-136338R | Cimetidine sulfoxide (Standard) | 54237-72-8 | Reference Standards |
| HY-136339 | Cbl-b-IN-1 | 2368841-84-1 | Reference compound |
| HY-13634 | Ezatiostat (hydrochloride) | 286942-97-0 | Peptides |
| HY-136340 | 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione | 37413-91-5 | Reference compound |
| HY-136341 | 7,8-Dihydroneopterin | 1218-98-0 | Natural Products |
| HY-136341R | 7,8-Dihydroneopterin (Standard) | 1218-98-0 | Reference Standards |
| HY-136342 | Antitumor agent-23 | 2355185-12-3 | Reference compound |
| HY-136344 | Simvastatin Acyl-β-D-glucuronide | 463962-56-3 | Reference compound |
| HY-136345 | (Rac)-3′-Hydroxy simvastatin | 126313-98-2 | Reference compound |
| HY-136346 | 2-Hydroxy atorvastatin lactone | 163217-74-1 | Reference compound |
| HY-136346S | Ortho-hydroxy atorvastatin lactone-d5 | 265989-50-2 | Isotope-Labeled Compounds |
| HY-136347 | 3α-Hydroxy pravastatin (sodium) | 81093-43-8 | Reference compound |
| HY-136347R | 3α-Hydroxy pravastatin (sodium) (Standard) | 81093-43-8 | Reference Standards |
| HY-136348 | ML338 | 1630160-25-6 | Reference compound |
| HY-13634A | Ezatiostat | 168682-53-9 | Peptides |
| HY-13634B | TLK117 | 152684-53-2 | Peptides |
| HY-13635 | Finasteride | 98319-26-7 | Reference compound |
| HY-136350 | BRD9500 | 1630760-75-6 | Reference compound |
| HY-136350B | (S)-BRD9500 | 1630760-76-7 | Reference compound |
| HY-136351 | THZ-P1-2 | 2058075-45-7 | Reference compound |
| HY-136352 | Adenosine 5'-succinate | 102029-71-0 | Reference compound |
| HY-136355 | Picoxystrobin | 117428-22-5 | Reference compound |
| HY-136355R | Picoxystrobin (Standard) | 117428-22-5 | Reference Standards |
| HY-136355S | Picoxystrobin-d3 | | Isotope-Labeled Compounds |
| HY-136356 | Triclopyricarb | 902760-40-1 | Reference compound |
| HY-136357 | Tribenuron | 106040-48-6 | Reference compound |
| HY-136358 | LDN-211904 | 1198408-39-7 | Reference compound |
| HY-13635A | Finasteride (acetate) | 222989-99-3 | Reference compound |
| HY-13635R | Finasteride (Standard) | 98319-26-7 | Reference Standards |
| HY-13635S | Finasteride-d9 | 1131342-85-2 | Isotope-Labeled Compounds |
| HY-13636 | Fulvestrant | 129453-61-8 | Reference compound |
| HY-136360 | MI-3454 | 2134169-43-8 | Reference compound |
| HY-136362 | ARRY-382 | 1313407-95-2 | Reference compound |
| HY-136363 | MDR-652 | 1933528-96-1 | Reference compound |
| HY-136367 | Diclofop-methyl | 51338-27-3 | Reference compound |
| HY-136367R | Diclofop-methyl (Standard) | 51338-27-3 | Reference Standards |
| HY-136369 | Ethofumesate | 26225-79-6 | Reference compound |
| HY-136369R | Ethofumesate (Standard) | 26225-79-6 | Reference Standards |
| HY-13636A | Fulvestrant (S enantiomer) | 1316849-17-8 | Reference compound |
| HY-13636B | Fulvestrant (R enantiomer) | 1807900-80-6 | Reference compound |
| HY-13636R | Fulvestrant (Standard) | 129453-61-8 | Reference Standards |
| HY-13636S | Fulvestrant-d3 | | Isotope-Labeled Compounds |
| HY-13636S1 | Fulvestrant-d5 | | Isotope-Labeled Compounds |
| HY-13637 | Ganciclovir | 82410-32-0 | Reference compound |
| HY-136370 | Bromoxynil octanoate | 1689-99-2 | Reference compound |
| HY-136370R | Bromoxynil octanoate (Standard) | 1689-99-2 | Reference Standards |
| HY-136371 | Fluroxypyr-meptyl | 81406-37-3 | Reference compound |
| HY-136371R | Fluroxypyr-meptyl (Standard) | 81406-37-3 | Reference Standards |
| HY-136372 | Diquat (dibromide hydrate) | 6385-62-2 | Reference compound |
| HY-136372R | Diquat (dibromide hydrate) (Standard) | 6385-62-2 | Reference Standards |
| HY-136373 | Metazachlor | 67129-08-2 | Reference compound |
| HY-136373R | Metazachlor (Standard) | 67129-08-2 | Reference Standards |
| HY-136374 | Haloxyfop-P-methyl | 72619-32-0 | Reference compound |
| HY-136374R | Haloxyfop-P-methyl (Standard) | 72619-32-0 | Reference Standards |
| HY-136375 | Cyanazine | 21725-46-2 | Reference compound |
| HY-136375R | Cyanazine (Standard) | 21725-46-2 | Reference Standards |
| HY-136375S | Cyanazine-d5 | 1190003-29-2 | Isotope-Labeled Compounds |
| HY-136376 | Mefenpyr-diethyl | 135590-91-9 | Reference compound |
| HY-136376R | Mefenpyr-diethyl (Standard) | 135590-91-9 | Reference Standards |
| HY-136377 | Fluoroglycofen | 77501-60-1 | Reference compound |
| HY-136377R | Fluoroglycofen (Standard) | 77501-60-1 | Reference Standards |
| HY-136379 | CID44216842 | 1222513-26-9 | Reference compound |
| HY-13637A | Ganciclovir (sodium) | 107910-75-8 | Reference compound |
| HY-13637AR | Ganciclovir (sodium) (Standard) | 107910-75-8 | Reference Standards |
| HY-13637B | Ganciclovir (hydrate) | 1359968-33-4 | Reference compound |
| HY-13637R | Ganciclovir (Standard) | 82410-32-0 | Reference Standards |
| HY-13637S | Ganciclovir-d5 | 1189966-73-1 | Isotope-Labeled Compounds |
| HY-13638 | GDC-0152 | 873652-48-3 | Reference compound |
| HY-136380 | Clodinafop-propargyl | 105512-06-9 | Reference compound |
| HY-136380R | Clodinafop-propargyl (Standard) | 105512-06-9 | Reference Standards |
| HY-136380S | Clodinafop-propargyl-13C6 | | Isotope-Labeled Compounds |
| HY-136381 | N-Nitrosoglyphosate (sodium) | 56516-71-3 | Reference compound |
| HY-136382S | Sulfachloropyridazine-d4 | 1795037-54-5 | Isotope-Labeled Compounds |
| HY-136383 | AZA1 | 1071098-42-4 | Reference compound |
| HY-136384 | Diethofencarb | 87130-20-9 | Reference compound |
| HY-136384R | Diethofencarb (Standard) | 87130-20-9 | Reference Standards |
| HY-136386 | N-Acetyl-D-cysteine | 26117-28-2 | Reference compound |
| HY-136386R | N-Acetyl-D-cysteine (Standard) | 26117-28-2 | Reference Standards |
| HY-136390 | ML417 | 1386162-69-1 | Reference compound |
| HY-136392 | IKK-IN-3 | 615528-53-5 | Reference compound |
| HY-136393 | IKK-IN-4 | 615529-94-7 | Reference compound |
| HY-136394 | Diafenthiuron | 80060-09-9 | Reference compound |
| HY-136394R | Diafenthiuron (Standard) | 80060-09-9 | Reference Standards |
| HY-136395 | Cartap | 15263-53-3 | Reference compound |
| HY-136396 | Chlorempenthrin | 54407-47-5 | Reference compound |
| HY-13640 | Rabacfosadine | 859209-74-8 | Reference compound |
| HY-136403 | TIS108 | 1315459-30-3 | Reference compound |
| HY-136404 | Melanin probe-1 | 1420844-62-7 | Reference compound |
| HY-136405 | Melanin probe-2 | 1285446-04-9 | Reference compound |
| HY-136406 | Bongkrekic acid | 11076-19-0 | Reference compound |
| HY-136406S | Bongkrekic acid-13C28 | | Isotope-Labeled Compounds |
| HY-136408 | Malonyl CoA (lithium) | 108347-84-8 | Reference compound |
| HY-136409 | N-Decanoyl-L-homoserine lactone | 177315-87-6 | Reference compound |
| HY-136409R | N-Decanoyl-L-homoserine lactone (Standard) | 177315-87-6 | Reference Standards |
| HY-13640A | Rabacfosadine (succinate) | 1431856-99-3 | Reference compound |
| HY-13641 | Mitobronitol | 488-41-5 | Reference compound |
| HY-136410 | 4-hydroxy Nonenal Mercapturic Acid | 146764-24-1 | Reference compound |
| HY-136417 | Pd(II)TPBP | 119654-64-7 | Biochemical Assay Reagents |
| HY-13642 | RG108 | 48208-26-0 | Reference compound |
| HY-136420 | SJF-0628 | 2413035-41-1 | Reference compound |
| HY-136424 | GPI-1485 | 186268-78-0 | Reference compound |
| HY-136425 | Fosetyl-aluminum | 39148-24-8 | Reference compound |
| HY-136425R | Fosetyl-aluminum (Standard) | 39148-24-8 | Reference Standards |
| HY-136426 | Trifludimoxazin | 1258836-72-4 | Reference compound |
| HY-136427 | KRM-III | 79220-94-3 | Reference compound |
| HY-136428 | Desoxycarbadox | 55456-55-8 | Reference compound |
| HY-136428R | Desoxycarbadox (Standard) | 55456-55-8 | Reference Standards |
| HY-136428S | Desoxycarbadox-d3 | 1448350-02-4 | Isotope-Labeled Compounds |
| HY-136429 | Ethylhydrocupreine | 522-60-1 | Reference compound |
| HY-136429A | Ethylhydrocupreine (hydrochloride) | 3413-58-9 | Reference compound |
| HY-136429AR | Ethylhydrocupreine (hydrochloride) (Standard) | 3413-58-9 | Reference Standards |
| HY-13643 | Daminozide | 1596-84-5 | Natural Products |
| HY-136430 | JCN037 | 2305154-31-6 | Reference compound |
| HY-136431 | BC-DXI-843 | 2421117-98-6 | Reference compound |
| HY-136432 | Mc-Gly-Gly-Phe-Gly-PAB-OH | 2632342-05-1 | ADC Related |
| HY-136432A | Mc-Gly-Gly-Phe-Gly-PAB-OH (TFA) | | ADC Related |
| HY-136433 | N,N'-Dinitrosopiperazine | 140-79-4 | Reference compound |
| HY-136433S | N,N'-Dinitrosopiperazine-d8 | 69340-07-4 | Isotope-Labeled Compounds |
| HY-136434 | m-Chloramphenicol | 7411-65-6 | Reference compound |
| HY-136435 | Mapenterol (hydrochloride) | 54238-51-6 | Reference compound |
| HY-136435S1 | Mapenterol-d6 (hydrochloride) | 1246816-02-3 | Isotope-Labeled Compounds |
| HY-136436 | Ternidazole (hydrochloride) | 70028-95-4 | Reference compound |
| HY-136436R | Ternidazole (hydrochloride) (Standard) | 70028-95-4 | Reference Standards |
| HY-136436S | Ternidazole-d6 (hydrochloride) | 1346599-62-9 | Isotope-Labeled Compounds |
| HY-136437 | CXCR4 antagonist 1 | 675135-69-0 | Reference compound |
| HY-136438 | Toltrazuril sulfoxide | 69004-15-5 | Reference compound |
| HY-136438R | Toltrazuril sulfoxide (Standard) | 69004-15-5 | Reference Standards |
| HY-136439 | 4-Epianhydrotetracycline (hydrochloride) | 4465-65-0 | Reference compound |
| HY-136439R | 4-Epianhydrotetracycline (hydrochloride) (Standard) | 4465-65-0 | Reference Standards |
| HY-13643R | Daminozide (Standard) | 1596-84-5 | Reference Standards |
| HY-13644 | Gusperimus | 98629-43-7 | Reference compound |
| HY-136440 | Hydroxymetronidazole | 4812-40-2 | Reference compound |
| HY-136440R | Hydroxymetronidazole (Standard) | 4812-40-2 | Reference Standards |
| HY-136440S | Hydroxymetronidazole-d4 | 1215071-08-1 | Isotope-Labeled Compounds |
| HY-136440S1 | Hydroxymetronidazole-d2 | 2196180-19-3 | Isotope-Labeled Compounds |
| HY-136441 | Triclosan-methyl | 4640-01-1 | Reference compound |
| HY-136441S | Triclosan-methyl-d3 | 1020720-00-6 | Isotope-Labeled Compounds |
| HY-136443 | 4-Epitetracycline (hydrochloride) | 23313-80-6 | Reference compound |
| HY-136443R | 4-Epitetracycline (hydrochloride) (Standard) | 23313-80-6 | Reference Standards |
| HY-136444 | 2-NP-AOZ | 19687-73-1 | Reference compound |
| HY-136444R | 2-NP-AOZ (Standard) | 19687-73-1 | Reference Standards |
| HY-136444S | 2-NP-AOZ-d4 | 1007478-57-0 | Isotope-Labeled Compounds |
| HY-136445 | Terbuthylazine-desethyl | 30125-63-4 | Reference compound |
| HY-136445R | Terbuthylazine-desethyl (Standard) | 30125-63-4 | Reference Standards |
| HY-136445S | Terbuthylazine-desethyl-d9 | 1219798-52-3 | Isotope-Labeled Compounds |
| HY-136447 | ASP4132 | 1640294-30-9 | Reference compound |
| HY-136448 | SJ000025081 | 421571-66-6 | Reference compound |
| HY-136449 | Bromchlorbuterol (hydrochloride) | 78982-84-0 | Reference compound |
| HY-13644A | Gusperimus trihydrochloride | 85468-01-5 | Reference compound |
| HY-13645 | Henatinib | 1239269-51-2 | Reference compound |
| HY-136450 | Triclabendazole sulfoxide | 100648-13-3 | Reference compound |
| HY-136450R | Triclabendazole sulfoxide (Standard) | 100648-13-3 | Reference Standards |
| HY-136450S | Triclabendazole sulfoxide-d3 | | Isotope-Labeled Compounds |
| HY-136450S1 | Triclabendazole sulfoxide-13C,d3 | | Isotope-Labeled Compounds |
| HY-136451S | Triclabendazole sulfone-d3 | | Isotope-Labeled Compounds |
| HY-136453 | CR-1-31-B | 1352914-52-3 | Reference compound |
| HY-136453A | CR-1-30-B | 1352914-53-4 | Reference compound |
| HY-136456 | 2-NP-AMOZ | 183193-59-1 | Reference compound |
| HY-136456R | 2-NP-AMOZ (Standard) | 183193-59-1 | Reference Standards |
| HY-136456S | 2-NP-AMOZ-d5 | 1173097-59-0 | Isotope-Labeled Compounds |
| HY-136457 | 2-NP-AHD | 623145-57-3 | Reference compound |
| HY-136457R | 2-NP-AHD (Standard) | 623145-57-3 | Reference Standards |
| HY-136457S | 2-NP-AHD-13C3 | 1007476-86-9 | Isotope-Labeled Compounds |
| HY-136458 | 3-ANOT | 3572-44-9 | Reference compound |
| HY-136458R | 3-ANOT (Standard) | 3572-44-9 | Reference Standards |
| HY-136459 | NMDA receptor antagonist 2 | 875898-41-2 | Reference compound |
| HY-13646 | Encequidar | 849675-66-7 | Reference compound |
| HY-136460 | Calcium ionophore I | 58801-34-6 | Reference compound |
| HY-136461 | Polyoxin D | 22976-86-9 | Reference compound |
| HY-136462 | CYM50358 | 1314212-39-9 | Reference compound |
| HY-136464 | β-catenin-IN-2 | 1458664-10-2 | Reference compound |
| HY-136465 | A2ti-1 | 570390-00-0 | Reference compound |
| HY-136466 | A2ti-2 | 482646-13-9 | Reference compound |
| HY-13646A | Encequidar (mesylate) | 849675-87-2 | Reference compound |
| HY-13646B | Encequidar (hydrochloride) | 849675-88-3 | Reference compound |
| HY-13646C | Encequidar (mesylate hydrochloride) | 2097125-58-9 | Reference compound |
| HY-13647 | HMN-176 | 173529-10-7 | Reference compound |
| HY-136471 | Anticonvulsant agent 6 | 87213-50-1 | Reference compound |
| HY-136473 | CTX-0124143 | 423731-64-0 | Reference compound |
| HY-136474 | Amidephrine | 37571-84-9 | Reference compound |
| HY-136476 | Mg(II) protoporphyrin IX | 14947-11-6 | Reference compound |
| HY-136476A | Mn(II) protoporphyrin IX | 21393-64-6 | Reference compound |
| HY-136476B | Cu(II) protoporphyrin IX | 14494-37-2 | Reference compound |
| HY-136476C | Ni(II) protoporphyrin IX | 15415-30-2 | Reference compound |
| HY-136476D | Ga(III) protoporphyrin IX | 222556-71-0 | Reference compound |
| HY-136476E | Cr(III) protoporphyrin IX | 84640-43-7 | Reference compound |
| HY-136476F | Cd(II) protoporphyrin IX | 80216-25-7 | Reference compound |
| HY-136476G | Pt(II) protoporphyrin IX | 98303-94-7 | Reference compound |
| HY-136477 | Pentagamavunon-1 | 27060-70-4 | Reference compound |
| HY-136479 | F0911-7667 | 361198-09-6 | Reference compound |
| HY-13648 | Incyclinide | 15866-90-7 | Reference compound |
| HY-136480 | Chrysamine G | 6472-91-9 | Reference compound |
| HY-136482 | Nemadipine B | 79925-38-5 | Reference compound |
| HY-136484 | FEN1-IN-3 | 2109805-87-8 | Reference compound |
| HY-136485 | FEN1-IN-4 | 1995893-58-7 | Reference compound |
| HY-136486 | Lasiocarpine N-oxide | 127-30-0 | Natural Products |
| HY-136487 | Buspirone N-oxide | 220747-81-9 | Reference compound |
| HY-136489 | KU-0058948 | 763111-49-5 | Reference compound |
| HY-136489A | KU-0058948 (hydrochloride) | 2108829-86-1 | Reference compound |
| HY-13649 | Indibulin | 204205-90-3 | Reference compound |
| HY-136490 | Psychosine | 2238-90-6 | Reference compound |
| HY-136490S | Psychosine-d5 | 2260670-12-8 | Isotope-Labeled Compounds |
| HY-136490S1 | Psychosine-d7 | 2315262-31-6 | Isotope-Labeled Compounds |
| HY-136492S | Acetylclonidine-d4 | | Isotope-Labeled Compounds |
| HY-136494 | Fluprostenol | 40666-16-8 | Reference compound |
| HY-136497 | Coenzyme FO | 37333-48-5 | Reference compound |
| HY-136498 | T-705RMP | 356783-08-9 | Reference compound |
| HY-136498A | T-705RMP (ammonium) | 2096342-42-4 | Reference compound |
| HY-136498AR | T-705RMP (ammonium) (Standard) | 2096342-42-4 | Reference Standards |
| HY-136499 | DI-82 | 1638148-50-1 | Reference compound |
| HY-13650 | Indisulam | 165668-41-7 | Reference compound |
| HY-136500 | Prostaglandin H2 | 42935-17-1 | Natural Products |
| HY-136501 | MRS2395 | 491611-55-3 | Reference compound |
| HY-136502 | (E)-Aztreonam | 99341-02-3 | Reference compound |
| HY-136504 | Bianthrone | 434-85-5 | Reference compound |
| HY-136506 | NUC-7738 | 2348493-39-8 | Reference compound |
| HY-136509 | CIL62 | 117593-36-9 | Reference compound |
| HY-136511 | Epicaptopril | 63250-36-2 | Reference compound |
| HY-136512 | Streptazolin | 80152-07-4 | Natural Products |
| HY-136513 | Bifenox | 42576-02-3 | Reference compound |
| HY-136513S | Bifenox-d3 | | Isotope-Labeled Compounds |
| HY-136514 | Tampramine | 83166-17-0 | Reference compound |
| HY-136517 | Clenhexerol | 38339-23-0 | Reference compound |
| HY-136520B | Xanthoanthrafil | 1020251-53-9 | Reference compound |
| HY-136521 | AZ13824374 | 3040082-19-4 | Reference compound |
| HY-136522 | S2116 | 2262489-89-2 | Reference compound |
| HY-136523 | S2157 | 2262488-39-9 | Reference compound |
| HY-136526 | BCR-ABL-IN-3 | 2240191-12-0 | Reference compound |
| HY-136527 | BMS-986251 | 2460133-35-9 | Reference compound |
| HY-136528 | RA-9 | 919091-63-7 | Reference compound |
| HY-13653 | (-)-Epigallocatechin Gallate | 989-51-5 | Natural Products |
| HY-136530 | SR18662 | 2505001-62-5 | Reference compound |
| HY-136531 | XMU-MP-3 | 2031152-08-4 | Reference compound |
| HY-136532 | ZT-1a | 212135-62-1 | Reference compound |
| HY-136534 | RET V804M-IN-1 | 2414909-94-5 | Reference compound |
| HY-136535 | Anizatrectinib | 1824664-89-2 | Reference compound |
| HY-136537A | N-β-alanyldopamine (hydrochloride) | 58077-93-3 | Reference compound |
| HY-136538 | LQZ-7I | 195822-23-2 | Reference compound |
| HY-13653R | (-)-Epigallocatechin Gallate (Standard) | 989-51-5 | Reference Standards |
| HY-13653S | (+/-)-Epigallocatechin Gallate-13C3 | | Isotope-Labeled Compounds |
| HY-13653S1 | (-)-Epigallocatechin Gallate-d4 | | Isotope-Labeled Compounds |
| HY-136540 | Resolvin D3 | 916888-47-6 | Reference compound |
| HY-136540S | Resolvin D3-d5 | | Isotope-Labeled Compounds |
| HY-136541 | YB-0158 | 1144043-83-3 | Reference compound |
| HY-136542 | H-β-Ala-AMC (TFA) | 201847-54-3 | Reference compound |
| HY-136546 | Stafia-1 | 2582757-90-0 | Reference compound |
| HY-136547 | Boc-Val-Ala-PAB | 1884577-99-4 | Reference compound |
| HY-136548 | Tenofovir diphosphate | 166403-66-3 | Reference compound |
| HY-136548A | Tenofovir diphosphate (triethylamine) | 2122333-63-3 | Reference compound |
| HY-136548B | Tenofovir diphosphate (disodium) | 2738719-07-6 | Reference compound |
| HY-136552 | β-Bisabolene | 495-61-4 | Natural Products |
| HY-136554 | WYC-210 | 2131803-93-3 | Reference compound |
| HY-136555 | GSK717 | 1595278-21-9 | Reference compound |
| HY-136556 | Factor B-IN-1 | 1481631-75-7 | Reference compound |
| HY-136557 | AFM32a | 2095109-82-1 | Reference compound |
| HY-136557A | AFM32a (hydrochloride) | 2988594-85-8 | Reference compound |
| HY-136559 | 6-Azathymine | 932-53-6 | Reference compound |
| HY-13655A | Isatoribine | 122970-40-5 | Reference compound |
| HY-13656 | Isofludelone | 691868-19-6 | Reference compound |
| HY-136560 | 6-Azathymine acid | 13924-15-7 | Reference compound |
| HY-136561 | GRK5-IN-2 | 1642839-27-7 | Reference compound |
| HY-136562 | N-Arachidonyl maleimide | 876305-42-9 | Reference compound |
| HY-136563 | RA375 | 2649154-57-2 | Peptides |
| HY-136564 | DAD (dichloride) | | Reference compound |
| HY-136564A | DAD | | Reference compound |
| HY-136567 | TBAP-001 | 1777832-90-2 | Reference compound |
| HY-136568 | Stafia-1-dipivaloyloxymethyl ester | 2582755-72-2 | Reference compound |
| HY-136569 | DSR-141562 | 2007975-22-4 | Reference compound |
| HY-136570 | GSK778 | 2451862-42-1 | Reference compound |
| HY-136570A | GSK778 (hydrochloride) | 2863657-79-6 | Reference compound |
| HY-136571 | GSK046 | 2474876-09-8 | Reference compound |
| HY-136572 | CEM114 | 2279062-54-1 | Reference compound |
| HY-136573 | 5-Hydroxytoluene-2,4-disulphonic acid (diammonium) | | Reference compound |
| HY-136574 | 2-Hydroxy-4-methylbenzenesulphonic acid (ammonium) | 79093-71-3 | Reference compound |
| HY-136575 | 4-Hydroxy-2-methylbenzenesulfonic acid (ammonium) | 2742982-16-5 | Reference compound |
| HY-136576 | RP101075 | 1306760-73-5 | Reference compound |
| HY-136577 | RP101442 | 1306761-08-9 | Reference compound |
| HY-136578 | RP101988 | 2990018-57-8 | Reference compound |
| HY-136579 | ASN007 | 2055597-12-9 | Reference compound |
| HY-136579A | ASN007 (benzenesulfonate) | 2055597-39-0 | Reference compound |
| HY-136582 | Masofaniten | 2416716-62-4 | Reference compound |
| HY-136583 | 28-Epirapamycin | 253431-35-5 | Reference compound |
| HY-136584 | 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid | 413624-71-2 | Reference compound |
| HY-136586 | Loperamide phenyl | 1391052-94-0 | Reference compound |
| HY-136587 | Oxomemazine | 3689-50-7 | Reference compound |
| HY-136587R | Oxomemazine (Standard) | 3689-50-7 | Reference Standards |
| HY-136589 | Verapamil EP Impurity C (hydrochloride) | 51012-67-0 | Reference compound |
| HY-13659 | KRN5500 | 151276-95-8 | Reference compound |
| HY-136590 | 2-Nitrosopyridine | 79917-37-6 | Reference compound |
| HY-136591 | Demoxepam | 963-39-3 | Reference compound |
| HY-136591R | Demoxepam (Standard) | 963-39-3 | Reference Standards |
| HY-136592 | 1-Hydroxy-ibuprofen | 53949-53-4 | Reference compound |
| HY-136593 | (S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid | 23508-35-2 | Reference compound |
| HY-136595 | 3,5-Difluoro-L-tyrosine | 73246-30-7 | Reference compound |
| HY-136596 | Apalutamide-COOH | 1332391-04-4 | Reference compound |
| HY-136596R | Apalutamide-COOH (Standard) | 1332391-04-4 | Reference Standards |
| HY-136597 | Remdesivir O-desphosphate acetonide impurity | 1191237-80-5 | Reference compound |
| HY-13660 | Mocravimod (hydrochloride) | 509088-69-1 | Reference compound |
| HY-136604 | RAD51-IN-3 | 2301084-99-9 | Reference compound |
| HY-136605 | DGY-06-116 | 2556836-50-9 | Reference compound |
| HY-136606 | SARS-CoV MPro-IN-1 | 2413716-71-7 | Reference compound |
| HY-136607 | DiAzK | 2231405-65-3 | Reference compound |
| HY-136608 | 5-AAM-2-CP | 175424-74-5 | Reference compound |
| HY-136609 | 5-AMAM-2-CP | 864628-19-3 | Reference compound |
| HY-13661 | 7-Hydroxystaurosporine | 112953-11-4 | Reference compound |
| HY-136610 | Chlorpyrifos-oxon | 5598-15-2 | Reference compound |
| HY-136610S | Chlorpyrifos-oxon-d10 | 1794779-85-3 | Isotope-Labeled Compounds |
| HY-136611 | ω-Hydroxy-DEET | 72236-22-7 | Reference compound |
| HY-136611R | ω-Hydroxy-DEET (Standard) | 72236-22-7 | Reference Standards |
| HY-136612 | DCBA | 72236-23-8 | Reference compound |
| HY-136612R | DCBA (Standard) | 72236-23-8 | Reference Standards |
| HY-136613 | Demethyl linezolid | 168828-65-7 | Reference compound |
| HY-136614 | H-Val-βNA | 729-24-8 | Reference compound |
| HY-136615 | 5-Hydroxydecanoate (sodium) | 71186-53-3 | Reference compound |
| HY-13662 | Lansoprazole | 103577-45-3 | Reference compound |
| HY-136621 | 5-HT1A modulator 2 (hydrochloride) | 3880-76-0 | Reference compound |
| HY-136622 | A-420983 | 330789-03-2 | Reference compound |
| HY-136623 | BW443C | 88331-14-0 | Reference compound |
| HY-136625 | LY134046 | 71274-97-0 | Reference compound |
| HY-136626 | Z-Ala-Ala-Asn-AMC | 149697-16-5 | Peptides |
| HY-136627 | PGF2α analogue-1 | 291303-34-9 | Reference compound |
| HY-136628 | RU 25434 | 62622-76-8 | Reference compound |
| HY-13662A | Lansoprazole (sodium) | 226904-00-3 | Reference compound |
| HY-13662B | (R)-Lansoprazole | 138530-94-6 | Reference compound |
| HY-13662BR | (R)-Lansoprazole (Standard) | 138530-94-6 | Reference Standards |
| HY-13662BS | (R)-Lansoprazole-d4 | | Isotope-Labeled Compounds |
| HY-13662C | (S)-Lansoprazole | 138530-95-7 | Reference compound |
| HY-13662R | Lansoprazole (Standard) | 103577-45-3 | Reference Standards |
| HY-13662S | Lansoprazole-d4 | 934294-22-1 | Isotope-Labeled Compounds |
| HY-136630 | Felotaxel | 944154-59-0 | Reference compound |
| HY-136631 | PF-04279405 | 955881-01-3 | Reference compound |
| HY-136633 | Pyroxasulfone | 447399-55-5 | Reference compound |
| HY-136633R | Pyroxasulfone (Standard) | 447399-55-5 | Reference Standards |
| HY-136634 | BTM-1042 | 72293-40-4 | Reference compound |
| HY-136637 | NPD-001 | 469863-16-9 | Reference compound |
| HY-136638 | ML328 | 634175-34-1 | Reference compound |
| HY-13664 | Folinic acid (calcium) | 1492-18-8 | Natural Products |
| HY-136640 | BCL6-IN-4 | 2253879-65-9 | Reference compound |
| HY-136641 | NOTA-FAPI | 2374782-03-1 | Reference compound |
| HY-136642 | Fluocinolone | 807-38-5 | Reference compound |
| HY-136644 | PD-217014-methyl ester | 444088-20-4 | Reference compound |
| HY-136644A | PD-217014 | 335458-65-6 | Reference compound |
| HY-136645 | EP4 receptor antagonist 2 | 1965316-82-8 | Reference compound |
| HY-136647 | 8-Bromoadenosine 5'-triphosphate (tetrasodium) | 35892-96-7 | Reference compound |
| HY-136648 | 2'-Deoxyadenosine-5'-triphosphate | 1927-31-7 | Oligonucleotides |
| HY-136648A | 2'-Deoxyadenosine-5'-triphosphate (trisodium) | 54680-12-5 | Biochemical Assay Reagents |
| HY-136648AR | 2'-Deoxyadenosine-5'-triphosphate (trisodium) (Standard) | 54680-12-5 | Reference Standards |
| HY-136648S | 2'-Deoxyadenosine-5'-triphosphate-13C10,15N5 (tetraammonia) | | Isotope-Labeled Compounds |
| HY-136648S1 | 2'-Deoxyadenosine-5'-triphosphate-13C10,15N5 (dilithium) | | Isotope-Labeled Compounds |
| HY-136648S2 | 2'-Deoxyadenosine-5'-triphosphate-15N5,d14 (dilithium) | | Isotope-Labeled Compounds |
| HY-136648S3 | 2'-Deoxyadenosine-5'-triphosphate-d14 (dilithium) | 2687960-68-3 | Isotope-Labeled Compounds |
| HY-136648S4 | 2'-Deoxyadenosine-5'-triphosphate-15N5 (dilithium) | | Isotope-Labeled Compounds |
| HY-136648S5 | 2'-Deoxyadenosine-5'-triphosphate-13C10 (dilithium) | | Isotope-Labeled Compounds |
| HY-136649 | 2'-Deoxy-2'-fluoroadenosine 5'-triphosphate (tetralithium) | | Oligonucleotides |
| HY-13664R | Folinic acid (calcium) (Standard) | 1492-18-8 | Reference Standards |
| HY-136650 | Fludarabine triphosphate | 74832-57-8 | Reference compound |
| HY-136650A | Fludarabine triphosphate (trisodium) | | Reference compound |
| HY-136651 | BNTA | 685119-25-9 | Reference compound |
| HY-136653 | Ciramadol | 63269-31-8 | Reference compound |
| HY-136654 | LPK-26 (hydrochloride) | 492451-07-7 | Reference compound |
| HY-136656 | Maltotriitol | 32860-62-1 | Biochemical Assay Reagents |
| HY-136657 | SC-43 | 1400989-25-4 | Reference compound |
| HY-136658 | 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea | 1313019-65-6 | Reference compound |
| HY-136659 | Ro 04-5595 | 194089-07-1 | Reference compound |
| HY-13666 | Levamisole (hydrochloride) | 16595-80-5 | Reference compound |
| HY-136660 | PQR626 | 1927857-98-4 | Reference compound |
| HY-136661 | (-)-N6-Phenylisopropyl adenosine | 38594-96-6 | Reference compound |
| HY-136664A | Neothorin (disodium) | 3547-38-4 | Biochemical Assay Reagents |
| HY-136665 | Boc-D-Phe-Pro-OH | 38675-10-4 | Reference compound |
| HY-136666 | Antibiotic AC4437 | 63487-84-3 | Reference compound |
| HY-13666R | Levamisole (hydrochloride) (Standard) | 16595-80-5 | Reference Standards |
| HY-13666S | Levamisole-d5 (hydrochloride) | 1246819-64-6 | Isotope-Labeled Compounds |
| HY-13667 | Levoleucovorin (Calcium) | 80433-71-2 | Natural Products |
| HY-136672 | (E)-HBT-O | 2056899-56-8 | Dye Reagents |
| HY-136674 | Aftin-5 | 1461717-05-4 | Reference compound |
| HY-136675 | ASMI | 1850419-05-4 | Reference compound |
| HY-136676 | Cgp 38560 (methanesulfonate) | 122088-76-0 | Reference compound |
| HY-136677 | Lnd 796 | 118549-42-1 | Reference compound |
| HY-136678A | SB 258741 (hydrochloride) | | Reference compound |
| HY-136679 | TD114-2 | 436866-52-3 | Reference compound |
| HY-13667R | Levoleucovorin (Calcium) (Standard) | 80433-71-2 | Reference Standards |
| HY-13668 | Lomeguatrib | 192441-08-0 | Reference compound |
| HY-136684 | BrBzGCp2 | 166038-00-2 | Reference compound |
| HY-136686 | IDH-C227 | 1355324-14-9 | Reference compound |
| HY-136688 | MI-389 | 2222635-92-7 | Reference compound |
| HY-136689 | Taxin B | 168109-52-2 | Natural Products |
| HY-13669 | Lomustine | 13010-47-4 | Reference compound |
| HY-136690 | Triasulfuron | 82097-50-5 | Reference compound |
| HY-136690R | Triasulfuron (Standard) | 82097-50-5 | Reference Standards |
| HY-136691 | Episesartemin A | 77449-31-1 | Natural Products |
| HY-136693 | L-654284 | 98719-20-1 | Reference compound |
| HY-136694 | Senkyunolide E | 94530-83-3 | Natural Products |
| HY-136696 | 11-Deoxy-16,16-dimethyl-PGE2 | 53658-98-3 | Reference compound |
| HY-136699 | Excisanin A | 78536-37-5 | Natural Products |
| HY-13669R | Lomustine (Standard) | 13010-47-4 | Reference Standards |
| HY-13670 | Lurtotecan | 149882-10-0 | Reference compound |
| HY-136702 | L-97-1 | 770703-20-3 | Reference compound |
| HY-136703 | Lopinavir Metabolite M-1 | 192725-39-6 | Reference compound |
| HY-136704 | GLS1 Inhibitor-1 | 1832646-52-2 | Reference compound |
| HY-136705 | MeO-Suc-Ala-Ala-Pro-Ala-CMK | 111682-13-4 | Reference compound |
| HY-136706 | Luciferase-IN-1 | 10205-56-8 | Reference compound |
| HY-136707 | DGAT-1 inhibitor 3 | 1231243-91-6 | Reference compound |
| HY-13670A | Lurtotecan (dihydrochloride) | 155773-58-3 | Reference compound |
| HY-13671 | LW6 | 934593-90-5 | Reference compound |
| HY-136711 | CDK7-IN-2 (hydrochloride hydrate) | 2326428-24-2 | Reference compound |
| HY-136714 | Bcl-2-IN-3 | 383860-03-5 | Reference compound |
| HY-136717 | FBPase-1 inhibitor-1 | 883973-99-7 | Reference compound |
| HY-136718 | CLEFMA | 1246964-32-8 | Reference compound |
| HY-13672 | LY2334737 | 892128-60-8 | Reference compound |
| HY-136720 | ZXX2-77 | 304913-22-2 | Reference compound |
| HY-136726 | CGP-82996 | 359886-84-3 | Reference compound |
| HY-136727 | Ac-LEVD-CHO | 402832-01-3 | Peptides |
| HY-136728 | Ac-YVAD-AOM | 154674-81-4 | Peptides |
| HY-13673 | Goserelin | 65807-02-5 | Peptides |
| HY-136731 | APE1-IN-1 | 524708-03-0 | Reference compound |
| HY-136733 | Ac-DNLD-CHO | 775289-20-8 | Peptides |
| HY-136735 | IRE1α kinase-IN-1 | 2328097-41-0 | Reference compound |
| HY-136736 | β-Secretase Inhibitor II | 263563-09-3 | Reference compound |
| HY-13673A | Goserelin (acetate) | 145781-92-6 | Peptides |
| HY-13673S | Goserelin-d10 | | Isotope-Labeled Compounds |
| HY-13673S1 | Goserelin-d7 | | Isotope-Labeled Compounds |
| HY-13673S2 | Goserelin-d7 (TFA) | | Isotope-Labeled Compounds |
| HY-13674 | Maytansine | 35846-53-8 | Natural Products |
| HY-136741 | BOT-64 | 113760-29-5 | Reference compound |
| HY-136742 | BACE2-IN-1 | 1676107-08-6 | Reference compound |
| HY-136744 | Caspase-9 Inhibitor III | 403848-57-7 | Reference compound |
| HY-136747 | Nek2/Hec1-IN-1 | 560103-80-2 | Reference compound |
| HY-136748 | HIF-2α-IN-4 | 882268-69-1 | Reference compound |
| HY-13675 | ME-143 | 852536-39-1 | Reference compound |
| HY-136750 | Z-LLY-FMK | 133410-84-1 | Reference compound |
| HY-136752 | CYP51-IN-2 | 1155361-00-4 | Reference compound |
| HY-136754 | CYP51-IN-4 | 1155361-02-6 | Reference compound |
| HY-136756 | CYP51-IN-6 | 1155361-04-8 | Reference compound |
| HY-136757 | CYP51-IN-7 | 1155361-05-9 | Reference compound |
| HY-136758 | CYP51-IN-8 | 1155361-06-0 | Reference compound |
| HY-136759 | CYP51-IN-9 | 1155361-07-1 | Reference compound |
| HY-13676 | Megestrol acetate | 595-33-5 | Reference compound |
| HY-136762 | CYP51-IN-12 | 1155361-10-6 | Reference compound |
| HY-136763 | CYP51-IN-13 | 1155361-11-7 | Reference compound |
| HY-136764 | CYP51-IN-14 | 1155361-12-8 | Reference compound |
| HY-136765 | PI3K-IN-11 | 884539-95-1 | Reference compound |
| HY-136767 | Cladosporin | 35818-31-6 | Natural Products |
| HY-136769 | Biotin-HPDP | 129179-83-5 | Biochemical Assay Reagents |
| HY-13676R | Megestrol acetate (Standard) | 595-33-5 | Reference Standards |
| HY-13676S | Megestrol acetate-d3 | 162462-72-8 | Isotope-Labeled Compounds |
| HY-13676S1 | Megestrol acetate-d3-1 | | Isotope-Labeled Compounds |
| HY-13677 | 6-Mercaptopurine | 50-44-2 | Reference compound |
| HY-136772 | Pomalidomide-PEG1-NH2 (hydrochloride) | 2380273-67-4 | Reference compound |
| HY-136773 | KER047 | 2248154-85-8 | Reference compound |
| HY-136773A | KER047 (succinate) | 2416307-25-8 | Reference compound |
| HY-136774 | BCL6-IN-5 | 2253878-09-8 | Reference compound |
| HY-13677A | 6-Mercaptopurine hydrate | 6112-76-1 | Reference compound |
| HY-13677AR | 6-Mercaptopurine hydrate (Standard) | 6112-76-1 | Reference Standards |
| HY-13677R | 6-Mercaptopurine (Standard) | 50-44-2 | Reference Standards |
| HY-13677S | 6-Mercaptopurine-d2 | 82677-93-8 | Isotope-Labeled Compounds |
| HY-13677S1 | 6-Mercaptopurine-13C2,15N | 1190008-04-8 | Isotope-Labeled Compounds |
| HY-13678 | Meropenem | 96036-03-2 | Natural Products |
| HY-136780 | SEN177 | 2117405-13-5 | Reference compound |
| HY-136782 | ST-148 (maleate) | 390803-40-4 | Reference compound |
| HY-136784 | Rhod-2 (potassium) | 663625-18-1 | Dye Reagents |
| HY-136788 | ALK4290 | 1251528-23-0 | Reference compound |
| HY-136788A | ALK4290 (dihydrochloride) | 1372127-19-9 | Reference compound |
| HY-136789 | Tuxobertinib | 2414572-47-5 | Reference compound |
| HY-13678A | Meropenem (trihydrate) | 119478-56-7 | Reference compound |
| HY-13678AR | Meropenem (trihydrate) (Standard) | 119478-56-7 | Reference Standards |
| HY-13678S | Meropenem-d6 | 1217976-95-8 | Isotope-Labeled Compounds |
| HY-13678S1 | Meropenem-d6-1 | 1133424-00-6 | Isotope-Labeled Compounds |
| HY-13679 | Sodium 2-mercaptoethanesulfonate | 19767-45-4 | Reference compound |
| HY-136791 | BN52115 | 120908-94-3 | Reference compound |
| HY-136794 | SB-284851-BT | 219769-23-0 | Reference compound |
| HY-136797 | BP13944 | 1622060-51-8 | Reference compound |
| HY-136799 | Rediocide C | 677277-98-4 | Natural Products |
| HY-13679R | Sodium 2-mercaptoethanesulfonate (Standard) | 19767-45-4 | Reference Standards |
| HY-13680 | Meisoindigo | 97207-47-1 | Natural Products |
| HY-136800 | Posatirelin | 78664-73-0 | Reference compound |
| HY-136802 | LolCDE-IN-3 | 1639933-79-1 | Reference compound |
| HY-136804 | CypD-IN-29 | 1115335-95-9 | Reference compound |
| HY-136805 | Kv1.5-IN-1 | 1469902-72-4 | Reference compound |
| HY-136806 | PI3K-IN-12 | 1807551-44-5 | Reference compound |
| HY-136807 | Tpl2-IN-I | 915009-13-1 | Reference compound |
| HY-136808 | Pfn1-IN-1 | 919010-46-1 | Reference compound |
| HY-136809 | PRMT6-IN-2 | 912970-79-7 | Reference compound |
| HY-13681 | Methylprednisolone acetate | 53-36-1 | Reference compound |
| HY-136813 | Multitarget AD inhibitor-1 | 2205015-77-4 | Reference compound |
| HY-136817 | Nanaomycin αA | 58286-56-9 | Natural Products |
| HY-136818 | DA 4643 (dihydrochloride) | 95833-19-5 | Reference compound |
| HY-136819 | Primordazine NC-6364997 | 312532-31-3 | Reference compound |
| HY-13681R | Methylprednisolone acetate (Standard) | 53-36-1 | Reference Standards |
| HY-13681S | Methylprednisolone acetate-d6 | | Isotope-Labeled Compounds |
| HY-13682 | Mifamurtide | 83461-56-7 | Reference compound |
| HY-136820S1 | Taurultam-d2 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-136821 | Polymyxin D2 | 34167-45-8 | Reference compound |
| HY-136822 | Antibiotic A40104A | 69659-06-9 | Natural Products |
| HY-136824 | Napyradiomycin A1 | 103106-24-7 | Natural Products |
| HY-136828 | LL-BM123α | 52932-62-4 | Reference compound |
| HY-136829 | BPH-675 | 946417-21-6 | Reference compound |
| HY-13682A | Mifamurtide (sodium hydrate) | 838853-48-8 | Reference compound |
| HY-13682B | Mifamurtide (sodium) | 90825-43-7 | Reference compound |
| HY-13682C | Mifamurtide (TFA) | | Reference compound |
| HY-13683 | Mifepristone | 84371-65-3 | Reference compound |
| HY-136830 | ADP-Glucose (disodium) | 102129-65-7 | Biochemical Assay Reagents |
| HY-136831 | SR2640 | 105350-26-3 | Reference compound |
| HY-136832 | Noribogaine (hydrochloride) | 110514-35-7 | Reference compound |
| HY-136833 | X5050 | 2404756-81-4 | Reference compound |
| HY-136835 | GJ071 (oxalate) | 1216676-34-4 | Reference compound |
| HY-136838 | (R)-Donepezil | 142698-19-9 | Reference compound |
| HY-13683R | Mifepristone (Standard) | 84371-65-3 | Reference Standards |
| HY-13683S | Mifepristone-d3 | | Isotope-Labeled Compounds |
| HY-13683S1 | Mifepristone-13C,d3 | | Isotope-Labeled Compounds |
| HY-13683S2 | Mifepristone-d6 | 1228097-18-4 | Isotope-Labeled Compounds |
| HY-136840 | (±)-Apomorphine | 61503-74-0 | Reference compound |
| HY-136841 | SLM6 | 22242-91-7 | Reference compound |
| HY-136842 | Oxetorone (fumarate) | 34522-46-8 | Reference compound |
| HY-136848 | SM1-71 | 2088179-99-9 | Reference compound |
| HY-136849 | TL13-68 | | Reference compound |
| HY-13685 | Miltefosine | 58066-85-6 | Reference compound |
| HY-136855 | MitoPBN | 652968-37-1 | Reference compound |
| HY-136857 | BRD4 degrader-3 | 2413382-30-4 | Reference compound |
| HY-136859 | BATCP | 787549-23-9 | Reference compound |
| HY-13685S1 | Miltefosine-d4 | | Isotope-Labeled Compounds |
| HY-13686 | PQ401 | 196868-63-0 | Reference compound |
| HY-136860 | (R)-Venlafaxine | 93413-46-8 | Reference compound |
| HY-136861 | Antibacterial agent 192 | 387832-36-2 | Reference compound |
| HY-136865 | MeOSuc-AAPV-AMC | 72252-90-5 | Dye Reagents |
| HY-136866 | Aβ42-IN-2 | 1914989-80-2 | Reference compound |
| HY-136868 | Resorufin-β-D-glucopyranoside, 98% | 101490-85-1 | Biochemical Assay Reagents |
| HY-136869 | MHAPC-Chol | 1027801-74-6 | Biochemical Assay Reagents |
| HY-13687 | IKK 16 | 873225-46-8 | Reference compound |
| HY-136870 | Kyoto probe 1 | 2088021-81-0 | Dye Reagents |
| HY-136871 | Decarestrictin A1 | 127393-90-2 | Reference compound |
| HY-136872 | PBFI-AM | 124549-23-1 | Dye Reagents |
| HY-136873 | UCB-J | 2242957-52-2 | Reference compound |
| HY-13687A | IKK 16 (hydrochloride) | 1186195-62-9 | Reference compound |
| HY-13688 | PJ34 (hydrochloride) | 344458-15-7 | Reference compound |
| HY-136880 | Flufylline | 82190-91-8 | Reference compound |
| HY-136882 | TM-1 | 921099-13-0 | Reference compound |
| HY-136883S | Benzophenone-9-d6 | | Isotope-Labeled Compounds |
| HY-136884 | DAR-4M | 339527-79-6 | Reference compound |
| HY-136885 | (S,S)-TAPI-0 | 143457-40-3 | Reference compound |
| HY-136886 | IR-820 | 172616-80-7 | Dye Reagents |
| HY-136887 | Arphamenine B (hemisulfate) | 144110-38-3 | Reference compound |
| HY-136888 | MeOSuc-AAPV-CMK | 65144-34-5 | Peptides |
| HY-13688A | PJ34 | 344458-19-1 | Reference compound |
| HY-13689 | Go 6983 | 133053-19-7 | Reference compound |
| HY-136891 | AHR-16303B | 117023-62-8 | Reference compound |
| HY-136894 | Rhod-5N | 888229-31-0 | Dye Reagents |
| HY-136895 | AZ12672857 | 945396-55-4 | Reference compound |
| HY-136896 | FFA3 agonist 1 | 886358-51-6 | Reference compound |
| HY-136898 | PS-915 (dihydrochloride) | 86356-77-6 | Reference compound |
| HY-13690 | Mitotane | 53-19-0 | Reference compound |
| HY-136901 | Fusarochromanone | 802915-53-3 | Natural Products |
| HY-136905 | AMPA receptor antagonist-2 | 732277-05-3 | Reference compound |
| HY-136907S | (S)-(-)-Verapamil-d3 (hydrochloride) | 1398112-33-8 | Isotope-Labeled Compounds |
| HY-136908 | W140 (TFA) | 909725-64-0 | Biochemical Assay Reagents |
| HY-136909 | SR33805 | 121345-64-0 | Reference compound |
| HY-13690R | Mitotane (Standard) | 53-19-0 | Reference Standards |
| HY-13690S1 | Mitotane-13C6 | 1261396-21-7 | Isotope-Labeled Compounds |
| HY-13690S2 | Mitotane-d8 | 2673270-14-7 | Isotope-Labeled Compounds |
| HY-13690S3 | Mitotane-13C12 | 2483736-36-1 | Isotope-Labeled Compounds |
| HY-13691 | MKC-1 | 125313-92-0 | Reference compound |
| HY-136910 | USP7-797 | 2413944-70-2 | Reference compound |
| HY-136913 | (Rac)-Rhododendrol | 69617-84-1 | Reference compound |
| HY-136915 | Pyrisoxazole | 847749-37-5 | Reference compound |
| HY-136916 | Hydroxythiovardenafil | 912576-30-8 | Reference compound |
| HY-136920 | CBP/p300-IN-8 | 2304416-91-7 | Reference compound |
| HY-136922 | Orexin receptor antagonist 2 | 1457940-75-8 | Reference compound |
| HY-136924 | FP-Biotin | 259270-28-5 | Reference compound |
| HY-136926 | Candicidin A3 | 58591-23-4 | Reference compound |
| HY-136927 | MSA-2 | 129425-81-6 | Reference compound |
| HY-13693 | Mometasone furoate | 83919-23-7 | Reference compound |
| HY-136930 | 6-Iododiosmin | 1431536-92-3 | Reference compound |
| HY-136931 | Picropodophyllol | 3811-15-2 | Natural Products |
| HY-136933 | Gitoxin | 4562-36-1 | Natural Products |
| HY-136933R | Gitoxin (Standard) | 4562-36-1 | Reference Standards |
| HY-136934 | Reversin 205 | 174630-05-8 | Peptides |
| HY-136935 | Alloyohimbine | 522-94-1 | Natural Products |
| HY-136936 | PYBG-BODIPY | 2068027-79-0 | Dye Reagents |
| HY-136937 | PYBG-TMR | 2067339-51-7 | Dye Reagents |
| HY-136938 | NEO2734 | 2081072-29-7 | Reference compound |
| HY-136939 | CFTR corrector 6 | 2226970-01-8 | Reference compound |
| HY-13693R | Mometasone furoate (Standard) | 83919-23-7 | Reference Standards |
| HY-13693S | Mometasone furoate-d3 | | Isotope-Labeled Compounds |
| HY-13693S2 | Mometasone furoate-13C,d6 | | Isotope-Labeled Compounds |
| HY-13694 | Methionine | 348-67-4 | Reference compound |
| HY-136941 | Antioxidant 1024 | 32687-78-8 | Reference compound |
| HY-136941R | Antioxidant 1024 (Standard) | 32687-78-8 | Reference Standards |
| HY-136942 | DS1 | 372497-52-4 | Reference compound |
| HY-136943 | K-41 | 53026-37-2 | Natural Products |
| HY-136945 | StA-IFN-1 | 300839-31-0 | Reference compound |
| HY-136946 | HITCI | 19764-96-6 | Dye Reagents |
| HY-136947 | RJR-2429 | 91556-75-1 | Reference compound |
| HY-13694R | Methionine (Standard) | 348-67-4 | Reference Standards |
| HY-13694S | Methionine-d3 | 284665-18-5 | Isotope-Labeled Compounds |
| HY-13694S1 | Methionine-d4 | | Isotope-Labeled Compounds |
| HY-136951 | cp028 | 347397-83-5 | Reference compound |
| HY-136952 | p-SCN-Bn-HOPO | 1822331-55-4 | Reference compound |
| HY-136953 | LL-BM123γ1 | 60830-76-4 | Reference compound |
| HY-136954 | LL-BM123γ2 | 60830-75-3 | Reference compound |
| HY-136957 | Fluorescein-6-isothiocyanate | 18861-78-4 | Dye Reagents |
| HY-136959 | M133 | 2127411-61-2 | Reference compound |
| HY-13696 | MSX-122 | 897657-95-3 | Reference compound |
| HY-136960 | β2AR antagonist 1 | 2135743-21-2 | Reference compound |
| HY-136961 | NK 1971 | 35020-81-6 | Reference compound |
| HY-136962 | ASB-14 | 216667-08-2 | Biochemical Assay Reagents |
| HY-136964 | Sulfo-NHS-Biotin (sodium) | 194041-65-1 | Reference compound |
| HY-136968 | epi-Doramectin | 1987882-62-1 | Reference compound |
| HY-136969 | RU 752 | 51390-69-3 | Reference compound |
| HY-136972 | (-)-GB-1a | 220611-41-6 | Natural Products |
| HY-136973 | Biliverdin (dihydrochloride) | 55482-27-4 | Biochemical Assay Reagents |
| HY-136975 | Caspase-3-IN-1 | 872254-32-5 | Reference compound |
| HY-136976 | WST-1 | 150849-52-8 | Dye Reagents |
| HY-136977 | EEDi-5285 | 2488952-40-3 | Reference compound |
| HY-136978 | OP-5244 | 2381268-71-7 | Reference compound |
| HY-136978A | OP-5244 (sodium) | | Reference compound |
| HY-136979 | RBN012759 | 2360851-29-0 | Reference compound |
| HY-136980 | Aspartylglutamate | 6157-06-8 | Peptides |
| HY-136986 | Desthiazolylmethyl ritonavir | 256328-82-2 | Reference compound |
| HY-13699 | NBI-42902 | 352290-60-9 | Reference compound |
| HY-136990 | GLPG0259 | 959754-85-9 | Reference compound |
| HY-136991 | Basacv | 95676-71-4 | Reference compound |
| HY-136994 | Sphingolactone-24 | 881177-99-7 | Reference compound |
| HY-136995 | AFD-21 (maleate) | 99465-44-8 | Reference compound |
| HY-136997 | M-5MPEP | 872428-47-2 | Reference compound |
| HY-136998 | 10-Nitro-9-octadecenoic acid | 88127-53-1 | Biochemical Assay Reagents |
| HY-136999 | 7-O-Methyleucomol | 17934-15-5 | Natural Products |
| HY-13700 | Nedaplatin | 95734-82-0 | Reference compound |
| HY-137000 | 4-Prenyloxyresveratrol | 69065-16-3 | Natural Products |
| HY-137002 | Fmoc-N-Me-Arg(Pbf)-OH | 913733-27-4 | Peptides |
| HY-137004 | Indazole-Cl | 848142-62-1 | Reference compound |
| HY-137005 | CS1 | 1448009-94-6 | Reference compound |
| HY-137006 | MTT Formazan | 57360-69-7 | Reference compound |
| HY-137007 | SMA-12b | 1496553-39-9 | Reference compound |
| HY-13701 | Nelarabine | 121032-29-9 | Reference compound |
| HY-137011 | 3,9-Dihydroeucomin | 887375-68-0 | Natural Products |
| HY-137012 | 8-iso Prostaglandin F1α | 26771-96-0 | Reference compound |
| HY-137012S | 8-iso Prostaglandin F1α-d9 | | Isotope-Labeled Compounds |
| HY-137015 | trans-Khellactone | 23458-04-0 | Natural Products |
| HY-137016 | 8-Pcpt-cGMP | 54364-02-2 | Reference compound |
| HY-137016A | 8-Pcpt-cGMP (sodium) | 51239-26-0 | Reference compound |
| HY-137018 | 27-Alkyne cholesterol | 1527467-07-7 | Reference compound |
| HY-13701R | Nelarabine (Standard) | 121032-29-9 | Reference Standards |
| HY-13702 | Nilutamide | 63612-50-0 | Reference compound |
| HY-137020 | 7-Hydroxydichloromethotrexate | 751-75-7 | Reference compound |
| HY-137023 | Sulfo-Cy7 amine | 2236573-39-8 | Reference compound |
| HY-137024 | 15-Keto-PGA1 | 61600-67-7 | Reference compound |
| HY-137025 | (S)-NIFE | 328406-65-1 | Reference compound |
| HY-137028 | 2′-Thioadenosine | 136904-69-3 | Reference compound |
| HY-13702R | Nilutamide (Standard) | 63612-50-0 | Reference Standards |
| HY-13702S | Nilutamide-d6 | 1189477-66-4 | Isotope-Labeled Compounds |
| HY-13703 | Nimustine | 42471-28-3 | Reference compound |
| HY-137030S | 2-Benzotriazol-2-yl-4,6-bis(1-methyl-1-phenylethyl)phenol-d4 (UV-234-d4) | | Isotope-Labeled Compounds |
| HY-137031 | Spinetoram L | 187166-15-0 | Reference compound |
| HY-137034 | (+)-Secolongifolene-diol | 53587-37-4 | Natural Products |
| HY-137037 | Ingenol 20-palmitate | 39071-33-5 | Natural Products |
| HY-137038 | N-alpha-Tosyl-Lys chloromethyl ketone (hydrochloride) | 4238-41-9 | Reference compound |
| HY-13703A | Nimustine (hydrochloride) | 55661-38-6 | Reference compound |
| HY-13704 | SN-38 | 86639-52-3 | Natural Products |
| HY-137040A | Tiemonium (iodide) | 144-12-7 | Reference compound |
| HY-137042 | Cyanine5 alkyne | 1223357-57-0 | Dye Reagents |
| HY-137043 | 9-Keto Travoprost | 1219032-18-4 | Reference compound |
| HY-137045 | Bisindolylmaleimide VII | 137592-47-3 | Reference compound |
| HY-137046 | Nek2-IN-4 | 2225902-88-3 | Reference compound |
| HY-137048 | PF-00835231 | 870153-29-0 | Reference compound |
| HY-137049 | Co 101244 | 193359-26-1 | Reference compound |
| HY-13704R | SN-38 (Standard) | 86639-52-3 | Reference Standards |
| HY-13704S | SN-38-d3 | 718612-49-8 | Isotope-Labeled Compounds |
| HY-13705 | NM-3 | 181427-78-1 | Reference compound |
| HY-137054 | Ukrain | 138069-52-0 | Reference compound |
| HY-137055 | PF-3774076 | 1171824-96-6 | Reference compound |
| HY-137056 | LY164929 | 113573-18-5 | Reference compound |
| HY-13706 | CAY10471 (Racemate) | 844639-57-2 | Reference compound |
| HY-137061 | AZ-GHS-22 | 1143020-91-0 | Reference compound |
| HY-137063 | (+)-ITD-1 | 1409968-46-2 | Reference compound |
| HY-137064 | Memantine lactose adduct | 1159637-28-1 | Reference compound |
| HY-137067 | IMT1B | 2304621-06-3 | Reference compound |
| HY-13706A | CAY10471 | 627865-18-3 | Reference compound |
| HY-13707 | Tin(IV) mesoporphyrin IX (dichloride) | 106344-20-1 | Reference compound |
| HY-137070 | Rivaroxaban diol | 1160170-00-2 | Reference compound |
| HY-137073 | Cy7 alkyne (chloride) | 1998119-13-3 | Reference compound |
| HY-137075 | (±)-JQ1 | 1268524-69-1 | Reference compound |
| HY-137076 | N-Octylnortadalafil | 1173706-35-8 | Reference compound |
| HY-13708 | SUN C5174 | 191592-36-6 | Reference compound |
| HY-137083 | Trifluoperazine N-Glucuronide | 165602-90-4 | Reference compound |
| HY-137083A | Trifluoperazine N-glucuronide (chloride) | 145850-78-8 | Reference compound |
| HY-137083S | Trifluoperazine N-glucuronide-d3 | | Isotope-Labeled Compounds |
| HY-137084 | Antibiotic AB023a | 141443-39-2 | Reference compound |
| HY-137085 | Antibiotic AB023b | 141443-40-5 | Reference compound |
| HY-137088 | Imiclopazine | 7414-95-1 | Reference compound |
| HY-137089 | Azacosterol (dihydrochloride) | 1249-84-9 | Reference compound |
| HY-13709 | Gantacurium (chloride) | 213998-46-0 | Reference compound |
| HY-137092 | IACS-13909 | 2160546-07-4 | Reference compound |
| HY-137093 | Orexin receptor antagonist 3 | 1293282-55-9 | Reference compound |
| HY-137098 | Sulfo-Cy3 maleimide (potassium) | 1656990-68-9 | Dye Reagents |
| HY-137099 | Genistein 7-sulfate | 182322-62-9 | Reference compound |
| HY-137099A | Genistein 7-sulfate (sodium) | | Reference compound |
| HY-13710 | Dimethindene | 5636-83-9 | Reference compound |
| HY-137100 | Cy 5 hydrazide | 1427705-31-4 | Dye Reagents |
| HY-137103 | BTC-AM | 176767-94-5 | Dye Reagents |
| HY-137107 | Radafaxine | 192374-14-4 | Reference compound |
| HY-137108 | Sp-8-pCPT-cGMPS | 160385-87-5 | Reference compound |
| HY-13710A | Dimethindene (maleate) | 3614-69-5 | Reference compound |
| HY-13710AR | Dimethindene (maleate) (Standard) | 3614-69-5 | Reference Standards |
| HY-137110 | Axitinib sulfoxide | 1347304-18-0 | Reference compound |
| HY-137111 | p-MPPF (dihydrochloride) | 223699-41-0 | Reference compound |
| HY-137111A | p-MPPF | 155204-26-5 | Reference compound |
| HY-137115 | BODIPY-Cyclopamine | 334658-24-1 | Dye Reagents |
| HY-137116 | Ser-Tyr β-naphthylamide | 24008-82-0 | Biochemical Assay Reagents |
| HY-137117 | 15-keto-PGE1 | 22973-19-9 | Reference compound |
| HY-137119 | (±)5-iPF2α-VI | 179094-11-2 | Reference compound |
| HY-137119A | 8,12-iso-iPF2α-VI | 1445349-99-4 | Reference compound |
| HY-137119AS | 8,12-iso-iPF2α-VI-d11 | | Isotope-Labeled Compounds |
| HY-137121 | YKAs3003 | 329180-48-5 | Reference compound |
| HY-137122 | 3-Pyridine toxoflavin | 32502-20-8 | Reference compound |
| HY-137124 | BB-F-Yne | 2219331-30-1 | Reference compound |
| HY-137125 | BB-Cl-Yne | 2219324-71-5 | Reference compound |
| HY-137126 | Photosensitizer Pc 4 | 135719-28-7 | Reference compound |
| HY-137128 | BTC (tetrapotassium) | 216453-54-2 | Dye Reagents |
| HY-137129 | 10-Formyl-7,8-dihydrofolic acid | 28459-40-7 | Natural Products |
| HY-13713 | LY377604 | 204592-94-9 | Reference compound |
| HY-137131 | DC-Chol (hydrochloride) | 166023-21-8 | Oligonucleotides |
| HY-137133 | Prostaglandin E1 alcohol | 21562-57-2 | Reference compound |
| HY-137134 | D-Glucuronic acid,2-propen-1-yl ester | 188717-04-6 | Biochemical Assay Reagents |
| HY-137135 | Cantharidic acid | 28874-45-5 | Reference compound |
| HY-137135A | Cantharidic acid (disodium) | 1465-77-6 | Reference compound |
| HY-137139 | 10'-Desmethoxystreptonigrin | 136803-89-9 | Natural Products |
| HY-13714 | Nolatrexed | 147149-76-6 | Reference compound |
| HY-137141 | 16-Keto Aspergillimide | 199784-50-4 | Natural Products |
| HY-137144 | Fulvestrant-3-boronic acid | 1853279-29-4 | Reference compound |
| HY-137145 | galacto-Dapagliflozin | 1408245-02-2 | Reference compound |
| HY-137148 | DIOA | 81166-47-4 | Reference compound |
| HY-137149 | Lonazolac (hemicalcium) | 75821-71-5 | Reference compound |
| HY-13715 | Norepinephrine | 51-41-2 | Natural Products |
| HY-137152 | 8-Aminoclonazolam | 71368-66-6 | Reference compound |
| HY-137153 | Afzelechin 3-O-xyloside | 512781-45-2 | Natural Products |
| HY-137155 | Dapsone hydroxylamine | 32695-27-5 | Reference compound |
| HY-137155S | Dapsone hydroxylamine-d4 | 1330185-26-6 | Isotope-Labeled Compounds |
| HY-137157 | Suprofen (L-lysine) | 69317-48-2 | Reference compound |
| HY-137158 | 16-Phenoxy tetranor Prostaglandin E2 | 54382-74-0 | Reference compound |
| HY-137159 | Bestatin methyl ester | 65322-89-6 | Reference compound |
| HY-13715A | Norepinephrine (hydrochloride) | 329-56-6 | Natural Products |
| HY-13715AR | Norepinephrine (hydrochloride) (Standard) | 329-56-6 | Reference Standards |
| HY-13715B | Norepinephrine (bitartrate monohydrate) | 108341-18-0 | Natural Products |
| HY-13715BR | Norepinephrine (bitartrate monohydrate) (Standard) | 108341-18-0 | Reference Standards |
| HY-13715C | Norepinephrine (tartrate) | 51-40-1 | Natural Products |
| HY-13715R | Norepinephrine (Standard) | 51-41-2 | Reference Standards |
| HY-13715S | (Rac)-Norepinephrine-d3 (formate) | | Isotope-Labeled Compounds |
| HY-13716 | Noscapine | 128-62-1 | Natural Products |
| HY-137160 | (±)-Ketoprofen glucuronide | 76690-94-3 | Reference compound |
| HY-137164 | Ala-Ala-Phe-AMC | 62037-41-6 | Reference compound |
| HY-137164A | Ala-Ala-Phe-AMC (TFA) | 62037-42-7 | Peptides |
| HY-137167 | Guanylyl imidodiphosphate (lithium) | 64564-03-0 | Reference compound |
| HY-137168 | LAB 149202F | 94343-58-5 | Reference compound |
| HY-13716A | Noscapine (hydrochloride) | 912-60-7 | Natural Products |
| HY-13716R | Noscapine (Standard) | 128-62-1 | Reference Standards |
| HY-13716S | Noscapine-13C,d3 | 1217680-57-3 | Isotope-Labeled Compounds |
| HY-13717 | AGN194204 | 220619-73-8 | Reference compound |
| HY-137172 | ETH 157 | 61595-77-5 | Reference compound |
| HY-137173 | Laidlomycin propionate | 78734-47-1 | Reference compound |
| HY-137175 | TMBIM6 antagonist-1 | 123134-61-2 | Reference compound |
| HY-137175A | CDC25B-IN-2 | 134271-74-2 | Reference compound |
| HY-137178 | 20α,22R-Dihydroxycholesterol | 596-94-1 | Reference compound |
| HY-137179 | Glyco-diosgenin | 1402423-29-3 | Reference compound |
| HY-13718 | Oglufanide | 38101-59-6 | Natural Products |
| HY-137180 | Naloxonazine | 82824-01-9 | Reference compound |
| HY-137181 | 9-Carboxymethoxymethylguanine | 80685-22-9 | Reference compound |
| HY-137186 | Suc-Gly-Gly-Phe-pNA | 68982-90-1 | Peptides |
| HY-137187 | FB23 | 2243736-35-6 | Reference compound |
| HY-137188 | Perindopril acyl-β-D-glucuronide | 120398-66-5 | Reference compound |
| HY-13718A | Oglufanide (disodium) | 237068-57-4 | Reference compound |
| HY-13719 | Oleandrin | 465-16-7 | Natural Products |
| HY-137191 | CH7233163 | 2923365-71-1 | Reference compound |
| HY-137193 | 5,6-Dihydroabiraterone | 219843-75-1 | Reference compound |
| HY-137194 | Ethynyl estradiol 3-b-D-glucuronide | 60134-76-1 | Biochemical Assay Reagents |
| HY-137196 | Anhydrochlortetracycline (hydrochloride) | 65490-24-6 | Reference compound |
| HY-137197 | 6β-Hydroxy dexamethasone | 55879-47-5 | Reference compound |
| HY-137198 | 4-Nitrophenyl β-D-maltoside | 56846-39-0 | Biochemical Assay Reagents |
| HY-137199 | Pro-Phe-Arg-AMC | 65147-21-9 | Peptides |
| HY-13719R | Oleandrin (Standard) | 465-16-7 | Reference Standards |
| HY-13720 | Pergolide | 66104-22-1 | Reference compound |
| HY-137200 | N-Desmethyl Bendamustine | 41515-13-3 | Reference compound |
| HY-137201 | 2-Phenylethyl β-D-thiogalactoside | 63407-54-5 | Biochemical Assay Reagents |
| HY-137204 | COR659 | 544450-68-2 | Reference compound |
| HY-137206 | ALV2 | 2438124-95-7 | Reference compound |
| HY-137207 | MK-28 | 864388-65-8 | Reference compound |
| HY-137208 | Chondroitin disaccharide Δdi-0S (sodium) | 136132-69-9 | Reference compound |
| HY-13720A | Pergolide (mesylate) | 66104-23-2 | Reference compound |
| HY-13720AR | Pergolide (mesylate) (Standard) | 66104-23-2 | Reference Standards |
| HY-13720AS | Pergolide-d7 (mesylate) | | Isotope-Labeled Compounds |
| HY-13720S | Pergolide-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13721 | Phenoxodiol | 81267-65-4 | Reference compound |
| HY-137211 | Hydrocortisone-21-lysinate | 95924-98-4 | Reference compound |
| HY-137213 | Fluvastatin lactone | 94061-83-3 | Reference compound |
| HY-137215 | 4'-trans-Hydroxy Cilostazol | 87153-04-6 | Reference compound |
| HY-137215S | 4'-trans-Hydroxy Cilostazol-d5 | | Isotope-Labeled Compounds |
| HY-137215S1 | 4-cis-Hydroxy Cilostazol-d5 | | Isotope-Labeled Compounds |
| HY-137215S2 | 4'-trans-Hydroxy Cilostazol-d4 | | Isotope-Labeled Compounds |
| HY-137217 | α-Artemether | 71939-51-0 | Reference compound |
| HY-137219 | Δ12(E)-Prostaglandin D2 | 64072-89-5 | Reference compound |
| HY-13722 | HPPH | 149402-51-7 | Reference compound |
| HY-137220 | Z-Gly-Pro-pNA | 65022-15-3 | Reference compound |
| HY-137222S | 4',5-Dihydroxy Diclofenac-13C6 | 1309283-30-4 | Isotope-Labeled Compounds |
| HY-137225 | HTS07944 | 706758-28-3 | Reference compound |
| HY-137227 | 15(R)-PTA2 | 71154-83-1 | Reference compound |
| HY-137228 | 4-Nitrophenylmaltohexaoside | 74173-30-1 | Biochemical Assay Reagents |
| HY-137229 | Avermectin B1a monosaccharide | 71831-09-9 | Reference compound |
| HY-13723 | Pimecrolimus | 137071-32-0 | Reference compound |
| HY-137231A | (S)-UFR2709 | 1431628-22-6 | Reference compound |
| HY-137231B | (S)-UFR2709 (hydrochloride) | 2934318-93-9 | Reference compound |
| HY-137232 | 4-Methylumbelliferyl-β-D-lactoside | 84325-23-5 | Biochemical Assay Reagents |
| HY-137234 | DM-β-CD | 51166-71-3 | Biochemical Assay Reagents |
| HY-137236 | 6β-Hydroxy metandienone | 33526-41-9 | Reference compound |
| HY-137238 | Ethyl mycophenolate | 32483-51-5 | Reference compound |
| HY-137239 | 1,4-DPCA ethyl ester | 86443-19-8 | Reference compound |
| HY-13723A | Pimecrolimus (hydrate) | 1000802-56-1 | Reference compound |
| HY-13723R | Pimecrolimus (Standard) | 137071-32-0 | Reference Standards |
| HY-13724 | Pipendoxifene | 198480-55-6 | Reference compound |
| HY-137242 | Ingenol-3-palmitate | 52557-26-3 | Natural Products |
| HY-137243 | Adenosine 3',5'-diphosphate (disodium) | 75431-54-8 | Reference compound |
| HY-137245 | Emlenoflast | 1995067-59-8 | Reference compound |
| HY-137245A | Emlenoflast (sodium) | 2380032-29-9 | Reference compound |
| HY-137246 | CD73-IN-3 | 2375815-63-5 | Reference compound |
| HY-137247 | 16-Mercaptopalmitic acid | 69839-68-5 | Reference compound |
| HY-137249 | Resorufin-β-D-galactopyranoside | 95079-19-9 | Biochemical Assay Reagents |
| HY-13724B | Pipendoxifene hydrochloride | 245124-69-0 | Reference compound |
| HY-13725 | Pirarubicin | 72496-41-4 | Reference compound |
| HY-137251 | Sulfo-MBS (sodium) | 92921-25-0 | Reference compound |
| HY-137252 | 22,23-Dihydroavermectin B1a aglycon | 73162-95-5 | Reference compound |
| HY-137254 | SKF-80723 | 71636-62-9 | Reference compound |
| HY-137255 | Taurolithocholic acid 3-sulfate (disodium) | 64936-83-0 | Biochemical Assay Reagents |
| HY-137255S | Taurolithocholic acid-3-Sulfate-d4 (disodium salt) | | Isotope-Labeled Compounds |
| HY-137257 | Carbamyl-PAF | 91575-58-5 | Reference compound |
| HY-137258 | (±)-N-3-Benzylnirvanol | 93879-40-4 | Reference compound |
| HY-13725A | Pirarubicin (Hydrochloride) | 95343-20-7 | Reference compound |
| HY-13725AR | Pirarubicin (Hydrochloride) (Standard) | 95343-20-7 | Reference Standards |
| HY-13725R | Pirarubicin (Standard) | 72496-41-4 | Reference Standards |
| HY-13726 | Piroxantrone | 91441-23-5 | Reference compound |
| HY-137261 | UDP-β-D-glucose (disodium) | 7333-33-7 | Reference compound |
| HY-137262 | Protein deglycase DJ-1 against-1 | 724737-74-0 | Reference compound |
| HY-137263 | Propionylmaridomycin | 35775-65-6 | Reference compound |
| HY-137265 | Aminomethyltrioxsalen (hydrochloride) | 62442-61-9 | Reference compound |
| HY-137267 | 10-Methyl-10-deazaaminopterin | 80576-77-8 | Reference compound |
| HY-137268 | 2-Nitrophenyl β-D-cellobioside | 70867-33-3 | Biochemical Assay Reagents |
| HY-13727 | Pixantrone (free base) | 144510-96-3 | Reference compound |
| HY-137270 | 16,16-Dimethyl PGA2 | 41691-92-3 | Reference compound |
| HY-137273 | Sucrose octasulfate (sodium) | 74135-10-7 | Reference compound |
| HY-137276 | 5-Bromo-3-indolyl β-D-galactopyranoside | 97753-82-7 | Dye Reagents |
| HY-137279 | Naloxone methiodide | 93302-47-7 | Reference compound |
| HY-13727A | Pixantrone | 144675-97-8 | Reference compound |
| HY-13727AR | Pixantrone (Standard) | 144675-97-8 | Reference Standards |
| HY-13727AS | Pixantrone-d8 | | Isotope-Labeled Compounds |
| HY-13727B | Pixantrone (hydrochloride) | 175989-38-5 | Reference compound |
| HY-13728 | Plevitrexed | 153537-73-6 | Reference compound |
| HY-137281 | HMB-Val-Ser-Leu-VE | 862891-04-1 | Peptides |
| HY-137286 | Z-Leu-Leu-Glu-βNA | 75873-85-7 | Peptides |
| HY-137288 | 17-Phenyl-18,19,20-trinor-PGD2 | 85280-91-7 | Reference compound |
| HY-13728A | (R)-Plevitrexed | 153537-74-7 | Reference compound |
| HY-13728B | (Rac)-Plevitrexed | 153538-08-0 | Reference compound |
| HY-137292 | PTB7-Th | 1469791-66-9 | Reference compound |
| HY-137294 | BTPTT-4F | 2304444-49-1 | Reference compound |
| HY-137295 | Ingenol 3,20-dibenzoate | 59086-90-7 | Natural Products |
| HY-137296 | Lumogallion | 4386-25-8 | Dye Reagents |
| HY-137298 | LYS006 | 1799681-85-8 | Reference compound |
| HY-137298A | LYS006 (hydrochloride) | 2619563-79-8 | Reference compound |
| HY-13730 | Porfiromycin | 801-52-5 | Reference compound |
| HY-137300 | Hydroxy vardenafil | 224785-98-2 | Reference compound |
| HY-137301 | Mycophenolic acid glucuronide | 31528-44-6 | Reference compound |
| HY-137301R | Mycophenolic acid glucuronide (Standard) | 31528-44-6 | Reference Standards |
| HY-137301S | Mycophenolic acid glucuronide-d3 | | Isotope-Labeled Compounds |
| HY-137303 | FA-Gly-Leu-NH2 | 26400-33-9 | Reference compound |
| HY-137304 | 3α-Mannobiose | 23745-85-9 | Biochemical Assay Reagents |
| HY-137305 | O-Acetylgalanthamine | 25650-83-3 | Natural Products |
| HY-137306 | Pergolide sulfone | 72822-03-8 | Reference compound |
| HY-137307 | Cholest-5-ene-3ß,22(S)-diol | 22348-64-7 | Reference compound |
| HY-137307S | Cholest-5-ene-3ß,22(S)-diol-d7 | 1246302-91-9 | Isotope-Labeled Compounds |
| HY-137308 | 15(R)-Prostaglandin D2 | 59894-05-2 | Reference compound |
| HY-137309 | 4-Deoxy-4α-phorbol | 37415-57-9 | Natural Products |
| HY-13731 | PPI-2458 | 431077-35-9 | Reference compound |
| HY-137310 | 4-Hydroxy atorvastatin (hemicalcium) | 265989-44-4 | Reference compound |
| HY-137311A | (S)-Albuterol | 34271-50-6 | Reference compound |
| HY-137312A | Carbuterol (hydrochloride) | 34866-46-1 | Reference compound |
| HY-137313 | Octyl α-D-glucopyranoside | 29781-80-4 | Biochemical Assay Reagents |
| HY-137315 | TML-6 | 1462868-88-7 | Reference compound |
| HY-137315S | TML-6-d3 | 2673270-28-3 | Isotope-Labeled Compounds |
| HY-137316 | Phosphoramide mustard | 10159-53-2 | Reference compound |
| HY-137316A | Phosphoramide mustard (cyclohexanamine) | 1566-15-0 | Reference compound |
| HY-137316AR | Phosphoramide mustard (cyclohexanamine) (Standard) | 1566-15-0 | Reference Standards |
| HY-137318 | BM 15766 (sulfate) | 86621-94-5 | Reference compound |
| HY-13732 | Prednimustine | 29069-24-7 | Reference compound |
| HY-137320 | diABZI-C2-NH2 | 2137975-93-8 | Reference compound |
| HY-137321 | Estriol 3-glucuronide (sodium salt) | 15087-06-6 | Reference compound |
| HY-137322 | THX-B | 1372206-64-8 | Reference compound |
| HY-137323 | Leucinostatin H | 109539-58-4 | Peptides |
| HY-137324 | α-Apooxytetracycline | 18695-01-7 | Reference compound |
| HY-137325 | 2-Chloro-ATP | 49564-60-5 | Reference compound |
| HY-137325A | 2-Chloro-ATP (sodium) | 301334-89-4 | Reference compound |
| HY-13733 | Procarbazine (Hydrochloride) | 366-70-1 | Reference compound |
| HY-137330 | S-(2,4-Dinitrophenyl)glutathione | 26289-39-4 | Peptides |
| HY-137331 | FAPI-46 | 2374782-04-2 | Reference compound |
| HY-137332 | N-Methylspiroperidol | 87539-19-3 | Reference compound |
| HY-137333 | 4-Methylumbelliferyl β-D-cellobioside | 72626-61-0 | Dye Reagents |
| HY-137334 | Neuraminidase-IN-1 | 2379438-80-7 | Reference compound |
| HY-137335 | 6'-Sialyllactose (sodium) | 157574-76-0 | Reference compound |
| HY-137336 | 4-Methylumbelliferyl β-D-fucoside | 55487-93-9 | Biochemical Assay Reagents |
| HY-137337 | Suc-Ala-Ala-Phe-AMC | 71973-79-0 | Dye Reagents |
| HY-137339 | Amitriptyline N-β-D-glucuronide | 112806-33-4 | Reference compound |
| HY-13733A | Procarbazine | 671-16-9 | Reference compound |
| HY-13733R | Procarbazine (Hydrochloride) (Standard) | 366-70-1 | Reference Standards |
| HY-13734 | PX-12 | 141400-58-0 | Reference compound |
| HY-137340 | WH-10417-099 | 2769753-42-4 | Reference compound |
| HY-137341 | SK-3-91 | 2769753-23-1 | Reference compound |
| HY-137342 | SB1-G-187 | 2769753-18-4 | Reference compound |
| HY-137343 | DB-0646 | 2769753-59-3 | Reference compound |
| HY-137344 | dAURK-4 | 2705844-81-9 | Reference compound |
| HY-137344A | dAURK-4 (hydrochloride) | | Reference compound |
| HY-137345 | DB-3-291 | 2769753-64-0 | Reference compound |
| HY-137346 | DD-03-156 | 2769753-69-5 | Reference compound |
| HY-137348 | 10-Pyrene-PC | 95864-17-8 | Biochemical Assay Reagents |
| HY-13735 | Quinacrine | 83-89-6 | Reference compound |
| HY-137350 | 12-epi-LTB4 | 83709-73-3 | Reference compound |
| HY-137355 | 15(S)-15-methyl Prostaglandin D2 | 85280-90-6 | Reference compound |
| HY-137356 | Prochloraz manganese | 75747-77-2 | Reference compound |
| HY-137356R | Prochloraz manganese (Standard) | 75747-77-2 | Reference Standards |
| HY-13735A | Quinacrine (dihydrochloride) | 69-05-6 | Reference compound |
| HY-13735AR | Quinacrine (dihydrochloride) (Standard) | 69-05-6 | Reference Standards |
| HY-13735B | Quinacrine (hydrochloride hydrate) | 6151-30-0 | Reference compound |
| HY-13735C | l-Atabrine dihydrochloride | 56100-42-6 | Reference compound |
| HY-13735D | d-Atabrine dihydrochloride | 56100-41-5 | Reference compound |
| HY-13735E | Quinacrine (methanesulfonate) | 316-05-2 | Reference compound |
| HY-13735H | Quinacrine (acetate) | 78901-94-7 | Reference compound |
| HY-13736 | Quinagolide | 87056-78-8 | Reference compound |
| HY-137360 | Phosphine-biotin | 608514-42-7 | Reference compound |
| HY-137361 | Ramiprilat diketopiperazine | 108736-10-3 | Reference compound |
| HY-137362 | N2-Acetyl acyclovir | 110104-37-5 | Reference compound |
| HY-137362R | N2-Acetyl acyclovir (Standard) | 110104-37-5 | Reference Standards |
| HY-137364 | Disulfamide | 671-88-5 | Reference compound |
| HY-137367 | Z-Val-Val-Arg-AMC | 124485-41-2 | Peptides |
| HY-13736A | Quinagolide (hydrochloride) | 94424-50-7 | Reference compound |
| HY-13737 | R1530 | 882531-87-5 | Reference compound |
| HY-137370 | 2-Hexynyl-5′-N-ethylcarboxamidoadenosine | 141018-30-6 | Reference compound |
| HY-137371 | Lactonic sophorolipid | 148409-20-5 | Reference compound |
| HY-137371R | Lactonic sophorolipid (Standard) | 148409-20-5 | Reference Standards |
| HY-137373 | Rp-8-pCPT-cGMPS | 153660-04-9 | Reference compound |
| HY-137377 | TAS-119 | 1453099-83-6 | Reference compound |
| HY-137378A | 8-Br-PET-cGMP | 144510-04-3 | Reference compound |
| HY-13738 | Raloxifene | 84449-90-1 | Reference compound |
| HY-137381 | 6-Bnz-cAMP | 30275-80-0 | Reference compound |
| HY-137382 | 4-Methylumbelliferyl-N-acetyl-β-D-galactosaminide | 36476-29-6 | Biochemical Assay Reagents |
| HY-137383 | Sulfo-SANPAH | 102568-43-4 | Reference compound |
| HY-137386 | 2-Oxo-3-hydroxy-LSD | 111295-09-1 | Reference compound |
| HY-137387 | Carvedilol Glucuronide | 114869-83-9 | Reference compound |
| HY-137388A | p-F-HHSiD (hydrochloride) | 175615-76-6 | Reference compound |
| HY-137389 | Anhydro abiraterone | 154229-20-6 | Reference compound |
| HY-13738A | Raloxifene (hydrochloride) | 82640-04-8 | Natural Products |
| HY-13738AR | Raloxifene (hydrochloride) (Standard) | 82640-04-8 | Reference Standards |
| HY-13738R | Raloxifene (Standard) | 84449-90-1 | Reference Standards |
| HY-13738S | Raloxifene-d4 | 1185076-44-1 | Isotope-Labeled Compounds |
| HY-13738S2 | Raloxifene-d4 (hydrochloride) | 1188263-47-9 | Isotope-Labeled Compounds |
| HY-13738S3 | Raloxifene-d10 | | Isotope-Labeled Compounds |
| HY-13738S4 | Raloxifene-d10-1 | 2512224-37-0 | Isotope-Labeled Compounds |
| HY-13739 | Ranimustine | 58994-96-0 | Reference compound |
| HY-137390A | (3S,5R)-Fluvastatin (potassium) | 1009811-63-5 | Reference compound |
| HY-137391 | 2-Bromoestradiol | 15833-07-5 | Reference compound |
| HY-137392 | Cathepsin L-IN-4 | 161709-56-4 | Peptides |
| HY-137393 | 3α,5α-Tetrahydronorethisterone | 16392-60-2 | Reference compound |
| HY-137394 | Nicotredole | 29876-14-0 | Reference compound |
| HY-137396 | 6β-Hydroxy Eplerenone | 209253-80-5 | Reference compound |
| HY-137397 | 8-Hydroxyefavirenz | 205754-33-2 | Reference compound |
| HY-13740 | Resiquimod | 144875-48-9 | Reference compound |
| HY-137403 | 4-Methylumbelliferyl β-D-N,N′,N′′-triacetylchitotrioside | 53643-13-3 | Biochemical Assay Reagents |
| HY-137404 | Adenosine 5'-O-thiomonophosphate (dilithium) | 93839-85-1 | Biochemical Assay Reagents |
| HY-137406 | 1,2'-O-Dimethylguanosine | 73667-71-7 | Reference compound |
| HY-137407 | N-Phenylacetyl-L-homoserine lactone | 55154-48-8 | Reference compound |
| HY-137409 | Suc-AAA-pNA | 52299-14-6 | Peptides |
| HY-13740G | Resiquimod (GMP) | 144875-48-9 | GMP Small Molecules |
| HY-13740S | Resiquimod-d5 | 2252319-44-9 | Isotope-Labeled Compounds |
| HY-13741 | RH1 | 221635-42-3 | Reference compound |
| HY-137411 | (E/Z)-Linoleoyl-CoA | 40757-80-0 | Reference compound |
| HY-137412 | PGF2α 1,15-lactone | 55314-49-3 | Reference compound |
| HY-137414 | 20-Hydroxy Prostaglandin E2 | 57930-95-7 | Reference compound |
| HY-137416 | H-Glu(AMC)-OH | 72669-53-5 | Peptides |
| HY-137418 | 2-MeS-ATP | 43170-89-4 | Reference compound |
| HY-13742 | Ropidoxuridine | 93265-81-7 | Reference compound |
| HY-137421 | 4-Nitrophenyl N-acetyl-α-D-glucosaminide | 10139-02-3 | Biochemical Assay Reagents |
| HY-137422 | D-erythro-MAPP | 143492-38-0 | Reference compound |
| HY-137425 | N-Biotinyl-12-aminododecanoic acid | 135447-73-3 | Biochemical Assay Reagents |
| HY-137426 | Phenolphthalein β-D-glucuronide | 15265-26-6 | Biochemical Assay Reagents |
| HY-137426A | Phenolphthalein glucuronide (sodium) | 6820-54-8 | Reference compound |
| HY-137428 | (S,S)-EDDS | 20846-91-7 | Reference compound |
| HY-137429 | Valiloxibic acid | 238401-16-6 | Reference compound |
| HY-13743 | Roquinimex | 84088-42-6 | Reference compound |
| HY-137430 | Aldumastat | 1957278-93-1 | Reference compound |
| HY-137431 | Asundexian | 2064121-65-7 | Reference compound |
| HY-137431A | (R)-Asundexian | 2064124-85-0 | Reference compound |
| HY-137432 | Avotaciclib | 1983983-41-0 | Reference compound |
| HY-137432A | Avotaciclib (trihydrochloride) | 1983984-01-5 | Reference compound |
| HY-137432B | Avotaciclib (hydrochloride) | | Reference compound |
| HY-137432D | Avotaciclib (sulfate) | 1983984-04-8 | Reference compound |
| HY-137433 | Befotertinib | 1835667-63-4 | Reference compound |
| HY-137433A | Befotertinib (mesylate) | 2226167-02-6 | Reference compound |
| HY-137434 | Cedirogant | 2055496-11-0 | Reference compound |
| HY-137435 | Cirtuvivint | 2143917-62-6 | Reference compound |
| HY-137436 | Cotosudil | 1258833-31-6 | Reference compound |
| HY-137438 | Edralbrutinib | 1858206-58-2 | Reference compound |
| HY-137439 | Fanotaprim | 2120282-75-7 | Reference compound |
| HY-13744 | Rubitecan | 91421-42-0 | Natural Products |
| HY-137440 | Firazorexton | 2274802-95-6 | Reference compound |
| HY-137440A | Firazorexton (hydrate) | 2861934-86-1 | Reference compound |
| HY-137440B | (2R,3R)-Firazorexton | 2692692-00-3 | Reference compound |
| HY-137441 | Icapamespib | 1000999-96-1 | Reference compound |
| HY-137441A | Icapamespib (hydrochloride) | 2267287-26-1 | Reference compound |
| HY-137442 | Inupadenant | 2246607-08-7 | Reference compound |
| HY-137442A | Inupadenant (hydrochloride) | 2411004-22-1 | Reference compound |
| HY-137443 | Ipivivint | 1481617-15-5 | Reference compound |
| HY-137444 | Ludaterone | 124548-08-9 | Reference compound |
| HY-137445 | Modoflaner | 1331922-53-2 | Reference compound |
| HY-137446 | Mosliciguat | 2231749-54-3 | Reference compound |
| HY-137447 | Pirepemat | 1227638-29-0 | Reference compound |
| HY-137447A | Pirepemat (fumarate) | 2251806-70-7 | Reference compound |
| HY-137448 | Rezvilutamide | 1572045-62-5 | Reference compound |
| HY-137449 | Rintodestrant | 2088518-51-6 | Reference compound |
| HY-13745 | Sabarubicin | 211100-13-9 | Reference compound |
| HY-137450 | Senaparib | 1401682-78-7 | Reference compound |
| HY-137450A | Senaparib (hydrochloride) | 1401683-39-3 | Reference compound |
| HY-137451 | Sivopixant | 2414285-40-6 | Reference compound |
| HY-137451A | (E/Z)-Sivopixant | 1640808-39-4 | Reference compound |
| HY-137452 | Suntinorexton | 2274802-89-8 | Reference compound |
| HY-137452A | (R,R)-Suntinorexton | | Reference compound |
| HY-137453 | Tenofovir amibufenamide | 1571076-26-0 | Reference compound |
| HY-137453B | (1R)-Tenofovir amibufenamide | 1571076-15-7 | Reference compound |
| HY-137453C | (R,1R)-Tenofovir amibufenamide | 1571076-37-3 | Reference compound |
| HY-137454 | Teplinovivint | 1428064-91-8 | Reference compound |
| HY-137455 | Terevalefim | 1070881-42-3 | Reference compound |
| HY-137456 | Tilpisertib | 2065153-41-3 | Reference compound |
| HY-137457 | Venadaparib | 1681017-83-3 | Reference compound |
| HY-137457A | Venadaparib (hydrochloride) | 1681020-60-9 | Reference compound |
| HY-137458 | Vevorisertib | 1416775-46-6 | Reference compound |
| HY-137458A | Vevorisertib (trihydrochloride) | 1416775-08-0 | Reference compound |
| HY-137459 | Vocacapsaicin | 1931116-86-7 | Reference compound |
| HY-137459A | Vocacapsaicin (hydrochloride) | 1931116-92-5 | Reference compound |
| HY-13746 | Sardomozide | 149400-88-4 | Reference compound |
| HY-137460 | Vodobatinib | 1388803-90-4 | Reference compound |
| HY-137463 | AG-636 | 1623416-31-8 | Reference compound |
| HY-137464A | OATD-01 | 2088453-21-6 | Reference compound |
| HY-137465 | CG428 | 2412055-93-5 | Reference compound |
| HY-137466 | ARN-21934 | 2230854-93-8 | Reference compound |
| HY-13746B | Sardomozide dihydrochloride | 138794-73-7 | Reference compound |
| HY-13747 | Semustine | 13909-09-6 | Reference compound |
| HY-137471 | RBPJ Inhibitor-1 | 2682114-39-0 | Reference compound |
| HY-137472 | SAR502250 | 503860-57-9 | Reference compound |
| HY-137473 | Methyl pyropheophorbide-a | 6453-67-4 | Reference compound |
| HY-137474 | Purpurin 18 methyl ester | 51744-55-9 | Natural Products |
| HY-137475 | Chlorin e6 trimethyl ester | 35038-32-5 | Reference compound |
| HY-137477 | Spiropyran hexyl methacrylate | 2522597-48-2 | Reference compound |
| HY-137478 | KB-0742 | 2416873-83-9 | Reference compound |
| HY-137478A | KB-0742 (dihydrochloride) | 2416874-75-2 | Reference compound |
| HY-137479 | TEAD-IN-1 | 2412761-57-8 | Reference compound |
| HY-13748 | Silybin A | 22888-70-6 | Natural Products |
| HY-137483 | Prostaglandin D2 serinol amide | 851761-42-7 | Reference compound |
| HY-137487 | PROTAC BRAF-V600E degrader-1 | 2417296-84-3 | Reference compound |
| HY-137488 | PROTAC BRAF-V600E degrader-2 | 2417296-82-1 | Reference compound |
| HY-13748R | Silybin A (Standard) | 22888-70-6 | Reference Standards |
| HY-13749 | Sitagliptin | 486460-32-6 | Reference compound |
| HY-137490 | 4-Methylumbelliferyl α-L-arabinofuranoside | 77471-44-4 | Reference compound |
| HY-137492 | 16,16-Dimethyl-PGE2-4-(4-acetamidobenzamido)phenyl ester | 62873-55-6 | Reference compound |
| HY-137493 | 14,15-Leukotriene D4 | 75290-64-1 | Reference compound |
| HY-137494 | Ethyl β-carboline-3-carboxylate | 74214-62-3 | Reference compound |
| HY-137495 | GGACK | 65113-67-9 | Peptides |
| HY-137496 | 4-Methylumbelliferyl β-D-mannopyranoside | 67909-30-2 | Biochemical Assay Reagents |
| HY-137497 | KRAS inhibitor-9 | 300809-71-6 | Reference compound |
| HY-137498 | EBOV/MARV-IN-1 | 2479465-67-1 | Reference compound |
| HY-137499 | NT1-O12B | 2739805-63-9 | Oligonucleotides |
| HY-13749A | Sitagliptin (phosphate) | 654671-78-0 | Reference compound |
| HY-13749AS | Sitagliptin-d4 (phosphate) | 1432063-88-1 | Isotope-Labeled Compounds |
| HY-13749B | Sitagliptin (phosphate monohydrate) | 654671-77-9 | Reference compound |
| HY-13749BR | Sitagliptin (phosphate monohydrate) (Standard) | 654671-77-9 | Reference Standards |
| HY-13749C | (S)-Sitagliptin (phosphate) | 823817-58-9 | Reference compound |
| HY-13749CR | (S)-Sitagliptin (phosphate) (Standard) | 823817-58-9 | Reference Standards |
| HY-13749D | (Rac)-Sitagliptin | 823817-56-7 | Reference compound |
| HY-13749S1 | Sitagliptin-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13749S2 | Sitagliptin-d4 | | Isotope-Labeled Compounds |
| HY-13749S3 | Sitagliptin-d6 | 1133211-99-0 | Isotope-Labeled Compounds |
| HY-13750 | Ebselen | 60940-34-3 | Reference compound |
| HY-137500 | NT1-014B | 2739805-64-0 | Reference compound |
| HY-137501 | 306-O12B-3 | | Biochemical Assay Reagents |
| HY-137502 | ML267 | 1542213-67-1 | Reference compound |
| HY-137504 | 20-ethyl Prostaglandin F2α | 36950-85-3 | Reference compound |
| HY-137506 | XST-14 | 2607143-50-8 | Reference compound |
| HY-13751 | SR-31747 | 132173-07-0 | Reference compound |
| HY-137513 | N-Acetyl-D-glucosamine 6-sulfate (sodium) | 108321-79-5 | Biochemical Assay Reagents |
| HY-137516 | LC-2 | 2502156-03-6 | Reference compound |
| HY-137516A | LC-2 epimer | 2502156-12-7 | Reference compound |
| HY-13751A | SR-31747 (free base) | 132173-06-9 | Reference compound |
| HY-137521 | Z-PDLDA-NHOH | 123984-15-6 | Peptides |
| HY-137522 | Zidovudine O-β-D-glucuronide (sodium) | 133525-01-6 | Reference compound |
| HY-137522A | Zidovudine O-β-D-glucuronide | 117675-21-5 | Reference compound |
| HY-137522AS1 | Zidovudine Glucuronide-13C6 | | Isotope-Labeled Compounds |
| HY-137522S | Zidovudine O-β-D-glucuronide-d3 (sodium) | | Isotope-Labeled Compounds |
| HY-137528 | H-Glu(4MβNA)-OH | 24723-50-0 | Reference compound |
| HY-137529 | Nα-Benzoyl-L-arginine 4-nitroanilide (hydrochloride) | 21653-40-7 | Peptides |
| HY-13753 | Streptozotocin | 18883-66-4 | Natural Products |
| HY-137530 | 8-MA-cAMP | 33823-18-6 | Reference compound |
| HY-137531 | Pomalidomide-PEG1-C2-COOH | 2139348-60-8 | Reference compound |
| HY-137532 | 7-Hydroxyquetiapine | 139079-39-3 | Reference compound |
| HY-137532S | 7-Hydroxy Quetiapine-d8 | 1185098-57-0 | Isotope-Labeled Compounds |
| HY-137532S1 | 7-Hydroxyquetiapine-d4 (hemifumarate) | | Isotope-Labeled Compounds |
| HY-137537 | Pomalidomide-PEG2-azide | 2267306-14-7 | Reference compound |
| HY-137538 | Pomalidomide-PEG3-azide | 2267306-15-8 | Reference compound |
| HY-137540 | Phenyl-1-thio-β-D-glucopyranoside | 2936-70-1 | Biochemical Assay Reagents |
| HY-137541 | 2-Nitro-5-thiocyanatobenzoic acid | 30211-77-9 | Reference compound |
| HY-137543 | Δ8-Tetrahydrocannabivarin | 31262-38-1 | Reference compound |
| HY-137544 | 16-Phenyl tetranor Prostaglandin F2α | 38315-48-9 | Reference compound |
| HY-137546 | Reduced Haloperidol | 34104-67-1 | Reference compound |
| HY-137546S | Reduced Haloperidol-d4 | 1246820-79-0 | Isotope-Labeled Compounds |
| HY-137547 | 20-Hydroxy-PGF2α | 57930-92-4 | Reference compound |
| HY-137548 | 2′,3′-Dideoxy-3′-fluorouridine | 41107-56-6 | Reference compound |
| HY-13755 | Sulforaphane | 4478-93-7 | Natural Products |
| HY-137550 | 4-Nitrophenyl β-D-galactopyranoside | 3150-24-1 | Biochemical Assay Reagents |
| HY-137551 | Tiafenacil | 1220411-29-9 | Reference compound |
| HY-137551R | Tiafenacil (Standard) | 1220411-29-9 | Reference Standards |
| HY-137552 | MKI-1 | 1190277-80-5 | Reference compound |
| HY-137553 | β-Aminoarteether | 133162-24-0 | Reference compound |
| HY-137553A | β-Aminoarteether (maleate) | 133162-25-1 | Reference compound |
| HY-137555 | 11-dehydro-2,3-dinor Thromboxane B2 | 79250-60-5 | Reference compound |
| HY-137557 | Florzolotau | 1565797-16-1 | Reference compound |
| HY-13755A | (R)-Sulforaphane | 142825-10-3 | Natural Products |
| HY-13756 | Tacrolimus | 104987-11-3 | Natural Products |
| HY-137561 | Bexotegrast | 2376257-44-0 | Reference compound |
| HY-137561A | Bexotegrast (hydrochloride) | 2775365-40-5 | Reference compound |
| HY-137563 | A2793 | 88349-90-0 | Reference compound |
| HY-137564 | Desacetylcephalothin (sodium) | 5547-29-5 | Reference compound |
| HY-137565 | Hydroxy ritonavir | 176655-56-4 | Reference compound |
| HY-137566 | Cucumarioside H | 116524-58-4 | Natural Products |
| HY-137567 | Prostaglandin E1 ethanolamide | 210976-81-1 | Reference compound |
| HY-13756A | Tacrolimus (monohydrate) | 109581-93-3 | Natural Products |
| HY-13756R | Tacrolimus (Standard) | 104987-11-3 | Reference Standards |
| HY-13756S | Tacrolimus-13C,d2 | 1356841-89-8 | Isotope-Labeled Compounds |
| HY-13756S2 | Tacrolimus-d3 | | Isotope-Labeled Compounds |
| HY-13757 | Tamoxifen (Citrate) | 54965-24-1 | Reference compound |
| HY-137573 | Trotabresib | 1706738-98-8 | Reference compound |
| HY-137574 | 19(R)-Hydroxy prostaglandin E1 | 64625-55-4 | Reference compound |
| HY-137575 | Terbutalone | 139508-58-0 | Reference compound |
| HY-137575R | Terbutalone (Standard) | 139508-58-0 | Reference Standards |
| HY-137576 | DMT-dI Phosphoramidite | 141684-35-7 | Oligonucleotides |
| HY-13757A | Tamoxifen | 10540-29-1 | Reference compound |
| HY-13757AR | Tamoxifen (Standard) | 10540-29-1 | Reference Standards |
| HY-13757AS | Tamoxifen-d5 | 157698-32-3 | Isotope-Labeled Compounds |
| HY-13757AS1 | Tamoxifen-d3 | 508201-30-7 | Isotope-Labeled Compounds |
| HY-13757R | Tamoxifen (Citrate) (Standard) | 54965-24-1 | Reference Standards |
| HY-13757S | Tamoxifen-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-13758 | TAS-103 | 174634-08-3 | Reference compound |
| HY-137580 | N-Desmethyl Eletriptan | 153525-55-4 | Reference compound |
| HY-137583 | Peltatoside | 23284-18-6 | Natural Products |
| HY-137584 | 1a,1b-Dihomo prostaglandin E1 | 23452-98-4 | Reference compound |
| HY-137585 | 17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α | 294856-01-2 | Reference compound |
| HY-137589 | N6-Dimethyldeoxyadenosine | 35665-58-8 | Reference compound |
| HY-13758A | TAS-103 (dihydrochloride) | 174634-09-4 | Reference compound |
| HY-137591 | 13,14-Dihydro-15-keto-PGE1 | 5094-14-4 | Reference compound |
| HY-137592 | Nicotinamide 1,N6-ethenoadenine dinucleotide | 38806-38-1 | Dye Reagents |
| HY-137592A | Nicotinamide 1,N6-ethenoadenine dinucleotide (sodium) | | Reference compound |
| HY-13760 | Tasidotin hydrochloride | 623174-20-9 | Reference compound |
| HY-137600 | 1,N6-Ethenoadenosine | 39007-51-7 | Reference compound |
| HY-137602 | P1,P2-Diuridine-5’-diphosphate | 26184-65-6 | Reference compound |
| HY-137603 | Uridine-5'-O-(3-thiotriphosphate) | 79049-97-1 | Reference compound |
| HY-137604A | (γ-AmNS)UTP (trisodium) | | Reference compound |
| HY-137605 | WSF1-IN-1 | 2379577-82-7 | Reference compound |
| HY-137606 | Uridine adenosine tetraphosphate | 10527-48-7 | Reference compound |
| HY-137608 | Uridine 5'-O-thiodiphosphate | 221010-51-1 | Reference compound |
| HY-13761 | Teniposide | 29767-20-2 | Reference compound |
| HY-137611A | α,β-MTDP (trisodium) | 71370-60-0 | Reference compound |
| HY-137612 | Sp-UTP-α-S | 71214-29-4 | Reference compound |
| HY-137613 | Sp-TTPαS | 83199-32-0 | Reference compound |
| HY-137614 | Sp-GTPαS | 81570-51-6 | Reference compound |
| HY-137615 | Sp-GDPαS | 71481-45-3 | Reference compound |
| HY-137618 | Sp-dGTPαS | 80902-28-9 | Reference compound |
| HY-137618B | Rp-dGTPαS | 80902-29-0 | Reference compound |
| HY-137619 | Sp-dCTPαS | 80951-75-3 | Reference compound |
| HY-13761R | Teniposide (Standard) | 29767-20-2 | Reference Standards |
| HY-13762 | Tesmilifene | 98774-23-3 | Reference compound |
| HY-137620 | Sp-dATPαS | 80875-87-2 | Reference compound |
| HY-137622 | Sp-cGMPS | 86562-10-9 | Reference compound |
| HY-137623 | Sp-cCMPS | 87063-81-8 | Reference compound |
| HY-137624 | Sp-cAMPS-AM | 1037535-49-1 | Reference compound |
| HY-137626 | Sp-ATPαS | 58976-48-0 | Reference compound |
| HY-137627 | Sp-ADPαS | 59286-20-3 | Reference compound |
| HY-137628 | Sp-8-PIP cAMP | 156816-35-2 | Reference compound |
| HY-137629 | Sp-8-pCPT-PET-cGMPS | 1262749-63-2 | Reference compound |
| HY-13762A | Tesmilifene (hydrochloride) | 92981-78-7 | Reference compound |
| HY-13762AS | Tesmelefine-d4 (hydrochloride) | 1228786-71-7 | Isotope-Labeled Compounds |
| HY-13762S | Tesmilifene-d4 | | Isotope-Labeled Compounds |
| HY-137630 | Sp-8-pCPT-2'-O-Me-cAMPS | 634208-37-0 | Reference compound |
| HY-137632 | Sp-8-Cl-cAMPS | 142754-28-7 | Reference compound |
| HY-137633 | Sp-8-Br-PET-cGMPS | 172806-21-2 | Reference compound |
| HY-137635 | Sp-6-Phe-cAMPS | 169335-92-6 | Reference compound |
| HY-137638 | Sp-5,6-DCl-cBIMPS | 120912-54-1 | Reference compound |
| HY-137638A | Sp-5,6-DCl-cBIMPS (sodium) | 142439-96-1 | Reference compound |
| HY-137639 | Sp-8-Br-cGMPS | 153660-03-8 | Reference compound |
| HY-13764 | Tetrandrine | 518-34-3 | Natural Products |
| HY-137640 | Sp-8-Br-cAMPS | 127634-20-2 | Reference compound |
| HY-137640A | Sp-8-Br-cAMPS (sodium) | 1573115-90-8 | Reference compound |
| HY-137640B | Rp-8-Br-cAMPS | 129735-00-8 | Reference compound |
| HY-137640C | Rp-8-Br-cAMPS (sodium) | 925456-59-3 | Reference compound |
| HY-137641 | Sp-8-Br-2'-O-Me-cAMPS | 634208-34-7 | Reference compound |
| HY-13764R | Tetrandrine (Standard) | 518-34-3 | Reference Standards |
| HY-13765 | 6-Thioguanine | 154-42-7 | Reference compound |
| HY-137655 | BMS-P5 | 1549811-36-0 | Reference compound |
| HY-137655A | BMS-P5 (free base) | 1550371-22-6 | Reference compound |
| HY-137658 | Purine riboside triphosphate | 23197-96-8 | Reference compound |
| HY-137658A | Purine riboside-5'-O-triphosphate (sodium) | 35892-95-6 | Reference compound |
| HY-13765R | 6-Thioguanine (Standard) | 154-42-7 | Reference Standards |
| HY-13766 | Timcodar | 179033-51-3 | Reference compound |
| HY-137660 | pppApG | 68892-47-7 | Reference compound |
| HY-137662 | 5'-Phosphoguanylyl-(3',5')-guanosine | 33008-99-0 | Reference compound |
| HY-137665 | PET-cGMP | 78080-27-0 | Reference compound |
| HY-13766A | Timcodar (mesylate) | 183313-30-6 | Reference compound |
| HY-13767 | Tirapazamine | 27314-97-2 | Reference compound |
| HY-137672A | 2',3'-Cyclic NADP (disodium) | 100929-77-9 | Reference compound |
| HY-137673 | 2'-Deoxy-NAD+ | 6697-37-6 | Reference compound |
| HY-137673A | 2'-Deoxy-NAD+ (sodium) | 1514900-83-4 | Reference compound |
| HY-137677B | GTPγS (tetralithium) | 94825-44-2 | Reference compound |
| HY-13768 | Topotecan | 123948-87-8 | Reference compound |
| HY-137680 | GP4G | 4130-19-2 | Reference compound |
| HY-137683B | Guanosine 5'-O-(2-thiodiphosphate) (trilithium) | 97952-36-8 | Reference compound |
| HY-13768A | Topotecan (hydrochloride) | 119413-54-6 | Natural Products |
| HY-13768AR | Topotecan (hydrochloride) (Standard) | 119413-54-6 | Reference Standards |
| HY-13768C | Topotecan (hydrochloride hydrate) | 1044663-62-8 | Reference compound |
| HY-13768D | Topotecan (acetate) | 123948-88-9 | Reference compound |
| HY-13768S1 | Topotecan-d6 | 1044904-10-0 | Isotope-Labeled Compounds |
| HY-13769 | TPT-260 | 769856-81-7 | Reference compound |
| HY-137693 | ddTTPαS | 158705-77-2 | Reference compound |
| HY-137694B | ddTTP (trisodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-137695 | ddGTPαS | 371195-56-1 | Reference compound |
| HY-137696 | ddCTPαS | 209350-59-4 | Reference compound |
| HY-137697 | ddCTP | 66004-77-1 | Biochemical Assay Reagents |
| HY-137697B | ddCTP (trilithium) | 93939-77-6 | Reference compound |
| HY-137697D | ddCTP (trisodium) | | Oligonucleotides |
| HY-13769A | TPT-260 (Dihydrochloride) | 2076-91-7 | Reference compound |
| HY-13770 | Troxacitabine | 145918-75-8 | Oligonucleotides |
| HY-137701 | ddATPαS | 112820-39-0 | Reference compound |
| HY-137704 | 2′-Deoxy-ADPR | 111864-49-4 | Reference compound |
| HY-137709 | 2'2'-cGAMP | 1465774-27-9 | Reference compound |
| HY-13771 | Ursodeoxycholic acid | 128-13-2 | Natural Products |
| HY-13771A | Ursodeoxycholic acid (sodium) | 2898-95-5 | Natural Products |
| HY-13771R | Ursodeoxycholic acid (Standard) | 128-13-2 | Reference Standards |
| HY-13771S1 | Ursodeoxycholic acid-13C | 63296-46-8 | Isotope-Labeled Compounds |
| HY-13772 | Valrubicin | 56124-62-0 | Reference compound |
| HY-137721 | Cyclic tri-AMP | 54447-85-7 | Reference compound |
| HY-137724 | C-di-IMP | 79940-41-3 | Reference compound |
| HY-137724A | C-di-IMP (disodium) | | Reference compound |
| HY-13772R | Valrubicin (Standard) | 56124-62-0 | Reference Standards |
| HY-13773 | Motolimod | 926927-61-9 | Reference compound |
| HY-137742 | SBP-7455 | 1884222-74-5 | Reference compound |
| HY-13775 | XL019 | 945755-56-6 | Reference compound |
| HY-137756 | JAK2-IN-6 | 353512-04-6 | Reference compound |
| HY-13776 | XR9051 | 762219-35-2 | Reference compound |
| HY-137768 | Captopril EP Impurity B | 80629-35-2 | Reference compound |
| HY-137768R | Captopril EP Impurity B (Standard) | 80629-35-2 | Reference Standards |
| HY-137769 | Captopril EP Impurity C | 26473-47-2 | Reference compound |
| HY-137769R | Captopril EP Impurity C (Standard) | 26473-47-2 | Reference Standards |
| HY-13776A | XR9051 (hydrochloride) | 180422-22-4 | Reference compound |
| HY-13777 | Zoledronic Acid | 118072-93-8 | Reference compound |
| HY-137772 | Captopril EP Impurity E | 23500-15-4 | Reference compound |
| HY-137772R | Captopril EP Impurity E (Standard) | 23500-15-4 | Reference Standards |
| HY-137773 | N-Methyl pemetrexed | 869791-42-4 | Reference compound |
| HY-137774 | Clezutoclax | 1949843-71-3 | Reference compound |
| HY-137776 | Paclitaxel C | 153415-45-3 | Reference compound |
| HY-137776R | Paclitaxel C (Standard) | 153415-45-3 | Reference Standards |
| HY-137778 | 6-Bromo-2-naphthyl β-D-glucopyranoside | 15548-61-5 | Biochemical Assay Reagents |
| HY-137779 | 5-Bromo-4-chloro-3-indolyl β-D-glucopyranoside | 15548-60-4 | Biochemical Assay Reagents |
| HY-13777A | Zoledronic acid (monohydrate) | 165800-06-6 | Reference compound |
| HY-13777AR | Zoledronic acid (monohydrate) (Standard) | 165800-06-6 | Reference Standards |
| HY-13777B | Zoledronic acid (disodium tetrahydrate) | 165800-07-7 | Reference compound |
| HY-13777C | Zoledronate (disodium) | 131654-46-1 | Reference compound |
| HY-13777R | Zoledronic Acid (Standard) | 118072-93-8 | Reference Standards |
| HY-13777S | Zoledronic acid-d5 | | Isotope-Labeled Compounds |
| HY-13777S1 | Zoledronic acid-d3 | 1134798-26-7 | Isotope-Labeled Compounds |
| HY-137781 | Phenyl-β-D-glucuronide | 17685-05-1 | Biochemical Assay Reagents |
| HY-137782 | Palmitoleoyl-CoA | 18198-76-0 | Enzyme |
| HY-137782A | Palmitoleoyl-CoA (triammonium) | 1246304-41-5 | Enzyme |
| HY-137782B | Palmitoleoyl-CoA (lithium) | 324518-22-1 | Enzyme |
| HY-137783 | Resorufin β-D-glucuronide (sodium) | 125440-91-7 | Biochemical Assay Reagents |
| HY-137784 | Boc-Val-Pro-Arg-AMC (hydrochloride) | 70375-24-5 | Dye Reagents |
| HY-137785 | 2-Chloro-4-nitrophenyl-β-D-maltotrioside | 165522-16-7 | Biochemical Assay Reagents |
| HY-137786 | EGFR-IN-16 | 133550-22-8 | Reference compound |
| HY-137787 | Cyanosafracin B | 96996-50-8 | Reference compound |
| HY-137787R | Cyanosafracin B (Standard) | 96996-50-8 | Reference Standards |
| HY-137788 | α-Conotoxin GI | 76862-65-2 | Peptides |
| HY-137789 | Tazofelone | 107902-67-0 | Reference compound |
| HY-13779 | (E/Z)-J147 | 1146963-51-0 | Reference compound |
| HY-137790 | Bicuculline (methochloride) | 38641-83-7 | Reference compound |
| HY-137791 | MMBC | 137350-66-4 | Dye Reagents |
| HY-137793 | Pro-Leu-Gly-NHOH (hydrochloride) | 120928-08-7 | Peptides |
| HY-137794 | Tetramethylkaempferol | 16692-52-7 | Natural Products |
| HY-137798 | Chromozym PL | 88793-79-7 | Peptides |
| HY-137799 | NOBA | 55894-52-5 | Reference compound |
| HY-13779A | J147 | 1807913-16-1 | Reference compound |
| HY-13780 | Vinblastine (sulfate) | 143-67-9 | Natural Products |
| HY-137801 | Sesquicillin A | 51103-58-3 | Natural Products |
| HY-137802 | SAHO2 | 53199-56-7 | Reference compound |
| HY-137805 | Ferrozine | 69898-45-9 | Dye Reagents |
| HY-137806 | Descarbamylnovobiocin | 75057-97-5 | Reference compound |
| HY-137807 | Thymidine 5′-monophosphate p-nitrophenyl ester (sodium) | 98179-10-3 | Reference compound |
| HY-137808 | Succinyl-Coenzyme A (sodium) | 108347-97-3 | Reference compound |
| HY-13780R | Vinblastine (sulfate) (Standard) | 143-67-9 | Reference Standards |
| HY-13781 | Pemetrexed (disodium hemipenta hydrate) | 357166-30-4 | Reference compound |
| HY-137811 | Suc-AAPF-AMC | 88467-45-2 | Peptides |
| HY-137812 | p-Nitrophenyl β-D-lactoside | 4419-94-7 | Biochemical Assay Reagents |
| HY-137813 | PERK-IN-4 | 1337531-89-1 | Reference compound |
| HY-137813S | PERK-IN-4-d3 | | Isotope-Labeled Compounds |
| HY-137814 | 4-Nitrophenyl 4-guanidinobenzoate (hydrochloride) | 19135-17-2 | Reference compound |
| HY-137815 | 4-Nitrophenyl α-L-rhamnopyranoside | 18918-31-5 | Biochemical Assay Reagents |
| HY-137816 | 6-Chloro-3-indolyl-β-D-glucuronide (cyclohexylammonium) | 138182-20-4 | Reference compound |
| HY-137817 | BCH001 | 384859-58-9 | Reference compound |
| HY-137818 | SR19881 | 2213490-89-0 | Reference compound |
| HY-13782 | Tenofovir Disoproxil (fumarate) | 202138-50-9 | Reference compound |
| HY-137820 | Brr2-IN-3 | 2104030-82-0 | Reference compound |
| HY-137822 | p-Nitrophenyl α-D-mannopyranoside | 10357-27-4 | Biochemical Assay Reagents |
| HY-137823 | 4-Nitrophenyl-N-acetyl-β-D-galactosaminide | 14948-96-0 | Reference compound |
| HY-137824 | 4-Methylumbelliferyl-β-D-xylopyranoside | 6734-33-4 | Natural Products |
| HY-137826 | 4-Nitrophenyl β-D-N,N',N''-triacetylchitotriose | 7699-38-9 | Biochemical Assay Reagents |
| HY-137827 | 4-Nitrophenyl β-D-Cellobioside | 3482-57-3 | Dye Reagents |
| HY-137828 | 4-Nitrophenyl N,N′-diacetyl-β-D-chitobioside | 7284-16-4 | Biochemical Assay Reagents |
| HY-137829 | 5-Methyltetrahydrofolic acid (disodium) | 68792-52-9 | Reference compound |
| HY-13782A | Tenofovir Disoproxil | 201341-05-1 | Reference compound |
| HY-13782R | Tenofovir Disoproxil (fumarate) (Standard) | 202138-50-9 | Reference Standards |
| HY-13783 | BIBF0775 | 334951-90-5 | Reference compound |
| HY-137831 | TLBC | 562823-84-1 | Reference compound |
| HY-137833 | Naphthol AS-BI glucuronide | 37-87-6 | Biochemical Assay Reagents |
| HY-137834 | Gly-Pro-AMC (hydrobromide) | 115035-46-6 | Dye Reagents |
| HY-137834A | Gly-Pro-AMC | 67341-40-6 | Peptides |
| HY-137837 | D-Ile-Pro-Arg p-nitroanilide (dihydrochloride) | 96323-41-0 | Reference compound |
| HY-13784 | Pirodavir | 124436-59-5 | Reference compound |
| HY-137840 | Hippuryl-L-phenylalanine | 744-59-2 | Biochemical Assay Reagents |
| HY-137841 | L-Arginine-7-amido-4-methylcoumarin (hydrochloride) | 69304-16-1 | Biochemical Assay Reagents |
| HY-137843 | NSC 80467 | 101982-51-8 | Reference compound |
| HY-137844 | L-Leucine-7-amido-4-methylcoumarin (hydrochloride) | 62480-44-8 | Dye Reagents |
| HY-137845 | 4-Methylumbelliferyl β-D-galactopyranoside | 6160-78-7 | Dye Reagents |
| HY-137847 | 5-Bromo-4-chloro-3-indolyl sulfate (potassium) | 6578-07-0 | Biochemical Assay Reagents |
| HY-137848 | Thymine 1-β-D-arabinofuranoside | 605-23-2 | Reference compound |
| HY-137849 | RK-582 | 2171388-28-4 | Reference compound |
| HY-13785 | ZM 306416 | 690206-97-4 | Reference compound |
| HY-137851 | S-Pyruvylglutathione | 54398-03-7 | Peptides |
| HY-137853 | 4-Methylumbelliferyl-2-acetamido-2-deoxy-β-D-Glucopyranoside | 37067-30-4 | Dye Reagents |
| HY-137854 | Naphthol AS-BI N-acetyl-β-D-glucosaminide | 3395-37-7 | Biochemical Assay Reagents |
| HY-137855 | 4-Methylumbelliferyl sulfate (potassium) | 15220-11-8 | Biochemical Assay Reagents |
| HY-137858 | H-Gly-Arg-pNA (hydrochloride) | 125455-61-0 | Dye Reagents |
| HY-137859 | L-Proline 7-amido-4-methylcoumarin hydrobromide | 115388-93-7 | Biochemical Assay Reagents |
| HY-13786 | O6BTG-C8-αGlu | 793035-88-8 | Reference compound |
| HY-137862 | 1-Oleoyl lysophosphatidic acid | 65528-98-5 | Reference compound |
| HY-137862A | (Rac)-1-Oleoyl lysophosphatidic acid | 22002-87-5 | Reference compound |
| HY-137863 | Pemirolast | 69372-19-6 | Reference compound |
| HY-137864 | Amifostine thiol | 31098-42-7 | Reference compound |
| HY-137866 | Tubulin inhibitor 9 | 1151995-69-5 | Reference compound |
| HY-137868 | Decanoyl coenzyme A | 1264-57-9 | Reference compound |
| HY-137868A | Decanoyl coenzyme A (triammonium) | 799812-83-2 | Enzyme |
| HY-137869 | Magenta-β-D-GlcA | 144110-43-0 | Biochemical Assay Reagents |
| HY-137870 | γ-Glutamyl-β-naphthylamide | 14525-44-1 | Biochemical Assay Reagents |
| HY-137871 | Phenolphthalein monophosphate (dicyclohexylammonium) | 14815-59-9 | Biochemical Assay Reagents |
| HY-137872 | L-Leucyl-4-nitroanilide (hydrochloride) | 16010-98-3 | Biochemical Assay Reagents |
| HY-137873 | 4-Methylumbelliferyl-α-D-Glucopyranoside | 17833-43-1 | Dye Reagents |
| HY-137874 | L-Glutamic γ-monohydroxamate | 1955-67-5 | Peptides |
| HY-137875 | N-Benzoyl-Gly-His-Leu (hydrate) | 207386-83-2 | Peptides |
| HY-137877 | 7-Acetoxy-4-methylcoumarin | 2747-05-9 | Reference compound |
| HY-137878 | 2-O-(p-Nitrophenyl)-α-D-N-acetylneuraminic acid | 26112-88-9 | Reference compound |
| HY-13788 | LY 344864 | 186544-26-3 | Reference compound |
| HY-137881 | MEK-IN-4 | 297744-42-4 | Reference compound |
| HY-137882 | Glucocorticoid receptor agonist-1 Ala-Ala-Mal | 2166376-51-6 | Reference compound |
| HY-137883 | Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br | 2344809-82-9 | Reference compound |
| HY-137884 | 3-Indolyl acetate | 608-08-2 | Biochemical Assay Reagents |
| HY-137887 | Nα-Benzoyl-L-arginine-7-amido-4-methylcoumarin hydrochloride | 83701-04-6 | Biochemical Assay Reagents |
| HY-137888A | Oxidized ATP (trisodium salt) | 71997-40-5 | Reference compound |
| HY-13788A | LY 344864 (S-enantiomer) | 186544-27-4 | Reference compound |
| HY-13788B | LY 344864 hydrochloride | 1217756-94-9 | Reference compound |
| HY-13788C | LY 344864 (racemate) | 186543-64-6 | Reference compound |
| HY-137892 | GSK620 | 2088410-46-0 | Reference compound |
| HY-137894A | Tagtociclib (hydrate) | 2733575-91-0 | Reference compound |
| HY-137895 | L-Arginine p-nitroanilide dihydrochloride, 98% | 40127-11-5 | Biochemical Assay Reagents |
| HY-137896 | 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid (disodium) | 51023-76-8 | Dye Reagents |
| HY-137898 | Avilamycin A | 69787-79-7 | Natural Products |
| HY-137899 | Dephospho-CoA | 3633-59-8 | Natural Products |
| HY-137901 | L-Alanine 4-nitroanilide hydrochloride, 99% | 31796-55-1 | Biochemical Assay Reagents |
| HY-137902 | L-Arginine β-naphthylamide (hydrochloride) | 18905-73-2 | Biochemical Assay Reagents |
| HY-137905 | Pomalidomide-amido-C5-PEG2-C6-chlorine | 1835705-69-5 | Reference compound |
| HY-137907 | 6"-O-Acetylisoquercitrin | 54542-51-7 | Natural Products |
| HY-137908 | 11β-Misoprostol | 58717-36-5 | Reference compound |
| HY-137909 | Formoterol O-β-D-glucuronide | 615551-59-2 | Reference compound |
| HY-137910 | Tembotrione | 335104-84-2 | Reference compound |
| HY-137910R | Tembotrione (Standard) | 335104-84-2 | Reference Standards |
| HY-137911 | Sparsomycin | 1404-64-4 | Reference compound |
| HY-137912 | trans-Resveratrol-3-O-β-D-Glucuronide | 387372-17-0 | Reference compound |
| HY-137912S1 | Resveratrol-3-O-beta-D-glucuronide-13C6 | | Isotope-Labeled Compounds |
| HY-137916 | L-Histidine 7-amido-4-methylcoumarin | 191723-64-5 | Biochemical Assay Reagents |
| HY-137918 | TGF-βRI inhibitor 3 | 666729-57-3 | Reference compound |
| HY-137919 | Fluticasone 17β-carboxylic acid | 28416-82-2 | Reference compound |
| HY-137920 | Salvinorin A propionate | 689295-71-4 | Reference compound |
| HY-137922 | SHS4121705 | 2379550-82-8 | Reference compound |
| HY-137924 | JA2131 | 6505-99-3 | Reference compound |
| HY-137927 | Benapenem | 1312953-83-5 | Reference compound |
| HY-137928 | H-Ala-4MβNA (hydrochloride) | 3438-14-0 | Dye Reagents |
| HY-137929 | Deoxygerfelin | 36149-01-6 | Reference compound |
| HY-137931 | Testololactone | 4416-57-3 | Reference compound |
| HY-137932 | Resveratrol-3-O-sulfate (sodium) | 858127-11-4 | Reference compound |
| HY-137933 | 5,6,7-Trimethoxycoumarin | 55085-47-7 | Natural Products |
| HY-137934 | Deacetylforskolin | 64657-20-1 | Natural Products |
| HY-137936 | Terrecyclic Acid | 83058-94-0 | Reference compound |
| HY-137938 | Radicinol | 65647-66-7 | Natural Products |
| HY-137940 | β-Gentiobiose | 554-91-6 | Natural Products |
| HY-137941 | Roxatidine | 78273-80-0 | Reference compound |
| HY-137941R | Roxatidine (Standard) | 78273-80-0 | Reference Standards |
| HY-137941S | Roxatidine-d10 (hemioxalate) | | Isotope-Labeled Compounds |
| HY-137942 | 1-Naphthyl phosphate disodium salt, 98% | 2183-17-7 | Biochemical Assay Reagents |
| HY-137944 | 5α-Dihydro levonorgestrel | 78088-19-4 | Reference compound |
| HY-137945 | Phenethicillin (sodium) | 30302-52-4 | Reference compound |
| HY-137945R | Phenethicillin (sodium) (Standard) | 30302-52-4 | Reference Standards |
| HY-137946 | L-Leucine 4-methoxy-β-naphthylamide (hydrochloride) | 4467-68-9 | Peptides |
| HY-137949 | Formoxanthone A | 869880-32-0 | Natural Products |
| HY-137950 | Fmoc-Asp(OtBu)-Osu | 78553-23-8 | Peptides |
| HY-137951 | Metizolam | 40054-68-0 | Reference compound |
| HY-137954 | GRL-0496 | 1087243-14-8 | Reference compound |
| HY-137955 | MRS 2211 (sodium hydrate) | 1197030-56-0 | Reference compound |
| HY-137956 | Previridicatumtoxin | 1379585-81-5 | Reference compound |
| HY-137957 | Longiferone B | 1639810-67-5 | Natural Products |
| HY-137958 | Bemnifosbuvir (hemisulfate) | 2241337-84-6 | Reference compound |
| HY-137958A | Bemnifosbuvir | 1998705-64-8 | Reference compound |
| HY-137959 | Telmisartan acyl-β-D-glucuronide | 250780-40-6 | Biochemical Assay Reagents |
| HY-13796 | IPSU | 1373765-19-5 | Reference compound |
| HY-137960 | O,O-Dimethyl-cannabigerol | 29106-16-9 | Reference compound |
| HY-137961 | Cannabigerol monomethyl ether | 29106-17-0 | Reference compound |
| HY-137963 | Daidzein 4'-β-D-glucuronide | 264236-77-3 | Reference compound |
| HY-137966A | N-Desethyl Brinzolamide (oxalate) | 2775292-24-3 | Reference compound |
| HY-137967 | Genistein 7-β-D-Glucuronide | 38482-81-4 | Reference compound |
| HY-137968 | Avermectin B1a aglycon | 71828-14-3 | Reference compound |
| HY-137970 | Spinosyn D aglycone | 149439-79-2 | Reference compound |
| HY-137974 | 8-Epixanthatin | 30890-35-8 | Reference compound |
| HY-137975 | Exo2 | 304684-77-3 | Reference compound |
| HY-137976 | Penehyclidine (hydrochloride) | 151937-76-7 | Reference compound |
| HY-137977 | DMU-212 | 134029-62-2 | Reference compound |
| HY-137978 | Ezurpimtrostat | 1914148-72-3 | Reference compound |
| HY-137978A | Ezurpimtrostat (hydrochloride) | 1914148-73-4 | Reference compound |
| HY-137979 | Flunitrazolam | 2243815-18-9 | Reference compound |
| HY-137980 | Carbonate ionophore VII | 222310-82-9 | Reference compound |
| HY-137983 | 3-O-Acetylbetulin | 27570-20-3 | Reference compound |
| HY-137984 | Cnicin | 24394-09-0 | Reference compound |
| HY-137985 | Mer-NF5003F | 149598-70-9 | Reference compound |
| HY-137986 | LUF7244 | 1821638-43-0 | Reference compound |
| HY-137988 | Palvanil | 69693-13-6 | Natural Products |
| HY-137989 | Voriconazole N-oxide | 618109-05-0 | Reference compound |
| HY-137989A | Voriconazole N-oxide (hydrochloride) | | Reference compound |
| HY-137989S | Voriconazole N-oxide-d3 | 1217851-84-7 | Isotope-Labeled Compounds |
| HY-137990 | Questin | 3774-64-9 | Natural Products |
| HY-137992 | Aucuparin | 3687-28-3 | Reference compound |
| HY-137994 | Deschloroetizolam | 40054-73-7 | Reference compound |
| HY-137996 | Dehydrovomifoliol | 39763-33-2 | Natural Products |
| HY-138001 | WH-4-025 | 1876463-35-2 | Reference compound |
| HY-138007 | SR-1903 | 1414248-06-8 | Reference compound |
| HY-13801 | Fexinidazole | 59729-37-2 | Reference compound |
| HY-138011 | Dolutegravir O-β-D-glucuronide | 1485692-21-4 | Reference compound |
| HY-138013 | PF-06663195 | 1621585-22-5 | Reference compound |
| HY-138014 | Cinazepam | 172986-25-3 | Reference compound |
| HY-13801R | Fexinidazole (Standard) | 59729-37-2 | Reference Standards |
| HY-13802 | SC-514 | 354812-17-2 | Reference compound |
| HY-138023 | Leucomycin A4 | 18361-46-1 | Natural Products |
| HY-138026 | (3β)-3-Hydroxy-7-oxochol-5-en-24-oic acid | 25218-38-6 | Reference compound |
| HY-13803 | Tazemetostat | 1403254-99-8 | Reference compound |
| HY-138031 | Pteroylhexaglutamate | 35409-55-3 | Reference compound |
| HY-138035 | Tenellin | 53823-15-7 | Reference compound |
| HY-138037 | Aminopeptidase N inhibitor 1 | 596108-59-7 | Reference compound |
| HY-13803R | Tazemetostat (Standard) | 1403254-99-8 | Reference Standards |
| HY-13804 | PP1 | 172889-26-8 | Reference compound |
| HY-138040 | CRBN modulator-1 | 2407829-65-4 | Reference compound |
| HY-13805 | PP2 | 172889-27-9 | Reference compound |
| HY-138050 | Nyasol | 96895-25-9 | Natural Products |
| HY-138051 | TUPS | 950184-27-7 | Reference compound |
| HY-138053 | Ristocetin A (sulfate) | 90831-71-3 | Reference compound |
| HY-138054 | Cjoc42 | 2171519-89-2 | Reference compound |
| HY-138056 | 7-Acetyl paclitaxel | 92950-39-5 | Reference compound |
| HY-138058 | AF-CX 921 | 77946-49-7 | Reference compound |
| HY-138059 | SM-433 | 1071992-81-8 | Reference compound |
| HY-138059A | SM-433 (hydrochloride) | | Reference compound |
| HY-13806 | XL388 | 1251156-08-7 | Reference compound |
| HY-138060 | Moperone (hydrochloride) | 3871-82-7 | Reference compound |
| HY-138061 | DENV-IN-2 | 2253675-62-4 | Reference compound |
| HY-138063 | Siegeskaurolic acid | 52645-97-3 | Natural Products |
| HY-138064 | 4-APC (hydrobromide) | 1076196-38-7 | Reference compound |
| HY-138065 | Iodoacetyl-LC-biotin | 93285-75-7 | Reference compound |
| HY-138067 | SSAA09E2 | 883944-52-3 | Reference compound |
| HY-138068 | L-Tryptophanylglycine | 7360-09-0 | Reference compound |
| HY-13807 | UNC0646 | 1320288-17-2 | Reference compound |
| HY-138071 | 8α-Tigloyloxyhirsutinolide 13-O-acetate | 83182-58-5 | Natural Products |
| HY-138072 | EMI1 | 35773-42-3 | Reference compound |
| HY-138073 | Cryptomoscatone D2 | 276856-55-4 | Reference compound |
| HY-138074 | Milbemycin A4 oxime | 93074-04-5 | Reference compound |
| HY-138075 | Obafluorin | 92121-68-1 | Reference compound |
| HY-138077 | LSM-775 (maleate) | 101896-80-4 | Reference compound |
| HY-138078 | Lufotrelvir | 2468015-78-1 | Reference compound |
| HY-138079 | 2′,3′-cGMP (triethylamine) | 73647-09-3 | Reference compound |
| HY-13808 | UNC 0631 | 1320288-19-4 | Reference compound |
| HY-138081 | Mesulergine | 64795-35-3 | Reference compound |
| HY-138083 | Parvodicin C2 | 110882-85-4 | Natural Products |
| HY-138084 | SIC5-6 | 2410846-16-9 | Reference compound |
| HY-138088 | (+)-Epoxysuberosin | 80368-68-9 | Reference compound |
| HY-138089 | 17β-Hydroxy exemestane | 122370-91-6 | Reference compound |
| HY-138089S | 17β-Hydroxy exemestane-d3 | | Isotope-Labeled Compounds |
| HY-13809 | BMS-833923 | 1059734-66-5 | Reference compound |
| HY-138094 | N-(2-Hydroxyethyl)oxamic acid | 5270-73-5 | Reference compound |
| HY-138095 | ALEPH-4 | 123643-26-5 | Reference compound |
| HY-138096 | Z-LLF-CHO | 133429-58-0 | Peptides |
| HY-138097 | α-NETA | 115066-04-1 | Reference compound |
| HY-138098 | Sartorypyrone B | 1452396-11-0 | Natural Products |
| HY-13810 | PF-04880594 | 1111636-35-1 | Reference compound |
| HY-138100 | Hyalodendrin | 51920-94-6 | Natural Products |
| HY-138102 | SSAA09E3 | 52869-18-8 | Reference compound |
| HY-138104 | SL-164 | 3476-88-8 | Reference compound |
| HY-138106 | Fmoc-D-Cit-OH | 200344-33-8 | Peptides |
| HY-138107 | Arimistane | 1420-49-1 | Reference compound |
| HY-138109 | D-Pro-Phe-Arg-pNA (hydrochloride) | 62354-56-7 | Peptides |
| HY-13811 | NSC697923 | 343351-67-7 | Reference compound |
| HY-138110 | Toladryl | 19804-27-4 | Reference compound |
| HY-138110R | Toladryl (Standard) | 19804-27-4 | Reference Standards |
| HY-138111 | 4-Nitrophenyl β-D-cellotetraoside | 129411-62-7 | Dye Reagents |
| HY-138112S | β-Dihydroequilin-d3 | 350820-03-0 | Isotope-Labeled Compounds |
| HY-138112S1 | β-Dihydroequilin-d5 | | Isotope-Labeled Compounds |
| HY-138112S2 | β-Dihydroequilin-d4 | 350819-99-7 | Isotope-Labeled Compounds |
| HY-138113 | Pyrrothiogatain | 477888-48-5 | Reference compound |
| HY-138115 | 7ß,27-Dihydroxycholesterol | 240129-43-5 | Reference compound |
| HY-138118 | Propyl nicotinate | 7681-15-4 | Reference compound |
| HY-138119 | γ-Glutamylserine | 5875-35-4 | Reference compound |
| HY-138119A | γ-Glutamylserine (TFA) | | Peptides |
| HY-13812 | QNZ | 545380-34-5 | Reference compound |
| HY-138121 | PSB-KD107 | 955121-65-0 | Reference compound |
| HY-138122 | Porphine | 101-60-0 | Reference compound |
| HY-138123 | Fmoc-Glu(OtBu)-OSu | 101214-22-6 | Reference compound |
| HY-138126 | Dansyl-Tyr-Val-Gly | 113527-49-4 | Peptides |
| HY-138126A | Dansyl-Tyr-Val-Gly (TFA) | 350691-68-8 | Reference compound |
| HY-138127 | Gendenafil | 147676-66-2 | Reference compound |
| HY-138128 | Acetaminophen mercapturate | 52372-86-8 | Reference compound |
| HY-13813 | Blebbistatin | 674289-55-5 | Reference compound |
| HY-138130 | L-Guanosine | 26578-09-6 | Oligonucleotides |
| HY-138131 | SOD1-Derlin-1 inhibitor-1 | 840461-03-2 | Reference compound |
| HY-138134 | NOTP | 83834-39-3 | Biochemical Assay Reagents |
| HY-138136 | Ticlatone | 70-10-0 | Reference compound |
| HY-138137 | Menaquinone 6 | 84-81-1 | Natural Products |
| HY-138139A | AXC-715 (hydrochloride) | 2490497-93-1 | Reference compound |
| HY-138139B | AXC-715 (trihydrochloride) | 2479276-17-8 | Reference compound |
| HY-13814 | PR-619 | 2645-32-1 | Reference compound |
| HY-138140 | Desertomycin A | 121820-50-6 | Natural Products |
| HY-138142 | Euphol acetate | 13879-04-4 | Natural Products |
| HY-138143 | N-(p-Tosyl)-GPR-pNA (acetate) | 86890-95-1 | Dye Reagents |
| HY-138144 | Myceliothermophin E | 955083-90-6 | Natural Products |
| HY-138145 | 8-Acetyl-7-hydroxycoumarin | 6748-68-1 | Natural Products |
| HY-138146 | 4-Dehydrowithaferin A | 6850-30-2 | Natural Products |
| HY-138147 | DCP-Rho1 | 1001575-98-9 | Dye Reagents |
| HY-138148 | 13(S)-HPOTrE(γ) | 121107-97-9 | Reference compound |
| HY-138149 | 2-epi-Abamectin | 106434-14-4 | Reference compound |
| HY-13815 | KY02111 | 1118807-13-8 | Reference compound |
| HY-138151 | 3'-Hydroxy stanozolol | 125709-39-9 | Reference compound |
| HY-138152 | Z-D-Arg-Gly-Arg-pNA (dihydrochloride) | 113711-77-6 | Peptides |
| HY-138153 | JKE-1674 | 2421119-60-8 | Reference compound |
| HY-138154 | BLX-3887 | 934758-70-0 | Reference compound |
| HY-138155 | NSC15520 | 730960-98-2 | Reference compound |
| HY-138159 | Boc-Lys(Ac)-AMC | 233691-67-3 | Dye Reagents |
| HY-13816 | NU6027 | 220036-08-8 | Reference compound |
| HY-138161 | JR14a | 2411440-41-8 | Reference compound |
| HY-138162 | 5-Methoxy EiPT | 850032-66-5 | Reference compound |
| HY-138164 | Cafestol palmitate | 81760-46-5 | Reference compound |
| HY-138165 | Ac-Phe-NH2 | 7376-90-1 | Reference compound |
| HY-138166 | Rosuvastatin lactone | 503610-43-3 | Reference compound |
| HY-138166R | Rosuvastatin lactone (Standard) | 503610-43-3 | Reference Standards |
| HY-138166S | Rosuvastatin lactone-d6 | | Isotope-Labeled Compounds |
| HY-13817 | IU1 | 314245-33-5 | Reference compound |
| HY-138170 | ALC-0315 | 2036272-55-4 | Oligonucleotides |
| HY-138170A | ALC-0315 (Excipient) | 2036272-55-4 | Reference compound |
| HY-138171 | Lipid 5 | 2089251-33-0 | Biochemical Assay Reagents |
| HY-138176 | 7-Hydroxyrisperidone | 147663-04-5 | Reference compound |
| HY-138177 | Butyryl-Coenzyme A (sodium) | 125527-24-4 | Enzyme |
| HY-138179 | 7-APRA | 120709-09-3 | Reference compound |
| HY-13818 | Stattic | 19983-44-9 | Reference compound |
| HY-138181 | Contezolid phosphoramidic acid | 1807365-43-0 | Reference compound |
| HY-138185 | Collismycin A | 158792-24-6 | Natural Products |
| HY-138187 | 4-Hydroxy omeprazole sulfide | 103876-98-8 | Reference compound |
| HY-138188 | KRA-533 | 10161-87-2 | Reference compound |
| HY-13819 | MK-8745 | 885325-71-3 | Reference compound |
| HY-138192 | Octyl glucose neopentyl glycol | 1257853-32-9 | Reference compound |
| HY-138193 | Lauryl maltose neopentyl glycol | 1257852-96-2 | Reference compound |
| HY-138194 | Destomycin B | 11005-98-4 | Natural Products |
| HY-138196 | 5-Oxorosuvastatin methyl ester | 147118-39-6 | Reference compound |
| HY-138199S | Omeprazole sulfone N-oxide-13C,d3 | 2740875-18-5 | Isotope-Labeled Compounds |
| HY-138199S1 | Omeprazole sulfone N-oxide-d3 | 2748468-58-6 | Isotope-Labeled Compounds |
| HY-13820 | GSK2656157 | 1337532-29-2 | Reference compound |
| HY-138200 | Cy5 maleimide | 1437796-65-0 | Dye Reagents |
| HY-138201 | IM-93 | 1173657-73-2 | Reference compound |
| HY-138202 | Lck-IN-1 | 923596-52-5 | Reference compound |
| HY-138203 | Z-LE(OMe)TD(OMe)-FMK | 210344-93-7 | Peptides |
| HY-138206 | Prostaglandin E1 isopropyl ester | 217182-28-0 | Reference compound |
| HY-138207 | N-Oleoyl-L-phenylalanine | 136560-78-6 | Peptides |
| HY-138208 | Z-Phe-Tyr(tBu)-diazomethylketone | 114014-15-2 | Reference compound |
| HY-13821 | Epoxomicin | 134381-21-8 | Natural Products |
| HY-138210 | N,O-Diacetyltyramine | 14383-56-3 | Natural Products |
| HY-138211 | BE-26263 | 147716-81-2 | Natural Products |
| HY-138212 | Thiamphenicol palmitate | 52628-58-7 | Biochemical Assay Reagents |
| HY-138213 | Afzelechin-(4α→8)-epiafzelechin | 1383627-30-2 | Natural Products |
| HY-138215 | ADTL-EI1712 | 2414916-45-1 | Reference compound |
| HY-138216 | Despropylene gatifloxacin | 172426-86-7 | Reference compound |
| HY-138217 | Otophylloside B 4'''-O-α-L-cymaropyranoside | 171422-82-5 | Natural Products |
| HY-138218 | ALD-52 | 3270-02-8 | Reference compound |
| HY-13822 | SKI II | 312636-16-1 | Reference compound |
| HY-138222 | JANEX-1 (hydrochloride) | 188829-39-2 | Reference compound |
| HY-138223 | 6-Prenylindole | 23158-16-9 | Natural Products |
| HY-138226 | BODIPY 558/568 C12 | 158757-84-7 | Dye Reagents |
| HY-138227 | 3′-Deoxyadenosine 5′-diphosphate | 13052-95-4 | Reference compound |
| HY-138227A | 3′-Deoxyadenosine 5′-diphosphate (disodium) | 71997-31-4 | Reference compound |
| HY-13823 | C646 | 328968-36-1 | Reference compound |
| HY-138232 | Lys-psi(CH2NH)-Trp(Nps)-OMe | 141365-20-0 | Reference compound |
| HY-138233 | KUS121 | 1357164-52-3 | Reference compound |
| HY-138237 | 25I-NBMD (hydrochloride) | 1539266-14-2 | Reference compound |
| HY-138239 | WEE1-IN-3 | 2272976-28-8 | Reference compound |
| HY-138241 | PBD-BODIPY | 148185-52-8 | Dye Reagents |
| HY-138244 | 8-iso Prostaglandin F2β | 177020-26-7 | Reference compound |
| HY-138246 | Pentynoic acid STP ester (sodium) | 1807530-14-8 | Reference compound |
| HY-138247 | β-Lactamase-IN-2 | 2114651-20-4 | Reference compound |
| HY-138247R | β-Lactamase-IN-2 (Standard) | 2114651-20-4 | Reference Standards |
| HY-138253 | 2′,2′-Difluorodeoxyuridine | 114248-23-6 | Reference compound |
| HY-138253R | 2′,2′-Difluorodeoxyuridine (Standard) | 114248-23-6 | Reference Standards |
| HY-138253S | 2′,2′-Difluorodeoxyuridine-13C,15N2 | 1233921-75-9 | Isotope-Labeled Compounds |
| HY-138257 | (S)-Indeloxazine (benzenesulfonate) | 1214994-13-4 | Reference compound |
| HY-138257A | (R)-Indeloxazine (benzenesulfonate) | 1623762-83-3 | Reference compound |
| HY-138267 | 7-O-Acetylneocaesalpin N | 1309079-08-0 | Natural Products |
| HY-138269 | Barzuxetan | 157380-45-5 | Reference compound |
| HY-138269A | Barzuxetan (hydrochloride) | | Biochemical Assay Reagents |
| HY-13827 | JAK-IN-1 | 1334673-53-8 | Reference compound |
| HY-138270 | Tetrahydropteroylpentaglutamate | 41520-73-4 | Natural Products |
| HY-138271 | LH65.3 | 1494676-74-2 | Reference compound |
| HY-138273 | Sulfosuccinimidyl myristate (sodium) | 162823-01-0 | Reference compound |
| HY-138280 | DTHIB | 897326-30-6 | Reference compound |
| HY-138281 | Complement factor D-IN-2 | 1903742-34-6 | Reference compound |
| HY-138283 | MR837 | 1210906-48-1 | Reference compound |
| HY-138284 | Avenanthramide-C methyl ester | 955382-52-2 | Reference compound |
| HY-138287 | 4'-Aminomethyl-4,5',8-trimethylpsoralen | 64358-50-5 | Reference compound |
| HY-138289 | 4-acetoxy MPT | 2173386-55-3 | Reference compound |
| HY-13829 | BMS-585248 | 619331-12-3 | Reference compound |
| HY-138290 | Diclofenac acyl-β-D-glucuronide allyl ester | 698358-10-0 | Reference compound |
| HY-138291 | Ethoxyquin dimer | 74681-77-9 | Reference compound |
| HY-138293 | SY-5609 | 2417302-07-7 | Reference compound |
| HY-138294 | RAS/RAS-RAF-IN-1 | 2447039-81-6 | Reference compound |
| HY-138295 | KRAS inhibitor-10 | 2578876-75-0 | Reference compound |
| HY-138298 | Trastuzumab deruxtecan (solution) | 1826843-81-5 | ADC Related |
| HY-138298A | Trastuzumab deruxtecan | 1826843-81-5 | ADC Related |
| HY-138300 | ALC-0159 | 1849616-42-7 | Oligonucleotides |
| HY-138300A | ALC-0159 (Excipient) | 1849616-42-7 | Reference compound |
| HY-138301 | Miclxin | 2494198-61-5 | Reference compound |
| HY-138304 | CC-90001 | 1403859-14-2 | Reference compound |
| HY-138305 | HCV-IN-31 | 1998705-62-6 | Reference compound |
| HY-138307 | NH2-PEG-Strt (MW 10000) | | Reference compound |
| HY-138308 | NH2-PEG-Strt (MW 3000) | | Reference compound |
| HY-13831 | BPTU | 870544-59-5 | Reference compound |
| HY-138310 | Thiol-PEG-COOH (MW 5000) | | Reference compound |
| HY-138311 | Boc-NH-PEG-Thiol (MW 10000) | | Reference compound |
| HY-138312 | m-PEG1000-CH2COOH | | Reference compound |
| HY-138314 | m-PEG16-COOH | 2933174-52-6 | Reference compound |
| HY-138315 | Ms-PEG6-THP | 42607-89-6 | Reference compound |
| HY-138316 | THP-PEG10-C2-Boc | | Reference compound |
| HY-138317 | Tyk2-IN-10 | 2368945-72-4 | Reference compound |
| HY-138318 | DBCO-PEG3-amide-N-Fmoc | | Reference compound |
| HY-138319 | Benzyl-PEG25-amine | | Reference compound |
| HY-13832 | Atovaquone | 95233-18-4 | Reference compound |
| HY-138320 | Fmoc-N-amido-PEG36-Boc | | Reference compound |
| HY-138321 | Propargyl-PEG6-Br | 1973383-30-0 | Reference compound |
| HY-138322 | N-trifluoroacetyl-β-alanyl chloride | 87639-76-7 | ADC Related |
| HY-138323 | Benzyl-PEG36-alcohol | | Reference compound |
| HY-138324 | Ms-PEG6-MS | 109789-40-4 | Reference compound |
| HY-138325 | Azido-PEG6-THP | | Reference compound |
| HY-138326 | Bis-PEG18-Boc | | Reference compound |
| HY-138327 | 1,6-Bis(mesyloxy)hexane | 4239-24-1 | ADC Related |
| HY-138328 | Benzyl-PEG18-MS | | Reference compound |
| HY-138329 | THP-PEG24-THP | | Reference compound |
| HY-13832R | Atovaquone (Standard) | 95233-18-4 | Reference Standards |
| HY-13832S | Atovaquone-d4 | 2070015-14-2 | Isotope-Labeled Compounds |
| HY-13832S2 | Atovaquone-d5 | 1329792-63-3 | Isotope-Labeled Compounds |
| HY-13832S3 | cis-Atovaquone-d4 | | Isotope-Labeled Compounds |
| HY-13833 | Endochin | 354155-51-4 | Reference compound |
| HY-138330 | Fmoc-PEG5-NHBoc | | Reference compound |
| HY-138331 | Fmoc-N-amido-PEG6-amine | | Reference compound |
| HY-138332 | Benzyl-PEG24-MS | 2218463-20-6 | Reference compound |
| HY-138333 | Azido-PEG7-PFP ester | | Reference compound |
| HY-138334 | Propargyl-PEG1-THP | 119096-95-6 | Reference compound |
| HY-138335 | Boc-PEG8-Boc | 1432970-18-7 | Reference compound |
| HY-138336 | Br-PEG3-MS | 2702323-73-5 | Reference compound |
| HY-138337 | MS-PEG8-THP | | Reference compound |
| HY-138338 | Benzyl-PEG9-THP | 669556-53-0 | Reference compound |
| HY-138339 | Benzyl-PEG8-Br | | Reference compound |
| HY-13834 | GW844520 | 137735-25-2 | Reference compound |
| HY-138340 | THP-PEG8-Boc | | Reference compound |
| HY-138341 | Benzyl-PEG10-THP | | Reference compound |
| HY-138342 | Benzyl-PEG1-MS | 58841-52-4 | Reference compound |
| HY-138343 | Azido-PEG3-MS | 176520-24-4 | Reference compound |
| HY-138344 | MS-PEG10-THP | 42607-91-0 | Reference compound |
| HY-138345 | Benzyl-PEG11-Boc | | Reference compound |
| HY-138346 | Benzyl-PEG4-Boc | 2484091-04-3 | Reference compound |
| HY-138347 | THP-PEG10-Boc | | Reference compound |
| HY-138348 | THP-PEG2-methyl propionate | | Reference compound |
| HY-138349 | THP-PEG6-C2-Boc | | Reference compound |
| HY-138350 | Azido-PEG10-CH2CO2-NHS | | Reference compound |
| HY-138351 | Propargyl-PEG4-thioacetyl | | Reference compound |
| HY-138352 | THP-PEG4-Boc | | Reference compound |
| HY-138354 | Pyrroline-5-carboxylate | 2139-03-9 | Reference compound |
| HY-138354A | Pyrroline-5-carboxylate (sodium) | 72978-16-6 | Reference compound |
| HY-138355 | CHO-CH2-PEG1-CH2-Boc | 2230956-95-1 | Reference compound |
| HY-138358 | Azido-PEG23-C2-azide | | Reference compound |
| HY-13836 | ELQ-300 | 1354745-52-0 | Reference compound |
| HY-138360 | Benzyl-PEG18-THP | | Reference compound |
| HY-138362 | Br-PEG6-C2-acid | 309916-91-4 | Reference compound |
| HY-138363 | Azido-PEG6-MS | 352439-38-4 | Reference compound |
| HY-138364 | YUM70 | 423145-35-1 | Reference compound |
| HY-138365 | EMAC10101d | 2561476-24-0 | Reference compound |
| HY-138366 | Propargyl-PEG11-alcohol | | Reference compound |
| HY-138367 | Benzyl-PEG3-methyl ester | 127457-61-8 | Reference compound |
| HY-138368 | THP-PEG1-Boc | | Reference compound |
| HY-138369 | Methylamino-PEG3-benzyl | | Reference compound |
| HY-138370 | Boc-NH-PEG4-C2-Boc | 2138484-13-4 | Reference compound |
| HY-138371 | MS-PEG12-THP | 552886-58-5 | Reference compound |
| HY-138372 | Br-PEG4-THP | 1803547-60-5 | Reference compound |
| HY-138373 | Boc-PEG5-methyl ester | 1807530-04-6 | Reference compound |
| HY-138374 | Azido-PEG12-THP | | Reference compound |
| HY-138375 | Mal-PEG5-C2-NH2 (hydrochloride) | 2454216-21-6 | Reference compound |
| HY-138376 | Benzyl-PEG12-MS | | Reference compound |
| HY-138377 | Azido-PEG8-C-Boc | 1984776-39-7 | Reference compound |
| HY-138378 | Benzyl-PEG5-NHBoc | 2064292-55-1 | Reference compound |
| HY-138379 | Boc-PEG4-acid | 2244684-38-4 | Reference compound |
| HY-13838 | PLX647 | 873786-09-5 | Reference compound |
| HY-138380 | Mal-PEG4-C2-NH2 (TFA) | 2512227-13-1 | Reference compound |
| HY-138381 | Br-PEG6-C2-NHBoc | 2688072-13-9 | Reference compound |
| HY-138382 | m-PEG4-PFP ester | 2952895-31-5 | Reference compound |
| HY-138383 | CHO-C-PEG2-C-CHO | 92351-72-9 | Reference compound |
| HY-138384 | Br-PEG9-C2-NHBoc | | Reference compound |
| HY-138385 | MS-PEG5-THP | | Reference compound |
| HY-138386 | endo-BCN-PEG12-NH2 (hydrochloride) | | Reference compound |
| HY-138387 | 6-Azido-hexylamine | 349553-73-7 | ADC Related |
| HY-138388 | Azido-PEG4-formylhydrazine-Boc | | Reference compound |
| HY-138389 | THP-PEG13-OH | | Reference compound |
| HY-13838A | PLX647 (dihydrochloride) | 1779796-38-1 | Reference compound |
| HY-138390 | NH2-PEG10-C2-dimethylamino | | Reference compound |
| HY-138391 | Azido-PEG8-propargyl | 1196733-06-8 | Reference compound |
| HY-138392 | Mal-PEG25-NH2 (hydrochloride) | | Reference compound |
| HY-138393 | Benzyl-PEG6-acid | | Reference compound |
| HY-138395 | DSPE-PEG6-Mal | | Reference compound |
| HY-138396 | Rhodamine B PEG2-NH2 | | Reference compound |
| HY-138397 | Boc-NH-PEG15-C2-acid | | Reference compound |
| HY-138398 | BOC-NH-PEG2-propene | 2410236-85-8 | Reference compound |
| HY-138399 | Boc-NH-PEG22-C2-NH2 | | Reference compound |
| HY-138400 | Me-PEG18-NH2 | | Reference compound |
| HY-138401 | Dimethylamine-PEG19 | | Reference compound |
| HY-138402 | Boc-NH-PEG15-C1-acid | | Reference compound |
| HY-138403 | THP-C1-PEG5 | | Reference compound |
| HY-138404 | THP-PEG2-Mal | | Reference compound |
| HY-138406 | Boc-NH-PEG8-C2-Br | 2688072-12-8 | Reference compound |
| HY-138407 | Evixapodlin | 2374856-75-2 | Reference compound |
| HY-138408 | BocNH-PEG4-CH2CHO | 2708026-80-4 | Reference compound |
| HY-138409 | Dimethylamino-PEG11 | | Reference compound |
| HY-138410 | Boc-NH-PEG11-C2-acid | | Reference compound |
| HY-138411 | Cl-PEG6-acid | 2365309-92-6 | Reference compound |
| HY-138412 | Bromoacetic-PEG2-NHS ester | | Reference compound |
| HY-138413 | THP-PEG10-OH | 42607-90-9 | Reference compound |
| HY-138414 | Bromoacetic-PEG1-CH2-NHS ester | | Reference compound |
| HY-138415 | Azido-PEG11-CH2COOH | 2567584-97-6 | Reference compound |
| HY-138416 | Azido-PEG10-CH2COOH | | Reference compound |
| HY-138417 | Azido-PEG9-CH2COOH | | Reference compound |
| HY-138418 | Azido-PEG7-CH2COOH | 1446411-32-0 | Reference compound |
| HY-138419 | Biotin-PEG6-Silane | | Reference compound |
| HY-13842 | BX517 | 850717-64-5 | Reference compound |
| HY-138420 | m-PEG7-Silane | | Reference compound |
| HY-138421 | Hydroxy-PEG4-methyl acetate | 77303-64-1 | Reference compound |
| HY-138422 | Iodoacetyl-PEG4-NHS ester | 2517899-65-7 | Reference compound |
| HY-138423 | Acryloyl-PEG4-OH | 26150-06-1 | Reference compound |
| HY-138424 | m-PEG15-amine | | Reference compound |
| HY-138425 | Amino-PEG12-C2-azide | | Reference compound |
| HY-138426 | Biotin-PEG4-allyl | 1643661-79-3 | Reference compound |
| HY-138427 | m-PEG18-Mal | | Reference compound |
| HY-138428 | m-PEG9-Mal | | Reference compound |
| HY-138429 | COQ7-IN-2 | 2579696-76-5 | Reference compound |
| HY-138430 | Mal-PEG2-NHS | 329364-72-9 | Reference compound |
| HY-138432 | Boc-NH-PEG26-C2-NH2 | | Reference compound |
| HY-138433 | Benzyl-PEG1-propanol | 131326-24-4 | Reference compound |
| HY-138434 | Fmoc-NH-PEG14-acid | | Reference compound |
| HY-138435 | Azido-PEG13-acid | | Reference compound |
| HY-138436 | PEG2-ethyl acetate | 154773-33-8 | Reference compound |
| HY-138437 | Azido-PEG8-TFP ester | 1818294-49-3 | Reference compound |
| HY-138438 | Azido-PEG3-amino-OPSS | | Reference compound |
| HY-13844 | PDK1-IN-3 | 853909-77-0 | Reference compound |
| HY-138441 | Boc-NH-PEG11-NHS ester | | Reference compound |
| HY-138442 | Benzyl-PEG16-THP | | Reference compound |
| HY-138444 | Benzyl-PEG18-alcohol | | Reference compound |
| HY-138446 | Amino-PEG4-C2-SH (hydrochloride) | | Reference compound |
| HY-138447 | Mal-NH-PEG8-Boc | | Reference compound |
| HY-138448 | m-PEG750-Br | | Reference compound |
| HY-138449 | m-PEG6-Boc | | Reference compound |
| HY-138450 | Br-PEG4-methyl acetate | | Reference compound |
| HY-138451 | Amino-PEG7-C2-SH (hydrochloride) | | Reference compound |
| HY-138453 | ACT-1016-0707 | 2569467-78-1 | Reference compound |
| HY-138454 | MEG (hemisulfate) | 3979-00-8 | Reference compound |
| HY-138455 | Bis-isopropyl-PEG1 | 3944-35-2 | Reference compound |
| HY-138456 | Benzyl-PEG20-alcohol | | Reference compound |
| HY-138457 | Azido-PEG20-Boc | | Reference compound |
| HY-138459 | Propargyl-PEG9-THP | | Reference compound |
| HY-13846 | BM-1074 | 1391108-10-3 | Reference compound |
| HY-138460 | Propargyl-PEG10-alcohol | 2378150-09-3 | Reference compound |
| HY-138461 | Azido-PEG1 | 1517-05-1 | Reference compound |
| HY-138462 | Methyl acetate-PEG2-propanol | | Reference compound |
| HY-138463 | Azido-PEG36-NHS ester | | Reference compound |
| HY-138464 | Br-Boc-C2-azido | 1120364-53-5 | Reference compound |
| HY-138465 | THP-C4-PEG4 | | Reference compound |
| HY-138466 | Azido-PEG3-C6-Cl | 1625717-44-3 | Reference compound |
| HY-138467 | Mal-PFP ester | 138194-55-5 | Reference compound |
| HY-138468 | Boc-PEG25-benzyl | | Reference compound |
| HY-138469 | NH2-PEG3-C6-Cl | 1261350-60-0 | Reference compound |
| HY-13847 | GNE-555 | 1428902-71-9 | Reference compound |
| HY-138470 | Azido-PEG2-C6-Cl | 2568146-55-2 | Reference compound |
| HY-138471 | Azido-PEG2-C6-OH | | Reference compound |
| HY-138472 | Azido-PEG4-THP | 145927-74-8 | Reference compound |
| HY-138473 | Boc-PEG1-Boc | 727729-33-1 | Reference compound |
| HY-138474 | Boc-PEG1-PPG2-C2-azido | | Reference compound |
| HY-138475 | Boc-PEG2-ethoxyethane-PEG2-benzyl | 2111836-22-5 | Reference compound |
| HY-138476 | Benzyl-PEG2-ethoxyethane-PEG2 | 2115897-18-0 | Reference compound |
| HY-138477 | Benzyl-PEG24-THP | | Reference compound |
| HY-138478 | THP-PEG13-Boc | | Reference compound |
| HY-138479 | Benzyl-PEG2-ethanol | 2055300-50-8 | Reference compound |
| HY-13848 | Rugocrixan | 911715-90-7 | Reference compound |
| HY-138480 | Benzyl-PEG13-Boc | | Reference compound |
| HY-138481 | Boc-PEG4-methyl propionate | 2100306-74-7 | Reference compound |
| HY-138482 | MS-PEG1-THP | 1309248-13-2 | Reference compound |
| HY-138483 | THP-PEG9-OH | 669556-83-6 | Reference compound |
| HY-138484 | Folate-PEG3-amine | 710323-40-3 | ADC Related |
| HY-138485 | Boc-PEG1-PPG2-C2-NH2 | | Reference compound |
| HY-138486 | Br-PEG4-acid | 2680525-48-6 | Reference compound |
| HY-138487 | Benzyl-PEG5-acid | 2514948-41-3 | Reference compound |
| HY-138488 | Biotin-PEG4-PFP ester | 1334172-58-5 | ADC Related |
| HY-138489 | TRULI | 1424635-83-5 | Reference compound |
| HY-138490 | Iodoacetyl-PEG8-biotin | | Reference compound |
| HY-138491 | Iodoacetyl-PEG4-biotin | | Reference compound |
| HY-138492 | Boc-NH-PPG2 | 1312905-31-9 | Reference compound |
| HY-138493 | F-PEG2-S-Boc | | Reference compound |
| HY-138494 | Boc-NH-PEG12-NH-Boc | | Reference compound |
| HY-138495 | F-PEG2-SO2-COOH | | Reference compound |
| HY-138496 | F-PEG2-SO-COOH | | Reference compound |
| HY-138497 | F-PEG2-S-COOH | | Reference compound |
| HY-138498 | F-PEG2-COOH | 2383964-72-3 | Reference compound |
| HY-138500 | Mal-PEG12-NH-Boc | 2170654-80-3 | Reference compound |
| HY-138501 | GPR34 receptor antagonist 2 | 907952-06-1 | Reference compound |
| HY-138502 | Melarsomine | 128470-15-5 | Reference compound |
| HY-138502A | Melarsomine (dihydrochloride) | 89141-50-4 | Reference compound |
| HY-138503 | Biotin-PEG3-propargyl | 1421701-68-9 | Reference compound |
| HY-138504 | Bis-PEG2-Boc | 1611468-28-0 | Reference compound |
| HY-138505 | Iodoacetamido-PEG6-acid | | Reference compound |
| HY-138506 | DBCO-S-S-acid | 2749426-25-1 | ADC Related |
| HY-138507 | Desthiobiotin-PEG4-acid | | Reference compound |
| HY-138508 | Biotin-PEG2-methyl ethanethioate | | ADC Related |
| HY-138509 | NHS ester-PEG13-COOH | | Reference compound |
| HY-13851 | PS47 | 1180676-33-8 | Reference compound |
| HY-138511 | NHS ester-PEG7-COOH | | Reference compound |
| HY-138513 | Benzyl-PEG4-acyl chloride | | Reference compound |
| HY-138514 | CH2COOH-PEG9-CH2COOH | 2250056-46-1 | Reference compound |
| HY-138515 | Br-PEG7-NHBoc | | Reference compound |
| HY-138516 | CG-PEG5-azido | | Reference compound |
| HY-138517 | Thiol-C9-PEG7 | 130727-44-5 | Reference compound |
| HY-138518 | Azido-PEG3-aldehyde | 1807530-10-4 | Reference compound |
| HY-138519 | Bis-(Mal-PEG3)-PH-N-succinimidyl acetate | | Reference compound |
| HY-138520 | 5-[Boc(methyl)amino]pentanal | 1620280-47-8 | Reference compound |
| HY-138521 | Azido-C6-OH | 146292-90-2 | ADC Related |
| HY-138522 | NHS-bis-PEG2-amide-Mal | | Reference compound |
| HY-138523 | NH2-PEG3500-NH2 | | Reference compound |
| HY-138524 | Thiol-PEG2-acid | 1379649-73-6 | Reference compound |
| HY-138525 | Azido-PEG4-Thiol | 2720615-82-5 | Reference compound |
| HY-138526 | Thiol-C9-PEG4-acid | 716339-41-2 | Reference compound |
| HY-138527 | Thiol-C9-PEG4 | 130727-41-2 | Reference compound |
| HY-138528 | Thiol-C9-PEG5-acid | | Reference compound |
| HY-138529 | Thiol-C9-PEG5 | 130727-42-3 | Reference compound |
| HY-138530 | Thiol-PEG4-amide-NH2 | | Reference compound |
| HY-138531 | THP-PEG1-THP | 71033-27-7 | Reference compound |
| HY-138532 | m-PEG8-amide-C10-Thiol | | Reference compound |
| HY-138533 | Thiol-C10-amide-PEG8 | 1353948-95-4 | Reference compound |
| HY-138534 | THP-CH3-ethyl propionate | 3539-40-0 | Reference compound |
| HY-138535 | Azide-C2-Azide | 629-13-0 | ADC Related |
| HY-138536 | PROTAC CBP/P300 Degrader-1 | 2484739-48-0 | Reference compound |
| HY-138537 | NF-κB-IN-1 | 1227098-15-8 | Reference compound |
| HY-138538 | 2-Nitrobenzaldehyde Semicarbazone | 16004-43-6 | Reference compound |
| HY-138538R | 2-Nitrobenzaldehyde Semicarbazone (Standard) | 16004-43-6 | Reference Standards |
| HY-138538S | 2-Nitrobenzaldehyde semicarbazone-13C,15N2-1 | 957509-32-9 | Isotope-Labeled Compounds |
| HY-138539 | CBP/p300 ligand 2 | 2484741-78-6 | Reference compound |
| HY-138540 | 1-Dodecylimidazole | 4303-67-7 | Biochemical Assay Reagents |
| HY-138542 | RO0270608 | 220846-33-3 | Reference compound |
| HY-138543 | NITD-688 | 2407227-31-8 | Reference compound |
| HY-138545 | 4-Hydroxy-6-methylcoumarin | 13252-83-0 | Natural Products |
| HY-138546 | Fmoc-Tpi-OH | 204322-23-6 | Reference compound |
| HY-138547 | DHPTA | 3148-72-9 | Reference compound |
| HY-138548 | 4-Ethoxycoumarin | 35817-27-7 | Natural Products |
| HY-138550A | (S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 (TFA) | 2417370-48-8 | Reference compound |
| HY-138551A | (S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 (TFA) | 2417370-89-7 | Reference compound |
| HY-138553A | (S,R,S)-AHPC-isobutyl acetate-methanesulfonothioate-Me-C10-NH2 (TFA) | | Reference compound |
| HY-138554 | 3-Acetylcoumarin | 3949-36-8 | Reference compound |
| HY-138555 | PROTAC BRD4 Degrader-8 | 3026420-38-9 | Reference compound |
| HY-138556 | GPX4-IN-2 | 2485005-22-7 | Reference compound |
| HY-138557 | AKR1C3-IN-4 | 1284180-11-5 | Reference compound |
| HY-138558 | PAR-2-IN-1 | 1690176-75-0 | Reference compound |
| HY-138559 | GW604714X | 853953-65-8 | Reference compound |
| HY-13856 | (R)-PS210 | 1410101-89-1 | Reference compound |
| HY-138560 | Cross-linked dextran G 50 | 9048-71-9 | Biochemical Assay Reagents |
| HY-138560A | Cross-linked dextran G 50, medium | 9048-71-9 | Biochemical Assay Reagents |
| HY-138560B | Cross-linked dextran G 50, fine | 9048-71-9 | Biochemical Assay Reagents |
| HY-138561 | EFdA-TP | 950913-56-1 | Reference compound |
| HY-138561A | EFdA-TP (tetraammonium) | | Reference compound |
| HY-138561B | EFdA-TP (tetrasodium) | 2883783-00-2 | Reference compound |
| HY-138561C | EFdA-TP (tetralithium) | | Reference compound |
| HY-138562 | HIV-1 Nef-IN-1 | 13728-56-8 | Reference compound |
| HY-138563 | GSK973 | 2138473-38-6 | Reference compound |
| HY-138563A | (2R,3R)-GSK973 | | Reference compound |
| HY-138564 | NOS-IN-1 | 165383-72-2 | Reference compound |
| HY-138565 | K-975 | 2563855-03-6 | Reference compound |
| HY-138568 | HPK1-IN-3 | 2739844-34-7 | Reference compound |
| HY-138569 | HPK1-IN-4 | 2739844-28-9 | Reference compound |
| HY-138570 | HLE-IN-1 | 13947-21-2 | Reference compound |
| HY-138572 | Fanetizole | 79069-94-6 | Reference compound |
| HY-138573 | N-Acetyl Adamantamine | 880-52-4 | Reference compound |
| HY-138573S | N-Acetyl Adamantamine-d3 | 1217704-63-6 | Isotope-Labeled Compounds |
| HY-138576 | Antifungal agent 6 | 332849-40-8 | Reference compound |
| HY-138577 | 2'-F-Bz-dC Phosphoramidite | 161442-19-9 | Oligonucleotides |
| HY-138578 | 2'-O-Me-C(Bz) Phosphoramidite | 110764-78-8 | Oligonucleotides |
| HY-138579 | 2'-OMe-G(ibu) Phosphoramidite | 150780-67-9 | Oligonucleotides |
| HY-138580 | 2'-OMe-A(Bz) Phosphoramidite | 110782-31-5 | Oligonucleotides |
| HY-138581 | DMT-dA(PAc) Phosphoramidite | 110543-74-3 | Oligonucleotides |
| HY-138582 | N6-Methyl-dA phosphoramidite | 105931-58-6 | Oligonucleotides |
| HY-138583 | Ac-dA Phosphoramidite | 1027734-01-5 | Oligonucleotides |
| HY-138584 | IBU-DC Phosphoramidite | 110522-84-4 | Oligonucleotides |
| HY-138585 | DMT-dG(dmf) Phosphoramidite | 330628-04-1 | Oligonucleotides |
| HY-138586 | DMT-dC(ac) Phosphoramidite | 154110-40-4 | Oligonucleotides |
| HY-138587 | 7-TFA-ap-7-Deaza-ddG | 114748-68-4 | Reference compound |
| HY-138588 | 7-TFA-ap-7-Deaza-ddA | 114748-71-9 | Reference compound |
| HY-138589 | 7-TFA-ap-7-Deaza-dG | 666847-77-4 | Oligonucleotides |
| HY-13858A | Sarecycline (hydrochloride) | 1035979-44-2 | Reference compound |
| HY-13858AR | Sarecycline (hydrochloride) (Standard) | 1035979-44-2 | Reference Standards |
| HY-13859 | Clevudine | 163252-36-6 | Oligonucleotides |
| HY-138590 | 7-TFA-ap-7-Deaza-dA | 178420-75-2 | Oligonucleotides |
| HY-138591 | 7-Deaza-2',3'-dideoxyadenosine | 40627-30-3 | Oligonucleotides |
| HY-138592 | 7-Deaza-2',3'-dideoxyguanosine | 111869-49-9 | Reference compound |
| HY-138593 | 5-O-TBDMS-N4-Benzoyl-2-deoxycytidine | 51549-36-1 | Oligonucleotides |
| HY-138594 | 5'-O-TBDMS-N2-ibu-dG | 85326-10-9 | Oligonucleotides |
| HY-138595 | 5'-O-TBDMS-Bz-dA | 51549-39-4 | Oligonucleotides |
| HY-138596 | 5'-O-TBDMS-dU | 76223-04-6 | Oligonucleotides |
| HY-138597 | 5'-O-TBDMS-dT | 40733-28-6 | Oligonucleotides |
| HY-138598 | 5'-O-TBDMS-dG | 51549-33-8 | Oligonucleotides |
| HY-138599 | 5'-O-TBDMS-dA | 51549-30-5 | Oligonucleotides |
| HY-138600 | 5'-O-DMT-N6-ibu-dA | 190834-10-7 | Oligonucleotides |
| HY-138601 | 5'-O-DMT-N4-Bz-5-Me-dC | 104579-03-5 | Oligonucleotides |
| HY-138602 | 5'-O-DMT-N4-Ac-2'-F-dC | 159414-98-9 | Oligonucleotides |
| HY-138603 | 5'-O-DMT-N4-Bz-2'-F-dC | 146954-77-0 | Oligonucleotides |
| HY-138604 | 5'-O-DMT-N6-Me-2'-dA | 98056-69-0 | Oligonucleotides |
| HY-138605 | 5'-O-DMT-ibu-dC | 100898-62-2 | Oligonucleotides |
| HY-138606 | 5'-O-DMT-PAC-dA | 110522-82-2 | Oligonucleotides |
| HY-138607 | 5'-O-DMT-N2-DMF-dG | 40094-22-2 | Oligonucleotides |
| HY-138608 | 5'-O-DMT-rI | 119898-59-8 | Oligonucleotides |
| HY-138609 | 5'-O-DMT-rU | 81246-79-9 | Oligonucleotides |
| HY-13861 | GW7647 | 265129-71-3 | Reference compound |
| HY-138610 | 5'-O-DMT-Bz-rC | 81246-76-6 | Oligonucleotides |
| HY-138611 | 5'-O-DMT-2'-O-TBDMS-Bz-rC | 81256-87-3 | Oligonucleotides |
| HY-138612 | 5'-O-DMT-3'-O-TBDMS-Ac-rC | 123956-65-0 | Oligonucleotides |
| HY-138613 | 5'-O-DMT-2'-O-TBDMS-rI | 127212-34-4 | Oligonucleotides |
| HY-138614 | 5'-O-DMT-2'-O-TBDMS-Ac-rC | 121058-85-3 | Oligonucleotides |
| HY-138615 | Deoxythymidine-5'-triphosphate | 365-08-2 | Oligonucleotides |
| HY-138615A | Deoxythymidine-5'-triphosphate (sodium hydrate) | | Oligonucleotides |
| HY-138615S1 | Deoxythymidine-5'-triphosphate-15N2 (dilithium) | | Isotope-Labeled Compounds |
| HY-138615S2 | Deoxythymidine-5'-triphosphate-13C10 (dilithium) | | Isotope-Labeled Compounds |
| HY-138615S3 | Deoxythymidine-5'-triphosphate-15N2,d15 (dilithium) | | Isotope-Labeled Compounds |
| HY-138615S4 | Deoxythymidine-5'-triphosphate-13C10,15N2 (dilithium) | 2483830-18-6 | Isotope-Labeled Compounds |
| HY-138616 | dGTP | 2564-35-4 | Oligonucleotides |
| HY-138616S | dGTP-15N5 (dilithium) | 95648-75-2 | Isotope-Labeled Compounds |
| HY-138616S1 | dGTP-d14 (dilithium) | | Isotope-Labeled Compounds |
| HY-138616S2 | dGTP-15N5,d14 (dilithium) | | Isotope-Labeled Compounds |
| HY-138616S3 | dGTP-13C10 (dilithium) | | Isotope-Labeled Compounds |
| HY-138616S4 | dGTP-13C10,15N5 (dilithium) | | Isotope-Labeled Compounds |
| HY-138617 | AI-10-47 | 1256094-31-1 | Reference compound |
| HY-13862 | AZD1080 | 612487-72-6 | Reference compound |
| HY-138620 | MCU-i4 | 371924-24-2 | Reference compound |
| HY-138621 | Antibacterial agent 19 | 79660-59-6 | Reference compound |
| HY-138622 | 24:0 Lyso PC | 325171-59-3 | Oligonucleotides |
| HY-138622S | 24:0 Lyso PC-13C6 | 2483735-01-7 | Isotope-Labeled Compounds |
| HY-138622S1 | 24:0 Lyso PC-d4 | 2483831-13-4 | Isotope-Labeled Compounds |
| HY-138623 | GSK789 | 2540591-06-6 | Reference compound |
| HY-138625 | LOX-IN-3 | 2409963-83-1 | Reference compound |
| HY-138625A | LOX-IN-3 (dihydrochloride) | 2409964-23-2 | Reference compound |
| HY-138625B | LOX-IN-3 (dihydrochloride monohydrate) | 2414974-55-1 | Reference compound |
| HY-138626 | ACH-000143 | 2225836-30-4 | Reference compound |
| HY-138627 | AST5902 | 2412155-74-7 | Reference compound |
| HY-138627A | AST5902 (trimesylate) | 2929417-90-1 | Reference compound |
| HY-138627AR | AST5902 (trimesylate) (Standard) | 2929417-90-1 | Reference Standards |
| HY-138627B | AST5902 (mesylate) | 2412155-75-8 | Reference compound |
| HY-13863 | Hydroxy-Dynasore | 1256493-34-1 | Reference compound |
| HY-138630 | AG-270 | 2201056-66-6 | Reference compound |
| HY-138632 | PROTAC BRD4 Degrader-9 | 2417370-42-2 | ADC Related |
| HY-138633 | PROTAC BRD4 Degrader-10 | 2417370-49-9 | ADC Related |
| HY-138634 | PROTAC BRD4 Degrader-11 | | ADC Related |
| HY-138635 | PROTAC BRD4 Degrader-12 | 2417370-90-0 | ADC Related |
| HY-138636 | PROTAC BRD4 Degrader-13 | 2417370-71-7 | ADC Related |
| HY-138637 | PROTAC BRD4 Degrader-14 | | Reference compound |
| HY-138638 | Cross-linked dextran LH 20 | 9041-37-6 | Reference compound |
| HY-138639 | PW0787 | 2624131-45-7 | Reference compound |
| HY-13864 | PF-4989216 | 1276553-09-3 | Reference compound |
| HY-138641 | Bavdegalutamide | 2222112-77-6 | Reference compound |
| HY-138642 | Vepdegestrant | 2229711-68-4 | Reference compound |
| HY-138642A | (Rac)-Vepdegestrant | 2229711-08-2 | Reference compound |
| HY-138643 | Cl-NQTrp | 185351-23-9 | Reference compound |
| HY-138645 | 5-Iminodaunorubicin | 72983-78-9 | Reference compound |
| HY-138645A | 5-Iminodaunorubicin (hydrochloride) | 67324-99-6 | Reference compound |
| HY-138646 | Poly(deoxyadenylic-thymidylic) acid (sodium) | 86828-69-5 | Biochemical Assay Reagents |
| HY-138647 | TGP-377/421 | 16752-89-9 | Reference compound |
| HY-138648 | PB1 | 188714-28-5 | Reference compound |
| HY-138649 | PB2 | 914940-24-2 | Reference compound |
| HY-13865 | P 22077 | 1247819-59-5 | Reference compound |
| HY-138650 | Monocaprylin | 26402-26-6 | Reference compound |
| HY-138651 | PAB-Val-Lys-Boc | 1432969-86-2 | ADC Related |
| HY-138652 | L-Histidine benzyl ester (bistosylate) | 24593-59-7 | Reference compound |
| HY-138653 | Lipase Substrate | 195833-46-6 | Reference compound |
| HY-138655 | RapiFluor-MS | 1429047-69-7 | Reference compound |
| HY-138657 | NCGC00378430 | 920650-00-6 | Reference compound |
| HY-138658 | Janelia Fluor® 526, SE | | Dye Reagents |
| HY-138659 | Janelia Fluor® 646, Tetrazine | 2042192-00-5 | Dye Reagents |
| HY-13866 | Ro 31-8220 (mesylate) | 138489-18-6 | Reference compound |
| HY-138660 | HM Janelia Fluor® 526, SE | 2376841-30-2 | Dye Reagents |
| HY-138665 | HHS-0701 | 2851993-91-2 | Reference compound |
| HY-138668 | JW-65 | 2763378-71-6 | Reference compound |
| HY-138669 | C004019 | 2417159-57-8 | Reference compound |
| HY-13866A | Ro 31-8220 | 125314-64-9 | Reference compound |
| HY-13867 | Bisindolylmaleimide I | 133052-90-1 | Reference compound |
| HY-138671 | DprE1-IN-4 | 2419160-96-4 | Reference compound |
| HY-138678 | (R,S,S)-VH032 | 2230826-33-0 | Reference compound |
| HY-138678B | (S,R,R)-VH032 | 2489876-59-5 | Reference compound |
| HY-138679 | Aberrant tau ligand 2 | 2417159-58-9 | Reference compound |
| HY-13867A | Bisindolylmaleimide I (hydrochloride) | 176504-36-2 | Reference compound |
| HY-13868 | SCH-53870 | 188480-50-4 | Reference compound |
| HY-138682 | STING-IN-2 | 346691-38-1 | Reference compound |
| HY-138683 | STING-IN-3 | 2244881-69-2 | Reference compound |
| HY-138684 | MRTX9768 | 2629314-68-5 | Reference compound |
| HY-138684A | MRTX9768 (hydrochloride) | | Reference compound |
| HY-138686 | GPR30 agonist-1 | 415919-74-3 | Reference compound |
| HY-138687 | Nirmatrelvir | 2628280-40-8 | Reference compound |
| HY-138687R | Nirmatrelvir (Standard) | 2628280-40-8 | Reference Standards |
| HY-138687S | Nirmatrelvir-d9 | 2861202-76-6 | Isotope-Labeled Compounds |
| HY-138687S1 | Nirmatrelvir-d6 | 2861202-75-5 | Isotope-Labeled Compounds |
| HY-138688 | Cinnamyl-3,4-dihydroxy-α-cyanocinnamate | 132465-11-3 | Reference compound |
| HY-138690 | Estrogen receptor modulator 6 | 787621-78-7 | Reference compound |
| HY-138691 | JQKD82 | 2410512-38-6 | Reference compound |
| HY-138691A | JQKD82 (trihydrochloride) | 2863676-87-1 | Reference compound |
| HY-138691B | JQKD82 (dihydrochloride) | 2863635-05-4 | Reference compound |
| HY-138692 | Azido-PEG4-azide | 182760-73-2 | Reference compound |
| HY-138694 | 5-Benzyloxygramine | 1453-97-0 | Reference compound |
| HY-138694R | 5-Benzyloxygramine (Standard) | 1453-97-0 | Reference Standards |
| HY-138695 | Orexin 2 Receptor Agonist 2 | 2114324-60-4 | Reference compound |
| HY-138696 | Zanzalintinib | 2367004-54-2 | Reference compound |
| HY-138697 | S65487 | 1644600-79-2 | Reference compound |
| HY-138697A | S65487 (sulfate) | 2416937-01-2 | Reference compound |
| HY-138697B | S65487 (hydrochloride) | 1644543-95-2 | Reference compound |
| HY-138698 | FT206 | 2278274-34-1 | Reference compound |
| HY-138706 | Azido-PEG8-azide | 361543-07-9 | Reference compound |
| HY-138707 | Azido-PEG7-NHS ester | | Reference compound |
| HY-138708 | Azido-PEG8-NHBoc | 2231845-12-6 | Reference compound |
| HY-138709 | Benzyl-PEG6-Ots | 129086-11-9 | Reference compound |
| HY-138710 | Benzyl-PEG7-Ots | | Reference compound |
| HY-138711 | Benzyl-PEG8-Ots | 1144113-17-6 | Reference compound |
| HY-138712 | Benzyl-PEG9-Ots | 393517-91-4 | Reference compound |
| HY-138713 | Benzyl-PEG10-Ots | | Reference compound |
| HY-138714 | Benzyl-PEG12-Ots | | Reference compound |
| HY-138715 | Benzyl-PEG4-Azido | 86770-71-0 | Reference compound |
| HY-138716 | m-PEG9-azide | 1354521-95-1 | Reference compound |
| HY-138717 | m-PEG13-azide | | Reference compound |
| HY-138718 | m-PEG14-NHS ester | | Reference compound |
| HY-138719 | m-PEG5-Propyne | 1101668-41-0 | Reference compound |
| HY-138720 | Fmoc-PEG9-NHS ester | | Reference compound |
| HY-138721 | Fmoc-PEG10-NHS ester | | Reference compound |
| HY-138722 | Mal-PEG10-Boc | | Reference compound |
| HY-138723 | Mal-PEG10-acid | | Reference compound |
| HY-138726 | Mal-PEG10-NHS ester | | Reference compound |
| HY-138727 | Mal-amido-PEG3-acid | 2055353-75-6 | Reference compound |
| HY-138728 | Mal-amido-PEG5-acid | | Reference compound |
| HY-138729 | Mal-amido-PEG3-NHS ester | 2055353-77-8 | Reference compound |
| HY-13873 | IKK-IN-1 | 406211-06-1 | Reference compound |
| HY-138730 | Mal-amido-PEG7-NHS ester | | Reference compound |
| HY-138731 | Mal-amido-PEG9-NHS ester | 2575631-92-2 | Reference compound |
| HY-138732 | m-PEG5-amino-Mal | | Reference compound |
| HY-138733 | Propargyl-PEG13-Boc | | Reference compound |
| HY-138734 | Propargyl-PEG2-NHS ester | 2512228-06-5 | Reference compound |
| HY-138735 | Propargyl-PEG13-OH | | Reference compound |
| HY-138736 | Propargyl-PEG5-Br | 1287660-83-6 | Reference compound |
| HY-138737 | Propargyl-PEG7-Br | | Reference compound |
| HY-138738 | Propargyl-PEG5-azide | 1589522-62-2 | Reference compound |
| HY-138739 | Azido-PEG10-propargyl | | Reference compound |
| HY-138740 | Azido-PEG2-propargyl | 1245006-63-6 | Reference compound |
| HY-138741 | Azido-PEG12-propargyl | 2264091-72-5 | Reference compound |
| HY-138742 | HPK1-IN-7 | 2320462-65-3 | Reference compound |
| HY-138744 | DBCO-PEG13-NHS ester | | Reference compound |
| HY-138745 | Bis-sulfone-PEG3-Azide | 1802908-01-5 | ADC Related |
| HY-138746 | EGFR-IN-15 | 2573869-16-4 | Reference compound |
| HY-138747 | Bis-sulfone-PEG4-Tetrazine | | Reference compound |
| HY-138748 | S-acetyl-PEG5-alcohol | 1000415-61-1 | Reference compound |
| HY-138749 | Biotin alkyne | 773888-45-2 | Reference compound |
| HY-138751 | limertinib | 1934259-00-3 | Reference compound |
| HY-138751A | limertinib (diTFA) | | Reference compound |
| HY-138752 | S-acetyl-PEG4-amine | 1404111-71-2 | Reference compound |
| HY-138752A | S-acetyl-PEG4-amine (TFA) | | Reference compound |
| HY-138755 | S-acetyl-PEG4-NHBoc | 1404111-70-1 | Reference compound |
| HY-138756 | PC DBCO-PEG4-NHS ester | 2055025-02-8 | Reference compound |
| HY-138758 | S-acetyl-PEG4-Thiol | | Reference compound |
| HY-138759 | Thiol-PEG3-NHBoc | 1895922-68-5 | Reference compound |
| HY-138760 | SEluc-2 | 2421112-19-6 | Dye Reagents |
| HY-138763 | Propargyl-PEG11-acid | | Reference compound |
| HY-138764 | Propargyl-PEG12-acid | | Reference compound |
| HY-138765 | Propargyl-PEG7-amine | | Reference compound |
| HY-138766 | Propargyl-PEG11-amine | | Reference compound |
| HY-138767 | AKT-IN-5 | 1402608-05-2 | Reference compound |
| HY-138769 | Azido-PEG12-alcohol | 1111239-69-0 | Reference compound |
| HY-138771 | Thalidomide-NH-PEG3-COOH | 2375283-62-6 | Reference compound |
| HY-138772 | Thalidomide-NH-PEG2-COOH | 2412056-45-0 | Reference compound |
| HY-138773 | Thalidomide-PEG5-COOH | 2688100-28-7 | Reference compound |
| HY-138774 | Thalidomide-PEG4-COOH | 2828438-28-2 | Reference compound |
| HY-138775 | Thalidomide-PEG3-COOH | 2682112-08-7 | Reference compound |
| HY-138776 | Thalidomide-Propargyne-PEG3-COOH | 2797649-54-6 | Reference compound |
| HY-138777 | Thalidomide-Propargyne-PEG2-COOH | 2797619-65-7 | Reference compound |
| HY-138778 | Thalidomide-Propargyne-PEG1-COOH | 2828438-36-2 | Reference compound |
| HY-138779 | ICCB-19 (hydrochloride) | 1803605-68-6 | Reference compound |
| HY-138780 | Thalidomide-Piperazine-PEG3-COOH | 2797619-63-5 | Reference compound |
| HY-138781 | Thalidomide-Piperazine-PEG2-COOH | 2797430-20-5 | Reference compound |
| HY-138782 | Thalidomide-Piperazine-PEG1-COOH | 2731007-11-5 | Reference compound |
| HY-138783 | Thalidomide-Piperazine-Piperidine | 2229716-11-2 | Reference compound |
| HY-138783A | Thalidomide-Piperazine-Piperidine (hydrochloride) | 2599846-44-1 | Reference compound |
| HY-138784 | Thalidomide-PEG5-NH2 | 2460263-40-3 | Reference compound |
| HY-138784A | Thalidomide-PEG5-NH2 (hydrochloride) | 2703775-06-6 | Reference compound |
| HY-138785 | Thalidomide-5-PEG4-NH2 | 2743434-16-2 | Reference compound |
| HY-138785A | Thalidomide-5-PEG4-NH2 (hydrochloride) | 2743434-24-2 | Reference compound |
| HY-138786 | Thalidomide-5-PEG3-NH2 | 2743432-13-3 | Reference compound |
| HY-138786A | Thalidomide-5-PEG3-NH2 (hydrochloride) | 2761385-81-1 | Reference compound |
| HY-138787 | Thalidomide-Piperazine-PEG3-NH2 | 2357113-68-7 | Reference compound |
| HY-138788 | Thalidomide-Piperazine-PEG2-NH2 | 2357110-14-4 | Reference compound |
| HY-138788A | Thalidomide-Piperazine-PEG2-NH2 (diTFA) | | Reference compound |
| HY-138789 | Thalidomide-Piperazine-PEG1-NH2 | 2357111-29-4 | Reference compound |
| HY-138789A | Thalidomide-Piperazine-PEG1-NH2 (diTFA) | | Reference compound |
| HY-138790 | Glutarimide-Isoindolinone-NH-PEG4-COOH | 2927334-86-7 | Reference compound |
| HY-138791 | Glutarimide-Isoindolinone-NH-PEG3-COOH | 2803819-65-8 | Reference compound |
| HY-138792 | Glutarimide-Isoindolinone-NH-PEG2-COOH | 2803827-03-2 | Reference compound |
| HY-138793 | 2-(2,6-Dioxopiperidin-3-yl)phthalimidine | 26581-81-7 | Reference compound |
| HY-138794 | XL177A | 2417089-74-6 | Reference compound |
| HY-138794A | (Rac)-XL177A | 2417089-73-5 | Reference compound |
| HY-138795 | Curcumin-β-D-glucuronide | 227466-72-0 | Reference compound |
| HY-138796 | Griseolutein A | 573-84-2 | Reference compound |
| HY-138797 | Griseolutein B | 2072-68-6 | Reference compound |
| HY-138799 | KA2507 | 1636894-46-6 | Reference compound |
| HY-138799A | KA2507 (monohydrochloride) | 2972712-63-1 | Reference compound |
| HY-138800 | Spinosad | 168316-95-8 | Natural Products |
| HY-138802 | ML089 | 1306638-12-9 | Reference compound |
| HY-138806 | PAQ | 943902-10-1 | Reference compound |
| HY-138809 | FAUC 346 | 474432-65-0 | Reference compound |
| HY-138812 | Antileishmanial agent-28 | 1135272-09-1 | Reference compound |
| HY-138813 | N-Desethyl Sunitinib (hydrochloride) | | Reference compound |
| HY-138813A | (E/Z)-N-Desethylsunitinib (hydrochloride) | 1261432-05-6 | Reference compound |
| HY-138813R | N-Desethyl Sunitinib (hydrochloride) (Standard) | | Reference Standards |
| HY-138815 | (S)-N-(1H-Indole-3-acetyl)tryptophan | 57105-53-0 | Reference compound |
| HY-138815S | (S)-N-(1H-Indole-3-acetyl)tryptophan-d4 | | Isotope-Labeled Compounds |
| HY-138816 | Nav1.7-IN-15 | 1356834-62-2 | Reference compound |
| HY-138818 | N,O-Didesmethylvenlafaxine | 135308-74-6 | Reference compound |
| HY-138819 | IMB5046 | 1001571-08-9 | Reference compound |
| HY-138820 | SW02 | 1010820-68-4 | Reference compound |
| HY-138821 | BCIP (potassium) | 102185-49-9 | Biochemical Assay Reagents |
| HY-138822 | 2,3-Diphospho-D-glyceric acid (pentasodium salt) | 102783-53-9 | Reference compound |
| HY-138825 | NCGC00188636 | 1039980-33-0 | Reference compound |
| HY-138830 | TAK-418 | 1818252-53-7 | Reference compound |
| HY-138830A | (S,S)-TAK-418 | 1818253-48-3 | Reference compound |
| HY-138831 | AES-350 | 847249-57-4 | Reference compound |
| HY-138832 | BM-1244 | 1619923-32-8 | Reference compound |
| HY-138839 | Allyphenyline (oxalate) | 1092984-08-1 | Reference compound |
| HY-138842 | DDN | 118006-14-7 | Reference compound |
| HY-138843 | FTO-IN-1 | 2243944-92-3 | Reference compound |
| HY-138843A | FTO-IN-1 (TFA) | 2797619-81-7 | Reference compound |
| HY-138844 | 3-AP-Me | 1184391-57-8 | Reference compound |
| HY-138845 | Pomalidomide-C4-NH2 | 1957236-34-8 | Reference compound |
| HY-138845A | Pomalidomide-C4-NH2 (hydrochloride) | 2162120-73-0 | Reference compound |
| HY-138846 | Thalidomide-NH-C8-NH2 | 1957236-36-0 | Reference compound |
| HY-138846A | Thalidomide-NH-C8-NH2 (hydrochloride) | 2446474-06-0 | Reference compound |
| HY-138847 | Thalidomide-O-C3-NH2 | 2509360-22-7 | Reference compound |
| HY-138847A | Thalidomide-4-O-C3-NH2 (hydrochloride) | 2913240-95-4 | Reference compound |
| HY-138848 | Thalidomide-4-O-C5-NH2 | 2307477-23-0 | Reference compound |
| HY-138848A | Thalidomide-4-O-C5-NH2 (hydrochloride) | 2419145-66-5 | Reference compound |
| HY-138849 | Thalidomide-NH-amido-C2-NH2 | 2763827-10-5 | Reference compound |
| HY-138849A | Thalidomide-NH-amido-C2-NH2 (hydrochloride) | 2983057-90-3 | Reference compound |
| HY-138850 | Thalidomide-NH-amido-C3-NH2 | 2763827-11-6 | Reference compound |
| HY-138850A | Thalidomide-NH-amido-C3-NH2 (hydrochloride) | | Reference compound |
| HY-138851 | Thalidomide-NH-amido-C5-NH2 | 2763827-12-7 | Reference compound |
| HY-138851A | Thalidomide-NH-amido-C5-NH2 (hydrochloride) | | Reference compound |
| HY-138852 | Thalidomide-NH-amido-C6-NH2 | 2763827-13-8 | Reference compound |
| HY-138852A | Thalidomide-NH-amido-C6-NH2 (hydrochloride) | | Reference compound |
| HY-138853 | Thalidomide-NH-amido-C8-NH2 | 2983057-93-6 | Reference compound |
| HY-138853A | Thalidomide-NH-amido-C8-NH2 (hydrochloride) | 2983057-94-7 | Reference compound |
| HY-138854 | Thalidomide-NH-amido-PEG1-C2-NH2 | 2983036-28-6 | Reference compound |
| HY-138854A | Thalidomide-NH-amido-PEG1-C2-NH2 (hydrochloride) | 2983036-29-7 | Reference compound |
| HY-138855 | Thalidomide-NH-amido-PEG2-C2-NH2 | 2983036-90-2 | Reference compound |
| HY-138855A | Thalidomide-NH-amido-PEG2-C2-NH2 (hydrochloride) | 2983036-91-3 | Reference compound |
| HY-138856 | Thalidomide-NH-amido-PEG3-C2-NH2 | 2983036-98-0 | Reference compound |
| HY-138856A | Thalidomide-NH-amido-PEG3-C2-NH2 (hydrochloride) | 2983036-99-1 | Reference compound |
| HY-138857 | Thalidomide-NH-amido-PEG4-C2-NH2 | 2653336-34-4 | Reference compound |
| HY-138857A | Thalidomide-NH-amido-PEG4-C2-NH2 (hydrochloride) | 2983037-00-7 | Reference compound |
| HY-138858 | Thalidomide-amido-PEG2-NH2 | 2380273-72-1 | Reference compound |
| HY-138858A | Thalidomide-amido-PEG2-NH2 (hydrochloride) | 2380273-73-2 | Reference compound |
| HY-138859 | Pomalidomide-amino-PEG4-NH2 | 2331259-44-8 | Reference compound |
| HY-138859A | Pomalidomide-amino-PEG4-NH2 (hydrochloride) | 2331259-45-9 | Reference compound |
| HY-138860 | Thalidomide-O-C11-acid | 3023879-35-5 | Reference compound |
| HY-138861 | (S,R,S)-AHPC-C1-NH2 | 2010986-20-4 | Reference compound |
| HY-138861A | (S,R,S)-AHPC-C1-NH2 (hydrochloride) | 2361120-26-3 | Reference compound |
| HY-138862 | (S,R,S)-AHPC-C1-Br | 2379404-33-6 | Reference compound |
| HY-138865 | BiCAPPA | 119662-55-4 | Reference compound |
| HY-138866 | Dimethylamiloride | 1214-79-5 | Reference compound |
| HY-138867S | N-Acetyl(mono)desethylchloroquine-d4 | 1216619-20-3 | Isotope-Labeled Compounds |
| HY-138868 | 17-Phenyl trinor prostaglandin E2 ethyl amide | 1219032-20-8 | Reference compound |
| HY-138869 | AubipyOMe | 1221591-26-9 | Reference compound |
| HY-138870 | Enzyme-IN-3 (disodium) | 122855-18-9 | Reference compound |
| HY-138871 | cPLA2α-IN-derivative 1 | 1233706-89-2 | Reference compound |
| HY-138873 | (±)-Threo-Isopropylphenidate (hydrochloride) | 1262795-94-7 | Reference compound |
| HY-138875 | Tetraacetylphytosphingosine | 13018-48-9 | Natural Products |
| HY-138877 | Phosphoglycolic acid | 13147-57-4 | Reference compound |
| HY-138877A | Phosphoglycolic acid (lithium) | | Natural Products |
| HY-138879 | CP-601927 | 357425-02-6 | Reference compound |
| HY-138879A | (Rac)-CP-601927 (hydrochloride) | 230615-01-7 | Reference compound |
| HY-138879B | CP-601932 | 357425-68-4 | Reference compound |
| HY-138880 | 2′,3′-Di-O-acetylguanosine | 42167-65-7 | Oligonucleotides |
| HY-138881 | Lenalidomide-6-F | 2468780-87-0 | Reference compound |
| HY-138882 | Lenalidomide-4-aminomethyl | 790652-68-5 | Reference compound |
| HY-138882A | Lenalidomide-4-aminomethyl (hydrochloride) | 444289-05-8 | Reference compound |
| HY-138885 | Tryptamine guanosine carbamate | 1414808-96-0 | Oligonucleotides |
| HY-138886 | RL5a | 133671-66-6 | Reference compound |
| HY-138887 | Decyl maltose neopentyl glycol | 1257852-99-5 | Reference compound |
| HY-138889 | (8Z,14Z)-Eicosadienoic acid | 135498-07-6 | Reference compound |
| HY-138896 | (9E,11E)-9-Nitro-9,11-octadecadienoic acid | 1417651-32-1 | Reference compound |
| HY-138903 | L-Homocysteic acid | 14857-77-3 | Peptides |
| HY-138905 | S-15176 (difumarate) | 148913-55-7 | Biochemical Assay Reagents |
| HY-138906 | 25C-NBF (hydrochloride) | 1539266-21-1 | Reference compound |
| HY-138912 | Cho-Arg (TFA) | 1609010-56-1 | Biochemical Assay Reagents |
| HY-138913 | 2H-Cho-Arg (TFA) | 1609010-59-4 | Biochemical Assay Reagents |
| HY-138916 | PF-06672131 | 1621002-27-4 | Reference compound |
| HY-13892 | Dovitinib (dilactic acid) | 852433-84-2 | Reference compound |
| HY-138931 | TBK1/IKKε-IN-6 | 2306877-20-1 | Reference compound |
| HY-138933 | (±)-Geosmin | 16423-19-1 | Reference compound |
| HY-138935 | Iclepertin | 1421936-85-7 | Reference compound |
| HY-138936 | SSK1 | 2629250-69-5 | Reference compound |
| HY-138937 | NDB | 1660153-08-1 | Reference compound |
| HY-138939 | 5-LOX-IN-2 | 179691-97-5 | Reference compound |
| HY-13894 | Tyrphostin AG1296 | 146535-11-7 | Reference compound |
| HY-138940 | 3-Methoxy PCE (hydrochloride) | 1797121-52-8 | Reference compound |
| HY-138941 | Octaethylene glycol monododecyl ether | 3055-98-9 | Reference compound |
| HY-138943 | 5-Fluorouridine 5'-O-β-D-galactopyranoside | 149965-92-4 | Reference compound |
| HY-138944 | SGLT1/2-IN-1 | 1673514-65-2 | Reference compound |
| HY-138945 | SYY-B085-1 | 2379416-47-2 | Reference compound |
| HY-138946 | XY028-140 | 2229974-83-6 | Reference compound |
| HY-138947 | KB-R7943 | 182004-64-4 | Reference compound |
| HY-13895 | WHI-P154 | 211555-04-3 | Reference compound |
| HY-138951 | AY77 | 1835734-92-3 | Peptides |
| HY-138953 | Epiboxidine | 188895-96-7 | Reference compound |
| HY-138953A | Epiboxidine (hydrochloride) | 862909-67-9 | Reference compound |
| HY-138956 | MAY0132 | 1895861-88-7 | Reference compound |
| HY-138958 | HT1171 | 192880-96-9 | Reference compound |
| HY-13896 | PD168393 | 194423-15-9 | Reference compound |
| HY-138960 | 6-Chloro-3-indolyl α-D-galactopyranoside | 198402-61-8 | Biochemical Assay Reagents |
| HY-138961 | ER-27319 | 201010-95-9 | Reference compound |
| HY-138962 | κ-Carrageenan | 11114-20-8 | Natural Products |
| HY-138965A | Pomalidomide-5-C2-NH2 (hydrochloride) | | Reference compound |
| HY-138967 | BRF110 | 2095489-35-1 | Reference compound |
| HY-138969 | (±)10(11)-EDP ethanolamide | 2123484-71-7 | Reference compound |
| HY-13897 | CNX-2006 | 1375465-09-0 | Reference compound |
| HY-138970 | (±)19(20)-EDP ethanolamide | 2123485-34-5 | Reference compound |
| HY-138971 | (±)17(18)-EpETE-ethanolamide | 2123491-23-4 | Reference compound |
| HY-138973 | Neramexane | 219810-59-0 | Reference compound |
| HY-138973A | Neramexane (mesylate) | 457068-92-7 | Reference compound |
| HY-138978 | MF-095 | 2241021-89-4 | Reference compound |
| HY-138979 | Lipoxygenin | 2247911-68-6 | Reference compound |
| HY-13898 | Taselisib | 1282512-48-4 | Reference compound |
| HY-138982 | D-2-Thiolhistidine | 1195264-93-7 | Reference compound |
| HY-138984 | GRT2932Q | 228246-34-2 | Reference compound |
| HY-138985 | CAY10568 | 22913-17-3 | Natural Products |
| HY-138989 | 15-LOX-1 inhibitor 1 | 2349374-37-2 | Reference compound |
| HY-138990 | GK563 | 2351820-19-2 | Reference compound |
| HY-138992 | 2,3-Indolobetulin | 2365493-59-8 | Reference compound |
| HY-138993 | NNMT-IN-6 | 2368247-39-4 | Reference compound |
| HY-138993A | NNMT-IN-6 (hydrochloride) | 3031756-18-7 | Reference compound |
| HY-138995 | IMP-1710 | 2383117-96-0 | Reference compound |
| HY-138996 | GLP-1 receptor agonist 8 | 2401892-86-0 | Reference compound |
| HY-138997 | MBX-102 acid | 23953-39-1 | Reference compound |
| HY-139001 | JKE-1716 | 2421118-05-8 | Reference compound |
| HY-139002 | CYP4Z1-IN-2 | 2428734-45-4 | Reference compound |
| HY-139003S | 4'-Hydroxywarfarin-d4 | 94820-63-0 | Isotope-Labeled Compounds |
| HY-139004 | SGC-CK2-1 | 2470424-39-4 | Reference compound |
| HY-139005 | BODIPY aminoacetaldehyde diethyl acetal | 247069-93-8 | Reference compound |
| HY-139006 | N-Oleoyl glutamine | 247150-73-8 | Peptides |
| HY-139007 | BLT-4 | 251917-79-0 | Reference compound |
| HY-139008 | RC363 | 2584411-86-7 | Reference compound |
| HY-139009 | HA15-Biotin | 1965310-52-4 | Reference compound |
| HY-13901 | GANT 61 | 500579-04-4 | Reference compound |
| HY-139010 | Merafloxacin | 91188-00-0 | Reference compound |
| HY-139011 | IV-361 | 2055741-39-2 | Reference compound |
| HY-139012 | RC574 | 2584411-87-8 | Reference compound |
| HY-139014 | N-ε-propargyloxycarbonyl-L-lysine | 1215204-46-8 | Dye Reagents |
| HY-139015 | 5-Aza-4'-thio-2'-deoxycytidine | 169514-76-5 | Reference compound |
| HY-139017 | TLR7/8 agonist 4 | 2388520-33-8 | Reference compound |
| HY-139017A | TLR7/8 agonist 4 (TFA) | 2388520-34-9 | Reference compound |
| HY-139018 | TLR7/8 agonist 4 hydroxy-PEG10-acid | 2388520-17-8 | ADC Related |
| HY-139018A | TLR7/8 agonist 4 hydroxy-PEG10-acid (hydrochloride) | 2388520-36-1 | ADC Related |
| HY-139019 | ACAT-IN-2 | 199984-55-9 | Reference compound |
| HY-13902 | Berzosertib | 1232416-25-9 | Reference compound |
| HY-139020 | ACAT-IN-3 | 454203-25-9 | Reference compound |
| HY-139021 | ACAT-IN-4 | 454203-56-6 | Reference compound |
| HY-139021A | ACAT-IN-4 (hydrochloride) | 199984-46-8 | Reference compound |
| HY-139022 | ACAT-IN-5 | 199983-93-2 | Reference compound |
| HY-139023 | ACAT-IN-6 | 454203-45-3 | Reference compound |
| HY-139024 | ACAT-IN-7 | 199984-38-8 | Reference compound |
| HY-139025 | ACAT-IN-8 | 199984-35-5 | Reference compound |
| HY-139026 | ACAT-IN-9 | 199984-40-2 | Reference compound |
| HY-139027 | ACAT-IN-10 | 454203-40-8 | Reference compound |
| HY-139027A | ACAT-IN-10 (dihydrochloride) | 199983-77-2 | Reference compound |
| HY-139029 | 3-O-Acetylbetulin aldehyde | 27570-21-4 | Natural Products |
| HY-139030 | 28-O-Acetylbetulin | 27686-35-7 | Natural Products |
| HY-139031 | ALDH1A2-IN-1 | 2204229-64-9 | Reference compound |
| HY-139032 | CM121 | 2204230-40-8 | Reference compound |
| HY-139035 | CRHR1 antagonist 1 | 276890-57-4 | Reference compound |
| HY-139036 | Dicyanocobinamide | 27792-36-5 | Reference compound |
| HY-139037 | 8-Aminoguanine | 28128-41-8 | Reference compound |
| HY-139038 | TDRL-X80 | 292065-64-6 | Reference compound |
| HY-139039 | BSJ-4-116 | 2519823-34-6 | Reference compound |
| HY-13904 | Flumatinib | 895519-90-1 | Reference compound |
| HY-139040 | 2-(Tetradecylthio)acetic acid | 2921-20-2 | Reference compound |
| HY-139041 | Palmitoylcholine (chloride) | 2932-74-3 | Reference compound |
| HY-139043 | 6-B345TTQ | 297157-87-0 | Reference compound |
| HY-139044 | VU6000918 | 2101737-32-8 | Reference compound |
| HY-139045 | 2,4-DMA (hydrochloride) | 33189-36-5 | Reference compound |
| HY-139047 | SW157765 | 332063-87-3 | Reference compound |
| HY-139048 | Fluoroethylnormemantine | 1639210-26-6 | Reference compound |
| HY-139048A | Fluoroethylnormemantine (hydrochloride) | 1639210-25-5 | Reference compound |
| HY-13904S | Flumatinib-d3 | | Isotope-Labeled Compounds |
| HY-13905 | Flumatinib (mesylate) | 895519-91-2 | Reference compound |
| HY-139052 | III-31-C | 398515-96-3 | Reference compound |
| HY-139054 | 4'-Methoxyflavone | 4143-74-2 | Natural Products |
| HY-139055 | NCTT-956 | 438575-88-3 | Reference compound |
| HY-139056 | SU0268 | 2210228-45-6 | Reference compound |
| HY-139058 | 23-epi-26-Deoxyactein | 501938-01-8 | Natural Products |
| HY-139058R | 23-epi-26-Deoxyactein (Standard) | 501938-01-8 | Reference Standards |
| HY-139059 | ERD03 | 1377897-01-2 | Reference compound |
| HY-13906 | Largazole | 1009815-87-5 | Natural Products |
| HY-139060 | Bis-PEG12-endo-BCN | | Reference compound |
| HY-139061 | Palmitoyl 3-carbacyclic phosphatidic acid | 476310-22-2 | Reference compound |
| HY-139062 | C6 Urea Ceramide | 486991-52-0 | Reference compound |
| HY-139063 | 16-Phenoxy tetranor prostaglandin F2α | 51705-19-2 | Reference compound |
| HY-139064 | NPBA | 524033-40-7 | Reference compound |
| HY-139065 | AMPC | 2254434-33-6 | Reference compound |
| HY-139066 | Punicic acid | 544-72-9 | Natural Products |
| HY-139067 | 25(S)-27-Hydroxy cholesterol | 56845-83-1 | Reference compound |
| HY-139068 | Ibuprofen arginine | 57469-82-6 | Reference compound |
| HY-139069 | p-Nitrophenyl galacto-N-bioside | 59837-14-8 | Biochemical Assay Reagents |
| HY-13907 | TCS 359 | 301305-73-7 | Reference compound |
| HY-139070 | D-Glyceric acid | 6000-40-4 | Natural Products |
| HY-139070A | D-Glyceric acid (sodium) | 109175-64-6 | Natural Products |
| HY-139071 | Boc-D-Leu-Osu | 60111-76-4 | Reference compound |
| HY-139076 | Menin-MLL inhibitor 19 | 2360487-93-8 | Reference compound |
| HY-139077 | SCD1 inhibitor-3 | 1282606-48-7 | Reference compound |
| HY-139078 | Furosine (dihydrochloride) | 157974-36-2 | Reference compound |
| HY-139081 | GDC-0310 | 1788063-52-4 | Reference compound |
| HY-139084 | XL388-C2-NH2 | 2250061-94-8 | Reference compound |
| HY-139085A | XL388-C2-amide-PEG9-NH2 (hydrochloride) | | Reference compound |
| HY-139085B | XL388-C2-amide-PEG9-NH2 (TFA) | | Reference compound |
| HY-139087 | Erastin2 | 1695533-44-8 | Reference compound |
| HY-139088 | PAD3-IN-1 | 1671088-84-8 | Reference compound |
| HY-139089 | (Z)-Entacapone | 145195-63-7 | Reference compound |
| HY-139089S | (Z)-Entacapone-d10 | | Isotope-Labeled Compounds |
| HY-13909 | RGFP966 | 1357389-11-7 | Reference compound |
| HY-139090 | 3-Oxobetulin acetate | 136587-07-0 | Reference compound |
| HY-139091 | FEMA 4774 | 1359963-68-0 | Reference compound |
| HY-139092 | IL-4-inhibitor-1 | 1332184-63-0 | Reference compound |
| HY-139093 | Paracetamol-cysteine | 53446-10-9 | Peptides |
| HY-139093A | Paracetamol-cysteine (TFA) | 1331891-93-0 | Reference compound |
| HY-139094 | A6770 | 1331754-16-5 | Reference compound |
| HY-139095 | Cipamfylline | 132210-43-6 | Reference compound |
| HY-139096 | 4-Pentadecylbenzylphosphonic acid | 1306684-90-1 | Reference compound |
| HY-139097 | C12-Sphingosine | 128427-86-1 | Reference compound |
| HY-139098 | 7-Methyl-diguanosine triphosphate | 62828-64-2 | Oligonucleotides |
| HY-139099 | Diguanosine 5′-triphosphate | 6674-45-9 | Oligonucleotides |
| HY-139099A | Diguanosine 5′-triphosphate (lithium) | | Biochemical Assay Reagents |
| HY-13910 | Tenofovir | 147127-20-6 | Reference compound |
| HY-139100 | N7-Methyl-guanosine-5'-triphosphate-5'-adenosine | 62828-63-1 | Oligonucleotides |
| HY-139100B | m7G(5')ppp(5')A (diammonium) | 75252-10-7 | Oligonucleotides |
| HY-139101 | Guanosine 5'-triphosphate-5'-adenosine | 10527-47-6 | Oligonucleotides |
| HY-139101A | Guanosine 5'-triphosphate-5'-adenosine (triammonium) | | Oligonucleotides |
| HY-139102 | Thailanstatin B | 1426953-23-2 | Reference compound |
| HY-139103 | Thailanstatin C | 1426953-24-3 | Natural Products |
| HY-139104 | Thailanstatin D | 1609105-89-6 | Natural Products |
| HY-139105 | 20-O-Demethyl-AP3 | 72902-38-6 | Reference compound |
| HY-139106 | N-Demethylansamitocin P-3 | 77353-69-6 | Natural Products |
| HY-139107 | Biotin-PEG4-SS-azide | | ADC Related |
| HY-139108 | DCH36_06 | 593273-05-3 | Reference compound |
| HY-139109 | IR-783 | 115970-66-6 | Dye Reagents |
| HY-13910A | Tenofovir (hydrate) | 206184-49-8 | Reference compound |
| HY-13910AR | Tenofovir (hydrate) (Standard) | 206184-49-8 | Reference Standards |
| HY-13910B | Tenofovir (maleate) | 1236287-04-9 | Reference compound |
| HY-13910R | Tenofovir (Standard) | 147127-20-6 | Reference Standards |
| HY-13911 | Hydroxyfasudil | 105628-72-6 | Reference compound |
| HY-139111 | Oxocarbazate | 1014405-03-8 | Reference compound |
| HY-139112 | Leukotriene B4 dimethyl amide | 83024-92-4 | Reference compound |
| HY-139114 | 20-Carboxyarachidonic acid | 79551-84-1 | Natural Products |
| HY-139116 | Piperidine-4-sulfonic acid | 72450-62-5 | Reference compound |
| HY-139117 | 6,2′,4′-Trimethoxyflavone | 720675-90-1 | Reference compound |
| HY-139118 | NSC308848 | 69408-82-8 | Reference compound |
| HY-139119 | Prostaglandin F2α dimethyl amide | 68192-15-4 | Reference compound |
| HY-13911A | Hydroxyfasudil (hydrochloride) | 155558-32-0 | Reference compound |
| HY-13912 | IWP-2 | 686770-61-6 | Reference compound |
| HY-139120 | 19(R)-hydroxy Prostaglandin E2 | 64625-54-3 | Reference compound |
| HY-139121 | 15(R)-17-Phenyl trinor Prostaglandin F2α | 41639-71-8 | Reference compound |
| HY-139122 | Butyrylhydroxamic acid | 4312-91-8 | Reference compound |
| HY-139124 | 15(R)-15-Methyl Prostaglandin F2α | 35864-81-4 | Reference compound |
| HY-139125 | DCHC | 302953-06-6 | Reference compound |
| HY-139126 | (±)-Muscarine (chloride) | 2936-25-6 | Reference compound |
| HY-139128 | α-Methyl-DL-methionine | 2749-07-7 | Peptides |
| HY-139129 | N-(3-Pyridyl)indomethacinamide | 261766-29-4 | Reference compound |
| HY-13912G | IWP-2 (GMP) | 686770-61-6 | GMP Small Molecules |
| HY-13913 | NS-398 | 123653-11-2 | Reference compound |
| HY-139131 | Australine (hydrochloride) | 186766-07-4 | Reference compound |
| HY-139132 | Met-F-AEA | 166100-39-6 | Reference compound |
| HY-139133 | L-NASPA | 155915-46-1 | Biochemical Assay Reagents |
| HY-139134 | S-2E | 155730-92-0 | Reference compound |
| HY-139135 | Methyl-L-NIO (hydrochloride) | 150403-96-6 | Reference compound |
| HY-139137 | N-Acetyl-S-geranylgeranyl-L-cysteine | 139332-94-8 | Reference compound |
| HY-139138 | Naphthofluorescein di-(β-D-galactopyranoside) | 133551-98-1 | Biochemical Assay Reagents |
| HY-139139 | MAT2A inhibitor 3 | 2439271-82-4 | Reference compound |
| HY-13914 | Roniciclib | 1223498-69-8 | Reference compound |
| HY-139140 | BAY R3401 | 100276-03-7 | Reference compound |
| HY-139142 | Simufilam | 1224591-33-6 | Reference compound |
| HY-139142A | Simufilam (dihydrochloride) | 2480226-06-8 | Reference compound |
| HY-139142B | Simufilam (hydrochloride) | 2480226-07-9 | Reference compound |
| HY-139143 | WWL154 | 1338574-93-8 | Reference compound |
| HY-139144 | YM-08 | 812647-88-4 | Reference compound |
| HY-139145 | Etbicyphat | 1005-93-2 | Reference compound |
| HY-139145S | Etbicyphat-13C3 | | Isotope-Labeled Compounds |
| HY-139147 | iHCK-37 | 516478-09-4 | Reference compound |
| HY-139148 | UMB298 | 2266569-73-5 | Reference compound |
| HY-139149 | NiCur | 2674753-39-8 | Reference compound |
| HY-139149A | (E/Z)-NiCur | 63476-70-0 | Reference compound |
| HY-13915 | NSC348884 | 81624-55-7 | Reference compound |
| HY-139150 | EZH2-IN-4 | 2088132-99-2 | Reference compound |
| HY-139156 | SK-575 | 2523016-96-6 | Reference compound |
| HY-139158 | Ainuovirine | 1097628-00-6 | Reference compound |
| HY-139161 | Penflufen | 494793-67-8 | Reference compound |
| HY-139161R | Penflufen (Standard) | 494793-67-8 | Reference Standards |
| HY-139162 | BGN3 | 1151762-33-2 | Reference compound |
| HY-139163 | BGSN3 | 2996069-91-9 | Reference compound |
| HY-139165 | AT-9010 | 1261253-79-5 | Reference compound |
| HY-139165A | AT-9010 (tetrasodium) | 1621884-18-1 | Reference compound |
| HY-139165B | AT-9010 (triethylamine) | 2648089-95-4 | Reference compound |
| HY-139166 | N-Palmitoyl-L-aspartate | 1782-17-8 | Reference compound |
| HY-139167 | 7-Hydroxywarfarin | 17834-03-6 | Reference compound |
| HY-13917 | PND-1186 | 1061353-68-1 | Reference compound |
| HY-139170 | CAY10746 | 2247240-76-0 | Reference compound |
| HY-139171 | F092 | 2250261-59-5 | Reference compound |
| HY-139172 | MD001 | 2254605-76-8 | Reference compound |
| HY-139175 | ZLY032 | 2314465-67-1 | Reference compound |
| HY-139177 | PPARα agonist 2 | 2376590-40-6 | Reference compound |
| HY-139179 | STING agonist-14 | 2411100-70-2 | Reference compound |
| HY-13917A | PND-1186 (hydrochloride) | 1356154-94-3 | Reference compound |
| HY-13918 | Etimizol | 64-99-3 | Reference compound |
| HY-139180 | PRGL493 | 2479378-45-3 | Reference compound |
| HY-139181 | NR160 | 2484895-50-1 | Reference compound |
| HY-139182 | MAGL-IN-3 | 2514-37-6 | Reference compound |
| HY-139185 | PROTAC ERRα Degrader-3 | 2306388-65-6 | Reference compound |
| HY-139186 | PROTAC KRAS G12C degrader-1 | 2984236-79-3 | Reference compound |
| HY-139188 | CC260 | 2411088-26-9 | Reference compound |
| HY-139189 | DHODH-IN-16 | 2511248-11-4 | Reference compound |
| HY-13919 | Napabucasin | 83280-65-3 | Reference compound |
| HY-139192 | Brophenexin | 2243506-33-2 | Reference compound |
| HY-139192A | Brophenexin (free base) | 1353979-43-7 | Reference compound |
| HY-139193 | TH1760 | 2567914-01-4 | Reference compound |
| HY-139196 | ThioLox | 1202193-89-2 | Reference compound |
| HY-139199 | 4-Hydroxyphenylbutazone | 16860-43-8 | Reference compound |
| HY-139199R | 4-Hydroxyphenylbutazone (Standard) | 16860-43-8 | Reference Standards |
| HY-139200 | DOTMA | 104872-42-6 | Oligonucleotides |
| HY-139201 | Poly-D-lysine hydrobromide (MW 30000-70000) | 27964-99-4 | Reference compound |
| HY-139201A | Poly-D-lysine hydrobromide (MW 70000-150000) | 27964-99-4 | Reference compound |
| HY-139201B | Poly-D-lysine hydrobromide (MW 84000) | 27964-99-4 | Reference compound |
| HY-139201C | Poly-D-lysine hydrobromide (MW 1000-5000) | 27964-99-4 | Biochemical Assay Reagents |
| HY-139201D | Poly-D-lysine hydrobromide (MW 4000-15000) | 27964-99-4 | Biochemical Assay Reagents |
| HY-139201E | Poly-D-lysine hydrobromide (MW 150000-300000) | 27964-99-4 | Biochemical Assay Reagents |
| HY-139201H | Poly-D-lysine hydrobromide (MW ≥300000) | 27964-99-4 | Biochemical Assay Reagents |
| HY-139202 | XVA143 | 264275-77-6 | Reference compound |
| HY-139203 | IL-17 modulator 3 | 2467731-88-8 | Reference compound |
| HY-139204 | BMS-986242 | 1923844-48-7 | Reference compound |
| HY-139205 | BMT-297376 | 2251031-81-7 | Reference compound |
| HY-139206 | LY3509754 | 2452464-73-0 | Reference compound |
| HY-139211 | Difluorinated Curcumin | 1170354-22-9 | Reference compound |
| HY-139212 | IXA6 | 1021106-40-0 | Reference compound |
| HY-139214 | IXA4 | 1185329-96-7 | Reference compound |
| HY-139218 | (S,R,S)-AHPC-Me-C6-NH2 | 2411422-49-4 | Reference compound |
| HY-139223 | pEBOV-IN-1 | 1252187-41-9 | Reference compound |
| HY-139227 | Thalidomide 4'-oxyacetamide-C1-PEG3-C3-amine (hydrochloride) | 2564466-93-7 | Reference compound |
| HY-139230 | OLHHA | 1258011-97-0 | Reference compound |
| HY-139231 | 1-Palmitoyl-2-formylyl PC | 2194571-25-8 | Reference compound |
| HY-139232 | 17(R)-Resolvin D3 | 1427475-53-3 | Reference compound |
| HY-139233 | 25P-NBOMe (hydrochloride) | 1539266-43-7 | Reference compound |
| HY-139235S | N-Linolenoylethanolamine-d4 | 1451194-68-5 | Isotope-Labeled Compounds |
| HY-139237 | PCEEA (hydrochloride) | 1798021-89-2 | Reference compound |
| HY-139239 | Bipiperidinyl 4-ANPP | 2515737-24-1 | Reference compound |
| HY-139240 | Cannabidihexol | 2552798-21-5 | Reference compound |
| HY-139244S | Norgestimate-d6 | 1263194-12-2 | Isotope-Labeled Compounds |
| HY-139245 | MC-Ala-Ala-Asn-PAB | 1638970-44-1 | ADC Related |
| HY-139246 | α-Pyrrolidinocyclohexanophenone (hydrochloride) | 1803168-16-2 | Reference compound |
| HY-139247 | pNPS-DHA | 2454246-25-2 | Reference compound |
| HY-139248 | Paclitaxel octadecanedioate | 2089211-45-8 | Reference compound |
| HY-13925 | PD0166285 | 185039-89-8 | Reference compound |
| HY-139250 | 1-Myristin-2-Olein-3-Butyrin | 1122578-93-1 | Reference compound |
| HY-139251 | 1-Myristoyl-2-palmitoyl-3-butyryl-rac-glycerol | 1122578-89-5 | Reference compound |
| HY-139252 | Anticancer agent 225 | 2251753-61-2 | Reference compound |
| HY-139253 | MRIA9 | 2750707-05-0 | Reference compound |
| HY-139254 | Indirubin-3′-oxime | 667463-82-3 | Reference compound |
| HY-13925A | PD0166285 (dihydrochloride) | 212391-63-4 | Reference compound |
| HY-139261 | 1-Deoxysphingosine (m18:1(14Z)) | 2190487-94-4 | Natural Products |
| HY-139262 | FNC-TP | 2457357-99-0 | Reference compound |
| HY-139262A | FNC-TP (trisodium) | | Reference compound |
| HY-139264 | Cloniprazepam | 1998158-84-1 | Reference compound |
| HY-139265 | 3,4-Mdma tert-butyl carbamate | 1228259-70-8 | Reference compound |
| HY-139266 | 7'-Methoxy NABUTIE | 1438278-55-7 | Reference compound |
| HY-139267 | (±)19(20)-EpDTE | 1359721-83-7 | Reference compound |
| HY-139268 | (±)7(8)-EpDTE | 1616607-36-3 | Reference compound |
| HY-13927 | Acetildenafil | 831217-01-7 | Reference compound |
| HY-139272 | Eicosapentaenoyl 1-propanol-2-amide | 1638355-66-4 | Reference compound |
| HY-139276 | Pal-Glu(OSu)-OH | 294855-91-7 | Reference compound |
| HY-139279 | Zotizalkib | 2648641-36-3 | Reference compound |
| HY-13927R | Acetildenafil (Standard) | 831217-01-7 | Reference Standards |
| HY-13928 | GW0742 | 317318-84-6 | Reference compound |
| HY-139282 | C16 1-Deoxyceramide (m18:1/16:0) | 1246298-56-5 | Reference compound |
| HY-139283 | C24:1 1-Deoxyceramide (m18:1/24:1(15Z)) | 1246298-58-7 | Reference compound |
| HY-139284 | C24:1 Dihydro 1-deoxyceramide (m18:0/24:1) | 1246298-60-1 | Reference compound |
| HY-139285 | Arachidonic acid-alkyne | 1219038-32-0 | Reference compound |
| HY-139286 | Photoclick sphingosine | 1823021-14-2 | Reference compound |
| HY-139287 | M1002 | 823830-85-9 | Reference compound |
| HY-139289 | ART812 | 2607138-82-7 | Reference compound |
| HY-139289S | ART899 | 2607139-85-3 | Isotope-Labeled Compounds |
| HY-13929 | Isocarboxazid | 59-63-2 | Reference compound |
| HY-139290 | RGLS4326 | 2229964-07-0 | Oligonucleotides |
| HY-139290A | RGLS4326 (sodium) | | Oligonucleotides |
| HY-139292 | Fmoc-NH-PEG6-alcohol | 1884208-29-0 | Reference compound |
| HY-139293 | PF-07059013 | 2435610-93-6 | Reference compound |
| HY-139294 | PROTAC BRD4 Degrader-15 | 2417370-67-1 | Reference compound |
| HY-139296 | PP2A Cancerous-IN-1 | 1403933-79-8 | Reference compound |
| HY-139297 | SCR130 | 2377858-38-1 | Reference compound |
| HY-139298 | L319 | 1351586-50-9 | Oligonucleotides |
| HY-13929R | Isocarboxazid (Standard) | 59-63-2 | Reference Standards |
| HY-13930 | Miquelianin | 22688-79-5 | Natural Products |
| HY-139300 | Epitinib | 1203902-67-3 | Reference compound |
| HY-139300A | Epitinib (succinate) | 2252334-12-4 | Reference compound |
| HY-139301 | DDO-5936 | 2355377-13-6 | Reference compound |
| HY-139303 | LUF5771 | 1141802-49-4 | Reference compound |
| HY-139304 | PROTAC Bcl-xL ligand-1 | 3029365-95-2 | Reference compound |
| HY-139305 | CL4H6 | 2256087-35-9 | Reference compound |
| HY-139306 | BAMEA-O16B | 2490668-30-7 | Oligonucleotides |
| HY-139307 | MG-2119 | 1065500-40-4 | Reference compound |
| HY-139308 | T0467 | 859518-94-8 | Reference compound |
| HY-139309 | PROTAC Bcl-xL degrader-2 | 2920415-08-1 | Reference compound |
| HY-13930R | Miquelianin (Standard) | 22688-79-5 | Reference Standards |
| HY-139310 | GLPG2938 | 2130996-00-6 | Reference compound |
| HY-139311 | YH-53 | 1471484-62-4 | Reference compound |
| HY-139312 | L-Mannitol | 643-01-6 | Reference compound |
| HY-139312S | L-Mannitol-1-13C | | Isotope-Labeled Compounds |
| HY-139313 | NHE3-IN-2 | 92434-13-4 | Reference compound |
| HY-139314 | A2B receptor antagonist 2 | 784-90-7 | Reference compound |
| HY-139315 | PROTAC IRAK4 degrader-4 | 2360528-45-4 | Reference compound |
| HY-139316 | PROTAC IRAK4 degrader-5 | 2360530-61-4 | Reference compound |
| HY-139317 | PROTAC IRAK4 degrader-6 | 2360530-72-7 | Reference compound |
| HY-139319 | LDHA-IN-3 | 227010-33-5 | Reference compound |
| HY-139322 | PEG-8 laurate | 35179-86-3 | Reference compound |
| HY-139323 | TLR7/8-IN-1 | 2205095-75-4 | Reference compound |
| HY-139324 | Cu(II)GTSM | 68341-14-0 | Reference compound |
| HY-139325 | NHS-Modified MMAF | 1404073-10-4 | Reference compound |
| HY-139325A | NHS-Modified MMAF (TFA) | | ADC Related |
| HY-139326 | NHS-MMAF | 1404073-19-3 | Reference compound |
| HY-139327 | CDK12-IN-4 | 2651196-69-7 | Reference compound |
| HY-139328 | CDK12-IN-5 | 2651200-35-8 | Reference compound |
| HY-139329 | CDK12-IN-6 | 2651196-71-1 | Reference compound |
| HY-139330 | MGH-CP1 | 896657-58-2 | Reference compound |
| HY-139331 | 20S Proteasome-IN-1 | 858557-69-4 | Reference compound |
| HY-139332 | Pomalidomide 4'-PEG6-azide | 2624181-62-8 | Reference compound |
| HY-139333 | Pomalidomide 4'-PEG5-azide | 2624181-61-7 | Reference compound |
| HY-139334 | VH 101 phenol-alkylC6-amine (dihydrochloride) | 2564467-16-7 | Reference compound |
| HY-139335 | VH 101 phenol-alkylC4-amine (dihydrochloride) | 2564467-03-2 | Reference compound |
| HY-139336 | Pomalidomide-C5-azide | 2434629-02-2 | Reference compound |
| HY-139337 | SMCy5.5 | 2417507-09-4 | Dye Reagents |
| HY-139338 | Erlose | 13101-54-7 | Natural Products |
| HY-139339 | Pomalidomide 4'-alkylC6-azide | 2375555-72-7 | Reference compound |
| HY-139340 | Photo-lenalidomide-acid | 2363154-39-4 | Reference compound |
| HY-139341 | Pomalidomide 4'-alkylC3-azide | 2357108-05-3 | Reference compound |
| HY-139342 | CDK7-IN-4 | 2326428-25-3 | Reference compound |
| HY-139343 | Pomalidomide 4'-alkylC2-azide | 2296708-61-5 | Reference compound |
| HY-139344 | FC-11 | 2271035-37-9 | Reference compound |
| HY-139345 | (S,R,S)-AHPC-CO-C9-acid | 2172819-78-0 | Reference compound |
| HY-139346 | VX-150 | 1793080-72-4 | Reference compound |
| HY-139347 | Mazisotine | 1638588-92-7 | Reference compound |
| HY-139347A | Mazisotine (tartrate) | 2919211-45-1 | Reference compound |
| HY-139348 | PFI-90 | 53995-62-3 | Reference compound |
| HY-139349 | Finasteride carboxaldehyde | 154387-61-8 | Reference compound |
| HY-139351 | Gibberellins A4/A7 | 8030-53-3 | Reference compound |
| HY-139352 | Betamethasone 21-valerate | 2240-28-0 | Reference compound |
| HY-139352R | Betamethasone 21-valerate (Standard) | 2240-28-0 | Reference Standards |
| HY-139353 | Fmoc-Phe-Lys(Boc)-PAB | 206133-42-8 | ADC Related |
| HY-139355 | (S)-GS-621763 | 2563617-99-0 | Reference compound |
| HY-139359 | 4-Fluoro pentedrone (hydrochloride) | 2469350-88-5 | Reference compound |
| HY-13936 | 1-Methylimidazoleacetic acid | 2625-49-2 | Natural Products |
| HY-139360 | 3',4'-Methylenedioxy-N-tert-butylcathinone (hydrochloride) | 2469270-98-0 | Reference compound |
| HY-139361 | Sulfopin | 2451481-08-4 | Reference compound |
| HY-139362 | Enpp-1-IN-2 | 2378640-92-5 | Reference compound |
| HY-139363 | AB-FUBINACA isomer 2 | 2365471-64-1 | Reference compound |
| HY-139364 | mPGES1-IN-4 | 2253745-78-5 | Reference compound |
| HY-139365 | mPGES1-IN-5 | 2253745-70-7 | Reference compound |
| HY-139367 | α-Hydroxy flubromazolam | 2204237-96-5 | Reference compound |
| HY-139369 | QD394 | 2132411-21-1 | Reference compound |
| HY-13936S | 2-(1-Methyl-1H-imidazol-4-yl)acetic acid-d3 | 122380-33-0 | Isotope-Labeled Compounds |
| HY-139370 | 4-Fluoro PV9 (hydrochloride) | 2117405-40-8 | Reference compound |
| HY-139371 | 3-Desoxy-3,4-methylenedioxy pyrovalerone (hydrochloride) | 2117405-33-9 | Reference compound |
| HY-139373 | 2-(Aminomethyl)-4-methylphenol (hydrochloride) | 2044714-53-4 | Reference compound |
| HY-139374 | Zabedosertib | 1931994-81-8 | Reference compound |
| HY-139376 | FGFR1 inhibitor-2 | 2410612-08-5 | Reference compound |
| HY-139377 | 4-Methoxy-α-pyrrolidinopropiophenone (hydrochloride) | 1794760-01-2 | Reference compound |
| HY-139378 | 5-IAI (hydrochloride) | 1782044-60-3 | Reference compound |
| HY-13938 | Iretol | 487-71-8 | Reference compound |
| HY-139381 | MitoEbselen-2 (chloride) | 1638973-78-0 | Reference compound |
| HY-139382 | 2-(Isopentylamino)naphthalene-1,4-dione | 1607447-79-9 | Reference compound |
| HY-139384 | FAAH inhibitor 2 | 1450603-63-0 | Reference compound |
| HY-139386 | 15β-Travoprost | 1420791-14-5 | Reference compound |
| HY-139388 | Para-fluoro methylaminorex | 1364933-64-1 | Reference compound |
| HY-139390 | 3,4-Difluoro U-50488 (hydrochloride) | 1339332-99-8 | Reference compound |
| HY-139391 | (±)10(11)-DiHDPA | 1345275-22-0 | Reference compound |
| HY-139392S | Octanoyl-L-carnitine-d3 (chloride) | 1334532-24-9 | Isotope-Labeled Compounds |
| HY-139393 | EOS (d18:1/32:1/18:2) | 1318771-31-1 | Reference compound |
| HY-139394 | Arachidonoyl-1-thio-glycerol | 1309664-54-7 | Reference compound |
| HY-139396 | BMS-986299 | 2242952-69-6 | Reference compound |
| HY-139397 | TJ-M2010-5 | 1357471-57-8 | Reference compound |
| HY-139398 | TBI-223 | 2071265-08-0 | Reference compound |
| HY-139399 | Safimaltib | 2230273-76-2 | Reference compound |
| HY-139400 | Pociredir | 2490676-18-9 | Reference compound |
| HY-139400A | Pociredir (hydrochloride) | 2490676-19-0 | Reference compound |
| HY-139401 | FAPI-34 | 2374782-07-5 | Reference compound |
| HY-139402 | MRTX849 acid | 2561529-96-0 | Reference compound |
| HY-139403 | MRTX849 ethoxypropanoic acid | 2561529-98-2 | Reference compound |
| HY-139404 | C10 AV Ceramide (d18:1/10:0) | 1263052-40-9 | Dye Reagents |
| HY-139406 | 1,2-Dioctanoyl-sn-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) (ammonium) | 1246303-11-6 | Reference compound |
| HY-139407 | 3-C12-NBD-cholesterol | 1246303-05-8 | Dye Reagents |
| HY-139408 | 17-Oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-docosahexaenoic acid | 1233715-28-0 | Natural Products |
| HY-139409 | 2-Deoxy-D-glucose 6-phosphate | 3573-50-0 | Reference compound |
| HY-139409A | 2-Deoxy-D-glucose 6-phosphate (disodium) | 33068-19-8 | Reference compound |
| HY-13941 | 1-Naphthyl PP1 | 221243-82-9 | Reference compound |
| HY-139410 | Sodium caseinates | 9005-46-3 | Biochemical Assay Reagents |
| HY-139411 | White mineral oil | 8042-47-5 | Biochemical Assay Reagents |
| HY-139413 | β-D-Glucan | 9041-22-9 | Biochemical Assay Reagents |
| HY-139414 | Lysophosphatidylcholines | 9008-30-4 | Biochemical Assay Reagents |
| HY-139415 | Polyethylene glycol monoisotridecyl ether | 9043-30-5 | Biochemical Assay Reagents |
| HY-139417S | Docosapentaenoic acid-d5 | 1215168-70-9 | Isotope-Labeled Compounds |
| HY-139419 | Bimatoprost grenod | 1194396-71-8 | Reference compound |
| HY-13941B | 1-Naphthyl PP1 (hydrochloride) | 956025-47-1 | Reference compound |
| HY-13942 | 1-NM-PP1 | 221244-14-0 | Reference compound |
| HY-139420 | Tafluprost ethyl amide | 1185851-52-8 | Reference compound |
| HY-139420R | Tafluprost ethyl amide (Standard) | 1185851-52-8 | Reference Standards |
| HY-139421 | (Z)-16-(Ethylcarbamoylamino)hexadec-11-enoic acid | 1184844-74-3 | Reference compound |
| HY-139423 | JAK1-IN-8 | 1973485-18-5 | Reference compound |
| HY-139424 | SQ609 | 627052-25-9 | Reference compound |
| HY-139425 | Cyclo(Pro-Ala) | 65556-33-4 | Reference compound |
| HY-139426 | ML-SI3 | 891016-02-7 | Reference compound |
| HY-139426A | (rel)-ML-SI3 | 2108567-79-7 | Reference compound |
| HY-139427 | 3-Methylglutaconic acid | 5746-90-7 | Reference compound |
| HY-139427S | 3-Methylglutaconic acid-13C3 | 1255644-45-1 | Isotope-Labeled Compounds |
| HY-139428 | Hydroxydehydro Nifedipine Carboxylate | 34783-31-8 | Reference compound |
| HY-139429S | (−)-11-Hydroxy-Δ8-THC-d3 | | Isotope-Labeled Compounds |
| HY-13943 | CNX-774 | 1202759-32-7 | Reference compound |
| HY-139430 | 4-Isopropylcatechol | 2138-43-4 | Reference compound |
| HY-139431 | NAG-thiazoline | 179030-22-9 | Reference compound |
| HY-139432 | 2-(Morpholinothio)benzothiazole | 102-77-2 | Reference compound |
| HY-139433 | 6-Hydroxy etodolac | 101901-06-8 | Reference compound |
| HY-139434 | JMJD6-IN-1 | 899548-78-8 | Reference compound |
| HY-139436 | ARD-2585 | 2757422-79-8 | Reference compound |
| HY-139439 | SBI-581 | | Reference compound |
| HY-139440 | DL-Leucyl-DL-phenylalanine | 56217-82-4 | Reference compound |
| HY-139441 | DM21 | 2243689-80-5 | ADC Related |
| HY-139442 | RdRP-IN-2 | 2863657-16-1 | Reference compound |
| HY-139446 | Trimethylolpropane ethoxylate triacrylate | 28961-43-5 | Biochemical Assay Reagents |
| HY-139449 | CDK4/6-IN-5 | 2380321-50-4 | Reference compound |
| HY-13945 | NVP 231 | 362003-83-6 | Reference compound |
| HY-139451 | ELOVL6-IN-3 | 712346-06-0 | Reference compound |
| HY-139452 | PFB-FDGlu | 209540-62-5 | Reference compound |
| HY-139453 | LP-184 | 924835-67-6 | Reference compound |
| HY-139453A | LP-284 | 2412580-47-1 | Reference compound |
| HY-139458 | MDM2-IN-21 | 939981-88-1 | Reference compound |
| HY-13946 | BML-277 | 516480-79-8 | Reference compound |
| HY-139461S | 5-Acetylamino-6-formylamino-3-methyluracil-d3 | 1216442-68-0 | Isotope-Labeled Compounds |
| HY-139464 | Q134R | 2022949-46-6 | Reference compound |
| HY-139465 | Aficamten | 2364554-48-1 | Reference compound |
| HY-139466 | PF-03622905 | 1072100-15-2 | Reference compound |
| HY-139467 | PF-04577806 | 1072100-81-2 | Reference compound |
| HY-139468 | Ala-Glu-OH | 13187-90-1 | Peptides |
| HY-139474S | N-Acetyl-S-(carbamoylethyl)-L-cysteine-d3 | 1795786-57-0 | Isotope-Labeled Compounds |
| HY-139474S1 | N-Acetyl-S-(carbamoylethyl)-L-cysteine-d4 | 2714331-84-5 | Isotope-Labeled Compounds |
| HY-13948 | Angiotensin II human | 4474-91-3 | Peptides |
| HY-139480 | Poly(ethylene glycol) dithiol (Mn 3400) | 68865-60-1 | Reference compound |
| HY-139480A | Poly(ethylene glycol) dithiol (Mn 1000) | 68865-60-1 | Biochemical Assay Reagents |
| HY-139480B | Poly(ethylene glycol) dithiol (Mn 1500) | 68865-60-1 | Biochemical Assay Reagents |
| HY-139481 | TL-895 | 1415823-49-2 | Reference compound |
| HY-139482 | tri-GalNAc-COOH | 1953146-81-0 | Reference compound |
| HY-139483S | Epinephrine Sulfonic acid-d3 | 1346604-55-4 | Isotope-Labeled Compounds |
| HY-139485 | BMS-986224 | 2055200-88-7 | Reference compound |
| HY-139486 | AM-8123 | 2049973-02-4 | Reference compound |
| HY-13948A | Angiotensin II human (acetate) | 68521-88-0 | Peptides |
| HY-13948B | Angiotensin II human (TFA) | 2761969-44-0 | Peptides |
| HY-13948BS | Angiotensin II human-13C6,15N (TFA) | | Isotope-Labeled Compounds |
| HY-13948F | Biotin-Ahx-Angiotensin II human | 115102-72-2 | Peptides |
| HY-13948F1 | Angiotensin II human, FAM-labeled | | Peptides |
| HY-13949 | SRPIN340 | 218156-96-8 | Reference compound |
| HY-139491S | N-(Acetyl-d3)-S-benzyl-L-cysteine | 201404-15-1 | Isotope-Labeled Compounds |
| HY-13950 | S186 | 97759-16-5 | Reference compound |
| HY-139504 | Gamcemetinib | 1887069-10-4 | Reference compound |
| HY-139505 | N-Acetyl glufosinate-d3 (sodium) | 1356933-74-8 | Isotope-Labeled Compounds |
| HY-139506S | 1-(3-Carboxypropyl)-3,7-dimethylxanthine-d6 | 1246816-64-7 | Isotope-Labeled Compounds |
| HY-139507S | Z,Z-Dienestrol-d6 | 91297-99-3 | Isotope-Labeled Compounds |
| HY-139509S | Capsiamide-d3 | 1795031-33-2 | Isotope-Labeled Compounds |
| HY-13951 | Zenidolol (hydrochloride) | 72795-01-8 | Reference compound |
| HY-139514 | RB-3 | 2396639-11-3 | Reference compound |
| HY-139516 | AZD4694 Precursor | 1211333-20-8 | Reference compound |
| HY-139517S1 | N-Desethyl etifoxine--13C,d3 | 2747914-26-5 | Isotope-Labeled Compounds |
| HY-139519S | N-Desmethyl diphenhydramine-d3 (hydrochloride) | 1794759-12-8 | Isotope-Labeled Compounds |
| HY-13952 | TP-808 | 852821-06-8 | Reference compound |
| HY-13953 | JIB-04 | 199596-05-9 | Reference compound |
| HY-139532S | (S)-Tomoxetine-d3 (hydrochloride) | 1217703-95-1 | Isotope-Labeled Compounds |
| HY-139533 | Phosphatidylinositols, soya, sodium salts | 383907-36-6 | Reference compound |
| HY-139534 | ARI-1 | | Reference compound |
| HY-139534A | (S)-ARI-1 | 2003228-82-6 | Reference compound |
| HY-139535 | Luxeptinib | 1616428-23-9 | Reference compound |
| HY-139536 | MAT2A inhibitor 4 | 1391934-91-0 | Reference compound |
| HY-139539 | Thalidomide-5-COOH | 1216805-11-6 | Reference compound |
| HY-13954 | A 839977 | 870061-27-1 | Reference compound |
| HY-139540 | Pomalidomide-6-OH | 1547162-44-6 | Reference compound |
| HY-139541 | Pomalidomide-5-O-CH3 | 1547163-02-9 | Reference compound |
| HY-139542 | Pomalidomide-6-O-CH3 | 1547163-08-5 | Reference compound |
| HY-139543 | Thalidomide-5-PEG2-Cl | 2230956-57-5 | Reference compound |
| HY-139544 | Thalidomide-5-propoxyethanamine | 2357107-60-7 | Reference compound |
| HY-139545 | Thalidomide-4-C3-NH2 (hydrochloride) | 2357110-84-8 | Reference compound |
| HY-139546 | Thalidomide-5-propargyne-NH2 (hydrochloride) | 2490402-62-3 | Reference compound |
| HY-139547 | Thalidomide-5,6-Cl | 2648939-40-4 | Reference compound |
| HY-139548 | Thalidomide-5-methyl | 40313-92-6 | Reference compound |
| HY-139549 | Thalidomide-benzo | 458151-34-3 | Reference compound |
| HY-13955 | Telmisartan | 144701-48-4 | Reference compound |
| HY-139551 | Guraxetan | | Reference compound |
| HY-139553 | Zunsemetinib | 1640282-42-3 | Reference compound |
| HY-139553A | (R)-Zunsemetinib | 1640282-44-5 | Reference compound |
| HY-139554 | Zifanocycline | 1420294-56-9 | Reference compound |
| HY-139554A | Zifanocycline (TFA) | | Reference compound |
| HY-139554AR | Zifanocycline (TFA) (Standard) | | Reference Standards |
| HY-139555 | Zectivimod | 1623066-63-6 | Reference compound |
| HY-139556 | Zavacorilant | 1781245-13-3 | Reference compound |
| HY-139557 | Zastaprazan | 2133852-18-1 | Reference compound |
| HY-139558 | Zapnometinib | 303175-44-2 | Reference compound |
| HY-139559 | Vornorexant | 1517965-94-4 | Reference compound |
| HY-13955R | Telmisartan (Standard) | 144701-48-4 | Reference Standards |
| HY-13955S | Telmisartan-d3 | 1189889-44-8 | Isotope-Labeled Compounds |
| HY-13955S1 | Telmisartan-d4 | | Isotope-Labeled Compounds |
| HY-13955S2 | Telmisartan-13C,d3 | 1261396-33-1 | Isotope-Labeled Compounds |
| HY-13955S3 | Telmisartan-d7 | 1794754-60-1 | Isotope-Labeled Compounds |
| HY-13956 | Pioglitazone | 111025-46-8 | Reference compound |
| HY-139560 | KDM2B-IN-1 | 1965248-33-2 | Reference compound |
| HY-139561 | KDM2B-IN-2 | 1965248-01-4 | Reference compound |
| HY-139562 | BMS-986318 | 2314378-09-9 | Reference compound |
| HY-139563 | Lenalidomide-C10-OH | 2503018-12-8 | Reference compound |
| HY-139564 | DOTA Zoledronate | 1908409-18-6 | Reference compound |
| HY-139566 | Abrucomstat | 100502-66-7 | Reference compound |
| HY-139567 | Afimetoran | 2171019-55-7 | Reference compound |
| HY-139568 | Deutarserine | 103292-62-2 | Reference compound |
| HY-139569 | Ebaresdax | 1334471-39-4 | Reference compound |
| HY-139569A | Ebaresdax (hydrochloride) | 1334385-87-3 | Reference compound |
| HY-13956A | (R)-Pioglitazone-d1 | 1259828-75-5 | Isotope-Labeled Compounds |
| HY-13956B | Pioglitazone (potassium) | 1266523-09-4 | Reference compound |
| HY-13956C | (R)-Pioglitazone | 959687-65-1 | Reference compound |
| HY-13956R | Pioglitazone (Standard) | 111025-46-8 | Reference Standards |
| HY-13956S | Pioglitazone-d4 | 1134163-29-3 | Isotope-Labeled Compounds |
| HY-13956S1 | Pioglitazone-d4 (alkyl) | 1134163-31-7 | Isotope-Labeled Compounds |
| HY-139570 | Ecubectedin | 2248127-53-7 | Reference compound |
| HY-139571 | Edaxeterkib | 1695534-88-3 | Reference compound |
| HY-139572 | Enuvaptan | 2145062-48-0 | Reference compound |
| HY-139573 | Etavopivat | 2245053-57-8 | Reference compound |
| HY-139573A | (Rac)-Etavopivat | 2622070-93-1 | Reference compound |
| HY-139574 | Firzacorvir | 2243747-96-6 | Reference compound |
| HY-139575 | Guretolimod | 1488364-57-3 | Reference compound |
| HY-139575A | Guretolimod (hydrochloride) | | Reference compound |
| HY-139576 | Larsucosterol | 884905-07-1 | Reference compound |
| HY-139576A | Larsucosterol (sodium) | 1174047-40-5 | Reference compound |
| HY-139576B | Larsucosterol (trimethylamine) | | Reference compound |
| HY-139577 | Ninerafaxstat | 2254741-41-6 | Reference compound |
| HY-139577A | Ninerafaxstat (trihydrochloride) | 2311824-72-1 | Reference compound |
| HY-139578 | Ocarocoxib | 215122-22-8 | Reference compound |
| HY-139579 | Pafolacianine | 1628423-76-6 | Dye Reagents |
| HY-139580 | Plazinemdor | 2378285-59-5 | Reference compound |
| HY-139581 | Ropanicant | 2414674-70-5 | Reference compound |
| HY-139582 | Simpinicline | 753015-44-0 | Reference compound |
| HY-139583 | Sunobinop | 1126793-40-5 | Reference compound |
| HY-139584 | Temgicoluril | 10095-06-4 | Reference compound |
| HY-139585 | Tigulixostat | 1287766-55-5 | Reference compound |
| HY-139586 | Ulevostinag | 2082743-96-0 | Reference compound |
| HY-139586B | Ulevostinag (isomer 2) | 2082743-99-3 | Reference compound |
| HY-139586C | Ulevostinag (isomer 3) | 2082743-98-2 | Reference compound |
| HY-139586D | Ulevostinag (isomer 4) | 2082743-97-1 | Reference compound |
| HY-139587 | Umifoxolaner | 2021230-37-3 | Reference compound |
| HY-139588 | Vemircopan | 2086178-00-7 | Reference compound |
| HY-139589 | Zaloglanstat | 1513852-12-4 | Reference compound |
| HY-13959 | MS436 | 1395084-25-9 | Reference compound |
| HY-139590 | Zeteletinib | 2216753-97-6 | Reference compound |
| HY-139590A | Zeteletinib (hemiadipate) | 2375837-06-0 | Reference compound |
| HY-139593S | Polθ-IN-1-d3 | 2598122-35-9 | Isotope-Labeled Compounds |
| HY-139594 | Polyketide synthase 13-IN-1 | 2345638-96-0 | Reference compound |
| HY-139595 | Polyketide synthase 13-IN-2 | 2219338-48-2 | Reference compound |
| HY-139596 | Polyketide synthase 13-IN-3 | 2221801-50-7 | Reference compound |
| HY-139597 | Temocillin (disodium) | 61545-06-0 | Reference compound |
| HY-139597R | Temocillin (disodium) (Standard) | 61545-06-0 | Reference Standards |
| HY-139598 | LFHP-1c | 2102347-47-5 | Reference compound |
| HY-13960 | GSK1324726A | 1300031-52-0 | Reference compound |
| HY-139600 | KDM2B-IN-3 | 1966933-87-8 | Reference compound |
| HY-139601 | KDM2B-IN-4 | 1966933-85-6 | Reference compound |
| HY-139602 | (+)-JNJ-A07 | 2135640-93-4 | Reference compound |
| HY-139602C | (-)-JNJ-A07 | 2135640-92-3 | Reference compound |
| HY-139603 | MYF-01-37 | 2416417-65-5 | Reference compound |
| HY-139604 | PCC0208017 | 2623158-64-3 | Reference compound |
| HY-139605 | GLUT inhibitor-1 | 2421141-40-2 | Reference compound |
| HY-139606 | VCP/p97 inhibitor-1 | 2630950-38-6 | Reference compound |
| HY-139607 | SSAO inhibitor-1 | 2242883-04-9 | Reference compound |
| HY-139609 | Camonsertib | 2417489-10-0 | Reference compound |
| HY-13961 | GLPG0634 analog | 1206101-20-3 | Reference compound |
| HY-139610S | 3-Sulfo-glycodeoxycholic acid-d4 (disodium) | | Isotope-Labeled Compounds |
| HY-139610S1 | 3-Sulfo-glycodeoxycholic acid-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-139611 | Navlimetostat | 2630904-45-7 | Reference compound |
| HY-139611B | (S)-Navlimetostat | 2630904-44-6 | Reference compound |
| HY-139611C | Navlimetostat (hydrochloride) | | Reference compound |
| HY-139612 | Opnurasib | 2653994-08-0 | Reference compound |
| HY-139612A | (S)-JDQ-443 | 2653994-10-4 | Reference compound |
| HY-139614S | Cholic acid 3-sulfate-d4 (disodium) | | Isotope-Labeled Compounds |
| HY-139615 | Sec61-IN-1 | 2484865-42-9 | Reference compound |
| HY-139616 | Sec61-IN-2 | 2484865-72-5 | Reference compound |
| HY-139617 | Sec61-IN-3 | 2484862-54-4 | Reference compound |
| HY-139618 | Dup-721 | 104421-21-8 | Reference compound |
| HY-139618R | Dup-721 (Standard) | 104421-21-8 | Reference Standards |
| HY-139619 | LT-850-166 | 3031480-22-2 | Reference compound |
| HY-13962 | SGI-1027 | 1020149-73-8 | Reference compound |
| HY-139620 | MS83 | 2762181-19-9 | Reference compound |
| HY-139620A | MS83 epimer 1 | | Reference compound |
| HY-139621 | Colibactin 742 | 2916559-62-9 | Reference compound |
| HY-139622 | DN-F01 | 30388-31-9 | Reference compound |
| HY-139623 | A4B17 | 2759918-91-5 | Reference compound |
| HY-139624 | JNK3 inhibitor-1 | 2622877-97-6 | Reference compound |
| HY-139625 | Dolastatinol | 2759918-83-5 | Reference compound |
| HY-139626 | EPZ-719 | 2697176-16-0 | Reference compound |
| HY-139627 | P2X receptor-1 | 3051864-35-5 | Reference compound |
| HY-139628 | JPD447 | 2883235-86-5 | Reference compound |
| HY-139629 | ANAT inhibitor-1 | 331751-78-1 | Reference compound |
| HY-13963 | ZCL278 | 587841-73-4 | Reference compound |
| HY-139630 | ANAT inhibitor-2 | 1048244-34-3 | Reference compound |
| HY-139631 | HIV-1 inhibitor-9 | 2708201-36-7 | Reference compound |
| HY-139635 | Anticancer agent 11 | 2332936-95-3 | Reference compound |
| HY-139636 | MCA17-1 | 2661480-70-0 | Reference compound |
| HY-139637 | (±)-Silybin | 36804-17-8 | Reference compound |
| HY-139638 | MEK4 inhibitor-1 | 2570386-36-4 | Reference compound |
| HY-139639 | MEK4 inhibitor-2 | 2833643-78-8 | Reference compound |
| HY-13964 | YIL781 | 875258-85-8 | Reference compound |
| HY-139640 | PTP1B-IN-13 | 650621-20-8 | Reference compound |
| HY-139641 | PTP1B-IN-14 | 724451-35-8 | Reference compound |
| HY-139642 | Mal-(CH2)5-Val-Cit-PAB-Eribulin | 2130869-21-3 | ADC Related |
| HY-139643 | CXCR7 antagonist-1 | 1613021-99-0 | Reference compound |
| HY-139643A | CXCR7 antagonist-1 (hydrochloride) | 2990472-61-0 | Reference compound |
| HY-139644 | MIPS521 | 1146188-19-3 | Reference compound |
| HY-139645 | MtDTBS-IN-1 | | Reference compound |
| HY-139646 | KMG-104 | 852057-94-4 | Dye Reagents |
| HY-139647 | (+)-Cinchonaminone | 60305-15-9 | Reference compound |
| HY-139648 | PREP inhibitor-1 | 2760543-16-4 | Reference compound |
| HY-139649 | Ten01 | | Reference compound |
| HY-13964A | YIL781 (hydrochloride) | 1640226-17-0 | Reference compound |
| HY-13965 | Parmodulin 2 | 423735-93-7 | Reference compound |
| HY-139650 | HDAC1/2-IN-3 | 2121516-17-2 | Reference compound |
| HY-139651 | CDK2-IN-7 | 2498658-13-0 | Reference compound |
| HY-139652 | PLK1-IN-2 | 2640254-52-8 | Reference compound |
| HY-139653 | IDO-IN-14 | 2568302-02-1 | Reference compound |
| HY-139654 | α/β-Hydrolase-IN-1 | 2696301-42-3 | Reference compound |
| HY-139655 | cIAP1 Ligand-Linker Conjugates 16 | 2143956-63-0 | Reference compound |
| HY-139656 | cIAP1 ligand 4 | 2891589-73-2 | Reference compound |
| HY-139657 | ThrRS-IN-2 | 468750-19-8 | Reference compound |
| HY-139658 | D-Xylofuranose, 1,2,3,5-tetraacetate | 42927-46-8 | Reference compound |
| HY-139659 | ARD-61 | 2316837-08-6 | Reference compound |
| HY-13966 | 2-Deoxy-D-glucose | 154-17-6 | Natural Products |
| HY-139660 | PROTAC PTK6 ligand-1 | 2408341-98-8 | Reference compound |
| HY-139661 | Boc-bipiperidine-ethynylbenzoic acid | 2308497-81-4 | Reference compound |
| HY-139662 | HB007 | 2387821-46-5 | Reference compound |
| HY-139663 | IHVR-17028 | 1428247-78-2 | Reference compound |
| HY-139664 | GSK-3685032 | 2170137-61-6 | Reference compound |
| HY-139664A | (R)-GSK-3685032 | 2170140-50-6 | Reference compound |
| HY-139664B | (S)-GSK-3685032 | 2170142-58-0 | Reference compound |
| HY-139665 | VB124 | 2230186-18-0 | Reference compound |
| HY-139666 | N-Palmitoyl-L-glutamine | 58725-34-1 | Reference compound |
| HY-139666R | N-Palmitoyl-L-glutamine (Standard) | 58725-34-1 | Reference Standards |
| HY-139667 | PKM2-IN-3 | 2408841-19-8 | Reference compound |
| HY-139668 | VGD071 | 2826992-31-6 | Reference compound |
| HY-139669 | Antifungal agent 13 | 2834776-94-0 | Reference compound |
| HY-13966S | 2-Deoxy-D-glucose-d1 | 188004-07-1 | Isotope-Labeled Compounds |
| HY-13966S2 | 2-Deoxy-D-glucose-13C | 201612-55-7 | Isotope-Labeled Compounds |
| HY-13966S3 | 2-Deoxy-D-glucose-13C6 | 201740-77-4 | Isotope-Labeled Compounds |
| HY-13966S4 | 2-Deoxy-D-glucose-13C-1 | 119897-50-6 | Isotope-Labeled Compounds |
| HY-13967 | AMG 837 | 865231-46-5 | Reference compound |
| HY-139670 | PSMA–DA1 | 2703051-77-6 | Reference compound |
| HY-139671 | Ultrashort α,β-Peptide | 2738334-37-5 | Reference compound |
| HY-139672 | BRD5018 | 2245231-51-8 | Reference compound |
| HY-139673 | BG dimer | 2700187-91-1 | Dye Reagents |
| HY-139675 | GPR84 antagonist 1 | 2762180-28-7 | Reference compound |
| HY-139676 | RMG8-8 | 3030216-89-5 | Reference compound |
| HY-139677 | 5-HT7R antagonist 1 | 2759919-13-4 | Reference compound |
| HY-139677A | 5-HT7R antagonist 1 (free base) | 2337008-64-5 | Reference compound |
| HY-139678 | SC13 | 2839142-69-5 | Reference compound |
| HY-139679 | Antibacterial agent 28 | 2673185-41-4 | Reference compound |
| HY-13967A | AMG 837 (sodium salt) | 865231-45-4 | Reference compound |
| HY-13967B | AMG 837 (calcium hydrate) | 1259389-38-2 | Reference compound |
| HY-13968 | JW 55 | 664993-53-7 | Reference compound |
| HY-139680 | Dopamine D3 receptor antagonist-1 | 3052236-36-6 | Reference compound |
| HY-139681 | Dopamine D3 receptor antagonist-2 | 3052236-39-9 | Reference compound |
| HY-139682 | Dovitinib-RIBOTAC | 2759351-68-1 | Reference compound |
| HY-139682A | Dovitinib-RIBOTAC (TFA) | 2759351-69-2 | Reference compound |
| HY-139683 | Antiviral agent 5 | 2698336-82-0 | Reference compound |
| HY-139684 | MNK1/2-IN-5 | 1426928-20-2 | Reference compound |
| HY-139685 | ABP 25 | 2965359-45-7 | Reference compound |
| HY-139686 | IL-17A inhibitor 2 | 2452464-77-4 | Reference compound |
| HY-139687S | Ractopamine Ketone-d6 (hydrochloride) | 1185012-24-1 | Isotope-Labeled Compounds |
| HY-139688S | (±)-Voriconazole-d3 | | Isotope-Labeled Compounds |
| HY-139689S | rac-trans-N-Desmethyl sertraline-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-139690 | CCG258747 | 2615910-00-2 | Reference compound |
| HY-139691 | SR15006 | 2505001-54-5 | Reference compound |
| HY-139692 | EAAT2 activator 1 | 892415-28-0 | Reference compound |
| HY-139693 | PTPN22-IN-1 | 2580935-57-3 | Reference compound |
| HY-139694 | hA3AR agonist 1 | 2821704-65-6 | Reference compound |
| HY-139695 | Spectinamide 1599 | 1620153-85-6 | Reference compound |
| HY-139696 | AKR1B10-IN-1 | 2136579-33-2 | Reference compound |
| HY-139697 | HAV 3C proteinase-IN-1 | 1626408-58-9 | Reference compound |
| HY-139698 | GT-1 | 1401527-90-9 | Reference compound |
| HY-139699 | GT-055 | 2842084-52-8 | Reference compound |
| HY-139701 | NI-Pano | 2733559-66-3 | Reference compound |
| HY-139702 | α5β1 integrin agonist-1 | 2756557-83-0 | Reference compound |
| HY-139703 | Se-DMC | 2098850-81-6 | Reference compound |
| HY-139704 | Eroonazole | 305376-22-1 | Reference compound |
| HY-139705 | Anticancer agent 12 | 2832055-89-5 | Reference compound |
| HY-139707 | Thalidomide-NH-CBP/p300 ligand 2 | 2484739-21-9 | Reference compound |
| HY-139708 | NMDA receptor antagonist-3 | 2762181-52-0 | Reference compound |
| HY-139709 | Glucocorticoids receptor agonist 1 | 694526-54-0 | Reference compound |
| HY-13971 | GPR40 Activator 1 | 1309435-60-6 | Reference compound |
| HY-139710 | Glucocorticoids receptor agonist 2 | 614761-20-5 | Reference compound |
| HY-139711 | Anticancer agent 13 | 38116-01-7 | Reference compound |
| HY-139712 | PDGFP 1 | | Reference compound |
| HY-139713 | Antifungal agent 14 | 2710259-38-2 | Reference compound |
| HY-139714 | IMD-vanillin | 2928463-38-9 | Reference compound |
| HY-139715 | IMD-ferulic | | Reference compound |
| HY-139716 | IMD-catechol | 2928463-39-0 | Reference compound |
| HY-139717 | IMD-biphenylA | 2928463-40-3 | Reference compound |
| HY-139718 | IMD-biphenylB | 2928463-41-4 | Reference compound |
| HY-139719 | IMD-biphenylC | 2928463-42-5 | Reference compound |
| HY-13972 | Mutant IDH1 inhibitor | 1429180-08-4 | Reference compound |
| HY-139720 | β-Secretase Inhibitor III | 2760674-85-7 | Reference compound |
| HY-139721 | Tenofovir-C3-O-C15-CF3 (ammonium) | 2611373-80-7 | Reference compound |
| HY-139722 | Tenofovir-C3-O-C12-trimethylsilylacetylene (ammonium) | 2611373-74-9 | Reference compound |
| HY-139723 | Antidepressant agent 2 | 2822600-09-7 | Reference compound |
| HY-139725 | CDK5-IN-1 | 2639540-19-3 | Reference compound |
| HY-139726 | Mal-PEG4-Val-Cit-PAB-MMAE | | Reference compound |
| HY-139727 | S(-)-Bisoprolol | 99103-03-4 | Reference compound |
| HY-139727A | S(-)-Bisoprolol (fumarate) | 1426853-23-7 | Reference compound |
| HY-139728 | N,N,N′,N′-Tetracyclohexyl-3-oxapentanediamide | 74267-27-9 | Reference compound |
| HY-139729 | HOPan | 18679-90-8 | Reference compound |
| HY-139730 | c-ABL-IN-1 | 2304918-82-7 | Reference compound |
| HY-139731 | Transketolase-IN-1 | 2763650-87-7 | Reference compound |
| HY-139732 | SARS-CoV-2-IN-8 | | Reference compound |
| HY-139733 | β-N-Acetyl-D-hexosaminidase-IN-1 | 2760672-89-5 | Reference compound |
| HY-139735 | Antitumor agent-29 | 2847856-44-2 | Reference compound |
| HY-139738 | TIM-3-IN-1 | 2883237-04-3 | Reference compound |
| HY-139739 | Antibacterial agent 31 | 2719842-14-3 | Reference compound |
| HY-13973A | GSK-3 inhibitor 1 | 603272-51-1 | Reference compound |
| HY-139740 | Aβ Fibrillization modulator 1 | 2847131-53-5 | Reference compound |
| HY-139741 | cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) | | Peptides |
| HY-139742 | ADTL-SA1215 | 782387-91-1 | Reference compound |
| HY-139743 | Aditoprime | 56066-63-8 | Reference compound |
| HY-139743R | Aditoprime (Standard) | 56066-63-8 | Reference Standards |
| HY-139744 | FPI-1465 | 1452458-70-6 | Reference compound |
| HY-139745 | FPI-1523 (sodium) | 1452459-52-7 | Reference compound |
| HY-139745A | FPI-1523 | 1452459-50-5 | Reference compound |
| HY-139746 | FPI-1602 | 1452460-31-9 | Reference compound |
| HY-139747 | Antibacterial agent 32 | 1436862-65-5 | Reference compound |
| HY-139748 | ETX0462 | | Reference compound |
| HY-139749 | Antibacterial agent 33 | 1426572-59-9 | Reference compound |
| HY-139750 | Antibacterial agent 34 | 1426572-58-8 | Reference compound |
| HY-139751 | β-Lactamase-IN-4 | 1463520-91-3 | Reference compound |
| HY-139752 | Antibacterial agent 35 | 1426572-56-6 | Reference compound |
| HY-139754 | Antibacterial agent 37 | 1452459-04-9 | Reference compound |
| HY-139755 | Antibacterial agent 38 | 1452459-12-9 | Reference compound |
| HY-139756 | Antibacterial agent 39 | 1426572-46-4 | Reference compound |
| HY-139757 | Antibacterial agent 40 | 1817768-97-0 | Reference compound |
| HY-139758 | Antibacterial agent 41 | 1426572-45-3 | Reference compound |
| HY-139759 | Antibacterial agent 42 | 1426572-47-5 | Reference compound |
| HY-139760 | Antibacterial agent 43 | 1426572-48-6 | Reference compound |
| HY-139761 | Antibacterial agent 44 | 1426572-49-7 | Reference compound |
| HY-139762 | Antibacterial agent 45 | 1426572-50-0 | Reference compound |
| HY-139763 | Antibacterial agent 46 | 1426572-51-1 | Reference compound |
| HY-139764 | Antibacterial agent 47 | 1426572-52-2 | Reference compound |
| HY-139765 | Antibacterial agent 48 | 1426572-53-3 | Reference compound |
| HY-139766 | Antibacterial agent 49 | 1426572-54-4 | Reference compound |
| HY-139767 | Antibacterial agent 50 | 1436862-71-3 | Reference compound |
| HY-139768 | Antibacterial agent 51 | 1436862-69-9 | Reference compound |
| HY-139769 | Antibacterial agent 52 | 1426572-60-2 | Reference compound |
| HY-13976A | PRL-8-53 | 51352-87-5 | Reference compound |
| HY-139770 | Antibacterial agent 53 | 1426572-61-3 | Reference compound |
| HY-139771 | Antibacterial agent 54 | 1426572-62-4 | Reference compound |
| HY-139772 | Antibacterial agent 55 | 1426572-63-5 | Reference compound |
| HY-139773 | Antibacterial agent 56 | 1426572-64-6 | Reference compound |
| HY-139774 | Antibacterial agent 57 | 1426572-67-9 | Reference compound |
| HY-139775 | Antibacterial agent 58 | 1426572-65-7 | Reference compound |
| HY-139776 | Antibacterial agent 59 | 1426572-66-8 | Reference compound |
| HY-139777 | Antibacterial agent 60 | 1426572-68-0 | Reference compound |
| HY-139778 | Antibacterial agent 61 | 1426572-69-1 | Reference compound |
| HY-139779 | β-Lactamase-IN-5 | 1463521-39-2 | Reference compound |
| HY-13977A | PKR-IN-C16 | 608512-97-6 | Reference compound |
| HY-139780 | JNJ-61803534 | 1917306-14-9 | Reference compound |
| HY-139781 | PD-L1-IN-1 | 2767424-13-3 | Reference compound |
| HY-139782 | SKLB325 | 66680-03-3 | Reference compound |
| HY-139783 | 3-Campholenyl-2-butanol | 65113-99-7 | Reference compound |
| HY-139784 | Idroxioleic acid | 182370-45-2 | Reference compound |
| HY-139785 | Cavrotolimod | 2378664-12-9 | Reference compound |
| HY-139785A | Cavrotolimod (sodium) | | Oligonucleotides |
| HY-139786 | Cofirasersen | 2247669-96-9 | Reference compound |
| HY-139786A | Cofirasersen (sodium) | | Oligonucleotides |
| HY-139787 | Donidalorsen | 2304692-48-4 | Reference compound |
| HY-139787A | Donidalorsen (sodium) | 2304701-45-7 | Oligonucleotides |
| HY-139788 | Fesomersen | 2380135-03-3 | Oligonucleotides |
| HY-139788A | Fesomersen (sodium) | 2380288-85-5 | Oligonucleotides |
| HY-13979 | DDR1-IN-1 | 1449685-96-4 | Reference compound |
| HY-139791 | Azetukalner | 1009344-33-5 | Reference compound |
| HY-139792 | Besigliptin (tosylate) | 1177460-72-8 | Reference compound |
| HY-139793 | UDP-glucosamine (disodium) | 1355005-51-4 | Reference compound |
| HY-139794 | SDZ283-910 | 164514-54-9 | Reference compound |
| HY-139795 | ZYJ-25e | 1287261-04-4 | Reference compound |
| HY-139796 | ZYJ-34v | 1450662-32-4 | Reference compound |
| HY-139798 | Iboxamycin | 2640000-92-4 | Reference compound |
| HY-139799 | Sch 202596 | 196615-89-1 | Reference compound |
| HY-13979A | DDR1-IN-1 dihydrochloride | 1780303-76-5 | Reference compound |
| HY-13980 | UNC0642 | 1481677-78-4 | Reference compound |
| HY-139800 | (-)-Glycinol | 69393-95-9 | Natural Products |
| HY-139801 | Indolapril (hydrochloride) | 80828-32-6 | Reference compound |
| HY-139802 | L-779976 | 214770-19-1 | Reference compound |
| HY-139803 | SCH-39370 | 115406-23-0 | Reference compound |
| HY-139804 | CTK7A | 1297262-16-8 | Reference compound |
| HY-139805 | Ticarcillin | 34787-01-4 | Reference compound |
| HY-139805A | Ticarcillin (monosodium) | 74682-62-5 | Reference compound |
| HY-139806 | SRA880 (free base) | 187218-90-2 | Reference compound |
| HY-139807 | JAK-IN-14 | 1973485-06-1 | Reference compound |
| HY-139808S | (±)-cis-N-Desmethylsertraline-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-139809S | Cinnarizine-d8 (dihydrochloride) | 1276545-36-8 | Isotope-Labeled Compounds |
| HY-13981 | Ligandrol | 1165910-22-4 | Reference compound |
| HY-139811S | Glimepiride-d4 | | Isotope-Labeled Compounds |
| HY-139813 | Phenanthriplatin | 1416900-51-0 | Reference compound |
| HY-139815 | ZYJ-34c | 1314556-93-8 | Reference compound |
| HY-139816 | BTNPO | 2507992-93-8 | Dye Reagents |
| HY-139817 | Antiviral agent 8 | 2634704-26-8 | Reference compound |
| HY-139818 | Mal-PEG-PLA (PEG MW 3000 & PLA MW 70,000) | | Biochemical Assay Reagents |
| HY-139819 | MPEG-PLA (PEG MW 3000 & PLA MW 50,000) | | Reference compound |
| HY-13982 | JSH-23 | 749886-87-1 | Reference compound |
| HY-139820 | FTO-IN-4 | 2763577-74-6 | Reference compound |
| HY-139821 | FTO-IN-5 | 2763577-75-7 | Reference compound |
| HY-139822 | VEGFR-2-IN-10 | 2760792-40-1 | Reference compound |
| HY-139823 | PRMT5-IN-10 | 2567564-23-0 | Reference compound |
| HY-139823A | PRMT5-IN-11 | 2567564-33-2 | Reference compound |
| HY-139824 | Nitro-coronene | 2842847-23-6 | Reference compound |
| HY-139825 | Indoluidin E | 2763081-76-9 | Reference compound |
| HY-139826 | CuATSP | 68341-12-8 | Reference compound |
| HY-139827 | CuATSM | 68341-09-3 | Reference compound |
| HY-139828 | Anticancer agent 14 | 2762698-14-4 | Reference compound |
| HY-13983 | IDO-IN-7 | 1402836-58-1 | Reference compound |
| HY-139830 | Dyrk1A-IN-1 | 2858696-72-5 | Reference compound |
| HY-139831 | Galectin-8-IN-1 | 3028946-23-5 | Reference compound |
| HY-139832 | MCX 28 | 1414453-58-9 | Reference compound |
| HY-139833 | Anti-inflammatory agent 6 | | Reference compound |
| HY-139834 | Antistaphylococcal agent 1 | 2350182-68-0 | Reference compound |
| HY-139835 | Antistaphylococcal agent 2 | 2350182-67-9 | Reference compound |
| HY-139836 | Antistaphylococcal agent 3 | 2350182-65-7 | Reference compound |
| HY-139837 | GDC-4379 | 2252277-73-7 | Reference compound |
| HY-139838 | Epyrifenacil | 353292-31-6 | Reference compound |
| HY-139839 | Y12196 | 1671025-91-4 | Reference compound |
| HY-13984 | Mutant EGFR inhibitor | 1421373-62-7 | Reference compound |
| HY-139840 | GCPII-IN-1 | 1025796-32-0 | Reference compound |
| HY-139840A | GCPII-IN-1 (TFA) | 1269794-89-9 | Reference compound |
| HY-139842 | Homobrassinolide | 74174-44-0 | Biochemical Assay Reagents |
| HY-139844 | Anti-inflammatory agent 7 | 2759194-24-4 | Reference compound |
| HY-139845 | Antiviral agent 9 | | Reference compound |
| HY-139846 | MK-4688 | 1616428-79-5 | Reference compound |
| HY-139847 | RORγt inverse agonist 23 | 2230779-18-5 | Reference compound |
| HY-139848 | WS-898 | 2891562-77-7 | Reference compound |
| HY-13985 | Nav1.7 inhibitor | 1355631-24-1 | Reference compound |
| HY-139850 | GPS491 | 2655502-29-5 | Reference compound |
| HY-139851 | Fungicide5 | 2344721-61-3 | Reference compound |
| HY-139852 | PLAP-IN-1 | 2857113-78-9 | Reference compound |
| HY-139853 | BMS-986278 | 2170126-74-4 | Reference compound |
| HY-139854 | DNDI-6148 | 2243909-59-1 | Reference compound |
| HY-139855 | ZG-2033 | 2685739-28-8 | Reference compound |
| HY-139856 | Mal-Ala-Ala-PAB-PNP | 2003260-14-6 | ADC Related |
| HY-139857 | Piceid 6″-O-azelaic acid ester | | Reference compound |
| HY-139858 | TGFβR-IN-1 | 2857845-36-2 | Reference compound |
| HY-139859 | APN-PEG36-tetrazine | | ADC Related |
| HY-13986 | Merimepodib | 198821-22-6 | Reference compound |
| HY-139860 | Anticancer agent 15 | 2710312-73-3 | Reference compound |
| HY-139861 | CBP/p300-IN-14 | 2725036-10-0 | Reference compound |
| HY-139862 | Keap1-Nrf2-IN-3 | 2095066-47-8 | Reference compound |
| HY-139863 | Antibacterial agent 62 | 3031364-03-8 | Reference compound |
| HY-139865 | 142I5 | 2865171-75-9 | Reference compound |
| HY-139866 | SARS-CoV-2-IN-9 | 1453052-57-7 | Reference compound |
| HY-139868 | BAY-091 | 2922280-34-8 | Reference compound |
| HY-13986A | (R)-Merimepodib | 2748420-50-8 | Reference compound |
| HY-13987 | (R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid | 103733-65-9 | Reference compound |
| HY-139871 | hTrkA-IN-2 | 2986533-14-4 | Reference compound |
| HY-139872 | eIF4A3-IN-4 | 2861994-92-3 | Reference compound |
| HY-139873 | CXCR2 antagonist 2 | 2647464-91-1 | Reference compound |
| HY-139874 | CXCR2 antagonist 3 | 2647464-92-2 | Reference compound |
| HY-139875 | JH-XVI-178 | 2648453-53-4 | Reference compound |
| HY-139876 | APJ receptor agonist 3 | 2759159-56-1 | Reference compound |
| HY-139877 | OXS007417 | 2761147-94-6 | Reference compound |
| HY-139878 | MLKL-IN-1 | 2837019-30-2 | Reference compound |
| HY-139879 | PARP1-IN-6 | 1654735-36-0 | Reference compound |
| HY-13988 | AT-56 | 162640-98-4 | Reference compound |
| HY-139880 | PI3Kγ inhibitor 5 | 2566569-31-9 | Reference compound |
| HY-139881 | BTK inhibitor 19 | 2557174-19-1 | Reference compound |
| HY-139882 | Anticancer agent 16 | 2761205-38-1 | Reference compound |
| HY-139883 | IDO-IN-15 | 2433886-87-2 | Reference compound |
| HY-139884 | EGFR-IN-18 | 2765573-34-8 | Reference compound |
| HY-139885 | c-Myc inhibitor 4 | 2763366-92-1 | Reference compound |
| HY-139886 | gTPA2-OMe | 2738342-65-7 | Reference compound |
| HY-139887 | Antibacterial agent 63 | 2910919-43-4 | Reference compound |
| HY-139888 | Plasma kallikrein-IN-1 | 2691030-28-9 | Reference compound |
| HY-139889 | DHODH-IN-18 | 2685799-97-5 | Reference compound |
| HY-13989 | b-AP15 | 1009817-63-3 | Reference compound |
| HY-139890 | DC-Srci-6649 | 1037545-61-1 | Reference compound |
| HY-139891 | Trk-IN-6 | 2489327-43-5 | Reference compound |
| HY-139892 | XR8-69 | 2817811-10-0 | Reference compound |
| HY-139893 | ERGi-USU-6 (mesylate) | 2756327-67-8 | Reference compound |
| HY-139894 | KRAS G12D inhibitor 5 | 2621928-53-6 | Reference compound |
| HY-139897 | CX 717 | 867276-98-0 | Reference compound |
| HY-139899 | S6821 | 1119831-25-2 | Reference compound |
| HY-13990 | NVP-TNKS656 | 1419949-20-4 | Reference compound |
| HY-139900 | Benzyl 2-hydroxy-6-methoxybenzoate | 24474-71-3 | Reference compound |
| HY-139901 | Chk1-IN-6 | 2428423-77-0 | Reference compound |
| HY-139902 | Quorum sensing-IN-1 | 2762184-06-3 | Reference compound |
| HY-139903 | Antifungal agent 18 | 2572713-30-3 | Reference compound |
| HY-139904 | TRPA1 Antagonist 3 | 71291-80-0 | Reference compound |
| HY-139905 | Antifungal agent 19 | | Reference compound |
| HY-139906 | CXCL12 ligand 1 | 2045891-59-4 | Reference compound |
| HY-139907 | DG013A | 2007955-07-7 | Reference compound |
| HY-139907A | DG013B | 2758817-06-8 | Reference compound |
| HY-139907B | DG013A (formate) | | Reference compound |
| HY-139907C | DG013B (formate) | | Reference compound |
| HY-139908 | MERS-CoV-IN-1 | 2245697-92-9 | Reference compound |
| HY-139909 | CL2E-SN38 | 1639139-65-3 | ADC Related |
| HY-139909A | CL2E-SN38 (TFA) | | ADC Related |
| HY-13991 | CCG-1423 | 285986-88-1 | Reference compound |
| HY-139910 | KRAS G12D inhibitor 6 | 2648552-32-1 | Reference compound |
| HY-139911 | KRAS G12D inhibitor 7 | 2648552-34-3 | Reference compound |
| HY-139912 | Biotin-aniline | 769933-15-5 | Reference compound |
| HY-139915 | MPO-IN-1 | 2471981-21-0 | Reference compound |
| HY-13991A | (S)-CCG-1423 | 2319939-24-5 | Reference compound |
| HY-13992 | AP20187 | 195514-80-8 | Reference compound |
| HY-139920 | Oritinib | 2035089-28-0 | Reference compound |
| HY-139920A | Oritinib (mesylate) | 2180164-79-6 | Reference compound |
| HY-139924S | 3β-Cholic acid-d4 | | Isotope-Labeled Compounds |
| HY-139926S | PtdIns-(4,5)-P2 (1,2-dipamitoyl)-d62 (trisodium) | | Isotope-Labeled Compounds |
| HY-139928S | Valeryl-L-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-13993 | Ro 25-6981 | 169274-78-6 | Reference compound |
| HY-139931S | 1-Stearoyl-2-Arachidonoyl-d8-sn-glycero-3-PC | 161922-50-5 | Isotope-Labeled Compounds |
| HY-139937S | (±)14(15)-EET-d11 methyl ester | | Isotope-Labeled Compounds |
| HY-139938S | (±)11(12)-EET methyl ester-d11 | | Isotope-Labeled Compounds |
| HY-139939S | Isovaleryl-DL-carnitine-d3 (chloride) | | Isotope-Labeled Compounds |
| HY-13993A | Ro 25-6981 (Maleate) | 1312991-76-6 | Reference compound |
| HY-13993B | Ro 25-6981 (hydrochloride) | 919289-58-0 | Reference compound |
| HY-13994 | Mps1-IN-2 | 1228817-38-6 | Reference compound |
| HY-139942S | (±)9(10)-EpOME-d4 | 1215168-54-9 | Isotope-Labeled Compounds |
| HY-139945S | (±)15-HETE-d8 | 2525175-31-7 | Isotope-Labeled Compounds |
| HY-13995 | Sevelamer | 52757-95-6 | Reference compound |
| HY-139950 | Rasarfin | 674359-73-0 | Reference compound |
| HY-139951S | 3-Hydroxy-3-methylglutaryl-Coenzyme A-d3 (ammonium) | | Isotope-Labeled Compounds |
| HY-139952S | Prostaglandin D2 Dopamine-d4 | | Isotope-Labeled Compounds |
| HY-139956 | Mal-amido-PEG9-Val-Ala-PAB-SG3200 | 1817788-75-2 | ADC Related |
| HY-139957 | Mal-amido-PEG8-Val-Ala-PAB-SG3200 | 2025353-40-4 | ADC Related |
| HY-139959S | (±)12(13)-EpOME-d4 | | Isotope-Labeled Compounds |
| HY-13995A | Sevelamer (hydrochloride) | 152751-57-0 | Reference compound |
| HY-13995B | Sevelamer (carbonate) | 845273-93-0 | Reference compound |
| HY-139961S | (±)14(15)-EET-d11 | 2699608-29-0 | Isotope-Labeled Compounds |
| HY-139965S | 4-hydroxy Nonenal Glutathione-d3 (TFA) | | Isotope-Labeled Compounds |
| HY-139967S | PGPC-d6 | | Isotope-Labeled Compounds |
| HY-139968S | 13,14-Dihydro-15(R,S)-hydroxy-16,16-difluoro Prostaglandin E1-d4 | | Isotope-Labeled Compounds |
| HY-139969S | 1-Arachidonoyl-d5-rac-glycerol | 2568492-44-2 | Isotope-Labeled Compounds |
| HY-13997 | Ombitasvir | 1258226-87-7 | Reference compound |
| HY-139970 | VPC-13789 | 2761146-51-2 | Reference compound |
| HY-139971 | Antibacterial agent 64 | 618865-52-4 | Reference compound |
| HY-139972 | PROTAC(H-PGDS)-7 | 2761281-50-7 | Reference compound |
| HY-139973 | OAB-14 | 2140911-49-3 | Reference compound |
| HY-139974 | BChE-IN-2 | | Reference compound |
| HY-139975 | Antitumor agent-31 | 2703000-00-2 | Dye Reagents |
| HY-139976 | 1-SG | 2839421-83-7 | Reference compound |
| HY-139979 | USP5-IN-1 | 2851040-81-6 | Reference compound |
| HY-13998 | Dasabuvir | 1132935-63-7 | Reference compound |
| HY-139980 | CDK9-IN-13 | 2768712-71-4 | Reference compound |
| HY-139981 | Microtubule destabilizing agent-1 | 2850370-28-2 | Reference compound |
| HY-139982 | OX11 | 2414598-74-4 | Reference compound |
| HY-139983 | SDH-IN-1 | 2685795-52-0 | Reference compound |
| HY-139984 | BIIB091 | 2247614-80-6 | Reference compound |
| HY-139985 | NBD-14189 | 2234273-72-2 | Reference compound |
| HY-139986 | CDK7-IN-5 | 1817006-50-0 | Reference compound |
| HY-139987 | LeuRS-IN-1 | 1364914-72-6 | Reference compound |
| HY-139987A | LeuRS-IN-1 (hydrochloride) | 1364683-67-9 | Reference compound |
| HY-139988 | 2-O-DMT-Sulfonyldiethanol phosphoramidite | 108783-02-4 | Reference compound |
| HY-139989 | NBD-14270 | 2411819-82-2 | Reference compound |
| HY-13998A | Dasabuvir (sodium) | 1132940-11-4 | Reference compound |
| HY-13998R | Dasabuvir (Standard) | 1132935-63-7 | Reference Standards |
| HY-13999 | NSI-189 | 1270138-40-3 | Reference compound |
| HY-139990 | CSF1R-IN-3 | 2760584-90-3 | Reference compound |
| HY-139991 | Neuraminidase-IN-3 | 2699874-41-2 | Reference compound |
| HY-139993 | HIF-PHD-IN-2 | 2711720-45-3 | Reference compound |
| HY-139994 | XN methyl pyrazole | 2820169-36-4 | Reference compound |
| HY-139995 | Spermine Prodrug-1 | 2576358-68-2 | Reference compound |
| HY-139996 | Pomalidomide-C5-Dovitinib | 2732969-67-2 | Reference compound |
| HY-139997 | DDC-01-163 | 2140806-84-2 | Reference compound |
| HY-139998 | PCSK9-IN-3 | 2867496-34-0 | Reference compound |
| HY-139999 | LCL-PEG3-N3 | 3033849-90-7 | Reference compound |
| HY-139999A | LCL-PEG3-N3 (hydrochloride) | 3033849-91-8 | Reference compound |
| HY-13999A1 | NSI-189 (phosphate) | 1270138-41-4 | Reference compound |
| HY-140000 | Methylamino-PEG1-acid | 1367918-21-5 | Reference compound |
| HY-140001 | Amino-PEG3-C2-sulfonic acid | 1817735-43-5 | Reference compound |
| HY-140002 | Amino-PEG1-C2-acid | 144942-89-2 | Reference compound |
| HY-140003 | Tetraethyl butane-1,4-diylbis(phosphonate) | 7203-67-0 | Reference compound |
| HY-140004 | Azide-PEG3-Tos | 178685-33-1 | ADC Related |
| HY-140005 | Aminooxy-PEG3-acid | 1807540-79-9 | Reference compound |
| HY-140006 | Diketone-PEG4-PFP ester | 2353409-84-2 | Reference compound |
| HY-140007 | Acrylate-PEG-NH2 (MW 2000) | | Reference compound |
| HY-140008 | DOTA-PEG5-amine | | Reference compound |
| HY-140009 | Azido-PEG1-C2-acid | 1393330-34-1 | Reference compound |
| HY-140010 | N-methyl-N'-(azide-PEG3)-Cy3 | 2107273-16-3 | Reference compound |
| HY-140011 | Acid-C2-PEG3-NHS ester | 1835759-79-9 | Reference compound |
| HY-140012 | Azido-PEG4-beta-D-glucose | 1609083-15-9 | Reference compound |
| HY-140013 | Fmoc-NH-PEG1-C2-acid | 1654740-73-4 | Reference compound |
| HY-140014 | Val-Cit | 159858-33-0 | ADC Related |
| HY-140015 | TCO-PEG3-acid | 2141981-86-2 | Reference compound |
| HY-140015A | (S,E)-TCO2-PEG3-acid | | Reference compound |
| HY-140016 | Bis-(m-PEG4)-amidohexanoic acid | 2353409-74-0 | Reference compound |
| HY-140017 | PEG2-bis(phosphonic acid) | 116604-42-3 | Reference compound |
| HY-140018 | Thiol-PEG3-acid | 1347750-82-6 | Reference compound |
| HY-140019 | Azido-PEG3-amide-C3-triethoxysilane | 2243566-43-8 | Reference compound |
| HY-140020 | Propargyl-PEG10-acid | 2055022-18-7 | Reference compound |
| HY-140021 | Propargyl-PEG13-acid | | Reference compound |
| HY-140022 | Propargyl-PEG14-acid | | Reference compound |
| HY-140023 | Propargyl-PEG4-CH2COOH | 1429934-37-1 | Reference compound |
| HY-140024 | Propargyl-PEG4-CH2-acid | 1872433-74-3 | Reference compound |
| HY-140025 | Propargyl-PEG4-CH2CO2-NHS | 2144777-76-2 | Reference compound |
| HY-140026 | Propargyl-PEG1-Boc | 488150-84-1 | Reference compound |
| HY-140027 | Propargyl-PEG3-Boc | 1374658-84-0 | Reference compound |
| HY-140028 | Propargyl-PEG4-Boc | 1355197-66-8 | Reference compound |
| HY-140029 | Propargyl-PEG10-Boc | 2055022-22-3 | Reference compound |
| HY-140030 | Propargyl-PEG14-Boc | | Reference compound |
| HY-140031 | Propargyl-PEG3-OCH2-Boc | 888010-02-4 | Reference compound |
| HY-140032 | Alkyne-ethyl-PEG1-Boc | 2100306-55-4 | Reference compound |
| HY-140033 | Propargyl-PEG3-amine | 932741-19-0 | Reference compound |
| HY-140034 | Propargyl-PEG12-amine | 2264091-73-6 | Reference compound |
| HY-140035 | Propargyl-PEG24-amine | | Reference compound |
| HY-140036 | Propargyl-PEG3-bromide | 203740-63-0 | Reference compound |
| HY-140037 | Mal-PEG4-propargyl | 1262681-30-0 | Reference compound |
| HY-140038 | Bis-propargyl-PEG1 | 40842-04-4 | Reference compound |
| HY-140039 | Bis-propargyl-PEG11 | 1351373-49-3 | Reference compound |
| HY-140040 | Bis-propargyl-PEG12 | 1351373-50-6 | Reference compound |
| HY-140041 | Bis-propargyl-PEG13 | | Reference compound |
| HY-140042 | Bis-propargyl-O-PEG17 | | Reference compound |
| HY-140043 | N-Me-N-bis(PEG2-propargyl) | 1835759-84-6 | Reference compound |
| HY-140044 | Propargyl-PEG2-methylamine | 1835759-76-6 | Reference compound |
| HY-140045 | Propargyl-PEG4-methylamine | 1807530-11-5 | Reference compound |
| HY-140046 | Propargyl-PEG5-MS | 1036204-62-2 | Reference compound |
| HY-140047 | Propargyl-PEG4-sulfonic acid | 1817735-29-7 | Reference compound |
| HY-140048 | Propargyl-PEG4-5-nitrophenyl carbonate | 1422540-81-5 | Reference compound |
| HY-140049 | Boc-aminooxy-PEG1-propargyl | 1895922-72-1 | Reference compound |
| HY-140050 | Boc-aminooxy-PEG2-propargyl | 1895922-74-3 | Reference compound |
| HY-140051 | N-Boc-aminoxy-PEG3-propargyl | 1951439-46-5 | Reference compound |
| HY-140052 | Boc-aminooxy-PEG4-propargyl | 1895922-77-6 | Reference compound |
| HY-140053 | Boc-aminooxy-PEG5-propargyl | 2086688-98-2 | Reference compound |
| HY-140054 | t-Boc-aminooxy-PEG6-propargyl | 2093152-83-9 | Reference compound |
| HY-140055 | Thalidomide-PEG4-Propargyl | 2098799-77-8 | Reference compound |
| HY-140056 | Aminooxy-PEG1-propargyl | 1895922-69-6 | Reference compound |
| HY-140057 | Aminooxy-PEG3-propargyl | 1807537-27-4 | Reference compound |
| HY-140058 | Aminooxy-PEG4-propargyl | 1835759-78-8 | Reference compound |
| HY-140059 | Propargyl-PEG3-methane | 89635-82-5 | Reference compound |
| HY-140060 | Propargyl-PEG7-methane | 2730134-74-2 | Reference compound |
| HY-140061 | Propargyl-PEG11-methane | 2250411-18-6 | Reference compound |
| HY-140062 | Propargyl-PEG17-methane | 2169967-47-7 | Reference compound |
| HY-140063 | Propargyl-PEG4-CH2-methyl ester | 1872433-63-0 | Reference compound |
| HY-140064 | Propargyl-PEG1-acrylate | 52436-42-7 | Reference compound |
| HY-140065 | endo-BCN-PEG8-acid | 2126805-02-3 | Reference compound |
| HY-140066 | endo-BCN-PEG12-acid | | Reference compound |
| HY-140067 | endo-BCN-PEG2-C2-NHS ester | 2243565-12-8 | Reference compound |
| HY-140068 | endo-BCN-PEG3-NHS ester | 2101206-94-2 | Reference compound |
| HY-140069 | endo-BCN-PEG4-NHS ester | 2252422-32-3 | Reference compound |
| HY-140070 | endo-BCN-PEG8-NHS ester | 1608140-48-2 | Reference compound |
| HY-140072 | endo-BCN-PEG2-PFP ester | 1421932-53-7 | Reference compound |
| HY-140073 | endo-BCN-PEG4-PFP ester | 2904607-26-5 | Reference compound |
| HY-140074 | endo-BCN-PEG4-Boc | 1807501-83-2 | Reference compound |
| HY-140075 | endo-BCN-PEG6-Boc | | Reference compound |
| HY-140076 | endo-BCN-PEG2-alcohol | 1807501-85-4 | Reference compound |
| HY-140077 | endo-BCN-PEG3-NH-Boc | 1807501-84-3 | Reference compound |
| HY-140078 | bis-PEG2-endo-BCN | 1476737-97-9 | ADC Related |
| HY-140079 | Bis-PEG23-endo-BCN | | Reference compound |
| HY-140080 | Gly-PEG3-endo-BCN | 2354291-37-3 | Reference compound |
| HY-140081 | Boc-gly-PEG3-endo-BCN | 2110444-63-6 | ADC Related |
| HY-140082 | Hydroxy-Amino-bis(PEG2-propargyl) | 2100306-77-0 | Reference compound |
| HY-140083 | Propargyl-PEG2-N-bis(PEG2) | 2100306-62-3 | Reference compound |
| HY-140084 | N-(Propargyl-PEG4)-N-bis(PEG4-acid) | 2093153-09-2 | Reference compound |
| HY-140085 | N-(PEG2-C2-acid)-N-bis(PEG2-propargyl) | 2100306-49-6 | Reference compound |
| HY-140086 | N-(Amino-PEG1)-N-bis(PEG2-propargyl) | 2100306-47-4 | Reference compound |
| HY-140087 | N-(Amino-PEG2)-N-bis(PEG3-azide) | 2606952-86-5 | Reference compound |
| HY-140088 | NH-bis(PEG2-propargyl) | 2100306-83-8 | Reference compound |
| HY-140089 | N-Boc-N-bis(PEG2-propargyl) | 2100306-86-1 | Reference compound |
| HY-140090 | N-(Boc-PEG1)-N-bis(PEG2-propargyl) | 2100306-63-4 | Reference compound |
| HY-140091 | N-(Aminooxy-PEG2)-N-bis(PEG3-propargyl) | 2112737-71-8 | Reference compound |
| HY-140092 | N-(t-Boc-Aminooxy-PEG2)-N-bis(PEG3-propargyl) | 2112737-60-5 | Reference compound |
| HY-140093 | N-(PEG2-Boc)-N-bis(PEG2-propargyl) | 2100306-69-0 | Reference compound |
| HY-140094 | N-(Propargyl-PEG2)-N-Boc-PEG3-t-butyl ester | 2093152-78-2 | Reference compound |
| HY-140095 | N-(Propargyl-PEG4-carbonyl)-N-bis(PEG1-methyl ester) | 2112732-01-9 | Reference compound |
| HY-140096 | Aminoethyl-SS-propionic acid | 15579-00-7 | ADC Related |
| HY-140097 | Amino-SS-PEG12-acid | | ADC Related |
| HY-140098 | Boc-Cystamine | 485800-26-8 | ADC Related |
| HY-140099 | Amino-ethyl-SS-PEG3-NHBoc | 2144777-87-5 | ADC Related |
| HY-140100 | Azidoethyl-SS-propionic acid | 2228857-32-5 | ADC Related |
| HY-140101 | Azido-C2-SS-PEG2-C2-acid | 2144777-72-8 | ADC Related |
| HY-140102 | Azidoethyl-SS-propionic NHS ester | 2243566-44-9 | ADC Related |
| HY-140103 | Azidoethyl-SS-ethylalcohol | 1807540-82-4 | Reference compound |
| HY-140104 | Azidoethyl-SS-ethylamine | 1807512-40-8 | ADC Related |
| HY-140105 | Azidoethyl-SS-ethylazide | 352305-38-5 | ADC Related |
| HY-140106 | Azido-PEG3-SS-PEG3-azide | 1310827-27-0 | Reference compound |
| HY-140107 | Azidoethyl-SS-PEG2-Boc | 2144777-83-1 | Reference compound |
| HY-140108 | Propargyl-PEG1-SS-alcohol | 1391914-41-2 | ADC Related |
| HY-140109 | Propargyl-PEG1-SS-PEG1-acid | 1807503-85-0 | ADC Related |
| HY-140110 | Propargyl-PEG1-SS-PEG1-PFP ester | 1817735-30-0 | ADC Related |
| HY-140111 | Propargyl-PEG1-SS-PEG1-propargyl | 1964503-40-9 | ADC Related |
| HY-140112 | Acid-PEG2-SS-PEG2-acid | 1807539-10-1 | ADC Related |
| HY-140113 | Acid-PEG3-SS-PEG3-acid | 2055014-98-5 | ADC Related |
| HY-140114 | Acid-PEG4-S-S-PEG4-acid | 2055015-40-0 | Reference compound |
| HY-140115 | Bis-(PEG6-acid)-SS | 2055014-97-4 | ADC Related |
| HY-140116 | Boc-NH-ethyl-SS-propionic acid | 485800-27-9 | ADC Related |
| HY-140117 | Boc-aminooxy-ethyl-SS-propanol | 2128735-21-5 | ADC Related |
| HY-140118 | Fmoc-NH-ethyl-SS-propionic acid | 864235-83-6 | ADC Related |
| HY-140119 | Fmoc-NH-ethyl-SS-propionic NHS ester | 2128735-23-7 | ADC Related |
| HY-140120 | Mal-NH-ethyl-SS-propionic acid | 2128735-24-8 | ADC Related |
| HY-140121 | m-PEG6-SS-PEG6-methyl | 1007386-15-3 | ADC Related |
| HY-140122 | THP-SS-alcohol | 877864-04-5 | ADC Related |
| HY-140123 | THP-SS-PEG1-Boc | 1807503-88-3 | ADC Related |
| HY-140124 | THP-SS-PEG1-Tos | 1807512-37-3 | ADC Related |
| HY-140125 | 2-Hydroxyethyl disulfide mono-tosylate | 1807530-16-0 | ADC Related |
| HY-140126 | Bis-Tos-(2-hydroxyethyl disulfide) | 69981-39-1 | ADC Related |
| HY-140127 | Azide-C2-SS-C2-biotin | 1620523-64-9 | ADC Related |
| HY-140128 | DBCO-S-S-PEG3-biotin | 1430408-09-5 | Reference compound |
| HY-140129 | NHS-SS-biotin | 122266-55-1 | ADC Related |
| HY-140130 | PC Biotin-PEG3-alkyne | 1869922-24-6 | ADC Related |
| HY-140131 | Biotin-PEG4-PC-PEG4-alkyne | | Reference compound |
| HY-140132 | PC Biotin-PEG3-azide | 1937270-46-6 | ADC Related |
| HY-140133 | PC-Biotin-PEG4-PEG3-azide | 2055198-04-2 | ADC Related |
| HY-140134 | PC Biotin-PEG3-NHS ester | 2353409-93-3 | ADC Related |
| HY-140135 | PC-Biotin-PEG4-NHS carbonate | 2055198-03-1 | Reference compound |
| HY-140136 | PC DBCO-PEG3-biotin | | ADC Related |
| HY-140137 | WSPC Biotin-PEG3-DBCO | | Reference compound |
| HY-140138 | PC SPDP-NHS carbonate ester | 2279944-61-3 | ADC Related |
| HY-140139 | PC Alkyne-PEG4-NHS ester | 1802907-98-7 | ADC Related |
| HY-140140 | PC Mal-NHS carbonate ester | 1408057-91-9 | ADC Related |
| HY-140141 | PC Methyltetrazine-PEG4-NHS carbonate ester | 2055736-28-0 | Reference compound |
| HY-140142 | PC Azido-PEG11-NHS carbonate ester | | Reference compound |
| HY-140143 | Mal-PEG4-Val-Cit-PAB-OH | 2055041-39-7 | ADC Related |
| HY-140144 | Mal-PEG1-Val-Cit-PAB-PNP | 2249935-92-8 | ADC Related |
| HY-140145 | Mal-PEG4-Val-Cit-PAB-PNP | 2112738-09-5 | ADC Related |
| HY-140146 | Mal-amido-PEG2-Val-Cit-PAB-OH | | ADC Related |
| HY-140147 | Mal-amido-PEG2-Val-Cit-PAB-PNP | 2112738-13-1 | ADC Related |
| HY-140148 | Azido-PEG3-Val-Cit-PAB-OH | 2055024-65-0 | ADC Related |
| HY-140149 | Azido-PEG4-Val-Cit-PAB-OH | 2055024-64-9 | ADC Related |
| HY-140150 | Azido-PEG3-Val-Cit-PAB-PNP | 2055047-18-0 | ADC Related |
| HY-140152 | BCN-PEG3-VC-PFP ester | 2353409-45-5 | ADC Related |
| HY-140153 | Methylamino-PEG2-acid | 1807503-87-2 | Reference compound |
| HY-140154 | Methylamino-PEG1-Boc | 1807521-03-4 | Reference compound |
| HY-140155 | Methylamino-PEG2-Boc | 1807521-04-5 | Reference compound |
| HY-140156 | Methylamino-PEG4-Boc | 1621616-14-5 | Reference compound |
| HY-140157 | N-Me-N-bis(PEG4-C2-Boc) | | Reference compound |
| HY-140158 | Methylamino-PEG3-azide | 1355197-57-7 | Reference compound |
| HY-140159 | Methylamino-PEG5-azide | 2055046-24-5 | Reference compound |
| HY-140161 | PEG3-methylamine | 282551-10-4 | Reference compound |
| HY-140162 | Hydroxy-PEG4-methylamine | 90430-59-4 | Reference compound |
| HY-140163 | N,N'-DME-N-PEG2-Boc | 2279944-69-1 | Reference compound |
| HY-140164 | Azido-PEG2-C2-sulfonic acid | 1817735-39-9 | Reference compound |
| HY-140165 | Bis-PEG3-sulfonic acid | 255831-16-4 | Reference compound |
| HY-140166 | Bis-PEG4-sulfonic acid | 1807539-08-7 | Reference compound |
| HY-140167 | Carboxy-PEG2-sulfonic acid | 1817735-45-7 | Reference compound |
| HY-140168 | Carboxy-PEG4-sulfonic acid | 1817735-25-3 | Reference compound |
| HY-140169 | Carboxy-PEG5-sulfonic acid | 1817735-38-8 | Reference compound |
| HY-140170 | m-PEG4-sulfonic acid | 787524-78-1 | Reference compound |
| HY-140171 | m-PEG5-sulfonic acid | 1807505-35-6 | Reference compound |
| HY-140172 | Boc-NH-PEG3-sulfonic acid | 1817735-32-2 | Reference compound |
| HY-140173 | Boc-PEG2-sulfonic acid | 1817735-40-2 | Reference compound |
| HY-140174 | Boc-PEG4-sulfonic acid | 1817735-26-4 | Reference compound |
| HY-140175 | Butoxycarbonyl-PEG5-sulfonic acid | 1817735-28-6 | Reference compound |
| HY-140176 | Amino-PEG10-acid | 2170987-85-4 | Reference compound |
| HY-140177 | Amino-PEG12-acid | 1415408-69-3 | Reference compound |
| HY-140178 | Amino-PEG14-acid | | Reference compound |
| HY-140179 | Amino-PEG16-acid | 2922656-52-6 | Reference compound |
| HY-140180 | Amino-PEG20-acid | | Reference compound |
| HY-140181 | Amino-PEG23-acid | | Reference compound |
| HY-140182 | Amino-PEG24-acid | 2563873-76-5 | Reference compound |
| HY-140183 | Amino-PEG25-acid | | Reference compound |
| HY-140184 | Amino-PEG28-acid | | Reference compound |
| HY-140185 | Amino-PEG32-acid | | Reference compound |
| HY-140186 | Amino-PEG36-acid | 2241751-76-6 | Reference compound |
| HY-140187 | Amino-PEG36-CONH-PEG36-acid | | Reference compound |
| HY-140188 | Amino-PEG6-amido-C16-COOH | | Reference compound |
| HY-140189 | Amino-PEG3-CH2COOH | 134978-99-7 | Reference compound |
| HY-140190 | Amino-PEG2-(CH2)3COOH | 1263046-77-0 | Reference compound |
| HY-140191 | Amino-PEG4-(CH2)3CO2H | 144598-03-8 | Reference compound |
| HY-140193 | Amino-PEG4-Boc | 581065-95-4 | Reference compound |
| HY-140194 | Amino-PEG5-Boc | 1446282-18-3 | Reference compound |
| HY-140195 | Amino-PEG9-Boc | 1818294-44-8 | Reference compound |
| HY-140196 | Amino-PEG10-Boc | 1818294-42-6 | Reference compound |
| HY-140197 | Amino-PEG12-Boc | 1383814-00-3 | Reference compound |
| HY-140198 | Amino-PEG20-Boc | | Reference compound |
| HY-140199 | Amino-PEG24-Boc | 2170987-96-7 | Reference compound |
| HY-140200 | Amino-PEG36-Boc | | Reference compound |
| HY-140201 | Amino-PEG6-amido-C16-Boc | | Reference compound |
| HY-140202 | Amino-PEG9-amido-C16-Boc | | Reference compound |
| HY-140204 | Amino-PEG9-alcohol | 15332-95-3 | Reference compound |
| HY-140205 | Amino-PEG12-alcohol | 1345681-71-1 | Reference compound |
| HY-140206 | Amino-PEG24-alcohol | 2226726-55-0 | Reference compound |
| HY-140207 | Amino-PEG36-alcohol | 2718868-96-1 | Reference compound |
| HY-140208 | 2,2-Oxybis(ethylamine) | 2752-17-2 | Reference compound |
| HY-140209 | Amino-PEG7-amine | 332941-25-0 | Reference compound |
| HY-140210 | Amino-PEG9-amine | 474082-35-4 | Reference compound |
| HY-140211 | Amino-PEG23-amine | 2673284-93-8 | Reference compound |
| HY-140212 | Azido-PEG1-amine | 464190-91-8 | Reference compound |
| HY-140213 | Azido-PEG2-C2-amine | 166388-57-4 | ADC Related |
| HY-140214 | Azido-PEG5-amine | 516493-93-9 | Reference compound |
| HY-140215 | Azido-PEG6-amine | 957486-82-7 | ADC Related |
| HY-140216 | Azido-PEG8-amine | 857891-82-8 | Reference compound |
| HY-140217 | Azido-PEG10-amine | 912849-73-1 | Reference compound |
| HY-140218 | Azido-PEG11-amine | 1800414-71-4 | Reference compound |
| HY-140219 | Azido-PEG23-amine | 2172677-19-7 | Reference compound |
| HY-140220 | Azido-PEG35-amine | 2301851-71-6 | Reference compound |
| HY-140221 | Azido-PEG1-C2-methylamine | 1835759-88-0 | Reference compound |
| HY-140222 | Amino-PEG2-C2-hydrazide-Boc | 2100306-60-1 | Reference compound |
| HY-140223 | Amino-PEG4-hydrazide-Boc | 1263047-17-1 | Reference compound |
| HY-140224 | Amino-PEG8-hydrazide-Boc | 1334169-96-8 | Reference compound |
| HY-140225 | m-PEG5-NH2 | 5498-83-9 | Reference compound |
| HY-140226 | m-PEG10-amine | 1383658-09-0 | ADC Related |
| HY-140227 | m-PEG12-amine | 1977493-48-3 | ADC Related |
| HY-140228 | m-PEG24-NH2 | 2151823-08-2 | Reference compound |
| HY-140229 | m-PEG36-amine | | Reference compound |
| HY-140230 | m-PEG48-amine | 2416858-25-6 | Reference compound |
| HY-140231 | Boc-NH-PEG6-amine | 1091627-77-8 | Reference compound |
| HY-140232 | Boc-NH-PEG7-NH2 | 206265-98-7 | Reference compound |
| HY-140233 | Boc-amido-PEG9-amine | 890091-43-7 | Reference compound |
| HY-140234 | Boc-NH-PEG11-NH2 | 1233234-77-9 | Reference compound |
| HY-140235 | Boc-NH-PEG15-NH2 | 2222566-55-2 | Reference compound |
| HY-140236 | Boc-NH-PEG23-NH2 | | Reference compound |
| HY-140237 | Boc-Gly-amido-C-PEG3-C3-amine | 525583-49-7 | Reference compound |
| HY-140238 | Cbz-N-PEG15-amine | | Reference compound |
| HY-140239 | Amino-PEG4-benzyl ester | 1351397-21-1 | Reference compound |
| HY-140240 | Amino-PEG6-Thalidomide | | Reference compound |
| HY-140241 | NH2-PEG4-Glu(OH)-NH-m-PEG24 | | Reference compound |
| HY-140242 | NH2-PEG4-Lys(Boc)-NH-(m-PEG24) | | ADC Related |
| HY-140243 | 1,1,1-Trifluoroethyl-PEG4-amine | 1872433-72-1 | Reference compound |
| HY-140244 | Gly-PEG3-amine | 2110448-97-8 | ADC Related |
| HY-140245 | N-(Amino-PEG3)-N-bis(PEG3-acid) | 2055042-59-4 | Reference compound |
| HY-140246 | N-(PEG3-acid)-N-bis(PEG3-amine) | 2183440-35-7 | Reference compound |
| HY-140247 | N-(Azido-PEG3)-N-(PEG2-amine)-PEG3-acid | 2183440-70-0 | Reference compound |
| HY-140248 | N-(Mal-PEG6)-N-bis(PEG3-amine) | 2055040-99-6 | Reference compound |
| HY-140249 | Tri(Amino-PEG3-amide)-amine | 2523025-40-1 | Reference compound |
| HY-140249A | Tri(Amino-PEG3-amide)-amine (TFA) | | Reference compound |
| HY-140250 | Tri(Amino-PEG4-amide)-amine | | Reference compound |
| HY-140250A | Tri(Amino-PEG4-amide)-amine (TFA) | | Reference compound |
| HY-140251 | Tri(Amino-PEG5-amide)-amine | 2055013-52-8 | Reference compound |
| HY-140252 | NH-bis(C1-PEG1-Boc) | 2171072-53-8 | Reference compound |
| HY-140253 | N-(Amino-PEG3)-N-bis(PEG3-Boc) | 2055042-62-9 | Reference compound |
| HY-140254 | N-(Amino-PEG3)-N-bis(PEG4-Boc) | 2353409-57-9 | Reference compound |
| HY-140255 | N-(Amino-PEG4)-N-bis(PEG4-Boc) | 2093153-97-8 | Reference compound |
| HY-140256 | NH-bis(PEG2-C2-Boc) | 1964503-36-3 | Reference compound |
| HY-140257 | NH-bis(PEG3-Boc) | 1814901-03-5 | Reference compound |
| HY-140258 | NH-bis(PEG4-Boc) | 2055041-41-1 | Reference compound |
| HY-140259 | N-(Boc-PEG4)-NH-PEG4-NH-Boc | 2112737-17-2 | Reference compound |
| HY-140260 | NH-bis(PEG3-C2-NH-Boc) | 2055024-51-4 | Reference compound |
| HY-140261 | NH-bis(PEG4-C2-NH-Boc) | 2182601-75-6 | Reference compound |
| HY-140262 | Amino-Tri-(m-PEG4-ethoxymethyl)-methane | 1428661-67-9 | Reference compound |
| HY-140263 | NH-bis(m-PEG4) | 123852-08-4 | Reference compound |
| HY-140264 | NH-bis(m-PEG8) | 2055013-64-2 | Reference compound |
| HY-140265 | DBCO-PEG1-acid | 2228857-38-1 | Reference compound |
| HY-140266 | DBCO-PEG2-acid | 2304558-25-4 | Reference compound |
| HY-140267 | DBCO-PEG5-acid | 2764923-65-9 | Reference compound |
| HY-140268 | DBCO-PEG8-acid | 2765066-35-9 | Reference compound |
| HY-140269 | DBCO-PEG12-acid | 2754384-72-8 | Reference compound |
| HY-140270 | DBCO-NHCO-PEG13-acid | | Reference compound |
| HY-140271 | DBCO-PEG1-NHS ester | 2228857-34-7 | Reference compound |
| HY-140272 | DBCO-PEG4-NHS ester | 1427004-19-0 | Reference compound |
| HY-140273 | DBCO-PEG8-NHS ester | 2553412-88-5 | Reference compound |
| HY-140274 | DBCO-PEG12-NHS ester | 2093934-94-0 | Reference compound |
| HY-140275 | DBCO-NHCO-PEG5-NHS ester | 1378531-80-6 | Reference compound |
| HY-140276 | DBCO-NHCO-PEG13-NHS ester | | Reference compound |
| HY-140277 | DBCO-PEG2-PFP ester | 2304558-23-2 | Reference compound |
| HY-140278 | DBCO-PEG4-PFP ester | | Reference compound |
| HY-140279 | DBCO-PEG4-alcohol | 1416711-60-8 | Reference compound |
| HY-140280 | DBCO-PEG1 | 1839049-33-0 | Reference compound |
| HY-140281 | DBCO-C-PEG1 | 2377004-09-4 | Reference compound |
| HY-140282 | DBCO-PEG1-amine | 2364591-79-5 | Reference compound |
| HY-140283 | DBCO-PEG2-amine | 2250216-96-5 | Reference compound |
| HY-140284 | DBCO-PEG6-amine | 2353409-98-8 | Reference compound |
| HY-140284A | DBCO-PEG6-amine (TFA) | | Reference compound |
| HY-140285 | DBCO-PEG9-amine | 2353409-99-9 | Reference compound |
| HY-140286 | Sulfo DBCO-PEG4-amine | 2055198-05-3 | Reference compound |
| HY-140287 | DBCO-C2-PEG4-amine | | Reference compound |
| HY-140288 | DBCO-C3-PEG4-amine | | Reference compound |
| HY-140289 | DBCO-PEG1-NH-Boc | 2364591-77-3 | Reference compound |
| HY-140290 | DBCO-PEG2-NH-Boc | 2377004-08-3 | Reference compound |
| HY-140291 | DBCO-PEG4-NH-Boc | 2353410-17-8 | Reference compound |
| HY-140292 | DBCO-PEG9-NH-Boc | | Reference compound |
| HY-140293 | DBCO-NH-Boc | 1539290-74-8 | Reference compound |
| HY-140294 | DBCO-C2-PEG4-NH-Boc | | Reference compound |
| HY-140295 | DBCO-C3-PEG4-NH-Boc | | Reference compound |
| HY-140296 | BDP FL DBCO | 2093197-94-3 | Dye Reagents |
| HY-140297 | Carboxyrhodamine 110-PEG4-DBCO | | Reference compound |
| HY-140301 | DBCO-PEG4-Desthiobiotin | 2032788-37-5 | Reference compound |
| HY-140302 | DBCO-PEG5-DBCO | 2363130-04-3 | Reference compound |
| HY-140303 | DBCO-PEG9-DBCO | 2353409-50-2 | Reference compound |
| HY-140304 | DBCO-PEG10-DBCO | | Reference compound |
| HY-140305 | DBCO-PEG13-DBCO | | Reference compound |
| HY-140306 | Mal-Sulfo-DBCO | 2028281-86-7 | ADC Related |
| HY-140307 | Sulfo DBCO-PEG4-Maleimide | 2055198-07-5 | Reference compound |
| HY-140307A | Sulfo DBCO-PEG4-Maleimide (TEA) | | Reference compound |
| HY-140308 | DBCO-PEG4-triethoxysilane | 2353410-02-1 | Reference compound |
| HY-140309 | Gly-Gly-Gly-PEG4-DBCO | 2353409-80-8 | ADC Related |
| HY-140310 | TCO-PEG4-DBCO | 1801863-88-6 | ADC Related |
| HY-140312 | Methyltetrazine-PEG12-DBCO | | Reference compound |
| HY-140313 | Methyltetrazine-DBCO | 1802238-48-7 | ADC Related |
| HY-140314 | DOTA-PEG5-C6-DBCO | | Reference compound |
| HY-140315 | m-PEG4-NH-DBCO | 2228857-36-9 | Reference compound |
| HY-140316 | m-PEG8-DBCO | | Reference compound |
| HY-140317 | m-PEG12-DBCO | | Reference compound |
| HY-140318 | DBCO-mPEG (MW 2kDa) | | Reference compound |
| HY-140319 | DBCO-mPEG (MW 5kDa) | | Reference compound |
| HY-140320 | DBCO-mPEG (MW 10kDa) | | Reference compound |
| HY-140321 | DBCO-mPEG (MW 20kDa) | | Reference compound |
| HY-140322 | DBCO-mPEG (MW 30kDa) | | Reference compound |
| HY-140323 | Tetraethyl heptane-1,7-diylbis(phosphonate) | 5943-17-9 | Reference compound |
| HY-140324 | Tetraethyl octane-1,8-diylbis(phosphonate) | 5943-61-3 | Reference compound |
| HY-140325 | Tetraethyl decane-1,10-diylbis(phosphonate) | 5943-62-4 | Reference compound |
| HY-140326 | Hexane-1,6-diyldiphosphonic acid | 4721-22-6 | Reference compound |
| HY-140327 | [10-(Diethoxy-phosphoryl)-decyl]-phosphonic acid | 1446282-24-1 | Reference compound |
| HY-140328 | 4-Bromobutylphosphonic acid | 1190-14-3 | Reference compound |
| HY-140329 | 6-Bromohexylphosphonic acid | 133345-66-1 | Reference compound |
| HY-140330 | (10-BRomodecyl)phosphonic acid | 934985-98-5 | Reference compound |
| HY-140331 | Diethyl 4-bromobutylphosphonate | 63075-66-1 | Reference compound |
| HY-140332 | Diethyl 8-bromooctylphosphonate | 124939-70-4 | Reference compound |
| HY-140333 | Diethyl 10-bromodecylphosphonate | 272785-01-0 | Reference compound |
| HY-140334 | Diethyl 12-bromododecylphosphonate | 264231-28-9 | Reference compound |
| HY-140335 | Alkynyl myristic acid | 82909-47-5 | Reference compound |
| HY-140336 | C-NH-Boc-C-Bis-(C-PEG1-Boc) | 1807503-91-8 | Reference compound |
| HY-140337 | Ph-Bis(C1-N-(C2-NH-Boc)2) | 1807521-06-7 | Reference compound |
| HY-140338 | Benzenedimethanamine-diethylamine | 71277-17-3 | Reference compound |
| HY-140339 | ANB-NOS | 60117-35-3 | Reference compound |
| HY-140340 | Fmoc-NH-pentanoic acid-NHS-SO3Na | | Reference compound |
| HY-140341 | Sulfo-NHS-Acetate | 152305-87-8 | Reference compound |
| HY-140341A | Sulfo-NHS-Acetate (sodium) | 221222-61-3 | Reference compound |
| HY-140342 | Boc-C16-NHS ester | 843666-34-2 | Reference compound |
| HY-140343 | Ac4GalNAl | 1673590-09-4 | Reference compound |
| HY-140345 | L-Homopropargylglycine | 98891-36-2 | Reference compound |
| HY-140345A | L-Homopropargylglycine (hydrochloride) | 942518-19-6 | Reference compound |
| HY-140346 | L-Azidohomoalanine | 120042-14-0 | Reference compound |
| HY-140346A | L-Azidohomoalanine (hydrochloride) | 942518-29-8 | Reference compound |
| HY-140346AS | L-Azidohomoalanine-1,2,3,4-13C4 (hydrochloride) | 2483829-89-4 | Isotope-Labeled Compounds |
| HY-140347 | APN-C3-NH-Boc | 1539292-60-8 | Reference compound |
| HY-140348 | APN-NH2 | 1539292-61-9 | Reference compound |
| HY-140349 | AZD-CO-C2-Ph-amido-Ph-azide | 1383544-71-5 | Reference compound |
| HY-140350 | 5-endo-BCN-pentanoic acid | 2364591-80-8 | Reference compound |
| HY-140351 | Azide-PEG4-Tos | 168640-82-2 | Reference compound |
| HY-140352 | Azide-PEG5-Tos | 236754-49-7 | ADC Related |
| HY-140353 | Azide-PEG6-Tos | 906007-10-1 | Reference compound |
| HY-140354 | Azide-PEG7-Tos | 1418561-41-7 | Reference compound |
| HY-140355 | Azide-PEG12-Tos | 1821464-56-5 | Reference compound |
| HY-140356 | Tos-PEG6-OH | 42749-28-0 | Reference compound |
| HY-140357 | Tos-PEG9 | 62573-11-9 | Reference compound |
| HY-140358 | PEG20-Tos | 2179113-08-5 | Reference compound |
| HY-140359 | m-PEG7-Tos | 79622-11-0 | Reference compound |
| HY-140360 | m-PEG10-Tos | 211859-75-5 | Reference compound |
| HY-140361 | m-PEG11-Tos | | Reference compound |
| HY-140362 | m-PEG2-MS | 60696-83-5 | Reference compound |
| HY-140363 | m-PEG3-OMs | 74654-05-0 | Reference compound |
| HY-140364 | m-PEG6-MS | 130955-39-4 | Reference compound |
| HY-140365 | Tos-PEG13-Boc | 2820397-84-8 | Reference compound |
| HY-140366 | Tos-PEG5-CH2COOtBu | 1949793-62-7 | Reference compound |
| HY-140367 | Bis-Tos-PEG6 | 42749-27-9 | Reference compound |
| HY-140368 | Bis-Tos-PEG7 | 69502-27-8 | Reference compound |
| HY-140369 | Tos-PEG8-Tos | 57436-38-1 | Reference compound |
| HY-140370 | Tos-PEG9-Tos | 109635-64-5 | Reference compound |
| HY-140371 | Tos-PEG12-Tos | 1456708-45-4 | Reference compound |
| HY-140372 | Tos-PEG20-Tos | | Reference compound |
| HY-140373 | Tos-PEG21-Tos | | Reference compound |
| HY-140374 | Propargyl-PEG2-Tos | 145916-41-2 | Reference compound |
| HY-140375 | Tos-PEG3-C2-methyl ester | 1239588-09-0 | Reference compound |
| HY-140376 | Boc-NH-PEG7-Tos | 1292268-14-4 | Reference compound |
| HY-140377 | Boc-Aminooxy-PEG4-Tos | 1807539-01-0 | Reference compound |
| HY-140378 | t-Boc-Aminooxy-PEG8-MS | | Reference compound |
| HY-140379 | 1,1,1-Trifluoroethyl-PEG4-Tos | 1872433-61-8 | Reference compound |
| HY-140380 | Tos-aminoxy-Boc-PEG4-Tos | 1817735-42-4 | Reference compound |
| HY-140381 | Azide-PEG2-MS | 176520-23-3 | Reference compound |
| HY-140382 | Ms-PEG2-MS | 34604-52-9 | Reference compound |
| HY-140383 | Ms-PEG2-C2-Boc | 1312309-62-8 | Reference compound |
| HY-140384 | Ms-PEG5-t-butyl ester | 870487-48-2 | Reference compound |
| HY-140385 | Ms-PEG8-Boc | 2097604-01-6 | Reference compound |
| HY-140386 | Ms-PEG10-t-butyl ester | | Reference compound |
| HY-140387 | Ms-PEG12-Boc | | Reference compound |
| HY-140388 | PEG4-MS | 65883-12-7 | Reference compound |
| HY-140389 | PEG7-O-MS | 1217601-12-1 | Reference compound |
| HY-140390 | Boc-N-PEG2-MS | 302331-20-0 | Reference compound |
| HY-140391 | Boc-NH-PEG4-MS | 1447797-72-9 | Reference compound |
| HY-140392 | Boc-N-Amido-PEG5-MS | 2128735-28-2 | Reference compound |
| HY-140393 | N-(Tos-PEG4)-N-bis(PEG4-Boc) | 2112737-74-1 | Reference compound |
| HY-140394 | Aminooxy-PEG4-acid | 1807537-38-7 | Reference compound |
| HY-140395 | Aminooxy-PEG8-acid | 2055269-60-6 | Reference compound |
| HY-140396 | Aminooxy-PEG3-bromide | 1895922-73-2 | Reference compound |
| HY-140396A | Aminooxy-PEG3-bromide (hydrochloride) | | Reference compound |
| HY-140396C | Aminooxy-PEG3-bromide (hydrobromide) | | Reference compound |
| HY-140397 | m-PEG2-Amino | 54149-49-4 | Reference compound |
| HY-140398 | m-PEG3-Aminooxy | 248275-10-7 | Reference compound |
| HY-140399 | Aminooxy-PEG7-methane | 1370698-27-3 | Reference compound |
| HY-140400 | Aminooxy-PEG8-methane | 2055024-52-5 | Reference compound |
| HY-140401 | Aminooxy-PEG3-C2-Boc | 1835759-72-2 | Reference compound |
| HY-140402 | Aminooxy-PEG4-C2-Boc | 2100306-82-7 | Reference compound |
| HY-140403 | Aminooxy-PEG4-CH2-Boc | 2062663-62-9 | Reference compound |
| HY-140404 | Aminooxy-PEG3-methyl ester | 2086689-03-2 | Reference compound |
| HY-140405 | 1-(t-Boc-Aminooxy)-3-aminooxy-propane | 1352546-80-5 | Reference compound |
| HY-140406 | Aminooxy-PEG3-C2-NH-Boc | 2062663-65-2 | Reference compound |
| HY-140407 | Bis-aminooxy-PEG1 | 93460-33-4 | Reference compound |
| HY-140408 | Bis-aminooxy-PEG2 | 98627-71-5 | Reference compound |
| HY-140409 | Bis-aminooxy-PEG3 | 98627-70-4 | Reference compound |
| HY-140410 | Bis-aminooxy-PEG4 | 98627-72-6 | Reference compound |
| HY-140411 | Bis-aminooxy-PEG7 | 1383980-52-6 | Reference compound |
| HY-140412 | Boc-Aminooxy-PEG3-acid | 1835759-82-4 | Reference compound |
| HY-140413 | Boc-aminoxy-PEG4-acid | 2062663-68-5 | Reference compound |
| HY-140414 | t-Boc-Aminooxy-PEG12-acid | | Reference compound |
| HY-140415 | Boc-Aminooxy-PEG2-CH2COOH | 2098983-14-1 | Reference compound |
| HY-140416 | Boc-Aminooxy-PEG4-CH2CO2H | 2028281-90-3 | Reference compound |
| HY-140417 | t-Boc-Aminooxy-PEG4-NHS ester | 2401831-99-8 | Reference compound |
| HY-140418 | t-Boc-Aminooxy-PEG12-NHS ester | | Reference compound |
| HY-140419 | t-Boc-Aminooxy-PEG12-Boc | | Reference compound |
| HY-140420 | Boc-Aminooxy-PEG4-CH2-Boc | 2062663-63-0 | Reference compound |
| HY-140421 | Boc-Aminooxy-PEG2 | 1807503-86-1 | Reference compound |
| HY-140422 | t-Boc-Aminooxy-PEG3-alcohol | 252378-66-8 | Reference compound |
| HY-140423 | Boc-Aminoxy-PEG4-OH | 918132-14-6 | Reference compound |
| HY-140424 | t-Boc-Aminooxy-PEG8-alcohol | 2353410-14-5 | Reference compound |
| HY-140425 | Boc-Aminooxy-PEG1-C2-NH2 | 1844894-82-1 | Reference compound |
| HY-140426 | Boc-Aminooxy-PEG2-C2-amine | 252378-69-1 | Reference compound |
| HY-140427 | Boc-Aminooxy-PEG3-C2-NH2 | 1235514-18-7 | Reference compound |
| HY-140428 | Boc-Aminooxy-PEG5-amine | 2250216-94-3 | Reference compound |
| HY-140429 | t-Boc-Aminooxy-PEG7-amine | 2226611-29-4 | Reference compound |
| HY-140430 | Boc-Aminooxy-PEG1-azide | 2100306-67-8 | Reference compound |
| HY-140431 | t-Boc-Aminooxy-PEG2-azide | 252378-68-0 | Reference compound |
| HY-140432 | Boc-Aminooxy-PEG3-azide | 1235514-15-4 | Reference compound |
| HY-140433 | Boc-Aminooxy-PEG4-azide | 2100306-64-5 | Reference compound |
| HY-140434 | t-Boc-Aminooxy-PEG5-azide | 2250216-95-4 | Reference compound |
| HY-140435 | Boc-Aminooxy-PEG3-bromide | 918132-15-7 | Reference compound |
| HY-140436 | t-Boc-Aminooxy-PEG7-bromide | 2353410-15-6 | Reference compound |
| HY-140437 | t-Boc-Aminooxy-PEG7-methane | 2055041-27-3 | Reference compound |
| HY-140438 | Boc-Aminooxy-PEG4-NH2 | 2062663-66-3 | Reference compound |
| HY-140439 | Boc-Aminooxy-PEG3-thiol | 1895922-75-4 | Reference compound |
| HY-140440 | Fmoc-aminooxy-PEG4-acid | 1895922-70-9 | Reference compound |
| HY-140441 | Fmoc-aminooxy-PEG12-acid | | Reference compound |
| HY-140442 | Fmoc-aminooxy-PEG12-NHS ester | | Reference compound |
| HY-140443 | Cbz-aminooxy-PEG8-acid | 2353410-09-8 | Reference compound |
| HY-140444 | Cbz-aminooxy-PEG8-Boc | | Reference compound |
| HY-140445 | 1,1,1-Trifluoroethyl-PEG4-aminooxy | 1895922-78-7 | Reference compound |
| HY-140446 | N-(Aminooxy-PEG3)-N-bis(PEG4-Boc) | 2112737-19-4 | Reference compound |
| HY-140447 | Diketone-PEG11-PFP ester | | Reference compound |
| HY-140448 | Diketone-PEG4-Biotin | 2353409-85-3 | Reference compound |
| HY-140449 | Diketone-PEG12-Biotin | | Reference compound |
| HY-140450 | Diketone-PEG12-DBCO | | Reference compound |
| HY-140451 | Diketone-PEG11-Diketone | | Reference compound |
| HY-140452 | Azido-PEG2-C2-acid | 1312309-63-9 | Reference compound |
| HY-140453 | Azido-PEG6-acid | 361189-66-4 | Reference compound |
| HY-140454 | Azido-PEG8-acid | 1214319-92-2 | ADC Related |
| HY-140455 | Azido-PEG10-acid | 1644163-57-4 | Reference compound |
| HY-140456 | Azido-PEG12-acid | 2152679-71-3 | Reference compound |
| HY-140457 | Azido-PEG24-acid | 2195075-62-6 | Reference compound |
| HY-140458 | Azido-PEG36-acid | | Reference compound |
| HY-140459 | 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid | 846549-37-9 | Reference compound |
| HY-140460 | Fmoc-N-PEG7-acid | 1863885-74-8 | Reference compound |
| HY-140461 | Fmoc-NH-PEG10-acid | 2101563-45-3 | Reference compound |
| HY-140462 | Fmoc-N-PEG20-acid | 1952360-93-8 | Reference compound |
| HY-140463 | Fmoc-N-PEG23-acid | | Reference compound |
| HY-140464 | Fmoc-N-PEG36-acid | 2649489-46-1 | Reference compound |
| HY-140465 | Fmoc-NMe-PEG4-C2-acid | 2170240-98-7 | Reference compound |
| HY-140466 | Fmoc-NH-PEG11-CH2COOH | 2629308-66-1 | Reference compound |
| HY-140467 | Fmoc-NH-PEG12-CH2COOH | 2291257-76-4 | Reference compound |
| HY-140468 | Boc-N-amido-PEG3-acid | 1347750-75-7 | Reference compound |
| HY-140469 | Boc-NH-PEG7-acid | 2055044-68-1 | Reference compound |
| HY-140470 | Boc-NH-PEG8-CH2CH2COOH | 1334169-93-5 | Reference compound |
| HY-140471 | Boc-NH-PEG10-CH2CH2COOH | 2410598-01-3 | Reference compound |
| HY-140472 | Boc-NH-PEG12-CH2CH2COOH | 1415981-79-1 | Reference compound |
| HY-140473 | Boc-NH-PEG20-CH2CH2COOH | 2941512-86-1 | Reference compound |
| HY-140474 | Boc-NH-PEG24-CH2CH2COOH | 2839118-68-0 | Reference compound |
| HY-140475 | Boc-NH-PEG36-CH2CH2COOH | | Reference compound |
| HY-140476 | Boc-NH-PEG1-CH2COOH | 142929-49-5 | Reference compound |
| HY-140477 | Boc-NH-PEG6-CH2COOH | 391684-36-9 | Reference compound |
| HY-140478 | Boc-NH-PEG4-C3-acid | 1416777-48-4 | Reference compound |
| HY-140479 | Acid-PEG1-C2-Boc | 2086689-08-7 | Reference compound |
| HY-140480 | Acid-PEG2-C2-Boc | 2086688-99-3 | Reference compound |
| HY-140481 | Acid-PEG5-C2-Boc | 1309460-29-4 | Reference compound |
| HY-140482 | Acid-PEG6-C2-Boc | 2093153-84-3 | Reference compound |
| HY-140483 | Acid-C1-PEG5-Boc | 2304558-22-1 | Reference compound |
| HY-140484 | Acid-PEG3-mono-methyl ester | 1807505-26-5 | Reference compound |
| HY-140485 | Acid-PEG5-mono-methyl ester | 1309460-30-7 | Reference compound |
| HY-140486 | Acid-PEG6-mono-methyl ester | 1807512-38-4 | Reference compound |
| HY-140487 | Cbz-NH-PEG2-C2-acid | 1347750-76-8 | Reference compound |
| HY-140488 | Cbz-NH-PEG3-C2-acid | 1310327-18-4 | Reference compound |
| HY-140489 | Cbz-NH-PEG5-C2-acid | 1347750-74-6 | Reference compound |
| HY-140490 | Cbz-N-PEG10-acid | | Reference compound |
| HY-140491 | Cbz-N-amido-PEG20-acid | | Reference compound |
| HY-140492 | Biotin-PEG8-acid | 2143964-62-7 | Reference compound |
| HY-140493 | Biotin-PEG12-acid | 1621423-14-0 | Reference compound |
| HY-140494 | Biotin-PEG36-acid | | Reference compound |
| HY-140495 | DNP-PEG6-acid | | Reference compound |
| HY-140496 | DNP-PEG12-acid | | Reference compound |
| HY-140497 | Hydroxy-PEG2-CH2COOH | 51951-04-3 | Reference compound |
| HY-140497A | Hydroxy-PEG2-CH2COONa | 42588-76-1 | Reference compound |
| HY-140498 | Hydroxy-PEG4-CH2COOH | 70678-95-4 | Reference compound |
| HY-140499 | m-PEG9-acid | 2576495-35-5 | Reference compound |
| HY-140500 | m-PEG10-acid | 2409969-94-2 | ADC Related |
| HY-140501 | m-PEG11-acid | 2280998-74-3 | ADC Related |
| HY-140502 | m-PEG17-acid | 2346581-96-0 | Reference compound |
| HY-140503 | m-PEG8-ethoxycarbonyl-propanoic acid | 2353409-75-1 | Reference compound |
| HY-140504 | m-PEG12-COO-propanoic acid | 2168540-50-7 | Reference compound |
| HY-140505 | m-PEG3-Propanoyl chloride | 66722-87-0 | Reference compound |
| HY-140506 | m-PEG6-O-CH2COOH | 75427-75-7 | Reference compound |
| HY-140507 | m-PEG4-CH2-acid | 874208-84-1 | Reference compound |
| HY-140508 | m-PEG12-NH-C2-acid | 1949843-39-3 | Reference compound |
| HY-140509 | TAMRA-PEG4-acid | 1909223-02-4 | Dye Reagents |
| HY-140510 | N-Methyl-N-(t-Boc)-PEG4-acid | 1260431-01-3 | Reference compound |
| HY-140511 | Acid-PEG3-PFP ester | 1835759-67-5 | Reference compound |
| HY-140512 | Acid-PEG5-TEMPO | 2055040-79-2 | Reference compound |
| HY-140513 | Active-mono-sulfone-PEG8-acid | 2055048-45-6 | Reference compound |
| HY-140514 | NH-bis(PEG2-C2-acid) | 1919044-99-7 | Reference compound |
| HY-140515 | NH-bis(PEG3-acid) | 1814901-04-6 | Reference compound |
| HY-140516 | NH-bis(PEG4-acid) | 2055041-59-1 | Reference compound |
| HY-140517 | N-(Azido-PEG3)-N-bis(PEG3-acid) | 2055042-57-2 | Reference compound |
| HY-140518 | N-(Azido-PEG3)-N-bis(PEG4-acid) | 2112731-54-9 | Reference compound |
| HY-140519 | N-(Azido-PEG4)-N-bis(PEG4-acid) | 2093152-80-6 | Reference compound |
| HY-140520 | N-(acid-PEG3)-N-bis(PEG3-azide) | 2182602-17-9 | Reference compound |
| HY-140521 | N-(Acid-PEG2)-N-bis(PEG3-azide) | 2320560-35-6 | Reference compound |
| HY-140522 | 2-(Azido-PEG3-amido)-1,3-bis(carboxylethoxy)propane | 2086689-05-4 | Reference compound |
| HY-140523 | Azido-PEG4-amido-tri-(carboxyethoxymethyl)-methane | 1398044-51-3 | Reference compound |
| HY-140524 | N-(Azido-PEG2)-N-Boc-PEG3-acid | 2086689-01-0 | Reference compound |
| HY-140525 | N-(Azido-PEG2)-N-Boc-PEG4-acid | 2093153-82-1 | Reference compound |
| HY-140526 | N-(Azido-PEG3)-N-Boc-PEG3-acid | 2112731-52-7 | Reference compound |
| HY-140527 | 1,3-bis(carboxyethoxy)-2,2-bis(carboxyethoxy)propane | 35638-19-8 | Reference compound |
| HY-140528 | N-Biotin-N-bis(PEG4-acid) | 1964503-35-2 | Reference compound |
| HY-140529 | N-Mal-N-bis(PEG2-acid) | 2110449-02-8 | Reference compound |
| HY-140530 | Mal-N-bis(PEG4-C2-acid) | 2100306-52-1 | Reference compound |
| HY-140531 | N-(Biotin-PEG4)-N-bis(PEG4-acid) | 2112731-48-1 | Reference compound |
| HY-140531A | N-(Biotin-PEG4)-N-bis(PEG4-acid) (hydrochloride) | 2112731-49-2 | Reference compound |
| HY-140532 | N-(Amino-PEG4)-N-Biotin-PEG4-acid | 2100306-84-9 | Reference compound |
| HY-140533 | N-(Azido-PEG2)-N-biotin-PEG3-acid | 2112731-59-4 | Reference compound |
| HY-140534 | 4-(N-Boc-amino)-1,6-heptanedioic acid | 848242-88-6 | Reference compound |
| HY-140535 | Boc-NH-Bis(acid-PEG1-m) | 1398044-54-6 | Reference compound |
| HY-140536 | N-(Boc-PEG3)-N-bis(PEG3-acid) | 2055042-61-8 | Reference compound |
| HY-140537 | N-(Boc-PEG5)-N-bis(PEG4-acid) | 2093152-87-3 | Reference compound |
| HY-140538 | N-Boc-N-bis(PEG2-acid) | 2054339-01-2 | Reference compound |
| HY-140539 | N-Boc-N-bis(PEG3-acid) | 2055023-35-1 | Reference compound |
| HY-140540 | N-Boc-N-bis(PEG4-acid) | 2093152-88-4 | Reference compound |
| HY-140541 | Tri-(PEG1-C2-acid) | 1381861-95-5 | Reference compound |
| HY-140542 | N-Benzyl-N-bis(PEG3-acid) | 2093154-03-9 | Reference compound |
| HY-140543 | N-DBCO-N-bis(PEG2-C2-acid) | 2110449-00-6 | Reference compound |
| HY-140544 | N-(Azido-PEG2)-N-Fluorescein-PEG3-acid | 2086689-04-3 | Reference compound |
| HY-140545 | N-(Azido-PEG2)-N-fluorescein-PEG4-acid | 2086689-06-5 | Reference compound |
| HY-140546 | N-(Azido-PEG3)-N-Fluorescein-PEG4-acid | 2100306-72-5 | Reference compound |
| HY-140547 | NH-bis-PEG3 | 25743-12-8 | Reference compound |
| HY-140548 | NH-bis-PEG4 | 63721-14-2 | Reference compound |
| HY-140549 | NH-bis-PEG5 | 63721-06-2 | Reference compound |
| HY-140550 | NH-bis(C2-PEG1-azide) | 2100306-81-6 | Reference compound |
| HY-140551 | NH-bis(PEG3-azide) | 1258939-39-7 | Reference compound |
| HY-140552 | N-(Azido-PEG3)-NH-PEG3-acid | 2183440-72-2 | Reference compound |
| HY-140553 | N-Boc-N-bis-PEG5 | 2093154-02-8 | Reference compound |
| HY-140554 | N-Boc-N-bis(C2-PEG1-azide) | 2100306-79-2 | Reference compound |
| HY-140555 | N-Boc-N-bis(PEG3-azide) | 1258939-38-6 | Reference compound |
| HY-140556 | N-Boc-N-bis(PEG4-azide) | 2055041-25-1 | Reference compound |
| HY-140557 | N-Boc-N-bis(PEG3-NHS ester) | 2055042-31-2 | Reference compound |
| HY-140558 | N-Boc-N-bis(PEG4-NHS ester) | 2093153-08-1 | Reference compound |
| HY-140559 | N-(Azido-PEG2)-N-Boc-PEG3-NHS ester | 2093153-85-4 | Reference compound |
| HY-140560 | N-(Azido-PEG2)-N-Boc-PEG4-NHS ester | 2093153-95-6 | Reference compound |
| HY-140561 | N-(Azido-PEG3)-N-Boc-PEG3-NHS ester | 2112731-51-6 | Reference compound |
| HY-140562 | N-(Azido-PEG2)-N-Boc-PEG3-Boc | 2093153-07-0 | Reference compound |
| HY-140563 | N-(Azido-PEG2)-N-Boc-PEG4-Boc | 2093153-83-2 | Reference compound |
| HY-140564 | N-(Azido-PEG3)-N-Boc-PEG3-t-butyl ester | 2112732-03-1 | Reference compound |
| HY-140565 | N-(Azido-PEG3)-N-Boc-PEG4-Boc | 2112731-94-7 | Reference compound |
| HY-140566 | N-Azido-PEG4-N-Boc-N-PEG3-Boc | 2093152-85-1 | Reference compound |
| HY-140567 | N-(Azido-PEG4)-N-Boc-PEG4-Boc | 2112737-20-7 | Reference compound |
| HY-140568 | N-(Hydroxy-PEG3)-N-Boc-PEG4-Boc | | Reference compound |
| HY-140569 | N-(PEG1-OH)-N-Boc-PEG2-propargyl | 2100306-85-0 | Reference compound |
| HY-140570 | N-Mal-N-bis(PEG2-amine) | 2128735-20-4 | Reference compound |
| HY-140571 | N-Mal-N-bis(PEG2-NHS ester) | 2182601-73-4 | Reference compound |
| HY-140572 | N-Mal-N-bis(PEG4-NHS ester) | 2112738-60-8 | Reference compound |
| HY-140573 | N-Mal-N-bis(PEG4-amine) | 2128735-22-6 | Reference compound |
| HY-140574 | N-Mal-N-bis(PEG2-NH-Boc) | 2128735-26-0 | Reference compound |
| HY-140575 | N-Mal-N-bis(PEG4-NH-Boc) | 2128735-27-1 | Reference compound |
| HY-140576 | N-Mal-N-bis(PEG2-C2-Boc) | 2100306-51-0 | Reference compound |
| HY-140577 | N-Me-N-bis-PEG3 | 342818-95-5 | Reference compound |
| HY-140578 | N-Me-N-bis-PEG4 | 2055046-22-3 | Reference compound |
| HY-140579 | N-Me-N-bis(PEG4-acid) | 2055014-77-0 | Reference compound |
| HY-140580 | Bis(m-PEG4)-N-OH | 2182601-79-0 | Reference compound |
| HY-140581 | N-(Azido-PEG3)-N-Biotin-PEG4-methyl ester | 2100306-76-9 | Reference compound |
| HY-140582 | N-(DBCO-PEG4)-N-Biotin-PEG4-NHS | 2353409-72-8 | Reference compound |
| HY-140583 | N-Desthiobiotin-N-bis(PEG4-NHS ester) | 2353409-61-5 | Reference compound |
| HY-140584 | N-Desthiobiotin-N-bis(PEG4-t-butyl ester) | 2353409-60-4 | Reference compound |
| HY-140585 | N-DBCO-N-bis(PEG2-C2-NHS ester) | 2128735-29-3 | Reference compound |
| HY-140586 | N-Benzyl-N-bis-PEG2 | 119580-47-1 | Reference compound |
| HY-140587 | N-Benzyl-N-bis-PEG4 | 1680183-01-0 | Reference compound |
| HY-140588 | Benzyl-N-bis(PEG3-Boc) | | Reference compound |
| HY-140589 | Acid-PEG4-S-PEG4-acid | 2055041-21-7 | Reference compound |
| HY-140590 | Azido-PEG3-S-PEG3-azide | 2055023-77-1 | Reference compound |
| HY-140591 | Azido-PEG3-S-PEG4-propargyl | 2055041-24-0 | Reference compound |
| HY-140592 | Azido-PEG3-S-PEG4-t-butyl ester | 2055041-19-3 | Reference compound |
| HY-140593 | m-PEG3-S-PEG2-OH | 2173095-09-3 | Reference compound |
| HY-140594 | m-PEG3-S-PEG4-propargyl | 2055040-85-0 | Reference compound |
| HY-140595 | m-PEG3-S-PEG1-C2-Boc | 2365419-97-0 | Reference compound |
| HY-140596 | m-PEG3-S-PEG3-Boc | 2055040-96-3 | Reference compound |
| HY-140597 | Propargyl-PEG4-S-PEG4-acid | 2055041-20-6 | Reference compound |
| HY-140598 | Propargyl-PEG4-S-PEG4-propargyl | 2055041-17-1 | Reference compound |
| HY-140599 | Propargyl-PEG4-S-PEG4-Boc | 2055041-18-2 | Reference compound |
| HY-140600 | S-Bis-(PEG4-Boc) | | Reference compound |
| HY-140601 | Sulfone-Bis-PEG4-acid | 2055024-37-6 | Reference compound |
| HY-140602 | Azido-PEG3-Sulfone-PEG4-acid | 2055024-42-3 | Reference compound |
| HY-140603 | Azide-PEG3-Sulfone-PEG3-azide | 2055024-45-6 | Reference compound |
| HY-140604 | Azido-PEG3-Sulfone-PEG4-Boc | 2055023-76-0 | Reference compound |
| HY-140605 | m-PEG3-Sulfone-PEG3-acid | 1919045-04-7 | Reference compound |
| HY-140606 | m-PEG3-Sulfone-PEG3-azide | 1895922-76-5 | Reference compound |
| HY-140607 | m-PEG3-Sulfone-PEG3 | 1919045-00-3 | Reference compound |
| HY-140608 | m-PEG3-Sulfone-PEG4-propargyl | 2055041-02-4 | Reference compound |
| HY-140609 | m-PEG3-Sulfone-PEG3-Boc | 2055041-00-2 | Reference compound |
| HY-140610 | Propargyl-PEG4-Sulfone-PEG4-acid | 2055024-41-2 | Reference compound |
| HY-140611 | Propargyl-peg3-sulfone-peg3-propargyl | 2055024-44-5 | Reference compound |
| HY-140612 | Propargyl-PEG4-Sulfone-PEG4-Boc | 2055024-43-4 | Reference compound |
| HY-140613 | Boc-PEG4-sulfone-PEG4-Boc | | Reference compound |
| HY-140614 | DNP-PEG4-NHS ester | 858126-78-0 | Reference compound |
| HY-140615 | DNP-PEG12-NHS ester | | Reference compound |
| HY-140616 | DNP-PEG6-Boc | | Reference compound |
| HY-140617 | DNP-PEG3-azide | 951671-87-7 | Reference compound |
| HY-140618 | DNP-PEG4-alcohol | 1807520-99-5 | Reference compound |
| HY-140619 | DNP-PEG4-DBCO | 2149585-17-9 | Reference compound |
| HY-140620 | m-PEG4-aldehyde | 197513-96-5 | Reference compound |
| HY-140621 | m-PEG3-0-benzaldehyde | 153364-63-7 | Reference compound |
| HY-140622 | Ald-Ph-amido-PEG24-acid | | Reference compound |
| HY-140623 | Ald-Ph-PEG24-NHS ester | | Reference compound |
| HY-140624 | Ald-Ph-PEG12-TFP ester | | Reference compound |
| HY-140625 | Ald-Ph-PEG24-TFP ester | | Reference compound |
| HY-140626 | Ald-Ph-PEG4-Boc | 1807518-64-4 | Reference compound |
| HY-140627 | Ald-Ph-PEG6-Boc | 2055013-49-3 | Reference compound |
| HY-140628 | Ald-Ph-PEG2-Boc | 2100306-65-6 | Reference compound |
| HY-140629 | Ald-Ph-PEG5-Boc | 1433996-83-8 | Reference compound |
| HY-140630 | Ald-CH2-PEG4-Boc | 1415329-20-2 | Reference compound |
| HY-140631 | Ald-CH2-PEG10-Boc | 2353410-05-4 | Reference compound |
| HY-140632 | Ald-Ph-amido-C2-PEG2-amine | 2055013-56-2 | Reference compound |
| HY-140633 | Ald-C2-PEG4-azide | 2030118-14-8 | Reference compound |
| HY-140634 | Ald-CH2-PEG5-azide | 1446282-38-7 | ADC Related |
| HY-140635 | Ald-CH2-PEG8-azide | 2353410-13-4 | Reference compound |
| HY-140636 | Ald-Ph-PEG2-NH-Boc | 1807503-90-7 | Reference compound |
| HY-140637 | Acrylate-PEG-NH2 (MW 10000) | | Reference compound |
| HY-140638 | Acrylate-PEG-OH (MW 3400) | | Reference compound |
| HY-140639 | Acrylate-PEG-OH (MW 5000) | | Reference compound |
| HY-140640 | Acrylate-PEG-OH (MW 10000) | | Reference compound |
| HY-140641 | HO-PEG-amine (MW 10000) | | Reference compound |
| HY-140642 | Aminooxy-PEG-OH (MW 2000) | | Reference compound |
| HY-140643 | Amine-PEG-CH2COOH (MW 2000) | | Reference compound |
| HY-140644 | Amine-PEG-CH2COOH (MW 3400) | | Reference compound |
| HY-140645 | Amine-PEG-CH2COOH (MW 5000) | | Reference compound |
| HY-140646 | PEG-bis-amine (MW 2000) | 24991-53-5 | Biochemical Assay Reagents |
| HY-140647 | PEG-bis-amine (MW 3400) | 24991-53-5 | Biochemical Assay Reagents |
| HY-140648 | Amine-PEG-amine (MW 5000) | | Reference compound |
| HY-140649 | PEG-bis-amine (MW 20000) | 24991-53-5 | Biochemical Assay Reagents |
| HY-140650 | Amine-PEG-amine (MW 35000) | | Reference compound |
| HY-140651 | Amine-PEG-thiol (MW 2000) | | Reference compound |
| HY-140652 | Amine-PEG-thiol (MW 3400) | | Reference compound |
| HY-140653 | Amine-PEG-thiol (MW 5000) | | Reference compound |
| HY-140654 | Biotin-PEG-amine (MW 2000) | | Reference compound |
| HY-140655 | Biotin-PEG-amine (MW 3400) | | Reference compound |
| HY-140656 | Biotin-PEG-Biotin (MW 1000) | | Reference compound |
| HY-140656A | Biotin-PEG-Biotin | 194920-55-3 | Reference compound |
| HY-140656B | Biotin-PEG-Biotin (MW 2000) | | Reference compound |
| HY-140656C | Biotin-PEG-Biotin (MW 3400) | | Reference compound |
| HY-140656D | Biotin-PEG-Biotin (MW 5000) | | Reference compound |
| HY-140656E | Biotin-PEG-Biotin (MW 10000) | | Reference compound |
| HY-140656F | Biotin-PEG-Biotin (MW 20000) | | Dye Reagents |
| HY-140657 | Biotin-PEG-triethoxysilane (MW 1000) | | Reference compound |
| HY-140658 | Biotin-PEG-triethoxysilane (MW 2000) | | Reference compound |
| HY-140659 | Biotin-PEG-triethoxysilane (MW 5000) | | Reference compound |
| HY-140660 | Azide-PEG-alcohol (MW 2000) | | Reference compound |
| HY-140661 | Azide-PEG-amine (MW 2000) | | Reference compound |
| HY-140662 | Azide-PEG-amine (MW 3500) | | Reference compound |
| HY-140663 | Azide-PEG-amine (MW 5000) | | Reference compound |
| HY-140664 | Azide-PEG-azide (MW 2000) | | Reference compound |
| HY-140665 | Azide-PEG-azide (MW 5000) | | Reference compound |
| HY-140666 | Azide-PEG-azide (MW 10000) | | Reference compound |
| HY-140667 | Azide-PEG-azide (MW 20000) | | Reference compound |
| HY-140668 | Fmoc-N-PEG-CH2COOH (MW 3400) | | Reference compound |
| HY-140669 | Fmoc-N-PEG-CH2COOH (MW 5000) | | Reference compound |
| HY-140670 | m-PEG-acrylate (MW 2000) | | Reference compound |
| HY-140671 | m-PEG-acrylate (MW 10000) | | Reference compound |
| HY-140672 | m-PEG-acrylate (MW 20000) | | Reference compound |
| HY-140673 | m-PEG-acrylate (MW 30000) | | Reference compound |
| HY-140674 | m-PEG-Butyraldehyde (MW 5000) | | Reference compound |
| HY-140675 | mPEG-amine (MW 1000) | 80506-64-5 | Biochemical Assay Reagents |
| HY-140676 | mPEG-amine (MW 2000) | 80506-64-5 | Biochemical Assay Reagents |
| HY-140677 | mPEG-amine (MW 5000) | 80506-64-5 | Biochemical Assay Reagents |
| HY-140678 | mPEG-amine (MW 10000) | 80506-64-5 | Biochemical Assay Reagents |
| HY-140679 | mPEG-amine (MW 20000) | 80506-64-5 | Biochemical Assay Reagents |
| HY-140680 | m-PEG-Lys-NHS ester (MW 20000) | | Reference compound |
| HY-140681 | m-PEG-Lys-NHS ester (MW 40000) | | Reference compound |
| HY-140682 | m-PEG-azide (MW 2000) | | Reference compound |
| HY-140683 | m-PEG-azide (MW 5000) | | Reference compound |
| HY-140684 | m-PEG-azide (MW 10000) | | Reference compound |
| HY-140685 | m-PEG-azide (MW 20000) | | Reference compound |
| HY-140686 | m-PEG-CH2COOH (MW 2000) | | Reference compound |
| HY-140687 | m-PEG-CH2COOH (MW 5000) | | Reference compound |
| HY-140688 | m-PEG-CH2COOH (MW 20000) | | Reference compound |
| HY-140689 | m-PEG-mal (MW 2000) | | Reference compound |
| HY-140691 | m-PEG-mal (MW 10000) | | Reference compound |
| HY-140692 | m-PEG-mal (MW 20000) | | Reference compound |
| HY-140693 | m-PEG-mal (MW 30000) | | Reference compound |
| HY-140694 | m-PEG-NPC (MW 20000) | | Reference compound |
| HY-140695 | m-PEG-Aminooxy (MW 2000) | | Reference compound |
| HY-140696 | m-PEG-OH (MW 2000) | 9004-74-4 | Reference compound |
| HY-140696B | m-PEG-OH (MW 550) | 9004-74-4 | Biochemical Assay Reagents |
| HY-140696C | m-PEG-OH (MW 20000) | 9004-74-4 | Biochemical Assay Reagents |
| HY-140696D | m-PEG-OH (MW 10000) | 9004-74-4 | Biochemical Assay Reagents |
| HY-140696E | m-PEG-OH (MW 1000) | 9004-74-4 | Biochemical Assay Reagents |
| HY-140696H | m-PEG-OH (MW 750) | 9004-74-4 | Biochemical Assay Reagents |
| HY-140697 | m-PEG-OH (MW5000) | 9004-74-4 | Reference compound |
| HY-140698 | m-PEG-NHS ester (MW 5000) | 92451-01-9 | Biochemical Assay Reagents |
| HY-140699 | m-PEG-NHS ester (MW 10000) | 92451-01-9 | Biochemical Assay Reagents |
| HY-140700 | m-PEG-NHS ester (MW 20000) | 92451-01-9 | Biochemical Assay Reagents |
| HY-140701 | m-PEG-Succinimidyl Succinate (MW 5000) | | Reference compound |
| HY-140702 | m-PEG-triethoxysilane (MW 1000) | | Reference compound |
| HY-140703 | m-PEG-triethoxysilane (MW 2000) | | Reference compound |
| HY-140704 | m-PEG-triethoxysilane (MW 5000) | | Reference compound |
| HY-140705 | m-PEG-Tos (MW 2000) | | Reference compound |
| HY-140706 | m-PEG-thiol (MW 2000) | 134874-49-0 | Reference compound |
| HY-140707 | m-PEG-thiol (MW 5000) | | Reference compound |
| HY-140708 | m-PEG-thiol (MW 10000) | | Reference compound |
| HY-140709 | m-PEG-thiol (MW 20000) | | Reference compound |
| HY-140710 | m-PEG-Tresyl (MW 5000) | | Reference compound |
| HY-140711 | HO-PEG-CH2COOH (MW 3400) | | Reference compound |
| HY-140712 | HO-PEG-CH2COOH (MW 5000) | | Reference compound |
| HY-140713 | HO-PEG-amine (MW 1000) | | Reference compound |
| HY-140714 | HO-PEG-amine (MW 2000) | | Reference compound |
| HY-140715 | HO-PEG-amine (MW 3400) | | Reference compound |
| HY-140716 | HO-PEG-amine (MW 5000) | | Reference compound |
| HY-140717 | HO-PEG-mal (MW 3400) | | Reference compound |
| HY-140718 | HO-PEG-mal (MW 5000) | | Reference compound |
| HY-140719 | Mal-PEG-mal (MW 2000) | | Reference compound |
| HY-140720 | Mal-PEG-mal (MW 3400) | | Reference compound |
| HY-140721 | Mal-PEG-mal (MW 5000) | | Reference compound |
| HY-140722 | Mal-PEG-Succinimidyl Valerate (MW 20000) | | Reference compound |
| HY-140723 | Carboxymethyl-PEG-Carboxymethyl (MW 5000) | | Reference compound |
| HY-140724 | Bis-PEG-TFP ester (MW 5000) | | Reference compound |
| HY-140725 | Boc-NH-PEG-amine (MW 2000) | | Reference compound |
| HY-140726 | Boc-NH-PEG-amine (MW 3400) | | Reference compound |
| HY-140727 | Boc-NH-PEG-amine (MW 5000) | | Reference compound |
| HY-140728 | Thiol-PEG-CH2COOH (MW 2000) | | Reference compound |
| HY-140729 | Thiol-PEG-CH2COOH (MW 3400) | | Reference compound |
| HY-140730 | Thiol-PEG-CH2COOH (MW 5000) | | Reference compound |
| HY-140731 | TCO-PEG-TCO (MW 5000) | | Reference compound |
| HY-140732 | Dioxoisoindolin-O-PEG-OH (MW 2000) | | Reference compound |
| HY-140733 | Dioxoisoindolin-O-PEG-OMe (MW 2000) | | Reference compound |
| HY-140734 | DSPE-PEG-Amine, MW 3400 | | Reference compound |
| HY-140735 | DSPE-PEG-Amine, MW 5000 | | Reference compound |
| HY-140736 | DSPE-PEG-Biotin, MW 2000 | 385437-57-0 | Oligonucleotides |
| HY-140736A | DSPE-PEG-Biotin, MW 1000 | 385437-57-0 | Biochemical Assay Reagents |
| HY-140736B | DSPE-PEG-Biotin, MW 5000 | 385437-57-0 | Biochemical Assay Reagents |
| HY-140737 | DSPE-PEG-CH2COOH, MW 2000 | | Reference compound |
| HY-140738 | DSPE-PEG-CH2COOH, MW 5000 | | Reference compound |
| HY-140739 | DSPE-PEG2000-Maleimide | | Oligonucleotides |
| HY-140739A | DSPE-PEG2000-Maleimide (free acid) | 185844-12-6 | Reference compound |
| HY-140740 | DSPE-PEG-Maleimide, MW 5000 | | Reference compound |
| HY-140741 | DSPE-PEG-OH, MW 2000 | | Oligonucleotides |
| HY-140742 | Benzyl-PEG2-amine | 1268135-96-1 | Reference compound |
| HY-140743 | Benzyl-PEG5-amine | 86770-77-6 | Reference compound |
| HY-140744 | Benzyl-PEG5-azide | 86770-72-1 | Reference compound |
| HY-140745 | Benzyloxy carbonyl-PEG3-C2-acid | 2100306-73-6 | Reference compound |
| HY-140746 | Benzyloxy carbonyl-PEG3-NHS ester | 2100306-68-9 | Reference compound |
| HY-140747 | BnO-PEG1-CH2CO2tBu | 1309451-06-6 | Reference compound |
| HY-140748 | BnO-PEG4-Boc | 1807503-89-4 | Reference compound |
| HY-140749 | BnO-PEG5-Boc | 1807537-31-0 | Reference compound |
| HY-140750 | Benzyloxy carbonyl-PEG3-C2-Boc | 1835759-86-8 | Reference compound |
| HY-140751 | Benzyl-PEG5-MS | 1807539-07-6 | Reference compound |
| HY-140752 | DOTA-PEG5-azide | | Reference compound |
| HY-140753 | DOTA-(t-butyl)3-PEG5-azide | | Reference compound |
| HY-140754 | Bromoacetamido-PEG5-DOTA | 2353410-19-0 | Reference compound |
| HY-140755 | Aeide-C1-NHS ester | 824426-32-6 | Reference compound |
| HY-140756 | Azido-PEG1-NHS ester | 1807530-06-8 | Reference compound |
| HY-140757 | Azido-PEG5-NHS ester | 1433996-86-1 | Reference compound |
| HY-140758 | Azido-PEG9-NHS ester | | Reference compound |
| HY-140759 | Azido-PEG10-NHS ester | 2801772-86-9 | Reference compound |
| HY-140760 | Azido-PEG12-NHS ester | 2363756-50-5 | Reference compound |
| HY-140761 | Azido-PEG16-NHS ester | | Reference compound |
| HY-140762 | Azido-PEG24-NHS ester | 2375600-46-5 | Reference compound |
| HY-140763 | Azido-PEG1-CH2CO2-NHS | 1480545-09-2 | Reference compound |
| HY-140764 | Azido-PEG3-NHS ester | 1092654-47-1 | Reference compound |
| HY-140765 | Azido-PEG4-NHS-ester | 1807534-82-2 | Reference compound |
| HY-140766 | Azido-PEG5-CH2CO2-NHS | 2144777-77-3 | Reference compound |
| HY-140767 | Azido-PEG8-C1-NHS ester | 2182601-81-4 | Reference compound |
| HY-140768 | Azido-PEG3-O-NHS ester | 2110448-98-9 | Reference compound |
| HY-140769 | Azido-PEG5-succinimidyl carbonate | 1402411-88-4 | Reference compound |
| HY-140770 | Azido-PEG3-aminoacetic acid-NHS ester | 2170240-91-0 | Reference compound |
| HY-140771 | Azido-PEG1-PFP ester | 1807505-32-3 | Reference compound |
| HY-140772 | Azido-PEG6-PFP ester | 1818294-47-1 | Reference compound |
| HY-140773 | Azido-PEG8-PFP ester | 2055014-62-3 | Reference compound |
| HY-140774 | Azido-PEG8-CH2COO-PFP | 2182601-80-3 | Reference compound |
| HY-140775 | Azido-PEG1-Boc | 1374658-85-1 | Reference compound |
| HY-140776 | Azido-PEG2-C2-Boc | 1271728-79-0 | Reference compound |
| HY-140777 | Azido-PEG4-Boc | 581066-04-8 | Reference compound |
| HY-140778 | Azide-PEG5-Boc | 1415800-41-7 | Reference compound |
| HY-140779 | Azido-PEG6-C2-Boc | 406213-76-1 | Reference compound |
| HY-140780 | Azido-PEG9-Boc | 1818294-43-7 | Reference compound |
| HY-140781 | Azido-PEG10-Boc | 2490419-48-0 | Reference compound |
| HY-140782 | Azido-PEG12-Boc | | Reference compound |
| HY-140783 | Azido-PEG15-t-butyl ester | | Reference compound |
| HY-140784 | Azido-PEG16-Boc | | Reference compound |
| HY-140785 | Azido-PEG36-Boc | | Reference compound |
| HY-140786 | Azido-PEG4-amido-PEG4-Boc | | Reference compound |
| HY-140787 | Azide-PEG6-amido-C16-Boc | | Reference compound |
| HY-140788 | Azide-PEG9-amido-C4-Boc | | Reference compound |
| HY-140789 | Azide-PEG9-amido-C8-Boc | | Reference compound |
| HY-140790 | Azide-PEG9-amido-C12-Boc | | Reference compound |
| HY-140791 | Azide-PEG9-amido-C16-Boc | | Reference compound |
| HY-140792 | Azido-PEG1-C1-Boc | 1820717-35-8 | Reference compound |
| HY-140793 | Azido-PEG2-C1-Boc | 251564-45-1 | Reference compound |
| HY-140794 | Azido-PEG3-C-Boc | 172531-36-1 | Reference compound |
| HY-140795 | Azido-PEG5-Boc | 1448451-72-6 | Reference compound |
| HY-140796 | Azido-PEG6-C1-Boc | 297162-49-3 | Reference compound |
| HY-140797 | Azido-PEG2-alcohol | 139115-90-5 | Reference compound |
| HY-140798 | Azido-PEG7-alcohol | 1274892-60-2 | Reference compound |
| HY-140799 | Azide-PEG8-alcohol | 352439-36-2 | Reference compound |
| HY-140800 | Azido-PEG9-alcohol | 1984776-37-5 | Reference compound |
| HY-140801 | Azido-PEG10-alcohol | 877239-09-3 | Reference compound |
| HY-140802 | Azido-PEG11-alcohol | 2252392-53-1 | Reference compound |
| HY-140803 | Azide-PEG12-alcohol | 1821464-55-4 | Reference compound |
| HY-140804 | Azide-PEG16-alcohol | | Reference compound |
| HY-140805 | Azido-PEG20-alcohol | 1637297-21-2 | Reference compound |
| HY-140806 | Azido-PEG24-alcohol | 2415674-94-9 | Reference compound |
| HY-140807 | Azido-PEG36-alcohol | | Reference compound |
| HY-140808 | Azido-PEG3-C3-OH | 1807512-36-2 | Reference compound |
| HY-140809 | Azido-PEG4-(CH2)3OH | 2028281-87-8 | Reference compound |
| HY-140810 | 3-(Azido-PEG5-amino)propanol | 2228857-31-4 | Reference compound |
| HY-140812 | Azido-PEG3-phosphonic acid | 1964503-38-5 | Reference compound |
| HY-140813 | Azido-PEG3-phosphonic acid ethyl ester | 1337527-24-8 | Reference compound |
| HY-140814 | Azido-PEG4-hydrazide | 2170240-96-5 | Reference compound |
| HY-140815 | Azido-PEG8-hydrazide | 2353410-11-2 | Reference compound |
| HY-140816 | Azido-PEG2-hydrazide-Boc | 2100306-56-5 | Reference compound |
| HY-140817 | Azido-PEG4-hydrazide-Boc | 1919045-01-4 | Reference compound |
| HY-140818 | Azido-PEG8-hydrazide-Boc | 2353410-12-3 | Reference compound |
| HY-140819 | Bromo-PEG1-C2-azide | 1144106-65-9 | Reference compound |
| HY-140820 | Bromo-PEG3-azide | 1446282-43-4 | Reference compound |
| HY-140821 | Bromo-PEG4-azide | 1951439-37-4 | Reference compound |
| HY-140822 | Bromo-PEG5-azide | 1402411-90-8 | Reference compound |
| HY-140823 | Bromo-PEG6-azide | 2062663-64-1 | Reference compound |
| HY-140825 | Bromoacetamido-PEG3-azide | 940005-81-2 | Reference compound |
| HY-140826 | Bromoacetamido-PEG5-azide | 1415800-37-1 | Reference compound |
| HY-140827 | m-PEG3-azide | 74654-06-1 | Reference compound |
| HY-140828 | m-PEG4-azide | 606130-90-9 | Reference compound |
| HY-140829 | m-PEG11-azide | | Reference compound |
| HY-140830 | m-PEG12-azide | 2170098-29-8 | Reference compound |
| HY-140831 | m-PEG16-azide | | Reference compound |
| HY-140832 | m-PEG24-azide | 2563873-82-3 | Reference compound |
| HY-140833 | m-PEG36-azide | | Reference compound |
| HY-140834 | Boc-N-Amido-PEG2-C2-azide | 950683-55-3 | Reference compound |
| HY-140835 | Boc-N-Amido-PEG3-azide | 642091-68-7 | Reference compound |
| HY-140836 | Boc-NH-PEG4-azide | 940951-99-5 | Reference compound |
| HY-140837 | Boc-NH-PEG5-azide | 911209-07-9 | Reference compound |
| HY-140838 | Boc-NH-PEG6-azide | 1292268-15-5 | Reference compound |
| HY-140839 | Boc-NH-PEG7-azide | 206265-96-5 | Reference compound |
| HY-140840 | Boc-NH-PEG9-azide | 2112731-50-5 | Reference compound |
| HY-140841 | APN-C3-PEG4-azide | 2183440-32-4 | Reference compound |
| HY-140842 | Azido-PEG4-nitrile | 2194563-82-9 | Reference compound |
| HY-140843 | 1-Isothiocyanato-PEG3-azide | 1310686-23-7 | Reference compound |
| HY-140844 | Thalidomide-O-PEG4-azide | 2380318-57-8 | Reference compound |
| HY-140845 | 1,1,1-Trifluoroethyl-PEG2-azide | 1835759-68-6 | Reference compound |
| HY-140846 | N-Fmoc-N'-(azido-PEG4)-L-Lysine | | Reference compound |
| HY-140847 | N-Fmoc-N'-(azido-PEG4)-L-Lysine-PFP ester | | Reference compound |
| HY-140848 | Azide-PEG3-L-alanine-Fmoc | 2054345-69-4 | Reference compound |
| HY-140849 | Azido-PEG3-Ala-Boc | 2054345-68-3 | Reference compound |
| HY-140850 | Azide-PEG3-C1-Ala | 2054345-67-2 | Reference compound |
| HY-140851 | Azido-PEG1-methyl ester | 1835759-80-2 | Reference compound |
| HY-140852 | Azido-PEG3-methyl ester | 2086689-07-6 | Reference compound |
| HY-140853 | Azido-PEG3-CH2CO2Me | 1253389-31-9 | Reference compound |
| HY-140854 | Azido-PEG4-(CH2)3-methyl ester | 1835759-71-1 | Reference compound |
| HY-140855 | Azido-PEG4-oxazolidin-2-one | 1919045-03-6 | Reference compound |
| HY-140856 | Azido-PEG5-triethoxysilane | | Reference compound |
| HY-140857 | Iodoacetamide-PEG3-azide | 1594986-04-5 | Reference compound |
| HY-140858 | Azido-PEG4-4-nitrophenyl carbonate | 1422540-98-4 | Reference compound |
| HY-140859 | S-Acetyl-PEG3-azide | 1310827-26-9 | Reference compound |
| HY-140860 | Trityl-PEG8-azide | 1818294-30-2 | Reference compound |
| HY-140861 | Trityl-PEG10-azide | 877239-08-2 | Reference compound |
| HY-140862 | Phthalamide-PEG3-azide | 134179-44-5 | Reference compound |
| HY-140863 | PC-PEG11-Azide | 2353409-89-7 | Reference compound |
| HY-140865 | 2-(Azido-PEG3-amido)-1,3-bis(NHS ester) | 2320560-36-7 | Reference compound |
| HY-140866 | N-(Azido-PEG4)-N-bis(PEG4-NHS ester) | 2353409-90-0 | Reference compound |
| HY-140867 | N-(Azido-PEG2)-N-bis(PEG4-Boc) | 2112731-81-2 | Reference compound |
| HY-140868 | N-(Azido-PEG3)-N-bis(PEG3-Boc) | 2055042-56-1 | Reference compound |
| HY-140869 | N-(Azido-PEG3)-N-bis(PEG4-Boc) | 2353409-58-0 | Reference compound |
| HY-140870 | N-(Azido-PEG4)-N-bis(PEG4-t-butyl ester) | 2093152-79-3 | Reference compound |
| HY-140871 | N-(Boc-PEG3)-N-bis(PEG3-azide) | 2182602-15-7 | Reference compound |
| HY-140872 | N-(Boc-PEG2)-N-bis(PEG3-azide) | 2353409-46-6 | Reference compound |
| HY-140873 | N-(Azido-PEG3)-N-bis(PEG1-t-butyl ester) | 2086689-00-9 | Reference compound |
| HY-140874 | Azido-PEG4-Amido-tri-(t-butoxycarbonylethoxymethyl)-methane | 1421933-29-0 | Reference compound |
| HY-140875 | Propargyl-PEG3-triethoxysilane | 2250216-92-1 | Reference compound |
| HY-140876 | Propargyl-PEG3-methyl ester | 2086689-09-8 | Reference compound |
| HY-140877 | Dde Biotin-PEG4-TAMRA-PEG4 Alkyne | 2353409-55-7 | Dye Reagents |
| HY-140878 | Boc-NH-PEG3-propargyl | 1333880-60-6 | Reference compound |
| HY-140879 | Boc-N-Amido-PEG4-propargyl | 1219810-90-8 | Reference compound |
| HY-140880 | Boc-NH-PEG5-propargyl | 2062663-67-4 | Reference compound |
| HY-140881 | Boc-NH-PEG6-propargyl | 1262991-52-5 | Reference compound |
| HY-140882 | Boc-NH-PEG7-propargyl | 2112737-90-1 | Reference compound |
| HY-140883 | Boc-NH-PEG8-propargyl | 2183440-31-3 | Reference compound |
| HY-140884 | Boc-NH-PEG9-propargyl | | Reference compound |
| HY-140885 | Boc-NH-PEG12-propargyl | | Reference compound |
| HY-140886 | 1,1,1-Trifluoroethyl-PEG2-propargyl | 1835759-73-3 | Reference compound |
| HY-140887 | 1,1,1-Trifluoroethyl-PEG4-propargyl | 1817735-37-7 | Reference compound |
| HY-140888 | Biotin-PEG2-NHS ester | 596820-83-6 | Reference compound |
| HY-140889 | Biotin-PEG4-NHS ester | 459426-22-3 | Reference compound |
| HY-140890 | Biotin-PEG6-NHS ester | 2055045-04-8 | Reference compound |
| HY-140891 | Biotin-PEG8-NHS ester | 2143968-03-8 | Reference compound |
| HY-140892 | Biotin-PEG12-NHS ester | 1934296-88-4 | Reference compound |
| HY-140893 | Biotin-PEG6-alcohol | 906099-89-6 | Reference compound |
| HY-140894 | Biotin-PEG8-alcohol | 2182601-20-1 | Reference compound |
| HY-140895 | Biotin-PEG4-amine | 663171-32-2 | Reference compound |
| HY-140896 | Biotin-PEG5-amine | 113072-75-6 | Reference compound |
| HY-140897 | Biotin-PEG6-amine | 2757573-29-6 | Reference compound |
| HY-140898 | Biotin-PEG7-amine | 1334172-76-7 | Reference compound |
| HY-140899 | Biotin-PEG8-amine | 2183447-27-8 | Reference compound |
| HY-140900 | Biotin-PEG11-amine | 1418022-42-0 | Reference compound |
| HY-140901 | Biotin-PEG23-amine | | Reference compound |
| HY-140902 | rel-Biotin-PEG3-C3-NH2 | 1374658-86-2 | Reference compound |
| HY-140902A | Biotin-PEG3-C3-NH2 | 183896-00-6 | Reference compound |
| HY-140903 | Biotin-PEG4-TFP ester | 2985664-57-9 | Reference compound |
| HY-140904 | Biotin-PEG12-TFP ester | | Reference compound |
| HY-140905 | Biotin-PEG24-TFP ester | | Reference compound |
| HY-140906 | Biotin-PEG36-PFP ester | | Reference compound |
| HY-140907 | Biotin-PEG3-Mal | 1431618-70-0 | Reference compound |
| HY-140908 | Biotin-PEG6-Mal | 1808990-66-0 | Reference compound |
| HY-140909 | Biotin-PEG11-Mal | 1646619-56-8 | Reference compound |
| HY-140910 | Biotin-PEG4-azide | 1309649-57-7 | Reference compound |
| HY-140911 | Biotin-PEG6-azide | 1085938-09-5 | Reference compound |
| HY-140912 | Biotin-PEG11-azide | 2276672-04-7 | Reference compound |
| HY-140913 | Biotin-PEG23-azide | | Reference compound |
| HY-140914 | Biotin-PEG4-Amide-C6-Azide | 1006592-62-6 | Reference compound |
| HY-140915 | Biotin-PEG4-Picolyl azide | 2222687-71-8 | Reference compound |
| HY-140916 | Dde Biotin-PEG4-azide | 1802907-93-2 | Reference compound |
| HY-140917 | Dde Biotin-PEG4-Picolyl azide | 2055048-42-3 | Reference compound |
| HY-140918 | Diazo Biotin-PEG3-azide | 1339202-33-3 | Reference compound |
| HY-140919 | N-(Azido-PEG4)-biocytin | 2055042-70-9 | Reference compound |
| HY-140920 | UV Cleavable Biotin-PEG2-Azide | 1192802-98-4 | Reference compound |
| HY-140921 | Biotin-PEG4-amino-t-Bu-DADPS-C6-azide | 1260247-50-4 | Reference compound |
| HY-140922 | Biotin-PEG4-alkyne | 1458576-00-5 | Reference compound |
| HY-140923 | Biotin-PEG4-amide-Alkyne | 1006592-45-5 | Reference compound |
| HY-140924 | Dde Biotin-PEG4-alkyne | 1802908-00-4 | Reference compound |
| HY-140925 | Diazo Biotin-PEG3-alkyne | 1884349-58-9 | Reference compound |
| HY-140926 | N-(Propargyl-PEG4)-biocytin | 2055042-71-0 | Reference compound |
| HY-140927 | Azido-C3-UV-biotin | | Reference compound |
| HY-140928 | Biotin-PEG4-amino-t-Bu-DADPS-C3-alykne | 2241685-22-1 | Reference compound |
| HY-140929 | Bis-Biotin-PEG23 | 293298-36-9 | Reference compound |
| HY-140930 | Diazo Biotin-PEG3-DBCO | | ADC Related |
| HY-140931 | Dde Biotin-PEG4-DBCO | 1807512-43-1 | Reference compound |
| HY-140932 | Biotin-PEG4-hydrazide | 756525-97-0 | Reference compound |
| HY-140932A | Biotin-PEG4-hydrazide (TFA) | | Reference compound |
| HY-140933 | Biotin-PEG12-hydrazide | | Reference compound |
| HY-140934 | Biotin-PEG2-NH-Boc | 175885-18-4 | Reference compound |
| HY-140935 | Biotin-PEG5-NH-Boc | 189209-28-7 | Reference compound |
| HY-140936 | Biotin-PEG6-Boc | 1352814-07-3 | Reference compound |
| HY-140937 | Biotin-amido-PEG4-PFP ester | | Reference compound |
| HY-140938 | Biotin-PEG3-oxyamine | 1786206-22-1 | Reference compound |
| HY-140939 | Biotin-PEG11-oxyamine | | Reference compound |
| HY-140940 | Biotin-PEG4-methyltetrazine | 1835759-81-3 | Reference compound |
| HY-140941 | Biotin-PEG2-C2-iodoacetamide | 292843-75-5 | Reference compound |
| HY-140942 | Biotin-PEG6-Thalidomide | 2144775-48-2 | Reference compound |
| HY-140943 | Biotin-PEG7-thiourea | 2353409-59-1 | Reference compound |
| HY-140944 | Biotin-PEG3-SS-azide | | ADC Related |
| HY-140945 | Fmoc-Lys (biotin-PEG12)-OH | | Reference compound |
| HY-140946 | TAMRA-PEG3-biotin | 2279944-59-9 | Dye Reagents |
| HY-140947 | TAMRA-Azide-PEG-biotin | 1797415-74-7 | Dye Reagents |
| HY-140948 | (5,6)TAMRA-PEG3-Azide-PEG3-Desthiobiotin | | Dye Reagents |
| HY-140949 | N-(Biotin)-N-bis(PEG1-alcohol) | 2100306-75-8 | Reference compound |
| HY-140950 | m-PEG8-DSPE | | Biochemical Assay Reagents |
| HY-140951 | m-PEG12-DSPE | | Reference compound |
| HY-140952 | m-PEG24-DSPE | | Reference compound |
| HY-140953 | DSPE-PEG4-acid | 2112738-58-4 | Reference compound |
| HY-140954 | DSPE-PEG5-azide | 2112737-73-0 | Reference compound |
| HY-140955 | DSPE-PEG4-DBCO | 2112738-14-2 | Reference compound |
| HY-140956 | DSPE-PEG8-Mal | 2112737-94-5 | Biochemical Assay Reagents |
| HY-140957 | Mal-PEG12-DSPE | | Reference compound |
| HY-140958 | DSPE-PEG5-propargyl | 2112737-93-4 | Reference compound |
| HY-140959 | DSPE-PEG13-TFP ester | | Reference compound |
| HY-140960 | DSPE-PEG-2-Aminoethyl-alpha-mannopyranoside, MW 2000 | | Reference compound |
| HY-140962 | Mal-PEG12-acid | 2445165-75-1 | Reference compound |
| HY-140963 | Mal-PEG12-NHS ester | 2669737-09-9 | Reference compound |
| HY-140964 | Mal-PEG2-C2-Boc | 1374666-31-5 | Reference compound |
| HY-140965 | Mal-PEG5-Boc | 2250216-91-0 | Reference compound |
| HY-140966 | Mal-PEG12-Boc | | Reference compound |
| HY-140967 | Mal-Amido-PEG4-Boc | 1415800-35-9 | Reference compound |
| HY-140968 | Mal-PEG2-alcohol | 34321-81-8 | Reference compound |
| HY-140969 | Mal-PEG3-alcohol | 146551-23-7 | Reference compound |
| HY-140970 | Mal-PEG8-alcohol | 2353409-63-7 | Reference compound |
| HY-140971 | Mal-PEG12-alcohol | | Reference compound |
| HY-140972 | Mal-amido-PEG9-NH-Boc | 2182602-20-4 | Reference compound |
| HY-140973 | Mal-amido-PEG10-acid | 2785355-74-8 | Reference compound |
| HY-140974 | Mal-amido-PEG12-acid | 2378428-27-2 | Reference compound |
| HY-140975 | Mal-amido-PEG24-acid | 2171095-70-6 | Reference compound |
| HY-140976 | Mal-amido-PEG9-amine | 2182602-22-6 | Reference compound |
| HY-140976A | Mal-amido-PEG9-amine (TFA) | 2569576-12-9 | Reference compound |
| HY-140977 | Mal-amido-PEG12-NHS ester | 2101722-60-3 | Reference compound |
| HY-140978 | Mal-amido-PEG4-TFP ester | 1807540-84-6 | Reference compound |
| HY-140979 | Mal-amido-PEG8-TFP ester | 1924596-31-5 | Reference compound |
| HY-140980 | Mal-amido-PEG12-TFP ester | | Reference compound |
| HY-140981 | Mal-amido-PEG24-TFP ester | 2384191-62-0 | Reference compound |
| HY-140982 | m-PEG8-Mal | 1334169-90-2 | Reference compound |
| HY-140983 | m-PEG12-Mal | 2853560-28-6 | Reference compound |
| HY-140984 | m-PEG24-Mal | 2579693-28-8 | Reference compound |
| HY-140985 | m-PEG36-Mal | | Reference compound |
| HY-140986 | m-PEG48-Mal | | Reference compound |
| HY-140987 | 5-Maleimidovaleric acid | 57078-99-6 | ADC Related |
| HY-140988 | Mal-NH2 (TFA) | 146474-00-2 | Reference compound |
| HY-140989 | Mal-PEG1-bromide | 1823885-81-9 | Reference compound |
| HY-140990 | 6-Maleimidocaproic acid-PFP ester | 692739-25-6 | Reference compound |
| HY-140991 | Mal-NH-Boc | 134272-63-2 | Reference compound |
| HY-140992 | Mal-C4-NH-Boc | 124529-64-2 | Reference compound |
| HY-140993 | Bis-Mal-PEG3 | 1008402-47-8 | Reference compound |
| HY-140994 | Bis-Mal-PEG6 | 2458811-07-7 | Reference compound |
| HY-140995 | Bis-Mal-PEG11 | | Reference compound |
| HY-140996 | Bis-Mal-PEG19 | | Reference compound |
| HY-140997 | Mal-PEG4-Glu(OH)-NH-m-PEG24 | 2204309-09-9 | Reference compound |
| HY-140998 | Mal-PEG4-Glu(TFP ester)-NH-m-PEG24 | 2408741-87-5 | Reference compound |
| HY-140999 | Mal-PEG4-Lys(t-Boc)-NH-m-PEG24 | | Reference compound |
| HY-141000 | Mal-PEG4-Lys(TFA)-NH-m-PEG24 | | Reference compound |
| HY-141001 | Bis-Mal-Lysine-PEG4-acid | 1426164-52-4 | Reference compound |
| HY-141002 | Bis-Mal-Lysine-PEG4-TFP ester | 1426164-53-5 | Reference compound |
| HY-141003 | 3,4-Dibromo-Mal-PEG8-acid | | Reference compound |
| HY-141004 | 3,4-Dibromo-Mal-PEG2-amine | 1807534-86-6 | Reference compound |
| HY-141004A | 3,4-Dibromo-Mal-PEG2-amine (TFA) | 2296708-07-9 | Reference compound |
| HY-141005 | 3,4-Dibromo-Mal-PEG2-N-Boc | 1807537-43-4 | Reference compound |
| HY-141006 | 3,4-Dibromo-Mal-PEG4-Boc | 2030168-38-6 | Reference compound |
| HY-141007 | 3,4-Dibromo-Mal-PEG8-Boc | 2055198-02-0 | Reference compound |
| HY-141008 | Tri(Mal-PEG2-amide)-amine | | Reference compound |
| HY-141009 | N-(Mal-PEG6)-N-bis(PEG7-TCO) | 2093152-84-0 | Reference compound |
| HY-141010 | Thalidomide-O-PEG4-amine | 2401832-00-4 | Reference compound |
| HY-141010A | Thalidomide-O-PEG4-amine (hydrochloride) | 2820929-03-9 | Reference compound |
| HY-141010B | Thalidomide-O-PEG4-amine (TFA) | 2934561-88-1 | Reference compound |
| HY-141011 | Thalidomide-O-amido-PEG4-azide | 2411681-89-3 | Reference compound |
| HY-141012 | Thalidomide-O-PEG4-NHS ester | 2411681-88-2 | Reference compound |
| HY-141013 | Thalidomide-O-amido-PEG4-propargyl | 2496687-00-2 | Reference compound |
| HY-141014 | Thalidomide-O-PEG4-Boc | 2411681-87-1 | Reference compound |
| HY-141015 | Pomalidomide-PEG4-azide | 2271036-47-4 | Reference compound |
| HY-141016 | (S,R,S)-AHPC-PEG2-acid | 2172820-09-4 | Reference compound |
| HY-141019 | Bis-PEG11-acid | 2097010-30-3 | Reference compound |
| HY-141020 | Bis-PEG12-acid | 2667583-09-5 | Reference compound |
| HY-141021 | Bis-PEG13-acid | 2225903-66-0 | Reference compound |
| HY-141022 | Bis-PEG14-acid | | Reference compound |
| HY-141023 | Bis-PEG15-acid | | Reference compound |
| HY-141024 | Bis-PEG17-acid | 2226897-74-9 | Reference compound |
| HY-141025 | Bis-PEG21-acid | | Reference compound |
| HY-141026 | Bis-PEG25-acid | 2567200-14-8 | Reference compound |
| HY-141027 | Bis-PEG29-acid | | Reference compound |
| HY-141028 | N,N'-DME-N,N'-Bis-PEG2-acid | 2062663-61-8 | Reference compound |
| HY-141029 | N-Hydroxypropyl-N’-(azide-PEG3)-Cy3 | | Reference compound |
| HY-141030 | N-(m-PEG4)-N'-(azide-PEG4)-Cy3 | 2107273-38-9 | Reference compound |
| HY-141031 | N-Methyl-N'-methyl-O-(m-PEG4)-O'-(azide-PEG4)-Cy3 | 2107273-64-1 | Reference compound |
| HY-141032 | N-methyl-N'-methyl-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy3 | 2107273-62-9 | Reference compound |
| HY-141033 | Cy5-PEG4-acid | | Reference compound |
| HY-141034 | Cy5-PEG6-acid | | Reference compound |
| HY-141035 | N-(m-PEG4)-N'-(PEG2-acid)-Cy5 | 2107273-24-3 | Reference compound |
| HY-141036 | N-(m-PEG4)-N'-(PEG4-acid)-Cy5 | 2107273-32-3 | Reference compound |
| HY-141037 | N-(m-PEG9)-N'-(PEG5-acid)-Cy5 | 2107273-26-5 | Reference compound |
| HY-141038 | N-(m-PEG4)-N'-(Acid-PEG3)-benzothiazole Cy5 | 2107273-80-1 | Reference compound |
| HY-141040 | N-methyl-N'-methyl-O-(m-PEG4)-O'-(acid-PEG5)-Cy5 | | Reference compound |
| HY-141041 | N-(Azide-PEG3)-N'-(PEG4-acid)-Cy5 | 2107273-42-5 | Reference compound |
| HY-141042 | Bis-(N,N'-carboxyl-PEG4)-Cy5 | 2107273-44-7 | Reference compound |
| HY-141043 | N,N'-bis-(Acid-PEG3)-benzothiazole Cy5 | 2107273-82-3 | Reference compound |
| HY-141044 | Cy5-PEG6-NHS ester | | Dye Reagents |
| HY-141045 | N-(m-PEG4)-N'-(PEG2-NHS ester)-Cy5 | 2107273-28-7 | Dye Reagents |
| HY-141046 | N-(m-PEG4)-N'-(PEG4-NHS ester)-Cy5 | 2107273-30-1 | Reference compound |
| HY-141047 | Bis-(N,N'-PEG4-NHS ester)-Cy5 | 2107273-48-1 | Reference compound |
| HY-141048 | N-(Azide-PEG3)-N'-(PEG4-NHS ester)-Cy5 | | Reference compound |
| HY-141049 | N-methyl-N'-(propargyl-PEG4)-Cy5 | 2107273-04-9 | Reference compound |
| HY-141050 | N-PEG3-N'-(propargyl-PEG4)-Cy5 | 2107273-06-1 | Reference compound |
| HY-141051 | N-(m-PEG9)-N'-(propargyl-PEG8)-Cy5 | 2107273-10-7 | Reference compound |
| HY-141052 | N-methyl-N'-methyl-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy5 | 2107273-50-5 | Reference compound |
| HY-141053 | N-(m-PEG4)-N'-(m-PEG4)-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy5 | 2107273-54-9 | Reference compound |
| HY-141054 | N,N'-bis-(propargyl-PEG4)-Cy5 | 2107273-08-3 | Reference compound |
| HY-141055 | Cy5-PEG5-amine (hydrochloride) | | Reference compound |
| HY-141056 | N-(m-PEG4)-N'-(amino-PEG3)-Cy5 | 2107272-96-6 | Reference compound |
| HY-141058 | Cy5-PEG3-azide | | Dye Reagents |
| HY-141059 | Cy5-PEG5-azide (bromide) | | Dye Reagents |
| HY-141061 | N-PEG3-N'-(azide-PEG3)-Cy5 | 2226235-96-5 | Reference compound |
| HY-141062 | N-Methyl-N'-(azido-PEG2-C5)-Cy5 | | Reference compound |
| HY-141063 | N-(m-PEG4)-N'-(azide-PEG3)-Cy5 | 2107273-02-7 | Reference compound |
| HY-141064 | N-(azide-PEG3)-N'-(m-PEG4)-Benzothiazole Cy5 | 2107273-88-9 | Reference compound |
| HY-141065 | N-(azide-PEG3)-N'-(Amine-C3-Amide-PEG4)-Cy5 | 2107273-70-9 | Reference compound |
| HY-141067 | N-methyl-N'-methyl-O-(m-PEG4)-O'-(azide-PEG4)-Cy5 | 2107273-56-1 | Reference compound |
| HY-141068 | N-(m-PEG4)-N'-(m-PEG4)-O-(m-PEG4)-O'-(azide-PEG4)-Cy5 | 2107273-58-3 | Reference compound |
| HY-141069 | N-(m-PEG4)-N'-(Biotin-PEG2-amido-PEG4)-Cy5 | 2107273-78-7 | Reference compound |
| HY-141070 | N-(m-PEG4)-N'-(biotin-PEG3)-Cy5 | 2107273-68-5 | Reference compound |
| HY-141071 | N-(m-PEG4)-N'-(DBCO-PEG4)-Cy5 | 2107273-76-5 | Reference compound |
| HY-141072 | N-Methyl-N'-(hydroxy-PEG2)-Cy5 | 2107273-22-1 | Reference compound |
| HY-141073 | N-(m-PEG4)-N'-(hydroxy-PEG2)-Cy5 | 2107273-12-9 | Reference compound |
| HY-141074 | N-(m-PEG4)-N'-hydroxypropyl-Cy5 | 2107273-20-9 | Reference compound |
| HY-141075 | N-(m-PEG4)-N'-(4-Hydroxycyclohexyl-1-amido-PEG4)-Cy5 | 2107273-72-1 | Reference compound |
| HY-141076 | N-(m-PEG4)-N'-(PEG3-Mal)-Cy5 | 2839527-02-3 | Reference compound |
| HY-141077 | N-(Ac-PEG3)-N'-(azide-PEG3)-Cy7 (chloride) | 2107273-00-5 | Reference compound |
| HY-141078 | N-(m-PEG4)-N'-(azide-PEG4)-Cy7 | 2107273-40-3 | Reference compound |
| HY-141079 | N,N'-bis-(azide-PEG3)-chlorocyclohexenyl Cy7 | 2107273-84-5 | Reference compound |
| HY-141080 | Fluorescein-PEG3-amine | 1807539-04-3 | Reference compound |
| HY-141081 | Fluorescein-PEG3-NH-Boc | 1807534-77-5 | Reference compound |
| HY-141082 | Fluorescein-PEG5-NHS ester | 2353409-62-6 | Reference compound |
| HY-141083 | Fluorescein-PEG6-NHS ester | 1818294-35-7 | Reference compound |
| HY-141084 | Fluorescein-PEG6-bis-NHS ester | 2055105-59-2 | Reference compound |
| HY-141085 | Carboxyfluorescein-PEG12-NHS | 2246595-66-2 | Dye Reagents |
| HY-141086 | BDP FL-PEG5-azide | 2093197-91-0 | Reference compound |
| HY-141087 | BDP FL-PEG5-propargyl | 2093197-93-2 | Reference compound |
| HY-141088 | BDP FL-PEG4-TCO | 2183473-16-5 | Reference compound |
| HY-141089 | Carboxyrhodamine 110-PEG4-alkyne | 2055103-66-5 | Reference compound |
| HY-141090 | Carboxyrhodamine 110-PEG3-Azide | 1536327-95-3 | Reference compound |
| HY-141091 | Biotin-PEG4-Dde-TAMRA-PEG3-Azide | 2353409-56-8 | Dye Reagents |
| HY-141092 | Pyrene-PEG2-azide | 2135330-58-2 | Reference compound |
| HY-141093 | Pyrene-PEG5-alcohol | 1817735-44-6 | Reference compound |
| HY-141094 | Pyrene-PEG5-biotin | | Reference compound |
| HY-141095 | Pyrene-PEG5-propargyl | 1817735-33-3 | Reference compound |
| HY-141096 | Acid-PEG9-NHS ester | 1895916-27-4 | Reference compound |
| HY-141097 | Acid-PEG13-NHS ester | 2152679-62-2 | Reference compound |
| HY-141098 | Acid-PEG25-NHS ester | 2563872-17-1 | Reference compound |
| HY-141099 | Di(N-succinimidyl)adipate | 59156-70-6 | Reference compound |
| HY-141100 | Bis-PEG11-NHS ester | | Reference compound |
| HY-141101 | Fmoc-PEG12-NHS ester | 2227246-92-4 | Reference compound |
| HY-141102 | Fmoc-PEG24-NHS ester | | Reference compound |
| HY-141103 | Fmoc-NMe-PEG4-NHS ester | 2228857-30-3 | Reference compound |
| HY-141104 | m-PEG10-NHS ester | 2490419-63-9 | Reference compound |
| HY-141105 | m-PEG11-NHS ester | | Reference compound |
| HY-141106 | m-PEG12-NHS ester | 2207596-93-6 | Reference compound |
| HY-141107 | m-PEG13-NHS ester | | Reference compound |
| HY-141108 | m-PEG17-NHS ester | | Reference compound |
| HY-141109 | m-PEG25-NHS ester | | Reference compound |
| HY-14111 | GSK189254A | 720690-73-3 | Reference compound |
| HY-141110 | m-PEG37-NHS ester | | Reference compound |
| HY-141111 | m-PEG8-ethoxycarbonyl-NHS ester | 2353409-76-2 | Reference compound |
| HY-141112 | m-PEG3-succinimidyl carbonate | 477775-77-2 | Reference compound |
| HY-141113 | m-PEG4-O-NHS ester | 147912-03-6 | Reference compound |
| HY-141114 | m-PEG8-succinimidyl carbonate | 1372860-04-2 | Reference compound |
| HY-141115 | Mal-NO2-Ph-PEG12-NHS | | Reference compound |
| HY-141116 | Boc-N-PEG1-C2-NHS ester | 1260092-55-4 | Reference compound |
| HY-141117 | Boc-NH-PEG2-C2-NHS ester | 2183440-73-3 | Reference compound |
| HY-141118 | Boc-NH-PEG3-NHS ester | 2250216-93-2 | Reference compound |
| HY-141119 | Boc-NH-PEG4-NHS ester | 859230-20-9 | Reference compound |
| HY-141120 | Boc-NH-PEG10-NHS ester | | Reference compound |
| HY-141121 | T-Butoxycarbonyl-PEG1-NHS ester | 2228857-37-0 | Reference compound |
| HY-141122 | Boc-PEG4-C2-NHS ester | 1835759-75-5 | Reference compound |
| HY-141123 | SPDP-C6-Gly-Leu-NHS ester | | ADC Related |
| HY-141124 | NHS-PEG4-(m-PEG4)3-ester | 1333154-70-3 | Reference compound |
| HY-141125 | NHS-PEG4-(m-PEG12)3-ester | | Reference compound |
| HY-141126 | Azido-PEG4-alpha-D-mannose | 1632372-86-1 | Reference compound |
| HY-141127 | Azido-PEG4-tetra-Ac-beta-D-glucose | 153252-44-9 | Reference compound |
| HY-141128 | Ac4GalNAz | 653600-56-7 | Reference compound |
| HY-14113 | 2-Acetyl-4-tetrahydroxybutyl imidazole | 94944-70-4 | Reference compound |
| HY-141130 | LG-PEG10-click-DBCO-Oleic | | Reference compound |
| HY-141131 | Propargyl-PEG2-beta-D-glucose | 2353409-73-9 | Reference compound |
| HY-141132 | Propargyl-PEG4-beta-D-glucose | 1397682-63-1 | Reference compound |
| HY-141133 | Propargyl-PEG4-tetra-Ac-beta-D-glucose | 1360446-31-6 | Reference compound |
| HY-141135 | Propargyl-PEG4-tetra-Ac-beta-D-galactose | 1397682-61-9 | Reference compound |
| HY-141136 | Ac4GlcNAlk | 1361993-37-4 | Reference compound |
| HY-141137 | 2,3,4,6-Tetra-o-acetyl-alpha-galactosylpyranosyl bromide | 529493-92-3 | Reference compound |
| HY-141139 | 1-(Isopropylthio)-2,3,4,6-tetra-o-Ac-beta-D-glucosylpyranose | | Reference compound |
| HY-141140 | 5-Ethynyluridine | 69075-42-9 | Reference compound |
| HY-141141 | Boc-Val-Cit-PAB | 870487-09-5 | ADC Related |
| HY-141142 | Boc-Val-Cit-PAB-PNP | 870487-10-8 | ADC Related |
| HY-141143 | MC(C5)-Val-Cit | 2504147-59-3 | ADC Related |
| HY-141144 | OPSS-Val-Cit-PAB-OH | | ADC Related |
| HY-141145 | OPSS-Val-Cit-PAB-PNP | | ADC Related |
| HY-141146 | Mal-amido-PEG8-val-gly-PAB-OH | 2353409-52-4 | ADC Related |
| HY-141147 | 7-O-(Amino-PEG4)-paclitaxel | | Reference compound |
| HY-141148 | 7-O-(Cbz-N-amido-PEG4)-paclitaxel | | Reference compound |
| HY-141149 | Fmoc-PEG4-Ala-Ala-Asn-PAB | 2055048-57-0 | ADC Related |
| HY-141150 | Azido-PEG5-Ala-Ala-Asn-PAB | 2055048-54-7 | ADC Related |
| HY-141151 | Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB | 2055042-69-6 | ADC Related |
| HY-141152 | Azido-PEG4-Ala-Ala-Asn(Trt)-PAB | 2055042-67-4 | Reference compound |
| HY-141153 | Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP | 2055042-82-3 | Reference compound |
| HY-141154 | Amino-PEG4-Val-Cit-PAB-MMAE | 1492056-71-9 | ADC Related |
| HY-141155 | endo-BCN-PEG4-Val-Cit-PAB-MMAE | 2762519-08-2 | ADC Related |
| HY-141156 | Mal-PEG8-Val-Cit-PAB-MMAE | 2353409-69-3 | ADC Related |
| HY-141158 | N-(Iodoacetamido)-Doxorubicin | 114390-30-6 | ADC Related |
| HY-141159 | TCO-PEG4-acid | 1802913-21-8 | Reference compound |
| HY-141159A | (S)-TCO-PEG4-acid | | Reference compound |
| HY-141159B | (S,E)-TCO2-PEG4-COOH | | Reference compound |
| HY-141160 | TCO-PEG6-acid | 2353409-97-7 | Reference compound |
| HY-141161 | TCO-PEG8-acid | 2353410-03-2 | Reference compound |
| HY-141161A | (S,E)-TCO2-PEG8-acid | | Reference compound |
| HY-141161B | (R,E)-TCO-PEG8-acid | | ADC Related |
| HY-141162 | TCO-PEG12-acid | | Reference compound |
| HY-141163 | TCO-PEG24-acid | | Reference compound |
| HY-141164 | TCO-PEG36-acid | | Reference compound |
| HY-141165 | TCO-NHS ester | 1191901-33-3 | Reference compound |
| HY-141166 | TCO-PEG3-NHS ester | 2141981-88-4 | Reference compound |
| HY-141166A | (S,E)-TCO2-PEG3-NHS ester | | Reference compound |
| HY-141167A | TCO-PEG4-NHS ester | 1621096-79-4 | Reference compound |
| HY-141167B | (S)-TCO-PEG4-NHS ester | | ADC Related |
| HY-141168 | TCO-PEG6-NHS ester | 2353409-96-6 | Reference compound |
| HY-141169 | TCO-PEG8-NHS ester | 2353409-95-5 | Reference compound |
| HY-141169A | (S,E)-TCO2-PEG8-NHS ester | | ADC Related |
| HY-141169B | (R,E)-TCO-PEG8-NHS ester | | ADC Related |
| HY-14117 | Enprofylline | 41078-02-8 | Reference compound |
| HY-141170 | TCO-PEG12-NHS ester | 2185016-39-9 | ADC Related |
| HY-141171 | TCO-PEG24-NHS ester | 2055646-26-7 | Reference compound |
| HY-141172 | TCO-PEG2-Sulfo-NHS ester | 2353409-47-7 | Reference compound |
| HY-141172A | TCO-PEG2-Sulfo-NHS ester (sodium) | | Reference compound |
| HY-141173 | TCO-PEG8-TFP ester | 2353410-06-5 | Reference compound |
| HY-141174 | TCO-PEG12-TFP ester | | Reference compound |
| HY-141175 | TCO-PNB ester | 1438415-89-4 | Reference compound |
| HY-141176 | TCO-amine | 1609736-43-7 | Reference compound |
| HY-141177 | TCO-PEG2-amine | 2141981-87-3 | Reference compound |
| HY-141178 | TCO-PEG3-amine | 1800507-93-0 | Reference compound |
| HY-141178A | (S)-TCO-PEG3-amine | | Reference compound |
| HY-141179 | TCO-PEG4-amine | 2243569-24-4 | Reference compound |
| HY-141180 | TCO-PEG6-amine | 2353409-94-4 | Reference compound |
| HY-141181 | TCO-PEG8-amine | 2353409-92-2 | Reference compound |
| HY-141182 | TCO-C3-PEG3-C3-amine | 2028288-77-7 | Reference compound |
| HY-141183 | TCO-PEG4-biotin | 2183440-30-2 | Reference compound |
| HY-141184 | TCO-PEG9-maleimide | 2183440-37-9 | Reference compound |
| HY-141185 | TCO-PEG3-amide-C3-triethoxysilane | 2250217-32-2 | Reference compound |
| HY-141186 | TCO-OH | 85081-69-2 | Reference compound |
| HY-141186A | (R)-TCO-OH | 39637-78-0 | Reference compound |
| HY-141187 | TCO-PEG3-TCO | 2243569-22-2 | Reference compound |
| HY-141188 | TCO-PEG4-TCO | 2243569-23-3 | Reference compound |
| HY-141189 | TCO-PEG8-TCO | 2353409-67-1 | Reference compound |
| HY-141190 | Gly-Gly-Gly-PEG3-TCO | 2353409-81-9 | ADC Related |
| HY-141191 | N-Boc-PEG5-alcohol | 1404111-67-6 | Reference compound |
| HY-141192 | N-Boc-PEG8-alcohol | 1345337-22-5 | Reference compound |
| HY-141193 | N-Boc-PEG12-alcohol | 2218463-36-4 | Reference compound |
| HY-141194 | N-Boc-PEG16-alcohol | | Reference compound |
| HY-141195 | N-Boc-PEG24-alcohol | | Reference compound |
| HY-141196 | N-Boc-PEG36-alcohol | | Reference compound |
| HY-141197 | N-Boc-PEG23-bromide | 2252157-01-8 | Reference compound |
| HY-141198 | Boc-NH-PEG2-NH-Boc | 475591-59-4 | Reference compound |
| HY-141199 | Bromoacetamido-C2-PEG2-NH-Boc | 182244-33-3 | Reference compound |
| HY-141200 | Bromoacetamido-PEG3-NH-Boc | 1421933-39-2 | Reference compound |
| HY-141201 | m-PEG3-aminooxy-Boc | 1835759-87-9 | Reference compound |
| HY-141202 | Hydroxy-PEG5-Boc | 850090-09-4 | Reference compound |
| HY-141203 | Hydroxy-PEG6-Boc | 361189-64-2 | Reference compound |
| HY-141204 | Hydroxy-PEG7-Boc | 2737223-20-8 | Reference compound |
| HY-141205 | Hydroxy-PEG9-Boc | 2055042-66-3 | Reference compound |
| HY-141206 | Hydroxy-PEG11-Boc | | Reference compound |
| HY-141207 | Hydroxy-PEG20-Boc | | Reference compound |
| HY-141208 | Hydroxy-PEG1-CH2-Boc | 287174-32-7 | Reference compound |
| HY-141209 | Hydroxy-PEG3-CH2-Boc | 518044-31-0 | Reference compound |
| HY-14121 | MRS 1754 | 264622-58-4 | Reference compound |
| HY-141210 | Hydroxy-PEG4-O-Boc | 1807530-05-7 | Reference compound |
| HY-141211 | Hydroxy-PEG6-CH2-Boc | 297162-47-1 | Reference compound |
| HY-141212 | Hydroxy-PEG3-PFP ester | 1807537-40-1 | Reference compound |
| HY-141213 | Bromo-PEG2-alcohol | 57641-66-4 | Reference compound |
| HY-141214 | Bromo-PEG5-alcohol | 957205-14-0 | Reference compound |
| HY-141215 | Bromo-PEG6-alcohol | 136399-05-8 | Reference compound |
| HY-141217 | m-PEG7-alcohol | 4437-01-8 | Reference compound |
| HY-141218 | m-PEG10-alcohol | 27425-92-9 | ADC Related |
| HY-141219 | m-PEG11-OH | 2168540-65-4 | Reference compound |
| HY-141220 | m-PEG12-OH | 2050595-03-2 | ADC Related |
| HY-141221 | m-PEG15-alcohol | 2258654-78-1 | Reference compound |
| HY-141222 | m-PEG16-alcohol | 133604-58-7 | Reference compound |
| HY-141223 | m-PEG19-alcohol | 2412813-38-6 | Reference compound |
| HY-141224 | m-PEG23-alcohol | | Reference compound |
| HY-141225 | m-PEG24-alcohol | 2376450-73-4 | Reference compound |
| HY-141226 | m-PEG36-alcohol | | Reference compound |
| HY-141227 | THP-PEG11-OH | | Reference compound |
| HY-141228 | THP-PEG8-Tos | 669556-37-0 | Reference compound |
| HY-141229 | Methoxy-Tr-NH-PEG7 | 2353409-88-6 | Reference compound |
| HY-141230 | Hexaethylene glycol | 2615-15-8 | Reference compound |
| HY-141231 | Heptaethylene glycol | 5617-32-3 | Reference compound |
| HY-141232 | Decaethylene glycol | 5579-66-8 | Reference compound |
| HY-141233 | Dodecaethylene glycol | 6790-09-6 | Reference compound |
| HY-141234 | HO-PEG13-OH | 17598-96-8 | Reference compound |
| HY-141235 | HO-PEG16-OH | 6812-36-8 | Reference compound |
| HY-141236 | HO-PEG20-OH | 351342-08-0 | Reference compound |
| HY-141237 | HO-PEG21-OH | 928211-42-1 | Reference compound |
| HY-141238 | HO-PEG24-OH | 2243942-52-9 | Reference compound |
| HY-141239 | Hydroxy-PEG1-C2-methyl ester | 93673-82-6 | Reference compound |
| HY-141240 | Hydroxy-PEG2-C2-methyl ester | 457897-73-3 | Reference compound |
| HY-141241 | Hydroxy-PEG3-C2-methyl ester | 2086688-97-1 | Reference compound |
| HY-141242 | Hydroxy-PEG4-C2-methyl ester | 2228857-35-8 | Reference compound |
| HY-141243 | Hydroxy-PEG5-C2-methyl ester | 2100306-80-5 | Reference compound |
| HY-141244 | Hydroxy-PEG3-acrylate | 16695-45-7 | Reference compound |
| HY-141245 | Hydroxy-PEG4-C2-nitrile | 2194563-83-0 | Reference compound |
| HY-141246 | 1-Isothiocyanato-PEG4-alcohol | 1835759-69-7 | Reference compound |
| HY-141247 | 1,1,1-Trifluoroethyl-PEG4-alcohol | 1807512-41-9 | Reference compound |
| HY-141248 | 2-(Azido-PEG2-amido)-1,3-propandiol | 1398044-52-4 | Reference compound |
| HY-141249 | Azido-PEG4-Amido-Tris | 1398044-55-7 | Reference compound |
| HY-141250 | Hydroxy-Amino-bis(PEG1-C2-Boc) | 1415800-34-8 | Reference compound |
| HY-141251 | N-(Hydroxy-PEG3)-N-bis(PEG4-Boc) | 2112734-70-8 | Reference compound |
| HY-141252 | N,N-Diethanol amine-PEG4-Boc | 2279944-66-8 | Reference compound |
| HY-141253 | N-Boc-Tris | 146651-71-0 | Reference compound |
| HY-141254 | N-(Boc-PEG3)-N-bis(PEG2-alcohol) | 2055042-60-7 | Reference compound |
| HY-141255 | Bis-PEG9-PFP ester | 1334170-00-1 | Reference compound |
| HY-141256 | Bis-PEG13-PFP ester | 1383567-59-6 | Reference compound |
| HY-141258 | Bis-PEG25-TFP ester | 2567199-52-2 | Reference compound |
| HY-141259 | C-NH-Boc-C-Bis-(C1-PEG1-PFP) | 1807521-01-2 | Reference compound |
| HY-14126 | BIO-1211 | 187735-94-0 | Peptides |
| HY-141260 | Methyltetrazine-propylamine | 1802978-47-7 | Reference compound |
| HY-141261 | Methyltetrazine-PEG4-amine | 1802908-05-9 | Reference compound |
| HY-141262 | Methyltetrazine-PEG24-amine | 2353410-18-9 | Reference compound |
| HY-141263 | Methyltetrazine-acid | 1380500-88-8 | Reference compound |
| HY-141264 | Methyltetrazine-PEG4-acid | 1802907-91-0 | Reference compound |
| HY-141265 | Methyltetrazine-PEG8-acid | 2183440-33-5 | Reference compound |
| HY-141266 | Methyltetrazine-PEG13-acid | | Reference compound |
| HY-141267 | Methyltetrazine-PEG25-acid | | Reference compound |
| HY-141268 | Methyltetrazine-Sulfo-NHS ester (sodium) | 1821017-46-2 | Reference compound |
| HY-141269 | Methyltetrazine-PEG5-NHS ester | 1802907-92-1 | Reference compound |
| HY-14127 | R121919 | 195055-03-9 | Reference compound |
| HY-141270 | Methyltetrazine-PEG8-NHS ester | 2183440-34-6 | Reference compound |
| HY-141271 | Methyltetrazine-PEG13-NHS ester | | Reference compound |
| HY-141272 | Methyltetrazine-PEG24-NHS ester | | Reference compound |
| HY-141273 | Methyltetrazine-PEG8-PFP ester | 2353409-49-9 | Reference compound |
| HY-141274 | 4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenol | 58884-35-8 | Reference compound |
| HY-141275 | Methyltetrazine-PEG5-alkyne | 1802907-97-6 | Reference compound |
| HY-141276 | Methyltetrazine-amido-PEG5-alkyne | 2322322-23-4 | Reference compound |
| HY-141277 | Methyltetrazine-amido-PEG7-azide | 2112731-46-9 | Reference compound |
| HY-141278 | Methyltetrazine-PEG4-maleimide | 1802908-02-6 | Reference compound |
| HY-141279 | Methyltetrazine-PEG4-NH-Boc | 2194563-84-1 | Reference compound |
| HY-14128 | NBI-34041 | 268545-87-5 | Reference compound |
| HY-141280 | Methyltetrazine-PEG24-NH-Boc | | Reference compound |
| HY-141281 | Methyltetrazine-PEG13-Boc | | Reference compound |
| HY-141282 | Methyltetrazine-PEG24-Boc | | Reference compound |
| HY-141283 | Methyltetrazine-PEG5-triethoxysilane | 2353410-01-0 | Reference compound |
| HY-141284 | Gly-Gly-Gly-PEG4-methyltetrazine | 2353409-82-0 | ADC Related |
| HY-141285 | TAMRA-PEG4-tetrazine | | Dye Reagents |
| HY-141286 | TAMRA-PEG4-methyltetrazine | 2163772-19-6 | Dye Reagents |
| HY-141287 | N-(Azido-PEG3)-N-(PEG2-NH-Boc)-PEG3-acid | 2183440-74-4 | Reference compound |
| HY-141288 | N-(Biotin-PEG4)-N-bis(PEG4-Boc) | 2112730-79-5 | Reference compound |
| HY-141289 | N-(Propanoic acid)-N-bis(m-PEG12) | | Reference compound |
| HY-14129 | CP 316311 | 175139-41-0 | Reference compound |
| HY-141290 | Bis-(m-PEG8-amido)-hexanoic acid | 2353409-77-3 | Reference compound |
| HY-141291 | N'-Boc-N-(Gly-Oleoyl)-Lys | 2353409-71-7 | Reference compound |
| HY-141292 | Oleoyl-Gly-Lys-N-(m-PEG11) | | ADC Related |
| HY-141293 | Oleic-DBCO | 2279951-78-7 | Reference compound |
| HY-141294 | PEG3-bis(phosphonic acid) | 254762-10-2 | Reference compound |
| HY-141295 | PEG3-bis-(ethyl phosphonate) | 160625-24-1 | Reference compound |
| HY-141296 | PEG5-bis-(Ethyl phosphonate) | 1446282-28-5 | Reference compound |
| HY-141297 | Bromo-PEG2-phosphonic acid | 1446282-44-5 | Reference compound |
| HY-141298 | Bromo-PEG5-phosphonic acid | 1446282-37-6 | Reference compound |
| HY-141299 | Bromo-PEG2-phosphonic acid diethyl ester | 1226767-94-7 | Reference compound |
| HY-14130 | CP 376395 | 175140-00-8 | Reference compound |
| HY-141300 | Bromo-PEG3-phosphonic acid diethyl ester | 1148026-98-5 | Reference compound |
| HY-141301 | Bromo-PEG5-phosphonic acid diethyl ester | 1446282-41-2 | Reference compound |
| HY-141302 | Carboxy-PEG4-phosphonic acid | 1623791-69-4 | Reference compound |
| HY-141303 | Carboxy-PEG4-phosphonic acid ethyl ester | 1964503-39-6 | Reference compound |
| HY-141304 | Boc-PEG4-phosphonic acid ethyl ester | 1623791-77-4 | Reference compound |
| HY-141305 | Diethoxy-phosphorylethyl-PEG5-ethylphosphonic acid | 1446282-17-2 | Reference compound |
| HY-141306 | m-PEG2-phosphonic acid | 96962-41-3 | Reference compound |
| HY-141307 | m-PEG4-phosphonic acid | 1872433-62-9 | Reference compound |
| HY-141308 | m-PEG5-phosphonic acid | 1807512-39-5 | Reference compound |
| HY-141309 | m-PEG4-(CH2)6-Phosphonic acid | 2028281-85-6 | Reference compound |
| HY-141310 | m-PEG6-(CH2)6-Phosphonic acid | 2028284-71-9 | Reference compound |
| HY-141311 | m-PEG4-phosphonic acid ethyl ester | 1872433-73-2 | Reference compound |
| HY-141312 | m-PEG5-phosphonic acid ethyl ester | 1807512-42-0 | Reference compound |
| HY-141313 | m-PEG9-phosphonic acid ethyl ester | 2699881-07-5 | Reference compound |
| HY-141314 | m-PEG4-C6-phosphonic acid ethyl ester | 2028281-89-0 | Reference compound |
| HY-141315 | m-PEG6-C6-phosphonic acid ethyl ester | 2028281-88-9 | Reference compound |
| HY-141316 | m-PEG8-(CH2)12-phosphonic acid ethyl ester | 2112737-70-7 | Reference compound |
| HY-141317 | S-acetyl-PEG3-phosphonic acid ethyl ester | 2173125-29-4 | Reference compound |
| HY-141318 | Thiol-PEG3-phosphonic acid | 1360716-36-4 | Reference compound |
| HY-141319 | Thiol-PEG3-phosphonic acid ethyl ester | 1360716-43-3 | Reference compound |
| HY-14132 | BMS-665053 | 1173435-64-7 | Reference compound |
| HY-141320 | PEG2-bis(phosphonic acid diethyl ester) | 500347-73-9 | Reference compound |
| HY-141321 | PEG3-bis(phosphonic acid diethyl ester) | 1807539-03-2 | Reference compound |
| HY-141322 | PEG4-bis(phosphonic acid diethyl ester) | 106338-06-1 | Reference compound |
| HY-141323 | C2-Bis-phosphoramidic acid diethyl ester | 34008-16-7 | Reference compound |
| HY-141324 | Tetraethyl butane-1,4-diylbis(phosphoramidate) | 720707-93-7 | Reference compound |
| HY-141325 | C6-Bis-phosphoramidic acid diethyl ester | 1446282-35-4 | Reference compound |
| HY-141326 | Thiol-PEG12-acid | 2211174-73-9 | Reference compound |
| HY-141327 | Thiol-PEG3-Boc | 1446282-39-8 | Reference compound |
| HY-141328 | Thiol-PEG4-Boc | 564476-33-1 | Reference compound |
| HY-141329 | m-PEG6-thiol | 441771-60-4 | Reference compound |
| HY-141330 | m-PEG8-thiol | 651042-83-0 | Reference compound |
| HY-141331 | m-PEG12-Thiol | 2413368-61-1 | Reference compound |
| HY-141332 | Lipoamido-PEG4-acid | 1314378-10-3 | Reference compound |
| HY-141333 | Lipoamido-PEG8-acid | 1334172-70-1 | Reference compound |
| HY-141334 | Lipoamido-PEG12-acid | 2407442-47-9 | Reference compound |
| HY-141335 | Lipoamido-PEG24-acid | | Reference compound |
| HY-141336 | α-Lipoic acid-NHS | 40846-94-4 | Reference compound |
| HY-141337 | Lipoamido-PEG2-OH | 1674386-82-3 | Reference compound |
| HY-141338 | Lipoamide-PEG3-Mal | 1314378-19-2 | Reference compound |
| HY-141339 | Lipoamide-PEG11-Mal | | Reference compound |
| HY-14134 | BMS-378806 | 357263-13-9 | Reference compound |
| HY-141340 | S-acetyl-PEG3-alcohol | 153870-20-3 | Reference compound |
| HY-141341 | S-acetyl-PEG4-alcohol | 223611-42-5 | Reference compound |
| HY-141342 | S-acetyl-PEG12-alcohol | | Reference compound |
| HY-141343 | S-acetyl-PEG16-alcohol | | Reference compound |
| HY-141344 | S-acetyl-PEG20-alcohol | | Reference compound |
| HY-141345 | S-acetyl-PEG2-Boc | 1820641-93-7 | Reference compound |
| HY-141346 | S-acetyl-PEG3-Boc | 1818294-27-7 | Reference compound |
| HY-141347 | S-acetyl-PEG4-Boc | 1818294-26-6 | Reference compound |
| HY-141348 | S-acetyl-PEG6-Boc | 1818294-39-1 | Reference compound |
| HY-141349 | S-Acetyl-PEG3-C2-acid | 1421933-33-6 | Reference compound |
| HY-14135 | BMS 488043 | 452296-83-2 | Reference compound |
| HY-141350 | S-acetyl-PEG4-propargyl | 1422540-88-2 | Reference compound |
| HY-141351 | m-PEG3-S-Acetyl | 857284-78-7 | Reference compound |
| HY-141352 | SPDP-PEG4-acid | 581065-97-6 | Reference compound |
| HY-141353 | SPDP-PEG12-acid | | ADC Related |
| HY-141354 | SPDP-PEG24-acid | | Reference compound |
| HY-141355 | OPSS-PEG36-acid | | ADC Related |
| HY-141356 | SPDP-PEG12-NHS ester | 2601437-72-1 | Reference compound |
| HY-141357 | SPDP-PEG24-NHS ester | | Reference compound |
| HY-141358 | SPDP-PEG36-NHS ester | | ADC Related |
| HY-141359 | (2-Pyridyldithio)-PEG4-alcohol | 851961-99-4 | Reference compound |
| HY-14136 | Rimonabant | 168273-06-1 | Reference compound |
| HY-141360 | (2-Pyridyldithio)-PEG4-propargyl | 2170240-99-8 | Reference compound |
| HY-141361 | (2-Pyridyldithio)-PEG2-Boc | 2144777-73-9 | Reference compound |
| HY-141362 | Bromo-PEG2-C2-acid | 1807503-92-9 | Reference compound |
| HY-141363 | Bromo-PEG4-acid | 1393330-38-5 | Reference compound |
| HY-141364 | Bromo-PEG1-C2-Boc | 1393330-36-3 | Reference compound |
| HY-141365 | Bromo-PEG2-C2-Boc | 1381861-91-1 | Reference compound |
| HY-141366 | Bromo-PEG5-Boc | 1415800-38-2 | Reference compound |
| HY-141367 | Bromo-PEG6-Boc | 1393330-41-0 | Reference compound |
| HY-141368 | Bromo-PEG8-Boc | 1623792-00-6 | Reference compound |
| HY-141369 | Bromo-PEG24-Boc | | Reference compound |
| HY-14136S | Rimonabant-d10 | 929221-88-5 | Isotope-Labeled Compounds |
| HY-14137 | Rimonabant (Hydrochloride) | 158681-13-1 | Reference compound |
| HY-141370 | Bromo-PEG1-CH2-Boc | 157759-50-7 | Reference compound |
| HY-141371 | Bromo-PEG2-CH2-Boc | 1807518-63-3 | Reference compound |
| HY-141372 | Bromo-PEG3-CH2-Boc | 2100306-71-4 | Reference compound |
| HY-141373 | Bromo-PEG3-bromide | 31255-26-2 | Reference compound |
| HY-141374 | Bromo-PEG5-bromide | 67705-77-5 | Reference compound |
| HY-141375 | m-PEG5-Br | 854601-80-2 | Reference compound |
| HY-141376 | m-PEG6-Br | 125562-29-0 | Reference compound |
| HY-141377 | m-PEG9-Br | 125562-30-3 | Reference compound |
| HY-141378 | m-PEG12-Br | 1620461-89-3 | Reference compound |
| HY-141379 | N-Bromoacetyl-β-alanine | 89520-11-6 | ADC Related |
| HY-14137R | Rimonabant (Hydrochloride) (Standard) | 158681-13-1 | Reference Standards |
| HY-14137S | Rimonabant-d10 (hydrochloride) | 1044909-61-6 | Isotope-Labeled Compounds |
| HY-141380 | Bromoacetamido-PEG2-C2-acid | 1415800-44-0 | Reference compound |
| HY-141381 | Bromoacetamido-PEG3-C2-acid | 1807534-79-7 | Reference compound |
| HY-141382 | Bromoacetamido-PEG4-acid | 1807518-67-7 | ADC Related |
| HY-141383 | Bromoacetamido-PEG8-acid | 1698019-89-4 | Reference compound |
| HY-141384 | 2-Bromo-2,2-dimethyl-acetamido-PEG3-acid | 2279944-67-9 | Reference compound |
| HY-141385 | N-Succinimidyl 3-(Bromoacetamido)propionate | 57159-62-3 | ADC Related |
| HY-141386 | Bromoacetamido-PEG2-C2-NHS ester | 1353011-78-5 | Reference compound |
| HY-141387 | Bromoacetamido-PEG4-NHS ester | 1260139-70-5 | Reference compound |
| HY-141388 | Bromoacetamido-PEG3-C2-Boc | 1807537-33-2 | Reference compound |
| HY-141389 | Bromoacetamido-PEG8-Boc | 2055041-16-0 | Reference compound |
| HY-141390 | Bromoacetamido-PEG9-ethylcarbamoyl-C4-Boc | | Reference compound |
| HY-141391 | Bromoacetamido-PEG9-ethylcarbamoyl-C8-Boc | | Reference compound |
| HY-141392 | Bromoacetamido-PEG9-ethylcarbamoyl-C12-Boc | | Reference compound |
| HY-141393 | Bis-Bromoacetamido-PEG11 | | Reference compound |
| HY-141394 | Chloroacetamido-PEG4-NHS ester | 1353011-95-6 | Reference compound |
| HY-141395 | m-PEG4-Boc | 883554-11-8 | ADC Related |
| HY-141396 | m-PEG5-Boc | 874208-93-2 | Reference compound |
| HY-141397 | m-PEG8-T-Butyl ester | 2768015-32-1 | Reference compound |
| HY-141398 | m-PEG9-t-Butyl ester | 2768015-30-9 | Reference compound |
| HY-141399 | m-PEG10-T-Butyl ester | 2768015-31-0 | Reference compound |
| HY-141400 | m-PEG12-Boc | | Reference compound |
| HY-141401 | m-PEG13-Boc | | Reference compound |
| HY-141402 | m-PEG4-Hydrazide | 1449390-68-4 | Reference compound |
| HY-141403 | m-PEG37-hydrazide | | Reference compound |
| HY-141404 | m-PEG4-CH2-methyl ester | 1920109-55-2 | Reference compound |
| HY-141405 | m-PEG7-4-nitrophenyl carbonate | 678150-56-6 | Reference compound |
| HY-141406 | m-PEG5-2-methylacrylate | 48074-75-5 | Reference compound |
| HY-141407 | m-PEG3-amido-C3-triethoxysilane | 2243566-45-0 | Reference compound |
| HY-141408 | m-PEG5-triethoxysilane | 2243566-42-7 | Reference compound |
| HY-141410 | Fluticasone dimer impurity | 220589-37-7 | Reference compound |
| HY-141411 | (Rac)-Zevaquenabant | 1610420-28-4 | Reference compound |
| HY-141411A | Zevaquenabant | 1998760-00-1 | Reference compound |
| HY-141411B | (R)-Zevaquenabant | | Reference compound |
| HY-141412 | D-(-)-3-Phosphoglyceric acid (disodium) | 80731-10-8 | Reference compound |
| HY-141413 | Benzyl 2,3-Di-O-benzyl-4-O-benzoyl-β-D-galactopyranoside | 57783-81-0 | Biochemical Assay Reagents |
| HY-141415 | Tween 20 | 9005-64-5 | Biochemical Assay Reagents |
| HY-141420 | PtdIns-(3,4,5)-P3(1,2-dihexanoyl) (ammonium) | 799268-62-5 | Biochemical Assay Reagents |
| HY-141422A | 4,4-Diphenylbutylamine (hydrochloride) | 22101-90-2 | Reference compound |
| HY-141423 | Thalidomide-O-amide-C5-NH2 | 2360527-40-6 | Reference compound |
| HY-141423A | Thalidomide-O-amide-C5-NH2 (TFA) | 2748161-83-1 | Reference compound |
| HY-141425 | NSC73306 | 79560-74-0 | Reference compound |
| HY-141426 | MDL-860 | 78940-62-2 | Reference compound |
| HY-141427 | MOCPAC | 787549-26-2 | Reference compound |
| HY-141429 | AS-99 (free base) | 2323623-93-2 | Reference compound |
| HY-141429A | AS-99 (TFA) | | Reference compound |
| HY-141429C | AS-99 | | Reference compound |
| HY-141430 | AS-85 | 2323623-80-7 | Reference compound |
| HY-141431 | Cbl-b-IN-2 | 2503325-21-9 | Reference compound |
| HY-141432 | NX-1607 | 2573775-59-2 | Reference compound |
| HY-141432G | NX-1607 (GMP) | 2573775-59-2 | GMP Small Molecules |
| HY-141434 | 5-OxoETE methyl ester | 74785-00-5 | Reference compound |
| HY-141436 | Sucrosofate (potassium) | 73264-44-5 | Reference compound |
| HY-141436R | Sucrosofate (potassium) (Standard) | 73264-44-5 | Reference Standards |
| HY-141438 | SIM1 | 2719051-84-8 | Reference compound |
| HY-141438A | cis-SIM1 | 2719051-98-4 | Reference compound |
| HY-141439 | TBE 31 | 936475-62-6 | Reference compound |
| HY-14144 | Aclidinium (Bromide) | 320345-99-1 | Reference compound |
| HY-141441 | Novobiocic acid | 485-23-4 | Reference compound |
| HY-141442 | Dihydronovobiocin | 29826-16-2 | Natural Products |
| HY-141445 | MNP-Glc | 70622-80-9 | Biochemical Assay Reagents |
| HY-141447 | Z-LYS-SBZL (monohydrochloride) | 69861-89-8 | Peptides |
| HY-141448 | NRX-2663 | 2763260-34-8 | Reference compound |
| HY-141449 | NRX-103094 | 2763260-36-0 | Reference compound |
| HY-14144R | Aclidinium (Bromide) (Standard) | 320345-99-1 | Reference Standards |
| HY-141450 | NRX-103095 | 2763260-38-2 | Reference compound |
| HY-141453 | Desmethyl-WEHI-345 analog | 1354825-03-8 | Reference compound |
| HY-141454 | TLR8 agonist 2 | 2412937-64-3 | Reference compound |
| HY-141454A | TLR8 agonist 2 (hydrochloride) | 2412937-65-4 | Reference compound |
| HY-141459 | Squamolone | 40451-67-0 | Natural Products |
| HY-141464 | Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH | 131287-39-3 | Reference compound |
| HY-141465 | 3-Hydroxybutyryl-CoA | 2871-66-1 | Enzyme |
| HY-141466 | Crotonyl-CoA | 992-67-6 | Reference compound |
| HY-141466A | Crotonyl-CoA (tetrasodium) | | Natural Products |
| HY-141467 | Propionyl CoA | 317-66-8 | Enzyme |
| HY-141468 | β-Chlornaltrexamine (dihydrochloride) | 67025-98-3 | Reference compound |
| HY-141469 | 6,9,12,15,18-Heneicosapentaenoic acid | 65919-53-1 | Reference compound |
| HY-14147 | Renzapride | 112727-80-7 | Reference compound |
| HY-141472 | 7-Methylguanosine 5'-diphosphate (sodium) | 104809-16-7 | Reference compound |
| HY-141473 | Malonyl CoA (tetralithium) | 116928-84-8 | Enzyme |
| HY-141474 | Glutaryl coenzyme A (lithium) | 103192-48-9 | Biochemical Assay Reagents |
| HY-141475 | Acetoacetyl coenzyme A (sodium) | 102029-52-7 | Reference compound |
| HY-141476 | PI3K/mTOR Inhibitor-3 | 1363338-53-7 | Reference compound |
| HY-141477 | RM-018 | 2641993-55-5 | Reference compound |
| HY-141478 | Antitumor agent-28 | 2097499-67-5 | Reference compound |
| HY-141479A | Butyryl-Coenzyme A (trisodium) | | Enzyme |
| HY-141479B | Butyryl-Coenzyme A (lithium hydrate) | 1107039-35-9 | Enzyme |
| HY-14147A | (S)-Renzapride | | Reference compound |
| HY-14148 | Renzapride (hydrochloride) | 109872-41-5 | Reference compound |
| HY-141480 | GSK-3β inhibitor 3 | 1448990-73-5 | Reference compound |
| HY-141481 | DP-C-4 | | Reference compound |
| HY-141482 | WSB1 Degrader 1 | 2306039-66-5 | Reference compound |
| HY-141483 | DEAE Cross-linked dextran A 50 | 39455-31-7 | Biochemical Assay Reagents |
| HY-141486 | (Rac)-PROTAC PARP/EGFR ligand 1 | 2935073-36-0 | Reference compound |
| HY-141486A | PROTAC PARP/EGFR ligand 1 | 2661609-57-8 | Reference compound |
| HY-141487 | CLP-3094 | 312749-73-8 | Reference compound |
| HY-141488 | Lacto-N-biose I | 50787-09-2 | Natural Products |
| HY-14149 | Cisapride | 81098-60-4 | Reference compound |
| HY-141490 | Beta-D-Glucopyranosyl nitromethane | 81846-60-8 | Reference compound |
| HY-141494 | Pparδ agonist 5 | | Reference compound |
| HY-141495 | (Rac)-Razpipadon | 1643462-93-4 | Reference compound |
| HY-141495A | Razpipadon | 1643489-35-3 | Reference compound |
| HY-141496 | A-77636 | 778546-51-3 | Reference compound |
| HY-14149A | Cisapride (monohydrate) | 260779-88-2 | Reference compound |
| HY-14149R | Cisapride (Standard) | 81098-60-4 | Reference Standards |
| HY-14149S | Cisapride-d6 | 2738376-71-9 | Isotope-Labeled Compounds |
| HY-141508 | Flazin | 100041-05-2 | Natural Products |
| HY-14151 | Prucalopride | 179474-81-8 | Reference compound |
| HY-141510 | myo-Inositol trispyrophosphate (hexasodium) | 23103-35-7 | Reference compound |
| HY-141510A | myo-Inositol trispyrophosphate (hexa-triethylamine) | 851086-77-6 | Reference compound |
| HY-141511 | Coppersensor 1 | 874748-20-6 | Dye Reagents |
| HY-141512 | JB170 | 2705844-82-0 | Reference compound |
| HY-141513 | NH-3 | 447415-26-1 | Reference compound |
| HY-141514 | MSA-2 dimer | 2377881-92-8 | Reference compound |
| HY-141515 | BMS-986121 | 313671-26-0 | Reference compound |
| HY-141519 | PI-55 | 1122579-42-3 | Reference compound |
| HY-14151R | Prucalopride (Standard) | 179474-81-8 | Reference Standards |
| HY-14151S | Prucalopride-13C,d3 | 2140306-00-7 | Isotope-Labeled Compounds |
| HY-14152 | Prucalopride (hydrochloride) | 179474-80-7 | Reference compound |
| HY-141520 | ART558 | 2603528-97-6 | Reference compound |
| HY-141521 | Amelenodor | 2389235-01-0 | Reference compound |
| HY-141522 | Cross-linked dextran G 100 | 9050-94-6 | Biochemical Assay Reagents |
| HY-141522A | Cross-linked dextran G 100, coarse | 9050-94-6 | Biochemical Assay Reagents |
| HY-141523 | Vociprotafib | 2172652-48-9 | Reference compound |
| HY-141524 | RMC-3943 | 1801764-60-2 | Reference compound |
| HY-141525 | SCD1 inhibitor-4 | 1295541-87-5 | Reference compound |
| HY-141526 | O-Methyl-D-tyrosine | 39878-65-4 | Peptides |
| HY-14153 | Tegaserod | 145158-71-0 | Reference compound |
| HY-141530 | Clopidogrel-β-D-glucuronide | 1314116-53-4 | Reference compound |
| HY-141532 | D-Erythritol 4-phosphate | 7183-41-7 | Reference compound |
| HY-141535 | IL-17 modulator 1 | 2446803-85-4 | Reference compound |
| HY-141535A | IL-17 modulator 1 (disodium) | 2446803-91-2 | Reference compound |
| HY-141536 | PSMA-ALB-56 | 2306049-48-7 | ADC Related |
| HY-141537 | ABR-238901 | 1638200-22-2 | Reference compound |
| HY-141539 | SETDB1-TTD-IN-1 | 2755823-12-0 | Reference compound |
| HY-141539A | SETDB1-TTD-IN-1 (TFA) | | Reference compound |
| HY-14153A | Tegaserod (maleate) | 189188-57-6 | Reference compound |
| HY-14153AS | Tegaserod-13C,d3 (maleate) | | Isotope-Labeled Compounds |
| HY-14153S | Tegaserod-d11 | 1134188-56-9 | Isotope-Labeled Compounds |
| HY-14154 | THRX-194556 | 886579-13-1 | Reference compound |
| HY-141540 | Lactyl-CoA | 1926-57-4 | Reference compound |
| HY-141543 | YW2065 | 2131223-85-1 | Reference compound |
| HY-141546 | Pocenbrodib | 2304372-79-8 | Reference compound |
| HY-141547 | Nav1.7-IN-8 | 1432913-44-4 | Reference compound |
| HY-141549 | BPK-21 | 2305052-77-9 | Reference compound |
| HY-14155 | MMP145 | 1025717-75-2 | Reference compound |
| HY-141550 | BPK-25 | 2305052-86-0 | Reference compound |
| HY-141551 | GNE-274 | 2369048-69-9 | Reference compound |
| HY-141551B | (R)-GNE-274 | | Reference compound |
| HY-141552 | FC9402 | 2452401-65-7 | Reference compound |
| HY-141553 | Methyl alpha-eleostearate | 4175-47-7 | Biochemical Assay Reagents |
| HY-141554 | Dihydrotetrabenazine | 3466-75-9 | Reference compound |
| HY-141555 | 5,5′-(1,3-Propanediyl)bis-1,3,4-oxadiazole-2(3H)-thione | 333409-31-7 | Reference compound |
| HY-14156 | 11β-HSD1-IN-15 | 946398-78-3 | Reference compound |
| HY-141566 | EZH2-IN-5 | 1403258-69-4 | Reference compound |
| HY-141567 | Pseudouridine 5'-triphosphate | 1175-34-4 | Oligonucleotides |
| HY-141567A | Pseudouridine 5'-triphosphate (trisodium) solution (100mM) | | Oligonucleotides |
| HY-141569 | Ganglioside GD1a | 12707-58-3 | Natural Products |
| HY-14157 | ADL-5747 | 850176-30-6 | Reference compound |
| HY-141570 | Lyso-PAF C-16 | 52691-62-0 | Reference compound |
| HY-141570S | Lyso-PAF C-16-d4 | 201216-37-7 | Isotope-Labeled Compounds |
| HY-141571 | DOPG (sodium) | 67254-28-8 | Biochemical Assay Reagents |
| HY-141572 | 1,2-Dioleoyl-sn-glycerol | 24529-88-2 | Biochemical Assay Reagents |
| HY-141573 | Oleyl alcohol | 143-28-2 | Reference compound |
| HY-141574 | 1,2-Didecanoyl-Sn-glycerol | 60514-49-0 | Reference compound |
| HY-141575 | C12-NBD-ceramide | 202850-01-9 | Dye Reagents |
| HY-141576 | C6-NBD Sphinganine | 114301-97-2 | Dye Reagents |
| HY-141577 | C12-NBD Sphinganine | 474943-05-0 | Dye Reagents |
| HY-141578 | C18:1-Ceramide | 5966-28-9 | Reference compound |
| HY-141578S | C18:1-Ceramide-13C18 | | Isotope-Labeled Compounds |
| HY-141578S1 | C18:1 Ceramide-d7 | 1942907-50-7 | Isotope-Labeled Compounds |
| HY-141579 | Sphingosine (d17:1) | 6918-48-5 | Natural Products |
| HY-14157A | ADL-5747 (hydrochloride) | 1187653-56-0 | Reference compound |
| HY-141580 | C18 Dihydroceramide | 2304-80-5 | Natural Products |
| HY-141580S | C18 Dihydroceramide-d3 | 2692624-27-2 | Isotope-Labeled Compounds |
| HY-141580S1 | C18 Dihydroceramide-d3-1 | 2699606-99-8 | Isotope-Labeled Compounds |
| HY-141581 | Lyso-PAF C-18 | 74430-89-0 | Reference compound |
| HY-141581S | Lyso-PAF C-18-d4 | | Isotope-Labeled Compounds |
| HY-141582 | Ceramide 3 | 34354-88-6 | Biochemical Assay Reagents |
| HY-141582S | Ceramide 3-d3 | 1354806-91-9 | Isotope-Labeled Compounds |
| HY-141584 | ATSP-7041 | 1451197-99-1 | Peptides |
| HY-141591 | CYT296 | 1799392-31-6 | Reference compound |
| HY-141593 | Modified MMAF-C5-COOH | 1404071-65-3 | ADC Related |
| HY-141594 | Modified MMAF | 1352202-47-1 | Reference compound |
| HY-141596 | Lys-Nε-SPDB-DM4 | 1280215-91-9 | ADC Related |
| HY-141597 | Acid-C3-SSPy | 250266-79-6 | ADC Related |
| HY-141598 | Datopotamab deruxtecan | 2238831-60-0 | ADC Related |
| HY-14160 | CB2 receptor agonist 7 | 871819-90-8 | Reference compound |
| HY-141600 | Aprutumab ixadotin | 1708947-48-1 | Reference compound |
| HY-141601 | Telisotuzumab vedotin | 1714088-51-3 | ADC Related |
| HY-141602 | Pinatuzumab vedotin | 1313706-14-7 | Reference compound |
| HY-141604 | Glembatumumab vedotin | 1182215-65-1 | Reference compound |
| HY-141606 | Anetumab ravtansine | 1375258-01-7 | Reference compound |
| HY-141607 | Indatuximab ravtansine | 1238517-16-2 | ADC Related |
| HY-141609 | IK-175 | 2247950-42-9 | Reference compound |
| HY-141610 | Methyl heptanoate | 106-73-0 | Biochemical Assay Reagents |
| HY-141612 | Pyrrolidino PAF C-16 | 91021-63-5 | Reference compound |
| HY-141613 | 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine (sodium) | 90693-88-2 | Oligonucleotides |
| HY-141613A | Dioleyl phosphatidylserine | 6811-55-8 | Reference compound |
| HY-141614 | 1,2-Diarachidoyl-sn-glycero-3-phosphocholine | 61596-53-0 | Biochemical Assay Reagents |
| HY-141615 | 1,2-Dipalmitoyl-sn-glycero-3-phospho-N,N-dimethylethanolamine | 3922-61-0 | Biochemical Assay Reagents |
| HY-141616 | 1-Heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine | 50930-23-9 | Natural Products |
| HY-141616S | 1-Heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine-d5 | 2342575-12-4 | Isotope-Labeled Compounds |
| HY-141617 | 1-Palmitoyl-2-hydroxy-sn-glycero-3-PE | 53862-35-4 | Reference compound |
| HY-141617S | 1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PE | 2747981-09-3 | Isotope-Labeled Compounds |
| HY-141619 | Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:5) | 8064-90-2 | Reference compound |
| HY-141619A | Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:19) | 8064-90-2 | Reference compound |
| HY-14162 | AM103 (free acid) | 936349-47-2 | Reference compound |
| HY-141621 | ACT-606559 | | Reference compound |
| HY-141622 | SDZ 224-015 | 161511-45-1 | Reference compound |
| HY-141623 | SRI-37330 (hydrochloride) | 2322245-49-6 | Reference compound |
| HY-141625 | TRC160334 | 1293289-69-6 | Reference compound |
| HY-141625A | TRC160334 (sodium) | 1293290-41-1 | Reference compound |
| HY-141626S | 6β-Hydroxytestosterone-d7 | | Isotope-Labeled Compounds |
| HY-141627 | Heparin disaccharide I-S (tetrasodium) | 136098-10-7 | Biochemical Assay Reagents |
| HY-141629 | N-Palmitoyl-D-sphingomyelin | 6254-89-3 | Reference compound |
| HY-141629S | N-Palmitoyl-D-sphingomyelin-d31 | 807617-46-5 | Isotope-Labeled Compounds |
| HY-141629S1 | N-Palmitoyl-D-sphingomyelin-13C | 144236-99-7 | Isotope-Labeled Compounds |
| HY-141629S2 | N-Palmitoyl-D-sphingomyelin-d9 | 2415226-88-7 | Isotope-Labeled Compounds |
| HY-14163 | AM103 | 1147872-22-7 | Reference compound |
| HY-141630 | Sphingosine-1-phosphate (d17:1) | 474923-27-8 | Reference compound |
| HY-141631 | Dihomo-γ-Linolenoyl PAF C-16 | 155575-01-2 | Biochemical Assay Reagents |
| HY-141632 | Sphinganine-C17 | 32164-02-6 | Reference compound |
| HY-141633 | Sucrose, monolaurate | 25339-99-5 | Biochemical Assay Reagents |
| HY-141634 | Methyl octacosanoate | 55682-92-3 | Biochemical Assay Reagents |
| HY-141635 | cis-11,14-Eicosadienoic acid methyl ester | 61012-46-2 | Reference compound |
| HY-141636 | 1-PalMitoyl-2-arachidoyllecithin | 35418-58-7 | Biochemical Assay Reagents |
| HY-141636S | 1-PalMitoyl-2-arachidoyllecithin-d9-1 | 1872379-11-7 | Isotope-Labeled Compounds |
| HY-141637 | 2-Deoxy-2-fluoro-D-glucose | 29702-43-0 | Biochemical Assay Reagents |
| HY-141637S | 2-Deoxy-2-fluoro-D-glucose-13C | 478518-95-5 | Isotope-Labeled Compounds |
| HY-141637S1 | 2-Deoxy-2-fluoro-D-glucose-13C,d7 | | Isotope-Labeled Compounds |
| HY-141638 | Me-IQ | 77094-11-2 | Reference compound |
| HY-141639 | 3-Hydroxyheptadecanoic acid | 40165-89-7 | Reference compound |
| HY-14164 | Zileuton | 111406-87-2 | Reference compound |
| HY-141640 | MS154 | 2550393-21-8 | Reference compound |
| HY-141641 | N-(3-Oxopentanoyl)-L-homoserine lactone | 148433-21-0 | Reference compound |
| HY-141642 | Triheptadecanoin | 2438-40-6 | Reference compound |
| HY-141642S | Triheptadecanoin-d5 | 944795-74-8 | Isotope-Labeled Compounds |
| HY-141644 | PY-60 | 2765218-56-0 | Reference compound |
| HY-141645 | IMM-H007 | 1221412-23-2 | Reference compound |
| HY-141646 | MIT-PZR | 2376848-06-3 | Dye Reagents |
| HY-141647 | [18F]-Labeled L-dopa precursor | 1614253-58-5 | Reference compound |
| HY-141648 | Antibacterial agent 219 | 1649473-91-5 | Reference compound |
| HY-141649 | Anticancer agent 251 | 1648546-79-5 | Reference compound |
| HY-14164A | Zileuton (sodium) | 118569-21-4 | Reference compound |
| HY-14164R | Zileuton (Standard) | 111406-87-2 | Reference Standards |
| HY-14164S | Zileuton-d4 | 1189878-76-9 | Isotope-Labeled Compounds |
| HY-14164S1 | Zileuton-13C2,15N | | Isotope-Labeled Compounds |
| HY-14165 | Veliflapon | 128253-31-6 | Reference compound |
| HY-141651 | (S,R,S)-AHPC-C3-COOH | 2172819-73-5 | Reference compound |
| HY-141652 | N-2-Azidoethyl betulonamide | 2055270-64-7 | Reference compound |
| HY-141653 | MK-8666 (tromethamine) | 2056254-98-7 | Reference compound |
| HY-141659 | CMPD-39 | 2242582-40-5 | Reference compound |
| HY-14165A | (S)-Veliflapon | 128253-32-7 | Reference compound |
| HY-14166 | MK-886 | 118414-82-7 | Reference compound |
| HY-141660 | BSc3094 | 946857-84-7 | Reference compound |
| HY-141661 | Aβ/tau aggregation-IN-1 | 2252162-81-3 | Reference compound |
| HY-141662 | 2',3'-cGAMP-C2-PPA | 2586047-11-0 | ADC Related |
| HY-141663 | 2',3'-cGAMP-C2-SH | 2133823-39-7 | ADC Related |
| HY-141664 | PPA | 452072-22-9 | ADC Related |
| HY-141666 | MYC-IN-2 | 2244979-61-9 | Reference compound |
| HY-141667 | MBD | 33984-50-8 | Dye Reagents |
| HY-141668 | BCAT-IN-1 | 1875078-61-7 | Reference compound |
| HY-141669 | BCAT-IN-2 | 1800024-45-6 | Reference compound |
| HY-14166A | MK-886 (sodium salt) | 118427-55-7 | Reference compound |
| HY-14167 | GW842166X | 666260-75-9 | Reference compound |
| HY-141672 | 17β-Estradiol sulfate (sodium) | 4999-79-5 | Reference compound |
| HY-141672S1 | 17β-Estradiol sulfate-d4 (sodium) | 352431-50-6 | Isotope-Labeled Compounds |
| HY-141674 | DMG-PEG | 1397695-86-1 | Biochemical Assay Reagents |
| HY-141675 | Geranyl monophosphate | 1609182-56-0 | Natural Products |
| HY-141676 | HyT36 | 1323151-45-6 | Reference compound |
| HY-141677 | INCB059872 | 1802909-49-4 | Reference compound |
| HY-141677A | INCB059872 (dihydrochloride) | | Reference compound |
| HY-141677B | INCB059872 (tosylate) | 2081940-67-0 | Reference compound |
| HY-141680 | CPS2 | 2756741-90-7 | Reference compound |
| HY-141685 | 3-Methylthienyl-carbonyl-JNJ-7706621 | 443798-09-2 | Reference compound |
| HY-141687 | NSC 107512 | 22242-89-3 | Reference compound |
| HY-141689 | BTK-IN-3 | 1226872-27-0 | Reference compound |
| HY-141690A | PI3K-IN-19 (hydrochloride) | 2132943-80-5 | Reference compound |
| HY-141692 | IL-17 modulator 4 | 2446803-65-0 | Reference compound |
| HY-141692A | IL-17 modulator 4 (sulfate) | 2446806-90-0 | Reference compound |
| HY-141692B | (R)-IL-17 modulator 4 | 2446804-29-9 | Reference compound |
| HY-141696S | 3-Hydroxy Mepivacaine-d3 | 1346597-79-2 | Isotope-Labeled Compounds |
| HY-141699 | FATP1-IN-1 | 1431945-95-7 | Reference compound |
| HY-141700 | FATP1-IN-2 | 2650944-83-3 | Reference compound |
| HY-141701 | mTOR/HDAC-IN-1 | 2815286-02-1 | Reference compound |
| HY-141703 | DC-BPi-11 | 2758411-61-7 | Reference compound |
| HY-141703A | DC-BPi-11 (hydrochloride) | | Reference compound |
| HY-14171 | Bexarotene | 153559-49-0 | Reference compound |
| HY-141711 | VU6028418 | 2649803-05-2 | Reference compound |
| HY-141714 | SBC-115337 | 423148-46-3 | Reference compound |
| HY-141715 | BRD-8000.3 | 2365504-95-4 | Reference compound |
| HY-141716 | SW2_110A | | Reference compound |
| HY-141718S | N-Acetyl-S-(trichlorovinyl)-L-cysteine-d3 | 1346616-95-2 | Isotope-Labeled Compounds |
| HY-14171R | Bexarotene (Standard) | 153559-49-0 | Reference Standards |
| HY-14171S | Bexarotene-d4 | 2182068-00-2 | Isotope-Labeled Compounds |
| HY-14171S2 | Bexarotene-13C6 | | Isotope-Labeled Compounds |
| HY-141720 | 4-(2,4,4-Trimethylpentan-2-yl)benzene-PEG4-OH | 2315-63-1 | Reference compound |
| HY-141720S | N-Acetyl sulfadiazine-d4 | 1219149-66-2 | Isotope-Labeled Compounds |
| HY-141721S | 2-(((7-Methyloctyl)oxy)carbonyl)benzoic acid-d4 | 1332965-96-4 | Isotope-Labeled Compounds |
| HY-141722S | Carboxyphosphamide-d4 | 1246817-74-2 | Isotope-Labeled Compounds |
| HY-141724 | PCSK9 ligand 1 | 2215931-60-3 | Reference compound |
| HY-141725S | N-Acetyl Tizanidine-d4 | 1276602-33-5 | Isotope-Labeled Compounds |
| HY-141728 | Bis(1-chloro-2-propyl) phosphate | 789440-10-4 | Reference compound |
| HY-141729 | Biotin-NH-PSMA-617 | | Dye Reagents |
| HY-141736S | Acetaminophen dimer-d6 | 1794817-30-3 | Isotope-Labeled Compounds |
| HY-141739S | Promethazine sulfoxide-d6 | 1189892-93-0 | Isotope-Labeled Compounds |
| HY-14174 | MRK-560 | 677772-84-8 | Reference compound |
| HY-141740S | Hydroxymethyl Tolperisone-d10 (hydrochloride) | 1346605-29-5 | Isotope-Labeled Compounds |
| HY-141742S | N-Demethyl Promethazine-d3 (hydrochloride) | 1330173-19-7 | Isotope-Labeled Compounds |
| HY-141744S | 4,4'-Dinitrocarbanilide-d8 | 1156508-87-0 | Isotope-Labeled Compounds |
| HY-141745S | 2-(((4-Methyl-7-oxooctyl)oxy)carbonyl)benzoic acid-d4 | 1332966-00-3 | Isotope-Labeled Compounds |
| HY-141749A | Clopidogrel carboxylic acid | 144457-28-3 | Reference compound |
| HY-141749AS | Clopidogrel carboxylic acid-d4 | 1217614-64-6 | Isotope-Labeled Compounds |
| HY-141749B | Clopidogrel carboxylic acid (hydrochloride) | 144750-42-5 | Reference compound |
| HY-141749S | (Rac)-Clopidogrel carboxylic acid-d4 | 1246814-52-7 | Isotope-Labeled Compounds |
| HY-14175 | Begacestat | 769169-27-9 | Reference compound |
| HY-141750S1 | N-Desmethyl Zolmitriptan-d3 | 1217623-11-4 | Isotope-Labeled Compounds |
| HY-141757S | Des-p-fluorobenzyl mosapride-d5 | 1246814-79-8 | Isotope-Labeled Compounds |
| HY-14176 | Compound E | 209986-17-4 | Reference compound |
| HY-141760S | N-Acetyl sulfamethazine-d4 | 1189891-99-3 | Isotope-Labeled Compounds |
| HY-141764S | 2,2-Bis(p-hydroxyphenyl)-1,1,1-trichloroethane-d8 | 1794780-53-2 | Isotope-Labeled Compounds |
| HY-14176A | (1R,3S)-Compound E | 504428-17-5 | Reference compound |
| HY-14176G | Compound E (GMP) | 209986-17-4 | GMP Small Molecules |
| HY-14177 | Raf inhibitor 1 | 1093100-40-3 | Reference compound |
| HY-141771S | Bis(1,3-dichloro-2-propyl) phosphate-d10 | 1477495-19-4 | Isotope-Labeled Compounds |
| HY-141773S | Benzydamine N-oxide-d6 | 1246820-03-0 | Isotope-Labeled Compounds |
| HY-141776S | Omeprazole sulfide-d3 | 922730-98-1 | Isotope-Labeled Compounds |
| HY-141778S | Retinoic acid ethyl ester-d5 | 78995-96-7 | Isotope-Labeled Compounds |
| HY-14177A | Raf inhibitor 1 (dihydrochloride) | 1191385-19-9 | Reference compound |
| HY-14178 | VX-11e | 896720-20-0 | Reference compound |
| HY-141780S | Demethyl Benzydamine-d3 (hydrochloride) | 1246817-08-2 | Isotope-Labeled Compounds |
| HY-141785S | Didesmethylcitalopram-d6 (hydrochloride) | 1189865-88-0 | Isotope-Labeled Compounds |
| HY-141789S | Desethylene Ciprofloxacin-d4 (hydrochloride) | 1330261-13-6 | Isotope-Labeled Compounds |
| HY-14178A | (R)-VX-11e | 1680187-43-2 | Reference compound |
| HY-14179 | PPQ-102 | 931706-15-9 | Reference compound |
| HY-141790S | O-Desmethyl Indomethacin-d4 | 1189916-55-9 | Isotope-Labeled Compounds |
| HY-141793 | ATRA-biotin | 2226143-93-5 | Reference compound |
| HY-141795 | Posovolone | 256955-84-7 | Reference compound |
| HY-141796 | MS67 | 2407452-77-9 | Reference compound |
| HY-141797 | MS33 | 2407449-11-8 | Reference compound |
| HY-141798 | OICR-9429-N-C2-NH2 | 2407457-55-8 | Reference compound |
| HY-141799 | Dimethyl-F-OICR-9429-COOH | 2407458-49-3 | Reference compound |
| HY-14180 | PHA 408 | 503555-55-3 | Reference compound |
| HY-141800 | MurA-IN-1 | 354815-90-0 | Reference compound |
| HY-141804 | ER176 | 1373887-29-6 | Reference compound |
| HY-141805 | MHY-1685 | 27406-31-1 | Reference compound |
| HY-141806 | Urease-IN-1 | 2719841-54-8 | Reference compound |
| HY-141807 | MS21 | 2376137-05-0 | Reference compound |
| HY-141808 | AZD-CO-Ph-PEG4-Ph-CO-AZD | 2569143-72-0 | Reference compound |
| HY-141809 | GPX4-IN-3 | 2761004-85-5 | Reference compound |
| HY-14181 | Cinaciguat | 329773-35-5 | Reference compound |
| HY-141810 | MT-134 | 2968308-52-1 | Reference compound |
| HY-141811 | Antifungal agent 11 | 2966848-10-0 | Reference compound |
| HY-141812 | Antifungal agent 12 | 2966848-11-1 | Reference compound |
| HY-141813 | Autophagy-IN-C1 | 1494665-31-4 | Reference compound |
| HY-141814 | TSWV-IN-1 | | Reference compound |
| HY-14181A | Cinaciguat (hydrochloride) | 646995-35-9 | Reference compound |
| HY-14182 | Vernakalant | 794466-70-9 | Reference compound |
| HY-141828 | Antibacterial agent 26 | 75369-40-3 | Reference compound |
| HY-141829 | Antibacterial agent 27 | 65795-51-9 | Reference compound |
| HY-14182S | Vernakalant-d6 (hydrochloride) | 866455-16-5 | Isotope-Labeled Compounds |
| HY-14183 | Vernakalant (Hydrochloride) | 748810-28-8 | Reference compound |
| HY-141832 | mGluR5 modulator 1 | 1261171-52-1 | Reference compound |
| HY-141833 | Bi-Mc-VC-PAB-MMAE | 1620837-70-8 | ADC Related |
| HY-141834 | Carboxylesterase-IN-1 | 2609018-59-7 | Reference compound |
| HY-141836 | MMV666810 | 1450666-97-3 | Reference compound |
| HY-141837 | MMV674850 | 1820874-51-8 | Reference compound |
| HY-141839 | GLP-1R modulator C16 | 875005-43-9 | Reference compound |
| HY-14184 | Macitentan | 441798-33-0 | Reference compound |
| HY-141840 | GLP-1R modulator C5 | 421578-93-0 | Reference compound |
| HY-141841 | SARS-CoV-2-IN-7 | 2570461-66-2 | Reference compound |
| HY-141842 | GLP-1R modulator L7-028 | 2648317-95-5 | Reference compound |
| HY-141843 | BRD4-IN-2 | 2679925-55-2 | Reference compound |
| HY-141844 | HDAC/BET-IN-1 | 2757573-68-3 | Reference compound |
| HY-141845 | S1P2 antagonist 1 | 2262402-83-3 | Reference compound |
| HY-141846 | Antifungal agent 17 | | Reference compound |
| HY-141848A | (S,S)-BMS-984923 | 1375752-77-4 | Reference compound |
| HY-14184A | Macitentan (n-butyl analogue) | 556797-16-1 | Reference compound |
| HY-14184R | Macitentan (Standard) | 441798-33-0 | Reference Standards |
| HY-14184S | Macitentan-d4 | 1258428-05-5 | Isotope-Labeled Compounds |
| HY-14185 | Lixivaptan | 168079-32-1 | Reference compound |
| HY-141851 | UDP-glucose dehydrogenase | 9028-26-6 | Enzyme |
| HY-141852 | STAMBP-IN-1 | 896683-78-6 | Reference compound |
| HY-141854S | 2-Butanone 2,4-dinitrophenylhydrazone-d3 | 259824-58-3 | Isotope-Labeled Compounds |
| HY-141855S | Acetaldehyde 2,4-Dinitrophenylhydrazone-3,5,6-d3 | 259824-51-6 | Isotope-Labeled Compounds |
| HY-141856S | Acrolein 2,4-dinitrophenylhydrazone-3,5,6-d3 | 259824-62-9 | Isotope-Labeled Compounds |
| HY-141857S | 5-(4-Hydroxyphenyl)-5-phenyl-d5-hydantoin-2,4,5-13C3 | | Isotope-Labeled Compounds |
| HY-141858 | Lynamicin B | 861149-19-1 | Natural Products |
| HY-141859 | PPO-IN-1 | 2763288-69-1 | Reference compound |
| HY-14186 | KVI-020 | 1000306-34-2 | Reference compound |
| HY-141860 | PSMA-Val-Cit-PAB-MMAE | 2748039-79-2 | ADC Related |
| HY-141861 | Anticancer agent 17 | 3031370-98-3 | Reference compound |
| HY-141862 | Zanamivir-Cholesterol Conjugate | 2478446-18-1 | Reference compound |
| HY-141863 | Lepidozin G | 2869125-43-7 | Reference compound |
| HY-141864 | ITK/TRKA-IN-1 | 2655557-54-1 | Reference compound |
| HY-141865 | Adenosine receptor antagonist 1 | 2682930-40-9 | Reference compound |
| HY-141866 | Acid Ceramidase-IN-1 | 2415225-30-6 | Reference compound |
| HY-141867 | Z-FF-FMK | 105608-85-3 | Peptides |
| HY-141868 | SB-682330A | 502498-66-0 | Reference compound |
| HY-14187 | Amiodarone | 1951-25-3 | Reference compound |
| HY-141873 | Wnt/β-catenin agonist 2 | 943820-93-7 | Reference compound |
| HY-141874 | PRMT5-IN-12 | 2568927-94-4 | Reference compound |
| HY-141875 | PRMT5-IN-13 | 2376795-15-0 | Reference compound |
| HY-141876 | PRMT5-IN-14 | 2278356-90-2 | Reference compound |
| HY-141877 | MS4322 | 2375432-47-4 | Reference compound |
| HY-141877B | MS4322 (isomer) | 2601727-80-2 | Reference compound |
| HY-141878 | di-Ellipticine-RIBOTAC | 2767983-76-4 | Reference compound |
| HY-14187S | Amiodarone-d10 (hydrochloride) | 1261393-77-4 | Isotope-Labeled Compounds |
| HY-14187S1 | Amiodarone-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-14188 | Amiodarone (hydrochloride) | 19774-82-4 | Reference compound |
| HY-141881 | PROTAC-O4I2 | 2785323-62-6 | Reference compound |
| HY-141882 | DC-LC3in-D5 | 2868312-73-4 | Reference compound |
| HY-141884 | 2',3'-O-Isopropylidenecytidine | 362-42-5 | Biochemical Assay Reagents |
| HY-141885 | APOL1-IN-1 | 2446817-72-5 | Reference compound |
| HY-141887 | Thalidomide-O-C6-NHBoc | 2509093-23-4 | Reference compound |
| HY-141888S | DL-Dipalmitoylphosphatidylcholine-d62 | 29287-66-9 | Isotope-Labeled Compounds |
| HY-141889 | MLKL-IN-2 | 899759-16-1 | Reference compound |
| HY-14188R | Amiodarone (hydrochloride) (Standard) | 19774-82-4 | Reference Standards |
| HY-14188S | Amiodarone-d4 (hydrochloride) | 1216715-80-8 | Isotope-Labeled Compounds |
| HY-14189 | Valategrast (hydrochloride) | 828271-96-1 | Reference compound |
| HY-141890 | BAZ1A-IN-1 | 941521-45-5 | Reference compound |
| HY-141891 | M435-1279 | 1359431-16-5 | Reference compound |
| HY-141892A | DSPE-PEG Carboxylic acid (sodium), MW 2000 | 1403744-37-5 | Oligonucleotides |
| HY-141893 | 3-Cyanovinylcarbazole phosphoramidite | 1157899-72-3 | Reference compound |
| HY-141894 | 5-Ph-IAA-AM | 2990123-10-7 | Reference compound |
| HY-141895 | Vps34-IN-3 | 2770104-92-0 | Reference compound |
| HY-141896 | RET-IN-7 | 2763386-05-4 | Reference compound |
| HY-141898 | Biotin-4-aminophenol | 901770-40-9 | Dye Reagents |
| HY-14190 | Valategrast | 220847-86-9 | Reference compound |
| HY-141900S | Acetyl-N-deisopropyl-Zilpaterol-d3 | | Isotope-Labeled Compounds |
| HY-141901S | Dehydroepiandrosterone-d6 | 1261254-39-0 | Isotope-Labeled Compounds |
| HY-141901S2 | Dehydroepiandrosterone-13C3 | 2483735-10-8 | Isotope-Labeled Compounds |
| HY-141902S | Fmoc-Glu(OtBu)-OH-13C5,15N | 1261078-12-9 | Isotope-Labeled Compounds |
| HY-141903S | Taurocholic acid-3-o-glucuronide-d4 | | Isotope-Labeled Compounds |
| HY-141905S | Isophorone Diamine-13C,15N2 | | Isotope-Labeled Compounds |
| HY-141907S | 17β-Estradiol-13C3 | 1261254-48-1 | Isotope-Labeled Compounds |
| HY-141909S | 4-Fluoroiodobenzene-13C6 | | Isotope-Labeled Compounds |
| HY-141911S | Tauroursodeoxycholic Acid-3-Sulfate Sodium Salt-d4 | | Isotope-Labeled Compounds |
| HY-141913S | 3-Chlorotyrosine-13C9, 15N (hydrochloride) | | Isotope-Labeled Compounds |
| HY-141914S | Cortisol-21-glucuronide-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-141916S | Taurodeoxycholic Acid-3-Sulfate-d4(Sodium Salt) | | Isotope-Labeled Compounds |
| HY-141917S | 3-Methyluric Acid-13C4,15N3 | 1173019-10-7 | Isotope-Labeled Compounds |
| HY-141918S | Chenodeoxycholic acid 3-sulfate-d4 | | Isotope-Labeled Compounds |
| HY-141919S | 1-Bromo-4-iodobenzene-13C6 | | Isotope-Labeled Compounds |
| HY-141921S | Dehydroepiandrosterone sulfate (sodium)-d6 | 1261254-41-4 | Isotope-Labeled Compounds |
| HY-141923S | Pyridoxamine-d3 (dihydrochloride) | 1173023-45-4 | Isotope-Labeled Compounds |
| HY-141925S | 3-Octanone-13C | | Isotope-Labeled Compounds |
| HY-141926S | Deoxycholic Acid-3-Sulfate Sodium Salt-d4 | | Isotope-Labeled Compounds |
| HY-141928S | 4-Bromoanisole-13C6 | 1538556-42-1 | Isotope-Labeled Compounds |
| HY-141929S | β-aminomethyl-L-alanine-13C,15N2(dihydrochloride) | | Isotope-Labeled Compounds |
| HY-141931S | Glycolithocholic acid 3-sulfate-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-141931S1 | Glycolithocholic acid 3-sulfate-d4 (disodium) | | Isotope-Labeled Compounds |
| HY-141932S | 4,4′-Methylenedianiline-15N2, 13C | 2416442-06-1 | Isotope-Labeled Compounds |
| HY-141933S | 3-Epi-25-Hydroxyvitamin D3-d3 | 2206653-61-2 | Isotope-Labeled Compounds |
| HY-141934S | 2-Methylthiopurine-13C, d3 | | Isotope-Labeled Compounds |
| HY-141936S | Glycochenodeoxychlolic Acid-3-Sulfate-d4(sodium salt) | | Isotope-Labeled Compounds |
| HY-141939S | Triiodothyronine-13C6( hydrochloride) | 1217473-60-3 | Isotope-Labeled Compounds |
| HY-141941S | Triazole Lactic Acid-13C2, 15N3 | | Isotope-Labeled Compounds |
| HY-141943S | Glycocholic Acid-3-Sulfate-d4 (sodium salt) | | Isotope-Labeled Compounds |
| HY-141944S | Cortisol-21-sulfate-d4 (sodium salt) | 2687961-03-9 | Isotope-Labeled Compounds |
| HY-141945S | Taurochenodeoxycholic acid-3-o-glucuronide-d4(disodium salt) | | Isotope-Labeled Compounds |
| HY-141958S | Ciclesonide-d11 | | Isotope-Labeled Compounds |
| HY-14196 | Toloxatone | 29218-27-7 | Reference compound |
| HY-14197 | Clorgyline | 17780-72-2 | Reference compound |
| HY-14197A | Clorgyline hydrochloride | 17780-75-5 | Reference compound |
| HY-14198 | Selegiline | 14611-51-9 | Reference compound |
| HY-141987S1 | 2-Hydroxy atorvastatin sodium salt-d5 | | Isotope-Labeled Compounds |
| HY-14198R | Selegiline (Standard) | 14611-51-9 | Reference Standards |
| HY-14198S | Selegiline-d5 | 1217976-51-6 | Isotope-Labeled Compounds |
| HY-14199 | Selegiline (hydrochloride) | 14611-52-0 | Reference compound |
| HY-14199S | Selegiline-d5 (hydrochloride) | 1217705-21-9 | Isotope-Labeled Compounds |
| HY-14200 | (S)-Rasagiline | 185517-74-2 | Reference compound |
| HY-142003 | 27-O-Demethylrapamycin | 141392-23-6 | Reference compound |
| HY-142006 | (-)-Jasmonoyl-L-isoleucine | 120330-93-0 | Natural Products |
| HY-142009 | Antiviral agent 10 | 312615-62-6 | Reference compound |
| HY-14200A | (S)-Rasagiline mesylate | 202464-88-8 | Reference compound |
| HY-14201 | Lazabemide | 103878-84-8 | Reference compound |
| HY-142013 | Blestriarene B | 127211-03-4 | Natural Products |
| HY-142016 | Retinol, palmitate, 9-cis,13-cis- | 34356-30-4 | Reference compound |
| HY-142019 | Tanshinol borneol ester | 1623012-10-1 | Natural Products |
| HY-14202 | Lazabemide (hydrochloride) | 103878-83-7 | Reference compound |
| HY-142021 | Z-Leu-Arg-AMC | 156192-32-4 | Reference compound |
| HY-142025 | Daumone | 690991-47-0 | Natural Products |
| HY-142026 | Vitisin A | 142449-89-6 | Natural Products |
| HY-142028A | Acyclovir triphosphate (sodium) | 221119-43-3 | Biochemical Assay Reagents |
| HY-14203 | (R)-Safinamide | 174756-44-6 | Reference compound |
| HY-142030 | TRPC5 modulator-1 | 1877343-90-2 | Reference compound |
| HY-142031 | 4-Piperidinecarboxamide | 519034-65-2 | Reference compound |
| HY-142032 | RBM10-8 | 2407372-42-1 | Reference compound |
| HY-142035 | N-Propargylglycine | 58160-95-5 | Reference compound |
| HY-142037 | Geranylacetone | 3796-70-1 | Natural Products |
| HY-142041 | Borocaptate (sodium ) | 144885-51-8 | Reference compound |
| HY-142042 | 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles | 287196-91-2 | Reference compound |
| HY-14205 | NW-1772 | 911290-35-2 | Reference compound |
| HY-142050 | (R)-IDHP | 950665-05-1 | Natural Products |
| HY-142052 | Anhydrotetracycline | 1665-56-1 | Reference compound |
| HY-142058 | Feudomycin B | 79438-97-4 | Reference compound |
| HY-142059 | PDE5-IN-4 | 224788-36-7 | Reference compound |
| HY-142063 | Petasitenine | 60102-37-6 | Reference compound |
| HY-142066 | 4′-Demethylnobiletin | 34810-62-3 | Reference compound |
| HY-142069 | KB-R7785 | 168158-16-5 | Reference compound |
| HY-142072 | Albomycin | 1414-39-7 | Reference compound |
| HY-142073 | (+)-Dihydrocalanolide A | 183904-53-2 | Reference compound |
| HY-142074 | Inophyllum B | 41135-06-2 | Reference compound |
| HY-142075 | Antibacterial agent 134 | 14474-71-6 | Natural Products |
| HY-142076 | CDK4/6-IN-15 | 2078047-99-9 | Reference compound |
| HY-142076A | CDK4/6-IN-15 (hydrochloride) | | Reference compound |
| HY-142080 | Pimeloyl-CoA | 18907-20-5 | Enzyme |
| HY-142080A | Pimeloyl-CoA (lithium) | | Reference compound |
| HY-142082 | Isohopeaphenol | 197446-77-8 | Natural Products |
| HY-142085 | Antiproliferative agent-20 | 1344715-94-1 | Reference compound |
| HY-142086 | Antitumor agent-40 | 2096500-09-1 | Reference compound |
| HY-142087 | Beauverolide Ja | 76265-41-3 | Reference compound |
| HY-142088 | Beauverolide Ka | 76265-42-4 | Reference compound |
| HY-142090 | Donetidine | 99248-32-5 | Reference compound |
| HY-142093 | NSD3-IN-1 | 347340-51-6 | Reference compound |
| HY-142094 | NSD3-IN-2 | 675190-57-5 | Reference compound |
| HY-142095 | NSD3-IN-3 | 445416-12-6 | Reference compound |
| HY-142096 | Glycyuralin E | 1879910-26-5 | Reference compound |
| HY-142097 | Glicophenone | 303175-66-8 | Reference compound |
| HY-142098 | 3′-Hydroxy-4′-O-methylglabridin | 175554-11-7 | Reference compound |
| HY-142099 | Hispaglabridin A | 68978-03-0 | Reference compound |
| HY-14210 | TNAP-IN-1 | 496014-13-2 | Reference compound |
| HY-142100 | Licoagrochalcone C | 325144-68-1 | Reference compound |
| HY-142101 | 3,4-Didehydroglabridin | 214283-58-6 | Reference compound |
| HY-142101S | 5,6-Orthoquinone Primaquine-d6 (hydrobromide) | | Isotope-Labeled Compounds |
| HY-142102 | T988C | 823802-57-9 | Reference compound |
| HY-142104 | 2-CTC Resin (100-200 mesh,1% DVB,0.4-3.0mmol/g) | 934816-82-7 | Biochemical Assay Reagents |
| HY-142105 | 2-Ethyl-2-hydroxybutanoic acid | 3639-21-2 | Reference compound |
| HY-142105R | 2-Ethyl-2-hydroxybutanoic acid (Standard) | 3639-21-2 | Reference Standards |
| HY-142107S | 9-cis,13-cis-Retinol-d5 | | Isotope-Labeled Compounds |
| HY-142114 | SRI-37330 | 2322245-42-9 | Reference compound |
| HY-142117 | Adenophostin A | 149091-92-9 | Reference compound |
| HY-142117S | 6-Sulfatoxy Melatonin-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-142117S1 | 6-Sulfatoxy Melatonin-d4 | 1309935-98-5 | Isotope-Labeled Compounds |
| HY-142118 | Trabedersen | 925681-61-4 | Oligonucleotides |
| HY-142118A | Trabedersen (sodium) | | Oligonucleotides |
| HY-142119 | Penehyclidine | 87827-02-9 | Reference compound |
| HY-142119S | 5-Hydroxy tryptophol β-D-glucuronide-d4 | | Isotope-Labeled Compounds |
| HY-142121 | Iopentol | 89797-00-2 | Reference compound |
| HY-142121R | Iopentol (Standard) | 89797-00-2 | Reference Standards |
| HY-142122 | Imipramine N-oxide | 6829-98-7 | Reference compound |
| HY-142122R | Imipramine N-oxide (Standard) | 6829-98-7 | Reference Standards |
| HY-142123 | Fluocortolone | 152-97-6 | Reference compound |
| HY-142123R | Fluocortolone (Standard) | 152-97-6 | Reference Standards |
| HY-142124 | Kalimantacin A | 174513-95-2 | Natural Products |
| HY-142125 | Broussochalcone A | 99217-68-2 | Natural Products |
| HY-142125S1 | 7-Hydroxy Granisetron-d3 | 2124272-02-0 | Isotope-Labeled Compounds |
| HY-142127 | Ribostamycin | 25546-65-0 | Natural Products |
| HY-142127S | 2-(α-D-Mannopyranosyl)-L-tryptophan-d4 | 2230887-20-2 | Isotope-Labeled Compounds |
| HY-142128 | Cymal-6 | 228579-27-9 | Reference compound |
| HY-142129 | Pyrocholecalciferol | 10346-43-7 | Reference compound |
| HY-142139S | (S,S)-Iso Valganciclovir-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-142140S | 3-epi-25-Hydroxy Vitamin D3-d6 | 2483831-27-0 | Isotope-Labeled Compounds |
| HY-142159 | FXR/TGR5 agonist 1 | 2677689-72-2 | Reference compound |
| HY-142160 | GNE-9815 | 2729996-45-4 | Reference compound |
| HY-142161 | ABD957 | 3007772-60-0 | Reference compound |
| HY-142162 | LSN3318839 | 2764704-18-7 | Reference compound |
| HY-142162A | (S,R)-LSN3318839 | 2765539-92-0 | Reference compound |
| HY-142163 | S62798 | 2107353-05-7 | Reference compound |
| HY-142165S | (R)-Norverapamil-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-14217 | Quizartinib (dihydrochloride) | 1132827-21-4 | Reference compound |
| HY-14218 | Ditolylguanidine | 97-39-2 | Reference compound |
| HY-142180S | cis (2,3)-Dihydro tetrabenazine-d6 | 1351947-42-6 | Isotope-Labeled Compounds |
| HY-142193S | (-)-Erinacin A-d3 | | Isotope-Labeled Compounds |
| HY-142196S | Betamethasone 17-propionate-d5 | | Isotope-Labeled Compounds |
| HY-14220 | CB-184 | 165307-47-1 | Reference compound |
| HY-142209 | ABBV-167 | 1351456-78-4 | Reference compound |
| HY-14221 | Siramesine | 147817-50-3 | Reference compound |
| HY-142211 | PRMT5-IN-15 | 2410637-87-3 | Reference compound |
| HY-142214 | TRPA1-IN-1 | 2376824-92-7 | Reference compound |
| HY-142217S | Quetiapine dimer impurity-d8 | | Isotope-Labeled Compounds |
| HY-14221A | Siramesine (hydrochloride) | 224177-60-0 | Reference compound |
| HY-14221B | Siramesine (fumarate) | 163630-79-3 | Reference compound |
| HY-14222 | UMB24 | 1033-69-8 | Reference compound |
| HY-142221 | ARB-272572 | 2368182-63-0 | Reference compound |
| HY-14223 | SM-21 | 155058-71-2 | Reference compound |
| HY-142240 | Crisugabalin | 2209104-84-5 | Reference compound |
| HY-142249S | Brexpiprazole-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-14225 | BMS-764459 | 1188407-45-5 | Reference compound |
| HY-142253 | HIV-1 inhibitor-10 | 1449660-81-4 | Reference compound |
| HY-142255S1 | Saroglitazar sulfoxide-d4 | | Isotope-Labeled Compounds |
| HY-142259S | Desisobutyryl ciclesonide-d11 | | Isotope-Labeled Compounds |
| HY-14226 | LIMK-IN-3 | 1116570-97-8 | Reference compound |
| HY-142265 | NVS-BET-1 | 1639115-52-8 | Reference compound |
| HY-142266S | Retigabine N-β-D-glucuronide-d4 | | Isotope-Labeled Compounds |
| HY-14227 | LIMK-IN-1 | 1116571-01-7 | Reference compound |
| HY-142275S | (-)-Nebivolol-d4 (hydrochloride) | 2124271-48-1 | Isotope-Labeled Compounds |
| HY-142279S | 17β-Estradiol 17-acetate 3-β-D-glucuronide-d3 | | Isotope-Labeled Compounds |
| HY-142283 | Dosimertinib | 2403760-70-1 | Isotope-Labeled Compounds |
| HY-142283AS | Dosimertinib (mesylate) | 2403760-72-3 | Isotope-Labeled Compounds |
| HY-142283BS | N-Desmethyl dosimertinib-d5 | 2719691-00-4 | Isotope-Labeled Compounds |
| HY-142283CS | N-Methyl-dosimertinib-d5 | 2719690-98-7 | Isotope-Labeled Compounds |
| HY-142287 | Con B-1 | 2415537-51-6 | Reference compound |
| HY-14229 | TGR5 Receptor Agonist | 1197300-24-5 | Reference compound |
| HY-142295 | GNF2133 | 2561414-56-8 | Reference compound |
| HY-142295A | GNF2133 (hydrochloride) | 2561414-57-9 | Reference compound |
| HY-142296 | RORγt inhibitor 1 | 1561770-72-6 | Reference compound |
| HY-14230 | INCB9471 | 869769-98-2 | Reference compound |
| HY-14231 | CCR5 antagonist 5 | 869725-27-9 | Reference compound |
| HY-142310S | Betamethasone 21-acetate 17-propionate-d3 | | Isotope-Labeled Compounds |
| HY-14232 | TTA-A8 | 1146395-46-1 | Reference compound |
| HY-142328S | Propantheline-d3 (iodide) | | Isotope-Labeled Compounds |
| HY-14233 | Omecamtiv mecarbil | 873697-71-3 | Reference compound |
| HY-142333 | Hexadecanedioic acid mono-L-carnitine ester | 42150-38-9 | Reference compound |
| HY-14233S | Omecamtiv mecarbil-d8 | | Isotope-Labeled Compounds |
| HY-14234 | Glucocorticoid receptor agonist | 1245526-82-2 | Reference compound |
| HY-14240 | PG 116800 | 291533-11-4 | Reference compound |
| HY-142422S | (Rac)-trans-Bifenthrin-d5 | | Isotope-Labeled Compounds |
| HY-14243 | CEP-14083 | 856692-39-2 | Reference compound |
| HY-142433 | ERK1/2 inhibitor 7 | 2648455-13-2 | Reference compound |
| HY-142437 | ERK1/2 inhibitor 8 | 2648368-43-6 | Reference compound |
| HY-142440S | Apatinib 25-N-oxide-d8 (dihydrochloride) | | Isotope-Labeled Compounds |
| HY-142441 | THR-β agonist 1 | 2648403-17-0 | Reference compound |
| HY-142444 | SSAO/VAP-1 inhibitor 1 | 2647975-06-0 | Reference compound |
| HY-142448S | Nicotinic acid riboside methyl ester-d4 (triflate) | | Isotope-Labeled Compounds |
| HY-142452 | Pan-RAF kinase inhibitor 1 | 2648838-76-8 | Reference compound |
| HY-142457 | KRAS G12C inhibitor 26 | 2648584-52-3 | Reference compound |
| HY-142458 | KRAS G12C inhibitor 27 | 2648584-51-2 | Reference compound |
| HY-142460 | KRAS G12C inhibitor 28 | 2649004-88-4 | Reference compound |
| HY-142467 | HIV-1 inhibitor-11 | | Reference compound |
| HY-142468 | HIV-1 inhibitor-12 | | Reference compound |
| HY-14247 | Fadrozole (hydrochloride) | 102676-31-3 | Reference compound |
| HY-142471 | ZL-2201 (free base) | 2646592-18-7 | Reference compound |
| HY-142471A | ZL-2201 | 2865115-39-3 | Reference compound |
| HY-142475S | N,N'-Bis(2,6-dimethylphenyl)-1,4-piperazinediacetamide-d8 | 2751283-52-8 | Isotope-Labeled Compounds |
| HY-142478 | KRAS G12C inhibitor 29 | 847337-63-7 | Reference compound |
| HY-14247A | Fadrozole | 102676-47-1 | Reference compound |
| HY-14247B | Fadrozole (hydrochloride hemihydrate) | 176702-70-8 | Reference compound |
| HY-14248 | Letrozole | 112809-51-5 | Natural Products |
| HY-142481 | KRAS G12C inhibitor 30 | 2752352-90-0 | Reference compound |
| HY-142485 | KRAS G12C inhibitor 31 | 2752352-86-4 | Reference compound |
| HY-142487 | KRAS G12C inhibitor 32 | 2756739-00-9 | Reference compound |
| HY-14248R | Letrozole (Standard) | 112809-51-5 | Reference Standards |
| HY-14248S | Letrozole-d4 | 1133712-96-5 | Isotope-Labeled Compounds |
| HY-14249 | Bicalutamide | 90357-06-5 | Reference compound |
| HY-142490 | KRAS G12C inhibitor 33 | 2648985-02-6 | Reference compound |
| HY-14249R | Bicalutamide (Standard) | 90357-06-5 | Reference Standards |
| HY-14249S | Bicalutamide-d4 | 1185035-71-5 | Isotope-Labeled Compounds |
| HY-14249S1 | Bicalutamide-d5 | | Isotope-Labeled Compounds |
| HY-14250 | PF-998425 | 1076225-27-8 | Reference compound |
| HY-14250A | (Rac)-PF-998425 | 1076225-26-7 | Reference compound |
| HY-142511 | KRAS G12C inhibitor 34 | 2749948-26-1 | Reference compound |
| HY-142512 | EGFR-IN-24 | 2757548-54-0 | Reference compound |
| HY-142515S | 7α-Thiomethyl spironolactone-d7 | | Isotope-Labeled Compounds |
| HY-142517 | EGFR-IN-25 | 2749562-63-6 | Reference compound |
| HY-142518 | EGFR-IN-26 | 2375470-64-5 | Reference compound |
| HY-142519 | EGFR-IN-27 | 2752328-62-2 | Reference compound |
| HY-14252 | Milrinone | 78415-72-2 | Reference compound |
| HY-142520 | I-BET567 | 1887237-54-8 | Reference compound |
| HY-142521 | BLT2 probe 1 | 2893803-05-7 | Reference compound |
| HY-142523 | H7 | 2803681-14-1 | Dye Reagents |
| HY-14252A | Milrinone (lactate) | 100286-97-3 | Reference compound |
| HY-14252R | Milrinone (Standard) | 78415-72-2 | Reference Standards |
| HY-14252S | Milrinone-d3 | 2749393-50-6 | Isotope-Labeled Compounds |
| HY-142533 | HL-PEG2k | | Reference compound |
| HY-142537S | p-t-Butylphenyl diphenyl phosphate-d10 | | Isotope-Labeled Compounds |
| HY-14254 | Olprinone (Hydrochloride) | 119615-63-3 | Reference compound |
| HY-142545 | Antibacterial agent 68 | 2887429-54-9 | Reference compound |
| HY-142547S | S 421-d4 | 2714435-90-0 | Isotope-Labeled Compounds |
| HY-14254A | Olprinone | 106730-54-5 | Reference compound |
| HY-14255 | Levcromakalim | 94535-50-9 | Reference compound |
| HY-142555S | Bisphenol A monosulfate-d6 (sodium) | 2733721-65-6 | Isotope-Labeled Compounds |
| HY-14256 | BMS-191095 | 166095-21-2 | Reference compound |
| HY-142566S | Mianserin-d3 (dihydrochloride） | | Isotope-Labeled Compounds |
| HY-142567S | Pregnanetriol-d4 | 2687960-83-2 | Isotope-Labeled Compounds |
| HY-14257 | BMS-191095 (hydrochloride) | 166095-95-0 | Reference compound |
| HY-142578S | Perindoprilat-d4 | 1356841-18-3 | Isotope-Labeled Compounds |
| HY-14258 | Escitalopram | 128196-01-0 | Natural Products |
| HY-142581S | 1-Naphthol β-D-glucuronide-d7 (sodium) | | Isotope-Labeled Compounds |
| HY-14258A | Escitalopram (oxalate) | 219861-08-2 | Reference compound |
| HY-14258AR | Escitalopram (oxalate) (Standard) | 219861-08-2 | Reference Standards |
| HY-14258AS | Escitalopram-d6 (oxalate) | 1217733-09-9 | Isotope-Labeled Compounds |
| HY-14258AS1 | Escitalopram-d4 (oxalate) | | Isotope-Labeled Compounds |
| HY-142592S | Clozapine EP impurity D-d8 | | Isotope-Labeled Compounds |
| HY-142598S | Serotonin-d4 β-D-glucuronide | | Isotope-Labeled Compounds |
| HY-14260 | RS 8359 | 105365-76-2 | Reference compound |
| HY-14261 | Vilazodone (Hydrochloride) | 163521-08-2 | Reference compound |
| HY-142617 | ACT-1004-1239 | 2178049-58-4 | Reference compound |
| HY-142618 | TNF-α-IN-6 | 2699704-20-4 | Reference compound |
| HY-142619 | TP0586352 | 2427626-11-5 | Reference compound |
| HY-14261R | Vilazodone (Hydrochloride) (Standard) | 163521-08-2 | Reference Standards |
| HY-14261S | Vilazodone-d8 | 1794789-93-7 | Isotope-Labeled Compounds |
| HY-14262 | Vilazodone | 163521-12-8 | Reference compound |
| HY-142620 | TRPV4 antagonist 3 | 2681273-35-6 | Reference compound |
| HY-142621 | BCPyr | 2669844-82-8 | Reference compound |
| HY-14262R | Vilazodone (Standard) | 163521-12-8 | Reference Standards |
| HY-14262S1 | Vilazodone-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-14263 | Pericyazine | 2622-26-6 | Reference compound |
| HY-142636S | Propylthiouracil-d5 (sodium) | | Isotope-Labeled Compounds |
| HY-14264 | Cyamemazine | 3546-03-0 | Reference compound |
| HY-142641S | 4-Hydroxy triamterene sulfate-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-142643 | CETP-IN-4 | 1648889-70-6 | Reference compound |
| HY-142644 | ATX inhibitor 7 | 1646784-47-5 | Reference compound |
| HY-142645 | TP0591816 | 2448519-26-2 | Reference compound |
| HY-142646 | PI3Kδ-IN-9 | 2135922-40-4 | Reference compound |
| HY-142647 | EB-42486 | 2390475-81-5 | Reference compound |
| HY-142648 | MLT-985 | 1832576-25-6 | Reference compound |
| HY-142648A | (R)-MLT-985 | 1832577-07-7 | Reference compound |
| HY-14264S | Cyamemazine-d6 | 1216608-24-0 | Isotope-Labeled Compounds |
| HY-142651S | Prochlorperazine-d3 (mesylate) | | Isotope-Labeled Compounds |
| HY-142654 | ATX-002 | 1777792-34-3 | Reference compound |
| HY-142655 | Ftase inhibitor III | 2710375-18-9 | Reference compound |
| HY-142656 | PIM-IN-1 | 2698319-19-4 | Reference compound |
| HY-142657 | PARP1-IN-7 | 2084112-75-2 | Reference compound |
| HY-142658 | BAY-6672 | 2247517-53-7 | Reference compound |
| HY-142658A | BAY-6672 (hydrochloride) | 2247520-31-4 | Reference compound |
| HY-142659 | IRE1α kinase-IN-6 | 2715123-88-7 | Reference compound |
| HY-14266 | Dapivirine | 244767-67-7 | Reference compound |
| HY-142660 | PDE2A-IN-1 | 2648290-28-0 | Reference compound |
| HY-142661 | BAY 1217224 | 1639886-32-0 | Reference compound |
| HY-142662 | PROTAC IRAK3 degrade-1 | 2712600-00-3 | Reference compound |
| HY-142662A | PROTAC IRAK3 degrade-1 (formic) | | Reference compound |
| HY-142663 | OI338 | | Reference compound |
| HY-142669 | Lp-PLA2-IN-4 | 2738877-91-1 | Reference compound |
| HY-14266A | Dapivirine (hydrochloride) | 244768-47-6 | Reference compound |
| HY-14266S | Dapivirine-d11 | 1329613-10-6 | Isotope-Labeled Compounds |
| HY-14266S1 | Dapivirine-d4 | 1309283-15-5 | Isotope-Labeled Compounds |
| HY-14267 | Lersivirine | 473921-12-9 | Reference compound |
| HY-142670 | Lp-PLA2-IN-5 | 2738877-85-3 | Reference compound |
| HY-142671 | ATR-IN-5 | 2601571-19-9 | Reference compound |
| HY-142672 | ATR-IN-6 | 2746446-99-9 | Reference compound |
| HY-142674 | BRD4-BD1/2-IN-1 | 1781219-19-9 | Reference compound |
| HY-142675 | BRD4-BD1/2-IN-2 | 2743464-27-7 | Reference compound |
| HY-142676 | PI3K-IN-26 | 1918151-65-1 | Reference compound |
| HY-142677 | PI3K-IN-27 | 2742654-38-0 | Reference compound |
| HY-142678 | EGFR-IN-21 | 2648206-31-7 | Reference compound |
| HY-142679 | EGFR-IN-22 | 2634646-14-1 | Reference compound |
| HY-14268 | Febuxostat | 144060-53-7 | Reference compound |
| HY-142680 | EGFR-IN-23 | 2747133-37-3 | Reference compound |
| HY-142681 | EGFR-IN-28 | 2754392-31-7 | Reference compound |
| HY-142682 | SCP1-IN-1 | 2764615-55-4 | Reference compound |
| HY-142683 | SCP1-IN-2 | 2764615-56-5 | Reference compound |
| HY-142684 | Pyruvate Carboxylase-IN-1 | 70205-50-4 | Reference compound |
| HY-142686 | SGK1-IN-3 | 2891696-18-5 | Reference compound |
| HY-142686A | SGK1-IN-3 (hydrochloride) | | Reference compound |
| HY-142687 | SGK1-IN-4 | 1628048-93-0 | Reference compound |
| HY-142688 | Carboxylesterase-IN-2 | 2764748-88-9 | Reference compound |
| HY-142689 | Carboxylesterase-IN-3 | 2764748-92-5 | Reference compound |
| HY-14268A | Febuxostat (sodium) | 1140907-13-6 | Reference compound |
| HY-14268R | Febuxostat (Standard) | 144060-53-7 | Reference Standards |
| HY-14268S | Febuxostat-d9 | 1246819-50-0 | Isotope-Labeled Compounds |
| HY-14268S1 | Febuxostat-d7 | 1285539-74-3 | Isotope-Labeled Compounds |
| HY-14268S2 | Febuxostat-d3 | | Isotope-Labeled Compounds |
| HY-14268S3 | Febuxostat-d5 | | Isotope-Labeled Compounds |
| HY-142690 | HDAC-IN-27 | 2763368-89-2 | Reference compound |
| HY-142690A | HDAC-IN-27 (dihydrochloride) | 3069831-25-7 | Reference compound |
| HY-142691 | DCN1-UBC12-IN-1 | 2374827-31-1 | Reference compound |
| HY-142692 | DCN1-UBC12-IN-3 | 2374827-45-7 | Reference compound |
| HY-142693 | Angiogenesis agent 1 | 2765218-28-6 | Reference compound |
| HY-142694 | DCN1-UBC12-IN-2 | 2374827-47-9 | Reference compound |
| HY-142695 | Antibacterial synergist 1 | 2885170-11-4 | Reference compound |
| HY-142696 | CDK6/PIM1-IN-1 | 2677026-14-9 | Reference compound |
| HY-142697 | SGC agonist 1 | 1426309-31-0 | Reference compound |
| HY-142698 | SGC agonist 2 | 2735713-77-4 | Reference compound |
| HY-142699 | SSTR4 agonist 2 | 1638589-52-2 | Reference compound |
| HY-14270 | Lodoxamide | 53882-12-5 | Reference compound |
| HY-142700 | SSTR4 agonist 3 | 2744188-34-7 | Reference compound |
| HY-142701 | SSTR4 agonist 4 | 2747928-27-2 | Reference compound |
| HY-142703 | RORγt inverse agonist 28 | 2741870-21-1 | Reference compound |
| HY-142704 | BRD4 D1-IN-1 | 2863623-98-5 | Reference compound |
| HY-142705 | BRD4 D1-IN-2 | 2863687-22-1 | Reference compound |
| HY-142706 | MAO A/HDAC-IN-1 | 3031466-56-2 | Reference compound |
| HY-142708 | α-Pyridoin | 1141-05-5 | Reference compound |
| HY-14270R | Lodoxamide (Standard) | 53882-12-5 | Reference Standards |
| HY-14271 | Acreozast | 123548-56-1 | Reference compound |
| HY-14272 | Ravuconazole | 182760-06-1 | Reference compound |
| HY-142723 | KCa2 channel modulator 1 | 1019106-73-0 | Reference compound |
| HY-142725S | Melaminsulfone-d3 (sodium) | 2733972-41-1 | Isotope-Labeled Compounds |
| HY-14272R | Ravuconazole (Standard) | 182760-06-1 | Reference Standards |
| HY-14272S | Ravuconazole-d4 | 1329499-27-5 | Isotope-Labeled Compounds |
| HY-14273 | Isavuconazole | 241479-67-4 | Reference compound |
| HY-142735 | KCa2 channel modulator 2 | 2764618-34-8 | Reference compound |
| HY-142738S | Carboxymefloquine-d3 | 2469206-35-5 | Isotope-Labeled Compounds |
| HY-14273R | Isavuconazole (Standard) | 241479-67-4 | Reference Standards |
| HY-14273S | Isavuconazole-d4 | 1346598-58-0 | Isotope-Labeled Compounds |
| HY-14274 | Anastrozole | 120511-73-1 | Reference compound |
| HY-142740 | Rha-PEG3-SMCC | 2794904-62-2 | ADC Related |
| HY-142743 | Y08175 | 2223014-57-9 | Reference compound |
| HY-14274R | Anastrozole (Standard) | 120511-73-1 | Reference Standards |
| HY-14274S | Anastrozole-d12 | 120512-32-5 | Isotope-Labeled Compounds |
| HY-14275 | Verapamil | 52-53-9 | Reference compound |
| HY-142751S | Fenthion sulfone-d6 | 2469195-97-7 | Isotope-Labeled Compounds |
| HY-14275S | Verapamil-d3 | 152561-91-6 | Isotope-Labeled Compounds |
| HY-14275S1 | Verapamil-d7 | 100578-79-8 | Isotope-Labeled Compounds |
| HY-14275S2 | Verapamil-d6 | | Isotope-Labeled Compounds |
| HY-14276 | Gallopamil | 16662-47-8 | Reference compound |
| HY-142768S | Homovanillic acid sulfate-d3 (sodium) | 1189690-01-4 | Isotope-Labeled Compounds |
| HY-14276A | Gallopamil (hydrochloride) | 16662-46-7 | Reference compound |
| HY-14277 | Levocabastine | 79516-68-0 | Reference compound |
| HY-142772 | Y08284 | 2688745-47-1 | Reference compound |
| HY-142774 | Lp-PLA2-IN-6 | 2637485-13-1 | Reference compound |
| HY-142777 | Lp-PLA2-IN-9 | 2637485-12-0 | Reference compound |
| HY-142778 | Lp-PLA2-IN-10 | 2756855-45-3 | Reference compound |
| HY-142779 | Lp-PLA2-IN-11 | 1620680-19-4 | Reference compound |
| HY-14277A | Levocabastine (hydrochloride) | 79547-78-7 | Reference compound |
| HY-14277AR | Levocabastine (hydrochloride) (Standard) | 79547-78-7 | Reference Standards |
| HY-142784S | Isopropyl diphenyl phosphate-d7 | 2469626-65-9 | Isotope-Labeled Compounds |
| HY-142786S | Di-o-tolyl-phosphate-d14 | 2517379-41-6 | Isotope-Labeled Compounds |
| HY-142788S | Tofenacin hydrochloride salt-d4 | | Isotope-Labeled Compounds |
| HY-142798S | 16-Keto 17β-Estradiol-d5 (Major) | | Isotope-Labeled Compounds |
| HY-14280 | Entacapone | 130929-57-6 | Reference compound |
| HY-142805S | 17-Epiestriol-d5 | | Isotope-Labeled Compounds |
| HY-142806 | RORγt inverse agonist 26 | 2738333-10-1 | Reference compound |
| HY-14280A | Entacapone (sodium salt) | 1047659-02-8 | Reference compound |
| HY-14280R | Entacapone (Standard) | 130929-57-6 | Reference Standards |
| HY-14280S | Entacapone-d10 | 1185241-19-3 | Isotope-Labeled Compounds |
| HY-14281 | Trilostane | 13647-35-3 | Reference compound |
| HY-142812 | GRK6-IN-1 | 2677786-61-5 | Reference compound |
| HY-142813S | Procymidox-d5 | | Isotope-Labeled Compounds |
| HY-142817 | GRK6-IN-2 | 2677786-27-3 | Reference compound |
| HY-14281R | Trilostane (Standard) | 13647-35-3 | Reference Standards |
| HY-14281S | Trilostane-d3 | | Isotope-Labeled Compounds |
| HY-14281S2 | Trilostane-d3-1 | 2026644-48-2 | Isotope-Labeled Compounds |
| HY-14282 | Lanoconazole | 101530-10-3 | Reference compound |
| HY-142820 | B-Raf IN 5 | 2648698-30-8 | Reference compound |
| HY-142828S | (Rac)-galaxolidone-d6 | | Isotope-Labeled Compounds |
| HY-14282A | (Z)-Lanoconazole | 101529-65-1 | Reference compound |
| HY-14282R | Lanoconazole (Standard) | 101530-10-3 | Reference Standards |
| HY-14283 | Luliconazole | 187164-19-8 | Reference compound |
| HY-142830 | B-Raf IN 6 | 2648698-34-2 | Reference compound |
| HY-142834 | RORγt/DHODH-IN-2 | 2641758-86-1 | Reference compound |
| HY-14283R | Luliconazole (Standard) | 187164-19-8 | Reference Standards |
| HY-14283S | Luliconazole-13C7 | | Isotope-Labeled Compounds |
| HY-14283S1 | Luliconazole-d3 | | Isotope-Labeled Compounds |
| HY-14284 | Nilvadipine | 75530-68-6 | Reference compound |
| HY-142842S | Carboxy primaquine-d4 | 2469039-32-3 | Isotope-Labeled Compounds |
| HY-142843 | RORγt/DHODH-IN-1 | 2764662-15-7 | Reference compound |
| HY-142847 | RORγt/DHODH-IN-3 | 2764662-16-8 | Reference compound |
| HY-142849 | Carbonic anhydrase inhibitor 2 | 2758231-43-3 | Reference compound |
| HY-14284R | Nilvadipine (Standard) | 75530-68-6 | Reference Standards |
| HY-14284S | Nilvadipine-d4 | | Isotope-Labeled Compounds |
| HY-142853 | Carbonic anhydrase inhibitor 3 | 2758231-56-8 | Reference compound |
| HY-142856S | Methapyrilene-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-142858S | 3-Hydroxychrysene-d11 | 2468771-62-0 | Isotope-Labeled Compounds |
| HY-14286 | Levosimendan | 141505-33-1 | Reference compound |
| HY-142868 | ONO-8713 | 459411-08-6 | Reference compound |
| HY-14286R | Levosimendan (Standard) | 141505-33-1 | Reference Standards |
| HY-142870 | ZY-444 | 1802650-31-2 | Reference compound |
| HY-142876S | Benz[a]anthracen-3-ol-d11 | | Isotope-Labeled Compounds |
| HY-142881 | D-MoDE-A (1) | 2378837-67-1 | Reference compound |
| HY-142885 | M-MoDE-A (2) | 2378837-56-8 | Reference compound |
| HY-142887S | Mono(2-hydroxyisobutyl)phthalate-d4 | 2119597-90-7 | Isotope-Labeled Compounds |
| HY-14289 | Cimetidine | 51481-61-9 | Reference compound |
| HY-14289A | Cimetidine (hydrochloride) | 70059-30-2 | Reference compound |
| HY-14289AR | Cimetidine (hydrochloride) (Standard) | 70059-30-2 | Reference Standards |
| HY-14289R | Cimetidine (Standard) | 51481-61-9 | Reference Standards |
| HY-14289S | Cimetidine-d3 | 1185237-29-9 | Isotope-Labeled Compounds |
| HY-14290 | Pinacidil | 60560-33-0 | Reference compound |
| HY-142907S | (2-Fluoro-4-biphenyl)acetic acid-d5 | 2733149-72-7 | Isotope-Labeled Compounds |
| HY-142908 | Maximiscin | 1612154-44-5 | Reference compound |
| HY-14290A | Pinacidil (monohydrate) | 85371-64-8 | Reference compound |
| HY-14290R | Pinacidil (Standard) | 60560-33-0 | Reference Standards |
| HY-14291 | Vildagliptin | 274901-16-5 | Reference compound |
| HY-142912 | Stemphyperylenol | 102694-33-7 | Reference compound |
| HY-142913 | ABL-L | 1613152-39-8 | Reference compound |
| HY-142914 | Antifungal agent 21 | 1622299-33-5 | Reference compound |
| HY-142916 | Insecticidal agent 1 | | Reference compound |
| HY-142917 | THR-β agonist 4 | 2673409-25-9 | Reference compound |
| HY-142918 | μ opioid receptor agonist 1 | 2667632-83-7 | Reference compound |
| HY-142919 | μ opioid receptor agonist 2 | 2671755-38-5 | Reference compound |
| HY-14291A | Vildagliptin (dihydrate) | 2133364-01-7 | Reference compound |
| HY-14291B | (2R)-Vildagliptin | 1036959-27-9 | Reference compound |
| HY-14291R | Vildagliptin (Standard) | 274901-16-5 | Reference Standards |
| HY-14291S | Vildagliptin-d3 | 1217546-82-1 | Isotope-Labeled Compounds |
| HY-14291S1 | Vildagliptin-d7 | 1133208-42-0 | Isotope-Labeled Compounds |
| HY-14291S2 | Vildagliptin-13C5,15N | 1044741-01-6 | Isotope-Labeled Compounds |
| HY-14291S5 | Vildagliptin-d6 | | Isotope-Labeled Compounds |
| HY-14292 | NVP-DPP728 | 247016-69-9 | Reference compound |
| HY-142920 | LMP7-IN-1 | 2671040-07-4 | Reference compound |
| HY-142921 | FGFR-IN-2 | 2665665-09-6 | Reference compound |
| HY-142922 | BCR-ABL-IN-4 | 2669790-59-2 | Reference compound |
| HY-142923 | AR antagonist 2 | 2275752-15-1 | Reference compound |
| HY-142924 | ATR-IN-8 | 2672511-20-3 | Reference compound |
| HY-142925 | ER degrader 1 | 2667015-33-8 | Reference compound |
| HY-142926 | ER degrader 2 | 2390147-41-6 | Reference compound |
| HY-142927 | ER degrader 3 | 2254818-47-6 | Reference compound |
| HY-142928 | MAT2A-IN-1 | 2667053-18-9 | Reference compound |
| HY-142929 | MAT2A-IN-2 | 2565671-21-6 | Reference compound |
| HY-14293 | NVP-DPP728 (dihydrochloride) | 207556-62-5 | Reference compound |
| HY-142930 | MAT2A-IN-3 | 2377493-28-0 | Reference compound |
| HY-142931 | ATM-IN-1 | 2662761-76-2 | Reference compound |
| HY-142932 | BTK-IN-6 | 2662512-08-3 | Reference compound |
| HY-142933 | IDO-IN-16 | 2663591-36-2 | Reference compound |
| HY-142934 | RORγt inhibitor 2 | 2673278-10-7 | Reference compound |
| HY-142935 | RORγt modulator 2 | 2247083-47-0 | Reference compound |
| HY-142936 | RORγt modulator 3 | 2230877-38-8 | Reference compound |
| HY-142937 | RORγt agonist 2 | 2663787-92-4 | Reference compound |
| HY-142938 | RORγt agonist 3 | 2664106-24-3 | Reference compound |
| HY-142939 | RORγt modulator 4 | 2188177-73-1 | Reference compound |
| HY-14294 | Capravirine | 178979-85-6 | Reference compound |
| HY-142940 | RORγt modulator 5 | 2119042-65-6 | Reference compound |
| HY-142941 | Glucocorticoid receptor-IN-1 | 2662908-25-8 | Reference compound |
| HY-142942 | Glucocorticoid receptor-IN-2 | 2664932-65-2 | Reference compound |
| HY-142943 | DNA-PK-IN-1 | 2663850-40-4 | Reference compound |
| HY-142944 | DNA-PK-IN-2 | 2665720-22-7 | Reference compound |
| HY-142945 | KRAS G12C inhibitor 43 | 2648808-69-7 | Reference compound |
| HY-142946 | KRAS G12C inhibitor 44 | 2927439-07-2 | Reference compound |
| HY-142947 | KRAS G12C inhibitor 45 | 2670380-74-0 | Reference compound |
| HY-142948 | KRAS G12C inhibitor 46 | 2573769-23-8 | Reference compound |
| HY-142949 | ALK5-IN-7 | 2657720-07-3 | Reference compound |
| HY-142950 | ALK5-IN-6 | 2657720-04-0 | Reference compound |
| HY-142952 | UNC6864 (Kei) | | Reference compound |
| HY-142953 | UNC6349 (Ket2) | | Reference compound |
| HY-142954 | UNC6212 (Kme2) | | Reference compound |
| HY-142955 | Dual photoCORM 1 | 2892235-55-9 | Reference compound |
| HY-142956 | ROS-ERS inducer 1 | | Reference compound |
| HY-142957 | NaPi2b-IN-1 | 1453116-06-7 | Reference compound |
| HY-142958 | NF-κB-IN-2 | 1821386-63-3 | Reference compound |
| HY-14296 | PF-610355 | 862541-45-5 | Reference compound |
| HY-142963 | TLR4/NF-κB/MAPK-IN-1 | 2767567-26-8 | Reference compound |
| HY-142965 | HDAC-IN-28 | 1621154-88-8 | Reference compound |
| HY-142967 | TGFβ-IN-1 | 883560-84-7 | Reference compound |
| HY-14297 | Milveterol | 652990-07-3 | Reference compound |
| HY-142971 | 1-Myristoyl-2-Linoleoyl-3-Oleoyl-rac-glycerol | 108961-58-6 | Reference compound |
| HY-142972 | 19(S)-HETE | 115461-40-0 | Reference compound |
| HY-142974 | 1,2-Dioleoyl-3-Docosohexaenoyl-rac-glycerol | 116198-39-1 | Reference compound |
| HY-142975 | N-Pentadecanoyl-psychosine | 112726-51-9 | Reference compound |
| HY-142976 | Tetranor-12(S)-HETE | 121842-79-3 | Reference compound |
| HY-142977 | 6-Oxohexyl 2-hexyldecanoate, 80% (ELSD) | 1849616-54-1 | Biochemical Assay Reagents |
| HY-142978 | 18:0 mPEG2000 PE | 156543-00-9 | Biochemical Assay Reagents |
| HY-142979 | DSPE-PEG 2000 | 892144-24-0 | Biochemical Assay Reagents |
| HY-14298 | Milveterol (hydrochloride) | 804518-03-4 | Reference compound |
| HY-142980 | Dioleoylphosphatidylglycerol | 62700-69-0 | Biochemical Assay Reagents |
| HY-142981 | Dioctadecylamine | 112-99-2 | Biochemical Assay Reagents |
| HY-142982 | Palmitoyloleoylphosphatidylglycerol | 81490-05-3 | Biochemical Assay Reagents |
| HY-142983 | DMPE | 20255-95-2 | Biochemical Assay Reagents |
| HY-142984 | Decanoic acid, 2-hexyl-, 6-oxohexyl ester-1 | 1849616-53-0 | Biochemical Assay Reagents |
| HY-142985 | Oleyl Mesylate | 35709-09-2 | Biochemical Assay Reagents |
| HY-142986 | Dlin-MeOH | 1169768-28-8 | Biochemical Assay Reagents |
| HY-142987 | Linoleyl methane sulfonate | 51154-39-3 | Biochemical Assay Reagents |
| HY-142988 | 1-Stearoyl-2-myristoyl-sn-glycero-3-PC | 20664-02-2 | Biochemical Assay Reagents |
| HY-142989 | 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine | 99296-81-8 | Biochemical Assay Reagents |
| HY-14299 | Indacaterol | 312753-06-3 | Reference compound |
| HY-142990 | 1-Oleoyl-2-palmitoyl-sn-glycero-3-PC | 59491-62-2 | Biochemical Assay Reagents |
| HY-142991 | 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol | 185435-28-3 | Biochemical Assay Reagents |
| HY-142992 | LNP Lipid-2 | 2036272-65-6 | Biochemical Assay Reagents |
| HY-142993 | Dielaidoylphosphatidylethanolamine | 16777-83-6 | Biochemical Assay Reagents |
| HY-142994 | Wybutosine | 55196-46-8 | Biochemical Assay Reagents |
| HY-142995 | DODAP (hydrochloride) | 329009-00-9 | Biochemical Assay Reagents |
| HY-142996 | BGTC | 182056-06-0 | Biochemical Assay Reagents |
| HY-142997 | DOSPA | 282533-23-7 | Biochemical Assay Reagents |
| HY-142998 | Vaxfectin | 370108-99-9 | Biochemical Assay Reagents |
| HY-142999 | DOIC | 1292821-06-7 | Biochemical Assay Reagents |
| HY-14299A | Indacaterol (maleate) | 753498-25-8 | Reference compound |
| HY-14299AR | Indacaterol (maleate) (Standard) | 753498-25-8 | Reference Standards |
| HY-14299B | (S)-Indacaterol | 1235445-80-3 | Reference compound |
| HY-14299C | Indacaterol (xinafoate) | 1000160-97-3 | Reference compound |
| HY-14299D | Indacaterol (acetate) | 1000160-96-2 | Reference compound |
| HY-14299R | Indacaterol (Standard) | 312753-06-3 | Reference Standards |
| HY-14299S | Indacaterol-d3 | 2699828-16-3 | Isotope-Labeled Compounds |
| HY-14300 | Vilanterol | 503068-34-6 | Reference compound |
| HY-14300A | Vilanterol (trifenatate) | 503070-58-4 | Reference compound |
| HY-14300AS | Vilanterol-d4 (trifenatate) | 2021249-10-3 | Isotope-Labeled Compounds |
| HY-14300S2 | Vilanterol-d12 | | Isotope-Labeled Compounds |
| HY-14301 | Olodaterol | 868049-49-4 | Reference compound |
| HY-143017S | 4-Hydroxy Atorvastatin-d5 (disodium) | | Isotope-Labeled Compounds |
| HY-14301A | Olodaterol (hydrochloride) | 869477-96-3 | Reference compound |
| HY-14301AR | Olodaterol (hydrochloride) (Standard) | 869477-96-3 | Reference Standards |
| HY-14302 | Salmeterol | 89365-50-4 | Reference compound |
| HY-143021S | 1,3-Dioleoylglycerol-d5 | 1246523-70-5 | Isotope-Labeled Compounds |
| HY-14302S1 | Salmeterol-d5 | 1093433-84-1 | Isotope-Labeled Compounds |
| HY-14304 | Zinterol | 37000-20-7 | Reference compound |
| HY-14304A | Zinterol (hydrochloride) | 38241-28-0 | Reference compound |
| HY-14305 | BMS-582949 | 623152-17-0 | Reference compound |
| HY-14305A | BMS-582949 (hydrochloride) | 912806-16-7 | Reference compound |
| HY-14307 | Necrocide 1 | 1247028-61-0 | Reference compound |
| HY-14307A | (R)-Necrocide 1 | 1247028-62-1 | Reference compound |
| HY-14308 | GS-9851 | 1064684-44-1 | Reference compound |
| HY-14312 | A 85380 | 161416-98-4 | Reference compound |
| HY-14314 | ABT-418 | 147402-53-7 | Reference compound |
| HY-14316 | Tebanicline | 198283-73-7 | Reference compound |
| HY-14316A | Tebanicline (dihydrochloride) | 209326-19-2 | Reference compound |
| HY-14316B | Tebanicline (hydrochloride) | 203564-54-9 | Reference compound |
| HY-14316C | Tebanicline (tosylate) | 198283-74-8 | Reference compound |
| HY-14319A | Sazetidine A (hydrochloride) | 1197329-42-2 | Reference compound |
| HY-14319B | Sazetidine A (dihydrochloride) | 2455450-63-0 | Reference compound |
| HY-143200 | OSBPL7-IN-1 | 1269826-44-9 | Reference compound |
| HY-143201 | DS20362725 | 2735803-20-8 | Reference compound |
| HY-143202 | DPhPC | 207131-40-6 | Biochemical Assay Reagents |
| HY-143203 | 18:0-18:2 PE | 7266-53-7 | Biochemical Assay Reagents |
| HY-143204 | (Rac)-POPC | 26662-91-9 | Biochemical Assay Reagents |
| HY-143205 | Desthiobiotin polyethyleneoxide iodoacetamide | | Reference compound |
| HY-143206 | Tyrosinase/elastase-IN-1 | | Reference compound |
| HY-143207 | 10-Formyl-5,8-dideazafolic acid | 61038-31-1 | Reference compound |
| HY-143208 | HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt | 2641500-83-4 | Reference compound |
| HY-143209A | DSPE-PEG1000-OH (sodium) | 871327-06-9 | Natural Products |
| HY-143209B | DSPE-PEG3400 | 145035-96-7 | Biochemical Assay Reagents |
| HY-143210 | Transfectam | 124050-77-7 | Biochemical Assay Reagents |
| HY-143211 | Murapalmitine | 133863-30-6 | Biochemical Assay Reagents |
| HY-143212 | 18:0-22:6 DG | 65886-80-8 | Biochemical Assay Reagents |
| HY-143216 | Ensitrelvir | 2647530-73-0 | Reference compound |
| HY-143216A | Ensitrelvir (fumarate) | 2757470-18-9 | Reference compound |
| HY-143218 | TPE-MI | 1245606-71-6 | Dye Reagents |
| HY-143219 | SS-Inclisiran (sodium) | | Oligonucleotides |
| HY-143220 | SS(no Galnac)-Inclisiran (sodium) | | Oligonucleotides |
| HY-143221 | AS-Inclisiran (sodium) | | Oligonucleotides |
| HY-143224 | NCGC00138783 | | Reference compound |
| HY-143224A | NCGC00138783 (free base) | 896700-07-5 | Reference compound |
| HY-143224B | NCGC00138783 (TFA) | | Reference compound |
| HY-143225 | NCGC00538431 | | Reference compound |
| HY-143226 | DK1 | 1187568-17-7 | Reference compound |
| HY-143227 | DK3 | 1187568-16-6 | Reference compound |
| HY-143228 | SH-42 | 2143952-36-5 | Reference compound |
| HY-143230 | Custirsen | 890056-27-6 | Oligonucleotides |
| HY-143230A | Custirsen (sodium) | | Oligonucleotides |
| HY-143231 | IRAK4-IN-8 | 2033070-97-0 | Reference compound |
| HY-143232 | Antibacterial agent 73 | 414885-92-0 | Reference compound |
| HY-143233 | PIM-1/HDAC-IN-1 | 2897622-19-2 | Reference compound |
| HY-143234 | mIDH1-IN-1 | 2757155-96-5 | Reference compound |
| HY-143235 | BRD4 Inhibitor-15 | 2761366-60-1 | Reference compound |
| HY-143236 | DHFR-IN-1 | 2757991-65-2 | Reference compound |
| HY-143237 | ATX inhibitor 11 | 2485779-27-7 | Reference compound |
| HY-143238 | FY-56 | | Reference compound |
| HY-143239 | PPARα/γ agonist 1 | | Reference compound |
| HY-143241 | HDAC-IN-34 | 2857097-33-5 | Reference compound |
| HY-143242 | Phidianidine B | 1301638-42-5 | Natural Products |
| HY-143243 | Antioxidant agent-5 | 2684291-60-7 | Reference compound |
| HY-143244 | Monoamine Oxidase B inhibitor 1 | 2807477-70-7 | Reference compound |
| HY-143245 | Monoamine Oxidase B inhibitor 2 | 2807477-26-3 | Reference compound |
| HY-143246 | EGFR kinase inhibitor 1 | 2413958-04-8 | Reference compound |
| HY-143247 | Tubulin polymerization-IN-2 | 2873399-22-3 | Reference compound |
| HY-143248 | KR-39038 | 2770300-35-9 | Reference compound |
| HY-143249 | MtMetAP1-IN-1 | | Reference compound |
| HY-14325 | L-745870 | 158985-00-3 | Reference compound |
| HY-143250 | Tubulin inhibitor 12 | 92575-00-3 | Reference compound |
| HY-143251 | Tubulin inhibitor 13 | 2883436-66-4 | Reference compound |
| HY-143252 | CEase-IN-1 | 2985688-68-2 | Reference compound |
| HY-143253 | Estrogen receptor antagonist 7 | 2889371-04-2 | Reference compound |
| HY-143254 | Enpp-1-IN-10 | 2631704-38-4 | Reference compound |
| HY-143255 | Enpp-1-IN-11 | | Reference compound |
| HY-143256 | Enpp-1-IN-12 | 2631703-41-6 | Reference compound |
| HY-143257 | CDK4/6-IN-7 | 2649120-20-5 | Reference compound |
| HY-143258 | CDK4/6-IN-8 | 2649120-22-7 | Reference compound |
| HY-143259 | BE1218 | 2893967-40-1 | Reference compound |
| HY-14325A | L-745870 (trihydrochloride) | 866021-03-6 | Reference compound |
| HY-14325B | L-745870 (hydrochloride) | 1173023-36-3 | Reference compound |
| HY-143260 | GSK-3β inhibitor 6 | | Reference compound |
| HY-143261 | GSK-3β inhibitor 7 | | Reference compound |
| HY-143263 | FAAH/MAGL-IN-1 | | Reference compound |
| HY-143264 | FAAH/MAGL-IN-2 | 2765077-82-3 | Reference compound |
| HY-143265 | Topoisomerase I inhibitor 2 | 2588211-44-1 | Reference compound |
| HY-143266 | Topoisomerase I inhibitor 3 | 2588211-50-9 | Reference compound |
| HY-143267 | Estrogen receptor antagonist 8 | 2889370-92-5 | Reference compound |
| HY-143268 | HPA-IN-1 | | Reference compound |
| HY-143269 | HPA-IN-2 | 2885971-91-3 | Reference compound |
| HY-14327 | FAUC 213 | 337972-47-1 | Reference compound |
| HY-143270 | PROTAC BRD9-binding moiety 5 | 893633-37-9 | Reference compound |
| HY-143271 | RORγt inverse agonist 29 | | Reference compound |
| HY-143272 | FGFR1 inhibitor-6 | | Reference compound |
| HY-143273 | DENV-IN-6 | 2375780-95-1 | Reference compound |
| HY-143274 | DENV-IN-5 | 2375781-06-7 | Reference compound |
| HY-143275 | HL-8 | 2766352-64-9 | Reference compound |
| HY-143276 | (S,S,R)-AHPC-C6-NH2 | 2411422-68-7 | Reference compound |
| HY-143276A | (S,S,R)-AHPC-C6-NH2 (hydrochloride) | | Reference compound |
| HY-143277 | HL-2 | 2766352-49-0 | Reference compound |
| HY-143278 | FLT3-IN-13 | | Reference compound |
| HY-143279 | Topoisomerase II inhibitor 3 | 99140-25-7 | Reference compound |
| HY-14328 | Sonepiprazole | 170858-33-0 | Reference compound |
| HY-143280 | Topoisomerase II inhibitor 4 | 2560590-49-8 | Reference compound |
| HY-143281 | Topoisomerase II inhibitor 5 | | Reference compound |
| HY-143285 | AMC-GlcNAc | | Dye Reagents |
| HY-143286 | PF15 | 2892631-70-6 | Reference compound |
| HY-143286A | PF15 (TFA) | | Reference compound |
| HY-143287 | NTPDase-IN-1 | 2962812-29-7 | Reference compound |
| HY-143288 | NTPDase-IN-2 | 2883147-47-3 | Reference compound |
| HY-143289 | NTPDase-IN-3 | 2883147-45-1 | Reference compound |
| HY-14328A | Sonepiprazole (hydrochloride) | 170857-36-0 | Reference compound |
| HY-143290 | Antibacterial agent 118 | | Reference compound |
| HY-143291 | AChE-IN-9 | | Reference compound |
| HY-143292 | Antibacterial agent 81 | 2873395-27-6 | Reference compound |
| HY-143293 | VEGFR-IN-3 | 2874264-13-6 | Reference compound |
| HY-143294 | sEH inhibitor-2 | 2816102-69-7 | Reference compound |
| HY-143295 | Pim-1 kinase inhibitor 1 | 2803505-57-7 | Reference compound |
| HY-143296 | SphK1-IN-1 | | Reference compound |
| HY-143299 | BRD4-BD1-IN-1 | 2761321-18-8 | Reference compound |
| HY-14330 | ABT-724 | 70006-24-5 | Reference compound |
| HY-143300 | BRD4-BD1-IN-2 | 2761321-26-8 | Reference compound |
| HY-143301 | Topoisomerase I inhibitor 4 | 2485135-31-5 | Reference compound |
| HY-143302 | Anticancer agent 31 | 2222930-72-3 | Reference compound |
| HY-143303 | Anticancer agent 32 | 2222930-76-7 | Reference compound |
| HY-143305 | PD-1/PD-L1-IN-25 | 2768759-52-8 | Reference compound |
| HY-143306 | IDH1 Inhibitor 5 | 1940128-37-9 | Reference compound |
| HY-143312 | V-0219 | 878453-71-5 | Reference compound |
| HY-143312A | V-0219 (hydrochloride) | 2922283-73-4 | Reference compound |
| HY-143312B | (R)-V-0219 | 3031984-80-9 | Reference compound |
| HY-143312C | (S)-V-0219 | 3031984-78-5 | Reference compound |
| HY-143312D | (R)-V-0219 (hydrochloride) | | Reference compound |
| HY-143312E | (S)-V-0219 (hydrochloride) | | Reference compound |
| HY-143313 | Protease-Activated Receptor-1 antagonist 1 | | Reference compound |
| HY-143314 | Protease-Activated Receptor-1 antagonist 2 | 1454588-34-1 | Reference compound |
| HY-143315 | Protease-Activated Receptor-1 antagonist 3 | | Reference compound |
| HY-143316 | NPR-C activator 1 | 2768328-61-4 | Reference compound |
| HY-143317 | XY153 | 2933176-32-8 | Reference compound |
| HY-143319 | SPH5030 | 2364326-23-6 | Reference compound |
| HY-143320 | STING agonist-17 | 2816929-47-0 | Reference compound |
| HY-143321 | STING agonist-13 | 2816929-48-1 | Reference compound |
| HY-143322 | CRK12-IN-2 | 1990479-17-8 | Reference compound |
| HY-143323 | HER2-IN-9 | | Reference compound |
| HY-143324 | A2AAR/HDAC-IN-1 | 2767560-51-8 | Reference compound |
| HY-143325 | A2AAR/HDAC-IN-2 | 2767560-94-9 | Reference compound |
| HY-143326 | Antibacterial agent 83 | 2413865-92-4 | Reference compound |
| HY-143327 | PROTAC BRD4 Degrader-16 | 2585561-36-8 | Reference compound |
| HY-143328 | PROTAC BRD4 Degrader-17 | 2585561-49-3 | Reference compound |
| HY-143329 | MAO-B-IN-3 | | Reference compound |
| HY-143330 | MAO-B-IN-4 | | Reference compound |
| HY-143332 | TRIM24/BRPF1-IN-2 | 3033288-68-2 | Reference compound |
| HY-143333 | Nrf2 activator-3 | 2766570-23-2 | Reference compound |
| HY-143334 | Antifungal agent 84 | 2901064-07-9 | Reference compound |
| HY-143335 | Antifungal agent 52 | 2901064-06-8 | Reference compound |
| HY-143337 | EGFR-IN-47 | 3034649-73-2 | Reference compound |
| HY-143338 | ART-IN-1 | 2418014-98-7 | Reference compound |
| HY-143339 | CBP/p300-IN-15 | 2379409-91-1 | Reference compound |
| HY-14334 | SAM-315 | 744218-85-7 | Reference compound |
| HY-143340 | LEB-03-145 | 2858812-90-3 | Reference compound |
| HY-143342 | LEB-03-144 | 2858812-89-0 | Reference compound |
| HY-143343 | LEB-03-153 | 2858812-88-9 | Reference compound |
| HY-143344 | NJH-2-056 | 2858812-69-6 | Reference compound |
| HY-143345 | EN523 | 2094893-05-5 | Reference compound |
| HY-143346 | CCW16 | 2361138-33-0 | Reference compound |
| HY-143348 | NJH-2-030 | 2709040-02-6 | Reference compound |
| HY-14335 | Ro 04-6790 | 202466-68-0 | Reference compound |
| HY-143355S | Albendazole-2-Aminosulfone-d3 (hydrochloride) | 1435902-07-0 | Isotope-Labeled Compounds |
| HY-143359 | COTI-219 | 1039455-85-0 | Reference compound |
| HY-143359S | COTI-219-d8 | | Isotope-Labeled Compounds |
| HY-14335A | Ro 04-6790 di(hydrochloride) | 1197333-95-1 | Reference compound |
| HY-14336 | SB 271046 | 209481-20-9 | Reference compound |
| HY-143367S | 27-Hydroxy cholesterol-d6 | 1246302-95-3 | Isotope-Labeled Compounds |
| HY-143368S | L-Phenylmercapturic acid-d5 | 1331906-27-4 | Isotope-Labeled Compounds |
| HY-14336A | SB 271046 (Hydrochloride) | 209481-24-3 | Reference compound |
| HY-14337 | MS 245 | 263384-65-2 | Reference compound |
| HY-143377 | Cdc7-IN-8 | 2606780-38-3 | Reference compound |
| HY-14338 | Idalopirdine | 467459-31-0 | Reference compound |
| HY-143380 | Cdc7-IN-9 | 2649407-21-4 | Reference compound |
| HY-143385 | Cdc7-IN-12 | 2764865-33-8 | Reference compound |
| HY-143387 | Cdc7-IN-13 | 2764866-23-9 | Reference compound |
| HY-143389 | Cdc7-IN-14 | 2764866-21-7 | Reference compound |
| HY-14338A | Idalopirdine (hydrochloride) | 467458-02-2 | Reference compound |
| HY-14339 | Intepirdine | 607742-69-8 | Reference compound |
| HY-143390 | NMDA receptor modulator 2 | 2758255-05-7 | Reference compound |
| HY-143391 | NMDA receptor modulator 3 | 2758256-02-7 | Reference compound |
| HY-143393 | NMDA receptor modulator 4 | 2758256-71-0 | Reference compound |
| HY-143396 | NMDA receptor modulator 5 | 2758256-97-0 | Reference compound |
| HY-143397 | NMDA receptor modulator 6 | 2758256-85-6 | Reference compound |
| HY-143398 | PARP10/15-IN-1 | 2892065-01-7 | Reference compound |
| HY-14340 | WAY-181187 | 554403-49-5 | Peptides |
| HY-143400 | HSP70-IN-3 | | Reference compound |
| HY-143401 | Hit 1 | 2785377-42-4 | Reference compound |
| HY-143402 | Topoisomerase I/II inhibitor 2 | 2770804-58-3 | Reference compound |
| HY-143403 | PI3K-IN-31 | 1359956-12-9 | Reference compound |
| HY-143404 | PI3K-IN-30 | 2281803-22-1 | Reference compound |
| HY-143405 | Antifungal agent 24 | 2566522-60-7 | Reference compound |
| HY-143406 | Antifungal agent 25 | 2566522-50-5 | Reference compound |
| HY-143407 | FAK-IN-3 | 2882094-29-1 | Reference compound |
| HY-143408 | OYYF-175 | 65829-22-3 | Reference compound |
| HY-143409 | Antimalarial agent 10 | 2747280-03-9 | Reference compound |
| HY-143410 | Anti-inflammatory agent 16 | | Reference compound |
| HY-143411 | GEM144 | 2487526-28-1 | Reference compound |
| HY-143412 | MIR002 | 2217671-64-0 | Reference compound |
| HY-143413 | BuChE-IN-2 | 2745118-93-6 | Reference compound |
| HY-143414 | Metallo-β-lactamase-IN-6 | 1439899-44-1 | Reference compound |
| HY-143415 | Metallo-β-lactamase-IN-7 | 2752453-58-8 | Reference compound |
| HY-143417 | SARS-CoV-2-IN-16 | 2761911-40-2 | Reference compound |
| HY-143418 | SARS-CoV-2-IN-17 | 2761911-44-6 | Reference compound |
| HY-143419 | ATX inhibitor 14 | 2484811-39-2 | Reference compound |
| HY-14342 | MK-5046 | 1022152-70-0 | Reference compound |
| HY-143420 | ATX inhibitor 15 | 2484811-52-9 | Reference compound |
| HY-143421 | Curcumin monoglucuronide | 2171091-50-0 | Reference compound |
| HY-143422 | MALT1-IN-3 | 2504229-63-2 | Reference compound |
| HY-143422A | (R)-MALT1-IN-3 | 2504229-61-0 | Reference compound |
| HY-143423 | MALT1-IN-5 | 2434602-73-8 | Reference compound |
| HY-143423A | (S)-MALT1-IN-5 | 2434602-25-0 | Reference compound |
| HY-143424 | MALT1-IN-6 | 2254669-07-1 | Reference compound |
| HY-143425 | MALT1-IN-7 | 2178993-11-6 | Reference compound |
| HY-143425A | (R)-MALT1-IN-7 | 2178993-10-5 | Reference compound |
| HY-143426 | MALT1-IN-8 | 2244109-29-1 | Reference compound |
| HY-143427 | MALT1-IN-9 | 2577170-77-3 | Reference compound |
| HY-143429 | Cdc7-IN-15 | 1244027-03-9 | Reference compound |
| HY-14342A | (R)-MK-5046 | 1021736-25-3 | Reference compound |
| HY-143430 | (S)-LY3177833 | 1627696-52-9 | Reference compound |
| HY-143430A | (S)-LY3177833 (hydrate) | 2733342-93-1 | Reference compound |
| HY-143431 | Cdc7-IN-17 | 2253686-94-9 | Reference compound |
| HY-143432 | Cdc7-IN-18 | 2562329-14-8 | Reference compound |
| HY-143432A | (S)-Cdc7-IN-18 | 2562329-13-7 | Reference compound |
| HY-143433 | Cdc7-IN-19 | 2606780-39-4 | Reference compound |
| HY-143434 | FLT3/D835Y-IN-1 | 2648799-49-7 | Reference compound |
| HY-143435 | AG6033 | 329706-62-9 | Reference compound |
| HY-143436 | TNIK-IN-4 | 2754266-04-9 | Reference compound |
| HY-143437 | TNIK-IN-5 | 2754265-66-0 | Reference compound |
| HY-143438 | 2-PAT | 134467-58-6 | Reference compound |
| HY-143439 | LX-039 | 2135341-09-0 | Reference compound |
| HY-143440 | CBP/p300-IN-16 | | Reference compound |
| HY-143441 | CBP/p300-IN-17 | 2259640-87-2 | Reference compound |
| HY-143442 | CBP/p300-IN-18 | 2983027-64-9 | Reference compound |
| HY-143443 | DS17701585 | 2983027-66-1 | Reference compound |
| HY-143444 | JAK-IN-20 | 1654776-91-6 | Reference compound |
| HY-143445 | EGFR-IN-48 | 2882851-77-4 | Reference compound |
| HY-143446 | Tubulin polymerization-IN-7 | 1394017-46-9 | Reference compound |
| HY-143447 | Tubulin polymerization-IN-8 | 2768485-08-9 | Reference compound |
| HY-143448 | Tyrosinase-IN-1 | 1164200-43-4 | Reference compound |
| HY-143449 | Tyrosinase-IN-2 | 180864-33-9 | Reference compound |
| HY-143450 | Tyrosinase-IN-3 | 2409081-40-7 | Reference compound |
| HY-143451 | Tyrosinase-IN-4 | 19275-70-8 | Reference compound |
| HY-143452 | MtTMPK-IN-4 | 2225889-49-4 | Reference compound |
| HY-143454 | Germination-IN-1 | 65384-76-1 | Reference compound |
| HY-143455 | Germination-IN-2 | 89846-43-5 | Reference compound |
| HY-143456 | Anti-inflammatory agent 18 | 2873386-66-2 | Reference compound |
| HY-143457 | Anti-inflammatory agent 19 | 2873386-63-9 | Reference compound |
| HY-143458 | FAK PROTAC B5 | 2471525-44-5 | Reference compound |
| HY-143459 | Tyrosinase-IN-5 | 2525175-90-8 | Reference compound |
| HY-14346 | PD153035 | 153436-54-5 | Reference compound |
| HY-143460 | CAXII-IN-1 | 2479918-59-5 | Reference compound |
| HY-143461 | CK2 inhibitor 3 | | Reference compound |
| HY-143462 | c-Met/HDAC-IN-2 | 2740495-53-6 | Reference compound |
| HY-143463 | AC-386 | 1902910-89-7 | Reference compound |
| HY-143464 | BChE-IN-4 | 2304818-41-3 | Reference compound |
| HY-143465 | BChE-IN-5 | 2983586-25-8 | Reference compound |
| HY-143466 | ULK1-IN-2 | 2497409-01-3 | Reference compound |
| HY-143467 | SARS-CoV-IN-4 | 2445585-37-3 | Reference compound |
| HY-143468 | MEK-IN-5 | 2417022-06-9 | Reference compound |
| HY-143469 | NPP1-IN-1 | 2493063-65-1 | Reference compound |
| HY-14347 | EBE-A22 | 229476-53-3 | Reference compound |
| HY-143470 | SARS-CoV-2-IN-18 | 184904-82-3 | Reference compound |
| HY-143471 | WNY0824 | 2412707-81-2 | Reference compound |
| HY-143472 | PI3Kδ-IN-11 | 2413257-51-7 | Reference compound |
| HY-143473 | FabG1-IN-1 | 1051177-61-7 | Reference compound |
| HY-143474 | POP-IN-3 | 2554621-98-4 | Reference compound |
| HY-143475 | POP-IN-2 | 2743432-81-5 | Reference compound |
| HY-143476 | Plasma kallikrein-IN-2 | | Reference compound |
| HY-143477 | Factor XI-IN-1 | 2720619-72-5 | Reference compound |
| HY-143478 | HIV-IN-1 | 2756837-91-7 | Reference compound |
| HY-143479 | HIV-IN-2 | 2756838-41-0 | Reference compound |
| HY-14348 | GSK163090 | 844903-58-8 | Reference compound |
| HY-143480 | RIPK1-IN-15 | 2755704-34-6 | Reference compound |
| HY-143481 | Nav1.8-IN-2 | 2756250-30-1 | Reference compound |
| HY-143482 | MMV688844 | 2650213-59-3 | Reference compound |
| HY-143483 | NBTIs-IN-5 | 2767443-78-5 | Reference compound |
| HY-143484 | 844-TFM | 2767443-97-8 | Reference compound |
| HY-143485 | IRAK4-IN-9 | 2681278-07-7 | Reference compound |
| HY-143486 | IRAK4-IN-10 | 2681278-09-9 | Reference compound |
| HY-143487 | Antimalarial agent 12 | 2715225-58-2 | Reference compound |
| HY-143488 | Neuraminidase-IN-8 | 2716197-09-8 | Reference compound |
| HY-143490 | PAK4-IN-2 | 2488706-33-6 | Reference compound |
| HY-143491 | VS 8 | 2471865-38-8 | Reference compound |
| HY-143492 | Influenza virus-IN-1 | 108729-21-1 | Reference compound |
| HY-143493 | Influenza virus-IN-2 | 2411584-06-8 | Reference compound |
| HY-143494 | RSV/IAV-IN-3 | 2395007-81-3 | Reference compound |
| HY-143495 | RSV-IN-3 | 862825-90-9 | Reference compound |
| HY-143496 | RSV-IN-4 | 862825-89-6 | Reference compound |
| HY-143497 | HDAC1/2 and CDK2-IN-1 | 2418559-01-8 | Reference compound |
| HY-143498 | ERCC1-XPF-IN-1 | 2411584-25-1 | Reference compound |
| HY-143499 | hMAO-B-IN-3 | 2581113-51-9 | Reference compound |
| HY-14350 | AC-55541 | 916170-19-9 | Reference compound |
| HY-143504S | Mono(3-hydroxybutyl)phthalate-d4 | 2119601-77-1 | Isotope-Labeled Compounds |
| HY-14351 | AC-264613 | 1051487-82-1 | Reference compound |
| HY-143510 | RMC-4627 | 2250059-52-8 | Reference compound |
| HY-143518 | TP-16 | 2332972-26-4 | Reference compound |
| HY-143519S | Isopropyl phenyl-d7 | 2469037-60-1 | Isotope-Labeled Compounds |
| HY-143527S | Clavulanic acid methyl ester-d3 | 1821757-56-5 | Isotope-Labeled Compounds |
| HY-14353 | GSK-9772 | 928035-84-1 | Reference compound |
| HY-143535 | HG122 | 1854976-77-4 | Reference compound |
| HY-143539 | YQ456 | 2093946-08-6 | Reference compound |
| HY-143542S | Nor neostigmine-d6 | 2470126-73-7 | Isotope-Labeled Compounds |
| HY-143545 | RET-IN-8 | 2642164-75-6 | Reference compound |
| HY-143546 | RET-IN-9 | 2649418-11-9 | Reference compound |
| HY-143547S | L-Hercynine-d3 | 1639966-63-4 | Isotope-Labeled Compounds |
| HY-143557 | Trk-IN-7 | 2383011-61-6 | Reference compound |
| HY-14356 | ADL5859 | 850305-06-5 | Reference compound |
| HY-143561 | Trk-IN-8 | 2762200-57-5 | Reference compound |
| HY-143563 | NLRP3 antagonist 1 | 2454017-83-3 | Reference compound |
| HY-143564S | Glycinexylidide-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143568 | P2X3 antagonist 36 | 2310263-59-1 | Reference compound |
| HY-14357 | BMS 695735 | 1054315-48-8 | Reference compound |
| HY-143576 | P2X3 antagonist 37 | 2649318-40-9 | Reference compound |
| HY-143581 | ATX inhibitor 8 | 2156656-37-8 | Reference compound |
| HY-143582 | ATX inhibitor 9 | 2640300-87-2 | Reference compound |
| HY-143583 | ATX inhibitor 10 | 2648969-30-4 | Reference compound |
| HY-143584 | AZ5576 | 2751721-40-9 | Reference compound |
| HY-143585 | CDK9-IN-14 | 2650640-17-6 | Reference compound |
| HY-143586 | CDK7-IN-8 | 2654003-64-0 | Reference compound |
| HY-143587 | CDK7-IN-2 | 2326428-19-5 | Reference compound |
| HY-143588 | KRAS G12C inhibitor 35 | 2650550-87-9 | Reference compound |
| HY-143589 | Glecirasib | 2657613-87-9 | Reference compound |
| HY-143590 | KRAS G12C inhibitor 37 | 2241720-04-5 | Reference compound |
| HY-143591 | KRAS G12C inhibitor 38 | 2660129-56-4 | Reference compound |
| HY-143592 | KRAS G12C inhibitor 39 | 2326522-16-9 | Reference compound |
| HY-143594 | KRAS G12C inhibitor 40 | 2660014-14-0 | Reference compound |
| HY-143596 | KRAS G12C inhibitor 41 | 2660014-65-1 | Reference compound |
| HY-143598 | KRAS G12C inhibitor 42 | 2454488-02-7 | Reference compound |
| HY-143599 | KRAS G12D inhibitor 8 | 2648221-05-8 | Reference compound |
| HY-143602 | KRAS G12D inhibitor 9 | 2648551-39-5 | Reference compound |
| HY-143603 | KRAS G12D inhibitor 10 | 2648551-54-4 | Reference compound |
| HY-143604 | KRAS G12D inhibitor 11 | 2648551-72-6 | Reference compound |
| HY-143606 | KRAS G12D inhibitor 12 | 2648552-54-7 | Reference compound |
| HY-143607 | KRAS G12D inhibitor 13 | 2648552-62-7 | Reference compound |
| HY-14361 | MK-4965 | 920035-77-4 | Reference compound |
| HY-143610 | AKT-IN-7 | 2654025-97-3 | Reference compound |
| HY-143611 | AKT-IN-8 | 2654026-13-6 | Reference compound |
| HY-143613 | THR-β agonist 2 | 2440027-77-8 | Reference compound |
| HY-143613A | THR-β agonist 2 (diacetate) | | Reference compound |
| HY-143614 | THR-β agonist 3 | 2656400-84-7 | Reference compound |
| HY-143615 | RET-IN-10 | 2662622-44-6 | Reference compound |
| HY-143616 | EZH2-IN-7 | 2659225-28-0 | Reference compound |
| HY-143617 | photoCORM-1 | 2892235-56-0 | Reference compound |
| HY-143618 | photoCORM-2 | 2892235-54-8 | Reference compound |
| HY-14362 | GSK-25 | 874119-56-9 | Reference compound |
| HY-143623S | Neo Spiramycin I-d3 | | Isotope-Labeled Compounds |
| HY-14363 | TUG-424 | 1082058-99-8 | Reference compound |
| HY-14364 | A-987306 | 1082954-71-9 | Reference compound |
| HY-143641 | Anticancer agent 25 | 2401013-08-7 | Reference compound |
| HY-143643 | Antibacterial agent 72 | 2412500-67-3 | Reference compound |
| HY-143645S | Glycochenodeoxycholic acid 3-sulfate-d5 (disodium) | | Isotope-Labeled Compounds |
| HY-14365 | TC-G 1004 | 1061747-72-5 | Reference compound |
| HY-143652S | trans-Hydroxy praziquantel-d5 | 1792180-18-7 | Isotope-Labeled Compounds |
| HY-143653 | BCL6-IN-6 | 2408882-54-0 | Reference compound |
| HY-143654 | WW437 | | Reference compound |
| HY-143655 | QW24 | 2416312-06-4 | Reference compound |
| HY-143656 | SH379 | 2338793-00-1 | Reference compound |
| HY-143657 | Myoferlin inhibitor 1 | 2366279-99-2 | Reference compound |
| HY-143658 | SH498 | 2125724-38-9 | Reference compound |
| HY-143659 | QW30 | 1714112-25-0 | Reference compound |
| HY-14366 | Antibiotic A-33853 | 80148-45-4 | Natural Products |
| HY-143660 | LG308 | 1428341-65-4 | Reference compound |
| HY-143662S | (±)12(13)-DiHOME-d4 | | Isotope-Labeled Compounds |
| HY-143664S | (±)14(15)-DiHET-d11 | | Isotope-Labeled Compounds |
| HY-143665S | Nor-W-18-d4 | 2701349-29-1 | Isotope-Labeled Compounds |
| HY-143666S | DPPI-3,4,5-P3-d62 (sodium) | | Isotope-Labeled Compounds |
| HY-14367 | Emicerfont | 786701-13-1 | Reference compound |
| HY-143670S | 1-Palmitoyl-2-arachidonoyl-3-palmitoyl-sn-glycerol-d9 | | Isotope-Labeled Compounds |
| HY-143671S | 1-Stearoyl-2-arachidonoyl-sn-glycero-3-PE-d11 | 2750554-96-0 | Isotope-Labeled Compounds |
| HY-143675S | 1-Palmitoyl-2-palmitoyl-sn-glycero-3-PS-d9 | | Isotope-Labeled Compounds |
| HY-143676S | (1E,4Z,6E)-Curcumin-d6 | 1335198-02-1 | Isotope-Labeled Compounds |
| HY-143677S | (±)11-HETE-d8 | 2750534-80-4 | Isotope-Labeled Compounds |
| HY-143678 | Citrulline-specific probe-biotin | 2468149-70-2 | Reference compound |
| HY-143679S | 4-(3',6'-Dimethyl-3'-heptyl)phenol diethoxylate-13C6 | 1173019-36-7 | Isotope-Labeled Compounds |
| HY-143681S | (Rac)-2-Palmitoyl-3-chloropropanediol-d5 | 1329614-79-0 | Isotope-Labeled Compounds |
| HY-143684S | N-(3-Mercapto-2-methylpropanoyl)glycine-d5 | 1184993-97-2 | Isotope-Labeled Compounds |
| HY-143686 | ImmTher | 143005-30-5 | Biochemical Assay Reagents |
| HY-143688 | EDMPC | 183283-19-4 | Biochemical Assay Reagents |
| HY-143689 | 18:1 Ethylene Glycol | 928-24-5 | Biochemical Assay Reagents |
| HY-14369 | Elagolix sodium | 832720-36-2 | Reference compound |
| HY-143690S | Oxybutynin-10d (hydrochloride) | 120092-65-1 | Isotope-Labeled Compounds |
| HY-143691 | MGlc-DAG | 2021179-21-3 | Biochemical Assay Reagents |
| HY-143692 | SQDG | 123036-44-2 | Biochemical Assay Reagents |
| HY-143693 | DGDG | 63142-69-8 | Biochemical Assay Reagents |
| HY-143695 | 16:0 TAP | 139984-36-4 | Biochemical Assay Reagents |
| HY-143699S | (Rac)-1,2-Bis-palmitol-3-chloropropanediol-d5 | 1185057-55-9 | Isotope-Labeled Compounds |
| HY-14369R | Elagolix sodium (Standard) | 832720-36-2 | Reference Standards |
| HY-14369S | Elagolix-13C,d3 (sodium) | | Isotope-Labeled Compounds |
| HY-14370 | LX2931 | 948840-25-3 | Reference compound |
| HY-143700 | 18:0 DAP | 121315-93-3 | Biochemical Assay Reagents |
| HY-143702 | Fluorescent DOTAP | 1010076-97-7 | Biochemical Assay Reagents |
| HY-143704S | 5-Aminosalicylic acid-13C6 (hydrochloride) | 1261398-47-3 | Isotope-Labeled Compounds |
| HY-143709S | Phthalic acid bis(3,7-dimethyloctyl) ester-d4 | 1398065-81-0 | Isotope-Labeled Compounds |
| HY-143711S | Trimethyllysine-d9 | 1182037-78-0 | Isotope-Labeled Compounds |
| HY-143712 | Allolithocholic acid | 2276-94-0 | Reference compound |
| HY-143712R | Allolithocholic acid (Standard) | 2276-94-0 | Reference Standards |
| HY-143712S1 | Allolithocholic Acid-d4 | | Isotope-Labeled Compounds |
| HY-143713 | Aurora A inhibitor 1 | 2677799-04-9 | Reference compound |
| HY-143714 | Cathepsin K inhibitor 2 | 2672478-52-1 | Reference compound |
| HY-143715 | Cereblon inhibitor 1 | 2672489-14-2 | Reference compound |
| HY-143716 | JAK3/BTK-IN-1 | 2674036-91-8 | Reference compound |
| HY-143717 | JAK3/BTK-IN-2 | 2674036-93-0 | Reference compound |
| HY-143718 | JAK3/BTK-IN-3 | 2674036-98-5 | Reference compound |
| HY-143719 | JAK3/BTK-IN-4 | 2673196-38-6 | Reference compound |
| HY-14372 | BS-194 | 1092443-55-4 | Reference compound |
| HY-143720 | JAK3/BTK-IN-5 | 2673196-75-1 | Reference compound |
| HY-143721 | SSAO inhibitor-2 | 2671028-06-9 | Reference compound |
| HY-143723 | SSAO inhibitor-3 | 2671028-09-2 | Reference compound |
| HY-143726 | RIPK1-IN-8 | 2319663-07-3 | Reference compound |
| HY-143727 | RIPK1-IN-9 | 2682889-57-0 | Reference compound |
| HY-143728 | RIPK1-IN-10 | 2682889-51-4 | Reference compound |
| HY-143729 | EGFR-IN-29 | 2682200-93-5 | Reference compound |
| HY-14373 | CB30865 | 206275-15-2 | Reference compound |
| HY-143730 | BTK inhibitor 20 | 2696450-27-6 | Reference compound |
| HY-143733 | HER2-IN-5 | 2691891-36-6 | Reference compound |
| HY-143734 | HER2-IN-6 | 2691891-38-8 | Reference compound |
| HY-143735 | RAD51-IN-4 | 2267336-26-3 | Reference compound |
| HY-143736 | RAD51-IN-5 | 2690367-19-0 | Reference compound |
| HY-143737 | RAD51-IN-6 | 2690367-57-6 | Reference compound |
| HY-14374 | GPP78 | 1202580-59-3 | Reference compound |
| HY-143741 | RAD51-IN-7 | 2690368-52-4 | Reference compound |
| HY-143743 | Cap-dependent endonuclease-IN-2 | 2303917-78-2 | Reference compound |
| HY-143744 | Suraxavir marboxil | 2364589-86-4 | Reference compound |
| HY-143747 | Cap-dependent endonuclease-IN-5 | 2416258-53-0 | Reference compound |
| HY-143749 | Cap-dependent endonuclease-IN-6 | 2489248-15-7 | Reference compound |
| HY-14375 | CB 300919 | 289715-28-2 | Reference compound |
| HY-143750 | Cap-dependent endonuclease-IN-7 | 2485715-97-5 | Reference compound |
| HY-143752 | Cap-dependent endonuclease-IN-8 | 2454680-16-9 | Reference compound |
| HY-143755 | Cap-dependent endonuclease-IN-9 | 2631005-84-8 | Reference compound |
| HY-143757 | Cap-dependent endonuclease-IN-10 | 2663989-04-4 | Reference compound |
| HY-14376 | Redafamdastat | 1020315-31-4 | Reference compound |
| HY-143762 | Cap-dependent endonuclease-IN-12 | 2460686-97-7 | Reference compound |
| HY-143766 | Cap-dependent endonuclease-IN-13 | 2703046-60-8 | Reference compound |
| HY-143767S | N-Desmethyl Azelastine-d4-1 | | Isotope-Labeled Compounds |
| HY-143768 | Cap-dependent endonuclease-IN-14 | 2740486-73-9 | Reference compound |
| HY-143769 | Cap-dependent endonuclease-IN-15 | 2581298-44-2 | Reference compound |
| HY-143770 | Cap-dependent endonuclease-IN-16 | 2643370-92-5 | Reference compound |
| HY-143771 | Cap-dependent endonuclease-IN-17 | 2649362-71-8 | Reference compound |
| HY-143772S | 4-Hydroxy Aceclofenac-d4 | | Isotope-Labeled Compounds |
| HY-143773S | 5-Hydroxy Imidacloprid-d4 | | Isotope-Labeled Compounds |
| HY-143775 | Cap-dependent endonuclease-IN-20 | 2656435-01-5 | Reference compound |
| HY-143776 | Cap-dependent endonuclease-IN-22 | 2641942-32-5 | Reference compound |
| HY-143777S | (R)-Etodolac-d4 | 1134124-17-6 | Isotope-Labeled Compounds |
| HY-143778S | Clavulanic acid methyl ester-13C,d3 | | Isotope-Labeled Compounds |
| HY-143780S | Oseltamivir-d5 (hydrochloride) | 2140263-19-8 | Isotope-Labeled Compounds |
| HY-143781 | Cap-dependent endonuclease-IN-26 | 1370238-26-8 | Reference compound |
| HY-143782S | Enalaprilat-d5 (maleate) | | Isotope-Labeled Compounds |
| HY-143784S | C14 Benzalkonium-1 acid-13C2,d11 (chloride) | | Isotope-Labeled Compounds |
| HY-143785S | rel-Saxagliptin-15N,d2 (hydrochloride) | 1309934-06-2 | Isotope-Labeled Compounds |
| HY-143786S | Tazobactum ester-13C,d3 | | Isotope-Labeled Compounds |
| HY-143787 | ALOX15-IN-1 | 2764818-24-6 | Reference compound |
| HY-143788S | Pasireotide-d7 (TFA) | | Isotope-Labeled Compounds |
| HY-143789S | Perindopril-d4 | 1356929-58-2 | Isotope-Labeled Compounds |
| HY-143790S | N-2-(Hydroxyethyl)-L-valine-d4 | 120398-50-7 | Isotope-Labeled Compounds |
| HY-143791 | ALOX15-IN-2 | 2764818-23-5 | Reference compound |
| HY-143792 | HTT-D3 | 2254502-89-9 | Reference compound |
| HY-143793 | RBP4 inhibitor 1 | 1198180-03-8 | Reference compound |
| HY-143794S | Levothyroxine-d3 | | Isotope-Labeled Compounds |
| HY-143795S | 1,3-Dinitroglycerin-d5 | 2733972-23-9 | Isotope-Labeled Compounds |
| HY-143796S | (S)-Etodolac-d4 | | Isotope-Labeled Compounds |
| HY-143797S | Almotriptan-d6 (maleate) | | Isotope-Labeled Compounds |
| HY-143798S | R (-) Tolperisone-d10 | 2514950-90-2 | Isotope-Labeled Compounds |
| HY-143799S | 1,2-Dinitroglycerin-d5 | | Isotope-Labeled Compounds |
| HY-14380 | PF-3845 | 1196109-52-0 | Reference compound |
| HY-143800S | S (+) Tolperisone-d10 | | Isotope-Labeled Compounds |
| HY-143801S | N1, N10-Diacetyl triethylenetetramine-d4 | 2733833-08-2 | Isotope-Labeled Compounds |
| HY-143801S1 | N1, N10-Diacetyl triethylenetetramine-d8 | | Isotope-Labeled Compounds |
| HY-143802S | Lovastatin hydroxy-d3 (ammonium) | | Isotope-Labeled Compounds |
| HY-143803S | Oxaflumazine-d8 (disuccinate) | | Isotope-Labeled Compounds |
| HY-143804S | Cefditoren-13C,d3 | | Isotope-Labeled Compounds |
| HY-143805S | (R)-Stiripentol-d9 | | Isotope-Labeled Compounds |
| HY-143807S | (Rac)-Ezetimibe-d4 | | Isotope-Labeled Compounds |
| HY-143808S | (S)-Stiripentol-d9 | | Isotope-Labeled Compounds |
| HY-143809S | Repaglinide M1-d5 | 2519482-60-9 | Isotope-Labeled Compounds |
| HY-143810S | N-Desmethyl Mifepristone-d3 | | Isotope-Labeled Compounds |
| HY-143811S | N-Nitroso-DL-proline-d3 | 65807-08-1 | Isotope-Labeled Compounds |
| HY-143812S | N-Nitroso-3-azabicyclo[3.3.0]octane-d4 | 1346604-35-0 | Isotope-Labeled Compounds |
| HY-143813S | 2-Oxo Prasugrel-d4 (hydrochloride) | 2012598-55-7 | Isotope-Labeled Compounds |
| HY-143815 | m-PEG18-acid | | Reference compound |
| HY-143816S | 4-Hydroxy Atorvastatin-d5 (hemicalcium) | 265989-45-5 | Isotope-Labeled Compounds |
| HY-143817S | Clopidogrel-d3 (hydrochloride) | 2140305-74-2 | Isotope-Labeled Compounds |
| HY-143819 | Propargyl-PEG-amine | 956348-61-1 | Reference compound |
| HY-143820 | Propargyl-PEG-acid | 1421676-62-1 | Reference compound |
| HY-143821 | t-Boc-Aminooxy-PEG4-amine | 2496687-02-4 | Reference compound |
| HY-143822S | N-Methyl-N’-nitrosopiperazine-d4 | 756524-88-6 | Isotope-Labeled Compounds |
| HY-143823S | Pyridoxamine-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143824S | Malachite green-d5 (picrate) | 1258668-21-1 | Isotope-Labeled Compounds |
| HY-143825 | t-Boc-Aminooxy-PEG11-amine | 1630094-83-5 | Reference compound |
| HY-143826S | O-Desmethyl Mebeverine alcohol-d5 (citrate) | | Isotope-Labeled Compounds |
| HY-143827 | Biotin-PEG10-amine | | Reference compound |
| HY-143828 | t-Boc-N-amido-PEG10-Br | 2787474-57-9 | Reference compound |
| HY-143829 | t-Boc-N-amido-PEG15-Br | | Reference compound |
| HY-14383 | Vosilasarm | 1182367-47-0 | Reference compound |
| HY-143830 | t-Boc-N-amido-PEG2-C6-Cl | 920264-35-3 | Reference compound |
| HY-143831S | Cefepime-d8 (sulfate) | 131857-33-5 | Isotope-Labeled Compounds |
| HY-143832 | Cbz-PEG5-Br | 2710803-69-1 | Reference compound |
| HY-143833 | Iodo-PEG7-alcohol | | Reference compound |
| HY-143834S | O-Desacetyl-N-desmethyl Diltiazem-d3 | | Isotope-Labeled Compounds |
| HY-143835 | Acid-PEG9-t-butyl ester | | Reference compound |
| HY-143836 | Acid-PEG10-t-butyl ester | | Reference compound |
| HY-143837 | Acid-PEG12-t-butyl ester | | Reference compound |
| HY-143838 | Acid-PEG14-t-butyl ester | | Reference compound |
| HY-143839S | N-Ethyl-N-nitroso-1-propanamine-d4 | 2733722-83-1 | Isotope-Labeled Compounds |
| HY-143840S | 2-Hydroxy Atorvastatin-d5 (disodium) | 1276537-19-9 | Isotope-Labeled Compounds |
| HY-143841 | Mal-amido-PEG15-acid | | Reference compound |
| HY-143842 | Mal-amido-PEG3-alcohol | | Reference compound |
| HY-143843S | Isosorbide-2-mononitrate-13C6 | 1391051-97-0 | Isotope-Labeled Compounds |
| HY-143844 | Bromo-PEG7-amine | | Reference compound |
| HY-143844B | Bromo-PEG7-amine (hydrobromide) | | Reference compound |
| HY-143848S | Tadalafil-13C,d3 | 1261364-86-6 | Isotope-Labeled Compounds |
| HY-143849 | N-bis(t-boc-N-amido-PEG3)-N-(PEG3-acid) (hydrochloride) | | Reference compound |
| HY-143850S | Methyl diethyldithiocarbamate-d3 | 1246816-30-7 | Isotope-Labeled Compounds |
| HY-143851S | N-Nitrosomethylethylamine-d5 | 69278-56-4 | Isotope-Labeled Compounds |
| HY-143852S | N-Nitrosoethylmethylamine-d3 | 69278-54-2 | Isotope-Labeled Compounds |
| HY-143854S | N-Nitroso-N-methyl-4-aminobutyric acid-d3 | 1184996-41-5 | Isotope-Labeled Compounds |
| HY-143855 | Biotin-PEG10-NHS ester | | Reference compound |
| HY-143856S | Loperamide-d6 | 1189574-93-3 | Isotope-Labeled Compounds |
| HY-143857S | 22:0 Lyso PC-13C6 | 2483735-02-8 | Isotope-Labeled Compounds |
| HY-143858S | Nitrosotetracaine-d6 | | Isotope-Labeled Compounds |
| HY-143859S | Metoprolol dimer-d10 | | Isotope-Labeled Compounds |
| HY-143860S | C14 Benzalkonium chloride -1 acid-d5 | | Isotope-Labeled Compounds |
| HY-143861S | Orphenadrine-d3 | 1185011-75-9 | Isotope-Labeled Compounds |
| HY-143862 | Pparδ agonist 7 | 2340432-40-6 | Reference compound |
| HY-143863 | PPARδ agonist 8 | 2697129-55-6 | Reference compound |
| HY-143864 | S1PR1 agonist 1 | 2700209-37-4 | Reference compound |
| HY-143865 | S1PR1 agonist 2 | 2695535-01-2 | Reference compound |
| HY-143866 | Kallikrein-IN-1 | 1933514-53-4 | Reference compound |
| HY-143867 | Kallikrein-IN-2 | 2702983-84-2 | Reference compound |
| HY-143868 | HPK1-IN-27 | 2268794-52-9 | Reference compound |
| HY-143869 | HPK1-IN-28 | 2699603-89-7 | Reference compound |
| HY-143870 | HPK1-IN-29 | 2699604-50-5 | Reference compound |
| HY-143871 | HPK1-IN-30 | 2700292-56-2 | Reference compound |
| HY-143872 | Bcl-2-IN-4 | 2703134-40-9 | Reference compound |
| HY-143873 | Bcl-2-IN-5 | 2728752-20-1 | Reference compound |
| HY-143874 | HER2-IN-7 | 2387574-01-6 | Reference compound |
| HY-143876S | L-Argininosuccinic acid-13C6,15N4 (barium, dihydrate) | 2483829-90-7 | Isotope-Labeled Compounds |
| HY-143877 | NN-390 | 2490284-25-6 | Reference compound |
| HY-143878 | MRGPRX1 agonist 2 | 302952-43-8 | Reference compound |
| HY-143879 | MRGPRX1 agonist 3 | 2764889-51-0 | Reference compound |
| HY-14388 | PF-232798 | 849753-15-7 | Reference compound |
| HY-143880 | MRGPRX1 agonist 4 | 2764889-60-1 | Reference compound |
| HY-143881 | FGFR4-IN-6 | 2760970-10-1 | Reference compound |
| HY-143882 | MS5033 | 2376137-29-8 | Reference compound |
| HY-143883 | MS143 | 2376137-41-4 | Reference compound |
| HY-143884 | JAK2/TYK2-IN-1 | 2613434-12-9 | Reference compound |
| HY-143885 | JAK1/TYK2-IN-3 | 2734918-37-5 | Reference compound |
| HY-143886 | AD011 | 3010931-91-3 | Reference compound |
| HY-143887 | AD012 | 3010931-94-6 | Reference compound |
| HY-143888 | AD013 | 3010931-81-1 | Reference compound |
| HY-143889 | Senexin C | 2375554-02-0 | Reference compound |
| HY-14389 | LP-261 | 915412-67-8 | Reference compound |
| HY-143890 | MRS4738 | 2801625-42-1 | Reference compound |
| HY-143891 | Chromenone 1 | 1639929-29-5 | Reference compound |
| HY-143892 | Keap1-Nrf2-IN-5 | 2696272-70-3 | Reference compound |
| HY-143893 | Keap1-Nrf2-IN-6 | | Reference compound |
| HY-143894 | FLT3-IN-11 | 2499966-50-4 | Reference compound |
| HY-143895 | FLT3-IN-12 | 2499966-67-3 | Reference compound |
| HY-143896 | STING agonist-7 | 2767442-46-4 | Reference compound |
| HY-143897 | PIM1-IN-3 | 2762767-56-4 | Reference compound |
| HY-143898 | PIM1-IN-4 | 2762767-48-4 | Reference compound |
| HY-143899 | FBA-IN-1 | 2605897-57-0 | Reference compound |
| HY-14390 | LAS101057 | 925676-48-8 | Reference compound |
| HY-143900 | BTK-IN-7 | 2952702-39-3 | Reference compound |
| HY-143901 | EGFR-IN-40 | 1466445-39-5 | Reference compound |
| HY-143902 | ZL-Pin01 | 1047464-92-5 | Reference compound |
| HY-143903 | ZL-Pin13 | 2883498-73-3 | Reference compound |
| HY-143904 | PROTAC TTK degrader-1 | 2953426-43-0 | Reference compound |
| HY-143905 | PROTAC TTK degrader-2 | 2953426-48-5 | Reference compound |
| HY-143906 | URAT1 inhibitor 2 | 2803951-18-8 | Reference compound |
| HY-143907S | Atorvastatin EP impurity H-d5 | | Isotope-Labeled Compounds |
| HY-143909S | Di(2-ethylhexyl) azelate-d14 | | Isotope-Labeled Compounds |
| HY-14391 | PSI-353661 | 1231747-08-2 | Reference compound |
| HY-143910S | Azelaic acid 2-ethylhexyl monoester-d14 | | Isotope-Labeled Compounds |
| HY-143911S | Acetaminophen glucuronide-d3 | 1260981-52-9 | Isotope-Labeled Compounds |
| HY-143912S | Aclonifen-d5 | 2469279-06-7 | Isotope-Labeled Compounds |
| HY-143913S | Aripiprazole metabolite-d6 | | Isotope-Labeled Compounds |
| HY-143914S | N-Nitroso-Acebutolol-d7 | | Isotope-Labeled Compounds |
| HY-143915S | Amitriptyline-N-glucuronide-d3 | | Isotope-Labeled Compounds |
| HY-143916S | AMX208-d3 | 2643376-30-9 | Isotope-Labeled Compounds |
| HY-143917S | (Rac)-Aprepitant-d4 | 2748471-42-1 | Isotope-Labeled Compounds |
| HY-143918S | 4'-Hydroxy Atomoxetine-d3 (hemioxalate) | | Isotope-Labeled Compounds |
| HY-143919S | Sulfosate-d9 | | Isotope-Labeled Compounds |
| HY-14392 | 5,6-Dichlorobenzimidazole riboside | 53-85-0 | Oligonucleotides |
| HY-143921S | Almorexant (αS,1S) isomer-13C,d3 | | Isotope-Labeled Compounds |
| HY-143922S | N-Desmethyl Bedaquiline-d6 | 2271264-26-5 | Isotope-Labeled Compounds |
| HY-143923S | Belinostat amide-d5 | | Isotope-Labeled Compounds |
| HY-143924S | Belinostat acid-d5 | 2130853-04-0 | Isotope-Labeled Compounds |
| HY-143925S | Betahistine impurity 5-13C,d3 | | Isotope-Labeled Compounds |
| HY-143926S | Methyl Belinostat-d5 | | Isotope-Labeled Compounds |
| HY-143927S | Belinostat glucuronide-d5 | | Isotope-Labeled Compounds |
| HY-143928S | 4-Hydroxy biphenyl sulfate-d5 (sodium) | | Isotope-Labeled Compounds |
| HY-143929S | Bazedoxifene-5-glucuronide-d4 | | Isotope-Labeled Compounds |
| HY-14393 | Emodin | 518-82-1 | Natural Products |
| HY-143930S | Dihydroxy Bendamustine-d8 | | Isotope-Labeled Compounds |
| HY-143931S | N-Desmethyl citalopram-d4 (oxalate) | 2747915-54-2 | Isotope-Labeled Compounds |
| HY-143932S | Desmethyl Bendamustine-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143933S | Sulfociprofloxacin-d8 (triethylamine) | | Isotope-Labeled Compounds |
| HY-143934S | 4-Oxo cyclophosphamide-d8 | | Isotope-Labeled Compounds |
| HY-143935S | 7-Hydroxycoumarin sulfate-d5 | 1215683-02-5 | Isotope-Labeled Compounds |
| HY-143936S | Chloroxuron-d6 | 2030182-44-4 | Isotope-Labeled Compounds |
| HY-143937S | Carbidopa-d3 | 1276732-89-8 | Isotope-Labeled Compounds |
| HY-143938S | Cyclobenzaprine impurity 2-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143939S | DL-Glutaryl carnitine-13C,d3 | | Isotope-Labeled Compounds |
| HY-14393R | Emodin (Standard) | 518-82-1 | Reference Standards |
| HY-14393S | Emodin-d4 | 132796-52-2 | Isotope-Labeled Compounds |
| HY-14394 | TBB | 17374-26-4 | Reference compound |
| HY-143940S | Cabergoline isomer-d6 | | Isotope-Labeled Compounds |
| HY-143941S | Hydroxychloroquine EP impurity D-d5 (dihydrochloride) | | Isotope-Labeled Compounds |
| HY-143942S | Cefditoren-d3 | | Isotope-Labeled Compounds |
| HY-143943S | Felodipine 3,5-dimethyl ester-13C2,d6 | | Isotope-Labeled Compounds |
| HY-143949S | (Rac)-N-desmethyl Dapoxetine-d7 (hydrochloride) | 2747915-74-6 | Isotope-Labeled Compounds |
| HY-143950S | DOTAP-d9 (iodide) | | Isotope-Labeled Compounds |
| HY-143951S | Disulfiram impurity 1-d10 | 2749799-73-1 | Isotope-Labeled Compounds |
| HY-143952S | 9-Dihydroestradiol-d3 | | Isotope-Labeled Compounds |
| HY-143953S | Estrone ß-D-Glucuronide-d4 (lithium) | | Isotope-Labeled Compounds |
| HY-143954S | Epinephrine impurity 19-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143955S | Ebastine-d5 (fumarate) | 1316815-02-7 | Isotope-Labeled Compounds |
| HY-143956S | Fluorofenidone impurity 1-d3 | | Isotope-Labeled Compounds |
| HY-143957S | Fenretinide glucuronide-d4 | 2118244-60-1 | Isotope-Labeled Compounds |
| HY-143958S | 4'-Hydroxy Fenretinide-d4 | 2714413-41-7 | Isotope-Labeled Compounds |
| HY-143959S | Fingolimod Mono-lactate-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143960S | Givinostat impurity 1-d10 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143961S | Givinostat impurity 5-d4 | | Isotope-Labeled Compounds |
| HY-143963S | Irbesartan impurity 20-d4 | | Isotope-Labeled Compounds |
| HY-143964S | Irbesartan impurity 14-d4 | | Isotope-Labeled Compounds |
| HY-143965S | Imidacloprid impurity 2-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143966S | 5-Hydroxy Indapamide-13C,d3 | | Isotope-Labeled Compounds |
| HY-143967S | Iloperidone metabolite P95-13C,d3 | 2747914-96-9 | Isotope-Labeled Compounds |
| HY-143968S | Ketotifen impurity 3-d4 | | Isotope-Labeled Compounds |
| HY-143969S | KL140061A-d4 | | Isotope-Labeled Compounds |
| HY-14397 | Indomethacin | 53-86-1 | Reference compound |
| HY-143970S | Ivabradine impurity 7-d6 | 2733718-12-0 | Isotope-Labeled Compounds |
| HY-143971S | Glycinexylidide-d6 | 1217098-46-8 | Isotope-Labeled Compounds |
| HY-143972S | 7-Hydroxy loxapine-d8 | | Isotope-Labeled Compounds |
| HY-143973S | Iacvita-d10 | | Isotope-Labeled Compounds |
| HY-143974S | Imiquimod impurity 1-d6 | | Isotope-Labeled Compounds |
| HY-143975S | Loxapine impurity 2-d8 | | Isotope-Labeled Compounds |
| HY-143976S | 3-Hydroxy imiquimod-d4 | | Isotope-Labeled Compounds |
| HY-143977S | Loxapine impurity 3-d8 (iodide) | | Isotope-Labeled Compounds |
| HY-143978S | cis-4’-Hydroxy CCNU Lomustine-d4 | | Isotope-Labeled Compounds |
| HY-143979S | 1-(2-Chloroethyl)-3-((1R,4R)-4-hydroxycyclohexyl)-1-nitrosourea-d4 | | Isotope-Labeled Compounds |
| HY-14397A | Indomethacin (sodium hydrate) | 74252-25-8 | Reference compound |
| HY-14397AR | Indomethacin (sodium hydrate) (Standard) | 74252-25-8 | Reference Standards |
| HY-14397G | Indomethacin (GMP) | 53-86-1 | GMP Small Molecules |
| HY-14397R | Indomethacin (Standard) | 53-86-1 | Reference Standards |
| HY-14397S | Indomethacin-d4 | 87377-08-0 | Isotope-Labeled Compounds |
| HY-14397S1 | Indomethacin-d4 Methyl Ester | 1217064-61-3 | Isotope-Labeled Compounds |
| HY-14397S2 | Indometacin-d7 | | Isotope-Labeled Compounds |
| HY-14397S3 | Indomethacin-13C6 | | Isotope-Labeled Compounds |
| HY-14398 | Celecoxib | 169590-42-5 | Reference compound |
| HY-143980S | Losartan impurity 21-d4 | | Isotope-Labeled Compounds |
| HY-143981S | 15-Hydroxy Lubiprostone-d7 | 1217511-55-1 | Isotope-Labeled Compounds |
| HY-143982S | Mianserin EP impurity E-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143983S | Desmethyl Mirtazapine-d4 (hydrochloride) | 1188266-12-7 | Isotope-Labeled Compounds |
| HY-143984S | Minodronic acid impurity 2-d4 | | Isotope-Labeled Compounds |
| HY-143985S | Maytansinoid DM4 impurity 5-d6 | | Isotope-Labeled Compounds |
| HY-143986S | DM50 impurity 1-d9 | | Isotope-Labeled Compounds |
| HY-143986S1 | DM50 impurity 1-d9-1 | | Isotope-Labeled Compounds |
| HY-143987 | DM51 impurity 1 | | Reference compound |
| HY-143987S | DM51 impurity 1-d9 | | Isotope-Labeled Compounds |
| HY-143988S | Nefazodone impurity 3-d6 | | Isotope-Labeled Compounds |
| HY-143989S | N,N-Didesmethyl Mifepristone-d4 | | Isotope-Labeled Compounds |
| HY-14398G | Celecoxib (GMP) | 169590-42-5 | GMP Small Molecules |
| HY-14398GL | Celecoxib (GMP Like) | 169590-42-5 | GMP Small Molecules |
| HY-14398R | Celecoxib (Standard) | 169590-42-5 | Reference Standards |
| HY-14398S | Celecoxib-d7 | 544686-21-7 | Isotope-Labeled Compounds |
| HY-14398S1 | Celecoxib-d3 | 544686-18-2 | Isotope-Labeled Compounds |
| HY-14399 | Itanapraced | 749269-83-8 | Reference compound |
| HY-143990S | Modafinil EP impurity B-d5 | 1329496-95-8 | Isotope-Labeled Compounds |
| HY-143991S | Modafinil acid sulfone-d5 | 2747915-46-2 | Isotope-Labeled Compounds |
| HY-143992S | Maytansinoid DM4 impurity 2-d6 | | Isotope-Labeled Compounds |
| HY-143993S | Maytansinoid DM4 impurity 3-d6 | | Isotope-Labeled Compounds |
| HY-143994S | Metopimazine acid-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143995S | Nuarimol-d4 | | Isotope-Labeled Compounds |
| HY-143996S | Mevalonic acid-13C,d3 (sodium) | 2747918-57-4 | Isotope-Labeled Compounds |
| HY-143997S | (Rac)-Nicotine EP impurity A-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-143999S | Norgestimate-d3 | | Isotope-Labeled Compounds |
| HY-144000 | DSPE-PEG-PDP | 474922-24-2 | Biochemical Assay Reagents |
| HY-144000A | DSPE-PEG2000-PDP | 474922-24-2 | Biochemical Assay Reagents |
| HY-144001 | DSPE-PEG-Carboxylic Acid | 474922-20-8 | Biochemical Assay Reagents |
| HY-144002 | RIBI-529 | 216014-46-9 | Biochemical Assay Reagents |
| HY-144003 | BAY-R 1005 | 294664-93-0 | Biochemical Assay Reagents |
| HY-144004 | DSPE-PEG2000-Mal (ammonium) | 474922-22-0 | Biochemical Assay Reagents |
| HY-144004A | DSPE-PEG5000-Mal (ammonium) | 474922-22-0 | Biochemical Assay Reagents |
| HY-144005 | C16 PEG2000 Ceramide | 212116-78-4 | Biochemical Assay Reagents |
| HY-144005A | C16 PEG750 Ceramide | 212116-78-4 | Biochemical Assay Reagents |
| HY-144005B | C16 PEG5000 Ceramide | 212116-78-4 | Biochemical Assay Reagents |
| HY-144006 | DMPE-PEG2000 | 474922-82-2 | Biochemical Assay Reagents |
| HY-144007 | Chol-PEG | 27321-96-6 | Biochemical Assay Reagents |
| HY-144008 | C8 PEG-Ceramide | 212116-76-2 | Biochemical Assay Reagents |
| HY-144008A | C8 PEG5000 Ceramide | 212116-76-2 | Biochemical Assay Reagents |
| HY-144008B | C8 PEG750 Ceramide | 212116-76-2 | Reference compound |
| HY-144009 | DSPE-PEG-Folate, MW 3350 | 1236288-25-7 | Biochemical Assay Reagents |
| HY-14401 | Encaleret | 787583-71-5 | Reference compound |
| HY-144010 | 18:1 PEG2000 PE | 474922-90-2 | Biochemical Assay Reagents |
| HY-144011 | DSPE-PEG-Cyanur | 1246304-74-4 | Biochemical Assay Reagents |
| HY-144012 | DPPE-PEG2000 | 474922-84-4 | Biochemical Assay Reagents |
| HY-144012A | DPPE-PEG350 | 474922-84-4 | Biochemical Assay Reagents |
| HY-144012B | DPPE-PEG550 | 474922-84-4 | Biochemical Assay Reagents |
| HY-144012C | DPPE-PEG750 | 474922-84-4 | Biochemical Assay Reagents |
| HY-144012D | DPPE-PEG1000 | 474922-84-4 | Biochemical Assay Reagents |
| HY-144012E | DPPE-PEG3000 | 474922-84-4 | Biochemical Assay Reagents |
| HY-144012H | DPPE-PEG5000 | 474922-84-4 | Biochemical Assay Reagents |
| HY-144013 | 18:0 mPEG2000 PE (ammonium) | 474922-77-5 | Biochemical Assay Reagents |
| HY-144013A | 18:0 mPEG350 PE (ammonium) | 474922-77-5 | Biochemical Assay Reagents |
| HY-144013B | 18:0 mPEG550 PE (ammonium) | 474922-77-5 | Biochemical Assay Reagents |
| HY-144013C | 18:0 mPEG750 PE (ammonium) | 474922-77-5 | Biochemical Assay Reagents |
| HY-144013D | 18:0 mPEG1000 PE (ammonium) | 474922-77-5 | Biochemical Assay Reagents |
| HY-144013E | 18:0 mPEG3000 PE (ammonium) | 474922-77-5 | Biochemical Assay Reagents |
| HY-144013H | 18:0 mPEG5000 PE (ammonium) | 474922-77-5 | Biochemical Assay Reagents |
| HY-144014 | MVL5 | 464926-03-2 | Biochemical Assay Reagents |
| HY-144015 | 14:1 EPC (trifluoromethanesulfonate) | 1246304-44-8 | Biochemical Assay Reagents |
| HY-144016 | 16:0 EPC (chloride) | 328250-18-6 | Biochemical Assay Reagents |
| HY-144017 | 12:0 EPC (chloride) | 474945-22-7 | Biochemical Assay Reagents |
| HY-144018 | 18:1 EPC (chloride) | 474945-24-9 | Biochemical Assay Reagents |
| HY-144019 | 18:0 EPC (chloride) | 328268-13-9 | Biochemical Assay Reagents |
| HY-144020 | 14:0 DAP | 72719-84-7 | Biochemical Assay Reagents |
| HY-144021 | 14:0 EPC (chloride) | 186492-53-5 | Biochemical Assay Reagents |
| HY-144022 | 16:0 DAP | 96326-74-8 | Biochemical Assay Reagents |
| HY-144023 | 16:0-18:1 EPC (chloride) | 328250-19-7 | Biochemical Assay Reagents |
| HY-144024S | 5-PAHSA-d9 | 1809226-17-2 | Isotope-Labeled Compounds |
| HY-144025 | DOBAQ | 1360461-69-3 | Biochemical Assay Reagents |
| HY-144026S | 9-PAHSA-d9 | 1809222-43-2 | Isotope-Labeled Compounds |
| HY-144027 | Dolichol (13~21) | 153857-77-3 | Biochemical Assay Reagents |
| HY-144028 | Pan-Trk-IN-2 | 2583778-77-0 | Reference compound |
| HY-144029 | RET-IN-13 | 2684258-54-4 | Reference compound |
| HY-14403 | ERK5-IN-1 | 1234479-76-5 | Reference compound |
| HY-144030 | RET-IN-12 | 2684252-55-7 | Reference compound |
| HY-144031S | Tyk2-IN-8 | 2704587-24-4 | Isotope-Labeled Compounds |
| HY-144032 | Tyk2-IN-9 | 2694816-85-6 | Reference compound |
| HY-144033 | GLP-1R agonist 1 | 2711019-49-5 | Reference compound |
| HY-144034 | GLP-1R agonist 3 | 2428640-18-8 | Reference compound |
| HY-144035 | GLP-1R agonist 4 | 2401894-26-4 | Reference compound |
| HY-144036 | DNA-PK-IN-3 | 2734846-19-4 | Reference compound |
| HY-144037 | DNA-PK-IN-4 | 2722645-10-3 | Reference compound |
| HY-144038 | DNA-PK-IN-5 | 2719736-43-1 | Reference compound |
| HY-144039 | DNA-PK-IN-6 | 2711810-41-0 | Reference compound |
| HY-144040 | CSF1R-IN-4 | 2716185-86-1 | Reference compound |
| HY-144041 | CSF1R-IN-5 | 2716184-93-7 | Reference compound |
| HY-144042 | CSF1R-IN-6 | 2716184-87-9 | Reference compound |
| HY-144043 | ALK5-IN-8 | 2705900-81-6 | Reference compound |
| HY-144044 | EGFR-IN-30 | 2726463-68-7 | Reference compound |
| HY-144045 | HBV-IN-14 | 2712529-19-4 | Reference compound |
| HY-144046 | HBV-IN-15 | 2413192-50-2 | Reference compound |
| HY-144047 | HBV-IN-16 | 2355225-38-4 | Reference compound |
| HY-144048 | EGFR-IN-31 | 2701563-03-1 | Reference compound |
| HY-144049 | EGFR-IN-32 | 2701553-78-6 | Reference compound |
| HY-14405 | Casopitant | 414910-27-3 | Reference compound |
| HY-144050 | EGFR-IN-33 | 2711105-59-6 | Reference compound |
| HY-144051 | EGFR-IN-34 | | Reference compound |
| HY-144052 | EGFR-IN-35 | 2711105-57-4 | Reference compound |
| HY-144053 | EGFR-IN-36 | 2711105-54-1 | Reference compound |
| HY-144054 | EGFR-IN-37 | 2711105-53-0 | Reference compound |
| HY-144055 | EGFR-IN-38 | 2711105-50-7 | Reference compound |
| HY-144056 | EGFR-IN-39 | 2711105-48-3 | Reference compound |
| HY-144057 | JAK-IN-17 | | Reference compound |
| HY-144058 | JAK-IN-18 | 2247925-32-0 | Reference compound |
| HY-144059 | AKT-IN-9 | 2709045-53-2 | Reference compound |
| HY-14405A | Casopitant (mesylate) | 414910-30-8 | Reference compound |
| HY-14405B | (R)-Casopitant | 414910-26-2 | Reference compound |
| HY-144060 | AKT-IN-10 | 2709045-56-5 | Reference compound |
| HY-144061 | INSCoV-601I(1) | 2735704-19-3 | Reference compound |
| HY-144062 | INSCoV-614(1B) | 2735704-33-1 | Reference compound |
| HY-144063 | INSCoV-600K(1) | 2735704-15-9 | Reference compound |
| HY-144064 | Adenosine receptor antagonist 2 | 2703054-47-9 | Reference compound |
| HY-144065 | Cap-dependent endonuclease-IN-19 | 2567929-06-8 | Reference compound |
| HY-144066 | Cap-dependent endonuclease-IN-21 | 2741952-35-0 | Reference compound |
| HY-144067 | Cap-dependent endonuclease-IN-23 | 2741952-36-1 | Reference compound |
| HY-144068 | Cap-dependent endonuclease-IN-25 | 2415788-71-3 | Reference compound |
| HY-144069 | Pan-Trk-IN-3 | 2763637-66-5 | Reference compound |
| HY-14406A | L-733060 (hydrochloride) | 148687-76-7 | Reference compound |
| HY-14407 | Fosaprepitant | 172673-20-0 | Reference compound |
| HY-144070 | ErSO-DFP | 2768139-76-8 | Reference compound |
| HY-144070A | (Rac)-ErSO-DFP | 2768139-73-5 | Reference compound |
| HY-144071 | MurB-IN-1 | 2883232-46-8 | Reference compound |
| HY-144072 | MRS4620 | 2411665-73-9 | Reference compound |
| HY-144073 | HPK1-IN-21 | 2413804-83-6 | Peptides |
| HY-144074 | LRRK2-IN-4 | 2641054-59-1 | Reference compound |
| HY-144075 | JAK-IN-19 | | Reference compound |
| HY-144076 | t-Boc-amido-PEG10-acid | | Reference compound |
| HY-144077 | Bromo-PEG7-CH2COOtBu | | Reference compound |
| HY-144078 | Bromo-PEG8-CH2COOtBu | | Reference compound |
| HY-144079 | Bromo-C4-PEG4-t-butyl ester | | Reference compound |
| HY-14407A | Fosaprepitant (dimeglumine) | 265121-04-8 | Reference compound |
| HY-14407AR | Fosaprepitant (dimeglumine) (Standard) | 265121-04-8 | Reference Standards |
| HY-14407AS | Fosaprepitant-d4 (dimeglumine) | | Isotope-Labeled Compounds |
| HY-14408 | Lu AA47070 | 913842-25-8 | Reference compound |
| HY-144080 | Bromo-PEG5-CH2COOtBu | | Reference compound |
| HY-144081 | HO-PEG18-OH | 4445-03-8 | Reference compound |
| HY-144082 | C18-PEG13-acid | | Reference compound |
| HY-144083S | L-Carnitine(mono)-O-3-dl-hydroxypalmitoyl-d3 (perchlorate) | 2245711-29-7 | Isotope-Labeled Compounds |
| HY-144084S | L-Carnitine(mono)-O-glutaryl-d3 (perchlorate) | 2245711-21-9 | Isotope-Labeled Compounds |
| HY-144085S | D-Fructose-6-phosphate-13C6 (disodium x.hydrate) | | Isotope-Labeled Compounds |
| HY-144086S | 22:0 Lyso-PC-d4 | 2483831-14-5 | Isotope-Labeled Compounds |
| HY-144087 | TYK2-IN-11 | 2757009-40-6 | Reference compound |
| HY-144088 | ZYF0033 | 2380300-79-6 | Reference compound |
| HY-14409 | Lu AA41063 | 851202-49-8 | Reference compound |
| HY-144091 | HPK1-IN-24 | 2294966-07-5 | Reference compound |
| HY-144092 | HPK1-IN-25 | 2403600-50-8 | Reference compound |
| HY-144093 | HPK1-IN-26 | 2229042-24-2 | Reference compound |
| HY-144096 | EZH2-IN-11 | 2387402-80-2 | Reference compound |
| HY-144097 | HER2-IN-8 | 2704630-49-7 | Reference compound |
| HY-144098 | HDAC8-IN-2 | 2824131-20-4 | Reference compound |
| HY-144099 | Keap1-Nrf2-IN-4 | 2851480-01-6 | Reference compound |
| HY-144100 | β-Lactamase-IN-7 | 2419903-21-0 | Reference compound |
| HY-144102 | HDAC-IN-29 | 2695593-95-2 | Reference compound |
| HY-144103 | Neuraminidase-IN-4 | | Reference compound |
| HY-144104 | NSC90616 | | Reference compound |
| HY-144105 | NSC405640 | 1135-99-5 | Reference compound |
| HY-144106 | HCV-IN-33 | 2757963-83-8 | Reference compound |
| HY-144107 | HCV-IN-34 | 2425805-22-5 | Reference compound |
| HY-144108 | HCV-IN-35 | 2757963-82-7 | Reference compound |
| HY-144109 | HCV-IN-36 | 2757963-81-6 | Reference compound |
| HY-14411 | JNK-1-IN-1 | 1262406-02-9 | Reference compound |
| HY-144110 | HCV-IN-37 | 2425804-98-2 | Reference compound |
| HY-144111 | PPARα/δ agonist 1 | 2760128-48-9 | Reference compound |
| HY-144112 | HIV-1 inhibitor-13 | 2761172-60-3 | Reference compound |
| HY-144113 | HIV-1 inhibitor-14 | 2761172-65-8 | Reference compound |
| HY-144115 | A1AR antagonist 1 | 2760128-99-0 | Reference compound |
| HY-144116 | A1AR antagonist 2 | 1441961-74-5 | Reference compound |
| HY-144117 | GFB-12811 | 2775311-17-4 | Reference compound |
| HY-144118 | Cas9-IN-1 | 2866499-55-8 | Reference compound |
| HY-144119 | Cas9-IN-2 | 1030133-34-6 | Reference compound |
| HY-14412 | p38α inhibitor 4 | 1262406-08-5 | Reference compound |
| HY-144120 | αGalCer-RBD | | Reference compound |
| HY-144121 | Ph-Ph+ | | Reference compound |
| HY-144122 | HIV-1 inhibitor-15 | 2757182-99-1 | Reference compound |
| HY-144123 | HIV-1 inhibitor-16 | 2719675-72-4 | Reference compound |
| HY-144124 | 5-C-heptyl-DNJ | 2734265-63-3 | Reference compound |
| HY-144125 | Antitumor agent-41 | | Reference compound |
| HY-144126 | S1P1 agonist 5 | 2760666-20-2 | Reference compound |
| HY-144127 | AR antagonist 3 | 349573-58-6 | Reference compound |
| HY-144128 | hGGPPS-IN-1 | 1429012-38-3 | Reference compound |
| HY-144129 | hGGPPS-IN-2 | 2241547-82-8 | Reference compound |
| HY-14413 | SR3335 | 293753-05-6 | Reference compound |
| HY-144130 | hGGPPS-IN-3 | 2763223-96-5 | Reference compound |
| HY-144131 | RET-IN-11 | 2764891-88-3 | Reference compound |
| HY-144132 | αβ-Tubulin-IN-1 | 2478584-74-4 | Reference compound |
| HY-144133 | GLP-1R agonist 5 | 2749609-30-9 | Reference compound |
| HY-144134 | GLP-1R agonist 6 | 2755653-78-0 | Reference compound |
| HY-144135 | GLP-1R agonist 7 | 2749608-65-7 | Reference compound |
| HY-144136 | GLP-1R agonist 8 | 2736446-82-3 | Reference compound |
| HY-144137 | Estrogen receptor antagonist 1 | 2751609-45-5 | Reference compound |
| HY-144138 | Estrogen receptor antagonist 2 | 2735803-90-2 | Reference compound |
| HY-144139 | Estrogen receptor antagonist 3 | 2730011-50-2 | Reference compound |
| HY-14414 | GSK4112 | 1216744-19-2 | Reference compound |
| HY-144140S | 4-Nitroso hydrochlorothiazide-13C,15N2,d2 | | Isotope-Labeled Compounds |
| HY-144141S | Nortriptyline impurity 3-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144142S | Orphenadrine impurity 6-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144143S | N-Desmethyl Olopatadine-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144144S | (E)-N-Desmethyl Olopatadine-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144145S | Hydroxy Pioglitazone (M-II)-d4 | 2747917-81-1 | Isotope-Labeled Compounds |
| HY-144146S | Pramipexole impurity 7-d10 | | Isotope-Labeled Compounds |
| HY-144147S | N-Methyl Quinidine-d3 (iodide) | | Isotope-Labeled Compounds |
| HY-144148S | Pyroxsulam-13C,d3 | | Isotope-Labeled Compounds |
| HY-144149S | 3'-p-Hydroxy paclitaxel-d5 | | Isotope-Labeled Compounds |
| HY-14415 | SR8278 | 1254944-66-5 | Reference compound |
| HY-144150S | Pelubiprofen impurity 2-13C2,d6 | | Isotope-Labeled Compounds |
| HY-144151S | Phenylsulfate-d5 (sodium) | | Isotope-Labeled Compounds |
| HY-144152S | Catechol sulfate-d4 (sodium) | | Isotope-Labeled Compounds |
| HY-144153S | S-(1,2-Dichlorovinyl)glutathione-13C2,15N | | Isotope-Labeled Compounds |
| HY-144154S | (Rac)-Rivastigmine-d6 (tartrate) | | Isotope-Labeled Compounds |
| HY-144155S | 5-Hydroxy Rosiglitazone-d4 | 1246817-46-8 | Isotope-Labeled Compounds |
| HY-144155S1 | 5-Hydroxy Rosiglitazone-d4-1 | 1794759-89-9 | Isotope-Labeled Compounds |
| HY-144156S | 7-Hydroxy Ropinirole-d14 | | Isotope-Labeled Compounds |
| HY-144157S | N-Acetyl Retigabine-d3 (dihydrochloride) | 2749395-13-7 | Isotope-Labeled Compounds |
| HY-144158S | Resveratrol 3-sulfate-d4 (triethylamine) | | Isotope-Labeled Compounds |
| HY-144159S | Resveratrol 3,5-diglucuronide-d4 | | Isotope-Labeled Compounds |
| HY-144161S | (Rac)-Ramosetron-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144162S | (Rac)-Selegiline-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144163S | Descarbon Sildenafil-d3 | | Isotope-Labeled Compounds |
| HY-144164S | Sumatriptan-d6 (hemisuccinate) | 1397195-80-0 | Isotope-Labeled Compounds |
| HY-144165S | Silodosin metabolite-d4 | | Isotope-Labeled Compounds |
| HY-144166S | Silodosin glucuronide-d4 (lithium) | | Isotope-Labeled Compounds |
| HY-144167S | Methiocarb sulfone-d3 | 2733969-33-8 | Isotope-Labeled Compounds |
| HY-144168 | STING agonist-8 | 2745723-90-2 | Reference compound |
| HY-144168A | STING agonist-8 (dihydrochloride) | | Reference compound |
| HY-144169 | DHODH-IN-19 | 2742675-85-8 | Reference compound |
| HY-14417 | VU0155041 | 1093757-42-6 | Reference compound |
| HY-144170 | RET-IN-14 | 2755843-62-8 | Reference compound |
| HY-144171S | Meobal-d3 | | Isotope-Labeled Compounds |
| HY-144172S | XMC-d3 | | Isotope-Labeled Compounds |
| HY-144173S | 2,3,5-Trimethacarb-d3 | | Isotope-Labeled Compounds |
| HY-144174S | Methylacifluorfen-d3 | | Isotope-Labeled Compounds |
| HY-144175 | CDK7-IN-12 | 2750638-94-7 | Reference compound |
| HY-144176 | HIF-2α-IN-5 | 2388500-66-9 | Reference compound |
| HY-144177S | Benzthiazuron-d3 | | Isotope-Labeled Compounds |
| HY-144178 | HIF-2α-IN-6 | 2755401-07-9 | Reference compound |
| HY-144179 | MAT2A-IN-4 | 2439272-57-6 | Reference compound |
| HY-14417A | (1R,2S)-VU0155041 | 1263273-14-8 | Reference compound |
| HY-14417B | VU0155041 (sodium) | 1259372-69-4 | Reference compound |
| HY-14418 | VU0361737 | 1161205-04-4 | Reference compound |
| HY-144180S | Fluometuron-desmethyl-d3 | | Isotope-Labeled Compounds |
| HY-144181 | MAT2A-IN-5 | 2756458-55-4 | Reference compound |
| HY-144182S | Metoxuron-monomethyl-d3 | | Isotope-Labeled Compounds |
| HY-144184 | MAT2A-IN-6 | 2756458-72-5 | Reference compound |
| HY-144185 | MAT2A-IN-7 | 2756458-77-0 | Reference compound |
| HY-144186S | Bromuron-d6 | 2030182-53-5 | Isotope-Labeled Compounds |
| HY-144187 | PRMT5-IN-16 | 2755304-16-4 | Reference compound |
| HY-144188 | PRMT5-IN-17 | 2755304-03-9 | Reference compound |
| HY-144189 | PRMT5-IN-18 | 2756849-68-8 | Reference compound |
| HY-14419 | TCN238 | 125404-04-8 | Reference compound |
| HY-144190 | MIF-IN-1 | 851095-20-0 | Reference compound |
| HY-144191S | Dichlorprop-methyl ester-d3 | | Isotope-Labeled Compounds |
| HY-144192S | MCPA methyl ester-d3 | | Isotope-Labeled Compounds |
| HY-144193S | MCPP methyl ester-d3 | | Isotope-Labeled Compounds |
| HY-144194 | MIF-IN-2 | 2756410-57-6 | Reference compound |
| HY-144195 | MIF-IN-3 | 2756410-83-8 | Reference compound |
| HY-144196 | MIF-IN-4 (hydrochloride) | 2489514-05-6 | Reference compound |
| HY-144197 | CCR8 antagonist 1 | 723304-76-5 | Reference compound |
| HY-144198S | Saxagliptin-13C,d2 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144199S | 5-Hydroxy Saxagliptin-13C,d2 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144200 | CCR8 antagonist 2 | 2756350-98-6 | Reference compound |
| HY-144201S | Serotonin glucuronide-d4 | 1620326-22-8 | Isotope-Labeled Compounds |
| HY-144202 | Estrogen receptor antagonist 4 | 2730011-45-5 | Reference compound |
| HY-144203S | Trospium EP impurity C-d8 (chloride) | | Isotope-Labeled Compounds |
| HY-144204 | Estrogen receptor antagonist 5 | 2136600-69-4 | Reference compound |
| HY-144205 | TRPC5-IN-2 | 2304552-99-4 | Reference compound |
| HY-144206 | Estrogen receptor antagonist 6 | 2136600-70-7 | Reference compound |
| HY-144207 | SOS1-IN-9 | 2758900-76-2 | Reference compound |
| HY-144208 | TRPC5-IN-3 | 2758126-11-1 | Reference compound |
| HY-144209 | CD73-IN-6 | 2757808-96-9 | Reference compound |
| HY-144210 | SOS1-IN-6 | 2751718-88-2 | Reference compound |
| HY-144211 | SOS1-IN-7 | 2755415-30-4 | Reference compound |
| HY-144212 | SOS1-IN-8 | 2759387-92-1 | Reference compound |
| HY-144213 | SOS1-IN-10 | 2758690-15-0 | Reference compound |
| HY-144214 | ATR-IN-10 | 2713577-93-4 | Reference compound |
| HY-144215 | TLR8 agonist 4 | 2761697-69-0 | Reference compound |
| HY-144216S | (S)-Cetirizine-d4 (dihydrochloride) | | Isotope-Labeled Compounds |
| HY-144217 | SKLB-197 | 2713577-16-1 | Reference compound |
| HY-144219S | Dehydro trospium-d10 (chloride) | | Isotope-Labeled Compounds |
| HY-14422 | SR1078 | 1246525-60-9 | Reference compound |
| HY-144220 | NLRP3/AIM2-IN-1 | | Reference compound |
| HY-144221S | Tiotropium bromide EP impurity A-d6 | | Isotope-Labeled Compounds |
| HY-144222 | NSC 828467 | | Reference compound |
| HY-144223 | NLRP3/AIM2-IN-2 | 791840-86-3 | Reference compound |
| HY-144224S | Tianeptine-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144225 | Anticancer agent 26 | | Reference compound |
| HY-144226 | NLRP3/AIM2-IN-3 | 1787787-60-3 | Reference compound |
| HY-144227 | Anticancer agent 27 | 2768083-61-8 | Reference compound |
| HY-144228S | Hydroxy Tipelukast-d6 | 2714417-27-1 | Isotope-Labeled Compounds |
| HY-144228S1 | Hydroxy Tipelukast-d6 (sodium) | 2714473-19-3 | Isotope-Labeled Compounds |
| HY-144229 | trans-Cephalosporin | 2757462-75-0 | Reference compound |
| HY-14423 | Velneperit | 342577-38-2 | Reference compound |
| HY-144230S | Thiorphan methoxyacetophenone-d5 | 1398044-41-1 | Isotope-Labeled Compounds |
| HY-144232 | Anticancer agent 28 | 2768083-57-2 | Reference compound |
| HY-144233S | N1-Acetyl triethylenetetramine-d8 (trihydrochloride) | | Isotope-Labeled Compounds |
| HY-144235S | cis-Dihydro Tetrabenazine-d7 | 1217719-21-5 | Isotope-Labeled Compounds |
| HY-144236 | ZLD2218 | 2713974-32-2 | Reference compound |
| HY-144237 | BRP-201 | 2227434-74-2 | Reference compound |
| HY-144238 | mPGES1-IN-6 | 2914158-00-0 | Reference compound |
| HY-144239S | Venlafaxine N-oxide-d6 | | Isotope-Labeled Compounds |
| HY-144241S | DL-Alpha-tocopherol nicotinate-d9 | | Isotope-Labeled Compounds |
| HY-144242S | Voriconazole EP impurity D-d3 | | Isotope-Labeled Compounds |
| HY-144243S | Vitamin B5-d4 (calcium) | | Isotope-Labeled Compounds |
| HY-144245S | 5-Hydroxyl ZLN005-d13 | | Isotope-Labeled Compounds |
| HY-144246S | Zofenoprilat-NES-d5 | | Isotope-Labeled Compounds |
| HY-144247S | Edaravone glucuronide-d5 (sodium) | | Isotope-Labeled Compounds |
| HY-144248S | Levomedetomidine-13C,d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-144249S | (S)-Pantoprazole-d6 | | Isotope-Labeled Compounds |
| HY-14425 | Peturadol | 686301-48-4 | Reference compound |
| HY-144250S | Glycyl-L-proline-15N,d2 (trifluoroacetate) | | Isotope-Labeled Compounds |
| HY-144252 | Antibacterial agent 69 | 2915755-61-0 | Reference compound |
| HY-144253 | AKT-IN-11 | | Reference compound |
| HY-144254 | PI3Kδ-IN-10 | 2409725-49-9 | Reference compound |
| HY-144255 | Antibacterial agent 70 | | Reference compound |
| HY-144256 | CHD1Li 6.11 | 2716890-91-2 | Reference compound |
| HY-144258 | PD-1/PD-L1-IN-14 | 2499965-12-5 | Reference compound |
| HY-144259 | Metallo-β-lactamase-IN-2 | 1501705-61-8 | Reference compound |
| HY-14426 | L-655708 | 130477-52-0 | Reference compound |
| HY-144260 | 3CPLro-IN-1 | 2432956-06-2 | Reference compound |
| HY-144261 | Metallo-β-lactamase-IN-3 | 128294-71-3 | Reference compound |
| HY-144262 | Metallo-β-lactamase-IN-4 | 2711044-25-4 | Reference compound |
| HY-144263 | 3CPLro-IN-2 | 2758278-51-0 | Reference compound |
| HY-144264 | hCAII-IN-6 | 3067465-38-4 | Reference compound |
| HY-144265 | PDE4-IN-5 | 2768626-06-6 | Reference compound |
| HY-144266 | TP-060 | 2601393-20-6 | Reference compound |
| HY-144267 | Glucosylceramide synthase-IN-2 | 2597958-02-4 | Reference compound |
| HY-144268 | hCAII-IN-7 | | Reference compound |
| HY-144269 | SHR902275 | 2695506-82-0 | Reference compound |
| HY-14427 | 4E1RCat | 328998-25-0 | Reference compound |
| HY-144270 | Glucosylceramide synthase-IN-3 | 3029827-91-3 | Reference compound |
| HY-144271 | RAF-IN-1 | 2695505-82-7 | Reference compound |
| HY-144272 | AChE-IN-5 | | Reference compound |
| HY-144273 | IDO1-IN-13 | | Reference compound |
| HY-144274 | IDO1-IN-14 | | Reference compound |
| HY-144276 | RIPK1-IN-11 | 2173557-02-1 | Reference compound |
| HY-144277 | RIPK1-IN-12 | 2173556-92-6 | Peptides |
| HY-144278 | Anti-MRSA agent 1 | 2627336-02-9 | Reference compound |
| HY-144279 | MsbA-IN-1 | 2918334-61-7 | Reference compound |
| HY-14428 | ICG-001 | 780757-88-2 | Reference compound |
| HY-144280 | MsbA-IN-2 | 2909443-16-7 | Reference compound |
| HY-144281 | MsbA-IN-3 | 2909443-78-1 | Reference compound |
| HY-144282 | MsbA-IN-4 | 2909443-80-5 | Reference compound |
| HY-144283 | BLK-IN-1 | 1431727-00-2 | Reference compound |
| HY-144284 | MsbA-IN-5 | 2909443-06-5 | Reference compound |
| HY-144285 | CXCR4 antagonist 4 | 2761009-30-5 | Peptides |
| HY-144286 | CXCR4 antagonist 3 | 2761009-43-0 | Reference compound |
| HY-144287 | Glucokinase activator 3 | 1001417-92-0 | Reference compound |
| HY-144288 | BLK-IN-2 | 2694871-86-6 | Reference compound |
| HY-144289 | BMS-820132 | 1001419-18-6 | Reference compound |
| HY-14429 | (-)-Irofulven | 158440-71-2 | Reference compound |
| HY-144290 | ARN25068 | 2649882-80-2 | Reference compound |
| HY-144291 | LY3154885 | 2379422-72-5 | Reference compound |
| HY-144292 | HDAC-IN-30 | 2756809-34-2 | Peptides |
| HY-144293 | HDAC-IN-31 | 1916505-13-9 | Reference compound |
| HY-144294 | Purine phosphoribosyltransferase-IN-1 | 2784631-28-1 | Reference compound |
| HY-144295 | PI3Kα-IN-5 | 2237953-19-2 | Reference compound |
| HY-144296 | Purine phosphoribosyltransferase-IN-2 | 2784631-30-5 | Reference compound |
| HY-144297 | HDAC1-IN-3 | 2482998-35-4 | Reference compound |
| HY-144298 | HDAC1-IN-4 | 2482998-39-8 | Reference compound |
| HY-144299 | Tubulin polymerization-IN-5 | | Reference compound |
| HY-14430 | Cipargamin | 1193314-23-6 | Reference compound |
| HY-144300 | Rifasutenizol | 1001314-13-1 | Reference compound |
| HY-144301 | AAK1-IN-2 | 1802703-21-4 | Reference compound |
| HY-144301A | AAK1-IN-2 (TFA) | 2761587-28-2 | Reference compound |
| HY-144302 | AAK1-IN-3 | 1802703-20-3 | Reference compound |
| HY-144302A | AAK1-IN-3 (TFA) | 2761587-27-1 | Reference compound |
| HY-144303 | Xanthine oxidase-IN-4 | 2642137-96-8 | Reference compound |
| HY-144304 | PROTAC EGFR degrader 2 | 3031336-58-7 | Reference compound |
| HY-144305 | KPH2f | 2760615-09-4 | Reference compound |
| HY-144306 | ERα degrader 4 | | Reference compound |
| HY-144307 | Aurora A/PKC-IN-1 | 3031505-76-4 | Reference compound |
| HY-144308 | RMS-07 | 2645409-78-3 | Reference compound |
| HY-144309 | Cholesterol 24-hydroxylase-IN-1 | 1613480-70-8 | Reference compound |
| HY-14431 | Cerlapirdine | 925448-93-7 | Reference compound |
| HY-144310 | DX3-213B | 2749555-66-4 | Reference compound |
| HY-144311 | OXPHOS-IN-1 | 2749554-48-9 | Reference compound |
| HY-144312 | Thiobis-β-Galactose-propyne | 1989627-40-8 | Reference compound |
| HY-144313 | Galectin-3-IN-2 | 2883648-71-1 | Reference compound |
| HY-144314 | PSDalpha | 2906869-08-5 | Reference compound |
| HY-144315 | CYD19 | 2415281-52-4 | Reference compound |
| HY-144316 | ZLWH-23 | 2765251-12-3 | Reference compound |
| HY-144318 | CREB-IN-1 (TFA) | 2912285-84-6 | Reference compound |
| HY-144319 | SHR5133 | 2270943-23-0 | Reference compound |
| HY-14431A | Cerlapirdine (hydrochloride) | 925447-04-7 | Reference compound |
| HY-14432 | Pavinetant | 941690-55-7 | Reference compound |
| HY-144320 | HBV-IN-17 | 2270943-13-8 | Reference compound |
| HY-144321 | Trk-IN-9 | 2758623-12-8 | Reference compound |
| HY-144322 | HBV-IN-18 | 2766688-73-5 | Reference compound |
| HY-144323 | YF135 | 2913177-53-2 | Reference compound |
| HY-144324 | AChE-IN-6 | 2758788-95-1 | Reference compound |
| HY-144325 | CYP121A1-IN-1 | | Reference compound |
| HY-144326 | Aβ-IN-1 | 2766509-32-2 | Reference compound |
| HY-144327 | Aβ-IN-2 | | Reference compound |
| HY-144328 | STING agonist-10 | 2259308-69-3 | Reference compound |
| HY-144329 | STING agonist-11 | 2259308-68-2 | Reference compound |
| HY-144330 | TDI-6118 | | Reference compound |
| HY-144331 | Antitumor agent-42 | 2763621-91-4 | Reference compound |
| HY-144332 | PHD2/HDACs-IN-1 | 2339867-53-5 | Reference compound |
| HY-144333 | DNA crosslinker 1 (dihydrochloride) | 2761734-27-2 | Reference compound |
| HY-144334 | CHIKV-IN-3 | | Peptides |
| HY-144335 | DNA crosslinker 2 (dihydrochloride) | 2761734-25-0 | Reference compound |
| HY-144336 | DNA crosslinker 3 (dihydrochloride) | 2761734-21-6 | Reference compound |
| HY-144337 | DNA crosslinker 4 (dihydrochloride) | 2761734-23-8 | Reference compound |
| HY-144338 | PARP1/BRD4-IN-1 | 2758117-74-5 | Reference compound |
| HY-144339 | AhR agonist 2 | 2975270-19-8 | Reference compound |
| HY-14434 | Asunaprevir | 630420-16-5 | Reference compound |
| HY-144340 | Antitumor agent-43 | 2766035-37-2 | Reference compound |
| HY-144341 | DprE1-IN-1 | 920459-41-2 | Reference compound |
| HY-144343S | (Rac)-cis-3-hydroxy glyburide-13C,d3 | 1217848-91-3 | Isotope-Labeled Compounds |
| HY-144344S | Benzyl(2R)-3-N,N-dibenzylamino-2-fluoropropanoate-13C3 | 1217853-98-9 | Isotope-Labeled Compounds |
| HY-144345S | L-γ-Glutamyl-L-cysteinyl-L-lysine-13C5,15N | 1356841-92-3 | Isotope-Labeled Compounds |
| HY-144347 | HF51116 | 2177311-29-2 | Reference compound |
| HY-144348S | N-[4-(2-Pyridinyl)benzoyl]glycine-13C2,15N | 1391053-26-1 | Isotope-Labeled Compounds |
| HY-14435 | Pyridone 6 | 457081-03-7 | Reference compound |
| HY-144354S | S-Benzyl-DL-cysteine-2,3,3-d3 | 51494-04-3 | Isotope-Labeled Compounds |
| HY-144355S | N-Acetyl-S-propyl-L-cysteine-d7 | 1331909-69-3 | Isotope-Labeled Compounds |
| HY-144359S | 2-(4-Hydroxyphenyl)-L-glycine-d2 | 1213379-02-2 | Isotope-Labeled Compounds |
| HY-144361 | Antitumor agent-44 | 1811548-74-9 | Reference compound |
| HY-144362S | N-Acetyl-S-(2,5-dimethylbenzene)-L-cysteine-d3 | 1331909-07-9 | Isotope-Labeled Compounds |
| HY-144364S | N-Acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine-d3 | | Isotope-Labeled Compounds |
| HY-144364S1 | cis-N-Acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine-d3 | | Isotope-Labeled Compounds |
| HY-144365S | N-Acetyl-S-(2-hydroxypropyl)cysteine-d3 (dicyclohexylammonium) | 1356934-59-2 | Isotope-Labeled Compounds |
| HY-144366 | P-gp inhibitor 3 | 2766451-11-8 | Reference compound |
| HY-144367S | N-Acetyl-S-(2-hydroxy-3-propionamide)-L-cysteine-d3 (dicyclohexylammonium) | | Isotope-Labeled Compounds |
| HY-144368 | CO delivery molecule 1 | 1972616-04-8 | Reference compound |
| HY-144369 | Proteasome-IN-4 | | Reference compound |
| HY-144371 | DHODH-IN-20 | 2639835-02-0 | Reference compound |
| HY-144372 | TRPV1 antagonist 3 | 2765294-54-8 | Reference compound |
| HY-144373 | IL-17 modulator 6 | 2725869-16-7 | Reference compound |
| HY-144375 | Monoacylglycerol lipase inhibitor 1 | 2714570-98-4 | Reference compound |
| HY-144376 | Carbonic anhydrase inhibitor 4 | 2764889-93-0 | Reference compound |
| HY-144377 | RXR antagonist 1 | 3010910-40-1 | Reference compound |
| HY-144378S | Thiorphan methoxyacetophenone derivative-d7 | 1346603-29-9 | Isotope-Labeled Compounds |
| HY-144381 | Glutamate-5-kinase-IN-1 | | Reference compound |
| HY-144382 | Glutamate-5-kinase-IN-2 | | Reference compound |
| HY-144383 | RXR antagonist 2 | 3010910-41-2 | Reference compound |
| HY-144386S | N-Desmethyl L-ergothioneine methyl ester-d6 | 1795785-97-5 | Isotope-Labeled Compounds |
| HY-144387 | Antibacterial agent 71 | | Reference compound |
| HY-144388 | ChE/Aβ1-42-IN-1 | 2761149-22-6 | Reference compound |
| HY-144389 | hAChE/Aβ1-42-IN-1 | 2761149-17-9 | Reference compound |
| HY-144390 | (S)-S007-1558 | 1327156-14-8 | Reference compound |
| HY-144391 | Chitin synthase inhibitor 1 | 2763387-69-3 | Reference compound |
| HY-144392 | AChE/BuChE-IN-1 | 84212-49-7 | Reference compound |
| HY-144393 | P-gp/BCRP-IN-1 | 2764596-06-5 | Reference compound |
| HY-144394 | Antitumor agent-45 | 2581082-74-6 | Reference compound |
| HY-144395 | HDAC6-IN-4 | 2709103-20-6 | Reference compound |
| HY-144396 | SHP2-IN-8 | 1801692-60-3 | Reference compound |
| HY-144397 | LEO 134310 | 2089130-74-3 | Reference compound |
| HY-144399 | CD33 splicing modulator 1 | 2762547-05-5 | Reference compound |
| HY-144399A | CD33 splicing modulator 1 (hydrochloride) | 2762547-06-6 | Reference compound |
| HY-14440 | MP7 | 1001409-50-2 | Reference compound |
| HY-144401 | DS-3801b | 1369412-66-7 | Reference compound |
| HY-144403S | S-(N-Methylcarbamoyl)glutathione-d3 | 127633-23-2 | Isotope-Labeled Compounds |
| HY-144406S | N-Acetyl-S-(3-hydroxypropyl)cysteine-d3 (dicyclohexylammonium) | | Isotope-Labeled Compounds |
| HY-144407S | N-Acetyl-S-(2-carboxyethyl)-L-cysteine-d3 | 1260619-43-9 | Isotope-Labeled Compounds |
| HY-144408S | N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine-d3 | 131685-10-4 | Isotope-Labeled Compounds |
| HY-144409S | N-Acetyl-S-(2-cyanoethyl)-L-cysteine-d3 | 1260619-59-7 | Isotope-Labeled Compounds |
| HY-14441 | ML 10302 | 148868-55-7 | Reference compound |
| HY-144410S | N-(2-Benzoylmercaptopropionyl)glycine ethyl ester-d3 | 1189930-99-1 | Isotope-Labeled Compounds |
| HY-144414S | N-Acetyl-S-ethyl-L-cysteine-d5 | 1279033-91-8 | Isotope-Labeled Compounds |
| HY-144416S | Diethyl 2-ethyl-2-acetamidomalonate-d3 | 1246820-39-2 | Isotope-Labeled Compounds |
| HY-144418S | DL-2-Amino-3-(hydroxy-amino)propionic acid-15N | 1219426-14-8 | Isotope-Labeled Compounds |
| HY-144419 | Adenosine receptor antagonist 3 | 2400864-80-2 | Reference compound |
| HY-14442 | ML 10302 (hydrochloride) | 186826-17-5 | Reference compound |
| HY-144420 | Neuraminidase-IN-5 | 2473524-63-7 | Reference compound |
| HY-144421S | N-Acetyl-DL-glufosinate-d3 (hydrate) | | Isotope-Labeled Compounds |
| HY-144422 | RET-IN-15 | 2643375-86-2 | Reference compound |
| HY-144423 | Trk-IN-10 | 2700265-61-6 | Reference compound |
| HY-144424 | Trk-IN-11 | 2700265-62-7 | Reference compound |
| HY-144425 | BSc5367 | 3029584-84-4 | Reference compound |
| HY-144426 | Neuraminidase-IN-6 | 2738526-22-0 | Reference compound |
| HY-144427S | Vitamin E-13C2,d6 | 2483824-69-5 | Isotope-Labeled Compounds |
| HY-144428 | Bcl-2/Mcl-1-IN-2 | 2673361-07-2 | Reference compound |
| HY-144429 | TRPC5-IN-4 | 2762315-39-7 | Reference compound |
| HY-14443 | XMD8-92 | 1234480-50-2 | Reference compound |
| HY-144430 | Bcl-2/Mcl-1-IN-1 | 2673361-08-3 | Reference compound |
| HY-144431 | Bcl-2/Mcl-1-IN-3 | 2088981-53-5 | Reference compound |
| HY-144432S | Vitamin B5-13C3,15N (hemicalcium hemihydrate) | 2483830-09-5 | Isotope-Labeled Compounds |
| HY-144433 | DNMT3A-IN-1 | 1403598-56-0 | Reference compound |
| HY-144434 | RSK-IN-1 | 2761698-77-3 | Reference compound |
| HY-144435 | ATR-IN-11 | | Reference compound |
| HY-144436 | ATR-IN-12 | | Reference compound |
| HY-144437 | ALK5-IN-9 | 2489611-06-3 | Reference compound |
| HY-144438 | Aurora/LIM kinase-IN-1 | | Reference compound |
| HY-144439 | HTS07545 | 118666-03-8 | Reference compound |
| HY-14444 | Plinabulin | 714272-27-2 | Reference compound |
| HY-144440 | JAK1-IN-9 | 2875041-96-4 | Reference compound |
| HY-144441 | NSC81111 | 1678-14-4 | Reference compound |
| HY-144442 | PD-1/PD-L1-IN-15 | | Reference compound |
| HY-144443 | PD-1/PD-L1-IN-16 | | Reference compound |
| HY-144444 | NSC381467 | 1033006-96-0 | Reference compound |
| HY-144445 | NSC114126 | 24909-18-0 | Reference compound |
| HY-144446 | BuChE-IN-1 | 2669070-40-8 | Reference compound |
| HY-144447 | PD-1/PD-L1-IN-17 | 2851938-36-6 | Reference compound |
| HY-144448 | FAK-IN-2 | 2872588-02-6 | Reference compound |
| HY-144449 | mTOR/HDAC6-IN-1 | 2986747-52-6 | Reference compound |
| HY-14444S | Plinabulin-d1 | 2054938-28-0 | Isotope-Labeled Compounds |
| HY-14445 | FK 3311 | 116686-15-8 | Reference compound |
| HY-144450 | PI3K-IN-29 | 2768005-77-0 | Reference compound |
| HY-144451 | TRK-IN-12 | 2823342-34-1 | Reference compound |
| HY-144452 | Immunoproteasome inhibitor 1 | 2755772-63-3 | Reference compound |
| HY-144456 | Xanthine oxidase-IN-5 | 2276711-87-4 | Reference compound |
| HY-144464 | SARS-CoV-2 Mpro-IN-1 | 2758359-91-8 | Reference compound |
| HY-144465 | IDO1-IN-15 | 2126853-17-4 | Reference compound |
| HY-144466 | IDO1-IN-16 | 2677054-63-4 | Reference compound |
| HY-144468 | IDO1-IN-17 | 2677054-58-7 | Reference compound |
| HY-14447 | Bilastine | 202189-78-4 | Reference compound |
| HY-14447R | Bilastine (Standard) | 202189-78-4 | Reference Standards |
| HY-14447S | Bilastine-d6 | 1215358-58-9 | Isotope-Labeled Compounds |
| HY-14447S1 | Bilastine-d4 | 2747918-37-0 | Isotope-Labeled Compounds |
| HY-144497 | HE-S2 | 2939851-67-7 | ADC Related |
| HY-14450 | JNJ-31020028 | 1094873-14-9 | Reference compound |
| HY-144501 | D18 | 2230218-36-5 | Reference compound |
| HY-144507S | Methylergonovine-13C,d3 | | Isotope-Labeled Compounds |
| HY-144509S | l-α-tocopherol acetate-13C4,d6 | | Isotope-Labeled Compounds |
| HY-14451 | PF-4778574 | 1219633-99-4 | Reference compound |
| HY-144513 | Stigmastan-3β-ol | 19466-47-8 | Natural Products |
| HY-144513S | Stigmastan-3β-ol-d5 | 2483831-96-3 | Isotope-Labeled Compounds |
| HY-14452 | Fatostatin | 125256-00-0 | Reference compound |
| HY-144524S | Nitroso diisobutylamine-d4 | 1794897-96-3 | Isotope-Labeled Compounds |
| HY-14452A | Fatostatin (hydrobromide) | 298197-04-3 | Reference compound |
| HY-14454 | TPh A | 21306-65-0 | Reference compound |
| HY-144549 | LXR agonist 1 | 1779524-90-1 | Reference compound |
| HY-144554 | Aminooxy CatB-LXR | 1779524-93-4 | ADC Related |
| HY-14456A | MAC13243 | 1071638-38-4 | Reference compound |
| HY-144577S | Ortho-hydroxy atorvastatin-d5 (calcium) | 265989-47-7 | Isotope-Labeled Compounds |
| HY-144584 | AGL-0182-30 | | Reference compound |
| HY-144585 | AGD-0182 | 1835700-14-5 | Reference compound |
| HY-14460 | AM679 | 1206880-66-1 | Reference compound |
| HY-144603 | Neuropeptide Y Y1 receptor antagonist 1 | 2773476-40-5 | Dye Reagents |
| HY-144604 | FPR2 agonist 2 | 2829263-20-7 | Reference compound |
| HY-144605 | PROTAC EGFR degrader 3 | 2768472-28-0 | Reference compound |
| HY-144606 | Mu opioid receptor antagonist 1 | 2767446-03-5 | Reference compound |
| HY-144607 | Mu opioid receptor antagonist 2 | 2773925-64-5 | Reference compound |
| HY-144608 | Mu opioid receptor antagonist 3 | 2773925-66-7 | Reference compound |
| HY-144609 | Mu opioid receptor antagonist 4 | 2773925-74-7 | Reference compound |
| HY-144610 | Mu opioid receptor antagonist 5 | 1124167-61-8 | Reference compound |
| HY-144612 | NS2B/NS3-IN-2 | 3010940-08-3 | Reference compound |
| HY-144614 | JH-XVII-10 | 3034312-17-6 | Reference compound |
| HY-144617 | JH-XIV-68-3 | 2426628-29-5 | Reference compound |
| HY-144618 | Antibacterial agent 74 | 1644387-48-3 | Reference compound |
| HY-144619 | TLR7/8 antagonist 2 | 2769085-03-0 | Reference compound |
| HY-14462 | NP118809 | 41332-24-5 | Reference compound |
| HY-144621 | Antibacterial agent 75 | 2765224-33-5 | Reference compound |
| HY-144623 | Antiviral agent 15 | | Reference compound |
| HY-144624 | PROTAC Axl Degrader 1 | | Reference compound |
| HY-144627 | PROTAC Axl Degrader 2 | | Reference compound |
| HY-144628 | Fmoc-Asn-Pro-Val-PABC-PNP | 2893871-64-0 | Reference compound |
| HY-144629 | Asn-Pro-Val-PABC-MMAE (TFA) | 2893871-67-3 | Reference compound |
| HY-14463 | Onalespib | 912999-49-6 | Reference compound |
| HY-144630 | diSPhMC-Asn-Pro-Val-PABC-MMAE | 2893871-68-4 | Reference compound |
| HY-144632 | Antifungal agent 22 | 2640054-39-1 | Reference compound |
| HY-144634 | DDO-7263 | 2254004-96-9 | Reference compound |
| HY-144635 | Nrf2-ARE/hMAO-B/QR2 modulator 1 | | Reference compound |
| HY-144636 | Atg4B-IN-2 | 2765008-88-4 | Reference compound |
| HY-144637 | Autophagy inducer 2 | 2684238-37-5 | Reference compound |
| HY-144638 | JMX0293 | | Reference compound |
| HY-144639 | Carbonic anhydrase inhibitor 5 | | Reference compound |
| HY-14464 | PF-00489791 | 853003-48-2 | Reference compound |
| HY-144640 | Carbonic anhydrase inhibitor 6 | 1013213-84-7 | Reference compound |
| HY-144641 | Carbonic anhydrase inhibitor 7 | 546105-61-7 | Reference compound |
| HY-144642 | PARP-1-IN-1 | 2763840-83-9 | Reference compound |
| HY-144643 | CYP51/HDAC-IN-1 | 2502095-64-7 | Reference compound |
| HY-144644 | NS2B/NS3-IN-3 | 2832876-90-9 | Reference compound |
| HY-144644A | NS2B/NS3-IN-3 (hydrochloride) | 2832876-91-0 | Reference compound |
| HY-144645 | SP-471P | 2768011-36-3 | Reference compound |
| HY-144646 | SP-471 | 2768010-39-3 | Reference compound |
| HY-144647 | SP inhibitor 1 | 2766185-81-1 | Reference compound |
| HY-144648 | Mpro/PLpro-IN-1 | 2766185-78-6 | Reference compound |
| HY-144649 | PD-1/PD-L1-IN-24 | 2667680-33-1 | Reference compound |
| HY-14465 | PF 02367982 | 913344-84-0 | Reference compound |
| HY-144650 | Hsp90-Cdc37-IN-3 | 2361009-68-7 | Reference compound |
| HY-144651 | IDO1-IN-18 | 2328099-08-5 | Reference compound |
| HY-144652 | IDO1-IN-19 | 2328099-11-0 | Reference compound |
| HY-144653 | PDGFR-IN-1 | 2644673-07-2 | Reference compound |
| HY-144654 | HDAC/Top-IN-1 | 2411379-14-9 | Reference compound |
| HY-144655 | IP2 | 2247640-44-2 | Reference compound |
| HY-144656 | Steroid sulfatase-IN-1 | 2403716-19-6 | Reference compound |
| HY-144657 | (4S)-PROTAC SOS1 degrader-1 | 2913176-81-3 | Reference compound |
| HY-144657A | (4S)-PROTAC SOS1 degrader-1 (diTFA) | | Reference compound |
| HY-144658 | FXIa-IN-8 | 2744293-04-5 | Reference compound |
| HY-144659 | Metallo-β-lactamase-IN-5 | 1417737-65-5 | Reference compound |
| HY-14466 | GW 848687X | 612831-24-0 | Reference compound |
| HY-144660 | AChE-IN-7 | 2699090-78-1 | Reference compound |
| HY-144661 | KRAS G12D inhibitor 14 | 2765254-39-3 | Reference compound |
| HY-144663 | MtTMPK-IN-1 | 2799607-58-0 | Reference compound |
| HY-144664 | MtTMPK-IN-2 | 2799607-71-7 | Reference compound |
| HY-144665 | MtTMPK-IN-3 | 2799607-80-8 | Reference compound |
| HY-144666 | GLS-1-IN-1 | | Reference compound |
| HY-144667 | ALDH1A3-IN-1 | 1695970-90-1 | Reference compound |
| HY-144668 | RdRP-IN-4 | | Reference compound |
| HY-144669 | ALDH1A3-IN-2 | 886502-08-5 | Reference compound |
| HY-14467 | GSK-269984A | 892664-04-9 | Reference compound |
| HY-144670 | ALDH3A1-IN-1 | 1039855-56-5 | Reference compound |
| HY-144671 | ALDH3A1-IN-2 | 374635-48-0 | Reference compound |
| HY-144672 | A2A receptor antagonist 2 | 2767206-20-0 | Reference compound |
| HY-144673 | LSD1-IN-12 | 1228143-76-7 | Reference compound |
| HY-144675 | LSD1-IN-13 | 2170212-33-4 | Reference compound |
| HY-144675A | LSD1-IN-13 (hydrochloride) | 2170347-90-5 | Reference compound |
| HY-144676 | pan-HER-IN-1 | 1639040-94-0 | Reference compound |
| HY-144677 | pan-HER-IN-2 | 1639040-95-1 | Reference compound |
| HY-144680 | BLU-945 | 2660250-10-0 | Reference compound |
| HY-144681 | Ceperognastat | 2241514-56-5 | Reference compound |
| HY-144681A | rel-Ceperognastat | 2241514-58-7 | Reference compound |
| HY-144682 | (2R,4R)-LY3372689 | | Reference compound |
| HY-144683 | PF-07038124 | 2415085-44-6 | Reference compound |
| HY-144683A | PF-07038124 (hydrochloride) | 2415317-57-4 | Reference compound |
| HY-144684 | PDE4-IN-8 | 2415085-45-7 | Reference compound |
| HY-144685 | ATM Inhibitor-2 | 2769140-29-4 | Reference compound |
| HY-144686 | ATM Inhibitor-3 | 2769140-52-3 | Reference compound |
| HY-144687 | ATM Inhibitor-4 | 2769140-74-9 | Reference compound |
| HY-144688 | HIV-1 protease-IN-1 | 2765293-30-7 | Reference compound |
| HY-144689 | BChE-IN-3 | | Reference compound |
| HY-144690 | D5261 | 1574574-57-4 | Reference compound |
| HY-144691 | PP-C8 | 3032108-74-7 | Reference compound |
| HY-144692 | MEK/PI3K-IN-1 | 2281803-28-7 | Reference compound |
| HY-144693 | MEK/PI3K-IN-2 | 2281803-33-4 | Reference compound |
| HY-144694 | HDAC/HSP90-IN-3 | 2700035-54-5 | Reference compound |
| HY-144695 | Dyrk1A/α-synuclein-IN-1 | 2789711-47-1 | Reference compound |
| HY-144696 | Dyrk1A/α-synuclein-IN-2 | 2789711-66-4 | Reference compound |
| HY-144697 | p38 MAPK-IN-3 | | Reference compound |
| HY-144698 | mGlu4 receptor agonist 1 | 1678501-16-0 | Reference compound |
| HY-144699 | ERRα antagonist-2 | 3032965-02-6 | Reference compound |
| HY-144700 | Antileishmanial agent-3 | 2755930-28-8 | Reference compound |
| HY-144701 | SABA1 | 690681-65-3 | Reference compound |
| HY-144701R | SABA1 (Standard) | 690681-65-3 | Reference Standards |
| HY-144705 | GAT564 | 2851895-01-5 | Reference compound |
| HY-144706 | Axl-IN-3 | 2783991-34-2 | Reference compound |
| HY-144707 | AK-778-XXMU | 1227045-76-2 | Reference compound |
| HY-144708 | Axl-IN-4 | 1176456-11-3 | Reference compound |
| HY-144709 | FLT3/ITD-IN-1 | | Reference compound |
| HY-14471 | Cetilistat | 282526-98-1 | Reference compound |
| HY-144710 | FLT3/ITD-IN-2 | 2489446-59-3 | Reference compound |
| HY-144711 | FLT3/ITD-IN-3 | 2489446-47-9 | Reference compound |
| HY-144712 | L5-DA | 2986876-41-7 | Reference compound |
| HY-144713 | PTP1B-IN-16 | 2848581-86-0 | Reference compound |
| HY-144714 | HIV-1 inhibitor-18 | 2764787-56-4 | Reference compound |
| HY-144715 | HIV-1 inhibitor-17 | 2764787-76-8 | Reference compound |
| HY-144716 | PTP1B-IN-19 | 2848581-83-7 | Reference compound |
| HY-144717 | PTP1B-IN-18 | 2848581-84-8 | Reference compound |
| HY-144718 | PTP1B-IN-17 | 2848581-85-9 | Reference compound |
| HY-14471R | Cetilistat (Standard) | 282526-98-1 | Reference Standards |
| HY-14472 | Tesofensine | 195875-84-4 | Reference compound |
| HY-144720 | BRG1-IN-1 | 2616813-99-9 | Reference compound |
| HY-144721 | Antitubercular agent-11 | 3032629-09-4 | Reference compound |
| HY-144722 | Antitubercular agent-12 | 905677-04-5 | Reference compound |
| HY-144723 | Antitubercular agent-13 | 3032629-25-4 | Reference compound |
| HY-144724 | HSP90-IN-10 | 2881071-86-7 | Reference compound |
| HY-144725 | HDAC1/6-IN-1 | 2630989-02-3 | Reference compound |
| HY-144727 | Anti-inflammatory agent 11 | 63932-07-0 | Reference compound |
| HY-144728 | MraY-IN-3 (hydrochloride) | | Reference compound |
| HY-144729 | Antibacterial agent 82 | 3032608-35-5 | Reference compound |
| HY-144730 | gp120-IN-1 | 5948-75-4 | Reference compound |
| HY-144731 | gp120-IN-2 | 123629-42-5 | Reference compound |
| HY-144732 | TRK/ALK-IN-1 | | Reference compound |
| HY-144733 | ERα antagonist 1 | 2762423-09-4 | Reference compound |
| HY-144734 | Pantothenate kinase-IN-1 | 1024168-48-6 | Reference compound |
| HY-144735 | Anti-inflammatory agent 14 | 894496-27-6 | Reference compound |
| HY-144736 | NS2B/NS3-IN-4 | 2910757-30-9 | Reference compound |
| HY-144737 | Anti-inflammatory agent 15 | 474516-87-5 | Reference compound |
| HY-144738 | Dual FAAH/sEH-IN-1 | 2756099-59-7 | Reference compound |
| HY-144739 | BACE1-IN-8 | | Reference compound |
| HY-144740 | NS2B/NS3-IN-5 | 2910757-21-8 | Reference compound |
| HY-144741 | BACE1-IN-9 | 2872604-91-4 | Reference compound |
| HY-144742 | NS2B/NS3-IN-6 | 2459657-57-7 | Reference compound |
| HY-144743 | ATX inhibitor 12 | 2771312-16-2 | Reference compound |
| HY-144744 | NF-κB-IN-3 | 1873311-82-0 | Reference compound |
| HY-144745 | HSR1304 | 2763363-08-0 | Reference compound |
| HY-144746 | PD-1/PD-L1-IN-26 | 2966090-78-6 | Reference compound |
| HY-144747 | Hydroxyethylamine | 1418733-36-4 | Reference compound |
| HY-144748 | Tubulin inhibitor 17 | 2839151-13-0 | Reference compound |
| HY-144749 | AKR1C3-IN-5 | 2839142-93-5 | Reference compound |
| HY-144752 | cSPM | | Reference compound |
| HY-144753 | AChE/BChE-IN-2 | 2761991-42-6 | Reference compound |
| HY-144754 | VEGFR-2-IN-13 | 2839104-01-5 | Reference compound |
| HY-144755 | MC2652 | 2771425-46-6 | Reference compound |
| HY-144756 | LSD1-IN-15 | | Reference compound |
| HY-144757 | LSD1-IN-16 | | Reference compound |
| HY-144758 | LSD1-IN-17 | | Reference compound |
| HY-144759 | FGFR4-IN-9 | | Reference compound |
| HY-144760 | EGFR-IN-3 | 3031812-65-1 | Reference compound |
| HY-144761 | TOPK-p38/JNK-IN-1 | 2745108-35-2 | Reference compound |
| HY-144762 | K027 | 6586-37-4 | Reference compound |
| HY-144763 | XPO1-IN-1 | | Reference compound |
| HY-144764 | 5-HT1A antagonist 1 | | Reference compound |
| HY-144765 | NF-κB-IN-4 | | Reference compound |
| HY-144766 | ATX inhibitor 13 | 2485779-34-6 | Reference compound |
| HY-144767 | PA3552-IN-1 | 1008121-12-7 | Reference compound |
| HY-144768 | (R)-Chol-TPP | | Reference compound |
| HY-144769 | SDOX | 2921601-78-5 | Reference compound |
| HY-14477 | UPF-1035 | 370872-09-6 | Reference compound |
| HY-144770 | SARS-CoV-2-IN-13 | 56961-10-5 | Reference compound |
| HY-144771 | SARS-CoV-2-IN-14 | 22203-98-1 | Reference compound |
| HY-144772 | SARS-CoV-2-IN-15 | 1580-42-3 | Reference compound |
| HY-144773 | Loxoprofenol-SRS | 83648-76-4 | Reference compound |
| HY-144773A | Loxoprofenol-SRS (tromethamine) | 2582872-01-1 | Reference compound |
| HY-144774 | Topoisomerase I inhibitor 5 | 2513461-95-3 | Reference compound |
| HY-144775 | AChE-IN-10 | 2770832-90-9 | Reference compound |
| HY-144776 | NAT | 831243-31-3 | Reference compound |
| HY-144777 | FLT3-IN-14 | 2620551-45-1 | Reference compound |
| HY-144778 | IDO1/TDO-IN-1 | 2379527-72-5 | Reference compound |
| HY-144779 | HDAC10-IN-1 | | Reference compound |
| HY-14478 | UPF 1069 | 1048371-03-4 | Reference compound |
| HY-144780 | CXCR2 antagonist 4 | | Reference compound |
| HY-144781 | CXCR2 antagonist 5 | | Reference compound |
| HY-144782 | HDAC10-IN-2 | | Reference compound |
| HY-144782A | HDAC10-IN-2 (hydrochloride) | | Reference compound |
| HY-144783 | CXCR2 antagonist 6 | | Reference compound |
| HY-144784 | CXCR2 antagonist 7 | | Reference compound |
| HY-144786 | Tubulin polymerization-IN-4 | 2835559-00-5 | Reference compound |
| HY-144790 | AChE-IN-12 | 2764664-52-8 | Reference compound |
| HY-144791 | Bcl-2-IN-6 | 3027734-50-2 | Reference compound |
| HY-144792 | Bcl-2-IN-7 | 3027734-46-6 | Reference compound |
| HY-144793 | Deac-SS-Biotin | | Reference compound |
| HY-144794 | EGFR-IN-46 | 2764772-88-3 | Reference compound |
| HY-144795 | VEGFR-2-IN-14 | | Reference compound |
| HY-144796 | VEGFR-2-IN-15 | 3033033-20-1 | Reference compound |
| HY-144797 | Tubulin inhibitor 22 | 3033038-38-6 | Reference compound |
| HY-144798 | FWM-5 | 2757194-04-8 | Reference compound |
| HY-144799 | FWM-4 | 2757194-03-7 | Reference compound |
| HY-144800 | FWM-1 | | Reference compound |
| HY-144801 | DDO-02005 (free base) | 1186134-30-4 | Reference compound |
| HY-144801A | DDO-02005 | 1186049-44-4 | Reference compound |
| HY-144802 | DDO-02001 | 1186049-49-9 | Reference compound |
| HY-144803 | VEGFR-2-IN-16 | 3033041-36-7 | Reference compound |
| HY-144804 | VEGFR-2-IN-17 | 3033041-34-5 | Reference compound |
| HY-144805 | VEGFR-2-IN-18 | 3033041-38-9 | Reference compound |
| HY-144806 | PI3K/AKT-IN-1 | 3033069-84-7 | Reference compound |
| HY-144807 | Carbonic anhydrase inhibitor 9 | 3033042-50-8 | Reference compound |
| HY-144808 | Anticancer agent 40 | 2760658-33-9 | Reference compound |
| HY-144809 | Pancreatic lipase/Carboxylesterase 1-IN-1 | 194235-21-7 | Reference compound |
| HY-144810 | CDK2-IN-8 | 2919216-36-5 | Reference compound |
| HY-144811 | CDK2-IN-9 | 2919216-33-2 | Reference compound |
| HY-144812 | Gü1303 | 1043922-53-7 | Reference compound |
| HY-144813 | Gü2602 | 1627094-88-5 | Reference compound |
| HY-144817 | Tubulin inhibitor 27 | 184579-57-5 | Reference compound |
| HY-144818 | Tubulin inhibitor 23 | 170488-57-0 | Reference compound |
| HY-144820 | JO146 | 130727-21-8 | Reference compound |
| HY-144822 | Anti-MRSA agent 2 | 2597082-01-2 | Reference compound |
| HY-144823 | Anti-MRSA agent 3 | 2416909-42-5 | Reference compound |
| HY-144824 | Monoamine oxidase/Aromatase-IN-1 | | Reference compound |
| HY-144825 | Chol-CTPP | | Reference compound |
| HY-144826 | ZDWX-25 | 2668297-70-7 | Reference compound |
| HY-144827 | AM8936 | 2820337-96-8 | Reference compound |
| HY-144828 | RIP1/RIP3/MLKL activator 1 | 2682850-41-3 | Reference compound |
| HY-14483 | AF-353 | 865305-30-2 | Reference compound |
| HY-144830 | 6BrCaQ | 954416-67-2 | Reference compound |
| HY-144831 | 6BrCaQ-C10-TPP | | Reference compound |
| HY-144833 | SARS-CoV-2 3CLpro-IN-1 | 2757970-20-8 | Reference compound |
| HY-144835 | Camibirstat | 2671128-05-3 | Reference compound |
| HY-14483A | AF-353 (hydrochloride) | 927887-18-1 | Reference compound |
| HY-144841 | Cemsidomide | 2504235-67-8 | Reference compound |
| HY-144841A | (Rac)-Cemsidomide | 2504233-68-3 | Reference compound |
| HY-14485 | Ro-51 | 1050670-85-3 | Reference compound |
| HY-144856S1 | Sapropterin-d3 | 2747956-15-4 | Isotope-Labeled Compounds |
| HY-144858 | EZM0414 | 2411748-50-8 | Reference compound |
| HY-14486 | Elinogrel (potassium) | 936501-01-8 | Reference compound |
| HY-144863 | BAY 1214784 | 1631164-25-4 | Reference compound |
| HY-144867 | CCT245232 | 1693731-14-4 | Reference compound |
| HY-144868 | Glutathione synthesis-IN-1 | 2632968-72-8 | Reference compound |
| HY-144869 | OTS447 | 1356943-67-3 | Reference compound |
| HY-144870 | STAT3-IN-7 | 2237955-91-6 | Reference compound |
| HY-144871 | STAT3-IN-8 | 2237957-26-3 | Reference compound |
| HY-144872 | RJ-34 | 1170694-29-7 | Reference compound |
| HY-144873 | AVJ16 | 2775241-92-2 | Reference compound |
| HY-144874 | AZ3391 | 2756333-42-1 | Reference compound |
| HY-144875 | CTX-712 | 2144751-78-8 | Reference compound |
| HY-144876 | RIDR-PI-103 | 2581114-71-6 | Reference compound |
| HY-144878 | VPC-70619 | 2361742-30-3 | Reference compound |
| HY-144880 | SC209 | 1977557-86-0 | ADC Related |
| HY-144881 | (S)-HH2853 | 2202678-05-3 | Reference compound |
| HY-144882 | (R)-HH2853 | 2202678-06-4 | Reference compound |
| HY-144893 | OKI-006 | 1315334-23-6 | Reference compound |
| HY-144894 | AM-5308 | 2410796-89-1 | Reference compound |
| HY-144896 | FHT-1015 | 2368903-18-6 | Reference compound |
| HY-144897 | FHT-1204 | 2468048-24-8 | Reference compound |
| HY-144898 | SB-216 | 2756818-39-8 | Reference compound |
| HY-144899 | ASR-490 | 2690312-67-3 | Reference compound |
| HY-144900 | Topramezone | 210631-68-8 | Reference compound |
| HY-144900R | Topramezone (Standard) | 210631-68-8 | Reference Standards |
| HY-144903 | Migoprotafib | 2377352-49-1 | Reference compound |
| HY-144904 | MC4343 | | Reference compound |
| HY-144906 | THP104c | 877792-12-6 | Reference compound |
| HY-144913S | Bempedoic acid impurity 1-d4 | 2408132-01-2 | Isotope-Labeled Compounds |
| HY-144927S | C14 Benzalkonium chloride -1 ketone-d5 | | Isotope-Labeled Compounds |
| HY-144947S | Beclomethasone-17-monopropionate-d3 | | Isotope-Labeled Compounds |
| HY-14495 | BMS-604992 | 674343-47-6 | Reference compound |
| HY-144950S | 3-Hydroxy benzopyrene-d11 | 1246819-35-1 | Isotope-Labeled Compounds |
| HY-14495A | BMS-604992 (free base) | 760944-56-7 | Reference compound |
| HY-14495B | BMS-604992 (dihydrochloride) | 1469750-46-6 | Reference compound |
| HY-144962 | SOS1-IN-11 | 2654741-64-5 | Reference compound |
| HY-144965 | SOS1-IN-12 | 2654741-56-5 | Reference compound |
| HY-144967 | SOS1-IN-13 | 2654741-45-2 | Reference compound |
| HY-144969S | (-)-2-Methyl-isoborneol-d3 | 135441-89-3 | Isotope-Labeled Compounds |
| HY-144971 | dCeMM2 | 296771-07-8 | Reference compound |
| HY-144976 | dCeMM3 | 311787-85-6 | Reference compound |
| HY-144977 | dCeMM4 | 1281683-44-0 | Reference compound |
| HY-144980 | E3 ligase Ligand 21 | 2504233-73-0 | Reference compound |
| HY-144981 | HQ461 | 1226443-41-9 | Reference compound |
| HY-144982 | NRX-1532 | | Reference compound |
| HY-144983 | E3 ligase Ligand 22 | 2377849-57-3 | Reference compound |
| HY-144984 | NRX-1933 | 2763260-30-4 | Reference compound |
| HY-144985 | E3 ligase Ligand 23 | 444287-56-3 | Reference compound |
| HY-144987 | RBN013209 | 2597933-17-8 | Reference compound |
| HY-144988 | CD38 inhibitor 2 | 2597933-78-1 | Reference compound |
| HY-144991 | Aurora kinase inhibitor-8 | 2133001-88-2 | Reference compound |
| HY-144993 | PI3Kδ/γ-IN-1 | 1980884-01-2 | Reference compound |
| HY-144995 | BSJ-02-162 | 2139329-47-6 | Reference compound |
| HY-144998 | NVP-DKY709 | 2291360-73-9 | Reference compound |
| HY-144999 | LEB-03-146 | 2858812-91-4 | Reference compound |
| HY-145000 | N-Desalkyludenafil | 319491-68-4 | Reference compound |
| HY-145001 | 20-HC-Me-Pyrrolidine | | Reference compound |
| HY-145003S | 4(Z),7(Z)-Decadienoic acid-d5 | 2714087-40-6 | Isotope-Labeled Compounds |
| HY-145004S | (±)8,9-DiHETrE-d11 | | Isotope-Labeled Compounds |
| HY-145008S | (±)9(10)-DiHOME-d4 | 1215168-76-5 | Isotope-Labeled Compounds |
| HY-145009 | SN-008 | 2249106-01-0 | Reference compound |
| HY-145010 | SN-011 | 2249435-90-1 | Reference compound |
| HY-145012S | W-19-d4 (hydrochloride) | 2749974-94-3 | Isotope-Labeled Compounds |
| HY-145013 | tri-GalNAc-COOH (acetylation) | 3008204-26-7 | Reference compound |
| HY-145015 | Tuspetinib | 2294874-49-8 | Reference compound |
| HY-145015A | Tuspetinib (hydrate) | 2758339-04-5 | Reference compound |
| HY-145016 | HN37 | 1821222-10-9 | Reference compound |
| HY-145017 | KRAS G12C inhibitor 20 | 2640858-10-0 | Reference compound |
| HY-145018 | KRAS G12C inhibitor 21 | 2737269-61-1 | Reference compound |
| HY-145019 | KRAS G12C inhibitor 22 | 2736599-72-5 | Reference compound |
| HY-145020 | KRAS G12C inhibitor 23 | 2735721-00-1 | Reference compound |
| HY-145022 | KRAS G12C inhibitor 25 | 2734060-73-0 | Reference compound |
| HY-145023 | RET-IN-5 | 2725770-20-5 | Reference compound |
| HY-145024 | RET-IN-6 | 2715208-83-4 | Reference compound |
| HY-145025 | ERK1/2 inhibitor 3 | 2737294-99-2 | Reference compound |
| HY-145026 | ERK1/2 inhibitor 4 | 2490396-99-9 | Reference compound |
| HY-145027 | ERK1/2 inhibitor 5 | 2560552-75-0 | Reference compound |
| HY-145028 | ERK1/2 inhibitor 6 | 2634816-13-8 | Reference compound |
| HY-145029 | SYK/JAK-IN-1 | 2737326-28-0 | Reference compound |
| HY-14503 | MDR-1339 | 1018946-38-7 | Reference compound |
| HY-145033 | VL-6 | 2274813-29-3 | Reference compound |
| HY-145034 | KIF18A-IN-1 | 2600559-12-2 | Reference compound |
| HY-145035 | HPK1-IN-9 | 2734168-78-4 | Reference compound |
| HY-145036 | HPK1-IN-10 | 2734168-69-3 | Reference compound |
| HY-145037 | HPK1-IN-11 | 2734167-68-9 | Reference compound |
| HY-145038 | HPK1-IN-12 | 2734168-51-3 | Reference compound |
| HY-145039 | HPK1-IN-13 | 2734168-30-8 | Reference compound |
| HY-145040 | HPK1-IN-14 | 2734168-45-5 | Reference compound |
| HY-145041 | HPK1-IN-15 | 2201098-03-3 | Reference compound |
| HY-145042 | HPK1-IN-16 | 2294965-95-8 | Reference compound |
| HY-145043 | FGFR-IN-1 | 1513860-41-7 | Reference compound |
| HY-145044 | HPK1-IN-17 | 2403600-07-5 | Reference compound |
| HY-145045 | HPK1-IN-18 | 2403598-42-3 | Reference compound |
| HY-145046 | SOS1-IN-3 | 2359689-76-0 | Reference compound |
| HY-145047 | SOS1-IN-4 | 2738392-83-9 | Reference compound |
| HY-145048 | SOS1-IN-5 | 2716956-47-5 | Reference compound |
| HY-145049 | HBV-IN-6 | 2724224-47-7 | Reference compound |
| HY-145050 | HBV-IN-7 | 2724224-49-9 | Reference compound |
| HY-145051 | HBV-IN-8 | 2724224-57-9 | Reference compound |
| HY-145052 | HBV-IN-9 | 2170998-69-1 | Reference compound |
| HY-145053 | HBV-IN-10 | 2716907-16-1 | Reference compound |
| HY-145053A | (5S,8R)-HBV-IN-10 | 2716907-15-0 | Reference compound |
| HY-145055 | HBV-IN-11 | 2226178-41-0 | Reference compound |
| HY-145056 | ART615 | 3031765-75-7 | Reference compound |
| HY-145057 | PP-biotin | 1801423-93-7 | Reference compound |
| HY-145059 | HBV-IN-12 | 2724229-06-3 | Reference compound |
| HY-145060 | HBV-IN-13 | 2724228-72-0 | Reference compound |
| HY-145061 | ADAMTS-5-IN-3 | 2688733-96-0 | Reference compound |
| HY-145062 | Enpp-1-IN-4 | 2376600-89-2 | Reference compound |
| HY-145063 | Enpp-1-IN-5 | 2230916-95-5 | Reference compound |
| HY-145064 | Enpp-1-IN-6 | 2718971-29-8 | Reference compound |
| HY-145065 | Enpp-1-IN-7 | | Reference compound |
| HY-145066 | Gly-Gly-Gly-PEG4-azide | | ADC Related |
| HY-145069 | Enpp-1-IN-8 | 2718971-08-3 | Reference compound |
| HY-14507 | YK-4-279 | 1037184-44-3 | Reference compound |
| HY-145070 | Enpp-1-IN-9 | 2718970-70-6 | Reference compound |
| HY-145071 | PROTAC ERα Y537S degrader-1 | 2667598-05-0 | Reference compound |
| HY-145072 | BSJ-01-175 | 2227392-55-2 | Reference compound |
| HY-145073 | PROTAC ER Degrader-10 | 2504911-58-2 | Reference compound |
| HY-145078 | PNU-EDA-Gly5 | 1957223-28-7 | ADC Related |
| HY-145079 | Bunamidine (hydrochloride) | 1055-55-6 | Reference compound |
| HY-145080 | Dynole 2−24 | 1416313-72-8 | Reference compound |
| HY-145081 | Pitnot-2 | 1576239-29-6 | Reference compound |
| HY-145082 | 4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide (potassium) | 1419320-93-6 | Reference compound |
| HY-145086 | R-PSOP | 1185189-97-2 | Reference compound |
| HY-145087 | NP3-146 | 210826-47-4 | Reference compound |
| HY-145087A | NP3-146 (sodium) | 1995068-96-6 | Reference compound |
| HY-145090 | DBCO-N-bis(PEG4-NHS ester) | 2639395-38-1 | ADC Related |
| HY-145102 | NCT-58 | 2411429-33-7 | Reference compound |
| HY-145103 | UNC6934 | 2561494-77-5 | Reference compound |
| HY-145104 | Antioxidant agent-1 | 136068-43-4 | Reference compound |
| HY-145105 | Inonophenol C | 3017174-74-9 | Reference compound |
| HY-145106 | Histamine H4 receptor antagonist-1 | 1246207-84-0 | Reference compound |
| HY-145107 | HPK1-IN-19 | 2227609-33-6 | Reference compound |
| HY-145108 | FAK-IN-1 | 2553215-22-6 | Reference compound |
| HY-145109 | HPK1-IN-20 | 2561490-78-4 | Reference compound |
| HY-145110 | IGF-1R inhibitor-2 | 1116236-15-7 | Reference compound |
| HY-145111 | TNK2-IN-1 | 2574456-10-1 | Reference compound |
| HY-145112 | AChE-IN-3 | 2713548-95-7 | Reference compound |
| HY-145115 | Adeninobananin | 858956-99-7 | Reference compound |
| HY-145119 | GS-621763 | 2647442-13-3 | Reference compound |
| HY-145119AS | Mindeudesivir (hydrobromide) | 2779498-79-0 | Isotope-Labeled Compounds |
| HY-145119S | Mindeudesivir | 2647442-33-7 | Isotope-Labeled Compounds |
| HY-145120 | RG6344 | 2649372-20-1 | Reference compound |
| HY-145121 | DS96432529 | 2871872-79-4 | Reference compound |
| HY-145122 | ELOVL1-IN-1 | 2227482-41-7 | Reference compound |
| HY-145124 | TRPM8 antagonist 3 | 2102179-29-1 | Reference compound |
| HY-145125 | SJ995973 | 2882065-25-8 | Reference compound |
| HY-145126 | CP-628006 | 305822-08-6 | Reference compound |
| HY-145127 | ETZ | 2989379-61-3 | Dye Reagents |
| HY-145128 | GR103545 | 126766-43-6 | Reference compound |
| HY-145143 | anti-TNBC agent-1 | 2289585-58-4 | Reference compound |
| HY-145147 | AAA-10 | 2758171-70-7 | Reference compound |
| HY-145147A | AAA-10 (formic) | | Reference compound |
| HY-145148 | Hemiasterlin derivative-1 | 1887046-60-7 | ADC Related |
| HY-145149 | Duostatin 5 | 2124210-34-8 | ADC Related |
| HY-145150 | TRPC5-IN-1 | 2265215-18-5 | Reference compound |
| HY-145151 | TRPC6-IN-2 | 2308595-83-5 | Reference compound |
| HY-145152 | Biotin-Thalidomide | 2230857-87-9 | Reference compound |
| HY-145153 | S-777469 | 885496-53-7 | Reference compound |
| HY-145154 | Digoxigenin monodigitoxoside | 5352-63-6 | Reference compound |
| HY-145155 | Calpain-2-IN-1 | 144231-85-6 | Reference compound |
| HY-145157 | Ferric nitrilotriacetate | 16448-54-7 | Reference compound |
| HY-145158 | Temocillin | 66148-78-5 | Reference compound |
| HY-145159 | SHP2 protein degrader-1 | 2624181-69-5 | Reference compound |
| HY-145162 | SHP2-D26 | 2458219-65-1 | Reference compound |
| HY-145169 | AZ194 | 2241651-99-8 | Reference compound |
| HY-14517 | H3R antagonist 5 | 879368-27-1 | Reference compound |
| HY-145177 | Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc | 1799711-31-1 | Reference compound |
| HY-14518 | Aminopterin | 54-62-6 | Reference compound |
| HY-14518A | Aminopterin (sodium) | 58602-66-7 | Reference compound |
| HY-14518R | Aminopterin (Standard) | 54-62-6 | Reference Standards |
| HY-14519 | Methotrexate | 59-05-2 | ADC Related |
| HY-145191 | MrgprX2 antagonist-1 | 2642162-06-7 | Reference compound |
| HY-145192 | MrgprX2 antagonist-2 | 2642346-30-1 | Reference compound |
| HY-145193 | MrgprX2 antagonist-3 | 2642174-19-2 | Reference compound |
| HY-145193A | (R)-MrgprX2 antagonist-3 | 2642174-20-5 | Reference compound |
| HY-145194 | MrgprX2 antagonist-4 | 2641398-04-9 | Reference compound |
| HY-145195 | MrgprX2 antagonist-5 | 2527815-74-1 | Reference compound |
| HY-145196 | RTICBM-189 | 551909-15-0 | Reference compound |
| HY-145197 | MPO-IN-3 | 1435469-45-6 | Reference compound |
| HY-14519A | Methotrexate (disodium) | 7413-34-5 | ADC Related |
| HY-14519B | Methotrexate (hydrate) | 133073-73-1 | Biochemical Assay Reagents |
| HY-14519CS | (R)-Methotrexate-d3 | | Isotope-Labeled Compounds |
| HY-14519D | Methotrexate (monohydrate) | 6745-93-3 | ADC Related |
| HY-14519R | Methotrexate (Standard) | 59-05-2 | Reference Standards |
| HY-14519S | Methotrexate-d3 | 432545-63-6 | Isotope-Labeled Compounds |
| HY-14519S1 | Methotrexate-d3 (diammonium) | | Isotope-Labeled Compounds |
| HY-14520 | Tetrahydrofolic acid | 135-16-0 | Natural Products |
| HY-14520A | (6S)-Tetrahydrofolic acid | 71963-69-4 | Reference compound |
| HY-14520B | Tetrahydrofolic acid (trihydrochloride) | 150731-85-4 | Reference compound |
| HY-14520S | Tetrahydrofolic acid-d4 | 1356841-72-9 | Isotope-Labeled Compounds |
| HY-14520S1 | Tetrahydrofolic acid-13C5 | | Isotope-Labeled Compounds |
| HY-14520S2 | Tetrahydrofolic acid-13C6 | 212248-88-9 | Isotope-Labeled Compounds |
| HY-14521 | Lometrexol | 106400-81-1 | Reference compound |
| HY-14521A | Lometrexol (disodium) | 120408-07-3 | Reference compound |
| HY-14521B | Lometrexol (hydrate) | 1435784-14-7 | Reference compound |
| HY-14522 | LY 222306 | 154446-98-7 | Reference compound |
| HY-145225 | DLin-K-C3-DMA | 1217306-46-1 | Reference compound |
| HY-145226 | XY-06-007 | 2757045-94-4 | Reference compound |
| HY-14523 | LY 254155 | 135503-67-2 | Reference compound |
| HY-145230 | FGFR2-IN-1 | 2677709-76-9 | Reference compound |
| HY-145231 | FGFR2-IN-2 | 2677709-81-6 | Reference compound |
| HY-145232 | PhosTAC7 | 3016307-75-5 | Reference compound |
| HY-145233 | PfPKG-IN-1 | 2866493-89-0 | Reference compound |
| HY-145234 | GPBAR1-IN-3 | 2760546-05-0 | Reference compound |
| HY-145235 | AChE-IN-4 | | Reference compound |
| HY-145236 | Analgesic agent-1 | 2230243-92-0 | Reference compound |
| HY-145237 | BM213 | 2891606-02-1 | Reference compound |
| HY-145238 | FTO-IN-6 | 2968347-63-7 | Reference compound |
| HY-145239 | PD-1/PD-L1-IN-13 | 2865841-81-0 | Reference compound |
| HY-145240 | eIF4E-IN-1 | 2573979-31-2 | Reference compound |
| HY-145241 | TBTDC | 2866214-44-8 | Reference compound |
| HY-145243 | PDPOB | 2351900-45-1 | Reference compound |
| HY-145244 | APN/AKT-IN-1 | 2854340-31-9 | Reference compound |
| HY-145245 | TLR4-IN-C34-C2-amide-C6-OH | | Reference compound |
| HY-145246 | Biotin-PEG8-Vidarabine | | Reference compound |
| HY-145247 | Biotin-PEG7-C2-S-Vidarabine | | Reference compound |
| HY-145248 | Biotin-PEG7-C2-NH-Vidarabine-S-CH3 | | Reference compound |
| HY-145249 | ATP-PEG8-Biotin | | Reference compound |
| HY-145250 | NK1 receptor antagonist 2 | 579475-17-5 | Reference compound |
| HY-145253 | Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH | | Reference compound |
| HY-145254 | Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH | | Reference compound |
| HY-145255 | Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH | 1637413-46-7 | Reference compound |
| HY-145256 | GABAA receptor agent 4 | 2035203-91-7 | Reference compound |
| HY-145257 | GABAA receptor agent 5 | 1808389-92-5 | Reference compound |
| HY-145258 | GABAA receptor agent 6 | 1808463-81-1 | Reference compound |
| HY-145259 | HDAC6-IN-3 | 3023019-99-7 | Reference compound |
| HY-14526 | 5-DACTHF | 118252-44-1 | Reference compound |
| HY-145260 | BRD4/CK2-IN-1 | 2756851-99-5 | Reference compound |
| HY-145261 | hDHODH-IN-8 | 2757405-31-3 | Reference compound |
| HY-145262 | eIF4E-IN-2 | 2575840-38-7 | Reference compound |
| HY-145263 | VD2173 | 2574389-19-6 | Reference compound |
| HY-145263A | VD2173 epimer-1 | | Reference compound |
| HY-145264 | OARV-771 | 2683008-37-7 | Reference compound |
| HY-145265 | Antimicrobial photosensitizer-1 | 2933179-62-3 | Reference compound |
| HY-145266 | OM-1700 | 2406276-78-4 | Reference compound |
| HY-145267 | OM-153 | 2406278-81-5 | Reference compound |
| HY-145268 | SLEC-11 | 863761-17-5 | Reference compound |
| HY-145269 | AL-GDa62 | 2761538-66-1 | Reference compound |
| HY-145270 | ELOVL1-IN-2 | 2761063-79-8 | Reference compound |
| HY-145272 | ELOVL1-IN-3 | 2761063-99-2 | Reference compound |
| HY-145273 | EB-0150 | 2832824-40-3 | Reference compound |
| HY-145274 | EB-0156 | 2832824-43-6 | Reference compound |
| HY-145275 | EB-0176 | 2758314-64-4 | Reference compound |
| HY-145276 | SARS-CoV-2-IN-10 | 2722634-95-7 | Reference compound |
| HY-145277 | SARS-CoV-2-IN-11 | 2722635-28-9 | Reference compound |
| HY-145278 | RXFP3/4 agonist 2 | 2752378-78-0 | Reference compound |
| HY-145279 | RXFP3 agonist 1 | 2752378-24-6 | Reference compound |
| HY-145280 | IDO1/2-IN-1 | 2310286-45-2 | Reference compound |
| HY-145280A | IDO1/2-IN-1 (hydrochloride) | 2310286-60-1 | Reference compound |
| HY-145281 | MS98 | 2376137-31-2 | Reference compound |
| HY-145282 | MS170 | 2376136-61-5 | Reference compound |
| HY-145284 | APJ receptor agonist 4 | 2762567-70-2 | Reference compound |
| HY-145285 | APJ receptor agonist 5 | 2135514-20-2 | Reference compound |
| HY-145286 | IMPDH2-IN-2 | 1434517-02-8 | Reference compound |
| HY-145287 | S-MGB-234 | 1970223-53-0 | Reference compound |
| HY-145287A | S-MGB-234 (TFA) | 1970223-54-1 | Reference compound |
| HY-145288 | Antitumor agent-36 | 3005986-81-9 | Reference compound |
| HY-145289 | Antitumor agent-37 | 3032101-64-4 | Reference compound |
| HY-145290 | CPT-Se3 | 2968315-02-6 | Reference compound |
| HY-145291 | CPT-Se4 | 2968315-03-7 | Reference compound |
| HY-145292 | TNIK-IN-2 | 2754265-76-2 | Reference compound |
| HY-145293 | TNIK-IN-3 | 2754265-25-1 | Reference compound |
| HY-145294 | ROCK2-IN-5 | 3031515-48-4 | Reference compound |
| HY-145295 | Flupyradifurone | 951659-40-8 | Reference compound |
| HY-145295R | Flupyradifurone (Standard) | 951659-40-8 | Reference Standards |
| HY-145296 | Triflumezopyrim | 1263133-33-0 | Reference compound |
| HY-145297 | Flupyrimin | 1689566-03-7 | Reference compound |
| HY-145297R | Flupyrimin (Standard) | 1689566-03-7 | Reference Standards |
| HY-145298 | Dicloromezotiaz | 1263629-39-5 | Reference compound |
| HY-145299 | nAChR modulator-1 | 1902218-84-1 | Reference compound |
| HY-14530 | Pelitrexol | 446022-33-9 | Reference compound |
| HY-145300 | nAChR modulator-2 | 1700657-87-9 | Reference compound |
| HY-145301 | Mycobactin-IN-1 | 65840-95-1 | Reference compound |
| HY-145302 | Mycobactin-IN-2 | 421573-09-3 | Reference compound |
| HY-145303 | DX2-201 | 2749554-00-3 | Reference compound |
| HY-145304 | DX3-235 | 2749555-39-1 | Reference compound |
| HY-145306 | DX3-234 | 2941323-59-5 | Reference compound |
| HY-145307 | DATPT | 2891582-75-3 | Reference compound |
| HY-145308 | Heterobivalent ligand-1 | 2888568-58-7 | Reference compound |
| HY-145309 | eIF4E-IN-3 | 2573979-29-8 | Reference compound |
| HY-14531 | Talarozole | 201410-53-9 | Reference compound |
| HY-145310 | ZL0590 | 2230496-99-6 | Reference compound |
| HY-145311 | Bis-Pro-5FU | 2155827-07-7 | Reference compound |
| HY-145312 | ATR-IN-4 | 2574545-45-0 | Reference compound |
| HY-145313 | TTBK1-IN-2 | 2765453-51-6 | Reference compound |
| HY-145314 | TC113 | | Reference compound |
| HY-145316 | Vanin-1-IN-2 | 2054952-13-3 | Reference compound |
| HY-145317 | LRRK2-IN-2 | 2641059-19-8 | Reference compound |
| HY-145318 | LRRK2-IN-3 | 2641054-60-4 | Reference compound |
| HY-145319 | FPFT-2216 | 2367619-87-0 | Reference compound |
| HY-14532 | Brincidofovir | 444805-28-1 | Reference compound |
| HY-145320 | TMX-4113 | 2766385-92-4 | Reference compound |
| HY-145321 | TMX-4100 | 2367619-63-2 | Reference compound |
| HY-145322 | TMX-4116 | 2766385-56-0 | Reference compound |
| HY-145323 | Mitochondria-Targeted Photoactivatable Prodrug | 2883123-79-1 | Reference compound |
| HY-145324 | Antiviral agent 14 | 2755814-80-1 | Reference compound |
| HY-145325 | Antibacterial agent 66 | | Reference compound |
| HY-145326 | Antibacterial agent 67 | 2488900-01-0 | Reference compound |
| HY-145327 | Antimalarial agent 7 | 2756414-77-2 | Reference compound |
| HY-145328 | PARP-1/2-IN-1 | 1903744-45-5 | Reference compound |
| HY-14533 | K 01-162 | 677746-25-7 | Reference compound |
| HY-145330 | NSC639828 | 134742-26-0 | Reference compound |
| HY-145331 | ARG1-IN-1 | 2376189-62-5 | Reference compound |
| HY-145331A | ARG1-IN-1 (hydrochloride) | | Reference compound |
| HY-145332 | IDO1-IN-11 | 2306411-34-5 | Reference compound |
| HY-145334 | CD73-IN-5 | 2412019-99-7 | Reference compound |
| HY-145335 | GSK2818713 | 1422484-32-9 | Reference compound |
| HY-145336 | JAK1/TYK2-IN-1 | 1883300-48-8 | Reference compound |
| HY-145337 | FT3967385 | | Reference compound |
| HY-145338 | PI3Kβ-IN-1 | 2215098-77-2 | Reference compound |
| HY-145339 | ARN19702 | 1971937-18-4 | Reference compound |
| HY-145340 | 2'-O-Propargyl A(Bz)-3'-phosphoramidite | 171486-59-2 | Reference compound |
| HY-145341 | GNE-149 | 1953132-75-6 | Reference compound |
| HY-145343 | RO7185876 | 2226038-71-5 | Reference compound |
| HY-145343A | (9R)-RO7185876 | 2226077-86-5 | Reference compound |
| HY-145344 | ONO-8430506 | 1354805-08-5 | Reference compound |
| HY-145345 | BACE1-IN-6 | 2079945-75-6 | Reference compound |
| HY-145346 | NLG802 | 2071683-99-1 | Reference compound |
| HY-145347 | GSK232 | 2702984-69-6 | Reference compound |
| HY-145348 | MK-5204 | 1207751-75-4 | Reference compound |
| HY-145349 | FXIa-IN-6 | 1551459-37-0 | Reference compound |
| HY-14535 | SEN-1269 | 956128-01-1 | Reference compound |
| HY-145350 | HDAC-IN-26 | 2410542-97-9 | Reference compound |
| HY-145351 | BAY 1003803 | 1152781-51-5 | Reference compound |
| HY-145352 | ChemR23-IN-2 | 2465086-50-2 | Reference compound |
| HY-145353 | HTL22562 | 2097085-63-5 | Reference compound |
| HY-145354 | FXIa-IN-7 | 2488952-56-1 | Reference compound |
| HY-145355 | IDO1-IN-12 | 2379570-48-4 | Reference compound |
| HY-145356 | HbF inducer-1 | 2987004-95-3 | Reference compound |
| HY-145357 | SGLT1/2-IN-2 | 2387812-73-7 | Reference compound |
| HY-145358 | FAP-PI3KI1 | 2415941-98-7 | Reference compound |
| HY-145359 | eIF4A3-IN-5 | 2100145-31-9 | Reference compound |
| HY-14536 | Methylene Blue | 61-73-4 | Dye Reagents |
| HY-145360 | eIF4A3-IN-6 | 2100133-77-3 | Reference compound |
| HY-145361 | eIF4A3-IN-7 | 2374759-82-5 | Reference compound |
| HY-145362 | S1P1 agonist 4 | 1883345-11-6 | Reference compound |
| HY-145363 | αvβ5 integrin-IN-1 | 2615912-33-7 | Reference compound |
| HY-145364 | Ghrelin receptor full agonist-2 | 2602452-73-1 | Reference compound |
| HY-145365 | DGN549-L | 1884276-68-9 | ADC Related |
| HY-145367 | Ala-CO-amide-C4-Boc | | ADC Related |
| HY-145368 | Tri-GalNAc-NHS ester | 1953146-83-2 | Reference compound |
| HY-145368B | Tri-GalNAc(OAc)3-Perfluorophenyl | | Reference compound |
| HY-145369 | DS34942424 | 2967655-39-4 | Reference compound |
| HY-14536A | Methylene blue (purity≥70%) | 61-73-4 | Reference compound |
| HY-14536R | Methylene Blue (Standard) | 61-73-4 | Reference Standards |
| HY-14537 | Latrepirdine (dihydrochloride) | 97657-92-6 | Reference compound |
| HY-145370 | GluN2B receptor modulator-1 | 2222010-71-9 | Reference compound |
| HY-145371 | ATG7-IN-1 | 2226229-87-2 | Reference compound |
| HY-145372 | γ-Secretase modulator 10 | 2694817-84-8 | Reference compound |
| HY-145373 | BMS-986143 | 1643372-83-1 | Reference compound |
| HY-145374 | AL-611 | 2481279-61-0 | Reference compound |
| HY-145375 | NS5A-IN-1 | | Reference compound |
| HY-145376 | Cholera autoinducer 1 | 1004296-82-5 | Reference compound |
| HY-145379 | Miaosporone A | | Reference compound |
| HY-14538 | Haloperidol | 52-86-8 | Reference compound |
| HY-145381 | 11β-HSD1-IN-6 | 1303515-33-4 | Reference compound |
| HY-145383 | Biotin-PEG4-dialkoxydiphenylsilane-picolyl azide | 2599839-59-3 | Dye Reagents |
| HY-145384 | ROC-0929 | 1048660-43-0 | Reference compound |
| HY-145385 | Coelenteramide | 50611-86-4 | Dye Reagents |
| HY-145386 | (S,S)-CPI-1612 | 2374971-82-9 | Reference compound |
| HY-145387 | MRT-81 | 1263132-08-6 | Reference compound |
| HY-145388 | AU-15330 | 2380274-50-8 | Reference compound |
| HY-145388B | AU-16235 | 2380275-40-9 | Reference compound |
| HY-145389 | SZ-015268 | 2654003-68-4 | Reference compound |
| HY-14538A | Haloperidol (hydrochloride) | 1511-16-6 | Reference compound |
| HY-14538B | Haloperidol (lactate) | 53515-91-6 | Reference compound |
| HY-14538R | Haloperidol (Standard) | 52-86-8 | Reference Standards |
| HY-14538S | Haloperidol-d4 | 1189986-59-1 | Isotope-Labeled Compounds |
| HY-14538S1 | Haloperidol-d4-1 | 136765-35-0 | Isotope-Labeled Compounds |
| HY-14538S2 | Haloperidol-d4 N-Oxide | 1246815-56-4 | Isotope-Labeled Compounds |
| HY-14538S3 | Haloperidol-13C6 | | Isotope-Labeled Compounds |
| HY-14539 | Clozapine | 5786-21-0 | Reference compound |
| HY-145390 | Nrf2 activator-1 | 2230697-41-1 | Reference compound |
| HY-145390A | (R,R)-Nrf2 activator-1 | | Reference compound |
| HY-145391 | Triperiden | 14617-17-5 | Reference compound |
| HY-145392 | ACSS2-IN-1 | 2711039-08-4 | Reference compound |
| HY-145393 | 5-HT2A receptor agonist-1 | 2698331-34-7 | Reference compound |
| HY-145394 | CDK7-IN-6 | 2378710-04-2 | Reference compound |
| HY-145395 | PROTAC BRD9 Degrader-2 | 2633631-78-2 | Reference compound |
| HY-145396 | PLGA-PEG-NH2 | | Oligonucleotides |
| HY-145396A | PLGA20000-PEG1000-NH2 | | Biochemical Assay Reagents |
| HY-145396B | PLGA20000-PEG2000-NH2 | | Biochemical Assay Reagents |
| HY-145396C | PLGA20000-PEG5000-NH2 | | Biochemical Assay Reagents |
| HY-145396D | PLGA20000-PEG10000-NH2 | | Biochemical Assay Reagents |
| HY-145397 | (4-NH2)-Exatecan | 2495742-21-5 | Reference compound |
| HY-145397A | (R)-(4-NH2)-Exatecan | | Reference compound |
| HY-145397S | (4-NH2)-Exatecan-d5 | | Isotope-Labeled Compounds |
| HY-145399 | AZ14170133 | 2495742-34-0 | ADC Related |
| HY-14539A | Clozapine (hydrochloride) | 54241-01-9 | Reference compound |
| HY-14539B | Clozapine (dihydrochloride) | 2711603-38-0 | Reference compound |
| HY-14539R | Clozapine (Standard) | 5786-21-0 | Reference Standards |
| HY-14539S | Clozapine-d8 | 1185053-50-2 | Isotope-Labeled Compounds |
| HY-14539S2 | Clozapine-d4 | 204395-52-8 | Isotope-Labeled Compounds |
| HY-14539S3 | Clozapine-d3 | 1215691-72-7 | Isotope-Labeled Compounds |
| HY-145400 | PROTAC BRD9 Degrader-3 | 2633632-05-8 | Reference compound |
| HY-145402 | CDK7-IN-7 | 2640208-01-9 | Reference compound |
| HY-145403 | PROTAC BRD9 Degrader-4 | 2633632-34-3 | Reference compound |
| HY-145404 | Mitragynine pseudoindoxyl | 2035457-43-1 | Reference compound |
| HY-145405 | C12-200 | 1220890-25-4 | Oligonucleotides |
| HY-145406 | IHCH-3064 | 2420562-65-6 | Reference compound |
| HY-145407 | 16,17-Dihydroheronamide C | 2698333-36-5 | Reference compound |
| HY-145407A | ent-Heronamide C | | Reference compound |
| HY-145408 | CDK7/9-IN-1 | 2747919-19-1 | Reference compound |
| HY-145409 | SR-0813 | 2597186-19-9 | Reference compound |
| HY-14541 | Olanzapine | 132539-06-1 | Reference compound |
| HY-145411 | PEG2000-C-DMG | | Oligonucleotides |
| HY-145412 | GLP-1 receptor agonist 7 | 2736447-04-2 | Reference compound |
| HY-145413 | BRD2889 | 1415153-39-7 | Reference compound |
| HY-145414 | DYSP-C34 | 2559734-98-2 | Reference compound |
| HY-145415 | W13 | 1060518-03-7 | Reference compound |
| HY-145416 | G247 | | Reference compound |
| HY-145417 | G092 | 2909443-24-7 | Reference compound |
| HY-145418 | IRE1α kinase-IN-3 | 2416223-41-9 | Reference compound |
| HY-145419 | IRE1α kinase-IN-4 | 2771006-45-0 | Reference compound |
| HY-14541A | Olanzapine (hydrochloride) | 783334-36-1 | Reference compound |
| HY-14541R | Olanzapine (Standard) | 132539-06-1 | Reference Standards |
| HY-14541S | Olanzapine-d3 | 786686-79-1 | Isotope-Labeled Compounds |
| HY-14541S1 | Olanzapine-d4 | 1252611-62-3 | Isotope-Labeled Compounds |
| HY-14541S2 | Olanzapine-d8 | 1093380-13-2 | Isotope-Labeled Compounds |
| HY-14542 | Ziprasidone | 146939-27-7 | Reference compound |
| HY-145420 | IRE1α kinase-IN-5 | 2771006-47-2 | Reference compound |
| HY-145422 | KIRA9 | 2922507-65-9 | Reference compound |
| HY-145424 | CDK7-IN-10 | 2588110-62-5 | Reference compound |
| HY-145425 | PAIR2 | 2771006-54-1 | Reference compound |
| HY-145426 | MPT0B390 | 1817802-18-8 | Reference compound |
| HY-145427 | NU5455 | 1257235-99-6 | Reference compound |
| HY-145428 | BT-GSI | | Reference compound |
| HY-145429 | IL-17A modulator-2 | 2748749-47-3 | Reference compound |
| HY-14542A | Ziprasidone (hydrochloride) | 122883-93-6 | Reference compound |
| HY-14542B | Ziprasidone (mesylate trihydrate) | 199191-69-0 | Reference compound |
| HY-14542C | Ziprasidone (mesylate) | 185021-64-1 | Reference compound |
| HY-14542S | Ziprasidone-d8 | 1126745-58-1 | Isotope-Labeled Compounds |
| HY-14543 | Sertindole | 106516-24-9 | Reference compound |
| HY-145430 | IL-17A modulator-1 | 2748749-29-1 | Reference compound |
| HY-145431 | (S)-GSK1379725A | 2359618-49-6 | Reference compound |
| HY-145432 | PI3K-IN-28 | 2747100-02-1 | Reference compound |
| HY-145433 | 17β-HSD1-IN-1 | 2760791-96-4 | Reference compound |
| HY-145434 | IL-17 modulator 5 | 2724206-27-1 | Reference compound |
| HY-145435 | SARS-CoV-2-IN-12 | 2721455-52-1 | Reference compound |
| HY-145436 | KRAS inhibitor-11 | 2761218-40-8 | Reference compound |
| HY-145437 | N'-(2-Fluorophenyl)pyrazine-2-carbohydrazide | 2881111-79-9 | Reference compound |
| HY-145438 | Antitumor agent-38 | 2744193-34-6 | Reference compound |
| HY-145439 | Colistin adjuvant-1 | 2862800-15-3 | Reference compound |
| HY-14543S | Sertindole-d4 | 1794737-42-0 | Isotope-Labeled Compounds |
| HY-14544 | Quetiapine | 111974-69-7 | Reference compound |
| HY-145440 | Colistin adjuvant-2 | 2862800-23-3 | Reference compound |
| HY-145441 | GEM–IB | 2866211-93-8 | Reference compound |
| HY-145442 | 8-Azanebularine | 38874-46-3 | Reference compound |
| HY-145443 | Fludarabine-Cl | 2734853-80-4 | Reference compound |
| HY-145444 | EPZ028862 | 1887082-53-2 | Reference compound |
| HY-145445 | BIOTIN-PEG11-SH | 1650579-23-9 | Dye Reagents |
| HY-145446 | SGC-SMARCA-BRDVIII | 1997319-84-2 | Reference compound |
| HY-145448 | MC-VC-PABC-amide-PEG1-CH2-CC-885 | 2722697-82-5 | Reference compound |
| HY-145449 | CC-885-CH2-PEG1-NH-CH3 | 2722698-03-3 | ADC Related |
| HY-145449A | CC-885-CH2-PEG1-NH-CH3 (TFA) | | ADC Related |
| HY-14544AS | Quetiapine-d4 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-14544R | Quetiapine (Standard) | 111974-69-7 | Reference Standards |
| HY-14545 | Amisulpride | 71675-85-9 | Reference compound |
| HY-145450 | ATR-IN-9 | 2417513-43-8 | Reference compound |
| HY-145452 | 5-Octyl-α-ketoglutarate | 1616344-00-3 | Reference compound |
| HY-145453 | Propacetamol | 66532-85-2 | Reference compound |
| HY-145453R | Propacetamol (Standard) | 66532-85-2 | Reference Standards |
| HY-145454 | (R)-Preclamol | 85976-54-1 | Reference compound |
| HY-145454A | Preclamol | 85966-89-8 | Reference compound |
| HY-145455 | Salazopyridazine | 22933-72-8 | Reference compound |
| HY-145456 | Gallium 8-Hydroxyquinolinate | 14642-34-3 | Reference compound |
| HY-145458 | GLP-1 receptor agonist 9 | 2401892-71-3 | Reference compound |
| HY-145459 | N-Boc Ketamine | 1461707-29-8 | Reference compound |
| HY-14545A | Amisulpride (hydrochloride) | 81342-13-4 | Reference compound |
| HY-14545R | Amisulpride (Standard) | 71675-85-9 | Reference Standards |
| HY-14545S | Amisulpride-d5 | 1216626-17-3 | Isotope-Labeled Compounds |
| HY-14545S1 | Amisulpride-d5 N-Oxide | 1794756-15-2 | Isotope-Labeled Compounds |
| HY-14546 | Aripiprazole | 129722-12-9 | Reference compound |
| HY-145461 | Hydroxy lenalidomide | 1421593-78-3 | Reference compound |
| HY-145462 | N-cis-Octadec-9Z-enoyl-L-homoserine lactone | 1400974-23-3 | Reference compound |
| HY-145463 | α-Methylserotonin | 304-52-9 | Reference compound |
| HY-145464 | 4-Propanoyloxy DMT | 1373882-11-1 | Reference compound |
| HY-145466 | EVT-401 | | Reference compound |
| HY-145467 | C16 Ceramide-1-phosphate (d18:1/16:0) (ammonium) | 1246303-22-9 | Natural Products |
| HY-145468 | GPR52 antagonist-1 | 1239987-91-7 | Reference compound |
| HY-145469 | Linoleic acid alkyne | 1219038-31-9 | Natural Products |
| HY-14546A | Aripiprazole (monohydrate) | 851220-85-4 | Reference compound |
| HY-14546R | Aripiprazole (Standard) | 129722-12-9 | Reference Standards |
| HY-14546S | Aripiprazole-d8 | 1089115-06-9 | Isotope-Labeled Compounds |
| HY-14546S1 | Aripiprazole (1,1,2,2,3,3,4,4-d8) | 1089115-04-7 | Isotope-Labeled Compounds |
| HY-14547 | Bifeprunox | 350992-10-8 | Reference compound |
| HY-145471 | KSQ-4279 | 2446480-97-1 | Reference compound |
| HY-145471A | KSQ-4279 (gentisate) | 2938991-80-9 | Reference compound |
| HY-145472 | Sphingosine (d18:1) alkyne | 954096-91-4 | Reference compound |
| HY-145473 | 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE | 947381-58-0 | Reference compound |
| HY-145473S | 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE-d11 | | Isotope-Labeled Compounds |
| HY-145474 | 17(R)-Resolvin D1 methyl ester | 937738-64-2 | Reference compound |
| HY-145475 | Nervonoyl ethanolamide | 887405-21-2 | Reference compound |
| HY-145476 | N-Nitrosoanatabine | 887407-16-1 | Reference compound |
| HY-145476S | N-Nitrosoanatabine-d4 | 1020719-69-0 | Isotope-Labeled Compounds |
| HY-145477 | 8(R),11(S)-DiHODE | 885215-81-6 | Reference compound |
| HY-145479 | PROTAC AR-V7 degrader-1 | 2767440-24-2 | Reference compound |
| HY-14547A | Bifeprunox (mesylate) | 350992-13-1 | Reference compound |
| HY-145480 | Silodosin Glucuronide (sodium) | 879292-24-7 | Reference compound |
| HY-145481 | 1,3-Olein-2-Lignocerin | 869989-78-6 | Reference compound |
| HY-145482 | W36017 | 21236-54-4 | Reference compound |
| HY-145482R | W36017 (Standard) | 21236-54-4 | Reference Standards |
| HY-145483 | KT-474 | 2432994-31-3 | Reference compound |
| HY-145484 | PROTAC IRAK4 ligand-3 | 2434848-46-9 | Reference compound |
| HY-145485 | HS-PEG-SH (MW 3400) | | Reference compound |
| HY-145486 | 1-Arachidonoyl-sn-glycerol 3-phosphate (ammonium) | 799268-65-8 | Biochemical Assay Reagents |
| HY-145488 | MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D | 2222445-87-4 | ADC Related |
| HY-145489 | Mal-PEG2-Val-Cit-PABA | 1662687-83-3 | ADC Related |
| HY-145490 | trans-Hydroxy Glimepiride | 600177-94-4 | Reference compound |
| HY-145490S1 | trans-Hydroxy Glimepiride-d4 | 2749985-37-1 | Isotope-Labeled Compounds |
| HY-145491 | Resolvin D5 | 578008-43-2 | Natural Products |
| HY-145492 | Δ7(Z)-C14-HSL | 482598-46-9 | Reference compound |
| HY-145493 | C12 NBD Galactosylceramide | 474942-98-8 | Dye Reagents |
| HY-145497 | Dipentamethylenethiuram Tetrasulfide | 120-54-7 | Reference compound |
| HY-145498 | HDMAPP (triammonium) | 443892-56-6 | Reference compound |
| HY-145499 | XTT (sodium hydrate) | 413585-64-5 | Dye Reagents |
| HY-14550 | TP-10 | 898563-00-3 | Reference compound |
| HY-145501A | Sucrose hexasulfate (potassium) | 386229-70-5 | Biochemical Assay Reagents |
| HY-145502 | 1,2-Dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) (sodium) | 384835-52-3 | Reference compound |
| HY-145503 | Decanoyl-L-carnitine (chloride) | 369651-88-7 | Reference compound |
| HY-145503S | Decanoyl-L-carnitine-d9 (chloride) | 2847775-92-0 | Isotope-Labeled Compounds |
| HY-145504 | 12-Dipalmitoyl-3-Linoelaidoyl-rac-glycerol | 344791-14-6 | Reference compound |
| HY-145505 | 1-Oleoyl-2-hydroxy-sn-glycero-3-PG (sodium) | 326495-24-3 | Biochemical Assay Reagents |
| HY-145506 | 1-Stearoyl-2-hydroxy-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium) | 326495-23-2 | Biochemical Assay Reagents |
| HY-145507 | 1-Palmitoyl-2-hydroxy-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium) | 326495-22-1 | Biochemical Assay Reagents |
| HY-145508 | 1,2-Dilauroyl-sn-glycero-3-PG (sodium) | 322647-27-8 | Biochemical Assay Reagents |
| HY-145509 | N-(3-Hydroxy-7-cis tetradecenoyl)-L-Homoserine lactone | 273734-65-9 | Reference compound |
| HY-14550A | PDE10-IN-5 | 898562-99-7 | Reference compound |
| HY-14551 | Osanetant | 160492-56-8 | Reference compound |
| HY-145510 | 1,2-Dipalmitoyl-3-Arachidonoyl-rac-glycerol | 263386-70-5 | Reference compound |
| HY-145511 | 10(S)-HOME | 263023-34-3 | Reference compound |
| HY-145512 | N-(α-Linolenoyl) tyrosine | 259143-19-6 | Peptides |
| HY-145513 | CL2-MMT-SN38 | 1084888-82-3 | Reference compound |
| HY-145514 | dTAGV-1 (TFA) | 2624313-15-9 | Reference compound |
| HY-145514A | dTAGV-1-NEG | 2451573-87-6 | Reference compound |
| HY-145514B | dTAGV-1-NEG (TFA) | | Reference compound |
| HY-145514C | dTAGV-1 (hydrochloride) | 2624313-16-0 | Reference compound |
| HY-145516 | Desmethyl Bosentan | 253688-61-8 | Reference compound |
| HY-145517 | C6-Phytoceramide | 249728-94-7 | Reference compound |
| HY-145519 | Mu-6S-Palm-β-Glc | 229644-17-1 | Dye Reagents |
| HY-14551B | (S)-Osanetant | 182621-58-5 | Reference compound |
| HY-14551C | Osanetant (monohydrochloride) | 173050-51-6 | Reference compound |
| HY-14552 | Talnetant | 174636-32-9 | Reference compound |
| HY-145520 | (±)-2'-hydroxy Ceramide (d18:0/18:0) | 215528-91-9 | Reference compound |
| HY-145521 | 5(S)-HETrE | 195061-94-0 | Reference compound |
| HY-145522 | 13-Dimyristoyl-2-Eicosapentaenoyl Glycerol | 191786-55-7 | Reference compound |
| HY-145523 | OH-Chol | 191173-82-7 | Biochemical Assay Reagents |
| HY-145525 | Linoleoyl-L-carnitine (chloride) | 173686-75-4 | Reference compound |
| HY-145526 | Hydroxy celecoxib | 170571-00-3 | Reference compound |
| HY-145527 | Hexanoyl-L-carnitine (chloride) | 162067-53-0 | Natural Products |
| HY-145528 | Heptanoyl-L-carnitine (chloride) | 162041-08-9 | Reference compound |
| HY-145529 | Valeryl-L-carnitine (chloride) | 162040-64-4 | Natural Products |
| HY-14552A | Talnetant (hydrochloride) | 204519-66-4 | Reference compound |
| HY-145530 | (S)-Hydroxychloroquine (sulfate) | 155204-09-4 | Reference compound |
| HY-145531 | Mirtazapine N-oxide | 155172-12-6 | Reference compound |
| HY-145532 | S-Allylmercaptocysteine | 2281-22-3 | Reference compound |
| HY-145533 | 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid | 153666-19-4 | Reference compound |
| HY-145534 | trans-2-Octenoyl-L-carnitine | 152064-94-3 | Reference compound |
| HY-145535 | Tetracosanoyl-sulfatide | 151122-71-3 | Reference compound |
| HY-145537 | 1,3-Dipalmitoyl-2-eicosapentaenoyl glycerol | 148691-18-3 | Reference compound |
| HY-145538 | 2'-Deoxyguanosine 5'-monophosphate (disodium hydrate) | 146877-98-7 | Reference compound |
| HY-145539 | 12-Dipalmitoyl-sn-glycero-3-PS (sodium salt) | 145849-32-7 | Reference compound |
| HY-145539S | 12-Dipalmitoyl-sn-glycero-3-PS-d62 (sodium salt) | 327178-94-9 | Isotope-Labeled Compounds |
| HY-14554 | Pomaglumetad methionil (anhydrous) | 635318-55-7 | Reference compound |
| HY-145540 | 1,2-Dipalmitoyl-3-Octanoyl-rac-glycerol | 145134-89-0 | Reference compound |
| HY-145541 | 12-Dinonadecanoyl-rac-glycerol | 140456-19-5 | Reference compound |
| HY-145542 | Isovalerylcarnitine (chloride) | 139144-12-0 | Reference compound |
| HY-145542S | Isovalerylcarnitine-d9 (chloride) | 1334532-23-8 | Isotope-Labeled Compounds |
| HY-145543 | 9(S)10(S)13(S)-TriHOME | 135214-44-7 | Natural Products |
| HY-145544 | 1-Lauroyl-2-Elaidoyl-3-Palmitoyl-rac-glycerol | 134907-94-1 | Reference compound |
| HY-145545 | 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PE | 131350-53-3 | Reference compound |
| HY-145546 | 14(15)-EpETE | 131339-24-7 | Reference compound |
| HY-145547 | 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine | 123060-40-2 | Biochemical Assay Reagents |
| HY-145548 | cis-4,10,13,16-Docosatetraenoic acid | 122068-08-0 | Reference compound |
| HY-145549 | C20 Sphingomyelin (d18:1/20:0) | 121999-68-6 | Reference compound |
| HY-145550 | Amredobresib | 1610044-98-8 | Reference compound |
| HY-145551 | Atinvicitinib | 2169273-59-8 | Reference compound |
| HY-145552 | Azilsartan mepixetil | 1596357-16-2 | Reference compound |
| HY-145552A | Azilsartan mepixetil (potassium) | 2153458-32-1 | Reference compound |
| HY-145552S | Azilsartan mepixetil-d5 | | Isotope-Labeled Compounds |
| HY-145553 | Azilsartan mopivabil | 2271428-31-8 | Reference compound |
| HY-145554 | Bafrekalant | 2256770-44-0 | Reference compound |
| HY-145555 | Bersiporocin | 2241808-52-4 | Reference compound |
| HY-145556 | Bexirestrant | 2505067-70-7 | Reference compound |
| HY-145557 | Bezuclastinib | 1616385-51-3 | Reference compound |
| HY-145558 | Bliretrigine | 1233229-75-8 | Reference compound |
| HY-145559 | Cemdomespib | 1450642-92-8 | Reference compound |
| HY-145560 | Claficapavir | 2055732-24-4 | Reference compound |
| HY-145561 | Cudetaxestat | 1782070-21-6 | Reference compound |
| HY-145563 | Eciruciclib | 1868086-40-1 | Reference compound |
| HY-145564 | Emprumapimod | 765914-60-1 | Reference compound |
| HY-145564A | Emprumapimod (hydrochloride) | | Reference compound |
| HY-145565 | Enbezotinib | 2359649-81-1 | Reference compound |
| HY-145567 | Fasedienol | 23062-06-8 | Reference compound |
| HY-145568 | Feniralstat | 2166320-76-7 | Reference compound |
| HY-145569 | Fipravirimat | 1818867-24-1 | Reference compound |
| HY-145569A | Fipravirimat (dihydrochloride) | 2442512-14-1 | Reference compound |
| HY-14557 | Pimavanserin | 706779-91-1 | Reference compound |
| HY-145572 | Imlunestrant | 2408840-26-4 | Reference compound |
| HY-145572A | Imlunestrant (tosylate) | 2408840-41-3 | Reference compound |
| HY-145572B | (S)-Imlunestrant (tosylate) | 2408840-43-5 | Reference compound |
| HY-145574 | Iruplinalkib | 1854943-32-0 | Reference compound |
| HY-145575 | Itruvone | 21321-89-1 | Reference compound |
| HY-145576 | 2-Amino-8-oxononanoic acid | 1219456-00-4 | Reference compound |
| HY-145576B | 2-Amino-8-oxononanoic acid (hydrochloride) | 2984160-77-0 | Reference compound |
| HY-145577 | Lafadofensine | 914989-90-5 | Reference compound |
| HY-145577A | Lafadofensine (D-(-)-Mandelic acid) | | Reference compound |
| HY-145578 | Linaprazan glurate | 1228559-81-6 | Reference compound |
| HY-145579 | Linvencorvir | 1808248-05-6 | Reference compound |
| HY-145579R | Linvencorvir (Standard) | 1808248-05-6 | Reference Standards |
| HY-14557A | Pimavanserin (hemitartrate) | 706782-28-7 | Reference compound |
| HY-14557R | Pimavanserin (Standard) | 706779-91-1 | Reference Standards |
| HY-14558 | Tandospirone | 87760-53-0 | Reference compound |
| HY-145580 | Minzasolmin | 1802518-92-8 | Reference compound |
| HY-145580A | (S)-Minzasolmin | 1802518-91-7 | Reference compound |
| HY-145581 | Mitiperstat | 1933460-19-5 | Reference compound |
| HY-145583 | Mufemilast | 1255909-03-5 | Reference compound |
| HY-145584 | Nesuparib | 2055357-64-5 | Reference compound |
| HY-145585 | Onfasprodil | 1892581-29-1 | Reference compound |
| HY-145586 | Onradivir | 2200336-20-3 | Reference compound |
| HY-145586A | Onradivir (monohydrate) | 2375241-19-1 | Reference compound |
| HY-145587 | Paltimatrectinib | 2353522-15-1 | Reference compound |
| HY-145588 | Povorcitinib | 1637677-22-5 | Reference compound |
| HY-145588A | Povorcitinib (phosphate) | 1637677-33-8 | Reference compound |
| HY-145589 | Rafutrombopag | 2600513-51-5 | Reference compound |
| HY-14558R | Tandospirone (Standard) | 87760-53-0 | Reference Standards |
| HY-14558S | Tandospirone-d8 | 1794835-73-6 | Isotope-Labeled Compounds |
| HY-14559 | PRX-07034 (hydrochloride) | 903580-39-2 | Reference compound |
| HY-145590 | Retezorogant | 1950570-48-5 | Reference compound |
| HY-145592 | Ruzotolimod | 1948241-60-8 | Reference compound |
| HY-145593 | Aminooxy-PEG2-BCN | 2253965-14-7 | ADC Related |
| HY-145594 | Safusidenib | 1898206-17-1 | Reference compound |
| HY-145595 | Ferroptosis inducer-1 | 2375357-96-1 | Reference compound |
| HY-145595A | (1R,3R)-Ferroptosis inducer-1 | 2375357-97-2 | Reference compound |
| HY-145596 | Sirpefenicol | 1632310-24-7 | Reference compound |
| HY-145597 | KL-11743 | 1369452-53-8 | Reference compound |
| HY-145598 | Sovleplenib | 1415792-84-5 | Reference compound |
| HY-145599 | Tanuxiciclib | 1983983-64-7 | Reference compound |
| HY-145599A | Tanuxiciclib (trihydrochloride) | 1983984-11-7 | Reference compound |
| HY-14560 | Reboxetine | 71620-89-8 | Reference compound |
| HY-145601 | Tinengotinib | 2230490-29-4 | Reference compound |
| HY-145602 | Tulmimetostat | 2567686-02-4 | Reference compound |
| HY-145603 | Vanzacaftor | 2374124-49-7 | Reference compound |
| HY-145603A | (R)-Vanzacaftor | 2374124-48-6 | Reference compound |
| HY-145603S | Vanzacaftor-d4 | | Isotope-Labeled Compounds |
| HY-145604 | Vicasinabin | 1433361-02-4 | Reference compound |
| HY-145605 | Vutiglabridin | 1800188-47-9 | Reference compound |
| HY-145607 | Zagociguat | 2201048-82-8 | Reference compound |
| HY-145608 | Zilurgisertib | 2173389-57-4 | Reference compound |
| HY-145609 | Debotansine | | Reference compound |
| HY-14560A | (R,R)-Reboxetine (mesylate) | 105017-39-8 | Reference compound |
| HY-14560C | Reboxetine (mesylate) | 98769-84-7 | Reference compound |
| HY-14560CR | Reboxetine (mesylate) (Standard) | 98769-84-7 | Reference Standards |
| HY-14560S | Reboxetine-d5 (mesylate) | 1285918-53-7 | Isotope-Labeled Compounds |
| HY-14561 | Idazoxan | 79944-58-4 | Reference compound |
| HY-145610 | Mepixetil | | Reference compound |
| HY-145611 | Mopivabil | 2988562-84-9 | Reference compound |
| HY-145612 | Sudan red 7B | 6368-72-5 | Reference compound |
| HY-145612S | Sudan red 7B-d5 | | Isotope-Labeled Compounds |
| HY-145613 | 5-Phenylpentan-2-one | 2235-83-8 | Reference compound |
| HY-145614 | Sucistil | | Reference compound |
| HY-145615 | Pomalidomide-C12-NH2 (hydrochloride) | 2862774-02-3 | Reference compound |
| HY-145616 | Sudocetaxel | 1234218-62-2 | Reference compound |
| HY-145618 | Polvitolimod | 2389988-81-0 | Reference compound |
| HY-145619 | Abimtrelvir | 2647530-75-2 | Reference compound |
| HY-14561A | Idazoxan (hydrochloride) | 79944-56-2 | Reference compound |
| HY-14562 | TBPB | 634616-95-8 | Reference compound |
| HY-145620 | Zuvotolimod | 2355262-97-2 | ADC Related |
| HY-145622 | Mecbotamab vedotin | 2460400-64-8 | Reference compound |
| HY-145623 | Mulnitorsen | 2576358-63-7 | Reference compound |
| HY-145624 | Obeversen | 2304711-30-4 | Oligonucleotides |
| HY-145626 | Ozuriftamab | 2460399-44-2 | Inhibitory Antibodies |
| HY-145627 | Ozuriftamab vedotin | 2460400-11-5 | Reference compound |
| HY-145628 | CM398 | 1121931-70-1 | Reference compound |
| HY-145629 | Palsucibep pegol | 2218524-43-5 | Inhibitory Antibodies |
| HY-14563 | VU10010 | 633283-39-3 | Reference compound |
| HY-145632A | Pemvidutide (TFA) | | Peptides |
| HY-145633 | Sozinibercept | 2568358-31-4 | Inhibitory Antibodies |
| HY-145638 | Xalnesiran | 2538784-48-2 | Reference compound |
| HY-145638A | Xalnesiran (sodium) | 2538784-49-3 | Oligonucleotides |
| HY-14564 | GTS-21 | 148372-04-7 | Reference compound |
| HY-145640 | Vimnerixin | 1418112-77-2 | Reference compound |
| HY-145641 | Crexavibart | 2599039-61-7 | Inhibitory Antibodies |
| HY-145642 | Masavibart | 2640223-84-1 | Inhibitory Antibodies |
| HY-145643 | Nepuvibart | 2640224-48-0 | Inhibitory Antibodies |
| HY-145644 | Ogalvibart | 2599039-60-6 | Inhibitory Antibodies |
| HY-145645 | Paridiprubart | 2641646-59-3 | Inhibitory Antibodies |
| HY-14564A | GTS-21 (dihydrochloride) | 156223-05-1 | Reference compound |
| HY-14565 | Pozanicline | 161417-03-4 | Reference compound |
| HY-145651 | Et-29 | 2166487-23-4 | Reference compound |
| HY-145652 | Narmafotinib | 1393653-34-3 | Reference compound |
| HY-145653 | GSK2647544 | 1380426-95-8 | Reference compound |
| HY-145655 | CDK7-IN-11 | 2414896-32-3 | Reference compound |
| HY-145656 | 3-Oxochenodeoxycholic acid | 4185-00-6 | Reference compound |
| HY-145657 | Benzoquinoquinoxaline | 207671-99-6 | Reference compound |
| HY-14566 | Donepezil | 120014-06-4 | Reference compound |
| HY-145663 | HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM | 2243689-64-5 | ADC Related |
| HY-145664 | Myt1-IN-1 | 2719749-02-5 | Reference compound |
| HY-145665 | Myt1-IN-2 | 2719748-43-1 | Reference compound |
| HY-145666 | Myt1-IN-3 | 2719793-54-9 | Reference compound |
| HY-145667 | Biotinylated-JQ1 | 1635437-52-3 | Reference compound |
| HY-145668 | Cyclopentenyl uracil | 90597-20-9 | Reference compound |
| HY-145669 | DIF-3 | 113411-17-9 | Reference compound |
| HY-14566A | (S)-Donepezil | 142057-80-5 | Reference compound |
| HY-14566R | Donepezil (Standard) | 120014-06-4 | Reference Standards |
| HY-14566S | Donepezil-d7 (hydrochloride) | 1261394-20-0 | Isotope-Labeled Compounds |
| HY-14566S1 | Donepezil-d5 | 1128086-25-8 | Isotope-Labeled Compounds |
| HY-14566S3 | Donepezil-d4 | 1219908-72-1 | Isotope-Labeled Compounds |
| HY-14567 | Ciproxifan | 184025-18-1 | Reference compound |
| HY-145670 | cis,trans-Germacrone | 32663-51-7 | Reference compound |
| HY-145671 | 5-(3-hydroxyphenyl)-5-phenylhydantoin | 30074-03-4 | Reference compound |
| HY-145673 | Thiamphenicol glycinate | 2393-92-2 | Reference compound |
| HY-145674 | HDP 30.1699 | 2004724-36-9 | Reference compound |
| HY-145675A | (R)-TCB2 | 912342-36-0 | Reference compound |
| HY-145676 | Sodium phenyl ethylamido hyaluronate（20% substitution） | | Reference compound |
| HY-145676A | Sodium phenyl ethylamido hyaluronate（30% substitution） | | Reference compound |
| HY-145676E | Sodium phenyl ethylamido hyaluronate（10% substitution） | | Reference compound |
| HY-145678 | α-HNJNAc | 1417906-42-3 | Reference compound |
| HY-14567A | Ciproxifan (hydrochloride) | 1049741-81-2 | Reference compound |
| HY-14568 | DCCCyB | 1236046-15-3 | Reference compound |
| HY-145684 | EP2 receptor antagonist-1 | 848920-08-1 | Reference compound |
| HY-145685 | RECQL5-IN-1 | 2718170-45-5 | Reference compound |
| HY-145686 | AV023 | 1107710-62-2 | Reference compound |
| HY-145687 | HDAC-IN-32 | 2766688-17-7 | Reference compound |
| HY-145688 | HDAC-IN-33 | 2766688-19-9 | Reference compound |
| HY-145689 | PI5P4Ks-IN-1 | 959560-36-2 | Reference compound |
| HY-14569 | CDPPB | 781652-57-1 | Reference compound |
| HY-145690 | HP1328 | 2245074-20-6 | Reference compound |
| HY-145691 | HP1142 | 381173-58-6 | Reference compound |
| HY-145692 | Cas9-IN-3 | 2322051-02-3 | Reference compound |
| HY-145693 | CDK5-IN-2 | 2639542-22-4 | Reference compound |
| HY-145694 | CDK5-IN-3 | 2639542-32-6 | Reference compound |
| HY-145695 | Dual AChE-MAO B-IN-1 | | Reference compound |
| HY-145696 | SJ10542 | 2789678-92-6 | Reference compound |
| HY-145697 | GPR84 antagonist 2 | 2244269-74-5 | Reference compound |
| HY-145698 | UCSF678 | 2361697-55-2 | Reference compound |
| HY-145699 | UCSF686 | 2248852-19-7 | Reference compound |
| HY-14570 | Triphen diol | 1213777-80-0 | Reference compound |
| HY-145700 | UCSF648 | 2637090-55-0 | Reference compound |
| HY-145701 | MEK1/2-IN-2 | | Reference compound |
| HY-145702 | MAP855 | 1660107-77-6 | Reference compound |
| HY-145703 | SHP2 protein degrader-2 | 2740582-16-3 | Reference compound |
| HY-145704 | Antimalarial agent 8 | 2715222-97-0 | Reference compound |
| HY-145705 | Pencitabine | 2249843-29-4 | Reference compound |
| HY-145706 | A2A/A1 AR antagonist-1 | 2445615-24-5 | Reference compound |
| HY-145707 | BAY-179 | 2764880-87-5 | Reference compound |
| HY-145708 | Dual AChE-MAO B-IN-2 | 1801157-64-1 | Reference compound |
| HY-145709 | Ar-V7-IN-1 | 2230880-25-6 | Reference compound |
| HY-14571 | E7820 | 289483-69-8 | Reference compound |
| HY-145712 | ElteN378 | 1421366-99-5 | Reference compound |
| HY-145713 | GS-8873 | 2241575-59-5 | Reference compound |
| HY-145713A | GS-8873 (TFA) | 2241575-60-8 | Reference compound |
| HY-145714 | NHS-NH-(diethylamino)ethyl benzoate | 2050902-45-7 | Reference compound |
| HY-145715 | Azido-PEG2-VHL | 2597167-22-9 | Reference compound |
| HY-145716 | Nafoxidine | 1845-11-0 | Reference compound |
| HY-145717 | Deoliosyl-3C-α-L-digitoxosyl-MTM | 1009637-75-5 | Reference compound |
| HY-14572 | PR-104A | 680199-06-8 | Reference compound |
| HY-145720 | Cemdisiran | 1639264-46-2 | Oligonucleotides |
| HY-145720A | Cemdisiran (sodium) | | Oligonucleotides |
| HY-145721 | Mongersen | 1443994-46-4 | Oligonucleotides |
| HY-145721A | Mongersen (sodium) | 1443994-98-6 | Oligonucleotides |
| HY-145722 | Apatorsen (sodium) | 915443-09-3 | Oligonucleotides |
| HY-145722A | Apatorsen | 1002331-21-6 | Oligonucleotides |
| HY-145723 | MAX-40279 | 2070931-57-4 | Reference compound |
| HY-145723A | MAX-40279 (hydrochloride) | 2388506-51-0 | Reference compound |
| HY-145723B | MAX-40279 (hemifumarate) | 2388506-43-0 | Reference compound |
| HY-145723C | MAX-40279 (hemiadipate) | 2388506-44-1 | Reference compound |
| HY-145724 | Drisapersen | 1251830-50-8 | Oligonucleotides |
| HY-145724A | Drisapersen (sodium) | 1181666-20-5 | Oligonucleotides |
| HY-145725 | Baliforsen (sodium) | 1687746-79-7 | Oligonucleotides |
| HY-145725A | Baliforsen | 1698048-23-5 | Oligonucleotides |
| HY-145726 | ISIS 104838 | 250755-32-9 | Oligonucleotides |
| HY-145726A | ISIS 104838 (sodium) | | Oligonucleotides |
| HY-145727 | Volanesorsen | 915430-78-3 | Oligonucleotides |
| HY-145727A | Volanesorsen (sodium) | 1573402-50-2 | Oligonucleotides |
| HY-145728 | Alicaforsen | 185229-68-9 | Oligonucleotides |
| HY-145728A | Alicaforsen (sodium) | 331257-52-4 | Oligonucleotides |
| HY-145728B | (R/S)-Alicaforsen | | Oligonucleotides |
| HY-145729 | Danvatirsen | 1402357-06-5 | Oligonucleotides |
| HY-145729A | Danvatirsen (sodium) | | Oligonucleotides |
| HY-14573 | SJG-136 | 232931-57-6 | ADC Related |
| HY-145731 | Fructose-leucine | 34393-18-5 | Reference compound |
| HY-145733 | DI-1859 | 2247061-09-0 | Reference compound |
| HY-145734 | AMXI-5001 | 2170491-77-5 | Reference compound |
| HY-145734A | AMXI-5001 (hydrochloride) | | Reference compound |
| HY-145735 | Allyl (2-aminoethyl)carbamate | 223741-66-0 | Reference compound |
| HY-145736 | β-Glucuronide-dPBD-PEG5-NH2 | 2246363-68-6 | ADC Related |
| HY-145736A | β-Glucuronide-dPBD-PEG5-NH2 (TFA) | 2246364-63-4 | ADC Related |
| HY-145737 | PROTAC SOS1 degrader-1 | 2913185-35-8 | Reference compound |
| HY-145737A | PROTAC SOS1 degrader-1 (TFA) | | Reference compound |
| HY-145739 | ATX-0114 | 2230647-30-8 | Reference compound |
| HY-14574 | PF-03814735 | 942487-16-3 | Reference compound |
| HY-145741 | MptpB-IN-1 | 2244622-44-2 | Reference compound |
| HY-145742 | 1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol (sodium) | 200880-42-8 | Oligonucleotides |
| HY-145742S | 1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol-d70 (sodium) | 326495-47-0 | Isotope-Labeled Compounds |
| HY-145746 | Sulfo-Cy5 azide | 1782950-80-4 | Dye Reagents |
| HY-145748 | SYUIQ-5 | 188630-47-9 | Reference compound |
| HY-145749 | PARPYnD | 2561483-27-8 | Reference compound |
| HY-14575 | Nastorazepide (hemicalcium) | 343326-69-2 | Reference compound |
| HY-145750 | Trimethylolpropane tris(3-mercaptopropionate) | 33007-83-9 | Biochemical Assay Reagents |
| HY-145751 | 7α-Hydroxy-DHEA | 53-00-9 | Natural Products |
| HY-145752 | HaloPROTAC-E | 2365478-58-4 | Reference compound |
| HY-145755 | Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine | 906258-48-8 | Reference compound |
| HY-145757 | Elevenostat | 1454902-97-6 | Reference compound |
| HY-145758 | FEN1-IN-SC13 | 2098776-03-3 | Reference compound |
| HY-145759 | Mutant p53 modulator-1 | 2746371-35-5 | Reference compound |
| HY-145761 | AMPA-IN-1 | 2097604-91-4 | Reference compound |
| HY-145762 | YM281 | 2230914-84-6 | Reference compound |
| HY-145765 | JQAD1 | 2417097-18-6 | Reference compound |
| HY-145766 | Anisole-piperazine-methanone-benzothiazole-p-methylpiperidine | 906258-69-3 | Reference compound |
| HY-145767A | SN-38-CO-DMEDA (TFA) | 1224601-17-5 | ADC Related |
| HY-145768 | PD-1/PD-L1-IN-18 | 2648851-27-6 | Reference compound |
| HY-145769 | N2S2-CBMBC | 2547100-02-5 | Reference compound |
| HY-145770 | PD-1/PD-L1-IN-19 | 2156651-18-0 | Reference compound |
| HY-145771 | PD-1/PD-L1-IN-20 | 2159138-01-7 | Reference compound |
| HY-145772 | PD-1/PD-L1-IN-21 | 2158336-16-2 | Reference compound |
| HY-145773 | PD-1/PD-L1-IN-22 | 2159063-12-2 | Reference compound |
| HY-145774 | PD-1/PD-L1-IN-23 | 2597056-04-5 | Reference compound |
| HY-145775 | hIgG-hFc receptor-IN-1 | 1425051-22-4 | Reference compound |
| HY-145776 | ALV1 | 2438124-79-7 | Reference compound |
| HY-145777 | AGI-43192 | 2377491-54-6 | Reference compound |
| HY-145778 | AGI-41998 | 2377492-26-5 | Reference compound |
| HY-145779 | H-Glu(Met-OH)-OH | 17663-87-5 | Peptides |
| HY-145779A | H-Glu(Met-OH)-OH (TFA) | | Peptides |
| HY-14578 | Taxiresinol | 40951-69-7 | Natural Products |
| HY-145780 | Cytidine 5′-diphosphoethanolamine | 3036-18-8 | Reference compound |
| HY-145781 | β-L-Fucopyranosyl phosphate | 16562-59-7 | Reference compound |
| HY-145781A | β-L-Fucopyranosyl phosphate (cyclohexanamine) | 40591-57-9 | Biochemical Assay Reagents |
| HY-145782 | Witepsol | 91744-42-2 | Biochemical Assay Reagents |
| HY-145785 | ADH-6 | 2227429-65-2 | Reference compound |
| HY-145785A | ADH-6 (TFA) | 2990065-87-5 | Reference compound |
| HY-145786 | Abiraterone decanoate | 2486052-18-8 | Reference compound |
| HY-145788 | 5-Cyclopropylpentanal | 147159-38-4 | Reference compound |
| HY-145789 | Difluorocyclooctyne-CH2-benzoic acid | 1047997-30-7 | Biochemical Assay Reagents |
| HY-14579 | (+)-Isolariciresinol | 548-29-8 | Natural Products |
| HY-145790 | Difluorocyclooctyne-CH2-COOH | 1047997-31-8 | Biochemical Assay Reagents |
| HY-145791 | Dideoxycytidinene | 7481-88-1 | Reference compound |
| HY-145793 | FTT5 | 2328129-27-5 | Oligonucleotides |
| HY-145794 | ZA3-Ep10 | 2090299-48-0 | Oligonucleotides |
| HY-145795 | OF-02 | 1883431-67-1 | Oligonucleotides |
| HY-145796 | 503O13 | 1566560-20-0 | Biochemical Assay Reagents |
| HY-145797 | L343 | 1443520-22-6 | Biochemical Assay Reagents |
| HY-145798 | N1,N3,N5-Tris(4-dodecylhexadecyl)benzene-1,3,5-tricarboxamide | 2922283-38-1 | Oligonucleotides |
| HY-145799 | 5A2-SC8 | 1857341-90-2 | Oligonucleotides |
| HY-145799A | 5A2-SC8 (TFA) | | Reference compound |
| HY-145800 | GFP150 (TFA) | 2366176-90-9 | Dye Reagents |
| HY-145801 | XT2 | 2582816-37-1 | Reference compound |
| HY-145802 | KIF18A-IN-2 | 2600559-20-2 | Reference compound |
| HY-145803 | KIF18A-IN-3 | 2600577-49-7 | Reference compound |
| HY-145804 | Palacaparib | 2756333-39-6 | Reference compound |
| HY-145806 | 13-cis-Retinyl acetate | 34356-31-5 | Reference compound |
| HY-145809 | FASN-IN-5 | 1309805-49-9 | Reference compound |
| HY-14581 | Palomid 529 | 914913-88-5 | Reference compound |
| HY-145812 | CRK12-IN-1 | 1990479-14-5 | Reference compound |
| HY-145813 | MU1656 | 2766698-38-6 | Reference compound |
| HY-145814 | HSP90-IN-9 | 2765247-36-5 | Reference compound |
| HY-145815 | JPS014 | 2669785-76-4 | Reference compound |
| HY-145815A | JPS014 (TFA) | | Reference compound |
| HY-145816 | JPS016 | 2669785-77-5 | Reference compound |
| HY-145816A | JPS016 (TFA) | | Reference compound |
| HY-145817 | (Rac)-lunresertib | 2719749-28-5 | Reference compound |
| HY-145817A | lunresertib | 2719793-90-3 | Reference compound |
| HY-145817B | (R)-lunresertib | 2719793-91-4 | Reference compound |
| HY-145818 | JPS035 | 2669785-84-4 | Reference compound |
| HY-145819 | JPS036 | 2669785-85-5 | Reference compound |
| HY-145820 | Tubulin inhibitor 14 | 2767446-34-2 | Reference compound |
| HY-145821 | Tubulin inhibitor 15 | 2767446-36-4 | Reference compound |
| HY-145822 | Tubulin inhibitor 16 | 2767446-32-0 | Reference compound |
| HY-145823 | EGFR-IN-42 | 3031307-73-7 | Reference compound |
| HY-145824 | EGFR-IN-43 | 3031307-74-8 | Reference compound |
| HY-145825 | Mcl-1 inhibitor 7 | 2417463-87-5 | Reference compound |
| HY-145825A | (E)-Mcl-1 inhibitor 7 | 2417463-86-4 | Reference compound |
| HY-145826 | Mcl-1 inhibitor 8 | 2388471-31-4 | Reference compound |
| HY-145827 | KIF18A-IN-4 | 1197522-21-6 | Reference compound |
| HY-145828 | Microtubule inhibitor 2 | 3031328-45-4 | Reference compound |
| HY-145829 | Tofacitinib Prodrug-1 | | Reference compound |
| HY-145830 | AC1-IN-1 | 2762422-55-7 | Reference compound |
| HY-145831 | sEH/AChE-IN-1 | 2490589-08-5 | Reference compound |
| HY-145832 | sEH/AChE-IN-2 | 2490589-09-6 | Reference compound |
| HY-145833 | sEH/AChE-IN-3 | 2490589-11-0 | Reference compound |
| HY-145833A | sEH/AChE-IN-4 | 2490589-12-1 | Reference compound |
| HY-145835 | PERK-IN-5 | 2616821-91-9 | Reference compound |
| HY-145835A | (S)-PERK-IN-5 | 2616821-92-0 | Reference compound |
| HY-145836 | FGFR4-IN-8 | 2765240-52-4 | Reference compound |
| HY-145837 | Y1R probe-1 | 2773476-41-6 | Reference compound |
| HY-145838 | AAK1-IN-4 | 1815612-79-3 | Reference compound |
| HY-145839 | AAK1-IN-5 | 1815613-44-5 | Reference compound |
| HY-145840 | Pol I-IN-1 | 2765318-69-0 | Reference compound |
| HY-145841 | 5-HT2A receptor agonist-2 | 528525-37-3 | Reference compound |
| HY-145842 | Encephalitic alphavirus-IN-1 | | Reference compound |
| HY-145843 | c-Myc inhibitor 5 | | Reference compound |
| HY-145844 | EGFR-IN-44 | | Reference compound |
| HY-145845 | HDAC1/MAO-B-IN-1 | 2759855-37-1 | Reference compound |
| HY-145846 | iNOs-IN-1 | | Reference compound |
| HY-145848 | ERRγ agonist-1 | | Reference compound |
| HY-145849 | VEGFR2-IN-1 | 2765224-55-1 | Reference compound |
| HY-14584A | PQ-1 (succinate) | 955995-51-4 | Reference compound |
| HY-14585 | Estrone O-sulfamate | 148672-09-7 | Reference compound |
| HY-145850 | EV-A71-IN-1 | 2413648-96-9 | Reference compound |
| HY-145851 | Top/HDAC-IN-1 | 2775446-49-4 | Reference compound |
| HY-145852 | Top/HDAC-IN-2 | 2775446-64-3 | Reference compound |
| HY-145853 | GA-O-02 | | Reference compound |
| HY-145854 | GA-O-06 | | Reference compound |
| HY-145855 | J-1063 | 2374772-46-8 | Reference compound |
| HY-145856 | VEGFR-2-IN-11 | | Reference compound |
| HY-145857 | GRP78-IN-1 | | Reference compound |
| HY-145858 | Chalcones A-N-5 | 2756846-09-8 | Reference compound |
| HY-145859 | Topo I-IN-1 | 2763655-68-9 | Reference compound |
| HY-14586 | Irosustat | 288628-05-7 | Reference compound |
| HY-145860 | PHGDH-IN-2 | | Reference compound |
| HY-145861 | LSD1-IN-14 | 2698340-11-1 | Reference compound |
| HY-145862 | 5-HT6/5-HT2AR antagonist-1 | 2763654-60-8 | Reference compound |
| HY-145864 | VEGFR-2-IN-12 | | Reference compound |
| HY-145865 | c-Met/MEK1/Flt-3-IN-1 | | Reference compound |
| HY-145866 | Antiproliferative agent-3 | | Reference compound |
| HY-145867 | EGFR-IN-45 | 2765560-03-8 | Reference compound |
| HY-145868 | Tubulin polymerization-IN-3 | | Reference compound |
| HY-145869 | Anti-inflammatory agent 12 | | Reference compound |
| HY-145870 | Anti-inflammatory agent 13 | | Reference compound |
| HY-145871 | BA38017 | 1333905-67-1 | Reference compound |
| HY-145872 | HBV-IN-20 | 2750254-34-1 | Reference compound |
| HY-145873 | BI-10 | 2759037-58-4 | Reference compound |
| HY-145874 | Antibacterial agent 76 | 2902561-25-3 | Reference compound |
| HY-145875 | Antibacterial agent 77 | 2902561-28-6 | Reference compound |
| HY-145876 | Antibacterial agent 78 | 2902561-42-4 | Reference compound |
| HY-145877 | Antibacterial agent 79 | 2902561-44-6 | Reference compound |
| HY-145878 | Antibacterial agent 80 | 2902561-34-4 | Reference compound |
| HY-145879 | Nrf2 activator-2 | 2770448-53-6 | Reference compound |
| HY-14588 | Lopinavir | 192725-17-0 | Reference compound |
| HY-145880 | Elongation factor P-IN-1 | 2906180-02-5 | Reference compound |
| HY-145881 | Elongation factor P-IN-2 | 2906180-05-8 | Reference compound |
| HY-145882 | BOD-NH-NP | 3004972-07-7 | Dye Reagents |
| HY-145884 | BTK-IN-8 | 2824922-28-1 | Reference compound |
| HY-145885 | TLR7/8 agonist 6 | 2115702-83-3 | Reference compound |
| HY-145886 | TLR7/8 antagonist 1 | 2901020-63-9 | Reference compound |
| HY-145887 | BCR-ABL1-IN-1 | 1488090-21-6 | Reference compound |
| HY-145888 | Antioxidant agent-2 | 2250106-92-2 | Reference compound |
| HY-145889 | LC kinetic stabilizer-1 | 2495750-19-9 | Reference compound |
| HY-14588R | Lopinavir (Standard) | 192725-17-0 | Reference Standards |
| HY-14588S | (rel)-Lopinavir-d8 | 1322625-54-6 | Isotope-Labeled Compounds |
| HY-14588S1 | Lopinavir-d8 | 1224729-35-4 | Isotope-Labeled Compounds |
| HY-14588S2 | Lopinavir-d7 | 1432060-78-0 | Isotope-Labeled Compounds |
| HY-14589 | Chrysin | 480-40-0 | Natural Products |
| HY-145890 | LC kinetic stabilizer-2 | 2495750-20-2 | Reference compound |
| HY-145891 | B10-S | 2210238-26-7 | Reference compound |
| HY-145892 | MrgprX2 antagonist-6 | 2902573-97-9 | Reference compound |
| HY-145893 | MrgprX2 antagonist-7 | 2902573-98-0 | Reference compound |
| HY-145894 | NaPi2b-IN-2 | 2227445-31-8 | Reference compound |
| HY-145895 | SNIPER(TACC3)-11 | 2906151-68-4 | Reference compound |
| HY-145896 | Anti-osteoporosis agent-1 | 2761577-50-6 | Reference compound |
| HY-145897 | NMDA-IN-2 | 2761731-14-8 | Reference compound |
| HY-145898 | WBC100 | 2095780-08-6 | Reference compound |
| HY-145899 | PKN1/2-IN-1 | 942425-34-5 | Reference compound |
| HY-14589R | Chrysin (Standard) | 480-40-0 | Reference Standards |
| HY-14590 | Kaempferol | 520-18-3 | Natural Products |
| HY-145900 | S100A2-p53-IN-1 | 2766609-08-7 | Reference compound |
| HY-145902 | PDGFRα/FLT3-ITD-IN-1 | 2761259-05-4 | Reference compound |
| HY-145903 | PDGFRα/FLT3-ITD-IN-2 | 2761259-09-8 | Reference compound |
| HY-145904 | PDGFRα/FLT3-ITD-IN-3 | 2761259-22-5 | Reference compound |
| HY-145905 | D4R antagonist-1 | 2846077-19-6 | Reference compound |
| HY-145906 | D4R antagonis-2 | 2846077-70-9 | Reference compound |
| HY-145907 | p53-HDM2-IN-1 | | Reference compound |
| HY-145908 | Antitumor agent-49 | 2763914-21-0 | Reference compound |
| HY-145909 | BRD4 Inhibitor-17 | 2835555-10-5 | Reference compound |
| HY-14590R | Kaempferol (Standard) | 520-18-3 | Reference Standards |
| HY-145910 | NLRP3-IN-6 | | Reference compound |
| HY-145911 | NLRP3-IN-7 | | Reference compound |
| HY-145912 | RYL-552S | 1801444-69-8 | Reference compound |
| HY-145913 | m7GpppApG | 80010-97-5 | Oligonucleotides |
| HY-145913A | m7GpppApG (triammonium) | | Oligonucleotides |
| HY-145915 | ZINC09659342 | 1668604-47-4 | Reference compound |
| HY-145915A | (E/Z)-ZINC09659342 | 591726-26-0 | Reference compound |
| HY-145917 | SARM1-IN-2 | 2396592-52-0 | Reference compound |
| HY-145918 | MRT-14 | 1263131-83-4 | Reference compound |
| HY-145919 | hGPR91 antagonist 3 | 1314796-31-0 | Reference compound |
| HY-14592 | Tectochrysin | 520-28-5 | Natural Products |
| HY-145921 | ChemR23-IN-3 | 3032433-98-7 | Reference compound |
| HY-145922 | ChemR23 ligand-1 | | Reference compound |
| HY-145923 | Osunprotafib | 2489404-97-7 | Reference compound |
| HY-145924 | BAY 2666605 | 2275774-60-0 | Reference compound |
| HY-145925B | CFT8634 | 2704617-96-7 | Reference compound |
| HY-145925C | (S,R)-CFT8634 | 2704617-95-6 | Reference compound |
| HY-145926 | MRTX0902 | 2654743-22-1 | Reference compound |
| HY-145927 | NXP800 | 1693734-80-3 | Reference compound |
| HY-145928 | Divarasib | 2417987-45-0 | Reference compound |
| HY-145928B | Divarasib (adipate) | 2762240-36-6 | Reference compound |
| HY-145929 | MC-Val-Cit-PAB-Exatecan | 2504068-28-2 | ADC Related |
| HY-14592R | Tectochrysin (Standard) | 520-28-5 | Reference Standards |
| HY-145931 | CC214-2 | 1228012-18-7 | Reference compound |
| HY-145932 | DMA-135 (hydrochloride) | 2237925-62-9 | Reference compound |
| HY-145933 | BJJF078 | 2531244-56-9 | Reference compound |
| HY-145934 | UDP-GalNAz (disodium) | 653600-61-4 | Oligonucleotides |
| HY-145934A | UDP-GlcNAz (disodium) | 1611490-64-2 | Biochemical Assay Reagents |
| HY-145935 | NT219 | 1198078-60-2 | Reference compound |
| HY-145937 | PK9327 | 2413987-20-7 | Reference compound |
| HY-145938 | OncoFAP | 2639365-69-6 | Reference compound |
| HY-145939 | BAY-888 | 2468783-75-5 | Reference compound |
| HY-145940 | BAY-204 | 2468784-57-6 | Reference compound |
| HY-145941 | AETA | 44992-01-0 | Biochemical Assay Reagents |
| HY-145942 | Octenyl succinic anhydride | 26680-54-6 | Biochemical Assay Reagents |
| HY-145943 | MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT | 2639190-44-4 | ADC Related |
| HY-145944 | ASR-488 | 2690312-65-1 | Reference compound |
| HY-145945 | MAGL-IN-6 | 2414320-29-7 | Reference compound |
| HY-145946 | BRM/BRG1 ATP Inhibitor-2 | 2368900-77-8 | Reference compound |
| HY-145947 | PROTAC BRD9 Degrader-5 | 2704616-86-2 | Reference compound |
| HY-145949 | Remdesivir de(ethylbutyl 2-aminopropanoate) | 2607871-93-0 | Reference compound |
| HY-14595 | Biochanin A | 491-80-5 | Natural Products |
| HY-145950 | 2′-Deoxy-5-nitrocytidine | 69100-02-3 | Reference compound |
| HY-145951 | Amidate-VC-PAB-MMAF | 2202782-90-7 | ADC Related |
| HY-145952 | (2E,9Z)-Octadeca-2,9-dienoic acid | 182369-03-5 | Reference compound |
| HY-145953 | VY-3-135 | 1824637-41-3 | Reference compound |
| HY-145954 | NAT2-IN-1 | 856005-97-5 | Reference compound |
| HY-145955 | Stearoyl glutamic acid (sodium) | 38517-23-6 | Reference compound |
| HY-145958 | Sirt2-IN-6 | 2243151-81-5 | Reference compound |
| HY-145959 | AMPA receptor antagonist-3 | 923272-18-8 | Reference compound |
| HY-14595R | Biochanin A (Standard) | 491-80-5 | Reference Standards |
| HY-14596 | Genistein | 446-72-0 | Natural Products |
| HY-145960 | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 | 2413016-49-4 | Reference compound |
| HY-145961 | TLR7 agonist 4 | 2413016-42-7 | Reference compound |
| HY-145962 | MRTX-EX185 | | Reference compound |
| HY-145962A | MRTX-EX185 (formic) | | Reference compound |
| HY-145963 | DRB18 | 2863686-81-9 | Reference compound |
| HY-145964 | INE963 | 2640567-43-5 | Reference compound |
| HY-145965 | Ferroportin-IN-1 | 2443432-65-1 | Reference compound |
| HY-145967 | FT709 | 2413991-74-7 | Reference compound |
| HY-145967A | (R)-FT709 | 2413991-75-8 | Reference compound |
| HY-145969 | β-S-ARCA | 1093268-63-3 | Oligonucleotides |
| HY-145969A | β-S-ARCA (triammonium) | | Oligonucleotides |
| HY-14596R | Genistein (Standard) | 446-72-0 | Reference Standards |
| HY-14596S | Genistein-d4 | 187960-08-3 | Isotope-Labeled Compounds |
| HY-145973 | 3'OMe-m7GpppAmpG | 2089461-55-0 | Oligonucleotides |
| HY-145973A | 3'OMe-m7GpppAmpG (ammonium) solution (100mM) | | Oligonucleotides |
| HY-145974 | m7GpppAmpG | 62858-30-4 | Oligonucleotides |
| HY-145974A | m7GpppAmpG (ammonium) | | Oligonucleotides |
| HY-145975 | m7Gpppm6AmpG | 71340-22-2 | Oligonucleotides |
| HY-145975A | m7Gpppm6AmpG (ammonium) solution (100mM) | | Oligonucleotides |
| HY-145976 | m7GpppGpG | 133608-76-1 | Oligonucleotides |
| HY-145977 | m7GpppGmpG | 1258049-00-1 | Oligonucleotides |
| HY-145977A | m7GpppGmpG (ammonium) | | Oligonucleotides |
| HY-145979 | m7GpppUmpG | 2638447-87-5 | Oligonucleotides |
| HY-14598 | Diethylstilbestrol | 56-53-1 | Reference compound |
| HY-145980 | m7GpppUpG | 2638447-85-3 | Oligonucleotides |
| HY-145981 | m7GpppCpG | 2638447-78-4 | Oligonucleotides |
| HY-145982 | m7GpppCmpG | 2089461-56-1 | Oligonucleotides |
| HY-145983 | Suc-Gly-Pro-AMC | 80049-85-0 | Reference compound |
| HY-145985 | CBR-3465 | 2225883-59-8 | Reference compound |
| HY-145986 | CBR-6672 | 2225885-40-3 | Reference compound |
| HY-145988 | COX-2-IN-11 | 1023741-06-1 | Reference compound |
| HY-145989 | Aminobenzenesulfonic auristatin E | 1800462-99-0 | ADC Related |
| HY-145989A | Aminobenzenesulfonic auristatin E (TFA) | | ADC Related |
| HY-145989S | Aminobenzenesulfonic auristatin E-d8 | | Isotope-Labeled Compounds |
| HY-14598R | Diethylstilbestrol (Standard) | 56-53-1 | Reference Standards |
| HY-14598S | Diethylstilbestrol-d8 | 91318-10-4 | Isotope-Labeled Compounds |
| HY-14598S1 | Diethylstilbestrol-d3 | 58322-36-4 | Isotope-Labeled Compounds |
| HY-145990 | FABPs ligand 6 | 2988135-14-2 | Reference compound |
| HY-145991 | Ribavirin carboxylic acid | 39925-19-4 | Reference compound |
| HY-145991R | Ribavirin carboxylic acid (Standard) | 39925-19-4 | Reference Standards |
| HY-145992 | KCNQ1 activator-1 | 1008671-38-2 | Reference compound |
| HY-145994 | Obeldesivir | 2647441-36-7 | Reference compound |
| HY-145995 | CS12192 | 1888318-68-0 | Reference compound |
| HY-145996 | STC314 | 186295-19-2 | Reference compound |
| HY-145997 | MRGPRX4 modulator-1 | 2492596-61-7 | Reference compound |
| HY-145998 | 2′-O-Methyl-8-methyl guanosine | 2306782-64-7 | Oligonucleotides |
| HY-14600 | Rosiglitazone (maleate) | 155141-29-0 | Reference compound |
| HY-146000 | Influenza virus-IN-3 | 2412451-16-0 | Reference compound |
| HY-146001 | Influenza virus-IN-4 | 2133818-85-4 | Reference compound |
| HY-146002 | IDH2R140Q-IN-1 | 2469044-23-1 | Reference compound |
| HY-146003 | FAAL-IN-1 | 1965250-07-0 | Reference compound |
| HY-146004 | Influenza A virus-IN-4 | 2390067-58-8 | Reference compound |
| HY-146005 | Tau-aggregation and neuroinflammation-IN-1 | 2175953-98-5 | Reference compound |
| HY-146006 | Tubulin/MMP-IN-1 | | Reference compound |
| HY-146007 | hCAIX-IN-17 | | Reference compound |
| HY-146008 | hCAII-IN-3 | 2770927-76-7 | Reference compound |
| HY-146009 | AL-470 | 2671019-15-9 | Reference compound |
| HY-14600R | Rosiglitazone (maleate) (Standard) | 155141-29-0 | Reference Standards |
| HY-14601 | Pioglitazone (hydrochloride) | 112529-15-4 | Reference compound |
| HY-146010 | Carbonic anhydrase inhibitor 13 | 2488872-31-5 | Reference compound |
| HY-146011 | HBV-IN-21 | 2460957-52-0 | Reference compound |
| HY-146012 | HIV-1 protease-IN-4 | | Reference compound |
| HY-146013 | Sirt1/2-IN-1 | 2402779-21-7 | Reference compound |
| HY-146014 | Multi-kinase-IN-1 | 2470807-67-9 | Reference compound |
| HY-146015 | HIV-1 inhibitor-21 | 2554620-04-9 | Reference compound |
| HY-146016 | PI3K/mTOR Inhibitor-5 | 2456295-60-4 | Reference compound |
| HY-146017 | HIV-1 inhibitor-22 | 2554618-33-4 | Reference compound |
| HY-146018 | HIV-1 inhibitor-23 | 2554622-28-3 | Reference compound |
| HY-146019 | HIV-1 inhibitor-24 | 2475658-75-2 | Reference compound |
| HY-146019A | HIV-1 inhibitor-25 | 2475658-74-1 | Reference compound |
| HY-14601R | Pioglitazone (hydrochloride) (Standard) | 112529-15-4 | Reference Standards |
| HY-14602 | Tramiprosate | 3687-18-1 | Natural Products |
| HY-146020 | Topoisomerase IIα-IN-1 | 2407521-87-1 | Reference compound |
| HY-146021 | Topoisomerase IIα-IN-2 | 2407521-90-6 | Reference compound |
| HY-146022 | SIAIS117 | 2353494-84-3 | Reference compound |
| HY-146023 | Antifungal agent 27 | 2987755-90-6 | Reference compound |
| HY-146024 | Antifungal agent 28 | | Reference compound |
| HY-146025 | Antitumor agent-F10 | 2371727-65-8 | Reference compound |
| HY-146026 | Androgen receptor antagonist 3 | 353484-46-5 | Reference compound |
| HY-146027 | Androgen receptor antagonist 4 | 354815-43-3 | Reference compound |
| HY-146029 | Apoptosis inducer 3 | 2420443-14-5 | Reference compound |
| HY-14602R | Tramiprosate (Standard) | 3687-18-1 | Reference Standards |
| HY-14602S | Tramiprosate-d6 | 1131576-06-1 | Isotope-Labeled Compounds |
| HY-14603 | Clioquinol | 130-26-7 | Reference compound |
| HY-146030 | Anticancer agent 46 | 2426686-17-9 | Reference compound |
| HY-146031 | A3N19 | 2249755-49-3 | Reference compound |
| HY-146032 | p38-α MAPK-IN-4 | 2396754-57-5 | Reference compound |
| HY-146033 | HPV18-IN-1 | 331851-78-6 | Reference compound |
| HY-146034 | NOD1/2 antagonist-1 | 2704623-69-6 | Reference compound |
| HY-146035 | AChE-IN-14 | 2390042-05-2 | Reference compound |
| HY-146036 | NADH-IN-1 | 1432445-15-2 | Reference compound |
| HY-146037 | Aurora A inhibitor 2 | 2412144-74-0 | Reference compound |
| HY-146038 | Antitumor agent-55 | 2522594-49-4 | Reference compound |
| HY-146039 | AChE-IN-15 | 2242792-25-0 | Reference compound |
| HY-14603R | Clioquinol (Standard) | 130-26-7 | Reference Standards |
| HY-14604 | Xaliproden (hydrochloride) | 90494-79-4 | Reference compound |
| HY-146040 | Anticancer agent 47 | 2461795-23-1 | Reference compound |
| HY-146041 | Antiparasitic agent-2 | 2494277-80-2 | Reference compound |
| HY-146042 | Antiparasitic agent-4 | 2253996-66-4 | Reference compound |
| HY-146043 | Antiparasitic agent-5 | 2494276-55-8 | Reference compound |
| HY-146044 | Antiparasitic agent-6 | 2253996-73-3 | Reference compound |
| HY-146045 | Antiparasitic agent-7 | 2253996-75-5 | Reference compound |
| HY-146046 | Antitumor agent-56 | 2411579-53-6 | Reference compound |
| HY-146047 | Antibacterial agent 94 | 1666134-58-2 | Reference compound |
| HY-146048 | Antitumor agent-57 | 2432823-48-6 | Reference compound |
| HY-146049 | Antitrypanosomal agent 4 | 2456427-48-6 | Reference compound |
| HY-14605 | Rasagiline (mesylate) | 161735-79-1 | Reference compound |
| HY-146050 | Antitubercular agent-17 | 2328751-33-1 | Reference compound |
| HY-146051 | Antitubercular agent-18 | 1308272-99-2 | Reference compound |
| HY-146052 | Autophagy inducer 3 | 2691054-63-2 | Reference compound |
| HY-146053 | CXCR4 modulator-1 | 1381178-26-2 | Reference compound |
| HY-146054 | CXCR4 modulator-2 | 2488943-55-9 | Reference compound |
| HY-146055 | Antituberculosis agent-1 | 2411740-98-0 | Reference compound |
| HY-146056 | Anabolic agent-1 | 2439179-74-3 | Reference compound |
| HY-146057 | Antituberculosis agent-2 | 2411741-01-8 | Reference compound |
| HY-146058 | NF-κB/PON1-IN-1 | 2419107-97-2 | Reference compound |
| HY-146059 | Antibacterial agent 99 | 2452306-13-5 | Reference compound |
| HY-14605A | Rasagiline | 136236-51-6 | Reference compound |
| HY-14605AR | Rasagiline (Standard) | 136236-51-6 | Reference Standards |
| HY-14605BS | Rasagiline-13C3 (mesylate racemic) | 1216757-55-9 | Isotope-Labeled Compounds |
| HY-14605R | Rasagiline (mesylate) (Standard) | 161735-79-1 | Reference Standards |
| HY-14605S | Rasagiline-13C3 (mesylate) | 1391052-18-8 | Isotope-Labeled Compounds |
| HY-146060 | Antibacterial agent 100 | 2452306-14-6 | Reference compound |
| HY-146061 | KRAS G12C inhibitor 48 | 3033236-94-8 | Reference compound |
| HY-146062 | Antibacterial agent 101 | 2452306-15-7 | Reference compound |
| HY-146063 | Anticancer agent 54 | 2933882-99-4 | Reference compound |
| HY-146064 | OPN expression inhibitor 1 | 2257492-95-6 | Reference compound |
| HY-146065 | FAK-IN-4 | 3032200-62-4 | Reference compound |
| HY-146066 | α7 nAchR-JAK2-STAT3 agonist 1 | 2108714-20-9 | Reference compound |
| HY-146066A | (R)-α7 nAchR-JAK2-STAT3 agonist 1 | | Reference compound |
| HY-146067 | β-Nor-lapachone | 52436-88-1 | Reference compound |
| HY-146068 | AEP-IN-1 | 3032742-75-6 | Reference compound |
| HY-146069 | ABBV-318 | 1802848-94-7 | Reference compound |
| HY-14607 | Besipirdine (hydrochloride) | 130953-69-4 | Reference compound |
| HY-146070 | Elastase-IN-1 | 678152-73-3 | Reference compound |
| HY-146071 | Antitrypanosomal agent 5 | | Reference compound |
| HY-146072 | IRAK4-IN-11 | 3032742-74-5 | Reference compound |
| HY-146073 | IRAK4-IN-12 | | Reference compound |
| HY-146074 | RUVBL1/2 ATPase-IN-1 | 423128-55-6 | Reference compound |
| HY-146075 | β-Lactamase-IN-8 | 1929555-36-1 | Reference compound |
| HY-146076 | 5-HT6/5-HT2A receptor ligand-1 | 2411088-07-6 | Reference compound |
| HY-146077 | 5-HT6/5-HT2A receptor ligand-2 | 2411088-16-7 | Reference compound |
| HY-146078 | Antimicrobial agent-1 | 2579696-45-8 | Reference compound |
| HY-146079 | Antifungal agent 31 | 2077083-94-2 | Reference compound |
| HY-14608 | L-Glutamic acid | 56-86-0 | Natural Products |
| HY-146080 | Antitumor agent-61 | 2408917-12-2 | Reference compound |
| HY-146081 | CD22 ligand-1 | 2493080-27-4 | Reference compound |
| HY-146082 | (Z)-α-Cyanostilbene | 6114-57-4 | Reference compound |
| HY-146083 | (Z)-p-cyano-α-Cyanostilbene | 54676-54-9 | Reference compound |
| HY-146084 | PCSK9 modulator-3 | 2476490-18-1 | Reference compound |
| HY-146085 | PCSK9 modulator-4 | 2476490-20-5 | Reference compound |
| HY-146086 | Nrf2 activator-4 | 2383016-68-8 | Reference compound |
| HY-146087 | Autophagy inducer 4 | 2486455-03-0 | Reference compound |
| HY-146088 | HIV-1 inhibitor-31 | 920036-04-0 | Reference compound |
| HY-146089 | HIV-1 inhibitor-32 | 1033950-94-5 | Reference compound |
| HY-14608A | L-Glutamic acid (monosodium salt) | 142-47-2 | Natural Products |
| HY-14608AR | L-Glutamic acid (monosodium salt) (Standard) | 142-47-2 | Reference Standards |
| HY-14608R | L-Glutamic acid (Standard) | 56-86-0 | Reference Standards |
| HY-14608S | L-Glutamic acid-13C | 115473-51-3 | Isotope-Labeled Compounds |
| HY-14608S1 | L-Glutamic acid-1-13C | 81201-99-2 | Isotope-Labeled Compounds |
| HY-14608S10 | L-Glutamic acid-13C2 | 115473-56-8 | Isotope-Labeled Compounds |
| HY-14608S12 | L-Glutamic acid-14C | 24016-48-6 | Isotope-Labeled Compounds |
| HY-14608S2 | L-Glutamic acid-15N | 21160-87-2 | Isotope-Labeled Compounds |
| HY-14608S3 | L-Glutamic acid-13C5,15N | 202468-31-3 | Isotope-Labeled Compounds |
| HY-14608S4 | L-Glutamic acid-13C5,15N,d5 | 1420815-74-2 | Isotope-Labeled Compounds |
| HY-14608S5 | L-Glutamic acid-13C5 | 55443-55-5 | Isotope-Labeled Compounds |
| HY-14608S6 | L-Glutamic acid-5-13C | 81202-00-8 | Isotope-Labeled Compounds |
| HY-14608S7 | L-Glutamic acid-d5 | 2784-50-1 | Isotope-Labeled Compounds |
| HY-14608S8 | L-Glutamic acid-d3 | 203805-84-9 | Isotope-Labeled Compounds |
| HY-14608S9 | L-Glutamic acid-15N,d5 | | Isotope-Labeled Compounds |
| HY-14609 | MPEP (Hydrochloride) | 219911-35-0 | Reference compound |
| HY-146090 | HIV-1 inhibitor-33 | 2395777-43-0 | Reference compound |
| HY-146091 | HIV-1 inhibitor-34 | 2395777-45-2 | Reference compound |
| HY-146092 | Apoptosis inducer 4 | 2408050-83-7 | Reference compound |
| HY-146093 | Antitumor agent-62 | 2460735-29-7 | Reference compound |
| HY-146094 | Antitumor agent-63 | 1627600-90-1 | Reference compound |
| HY-146095 | p53 Activator 2 | 2338764-89-7 | Reference compound |
| HY-146096 | RMS3 | 2497686-66-3 | Reference compound |
| HY-146097 | RMS5 | 2497686-68-5 | Reference compound |
| HY-146098 | Antibacterial agent 105 | 2364493-24-1 | Reference compound |
| HY-146099 | GABAA receptor agent 7 | 2376841-18-6 | Reference compound |
| HY-14609A | MPEP | 96206-92-7 | Reference compound |
| HY-146100 | GABAA receptor agent 8 | 2376841-54-0 | Reference compound |
| HY-146101 | NMDA receptor antagonist 5 | 2415998-36-4 | Reference compound |
| HY-146102 | M1 ligand 1 | 2479356-53-9 | Reference compound |
| HY-146103 | Antiproliferative agent-7 | 2497687-47-3 | Reference compound |
| HY-146104 | Antimycobacterial agent-1 | 2409926-02-7 | Reference compound |
| HY-146105 | Anticancer agent 65 | 2407861-48-5 | Reference compound |
| HY-146106 | Antitubercular agent-22 | | Reference compound |
| HY-146107 | Antitubercular agent-23 | | Reference compound |
| HY-146108 | RSV-IN-5 | 2415018-86-7 | Reference compound |
| HY-146109 | RyRs activator 1 | 2571579-14-9 | Reference compound |
| HY-14611 | 3,3'-Difluorobenzaldazine | 15332-10-2 | Reference compound |
| HY-146110 | RyRs activator 2 | 2408415-52-9 | Reference compound |
| HY-146111 | IRAK4-IN-13 | 2667681-57-2 | Reference compound |
| HY-146112 | IRAK4-IN-14 | 2667681-71-0 | Reference compound |
| HY-146113 | IRAK4-IN-15 | 2667681-85-6 | Reference compound |
| HY-146114 | Antitumor agent-67 | 2820146-10-7 | Reference compound |
| HY-146115 | TRK-IN-19 | | Reference compound |
| HY-146116 | Antifungal agent 32 | 1809167-48-3 | Reference compound |
| HY-146117 | P-gp modulator 2 | 2987145-05-9 | Reference compound |
| HY-146118 | P-gp modulator 3 | 2987145-15-1 | Reference compound |
| HY-146119 | Antitubercular agent-24 | 1845719-43-8 | Reference compound |
| HY-14612 | CPPHA | 693288-97-0 | Reference compound |
| HY-146120 | Antitubercular agent-25 | 1845719-91-6 | Reference compound |
| HY-146121 | Antitubercular agent-26 | 1845720-46-8 | Reference compound |
| HY-146122 | ATX inhibitor 19 | 2691937-01-4 | Reference compound |
| HY-146123 | ATX inhibitor 20 | 2691937-03-6 | Reference compound |
| HY-146124 | ATX inhibitor 21 | 2691936-89-5 | Reference compound |
| HY-146125 | CGCG/CGG ligand 1 | 2488185-65-3 | Reference compound |
| HY-146126 | NS5A-IN-4 | 2088243-03-0 | Reference compound |
| HY-146127 | Grb2 SH2 domain inhibitor 1 | | Reference compound |
| HY-146127A | Grb2 SH2 domain inhibitor 1 (TFA) | | Peptides |
| HY-146128 | Anti-hyperglycemic agent-1 | 2488372-34-3 | Reference compound |
| HY-146129 | Aldose reductase-IN-5 | 2480090-03-5 | Reference compound |
| HY-146130 | ATG7-IN-2 | 2226227-75-2 | Reference compound |
| HY-146131 | ATG7-IN-3 | 2226229-76-9 | Reference compound |
| HY-146132 | EGFR-IN-55 | 2057423-46-6 | Reference compound |
| HY-146133 | LA-Bac8c | | Peptides |
| HY-146134 | PGN36 | 1564253-75-3 | Reference compound |
| HY-146135 | Tau-aggregation-IN-1 | 1619269-19-0 | Reference compound |
| HY-146136 | EGFR-IN-56 | 2477726-83-1 | Reference compound |
| HY-146137 | Transthyretin-IN-1 | | Reference compound |
| HY-146138 | EGFR-IN-57 | 2492382-37-1 | Reference compound |
| HY-146139 | Aβ-IN-3 | 2477606-87-2 | Reference compound |
| HY-146140 | Aβ-IN-4 | 2477606-97-4 | Reference compound |
| HY-146141 | EphA2 agonist 2 | 2169273-66-7 | Reference compound |
| HY-146142 | AChE/BuChE-IN-2 | 1946008-31-6 | Reference compound |
| HY-146143 | Falcipain-2/3-IN-2 | 946209-23-0 | Reference compound |
| HY-146144 | HIF-IN-1 | 2393928-76-0 | Reference compound |
| HY-146145 | Metyltetraprole | 1472649-01-6 | Reference compound |
| HY-146146 | Kolavenic acid analog | 2379777-37-2 | Reference compound |
| HY-146147 | Influenza virus-IN-5 | 2581825-57-0 | Reference compound |
| HY-146148 | KDM4C-IN-1 | 52348-60-4 | Reference compound |
| HY-146149 | MAO-B-IN-11 | 192383-78-1 | Reference compound |
| HY-14614A | S-Adenosyl-L-methionine (chloride dihydrochloride) | 86867-01-8 | Reference compound |
| HY-14614D | S-Adenosyl-L-methionine (iodide) | 3493-13-8 | Natural Products |
| HY-14615 | [6]-Gingerol | 23513-14-6 | Natural Products |
| HY-146150 | MAO-B-IN-12 | 2394733-97-0 | Reference compound |
| HY-146151 | γ-Secretase modulator 12 | 2204249-82-9 | Reference compound |
| HY-146152 | ASGPR modulator-1 | 2052968-88-2 | Reference compound |
| HY-146153 | HDAC-IN-40 | 2463198-51-6 | Reference compound |
| HY-146154 | EGFR-IN-58 | | Reference compound |
| HY-146155 | TRPC4/5-IN-1 | 3032263-08-1 | Reference compound |
| HY-146156 | α-Glucosidase-IN-7 | | Reference compound |
| HY-146157 | SARS-CoV-2-IN-22 | 2710278-53-6 | Reference compound |
| HY-146158 | Fudapirine | 1859978-72-5 | Reference compound |
| HY-146159 | PI3K/HDAC-IN-2 | 2361418-65-5 | Reference compound |
| HY-14615R | [6]-Gingerol (Standard) | 23513-14-6 | Reference Standards |
| HY-14616 | Shogaol | 555-66-8 | Natural Products |
| HY-146160 | PARP-1/HDAC-IN-1 | 3032621-10-3 | Reference compound |
| HY-146161 | COX-2/NO-IN-1 | 2989882-91-7 | Reference compound |
| HY-146162 | Colletotrichalactones A | 2751633-79-9 | Reference compound |
| HY-146163 | Topoisomerase II inhibitor 7 | 2697171-03-0 | Reference compound |
| HY-146164 | Tubulin polymerization-IN-21 | 2703017-14-3 | Reference compound |
| HY-146165 | Metallo-β-lactamase-IN-8 | 1610537-25-1 | Reference compound |
| HY-146166 | PT4 | 1280738-47-7 | Reference compound |
| HY-146167 | iNOS/PGE2-IN-1 | | Reference compound |
| HY-146168 | Nrf2 activator-5 | 1012860-13-7 | Reference compound |
| HY-146169 | Antitumor agent-68 | 2566497-96-7 | Reference compound |
| HY-14616R | Shogaol (Standard) | 555-66-8 | Reference Standards |
| HY-14617 | Paradol | 27113-22-0 | Natural Products |
| HY-146170 | Anticancer agent 69 | | Reference compound |
| HY-146171 | FabH-IN-1 | 2692652-49-4 | Reference compound |
| HY-146172 | Antioxidant agent-3 | 2710376-48-8 | Reference compound |
| HY-146173 | KCa1.1 channel activator-1 | | Reference compound |
| HY-146174 | KCa1.1 channel activator-2 | | Reference compound |
| HY-146177 | CYP3A4 enzyme-IN-1 | 2531281-25-9 | Reference compound |
| HY-146178 | IMP2-IN-1 | 1480482-51-6 | Reference compound |
| HY-146179 | IMP2-IN-2 | 1448353-39-6 | Reference compound |
| HY-14617R | Paradol (Standard) | 27113-22-0 | Reference Standards |
| HY-14618 | Zingiberene | 495-60-3 | Natural Products |
| HY-146180 | FSDD0I | | Reference compound |
| HY-146181 | FSDD1I | | Reference compound |
| HY-146182 | FSDD3I | | Reference compound |
| HY-146183 | BCL6-IN-9 | 2378852-76-5 | Reference compound |
| HY-146184 | CCT373567 | 2378853-67-7 | Reference compound |
| HY-146185 | CCT373566 | 2378853-66-6 | Reference compound |
| HY-146186 | JAK2 JH2 binder-1 | 2923309-41-3 | Reference compound |
| HY-146187 | Antitumor agent-69 | 2417651-42-2 | Reference compound |
| HY-146188 | Topoisomerase II inhibitor 8 | 2493298-68-1 | Reference compound |
| HY-146189 | Topoisomerase II inhibitor 9 | 2413901-61-6 | Reference compound |
| HY-146190 | Callophycin A | 1345674-93-2 | Reference compound |
| HY-146191 | Zika virus-IN-1 | 2527912-80-5 | Reference compound |
| HY-146192 | Zika virus-IN-2 | 2527912-53-2 | Reference compound |
| HY-146193 | Zika virus-IN-3 | 2527915-11-1 | Reference compound |
| HY-146194 | NHEJ inhibitor-1 | | Reference compound |
| HY-146195 | MAPK-IN-1 | 2470587-69-8 | Reference compound |
| HY-146196 | Anticandidal agent-1 | 2548852-85-1 | Reference compound |
| HY-146197 | Apoptotic agent-1 | 2490538-26-4 | Reference compound |
| HY-146198 | COX-2-IN-19 | 2497530-12-6 | Reference compound |
| HY-146199 | Antibacterial agent 108 | 900784-30-7 | Reference compound |
| HY-146200 | PI3K/mTOR Inhibitor-8 | 2492376-85-7 | Reference compound |
| HY-146201 | PDE4B/7A-IN-1 | 2511632-25-8 | Reference compound |
| HY-146202 | PDE4B/7A-IN-2 | 2511632-55-4 | Reference compound |
| HY-146203 | FAK inhibitor 6 | 2410056-27-6 | Reference compound |
| HY-146204 | HIV-1 capsid inhibitor 1 | 2396382-78-6 | Reference compound |
| HY-146205 | ATX inhibitor 18 | 2402772-30-7 | Reference compound |
| HY-146206 | HCAIX-IN-1 | 2389034-65-3 | Reference compound |
| HY-146207 | HCAIX-IN-2 | 2389034-45-9 | Reference compound |
| HY-146208 | BRD4 Inhibitor-20 | 2490311-14-1 | Reference compound |
| HY-146209 | Tubulin polymerization-IN-13 | 2426665-56-5 | Reference compound |
| HY-14620A | Farnesene (mixture of isomers) | 125037-13-0 | Reference compound |
| HY-14621 | Zingerone | 122-48-5 | Natural Products |
| HY-146210 | EGFR-IN-50 | 2044508-48-5 | Reference compound |
| HY-146211 | Tubulin polymerization-IN-14 | 2417134-05-3 | Reference compound |
| HY-146212 | HDAC/HSP90-IN-4 | | Reference compound |
| HY-146213 | CDK4/6-IN-12 | 2445205-24-1 | Reference compound |
| HY-146214 | CDK4/6-IN-13 | 1908454-70-5 | Reference compound |
| HY-146215 | IDO1-IN-20 | 2415246-15-8 | Reference compound |
| HY-146216 | MMP-9-IN-3 | 2581824-48-6 | Reference compound |
| HY-146217 | MMP-9-IN-4 | 2581824-39-5 | Reference compound |
| HY-146218 | MMP-9-IN-5 | 2581824-80-6 | Reference compound |
| HY-146219 | Biotin-nPEG-amine | 604786-74-5 | Reference compound |
| HY-14621R | Zingerone (Standard) | 122-48-5 | Reference Standards |
| HY-14622 | Necrostatin 2 | 852391-19-6 | Reference compound |
| HY-146220 | MrgprX2 antagonist-8 | 2768216-96-0 | Reference compound |
| HY-146221 | Dyrk1A-IN-5 | 1685235-41-9 | Reference compound |
| HY-146223 | AZD4625 | | Reference compound |
| HY-146223A | (3R,10R,14aS)-AZD4625 | | Reference compound |
| HY-146225 | α-Amylase/α-Glucosidase-IN-2 | 2446063-14-3 | Reference compound |
| HY-146226 | Viral 2C protein inhibitor 1 | 1594427-18-5 | Reference compound |
| HY-146227 | DNA topoisomerase II inhibitor 1 | 2459950-15-1 | Reference compound |
| HY-146228 | HSP90-IN-13 | 2446055-29-2 | Reference compound |
| HY-146229 | VEGFR-2-IN-25 | 2439096-02-1 | Reference compound |
| HY-14622A | Necrostatin 2 (racemate) | 852391-15-2 | Reference compound |
| HY-14622B | Necrostatin 2 (S enantiomer) | 852391-20-9 | Reference compound |
| HY-146230 | VEGFR-2-IN-26 | 2439096-06-5 | Reference compound |
| HY-146231 | SS47 | 2636072-62-1 | Reference compound |
| HY-146231A | SS47 (TFA) | | Reference compound |
| HY-146232 | F 13714 | 208109-38-0 | Reference compound |
| HY-146236 | VEGFR-2-IN-27 | 2439096-14-5 | Reference compound |
| HY-146237 | Golcadomide | 2379572-34-4 | Reference compound |
| HY-146238 | EGFR/HER2/TS-IN-1 | 2444363-11-3 | Reference compound |
| HY-146239 | EGFR/HER2/TS-IN-2 | 2444364-04-7 | Reference compound |
| HY-146240 | ALDH1A1-IN-3 | 2439177-97-4 | Reference compound |
| HY-146241 | SN40 | 2768663-14-3 | Reference compound |
| HY-146241B | SN40 (hydrochloride) | 2768663-15-4 | Reference compound |
| HY-146242 | SN05 | 2768663-51-8 | Reference compound |
| HY-146243 | TH-Z835 | 2766209-50-9 | Reference compound |
| HY-146244 | Agatolimod | 525625-52-9 | Oligonucleotides |
| HY-146244A | Biotin-labeled Agatolimod (sodium) | | Oligonucleotides |
| HY-146244B | FITC-labeled Agatolimod (sodium) | | Oligonucleotides |
| HY-146245 | ODN 1826 | 202668-42-6 | Oligonucleotides |
| HY-146245A | Biotin-labeled ODN 1826 (sodium) | | Oligonucleotides |
| HY-146245B | FITC-labeled ODN 1826 (sodium) | | Oligonucleotides |
| HY-146245C | ODN 1826 (sodium) | | Oligonucleotides |
| HY-146245F | FAM-labeled ODN 1826 (sodium) | | Oligonucleotides |
| HY-146246 | EIDD-2749 | 1613589-24-4 | Reference compound |
| HY-146247A | 4'-Fluorouridine triphosphate (sodium) | | Reference compound |
| HY-146248 | TFMU-ADPr | 2412923-11-4 | Dye Reagents |
| HY-146248A | TFMU-ADPr (triethylamine) | | Reference compound |
| HY-146248B | TFMU-ADPr (diammonium) | | Reference compound |
| HY-146250 | Antitumor agent-71 | 2011756-99-1 | Reference compound |
| HY-146251 | BuChE-IN-6 | 2003213-07-6 | Reference compound |
| HY-146252 | hCAXII-IN-4 | 2414601-79-7 | Reference compound |
| HY-146253 | CDK1/2/4-IN-1 | 2414633-49-9 | Reference compound |
| HY-146254 | hCAIX-IN-12 | 2414598-85-7 | Reference compound |
| HY-146256 | hCAXII-IN-5 | 2414629-92-6 | Reference compound |
| HY-146257 | hCAIX/XII-IN-2 | 2414629-82-4 | Reference compound |
| HY-146258 | hCAIX/XII-IN-3 | 2414629-94-8 | Reference compound |
| HY-146259 | hCAIX/XII-IN-4 | 1119200-33-7 | Reference compound |
| HY-146260 | NVP-CLR457 | 1453082-52-4 | Reference compound |
| HY-146261 | HI5 | 2411548-90-6 | Reference compound |
| HY-146262 | LDC0496 | 2411874-83-2 | Reference compound |
| HY-146263 | ThrRS-IN-3 | 3031483-23-2 | Reference compound |
| HY-146267 | ERα degrader 5 | 2941268-96-6 | Reference compound |
| HY-146268 | CaMKIIα-IN-1 | 3031484-08-6 | Reference compound |
| HY-146269 | 11-Desethyl Irinotecan | 103816-16-6 | Reference compound |
| HY-146270 | pUL89 Endonuclease-IN-1 | 391680-92-5 | Reference compound |
| HY-146271 | pUL89 Endonuclease-IN-2 | 519021-48-8 | Reference compound |
| HY-146272 | Vasopressin V2 receptor antagonist 1 | 2648650-50-2 | Reference compound |
| HY-146273 | Xanthine oxidase-IN-7 | 2411698-59-2 | Reference compound |
| HY-146274 | c-Met-IN-10 | 2415291-03-9 | Reference compound |
| HY-146275 | LXRβ agonist-3 | 2416049-12-0 | Reference compound |
| HY-146276 | CDK/HDAC-IN-2 | 2580938-58-3 | Reference compound |
| HY-146277 | CBP/p300-IN-19 | 2592638-13-4 | Reference compound |
| HY-146277A | CBP/p300-IN-19 (hydrochloride) | 2592638-14-5 | Reference compound |
| HY-146279S | Amino-2-deoxy-D-galactose-15N (hydrochloride) | 478518-55-7 | Isotope-Labeled Compounds |
| HY-146280 | mGAT3/4-IN-1 | 2556833-57-7 | Reference compound |
| HY-146281 | mGAT3/4-IN-2 | 2556833-68-0 | Reference compound |
| HY-146282 | mGAT-IN-1 | 2556833-08-8 | Reference compound |
| HY-146283 | LSD1-IN-18 | 2983011-61-4 | Reference compound |
| HY-146284 | LSD1-IN-19 | 2983011-81-8 | Reference compound |
| HY-146285 | LSD1-IN-20 | 1239589-91-3 | Reference compound |
| HY-146286 | Anticancer agent 44 | 2770943-86-5 | Reference compound |
| HY-146287 | Zn(BQTC) | 2785342-54-1 | Reference compound |
| HY-146288 | LXR agonist 2 | 2978788-07-5 | Reference compound |
| HY-146290 | Anticancer agent 45 | 2770943-87-6 | Reference compound |
| HY-146291 | BET-IN-7 | 303985-05-9 | Reference compound |
| HY-146292 | BET-IN-8 | 2769893-19-6 | Reference compound |
| HY-146293 | HDAC6/HSP90-IN-1 | 2411955-43-4 | Reference compound |
| HY-146294 | COX-2/5-LOX-IN-1 | 2410384-50-6 | Reference compound |
| HY-146295 | COX-2/5-LOX-IN-2 | 2410384-59-5 | Reference compound |
| HY-146296 | Xanthine oxidoreductase-IN-1 | 2396612-00-1 | Reference compound |
| HY-146297 | Xanthine oxidoreductase-IN-2 | 2396612-45-4 | Reference compound |
| HY-146298 | Mt KARI-IN-1 | 2987760-64-3 | Reference compound |
| HY-146299 | Mt KARI-IN-2 | 2413974-52-2 | Reference compound |
| HY-146300 | Mt KARI-IN-4 | 2413974-53-3 | Reference compound |
| HY-146301 | Mt KARI-IN-5 | 2413974-69-1 | Reference compound |
| HY-146302 | 14-3-3η Protein inhibitor 1 | 2770842-10-7 | Reference compound |
| HY-146303 | C-RAF kinase-IN-1 | 2770957-08-7 | Reference compound |
| HY-146304 | YXL-13 | 2415981-79-0 | Reference compound |
| HY-146305 | α-Glucosidase-IN-4 | 2410538-67-7 | Reference compound |
| HY-146306 | Neuraminidase-IN-9 | 2217630-64-1 | Reference compound |
| HY-146307 | TrxR-IN-3 | 2445565-58-0 | Reference compound |
| HY-146308 | HIV-1 inhibitor-26 | 2415504-88-8 | Reference compound |
| HY-146309 | iNOS-IN-2 | 2419891-42-0 | Reference compound |
| HY-146310 | Tubulin polymerization-IN-15 | 2055517-66-1 | Reference compound |
| HY-146311 | Tubulin polymerization-IN-16 | 2296731-38-7 | Reference compound |
| HY-146312 | AChE/BChE/MAO-B-IN-1 | 2416910-82-0 | Reference compound |
| HY-146313 | BChE-IN-7 | 2416910-85-3 | Reference compound |
| HY-146314 | MAO-B-IN-9 | 2416910-88-6 | Reference compound |
| HY-146315 | AChE/BChE-IN-6 | 2416910-94-4 | Reference compound |
| HY-146316 | Topoisomerase II inhibitor 6 | 2987586-62-7 | Reference compound |
| HY-146317 | P1788 | 2554623-76-4 | Reference compound |
| HY-146318 | MIF-IN-5 | 2582755-31-3 | Reference compound |
| HY-146319 | MIF-IN-6 | 2582758-61-8 | Reference compound |
| HY-146320 | ANO1-IN-1 | 407587-01-3 | Reference compound |
| HY-146321 | ANO1-IN-2 | 637314-12-6 | Reference compound |
| HY-146323 | Antitumor agent-58 | | Reference compound |
| HY-146324 | PROTAC eEF2K degrader-1 | 2458170-54-0 | Reference compound |
| HY-146325 | HSP90-IN-11 | 2986564-20-7 | Reference compound |
| HY-146327 | PqsR/LasR-IN-1 | 924818-33-7 | Reference compound |
| HY-146327R | PqsR/LasR-IN-1 (Standard) | 924818-33-7 | Reference Standards |
| HY-146328 | PqsR/LasR-IN-2 | 2071705-93-4 | Reference compound |
| HY-146328R | PqsR/LasR-IN-2 (Standard) | 2071705-93-4 | Reference Standards |
| HY-146329 | PqsR/LasR-IN-3 | 2581109-51-3 | Reference compound |
| HY-146329R | PqsR/LasR-IN-3 (Standard) | 2581109-51-3 | Reference Standards |
| HY-146330 | FtsZ-IN-2 | 2249757-45-5 | Reference compound |
| HY-146331 | PC190723 | 951120-33-5 | Reference compound |
| HY-146332 | Collagen-IN-1 | 104260-73-3 | Reference compound |
| HY-146333 | TRAP-6-IN-1 | 2068737-10-8 | Reference compound |
| HY-146334 | DFBTA | 2966044-07-3 | Reference compound |
| HY-146335 | CLK1/4-IN-1 | 3029431-90-8 | Reference compound |
| HY-146336 | PARP1/2/TNKS1/2-IN-1 | 2243453-32-7 | Reference compound |
| HY-146337 | Dyrk1A/B-IN-1 | 3032401-50-3 | Reference compound |
| HY-146338 | RPR103611 | 150840-75-8 | Reference compound |
| HY-146339 | HIV-1 inhibitor-27 | 2302046-54-2 | Reference compound |
| HY-146341 | FAAH-IN-5 | 1338575-38-4 | Reference compound |
| HY-146342 | FAAH/MAGL-IN-3 | 2848719-34-4 | Reference compound |
| HY-146343 | BMI-Glu | | Dye Reagents |
| HY-146344 | Antiviral agent 17 | 158227-81-7 | Reference compound |
| HY-146344R | Antiviral agent 17 (Standard) | 158227-81-7 | Reference Standards |
| HY-146345 | Antiviral agent 18 | 2170185-97-2 | Reference compound |
| HY-146346 | HD-TAC7 | 2978763-95-8 | Reference compound |
| HY-146347 | MAO-B-IN-10 | 2376710-36-8 | Reference compound |
| HY-146348 | Tuberculosis inhibitor 5 | | Reference compound |
| HY-146349 | PROTAC EGFR degrader 4 | 2882845-50-1 | Reference compound |
| HY-146350 | TrxR-IN-4 | 2414906-32-2 | Reference compound |
| HY-146351 | HDAC-IN-38 | 2408123-36-2 | Reference compound |
| HY-146352 | HIV-1 inhibitor-28 | 2642218-07-1 | Reference compound |
| HY-146353 | HIV-1 inhibitor-29 | 2642217-95-4 | Reference compound |
| HY-146354 | Antiproliferative agent-4 | | Reference compound |
| HY-146355 | hCAII-IN-2 | 2408599-78-8 | Reference compound |
| HY-146356 | Adenylyl cyclase type 2 agonist-1 | 2414908-52-2 | Reference compound |
| HY-146357 | Anticancer agent 48 | 2395009-13-7 | Reference compound |
| HY-146358 | Anticancer agent 49 | 2395009-34-2 | Reference compound |
| HY-146362 | Tubulin polymerization-IN-17 | 2454175-89-2 | Reference compound |
| HY-146363 | HIV-IN-4 | 2408729-03-1 | Reference compound |
| HY-146364 | CI-39 | 2132412-25-8 | Natural Products |
| HY-146365 | HIV-1 inhibitor-30 | 2132412-77-0 | Reference compound |
| HY-146366 | Tubulin inhibitor 26 | 2379241-70-8 | Reference compound |
| HY-146367 | VEGFR-2-IN-19 | 2456315-41-4 | Reference compound |
| HY-146368 | PROTAC VEGFR-2 degrader-1 | 2601594-19-6 | Reference compound |
| HY-146369 | PROTAC VEGFR-2 degrader-2 | 2353417-85-1 | Reference compound |
| HY-146370 | COX-2-IN-12 | 2986222-50-6 | Reference compound |
| HY-146371 | COX-2-IN-13 | 2987588-45-2 | Reference compound |
| HY-146372 | CXCR4 antagonist 5 | 2304749-86-6 | Reference compound |
| HY-146373 | Antibacterial agent 95 | 2413006-48-9 | Reference compound |
| HY-146374 | Antibacterial agent 96 | 2413006-62-7 | Reference compound |
| HY-146375 | UniPR505 | 2938227-14-4 | Reference compound |
| HY-146376 | Tubulin polymerization-IN-18 | 1258011-23-2 | Reference compound |
| HY-146377 | Tubulin polymerization-IN-19 | 2340345-85-7 | Reference compound |
| HY-146378 | Tubulin polymerization-IN-20 | 2410619-45-1 | Reference compound |
| HY-146379 | SARS-CoV-2-IN-19 | 2244991-17-9 | Reference compound |
| HY-146380 | S1427 | 2447061-40-5 | Reference compound |
| HY-146381 | SARS-CoV-2-IN-20 | 1260244-33-4 | Reference compound |
| HY-146382 | WRNA10 | 1174719-68-6 | Reference compound |
| HY-146383 | H3R antagonist 2 | 2970985-05-6 | Reference compound |
| HY-146384 | CRM1 degrader 1 | 2986647-41-8 | Reference compound |
| HY-146385 | hCAI/II-IN-1 | 2422028-82-6 | Reference compound |
| HY-146386 | SIRT5 inhibitor 2 | 340306-87-8 | Reference compound |
| HY-146387 | SIRT5 inhibitor 3 | 2128651-12-5 | Reference compound |
| HY-146388 | Mtb ATP synthase-IN-1 | 2642394-38-3 | Reference compound |
| HY-146389 | Anticancer agent 50 | 2487457-15-6 | Reference compound |
| HY-146390 | Antiproliferative agent-5 | 2459892-41-0 | Reference compound |
| HY-146391 | P-gp inhibitor 4 | 2652001-05-1 | Reference compound |
| HY-146392 | HDAC-IN-39 | 2414046-33-4 | Reference compound |
| HY-146393 | PROTAC CYP1B1 degrader-1 | 2411389-67-6 | Reference compound |
| HY-146394 | HBV-IN-22 | 2338573-94-5 | Reference compound |
| HY-146395 | HBV-IN-23 | 2413649-89-3 | Reference compound |
| HY-146396 | Anticancer agent 51 | 2521777-38-6 | Reference compound |
| HY-146397 | TD-802 | 2760703-21-5 | Reference compound |
| HY-146398 | AMPK activator 6 | 189299-03-4 | Reference compound |
| HY-146399 | AChE/BChE-IN-9 | 2761542-55-4 | Reference compound |
| HY-146400 | Antibacterial agent 97 | 1714961-61-1 | Reference compound |
| HY-146401 | CXCR4 antagonist 6 | 2304750-68-1 | Reference compound |
| HY-146403 | Antibacterial agent 98 | 2408695-41-8 | Reference compound |
| HY-146404 | T761-0184 | 1340907-57-4 | Reference compound |
| HY-146405 | nAChR antagonist 1 | 2987393-37-1 | Reference compound |
| HY-146406 | Anticancer agent 52 | 2388983-64-8 | Reference compound |
| HY-146407 | Anticancer agent 53 | 1926985-18-3 | Reference compound |
| HY-146408 | ALK-IN-21 | 2901889-01-6 | Reference compound |
| HY-146409 | Antitumor agent-59 | 2409952-04-9 | Reference compound |
| HY-146410 | AT2R antagonist 1 | 2709031-17-2 | Reference compound |
| HY-146411 | microRNA-21-IN-1 | 2848720-31-8 | Reference compound |
| HY-146412 | Vanin-1-IN-3 | 2940964-70-3 | Reference compound |
| HY-146413 | HF50731 | 2484771-19-7 | Reference compound |
| HY-146414 | Antitumor photosensitizer-1 | 2344751-89-7 | Reference compound |
| HY-146416 | Antitumor photosensitizer-2 | 2344751-92-2 | Reference compound |
| HY-146417 | Antiviral agent 19 | 1807887-16-6 | Reference compound |
| HY-146418 | Antiviral agent 20 | 2407570-07-2 | Reference compound |
| HY-146419 | Anti-inflammatory agent 20 | 2127403-65-8 | Reference compound |
| HY-146420 | GRP78-IN-2 | 1882875-63-9 | Reference compound |
| HY-146421 | Anti-inflammatory agent 21 | 2408836-40-6 | Reference compound |
| HY-146422 | PROTAC EGFR degrader 5 | 2409793-36-6 | Reference compound |
| HY-146423 | PROTAC EGFR degrader 6 | 2409793-28-6 | Reference compound |
| HY-146424 | OBHS | 870614-18-9 | Reference compound |
| HY-146426 | MraY-IN-2 | | Reference compound |
| HY-146427 | Antifungal agent 29 | | Reference compound |
| HY-146428 | Anti-MRSA agent 4 | | Reference compound |
| HY-146429 | NaPi2b-IN-3 | 2227443-66-3 | Reference compound |
| HY-146431 | AT1R antagonist 1 | 2848719-80-0 | Reference compound |
| HY-146432 | Antitumor agent-60 | 865784-65-2 | Reference compound |
| HY-146433 | Anticancer agent 55 | 2408800-91-7 | Reference compound |
| HY-146434 | TGFβ-IN-2 | 2387678-02-4 | Reference compound |
| HY-146435 | Anti-inflammatory agent 22 | 2721484-76-8 | Reference compound |
| HY-146436 | AT1R antagonist 2 | 2848719-76-4 | Reference compound |
| HY-146437 | Topoisomerase I inhibitor 6 | 2393082-56-7 | Reference compound |
| HY-146438 | PPARγ agonist 3 | 2011801-48-0 | Reference compound |
| HY-146439 | PPARγ agonist 4 | 2380227-06-3 | Reference compound |
| HY-14644 | Apilimod | 541550-19-0 | Reference compound |
| HY-146440 | LSD1/ER-IN-1 | | Reference compound |
| HY-146441 | Prohibitin ligand 1 | | Reference compound |
| HY-146442 | BRAF V600E/CRAF-IN-1 | 2499499-56-6 | Reference compound |
| HY-146443 | BRAF V600E/CRAF-IN-2 | 2499499-62-4 | Reference compound |
| HY-146444 | Anticancer agent 56 | 2241915-59-1 | Reference compound |
| HY-146445 | P300 bromodomain-IN-1 | | Reference compound |
| HY-146446 | PXYC1 | 865098-81-3 | Reference compound |
| HY-146446R | PXYC1 (Standard) | 865098-81-3 | Reference Standards |
| HY-146447 | PXYC13 | 1031940-69-8 | Reference compound |
| HY-146448 | PXYD3 | 2680554-46-3 | Reference compound |
| HY-146449 | PXYD4 | 2712534-78-4 | Reference compound |
| HY-14644A | Apilimod (mesylate) | 870087-36-8 | Reference compound |
| HY-14644B | Apilimod (hydrochloride) | 870087-37-9 | Reference compound |
| HY-14645 | (-)-DHMEQ | 287194-40-5 | Reference compound |
| HY-146450 | PXYC2 | 865101-22-0 | Reference compound |
| HY-146451 | PXYC12 | 1112415-91-4 | Reference compound |
| HY-146452 | Anticancer agent 57 | 2408017-71-8 | Reference compound |
| HY-146453 | TGR5 Receptor Agonist 3 | 2643391-08-4 | Reference compound |
| HY-146454 | Antiproliferative agent-6 | 2389016-82-2 | Reference compound |
| HY-146455 | DPP-4-IN-3 | 2402735-14-0 | Reference compound |
| HY-146456 | A1AR antagonist 3 | 2413257-73-3 | Reference compound |
| HY-146457 | A3AR antagonist 1 | 2413257-74-4 | Reference compound |
| HY-146458 | Antibacterial agent 102 | 2413293-65-7 | Reference compound |
| HY-146459 | Akt1-IN-1 | | Reference compound |
| HY-14645A | (+)-DHMEQ | 287194-41-6 | Reference compound |
| HY-14645B | DHMEQ (racemate) | 287194-38-1 | Reference compound |
| HY-146460 | Antimicrobial agent-2 | 2412592-33-5 | Reference compound |
| HY-146461 | Anticancer agent 58 | | Reference compound |
| HY-146462 | Anticancer agent 59 | 2366170-11-6 | Reference compound |
| HY-146463 | NusB-IN-1 | 2923738-92-3 | Reference compound |
| HY-146464 | Antifungal agent 30 | 2422019-91-6 | Reference compound |
| HY-146465 | Anticancer agent 60 | 2162169-14-2 | Reference compound |
| HY-146466 | Anticancer agent 61 | 2413148-53-3 | Reference compound |
| HY-146467 | Anticancer agent 62 | 2413148-58-8 | Reference compound |
| HY-146468 | DPP-4/GPR119 modulator 1 | 2411099-68-6 | Reference compound |
| HY-146469 | DPP-4/GPR119 modulator 2 | 2010927-65-6 | Reference compound |
| HY-146470 | Antibacterial agent 103 | 2396409-46-2 | Reference compound |
| HY-146471 | EGFR-IN-51 | 2418549-32-1 | Reference compound |
| HY-146472 | EGFR-IN-52 | 454436-75-0 | Reference compound |
| HY-146473 | EGFR-IN-53 | 2418549-33-2 | Reference compound |
| HY-146474 | EGFR-IN-54 | 2418549-30-9 | Reference compound |
| HY-146475 | KRAS inhibitor-17 | 2230873-65-9 | Reference compound |
| HY-146476 | KRAS inhibitor-18 | 2230873-66-0 | Reference compound |
| HY-146477S | Hydroxy Bezafibrate-d6 | 2673270-01-2 | Isotope-Labeled Compounds |
| HY-146478 | A1/A3 AR antagonist 1 | 312929-49-0 | Reference compound |
| HY-146479 | A1/A3 AR antagonist 2 | 2408833-02-1 | Reference compound |
| HY-14648 | Dexamethasone | 50-02-2 | Reference compound |
| HY-146480 | PPARγ agonist 5 | 915124-86-6 | Reference compound |
| HY-146481S | Lansoprazole sulfone N-oxide-d4 | 1190009-70-1 | Isotope-Labeled Compounds |
| HY-146482 | PPARγ agonist 6 | 2428742-08-7 | Reference compound |
| HY-146483 | Anti-Aβ agent 1A | 2313346-53-9 | Reference compound |
| HY-146484S | Flunisolide acetate-d6 | | Isotope-Labeled Compounds |
| HY-146485S | Fulvestrant-9-sulfone-d3 | | Isotope-Labeled Compounds |
| HY-146486 | P2Y2R/GPR17 antagonist 1 | 2395016-49-4 | Reference compound |
| HY-146487 | Anti-infective agent 1 | 2348-77-8 | Reference compound |
| HY-146488 | Anti-infective agent 2 | 2521629-84-3 | Reference compound |
| HY-146489 | Anti-infective agent 3 | 2521629-86-5 | Reference compound |
| HY-14648A | Dexamethasone acetate | 1177-87-3 | Reference compound |
| HY-14648AR | Dexamethasone acetate (Standard) | 1177-87-3 | Reference Standards |
| HY-14648C | Dexamethasone (Water Soluble) | 50-02-2 | Reference compound |
| HY-14648G | Dexamethasone (GMP) | 50-02-2 | GMP Small Molecules |
| HY-14648R | Dexamethasone (Standard) | 50-02-2 | Reference Standards |
| HY-14648S | Dexamethasone-d5 | 358731-91-6 | Isotope-Labeled Compounds |
| HY-14648S1 | Dexamethasone-d5-1 | | Isotope-Labeled Compounds |
| HY-14648S2 | Dexamethasone-d4 | 2305607-27-4 | Isotope-Labeled Compounds |
| HY-14648S3 | Dexamethasone-4,6α,21,21-d4 | 2483831-63-4 | Isotope-Labeled Compounds |
| HY-14648S5 | Dexamethasone-d3-1 | | Isotope-Labeled Compounds |
| HY-14649 | Retinoic acid | 302-79-4 | Natural Products |
| HY-146491 | VEGFR-2/BRAF-IN-1 | | Reference compound |
| HY-146492 | VEGFR-2/BRAF-IN-2 | | Reference compound |
| HY-146494 | Androgen receptor antagonist 5 | 2586195-28-8 | Reference compound |
| HY-146495 | Antitubercular agent-19 | 2248171-05-1 | Reference compound |
| HY-146496 | Antitubercular agent-20 | 2413124-92-0 | Reference compound |
| HY-146497 | Topoisomerase I inhibitor 7 | 2408639-81-4 | Reference compound |
| HY-146498 | Antiplatelet agent 1 | 2493297-12-2 | Reference compound |
| HY-146499 | Antiplatelet agent 2 | 1395047-93-4 | Reference compound |
| HY-14649G | Retinoic acid (GMP) | 302-79-4 | GMP Small Molecules |
| HY-14649R | Retinoic acid (Standard) | 302-79-4 | Reference Standards |
| HY-14649S2 | 11-cis-Retinoic Acid-d5 | | Isotope-Labeled Compounds |
| HY-14649S3 | Retinoic acid-d6 | 2483831-72-5 | Isotope-Labeled Compounds |
| HY-14649S4 | Retinoic acid-d5 | 78996-15-3 | Isotope-Labeled Compounds |
| HY-14649S5 | Retinoic acid-d3 | 154461-49-1 | Isotope-Labeled Compounds |
| HY-14649S6 | Retinoic acid-d3-1 | 3041101-53-2 | Isotope-Labeled Compounds |
| HY-14650 | DHEA | 53-43-0 | Natural Products |
| HY-146501 | PARP10/15-IN-2 | 2892064-99-0 | Reference compound |
| HY-146502 | PARP10/15-IN-3 | 2892064-88-7 | Reference compound |
| HY-146503 | Antibacterial agent 86 | 2807530-12-5 | Reference compound |
| HY-146504 | Topoisomerase I/II inhibitor 3 | 2770804-74-3 | Reference compound |
| HY-146505 | Tubulin polymerization-IN-6 | 2768613-52-9 | Reference compound |
| HY-146506 | isoCA-4 | 1067880-31-2 | Reference compound |
| HY-14650R | DHEA (Standard) | 53-43-0 | Natural Products |
| HY-146511 | Anticancer agent 41 | 1394077-28-1 | Reference compound |
| HY-146516 | Anticancer agent 42 | 2687265-18-3 | Reference compound |
| HY-146517 | Orexin receptor antagonist 4 | 2251017-69-1 | Reference compound |
| HY-146518 | TRK-IN-13 | 1365221-52-8 | Reference compound |
| HY-146519 | TRK-IN-14 | 1365212-84-5 | Reference compound |
| HY-14652 | Tamibarotene | 94497-51-5 | Reference compound |
| HY-146521 | TRK-IN-15 | 1365213-20-2 | Reference compound |
| HY-146522 | TRK-IN-16 | 1365212-81-2 | Reference compound |
| HY-146523 | TRK-IN-17 | 2409544-80-3 | Reference compound |
| HY-146524 | TRK-IN-18 | 2412008-91-2 | Reference compound |
| HY-146525S | Docusate-d34 (sodium) | 175736-89-7 | Isotope-Labeled Compounds |
| HY-146527 | c-ABL-IN-2 | 2574593-54-5 | Reference compound |
| HY-146528 | c-ABL-IN-3 | 2626934-64-1 | Reference compound |
| HY-14653 | Amsilarotene | 125973-56-0 | Reference compound |
| HY-146530 | c-ABL-IN-4 | 2626934-68-5 | Reference compound |
| HY-146533 | KRAS inhibitor-12 | 2230874-00-5 | Reference compound |
| HY-146534S | Diazinon-d10 | 100155-47-3 | Isotope-Labeled Compounds |
| HY-146537 | KRAS G12C inhibitor 47 | 2253119-24-1 | Reference compound |
| HY-146539 | HDAC-IN-35 | | Reference compound |
| HY-14654 | Aspirin | 50-78-2 | Reference compound |
| HY-146540 | GEM-5 | 2233543-49-0 | Reference compound |
| HY-146541 | FGFR4-IN-10 | 2857862-25-8 | Reference compound |
| HY-146543 | KRAS inhibitor-13 | 2230873-96-6 | Reference compound |
| HY-146544 | KRAS inhibitor-14 | 2230873-78-4 | Reference compound |
| HY-146545 | KRAS inhibitor-15 | 2230873-75-1 | Reference compound |
| HY-146546 | KRAS inhibitor-16 | 2230873-67-1 | Reference compound |
| HY-146547 | Anti-inflammatory agent 17 | 2763226-84-0 | Reference compound |
| HY-146548 | Anticancer agent 43 | 2470015-35-9 | Reference compound |
| HY-146549 | RmlA-IN-1 | 1415030-78-2 | Reference compound |
| HY-14654A | Aspirin (lithium) | 552-98-7 | Reference compound |
| HY-14654B | Aspirin (DL-lysine) | 62952-06-1 | Reference compound |
| HY-14654C | Aspirin (calcium) | 69-46-5 | Reference compound |
| HY-14654R | Aspirin (Standard) | 50-78-2 | Reference Standards |
| HY-14654S | Aspirin-d3 | 921943-73-9 | Isotope-Labeled Compounds |
| HY-14654S1 | Aspirin-d4 | 97781-16-3 | Isotope-Labeled Compounds |
| HY-14655 | Sulfasalazine | 599-79-1 | Reference compound |
| HY-146551 | RmlA-IN-2 | 2866140-40-9 | Reference compound |
| HY-146552 | PDHK-IN-4 | | Reference compound |
| HY-146554 | PDHK-IN-5 | | Reference compound |
| HY-146555 | Antitubercular agent-14 | 2408627-49-4 | Reference compound |
| HY-146556 | Antitubercular agent-15 | | Reference compound |
| HY-146557 | Antitubercular agent-16 | | Reference compound |
| HY-14655R | Sulfasalazine (Standard) | 599-79-1 | Reference Standards |
| HY-14655S | Sulfasalazine-d4 | 1346606-50-5 | Isotope-Labeled Compounds |
| HY-14655S1 | Sulfasalazine-d3,15N | | Isotope-Labeled Compounds |
| HY-14656 | Diltiazem (hydrochloride) | 33286-22-5 | Reference compound |
| HY-146560 | Xanthine oxidase-IN-6 | | Reference compound |
| HY-146561 | S-HP210 | | Reference compound |
| HY-146564 | R-HP210 | | Reference compound |
| HY-146564A | HP210 | 728039-52-9 | Reference compound |
| HY-146565 | DNA-PK-IN-8 | 2823369-81-7 | Reference compound |
| HY-146566 | DNA-PK-IN-9 | | Reference compound |
| HY-14656R | Diltiazem (hydrochloride) (Standard) | 33286-22-5 | Reference Standards |
| HY-14656S | Diltiazem-d3 (hydrochloride) | 1217623-80-7 | Isotope-Labeled Compounds |
| HY-14656S1 | Diltiazem-(acetoxy-d3) (hydrochloride) | 1217860-13-3 | Isotope-Labeled Compounds |
| HY-14656S2 | Diltiazem-d6 (hydrochloride) | 1309283-34-8 | Isotope-Labeled Compounds |
| HY-14656S3 | Diltiazem-d5 (hydrochloride) | 2012598-70-6 | Isotope-Labeled Compounds |
| HY-14657 | Dantrolene (sodium) | 14663-23-1 | Reference compound |
| HY-146573 | AKR1C3-IN-6 | 2137881-54-8 | Reference compound |
| HY-146574 | AKR1C3-IN-7 | | Reference compound |
| HY-146575 | AKR1C3-IN-8 | | Reference compound |
| HY-146577 | Keap1-Nrf2-IN-7 | 2769963-42-8 | Reference compound |
| HY-146578 | Keap1-Nrf2-IN-8 | 2769963-54-2 | Reference compound |
| HY-14658 | Thalidomide | 50-35-1 | Reference compound |
| HY-146580 | Cathepsin C-IN-3 | 2825567-71-1 | Reference compound |
| HY-146581 | Cathepsin C-IN-4 | 2825567-86-8 | Reference compound |
| HY-146584 | Cathepsin C-IN-5 | 2825567-97-1 | Reference compound |
| HY-146586 | Haspin-IN-1 | 2768474-30-0 | Reference compound |
| HY-146587 | Haspin-IN-2 | 2768474-47-9 | Reference compound |
| HY-146588 | NMDA receptor antagonist 4 | 1607589-56-9 | Reference compound |
| HY-14658A | (S)-Thalidomide | 841-67-8 | Reference compound |
| HY-14658B | (R)-Thalidomide | 2614-06-4 | Reference compound |
| HY-14658R | Thalidomide (Standard) | 50-35-1 | Reference Standards |
| HY-14658S | Thalidomide-d4 | 1219177-18-0 | Isotope-Labeled Compounds |
| HY-146591 | Antibacterial agent 87 | 2798821-48-2 | Reference compound |
| HY-146593 | Antibacterial agent 88 | 2798821-49-3 | Reference compound |
| HY-146594 | NLRP3-IN-8 | 2768650-56-0 | Reference compound |
| HY-146595 | FtsZ-IN-1 | 2516246-24-3 | Reference compound |
| HY-146596 | Axl-IN-5 | 2642224-24-4 | Reference compound |
| HY-14660 | Dabrafenib | 1195765-45-7 | Reference compound |
| HY-146600S | Hydroxyfenbendazole-d3 | 1596803-40-5 | Isotope-Labeled Compounds |
| HY-146604S | Desisopropylatrazine-d5 | 1189961-78-1 | Isotope-Labeled Compounds |
| HY-14660A | Dabrafenib (Mesylate) | 1195768-06-9 | Reference compound |
| HY-14660R | Dabrafenib (Standard) | 1195765-45-7 | Reference Standards |
| HY-14660S | Dabrafenib-d9 | 1423119-98-5 | Isotope-Labeled Compounds |
| HY-14661 | SB-743921 (free base) | 618430-39-0 | Reference compound |
| HY-146615 | Axl-IN-6 | 2642224-22-2 | Reference compound |
| HY-146616 | GLS1 Inhibitor-3 | 2435781-94-3 | Reference compound |
| HY-146617 | GLS1 Inhibitor-4 | 2768599-97-7 | Reference compound |
| HY-146619 | RAGE/SERT-IN-1 | 2766739-35-7 | Reference compound |
| HY-146626S | 1,3,5(10)-Estratriene-17α-ethyl-3,17β-diol 3-methyl ether-d5 | | Isotope-Labeled Compounds |
| HY-146627S | 5-Cholesten-24(RS)-methyl-3β-ol-d3 | | Isotope-Labeled Compounds |
| HY-146628S | 5-Hydroxy-L-tryptophan-4,6,7-d3 | | Isotope-Labeled Compounds |
| HY-146629S | 4-Methoxy estrone-d4 | | Isotope-Labeled Compounds |
| HY-146630S | 17β-Dihydroequilenin-4,16,16-d3 | 1276056-90-6 | Isotope-Labeled Compounds |
| HY-146631S | 4-Hydroxy-17β-estradiol-1,2,16,16,17-d5 | 221093-38-5 | Isotope-Labeled Compounds |
| HY-146633S | 24(RS)-Hydroxycholesterol-d7 | 144154-78-9 | Isotope-Labeled Compounds |
| HY-146635S | (25RS)-26-Hydroxycholesterol-d4 | | Isotope-Labeled Compounds |
| HY-146636 | Haspin-IN-3 | 2416569-95-2 | Reference compound |
| HY-146637 | VIM-2-IN-1 | 2452118-54-4 | Reference compound |
| HY-146638S | 5α-Pregnan-11β,17α,21-triol-3,20-dione-1,2,4,5-d4 | 252976-11-7 | Isotope-Labeled Compounds |
| HY-14664 | Fluvastatin | 93957-54-1 | Reference compound |
| HY-146643 | sEH inhibitor-3 | 1809885-35-5 | Reference compound |
| HY-146646 | Bleomycin A2 | 41432-97-7 | Reference compound |
| HY-146647S | Cholesta-3,5-diene-7-one-25,26,26,26,27,27,27-d7 | | Isotope-Labeled Compounds |
| HY-146648 | Cyclophilin inhibitor 3 | 1676100-30-3 | Reference compound |
| HY-146649 | LmCPB-IN-1 | 2151025-98-6 | Reference compound |
| HY-14664A | Fluvastatin (sodium) | 93957-55-2 | Reference compound |
| HY-14664AR | Fluvastatin (sodium) (Standard) | 93957-55-2 | Reference Standards |
| HY-14664AS | Fluvastatin-d6 (sodium) | | Isotope-Labeled Compounds |
| HY-14664B | (3R,5S)-Fluvastatin | 155229-75-7 | Reference compound |
| HY-14664C | (3S,5R)-Fluvastatin (sodium) | 94061-81-1 | Reference compound |
| HY-14664CS | (3S,5R)-Fluvastatin-d6 (sodium) | 2249799-35-5 | Isotope-Labeled Compounds |
| HY-14664D | Fluvastatin (sodium monohydrate) | 201541-53-9 | Reference compound |
| HY-14664DS | (3S,5R)-Fluvastatin-d6 | 2249799-34-4 | Isotope-Labeled Compounds |
| HY-14664F | (3R,5S)-Fluvastatin (sodium) | 94061-80-0 | Reference compound |
| HY-146650 | LpxC-IN-9 | 2756125-46-7 | Reference compound |
| HY-146651 | MPO-IN-4 | 2088545-68-8 | Reference compound |
| HY-146652 | UGM-IN-3 | 2254751-04-5 | Reference compound |
| HY-146653 | Glyoxalase I inhibitor 1 | 1622952-07-1 | Reference compound |
| HY-146654 | Glyoxalase I inhibitor 2 | 2314467-61-1 | Reference compound |
| HY-146655 | Glyoxalase I inhibitor 3 | 1415388-25-8 | Reference compound |
| HY-146656 | Glyoxalase I inhibitor 4 | 250155-72-7 | Reference compound |
| HY-146656S | S-Sulfo-DL-cysteine-2,3,3-d3 | 2687960-80-9 | Isotope-Labeled Compounds |
| HY-146657 | 4BAB | 828262-76-6 | Reference compound |
| HY-146658 | Glutaminase-IN-4 | 1439390-05-2 | Reference compound |
| HY-146659S | S-Phenyl-DL-cysteine-3,3-d2 | | Isotope-Labeled Compounds |
| HY-146660 | BRD4 Inhibitor-18 | 2451219-73-9 | Reference compound |
| HY-146661 | Aldose reductase-IN-4 | 2446136-17-8 | Reference compound |
| HY-146662 | HPGDS inhibitor 3 | 2255311-93-2 | Reference compound |
| HY-146663 | AChE/BChE-IN-3 | 2410992-65-1 | Reference compound |
| HY-146663A | AChE/BChE-IN-3 (hydrochloride) | 2410992-69-5 | Reference compound |
| HY-146664 | AChE/BChE-IN-4 | 2294963-47-4 | Reference compound |
| HY-146665 | AChE/BChE-IN-5 | 2410992-68-4 | Reference compound |
| HY-146666 | STAT3-IN-9 | 2987726-27-0 | Reference compound |
| HY-146667 | POP-IN-1 | 2743432-99-5 | Reference compound |
| HY-146668 | AChE/BChE-IN-8 | 2421120-96-7 | Reference compound |
| HY-146669 | BChE-IN-6 | 2421121-10-8 | Reference compound |
| HY-14667 | Lomitapide | 182431-12-5 | Reference compound |
| HY-146670 | KDM5B-IN-3 | 1385101-10-9 | Reference compound |
| HY-146671 | ITK inhibitor 5 | 2404603-41-2 | Reference compound |
| HY-146672 | ITK inhibitor 6 | 2404604-06-2 | Reference compound |
| HY-146673 | IDO1/TDO-IN-2 | 5466-47-7 | Reference compound |
| HY-146674 | IDO1/TDO-IN-3 | 2347579-03-5 | Reference compound |
| HY-146676 | UR-MB108 | 2412461-98-2 | Reference compound |
| HY-146677 | 5-HT6R/MAO-B modulator 1 | 2986222-45-9 | Reference compound |
| HY-146678 | HDAC6-IN-5 | 2413603-15-1 | Reference compound |
| HY-146679 | HDAC6-IN-6 | 2413603-10-6 | Reference compound |
| HY-14667S | Lomitapide-d8 | 2459377-96-7 | Isotope-Labeled Compounds |
| HY-14667S1 | Lomitapide-d4 | 857296-42-5 | Isotope-Labeled Compounds |
| HY-14668 | Lomitapide (mesylate) | 202914-84-9 | Reference compound |
| HY-146680 | FLT3/ITD-IN-4 | 2278278-04-7 | Reference compound |
| HY-146681 | PAK1-IN-1 | 2485732-30-5 | Reference compound |
| HY-146682 | KS100 | 2408477-54-1 | Reference compound |
| HY-146683 | KS106 | 2408477-50-7 | Reference compound |
| HY-146684 | HDAC-IN-36 | 2482992-54-9 | Reference compound |
| HY-146686 | BuChE-IN-3 | 2499488-78-5 | Reference compound |
| HY-146687 | BuChE-IN-4 | 2499490-52-5 | Reference compound |
| HY-146688 | SYN20028567 | 1214563-94-6 | Reference compound |
| HY-146689 | SIRT1-IN-2 | 2470969-89-0 | Reference compound |
| HY-14669 | Niraxostat | 206884-98-2 | Reference compound |
| HY-146690 | SIRT1-IN-3 | 2470969-91-4 | Reference compound |
| HY-146691 | hMAO-B-IN-2 | 2454459-87-9 | Reference compound |
| HY-146692 | IQTub4P | 2376321-67-2 | Reference compound |
| HY-146693 | CJJ300 | 1807631-83-9 | Reference compound |
| HY-146694 | RIPK2-IN-1 | 2245820-70-4 | Reference compound |
| HY-146695 | S100P-IN-1 | 690991-06-1 | Reference compound |
| HY-146696 | mEH-IN-1 | 2418576-06-2 | Reference compound |
| HY-146697 | IHMT-TRK-284 | 2416844-79-4 | Reference compound |
| HY-146699 | MtTMPK-IN-5 | 2987763-18-6 | Reference compound |
| HY-14670 | Firocoxib | 189954-96-9 | Reference compound |
| HY-146700 | MtTMPK-IN-6 | 2225885-99-2 | Reference compound |
| HY-146701 | MtTMPK-IN-7 | 2987482-25-5 | Reference compound |
| HY-146702 | MtTMPK-IN-8 | 2990619-92-4 | Reference compound |
| HY-146703 | MtTMPK-IN-9 | 2987299-68-1 | Reference compound |
| HY-146704 | COX-2/sEH-IN-1 | 2474977-38-1 | Reference compound |
| HY-146705 | PqsR-IN-1 | 1333636-58-0 | Reference compound |
| HY-146706 | PqsR-IN-2 | 2982271-63-4 | Reference compound |
| HY-146708S | ((2R,3S,4R,5R)-5-(2-Amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate-15N4 (sodium) | 1257650-86-4 | Isotope-Labeled Compounds |
| HY-146709 | BET bromodomain inhibitor 2 | 2414195-69-8 | Reference compound |
| HY-14670R | Firocoxib (Standard) | 189954-96-9 | Reference Standards |
| HY-14670S | Firocoxib-d4 | 1325700-11-5 | Isotope-Labeled Compounds |
| HY-146710 | RET-IN-16 | 2259657-48-0 | Reference compound |
| HY-146711 | Tubulin inhibitor 24 | 2415761-65-6 | Reference compound |
| HY-146712S | N-(4-Hydroxyphenyl)acetamide sulfate-d3 (sodium) | 2733160-80-8 | Isotope-Labeled Compounds |
| HY-146713S | (±)-7-Methyl-nonanoic acid-d3 | 2708280-22-0 | Isotope-Labeled Compounds |
| HY-146715 | IDO/Tubulin-IN-2 | 2409479-24-7 | Reference compound |
| HY-146716S | N-Acetyl-S-(N-methyl-carbamoyl)-L-cysteine-d3 (dicyclohexylamine) | | Isotope-Labeled Compounds |
| HY-146717S | N-Acetyl-S-(3-hydroxypropyl)-L-cysteine-d6 (dicyclohexylamine) | | Isotope-Labeled Compounds |
| HY-146718 | Tubulin polymerization-IN-9 | 2485020-93-5 | Reference compound |
| HY-146719S | Nalpha-Acetyl-DL-glutamine-2,3,3,4,4-d5 | 14341-82-3 | Isotope-Labeled Compounds |
| HY-14672 | Soblidotin | 149606-27-9 | Reference compound |
| HY-146721S | Epicholesterol-2,2,3,4,4,6-d6 | 92543-07-2 | Isotope-Labeled Compounds |
| HY-146722 | Antibacterial agent 89 | 2589639-87-0 | Reference compound |
| HY-146723 | IKKβ-IN-1 | 2410423-31-1 | Reference compound |
| HY-146724 | Dot1L-IN-7 | 2580940-76-5 | Reference compound |
| HY-146725 | FBPase-IN-1 | 20362-54-3 | Reference compound |
| HY-146726S | pentadecanoate-d29 | 352431-43-7 | Isotope-Labeled Compounds |
| HY-146727 | JAK3-IN-11 | 2412734-00-8 | Reference compound |
| HY-146728 | STAT3-IN-10 | 2499491-04-0 | Reference compound |
| HY-146729 | ASK1-IN-3 | 2426705-19-1 | Reference compound |
| HY-146731 | PPARγ agonist 1 | 3032632-09-7 | Reference compound |
| HY-146732S | Acetyl-L-threonine-d5 | | Isotope-Labeled Compounds |
| HY-146733 | PPARα agonist 1 | 3032632-02-0 | Reference compound |
| HY-146734S | 17β-Dihydroequilenin 3-sulfate-4,16,16-d3 (sodium) | 1276056-91-7 | Isotope-Labeled Compounds |
| HY-146735 | MNK1/2-IN-6 | 2771087-94-4 | Reference compound |
| HY-146736S | 17β-Dihydroequilin 3-sulfate-2,4,16,16-d4 (sodium) | 352431-51-7 | Isotope-Labeled Compounds |
| HY-146737S | Tripentadecanoin-d5 | 1219804-57-5 | Isotope-Labeled Compounds |
| HY-146738 | GSD-11 | | Reference compound |
| HY-146739 | BRD4 Inhibitor-19 | 2757865-63-5 | Reference compound |
| HY-14674 | CP-724714 | 383432-38-0 | Reference compound |
| HY-146740 | PD-1/PD-L1-IN-27 | 2891831-47-1 | Reference compound |
| HY-146741 | SDR-04 | 879593-54-1 | Reference compound |
| HY-146742 | PPARγ agonist 2 | 3024531-27-6 | Reference compound |
| HY-146743 | Antitumor agent-53 | 2757145-67-6 | Reference compound |
| HY-146744 | Antileishmanial agent-4 | 2922333-23-9 | Reference compound |
| HY-146745 | Antileishmanial agent-5 | 2922333-29-5 | Reference compound |
| HY-146746 | HIV-1 inhibitor-19 | 2649837-82-9 | Reference compound |
| HY-146747 | Antifungal agent 26 | 2769834-78-6 | Reference compound |
| HY-146748 | Sorbicillin | 79950-85-9 | Reference compound |
| HY-146749 | FLT3/TrKA-IN-1 | | Reference compound |
| HY-146750 | HDAC-IN-37 | 2766466-56-0 | Reference compound |
| HY-146751 | PI3K/Akt/mTOR-IN-2 | 2757804-89-8 | Reference compound |
| HY-146752 | α-Amylase-IN-1 | | Reference compound |
| HY-146753 | HIV-1 inhibitor-20 | 2758387-58-3 | Reference compound |
| HY-146754 | MMP2-IN-1 | 2764598-01-6 | Reference compound |
| HY-146755 | TIY-7 | 2846435-83-2 | Reference compound |
| HY-146756 | 22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin | 2780409-77-8 | Reference compound |
| HY-146757 | RIPK1-IN-13 | 1574547-67-3 | Reference compound |
| HY-146758 | RIPK1-IN-14 | 2919964-79-5 | Reference compound |
| HY-146759 | ZM514 | | Reference compound |
| HY-146760S | C15 Glucosyl(β) ceramide-d7 | 2315262-18-9 | Isotope-Labeled Compounds |
| HY-146761S | 3-O-Sulfo-D-galactosyl-β1-1'-N-tridecanoyl-D-erythro-sphingosine-d7 | 2315262-25-8 | Isotope-Labeled Compounds |
| HY-146762 | MAO-B-IN-7 | 2851012-65-0 | Reference compound |
| HY-146763S | N-Tridecanoyl-D-erythro-sphinganine-d7 | 2315262-21-4 | Isotope-Labeled Compounds |
| HY-146764S | D-Lactosyl-β-1,1'-N-pentadecanoyl-D-erythro-sphingosine-d7 | 2315262-20-3 | Isotope-Labeled Compounds |
| HY-146765 | AMS-17 | 3019885-78-7 | Reference compound |
| HY-146766S | D-Galactosyl-β-1,1'-N-tridecanoyl-D-erythro-sphingosine-d7 | 2315262-19-0 | Isotope-Labeled Compounds |
| HY-146767S | (3β,5α,6β)-3,5,6-Trihydroxycholan-24-oic acid-d4 | | Isotope-Labeled Compounds |
| HY-146768S | 24(R/S),25-Epoxycholesterol-d6 | 1246302-86-2 | Isotope-Labeled Compounds |
| HY-146769 | Antimalarial agent 11 | 1214454-56-4 | Reference compound |
| HY-146770S | Dihydro FF-MAS-d6 | 2315262-47-4 | Isotope-Labeled Compounds |
| HY-146772S | 1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium-d5 (bromide) | 1579992-96-3 | Isotope-Labeled Compounds |
| HY-146773S | 7α-Hydroxy-3-oxocholest-4-enoic acid-d3 | 2342573-89-9 | Isotope-Labeled Compounds |
| HY-146774S | 14:1 cholesteryl ester-d7 | 2342574-68-7 | Isotope-Labeled Compounds |
| HY-146775S | Dihydro T-MAS-d6 | 2315262-48-5 | Isotope-Labeled Compounds |
| HY-146776S | 5β,6β-Epoxycholestanol-d7 | 127684-06-4 | Isotope-Labeled Compounds |
| HY-146777S | 14-Demethyl-lanosterol-d6 | 1246298-30-5 | Isotope-Labeled Compounds |
| HY-146778 | Tubulin inhibitor 25 | 2411697-71-5 | Reference compound |
| HY-146779S | 16:1 Cholesteryl ester-d7 | 1416275-33-6 | Isotope-Labeled Compounds |
| HY-146780 | TGFβRI-IN-4 | 2421135-03-5 | Reference compound |
| HY-146781S | 20:3 Cholesteryl ester-d7 | 2342574-76-7 | Isotope-Labeled Compounds |
| HY-146782 | EGFR-IN-49 | 2459932-81-9 | Reference compound |
| HY-146783 | ZINC194100678 | 1995025-05-2 | Reference compound |
| HY-146784S | 7α,24(R/S)-Dihydroxycholesterol-d7 | 2260669-20-1 | Isotope-Labeled Compounds |
| HY-146785S | 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphate-13C16 (sodium) | 2260669-38-1 | Isotope-Labeled Compounds |
| HY-146786 | ZMF-10 | 2415295-37-1 | Reference compound |
| HY-146787S | 7α,24(R/S)-Dihydroxycholestenone-d7 | 2260669-21-2 | Isotope-Labeled Compounds |
| HY-146788S | 7α,27-Dihydroxycholesterol-d6 | 2260669-25-6 | Isotope-Labeled Compounds |
| HY-146789 | PI3Kδ/γ-IN-2 | 2412195-89-0 | Reference compound |
| HY-14679 | GSK3β inhibitor II | 478482-75-6 | Reference compound |
| HY-146790S | 7ß,27-Dihydroxycholesterol-d6 | 2260669-26-7 | Isotope-Labeled Compounds |
| HY-146791S | 1',3'-Bis[1,2-dilinoleoyl-sn-glycero-3-phospho]-glycerol-d5 (ammonium) | 2315262-46-3 | Isotope-Labeled Compounds |
| HY-146792 | PLK1-IN-4 | 2622273-55-4 | Reference compound |
| HY-146793S | 3β-Hydroxy-7-oxocholest-5-enoic acid-d3 | 2342573-92-4 | Isotope-Labeled Compounds |
| HY-146794S | 1-Pentadecanoyl-2-oleoyl-sn-glycero-3-phosphocholine-d7 | 2097561-16-3 | Isotope-Labeled Compounds |
| HY-146795S | 15:0-18:1 DG-d7 | 2097561-14-1 | Isotope-Labeled Compounds |
| HY-146796S | 15:0 Cholesteryl ester-d7 | 2260669-27-8 | Isotope-Labeled Compounds |
| HY-146797S | Cholesteryldocosa-7,10,13,16-tetraenoate-d7 | 2342574-92-7 | Isotope-Labeled Compounds |
| HY-146798S | 1-Pentadecanoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine-d7 | 2097561-15-2 | Isotope-Labeled Compounds |
| HY-146799S | 15:0-18:1-15:0 TG-d7 | 2097561-17-4 | Isotope-Labeled Compounds |
| HY-146800S | 18:1 SM-d9 | 2260669-50-7 | Isotope-Labeled Compounds |
| HY-146801 | PDHK-IN-3 | | Reference compound |
| HY-146802 | NLRP3-IN-9 | 2768759-64-2 | Reference compound |
| HY-146804 | HIV-1 protease-IN-3 | | Reference compound |
| HY-146805 | EB1 | 42951-68-8 | Reference compound |
| HY-146806 | YL93 | 2771313-42-7 | Reference compound |
| HY-146807 | Type II TRK inhibitor 1 | 2937543-72-9 | Reference compound |
| HY-146808 | Galectin-3 antagonist 1 | 2921603-03-2 | Reference compound |
| HY-146809 | Galectin-3 antagonist 2 | 2921603-02-1 | Reference compound |
| HY-146810 | PRMT4-IN-1 | | Reference compound |
| HY-146811 | HSGN-94 | 2570797-85-0 | Reference compound |
| HY-146812 | DIZ-3 | 2675490-72-7 | Reference compound |
| HY-146813 | EBOV/MARV-IN-2 | 2687244-84-2 | Reference compound |
| HY-146814 | EBOV/MARV-IN-3 | 2687245-05-0 | Reference compound |
| HY-146815 | CP19 | 1018148-68-9 | Reference compound |
| HY-146816 | NBTIs-IN-6 | 2422893-97-6 | Reference compound |
| HY-146817 | Tubulin polymerization-IN-11 | 2470063-59-1 | Reference compound |
| HY-146818 | Tubulin polymerization-IN-12 | 2377301-45-4 | Reference compound |
| HY-146819 | CAIX/CAXII-IN-1 | 2439165-37-2 | Reference compound |
| HY-14682 | GSK319347A | 862812-98-4 | Reference compound |
| HY-146820S | 1-Pentadecanoyl-2-oleoyl-sn-glycero-3-phospho-L-serine-d7 (sodium) | 2260669-40-5 | Isotope-Labeled Compounds |
| HY-146821S | 2,3-Dihydroxypropyl ((R)-2-(oleoyloxy)-3-(pentadecanoyloxy)propyl) phosphate-d7 (sodium) | 2260669-42-7 | Isotope-Labeled Compounds |
| HY-146822S | 6αOH Chol ester-d7 | 2260669-30-3 | Isotope-Labeled Compounds |
| HY-146823S | Desmosterol ester-d6 | 2260669-31-4 | Isotope-Labeled Compounds |
| HY-146824S | 17:0-18:1 PI-d5 (ammonium) | 2342575-35-1 | Isotope-Labeled Compounds |
| HY-146825S | 1-Pentadecanoyl-2-oleoyl-sn-glycero-3-phosphoinositol-d7 (ammonium) | 2260669-44-9 | Isotope-Labeled Compounds |
| HY-146826S | 1,3-16:1 DG-d5 | 1246523-68-1 | Isotope-Labeled Compounds |
| HY-146827S | 17:0-20:3 PI-d5 (ammonium) | 2342575-37-3 | Isotope-Labeled Compounds |
| HY-146828S | CER10-d9 | 2260669-52-9 | Isotope-Labeled Compounds |
| HY-146829S | 1-Pentadecanoyl-2-oleoyl-sn-glycero-3-phosphate-d7 (sodium) | 2260669-46-1 | Isotope-Labeled Compounds |
| HY-146830S | 17:0-22:4 PI-d5 (ammonium) | 2342575-39-5 | Isotope-Labeled Compounds |
| HY-146831S | CER3-d9 | 2260669-53-0 | Isotope-Labeled Compounds |
| HY-146832S | 1,3-17:0 DG-d5 | 1246523-65-8 | Isotope-Labeled Compounds |
| HY-146833S | 1-Oleoyl-2-hydroxy-sn-glycero-3-phosphatidylethanolamine-d7 | 2260669-47-2 | Isotope-Labeled Compounds |
| HY-146834S | 1,3-18:0 DG-d5 | 1246523-69-2 | Isotope-Labeled Compounds |
| HY-146835S | (Rac)-16:0PI(3,5)P2-d5 (ammonium) | 2260669-78-9 | Isotope-Labeled Compounds |
| HY-146836S | (Rac)-16:0 PI(5)P-d5 (ammonium) | | Isotope-Labeled Compounds |
| HY-146836S1 | 16:0 PI(5)P-d5 (ammonium) | 2260669-80-3 | Isotope-Labeled Compounds |
| HY-146836S2 | (Rac)-16:0 PI(5)P-d5 (diammonium) | | Isotope-Labeled Compounds |
| HY-146837S | C18(plasm)-18:1 PE-d9 | 2315262-04-3 | Isotope-Labeled Compounds |
| HY-146838S | 17:0-18:1 PC-d5 | 2342575-55-5 | Isotope-Labeled Compounds |
| HY-146839S | 17:0-16:1 PC-d5 | 2342575-79-3 | Isotope-Labeled Compounds |
| HY-146840S | 17:0-14:1 PC-d5 | | Isotope-Labeled Compounds |
| HY-146841S | 19:0 Lyso PC-d5 | 2342575-08-8 | Isotope-Labeled Compounds |
| HY-146842S | 15:0 Lyso PE-d5 | 2342574-96-1 | Isotope-Labeled Compounds |
| HY-146843S | 17:0 Lyso PE-d5 | 2342575-10-2 | Isotope-Labeled Compounds |
| HY-146844S | 19:0 Lyso PE-d5 | 2342575-09-9 | Isotope-Labeled Compounds |
| HY-146845S | 17:0-22:4 PE-d5 | 2342575-44-2 | Isotope-Labeled Compounds |
| HY-146846S | 17:0-20:3 PE-d5 | 2342575-53-3 | Isotope-Labeled Compounds |
| HY-146847S | 17:0-18:1 PE-d5 | 2342575-56-6 | Isotope-Labeled Compounds |
| HY-146848S | C18(plasm)-18:1 PC-d9 | 2315262-03-2 | Isotope-Labeled Compounds |
| HY-146849S | 17:0-22:4 PC-d5 | 2342575-43-1 | Isotope-Labeled Compounds |
| HY-146850S | 17:0-20:3 PC-d5 | 2342575-54-4 | Isotope-Labeled Compounds |
| HY-146851S | 17:0-16:1 PE-d5 | 2342575-77-1 | Isotope-Labeled Compounds |
| HY-146852S | 17:0-14:1 PE-d5 | 2342575-78-2 | Isotope-Labeled Compounds |
| HY-146853S | 17:0-14:1 PG-d5 | 2342575-74-8 | Isotope-Labeled Compounds |
| HY-146854S | 15:0 Lyso PG-d5 | 2342574-98-3 | Isotope-Labeled Compounds |
| HY-146855S | 19:0 Lyso PG-d5 | 2342575-14-6 | Isotope-Labeled Compounds |
| HY-146856S | 17:0 Lyso PG-d5 | 2342575-16-8 | Isotope-Labeled Compounds |
| HY-146857S | 17:0-22:4 PG-d5 | 2342575-46-4 | Isotope-Labeled Compounds |
| HY-146858S | 17:0-20:3 PG-d5 | 2342575-52-2 | Isotope-Labeled Compounds |
| HY-146859S | 17:0-18:1 PG-d5 | 2342575-59-9 | Isotope-Labeled Compounds |
| HY-146860S | 17:0-16:1 PG-d5 | 2342575-72-6 | Isotope-Labeled Compounds |
| HY-146861S | 1-Pentadecanoyl-2-hydroxy-sn-glycero-3-phospho-L-serine-d5 (sodium) | 2342575-00-0 | Isotope-Labeled Compounds |
| HY-146862S | D-myo-Inositol, 1-[(2R)-2-hydroxy-3-[(1-oxononadecyl)oxy]propyl-1,1,2,3,3-d5 hydrogen phosphate], ammonium salt (1:1) | 2342575-23-7 | Isotope-Labeled Compounds |
| HY-146863 | Tubulin polymerization-IN-10 | 2238784-19-3 | Reference compound |
| HY-146864S | 1-Nonadecanoyl-2-hydroxy-sn-glycero-3-phospho-L-serine-d5 (sodium) | 2342575-18-0 | Isotope-Labeled Compounds |
| HY-146865S | 1-Heptadecanoyl-2-hydroxy-sn-glycero-3-phospho-L-serine-d5 (sodium) | 2342575-21-5 | Isotope-Labeled Compounds |
| HY-146866S | 1-Heptadecanoyl-2-docosatetraenoyl-sn-glycero-3-phospho- L-serine-d5 (sodium) | 2342575-48-6 | Isotope-Labeled Compounds |
| HY-146867S | 1-Heptadecanoyl-2-eicosatrienoyl-sn-glycero-3-phospho- L-serine-d5 (sodium) | 2342575-50-0 | Isotope-Labeled Compounds |
| HY-146868S | 1-Heptadecanoyl-2-oleoyl-sn-glycero-3-phospho- L-serine-d5 (sodium) | 2342575-61-3 | Isotope-Labeled Compounds |
| HY-146869S | 1-Heptadecanoyl-2-palmitoleoyl-sn-glycero-3-phospho- L-serine-d5 (sodium) | 2342575-67-9 | Isotope-Labeled Compounds |
| HY-14687 | (rac)-Talazoparib | 1207454-56-5 | Reference compound |
| HY-146870S | 1-Heptadecanoyl-2-myristoleoyl-sn-glycero-3-phospho- L-serine-d5 (sodium) | 2342575-69-1 | Isotope-Labeled Compounds |
| HY-146871S | D-myo-Inositol, 1-[(2R)-2-hydroxy-3-[(1-oxopentadecyl)oxy]propyl-1,1,2,3,3-d5 hydrogen phosphate], ammonium salt (1:1) | 2342575-02-2 | Isotope-Labeled Compounds |
| HY-146872S | D-myo-Inositol, 1-[(2R)-2-hydroxy-3-[(1-oxoheptadecyl)oxy]propyl-1,1,2,3,3-d5 hydrogen phosphate], ammonium salt (1:1) | 2342575-26-0 | Isotope-Labeled Compounds |
| HY-146873S | D-myo-Inositol, 1-[(2R)-3-[(1-oxoheptadecyl)oxy]-2-[[(9Z)-1-oxo-9-tetradecen-1-yl]oxy]propyl hydrogen phosphate], ammonium salt (1:1) | 2342575-29-3 | Isotope-Labeled Compounds |
| HY-146874S | D-myo-Inositol, 1-[(2R)-3-[(1-oxoheptadecyl)oxy]-2-[[(9Z)-1-oxo-9-hexadecen-1-yl]oxy]propyl hydrogen phosphate], ammonium salt (1:1) | 2342575-32-8 | Isotope-Labeled Compounds |
| HY-146875S | 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol-d31 (ammonium) | 799812-61-6 | Isotope-Labeled Compounds |
| HY-146876S | C18:0 GM1 Ganglioside-d5 (ammonium) | 2260669-93-8 | Isotope-Labeled Compounds |
| HY-146877S | 16:0-18:1 PG-d31 | 327178-87-0 | Isotope-Labeled Compounds |
| HY-146878S | 16:0-18:1 PG-d5 | 1246298-34-9 | Isotope-Labeled Compounds |
| HY-146879S | 26:0 Lyso PC-d4 | 1246303-15-0 | Isotope-Labeled Compounds |
| HY-14688 | CEP-8983 | 374071-46-2 | Reference compound |
| HY-146880S | 14:0-14:0 PC-d27 | 185906-02-9 | Isotope-Labeled Compounds |
| HY-146881S | 1-Myristoyl-2-myristoyl-sn-glycero-3-phosphocholine-d27 | 185906-03-0 | Isotope-Labeled Compounds |
| HY-146882S | 16:0-18:1 PE-d31 | 326495-44-7 | Isotope-Labeled Compounds |
| HY-146883 | As-358 | 2222042-47-7 | Reference compound |
| HY-146883A | As-358 (hydrochloride) | 2374723-26-7 | Reference compound |
| HY-146884 | MET kinase-IN-3 | 1446324-02-2 | Reference compound |
| HY-146885S | 16:0-18:1 PS-d31 (sodium) | 327178-96-1 | Isotope-Labeled Compounds |
| HY-146886 | FLT3-IN-15 | 2435562-99-3 | Reference compound |
| HY-146887 | USP7-IN-9 | 2444374-01-8 | Reference compound |
| HY-146888 | HIV-1 protease-IN-2 | 2248124-46-9 | Reference compound |
| HY-146889 | ATX inhibitor 16 | 2484811-36-9 | Reference compound |
| HY-14689 | Ecopipam (hydrochloride) | 190133-94-9 | Reference compound |
| HY-146890 | ATX inhibitor 17 | 2750152-64-6 | Reference compound |
| HY-146891S | 16:0-16:0 PC-d31 | 56952-02-4 | Isotope-Labeled Compounds |
| HY-146892S | 1-Palmitoyl-2-palmitoyl-sn-glycero-3-phosphocholine-d31 | 69285-95-6 | Isotope-Labeled Compounds |
| HY-146893S | 18:0-18:0 PC-d35 | 327178-88-1 | Isotope-Labeled Compounds |
| HY-146894S | 1-Stearoyl-2-stearoyl-sn-glycero-3-phosphocholine-d35 | 327178-89-2 | Isotope-Labeled Compounds |
| HY-146895S | 14:0 Lyso PC-d27 | 327178-90-5 | Isotope-Labeled Compounds |
| HY-146896S | 16:0-18:1 PA-d31 (sodium) | 474943-59-4 | Isotope-Labeled Compounds |
| HY-146897S | 1-Deoxy-L-threo-sphinganine-d3 | 1246298-32-7 | Isotope-Labeled Compounds |
| HY-146898S | 1-Desoxymethylsphinganine-d5 | 1246298-43-0 | Isotope-Labeled Compounds |
| HY-146899S | CER6-2’R-d9 | 2260670-10-6 | Isotope-Labeled Compounds |
| HY-14690 | Ecopipam | 112108-01-7 | Reference compound |
| HY-146900S | Lyso GB3-d7 | 2315262-44-1 | Isotope-Labeled Compounds |
| HY-146901S | 15:0 SM (d18:1/15:0)-d9 | 2315262-22-5 | Isotope-Labeled Compounds |
| HY-146902S | C15 Ceramide-1-phosphate-d7 | 2315262-27-0 | Isotope-Labeled Compounds |
| HY-146903S | Lyso iGB3-d7 | 2315262-49-6 | Isotope-Labeled Compounds |
| HY-146904S | 3-Keto sphinganine-d7 | | Isotope-Labeled Compounds |
| HY-146905S | CER6-2’S-d9 | 2260670-11-7 | Isotope-Labeled Compounds |
| HY-146906S | C18 Glucosyl(ß) ceramide-d5 | 2260670-13-9 | Isotope-Labeled Compounds |
| HY-146907S | C18:1 Glucosyl ceramide-d5 | 2260670-16-2 | Isotope-Labeled Compounds |
| HY-146908S | N-Pentadecanoyl-D-erythro-sphingosine-d7 | | Isotope-Labeled Compounds |
| HY-146909S | CER5-2’R-d9 | 2260670-31-1 | Isotope-Labeled Compounds |
| HY-14690B | rel-Ecopipam (hydrobromide) | 1227675-51-5 | Reference compound |
| HY-14690S | Ecopipam-d4 | | Isotope-Labeled Compounds |
| HY-14691 | Refametinib | 923032-37-5 | Reference compound |
| HY-146910S | CER1 (d18:1/26:0/18:1)-d9 | 2260670-32-2 | Isotope-Labeled Compounds |
| HY-146911S | CER9 (t18:0/26:0/18:1)-d9 | 2260670-35-5 | Isotope-Labeled Compounds |
| HY-146912S | 14:0-16:1-14:0 TG-d5 | 944709-23-3 | Isotope-Labeled Compounds |
| HY-146913S | 15:0-18:1-15:0 TG-d5 | 944709-24-4 | Isotope-Labeled Compounds |
| HY-146914S | 16:0-18:0-16:0 TG-d5 | 944709-25-5 | Isotope-Labeled Compounds |
| HY-146915S | 17:0-17:1-17:0 TG-d5 | 958760-74-2 | Isotope-Labeled Compounds |
| HY-146916S | 19:0-12:0-19:0 TG-d5 | 944709-21-1 | Isotope-Labeled Compounds |
| HY-146917S | 20:0-20:1-20:0 TG-d5 | 958764-14-2 | Isotope-Labeled Compounds |
| HY-146918S | 16:0 (Rac)-PtdEG-d71 | 2260670-48-0 | Isotope-Labeled Compounds |
| HY-146919S | 4E,14Z-Sphingadiene-d7 | | Isotope-Labeled Compounds |
| HY-146920S | 3-O-Sulfo-galactosyl(β)sphingosine (d18:1)-d7 (ammonium) | | Isotope-Labeled Compounds |
| HY-146921S | 3-O-Sulfo-D-galactosyl-ß1-1’-N-nervonoyl-D-erythro-sphingosine-d7 (ammonium) | | Isotope-Labeled Compounds |
| HY-146922S | D-Galactosyl-ß-1,1' N-nervonoyl-D-erythro-sphingosine-d7 | | Isotope-Labeled Compounds |
| HY-146923S | D-Lactosyl-ß-1,1' N-nervonoyl-D-erythro-sphingosine-d7 | | Isotope-Labeled Compounds |
| HY-146924S | 16:0 (Rac)-PC-d80 | 100412-79-1 | Isotope-Labeled Compounds |
| HY-146925S | 15:0 Lyso PC-d5 | 2342574-95-0 | Isotope-Labeled Compounds |
| HY-146926S | 16:0 Coenzyme A-d4 | 2260670-64-0 | Isotope-Labeled Compounds |
| HY-146927S | 24:0 Coenzyme A-d4 | 2260670-66-2 | Isotope-Labeled Compounds |
| HY-146928S | C26 D,L-Carnitine-d9 | 2260670-67-3 | Isotope-Labeled Compounds |
| HY-146929S | 18:1 SM (d18:1/18:1)-d9 | 2342574-42-7 | Isotope-Labeled Compounds |
| HY-146930S | 16:1 SM (d18:1/16:1)-d9 | 2342574-45-0 | Isotope-Labeled Compounds |
| HY-146931S | 20:1 SM (d18:1/20:1)-d9 | 2342574-48-3 | Isotope-Labeled Compounds |
| HY-146932S | 22:1 SM (d18:1/22:1)-d9 | 2342574-51-8 | Isotope-Labeled Compounds |
| HY-146933S | 24:1 SM (d18:1/24:1)-d9 | 2342574-54-1 | Isotope-Labeled Compounds |
| HY-146934S | C22:1 Ceramide-d7 | 2342574-57-4 | Isotope-Labeled Compounds |
| HY-146935S | C20:1 Ceramide-d7 | 2342574-60-9 | Isotope-Labeled Compounds |
| HY-146936S | C16:1 Ceramide-d7 | 1942907-49-4 | Isotope-Labeled Compounds |
| HY-146937S | CER11-2’S-d9 | 2260670-22-0 | Isotope-Labeled Compounds |
| HY-146938S | CER11-2’R-d9 | 2260670-23-1 | Isotope-Labeled Compounds |
| HY-146939S | CER7-2’R,6R-d9 | 2260670-24-2 | Isotope-Labeled Compounds |
| HY-146940S | CER7-2’S,6R-d9 | 2260670-25-3 | Isotope-Labeled Compounds |
| HY-146941S | CER8-d9 | 2260670-29-7 | Isotope-Labeled Compounds |
| HY-146942S | CER5-2’S-d9 | 2260670-30-0 | Isotope-Labeled Compounds |
| HY-146943S | 24:0 L-carnitine-d4 | 2260670-68-4 | Isotope-Labeled Compounds |
| HY-146944S | 12-PAHSA-13C16 | 2342575-05-5 | Isotope-Labeled Compounds |
| HY-146945S | Arachidonoyl LPA-d5 | | Isotope-Labeled Compounds |
| HY-146946S | D-Myo-phosphatidylinositol 3,4,5-trisphosphate diC16-d5 | | Isotope-Labeled Compounds |
| HY-146947S | D-Myo-phosphatidylinositol 4-phosphate diC16-d5 | | Isotope-Labeled Compounds |
| HY-146948S | D-Myo-phosphatidylinositol 4,5-bisphosphate diC16-d5 | | Isotope-Labeled Compounds |
| HY-146949S | D-Myo-phosphatidylinositol diC16-d5 | | Isotope-Labeled Compounds |
| HY-146950S | PAPEth-d5 | | Isotope-Labeled Compounds |
| HY-146951S | PLPEth-d5 | | Isotope-Labeled Compounds |
| HY-146952S | POPEth-d5 | 1612140-92-7 | Isotope-Labeled Compounds |
| HY-146953S | SLPEth-d5 | | Isotope-Labeled Compounds |
| HY-146954S | SOPEth-d5 | | Isotope-Labeled Compounds |
| HY-146955S | Linoleoyl LPA-d5 | | Isotope-Labeled Compounds |
| HY-146956S | Oleoyl LPA-d5 | | Isotope-Labeled Compounds |
| HY-146957 | ZIKV-IN-1 | 2762166-06-1 | Reference compound |
| HY-146958 | MAO-B-IN-8 | 1638956-60-1 | Reference compound |
| HY-146959 | K203 | 955034-69-2 | Reference compound |
| HY-146963S | Amitraz metabolite-d3 | 1255517-75-9 | Isotope-Labeled Compounds |
| HY-146965S | Hydroxytriclabendazole-d3 | | Isotope-Labeled Compounds |
| HY-146966S | 2-NP-DNSAH-13C6 | | Isotope-Labeled Compounds |
| HY-146967S | 4-(3,6-Dimethylhept-3-yl)phenol-13C6 | 1173020-38-6 | Isotope-Labeled Compounds |
| HY-146968S | Alloerythro-Isoxsuprine-13C6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-146969S | Bisdesoxyquinoceton-13C6 | | Isotope-Labeled Compounds |
| HY-146970 | Lankacyclinone C | | Reference compound |
| HY-146971 | Anti-inflammatory agent 38 | 3032633-42-1 | Reference compound |
| HY-146972S | Zearalenone-14-O-β-glucoside-13C6 | | Isotope-Labeled Compounds |
| HY-146973 | HIV-IN-3 | 3032454-77-3 | Reference compound |
| HY-146974 | PDE4-IN-9 | 2519450-32-7 | Reference compound |
| HY-146975S | Descyclopropyl-dicyclanil-15N3 | | Isotope-Labeled Compounds |
| HY-146976S | Nifuraldezone-15N3 | | Isotope-Labeled Compounds |
| HY-146977 | LDHA/PDKs-IN-1 | 2490699-40-4 | Reference compound |
| HY-146978 | LDHA/PDKs-IN-2 | 2490699-44-8 | Reference compound |
| HY-146979 | hA2A/hCA XII modulator 1 | 2548963-55-7 | Reference compound |
| HY-146980 | GLUT4-IN-2 | 2454113-83-6 | Reference compound |
| HY-146981 | α-Glucosidase-IN-3 | 2758286-48-3 | Reference compound |
| HY-146982 | hCAII-IN-1 | 1807520-24-6 | Reference compound |
| HY-146983 | hCAIX-IN-3 | 2375461-31-5 | Reference compound |
| HY-146984 | α-Amylase-IN-2 | 2758286-53-0 | Reference compound |
| HY-146985 | Cathepsin X-IN-1 | 2418577-51-0 | Reference compound |
| HY-146986S1 | N-acetyl-D-talosamine-13C | 875654-29-8 | Isotope-Labeled Compounds |
| HY-146987 | FWM-3 | 714923-33-8 | Reference compound |
| HY-146988 | hCAIX/XII-IN-1 | 3033040-76-2 | Reference compound |
| HY-146989S | 4-O-β-D-Galactopyranosyl-D-mannose-13C | | Isotope-Labeled Compounds |
| HY-146990S | 3-Deoxy-3-fluoro-D-glucose-13C | 478518-97-7 | Isotope-Labeled Compounds |
| HY-146992S | α-D-Glucopyranosyl 1-phosphate-13C (dicyclohexylamine, monohydrate) | 478518-99-9 | Isotope-Labeled Compounds |
| HY-146993S | 3-O-Methyl-D-glucose-13C | 478529-34-9 | Isotope-Labeled Compounds |
| HY-146994S | L-Idose-13C | | Isotope-Labeled Compounds |
| HY-146994S1 | L-Idose-13C-1 | | Isotope-Labeled Compounds |
| HY-146994S2 | L-Idose-13C-2 | 115973-80-3 | Isotope-Labeled Compounds |
| HY-146995S | Glycolaldehyde-1-13C | 71122-42-4 | Isotope-Labeled Compounds |
| HY-146995S1 | Glycolaldehyde-2-13C | 478529-67-8 | Isotope-Labeled Compounds |
| HY-146996S | β-lactosyl-13C | | Isotope-Labeled Compounds |
| HY-146997 | TRβ agonist 1 | 2770681-85-9 | Reference compound |
| HY-146998 | SARS-CoV-2 3CLpro-IN-2 | 2765088-93-3 | Reference compound |
| HY-146999 | YM458 | 2770108-93-3 | Reference compound |
| HY-147000 | DNA Gyrase-IN-1 | 3031486-11-7 | Reference compound |
| HY-147001 | 5-O-Demethyl-28-hydroxy-Avermectin A1a | 96722-46-2 | Reference compound |
| HY-147002 | 7-O-Methyl Ivermectin B1a | | Reference compound |
| HY-147003 | MMV687807 | 1417658-11-7 | Reference compound |
| HY-147004 | A-908292 | 903886-95-3 | Reference compound |
| HY-147005 | piCRAC-1 | 2418049-54-2 | Reference compound |
| HY-147006 | Zovodotin | 1800462-96-7 | Reference compound |
| HY-147007 | β-catenin-IN-3 | 1005288-15-2 | Reference compound |
| HY-147008 | XP-524 | 2344825-52-9 | Reference compound |
| HY-147010 | STING agonist-12 | 2259624-71-8 | Reference compound |
| HY-147011 | FTO-IN-7 | 2243736-37-8 | Reference compound |
| HY-147012 | GalNAc-L96 | 1159408-62-4 | Reference compound |
| HY-147013 | Caprochlorone | 13878-10-9 | Reference compound |
| HY-147014 | Cyclic HPMPC | 127757-45-3 | Reference compound |
| HY-147015 | HOE961 | 152819-48-2 | Reference compound |
| HY-147016 | NIOCH 14 | 1268015-38-8 | Reference compound |
| HY-147017 | GSK2556286 | 1210456-20-4 | Reference compound |
| HY-147018 | 1-Octylnonyl 8-[[8-[(1-ethylnonyl)oxy]-8-oxooctyl](2-hydroxyethyl)amino]octanoate | 2089251-75-0 | Biochemical Assay Reagents |
| HY-147020 | Coronastat | 2922281-15-8 | Reference compound |
| HY-147021 | MC-Val-D-Cit-PAB-PNP | 1350456-66-4 | ADC Related |
| HY-147021A | MC-D-Val-Cit-PAB-PNP | 1350456-64-2 | Reference compound |
| HY-147025 | (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine | 2347517-69-3 | Reference compound |
| HY-147026 | CDK9-IN-15 | 852678-17-2 | Reference compound |
| HY-147027 | PARP-1-IN-2 | 684234-55-7 | Reference compound |
| HY-147028 | M4 mAChR agonist-1 | 785705-53-5 | Reference compound |
| HY-147029 | HIF1-IN-3 | 333314-79-7 | Reference compound |
| HY-147030 | PARP1-IN-8 | 836640-15-4 | Reference compound |
| HY-147031 | JAMM protein inhibitor 2 | 848249-35-4 | Reference compound |
| HY-147032 | USP8-IN-1 | 2477650-96-5 | Reference compound |
| HY-147037 | AMPK activator 7 | 1623138-03-3 | Reference compound |
| HY-147038 | AMPK activator 8 | 1852451-96-7 | Reference compound |
| HY-147039 | BOLD-100 (free base) | 783324-98-1 | Reference compound |
| HY-147040 | ABN401 | 2242563-15-9 | Reference compound |
| HY-147041 | Selvigaltin | 1978336-95-6 | Reference compound |
| HY-147041A | (2S)-Selvigaltin | | Reference compound |
| HY-147045 | UCB-5307 | 1515887-44-1 | Reference compound |
| HY-147046 | ET-JQ1-OH | 2421153-77-5 | Reference compound |
| HY-147047 | InhA-IN-2 | 2428737-43-1 | Reference compound |
| HY-147048 | STAT3 degrader-1 | 2497585-16-5 | Reference compound |
| HY-147049 | PAL-4 | 2609594-35-4 | Reference compound |
| HY-147050 | Ahx-DM1 | 1702356-21-5 | Reference compound |
| HY-147050A | Ahx-DM1 (TFA) | 1702356-22-6 | Reference compound |
| HY-147051 | Nelremagpran | 2492595-24-9 | Reference compound |
| HY-147052 | Boc-Pip-butyn | 1346153-07-8 | Reference compound |
| HY-147053 | 2-(Diethylamino)ethyl (3-(octyloxy)phenyl)carbamate (hydrochloride) | 32223-82-8 | Reference compound |
| HY-147054 | Zedoresertib | 2243882-74-6 | Reference compound |
| HY-147055 | THR-β agonist 5 | 2542029-74-1 | Reference compound |
| HY-147056 | PKRA83 | 1233926-87-8 | Reference compound |
| HY-147057 | Rofapitide tetraxetan | 2581741-18-4 | Reference compound |
| HY-147057A | Rofapitide tetraxetan (acetate) | | Reference compound |
| HY-147058 | SW2_152F | | Reference compound |
| HY-147059 | Dieckol | 88095-77-6 | Natural Products |
| HY-147059R | Dieckol (Standard) | 88095-77-6 | Reference Standards |
| HY-147060 | Dyrk1A-IN-3 | 2493976-27-3 | Reference compound |
| HY-147061 | 2-Deoxyribose 5-phosphate (disodium) | 102916-66-5 | Reference compound |
| HY-147061R | 2-Deoxyribose 5-phosphate (disodium) (Standard) | 102916-66-5 | Reference Standards |
| HY-147062 | N-Acetyl-D-galactosamine-6-phosphate | 18191-20-3 | Reference compound |
| HY-147063 | N-Acetyl-α-D-glucosamine 1-phosphate (disodium) | 31281-59-1 | Reference compound |
| HY-147063R | N-Acetyl-α-D-glucosamine 1-phosphate (disodium) (Standard) | 31281-59-1 | Reference Standards |
| HY-147064 | DL-4-Hydroxy-2-ketoglutarate (lithium) | | Reference compound |
| HY-147064A | DL-4-Hydroxy-2-ketoglutarate | 1187-99-1 | Reference compound |
| HY-147065 | γ-L-Glutamyl-S-allyl-L-cysteine | 1299925-32-8 | Natural Products |
| HY-147066 | Dyrk1A-IN-4 | 2091883-59-7 | Reference compound |
| HY-147067 | 16:0-18:2 PA (sodium) | 322647-59-6 | Biochemical Assay Reagents |
| HY-147071 | 1,2-Diarachidonoyl-sn-glycero-3-phosphoethanolamine | 5634-86-6 | Biochemical Assay Reagents |
| HY-147072 | 1-Stearoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine (sodium) | 322647-11-0 | Biochemical Assay Reagents |
| HY-147074 | 18:2 PG | 322729-38-4 | Biochemical Assay Reagents |
| HY-147076 | 20:4 PG (sodium) | 474943-21-0 | Biochemical Assay Reagents |
| HY-147078 | EJMC-1 | 397281-20-8 | Reference compound |
| HY-147079 | Egaptivon pegol | 934868-74-3 | Oligonucleotides |
| HY-147079A | Egaptivon pegol (sodium) | | Oligonucleotides |
| HY-147080 | Avacincaptad pegol sodium | 1491144-00-3 | Oligonucleotides |
| HY-147081 | AS 1411 | 301636-59-9 | Oligonucleotides |
| HY-147081A | AS 1411 (sodium) | | Oligonucleotides |
| HY-147081B | AS 1411 (triethylamine) | | Oligonucleotides |
| HY-147082 | GA-017 | 2351906-74-4 | Reference compound |
| HY-147083 | SGC-AAK1-1N | 2242913-80-8 | Reference compound |
| HY-147084 | KY371 | | Reference compound |
| HY-147085 | Loratadine n-oxide | 165739-62-8 | Reference compound |
| HY-147086 | CAY10789 | 123226-28-8 | Reference compound |
| HY-147087 | YSK 05 | 1318793-78-0 | Reference compound |
| HY-147088 | TEAD-IN-2 | 2563849-97-6 | Reference compound |
| HY-147089 | PRRSV/CD163-IN-1 | 560995-89-3 | Reference compound |
| HY-147090 | Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH | 2750350-39-9 | Reference compound |
| HY-147091 | Tazemetostat de(methyl morpholine)-COOH | 2685873-44-1 | Reference compound |
| HY-147092 | Oryzalin | 19044-88-3 | Reference compound |
| HY-147092R | Oryzalin (Standard) | 19044-88-3 | Reference Standards |
| HY-147093 | vc-PAB-DMEA-PNU159682 | 2227350-96-9 | ADC Related |
| HY-147094 | vc-PABC-DM1 | 1416792-90-9 | Reference compound |
| HY-147095 | Val-Ala-PABC-Exatecan | 2845164-91-0 | Reference compound |
| HY-147095A | Val-Ala-PABC-Exatecan (trifluoroacetate) | 2928571-45-1 | ADC Related |
| HY-147097 | EDA-DA | 87156-00-1 | Reference compound |
| HY-147097A | EDA-DA (TFA) | 87156-01-2 | Reference compound |
| HY-147098 | dTAG-47 | 2265886-81-3 | Reference compound |
| HY-147099 | dTAG-47-NEG | | Reference compound |
| HY-14710 | AZ3146 | 1124329-14-1 | Reference compound |
| HY-147100 | α1A-AR Degrader 9c | 2863635-02-1 | Reference compound |
| HY-147101 | SK-575-NEG | 2523017-04-9 | Reference compound |
| HY-147102 | tri-GalNAc biotin | | Reference compound |
| HY-147104 | Fmoc-Lys(5-FITC)-OH | 1095493-05-2 | Dye Reagents |
| HY-147105 | LRH-1 modulator-1 | 2244781-29-9 | Reference compound |
| HY-147105A | (+)-LRH-1 modulator-1 | | Reference compound |
| HY-147106 | Mrgx2 antagonist-1 | 2767110-35-8 | Reference compound |
| HY-147107 | OfHex1-IN-2 | 58125-33-0 | Reference compound |
| HY-147108 | Mitochondria degrader-1 | 2241669-05-4 | Reference compound |
| HY-14711 | Reversine | 656820-32-5 | Reference compound |
| HY-147110 | APX2039 | 2342606-49-7 | Reference compound |
| HY-147112 | MNP-GAL | 70622-78-5 | Reference compound |
| HY-147113 | 2-Methyl-3-buten-1-ol | 4516-90-9 | Reference compound |
| HY-147114 | 3-Methyl-8-(2'-deoxy-β-D-ribofuranosyl)isoxanthopterin | 170379-51-8 | Dye Reagents |
| HY-147115 | 4-Azidophlorizin | 79541-46-1 | Reference compound |
| HY-147116 | 4-[3-(Trifluoromethyl)diazirin-3-yl] benzoic acid N-hydroxysuccinimide ester | 87736-89-8 | Reference compound |
| HY-147117 | NHS-SS-Ac | 2750799-11-0 | Reference compound |
| HY-147119 | INX-SM-6 | 2734878-16-9 | ADC Related |
| HY-147124 | RIG012 | 2642218-43-5 | Reference compound |
| HY-147131 | CDK9-IN-30 | 748146-89-6 | Reference compound |
| HY-147132 | GluR6 antagonist-1 | 323176-64-3 | Reference compound |
| HY-147133 | VEGFR2-IN-2 | 737818-56-3 | Reference compound |
| HY-147134 | GSK-3β inhibitor 10 | 1198098-03-1 | Reference compound |
| HY-147135 | MYF-03-69 | 2416418-11-4 | Reference compound |
| HY-147136 | MYF-03-176 | 2857937-59-6 | Reference compound |
| HY-14714 | NSC-207895 | 58131-57-0 | Reference compound |
| HY-147140 | BOS-318 | 2387633-15-8 | Reference compound |
| HY-147141 | HS-276 | 2767422-72-8 | Reference compound |
| HY-147149 | BPN-15477 | 1971086-99-3 | Reference compound |
| HY-14715 | CCT241533 | 1262849-73-9 | Reference compound |
| HY-147150 | 8-Azido-cADPR | 150424-94-5 | Reference compound |
| HY-147151 | AMCPy | 439858-38-5 | Reference compound |
| HY-147152 | 1-Myristoyl-3-chloropropanediol | 30557-03-0 | Reference compound |
| HY-147158 | ZXH-1-161 | 2407654-51-5 | Reference compound |
| HY-14715B | CCT241533 (hydrochloride) | 1431697-96-9 | Reference compound |
| HY-14716 | CCT239065 | 1163719-51-4 | Reference compound |
| HY-147164 | MC-Gly-Gly-Phe-Gly-PAB-PNP | 2632342-16-4 | ADC Related |
| HY-147165 | VT02956 | 2999763-09-4 | Reference compound |
| HY-147165A | VT02956 (hydrochloride) | | Reference compound |
| HY-147166 | 2-Carboxyanthracene MTSEA amide | 1159977-18-0 | Reference compound |
| HY-147167 | Bz-D-Arg-pNA (hydrochloride) | 21653-41-8 | Reference compound |
| HY-147168 | Biocytin hydrazide | 102743-85-1 | Reference compound |
| HY-147169 | Biotin-X-NTA | 856661-92-2 | Dye Reagents |
| HY-147170 | (1,1'-Dipyrenyl)dimethyl ether | 74833-81-1 | Dye Reagents |
| HY-147171 | 2,7-Bis(alloxycarbonylamino)-9-chloroacridine | 887353-21-1 | Dye Reagents |
| HY-147172 | Ru(bpy)2(dcbpy)NHS (dihexafluorophosphate) | 160525-49-5 | Dye Reagents |
| HY-147173 | FAPI-74 | 2374782-76-8 | Reference compound |
| HY-147174 | PROTAC_ERRα | 1801547-15-8 | Reference compound |
| HY-147177 | Bodipy 8-chloromethane | 208462-25-3 | Dye Reagents |
| HY-147178 | C-6 NBD-dihydro-Ceramide | 114301-95-0 | Reference compound |
| HY-147179 | INX-SM-56 | 2734878-18-1 | ADC Related |
| HY-14718 | Resminostat | 864814-88-0 | Reference compound |
| HY-147180 | Dansyl-DL-valine (cyclohexylammonium) | 84540-67-0 | Reference compound |
| HY-147181 | 1,3-Di-(2-pyrenyl)propane | 97325-55-8 | Dye Reagents |
| HY-147182 | 3,6-Diamino-9(10H)-acridone | 42832-87-1 | Reference compound |
| HY-147183 | JBJ-09-063 | 2820336-67-0 | Reference compound |
| HY-147183A | JBJ-09-063 (TFA) | | Reference compound |
| HY-147183B | JBJ-09-063 (hydrochloride) | | Reference compound |
| HY-147185 | PRMT7-IN-1 | 2247753-73-5 | Reference compound |
| HY-147186 | 5,5'-Difluoro BAPTA | 156027-00-8 | Reference compound |
| HY-147187 | MNK8 | 2055078-49-2 | Reference compound |
| HY-14718A | Resminostat (hydrochloride) | 1187075-34-8 | Reference compound |
| HY-14719 | RO4987655 | 874101-00-5 | Reference compound |
| HY-147190 | ATR-IN-19 | 2648989-61-9 | Reference compound |
| HY-147192 | (S,R,S)-AHPC-O-PEG1-propargyl | 2098799-79-0 | Reference compound |
| HY-147193 | Nampt-IN-10 (TFA) | 2567724-20-1 | Reference compound |
| HY-147193A | Nampt-IN-10 (trihydrochloride) | | Reference compound |
| HY-147195 | QH536 | 2754254-07-2 | Reference compound |
| HY-147196 | KB03-SLF | 2384184-42-1 | Reference compound |
| HY-147198 | Antimalarial agent 13 | 431884-01-4 | Reference compound |
| HY-14720 | Rabusertib | 911222-45-2 | Reference compound |
| HY-147202 | BRD4 Inhibitor-24 | 309951-18-6 | Reference compound |
| HY-147203 | 5-HT2B antagonist-1 | 393129-91-4 | Reference compound |
| HY-147204 | Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE | 1638970-46-3 | Reference compound |
| HY-147205 | Biotin-PEG-OH (MW 1000) | | Reference compound |
| HY-147205A | Biotin-PEG-OH (MW 2000) | | Reference compound |
| HY-147205B | Biotin-PEG-OH (MW 3400) | | Dye Reagents |
| HY-147205C | Biotin-PEG-OH (MW 5000) | | Reference compound |
| HY-147205D | Biotin-PEG-OH (MW 10000) | | Reference compound |
| HY-147205E | Biotin-PEG-OH (MW 20000) | | Dye Reagents |
| HY-147206 | Biotin-PEG-Alk (MW 600) | | Dye Reagents |
| HY-147206A | Biotin-PEG-Alk (MW 1000) | | Dye Reagents |
| HY-147206B | Biotin-PEG-Alk (MW 2000) | | Dye Reagents |
| HY-147206C | Biotin-PEG-Alk (MW 3400) | | Dye Reagents |
| HY-147206D | Biotin-PEG-Alk (MW 5000) | | Reference compound |
| HY-147206E | Biotin-PEG-Alk (MW 10000) | | Dye Reagents |
| HY-147206F | Biotin-PEG-Alk (MW 20000) | | Dye Reagents |
| HY-147207 | Phospholipid-PEG-Biotin (MW 1000) | | Biochemical Assay Reagents |
| HY-147207A | Phospholipid-PEG-Biotin (MW 2000) | | Biochemical Assay Reagents |
| HY-147207B | Phospholipid-PEG-Biotin (MW 3400) | | Biochemical Assay Reagents |
| HY-147207C | Phospholipid-PEG-Biotin (MW 5000) | | Biochemical Assay Reagents |
| HY-147207D | Phospholipid-PEG-Biotin (MW 10000) | | Biochemical Assay Reagents |
| HY-147207E | Phospholipid-PEG-Biotin (MW 20000) | | Biochemical Assay Reagents |
| HY-147208 | MSC-4106 | 2738542-58-8 | Reference compound |
| HY-14721 | Tepotinib | 1100598-32-0 | Reference compound |
| HY-147214 | GNE-7883 | 2648450-42-2 | Reference compound |
| HY-147215 | UC-1V150 | 927822-45-5 | Reference compound |
| HY-147216 | AXKO-0046 | | Reference compound |
| HY-147216A | AXKO-0046 (dihydrochloride) | | Reference compound |
| HY-147217 | Bepirovirsen | 1403787-62-1 | Oligonucleotides |
| HY-147217A | Bepirovirsen (sodium) | 2563929-84-8 | Oligonucleotides |
| HY-147218 | PF-07265807 | 2412356-57-9 | Reference compound |
| HY-147219 | SIAIS164018 | 2353492-68-7 | Reference compound |
| HY-147219A | SIAIS164018 (hydrochloride) | | Reference compound |
| HY-14721A | Tepotinib (hydrochloride) | 1103508-80-0 | Reference compound |
| HY-14721R | Tepotinib (Standard) | 1100598-32-0 | Reference Standards |
| HY-14722 | NVP-BSK805 | 1092499-93-8 | Reference compound |
| HY-147220 | Dexamethasone oxetanone | 4089-36-5 | Reference compound |
| HY-147222 | SAE-14 | 1241280-25-0 | Reference compound |
| HY-147225 | TSPO Ligand-Linker Conjugates 1 | | Reference compound |
| HY-147226 | EP3 antagonist 3 | 1227827-88-4 | Reference compound |
| HY-147228 | NR2F6 modulator-1 | 904449-84-9 | Reference compound |
| HY-147229 | GDC-6036-NH | 2417918-80-8 | Reference compound |
| HY-14722A | NVP-BSK805 (dihydrochloride) | 1942919-79-0 | Reference compound |
| HY-14722C | NVP-BSK805 (trihydrochloride) | 2320258-95-3 | Reference compound |
| HY-14723 | AMG-458 | 913376-83-7 | Reference compound |
| HY-147230 | EZH2-IN-13 | 1403255-41-3 | Reference compound |
| HY-147231 | SG3400 delate(Mal-amido-PEG8) | 2125685-22-3 | Reference compound |
| HY-147232 | N-Acryloyl-1-pyrenebutylamine | 133399-57-2 | Dye Reagents |
| HY-147233 | MIND4-19 | 129544-85-0 | Reference compound |
| HY-147234 | Sirtuin modulator 2 | 667910-69-2 | Reference compound |
| HY-147235 | RIPK2-IN-2 | 2143956-20-9 | Reference compound |
| HY-147236 | TLR7/8 agonist 7 | 2567953-47-1 | Reference compound |
| HY-147237 | LpxC-IN-10 | 2413574-64-6 | Reference compound |
| HY-147238 | Antifungal agent 35 | 2085274-00-4 | Reference compound |
| HY-147239 | MC-VA-PABC-MMAE | 1818864-51-5 | ADC Related |
| HY-147240 | Acloproxalap | 1824609-67-7 | Reference compound |
| HY-147241 | Alpibectir | 2285440-39-1 | Reference compound |
| HY-147243 | Ansornitinib | 1448874-96-1 | Reference compound |
| HY-147245 | Basroparib | 1858179-75-5 | Reference compound |
| HY-147246 | Berberine ursodeoxycholate | 1868138-66-2 | Reference compound |
| HY-147247 | Fosimdesonide | | Reference compound |
| HY-147248 | Opadotina | | Reference compound |
| HY-147249 | CFTR corrector 8 | 1918142-35-4 | Reference compound |
| HY-147250 | Lirafugratinib | 2549174-42-5 | Reference compound |
| HY-147250A | Lirafugratinib (hydrochloride) | 2688040-45-9 | Reference compound |
| HY-147251 | SRI 6409-94 | 127697-58-9 | Reference compound |
| HY-147252 | Bezeparsen | 2639640-84-7 | Oligonucleotides |
| HY-147252A | Bezeparsen (sodium) | | Oligonucleotides |
| HY-147253 | Brogidirsen | 2409088-11-3 | Oligonucleotides |
| HY-147253A | Brogidirsen (sodium) | | Oligonucleotides |
| HY-147254 | Cadisegliatin | 859525-02-3 | Reference compound |
| HY-147255 | Canocapavir | 2137847-19-7 | Reference compound |
| HY-147255A | (S)-Canocapavir | 2137847-77-7 | Reference compound |
| HY-147256 | Cavutilide | 1276186-19-6 | Reference compound |
| HY-147257 | Cofrogliptin | 1844874-26-5 | Reference compound |
| HY-147259 | Dalmelitinib | 1637658-98-0 | Reference compound |
| HY-147261 | B026 | 2379416-48-3 | Reference compound |
| HY-147263 | Dovramilast | 340019-69-4 | Reference compound |
| HY-147264 | Edecesertib | 2408839-73-4 | Reference compound |
| HY-147265 | Eldocasiran | 2615098-65-0 | Oligonucleotides |
| HY-147265A | Eldocasiran (sodium) | | Oligonucleotides |
| HY-147266 | Elebsiran sodium | | Oligonucleotides |
| HY-147266A | Elebsiran | 2648009-64-5 | Oligonucleotides |
| HY-147267 | Evazarsen | 2589926-22-5 | Oligonucleotides |
| HY-147267A | Evazarsen (sodium) | 2589926-24-7 | Oligonucleotides |
| HY-147268 | Exarafenib | 2639957-39-2 | Reference compound |
| HY-147269 | Fosclevudine alafenamide | 1951476-79-1 | Reference compound |
| HY-147270 | MC-VA-PAB-Exatecan | 2680543-57-9 | ADC Related |
| HY-147271 | Mal-PEG8-Val-Ala-PAB-Exatecan | 2679821-39-5 | ADC Related |
| HY-147273 | Fulimetibant | 2231142-90-6 | Reference compound |
| HY-147274 | Funobactam | 2365454-12-0 | Reference compound |
| HY-147275 | Tazide | | Reference compound |
| HY-147276 | Izuforant | 1429374-83-3 | Reference compound |
| HY-147277 | Lorundrostat | 1820940-17-7 | Reference compound |
| HY-147278 | Manusiran | 2646704-10-9 | Oligonucleotides |
| HY-147278A | Manusiran (sodium) | | Oligonucleotides |
| HY-147279 | Milpocitide | 2643306-81-2 | Reference compound |
| HY-14728 | Aleglitazar | 475479-34-6 | Reference compound |
| HY-147280 | Misetionamide | 856785-75-6 | Reference compound |
| HY-147281 | BAY 1135626 | 1404071-37-9 | ADC Related |
| HY-147282 | Amgen-23 | 1448706-15-7 | Reference compound |
| HY-147283 | MK2-IN-4 | 1105658-32-9 | Reference compound |
| HY-147284 | PI3K-IN-37 | 1257547-40-2 | Reference compound |
| HY-147285 | PI3K/mTOR Inhibitor-9 | 1392421-71-4 | Reference compound |
| HY-147286 | Ac-Lys-Val-Cit-PABC-MMAE | 1650569-89-3 | ADC Related |
| HY-147286A | Ac-Lys-Val-Cit-PABC-MMAE (formic) | | ADC Related |
| HY-147287 | Glu-urea-Glu-NHS ester | 1228927-36-3 | Reference compound |
| HY-147288 | NSC 694621 | 104857-29-6 | Reference compound |
| HY-147289 | NSC 698600 | 908069-17-0 | Reference compound |
| HY-147290 | NSC 694623 | 907957-34-0 | Reference compound |
| HY-147291 | VPC-70063 | 13571-44-3 | Reference compound |
| HY-147292 | Nelutroctiv | 2299177-09-4 | Reference compound |
| HY-147293 | Nenocorilant | 1496509-78-4 | Reference compound |
| HY-147294 | Nivasorexant | 1435480-40-2 | Reference compound |
| HY-147295 | Odetiglucan | 53238-80-5 | Reference compound |
| HY-147296 | Omesdafexor | 2244440-85-3 | Reference compound |
| HY-147297 | Pelecopan | 2378380-49-3 | Reference compound |
| HY-147298 | Plogosertib | 1137212-79-3 | Reference compound |
| HY-147299 | Povafonidine | 177843-85-5 | Reference compound |
| HY-147300 | Puliginurad | 2013582-27-7 | Reference compound |
| HY-147301 | Resomelagon | 1809420-71-0 | Reference compound |
| HY-147301A | Resomelagon (acetate) | 1809420-72-1 | Reference compound |
| HY-147301B | Resomelagon (methanesulfonate) | 2933183-20-9 | Reference compound |
| HY-147303 | Sacibertinib | 1351941-69-9 | Reference compound |
| HY-147304 | BPH-1086 | 1226901-43-4 | Reference compound |
| HY-147306 | ZLc-002 | 1446971-41-0 | Reference compound |
| HY-147306A | (S)-ZLc002 | 308277-46-5 | Reference compound |
| HY-147307 | MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan | 2414393-22-7 | ADC Related |
| HY-147308 | Zelenirstat | 1215011-08-7 | Reference compound |
| HY-147309 | 16-Azidohexadecanoic acid | 112668-54-9 | Reference compound |
| HY-14731 | VE-821 | 1232410-49-9 | Reference compound |
| HY-147310 | CU-CPD107 | 2573912-32-8 | Reference compound |
| HY-147311 | NSC622608 | 2593254-90-9 | Reference compound |
| HY-147312 | GSK-1520489A | 1042433-41-9 | Reference compound |
| HY-147313 | TH10785 | 1002801-51-5 | Reference compound |
| HY-147314 | HIV-IN-6 | 301357-74-4 | Reference compound |
| HY-147315 | CFTR corrector 9 | 909861-78-5 | Reference compound |
| HY-147316 | TP-5801 | 2574474-81-8 | Reference compound |
| HY-147316A | TP-5801 (TFA) | | Reference compound |
| HY-147317 | Epothilone E | 201049-37-8 | Reference compound |
| HY-147318 | PBENZ-DBRMD | 1454662-41-9 | Reference compound |
| HY-147319 | RTI-7470-44 | 825658-63-7 | Reference compound |
| HY-147320 | 3'-DMTr-dG(dmf) | 261728-23-8 | Reference compound |
| HY-147321 | 3'-DMTr-dG(iBu) | 140839-24-3 | Reference compound |
| HY-147322 | YAP/TAZ inhibitor-2 | 2762617-31-0 | Reference compound |
| HY-147323 | Ferulic acid 4-O-sulfate | 86321-29-1 | Reference compound |
| HY-147323R | Ferulic acid 4-O-sulfate (Standard) | 86321-29-1 | Reference Standards |
| HY-147325 | bisSP1 | 2253947-15-6 | ADC Related |
| HY-147327 | N-Formylsarcolysine | 26367-45-3 | Reference compound |
| HY-147328 | LCS3 | 109844-92-0 | Reference compound |
| HY-147329 | RAGE 229 | 2143072-85-7 | Reference compound |
| HY-147330 | SJ1008030 | 2863634-96-0 | Reference compound |
| HY-147330A | SJ1008030 (TFA) | 2863634-97-1 | Reference compound |
| HY-147330B | SJ1008030 (formic) | | Reference compound |
| HY-147331 | Oseltamivir acid methyl ester | 208720-71-2 | Reference compound |
| HY-147331A | Oseltamivir acid methyl ester (hydrochloride) | 208720-78-9 | Reference compound |
| HY-147332 | TCL053 | 2361162-70-9 | Reference compound |
| HY-147333 | Trimipramine N-oxide | 14171-70-1 | Reference compound |
| HY-147335 | 6,9,12,15-Hexadecatetraenoic acid-ethyl ester | 845779-89-7 | Reference compound |
| HY-147336 | Desmethylazelastine | 47491-38-3 | Reference compound |
| HY-147337 | MeTC7 | 1817841-22-7 | Reference compound |
| HY-147338 | 5-Methylcytidine 5′-triphosphate | 327174-86-7 | Reference compound |
| HY-147338A | 5-Methylcytidine 5′-triphosphate (trisodium) | | Reference compound |
| HY-147338S | 5-Methylcytidine 5′-triphosphate-d3 (trisodium) | | Isotope-Labeled Compounds |
| HY-147338S1 | 5-Methylcytidine 5′-triphosphate-15N2,13C (trisodium) | | Isotope-Labeled Compounds |
| HY-147338S2 | 5-Methylcytidine 5′-triphosphate-d8 (trisodium) | | Isotope-Labeled Compounds |
| HY-147339 | M7G(3'-OMe-5')pppA(2'-OMe) | | Oligonucleotides |
| HY-14734 | Anamorelin | 249921-19-5 | Reference compound |
| HY-147342 | β-Benzamide adenine dinucleotide | 156724-91-3 | Reference compound |
| HY-147346 | Zelicapavir | 2070852-76-3 | Reference compound |
| HY-147348 | 4-Formylcolchicine | 2730-82-7 | Reference compound |
| HY-147349 | ANT3310 (sodium) | 2410688-61-6 | Reference compound |
| HY-14734A | Anamorelin (hydrochloride) | 861998-00-7 | Reference compound |
| HY-14734B | Anamorelin (Fumarate) | 339539-92-3 | Reference compound |
| HY-14734R | Anamorelin (Standard) | 249921-19-5 | Reference Standards |
| HY-14735 | Arbaclofen placarbil | 847353-30-4 | Reference compound |
| HY-147351 | GPR40 agonist 6 | 1798751-25-3 | Reference compound |
| HY-147352 | NMDA receptor potentiator-1 | 486427-18-3 | Reference compound |
| HY-147353 | Phenylsulfamide | 15959-53-2 | Reference compound |
| HY-147354 | TriGalNAc CBz | 186613-57-0 | Reference compound |
| HY-147356 | ERCC1-XPF-IN-2 | 1808986-37-9 | Reference compound |
| HY-147357 | TRPC3/6-IN-1 | 736945-96-3 | Reference compound |
| HY-147358 | Yimitasvir (diphosphate) | 1959593-63-5 | Reference compound |
| HY-147358A | Yimitasvir | 1959593-23-7 | Reference compound |
| HY-147358C | (1R,4S)-Yimitasvir (diphosphate) | 2734870-15-4 | Reference compound |
| HY-147359 | Boanmycin | 37293-17-7 | Reference compound |
| HY-14736 | Azilsartan medoxomil | 863031-21-4 | Reference compound |
| HY-147360 | Tribendimidine | 115103-15-6 | Reference compound |
| HY-147361 | LDCA | 349106-80-5 | Reference compound |
| HY-147362 | MAO-B-IN-14 | 1904610-48-5 | Reference compound |
| HY-147363 | DIBAC-GGFG-NH2CH2-Dxd | 2758875-01-1 | Reference compound |
| HY-147364 | 5-(3-Hydroxybenzylidene)-rhodanine | 37530-35-1 | Reference compound |
| HY-147365 | Acifluorfen-methyl | 50594-67-7 | Reference compound |
| HY-147366 | RBP4 ligand-1 | 260553-24-0 | Reference compound |
| HY-147367 | AM-1488 | 2079895-60-4 | Reference compound |
| HY-147368 | PKM2 activator 2 | 1186660-06-9 | Reference compound |
| HY-147369 | NFATc1-IN-1 | 1912422-56-0 | Reference compound |
| HY-14736R | Azilsartan medoxomil (Standard) | 863031-21-4 | Reference Standards |
| HY-14737 | Ceftaroline fosamil | 400827-46-5 | Reference compound |
| HY-147370 | HIV-1 inhibitor-46 | 332947-35-0 | Reference compound |
| HY-147371 | Quinoprazine | 115618-99-0 | Reference compound |
| HY-147372 | SJ000063181 | 945189-68-4 | Reference compound |
| HY-147373 | DA-PROTAC | 2488660-12-2 | Reference compound |
| HY-147374 | Bromodomain inhibitor-9 | 1870849-34-5 | Reference compound |
| HY-147375 | Bromodomain inhibitor-10 | 1870849-58-3 | Reference compound |
| HY-147376 | hACC2-IN-1 | 192323-14-1 | Reference compound |
| HY-147377 | N-Salicyloyltryptamine | 31384-98-2 | Reference compound |
| HY-147379 | Hepcidin antagonist-1 | 338965-09-6 | Reference compound |
| HY-14737A | Ceftaroline fosamil (hydrate) | 400827-55-6 | Reference compound |
| HY-14737R | Ceftaroline fosamil (Standard) | 400827-46-5 | Reference Standards |
| HY-14738 | Ceftaroline fosamil (inner) | 229016-73-3 | Reference compound |
| HY-147381 | MetRS-IN-1 | 24015-12-5 | Reference compound |
| HY-147382 | Neuronotoxicity-IN-1 | 190843-45-9 | Reference compound |
| HY-147383 | NS-8 | 186033-14-7 | Reference compound |
| HY-147384 | CXL-1020 | 950834-06-7 | Reference compound |
| HY-147385 | CCR4 antagonist 3 | 1957-01-3 | Reference compound |
| HY-147386 | CDK-IN-10 | 660822-84-4 | Reference compound |
| HY-147387 | DSS30 | 883027-32-5 | Reference compound |
| HY-147388 | hiCE inhibitor-1 | 2654-68-4 | Reference compound |
| HY-147389 | Enpp-1-IN-14 | 2687222-59-7 | Reference compound |
| HY-14739 | Choline Fenofibrate | 856676-23-8 | Reference compound |
| HY-147390 | MIF098 | 1208448-95-6 | Reference compound |
| HY-147391 | ASIC-IN-1 | 308088-10-0 | Reference compound |
| HY-147392 | CXCR2 antagonist 8 | 182498-30-2 | Reference compound |
| HY-147393 | Factor VII-IN-1 | 244206-28-8 | Reference compound |
| HY-147394 | GPR41 agonist-1 | 506417-09-0 | Reference compound |
| HY-147395 | GPR52 agonist-1 | 1207965-40-9 | Reference compound |
| HY-147397 | PKM2 activator 3 | 1346113-84-5 | Reference compound |
| HY-147398 | Dopamine D4 receptor antagonist-1 | 444724-92-9 | Reference compound |
| HY-147399 | 5-HT7 agonist 2 | 1206846-61-8 | Reference compound |
| HY-14739R | Choline Fenofibrate (Standard) | 856676-23-8 | Reference Standards |
| HY-14740 | Elvitegravir | 697761-98-1 | Reference compound |
| HY-147400 | Sipagladenant | 858979-50-7 | Reference compound |
| HY-147401 | Sitagliptin fenilalanil | 1339955-03-1 | Reference compound |
| HY-147401A | Sitagliptin fenilalanil (hydrochloride) | 1339954-75-4 | Reference compound |
| HY-147402 | Taragarestrant | 2118899-51-5 | Reference compound |
| HY-147402A | Taragarestrant (meglumine) | 2446618-18-2 | Reference compound |
| HY-147404 | Tilpisertib fosmecarbil | 2567459-64-5 | Reference compound |
| HY-147404A | Tilpisertib fosmecarbil (TFA) | 2567459-65-6 | Reference compound |
| HY-147405 | Tinlorafenib | 2573781-75-4 | Reference compound |
| HY-147406 | Tonlamarsen | 2589926-20-3 | Oligonucleotides |
| HY-147406A | Tonlamarsen (sodium) | 2589926-21-4 | Oligonucleotides |
| HY-147407 | Imbotolimod | | Reference compound |
| HY-147408 | Rezetecán | | Reference compound |
| HY-147409 | Ulecaciclib | 2075750-05-7 | Reference compound |
| HY-14740R | Elvitegravir (Standard) | 697761-98-1 | Reference Standards |
| HY-14740S | Elvitegravir-d8 | | Isotope-Labeled Compounds |
| HY-14740S1 | Elvitegravir-d6 | | Isotope-Labeled Compounds |
| HY-14740S2 | Elvitegravir-13C6 | | Isotope-Labeled Compounds |
| HY-14741 | Epetirimod | 227318-71-0 | Reference compound |
| HY-147410 | Ulefnersen | 2589926-25-8 | Oligonucleotides |
| HY-147410A | Ulefnersen (sodium) | 2589926-27-0 | Oligonucleotides |
| HY-147411 | Ulonivirine | 1591823-76-5 | Reference compound |
| HY-147412 | Ultevursen | 2642382-41-8 | Oligonucleotides |
| HY-147412A | Ultevursen (sodium) | | Oligonucleotides |
| HY-147414 | Vamotinib | 1416241-23-0 | Reference compound |
| HY-147416 | Vipoglanstat | 1360622-01-0 | Reference compound |
| HY-147419 | Vulolisib | 2390105-79-8 | Reference compound |
| HY-14742 | Faxeladol | 433265-65-7 | Reference compound |
| HY-147420 | Xelaglifam | 2230597-99-4 | Reference compound |
| HY-147421 | Xilmenolone | 2368807-26-3 | Reference compound |
| HY-147422 | Xininurad | 2365178-28-3 | Reference compound |
| HY-147423 | Zandatrigine | 2154406-04-7 | Reference compound |
| HY-147424 | Zegruvirimat | 2122781-86-4 | Reference compound |
| HY-147425 | Zerlasiran | 2646703-64-0 | Oligonucleotides |
| HY-147425A | Zerlasiran (sodium) | | Oligonucleotides |
| HY-147426 | Zifcasiran | 2437257-11-7 | Oligonucleotides |
| HY-147426A | Zifcasiran (sodium) | 2437257-12-8 | Oligonucleotides |
| HY-147428 | Zolunicant | 188125-42-0 | Reference compound |
| HY-147429 | Zosurabalpin | 2379336-76-0 | Reference compound |
| HY-147429A | Zosurabalpin (TFA) | | Reference compound |
| HY-14743 | Golotimod | 229305-39-9 | Reference compound |
| HY-14743A | Golotimod (TFA) | 2828433-07-2 | Reference compound |
| HY-14743B | Golotimod (hydrochloride) | 1029401-59-9 | Reference compound |
| HY-14744 | Levamlodipine | 103129-82-4 | Reference compound |
| HY-14744A | Levamlodipine (besylate) | 150566-71-5 | Reference compound |
| HY-14744B | Levamlodipine (hydrochloride) | 865430-76-8 | Reference compound |
| HY-14744C | Levamlodipine (hydrobromide) | 865430-78-0 | Reference compound |
| HY-14744D | Levamlodipine (besylate Hemipentahydrate) | 884648-62-8 | Reference compound |
| HY-14744S | Levamlodipine-d4 | 1346617-19-3 | Isotope-Labeled Compounds |
| HY-14747 | Piragliatin | 625114-41-2 | Reference compound |
| HY-14749 | Pyronaridine | 74847-35-1 | Reference compound |
| HY-14749A | Pyronaridine (tetraphosphate) | 76748-86-2 | Reference compound |
| HY-14749AR | Pyronaridine (tetraphosphate) (Standard) | 76748-86-2 | Reference Standards |
| HY-14749AS | Pyronaridine-d4 (tetraphosphate) | 1186026-25-4 | Isotope-Labeled Compounds |
| HY-14750 | Rabeximod | 872178-65-9 | Reference compound |
| HY-147500 | TRβ agonist 2 | 2411099-30-2 | Reference compound |
| HY-147501 | TRβ agonist 3 | 2411099-46-0 | Reference compound |
| HY-147502 | Vin-C01 | 23173-26-4 | Reference compound |
| HY-147503 | Vin-F03 | 2180917-11-5 | Reference compound |
| HY-147504 | Anticancer agent 63 | 2529657-32-5 | Reference compound |
| HY-147505 | Antitubercular agent-21 | 2412142-93-7 | Reference compound |
| HY-147506 | NOD2 antagonist 1 | 2411441-54-6 | Reference compound |
| HY-147507 | SBP-1 | 2451986-45-9 | Dye Reagents |
| HY-147508 | SBP-2 | 2494035-92-4 | Dye Reagents |
| HY-147509 | SBP-3 | 2494035-93-5 | Dye Reagents |
| HY-14751 | Rolapitant | 552292-08-7 | Reference compound |
| HY-147511 | PPARγ agonist 7 | 2569295-93-6 | Reference compound |
| HY-147512 | CB1/2 agonist 1 | 2986688-90-6 | Reference compound |
| HY-147513 | AKT-IN-12 | 2396718-52-6 | Reference compound |
| HY-147514 | Anticancer agent 64 | 2387902-92-1 | Reference compound |
| HY-147515 | FGFR4-IN-11 | 2396664-85-8 | Reference compound |
| HY-147516 | SARS-CoV-2-IN-21 | 89971-88-0 | Reference compound |
| HY-147517 | Keap1-Nrf2-IN-9 | 2769963-24-6 | Reference compound |
| HY-147518 | p38-α MAPK-IN-5 | 1443242-46-3 | Reference compound |
| HY-147519 | ARUK3001185 | 2411969-39-4 | Reference compound |
| HY-14751A | Rolapitant (hydrochloride) | 858102-79-1 | Reference compound |
| HY-14751R | Rolapitant (Standard) | 552292-08-7 | Reference Standards |
| HY-14752 | Ronacaleret | 753449-67-1 | Reference compound |
| HY-147520 | FAK-IN-5 | 2408317-70-2 | Reference compound |
| HY-147521 | Antitumor photosensitizer-3 | | Reference compound |
| HY-147522 | ADG-2e | 2419951-75-8 | Reference compound |
| HY-147525 | PROTAC EZH2 Degrader-1 | 2641601-67-2 | Reference compound |
| HY-147526 | RM-581 | 2086809-59-6 | Reference compound |
| HY-147527 | CDK8-IN-5 | 2855087-10-2 | Reference compound |
| HY-147528 | mGluR2 modulator 2 | 1004614-86-1 | Reference compound |
| HY-147529 | mGluR2 modulator 3 | 1004614-58-7 | Reference compound |
| HY-14753 | Rosonabant | 861151-12-4 | Reference compound |
| HY-147530 | mGluR2 modulator 4 | 2582758-47-0 | Reference compound |
| HY-147531 | Antibacterial agent 106 | 2459657-11-3 | Reference compound |
| HY-147532 | CB2R probe 1 | 2634714-79-5 | Reference compound |
| HY-147533 | RORγt inverse agonist 30 | 1445901-41-6 | Reference compound |
| HY-147534 | Antileishmanial agent-6 | | Reference compound |
| HY-147535 | Antileishmanial agent-7 | 503323-06-6 | Reference compound |
| HY-147536 | Antileishmanial agent-8 | 2477608-96-9 | Reference compound |
| HY-147537 | Antileishmanial agent-9 | 2477608-91-4 | Reference compound |
| HY-147538 | Antitumor agent-64 | 2396562-55-1 | Reference compound |
| HY-147539 | Antitumor agent-65 | 2456288-82-5 | Reference compound |
| HY-14754 | Salirasib | 162520-00-5 | Reference compound |
| HY-147540 | Antitumor agent-66 | 2456288-81-4 | Reference compound |
| HY-147541 | A2A/A3 AR antagonist-1 | 1448221-36-0 | Reference compound |
| HY-147542 | Melatonin receptor agonist 1 | 2411150-76-8 | Reference compound |
| HY-147543 | A1AR antagonist 4 | 1031993-35-7 | Reference compound |
| HY-147544 | A1AR antagonist 5 | 1030509-01-3 | Reference compound |
| HY-147545 | A1AR antagonist 6 | 329693-22-3 | Reference compound |
| HY-147546 | Antibacterial agent 107 | 2454636-44-1 | Reference compound |
| HY-147547 | SV5 | 2581825-37-6 | Reference compound |
| HY-147548 | Keap1-Nrf2-IN-10 | 2445349-54-0 | Reference compound |
| HY-147549 | Antitrypanosomal agent 6 | 2492436-35-6 | Reference compound |
| HY-14754R | Salirasib (Standard) | 162520-00-5 | Reference Standards |
| HY-147550 | Antitrypanosomal agent 7 | 2492436-38-9 | Reference compound |
| HY-147552 | HIV-1 inhibitor-35 | 2416971-32-7 | Reference compound |
| HY-147553 | HIV-1 inhibitor-36 | 2170506-18-8 | Reference compound |
| HY-147554 | HIV-1 inhibitor-37 | 2416971-40-7 | Reference compound |
| HY-147555 | HIV-1 inhibitor-38 | 2416971-48-5 | Reference compound |
| HY-147556 | SK3 Channel-IN-1 | 2396571-04-1 | Reference compound |
| HY-147557 | PAC1R antagonist 1 | 2305204-24-2 | Reference compound |
| HY-147558 | CB1R Allosteric modulator 1 | 2513102-41-3 | Reference compound |
| HY-147559 | CB1R Allosteric modulator 2 | 2513102-64-0 | Reference compound |
| HY-14756 | Totrombopag | 376592-42-6 | Reference compound |
| HY-147560 | σ1 Receptor/μ Opioid receptor modulator 1 | 2412700-00-4 | Reference compound |
| HY-147561 | ALPK1-IN-1 | 2765457-72-3 | Reference compound |
| HY-147562 | ALPK1-IN-2 | 2765633-68-7 | Reference compound |
| HY-147563 | RET-IN-17 | 1885880-08-9 | Reference compound |
| HY-147564 | RET-IN-18 | 2759292-94-7 | Reference compound |
| HY-147565 | ATR-IN-13 | 2758113-84-5 | Reference compound |
| HY-147566 | ATR-IN-14 | 2765785-88-2 | Reference compound |
| HY-147567 | ATR-IN-15 | 2756665-52-6 | Reference compound |
| HY-147568 | ATR-IN-16 | 2756589-62-3 | Reference compound |
| HY-147569 | ATR-IN-17 | 2761194-15-2 | Reference compound |
| HY-14757 | Trelanserin | 189003-92-7 | Reference compound |
| HY-147570 | ATR-IN-18 | 2766407-55-8 | Reference compound |
| HY-147571 | BET-IN-9 | 2758778-88-8 | Reference compound |
| HY-147572 | BET-IN-10 | 2758778-95-7 | Reference compound |
| HY-147573 | BRD4 Inhibitor-23 | 2760307-53-5 | Reference compound |
| HY-147574 | Axl-IN-7 | 1770821-83-4 | Reference compound |
| HY-147575 | Axl-IN-8 | 2231424-62-5 | Reference compound |
| HY-147576 | Axl-IN-9 | 2487649-73-8 | Reference compound |
| HY-147577 | Axl-IN-10 | 2487649-61-4 | Reference compound |
| HY-147578 | Axl-IN-11 | 2758688-17-2 | Reference compound |
| HY-147579 | Axl-IN-12 | 2758062-17-6 | Reference compound |
| HY-14758 | Adipiplon | 840486-93-3 | Reference compound |
| HY-147580 | BTK-IN-10 | 2758596-07-3 | Reference compound |
| HY-147581 | BTK-IN-11 | 2765852-46-6 | Reference compound |
| HY-147582 | BTK-IN-12 | 2762043-53-6 | Reference compound |
| HY-147584 | BTK-IN-14 | 2764674-60-2 | Reference compound |
| HY-147585 | C5aR-IN-1 | 2761048-02-4 | Reference compound |
| HY-147586 | C5aR-IN-2 | 2761048-06-8 | Reference compound |
| HY-147587 | C5aR-IN-3 | 2761048-50-2 | Reference compound |
| HY-147588 | CD73-IN-7 | 2763709-14-2 | Reference compound |
| HY-147589 | CD73-IN-8 | 2763710-08-1 | Reference compound |
| HY-14759 | Aleplasinin | 481629-87-2 | Reference compound |
| HY-147590 | CD73-IN-9 | 2766565-88-0 | Reference compound |
| HY-147591 | CD73-IN-10 | 2766565-91-5 | Reference compound |
| HY-147592 | CD73-IN-11 | 2766566-11-2 | Reference compound |
| HY-147593 | CD73-IN-12 | 2773502-79-5 | Reference compound |
| HY-147594 | CD73-IN-13 | 2773423-69-9 | Reference compound |
| HY-147595 | KRAS G12D inhibitor 15 | 2763155-39-9 | Reference compound |
| HY-147597 | CDK7-IN-13 | 2765676-20-6 | Reference compound |
| HY-147598 | CDK7-IN-14 | 2765676-49-9 | Reference compound |
| HY-147600 | CDK7-IN-15 | 2765676-02-4 | Reference compound |
| HY-147601 | CDK7-IN-16 | 2765676-32-0 | Reference compound |
| HY-147602 | CDK7-IN-17 | 2765676-60-4 | Reference compound |
| HY-147603 | CDK7-IN-18 | 2765676-81-9 | Reference compound |
| HY-147604 | Factor B-IN-2 | 2760669-72-3 | Reference compound |
| HY-147605 | Factor B-IN-3 | 2760669-74-5 | Reference compound |
| HY-147606 | Factor B-IN-4 | 2760669-84-7 | Reference compound |
| HY-147607 | Lanoracopan | 2797066-85-2 | Reference compound |
| HY-147608 | CSF1R-IN-7 | 2738328-56-6 | Reference compound |
| HY-147609 | CSF1R-IN-8 | 2765301-60-6 | Reference compound |
| HY-14761 | Bentamapimod | 848344-36-5 | Reference compound |
| HY-147610 | CSF1R-IN-9 | 2765301-84-4 | Reference compound |
| HY-147611 | CSF1R-IN-10 | 2765301-88-8 | Reference compound |
| HY-147612 | Tyrosine kinase-IN-4 | 765949-21-1 | Reference compound |
| HY-147613 | PI3K/mTOR Inhibitor-6 | 2456295-59-1 | Reference compound |
| HY-147614 | PI3K/mTOR Inhibitor-7 | 2456295-65-9 | Reference compound |
| HY-147615 | CSF1R-IN-12 | 2361556-35-4 | Reference compound |
| HY-147616 | CSF1R-IN-13 | 2361556-61-6 | Reference compound |
| HY-147617 | CSF1R-IN-14 | 2361378-89-2 | Reference compound |
| HY-147619 | FGFR-IN-4 | 2761211-49-6 | Reference compound |
| HY-14762 | Besifloxacin | 141388-76-3 | Reference compound |
| HY-147620 | FGFR-IN-5 | 2762750-70-7 | Reference compound |
| HY-147621 | FGFR-IN-6 | 2762955-18-8 | Reference compound |
| HY-147622 | GLP-1R agonist 9 | 2401894-00-4 | Reference compound |
| HY-147623 | GLP-1R agonist 10 | 2762515-25-1 | Reference compound |
| HY-147625 | GLP-1R agonist 12 | 2765595-19-3 | Reference compound |
| HY-147626 | GLP-1R agonist 13 | 2768016-72-2 | Reference compound |
| HY-147627 | GLP-1R agonist 14 | 2758666-01-0 | Reference compound |
| HY-147628 | GLP-1R agonist 15 | 2763621-11-8 | Reference compound |
| HY-147629 | GLP-1R agonist 16 | 2763329-13-9 | Reference compound |
| HY-14763 | Cariprazine | 839712-12-8 | Reference compound |
| HY-147631 | KRAS G12C inhibitor 50 | 2760354-12-7 | Reference compound |
| HY-147632 | KRAS G12C inhibitor 51 | 2762632-78-8 | Reference compound |
| HY-147633 | KRAS G12C inhibitor 52 | 2761204-87-7 | Reference compound |
| HY-147634 | KRAS G12C inhibitor 53 | 2761968-93-6 | Reference compound |
| HY-147635 | KRAS G12C inhibitor 54 | 2765580-17-2 | Reference compound |
| HY-147636 | KRAS G12C inhibitor 55 | 2508134-76-5 | Reference compound |
| HY-147637 | EphA2 agonist 1 | 2611459-57-3 | Reference compound |
| HY-147638 | MONIRO-1 | 1909225-94-0 | Reference compound |
| HY-147639 | Cav 2.2/3.2 blocker 1 | 2987640-67-3 | Reference compound |
| HY-14763A | Cariprazine (hydrochloride) | 1083076-69-0 | Reference compound |
| HY-14763R | Cariprazine (Standard) | 839712-12-8 | Reference Standards |
| HY-14763S | Cariprazine-d6 | 1308278-67-2 | Isotope-Labeled Compounds |
| HY-14763S1 | Cariprazine-d8 | 1308278-50-3 | Isotope-Labeled Compounds |
| HY-147642 | ChemR23-IN-4 | 2465085-23-6 | Reference compound |
| HY-147643 | Aminoacyl tRNA synthetase-IN-2 | 93218-59-8 | Reference compound |
| HY-147644 | α-Synuclein inhibitor 3 | 2687831-18-9 | Reference compound |
| HY-147645 | FBPase-IN-2 | 127143-25-3 | Reference compound |
| HY-147646 | CDK1/Cyc B-IN-1 | 2459916-56-2 | Reference compound |
| HY-147647 | Glyoxalase I inhibitor 5 | 2455508-17-3 | Reference compound |
| HY-147648 | Glyoxalase I inhibitor 6 | 2455508-19-5 | Reference compound |
| HY-147649 | Glyoxalase I inhibitor 7 | 2455508-31-1 | Reference compound |
| HY-147650 | HIV-1 protease-IN-5 | 2525173-96-8 | Reference compound |
| HY-147651 | β-catenin-IN-4 | 2353536-67-9 | Reference compound |
| HY-147652 | G-quadruplex DNA fluorescence probe 1 | | Dye Reagents |
| HY-147653 | Integrase-LEDGF/p75 allosteric inhibitor 1 | 1431738-14-5 | Reference compound |
| HY-147654 | PROTAC Hemagglutinin Degrader-1 | 3031330-66-9 | Reference compound |
| HY-147655 | CQ211 | 2648986-65-4 | Reference compound |
| HY-147656 | NAMPT degrader-1 | 3011778-39-2 | Reference compound |
| HY-147657 | GABAA receptor modulator-2 | 2413850-54-9 | Reference compound |
| HY-147658 | AChE/BChE/BACE-1-IN-1 | 1321361-13-0 | Reference compound |
| HY-147659 | AChE/BChE/BACE-1-IN-2 | 1877000-20-8 | Reference compound |
| HY-147660 | IMMH001 | 1418093-75-0 | Reference compound |
| HY-147661 | DHFR-IN-2 | 331942-46-2 | Reference compound |
| HY-147662 | hCAIX-IN-5 | 2451479-57-3 | Reference compound |
| HY-147663 | hCAIX-IN-6 | 2451479-86-8 | Reference compound |
| HY-147664 | hCAXII-IN-1 | 2451479-66-4 | Reference compound |
| HY-147665 | hCAIX-IN-7 | 2451479-58-4 | Reference compound |
| HY-147666 | α-Synuclein inhibitor 4 | 2489813-08-1 | Reference compound |
| HY-147667 | α-Synuclein inhibitor 5 | 2489813-11-6 | Reference compound |
| HY-147668 | α-Synuclein inhibitor 6 | 2489813-02-5 | Reference compound |
| HY-147669 | α-Synuclein inhibitor 7 | 2489813-04-7 | Reference compound |
| HY-147670 | TPB15 | 2170347-69-8 | Reference compound |
| HY-147671 | CB 168 | 1241942-59-5 | Reference compound |
| HY-147672 | IleRS-IN-1 | 2502167-19-1 | Reference compound |
| HY-147674 | Isoleucyl tRNA synthetase-IN-2 | 2494195-61-6 | Reference compound |
| HY-147678 | GPR40 agonist 5 | 2443384-60-7 | Reference compound |
| HY-14768 | Favipiravir | 259793-96-9 | Reference compound |
| HY-147681 | SUN13837 | 1080650-67-4 | Reference compound |
| HY-147682 | NF-κB-IN-5 | 2425675-52-9 | Reference compound |
| HY-147683 | FGFR-IN-3 | 2488762-63-4 | Reference compound |
| HY-147684 | FGFR-IN-7 | 2488764-17-4 | Reference compound |
| HY-14768A | Favipiravir (sodium) | 1366418-99-6 | Reference compound |
| HY-14768R | Favipiravir (Standard) | 259793-96-9 | Reference Standards |
| HY-14768S | Favipiravir-13C15N | | Isotope-Labeled Compounds |
| HY-14769 | Folitixorin | 3432-99-3 | Reference compound |
| HY-147690 | Photosensitizer-2 | 2138330-43-3 | Reference compound |
| HY-147691 | MPO-IN-5 | 2476764-11-9 | Reference compound |
| HY-147692 | COX-2-IN-14 | 2428387-48-6 | Reference compound |
| HY-147693 | COX-1/2-IN-3 | 2428387-82-8 | Reference compound |
| HY-147694 | c-Met-IN-11 | 1446324-05-5 | Reference compound |
| HY-147695 | c-Met-IN-12 | 2426675-70-7 | Reference compound |
| HY-147696 | SMTIN-T140 | 2851532-40-4 | Reference compound |
| HY-147697 | LSD1-IN-21 | | Reference compound |
| HY-147698 | ZLHQ-5f | 2851977-85-8 | Reference compound |
| HY-147699 | FRα-IN-1 | 2028296-64-0 | Reference compound |
| HY-14769A | Folitixorin (calcium) | 133978-75-3 | Reference compound |
| HY-14770 | Ibodutant | 522664-63-7 | Reference compound |
| HY-147700 | Antiviral agent 21 | 2420396-84-3 | Reference compound |
| HY-147701 | OfHex1-IN-1 | | Reference compound |
| HY-147702 | BB 0305179 | 2512200-83-6 | Reference compound |
| HY-147703 | Aurora kinase inhibitor-9 | 2419107-09-6 | Reference compound |
| HY-147704 | Antimycobacterial agent-2 | 62670-49-9 | Reference compound |
| HY-147705 | PPARγ phosphorylation inhibitor 1 | 2882975-84-8 | Reference compound |
| HY-147706 | AR524 | 2568148-31-0 | Reference compound |
| HY-147707 | CB2 receptor antagonist 1 | 2772693-05-5 | Reference compound |
| HY-147708 | T-Type calcium channel inhibitor 2 | 2771965-57-0 | Reference compound |
| HY-147709 | Tyrosinase-IN-6 | 2569221-17-4 | Reference compound |
| HY-14771 | Imeglimin | 775351-65-0 | Reference compound |
| HY-147710 | PIN1 inhibitor 2 | 2417101-28-9 | Reference compound |
| HY-147711 | α-Amylase/α-Glucosidase-IN-1 | 329783-03-1 | Reference compound |
| HY-147712 | PKC-IN-4 | 2636771-29-2 | Reference compound |
| HY-147713 | FGFR3-IN-1 | 2428743-04-6 | Reference compound |
| HY-147714 | FGFR3-IN-2 | 2428742-58-7 | Reference compound |
| HY-147715 | FGFR3-IN-3 | 2428738-41-2 | Reference compound |
| HY-147716 | CDK8-IN-6 | 2415156-27-1 | Reference compound |
| HY-147717 | CDK8-IN-7 | 2415156-30-6 | Reference compound |
| HY-147718 | α-Glucosidase-IN-5 | 111316-33-7 | Reference compound |
| HY-147719 | COX-2-IN-16 | 1610894-92-2 | Reference compound |
| HY-14771A | Imeglimin (hydrochloride) | 775351-61-6 | Reference compound |
| HY-14771S | Imeglimin-d3 | | Isotope-Labeled Compounds |
| HY-147720 | γ-Secretase modulator 11 | 2434630-29-0 | Reference compound |
| HY-147720A | γ-Secretase modulator 11 (hydrochloride) | 2434630-30-3 | Reference compound |
| HY-147721 | Dihydropteroate synthase-IN-1 | 2418026-70-5 | Reference compound |
| HY-147722 | hCAIX-IN-8 | 2414633-40-0 | Reference compound |
| HY-147723 | HIV-1 inhibitor-39 | 2414099-82-2 | Reference compound |
| HY-147724 | Microtubule inhibitor 3 | 1236141-96-0 | Reference compound |
| HY-147725 | Microtubule inhibitor 4 | 2411962-64-4 | Reference compound |
| HY-147726 | Microtubule inhibitor 5 | 2416338-55-9 | Reference compound |
| HY-147727 | Microtubule inhibitor 6 | 2416338-64-0 | Reference compound |
| HY-147728 | Microtubule inhibitor 7 | 2416338-65-1 | Reference compound |
| HY-147729 | UIAA-II-232 | 2428407-03-6 | Reference compound |
| HY-14773 | Mirabegron | 223673-61-8 | Reference compound |
| HY-147730 | HDAC6-IN-8 | 2796282-49-8 | Reference compound |
| HY-147731 | HDAC6-IN-9 | 2796282-58-9 | Reference compound |
| HY-147732 | sEH inhibitor-4 | 2851838-08-7 | Reference compound |
| HY-147733 | sEH inhibitor-5 | 2752467-28-8 | Reference compound |
| HY-147734 | Calpain Inhibitor-2 | 2413962-65-7 | Reference compound |
| HY-147735 | GABAA receptor agonist 1 | | Reference compound |
| HY-147736 | GABAA receptor agonist 2 | | Reference compound |
| HY-147737S | Ammonium-15N,d4 (chloride) | 99011-95-7 | Isotope-Labeled Compounds |
| HY-147738 | SQM-NBD | 2786704-34-3 | Dye Reagents |
| HY-14773R | Mirabegron (Standard) | 223673-61-8 | Reference Standards |
| HY-14773S | (Rac)-Mirabegron-d5 | 1215807-38-7 | Isotope-Labeled Compounds |
| HY-14773S1 | Mirabegron-d8 | | Isotope-Labeled Compounds |
| HY-14773S3 | Mirabegron-d5 | 1258889-45-0 | Isotope-Labeled Compounds |
| HY-14774 | Monepantel | 887148-69-8 | Reference compound |
| HY-147740 | WEHI-150 | 70492-21-6 | Reference compound |
| HY-147741 | DPPY | 2095883-62-6 | Reference compound |
| HY-147742 | Thi-DPPY | 2307699-34-7 | Reference compound |
| HY-147743 | SMO-IN-1 | 1126365-66-9 | Reference compound |
| HY-147744 | AZD7254 | 1126366-28-6 | Reference compound |
| HY-147745 | MMP2-IN-2 | 1772-39-0 | Reference compound |
| HY-147746 | MMP2-IN-3 | 897799-81-4 | Reference compound |
| HY-147747 | HSP90-IN-12 | 2408643-60-5 | Reference compound |
| HY-147748 | COX-2-IN-17 | 2411390-10-6 | Reference compound |
| HY-14774R | Monepantel (Standard) | 887148-69-8 | Reference Standards |
| HY-14774S | (Rac)-Monepantel-d5 | 2747918-33-6 | Isotope-Labeled Compounds |
| HY-14774S1 | (Rac)-Monepantel sulfone-d5 | 2747918-68-7 | Isotope-Labeled Compounds |
| HY-14775 | Nesbuvir | 691852-58-1 | Reference compound |
| HY-147750 | TDP1 Inhibitor-2 | 859142-95-3 | Reference compound |
| HY-147751 | APJ receptor agonist 6 | 1965244-85-2 | Reference compound |
| HY-147754 | JAK3/BTK-IN-6 | 2243136-03-8 | Reference compound |
| HY-147755 | C16-K-cBB1 | | Reference compound |
| HY-147756 | Nampt-IN-7 | 1223378-42-4 | Reference compound |
| HY-147757 | PPARγ/δ modulator 1 | 2089159-00-0 | Reference compound |
| HY-147758 | BACE1/2-IN-1 | 2671036-34-1 | Reference compound |
| HY-14776 | Quarfloxin | 865311-47-3 | Reference compound |
| HY-147760 | Dyrk1A-IN-2 | | Reference compound |
| HY-147761 | GAK inhibitor 2 | 2396706-31-1 | Reference compound |
| HY-147762 | NRP1 antagonist 2 | 483289-96-9 | Reference compound |
| HY-147763 | HCV-IN-39 | 2087916-31-0 | Reference compound |
| HY-147764 | HCV-IN-40 | 2087916-66-1 | Reference compound |
| HY-147765 | Anti-Trypanosoma cruzi agent-3 | 2397639-23-3 | Reference compound |
| HY-147766 | Antileishmanial agent-10 | 2397639-33-5 | Reference compound |
| HY-147767 | PI3Kα-IN-6 | 2272894-14-9 | Reference compound |
| HY-147768 | PI3K/AKT-IN-2 | 2684412-41-5 | Reference compound |
| HY-147769 | Anti-inflammatory agent 23 | | Reference compound |
| HY-14777 | Radiprodil | 496054-87-6 | Reference compound |
| HY-147770 | NF-κB-IN-6 | | Reference compound |
| HY-147771 | ZLWT-37 | 2813347-44-1 | Reference compound |
| HY-147772 | ZC0101 | 2541604-52-6 | Reference compound |
| HY-147773 | NAAA-IN-1 | 1439366-66-1 | Reference compound |
| HY-147774 | Cathepsin K inhibitor 6 | 325775-42-6 | Reference compound |
| HY-147775 | NAAA-IN-3 | 1831115-59-3 | Reference compound |
| HY-147776 | Antiproliferative agent-8 | | Reference compound |
| HY-147777 | 14α-Demethylase/DNA Gyrase-IN-2 | 2330812-64-9 | Reference compound |
| HY-147778 | 14α-Demethylase/DNA Gyrase-IN-1 | | Reference compound |
| HY-147779 | VEGFR-2-IN-20 | 2404581-25-3 | Reference compound |
| HY-14778 | Retosiban | 820957-38-8 | Reference compound |
| HY-147780 | Fissitungfine B | 1996671-09-0 | Reference compound |
| HY-147781 | Anticancer agent 66 | 2691895-64-2 | Reference compound |
| HY-147782 | Anticancer agent 67 | 2691895-66-4 | Reference compound |
| HY-147783 | Anticancer agent 68 | 2692652-36-9 | Reference compound |
| HY-147784 | HZ-A-005 | 2041789-14-2 | Reference compound |
| HY-147785 | Pim-1 kinase inhibitor 2 | 2543624-91-3 | Reference compound |
| HY-147786 | TGFβRI-IN-5 | 2541690-15-5 | Reference compound |
| HY-147787 | Urease-IN-3 | 2543651-72-3 | Reference compound |
| HY-147788 | hDHODH-IN-9 | 133676-47-8 | Reference compound |
| HY-147789 | FPDT | | Reference compound |
| HY-14778A | (S)-Retosiban | 2994298-20-1 | Reference compound |
| HY-14779 | Riociguat | 625115-55-1 | Reference compound |
| HY-147790 | MDH1-IN-1 | 2143463-31-2 | Reference compound |
| HY-147791 | MDH1-IN-2 | 2143463-35-6 | Reference compound |
| HY-147792 | WNY1613 | 2650546-39-5 | Reference compound |
| HY-147793 | FGFR4-IN-12 | 2423992-63-4 | Reference compound |
| HY-147794 | COX-2-IN-18 | 1038061-96-9 | Reference compound |
| HY-147795 | Nampt-IN-8 | 2453183-75-8 | Reference compound |
| HY-147796 | EGFR/HER2/CDK9-IN-1 | 879730-44-6 | Reference compound |
| HY-147797 | EGFR/HER2/CDK9-IN-2 | 1180924-34-8 | Reference compound |
| HY-147798 | EGFR/HER2/CDK9-IN-3 | 422276-47-9 | Reference compound |
| HY-147799 | hCA XII/II/IX-IN-1 | | Reference compound |
| HY-14779R | Riociguat (Standard) | 625115-55-1 | Reference Standards |
| HY-14779S | Riociguat-13C,d6 | | Isotope-Labeled Compounds |
| HY-14779S3 | Riociguat-d3 | 1304478-72-5 | Isotope-Labeled Compounds |
| HY-14780 | Viquidacin | 904302-98-3 | Reference compound |
| HY-147800 | VEGFR-2-IN-21 | 2531029-88-4 | Reference compound |
| HY-147801 | Topoisomerase IIα-IN-3 | 2538528-11-7 | Reference compound |
| HY-147802 | EGFR-IN-59 | 2529891-44-7 | Reference compound |
| HY-147803 | TrxR-IN-5 | | Reference compound |
| HY-147804 | SARS-CoV-2 3CLpro-IN-3 | 2505241-13-2 | Reference compound |
| HY-147805 | SARS-CoV-2 3CLpro-IN-4 | 2505241-31-4 | Reference compound |
| HY-147806 | Antiparasitic agent-8 | 2538594-33-9 | Reference compound |
| HY-147807 | HIV-1 inhibitor-40 | 2789676-44-2 | Reference compound |
| HY-147808 | CXCR4 antagonist 7 | 1185451-72-2 | Reference compound |
| HY-147809 | COX-2-IN-20 | 2529451-43-0 | Reference compound |
| HY-14781 | Levomefolic acid | 31690-09-2 | Natural Products |
| HY-147810 | 5-HT7 receptor ligand 1 | 2758571-64-9 | Reference compound |
| HY-147811 | Heterophdoid A | 2756016-53-0 | Natural Products |
| HY-147812 | POLA1 inhibitor 1 | 2217671-41-3 | Reference compound |
| HY-147813 | HIF-1α-IN-3 | 2170715-64-5 | Reference compound |
| HY-147814 | KFU-127 | | Reference compound |
| HY-147815 | COX-2-IN-21 | 2519631-11-7 | Reference compound |
| HY-147816 | Anticancer agent 70 | 2521770-35-2 | Reference compound |
| HY-147817 | Heme Oxygenase-2-IN-1 | 2994198-37-5 | Reference compound |
| HY-147818 | DNA Gyrase-IN-2 | 2522666-80-2 | Reference compound |
| HY-147819 | DNA Gyrase-IN-3 | 2522667-08-7 | Reference compound |
| HY-14781A | Levomefolic acid (magnesium) | 1429498-11-2 | Reference compound |
| HY-14781S1 | Levomefolic acid-13C,d3 | 1356019-94-7 | Isotope-Labeled Compounds |
| HY-14781S2 | Levomefolic acid-13C5 | 2687960-08-1 | Isotope-Labeled Compounds |
| HY-14781S3 | Levomefolic acid-d3 | | Isotope-Labeled Compounds |
| HY-14782 | Adoprazine | 222551-17-9 | Reference compound |
| HY-147820 | AY1511 | 2559709-99-6 | Reference compound |
| HY-147821 | CB1-IN-2 | 2527805-39-4 | Reference compound |
| HY-147822 | Apoptosis inducer 6 | 2529913-90-2 | Reference compound |
| HY-147823 | α-Glucosidase-IN-6 | 2497685-29-5 | Reference compound |
| HY-147824 | Tubulin polymerization-IN-22 | 2493052-22-3 | Reference compound |
| HY-147825 | EGFR/BRAFV600E-IN-1 | 2492429-45-3 | Reference compound |
| HY-147826 | EGFR-IN-60 | 2699877-43-3 | Reference compound |
| HY-147827 | hCAIX-IN-10 | 2497504-72-8 | Reference compound |
| HY-147828 | hCAIX-IN-11 | 2497504-81-9 | Reference compound |
| HY-147829 | hCAXII-IN-2 | 2497504-86-4 | Reference compound |
| HY-14782A | Adoprazine (hydrochloride) | 222551-05-5 | Reference compound |
| HY-14783 | Apricoxib | 197904-84-0 | Reference compound |
| HY-147830 | PDE4B-IN-3 | 2819779-01-4 | Reference compound |
| HY-147831 | EIF2α activator 1 | 2851820-52-3 | Reference compound |
| HY-147832 | EIF2α activator 2 | 1501618-04-7 | Reference compound |
| HY-147833 | ALK-IN-22 | 2468219-09-0 | Reference compound |
| HY-147834 | STING agonist-9 | 2653337-73-4 | Reference compound |
| HY-147835 | Antibacterial agent 109 | 2649396-65-4 | Reference compound |
| HY-147836 | Akt/NF-κB/JNK-IN-1 | | Reference compound |
| HY-147838 | Nampt-IN-9 | 2180973-35-5 | Reference compound |
| HY-147839 | Topoisomerase II inhibitor 10 | 2488208-96-2 | Reference compound |
| HY-14784 | Bederocin | 757942-43-1 | Reference compound |
| HY-147840 | HDAC-IN-41 | 2490309-83-4 | Reference compound |
| HY-147841 | HIV-1 inhibitor-41 | | Reference compound |
| HY-147844 | F8-S43-S3 | 1632320-78-5 | Reference compound |
| HY-147845 | F8-S40 | 301347-96-6 | Reference compound |
| HY-147846 | AChE/PDE4-IN-1 | | Reference compound |
| HY-147848 | Tubulin polymerization-IN-27 | 2462030-32-4 | Reference compound |
| HY-147849 | JMI-105 | 2227315-30-0 | Reference compound |
| HY-14785 | Befiradol | 208110-64-9 | Reference compound |
| HY-147850 | JMI-346 | 2091841-46-0 | Reference compound |
| HY-147851 | BACE1-IN-12 | 2479315-19-8 | Reference compound |
| HY-147852 | B-Raf IN 7 | 2477725-07-6 | Reference compound |
| HY-147853 | B-Raf IN 8 | 1215313-19-1 | Reference compound |
| HY-147854 | B-Raf IN 9 | 2477725-18-9 | Reference compound |
| HY-147855 | ACA-28 | 948044-25-5 | Reference compound |
| HY-147856 | Antileishmanial agent-11 | 2253635-71-9 | Reference compound |
| HY-147857 | Antileishmanial agent-12 | 2482764-71-4 | Reference compound |
| HY-147858 | PROTAC EGFR degrader 7 | | Reference compound |
| HY-147858A | PROTAC EGFR degrader 7 (diTFA) | | Reference compound |
| HY-147859 | BChE-IN-8 | 2653349-78-9 | Reference compound |
| HY-14785A | Befiradol (hydrochloride) | 2436760-81-3 | Reference compound |
| HY-14786 | Darotropium (bromide) | 850607-58-8 | Reference compound |
| HY-147860 | EGFR-IN-61 | 2890261-81-9 | Reference compound |
| HY-147861 | Topoisomerase II inhibitor 11 | 2476559-00-7 | Reference compound |
| HY-147862 | EGFR-IN-62 | 2890261-65-9 | Reference compound |
| HY-147863 | HBV-IN-24 | | Reference compound |
| HY-147864 | c-Fms-IN-12 | 2145102-33-4 | Reference compound |
| HY-147865 | Apoptosis inducer 8 | 2470024-51-0 | Reference compound |
| HY-147866 | Antibacterial agent 110 | | Reference compound |
| HY-147867 | MMP-2/9-IN-1 | 2415311-84-9 | Reference compound |
| HY-147868 | DC-CPin711 | 2447559-21-7 | Reference compound |
| HY-147869 | DC-CPin7 | 893781-17-4 | Reference compound |
| HY-147870 | COX-2-IN-22 | 2447589-08-2 | Reference compound |
| HY-147871 | Antimycobacterial agent-3 | 2469881-50-1 | Reference compound |
| HY-147872 | VEGFR-2-IN-22 | 2447587-73-5 | Reference compound |
| HY-147873 | NMDAR/HDAC-IN-1 | | Reference compound |
| HY-147874 | ANO1-IN-3 | 2494280-04-3 | Reference compound |
| HY-147875 | Aldose reductase-IN-6 | 2470019-41-9 | Reference compound |
| HY-147876 | Antimicrobial agent-3 | 1902712-34-8 | Reference compound |
| HY-147877 | Topoisomerase II inhibitor 12 | 2304527-20-4 | Reference compound |
| HY-147878 | Antibacterial agent 111 | 2448358-84-5 | Reference compound |
| HY-147879 | α-Glucosidase-IN-8 | 2448345-96-6 | Reference compound |
| HY-14788 | Drinabant | 358970-97-5 | Reference compound |
| HY-147880 | BChE-IN-9 | 2468035-31-4 | Reference compound |
| HY-147881 | Anti-Influenza agent 3 | 2481321-20-2 | Reference compound |
| HY-147882 | Anti-MRSA agent 6 | 2452302-73-5 | Reference compound |
| HY-147883 | Antitubercular agent-27 | 2460651-09-4 | Reference compound |
| HY-147884 | Antitubercular agent-28 | 2460651-10-7 | Reference compound |
| HY-147885 | HCV-IN-41 | 2468169-71-1 | Reference compound |
| HY-147886 | PARP1-IN-11 | 2482484-87-5 | Reference compound |
| HY-147887 | Tubulin inhibitor 28 | 71112-91-9 | Reference compound |
| HY-147888 | Tubulin inhibitor 29 | 2905-15-9 | Reference compound |
| HY-147889 | BBR-BODIPY | 2456476-47-2 | Dye Reagents |
| HY-14789 | (R)-Elagolix | 834153-87-6 | Reference compound |
| HY-147890 | Angiogenesis inhibitor 2 | 2151067-32-0 | Reference compound |
| HY-147891 | Angiogenesis inhibitor 3 | 2507759-39-7 | Reference compound |
| HY-147892 | HDAC-IN-42 | 2454024-18-9 | Reference compound |
| HY-147894 | PCAF-IN-1 | 2439194-86-0 | Reference compound |
| HY-147895 | PCAF-IN-2 | 56173-05-8 | Reference compound |
| HY-147896 | Tubulin polymerization-IN-29 | 630058-59-2 | Reference compound |
| HY-147897 | Apoptosis inducer 9 | 2551067-10-6 | Reference compound |
| HY-147898 | PI3K-IN-33 | 2458163-92-1 | Reference compound |
| HY-147899 | PI3K-IN-34 | 2458163-94-3 | Reference compound |
| HY-14790 | Esreboxetine | 98819-76-2 | Reference compound |
| HY-147900 | PI3K-IN-35 | 2458163-99-8 | Reference compound |
| HY-147901 | KDM1/CDK1-IN-1 | 2938990-92-0 | Reference compound |
| HY-147902 | VEGFR-2-IN-24 | 2455414-26-1 | Reference compound |
| HY-147903 | HIV-1 inhibitor-42 | 2459929-46-3 | Reference compound |
| HY-147904 | HIV-IN-5 | 2459929-62-3 | Reference compound |
| HY-147905 | CDK9-IN-18 | 1804127-83-0 | Reference compound |
| HY-147906 | Anticancer agent 71 | 2453228-45-8 | Reference compound |
| HY-147907 | Adenosine receptor inhibitor 1 | 2550400-52-5 | Reference compound |
| HY-147908 | Adenosine receptor inhibitor 2 | 2550401-76-6 | Reference compound |
| HY-147909 | Anticancer agent 72 | 2460167-51-3 | Reference compound |
| HY-14791 | Ibipinabant | 464213-10-3 | Reference compound |
| HY-147910 | Carpro-AM1 | 2499489-76-6 | Reference compound |
| HY-147911 | COX-2/PI3K-IN-1 | | Reference compound |
| HY-147912 | COX-2/PI3K-IN-2 | 2459938-28-2 | Reference compound |
| HY-147913 | PI3K/Akt/mTOR-IN-3 | 2457245-94-0 | Reference compound |
| HY-147914 | NSD2-IN-1 | 2797183-37-8 | Reference compound |
| HY-147915 | Benz-AP | 2416220-53-4 | Reference compound |
| HY-147917 | RNA polymerase II-IN-2 | 2891451-33-3 | Reference compound |
| HY-147918 | Anticancer agent 73 | 124811-87-6 | Reference compound |
| HY-147919 | Antifungal agent 33 | 2445277-57-4 | Reference compound |
| HY-14791A | (±)-Ibipinabant | 362519-49-1 | Reference compound |
| HY-14792 | Inolitazone | 223132-37-4 | Reference compound |
| HY-147920 | PIM1-IN-6 | 2439168-69-9 | Reference compound |
| HY-147921 | PIM1-IN-7 | 2439168-72-4 | Reference compound |
| HY-147922 | hCAI/II-IN-2 | 2480283-75-6 | Reference compound |
| HY-147923 | hCAI/II-IN-3 | 2480283-93-8 | Reference compound |
| HY-147924 | Keap1-Nrf2-IN-11 | 2796292-75-4 | Reference compound |
| HY-147925 | hCAI/II-IN-4 | 2480284-01-1 | Reference compound |
| HY-147926 | VEGFR-2-IN-28 | 2447597-39-7 | Reference compound |
| HY-147927 | Human enteropeptidase-IN-1 | 1802891-20-8 | Reference compound |
| HY-147928 | Apoptotic agent-2 | 2482310-18-7 | Reference compound |
| HY-147929 | Apoptotic agent-3 | 2482310-23-4 | Reference compound |
| HY-14792B | Inolitazone (dihydrochloride) | 223132-38-5 | Reference compound |
| HY-14793 | Lensiprazine | 327026-93-7 | Reference compound |
| HY-147930 | ACC1/2-IN-1 | 2350219-22-4 | Reference compound |
| HY-147931 | Human enteropeptidase-IN-2 | 3031537-31-9 | Reference compound |
| HY-147932 | ACC1/2-IN-2 | 1031411-94-5 | Reference compound |
| HY-147933 | Antitrypanosomal agent 8 | 332376-42-8 | Reference compound |
| HY-147934 | HDAC8-IN-3 | 2432825-93-7 | Reference compound |
| HY-147936 | TP0556351 | 2787582-17-4 | Reference compound |
| HY-147937 | AKT-IN-13 | 2459489-51-9 | Reference compound |
| HY-147938 | AChE-IN-19 | 2742707-36-2 | Reference compound |
| HY-147939 | AChE/BuChE-IN-3 | 2742707-47-5 | Reference compound |
| HY-14794 | Dextromilnacipran | 96847-55-1 | Reference compound |
| HY-147940 | TbPTR1 inhibitor 1 | 2499713-65-2 | Reference compound |
| HY-147941 | MS9427 | 2772613-37-1 | Reference compound |
| HY-147941A | MS9427 (TFA) | | Reference compound |
| HY-147942 | MS9449 | 2772612-96-9 | Reference compound |
| HY-147943 | PROTAC BTK Degrader-1 | 2801715-13-7 | Reference compound |
| HY-147944 | Antimicrobial agent-4 | 2429922-67-6 | Reference compound |
| HY-147945 | DNA gyrase B-IN-1 | | Reference compound |
| HY-147946 | PDE1-IN-4 | 3031349-98-8 | Reference compound |
| HY-147947 | Tubulin polymerization-IN-30 | 2521560-46-1 | Reference compound |
| HY-147948 | DNA Gyrase-IN-4 | 2416400-32-1 | Reference compound |
| HY-147949 | SKLB0565 | 2414607-10-4 | Reference compound |
| HY-14794A | Levomilnacipran | 96847-54-0 | Reference compound |
| HY-14794AS | Levomilnacipran-d10 (hydrochloride) | 2747914-23-2 | Isotope-Labeled Compounds |
| HY-14795 | Mimopezil | 180694-97-7 | Reference compound |
| HY-147950 | PDE4-IN-10 | 2413564-66-4 | Reference compound |
| HY-147951 | COX-2/5-LOX-IN-3 | 2481484-51-7 | Reference compound |
| HY-147952 | AChE-IN-20 | 2428389-65-3 | Reference compound |
| HY-147953 | MAO-B-IN-13 | 2105918-34-9 | Reference compound |
| HY-147954 | α-Glycosidase-IN-1 | 2428389-66-4 | Reference compound |
| HY-147955 | hCAI/II-IN-5 | 2428389-67-5 | Reference compound |
| HY-147956 | hCA VB-IN-1 | | Reference compound |
| HY-147957 | Antibacterial agent 112 | | Reference compound |
| HY-147958 | Antibacterial agent 113 | | Reference compound |
| HY-147959 | Antibacterial agent 114 | 2733391-71-2 | Reference compound |
| HY-14796 | Olesoxime | 22033-87-0 | Reference compound |
| HY-147960 | Glycosyltransferase-IN-1 | | Reference compound |
| HY-147961 | COX-2-IN-23 | 2417995-08-3 | Reference compound |
| HY-147962 | AChE/HDAC-IN-1 | 2414053-06-6 | Reference compound |
| HY-147963 | COX-2-IN-24 | 2417995-10-7 | Reference compound |
| HY-147964 | α-Glucosidase-IN-9 | 735273-33-3 | Reference compound |
| HY-147965 | α-Glucosidase-IN-10 | 2586282-68-8 | Reference compound |
| HY-147966 | HDAC-IN-43 | 1809163-24-3 | Reference compound |
| HY-147967 | EGFR-IN-63 | 2414635-72-4 | Reference compound |
| HY-147968 | Anticancer agent 74 | 2242503-82-6 | Reference compound |
| HY-147969 | Antiangiogenic agent 2 | 2422149-84-4 | Reference compound |
| HY-14797 | Ombrabulin | 181816-48-8 | Reference compound |
| HY-147970 | Antifungal agent 34 | 2036123-97-2 | Reference compound |
| HY-147971 | Anticancer agent 75 | 2414491-13-5 | Reference compound |
| HY-147972 | NF-κB/MAPK-IN-1 | 2413940-56-2 | Reference compound |
| HY-147973 | IZTZ-1 | 2636771-45-2 | Reference compound |
| HY-147974 | HSP90-IN-14 | 1995132-67-6 | Reference compound |
| HY-147975 | JAK3-IN-12 | 1430095-86-5 | Reference compound |
| HY-147976 | Glucocerebrosidase-IN-1 | 2279945-76-3 | Reference compound |
| HY-147976A | Glucocerebrosidase-IN-1 (hydrochloride) | 2279945-77-4 | Reference compound |
| HY-147977 | ALR1/2-IN-1 | 2419233-57-9 | Reference compound |
| HY-147978 | CXCR4 antagonist 8 | 2304750-84-1 | Reference compound |
| HY-147979 | CXCR4 antagonist 9 | 2304750-83-0 | Reference compound |
| HY-14798 | Palifosfamide | 31645-39-3 | Reference compound |
| HY-147980 | Aβ-IN-5 | 2417977-65-0 | Reference compound |
| HY-147981 | Tubulin polymerization-IN-31 | 2421121-79-9 | Reference compound |
| HY-147982 | GABA-AT-IN-1 | 242148-96-5 | Reference compound |
| HY-147983 | PI3Kα-IN-8 | 2315320-24-0 | Reference compound |
| HY-147984 | hCAXII-IN-3 | 2417232-24-5 | Reference compound |
| HY-147985 | hCA I-IN-1 | 2417232-26-7 | Reference compound |
| HY-147986 | hCA I-IN-2 | 2417232-12-1 | Reference compound |
| HY-147987 | FFA1 agonist-1 | 2417231-16-2 | Reference compound |
| HY-147988 | DNA Gyrase-IN-5 | 2417016-23-8 | Reference compound |
| HY-14798R | Palifosfamide (Standard) | 31645-39-3 | Reference Standards |
| HY-14799 | Palovarotene | 410528-02-8 | Reference compound |
| HY-147990 | PDE5-IN-5 | 2414921-33-6 | Reference compound |
| HY-147991 | PDE5/HDAC-IN-1 | 2414921-48-3 | Reference compound |
| HY-147992 | EGFR/HER2-IN-4 | 1879071-89-2 | Reference compound |
| HY-147993 | Aurora kinase inhibitor-10 | 2417228-90-9 | Reference compound |
| HY-147994 | EGFR/HER2-IN-5 | 1879071-97-2 | Reference compound |
| HY-147995 | EGFR-IN-64 | 2416924-93-9 | Reference compound |
| HY-147996 | EGFR-IN-67 | 2416924-99-5 | Reference compound |
| HY-147997 | EGFR-IN-68 | 2416925-03-4 | Reference compound |
| HY-147998 | Enpp-1-IN-13 | 2417022-19-4 | Reference compound |
| HY-147999 | GlcN-6-P Synthase-IN-1 | 2415311-87-2 | Reference compound |
| HY-14800 | Radezolid | 869884-78-6 | Reference compound |
| HY-148000 | sEH inhibitor-6 | 1205963-04-7 | Reference compound |
| HY-148001 | EWP 815 | 20231-01-0 | Reference compound |
| HY-148002 | 1'-Hydroxy Midazolam-β-D-glucuronide | 81256-81-7 | Reference compound |
| HY-148009 | Cardiolipin (16:0/18:1/16:0/18:1) (sodium) | 2260669-35-8 | Reference compound |
| HY-14800R | Radezolid (Standard) | 869884-78-6 | Reference Standards |
| HY-14801 | Sivifene | 2675-35-6 | Reference compound |
| HY-148012 | SOP1812 | 2546091-70-5 | Reference compound |
| HY-148013 | K284-6111 | 702668-62-0 | Reference compound |
| HY-148015 | Enbezotinib (enantiomer) | 2359650-19-2 | Reference compound |
| HY-148016 | I-287 | 2014368-93-3 | Reference compound |
| HY-148019 | 2′-Deoxy-2′-fluoro-N-methyladenosine | 134444-58-9 | Reference compound |
| HY-14802 | Talarozole (R enantiomer) | 870093-23-5 | Reference compound |
| HY-148026 | Sonrotoclax | 2383086-06-2 | Reference compound |
| HY-148029 | Dazostinag (disodium) | 2553413-93-5 | Reference compound |
| HY-14802C | (+)-Talarozole | 201410-66-4 | Reference compound |
| HY-14802D | (-)-Talarozole | 201410-67-5 | Reference compound |
| HY-14803 | Tasimelteon | 609799-22-6 | Reference compound |
| HY-148030 | XL01126 | 3011029-58-3 | Reference compound |
| HY-148031 | MC-Ala-Ala-Asn-PAB-PNP | 1638970-45-2 | ADC Related |
| HY-148033 | Trimethyl chitosan | 52349-26-5 | Reference compound |
| HY-148034 | Plm IV inhibitor-1 | 1539276-41-9 | Reference compound |
| HY-148035 | Plm IV inhibitor-2 | 1539276-38-4 | Reference compound |
| HY-148036 | FLT3-IN-16 | 298207-49-5 | Reference compound |
| HY-148036S | FLT3-IN-16-d1 | | Isotope-Labeled Compounds |
| HY-148037 | Thrombin inhibitor 5 | 328108-09-4 | Reference compound |
| HY-148038 | 5-HT3 antagonist 5 | 901599-43-7 | Reference compound |
| HY-14803R | Tasimelteon (Standard) | 609799-22-6 | Reference Standards |
| HY-14803S | Tasimelteon-d5 | 1962124-51-1 | Isotope-Labeled Compounds |
| HY-14804 | Tasisulam | 519055-62-0 | Reference compound |
| HY-148040 | VEGFR-2-IN-29 | 62802-77-1 | Reference compound |
| HY-148041 | ATPase-IN-2 | 85573-18-8 | Reference compound |
| HY-148042 | HIV-1 inhibitor-47 | 137448-39-6 | Reference compound |
| HY-148043 | Schnurri-3 inhibitor-1 | 736154-60-2 | Reference compound |
| HY-148044 | UNC10201652 | 372495-52-8 | Reference compound |
| HY-148045 | TLR9-IN-1 | 2226366-86-3 | Reference compound |
| HY-148046 | USP15-IN-1 | 2260826-16-0 | Reference compound |
| HY-148049 | TT3 | 1821214-50-9 | Reference compound |
| HY-14804A | Tasisulam (sodium) | 519055-63-1 | Reference compound |
| HY-14805 | Tecovirimat | 869572-92-9 | Reference compound |
| HY-148051 | Ilaprazole sulfone | 172152-37-3 | Reference compound |
| HY-148052 | RIPK3-IN-2 | 2665669-32-7 | Reference compound |
| HY-148053 | Rezivertinib analogue 1 | 2227103-37-7 | Reference compound |
| HY-148053R | Rezivertinib analogue 1 (Standard) | 2227103-37-7 | Reference Standards |
| HY-148054 | Antifungal agent 36 | 34967-98-1 | Reference compound |
| HY-148055 | Wnt/β-catenin agonist 3 | 912790-59-1 | Reference compound |
| HY-148055A | Wnt/β-catenin agonist 3 (hydrochloride) | | Reference compound |
| HY-148057 | TCO-PEG4-VC-PAB-MMAE | 2758671-45-1 | ADC Related |
| HY-148058 | Topoisomerase I inhibitor 8 | 210346-40-0 | Reference compound |
| HY-148059 | Uplarafenib | 1425485-87-5 | Reference compound |
| HY-14805A | Tecovirimat (monohydrate) | 1162664-19-8 | Reference compound |
| HY-14805R | Tecovirimat (Standard) | 869572-92-9 | Reference Standards |
| HY-14805S | Tecovirimat-d4 | | Isotope-Labeled Compounds |
| HY-14806 | Teneligliptin | 760937-92-6 | Reference compound |
| HY-148060 | JAK-IN-21 | 2445499-20-5 | Reference compound |
| HY-148061 | DB1113 | 2769753-53-7 | Reference compound |
| HY-148062 | RSS0680 | 2769753-48-0 | Reference compound |
| HY-148063 | DB0614 | 2769753-47-9 | Reference compound |
| HY-148065 | FMF-06-098-1 | 2769753-07-1 | Reference compound |
| HY-148066 | DB0662 | 2769753-51-5 | Reference compound |
| HY-148067 | XMT-1519 conjugate-1 | 2720500-19-4 | ADC Related |
| HY-148067A | XMT-1519 conjugate-1 (TFA) | | ADC Related |
| HY-148068 | STING agonist-20 | 2591300-72-8 | Reference compound |
| HY-14806A | Teneligliptin (hydrobromide) | 906093-29-6 | Reference compound |
| HY-14806B | Teneligliptin (hydrobromide hydrate) | 1572583-29-9 | Reference compound |
| HY-14806R | Teneligliptin (Standard) | 760937-92-6 | Reference Standards |
| HY-14806S | Teneligliptin-d8 | 1391012-95-5 | Isotope-Labeled Compounds |
| HY-14806S1 | Teneligliptin-d4 | | Isotope-Labeled Compounds |
| HY-14806S2 | Teneligliptin-d5 | | Isotope-Labeled Compounds |
| HY-14807 | Tosedostat | 238750-77-1 | Reference compound |
| HY-148070 | FLT3-IN-17 | 2758999-62-9 | Reference compound |
| HY-148071 | Epocholeone | 162922-31-8 | Reference compound |
| HY-148072 | MM3122 | 2574390-27-3 | Reference compound |
| HY-148073 | MeO-Succ-Arg-Pro-Tyr-AMC | | Dye Reagents |
| HY-148074 | Zelnecirnon | 2366152-15-8 | Reference compound |
| HY-148075 | PI4KIIIbeta-IN-11 | 2365241-79-6 | Reference compound |
| HY-148076 | A2A receptor antagonist 3 | 2738606-83-0 | Reference compound |
| HY-148077 | Phosphoglycolohydroxamic acid | 51528-59-7 | Reference compound |
| HY-148078 | PFM03 | 1558598-48-3 | Reference compound |
| HY-14808 | Adarotene | 496868-77-0 | Reference compound |
| HY-148080 | Indole-C2-amide-C2-NH2 | 215789-29-0 | Reference compound |
| HY-148083 | TBBPA-sulfate | 902525-22-8 | Reference compound |
| HY-148087 | AZD5462 | 2787501-83-9 | Reference compound |
| HY-148088 | M1069 | 3027658-65-4 | Reference compound |
| HY-148088A | M1069 (free base) | 2459881-03-7 | Reference compound |
| HY-148089 | Eplontersen | 1637600-16-8 | Oligonucleotides |
| HY-148089A | Eplontersen (sodium) | 2131025-75-5 | Oligonucleotides |
| HY-14809 | Amenamevir | 841301-32-4 | Reference compound |
| HY-148091 | Duocarmycin analog-2 | 1164275-01-7 | Reference compound |
| HY-148092 | PM-43I | 1637532-77-4 | Reference compound |
| HY-148093 | PM-81I | 1637532-83-2 | Reference compound |
| HY-148096 | STAT6-IN-1 | 1637532-68-3 | Reference compound |
| HY-148098 | Pan KRas-IN-1 | 2791263-84-6 | Reference compound |
| HY-148099 | USP1-IN-2 | 2098212-05-4 | Reference compound |
| HY-14809R | Amenamevir (Standard) | 841301-32-4 | Reference Standards |
| HY-14810 | Atigliflozin | 647834-15-9 | Reference compound |
| HY-148100 | Emapticap pegol | 1390630-22-4 | Oligonucleotides |
| HY-148100A | Emapticap pegol (sodium) | | Oligonucleotides |
| HY-148103 | SR12418 | 1801185-08-9 | Reference compound |
| HY-148104 | ACSS2-IN-2 | 2332820-04-7 | Reference compound |
| HY-148105 | DS12881479 | 2373065-59-7 | Reference compound |
| HY-148106 | MEL23 | 642072-49-9 | Reference compound |
| HY-148108 | AChE-IN-27 | 177028-90-9 | Reference compound |
| HY-148109 | FAK-IN-7 | 19948-85-7 | Reference compound |
| HY-14811 | Beloranib | 251111-30-5 | Reference compound |
| HY-148110 | FAK-IN-8 | 1374959-91-7 | Reference compound |
| HY-148111 | Antitubercular agent-33 | 476317-29-0 | Reference compound |
| HY-148112 | Casein kinase 1δ-IN-1 | 851871-94-8 | Reference compound |
| HY-148113 | PG 34 | 1681056-62-1 | Reference compound |
| HY-148114 | MOPIPP | 1485521-76-3 | Reference compound |
| HY-148115 | S1p receptor agonist 2 | 1354908-17-0 | Reference compound |
| HY-148116 | DN02 | | Reference compound |
| HY-148117 | MD13 | 2758431-97-7 | Reference compound |
| HY-148118 | Tri-GalNAc(OAc)3 | 1159408-64-6 | Reference compound |
| HY-148118A | Tri-GalNAc(OAc)3 (TFA) | 1159408-65-7 | Reference compound |
| HY-14811A | Beloranib (hemioxalate) | 529511-79-3 | Reference compound |
| HY-14812 | Karenitecin | 203923-89-1 | Reference compound |
| HY-148122 | NW 1028 | 2749599-78-6 | Reference compound |
| HY-148123 | Glycerophospholipids, cephalins | 39382-08-6 | Biochemical Assay Reagents |
| HY-148124 | 6-epi Doxycycline | 3219-99-6 | Reference compound |
| HY-148127 | TAM558 | 1802499-21-3 | ADC Related |
| HY-148128 | TAM470 | 1802498-63-0 | ADC Related |
| HY-148129 | TRPC6-IN-3 | 2311863-36-0 | Reference compound |
| HY-14813 | Cutamesine | 165377-43-5 | Reference compound |
| HY-148130 | Rugonersen | 2591587-57-2 | Oligonucleotides |
| HY-148130A | Rugonersen (sodium) | 2591588-58-6 | Oligonucleotides |
| HY-148132 | GSK-3β inhibitor 11 | 536731-65-4 | Reference compound |
| HY-148133 | GSK-3β inhibitor 12 | 784170-07-6 | Reference compound |
| HY-148134 | 5-LOX-IN-1 | 55040-82-9 | Reference compound |
| HY-148135 | hCAI/II-IN-6 | 694466-00-7 | Reference compound |
| HY-148136 | sEH inhibitor-7 | 340221-20-7 | Reference compound |
| HY-148137 | CB1 agonist 1 | 851212-80-1 | Reference compound |
| HY-148138 | Deaminase inhibitor-1 | 397878-17-0 | Reference compound |
| HY-148139 | Cross-linked dextran G 75 | 37224-29-6 | Biochemical Assay Reagents |
| HY-148139A | Cross-linked dextran G 75, coarse | 37224-29-6 | Biochemical Assay Reagents |
| HY-14814 | Delafloxacin | 189279-58-1 | Reference compound |
| HY-148140 | Cross-linked dextran G 25 | 9041-35-4 | Reference compound |
| HY-148140A | Cross-linked dextran G 25, coarse | 9041-35-4 | Biochemical Assay Reagents |
| HY-148140B | Cross-linked dextran G 25, medium | 9041-35-4 | Biochemical Assay Reagents |
| HY-148140C | Cross-linked dextran G 25, fine | 9041-35-4 | Biochemical Assay Reagents |
| HY-148141 | JPE-1375 | 1254036-23-1 | Reference compound |
| HY-148142 | Pomalidomide-C3-NHS ester | 2828476-87-3 | Reference compound |
| HY-148143 | Pomalidomide-C6-NHS ester | 2828476-88-4 | Reference compound |
| HY-148144 | Clobutinol | 14860-49-2 | Reference compound |
| HY-148144A | Clobutinol (hydrochloride) | 1215-83-4 | Reference compound |
| HY-148144AR | Clobutinol (hydrochloride) (Standard) | 1215-83-4 | Reference Standards |
| HY-148145 | Mebanazine | 65-64-5 | Reference compound |
| HY-148146 | Phenoxypropazine | 3818-37-9 | Reference compound |
| HY-148147 | Metamizole | 50567-35-6 | Reference compound |
| HY-14814A | Delafloxacin (meglumine) | 352458-37-8 | Reference compound |
| HY-14814AR | Delafloxacin (meglumine) (Standard) | 352458-37-8 | Reference Standards |
| HY-14814R | Delafloxacin (Standard) | 189279-58-1 | Reference Standards |
| HY-14814S | Delafloxacin-d5 | | Isotope-Labeled Compounds |
| HY-14815 | Fosbretabulin | 222030-63-9 | Reference compound |
| HY-148151 | (-)-5′-Noraristeromycin | 150132-22-2 | Reference compound |
| HY-148152 | PSMA I&S | 2639475-07-1 | Reference compound |
| HY-148152A | PSMA I&S (TFA) | | Reference compound |
| HY-148153 | C6-Amide-(PEG)n-CH3 | | Reference compound |
| HY-148154 | Poly(oxy-1,2-ethanediyl)-propoxy-amide-C6 | | Reference compound |
| HY-148155 | Iotroxic acid | 51022-74-3 | Reference compound |
| HY-148156 | Hydroxydione | 303-01-5 | Reference compound |
| HY-148157 | Amylocaine | 644-26-8 | Reference compound |
| HY-148158 | Pivalylbenzhydrazine | 306-19-4 | Reference compound |
| HY-148159 | Safrazine | 33419-68-0 | Reference compound |
| HY-148160 | Diamthazole | 95-27-2 | Reference compound |
| HY-148160A | Diamthazole (hydrochloride) | 17140-69-1 | Reference compound |
| HY-148161 | L82-G17 | 92285-87-5 | Reference compound |
| HY-148162 | Kayexalate | 37349-16-9 | Reference compound |
| HY-148163 | Polystyrene sulfonic acid (30% in water) | 28210-41-5 | Reference compound |
| HY-148165 | L-Cytidine | 26524-60-7 | Oligonucleotides |
| HY-148166 | L-Inosine | 21138-24-9 | Oligonucleotides |
| HY-148167 | 2'-Deoxy-2'-fluoro-l-uridine | 622785-69-7 | Oligonucleotides |
| HY-148168 | L-5-Methyluridine | 26879-47-0 | Oligonucleotides |
| HY-148169 | 2'-Deoxy-L-guanosine | 22837-44-1 | Oligonucleotides |
| HY-14817 | Indeglitazar | 835619-41-5 | Reference compound |
| HY-148170 | L-I-OddU | 207920-87-4 | Oligonucleotides |
| HY-148171 | L-2'-Fd4C | 221662-50-6 | Oligonucleotides |
| HY-148172 | L-Fd4A | 210474-65-0 | Oligonucleotides |
| HY-148173 | NUCC-0223619 | 1923835-78-2 | Reference compound |
| HY-148174 | JNJ-3790339 | 93076-87-0 | Reference compound |
| HY-148176 | ANEB-001 | 791848-71-0 | Reference compound |
| HY-148177 | Sutidiazine | 1821293-40-6 | Reference compound |
| HY-148178 | MMV688533 | 2260904-47-8 | Reference compound |
| HY-148179 | Neuropeptide Y5 receptor ligand-1 | 322723-35-3 | Reference compound |
| HY-14818 | Laninamivir | 203120-17-6 | Reference compound |
| HY-148180 | Antimycobacterial agent-4 | 476319-66-1 | Reference compound |
| HY-148181 | c-Fms-IN-13 | 885704-58-5 | Reference compound |
| HY-148183 | Homologous recombination-IN-1 | 391889-85-3 | Reference compound |
| HY-148184 | USP1-IN-3 | 2821749-58-8 | Reference compound |
| HY-148185 | T01-1 | 2356229-14-4 | Reference compound |
| HY-148187 | NLRP3-IN-11 | 2769040-91-5 | Reference compound |
| HY-148189 | Aldometanib | 2904601-67-6 | Reference compound |
| HY-14818A | Laninamivir octanoate | 203120-46-1 | Reference compound |
| HY-14818B | Laninamivir (TFA) | 203120-18-7 | Reference compound |
| HY-14818C | Laninamivir octanoate (hydrate) | 1233643-88-3 | Reference compound |
| HY-14818R | Laninamivir (Standard) | 203120-17-6 | Reference Standards |
| HY-14818S1 | Laninamivir-13C,15N2 | | Isotope-Labeled Compounds |
| HY-148190 | Sheng Gelieting | 1152810-23-5 | Reference compound |
| HY-148191 | CL-197 | 1030595-07-3 | Reference compound |
| HY-148193 | Tubulin polymerization-IN-38 | 1005192-31-3 | Reference compound |
| HY-148194 | SC239 | 1977557-97-3 | ADC Related |
| HY-148195 | NNZ 2591 | 847952-38-9 | Peptides |
| HY-148197 | Glutathionylspermidine | 33932-35-3 | Peptides |
| HY-148198 | S1P5 receptor agonist-1 | 2373330-78-8 | Reference compound |
| HY-14820 | Macimorelin | 381231-18-1 | Reference compound |
| HY-148200 | L2H2-6OTD | 1016263-75-4 | Reference compound |
| HY-148200A | L2H2-6OTD (diformic) | | Reference compound |
| HY-148201 | Oleana-2,12-dien-28-oic acid | 272108-04-0 | Reference compound |
| HY-148202 | Influenza antiviral conjugate-1 | 2567770-65-2 | Reference compound |
| HY-148203 | Mcl-1 inhibitor 9 | 1883727-31-8 | Reference compound |
| HY-148204 | Gallichrome | 39000-29-8 | Reference compound |
| HY-148205 | Trypanothione | 96304-42-6 | Reference compound |
| HY-148206 | DMX-129 | 1623123-95-4 | Reference compound |
| HY-148207 | S-Benzylglutathione | 6803-17-4 | Reference compound |
| HY-148208 | S-(p-Nitrobenzyl)glutathione | 6803-19-6 | Reference compound |
| HY-148209 | Balhimycin | 140932-79-2 | Peptides |
| HY-14820A | Macimorelin (acetate) | 945212-59-9 | Reference compound |
| HY-14821 | Namitecan | 372105-27-6 | Reference compound |
| HY-148210 | AMPK activator 9 | 1858204-23-5 | Reference compound |
| HY-148211 | Tetrazine-PEG7-amine (hydrochloride) | | ADC Related |
| HY-148212 | GLP-1R agonist 17 | 2749609-28-5 | Reference compound |
| HY-148213 | CDK2/4/6-IN-1 | 2803837-13-8 | Reference compound |
| HY-148214 | CDK2/4/6-IN-2 | 2531748-80-6 | Reference compound |
| HY-148215 | Hsp90-IN-17 | 1253584-78-9 | Reference compound |
| HY-148215A | Hsp90-IN-17 (hydrochloride) | 1253584-63-2 | Reference compound |
| HY-148216 | HBPC–GSH | 156727-62-7 | Reference compound |
| HY-148217 | DB02307 | 101222-71-3 | Reference compound |
| HY-148218 | N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine | 306748-45-8 | Peptides |
| HY-148223 | Tolindate | 27877-51-6 | Reference compound |
| HY-148224 | Pifoxime | 31224-92-7 | Reference compound |
| HY-148225 | Fulvestrant 3-β-D-Glucuronide | 261506-27-8 | Reference compound |
| HY-148226 | 20-5,14-HEDGE | 1092380-14-7 | Reference compound |
| HY-148228 | ROS kinases-IN-1 | 370096-57-4 | Reference compound |
| HY-14823 | Sobetirome | 211110-63-3 | Reference compound |
| HY-148230 | TFEB Decoy ODN (sodium) | | Oligonucleotides |
| HY-148231 | Dideoxy-amanitin | 58255-46-2 | ADC Related |
| HY-148232 | BAY-3153 | 2771319-69-6 | Reference compound |
| HY-148233S | JNJ-6204 | 2765264-50-2 | Isotope-Labeled Compounds |
| HY-148234 | M4K2234 | 2421141-51-5 | Reference compound |
| HY-148235 | TP-051 | 858097-86-6 | Reference compound |
| HY-148236 | BAY-390 | 2741956-55-6 | Reference compound |
| HY-148237 | JNJ-54119936 | 1599531-55-1 | Reference compound |
| HY-148238 | GNE-2256 | 2102170-43-2 | Reference compound |
| HY-148239 | TP-030-2 | 2095514-84-2 | Reference compound |
| HY-14824 | Sofiniclin | 799279-80-4 | Reference compound |
| HY-148240 | JNJ-65355394 | 2230598-99-7 | Reference compound |
| HY-148241 | A-446 | | Reference compound |
| HY-148242 | BAY-069 | 2639638-66-5 | Reference compound |
| HY-148242A | BAY-252 | 2639638-67-6 | Reference compound |
| HY-148242B | BAY-5000 | 2639435-48-4 | Reference compound |
| HY-148243 | IGUANA-1 (free base) | 2756014-24-9 | Reference compound |
| HY-148244 | MS47134 | | Reference compound |
| HY-148245 | OH-Glu-Val-Cit-PAB-MMAE | 1895916-23-0 | ADC Related |
| HY-148246 | MU1700 | | Reference compound |
| HY-148247 | BI-2081 | 1458656-71-7 | Reference compound |
| HY-148248 | BI-2540 | 875145-22-5 | Reference compound |
| HY-148249 | NVS-MALT1 | 2772439-62-8 | Reference compound |
| HY-14824A | Sofinicline (benzenesulfonate) | 876170-44-4 | Reference compound |
| HY-14825 | Tarafenacin | 385367-47-5 | Reference compound |
| HY-148250 | TP-050 | | Reference compound |
| HY-148251 | MU1742 | | Reference compound |
| HY-148252 | ADRA1D receptor antagonist 1 (free base) | 1191908-24-3 | Reference compound |
| HY-148253 | TP-030-1 | 2095514-75-1 | Reference compound |
| HY-148254 | 8RK64 | 2705841-52-5 | Reference compound |
| HY-148255 | QN523 | 878581-60-3 | Reference compound |
| HY-148258 | GDC-2394 | 2238822-07-4 | Reference compound |
| HY-148259 | SF-1 antagonist-1 | 2842079-86-9 | Reference compound |
| HY-14825A | Tarafenacin (D-tartrate) | 1159101-48-0 | Reference compound |
| HY-148260 | KRAS G12D inhibitor 16 | 2648221-12-7 | Reference compound |
| HY-148261 | KRAS G12C inhibitor 56 | 2749963-77-5 | Reference compound |
| HY-148262 | SphK1-IN-3 | | Reference compound |
| HY-148263 | Biotin-PEG-Thiol (MW 2000) | | Dye Reagents |
| HY-148264 | Imdatifan | 2511247-29-1 | Reference compound |
| HY-148265 | Antiproliferative agent-14 | 1885900-35-5 | Reference compound |
| HY-148266 | UBA5-IN-1 | 1831169-11-9 | Reference compound |
| HY-14827 | Zicronapine | 170381-16-5 | Reference compound |
| HY-148272 | IL-17A modulator-3 | 2467732-95-0 | Reference compound |
| HY-148273 | Setidegrasib | 2821793-99-9 | Reference compound |
| HY-148274 | KTX-582 | 2573298-13-0 | Reference compound |
| HY-148275 | KTX-955 | 2573302-50-6 | Reference compound |
| HY-148276 | KTX-497 | 2432993-46-7 | Reference compound |
| HY-148277 | KTX-612 | 2573298-14-1 | Reference compound |
| HY-148278 | BI-0474 | 2750570-55-7 | Reference compound |
| HY-148279 | c-Met-IN-15 | 330572-32-2 | Reference compound |
| HY-14827A | Zicronapine (fumarate) | 170381-17-6 | Reference compound |
| HY-14828 | Afacifenacin | 877606-63-8 | Reference compound |
| HY-148281 | TMX-2164 | 2418022-85-0 | Reference compound |
| HY-148283 | WAY-309236 | 690697-43-9 | Reference compound |
| HY-148284 | Berbamine acetate | 73885-53-7 | Reference compound |
| HY-148285 | Succinyl CoA | 604-98-8 | Reference compound |
| HY-148286 | Gentamicin C1a | 26098-04-4 | Reference compound |
| HY-148286R | Gentamicin C1a (Standard) | 26098-04-4 | Reference Standards |
| HY-14829 | Afegostat | 169105-89-9 | Reference compound |
| HY-148290 | KTX-951 | 2573298-36-7 | Reference compound |
| HY-148292 | C16-Sphingosine-1-phosphate | 709026-60-8 | Reference compound |
| HY-148294 | Monogalactosyl diglyceride | 41670-62-6 | Reference compound |
| HY-148296 | 4-Methoxyestradiol | 26788-23-8 | Natural Products |
| HY-148297 | Ocadusertib | 2382811-41-6 | Reference compound |
| HY-148298 | CatD-IN-1 | 1628521-28-7 | Reference compound |
| HY-14829A | Afegostat (hydrochloride) | 161302-93-8 | Reference compound |
| HY-14829B | Afegostat (tartrate) | 919364-56-0 | Reference compound |
| HY-14829E | Afegostat (D-Tartrate) | 957230-65-8 | Reference compound |
| HY-14829F | L-Afegostat | 202979-51-9 | Reference compound |
| HY-14829H | Afegostat (TFA) | 1084896-50-3 | Reference compound |
| HY-14830 | SAR 97276 | 321915-72-4 | Reference compound |
| HY-148301 | 6α-Hydroxyestradiol | 1229-24-9 | Reference compound |
| HY-148304 | VU6036720 | 3026597-12-3 | Reference compound |
| HY-148304A | VU6036720 (hydrochloride) | | Reference compound |
| HY-148305 | PD-1/PD-L1-IN-28 | 2499965-07-8 | Reference compound |
| HY-148306 | γ-Secretase modulator 14 | 1420200-85-6 | Reference compound |
| HY-148308 | hRSV-IN-1 | 749868-66-4 | Reference compound |
| HY-148309 | Anti-Influenza agent 4 | 522625-85-0 | Reference compound |
| HY-14831 | Arhalofenate | 24136-23-0 | Reference compound |
| HY-148310 | Flaviviruses-IN-2 | 1009762-84-8 | Reference compound |
| HY-148312 | Sirtuin modulator 4 | 327104-77-8 | Reference compound |
| HY-148313 | PKM2 activator 4 | 781656-66-4 | Reference compound |
| HY-148314 | ROS kinases-IN-2 | 687576-28-9 | Reference compound |
| HY-148315 | GLUT1-IN-2 | 305357-89-5 | Reference compound |
| HY-148316 | hVEGF-IN-2 | 186610-88-8 | Reference compound |
| HY-148317 | PI3Kγ inhibitor 6 | 900515-01-7 | Reference compound |
| HY-148318 | CK2α-IN-1 | 443747-52-2 | Reference compound |
| HY-14832 | Ataluren | 775304-57-9 | Reference compound |
| HY-148322 | Sirtuin modulator 5 | 694469-31-3 | Reference compound |
| HY-148323 | Anti-Trypanosoma cruzi agent-4 | 10001-31-7 | Reference compound |
| HY-148324 | PKM2 activator 5 | 796092-26-7 | Reference compound |
| HY-148325 | α7 Nicotinic receptor agonist-1 | 220100-05-0 | Reference compound |
| HY-148326 | Glu(OtBu)-Val-Cit-PAB-OH | 2757059-05-3 | ADC Related |
| HY-148327 | AK-IN-1 | 378775-98-5 | Reference compound |
| HY-148328 | CK2-IN-4 | 313985-59-0 | Reference compound |
| HY-148329 | GSK3-IN-2 | 380450-97-5 | Reference compound |
| HY-14832R | Ataluren (Standard) | 775304-57-9 | Reference Standards |
| HY-14832S1 | Ataluren-13C6 | | Isotope-Labeled Compounds |
| HY-14833 | Atiratecan | 867063-97-6 | Reference compound |
| HY-148331 | Z-Thioprolyl-Thioproline | 118059-40-8 | Reference compound |
| HY-148332 | Z-Thioprolyl-Thiazolidine | 118059-38-4 | Reference compound |
| HY-148333 | MS177 | 2225938-86-1 | Reference compound |
| HY-148334 | MS8815 | 2855085-25-3 | Reference compound |
| HY-148335 | IRG1-IN-1 | 2407652-42-8 | Reference compound |
| HY-148337 | Thr-Val-Leu | 66317-22-4 | Peptides |
| HY-148338 | TLR8 agonist 5 | 2413016-41-6 | Reference compound |
| HY-148339 | Fmoc-VAP-MMAE | 1912408-91-3 | ADC Related |
| HY-14834 | Budiodarone | 335148-45-3 | Reference compound |
| HY-148340 | 24RBPyBC | 185675-92-7 | Reference compound |
| HY-148346 | STING agonist-20-Ala-amide-PEG2-C2-NH2 | 2720500-49-0 | Reference compound |
| HY-148346A | STING agonist-20-Ala-amide-PEG2-C2-NH2 (TFA) | | ADC Related |
| HY-148348 | AB-836 | 2445597-31-7 | Reference compound |
| HY-148349 | PF-07258669 | 2755890-53-8 | Reference compound |
| HY-148349A | (2R,2R)-PF-07258669 | 2755890-68-5 | Reference compound |
| HY-14834A | Budiodarone (tartrate) | 478941-93-4 | Reference compound |
| HY-14835 | Burapitant | 537034-22-3 | Reference compound |
| HY-148350 | DS69910557 | 3032750-17-4 | Reference compound |
| HY-148351 | BAY-0069 | 420826-65-9 | Reference compound |
| HY-148352 | BAY-4931 | 423150-91-8 | Reference compound |
| HY-148353 | PF-06455943 | 1527474-15-2 | Reference compound |
| HY-148360 | Notum pectinacetylesterase-1 | 460727-10-0 | Reference compound |
| HY-148361 | Fluorogen binding modulator-1 | 510716-65-1 | Reference compound |
| HY-148362 | Pomalidomide-C6-O-C5-O-C4-COOH | 2375774-54-0 | Reference compound |
| HY-148363 | Heptadecan-9-yl 8-((6-(decyloxy)-6-oxohexyl)(2-hydroxyethyl)amino)octanoate | 2714482-26-3 | Biochemical Assay Reagents |
| HY-148364 | ZINC00784494 | 317328-17-9 | Reference compound |
| HY-148365 | NecroIr1 | | Reference compound |
| HY-148366 | NecroIr2 | | Reference compound |
| HY-148367A | (1s,4s)-Menin-MLL inhibitor-23 | | Reference compound |
| HY-148368 | CYD-4-61 | 1425944-33-7 | Reference compound |
| HY-148369 | U7D-1 | | Reference compound |
| HY-14837 | Amizon | 201349-37-3 | Reference compound |
| HY-148370 | IONIS-FB-LRx | 2272975-74-1 | Oligonucleotides |
| HY-148370A | IONIS-FB-LRx (sodium) | | Oligonucleotides |
| HY-148371 | Glp-Trp-OEt | 87694-58-4 | Reference compound |
| HY-148372 | For-Met-Leu-pNA | 111150-07-3 | Reference compound |
| HY-148373 | BRM/BRG1 ATP Inhibitor-3 | 2368901-31-7 | Reference compound |
| HY-148374 | BRM/BRG1 ATP Inhibitor-4 | 2422030-94-0 | Reference compound |
| HY-148375 | Abiraterone sulfate | 1993430-25-3 | Reference compound |
| HY-148375R | Abiraterone sulfate (Standard) | 1993430-25-3 | Reference Standards |
| HY-148376 | Abiraterone N-oxide | 2378463-76-2 | Reference compound |
| HY-148377 | Abiraterone sulfate N-oxide | 1993430-24-2 | Reference compound |
| HY-148378 | 5β-Dihydrocortisone acetate | 1499-59-8 | Reference compound |
| HY-148379 | Tetrahydrocortisone acetate | 17736-20-8 | Reference compound |
| HY-14838 | Etamicastat | 760173-05-5 | Reference compound |
| HY-148380 | Mal-PEG8-Phe-Lys-PAB-Exatecan | 2679821-44-2 | ADC Related |
| HY-148380A | Mal-PEG8-Phe-Lys-PAB-Exatecan (TFA) | | Reference compound |
| HY-148381 | A947 | 2378056-80-3 | Reference compound |
| HY-148382 | RI-962 | 2763831-53-2 | Reference compound |
| HY-148383 | DP00477 | 169120-56-3 | Reference compound |
| HY-148384 | UHMCP1 | 2103079-87-2 | Reference compound |
| HY-148384A | UHMCP1 (dihydrochloride) | 2925647-93-2 | Reference compound |
| HY-148385 | Ganglioside GM2 | 127663-77-8 | Natural Products |
| HY-148387 | SARS-CoV-2-IN-35 | 2757763-47-4 | Reference compound |
| HY-148388 | N-Stearoylsphingomyelin | 58909-84-5 | Reference compound |
| HY-148389 | Disialo-Asn | 68141-38-8 | Peptides |
| HY-14838A | Etamicastat (hydrochloride) | 677773-32-9 | Reference compound |
| HY-14839 | Evatanepag | 223488-57-1 | Reference compound |
| HY-148390 | Sialylglyco peptide | 67299-24-5 | Reference compound |
| HY-148391 | 23-Oxa-OSW-1 | 790224-37-2 | Reference compound |
| HY-148392 | Neu5Gcα(2-6) N-Glycan-Asn | 82516-83-4 | Reference compound |
| HY-148393 | G0 N-glycan-Asn | 68418-91-7 | Reference compound |
| HY-148394 | UCK2 Inhibitor-1 | 902289-98-9 | Reference compound |
| HY-148395 | UCK2 Inhibitor-2 | 866842-71-9 | Reference compound |
| HY-148396 | UCK2 Inhibitor-3 | 2376687-49-7 | Reference compound |
| HY-148399 | Mal-VC-PAB-PNP-CDN-A | 2640880-35-7 | ADC Related |
| HY-14839A | Evatanepag (sodium) | 223490-49-1 | Reference compound |
| HY-14840 | Phenylpiracetam | 77472-70-9 | Reference compound |
| HY-148402 | p53 Activator 3 | 2636839-90-0 | Reference compound |
| HY-148404 | p53 Activator 5 | 2636840-37-2 | Reference compound |
| HY-148406 | (S,R,S)-AHPC-C10-NHBoc | 2412055-13-9 | Reference compound |
| HY-148407 | lucPpy-IN-1 | 546100-66-7 | Dye Reagents |
| HY-148408 | SIRT2-IN-11 | 1005095-06-6 | Reference compound |
| HY-148409 | MMRi62 | 352693-80-2 | Reference compound |
| HY-14840A | (R)-Phenylpiracetam | 949925-07-9 | Reference compound |
| HY-14841 | Gisadenafil | 334826-98-1 | Reference compound |
| HY-148410 | Zorevunersen | 2415330-04-8 | Oligonucleotides |
| HY-148410A | Zorevunersen (sodium) | 2415330-05-9 | Oligonucleotides |
| HY-148410C | Zorevunensen negative control | | Oligonucleotides |
| HY-148411 | Abetimus | 167362-48-3 | Reference compound |
| HY-148412 | Monarsen | 864021-55-6 | Oligonucleotides |
| HY-148412A | Monarsen (sodium) | | Oligonucleotides |
| HY-148413 | Aprinocarsen (sodium) | 331257-53-5 | Oligonucleotides |
| HY-148415 | Ac-Phe-Gly-pNA | 34336-99-7 | Reference compound |
| HY-148416 | p53 Activator 7 | 2849340-59-4 | Reference compound |
| HY-148417 | ZZL-7 | 99141-91-0 | Reference compound |
| HY-148418 | TUG-499 | 1206629-08-4 | Reference compound |
| HY-148419 | Ralometostat | 2760481-53-4 | Reference compound |
| HY-14842 | Givinostat | 497833-27-9 | Reference compound |
| HY-148420 | CDN-A | 2586047-09-6 | Reference compound |
| HY-148422 | Rohinitib | 1139253-73-8 | Reference compound |
| HY-148423 | Picarbutrazox | 500207-04-5 | Reference compound |
| HY-148424 | PBD dimer-2 | 145325-57-1 | ADC Related |
| HY-148425 | Mal-amide-PEG8-Val-Ala-PAB-PNP | 2210247-59-7 | ADC Related |
| HY-148426 | OSu-PEG4-VC-PAB-MMAE | 2762518-86-3 | ADC Related |
| HY-148429 | Antimalarial agent 17 | 508187-76-6 | Reference compound |
| HY-14842A | Givinostat (hydrochloride) | 199657-29-9 | Reference compound |
| HY-14842B | Givinostat (hydrochloride monohydrate) | 732302-99-7 | Reference compound |
| HY-14843 | Imagabalin | 610300-07-7 | Reference compound |
| HY-148430 | Aromatase-IN-2 | 121768-39-6 | Reference compound |
| HY-148431 | Antimicrobial agent-14 | 380576-68-1 | Reference compound |
| HY-148432 | FGF22-IN-1 | 113143-13-8 | Reference compound |
| HY-148433 | SpdSyn binder-1 | 251106-30-6 | Reference compound |
| HY-148435 | Glucocorticoid receptor agonist-2 | 2166378-92-1 | Reference compound |
| HY-148436 | Glucocorticoid receptor agonist-2 Ala-Ala-Mal | 2166376-64-1 | ADC Related |
| HY-148439 | RMC-6236 | 2765081-21-6 | Reference compound |
| HY-14844 | Lagociclovir | 92562-88-4 | Reference compound |
| HY-148440 | RL-0070933 | 301326-41-0 | Reference compound |
| HY-148441 | NDH-1 inhibitor-1 | 173964-49-3 | Reference compound |
| HY-148442 | ecMetAP-IN-1 | 7471-12-7 | Reference compound |
| HY-148443 | eIF4A3-IN-9 | 1402931-71-8 | Reference compound |
| HY-148444 | eIF4A3-IN-10 | 1402931-72-9 | Reference compound |
| HY-148445 | eIF4A3-IN-11 | 1402931-70-7 | Reference compound |
| HY-148446 | eIF4A3-IN-12 | 1402931-76-3 | Reference compound |
| HY-148447 | eIF4A3-IN-13 | 1402931-85-4 | Reference compound |
| HY-148448 | eIF4A3-IN-14 | 1402931-65-0 | Reference compound |
| HY-148449 | eIF4A3-IN-15 | 1402931-66-1 | Reference compound |
| HY-148450 | eIF4A3-IN-16 | 1402931-74-1 | Reference compound |
| HY-148451 | eIF4A3-IN-17 | 1402931-75-2 | Reference compound |
| HY-148452 | eIF4A3-IN-18 | 1402931-84-3 | Reference compound |
| HY-148453 | Antiproliferative agent-16 | 15641-17-5 | Reference compound |
| HY-148454 | Necroptosis-IN-3 | 547698-18-0 | Reference compound |
| HY-148455 | Casein kinase 1δ-IN-3 | 349438-77-3 | Reference compound |
| HY-148456 | Anti-inflammatory agent 34 | 867301-81-3 | Reference compound |
| HY-148457 | Avacincaptad pegol | 1613641-69-2 | Oligonucleotides |
| HY-148458 | EZH2-IN-14 | 1979157-17-9 | Reference compound |
| HY-148459 | ATAC21 | 2101204-23-1 | ADC Related |
| HY-14846 | Litronesib | 910634-41-2 | Reference compound |
| HY-148461 | Mal-VC-PAB-PNP | 1096584-62-1 | ADC Related |
| HY-148462 | Fmoc-Ala-Ala-PAB | 1384263-83-5 | ADC Related |
| HY-148463 | MP-Ala-Ala-PAB | 1949793-47-8 | ADC Related |
| HY-148464 | MC-Ala-Ala-PAB | 1949793-44-5 | ADC Related |
| HY-148465 | Gadoteric acid | 72573-82-1 | Natural Products |
| HY-148466 | IGUANA-1 | 2756014-25-0 | Reference compound |
| HY-148467 | METTL3-IN-1 | 2648257-77-4 | Reference compound |
| HY-148468 | METTL3-IN-2 | 2767258-88-6 | Reference compound |
| HY-148469 | METTL3-IN-3 | 2767003-71-2 | Reference compound |
| HY-14846A | Litronesib (Racemate) | 546111-97-1 | Reference compound |
| HY-148470A | C4-Amide-C4-NH2 | 1018541-17-7 | Reference compound |
| HY-148471A | C3-Amide-C4-NH2 | 65389-82-4 | Reference compound |
| HY-148472A | C2-Amide-C4-NH2 | 99789-97-6 | Reference compound |
| HY-148475 | (R)-SEMBL | 1443449-07-7 | Reference compound |
| HY-148476 | Tri-GalNAc-DBCO | | Reference compound |
| HY-148478 | MMV688845 | 2208962-35-8 | Reference compound |
| HY-14848 | Naluzotan | 740873-06-7 | Reference compound |
| HY-148480 | Nrf2 activator-6 | 2728780-74-1 | Reference compound |
| HY-148481 | USP7-IN-10 | 2755995-01-6 | Reference compound |
| HY-148481A | USP7-IN-10 (hydrochloride) | | Reference compound |
| HY-148482 | USP7-IN-11 | 2763872-32-6 | Reference compound |
| HY-148484 | Pomalidomide-5'-PEG5-C2-COOH | 2412056-50-7 | Reference compound |
| HY-148488 | A18-Iso5-2DC18 | 2412492-09-0 | Reference compound |
| HY-148489 | CSNK1-IN-1 | 2468784-55-4 | Reference compound |
| HY-14848A | Naluzotan (hydrochloride) | 740873-82-9 | Reference compound |
| HY-14849 | PTZ601 | 426253-04-5 | Reference compound |
| HY-148491 | CSNK1-IN-2 | 2468783-76-6 | Reference compound |
| HY-148492 | Mrgx2 antagonist-2 | 2767111-67-9 | Reference compound |
| HY-148493 | MK-3402 | 2058151-78-1 | Reference compound |
| HY-148494 | Tivumecirnon | 2174938-78-2 | Reference compound |
| HY-148495 | Carnosine conjugated hyalyronate | | Reference compound |
| HY-14850 | Sograzepide | 155488-25-8 | Reference compound |
| HY-148502 | VU6019650 | 2926782-31-0 | Reference compound |
| HY-148503 | 5'-ODMT cEt N-Bz A Phosphoramidite (Amidite) | 1197033-19-4 | Oligonucleotides |
| HY-148504 | 5'-ODMT cEt G Phosphoramidite (Amidite) | 945628-66-0 | Oligonucleotides |
| HY-148505 | 5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite) | 1197033-17-2 | Oligonucleotides |
| HY-148506 | 5'-ODMT cEt m5U Phosphoramidite (Amidite) | 1197033-22-9 | Oligonucleotides |
| HY-148507 | GSK1790627 | 871701-87-0 | Reference compound |
| HY-148508 | PhosTAC3 | | Reference compound |
| HY-148509 | PhosTAC5 | | Reference compound |
| HY-14851 | MRE 0094 | 131865-88-8 | Reference compound |
| HY-148510 | HKB99 | 2414908-90-8 | Reference compound |
| HY-148511 | Vidutolimod | 147063-80-7 | Oligonucleotides |
| HY-148511A | Vidutolimod (sodium) | | Oligonucleotides |
| HY-148514 | CT52923 | 205256-55-9 | Reference compound |
| HY-148516 | MPH-220 | 2649776-79-2 | Reference compound |
| HY-148516A | (R)-MPH-220 | | Reference compound |
| HY-148517 | AZD0095 | 2750001-23-9 | Reference compound |
| HY-148518 | MSC-1186 | 2871698-23-4 | Reference compound |
| HY-14852 | Tafamidis | 594839-88-0 | Reference compound |
| HY-148520 | QM295 | 1241046-32-1 | Reference compound |
| HY-148521 | PROTAC FLT3/CDK9 degrader-1 | | Reference compound |
| HY-148522 | FLT3-IN-18 | 752191-77-8 | Reference compound |
| HY-148523 | HQ005 | 2750644-31-4 | Reference compound |
| HY-148524 | β2AR/M-receptor agonist-1 | 2230520-62-2 | Reference compound |
| HY-148525 | PF-4348235 | 1017857-38-3 | Reference compound |
| HY-148526 | β2AR/M3-receptor agonist-1 | 1206887-00-4 | Reference compound |
| HY-148527 | LAS190792 | 1347232-69-2 | Reference compound |
| HY-148528 | SC-VC-PAB-N-Me-L-Ala-Maytansinol | 2226467-76-9 | Reference compound |
| HY-148529 | Midaglizole | 66529-17-7 | Reference compound |
| HY-14852A | Tafamidis meglumine | 951395-08-7 | Reference compound |
| HY-14852S | Tafamidis-d3 | | Isotope-Labeled Compounds |
| HY-14853 | Darexaban | 365462-23-3 | Reference compound |
| HY-148530 | YX-2-107 | 2417408-46-7 | Reference compound |
| HY-148531 | PF-07054894 | 2413693-96-4 | Reference compound |
| HY-148533 | β2AR agonist /M-receptor antagonist-1 | 2772700-36-2 | Reference compound |
| HY-148535 | Calpain Inhibitor XI | 145731-49-3 | Reference compound |
| HY-14854 | Tecarfarin | 867257-26-9 | Reference compound |
| HY-148542 | EpoY | 245660-13-3 | Reference compound |
| HY-148545 | SHMT-IN-3 | 330638-43-2 | Reference compound |
| HY-148546 | STING agonist-21 | 2375419-35-3 | Reference compound |
| HY-148547 | q-FTAA | 1352477-22-5 | Reference compound |
| HY-148548 | p-HTAA | 1175142-38-7 | Reference compound |
| HY-148549 | MC-PEG2-Boc | 640267-55-6 | Reference compound |
| HY-14854A | Tecarfarin (sodium) | 1004551-83-0 | Reference compound |
| HY-14854S | Tecarfarin-13C,d3 | | Isotope-Labeled Compounds |
| HY-14855 | Tedizolid | 856866-72-3 | Reference compound |
| HY-148550 | MC-PEG2-NH2 | 640267-62-5 | Reference compound |
| HY-148552 | Anti-inflammatory agent 35 | 2293951-00-3 | Reference compound |
| HY-148553 | Anti-inflammatory agent 36 | 2293951-01-4 | Reference compound |
| HY-148555 | AXC-879 | 2479277-22-8 | Reference compound |
| HY-148556 | Thalidomide-O-C6-azide | 2411389-65-4 | Reference compound |
| HY-148558 | P2X7 receptor antagonist-3 | 1627900-92-8 | Reference compound |
| HY-148559 | 4A3-SC8 | 1857340-78-3 | Reference compound |
| HY-14855A | (S)-Tedizolid | 1431699-67-0 | Reference compound |
| HY-14855AR | (S)-Tedizolid (Standard) | 1431699-67-0 | Reference Standards |
| HY-14855B | Tedizolid (phosphate) | 856867-55-5 | Reference compound |
| HY-14855BR | Tedizolid (phosphate) (Standard) | 856867-55-5 | Reference Standards |
| HY-14855R | Tedizolid (Standard) | 856866-72-3 | Reference Standards |
| HY-14855S | Tedizolid-13C,d3 | 2931763-72-1 | Isotope-Labeled Compounds |
| HY-14856 | Atagabalin | 223445-75-8 | Reference compound |
| HY-148560 | ccc_R08 | 2919019-72-8 | Reference compound |
| HY-148560A | trans-ccc_R08 | 2413192-49-9 | Reference compound |
| HY-148560B | cis-ccc_R08 | 2413192-48-8 | Reference compound |
| HY-148561 | CDK8-IN-12 | 2613307-67-6 | Reference compound |
| HY-148563 | GPR81 agonist 2 | 1143024-28-5 | Reference compound |
| HY-148564 | TBI-166 | 1353734-12-9 | Reference compound |
| HY-148565 | SERT-IN-2 | 2055228-33-4 | Reference compound |
| HY-148566 | OUL232 | 943119-42-4 | Reference compound |
| HY-148567 | TMV-IN-1 | 2883408-27-1 | Reference compound |
| HY-148568 | TMV-IN-2 | 2883408-32-8 | Reference compound |
| HY-148569 | TMV-IN-3 | 2883408-35-1 | Reference compound |
| HY-14856A | iso-Atagabalin (hydrochloride) | 223445-68-9 | Reference compound |
| HY-14857 | Carotegrast | 401904-75-4 | Reference compound |
| HY-148570 | PHGDH-IN-3 | 2893778-31-7 | Reference compound |
| HY-148571 | TP0597850 | 2642181-22-2 | Reference compound |
| HY-148572 | NAMPT/IDO1-IN-1 | 2247884-06-4 | Reference compound |
| HY-148573 | sEH inhibitor-14 | 2890221-26-6 | Reference compound |
| HY-148574 | MCT1-IN-3 | 2878360-80-4 | Reference compound |
| HY-148575 | α-Glucosidase-IN-23 | 161187-57-1 | Reference compound |
| HY-148576 | Antibacterial agent 136 | | Reference compound |
| HY-148578 | CamA-IN-1 | 2924055-46-7 | Reference compound |
| HY-14858 | Derenofylline | 251945-92-3 | Reference compound |
| HY-148585 | BTK-IN-22 | 2573048-10-7 | Reference compound |
| HY-148586 | β-Estradiol 17-hemisuccinate | 7698-93-3 | Reference compound |
| HY-14859 | Dipraglurant | 872363-17-2 | Reference compound |
| HY-148591 | GSK761 | | Reference compound |
| HY-148592 | Antitumor agent-87 | 1422527-88-5 | Reference compound |
| HY-148594 | BTK-IN-23 | 2573048-11-8 | Reference compound |
| HY-148595 | Antitumor agent-88 | 1422527-87-4 | Reference compound |
| HY-148597 | FGFR-IN-10 | 2847092-41-3 | Reference compound |
| HY-148598 | Curcumin 5-8 | 890984-26-6 | Natural Products |
| HY-14860 | 1-Deoxynojirimycin | 19130-96-2 | Natural Products |
| HY-148601 | 1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol | 217939-97-4 | Biochemical Assay Reagents |
| HY-148602 | KH-4-43 | 2813310-07-3 | Reference compound |
| HY-148606 | STING modulator-3 | 2839639-94-8 | Reference compound |
| HY-148608 | LysoPalloT-NH-amide-C3-ph-m-O-C11 | 1778686-61-5 | Reference compound |
| HY-14860A | 1-Deoxynojirimycin (hydrochloride) | 73285-50-4 | Natural Products |
| HY-14860R | 1-Deoxynojirimycin (Standard) | 19130-96-2 | Reference Standards |
| HY-148610 | LDH-IN-2 | 893739-96-3 | Reference compound |
| HY-148611 | NSC339614 (potassium) | 1135037-53-4 | Reference compound |
| HY-148614 | Isocaproaldehyde | 1119-16-0 | Natural Products |
| HY-148615 | NPD10084 | 1040706-91-9 | Reference compound |
| HY-148616 | α-Pseudouridine | 10017-66-0 | Reference compound |
| HY-148617 | ALDH2 modulator 1 | 1629615-99-1 | Reference compound |
| HY-14862 | Latrepirdine | 3613-73-8 | Reference compound |
| HY-148624 | CHDI-00484077 | 3025894-92-9 | Reference compound |
| HY-148625 | PDE9-IN-2 | 917089-10-2 | Reference compound |
| HY-148626 | CVI-LM001 | | Reference compound |
| HY-148629 | GDC-0134 | 1637394-01-4 | Reference compound |
| HY-14863 | Lunacalcipol | 250384-82-8 | Reference compound |
| HY-14864 | Mapracorat | 887375-26-0 | Reference compound |
| HY-148642 | 12-Hydroxynevirapine | 133627-24-4 | Reference compound |
| HY-148643 | STING modulator-5 | 2305940-22-9 | Reference compound |
| HY-148644 | STING-IN-6 | 2305940-34-3 | Reference compound |
| HY-148645 | STING modulator-4 | 2839639-72-2 | Reference compound |
| HY-148646 | p-NH2-CHX-A"-DTPA | 1105741-38-5 | Reference compound |
| HY-148646A | p-NH2-CHX-A"-DTPA (hydrochloride hydrate) | | Biochemical Assay Reagents |
| HY-148647 | Mipomersen | 1000120-98-8 | Oligonucleotides |
| HY-148648 | Lipid 29 | 2244716-55-8 | Reference compound |
| HY-148649 | Demethyl bleomycin A2 | 41089-03-6 | Reference compound |
| HY-14864A | (S)-Mapracorat | 887375-15-7 | Reference compound |
| HY-14865 | Omadacycline | 389139-89-3 | Reference compound |
| HY-148650 | Sortilin antagonist 1 | 2691846-93-0 | Reference compound |
| HY-148650A | (R)-Sortilin antagonist 1 | 2889422-86-8 | Reference compound |
| HY-148651 | CDK2-IN-15 | 1219915-83-9 | Natural Products |
| HY-148653 | (+)-C-BVDU | 95463-56-2 | Reference compound |
| HY-148656 | PNB-001 | 1528760-09-9 | Reference compound |
| HY-148657 | Aminopterin N-hydroxysuccinimide ester | 98457-88-6 | Reference compound |
| HY-14865A | Omadacycline (mesylate) | 1196800-40-4 | Reference compound |
| HY-14865B | Omadacycline (tosylate) | 1075240-43-5 | Reference compound |
| HY-14865BR | Omadacycline (tosylate) (Standard) | 1075240-43-5 | Reference Standards |
| HY-14865C | Omadacycline (hydrochloride) | 1196800-39-1 | Reference compound |
| HY-14865CR | Omadacycline (hydrochloride) (Standard) | 1196800-39-1 | Reference Standards |
| HY-14865R | Omadacycline (Standard) | 389139-89-3 | Reference Standards |
| HY-14865S | Omadacycline-d9 | 2272886-41-4 | Isotope-Labeled Compounds |
| HY-14866 | Raseglurant | 757950-09-7 | Reference compound |
| HY-148660 | SFI003 | 2361332-90-1 | Reference compound |
| HY-148662 | Pomalidomide-PEG5-C2-NH2 (hydrochloride) | 2357117-23-6 | Reference compound |
| HY-148663 | Mitogenic Pentapeptide | 87173-03-3 | Peptides |
| HY-148664 | eIF4E-IN-4 | 1373822-39-9 | Reference compound |
| HY-148665 | FABP-IN-2 | 1426533-99-4 | Reference compound |
| HY-148666 | H-Gly-Oet | 459-73-4 | Biochemical Assay Reagents |
| HY-148667 | H-Cys(Acm)-OH | 19647-70-2 | Biochemical Assay Reagents |
| HY-148668 | MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan | 2414254-51-4 | Reference compound |
| HY-148668A | MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan | 2414254-52-5 | Reference compound |
| HY-148669 | Bleximenib | 2654081-35-1 | Reference compound |
| HY-148669A | Bleximenib (oxalate) | 2866179-95-3 | Reference compound |
| HY-148669B | (S)-Bleximenib (oxalate) | | Reference compound |
| HY-148670 | Pulmonary arterial hypertension agent-1 | 1201082-00-9 | Reference compound |
| HY-148671 | (S,R,S)-AHPC-amido-C7-acid | 2172819-76-8 | Reference compound |
| HY-148672 | 2-Nitrophenyl a-D-glucopyranoside | 56193-44-3 | Biochemical Assay Reagents |
| HY-148673 | AZD0780 | 2455427-91-3 | Reference compound |
| HY-148674 | PRMT5-IN-25 | 2691869-82-4 | Reference compound |
| HY-148676 | Emilumenib | 2440018-29-9 | Reference compound |
| HY-148677S | 2,3-Dihydroxy-2-methylbutanoic acid-d3 | | Isotope-Labeled Compounds |
| HY-148682 | 18β-Glycyrrhetyl-3-O-sulfate | 10251-38-4 | Reference compound |
| HY-148682R | 18β-Glycyrrhetyl-3-O-sulfate (Standard) | 10251-38-4 | Reference Standards |
| HY-148682S1 | 18β-Glycyrrhetyl-3-O-sulfate-d2 | | Isotope-Labeled Compounds |
| HY-148682S2 | 18β-Glycyrrhetyl-3-O-sulfate-d3 | | Isotope-Labeled Compounds |
| HY-148683 | EG-011 | 2377113-41-0 | Reference compound |
| HY-148684 | AMPK activator 10 | 1914176-03-6 | Reference compound |
| HY-148685 | KM04416 | 26530-26-7 | Reference compound |
| HY-148687 | SPC5001 | | Oligonucleotides |
| HY-148687A | SPC5001 (sodium) | | Oligonucleotides |
| HY-148688 | ASO 556089 sodium | | Oligonucleotides |
| HY-148689 | SPC4061 | 1018108-22-9 | Reference compound |
| HY-148689A | SPC4061 (sodium) | | Oligonucleotides |
| HY-148690 | L18-MDP | 60398-08-5 | Peptides |
| HY-148691 | PROTAC PTPN2 degrader-1 | 2655638-07-4 | Reference compound |
| HY-148692 | OSM-SMI-10B | | Reference compound |
| HY-148692A | (E/Z)-OSM-SMI-10B | 2502294-55-3 | Reference compound |
| HY-148693 | OSM-SMI-8 | 1689690-20-7 | Reference compound |
| HY-148693A | (E/Z)-OSM-SMI-8 | | Reference compound |
| HY-148694 | ISX-3 | 912789-08-3 | Reference compound |
| HY-148695B | ADR58 (sodium) | | Oligonucleotides |
| HY-148695C | Truncated ADR58 (sodium) | | Oligonucleotides |
| HY-148696A | Gly-Cyclopropane-Exatecan | 2414254-49-0 | Reference compound |
| HY-148696B | Gly-(S)-Cyclopropane-Exatecan | | Reference compound |
| HY-148697 | Nigerose | 497-48-3 | Reference compound |
| HY-148698 | 2MD | 213250-70-5 | Reference compound |
| HY-148699 | HRO761 | 2869954-34-5 | Reference compound |
| HY-14870 | Selexipag | 475086-01-2 | Reference compound |
| HY-148700 | Werner syndrome RecQ helicase-IN-2 | 2869954-51-6 | Reference compound |
| HY-148701 | mono-Pal-MTO | 1349197-89-2 | Biochemical Assay Reagents |
| HY-148702 | di-Pal-MTO | 1349197-90-5 | Oligonucleotides |
| HY-148705 | Isomitomycin A | 91917-64-5 | Reference compound |
| HY-148706 | STAT3-IN-17 | 1245814-52-1 | Reference compound |
| HY-148707 | SphK1&2-IN-1 | 1415662-57-5 | Reference compound |
| HY-148708 | Oleoyl-D-lysine | 2240164-55-8 | Reference compound |
| HY-148709 | ARTD10/PARP10-IN-1 | 1708103-76-7 | Reference compound |
| HY-14870R | Selexipag (Standard) | 475086-01-2 | Reference Standards |
| HY-14870S1 | Selexipag-d7 | 1265295-21-3 | Isotope-Labeled Compounds |
| HY-14870S3 | Selexipag-d6 | 1265295-92-8 | Isotope-Labeled Compounds |
| HY-14871 | Tenifatecan | 850728-18-6 | Reference compound |
| HY-148710 | ARTD10/PARP10-IN-2 | 1708103-69-8 | Reference compound |
| HY-148711 | STL1267 | 1429024-58-7 | Reference compound |
| HY-148712 | SIRT6 activator 12q | 2601734-99-8 | Reference compound |
| HY-148713 | Anti-CSCs agent-1 | 2251753-58-7 | Reference compound |
| HY-148717 | NSC363998 (free base) | 159357-82-1 | Reference compound |
| HY-148718 | 4-Chloro Trazodone (hydrochloride) | 1263278-77-8 | Reference compound |
| HY-148718R | 4-Chloro Trazodone (hydrochloride) (Standard) | 1263278-77-8 | Reference Standards |
| HY-148719 | ARN24139 | 2699768-78-8 | Reference compound |
| HY-14872 | Tideglusib | 865854-05-3 | Reference compound |
| HY-14873 | Tonapofylline | 340021-17-2 | Reference compound |
| HY-148730 | BRD7586 | 895460-70-5 | Reference compound |
| HY-148732 | LU-005i | 1620107-33-6 | Reference compound |
| HY-148739 | dBRD 9-A | 2170679-42-0 | Reference compound |
| HY-14874 | Topiroxostat | 577778-58-6 | Reference compound |
| HY-148740 | Werner syndrome RecQ helicase-IN-3 | 2869954-98-1 | Reference compound |
| HY-148741 | Werner syndrome RecQ helicase-IN-4 | 2869954-53-8 | Reference compound |
| HY-148742 | RET-IN-21 | 2414373-42-3 | Reference compound |
| HY-148744 | 3-Deoxy-D-manno-2-octulosonic acid (ammonium), 97% | 103404-70-2 | Biochemical Assay Reagents |
| HY-148745 | JG-258 | 2241517-83-7 | Reference compound |
| HY-148748 | Butyzamide | 1110767-45-7 | Reference compound |
| HY-14874R | Topiroxostat (Standard) | 577778-58-6 | Reference Standards |
| HY-14874S | Topiroxostat-d4 | 2732868-49-2 | Isotope-Labeled Compounds |
| HY-14875 | Verucerfont | 885220-61-1 | Reference compound |
| HY-148751 | TRPV1 activator-1 | 1803181-80-7 | Reference compound |
| HY-148752 | TRPV1 activator-2 | 17514-11-3 | Reference compound |
| HY-148753 | PARP10-IN-2 | 1042780-52-8 | Reference compound |
| HY-148754 | PARP10-IN-3 | 2225800-19-9 | Reference compound |
| HY-148755 | ERX-41 | 2440087-54-5 | Reference compound |
| HY-148756 | NG-497 | 2598242-66-9 | Reference compound |
| HY-148757 | TIM-063 | 2493978-38-2 | Reference compound |
| HY-148758 | PCSK9-IN-13 | 2244129-23-3 | Reference compound |
| HY-148761 | PSMA I&T | 2192281-54-0 | ADC Related |
| HY-148763 | CK2-IN-6 | 1309835-18-4 | Reference compound |
| HY-148764 | M47 | 890808-56-7 | Reference compound |
| HY-148765 | CLK8 | 898920-65-5 | Reference compound |
| HY-148766 | VU661 | 37648-76-3 | Reference compound |
| HY-148767 | MLKL-IN-5 | 2755872-58-1 | Reference compound |
| HY-148768 | AB-506 | 2245020-50-0 | Reference compound |
| HY-148769 | Cefiderocol catechol 3-methoxy | 2243393-93-1 | Reference compound |
| HY-14877 | Anagliptin | 739366-20-2 | Reference compound |
| HY-148771 | MTX-23 | 2488296-74-6 | Reference compound |
| HY-148772 | PTC258 | 2476724-74-8 | Reference compound |
| HY-148773 | MC-Gly-Gly-Phe-Boc | 1599440-14-8 | Reference compound |
| HY-148775 | PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) | | Oligonucleotides |
| HY-148775A | mPEG-PLGA (21500-26500) | 743423-15-6 | Oligonucleotides |
| HY-148775B | PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) | | Biochemical Assay Reagents |
| HY-148776 | PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) | | Reference compound |
| HY-148777 | A031 | 2682255-44-1 | Reference compound |
| HY-148778 | FGFR3-IN-4 | 2833706-13-9 | Reference compound |
| HY-148779 | FGFR3-IN-5 | 2446664-72-6 | Reference compound |
| HY-14877A | Anagliptin (hydrochloride) | 1359670-56-6 | Reference compound |
| HY-14877S1 | Anagliptin-d7 | | Isotope-Labeled Compounds |
| HY-14878 | (2R)-Atecegatran | 917904-13-3 | Reference compound |
| HY-148780 | HBV-IN-29 | 2413192-59-1 | Reference compound |
| HY-148781 | HBV-IN-30 | 2413192-92-2 | Reference compound |
| HY-148782 | HBV-IN-31 | 2413192-95-5 | Reference compound |
| HY-148783 | HBV-IN-32 | 2413193-04-9 | Reference compound |
| HY-148785 | Nimucitinib | 2740557-24-6 | Reference compound |
| HY-148787 | Oditrasertib | 2252271-93-3 | Reference compound |
| HY-148788 | Osivelotor | 2417955-18-9 | Reference compound |
| HY-148789 | Palazestrant | 2092925-89-6 | Reference compound |
| HY-14879 | Avibactam (free acid) | 1192500-31-4 | Reference compound |
| HY-148790 | Pralurbactam | 2163782-59-8 | Reference compound |
| HY-148791 | Pumecitinib | 2401057-12-1 | Reference compound |
| HY-148792 | Relutrigine | 2392951-29-8 | Reference compound |
| HY-148793 | Resencatinib | 2546117-79-5 | Reference compound |
| HY-148794 | Risvodetinib | 2031185-00-7 | Reference compound |
| HY-148795 | Ritivixibat | 2460667-52-9 | Reference compound |
| HY-148796 | Rizedisben | 1311570-07-6 | Dye Reagents |
| HY-148797 | Rolusafine | 2089153-78-4 | Reference compound |
| HY-148799 | Sevasemten | 2417395-15-2 | Reference compound |
| HY-14879A | Avibactam (sodium) | 1192491-61-4 | Reference compound |
| HY-14879AR | Avibactam (sodium) (Standard) | 1192491-61-4 | Reference Standards |
| HY-14879B | Avibactam (sodium hydrate) | 2938989-90-1 | Reference compound |
| HY-14879BR | Avibactam (sodium hydrate) (Standard) | 2938989-90-1 | Reference Standards |
| HY-14879C | Avibactam (sodium dihydrate) | | Reference compound |
| HY-14879D | ent-Avibactam (sodium) | 396731-20-7 | Reference compound |
| HY-14879R | Avibactam (free acid) (Standard) | 1192500-31-4 | Reference Standards |
| HY-14879S2 | Avibactam sodium salt-13C5 | | Isotope-Labeled Compounds |
| HY-14880 | Bavisant | 929622-08-2 | Reference compound |
| HY-148800 | Suzetrigine | 2649467-58-1 | Reference compound |
| HY-148801 | Tamuzimod | 2097854-81-2 | Reference compound |
| HY-148802 | Taplucainium (chloride) | 2489565-37-7 | Reference compound |
| HY-148803 | Vabametkib | 1571903-56-4 | Reference compound |
| HY-148804 | Vemtoberant | 2169905-68-2 | Reference compound |
| HY-148804A | Vemtoberant (mesylate) | 2169905-97-7 | Reference compound |
| HY-148805 | Vonifimod | 2118903-18-5 | Reference compound |
| HY-148806 | Zatonacaftor | 2301945-38-8 | Reference compound |
| HY-148807 | Zavondemstat | 1851412-93-5 | Reference compound |
| HY-148807A | Zavondemstat (L-lysine) | 2908753-10-4 | Reference compound |
| HY-148807B | (S)-Zavondemstat | | Reference compound |
| HY-148808 | Zelasudil | 2365193-22-0 | Reference compound |
| HY-14880A | Bavisant (dihydrochloride) | 929622-09-3 | Reference compound |
| HY-14880B | Bavisant (dihydrochloride hydrate) | 1103522-80-0 | Reference compound |
| HY-14881 | Bedaquiline | 843663-66-1 | Reference compound |
| HY-148810 | Zongertinib | 2728667-27-2 | Reference compound |
| HY-148811 | Zurletrectinib | 2403703-30-8 | Reference compound |
| HY-148812 | Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan | 2766786-76-7 | ADC Related |
| HY-148813 | AK-2292 | 2984506-77-4 | Reference compound |
| HY-148814 | BI-3231 | 2894848-07-6 | Reference compound |
| HY-148815 | Nampt activator-1 | 701929-65-9 | Reference compound |
| HY-148816 | SG-094 | 2922283-37-0 | Reference compound |
| HY-148817 | WDR5-0102 | 824960-50-1 | Reference compound |
| HY-148818 | S-Me-DM4 | 890654-03-2 | Reference compound |
| HY-148819 | NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT | 2857037-69-3 | Reference compound |
| HY-148819A | NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (hydrochloride) | | Reference compound |
| HY-14881A | Bedaquiline (fumarate) | 845533-86-0 | Reference compound |
| HY-14881AR | Bedaquiline (fumarate) (Standard) | 845533-86-0 | Reference Standards |
| HY-14881B | (Rac)-Bedaquiline | 654655-80-8 | Reference compound |
| HY-14881R | Bedaquiline (Standard) | 843663-66-1 | Reference Standards |
| HY-14881S1 | (Rac)-Bedaquiline-d6 | 2517573-53-2 | Isotope-Labeled Compounds |
| HY-14881S2 | Bedaquiline impurity 2-d6 | | Isotope-Labeled Compounds |
| HY-14882 | Cenicriviroc | 497223-25-3 | Reference compound |
| HY-148820 | Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT | 2857037-70-6 | Reference compound |
| HY-148822 | Nampt activator-2 | 2237268-90-3 | Reference compound |
| HY-148824S | Dimethenamid ESA-d6 | | Isotope-Labeled Compounds |
| HY-148825 | NP10679 | 2914889-88-4 | Reference compound |
| HY-148826 | Rovunaptabin | 145563-68-4 | Oligonucleotides |
| HY-148827 | GEM-231 | 255810-66-3 | Oligonucleotides |
| HY-148827A | GEM-231 (sodium) | | Oligonucleotides |
| HY-148828 | LSP-GR3 | 1235945-37-5 | Oligonucleotides |
| HY-148828A | LSP-GR3 (sodium) | | Oligonucleotides |
| HY-14882A | Cenicriviroc Mesylate | 497223-28-6 | Reference compound |
| HY-148830 | Piperazine-bis(ethyl octadeca-9,12-dienoate) | 2832061-33-1 | Biochemical Assay Reagents |
| HY-148831 | Antibacterial agent 135 | 2233569-54-3 | Reference compound |
| HY-148832 | BTK-IN-20 | 1581714-50-2 | Reference compound |
| HY-148833 | MDM2-p53-IN-16 | 1917350-09-4 | Reference compound |
| HY-148834 | Pomalidomide-piperazine | 2154342-57-9 | Reference compound |
| HY-148835 | AzGGK | 2407768-11-8 | Reference compound |
| HY-148835A | AzGGK (TFA) | | Reference compound |
| HY-148836 | c-Myc inhibitor 6 | 2768765-58-6 | Reference compound |
| HY-148837 | PROTAC c-Myc degrader-1 | 2883535-99-5 | Reference compound |
| HY-148838 | c-Myc inhibitor 8 | 2173505-97-8 | Reference compound |
| HY-148839 | c-Myc inhibitor 9 | 2799717-96-5 | Reference compound |
| HY-148840 | Sulfo DBCO-PEG3-NHS ester | | Reference compound |
| HY-148840A | Sulfo DBCO-PEG3-NHS ester (TEA) | | Reference compound |
| HY-148842 | C14-4 | 2639634-80-1 | Oligonucleotides |
| HY-148844 | GCGR antagonist 2 | 280134-25-0 | Reference compound |
| HY-148846 | Mosapride N-Oxide | 1161443-73-7 | Reference compound |
| HY-148847 | HPK1-IN-32 | 2766481-17-6 | Reference compound |
| HY-14885 | Eliglustat | 491833-29-5 | Reference compound |
| HY-148850 | AZD-2207 | 866598-45-0 | Reference compound |
| HY-148851 | Bacteriochlorophyll a, from Rhodopseudomonas sphaeroides (under argon) | 17499-98-8 | Natural Products |
| HY-148853 | SRI-42127 | 2727872-68-4 | Reference compound |
| HY-148855 | OF-C4-Deg-Lin | 2383003-60-7 | Reference compound |
| HY-148859 | AA-T3A-C12 | 2938207-23-7 | Reference compound |
| HY-14885A | Eliglustat (hemitartrate) | 928659-70-5 | Reference compound |
| HY-14885R | Eliglustat (Standard) | 491833-29-5 | Reference Standards |
| HY-14885S | Eliglustat-d15 (tartrate) | 1884556-84-6 | Isotope-Labeled Compounds |
| HY-14885S1 | Eliglustat-d4 | | Isotope-Labeled Compounds |
| HY-14885S2 | Eliglustat-d15 | 1628700-80-0 | Isotope-Labeled Compounds |
| HY-14886 | Fasitibant (chloride) | 1157852-02-2 | Reference compound |
| HY-148860 | NVP-DFF332 | 2734922-78-0 | Reference compound |
| HY-148862 | Cavα2δ1&NET-IN-1 | 2314361-39-0 | Reference compound |
| HY-148863 | Cavα2δ1&NET-IN-2 | 2143586-17-6 | Reference compound |
| HY-148864 | JQ1-TCO | | Reference compound |
| HY-148864A | (Z)-JQ1-TCO | 2087490-43-3 | Reference compound |
| HY-148865 | Puromycin-bis(PEG2-amide)-Biotin | 2379889-82-2 | Reference compound |
| HY-148866 | Cavα2δ1&NET-IN-3 | 2143584-82-9 | Reference compound |
| HY-148867 | UCM-1306 | 2258608-78-3 | Reference compound |
| HY-148868 | Akt1&PKA-IN-1 | 1334107-58-2 | Reference compound |
| HY-148868A | Akt1&PKA-IN-2 | 1334108-00-7 | Reference compound |
| HY-148869A | Hexanoyl-Coenzyme A (triammonium) | 799812-81-0 | Enzyme |
| HY-14887 | Fedovapagon | 347887-36-9 | Reference compound |
| HY-148870 | Maytansinoid B | 1628543-40-7 | ADC Related |
| HY-148871 | Mc-Val-Cit-PAB-Gefitinib (chloride) | | ADC Related |
| HY-148872 | Thalidomide-5-NH2-C8-NH2 (TFA) | 2097509-49-2 | Reference compound |
| HY-148874 | FXR antagonist 2 | 1660153-21-8 | Reference compound |
| HY-148874A | FXR antagonist 2 (hydrochloride) | | Reference compound |
| HY-148875 | Py-MAA-Val-Cit-PAB-MMAE | 2247398-68-9 | ADC Related |
| HY-148877 | AT-533 | 908112-37-8 | Reference compound |
| HY-148878 | Ras modulator-1 | 623935-08-0 | Reference compound |
| HY-148880 | VHLL-BCN | 2874203-49-1 | Reference compound |
| HY-148896 | (S,R,S)-AHPC-C2-PEG3-BCN | 2876198-36-4 | Reference compound |
| HY-148899 | Mcl-1 inhibitor 10 | 1580484-33-8 | Reference compound |
| HY-148900 | SCFSkp2-IN-2 | 1375060-02-8 | Reference compound |
| HY-148901 | CMB-087229 | 1227692-67-2 | Reference compound |
| HY-148904 | Allylic-SAM | 875155-64-9 | Reference compound |
| HY-148905 | p-Aminophenylmercuric acetate | 6283-24-5 | Biochemical Assay Reagents |
| HY-148906 | Anticancer agent 95 | 853302-91-7 | Reference compound |
| HY-148907 | CS640 | 2388506-83-8 | Reference compound |
| HY-148908 | TNF-α-IN-8 | 444287-85-8 | Reference compound |
| HY-148909 | Isopropyl dodec-11-enylfluorophosphonate | 623114-64-7 | Reference compound |
| HY-14891 | Fosdevirine | 1018450-26-4 | Reference compound |
| HY-148910 | Paromamine | 534-47-4 | Reference compound |
| HY-148913 | CS587 | 2388506-69-0 | Reference compound |
| HY-148918 | E722-2648 | 931963-55-2 | Reference compound |
| HY-148919A | Isopentenyl pyrophosphate (triammonium) | 116057-53-5 | Natural Products |
| HY-148919B | Isopentenyl pyrophosphate (trilithium) | 18687-43-9 | Natural Products |
| HY-14892 | Gemigliptin | 911637-19-9 | Reference compound |
| HY-148921 | SDH-IN-2 | 1823354-06-8 | Reference compound |
| HY-148922 | PPARα/γ agonist 2 | 2213365-56-9 | Reference compound |
| HY-148923 | MC0704 | 3034176-57-0 | Reference compound |
| HY-148925 | α-Amyrenone | 638-96-0 | Natural Products |
| HY-148926 | HSD17B13-IN-1 | 2770246-02-9 | Reference compound |
| HY-14892A | Gemigliptin (tartrate) | 1374639-74-3 | Reference compound |
| HY-148933 | ALKBH5-IN-2 | 1008951-10-7 | Reference compound |
| HY-148937 | Oroselol | 1891-25-4 | Natural Products |
| HY-148939 | MPX-004 | 1688684-07-2 | Reference compound |
| HY-14894 | Ipragliflozin | 761423-87-4 | Reference compound |
| HY-148940 | Docosahexaenoyl glycerol | 140670-40-2 | Reference compound |
| HY-148944 | Didocosahexaenoin | 124538-05-2 | Reference compound |
| HY-148947 | Cy5 Phosphoramidite | 182873-67-2 | Dye Reagents |
| HY-148948 | Nampt activator-3 | 2790481-63-7 | Reference compound |
| HY-148949 | Kallikrein 5-IN-2 | 2361160-57-6 | Reference compound |
| HY-148949A | Kallikrein 5-IN-2 (TFA) | | Reference compound |
| HY-14894A | Ipragliflozin (L-Proline) | 951382-34-6 | Reference compound |
| HY-14894R | Ipragliflozin (Standard) | 761423-87-4 | Reference Standards |
| HY-14894S2 | Pragliflozin-13C6 | 2743031-48-1 | Isotope-Labeled Compounds |
| HY-14895 | Fabomotizole | 173352-21-1 | Reference compound |
| HY-148953 | MTR-106 | 1639357-93-9 | Reference compound |
| HY-148957 | 5-Bromo-2′-deoxy-2′-fluorouridine | 55612-18-5 | Reference compound |
| HY-14895A | Fabomotizole (hydrochloride) | 173352-39-1 | Reference compound |
| HY-14895B | Fabomotizole di(hydrochloride) | 189638-30-0 | Reference compound |
| HY-14895R | Fabomotizole (Standard) | 173352-21-1 | Reference Standards |
| HY-14896 | Opicapone | 923287-50-7 | Reference compound |
| HY-148960 | Bis(diazoacetyl)butane | 1448-16-4 | Reference compound |
| HY-148962 | LY2880070 | 1375637-35-6 | Reference compound |
| HY-148963 | HSP90-IN-20 | 747414-31-9 | Reference compound |
| HY-148964 | Thiotraniliprole | 1442448-92-1 | Reference compound |
| HY-148965S | PtdIns(3)P-d62 (ammonium) | | Isotope-Labeled Compounds |
| HY-148968 | Metham (sodium) | 137-42-8 | Reference compound |
| HY-14896R | Opicapone (Standard) | 923287-50-7 | Reference Standards |
| HY-14897 | Rezatomidine | 847829-38-3 | Reference compound |
| HY-148971A | PtdIns-(345)-P3 (12-dipalmitoyl) (sodium) | 1628353-02-5 | Reference compound |
| HY-148973 | ZW290 | 2411852-67-8 | Reference compound |
| HY-148974 | PLK1-IN-5 | 1001343-34-5 | Reference compound |
| HY-148977 | 18:0,22:6 PS (sodium) | 474943-18-5 | Reference compound |
| HY-148978 | 18:0,18:1 PS (sodium) | 321883-23-2 | Reference compound |
| HY-148978R | 18:0,18:1 PS (sodium) (Standard) | 321883-23-2 | Reference Standards |
| HY-148979 | 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine | 61216-62-4 | Dye Reagents |
| HY-14898 | AGN 210676 | 910562-15-1 | Reference compound |
| HY-148980 | Polyinosinic acid | 30918-54-8 | Reference compound |
| HY-148980A | Polyinosinic acid (sodium) | 33378-44-8 | Reference compound |
| HY-14899 | Taprenepag | 752187-80-7 | Reference compound |
| HY-148992 | APX879 | 1801372-27-9 | Natural Products |
| HY-148994 | Methotrexate-γ-aspartate | 64801-58-7 | Reference compound |
| HY-14900 | Tedalinab | 916591-01-0 | Reference compound |
| HY-149000 | PI3Kα-IN-7 | 2417098-53-2 | Reference compound |
| HY-149001 | PARP1-IN-9 | 2494000-71-2 | Reference compound |
| HY-149002 | Topoisomerase I/II inhibitor 4 | 3031403-77-4 | Reference compound |
| HY-149003 | PARP1-IN-10 | 2494001-21-5 | Reference compound |
| HY-149004 | SLF1081851 | 2763730-97-6 | Reference compound |
| HY-149004A | SLF1081851 (TFA) | 2763730-98-7 | Reference compound |
| HY-149004B | SLF1081851 (hydrochloride) | 2999629-35-3 | Reference compound |
| HY-149005 | PRMT5-IN-19 | 2783961-86-2 | Reference compound |
| HY-149006 | CK156 | 2910938-59-7 | Reference compound |
| HY-149007 | STAT3-IN-11 | 2503096-50-0 | Reference compound |
| HY-149008 | α-Amylase-IN-3 | 93944-58-2 | Reference compound |
| HY-149009 | Bcl-2-IN-9 | 2490542-33-9 | Reference compound |
| HY-14901 | Telapristone | 198414-30-1 | Reference compound |
| HY-149010 | NXPZ-2 | 2254492-08-3 | Reference compound |
| HY-149011 | CA IX-IN-1 | | Reference compound |
| HY-149012 | AChE/hCA I/II-IN-1 | 2049681-10-7 | Reference compound |
| HY-149013 | Anti-MRSA agent 5 | 2490154-44-2 | Reference compound |
| HY-149014 | OX2R-IN-1 | 2639148-08-4 | Reference compound |
| HY-149015 | FTase-IN-1 | 2490538-41-3 | Reference compound |
| HY-149016 | Tubulin polymerization-IN-25 | 2490538-46-8 | Reference compound |
| HY-149017 | Apoptosis inducer 7 | 2252278-57-0 | Reference compound |
| HY-149018 | ATX inhibitor 22 | 2969213-59-8 | Reference compound |
| HY-149019 | Antitumor agent-70 | 2454133-88-9 | Reference compound |
| HY-14902 | Tofogliflozin | 903565-83-3 | Reference compound |
| HY-149020 | Tubulin polymerization-IN-26 | 2490291-68-2 | Reference compound |
| HY-149021 | Tubulin polymerization-IN-28 | 2481404-89-9 | Reference compound |
| HY-149022 | HSV-1/HSV-2-IN-1 | 2490468-31-8 | Reference compound |
| HY-149023 | HSV-1/HSV-2-IN-2 | 2490468-39-6 | Reference compound |
| HY-149024 | VEGFR-2-IN-23 | 2411174-53-1 | Reference compound |
| HY-149025 | DPTIP-prodrug 18 | 2881068-33-1 | Reference compound |
| HY-149026 | GNE-064 | 1997321-20-6 | Reference compound |
| HY-149028 | Mem-C1C18 | | Dye Reagents |
| HY-149029 | TH-6 | 3031349-25-1 | Reference compound |
| HY-14903 | Ulimorelin | 842131-33-3 | Reference compound |
| HY-149030 | DHODH-IN-21 | 2450341-39-4 | Reference compound |
| HY-149031 | DHODH-IN-22 | 2450341-75-8 | Reference compound |
| HY-149032 | Kobusine derivative-1 | | Reference compound |
| HY-149033 | Kobusine derivative-2 | | Reference compound |
| HY-149034 | Influenza A virus-IN-8 | | Peptides |
| HY-149035 | PAA4 | | Reference compound |
| HY-149036 | PAA5 | | Reference compound |
| HY-149037 | GL67 | 179075-30-0 | Biochemical Assay Reagents |
| HY-149037A | GL67 (pentahydrochloride) | | Reference compound |
| HY-149039 | Amine-PEG4-amido-tri-(carboxyethoxymethyl)-methane | 2840751-73-5 | Reference compound |
| HY-14904 | Umifenovir | 131707-25-0 | Reference compound |
| HY-149041 | Coretinphencone | 1631711-77-7 | Natural Products |
| HY-149048 | Adenosylhomocysteinase | 9025-54-1 | Enzyme |
| HY-149049 | Cajaninstilbene acid | 87402-84-4 | Natural Products |
| HY-14904A | Umifenovir (hydrochloride) | 131707-23-8 | Reference compound |
| HY-14904AR | Umifenovir (hydrochloride) (Standard) | 131707-23-8 | Reference Standards |
| HY-14904AS | Umifenovir-d6 (hydrochloride) | 2928218-29-3 | Isotope-Labeled Compounds |
| HY-14904R | Umifenovir (Standard) | 131707-25-0 | Reference Standards |
| HY-14905 | Uridine triacetate | 4105-38-8 | Reference compound |
| HY-149050 | Viral polymerase-IN-1 (hydrochloride) | 2367587-02-6 | Reference compound |
| HY-149051 | BGB-8035 | 2283349-24-4 | Reference compound |
| HY-149052 | SZM-1209 | 2919801-86-6 | Reference compound |
| HY-149053 | OY-101 | 41183-02-2 | Reference compound |
| HY-149053A | (S)-OY-101 | 2924484-79-5 | Reference compound |
| HY-149053B | (R)-OY-101 | 23495-82-1 | Reference compound |
| HY-149054 | GSK-3β inhibitor 13 | 2227316-74-5 | Reference compound |
| HY-149055 | ACT-777991 | 1967811-46-6 | Reference compound |
| HY-149056 | GNE-6893 | 2415374-98-8 | Reference compound |
| HY-149056A | (3S,4R)-GNE-6893 | 2415374-97-7 | Reference compound |
| HY-149057 | Neuraminidase-IN-12 | 2218480-15-8 | Reference compound |
| HY-149058 | Neuraminidase-IN-13 | 2222067-23-2 | Reference compound |
| HY-149059 | Neuraminidase-IN-14 | | Reference compound |
| HY-149060 | Neuraminidase-IN-15 | | Reference compound |
| HY-149061 | Anticancer agent 99 | 2914922-83-9 | Reference compound |
| HY-149062 | Anticancer agent 102 | 2914922-86-2 | Reference compound |
| HY-149063 | Antitumor agent-92 | 2922842-01-9 | Reference compound |
| HY-149064 | Antituberculosis agent-9 | 2998587-72-5 | Reference compound |
| HY-149065 | D-685 | 2893801-00-6 | Reference compound |
| HY-149067 | Antifungal agent 47 | 2719867-46-4 | Reference compound |
| HY-149068 | TSC24 | | Reference compound |
| HY-149069 | TSC25 | | Reference compound |
| HY-14907 | Verubulin | 827031-83-4 | Reference compound |
| HY-149070 | 3′-Azido-2′,3′-dideoxy-5-hydroxyuridine | 111495-90-0 | Oligonucleotides |
| HY-149071 | TLR7 agonist 10 | 2389988-34-3 | Reference compound |
| HY-149072 | TLR7 agonist 11 | 2389988-36-5 | Reference compound |
| HY-149073 | TSC26 | | Reference compound |
| HY-149075 | MR22 | 3027761-24-3 | Reference compound |
| HY-149076 | hGAPDH-IN-1 | | Reference compound |
| HY-149077 | 2′-Deoxy-5-methoxyuridine | 37805-95-1 | Reference compound |
| HY-149078 | Antiparasitic agent-14 | | Reference compound |
| HY-149079 | Antiparasitic agent-15 | | Reference compound |
| HY-14908 | Vidofludimus | 717824-30-1 | Reference compound |
| HY-149080 | Antiparasitic agent-16 | | Reference compound |
| HY-149081 | ERα degrader 6 | 2775441-10-4 | Reference compound |
| HY-149082 | LTB4 antagonist 1 | 2929239-84-7 | Reference compound |
| HY-149083 | LTB4 antagonist 2 | 2929239-85-8 | Reference compound |
| HY-149084 | LTB4 antagonist 3 | 2929239-87-0 | Reference compound |
| HY-149085 | XS-060 | 346721-50-4 | Reference compound |
| HY-149085A | (E)-XS-060 | 2787626-06-4 | Reference compound |
| HY-149086 | BPA-B9 | | Reference compound |
| HY-149087 | MR2938 | 1044870-65-6 | Reference compound |
| HY-149088 | Neuraminidase-IN-16 | | Reference compound |
| HY-149089 | Antibacterial agent 138 | | Reference compound |
| HY-14908A | Vidofludimus (hemicalcium) | 1354012-90-0 | Reference compound |
| HY-14909 | Bardoxolone | 218600-44-3 | Reference compound |
| HY-149090 | AChE/BuChE/MAO-B-IN-2 | | Reference compound |
| HY-149091 | KDM5B-IN-4 | | Reference compound |
| HY-149092 | Anticancer agent 109 | 2097497-16-8 | Reference compound |
| HY-149093 | Antileishmanial agent-14 | 1638956-72-5 | Reference compound |
| HY-149094 | Neuroprotective agent 1 | 2344786-13-4 | Reference compound |
| HY-149095 | Antibacterial agent 139 | | Reference compound |
| HY-149096 | CCR7 antagonist 1 | | Reference compound |
| HY-149097 | ITH12711 | 3042876-07-0 | Reference compound |
| HY-149098 | SJ1461 | 2924546-70-1 | Reference compound |
| HY-149099 | RET-IN-22 | 2918281-79-3 | Reference compound |
| HY-149100 | PLK1-IN-6 | | Reference compound |
| HY-149101 | Riboxin | 86-04-4 | Reference compound |
| HY-149102 | LE 28 | 1416080-97-1 | Dye Reagents |
| HY-149105 | FSH receptor antagonist 1 | 487064-35-7 | Reference compound |
| HY-149117 | AF430 NHS ester | 467233-94-9 | Dye Reagents |
| HY-149120 | ASM-IN-1 | 2913151-46-7 | Reference compound |
| HY-149121 | NLRP3-IN-14 | 2767369-80-0 | Reference compound |
| HY-149122 | NLRP3-IN-15 | 2767369-71-9 | Reference compound |
| HY-149123 | NLRP3-IN-16 | 2906872-59-9 | Reference compound |
| HY-149125 | Globotriaosylceramide (porcine RBC) | 71965-57-6 | Natural Products |
| HY-149127 | Rosolutamide | 1039760-91-2 | Reference compound |
| HY-14913 | Apricitabine | 160707-69-7 | Reference compound |
| HY-149132 | Dendrogenin A | 1191043-85-2 | Biochemical Assay Reagents |
| HY-149136 | MORF-627 | 2412688-16-3 | Reference compound |
| HY-14914 | Azilsartan | 147403-03-0 | Reference compound |
| HY-149143 | JNJ-28583113 | 2765255-93-2 | Reference compound |
| HY-149145 | Ena15 | 956935-02-7 | Reference compound |
| HY-149149 | Incadronic acid | 124351-85-5 | Reference compound |
| HY-14914R | Azilsartan (Standard) | 147403-03-0 | Reference Standards |
| HY-14914S | Azilsartan-d5 | 1346599-45-8 | Isotope-Labeled Compounds |
| HY-14914S1 | Azilsartan-d4 | 1794817-45-0 | Isotope-Labeled Compounds |
| HY-14915 | Bedoradrine | 194785-19-8 | Reference compound |
| HY-149152 | PtdIns-(4,5)-P2 (1,2-dioctanoyl) | 204858-53-7 | Reference compound |
| HY-149154 | (4S,5S,6S,12aS)-Oxytetracycline | 423769-22-6 | Reference compound |
| HY-149155 | o-Cymen-5-ol | 39660-61-2 | Reference compound |
| HY-149156 | Lipid C24 | 2767561-52-2 | Biochemical Assay Reagents |
| HY-149157 | L-Lysine (orotate) | 28003-86-3 | Natural Products |
| HY-14915A | Bedoradrine (sulfate) | 194785-31-4 | Reference compound |
| HY-14916 | Camobucol | 216167-92-9 | Reference compound |
| HY-149160 | 5′-Amino-5′-deoxythymidine | 25152-20-9 | Oligonucleotides |
| HY-149164 | BTB09089 | 245728-44-3 | Reference compound |
| HY-149165 | Glucocorticoid receptor modulator 2 | 2452396-89-1 | Reference compound |
| HY-149167 | ATX-0126 | 2230647-37-5 | Oligonucleotides |
| HY-149169 | Phevamine A | 2280874-34-0 | Natural Products |
| HY-14917 | Capadenoson | 544417-40-5 | Reference compound |
| HY-149170 | FFN246 | 2210244-83-8 | Dye Reagents |
| HY-149173 | CDK-IN-11 | 2376876-87-6 | Reference compound |
| HY-149179 | Polymyxin B | 1404-26-8 | Reference compound |
| HY-149182 | Lucifer yellow iodoacetamide (dipotassium) | 176182-05-1 | Dye Reagents |
| HY-14919 | Denibulin | 284019-34-7 | Reference compound |
| HY-149190 | GPR35 agonist 5 | 2226201-24-5 | Reference compound |
| HY-149199 | Sulfosate | 81591-81-3 | Reference compound |
| HY-14919A | Denibulin (hydrochloride) | 779356-64-8 | Reference compound |
| HY-14920 | Dexelvucitabine | 134379-77-4 | Reference compound |
| HY-149200 | Lysine-methotrexate | 80407-56-3 | Reference compound |
| HY-149202 | UT-11 | | Reference compound |
| HY-149203 | MQA-P | | Dye Reagents |
| HY-149203A | MQA-P (TFA) | | Dye Reagents |
| HY-149204 | SYNTi | | Reference compound |
| HY-149205 | CXJ-2 | 2919976-92-2 | Reference compound |
| HY-149206 | HPK1-IN-33 | 2920000-86-6 | Reference compound |
| HY-149207 | Tyrosinase-IN-11 | 240797-64-2 | Reference compound |
| HY-149208 | HDAC-IN-53 | 2921948-27-6 | Reference compound |
| HY-149209 | LL-K8-22 | | Reference compound |
| HY-14921 | Elsibucol | 216167-95-2 | Reference compound |
| HY-149210 | S1PR1 Radioligand 1 | 2845249-11-6 | Reference compound |
| HY-149211 | AChE/BChE-IN-12 | | Reference compound |
| HY-149212 | SD-6 | 744206-31-3 | Reference compound |
| HY-149213 | LSD1-IN-24 | 4734-59-2 | Reference compound |
| HY-149214 | Anticancer agent 100 | 2914922-73-7 | Reference compound |
| HY-149215 | Anticancer agent 101 | 2914922-80-6 | Reference compound |
| HY-149216 | Anticancer agent 103 | 2914922-78-2 | Reference compound |
| HY-149217 | Antiviral agent 27 | 2270947-36-7 | Reference compound |
| HY-149218 | THR-β agonist 6 | 2791290-58-7 | Reference compound |
| HY-149219 | BIBD-124 | 2716871-93-9 | Reference compound |
| HY-14922 | Fosalvudine tidoxil | 763903-67-9 | Reference compound |
| HY-149220 | 5'-Protected 2,2'-anhydrouridine | 173170-12-2 | Oligonucleotides |
| HY-149221 | Apoptosis inducer 11 | | Reference compound |
| HY-149222 | Apoptosis inducer 12 | 1971096-01-1 | Reference compound |
| HY-149223 | FtsZ-IN-5 | | Reference compound |
| HY-149224 | FtsZ-IN-6 | | Reference compound |
| HY-149225 | FtsZ-IN-7 | | Reference compound |
| HY-149226 | FtsZ-IN-8 | | Reference compound |
| HY-149227 | IDO1-IN-21 | 2892432-98-1 | Reference compound |
| HY-149228 | USP28-IN-2 | 2931509-11-2 | Reference compound |
| HY-149229 | USP28-IN-3 | 2931509-14-5 | Reference compound |
| HY-14923 | Ilepatril | 473289-62-2 | Reference compound |
| HY-149230 | USP28-IN-4 | 2931509-15-6 | Reference compound |
| HY-149231 | Anticancer agent 104 | 3047612-51-8 | Reference compound |
| HY-149232 | HPK1-IN-35 | 2935903-77-6 | Reference compound |
| HY-149233 | hAChE-IN-1 | | Reference compound |
| HY-149234 | MAO-B-IN-18 | | Reference compound |
| HY-149235 | PI3Kδ-IN-12 | | Reference compound |
| HY-149236 | PROTAC GPX4 degrader-1 | 2916433-81-1 | Reference compound |
| HY-149237 | hAChE-IN-2 | | Reference compound |
| HY-149238 | Topo II/HDAC-IN-1 | 2922269-18-7 | Reference compound |
| HY-149239 | Topo II/HDAC-IN-2 | 2922269-24-5 | Reference compound |
| HY-14924 | Inakalant | 335619-18-6 | Reference compound |
| HY-149240 | Anticancer agent 108 | | Reference compound |
| HY-149241 | SHP2-IN-13 | 2951854-02-5 | Reference compound |
| HY-149242 | MAO-B-IN-20 | | Reference compound |
| HY-149243 | BChE-IN-16 | | Reference compound |
| HY-149244 | Nrf2 activator-7 | 2456295-39-7 | Reference compound |
| HY-149245 | Keap1-Nrf2-IN-15 | 2456295-45-5 | Reference compound |
| HY-149246 | Aβ-IN-6 | | Reference compound |
| HY-149247 | Antipsychotic agent-2 | | Reference compound |
| HY-149248 | NF-κB-IN-8 | 2924565-59-1 | Reference compound |
| HY-149249 | MY-943 | | Reference compound |
| HY-14925 | Lapaquistat | 189059-71-0 | Reference compound |
| HY-149250 | MDMX/MDM2-IN-2 | 3043723-74-3 | Reference compound |
| HY-149251 | DENV-IN-10 | | Reference compound |
| HY-149252 | Tubulin inhibitor 32 | 2923531-39-7 | Reference compound |
| HY-149253 | OY-201 | 2962943-05-9 | Reference compound |
| HY-149254 | PTP1B/AKR1B1-IN-1 | | Reference compound |
| HY-149255 | PTP1B/AKR1B1-IN-2 | | Reference compound |
| HY-149256 | PLpro/RBD-IN-1 | 1282451-83-5 | Reference compound |
| HY-149257 | HAT-SIL-TG-1&AT | 2973282-50-5 | Reference compound |
| HY-149258 | KWCN-41 | 2913223-17-1 | Reference compound |
| HY-149259 | FAK-IN-9 | 2911655-93-9 | Reference compound |
| HY-14926 | Levonadifloxacin | 154357-42-3 | Reference compound |
| HY-149260 | HIF-1 inhibitor-5 | | Reference compound |
| HY-149261 | H1k | | Reference compound |
| HY-149262 | CLK1-IN-3 | 2922550-28-3 | Reference compound |
| HY-149263 | HAA-09 | 1422051-33-9 | Reference compound |
| HY-149264 | SARS-CoV-2 3CLpro-IN-13 | 622794-09-6 | Reference compound |
| HY-149265 | ROS-generating agent 1 | 2369030-41-9 | Reference compound |
| HY-149266 | THK01 | 2226941-26-8 | Reference compound |
| HY-149267 | STING agonist-30 | 2951078-67-2 | Reference compound |
| HY-149268 | JNK3 inhibitor-6 | | Reference compound |
| HY-149269 | COX-2-IN-30 | 1160498-08-7 | Reference compound |
| HY-14926A | Levonadifloxacin (arginine) (hydrate) | 627891-34-3 | Reference compound |
| HY-14926B | Levonadifloxacin (arginine) | 306748-89-0 | Reference compound |
| HY-14926R | Levonadifloxacin (Standard) | 154357-42-3 | Reference Standards |
| HY-14927 | Lificiguat | 170632-47-0 | Reference compound |
| HY-149270 | COX-2-IN-31 | | Reference compound |
| HY-149271 | Anti-MRSA agent 7 | | Reference compound |
| HY-149272 | tau/Aβ40 aggregation-IN-1 | 2973377-10-3 | Reference compound |
| HY-149273 | hBChE-IN-1 | 1776948-12-9 | Reference compound |
| HY-149274 | Sigma-1 receptor antagonist 4 | | Reference compound |
| HY-149275 | PKM2/PDK1-IN-1 | 3041957-90-5 | Reference compound |
| HY-149276 | SLC26A3-IN-2 | 950348-60-4 | Reference compound |
| HY-149277 | FM04 | 1807320-40-6 | Reference compound |
| HY-149278 | Complement C1s-IN-1 | 3033831-40-9 | Reference compound |
| HY-149279 | JNK3 inhibitor-7 | 3034676-52-0 | Reference compound |
| HY-14928 | Lobeglitazone | 607723-33-1 | Reference compound |
| HY-149280 | JNK3 inhibitor-8 | 3034676-53-1 | Reference compound |
| HY-149281 | IL-1β-IN-1 | 2780364-50-1 | Reference compound |
| HY-149282 | IL-1β-IN-2 | 2242896-76-8 | Reference compound |
| HY-149283 | JAK/HDAC-IN-2 | 3029138-43-7 | Reference compound |
| HY-149284 | JAK/HDAC-IN-3 | 3029138-70-0 | Reference compound |
| HY-149285 | NT160 | 1418293-40-9 | Reference compound |
| HY-149286 | Antibacterial agent 142 | 3037009-24-5 | Reference compound |
| HY-149287 | hAChE/hBACE-1-IN-1 | | Reference compound |
| HY-149288 | hAChE/hBACE-1-IN-2 | | Reference compound |
| HY-149289 | DNMT-IN-3 | 1683516-27-9 | Reference compound |
| HY-14928A | Lobeglitazone (sulfate) | 763108-62-9 | Reference compound |
| HY-14928S1 | Lobeglitazone-d4 | | Isotope-Labeled Compounds |
| HY-14929 | Migalastat | 108147-54-2 | Reference compound |
| HY-149290 | AMX12006 | 2639775-01-0 | Reference compound |
| HY-149291 | ATM Inhibitor-7 | 3033712-80-7 | Reference compound |
| HY-149292 | SR-4133 | 2999645-23-5 | Reference compound |
| HY-149294 | DNA Gyrase-IN-8 | 2925308-76-3 | Reference compound |
| HY-149295 | PROTAC ERα Degrader-4 | 2521299-80-7 | Reference compound |
| HY-149296 | JAK1-IN-12 | 2945204-95-3 | Reference compound |
| HY-149297 | PSMA-IN-1 | | Reference compound |
| HY-149298 | PSMA-IN-2 | 2946600-14-0 | Reference compound |
| HY-149299 | PYZ18 | 1447578-01-9 | Reference compound |
| HY-14929A | Migalastat (hydrochloride) | 75172-81-5 | Reference compound |
| HY-14930 | Mirodenafil | 862189-95-5 | Reference compound |
| HY-149300 | SB-1436 | 2925298-08-2 | Reference compound |
| HY-149301 | hCAIX-IN-18 | 2925261-76-1 | Reference compound |
| HY-149302 | MC4033 | 28532-21-0 | Reference compound |
| HY-149303 | Potassium tert-butoxide | 865-47-4 | Biochemical Assay Reagents |
| HY-149304 | SARS-CoV-2-IN-40 | 2984557-53-9 | Reference compound |
| HY-149305 | PptT-IN-4 | 2948309-57-5 | Reference compound |
| HY-149306 | MS78 | 3034773-00-4 | Reference compound |
| HY-149307 | CYCA-117-70 | 1958262-04-8 | Reference compound |
| HY-149308 | MKA031 | 2951012-00-1 | Reference compound |
| HY-149309 | Topoisomerase inhibitor 2 | 2713986-17-3 | Reference compound |
| HY-14930A | Mirodenafil (dihydrochloride) | 862189-96-6 | Reference compound |
| HY-14931 | Naproxcinod | 163133-43-5 | Reference compound |
| HY-149310 | Dim16 | 2743448-32-8 | Reference compound |
| HY-149311 | PPO-IN-2 | 1879036-88-0 | Reference compound |
| HY-149312 | PPO-IN-3 | 1879036-82-4 | Reference compound |
| HY-149313 | α‑Amylase-IN-1 | 148404-10-8 | Reference compound |
| HY-149314 | SARS-CoV-2-IN-47 | | Reference compound |
| HY-149315 | SARS-CoV-2-IN-48 | | Reference compound |
| HY-149316 | Smurf1-IN-1 | 1824708-03-3 | Reference compound |
| HY-149317 | ZINC475239213 | 2871002-89-8 | Reference compound |
| HY-149318 | VRT-534 | 926664-32-6 | Reference compound |
| HY-149319 | ZINC61142882 | 3034181-87-5 | Reference compound |
| HY-14932 | Pafuramidine | 186953-56-0 | Reference compound |
| HY-149320 | Acryl42-10 | | Reference compound |
| HY-149321 | SARS-CoV-2 nsp14-IN-3 | 2920574-16-7 | Reference compound |
| HY-149322 | Z795161988 | 3034181-88-6 | Reference compound |
| HY-149323 | SDH-IN-4 | 2982993-88-2 | Reference compound |
| HY-149324 | SP27 | 3034805-75-6 | Reference compound |
| HY-149325 | RPE65-IN-1 | 1141779-07-8 | Reference compound |
| HY-149327 | Anticancer agent 131 | 2864443-47-8 | Reference compound |
| HY-149328 | phoBET1 | 3033545-34-2 | Reference compound |
| HY-149329 | hCAIX/VII-IN-1 | 2990559-21-0 | Reference compound |
| HY-14932A | Pafuramidine (maleate) | 837369-26-3 | Reference compound |
| HY-14932R | Pafuramidine (Standard) | 186953-56-0 | Reference Standards |
| HY-14933 | Prinaberel | 524684-52-4 | Reference compound |
| HY-149330 | HA5 | 2378406-17-6 | Reference compound |
| HY-149331 | TNF-α-IN-11 | 2945197-77-1 | Reference compound |
| HY-149332 | α-Glucosidase-IN-26 | | Reference compound |
| HY-149333 | BO-1 | | Reference compound |
| HY-149334 | ZLD115 | 2980653-93-6 | Reference compound |
| HY-149335 | Sigma-1 receptor antagonist 5 | 2952808-33-0 | Reference compound |
| HY-149336 | D1R antagonist 1 | 2983777-67-7 | Reference compound |
| HY-149337 | D3R ligand 1 | 2983777-91-7 | Reference compound |
| HY-149338 | NNRT-IN-3 | | Reference compound |
| HY-149339 | hnNOS-IN-2 | 2700326-00-5 | Reference compound |
| HY-14934 | Rosabulin | 501948-05-6 | Reference compound |
| HY-149340 | PD07 | | Reference compound |
| HY-149341 | α-Glucosidase-IN-28 | 2949513-10-2 | Reference compound |
| HY-149342 | α-Glucosidase-IN-29 | 2949513-11-3 | Reference compound |
| HY-149343 | Anticancer agent 132 | | Reference compound |
| HY-149344 | Anticancer agent 133 | 2758905-51-8 | Reference compound |
| HY-149345 | IRAK4-IN-24 | 2952533-54-7 | Reference compound |
| HY-149346 | Mtb-IN-2 | 2861190-30-7 | Reference compound |
| HY-149347 | Mtb-IN-3 | 3052302-61-8 | Reference compound |
| HY-149348 | DiPT-4 | 3052259-89-6 | Reference compound |
| HY-149349 | MtUng-IN-1 | 359826-99-6 | Reference compound |
| HY-14935 | Sodelglitazar | 447406-78-2 | Reference compound |
| HY-149350 | HIV-1 inhibitor-57 | 2745197-24-2 | Reference compound |
| HY-149351 | NF-κB-IN-10 | 3052257-09-4 | Reference compound |
| HY-149352 | DG1 | | Reference compound |
| HY-149353 | Antibacterial agent 145 | | Reference compound |
| HY-149354 | Aurora kinase-IN-4 | 2877011-84-0 | Reference compound |
| HY-149355 | COX-2-IN-33 | 3049405-60-6 | Reference compound |
| HY-149356 | PD-1/PD-L1-IN-31 | 3049472-36-5 | Reference compound |
| HY-149357 | Yhhu6669 | 2569526-80-1 | Reference compound |
| HY-149358 | NK3R-IN-1 | 2854331-14-7 | Reference compound |
| HY-149359 | IHMT-IDH1-053 | 3049485-80-2 | Reference compound |
| HY-14936 | Sofigatran | 187602-11-5 | Reference compound |
| HY-149360 | P-gb-IN-1 | 2632874-49-6 | Reference compound |
| HY-149361 | VEGFR2-IN-4 | 3049398-38-8 | Reference compound |
| HY-149362 | MTase-IN-1 | | Reference compound |
| HY-149363 | Tubulin polymerization-IN-43 | 2773345-90-5 | Reference compound |
| HY-149364 | Tubulin inhibitor 34 | 3048497-78-2 | Reference compound |
| HY-149365 | SIKs-IN-1 | 2927557-06-8 | Reference compound |
| HY-149366 | ABCB1-IN-1 | 2986412-70-6 | Reference compound |
| HY-149367 | Anticancer agent 136 | 3049419-74-8 | Reference compound |
| HY-149368 | SARS-CoV-2-IN-51 | 3049478-88-5 | Reference compound |
| HY-149369 | HDAC-IN-59 | 2944459-43-0 | Reference compound |
| HY-14937 | Succinobucol | 216167-82-7 | Reference compound |
| HY-149370 | HDAC-IN-60 | 2944459-58-7 | Reference compound |
| HY-149371 | HDAC6-IN-16 | | Reference compound |
| HY-149372 | HDAC6-IN-17 | | Reference compound |
| HY-149373 | Garcinone B | 76996-28-6 | Natural Products |
| HY-149374 | Tubulin inhibitor 36 | | Reference compound |
| HY-149375 | Tubulin inhibitor 37 | | Reference compound |
| HY-149376 | Tubulin inhibitor 38 | | Reference compound |
| HY-149377 | MMP13-IN-4 | 514855-02-8 | Reference compound |
| HY-149378 | MMP13-IN-5 | | Reference compound |
| HY-149379 | DNA gyrase B-IN-3 | 2412834-56-9 | Reference compound |
| HY-14938 | Tipelukast | 125961-82-2 | Reference compound |
| HY-149380 | Vem-L-Cy5 | | Reference compound |
| HY-149386 | D3R/MOR antagonist 1 | 3033883-15-4 | Reference compound |
| HY-149387 | D3R/MOR antagonist 2 | 3033883-17-6 | Reference compound |
| HY-149388 | Anticancer agent 139 | 2954795-29-8 | Reference compound |
| HY-149389 | PNMT-IN-1 | | Reference compound |
| HY-14939 | Vapitadine | 793655-64-8 | Reference compound |
| HY-149390 | TrxR1-IN-1 | 3052303-04-2 | Reference compound |
| HY-149391 | PROTAC BTK Degrader-6 | 2767204-39-5 | Reference compound |
| HY-149392 | HBV-IN-35 | | Reference compound |
| HY-149393 | RIPK3-IN-3 | 3052303-53-1 | Reference compound |
| HY-149394 | PRDX1-IN-1 | | Reference compound |
| HY-149395 | MmpL3-IN-3 | 1639438-67-7 | Reference compound |
| HY-149396 | FXIIa-IN-1 | 3052551-19-3 | Reference compound |
| HY-149397 | FXIIa-IN-2 | 3052551-17-1 | Reference compound |
| HY-149398 | PARP-1/2-IN-2 | 3052304-23-8 | Reference compound |
| HY-149399 | GABA-IN-1 | | Reference compound |
| HY-14939A | Vapitadine (hydrochloride) | 279253-83-7 | Reference compound |
| HY-14940 | Volinanserin | 139290-65-6 | Reference compound |
| HY-149400 | GABA-IN-2 | 2363715-13-1 | Reference compound |
| HY-149401 | EGFR-IN-82 | 2568086-81-5 | Reference compound |
| HY-149402 | hCA XII-IN-6 | | Reference compound |
| HY-149403 | J-1048 | 2374772-60-6 | Reference compound |
| HY-149404 | Tyrosinase-IN-12 | 1860779-42-5 | Reference compound |
| HY-149405 | Squalene synthase-IN-1 | | Reference compound |
| HY-149406 | AMPK activator 12 | 431920-24-0 | Reference compound |
| HY-149407 | Multi-kinase-IN-4 | | Reference compound |
| HY-149408 | MAOA-IN-1 | | Reference compound |
| HY-149409 | α-Glucosidase-IN-31 | | Reference compound |
| HY-14940A | (S)-Volinanserin | 175673-57-1 | Reference compound |
| HY-14940S | Volinanserin-d4 (hydrochloride) | 1217617-73-6 | Isotope-Labeled Compounds |
| HY-14941 | Elacytarabine | 188181-42-2 | Reference compound |
| HY-149410 | MSN8C | 1314798-31-6 | Reference compound |
| HY-149412 | MHJ-627 | | Reference compound |
| HY-149413 | FHND5071 | 2761152-16-1 | Isotope-Labeled Compounds |
| HY-149414 | MY-673 | 2944459-96-3 | Reference compound |
| HY-149415 | Multi-kinase-IN-5 | | Reference compound |
| HY-149416 | Mal-PEG8-Val-Ala-PAB-SB-743921 | | ADC Related |
| HY-149417 | BChE/HDAC6-IN-1 | 2925457-27-6 | Reference compound |
| HY-149418 | BChE/HDAC6-IN-2 | 2925457-33-4 | Reference compound |
| HY-149419 | GST-IN-1 | 2987870-87-9 | Reference compound |
| HY-14942 | Berubicin | 677017-23-1 | Reference compound |
| HY-149420 | BRD7-IN-2 | 3032601-06-9 | Reference compound |
| HY-149421 | BRD7-IN-3 | 3032601-04-7 | Reference compound |
| HY-149422 | NIR-FP | | Dye Reagents |
| HY-149423 | PI5P4K-β-IN-1 | 332407-28-0 | Reference compound |
| HY-149424 | PI5P4K-β-IN-2 | | Reference compound |
| HY-149425 | SIRT5 inhibitor 6 | 2834736-82-0 | Reference compound |
| HY-149426 | SIRT5 inhibitor 7 | 2951090-00-7 | Reference compound |
| HY-149427 | PI3Kα-IN-12 | 2966861-50-5 | Reference compound |
| HY-149428 | AD4 | 2918262-09-4 | Reference compound |
| HY-149429 | PPARδ agonist 9 | 928023-21-6 | Reference compound |
| HY-14942A | Berubicin (hydrochloride) | 293736-67-1 | Reference compound |
| HY-14943 | Darinaparsin | 69819-86-9 | Reference compound |
| HY-149430 | YIAD-0205 | 2446054-34-6 | Reference compound |
| HY-149431 | NDNA4 | | Reference compound |
| HY-149432 | NDNA3 | | Reference compound |
| HY-149433 | BWA-522 | 3042820-12-9 | Reference compound |
| HY-149434 | PROTAC AR-NTD degrader 1 | 3032601-92-3 | Reference compound |
| HY-149435 | HBV-IN-36 | | Reference compound |
| HY-149436 | CDK2/Bcl2-IN-1 | | Reference compound |
| HY-149439 | COH1 | 20217-22-5 | Reference compound |
| HY-14944 | Homoharringtonine | 26833-87-4 | Natural Products |
| HY-149442 | APE1-IN-3 | 1227098-30-7 | Reference compound |
| HY-149448 | Poly-γ-benzyl-L-glutamate (MW 150000-350000) | 25014-27-1 | Biochemical Assay Reagents |
| HY-149449 | Poly-L-γ-glutamic acid (sodium) | 208106-41-6 | Biochemical Assay Reagents |
| HY-14944R | Homoharringtonine (Standard) | 26833-87-4 | Reference Standards |
| HY-14945 | Remogliflozin etabonate | 442201-24-3 | Reference compound |
| HY-149450 | Aflastatin A | 179729-59-0 | Natural Products |
| HY-149451 | SYHA1815 | 2760195-67-1 | Reference compound |
| HY-149452 | SJ1008066 | 2758867-71-7 | Reference compound |
| HY-149453 | MCUF-651 | 2747162-85-0 | Reference compound |
| HY-149454 | P2Y1/P2Y12 antagonist-1 | 2738381-94-5 | Reference compound |
| HY-149455 | GPX4-IN-8 | 2703776-20-7 | Reference compound |
| HY-149458 | FHT-2344 | 2468058-90-2 | Reference compound |
| HY-149459A | Phototrexate | 2268033-83-4 | Reference compound |
| HY-14946 | Amifampridine | 54-96-6 | Reference compound |
| HY-149460 | Harmaline analog | 2411677-02-4 | Reference compound |
| HY-149461 | KB-05 | 1956368-15-2 | Reference compound |
| HY-149462 | KN1022 | 205255-11-4 | Reference compound |
| HY-149463 | EZH2-IN-16 | 2238820-26-1 | Reference compound |
| HY-149464 | ARN22089 | 2248691-29-2 | Reference compound |
| HY-149468 | Antiviral agent 38 | 2247932-38-1 | Reference compound |
| HY-149469 | 3,7,2',4'-Tetramethoxy-5-hydroxyflavone | 19056-75-8 | Natural Products |
| HY-14946A | Amifampridine (phosphate) | 446254-47-3 | Reference compound |
| HY-14946R | Amifampridine (Standard) | 54-96-6 | Reference Standards |
| HY-14946S | Amifampridine-d3 | 2732980-95-7 | Isotope-Labeled Compounds |
| HY-14947 | Balamapimod | 863029-99-6 | Reference compound |
| HY-149470 | MOZ-IN-3 | | Reference compound |
| HY-149471 | hTYR/AbTYR-IN-1 | 1625821-37-5 | Reference compound |
| HY-149472 | Anti-osteoporosis agent-4 | | Reference compound |
| HY-149473 | AChE-IN-39 | | Reference compound |
| HY-149474 | HDAC-IN-63 | 2920046-95-1 | Reference compound |
| HY-149475 | VEGFR-2-IN-33 | | Reference compound |
| HY-149476 | 5-LOX-IN-5 | | Reference compound |
| HY-149477 | IHC3 | | Reference compound |
| HY-149478 | JT002 | 2238820-43-2 | Reference compound |
| HY-149479 | Quorum sensing-IN-3 | 5005-14-1 | Reference compound |
| HY-14948 | Carisbamate | 194085-75-1 | Reference compound |
| HY-149480 | ERD-3111 | 2832865-25-3 | Reference compound |
| HY-149481 | D4R agonist-1 | "2826198-44-9
" | Reference compound |
| HY-149482 | LN5P45 | | Reference compound |
| HY-149483 | CVN417 | 2919851-73-1 | Reference compound |
| HY-149484 | AChE/BChE-IN-15 | | Reference compound |
| HY-149485 | JNK2-IN-1 | 2998941-15-2 | Reference compound |
| HY-149486 | FGFR1 inhibitor 7 | | Reference compound |
| HY-149487 | FGFR1 inhibitor-8 | | Reference compound |
| HY-149488 | FGFR1 inhibitor-9 | | Reference compound |
| HY-149489 | JH-131e-153 | 742104-91-2 | Reference compound |
| HY-14948A | (R)-Carisbamate | 194085-74-0 | Reference compound |
| HY-14948S | Carisbamate-d4 | 1292841-50-9 | Isotope-Labeled Compounds |
| HY-14948S1 | (R)-Carisbamate-d4 | 1287128-99-7 | Isotope-Labeled Compounds |
| HY-14948S2 | (Rac)-Carisbamate-d4 | 1329808-36-7 | Isotope-Labeled Compounds |
| HY-14949 | Cevipabulin | 849550-05-6 | Reference compound |
| HY-149490 | AJH-836 | 388621-67-8 | Reference compound |
| HY-149491 | HIV-IN-7 | 3032472-86-6 | Natural Products |
| HY-149492 | Phosphatase-IN-1 | 2889356-55-0 | Reference compound |
| HY-149493 | IHMT-PI3K-455 | 3047746-40-4 | Reference compound |
| HY-149495 | CP-07 | | Reference compound |
| HY-149496 | Akt/NF-κB/MAPK-IN-1 | | Reference compound |
| HY-149497 | HDAC6-IN-19 | | Reference compound |
| HY-149498 | Carbonic anhydrase inhibitor 15 | | Reference compound |
| HY-14949C | Cevipabulin fumarate | 849550-67-0 | Reference compound |
| HY-14950 | Dalcetrapib | 211513-37-0 | Reference compound |
| HY-149500 | CITFA | 2379989-52-1 | Reference compound |
| HY-149503 | 4-Hydroxy nebivolol (hydrochloride) | 2717115-85-8 | Reference compound |
| HY-149504 | 3-Hydroxy darifenacin | 206048-82-0 | Reference compound |
| HY-149505 | (±)-10-Hydroxy-12(Z),15(Z)-octadecadienoic acid | 34932-14-4 | Reference compound |
| HY-149506 | 1,3-Didecanoylglycerol | 17598-93-5 | Reference compound |
| HY-149507 | 1,3-Capryloyl-2-oleoylglycerol | 109796-58-9 | Reference compound |
| HY-149508 | Nrf2-IN-3 | 6325-13-9 | Reference compound |
| HY-149509 | α-Synuclein inhibitor 9 | 1510825-03-2 | Reference compound |
| HY-14951 | Firategrast | 402567-16-2 | Reference compound |
| HY-149510 | MET/PDGFRA-IN-1 | | Reference compound |
| HY-149511 | MET/PDGFRA-IN-2 | | Reference compound |
| HY-149512 | FGFR1/VEGFR2-IN-1 | | Reference compound |
| HY-149513 | EP12 | 2882916-73-4 | Reference compound |
| HY-149514 | BC-05 | 2260717-73-3 | Reference compound |
| HY-149515 | MAO-IN-3 | 797805-26-6 | Reference compound |
| HY-149516 | Human enteropeptidase-IN-3 | 1958037-36-9 | Reference compound |
| HY-149517 | EGFR/BRAFV600E-IN-2 | | Reference compound |
| HY-149518 | EGFR/BRAFV600E-IN-3 | | Reference compound |
| HY-149519 | BRD4 Inhibitor-28 | 2468960-80-5 | Reference compound |
| HY-14952 | Giripladib | 865200-20-0 | Reference compound |
| HY-149520 | HPK1-IN-39 | | Reference compound |
| HY-149521 | PI3K-IN-47 | | Reference compound |
| HY-149522 | WK499 | | Reference compound |
| HY-149523 | Anticancer agent 157 | | Reference compound |
| HY-149524 | SIRT5 inhibitor 8 | | Reference compound |
| HY-149525 | SIRT5 inhibitor 9 | | Reference compound |
| HY-149526 | cGAS-IN-1 | 858770-07-7 | Reference compound |
| HY-149527 | MAO-B-IN-23 | 2107978-22-1 | Reference compound |
| HY-149528 | MAO-B-IN-24 | | Reference compound |
| HY-149529 | HDAC8-IN-5 | | Reference compound |
| HY-14953 | Imepitoin | 188116-07-6 | Reference compound |
| HY-149530 | EGFR-IN-86 | 3055550-22-3 | Reference compound |
| HY-149531 | HSP90-IN-25 | | Reference compound |
| HY-149532 | α-Glucosidase-IN-33 | | Reference compound |
| HY-149533 | α-Glucosidase-IN-34 | | Reference compound |
| HY-149534 | DNA Gyrase-IN-9 | | Reference compound |
| HY-149535 | Iscartrelvir | 2921711-74-0 | Reference compound |
| HY-149536 | TWIK-1/TREK-1-IN-1 | 1440532-30-8 | Reference compound |
| HY-149537 | TWIK-1/TREK-1-IN-2 | 1440532-32-0 | Reference compound |
| HY-149538 | TWIK-1/TREK-1-IN-3 | 1440532-33-1 | Reference compound |
| HY-149539 | PLM-101 | | Reference compound |
| HY-149540 | CTL-06 | | Reference compound |
| HY-149541 | CTL-12 | | Reference compound |
| HY-149542 | GSK-3β inhibitor 15 | | Reference compound |
| HY-149545 | 1,3-Palmitin-2-docosahexaenoin | 214038-32-1 | Reference compound |
| HY-149547 | DRF-4015 | 905838-14-4 | Reference compound |
| HY-149548 | 2,3-Dinor-8-iso prostaglandin F1α | 221664-04-6 | Reference compound |
| HY-149549 | 1-Stearoyl-3-Oleoyl-rac-glycerol | 18266-27-8 | Reference compound |
| HY-14955 | Managlinat dialanetil | 280782-97-0 | Reference compound |
| HY-149550 | 1,2-Eucin(13Z)-olein | 675876-04-7 | Natural Products |
| HY-149552 | Ac4-5SGlcNAc | 67561-97-1 | Reference compound |
| HY-149554 | 17-Phenyl trinor Prostaglandin F2α dimethyl amide | 155205-90-6 | Reference compound |
| HY-149555 | DNL343 | 2278265-85-1 | Reference compound |
| HY-149556 | MTX-241F | | Reference compound |
| HY-149557 | α-Amylase/α-Glucosidase-IN-5 | | Reference compound |
| HY-149558 | CXCR4-IN-2 | | Reference compound |
| HY-149559 | Thalidomide-5-O-C2-NH2 (hydrochloride) | 2694727-89-2 | Reference compound |
| HY-14955A | (Rac)-Managlinat dialanetil | 347870-26-2 | Reference compound |
| HY-14956 | Nemonoxacin | 378746-64-6 | Reference compound |
| HY-149560 | Thalidomide-5-O-C3-NH2 (hydrochloride) | 2694727-94-9 | Reference compound |
| HY-149561 | Thalidomide-5-O-C4-NH2 (hydrochloride) | 2694727-93-8 | Reference compound |
| HY-149562 | Thalidomide-5-O-C5-NH2 (hydrochloride) | 2761385-94-6 | Reference compound |
| HY-149563 | Thalidomide-5-O-C6-NH2 (hydrochloride) | 2761398-05-2 | Reference compound |
| HY-149564 | Thalidomide-5-O-C7-NH2 (hydrochloride) | | Reference compound |
| HY-149565 | Thalidomide-5-O-C8-NH2 (hydrochloride) | | Reference compound |
| HY-149566 | Thalidomide-5-O-C9-NH2 (hydrochloride) | | Reference compound |
| HY-149567 | Thalidomide-5-O-C10-NH2 (hydrochloride) | | Reference compound |
| HY-149568 | Thalidomide-5-O-C11-NH2 (hydrochloride) | | Reference compound |
| HY-149569 | Thalidomide-5-O-C12-NH2 (hydrochloride) | | Reference compound |
| HY-14956S | Nemonoxacin-d3 | | Isotope-Labeled Compounds |
| HY-14956S1 | Nemonoxacin-d3-1 | | Isotope-Labeled Compounds |
| HY-14956S2 | Nemonoxacin-d4 | | Isotope-Labeled Compounds |
| HY-14957 | Ozenoxacin | 245765-41-7 | Reference compound |
| HY-149570 | Thalidomide-5-O-C13-NH2 (hydrochloride) | | Reference compound |
| HY-149571 | Thalidomide-5-O-C14-NH2 (hydrochloride) | | Reference compound |
| HY-149572 | Thalidomide-4-O-C9-NH2 (hydrochloride) | | Reference compound |
| HY-149573 | Thalidomide-4-O-C11-NH2 (hydrochloride) | | Reference compound |
| HY-149574 | Thalidomide-4-O-C12-NH2 (hydrochloride) | | Reference compound |
| HY-149575 | Thalidomide-4-O-C13-NH2 (hydrochloride) | | Reference compound |
| HY-149576 | Thalidomide-4-O-C14-NH2 (hydrochloride) | | Reference compound |
| HY-149577 | EBV lytic cycle inducer-1 | 394668-43-0 | Reference compound |
| HY-149578 | Tubulin/HDAC-IN-3 | | Reference compound |
| HY-149579 | α-Glucosidase-IN-36 | 3025234-94-7 | Reference compound |
| HY-14957AS | Ozenoxacin-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-14957R | Ozenoxacin (Standard) | 245765-41-7 | Reference Standards |
| HY-14957S | Ozenoxacin-d3 | | Isotope-Labeled Compounds |
| HY-14958 | Pardoprunox | 269718-84-5 | Reference compound |
| HY-149580 | NF-κB-IN-12 | | Reference compound |
| HY-149581 | DprE1-IN-9 | 2906099-98-5 | Reference compound |
| HY-149582 | Aβ-IN-7 | | Reference compound |
| HY-149583 | Aβ-IN-8 | | Reference compound |
| HY-149584 | CIDD-0149897 | 2862784-20-9 | Reference compound |
| HY-149585 | Chitin synthase inhibitor 14 | 2922114-19-8 | Reference compound |
| HY-149586 | ROS-IN-2 | | Reference compound |
| HY-149587 | Callosobruchusic acid | 87172-91-6 | Reference compound |
| HY-149588 | 17-Trifluoromethylphenyl trinor prostaglandin F2α methyl ester | 195503-20-9 | Reference compound |
| HY-149589 | 11(Z),14(Z)-Eicosadienoic acid | 5598-38-9 | Reference compound |
| HY-14958A | Pardoprunox (hydrochloride) | 269718-83-4 | Reference compound |
| HY-14959 | Ulipristal | 159811-51-5 | Reference compound |
| HY-149594 | CL-Pa | | Dye Reagents |
| HY-149595 | LSD1-UM-109 | 2252446-26-5 | Reference compound |
| HY-149596 | PTZ-LD | 2231747-49-0 | Dye Reagents |
| HY-149597 | Lysyl hydroxylase 2-IN-1 | | Reference compound |
| HY-14959S | Ulipristal-d3 | | Isotope-Labeled Compounds |
| HY-149600 | SDH-IN-7 | 2757173-36-5 | Reference compound |
| HY-149601 | SDH-IN-8 | 2757173-77-4 | Reference compound |
| HY-149602 | Glutaminase C-IN-2 | 3056437-77-2 | Reference compound |
| HY-149603 | Antifungal agent 78 | | Reference compound |
| HY-149604 | NLRP3-IN-21 | 2956791-61-8 | Reference compound |
| HY-149605 | KHK-IN-4 | 3034829-40-5 | Reference compound |
| HY-149606 | TKB245 | 2892688-16-1 | Reference compound |
| HY-149607 | SHP2-IN-22 | 2802453-88-7 | Reference compound |
| HY-149608 | Nurr1 agonist 5 | 3033875-32-7 | Reference compound |
| HY-149609 | Nurr1 agonist 6 | 3033875-47-4 | Reference compound |
| HY-149610 | Antibacterial agent 156 | 3032400-44-2 | Reference compound |
| HY-149611 | Lysyl hydroxylase 2-IN-2 | | Reference compound |
| HY-149614 | Laccase-IN-1 | 2991094-41-6 | Reference compound |
| HY-149615 | Antibacterial agent 157 | 2573134-85-5 | Reference compound |
| HY-149616 | PPM-3 | 3032388-42-1 | Reference compound |
| HY-149617 | CYP51/PD-L1-IN-4 | | Reference compound |
| HY-149618 | Cy5-PEG3-endo-BCN | 1881221-50-6 | Dye Reagents |
| HY-149619 | Cy5-PEG7-endo-BCN | | Dye Reagents |
| HY-149620 | Cy5-PEG2-exo-BCN | | Dye Reagents |
| HY-149622 | Bcl-2-IN-12 | 1383737-59-4 | Reference compound |
| HY-149623 | Bcl-2-IN-13 | 1421687-31-1 | Reference compound |
| HY-149624 | Bcl-2-IN-14 | | Reference compound |
| HY-149625 | Bcl-2-IN-15 | | Reference compound |
| HY-149628 | HM-1228 | | Biochemical Assay Reagents |
| HY-149629S | WD-890 | 2914130-91-7 | Isotope-Labeled Compounds |
| HY-149630 | VEGFR2/HDAC1-IN-1 | 3024922-89-9 | Reference compound |
| HY-149631 | HFY-4A | 2094810-82-7 | Reference compound |
| HY-149632 | EGFR/HER2/DHFR-IN-2 | | Reference compound |
| HY-149633 | EGFR/HER2/DHFR-IN-3 | | Reference compound |
| HY-149634 | PI3Kδ-IN-17 | 2768181-63-9 | Reference compound |
| HY-149635 | HIF-1α-IN-6 | | Reference compound |
| HY-149636 | Multi-target kinase inhibitor 2 | | Reference compound |
| HY-149637 | HSP70/SIRT2-IN-1 | | Reference compound |
| HY-149638 | HSP70/SIRT2-IN-2 | 1796557-72-6 | Reference compound |
| HY-149641 | CDK9-IN-29 | 2737262-24-5 | Reference compound |
| HY-149642 | hDHODH-IN-13 | 3032611-13-2 | Reference compound |
| HY-149644 | CB2R agonist 3 | 444331-43-5 | Reference compound |
| HY-149645 | CB2 receptor antagonist 2 | | Reference compound |
| HY-149646 | HDAC6-IN-24 | | Reference compound |
| HY-149647 | HD-2a | 606148-05-4 | Reference compound |
| HY-149648 | JNJ-8003 | | Reference compound |
| HY-149649 | SARS-CoV-2-IN-64 | | Reference compound |
| HY-149650 | TLR4 agonist-1 | 2374139-51-0 | Reference compound |
| HY-149650A | TLR4 agonist-1 (TEA) | 3020639-70-4 | Reference compound |
| HY-149651 | GPR139 agonist-2 | 2983118-29-0 | Reference compound |
| HY-149652 | IRF5-IN-1 | 689270-18-6 | Reference compound |
| HY-149653 | SDH-IN-10 | | Reference compound |
| HY-149654 | FAAH/cPLA2α-IN-1 | 1696401-38-3 | Reference compound |
| HY-149655 | D1N8 | 2894770-40-0 | Reference compound |
| HY-149656 | D1N52 | 2894770-48-8 | Reference compound |
| HY-149657 | SREBP/SCAP-IN-1 | 2763493-89-4 | Reference compound |
| HY-149658 | SREBP/SCAP-IN-2 | 2763493-94-1 | Reference compound |
| HY-149659 | ARUK2007145 | | Reference compound |
| HY-149661 | PDE5-IN-11 | | Reference compound |
| HY-149662 | TMDJ-035 | 2681302-83-8 | Reference compound |
| HY-149663 | BMS-986172 | 1808258-99-2 | Reference compound |
| HY-149664 | 3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol | 137056-72-5 | Biochemical Assay Reagents |
| HY-149665 | BMS-684 | 313552-29-3 | Reference compound |
| HY-149666 | BMS-496 | 2407854-31-1 | Reference compound |
| HY-149667 | BMS-332 | 2407892-15-1 | Reference compound |
| HY-149668 | α-Glucosidase-IN-41 | 3012673-89-8 | Reference compound |
| HY-149669 | PH14 | | Reference compound |
| HY-14967 | NSC 66811 | 6964-62-1 | Reference compound |
| HY-149670 | Ferroptosis-IN-3 | 3017222-33-9 | Reference compound |
| HY-149671 | Anti-inflammatory agent 63 | 2347694-79-3 | Reference compound |
| HY-149672 | ABBV-467 | 2287186-66-5 | Reference compound |
| HY-149673 | XPW1 | 2700286-66-2 | Reference compound |
| HY-149674 | VEGFR-2/c-Met-IN-1 | 3017162-02-3 | Reference compound |
| HY-149675 | VEGFR-2/c-Met-IN-2 | 3017162-04-5 | Reference compound |
| HY-149676 | α-Glucosidase-IN-42 | | Reference compound |
| HY-149677 | ZK53 | 3031789-26-8 | Reference compound |
| HY-149678 | PROTAC eDHFR Degrader-1 | 2849442-92-6 | Reference compound |
| HY-149679 | PROTAC eDHFR Degrader-2 | 2849442-91-5 | Reference compound |
| HY-149680 | CatD-P1 | | Reference compound |
| HY-149681 | Beclin1-Bcl-2 interaction inhibitor 1 | | Reference compound |
| HY-149682 | WAY-659873 | 868268-81-9 | Reference compound |
| HY-149683 | WAY-639228 | 179051-05-9 | Reference compound |
| HY-149684 | WAY-621924 | 745789-70-2 | Reference compound |
| HY-149685 | WAY-608106 | 685137-44-4 | Reference compound |
| HY-149686 | WAY-299765 | 106578-02-3 | Reference compound |
| HY-149687 | 4-Ketobenzotriazine-CH2-S-(CH2)2-COOH | 170033-08-6 | Reference compound |
| HY-149688 | 4-Ketobenzotriazine-CH2-S-(CH2)5-COOH | 221334-33-4 | Reference compound |
| HY-149689 | 4-Ketobenzotriazine-O-CH2-COOH | 113939-90-5 | Reference compound |
| HY-149690 | O-Phthalimide-C1-S-C1-acid | 221334-38-9 | Reference compound |
| HY-149691 | O-Phthalimide-C1-S-C5-acid | 221334-51-6 | Reference compound |
| HY-149693 | Aurora kinase inhibitor-11 | 923946-98-9 | Reference compound |
| HY-149694 | Aurora kinase inhibitor-12 | | Reference compound |
| HY-149695 | EGFR-IN-91 | 3032113-20-2 | Reference compound |
| HY-149696 | IR-Crizotinib | 2387927-74-2 | Reference compound |
| HY-149697 | Insecticidal agent 6 | 1699760-76-3 | Reference compound |
| HY-149698 | Tyrosinase-IN-17 | 2427043-61-4 | Reference compound |
| HY-149699 | DHFR-IN-12 | | Reference compound |
| HY-149700 | ROCK2-IN-7 | 3000541-95-4 | Reference compound |
| HY-149702 | M1/M4 muscarinic agonist 1 | | Reference compound |
| HY-149703 | M1/M4 muscarinic agonist 2 | | Reference compound |
| HY-149704 | M1/M2/M4 muscarinic agonist 1 | 2640109-42-6 | Reference compound |
| HY-149705 | ICMT-IN-7 | 1313603-21-2 | Reference compound |
| HY-149706 | ICMT-IN-12 | 1313603-25-6 | Reference compound |
| HY-149707 | ICMT-IN-21 | 1310740-69-2 | Reference compound |
| HY-149708 | UCM-13207 | 1621536-10-4 | Reference compound |
| HY-149709 | ICMT-IN-35 | | Reference compound |
| HY-14971 | (E)-Akt inhibitor-IV | 959841-49-7 | Reference compound |
| HY-149710 | POP-3MB | 1144114-27-1 | Reference compound |
| HY-149711 | Farnesylcysteine | 68000-92-0 | Reference compound |
| HY-149712 | Spermatinamine | 1001438-81-8 | Natural Products |
| HY-149713 | J1-1 | 1244769-10-5 | Reference compound |
| HY-149714 | J6-3 | | Reference compound |
| HY-149715 | R1-11 | | Reference compound |
| HY-149716 | MEY-003 | 3047891-88-0 | Reference compound |
| HY-149717 | Antitumor agent-122 | 2378641-43-9 | Reference compound |
| HY-149718 | Antitumor agent-123 | | Reference compound |
| HY-149719 | Ferroptosis-IN-4 | 2798922-35-5 | Reference compound |
| HY-14971A | AKT inhibitor IV | 681281-88-9 | Reference compound |
| HY-149720 | GRL018-21 | | Reference compound |
| HY-149721 | HDAC4-IN-1 | 1418293-39-6 | Reference compound |
| HY-149722 | Antiparasitic agent-20 | | Reference compound |
| HY-149723 | Ferroptosis-IN-5 | 2991058-60-5 | Reference compound |
| HY-149724 | Anti-inflammatory agent 65 | 3035442-58-8 | Reference compound |
| HY-149725 | proMMP-9 selective inhibitor-1 | | Reference compound |
| HY-149726 | EZH2-IN-17 | 2489672-09-3 | Reference compound |
| HY-149727 | β2AR agonist 2 | | Reference compound |
| HY-149728 | β2AR agonist 3 | 2304455-74-9 | Reference compound |
| HY-149729 | ICMT-IN-53 | 1443253-17-5 | Reference compound |
| HY-14973 | Vidupiprant | 1169483-24-2 | Reference compound |
| HY-149730 | ICMT-IN-54 | 908856-14-4 | Reference compound |
| HY-149731 | M1/M2/M4 muscarinic agonist 2 | | Reference compound |
| HY-149732 | M1/M4 muscarinic agonist 3 | 2640109-30-2 | Reference compound |
| HY-149733 | M1/M2/M4 muscarinic agonist 3 | 2640109-28-8 | Reference compound |
| HY-149734 | MA220607 | 2922826-56-8 | Reference compound |
| HY-149735 | BET-IN-20 | 1300735-76-5 | Reference compound |
| HY-149736 | ATP Synthesis-IN-3 | 3032416-36-4 | Reference compound |
| HY-149737 | FXn | | Reference compound |
| HY-149738 | FXh | 2408732-55-6 | Reference compound |
| HY-149739 | WAY-620445 | 728924-73-0 | Reference compound |
| HY-14974 | R 1487 | 449811-92-1 | Reference compound |
| HY-149740 | WAY-354436 | 850023-52-8 | Reference compound |
| HY-149741 | WAY-639872 | 796119-18-1 | Reference compound |
| HY-149742 | WAY-313318 | 351993-88-9 | Reference compound |
| HY-149743 | WAY-606376 | 522639-94-7 | Reference compound |
| HY-149744 | FXb | 2408732-52-3 | Reference compound |
| HY-149745 | 2-Oxabicyclo[3.3.1]non-6-en-8-ol-3,5-COOH | 472960-18-2 | Reference compound |
| HY-149748 | (5α)-Pregnan-20-one-succinic | 2452-44-0 | Reference compound |
| HY-149749 | Methylthiomcresol-C3-COOH | 848486-51-1 | Reference compound |
| HY-14975 | R1487 (Hydrochloride) | 449808-64-4 | Reference compound |
| HY-149750 | Methylthiomcresol-C4-COOH | 848486-53-3 | Reference compound |
| HY-149751 | Methylthiomcresol-C5-COOH | 848486-55-5 | Reference compound |
| HY-149752 | Methylthiomcresol-C1-benzoic acid | 848486-56-6 | Reference compound |
| HY-149753 | Methylthiomcresol-succinaldehydic acid | 848486-57-7 | Reference compound |
| HY-149754 | Ursodeoxycholic acid 7-N-acetylglucosaminide | 145624-10-8 | Reference compound |
| HY-149759 | SHP2-IN-23 | 2415989-91-0 | Reference compound |
| HY-149760 | PVD-06 | 3032975-48-4 | Reference compound |
| HY-149761 | GSK023 | | Reference compound |
| HY-149762 | IMBI | 2785359-14-8 | Reference compound |
| HY-149763 | Aβ42 agonist-1 | 50635-12-6 | Reference compound |
| HY-149764 | Aβ42 agonist-2 | 6314-40-5 | Reference compound |
| HY-149765 | Bone-1064 | 2481214-36-0 | Reference compound |
| HY-149766 | PB94 | 3032970-74-1 | Reference compound |
| HY-149767 | CMX990 | 2882934-64-5 | Reference compound |
| HY-149769 | CP-506 | 2227303-52-6 | Reference compound |
| HY-14977 | CS-0777-P | 840523-39-9 | Reference compound |
| HY-149770 | CYP4A11/CYP4F2-IN-2 | 2280834-99-1 | Reference compound |
| HY-149772 | Ciguatoxin CTX 3C | 148471-85-6 | Reference compound |
| HY-149773S | HPK1-IN-40-d2 | | Isotope-Labeled Compounds |
| HY-149774 | GC-78-HCl | 3022242-53-8 | Reference compound |
| HY-149775 | Urease-IN-10 | 1012205-70-7 | Reference compound |
| HY-149776 | RGH-560 | 2408799-43-7 | Reference compound |
| HY-149777 | B3GNT2-IN-1 | 3033557-95-5 | Reference compound |
| HY-149778 | Antifungal agent 87 | 692730-21-5 | Reference compound |
| HY-149779 | RyR2 stabilizer-1 | 3012675-16-7 | Reference compound |
| HY-149780 | Flavokawain 1i | 1098176-51-2 | Reference compound |
| HY-149781 | STING agonist-34 | 2913152-30-2 | Reference compound |
| HY-149782 | Phosphodiesterase-IN-1 | 521297-42-7 | Reference compound |
| HY-14979 | ML786 | 1237586-97-8 | Reference compound |
| HY-149799 | 28-O-Imidazolyl-azepano-betulin | | Reference compound |
| HY-14979A | ML786 (dihydrochloride) | 1237536-18-3 | Reference compound |
| HY-149800 | PARP-1-IN-3 | 2976342-33-1 | Reference compound |
| HY-149801A | Antibacterial agent 140 (chloride) | | Reference compound |
| HY-149802 | SLC26A3-IN-1 | 307552-53-0 | Reference compound |
| HY-149803 | S1R agonist 1 | 193354-70-0 | Reference compound |
| HY-149803A | S1R agonist 1 (hydrochloride) | 242487-82-7 | Reference compound |
| HY-149804 | S1R agonist 2 | 150085-21-5 | Reference compound |
| HY-149804A | S1R agonist 2 (hydrochloride) | | Reference compound |
| HY-149805 | Anticancer agent 110 | 887349-03-3 | Reference compound |
| HY-149806 | Bromodomain IN-2 | 2445335-77-1 | Reference compound |
| HY-149807 | TGR5 agonist 1 | | Reference compound |
| HY-149808 | TGR5 agonist 2 | | Reference compound |
| HY-149809 | AcrB-IN-1 | 2890177-82-7 | Reference compound |
| HY-14981 | GSK2334470 | 1227911-45-6 | Reference compound |
| HY-149810 | AcrB-IN-2 | 2890177-90-7 | Reference compound |
| HY-149811 | AcrB-IN-3 | 2890177-94-1 | Reference compound |
| HY-149812 | AcrB-IN-4 | 2890177-95-2 | Reference compound |
| HY-149813 | P-gp inhibitor 14 | 2892571-47-8 | Reference compound |
| HY-149814 | PDK-IN-1 | 2897696-10-3 | Reference compound |
| HY-149815 | HBV-IN-33 | | Reference compound |
| HY-149816 | Anti-inflammatory agent 41 | 2896204-90-1 | Reference compound |
| HY-149817 | AChE-IN-29 | | Reference compound |
| HY-149818 | 8BTC | 3064070-24-9 | Reference compound |
| HY-149819 | CDK/HDAC-IN-3 | 2944087-54-9 | Reference compound |
| HY-149820 | MAO-B-IN-22 | 2902600-76-2 | Reference compound |
| HY-149821 | Antifungal agent 50 | 2896209-33-7 | Reference compound |
| HY-149822 | Antifungal agent 51 | 2896209-47-3 | Reference compound |
| HY-149823 | TRPV4 antagonist 4 | 2918803-89-9 | Reference compound |
| HY-149824 | EGFR T790M/L858R-IN-2 | 2955607-40-4 | Reference compound |
| HY-149825 | MTHFD2-IN-1 | | Reference compound |
| HY-149826 | MTHFD2-IN-2 | | Reference compound |
| HY-149827 | MTHFD2-IN-3 | | Reference compound |
| HY-149828 | MTHFD2-IN-4 | | Reference compound |
| HY-149828A | MTHFD2-IN-4 (sodium) | | Reference compound |
| HY-149829 | Antitumor agent-97 | 2654024-16-3 | Reference compound |
| HY-149830 | PD-L1-IN-2 | 2894733-91-4 | Reference compound |
| HY-149831 | ZLY28 | 3004676-77-8 | Reference compound |
| HY-149832 | Anticancer agent 114 | | Reference compound |
| HY-149833 | ERRγ inverse agonist 2 | 324022-01-7 | Reference compound |
| HY-149834 | Antileishmanial agent-18 | 1007567-02-3 | Reference compound |
| HY-149835 | TTX-P | | Dye Reagents |
| HY-149836 | 3-MeOARh-NTR | | Dye Reagents |
| HY-149836A | 3-MeOARh-NTR (chloride) | | Dye Reagents |
| HY-149837 | PRO-F | | Dye Reagents |
| HY-149838 | NF-κB-IN-9 | 3033815-24-3 | Reference compound |
| HY-149839 | Antitumor agent-112 | | Reference compound |
| HY-14984 | N6022 | 1208315-24-5 | Reference compound |
| HY-149840 | Antitumor agent-113 | | Reference compound |
| HY-149841 | AKT-IN-17 | | Reference compound |
| HY-149842 | AKT-IN-18 | | Reference compound |
| HY-149843 | LC-MB12 | 2828438-38-4 | Reference compound |
| HY-149844 | S-F24 | 2946669-78-7 | Reference compound |
| HY-149845 | PROTAC GSK-3β Degrader-1 | | Reference compound |
| HY-149846 | SIQ17 | 2151881-74-0 | Reference compound |
| HY-149847 | JH530 | 2928616-74-2 | Reference compound |
| HY-149848 | MMP-9-IN-6 | 2241964-36-1 | Reference compound |
| HY-149849 | TS-IN-2 | 2945983-00-4 | Reference compound |
| HY-14985 | BAY 61-3606 (dihydrochloride) | 648903-57-5 | Reference compound |
| HY-149850 | p38 Kinase inhibitor 5 | 2929285-29-8 | Reference compound |
| HY-149851 | DNA Gyrase-IN-7 | 2925308-68-3 | Reference compound |
| HY-149852 | Anti-osteoporosis agent-3 | 2944463-16-3 | Reference compound |
| HY-149853 | AD186 | | Reference compound |
| HY-149854 | AB21 | 3026677-23-3 | Reference compound |
| HY-149854A | AB21 (oxalate) | | Reference compound |
| HY-149854B | AB21 (hydrochloride) | 3026677-24-4 | Reference compound |
| HY-149855 | AB10 | | Reference compound |
| HY-149856 | Tubulin inhibitor 33 | 2944462-67-1 | Reference compound |
| HY-149857 | Antitubercular agent-37 | 21696-12-8 | Reference compound |
| HY-149858 | β-catenin-IN-7 | 2952779-17-6 | Reference compound |
| HY-149859 | HDAC-IN-58 | 2071224-39-8 | Reference compound |
| HY-14986 | JAK-IN-32 | 936091-56-4 | Reference compound |
| HY-149860 | FAP-IN-1 | 2956858-96-9 | Reference compound |
| HY-149861 | Mip-IN-1 | 2984599-57-5 | Reference compound |
| HY-149862 | ARD-2051 | 2632305-17-8 | Reference compound |
| HY-149863 | DDO-8926 | 3017181-08-4 | Reference compound |
| HY-149864 | Insecticidal agent 3 | | Reference compound |
| HY-149865 | TPE-1p | | Dye Reagents |
| HY-149866 | HIV-1 inhibitor-58 | 3034064-68-8 | Reference compound |
| HY-149867 | Nurr1 agonist 4 | 87645-58-7 | Reference compound |
| HY-149868 | SARS-CoV-2-IN-42 | | Reference compound |
| HY-149869 | PSMA-IN-3 | 2941187-68-2 | Reference compound |
| HY-14987 | AX20017 | 329221-38-7 | Reference compound |
| HY-149870 | PROTAC CDK9 degrader-8 | 2994191-89-6 | Reference compound |
| HY-149872 | DCA-RMR1 | 3050582-94-7 | Reference compound |
| HY-149873 | Anticancer agent 126 | 3033748-20-5 | Reference compound |
| HY-149874 | BMS-502 | 2407854-18-4 | Reference compound |
| HY-149875 | T3SS-IN-1 | | Reference compound |
| HY-149876 | SDH-IN-5 | 2922765-95-3 | Reference compound |
| HY-149877 | hDHODH-IN-12 | | Reference compound |
| HY-149878 | BD-9136 | 3037514-38-5 | Reference compound |
| HY-149879 | Npx-Au | 3036175-27-3 | Reference compound |
| HY-14988 | I-A09 | 1143579-76-3 | Reference compound |
| HY-149880 | c-Met-IN-18 | 3034863-56-1 | Reference compound |
| HY-149881 | Quorum sensing-IN-2 | 2925926-80-1 | Reference compound |
| HY-149882 | Antimalarial agent 27 | | Reference compound |
| HY-149883 | IZS-L | 1173464-62-4 | Reference compound |
| HY-149884 | IZS-P | 1173464-65-7 | Reference compound |
| HY-149885 | IZS-M | 2950167-07-2 | Reference compound |
| HY-149886 | HIF-2α-IN-9 | 2648334-36-3 | Reference compound |
| HY-149887 | H3B-968 | 2912294-90-5 | Reference compound |
| HY-149888 | AChE-IN-31 | 1325209-07-1 | Reference compound |
| HY-149889 | EGFR-IN-78 | 3042104-73-1 | Reference compound |
| HY-14989 | SQ109 | 502487-67-4 | Reference compound |
| HY-149890 | Anticancer agent 130 | 3038738-52-9 | Reference compound |
| HY-149891 | HSP90-IN-23 | 2944100-30-3 | Reference compound |
| HY-149892S | TYK2 JH2-IN-1-d3 | 2376999-19-6 | Isotope-Labeled Compounds |
| HY-149893 | MGAT2-IN-4 | 1841424-92-7 | Reference compound |
| HY-149894 | MC-1-F2 | 2376894-10-7 | Reference compound |
| HY-149895 | Syk-IN-7 | 3050715-41-5 | Reference compound |
| HY-149896 | Antitumor agent-107 | 3052360-22-9 | Reference compound |
| HY-149897 | HA-CD44 interaction inhibitor 2 | 3009761-01-4 | Reference compound |
| HY-149898 | HA-CD44 interaction inhibitor 1 | 3052354-70-5 | Reference compound |
| HY-149899 | VDR agonist 2 | 3052323-55-1 | Reference compound |
| HY-14989R | SQ109 (Standard) | 502487-67-4 | Reference Standards |
| HY-14990 | Sudoterb | 676266-31-2 | Reference compound |
| HY-149900 | Antiviral agent 33 | 2982270-24-4 | Reference compound |
| HY-149901 | USP8-IN-2 | 2477651-11-7 | Reference compound |
| HY-149902 | USP8-IN-3 | 2477651-10-6 | Reference compound |
| HY-149906 | Trecovirsen | 153021-75-1 | Oligonucleotides |
| HY-149906A | FITC-Trecovirsen (sodium) | | Oligonucleotides |
| HY-149906C | Trecovirsen (sodium) | | Oligonucleotides |
| HY-14990A | Sudoterb (hydrochloride) | 1044503-04-9 | Reference compound |
| HY-149911 | GY1-22 | 326903-84-8 | Reference compound |
| HY-149912 | CZS-241 | 3016297-55-2 | Reference compound |
| HY-149913 | NR2F1 agonist 1 | 374101-64-1 | Reference compound |
| HY-149914 | WCA-814 | 2951858-45-8 | Reference compound |
| HY-149915 | MAT2A-IN-10 | 2924825-23-8 | Reference compound |
| HY-149916 | A2AR-antagonist-1 | 2922920-71-4 | Reference compound |
| HY-149917 | ITK degrader 1 | | Reference compound |
| HY-149918 | Antiproliferative agent-23 | 3049213-47-7 | Reference compound |
| HY-149919 | Antimalarial agent 23 | | Reference compound |
| HY-14992 | Bay 60-7550 | 439083-90-6 | Reference compound |
| HY-149920 | Anticancer agent 98 | 2857070-72-3 | Reference compound |
| HY-149921 | Antiangiogenic agent 3 | | Reference compound |
| HY-149922 | DKI5 | 1101130-96-4 | Reference compound |
| HY-149923 | GPX4-IN-4 | 2920221-53-8 | Reference compound |
| HY-149924 | CST626 | 3033993-13-1 | Reference compound |
| HY-149925 | DNA Gyrase-IN-6 | 3034242-80-0 | Reference compound |
| HY-149926 | Cathepsin Inhibitor 3 | 3026372-49-3 | Reference compound |
| HY-149927 | Antitumor agent-91 | 3035360-70-1 | Reference compound |
| HY-149928 | NNRT-IN-1 | 2925364-09-4 | Reference compound |
| HY-149929 | EBL-3183 | 2872672-18-7 | Reference compound |
| HY-14993 | SCH79797 | 245520-69-8 | Reference compound |
| HY-149930 | YL5084 | 2440199-73-3 | Reference compound |
| HY-149931 | BMV109 | 1458731-58-2 | Dye Reagents |
| HY-149933 | AM841 | 871978-21-1 | Reference compound |
| HY-149934 | DCAF1 binder 1 | 3053860-67-3 | Reference compound |
| HY-149935 | OICR-8268 | 3000549-26-5 | Reference compound |
| HY-149936 | HIV-1 protease-IN-8 | 2925287-55-2 | Reference compound |
| HY-149937 | Antimalarial agent 24 | 2299199-54-3 | Reference compound |
| HY-149938 | Antimalarial agent 25 | 2944456-41-9 | Reference compound |
| HY-149939 | Antimalarial agent 26 | 2299199-56-5 | Reference compound |
| HY-14994 | SCH79797 (dihydrochloride) | 1216720-69-2 | Reference compound |
| HY-149940 | SIMR3030 | 2708270-99-7 | Reference compound |
| HY-149941 | hNTS1R agonist-1 | | Reference compound |
| HY-149942 | PAP-IN-1 | | Reference compound |
| HY-149943 | PAP-IN-2 | | Reference compound |
| HY-149944 | Analgesic agent-2 | 2983892-65-3 | Reference compound |
| HY-149946 | HDAC-IN-57 | 2716217-79-5 | Reference compound |
| HY-149948 | PROTAC BRD3/BRD4-L degrader-2 | | Reference compound |
| HY-149949 | Anticancer agent 105 | 2450987-57-0 | Reference compound |
| HY-149950 | Anticancer agent 106 | 3009090-13-2 | Reference compound |
| HY-149951 | Anticancer agent 107 | 2397573-96-3 | Reference compound |
| HY-149952 | ATR-IN-23 | 2923800-62-6 | Reference compound |
| HY-149953 | FABP4-IN-2 | 2983117-36-6 | Reference compound |
| HY-149954 | SARS-CoV-2-IN-39 | 2882823-03-0 | Reference compound |
| HY-149955 | SARS-CoV-2-IN-38 | 2882823-27-8 | Reference compound |
| HY-149956 | Antileishmanial agent-15 | 2934738-38-0 | Reference compound |
| HY-149957 | Antileishmanial agent-16 | 2934738-41-5 | Reference compound |
| HY-149958 | Antileishmanial agent-17 | 2934738-40-4 | Reference compound |
| HY-149959 | Mps1-IN-6 | 3043761-59-4 | Reference compound |
| HY-149960 | Antiparasitic agent-17 | 3043821-43-5 | Reference compound |
| HY-149961 | Anti-inflammatory agent 40 | 3043821-37-7 | Reference compound |
| HY-149962 | PROTAC CDK9 degrader-5 | 2935587-89-4 | Reference compound |
| HY-149963 | PROTAC CDK9 degrader-6 | 2935587-91-8 | Reference compound |
| HY-149964 | PROTAC CDK9 degrader-7 | 2935587-90-7 | Reference compound |
| HY-149965 | TRK-IN-23 | 2924344-29-4 | Reference compound |
| HY-149966 | PB131 | 2924425-63-6 | Reference compound |
| HY-149967 | GluN2B-NMDAR antagonist-1 | 3043727-74-5 | Reference compound |
| HY-149968 | LSD1-IN-25 | 2911585-60-7 | Reference compound |
| HY-149969 | ER degrader 4 | 2913192-39-7 | Reference compound |
| HY-149970 | ER degrader 5 | 2913192-47-7 | Reference compound |
| HY-149971 | XJ02862-S2 | 3023355-55-4 | Reference compound |
| HY-149972 | Antitumor agent-96 | 3041063-90-2 | Reference compound |
| HY-149973 | α-Amylase-IN-4 | | Reference compound |
| HY-149974 | CDK8-IN-13 | 918523-75-8 | Reference compound |
| HY-149975 | AMPA receptor modulator-4 | 2917551-59-6 | Reference compound |
| HY-149976 | Pim-1 kinase inhibitor 4 | 3026670-71-0 | Reference compound |
| HY-149977 | Anticancer agent 111 | | Reference compound |
| HY-149978 | LSD1-IN-26 | 3041141-72-1 | Reference compound |
| HY-149979 | SLC7A11-IN-1 | 3049302-90-8 | Reference compound |
| HY-14998 | Halofenate | 26718-25-2 | Reference compound |
| HY-149980 | DCN-83 | | Reference compound |
| HY-149981 | P-gp inhibitor 13 | 3041121-57-4 | Reference compound |
| HY-149982 | IDO1-IN-22 | 2126853-16-3 | Reference compound |
| HY-149983 | Antibacterial agent 141 | 2930013-56-0 | Reference compound |
| HY-149984 | MAO-B-IN-21 | 2956426-18-7 | Reference compound |
| HY-149985 | Antitrypanosomal agent 12 | | Reference compound |
| HY-149986 | Antitrypanosomal agent 13 | | Reference compound |
| HY-149987 | LY3522348 | 2568608-48-8 | Reference compound |
| HY-149988 | UNP-6457 | | Reference compound |
| HY-149989 | Ack1 inhibitor 1 | 2924415-92-7 | Reference compound |
| HY-149991 | HIV-1 inhibitor-56 | 2952530-45-7 | Reference compound |
| HY-149992 | MyD88-IN-1 | 2911609-80-6 | Reference compound |
| HY-149993 | hBChE-IN-2 | 2923366-36-1 | Reference compound |
| HY-149994 | DS43260857 | 1612158-07-2 | Reference compound |
| HY-149995 | Pim-1 kinase inhibitor 5 | 2928606-67-9 | Reference compound |
| HY-149996 | Pim-1 kinase inhibitor 6 | 2928606-69-1 | Reference compound |
| HY-149997 | Anticancer agent 120 | 2928614-22-4 | Reference compound |
| HY-149998 | Antimycobacterial agent-5 | | Reference compound |
| HY-149999 | Xeniafaraunol A | 161162-29-4 | Natural Products |
| HY-15000 | EMD534085 | 858668-07-2 | Reference compound |
| HY-150002 | Antibacterial agent 115 | 2259732-60-8 | Reference compound |
| HY-150003 | Aβ1–42 aggregation inhibitor 1 | 2439107-75-0 | Reference compound |
| HY-150004 | c-Met/HDAC-IN-3 | 2439175-23-0 | Reference compound |
| HY-150006 | Pomalidomide-C2-acid | 2225940-46-3 | Reference compound |
| HY-15001 | Stemregenin 1 | 1227633-49-9 | Reference compound |
| HY-150012 | N-Lactoyl-Phenylalanine | 183241-73-8 | Natural Products |
| HY-150012S1 | N-Lactoyl-Phenylalanine-13C6 | | Isotope-Labeled Compounds |
| HY-150013 | H-Met-Met-OH | 7349-78-2 | Reference compound |
| HY-150014 | AMT-NHS | 2925268-86-4 | Reference compound |
| HY-150015 | 4,5'-Dimethylangelicin-NHS | | Reference compound |
| HY-150017 | 2'-O-Methyl-5-methyl-U CEP | 153631-20-0 | Reference compound |
| HY-150019 | PI3K-IN-36 | 1401436-93-8 | Reference compound |
| HY-15001A | Stemregenin 1 (hydrochloride) | 2319882-01-2 | Reference compound |
| HY-15001G | Stemregenin 1 (GMP) | 1227633-49-9 | GMP Small Molecules |
| HY-15002 | AST 487 | 630124-46-8 | Reference compound |
| HY-150021 | GRK5-IN-3 | 2410793-22-3 | Reference compound |
| HY-150022 | GRK5-IN-4 | 2410794-89-5 | Reference compound |
| HY-150023 | BI-1622 | 2681392-19-6 | Reference compound |
| HY-150024 | BI-4142 | 2682003-36-5 | Reference compound |
| HY-150025 | (4aS,8aR)-NPD-001 | 2366272-43-5 | Reference compound |
| HY-150026 | Multi-kinase-IN-2 | 2095628-21-8 | Reference compound |
| HY-150027 | Multi-kinase-IN-3 | 2091950-43-3 | Reference compound |
| HY-150028 | CB1/2 agonist 2 | 2772379-97-0 | Reference compound |
| HY-150029 | CB1/2 agonist 3 | 2772655-86-2 | Reference compound |
| HY-15003 | ATH686 | 853299-52-2 | Reference compound |
| HY-150030 | CB1/2 agonist 4 | 2772949-38-7 | Reference compound |
| HY-150031 | MFI8 | 694488-83-0 | Reference compound |
| HY-150034 | PI3K-IN-38 | 1382979-64-7 | Reference compound |
| HY-150036 | Anthramycin | 4803-27-4 | Reference compound |
| HY-150039 | CCG-271423 | 2750413-88-6 | Reference compound |
| HY-15004 | AUZ 454 | 853299-07-7 | Reference compound |
| HY-150040 | CCG-273463 | 2750413-99-9 | Reference compound |
| HY-150041 | TL4830031 | 2084107-15-1 | Reference compound |
| HY-150042 | TDI-011536 | 2687970-96-1 | Reference compound |
| HY-150043 | MDTF (free acid) | 2102021-49-6 | ADC Related |
| HY-150043A | MDTF | | ADC Related |
| HY-150044 | Type II topoisomerase inhibitor 1 | 2245691-60-3 | Reference compound |
| HY-150045 | TP0480066 | 2245693-15-4 | Reference compound |
| HY-150046 | Nek2-IN-6 | 2410376-96-2 | Reference compound |
| HY-150048 | BK50164 | 2204291-78-9 | Reference compound |
| HY-150049 | γ-Secretase modulator 13 | 1353570-40-7 | Reference compound |
| HY-15005 | Sofosbuvir | 1190307-88-0 | Reference compound |
| HY-150050 | gamma-secretase modulator 5 | 1353570-53-2 | Reference compound |
| HY-150051 | IL-2-IN-1 | 245747-10-8 | Reference compound |
| HY-150052 | Plasma kallikrein-IN-3 | 1357950-47-0 | Reference compound |
| HY-150053 | JNK-IN-11 | 676594-38-0 | Reference compound |
| HY-150055 | iNOs-IN-3 | 2241674-94-0 | Reference compound |
| HY-150056 | CB1R Allosteric modulator 3 | 2633686-36-7 | Reference compound |
| HY-150057 | CB1R Allosteric modulator 4 | 2633686-53-8 | Reference compound |
| HY-150058 | Bocconoline | 32906-88-0 | Natural Products |
| HY-150059 | P2X7 receptor antagonist-2 | 851269-75-5 | Reference compound |
| HY-15005A | PSI-7976 | 1190308-01-0 | Reference compound |
| HY-15005B | Sofosbuvir impurity C | 1496552-28-3 | Reference compound |
| HY-15005C | Sofosbuvir impurity A | 1496552-16-9 | Reference compound |
| HY-15005R | Sofosbuvir (Standard) | 1190307-88-0 | Reference Standards |
| HY-15005S | Sofosbuvir-13C,d3 | | Isotope-Labeled Compounds |
| HY-15005S1 | Sofosbuvir-d6 | 1868135-06-1 | Isotope-Labeled Compounds |
| HY-150060 | PDE4-IN-11 | 524734-30-3 | Reference compound |
| HY-150061 | NVP-BBD130 | 853910-61-9 | Reference compound |
| HY-150062 | SARS-CoV-2 nsp3-IN-1 | 2892105-43-8 | Reference compound |
| HY-150063 | Antibacterial agent 116 | 99330-28-6 | Reference compound |
| HY-150064 | SARS-CoV-2 nsp3-IN-2 | 2038858-11-4 | Reference compound |
| HY-150065 | Antimalarial agent 15 | 956928-33-9 | Reference compound |
| HY-150066 | Antimalarial agent 16 | 2773408-33-4 | Reference compound |
| HY-150067 | CB1R antagonist 1 | 334668-69-8 | Reference compound |
| HY-150068 | EP4 receptor agonist 1 | 691869-12-2 | Reference compound |
| HY-150069 | UBX1325 | 2271269-01-1 | Reference compound |
| HY-15007 | L 366509 | 138382-23-7 | Reference compound |
| HY-150070 | Butabindide | 175553-48-7 | Reference compound |
| HY-150072 | DS89002333 | 2832159-79-0 | Reference compound |
| HY-150072A | (2S,4R)-DS89002333 | | Reference compound |
| HY-150072B | (R)-DS89002333 | | Reference compound |
| HY-150073 | DS01080522 | 2832159-84-7 | Reference compound |
| HY-150074 | STING agonist-18 | 2138299-68-8 | Reference compound |
| HY-150074A | STING agonist-18 (diTFA) | 2138299-69-9 | Reference compound |
| HY-150075 | STING agonist-19 | 2886007-54-9 | Reference compound |
| HY-150076 | BLU2864 | 2810747-89-6 | Reference compound |
| HY-150077 | Utrophin modulator 1 | | Reference compound |
| HY-150078 | OX01914 | 49676-35-9 | Reference compound |
| HY-150079 | HIV-1 integrase inhibitor 10 | | Reference compound |
| HY-15008 | L-368,899 | 148927-60-0 | Reference compound |
| HY-150080 | GSK3739936 | 1803444-21-4 | Reference compound |
| HY-150081 | PRMT5-IN-21 | 2922673-38-7 | Reference compound |
| HY-150082 | CP681301 | 865317-32-4 | Reference compound |
| HY-150084 | (±)14,15-Epoxyeicosatrienoic acid | 197508-62-6 | Natural Products |
| HY-150086 | Copper Fluor-4 | 2365532-64-3 | Dye Reagents |
| HY-150087 | Ctrl-CF4-S2 | 2365532-65-4 | Dye Reagents |
| HY-150089 | SRI-37240 | 883956-47-6 | Reference compound |
| HY-15009 | Fuscoside | 131631-89-5 | Reference compound |
| HY-150090 | SRI-41315 | 1613509-49-1 | Reference compound |
| HY-150091 | 11,12-Epoxyeicosatrienoic acid | 81276-02-0 | Biochemical Assay Reagents |
| HY-150092 | 8(S),9(R)-EET | 123931-39-5 | Natural Products |
| HY-150092S | (2S,3R)-8(9)-EET-d11 | | Isotope-Labeled Compounds |
| HY-150095 | YE6144 | | Reference compound |
| HY-150096 | Zasocitinib | 2272904-53-5 | Reference compound |
| HY-150097 | Recombinant Human Serum Albumin(rHSA) | | Biochemical Assay Reagents |
| HY-15010 | L-371,257 | 162042-44-6 | Reference compound |
| HY-150100 | Tyrosine 3-monooxygenase | 9036-22-0 | Enzyme |
| HY-150102 | EPI-7170 | 2139288-26-7 | Reference compound |
| HY-150105 | BMF-219 | 2448172-22-1 | Reference compound |
| HY-150109 | Purinostat (mesylate) | 2650188-32-0 | Reference compound |
| HY-150109A | Purinostat | 1929583-17-4 | Reference compound |
| HY-15011 | L-372662 | 162045-26-3 | Reference compound |
| HY-150115 | Lipid 10 | 2430034-02-7 | Reference compound |
| HY-150116 | Lipid 1 | 2226547-17-5 | Oligonucleotides |
| HY-150117 | Lipid 6 | 2226547-22-2 | Oligonucleotides |
| HY-150118 | Lipid 8 | 2226547-25-5 | Reference compound |
| HY-150123 | Quinidine methiodide | 42982-87-6 | Reference compound |
| HY-150124 | K34c | 939769-93-4 | Reference compound |
| HY-150124A | K34c (hydrochloride) | 2986315-25-5 | Reference compound |
| HY-150125 | SCD1-IN-1 | 1111078-63-7 | Reference compound |
| HY-150132 | Heptakis(2,3-dimethyl)-β-cyclodextrin | 123155-05-5 | Biochemical Assay Reagents |
| HY-150135B | D-myo-Inositol 1,4,5-trisphosphate (tripotassium) | 141611-11-2 | Reference compound |
| HY-150137 | Iomeprol | 78649-41-9 | Reference compound |
| HY-150138 | Gavestinel | 153436-22-7 | Reference compound |
| HY-150144 | Uracil-m7GpppAmpG (ammonium) | | Biochemical Assay Reagents |
| HY-150145 | Cy5-UTP | | Biochemical Assay Reagents |
| HY-150145A | Cy5-UTP (sodium) (10mM in Water) | | Biochemical Assay Reagents |
| HY-150147 | CAM833 | 2758364-02-0 | Reference compound |
| HY-15015 | OT-R antagonist 1 | 364071-17-0 | Reference compound |
| HY-150150 | SiRNA Negative Control | | Oligonucleotides |
| HY-150156 | Anti-inflammatory agent 32 | 2577388-38-4 | Reference compound |
| HY-150158 | TMX-201 | 1149339-78-5 | Reference compound |
| HY-150159S | Cotinine-d3 N-β-D-Glucuronide | | Isotope-Labeled Compounds |
| HY-15015A | OT-R antagonist 2 | 364071-16-9 | Reference compound |
| HY-150163 | RBM14C12 | 1309763-43-6 | Reference compound |
| HY-150166 | ClpB-IN-1 | 1453172-23-0 | Reference compound |
| HY-150167 | TH-Z93 | 2260887-09-8 | Reference compound |
| HY-150168 | TH-Z145 | 2260887-57-6 | Reference compound |
| HY-150169 | THRX-144644 | 2442519-59-5 | Reference compound |
| HY-150175 | HKSOX-1 | 1786411-17-3 | Dye Reagents |
| HY-150177 | Mannose 6 phosphate | 3672-15-9 | Reference compound |
| HY-150184 | And1-IN-1 | 2451028-69-4 | Reference compound |
| HY-150185 | RXFP2 agonist 1 | 2971704-58-0 | Reference compound |
| HY-150186 | RXFP2 agonist 2 | 2971704-85-3 | Reference compound |
| HY-15018A | SSR126768A (free base) | 785048-28-4 | Reference compound |
| HY-150190 | F5446 | 2304465-89-0 | Reference compound |
| HY-150194S | Fructose-glutamic acid-13C6 | 1083053-45-5 | Isotope-Labeled Compounds |
| HY-150202 | L1-PEG2-TATE | 2794143-66-9 | Reference compound |
| HY-150203 | GLPG3970 | 2403733-82-2 | Reference compound |
| HY-150204 | ONO-0740556 | 2250210-69-4 | Reference compound |
| HY-150205 | Succinate/succinate receptor antagonist 1 | 2361972-29-2 | Reference compound |
| HY-150206 | NLRP3-IN-13 | 1704638-35-6 | Reference compound |
| HY-150207 | RBN-3143 | 2360853-16-1 | Reference compound |
| HY-150209 | MODAG-001 | 2648041-72-7 | Reference compound |
| HY-150210 | FSHR agonist 1 | 1256776-89-2 | Reference compound |
| HY-150211 | DC-BPi-03 | 2758411-46-8 | Reference compound |
| HY-150212 | Tilsotolimod | 1948266-37-2 | Oligonucleotides |
| HY-150212A | Tilsotolimod (sodium) | 2089768-67-0 | Oligonucleotides |
| HY-150213 | ODN BW001 | 886862-38-0 | Oligonucleotides |
| HY-150213A | ODN BW001 (sodium) | | Oligonucleotides |
| HY-150214 | ODN MT01 | 1817821-77-4 | Oligonucleotides |
| HY-150214A | ODN MT 01 (sodium) | | Oligonucleotides |
| HY-150215 | ODN 105870 | 1965342-40-8 | Oligonucleotides |
| HY-150215A | ODN 105870 (sodium) | | Oligonucleotides |
| HY-150217 | CpG ODN 10101 | 1234402-77-7 | Oligonucleotides |
| HY-150217A | CpG ODN 10101 (sodium) | | Oligonucleotides |
| HY-150218 | Agatolimod (sodium) | 541547-35-7 | Oligonucleotides |
| HY-150219 | ODN M326 | 557124-74-0 | Reference compound |
| HY-150219A | ODN M326 (sodium) | | Reference compound |
| HY-150220 | 1,5-Dihexadecyl N-(3-carboxy-1-oxopropyl)-L-glutamate | 125401-63-0 | Reference compound |
| HY-150221 | DB008 | 2991637-98-8 | Reference compound |
| HY-150223 | GalNAc unconjugated/naked Inclisiran | | Oligonucleotides |
| HY-150224 | GalNAc unconjugated/naked Fitusiran (sodium) | | Oligonucleotides |
| HY-150226 | Enzyme-IN-1 | 868540-02-7 | Reference compound |
| HY-150228 | MitoCur-1 | | Reference compound |
| HY-150229 | 306-N16B | 2803699-70-7 | Reference compound |
| HY-15023 | Cligosiban | 900510-03-4 | Reference compound |
| HY-150230 | Desthiobiotin-Iodoacetamide | 2924824-04-2 | Reference compound |
| HY-150231 | SU056 | 2376580-08-2 | Reference compound |
| HY-150232 | MALT1-IN-11 | 2812352-99-9 | Reference compound |
| HY-150233 | Cys-McMMAF | 1160590-05-5 | ADC Related |
| HY-150234 | LabMol-319 | 381188-63-2 | Reference compound |
| HY-150235 | Galectin-8N-IN-1 | 2667628-25-1 | Reference compound |
| HY-150236 | FITC-labeled Tominersen (sodium) | | Oligonucleotides |
| HY-150237 | FITC-labeled Drisapersen (sodium) | | Oligonucleotides |
| HY-150238 | IDH1 Inhibitor 7 | 2135309-56-5 | Reference compound |
| HY-150238S | IDH1 Inhibitor 7-d2 | 2135309-51-0 | Isotope-Labeled Compounds |
| HY-150239 | BAY-364 | 2097610-30-3 | Reference compound |
| HY-150240 | DOPE-GA | 228706-30-7 | Reference compound |
| HY-150241 | DOPE-NHS | 1010188-79-0 | Biochemical Assay Reagents |
| HY-150242A | Cbz-Ala-Ala-Asn (TFA) | | Peptides |
| HY-150245 | mHTT-IN-1 | 2839311-21-4 | Reference compound |
| HY-150246 | RNA splicing modulator 1 | 2726461-38-5 | Reference compound |
| HY-150247 | RNA splicing modulator 2 | 2726461-41-0 | Reference compound |
| HY-150248 | RNA splicing modulator 3 | 2726461-43-2 | Reference compound |
| HY-150249 | GSK3735967 | 2170136-86-2 | Reference compound |
| HY-15025 | Sildenafil | 139755-83-2 | Reference compound |
| HY-150250 | B-Raf IN 13 | 2573782-74-6 | Reference compound |
| HY-150251 | STAT3 degrader-2 | 2497583-03-4 | Reference compound |
| HY-150252 | ATIC-IN-1 | 1402453-15-9 | Reference compound |
| HY-150252A | ATIC-IN-1 (acetate) | | Reference compound |
| HY-150254 | SLB1122168 | 2999629-17-1 | Reference compound |
| HY-150254A | SLB1122168 (formic) | | Reference compound |
| HY-150255 | IMP2-IN-3 | 1448353-63-6 | Reference compound |
| HY-150256 | YTP-17 | | Reference compound |
| HY-150257 | Xanthine oxidase-IN-10 | 851429-65-7 | Reference compound |
| HY-150257A | Xanthine oxidase-IN-11 | | Reference compound |
| HY-150258 | TRK-IN-22 | | Reference compound |
| HY-150259 | MDEG-541 | | Reference compound |
| HY-15025A | Sildenafil (citrate) | 171599-83-0 | Reference compound |
| HY-15025AR | Sildenafil (citrate) (Standard) | 171599-83-0 | Reference Standards |
| HY-15025AS | Sildenafil (citrate)-d8 | 1215071-03-6 | Isotope-Labeled Compounds |
| HY-15025S | Sildenafil-d3 | 1126745-90-1 | Isotope-Labeled Compounds |
| HY-15025S1 | Sildenafil-d8 | 951385-68-5 | Isotope-Labeled Compounds |
| HY-15025S2 | Sildenafil-d3-1 | 1126745-87-6 | Isotope-Labeled Compounds |
| HY-15025S3 | Sildenafil-d5 | 951385-70-9 | Isotope-Labeled Compounds |
| HY-15026 | ATB-429 | 915282-45-0 | Reference compound |
| HY-150260 | SA09-Cu | 155641-16-0 | Reference compound |
| HY-150265 | TNH | 2137895-00-0 | Reference compound |
| HY-150266 | A-1293102 | 1565759-96-7 | Reference compound |
| HY-150268 | BET-IN-16 | 2089390-09-8 | Reference compound |
| HY-150269 | RS5517 | 2227017-46-9 | Reference compound |
| HY-15027 | 5-Aminosalicylic Acid | 89-57-6 | Natural Products |
| HY-150270 | NP-1815-PX | 1239578-79-0 | Reference compound |
| HY-150270A | NP-1815-PX (sodium) | 1239578-80-3 | Reference compound |
| HY-150278 | Peptone from casein | 91079-40-2 | Biochemical Assay Reagents |
| HY-150279 | PolQi2 | 2565638-16-4 | Reference compound |
| HY-15027R | 5-Aminosalicylic Acid (Standard) | 89-57-6 | Reference Standards |
| HY-15027S | 5-Aminosalicylic Acid-d3 (hydrochloride) | 1346601-18-0 | Isotope-Labeled Compounds |
| HY-15027S1 | 5-Aminosalicylic acid-d3 | 1309283-32-6 | Isotope-Labeled Compounds |
| HY-15027S2 | 5-Aminosalicylic acid-13C6 | 1189709-96-3 | Isotope-Labeled Compounds |
| HY-15027S3 | 5-Aminosalicylic acid-d3 (disodium) | | Isotope-Labeled Compounds |
| HY-15027S4 | 5-Aminosalicylic acid-d7 | | Isotope-Labeled Compounds |
| HY-15028 | Otenaproxesul | 1226895-20-0 | Reference compound |
| HY-150287 | Insulin-Transferrin-Selenium, 100X | | Biochemical Assay Reagents |
| HY-150287A | Insulin-Transferrin-Selenium-Ethanolamine | | Biochemical Assay Reagents |
| HY-150287B | Insulin-Transferrin-Selenium-Sodium Pyruvate | | Biochemical Assay Reagents |
| HY-150289 | GNE-235 | | Reference compound |
| HY-15028A | (S)-Otenaproxesul | 1000700-29-7 | Reference compound |
| HY-15029 | (±)-Naproxen | 23981-80-8 | Reference compound |
| HY-150298 | Soquelitinib | 2226636-04-8 | Reference compound |
| HY-15029R | (±)-Naproxen (Standard) | 23981-80-8 | Reference Standards |
| HY-15029S | (±)-Naproxen-d3 | 958293-79-3 | Isotope-Labeled Compounds |
| HY-15029S1 | (±)-Naproxen-d3-1 | 958293-77-1 | Isotope-Labeled Compounds |
| HY-15029S2 | (±)-Naproxen-13C,d3 | 1261392-52-2 | Isotope-Labeled Compounds |
| HY-15030 | Naproxen | 22204-53-1 | Reference compound |
| HY-150306 | IM-250 | 2305750-23-4 | Reference compound |
| HY-150307 | KP-302 | 2082765-42-0 | Reference compound |
| HY-150308 | SR10221 | 1415321-64-0 | Reference compound |
| HY-150309 | PI3K-IN-54 | 1336890-05-1 | Reference compound |
| HY-15030A | Naproxen (sodium) | 26159-34-2 | Reference compound |
| HY-15030AR | Naproxen (sodium) (Standard) | 26159-34-2 | Reference Standards |
| HY-15030R | Naproxen (Standard) | 22204-53-1 | Reference Standards |
| HY-15030S1 | Naproxen-d3 | 1094102-82-5 | Isotope-Labeled Compounds |
| HY-15031 | l-Naproxen | 23979-41-1 | Reference compound |
| HY-150311 | endo-BCN-PEG24-NHS ester | | Reference compound |
| HY-150314 | MCT-IN-1 | 1685273-57-7 | Reference compound |
| HY-15033 | ATB-343 | 1000700-26-4 | Reference compound |
| HY-150330 | DNA ligase-IN-1 | 68302-07-8 | Reference compound |
| HY-150331 | DNA ligase-IN-2 | 635681-64-0 | Oligonucleotides |
| HY-150332 | N-Propionitrile Chlorphine (hydrochloride) | 16145-71-4 | Reference compound |
| HY-150333 | MMB-ICA | 1188516-52-0 | Reference compound |
| HY-150334 | Rilmazolam | 50330-59-1 | Reference compound |
| HY-150335 | Dehydrocannabifuran | 56154-59-7 | Reference compound |
| HY-150337 | Isopropylphenidine (hydrochloride) | 6267-56-7 | Reference compound |
| HY-150338 | N-Propyl Ephenidine (hydrochloride) | 6266-42-8 | Reference compound |
| HY-150339 | AB-INACA | 1887742-41-7 | Reference compound |
| HY-15034 | Indomethacin (sodium) | 7681-54-1 | Reference compound |
| HY-150340 | N-Butyl Pentedrone (hydrochloride) | 18268-13-8 | Reference compound |
| HY-150341 | Ortho-methyl 4-anilino-1-boc-piperidine | 1154101-90-2 | Reference compound |
| HY-150342 | 1-Propinoyl Lysergic acid methylisopropylamide | 3028950-73-1 | Reference compound |
| HY-150343 | (±)-3-Methyl nimetazepam | 89141-65-1 | Reference compound |
| HY-150344 | Abnormal cannabidivarin | 55824-20-9 | Reference compound |
| HY-150345 | Δ8-THC Glucuronide | 62667-60-1 | Reference compound |
| HY-150346 | 1cP-MiPLA | 3028950-74-2 | Reference compound |
| HY-150347 | Cannabigerol diacetate | 1040411-87-7 | Reference compound |
| HY-150348 | Cannabidivarin diacetate | 2552800-24-3 | Reference compound |
| HY-150349 | (±)-3-Methyl nitrazepam | 4928-07-8 | Reference compound |
| HY-15035 | S-Diclofenac | 912758-00-0 | Reference compound |
| HY-150350 | 20mM HEPES, 150 mM NaCl, 240mM Sucrose, pH 7.2 buffer | | Biochemical Assay Reagents |
| HY-15036 | Diclofenac | 15307-86-5 | Reference compound |
| HY-15036A | Diclofenac (diethylamine) | 78213-16-8 | Reference compound |
| HY-15036AR | Diclofenac (diethylamine) (Standard) | 78213-16-8 | Reference Standards |
| HY-15036B | Diclofenac deanol | 81811-14-5 | Reference compound |
| HY-15036R | Diclofenac (Standard) | 15307-86-5 | Reference Standards |
| HY-15036S | Diclofenac-d4 | 153466-65-0 | Isotope-Labeled Compounds |
| HY-15036S1 | Diclofenac-13C6 | 1261393-71-8 | Isotope-Labeled Compounds |
| HY-15037 | Diclofenac (Sodium) | 15307-79-6 | Reference compound |
| HY-15037R | Diclofenac (Sodium) (Standard) | 15307-79-6 | Reference Standards |
| HY-15037S | Diclofenac-13C6 (sodium heminonahydrate) | | Isotope-Labeled Compounds |
| HY-15037S1 | Diclofenac-d4 (sodium) | 154523-54-3 | Isotope-Labeled Compounds |
| HY-15037S2 | Diclofenac-13C6 (sodium) | 1261393-73-0 | Isotope-Labeled Compounds |
| HY-15038 | Diclofenac (potassium) | 15307-81-0 | Reference compound |
| HY-15038R | Diclofenac (potassium) (Standard) | 15307-81-0 | Reference Standards |
| HY-15039 | SSR240612 | 464930-42-5 | Reference compound |
| HY-150400 | XF056-132 (free base) | 2407450-73-9 | Reference compound |
| HY-150400A | XF056-132 | 2694057-55-9 | Reference compound |
| HY-150401 | Exatecan-amide-cyclopropanol | 2414254-34-3 | Reference compound |
| HY-150402 | MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan | 2414254-41-2 | ADC Related |
| HY-150403 | XF067-68 | 2407452-79-1 | Reference compound |
| HY-150407 | TSPO ligand-1 | 4560-08-1 | Reference compound |
| HY-150408 | FBnG-(Cys-acetamide)-CH2-PEG3-CH2-CH2-CH2-NH2 | 2241669-84-9 | Reference compound |
| HY-150409 | TSPO ligand-2 | 1160640-95-8 | Reference compound |
| HY-15041 | NVP-SAA164 | 312722-60-4 | Reference compound |
| HY-150410 | TSPO ligand-3 | 2241669-89-4 | Reference compound |
| HY-150411 | Cys-C-cGMP | 2241669-85-0 | Reference compound |
| HY-150412 | VU0364739 | 1244639-78-8 | Reference compound |
| HY-15042 | MK 0686 | 578727-68-1 | Reference compound |
| HY-15043 | ELN-441958 | 913064-47-8 | Reference compound |
| HY-15044 | NU1025 | 90417-38-2 | Reference compound |
| HY-15045 | INO-1001 | 501364-82-5 | Reference compound |
| HY-15045A | INO-1001 (mesylate) | 501364-91-6 | Reference compound |
| HY-15046 | EB-47 | 366454-36-6 | Reference compound |
| HY-15048 | GPI 15427 | 805242-85-7 | Reference compound |
| HY-15050 | KCL-440 | 651029-09-3 | Reference compound |
| HY-150500 | HDAC-IN-44 | 2414921-46-1 | Reference compound |
| HY-150501 | Diprovocim-X | 3005274-77-8 | Reference compound |
| HY-150502 | Poly(styrenyl acetal trehalose) | | Reference compound |
| HY-150503 | KH-259 | 3023019-93-1 | Reference compound |
| HY-150504 | ERAP2-IN-1 | 2420551-38-6 | Reference compound |
| HY-150505 | DC-U4106 | 2410534-62-0 | Reference compound |
| HY-150506 | SPR7 | 3032859-14-3 | Reference compound |
| HY-150507 | JNJ-4355 | 2697112-33-5 | Reference compound |
| HY-150508 | MK-0159 | 2641484-61-7 | Reference compound |
| HY-150510 | MS8511 | 2866408-21-9 | Reference compound |
| HY-150510A | MS8511 (hydrochloride) | 3031788-28-7 | Reference compound |
| HY-150511 | 3-(3-Phenoxybenzyl)amino-β-carboline | 1327080-54-5 | Reference compound |
| HY-150513 | SLP9101555 | | Reference compound |
| HY-150514 | ARN1468 | 1381459-14-8 | Reference compound |
| HY-150516S | BET-IN-12 | 1800343-11-6 | Isotope-Labeled Compounds |
| HY-150519S | 2-Chloro-2-methylpropane-d9 | 918-20-7 | Isotope-Labeled Compounds |
| HY-150520 | Neomycin | 1404-04-2 | Reference compound |
| HY-150521 | Hispolon | 173933-40-9 | Natural Products |
| HY-150521R | Hispolon (Standard) | 173933-40-9 | Reference Standards |
| HY-150523 | Ristocetin | 1404-55-3 | Reference compound |
| HY-150523S | Sodium borodeuteride-d4 | 15681-89-7 | Isotope-Labeled Compounds |
| HY-150524 | UDP-Galactose | 2956-16-3 | Reference compound |
| HY-150525 | Vitamin B6 | 8059-24-3 | Reference compound |
| HY-150525S | Acetyl-1,2 Coenzyme A-13c2 (Lithium) | | Isotope-Labeled Compounds |
| HY-150526 | EGCG-4″-sulfate | 2708237-76-5 | Reference compound |
| HY-150527S | Drotaveraldine-d10 | | Isotope-Labeled Compounds |
| HY-150528S | rac-Clopidogrel Amide-d4 | 1219423-91-2 | Isotope-Labeled Compounds |
| HY-150531S | Safinamide d3 | 1147299-71-5 | Isotope-Labeled Compounds |
| HY-150532S | (Rac)-Vitamin B5,Calcium Salt Hydrate-13C3 15N | | Isotope-Labeled Compounds |
| HY-150533S | (E/Z)-Mycophenolic Acid-13C,d3 | 1261432-16-9 | Isotope-Labeled Compounds |
| HY-150534 | Anti-melanoma agent 1 | 2418579-17-4 | Reference compound |
| HY-150535S | Bromoethanol-d4 | 81764-55-8 | Isotope-Labeled Compounds |
| HY-150536 | EP39 | | Reference compound |
| HY-150537 | AChE/GSK-3β-IN-1 | 2412364-73-7 | Reference compound |
| HY-150538 | STAT3-IN-12 | 2980758-31-2 | Reference compound |
| HY-150539 | IAB15 | 2987139-91-1 | Reference compound |
| HY-150540 | Bcl-2-IN-10 | 2773354-28-0 | Reference compound |
| HY-150541 | IAA65 | 2987139-96-6 | Reference compound |
| HY-150542 | Steroid sulfatase-IN-2 | 2413880-39-2 | Reference compound |
| HY-150543 | Steroid sulfatase-IN-3 | 2413880-53-0 | Reference compound |
| HY-150544S | N-Desmethyl selegiline-d5 (hydrochloride) | 1217774-73-6 | Isotope-Labeled Compounds |
| HY-150545 | AChE-IN-21 | 2413656-04-7 | Reference compound |
| HY-150547 | RSV-IN-6 | 2415152-41-7 | Reference compound |
| HY-150548 | COX-2/15-LOX-IN-1 | 2413565-15-6 | Reference compound |
| HY-150549 | HIV-1 protease-IN-6 | 2892016-32-7 | Reference compound |
| HY-150550 | COX-2-IN-26 | 2413565-19-0 | Reference compound |
| HY-150551 | COX-2-IN-27 | 2413565-17-8 | Reference compound |
| HY-150552 | JNK3 inhibitor-2 | 2366264-18-6 | Reference compound |
| HY-150553 | COX-2-IN-28 | 2413565-18-9 | Reference compound |
| HY-150554 | Antitubercular agent-29 | | Reference compound |
| HY-150555 | P-CAB agent 1 | 2374139-68-9 | Reference compound |
| HY-150557 | CYP1B1-IN-1 | 842122-33-2 | Reference compound |
| HY-150558 | CYP1B1-IN-2 | 727730-24-7 | Reference compound |
| HY-150559 | SMS2-IN-3 | 2414240-89-2 | Reference compound |
| HY-15056 | AMG 9090 | 118215-82-0 | Reference compound |
| HY-150560 | α-Glucosidase-IN-11 | 2411744-76-6 | Reference compound |
| HY-150561 | Trk-IN-20 | 2460924-63-2 | Reference compound |
| HY-150562 | CDK9-IN-19 | 2479306-60-8 | Reference compound |
| HY-150563 | Neuroinflammatory-IN-2 | 2361384-14-5 | Reference compound |
| HY-150564 | SMO-IN-2 | 1822355-27-0 | Reference compound |
| HY-150565 | P-gp inhibitor 5 | 2451298-06-7 | Reference compound |
| HY-150566 | BCR-ABL-IN-5 | 1795736-60-5 | Reference compound |
| HY-150567 | SMO-IN-3 | 2376914-71-3 | Reference compound |
| HY-150569 | BCR-ABL-IN-6 | 2499499-26-0 | Reference compound |
| HY-150570 | Carbonic anhydrase inhibitor 14 | 2410402-75-2 | Reference compound |
| HY-150571 | Anticancer agent 76 | 2448091-11-8 | Reference compound |
| HY-150572 | CDK2-IN-11 | 2410402-82-1 | Reference compound |
| HY-150573 | CDK2-IN-12 | 2410402-88-7 | Reference compound |
| HY-150574 | CYP3A4-IN-1 | 2771297-34-6 | Reference compound |
| HY-150576 | c-Met-IN-13 | 2377724-93-9 | Reference compound |
| HY-150577 | HDAC-IN-45 | 2421122-61-2 | Reference compound |
| HY-150578 | Keap1-Nrf2-IN-12 | 2250082-04-1 | Reference compound |
| HY-150579 | Keap1-Nrf2-IN-13 | 2456294-92-9 | Reference compound |
| HY-150580 | CYP3A4-IN-2 | 2562383-94-0 | Reference compound |
| HY-150581 | CYP3A4-IN-3 | 2562384-19-2 | Reference compound |
| HY-150582 | c-Met-IN-14 | 2443380-34-3 | Reference compound |
| HY-150583 | Chitin synthase inhibitor 2 | 2416338-24-2 | Reference compound |
| HY-150584 | Chitin synthase inhibitor 3 | 2416338-26-4 | Reference compound |
| HY-150585 | BuChE-IN-5 | 2402753-39-1 | Reference compound |
| HY-150586 | PTG-0861 | 2494082-34-5 | Reference compound |
| HY-150587 | Anti-inflammatory agent 31 | 3051838-54-8 | Reference compound |
| HY-150588 | InhA-IN-3 | 900701-83-9 | Reference compound |
| HY-150589 | InhA-IN-4 | 894309-72-9 | Reference compound |
| HY-150590 | 20S Proteasome-IN-2 | 2028300-31-2 | Reference compound |
| HY-150591 | 20S Proteasome-IN-3 | 1803040-07-4 | Reference compound |
| HY-150592 | Aurora kinase-IN-2 | 2241914-86-1 | Reference compound |
| HY-150593 | IRAK4-IN-16 | 1812188-83-2 | Reference compound |
| HY-150594 | IRAK4-IN-17 | 2183503-33-3 | Reference compound |
| HY-150595 | HDAC6-IN-10 | 2408286-73-5 | Reference compound |
| HY-150596 | CT1-3 | 2460738-32-1 | Reference compound |
| HY-150597 | HDAC-IN-46 | 2562386-85-8 | Reference compound |
| HY-150598 | CHMFL-PI4K-127 | 2377604-81-2 | Reference compound |
| HY-150599 | HIV-1 inhibitor-43 | 2493426-43-8 | Reference compound |
| HY-150600 | NS2B/NS3-IN-7 | 3035421-16-7 | Reference compound |
| HY-150601 | Estrogen receptor-IN-1 | 74027-99-9 | Reference compound |
| HY-150602 | 20S Proteasome activator 1 | 2761578-18-9 | Reference compound |
| HY-150603 | STAT3-IN-13 | 2248552-86-3 | Reference compound |
| HY-150605 | ERK5-IN-3 | 1888305-85-8 | Reference compound |
| HY-150606 | ERK5-IN-4 | 1888305-17-6 | Reference compound |
| HY-150607 | UNC7467 | 2922283-43-8 | Reference compound |
| HY-150608 | PROTAC STING Degrader-1 | 2762552-74-7 | Reference compound |
| HY-150609 | SHP2/CDK4-IN-1 | 2924036-87-1 | Reference compound |
| HY-150610 | EGFR-IN-69 | 2433837-65-9 | Reference compound |
| HY-150611 | EGFR-IN-70 | 2926716-96-1 | Reference compound |
| HY-150612 | (R)-STU104 | 2767124-77-4 | Reference compound |
| HY-150613 | PARP1/BRD4-IN-2 | 3037993-97-5 | Reference compound |
| HY-150614 | Autotaxin-IN-6 | 2800898-98-8 | Reference compound |
| HY-150615 | SphK1-IN-2 | 3031483-60-7 | Reference compound |
| HY-150616 | SJPYT-195 | 2973762-16-0 | Reference compound |
| HY-150617 | Lartesertib | 2495096-26-7 | Reference compound |
| HY-150617A | (Rac)-Lartesertib | 2020089-41-0 | Reference compound |
| HY-150618 | PI3Kα-IN-9 | 2715287-67-3 | Reference compound |
| HY-150619 | KDM4-IN-4 | 2230475-63-3 | Reference compound |
| HY-150620 | BI-0282 | 1883383-48-9 | Reference compound |
| HY-150621 | AS1134900 | 149760-98-5 | Reference compound |
| HY-150622 | SARS-CoV-2 nsp13-IN-1 | 1005304-44-8 | Reference compound |
| HY-150623 | SARS-CoV-2 nsp13-IN-2 | 522660-61-3 | Reference compound |
| HY-150624 | SARS-CoV-2 nsp13-IN-3 | 1015582-31-6 | Reference compound |
| HY-150625 | SARS-CoV-2 nsp13-IN-4 | 923140-39-0 | Reference compound |
| HY-150626 | SARS-CoV-2 nsp13-IN-5 | 912799-11-2 | Reference compound |
| HY-150627S | Pyrene-d10 | 1718-52-1 | Isotope-Labeled Compounds |
| HY-150628S | 2-Oxobutanoic acid-13C,d1 (sodium hydrate) | 1049741-69-6 | Isotope-Labeled Compounds |
| HY-150629S | 2-Ketobutyric acid-13C4,3,3-d2 sodium salt hydrate | | Isotope-Labeled Compounds |
| HY-150630 | ALR2-IN-1 | 2799695-54-6 | Reference compound |
| HY-150631S | Glutathione-glycine-13C2,15N (trifluoroacetate) | | Isotope-Labeled Compounds |
| HY-150632 | SARS-CoV-2 nsp13-IN-6 | 951588-85-5 | Reference compound |
| HY-150635S | Uridine-5'-monophosphate-15N2 (sodium) | | Isotope-Labeled Compounds |
| HY-150636 | Autophagy-IN-1 | 3031485-19-2 | Reference compound |
| HY-150637 | Mab Aspartate Decarboxylase-IN-1 | 2755712-12-8 | Reference compound |
| HY-150638 | PI3Kδ/γ-IN-3 | 2730151-31-0 | Reference compound |
| HY-150639 | Everafenib | 2923700-82-5 | Reference compound |
| HY-15064 | HC-030031 | 349085-38-7 | Reference compound |
| HY-150640 | Rho-Kinase-IN-2 | 2573071-18-6 | Reference compound |
| HY-150641 | CDK-IN-9 | 3031561-92-6 | Reference compound |
| HY-150642S | Guanosine-5 '- monophosphate-15n5 (sodium) | | Isotope-Labeled Compounds |
| HY-150643 | RSK2-IN-2 | 1637749-78-0 | Reference compound |
| HY-150644 | S07-2010 | 1223194-71-5 | Reference compound |
| HY-150646 | S07-2009 | 1580241-55-9 | Reference compound |
| HY-150648 | S07-2008 | 1090816-80-0 | Reference compound |
| HY-150649 | S07-2005 (racemic) | 1826337-40-9 | Reference compound |
| HY-15065 | Chembridge-5861528 | 332117-28-9 | Reference compound |
| HY-150650 | S07-2001 | 1197904-57-6 | Reference compound |
| HY-150651S | Uridine 5′-monophosphate-15n2 (sodium) | | Isotope-Labeled Compounds |
| HY-150652 | FGFR-IN-8 | 2640217-64-5 | Reference compound |
| HY-150654 | WDR5-IN-5 | 2417012-26-9 | Reference compound |
| HY-150655 | Hsp90-IN-15 | 2252283-32-0 | Reference compound |
| HY-150656S | Adenosine-5′-monophosphate-15N5 (sodium) | | Isotope-Labeled Compounds |
| HY-150658S | DMT-2′O-TBDMS-rA(ac)-1-15N phosphoramidite | | Isotope-Labeled Compounds |
| HY-150659S | Adenosine-5′-triphosphate-d14 (disodium) | | Isotope-Labeled Compounds |
| HY-15066 | CNQX | 115066-14-3 | Reference compound |
| HY-150660S | Ercalcidiol-13C5 | 2785319-25-5 | Isotope-Labeled Compounds |
| HY-150661S | 3-epi-Calcifediol-13C5 | 2482467-12-7 | Isotope-Labeled Compounds |
| HY-150662S | 2-(7-Hydroxycoumarin-4-yl)-propanoic acid methyl ester-d3 | | Isotope-Labeled Compounds |
| HY-150663S | Calcitriol-13C5 | | Isotope-Labeled Compounds |
| HY-150664S | 4-Methoxy-benzoic acid-d3 | 27914-54-1 | Isotope-Labeled Compounds |
| HY-150665S | N-Dansyl-d6 1,4-diaminobutane, 97% (CP) | | Isotope-Labeled Compounds |
| HY-150666S | 1-(3,4-Dimethoxy-d6-benzoyl)piperidine | | Isotope-Labeled Compounds |
| HY-150667S | 2-Amino-6-(3-methoxy-anilino)purine-d3 | | Isotope-Labeled Compounds |
| HY-150668S | Methyl 4-(benzyloxy)-3,5-dimethoxy-benzoate-d6 | | Isotope-Labeled Compounds |
| HY-150669S | HI-P224-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-15066A | CNQX (disodium) | 479347-85-8 | Reference compound |
| HY-15067 | DNQX | 2379-57-9 | Reference compound |
| HY-150670S | Dansyl-2-(2-azidoethoxy)ethanamine-d6 | | Isotope-Labeled Compounds |
| HY-150671S | Methyl suberanilate-d5 | | Isotope-Labeled Compounds |
| HY-150672S | Tetra-O-acetyl-β-D-glucopyranosylvanilin-d3 | | Isotope-Labeled Compounds |
| HY-150673S | Curcumin diglucoside-d6 | | Isotope-Labeled Compounds |
| HY-150674S | Curcumin-diglucoside tetraacetate-d6 | | Isotope-Labeled Compounds |
| HY-150675S | N-Dansyl 6-aminohexanol-d6 | | Isotope-Labeled Compounds |
| HY-150676S | N-Dansyl 1,3-diaminopropane-d6 | | Isotope-Labeled Compounds |
| HY-150677S | Desethylchloroquine-d5 (dioxalate) | | Isotope-Labeled Compounds |
| HY-150678S | Adenosine:H20-13c | | Isotope-Labeled Compounds |
| HY-150679S | Remdesivir-13C6 | | Isotope-Labeled Compounds |
| HY-15068 | NBQX | 118876-58-7 | Reference compound |
| HY-150680 | SARS-CoV-2 nsp14-IN-1 | 2816165-02-1 | Reference compound |
| HY-150681 | SARS-CoV-2 nsp14-IN-2 | 2816165-16-7 | Reference compound |
| HY-150682 | FXIa-IN-9 | 2816108-87-7 | Reference compound |
| HY-150683 | NC-III-49-1 | 3031654-46-0 | Reference compound |
| HY-150684 | GXH-II-052 | 3031654-49-3 | Reference compound |
| HY-150685 | Topo I/COX-2-IN-1 | 3031418-84-2 | Reference compound |
| HY-150686 | Chitin synthase inhibitor 4 | 2755847-31-3 | Reference compound |
| HY-150687 | ZINC12409120 | 1010888-06-8 | Reference compound |
| HY-150688 | JAK3-IN-13 | 2803329-86-2 | Reference compound |
| HY-15068A | NBQX (disodium) | 479347-86-9 | Reference compound |
| HY-15069 | Fanapanel | 161605-73-8 | Reference compound |
| HY-150691 | SARS 3CLpro-IN-1 | 2409178-86-3 | Reference compound |
| HY-150692 | Estrogen receptor α antagonist 1 | 2580941-45-1 | Reference compound |
| HY-150693 | Estrogen receptor β antagonist 2 | 2580941-14-4 | Reference compound |
| HY-150694 | HDAC6-IN-11 | 2409072-27-9 | Reference compound |
| HY-150695 | hCAIX/XII-IN-5 | 2421127-99-1 | Reference compound |
| HY-150696 | Antitumor agent-72 | 2676942-92-8 | Reference compound |
| HY-150697 | HIV-1 inhibitor-44 | | Reference compound |
| HY-150699 | TXA6101 | 1459695-66-9 | Reference compound |
| HY-15069A | Fanapanel (hydrate) | 1255517-78-2 | Reference compound |
| HY-15070 | YM 900 | 143151-35-3 | Reference compound |
| HY-150700 | RLX-33 | 2784577-71-3 | Reference compound |
| HY-150701 | INCB13739 | 869974-19-6 | Reference compound |
| HY-150702 | MAGLi 432 | 2361575-20-2 | Reference compound |
| HY-150703S | DL-4-Methoxyestradiol-13C6 | | Isotope-Labeled Compounds |
| HY-150706S | D-fructose-6-phosphate-13C6 | | Isotope-Labeled Compounds |
| HY-150707S | DL-A-phosphatidylcholine, dipalmitoyl-13C40 | | Isotope-Labeled Compounds |
| HY-150708S | Ethyl 2-hydroxy-2-methyl-3-oxobutanoate-13C | 1225273-82-4 | Isotope-Labeled Compounds |
| HY-150709S | Adenosine 5'-triphosphate-13C10,15N5 (ammonium) | | Isotope-Labeled Compounds |
| HY-150709S1 | Adenosine 5'-triphosphate-13C10,15N5 (dilithium) | | Isotope-Labeled Compounds |
| HY-15071 | YM90K | 154164-30-4 | Reference compound |
| HY-150710S | Cytidine 5'-triphosphate-13C9,15N3 (ammonium) | | Isotope-Labeled Compounds |
| HY-150711S | Guanosine-13C10,15N5 (ammonium) | 2483830-19-7 | Isotope-Labeled Compounds |
| HY-150712S | Uridine triphosphate-13C9,15N2 (dilithium) | 2483830-24-4 | Isotope-Labeled Compounds |
| HY-150716S | Iodopropamine-d3 | 1189947-73-6 | Isotope-Labeled Compounds |
| HY-150717 | RSK2-IN-3 | 1627136-54-2 | Reference compound |
| HY-150718S | α-Ketoisohexanoic acid-d3 (sodium) | 172330-01-7 | Isotope-Labeled Compounds |
| HY-150719 | AIMP2-DX2-IN-1 | 848256-17-7 | Reference compound |
| HY-15072 | Zonampanel | 210245-80-0 | Reference compound |
| HY-150720 | TYK2-IN-12 | 2244061-66-1 | Reference compound |
| HY-150721 | COX-2-IN-29 | 3033545-21-7 | Reference compound |
| HY-150722 | HDAC6-IN-12 | 2803866-44-4 | Reference compound |
| HY-150723 | PBI-6DNJ | 2857098-72-5 | Reference compound |
| HY-150724 | ODN 1018 | 937402-51-2 | Oligonucleotides |
| HY-150724A | Biotin-labeled ODN 1018 (sodium) | | Oligonucleotides |
| HY-150724B | FITC-labeled ODN 1018 (sodium) | | Oligonucleotides |
| HY-150724C | ODN 1018 (sodium) | | Oligonucleotides |
| HY-150725 | ODN 1585 | 386832-46-8 | Oligonucleotides |
| HY-150725A | Biotin-labeled ODN 1585 (sodium) | | Oligonucleotides |
| HY-150725B | FITC-labeled ODN 1585 (sodium) | | Oligonucleotides |
| HY-150725C | ODN 1585 (sodium) | | Oligonucleotides |
| HY-150726 | ODN 1668 | 1186063-66-0 | Oligonucleotides |
| HY-150726A | Biotin-labeled ODN 1668 (sodium) | | Oligonucleotides |
| HY-150726B | FITC-labeled ODN 1668 (sodium) | | Oligonucleotides |
| HY-150726C | ODN 1668 (sodium) | | Oligonucleotides |
| HY-150727 | SIRT5 inhibitor 4 | 708992-34-1 | Reference compound |
| HY-150728 | AChE-IN-22 | 3032264-62-0 | Reference compound |
| HY-150729 | ODN 1982 | 207623-15-2 | Oligonucleotides |
| HY-150729A | ODN 1982 (sodium) | | Oligonucleotides |
| HY-15073 | Becampanel | 188696-80-2 | Reference compound |
| HY-150730 | FAK-IN-6 | 3033299-38-3 | Reference compound |
| HY-150731 | Pim-1 kinase inhibitor 3 | 2801695-39-4 | Reference compound |
| HY-150732 | IRAK4-IN-18 | | Reference compound |
| HY-150733 | IRAK4-IN-19 | 3032075-32-1 | Reference compound |
| HY-150734 | ODN 2007 | 455348-63-7 | Oligonucleotides |
| HY-150734A | ODN 2007 (sodium) | | Oligonucleotides |
| HY-150735 | IRAK4-IN-20 | 1931994-80-7 | Reference compound |
| HY-150736 | ODN 20844 | 1964506-29-3 | Oligonucleotides |
| HY-150736A | ODN 20844 (sodium) | | Oligonucleotides |
| HY-150737 | MI-1851 | 2417283-44-2 | Reference compound |
| HY-150738 | ODN 2088 | 1146541-45-8 | Oligonucleotides |
| HY-150738A | Biotin-labeled ODN 2088 (sodium) | | Oligonucleotides |
| HY-150738B | FITC-labeled ODN 2088 (sodium) | | Oligonucleotides |
| HY-150738C | ODN 2088 (sodium) | | Oligonucleotides |
| HY-150739 | ODN 21158 | 1964506-31-7 | Oligonucleotides |
| HY-150739A | ODN 21158 (sodium) | | Oligonucleotides |
| HY-15074 | SPD-502 | 245063-59-6 | Reference compound |
| HY-150740 | ODN 21595 | 1964506-28-2 | Oligonucleotides |
| HY-150740A | ODN 21595 (sodium) | | Oligonucleotides |
| HY-150741 | ODN 2216 | 332437-00-0 | Oligonucleotides |
| HY-150741A | Biotin-labeled ODN 2216 (sodium) | | Oligonucleotides |
| HY-150741B | FITC-labeled ODN 2216 (sodium) | | Oligonucleotides |
| HY-150741C | ODN 2216 (sodium) | | Oligonucleotides |
| HY-150742 | ODN 2336 | 332956-64-6 | Oligonucleotides |
| HY-150742A | ODN 2336 (sodium) | | Oligonucleotides |
| HY-150743 | ODN 2395 | 1254617-22-5 | Oligonucleotides |
| HY-150743A | Biotin-labeled ODN 2395 (sodium) | | Oligonucleotides |
| HY-150743B | FITC-labeled ODN 2395 (sodium) | | Oligonucleotides |
| HY-150743C | ODN 2395 (sodium) | | Oligonucleotides |
| HY-150744 | ODN 24888 | 1964506-30-6 | Oligonucleotides |
| HY-150744A | ODN 24888 (sodium) | | Oligonucleotides |
| HY-150745 | ODN 24987 | 1682661-48-8 | Oligonucleotides |
| HY-150745A | ODN 24987 (sodium) | | Oligonucleotides |
| HY-150746 | ODN 24991 | 1682661-49-9 | Oligonucleotides |
| HY-150746A | ODN 24991 (sodium) | | Oligonucleotides |
| HY-150747 | ODN 6016 | 1271731-64-6 | Oligonucleotides |
| HY-150747A | ODN 6016 (sodium) | | Oligonucleotides |
| HY-150748 | ODN D-SL01 | 1198621-84-9 | Oligonucleotides |
| HY-150748A | ODN D-SL01 (sodium) | | Oligonucleotides |
| HY-150749 | ODN D-SL03 | 1198621-85-0 | Oligonucleotides |
| HY-150749A | ODN D-SL03 (sodium) | | Oligonucleotides |
| HY-150750 | ODN M362 | 934655-87-5 | Oligonucleotides |
| HY-150750A | ODN M362 (sodium) | | Oligonucleotides |
| HY-150751 | ODN TTAGGG | 1801724-76-4 | Oligonucleotides |
| HY-150751A | Biotin-labeled ODN TTAGGG (sodium) | | Oligonucleotides |
| HY-150751B | FITC-labeled ODN TTAGGG (sodium) | | Oligonucleotides |
| HY-150751C | ODN TTAGGG (sodium) | | Oligonucleotides |
| HY-150752 | BTK-IN-15 | 2820426-92-2 | Reference compound |
| HY-150753 | RS6212 | 2097925-52-3 | Reference compound |
| HY-150754 | FtsZ-IN-4 | 2882904-64-3 | Reference compound |
| HY-150755 | Topo I/COX-2-IN-2 | 2841455-91-0 | Reference compound |
| HY-150756 | EBOV-GP-IN-1 | 3032283-85-2 | Reference compound |
| HY-150757 | Autophagy-IN-2 | 2755454-90-9 | Reference compound |
| HY-150758 | NDM-1 inhibitor-3 | | Reference compound |
| HY-150759 | HIV-1 inhibitor-45 | 2677762-43-3 | Reference compound |
| HY-15076 | SPD-502 (sodium) | 205645-02-9 | Reference compound |
| HY-150760 | GSK5852 | 1331942-30-3 | Reference compound |
| HY-150761 | MY-875 | | Reference compound |
| HY-150762S | Adenosine 5'-Triphosphaye (ATP)-d16, ammonium salt-d12(1:4) | 2483831-65-6 | Isotope-Labeled Compounds |
| HY-150763S | Cytidine 5'-Triphosphate (ammonium salt)-d8 | 2483831-66-7 | Isotope-Labeled Compounds |
| HY-150764S | 2-(ethylamino)cyclohexa-2,5-diene-1,4-dione-d5 | | Isotope-Labeled Compounds |
| HY-150765 | PARP1-IN-12 | | Reference compound |
| HY-150766 | KPC-2-IN-1 | 2232877-85-7 | Reference compound |
| HY-150767 | KPC-2-IN-2 | 3034185-71-9 | Reference compound |
| HY-150768S | Guanosine 5'-triphosphate (GTP), ammonium salt-d27 | 2483831-68-9 | Isotope-Labeled Compounds |
| HY-150769 | ZLM-66 | 3033486-43-7 | Reference compound |
| HY-150770S | Adenosine 5'-triphosphate(ATP)-d4 (ammonium salt) | 2483831-82-7 | Isotope-Labeled Compounds |
| HY-150771S | Uridine 5'-triphosphate (ammonium salt)-d8 | 2483831-69-0 | Isotope-Labeled Compounds |
| HY-150772 | Tubulin/HDAC-IN-1 | 2413587-26-3 | Reference compound |
| HY-150773S | Guanosine 5'-triphosphate(GTP)-d4 (ammonium salt) | 2483831-83-8 | Isotope-Labeled Compounds |
| HY-150774 | HDAC6/HSP90-IN-2 | 2803866-22-8 | Reference compound |
| HY-150775 | CYP19A1-IN-2 | 3033282-93-5 | Reference compound |
| HY-150776S | L-carnitine: CLO4, 3-hydroxyisovaleryl-d3 | 2245711-23-1 | Isotope-Labeled Compounds |
| HY-150777S | Cytidine 5'-triphosphate(CTP)-d4 (ammonium salt) | | Isotope-Labeled Compounds |
| HY-150778S | Uridine 5'-triphosphate(UTP)-d4 (ammonium) | | Isotope-Labeled Compounds |
| HY-150779S | Choline-d13 (sulfate) | 2483831-84-9 | Isotope-Labeled Compounds |
| HY-15078 | NS1219 | 233603-81-1 | Reference compound |
| HY-150780S | Cytidine 5'-triphosphate (ammonium salt)-d2 | 2483831-93-0 | Isotope-Labeled Compounds |
| HY-150781 | EGFR-IN-71 | 2676155-98-7 | Reference compound |
| HY-150782 | UNC-CA359 | 2676156-05-9 | Reference compound |
| HY-150783 | SARS-CoV-2-IN-24 | | Reference compound |
| HY-150784 | XR8-89 | 2817811-16-6 | Reference compound |
| HY-150785 | TAS1553 | 2166023-31-8 | Reference compound |
| HY-150786 | PLP_Snyder530 | | Reference compound |
| HY-150787 | BMS-986339 | 2477873-64-4 | Reference compound |
| HY-150789 | SARS-CoV-2-IN-23 | | Reference compound |
| HY-15079 | Talampanel | 161832-65-1 | Reference compound |
| HY-150790 | BMS-986141 | 1478711-48-6 | Reference compound |
| HY-150791 | FLDP-5 | 950665-12-0 | Reference compound |
| HY-150792S | Inosine-15N4 | 204634-01-5 | Isotope-Labeled Compounds |
| HY-150793 | SY-LB-57 | 2253719-35-4 | Reference compound |
| HY-150794 | FLDP-8 | 861968-02-7 | Reference compound |
| HY-150795 | SY-LB-35 | 2603461-70-5 | Reference compound |
| HY-150796S | Guanosine 5'-triphosphate, ammonium salt-15N5 | | Isotope-Labeled Compounds |
| HY-150797 | QA-68 | | Reference compound |
| HY-150798S | Uridine 5'-triphosphate (ammonium salt)-15N2 | | Isotope-Labeled Compounds |
| HY-150799 | CRBN ligand-1 | 3032314-67-0 | Reference compound |
| HY-150803 | VHL Ligand 14 | 2010986-87-3 | Reference compound |
| HY-15082 | Irampanel | 206260-33-5 | Reference compound |
| HY-150839 | E3 ligase Ligand PG | 14149-34-9 | Reference compound |
| HY-15084 | Dizocilpine (maleate) | 77086-22-7 | Reference compound |
| HY-150843S | Adenosine 5'-triphosphate-15N5 (ammonium) | | Isotope-Labeled Compounds |
| HY-150844S | Ethylbenzene-2,3,4,5,6-d5 | 20302-26-5 | Isotope-Labeled Compounds |
| HY-150845S | Bis(2-chloroethoxy)-methane-d8 | 93966-78-0 | Isotope-Labeled Compounds |
| HY-150846S | 1,1,1,2-Tetrachloroethane-d2 | 117164-18-8 | Isotope-Labeled Compounds |
| HY-150847S | 1,2,3,4-Tetramethylbenzene-d14 | 350818-60-9 | Isotope-Labeled Compounds |
| HY-150848S | 2,3,6-Trichloroanisole-d3 | 1219798-64-7 | Isotope-Labeled Compounds |
| HY-150849S | (RS)-S-Adenosyl-L-methionine-d3 (S-methyl-d3) Tri(p-toluenesulfonate) Salt | 349560-27-6 | Isotope-Labeled Compounds |
| HY-15084A | (-)-Dizocilpine (maleate) | 121917-57-5 | Reference compound |
| HY-15084B | Dizocilpine | 77086-21-6 | Reference compound |
| HY-15085 | MDL 105519 | 161230-88-2 | Reference compound |
| HY-150850S | DL-Leucine-N-FMOC-d10 | | Isotope-Labeled Compounds |
| HY-150853S | 3-(Methyl-nitrosoamino)propionitrile-d3 | 1329834-39-0 | Isotope-Labeled Compounds |
| HY-150854S | Bis(8-methyl-1-nonyl) Phthalate-3,4,5,6-d4 | 1346604-79-2 | Isotope-Labeled Compounds |
| HY-150855S | Bis(7-methyl-1-octyl) Phthalate-3,4,5,6-d4 | 1332965-90-8 | Isotope-Labeled Compounds |
| HY-150857S | Thymine-α,α,α,6-d4 Glycol (mixture of diastereomers)-d4 | 132523-94-5 | Isotope-Labeled Compounds |
| HY-150859 | HDAC ligand-1 | 34840-28-3 | Reference compound |
| HY-15085A | (Z)-MDL 105519 | 179105-67-0 | Reference compound |
| HY-15086 | Selfotel | 110347-85-8 | Reference compound |
| HY-150863S | Monononyl phthalate-d4 | 2514564-42-0 | Isotope-Labeled Compounds |
| HY-150864S | Mono-n-Pentyl Phthalate-3,4,5,6-d4 | 1794756-28-7 | Isotope-Labeled Compounds |
| HY-150865S | Mono-n-Propyl Phthalate-3,4,5,6-d4 | 1795020-91-5 | Isotope-Labeled Compounds |
| HY-150871S | Uridine 5'-triphosphate-d7 (ammonium) | | Isotope-Labeled Compounds |
| HY-150873S | Bis(5-methylhexyl) Phthalate-3,4,5,6-d4 | 2708280-88-8 | Isotope-Labeled Compounds |
| HY-150879 | BMS-37 | 1675202-20-6 | Reference compound |
| HY-15087A | Spergualin (trihydrochloride) | 80952-47-2 | Reference compound |
| HY-150885 | BTK ligand 1 | 330785-90-5 | Reference compound |
| HY-150905 | EGFR ligand-2 | 2737283-20-2 | Reference compound |
| HY-15091 | Anisperimus | 170368-04-4 | Reference compound |
| HY-150910 | Brigatinib C | 1197958-75-0 | Reference compound |
| HY-150915S | Uracil 4,5-13c2 | 181517-15-7 | Isotope-Labeled Compounds |
| HY-150918S | 5-Methyl-1H-pyrazole-3-propanoic acid-13C5 | | Isotope-Labeled Compounds |
| HY-150926 | G12Si-1 | 2946593-42-4 | Reference compound |
| HY-150927 | G12Si-2 | 2946593-43-5 | Reference compound |
| HY-150929S | Cytidine 5'-triphosphate (CTP)-d5 (ammonium) | | Isotope-Labeled Compounds |
| HY-150930S | Cytidine 5'-triphosphate-15N3 (ammonium) | | Isotope-Labeled Compounds |
| HY-150931S | Uridine 5'-triphosphate (UTP)-d5 (tetraammonium) | | Isotope-Labeled Compounds |
| HY-150954S | L-Methionine-d3 (S-methyl-d3) Methyl-d3-sulfonium Chloride | | Isotope-Labeled Compounds |
| HY-150958 | RAD51-IN-8 | | Reference compound |
| HY-150959 | α-Glucosidase-IN-12 | 2816072-24-7 | Reference compound |
| HY-15096 | MKT-077 | 147366-41-4 | Dye Reagents |
| HY-150960 | α-Glucosidase-IN-13 | 2816072-18-9 | Reference compound |
| HY-150961 | α-Glucosidase-IN-14 | 2816072-15-6 | Reference compound |
| HY-150962S | 5-Hydroxycytosine-13C,15N2 | 181516-92-7 | Isotope-Labeled Compounds |
| HY-150963 | Renin inhibitor-1 | 1093082-54-2 | Reference compound |
| HY-150964S | S-Adenosyl-L-methionine-d3 (methylbenzenesulfonate) | | Isotope-Labeled Compounds |
| HY-150965 | NDT-30805 | | Reference compound |
| HY-150966 | Antiproliferative agent-10 | | Reference compound |
| HY-150967 | MmpL3-IN-1 | 2290534-93-7 | Reference compound |
| HY-150968 | Antiproliferative agent-11 | | Reference compound |
| HY-150969 | Antiproliferative agent-12 | | Reference compound |
| HY-15097 | Myricetin | 529-44-2 | Natural Products |
| HY-150970 | ICy-OH | 2863682-80-6 | Reference compound |
| HY-150971 | ICy-Q | 2863682-83-9 | Reference compound |
| HY-150972 | P163-0892 | 1574576-45-6 | Reference compound |
| HY-150973 | hCAII-IN-4 | 2816080-18-7 | Reference compound |
| HY-150974 | ROS1-IN-1 | 2883232-34-4 | Reference compound |
| HY-150975 | hCAII-IN-5 | 2816080-16-5 | Reference compound |
| HY-150976 | β-Glucuronidase/hCAII-IN-1 | 2816080-17-6 | Reference compound |
| HY-150977 | β-Glucuronidase/hCAII-IN-2 | 2816080-13-2 | Reference compound |
| HY-150978 | DDAO-C6 | 2102418-90-4 | Dye Reagents |
| HY-150979 | Gd-NMC-3 | 2678579-76-3 | Dye Reagents |
| HY-15097R | Myricetin (Standard) | 529-44-2 | Reference Standards |
| HY-15097S | Myricetin-13C3 | | Isotope-Labeled Compounds |
| HY-15098 | Apoptozole | 1054543-47-3 | Reference compound |
| HY-150980S | 1,2-O-Isopropylidene-β-L-idofuranuronic-6-13C acid γ-lactone | 40010-58-0 | Isotope-Labeled Compounds |
| HY-150981S | 1,2-O-Isopropylidene-a-D-glucofuranuronic-6-13C acid, γ-lactone | 40010-66-0 | Isotope-Labeled Compounds |
| HY-150983 | ATP synthase inhibitor 2 | 2814540-76-4 | Reference compound |
| HY-150983A | ATP synthase inhibitor 2 (TFA) | | Reference compound |
| HY-150985S | 2,2'-Dichloro bisphenol a mono-D-glucuronide-d12 | 2673270-16-9 | Isotope-Labeled Compounds |
| HY-150986S | Dihydrobupropion-d9 | 1215071-07-0 | Isotope-Labeled Compounds |
| HY-150987S | 2,2',6-Trichloro bisphenol A-d11 | | Isotope-Labeled Compounds |
| HY-150988S | 2,2'-Dichloro bisphenol A-d12 | 2748525-32-6 | Isotope-Labeled Compounds |
| HY-150989S | 1,4-Butanediol mononitrate-d8 | 1261398-94-0 | Isotope-Labeled Compounds |
| HY-15099 | NC 2300 | 221144-20-3 | Reference compound |
| HY-150991S | Desmethylsildenafil-d8 (citrate) | 1215071-06-9 | Isotope-Labeled Compounds |
| HY-150992S | 2,6-Dichloro bisphenol A-d12 | 2739737-75-6 | Isotope-Labeled Compounds |
| HY-150993S | Rosiglitazone-d5 (maleate) | 1215168-64-1 | Isotope-Labeled Compounds |
| HY-150994S | 2-Methoxy-3,5-dimethylpyrazine-d3 | 1335402-04-4 | Isotope-Labeled Compounds |
| HY-150997S | Hydroxyalprazolam-d4 | 1420291-59-3 | Isotope-Labeled Compounds |
| HY-150999S | 2,2′,5-Trichlorobiphenyl-3,4,4′,6,6′-d5 | | Isotope-Labeled Compounds |
| HY-15100 | Balicatib | 354813-19-7 | Reference compound |
| HY-151001S | EXP3174-d9 | | Isotope-Labeled Compounds |
| HY-151002S | M8 metabolite of Carvedilol-d5 | 2673270-31-8 | Isotope-Labeled Compounds |
| HY-151003S | D-Panthenol-d4 | 2673270-00-1 | Isotope-Labeled Compounds |
| HY-151017S | Mequitazine-d2 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-15102 | MK-0429 | 227963-15-7 | Reference compound |
| HY-151027S | Androsterone-d4 glucuronide | 2687960-87-6 | Isotope-Labeled Compounds |
| HY-151029S | Drotavering-d10 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-15103 | AH3960 | 862907-48-0 | Reference compound |
| HY-15104 | Ronacaleret (hydrochloride) | 702686-96-2 | Reference compound |
| HY-151048 | JBJ-07-149 | 2140807-58-3 | Reference compound |
| HY-15105 | SB-423562 | 351490-27-2 | Reference compound |
| HY-15105A | SB-423562 (hydrochloride) | 351490-72-7 | Reference compound |
| HY-15106 | SB-423557 | 351490-26-1 | Reference compound |
| HY-151066 | BMS-1233 | 2447065-99-6 | Reference compound |
| HY-151068S | 2,3′,4′,5-Tetrachlorobiphenyl-3,4,6-d3 | 1219794-77-0 | Isotope-Labeled Compounds |
| HY-151069 | TMX-2039 | 2488892-01-7 | Reference compound |
| HY-151070S | 2,3,4-Trichlorobiphenyl-2′,3′,4′,5′,6′-d5 | | Isotope-Labeled Compounds |
| HY-151071 | TMX-3013 | 2488761-18-6 | Reference compound |
| HY-151073S | 2′,3,4-Trichlorobiphenyl-3′,4′,5′,6′-d4 | | Isotope-Labeled Compounds |
| HY-151074S | 2,2′-Binaphthyl-d14 | 210487-05-1 | Isotope-Labeled Compounds |
| HY-151076S | 2,3,3′,4,5,5′-Hexachlorobiphenyl-2′,4′,6′-d3 | 1219798-69-2 | Isotope-Labeled Compounds |
| HY-151078S | 2,3′,5-Trichlorobiphenyl-2′,3,4,4′,6,6′-d6 | | Isotope-Labeled Compounds |
| HY-151079S | 2,3,4,5,6-Pentachlorobiphenyl-2′,3′,4′,5′,6′-d5 | 1219798-92-1 | Isotope-Labeled Compounds |
| HY-15108 | Purmorphamine | 483367-10-8 | Reference compound |
| HY-151080S | 2,4,5-Trichlorobiphenyl-2′,3′,4′,5′,6′-d5 | 1276197-33-1 | Isotope-Labeled Compounds |
| HY-151081S | 2,5-Dichlorobiphenyl-2′,3′,4′,5′,6′-d5 | 1219804-50-8 | Isotope-Labeled Compounds |
| HY-151082S | 2,2′,3,4,5,5′-Hexachlorobiphenyl-3′,4′,6′-d3 | 1219798-51-2 | Isotope-Labeled Compounds |
| HY-151083S | 2-tert-Butylamino-d9-4-chloro-6-cyclopropylamino-1,3,5-triazine | 1189419-70-2 | Isotope-Labeled Compounds |
| HY-151084S | 3-(3-Ethoxy-4-methoxyphenyl)propionic-2,2,3,3-d4 | 1398065-51-4 | Isotope-Labeled Compounds |
| HY-151085S | 3,4,5-Trichlorobiphenyl-2′,3′,4′,5′,6′-d5 | 93952-22-8 | Isotope-Labeled Compounds |
| HY-151086S | 3-Nitrofluoranthene-d9 | 350820-11-0 | Isotope-Labeled Compounds |
| HY-15108G | Purmorphamine (GMP) | 483367-10-8 | GMP Small Molecules |
| HY-151090S | 3,5-Dichlorobiphenyl-2′,3′,4′,5′,6′-d5 | 1276197-28-4 | Isotope-Labeled Compounds |
| HY-151091S | 6-Nitrochrysene-d11 | 203805-92-9 | Isotope-Labeled Compounds |
| HY-151092 | Anticancer agent 77 | 2787582-75-4 | Reference compound |
| HY-151093 | IDO2-IN-1 | 2803768-09-2 | Reference compound |
| HY-151094 | FTEAA | | Reference compound |
| HY-151095 | Phytoene desaturase-IN-1 | 2765793-54-0 | Reference compound |
| HY-151096 | ACT-660602 | 1646267-59-5 | Reference compound |
| HY-151097S | (±)-Benzfendizone-13C | | Isotope-Labeled Compounds |
| HY-151098S | Chlorpromazine-d6 (oxalate) | 1276197-23-9 | Isotope-Labeled Compounds |
| HY-151100 | GPR84 antagonist 3 | 2815263-05-7 | Reference compound |
| HY-151101 | MS159 | 3031353-59-7 | Reference compound |
| HY-151102 | Fabimycin | 2651965-71-6 | Reference compound |
| HY-151103 | Neuraminidase-IN-10 | 2685786-29-0 | Reference compound |
| HY-151104 | Neuraminidase-IN-11 | 2685786-28-9 | Reference compound |
| HY-151105 | CBR Agonist-1 | | Reference compound |
| HY-151106 | FTO-IN-8 | 2640366-38-5 | Reference compound |
| HY-151107 | CBR Agonist-2 | | Reference compound |
| HY-151108 | IDO1/TDO-IN-4 | 461424-21-5 | Reference compound |
| HY-151109 | IR-990 | | Dye Reagents |
| HY-151110 | PROTAC CDK12/13 Degrader-1 | | Reference compound |
| HY-151110A | PROTAC CDK12/13 Degrader-1 (TFA) | | Reference compound |
| HY-151111 | SPH3127 | 1399849-02-5 | Reference compound |
| HY-151113 | ZINC000104379474 | 1135190-41-8 | Reference compound |
| HY-151115 | JNJ-1289 | 792898-18-1 | Reference compound |
| HY-151116 | HER2-IN-10 | 1059177-03-5 | Reference compound |
| HY-151117S | Methylacetylene-d4 | 6111-63-3 | Isotope-Labeled Compounds |
| HY-151118 | HER2-IN-11 | | Reference compound |
| HY-151119 | Anticancer agent 78 | | Reference compound |
| HY-15112 | JTP-4819 | 162203-65-8 | Reference compound |
| HY-151120 | Anticancer agent 79 | | Reference compound |
| HY-151121 | Anticancer agent 80 | | Reference compound |
| HY-151122S | Methylacetylene-d1 | 7299-37-8 | Isotope-Labeled Compounds |
| HY-151123 | Pelacarsen | 1637637-70-7 | Oligonucleotides |
| HY-151123A | Pelacarsen (sodium) | 2172851-58-8 | Oligonucleotides |
| HY-151124S | n-Tetracontane-d82 | 1219802-99-9 | Isotope-Labeled Compounds |
| HY-151129 | nAChR-IN-1 | 849461-90-1 | Reference compound |
| HY-15113 | Y-29794 | 129184-48-1 | Reference compound |
| HY-151130S | 3′,4′-Dibenzyloxyaceto-phenone-d3 | 344299-53-2 | Isotope-Labeled Compounds |
| HY-151131S | Tri-iso-propyl-d21-phosphine carbon disulfide complex-d21 | 1219798-41-0 | Isotope-Labeled Compounds |
| HY-151132 | Glutaminyl cyclases-IN-1 | 3032400-33-9 | Reference compound |
| HY-151133 | Antiparasitic agent-9 | 2516237-50-4 | Reference compound |
| HY-151134 | HBV-IN-25 | 2161364-69-6 | Reference compound |
| HY-151135 | α-Glucosidase-IN-15 | 2820424-85-7 | Reference compound |
| HY-151136 | DY-46-2 | 1105110-83-5 | Reference compound |
| HY-151137 | HSP90/mTOR-IN-1 | 3033543-67-5 | Reference compound |
| HY-151138 | α-Glucosidase-IN-16 | 1606142-34-0 | Reference compound |
| HY-151139 | LJ-4517 | 2988849-20-1 | Reference compound |
| HY-15113A | Y-29794 (tosylate) | 143984-17-2 | Reference compound |
| HY-15114 | S 17092 | 176797-26-5 | Reference compound |
| HY-151140 | CYP11B1-IN-2 | | Reference compound |
| HY-151141 | α-Glucosidase-IN-17 | 2820424-84-6 | Reference compound |
| HY-151142 | α-Glucosidase-IN-18 | 2820424-81-3 | Reference compound |
| HY-151143 | α-Glucosidase-IN-19 | | Reference compound |
| HY-151144 | α-Glucosidase-IN-20 | 420809-56-9 | Reference compound |
| HY-151145 | α-Glucosidase-IN-21 | 321686-01-5 | Reference compound |
| HY-151146 | (1R,3S)-THCCA-Asn | 1349084-71-4 | Reference compound |
| HY-151148 | Trypanothione synthetase-IN-1 | 2355349-41-4 | Reference compound |
| HY-151149 | Trypanothione synthetase-IN-4 | | Reference compound |
| HY-151150 | Trypanothione synthetase-IN-2 | 3033799-60-6 | Reference compound |
| HY-151151 | Trypanothione synthetase-IN-3 | 1314875-96-1 | Reference compound |
| HY-151152 | AChE-IN-24 | 3033542-32-1 | Reference compound |
| HY-151153 | HDAC1-IN-5 | | Reference compound |
| HY-151154 | EGFR/HER2/DHFR-IN-1 | 2820126-37-0 | Reference compound |
| HY-151155 | ALK-IN-23 | 3033549-18-4 | Reference compound |
| HY-151156 | EGFR/HER2-IN-6 | 2820126-50-7 | Reference compound |
| HY-151158 | EGFR/HER2-IN-7 | 2820126-28-9 | Reference compound |
| HY-151159 | DHFR-IN-4 | 2820126-49-4 | Reference compound |
| HY-15116 | ONO 1603 | 117427-00-6 | Reference compound |
| HY-151160 | LasR-IN-1 | 3033530-75-2 | Reference compound |
| HY-151161 | EGFR/HER2-IN-8 | 2820126-32-5 | Reference compound |
| HY-151162 | HER2-IN-12 | 2820126-51-8 | Reference compound |
| HY-151164 | LasR-IN-2 | 3033530-61-6 | Reference compound |
| HY-151165 | LasR-IN-3 | 2810894-92-7 | Reference compound |
| HY-151165R | LasR-IN-3 (Standard) | 2810894-92-7 | Reference Standards |
| HY-151166 | β-Glucuronidase-IN-2 | | Reference compound |
| HY-151167 | LasR-IN-4 | 183488-96-2 | Reference compound |
| HY-151168 | 3-Chlorogentisyl alcohol | 32744-80-2 | Reference compound |
| HY-151169 | MDM2/4-p53-IN-1 | 3037300-57-2 | Reference compound |
| HY-151170 | MDM2/4-p53-IN-2 | 3037300-49-2 | Reference compound |
| HY-151171 | MDM2/4-p53-IN-3 | | Reference compound |
| HY-151172 | MDM2-p53-IN-15 | | Reference compound |
| HY-151173 | XO/COX/LOX-IN-1 | 2831329-35-0 | Reference compound |
| HY-151174 | PDE4-IN-12 | 2901084-32-8 | Reference compound |
| HY-151175S | (±)-2-Methylbutyryl chloride-d9 | 1219795-10-4 | Isotope-Labeled Compounds |
| HY-151176S | L-Methionine-methyl-sulfonium-d6 (chloride hydrochloride) | 63889-27-0 | Isotope-Labeled Compounds |
| HY-151180S | o-Tolyl-Isocyanated7 | 1219802-73-9 | Isotope-Labeled Compounds |
| HY-151182S | 1,3-Propane-dithiol-d6 | 1219803-51-6 | Isotope-Labeled Compounds |
| HY-151183S | N-Acetyl-S-phenyl-DL-cysteine-3,3-d2 | | Isotope-Labeled Compounds |
| HY-151185 | Sirt2-IN-7 | | Reference compound |
| HY-151186S | 4-n-Octyl-anisole-d17 | 1219794-56-5 | Isotope-Labeled Compounds |
| HY-151187S | 4-n-Butylanisole-2,3,5,6-d4 | 1219804-78-0 | Isotope-Labeled Compounds |
| HY-151188 | DHU-Se1 | | Reference compound |
| HY-151189 | ROCK-IN-4 | 2488395-07-7 | Reference compound |
| HY-151190 | cis-4-Br-2,5-F2-PCPA | 2821068-03-3 | Reference compound |
| HY-151191 | LSD1-IN-22 | 2821068-05-5 | Reference compound |
| HY-151192 | LSD1/2-IN-3 | 2821068-07-7 | Reference compound |
| HY-151193 | NNMT-IN-3 | 3031493-74-7 | Reference compound |
| HY-151194 | LSD1/2-IN-4 | 2821068-09-9 | Reference compound |
| HY-151195 | 20S Proteasome-IN-4 | 2827061-47-0 | Reference compound |
| HY-151196 | FXIa-IN-10 | 2816108-08-2 | Reference compound |
| HY-151197 | HIV protease-IN-1 | 2511547-82-1 | Reference compound |
| HY-151198 | CHF-6366 | 1615208-41-7 | Reference compound |
| HY-151199 | Steroid sulfatase/17β-HSD1-IN-1 | 2990549-70-5 | Reference compound |
| HY-151200 | Steroid sulfatase-IN-4 | 2990549-73-8 | Reference compound |
| HY-151201 | Steroid sulfatase/17β-HSD1-IN-3 | 2990549-76-1 | Reference compound |
| HY-151202 | Steroid sulfatase/17β-HSD1-IN-4 | 2990549-94-3 | Reference compound |
| HY-151203 | PKG1α activator 3 | 2773367-58-9 | Reference compound |
| HY-151204 | PknB-IN-1 | 1447917-39-6 | Reference compound |
| HY-151205 | Antituberculosis agent-3 | 369606-71-3 | Reference compound |
| HY-151206 | PknB-IN-2 | 500015-22-5 | Reference compound |
| HY-151207 | Anticancer agent 81 | 2820286-56-2 | ADC Related |
| HY-151208 | MAO-B-IN-16 | 1021238-13-0 | Reference compound |
| HY-151209 | MAO-B-IN-15 | 2032436-79-4 | Reference compound |
| HY-15121 | L-Theanine | 3081-61-6 | Natural Products |
| HY-151210 | MAO-B-IN-17 | 2890188-81-3 | Reference compound |
| HY-151211 | BTK-IN-16 | 2883232-92-4 | Reference compound |
| HY-151212 | BCP-T.A | 2786829-70-5 | Reference compound |
| HY-151214S | 4-Fluorobenzoyl-2,3,5,6-d4 chloride | 1071809-52-3 | Isotope-Labeled Compounds |
| HY-151215S | S-Sulfo-DL-cysteine-2,3,3-d3-1 | | Isotope-Labeled Compounds |
| HY-151216S | rel-Paroxetine-d4 (hydrochloride) | 1217683-35-6 | Isotope-Labeled Compounds |
| HY-151217 | Ipronidazole | 14885-29-1 | Reference compound |
| HY-151217R | Ipronidazole (Standard) | 14885-29-1 | Reference Standards |
| HY-15121R | L-Theanine (Standard) | 3081-61-6 | Reference Standards |
| HY-15121S | L-Theanine-d5 | 1217451-85-8 | Isotope-Labeled Compounds |
| HY-15121S1 | L-Theanine-13C2,15N2 | | Isotope-Labeled Compounds |
| HY-15122 | Sinomenine | 115-53-7 | Natural Products |
| HY-151220 | Androgen receptor-IN-4 | 2759137-87-4 | Reference compound |
| HY-151221 | CID 697851 | 312508-42-2 | Reference compound |
| HY-151223 | D-Glyceraldehyde 3-phosphate | 591-57-1 | Reference compound |
| HY-151224 | Thermospermine | 70862-11-2 | Reference compound |
| HY-151224R | Thermospermine (Standard) | 70862-11-2 | Reference Standards |
| HY-151226 | Glyceryl monostearate | 31566-31-1 | Reference compound |
| HY-151227 | VL285 Phenol | 1448188-69-9 | Reference compound |
| HY-151229 | S-Methyl-N,N-diethylthiolcarbamate | 686-07-7 | Reference compound |
| HY-15122A | Sinomenine hydrochloride | 6080-33-7 | Natural Products |
| HY-15122AR | Sinomenine hydrochloride (Standard) | 6080-33-7 | Reference Standards |
| HY-15122R | Sinomenine (Standard) | 115-53-7 | Reference Standards |
| HY-15123 | (S)-Flurbiprofen | 51543-39-6 | Reference compound |
| HY-151230 | (-)-Erteberel | 533884-08-1 | Reference compound |
| HY-151231 | 6-Hydroxyluteolin | 18003-33-3 | Natural Products |
| HY-151232 | Rilzabrutinib | 1575591-66-0 | Reference compound |
| HY-151233 | ALK5-IN-10 | 1352608-94-6 | Reference compound |
| HY-151236 | Antitubercular agent-30 | 384857-54-9 | Reference compound |
| HY-151239 | ONT-993 | 937263-81-5 | Reference compound |
| HY-15123R | (S)-Flurbiprofen (Standard) | 51543-39-6 | Reference Standards |
| HY-15124 | (S)-(-)-Bay-K-8644 | 98625-26-4 | Reference compound |
| HY-151240 | Galactosylceramide | 85305-88-0 | Reference compound |
| HY-151241 | Sinomenine N-oxide | 1000026-77-6 | Natural Products |
| HY-151243 | NCATS-SM1441 | 1964517-04-1 | Reference compound |
| HY-151245 | Neolinustatin | 72229-42-6 | Natural Products |
| HY-151247 | GnRH-R antagonist 1 | 2826273-90-7 | Reference compound |
| HY-151248 | HDAC2-IN-1 | 2919691-32-8 | Reference compound |
| HY-15125 | (R)-(+)-Bay-K-8644 | 98791-67-4 | Reference compound |
| HY-151250 | HIV-1 protease-IN-7 | 2916441-36-4 | Peptides |
| HY-151251 | CYP2C9/CYP2C19-IN-1 | 3010895-55-0 | Reference compound |
| HY-151252 | NIC-0102 | 2806031-94-5 | Reference compound |
| HY-151253 | CYP2C1/CYP2C19-IN-2 | 3010895-54-9 | Reference compound |
| HY-151254 | CYP2C19-IN-1 | 3010895-53-8 | Reference compound |
| HY-151255 | CDK8-IN-9 | 2850253-95-9 | Reference compound |
| HY-151256 | JAK-2/3-IN-2 | 2170398-48-6 | Reference compound |
| HY-151257 | IHMT-MST1-58 | 2414484-25-4 | Reference compound |
| HY-151258 | TK4g | 2232890-86-5 | Reference compound |
| HY-151259 | TK4b | 2232890-81-0 | Reference compound |
| HY-151260 | AChE/BACE1/GSK3β-IN-1 | 2866066-81-9 | Reference compound |
| HY-151261 | HDAC6-IN-13 | 2837128-41-1 | Reference compound |
| HY-151262 | JAK-IN-23 | 3031837-35-8 | Reference compound |
| HY-151263 | G4/HDAC-IN-1 | 3031784-60-5 | Reference compound |
| HY-151264 | BSP16 | 2727249-47-8 | Reference compound |
| HY-151265 | MMT5-14 | 2719679-31-7 | Reference compound |
| HY-151266 | AR antagonist 4 | 2883447-45-6 | Reference compound |
| HY-151267 | SARS-CoV-2-IN-25 | | Reference compound |
| HY-151267A | SARS-CoV-2-IN-25 (disodium) | | Reference compound |
| HY-151269 | SARS-CoV-2-IN-26 | | Reference compound |
| HY-151269A | SARS-CoV-2-IN-23 (disodium) | | Reference compound |
| HY-15127 | Isotretinoin | 4759-48-2 | Reference compound |
| HY-151270 | ALK5-IN-25 | 2785430-81-9 | Reference compound |
| HY-151271 | SARS-CoV-2-IN-27 | | Reference compound |
| HY-151271A | SARS-CoV-2-IN-27 (disodium) | | Reference compound |
| HY-151272 | ALK5-IN-26 | 2785430-82-0 | Reference compound |
| HY-151273 | ALK5-IN-27 | 2785430-83-1 | Reference compound |
| HY-151274 | SARS-CoV-2-IN-28 | | Reference compound |
| HY-151274A | SARS-CoV-2-IN-28 (disodium) | | Reference compound |
| HY-151275 | ALK5-IN-28 | 2785430-84-2 | Reference compound |
| HY-151276 | SARS-CoV-2-IN-29 | | Reference compound |
| HY-151276A | SARS-CoV-2-IN-29 (disodium) | | Reference compound |
| HY-151277 | ALK5-IN-29 | 2785430-85-3 | Reference compound |
| HY-151278 | SARS-CoV-2-IN-30 | | Reference compound |
| HY-151278A | SARS-CoV-2-IN-30 (disodium) | | Reference compound |
| HY-151279 | ALK5-IN-30 | 2785430-86-4 | Reference compound |
| HY-15127R | Isotretinoin (Standard) | 4759-48-2 | Reference Standards |
| HY-15127S | Isotretinoin-d5 | | Isotope-Labeled Compounds |
| HY-15128 | 9-cis-Retinoic acid | 5300-03-8 | Reference compound |
| HY-151280 | Antifungal agent 37 | 2833772-92-0 | Reference compound |
| HY-151281 | ALK5-IN-31 | 2785430-87-5 | Reference compound |
| HY-151282 | ALK5-IN-32 | 2785430-88-6 | Reference compound |
| HY-151283 | ALK5-IN-33 | 2785430-89-7 | Reference compound |
| HY-151284 | Antifungal agent 38 | 2833772-94-2 | Reference compound |
| HY-151285 | JAK-2/3-IN-3 | 2242031-31-6 | Reference compound |
| HY-151286 | Antitumor agent-73 | 2812356-72-0 | Reference compound |
| HY-151287 | KRAS inhibitor-20 | 2411786-32-6 | Reference compound |
| HY-151288 | KRAS inhibitor-21 | 2411786-50-8 | Reference compound |
| HY-151289 | ALK5-IN-34 | 2785430-90-0 | Reference compound |
| HY-15128R | 9-cis-Retinoic acid (Standard) | 5300-03-8 | Reference Standards |
| HY-15129 | O-Phospho-L-serine | 407-41-0 | Natural Products |
| HY-151292 | Antitumor agent-74 | 2827065-28-9 | Reference compound |
| HY-151295 | Antitumor agent-75 | 2827065-29-0 | Reference compound |
| HY-15129R | O-Phospho-L-serine (Standard) | 407-41-0 | Reference Standards |
| HY-15129S | O-Phospho-L-serine-13C3,15N | 2734706-69-3 | Isotope-Labeled Compounds |
| HY-15130 | DL-O-Phosphoserine | 17885-08-4 | Natural Products |
| HY-15130R | DL-O-Phosphoserine (Standard) | 17885-08-4 | Reference Standards |
| HY-15131 | PNRI-299 | 550368-41-7 | Reference compound |
| HY-15133 | PTP1B-IN-3 | 809272-64-8 | Reference compound |
| HY-151335 | KU-177 | 1160952-43-1 | Reference compound |
| HY-151337 | Aha1/Hsp90-IN-1 | 2768265-58-1 | Reference compound |
| HY-151338 | AChE-IN-25 | 2835538-69-5 | Reference compound |
| HY-151339 | Antitubercular agent-31 | 2764818-29-1 | Reference compound |
| HY-15133A | PTP1B-IN-3 (diammonium) | 2702673-78-5 | Reference compound |
| HY-15134 | ONT-093 | 216227-54-2 | Reference compound |
| HY-151340 | Antitubercular agent-32 | 2498762-42-6 | Reference compound |
| HY-151341 | HIF-1/2α-IN-1 | 2827693-99-0 | Reference compound |
| HY-151342 | Ser@TPP@CUR | | Reference compound |
| HY-151344 | HIF-1/2α-IN-2 | 862974-22-9 | Reference compound |
| HY-151348 | BACE1-IN-11 | 1803952-77-3 | Reference compound |
| HY-151350 | SphK2-IN-1 | 2927429-64-7 | Reference compound |
| HY-151351 | SphK2-IN-2 | 2927429-60-3 | Reference compound |
| HY-151352 | DHDPS-IN-1 | 1233344-34-7 | Reference compound |
| HY-151354 | Antibacterial agent 121 | 474099-18-8 | Reference compound |
| HY-151356 | Antibacterial agent 122 | 109310-99-8 | Reference compound |
| HY-151357 | MraY-IN-3 | 2851534-52-4 | Reference compound |
| HY-151358 | SENP2-IN-1 | 2986220-46-4 | Reference compound |
| HY-15136 | Lonafarnib | 193275-84-2 | Reference compound |
| HY-151360 | NHE3-IN-3 | 543734-50-5 | Reference compound |
| HY-151361 | AMPK-IN-3 | 2417674-27-0 | Reference compound |
| HY-151362 | Keap1-Nrf2-IN-14 | 1928782-31-3 | Reference compound |
| HY-151363 | IRAK4-IN-21 | 2170694-04-7 | Reference compound |
| HY-151364 | HDAC6/8/BRPF1-IN-1 | 2484255-65-2 | Reference compound |
| HY-151365 | IRAK4-IN-22 | 2170694-05-8 | Reference compound |
| HY-151366 | HDAC8/BRPF1-IN-1 | 2484255-85-6 | Reference compound |
| HY-151367 | SHR2415 | 2494010-42-1 | Reference compound |
| HY-151368 | AChE/BChE-IN-10 | 2924824-48-4 | Reference compound |
| HY-151369 | AV123 | 233605-81-7 | Reference compound |
| HY-15136B | (Rac)-Lonafarnib | 193275-86-4 | Reference compound |
| HY-15136R | Lonafarnib (Standard) | 193275-84-2 | Reference Standards |
| HY-151370 | AChE-IN-26 | 2977170-10-6 | Reference compound |
| HY-151371 | CDK8-IN-10 | 2457317-40-5 | Reference compound |
| HY-151372 | Protein kinase D inhibitor 1 | 2489320-03-6 | Reference compound |
| HY-151373 | MurA-IN-2 | 2164447-18-9 | Reference compound |
| HY-151374 | 3-IN-PP1 | 2227110-54-3 | Reference compound |
| HY-151375 | CDK9/10/GSK3β-IN-1 | 2423045-06-9 | Reference compound |
| HY-151376 | SAP2-IN-1 | 2512847-37-7 | Reference compound |
| HY-151377 | RET-IN-19 | 2484919-71-1 | Reference compound |
| HY-151379 | EM127 | 1886879-71-5 | Reference compound |
| HY-151380 | LANA-DNA-IN-1 | 2512847-06-0 | Reference compound |
| HY-151381 | hDHODH-IN-10 | 3033087-05-4 | Reference compound |
| HY-151382 | CK2-IN-3 | 2969205-85-2 | Reference compound |
| HY-151383 | DPP-4-IN-1 | 2215027-46-4 | Reference compound |
| HY-151384 | DPP-4-IN-2 | 2133900-95-3 | Reference compound |
| HY-151385 | VVD-118313 | 2875046-27-6 | Reference compound |
| HY-151385A | (R,R)-VVD-118313 | 2875046-31-2 | Reference compound |
| HY-151386 | BChE-IN-13 | 2700896-73-5 | Reference compound |
| HY-151387 | A2AAR antagonist 1 | 1784491-64-0 | Reference compound |
| HY-151388 | hMAO-B/MB-COMT-IN-1 | 254974-70-4 | Reference compound |
| HY-151389 | BChE-IN-14 | 2700896-78-0 | Reference compound |
| HY-151390 | hMAO-B/MB-COMT-IN-2 | 3033106-46-3 | Reference compound |
| HY-151391 | LPA5 antagonist 1 | 2839471-45-1 | Reference compound |
| HY-151392 | LPA5 antagonist 2 | 2839471-44-0 | Reference compound |
| HY-151393 | Tubulin polymerization-IN-32 | | Reference compound |
| HY-151394 | Tubulin polymerization-IN-33 | | Reference compound |
| HY-151395 | Tubulin polymerization-IN-34 | | Reference compound |
| HY-151396 | Tubulin polymerization-IN-35 | | Reference compound |
| HY-151397 | Tubulin polymerization-IN-36 | 2011784-91-9 | Reference compound |
| HY-151398 | Tubulin polymerization-IN-37 | 2011784-92-0 | Reference compound |
| HY-151399 | Antimicrobial agent-5 | 2978694-04-9 | Reference compound |
| HY-151400 | Antimicrobial agent-6 | 2978694-10-7 | Reference compound |
| HY-151401 | Antimicrobial agent-7 | | Reference compound |
| HY-151402 | Antimicrobial agent-8 | 2978694-22-1 | Reference compound |
| HY-151403 | Antimicrobial agent-9 | 2978694-25-4 | Reference compound |
| HY-151404 | Antitumor agent-76 | 2787593-12-6 | Reference compound |
| HY-151405 | Z164597606 | 1050587-57-9 | Reference compound |
| HY-151406 | hCAIX-IN-13 | 2813334-66-4 | Reference compound |
| HY-151407 | CDK1-IN-3 | 3032997-12-6 | Reference compound |
| HY-151408 | CDK1-IN-4 | 3032997-16-0 | Reference compound |
| HY-151409 | CDK1-IN-5 | 3032997-20-6 | Reference compound |
| HY-15141 | Staurosporine | 62996-74-1 | Natural Products |
| HY-151410 | Chitin synthase inhibitor 5 | 3033645-28-9 | Reference compound |
| HY-151411 | RUNX1/ETO tetramerization-IN-1 | 88755-39-9 | Reference compound |
| HY-151412 | T-271 | 1005775-58-5 | Reference compound |
| HY-151413 | MEN 10207 | 126050-12-2 | Peptides |
| HY-151414 | 3'-Deoxyinosine | 13146-72-0 | Reference compound |
| HY-151416 | Chitin synthase inhibitor 6 | 3033645-29-0 | Reference compound |
| HY-151417 | Chitin synthase inhibitor 7 | 3033645-30-3 | Reference compound |
| HY-151418 | Chitin synthase inhibitor 8 | 3033645-31-4 | Reference compound |
| HY-151419 | Chitin synthase inhibitor 9 | 2725074-96-2 | Reference compound |
| HY-15141G | Staurosporine (GMP) | 62996-74-1 | GMP Small Molecules |
| HY-15141R | Staurosporine (Standard) | 62996-74-1 | Reference Standards |
| HY-15142 | Doxorubicin (hydrochloride) | 25316-40-9 | Natural Products |
| HY-151420 | Chitin synthase inhibitor 10 | 2725075-01-2 | Reference compound |
| HY-151421 | Chitin synthase inhibitor 11 | 2725075-04-5 | Reference compound |
| HY-151422 | Chitin synthase inhibitor 12 | 2725075-05-6 | Reference compound |
| HY-151423 | Antifungal agent 39 | 2725074-94-0 | Reference compound |
| HY-151424 | Vimentin-IN-1 | 2319587-80-7 | Reference compound |
| HY-151425 | TDO-IN-1 | 2490672-92-7 | Reference compound |
| HY-151426 | Anticancer agent 83 | 904815-29-8 | Reference compound |
| HY-151427 | TGFβ1-IN-1 | 2348795-14-0 | Reference compound |
| HY-151428 | Antitumor agent-78 | 2870703-23-2 | Reference compound |
| HY-151429 | Antitumor agent-77 | 2870703-21-0 | Reference compound |
| HY-15142A | Doxorubicin | 23214-92-8 | Natural Products |
| HY-15142R | Doxorubicin (hydrochloride) (Standard) | 25316-40-9 | Reference Standards |
| HY-151430 | Nrf2/HO-1 activator 1 | 2883506-60-1 | Reference compound |
| HY-151431 | Nrf2/HO-1 activator 2 | 2883506-31-6 | Reference compound |
| HY-151432 | URAT1 inhibitor 3 | 2850331-30-3 | Reference compound |
| HY-151433 | Antiparasitic agent-10 | 2138480-87-0 | Reference compound |
| HY-151434 | GLS1 Inhibitor-6 | 3033615-55-0 | Reference compound |
| HY-151435 | CCR6 antagonist 1 | 588674-64-0 | Reference compound |
| HY-151436 | ZLMT-12 | 2841473-39-8 | Reference compound |
| HY-151437 | Antifungal agent 40 | | Reference compound |
| HY-151439 | Antifungal agent 41 | | Reference compound |
| HY-15144 | Trichostatin A | 58880-19-6 | Natural Products |
| HY-151440 | Antifungal agent 42 | | Reference compound |
| HY-151441 | LRRK2-IN-5 | 2892451-45-3 | Reference compound |
| HY-151442 | Antifungal agent 43 | | Reference compound |
| HY-151443 | HDAC-IN-47 | | Reference compound |
| HY-151444 | LRRK2-IN-6 | 2892451-17-9 | Reference compound |
| HY-151445 | ZIKV-IN-2 | 910582-16-0 | Reference compound |
| HY-151446 | ZIKV-IN-3 | 947699-46-9 | Reference compound |
| HY-151447 | ZIKV-IN-4 | | Reference compound |
| HY-151448 | ZIKV-IN-5 | | Reference compound |
| HY-15144B | (S)-Trichostatin A | 122292-85-7 | Reference compound |
| HY-15145 | SRT 1720 (monohydrochloride) | 2060259-60-9 | Reference compound |
| HY-151450 | Cav 3.2 inhibitor 1 | 2878598-59-3 | Reference compound |
| HY-151451 | Cav 3.2 inhibitor 2 | 2878598-92-4 | Reference compound |
| HY-151452 | Cav 3.2 inhibitor 3 | 2878598-69-5 | Reference compound |
| HY-151453 | Topoisomerase IIα-IN-4 | 2860554-26-1 | Reference compound |
| HY-151454S | N-Formyl palbociclib-d8 | | Isotope-Labeled Compounds |
| HY-151458 | VEGFR-2/DHFR-IN-1 | 2831498-15-6 | Reference compound |
| HY-151459 | VEGFR-2/DHFR-IN-2 | 2831498-09-8 | Reference compound |
| HY-15145A | SRT 1720 (dihydrochloride) | 2468639-77-0 | Reference compound |
| HY-15146 | NSC 74859 | 501919-59-1 | Reference compound |
| HY-151460 | GCN2-IN-7 | 2396465-33-9 | Reference compound |
| HY-151461 | CHNQD-01255 | 2756173-91-6 | Reference compound |
| HY-151462 | RP-6685 | 2832047-80-8 | Reference compound |
| HY-151463 | CDK8-IN-11 | 2839338-28-0 | Reference compound |
| HY-151463A | CDK8-IN-11 (hydrochloride) | | Reference compound |
| HY-151464 | SHP2/HDAC-IN-1 | 2831230-38-5 | Reference compound |
| HY-151465 | HIF-1α-IN-4 | 2826221-23-0 | Reference compound |
| HY-151466 | HIF-1α-IN-5 | 2826221-10-5 | Reference compound |
| HY-151468 | AIE-Cbz-LD-C7 | 2810130-33-5 | Dye Reagents |
| HY-151469 | Chitinase-IN-4 | 2901040-41-1 | Reference compound |
| HY-15147 | XAV-939 | 284028-89-3 | Reference compound |
| HY-151470 | Chitinase-IN-5 | 2901040-47-7 | Reference compound |
| HY-151471 | Anticancer agent 84 | 2714510-72-0 | Reference compound |
| HY-151472 | hCAIX/XII-IN-6 | 3031666-31-3 | Reference compound |
| HY-151473 | PIKfyve-IN-1 | 2857982-26-2 | Reference compound |
| HY-151474 | SARS-CoV-2-IN-31 | 1017691-52-9 | Reference compound |
| HY-151475 | GID4 Ligand 1 | 3031442-96-0 | Reference compound |
| HY-151476 | GID4 Ligand 2 | 3031442-90-4 | Reference compound |
| HY-151477 | SARS-CoV-2-IN-32 | 96068-42-7 | Reference compound |
| HY-151478 | SARS-CoV-2-IN-33 | 299919-79-2 | Reference compound |
| HY-151479 | GID4 Ligand 3 | 340007-39-8 | Reference compound |
| HY-15147G | XAV-939 (GMP) | 284028-89-3 | GMP Small Molecules |
| HY-15148 | Tipranavir | 174484-41-4 | Reference compound |
| HY-151480 | HP590 | 2971855-37-3 | Reference compound |
| HY-151481 | FXR antagonist 1 | 2295804-68-9 | Reference compound |
| HY-151481A | β-FXR antagonist 1 | 2295804-92-9 | Reference compound |
| HY-151482 | SARS-CoV-2 Mpro-IN-2 | 2768834-39-3 | Reference compound |
| HY-151483 | TK-129 | 3031476-73-7 | Reference compound |
| HY-151484 | Anti-infective agent 4 | 2738381-52-5 | Reference compound |
| HY-151485 | Anti-infective agent 5 | 2738381-47-8 | Reference compound |
| HY-151486 | GLUT1-IN-1 | | Reference compound |
| HY-151487 | CypD-IN-3 | 2651994-75-9 | Reference compound |
| HY-151488 | CypD-IN-4 | 3023438-19-6 | Reference compound |
| HY-151489 | CypE-IN-1 | 3023438-33-4 | Reference compound |
| HY-15148R | Tipranavir (Standard) | 174484-41-4 | Reference Standards |
| HY-15148S1 | Tipranavir-d7 | | Isotope-Labeled Compounds |
| HY-15149 | Romidepsin | 128517-07-7 | Reference compound |
| HY-151493 | CAII-IN-1 | | Reference compound |
| HY-151494 | CAII-IN-2 | | Reference compound |
| HY-151495 | CAII-IN-3 | | Reference compound |
| HY-151496 | H-Cys-Val-2-Nal-Met-OH | 158022-12-9 | Reference compound |
| HY-151497 | Antimicrobial agent-10 | | Reference compound |
| HY-151498 | PXS-4787 | 2409963-50-2 | Reference compound |
| HY-151498A | PXS-4787 (hydrochloride) | 2409964-40-3 | Reference compound |
| HY-151499 | PXS-6302 | 2584947-54-4 | Reference compound |
| HY-151499A | PXS-6302 (hydrochloride) | 2584947-79-3 | Reference compound |
| HY-15149S2 | Romidepsin-d7 | | Isotope-Labeled Compounds |
| HY-15150 | Bemcentinib | 1037624-75-1 | Reference compound |
| HY-151500 | JBSNF-000028 (free base) | 3026599-90-3 | Reference compound |
| HY-151500A | JBSNF-000028 (TFA) | | Reference compound |
| HY-151500B | JBSNF-000028 (hydrochloride) | | Reference compound |
| HY-151501 | Antimicrobial agent-11 | | Reference compound |
| HY-151502 | Antimicrobial agent-12 | | Reference compound |
| HY-151503 | MPM-1 | | Reference compound |
| HY-151504 | Engasertib | 1313439-71-2 | Reference compound |
| HY-151505 | CysOx2 | | Dye Reagents |
| HY-151506 | Phospholipid PL1 | 2274812-94-9 | Biochemical Assay Reagents |
| HY-151507 | 306Oi10 | 2322290-93-5 | Oligonucleotides |
| HY-151508 | Diamino lipid DAL4 | 2939000-43-6 | Biochemical Assay Reagents |
| HY-151509 | A2-Iso5-2DC18 | 2412492-07-8 | Reference compound |
| HY-15150G | Bemcentinib (GMP) | 1037624-75-1 | GMP Small Molecules |
| HY-151510 | A2-Iso5-4DC19 | 2412492-19-2 | Biochemical Assay Reagents |
| HY-151511 | A12-Iso5-2DC18 | 2412492-06-7 | Biochemical Assay Reagents |
| HY-151512 | A12-Iso5-4DC19 | 2412492-20-5 | Biochemical Assay Reagents |
| HY-151513 | Iso5-2DC18 | | Reference compound |
| HY-151514 | Antituberculosis agent-5 | 313981-44-1 | Reference compound |
| HY-151515 | Dopamine D2 receptor agonist-2 | 1610591-93-9 | Reference compound |
| HY-151516 | microRNA-21-IN-2 | 303018-40-8 | Reference compound |
| HY-151517 | SOS1-IN-14 | 2793405-20-4 | Reference compound |
| HY-151518 | Aminopeptidase-IN-1 | 374102-08-6 | Reference compound |
| HY-151519 | SIRT2-IN-9 | 522650-91-5 | Reference compound |
| HY-151520 | Wnt/β-catenin agonist 4 | 912784-79-3 | Reference compound |
| HY-151522 | SIRT2-IN-10 | 296793-09-4 | Reference compound |
| HY-151523 | KRas G12R inhibitor 1 | | Reference compound |
| HY-151524 | Cathepsin K inhibitor 3 | 1694638-70-4 | Reference compound |
| HY-151525 | YAP-TEAD-IN-2 | 2714432-83-2 | Reference compound |
| HY-151526 | LabMol-301 | 1360243-08-8 | Reference compound |
| HY-151527 | PI3K/Akt/CREB activator 1 | 2708177-73-3 | Reference compound |
| HY-151528 | PBRM1-BD2-IN-1 | 1915012-21-3 | Reference compound |
| HY-151529 | PBRM1-BD2-IN-2 | 2819989-57-4 | Reference compound |
| HY-151530 | PBRM1-BD2-IN-3 | 2819989-58-5 | Reference compound |
| HY-151531 | PBRM1-BD2-IN-4 | 2819989-60-9 | Reference compound |
| HY-151532 | PBRM1-BD2-IN-5 | 2819989-61-0 | Reference compound |
| HY-151533 | PBRM1-BD2-IN-6 | 2819989-67-6 | Reference compound |
| HY-151534 | PBRM1-BD2-IN-7 | 2819989-68-7 | Reference compound |
| HY-151535 | SARS-CoV-2 3CLpro-IN-5 | 2913186-57-7 | Reference compound |
| HY-151536 | meso-Benzothiazole-BODIPY 505/515 | | Dye Reagents |
| HY-151537 | Gol-NTR | 2968461-58-5 | Dye Reagents |
| HY-151538 | PBRM1-BD2-IN-8 | 2819989-75-6 | Reference compound |
| HY-151539 | TH470 | 2834739-51-2 | Reference compound |
| HY-15154 | NG 52 | 212779-48-1 | Reference compound |
| HY-151540 | MMP-7-IN-1 | 2865097-05-6 | Reference compound |
| HY-151541 | MLKL-IN-3 | 3031406-27-3 | Reference compound |
| HY-151542 | MLKL-IN-4 | 3031406-17-1 | Reference compound |
| HY-151544 | PNE-Lyso | | Dye Reagents |
| HY-151545 | WNK1-IN-1 | 324022-39-1 | Reference compound |
| HY-151546 | MRS4596 | 2840581-38-4 | Reference compound |
| HY-151547 | MRS4719 | 2840581-32-8 | Reference compound |
| HY-151548 | Mtb-cyt-bd oxidase-IN-1 | | Reference compound |
| HY-151549 | Mtb-cyt-bd oxidase-IN-2 | 1463475-67-3 | Reference compound |
| HY-15155 | MLN0905 | 1228960-69-7 | Reference compound |
| HY-151550 | Mtb-cyt-bd oxidase-IN-3 | | Reference compound |
| HY-151551 | Mtb-cyt-bd oxidase-IN-4 | | Reference compound |
| HY-151552 | Mtb-cyt-bd oxidase-IN-5 | | Reference compound |
| HY-151553 | Mtb-cyt-bd oxidase-IN-6 | 1246461-10-8 | Reference compound |
| HY-151554 | SQ-3 | | Reference compound |
| HY-151555 | Antifungal agent 44 | | Reference compound |
| HY-151556 | Antifungal agent 45 | | Reference compound |
| HY-151559 | Zn-DPA-maytansinoid conjugate 1 | 3034629-04-1 | Reference compound |
| HY-15156 | 1alpha, 24, 25-Trihydroxy VD2 | 457048-34-9 | Reference compound |
| HY-151560 | hDHODH-IN-11 | 2396653-34-0 | Reference compound |
| HY-151561 | WM382 | 2606990-92-3 | Reference compound |
| HY-151562 | AChE/BuChE/MAO-B-IN-1 | 2834758-29-9 | Reference compound |
| HY-151563 | OTUB1/USP8-IN-1 | 2858800-98-1 | Reference compound |
| HY-151563A | OTUB1/USP8-IN-1 (TFA) | | Reference compound |
| HY-151564 | Anticancer agent 85 | 2841658-29-3 | Reference compound |
| HY-151565 | Anticancer agent 86 | 2841406-04-8 | Reference compound |
| HY-151566 | Antifungal agent 46 | 2842067-19-8 | Reference compound |
| HY-151567 | Antibacterial agent 123 | 2615254-55-0 | Reference compound |
| HY-151568 | UCB7362 | | Reference compound |
| HY-151569 | SAHA-OH | 2857098-30-5 | Reference compound |
| HY-15157 | Calcitetrol | 72203-93-1 | Reference compound |
| HY-151570 | Anticancer agent 87 | | Reference compound |
| HY-151571 | ZG1077 | 2670380-82-0 | Reference compound |
| HY-151572 | Anticancer agent 88 | | Reference compound |
| HY-151573 | EGFR/CDK2-IN-1 | 2841405-96-5 | Reference compound |
| HY-151574 | PfGSK3/PfPK6-IN-1 | 2797225-49-9 | Reference compound |
| HY-151575 | PfGSK3/PfPK6-IN-2 | 2797225-47-7 | Reference compound |
| HY-151576 | PRMT5:MEP50 PPI | 3031536-71-4 | Reference compound |
| HY-151577 | STAT3-SH2 domain inhibitor 1 | 2816059-41-1 | Reference compound |
| HY-151578 | DPP IV/hCA II-IN-1 | 2836996-95-1 | Reference compound |
| HY-15158 | SBE13 (Hydrochloride) | 1052532-15-6 | Reference compound |
| HY-151580 | CDK2-IN-14 | 2862836-22-2 | Reference compound |
| HY-151580S | CDK2-IN-14-d3 | 2498658-25-4 | Isotope-Labeled Compounds |
| HY-151581 | HCVcc-IN-1 | 2977251-08-2 | Reference compound |
| HY-151587 | Anticancer agent 89 | 2977251-05-9 | Reference compound |
| HY-151588 | Anticancer agent 90 | 2977251-03-7 | Reference compound |
| HY-151589 | HCVcc-IN-2 | 2977251-02-6 | Reference compound |
| HY-15158A | SBE13 | 775294-82-1 | Reference compound |
| HY-15159 | Cyclapolin 9 | 40533-25-3 | Reference compound |
| HY-151590 | DKFZ-748 | 2490709-68-5 | Reference compound |
| HY-151591 | SPAA-52 | 2837000-75-4 | Reference compound |
| HY-151592 | Anticancer agent 91 | 2977251-00-4 | Reference compound |
| HY-151593 | dBRD4-BD1 | 2839318-19-1 | Reference compound |
| HY-151594 | iBRD4-BD1 | 2839318-17-9 | Reference compound |
| HY-151594A | iBRD4-BD1 (diTFA) | 2839318-20-4 | Reference compound |
| HY-151595 | Menin-MLL inhibitor-22 | 2851841-61-5 | Reference compound |
| HY-151596 | MAO-A/5-HT2AR-IN-1 | 2769156-00-3 | Reference compound |
| HY-151598 | Pks13-TE inhibitor 2 | 3031462-75-3 | Reference compound |
| HY-151599 | Pks13-TE inhibitor 3 | 3031462-62-8 | Reference compound |
| HY-15160 | TAK-960 | 1137868-52-0 | Reference compound |
| HY-151600 | Transketolase-IN-2 | 2757552-21-7 | Reference compound |
| HY-151604 | Transketolase-IN-3 | 2757552-03-5 | Reference compound |
| HY-151606 | Akt3 degrader 1 | 2836342-69-7 | Reference compound |
| HY-151608 | SARS-CoV-2 Mpro-IN-3 | 3031351-76-2 | Reference compound |
| HY-151609 | PARP7-IN-12 | 2819700-92-8 | Reference compound |
| HY-15160A | TAK-960 (hydrochloride) | 1137868-96-2 | Reference compound |
| HY-15160B | TAK-960 (dihydrochloride) | | Reference compound |
| HY-15160C | TAK-960 (monohydrochloride) | 2108449-45-0 | Reference compound |
| HY-15161 | Ro3280 | 1062243-51-9 | Reference compound |
| HY-151611 | UAMC-00050 | 2842774-51-8 | Reference compound |
| HY-151612 | Anti-infective agent 6 | 2839192-35-5 | Reference compound |
| HY-151613 | MS15 | 3035638-40-2 | Reference compound |
| HY-151613A | MS15 (TFA) | | Reference compound |
| HY-151614 | Anti-infective agent 7 | 2839192-25-3 | Reference compound |
| HY-151615 | DCI-Br-3 | | Dye Reagents |
| HY-151616 | sEH inhibitor-10 | | Reference compound |
| HY-151617 | sEH inhibitor-11 | | Reference compound |
| HY-151618 | Antitumor agent-79 | 2750233-50-0 | Reference compound |
| HY-151619 | sEH inhibitor-12 | | Reference compound |
| HY-15162 | Monomethyl auristatin E | 474645-27-7 | ADC Related |
| HY-151620 | Antitumor agent-80 | 2758520-84-0 | Reference compound |
| HY-151621 | sEH inhibitor-13 | | Reference compound |
| HY-151622 | PI3K/mTOR Inhibitor-11 | 2845104-25-6 | Reference compound |
| HY-151623 | ACBI2 | 2913161-19-8 | Reference compound |
| HY-151624 | PARP-2-IN-2 | 2915651-00-0 | Reference compound |
| HY-151625 | PARP-2-IN-3 | 2915650-86-9 | Reference compound |
| HY-151626 | MRV03-037 | 2797066-16-9 | Reference compound |
| HY-151627 | 11β-HSD1-IN-11 | 859721-81-6 | Reference compound |
| HY-151628 | MRV03-068 | 2797066-17-0 | Reference compound |
| HY-151629 | MRV03-069 | 2797066-18-1 | Reference compound |
| HY-15162A | MMAE-d8 | 2070009-72-0 | Isotope-Labeled Compounds |
| HY-15162G | Monomethyl auristatin E (GMP) | 474645-27-7 | GMP Small Molecules |
| HY-15162R | Monomethyl auristatin E (Standard) | 474645-27-7 | Reference Standards |
| HY-15163 | Zotiraciclib | 1204918-72-8 | Reference compound |
| HY-151630 | hCAIX-IN-16 | 2849348-38-3 | Reference compound |
| HY-151631 | MRV03-070 | 2797066-20-5 | Reference compound |
| HY-151632 | hCAIX-IN-15 | 2849348-43-0 | Reference compound |
| HY-151633 | hCAIX-IN-14 | 77113-78-1 | Reference compound |
| HY-151634 | Syk-IN-6 | 3018859-95-2 | Reference compound |
| HY-151635 | PI3K/VEGFR2-IN-1 | 2851067-08-6 | Reference compound |
| HY-151636 | 10-Undecynoyl-OSu | 1006592-57-9 | Reference compound |
| HY-151637 | Fmoc-N-propargyl-MPBA | 1009362-00-8 | Reference compound |
| HY-151638 | FMOC-3-azido-D-alanine | 1016163-79-3 | Reference compound |
| HY-151639 | (2S,4R)-H-L-Pro(4-N3)-OH | 1019849-13-8 | Reference compound |
| HY-151639A | (2S,4R)-H-L-Pro(4-N3)-OH (hydrochloride) | | Reference compound |
| HY-15163A | Zotiraciclib (hydrochloride) | 1354567-82-0 | Reference compound |
| HY-15164 | Icotinib (Hydrochloride) | 1204313-51-8 | Reference compound |
| HY-151640 | Fmoc-DAP-N3 | 1021422-85-4 | Reference compound |
| HY-151641 | 3-Azido-L-alanine | 105661-40-3 | Peptides |
| HY-151642 | 3-Azido-D-alanine | 105928-88-9 | Reference compound |
| HY-151642A | 3-Azido-D-alanine (hydrochloride) | 1379690-01-3 | Reference compound |
| HY-151643 | beta-Glc-TEG-Alkyne | 1072903-76-4 | Reference compound |
| HY-151644 | Fluorescein hydrazide | 78044-20-9 | Dye Reagents |
| HY-151645 | Alkyne-SNAP | 1104822-07-2 | Reference compound |
| HY-151646 | Alkyne-PEG5-SNAP | | Reference compound |
| HY-151647 | 3-Azidopropanoic acid-PFP ester | 1240801-10-8 | Reference compound |
| HY-151648 | Bis-propargyl-PEG18 | | Reference compound |
| HY-151649 | Biotin-PEG(4)-SS-Alkyne | 1260247-54-8 | Reference compound |
| HY-15164A | Icotinib | 610798-31-7 | Reference compound |
| HY-15164AR | Icotinib (Standard) | 610798-31-7 | Reference Standards |
| HY-15164AS | Icotinib-d4 | 1567366-82-8 | Isotope-Labeled Compounds |
| HY-151650 | N3-O2Oc-O2Oc-OH | 1254054-60-8 | Reference compound |
| HY-151651 | Hexaethylene glycol phosphoramidite | 125607-09-2 | Reference compound |
| HY-151652 | Boc-L-Cys(Propargyl)-OH | 1260119-25-2 | Reference compound |
| HY-151652A | Boc-L-Cys(Propargyl)-OH (DCHA) | | Reference compound |
| HY-151653 | H-D-Tyr(Propargyl)-OH | 1170674-20-0 | Reference compound |
| HY-151654 | N3-D-Lys(Boc)-OH | 1178899-92-7 | Reference compound |
| HY-151655 | 11-Azidoundecanoic acid | 118162-45-1 | Reference compound |
| HY-151656 | 15-Azido-pentadecanoic acid | 118162-46-2 | Reference compound |
| HY-151657 | Spermine(N3BBB) | 1190203-80-5 | Reference compound |
| HY-151658 | H-L-Lys(N3-Gly)-OH | 1198617-82-1 | Reference compound |
| HY-151658A | H-L-Lys(N3-Gly)-OH (hydrochloride) | | Reference compound |
| HY-151659 | Fmoc-L-Lys(N3-Gly)-OH | 1198617-89-8 | Reference compound |
| HY-15166 | (E/Z)-Zotiraciclib | 937270-47-8 | Reference compound |
| HY-151660 | Fmoc-D-Lys(N3)-OH | 1198791-53-5 | Reference compound |
| HY-151661 | N3-L-Val-OH (CHA) | 1217462-63-9 | Reference compound |
| HY-151662 | 4-Azido-2,3,5,6-tetrafluorobenzoic Acid | 122590-77-6 | Dye Reagents |
| HY-151663 | Fmoc-Abu(3-N3) (2R,3R) | 1229394-75-5 | Reference compound |
| HY-151664 | H-alpha-Prg-D-Ala-OH | 1231709-27-5 | Reference compound |
| HY-151665 | Alkyne-PEG2-iodide | 1234387-33-7 | Reference compound |
| HY-151666 | 6-Azido-D-lysine | 1418009-93-4 | Reference compound |
| HY-151666A | 6-Azido-D-lysine (hydrochloride) | 2098497-01-7 | Reference compound |
| HY-151667 | Biotin-C5-Azide | 1260586-88-6 | Dye Reagents |
| HY-151668 | Z-L-Aha-OH | 1263047-43-3 | Reference compound |
| HY-151668A | Z-L-Aha-OH (DCHA) | 1423018-09-0 | Reference compound |
| HY-151669 | Fmoc-D-Aha-OH | 1263047-53-5 | Reference compound |
| HY-15166A | (E/Z)-Zotiraciclib (hydrochloride) | 1321626-25-8 | Reference compound |
| HY-15166B | (E/Z)-Zotiraciclib (citrate) | 1204918-73-9 | Reference compound |
| HY-15167 | Glyoxalase I inhibitor | 221174-33-0 | Reference compound |
| HY-151670 | Biotin-PEG(4)-SS-Azide | 1260247-52-6 | Reference compound |
| HY-151671 | Fmoc-L-MeLys(N3)-OH | 1263721-14-7 | Reference compound |
| HY-151672 | Biotin-TEG-ATFBA | 1264662-85-2 | Reference compound |
| HY-151673 | Poc-Cystamine | 1266354-28-2 | Reference compound |
| HY-151673A | Poc-Cystamine (hydrochloride) | | Reference compound |
| HY-151674 | N3-L-Cys(Trt)-OH (CHA) | 1286670-90-3 | Reference compound |
| HY-151675 | H-L-Tyr(3-N3)-OH | 129960-90-3 | Reference compound |
| HY-151676 | Boc-L-Tyr(2-azidoethyl)-OH | 1434445-10-9 | Reference compound |
| HY-151677 | (2R,4S)-Boc-D-Pro(4-N3)-OH | 132622-77-6 | Reference compound |
| HY-151677A | (2R,4S)-Boc-D-Pro(4-N3)-OH (DCHA) | | Reference compound |
| HY-151678 | N3-L-Lys(Mtt)-OH | 1333231-26-7 | Reference compound |
| HY-151679 | Fmoc-L-Lys(4-N3-Z)-OH | 1446511-14-3 | Reference compound |
| HY-15167A | Glyoxalase I inhibitor (free base) | 174568-92-4 | Reference compound |
| HY-151680 | TAMRA alkyne, 6-isomer | 1352649-44-5 | Reference compound |
| HY-151681 | (2R,4R)-Fmoc-D-Pro(4-N3)-OH | 1378847-51-8 | Reference compound |
| HY-151682 | H-L-Lys(Norbornene-methoxycarbonyl)-OH | 1378916-76-7 | Reference compound |
| HY-151682A | H-L-Lys(Norbornene-methoxycarbonyl)-OH (hydrochloride) | 2560614-20-0 | Reference compound |
| HY-151683 | H-L-Ser(Propargyl)-OH | 1379150-93-2 | Reference compound |
| HY-151683A | H-L-Ser(Propargyl)-OH (hydrochloride) | 1379006-45-7 | Reference compound |
| HY-151684 | Boc-Ser(O-propargyl)-OH | 145205-94-3 | Reference compound |
| HY-151684A | Boc-Ser(O-propargyl)-OH (DCHA) | | Reference compound |
| HY-151685 | Kdo Azide | 1380099-68-2 | Reference compound |
| HY-151686 | Bz-(Me)Tz-NHS | 1454558-58-7 | Reference compound |
| HY-151687 | Fmoc-L-Tyr(2-azidoethyl)-OH | 1454816-10-4 | Reference compound |
| HY-151688 | 6-O-Propynyl-2'-deoxyguanosine | 1640051-47-3 | ADC Related |
| HY-151689 | (2S,3R)-Fmoc-Abu(3-N3)-OH | 146306-79-8 | Reference compound |
| HY-151690 | FAM hydrazide, 6-isomer | 151890-73-2 | Dye Reagents |
| HY-151691 | Trisulfo-Cy3 Methyltetrazine | 1676067-48-3 | Reference compound |
| HY-151692 | 18-Azido-stearic acid | 1529763-58-3 | Reference compound |
| HY-151693 | H-L-Tyr(2-azidoethyl)-OH (hydrochloride) | 1567845-62-8 | Reference compound |
| HY-151693A | H-L-Tyr(2-azidoethyl)-OH | 1570523-47-5 | Reference compound |
| HY-151694 | H-L-Orn(N3)-OH (hydrochloride) | 1782935-10-7 | Reference compound |
| HY-151695 | Fmoc-L-Lys(Pryoc)-OH | 1584133-25-4 | Reference compound |
| HY-151696 | TCO-PEG3-maleimide | 1809356-72-6 | Reference compound |
| HY-151697 | DACN(Tos2) | 1797508-57-6 | Reference compound |
| HY-151698 | TCO-NHS Ester (axial) | 1610931-22-0 | Reference compound |
| HY-151698A | (S,E)-TCO-NHS Ester | | Reference compound |
| HY-151698B | (R,E)-TCO-NHS Ester | 2829292-74-0 | Reference compound |
| HY-151699 | 6-Azidohexanoyl-Val-Cit-PAB-PNP | 1613321-01-9 | Reference compound |
| HY-151700 | 6-Azidohexanoyl-Val-Cit-PAB | 1613321-02-0 | Reference compound |
| HY-151701 | DiSulfo-Cy5 alkyne | 1617497-19-4 | Dye Reagents |
| HY-151701A | DiSulfo-Cy5 alkyne (TEA) | | Dye Reagents |
| HY-151702 | (2S)-N3-IsoSer | 1620171-65-4 | Oligonucleotides |
| HY-151702A | (2S)-N3-IsoSer (DCHA) | | Reference compound |
| HY-151703 | Boc-D-Lys(N3)-OH | 1620410-04-9 | Reference compound |
| HY-151703A | Boc-D-Lys(N3)-OH (CHA) | 1858224-39-1 | Reference compound |
| HY-151704 | ICG-alkyne | 1622335-41-4 | Reference compound |
| HY-151705 | Alkyne Cholesterol | 1631985-09-5 | Reference compound |
| HY-151706S | Temazepam glucuronide-d5 | | Isotope-Labeled Compounds |
| HY-151707 | DACN(Tos,Ns) | 1797508-58-7 | Reference compound |
| HY-151708 | CalFluor 488 Azide | 1798305-98-2 | Dye Reagents |
| HY-151709 | N3-L-Cit-OH | 1799421-66-1 | Reference compound |
| HY-151709A | N3-L-Cit-OH (DCHA) | 2737202-65-0 | Reference compound |
| HY-151710 | Sulfo-Cy3 Azide | 1801695-56-6 | Dye Reagents |
| HY-151711 | Sulfo-Cy5.5 Azide | 1955527-41-9 | Dye Reagents |
| HY-151712 | Sulfo-Cy5-Methyltetrazine | 1801924-46-8 | Dye Reagents |
| HY-151713 | Sulfo-Cy3-Methyltetrazine | 1801924-47-9 | Dye Reagents |
| HY-151714 | Biotin-MeTz | 1802883-51-7 | Reference compound |
| HY-151715 | N3-D-Dap(Fmoc)-OH | 1807631-13-5 | Reference compound |
| HY-151716 | Halo-DBCO | 1808119-16-5 | Reference compound |
| HY-151717 | N1-Azido-spermine (trihydrochloride) | 1823475-98-4 | Reference compound |
| HY-151718 | Boc-L-Tyr(PEG(3)-N3)-OH | 1831059-64-3 | Reference compound |
| HY-151718A | Boc-L-Tyr(PEG(3)-N3)-OH (DCHA) | | Reference compound |
| HY-151719 | Azidoacetic Acid | 18523-48-3 | Reference compound |
| HY-151720 | Cy5.5 DBCO | 1857352-95-4 | Reference compound |
| HY-151721 | H-D-Orn(N3)-OH (hydrochloride) | 1858224-08-4 | Reference compound |
| HY-151722 | Boc-D-Orn(N3)-OH (CHA) | 1858224-18-6 | Reference compound |
| HY-151723 | H-D-Aha-OH (hydrochloride) | 1858224-26-6 | Reference compound |
| HY-151724 | N3-Pen-Dde | 1867129-38-1 | Reference compound |
| HY-151725 | N3-Pen-Dtpp | 1867129-42-7 | Reference compound |
| HY-151726 | Azido-PEG(4)-Val-Cit-PAB-PNP | 1869126-60-2 | Reference compound |
| HY-151727 | Norbornene-NHS | 1888335-48-5 | Reference compound |
| HY-151728 | Trisulfo-Cy3-Alkyne | 1895849-34-9 | Dye Reagents |
| HY-151729 | N3-D-Dab(Boc)-OH | 1922891-74-4 | Reference compound |
| HY-151730 | (Me)Tz-butanoic acid | 1923268-81-8 | Reference compound |
| HY-151731 | N3-1,4-trans-CHC-OH | 1931895-14-5 | Reference compound |
| HY-151732 | Z-D-Dbu(N3)-OH | 1931958-82-5 | Reference compound |
| HY-151733 | Fmoc-D-Dbu(N3)-OH | 1932023-47-6 | Reference compound |
| HY-151734 | (2R,3S)-Fmoc-Abu(3-N3)-OH | 1932349-21-7 | Reference compound |
| HY-151735 | N3-L-Dab(Boc)-OH | 1932403-71-8 | Reference compound |
| HY-151736 | N3-L-Dap(Boc)-OH | 1932432-15-9 | Reference compound |
| HY-151737 | Z-L-Dbu(N3)-OH | 1932657-23-2 | Reference compound |
| HY-151738 | Fmoc-Aeg(N3)-OH | 1935981-35-3 | Reference compound |
| HY-151739 | 4-Pentynoyl-Val-Ala-PAB | 1956294-75-9 | Reference compound |
| HY-15174 | Dactolisib (Tosylate) | 1028385-32-1 | Reference compound |
| HY-151740 | 4-Pentynoyl-Val-Ala-PAB-PNP | 1956294-76-0 | ADC Related |
| HY-151741 | Biotin-PEG4-MeTz | 1962919-31-8 | Reference compound |
| HY-151742 | Norbornene-methyl-NHS | 1986791-87-0 | Reference compound |
| HY-151743 | N3-Cystamine-Suc-OSu | 1987341-40-1 | Reference compound |
| HY-151744 | N3-TFBA-O2Oc | 1993119-45-1 | Reference compound |
| HY-151745 | N3-TOTA-Suc | 1993176-74-1 | Reference compound |
| HY-151746 | N3-Gly-Gly-Gly-OH | 1993176-75-2 | Reference compound |
| HY-151747 | Chemical phosphorylation amidite | 202284-84-2 | Reference compound |
| HY-151748 | N3-L-Orn(Fmoc)-OH | 1994267-98-9 | Reference compound |
| HY-151749 | N3-D-Lys(Fmoc)-OH | 1994300-35-4 | Reference compound |
| HY-151750 | Pyrene phosphoramidite dU | 199920-17-7 | Dye Reagents |
| HY-151751 | BDP TMR alkyne | 2006345-32-8 | Dye Reagents |
| HY-151752 | Mal-AMCHC-N-Propargylamide | 2027476-42-0 | Reference compound |
| HY-151753 | Trisulfo-Cy5.5-Alkyne | 2055046-12-1 | Dye Reagents |
| HY-151754 | DACN(Tos2,6-OH) | 2109751-74-6 | Reference compound |
| HY-151755 | Sulfo-Cy3-Tetrazine | 2055138-86-6 | Dye Reagents |
| HY-151756 | diSulfo-Cy3 alkyne | 2055138-88-8 | Dye Reagents |
| HY-151757 | Trisulfo-Cy5-Alkyne | 2055138-90-2 | Dye Reagents |
| HY-151758 | Methyltetrazine-PEG12-NHS ester | | Reference compound |
| HY-151759 | Sulfo-Cy5-TCO | 2129525-69-3 | Dye Reagents |
| HY-15176 | Pyridostatin | 1085412-37-8 | Reference compound |
| HY-151760 | (2R,4S)-H-D-Pro(4-N3)-OH | 2137086-50-9 | Reference compound |
| HY-151760A | (2R,4S)-H-D-Pro(4-N3)-OH (hydrochloride) | | Reference compound |
| HY-151761 | H-L-Lys(4-N3-Z)-OH (hydrochloride) | 2084913-49-3 | Reference compound |
| HY-151762 | (2R,4S)-Fmoc-D-Pro(4-N3)-OH | 2137142-63-1 | Reference compound |
| HY-151763 | Boc-L-Aza-OH (CHA) | 2098496-88-7 | Reference compound |
| HY-151764 | N3-D-Orn(Boc)-OH | 2165877-62-1 | ADC Related |
| HY-151764A | N3-D-Orn(Boc)-OH (CHA) | | ADC Related |
| HY-151766 | DACN(Tos,Suc-OH) | 2109751-68-8 | Reference compound |
| HY-151767 | Boc-Cystamine-Poc | 2171512-56-2 | Reference compound |
| HY-151768 | H2N-PEG2-N3 (TosOH) | 2173092-98-1 | Reference compound |
| HY-151769 | TCO-PEG2-Sulfo-NHS ester-EDC Urea | 2353409-48-8 | Reference compound |
| HY-15176A | Pyridostatin (hydrochloride) | 1781882-65-2 | Reference compound |
| HY-15176B | Pyridostatin (TFA) | 1472611-44-1 | Reference compound |
| HY-15177 | PF-04691502 | 1013101-36-4 | Reference compound |
| HY-151771 | DACN(Tos,Mal) | 2411082-28-3 | Reference compound |
| HY-151772 | Methyltetrazine-PEG12-t-butyl ester | | Reference compound |
| HY-151773 | Methyltetrazine-PEG12-acid | | Reference compound |
| HY-151774 | TAMRA hydrazide (6-isomer) | 2183440-67-5 | Dye Reagents |
| HY-151775 | BDP tr azide | 2183473-27-8 | Dye Reagents |
| HY-151776 | Cy3 methyltetrazine | 2183473-57-4 | Dye Reagents |
| HY-151777 | N3-Gly-Gly-Gly-Gly-Gly-OH | 2250433-77-1 | Reference compound |
| HY-151778 | Fmoc-Abg(N3)-OH | 2250433-81-7 | Reference compound |
| HY-151779 | N3-L-Dab(Fmoc)-OH | 2250436-44-1 | Reference compound |
| HY-15178 | Oglemilast | 778576-62-8 | Reference compound |
| HY-151780 | Fmoc-L-Dap(Pentynoyl)-OH | 2250436-47-4 | Reference compound |
| HY-151781 | Fmoc-L-Dap(Poc)-OH | 2250437-44-4 | Reference compound |
| HY-151782 | H-(Gly)3-Lys(N3)-OH | 2250437-45-5 | Reference compound |
| HY-151782A | H-(Gly)3-Lys(N3)-OH (hydrochloride) | 2737202-70-7 | Reference compound |
| HY-151783 | DAPOA | 2389064-43-9 | Reference compound |
| HY-151783A | DAPOA (DCHA) | | Reference compound |
| HY-151784 | Boc-D-Aza-OH | 225780-77-8 | Reference compound |
| HY-151785 | H-L-Dbu(N3)-OH | 2389078-78-6 | Reference compound |
| HY-151785A | H-L-Dbu(N3)-OH (hydrochloride) | | Reference compound |
| HY-151786 | Fmoc-L-Lys(Pentynoyl-DIM)-OH | 2408993-33-7 | Reference compound |
| HY-151787 | Fmoc-L-Lys(N3-Aca-DIM)-OH | 2408993-39-3 | Reference compound |
| HY-151788 | MeO-PEG-alkyne (MW 750Da) | | Reference compound |
| HY-151789 | Sulfo DBCO-TFP Ester | 2268816-76-6 | Reference compound |
| HY-151790 | Alkyne-SS-COOH | 2279938-29-1 | Reference compound |
| HY-151791 | (S,R,S)-AHPC-C6-PEG3-butyl-N3 | 2300155-90-0 | Reference compound |
| HY-151792 | Pomalidomid-C6-PEG3-butyl-N3 | 2300178-66-7 | Reference compound |
| HY-151793 | 2-Azidoethyl β-D-lactoside | 230286-11-0 | Reference compound |
| HY-151794 | DACN(Ms) (hydrochloride) | 2331322-16-6 | Reference compound |
| HY-151795 | DACN(Tos) (hydrochloride) | 2331322-18-8 | Reference compound |
| HY-151796 | DACN(Ms,Ns) | 2411082-25-0 | Reference compound |
| HY-151797 | Ph-HTBA | 2368927-41-5 | Reference compound |
| HY-151798 | TDI-11861 | 2857049-72-8 | Reference compound |
| HY-151799 | P62-RNF168 agonist-1 | 2765180-17-2 | Reference compound |
| HY-15180 | Buparlisib (Hydrochloride) | 1312445-63-8 | Reference compound |
| HY-151800 | MAO-A/B-IN-2 | | Reference compound |
| HY-151801 | DIBA-Cy5 | | Dye Reagents |
| HY-151802 | CPUL1 | 2043660-80-4 | Reference compound |
| HY-151805 | RGT-068A | 2577171-33-4 | Reference compound |
| HY-151806 | HadAB-IN-1 | 1097120-47-2 | Reference compound |
| HY-151807 | 15-PGDH-IN-1 | 2241676-74-2 | Reference compound |
| HY-151808 | JS25 | 2411771-95-2 | Reference compound |
| HY-151809 | CYP4A11/CYP4F2-IN-1 | 502654-40-2 | Reference compound |
| HY-151810 | TP0472993 | 2126874-77-7 | Reference compound |
| HY-151811 | NAQ | | Reference compound |
| HY-151812 | CBP/p300-IN-20 | 2999742-92-4 | Reference compound |
| HY-151813 | NNMT-IN-4 | 2947393-64-6 | Reference compound |
| HY-151814 | (2S,4S)-Fmoc-L-Pro(4-NHPoc)-OH | 2451202-17-6 | Reference compound |
| HY-151815 | beta-Lac-TEG-N3 | 246855-74-3 | Reference compound |
| HY-151816 | alpha-Man-TEG-N3 | 246855-76-5 | Reference compound |
| HY-151817 | 5-Azidomethyl-uridine | 24751-67-5 | Reference compound |
| HY-151818 | 12-Azido-dodecanoyl-OSu | 2489524-00-5 | Reference compound |
| HY-151819 | N3Ac-OPhOMe | 2546513-31-7 | Reference compound |
| HY-15182 | Collagen proline hydroxylase inhibitor-1 | 223663-32-9 | Reference compound |
| HY-151820 | DBCO-PEG24-acid | 2765066-36-0 | Reference compound |
| HY-151821 | Sulfo DBCO-PEG3-acid | 2566404-75-7 | Reference compound |
| HY-151822 | Hydroxy-PEG3-DBCO | 2566404-76-8 | Reference compound |
| HY-151823 | 8-Azido-octanoyl-OSu | 2576471-56-0 | Reference compound |
| HY-151824 | Boc-L-Phe(4-NH-Poc)-OH | 2576508-03-5 | Reference compound |
| HY-151825 | Fmoc-L-Phe(4-NH-Poc)-OH | 2576508-07-9 | Reference compound |
| HY-151826 | Fmoc-D-Lys(pentynoyl)-OH | 2576508-18-2 | Reference compound |
| HY-151827 | DBCO-PEG2-NHS ester | 2585653-12-7 | Reference compound |
| HY-151828 | N3-Gly-Aeg(Fmoc)-OH | 2606227-07-8 | Reference compound |
| HY-151829 | Fmoc-L-Asn(EDA-N3)-OH | 2616562-74-2 | Reference compound |
| HY-15183 | Collagen proline hydroxylase inhibitor | 223666-07-7 | Reference compound |
| HY-151830 | Me-PMeOx(50)-N3 (MW 4.3kDa) | | Reference compound |
| HY-151831 | Me-PMeOx(100)-N3 (MW 8.5kDa) | | Reference compound |
| HY-151833 | Methyltetrazine-amido-N-bis(PEG4-acid) | 2639395-39-2 | Reference compound |
| HY-151834 | DBCO-PEG2-DBCO | 2639395-48-3 | Reference compound |
| HY-151835 | DBCO-PEG24-NHS ester | 2765066-38-2 | Reference compound |
| HY-151836 | (2S,3R)-H-Abu(3-N3)-OH (hydrochloride) | 2737202-63-8 | Reference compound |
| HY-151837 | H-L-Phe(4-NH-Poc)-OH (hydrochloride) | 2737202-66-1 | Reference compound |
| HY-151838 | (2S,3S)-H-Abu(3-N3)-OH (hydrochloride) | 2737202-68-3 | Reference compound |
| HY-151839 | (2R,4R)-H-D-Pro(4-N3)-OH (hydrochloride) | 2737202-69-4 | Reference compound |
| HY-15184 | Elaiophylin | 37318-06-2 | Reference compound |
| HY-151840 | 4-Azidobenzyl alcohol | 31499-54-4 | Reference compound |
| HY-151841 | N3-L-Lys(Boc)-OH | 333366-32-8 | Reference compound |
| HY-151842 | Fmoc-EDA-N3 | 432507-62-5 | Reference compound |
| HY-151843 | N3-L-Lys(Fmoc)-OH | 473430-12-5 | Reference compound |
| HY-151844 | 2-Azido-adenosine | 59587-07-4 | Reference compound |
| HY-151845 | N3-PhAc-OH | 62893-37-2 | Reference compound |
| HY-151846 | Boc-L-Pra-OH (DCHA) | 63039-49-6 | Reference compound |
| HY-151847 | N3-TEMPO | 63697-61-0 | Reference compound |
| HY-151848 | (2R,4R)-Boc-D-Pro(4-N3)-OH | 650601-59-5 | Reference compound |
| HY-151849 | Z-L-Dap(N3)-OH | 684270-44-8 | Reference compound |
| HY-15185 | Nirogacestat | 1290543-63-3 | Reference compound |
| HY-151850 | (2S,4R)-Fmoc-L-Pro(4-N3)-OH | 702679-55-8 | Reference compound |
| HY-151851 | 3-Azidopropanol | 72320-38-8 | Reference compound |
| HY-151852 | 9AzNue5Ac | 76487-51-9 | Reference compound |
| HY-151853A | N3-L-Leu-OH (BHA) | | Reference compound |
| HY-151854 | 4-(Azidomethyl)benzoic acid | 79584-03-5 | Reference compound |
| HY-151855 | Azido Myristic Acid | 80667-36-3 | ADC Related |
| HY-151856 | N3-1,4-cis-CHC-OH | 863222-21-3 | Reference compound |
| HY-151857 | TAMRA azide, 5-isomer | 825651-66-9 | Dye Reagents |
| HY-151858 | Boc-L-Lys(N3)-OH | 846549-33-5 | Reference compound |
| HY-151859 | N3-Gly-Gly-OH | 855750-87-7 | Reference compound |
| HY-151859A | N3-Gly-Gly-OH (DCHA) | 2706488-76-6 | Reference compound |
| HY-15185B | Nirogacestat (dihydrobromide) | 1962925-29-6 | Reference compound |
| HY-15186 | Ipatasertib | 1001264-89-6 | Reference compound |
| HY-151861 | N3-Aca-Aca-OH | 866363-71-5 | Reference compound |
| HY-151862 | 3-Azidopropylamine | 88192-19-2 | Reference compound |
| HY-151863 | alpha-GalNAc-TEG-N3 | 882873-70-3 | Reference compound |
| HY-151864 | DecarboxyBiotin-Alkyne | 887915-53-9 | Reference compound |
| HY-151865 | (2S,4S)-H-L-Pro(4-N3)-OH | 892128-58-4 | Reference compound |
| HY-151865A | (2S,4S)-H-L-Pro(4-N3)-OH (hydrochloride) | | Reference compound |
| HY-151866 | (2S)-N3-HABA | 959148-55-1 | Reference compound |
| HY-151866A | (S)-N3-HABA (DCHA) | | Reference compound |
| HY-151868S | Glycidyl oleate-d5 | 1426395-63-2 | Isotope-Labeled Compounds |
| HY-151869S | Benzenemethanamine,N-(methyl-d3)-,hydrochloride | 122025-10-9 | Isotope-Labeled Compounds |
| HY-15186A | Ipatasertib (dihydrochloride) | 1396257-94-5 | Reference compound |
| HY-15186C | Ipatasertib (tosylate) | 1491138-24-9 | Reference compound |
| HY-15187 | Filanesib | 885060-09-3 | Reference compound |
| HY-151870S | (±)-trans-4-Hydroxy-2-hexenal-5,5,6,6,6-d5 Dimethyl Acetal | 1219806-40-2 | Isotope-Labeled Compounds |
| HY-151871 | ICeD-2 | 3050598-72-3 | Reference compound |
| HY-151872 | HDAC-IN-48 | 3031411-05-6 | Reference compound |
| HY-151873 | SZM679 | 3027645-52-6 | Reference compound |
| HY-151874S | n-Octatriacontane-d78 | 1219803-25-4 | Isotope-Labeled Compounds |
| HY-151875 | MurA-IN-3 | 2866186-38-9 | Reference compound |
| HY-151876 | Glucocorticoid receptor modulator 1 | 2868357-11-1 | Reference compound |
| HY-151877S | Ethyl N-n-Butyl-d9-carbamate | 1276197-24-0 | Isotope-Labeled Compounds |
| HY-151878 | CDK7-IN-20 | 3034210-97-1 | Reference compound |
| HY-151879 | Tubulin inhibitor 30 | 2873383-67-4 | Reference compound |
| HY-15187A | (R)-Filanesib | 885060-08-2 | Reference compound |
| HY-15187B | Filanesib (TFA) | 1781834-99-8 | Reference compound |
| HY-15187C | Filanesib (hydrochloride) | 1385020-40-5 | Reference compound |
| HY-151880 | Antibacterial agent 124 | 2304448-00-6 | Reference compound |
| HY-151881 | SOS1-IN-15 | 2793404-47-2 | Reference compound |
| HY-151882 | EGFR-IN-73 | 2857033-34-0 | Reference compound |
| HY-151883 | APE1-IN-2 | 2923433-95-6 | Reference compound |
| HY-151884 | FUBP1-IN-2 | 1242862-71-0 | Reference compound |
| HY-151885 | Dual AChE-MAO B-IN-3 | | Reference compound |
| HY-151886 | NU223612 | 2759420-43-2 | Reference compound |
| HY-151888 | Anticancer agent 92 | | Reference compound |
| HY-15189 | 17-Aminogeldanamycin | 64202-81-9 | Reference compound |
| HY-151890 | NIR-βgal-2 | | Dye Reagents |
| HY-151891 | TASK-1-IN-1 | 600125-11-9 | Reference compound |
| HY-151892S | Glimepiride-d4(phenylethyl-α,α,β,β-d4)(cis/trans) | 2699607-96-8 | Isotope-Labeled Compounds |
| HY-151893S | 7-Methyl-d3-1-octyl-7,8,8,8-d4 Alcohol | 1794753-02-8 | Isotope-Labeled Compounds |
| HY-151894 | I-BET432 | | Reference compound |
| HY-151895S | (±)-1-Hexadecanoyl-3-chloropropane-d5-diol | 1189718-15-7 | Isotope-Labeled Compounds |
| HY-151896 | HDAC6-IN-14 | 3023019-97-5 | Reference compound |
| HY-151897 | HDAC-IN-49 | | Reference compound |
| HY-151898 | CDK4/6-IN-14 | 2699091-15-9 | Reference compound |
| HY-151899 | A3AR modulator 1 | 2991693-62-8 | Reference compound |
| HY-15190 | NVP-HSP990 | 934343-74-5 | Reference compound |
| HY-151900 | SARS-CoV-2 Mpro-IN-4 | | Reference compound |
| HY-151901 | SARS-CoV-2 Mpro-IN-5 | 3023276-79-8 | Reference compound |
| HY-151902 | SJ988497 | 2595365-41-4 | Reference compound |
| HY-151903S | FGFR2/3-IN-1 | 2640352-86-7 | Isotope-Labeled Compounds |
| HY-151904 | AXL-IN-13 | 2376928-82-2 | Reference compound |
| HY-151905 | D6808 | 3029240-84-1 | Reference compound |
| HY-15191 | Sabutoclax | 1228108-65-3 | Reference compound |
| HY-151910S | (±)-Fluoxetine-d4 Oxalate (trifluoromethylphen-d4-oxy) | 2708283-92-3 | Isotope-Labeled Compounds |
| HY-151910S1 | (±)-Fluoxetine-d5 Oxalate (phenyl-d5) | 1219804-82-6 | Isotope-Labeled Compounds |
| HY-151911S | Mono-Cyclohexyl Phthalate-3,4,5,6-d4 | 1398066-18-6 | Isotope-Labeled Compounds |
| HY-151912S | Picolinafen-d4 (4-Fluorophenyl-d4) | 2469244-77-5 | Isotope-Labeled Compounds |
| HY-151913S | Sebuthylazine-d5 (ethyl-d5) | 1219805-56-7 | Isotope-Labeled Compounds |
| HY-151914 | Antitumor agent-82 | 3037605-45-8 | Reference compound |
| HY-151915 | ATR-IN-20 | 3012609-63-8 | Reference compound |
| HY-151916 | Enpp/Carbonic anhydrase-IN-1 | 2883495-35-8 | Reference compound |
| HY-151917 | Enpp/Carbonic anhydrase-IN-2 | 2883495-39-2 | Reference compound |
| HY-151918 | Antibacterial agent 125 | 1274611-43-6 | Reference compound |
| HY-151919 | FAAH-IN-7 | 3037600-36-2 | Reference compound |
| HY-15191B | (S)-Sabutoclax | 1228178-73-1 | Reference compound |
| HY-15192 | GSK 650394 | 890842-28-1 | Reference compound |
| HY-151920 | BTK-IN-17 | | Reference compound |
| HY-151921 | Anti-inflammatory agent 33 | 2816993-09-4 | Reference compound |
| HY-151923 | ATF3 inducer 1 | 3038756-30-5 | Reference compound |
| HY-151924 | Antiviral agent 23 | 35940-03-5 | Reference compound |
| HY-151925 | Antibacterial agent 126 | | Reference compound |
| HY-151926 | Antiviral agent 24 | 23661-03-2 | Reference compound |
| HY-151927 | AChE-IN-28 | | Reference compound |
| HY-151928 | JNK3 inhibitor-3 | 2873465-25-7 | Reference compound |
| HY-151929 | JNK3 inhibitor-4 | 2409109-65-3 | Reference compound |
| HY-15193 | EMD638683 | 1181770-72-8 | Reference compound |
| HY-151930S | 8′-Hydroxy ABA-d8 | | Isotope-Labeled Compounds |
| HY-151930S1 | 8′-Hydroxy ABA-d2 | | Isotope-Labeled Compounds |
| HY-151931 | JA-ACC | 371778-55-1 | Reference compound |
| HY-151931S | JA-ACC-d3 | | Isotope-Labeled Compounds |
| HY-151932 | FXR agonist 3 | 3037847-72-3 | Reference compound |
| HY-151933 | HIV-1 inhibitor-49 | | Reference compound |
| HY-151934 | ERK-IN-6 | | Reference compound |
| HY-151935 | Antileishmanial agent-13 | 853725-86-7 | Reference compound |
| HY-151936 | LmNADK1-IN-1 | | Reference compound |
| HY-151937 | Antibacterial agent 127 | | Reference compound |
| HY-151938 | Reverse transcriptase-IN-3 | | Reference compound |
| HY-151939 | BLM-IN-2 | 3037604-86-4 | Reference compound |
| HY-15193A | EMD638683 (R-Form) | 1184940-47-3 | Reference compound |
| HY-15193B | EMD638683 (S-Form) | 1184940-46-2 | Reference compound |
| HY-15194 | Dimethylcurcumin | 52328-98-0 | Natural Products |
| HY-151940 | Mal-Pc | 2670367-74-3 | Reference compound |
| HY-151941 | MtInhA-IN-1 | | Reference compound |
| HY-151942 | Antitrypanosomal agent 10 | | Reference compound |
| HY-151943 | Antitrypanosomal agent 11 | | Reference compound |
| HY-151944 | Antibacterial agent 128 | 3059046-75-9 | Reference compound |
| HY-151945 | TRK II-IN-1 | 2904690-41-9 | Reference compound |
| HY-151946 | ALR2-IN-2 | | Reference compound |
| HY-151947 | ALR2-IN-3 | | Reference compound |
| HY-151948 | TrkA-IN-3 | 3026111-73-6 | Reference compound |
| HY-151949 | TrkA-IN-4 | 3026111-74-7 | Reference compound |
| HY-15195 | Avosentan | 290815-26-8 | Reference compound |
| HY-151950 | Antidepressant agent 3 | | Reference compound |
| HY-151951 | Antidepressant agent 4 | | Reference compound |
| HY-151952 | NLRP3-IN-12 | | Reference compound |
| HY-151953 | Antitubulin agent 1 | | Reference compound |
| HY-151954 | TGFβ1-IN-2 | 2883813-66-7 | Reference compound |
| HY-151955 | TGFβ1-IN-3 | 2883813-58-7 | Reference compound |
| HY-151956 | Mtb-cyt-bd oxidase-IN-7 | | Reference compound |
| HY-151957 | Antitubercular agent 34 | 2883173-23-5 | Reference compound |
| HY-151958 | Antitubercular agent-35 | | Reference compound |
| HY-151959 | FXR agonist 4 | 3025841-47-5 | Reference compound |
| HY-15196 | TAK-285 | 871026-44-7 | Reference compound |
| HY-151960 | Antitubercular agent-36 | 2883173-82-6 | Reference compound |
| HY-151961 | RSH-7 | 2764609-97-2 | Reference compound |
| HY-151962 | JNK3 inhibitor-5 | 2911640-63-4 | Reference compound |
| HY-151963 | PPARγ/GR modulator 1 | | Reference compound |
| HY-151965 | Antimalarial agent 18 | | Reference compound |
| HY-151966 | TD1092 | | Reference compound |
| HY-151967 | Anti-IAV agent 1 | | Reference compound |
| HY-151968 | KRAS G12C inhibitor 57 | 2821863-70-9 | Reference compound |
| HY-151969 | VEGFR-2-IN-30 | | Reference compound |
| HY-15197 | ABT-046 | 1031336-60-3 | Reference compound |
| HY-151970 | STING-IN-4 | 2250374-27-5 | Reference compound |
| HY-151971 | Aurora kinase-IN-3 | 2840558-83-8 | Reference compound |
| HY-151972 | BRD4 Inhibitor-25 | | Reference compound |
| HY-151973 | Xanthine oxidoreductase-IN-3 | 651769-78-7 | Reference compound |
| HY-151974 | Xanthine oxidoreductase-IN-4 | 1026587-58-5 | Reference compound |
| HY-151975 | Xanthine oxidoreductase-IN-5 | 1026652-90-3 | Reference compound |
| HY-151976 | STAT3-IN-15 | | Reference compound |
| HY-151977 | Tyrosinase-IN-7 | 2873418-52-9 | Reference compound |
| HY-151978 | ZC0109 | | Reference compound |
| HY-151979 | Tyrosinase-IN-8 | | Reference compound |
| HY-15198 | KG5 | 877874-85-6 | Reference compound |
| HY-151980 | Mps1-IN-5 | 2890819-31-3 | Reference compound |
| HY-151981 | EGFR-IN-74 | | Reference compound |
| HY-151982 | Tubulin polymerization-IN-39 | | Reference compound |
| HY-151983 | Thrombin inhibitor 6 | 1628224-94-1 | Reference compound |
| HY-151984 | CDK9-IN-22 | 2872677-61-5 | Reference compound |
| HY-151985 | TACC3 inhibitor 1 | 3033646-06-6 | Reference compound |
| HY-151986 | FOXM1-IN-1 | 2864407-22-5 | Reference compound |
| HY-151987 | RET-IN-20 | | Reference compound |
| HY-151988 | SARS-CoV-2-IN-36 | | Reference compound |
| HY-15199 | Agerafenib hydrochloride | 1227678-26-3 | Reference compound |
| HY-151990 | SARS-CoV-2/MERS Mpro-IN-1 | | Reference compound |
| HY-151991 | SARS-CoV-2/MERS Mpro-IN-2 | | Reference compound |
| HY-151993S | 2-Hydroxypropane-1,3-diyl distearate-d75 | 2692624-32-9 | Isotope-Labeled Compounds |
| HY-151994S | 1,3-Diolein-d66 | 2692624-33-0 | Isotope-Labeled Compounds |
| HY-151995S | 1,1',1''-(1,2,3-Propanetriyl-1,1,2,3,3-d5) tri-(11Z)-11-heptadecenoate | 2692624-35-2 | Isotope-Labeled Compounds |
| HY-151996 | Tubulin inhibitor 31 | | Reference compound |
| HY-151997S | 1,2-Dioleoyl-3-lauroyl-rac-glycerol-13C3 | 2692624-36-3 | Isotope-Labeled Compounds |
| HY-151999 | KRAS G12C inhibitor 65 | | Reference compound |
| HY-15200 | Agerafenib | 1188910-76-0 | Reference compound |
| HY-152000S | C18 Ganglioside GM1-d3 (ammonium) | 2692623-83-7 | Isotope-Labeled Compounds |
| HY-152001 | hCAIX-IN-24 | 3038222-64-6 | Reference compound |
| HY-152002S | Ganglioside GM3-d3 (ammonium) | 2692623-85-9 | Isotope-Labeled Compounds |
| HY-152003S | Ganglioside GM2-d3 (ammonium) | 2692623-87-1 | Isotope-Labeled Compounds |
| HY-152005 | SARS-CoV-2 3CLpro-IN-6 | 302821-53-0 | Reference compound |
| HY-152006S | Propionyl-L-carnitine-d3 (hydrochloride) | 2692623-94-0 | Isotope-Labeled Compounds |
| HY-152007S | Butyrylcarnitine-d3 (hydrochloride) | 2692623-96-2 | Isotope-Labeled Compounds |
| HY-152008S | Hexanoyl-L-carnitine-d3 (hydrochloride) | 2692624-43-2 | Isotope-Labeled Compounds |
| HY-152009 | SARS-CoV-2 3CLpro-IN-7 | 1164478-67-4 | Reference compound |
| HY-152010S | L-Octanoylcarnitine-d3 (hydrochloride) | 1297271-48-7 | Isotope-Labeled Compounds |
| HY-152011S | Lauroyl-L-carnitine-d3 (hydrochloride) | 1297271-52-3 | Isotope-Labeled Compounds |
| HY-152012S | Tetradecanoylcarnitine-d3 (hydrochloride) | 1297271-54-5 | Isotope-Labeled Compounds |
| HY-152013S | L-Palmitoylcarnitine-d3-1 (hydrochloride) | 2692623-98-4 | Isotope-Labeled Compounds |
| HY-152014S | Stearoylcarnitine-d3-1 (hydrochloride) | 2692624-00-1 | Isotope-Labeled Compounds |
| HY-152017S | C18 Globotriaosylceramide-d3 | 2692623-80-4 | Isotope-Labeled Compounds |
| HY-152019 | EGFR/C797S-IN-1 | 2378188-21-5 | Reference compound |
| HY-15202 | Binimetinib | 606143-89-9 | Reference compound |
| HY-152020S | Sphingosine-d9 (d18:1) | 2377379-55-8 | Isotope-Labeled Compounds |
| HY-152021S | C18 Ceramide-1-phosphate (d18:1/18:0)-d3 | 2692624-25-0 | Isotope-Labeled Compounds |
| HY-152022S | EOS (d18:1/32:0/18:2)-d9 | 2692624-26-1 | Isotope-Labeled Compounds |
| HY-152023S | (7Z,10Z,13Z)-7,10,13-Hexadecatrienoic-7,8,10,11,13,14-d6 acid | 2692623-88-2 | Isotope-Labeled Compounds |
| HY-152024S | Sebaleic acid-d19 | 2692624-10-3 | Isotope-Labeled Compounds |
| HY-152026 | NADPH oxidase-IN-1 | 2762405-17-2 | Reference compound |
| HY-152027 | HSP90-IN-18 | 2927442-45-1 | Reference compound |
| HY-152028 | HSP90-IN-19 | 2927442-48-4 | Reference compound |
| HY-15202R | Binimetinib (Standard) | 606143-89-9 | Reference Standards |
| HY-15202S1 | Binimetinib-d3 | 2890696-59-8 | Isotope-Labeled Compounds |
| HY-15202S3 | Binimetinib-d4 | 2890696-60-1 | Isotope-Labeled Compounds |
| HY-152030 | Tubulin/MMP-IN-2 | 2734877-51-9 | Reference compound |
| HY-152031 | Glutaminyl Cyclase Inhibitor 5 | 3033553-63-5 | Reference compound |
| HY-152032 | LSD1-IN-23 | 3033660-66-8 | Reference compound |
| HY-152033 | URAT1 inhibitor 4 | 2700292-02-8 | Reference compound |
| HY-152034 | STING-IN-5 | 2920064-17-9 | Reference compound |
| HY-152035 | Mycobacterial Zmp1-IN-1 | 3033421-29-0 | Reference compound |
| HY-152036 | SIAIS100 | 3033463-06-5 | Reference compound |
| HY-152036A | SIAIS100 (TFA) | | Reference compound |
| HY-152037 | AChE/Nrf2 modulator 1 | 2417117-84-9 | Reference compound |
| HY-152038 | SPEN-IN-1 | 2863686-82-0 | Reference compound |
| HY-152039S | 6PPD-quinone-d5 | 2750119-14-1 | Isotope-Labeled Compounds |
| HY-152039S1 | 6PPD-Q-13C6 | | Isotope-Labeled Compounds |
| HY-15204 | Tonabersat | 175013-84-0 | Reference compound |
| HY-152040S | Tenuazonic acid-(acetyl-13C2) (mixture of diastereomers) in methanol | 1486471-66-2 | Isotope-Labeled Compounds |
| HY-152041S | Sudan II-d6 | 1014689-15-6 | Isotope-Labeled Compounds |
| HY-152048S | Methomyl-d3 | 1398109-07-3 | Isotope-Labeled Compounds |
| HY-15204S | Tonabersat-d6 | 1329837-33-3 | Isotope-Labeled Compounds |
| HY-15205 | Ganetespib | 888216-25-9 | Reference compound |
| HY-152051S | Mabuterol-d9 (hydrochloride) | 1353867-83-0 | Isotope-Labeled Compounds |
| HY-152052S | Linalool-d5 | 159592-39-9 | Isotope-Labeled Compounds |
| HY-152055S | Glufosinate-d3 (hydrochloride) | 1323254-05-2 | Isotope-Labeled Compounds |
| HY-152056S | N-Acetyl glufosinate-d3 | 1356992-90-9 | Isotope-Labeled Compounds |
| HY-152057S | beta-Damascenone-d4 | 217482-71-8 | Isotope-Labeled Compounds |
| HY-15206 | Glibenclamide | 10238-21-8 | Reference compound |
| HY-152065S | 6-Octen-1,1-d2-1-ol, 3,7-dimethyl- | 76027-02-6 | Isotope-Labeled Compounds |
| HY-15206A | Glibenclamide (potassium) | 52169-36-5 | Reference compound |
| HY-15206R | Glibenclamide (Standard) | 10238-21-8 | Reference Standards |
| HY-15206S | Glyburide-d11 | 1189985-02-1 | Isotope-Labeled Compounds |
| HY-15206S1 | Glyburide-d3 | 1219803-02-7 | Isotope-Labeled Compounds |
| HY-15206S2 | Glibenclamide-13C6 | | Isotope-Labeled Compounds |
| HY-152070S | Demethylmaprotiline-d2 | | Isotope-Labeled Compounds |
| HY-152070S1 | Demethylmaprotiline-d2-1 | | Isotope-Labeled Compounds |
| HY-152072S | Deoxynivalenol-13C15 | 911392-36-4 | Isotope-Labeled Compounds |
| HY-152073 | BETA-1 | 2924598-24-1 | Dye Reagents |
| HY-152074 | CD73-IN-14 | 2407356-67-4 | Reference compound |
| HY-152075 | AXL-IN-14 | 2947506-65-0 | Reference compound |
| HY-152076 | Telomerase-IN-4 | 2892295-10-0 | Reference compound |
| HY-152077 | Telomerase-IN-5 | 2892295-16-6 | Reference compound |
| HY-152078 | Influenza virus-IN-6 | 2919303-26-5 | Reference compound |
| HY-152079 | CYP1B1-IN-3 | 2872575-51-2 | Reference compound |
| HY-15208 | Clamikalant (sodium) | 261717-22-0 | Reference compound |
| HY-152080 | TUL01101 | 2411222-97-2 | Reference compound |
| HY-152081 | DENV-IN-7 | 2499537-22-1 | Reference compound |
| HY-152082 | DENV-IN-8 | 1809464-07-0 | Reference compound |
| HY-152083 | DENV-IN-9 | 791838-63-6 | Reference compound |
| HY-152084 | Anticancer agent 93 | 94205-22-8 | Reference compound |
| HY-152085 | Anticancer agent 94 | | Reference compound |
| HY-152086 | DRP1i27 | 1453028-33-5 | Reference compound |
| HY-152086A | DRP1i27 (dihydrochloride) | | Reference compound |
| HY-152087 | DCZ19931 | 2789629-84-9 | Reference compound |
| HY-152088 | Neuroinflammatory-IN-3 | 1202404-23-6 | Reference compound |
| HY-152089 | SB26019 | 1233078-90-4 | Reference compound |
| HY-15208A | Clamikalant | 158751-64-5 | Reference compound |
| HY-15209 | Repaglinide | 135062-02-1 | Reference compound |
| HY-152090 | Antiproliferative agent-17 | 2882206-08-6 | Reference compound |
| HY-152091 | Antiproliferative agent-18 | 2882206-14-4 | Reference compound |
| HY-152092 | MMP-1-IN-1 | | Reference compound |
| HY-152093 | YL-939 | 3023925-68-7 | Reference compound |
| HY-152094 | SRD5A1-IN-1 | 2279077-93-7 | Reference compound |
| HY-152095 | PPI-GIT1/β-Pix interaction-IN-1 | 2070916-70-8 | Reference compound |
| HY-152096 | (R)-ZG197 | 2999672-72-7 | Reference compound |
| HY-152097 | (S)-ZG197 | 2999672-66-9 | Reference compound |
| HY-152098 | HX103 | 2566466-98-4 | Reference compound |
| HY-152099 | Antiproliferative agent-19 | | Reference compound |
| HY-15209R | Repaglinide (Standard) | 135062-02-1 | Reference Standards |
| HY-15209S | Repaglinide-d5 | 1217709-85-7 | Isotope-Labeled Compounds |
| HY-152100 | CUR5g | 1370032-20-4 | Reference compound |
| HY-152101 | LY1 | 2883813-32-7 | Reference compound |
| HY-152102 | BTCy | | Dye Reagents |
| HY-152103 | CB2-H | | Dye Reagents |
| HY-152104 | FGFR-IN-9 | 3024090-08-9 | Reference compound |
| HY-152105 | Metallo-β-lactamase-IN-9 | 1802363-75-2 | Reference compound |
| HY-152106 | BAY-7081 | 3036022-06-4 | Reference compound |
| HY-152107 | LRRK2-IN-7 | 2307277-93-4 | Reference compound |
| HY-152107A | (R,R)-LRRK2-IN-7 | 2307277-92-3 | Reference compound |
| HY-152108 | SARS-CoV-2 Mpro-IN-6 | 2768834-48-4 | Reference compound |
| HY-152109 | AChE/MAO-IN-1 | | Reference compound |
| HY-15211 | MRK 003 | 623165-93-5 | Reference compound |
| HY-152110 | AChE/MAO-IN-2 | | Reference compound |
| HY-152111 | AChE/MAO-B-IN-3 | | Reference compound |
| HY-152112 | AChE/BChE/MAO-B-IN-2 | | Reference compound |
| HY-152113 | AChE/BChE/MAO-B-IN-3 | | Reference compound |
| HY-152114 | AChE/BChE/MAO-B-IN-4 | | Reference compound |
| HY-152117 | Acetyl-CoA Carboxylase-IN-1 | 179343-23-8 | Reference compound |
| HY-152118 | CYP1B1-IN-4 | 2685779-55-7 | Reference compound |
| HY-152120 | (±)-Aiphanol | 578020-29-8 | Natural Products |
| HY-152121 | Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal | 2345732-89-8 | Reference compound |
| HY-152131 | CCR5 antagonist 2 | 1800570-93-7 | Reference compound |
| HY-152132 | CCR5 antagonist 3 | 1800570-92-6 | Reference compound |
| HY-152133 | PROTAC HDAC6 degrader 1 | 2785404-76-2 | Reference compound |
| HY-152134 | HDAC6 degrader-3 | 2785404-83-1 | Reference compound |
| HY-152135 | TJ08 | 2924274-19-9 | Reference compound |
| HY-152136 | Antituberculosis agent-6 | 2874263-72-4 | Reference compound |
| HY-152137 | Antituberculosis agent-7 | 2874263-73-5 | Reference compound |
| HY-152138 | Antituberculosis agent-8 | 2874263-74-6 | Reference compound |
| HY-152139 | Antibacterial agent 129 | 2874263-66-6 | Reference compound |
| HY-15214 | CARM1-IN-3 | 912970-67-3 | Reference compound |
| HY-152140 | hCAII-IN-8 | 952306-80-8 | Reference compound |
| HY-152141 | hCAII-IN-9 | 2878477-18-8 | Reference compound |
| HY-152142 | DN-1289 | 3026597-15-6 | Reference compound |
| HY-152143 | Tubulin polymerization-IN-41 | 2804026-81-9 | Reference compound |
| HY-152144 | EGFR-IN-75 | | Reference compound |
| HY-152145 | PROTAC SOS1 degrader-3 | 3029320-99-5 | Reference compound |
| HY-152146 | HDAC-IN-50 | 2653339-26-3 | Reference compound |
| HY-152147 | SZUH280 | 2770263-77-7 | Reference compound |
| HY-152148 | JZP-MA-11 | 1672691-50-7 | Reference compound |
| HY-152149 | CTP Synthetase-IN-1 | 2338811-71-3 | Reference compound |
| HY-15214A | CARM1-IN-3 (dihydrochloride) | | Reference compound |
| HY-152150 | Thrombin inhibitor 7 | 2866508-00-9 | Reference compound |
| HY-152152 | JZP-MA-13 | 3034900-00-7 | Reference compound |
| HY-152153 | GRP78-IN-3 | 2707510-30-1 | Reference compound |
| HY-152154 | Nampt degrader-2 | 3035008-40-0 | Reference compound |
| HY-152155 | ARUK2001607 | 2924824-56-4 | Reference compound |
| HY-152156 | Tubulin inhibitor 11 | 2366260-33-3 | Reference compound |
| HY-152157 | HIV-1 inhibitor-52 | 1818868-23-3 | Reference compound |
| HY-152158 | α-Glucosidase-IN-22 | 2870693-28-8 | Reference compound |
| HY-152159 | CYP4Z1-IN-1 | 2760611-38-7 | Reference compound |
| HY-152160 | HIV-1 inhibitor-50 | 2834087-69-1 | Reference compound |
| HY-152161 | HIV-1 inhibitor-51 | 2834087-82-8 | Reference compound |
| HY-152166 | NaV1.2/1.6 channel blocker-1 | 1199944-04-1 | Reference compound |
| HY-152168 | NSC 295642 | 77111-29-6 | Reference compound |
| HY-152169 | BIHC | 1642826-40-1 | Reference compound |
| HY-15217 | CHR-6494 | 1333377-65-3 | Reference compound |
| HY-152170 | bPiDI | 525596-64-9 | Reference compound |
| HY-152171 | GZ-11608 | 2141974-01-6 | Reference compound |
| HY-152173 | HDAC-IN-51 | 3026728-28-6 | Reference compound |
| HY-152174 | HDAC-IN-52 | 2075787-77-6 | Reference compound |
| HY-152175 | Antibacterial agent 130 | 1502721-60-9 | Reference compound |
| HY-152177 | JS6 | 950244-33-4 | Reference compound |
| HY-152182 | ML-SA5 | 2418670-70-7 | Reference compound |
| HY-152183 | FINDY | 1507367-37-4 | Reference compound |
| HY-152184 | SEW84 | 259089-67-3 | Reference compound |
| HY-152185 | BSJ-04-122 | 2513289-74-0 | Reference compound |
| HY-152187 | Topoisomerase IIα-IN-5 | 3037545-23-3 | Reference compound |
| HY-152188 | AKR1C3-IN-9 | 2924824-43-9 | Reference compound |
| HY-152189 | S19-1035 | 2986319-18-8 | Reference compound |
| HY-152190 | JB002 | 30408-07-2 | Reference compound |
| HY-152191 | ChoKα inhibitor-3 | 2883822-56-6 | Reference compound |
| HY-152193 | ChoKα inhibitor-4 | | Reference compound |
| HY-152194 | Tyrosinase-IN-10 | 2873418-48-3 | Reference compound |
| HY-152195 | ChoKα inhibitor-5 | | Reference compound |
| HY-152196 | CYP1B1-IN-5 | 176442-56-1 | Reference compound |
| HY-152197 | Tankyrase-IN-3 | 938893-79-9 | Reference compound |
| HY-152198 | Tankyrase-IN-4 | | Reference compound |
| HY-152199 | AMPD2 inhibitor 2 | 3026893-31-9 | Reference compound |
| HY-152200 | HIV-1 inhibitor-53 | 2883496-10-2 | Reference compound |
| HY-152201 | BTK-IN-18 | 1374239-71-0 | Reference compound |
| HY-152202 | Mitochondrial respiration-IN-3 | | Reference compound |
| HY-152203 | Mitochondrial respiration-IN-2 | 318498-81-6 | Reference compound |
| HY-152204 | Cathepsin L/S-IN-1 | | Reference compound |
| HY-152205 | JB061 | | Reference compound |
| HY-152206 | JB062 | 2417988-00-0 | Reference compound |
| HY-152207 | LWG-301 | 3038480-88-2 | Reference compound |
| HY-152208 | BPDA2 | 2907659-86-1 | Reference compound |
| HY-152209 | BRD4 Inhibitor-26 | | Reference compound |
| HY-15221 | Methylstat | 1310877-95-2 | Reference compound |
| HY-152210 | ASPER-29 | 2630388-03-1 | Reference compound |
| HY-152212 | BTK-IN-19 | 1374240-01-3 | Reference compound |
| HY-152213 | BET-IN-13 | 2506823-08-9 | Reference compound |
| HY-152214 | SIRT5 inhibitor 5 | 2883730-60-5 | Reference compound |
| HY-152215 | Dynamin IN-1 | 1345853-50-0 | Reference compound |
| HY-152216 | Dynamin IN-2 | 1345853-49-7 | Reference compound |
| HY-152217 | Clathrin-IN-2 | 2650733-69-8 | Reference compound |
| HY-152218 | Clathrin-IN-4 | 762242-59-1 | Reference compound |
| HY-152219 | CLK1-IN-2 | 3029431-68-0 | Reference compound |
| HY-15222 | Menin-MLL inhibitor MI-2 | 1271738-62-5 | Reference compound |
| HY-152220 | SPR39 | | Reference compound |
| HY-152221 | PCSK9-IN-10 | 368434-98-4 | Reference compound |
| HY-152222 | SPR38 | | Reference compound |
| HY-152223 | PCSK9-IN-11 | 2882035-56-3 | Reference compound |
| HY-152224 | SPR41 | | Reference compound |
| HY-152225 | MC2625 | 1776116-75-6 | Reference compound |
| HY-152226 | MC2590 | 2284460-01-9 | Reference compound |
| HY-152227 | PROTAC TYK2 degradation agent1 | 2921556-14-9 | Reference compound |
| HY-152228 | SMYD3-IN-2 | | Reference compound |
| HY-152229 | G0-C14 | 1510653-27-6 | Oligonucleotides |
| HY-15223 | MI-3 | 1271738-59-0 | Reference compound |
| HY-152231 | BODIPY FL thalidomide | 2740620-18-0 | Reference compound |
| HY-152232 | BChE-IN-15 | | Reference compound |
| HY-152233 | Reverse transcriptase-IN-4 | | Reference compound |
| HY-152235 | HDAC6-IN-15 | | Reference compound |
| HY-152236 | PRMT6-IN-3 | 2890765-10-1 | Reference compound |
| HY-152237 | TBK1-IN-1 | | Reference compound |
| HY-152238 | PI3K/mTOR Inhibitor-12 | 2891692-83-2 | Reference compound |
| HY-152239 | RdRP-IN-5 | 2915761-74-7 | Reference compound |
| HY-152239A | cis-RdRP-IN-5 | | Reference compound |
| HY-152239B | trans-RdRP-IN-5 | | Reference compound |
| HY-15224 | PCI-34051 | 950762-95-5 | Reference compound |
| HY-152240 | PD-1/PD-L1-IN-29 | 2665734-13-2 | Reference compound |
| HY-152241 | DS-9300 | 2259641-46-6 | Reference compound |
| HY-152242 | YEATS4-IN-1 | 3034365-92-6 | Reference compound |
| HY-152243 | YEATS4 binder-1 | 3034365-93-7 | Reference compound |
| HY-152245 | Physachenolide C | 791117-61-8 | Natural Products |
| HY-152246 | ZIM | 301298-87-3 | Reference compound |
| HY-152247 | DDO3711 | 2673364-10-6 | Reference compound |
| HY-152248 | ARS-2102 | 2098509-21-6 | Reference compound |
| HY-152249 | Antibacterial agent 131 | | Reference compound |
| HY-152250 | Antibacterial agent 132 | 3026790-18-8 | Reference compound |
| HY-152251 | CB2R/FAAH modulator-1 | 928892-60-8 | Reference compound |
| HY-152252 | Antibacterial agent 133 | | Reference compound |
| HY-152253 | CB2R/FAAH modulator-2 | 2876918-68-0 | Reference compound |
| HY-152254 | CB2R/FAAH modulator-3 | 2876918-67-9 | Reference compound |
| HY-152257 | HPK1-IN-31 | 3003026-16-9 | Reference compound |
| HY-152259 | TMV-IN-4 | 1820823-40-2 | Reference compound |
| HY-15226 | AZ505 | 1035227-43-0 | Reference compound |
| HY-152261 | MS6105 | 2891709-58-1 | Reference compound |
| HY-152263 | HEMTAC CDK4/6 degrader 1 | 2821803-61-4 | Reference compound |
| HY-152264 | CFTR activator 1 | 2768261-09-0 | Reference compound |
| HY-152265 | PARL-IN-1 | | Reference compound |
| HY-152265A | PARL-IN-1 (TFA) | | Reference compound |
| HY-15226A | AZ505 (ditrifluoroacetate) | 1035227-44-1 | Reference compound |
| HY-15227 | EPZ004777 | 1338466-77-5 | Reference compound |
| HY-152270 | Pirnabine | 19825-63-9 | Peptides |
| HY-15227A | EPZ004777 (hydrochloride) | 1380316-03-9 | Reference compound |
| HY-15228 | RX-3117 | 865838-26-2 | Reference compound |
| HY-15229 | Guadecitabine sodium | 929904-85-8 | Reference compound |
| HY-152292 | Zidesamtinib | 2739829-00-4 | Reference compound |
| HY-152293 | EVT801 | 1412453-70-3 | Reference compound |
| HY-152294 | 3′-Deoxy-3′-methyluridine | 444020-64-8 | Reference compound |
| HY-152295 | 3’-Deoxy-2’-thiouridine | 455951-69-6 | Oligonucleotides |
| HY-152296 | 8-Methyladenosine | 56973-12-7 | Oligonucleotides |
| HY-152297 | (1S)-1,4-Anhydro-1-C-(2,4-difluorophenyl)-D-ribitol | 263701-23-1 | Oligonucleotides |
| HY-152298 | 5-Fluoro-4’-thiouridine | 56527-42-5 | Oligonucleotides |
| HY-152299 | 5-(t-Butyloxycarbonylmethoxy)uridine | | Oligonucleotides |
| HY-15230 | Geldanamycin | 30562-34-6 | Natural Products |
| HY-152300 | N4,N4-Dimethylcytidine | 13007-43-7 | Oligonucleotides |
| HY-152301 | 3’-Deoxy-3’-fluoro-N6-methyladenosine | 122654-27-7 | Oligonucleotides |
| HY-152302 | 3’-Deoxy-3’-fluoro-5-methylcytidine | 847650-07-1 | Oligonucleotides |
| HY-152303 | N6-(4-Methoxybenzyl)adenosine | 23666-24-2 | Oligonucleotides |
| HY-152303S | N6-(4-Methoxybenzyl)adenosine-d3 | | Isotope-Labeled Compounds |
| HY-152304 | N-[(3-Methoxyphenyl)methyl]adenosine | 101565-95-1 | Oligonucleotides |
| HY-152305 | (1S)-1,4-Anhydro-1-C-(2,4-difluoro-5-methylphenyl)-D-ribitol | 875302-27-5 | Oligonucleotides |
| HY-152306 | N1,N3-Bis(cyanomethyl)pseudouridine | | Oligonucleotides |
| HY-152307 | 2-Chloro-N6-methyladenosine | 13406-50-3 | Oligonucleotides |
| HY-152308 | 3’-Deoxy-3’,5-difluorocytidine | 661470-65-1 | Oligonucleotides |
| HY-152309 | N-(3-Methylbutyl)adenosine | 17659-78-8 | Oligonucleotides |
| HY-15230R | Geldanamycin (Standard) | 30562-34-6 | Reference Standards |
| HY-15231 | PSI-352938 | 1199809-32-9 | Reference compound |
| HY-152310 | N4-(n-Palmitoyl)-4’-azido-2’-deoxy-2’-fluoro-arabinocytidine | | Oligonucleotides |
| HY-152311 | 2-Chloro-N6,N6-dimethyladenosine | 13406-53-6 | Oligonucleotides |
| HY-152312 | 8-Allyloxyadenosine | 2095417-69-7 | Oligonucleotides |
| HY-152313 | 2-Bromoadenosine | 146-76-9 | Oligonucleotides |
| HY-152314 | 2-Cyanoadenosine | 79936-11-1 | Oligonucleotides |
| HY-152315 | 3’-Azido-3’-deoxy-N6-methyladenosine | 889126-08-3 | Oligonucleotides |
| HY-152316 | 2-Chloro-N6-isopropyladenosine | 23541-30-2 | Oligonucleotides |
| HY-152317 | 5-Methyl-2-thio-xylo-uridine | 246857-26-1 | Oligonucleotides |
| HY-152318 | Adenosine-2-carboxamide | 70255-72-0 | Oligonucleotides |
| HY-152319 | 3’-Azido-3’-deoxy-N6,N6-dimethyladenosine | 384334-64-9 | Oligonucleotides |
| HY-15231A | (Rac)-PSI-352938 | 1231747-17-3 | Reference compound |
| HY-15232 | Tenofovir alafenamide | 379270-37-8 | Reference compound |
| HY-152320 | Adenosine-2-carboxy methyl amide | | Oligonucleotides |
| HY-152321 | 5-Hydroxy-arabinouridine | 69321-95-5 | Oligonucleotides |
| HY-152322 | 2-Chloro-N6-iso-pentenyladenosine | 65400-39-7 | Oligonucleotides |
| HY-152323 | N1-Methylsulfonyl pseudouridine | | Oligonucleotides |
| HY-152324 | 2-Chloro-N6-(2-hydroxyethyl)adenosine | 948298-76-8 | Oligonucleotides |
| HY-152325 | N1-(N,N-Dimethylaminocarbonyl)-pseudouridine | | Oligonucleotides |
| HY-152326 | 2’-β-C-Methyl-6-azauridine | 172605-95-7 | Oligonucleotides |
| HY-152327 | 2-Methylthio isopentenyladenosine | 20859-00-1 | Oligonucleotides |
| HY-152328 | 7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine | 2389988-43-4 | Oligonucleotides |
| HY-152329 | 3’-Deoxy-3’-fluoro-6-azauridine | 439579-23-4 | Oligonucleotides |
| HY-15232A | Tenofovir alafenamide fumarate | 379270-38-9 | Reference compound |
| HY-15232B | Tenofovir alafenamide hemifumarate | 1392275-56-7 | Reference compound |
| HY-15232BR | Tenofovir alafenamide hemifumarate (Standard) | 1392275-56-7 | Reference Standards |
| HY-15232S2 | Tenofovir alafenamide-d6 | | Isotope-Labeled Compounds |
| HY-15233 | Letermovir | 917389-32-3 | Reference compound |
| HY-152330 | 2’-Chloro-N6-(3-methoxy)benzyl adenosine | 722504-73-6 | Oligonucleotides |
| HY-152331 | 7-n-Propyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine | 2389988-44-5 | Oligonucleotides |
| HY-152332 | 2’-Chloro-N6-(4-methoxy)benzyl adenosine | 722504-77-0 | Oligonucleotides |
| HY-152333 | 7-n-Butyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine | 2389988-45-6 | Oligonucleotides |
| HY-152334 | 2’-Chloro-2’-deoxyadenosine | 2627-62-5 | Oligonucleotides |
| HY-152335 | 2’-Chloro-N6-(3-trifluoromethyl)benzyl adenosine | | Oligonucleotides |
| HY-152336 | N1-(2-Methyl)propyl pseudouridine | | Oligonucleotides |
| HY-152337 | 2’-Chloro-N6-(4-trifluoromethyl)benzyl adenosine | 722515-03-9 | Oligonucleotides |
| HY-152338 | 7-Propargyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine | 2389988-31-0 | Oligonucleotides |
| HY-152339 | N4-Amino-2’-β-C-methylcytidine | 622381-10-6 | Oligonucleotides |
| HY-15233R | Letermovir (Standard) | 917389-32-3 | Reference Standards |
| HY-15234 | Fluticasone furoate | 397864-44-7 | Reference compound |
| HY-152340 | 2’-Amino-2’-deoxy-5-fluoro-arabinouridine | 2305415-81-8 | Oligonucleotides |
| HY-152341 | 7-(Butyn-2-yl)-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine | 2389988-33-2 | Oligonucleotides |
| HY-152342 | N1-Methoxymethyl pseudouridine | 2131744-33-5 | Oligonucleotides |
| HY-152343 | 1-(β-D-Xylofuranosyl)-2-thiouracil | 2305416-17-3 | Oligonucleotides |
| HY-152344 | 2’-β-C-Methyl inosine | 374750-32-0 | Oligonucleotides |
| HY-152345 | N1-Ethoxymethyl pseudouridine | | Oligonucleotides |
| HY-152346 | N1-Benzoyl pseudouridine | | Oligonucleotides |
| HY-152347 | 1-Amino-3’-deoxy-7,8-dihydro-8-oxoguanosine | 2389988-59-2 | Oligonucleotides |
| HY-152348 | 2’-Deoxy-2’-fluoro-5-methyl-4’-thio-β-D-arabino uridine | 135123-34-1 | Oligonucleotides |
| HY-152349 | 2’-Deoxy-2’-fluoro-β-D-arabino-2-thiouridine | 1006872-85-0 | Oligonucleotides |
| HY-15234R | Fluticasone furoate (Standard) | 397864-44-7 | Reference Standards |
| HY-15234S | Fluticasone furoate-d3 | | Isotope-Labeled Compounds |
| HY-15234S1 | Fluticasone furoate-d5 | | Isotope-Labeled Compounds |
| HY-152350 | 2’-Deoxy-2’-fluoro-4’-thio-β-D-arabinouridine | 941610-00-0 | Oligonucleotides |
| HY-152351 | 8-Bromo-3’-deoxyguanosine | 847649-68-7 | Oligonucleotides |
| HY-152352 | 7,8-Dihydro-8-oxo-7-propargyl guanosine | 2763084-98-4 | Oligonucleotides |
| HY-152353 | 3’-Azido-3’-deoxy-2-thiouridine | 2305416-00-4 | Oligonucleotides |
| HY-152354 | 8-Benzyloxy-3’-deoxyguanosine | 2389988-57-0 | Oligonucleotides |
| HY-152355 | N6-Methyl-xylo-adenosine | 65494-95-3 | Oligonucleotides |
| HY-152356 | 8-Bromo-3’-deoxy-3’-fluoroguanosine | 847649-50-7 | Oligonucleotides |
| HY-152357 | N6,N6-Dimethyl-xylo-adenosine | 669055-52-1 | Oligonucleotides |
| HY-152358 | N3-Methyl-2’-O-methyluridine | 7103-27-7 | Oligonucleotides |
| HY-152359 | 8-Benzyloxy-3’-deoxy-3’-fluoroguanosine | 2389988-61-6 | Oligonucleotides |
| HY-15236 | PSI-6206 | 863329-66-2 | Reference compound |
| HY-152360 | 1-(β-D-Xylofuranosyl)-5-methylcytosine | 18492-10-9 | Oligonucleotides |
| HY-152361 | N6-Methyl-2’-β-C-methyladenosine | 565450-76-2 | Oligonucleotides |
| HY-152362 | 8-Hydroxy-3'-deoxy-3'-fluoroguanosine | | Oligonucleotides |
| HY-152363 | N3-Methyl-2’-O-(2-methoxyethyl)uridine | 2305416-12-8 | Oligonucleotides |
| HY-152364 | 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro guanosine | 2389988-55-8 | Oligonucleotides |
| HY-152365 | N6,N6-Dimethyl-2’-β-C-methyladenosine | 565450-77-3 | Oligonucleotides |
| HY-152366 | 3’-beta-C-Methyladenosine | 15397-13-4 | Oligonucleotides |
| HY-152367 | 8-Hydroxy-3'-deoxyguanosine | | Oligonucleotides |
| HY-152368 | 8-Hydrazinoadenosine | 3868-34-6 | Oligonucleotides |
| HY-152369 | 1,N6-Etheno-ara-adenosine | 2095417-09-5 | Oligonucleotides |
| HY-15236S | PSI-6206-13C,d3 | 1256490-42-2 | Isotope-Labeled Compounds |
| HY-15236S1 | PSI-6206-d1,13C,15N2 | | Isotope-Labeled Compounds |
| HY-15237 | SL 0101-1 | 77307-50-7 | Natural Products |
| HY-152370 | 3’-beta-C-Methyl-N6-methyladenosine | 565450-84-2 | Oligonucleotides |
| HY-152371 | 1,N6-Etheno-9-(β-D-xylofuranosyl)adenosine | 2095417-39-1 | Oligonucleotides |
| HY-152372 | Methyl 6-amino-9-β-D-ribofuranosyl-9H-purine-2-carboxylate | 70255-70-8 | Oligonucleotides |
| HY-152373 | 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy-3’-fluoro-xylo-guanosine | 2389988-56-9 | Oligonucleotides |
| HY-152374 | 3’-Deoxy-3’-fluoro-N6,N6-dimethyladenosine | 122654-28-8 | Oligonucleotides |
| HY-152375 | 8-Hydroxy-xyloguanosine | 2390368-04-2 | Oligonucleotides |
| HY-152376 | N6,N6-Dimethyl-3’-beta-C-methyl-adenosine | 565450-85-3 | Oligonucleotides |
| HY-152377 | 5-Hydroxy-2’-O-methyluridine | 2030403-78-0 | Oligonucleotides |
| HY-152378 | 2’-Deoxy-2’-fluoro-β-D-arabino-6-azauridine | 908129-24-8 | Oligonucleotides |
| HY-152379 | 3’-Deoxy-methyl-2-thiouridine | 2305416-19-5 | Oligonucleotides |
| HY-15238 | ST-836 | 1148156-63-1 | Reference compound |
| HY-152380 | 1,2,4-Triazine-3,5-dione 2-β-D-xylopyranoside | 93060-34-5 | Oligonucleotides |
| HY-152381 | 1,9-Dihydro-9-β-D-xylofuranosyl-6H-purin-6-one | 10517-16-5 | Oligonucleotides |
| HY-152382 | 3’-O-(2-Methoxyethyl)cytidine | 2305415-84-1 | Oligonucleotides |
| HY-152383 | 5-Difluoromethyluridine | 110483-84-6 | Oligonucleotides |
| HY-152384 | 5’(R)-C-Methyladenosine | 3253-81-4 | Oligonucleotides |
| HY-152385 | 5,6-Dihydro-ara-uridine | 30100-83-5 | Oligonucleotides |
| HY-152387 | 8-Chloro-arabinoadenosine | 769872-68-6 | Oligonucleotides |
| HY-152388 | 3’-beta-C-Methyluridine | 80541-15-7 | Oligonucleotides |
| HY-152389 | 6-Methylpurine-β-D-(3-azido-3-deoxy)riboside | 2095417-25-5 | Oligonucleotides |
| HY-15238A | ST-836 (hydrochloride) | 1415564-68-9 | Reference compound |
| HY-152390 | 2’-Fluoro-2’-deoxy-N6-methylarabinoadenosine | 126502-12-3 | Oligonucleotides |
| HY-152391 | 3’-beta-C-Methyl-5-methyluridine | 934002-35-4 | Oligonucleotides |
| HY-152392 | 2’-Fluoro-2’-deoxy-N6,N6-dimethylarabinoadenosine | 144924-81-2 | Oligonucleotides |
| HY-152393 | 3’-Deoxy-3’-α-C-methyl-5-methyluridine | 847650-50-4 | Oligonucleotides |
| HY-152394 | 3’-beta-C-Methylcytidine | 20724-72-5 | Oligonucleotides |
| HY-152395 | N-[[4-(Trifluoromethyl)phenyl]methyl]adenosine | 722505-71-7 | Oligonucleotides |
| HY-152396 | 1-(β-D-Xylofuranosyl)-N6-(m-methoxybenzyl)adenine | | Oligonucleotides |
| HY-152397 | 3’-Deoxy-N6-isopentenyl adenosine | 1237496-62-6 | Oligonucleotides |
| HY-152398 | 6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine | | Oligonucleotides |
| HY-152399 | 1-(β-D-Xylofuranosyl)-N6-(m-trifluoromethylbenzyl)adenine | | Oligonucleotides |
| HY-15240 | c-Kit-IN-1 | 1225278-16-9 | Reference compound |
| HY-152400 | 8-Bromo-9-(β-D-xylofuranosyl) guanine | 1212650-12-8 | Oligonucleotides |
| HY-152401 | 1-(β-D-Xylofuranosyl)-N6-Isopentenyladenine | | Oligonucleotides |
| HY-152402 | N6-(3-Trifluoromethylbenzyl)-2’-C-methyl adenosine | 2305415-78-3 | Oligonucleotides |
| HY-152403 | 3’-Deoxy-3’-fluoro-xylo-5-methylcytidine | | Oligonucleotides |
| HY-152404 | 3’-Deoxy-3’-fluoro-xylo-N6-(m-methoxybenzyl)adenosine | | Oligonucleotides |
| HY-152405 | 6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one | 85426-86-4 | Oligonucleotides |
| HY-152406 | 3’-Beta-C-Methyl-5-methylcytidine | | Oligonucleotides |
| HY-152407 | 7-Allyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine | 2389988-25-2 | Oligonucleotides |
| HY-152408 | 2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine | 124137-35-5 | Oligonucleotides |
| HY-152409 | N6-Benzyl-2’-C-methyladenosine | 849241-79-8 | Oligonucleotides |
| HY-15241 | NVP-LCQ195 | 902156-99-4 | Reference compound |
| HY-152410 | 6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine | | Oligonucleotides |
| HY-152411 | 3’-Beta-C-Methyl-inosine | | Oligonucleotides |
| HY-152412 | 3’-Deoxy-3’-α-C-methyl-5-fluorouridine | 37731-67-2 | Oligonucleotides |
| HY-152413 | N6-Furfuryl-2’-C-methyladenosine | 1042976-44-2 | Oligonucleotides |
| HY-152414 | 6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine | | Oligonucleotides |
| HY-152415 | 3’-Deoxy-3’-α-C-methyladenosine | 26383-05-1 | Oligonucleotides |
| HY-152416 | N6-Isopentenyl-2’-C-methyladenosine | 2305416-13-9 | Oligonucleotides |
| HY-152417 | N3-Ethyl pseudouridine | 2413585-37-0 | Oligonucleotides |
| HY-152418 | 3’-Beta-C-Methyl-N6-(m-methoxybenzyl)adenosine | | Oligonucleotides |
| HY-152419 | N6-(3-Methoxybenzyl)-2’-C-methyl adenosine | 2305415-85-2 | Oligonucleotides |
| HY-15242 | Capromorelin | 193273-66-4 | Reference compound |
| HY-152420 | 2-Trifluoromethyl adenosine | 4627-40-1 | Oligonucleotides |
| HY-152421 | 8-Benzyloxy-9-(β-D-xylofuranosyl)guanine | 2389988-19-4 | Oligonucleotides |
| HY-152422 | 3’-Beta-C-Methyl-N6-(m-trifluoromethylbenzyl)adenosine | | Oligonucleotides |
| HY-152423 | 3’-Deoxy-3’-α-C-methyl-N6,N6-dimethyladenosine | 2095417-44-8 | Oligonucleotides |
| HY-152424 | N6-(4-Methoxybenzyl)-2’-C-methyl adenosine | 2305415-98-7 | Oligonucleotides |
| HY-152425 | 2-Methylamino-N6-methyladenosine | 28360-91-0 | Oligonucleotides |
| HY-152426 | 1-Amino-8-benzyloxy-9-(β-D-xylofuranosyl)guanine | 2389988-20-7 | Oligonucleotides |
| HY-152427 | 3’-Beta-C-Methyl-N6-isopentenyl adenosine | | Oligonucleotides |
| HY-152428 | 3’-Deoxy-3’-α-C-methylguanosine | 444020-69-3 | Oligonucleotides |
| HY-152429 | 3’-Beta-C-ethynyl-5-trifluoromethyluridine | | Oligonucleotides |
| HY-15243 | Capromorelin (Tartrate) | 193273-69-7 | Reference compound |
| HY-152430 | 8-Hydroxymethyl guanosine | 54898-41-8 | Oligonucleotides |
| HY-152431 | 1-Amino-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine | 2389988-21-8 | Oligonucleotides |
| HY-152432 | 1-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine | 2389988-22-9 | Oligonucleotides |
| HY-152433 | N1-(1,1-Difluoroethyl)pseudouridine | | Oligonucleotides |
| HY-152434 | 5-Hydroxymethyl-arauridine | 28608-82-4 | Oligonucleotides |
| HY-152435 | 2’-Amino-2’-deoxy-5-methyl uridine | 869729-38-4 | Oligonucleotides |
| HY-152436 | 7-Cyclopropylmethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine | 2389988-23-0 | Oligonucleotides |
| HY-152437 | 3’-Amino-3’-deoxy-5-methyl uridine | 108630-07-5 | Oligonucleotides |
| HY-152438 | 6-Amino-3-ethynyl-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine | | Oligonucleotides |
| HY-152439 | 3’-Amino-3’-deoxy-5-fluorouridine | 80955-97-1 | Oligonucleotides |
| HY-15244 | Alpelisib | 1217486-61-7 | Reference compound |
| HY-152440 | 3’-Amino-3’-deoxycytidine | 70580-89-1 | Oligonucleotides |
| HY-152441 | 2-Aminomethyl adenosine | 2305415-79-4 | Oligonucleotides |
| HY-152442 | 3’-beta-C-Ethynyl-3-deazauridine | | Oligonucleotides |
| HY-152443 | 6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine | | Oligonucleotides |
| HY-152444 | 5-Hydroxymethyl-2’-O-(2-methoxyethyl)uridine | 2095417-51-7 | Oligonucleotides |
| HY-152445 | 3’-Amino-3’-deoxyuridine | 70580-90-4 | Oligonucleotides |
| HY-152446 | N4-Methylarabinocytidine | 13491-42-4 | Oligonucleotides |
| HY-152447 | 3’-beta-C-Ethynyl inosine | | Oligonucleotides |
| HY-152448 | 2’-Azido-2’-deoxycytidine | 51034-68-5 | Oligonucleotides |
| HY-152449 | 3’-Beta-C-ethynyl-N6-(m-trifluoromethyl benzyl)adenosine | | Oligonucleotides |
| HY-15244A | Alpelisib (hydrochloride) | 1584128-91-5 | Reference compound |
| HY-15245 | GSK2636771 | 1372540-25-4 | Reference compound |
| HY-152450 | 5-Hydroxymethyl-2’-β-C-methyluridine | 2305415-92-1 | Oligonucleotides |
| HY-152451 | 3’-Beta-C-ethynyl-N6-(m-methoxybenzyl)adenosine | | Oligonucleotides |
| HY-152452 | 2′-Amino-2′-deoxycytidine | 26889-42-9 | Oligonucleotides |
| HY-152453 | 3’-Beta-C-ethynyl-N6-iso-pentenyl adenosine | | Oligonucleotides |
| HY-152454 | 4’-α-C-Methylcytidine | 153186-29-9 | Oligonucleotides |
| HY-152455 | 3’-Deoxy-N6-(m-methoxy benzyl)adenosine | | Oligonucleotides |
| HY-152456 | 2’-Amino-2’-deoxy-5-methylcytidine | 869729-45-3 | Oligonucleotides |
| HY-152457 | 3’-Deoxy-3’-fluoro-beta-D-xylo-inosine | 171667-46-2 | Oligonucleotides |
| HY-152459 | 2-(n-Propylidene hydrazino) adenosine | 144348-05-0 | Oligonucleotides |
| HY-15246 | Tovorafenib | 1096708-71-2 | Reference compound |
| HY-152460 | 2-Chloro-N6-cyclopentyl-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine | 2216764-33-7 | Oligonucleotides |
| HY-152461 | N6-(3-Trifluoromethylbenzyl)-3’-deoxyadenosine | 2305415-80-7 | Oligonucleotides |
| HY-152462 | 8-Azaguanosine | 2133-80-4 | Oligonucleotides |
| HY-152463 | 4′-C-2-Propen-1-yluridine | 66723-28-2 | Oligonucleotides |
| HY-152464 | N1-Methyl-arabinoadenosine | 685880-77-7 | Oligonucleotides |
| HY-152465 | 5-Carboxymethyl-2-thiouridine | 58479-77-9 | Oligonucleotides |
| HY-152466 | 2’-O-Methyl-N1-methyladenosine | 91101-00-7 | Oligonucleotides |
| HY-152467 | 8-Aza-2’-beta-C-methylguanosine | | Oligonucleotides |
| HY-152468 | Antitumor agent-83 | | Reference compound |
| HY-152469 | Eleven-Nineteen-Leukemia Protein IN-1 | 2894121-68-5 | Reference compound |
| HY-15247 | Vistusertib | 1009298-59-2 | Reference compound |
| HY-152470 | Eleven-Nineteen-Leukemia Protein IN-2 | 2894121-78-7 | Reference compound |
| HY-152471 | Eleven-Nineteen-Leukemia Protein IN-3 | 2894121-83-4 | Reference compound |
| HY-152472 | ENT-C225 | 2919962-53-9 | Reference compound |
| HY-152473 | Topoisomerase IIα-IN-6 | | Reference compound |
| HY-152474 | 2’-β-C-Ethynylcytidine | 188413-99-2 | Oligonucleotides |
| HY-152475 | 2’-β-C-Ethynyladenosine | 640725-76-4 | Oligonucleotides |
| HY-152476 | 3’-β-C-Ethynyluridine | 180300-49-6 | Oligonucleotides |
| HY-152477 | 3’-β-C-Ethynyladenosine | 180300-54-3 | Oligonucleotides |
| HY-152478 | 3’-β-C-Ethynylguanosine | 180300-56-5 | Oligonucleotides |
| HY-152479 | Topoisomerase IIα-IN-7 | | Reference compound |
| HY-15248 | GDC-0349 | 1207360-89-1 | Reference compound |
| HY-152480 | 3’-O-(2-Methoxyethyl)-5-methylcytidine | 2243311-50-2 | Oligonucleotides |
| HY-152481 | N1-Methyl-2’-deoxy-2’-fluoroarabinoadenosine | | Oligonucleotides |
| HY-152482 | 3’-O-(2-Methoxyethyl)-2-thiouridine | 647839-20-1 | Oligonucleotides |
| HY-152483 | N4,N4-Dimethylarabinocytidine | 82855-64-9 | Oligonucleotides |
| HY-152484 | N7-Methyl-2’-deoxy-2’-fluoroarabinoguanosine | | Oligonucleotides |
| HY-152485 | 2-Amino-N6,N6-dimethyl-2’-deoxy-2’-fluoro-beta-D-arabino-adenosine | 2171103-80-1 | Oligonucleotides |
| HY-152486 | N1-Methyl-2’-deoxy-2’-fluoroarabinoguanosine | | Oligonucleotides |
| HY-152487 | 2-Amino-3’-deoxy-3’-fluoroadenosine | 125391-75-5 | Oligonucleotides |
| HY-152488 | 3’-β-C-Ethynyl-5-methyl uridine | 180300-52-1 | Oligonucleotides |
| HY-152489 | 8-Chloro-2’-deoxy-2’-fluoro inosine | | Oligonucleotides |
| HY-15249 | JZL 184 | 1101854-58-3 | Reference compound |
| HY-152490 | 3’-β-C-Ethynyl-N6,N6-dimethyladenosine | 565450-82-0 | Oligonucleotides |
| HY-152491 | 7-Cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-ribofuranosyl)guanine | 2763085-07-8 | Oligonucleotides |
| HY-152492 | 2’-Deoxy-2’-fluoro-N1-methyl inosine | 2376610-64-7 | Oligonucleotides |
| HY-152493 | 3’-O-(2-Methoxyethyl)guanosine | 256224-03-0 | Oligonucleotides |
| HY-152494 | 6-Methyl-9-(β-D-xylofuranosyl)purine | 16006-65-8 | Oligonucleotides |
| HY-152495 | MenA-IN-1 | | Reference compound |
| HY-152496 | 5-Hydroxymethyl xylouridine | 52448-09-6 | Oligonucleotides |
| HY-152497 | 3’-β-C-Methyl-2-thiouridine | | Oligonucleotides |
| HY-152498 | 3’-O-(2-Methoxyethyl)adenosine | 303197-30-0 | Oligonucleotides |
| HY-152499 | 1-Methyl-2'-O-methylinosine | 65150-69-8 | Oligonucleotides |
| HY-15250 | JZL195 | 1210004-12-8 | Reference compound |
| HY-152500 | 4-Deoxy-3’-β-C-methyluridine | 1106013-87-9 | Oligonucleotides |
| HY-152501 | 8-Chloro-2’-O-methyl inosine | | Oligonucleotides |
| HY-152502 | 5-N-Boc-aminomethyluridine | 2305415-73-8 | Oligonucleotides |
| HY-152503 | N6-Benzoyl-3’-O-(2-methoxyethyl)adenosine | 256223-99-1 | Oligonucleotides |
| HY-152504 | 2’-Deoxy-2’-fluoro-N1-methyladensoine | | Oligonucleotides |
| HY-152505 | 5-Methyl-4-thiouridine | 49555-43-3 | Oligonucleotides |
| HY-152506 | Antioxidant agent-8 | | Reference compound |
| HY-152507 | N1-Methyl-2’-beta-C-methyl inosine | | Oligonucleotides |
| HY-152508 | 8-Chloro-2’-beta-C-methyl inosine | 1106012-39-8 | Oligonucleotides |
| HY-152509 | N1-Methyl-2’-beta-C-methyl adenosine | | Oligonucleotides |
| HY-15251 | Reparixin | 266359-83-5 | Reference compound |
| HY-152510 | 5-(Aminomethyl)uridine | 190448-73-8 | Oligonucleotides |
| HY-152511 | 8-Methylthio-adenosine | 29836-01-9 | Oligonucleotides |
| HY-152512 | RLA-4842 | | Reference compound |
| HY-152513 | 2’-O-Methyl-4-thiouridine | 34218-80-9 | Oligonucleotides |
| HY-152514 | 5-Azidomethyl-2’-beta-methyl uridine | 2305415-72-7 | Oligonucleotides |
| HY-152516 | 2’-O-(2-Methoxyethyl) inosine | 545374-76-3 | Oligonucleotides |
| HY-152517 | 8-(Methylthio)guanosine | 2104-66-7 | Oligonucleotides |
| HY-152518 | 2’-O-Methyl-5-methyl-4-thiouridine | 2095417-26-6 | Oligonucleotides |
| HY-152519 | 5-(Aminomethyl)-2-thiouridine | 109666-14-0 | Oligonucleotides |
| HY-15251A | (Rac)-Reparixin | 957407-64-6 | Reference compound |
| HY-15252 | Reparixin (L-lysine salt) | 266359-93-7 | Reference compound |
| HY-152520 | RLA-5331 | | Reference compound |
| HY-152521 | 2-Amino-6-meThythio-9-(β-D-ribofuranosyl)-9H-purine | 4914-73-2 | Oligonucleotides |
| HY-152522 | 5-Fluoro-4’-C-methyluridine | 660845-69-2 | Oligonucleotides |
| HY-152523 | 5-(Azidomethyl) arauridine | 34349-03-6 | Oligonucleotides |
| HY-152524 | Androgen receptor antagonist 7 | 2409791-89-3 | Reference compound |
| HY-152525 | 5-(Azidomethyl)-2’-O-(2-methoxyethyl)uridine | 2305415-77-2 | Oligonucleotides |
| HY-152526 | 5-Fluoro-4’-C-methylcytidine | 791585-24-5 | Oligonucleotides |
| HY-152527 | 2’-Deoxy-2’-fluoro-4-thio-beta-D-arabinouridine | 892145-76-5 | Oligonucleotides |
| HY-152528 | 4’-C-Methyl-5-methylcytidine | 764644-12-4 | Oligonucleotides |
| HY-152529 | 4’-C-Methyl-5-methoxyuridine | 2305415-71-6 | Oligonucleotides |
| HY-15253 | Tiplaxtinin | 393105-53-8 | Reference compound |
| HY-152530 | 2’-beta-C-Methyl-4-thiouridine | 1106032-94-3 | Oligonucleotides |
| HY-152531 | 2-Amino-6-allyl thio-9-(beta-D-ribofuranosyl)-9H-purine | 92104-54-6 | Oligonucleotides |
| HY-152532 | 2’-Deoxy-2’-fluoro-6-S-Methyl-6-thio-ara-guanosine | 109304-11-2 | Oligonucleotides |
| HY-152533 | 5-Ethyl-4-thiouridine | 148744-32-5 | Oligonucleotides |
| HY-152534 | MenA-IN-2 | 3026690-49-0 | Reference compound |
| HY-152535 | ATV041 | 2935937-67-8 | Reference compound |
| HY-152536 | iNOS inhibitor-10 | 2918773-63-2 | Reference compound |
| HY-152537 | Antitumor agent-84 | | Reference compound |
| HY-152538 | Antitumor agent-85 | | Reference compound |
| HY-152539 | HIV-1 inhibitor-54 | 2771211-71-1 | Reference compound |
| HY-15254 | 3-O-(2-Aminoethyl)-25-hydroxyvitamin D3 | 163018-26-6 | Reference compound |
| HY-152540 | 5-Methoxy-4-thiouridine | 37805-89-3 | Oligonucleotides |
| HY-152541 | Adenosine 2-amidine hydrochloride | | Oligonucleotides |
| HY-152542 | 8-Allylthioadenosine | 75059-23-3 | Oligonucleotides |
| HY-152543 | 5-[3-[(Trifluoroacetyl)amino]propyl]uridine | 327623-80-3 | Oligonucleotides |
| HY-152544 | 8-Allylthioguanosine | 126092-30-6 | Oligonucleotides |
| HY-152545 | N1,N2-Dimethyl-2’-O-methylguanosine | 2305416-05-9 | Oligonucleotides |
| HY-152546 | 8-Allyloxyguanosine | 126138-81-6 | Oligonucleotides |
| HY-152547 | N2-[(N,N-Dimethyl amino]methylene-N1-methyl-2’-O-methylguanosine | 2305416-07-1 | Oligonucleotides |
| HY-152548 | 4’-C-Methyl-4-deoxyuridine | 1064364-21-1 | Oligonucleotides |
| HY-152549 | 2’-O-(2-Methoxyethyl)-2-aminoadenosine | 256224-13-2 | Oligonucleotides |
| HY-15255 | Zosuquidar | 167354-41-8 | Reference compound |
| HY-152551 | 4’-C-Methyl-2-thiouridine | 2305415-74-9 | Oligonucleotides |
| HY-152552 | α-Synuclein inhibitor 8 | 2883627-64-1 | Reference compound |
| HY-152553 | 4’-C-Methyl-N6-methyladenosine | 1064364-55-1 | Oligonucleotides |
| HY-152554 | 3’-Deoxy-3’-fluoro-xyloadenosine | 20535-16-4 | Oligonucleotides |
| HY-152555 | 2’-Amino-2’-deoxy-β-D-arabino-5-methyl uridine | 135304-48-2 | Oligonucleotides |
| HY-152556 | 3-Deaza-4’-C-methyluridine | 2305415-96-5 | Oligonucleotides |
| HY-152557 | 5-Methoxymethyluridine | 82448-44-0 | Oligonucleotides |
| HY-152558 | 5’(R)-C-Methyl-N6-methyladenosine | | Oligonucleotides |
| HY-152559 | 5-Ethoxymethyluridine | 95468-92-1 | Oligonucleotides |
| HY-15256 | Faldaprevir | 801283-95-4 | Reference compound |
| HY-152560 | HIV-1 inhibitor-55 | 2771211-73-3 | Reference compound |
| HY-152561 | 5’(R)-C-Methyl-2-thiouridine | 2305416-01-5 | Oligonucleotides |
| HY-152562 | N-Propargyladenosine | 67005-97-4 | Oligonucleotides |
| HY-152563 | N1-Methyl-2’-beta-C-methyl guanosine | | Oligonucleotides |
| HY-152564 | 2-Amino-N-(3-methyl-2-buten-1-yl)adenosine | 16051-64-2 | Oligonucleotides |
| HY-152565 | N6-Aminoadenosine | 5746-27-0 | Oligonucleotides |
| HY-152566 | N7-Methyl-2’-beta-C-methyl guanosine | | Oligonucleotides |
| HY-152567 | N1-Methyl-2’-O-(2-methoxyethyl) guanosine | | Oligonucleotides |
| HY-152568 | N7-Methyl-2’-O-(2-methoxyethyl) guanosine | | Oligonucleotides |
| HY-152569 | N1-Methyl-2’-O-(2-methoxyethyl) adenosine | | Oligonucleotides |
| HY-15256A | Faldaprevir (sodium) | 1215856-44-2 | Reference compound |
| HY-15256S | Faldaprevir-d6 | 2750534-88-2 | Isotope-Labeled Compounds |
| HY-15256S1 | Faldaprevir-d7 | 1613250-18-2 | Isotope-Labeled Compounds |
| HY-15257 | Mavoglurant | 543906-09-8 | Reference compound |
| HY-152570 | N6-Methyl-2’-O-(2-methoxyethyl) adenosine | | Oligonucleotides |
| HY-152571 | N1-Methyl-2’-O-(2-methoxyethyl) inosine | | Oligonucleotides |
| HY-152572 | 6-(4-Morpholinyl)-9-β-D-ribofuranosyl-9H-purine | 52940-48-4 | Oligonucleotides |
| HY-152573 | N1-Methyl-3’-O-(2-methoxyethyl) adenosine | | Oligonucleotides |
| HY-152574 | 5-Amino-2’-deoxy-2’-O-methyluridine hydrochloride | | Oligonucleotides |
| HY-152575 | N6-Methyl-3’-O-(2-methoxyethyl) adenosine | | Oligonucleotides |
| HY-152576 | CB2R agonist 1 | 1817633-49-0 | Reference compound |
| HY-152577 | 3’-O-(2-Methoxyethyl) inosine | | Oligonucleotides |
| HY-152578 | 7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 40627-31-4 | Oligonucleotides |
| HY-152579 | 6-(1-Piperazinyl)-9-β-D-ribofuranosyl-9H-purine | 121370-61-4 | Oligonucleotides |
| HY-15257A | Mavoglurant (racemate) | 1636881-61-2 | Reference compound |
| HY-15258 | Lesinurad | 878672-00-5 | Reference compound |
| HY-152580 | 5-[3-[(2,2,2-Trifluoroacetyl)amino]-1-propyn-1-yl]uridine | 120609-05-4 | Oligonucleotides |
| HY-152581 | CB2R antagonist 3 | | Reference compound |
| HY-152582 | 7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 40725-89-1 | Oligonucleotides |
| HY-152583 | 3’-Azido-3’-deoxy-5-methyl-beta-L-uridine | 2095417-10-8 | Oligonucleotides |
| HY-152584 | 3’-Deoxy-3’-fluoro-xyloguanosine | 125291-15-8 | Oligonucleotides |
| HY-152585 | 3’-Azido-3’-deoxy-5-fluoro-beta-L-uridine | 2095417-40-4 | Oligonucleotides |
| HY-152586 | 2′,3′-Anhydroadenosine | 2627-64-7 | Oligonucleotides |
| HY-152587 | N1-Methyl-3’-O-(2-methoxyethyl) inosine | | Oligonucleotides |
| HY-152588 | 3’-Deoxy-N1-methyladenosine | 77667-51-7 | Oligonucleotides |
| HY-152589 | Antiviral agent 25 | 2761367-25-1 | Reference compound |
| HY-15258A | Lesinurad (sodium) | 1151516-14-1 | Reference compound |
| HY-15258S1 | Lesinurad-d4 | 1850305-60-0 | Isotope-Labeled Compounds |
| HY-15259 | CP-640186 | 591778-68-6 | Reference compound |
| HY-152590 | 3’-Deoxy-N6-methyladenosine | 3616-27-1 | Oligonucleotides |
| HY-152591 | 4’-Methyl-5-methyluridine | 152540-75-5 | Oligonucleotides |
| HY-152592 | 3’-Azido-3’-deoxy-beta-L-cytidine | 2095417-59-5 | Oligonucleotides |
| HY-152593 | 3’-Deoxy-N1-methylguanosine | | Oligonucleotides |
| HY-152594 | Uridine-5-oxyacetic acid | 28144-25-4 | Oligonucleotides |
| HY-152595 | 3’-Azido-3’-deoxy-5-methyl-beta-L-cytidine | 2095417-52-8 | Oligonucleotides |
| HY-152597 | 3’-Azido-3’-deoxy-5-fluoro-beta-L-cytidine | 2095417-76-6 | Oligonucleotides |
| HY-152598 | N1-Methylxylo-guanosine | | Oligonucleotides |
| HY-152599 | 4’-Methyladenosine | 152540-76-6 | Oligonucleotides |
| HY-15259A | CP-640186 (hydrochloride) | 591778-70-0 | Reference compound |
| HY-15260 | XL413 | 1169558-38-6 | Reference compound |
| HY-152601 | 3’-Azido-3’-deoxy-beta-L-adenosine | 216976-76-0 | Oligonucleotides |
| HY-152602 | 1,3'-Dimethylguanosine | 74466-66-3 | Oligonucleotides |
| HY-152603 | 2-Amino-1-β-D-arabinofuranosyl-5-methyl-4(1H)-pyrimidinone | 10212-31-4 | Oligonucleotides |
| HY-152604 | 3,4-Dihydro-3-oxo-4-β-D-ribofuranosyl-2-pyrazinecarboxamide | 356782-84-8 | Oligonucleotides |
| HY-152605 | 2’-Deoxy-2’-fluoro-6-S-methyl-6-thio-arabino-inosine | 109304-12-3 | Oligonucleotides |
| HY-152606 | N6-Ethyl-2’-C-methyladenosine | 714250-18-7 | Oligonucleotides |
| HY-152607 | N,N-Dimethyl-2′-O-methyladenosine | 30891-53-3 | Oligonucleotides |
| HY-152608 | N6-iso-Propyladenosine | 17270-23-4 | Oligonucleotides |
| HY-152609 | N1-Cyanomethyl pseudouridine | | Oligonucleotides |
| HY-15260A | XL413 (monohydrochloride) | 2062200-97-7 | Reference compound |
| HY-15260C | XL413 (hydrochloride) | 1169562-71-3 | Reference compound |
| HY-152610 | 3′-C-Methylguanosine | 115303-89-4 | Oligonucleotides |
| HY-152611 | N1-Methyl-5-methyl ara-uridine | 887113-66-8 | Oligonucleotides |
| HY-152612 | 2’-Deoxy-2’-fluoro-5-hydroxymethyl arabinouridine | 94817-51-3 | Oligonucleotides |
| HY-152613 | N2-Ethylguanosine | 77312-39-1 | Oligonucleotides |
| HY-152614 | Antimalarial agent 19 | 2897630-89-4 | Reference compound |
| HY-152615 | 4’-Methylguanosine | 153186-32-4 | Oligonucleotides |
| HY-152616 | 2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one | 444020-71-7 | Oligonucleotides |
| HY-152617 | 4’-Thioinosine | 58004-19-6 | Oligonucleotides |
| HY-152618 | 3’-N-Acetyl-3’-amino-3’-deoxyuridine | 2305415-89-6 | Oligonucleotides |
| HY-152619 | N6,N6-Dimethyl-4’-thio-adenosine | 25795-69-1 | Oligonucleotides |
| HY-15262 | SRT 2104 | 1093403-33-8 | Reference compound |
| HY-152620 | 2-(N,N-Dimethylamino)-N6,N6-dimethyladenosine | 2305415-86-3 | Oligonucleotides |
| HY-152621 | N6-Ethyl-4’-thio-adenosine | | Oligonucleotides |
| HY-152622 | 3’-Deoxy-5-methyluridine | 7084-29-9 | Oligonucleotides |
| HY-152623 | 3’-O-Propargyladenosine | 2305416-10-6 | Oligonucleotides |
| HY-152624 | N6-Methyl-4’-thio-adenosine | 900810-24-4 | Oligonucleotides |
| HY-152625 | 2’-Beta-C-Ethynyl inosine | 2183487-92-3 | Oligonucleotides |
| HY-152626 | N6-Ethyl-2’-beta-C-ethynyl adenosine | | Oligonucleotides |
| HY-152627 | N6-Methyl-2’-beta-C-ethynyl adenosine | | Oligonucleotides |
| HY-152628 | 3’-Deoxy-3-deazauridine | 2095417-74-4 | Oligonucleotides |
| HY-152629 | 2’-β-C-Methyl-5-methyluridine | 119410-84-3 | Oligonucleotides |
| HY-15263 | Retaspimycin | 857402-23-4 | Reference compound |
| HY-152630 | 3’-Deoxy-5-fluorouridine | 18829-83-9 | Oligonucleotides |
| HY-152631 | 3’-Deoxy-5-methoxyuridine | 2095417-49-3 | Oligonucleotides |
| HY-152632 | BuChE-IN-7 | | Reference compound |
| HY-152633 | 3’-Deoxy-N6,N6-dimethyladenosine | 3608-59-1 | Oligonucleotides |
| HY-152634 | 8-Chloro-2’-deoxy-2’-fluoro-arabino adenosine | | Oligonucleotides |
| HY-152635 | 8-Chloro-2’-O-methyl adenosine | 634207-55-9 | Oligonucleotides |
| HY-152636 | 2-Cyanomethylthioadenosine | 2095417-67-5 | Oligonucleotides |
| HY-152637 | 2-Benzylthioadenosine | 43157-48-8 | Oligonucleotides |
| HY-152638 | 2-Amino-3’-O-methyladenosine | 80791-88-4 | Oligonucleotides |
| HY-152639 | 2’-Chlorothymidine | 54898-34-9 | Oligonucleotides |
| HY-15264 | MC 1046 | 126860-83-1 | Reference compound |
| HY-152640 | 5-Fluoro-4’-thio-cytidine | | Oligonucleotides |
| HY-152642 | 2’-Azido-2’-deoxy-5-methyl cytidine | 2095417-75-5 | Oligonucleotides |
| HY-152643 | 6-Methylpseudouridine | 1613530-10-1 | Oligonucleotides |
| HY-152644 | 2’-β-C-Methyl-5-methoxyuridine | 2072145-45-8 | Oligonucleotides |
| HY-152645 | 3’-Azido-3’-deoxy-5-methyluridine | 215176-58-2 | Oligonucleotides |
| HY-152646 | 3’-O-(2-Methoxyethyl)-2-aminoadenosine | 256224-02-9 | Oligonucleotides |
| HY-152647 | 6-Methoxypurine-9-beta-D-(3-methoxy riboside) | | Oligonucleotides |
| HY-152648 | N6-Ethyl-2’-O-methyladenosine | 157309-11-0 | Oligonucleotides |
| HY-152649 | N1-Cyclopropylmethylpseudouridine | 1613530-18-9 | Oligonucleotides |
| HY-15265 | Impurity F of Calcipotriol | 112875-61-3 | Reference compound |
| HY-152650 | N6-Methyl-2-methyl thioadenosine | 6741-71-5 | Oligonucleotides |
| HY-152651 | 5’(R)-C-Methyl-3-deazauridine | 2305415-82-9 | Oligonucleotides |
| HY-152652 | 5’(R)-C-Methylguanosine | 85421-89-2 | Oligonucleotides |
| HY-152653 | N6-iso-Propyl-2’-O-methyladenosine | 2803878-84-2 | Oligonucleotides |
| HY-152654 | 4′-Thiocytidine | 93080-09-2 | Oligonucleotides |
| HY-152655 | 6-Ethoxy-9-beta-D-(2-C-methyl-ribofuranosyl)purine | 848750-87-8 | Oligonucleotides |
| HY-152656 | 2-Hydrazinyl-adenosine | 15763-11-8 | Oligonucleotides |
| HY-152657 | N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine | 1613530-24-7 | Oligonucleotides |
| HY-152658 | 5-Phenylcytidine | 83866-19-7 | Oligonucleotides |
| HY-152659 | N1-Propargylpseudouridine | 1464021-70-2 | Oligonucleotides |
| HY-15266 | 24R-Calcipotriol | 112827-99-3 | Reference compound |
| HY-152660 | 2-Amino-6-O-methyl-2’-O-methyl purine riboside | | Oligonucleotides |
| HY-152661 | 2-Hydroxy-2’-deoxy-2’-fluoro-beta-D-arabino adenosine | 899827-82-8 | Oligonucleotides |
| HY-152662 | 2’,3’-Dideoxy-5-fluorocytidine | 107036-62-4 | Oligonucleotides |
| HY-152663 | 6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine | | Oligonucleotides |
| HY-152664 | 1-(2,3-Dideoxy-β-D-erythro-hexo pyranosyl)cytosine | 136020-18-3 | Oligonucleotides |
| HY-152665 | 1-(β-D-Xylofuranosyl)uracil | 16535-78-7 | Oligonucleotides |
| HY-152666 | 5-Methyl-4’-thiocytidine | 1312295-87-6 | Oligonucleotides |
| HY-152667 | 1-(β-D-Xylofuranosyl)-5-methyluracil | 52486-19-8 | Oligonucleotides |
| HY-152668 | Urease-IN-4 | | Reference compound |
| HY-152669 | Urease-IN-5 | | Reference compound |
| HY-15267 | MC 976 | 129831-99-8 | Reference compound |
| HY-152670 | JC2-11 | 937820-89-8 | Reference compound |
| HY-152671 | hMAO-B-IN-4 | 1666119-75-0 | Reference compound |
| HY-152672 | 9-(β-D-Xylofuranosyl)adenine | 524-69-6 | Oligonucleotides |
| HY-152673 | 9-(β-D-Xylofuranosyl)guanine | 27462-39-1 | Oligonucleotides |
| HY-152674 | 2′-Deoxy-2′-fluoro-5-methoxy-arabinouridine | 2305415-76-1 | Oligonucleotides |
| HY-152675 | 2’-Amino-2’-deoxy-β-D-arabinouridine | 68115-81-1 | Oligonucleotides |
| HY-152676 | 1-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyl-2,4(1H,3H)-pyrimidinedione | 83546-42-3 | Oligonucleotides |
| HY-152677 | N3-(2-Methoxy)ethyluridine | | Oligonucleotides |
| HY-152678 | 6-Methoxypurine-9-β-D-5’(R)-C-methylriboside | | Oligonucleotides |
| HY-152679 | 2-Amino-2′-O-(2-methoxy-2-oxoethyl)adenosine | 433288-71-2 | Oligonucleotides |
| HY-15267A | (24R)-MC 976 | 112828-09-8 | Reference compound |
| HY-15267B | (24S)-MC 976 | 112849-14-6 | Reference compound |
| HY-15268 | PP487 | 1092787-12-6 | Reference compound |
| HY-152680 | 4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine | 1704-25-2 | Oligonucleotides |
| HY-152681 | N3-[(Tetrahydro-2-furanyl)methyl]uridine | 122666-26-6 | Oligonucleotides |
| HY-152682 | 5-Ethyluridine | 25110-76-3 | Oligonucleotides |
| HY-152683 | 3-(2-Pyridinylmethyl)uridine | 1427676-15-0 | Oligonucleotides |
| HY-152684 | 2′-O-2-Propyn-1-ylguanosine | 206552-86-5 | Oligonucleotides |
| HY-152685 | 4-Amino-1-(β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine-5-carboxamide | | Oligonucleotides |
| HY-152686 | 2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-methoxy-9H-purine | 758705-70-3 | Oligonucleotides |
| HY-152687 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine | 1612191-99-7 | Oligonucleotides |
| HY-152688 | 3’-Azido-3’-deoxy-5-fluorouridine | 307520-05-4 | Oligonucleotides |
| HY-152689 | 2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)-beta-D-arabinouridine | 2072145-77-6 | Oligonucleotides |
| HY-15269 | PP30 | 1092788-09-4 | Reference compound |
| HY-152690 | 2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine | 2072145-51-6 | Oligonucleotides |
| HY-152691 | 2’-Deoxy-2’-fluoro-N3-(n-dodecyl)-beta-D-arabinouridine | 2072145-43-6 | Oligonucleotides |
| HY-152693 | N4-Methyl-2’-O-methyl-cytidine | 13048-95-8 | Oligonucleotides |
| HY-152694 | 5-Vinylcytidine | 1846584-62-0 | Oligonucleotides |
| HY-152695 | 6-Methoxy purine-9-beta-D-(3’-deoxy-3’-fluoro)riboside | 2072145-35-6 | Oligonucleotides |
| HY-152696 | 6-O-Methylinosine | 5746-29-2 | Oligonucleotides |
| HY-152697 | 2-Methyladenosine | 16526-56-0 | Oligonucleotides |
| HY-152698 | 5-Methyl-4’-thiouridine | 13406-51-4 | Oligonucleotides |
| HY-152699 | N6-Methyladenosine N1-oxide | 113509-54-9 | Oligonucleotides |
| HY-15270 | BMS-911543 | 1271022-90-2 | Reference compound |
| HY-152700 | 5-Methoxy-2-thiouridine | 30771-43-8 | Oligonucleotides |
| HY-152701 | 5-Aminocarbonylmethyl-2-thiouridine | 29900-40-1 | Oligonucleotides |
| HY-152702 | 2,8-Dimethyladenosine | 63954-66-5 | Oligonucleotides |
| HY-152703 | 2-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(beta-D-xylo furanosyl)purine | 2389988-30-9 | Oligonucleotides |
| HY-152704 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine | 1612191-98-6 | Oligonucleotides |
| HY-152705 | 5-Bromo-2’-deoxy-2’-fluoro-beta-D-arabinocytidine | 69123-93-9 | Oligonucleotides |
| HY-152706 | 2’-O-Methyl-N2,N2-dimethyl-guanosine | 113886-73-0 | Oligonucleotides |
| HY-152707 | 2-Amino-2′-C-methyladenosine | 640725-73-1 | Oligonucleotides |
| HY-152708 | 3’-Azido-3’-deoxy-5-trifluoromethyluridine | 2095417-62-0 | Oligonucleotides |
| HY-152709 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(5-phenylpyridin-3-yl)purine | 1612191-96-4 | Oligonucleotides |
| HY-15271 | WYE-687 | 1062161-90-3 | Reference compound |
| HY-152710 | 5-Methoxycarbonylmethyl-2-thiouridine | 20299-15-4 | Oligonucleotides |
| HY-152711 | 2-Chloro-2’-β-C-methyl-6-N,N-dimethyladenosine | 2095417-43-7 | Oligonucleotides |
| HY-152712 | 5-Bromo-3’-deoxy-3’-fluorouridine | 439579-22-3 | Oligonucleotides |
| HY-152713 | 3’-Azido-3’-deoxy-5-methoxyuridine | 2095417-70-0 | Oligonucleotides |
| HY-152714 | 5-Formyl-2’-O-methylcytidine | 176858-79-0 | Oligonucleotides |
| HY-152715 | 2’-C-β-Methyl-4-deoxyuridine | 1106032-88-5 | Oligonucleotides |
| HY-152717 | 2’-O-Methyl-2-thiouridine | 113886-72-9 | Oligonucleotides |
| HY-152718 | 4-Amino-1-(2-C-methyl-β-D-ribofuranosyl)-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile | 847651-51-8 | Oligonucleotides |
| HY-152719 | 8-Benzyloxyadenosine | 131265-29-7 | Oligonucleotides |
| HY-15271A | WYE-687 (dihydrochloride) | 1702364-87-1 | Reference compound |
| HY-15272 | WAY-600 | 1062159-35-6 | Reference compound |
| HY-152720 | 3’-Azido-3’-deoxyuridine | 70580-88-0 | Oligonucleotides |
| HY-152721 | 3’-O-Methyl-4-deoxy uridine | 2095417-12-0 | Oligonucleotides |
| HY-152723 | 2-Amino-N,N-dimethyl-2′-C-methyladenosine | 1336975-57-5 | Oligonucleotides |
| HY-152724 | 3’-Azido-3’-deoxy-5-iodouridine | 2072145-33-4 | Oligonucleotides |
| HY-152725 | N1-Benzyl pseudouridine | 1613530-22-5 | Oligonucleotides |
| HY-152726 | TLR7 agonist 9 | 2389988-38-7 | Reference compound |
| HY-152727 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(naphthalen-1-yl)purine | 1612191-92-0 | Oligonucleotides |
| HY-152728 | 3’-Azido-3’-deoxycytidine | 70580-87-9 | Oligonucleotides |
| HY-152729 | 5-(2-Amino-2-oxoethyl)uridine | 29569-30-0 | Oligonucleotides |
| HY-15273 | UNC0638 | 1255580-76-7 | Reference compound |
| HY-152730 | 3’-Deoxy-3’-fluoroinosine | 117517-20-1 | Oligonucleotides |
| HY-152731 | 3′-Deoxy-3′-methylcytidine | 444020-09-1 | Oligonucleotides |
| HY-152732 | 6-Methyluridine | 16710-13-7 | Oligonucleotides |
| HY-152733 | 8-Aza-7-bromo-7-deazaguanosine | 96555-37-2 | Oligonucleotides |
| HY-152734 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(pyridine-4-yl)purine | 1612191-93-1 | Oligonucleotides |
| HY-152735 | 5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine | 89128-99-4 | Oligonucleotides |
| HY-152736 | 3’-Deoxy-3’-fluoro-5-methyl-xylo-uridine | 917110-29-3 | Oligonucleotides |
| HY-152737 | 3’-Deoxy-3’-azido-isocytidine | 2095417-77-7 | Oligonucleotides |
| HY-152738 | 2’-β-C-Methyl-3-deazauri dine | 622379-93-5 | Oligonucleotides |
| HY-152739 | 5-(N-Isopentenyl-N-trifluoroacetyl) aminomethyluridine | 1613530-43-0 | Oligonucleotides |
| HY-15274 | L-798106 | 244101-02-8 | Reference compound |
| HY-152740 | 5-Pyrrolidinomethyluridine | 1613530-41-8 | Oligonucleotides |
| HY-152741 | 2’-β-C-Methyl-2-thiouridine | 1678507-60-2 | Oligonucleotides |
| HY-152742 | 8-(N,N-Dimethylaminomethyl)guanosine | | Oligonucleotides |
| HY-152743 | 8-Aza-7-deazguanosine | 85426-74-0 | Oligonucleotides |
| HY-152744 | 2’-O-Propargyladenosine | 151390-97-5 | Oligonucleotides |
| HY-152745 | 2’-β-C-Methyl-5-trifluoromethyluridine | 2072145-39-0 | Oligonucleotides |
| HY-152746 | 2-Amino-6-chloropurine-9-(2’-O-propargyl)riboside | 2095417-35-7 | Oligonucleotides |
| HY-152747 | 5-β-D-Ribofuranosyl-2(1H)-pyridinone | 188871-50-3 | Oligonucleotides |
| HY-152748 | Caspase-3/7 activator 1 | | Reference compound |
| HY-152749 | 2’-β-C-Methyl-5-fluorouridine | 23643-38-1 | Oligonucleotides |
| HY-15275 | BMS-265246 | 582315-72-8 | Reference compound |
| HY-152750 | 2-Amino-N6,N6-dimethyl-2’-O-methyladenosine | 2095417-19-7 | Oligonucleotides |
| HY-152752 | 2’,3’-Dideoxy-3’-fluorocytidine | 51246-79-8 | Oligonucleotides |
| HY-152753 | 3’-Deoxy-3’-fluoro-5-methyluridine | 125217-37-0 | Oligonucleotides |
| HY-152754 | 3’-Deoxy-3’-fluoro-2-thiouridine | 439579-24-5 | Oligonucleotides |
| HY-152755 | 4’-Cyanouridine | 232589-05-8 | Oligonucleotides |
| HY-152756 | Caspase-3/7 activator 2 | | Reference compound |
| HY-152757 | 3’-Deoxy-3’-fluoro-5-trifluoromethyluridine | 439579-21-2 | Oligonucleotides |
| HY-152758 | Caspase-3/7 activator 3 | | Reference compound |
| HY-152759 | 3’-Deoxy-3’-fluoro-xylocytidine | 26563-01-9 | Oligonucleotides |
| HY-15276 | 4-Aminonaphthalimide | 1742-95-6 | Reference compound |
| HY-152760 | 3’-Deoxy-3’-fluoro-5-fluorouridine | 112668-56-1 | Oligonucleotides |
| HY-152761 | 3’-Deoxy-3’-fluoro-5-methoxyluridine | 2072145-76-5 | Oligonucleotides |
| HY-152762 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-phenylpurine | 1612191-91-9 | Oligonucleotides |
| HY-152763 | 2’-Deoxy-2’-fluoro-5-methylcytidine | 182495-80-3 | Oligonucleotides |
| HY-152764 | 4’-α-C-Methyluridine | 153186-26-6 | Oligonucleotides |
| HY-152765 | 3′-Deoxy-3′-fluorouridine | 57944-13-5 | Oligonucleotides |
| HY-152766 | 6-(Thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside | 1612191-90-8 | Oligonucleotides |
| HY-152767 | N1-Ethylpseudouridine | 1613529-72-8 | Oligonucleotides |
| HY-152768 | N1-(1,1,1-Trifluoroethyl)pseudouridine | 1613529-80-8 | Oligonucleotides |
| HY-152769 | 2-Methoxy-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine | 1093278-52-4 | Oligonucleotides |
| HY-15277 | AM966 | 1228690-19-4 | Reference compound |
| HY-152770 | 6-(2-O-Methyl-beta-D-ribofuranosyl)-3-(2-oxo-propyl)-6H-imidazo[1,2-c]pyrimidin-5-one | 2095417-54-0 | Oligonucleotides |
| HY-152771 | 3′-Deoxy-3′-fluorocytidine | 123402-20-0 | Oligonucleotides |
| HY-152772 | 2-Amino-6-chloropurine-9-beta-D-(2’-deoxy-2’-fluoro)-arabinoriboside | 144924-88-9 | Oligonucleotides |
| HY-152773 | 2,6-Diamino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine | 103884-97-5 | Oligonucleotides |
| HY-152774 | Antitumor agent-86 | 2907704-65-6 | Reference compound |
| HY-152775 | RK-701 | 2648855-18-7 | Reference compound |
| HY-152775A | RK-0133114 | | Reference compound |
| HY-152776 | 2-Amino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine | 109304-04-3 | Oligonucleotides |
| HY-152777 | 5’(R)-C-Methyluridine | 72159-54-7 | Oligonucleotides |
| HY-152778 | 2-Chloro-3’-deoxy-3’-fluoroadenosine | 122654-30-2 | Oligonucleotides |
| HY-152779 | 5-Methoxy-5’(R)-C-methyluridine | | Oligonucleotides |
| HY-15278 | Epothilone D | 189453-10-9 | Reference compound |
| HY-152780 | 9-(2’-Deoxy-2’-fluoro-β-D-arabinofuranosyl)-9H-purine | 109304-16-7 | Oligonucleotides |
| HY-152781 | 5’(R)-C-Methyl-5-methyluridine | 129745-35-3 | Oligonucleotides |
| HY-152782 | 4’-Azido-2’-deoxy-2’-fluoro-beta-D-arabinouridine | 173379-73-2 | Oligonucleotides |
| HY-152783 | 5’(R)-C-Methyl-5-fluorouridine | | Oligonucleotides |
| HY-152784 | 5’(R)-C-Methylcytidine | 72159-53-6 | Oligonucleotides |
| HY-152785 | 9-(3-Deoxy-3-fluoro-beta-D-ribofuranosyl)-9H-Purine | 124775-29-7 | Oligonucleotides |
| HY-152787 | 5-(3-Azidopropyl)cytidine | | Oligonucleotides |
| HY-152788 | 2-Chloro-6-(furan-2-yl) purine-beta-D-(3’-deoxy-3’-fluoro)-riboside | 1612192-00-3 | Oligonucleotides |
| HY-152789 | 5-(2-Azidoethyl)cytidine | | Oligonucleotides |
| HY-15278A | (16R)-Epothilone D | | Reference compound |
| HY-15278R | Epothilone D (Standard) | 189453-10-9 | Reference Standards |
| HY-152790 | 5-(2-Hydroxyethyl)uridine | 102691-28-1 | Oligonucleotides |
| HY-152791 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-methyl-9H-purine | 1612191-88-4 | Oligonucleotides |
| HY-152792 | 2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]uridine | | Oligonucleotides |
| HY-152793 | 7-Cyano-7-deazaguanosine | 61210-21-7 | Oligonucleotides |
| HY-152794 | 7-Methyl wyosine | 577773-09-2 | Oligonucleotides |
| HY-152795 | N4-Desmethyl wyosine | 59327-60-5 | Oligonucleotides |
| HY-152796 | 5-Furan-2-yl-2’-O-methyl uridine | 2095417-32-4 | Oligonucleotides |
| HY-152797 | N4-Desmethyl-N5-Methyl wyosine | 59327-63-8 | Oligonucleotides |
| HY-152798 | 5-Iodo-2’-β-C-methyl uridine | 1203461-96-4 | Oligonucleotides |
| HY-152799 | 5-Naphthyl-beta-methylaminocarbony-2’-O-methyluridine | 1675178-56-9 | Oligonucleotides |
| HY-15280 | GSK2292767 | 1254036-66-2 | Reference compound |
| HY-152800 | 7-Deazaguanosine | 62160-23-0 | Oligonucleotides |
| HY-152801 | 5-Naphthyl-β-methylaminocarbony-3’-O-acetyl-2’-O-methyluridine | 2095417-03-9 | Oligonucleotides |
| HY-152802 | 2’-O-(3-Azidopropyl)-5-azacytidine | | Oligonucleotides |
| HY-152803 | 5-Iodo-3’-deoxy-3’-fluorouridine | 2072145-21-0 | Oligonucleotides |
| HY-152804 | 5-Iodo-2’-β-C-methyl cytidine | 2072145-60-7 | Oligonucleotides |
| HY-152805 | 9-(2-β-C-Methyl-β-D-ribofuranosyl)purine | 690269-86-4 | Oligonucleotides |
| HY-152806 | 2-Amino-6-chloro-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine | 640725-74-2 | Oligonucleotides |
| HY-152807 | 4’-Thioadenosine | 2500-80-3 | Oligonucleotides |
| HY-152808 | 6-(2-Furanyl)-9-β-D-ribofuranosyl-9H-purine | 352025-81-1 | Oligonucleotides |
| HY-152809 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(furan-2-yl)purine | 1612191-89-5 | Oligonucleotides |
| HY-15281 | QL-IX-55 | 1223002-54-7 | Reference compound |
| HY-152810 | 2-Amino-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine | 690269-87-5 | Oligonucleotides |
| HY-152811 | 2′-Deoxy-2′-fluoro-5-methyl-arabinocytidine | 78636-53-0 | Oligonucleotides |
| HY-152812 | 2-Chloro-2′-β-C-methyladenosine | 205171-11-5 | Oligonucleotides |
| HY-152813 | 2′-Deoxy-2′-fluoro-4-deoxy-arabinouridine | 136675-88-2 | Oligonucleotides |
| HY-152814 | 2′-β-C-Methyl isoguanosine | 714249-83-9 | Oligonucleotides |
| HY-152815 | 2′-Deoxy-2′-fluoro-3-deaza-arabinouridine | 2095417-48-2 | Oligonucleotides |
| HY-152816 | 2′-β-C-Methyl-2-methoxyadenosine | 1829554-43-9 | Oligonucleotides |
| HY-152817 | 2′-β-C-Methyl-beta-D-6-methylpurine riboside | 2095417-06-2 | Oligonucleotides |
| HY-152818 | 4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine | 443642-33-9 | Oligonucleotides |
| HY-152819 | 4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine | 847551-49-9 | Oligonucleotides |
| HY-15282 | E-64 | 66701-25-5 | Reference compound |
| HY-152820 | 2'-Deoxy-2'-fluoro-5-trifluoromethyl-arabinouridine | 114652-80-1 | Oligonucleotides |
| HY-152821 | 5-Methoxy-4’-thiouridine | | Oligonucleotides |
| HY-152822 | 5-Iodo-2’-O-methylcytidine | 847650-69-5 | Oligonucleotides |
| HY-152823 | 5-Benzylaminocarbonyl-2’-O-methyluridine | 1648558-95-5 | Oligonucleotides |
| HY-152824 | (R)-N-(2,3-Dihydro-1H-indenyl)-2-amino adenosine | | Oligonucleotides |
| HY-152827 | 4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine | 1611486-54-4 | Oligonucleotides |
| HY-152828 | 1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine | 70421-30-6 | Oligonucleotides |
| HY-15283 | Clopidogrel | 113665-84-2 | Reference compound |
| HY-152830 | Adrixetinib | 2394874-66-7 | Reference compound |
| HY-152830A | Adrixetinib (TFA) | | Reference compound |
| HY-152831 | 2-Amino-8-aza-7-deaza-7-iodoguanosine | 1997362-13-6 | Oligonucleotides |
| HY-152834 | 8-Methoxyadenosine | 3969-27-5 | Oligonucleotides |
| HY-152835 | 8-(Methylamino)adenosine | 13389-13-4 | Oligonucleotides |
| HY-152836 | 2’-O-Methyl-5-hydroxymethyluridine | 910050-95-2 | Oligonucleotides |
| HY-152837 | 1,3-Dimethyl pseudouridine | 64272-68-0 | Oligonucleotides |
| HY-152838 | Gemlapodect | 1380329-87-2 | Reference compound |
| HY-152839 | Elenestinib | 2505078-08-8 | Reference compound |
| HY-152839A | Elenestinib (phosphate) | 2832013-93-9 | Reference compound |
| HY-15283AS | (±)-Clopidogrel-d7 (sulfate) | 1346598-07-9 | Isotope-Labeled Compounds |
| HY-15283R | Clopidogrel (Standard) | 113665-84-2 | Reference Standards |
| HY-15284 | Prasugrel | 150322-43-3 | Reference compound |
| HY-152840 | Emzeltrectinib | 2223678-97-3 | Reference compound |
| HY-152843 | Fazamorexant | 1808918-69-5 | Reference compound |
| HY-152844 | Faznolutamide | 1272719-08-0 | Reference compound |
| HY-152845 | Ficonalkib | 2233574-95-1 | Reference compound |
| HY-152846 | Flizasertib | 2268739-68-8 | Reference compound |
| HY-152847 | Foslevcromakalim | 1802655-72-6 | Reference compound |
| HY-152848 | Fulzerasib | 2641747-54-6 | Reference compound |
| HY-152849 | Boditrectinib | 1940165-80-9 | Reference compound |
| HY-152849A | Boditrectinib (oxalate) | 2773577-41-4 | Reference compound |
| HY-15284A | Prasugrel (hydrochloride) | 389574-19-0 | Reference compound |
| HY-15284AR | Prasugrel (hydrochloride) (Standard) | 389574-19-0 | Reference Standards |
| HY-15284B | Prasugrel (Maleic acid) | 389574-20-3 | Reference compound |
| HY-15284R | Prasugrel (Standard) | 150322-43-3 | Reference Standards |
| HY-15284S | Prasugrel-d5 | 1127252-92-9 | Isotope-Labeled Compounds |
| HY-15284S1 | Prasugrel-d3 | 1127253-02-4 | Isotope-Labeled Compounds |
| HY-15284S2 | Prasugrel-d4 | 1189919-49-0 | Isotope-Labeled Compounds |
| HY-15284S3 | Prasugrel-13C6 | 1261394-83-5 | Isotope-Labeled Compounds |
| HY-15285 | Doxercalciferol-d3 | | Isotope-Labeled Compounds |
| HY-152850 | Gumelutamide | 1831085-48-3 | Reference compound |
| HY-152850A | Gumelutamide (monosuccinate) | 2842844-51-1 | Reference compound |
| HY-152851 | Izumerogant | 2299252-72-3 | Reference compound |
| HY-152852 | Mefatinib (free base) | 1639014-72-4 | Reference compound |
| HY-152852A | Mefatinib | 1989592-50-8 | Reference compound |
| HY-152852S | Mefatinib-d6 (free base) | | Isotope-Labeled Compounds |
| HY-152853 | 3-Methyl-5-β-D-ribofuranosyl-2,4(1H,3H)-pyrimidinedione | 81691-06-7 | Oligonucleotides |
| HY-152854 | 5-(Hydroxymethyl)cytidine | 19235-17-7 | Oligonucleotides |
| HY-152856 | Merigolix | 1454272-94-6 | Reference compound |
| HY-152857 | Muvalaplin | 2565656-70-2 | Reference compound |
| HY-152858 | 5-Methoxycarbonyl methyl uridine | 29428-50-0 | Oligonucleotides |
| HY-152859 | Brigimadlin | 2095116-40-6 | Reference compound |
| HY-15286 | Sodium 4-pentynoate | 101917-30-0 | Reference compound |
| HY-152860 | Darizmetinib | 2369583-33-3 | Reference compound |
| HY-152861 | Dazostinag | 2553413-86-6 | Reference compound |
| HY-152862 | Dibutepinephrine | 2735735-23-4 | Reference compound |
| HY-152863 | N6-Furfuryl-2-aminoadenosine | 26783-39-1 | Oligonucleotides |
| HY-152864 | 6-Methylpurine-2’-deoxy-2’-fluoro-beta-D-arabinoriboside | 2095417-72-2 | Oligonucleotides |
| HY-152865 | 7-(N-Acetylaminomethyl)-7-deazaguanosine | | Oligonucleotides |
| HY-152866 | N,N-Dimethyl-2'-O-methylcytidine | 34218-81-0 | Oligonucleotides |
| HY-152867 | 5-(Trifluoromethyl)uridine | 21618-67-7 | Oligonucleotides |
| HY-152868 | 3’-O-(2-Azidoethyl)adenosine | | Oligonucleotides |
| HY-152869 | 5-(Trifluoromethyl)cytidine | 76514-02-8 | Oligonucleotides |
| HY-15287 | Nelfinavir | 159989-64-7 | Reference compound |
| HY-152870 | 2’-O-(2-Azidoethyl)adenosine | 2226475-42-7 | Oligonucleotides |
| HY-152871 | Uridine 5-oxyacetic acid methyl ester | 66536-81-0 | Oligonucleotides |
| HY-152872 | Uridine-5-oxo-acetyl-(9-fluorenylmethyl) ester | | Oligonucleotides |
| HY-152873 | Uridine-5-(N-Fmoc-methylamino)-acetyl (9-fluorenylmethyl) ester | | Oligonucleotides |
| HY-152874 | 5-N-(t-Butyloxycarbonylmethyl)-N-trifluoro acetyl-aminomethyl-2’-O-methyluridine | | Oligonucleotides |
| HY-152875 | 5-Carboxymethyluridine | 20964-06-1 | Oligonucleotides |
| HY-152876 | 2′-O-Methyl-2-amino-6-chloropurine riboside | 194034-59-8 | Oligonucleotides |
| HY-152877 | Isocytidine | 489-59-8 | Oligonucleotides |
| HY-152878 | Arabinosylisocytosine | 10212-30-3 | Oligonucleotides |
| HY-152879 | 5-Benzylamino carbonyl-3’-O-acetyl-2’-O-methyluridine | 2095417-64-2 | Oligonucleotides |
| HY-15287A | Nelfinavir (Mesylate) | 159989-65-8 | Reference compound |
| HY-15287R | Nelfinavir (Standard) | 159989-64-7 | Reference Standards |
| HY-15287S | Nelfinavir-d3 | 1217629-70-3 | Isotope-Labeled Compounds |
| HY-15287S1 | Nelfinavir-d4 | | Isotope-Labeled Compounds |
| HY-15288 | PI3kδ inhibitor 1 | 1332075-63-4 | Reference compound |
| HY-152880 | 2’-Deoxy-2’-fluoro-arabino-tubercidine | 169516-61-4 | Oligonucleotides |
| HY-15289 | Ciproxifan (maleate) | 184025-19-2 | Reference compound |
| HY-152896 | Ys-II | 897386-27-5 | Natural Products |
| HY-152898A | Arachidonoyl CoA (triammonium) | 799812-93-4 | Enzyme |
| HY-152899 | Selachyl alcohol | 593-31-7 | Reference compound |
| HY-15290 | AIM-100 | 873305-35-2 | Reference compound |
| HY-152901 | Chol-N3 | 2106868-12-4 | Dye Reagents |
| HY-152903S | Sulfuric-34S acid (disodium) | 225640-22-2 | Isotope-Labeled Compounds |
| HY-152906 | Acid-PEG8-t-butyl ester | 3052794-63-2 | Reference compound |
| HY-152909 | Nystatin A2 | 65086-32-0 | Natural Products |
| HY-15291 | MBX-2982 | 1037792-44-1 | Reference compound |
| HY-152916 | mp-dLAE-PABC-MMAE | 2625616-44-4 | Reference compound |
| HY-152919 | Mal-amide-PEG8-Val-Cit-PAB-OH | 2387738-43-2 | ADC Related |
| HY-15292 | S107 | 927871-76-9 | Reference compound |
| HY-152925 | FA-15 | 4932-15-4 | Reference compound |
| HY-152927 | Hydroxypropylmethyl cellulose acetate succinate (Mw: 20-100k Da) | 71138-97-1 | Reference compound |
| HY-15293 | JTV-519 | 1038410-88-6 | Reference compound |
| HY-15293A | JTV-519 (free base) | 145903-06-6 | Reference compound |
| HY-15293B | JTV-519 (hemifumarate) | 1435938-25-2 | Reference compound |
| HY-15294 | CZC24832 | 1159824-67-5 | Reference compound |
| HY-152943 | MTK458 | 2499962-58-0 | Reference compound |
| HY-152943A | (Rac)-MTK458 | 2499962-44-4 | Reference compound |
| HY-152944 | S6K1-IN-DG2 | 871340-88-4 | Reference compound |
| HY-152945 | Antiproliferative agent-22 | 1374305-45-9 | Reference compound |
| HY-152947 | ELOVL6-IN-4 | 1170321-92-2 | Reference compound |
| HY-152949 | Myosin V-IN-1 | 1259177-59-7 | Reference compound |
| HY-15295 | Vonoprazan (Fumarate) | 881681-01-2 | Reference compound |
| HY-152954 | DRAK1/2-IN-1 | 1629227-34-4 | Reference compound |
| HY-152955 | STING agonist-22 | 2408723-12-4 | Reference compound |
| HY-152956 | STING agonist-23 | 2361570-16-1 | Reference compound |
| HY-152957 | STING agonist-24 | 2408722-91-6 | Reference compound |
| HY-152958 | STING agonist-25 | 2408723-10-2 | Reference compound |
| HY-152959 | STING agonist-26 | 2868261-48-5 | Reference compound |
| HY-15296 | Cabergoline | 81409-90-7 | Reference compound |
| HY-152960 | STING agonist-27 | 2868261-45-2 | Reference compound |
| HY-152961 | STING agonist-28 | 2868261-50-9 | Reference compound |
| HY-152962 | STING agonist-29 | 2868261-51-0 | Reference compound |
| HY-152963 | Tisotumab vedotin | 1418731-10-8 | ADC Related |
| HY-152965 | Biotin-doxorubicin | 3026061-30-0 | Reference compound |
| HY-152968 | 2’-O-t-Butyldimethylsilyladenosine | 69504-13-8 | Oligonucleotides |
| HY-152969 | 6-Chloro-N1-(trimethylsilylethoxymethyl)pseudouridine | | Oligonucleotides |
| HY-15296A | Cabergoline (diphosphate) | 85329-89-1 | Reference compound |
| HY-15296R | Cabergoline (Standard) | 81409-90-7 | Reference Standards |
| HY-15296S | Cabergoline-d5 | 1426173-20-7 | Isotope-Labeled Compounds |
| HY-15296S1 | Cabergoline-d6 | 2738376-76-4 | Isotope-Labeled Compounds |
| HY-15297 | Vesnarinone | 81840-15-5 | Reference compound |
| HY-152970 | 7'-O-DMT-morpholino uracil | 1127343-02-5 | Oligonucleotides |
| HY-152973 | 7'-O-DMT-morpholino thymine | 143485-05-6 | Oligonucleotides |
| HY-152974 | 1-(2,3,5-Tri-O-benzoyl-2-C-β-methyl-β-D-ribofuranosyl)-5-nitropyridine-2(1H)-one | 2072145-38-9 | Oligonucleotides |
| HY-152976 | N4-Benzoyl-7’-O-(4,4’-dimethoxytrityloxy)morpholinocytosine | 2304678-24-6 | Oligonucleotides |
| HY-152977 | 4-Chloro-7-(2-deoxy-3,5-bis-O-(p-toluoyl)-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine | | Oligonucleotides |
| HY-152978 | 2'-Deoxy-5'-O-DMT-N4-Fmoc-5-methylcytidine | 176755-86-5 | Oligonucleotides |
| HY-152979 | 2'-Deoxy-5'-O-DMT-N4-Fmoc-5-methylcytidine 3'-CE-phosphoramidite | 176755-87-6 | Oligonucleotides |
| HY-15298 | Grazoprevir | 1350514-68-9 | Reference compound |
| HY-152980 | 4-Chloro-7-(2-deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine | 97337-37-6 | Oligonucleotides |
| HY-152981 | Di-O-Toluoyl-1,2-dideoxy-D-ribose-6-chloro-7-iodo-7-deazapurine | | Oligonucleotides |
| HY-152982 | 1-(2-C-β-Methyl-β-D-ribofuranosyl)-5-nitropyridine-2(1H)-one | 2072145-17-4 | Oligonucleotides |
| HY-152983 | 2'-Deoxy-5'-O-DMT-N6-Fmoc-adenosine 3'CE-phosphoramidite | 109420-86-2 | Oligonucleotides |
| HY-152984 | N6-Benzoyl-7'-O-DMT-morpholino adenine | 2243974-77-6 | Oligonucleotides |
| HY-152985 | 3’-Azido-3’-deoxy-4-deoxyuridine | 2095417-07-3 | Oligonucleotides |
| HY-152986 | 4-Chloro-7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidine | 178995-71-6 | Oligonucleotides |
| HY-152987 | 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 652965-07-6 | Oligonucleotides |
| HY-152988 | N2-iso-Butyroyl-7'-O-DMT-morpholinoguanine | 2243974-78-7 | Oligonucleotides |
| HY-15298A | Grazoprevir potassium salt | 1206524-86-8 | Reference compound |
| HY-15298B | Grazoprevir hydrate | 1350462-55-3 | Reference compound |
| HY-15298C | Grazoprevir sodium salt | 1425038-27-2 | Reference compound |
| HY-152990 | Methyl 1,2,3,4-tetrahydro-α-hydroxy-2,4-dioxo-1-β-D-ribofuranosyl-5-pyrimidineacetate | 945684-13-9 | Oligonucleotides |
| HY-152991 | 6-Deoxo-8-oxo-3’-deoxy-guanosine | | Oligonucleotides |
| HY-152992 | 7-Cyano-7-deaza-2'-deoxy guanosine | 199859-58-0 | Oligonucleotides |
| HY-152993 | 2′-Deoxy-N-(2-furanylmethyl)guanosine | 1227069-12-6 | Oligonucleotides |
| HY-152994 | 1,2-Di-O-acetyl-3,5-di-O-benzoyl-D-xylofuranose | 85026-60-4 | Oligonucleotides |
| HY-152995 | Confidential | | Oligonucleotides |
| HY-152996 | 2′-Deoxy-8-(methylthio)adenosine | 29836-02-0 | Oligonucleotides |
| HY-152998 | 2’,3’,5’-Tri-O-acetyl-5-methoxycarbonylmethyl-2-thiouridine | 1613530-52-1 | Oligonucleotides |
| HY-15300 | Skepinone-L | 1221485-83-1 | Reference compound |
| HY-153002 | p38α inhibitor 3 | 260428-69-1 | Reference compound |
| HY-153005 | (2RS)-FPMPA | 135295-27-1 | Reference compound |
| HY-153006 | 2,7-Dichlorodihydrofluorescein | 106070-31-9 | Reference compound |
| HY-153007 | DHFR-IN-5 | 1142407-81-5 | Reference compound |
| HY-153007A | DHFR-IN-5 (hydrochloride) | 1142407-60-0 | Reference compound |
| HY-153008 | BCR-ABL-IN-7 | 688050-42-2 | Reference compound |
| HY-153009 | MMV676584 | 750621-19-3 | Reference compound |
| HY-15301 | CC0651 | 1319207-44-7 | Reference compound |
| HY-153010 | ER proteostasis regulator-1 | 912777-95-8 | Reference compound |
| HY-153011 | ROCK-IN-5 | 692870-25-0 | Reference compound |
| HY-153012 | Axl/Mer/CSF1R-IN-1 | 2394874-60-1 | Reference compound |
| HY-153013 | SN38-COOH | 2170118-23-5 | ADC Related |
| HY-153015 | Zalsupindole | 2481740-94-5 | Reference compound |
| HY-153015A | Zalsupindole (hydrobromide) | 2930845-96-6 | Reference compound |
| HY-153015B | Zalsupindole (hydrochloride) | 2930845-89-7 | Reference compound |
| HY-153015C | Zalsupindole (benzoate) | 2930845-92-2 | Reference compound |
| HY-153015D | Zalsupindole (mesylate) | 2930846-03-8 | Reference compound |
| HY-153016 | HIF-2α agonist 2 | 2750141-15-0 | Reference compound |
| HY-153017 | HIF-1 inhibitor-4 | 333357-56-5 | Reference compound |
| HY-153018 | PTP1B-IN-22 | 86109-60-6 | Reference compound |
| HY-153019 | NUCC-0000323 | 663212-78-0 | Reference compound |
| HY-153020 | HIF-PHD-IN-3 | 794582-71-1 | Reference compound |
| HY-153021 | NMT-IN-1 | 326879-46-3 | Reference compound |
| HY-153023 | PROTAC STAT3 degrader-2 | 2429877-78-9 | Reference compound |
| HY-153027 | Methylergometrine | 113-42-8 | Reference compound |
| HY-15303 | Pritelivir | 348086-71-5 | Reference compound |
| HY-153031 | Val-Cit-PAB-Exatecan | 2227350-99-2 | ADC Related |
| HY-153031A | Val-Cit-PAB-Exatecan (TFA) | 2928571-44-0 | ADC Related |
| HY-153032 | Val-Ala-PAB-MMAE | 1912408-92-4 | ADC Related |
| HY-153034 | LONP1-IN-2 | 2729981-17-1 | Reference compound |
| HY-153039 | Anhydroleucovorin | 7444-29-3 | Reference compound |
| HY-153039R | Anhydroleucovorin (Standard) | 7444-29-3 | Reference Standards |
| HY-15303A | Pritelivir (mesylate) | 1428333-96-3 | Reference compound |
| HY-15303B | Pritelivir (mesylate hydrate) | 1428321-10-1 | Reference compound |
| HY-15303S | Pritelivir-d4-1 | | Isotope-Labeled Compounds |
| HY-15304 | Dynasore | 304448-55-3 | Reference compound |
| HY-153040 | HPPE | 1325721-55-8 | Reference compound |
| HY-153042 | Thalidomide-NH-C2-azaspiro[3.5]nonane (hydrochloride) | 2573304-92-2 | Reference compound |
| HY-153043 | DM-CO-(CH2)5-SMe | 2243689-84-9 | Reference compound |
| HY-153045 | BAY-805 | 2925481-88-3 | Reference compound |
| HY-153045A | BAY-728 | | Reference compound |
| HY-153050 | JAK-IN-24 | 2042629-43-4 | Reference compound |
| HY-153051 | Antitumor agent-90 | 131268-74-1 | Reference compound |
| HY-153056 | BNN3 | 6947-38-2 | Reference compound |
| HY-153057 | PRMT5-IN-46 | 380192-76-7 | Reference compound |
| HY-153058 | LRRK2-IN-8 | 2770269-44-6 | Reference compound |
| HY-153059 | 5-(N-Methyl-N-trifluoroacetyl)aminomethyl uridine | 163496-07-9 | Reference compound |
| HY-15306 | Eltrombopag | 496775-61-2 | Reference compound |
| HY-153060 | β-D-Ribofuranose analogue 1 | 89129-10-2 | Reference compound |
| HY-153061 | 2’-O-Methylisocytidine | 175471-65-5 | Reference compound |
| HY-153062 | 6-Chloro-7-deazapurine-2F-β-D-arabinofuranose | 169516-60-3 | Reference compound |
| HY-153064 | MAX-10181 | 2171558-14-6 | Reference compound |
| HY-153065 | KIF18A-IN-6 | 2914879-10-8 | Reference compound |
| HY-153066 | VLS-1272 | 2914878-00-3 | Reference compound |
| HY-153067 | Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan | 2578019-72-2 | Reference compound |
| HY-153068 | CZL55 | 667408-87-9 | Reference compound |
| HY-153069 | GGFG-PAB-Exatecan | 251459-32-2 | Reference compound |
| HY-153069A | GGFG-PAB-Exatecan (TFA) | | ADC Related |
| HY-15306A | Eltrombopag (Olamine) | 496775-62-3 | Reference compound |
| HY-15306AR | Eltrombopag (Olamine) (Standard) | 496775-62-3 | Reference Standards |
| HY-15306R | Eltrombopag (Standard) | 496775-61-2 | Reference Standards |
| HY-15306S | Eltrombopag-13C4 | 1217230-31-3 | Isotope-Labeled Compounds |
| HY-15307 | Belumosudil | 911417-87-3 | Reference compound |
| HY-153070 | TLR7 agonist 5 | 2380231-67-2 | Reference compound |
| HY-153071 | TLR7 agonist 6 | 2380231-86-5 | Reference compound |
| HY-153072 | TLR7 agonist 7 | 2380231-77-4 | Reference compound |
| HY-153073 | TLR7 agonist 8 | 2380231-81-0 | Reference compound |
| HY-153074 | ISR-IN-1 | 1628478-15-8 | Reference compound |
| HY-153075 | ISR-IN-2 | 1628478-12-5 | Reference compound |
| HY-153076 | Flaviviruses-IN-3 | 420090-97-7 | Reference compound |
| HY-153077 | PFKFB3-IN-2 | 794552-84-4 | Reference compound |
| HY-153078 | MRTF/SRF-IN-1 | 1922098-90-5 | Reference compound |
| HY-153079 | eGFP mRNA(N1-Me-Pseudo UTP) | | Dye Reagents |
| HY-15307A | Belumosudil (mesylate) | 2109704-99-4 | Reference compound |
| HY-15307S | Belumosudil-d7 | | Isotope-Labeled Compounds |
| HY-15308 | Avermectin B1a | 65195-55-3 | Reference compound |
| HY-153080 | Firefly Luciferase mRNA(N1-Me-Pseudo UTP) | | Oligonucleotides |
| HY-153081 | eGFP circRNA | | Dye Reagents |
| HY-153082 | Firefly Luciferase circRNA | | Dye Reagents |
| HY-153083 | COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP) | | Oligonucleotides |
| HY-153084 | CD19 CAR mRNA (Mouse) | | Oligonucleotides |
| HY-153084A | CD19 CAR mRNA (Human) | | Oligonucleotides |
| HY-153085 | CD19 CAR circRNA | | Oligonucleotides |
| HY-153088 | CDK4/6-IN-16 | 1169694-98-7 | Reference compound |
| HY-153089 | GSK3-IN-3 | 331963-27-0 | Reference compound |
| HY-15308R | Avermectin B1a (Standard) | 65195-55-3 | Reference Standards |
| HY-153090 | Transketolase-IN-4 | 419547-73-2 | Reference compound |
| HY-153091 | BMY 14802 | 105565-56-8 | Reference compound |
| HY-153092 | Avenciguat | 1579514-06-9 | Reference compound |
| HY-153093 | MK-8189 | 1424371-93-6 | Reference compound |
| HY-153094 | BDM-2 | 1643876-33-8 | Reference compound |
| HY-153095 | PF-6870961 | 2857112-06-0 | Reference compound |
| HY-153095A | PF-6870961 (hydrochloride) | 2857112-07-1 | Reference compound |
| HY-153096 | OICR12694 | 2360625-97-2 | Reference compound |
| HY-153096A | OICR12694 (TFA) | 2360625-98-3 | Reference compound |
| HY-153098 | ARC186 | | Oligonucleotides |
| HY-153098A | ARC186 (sodium) | | Reference compound |
| HY-15310 | Ivermectin | 70288-86-7 | Natural Products |
| HY-153100 | (R)-mchm5U | 89665-84-9 | Reference compound |
| HY-153100A | (S)-mchm5U | 89665-83-8 | Reference compound |
| HY-153101 | Gal-G2-CNP | 157381-11-8 | Biochemical Assay Reagents |
| HY-153102 | G3-CNP | 118291-90-0 | Biochemical Assay Reagents |
| HY-153103 | LRRK2/NUAK1/TYK2-IN-1 | 2629192-96-5 | Reference compound |
| HY-153104 | CrBKA | 2260810-48-6 | Reference compound |
| HY-153108 | 3'-O-Me-m7G(5')ppp(5')A solution (100mM) | | Biochemical Assay Reagents |
| HY-15310R | Ivermectin (Standard) | 70288-86-7 | Reference Standards |
| HY-15311 | Avermectin B1 | 71751-41-2 | Natural Products |
| HY-153110 | Larotinib | 1438072-11-7 | Reference compound |
| HY-153110A | Larotinib (mesylate hydrate) | 2097129-93-4 | Reference compound |
| HY-153111 | EGFR/HER2-IN-9 | 1637253-79-2 | Reference compound |
| HY-153112 | DHODH-IN-23 | 1346705-53-0 | Reference compound |
| HY-153113 | Rongliflozin | 2648020-91-9 | Reference compound |
| HY-153114 | HEC96719 | 2181834-03-5 | Reference compound |
| HY-153115 | Plasma kallikrein-IN-4 | 1357954-34-7 | Reference compound |
| HY-153117 | Cyclohexyl [3,5-bis(methylthio)-4-isothiazolyl]carbamate | 311334-13-1 | Reference compound |
| HY-153118 | Deoxyribonucleic acid (sodium, from calf thymus, Type I, fibers) | 73049-39-5 | Biochemical Assay Reagents |
| HY-153119 | TMX-4153 | 2867519-91-1 | Reference compound |
| HY-15311R | Avermectin B1 (Standard) | 71751-41-2 | Reference Standards |
| HY-15312 | WP1066 | 857064-38-1 | Reference compound |
| HY-153120 | PI3K/mTOR Inhibitor-13 | 1621718-37-3 | Reference compound |
| HY-153120A | PI3K/mTOR Inhibitor-13 (sodium) | 2361009-23-4 | Reference compound |
| HY-153121 | Leritrelvir | 2923310-64-7 | Reference compound |
| HY-153122 | YCT529 (free acid) | 2863670-66-8 | Reference compound |
| HY-153122A | YCT529 | 2863670-67-9 | Reference compound |
| HY-153124 | β-Cyclodextrin, 2-hydroxyethyl ethers | 128446-32-2 | Biochemical Assay Reagents |
| HY-153125 | DLRIE | 199171-54-5 | Reference compound |
| HY-153126 | Yeast extract | 8013-01-2 | Biochemical Assay Reagents |
| HY-153127 | Florbenazine | 937245-42-6 | Reference compound |
| HY-153128 | DOCK2-IN-1 | 4590-86-7 | Reference compound |
| HY-153129 | EP2 receptor antagonist-2 | 615273-95-5 | Reference compound |
| HY-15313 | CBB1007 | 1379573-92-8 | Reference compound |
| HY-153132 | mGluR3 modulator-1 | 374548-18-2 | Reference compound |
| HY-153133 | CFTR corrector 11 | 688050-45-5 | Reference compound |
| HY-153136 | LNP Lipid-1 | 2089253-13-2 | Biochemical Assay Reagents |
| HY-153137 | Tri-N-tridecyl 3-(ethyl(methyl)amino)propanoate | 1566559-80-5 | Biochemical Assay Reagents |
| HY-153138 | FTT5 LLNs | 2803606-43-9 | Biochemical Assay Reagents |
| HY-15313B | CBB1007 (hydrochloride) | 2070014-96-7 | Reference compound |
| HY-15313C | CBB1007 (trihydrochloride) | 2070015-03-9 | Reference compound |
| HY-15314 | Ranirestat | 147254-64-6 | Reference compound |
| HY-15315 | Baricitinib | 1187594-09-7 | Reference compound |
| HY-153151 | Fmoc-DON-Boc | 1998724-98-3 | Reference compound |
| HY-153152 | DPTN (dihydrochloride) | 325767-87-1 | Reference compound |
| HY-153153 | Benzyl-PEG45-alcohol | 26403-74-7 | Reference compound |
| HY-153154 | COMC-6 | 106281-45-2 | Reference compound |
| HY-153158 | VEGFR2-IN-3 | 417717-09-0 | Reference compound |
| HY-153159 | Angiogenesis inhibitor 4 | 417719-77-8 | Reference compound |
| HY-15315A | Baricitinib (phosphate) | 1187595-84-1 | Reference compound |
| HY-15315R | Baricitinib (Standard) | 1187594-09-7 | Reference Standards |
| HY-15315S | Baricitinib-d5 | 1564241-79-7 | Isotope-Labeled Compounds |
| HY-15315S1 | Baricitinib-d3 | 1564242-30-3 | Isotope-Labeled Compounds |
| HY-153160 | PERK-IN-6 | 1337532-14-5 | Reference compound |
| HY-153161 | CASP8-IN-1 | 1956368-39-0 | Reference compound |
| HY-153165 | RXR antagonist 5 | 1807740-94-8 | Reference compound |
| HY-153166 | PT-65 | 2721998-87-2 | Reference compound |
| HY-153168 | Bemoradan | 112018-01-6 | Reference compound |
| HY-153169 | 6PPD-Q | 2754428-18-5 | Reference compound |
| HY-15317 | RI-1 | 415713-60-9 | Reference compound |
| HY-153172 | Phenylbenzothiazole-PEG4-OH | 2274723-90-7 | Reference compound |
| HY-153175 | BT44 | 924759-42-2 | Reference compound |
| HY-153176 | PAT-IN-1 | 2066571-97-7 | Reference compound |
| HY-153177 | PAT-IN-2 | 2066572-01-6 | Reference compound |
| HY-153178 | HECT E3-IN-1 | 1810058-52-6 | Reference compound |
| HY-153179 | Mal-Gly-PAB-Exatecan-D-glucuronic acid | 2763252-25-9 | ADC Related |
| HY-153180 | PB038 | 2851058-71-2 | Reference compound |
| HY-153181 | Trametiglue | 2666940-97-0 | Reference compound |
| HY-153182 | GBT1118 | 1628799-51-8 | Reference compound |
| HY-153183 | Lp-PLA2-IN-12 | 2637485-14-2 | Reference compound |
| HY-153184 | GalNAc-L96 (free base) | 1159408-61-3 | Oligonucleotides |
| HY-153185 | Decyclohexanamine-Exatecan | 2505045-51-0 | Reference compound |
| HY-153186 | LNP Lipid-3 | 2648693-32-5 | Oligonucleotides |
| HY-153187 | LNP Lipid-4 | 2795397-84-9 | Biochemical Assay Reagents |
| HY-153188 | JNJ-1013 | 2597343-08-1 | Reference compound |
| HY-153189 | TrkB-IN-1 | 1609067-49-3 | Reference compound |
| HY-15319 | AMG 487 | 473719-41-4 | Reference compound |
| HY-153190 | W1131 | 2740522-79-4 | Reference compound |
| HY-153190A | W1131 (TFA) | | Reference compound |
| HY-153191 | EZH2-IN-15 | 2098545-98-1 | Reference compound |
| HY-153192 | Nerandomilast | 1423719-30-5 | Reference compound |
| HY-153192A | Nerandomilast (dihydrate) | | Reference compound |
| HY-153193 | LSN3160440 | 2765539-59-9 | Reference compound |
| HY-153195 | Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2OH-Fmoc | 2169723-90-2 | Reference compound |
| HY-153196 | Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc | 2169723-91-3 | ADC Related |
| HY-153199 | MDM2/XIAP-IN-1 | 359595-95-2 | Reference compound |
| HY-15319A | (±)-AMG 487 | 947536-03-0 | Reference compound |
| HY-15319B | AMG 487 (S-enantiomer) | 473720-30-8 | Reference compound |
| HY-15320 | NBI-74330 | 855527-92-3 | Reference compound |
| HY-153200 | MDM2/XIAP-IN-2 | 2761969-85-9 | Reference compound |
| HY-153202 | SLMP53-2 | 1826116-38-4 | Reference compound |
| HY-153203 | Eicosapentaenoyl-CoA (triammonium) | 1246522-05-3 | Enzyme |
| HY-153204 | Isobutylquinoleine | 65442-31-1 | Natural Products |
| HY-153205 | Aluminum hydroxide adjuvant | | Reference compound |
| HY-153209 | Adjuvant-4 | | Reference compound |
| HY-153209G | Adjuvant-4 (GMP) | | GMP Small Molecules |
| HY-15321 | Etoricoxib | 202409-33-4 | Reference compound |
| HY-153213 | Org 274179-0 | 1421683-12-6 | Reference compound |
| HY-153214 | YW2036 | 2131223-92-0 | Reference compound |
| HY-153215 | MEL24 | 642072-48-8 | Reference compound |
| HY-153219 | P-CAB agent 2 (hydrochloride) | 2209911-80-6 | Reference compound |
| HY-153219A | P-CAB agent 2 | 1978371-23-1 | Reference compound |
| HY-15321A | Etoricoxib (hydrochloride) | 202409-40-3 | Reference compound |
| HY-15321R | Etoricoxib (Standard) | 202409-33-4 | Reference Standards |
| HY-15321S | Etoricoxib-d4 | 1131345-14-6 | Isotope-Labeled Compounds |
| HY-15321S1 | Etoricoxib-13C,d3 | 2748267-73-2 | Isotope-Labeled Compounds |
| HY-15321S2 | Etoricoxib-d3 | 850896-71-8 | Isotope-Labeled Compounds |
| HY-15322 | PRT062607 | 1370261-96-3 | Reference compound |
| HY-153220 | NX-2127 | 2416131-46-7 | Reference compound |
| HY-153220A | (R)-NX-2127 | 3024312-52-2 | Reference compound |
| HY-153221 | QR-6401 | 2845096-18-4 | Reference compound |
| HY-153222 | SEQ-9 | | Reference compound |
| HY-153224 | GLPG2534 | 2095615-97-5 | Reference compound |
| HY-153225 | PYR01 | 2560576-15-8 | Reference compound |
| HY-153226 | BET-IN-14 | 2243669-93-2 | Reference compound |
| HY-153227 | SU 5616 | 186611-58-5 | Reference compound |
| HY-153228 | Pomotrelvir | 2713437-86-4 | Reference compound |
| HY-153229 | Firefly luciferase mRNA-LNP | | Biochemical Assay Reagents |
| HY-15323 | PRT062607 (Hydrochloride) | 1370261-97-4 | Reference compound |
| HY-153230 | Firefly luciferase circRNA-LNP | | Biochemical Assay Reagents |
| HY-153231 | eGFP mRNA-LNP | | Biochemical Assay Reagents |
| HY-153231A | eGFP mRNA-LNP (500 ng/μL) | | Biochemical Assay Reagents |
| HY-153232 | eGFP circRNA-LNP | | Biochemical Assay Reagents |
| HY-153233 | CD19 car mRNA (Mouse)-LNP | | Biochemical Assay Reagents |
| HY-153234 | CD19 car circRNA-LNP | | Biochemical Assay Reagents |
| HY-153235 | COVID-19 Spike Protein mRNA-LNP | | Biochemical Assay Reagents |
| HY-153236 | Py-MAA-Val-Cit-PAB-DX8951 | 2504068-37-3 | ADC Related |
| HY-153238 | AN15368 | 2152662-92-3 | Reference compound |
| HY-153239 | Eltrombopag methyl ester | 1246929-01-0 | Reference compound |
| HY-15324 | PRT062607 (acetate) | 1370261-98-5 | Reference compound |
| HY-153240 | ACT-672125 | 1449367-94-5 | Reference compound |
| HY-153241 | GSK737 | 2748687-95-6 | Reference compound |
| HY-153242 | GSK217 | 2748687-92-3 | Reference compound |
| HY-153243 | IACS-9439 | 2231259-36-0 | Reference compound |
| HY-153244 | MFH290 | 2088715-91-5 | Reference compound |
| HY-153245 | JNJ-64264681 | 2101524-34-7 | Reference compound |
| HY-153246 | ALK2-IN-5 | 2414149-20-3 | Reference compound |
| HY-153247 | GSK3839919A | 2081127-77-5 | Reference compound |
| HY-153248 | PBR28 | 253307-65-2 | Reference compound |
| HY-153249 | DMT-2'-F-Cytidine Phosphoramidite | 200404-36-0 | Oligonucleotides |
| HY-153251 | DMT-2'-O-Methylguanosine phosphoramidite | 1159683-24-5 | Oligonucleotides |
| HY-153253 | DMT-2'-O-Methyladenosine phosphoramidite | 138906-75-9 | Oligonucleotides |
| HY-153254 | BMS905 | 2205846-49-5 | Reference compound |
| HY-153255 | BACE1-IN-13 | 1397683-26-9 | Reference compound |
| HY-153256 | EP3 antagonist 4 | 2408297-80-1 | Reference compound |
| HY-153258 | CaSR antagonist-1 | 1219811-83-2 | Reference compound |
| HY-153259 | TNKS1/2-IN-2 | 1498300-35-8 | Reference compound |
| HY-153260 | TP-1287 | 2044686-42-0 | Reference compound |
| HY-153261 | NLRP3-IN-17 | 2254432-75-0 | Reference compound |
| HY-153262 | KRASG12C IN-2 | 2706637-12-7 | Reference compound |
| HY-153263 | (Aminooxy)acetamide-Val-Cit-PAB-MMAE | 2446645-88-9 | ADC Related |
| HY-153264 | TAS2R14 agonist-1 | 2439115-08-7 | Reference compound |
| HY-153265 | TAS2R14 agonist-2 | 2883007-69-8 | Reference compound |
| HY-153268 | Silevertinib | 2607829-38-7 | Reference compound |
| HY-15327 | 1alpha, 25-Dihydroxy VD2-d6 | 216244-04-1 | Isotope-Labeled Compounds |
| HY-153272 | Antitumor agent-93 | 1681019-44-2 | Reference compound |
| HY-153274 | CWI1-2 | 2408590-36-1 | Reference compound |
| HY-153274A | CWI1-2 (hydrochloride) | 2408590-37-2 | Reference compound |
| HY-153276 | Androgen receptor-IN-5 | 1391944-16-3 | Reference compound |
| HY-153277 | Axl/Mer/CSF1R-IN-2 | 2394874-63-4 | Reference compound |
| HY-153278 | CDK7-IN-21 | 2766124-39-2 | Reference compound |
| HY-153279 | 5-LOX-IN-3 | 1875061-47-4 | Reference compound |
| HY-15328 | 25-Hydroxy VD2-d6 | 1262843-46-8 | Isotope-Labeled Compounds |
| HY-15329 | Maxacalcitol-d6 | | Isotope-Labeled Compounds |
| HY-15330 | Vitamin D2-d3 | 1217448-46-8 | Isotope-Labeled Compounds |
| HY-153306 | RLY-2608 | 2733573-94-7 | Reference compound |
| HY-153306A | (S)-RLY-2608 | 2733573-93-6 | Reference compound |
| HY-15331 | VD3-d6 | 118584-54-6 | Isotope-Labeled Compounds |
| HY-15332 | Alfacalcidol-d6 | 1641940-94-4 | Isotope-Labeled Compounds |
| HY-153320 | AZ-TAK1 | 1413440-36-4 | Reference compound |
| HY-153321 | NX-5948 | 2649400-34-8 | Reference compound |
| HY-153322 | ITK degrader 2 | 2858738-65-3 | Reference compound |
| HY-153324 | PS220 (sodium) | | Oligonucleotides |
| HY-153329 | TNF-α-IN-9 | 2054199-25-4 | Reference compound |
| HY-15333 | ZK-261991 | 886563-25-3 | Reference compound |
| HY-153330 | TNF-α-IN-10 | 2247720-56-3 | Reference compound |
| HY-153331 | DDO-2213 | 2378768-36-4 | Reference compound |
| HY-153332 | Tankyrase-IN-5 | 1460285-69-1 | Reference compound |
| HY-153333 | A1/A3 AR antagonist 3 | 2665804-57-7 | Reference compound |
| HY-153334 | Enpp-1-IN-15 | 2756218-99-0 | Reference compound |
| HY-153335 | Enpp-1-IN-16 | 2289739-47-3 | Reference compound |
| HY-153336 | CDK-IN-12 | 2789680-97-1 | Reference compound |
| HY-153337 | Pomalidomide-C11-NH2 | 2648285-39-4 | Reference compound |
| HY-153337A | Pomalidomide-C11-NH2 (hydrochloride) | 2722611-55-2 | Reference compound |
| HY-153339 | E235 | 891894-69-2 | Reference compound |
| HY-15334 | CEP-5214 | 402857-39-0 | Reference compound |
| HY-153340 | I-152 | 311343-11-0 | Reference compound |
| HY-153341 | CFT1946 | 2882165-79-7 | Reference compound |
| HY-153342 | Luxdegalutamide | 2750830-09-0 | Reference compound |
| HY-153343 | Veludacigib | 2732902-08-6 | Reference compound |
| HY-153343A | (S)-Veludacigib | 2732902-09-7 | Reference compound |
| HY-153344 | FX-909 | 2924573-90-8 | Reference compound |
| HY-153345 | Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br | 2345733-40-4 | Reference compound |
| HY-153346 | Elironrasib | 2641998-63-0 | Reference compound |
| HY-153347 | JY-2 | 339103-05-8 | Reference compound |
| HY-153348 | p38 Kinase inhibitor 4 | 13142-47-7 | Reference compound |
| HY-153349 | 2,3-Di(furan-2-yl)quinoxaline | 57490-73-0 | Dye Reagents |
| HY-15335 | Nutlin-3b | 675576-97-3 | Reference compound |
| HY-153350 | ERK-IN-7 | 2494010-63-6 | Reference compound |
| HY-153351 | IpOHA | 132418-03-2 | Reference compound |
| HY-153354 | PKR activator 4 | 2283420-05-1 | Reference compound |
| HY-153356 | MRT-2359 | 2803881-11-8 | Reference compound |
| HY-153357 | NRX-0492 | 2416130-57-7 | Reference compound |
| HY-153358 | TNG260 | 2935964-98-8 | Reference compound |
| HY-153358A | (S)-TNG260 | 2935964-93-3 | Reference compound |
| HY-153359 | M3913 | 2379783-62-5 | Reference compound |
| HY-15336 | AG 555 | 133550-34-2 | Reference compound |
| HY-153360 | MC-GGFG-AM-(10Me-11F-Camptothecin) | 2873460-70-7 | Reference compound |
| HY-153361 | YD23 | 2951015-29-3 | Reference compound |
| HY-153362 | HPK1-IN-34 | 2380300-99-0 | Reference compound |
| HY-153364 | FTX-6746 | 2829349-96-2 | Reference compound |
| HY-153365 | I-138 | 2098211-50-6 | Reference compound |
| HY-153366 | TNG-0746132 | 2821749-57-7 | Reference compound |
| HY-153367 | FHD-609 | 2676211-64-4 | Reference compound |
| HY-153368 | Zomiradomide | 2655656-99-6 | Reference compound |
| HY-153369 | BAY-747 | 1609342-18-8 | Reference compound |
| HY-15337 | Hesperidin | 520-26-3 | Natural Products |
| HY-153370 | DBCO-PEG3-oxyamine-Boc (hydrochloride) | | ADC Related |
| HY-153371 | 50-C2-C9-4tail | 1853203-01-6 | Biochemical Assay Reagents |
| HY-153372 | 93-O17S | 2227008-67-3 | Oligonucleotides |
| HY-153373 | 4A3-Cit | 2768211-13-6 | Biochemical Assay Reagents |
| HY-153375 | LNP Lipid-5 | 2430034-00-5 | Biochemical Assay Reagents |
| HY-153376 | LNP Lipid-6 | 2226547-32-4 | Biochemical Assay Reagents |
| HY-153377 | Lipid 14 | 2430034-05-0 | Oligonucleotides |
| HY-153378 | Lipid 15 | 2588111-36-6 | Oligonucleotides |
| HY-15337R | Hesperidin (Standard) | 520-26-3 | Reference Standards |
| HY-15338 | TG003 | 719277-26-6 | Reference compound |
| HY-153383 | PDCD4-IN-1 | 494763-64-3 | Reference compound |
| HY-153384 | EAPB 02303 | 1958290-51-1 | Reference compound |
| HY-153385 | TMX1 | | Reference compound |
| HY-153386 | CPD-1224 | 2891620-68-9 | Reference compound |
| HY-15338A | (E/Z)-TG003 | 300801-52-9 | Reference compound |
| HY-15339 | CVT-313 | 199986-75-9 | Reference compound |
| HY-153390 | AMG-193 | 2790567-82-5 | Reference compound |
| HY-153390A | (R)-AMG-193 | 2790567-83-6 | Reference compound |
| HY-153391 | PCSK9-IN-14 | 2913198-84-0 | Reference compound |
| HY-153392 | TYA-018 | 2653254-31-8 | Reference compound |
| HY-153393 | ATR-IN-21 | 2905312-17-4 | Reference compound |
| HY-153394 | Aflatoxin Q1 | 52819-96-2 | Natural Products |
| HY-153395 | PH-HG-005-5 | 2810895-93-1 | Reference compound |
| HY-153396 | Acid Ceramidase-IN-2 | 1005497-03-9 | Reference compound |
| HY-153398 | Enpp-1-IN-17 | 2289736-54-3 | Reference compound |
| HY-153399 | Fosigotifator | 2415715-84-1 | Reference compound |
| HY-153399A | ABBV-CLS-7262 | 2945073-88-9 | Reference compound |
| HY-15340 | LG100268 | 153559-76-3 | Reference compound |
| HY-153400 | ATR-IN-22 | 2905312-07-2 | Reference compound |
| HY-153401 | Topoisomerase II inhibitor 13 | 451515-89-2 | Reference compound |
| HY-153402 | Activated EG3 Tail | 1380600-06-5 | Reference compound |
| HY-153403 | Activated A Subunit | 956139-18-7 | Oligonucleotides |
| HY-153404 | Activated C Subunit | 956139-21-2 | Oligonucleotides |
| HY-153405 | Activated DPG Subunit | 1155309-89-9 | Oligonucleotides |
| HY-153406 | Activated T Subunit | 956139-30-3 | Oligonucleotides |
| HY-153407 | NCP2 Anchor | 1380600-13-4 | Reference compound |
| HY-153408 | 4-Hydroxylidocaine | 39942-41-1 | Reference compound |
| HY-153409 | Antifungal agent 48 | 2142003-75-4 | Reference compound |
| HY-15341 | BAM7 | 331244-89-4 | Reference compound |
| HY-153410 | Antifungal agent 49 | 1414861-21-4 | Reference compound |
| HY-153412 | KRAS inhibitor-22 | 2042365-57-9 | Reference compound |
| HY-153413 | Kras4B G12D-IN-1 | 2042365-85-3 | Reference compound |
| HY-153414 | GXF-111 | | Reference compound |
| HY-153415 | PROTAC BCR-ABL Degrader-1 | | Reference compound |
| HY-153416 | QR-0217 | 1027786-12-4 | Reference compound |
| HY-153417 | Anti-amyloid agent-1 | 1396778-73-6 | Reference compound |
| HY-153419 | BTTES | 1334179-86-0 | Reference compound |
| HY-15342 | Timapiprant | 851723-84-7 | Reference compound |
| HY-153421 | PRMT5-IN-28 | 2242753-66-6 | Reference compound |
| HY-153422 | PRMT5-IN-29 | 2242788-69-6 | Reference compound |
| HY-153423 | Mcl-1 inhibitor 12 | 2445466-24-8 | Reference compound |
| HY-153423A | Mcl-1 inhibitor 13 | 2445466-06-6 | Reference compound |
| HY-153424 | PROTAC SMARCA2 degrader-1 | 2892523-73-6 | Reference compound |
| HY-153425 | PROTAC SMARCA2 degrader-2 | 2892523-74-7 | Reference compound |
| HY-153426 | CDK9-IN-23 | 2761572-96-5 | Reference compound |
| HY-153427 | Tau protein aggregation-IN-1 | 916179-45-8 | Reference compound |
| HY-153428 | GGGDTDTC-Mc-vc-PAB-MMAE | | ADC Related |
| HY-153429 | WU-FA-01 | 882429-53-0 | Reference compound |
| HY-15342A | Timapiprant (sodium) | 950688-14-9 | Reference compound |
| HY-15343 | CEP-33779 | 1257704-57-6 | Reference compound |
| HY-153430 | Aβ/tau aggregation-IN-3 | 1210750-32-5 | Reference compound |
| HY-153431 | TRV-1387 | 1569645-63-1 | Reference compound |
| HY-153432 | TRV-7019 | 2598164-15-7 | Reference compound |
| HY-153433 | Serine Hydrolase inhibitor-21 | 366448-34-2 | Reference compound |
| HY-153434 | RIP1 kinase inhibitor 4 | 2919836-00-1 | Reference compound |
| HY-153435 | RIP1 kinase inhibitor 5 | 2428422-17-5 | Reference compound |
| HY-153436 | RIP1 kinase inhibitor 6 | 2428401-62-9 | Reference compound |
| HY-153437 | RIP1 kinase inhibitor 7 | 2428401-23-2 | Reference compound |
| HY-15344 | Ketone monoester | 1208313-97-6 | Reference compound |
| HY-153440 | JAK-IN-25 | 2127110-22-7 | Reference compound |
| HY-153441 | AXL-IN-15 | 1954722-22-5 | Reference compound |
| HY-153443 | CDK4-IN-2 | 2380320-68-1 | Reference compound |
| HY-153444 | Prifetrastat | 2569008-99-5 | Reference compound |
| HY-153445 | MEK-IN-6 | 2845151-86-0 | Reference compound |
| HY-153445A | MEK-IN-6 (hydrate) | 2845153-35-5 | Reference compound |
| HY-153446 | Tegeprotafib | 2407610-46-0 | Reference compound |
| HY-153448 | HPK1-IN-36 | 2738518-06-2 | Reference compound |
| HY-153449 | Decyl α-D-maltopyranoside | 168037-12-5 | Biochemical Assay Reagents |
| HY-15344A | (S,S)-Ketone monoester | 1251829-99-8 | Reference compound |
| HY-15345 | Tetrahydrouridine (dihydrate) | | Reference compound |
| HY-153450 | JBI-589 | 2308504-22-3 | Reference compound |
| HY-153451 | PCSK9-IN-15 | 2455423-94-4 | Reference compound |
| HY-153452 | PCSK9-IN-16 | 2455424-51-6 | Reference compound |
| HY-153453 | PCSK9-IN-17 | 2455424-72-1 | Reference compound |
| HY-153454 | PCSK9-IN-18 | 2455425-15-5 | Reference compound |
| HY-153455 | TRPC3/6-IN-2 | 2387893-55-0 | Reference compound |
| HY-153456 | Hedgehog IN-2 | 1126365-74-9 | Reference compound |
| HY-153457 | Hedgehog IN-3 | 1128191-09-2 | Reference compound |
| HY-153458 | Orexin receptor modulator-1 | 2125735-57-9 | Reference compound |
| HY-153459 | PROTAC BRD4 Degrader-19 | 2684292-71-3 | Reference compound |
| HY-15345A | Tetrahydrouridine | 18771-50-1 | Reference compound |
| HY-15345AS | Tetrahydrouridine-d3 | | Isotope-Labeled Compounds |
| HY-15346 | Copanlisib | 1032568-63-0 | Reference compound |
| HY-153460 | TLR7/8/9 antagonist 2 | 2920729-91-3 | Reference compound |
| HY-153461 | KRAS G12C inhibitor 58 | 2915599-52-7 | Reference compound |
| HY-153462 | ATR-IN-24 | 2370889-43-1 | Reference compound |
| HY-153464 | CXCR4-IN-1 | 2304750-48-7 | Reference compound |
| HY-153468 | ErSO-TFPy | 3035547-78-2 | Reference compound |
| HY-153469 | Benzyl DC-81 | 127810-79-1 | Reference compound |
| HY-15346A | Copanlisib (dihydrochloride) | 1402152-13-9 | Reference compound |
| HY-15346R | Copanlisib (Standard) | 1032568-63-0 | Reference Standards |
| HY-153471 | MOR agonist-1 | 2305781-14-8 | Reference compound |
| HY-153472 | VMAT2-IN-2 (tosylate) | 2608770-12-1 | Reference compound |
| HY-153473 | FLT3-IN-19 | 2237234-48-7 | Reference compound |
| HY-153474 | IRE1α kinase-IN-8 | 1338933-29-1 | Reference compound |
| HY-153475 | IRE1α kinase-IN-9 | 1338933-30-4 | Reference compound |
| HY-153476 | GIP/GLP-1 dual receptor agonist-1 | 2807481-02-1 | Peptides |
| HY-153477 | Thyroid hormone receptor beta agonist-1 | 2140902-80-1 | Reference compound |
| HY-153478 | Estrogen receptor modulator 7 | 2639168-13-9 | Reference compound |
| HY-153479 | Aganirsen | 1146887-67-3 | Oligonucleotides |
| HY-153479A | Aganirsen (sodium) | | Oligonucleotides |
| HY-153480 | ARC19499 | 1350667-54-7 | Oligonucleotides |
| HY-153480A | ARC19499 (sodium) | | Oligonucleotides |
| HY-153481 | ATL 1102 | 350263-41-1 | Oligonucleotides |
| HY-153481A | ATL 1102 (sodium) | | Oligonucleotides |
| HY-153482 | ATU027 | 1415935-22-6 | Oligonucleotides |
| HY-153482A | ATU027 (sodium) | | Oligonucleotides |
| HY-153483 | Bamosiran | 1337968-84-9 | Oligonucleotides |
| HY-153483A | Bamosiran (sodium) | | Oligonucleotides |
| HY-153484 | Bevasiranib | 959961-96-7 | Oligonucleotides |
| HY-153484A | Bevasiranib (sodium) | 849758-52-7 | Oligonucleotides |
| HY-153485 | Cimdelirsen | 2131025-82-4 | Oligonucleotides |
| HY-153485A | Cimdelirsen (sodium) | 2131025-83-5 | Oligonucleotides |
| HY-153486 | N3-VC-PAB-PNP | 2285374-43-6 | Reference compound |
| HY-153488 | ISIS 2503 | 149957-14-2 | Oligonucleotides |
| HY-153488A | ISIS 2503 (sodium) | | Oligonucleotides |
| HY-153489 | ISIS 329993 | 827355-42-0 | Oligonucleotides |
| HY-153489A | ISIS 329993 (sodium) | | Oligonucleotides |
| HY-15349 | Trovirdine | 149488-17-5 | Reference compound |
| HY-153490 | ISIS 5132 | 177075-18-2 | Oligonucleotides |
| HY-153490A | ISIS 5132 (sodium) | | Oligonucleotides |
| HY-153491 | Olezarsen | 2097587-83-0 | Oligonucleotides |
| HY-153491A | Olezarsen (sodium) | 2298451-31-5 | Oligonucleotides |
| HY-153492A | Olpasiran (sodium) | | Oligonucleotides |
| HY-153493 | PF-04523655 | 1420046-64-5 | Oligonucleotides |
| HY-153493A | PF-04523655 (sodium) | | Oligonucleotides |
| HY-153494 | Rosomidnar | 871597-03-4 | Oligonucleotides |
| HY-153494A | Rosomidnar (sodium) | | Oligonucleotides |
| HY-153495 | Prexigebersen | 202484-91-1 | Oligonucleotides |
| HY-153495A | Prexigebersen (sodium) | | Oligonucleotides |
| HY-153496 | Sepofarsen | 2227173-68-2 | Oligonucleotides |
| HY-153496A | Sepofarsen (sodium) | | Oligonucleotides |
| HY-153497 | Vupanorsen | 2097587-62-5 | Oligonucleotides |
| HY-153497A | Vupanorsen (sodium) | 2172852-12-7 | Oligonucleotides |
| HY-153499 | SMO-IN-4 | 1567963-99-8 | Reference compound |
| HY-15350 | Trovirdine (hydrochloride) | 148311-89-1 | Reference compound |
| HY-153508 | ANO1-IN-4 | 2098490-06-1 | Reference compound |
| HY-15351 | UC-781 | 178870-32-1 | Reference compound |
| HY-153511 | Rapamycin analog-2 | 2357217-22-0 | Reference compound |
| HY-153516 | NIK-IN-2 | 1202763-91-4 | Reference compound |
| HY-153519 | WWL0245 | 2869057-11-2 | Reference compound |
| HY-15352 | BMS 561390 | 214287-99-7 | Reference compound |
| HY-153521 | CCT374705 | 2640647-90-9 | Reference compound |
| HY-153523 | Hi 76-0079 | 374567-94-9 | Reference compound |
| HY-153524 | ATTO 425 NHS ester | 892156-28-4 | Dye Reagents |
| HY-153525 | FXR agonist 5 | 2414008-05-0 | Reference compound |
| HY-153526 | PI5P4Ks-IN-2 | 2766854-03-7 | Reference compound |
| HY-153527 | GalNac-L96 analog | 1159408-72-6 | Reference compound |
| HY-153528 | DMAA | 73671-86-0 | Natural Products |
| HY-153529 | PI5P4Ks-IN-3 | 2471969-07-8 | Reference compound |
| HY-15353 | Emivirine | 149950-60-7 | Reference compound |
| HY-153530 | LI-2242 | 2762762-17-2 | Reference compound |
| HY-153531 | PI5P4Kα-IN-1 | 2428737-31-7 | Reference compound |
| HY-153532 | CVM-05-002 | 2428738-43-4 | Reference compound |
| HY-153533 | GRL-1720 | 2835511-03-8 | Reference compound |
| HY-153533A | GRL-1720 (TFA) | | Reference compound |
| HY-153534 | microRNA-21-IN-3 | 2766106-83-4 | Reference compound |
| HY-153535 | THRβ receptor agonist-1 | 2403721-00-4 | Reference compound |
| HY-153536 | PROTAC BTK Degrader-3 | 2563861-90-3 | Reference compound |
| HY-153537 | AP-C1 | 2234280-26-1 | Reference compound |
| HY-153538 | AP-C2 | 682793-07-3 | Reference compound |
| HY-153539 | AP-C3 | 682795-78-4 | Reference compound |
| HY-153540 | AP-C4 | 682794-85-0 | Reference compound |
| HY-153541 | AP-C7 | 2234275-84-2 | Reference compound |
| HY-153542 | AP-C6 | 2234276-60-7 | Reference compound |
| HY-153543 | TLR7/8 agonist 8 | 2649170-16-9 | Reference compound |
| HY-153544 | TLR7/8 agonist 9 | 2649170-17-0 | Reference compound |
| HY-153545 | 9-Amino-NeuAc | 153232-60-1 | Reference compound |
| HY-153546 | STING agonist-31 | 2719001-44-0 | Reference compound |
| HY-153547 | HSP90-IN-21 | 2521791-38-6 | Reference compound |
| HY-153548 | P2X2/3 modulator-1 | 1217483-98-1 | Reference compound |
| HY-153549 | Pentixafor | 1341207-62-2 | Peptides |
| HY-15355 | Loviride | 147362-57-0 | Reference compound |
| HY-153550 | PSMA-1007 | 2226894-58-0 | Peptides |
| HY-153551 | HBED-CC-tris(tert-butyl ester) | 2097123-80-1 | Reference compound |
| HY-153551A | HBED-CC-tris(tert-butyl ester) (TFA) | | Reference compound |
| HY-153552 | NH2-UAMC1110 | 2758337-19-6 | Reference compound |
| HY-153552A | NH2-UAMC1110 (TFA) | 2990021-73-1 | Reference compound |
| HY-153553 | HPK1 antagonist-1 | 2628489-56-3 | Reference compound |
| HY-153554 | NLRP3-IN-18 | 2769040-06-2 | Reference compound |
| HY-153555 | KRAS G12D modulator-1 | 2883034-05-5 | Reference compound |
| HY-153556 | GW297361 | 388627-21-2 | Reference compound |
| HY-153557 | HER2-IN-13 | 2414056-34-9 | Reference compound |
| HY-153557A | HER2-IN-14 | 2414056-35-0 | Reference compound |
| HY-153559 | Lp-PLA2-IN-13 | 2756855-62-4 | Reference compound |
| HY-15356 | BIO-acetoxime | 667463-85-6 | Reference compound |
| HY-153560 | Lp-PLA2-IN-14 | 2756855-66-8 | Reference compound |
| HY-153561 | Lp-PLA2-IN-15 | 1865796-11-7 | Reference compound |
| HY-153561A | Lp-PLA2-IN-16 | 1865780-73-9 | Reference compound |
| HY-153563 | MMP-7-IN-2 | 2848717-49-5 | Reference compound |
| HY-153564 | ROCK-IN-6 | 2489328-74-5 | Reference compound |
| HY-153565 | Immune cell migration-IN-1 | 2316683-71-1 | Reference compound |
| HY-153566 | JAK1-IN-10 | 2416858-88-1 | Reference compound |
| HY-153567 | Immune cell migration-IN-2 | 2260679-24-9 | Reference compound |
| HY-153568 | JAK1-IN-11 | 2427608-43-1 | Reference compound |
| HY-153569 | ROCK-IN-7 | 2376635-95-7 | Reference compound |
| HY-15357 | ALK inhibitor 1 | 761436-81-1 | Reference compound |
| HY-153570 | Influenza virus-IN-7 | 2703046-92-6 | Reference compound |
| HY-153571 | Homo-BacPROTAC6 | | Reference compound |
| HY-153573 | SRG-II-19F | | Reference compound |
| HY-153574 | BI01826025 | | Reference compound |
| HY-153575 | BacPROTAC-1 | | Reference compound |
| HY-153576 | Antibacterial agent 143 | 299405-68-8 | Reference compound |
| HY-153577 | WT-TTR inhibitor 1 | 23983-05-3 | Reference compound |
| HY-153579 | Anti-inflammatory agent 42 | 877468-30-9 | Reference compound |
| HY-15358 | ALK inhibitor 2 | 761438-38-4 | Reference compound |
| HY-153580 | WIC1 | 943083-58-7 | Reference compound |
| HY-153581 | ARTD3/PARP3-IN-1 | 730949-09-4 | Reference compound |
| HY-153582 | ML 2-23 | | Reference compound |
| HY-153583 | HDAC8-IN-4 | 1600528-05-9 | Reference compound |
| HY-153584 | MRK-898 | 461450-30-6 | Reference compound |
| HY-153585 | IK-930 | 2563892-44-2 | Reference compound |
| HY-153588 | HSP90-IN-22 | 442898-75-1 | Reference compound |
| HY-15359 | Episilvestrol | 697235-39-5 | Natural Products |
| HY-153590 | PARP-1-IN-4 | 684234-56-8 | Reference compound |
| HY-153591 | ROS-IN-1 | 298193-11-0 | Reference compound |
| HY-153592 | Therapeutic agent-1 | 850020-01-8 | Reference compound |
| HY-153593 | BET bromodomain inhibitor 3 | 854137-39-6 | Reference compound |
| HY-153594 | Bcl-B inhibitor 1 | 79220-88-5 | Reference compound |
| HY-153595 | DAPK-IN-2 | 304000-05-3 | Reference compound |
| HY-153596 | SNX7 | 685097-43-2 | Reference compound |
| HY-153598 | LD4172 | 2782022-40-4 | Reference compound |
| HY-153600 | GGFG-amide-glycol-amide-Exatecan | 2866301-18-8 | ADC Related |
| HY-153601 | MC-VC-PAB-Cyclohexanediamine-Thailanstatin A | 1609108-96-4 | ADC Related |
| HY-153603 | B-Raf IN 15 | 832107-31-0 | Reference compound |
| HY-153604 | MC4171 | | Reference compound |
| HY-153606 | SOS1 agonist-1 | 2245237-61-8 | Reference compound |
| HY-153607 | HDAC-IN-55 | 1268674-16-3 | Reference compound |
| HY-153608 | JHDM-IN-1 | 1310809-17-6 | Reference compound |
| HY-153609 | AS-Patisiran (sodium) | | Oligonucleotides |
| HY-153610 | ARC7 | 681212-58-8 | Reference compound |
| HY-153611 | ARC12 | 64433-38-1 | Reference compound |
| HY-153612 | MMV009085 | 298217-59-1 | Reference compound |
| HY-153613 | Ac-PLVE-FMK | 2679825-26-2 | Reference compound |
| HY-153614 | Ac-VLPE-FMK | 2679825-27-3 | Reference compound |
| HY-153615 | CVN636 | 2226732-62-1 | Reference compound |
| HY-153617 | FOXO1-IN-3 | 2451093-95-9 | Reference compound |
| HY-153618 | Antifungal agent 53 | 2422019-76-7 | Reference compound |
| HY-153619 | Antifungal agent 54 | 2422019-78-9 | Reference compound |
| HY-153620 | Antifungal agent 55 | 2422019-80-3 | Reference compound |
| HY-153621 | Antifungal agent 56 | 2422019-82-5 | Reference compound |
| HY-153622 | Antifungal agent 57 | 2422019-92-7 | Reference compound |
| HY-153623 | Antifungal agent 58 | 2422019-94-9 | Reference compound |
| HY-153624 | Antifungal agent 59 | 2422019-96-1 | Reference compound |
| HY-153625 | STM2120 | 2762286-04-2 | Reference compound |
| HY-153626 | Chlamydia pneumoniae-IN-1 | 518010-44-1 | Reference compound |
| HY-153627 | GK13S | | Reference compound |
| HY-153628 | GPAT-IN-1 | 1204347-51-2 | Reference compound |
| HY-153629 | FSEN1 | 862808-01-3 | Reference compound |
| HY-153631 | Sulfo-TAG NHS ester (disodium) | 482618-42-8 | lead-like compound library |
| HY-153632 | PROTAC BRD9 Degrader-6 | 2676211-62-2 | Reference compound |
| HY-153637 | THR-β modulator-1 | 2770373-00-5 | Reference compound |
| HY-153638 | PTPN2/1-IN-2 | 2407611-02-1 | Reference compound |
| HY-153640 | AKT-IN-14 | 2781918-35-0 | Reference compound |
| HY-153640A | AKT-IN-14 (free base) | 2781918-27-0 | Reference compound |
| HY-153642 | MMAE-PAB(p-glucuronide)-PEG3-aminooxy | 1835250-20-8 | ADC Related |
| HY-153650 | JS11 | 1394592-04-1 | Reference compound |
| HY-153660 | Bivamelagon | 2641595-54-0 | Reference compound |
| HY-153660A | Bivamelagon (hydrochloride) | 2641595-55-1 | Reference compound |
| HY-153661 | Cereblon inhibitor 2 | 2639380-62-2 | Reference compound |
| HY-153662 | TH-Z816 | 2847881-42-7 | Reference compound |
| HY-153663 | TH-Z827 | 2847881-81-4 | Reference compound |
| HY-153665 | Deg-1 | 2761446-55-1 | Reference compound |
| HY-153668 | Bromodomain inhibitor-12 | 2010124-06-6 | Reference compound |
| HY-153668A | Bromodomain inhibitor-12 (edisylate) | 2010124-27-1 | Reference compound |
| HY-153669 | SB-649701 | 935262-95-6 | Reference compound |
| HY-153670 | IPG7236 | 2756350-91-9 | Reference compound |
| HY-153671 | 4'-Methyl-β-naphthoflavone | 1282513-75-0 | Reference compound |
| HY-153672 | Amine-PEG3-Lys(PEG3-N3)-PEG3-N3 | 2244602-35-3 | ADC Related |
| HY-153673 | PROTAC IRAK4 degrader-8 | 2911615-06-8 | Reference compound |
| HY-153674 | PROTAC SOS1 degrader-4 | | Reference compound |
| HY-153675 | BCPA | 547731-67-9 | Reference compound |
| HY-153676 | RET-IN-23 | 2479961-46-9 | Reference compound |
| HY-153678 | β-Catenin modulator-1 | 1053086-89-7 | Reference compound |
| HY-153679 | β-Catenin modulator-2 | 1015858-71-5 | Reference compound |
| HY-153680 | β-Catenin modulator-3 | 1015858-17-9 | Reference compound |
| HY-153681 | β-Catenin modulator-4 | 901751-85-7 | Reference compound |
| HY-153682 | β-Catenin modulator-5 | 902168-07-4 | Reference compound |
| HY-153686 | BVFP | 357158-20-4 | Reference compound |
| HY-153687 | SORT-PGRN interaction inhibitor 2 | 1008233-79-1 | Reference compound |
| HY-153688 | SORT-PGRN interaction inhibitor 3 | 2691846-87-2 | Reference compound |
| HY-15369 | FPA-124 | 902779-59-3 | Reference compound |
| HY-153690 | Progranulin modulator-1 | 2641013-11-6 | Reference compound |
| HY-153691 | BTB01303 | 652129-89-0 | Reference compound |
| HY-153692 | WRN inhibitor 1 | 2923008-44-8 | Reference compound |
| HY-153692A | (R)-WRN inhibitor 1 | | Reference compound |
| HY-153695 | TXA707 | 1609670-89-4 | Reference compound |
| HY-153697 | FAK-IN-10 | 491839-65-7 | Reference compound |
| HY-153698 | CC-3060 | 444288-86-2 | Reference compound |
| HY-153699 | SHP2-IN-14 | 2673400-91-2 | Reference compound |
| HY-15370 | SB-269970 | 201038-74-6 | Reference compound |
| HY-153700 | Estrogen receptor modulator 8 | 2170766-56-8 | Reference compound |
| HY-153701 | JAK-IN-26 | 2417134-93-9 | Reference compound |
| HY-153701S | Envudeucitinibum | 2417135-66-9 | Isotope-Labeled Compounds |
| HY-153702 | JAK-IN-27 | 2673176-36-6 | Reference compound |
| HY-153703 | PI3Kγ inhibitor 7 | 2575863-25-9 | Reference compound |
| HY-153704 | CDK4/6-IN-17 | 2035069-96-4 | Reference compound |
| HY-153705 | BTK-IN-25 | 2562351-92-0 | Reference compound |
| HY-153706 | URAT1 inhibitor 5 | 2102670-94-8 | Reference compound |
| HY-153708 | SGC-CLK-1 | 748142-15-6 | Reference compound |
| HY-15370A | SB-269970 (hydrochloride) | 261901-57-9 | Reference compound |
| HY-15371 | Forskolin | 66575-29-9 | Natural Products |
| HY-153710 | P2X3 antagonist 38 | 2545974-71-6 | Reference compound |
| HY-153711 | TRPA1-IN-2 | 2415206-22-1 | Reference compound |
| HY-153712 | JAK-IN-28 | 2445500-22-9 | Reference compound |
| HY-153713 | MYC-RIBOTAC | | Reference compound |
| HY-153714 | BN-104 | 2938995-50-5 | Reference compound |
| HY-153715 | NV-354 | 866465-21-6 | Reference compound |
| HY-153717 | LAU-0901 | 727358-25-0 | Reference compound |
| HY-153719 | NSC111552 | 40420-48-2 | Reference compound |
| HY-15371G | Forskolin (GMP) | 66575-29-9 | Reference compound |
| HY-15371R | Forskolin (Standard) | 66575-29-9 | Reference Standards |
| HY-15372 | GW6471 | 880635-03-0 | Reference compound |
| HY-153722 | Dodicin | 6843-97-6 | Reference compound |
| HY-153722A | Dodicin (hydrochloride) | 36895-38-2 | Reference compound |
| HY-153723 | BI-2493 | 2937344-16-4 | Reference compound |
| HY-153724 | BI-2865 | 2937327-93-8 | Reference compound |
| HY-153725 | 17:1 Lyso PC | 1246304-62-0 | Oligonucleotides |
| HY-153728 | WM-586 | 2894832-05-2 | Reference compound |
| HY-153728A | (R)-WM-586 | | Reference compound |
| HY-153729 | ATR-IN-29 | 2761193-67-1 | Reference compound |
| HY-15373 | Fenretinide | 65646-68-6 | Reference compound |
| HY-153730 | Hedgehog IN-5 | 1544681-93-7 | Reference compound |
| HY-153731 | USP1-IN-4 | 2878441-72-4 | Reference compound |
| HY-153732 | Insecticidal agent 2 | 201593-85-3 | Reference compound |
| HY-153733 | PDE5-IN-8 | 1233518-60-9 | Reference compound |
| HY-153734 | Inactive ASO (in vivo) sodium | | Oligonucleotides |
| HY-153735 | ERK-CLIPTAC | 2087490-46-6 | Reference compound |
| HY-153736 | NSC 194308 | 90379-42-3 | Reference compound |
| HY-153737 | 113-N16B | | Oligonucleotides |
| HY-153738 | ERK1/2 inhibitor 9 | 2169302-75-2 | Reference compound |
| HY-153739 | N3-PEG3-VC-PAB-MMAF | 2757277-32-8 | ADC Related |
| HY-15373R | Fenretinide (Standard) | 65646-68-6 | Reference Standards |
| HY-15374 | Frentizole | 26130-02-9 | Reference compound |
| HY-153740 | PF-07284892 | 2498597-94-5 | Reference compound |
| HY-153743 | Protein kinase inhibitor 4 | 2278205-04-0 | Reference compound |
| HY-153744 | JGK-068S | 2490431-16-6 | Reference compound |
| HY-153745 | Protein kinase inhibitor 5 | 2278204-94-5 | Reference compound |
| HY-153745A | Protein kinase inhibitor 5 (sulfate hydrate) | | Reference compound |
| HY-153746 | Kv3 modulator 5 | 1380696-68-3 | Reference compound |
| HY-153747 | Casein kinase 1δ-IN-4 | 851168-98-4 | Reference compound |
| HY-153748 | ML162-yne | 2883115-46-4 | Reference compound |
| HY-153749 | Nek2/Hec1-IN-2 | 544416-00-4 | Reference compound |
| HY-15375 | Allitinib | 897383-62-9 | Reference compound |
| HY-153750 | Wnt pathway inhibitor 3 | 663213-98-7 | Reference compound |
| HY-153751 | BRD4-IN-4 | 304685-40-3 | Reference compound |
| HY-153752 | TAO Kinase inhibitor 2 | 850467-77-5 | Reference compound |
| HY-153753 | Wnt pathway inhibitor 4 | 663214-57-1 | Reference compound |
| HY-153754 | Phosphatidylcholine transfer protein inhibitor-1 | 379723-99-6 | Reference compound |
| HY-153755 | Polθ-IN-7 | 2923356-52-7 | Reference compound |
| HY-153756 | GFP16 | 749212-56-4 | Reference compound |
| HY-153757 | Antioxidant agent-11 | 474379-42-5 | Reference compound |
| HY-153758 | Antiviral agent 30 | 381731-49-3 | Reference compound |
| HY-153759 | CRX000227 | 686769-92-6 | Reference compound |
| HY-15376 | Besipirdine | 119257-34-0 | Reference compound |
| HY-153760 | GSK-3β inhibitor 14 | 863004-48-2 | Reference compound |
| HY-153761 | ASK1-IN-4 | 1427538-26-8 | Reference compound |
| HY-153762 | COX-2-IN-32 | 2725863-08-9 | Reference compound |
| HY-153763 | PROT-IN-1 | 329935-45-7 | Reference compound |
| HY-153764 | IDO-IN-18 | 314027-92-4 | Reference compound |
| HY-153766 | PDE5-IN-9 | 157862-84-5 | Reference compound |
| HY-153767 | PK095 | 380314-37-4 | Reference compound |
| HY-153768 | KAT modulator-1 | 1314006-43-3 | Reference compound |
| HY-15377 | DL-Gabaculine (hydrochloride) | 59556-17-1 | Reference compound |
| HY-153770 | DHPN | 308123-27-5 | Reference compound |
| HY-153771 | Du011 | 890818-51-6 | Reference compound |
| HY-153772 | Androgen receptor antagonist 8 | 1572045-29-4 | Reference compound |
| HY-153773 | Z4P | 2361760-87-2 | Reference compound |
| HY-153775 | UC-764864 | 278806-03-4 | Reference compound |
| HY-15378 | Talibegron (hydrochloride) | 178600-17-4 | Reference compound |
| HY-153780 | Navepdekinra | 2467732-66-5 | Reference compound |
| HY-153782 | GSK878 | 2417048-11-2 | Reference compound |
| HY-153783 | OBI | | Dye Reagents |
| HY-153785 | NH2-C6-ARC186 (sodium) | | Oligonucleotides |
| HY-153787 | ATM Inhibitor-6 | 2765544-85-0 | Reference compound |
| HY-153788 | CK2-IN-7 | 2825012-70-0 | Reference compound |
| HY-153789 | PI5P4Kγ-IN-1 | 2419358-87-3 | Reference compound |
| HY-15379 | Atevirdine | 136816-75-6 | Reference compound |
| HY-153790 | FEN1-IN-5 | 824983-93-9 | Reference compound |
| HY-153791 | FEN1-IN-6 | 824983-84-8 | Reference compound |
| HY-153792 | FEN1-IN-7 | 824983-90-6 | Reference compound |
| HY-153793 | DGKζ-IN-1 | 2660218-70-0 | Reference compound |
| HY-153795 | Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan | 1599439-54-9 | ADC Related |
| HY-153796 | PROTAC Her3 Degrader-8 | 2103331-95-7 | Reference compound |
| HY-153797 | Dox-btn2 | 3026061-31-1 | Reference compound |
| HY-153798 | GLP-1 receptor agonist 10 | 3015555-46-8 | Reference compound |
| HY-15380 | PNU‐142721 | 185220-03-5 | Reference compound |
| HY-153800 | Monlunabant | 2712480-46-9 | Reference compound |
| HY-153800A | (R)-Monlunabant | 2765579-76-6 | Reference compound |
| HY-153802 | Antitumor agent-100 | 2841750-32-9 | Reference compound |
| HY-153802A | Antitumor agent-100 (hydrochloride) | 2841750-53-4 | Reference compound |
| HY-153803 | GBD-9 | 2864408-92-2 | Reference compound |
| HY-153804 | Naphthyridine carbamate dimer | 864627-58-7 | Reference compound |
| HY-153805 | Z-NCTS | 1373391-77-5 | Reference compound |
| HY-153806 | RapaBlock | 2474076-02-1 | Reference compound |
| HY-153807 | αvβ6 integrin inhibitor 2 | 313709-47-6 | Reference compound |
| HY-153808 | Complete Freund's adjuvant (CFA) | 9007-81-2 | Reference compound |
| HY-153808A | Incomplete Freund's adjuvant (IFA) | | Reference compound |
| HY-153808B | Complete Freund's adjuvant (CFA, 1 mg/ml) | 9007-81-2 | Reference compound |
| HY-15381 | Fingolimod phosphate | 402615-91-2 | Reference compound |
| HY-153810 | Mosnodenvir | 2890688-86-3 | Reference compound |
| HY-153811 | IAG933 | 2714434-21-4 | Reference compound |
| HY-153812 | AST 7062601 | 675197-89-4 | Reference compound |
| HY-153813 | Z16078526 | 852222-94-7 | Reference compound |
| HY-153815 | GLP-1 receptor agonist 11 | 2784590-83-4 | Reference compound |
| HY-153816 | GLP-1 receptor agonist 12 | 2775376-50-4 | Reference compound |
| HY-153816A | (1R)-GLP-1 receptor agonist 12 | 2775376-51-5 | Reference compound |
| HY-153817 | FXIa-IN-13 | 2629361-99-3 | Reference compound |
| HY-153818 | Sperm motility agonist-1 | 1796991-30-4 | Reference compound |
| HY-153819 | Sperm motility agonist-2 | 926079-67-6 | Reference compound |
| HY-15381S | Fingolimod phosphate-d4 | 1794828-93-5 | Isotope-Labeled Compounds |
| HY-15382 | FTY720 (S)-Phosphate | 402616-26-6 | Reference compound |
| HY-153820 | PROTAC BRD4 Degrader-20 | 2086300-61-8 | Reference compound |
| HY-153821 | PROTAC KRAS G12C degrader-2 | 2378257-72-6 | Reference compound |
| HY-153822 | JG-23 | 2640819-75-4 | Reference compound |
| HY-153829 | CH3OCO-D-CHA-Gly-Arg-pNA (acetate) | 80895-10-9 | Reference compound |
| HY-15382A | (S)-FTY720-phosphonate | 1142015-10-8 | Reference compound |
| HY-15383 | Glyparamide | 5581-42-0 | Reference compound |
| HY-153830 | LacCer (d18:1/16:0) | 4201-62-1 | Natural Products |
| HY-153831 | c-Met-IN-17 | 3034863-55-0 | Reference compound |
| HY-153832 | MSU-42011 | 2456434-36-7 | Reference compound |
| HY-153833 | PDS-0330 | 2904682-19-3 | Reference compound |
| HY-153834 | GTI 2040 | 236391-66-5 | Oligonucleotides |
| HY-153834A | GTI 2040 (sodium) | | Oligonucleotides |
| HY-153835 | Pegnivacogin | 959716-28-0 | Oligonucleotides |
| HY-153835A | Pegnivacogin (sodium) | | Oligonucleotides |
| HY-153836 | Anivamersen | 959716-29-1 | Oligonucleotides |
| HY-153836A | Anivamersen (sodium) | 959716-31-5 | Oligonucleotides |
| HY-153837 | ISIS 14803 | 223603-41-6 | Oligonucleotides |
| HY-153837A | ISIS 14803 (sodium) | | Oligonucleotides |
| HY-153838 | ODN 5328 | 500239-51-0 | Oligonucleotides |
| HY-153838A | ODN 5328 (sodium) | | Oligonucleotides |
| HY-153839 | ODN 4084-F | 1934318-44-1 | Oligonucleotides |
| HY-153839A | ODN 4084-F (sodium) | | Oligonucleotides |
| HY-15384 | Picoprazole | 78090-11-6 | Reference compound |
| HY-153840 | ODN INH 18 | 1934318-43-0 | Oligonucleotides |
| HY-153840A | ODN INH 18 (sodium) | | Oligonucleotides |
| HY-153840B | ODN INH 18 (triethylamine) | | Oligonucleotides |
| HY-153841 | ODN INH-1 | 1934318-42-9 | Oligonucleotides |
| HY-153841A | ODN INH-1 (sodium) | | Oligonucleotides |
| HY-153843 | RNA Aptamer Corn (sodium) | | Oligonucleotides |
| HY-153845 | RNA Aptamer Broccoli (sodium) | | Oligonucleotides |
| HY-153846 | RNA Aptamer Mango I (sodium) | | Oligonucleotides |
| HY-153847 | RNA Aptamer Mango ΙΙ (sodium) | | Oligonucleotides |
| HY-153848 | RNA Aptamer Mango Ⅳ (sodium) | | Oligonucleotides |
| HY-153849 | RNA Aptamer Mango Ⅲ (sodium) | | Oligonucleotides |
| HY-15385 | Imexon | 59643-91-3 | Reference compound |
| HY-153850 | RNA Aptamer Peach I (sodium) | | Oligonucleotides |
| HY-153851 | RNA Aptamer Peach Ⅱ (sodium) | | Oligonucleotides |
| HY-153852 | LNP Lipid-7 | 1190203-55-4 | Oligonucleotides |
| HY-153855 | Zamaporvint | 1900754-56-4 | Reference compound |
| HY-153856 | TAS2940 | 2451398-65-3 | Reference compound |
| HY-153856A | TAS2940 (fumarate) | 2758034-98-7 | Reference compound |
| HY-153857 | Lasmotinib | 2127107-15-5 | Reference compound |
| HY-153859 | Ser-SNAC (TFA) | 322650-05-5 | Reference compound |
| HY-15386 | Cimoxatone | 73815-11-9 | Reference compound |
| HY-153863 | MS934 | 2756323-15-4 | Reference compound |
| HY-153864 | PROTAC MEK1 Degrader-1 | 2671004-41-2 | Reference compound |
| HY-153865 | Lotiglipron | 2401892-75-7 | Reference compound |
| HY-153866 | CK1-IN-2 | 1383376-92-8 | Reference compound |
| HY-153866A | CK1-IN-2 (hydrochloride) | 1383377-49-8 | Reference compound |
| HY-15387 | Beclobrate | 55937-99-0 | Reference compound |
| HY-153873 | MSU38225 | 1629160-83-3 | Reference compound |
| HY-153878 | BCAT-IN-4 | 406190-85-0 | Reference compound |
| HY-153879 | C12-TLRa | | Reference compound |
| HY-15388 | Tazarotene | 118292-40-3 | Reference compound |
| HY-153880 | KRAS degrader-1 | 2795275-59-9 | Reference compound |
| HY-153881 | KRAS G12C degrader-1 | 2768099-51-8 | Reference compound |
| HY-153882 | 3'-DMTr-dA | 140712-82-9 | Oligonucleotides |
| HY-153886 | Wu-5 | 2630378-05-9 | Reference compound |
| HY-153887 | HyT36(-Cl) | | Reference compound |
| HY-153888 | M351-110 | 1215797-40-2 | Reference compound |
| HY-153889 | BTA-EG4 | 921193-28-4 | Reference compound |
| HY-15388R | Tazarotene (Standard) | 118292-40-3 | Reference Standards |
| HY-15388S | Tazarotene-d8 | | Isotope-Labeled Compounds |
| HY-15388S1 | Tazarotene-13C2,d2 | 2703541-64-2 | Isotope-Labeled Compounds |
| HY-15388S2 | Tazarotene-13C6 | | Isotope-Labeled Compounds |
| HY-15388S3 | Tazarotene-d6 | 1246815-76-8 | Isotope-Labeled Compounds |
| HY-153890 | NVOC cage-TMP-Halo | 2137894-98-3 | Reference compound |
| HY-153891 | Deruxtecan 2-hydroxypropanamide | 2577204-16-9 | Reference compound |
| HY-153891S | Deruxtecan 2-hydroxypropanamide-d5 | | Isotope-Labeled Compounds |
| HY-153892 | Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide | 2750623-07-3 | ADC Related |
| HY-153893 | Magmas-IN-1 | 1251957-89-7 | Reference compound |
| HY-153894 | SRX3177 | 2241237-51-2 | Reference compound |
| HY-153895 | SLU-PP-1072 | 2285432-57-5 | Reference compound |
| HY-153896 | LMTK3-IN-1 | 2764850-23-7 | Reference compound |
| HY-153897 | PSB-1901 | 2332835-02-4 | Reference compound |
| HY-153898 | rTRD01 | 1332175-56-0 | Reference compound |
| HY-153899 | KRAS G12C inhibitor 59 | 2914919-88-1 | Reference compound |
| HY-15390 | Thiambutosine | 500-89-0 | Reference compound |
| HY-153900 | TLR8 agonist 6 | 2616605-55-9 | Reference compound |
| HY-153901 | PROTAC EGFR degrader 8 | 2925923-46-0 | Reference compound |
| HY-153902 | DG-8 | | Dye Reagents |
| HY-153903 | RASP-IN-1 | 916056-81-0 | Reference compound |
| HY-153904 | Casein kinase 1δ-IN-5 | 1579991-10-8 | Reference compound |
| HY-153905 | Casein kinase 1δ-IN-6 | 1579991-01-7 | Reference compound |
| HY-153907 | SMP-88480 | | ADC Related |
| HY-153908 | SMP-93566 | | ADC Related |
| HY-153909 | SMP-33693 | | ADC Related |
| HY-15391 | Lucitanib | 1058137-23-7 | Reference compound |
| HY-153910 | AGPS-IN-1 | 2316782-88-2 | Reference compound |
| HY-153911 | H2-Gamendazole | 877768-84-8 | Reference compound |
| HY-153912 | 5-HT2A receptor agonist-3 | 1391499-52-7 | Reference compound |
| HY-153913 | MMP-9-IN-7 | 333746-76-2 | Reference compound |
| HY-153914 | B-Raf IN 14 | 326918-98-3 | Reference compound |
| HY-153915 | PI3Kα-IN-11 | 300803-79-6 | Reference compound |
| HY-153916 | TCRS-417 | 2032123-28-5 | Reference compound |
| HY-153917 | CRT0063465 | | Reference compound |
| HY-153918 | (R)-SKBG-1 | 2955634-67-8 | Reference compound |
| HY-153918A | (S)-SKBG-1 | 2955618-24-1 | Reference compound |
| HY-15391A | Lucitanib (dihydrochloride) | 2108875-91-6 | Reference compound |
| HY-15392 | Chroman 1 | 1273579-40-0 | Reference compound |
| HY-153920 | Pimicotinib | 2253123-16-7 | Reference compound |
| HY-153920A | Pimicotinib (hydrochloride) | 2866305-19-1 | Reference compound |
| HY-153921 | DEPN-8 | 135822-00-3 | Reference compound |
| HY-15392A | Chroman 1 (dihydrochloride) | | Reference compound |
| HY-15393 | VU 0357121 | 433967-28-3 | Reference compound |
| HY-153930 | h15-LOX-2 inhibitor 1 | 478040-08-3 | Reference compound |
| HY-153932 | NR-7h | 2550399-06-7 | Reference compound |
| HY-153934 | Tetrazole-C15-(N-acetylsulfamoyl)butanoic acid | 873874-16-9 | Reference compound |
| HY-153935 | EP4-IN-1 | 2455480-28-9 | Reference compound |
| HY-153936 | Methyl 12-methyltridecanoate | 5129-58-8 | Reference compound |
| HY-153937 | Skp2 inhibitor 2 | 2760612-77-7 | Reference compound |
| HY-153938 | PROTAC PTPN2 degrader-2 | 2912307-38-9 | Reference compound |
| HY-153938A | PROTAC PTPN2 degrader-2 (TFA) | 2912307-39-0 | Reference compound |
| HY-153939S | Idasanutlin-d3-1 | | Isotope-Labeled Compounds |
| HY-15394 | (Rac)-Rotigotine (hydrochloride) | 102120-99-0 | Reference compound |
| HY-153940 | SOS1/KRAS-IN-1 | 2836330-34-6 | Reference compound |
| HY-153941 | RET-IN-24 | 2583767-68-2 | Reference compound |
| HY-153942 | USP7-IN-12 | 2763698-01-5 | Reference compound |
| HY-153943 | DNA-PK-IN-10 | 2919315-89-0 | Reference compound |
| HY-153944 | KRAS G12C inhibitor 60 | | Reference compound |
| HY-153945 | BET-IN-15 | 2408994-22-7 | Reference compound |
| HY-153947 | PB089 | 2892336-54-6 | ADC Related |
| HY-153948 | CBP-IN-1 | 1936431-44-5 | Reference compound |
| HY-153949 | YK-2-69 | 2619846-89-6 | Reference compound |
| HY-15394A | (Rac)-Rotigotine | 92206-54-7 | Reference compound |
| HY-15394S | (Rac)-Rotigotine-d7 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-15394S1 | (Rac)-Rotigotine-d3 (hydrochloride) | 1215846-20-0 | Isotope-Labeled Compounds |
| HY-153950 | CDK7-IN-22 | 2173190-60-6 | Reference compound |
| HY-153951S | BTK-IN-26 | 2762043-61-6 | Isotope-Labeled Compounds |
| HY-153952 | Immuno modulator-1 | 2757469-20-6 | Reference compound |
| HY-153953 | Bcl-2-IN-11 | 2760536-88-5 | Reference compound |
| HY-153958 | PDS-MMAE | 1613113-44-2 | ADC Related |
| HY-153959 | Thalidomide-O-amido-C11-COOH | 2473270-96-9 | Reference compound |
| HY-153962 | SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 | 1373170-36-5 | Reference compound |
| HY-153963 | PF-06655075 | | Peptides |
| HY-153963A | PF-06655075 (TFA) | | Peptides |
| HY-153964 | PF-06478939 | | Peptides |
| HY-153964A | PF-06478939 (TFA) | | Peptides |
| HY-153967 | BLU0588 | 2810747-78-3 | Reference compound |
| HY-153968 | URAT1&XO inhibitor 1 | 2669726-78-5 | Reference compound |
| HY-153969 | URAT1 inhibitor 6 | 2244807-49-4 | Reference compound |
| HY-153970 | URAT1 inhibitor 7 | 1632002-28-8 | Reference compound |
| HY-153971 | URAT1 inhibitor 8 | 1632005-33-4 | Reference compound |
| HY-153972 | URAT1&XO inhibitor 2 | 1239488-96-0 | Reference compound |
| HY-153973 | WRN inhibitor 2 | 2923009-56-5 | Reference compound |
| HY-153976 | Fmoc-Gly3-VC-PAB-MMAE | | ADC Related |
| HY-153977 | GLX481304 | 701224-63-7 | Reference compound |
| HY-153978 | GLX481369 | | Reference compound |
| HY-15398 | Vitamin D3 | 67-97-0 | Natural Products |
| HY-153980 | K-80001 | 242800-40-4 | Reference compound |
| HY-153982 | PPARγ agonist 8 | 1049800-41-0 | Reference compound |
| HY-153986 | AEP-IN-2 | 2565572-83-8 | Reference compound |
| HY-153987 | STING agonist-33 | 2591300-32-0 | Reference compound |
| HY-153989 | SOS1-IN-16 | 2930763-85-0 | Reference compound |
| HY-15398A | 5,6-trans-Vitamin D3 | 22350-41-0 | Reference compound |
| HY-15398AR | 5,6-trans-Vitamin D3 (Standard) | 22350-41-0 | Reference Standards |
| HY-15398C | 3-epi-Vitamin D3 | 57651-82-8 | Reference compound |
| HY-15398R | Vitamin D3 (Standard) | 67-97-0 | Reference Standards |
| HY-15398S | Vitamin D3-d7 | 1627523-19-6 | Isotope-Labeled Compounds |
| HY-15398S1 | Vitamin D3-13C3 | | Isotope-Labeled Compounds |
| HY-15398S3 | Vitamin D3-d3 | 80666-48-4 | Isotope-Labeled Compounds |
| HY-15398S4 | Vitamin D3-13C5 | | Isotope-Labeled Compounds |
| HY-15399 | Vigabatrin | 68506-86-5 | Reference compound |
| HY-153990 | FKBP51F67V-selective antagonist Ligand2 | 1680228-76-5 | Reference compound |
| HY-153991 | STAT6-IN-2 | 1355594-85-2 | Reference compound |
| HY-153992 | STAT6-IN-3 | 371919-80-1 | Reference compound |
| HY-153993 | Pyrocatechol sulfate | 4918-96-1 | Natural Products |
| HY-153995A | D-Ribonic acid | 642-98-8 | Reference compound |
| HY-153996 | CT1113 | 2523435-18-7 | Reference compound |
| HY-153998 | BT100 (sodium) | | Oligonucleotides |
| HY-153999 | BT200 | | Oligonucleotides |
| HY-153999A | BT200 (sodium) | | Oligonucleotides |
| HY-15399R | Vigabatrin (Standard) | 68506-86-5 | Reference Standards |
| HY-15400 | Boc-D-Thr(Bzl)-OH | 69355-99-3 | Peptides |
| HY-154000 | 3,5’-Bis(O-t-butyldimethylsilyl)-2’-O-methyl-5-methyl cytidine | | Oligonucleotides |
| HY-154001 | 2'-Deoxy-8-methylthioguanosine | 157946-92-4 | Oligonucleotides |
| HY-154002 | 4-Amino-5-cyano-1-(2-deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine | | Oligonucleotides |
| HY-154003 | 7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine | 93366-89-3 | Oligonucleotides |
| HY-154005 | 4-Amino-6-bromo-5-cyano-1-(beta-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine | 1203470-58-9 | Oligonucleotides |
| HY-154008 | 6-Amino-4-methoxy-1-(2-deoxy-β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine | 100644-69-7 | Oligonucleotides |
| HY-15401 | WAY 163909 | 428868-32-0 | Reference compound |
| HY-154011 | 8-Amino-2′-deoxyadenosine | 13389-09-8 | Oligonucleotides |
| HY-154012 | 2'-Deoxy-8-methylamino-adenosine | 13389-10-1 | Oligonucleotides |
| HY-154016 | 5'-DMTr-dG(iBu)-Methyl phosphonamidite | 115131-08-3 | Oligonucleotides |
| HY-154017 | 2′-C-Methyl-6-O-methylinosine | 565450-78-4 | Oligonucleotides |
| HY-154018 | N4-Benzoyl-5-methylcytidine | 160107-15-3 | Oligonucleotides |
| HY-154019 | N4-Benzoyl-5'-O-DMT-5-methylcytidine | 160107-17-5 | Oligonucleotides |
| HY-15401A | WAY 163909 (hydrochloride) | 428868-35-3 | Reference compound |
| HY-15402 | Edonentan | 210891-04-6 | Reference compound |
| HY-154021A | 5-Fluoromethylornithine (dihydrochloride) | 124796-41-4 | Reference compound |
| HY-154023 | 5’-O-Benzoyl-2’,3’-di-O-acetyl-4’-C-fluoromethyluridine | | Oligonucleotides |
| HY-154024 | N4-Benzoyl-2’-O-(2-methoxyethyl)cytidine | 2305416-18-4 | Oligonucleotides |
| HY-154025 | 8-Azido-2′-deoxyadenosine | 131265-35-5 | Oligonucleotides |
| HY-154026 | 5-Amino-2'-deoxyuridine (monohydrochloride) | 73446-40-9 | Oligonucleotides |
| HY-154029 | 3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one | 1058167-74-0 | Oligonucleotides |
| HY-15402D | Edonentan (hydrate) | 264609-13-4 | Reference compound |
| HY-15403 | Atrasentan | 173937-91-2 | Reference compound |
| HY-154030 | N6-Benzoyl-3'-deoxy-5'-O-DMT-3'-fluoroadenosine | 170871-87-1 | Oligonucleotides |
| HY-154031 | 3'-F-3'-dA(Bz)-2'-Phosphoramidite | 2127174-09-6 | Oligonucleotides |
| HY-154034 | 5'-DMTr-T-Methyl phosphonamidite | 114079-04-8 | Oligonucleotides |
| HY-154035 | N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-2’-deoxycytidine | 121058-82-0 | Oligonucleotides |
| HY-154036 | 5′-DMTr-dC (Ac)-Methylphosphonamidite | 178094-78-5 | Oligonucleotides |
| HY-154037 | N6-Benzoyl-3'-fluoro-2',3'-dideoxyadenosine | 122712-71-4 | Oligonucleotides |
| HY-154038 | 2′,3′-Dideoxy-3′-fluoroadenosine | 87418-35-7 | Oligonucleotides |
| HY-15403A | Atrasentan (hydrochloride) | 195733-43-8 | Reference compound |
| HY-15404 | Darusentan | 171714-84-4 | Reference compound |
| HY-154040 | 5’-O-Benzoyl-3’-O-(4-methoxybenzyl)-2’-O,4’-C-methyleneuridine | | Oligonucleotides |
| HY-154042 | 5’-Azido-5’-deoxy-2’-O,4’-C-methyleneuridine | 2305415-75-0 | Oligonucleotides |
| HY-154044 | 3-Deoxy-1,2-O-isopropylidene-5-p-toluoyl-a-D-glycero-pent-3-enofuranose | 75096-63-8 | Oligonucleotides |
| HY-154045 | 3’-Deoxy-1,2-O-isopropylidene-5-O-(p-toluoyl)-L-arabinofuranose | 2072145-19-6 | Oligonucleotides |
| HY-154046 | 4,6-Diamino-1-(2-deoxy-beta-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine | 117818-23-2 | Oligonucleotides |
| HY-154047 | 6-Amino-4-hydrozino-1-(2-deoxy-β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine | | Oligonucleotides |
| HY-15405 | Teriflunomide | 163451-81-8 | Reference compound |
| HY-154050 | 3′-Chloro-3′-deoxy-5′-O-(triphenylmethyl)thymidine | 34627-62-8 | Oligonucleotides |
| HY-154052 | 5′-Amino-2′,5′-dideoxyuridine | 35959-38-7 | Oligonucleotides |
| HY-154054 | 5′-Azido-5′-deoxyadenosine | 737-76-8 | Oligonucleotides |
| HY-154055 | 5′-Azido-2′,5′-dideoxyadenosine | 42204-43-3 | Oligonucleotides |
| HY-154056 | 2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-3-deazauridine | 2072145-54-9 | Oligonucleotides |
| HY-154057 | 5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-2(1H)-pyridinone | | Oligonucleotides |
| HY-154058 | 9-(2-Deoxy-β-D-threo-pentofuranosyl)-9H-purin-6-amine | 13276-53-4 | Oligonucleotides |
| HY-154059 | 2’-Deoxy-2’-fluorouridine 5’-monophosphate triethyl ammonium | | Oligonucleotides |
| HY-15405R | Teriflunomide (Standard) | 163451-81-8 | Reference Standards |
| HY-15406 | BNC105P | 945771-96-0 | Reference compound |
| HY-154060 | N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-methoxyethyl)adenosine | 256224-00-7 | Oligonucleotides |
| HY-154061 | 2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-fluorouridine | 2072145-49-2 | Oligonucleotides |
| HY-154062 | 5'-DMTr-dA(Bz)-Methyl phosphonamidite | 114079-05-9 | Oligonucleotides |
| HY-154064 | 3’-O-MOE-A(Bz)-2’-CED-phosphoramidite | 256224-01-8 | Oligonucleotides |
| HY-154066 | 3’-Deoxy-3’-flluoro-3-deazauridine | 2072145-34-5 | Oligonucleotides |
| HY-15407 | Sacubitril | 149709-62-6 | Reference compound |
| HY-154071 | 2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methyluridine | 2072145-23-2 | Oligonucleotides |
| HY-154072 | 2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-trifluoromethyluridine | 2072145-74-3 | Oligonucleotides |
| HY-154077 | N4-Benzoyl-5-methyl-2’-O,4’-C-methylenecytidine | 206055-81-4 | Oligonucleotides |
| HY-154078 | 2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-fluorouridine | 2072145-63-0 | Oligonucleotides |
| HY-15407A | Sacubitril hemicalcium salt | 1369773-39-6 | Reference compound |
| HY-15407AS | Sacubitril-13C4 (hemicalcium salt) | | Isotope-Labeled Compounds |
| HY-15407AS1 | Sacubitril-d4 (hemicalcium salt) | | Isotope-Labeled Compounds |
| HY-15407AS2 | Sacubitril-d5 (hemicalcium) | | Isotope-Labeled Compounds |
| HY-15407B | Sacubitril (sodium) | 149690-05-1 | Reference compound |
| HY-15407BR | Sacubitril (sodium) (Standard) | 149690-05-1 | Reference Standards |
| HY-15407S | Sacubitril-d4 | 1884269-07-1 | Isotope-Labeled Compounds |
| HY-15407S3 | Sacubitril-13C4 | | Isotope-Labeled Compounds |
| HY-15408 | Trelagliptin | 865759-25-7 | Reference compound |
| HY-154080 | 5'-O-DMTr-2'-FU-methyl phosphonamidite | | Oligonucleotides |
| HY-154081 | 5’-O-DMTr-2’-OMeU-methyl phosphonamidite | 191786-64-8 | Oligonucleotides |
| HY-154082 | 5-Caroxy uracil-1-yl acetic acid benzyl ester | | Oligonucleotides |
| HY-154083 | 2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methoxyuridine | 2072145-81-2 | Oligonucleotides |
| HY-154085 | (2’,3’,5’-Tri-O-acetyl)uridine 5-carboxylic acid | 174653-39-5 | Oligonucleotides |
| HY-154086 | 5’-O-DMTr-2’,2’-difluoro-dC(Bz)-methyl phosphonamidite | | Oligonucleotides |
| HY-154087 | 3′-Bromo-3′-deoxythymidine | 99785-51-0 | Oligonucleotides |
| HY-154088 | 3′-Deoxy-3′-iodothymidine | 14260-82-3 | Oligonucleotides |
| HY-154089 | 3-Deoxy-1,2:5,6-bis-O-(1-methylethylidene)-α-D-ribo-hexofuranose | 4613-62-1 | Oligonucleotides |
| HY-15408A | Trelagliptin (succinate) | 1029877-94-8 | Reference compound |
| HY-15408AR | Trelagliptin (succinate) (Standard) | 1029877-94-8 | Reference Standards |
| HY-15408S | Trelagliptin-13C,d3 | 2707203-34-5 | Isotope-Labeled Compounds |
| HY-15409 | Empagliflozin | 864070-44-0 | Reference compound |
| HY-15409R | Empagliflozin (Standard) | 864070-44-0 | Reference Standards |
| HY-15409S | Empagliflozin-d4 | 2749293-95-4 | Isotope-Labeled Compounds |
| HY-15409S1 | Empagliflozin-13C6 | | Isotope-Labeled Compounds |
| HY-15409S2 | Empagliflozin-d6 | | Isotope-Labeled Compounds |
| HY-15410 | Gacyclidine | 68134-81-6 | Reference compound |
| HY-154109 | N1-Aminopseudouridine | | Oligonucleotides |
| HY-15410A | Gacyclidine (hydrochloride) | 131774-33-9 | Reference compound |
| HY-15411 | MK-0557 | 328232-95-7 | Reference compound |
| HY-154110 | N3-Aminopseudouridine | | Oligonucleotides |
| HY-154111 | 8-(N-Boc-aminomethyl)guanosine | | Oligonucleotides |
| HY-154112 | 2-Bromo-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine | 40896-58-0 | Oligonucleotides |
| HY-154114 | 2′-Deoxy-2-iodoadenosine | 118706-49-3 | Oligonucleotides |
| HY-154115 | 5’-O-Acetyl-5-acetyloxymethyluridine | 2305416-11-7 | Oligonucleotides |
| HY-154116 | 6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine | 161923-50-8 | Oligonucleotides |
| HY-154117 | 2',3',5'-Tri-O-benzoyl-2'-beta-C-methyl-6-azauridine | 622379-83-3 | Oligonucleotides |
| HY-154118 | 3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabino-6-azidouridine | 1013470-68-2 | Oligonucleotides |
| HY-154119 | 3’-Azido-3’-deoxy-6-azauridine | | Oligonucleotides |
| HY-15412 | HhAntag | 496794-70-8 | Reference compound |
| HY-154120 | 6-Aza-2'-deoxyuridine | 20500-29-2 | Oligonucleotides |
| HY-154121 | 2’-O-(2-Methoxyethyl)guanosine 5’-triphosphate (ammonium) | | Oligonucleotides |
| HY-154122 | 6-Amino-4-methoxy-1-(2-deoxy-a-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine | | Oligonucleotides |
| HY-154123 | N6-Benzoyl-2’-chloro-2’-deoxyadenosine | 2095417-58-4 | Oligonucleotides |
| HY-154124 | N6-Benzoyl-2'-chloro-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine | 2243079-24-3 | Oligonucleotides |
| HY-154125 | 6-Chloro-2-fluoropurine-9-b-D-(3,5-bis-O-(p-toluoyl)-2-deoxy)riboside | | Oligonucleotides |
| HY-154126 | 2’,3’,5’-Tri-O-benzoyl-5-hydroxy methyluridine (see GL100342) | 53910-92-2 | Oligonucleotides |
| HY-154127 | 2’,3’,5’-Tri-O-benzoyl-5-difluoromethyluridine | 2305416-06-0 | Oligonucleotides |
| HY-154128 | 1-(b-D-Xylofuranosyl)-5-fluorouracil | | Oligonucleotides |
| HY-154129 | 1-(b-D-Xylofuranosyl)-5-methoxyuracil | | Oligonucleotides |
| HY-15413 | Edivoxetine | 1194508-25-2 | Reference compound |
| HY-154130 | 1-(b-D-Xylofuranosyl)-5-trifluoromethyluracil | | Oligonucleotides |
| HY-154131 | 3-Deaza-xylouridine | | Oligonucleotides |
| HY-154132 | 1-(b-D-Xylofuranosyl)-N6-(p-methoxybenzyl) adenine | | Oligonucleotides |
| HY-154133 | 3’-Deoxy-3’-fluoro-xylo-5-methoxyuridine | | Oligonucleotides |
| HY-154134 | 3’-Deoxy-3’-fluoro-xylo-5-trifluoromethyluridine | | Oligonucleotides |
| HY-154135 | 3’-Deoxy-3’-fluoro-xylo-N6-(p-methoxybenzyl)adenosine | | Oligonucleotides |
| HY-154136 | 5-Fluoro-3’-beta-C-methyluridine | | Oligonucleotides |
| HY-154137 | 3’-Beta-C-Methyl-5-trifluoromethyluridine | | Oligonucleotides |
| HY-154138 | 3’-beta-C-Methyl-5-methoxyuridine | | Oligonucleotides |
| HY-154139 | 3’-Beta-C-Methyl-3-deazauridine | | Oligonucleotides |
| HY-15413A | Edivoxetine (hydrochloride) | 1194374-05-4 | Reference compound |
| HY-15414 | Vortioxetine | 508233-74-7 | Reference compound |
| HY-154140 | 3’-beta-C-Methyl-N6-(p-methoxybenzyl)adenosine | | Oligonucleotides |
| HY-154141 | 3’-Beta-C-Ethynyl-5-fluorouridine | | Oligonucleotides |
| HY-154142 | 3’-Beta-C-Ethynyl-5-methoxyuridine | | Oligonucleotides |
| HY-154143 | 3’-Beta-C-Ethynyl-4-deoxyuridine | | Oligonucleotides |
| HY-154144 | 2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-methyl uridine | 957535-53-4 | Oligonucleotides |
| HY-154145 | 2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-methoxy uridine | 2072145-79-8 | Oligonucleotides |
| HY-154146 | 5-Nitro-1-(3-azido-3-deoxy-β-D-ribofuranosyl)-2(1H)-pyridinone | 2072145-26-5 | Oligonucleotides |
| HY-154147 | 2’-Deoxy-N1-methylguanosine | 5132-79-6 | Oligonucleotides |
| HY-154148 | N6-Isopentenyl-2’-deoxy adenosine, 2’-deoxy riboprine | 25775-85-3 | Oligonucleotides |
| HY-15414A | Vortioxetine (hydrobromide) | 960203-27-4 | Reference compound |
| HY-15414AS | Vortioxetine-d8 (hydrobromide) | | Isotope-Labeled Compounds |
| HY-15414R | Vortioxetine (Standard) | 508233-74-7 | Reference Standards |
| HY-15414S | Vortioxetine-d8 | 2140316-62-5 | Isotope-Labeled Compounds |
| HY-15414S1 | Vortioxetine-d6 | 1629684-23-6 | Isotope-Labeled Compounds |
| HY-15414S2 | Vortioxetine-d4 | | Isotope-Labeled Compounds |
| HY-15415 | KB-R7943 (mesylate) | 182004-65-5 | Reference compound |
| HY-154150 | N-(1-Oxopropyl)cytidine | 60107-04-2 | Oligonucleotides |
| HY-154151 | N4-(3,3,3-Trifluoropropanoyl)cytidine | | Oligonucleotides |
| HY-154153 | 2-Methyl-2’-deoxyadenosine | 110952-90-4 | Oligonucleotides |
| HY-154154 | 3,5-Bis-O-(4-methylbenzoyl)-2-C-methyl-D-ribonic acid gama-lactone | 25137-77-3 | Oligonucleotides |
| HY-154156 | 2’-Deoxy-2’-fluoroadenosine 5’-monophosphate (triethylammonium) | | Oligonucleotides |
| HY-154157 | 2’-O-Methyladenosine 5’-monophosphate triethyl ammonium | | Oligonucleotides |
| HY-154158 | 2’-Deoxy-2’-fluoroguanosine 5’-monophosphate triethyl ammonium | | Oligonucleotides |
| HY-154159 | 2’-O,4’-C-Methyleneadenosine 5’-monophosphate (triethylammonium) | | Oligonucleotides |
| HY-15416 | NS309 | 18711-16-5 | Reference compound |
| HY-154160 | 5-(2-Hydroxyethyl)-2’,3’-di-O-toluoyl-2’-deoxyuridine | | Oligonucleotides |
| HY-154161 | 5-(2-Hydroxyethyl)-2’-deoxy uridine | 90301-60-3 | Oligonucleotides |
| HY-154167 | 5’-O-(4,4’-Dimethoxytrityl)-5-methoxyuridine | 2095417-73-3 | Oligonucleotides |
| HY-15417 | ML-7 (hydrochloride) | 110448-33-4 | Reference compound |
| HY-154170 | 2',3',5'-Tri-O-acetyl-2-thiouridine | 28542-31-6 | Oligonucleotides |
| HY-154171 | Deoxyribosyl dihydropyrimido[4,5-c][1,2]oxazin-7-one | 126128-42-5 | Reference compound |
| HY-154173 | 3’-O-(t-Butyldimethylsilyl)-2’-O-(2-methoxyethyl) uridine | 1345716-52-0 | Oligonucleotides |
| HY-154175 | 1-[6-(Diethoxyphosphinyl)-2-O-(2-methoxyethyl)-β-D-ribo-hexofuranosyl]uracil | | Oligonucleotides |
| HY-15418 | RS 504393 | 300816-15-3 | Reference compound |
| HY-154185 | 3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-5-methyl-β-D-arabino-uridine | 97614-47-6 | Oligonucleotides |
| HY-154186 | N6-Acetyloxymethyladenosine | | Oligonucleotides |
| HY-154187 | N6-Pivaloyloxymethyladenosine | | Oligonucleotides |
| HY-15419 | RS-127445 (hydrochloride) | 199864-86-3 | Reference compound |
| HY-154190 | 2',3',5'-Tri-O-benzoyl-6-azauridine | 1627-29-8 | Oligonucleotides |
| HY-154198 | 5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine | 112897-99-1 | Oligonucleotides |
| HY-15419A | RS-127445 | 199864-87-4 | Reference compound |
| HY-15420 | BML-190 | 2854-32-2 | Reference compound |
| HY-154200 | 3’-Deoxy-5-methycytidine | 7057-38-7 | Oligonucleotides |
| HY-154201 | 3’-Deoxy-O6-methyl inosine | 945215-53-2 | Oligonucleotides |
| HY-154202 | 2’-beta-C-Ethynyl-5-methyluridine | | Oligonucleotides |
| HY-154203 | 4-Deoxy-3’-deoxy-3’-fluoro uridine | | Oligonucleotides |
| HY-154204 | 2'-Deoxy-2'-fluoroarabino inosine | 98983-40-5 | Oligonucleotides |
| HY-154205 | 2’-Deoxy-2’-fluoroarabino-O6-methyl inosine | 109304-06-5 | Oligonucleotides |
| HY-154206 | N4-Benzo yl-5’-O-(4,4’-dimethoxytrityl)-aracytidine | 87418-76-6 | Oligonucleotides |
| HY-154207 | 2’-O-Acetyl-N4-benzoyl-5’-O-DMT arabinocytidine 3’-O-phosphoramidite | 675573-97-4 | Oligonucleotides |
| HY-154210 | DMTr-FNA-C(Bz)Phosphoramidite | 326802-62-4 | Oligonucleotides |
| HY-154211 | 5'-O-DMTr-dU-methyl phosphonamidite | | Oligonucleotides |
| HY-154212 | N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-5-methyl-2’-deoxycytidine | | Oligonucleotides |
| HY-154213 | 5’-O-DMTr-5-MedC (Ac)-methyl phosphonamidite | | Oligonucleotides |
| HY-154214 | 2-(3-Methyln-propylidene hydrazino) adenosine | | Oligonucleotides |
| HY-154215 | 2-(P-Cyanophenyl methylidene hydrazino) adenosine | | Oligonucleotides |
| HY-154217 | 3′,5′-Bis-O-(triphenylmethyl)uridine | 4710-75-2 | Oligonucleotides |
| HY-154218 | 2-O-Benzoyl-3-O-t-butyldiphenylsilyl-L-threono lactone | 1446785-28-9 | Oligonucleotides |
| HY-15422 | Dye 937 | 195199-04-3 | Dye Reagents |
| HY-154220 | N4-Benzoyl-2’-deoxy-2’,2’-diflurocytidine | 142816-70-4 | Oligonucleotides |
| HY-154221 | N4-Benzoyl-2'-deoxy-5'-O-DMT-2',2'-difluorocytidine | 142808-43-3 | Oligonucleotides |
| HY-154222 | 5’-O-DMTr-2’,2’-difluoro-dC(Bz)-3’-CED-phosphoramidite | 142808-44-4 | Oligonucleotides |
| HY-154223 | 5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyl-2-thiouridine | 302918-83-8 | Oligonucleotides |
| HY-154224 | 2’-O-Me-2-thio-U-3’-phos phoramidite | 302918-84-9 | Oligonucleotides |
| HY-154228 | 3’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl)-5-methyluridine | | Oligonucleotides |
| HY-154229 | 3’-O-DMT-N2-isobutyryl-2’-O-(2-methoxyethyl)guanosine | | Oligonucleotides |
| HY-154230 | Rev 2’-O-MOE-C(Bz)-5’-amidite | | Oligonucleotides |
| HY-154231 | 2’-Deoxy-2’-fluoro-alpha-D-arabinoguanosine | 2072145-29-8 | Oligonucleotides |
| HY-154232 | 4′,5′-Didehydro-5′-deoxyadenosine | 20535-04-0 | Oligonucleotides |
| HY-154233 | 5’-O-TBDPS-2,2’-anhydrouridine | 175013-46-4 | Oligonucleotides |
| HY-154234 | 5’-O-TBDPS-5-methyl-2,2’-anhydrouridine | 171763-19-2 | Oligonucleotides |
| HY-154235 | N2-iBu-2’,3’-bis-O-TBDMS guanosine | 79974-70-2 | Oligonucleotides |
| HY-154236 | 2’-Deoxy-2’-fluoro-3’,5’-bis-O-TBDMS-uridine | 139878-36-7 | Oligonucleotides |
| HY-154237 | 5’-O-DMTr-3’-deoxyuridine | 86234-42-6 | Oligonucleotides |
| HY-154238 | 5’-O-DMTr-3’-deoxyuridine 2’-CED phosphoramidite | 161503-98-6 | Oligonucleotides |
| HY-154239 | 5’-O-Triphenylmethyl-2’-deoxyuridine | 14270-73-6 | Oligonucleotides |
| HY-15424 | 5-Iodotubercidin | 24386-93-4 | Reference compound |
| HY-154240 | 2-Amino-2’,3’-bis-O-(2-methoxyethyl) adenosine | 847647-19-2 | Oligonucleotides |
| HY-154241 | 8-Methyl-2’-deoxyadenosine | 85562-60-3 | Oligonucleotides |
| HY-154242 | 8-Methylguanosine | 36799-17-4 | Oligonucleotides |
| HY-154243 | 8-Methyl-2’-deoxyguanosine | 85819-69-8 | Oligonucleotides |
| HY-154246 | 2’-Fluoro-2’-deoxy-arabinoadenosine 5’-triphosphate (triethylamine) | | Oligonucleotides |
| HY-154248 | 2’-Deoxy-3’,2-anhydrouridine | 26922-44-1 | Oligonucleotides |
| HY-15425 | PF-543 | 1415562-82-1 | Reference compound |
| HY-154251 | 2-Methoxy-9-β-D-ribofuranosyl-9H-purine | 39638-84-1 | Oligonucleotides |
| HY-154252 | 2’,3’,5’-Tri-O-benzoyl-5-hydroxymethyl-2’-β-C-methyluridine | 2305416-16-2 | Oligonucleotides |
| HY-154253 | 5-Azidomethyl-2'-deoxyuridine | 59090-48-1 | Oligonucleotides |
| HY-154254 | 2-Diethoxymethyl adenosine | | Oligonucleotides |
| HY-154255 | 5-(3-Azidopropyl)uridine | 1354419-08-1 | Oligonucleotides |
| HY-154256 | 5-(2-Azidoethyl)uridine | | Oligonucleotides |
| HY-154257 | N2-iso-Butyryl-8-azaguanosine | 2328168-83-6 | Oligonucleotides |
| HY-154258 | Rev 2’-O-MOE-5MeU-5’-amidite | 1345715-43-6 | Oligonucleotides |
| HY-154259 | Rev 2’-O-MOE-G(iBu)-5’-amidite | 725223-44-9 | Oligonucleotides |
| HY-15425A | PF-543 (Citrate) | 1415562-83-2 | Reference compound |
| HY-15425B | PF-543 (hydrochloride) | 1706522-79-3 | Reference compound |
| HY-15426 | PF-04957325 | 1305115-80-3 | Reference compound |
| HY-154260 | N6-Benzoyl-3'-O-DMT-2'-O-(2-methoxyethyl) adenosine | | Oligonucleotides |
| HY-154261 | Rev 2’-O-MOE-A(Bz)-5’-amidite | | Oligonucleotides |
| HY-154262 | N6-Ethyl-2’-deoxyadenosine | 136050-93-6 | Oligonucleotides |
| HY-154263 | 5’-O-DMTr-N6-ethyl-2’-deoxyadenosine | | Oligonucleotides |
| HY-154264 | 5’-O-DMTr-N6-ethyl-2’-deoxyadenosine 3’-CED phosphoramidite | | Oligonucleotides |
| HY-154265 | 2-Amino-2’-deoxy-N6,N6-dimethyl-2’-adenosine | 83061-20-5 | Oligonucleotides |
| HY-154266 | 2-Amino-2’-deoxy-N6-ethyl-adenosine | | Oligonucleotides |
| HY-154267 | 5'-O-DMT-2-thio-2'-dU-3'-phosphoramidite | 152753-94-1 | Oligonucleotides |
| HY-154268 | Confidential-2 | | Oligonucleotides |
| HY-154269 | Confiden | | Oligonucleotides |
| HY-15427 | GDC-0834 | 1133432-49-1 | Reference compound |
| HY-154270 | Confident | | Oligonucleotides |
| HY-154271 | TLR7 agonist 12 | 2389988-47-8 | Reference compound |
| HY-154273 | 2’,3’,5’-Tri-O-acetyl-5-cyanouridine | 1630743-99-5 | Oligonucleotides |
| HY-154274 | 5-Cyanouridine | 4425-57-4 | Oligonucleotides |
| HY-154275 | 4’-Methylthymidine | 139925-84-1 | Oligonucleotides |
| HY-154276 | 1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose | 1971879-01-2 | Oligonucleotides |
| HY-15427A | GDC-0834 (Racemate) | 1133432-46-8 | Reference compound |
| HY-15427B | GDC-0834 (S-enantiomer) | 1133432-50-4 | Reference compound |
| HY-154283 | 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)purine | 2389988-53-6 | Oligonucleotides |
| HY-154284 | 7,8-Dihydro-8-oxo-7-propargyl-3’-deoxy guanosine | 2389988-54-7 | Oligonucleotides |
| HY-154285 | 3’-O-(2-Methoxyethyl) uridine | 870599-31-8 | Oligonucleotides |
| HY-154286 | 1-O-Acetyl-2,3,5-tri-O-benzoyl-5(R)-C-methyl-D-ribo furanose | 72159-45-6 | Oligonucleotides |
| HY-154288 | 2’,3’,5’-Tri-O-benzoyl-5-iodouridine | 2880-91-3 | Oligonucleotides |
| HY-154289 | 2’,3’-Isopropylidene-5-hydroxyuridine | 20406-82-0 | Oligonucleotides |
| HY-154290 | N3,5-Dimethyl-2’-O-(2-methoxyethyl) uridine | | Oligonucleotides |
| HY-154291 | 3’-Deoxy-3’-fluoro-N1-methyluridine | | Oligonucleotides |
| HY-154292 | 3’-Deoxy-N1-Methyl inosine | | Oligonucleotides |
| HY-154293 | 3’-Deoxy-N6-ethyladenosine | 3608-60-4 | Oligonucleotides |
| HY-154294 | N1-Methyl ara-uridine | 17676-62-9 | Oligonucleotides |
| HY-154295 | 2’-Deoxy-2’-fluoro-N1-methyluridine | | Oligonucleotides |
| HY-154296 | 2'-Deoxy-2'-fluoro-ara-uridine | | Oligonucleotides |
| HY-154297 | N6-Dimethylamino methylidene-2’-deoxyisoguanosine | 146196-17-0 | Oligonucleotides |
| HY-154298 | N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine | 84138-86-3 | Oligonucleotides |
| HY-15430 | Encenicline | 550999-75-2 | Reference compound |
| HY-154300 | N-Benzoyl-3′-O-methyladenosine | 85090-30-8 | Oligonucleotides |
| HY-154302 | 5’-O-(4,4’-Dimethoxytrityl)-3’-O-levulinyl-2’-deoxyadenosine | 2072145-67-4 | Oligonucleotides |
| HY-154303 | 3’-O-Levulinyl-2’-deoxyadenosine | 440327-45-7 | Oligonucleotides |
| HY-154304 | 4’,5’-Didehydro-2’,5’-dideoxy-2’-fluorouridine | 1365255-75-9 | Oligonucleotides |
| HY-154305 | 5′-Azido-2′,5′-dideoxy-2′-fluorouridine | 1012080-88-4 | Oligonucleotides |
| HY-154306 | 5’-Deoxy-5’-iodo-2’-O-methyluridine | 194034-84-9 | Oligonucleotides |
| HY-154307 | 4′,5′-Didehydro-5′-deoxy-2′-O-methyluridine | 1848223-48-2 | Oligonucleotides |
| HY-154308 | 5’-Azido-5’-deoxy-2’-O-methyluridine | 194034-68-9 | Oligonucleotides |
| HY-154309 | 3'-O-tert-Butyldimethylsilyl-5'-O-DMT-2'-deoxyadenosine | 89947-86-4 | Oligonucleotides |
| HY-15430A | Encenicline hydrochloride | 550999-74-1 | Reference compound |
| HY-15431 | Capivasertib | 1143532-39-1 | Reference compound |
| HY-154310 | 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl) benzoyl-L-ribofuranose | | Oligonucleotides |
| HY-154312 | 3,5-Di-O-benzoyl-2-deoxy-2-fluoro-5-trifluoromethyl-arabinouridine | 117311-99-6 | Oligonucleotides |
| HY-154313 | Spiclomazine | 24527-27-3 | Reference compound |
| HY-154314 | N2-(Isopropylphenoxyacetyl)-2’-O-propargylguanosine | 2095417-23-3 | Oligonucleotides |
| HY-154315 | 3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-4-deoxy-arabinouridine | 136675-87-1 | Oligonucleotides |
| HY-154316 | 3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-3-Deaza-arabinouridine | 2095417-46-0 | Oligonucleotides |
| HY-154317 | 2’-O-Methyl-5-methyluridine 5’-triphosphate (triethylammonium) | | Oligonucleotides |
| HY-154318 | 1,2-Di-O-acetyl-3-azido-3-deoxy-5-O-(4-methyl)benzoyl-D-ribofuranose | 120143-22-8 | Oligonucleotides |
| HY-154319 | 1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine | 325683-89-4 | Oligonucleotides |
| HY-15431A | (R)-Capivasertib | 1143532-51-7 | Reference compound |
| HY-15432 | (E/Z)-NSC-687852 | 330450-45-8 | Reference compound |
| HY-154320 | 3’-Azido-3’-deoxy-3-deazauridine | 2305416-04-8 | Oligonucleotides |
| HY-154321 | Methyl 2-deoxy-3,5-di-O-benzoyl-2-fluoro-4-thio-D-arabinopentofuranoside | 221552-92-7 | Oligonucleotides |
| HY-154323 | 5’-DMTr-3’dA(Bz)-methylphosphonami dite | | Oligonucleotides |
| HY-154324 | 2′-Deoxy-2-thiouridine | 35059-12-2 | Oligonucleotides |
| HY-154325 | 1-(2-Deoxy-β-D-erythro-pentofuranosyl)-4(1H)-pyrimidinone | 37109-98-1 | Oligonucleotides |
| HY-154326 | 2-Deoxy-2’-deoxy-5’-(4,4’-dimethoxytrityl)uridine | 151503-26-3 | Oligonucleotides |
| HY-154327 | DMTr-dH2U-amidite | 151503-28-5 | Oligonucleotides |
| HY-154328 | 3’-beta-Azido-2’,3’-dideoxy-5’-O-(4-methoxy-trityl)uridine | 2072145-36-7 | Oligonucleotides |
| HY-154329 | 2-Deoxyuridine | 21052-20-0 | Oligonucleotides |
| HY-15433 | Quisinostat | 875320-29-9 | Reference compound |
| HY-154330 | 3'-beta-Azido-2',3'-dideoxyuridine | 101039-96-7 | Oligonucleotides |
| HY-154331 | 1-(5-O-Methoxytrityl-2-deoxy-β-D-xylofuranosyl)uracil | 2072145-82-3 | Oligonucleotides |
| HY-154332 | 8-(Phenylmethoxy)guanosine | 3868-36-8 | Oligonucleotides |
| HY-154333 | 2′-Deoxy-8-(phenylmethoxy)guanosine | 96964-90-8 | Oligonucleotides |
| HY-154334 | 2’-O-Acetyl-3’-azido-5’-O-(4-methylbenzoyl)-3’-deoxyuridine | 256485-42-4 | Oligonucleotides |
| HY-154335 | 1-(3-Deoxy-3-fluoro-β-D-xylofuranosyl)-2,4(1H,3H)-pyrimidinedione | 129885-95-6 | Oligonucleotides |
| HY-154336 | N-[2-[4-(1-Methylethyl)phenoxy]acetyl]guanosine | 937205-20-4 | Oligonucleotides |
| HY-154338 | N-Benzoyl-2′-O-2-propyn-1-yladenosine | 210096-44-9 | Oligonucleotides |
| HY-154339 | N4-Benzoyl-5'-O-DMT-2'-O-propargyl adenosine | 171486-51-4 | Oligonucleotides |
| HY-15433A | Quisinostat (dihydrochloride) | 875320-31-3 | Reference compound |
| HY-15434 | NG25 | 1315355-93-1 | Reference compound |
| HY-154340 | 2,3’-Anhydrothymidine | 15981-92-7 | Oligonucleotides |
| HY-154341 | 9-[2'-O-Acetyl-3'-azido-3'-deoxy-5'-O-toluoyl-b-L-ribofuranosyl)-6-chloropurine | 2095417-30-2 | Oligonucleotides |
| HY-154342 | N1-Ethyl-2’-O-TBDMS-5’-O-DMTr-3’-phosphoramidite | | Oligonucleotides |
| HY-154343 | 3′-Azido-3′-deoxy-5′-O-(triphenylmethyl)thymidine | 29706-84-1 | Oligonucleotides |
| HY-154344 | 5′-Deoxy-5′-iodo-5-methyluridine | 1884334-62-6 | Oligonucleotides |
| HY-154345 | 4′,5′-Didehydro-5′-deoxy-5-methyluridine | 1446748-33-9 | Oligonucleotides |
| HY-154346 | 5’-Azido-5’-deoxy-5-methyluridine | 1187022-65-6 | Oligonucleotides |
| HY-154347 | 5'-Deoxy-5‘-iodothymidine | 25953-14-4 | Oligonucleotides |
| HY-154348 | 4’,5’-Didehydro-5’-deoxy thymidine | 28034-72-2 | Oligonucleotides |
| HY-154349 | N2-iso-Butyroyl-2’-O-propargylguanosine | 2095417-55-1 | Oligonucleotides |
| HY-15434A | NG25 (trihydrochloride) | 2108554-00-1 | Reference compound |
| HY-15435 | CHAPS | 75621-03-3 | Reference compound |
| HY-154350 | 5'-O-DMT-N2-isobutyryl-2'-O-propargylguanosine | 171486-53-6 | Oligonucleotides |
| HY-154351 | N2-iBu-5’-O-DMTr-2’-O-propargylguanosine-3’-CED-phosphoramidite | 171486-61-6 | Oligonucleotides |
| HY-154352 | Methyl 2-deoxy-3,5-di-O-benzoyl-2-fluoro-4-thio-beta-D-arabinopentofuranoside | 197647-15-7 | Oligonucleotides |
| HY-154353 | 5’-O-(4,4’-Dimethoxytrityl)-2’-O-(2-methoxyethyl) adenosine | 1384253-67-1 | Oligonucleotides |
| HY-154354 | Methyl 3’-O-benzyl xyloriboside | 201014-45-1 | Oligonucleotides |
| HY-154355 | 2-Chloro-N6-cyclopentyl 2’-deoxy- adenosine | 215108-39-7 | Oligonucleotides |
| HY-154356 | 1-(alpha-L-Threofuranosyl)cytosine | 2166199-20-6 | Oligonucleotides |
| HY-154357 | 4’-alpha-C-Azido-2’,3’-bis(O-t-butyldimethylsilyl)uridine | | Oligonucleotides |
| HY-154358 | 4’-alpha-C-Allyl-2’,3’-bis(O-t-butyldimethylsilyl) uridine | 512184-18-8 | Oligonucleotides |
| HY-154359 | 2’-O-Acetyl-3’,5’-bis-O-benzoyl-6-aza-xylo uridine | 161615-21-0 | Oligonucleotides |
| HY-15435A | CHAPS (hydrate) | 331717-45-4 | Biochemical Assay Reagents |
| HY-154360 | 2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy guanosine | 2389988-71-8 | Oligonucleotides |
| HY-154361 | TLR7 agonist 13 | 2389988-70-7 | Reference compound |
| HY-154362 | 1,2-Di-O-acetyl-3-deoxy-3-fluoro-5-O-(4-methyl)benzoyl-D-ribofuranose | 1612192-28-5 | Oligonucleotides |
| HY-154362A | β-D-Ribofuranose, 3-deoxy-3-fluoro-, 1,2-diacetate 5-(4-methylbenzoate) | 1884324-98-4 | Reference compound |
| HY-154363 | 3-Cyanovinyl-9-(5’-O-DMT-2’-deoxyribofuranosyl)carbazole | | Oligonucleotides |
| HY-154364 | 3’-Deoxy-5-trifluoromethyluridine | 35463-35-5 | Oligonucleotides |
| HY-154365 | 5’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl) inosine | | Oligonucleotides |
| HY-154366 | 5'-DMT-2'-O-TBDMS-N1-Methyl-PseudoUridine-CE-Phosphoramidite | 875302-45-7 | Oligonucleotides |
| HY-154368 | DMTr-MOE-Inosine-3-CED-phosphoramidite | | Oligonucleotides |
| HY-154369 | 1,4-Anhydro-2,3-O-isopropylidene-5-O-t-butyldiphenylsilyl-4-thio-D-ribitol | 1320269-77-9 | Oligonucleotides |
| HY-15437 | SL327 | 305350-87-2 | Reference compound |
| HY-154370 | 2’,3’-Bis-O-(t-butyldimethylsilyl)-N1-methylpseudouridine | | Oligonucleotides |
| HY-154371 | 5’-O-Benzoyl-2’-O,4’-C-methyleneuridine | 293751-31-2 | Oligonucleotides |
| HY-154372 | 2′,5′-Dideoxy-5′-iodouridine | 58510-66-0 | Oligonucleotides |
| HY-154373 | 4′,5′-Didehydro-2′,5′-dideoxyuridine | 58096-66-5 | Oligonucleotides |
| HY-154374 | 5’-Azido-2’,5’-dideoxyuridine | 35959-37-6 | Oligonucleotides |
| HY-154375 | 5’-Deoxy-5’-iodo-2’-O-methyl-5-methyluridine | 187733-72-8 | Oligonucleotides |
| HY-154376 | 4’,5’-Didehydro-2’-O-methyl-5-methyluridine | 2095417-11-9 | Oligonucleotides |
| HY-154377 | 5'-Azido-5'-deoxy-2'-O-methyl-5-methyluridine | 187733-73-9 | Oligonucleotides |
| HY-154379 | 3',5'-Di-O-acetyl-2'-O-methyl-6-chloro-2-aminopurine riboside | 244184-56-3 | Oligonucleotides |
| HY-15438 | SB 415286 | 264218-23-7 | Reference compound |
| HY-154380 | 6-Chloro-9-(3,5-di-O-acetyl-2-O-methyl-β-D-ribofuranosyl)-9H-purine | 194034-61-2 | Oligonucleotides |
| HY-154381 | 5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)uridine | 2095417-41-5 | Oligonucleotides |
| HY-154382 | 4’,5’-Didehydro-2’-O-(2-methoxyethyl)uridine | 2095417-78-8 | Oligonucleotides |
| HY-154383 | 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)uridine | 2095417-60-8 | Oligonucleotides |
| HY-154384 | 5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)-5-methyluridine | 2095417-53-9 | Oligonucleotides |
| HY-154385 | 4’,5’-Didehydro-2’-O-(2-methoxyethyl)-5-methyluridine | 2095417-31-3 | Oligonucleotides |
| HY-154386 | 5’-Azido-5’-deoxy-2’-O-(2-methoxyethyl)-5-methyluridine | 2095417-42-6 | Oligonucleotides |
| HY-154387 | 1-Isopropyltryptophan | 1219485-46-7 | Reference compound |
| HY-15439 | (24S)-24,25-Dihydroxyvitamin D3 | 55700-58-8 | Reference compound |
| HY-154391 | 5-O-(tert-Butyldiphenylsilyl)-2,3-isopropylidene-D-ribonolactone | 130222-84-3 | Oligonucleotides |
| HY-154392 | 2-Chloro-2’-deoxy inosine | 136834-39-4 | Oligonucleotides |
| HY-154393 | 2-Chloro-2'-deoxy-6-O-methylinosine | 146196-07-8 | Oligonucleotides |
| HY-154394 | 2-Chloro-N6-methyl-2’-deoxyadenosine | 146196-08-9 | Oligonucleotides |
| HY-154395 | 2-Chloro-2′-deoxy-N,N-dimethyladenosine | 1858191-70-4 | Oligonucleotides |
| HY-154396 | 8-Chloro-2’-deoxy-2’-fluoroadenosine | | Oligonucleotides |
| HY-154397 | 2',3',5'-Tri-O-benzoyl-5-azacytidine | 28998-36-9 | Oligonucleotides |
| HY-154398 | 5-Aza-xylo-cytidine | | Oligonucleotides |
| HY-154399 | 5-Aza-3’-deoxycytidine | 455951-65-2 | Oligonucleotides |
| HY-15440 | Temsavir | 701213-36-7 | Reference compound |
| HY-154400 | 5-Aza-3’-beta-methylcytidine | | Oligonucleotides |
| HY-154402 | 2′-Azido-2′-deoxy-5-methyluridine | 97748-75-9 | Oligonucleotides |
| HY-154403 | 2’-Azido-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine | 2095417-08-4 | Oligonucleotides |
| HY-154404 | 2’,3’,5’-Tri-O-benzyl-4’-thio-arabinouridine | 267665-69-0 | Oligonucleotides |
| HY-154405 | 5’-Azido-5’-deoxyuridine | 39483-48-2 | Oligonucleotides |
| HY-154406 | 2′-Deoxy-N-methylguanosine | 19916-77-9 | Oligonucleotides |
| HY-154407 | 2’-Deoxy-N2,N2-dimethylguanosine | 88127-22-4 | Oligonucleotides |
| HY-154408 | 2'-O-Me-5-I-U-3'-phosphoramidite | | Oligonucleotides |
| HY-154409 | 2’-Fluoro-2’-deoxy-ara-A(Bz)-3’-phosphoramidite | 329187-86-2 | Oligonucleotides |
| HY-15440A | Fostemsavir | 864953-29-7 | Reference compound |
| HY-15440AR | Fostemsavir (Standard) | 864953-29-7 | Reference Standards |
| HY-15440AS | Fostemsavir-d8 | | Isotope-Labeled Compounds |
| HY-15440B | Fostemsavir Tris | 864953-39-9 | Reference compound |
| HY-15441 | Edelinontrine | 1082744-20-4 | Reference compound |
| HY-154410 | 5’-O-DMT-2’-deoxy-2’-fluoro-β-D-arabinouridine | 144822-63-9 | Oligonucleotides |
| HY-154412 | N4-Benzoyl-2’-deoxy-2’-fluoro-β-D-arabinocytidine | | Oligonucleotides |
| HY-154413 | DMT-2'-F-Bz-dC | 154771-33-2 | Oligonucleotides |
| HY-154414 | 2’-Fluoro-2’-deoxy-ara-C(Bz)-3’-phosphoramidite | 1404463-12-2 | Oligonucleotides |
| HY-154415 | 2’,3’,5’-Tri-O-benzoyl-2-thiouridine | 21052-18-6 | Oligonucleotides |
| HY-154416 | 5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-3-methyl-2-benzyloxypyridine | 1846584-69-7 | Oligonucleotides |
| HY-154417 | 2’,3’-Bis(O-t-butyldimethylsilyl)-2-thiouridine | 2305415-97-6 | Oligonucleotides |
| HY-154418 | 2’,3’-Bis(O-(t-butyldimethylsilyl)-5-methoxyuridine | 2305415-94-3 | Oligonucleotides |
| HY-154419 | N6-Benzoyl-2'-O-tert-butyldimethylsilyl-3'-O-DMT-adenosine | 1214886-17-5 | Oligonucleotides |
| HY-15442 | Biphenylindanone A | 866823-73-6 | Reference compound |
| HY-154420 | 2’,3’-Bis-(O-t-butyldimethylsilyl)uridine | 69504-12-7 | Oligonucleotides |
| HY-154421 | 2’,5’-Dideoxyuridine | 35959-50-3 | Oligonucleotides |
| HY-154422 | 2’-Amino-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine | 158665-47-5 | Oligonucleotides |
| HY-154423 | 2′-Azido-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine | 177980-10-8 | Oligonucleotides |
| HY-154424 | 2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine | 174221-86-4 | Oligonucleotides |
| HY-154425 | 2-Amino-7-propargyl-7,8-dihydro-8-oxo-9-(beta-D-3-deoxy-ribofuranosyl)purine | 2389988-75-2 | Oligonucleotides |
| HY-154426 | 2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy-3’-fluoroguanosine | 2389988-77-4 | Oligonucleotides |
| HY-154428 | 2'-Deoxy-N2-isopropyl guanosine | 201528-73-6 | Oligonucleotides |
| HY-154429 | 2'-Deoxy-N2,N2-diethyl guanosine | 236389-19-8 | Oligonucleotides |
| HY-15443 | AM251 | 183232-66-8 | Reference compound |
| HY-154430 | 2’-Deoxy-N2-cyclopentyl guanosine | 1353757-90-0 | Oligonucleotides |
| HY-154432 | N1-Methyl-2’-deoxyinosine | 72398-31-3 | Oligonucleotides |
| HY-154434 | 3’-O-(2-Methoxyethyl)-5-methyluridine | 303197-29-7 | Oligonucleotides |
| HY-154436 | Anticonvulsant agent 2 | 75220-84-7 | Reference compound |
| HY-154437 | 3’-β-Amino-2’,3’-dideoxy-5’-O-methoxy trityluridine | 2072145-31-2 | Oligonucleotides |
| HY-154438 | RDR 02308 | 4155-82-2 | Reference compound |
| HY-154439 | 3’-β-Amino-2’,3’-dideoxy-5’-O-trityl-5-methyl uridine | 204688-08-4 | Oligonucleotides |
| HY-15444 | D159687 | 1155877-97-6 | Reference compound |
| HY-154440 | 2-Amino-6-chloro-9-(3’-O-methyl-beta-D-ribofuranosyl)-9H-purine | | Oligonucleotides |
| HY-154441 | N4-Benzoyl-3'-O-DMT-2'-O-(2-methoxyethyl)-5-methylcytidine | | Oligonucleotides |
| HY-154442 | Rev 2’-O-MOE-5MeC(Bz)-5’-amidite | | Oligonucleotides |
| HY-154443 | Rev dC(Bz)-5'-amidite | 140712-83-0 | Oligonucleotides |
| HY-154444 | DMTr-TNA-5MeU-amidite | 325683-94-1 | Oligonucleotides |
| HY-154445 | DMTr-TNA-U-amidite | 325683-95-2 | Oligonucleotides |
| HY-154447 | 5’-O-(p-Toluoyl)-2’-O-acetyl-3’-deoxy-3’-fluoro-6-chloroinosine | 1612192-06-9 | Oligonucleotides |
| HY-154448 | 3,5-Bis-O-(2,4-dichlorobenzyl)guanosine | 2095417-36-8 | Oligonucleotides |
| HY-154449 | N4-Benzoyl-3’-O-(2-methoxyethyl)-5-methylcytidine | | Oligonucleotides |
| HY-15445 | CTEP | 871362-31-1 | Reference compound |
| HY-154450 | N4-Benzoyl-5’-O-DMT-3’-O-(2-methoxyethyl)-5-methylcytidine | 256223-98-0 | Oligonucleotides |
| HY-154452 | 2-Amino-3’,5’-di-O-acetyl-N6,N6-dimethyl-2’-O-methyladenosine | | Oligonucleotides |
| HY-154453 | 4-Deoxy-xylo-uridine | 63527-47-9 | Oligonucleotides |
| HY-154454 | 3’-Deoxy-2’,5’-di-O-acetyl-8-hydroxyguanosine | 2389988-72-9 | Oligonucleotides |
| HY-154456 | 2’-Deoxy-N6-cyclopentyladenosine | 170711-45-2 | Oligonucleotides |
| HY-154457 | 2’-Deoxy-N6-(4-methoxybenzyl)adenosine | 157640-47-6 | Oligonucleotides |
| HY-154458 | 2’-Deoxy-N6-(3-methoxybenzyl)adenosine | 1947400-98-7 | Oligonucleotides |
| HY-154459 | N4-Benzoyl-2’-deoxy-5’-O-DMTr-2’-fluoro- 5-methylcytidine | | Oligonucleotides |
| HY-15446 | Basimglurant | 802906-73-6 | Reference compound |
| HY-154461 | 5-Azidomethyl-2’,3’,5’-tri-O-benzoyl uridine | 1884334-72-8 | Oligonucleotides |
| HY-154462 | 5-Azidomethyl-2’-beta-methyl-2’,3’,5’-tri-O-benzoyluridine | 2305416-08-2 | Oligonucleotides |
| HY-154463 | N2-iso-Butyroyl-3’-deoxy-3’-fluoro guanosine | 2080404-20-0 | Oligonucleotides |
| HY-154464 | N2-iso-Butyroyl-5'-O-DMT-3'-deoxy-3'-fluoroguanosine | 2080404-19-7 | Oligonucleotides |
| HY-154465 | 3’-F-3’-dG(iBu)-2’-phosphoramidite | 2080404-21-1 | Oligonucleotides |
| HY-154466 | 5’-O-(4,4’-Dimethoxytrityl)-3’-O-methyluridine | 127212-40-2 | Oligonucleotides |
| HY-154467 | 2′-Deoxy-6-thioinosine | 2239-64-7 | Oligonucleotides |
| HY-154468 | 6-O-Methyl-2’-O-methylinosine | | Oligonucleotides |
| HY-154469 | 5’-O-DMTr-2’-O-MOE inosine 3’-P-methyl phosphonamidite | | Oligonucleotides |
| HY-154470 | 8-Aza-2’-deoxyguanosine | 4546-73-0 | Oligonucleotides |
| HY-154472 | N4-Ethyl-2’-deoxycytidine | 70465-61-1 | Oligonucleotides |
| HY-154473 | 2’-Deoxy-N4-ethyl-5-methylcytidine | 25406-43-3 | Oligonucleotides |
| HY-154474 | 3’,4-Dideoxyuridine | 2095417-04-0 | Oligonucleotides |
| HY-154475 | 9-(2'-O-Acetyl-5'-O-benzoyl-3'-deoxy-beta-D-ribofuranosyl)-6-chloropurine | 1347118-41-5 | Oligonucleotides |
| HY-154477 | 2-Amino-6-chloro-9-(3-deoxy-beta-D-ribofuanosyl)-9H-purine | 1055035-48-7 | Oligonucleotides |
| HY-154478 | 3’-O-Acetyl-N2-iso-Butyroyl-2’-deoxy-guanosine | 74925-81-8 | Oligonucleotides |
| HY-15448 | Tezacaftor | 1152311-62-0 | Reference compound |
| HY-154480 | N4-Benzoyl-3’-O-methylcytidine | 85079-03-4 | Oligonucleotides |
| HY-154481 | 3’-O-Me-C(Bz)-2’-phosphoramidite | 179479-03-9 | Oligonucleotides |
| HY-154482 | N2-iso-Butyroyl-3’-O-methylguanosine | 160107-07-3 | Oligonucleotides |
| HY-154483 | N2-iso-Butyroyl-5’-O-(4,4’-dimethoxytrityl)-3’-O-methylguanosine | 103285-33-2 | Oligonucleotides |
| HY-154484 | 3’-O-Me-G(iBu)-2’-phosphoramidite | 179479-04-0 | Oligonucleotides |
| HY-154485 | 5'-O-DMTr-2'-O-methyl-N6-methyl adenosine 3'-CED phosphoramidite | 2348385-04-4 | Oligonucleotides |
| HY-154486 | 5’-O-DMTr-2’-OMe-5MeU-P-methyl phosphonamidite | | Oligonucleotides |
| HY-154487 | Glycerol dioleate | 25637-84-7 | Reference compound |
| HY-154488 | 3′-O-[(1,1-Dimethylethyl)dimethylsilyl]-2′-O-methyluridine | 171268-84-1 | Oligonucleotides |
| HY-154489 | 5-Bromo-2’-deoxy-2’-fluoro-β-D-arabinouridine | 69123-97-3 | Oligonucleotides |
| HY-15448A | (Rac)-Tezacaftor | 1226709-85-8 | Reference compound |
| HY-15448S | Tezacaftor-d4 | 1961280-24-9 | Isotope-Labeled Compounds |
| HY-15448S1 | Tezacaftor-d6 | 1961280-94-3 | Isotope-Labeled Compounds |
| HY-15449 | Kaempferide | 491-54-3 | Natural Products |
| HY-154490 | 5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-uridine | 2095417-47-1 | Oligonucleotides |
| HY-154491 | 5’-Deoxy-5-methyluridine | 56971-08-5 | Oligonucleotides |
| HY-154492 | 2’,3’-Bis(O-t-butyldimethylsilyl)-4’,5’-didehydro-5’-deoxyuridine | 128070-78-0 | Oligonucleotides |
| HY-154495 | N3-Methyl-5-methyluridine | 3650-91-7 | Oligonucleotides |
| HY-154496 | 2’-Deoxy-N3-methylcytidine | 5040-21-1 | Oligonucleotides |
| HY-154496A | 2’-Deoxy-N3-methylcytidine (hydriodide) | 79043-77-9 | Reference compound |
| HY-154498 | 1,2-Di-O-acetyl-3,5-di-O-benzoyl-3-beta-C-methyl-D-ribofuranose | 22672-43-1 | Oligonucleotides |
| HY-154499 | Methyl 4-C-hydroxymethyl-2,3-O-isopropylidene-beta-D-ribofuranoside | 55797-67-6 | Oligonucleotides |
| HY-15449A | (S)-Kaempferide | | Reference compound |
| HY-15449R | Kaempferide (Standard) | 491-54-3 | Reference Standards |
| HY-15450 | INCB 3284 (dimesylate) | 887401-93-6 | Reference compound |
| HY-154501 | 5-O-Benzoyl-1,2,3-tri-O-acetyl-4-C-methyl-D-ribofuranose | 503543-44-0 | Oligonucleotides |
| HY-154503 | 3-O-(4-Methoxybenzyl)-4-C-hydroxymethyl-1,2-O-isopropylidine-alpha-D-ribofuranose | 225233-47-6 | Oligonucleotides |
| HY-154504 | 5’-O-(4,4’-Dimethoxytrityl)-2’-beta-C-methyl adenosine | 2305415-95-4 | Oligonucleotides |
| HY-154506 | N2-Phenoxyacetylguanosine | 119824-66-7 | Oligonucleotides |
| HY-154507 | N2-Phenoxyacetyl-3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)guanosine | 131474-72-1 | Oligonucleotides |
| HY-154508 | FdUMP (triethylammonium) | 134-46-3 | Oligonucleotides |
| HY-15450A | INCB 3284 | 887401-92-5 | Reference compound |
| HY-15451 | MDA 19 | 1048973-47-2 | Reference compound |
| HY-154510 | 2’-Deoxy-N4-methylcytidine | 22882-02-6 | Oligonucleotides |
| HY-154511 | 2’-Deoxy-N4,N4-dimethylcytidine | 53213-03-9 | Oligonucleotides |
| HY-154512 | 5’-Deoxy-N4,N4-dimethyl-5-fluorocytidine | 933443-84-6 | Oligonucleotides |
| HY-154513 | 2’-Deoxy-5,N4-dimethylcytidine | 25406-44-4 | Oligonucleotides |
| HY-154514 | 2’-Deoxy-5,N4,N4-trimethylcytidine | 25406-45-5 | Oligonucleotides |
| HY-154515 | 2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine | 1260177-41-0 | Oligonucleotides |
| HY-154516 | 2-Chloro-9-(beta-D-ribofuranosyl)purine | 5466-11-5 | Oligonucleotides |
| HY-154517 | N3-Cyanoethyl-5’-O-(4,4’-dimethoxytrityl)-2’-O-methyluridine | | Oligonucleotides |
| HY-15451R | MDA 19 (Standard) | 1048973-47-2 | Reference Standards |
| HY-15452 | Selisistat | 49843-98-3 | Reference compound |
| HY-154520 | 2-Chloro-3′-deoxyadenosine | 115044-75-2 | Oligonucleotides |
| HY-154521 | 2-(4-Methylbenzyl)thioadenosine | 2095417-16-4 | Oligonucleotides |
| HY-154522 | 2-(2,4-Dichlorobenzyl)thioadenosine | 2095417-37-9 | Oligonucleotides |
| HY-154523 | 2-(4-Cyanobenzyl)thioadenosine | 2095417-56-2 | Oligonucleotides |
| HY-154524 | 1-(2-Deoxy-β-D-threo-pentofuranosyl)thymine | 16053-52-4 | Oligonucleotides |
| HY-154525 | 2’-Deoxy-2’-(N-trifluoroacetyl)amino-5’-O-DMTr-uridine 3’-CED phosphoramidite | 126139-44-4 | Oligonucleotides |
| HY-154526 | 1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)uridine | 325683-90-7 | Oligonucleotides |
| HY-154528 | 2’-O-Phthalimidopropyl cytidine | 165381-50-0 | Oligonucleotides |
| HY-154529 | 5’-O-DMTr-3’-O-phthalimidopropyl cytidine | | Oligonucleotides |
| HY-15452A | (S)-Selisistat | 848193-68-0 | Reference compound |
| HY-15452B | (R)-Selisistat | 848193-69-1 | Reference compound |
| HY-15453 | Devimistat | 95809-78-2 | Reference compound |
| HY-154530 | DMTr-TNA-C(Bz)-amidite | 325683-96-3 | Oligonucleotides |
| HY-154531 | 2′,3′-Dideoxy-3′-fluoro-5-methylcytidine | 115249-95-1 | Oligonucleotides |
| HY-154532 | 9-(5(R)-C-Methyl-2,3,5-tri-O-benzoyl-D-ribofuranosyl)-6-chloropurine | | Oligonucleotides |
| HY-154533 | 3’-O-Acetyl-2’-deoxyuridine | 23197-88-8 | Oligonucleotides |
| HY-154534 | Alpha-Adenosine | 5682-25-7 | Oligonucleotides |
| HY-154535 | Alpha-inosine | 38183-47-0 | Oligonucleotides |
| HY-154536 | Alpha-Guanosine | 15398-66-0 | Oligonucleotides |
| HY-154537 | 3’-O-Methyl inosine | 75479-64-0 | Oligonucleotides |
| HY-15453S | Devimistat-d10 | 2586055-61-8 | Isotope-Labeled Compounds |
| HY-15454 | Xevinapant | 1071992-99-8 | Reference compound |
| HY-154540 | Alpha-5-Methyluridine | 3258-09-1 | Oligonucleotides |
| HY-154541 | N2,N2-Dimethylamino-6-deamino adenosine | 105208-35-3 | Oligonucleotides |
| HY-154542 | 5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-uridine | 42867-74-3 | Oligonucleotides |
| HY-154543 | 5’-O-(4,4’-Dimethoxytrityl)-3’-O-(2-methoxyethyl) uridine | | Oligonucleotides |
| HY-154544 | 3’-O-MOE-U-2’-phosphoramidite | 1452849-90-9 | Oligonucleotides |
| HY-154545 | 3’-O-MOE-5MeU-2’-phosphoramidite | 256223-93-5 | Oligonucleotides |
| HY-154546 | 3’-O-MOE-5Me-C(Bz)-2’-phosphoramidite | 1098233-10-3 | Oligonucleotides |
| HY-154547 | N2-iso-Butyroyl-3’-O-(methoxyethyl)guanosine | 256224-04-1 | Oligonucleotides |
| HY-154548 | N2-iso-Butyroyl-5’-O-DMT-3’-O-(methoxyethyl)guanosine | 256224-05-2 | Oligonucleotides |
| HY-154549 | 3’-O-MOE-G(iBu)-2’-phosphoramidite | 256224-06-3 | Oligonucleotides |
| HY-15455 | Roflumilast | 162401-32-3 | Reference compound |
| HY-154550 | 2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-5-methyl uridine | 2305415-91-0 | Oligonucleotides |
| HY-154551 | 3’-O-Methyl-5-methyluridine | 2305415-87-4 | Oligonucleotides |
| HY-154552 | 2’-O-Acetyl-5’-O-benzoyl-3’-O-(2-methoxyethyl) uridine | | Oligonucleotides |
| HY-154553 | 3’,5’-Di-O-acetylthymidine | 6979-97-1 | Oligonucleotides |
| HY-154554 | 3’,5’-Di-O-benzoyl thymidine | 35898-30-7 | Oligonucleotides |
| HY-154555 | 5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-5-fluoro-uridine | 160203-74-7 | Oligonucleotides |
| HY-154556 | 2′,3′-Dideoxy-5-fluorouridine | 15379-30-3 | Oligonucleotides |
| HY-154557 | 2′,3′-Didehydro-2′,3′-dideoxy-5-fluorouridine | 15379-29-0 | Oligonucleotides |
| HY-154558 | 2′-Deoxy-6-O-methylinosine | 37109-88-9 | Oligonucleotides |
| HY-154559 | 2′-Deoxy-2-hydrazinyladenosine | 1000296-26-3 | Oligonucleotides |
| HY-15455R | Roflumilast (Standard) | 162401-32-3 | Reference Standards |
| HY-15455S | Roflumilast-d4 | 1398065-69-4 | Isotope-Labeled Compounds |
| HY-15455S1 | Roflumilast-d4 N-Oxide | 1794760-31-8 | Isotope-Labeled Compounds |
| HY-15455S2 | Roflumilast-d3 | 1189992-00-4 | Isotope-Labeled Compounds |
| HY-15456 | NVP-BVU972 | 1185763-69-2 | Reference compound |
| HY-154560 | 2’,3’,5’-Tri-O-acetyl-N3-methyluridine | 64623-26-3 | Oligonucleotides |
| HY-154561 | 3’,5’-Di-O-acetyl-2’-deoxy-N3-methyl uridine | 2305416-14-0 | Oligonucleotides |
| HY-154562 | 3’,5’-Di-O-acetyl-2’-deoxy-5,N3-dimethyluridine | 144874-49-7 | Oligonucleotides |
| HY-154563 | 2’,3’,5’-Tri-O-acetyl-5,N3-dimethyluridine | 201421-00-3 | Oligonucleotides |
| HY-154564 | 5’-Deoxy-5’-N-methylaminothymidine | 75191-50-3 | Oligonucleotides |
| HY-154565 | 5’-Deoxy-5’-N,N-dimethylamino thymidine | 162466-79-7 | Oligonucleotides |
| HY-154566 | 5’-Deoxy-5’-N,N-diethylamino thymidine | 2305415-88-5 | Oligonucleotides |
| HY-154567 | 5’-Deoxy-5’-N-(2-chloroethyl)amino thymidine | 2305415-99-8 | Oligonucleotides |
| HY-154568 | 5’-Deoxy-5’-(4-morpholinyl)thymidine | 2305415-93-2 | Oligonucleotides |
| HY-154569 | 5’-Deoxy-5’-furfurylamino thymidine | 2305416-15-1 | Oligonucleotides |
| HY-15457 | Triciribine | 35943-35-2 | Reference compound |
| HY-154570 | 3’-N-Acetyl-3’-amino-3’-deoxy-2’,5’-di-O-acetyluridine | 2305416-09-3 | Oligonucleotides |
| HY-154571 | 2’,3’,5’-Tri-O-acetyl-6-S-methyl-6-thio-guanosine | 80681-58-9 | Oligonucleotides |
| HY-154572 | 9-(2-O-Acetyl-3,5-di-O-benzoyl-β-D-xylofuranosyl)-6-chloro-9H-purine | 132370-61-7 | Oligonucleotides |
| HY-154573 | 2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine | 86137-72-6 | Oligonucleotides |
| HY-154575 | 2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine | 882435-02-1 | Oligonucleotides |
| HY-154578 | N1-Methyl-2'-deoxyadenosine | 60192-55-4 | Reference compound |
| HY-154579 | 3’-Azido-N6-benzoyl-3’-deoxyadenosine | 103597-10-0 | Oligonucleotides |
| HY-15458 | SAR131675 | 1433953-83-3 | Reference compound |
| HY-154581 | 5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-cytidine | 2095417-02-8 | Oligonucleotides |
| HY-154582 | 5-Naphthyl-beta-methylaminocarbony-3’-O-acetyl-2’-O-methyl-5’-O-DMTr-uridine | 2095417-00-6 | Oligonucleotides |
| HY-154583 | 3’,5’-Bis-O-benzoyl-2’-deoxy-2’-fluoro-β-D-arabinouridine | 128496-10-6 | Oligonucleotides |
| HY-154585 | VP-U-6 | 2361324-80-1 | Oligonucleotides |
| HY-154587 | 1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil | 2095417-38-0 | Oligonucleotides |
| HY-154588 | 1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil | 2095417-68-6 | Oligonucleotides |
| HY-154589 | 3',5'-Di-O-benzoyl fialuridine | 97614-45-4 | Oligonucleotides |
| HY-15458A | (S)-SAR131675 | | Reference compound |
| HY-15459 | Cabazitaxel | 183133-96-2 | Natural Products |
| HY-154590 | 2’,3’-Di-O-isopropylidene-4’-alpha-C-azidouridine | 690271-27-3 | Oligonucleotides |
| HY-154592 | DMTr-TNA-G(O6-CONPh2)(N2Ac)-amidite | 325683-97-4 | Oligonucleotides |
| HY-154593 | N4-Benzoyl-5’-O-DMTr-2’-O-(N3-trifluoroacetyl) aminopropyl cytidine | 1053243-01-8 | Oligonucleotides |
| HY-154594 | 5-(Aminomethyl)-2′,3′-O-(1-methylethylidene)-2-thiouridine | 1428903-07-4 | Oligonucleotides |
| HY-154595 | 2’,3’,5’-Tri-O-benzoyl-4-thiouridine | 15049-50-0 | Oligonucleotides |
| HY-154596 | 2,6-Bis(4-morpholinyl)-9-b-D-ribofuranosyl-9H-purine | | Oligonucleotides |
| HY-154597 | 2’-Chloro-N6-benzyl adenosine | 23558-62-5 | Oligonucleotides |
| HY-154599 | 5-Me-3’-dU-2’-phosphoramidite | 142103-12-6 | Oligonucleotides |
| HY-15459R | Cabazitaxel (Standard) | 183133-96-2 | Reference Standards |
| HY-15459S | Cabazitaxel-d6 | 1383561-29-2 | Isotope-Labeled Compounds |
| HY-15459S1 | Cabazitaxel-d9 | 1383572-19-7 | Isotope-Labeled Compounds |
| HY-15460 | CHIR-090 | 728865-23-4 | Reference compound |
| HY-154600 | N4-Benzoyl-3’-deoxycytidine | 161110-00-5 | Oligonucleotides |
| HY-154601 | N4-Benzoyl-5’-O-(4,4-dimethoxytrityl)-3’-deoxy cytidine | 86234-45-9 | Oligonucleotides |
| HY-154602 | 2’-dG (iBu)-2’-phosphoramidite | 157327-97-4 | Oligonucleotides |
| HY-154604 | 1-(2'-Deoxy-5'-O-DMT-2'-fluoro-b-D-arabinofuranosyl)thymine 3'-CE phosphoramidite | 208193-48-0 | Oligonucleotides |
| HY-154605 | N2-iso-Butyroyl-2’-fluoro-2’-deoxyarabinoguanosine | 308356-20-9 | Oligonucleotides |
| HY-154606 | 2'-F-2'-ara-N2-ibu-dG Phosphoramidite | 1404463-20-2 | Oligonucleotides |
| HY-154607 | 3’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-3’-fluorouridine | 129015-60-7 | Oligonucleotides |
| HY-154608 | 3'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-3'-fluoro uridine-2'-CED-phosphoramidite | 129015-63-0 | Oligonucleotides |
| HY-154609 | 2’-Bromo-2’-deoxy-5-fluorouridine | 32791-82-5 | Oligonucleotides |
| HY-15460R | CHIR-090 (Standard) | 728865-23-4 | Reference Standards |
| HY-15461 | Ertugliflozin | 1210344-57-2 | Reference compound |
| HY-154610 | 6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine | 148171-35-1 | Oligonucleotides |
| HY-154611 | 2’-Deoxy-2’-fluoro-5-methyl-4’-thio-a-D-arabino uridine | 294868-24-9 | Oligonucleotides |
| HY-154612 | 2’-Deoxy-2’-fluoro-4’-thio-a-D-arabinouridine | | Oligonucleotides |
| HY-154613 | (2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione | 142189-87-5 | Oligonucleotides |
| HY-154614 | 5’-(4,4’-Dimethoxytrityl)-5-methyluridine | 138239-62-0 | Oligonucleotides |
| HY-154615 | N4-Benzoyl-5'-O-DMTr-2'-O-(N3-trifluoroacetyl) aminopropyl cytidine 3'-CED phosphoramidite | 165381-54-4 | Oligonucleotides |
| HY-154616 | 2’-O-Phthalimidopropyl uridine | 165381-44-2 | Oligonucleotides |
| HY-154617 | 6-S-(2-Cyanoethyl)-2’-deoxy-5’-O-DMTr--6-thioguanosine 3’-CED phosphoramidite | | Oligonucleotides |
| HY-154618 | N4-Bz-5'-O-DMTr-3'-deoxy-3'-fluoro-beta-D-xylofuranosyl cytidine-2'-CED-phosphoramidite | 1555759-30-2 | Oligonucleotides |
| HY-15461A | Ertugliflozin L-pyroglutamic acid | 1210344-83-4 | Reference compound |
| HY-15461R | Ertugliflozin (Standard) | 1210344-57-2 | Reference Standards |
| HY-15461S | Ertugliflozin-d5 | 1298086-22-2 | Isotope-Labeled Compounds |
| HY-15461S1 | Ertugliflozin-d9 | | Isotope-Labeled Compounds |
| HY-15462 | SRT3109 | 1204707-71-0 | Reference compound |
| HY-154620 | 2′-O-Hexadecyl-adenosine | 211690-85-6 | Oligonucleotides |
| HY-154621 | 3’-O-Hexadecanyl adenosine | | Oligonucleotides |
| HY-154622 | N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine | 2382942-34-7 | Oligonucleotides |
| HY-154623 | N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine 3’-CED phosphoramidite | 2382942-35-8 | Oligonucleotides |
| HY-154624 | 2’-O-Hexadecanyl-2-aminoadenosine | 2382942-28-9 | Oligonucleotides |
| HY-154625 | 3’-O-Hexadecanyl-2-aminoadenosine | | Oligonucleotides |
| HY-154626 | 2’-O-Hexadecanyl guanosine | 2382942-29-0 | Oligonucleotides |
| HY-154627 | N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine | 2382942-31-4 | Oligonucleotides |
| HY-154628 | N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine 3’-CED phosphoramidite | 2382942-32-5 | Oligonucleotides |
| HY-154629 | Sesame Oil | 8008-74-0 | Reference compound |
| HY-15463 | Imatinib | 152459-95-5 | Reference compound |
| HY-154630 | Polyoxypropylene stearyl ether | 25231-21-4 | Reference compound |
| HY-154631 | Peanut Oil | 8002-03-7 | Reference compound |
| HY-154632 | Omega 3 fatty acid triglycerides | | Reference compound |
| HY-154633 | 3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine | | Oligonucleotides |
| HY-154634 | Cyclomethicone | 69430-24-6 | Reference compound |
| HY-154635 | Oxidized paraffin (calcium) | 68476-81-3 | Reference compound |
| HY-154636 | Liquid Paraffin | 8012-95-1 | Reference compound |
| HY-154636A | Light Liquid Paraffin | 8012-95-1 | Reference compound |
| HY-154637 | Sucrose Stearate | 25168-73-4 | Reference compound |
| HY-154639 | Polyoxyl 20 Cetostearyl Ether | 68439-49-6 | Reference compound |
| HY-15463R | Imatinib (Standard) | 152459-95-5 | Reference Standards |
| HY-15463S | Imatinib-d8 | 1092942-82-9 | Isotope-Labeled Compounds |
| HY-15463S1 | Imatinib-d4 | 1134803-16-9 | Isotope-Labeled Compounds |
| HY-15463S2 | Imatinib-d3 (hydrochloride) | 1134803-18-1 | Isotope-Labeled Compounds |
| HY-15463S3 | Imatinib-13C,d3 | | Isotope-Labeled Compounds |
| HY-15464 | (R)-(-)-Gossypol | 90141-22-3 | Natural Products |
| HY-154640 | 2’,3’,5’-Tri-O-acetyl-5-(trifluoromethyl)uridine | 84500-34-5 | Oligonucleotides |
| HY-154642 | 2’-Bromo-2’-deoxy-5-methyluridine | 95585-76-5 | Oligonucleotides |
| HY-154643 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine | 1612192-04-7 | Oligonucleotides |
| HY-154644 | Soya Lecithin | 8030-76-0 | Reference compound |
| HY-154644A | Soy lecithin-90 | 8030-76-0 | Biochemical Assay Reagents |
| HY-154644B | Soy lecithin-80 | 8030-76-0 | Biochemical Assay Reagents |
| HY-154646 | 2',3,5'-Tri-O-benzoyl-4'-thiouridine | 2072145-30-1 | Oligonucleotides |
| HY-154647 | N3-(2S)-[2-(tert-Butoxycarbonyl)amino-3-(tert-butoxy carbonyl)]propyluridine | | Oligonucleotides |
| HY-15464A | (R)-(-)-Gossypol acetic acid | 866541-93-7 | Reference compound |
| HY-15464D | (S)-Gossypol (acetic acid) | 1189561-66-7 | Reference compound |
| HY-15465 | KN-93 | 139298-40-1 | Reference compound |
| HY-154652 | 1-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-2,4(1H,3H)-pyrimidinedione | 23643-36-9 | Oligonucleotides |
| HY-154653 | 9-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-9H-purin-2-amine | 1345969-99-4 | Oligonucleotides |
| HY-154654 | 9-(2-β-C-Methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine | 2095417-45-9 | Oligonucleotides |
| HY-154655 | 6-Methyl-9-(2-β-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine | 2095417-61-9 | Oligonucleotides |
| HY-154658 | 2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine | 2072145-47-0 | Oligonucleotides |
| HY-154659 | Polycarbophil | 9003-97-8 | Reference compound |
| HY-15465A | KN-93 (hydrochloride) | 1956426-56-4 | Reference compound |
| HY-15465B | KN-93 (phosphate) | 1913269-12-1 | Reference compound |
| HY-15466 | Izorlisib | 1007207-67-1 | Reference compound |
| HY-154660 | N4-Benzoyl-2’-deoxy-5-iodocytidine | 158042-39-8 | Oligonucleotides |
| HY-154662 | 2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine | 2072145-25-4 | Oligonucleotides |
| HY-154663 | 1-β-D-Arabinofuranosyl-5-bromo-2,4(1H,3H)-pyrimidinedione | 3370-69-2 | Oligonucleotides |
| HY-154665 | N4-Benzoyl-N-DMTr-morpholino-5-methylcytosine-5'-O-phosphoramidite | | Oligonucleotides |
| HY-154666 | 3’-Azido-3’-deoxyinosine | 946497-27-4 | Oligonucleotides |
| HY-154667 | 1,2-Di-O-acetyl-3,5-di-O-benzyl-D-xylofuranose | 146986-45-0 | Oligonucleotides |
| HY-154668 | 5'-Homocytidine | 55085-34-2 | Oligonucleotides |
| HY-154669 | 9-(2,3-Di-O-acetyl-6-O-benzoyl-5-deoxy-D-ribo-exofuranoyl)-6-chloropurine | | Oligonucleotides |
| HY-15467 | ZM323881 | 193001-14-8 | Reference compound |
| HY-154670 | 5’-Homoadenosine | | Oligonucleotides |
| HY-154674 | N1-Allylpseudouridine | 1613530-15-6 | Oligonucleotides |
| HY-154675 | 2-Aminopurine-9-beta-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside | 2095417-63-1 | Oligonucleotides |
| HY-154676 | Purine-9-b-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside | 132723-01-4 | Oligonucleotides |
| HY-154677 | 2-Aminopurine-9-beta-D-(2’-deoxy)riboside | | Oligonucleotides |
| HY-154678 | 4’-Azido-3’-O-benzoyl-5’-O-(m-chlorobenzoyl)-2’-deoxy-2’-fluoro-beta-D-arabinouridine | 1333126-30-9 | Oligonucleotides |
| HY-154679 | 2-Chloro-6-(thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside | 1612192-01-4 | Oligonucleotides |
| HY-15467A | ZM323881 (hydrochloride) | 193000-39-4 | Reference compound |
| HY-15468 | IOX2 | 931398-72-0 | Reference compound |
| HY-154680 | 2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)uridine | | Oligonucleotides |
| HY-154681 | 2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine | | Oligonucleotides |
| HY-154682 | 2’-Deoxy-2’-fluoro-N3-(n-dodecyl)uridine | | Oligonucleotides |
| HY-154683 | 3',5'-Di-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabinocytidine | 128495-99-8 | Oligonucleotides |
| HY-154684 | 5-Benzylamino carbonyl-3’-O-acetyl-2’-O-methyl-5’-O-DMTr-uridine | 2095417-22-2 | Oligonucleotides |
| HY-154686 | 1-(3-β-Azido-2,3-dideoxy-5-O-trityl-D-threopenta-furanosyl)thymine | 66503-47-7 | Oligonucleotides |
| HY-154688 | 5’-O-(4,4’-Dimethoxytrityl)-N6-phenoxyacetyl adenosine | 121076-16-2 | Oligonucleotides |
| HY-154689 | N,N-Dibenzoyl-2’-O-methyladdenosine | | Oligonucleotides |
| HY-15468A | IOX2 (sodium) | 2377239-85-3 | Reference compound |
| HY-15469 | GW791343 (dihydrochloride) | 1019779-04-4 | Reference compound |
| HY-154692 | 2′-Deoxy-5-methylisocytidine | 19316-88-2 | Oligonucleotides |
| HY-154696 | Ferric oxide, yellow | 51274-00-1 | Reference compound |
| HY-154696A | Ferric oxide, red | 1309-37-1 | Biochemical Assay Reagents |
| HY-154697 | 3-epi-Azido-3-deoxythymidine | 73971-82-1 | Oligonucleotides |
| HY-154698 | Homouridine | 30685-57-5 | Oligonucleotides |
| HY-154699 | 5-(2-Hydroxyethyl)cytidine | 137248-64-7 | Oligonucleotides |
| HY-15470 | GW791343 (trihydrochloride) | 309712-55-8 | Reference compound |
| HY-154703 | Aluminum magnesium silicate | 12511-31-8 | Reference compound |
| HY-154704 | Calcium carboxymethyl cellulose | 9050-04-8 | Reference compound |
| HY-154705 | N-DMTr-Morpholino-U-5'-O-phosphoramidite | | Oligonucleotides |
| HY-154706 | N-DMTr-Morpholino-T-5'-O-phosphoramidite | | Oligonucleotides |
| HY-154707 | N-DMTr-N4-benzoyl-morpholino-cytosine-5’-O-phosphoramidite | | Oligonucleotides |
| HY-154708 | N-DMTr-N6-Benzoyl-morpholino-A-5'-O-phosphoramidite | | Oligonucleotides |
| HY-154709 | N-DMTr-N2-Isobutyryl-morpholino-G-5'-O-phosphoramidite | | Oligonucleotides |
| HY-154717 | 2-Deoxy-2’-fluoroisocytidine | 1668560-65-3 | Oligonucleotides |
| HY-154718 | 2-Amino-6-chloropurine-3’,5’-di-O-acetyl-2’-deoxyriboside | 69992-11-6 | Oligonucleotides |
| HY-154719 | 5’-O-Benzoylthymidine | 65475-51-6 | Oligonucleotides |
| HY-15472 | PRX-08066 | 866206-54-4 | Reference compound |
| HY-154720 | 3-O-Benzoyl-1,2: 5,6-bis(di-O-isopropylidene)-alpha-D-galactofuranose | 29474-73-5 | Oligonucleotides |
| HY-154721 | 5’-O-DMTr-5-iodo-2’-dU-3’-CED phosphoramidite | 178925-48-9 | Oligonucleotides |
| HY-154722 | N6-Dimethylaminomethylidene isoguanosine | 156706-72-8 | Oligonucleotides |
| HY-154723 | 2’-Deoxy-2’-fluoro-N3-(4-hydroxybenzyl)uridine | | Oligonucleotides |
| HY-154724 | 2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine | | Oligonucleotides |
| HY-154725 | 2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine | | Oligonucleotides |
| HY-154726 | 2’-Deoxy-2’-fluoro- N3-(2S)-(2-amino-3-carbonyl)-propyluridine | | Oligonucleotides |
| HY-154727 | 2’-Deoxy-2’-fluoro-N3-(3-aminopropyl)uridine | | Oligonucleotides |
| HY-154729 | 3’-O-Methyl-2’-O-acetyl-5’-O-benzoyluridine | 2072145-71-0 | Oligonucleotides |
| HY-15472A | PRX-08066 (maleate) | 866206-55-5 | Reference compound |
| HY-15473 | MLN120B | 783348-36-7 | Reference compound |
| HY-154730 | 9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-6-chloropurine | 2072145-46-9 | Oligonucleotides |
| HY-154731 | 9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-2,6-dichloropurine | 2072145-40-3 | Oligonucleotides |
| HY-154732 | 2-Thiopseudouridine | 59464-18-5 | Oligonucleotides |
| HY-154733 | 9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[5-(propyn-1-yl)pyridin-3-yl]purine | 1612191-95-3 | Oligonucleotides |
| HY-154734 | N3-(4-Nitrobenzyl)uridine | | Oligonucleotides |
| HY-154735 | N3-Allyluridine | 103951-13-9 | Oligonucleotides |
| HY-154736 | N3-(Butyn-3-yl)uridine | | Oligonucleotides |
| HY-154737 | N3-[(Pyrid-4-yl)methyl]uridine | | Oligonucleotides |
| HY-154738 | N3-[3-(tert-Butoxycarbonyl)amino]propyluridine | | Oligonucleotides |
| HY-154739 | Cristobalite | 14464-46-1 | Reference compound |
| HY-154739A | Amorphous silica | 112945-52-5 | Reference compound |
| HY-15473A | MLN120B (dihydrochloride) | 1782573-78-7 | Reference compound |
| HY-154740 | 3′-Chloro-3′-deoxythymidine | 25526-94-7 | Oligonucleotides |
| HY-154740R | 3′-Chloro-3′-deoxythymidine (Standard) | 25526-94-7 | Reference Standards |
| HY-154741S | 6-β-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione-15N2 | | Isotope-Labeled Compounds |
| HY-154743S | 4-Pregnen-11β,21-diol-3,20-dione-d8 | | Isotope-Labeled Compounds |
| HY-154744S | Trimegestone sulfate pyridinium salt-13C,d3 | | Isotope-Labeled Compounds |
| HY-154746S | 3-HPMA Potassium Salt-3-13C3,15N | | Isotope-Labeled Compounds |
| HY-154747S | Carebastine-d6 | | Isotope-Labeled Compounds |
| HY-154749S | Repaglinide M2-d5 | | Isotope-Labeled Compounds |
| HY-15475 | UK-5099 | 56396-35-1 | Reference compound |
| HY-154752S | 8,9-Dehydroestrone-d4 | | Isotope-Labeled Compounds |
| HY-154754S | Saxagliptin Metabolite-15N,d2 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-154757S | Iloperidone metabolite P88-d3 | | Isotope-Labeled Compounds |
| HY-154758S | 6-Alpha-Methyl-Cortisol-d4 | | Isotope-Labeled Compounds |
| HY-154759S | 6-Alpha-Methyl-Prednisolone-d4 | | Isotope-Labeled Compounds |
| HY-15476 | VU 0364439 | 1246086-78-1 | Reference compound |
| HY-154761S | Clopidogrel-13C,d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-154762S | Acetaminophen glucuronide-d4 | | Isotope-Labeled Compounds |
| HY-154763S | 3-Ethyladenine-d5 (hydroiodide) | | Isotope-Labeled Compounds |
| HY-154768S | Ciprofloxacin-piperazinyl-N-sulfate-d8 | | Isotope-Labeled Compounds |
| HY-154769S | 5-Androsten-3-β-ol-17-one-d6 | | Isotope-Labeled Compounds |
| HY-15477 | YS-49 | 132836-42-1 | Reference compound |
| HY-154771S | Clopidogrelat-13C,d4 | | Isotope-Labeled Compounds |
| HY-154772S | trans-3’-Hydroxycotinine-O-β-glucuronide-d3 | | Isotope-Labeled Compounds |
| HY-154773S | Artesunate-13C4 | | Isotope-Labeled Compounds |
| HY-154774S | Tetrahydro-11-deoxy-Cortisol-d5-21-O-β-Glucuronide | | Isotope-Labeled Compounds |
| HY-154775S | Ethinylestradiol sulfate-d4 | | Isotope-Labeled Compounds |
| HY-154776S | 8,9-Dehydroestrone 2,4,16,16-d4 | | Isotope-Labeled Compounds |
| HY-154777S | l-Gatifloxacin-d4 | | Isotope-Labeled Compounds |
| HY-154778S | Floxuridine-d3 | | Isotope-Labeled Compounds |
| HY-154779 | 5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine | 910129-15-6 | Oligonucleotides |
| HY-154779R | 5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine (Standard) | 910129-15-6 | Reference Standards |
| HY-15477A | YS-49 (monohydrate) | 3028631-24-2 | Reference compound |
| HY-15478 | WZ811 | 55778-02-4 | Reference compound |
| HY-154780S | Desmethylcerivastatin-d7 (sodium) | | Isotope-Labeled Compounds |
| HY-154781S | Hydroxycerivastatin-d3 (sodium) | 1260180-67-3 | Isotope-Labeled Compounds |
| HY-154784S | 6-Hydroxynaloxone-d3 | | Isotope-Labeled Compounds |
| HY-154785S | 6-Naltrexol-d3 | | Isotope-Labeled Compounds |
| HY-154787S | Descarboethoxyloratadine-d6 (diacetate) | | Isotope-Labeled Compounds |
| HY-154788S | Losartan acid-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-154789 | RTIOXA-43 | 2832067-72-6 | Reference compound |
| HY-15479 | TTP 22 | 329907-28-0 | Reference compound |
| HY-154790 | STn/sialyl-Tn | 114661-01-7 | Reference compound |
| HY-154795 | Magnesium isoglycyrrhizinate (hydrate) | 658701-67-8 | Natural Products |
| HY-154796 | 2-Methoxy-2’-deoxyadenosine | 24757-70-8 | Oligonucleotides |
| HY-154796R | 2-Methoxy-2’-deoxyadenosine (Standard) | 24757-70-8 | Reference Standards |
| HY-154797 | N,N-Dimethyldoxorubicin | 70222-95-6 | Reference compound |
| HY-154798 | AMPA receptor modulator-5 | 2034182-22-2 | Reference compound |
| HY-154799 | Anticancer agent 112 | 2495321-37-2 | Reference compound |
| HY-15480 | NSC 42834 | 195371-52-9 | Reference compound |
| HY-154800 | Anticancer agent 113 | 2495323-17-4 | Reference compound |
| HY-154801 | Biotin-PEG3-CONH-Ph-CF3-diazirine | 2845211-64-3 | Reference compound |
| HY-154802 | TCO-GK-PEG4-NHS ester | 2307311-19-7 | ADC Related |
| HY-154803 | DLin-M-K-DMA | 1221271-55-1 | Oligonucleotides |
| HY-154804 | DLin-M-C4-DMA | 1226909-66-5 | Oligonucleotides |
| HY-154807 | DQn-1 | 57343-54-1 | Reference compound |
| HY-154809 | (R)-M3913 | 2379783-61-4 | Reference compound |
| HY-15481 | KU14R | 189224-48-4 | Reference compound |
| HY-154812 | Gintemetostat | 2604513-16-6 | Reference compound |
| HY-154813 | 3′,5′-Di-O-acetyl-2′-deoxy-2′-fluorouridine | 10212-13-2 | Oligonucleotides |
| HY-154814S | Monohydroxy-3-butenyl-mercapturic acid-13C3,15N (sodium) | | Isotope-Labeled Compounds |
| HY-154817 | Metobromuron | 3060-89-7 | Reference compound |
| HY-154817R | Metobromuron (Standard) | 3060-89-7 | Reference Standards |
| HY-154818 | Bovine Serum Albumin, Acetylated | | Biochemical Assay Reagents |
| HY-15482 | D-64131 | 74588-78-6 | Reference compound |
| HY-154821 | DRI-C21041 | 2101765-78-8 | Reference compound |
| HY-154821A | DRI-C21041 (DIEA) | | Reference compound |
| HY-154822 | DRI-C25441 | 2101765-83-5 | Reference compound |
| HY-154823 | Gcase activator 2 | 2759897-35-1 | Reference compound |
| HY-154825 | 20-Hydroxyvitamin D3 | 651734-12-2 | Natural Products |
| HY-154828 | Uridine 3′,5′-diphosphate | 2922-95-4 | Reference compound |
| HY-154829 | AC-099 | 849459-88-7 | Reference compound |
| HY-154829A | AC-099 (hydrochloride) | 849335-07-5 | Reference compound |
| HY-15483 | DY131 | 95167-41-2 | Reference compound |
| HY-154830 | Lysophosphatidylcholine C19:0 | 108273-88-7 | Reference compound |
| HY-154831 | C22-Ceramide | 27888-44-4 | Natural Products |
| HY-154832 | Cav 3.2 inhibitor 4 | 1416984-93-4 | Reference compound |
| HY-154834 | BHQ-1 NHS | 916753-61-2 | Dye Reagents |
| HY-154835 | N6-[[(4-Azidophenyl)methoxy]carbonyl]-L-lysine | 1513855-74-7 | Reference compound |
| HY-154837S | Lu AA39835-d3 | | Isotope-Labeled Compounds |
| HY-154839 | c-Myc inhibitor 10 | 2299227-75-9 | Reference compound |
| HY-15484 | Pifithrin-α (hydrobromide) | 63208-82-2 | Reference compound |
| HY-154840 | 4-Thiouridine 5′-triphosphate (tetralithium) | 20188-72-1 | Reference compound |
| HY-154840A | 4-Thiouridine 5′-triphosphate (tetrasodium) | 68507-49-3 | Reference compound |
| HY-154842 | S-Gem | 2169925-98-6 | Reference compound |
| HY-154843 | C-Gem | 2169926-00-3 | Reference compound |
| HY-154844 | FAP Ligand 1 | 2230625-76-8 | Reference compound |
| HY-154846 | 4'-Aarboxylic acid imrecoxib | 896729-08-1 | Reference compound |
| HY-154847 | WM-662 | 1308257-47-7 | Reference compound |
| HY-154848 | UCL-TRO-1938 | 2919575-27-0 | Reference compound |
| HY-15485 | Zardaverine | 101975-10-4 | Reference compound |
| HY-154850 | F-CRI1 | 2991453-50-8 | Reference compound |
| HY-154851 | GSK-3 inhibitor 3 | 2227279-84-5 | Reference compound |
| HY-154852 | GSK-3 inhibitor 4 | 2227279-83-4 | Reference compound |
| HY-154854 | BBDDL2059 | 2691174-27-1 | Reference compound |
| HY-154855 | HDAC-IN-56 | 2814571-89-4 | Reference compound |
| HY-154857 | 1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine | 89947-80-8 | Natural Products |
| HY-154858 | C55 Prenol | 50426-50-1 | Natural Products |
| HY-15486 | Salubrinal | 405060-95-9 | Reference compound |
| HY-154860 | PTD10 | 2642231-19-2 | Reference compound |
| HY-154861 | Anticancer agent 118 | 864443-43-6 | Reference compound |
| HY-154862 | Anticancer agent 119 | 2928614-16-6 | Reference compound |
| HY-154864 | Cholesteryl nonadecanoate | 25605-90-7 | Natural Products |
| HY-154865 | Anticancer agent 121 | 2924532-47-6 | Reference compound |
| HY-154866 | Anticancer agent 122 | 2924532-50-1 | Reference compound |
| HY-154867 | DNMT2-IN-1 | | Reference compound |
| HY-154868 | MMP-13-IN-1 | 2925249-49-4 | Reference compound |
| HY-154869 | PD-1/PD-L1-IN-34 | 2924403-17-6 | Reference compound |
| HY-15487 | CE-224535 | 724424-43-5 | Reference compound |
| HY-154871 | α-D-Glucosamine 1-phosphate | 2152-75-2 | Reference compound |
| HY-154878 | Cholera toxin B subunit biotin conjugate | | Biochemical Assay Reagents |
| HY-154878A | Cholera toxin B subunit peroxidase conjugate | | Biochemical Assay Reagents |
| HY-15488 | A 438079 | 899507-36-9 | Reference compound |
| HY-15488A | A 438079 (hydrochloride) | 899431-18-6 | Reference compound |
| HY-15489 | Scriptaid | 287383-59-9 | Reference compound |
| HY-15490 | PF-670462 (dihydrochloride) | 950912-80-8 | Reference compound |
| HY-154909 | 6-Azauridine triphosphate | 6198-30-7 | Reference compound |
| HY-154909A | 6-Azauridine triphosphate (ammonium) | | Oligonucleotides |
| HY-15491 | AG-024322 | 837364-57-5 | Reference compound |
| HY-154910 | CC214-1 | 1021920-32-0 | Reference compound |
| HY-154912 | PAT1inh-B01 | 1775330-54-5 | Reference compound |
| HY-154912A | PAT1inh-B01 (hydrochloride) | | Reference compound |
| HY-154914 | GK16S | | Reference compound |
| HY-154915 | MC-EVCit-PAB-MMAE | 2873452-49-2 | ADC Related |
| HY-154918 | LysoPE(18:2/0:0) | 85046-18-0 | Natural Products |
| HY-154919 | DC-Y13-27 | | Reference compound |
| HY-15492 | AG-13958 | 319460-94-1 | Reference compound |
| HY-154921 | Lactosylceramide (bovine buttermilk) | 4682-48-8 | Biochemical Assay Reagents |
| HY-154921A | Lactosylceramide (porcine RBC) | | Biochemical Assay Reagents |
| HY-154922 | Palmitoyl coenzyme A | 1763-10-6 | Biochemical Assay Reagents |
| HY-154923 | Pentadecanoyl coenzyme A | 24870-39-1 | Biochemical Assay Reagents |
| HY-154924 | Thio-NADP | 19254-05-8 | Biochemical Assay Reagents |
| HY-154925 | Thio-NADH | 1921-48-8 | Biochemical Assay Reagents |
| HY-154927 | DSPE-PEG-Cy5 | 2315262-02-1 | Reference compound |
| HY-154928 | GW6340 | 405910-78-3 | Reference compound |
| HY-15492A | AG-13958 (mono(hydrochloride)) | 319463-49-5 | Reference compound |
| HY-15493 | AN-019 | 879507-25-2 | Reference compound |
| HY-15494 | Picropodophyllin | 477-47-4 | Natural Products |
| HY-154944 | JG-2016 | 2887480-87-5 | Reference compound |
| HY-154945 | N-(5-Amino-1-ribosyl-4-imidazolecarbonyl)-L-aspartic acid | 17388-80-6 | Reference compound |
| HY-154946 | SUCNR1-IN-1 | 2711753-52-3 | Reference compound |
| HY-154949 | WDR5-IN-6 | 326901-92-2 | Reference compound |
| HY-15494S1 | Picropodophyllin-d6 | | Isotope-Labeled Compounds |
| HY-15495 | Tanzisertib | 899805-25-5 | Reference compound |
| HY-154951 | Oct4 inducer-2 | 1494691-70-1 | Reference compound |
| HY-154954 | Ogremorphin | 352563-21-4 | Reference compound |
| HY-154956 | PIKfyve-IN-2 | 2245319-25-7 | Reference compound |
| HY-154957 | mTOR inhibitor-11 | 3033409-32-1 | Reference compound |
| HY-154958 | mTOR inhibitor-12 | 3033409-34-3 | Reference compound |
| HY-154959 | AZD4747 | 2489226-14-2 | Reference compound |
| HY-154959A | (9R,12aR)-AZD4747 | | Reference compound |
| HY-15496 | E6201 | 603987-35-5 | Reference compound |
| HY-154960 | Tubulin/AKT1-IN-1 | 2988927-63-3 | Reference compound |
| HY-154961 | Mcl-1 inhibitor 14 | | Reference compound |
| HY-154962 | Mcl-1 inhibitor 15 | | Reference compound |
| HY-154964 | RSV L-protein-IN-2 | 774130-99-3 | Reference compound |
| HY-154965 | Simnotrelvir | 2920904-06-7 | Reference compound |
| HY-154966 | RSV L-protein-IN-3 | 868860-35-9 | Reference compound |
| HY-154967 | RSV L-protein-IN-4 | 851657-60-8 | Reference compound |
| HY-154968 | RSV L-protein-IN-5 | 851658-28-1 | Reference compound |
| HY-154969 | JAK-IN-29 | | Reference compound |
| HY-15497 | AZD7687 | 1166827-44-6 | Reference compound |
| HY-154970 | BMPR2-IN-1 | | Reference compound |
| HY-154970A | BMPR2-IN-1 (TFA) | | Reference compound |
| HY-154971 | Ara-SH | | Reference compound |
| HY-154972 | α-Amylase/α-Glucosidase-IN-3 | | Reference compound |
| HY-154973 | AMPK activator 11 | 2948304-00-3 | Reference compound |
| HY-154974 | LNP Lipid-8 | 2408140-60-1 | Oligonucleotides |
| HY-154975 | SARS-CoV-2-IN-49 | | Reference compound |
| HY-154976 | SARS-CoV-2-IN-50 | | Reference compound |
| HY-154977 | ETAP | 2575731-47-2 | Reference compound |
| HY-154978 | Cisplatin-resistant cells-IN-1 | | Reference compound |
| HY-154979 | Anti-hepatic fibrosis agent 2 | 2380421-60-1 | Reference compound |
| HY-15498 | Rimegepant | 1289023-67-1 | Reference compound |
| HY-154980 | GPR52 receptor modulator 1 | 2642079-89-6 | Reference compound |
| HY-154981 | Mal-L-Dap(Boc)-OSu | 1703778-79-3 | ADC Related |
| HY-154984 | JET-209 | | Reference compound |
| HY-154985 | DSO-5a | 2195411-63-1 | Reference compound |
| HY-154986 | MARK4 inhibitor 2 | | Reference compound |
| HY-154987 | MARK4 inhibitor 3 | | Reference compound |
| HY-154988 | MARK4 inhibitor 4 | | Reference compound |
| HY-154989 | RdRP-IN-6 | | Reference compound |
| HY-15498A | Rimegepant (sulfate hydrate) | 1374024-48-2 | Reference compound |
| HY-154990 | RdRP-IN-7 | | Reference compound |
| HY-154992 | 2,4-Difluorophenylethynylcobalamin | 2101750-19-8 | Reference compound |
| HY-154993 | Gamma-Glutamyl Transferase-IN-1 | 2956809-71-3 | Reference compound |
| HY-154994 | JAK-IN-30 | 2891469-99-9 | Reference compound |
| HY-154995 | N-4′-(p-Trifluoromethylphenyl)butyl-DAB | 3033570-20-3 | Reference compound |
| HY-154996 | Gamma-Glutamyl Transferase-IN-2 | 2956809-82-6 | Reference compound |
| HY-154997 | 7OQL | | Reference compound |
| HY-154998 | α-Glucosidase-IN-27 | | Reference compound |
| HY-15500 | JM6 | 1008119-83-2 | Reference compound |
| HY-155001 | CSF1R-IN-15 | 2925744-43-8 | Reference compound |
| HY-155002 | hCYP3A4 Fluorogenic substrate 1 | 186299-00-3 | Reference compound |
| HY-155003 | TPEQM-DMA | | Dye Reagents |
| HY-155004 | SDH-IN-3 | 2805297-11-2 | Reference compound |
| HY-155005 | EGFR mutant-IN-2 | 2770009-06-6 | Reference compound |
| HY-155006 | PCSK9-IN-19 | | Reference compound |
| HY-155007 | DNA gyrase B-IN-2 | | Reference compound |
| HY-155008 | PROTAC HK2 Degrader-1 | 3033812-84-6 | Reference compound |
| HY-155009 | PHD2-IN-1 | 2768219-28-7 | Reference compound |
| HY-155010 | Steroid sulfatase/17β-HSD1-IN-5 | | Reference compound |
| HY-155011 | MB076 | 2832966-95-5 | ADC Related |
| HY-155012 | Mcl-1 inhibitor 16 | | Reference compound |
| HY-155013 | SARS-CoV-2-IN-43 | 31356-11-3 | Reference compound |
| HY-155014 | SARS-CoV-2-IN-44 | 1311271-71-2 | Reference compound |
| HY-155015 | SARS-CoV-2-IN-45 | | Reference compound |
| HY-155016 | SARS-CoV-2-IN-46 | | Reference compound |
| HY-155017 | 6-Iodoamiloride | 60398-23-4 | Reference compound |
| HY-155018 | Anticancer agent 127 | 2410953-19-2 | Reference compound |
| HY-155019 | Anticancer agent 128 | 2941243-62-3 | Reference compound |
| HY-15502 | PF-3635659 | 931409-24-4 | Reference compound |
| HY-155020 | Antitumor agent-101 | 2848632-52-8 | Reference compound |
| HY-155021 | PROTAC α-synuclein degrader 5 | 2781922-42-5 | Reference compound |
| HY-155022 | AChE-IN-30 | 2937454-22-1 | Reference compound |
| HY-155023 | Apoptosis inducer 13 | | Reference compound |
| HY-155024 | HAT-IN-8 | | Reference compound |
| HY-155025 | Antitrypanosomal agent 14 | 1447933-37-0 | Reference compound |
| HY-155026 | UPCDC30766 | 2152623-68-0 | Reference compound |
| HY-155027 | DPP-4-IN-8 | | Reference compound |
| HY-155028 | FGFR-IN-11 | 2658488-68-5 | Reference compound |
| HY-155029 | sEH inhibitor-16 | 2999636-75-6 | Reference compound |
| HY-15503 | PHA-690509 | 492445-28-0 | Reference compound |
| HY-155030 | α-Glucosidase-IN-25 | 2941473-92-1 | Reference compound |
| HY-155031 | MCI | | Reference compound |
| HY-155032 | P-gp inhibitor 15 | 2303508-09-8 | Reference compound |
| HY-155033 | SSI-4 | 1875084-68-6 | Reference compound |
| HY-155034 | Antitumor agent-102 | | Reference compound |
| HY-155035 | S07-1066 | 876625-29-5 | Reference compound |
| HY-155036 | Z1078601926 | 1493256-85-1 | Reference compound |
| HY-155037 | VE-PTP-IN-1 | | Reference compound |
| HY-155038 | Antitumor agent-104 | 2245272-16-4 | Reference compound |
| HY-155039 | Antitumor agent-105 | | Reference compound |
| HY-15504 | RGB-286638 | 784210-87-3 | Reference compound |
| HY-155040 | Antitumor agent-106 | | Reference compound |
| HY-155041 | Antihypertensive agent 2 | | Reference compound |
| HY-155042 | Antihypertensive agent 3 | | Reference compound |
| HY-155043 | Tubulin polymerization-IN-42 | 2640220-51-3 | Reference compound |
| HY-155044 | TMV-IN-5 | 1207318-92-0 | Reference compound |
| HY-155045 | TMV-IN-6 | | Reference compound |
| HY-155046 | FGFR4-IN-14 | 3027827-02-4 | Reference compound |
| HY-155047 | BDM91514 | 2892824-90-5 | Reference compound |
| HY-155048 | BDM91270 | 2892824-11-0 | Reference compound |
| HY-155049 | NMDA receptor antagonist 6 | | Reference compound |
| HY-15504A | RGB-286638 (free base) | 784210-88-4 | Reference compound |
| HY-15505 | RWJ-67657 | 215303-72-3 | Reference compound |
| HY-155050 | PRMT5-IN-31 | | Reference compound |
| HY-155051 | Antiproliferative agent-25 | | Reference compound |
| HY-155052 | PAD4-IN-2 | 2642327-52-2 | Reference compound |
| HY-155052A | PAD4-IN-2 (TFA) | | Reference compound |
| HY-155053 | ZIKV-IN-6 | | Reference compound |
| HY-155054 | Cysteine protease inhibitor-3 | | Reference compound |
| HY-155055 | Antiproliferative agent-26 | | Reference compound |
| HY-155056 | SARS-CoV-2 Mpro-IN-7 | | Reference compound |
| HY-155057 | SARS-CoV-2 Mpro-IN-8 | | Reference compound |
| HY-155058 | Nav1.3 channel inhibitor 1 | | Reference compound |
| HY-155059 | Antimycobacterial agent-6 | | Reference compound |
| HY-15506 | TAK-593 | 1005780-62-0 | Reference compound |
| HY-155060 | Antibacterial agent 144 | | Reference compound |
| HY-155061 | hCYP1B1-IN-1 | | Reference compound |
| HY-155062 | IR-251 | | Dye Reagents |
| HY-155063 | TRAP1-IN-1 | 3031102-94-7 | Reference compound |
| HY-155064 | TRAP1-IN-2 | 3031102-92-5 | Reference compound |
| HY-155065 | SB-1295 | | Reference compound |
| HY-155066 | FD274 | 2641899-38-7 | Reference compound |
| HY-155067 | Antitubercular agent-38 | | Reference compound |
| HY-155068 | FC-116 | 2417298-29-2 | Reference compound |
| HY-155069 | Antiproliferative agent-27 | | Reference compound |
| HY-15507 | VGX-1027 | 6501-72-0 | Reference compound |
| HY-155070 | SRE-II | | Reference compound |
| HY-155071 | MmpL3-IN-2 | 2944458-65-3 | Reference compound |
| HY-155072 | PROTAC BTK Degrader-5 | | Reference compound |
| HY-155073 | Tubulin inhibitor 35 | 2247047-77-2 | Reference compound |
| HY-155074 | EGFR-IN-79 | | Reference compound |
| HY-155075 | NC-R17 | 3049087-34-2 | Reference compound |
| HY-155076 | HIV-1 protease-IN-9 | 2925381-27-5 | Reference compound |
| HY-155077 | JNK-IN-12 | | Reference compound |
| HY-155078 | BRD4 Inhibitor-27 | 930039-92-2 | Reference compound |
| HY-155079 | DZD1516 | 2387570-00-3 | Reference compound |
| HY-155079A | (R)-DZD1516 | 2387570-03-6 | Reference compound |
| HY-15508 | JANEX-1 | 202475-60-3 | Reference compound |
| HY-155084 | Antifungal agent 61 | 2982657-98-5 | Reference compound |
| HY-155085 | hAChE-IN-3 | 2983723-56-2 | Reference compound |
| HY-155086 | hAChE-IN-4 | 2983723-58-4 | Reference compound |
| HY-155087 | Anticancer agent 140 | 389571-37-3 | Reference compound |
| HY-155088 | MK-8768 | 1432729-22-0 | Reference compound |
| HY-155089 | IACS-52825 | 2640376-72-1 | Reference compound |
| HY-15509 | Semapimod | 352513-83-8 | Reference compound |
| HY-155090 | ATM Inhibitor-8 | 2956666-60-5 | Reference compound |
| HY-155091 | ATM Inhibitor-9 | 2951007-81-9 | Reference compound |
| HY-155092 | DNA polymerase-IN-2 | 2953023-80-6 | Reference compound |
| HY-155093 | GLUT1-IN-3 | | Reference compound |
| HY-155094 | DNA polymerase-IN-3 | 381689-75-4 | Reference compound |
| HY-155095 | DNA polymerase-IN-4 | 2953023-85-1 | Reference compound |
| HY-155096 | Antibacterial agent 149 | | Reference compound |
| HY-155097 | SARS-CoV-2-IN-53 | | Reference compound |
| HY-155098 | CNBCA | | Reference compound |
| HY-155099 | FGH31 | | Reference compound |
| HY-15509A | Semapimod (tetrahydrochloride) | 164301-51-3 | Reference compound |
| HY-15510 | Tenovin-6 | 1011557-82-6 | Reference compound |
| HY-155100 | BI 7446 | 2767011-00-5 | Reference compound |
| HY-155101 | PD-L1-IN-3 | 2953044-29-4 | Reference compound |
| HY-155102 | PROTAC TG2 degrader-2 | | Reference compound |
| HY-155103 | Antitrypanosomal agent 15 | 2961381-94-0 | Reference compound |
| HY-155104 | MBL-IN-1 | | Reference compound |
| HY-155105 | α-Glucosidase-IN-30 | 2966859-35-6 | Reference compound |
| HY-155106 | SMA4 | | Reference compound |
| HY-155107 | ND-011992 | 2446880-46-0 | Reference compound |
| HY-155108 | OATD-02 | 2146132-73-0 | Reference compound |
| HY-155108B | OATD-02 (hydrochloride) | | Reference compound |
| HY-155109 | Antitumor agent-114 | 2757762-91-5 | Reference compound |
| HY-15510B | Tenovin-6 (Hydrochloride) | 1011301-29-3 | Reference compound |
| HY-15511 | Tyrphostin A9 | 10537-47-0 | Reference compound |
| HY-155110 | Antiviral agent 34 | 945152-88-5 | Reference compound |
| HY-155111 | nSMase2-IN-1 | 2968322-24-7 | Reference compound |
| HY-155112 | Antiproliferative agent-30 | 2713553-88-7 | Reference compound |
| HY-155113 | PROTAC Hsp90α degrader 1 | 3031078-90-4 | Reference compound |
| HY-155114 | HIV-1 inhibitor-59 | | Reference compound |
| HY-155115 | LSD1-IN-27 | 2904571-94-2 | Reference compound |
| HY-155116 | 5-HT6 agonist 1 | | Reference compound |
| HY-155117 | MRS7925 | | Reference compound |
| HY-155118 | EGFR-IN-81 | 2968419-65-8 | Reference compound |
| HY-155119 | SARS-CoV-2-IN-54 | | Reference compound |
| HY-15512 | OTSSP167 | 1431697-89-0 | Reference compound |
| HY-155120 | Cbl-b-IN-5 | 2368835-59-8 | Reference compound |
| HY-155121 | SARS-CoV-2-IN-56 | 3033198-21-6 | Reference compound |
| HY-155122 | PARP-1-IN-13 | 2999661-74-2 | Reference compound |
| HY-155123 | Antioxidant agent-13 | 2966778-87-8 | Reference compound |
| HY-155124 | Antiproliferative agent-32 | 2925814-05-5 | Reference compound |
| HY-155126 | LZWL02003 | 1371564-45-2 | Reference compound |
| HY-155127 | Antiproliferative agent-33 | 477542-73-7 | Reference compound |
| HY-155128 | LANA-DNA-IN-2 | 3033110-75-4 | Reference compound |
| HY-155129 | Antiviral agent 36 | 3033039-89-0 | Reference compound |
| HY-15512A | OTSSP167 (hydrochloride) | 1431698-10-0 | Reference compound |
| HY-15513 | TC-DAPK 6 | 315694-89-4 | Reference compound |
| HY-155130 | Antimalarial agent 31 | 3033682-50-4 | Reference compound |
| HY-155131 | Y18501 | 2410627-32-4 | Reference compound |
| HY-155132 | IRAK4-IN-28 | 2952532-92-0 | Reference compound |
| HY-155133 | COX-2-IN-34 | 2788578-71-0 | Reference compound |
| HY-155134 | Eg5-IN-1 | 3026790-10-0 | Reference compound |
| HY-155135 | HPPD-IN-1 | | Reference compound |
| HY-155136 | NSC89641 | | Reference compound |
| HY-155137 | CHBO4 | 98991-32-3 | Reference compound |
| HY-155138 | GLS1 Inhibitor-7 | | Reference compound |
| HY-155139 | Tubulin polymerization-IN-45 | | Reference compound |
| HY-15514 | Merestinib | 1206799-15-6 | Reference compound |
| HY-155140 | BChE-IN-17 | 2425632-57-9 | Reference compound |
| HY-155141 | hCYP3A4-IN-1 | 3003751-14-9 | Reference compound |
| HY-155142 | CDD-1819 | 2894104-40-4 | Reference compound |
| HY-155143 | CDD-1733 | 2894104-33-5 | Reference compound |
| HY-155144 | CDD-1845 | 2894104-50-6 | Reference compound |
| HY-155146 | Anticancer agent 146 | | Reference compound |
| HY-155147 | GLP-1 receptor agonist 13 | | Reference compound |
| HY-155148 | MAT2A-IN-11 | | Reference compound |
| HY-155149 | MAT2A-IN-12 | 631897-75-1 | Reference compound |
| HY-15514A | Merestinib dihydrochloride | 1206801-37-7 | Reference compound |
| HY-15515 | SEA0400 | 223104-29-8 | Reference compound |
| HY-155150 | JH-XII-03-02 | 2415900-86-4 | Reference compound |
| HY-155151 | RIPK2/3-IN-1 | | Reference compound |
| HY-155152 | P-gp/BCRP-IN-2 | | Reference compound |
| HY-155153 | CDK9-IN-24 | | Reference compound |
| HY-155154 | PRMT4-IN-2 | | Reference compound |
| HY-155154A | PRMT4-IN-3 | | Reference compound |
| HY-155155 | SARS-CoV-2-IN-57 | 1265624-68-7 | Reference compound |
| HY-155156 | PF-07238025 | | Reference compound |
| HY-155157 | PF-07247685 | | Reference compound |
| HY-155158 | Anticancer agent 147 | 2241283-11-2 | Reference compound |
| HY-155159 | COX-2/15-LOX-IN-2 | | Reference compound |
| HY-15516 | Sotagliflozin | 1018899-04-1 | Reference compound |
| HY-155160 | COX-2/15-LOX-IN-3 | | Reference compound |
| HY-155161 | COX-2/15-LOX-IN-4 | | Reference compound |
| HY-155163 | APG-2449 | 2196186-84-0 | Reference compound |
| HY-155164 | WF-3681 | 105364-56-5 | Reference compound |
| HY-155165 | Dazonone | 105622-85-3 | Reference compound |
| HY-155166 | Carbethopendecinium (bromide) | 10567-02-9 | Reference compound |
| HY-155167 | Anticancer agent 151 | 1227476-97-2 | Reference compound |
| HY-155168 | Iso-RJW100 | 1276664-61-9 | Reference compound |
| HY-155169 | hLTA4H/hLTA4S-IN-1 | 128253-12-3 | Reference compound |
| HY-15517 | KN-92 | 176708-42-2 | Reference compound |
| HY-155170 | MTDH-SND1 blocker 1 | 1341030-00-9 | Reference compound |
| HY-155172 | ZX-J-19j | 1352576-02-3 | Reference compound |
| HY-155174 | Antiangiogenic agent 4 | 2974488-31-6 | Reference compound |
| HY-155175 | TIM-3-IN-2 | 1113126-49-0 | Reference compound |
| HY-155176 | SP-2-225 | 2364448-93-9 | Reference compound |
| HY-155177 | CDK9-IN-27 | | Reference compound |
| HY-155178 | Antiproliferative agent-34 | 2910858-34-1 | Reference compound |
| HY-155179 | ZMF-23 | | Reference compound |
| HY-15517A | KN-92 (phosphate) | 1135280-28-2 | Reference compound |
| HY-15517B | KN-92 (hydrochloride) | 1431698-47-3 | Reference compound |
| HY-15518 | LCL161 | 1005342-46-0 | Reference compound |
| HY-155180 | FD2056 | 2685870-87-3 | Reference compound |
| HY-155181 | hCES2-IN-1 | 2994634-52-3 | Reference compound |
| HY-155182 | HDAC-IN-62 | | Reference compound |
| HY-155183 | A3AR agonist 1 | | Reference compound |
| HY-155184 | A3AR agonist 2 | | Reference compound |
| HY-155185 | NMDA receptor antagonist 7 | | Reference compound |
| HY-155185A | NMDA receptor antagonist 8 | | Reference compound |
| HY-155186 | SARS-CoV-2 3CLpro-IN-19 | | Reference compound |
| HY-155187 | SARS-CoV-2 3CLpro-IN-20 | 878985-00-3 | Reference compound |
| HY-155188 | NWP-0476 | 2290611-26-4 | Reference compound |
| HY-155189 | IIIM-8 | 1128053-62-2 | Reference compound |
| HY-15519 | LBW242 | 867324-12-7 | Reference compound |
| HY-155190 | Antitubercular agent-39 | 1357796-08-7 | Reference compound |
| HY-155191 | Galectin-3/galectin-8-IN-1 | | Reference compound |
| HY-155192 | Galectin-3/galectin-8-IN-2 | | Reference compound |
| HY-155193 | XY-52 | | Reference compound |
| HY-155195 | FLT3/CHK1-IN-1 | 2991054-23-8 | Reference compound |
| HY-155196 | ER degrader 6 | 2922929-62-0 | Reference compound |
| HY-155197 | ER degrader 7 | 2922929-63-1 | Reference compound |
| HY-155198 | Antifungal agent 72 | 3032485-62-1 | Reference compound |
| HY-155199 | PDE1-IN-5 | 2982945-34-4 | Reference compound |
| HY-15520 | CGK733 | 905973-89-9 | Reference compound |
| HY-155200 | EGFR-IN-84 | | Reference compound |
| HY-155201 | YJ182 | 3035446-91-1 | Reference compound |
| HY-155202 | YJ196 | 3035447-45-8 | Reference compound |
| HY-155203 | Anticancer agent 154 | | Reference compound |
| HY-155204 | LTB4-IN-2 | | Reference compound |
| HY-155205 | GV150013X | 151386-96-8 | Reference compound |
| HY-155206 | (+)-OSU6162 | 160777-43-5 | Reference compound |
| HY-155207 | Antileishmanial agent-23 | 745033-86-7 | Reference compound |
| HY-155209 | SCD1 inhibitor-5 | 1673558-59-2 | Reference compound |
| HY-15521 | ETP-46464 | 1345675-02-6 | Reference compound |
| HY-155211 | mTOR inhibitor-13 | 1144075-44-4 | Reference compound |
| HY-155215 | Tenilapine | 82650-83-7 | Reference compound |
| HY-155216 | PKM2 activator 10 | 2490276-04-3 | Reference compound |
| HY-155218 | TMX-2172 | 2488892-09-5 | Reference compound |
| HY-155219 | TH9028 | 2379556-15-5 | Reference compound |
| HY-15522 | WAY-267464 | 847375-16-0 | Reference compound |
| HY-155221 | UNC7145 | 2561494-78-6 | Reference compound |
| HY-155222 | TW9 | 2614417-90-0 | Reference compound |
| HY-155224 | Sulpho NONOate | 61142-90-3 | Reference compound |
| HY-155226 | FLT3-IN-21 | | Reference compound |
| HY-155227 | ALK/EGFR-IN-1 | 2730430-08-5 | Reference compound |
| HY-155227A | ALK/EGFR-IN-2 | 2730432-75-2 | Reference compound |
| HY-155227B | ALK/EGFR-IN-3 | 2730432-72-9 | Reference compound |
| HY-155227S | ALK/EGFR-IN-1-d5 | 2730429-93-1 | Reference compound |
| HY-155228 | LK-44 | | Reference compound |
| HY-155229 | CBP/p300-IN-21 | 1065581-69-2 | Reference compound |
| HY-15523 | Braco-19 | 351351-75-2 | Reference compound |
| HY-155230 | T3SS-IN-2 | | Reference compound |
| HY-155231 | Neutrophil elastase inhibitor 4 | | Reference compound |
| HY-155232 | PI3Kδ-IN-16 | 2766437-35-6 | Reference compound |
| HY-155233 | Steroid sulfatase-IN-5 | | Reference compound |
| HY-155234 | Steroid sulfatase-IN-6 | | Reference compound |
| HY-155235 | Steroid sulfatase-IN-7 | | Reference compound |
| HY-155236 | Ancistrotecine B | | Natural Products |
| HY-155237 | LIN28-IN-1 | | Reference compound |
| HY-155238 | E2730 | 1520073-91-9 | Reference compound |
| HY-155239 | VEGFR-2-IN-35 | 2634356-52-6 | Reference compound |
| HY-15523A | Braco-19 (trihydrochloride) | 1177798-88-7 | Reference compound |
| HY-155240 | Tyrosinase-IN-13 | | Reference compound |
| HY-155241 | α-Amylase/α-Glucosidase-IN-4 | | Reference compound |
| HY-155242 | VEGFR-2-IN-36 | | Reference compound |
| HY-155243 | 12R-LOX-IN-1 | 857758-13-5 | Reference compound |
| HY-155244 | 12R-LOX-IN-2 | 3026677-37-9 | Reference compound |
| HY-155245 | A09-003 | 2911646-14-3 | Reference compound |
| HY-155246 | PARP1-IN-15 | | Reference compound |
| HY-155247 | Tyrosinase-IN-14 | | Reference compound |
| HY-155248 | HL23 | 1448355-15-4 | Reference compound |
| HY-155249 | KGP591 | 3018962-69-8 | Reference compound |
| HY-155250 | Antibacterial agent 154 | 2163048-45-9 | Reference compound |
| HY-155251 | anti-TNBC agent-3 | 2422001-25-8 | Reference compound |
| HY-155252 | Spinosyn A aglycone | 149560-97-4 | Reference compound |
| HY-155253 | Sphinganine-1-phosphate (d17:0) | 474923-29-0 | Natural Products |
| HY-155254 | Sodium ionophore VI | 80403-59-4 | Reference compound |
| HY-155255 | Thalidomide-5-PEG2-NH2 (hydrochloride) | 2761406-70-4 | Reference compound |
| HY-155256 | Thalidomide-5-PEG6-NH2 (hydrochloride) | | Reference compound |
| HY-155257 | Thalidomide-5-PEG7-NH2 (hydrochloride) | | Reference compound |
| HY-155258 | Pomalidomide-PEG7-NH2 (hydrochloride) | | Reference compound |
| HY-155259 | Pomalidomide-5-C3-NH2 (hydrochloride) | | Reference compound |
| HY-15526 | PSI-697 | 851546-61-7 | Reference compound |
| HY-155260 | Pomalidomide-5-C4-NH2 (hydrochloride) | | Reference compound |
| HY-155261 | Pomalidomide-5-C5-NH2 (hydrochloride) | 2925306-39-2 | Reference compound |
| HY-155262 | Pomalidomide-5-C6-NH2 (hydrochloride) | 3007650-02-1 | Reference compound |
| HY-155263 | Pomalidomide-5-C7-NH2 (hydrochloride) | 3032282-75-7 | Reference compound |
| HY-155264 | Pomalidomide-5-C8-NH2 (hydrochloride) | 2863635-03-2 | Reference compound |
| HY-155265 | Pomalidomide-5-C9-NH2 (hydrochloride) | 2925306-22-3 | Reference compound |
| HY-155266 | Pomalidomide-5-C10-NH2 (hydrochloride) | 2863635-00-9 | Reference compound |
| HY-155267 | Pomalidomide-5-C11-NH2 (hydrochloride) | | Reference compound |
| HY-155268 | Pomalidomide-5-C12-NH2 (hydrochloride) | | Reference compound |
| HY-155269 | Pomalidomide-5-C13-NH2 (hydrochloride) | | Reference compound |
| HY-15527 | Emapunil | 226954-04-7 | Reference compound |
| HY-155270 | Pomalidomide-5-C14-NH2 (hydrochloride) | | Reference compound |
| HY-155271 | hCAXII-IN-7 | | Reference compound |
| HY-155272 | SHP2-IN-16 | | Reference compound |
| HY-155273 | SHP2-IN-17 | 2941498-93-5 | Reference compound |
| HY-155274 | SHP2-IN-18 | 2941498-87-7 | Reference compound |
| HY-155275 | SHP2-IN-19 | 2941498-84-4 | Reference compound |
| HY-155276 | SHP2-IN-20 | 2941498-94-6 | Reference compound |
| HY-155277 | SHP2-IN-21 | 2941499-08-5 | Reference compound |
| HY-155278 | Anticancer agent 162 | 2761736-66-5 | Reference compound |
| HY-155279 | Antifungal agent 73 | 2923519-78-0 | Reference compound |
| HY-15528 | kb NB 142-70 | 1233533-04-4 | Reference compound |
| HY-155280 | SARS-CoV-2-IN-60 | | Reference compound |
| HY-155281 | Antiparasitic agent-18 | 2821884-59-5 | Reference compound |
| HY-155282 | FASN-IN-6 | 3032387-88-2 | Reference compound |
| HY-155283 | Zndm19 | 364055-05-0 | Reference compound |
| HY-155284 | K1833 | | Reference compound |
| HY-155285 | YS-363 | 2470908-90-6 | Reference compound |
| HY-155286 | (7S,8R,17S)-RCTR1 | 2095607-49-9 | Reference compound |
| HY-155288 | DosatiLink-1 | 2941512-37-2 | Reference compound |
| HY-155289 | DosatiLink-2 | 2941512-38-3 | Reference compound |
| HY-15529 | S0859 | 1019331-10-2 | Reference compound |
| HY-155290 | PonatiLink-1-24 | 2941512-45-2 | Reference compound |
| HY-155291 | 3'-Mant-GDP | 91828-87-4 | Reference compound |
| HY-155295 | Z-CITCO | 2583138-04-7 | Reference compound |
| HY-155297 | Nebidrazine | 55248-23-2 | Reference compound |
| HY-155299 | PITB | | Reference compound |
| HY-15530 | CID-2858522 | 758679-97-9 | Reference compound |
| HY-155300 | BLT2 antagonist-1 | 2069220-61-5 | Reference compound |
| HY-155301 | Antileishmanial agent-24 | 2999670-36-7 | Reference compound |
| HY-155302 | FLT3-IN-22 | | Reference compound |
| HY-155303 | DCLK1-IN-2 | 2978517-43-8 | Reference compound |
| HY-155304 | BuChE-IN-8 | | Reference compound |
| HY-155305 | BuChE-IN-9 | | Natural Products |
| HY-155306 | TGR5 agonist 3 | 2148317-51-3 | Reference compound |
| HY-155307 | TGR5 agonist 4 | | Reference compound |
| HY-155308 | SARS-CoV-2-IN-61 | 3044004-40-9 | Reference compound |
| HY-155309 | LM-41 | 2996821-30-6 | Reference compound |
| HY-15531 | Venetoclax | 1257044-40-8 | Reference compound |
| HY-155310 | AF-2112 | 2996821-62-4 | Reference compound |
| HY-155311 | NKG2D-IN-1 | | Reference compound |
| HY-155312 | NKG2D-IN-2 | | Reference compound |
| HY-155313 | β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE | | Reference compound |
| HY-155314 | Tubulin polymerization-IN-50 | 2998928-21-3 | Reference compound |
| HY-155315 | Tubulin polymerization-IN-51 | 2998928-27-9 | Reference compound |
| HY-155316 | 5-HT6R antagonist 2 | 1622175-20-5 | Reference compound |
| HY-155318A | GPR3 agonist-2 | 1983120-51-9 | Reference compound |
| HY-155319 | μ opioid receptor agonist 3 | 2378397-91-0 | Reference compound |
| HY-15531R | Venetoclax (Standard) | 1257044-40-8 | Reference Standards |
| HY-15531S | Venetoclax-d8 | 1257051-06-1 | Isotope-Labeled Compounds |
| HY-15531S1 | Venetoclax-d6 | | Isotope-Labeled Compounds |
| HY-15532 | SCH900776 | 891494-63-6 | Reference compound |
| HY-155320 | Mu opioid receptor antagonist 7 | 2378397-30-7 | Reference compound |
| HY-155321 | NXT-10796 | | Reference compound |
| HY-155322 | Cy3-PEG2-TCO | | Dye Reagents |
| HY-155323 | Cy3-PEG3-TCO | | Dye Reagents |
| HY-155324 | Cy3-PEG7-TCO | | Dye Reagents |
| HY-155325 | Cy3-PEG2-TCO4 | | Dye Reagents |
| HY-155326 | Cy3-PEG3-TCO4 | | Dye Reagents |
| HY-155327 | Cy3-PEG2-endo-BCN | 1663449-60-2 | Dye Reagents |
| HY-155327A | Cy3-PEG2-exo-BCN | | Dye Reagents |
| HY-155327B | Cy3-PEG2-endo-BCN (bromide) | | Dye Reagents |
| HY-155328 | GK444 | 3032392-39-2 | Reference compound |
| HY-155329 | GK718 | 3032392-65-4 | Reference compound |
| HY-15532B | SCH900776 (S-isomer) | 891494-64-7 | Reference compound |
| HY-15533 | LY 3000328 | 1373215-15-6 | Reference compound |
| HY-155330 | PZ-1922 | | Reference compound |
| HY-155330A | PZ-1922 (free base) | 1648745-65-6 | Reference compound |
| HY-155331 | Antifungal agent 77 | 2863678-89-9 | Reference compound |
| HY-155332 | AB131 | 720671-77-2 | Reference compound |
| HY-155333 | Antibiofilm agent-1 | 2001602-10-2 | Reference compound |
| HY-155334 | RyRs activator 4 | 2987900-56-9 | Reference compound |
| HY-155335 | FPR2 agonist 3 | 2829263-19-4 | Reference compound |
| HY-155336 | CB2R agonist 2 | | Reference compound |
| HY-155337 | eIF4E-IN-6 | | Reference compound |
| HY-155338 | SWTX-143 | 2766575-48-6 | Reference compound |
| HY-155339 | Anticancer agent 168 | 207399-56-2 | Reference compound |
| HY-15534 | JC-1 | 3520-43-2 | Dye Reagents |
| HY-155341 | HSK205 | 3022263-37-9 | Reference compound |
| HY-155342 | A3373 | 2324948-66-3 | Reference compound |
| HY-155343 | A4333 | 3025827-56-6 | Reference compound |
| HY-155344 | α-Glucosidase-IN-38 | 2991427-89-3 | Reference compound |
| HY-155345 | AChE-IN-45 | | Reference compound |
| HY-155346 | Free radical scavenger 1 | 2989970-81-0 | Reference compound |
| HY-155348 | Ru3 | | Reference compound |
| HY-155349 | AChE/BuChE-IN-4 | 1997158-25-4 | Reference compound |
| HY-15535 | DMAT | 749234-11-5 | Reference compound |
| HY-155350 | Tubulin polymerization-IN-53 | | Reference compound |
| HY-155351 | PARP7-IN-15 | 2819998-97-3 | Reference compound |
| HY-155352 | mGluR5 antagonist-1 | 2761424-76-2 | Reference compound |
| HY-155354 | Antimalarial agent 33 | | Reference compound |
| HY-155355 | LY836 | | Reference compound |
| HY-155356 | YN14 | | Reference compound |
| HY-155357 | Antibacterial agent 160 | 1854892-66-2 | Reference compound |
| HY-155358 | Os30 | 2998928-68-8 | Reference compound |
| HY-155359 | Tubulin polymerization-IN-55 | 2942396-29-2 | Reference compound |
| HY-15536 | Cebranopadol | 863513-91-1 | Reference compound |
| HY-155360 | MY-1076 | 3008262-76-5 | Reference compound |
| HY-155361 | PROTAC BRD9 Degrader-7 | | Reference compound |
| HY-155362 | Tubulin polymerization-IN-56 | 2966790-98-5 | Reference compound |
| HY-155363 | AMPK activator 13 | | Reference compound |
| HY-155364 | Antimicrobial agent-26 | 3026743-44-9 | Reference compound |
| HY-155365 | hAChE-IN-5 | 3007667-15-1 | Reference compound |
| HY-155366 | hAChE-IN-6 | 3007667-17-3 | Reference compound |
| HY-155367 | mAChR antagonist 1 | 101491-79-6 | Reference compound |
| HY-155368 | BChE-IN-20 | 1428439-79-5 | Reference compound |
| HY-155369 | BChE-IN-21 | | Reference compound |
| HY-15536A | Cebranopadol ((1α,4α)stereoisomer) | 863513-93-3 | Reference compound |
| HY-15536B | Cebranopadol (hemicitrate) | 863513-92-2 | Reference compound |
| HY-15537 | Tilbroquinol | 7175-09-9 | Reference compound |
| HY-155370 | IR808-TZ | | Reference compound |
| HY-155371 | BT-PROTAC | 3032848-64-6 | Reference compound |
| HY-155372 | α-Glucosidase-IN-39 | | Reference compound |
| HY-155373 | Antioxidant agent-16 | | Reference compound |
| HY-155374 | PP5-IN-1 | 1022417-69-1 | Reference compound |
| HY-155375 | AtPCO4-IN-1 | 316134-38-0 | Reference compound |
| HY-155376 | mTOR inhibitor-14 | | Reference compound |
| HY-155377 | PLK1/p38γ-IN-1 | 2418614-81-8 | Reference compound |
| HY-155378 | PZ-1190 | 1852517-78-2 | Reference compound |
| HY-155379 | β-Herpesvirus protease-IN-1 | | Reference compound |
| HY-15538 | Ebrotidine | 100981-43-9 | Reference compound |
| HY-155380 | Antiproliferative agent-41 | 225652-93-7 | Reference compound |
| HY-155381 | APS3 | 1225373-70-5 | Reference compound |
| HY-155382 | Lactate transportor 1 | | Reference compound |
| HY-155383 | TNIR7-1A | 2301931-35-9 | Reference compound |
| HY-155385 | 10-Oxo-12(Z),15(Z)-octadecadienoic acid | 1036406-73-1 | Reference compound |
| HY-155386 | Peroxynitrite (sodium) | 14042-01-4 | Reference compound |
| HY-155387 | ZK-PI-5 | | Reference compound |
| HY-155388 | ZK-PI-9 | | Reference compound |
| HY-155389 | Caspase-3 activator 2 | 2999724-52-4 | Reference compound |
| HY-15539 | Niperotidine | 84845-75-0 | Reference compound |
| HY-155390 | Caspase-3 activator 3 | 2999724-54-6 | Reference compound |
| HY-155391 | hCA/Wnt/β-catenin-IN-1 | 3032826-63-1 | Reference compound |
| HY-155392 | Mz325 | 3032670-12-2 | Reference compound |
| HY-155393 | PROTAC BRD4 Degrader-22 | 3032850-37-3 | Reference compound |
| HY-155394 | RyRs activator 5 | | Reference compound |
| HY-155395 | DDAN-MT | | Dye Reagents |
| HY-155396 | PRO-HD1 | | Reference compound |
| HY-155397 | PRO-HD2 | | Reference compound |
| HY-155398 | PRO-HD3 | | Reference compound |
| HY-155399 | Antitrypanosomal agent 16 | | Reference compound |
| HY-15540 | Metiamide | 34839-70-8 | Reference compound |
| HY-155400 | Antitrypanosomal agent 17 | | Reference compound |
| HY-155401 | Antitrypanosomal agent 18 | | Reference compound |
| HY-155402 | Antiproliferative agent-42 | 3002404-74-9 | Reference compound |
| HY-155403 | SCD1/5-IN-1 | 1241494-17-6 | Reference compound |
| HY-155404 | Adenylyl cyclase-IN-1 | 731827-16-0 | Reference compound |
| HY-155405 | Anti-inflammatory agent 64 | 3016401-76-3 | Reference compound |
| HY-155406 | Estrogen receptor modulator 10 | 2991504-90-4 | Reference compound |
| HY-155407 | ALR-6 | 6621-92-7 | Reference compound |
| HY-155408 | ALR-27 | 903639-13-4 | Reference compound |
| HY-155409 | ALR-38 | 241127-61-7 | Reference compound |
| HY-15541 | Zaltidine | 85604-00-8 | Reference compound |
| HY-155410 | HPSE1-IN-1 | 2876926-29-1 | Reference compound |
| HY-155411 | HPSE1-IN-2 | 2876926-27-9 | Reference compound |
| HY-155412 | PFI-6 | 2675452-91-0 | Reference compound |
| HY-155413 | Antiproliferative agent-43 | | Reference compound |
| HY-155414 | Neutrophil elastase inhibitor 5 | 3020696-44-7 | Reference compound |
| HY-155415 | PCSK9-IN-20 | 2929219-77-0 | Reference compound |
| HY-155416 | M56-S2 (iodide) | 1101867-17-7 | Reference compound |
| HY-155417 | GPR34 receptor antagonist 3 | | Reference compound |
| HY-155418 | ICMT-IN-2 | 1313602-91-3 | Reference compound |
| HY-155419 | ICMT-IN-5 | 1313602-92-4 | Reference compound |
| HY-15541A | Zaltidine (dihydrochloride) | 90274-23-0 | Reference compound |
| HY-155420 | ICMT-IN-9 | 1313602-93-5 | Reference compound |
| HY-155421 | ICMT-IN-11 | 1313602-94-6 | Reference compound |
| HY-155422 | ICMT-IN-13 | 1313602-95-7 | Reference compound |
| HY-155423 | ICMT-IN-14 | 1313602-97-9 | Reference compound |
| HY-155424 | ICMT-IN-15 | 1313602-98-0 | Reference compound |
| HY-155425 | ICMT-IN-17 | 1313602-99-1 | Reference compound |
| HY-155426 | ICMT-IN-19 | 1313603-00-7 | Reference compound |
| HY-155427 | ICMT-IN-20 | 1313603-01-8 | Reference compound |
| HY-155428 | ICMT-IN-22 | 1313603-09-6 | Reference compound |
| HY-155429 | ICMT-IN-24 | 1313603-10-9 | Reference compound |
| HY-15542A | FRAX597 | 1286739-19-2 | Reference compound |
| HY-15542B | FRAX486 | 1232030-35-1 | Reference compound |
| HY-15543 | CP-809101 | 479683-64-2 | Reference compound |
| HY-155430 | ICMT-IN-27 | 1313603-11-0 | Reference compound |
| HY-155431 | ICMT-IN-28 | 1313603-12-1 | Reference compound |
| HY-155432 | ICMT-IN-29 | 1313603-13-2 | Reference compound |
| HY-155433 | ICMT-IN-30 | 1313603-14-3 | Reference compound |
| HY-155434 | ICMT-IN-31 | 1313603-15-4 | Reference compound |
| HY-155435 | ICMT-IN-32 | 1313603-17-6 | Reference compound |
| HY-155436 | ICMT-IN-33 | 1313603-20-1 | Reference compound |
| HY-155437 | NEt-iFQ | 1251538-60-9 | Reference compound |
| HY-155438 | Mal-Cz | 2883232-96-8 | Reference compound |
| HY-155439 | FAK-IN-14 | 2766666-22-0 | Reference compound |
| HY-15543A | CP-809101 (hydrochloride) | 1215721-40-6 | Reference compound |
| HY-15544 | CCR1 antagonist 10 | 1010731-97-1 | Reference compound |
| HY-155440 | FAK-IN-15 | | Reference compound |
| HY-155441 | CDK2-IN-20 | | Reference compound |
| HY-155442 | MIQ-N-succinate | 1511896-15-3 | Reference compound |
| HY-155444 | AG5.0 | | Reference compound |
| HY-155445 | di-DTPA TL | 136687-39-3 | Reference compound |
| HY-155446 | di-DTPA-LTL | | Reference compound |
| HY-155447 | AG3.0 | | Reference compound |
| HY-155448 | GK56 | 250683-14-8 | Reference compound |
| HY-155449 | GK60 | 250683-13-7 | Reference compound |
| HY-15545 | AZD-4818 | 1003566-93-5 | Reference compound |
| HY-155450 | GK81 | 250682-96-3 | Reference compound |
| HY-155451 | GK83 | | Reference compound |
| HY-155452 | SG62 | 250683-07-9 | Reference compound |
| HY-155453 | IB87 | 1251913-63-9 | Reference compound |
| HY-155455 | Dicamba-(CH2)5-acid | 2892008-07-8 | Reference compound |
| HY-155456 | CYP2A6-IN-1 | | Reference compound |
| HY-155457 | Enpp-1-IN-19 | 2738583-25-8 | Reference compound |
| HY-155458 | HYDAMTIQ | 1201832-32-7 | Reference compound |
| HY-155459 | Tubulin polymerization-IN-57 | 95385-38-9 | Reference compound |
| HY-15546 | BMS-817399 | 1202400-18-7 | Reference compound |
| HY-155460 | Pks13-TE inhibitor 4 | 3032947-26-2 | Reference compound |
| HY-155461 | Antibiofilm agent-3 | | Reference compound |
| HY-155462 | hERG-IN-1 | | Reference compound |
| HY-155463 | NLRP3-IN-25 | 2660230-90-8 | Reference compound |
| HY-155464 | VEGFR-2/AURKA-IN-1 | | Reference compound |
| HY-155465 | HPPD-IN-2 | | Reference compound |
| HY-155466 | Boc-MIF-1-Am | | Reference compound |
| HY-155467 | MRS7935 | | Reference compound |
| HY-155468 | AG8.0 | 159173-58-7 | Reference compound |
| HY-155469 | IMP 241 | 391267-27-9 | Reference compound |
| HY-155470 | IMP 243 | 391267-29-1 | Reference compound |
| HY-155471 | IMP 245 | 608489-42-5 | Reference compound |
| HY-155472 | Mcl-1 inhibitor 17 | 892250-00-9 | Reference compound |
| HY-155473 | Phosphatidylcholine transfer protein inhibitor-2 | 379712-59-1 | Reference compound |
| HY-155474 | Me4Phen | | Reference compound |
| HY-155475 | mTORC1-IN-2 | 2974368-96-0 | Reference compound |
| HY-155476 | Influenza virus-IN-8 | 1627115-50-7 | Reference compound |
| HY-155477 | Cbl-b-IN-15 | | Reference compound |
| HY-155478 | Androgen receptor-IN-6 | 3016437-05-8 | Reference compound |
| HY-155479 | PqsR-IN-3 | 3033007-79-0 | Reference compound |
| HY-155480 | PSB-22034 | 2768131-22-0 | Reference compound |
| HY-155481 | CB2 receptor antagonist 3 | | Reference compound |
| HY-155481A | CB2 receptor antagonist 4 | | Reference compound |
| HY-155482 | NA-184 | 2688119-39-1 | Reference compound |
| HY-155483 | PSMA-BCH | 1703768-73-3 | Reference compound |
| HY-155484 | SOMCL-668 | 1422251-09-9 | Reference compound |
| HY-155485 | Abi-DZ-1 | | Reference compound |
| HY-155486 | HCy-AAN-Bio | | Reference compound |
| HY-155487 | JTE-151 | 1404380-58-0 | Reference compound |
| HY-155488 | SHEN26 | 2691076-98-7 | Reference compound |
| HY-155489 | DDO-2728 | 3029515-97-4 | Reference compound |
| HY-155490 | Nur77 antagonist 1 | 2378780-25-5 | Reference compound |
| HY-155491 | Antibacterial agent 166 | | Reference compound |
| HY-155492 | ERα degrader 7 | | Reference compound |
| HY-155493 | CYP19A1/CYP11B2-IN-1 | 183500-36-9 | Reference compound |
| HY-155494 | trans-Stilbene-NHCO-(CH2)3-acid | 316173-40-7 | Reference compound |
| HY-155495 | (±)-Bupropion-(CH2)3-OH (hydrochloride) | 80762-38-5 | Reference compound |
| HY-155498 | TETS-4-Methylaniline | | Reference compound |
| HY-155499 | AMOZ-CHPh-4-acid | 1149378-53-9 | Reference compound |
| HY-15550 | 4'-Hydroxy diclofenac | 64118-84-9 | Reference compound |
| HY-155500 | Digoxigenin NHS ester | 129273-26-3 | Reference compound |
| HY-155502 | AKR1C3-IN-10 | 3028287-43-3 | Reference compound |
| HY-155503 | Antitumor agent-103 | | Reference compound |
| HY-155504 | Metallo-β-lactamase-IN-11 | | Reference compound |
| HY-155505 | AHR agonist 4 | 2953023-30-6 | Reference compound |
| HY-155506 | NAMPT degrader-3 | | Reference compound |
| HY-155507 | c-Myc inhibitor 11 | | Reference compound |
| HY-155508 | c-Myc inhibitor 12 | 3040017-65-7 | Reference compound |
| HY-15550R | 4'-Hydroxy diclofenac (Standard) | 64118-84-9 | Reference Standards |
| HY-15550S | 4'-Hydroxy diclofenac-d4 | 254762-27-1 | Isotope-Labeled Compounds |
| HY-15550S1 | 4'-Hydroxy diclofenac-13C6 | 1189656-64-1 | Isotope-Labeled Compounds |
| HY-15551 | E-4031 | 113559-13-0 | Reference compound |
| HY-155510 | DprE1-IN-5 | | Reference compound |
| HY-155511 | DprE1-IN-6 | | Reference compound |
| HY-155512 | DprE1-IN-7 | | Reference compound |
| HY-155513 | Syk-IN-8 | 2568963-01-7 | Reference compound |
| HY-155514 | HA-IN-1 | | Reference compound |
| HY-155516 | KV1.3-IN-1 | | Reference compound |
| HY-155516A | cis-KV1.3-IN-1 | 3052324-05-4 | Reference compound |
| HY-155517 | INF200 | | Reference compound |
| HY-155518 | IRAK4-IN-25 | 2952533-47-8 | Reference compound |
| HY-155519 | IRAK4-IN-26 | 2952533-49-0 | Reference compound |
| HY-15551A | E-4031 (free base) | 113558-89-7 | Reference compound |
| HY-15552 | Podofilox | 518-28-5 | Natural Products |
| HY-155520 | Antileishmanial agent-19 | | Reference compound |
| HY-155521 | Enzyme-IN-2 | | Reference compound |
| HY-155522 | WES-1 | 2748673-86-9 | Reference compound |
| HY-155523 | Tubulin/HDAC-IN-2 | | Reference compound |
| HY-155524 | Anticancer agent 134 | | Reference compound |
| HY-155525 | Anti-NASH agent 1 | 2409685-41-0 | Reference compound |
| HY-155526 | FY-21 | 3049681-20-8 | Reference compound |
| HY-155527 | SARS-CoV-2 Mpro-IN-9 | 2754370-99-3 | Reference compound |
| HY-155528 | O4I4 | 412008-21-0 | Reference compound |
| HY-155529 | FD1024 | 1422456-47-0 | Reference compound |
| HY-15552R | Podofilox (Standard) | 518-28-5 | Reference Standards |
| HY-15552S | Podofilox-d6 | | Isotope-Labeled Compounds |
| HY-15553 | Mibefradil | 116644-53-2 | Reference compound |
| HY-155530 | PEX5-PEX14 PPI-IN-1 | | Reference compound |
| HY-155531 | PEX5-PEX14 PPI-IN-2 | | Reference compound |
| HY-155532 | 10m/ZS44 | 3008988-49-3 | Reference compound |
| HY-155533 | YF704 | 2956716-97-3 | Reference compound |
| HY-155534 | 17β-HSD10-IN-1 | 2316765-78-1 | Reference compound |
| HY-155535 | 17β-HSD10-IN-2 | 2316765-79-2 | Reference compound |
| HY-155536 | Antimalarial agent 28 | | Reference compound |
| HY-155537 | Pruvonertinib | 2064269-82-3 | Reference compound |
| HY-155538 | Cisd2 agonist 1 | 2916371-54-3 | Reference compound |
| HY-155539 | Cisd2 agonist 2 | 2916371-59-8 | Reference compound |
| HY-15553A | Mibefradil (dihydrochloride) | 116666-63-8 | Reference compound |
| HY-15553B | Mibefradil (dihydrochloride hydrate) | 1049728-52-0 | Reference compound |
| HY-155540 | SARS-CoV-2 3CLpro-IN-14 | 2945139-50-2 | Reference compound |
| HY-155541 | Antitumor agent-110 | 2563879-93-4 | Reference compound |
| HY-155542 | RORγ antagonist 1 | 3049676-15-2 | Reference compound |
| HY-155543 | Anticancer agent 135 | 2957914-60-0 | Reference compound |
| HY-155544 | Antitumor agent-111 | | Reference compound |
| HY-155545 | Antifungal agent 60 | | Reference compound |
| HY-155546 | Antimicrobial agent-22 | 2373339-51-4 | Reference compound |
| HY-155547 | HBV-IN-34 | 2716906-45-3 | Reference compound |
| HY-155548 | RORγt inverse agonist 31 | | Reference compound |
| HY-155549 | Antileishmanial agent-20 | | Reference compound |
| HY-15555 | EPZ005687 | 1396772-26-1 | Reference compound |
| HY-155550 | CSF1R-IN-17 | | Reference compound |
| HY-155551 | Anti-inflammatory agent 46 | 2925586-96-3 | Reference compound |
| HY-155552 | GSPT1 degrader-1 | | Reference compound |
| HY-155553 | GPR119 agonist 2 | 1384951-03-4 | Reference compound |
| HY-155554 | SCAL-255 | 2798953-61-2 | Reference compound |
| HY-155555 | SCAL-266 | 2798953-78-1 | Reference compound |
| HY-155556 | ZG36 | 2999673-34-4 | Reference compound |
| HY-155557 | Anti-inflammatory agent 45 | | Reference compound |
| HY-155558 | MptpB-IN-2 | 3028076-11-8 | Reference compound |
| HY-15556 | GSK269962A | 850664-21-0 | Reference compound |
| HY-155560 | Pomalidomide-C7-NH2 | 2093387-55-2 | Reference compound |
| HY-155568 | Anti-inflammatory agent 47 | 2925288-12-4 | Reference compound |
| HY-155569 | Chitin synthase inhibitor 13 | 2925228-79-9 | Reference compound |
| HY-15556A | GSK269962A (hydrochloride) | 2095432-71-4 | Reference compound |
| HY-15557 | AZ20 | 1233339-22-4 | Reference compound |
| HY-155570 | Anticancer agent 137 | | Reference compound |
| HY-155571 | MDM2/XIAP-IN-3 | 2925583-17-9 | Reference compound |
| HY-155572 | Nrf2 activator-8 | | Reference compound |
| HY-155574 | IRAK4-IN-27 | 2626988-86-9 | Reference compound |
| HY-155577 | MAO A/HSP90-IN-1 | 2927489-95-8 | Reference compound |
| HY-15558 | Hoechst 33258 | 23491-44-3 | Dye Reagents |
| HY-155580 | MAO A/HSP90-IN-2 | 2927489-99-2 | Reference compound |
| HY-155582 | BLK degrader 1 | 3049215-64-4 | Reference compound |
| HY-155583 | RNase L-IN-1 | | Reference compound |
| HY-155583A | RNase L-IN-1 (trihydrochloride) | | Reference compound |
| HY-155587 | Hydroxy-PP | 833481-60-0 | Reference compound |
| HY-15558A | Hoechst 33258 (trihydrochloride) | 23491-45-4 | Dye Reagents |
| HY-15559 | Hoechst 33342 | 23491-52-3 | Dye Reagents |
| HY-155593 | JNK-1-IN-2 | | Reference compound |
| HY-155594 | LT-540-717 | 2143089-35-2 | Reference compound |
| HY-155595 | SNM1A-IN-1 | | Reference compound |
| HY-155596 | h-NTPDase-IN-1 | | Reference compound |
| HY-155597 | h-NTPDase8-IN-1 | 716358-51-9 | Reference compound |
| HY-155599 | HIV-1 protease-IN-10 | 2982527-11-5 | Reference compound |
| HY-15559A | Hoechst 33342 (trihydrochloride) | 875756-97-1 | Dye Reagents |
| HY-15560 | Hoechst 34580 | 23555-00-2 | Dye Reagents |
| HY-155600 | 5′-Guanylyl methylenediphosphonate (sodium) | 10470-57-2 | Reference compound |
| HY-155601 | SARS-CoV-2-IN-52 | 1001242-49-4 | Reference compound |
| HY-155602 | CDK2-IN-18 | 364735-73-9 | Reference compound |
| HY-155609 | VEGFR-2-IN-31 | | Reference compound |
| HY-15560A | Hoechst 34580 (trihydrochloride) | 911004-45-0 | Biochemical Assay Reagents |
| HY-15560B | Hoechst 34580 (tetrahydrochloride) | 2310135-08-9 | Dye Reagents |
| HY-15561 | HOE-S 785026 | 132869-83-1 | Dye Reagents |
| HY-155610 | VEGFR-2-IN-32 | | Reference compound |
| HY-155611 | Cathepsin C-IN-6 | | Reference compound |
| HY-155612 | M826 | 321437-16-5 | Reference compound |
| HY-155612A | (Rac)-M826 | 2649883-37-2 | Reference compound |
| HY-155613 | M867 | 680999-39-7 | Reference compound |
| HY-155614 | KSK68 | 2566715-91-9 | Reference compound |
| HY-155615 | KSK67 | 2566715-93-1 | Reference compound |
| HY-155616 | KSK94 | 2566716-07-0 | Reference compound |
| HY-155619 | Protein kinase inhibitor 7 | 84478-11-5 | Reference compound |
| HY-15561B | HOE-S 785026 (trihydrochloride) | 2320308-12-9 | Dye Reagents |
| HY-15562 | HOE 32021 | 23623-06-5 | Dye Reagents |
| HY-155620 | PD10 | | Reference compound |
| HY-155621 | PD24 | | Reference compound |
| HY-155622 | PD25 | | Reference compound |
| HY-155628 | AMPA receptor modulator-6 | 516491-33-1 | Reference compound |
| HY-15563 | HOE 33187 | 23623-08-7 | Dye Reagents |
| HY-155635 | Nav1.8-IN-4 | 1620846-16-3 | Reference compound |
| HY-155639 | Tyramide alkyne | 2230051-33-7 | Reference compound |
| HY-15564 | AR 231453 | 733750-99-7 | Reference compound |
| HY-155640 | 5-FAM maleimide | 787632-00-2 | Dye Reagents |
| HY-155642 | PU-48 | 335394-78-0 | Reference compound |
| HY-155643 | PROTAC TG2 degrader-1 | 3033465-55-0 | Reference compound |
| HY-155644 | ROS inducer 1 | 2921602-31-3 | Reference compound |
| HY-155645 | Topoisomerase II inhibitor 15 | 451516-79-3 | Reference compound |
| HY-155646 | Anti-inflammatory agent 48 | | Reference compound |
| HY-155647 | Microtubule stabilizing agent-1 | | Reference compound |
| HY-155648 | Tuberculosis inhibitor 6 | 121041-08-5 | Reference compound |
| HY-155649 | Tuberculosis inhibitor 7 | 121041-20-1 | Reference compound |
| HY-15565 | APD668 | 832714-46-2 | Reference compound |
| HY-155650 | Tuberculosis inhibitor 8 | 141353-07-3 | Reference compound |
| HY-155651 | Tuberculosis inhibitor 9 | | Reference compound |
| HY-155652 | ABCG2-IN-1 | 2559759-40-7 | Reference compound |
| HY-155653 | ABCG2-IN-2 | 2559759-59-8 | Reference compound |
| HY-155654 | SARS-CoV-2 Mpro-IN-10 | 2982834-87-5 | Reference compound |
| HY-155655 | JC-229 | 3026716-22-0 | Reference compound |
| HY-155656 | Anti-inflammatory agent 49 | 851471-44-8 | Reference compound |
| HY-155657 | BT424 | 2755180-37-9 | Reference compound |
| HY-155658 | Antifungal agent 62 | | Reference compound |
| HY-155659 | 4A7C-301 | | Reference compound |
| HY-15566 | APD597 | 897732-93-3 | Reference compound |
| HY-155660 | Antifungal agent 63 | | Reference compound |
| HY-155661 | ROS inducer 2 | 2921602-19-7 | Reference compound |
| HY-155662 | ROS inducer 3 | 2921602-09-5 | Reference compound |
| HY-155663 | GPX4-IN-5 | 2922824-09-5 | Reference compound |
| HY-155664 | GPX4-IN-6 | 2922824-07-3 | Reference compound |
| HY-155666 | YXG-158 | 2952994-34-0 | Reference compound |
| HY-155667 | Z-Nle-Lys-Arg-AMC | 1135364-14-5 | Dye Reagents |
| HY-155667A | Z-Nle-Lys-Arg-AMC (acetate) | | Reference compound |
| HY-155668 | HMG-CoA Reductase-IN-1 | | Reference compound |
| HY-155669 | Antifungal agent 64 | | Reference compound |
| HY-155670 | Antifungal agent 65 | 1223550-31-9 | Reference compound |
| HY-155671 | HDAC6-IN-18 | | Reference compound |
| HY-155672 | JPC0323 | 5972-45-2 | Reference compound |
| HY-155673 | SLU-PP-332 | 303760-60-3 | Reference compound |
| HY-155675 | TPPC | | Reference compound |
| HY-155676 | eIF4E-IN-5 | | Reference compound |
| HY-155679 | SARS-CoV-2 nsp14-IN-4 | | Reference compound |
| HY-15568 | A-317491 | 475205-49-3 | Reference compound |
| HY-155680 | BET BD2-IN-1 | 2677039-24-4 | Reference compound |
| HY-155681 | SWS1 | 2922115-32-8 | Reference compound |
| HY-155682 | Antibacterial agent 150 | | Reference compound |
| HY-155684 | SA-PA | | Reference compound |
| HY-155685 | SA-VA | | Reference compound |
| HY-155686 | Tubulin polymerization-IN-44 | | Reference compound |
| HY-155687 | PDE5-IN-10 | | Reference compound |
| HY-155688 | Antimalarial agent 29 | 2821078-81-1 | Reference compound |
| HY-155689 | Antimalarial agent 30 | 1597425-64-3 | Reference compound |
| HY-15568A | A-317491 (sodium salt hydrate) | | Reference compound |
| HY-15569 | NU6102 | 444722-95-6 | Reference compound |
| HY-155690 | HIV-1 protease-IN-11 | 2925287-54-1 | Reference compound |
| HY-155691 | HIV-1 protease-IN-12 | 2925287-59-6 | Reference compound |
| HY-155692 | PDE4-IN-13 | | Reference compound |
| HY-155693 | Topoisomerase II inhibitor 16 | 2403729-27-9 | Reference compound |
| HY-155694 | hCA/VEGFR-2-IN-1 | | Reference compound |
| HY-155695 | HDAC-IN-61 | | Reference compound |
| HY-155697 | SGC-UBD253 | | Reference compound |
| HY-155698 | Mz438 | | Dye Reagents |
| HY-155699 | J27644 | 3033032-03-7 | Reference compound |
| HY-155700 | SDH-IN-6 | 3010257-33-4 | Reference compound |
| HY-155702 | Antifungal agent 66 | 1613152-33-2 | Reference compound |
| HY-155703 | LW3 | 2803367-68-0 | Reference compound |
| HY-155704 | Lyciumamide A | 1647111-40-7 | Natural Products |
| HY-155705 | BMP agonist 1 | | Reference compound |
| HY-155706 | MOR agonist-2 | 2833692-02-5 | Reference compound |
| HY-155707 | MOR agonist-3 | | Reference compound |
| HY-155708 | AChE/BChE-IN-13 | | Reference compound |
| HY-155709 | Antifungal agent 67 | 2925307-52-2 | Reference compound |
| HY-155710 | Antifungal agent 68 | 2925307-53-3 | Reference compound |
| HY-155711 | Antifungal agent 69 | 2925307-56-6 | Reference compound |
| HY-155712 | Antifungal agent 70 | 2925307-57-7 | Reference compound |
| HY-155713 | AChE-IN-34 | | Reference compound |
| HY-155714 | AChE-IN-35 | | Reference compound |
| HY-155715 | G43 | 690693-02-8 | Reference compound |
| HY-155716 | G43-C3-TEG | 2702262-15-3 | Reference compound |
| HY-155717 | NDBM | 2958641-42-2 | Reference compound |
| HY-155718 | fac-[Re(CO)3(L6)(H2O)][NO3] | | Reference compound |
| HY-155719 | fac-[Re(CO)3(L3)(H2O)][NO3] | | Reference compound |
| HY-15571A | VCH-286 | 891824-47-8 | Reference compound |
| HY-155720 | Mtb-IN-4 | 2306039-13-2 | Reference compound |
| HY-155721 | 22-(4′-py)-JA | 1178895-15-2 | Natural Products |
| HY-155722 | Mtb-IN-5 | 2954888-39-0 | Reference compound |
| HY-155723 | Leucettinib-92 | 2732859-57-1 | Reference compound |
| HY-155725 | Z26395438 | 2803-63-6 | Reference compound |
| HY-155726 | Cy-FBP/SBPase-IN-1 | 444792-16-9 | Reference compound |
| HY-155727 | Sirt1/2-IN-2 | 670267-73-9 | Reference compound |
| HY-155728 | Sirt1/2-IN-3 | 301313-42-8 | Reference compound |
| HY-155729 | Sirt1/2-IN-4 | 2999646-13-6 | Reference compound |
| HY-15573 | EI1 | 1418308-27-6 | Reference compound |
| HY-155730 | PI3K-IN-41 | | Reference compound |
| HY-155731 | Antiviral agent 35 | 2760972-52-7 | Reference compound |
| HY-155732 | NPD-2975 | 3032452-65-3 | Reference compound |
| HY-155733 | AChE/Aβ-IN-1 | | Reference compound |
| HY-155734 | SARS-CoV-2-IN-55 | | Reference compound |
| HY-155735 | AChE/Aβ-IN-2 | | Reference compound |
| HY-155736 | MAPK-IN-2 | | Reference compound |
| HY-155737 | ET receptor antagonist 1 | | Reference compound |
| HY-155738 | ET receptor antagonist 2 | | Reference compound |
| HY-155739 | ET receptor antagonist 3 | | Reference compound |
| HY-15574 | Piboserod | 152811-62-6 | Reference compound |
| HY-155740 | PD-1/PD-L1-IN-32 | 2765535-21-3 | Reference compound |
| HY-155741 | CB2 PET Radioligand 1 | | Reference compound |
| HY-155742 | CFTR corrector 12 | 958941-60-1 | Reference compound |
| HY-155743A | ddUTP (lithium), 100mM in H2O | | Biochemical Assay Reagents |
| HY-155744 | Acetylene-PEG3-MMAF-OMe | 1411977-91-7 | Reference compound |
| HY-155745 | Antitumor agent-115 | 2759277-20-6 | Reference compound |
| HY-155746 | JAK2-IN-9 | 2568842-26-0 | Reference compound |
| HY-155747 | FDW028 | 2768426-49-7 | Reference compound |
| HY-155748 | Antitumor agent-116 | | Reference compound |
| HY-155749 | AChE-IN-36 | 2978753-66-9 | Reference compound |
| HY-15574A | Piboserod (hydrochloride) | 178273-87-5 | Reference compound |
| HY-15575 | VcMMAE | 646502-53-6 | ADC Related |
| HY-155750 | AChE-IN-37 | 2978753-64-7 | Reference compound |
| HY-155751 | HMGB1-IN-1 | | Reference compound |
| HY-155752 | 3′-O-Benzoyl-ATP | 288375-18-8 | Reference compound |
| HY-155753 | Anti-inflammatory agent 50 | | Reference compound |
| HY-155754 | 3′-Acetate-ATP | 90290-58-7 | Reference compound |
| HY-155755 | hCES2A-IN-1 | | Reference compound |
| HY-155756 | 3′-Acetate-UTP | 90290-74-7 | Reference compound |
| HY-155757 | 3′-Phenylcarbamate-UTP | 401619-08-7 | Reference compound |
| HY-155758 | hCA/VEGFR-2-IN-2 | 2971782-66-6 | Reference compound |
| HY-155759 | HMGB1-IN-2 | | Reference compound |
| HY-15575G | VcMMAE (GMP) | 646502-53-6 | GMP Small Molecules |
| HY-15575S | VcMMAE-d8 | | Isotope-Labeled Compounds |
| HY-155760 | hCA/VEGFR-2-IN-3 | 2971782-73-5 | Reference compound |
| HY-155761 | Antifungal agent 71 | | Reference compound |
| HY-155762 | Anti-neuroinflammation agent 1 | 2968412-77-1 | Reference compound |
| HY-155763 | hCA/VEGFR-2-IN-4 | 2971782-83-7 | Reference compound |
| HY-155764 | COX-1/2-IN-4 | 2967296-91-7 | Reference compound |
| HY-155765 | Anti-inflammatory agent 51 | 2911610-03-0 | Reference compound |
| HY-155766 | PARP1-IN-14 | 2098639-70-2 | Reference compound |
| HY-155768 | COX-1/2-IN-5 | | Reference compound |
| HY-155769 | Antimicrobial agent-24 | | Reference compound |
| HY-15577 | GSK3787 | 188591-46-0 | Reference compound |
| HY-155770 | FLT3-IN-20 | | Reference compound |
| HY-155771 | 1-DCP | 2964462-17-5 | Reference compound |
| HY-155772 | LUF7690 | 2941609-83-0 | Dye Reagents |
| HY-155773 | VU534 | 923509-20-0 | Reference compound |
| HY-155774 | VU533 | 923417-09-8 | Reference compound |
| HY-15578 | McMMAF | 863971-19-1 | ADC Related |
| HY-155780 | Anti-inflammatory agent 52 | | Reference compound |
| HY-155781 | Anti-inflammatory agent 53 | | Reference compound |
| HY-155782 | Zharp2-1 | 2772600-18-5 | Reference compound |
| HY-155784 | SPC-180002 | 2170274-53-8 | Reference compound |
| HY-155785 | MTP | 2377372-62-6 | Reference compound |
| HY-155786 | 3,7-DMF | 20950-52-1 | Reference compound |
| HY-155787 | SHR5428 | | Reference compound |
| HY-155788 | DSPE-PEG-DBCO (ammonium) | 2052955-83-4 | Reference compound |
| HY-155789 | C17 Globotriaosylceramide (d18:1/17:0) | 536745-81-0 | Reference compound |
| HY-15578G | McMMAF (GMP) | 863971-19-1 | GMP Small Molecules |
| HY-15579 | MMAF | 745017-94-1 | ADC Related |
| HY-155792 | Troglitazone glucuronide | 127040-01-1 | Reference compound |
| HY-15579A | MMAF (hydrochloride) | 1415246-68-2 | ADC Related |
| HY-15579AS | MMAF-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-15579B | MMAF (sodium) | 1799706-65-2 | ADC Related |
| HY-15579BG | MMAF (sodium) (GMP) | 1799706-65-2 | GMP Small Molecules |
| HY-15579G | MMAF (GMP) | 745017-94-1 | GMP Small Molecules |
| HY-15580 | Dolastatin 10 | 110417-88-4 | Natural Products |
| HY-155801 | CRX 527 | 216014-14-1 | Reference compound |
| HY-155804 | RIP1 kinase inhibitor 8 | 2226735-54-0 | Reference compound |
| HY-155805 | CAF-382 | | Reference compound |
| HY-155806 | h-NTPDase-IN-2 | 2939933-03-4 | Reference compound |
| HY-155807 | DPP | 2668267-47-6 | Reference compound |
| HY-155808 | STAT3-IN-18 | 2668267-41-0 | Reference compound |
| HY-155809 | BET-IN-17 | | Reference compound |
| HY-15581 | MMAD | 203849-91-6 | ADC Related |
| HY-155810 | DQP-26 | 1449373-99-2 | Reference compound |
| HY-155811 | DQP-997-74 | 2377187-09-0 | Reference compound |
| HY-155812 | Tyrosine kinase-IN-6 | 2377507-01-0 | Reference compound |
| HY-155813 | MPI60 | 3032440-80-2 | Reference compound |
| HY-155814 | EML734 | 3031795-11-3 | Reference compound |
| HY-155815 | MS9715 | | Reference compound |
| HY-155816 | PROTAC NSD3 degrader-1 | | Reference compound |
| HY-155817 | UNC7096 | | Reference compound |
| HY-155818 | NSD2-IN-4 | 3035028-80-6 | Reference compound |
| HY-155819 | M3/PDE4 modulator-1 | | Reference compound |
| HY-15581S | MMAD-d8 | | Isotope-Labeled Compounds |
| HY-15582 | Auristatin E | 160800-57-7 | ADC Related |
| HY-155820 | Anti-inflammatory agent 54 | 2924156-46-5 | Reference compound |
| HY-155821 | Anti-inflammatory agent 55 | 2924156-51-2 | Reference compound |
| HY-155822 | TZ3O | | Reference compound |
| HY-155823 | TZ4M | | Reference compound |
| HY-155827 | h-NTPDase-IN-3 | 2939933-10-3 | Reference compound |
| HY-155828 | h-NTPDase-IN-4 | 2939933-09-0 | Reference compound |
| HY-155829 | h-NTPDase-IN-5 | 2939932-93-9 | Reference compound |
| HY-15582G | Auristatin E (GMP) | 160800-57-7 | GMP Small Molecules |
| HY-15583 | Auristatin F | 163768-50-1 | ADC Related |
| HY-155830 | PDE4-IN-14 | 2231329-25-0 | Reference compound |
| HY-155831 | HCV-IN-43 | 1850311-28-2 | Reference compound |
| HY-155832 | HCV-IN-44 | 1850311-55-5 | Reference compound |
| HY-155833 | PI3Kδ-IN-13 | 1686137-02-9 | Reference compound |
| HY-155834 | DprE1-IN-8 | 2679830-77-2 | Reference compound |
| HY-155836 | hPL-IN-1 | 2387374-26-5 | Reference compound |
| HY-155837 | hPL-IN-2 | 24900-61-6 | Reference compound |
| HY-15583S | Auristatin F-d8 | | Isotope-Labeled Compounds |
| HY-15584 | Taltobulin | 228266-40-8 | ADC Related |
| HY-155840 | KH16 | 3059680-59-7 | Reference compound |
| HY-155841 | Tubulin polymerization-IN-46 | | Reference compound |
| HY-155842S | 4-Hydroxy AtorvastatinAtorvastatin-d5 (hemicalcium) | | Isotope-Labeled Compounds |
| HY-155843 | CDK9-IN-25 | | Reference compound |
| HY-155844 | CDK9-IN-26 | | Reference compound |
| HY-155845 | Antileishmanial agent-21 | | Reference compound |
| HY-155846 | Antileishmanial agent-22 | | Reference compound |
| HY-155847 | LYP-IN-3 | | Reference compound |
| HY-155848 | LYP-IN-4 | | Reference compound |
| HY-155849 | PKM2-IN-4 | 2996165-24-1 | Reference compound |
| HY-15584A | Taltobulin (trifluoroacetate) | 228266-41-9 | ADC Related |
| HY-15584B | Taltobulin (hydrochloride) | | ADC Related |
| HY-15584C | (R)-Taltobulin | 228266-44-2 | Reference compound |
| HY-155850 | CIAC001 | 2649154-82-3 | Reference compound |
| HY-155851 | Lepadin E | 444914-19-6 | Natural Products |
| HY-155852 | Lepadin H | 412328-25-7 | Natural Products |
| HY-15586 | L67 | 325970-71-6 | Reference compound |
| HY-155863 | AJ2-71 | 2700323-17-5 | Reference compound |
| HY-155864 | AJ2-30 | 2700322-79-6 | Reference compound |
| HY-155868 | 5-Azacytidine 5′-triphosphate | 2226-74-6 | Oligonucleotides |
| HY-155868A | 5-Azacytidine 5′-triphosphate (sodium) | | Reference compound |
| HY-155869 | 5-fluoro-dCTP | 79671-09-3 | Reference compound |
| HY-155869A | 5-fluoro-dCTP (sodium) | | Reference compound |
| HY-15587 | L82 | 329227-30-7 | Reference compound |
| HY-155870 | DL-01 | 2821770-49-2 | ADC Related |
| HY-155870A | DL-01 (formic) | 2964513-44-6 | ADC Related |
| HY-155870B | DL-01 (TFA) | | ADC Related |
| HY-155874 | ZNL-05-044 | | Reference compound |
| HY-155876 | NVP-DFV890 | 2271394-34-2 | Reference compound |
| HY-155878 | 5-Fluoro-2′-deoxy-UTP | 2710-64-7 | Oligonucleotides |
| HY-155878A | 5-Fluoro-2′-deoxy-UTP (sodium) | 1630828-71-5 | Reference compound |
| HY-155879 | (±)-N-Methylcoclaurine | 1472-62-4 | Reference compound |
| HY-15588 | L189 | 64232-83-3 | Reference compound |
| HY-155880 | mPEG-amine (MW 350) | 80506-64-5 | Biochemical Assay Reagents |
| HY-155881 | mPEG-amine (MW 550) | 80506-64-5 | Biochemical Assay Reagents |
| HY-155882 | mPEG-amine (MW 750) | 80506-64-5 | Biochemical Assay Reagents |
| HY-155883 | mPEG-amine (MW 3400) | 80506-64-5 | Biochemical Assay Reagents |
| HY-155884 | mPEG-amine (MW 4000) | 80506-64-5 | Biochemical Assay Reagents |
| HY-155887 | DSPE-PEG-Amine, MW 3400 (ammonium) | 474922-26-4 | Biochemical Assay Reagents |
| HY-155888 | IV-255 | | Reference compound |
| HY-155889 | IV-275 | | Reference compound |
| HY-15589 | GW9508 | 885101-89-3 | Reference compound |
| HY-155890 | Fimepinostat (mesylate) | 1401998-36-4 | Reference compound |
| HY-15590 | AZ-23 | 915720-21-7 | Reference compound |
| HY-155901 | Mal-NH-PEG-NH2 (TFA) (MW 2000) | | Biochemical Assay Reagents |
| HY-155902 | Mal-PEG-OH (MW 5000) | 88504-24-9 | Biochemical Assay Reagents |
| HY-155902A | Mal-PEG-OH (MW 2000) | 88504-24-9 | Biochemical Assay Reagents |
| HY-155902B | Mal-PEG-OH (MW 1000) | 88504-24-9 | Biochemical Assay Reagents |
| HY-155907 | DSPE-PEG-Amine, MW 5000 (ammonium) | 474922-26-4 | Biochemical Assay Reagents |
| HY-155908 | DSPE-PEG-Amine, MW 10000 (ammonium) | 474922-26-4 | Biochemical Assay Reagents |
| HY-155909 | m-PEG-NHS ester (MW 3400) | 92451-01-9 | Biochemical Assay Reagents |
| HY-155909A | m-PEG-NHS ester (MW 1000) | 92451-01-9 | Biochemical Assay Reagents |
| HY-155909B | m-PEG-NHS ester (MW 550) | 92451-01-9 | Biochemical Assay Reagents |
| HY-155909C | m-PEG-NHS ester (MW 350) | 92451-01-9 | Biochemical Assay Reagents |
| HY-15591 | TMC647055 | 1204416-97-6 | Reference compound |
| HY-155912S | 2-Allyl-3-methylpyrazine-d3 | 1335436-12-8 | Isotope-Labeled Compounds |
| HY-155915 | mPEG-CHO (MW 350) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155916 | mPEG-CHO (MW 550) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155917 | mPEG-CHO (MW 750) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155918 | mPEG-CHO (MW 1000) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155919 | mPEG-CHO (MW 2000) | 70086-22-9 | Biochemical Assay Reagents |
| HY-15591A | TMC647055 (Choline salt) | | Reference compound |
| HY-15592 | Cabotegravir | 1051375-10-0 | Reference compound |
| HY-155920 | mPEG-CHO (MW 3400) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155921 | mPEG-CHO (MW 5000) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155922 | mPEG-CHO (MW 10000) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155923 | mPEG-CHO (MW 20000) | 70086-22-5 | Biochemical Assay Reagents |
| HY-155924 | DMPE-PEG350 | 474922-82-2 | Biochemical Assay Reagents |
| HY-155925 | DMPE-PEG550 | 474922-82-2 | Biochemical Assay Reagents |
| HY-155926 | DMPE-PEG750 | 474922-82-2 | Biochemical Assay Reagents |
| HY-155927 | DMPE-PEG1000 | 474922-82-2 | Biochemical Assay Reagents |
| HY-155928 | DMPE-PEG3000 | 474922-82-2 | Biochemical Assay Reagents |
| HY-155929 | DMPE-PEG5000 | 474922-82-2 | Biochemical Assay Reagents |
| HY-15592A | Cabotegravir (sodium) | 1051375-13-3 | Reference compound |
| HY-15592AS | Cabotegravir-d3 (sodium) | | Isotope-Labeled Compounds |
| HY-15592R | Cabotegravir (Standard) | 1051375-10-0 | Reference Standards |
| HY-15592S1 | Cabotegravir-d5 | 2750534-77-9 | Isotope-Labeled Compounds |
| HY-15592S2 | Cabotegravir-d3-1 | | Isotope-Labeled Compounds |
| HY-15593 | Pinometostat | 1380288-87-8 | Reference compound |
| HY-155930 | 18:1 PEG350 PE | 474922-90-2 | Biochemical Assay Reagents |
| HY-155931 | 18:1 PEG550 PE | 474922-90-2 | Biochemical Assay Reagents |
| HY-155932 | 18:1 PEG1000 PE | 474922-90-2 | Biochemical Assay Reagents |
| HY-155933 | 18:1 PEG3000 PE | 474922-90-2 | Biochemical Assay Reagents |
| HY-155934 | 18:1 PEG5000 PE | 474922-90-2 | Biochemical Assay Reagents |
| HY-155935 | N-[2-[(1-Oxohexadecyl)amino]ethyl]octadecanamide | 5136-44-7 | Reference compound |
| HY-155938 | Cyano-myracrylamide | 2801702-34-9 | Reference compound |
| HY-155939 | M4K2163 (dihydrochloride) | 2863635-04-3 | Reference compound |
| HY-15594 | Phen-DC3 | 942936-75-6 | Reference compound |
| HY-155941 | 5-Hydroxydecanoic acid | 624-00-0 | Reference compound |
| HY-155942 | B-Raf IN 19 | 708218-62-6 | Reference compound |
| HY-155943 | AMPK-IN-4 | 873077-70-4 | Reference compound |
| HY-155944 | Isbufylline | 90162-60-0 | Reference compound |
| HY-155945 | Firefly luciferase-IN-1 | 2765796-41-4 | Reference compound |
| HY-155948 | Uricosuric agent-1 | 91627-33-7 | Reference compound |
| HY-15594A | Phen-DC3 Trifluoromethanesulfonate | 929895-45-4 | Reference compound |
| HY-15595 | 360A | 794458-56-3 | Reference compound |
| HY-155950 | TH9619 | 2379556-22-4 | Reference compound |
| HY-155951 | JAK3-IN-14 | 454234-24-3 | Reference compound |
| HY-155952 | LOC1886 | 951948-38-2 | Reference compound |
| HY-155953 | 6-epi-COTC | 959150-61-9 | Reference compound |
| HY-155954 | UCM-1336 | 1621535-90-7 | Reference compound |
| HY-155956 | GM-90257 | 315703-81-2 | Reference compound |
| HY-155958 | Casein kinase 1δ-IN-9 | 854355-54-7 | Reference compound |
| HY-155959 | PD-1/PD-L1-IN-33 | 2975602-78-7 | Reference compound |
| HY-15595A | 360A (iodide) | 737763-37-0 | Reference compound |
| HY-155960 | SH491 | 2975285-28-8 | Reference compound |
| HY-155961 | Antidiabetic agent 2 | | Reference compound |
| HY-155962 | Tubulin polymerization-IN-47 | 2834087-62-4 | Reference compound |
| HY-155963 | Tubulin polymerization-IN-48 | 2982893-22-9 | Reference compound |
| HY-155964 | Anticancer agent 153 | 2982527-32-0 | Reference compound |
| HY-155965 | VEGFR/PARP-IN-1 | 3010256-54-6 | Reference compound |
| HY-155966 | CDK2-IN-19 | | Reference compound |
| HY-155967 | CB1R/AMPK modulator 1 | 2711012-08-5 | Reference compound |
| HY-155968 | HBV-IN-40 | | Reference compound |
| HY-155969 | EGFR-IN-83 | | Reference compound |
| HY-15597 | Salinomycin | 53003-10-4 | Reference compound |
| HY-155970 | Urease-IN-7 | 1129406-54-7 | Reference compound |
| HY-155971 | VISTA-IN-2 | 2614183-36-5 | Reference compound |
| HY-155972 | CRM1-IN-1 | | Reference compound |
| HY-155972A | CRM1-IN-2 | | Reference compound |
| HY-155973 | Urease-IN-8 | 517906-16-0 | Reference compound |
| HY-155974 | MeOIstPyrd | 2308548-54-9 | Reference compound |
| HY-155975 | PI3Kδ-IN-14 | | Reference compound |
| HY-155977 | Anti-osteoporosis agent-5 | 444908-22-9 | Reference compound |
| HY-155978 | RDN2150 | 2839429-51-3 | Reference compound |
| HY-155978A | RDN2150 (TFA) | | Reference compound |
| HY-155979 | SARS-CoV-2 3CLpro-IN-16 | 352659-40-6 | Reference compound |
| HY-15597R | Salinomycin (Standard) | 53003-10-4 | Reference Standards |
| HY-155980 | SARS-CoV-2 3CLpro-IN-17 | 3032604-33-1 | Reference compound |
| HY-155981 | SARS-CoV-2 3CLpro-IN-18 | 3032604-29-5 | Reference compound |
| HY-155982 | STAT3-IN-20 | 2768427-54-7 | Reference compound |
| HY-155983 | E07 aptamer | | Reference compound |
| HY-155985 | Anti-osteoporosis agent-6 | 445231-36-7 | Reference compound |
| HY-155987 | CK2-IN-8 | 442571-27-9 | Reference compound |
| HY-155988 | Sirtuin modulator 6 | 476633-98-4 | Reference compound |
| HY-155989 | GSK3-IN-4 | 748145-19-9 | Reference compound |
| HY-15598S | 20-HETE-d6 | 2548939-89-3 | Isotope-Labeled Compounds |
| HY-15599 | SSR128129E | 848318-25-2 | Reference compound |
| HY-155991 | RUNX-IN-2 | 2893777-88-1 | Reference compound |
| HY-155992 | WLB-89462 | 2849471-75-4 | Reference compound |
| HY-155993 | YCH1899 | 3032451-66-1 | Reference compound |
| HY-155994 | PIK5-12d | | Reference compound |
| HY-155995 | PRO-905 | 2762209-68-5 | Reference compound |
| HY-155996 | FD2157 | | Reference compound |
| HY-155997 | Anti-inflammatory agent 56 | 2413127-32-7 | Reference compound |
| HY-155998 | NF-κB-IN-11 | 2768833-35-6 | Reference compound |
| HY-155999 | MoTPS1-IN-1 | 2991072-02-5 | Reference compound |
| HY-15599A | SSR128129E (free acid) | 848463-13-8 | Reference compound |
| HY-15600 | UPF-648 | 213400-34-1 | Reference compound |
| HY-156001 | DUB-IN-7 | 2894064-79-8 | Reference compound |
| HY-156002 | LUNA18 | 2676177-63-0 | Reference compound |
| HY-156003 | HDAC-IN-64 | | Reference compound |
| HY-156004 | Ziapin 2 | 2399497-60-8 | Reference compound |
| HY-156005 | Antibacterial agent 153 | | Reference compound |
| HY-156007 | SARS-CoV-2 3CLpro-IN-21 | | Reference compound |
| HY-156008 | SARS-CoV-2-IN-58 | | Reference compound |
| HY-156009 | CDFI | 1199797-92-6 | Reference compound |
| HY-15600B | UPF-648 (sodium salt) | 1465017-87-1 | Reference compound |
| HY-15601 | Vesatolimod | 1228585-88-3 | Reference compound |
| HY-156010 | PPARγ-IN-2 | 2682078-97-1 | Reference compound |
| HY-156011 | PSEN1-IN-1 | | Reference compound |
| HY-156012 | PSEN1-IN-2 | | Reference compound |
| HY-156013 | CA inhibitor 2 | | Reference compound |
| HY-156014 | qsl-304 | | Reference compound |
| HY-156016 | HDAC/CD13-IN-1 | | Reference compound |
| HY-156017 | 5-HT6R antagonist 1 | | Reference compound |
| HY-156018 | PI3Kα-IN-13 | 2955529-67-4 | Reference compound |
| HY-156019 | FGFR1 inhibitor-10 | 2426769-76-6 | Reference compound |
| HY-15602 | Ledipasvir | 1256388-51-8 | Reference compound |
| HY-156020 | Glucocerebrosidase-IN-2 | 851185-20-1 | Reference compound |
| HY-156021 | Antitubercular agent-40 | 900314-03-6 | Reference compound |
| HY-156022 | Antitubercular agent-41 | 901032-23-3 | Reference compound |
| HY-156023 | Sirtuin modulator 7 | 863589-52-0 | Reference compound |
| HY-156024 | TEAD-IN-6 | 2821763-12-4 | Reference compound |
| HY-156025 | HCAR2 agonist 1 | 1066676-21-8 | Reference compound |
| HY-156026 | FAK-IN-11 | | Reference compound |
| HY-156027 | SIRT6-IN-3 | 3023471-40-8 | Reference compound |
| HY-156028 | FIKK9.1-IN-1 | 1448523-50-9 | Reference compound |
| HY-156029 | IA1-8H2 | 2755685-19-7 | Reference compound |
| HY-15602A | Ledipasvir (acetone) | 1441674-54-9 | Reference compound |
| HY-15602AS | Ledipasvir-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-15602B | Ledipasvir (D-tartrate) | 1502654-87-6 | Reference compound |
| HY-15602C | Ledipasvir (hydrochloride) | 2128695-48-5 | Reference compound |
| HY-15602D | Ledipasvir (diacetone) | 1502655-48-2 | Reference compound |
| HY-15602S | Ledipasvir-d6 | 2050041-12-6 | Isotope-Labeled Compounds |
| HY-15602S1 | Ledipasvir-d16 | | Isotope-Labeled Compounds |
| HY-15603 | TS-011 | 339071-18-0 | Reference compound |
| HY-156030 | AChE-IN-40 | | Reference compound |
| HY-156031 | BChE-IN-19 | | Reference compound |
| HY-156032 | PIMPC | 2250244-44-9 | Reference compound |
| HY-156033 | EGFR-IN-88 | 2944452-34-8 | Reference compound |
| HY-156034 | JT001 | 2238819-65-1 | Reference compound |
| HY-156034A | JT001 (sodium) | 2238820-09-0 | Reference compound |
| HY-156035 | Bz-DTPA | 102650-30-6 | Reference compound |
| HY-156038 | (S)-p-SCN-Bn-DOTA | 1020407-41-3 | Biochemical Assay Reagents |
| HY-15604 | AZD1208 | 1204144-28-4 | Reference compound |
| HY-156040 | Casein kinase 1δ-IN-10 | 332074-85-8 | Reference compound |
| HY-156041 | Lysophosphatidylethanolamines, egg | 97281-40-8 | Natural Products |
| HY-156045 | Cross-linked dextran G 15 | 11081-40-6 | Biochemical Assay Reagents |
| HY-156045A | Cross-linked dextran G 10 | 9050-68-4 | Biochemical Assay Reagents |
| HY-156045B | Cross-linked dextran G 150 | 12774-36-6 | Biochemical Assay Reagents |
| HY-156045C | Cross-linked dextran G 200 | 9041-36-5 | Biochemical Assay Reagents |
| HY-156048 | Trifluoromethyl-tubercidin | 1854086-05-7 | Reference compound |
| HY-15604A | AZD1208 (hydrochloride) | 1621866-96-3 | Reference compound |
| HY-15605 | Encorafenib | 1269440-17-6 | Reference compound |
| HY-156051 | Tetrazolast | 95104-27-1 | Reference compound |
| HY-156054 | N-Hydroxy riluzole | 179070-90-7 | Reference compound |
| HY-15605R | Encorafenib (Standard) | 1269440-17-6 | Reference Standards |
| HY-15605S | Encorafenib-13C,d3 | | Isotope-Labeled Compounds |
| HY-15606 | Tanaproget | 304853-42-7 | Reference compound |
| HY-156060 | NCI126224 | 65974-52-9 | Reference compound |
| HY-156061 | NAP-1 | 131721-28-3 | Reference compound |
| HY-156063 | (2R,4R)-UCB7362 | 2610631-17-7 | Reference compound |
| HY-156063A | (2R,4R)-UCB7362 (hydrochloride) | 2610631-18-8 | Reference compound |
| HY-156065 | S217879 | 2700303-28-0 | Reference compound |
| HY-156066 | Ferrostatin-1 diyne | 2226204-90-4 | Reference compound |
| HY-156069 | Methylspinazarin | 41768-12-1 | Reference compound |
| HY-15607 | WEHI-539 | 1431866-33-9 | Reference compound |
| HY-156074 | Erythromycin propionate | 134-36-1 | Reference compound |
| HY-156077 | anti-TNBC agent-2 | 2422001-22-5 | Reference compound |
| HY-156078 | α-Glucosidase-IN-32 | | Reference compound |
| HY-156079 | Antidepressant agent 5 | 1071049-42-7 | Reference compound |
| HY-15607A | WEHI-539 hydrochloride | 2070018-33-4 | Reference compound |
| HY-15608 | MPTP (hydrochloride) | 23007-85-4 | Reference compound |
| HY-156080 | PI3K-IN-48 | | Reference compound |
| HY-156081 | Nrf2 activator-9 | | Reference compound |
| HY-156082 | RyRs activator 3 | 2850333-35-4 | Reference compound |
| HY-156083 | CDK9-IN-28 | 3020773-81-0 | Reference compound |
| HY-156084 | LL-K9-3 | 2809353-52-2 | Reference compound |
| HY-156085 | LP23 | 3008239-25-3 | Reference compound |
| HY-156086 | TRK-IN-24 | 2937544-01-7 | Reference compound |
| HY-156087 | Cholicamideβ | | Reference compound |
| HY-156087G | Cholicamideβ (GMP) | | GMP Small Molecules |
| HY-156088 | SSE1806 | 3053861-26-7 | Reference compound |
| HY-156089 | Triptoquinone H | 268541-23-7 | Natural Products |
| HY-15608R | MPTP (hydrochloride) (Standard) | 23007-85-4 | Reference Standards |
| HY-15609 | AZD-3463 | 1356962-20-3 | Reference compound |
| HY-156090 | PK-10 | 3074451-41-2 | Reference compound |
| HY-156091 | PI3Kα/HDAC6-IN-1 | 3007565-26-3 | Reference compound |
| HY-156092 | Antitumor photosensitizer-4 | | Reference compound |
| HY-156093 | TPH1-IN-1 | 3040015-86-6 | Reference compound |
| HY-156094 | JMJD3/HDAC-IN-1 | 2883046-06-6 | ADC Related |
| HY-156095 | F7H | 897109-93-2 | Reference compound |
| HY-156096 | HDAC3-IN-2 | 3033039-28-7 | Reference compound |
| HY-156097 | Anticancer agent 158 | 2978685-72-0 | Reference compound |
| HY-156098 | c-Met-IN-19 | | Reference compound |
| HY-15610 | GDC-0623 | 1168091-68-6 | Reference compound |
| HY-156100 | C12-4 | 2639634-71-0 | Biochemical Assay Reagents |
| HY-156101 | Latanoprost amide | 919281-21-3 | Reference compound |
| HY-156102 | c-ABL-IN-5 | | Reference compound |
| HY-156103 | mHTT-IN-2 | 2743336-70-9 | Reference compound |
| HY-156104 | CaMKIIα-PHOTAC | 2481744-33-4 | Reference compound |
| HY-156105 | 8304-vs | | Reference compound |
| HY-156106 | VHL-IN-1 | 3033117-53-9 | Reference compound |
| HY-156107 | GPR55 agonist 3 | 3006105-44-5 | Reference compound |
| HY-156108 | 2-Chlorophenoxazine | 56821-03-5 | Reference compound |
| HY-156109 | PDK-IN-2 | 3032446-61-7 | Reference compound |
| HY-15611 | KPT-185 | 1333151-73-7 | Reference compound |
| HY-156110 | IGF2BP1-IN-1 | 3029447-08-0 | Reference compound |
| HY-156111 | ARD-1676 | 2632305-36-1 | Reference compound |
| HY-156112 | LM2I | 2055494-50-1 | Reference compound |
| HY-156113 | RET-IN-25 | 2965703-02-8 | Reference compound |
| HY-156114 | EGFR/CDK2-IN-2 | | Reference compound |
| HY-156115 | EGFR/CDK2-IN-3 | | Reference compound |
| HY-156116 | EGFR/CDK2-IN-4 | | Reference compound |
| HY-156117 | LB244 | | Reference compound |
| HY-156119 | MLKL-IN-6 | | Reference compound |
| HY-15612 | CDK4-IN-1 | 1256963-02-6 | Reference compound |
| HY-156120 | CD38 inhibitor 3 | 2857868-82-5 | Reference compound |
| HY-156121 | NLRP3-IN-20 | 2428478-22-0 | Reference compound |
| HY-156122 | DHFR-IN-8 | 3032441-09-8 | Reference compound |
| HY-156123 | DHFR-IN-9 | 3032441-13-4 | Reference compound |
| HY-156124 | Sigma-2 Radioligand 1 | 2860554-32-9 | Reference compound |
| HY-156125 | 14-3-3σ/ERα stabilizer-1 | | Reference compound |
| HY-156126 | Lentztrehalose C | 1808096-68-5 | Natural Products |
| HY-156128 | Imidafenacin Metabolite M4 | 503598-17-2 | Reference compound |
| HY-15613 | Maritoclax | 1227962-62-0 | Reference compound |
| HY-156130 | Menin-MLL inhibitor 29 | | Reference compound |
| HY-156131 | Loperamide | 53179-11-6 | Reference compound |
| HY-156133 | Dihydrospinosyn A aglycone | 727695-12-7 | Reference compound |
| HY-156135 | NSC194598 | 5358-76-9 | Reference compound |
| HY-156136 | 5-n-Heptyl-6-hydroxy-4,7-dioxobenzothiazole | 611207-02-4 | Reference compound |
| HY-156137 | UHDBT | 43152-58-5 | Reference compound |
| HY-156138A | CB-TE2A (tetrahydrochloride) | 1260798-95-5 | Biochemical Assay Reagents |
| HY-15614 | SC144 | 895158-95-9 | Reference compound |
| HY-156140 | Naa50-IN-1 | 2522920-65-4 | Reference compound |
| HY-156144 | p-Diazobenzoyl-biocytin (chloride) | 105319-12-8 | Biochemical Assay Reagents |
| HY-156145 | Biotin N-(bromoacetyl)hydrazide | 57170-18-0 | Biochemical Assay Reagents |
| HY-156146 | N-(4-Azido-2-nitrophenyl)-N''-biotinylnorspemidine | 786609-83-4 | Biochemical Assay Reagents |
| HY-156148 | BCR-ABL-IN-8 | 1808288-49-4 | Reference compound |
| HY-156149 | CYP51/PD-L1-IN-1 | 3032386-49-2 | Reference compound |
| HY-15614A | SC144 (hydrochloride) | 917497-70-2 | Reference compound |
| HY-15615 | TIC10 isomer | 41276-02-2 | Reference compound |
| HY-156150 | CYP51/PD-L1-IN-2 | 3032386-58-3 | Reference compound |
| HY-156151 | CYP51/PD-L1-IN-3 | 3032386-59-4 | Reference compound |
| HY-156152 | CARM1 degrader-1 | 3032785-00-2 | Reference compound |
| HY-156152A | CARM1 degrader-1 (hydrochloride) | | Reference compound |
| HY-156153 | CARM1 degrader-2 | 3032785-06-8 | Reference compound |
| HY-156157 | GPR55 agonist 4 | 3006105-55-8 | Reference compound |
| HY-156158 | IDH2R140Q-IN-2 | 2749568-16-7 | Reference compound |
| HY-156159 | Thalidomide-NH-C9-NH2 (hydrochloride) | 2305936-77-8 | Reference compound |
| HY-15616 | BMS-470539 | 457893-92-4 | Reference compound |
| HY-156160 | Thalidomide-NH-C10-NH2 (hydrochloride) | 2460022-53-9 | Reference compound |
| HY-156161 | Thalidomide-NH-C13-NH2 (hydrochloride) | | Reference compound |
| HY-156162 | Thalidomide-NH-C14-NH2 (hydrochloride) | | Reference compound |
| HY-156163 | Thalidomide-5-NH-PEG1-NH2 (hydrochloride) | 2863634-98-2 | Reference compound |
| HY-156164 | Thalidomide-5-NH-PEG2-NH2 (hydrochloride) | 2357110-58-6 | Reference compound |
| HY-156165 | Thalidomide-5-NH-PEG3-NH2 (hydrochloride) | 2863635-01-0 | Reference compound |
| HY-156166 | Thalidomide-5-NH-PEG4-NH4 (hydrochloride) | | Reference compound |
| HY-156167 | LRRK2-IN-10 | 2704562-80-9 | Reference compound |
| HY-156168 | M190S | 2578300-07-7 | Reference compound |
| HY-156169 | hCAIX/XII-IN-7 | | Reference compound |
| HY-15617 | JNK-IN-7 | 1408064-71-0 | Reference compound |
| HY-156170 | Thalidomide-5-NH-PEG5-NH2 (hydrochloride) | | Reference compound |
| HY-156171 | Thalidomide-5-NH-PEG6-NH2 (hydrochloride) | | Reference compound |
| HY-156172 | Thalidomide-NH-PEG6-NH2 (hydrochloride) | | Reference compound |
| HY-156174 | E104 | 1610431-21-4 | ADC Related |
| HY-156175 | TLR7 agonist 14 | 2832199-45-6 | Reference compound |
| HY-156176 | TLR7 agonist 15 | 2832199-53-6 | Reference compound |
| HY-156177 | TLR7 agonist 16 | 2832199-56-9 | Reference compound |
| HY-156179 | DDC 2′,3′-O-disulfate | | Reference compound |
| HY-15618 | MK-7622 | 1227923-29-6 | Reference compound |
| HY-156180 | DDC 3′-O-β-D glucuronide | | Reference compound |
| HY-156181 | hCAIX/XII-IN-8 | 59994-64-8 | Reference compound |
| HY-156182 | JNK-IN-14 | 2991432-56-3 | Reference compound |
| HY-156183 | Antiproliferative agent-37 | 2989275-31-0 | Reference compound |
| HY-156186 | Anticancer agent 160 | 2983122-03-6 | Natural Products |
| HY-156187 | Anticancer agent 161 | | Reference compound |
| HY-156188 | AChE-IN-41 | 3038811-77-4 | Reference compound |
| HY-156189 | CcpA-IN-1 | 2702277-62-9 | Reference compound |
| HY-15619 | Hoechst S 769121 | 74681-68-8 | Dye Reagents |
| HY-156190 | NR2F2-IN-1 | 1049691-47-5 | Reference compound |
| HY-156190A | NR2F2-IN-1 (free base) | 452087-38-6 | Reference compound |
| HY-156191 | Cholic acid anilide | 6912-96-5 | Reference compound |
| HY-156193 | PF-07208254 | 2573122-40-2 | Reference compound |
| HY-156194 | FLAP-IN-1 | 2041076-43-9 | Reference compound |
| HY-156195 | BHBM | 302807-84-7 | Reference compound |
| HY-156197 | Biotin-cholesterol | 2454045-15-7 | Oligonucleotides |
| HY-156198 | Bottromycin A2 | 15005-62-6 | Natural Products |
| HY-156199 | o-Cresol sulfate | 3233-56-5 | Natural Products |
| HY-15620 | Methylproamine | 188247-01-0 | Biochemical Assay Reagents |
| HY-156202 | Geranylgeranoic acid | 35750-48-2 | Reference compound |
| HY-156205 | CdnP-IN-1 | 691862-35-8 | Reference compound |
| HY-156206 | C24 Dihydro ceramide (d18:0/24:0) | 6063-36-1 | Natural Products |
| HY-156209 | Gb3(d18:1/16:0) | 137896-85-6 | Natural Products |
| HY-156209S | Gb3(d18:1/16:0)-d9 | 2738376-84-4 | Isotope-Labeled Compounds |
| HY-15621 | DMA | 188860-26-6 | Dye Reagents |
| HY-156214 | NICE-01 | 2982819-94-1 | Reference compound |
| HY-156215 | NCI-B16 | 802835-01-4 | Reference compound |
| HY-15621A | DMA (trihydrochloride) | 2095832-33-8 | Dye Reagents |
| HY-15622 | meta-iodoHoechst 33258 | 158013-42-4 | Dye Reagents |
| HY-156225 | MMAF-OtBu | 745017-95-2 | ADC Related |
| HY-156228 | RGB-1 | 930455-91-7 | Reference compound |
| HY-15623 | Hoechst 33258 analog | 258843-62-8 | Dye Reagents |
| HY-156237 | Beclin1-ATG14L interaction inhibitor 1 | 1243063-73-1 | Reference compound |
| HY-156239 | Dopamine D3 receptor ligand-5 | 2899250-94-1 | Reference compound |
| HY-15624 | Hoechst 33258 analog 2 | 23491-54-5 | Dye Reagents |
| HY-156241 | Meliadubin B | | Natural Products |
| HY-156242 | BQZ-485 | 1906915-49-8 | Reference compound |
| HY-156243 | GDI2-IN-1 | | Reference compound |
| HY-156244 | PROTAC GDI2 Degrader-1 | | Reference compound |
| HY-156246S | Desmethylrizatriptan-d3 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-156247 | IVMT-Rx-3 | | Reference compound |
| HY-156248S | Spironolactone-d6 | | Isotope-Labeled Compounds |
| HY-156249 | NMS-P528 | 1466546-45-1 | ADC Related |
| HY-15625 | Hoechst 33258 analog 3 | 23554-98-5 | Dye Reagents |
| HY-156250S | 7α-Methylthiol spironolactone-d5 | | Isotope-Labeled Compounds |
| HY-156251 | Antifungal agent 74 | 2856379-97-8 | Reference compound |
| HY-156252 | Antifungal agent 75 | 3013580-23-6 | Reference compound |
| HY-156253 | Anticancer agent 166 | 6630-80-4 | Reference compound |
| HY-156254 | COX-2-IN-35 | | Reference compound |
| HY-156255 | MAO-B-IN-25 | 2097148-47-3 | Reference compound |
| HY-156256 | Insecticidal agent 4 | 2989908-99-6 | Reference compound |
| HY-156257 | UNC9512 | 3032393-24-8 | Reference compound |
| HY-156258 | HDAC6-IN-21 | 2920929-76-4 | Reference compound |
| HY-156259 | PF-07202954 | 2639372-47-5 | Reference compound |
| HY-15626 | ortho-iodoHoechst 33258 | 158013-41-3 | Dye Reagents |
| HY-156260S | Gamma-6Z-Dodecenolactone-d2 | 1082581-86-9 | Isotope-Labeled Compounds |
| HY-156261 | Beef extract | 68990-09-0 | Biochemical Assay Reagents |
| HY-156262 | DEPC-Treated Water | | Biochemical Assay Reagents |
| HY-156263 | LB Broth Base, powder | | Biochemical Assay Reagents |
| HY-156264 | Augpenin | 86482-18-0 | Biochemical Assay Reagents |
| HY-156266 | Rhizochalinin | 321541-13-3 | Reference compound |
| HY-156267 | PPO-IN-4 | | Reference compound |
| HY-156268S | 2-(2-Furanyl)-5-methylpyrazine-d3 | 1335402-07-7 | Isotope-Labeled Compounds |
| HY-156269S | 2-(2-Furanyl)-6-methylpyrazine-d3 | 1335402-08-8 | Isotope-Labeled Compounds |
| HY-15627 | Hoechst 33342 analog | 178481-68-0 | Dye Reagents |
| HY-156270 | SDH-IN-9 | | Reference compound |
| HY-156271 | Tubulin polymerization-IN-52 | 2108615-05-8 | Reference compound |
| HY-156272 | HBV-IN-41 | 1967002-25-0 | Reference compound |
| HY-156273 | HDAC/JAK/BRD4-IN-1 | 2755325-84-7 | Reference compound |
| HY-156274 | HDAC6-IN-23 | 2991427-09-7 | Reference compound |
| HY-156275 | OSBP-IN-1 | 2890760-43-5 | Reference compound |
| HY-156276 | SP4e | | Reference compound |
| HY-156277 | SP4f | | Reference compound |
| HY-156278 | FB49 | | Reference compound |
| HY-156279 | HDAC6-IN-22 | | Reference compound |
| HY-15627A | Hoechst 33342 analog trihydrochloride | 159277-19-7 | Dye Reagents |
| HY-15628 | Hoechst 33258 analog 5 | 23491-55-6 | Dye Reagents |
| HY-156280 | RARα antagonist 1 | | Reference compound |
| HY-156281 | Antifungal agent 76 | 1615683-57-2 | Reference compound |
| HY-156282 | Antibacterial agent 158 | 2804045-21-2 | Reference compound |
| HY-156283 | Antibacterial agent 159 | 2804044-53-7 | Reference compound |
| HY-156284 | EGFR-IN-89 | 2413029-40-8 | Reference compound |
| HY-156285 | ZZM-1220 | | Reference compound |
| HY-156286 | GPX4-IN-7 | | Reference compound |
| HY-156287 | GCase modulator-1 | 796079-91-9 | Reference compound |
| HY-156288 | Anti-Influenza agent 5 | | Reference compound |
| HY-156289 | Anti-MRSA agent 8 | 3118-36-3 | Reference compound |
| HY-15629 | HOE 32020 | 23554-99-6 | Dye Reagents |
| HY-156290 | SAP-04 | 3053678-30-8 | Reference compound |
| HY-156291 | XSJ2-46 | 2265911-12-2 | Reference compound |
| HY-156292 | IHMT-EZH2-426 | 3018914-66-1 | Reference compound |
| HY-156293 | FPR1 antagonist 1 | | Reference compound |
| HY-156294 | FPR1 antagonist 2 | | Reference compound |
| HY-156296 | CDK9-Cyclin T1 PPI-IN-1 | 2995336-58-6 | Reference compound |
| HY-156297 | β5i-IN-1 | | Reference compound |
| HY-156298 | PARP1-IN-16 | | Reference compound |
| HY-156299 | NMS-P945 | 1466546-35-9 | ADC Related |
| HY-15630 | Hoechst 33342 analog 2 | 106050-84-4 | Dye Reagents |
| HY-156300 | Me-Tet-PEG4-NH2 | 2055646-21-2 | ADC Related |
| HY-156301 | Methyltetrazine-amido-PEG8-amine (Trifluoroacetate) | 2143958-58-9 | Reference compound |
| HY-156301A | Me-Tet-PEG8-NH2 (hydrochloride) | | ADC Related |
| HY-156302 | Coumarin-PEG2-endoBCN | 2488174-18-9 | Dye Reagents |
| HY-156303 | Coumarin-PEG2-TCO | 2488174-19-0 | Dye Reagents |
| HY-156304 | Coumarin-C2-TCO | 2488174-16-7 | Dye Reagents |
| HY-156305 | Coumarin-C2-exo-BCN | 2488174-17-8 | Dye Reagents |
| HY-156306 | Coumarin-PEG3-TCO | 2488319-02-2 | Dye Reagents |
| HY-156307 | Me-Tet-PEG3-Maleimide | 2141976-31-8 | ADC Related |
| HY-156308 | Me-Tet-PEG4-Maleimide | 1715913-76-0 | ADC Related |
| HY-156309 | Coumarin-PEG8-tetrazine | | Dye Reagents |
| HY-15630A | Hoechst 33342 analog 2 (trihydrochloride) | 155815-98-8 | Dye Reagents |
| HY-15631 | Hoechst 33258 analog 6 | 129244-66-2 | Dye Reagents |
| HY-156310 | BCN-endo-PEG7-NH2 | 2143968-34-5 | ADC Related |
| HY-156311 | BCN-endo-PEG2-maleimide | 2675364-08-4 | ADC Related |
| HY-156312 | Me-Tet-PEG8-Maleimide | 2143968-05-0 | ADC Related |
| HY-156313 | Me-Tet-PEG4-NHS | 2143968-22-1 | ADC Related |
| HY-156314 | ASN 07115873 | 626220-97-1 | Reference compound |
| HY-156315 | SCO-PEG2-NH2 | 2141976-34-1 | ADC Related |
| HY-156315A | SCO-PEG2-NH2 (formate) | | Reference compound |
| HY-156316 | SCO-PEG3-NH2 | 2141976-29-4 | ADC Related |
| HY-156316A | SCO-PEG3-NH2 (formate) | | Biochemical Assay Reagents |
| HY-156317 | BCN-endo-PEG7-maleimide | | ADC Related |
| HY-156318 | SCO-PEG3-Maleimide | 2141976-35-2 | ADC Related |
| HY-156319 | BCN-exo-PEG2-NH2 | 1357379-13-5 | ADC Related |
| HY-15632 | para-iodoHoechst 33258 | 158013-43-5 | Dye Reagents |
| HY-156320 | BCN-exo-PEG2-maleimide | 2141976-22-7 | ADC Related |
| HY-156321 | SCO-PEG7-Maleimide | 2143968-81-2 | ADC Related |
| HY-156322 | BCN-exo-PEG3-maleimide | 2919127-00-5 | ADC Related |
| HY-156323 | BCN-exo-PEG4-NHS | | ADC Related |
| HY-156324 | BCN-exo-PEG8-NHS | | ADC Related |
| HY-156325 | SARS-CoV-2-IN-62 | 2350285-18-4 | Reference compound |
| HY-156326S | (3E,5E)-Octadien-2-one-13C2 | | Isotope-Labeled Compounds |
| HY-156326S1 | (3E,5Z)-Octadien-2-one-13C2 | | Isotope-Labeled Compounds |
| HY-156327S | 2-Hexylcinnamyl-alcohol-d5 | | Isotope-Labeled Compounds |
| HY-156328 | NSC 48160 | 6640-90-0 | Reference compound |
| HY-156329 | sEH/FLAP-IN-1 | | Reference compound |
| HY-156330 | HIV-IN-9 | | Reference compound |
| HY-156331 | VU6004909 | 1860797-76-7 | Reference compound |
| HY-156332 | TNKS-2-IN-2 | 2719726-91-5 | Reference compound |
| HY-156333S | S-(2-Furanylmethyl) methanethioate-d2 | | Isotope-Labeled Compounds |
| HY-156334 | FAK-IN-12 | | Reference compound |
| HY-156335 | VU0531245 | 1396749-92-0 | Reference compound |
| HY-156336 | PLK1-IN-7 | 2938910-96-2 | Reference compound |
| HY-156337 | SARS-CoV-2-IN-63 | 2350285-21-9 | Reference compound |
| HY-156338 | Laccase-IN-2 | | Reference compound |
| HY-156339 | GABA receptor Antagonist 1 | | Reference compound |
| HY-156340 | Anti-inflammatory agent 58 | 3032851-09-2 | Reference compound |
| HY-156341S1 | LLIYYTSSLHSGVPSR-(Arg-13C6,15N4) (TFA) | | Isotope-Labeled Compounds |
| HY-156342 | Anti-inflammatory agent 59 | 3032851-11-6 | Reference compound |
| HY-156343S1 | SNNYATHYAESVK-(Lys-13C6,15N2) (TFA) | | Isotope-Labeled Compounds |
| HY-156344S1 | GLEWVAEIR-(Arg-13C6,15N4) (TFA) | | Isotope-Labeled Compounds |
| HY-156345S1 | LPFTFGQGTK-(Lys-13C6,15N2) (TFA) | | Isotope-Labeled Compounds |
| HY-156346 | HCoV-OC43-IN-1 | 2809363-81-1 | Reference compound |
| HY-156347S | (2-Methyl-3-furanyl)-dithio-2-propanone-d3 | 1335401-41-6 | Isotope-Labeled Compounds |
| HY-156348 | MAO-B-IN-26 | 38470-71-2 | Reference compound |
| HY-156349 | Sec61-IN-4 | | Reference compound |
| HY-156350 | SGC-STK17B-1 | 2650530-00-8 | Reference compound |
| HY-156351S | cis-4-Nonenal-d2 | | Isotope-Labeled Compounds |
| HY-156352S | Ethyl (S)-2-hydroxy-3-methylbutyrate-d5 | | Isotope-Labeled Compounds |
| HY-156354 | GPR61 Inverse agonist 1 | | Reference compound |
| HY-156355 | Sec61-IN-5 | | Reference compound |
| HY-156356 | AChE-IN-42 | | Reference compound |
| HY-156358 | AChE-IN-43 | | Reference compound |
| HY-156359 | Tuberculosis inhibitor 10 | | Reference compound |
| HY-156360 | Xanthine oxidase-IN-12 | 3041062-80-7 | Reference compound |
| HY-156361 | Tuberculosis inhibitor 11 | | Reference compound |
| HY-156363 | K-Ras-IN-2 | 905794-70-9 | Reference compound |
| HY-156366 | SNX7886 | 2924557-42-4 | Reference compound |
| HY-156367 | RIPK1-IN-16 | 2561431-77-2 | Reference compound |
| HY-156368 | RIPK3-IN-4 | 2304617-58-9 | Reference compound |
| HY-156369 | Urease-IN-9 | | Reference compound |
| HY-156370 | Tyrosinase-IN-15 | | Reference compound |
| HY-156371 | MIPS-21335 | 2569296-51-9 | Reference compound |
| HY-156372 | AChE-IN-44 | 2758685-58-2 | Reference compound |
| HY-156373 | MN714 | | Reference compound |
| HY-156374 | D359-0396 | 1031977-31-7 | Reference compound |
| HY-156375 | PKM2 activator 6 | | Reference compound |
| HY-156376 | Cu(II)-Elesclomol | 1224195-72-5 | Reference compound |
| HY-156377 | Biotin-PEG7-Maleimide | 1898221-65-2 | ADC Related |
| HY-156378 | Aurora A inhibitor 3 | | Reference compound |
| HY-156379 | Biotin-PEG8-Alkyne | 2143968-80-1 | Reference compound |
| HY-156380 | α-Amylase/α-Glucosidase-IN-6 | | Reference compound |
| HY-156381 | Biotin-PEG3-CoenzymeA | | Reference compound |
| HY-156382 | SPOP-IN-1 | 2136270-56-7 | Reference compound |
| HY-156383 | SCO-PEG3-NHS | 2141976-25-0 | Reference compound |
| HY-156384 | SCO-PEG4-NHS | 2141976-26-1 | Reference compound |
| HY-156385 | SCO-PEG8-NHS | 2143968-68-5 | Reference compound |
| HY-156386 | SCO-PEG3-COOH | 2141976-36-3 | Reference compound |
| HY-156387 | SCO-PEG4-COOH | 2141976-27-2 | Reference compound |
| HY-156388 | SCO-PEG8-COOH | 2143968-79-8 | Reference compound |
| HY-156389 | (R)-TCO4-PEG2-NH2 | | Reference compound |
| HY-156390 | (R)-TCO4-PEG7-NH2 | | Reference compound |
| HY-156391 | TCO4-PEG2-Maleimide | 2141981-85-1 | Reference compound |
| HY-156391A | (R)-TCO4-PEG2-Maleimide | | Reference compound |
| HY-156392 | TCO4-PEG7-Maleimide | | Reference compound |
| HY-156393 | Laxiflorin B | 165337-71-3 | Natural Products |
| HY-156394 | Laxiflorin B-4 | 2810956-32-0 | Reference compound |
| HY-156395 | MN551 | | Reference compound |
| HY-156397 | HTH-02-006 | | Reference compound |
| HY-156398 | Anti-inflammatory agent 60 | | Reference compound |
| HY-156399 | KR-27425 | | Reference compound |
| HY-15640 | Capsazepine | 138977-28-3 | Reference compound |
| HY-156400 | IDO1-IN-23 | 3007671-44-2 | Reference compound |
| HY-156401 | BRD9 Degrader-1 | | Reference compound |
| HY-156402 | AuM1Gly | | Reference compound |
| HY-156403 | AuM1Phe | | Reference compound |
| HY-156404 | PM-1 | 1449483-78-6 | Dye Reagents |
| HY-156405 | FTO-IN-10 | | Reference compound |
| HY-156406 | PITCOIN4 | | Reference compound |
| HY-156407 | Adam-20-S | 2413880-52-9 | Reference compound |
| HY-156408 | Spns2-IN-1 | | Reference compound |
| HY-156409 | ABBV-712 | 2368945-27-9 | Reference compound |
| HY-15641 | FG-2216 | 223387-75-5 | Reference compound |
| HY-156410 | FLT3-IN-23 | 2489528-97-2 | Reference compound |
| HY-156411 | NR-NO2 | 3033874-97-1 | Reference compound |
| HY-156412 | DHFR-IN-10 | 929484-47-9 | Reference compound |
| HY-156413 | NLRP3 agonist 1 | 2454019-69-1 | Reference compound |
| HY-156414 | DHFR-IN-11 | | Reference compound |
| HY-156415 | NLRP3 agonist 2 | | Reference compound |
| HY-156416 | LtaS-IN-2 | | Reference compound |
| HY-156418 | KY386 | 2787598-01-8 | Reference compound |
| HY-156419 | PARP7-IN-16 | 2435657-10-4 | Reference compound |
| HY-156419A | PARP7-IN-16 (free base) | 2136325-05-6 | Reference compound |
| HY-15642 | TD-198946 | 364762-86-7 | Reference compound |
| HY-156420 | ATUX-1215 | 2910929-53-0 | Reference compound |
| HY-156421 | QST4 | 2991427-35-9 | Reference compound |
| HY-156422 | KPZ560 | 2397562-43-3 | Reference compound |
| HY-156423 | Tubulin/JAK2-IN-1 | 2933938-46-4 | Reference compound |
| HY-156424 | NOX2-IN-1 | 2648709-25-3 | Reference compound |
| HY-156425 | NOX2-IN-2 | 2648709-79-7 | Reference compound |
| HY-156425A | NOX2-IN-2 (diTFA) | 2648709-80-0 | Reference compound |
| HY-156427 | Antileishmanial agent-25 | | Reference compound |
| HY-156429 | MK-1468 | 2769107-89-1 | Reference compound |
| HY-15643 | LY 303511 | 154447-38-8 | Reference compound |
| HY-156430 | MMP-7-IN-3 | 2865097-58-9 | Reference compound |
| HY-156431 | Anti-inflammatory agent 61 | | Reference compound |
| HY-156432 | ALK-IN-26 | 2447607-85-2 | Reference compound |
| HY-156434 | PDE11A4-IN-1 | 3027607-92-4 | Reference compound |
| HY-156435 | tau Protein/α-synuclein-IN-1 | | Reference compound |
| HY-156436 | Anti-inflammatory agent 62 | | Reference compound |
| HY-156437 | NBI-961 | 2225902-98-5 | Reference compound |
| HY-156438 | NT-0796 | 2272917-13-0 | Reference compound |
| HY-156439 | Antibiofilm agent-2 | 2977230-63-8 | Reference compound |
| HY-15643A | LY 303511 (hydrochloride) | 2070014-90-1 | Reference compound |
| HY-15643B | LY 303511 (dihydrochloride) | 854127-90-5 | Reference compound |
| HY-15644 | Tyrphostin 23 | 118409-57-7 | Reference compound |
| HY-156440 | 7-51A | | Reference compound |
| HY-156441 | SARS-CoV-2-IN-65 | | Reference compound |
| HY-156442 | MEDS433 | 2241027-61-0 | Reference compound |
| HY-156443 | YG1702 | 724737-08-0 | Reference compound |
| HY-156444 | HDAC1/CDK7-IN-1 | 2987905-95-1 | Reference compound |
| HY-156445 | PI3K/mTOR Inhibitor-14 | 2919684-77-6 | Reference compound |
| HY-156447 | α-Glucosidase-IN-40 | | Reference compound |
| HY-156448 | 80-O14B | 1624618-01-4 | Oligonucleotides |
| HY-156449 | STING-IN-7 | 899947-07-0 | Reference compound |
| HY-15645 | H4R antagonist 2 | 1148115-99-4 | Reference compound |
| HY-156450 | ERK5-IN-5 | 2318792-30-0 | Reference compound |
| HY-156451 | ERK5-IN-6 | 2734916-64-2 | Reference compound |
| HY-156452 | T-1-MCPAB | | Reference compound |
| HY-156453 | PAK4-IN-3 | | Reference compound |
| HY-156454 | UCB-6876 | 637324-45-9 | Reference compound |
| HY-156455 | SETD7-IN-1 | | Reference compound |
| HY-156456 | Elastase LasB-IN-1 | 2762675-17-0 | Reference compound |
| HY-156457 | EGFR-IN-90 | 3008611-00-2 | Reference compound |
| HY-156458 | SR-29065 | | Reference compound |
| HY-156459 | SARS-CoV-2 Mpro-IN-12 | 370583-15-6 | Reference compound |
| HY-15646 | UNC1999 | 1431612-23-5 | Reference compound |
| HY-156460 | CMKLR1 antagonist 1 | 3033101-08-2 | Reference compound |
| HY-156461S | Myrcenol-d6 | | Isotope-Labeled Compounds |
| HY-156462 | Topoisomerase I inhibitor 9 | 1228150-86-4 | Reference compound |
| HY-156464 | Topoisomerase I inhibitor 10 | | Reference compound |
| HY-156465 | RIOK2-IN-2 | 2648987-17-9 | Reference compound |
| HY-156466 | QL-1200186 | 2848664-42-4 | Reference compound |
| HY-156467 | Neladalkib | 2739866-40-9 | Reference compound |
| HY-156467A | Neladalkib (TFA) | | Reference compound |
| HY-156468 | Antioxidant agent-17 | | Reference compound |
| HY-156469 | NLRP3-IN-22 | 1193329-98-4 | Reference compound |
| HY-15647 | BRD9539 | 1374601-41-8 | Reference compound |
| HY-156470 | Multi-kinase-IN-6 | 3009081-73-3 | Reference compound |
| HY-156471 | RET-IN-26 | | Reference compound |
| HY-156472 | HDAC6-IN-25 | | Reference compound |
| HY-156475 | Me-Tet-PEG2-COOH | 2741759-99-7 | ADC Related |
| HY-156476 | Me-Tet-PEG2-NHS | 2740357-12-2 | ADC Related |
| HY-156477 | Me-Tet-PEG8-NHBoc | 2143968-21-0 | ADC Related |
| HY-156478 | Me-Tet-PEG4-NHBoc | 2143955-71-7 | ADC Related |
| HY-156479 | Me-Tet-PEG3-NHBoc | 2141976-32-9 | ADC Related |
| HY-15648 | GSK-J1 | 1373422-53-7 | Reference compound |
| HY-156480S | 3-Mercaptooctyl-acetate-d5 | | Isotope-Labeled Compounds |
| HY-156481 | SU-8000 | 2126-63-8 | Reference compound |
| HY-156482S | 3-Mercapto-1-octanol-d5 | | Isotope-Labeled Compounds |
| HY-156483 | TT-012 | 1164471-33-3 | Reference compound |
| HY-156485S | β-Thujene-d2 | | Isotope-Labeled Compounds |
| HY-156486S | 3,5-Dimethyl-2E-(propenyl)pyrazine-d3 | 1335436-58-2 | Isotope-Labeled Compounds |
| HY-156488 | TCO-PEG7-Maleimide | | Reference compound |
| HY-156489 | Epigenetic factor-IN-1 | 2640673-56-7 | Reference compound |
| HY-15648A | GSK-J2 | 1394854-52-4 | Reference compound |
| HY-15648B | GSK-J4 | 1373423-53-0 | Reference compound |
| HY-15648C | GSK-J5 | 1394854-51-3 | Reference compound |
| HY-15648D | GSK-J1 (lithium salt) | 2309668-29-7 | Reference compound |
| HY-15648F | GSK-J4 (hydrochloride) | 1797983-09-5 | Reference compound |
| HY-15648G | GSK-J1 (sodium) | 1797832-71-3 | Reference compound |
| HY-15648H | GSK-J5 (hydrochloride) | 1797983-32-4 | Reference compound |
| HY-15648I | GSK-J2 (sodium) | 2108665-15-0 | Reference compound |
| HY-15649 | UNC1215 | 1415800-43-9 | Reference compound |
| HY-156490 | Me-Tet-PEG5-NHS | 2096446-25-0 | ADC Related |
| HY-156491 | Me-Tet-PEG9-NHS | 2143955-78-4 | ADC Related |
| HY-156492 | Me-Tet-PEG4-COOH | 2141976-30-7 | ADC Related |
| HY-156493 | Me-Tet-PEG5-COOH | 2143964-72-9 | ADC Related |
| HY-156494 | Me-Tet-PEG9-COOH | 2143964-70-7 | ADC Related |
| HY-156495 | Biotin-PEG3-Me-Tet | 2143968-06-1 | ADC Related |
| HY-156497 | Biotin-PEG8-Me-Tet | 2143958-82-9 | Reference compound |
| HY-156498 | RMC-7977 | 2765082-12-8 | Reference compound |
| HY-156499 | RNF114 ligand 1 | 900137-36-2 | Reference compound |
| HY-15650 | SGC0946 | 1561178-17-3 | Reference compound |
| HY-156500 | ICMT-IN-1 | 1313603-22-3 | Reference compound |
| HY-156501 | BT101 (sodium) | | Oligonucleotides |
| HY-156502 | TINK-IN-1 | 1417795-25-5 | Reference compound |
| HY-156507 | DBCO-PEG3-NHS ester | 2163772-16-3 | Reference compound |
| HY-156508 | HPK1-IN-37 | 2766481-68-7 | Reference compound |
| HY-156509 | HPK1-IN-38 | 2578802-72-7 | Reference compound |
| HY-15651 | Alvelestat | 848141-11-7 | Reference compound |
| HY-156511 | ETC-168 | 1464150-99-9 | Reference compound |
| HY-156512 | DT-6 | 2414315-95-8 | Reference compound |
| HY-156513 | ZD06519 | 2873460-17-2 | ADC Related |
| HY-156514 | MC-GGFG-AM-(10NH2-11F-Camptothecin) | 2987938-97-4 | ADC Related |
| HY-156515 | MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) | 2987937-38-0 | ADC Related |
| HY-156516 | 10NH2-11F-Camptothecin | 2873460-30-9 | ADC Related |
| HY-156516A | 10NH2-11F-Camptothecin (TFA) | 2873461-64-2 | Reference compound |
| HY-156517 | 7Ethanol-10NH2-11F-Camptothecin | 2873460-31-0 | ADC Related |
| HY-156518 | Glucose-malemide | 2093979-63-4 | Reference compound |
| HY-156519 | ALPK1-IN-3 | 2765633-73-4 | Reference compound |
| HY-15651A | Alvelestat (tosylate) | 1240425-05-1 | Reference compound |
| HY-15651S | Alvelestat-13C,d3 | | Isotope-Labeled Compounds |
| HY-15652 | Freselestat | 208848-19-5 | Reference compound |
| HY-156520 | Immunosuppressant-1 | 1224571-03-2 | Reference compound |
| HY-156521 | αvβ1 integrin-IN-2 | 2234874-68-9 | Reference compound |
| HY-156522 | CRF1 receptor antagonist-1 | 2635364-30-4 | Reference compound |
| HY-156523 | TNIK&MAP4K4-IN-1 | 2478592-86-6 | Reference compound |
| HY-156524 | USP1-IN-5 | 2925547-94-8 | Reference compound |
| HY-156525 | USP1-IN-6 | 2925547-95-9 | Reference compound |
| HY-156526 | PHD-IN-1 | 2924182-31-8 | Reference compound |
| HY-156527 | PHD-IN-2 | 2924182-42-1 | Reference compound |
| HY-156528 | pan-KRAS-IN-4 | 2885961-55-5 | Reference compound |
| HY-156529 | pan-KRAS-IN-2 | 2882825-14-9 | Reference compound |
| HY-15652A | Freselestat (quarterhydrate) | | Reference compound |
| HY-15653 | Filorexant | 1088991-73-4 | Reference compound |
| HY-156530 | CYP11A1-IN-1 | 2744168-51-0 | Reference compound |
| HY-156532 | 5-HT2C agonist-3 | 2104810-18-4 | Reference compound |
| HY-156532A | 5-HT2C agonist-3 (free base) | 2104810-17-3 | Reference compound |
| HY-156532C | (-)-5-HT2C agonist-3 | 2104810-16-2 | Reference compound |
| HY-156533 | 5-HT2 agonist-1 | 2708279-78-9 | Reference compound |
| HY-156533A | 5-HT2 agonist-1 (free base) | 2708279-77-8 | Reference compound |
| HY-156534 | 5-HT2A&5-HT2C agonist-1 | 1640-02-4 | Reference compound |
| HY-156535 | JAK kinase-IN-1 | 2698389-43-2 | Reference compound |
| HY-156536 | RXFP1 receptor agonist-1 | 2924619-64-5 | Reference compound |
| HY-156537 | RXFP1 receptor agonist-2 | 2924460-54-6 | Reference compound |
| HY-156538 | RXFP1 receptor agonist-3 | 2924767-53-1 | Reference compound |
| HY-156539 | RXFP1 receptor agonist-4 | 2941376-76-5 | Reference compound |
| HY-15654 | Sodium 4-phenylbutyrate | 1716-12-7 | Reference compound |
| HY-156540 | RXFP1 receptor agonist-5 | 2941385-36-8 | Reference compound |
| HY-156541 | RXFP1 receptor agonist-6 | 2941346-85-4 | Reference compound |
| HY-156542 | RXFP1 receptor agonist-7 | 2941484-13-3 | Reference compound |
| HY-156543 | RXFP1 receptor agonist-8 | 2941271-76-5 | Reference compound |
| HY-156549 | KRAS G12C inhibitor 61 | 2300967-40-0 | Reference compound |
| HY-15654R | Sodium 4-phenylbutyrate (Standard) | 1716-12-7 | Reference Standards |
| HY-15654S | Phenylbutyrate-d11 (sodium) | 1392208-11-5 | Isotope-Labeled Compounds |
| HY-15655 | GW1929 | 196808-24-9 | Reference compound |
| HY-156550 | ROCK-IN-8 | 1621103-79-4 | Reference compound |
| HY-156551 | Porcn-IN-2 | 1900754-65-5 | Reference compound |
| HY-156552 | DDR1/2 inhibitor-2 | 2908756-11-4 | Reference compound |
| HY-156553 | BTK-IN-27 | 1841502-36-0 | Reference compound |
| HY-156554 | Raf inhibitor 3 | 1662682-11-2 | Reference compound |
| HY-156555 | pan-KRAS-IN-3 | 2875116-29-1 | Reference compound |
| HY-156556 | c-Fms-IN-14 | 1898210-99-5 | Reference compound |
| HY-156558 | SeGalNac | 1365541-49-6 | Reference compound |
| HY-156559 | GlcNAc-SH | 91288-32-3 | Reference compound |
| HY-15656 | Ceritinib | 1032900-25-6 | Reference compound |
| HY-156560 | Z-LVG | 119670-31-4 | Reference compound |
| HY-156562 | 5-PT | 92085-05-7 | Reference compound |
| HY-156562A | 5-PT (formic) | 2906227-87-8 | Reference compound |
| HY-156565 | Sumonerimod | 2433782-42-2 | Reference compound |
| HY-156565A | Sumonerimod (hemicalcium) | 2941310-03-6 | Reference compound |
| HY-156566 | PROTAC BRD4 Degrader-21 | 2503036-46-0 | Reference compound |
| HY-156567 | AMB639752 | 371210-26-3 | Reference compound |
| HY-156568 | SMD-3040 | 3033109-92-8 | Reference compound |
| HY-156568A | SMD-3040 (TFA) | | Reference compound |
| HY-156568B | SMD-3040 formate | | Reference compound |
| HY-156569 | DGKα-IN-2 | 2648556-92-5 | Reference compound |
| HY-15656A | Ceritinib dihydrochloride | 1380575-43-8 | Reference compound |
| HY-15656R | Ceritinib (Standard) | 1032900-25-6 | Reference Standards |
| HY-15656S | Ceritinib-d7 | 1632484-77-5 | Isotope-Labeled Compounds |
| HY-156570 | DGKα-IN-3 | 2648418-86-2 | Reference compound |
| HY-156571 | DGKα-IN-4 | 2648723-43-5 | Reference compound |
| HY-156572 | DGKζ-IN-3 | 2732901-70-9 | Reference compound |
| HY-156573 | DGKα&ζ-IN-1 | 2830643-06-4 | Reference compound |
| HY-156574 | DGKζ-IN-4 | 2778366-77-9 | Reference compound |
| HY-156575S | DGKα-IN-5 | 2886721-97-5 | Isotope-Labeled Compounds |
| HY-156576 | DGKα-IN-6 | 2886734-91-2 | Reference compound |
| HY-156577 | DGKα-IN-7 | 2886092-50-6 | Reference compound |
| HY-156578 | DGKα-IN-8 | 2886717-70-8 | Reference compound |
| HY-156579 | WRN inhibitor 3 | 2923009-48-5 | Reference compound |
| HY-15658 | GSK2801 | 1619994-68-1 | Reference compound |
| HY-156580 | WRN inhibitor 4 | 2923009-45-2 | Reference compound |
| HY-156581 | WRN inhibitor 5 | 2923009-95-2 | Reference compound |
| HY-156584 | ODE-Bn-PMEG | 1626364-18-8 | Reference compound |
| HY-156585 | CNS-11 | 445218-34-8 | Reference compound |
| HY-156586 | Egalognastat | 1884154-02-2 | Reference compound |
| HY-15659 | Wnt-C59 | 1243243-89-1 | Reference compound |
| HY-156590 | B-Raf IN 16 | 2304746-24-3 | Reference compound |
| HY-156591 | PROTAC MLKL Degrader-1 | 3032600-90-8 | Reference compound |
| HY-156592 | ROCK2-IN-6 | 2260506-59-8 | Reference compound |
| HY-156592A | ROCK2-IN-6 (hydrochloride) | 2762238-94-6 | Reference compound |
| HY-156593 | ROCK-IN-9 | 2643334-76-1 | Reference compound |
| HY-156595 | BCL6 ligand-1 | 2230407-20-0 | Reference compound |
| HY-156596 | Aneratrigine | 2097163-74-9 | Reference compound |
| HY-156596A | Aneratrigine (hydrochloride) | 2097163-75-0 | Reference compound |
| HY-156597 | Arbemnifosbuvir | 1998705-63-7 | Reference compound |
| HY-156598 | 1,3-Bis(carboxyphenoxy)propane | 221291-98-1 | Reference compound |
| HY-156599 | Bavtavirine | 1956373-71-9 | Reference compound |
| HY-15659G | Wnt-C59 (GMP) | 1243243-89-1 | GMP Small Molecules |
| HY-15660 | Efinaconazole | 164650-44-6 | Reference compound |
| HY-156601 | Bexicaserin | 2035818-24-5 | Reference compound |
| HY-156601A | (S)-Bexicaserin | 2035818-21-2 | Reference compound |
| HY-156602 | Bocodepsin | 1834513-65-3 | Reference compound |
| HY-156602A | Bocodepsin (hydrochloride) | 1834513-66-4 | Reference compound |
| HY-156603 | Canlitinib | 2222730-78-9 | Reference compound |
| HY-156604 | Cinsebrutinib | 2724962-58-5 | Reference compound |
| HY-156605 | Davelizomib | 2409841-51-4 | Reference compound |
| HY-156606 | Anticancer agent 142 | 2948338-60-9 | Reference compound |
| HY-156607 | Anticancer agent 143 | 2948339-38-4 | Reference compound |
| HY-156608 | Anticancer agent 144 | 2948340-59-6 | Reference compound |
| HY-156609 | FOXM1-IN-2 | 2694866-10-7 | Reference compound |
| HY-15660S | Efinaconazole-d4 | | Isotope-Labeled Compounds |
| HY-156612 | Friluglanstat | 1422203-86-8 | Reference compound |
| HY-156613 | Frunexian | 1803270-60-1 | Reference compound |
| HY-156614 | Icalcaprant | 2227384-17-8 | Reference compound |
| HY-156615 | Igermetostat | 2409538-60-7 | Reference compound |
| HY-156616 | VC1052 | 370108-98-8 | Biochemical Assay Reagents |
| HY-156617 | Cyclopropaneacetamide-Exatecan | 2414254-36-5 | ADC Related |
| HY-156617A | (αR)-Cyclopropaneacetamide-Exatecan | 2414254-37-6 | Reference compound |
| HY-156618 | Irpagratinib | 2230974-62-4 | Reference compound |
| HY-156619 | Labuxtinib | 1426449-01-5 | Reference compound |
| HY-15661A | OSI-413 (free base) | 183320-29-8 | Reference compound |
| HY-15662 | Tulathromycin A | 217500-96-4 | Reference compound |
| HY-156620 | Lacutoclax | 2291166-56-6 | Reference compound |
| HY-156621 | Lepzacitinib | 2321488-47-3 | Reference compound |
| HY-156622 | Leramistat | 1642602-54-7 | Reference compound |
| HY-156623 | Lerzeparib | 2459693-01-5 | Reference compound |
| HY-156624 | Lingdolinurad | 2088176-96-7 | Reference compound |
| HY-156625 | Nedometinib | 2252314-46-6 | Reference compound |
| HY-156626 | Nevadistinel | 2181816-92-0 | Reference compound |
| HY-156628 | Opevesostat | 2231294-96-3 | Reference compound |
| HY-156629 | Orziloben | 1555822-28-0 | Reference compound |
| HY-15662R | Tulathromycin A (Standard) | 217500-96-4 | Reference Standards |
| HY-15662S | Tulathromycin A-d7 | | Isotope-Labeled Compounds |
| HY-15663 | IPA-3 | 42521-82-4 | Reference compound |
| HY-156630 | Ionizable lipid-1 | 2055939-68-7 | Oligonucleotides |
| HY-156630A | Ionizable lipid-1 (hydrochloride) | | Biochemical Assay Reagents |
| HY-156631S | Pozdeutinurad | 2173408-41-6 | Isotope-Labeled Compounds |
| HY-156632 | Resigratinib | 2750709-91-0 | Reference compound |
| HY-156633 | Rezatapopt | 2636846-41-6 | Reference compound |
| HY-156634 | Risevistinel | 2591344-26-0 | Reference compound |
| HY-156635 | TIE-2/VEGFR-2 kinase-IN-3 | 433224-09-0 | Reference compound |
| HY-156637 | TIE-2/VEGFR-2 kinase-IN-4 | 433224-29-4 | Reference compound |
| HY-156638 | TIE-2/VEGFR-2 kinase-IN-5 | 1014407-83-0 | Reference compound |
| HY-156639 | EGFR/ErbB-2 inhibitor-1 | 1135150-79-6 | Reference compound |
| HY-15664 | Bivalirudin (TFA) | 1191386-55-6 | Peptides |
| HY-156640 | Rocbrutinib | 2485861-07-0 | Reference compound |
| HY-156641 | Sontigidomide | 2560577-69-5 | Reference compound |
| HY-156642 | (1-OH)-Exatecan | 2894780-53-9 | Reference compound |
| HY-156643 | Tacaciclib | 2768774-66-7 | Reference compound |
| HY-156645 | Tegomil fumarate | 1817769-42-8 | Reference compound |
| HY-156646 | Tibremciclib | 2397678-18-9 | Reference compound |
| HY-156647 | Usnoflast | 2455519-86-3 | Reference compound |
| HY-156648 | Vamagloxistat | 2408241-62-1 | Reference compound |
| HY-156648A | Vamagloxistat (sodium) | 2667602-26-6 | Reference compound |
| HY-156649 | Vorbipiprant | 1417742-86-9 | Reference compound |
| HY-15665 | XMD17-109 | 1435488-37-1 | Reference compound |
| HY-156650 | Votoplam | 2407849-89-0 | Reference compound |
| HY-156651 | Zevotrelvir | 2773516-53-1 | Reference compound |
| HY-156653S | Deunirmatrelvir | 2861202-79-9 | Isotope-Labeled Compounds |
| HY-156654 | Ibuzatrelvir | 2755812-39-4 | Reference compound |
| HY-156655 | Olgotrelvir | 2763596-71-8 | Reference compound |
| HY-156655A | Olgotrelvir (sodium) | 2763596-72-9 | Reference compound |
| HY-156656 | Tirfipiravir | 2759996-93-3 | Reference compound |
| HY-156659 | NC1 | 445406-82-6 | Reference compound |
| HY-15666 | Olverembatinib | 1257628-77-5 | Reference compound |
| HY-156661 | MurF-IN-1 | 303790-97-8 | Reference compound |
| HY-156662 | Casein kinase 1δ-IN-7 | 764694-25-9 | Reference compound |
| HY-156663 | Calcium Channel antagonist 2 | 874370-15-7 | Reference compound |
| HY-156664 | Calcium Channel antagonist 3 | 687573-14-4 | Reference compound |
| HY-156665 | HBV-IN-37 | 380483-01-2 | Reference compound |
| HY-156666 | Casein kinase 1δ-IN-8 | 851396-73-1 | Reference compound |
| HY-156667 | H4R antagonist 3 | 1003091-20-0 | Reference compound |
| HY-156668 | Rac1-IN-3 | 380470-06-4 | Reference compound |
| HY-156669 | Calcium Channel antagonist 4 | 687574-49-8 | Reference compound |
| HY-15666A | Olverembatinib (dimesylate) | 1421783-64-3 | Reference compound |
| HY-15666R | Olverembatinib (Standard) | 1257628-77-5 | Reference Standards |
| HY-15667 | P005091 | 882257-11-6 | Reference compound |
| HY-156670 | Camptothecin analog-1 | 2873460-51-4 | Reference compound |
| HY-156671 | RMC-4998 | 2642037-07-6 | Reference compound |
| HY-156671A | RMC-4998 (formic) | | Reference compound |
| HY-156672 | S6K2-IN-1 | | Reference compound |
| HY-156673 | m-Se3 | 2829939-44-6 | Reference compound |
| HY-156675 | Plecstatin-1 | 2119725-22-1 | Reference compound |
| HY-156675A | Plecstatin-1 (hydrochloride) | | Reference compound |
| HY-156677 | STC-15 | 2648257-56-9 | Reference compound |
| HY-156679 | VK-0214 | 852949-30-5 | Reference compound |
| HY-156680 | Vopimetostat | 2760483-96-1 | Reference compound |
| HY-156681 | Tersolisib | 2883540-92-7 | Reference compound |
| HY-156681A | (S)-Tersolisib | 2883540-91-6 | Reference compound |
| HY-156682 | JNT-517 | 2837993-05-0 | Reference compound |
| HY-156683 | CHK-336 | 2743436-86-2 | Reference compound |
| HY-156684 | Nedizantrep | 2376824-99-4 | Reference compound |
| HY-156685 | EDI048 | 2767264-57-1 | Reference compound |
| HY-156686 | NH2-methylpropanamide-Exatecan (TFA) | 1817857-35-4 | ADC Related |
| HY-156687 | GGFG-Eribulin | 2841688-66-0 | Reference compound |
| HY-156690 | 2-Quinizarincarboxylic acid | 6416-55-3 | Reference compound |
| HY-156691 | TLR7/8 agonist 4 hydroxy-PEG6-acid | 2388520-23-6 | Reference compound |
| HY-156691A | TLR7/8 agonist 4 hydroxy-PEG6-acid (hydrochloride) | | Reference compound |
| HY-156693 | MTvkPABC-P5 | 3027976-10-6 | Reference compound |
| HY-156693A | MTvkPABC-P5 (TFA) | | ADC Related |
| HY-156694 | Hydroxy-PP-Me | 833481-77-9 | Reference compound |
| HY-156696 | S3226 | 215183-03-2 | Reference compound |
| HY-156698 | HJM-561 | 2570251-68-0 | Reference compound |
| HY-15670 | BMS-906024 | 1401066-79-2 | Reference compound |
| HY-156700 | Lenalidomide-acetylene-Br | 2619512-84-2 | Reference compound |
| HY-156702 | HBV-IN-38 | 1834483-86-1 | Reference compound |
| HY-156703S | HBV-IN-39-d3 | 2173356-23-3 | Isotope-Labeled Compounds |
| HY-156704 | FGFR4-IN-16 | 1970120-44-5 | Reference compound |
| HY-156705 | CDK7-IN-25 | 2009209-60-1 | Reference compound |
| HY-156706 | JAK-IN-31 | 2597016-88-9 | Reference compound |
| HY-15671 | GKA50 | 851884-87-2 | Reference compound |
| HY-156711 | Ternatumoside II | 1473419-87-2 | Natural Products |
| HY-156712 | Depatuxizumab MMAE | | ADC Related |
| HY-156715 | MASTL-IN-1 | 3024916-67-1 | Reference compound |
| HY-156716 | MASTL-IN-2 | 3024916-69-3 | Reference compound |
| HY-156717 | RE-33 | 2923520-98-1 | Reference compound |
| HY-15671A | GKA50 (quarterhydrate) | | Reference compound |
| HY-15672 | FM19G11 | 329932-55-0 | Reference compound |
| HY-156722 | ER-34122 | 179325-62-3 | Reference compound |
| HY-156723 | 9-Chloromethyl-10-hydroxy-11-F-Camptothecin | 2414594-22-0 | Reference compound |
| HY-156726 | Pomalidomide-amino-PEG4-C4-Cl | 2924835-36-7 | Reference compound |
| HY-156727 | Val-Cit-PABC-Ahx-May | 2126749-74-2 | ADC Related |
| HY-156727A | Val-Cit-PABC-Ahx-May (TFA) | 2126749-75-3 | ADC Related |
| HY-15673 | KP372-1 | 1374996-60-7 | Reference compound |
| HY-156730 | KT-333 | 2502186-79-8 | Reference compound |
| HY-156730A | KT-333 (ammonium) | 2839758-34-6 | Reference compound |
| HY-156730B | KT-333 (diammonium) | 2502186-80-1 | Reference compound |
| HY-156731 | (8R,8'R)-Matairesinol 4,4'-di-O-β-D-glucopyranoside | 41948-08-7 | Natural Products |
| HY-156734 | D-4-77 | | Reference compound |
| HY-156735 | HSD17B13-IN-2 | 863564-24-3 | Reference compound |
| HY-156736 | HSD17B13-IN-3 | 313259-88-0 | Reference compound |
| HY-156737 | Tubulin polymerization-IN-49 | | Reference compound |
| HY-156741 | EGFR-IN-87 | 1835666-87-9 | Reference compound |
| HY-156743 | DCAF1 binder 2 | | Reference compound |
| HY-156744 | DBr-1 | | Reference compound |
| HY-156745 | DDa-1 | 3036944-98-3 | Reference compound |
| HY-156746 | DBt-10 | | Reference compound |
| HY-156747 | GSPT1 degrader-2 | 2803879-60-7 | Reference compound |
| HY-156748 | MC-PEG2-VA-PAB-Exatecan | 2845165-13-9 | Reference compound |
| HY-15675 | AZD1656 | 919783-22-5 | Reference compound |
| HY-156750 | (-)-10-epi-α-Cyperone | 2303-31-3 | Biochemical Assay Reagents |
| HY-156751 | (Rac)-GDC-2992 | 2753650-84-7 | Reference compound |
| HY-156751A | GDC-2992 | 2753651-10-2 | Reference compound |
| HY-156752 | Cyclosiversioside F 16,25-diacetate | 452919-90-3 | Reference compound |
| HY-156753 | NorA-IN-1 | 1389310-69-3 | Reference compound |
| HY-156754 | 3β-Hydroxy-lup-20(29)-en-16-one | 65043-60-9 | Reference compound |
| HY-156755 | Propargyl-PEG4-GGFG-DXd | 2762518-94-3 | ADC Related |
| HY-156756 | 7-Hydroxymethyl-10,11-MDCPT | 428816-69-7 | Reference compound |
| HY-156756S | 7-Hydroxymethyl-10,11-MDCPT-d5 | | Isotope-Labeled Compounds |
| HY-156757 | MDL-811 | 2275619-98-0 | Reference compound |
| HY-156758 | Mal-PEG8-Val-Cit-PAB-MMAF | | ADC Related |
| HY-156759 | METTL3-IN-5 | 2965311-25-3 | Reference compound |
| HY-15676 | Idasanutlin | 1229705-06-9 | Reference compound |
| HY-156762 | Cbl-b-IN-6 | 2815221-33-9 | Reference compound |
| HY-156763 | Cbl-b-IN-7 | 2815221-35-1 | Reference compound |
| HY-156764 | Cbl-b-IN-8 | 2815223-33-5 | Reference compound |
| HY-156765 | Cbl-b-IN-9 | 2815223-41-5 | Reference compound |
| HY-156766 | Cbl-b-IN-10 | 2815225-12-6 | Reference compound |
| HY-156767 | Cbl-b-IN-11 | 2815225-15-9 | Reference compound |
| HY-156768 | Cbl-b-IN-12 | 2851871-29-7 | Reference compound |
| HY-156769 | Cbl-b-IN-13 | 2368841-85-2 | Reference compound |
| HY-15676A | Idasanutlin (enantiomer) | | Reference compound |
| HY-15677 | INT-777 | 1199796-29-6 | Reference compound |
| HY-156771 | GPR88-IN-1 | 714265-50-6 | Reference compound |
| HY-156772 | GPR88 agonist 2 | 2821859-71-4 | Reference compound |
| HY-156773 | STM3006 | 2499664-52-5 | Reference compound |
| HY-156774 | CCW 28-3 | 2361142-23-4 | Reference compound |
| HY-156775 | Antitumor agent-119 | 913169-79-6 | Reference compound |
| HY-156776 | HAPSBC | 1376545-81-1 | Reference compound |
| HY-156777 | Antiproliferative agent-36 | 193828-76-1 | Reference compound |
| HY-156778 | Antitumor agent-120 | 948901-10-8 | Reference compound |
| HY-156779 | HSP90-IN-27 | 525577-38-2 | Reference compound |
| HY-15677A | INT-777 (R-enantiomer) | 1198786-98-9 | Reference compound |
| HY-156780 | NSC 689534 | 907958-80-9 | Reference compound |
| HY-156781 | Sirtuin-1 inhibitor 1 | 945114-10-3 | Reference compound |
| HY-156782 | DHX9-IN-1 | 2973747-89-4 | Reference compound |
| HY-156784 | ATX968 | 2973395-71-8 | Reference compound |
| HY-156787 | Porfimer sodium | 87806-31-3 | Reference compound |
| HY-15679 | PI4KIII beta inhibitor 3 | 1245319-54-3 | Reference compound |
| HY-156790 | FGFR3-IN-6 | 2833703-72-1 | Reference compound |
| HY-156791 | FGFR3-IN-7 | 2833703-79-8 | Reference compound |
| HY-156792 | RIOK2-IN-1 | 1088216-72-1 | Reference compound |
| HY-156793 | hRIO2 kinase ligand-1 | 923841-73-0 | Reference compound |
| HY-156794 | Enzomenib | 2412555-70-3 | Reference compound |
| HY-156795 | PROTAC CDK9/CycT1 Degrader-2 | 3020773-91-2 | Reference compound |
| HY-156796 | Akt/ROCK-IN-1 | 2983889-44-5 | Reference compound |
| HY-156798 | ADS032 | 2757333-37-0 | Reference compound |
| HY-156799 | Cholesterol 24-hydroxylase-IN-2 | 1613481-52-9 | Reference compound |
| HY-15680 | O-Propargyl-Puromycin | 1416561-90-4 | Reference compound |
| HY-156800 | PDDC | 2232878-43-0 | Reference compound |
| HY-15681 | Senexin A | 1366002-50-7 | Reference compound |
| HY-156810 | Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz | 2914227-56-6 | ADC Related |
| HY-156813 | Fmoc-Val-Ala-aminomethyl acetate | 2505045-86-1 | ADC Related |
| HY-156814 | HPP-9 | | Reference compound |
| HY-156815 | YL-365 | | Reference compound |
| HY-156816 | ON 108600 | 1585246-23-6 | Reference compound |
| HY-156817 | TNIK-IN-6 | 2375196-40-8 | Reference compound |
| HY-156818 | TNIK-IN-7 | 1417795-24-4 | Reference compound |
| HY-156819 | Zoldonrasib | 2922732-54-3 | Reference compound |
| HY-15681A | Senexin A (hydrochloride) | 1780390-76-2 | Reference compound |
| HY-15682 | TTNPB | 71441-28-6 | Reference compound |
| HY-156820 | HLDA-221 | | Reference compound |
| HY-156825 | Fmoc-Ser-Ribose(diBoc)-5-phosphatediAllyl | 2760364-52-9 | Reference compound |
| HY-156826 | DiBoc-Vidarabine-Ribose(diBoc)-2-cyanoethyl-diisopropylphosphoramidite | 2760364-53-0 | Reference compound |
| HY-156827 | MMH1 | | Reference compound |
| HY-156828 | MMH2 | | Reference compound |
| HY-156829 | PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) | | Reference compound |
| HY-156829A | PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) | | Reference compound |
| HY-15682G | TTNPB (GMP) | 71441-28-6 | GMP Small Molecules |
| HY-15682R | TTNPB (Standard) | 71441-28-6 | Reference Standards |
| HY-15683 | IDO5L | 914471-09-3 | Reference compound |
| HY-156830 | TGR5 Receptor Agonist 4 | 1872436-42-4 | Reference compound |
| HY-156830A | (4′R)-TGR5 Receptor Agonist 4 | 1872436-55-9 | Reference compound |
| HY-156831 | Lixosicone | 1610878-71-1 | Reference compound |
| HY-156832F | 5'6-FAM-GGUGAAAGACGAUGGACAATT,UUGUCCAUCGUCUUUCACCTT | | Dye Reagents |
| HY-156833F | 5'6-FAM-UUCUCCGAACGUGUCACGUTT, ACGUGACACGUUCGGAGAATT | | Dye Reagents |
| HY-156838 | Cyclophellitol aziridine | 136861-97-7 | Reference compound |
| HY-156842 | MCAAD-3 | 1625629-51-7 | Reference compound |
| HY-156843 | Antiproliferative agent-38 | 239-13-4 | Reference compound |
| HY-156846 | O-Benzoylhydroxylamine | 54495-98-6 | Reference compound |
| HY-156848 | Fmoc-GGFG-DXd | 1599440-11-5 | ADC Related |
| HY-156849 | Exatecan-methylacetamide-OH | 2594423-51-3 | ADC Related |
| HY-15685 | Ripasudil | 887375-67-9 | Reference compound |
| HY-156850 | ITF 3756 | 2247608-27-9 | Reference compound |
| HY-156856 | FL118-14-Propanol | 2821768-98-1 | ADC Related |
| HY-156857 | PPZ-A10 | 2941268-67-1 | Oligonucleotides |
| HY-156859 | NSC309401 (dihydrochloride) | 77681-42-6 | Reference compound |
| HY-156859A | NSC309401 | 750522-61-3 | Reference compound |
| HY-15685A | Ripasudil (free base) | 223645-67-8 | Reference compound |
| HY-156860 | WP 1122 | 1204310-73-5 | Reference compound |
| HY-156862 | (+)-Chloroquine | 58175-86-3 | Reference compound |
| HY-156863 | GRK2 Inhibitor 2 | 2592436-21-8 | Reference compound |
| HY-156865 | siFLUC (sodium) | | Oligonucleotides |
| HY-156868 | 22-Hydroxyvitamin D3 | 110927-46-3 | Reference compound |
| HY-15687 | SAR407899 (hydrochloride) | 923262-96-8 | Reference compound |
| HY-156871 | CAMK1D-IN-1 | 404828-08-6 | Reference compound |
| HY-156872 | MTX-216 | 1952236-19-9 | Reference compound |
| HY-156875 | 20-HETE inhibitor-1 | 2472030-28-5 | Reference compound |
| HY-156876 | 20-HETE inhibitor-2 | 2992666-48-3 | Reference compound |
| HY-156878 | Antiproliferative agent-39 | 871837-61-5 | Reference compound |
| HY-156879 | Antiproliferative agent-40 | 871837-59-1 | Reference compound |
| HY-15687A | SAR407899 | 923359-38-0 | Reference compound |
| HY-15688 | 8-OH-DPAT (hydrobromide) | 76135-31-4 | Reference compound |
| HY-156881 | PARG-IN-4 | 2988890-20-4 | Reference compound |
| HY-156882 | Biotin-PEG3-amide-C2-CO-Halofuginone | 2758563-75-4 | Reference compound |
| HY-156883 | Dasatinib analog-1 | 1174416-41-1 | Reference compound |
| HY-156889 | Cav 3.1 blocker 1 | 2158201-04-6 | Reference compound |
| HY-15689 | Epacadostat | 1204669-58-8 | Reference compound |
| HY-156895 | Ile-AMS | 213554-08-6 | Reference compound |
| HY-156895A | Ile-AMS (TFA) | | Reference compound |
| HY-156896 | Val-Cit-amide-Cbz-N(Me)-Maytansine | 1628543-59-8 | ADC Related |
| HY-156897 | Val-Cit-amide-Ph-Maytansine | | ADC Related |
| HY-15689R | Epacadostat (Standard) | 1204669-58-8 | Reference Standards |
| HY-156901 | MNG-14a | 1257853-50-1 | Reference compound |
| HY-156902 | Steroid sulfatase-IN-8 | 345222-92-6 | Reference compound |
| HY-156905 | 6-Azido-N-acetylgalactosamine-UDP | 1202854-87-2 | Reference compound |
| HY-156906 | UNC3474 | 1648707-79-2 | Reference compound |
| HY-156907 | ZINC49534341 | 1274013-03-4 | Reference compound |
| HY-156908 | 3-OH-Kynurenamine | 99362-47-7 | Reference compound |
| HY-156912 | Tyrosine kinase-IN-7 | 345615-74-9 | Reference compound |
| HY-156913 | Casein kinase 1δ-IN-13 | 345616-08-2 | Reference compound |
| HY-156914 | IGF-1R/SRC-IN-1 | 852367-46-5 | Reference compound |
| HY-156915 | Pim-1 kinase inhibitor 13 | 79492-49-2 | Reference compound |
| HY-156919 | p53 Activator 8 | 1426937-93-0 | Reference compound |
| HY-15691A | PF-4455242 (hydrochloride) | 1322001-35-3 | Reference compound |
| HY-15692 | PHD2-IN-3 | 1000025-14-8 | Reference compound |
| HY-156920 | VDX-111 | 158983-23-4 | Reference compound |
| HY-156922 | NPY-5 receptor antagonist-1 | 432506-24-6 | Reference compound |
| HY-156923 | Glucokinase activator 5 | 536736-95-5 | Reference compound |
| HY-156925 | PKA/AKAP-IN-1 | 299934-88-6 | Reference compound |
| HY-156936 | RCB-02-4-8 | 2941228-91-5 | Biochemical Assay Reagents |
| HY-156939 | ZnDTPA | 65229-17-6 | Reference compound |
| HY-15694 | SMIP004 | 143360-00-3 | Reference compound |
| HY-15695 | Puromycin aminonucleoside | 58-60-6 | Reference compound |
| HY-156955 | SUCNR1-IN-2 | 2988733-54-4 | Reference compound |
| HY-156958 | S-72 | 2446799-14-8 | Reference compound |
| HY-156959 | Ovalicin | 19683-98-8 | Reference compound |
| HY-15695R | Puromycin aminonucleoside (Standard) | 58-60-6 | Reference Standards |
| HY-156960 | JNJ-40929837 | 1191044-42-4 | Reference compound |
| HY-156960A | JNJ-40929837 (succinate) | 1191044-47-9 | Reference compound |
| HY-156961 | GLPG3667 | 2308520-97-8 | Reference compound |
| HY-156962 | BFF-816 | 2008006-36-6 | Reference compound |
| HY-156963 | Aderamastat | 877176-23-3 | Reference compound |
| HY-156964 | Benzmalecene | 148-07-2 | Reference compound |
| HY-156965 | BAY-771 | 2771756-82-0 | Reference compound |
| HY-156966 | ATG12-ATG3 inhibitor 1 | 333351-38-5 | Reference compound |
| HY-156967 | BAY 1892005 | 2036352-13-1 | Reference compound |
| HY-156968 | GLP-1 receptor agonist 14 | 3011682-51-9 | Reference compound |
| HY-156969 | Topoisomerase I inhibitor 11 | 2922723-28-0 | Reference compound |
| HY-15697 | TUG-770 | 1402601-82-4 | Reference compound |
| HY-156970 | Phosphatase Binder-1 | 2456385-41-2 | Reference compound |
| HY-156972 | NOP agonist-1 | 2099681-43-1 | Reference compound |
| HY-156973 | Tiopropamine | 39516-21-7 | Reference compound |
| HY-156975 | Sulfatrozole | 13369-07-8 | Reference compound |
| HY-156976 | Sulcardine | 343935-60-4 | Reference compound |
| HY-156976A | Sulcardine (hydrochloride) | 343935-48-8 | Reference compound |
| HY-156977 | Sitofibrate | 55902-94-8 | Reference compound |
| HY-156978 | Ritolukast | 111974-60-8 | Reference compound |
| HY-156979 | RBT-9 | 123307-75-5 | Reference compound |
| HY-15698 | CRT0066101 | 956123-34-5 | Reference compound |
| HY-156980 | Podilfen | 13409-53-5 | Reference compound |
| HY-156981 | Pirdonium (bromide) | 35620-67-8 | Reference compound |
| HY-156982 | Parpi | 1919043-65-4 | Reference compound |
| HY-156983 | MRS 5980 | 1639420-13-5 | Reference compound |
| HY-156984 | Monometacrine | 4757-49-7 | Reference compound |
| HY-156985 | Lipid AX4 | 2735814-23-8 | Biochemical Assay Reagents |
| HY-156986 | ITH15004 | 2600675-12-3 | Reference compound |
| HY-156987 | Iotasul | 71767-13-0 | Reference compound |
| HY-156988 | DPI-287 | 519058-13-0 | Reference compound |
| HY-156989 | Butobendine | 55769-65-8 | Reference compound |
| HY-15698A | CRT0066101 (dihydrochloride) | 1883545-60-5 | Reference compound |
| HY-15698B | CRT0066101 (trihydrochloride) | 1781742-22-0 | Reference compound |
| HY-15699 | SAR7334 | 1333210-07-3 | Reference compound |
| HY-156991 | NODAGA-NHS | 1407166-70-4 | Reference compound |
| HY-156992 | AT-035 | 2099680-55-2 | Reference compound |
| HY-156993 | NOP agonist-2 | 2099680-36-9 | Reference compound |
| HY-156994 | ASGPR ligand-1 | 1426160-58-8 | Reference compound |
| HY-156996 | AGI-134 | 1821461-84-0 | Reference compound |
| HY-156997 | ABX196 | 1161877-58-2 | Reference compound |
| HY-156998 | Troxacitabine triphosphate | 171039-00-2 | Reference compound |
| HY-15699A | SAR7334 (hydrochloride) | 1333207-63-8 | Reference compound |
| HY-15700 | PluriSIn 1 | 91396-88-2 | Reference compound |
| HY-157001 | 7-Deaza-dGTP (tetralithium) | | Oligonucleotides |
| HY-157002 | Prostaglandin E2 isopropyl ester | 71845-66-4 | Reference compound |
| HY-157003 | (S)-TCO-PEG2-NH2 | | ADC Related |
| HY-157006 | (S)-TCO-PEG3-NH2 | | ADC Related |
| HY-157007 | (S)-TCO-PEG7-NH2 | | ADC Related |
| HY-157008 | (S)-TCO-PEG2-Maleimide | | ADC Related |
| HY-15701 | Leukadherin-1 | 344897-95-6 | Reference compound |
| HY-157011 | JAK-IN-33 | 3032404-49-9 | Reference compound |
| HY-157012 | SCO-NHS carbonate | 2925279-71-4 | Reference compound |
| HY-157013 | UR-MB-355 | | Reference compound |
| HY-157014 | TPT-004 | 3032648-15-7 | Reference compound |
| HY-157015 | Antifungal agent 81 | | Reference compound |
| HY-157016 | OfChi-h-IN-1 | 902928-83-0 | Reference compound |
| HY-157018 | Antifungal agent 82 | | Reference compound |
| HY-157019 | UniPR1447 | 1809170-68-0 | Reference compound |
| HY-15701A | (Z)-Leukadherin-1 | 2055362-72-4 | Reference compound |
| HY-15701B | ADH-503 | 2055362-74-6 | Reference compound |
| HY-15702 | HJC0350 | 885434-70-8 | Reference compound |
| HY-157020 | UniPR1449 | | Reference compound |
| HY-157021 | SARS-CoV-2-IN-66 | 1807620-38-7 | Reference compound |
| HY-157022 | SARS-CoV-2-IN-67 | 2997784-47-9 | Reference compound |
| HY-157023 | RCB16007 | 2952530-26-4 | Reference compound |
| HY-157024 | Phytoene desaturase-IN-2 | | Reference compound |
| HY-157025 | Herbicidal agent 1 | | Reference compound |
| HY-157026 | Nurr1 agonist 7 | 228707-95-7 | Reference compound |
| HY-157027 | Antifungal agent 85 | 3017207-42-7 | Reference compound |
| HY-157028 | Antiparasitic agent-19 | 3032412-28-2 | Reference compound |
| HY-157029S | KRASG12D-IN-1 | | Isotope-Labeled Compounds |
| HY-15703 | QNZ46 | 1237744-13-6 | Reference compound |
| HY-157030 | NIEA | 75896-33-2 | Reference compound |
| HY-157031S | KRASG12D-IN-2 | | Isotope-Labeled Compounds |
| HY-157032 | Proteasome-IN-5 | 1613134-34-1 | Reference compound |
| HY-157033 | LMP7-IN-2 | 1613317-24-0 | Reference compound |
| HY-157034 | LU-002i | 1838705-22-8 | Reference compound |
| HY-157034A | LU-002i (TFA) | | Reference compound |
| HY-157035 | Proteasome β2c/i-IN-1 | 2322333-75-3 | Reference compound |
| HY-157036 | INSA | 2962939-33-7 | Dye Reagents |
| HY-157037 | OfChi-h-IN-2 | 902932-91-6 | Reference compound |
| HY-157038 | MAGL-IN-8 | 3017151-71-9 | Reference compound |
| HY-157039 | RIPK1-IN-17 | | Reference compound |
| HY-15704 | LH846 | 639052-78-1 | Reference compound |
| HY-157040 | MAGL-IN-9 | | Reference compound |
| HY-157041 | MAGL-IN-10 | 3017151-83-3 | Reference compound |
| HY-157042 | MAGL-IN-11 | 3017151-84-4 | Reference compound |
| HY-157043 | "Antibacterial agent 161 (trifluoromethanesulfonate
)" | | Reference compound |
| HY-157044 | "Antibacterial agent 162 (trifluoromethanesulfonate
)" | | Reference compound |
| HY-157045 | ATP Synthesis-IN-1 | | Reference compound |
| HY-157046 | ATP Synthesis-IN-2 | | Reference compound |
| HY-157047 | Anticancer agent 171 | | Reference compound |
| HY-157048 | Anticancer agent 172 | | Reference compound |
| HY-157049 | Caprylocaproyl Macrogolglycerides | | Reference compound |
| HY-15705 | GPR35 agonist 2 | 494191-73-0 | Reference compound |
| HY-157050S | 3-Hydroxygepirone-d8 | | Isotope-Labeled Compounds |
| HY-157051 | [Ru(DIP)2TAP]Cl2 | | Reference compound |
| HY-157052 | exo-BCN-Fmoc-L-Lysine | 1493802-76-8 | Reference compound |
| HY-157053 | [Ru(dppn)2phen](PF6)2 | | Reference compound |
| HY-157054 | endo-BCN-L-Lysine | 1493802-96-2 | Reference compound |
| HY-157054A | (Rac)-BCN-L-Lysine | 1580501-90-1 | Reference compound |
| HY-157055 | PD-1-IN-25 | 2413100-40-8 | Reference compound |
| HY-157056S | 5α-Estran-3β-ol-17-one-d3 | | Isotope-Labeled Compounds |
| HY-157057S | N-Desmethyldiltiazem-d5 (maleate) | | Isotope-Labeled Compounds |
| HY-157058S | 5-Hydroxynepafenac-d5 | 2012598-56-8 | Isotope-Labeled Compounds |
| HY-157059S | 6-O-Desmethylprazosin-d8 (TFA) | | Isotope-Labeled Compounds |
| HY-15706 | H2L 5765834 | 420841-84-5 | Reference compound |
| HY-157060S | 7-Hydroxycannabidivarin-d7 | 2249814-78-4 | Isotope-Labeled Compounds |
| HY-157061S | 7-Nor-7-carboxycannabidiol-d10 | | Isotope-Labeled Compounds |
| HY-157062S | 7-O-Desmethylprazosin-d8 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-157067 | KRAS G12C inhibitor 62 | 2658588-10-2 | Reference compound |
| HY-157068 | icFSP1 | 1115910-36-5 | Reference compound |
| HY-157069S | Prochlorperazine sulfoxide-d8 | 1215350-60-9 | Isotope-Labeled Compounds |
| HY-15707 | NS6180 | 353262-04-1 | Reference compound |
| HY-157070 | SCO-L-Lysine | 1309581-49-4 | Reference compound |
| HY-157071S | Seliciclib Carboxylic Acid-d7 | 849108-26-5 | Isotope-Labeled Compounds |
| HY-157072 | WAY-311474 | 569313-77-5 | Reference compound |
| HY-157073 | WAY-607695 | 380469-52-3 | Reference compound |
| HY-157074S | Tandospirone Acid Metabolite-d6 | 2012598-82-0 | Isotope-Labeled Compounds |
| HY-157075S | (Z)-Rilpivirine-d4 | | Isotope-Labeled Compounds |
| HY-157076S | exo-Hydroxytandospirone-d8 | | Isotope-Labeled Compounds |
| HY-157077S | 5-Hydroxysaxagliptin-13C,d2 (TFA) | 2012595-11-6 | Isotope-Labeled Compounds |
| HY-157078 | Eg5-IN-2 | 1629735-05-2 | ADC Related |
| HY-157079 | LP-6 | 1629736-79-3 | ADC Related |
| HY-15708 | LY2795050 | 1346133-08-1 | Reference compound |
| HY-157080 | Dibromomaleimide-C5-COOH | 1443214-97-8 | ADC Related |
| HY-157082 | ZHSI-1 | 2925912-67-8 | Reference compound |
| HY-157083 | mCMY020 | | Reference compound |
| HY-157084 | HS-291 | | Reference compound |
| HY-157085 | BX-2819 | 1184181-50-7 | Reference compound |
| HY-157086 | IR5790 | 192809-26-0 | Reference compound |
| HY-157087 | AChE/MAO-B-IN-4 | | Reference compound |
| HY-157088 | C105SR | | Reference compound |
| HY-157089 | AChE/MAO-B-IN-5 | | Reference compound |
| HY-15709 | AL 082D06 | 256925-03-8 | Reference compound |
| HY-157090 | AChE/MAO-B-IN-6 | | Reference compound |
| HY-157091 | Uridine, 5'-(P,P',P'',P''-tetrahydrogen imidotriphosphate) | 497064-75-2 | Oligonucleotides |
| HY-157092 | ICMT-IN-3 | 1313602-73-1 | Reference compound |
| HY-157092A | (S)-ICMT-IN-3 | | Reference compound |
| HY-157092B | (R)-ICMT-IN-3 | | Reference compound |
| HY-157093 | Cytidine, 5′-(P,P′,P′′,P′′-tetrahydrogen imidotriphosphate) | 497064-76-3 | Reference compound |
| HY-157094 | ICMT-IN-4 | 1313602-74-2 | Reference compound |
| HY-157095 | ICMT-IN-6 | 1313602-75-3 | Reference compound |
| HY-157096 | ICMT-IN-8 | 1313602-76-4 | Reference compound |
| HY-157097 | ICMT-IN-10 | 1313602-78-6 | Reference compound |
| HY-157098 | ICMT-IN-16 | 1313602-79-7 | Reference compound |
| HY-157099 | ICMT-IN-18 | 1313602-81-1 | Reference compound |
| HY-15710 | Cort108297 | 1018679-79-2 | Reference compound |
| HY-157100 | ICMT-IN-23 | 1313602-82-2 | Reference compound |
| HY-157101 | ICMT-IN-25 | 1313602-83-3 | Reference compound |
| HY-157102 | ICMT-IN-26 | 1313602-84-4 | Reference compound |
| HY-157103 | ICMT-IN-34 | 1313602-85-5 | Reference compound |
| HY-157104 | ICMT-IN-36 | 1313602-86-6 | Reference compound |
| HY-157105 | ICMT-IN-37 | 1313602-87-7 | Reference compound |
| HY-157106 | ICMT-IN-38 | 1313602-88-8 | Reference compound |
| HY-157107 | ICMT-IN-39 | 1313602-64-0 | Reference compound |
| HY-157108 | ICMT-IN-40 | 1313602-65-1 | Reference compound |
| HY-157109 | ICMT-IN-41 | 1313602-66-2 | Reference compound |
| HY-157110 | ICMT-IN-42 | 1313602-67-3 | Reference compound |
| HY-157111 | ICMT-IN-43 | 1313602-68-4 | Reference compound |
| HY-157112 | ICMT-IN-44 | 1313602-69-5 | Reference compound |
| HY-157113 | ICMT-IN-45 | 1313602-70-8 | Reference compound |
| HY-157114 | ICMT-IN-46 | 1313602-71-9 | Reference compound |
| HY-157115 | ICMT-IN-47 | 1313602-72-0 | Reference compound |
| HY-157116 | ICMT-IN-48 | 337486-54-1 | Reference compound |
| HY-157117 | ICMT-IN-49 | 303728-92-9 | Reference compound |
| HY-157118 | ICMT-IN-50 | 371940-21-5 | Reference compound |
| HY-157119 | ICMT-IN-51 | 1313602-89-9 | Reference compound |
| HY-157120 | ICMT-IN-52 | 1313602-90-2 | Reference compound |
| HY-157121 | JAK-IN-34 | 2068766-90-3 | Reference compound |
| HY-157122 | VJDT | 2765319-65-9 | Reference compound |
| HY-157123 | Tyrosinase-IN-18 | | Reference compound |
| HY-157124 | Tyrosinase-IN-19 | | Reference compound |
| HY-157125 | PI3Kα-IN-14 | 3026856-46-9 | Reference compound |
| HY-157126 | Pterostilbene-isothiocyanate | 1616974-29-8 | Reference compound |
| HY-157127 | Ketoprofen L-thyroxine ester | 3032398-41-4 | Reference compound |
| HY-157128 | PI3Kδ-IN-18 | 3019965-38-6 | Reference compound |
| HY-157129 | AMPK-α1β1γ1 activator 1 | 1943510-86-8 | Reference compound |
| HY-15713 | NMS-873 | 1418013-75-8 | Reference compound |
| HY-157130 | T3SS-IN-3 | | Reference compound |
| HY-157131 | TRPV2-selective blocker 1 | 2242724-49-6 | Reference compound |
| HY-157132 | FAAH-IN-8 | 2867633-84-7 | Reference compound |
| HY-157133 | TAS0612 | 2148902-58-1 | Reference compound |
| HY-157134 | Y08262 | 2450965-18-9 | Reference compound |
| HY-157135 | hCAIX-IN-19 | | Reference compound |
| HY-157136 | LFS-1107 | 1799330-91-8 | Reference compound |
| HY-157137 | PARP1-IN-17 | | Reference compound |
| HY-157138 | MMP-9-IN-8 | 2490543-89-8 | Reference compound |
| HY-157139 | ALP/Carbonic anhydrase-IN-1 | 2091887-74-8 | Reference compound |
| HY-15714 | NMS-859 | 1449236-96-7 | Reference compound |
| HY-157140 | HibK | 1644442-22-7 | Reference compound |
| HY-157141 | Antibacterial agent 163 | 16588-39-9 | Reference compound |
| HY-157142 | Antibacterial agent 165 | | Reference compound |
| HY-157143 | Antibacterial agent 164 | | Reference compound |
| HY-157144 | SARS-CoV-2-IN-68 | 2682897-84-1 | Reference compound |
| HY-157145 | SARS-CoV-2-IN-69 | 78471-90-6 | Reference compound |
| HY-157146 | NLRP3-IN-23 | | Reference compound |
| HY-157147 | NLRP3-IN-24 | | Reference compound |
| HY-157148 | 1D228 | 2925447-16-9 | Isotope-Labeled Compounds |
| HY-157149 | DS21150768 | | Reference compound |
| HY-157150 | mAC2-IN-1 | | Reference compound |
| HY-157151 | iPRMT1 | | Reference compound |
| HY-157152 | HDAC-IN-65 | | Reference compound |
| HY-157153 | hDHODH-IN-14 | 881826-17-1 | Reference compound |
| HY-157154 | MAT-POS-e194df51-1 | 2765433-05-2 | Reference compound |
| HY-157157 | PAD4-IN-3 | 2642327-44-2 | Reference compound |
| HY-157158 | TrxR-IN-6 | 3032446-53-7 | Reference compound |
| HY-157159 | BTK-IN-28 | | Reference compound |
| HY-15716 | Kobe0065 | 436133-68-5 | Reference compound |
| HY-157160 | PPO-IN-5 | | Reference compound |
| HY-157161 | 11β-HSD2-IN-1 | | Reference compound |
| HY-157162 | Insecticidal agent 5 | 3021587-00-5 | Reference compound |
| HY-157164 | PROTAC EZH2 Degrader-2 | | Reference compound |
| HY-157165 | Tubulin/PARP-IN-1 | | Reference compound |
| HY-157166 | EGFR kinase inhibitor 2 | | Reference compound |
| HY-157168 | TrkA-IN-6 | | Reference compound |
| HY-157169 | IBL-302 | 1414455-21-2 | Reference compound |
| HY-15717 | Kobe2602 | 454453-49-7 | Reference compound |
| HY-157170 | CYP450-IN-1 | | Reference compound |
| HY-157171 | Ac-YR-NH2 | | Reference compound |
| HY-157172 | MorHap | | Reference compound |
| HY-157173 | Mannosamine-biotin adduct | | Reference compound |
| HY-157174 | Mannosamine–desthiobiotin adduct | | Reference compound |
| HY-157175 | Mannosamine–lipoic acid adduct | | Reference compound |
| HY-157176 | BAX-IN-1 | 331261-91-7 | Reference compound |
| HY-157177 | WAY-322454 | 1008244-02-7 | Reference compound |
| HY-157178 | WAY-359473 | 314248-20-9 | Reference compound |
| HY-157179 | WAY-312491 | 609792-38-3 | Reference compound |
| HY-15718 | Istaroxime | 203737-93-3 | Reference compound |
| HY-157180 | WAY-327131 | 725695-33-0 | Reference compound |
| HY-157181 | Hal-HS | 151749-58-5 | Reference compound |
| HY-157182 | DNP-PEG2-NHCO-C2-DBCO | | Reference compound |
| HY-157183 | HSMO9 | 1313762-77-4 | Reference compound |
| HY-157184 | 1-Deoxydihydroceramide | 2415078-34-9 | Reference compound |
| HY-157185 | Etioporphyrin IV acid | | Reference compound |
| HY-157186 | (22R)-33,34,35-Trinorbacteriohopan-32-oic acid | 74431-96-2 | Reference compound |
| HY-157187 | Fenhexamid-1-pentanoic acid | 2248672-35-5 | Reference compound |
| HY-157188 | Fenhexamid-4-pentanoic acid | 2250414-53-8 | Reference compound |
| HY-157189 | GPR132 antagonist 1 | 898211-21-7 | Reference compound |
| HY-157189A | GPR132 antagonist 1 (dihydrocholide) | | Reference compound |
| HY-15718A | Istaroxime (hydrochloride) | 374559-48-5 | Reference compound |
| HY-15718B | Istaroxime (oxalate) | 203737-94-4 | Reference compound |
| HY-15719 | NU 7026 | 154447-35-5 | Reference compound |
| HY-157190 | Fenhexamid-butyric acid | 1160646-98-9 | Reference compound |
| HY-157191 | Fenhexamid-5-hexenoic acid | 2250414-52-7 | Reference compound |
| HY-157192 | Clothianidin-2-S-propanoic acid | 912270-45-2 | Reference compound |
| HY-157193 | Diacylglyceride | 73566-74-2 | Reference compound |
| HY-157194 | RL-6-Me-7-OH | 2184-54-5 | Reference compound |
| HY-157198 | Dinotefuran-NHCO-propionic acid | | Reference compound |
| HY-15720 | H-1152 | 451462-58-1 | Reference compound |
| HY-157200 | 2,4-DA-6-FP | 4261-17-0 | Reference compound |
| HY-157201 | ZEo | | Reference compound |
| HY-157202 | Zeoh | | Reference compound |
| HY-157203 | Cholic acid-cysteine-cyanuric chloride complex | | Reference compound |
| HY-157204 | ZEp | | Reference compound |
| HY-157205 | Zeph | | Reference compound |
| HY-157206 | ICMT-IN-55 | 1313602-77-5 | Reference compound |
| HY-157207S | N-Desmethyl-Atomoxetine labeled-d5 (hydrochloride) | 2712570-39-1 | Isotope-Labeled Compounds |
| HY-15720A | H-1152 (dihydrochloride) | 871543-07-6 | Reference compound |
| HY-15720B | Glycyl H-1152 (hydrochloride) | 913844-45-8 | Reference compound |
| HY-15721 | FH535 | 108409-83-2 | Reference compound |
| HY-157210 | CDK7-IN-26 | 3024545-79-4 | Reference compound |
| HY-157211 | Anti-inflammatory agent 66 | | Reference compound |
| HY-157212 | PARP-1/Proteasome-IN-1 | | Reference compound |
| HY-157213 | LWY713 | | Reference compound |
| HY-157214 | NVS-STG2 | 3030588-01-0 | Reference compound |
| HY-157215 | HDAC-IN-66 | | Reference compound |
| HY-157216 | HDAC1 Degrader-1 | | Reference compound |
| HY-157217 | Antitumor agent-99 | | Reference compound |
| HY-157218 | PPm | 2101951-47-5 | Reference compound |
| HY-157219 | HDAC6-IN-26 | 2991427-19-9 | Reference compound |
| HY-15722 | SB-222200 | 174635-69-9 | Reference compound |
| HY-157220 | Tolvaptan phosphate ester (sodium) | 942619-79-6 | Reference compound |
| HY-157221 | Biotin-16-dGTP (tetralithium) | | Oligonucleotides |
| HY-157222 | Antitumor agent-125 | | Reference compound |
| HY-157223 | ARN16186 | 2320555-85-7 | Reference compound |
| HY-157224 | Zearalanone carboxymethoxyl oxime | 102570-33-2 | Reference compound |
| HY-157225 | Brazilin-7-acetate | | Reference compound |
| HY-157226 | ORI-TRN-002 | | Reference compound |
| HY-157227 | VPC01091.4 | 945604-76-2 | Reference compound |
| HY-157228 | ACBI3 | 2938169-76-5 | Reference compound |
| HY-157229 | STX-721 | 2765525-82-2 | Reference compound |
| HY-15723 | NSC 23766 | 733767-34-5 | Reference compound |
| HY-157230 | XIAP antagonist 1 | 375835-04-4 | Reference compound |
| HY-157231A | HC-5404-Fu | 3034479-99-4 | Reference compound |
| HY-157232 | AC Antibody purification resin 2 | | ADC Related |
| HY-157233 | AC Antibody purification resin 1 | | ADC Related |
| HY-157234 | AC mAb-X purification resin | | ADC Related |
| HY-157235 | AC Antibody affinity resin | | ADC Related |
| HY-157236 | AEX Anion-exchange resin 1 | | ADC Related |
| HY-157237 | AEX Ion-exchange resin | | ADC Related |
| HY-157238 | AEX Anion-exchange resin 2 | | ADC Related |
| HY-157239 | AEX HQ Anion-exchange resin | | ADC Related |
| HY-15723A | NSC 23766 (trihydrochloride) | 1177865-17-6 | Reference compound |
| HY-15724 | Vercirnon | 698394-73-9 | Reference compound |
| HY-157240 | CEX Ion-exchange resin | | ADC Related |
| HY-157241 | CEX Cation-exchange resin 1 | | ADC Related |
| HY-157242 | CEX Polishing resin | | ADC Related |
| HY-157243 | CEX Cation-exchange resin 2 | | ADC Related |
| HY-157244 | Proteins separation resin | | ADC Related |
| HY-157245 | Hydrophobic polishing resin | | ADC Related |
| HY-157246 | Hydrophobic resin | | ADC Related |
| HY-157247S | Dodecyl N,N-dimethylaminoacetate-d6 | 2705076-41-9 | Isotope-Labeled Compounds |
| HY-157248 | Fmoc-3-Me-Glu(OtBu)-OH | 1429504-34-6 | Peptides |
| HY-157249 | Antiviral agent 43 | 2739990-96-4 | Reference compound |
| HY-15724A | Vercirnon (sodium) | 886214-18-2 | Reference compound |
| HY-15725 | CDDO-Im | 443104-02-7 | Reference compound |
| HY-157250 | BHD | 2749517-98-2 | Reference compound |
| HY-157251 | UNC8153 (TFA) | 2929304-61-8 | Reference compound |
| HY-157251A | UNC8153 | 2929304-60-7 | Reference compound |
| HY-157252 | CL4F8-6 | 2766493-12-1 | Biochemical Assay Reagents |
| HY-157253 | 13(S)-HODE-biotin | 1217458-58-6 | Reference compound |
| HY-157254 | AA10 | 2134106-02-6 | Reference compound |
| HY-157255S | α-Dimethylaminopentiophenone-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-157257 | Trimethoprim fumaric acid | 1546799-45-4 | Reference compound |
| HY-157258 | Trimethoprim pentanoic acid | 78025-89-5 | Reference compound |
| HY-157259 | Trimethoprim propanoic acid | 94236-24-5 | Reference compound |
| HY-15726 | ICI 89406 | 53671-71-9 | Reference compound |
| HY-157260 | Propylbenzene-(CH2)2-COOH | 1057602-98-8 | Reference compound |
| HY-157261 | UNC2383 | 2123481-48-9 | Reference compound |
| HY-157262 | Methyl isonicotinate-(CH2)2-COOH | 2710224-09-0 | Reference compound |
| HY-157269 | J10-1 | 1069110-72-0 | Reference compound |
| HY-15727 | Afuresertib | 1047644-62-1 | Reference compound |
| HY-157270 | 2-Heptylundecanol | 5333-44-8 | Reference compound |
| HY-157275 | Gly-Gly-Gly-PEG2-azide | 2222277-20-3 | ADC Related |
| HY-157277 | AdBeSA | 201480-32-2 | Reference compound |
| HY-15727A | Afuresertib (hydrochloride) | 1047645-82-8 | Reference compound |
| HY-15728 | Radotinib | 926037-48-1 | Reference compound |
| HY-157280 | AdCaPy | 307320-40-7 | ADC Related |
| HY-157281 | Photolumazine III | 23140-55-8 | Reference compound |
| HY-157282 | Photolumazine I | 29161-67-9 | Reference compound |
| HY-157284 | Cys-mc-MMAE | | ADC Related |
| HY-157287 | (S)-Phe-A110/B319 | | Reference compound |
| HY-157288 | (R)-Phe-A110/B319 | | Reference compound |
| HY-15728S | Radotinib-d6 | 2754051-83-5 | Isotope-Labeled Compounds |
| HY-15729 | Rociletinib | 1374640-70-6 | Reference compound |
| HY-157290 | HL403 | | Reference compound |
| HY-157291 | Antiviral agent 44 | 872201-68-8 | Reference compound |
| HY-157292 | 2E-3-F16 | 3002962-69-5 | Reference compound |
| HY-157294 | GSK866 | 1991970-93-4 | Reference compound |
| HY-157294A | (R)-GSK866 | 1094607-80-3 | Reference compound |
| HY-157295 | PI3K/HDAC-IN-3 | 3006905-22-9 | Reference compound |
| HY-157296 | AChE-IN-47 | 3033056-55-9 | Reference compound |
| HY-157297 | CDK-IN-13 | | Reference compound |
| HY-157298 | anti-TNBC agent-4 | 3027501-51-2 | Reference compound |
| HY-157299 | PDK-IN-3 | | Reference compound |
| HY-15729A | Rociletinib hydrobromide | 1446700-26-0 | Reference compound |
| HY-15730 | Poziotinib | 1092364-38-9 | Reference compound |
| HY-157300 | Antifungal agent 88 | | Reference compound |
| HY-157302 | c-Met-IN-21 | 3025958-01-1 | Reference compound |
| HY-157303 | SSTR5 antagonist 3 | 2851454-42-5 | Reference compound |
| HY-157305 | Jun11165 | | Reference compound |
| HY-157306 | HC-1310 | 2101230-88-8 | Reference compound |
| HY-157308 | α-Synuclein inhibitor 10 | 3050715-65-3 | Reference compound |
| HY-157309 | RIPK2-IN-4 | | Reference compound |
| HY-15731 | Estetrol | 15183-37-6 | Natural Products |
| HY-157311 | α-Glucosidase-IN-45 | 3026192-46-8 | Reference compound |
| HY-157312 | TM38837 | 1034264-77-1 | Reference compound |
| HY-157313 | Pancreatic lipase-IN-1 | | Reference compound |
| HY-157314 | HDAC6-IN-27 | 2758023-91-3 | Reference compound |
| HY-157315 | Fabl inhibitor 21272541 | 898527-42-9 | Reference compound |
| HY-157316 | TZ-NBD | | Dye Reagents |
| HY-157317 | Antitumor agent-126 | 3014356-10-3 | Reference compound |
| HY-157318 | PB17-026-01 | | Reference compound |
| HY-157319 | PI3Kα-IN-15 | 2893920-80-2 | Reference compound |
| HY-15731S | Estetrol-d4 | | Isotope-Labeled Compounds |
| HY-15732 | BGB-102 | 807640-87-5 | Reference compound |
| HY-157320 | Tubulin/PARP-IN-2 | | Reference compound |
| HY-157321 | hCAI/II-IN-7 | 14204-32-1 | Reference compound |
| HY-157322 | SAV13 | 423748-49-6 | Reference compound |
| HY-157323 | HDAC6-IN-28 | | Reference compound |
| HY-157324 | EGFR-IN-94 | | Reference compound |
| HY-157325 | RIPK2-IN-5 | 2885227-09-6 | Reference compound |
| HY-157326 | hMAO-B-IN-6 | 2764830-43-3 | Reference compound |
| HY-157327 | AKE-72 | 2566525-18-4 | Reference compound |
| HY-157328 | 7PCGY | 1415888-05-9 | Reference compound |
| HY-157329 | AD16 | 311315-04-5 | Reference compound |
| HY-15733 | Lucidin | 478-08-0 | Natural Products |
| HY-157330 | P-gp inhibitor 16 | | Reference compound |
| HY-157331 | DCZ5418 | 2883709-99-5 | Reference compound |
| HY-157332 | WDR5-IN-7 | 3032761-31-9 | Reference compound |
| HY-157333 | CYP51-IN-15 | 3034186-60-9 | Reference compound |
| HY-157334 | DEG-77 | 3032265-06-5 | Reference compound |
| HY-157335 | Mn(II)-DO3A (sodium) | 120066-53-7 | Reference compound |
| HY-157338 | NHS-Ala-Ala-Asn-active metabolite | 2231135-69-4 | ADC Related |
| HY-157339 | MMT-2'-O-Methyl adenosine (n-bz) CED phosphoramidite | 2645354-88-5 | Reference compound |
| HY-15733R | Lucidin (Standard) | 478-08-0 | Reference Standards |
| HY-15734 | AGI-6780 | 1432660-47-3 | Reference compound |
| HY-157340 | 2',3'-Dibenzoyl-1-methylpseudouridine | | Reference compound |
| HY-157343 | GD3 Ganglioside | 62010-37-1 | Natural Products |
| HY-157343A | GD3 Ganglioside (sodium) | | Natural Products |
| HY-157344 | Nutrient Broth | | Biochemical Assay Reagents |
| HY-157345 | Nutrient Agar | | Biochemical Assay Reagents |
| HY-157346 | LB Nutrient Agar | | Biochemical Assay Reagents |
| HY-157346A | LB Agar | | Biochemical Assay Reagents |
| HY-157347 | Yeast Nitrogen Base Medium | | Biochemical Assay Reagents |
| HY-157347A | Yeast Nitrogen Base Medium without Amino Acids | | Biochemical Assay Reagents |
| HY-157348 | Lauryl Sulfate Tryptose Broth | | Biochemical Assay Reagents |
| HY-157349 | Brilliant Green Lactose Bile Broth | | Biochemical Assay Reagents |
| HY-15735 | c-Met inhibitor 1 | 1357072-61-7 | Reference compound |
| HY-157350 | Violet Red Bile Agar | | Biochemical Assay Reagents |
| HY-157351 | E.Coli Broth | | Biochemical Assay Reagents |
| HY-157352 | Eosin-Methylene Blue Agar | | Biochemical Assay Reagents |
| HY-157353 | MacConkey Agar | | Biochemical Assay Reagents |
| HY-157354 | Urease Agar Base | | Biochemical Assay Reagents |
| HY-157355 | Brain Heart Infusion Broth | | Biochemical Assay Reagents |
| HY-157356 | Violet Red Bile Glucose Agar | | Biochemical Assay Reagents |
| HY-157357 | Fungi Agar Medium | | Biochemical Assay Reagents |
| HY-157358 | Corn Meal Medium | | Biochemical Assay Reagents |
| HY-157359 | Bacterial Organophosphorus Medium | | Biochemical Assay Reagents |
| HY-15736 | Sodium Channel inhibitor 1 | 1198117-23-5 | Reference compound |
| HY-157360 | Acetamide Agar | | Biochemical Assay Reagents |
| HY-157361 | Ethyl Violet Aziode Broth | | Biochemical Assay Reagents |
| HY-157362 | Tryptone Soya Broth | | Biochemical Assay Reagents |
| HY-157363 | Tryptone Soya Agar | | Biochemical Assay Reagents |
| HY-157364 | Levine Eosin-Methylene Blue Agar Medium | | Biochemical Assay Reagents |
| HY-157365 | Anaerobic Agar | | Biochemical Assay Reagents |
| HY-157366 | Sulfite Agar | | Biochemical Assay Reagents |
| HY-157367 | Bismuth Sulfite Agar Medium | | Biochemical Assay Reagents |
| HY-157368 | Bismuth Sulfite Agar | | Biochemical Assay Reagents |
| HY-157369 | Salmonella Arizona Agar | | Biochemical Assay Reagents |
| HY-15737 | DB07268 | 929007-72-7 | Reference compound |
| HY-157370 | Blood Enrichment Medium | | Biochemical Assay Reagents |
| HY-157371 | Blood Agar Base | | Biochemical Assay Reagents |
| HY-157372 | Peptone Bacteriological | | Biochemical Assay Reagents |
| HY-157373 | Bromcresol Purple Broth Base | | Biochemical Assay Reagents |
| HY-157374 | Beef Heart Infusion | | Biochemical Assay Reagents |
| HY-157375 | Brain Heart Infusion Agar | | Biochemical Assay Reagents |
| HY-157376 | Casein Agar | | Biochemical Assay Reagents |
| HY-157377 | Yeast Peptone Dextrose Agar | | Biochemical Assay Reagents |
| HY-157378 | YM11 Agar | | Biochemical Assay Reagents |
| HY-157379 | YM Agar | | Biochemical Assay Reagents |
| HY-15738 | GNF-5 | 778277-15-9 | Reference compound |
| HY-157380 | Salmonella-Shigella Agar | | Biochemical Assay Reagents |
| HY-157381 | China Blue Lactose Agar | | Biochemical Assay Reagents |
| HY-157382 | AChE-IN-51 | | Reference compound |
| HY-157384 | BChE-IN-22 | | Reference compound |
| HY-157385 | HDAC-IN-67 | 2821923-75-3 | Reference compound |
| HY-157386S | 8-(o-Fluoro-benzyl)theophylline methylsulfonyl-13C2 | | Isotope-Labeled Compounds |
| HY-157387 | c-Met-IN-22 | | Reference compound |
| HY-157388 | CARM1/HDAC2-IN-1 | | Reference compound |
| HY-157389 | AK-HW-90 | | Reference compound |
| HY-15739 | Ansamitocin P-3 | 66584-72-3 | Natural Products |
| HY-157390 | DPP-4-IN-9 | 2906243-39-6 | Reference compound |
| HY-157391 | ALK/ROS1-IN-3 | | Reference compound |
| HY-157392 | hMAO-A-IN-1 | 1039315-88-2 | Reference compound |
| HY-157393 | BET bromodomain inhibitor 4 | 2407658-41-5 | Reference compound |
| HY-157394 | eeAChE/eqBuChE-IN-1 | 2921654-26-2 | Reference compound |
| HY-157395 | malonyl-NAC | 2361327-06-0 | Reference compound |
| HY-157396 | JAB-2485 | 2899209-55-1 | Reference compound |
| HY-157397A | ANAT inhibitor-4 (dilithium) | | Reference compound |
| HY-157398 | EGFR T790M/L858R-IN-3 | | Reference compound |
| HY-157399 | EGFR/HER2-IN-10 | 2931499-82-8 | Reference compound |
| HY-15739R | Ansamitocin P-3 (Standard) | 66584-72-3 | Reference Standards |
| HY-15740 | Mc-MMAD | 1401963-15-2 | ADC Related |
| HY-157400 | hMAO-B-IN-7 | 2955577-14-5 | Reference compound |
| HY-157401 | HDAC6-IN-29 | | Reference compound |
| HY-157402 | Topoisomerase II/EGFR-IN-1 | | Reference compound |
| HY-157403 | Jun12682 | | Reference compound |
| HY-157404 | Pim-1/2 kinase inhibitor 2 | 2918764-16-4 | Reference compound |
| HY-157405 | DENV-IN-11 | | Reference compound |
| HY-157407 | Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan | 2699066-62-9 | ADC Related |
| HY-157408 | KDM4D-IN-3 | | Reference compound |
| HY-15741 | Mc-MMAE | 863971-24-8 | ADC Related |
| HY-157411 | anti-TNBC agent-5 | | Reference compound |
| HY-157412 | CRM1-IN-3 | 1114628-25-9 | Reference compound |
| HY-157413 | YS-67 | 2761327-15-3 | Reference compound |
| HY-157414 | Azide-A-DSBSO crosslinker | 1704097-02-8 | Reference compound |
| HY-157416 | COP1-ATGL modulator 1 | 2946701-09-1 | Reference compound |
| HY-157417 | G-quadruplex ligand 1 | 1023617-96-0 | Reference compound |
| HY-157418 | 1-Deoxy-Cer | 1645269-61-9 | Reference compound |
| HY-157419 | FL77-24 | 2413582-39-3 | Reference compound |
| HY-15742 | Vc-MMAD | 1401963-17-4 | ADC Related |
| HY-157420 | VEGFR-2-IN-38 | 3020790-57-9 | Reference compound |
| HY-157421 | Nampt activator-4 | 2847156-05-0 | Reference compound |
| HY-157422 | CSF1R-IN-19 | 1819989-27-9 | Reference compound |
| HY-157423 | 16:1 (DELTA 9-Cis) PC | 56815-99-7 | Biochemical Assay Reagents |
| HY-157424 | 3′-Phosphoadenosine 5′-phosphosulfate (tetralithium salt) | 102029-54-9 | Biochemical Assay Reagents |
| HY-157425 | 5-HT2CR agonist 1 | 1216074-15-5 | Reference compound |
| HY-157426 | GSPT1 degrader-3 | | Reference compound |
| HY-157428 | USP3 ZnF-UBD ligand-1 | 2419322-41-9 | Reference compound |
| HY-157429 | 25N-N1-Nap | 2865185-31-3 | Reference compound |
| HY-15743 | Birabresib | 202590-98-5 | Reference compound |
| HY-157430 | BET-IN-21 | 3014815-06-3 | Reference compound |
| HY-157431 | Mycobacterium Tuberculosis-IN-2 | 2284580-65-8 | Reference compound |
| HY-157432 | EGFR-IN-97 | 3020681-05-1 | Reference compound |
| HY-157433 | Mab-SaS-IN-1 | 773869-38-8 | Reference compound |
| HY-157434 | PCSK9-IN-23 | 2115700-96-2 | Reference compound |
| HY-157435 | PELI1-IN-1 | | Reference compound |
| HY-157436 | HDAC6-IN-30 | | Reference compound |
| HY-157437 | AChE/BChE-IN-16 | | Reference compound |
| HY-157438 | pppApA | 17730-98-2 | Reference compound |
| HY-157438A | pppApA (sodium) | | Reference compound |
| HY-157439 | SARS-CoV-2-IN-72 | | Reference compound |
| HY-15743A | (R)-Birabresib | 1983196-25-3 | Reference compound |
| HY-15743R | Birabresib (Standard) | 202590-98-5 | Reference Standards |
| HY-15744 | LY255283 | 117690-79-6 | Reference compound |
| HY-157440 | AChE/Aβ-IN-3 | | Reference compound |
| HY-157441 | AChE/Aβ-IN-4 | | Reference compound |
| HY-157442 | GLPG3312 | 2340388-72-7 | Reference compound |
| HY-157443 | Myt1-IN-4 | | Reference compound |
| HY-157444 | 5,3',4',3'',4'',5''-6-O-Ethyl-EGCG | 1613308-63-6 | Reference compound |
| HY-157445 | CBR1-IN-3 | 891101-69-2 | Reference compound |
| HY-157446 | MoTPS1/2-IN-1 | | Reference compound |
| HY-157447 | CBR1-IN-4 | 1798284-64-6 | Reference compound |
| HY-157448 | CBR1-IN-6 | | Reference compound |
| HY-157449 | CBR1-IN-5 | 1798284-62-4 | Reference compound |
| HY-15745 | PSI-7409 | 1015073-42-3 | Reference compound |
| HY-157450 | YF-Mo1 | 1119826-36-6 | Reference compound |
| HY-157451 | CBR1-IN-7 | 1119826-35-5 | Reference compound |
| HY-157452 | (8S)-Methyl zearalenone | 1137720-39-8 | Reference compound |
| HY-157453 | CCR4 antagonist 4 | 668980-17-4 | Reference compound |
| HY-157454 | Antiviral agent 48 | 3032868-59-7 | Reference compound |
| HY-157455 | AR antagonist 5 | 2902679-53-0 | Reference compound |
| HY-157456 | RIPK1-IN-19 | 2763831-43-0 | Reference compound |
| HY-157457 | Z21090 | 2992690-71-6 | Reference compound |
| HY-157458 | PDEδ autophagic degrader 1 | | Reference compound |
| HY-157459 | SDH-IN-11 | 2998946-58-8 | Reference compound |
| HY-15745A | PSI-7409 (tetrasodium) | 1621884-22-7 | Reference compound |
| HY-15746 | Dobutamine (hydrochloride) | 49745-95-1 | Reference compound |
| HY-157460 | BRD4 Inhibitor-29 | 902563-50-2 | Reference compound |
| HY-157461 | Glycation-IN-1 | 3023711-86-3 | Reference compound |
| HY-157462 | FC14-584B | 1358567-64-2 | Reference compound |
| HY-157464 | [Ru(phen)2(4-Me-Sal)]BF4 | | Reference compound |
| HY-157465 | MA-PEG4-VC-PAB-DMEA-duocarmycin DM | | ADC Related |
| HY-157465A | MA-PEG4-VC-PAB-DMEA-duocarmycin DM (TFA) | | Reference compound |
| HY-157466 | Antiparasitic agent-21 | | Reference compound |
| HY-157468 | (R)-ELX-02 | 1375073-95-2 | Reference compound |
| HY-15746A | Dobutamine | 34368-04-2 | Reference compound |
| HY-15746B | Dobutamine (tartrate) | 101626-66-8 | Reference compound |
| HY-15746R | Dobutamine (hydrochloride) (Standard) | 49745-95-1 | Reference Standards |
| HY-15746S | (rac)-Dobutamine-d4 (hydrochloride) | 1246815-74-6 | Isotope-Labeled Compounds |
| HY-15746S1 | (rac)-Dobutamine-d6 (hydrochloride) | 1246818-96-1 | Isotope-Labeled Compounds |
| HY-15747 | Deltarasin | 1440898-61-2 | Reference compound |
| HY-157470 | PPO-IN-6 | 125727-57-3 | Reference compound |
| HY-157471 | PPO-IN-7 | 103361-04-2 | Reference compound |
| HY-157476 | AChE-IN-53 | 2807436-94-6 | Reference compound |
| HY-157477 | SARS-CoV-2 3CLpro-IN-22 | | Reference compound |
| HY-157478 | CSNK2A-IN-1 | 3029550-24-8 | Reference compound |
| HY-157479 | DPI-2016 | 2760731-35-7 | Reference compound |
| HY-15747A | Deltarasin (hydrochloride) | 1613404-76-4 | Reference compound |
| HY-15748 | JNJ-40411813 | 1127498-03-6 | Reference compound |
| HY-157480 | EGFR/AURKB-IN-1 | 3008543-34-5 | Reference compound |
| HY-157481 | HDAC1-IN-6 | | Reference compound |
| HY-157482 | EBP-59 | | Reference compound |
| HY-157483 | P-gp inhibitor 18 | | Reference compound |
| HY-157484 | P-gp inhibitor 19 | | Reference compound |
| HY-157485 | Ebio1 | 339287-36-4 | Reference compound |
| HY-157486 | KMI169 | | Reference compound |
| HY-157487 | Anticancer agent 185 | | Reference compound |
| HY-157488 | α-Glucosidase-IN-46 | | Reference compound |
| HY-157489 | α-Glucosidase-IN-47 | | Reference compound |
| HY-15749 | XL228 | 898280-07-4 | Reference compound |
| HY-157490 | PARP/HDAC-IN-1 | | Reference compound |
| HY-157491 | K2-B4-5e | | Reference compound |
| HY-157492 | RO7075573 | 2097284-11-0 | Reference compound |
| HY-157493 | PR antagonist 1 | 936345-34-5 | Reference compound |
| HY-157494 | EP3 antagonist 5 | 499147-44-3 | Reference compound |
| HY-157495 | EP3 antagonist 6 | 499149-94-9 | Reference compound |
| HY-157496 | EP3 antagonist 7 | 740850-59-3 | Reference compound |
| HY-157497 | DA5-HTL | | Reference compound |
| HY-15750 | Cys-mcMMAD | | ADC Related |
| HY-157502S | Buctopamine-d9 | | Isotope-Labeled Compounds |
| HY-157503 | Photosensitizer-3 | 1928742-39-5 | Reference compound |
| HY-157504 | 2′-O-Methyl-5′-O-phosphonoadenylyl-(3′→5′)-guanosine (TEA) | 2638447-50-2 | Reference compound |
| HY-157507 | JC-010a | 2565765-13-9 | Reference compound |
| HY-157508 | VCP Activator 1 | 3061959-30-3 | Reference compound |
| HY-157510 | Thalidomide-O-C3-azide | 2758432-00-5 | Reference compound |
| HY-157511 | Thalidomide-O-C5-azide | 2411098-96-7 | Reference compound |
| HY-157512 | SJF-0661 | 2413035-43-3 | Reference compound |
| HY-157514 | Thalidomide 4'-ether-PEG1-azide | 2758432-02-7 | Reference compound |
| HY-157515 | Thalidomide 4'-ether-PEG2-azide | 2758431-90-0 | Reference compound |
| HY-157516 | CDK2-IN-22 | | Reference compound |
| HY-157517 | MAO-B-IN-29 | 122823-57-8 | Reference compound |
| HY-157518 | OJT008 | 256370-29-3 | Reference compound |
| HY-157519 | LAH-1 | 3018150-68-7 | Reference compound |
| HY-157520 | BChE-IN-25 | 79183-25-8 | Reference compound |
| HY-157521 | AANAT-IN-1 | 3055162-52-9 | Reference compound |
| HY-157522 | NCI-14465 | 1144534-31-5 | Reference compound |
| HY-157524 | 1,2-O-Dioctadecyl-sn-glycerol | 82188-61-2 | Biochemical Assay Reagents |
| HY-157526 | EGFR-TK-IN-1 | | Reference compound |
| HY-157527 | hAChE-IN-7 | 2978613-03-3 | Reference compound |
| HY-157528 | CJ28 | | Natural Products |
| HY-157529 | IR820-PTX | 2250419-19-1 | Dye Reagents |
| HY-15753 | Ellipticine | 519-23-3 | Natural Products |
| HY-157530 | VAP-1-IN-3 | | Reference compound |
| HY-157532 | AChE-IN-55 | | Reference compound |
| HY-157533 | AcrB-IN-5 | 81050-84-2 | Reference compound |
| HY-157534 | Pancreatic lipase-IN-2 | | Reference compound |
| HY-157535 | SHP2-IN-24 | | Reference compound |
| HY-157536 | SMT-738 | | Reference compound |
| HY-157537 | α-Amylase-IN-5 | 2996821-90-8 | Reference compound |
| HY-157538 | PDK4-IN-2 | 1616752-12-5 | Reference compound |
| HY-157539 | PB49673382 | 2763495-65-2 | Reference compound |
| HY-15753A | Ellipticine (hydrochloride) | 5081-48-1 | Natural Products |
| HY-15754 | CGP37157 | 75450-34-9 | Reference compound |
| HY-157542 | CG428-NEG | 2714560-39-9 | Reference compound |
| HY-157543 | Tubulin polymerization-IN-59 | | Reference compound |
| HY-157544 | PC5-VC-PAB-MMAE | 2922216-98-4 | ADC Related |
| HY-157546 | VEGFR-2-IN-40 | | Reference compound |
| HY-157547 | FXIa-IN-14 | 2423992-72-5 | Reference compound |
| HY-157548 | Antitumor agent-133 | | Reference compound |
| HY-157549 | Brivoligide | 1803075-42-4 | Oligonucleotides |
| HY-15755 | RKI-1447 | 1342278-01-6 | Reference compound |
| HY-157550 | DENV-IN-12 | 2581065-80-5 | Reference compound |
| HY-157553 | FAK-IN-19 | 863599-15-9 | Reference compound |
| HY-157554 | ZM640 | | Reference compound |
| HY-157555 | NLRP3-IN-29 | 2198483-40-6 | Reference compound |
| HY-157556 | BPP-2 | | Reference compound |
| HY-157557 | AP30663 | | Reference compound |
| HY-157558 | KDRLKZ-1 | | Reference compound |
| HY-157559 | KDRLKZ-2 | | Reference compound |
| HY-15756 | PTP1B-IN-4 | 765317-72-4 | Reference compound |
| HY-157560 | KDRLKZ-3 | | Reference compound |
| HY-157561 | K2-B4-3e | | Reference compound |
| HY-157562 | DS68591889 | 2488609-21-6 | Reference compound |
| HY-157563 | Dopamine D4 receptor ligand 2 | 219125-63-0 | Reference compound |
| HY-157564 | Antitumor agent-135 | 2922110-00-5 | Reference compound |
| HY-157565 | Bi Unit | 2306467-24-1 | Reference compound |
| HY-157566 | Lenalidomide 5'-piperazine-4-methylpiperidine (hydrochloride) | 2520105-60-4 | Reference compound |
| HY-157567 | FSI-TN42 | 2445840-25-3 | Reference compound |
| HY-157568S | Budesonide acid-d8 | | Isotope-Labeled Compounds |
| HY-157569 | PD1-PDL1-IN 2 | 2566710-63-0 | Reference compound |
| HY-15757 | SJB2-043 | 63388-44-3 | Reference compound |
| HY-157570 | Anti-inflammatory agent 70 | 2767427-87-0 | Reference compound |
| HY-157571S | N-6-[rel-(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-pyridinamine-Sonidegib-d8 | | Isotope-Labeled Compounds |
| HY-157573 | N-Acetylmuramic acid-azide | 2245794-64-1 | Reference compound |
| HY-157574 | TRPV6-IN-1 | 1819366-84-1 | Reference compound |
| HY-157577 | PROTAC(H-PGDS)-8 | 2761281-51-8 | Reference compound |
| HY-157578 | COX-2-IN-38 | 1018480-97-1 | Reference compound |
| HY-157579 | MS154N | 2675490-97-6 | Reference compound |
| HY-15758 | 3,3'-Diindolylmethane | 1968-05-4 | Natural Products |
| HY-157581 | MS39 | 2675490-92-1 | Reference compound |
| HY-157582 | MS39N | 2675490-96-5 | Reference compound |
| HY-157583 | COX-2-IN-39 | 1018480-89-1 | Reference compound |
| HY-157585S | 21-Dehydro Budesonide-d8-1 | | Isotope-Labeled Compounds |
| HY-157586 | 2-Linoleoyl-sn-glycero-3-phosphoethanolamine | 60701-98-6 | Reference compound |
| HY-157587 | E3 ligase Ligand-Linker Conjugate 29 | | Reference compound |
| HY-157588 | (S)-Thalidomide-Piperazine-CH2-Pyrrolidine-C2-OH | | Reference compound |
| HY-157589 | E3 ligase Ligand-Linker Conjugate 31 | | Reference compound |
| HY-15758R | 3,3'-Diindolylmethane (Standard) | 1968-05-4 | Reference Standards |
| HY-157590 | E3 ligase Ligand-Linker Conjugate 32 | | Reference compound |
| HY-157591 | MMH1-NR | | Reference compound |
| HY-157592 | MMH2-NR | | Reference compound |
| HY-157593 | E3 ligase Ligand-Linker Conjugate 35 | | Reference compound |
| HY-157594 | E3 ligase Ligand-Linker Conjugate 37 | | Reference compound |
| HY-157595 | E3 ligase Ligand-Linker Conjugate 38 | | Reference compound |
| HY-157596 | E3 ligase Ligand-Linker Conjugate 40 | | Reference compound |
| HY-157597 | E3 ligase Ligand-Linker Conjugate 42 | | Reference compound |
| HY-157598 | E3 ligase Ligand-Linker Conjugate 46 | | Reference compound |
| HY-157599 | E3 ligase Ligand-Linker Conjugate 65 | | Reference compound |
| HY-15759A | Napsagatran hydrate | 159668-20-9 | Reference compound |
| HY-15760 | Necrostatin-1 | 4311-88-0 | Reference compound |
| HY-157600 | E3 ligase Ligand-Linker Conjugate 66 | | Reference compound |
| HY-157601 | HSD17B13-IN-4 | | Reference compound |
| HY-157602 | DHX9-IN-8 | 2973746-64-2 | Reference compound |
| HY-157603 | DHX9-IN-7 | 2973400-87-0 | Reference compound |
| HY-157604 | DHX9-IN-9 | 2973400-46-1 | Reference compound |
| HY-157605 | DHX9-IN-11 | 2973402-91-2 | Reference compound |
| HY-157606 | DHX9-IN-13 | 2973399-28-7 | Reference compound |
| HY-157607 | DHX9-IN-15 | 2973398-27-3 | Reference compound |
| HY-157608 | DHX9-IN-10 | 2973746-79-9 | Reference compound |
| HY-157609 | DHX9-IN-12 | 2973747-13-4 | Reference compound |
| HY-15761 | AZD2858 | 486424-20-8 | Reference compound |
| HY-157610 | DHX9-IN-14 | 2973747-90-7 | Reference compound |
| HY-157611 | DHX9-IN-17 | 2973397-26-9 | Reference compound |
| HY-157612 | DHX9-IN-16 | 2973397-48-5 | Reference compound |
| HY-157613 | HSD17B13-IN-5 | | Reference compound |
| HY-157615 | HSD17B13-IN-6 | 2576696-34-7 | Reference compound |
| HY-157617 | 16:0 Cyclic LPA (ammonium) | 799268-71-6 | Biochemical Assay Reagents |
| HY-157618 | 18:0-18:1 PG (sodium) | 322647-48-3 | Oligonucleotides |
| HY-15762 | Valdecoxib | 181695-72-7 | Reference compound |
| HY-157620 | 18:0 Lyso PS (sodium) | 1246298-16-7 | Oligonucleotides |
| HY-157622 | 1-Palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine | 159701-21-0 | Biochemical Assay Reagents |
| HY-157623 | 16:0 Lyso PS | 143077-66-1 | Biochemical Assay Reagents |
| HY-157624 | 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine | 96998-01-5 | Oligonucleotides |
| HY-157625 | 1-Palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine | 96998-00-4 | Biochemical Assay Reagents |
| HY-157627 | HSD17B13-IN-9 | 2576690-78-1 | Reference compound |
| HY-157629 | 1-Palmitoyl-2-arachidonoyl-sn-glycero-3-PE | 70812-59-8 | Oligonucleotides |
| HY-15762R | Valdecoxib (Standard) | 181695-72-7 | Reference Standards |
| HY-15762S | Valdecoxib-d3 | 1219794-90-7 | Isotope-Labeled Compounds |
| HY-15763 | Erastin | 571203-78-6 | Reference compound |
| HY-157630 | HSD17B13-IN-10 | 2576696-23-4 | Reference compound |
| HY-157632 | HSD17B13-IN-13 | 2762668-28-8 | Reference compound |
| HY-157634 | E3 Ligase Ligand-linker Conjugate 91 | 2229713-40-8 | Reference compound |
| HY-157635 | E3 Ligase Ligand-linker Conjugate 92 | | Reference compound |
| HY-157636 | E3 Ligase Ligand-linker Conjugate 93 | | Reference compound |
| HY-157637 | E3 Ligase Ligand-linker Conjugate 94 | | Reference compound |
| HY-157639A | 18:2 Lyso PA (sodium) | | Reference compound |
| HY-15764 | A 419259 | 364042-47-7 | Reference compound |
| HY-157642 | 1-Hexanoyl-2-hydroxy-sn-glycero-3-phosphocholine | 58445-96-8 | Biochemical Assay Reagents |
| HY-157644 | 1-Heptanoyl-2-hydroxy-sn-glycero-3-phosphocholine | 160118-49-0 | Biochemical Assay Reagents |
| HY-157646 | MZ-101 | 2839908-40-4 | Reference compound |
| HY-157647 | 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC | 137254-39-8 | Reference compound |
| HY-15764A | A 419259 (trihydrochloride) | 1435934-25-0 | Reference compound |
| HY-15764G | A 419259 (GMP) | 364042-47-7 | GMP Small Molecules |
| HY-157650 | HSD17B13-IN-20 | 2919797-59-2 | Reference compound |
| HY-157652 | 18:0-20:4 PI(3,4,5)P3 | 799268-60-3 | Biochemical Assay Reagents |
| HY-157653 | HSD17B13-IN-22 | 2919797-60-5 | Reference compound |
| HY-157654 | HSD17B13-IN-26 | 2919797-61-6 | Reference compound |
| HY-157655 | Cafedrine-theodrenaline | 8004-31-7 | Reference compound |
| HY-157657 | Cardiolipin (16:1/16:1/16:1/16:1) (sodium salt) | 2260669-34-7 | Oligonucleotides |
| HY-157658 | K-8794 | 180577-26-8 | Reference compound |
| HY-157659 | WDR5-MLL1 antagonist 1 | 1422389-91-0 | Reference compound |
| HY-15766 | GNE-617 | 1362154-70-8 | Reference compound |
| HY-157660 | 15(R)-Prostaglandin F1α | 21562-54-9 | Reference compound |
| HY-157661 | 14:0 Cardiolipin (sodium) | 63988-21-6 | Biochemical Assay Reagents |
| HY-157662 | HSD17B13-IN-33 | 2730027-85-5 | Reference compound |
| HY-157663 | HSD17B13-IN-36 | 2730027-86-6 | Reference compound |
| HY-157664 | HSD17B13-IN-38 | 2730022-56-5 | Reference compound |
| HY-157665 | HSD17B13-IN-39 | 2730022-55-4 | Reference compound |
| HY-157666 | 13:0 PC | 71242-28-9 | Oligonucleotides |
| HY-157667 | HSD17B13-IN-44 | 2912452-29-8 | Reference compound |
| HY-157669 | 1-Oleoyl-sn-glycero-2,3-cyclic-phosphate (ammonium) | 799268-72-7 | Biochemical Assay Reagents |
| HY-15766A | GNE-617 (hydrochloride) | 2070014-99-0 | Reference compound |
| HY-15767 | TAK-632 | 1228591-30-7 | Reference compound |
| HY-157671 | HSD17B13-IN-45 | 2912452-50-5 | Reference compound |
| HY-157672 | 18:1-14:0 PC | 95896-56-3 | Oligonucleotides |
| HY-157673 | 1,2-Dipalmitoleoyl-sn-glycero-3-phosphoethanolamine | 61599-23-3 | Biochemical Assay Reagents |
| HY-157674 | HSD17B13-IN-46 | 2912453-90-6 | Reference compound |
| HY-157675 | 1,2-Dinervonoyl-sn-glycero-3-phosphocholine | 51779-96-5 | Oligonucleotides |
| HY-157676 | HSD17B13-IN-47 | 2912455-14-0 | Reference compound |
| HY-157678 | 1,2-Dilinoleoyl-sn-glycero-3-phospho-L-serine (sodium) | 321883-39-0 | Oligonucleotides |
| HY-157679 | 1-O-Hexadecyl-2-eicosapentaenoyl-SN-glycero-3-phosphocholine | 132196-28-2 | Oligonucleotides |
| HY-15768 | Ilomastat | 142880-36-2 | Reference compound |
| HY-157681 | 1,2-Dilinolenoyl-sn-glycero-3-phosphocholine | 2701-19-1 | Biochemical Assay Reagents |
| HY-157687 | 18:1 (Δ9-Trans) PC | 56782-46-8 | Oligonucleotides |
| HY-157688 | C18(Plasm) LPE | 174062-73-8 | Oligonucleotides |
| HY-157689 | 1,2-Dieicosenoyl-sn-glycero-3-phosphocholine | 61596-54-1 | Biochemical Assay Reagents |
| HY-15769 | WHI-P180 | 211555-08-7 | Reference compound |
| HY-157690 | 19(S),20(R)-EDP | 2460392-58-7 | Reference compound |
| HY-157690A | 19(R),20(S)-EDP | 2242542-60-3 | Reference compound |
| HY-157692 | 10:0 PS | 321863-22-3 | Biochemical Assay Reagents |
| HY-157693 | C18:1 Cyclic LPA | 799268-69-2 | Oligonucleotides |
| HY-157694 | 09:0 Lyso PC | 253678-66-9 | Oligonucleotides |
| HY-157695 | 1-(1Z-Octadecenyl)-2-docosahexaenoyl-sn-glycero-3-phosphocholine | 799268-64-7 | Oligonucleotides |
| HY-157696 | 18:0 Diether PC | 1188-85-8 | Biochemical Assay Reagents |
| HY-157697 | 1-1(Z)-Octadecenyl-2-arachidonoyl-sn-glycero-3-PE | 144371-69-7 | Biochemical Assay Reagents |
| HY-157698 | 1-1(Z)-Octadecenyl-2-arachidonoyl-sn-glycero-3-PC | 97802-56-7 | Biochemical Assay Reagents |
| HY-157699 | 1,2-Dioleoyl-sn-glycero-3-phospho-(1'-myo-inositol-5'-phosphate) (ammonium) | 1246303-10-5 | Biochemical Assay Reagents |
| HY-15769A | WHI-P180 (hydrochloride) | 153437-55-9 | Reference compound |
| HY-15770 | TR-14035 | 232271-19-1 | Reference compound |
| HY-157700 | Hexadecenyl-2-hydroxy-sn-glycero-3-PC | 97802-53-4 | Oligonucleotides |
| HY-157702 | 1-Heptadecenoyl-2-OH-sn-glycero-3-phosphoethanolamine | 1246298-09-8 | Biochemical Assay Reagents |
| HY-157703 | 18:1 PI(4,5)P2 | 799268-56-7 | Biochemical Assay Reagents |
| HY-157704 | 18:1 PI(3)P | 1246303-09-2 | Biochemical Assay Reagents |
| HY-157706 | PI(3,4)P2 (18:1) (ammonium salt) | 799268-54-5 | Biochemical Assay Reagents |
| HY-157707 | 18:1 PI(3,4,5)P3 | 799268-57-8 | Biochemical Assay Reagents |
| HY-157708 | HSD17B13-IN-67 | 2912457-83-9 | Reference compound |
| HY-15771 | Tirabrutinib | 1351636-18-4 | Reference compound |
| HY-157710 | HSD17B13-IN-68 | 3004660-61-8 | Reference compound |
| HY-157714 | 08:0 PI(3,4)P2 | 852043-35-7 | Biochemical Assay Reagents |
| HY-157715 | 1,2-Dioctanoyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4',5'-trisphosphate) (ammonium) | 852043-38-0 | Biochemical Assay Reagents |
| HY-157717 | HSD17B13-IN-70 | 3004660-93-6 | Reference compound |
| HY-157718 | 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine | 105370-99-8 | Biochemical Assay Reagents |
| HY-157719 | S-Adenosylhomocysteine sulfoxide | 29907-86-6 | Reference compound |
| HY-15771A | Tirabrutinib (hydrochloride) | 1439901-97-9 | Reference compound |
| HY-15772 | Osimertinib | 1421373-65-0 | Reference compound |
| HY-157720 | HSD17B13-IN-72 | 3004661-16-6 | Reference compound |
| HY-157721 | 1,2-Dibehenoyl-sn-glycero-3-phosphocholine | 17688-29-8 | Oligonucleotides |
| HY-157722 | HSD17B13-IN-73 | 3004661-39-3 | Reference compound |
| HY-157723 | HSD17B13-IN-74 | 2912458-81-0 | Reference compound |
| HY-157724 | HSD17B13-IN-76 | 2912459-00-6 | Reference compound |
| HY-157725 | C18:1 LPA | 799279-68-8 | Oligonucleotides |
| HY-157726 | HSD17B13-IN-77 | 2912459-67-5 | Reference compound |
| HY-157727 | HDHD4-IN-1 | 1447279-68-6 | Reference compound |
| HY-157728 | ML307 | | Reference compound |
| HY-157729 | 1-Undecanoylglycerol | 64633-19-8 | Reference compound |
| HY-15772A | Osimertinib (mesylate) | 1421373-66-1 | Reference compound |
| HY-15772AR | Osimertinib (mesylate) (Standard) | 1421373-66-1 | Reference Standards |
| HY-15772R | Osimertinib (Standard) | 1421373-65-0 | Reference Standards |
| HY-15772S | Osimertinib-d6 | 1638281-44-3 | Isotope-Labeled Compounds |
| HY-15772S1 | Osimertinib-13C,d3 | 2254100-49-5 | Isotope-Labeled Compounds |
| HY-15772S3 | Asandeutertinib | 1638281-46-5 | Isotope-Labeled Compounds |
| HY-15773 | PF-4708671 | 1255517-76-0 | Reference compound |
| HY-157730 | 2-Myristyldistearin | 57396-99-3 | Natural Products |
| HY-157731 | α-Laurodimyristin | 60138-12-7 | Natural Products |
| HY-157732 | 1,2-Dimyristoyl-3-palmitoyl-rac-glycerol | 60138-13-8 | Natural Products |
| HY-157733 | 1,2-Dioleoyl-3-behenoylglycerol | 77145-66-5 | Reference compound |
| HY-157734 | 1,2-Palmitate-3-elaidate | 93452-43-8 | Natural Products |
| HY-157735 | 2-Myristyldipalmitin | 56599-89-4 | Natural Products |
| HY-157736 | Tritetracosanoin | 56983-26-7 | Reference compound |
| HY-157737 | GVSKYG-PEG2-azide (TFA) | | Peptides |
| HY-157737A | GVSKYG-PEG2-azide (hydrochloride) | | ADC Related |
| HY-157738 | 1,2-Dilauroyl-3-myristoyl-rac-glycerol | 60175-30-6 | Reference compound |
| HY-157739 | 1,2-Dioleoyl-3-arachidoylglycerol | 77145-65-4 | Natural Products |
| HY-15774 | CBB1003 | 1379573-88-2 | Reference compound |
| HY-157740 | XSJ-10 | | Reference compound |
| HY-157741 | 1-Myristoyl-2-oleoyl-3-palmitoyl-rac-glycerol | 99131-43-8 | Reference compound |
| HY-157742 | 1,3-Dioleoyl-2-elaidoyl glycerol | 110170-81-5 | Reference compound |
| HY-157743 | SCH 60057 | 203061-35-2 | Natural Products |
| HY-157744 | Coumarin–quinone conjugate | 2741190-31-6 | Reference compound |
| HY-157745 | m-PEG-NHS ester (MW 40000) | 92451-01-9 | Reference compound |
| HY-157746 | CTPS1-IN-1 | 2341943-12-0 | Reference compound |
| HY-157747 | E3 Ligase Ligand-linker Conjugate 99 | | Reference compound |
| HY-157748 | E3 Ligase Ligand-linker Conjugate 100 | | Reference compound |
| HY-157749 | Thalidomide-piperazine-(S)-CH2-pyrrolidine-C2-O-CH2-COO-C(CH3)3 | | Reference compound |
| HY-15774A | CBB1003 (hydrochloride) | 2070015-02-8 | Reference compound |
| HY-15775 | Arginase inhibitor 1 | 1345808-25-4 | Reference compound |
| HY-157750 | MEK1/C-Raf-IN-1 | 946128-76-3 | Reference compound |
| HY-157751 | RIPK1-IN-21 | 3016304-64-3 | Reference compound |
| HY-157752 | E3 Ligase Ligand-linker Conjugate 101 | | Reference compound |
| HY-157753 | E3 Ligase Ligand-linker Conjugate 102 | | Reference compound |
| HY-157754 | E3 Ligase Ligand-linker Conjugate 103 | | Reference compound |
| HY-157756 | E3 Ligase Ligand-linker Conjugate 104 | | Reference compound |
| HY-157757 | E3 Ligase Ligand-linker Conjugate 105 | | Reference compound |
| HY-157758 | (S)-Thalidomide-piperazine-pyrimidine-piperazine-C2-O-CH2-COO-C(CH3)3 | | Reference compound |
| HY-157759 | (S)-Thalidomide-piperazine-pyrimidine-piperazine-C2-O-C2-OH | | Reference compound |
| HY-15776 | HG-9-91-01 | 1456858-58-4 | Reference compound |
| HY-157760 | (S)-Thalidomide-piperazine-pyrimidine-piperazine-C2-OH | | Reference compound |
| HY-157761 | E3 Ligase Ligand-linker Conjugate 106 | | Reference compound |
| HY-157762 | GPX4-IN-9 | 3032746-99-6 | Reference compound |
| HY-157763 | PROTAC BTK Degrader-8 | | Reference compound |
| HY-157764 | PROTAC ATR degrader-1 | 2925916-30-7 | Reference compound |
| HY-157765 | PROTAC ERα Degrader-6 | | Reference compound |
| HY-157766 | FAAH/TRPV1 blocker-1 | | Reference compound |
| HY-157767 | Abd110 | 3021581-79-0 | Reference compound |
| HY-15777 | Ribociclib | 1211441-98-3 | Reference compound |
| HY-157778 | MK-7845 | 2952554-69-5 | Isotope-Labeled Compounds |
| HY-157779 | TPA-NAC | | Reference compound |
| HY-15777A | Ribociclib hydrochloride | 1211443-80-9 | Reference compound |
| HY-15777AS | Ribociclib-d6 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-15777B | Ribociclib succinate | 1374639-75-4 | Reference compound |
| HY-15777C | Ribociclib succinate hydrate | 1374639-79-8 | Reference compound |
| HY-15777R | Ribociclib (Standard) | 1211441-98-3 | Reference Standards |
| HY-15777S | Ribociclib-d6 | 1328934-40-2 | Isotope-Labeled Compounds |
| HY-15777S1 | Ribociclib-d8 | 2167898-24-8 | Isotope-Labeled Compounds |
| HY-15778 | AVE 0991 | 304462-19-9 | Reference compound |
| HY-157783 | Dencatistat | 2377000-84-3 | Reference compound |
| HY-157784 | XPC-7724 | | Reference compound |
| HY-157786 | XPC-5462 | 2230145-14-7 | Reference compound |
| HY-157787 | Ginkgolic acid 2-phosphate | 2281761-58-6 | Reference compound |
| HY-157788 | ZX703 | | Reference compound |
| HY-15778A | AVE 0991 (sodium salt) | 306288-04-0 | Reference compound |
| HY-15779 | K145 | 1309444-75-4 | Reference compound |
| HY-157792 | Antidepressant agent 6 | | Reference compound |
| HY-157793 | SMU-L11 | | Reference compound |
| HY-157794 | 6-Nitroquinazoline | 7556-95-8 | Reference compound |
| HY-157795 | Exatecan analogue 1 | 2671770-58-2 | ADC Related |
| HY-157796 | β2AR agonist 4 | | Reference compound |
| HY-157797 | SN-38-CM2 | 2376127-86-3 | Reference compound |
| HY-15779A | K145 (hydrochloride) | 1449240-68-9 | Reference compound |
| HY-15780 | Brexpiprazole | 913611-97-9 | Reference compound |
| HY-157800 | Trilexium | 1983180-82-0 | Reference compound |
| HY-157802 | LTGO-33 | 2834106-06-6 | Reference compound |
| HY-157802A | (S)-LTGO-33 | | Reference compound |
| HY-157804 | PROTAC SARS-CoV-2 Mpro degrader-1 | 3029579-46-9 | Reference compound |
| HY-157805 | PROTAC SARS-CoV-2 Mpro degrader-2 | | Reference compound |
| HY-157806 | α-Synuclein inhibitor 12 | | Reference compound |
| HY-157807 | Prostaglandin E2-biotin | 2641624-60-2 | Reference compound |
| HY-157808 | Antibacterial agent 185 | | Reference compound |
| HY-157809 | Anti-inflammatory agent 74 | | Reference compound |
| HY-15780A | Brexpiprazole (hydrochloride) | 913612-38-1 | Reference compound |
| HY-15780R | Brexpiprazole (Standard) | 913611-97-9 | Reference Standards |
| HY-15780S | Brexpiprazole-d8 | 1427049-21-5 | Isotope-Labeled Compounds |
| HY-15780S1 | Brexpiprazole-d8-1 | 1427049-19-1 | Isotope-Labeled Compounds |
| HY-15781 | Morinidazole | 92478-27-8 | Reference compound |
| HY-157810 | AKR1C3-IN-11 | | Reference compound |
| HY-157811 | PD-1/PD-L1-IN-40 | | Reference compound |
| HY-157813 | 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan | 2964536-59-0 | ADC Related |
| HY-157814 | Menin-MLL inhibitor-25 | | Reference compound |
| HY-15781A | (R)-Morinidazole | 898230-59-6 | Reference compound |
| HY-15782 | YH16899 | 1428623-14-6 | Reference compound |
| HY-157820 | Galectin-4-IN-2 | 1044566-28-0 | Reference compound |
| HY-157821 | Galectin-4-IN-3 | 1044566-26-8 | Reference compound |
| HY-157822 | Galectin-8-IN-2 | 1044566-24-6 | Reference compound |
| HY-157824 | 6Lac[6]Met | 1132892-04-6 | Reference compound |
| HY-157829 | (R)-Palmitoyl-(2-methyl)ethanolamide | 179951-56-5 | Reference compound |
| HY-157833 | Heptadecanoyl ethanolamide | 53832-59-0 | Reference compound |
| HY-157838 | HMC-B17 | 2935913-83-8 | Reference compound |
| HY-157839 | PROTAC α-synuclein degrader 6 | 3032208-24-2 | Reference compound |
| HY-15784 | NPPM 6748-481 | 432020-20-7 | Reference compound |
| HY-157840 | Anti-infective agent 9 | 758689-17-7 | Reference compound |
| HY-157844 | NUCC-0226272 | 3004503-12-9 | Reference compound |
| HY-157847 | phospho-STAT3-IN-2 | | Reference compound |
| HY-157848 | SARS-CoV-2-IN-82 | 924058-34-4 | Reference compound |
| HY-15785 | Pimitespib | 1260533-36-5 | Reference compound |
| HY-157850 | BP-M345 | 1360119-00-1 | Reference compound |
| HY-157856 | rel-4(5)-Epdpe methyl ester | 121818-29-9 | Reference compound |
| HY-157856A | (Rac)-rel-4(5)-Epdpe methyl ester | 234087-65-1 | Reference compound |
| HY-15786 | SGE-201 | 35882-85-0 | Reference compound |
| HY-157870 | Mtb-IN-6 | | Reference compound |
| HY-157871 | TAK1-IN-5 | | Reference compound |
| HY-157872 | ALDH1A1-IN-4 | 23982-86-7 | Reference compound |
| HY-157876 | Anticancer agent 191 | | Reference compound |
| HY-157880 | N3-PC | | Reference compound |
| HY-157881 | 2-Mercaptoethanesulfonic acid (ampule,3.0M±0.1M in H2O) | 3375-50-6 | Biochemical Assay Reagents |
| HY-157883 | C7BzO | 565454-39-9 | Biochemical Assay Reagents |
| HY-157886 | TDP1 Inhibitor-3 | | Reference compound |
| HY-157887 | ADT-007 | 1945941-09-2 | Reference compound |
| HY-157888 | SHP2-IN-26 | | Reference compound |
| HY-157889 | ZINC000028464438 | 866123-66-2 | Reference compound |
| HY-15789 | Elbasvir | 1370468-36-2 | Reference compound |
| HY-157891 | JBC117 | 1214531-21-1 | Reference compound |
| HY-157892 | Antimalarial agent 38 | 123580-46-1 | Reference compound |
| HY-15789R | Elbasvir (Standard) | 1370468-36-2 | Reference Standards |
| HY-15790 | Elobixibat | 439087-18-0 | Reference compound |
| HY-157901 | 2,3-Dihydroxybutanoic acid | 3413-97-6 | Reference compound |
| HY-15790A | Elobixibat (hydrate) | 1633824-78-8 | Reference compound |
| HY-15790H | (S)-Elobixibat | 439087-68-0 | Reference compound |
| HY-15790R | Elobixibat (Standard) | 439087-18-0 | Reference Standards |
| HY-15790S | Elobixibat-d5 | | Isotope-Labeled Compounds |
| HY-15791 | FR173657 | 167838-64-4 | Reference compound |
| HY-157910 | (±)17(18)-EpETE methyl ester | 141339-46-0 | Reference compound |
| HY-157912 | EGFR-IN-102 | 2781912-10-3 | Reference compound |
| HY-157913 | PKM2-IN-6 | 771467-00-6 | Reference compound |
| HY-157914 | Dibenzyl-14-crown-4 | 106868-21-7 | Biochemical Assay Reagents |
| HY-157915 | HFPB | 2098575-63-2 | Biochemical Assay Reagents |
| HY-157916 | ARP | 139585-03-8 | Biochemical Assay Reagents |
| HY-157917 | Nitro-PAPS (disodium dihydrate) | | Biochemical Assay Reagents |
| HY-157918 | Carboxy-EG6-hexadecanethiol | 1432697-96-5 | Biochemical Assay Reagents |
| HY-157919 | Biotin-PEAC5-maleimide (hydrochloride) | 2377497-15-7 | Biochemical Assay Reagents |
| HY-15792 | (R)-FL118 | 151636-76-9 | Reference compound |
| HY-157920 | Biotin-PE-maleimide | 374592-99-1 | Biochemical Assay Reagents |
| HY-157921 | Amino-EG6-undecanethiol (hydrochloride) | 1392815-15-4 | Biochemical Assay Reagents |
| HY-157922 | Trehalose C12 | 64622-91-9 | Biochemical Assay Reagents |
| HY-157923 | Trehalose C14 | 64622-92-0 | Biochemical Assay Reagents |
| HY-157924 | Bis(benzo-15-crown-5) | 69271-98-3 | Biochemical Assay Reagents |
| HY-157925 | Bicyclo-PGE1 | 1283861-32-4 | Reference compound |
| HY-157926 | Nitroso-PSAP | 80459-15-0 | Biochemical Assay Reagents |
| HY-157928 | Keap1-Nrf2-IN-18 | | Reference compound |
| HY-157929 | Keap1-Nrf2-IN-19 | | Reference compound |
| HY-15793 | NBI-98782 | 85081-18-1 | Reference compound |
| HY-157930 | TP-2 | | Reference compound |
| HY-157931 | Anticancer agent 192 | | Reference compound |
| HY-157932 | MR24 | | Reference compound |
| HY-157933 | SF-C5-TPP | | Reference compound |
| HY-157934 | MAO-IN-4 | 3023217-85-5 | Reference compound |
| HY-157935 | 17β-HSD10-IN-3 | 2225109-18-0 | Reference compound |
| HY-157936 | GluN2B-NMDAR antagonist-2 | | Reference compound |
| HY-157937 | VISTA-IN-3 | 2994662-45-0 | Reference compound |
| HY-157938S | 6-ECDCA-d4 | 2025364-15-0 | Isotope-Labeled Compounds |
| HY-157939 | GPR183 antagonist-3 | | Reference compound |
| HY-15793A | Trans (2,3)-Dihydrotetrabenazine | 171598-74-6 | Reference compound |
| HY-15794 | Nemorubicin | 108852-90-0 | Reference compound |
| HY-157940 | Methylsolfonyl 25(S)-Δ7-dafachronic acid | | Reference compound |
| HY-157941 | ART0380 | 2267316-76-5 | Reference compound |
| HY-157942 | CYP1B1-IN-7 | 52601-58-8 | Reference compound |
| HY-157943 | Hexyl 5-aminolevulinate | 140898-97-1 | Dye Reagents |
| HY-15794A | Nemorubicin (hydrochloride) | 108943-08-4 | Reference compound |
| HY-15794G | Nemorubicin (GMP) | 108852-90-0 | GMP Small Molecules |
| HY-157950 | DSPE-PEG2000-triGalNAc (ammonium) | 2936651-86-2 | Reference compound |
| HY-157954 | WRN inhibitor 6 | | Reference compound |
| HY-157955 | TAAR1 agonist 1 | | Reference compound |
| HY-157955A | TAAR1 agonist 1 (hydrochloride) | | Reference compound |
| HY-157956 | LASSBio-873 | 873694-54-3 | Reference compound |
| HY-157958 | α7 nAChR Modulator-3 | | Reference compound |
| HY-157959 | Orphenadrine | 83-98-7 | Reference compound |
| HY-15796 | GNE0877 | 1374828-69-9 | Reference compound |
| HY-157960 | VEGFR-2-IN-42 | | Reference compound |
| HY-157963 | RIPK1-IN-23 | 3031534-16-1 | Reference compound |
| HY-157964 | DHC-156 | | Reference compound |
| HY-157965 | ZINC09875266 | 925200-00-6 | Reference compound |
| HY-157966 | SARS-CoV-2 3CLpro-IN-23 | | Reference compound |
| HY-15797 | UNC2250 | 1493694-70-4 | Reference compound |
| HY-157974 | [Ag(2,2′-bipy)(dppe)][CF3SO3] | | Reference compound |
| HY-157975 | LM11 | | Reference compound |
| HY-157976 | Dinorprostaglandin E1 | 7046-40-4 | Reference compound |
| HY-157977 | DOTA-GA-maleimide | 1800229-46-2 | Reference compound |
| HY-157978 | AChE-IN-59 | 2957916-86-6 | Reference compound |
| HY-157979 | AQP3-IN-1 | 198711-19-2 | Reference compound |
| HY-15798 | UNC2881 | 1493764-08-1 | Reference compound |
| HY-157980 | CDK9-IN-32 | | Reference compound |
| HY-157981 | AChE-IN-60 | | Reference compound |
| HY-157982 | BChE-IN-28 | | Reference compound |
| HY-157987 | MBX3135 | 1636878-36-8 | Reference compound |
| HY-15799 | AZD1283 | 919351-41-0 | Reference compound |
| HY-157990 | Wnt/β-catenin-IN-1 | | Reference compound |
| HY-157992 | LM-021 | 1022282-98-9 | Reference compound |
| HY-157993 | SAG-524 | 2246696-89-7 | Reference compound |
| HY-157994 | EGFR WT/T790M-IN-2 | | Reference compound |
| HY-157995 | Dyrk1A-IN-7 | | Reference compound |
| HY-157996 | CSF1R-IN-21 | 2935479-62-0 | Reference compound |
| HY-157997 | MHC02181 | 460999-85-3 | Reference compound |
| HY-157998 | mG2N001 | 2760515-88-4 | Reference compound |
| HY-157999 | SDI-118 | 1651179-19-9 | Reference compound |
| HY-15800 | CZC-25146 (hydrochloride) | 1330003-04-7 | Reference compound |
| HY-158000 | Bile acid probe 1 | 2148335-01-5 | Reference compound |
| HY-158001 | MHC00188 | 1380881-85-5 | Reference compound |
| HY-158002 | IDOR-4 | 2839901-24-3 | Reference compound |
| HY-158003 | COE-PNH2 | | Reference compound |
| HY-158004 | SMU101 | | Reference compound |
| HY-158005 | Anticancer agent 195 | | Reference compound |
| HY-158006 | SDX-7539 | 1631953-52-0 | Reference compound |
| HY-158007 | (RS)-G12Di-1 | | Reference compound |
| HY-158008 | (R)-G12Di-7 | 2946593-60-6 | Reference compound |
| HY-158009 | SGF29-IN-1 | 6638-82-0 | Reference compound |
| HY-15800A | CZC-25146 | 1191911-26-8 | Reference compound |
| HY-15801 | HG-14-10-04 | 1356962-34-9 | Reference compound |
| HY-158010 | FGFR3-IN-8 | | Reference compound |
| HY-158011 | FGFR3-IN-9 | 2446523-17-5 | Reference compound |
| HY-158012 | LY3056480 | 2064292-78-8 | Reference compound |
| HY-158013 | JJC8-088 | 1627576-82-2 | Reference compound |
| HY-158013A | JJC8-088 (dioxalate) | 2068692-71-5 | Reference compound |
| HY-158014 | JJC8-089 | 1627576-64-0 | Reference compound |
| HY-158016 | Antiproliferative agent-49 | | Reference compound |
| HY-158017 | WXM-1-170 | | Reference compound |
| HY-158018 | EGFR-TK-IN-2 | | Reference compound |
| HY-158019 | Anticancer agent 196 | | Reference compound |
| HY-15802 | WZ4003 | 1214265-58-3 | Reference compound |
| HY-158020 | Anticancer agent 197 | | Reference compound |
| HY-158021 | Tyrosinase-IN-26 | | Reference compound |
| HY-158022 | CTSL/CAPN1-IN-1 | | Reference compound |
| HY-158023 | DHODH-IN-26 | | Reference compound |
| HY-158024 | NDT-19795 | 2272917-12-9 | Reference compound |
| HY-158024A | (S)-NDT-19795 | | Reference compound |
| HY-158025 | Anticancer agent 198 | | Reference compound |
| HY-158026 | ALDH1A1-IN-5 | | Reference compound |
| HY-158027 | B-Raf IN 17 | | Reference compound |
| HY-158028 | PAN endonuclease-IN-2 | | Reference compound |
| HY-158029 | PI3Kα-IN-21 | | Reference compound |
| HY-158030 | HDAC6-IN-37 | 2986486-82-0 | Reference compound |
| HY-158031 | PLK1/BRD4-IN-5 | | Reference compound |
| HY-158034S | U-13C Hemicellulose from potato | | Isotope-Labeled Compounds |
| HY-158036 | PROTAC STING Degrader-2 | 3023095-61-3 | Reference compound |
| HY-158037 | α-Glucosidase-IN-55 | | Reference compound |
| HY-158038 | AurkA allosteric-IN-1 | | Reference compound |
| HY-158039 | YCH2823 | | Reference compound |
| HY-158045 | PROTAC PARP1 degrader-1 | | Reference compound |
| HY-158046 | UNC8899 | | Reference compound |
| HY-158047 | UNC8900 | | Reference compound |
| HY-158048 | UNC9036 | | Reference compound |
| HY-158049 | Anticancer agent 199 | 2422001-24-7 | Reference compound |
| HY-15805 | KIN-8194 | 330786-01-1 | Reference compound |
| HY-158050 | PXB17 | | Reference compound |
| HY-158051 | CIDD-0072424 | 1620195-03-0 | Reference compound |
| HY-158052 | PD-1/PD-L1 antagonist 1 | | Reference compound |
| HY-158053 | Antifungal agent 94 | 3030502-21-4 | Reference compound |
| HY-158054 | Antifungal agent 95 | 2883716-51-4 | Reference compound |
| HY-158056 | URAT1/GLUT9-IN-1 | 2883011-18-3 | Reference compound |
| HY-158057 | A2AR/A2BR antagonist 1 | | Reference compound |
| HY-158058 | WYJ-2 | 3029403-05-9 | Reference compound |
| HY-158059 | DS-1-38 | | Reference compound |
| HY-15805A | cis-KIN-8194 | 330792-60-4 | Reference compound |
| HY-158060 | MC2646 | | Reference compound |
| HY-158061 | Topoisomerase II inhibitor 20 | | Reference compound |
| HY-158061A | Topoisomerase II inhibitor 20 (TFA) | | Reference compound |
| HY-158062 | LC-1-40 | | Reference compound |
| HY-158064 | BTK-IN-36 | 2502301-31-5 | Reference compound |
| HY-158065 | Azido-mono-amide-DOTA-tris(t-Bu ester) | 1402795-92-9 | Biochemical Assay Reagents |
| HY-158066 | p-NH2-Bn-NOTA (hydrochloride hydrate) | | Biochemical Assay Reagents |
| HY-158067 | Deferoxamine-DBCO | 2359695-48-8 | Biochemical Assay Reagents |
| HY-158068 | Maleimido-mono-amide-DTPA (TFA) | | Biochemical Assay Reagents |
| HY-158069 | p-NH₂-Bn-DTPA-penta (t-Bu ester) | 205986-41-0 | Biochemical Assay Reagents |
| HY-158070 | Diamsar (hydrochloride) | 139265-92-2 | Biochemical Assay Reagents |
| HY-158071 | p-SCN-Bn-HEHA (hydrochloride) | | Biochemical Assay Reagents |
| HY-158072 | DOTAM-NHS-ester | 2236057-47-7 | Biochemical Assay Reagents |
| HY-158073 | ML2006a4 | 2943213-62-3 | Reference compound |
| HY-158075 | DNMT/HDAC-IN-1 | 2095619-17-1 | Reference compound |
| HY-158076 | S2/IAPinh | | Reference compound |
| HY-158077 | (R)-tetraMe-Tetraxetan | 148408-89-3 | Biochemical Assay Reagents |
| HY-158078 | Carbonic anhydrase inhibitor 21 | | Reference compound |
| HY-158080 | 2-Keto-L-gulonic acid | 526-98-7 | Biochemical Assay Reagents |
| HY-158082 | TRITC-dextran, MW 4000 | | Biochemical Assay Reagents |
| HY-158082A | TRITC-dextran, MW 20000 | | Biochemical Assay Reagents |
| HY-158082B | TRITC-dextran, MW 40000 | | Biochemical Assay Reagents |
| HY-158082C | TRITC-dextran, MW 70000 | | Biochemical Assay Reagents |
| HY-158082D | TRITC-dextran, MW 150000 | | Biochemical Assay Reagents |
| HY-158082E | TRITC-dextran, MW 500000 | | Biochemical Assay Reagents |
| HY-158082H | TRITC-dextran, MW 2000000 | | Biochemical Assay Reagents |
| HY-158084S | N-Nonanoylglycine-d2 | 3008541-78-1 | Isotope-Labeled Compounds |
| HY-158085S | N-Undecanoylglycine-d2 | 3008541-79-2 | Isotope-Labeled Compounds |
| HY-158086S | N-(1-Oxotridecyl)glycine-d2 | 3008541-80-5 | Isotope-Labeled Compounds |
| HY-158087S | N-(1-Oxopentadecyl)glycine-d2 | 3008541-82-7 | Isotope-Labeled Compounds |
| HY-158088S | N-(1-Oxoheptadecyl)glycine-d2 | 3008541-84-9 | Isotope-Labeled Compounds |
| HY-158089 | PLGA-COOH (MW 80000) (LA/GA 50:50) | | Oligonucleotides |
| HY-158090 | Triptolide palmitate | 2126920-51-0 | Reference compound |
| HY-158092 | ChEs/MAOs-IN-2 | 693268-77-8 | Reference compound |
| HY-158093 | NIC-12 | 2409826-23-7 | Reference compound |
| HY-158097 | IAV-IN-2 | | Reference compound |
| HY-158098 | FGFR1 inhibitor-11 | 2157482-40-9 | Reference compound |
| HY-158099 | Biotin-Cel | 2609685-71-2 | Reference compound |
| HY-158100 | SYD5115 | | Reference compound |
| HY-158101 | BMS-986365 | 2446928-30-7 | Reference compound |
| HY-158102 | ORIC-944 | 2369769-29-7 | Reference compound |
| HY-158102A | ORIC-944 (TFA) | | Reference compound |
| HY-158104 | LPPM-8 | | Reference compound |
| HY-158105 | ARV-393 | 2851885-95-3 | Reference compound |
| HY-158106 | AZD8421 | 3047321-53-6 | Reference compound |
| HY-158107 | BBO-8520 | 2893809-51-1 | Reference compound |
| HY-158108 | anti-TNBC agent-6 | | Reference compound |
| HY-158109 | M3554 | | ADC Related |
| HY-15811 | XMD8-87 | 1234480-46-6 | Reference compound |
| HY-158110 | Phenylcapsaicin | 848127-67-3 | Reference compound |
| HY-158111 | NLRP3-IN-34 | 1392502-55-4 | Reference compound |
| HY-158112 | Herbicidal agent 3 | | Reference compound |
| HY-158113 | CBPD-409 | 3037549-86-0 | Reference compound |
| HY-158114 | Pentadecanoic acid chloride | 17746-08-6 | Natural Products |
| HY-158115 | NST-628 | 3002056-30-3 | Reference compound |
| HY-158116 | VVD-214 | 3026500-20-6 | Reference compound |
| HY-158117 | [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 | | Reference compound |
| HY-158118 | Lys(CO-C3-p-I-Ph)-OMe | 2088426-96-2 | Reference compound |
| HY-158119A | PSMA-trillium | 3036415-37-6 | Reference compound |
| HY-15812 | Aurora kinase-IN-5 | 1234481-08-3 | Reference compound |
| HY-158120 | LasR agonist 1 | | Reference compound |
| HY-158122 | Lys(CO-C3-p-I-Ph)-O-tBu | 2703051-80-1 | Reference compound |
| HY-158123 | PSMA binder-1 | 2170653-14-0 | Reference compound |
| HY-158124 | LasR antagonist 1 | 1421464-74-5 | Reference compound |
| HY-158125 | PSMA binder-2 | 2149567-00-8 | Reference compound |
| HY-158126 | G-quadruplex ligand 2 | | Reference compound |
| HY-158127 | FABP1-IN-1 | 3048021-44-6 | Reference compound |
| HY-158128 | MK-8527 | 1810869-23-8 | Reference compound |
| HY-15813 | FIIN-1 | 1256152-35-8 | Reference compound |
| HY-158130 | FKBP51-Hsp90-IN-1 | 433313-64-5 | Reference compound |
| HY-158131 | FKBP51-Hsp90-IN-2 | 601511-07-3 | Reference compound |
| HY-158135 | Val-Cit-PAB-DEA-COOH | 2270986-50-8 | ADC Related |
| HY-158137 | Val-Cit-PAB-DEA-Dxd | 2964543-53-9 | ADC Related |
| HY-158138 | TOPOI/PARP-1-IN-1 | 2948352-16-5 | Reference compound |
| HY-15814 | HG-7-85-01 | 1258391-13-7 | Reference compound |
| HY-158141 | BRD1401 | | Reference compound |
| HY-158142 | PROTAC TYK2 degrader-1 | 2770470-20-5 | Reference compound |
| HY-158143 | PRMT5-IN-34 | | Reference compound |
| HY-158144 | GLPG2737 | 2093974-63-9 | Reference compound |
| HY-158145 | DS55980254 | 2488609-43-2 | Reference compound |
| HY-158146 | sGC activator 1 | 2101645-33-2 | Reference compound |
| HY-158147 | PI3Kδ-IN-20 | | Reference compound |
| HY-158148 | CSF1R-IN-23 | 2935480-17-2 | Reference compound |
| HY-158149 | T-1-PMPA | 1323883-62-0 | Reference compound |
| HY-15815 | Bromosporine | 1619994-69-2 | Reference compound |
| HY-158150 | 20S Proteasome-IN-5 | | Reference compound |
| HY-158151 | p53 Activator 12 | 2746374-04-7 | Reference compound |
| HY-158152 | PROTAC CRBN ligand-2 | | Reference compound |
| HY-158153 | EGFR-IN-108 | | Reference compound |
| HY-158154 | EGFR-IN-110 | | Reference compound |
| HY-158155 | CVN293 | 2815296-08-1 | Reference compound |
| HY-158156 | NF-κB-IN-16 | | Reference compound |
| HY-158157 | ZL-28-6 | 2739807-18-0 | Reference compound |
| HY-158158 | CARM1-IN-5 | | Reference compound |
| HY-158159 | IL17A-IN-1 | | Reference compound |
| HY-15816 | Ulixertinib | 869886-67-9 | Reference compound |
| HY-158160 | LBA-3 | 2918263-09-7 | Reference compound |
| HY-158161 | SLC6A19-IN-1 | | Reference compound |
| HY-158162 | SIRT3 activator 1 | | Reference compound |
| HY-158163 | Herbicidal agent 4 | | Reference compound |
| HY-158166 | DNA-PK-IN-13 | 3036751-03-5 | Reference compound |
| HY-158167 | AhR agonist 5 | | Reference compound |
| HY-158168 | AhR agonist 6 | 3033281-96-5 | Reference compound |
| HY-158169 | AhR agonist 7 | 3033281-98-7 | Reference compound |
| HY-15816A | Ulixertinib (hydrochloride) | 1956366-10-1 | Reference compound |
| HY-158170 | CDK7-IN-28 | | Reference compound |
| HY-158171 | Cbl-b-IN-17 | | Reference compound |
| HY-158172 | Cbl-b-IN-18 | | Reference compound |
| HY-158173 | Cbl-b-IN-19 | | Reference compound |
| HY-158174 | Cbl-b-IN-20 | | Reference compound |
| HY-158175 | EGFR T790M/L858R-IN-4 | 3032760-34-9 | Reference compound |
| HY-158176 | EGFR T790M/L858R-IN-5 | 3032760-70-3 | Reference compound |
| HY-158177 | EGFR T790M/L858R-IN-6 | 3032760-71-4 | Reference compound |
| HY-158178 | EGFR T790M/L858R-IN-7 | 3032760-90-7 | Reference compound |
| HY-158179 | A3AR agonist 3 | 3032474-53-3 | Reference compound |
| HY-158180 | A3AR agonist 4 | 3032475-23-0 | Reference compound |
| HY-158181 | A3AR agonist 5 | 3032475-38-7 | Reference compound |
| HY-158183 | NMD670 | 2354321-33-6 | Reference compound |
| HY-158185 | Isocycloseram | 2061933-85-3 | Reference compound |
| HY-158186S | Bisoprolol-d6 (hemifumarate) | | Isotope-Labeled Compounds |
| HY-158187S | R-(+)-Cibenzoline-d4 | | Isotope-Labeled Compounds |
| HY-158189 | TPP-Ce6 | 3030629-73-0 | Reference compound |
| HY-158190 | Rose Bengal Chloramphenicol Agar | | Biochemical Assay Reagents |
| HY-158192S | N-Desmethyl diltiazem-d4 | 1217975-79-5 | Isotope-Labeled Compounds |
| HY-158193 | N-Decanoyl cyclopentylamide | 540796-75-6 | Reference compound |
| HY-158194 | α2C adrenoceptor agonist 1 | 928115-79-1 | Reference compound |
| HY-158195 | DPP23 | 1262887-77-3 | Reference compound |
| HY-158196 | PERK/eIF2α activator 1 | 1178583-17-9 | Reference compound |
| HY-158197 | RC-106 | 1346216-50-9 | Reference compound |
| HY-158198 | PRXS571 | 2396759-31-0 | Reference compound |
| HY-158199 | BCN-HS-PEG2-bis(PNP) | 2126749-95-7 | Reference compound |
| HY-158201 | ATF4-IN-1 | 2991057-76-0 | Reference compound |
| HY-158202 | ATF4-IN-2 | 2991057-60-2 | Reference compound |
| HY-158203 | BMP agonist 2 | 1438900-88-9 | Reference compound |
| HY-158204 | CNB-001 | 1019110-87-2 | Reference compound |
| HY-158205 | HPO-DAEE | 1895934-61-8 | Reference compound |
| HY-158207S | (+)-Nebivolol-d4 | 2747915-48-4 | Isotope-Labeled Compounds |
| HY-158208 | PMMB276 | 2209036-28-0 | Reference compound |
| HY-158209 | Block polyoxyethylene-polyoxypropylene | 106392-12-5 | Reference compound |
| HY-158210 | Wnt/β-catenin-IN-3 | 1809413-98-6 | Reference compound |
| HY-158212 | Dyrk1A-IN-8 | 101578-13-6 | Reference compound |
| HY-158217 | GelMA, 30% methacrylation, Green Fluorescent | | Biochemical Assay Reagents |
| HY-158217A | GelMA, 60% methacrylation, Green Fluorescent | | Biochemical Assay Reagents |
| HY-158217B | GelMA, 90% methacrylation, Green Fluorescent | | Biochemical Assay Reagents |
| HY-158218 | GelMA, 30% methacrylation, Red Fluorescent | | Biochemical Assay Reagents |
| HY-158218A | GelMA, 60% methacrylation, red fluorescent | | Biochemical Assay Reagents |
| HY-158218B | GelMA, 90% methacrylation, red fluorescent | | Biochemical Assay Reagents |
| HY-158219 | Gelatin Methacryloyl, 30% methacrylation, blue fluorescent | | Biochemical Assay Reagents |
| HY-158219A | Gelatin Methacryloyl, 60% methacrylation, blue fluorescent | | Biochemical Assay Reagents |
| HY-158219B | Gelatin Methacryloyl, 90% methacrylation, blue fluorescent | | Biochemical Assay Reagents |
| HY-15822 | MF-438 | 921605-87-0 | Reference compound |
| HY-158220 | Hyaluronic acid Methacryloyl (MW 400 kDa) | | Biochemical Assay Reagents |
| HY-158220A | Hyaluronic acid Methacryloyl (MW 150 kDa) | | Biochemical Assay Reagents |
| HY-158220B | Hyaluronic acid methacryloyl (MW 10000) | | Biochemical Assay Reagents |
| HY-158220C | Hyaluronic acid methacryloyl (MW 50000) | | Biochemical Assay Reagents |
| HY-158221 | Chondroitin Sulfate Methacryloyl | | Biochemical Assay Reagents |
| HY-158222 | Alginate Methacryloyl (MW 50000) | | Biochemical Assay Reagents |
| HY-158222A | Alginate Methacryloyl (MW 300000) | | Biochemical Assay Reagents |
| HY-158223 | Carboxymethyl chitosan Methacryloyl | | Biochemical Assay Reagents |
| HY-158224 | Silk Fibroin Methacryloyl | | Biochemical Assay Reagents |
| HY-158225 | Methacrylated Type I collagen | | Biochemical Assay Reagents |
| HY-158226 | Elastin Methacrylated | | Biochemical Assay Reagents |
| HY-158227 | Dextran Methacryloyl (MW 200000) | | Biochemical Assay Reagents |
| HY-158227A | Dextran Methacryloyl (MW 500000) | | Biochemical Assay Reagents |
| HY-158228 | Poly-L-lysine Methacryloyl | | Biochemical Assay Reagents |
| HY-158229 | Heparin Methacrylate | | Biochemical Assay Reagents |
| HY-15823 | CAY10566 | 944808-88-2 | Reference compound |
| HY-158230 | SN-398 | 124623-00-3 | Reference compound |
| HY-158231 | Polyether F127 Diacrylate | | Biochemical Assay Reagents |
| HY-158233 | Apoptotic agent-4 | | Reference compound |
| HY-158235 | Tyrosinase-IN-27 | 2966803-96-1 | Reference compound |
| HY-158236 | ORL1 antagonist 2 | 1169982-72-2 | Reference compound |
| HY-158237 | PDE10A-IN-3 | 1006889-85-5 | Reference compound |
| HY-158238S | Silodosin β-D-glucuronide-d4 | 2851016-14-1 | Isotope-Labeled Compounds |
| HY-158239 | MS181 | | Reference compound |
| HY-158241 | GmhA-IN-1 | 1606387-54-5 | Reference compound |
| HY-158242 | Antibacterial agent 212 | | Reference compound |
| HY-158243 | Fallypride precursor | 166173-74-6 | Reference compound |
| HY-158245 | Herbicide safener-2 | 3027836-84-3 | Reference compound |
| HY-158246 | QPP-I-6 | 2864442-05-5 | Reference compound |
| HY-158248 | FGFR4-IN-19 | | Reference compound |
| HY-15825 | IWP L6 | 1427782-89-5 | Reference compound |
| HY-158251 | BIBD-300 | 3030758-22-3 | Reference compound |
| HY-158252S | Tiagabine-d5 (hydrochloride) | 1253297-72-1 | Isotope-Labeled Compounds |
| HY-158253 | Lectin from Helix pomatia, biotin conjugate | | Biochemical Assay Reagents |
| HY-158254S | (Rac)-Trandolaprilate-d5 | | Isotope-Labeled Compounds |
| HY-158255 | mPEG-PLGA (2000-80000) (LA/GA 50:50) | | Reference compound |
| HY-158255A | mPEG-PLGA (22500-26500) | 743423-15-6 | Reference compound |
| HY-158256 | Luciferase-IN-3 | 690987-97-4 | Dye Reagents |
| HY-158257 | Firefly luciferase-IN-4 | 370587-13-6 | Dye Reagents |
| HY-158258 | Antiviral agent 55 | 371137-60-9 | Reference compound |
| HY-15826 | SGC-CBP30 | 1613695-14-9 | Reference compound |
| HY-158261 | AChE-IN-63 | 876685-78-8 | Reference compound |
| HY-158262 | Bradykinin B1 receptor antagonist 1 | 578727-81-8 | Reference compound |
| HY-158264 | SNRI-IN-1 | 887766-95-2 | Reference compound |
| HY-158265 | FLT3D835Y/F691L-IN-1 | | Reference compound |
| HY-158266 | DOTA-PSMA-EB-01 | | Peptides |
| HY-158267 | Enrofloxacin/OVA | | Biochemical Assay Reagents |
| HY-158268 | 4-Hydroxynonenal/BSA | | Biochemical Assay Reagents |
| HY-158269 | T4-BSA | | Biochemical Assay Reagents |
| HY-15827 | NSC 405020 | 7497-07-6 | Reference compound |
| HY-158270 | Ethambutol-KLH | | Biochemical Assay Reagents |
| HY-158272 | Penicillin/OVA | | Biochemical Assay Reagents |
| HY-158273 | 2,4-D/BSA | | Biochemical Assay Reagents |
| HY-158274 | Gibberellins/BSA | | Biochemical Assay Reagents |
| HY-158275 | Rifampin/BSA | | Biochemical Assay Reagents |
| HY-158276 | Rifampin/KLH | | Biochemical Assay Reagents |
| HY-158277 | Streptomycin/BSA | | Biochemical Assay Reagents |
| HY-158278 | Aflatoxin B1/BSA | | Biochemical Assay Reagents |
| HY-158279 | Gentamicin/OVA | | Biochemical Assay Reagents |
| HY-15828 | Onvansertib | 1034616-18-6 | Reference compound |
| HY-158280 | Streptomycin/KLH | | Biochemical Assay Reagents |
| HY-158281 | Aflatoxin B1/KLH | | Biochemical Assay Reagents |
| HY-158282 | Pyrazinamide-KLH | | Biochemical Assay Reagents |
| HY-158283 | Ethambutol-BSA | | Biochemical Assay Reagents |
| HY-158284 | Penicillin G/BSA | | Biochemical Assay Reagents |
| HY-158285 | 25-OH Vitamin D3/BSA | | Biochemical Assay Reagents |
| HY-158286 | Streptomycin/OVA | | Biochemical Assay Reagents |
| HY-158287 | 2,4-D/KLH | | Biochemical Assay Reagents |
| HY-158288 | Pyrazinamide-BSA | | Biochemical Assay Reagents |
| HY-158289 | Isoniazid-KLH | | Biochemical Assay Reagents |
| HY-158290 | Natrexone/BSA | | Biochemical Assay Reagents |
| HY-158291 | Periplogenin/KLH | | Biochemical Assay Reagents |
| HY-158292 | Digoxin-OVA | | Biochemical Assay Reagents |
| HY-158293 | Toosendanin/OVA | | Biochemical Assay Reagents |
| HY-158294 | Toosendanin/BSA | | Biochemical Assay Reagents |
| HY-158295 | IAA/BSA | | Biochemical Assay Reagents |
| HY-158296 | Tetracycline/OVA | | Biochemical Assay Reagents |
| HY-158297 | Histamine/OVA | | Biochemical Assay Reagents |
| HY-158298 | Penicillin/BSA | | Biochemical Assay Reagents |
| HY-158299 | Periplogenin/BSA | | Biochemical Assay Reagents |
| HY-15830 | 25,26-Dihydroxyvitamin D3 | 29261-12-9 | Natural Products |
| HY-158300 | HCY/BSA | | Biochemical Assay Reagents |
| HY-158301 | MY-1B | 2929308-79-0 | Reference compound |
| HY-158302 | Glutor | 2561471-22-3 | Reference compound |
| HY-158303 | Chk2-IN-2 | 2984543-29-3 | Reference compound |
| HY-158304 | Rac1-IN-4 | 2924486-45-1 | Reference compound |
| HY-158305 | SM51a | 2764770-62-7 | Reference compound |
| HY-158306 | SM45a | 2764770-56-9 | Reference compound |
| HY-158307 | Z-Arg-Arg-βNA (acetate) | 2237216-27-0 | Peptides |
| HY-158308 | HDAC6-IN-41 | | Reference compound |
| HY-158309 | hOAT-IN-1 | 3057092-65-3 | Reference compound |
| HY-15831 | L-838417-d9 | 1213669-91-0 | Isotope-Labeled Compounds |
| HY-158310 | SOS1/EGFR-IN-1 | 2956724-20-0 | Reference compound |
| HY-158311 | Anti-osteoporosis agent-8 | | Reference compound |
| HY-158312 | UH15-38 | 2540881-21-6 | Reference compound |
| HY-158315 | NZ-97 | | Reference compound |
| HY-158316 | BTL-MK | 2758569-43-4 | Reference compound |
| HY-158317 | SFB-AMD3465 | 2416231-90-6 | Reference compound |
| HY-158318 | NUDT5/14 antagonist 1 | | Reference compound |
| HY-158319 | Mutant IDH1/NAMPT-IN-1 | 3040122-14-0 | Reference compound |
| HY-15832 | GSK 2830371 | 1404456-53-6 | Reference compound |
| HY-158320 | T3SS-IN-5 | | Reference compound |
| HY-158321 | SDH-IN-15 | | Reference compound |
| HY-158322 | nsp12-IN-1 | | Reference compound |
| HY-158323 | HGPRT/TBrHGPRT1-IN-1 | | Reference compound |
| HY-158325 | PROTAC FLT-3 degrader 4 | 2956722-48-6 | Reference compound |
| HY-158326 | FAP-IN-4 | | Reference compound |
| HY-158327 | Insecticidal agent 9 | | Reference compound |
| HY-158328A | CA IX/VEGFR-2-IN-2 | | Reference compound |
| HY-158329 | Alloc-DOX | 561022-65-9 | Reference compound |
| HY-15832A | (R)-GSK 2830371 | 2743427-27-0 | Reference compound |
| HY-15833 | Chlorthalidone | 77-36-1 | Reference compound |
| HY-158331 | Gal-ARV-771 | | Reference compound |
| HY-158332 | Sulotroban | 72131-33-0 | Reference compound |
| HY-158333 | Tasuldine | 88579-39-9 | Reference compound |
| HY-158334 | NDs-IN-1 | 3033806-97-9 | Reference compound |
| HY-158335 | DXR-IN-1 | | Reference compound |
| HY-158336 | E/Z-FETPY | 3056250-97-3 | Reference compound |
| HY-158337 | Nesosteine | 84210-62-8 | Reference compound |
| HY-158338 | ABHD antagonist 1 | 3034510-10-3 | Reference compound |
| HY-158339 | ABHD antagonist 2 | 3034510-43-2 | Reference compound |
| HY-15833R | Chlorthalidone (Standard) | 77-36-1 | Reference Standards |
| HY-15833S | Chlorthalidone-d4 | 1794941-44-8 | Isotope-Labeled Compounds |
| HY-158340 | TYK2 ligand 1 | 2770471-05-9 | Reference compound |
| HY-158341 | IOX5 | | Reference compound |
| HY-158342 | PROTAC TEAD degrader-1 | | Reference compound |
| HY-158343 | Thalidomide-NH-PEG2-C2-CH2 | 2064175-30-8 | Reference compound |
| HY-158345 | PROTAC VHL-type degrader-1 | 2821804-13-9 | Reference compound |
| HY-158346 | Polθ-IN-3 | 2922287-81-6 | Reference compound |
| HY-158347 | SARS-CoV-2 Mpro-IN-15 | | Reference compound |
| HY-158348 | m-PEG8-Lys(Mal)-Val-Ala-PAB-Ph-CO-Dazostinag | 2553413-13-9 | Reference compound |
| HY-158349 | Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag | 2553413-19-5 | ADC Related |
| HY-15834A | Eprosartan (mesylate) | 144143-96-4 | Reference compound |
| HY-15834AR | Eprosartan (mesylate) (Standard) | 144143-96-4 | Reference Standards |
| HY-15835 | CUDC-427 | 1446182-94-0 | Reference compound |
| HY-158351 | Mal-Val-Ala-PAB-NMe-CH2CH2-O-CO-Dazostinag | 2553412-83-0 | ADC Related |
| HY-158359 | 5′-XDP (sodium) | | Reference compound |
| HY-15836 | BAY 87-2243 | 1227158-85-1 | Reference compound |
| HY-158361 | Malt extract | | Biochemical Assay Reagents |
| HY-158362A | Monoglyceride lipase, Bacillus sp. | 9040-75-9 | Enzyme |
| HY-158363 | CSF1R-IN-25 | 2070864-23-0 | Reference compound |
| HY-158364 | NMT-IN-3 | 3061506-36-0 | Reference compound |
| HY-158365 | LRRK2-IN-14 | 2942328-06-3 | Reference compound |
| HY-158368 | PRDX1-IN-2 | 2566976-43-8 | Reference compound |
| HY-158369 | CK2-IN-10 | 831207-32-0 | Reference compound |
| HY-15837 | SAR-260301 | 1260612-13-2 | Reference compound |
| HY-158370 | CK2-IN-11 | 2938991-22-9 | Reference compound |
| HY-158371 | HDAC/CK2-IN-1 | 2599838-15-8 | Reference compound |
| HY-158372 | hCA I-IN-3 | | Reference compound |
| HY-158373 | Anticancer agent 213 | | Reference compound |
| HY-158374 | BIO-8169 | 2792153-06-9 | Reference compound |
| HY-158375 | MBL-IN-4 | | Reference compound |
| HY-158376 | mGluR7-IN-1 | | Reference compound |
| HY-158377 | CDK8/19-IN-2 | 3024381-54-9 | Reference compound |
| HY-158378 | Trivalent hydroxyarsinothricn | | Reference compound |
| HY-158379 | Antiparasitic agent-22 | | Reference compound |
| HY-15838 | ID-8 | 147591-46-6 | Reference compound |
| HY-158380 | UH-NIP-16 | | Reference compound |
| HY-158381 | PROTAC PTP1B degrader 1 | | Reference compound |
| HY-158382 | NH2-C4-PEG4-C5-COOH | | Reference compound |
| HY-158383 | Pomalidomide-CO-C3-PEG4-C6-NH2 | | Reference compound |
| HY-158385 | 5-Azido-PEG4-SS-UTP (tristriethylamine) | | Oligonucleotides |
| HY-158386 | IRE1a-IN-1 | 3033375-01-5 | Reference compound |
| HY-158387 | Anticancer agent 214 | 2916404-95-8 | Reference compound |
| HY-158388 | Anticancer agent 215 | 2916404-93-6 | Reference compound |
| HY-158389 | Anticancer agent 216 | 2916406-02-3 | Reference compound |
| HY-15839 | UNC 669 | 1314241-44-5 | Reference compound |
| HY-158390 | Anticancer agent 217 | 2916406-04-5 | Reference compound |
| HY-158391 | Anticancer agent 218 | 2916406-46-5 | Reference compound |
| HY-158392 | Anticancer agent 219 | 2916407-63-9 | Reference compound |
| HY-158393 | IRE1a-IN-2 | 3033375-24-2 | Reference compound |
| HY-158394 | TEAD-IN-12 | 3034813-66-3 | Reference compound |
| HY-158395 | TEAD-IN-13 | 3034813-74-3 | Reference compound |
| HY-158396 | TEAD-IN-14 | | Reference compound |
| HY-158398 | STAT6-IN-4 | 3033742-14-9 | Reference compound |
| HY-158399 | STAT6-IN-5 | 3033742-22-9 | Reference compound |
| HY-15840 | YLF-466D | 1273323-67-3 | Reference compound |
| HY-158400 | TEAD ligand 1 | 2971850-47-0 | Reference compound |
| HY-158401 | Antibiofilm agent-7 | | Reference compound |
| HY-158402 | Anti-inflammatory agent 84 | | Reference compound |
| HY-158403 | METTL3-IN-7 | | Reference compound |
| HY-158404 | METTL3-IN-8 | 932512-38-4 | Reference compound |
| HY-158405 | PAV-104 | 2923674-83-1 | Reference compound |
| HY-158407 | Anticancer agent 220 | | Reference compound |
| HY-158408 | NZ-66 | 3062992-25-7 | Reference compound |
| HY-158409 | Pan-RAS-IN-2 | 3034673-92-9 | Reference compound |
| HY-15841 | CEP-37440 | 1391712-60-9 | Reference compound |
| HY-158410 | PSA-IN-1 | | Reference compound |
| HY-158412 | BT317 | 38485-94-8 | Reference compound |
| HY-158415 | ATPase-IN-4 | 1219577-48-6 | Reference compound |
| HY-158417 | KSI-6666 | 1807873-14-8 | Reference compound |
| HY-158419 | PB(OH)3 | 1854111-80-0 | Reference compound |
| HY-15842 | SF1670 | 345630-40-2 | Reference compound |
| HY-158420 | STL001 | 3047493-70-6 | Reference compound |
| HY-158421 | MS-L6 | 63498-32-8 | Reference compound |
| HY-158422 | SARS-CoV-2 Mpro-IN-16 | | Reference compound |
| HY-158423 | NPD8790 | 615281-26-0 | Reference compound |
| HY-158424 | LSN3353871 | 2565657-20-5 | Reference compound |
| HY-158425 | Antimicrobial agent-31 | | Reference compound |
| HY-158426 | 2-APQC | 500271-63-6 | Reference compound |
| HY-158429 | PROTAC CYP1B1 degrader-2 | 2836297-26-6 | Reference compound |
| HY-15843 | MIR96-IN-1 | 1311982-88-3 | Reference compound |
| HY-158430 | CYP1B1 ligand 2 | 2836297-58-4 | Reference compound |
| HY-158431 | (S,R,S)-AHPC-Me-8-bromooctanoic acid | 2638512-58-8 | Reference compound |
| HY-158432 | GT-653 | | Reference compound |
| HY-158433 | KDM5B ligand 2 | | Reference compound |
| HY-158434 | IRAK1-IN-1 | | Reference compound |
| HY-158435 | P-gp inhibitor 23 | | Reference compound |
| HY-158436 | Antitumor agent-155 | | Reference compound |
| HY-158438 | MNK1/2-IN-8 | 2430793-35-2 | Reference compound |
| HY-158439 | anti-TNBC agent-7 | | Reference compound |
| HY-15844 | AG-825 | 149092-50-2 | Reference compound |
| HY-158440 | SARS-CoV-2 Mpro-IN-17 | | Reference compound |
| HY-158441 | A2G2S1 glycan (G2S1), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158442 | A2G2 glycan (G2) | | Biochemical Assay Reagents |
| HY-158443 | A2G2S1 glycan (G2S1), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158444 | A2G2 glycan (G2), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158445 | A2G2 glycan (G2), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158446 | A2G2 glycan (G2), APTS labelled | | Biochemical Assay Reagents |
| HY-158447 | A2G2 glycan (G2), procainamide labelled | | Biochemical Assay Reagents |
| HY-158448 | FA2G2 glycan (G2F) | | Biochemical Assay Reagents |
| HY-158449 | FA2G2 glycan (G2F), 2-AA labelled | | Biochemical Assay Reagents |
| HY-15845 | STF-083010 | 307543-71-1 | Reference compound |
| HY-158450 | FA2G2 glycan (G2F), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158451 | FA2G2 glycan (G2F), APTS labelled | | Biochemical Assay Reagents |
| HY-158452 | A3G3 glycan (G3) | | Biochemical Assay Reagents |
| HY-158453 | FA2B glycan (G0B), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158454 | FA2B glycan (G0B), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158455 | FA2[3]BG1 & FA2[6]BG1 glycan (G1B), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158456 | FA2[3]BG1 & FA2[6]BG1 glycan (G1B), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158457 | A2[3]G1 N-glycan | | Biochemical Assay Reagents |
| HY-158458 | A2[3]G1F1(α-1-3) glycan | | Biochemical Assay Reagents |
| HY-158459 | A2G2F2 glycan | | Biochemical Assay Reagents |
| HY-15846 | CPI-203 | 1446144-04-2 | Reference compound |
| HY-158460 | Alpha-Gal | | Biochemical Assay Reagents |
| HY-158461 | Alpha-Gal standard, 2-AA labelled | | Biochemical Assay Reagents |
| HY-158462 | Alpha-Gal standard, 2-AB labelled | | Biochemical Assay Reagents |
| HY-158463 | A2G2S2-KVANKT glycopeptide | | Biochemical Assay Reagents |
| HY-158464 | Fetuin glycoprotein | | Biochemical Assay Reagents |
| HY-158465 | GPEP FA2-KVANKT glycopeptide | | Biochemical Assay Reagents |
| HY-158466 | Human IgG Glycoprotein | | Biochemical Assay Reagents |
| HY-158467 | Core 1 O-glycan (C1), 2AB labelled | | Biochemical Assay Reagents |
| HY-158468 | Sialylated Core 1 O-glycan (C1S(3)1), 2AB labelled | | Biochemical Assay Reagents |
| HY-158469 | Disialylated Core 1 O-glycan (C1S(3,6)2), 2-AB labelled | | Biochemical Assay Reagents |
| HY-15846A | (Rac)-CPI-203 | 202591-23-9 | Reference compound |
| HY-15847 | HS38 | 1030203-81-6 | Reference compound |
| HY-158470 | Disialylated Core 2 O-glycan (C2S(3,3)2), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158471 | Core 1 O-glycan (C1) | | Biochemical Assay Reagents |
| HY-158472 | Sialylated Core 1 O-glycan (C1S(3)1) | | Biochemical Assay Reagents |
| HY-158473 | FA2[3]G1 & FA2[6]G1 glycan (G1F) | | Biochemical Assay Reagents |
| HY-158474 | A2G2S1 glycan (G2S1), APTS labelled | | Biochemical Assay Reagents |
| HY-158475 | A2G2S1 glycan (G2S1) | | Biochemical Assay Reagents |
| HY-158476 | FA2G2S1 glycan (G2FS1), procainamide labelled | | Biochemical Assay Reagents |
| HY-158477 | FA2G2S1 glycan (G2FS1) | | Biochemical Assay Reagents |
| HY-158478 | FA2[3]G1 & FA2[6]G1 glycan (G1F), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158479 | FA2[3]G1 & FA2[6]G1 glycan (G1F), APTS labelled | | Biochemical Assay Reagents |
| HY-15848 | AdipoRon | 924416-43-3 | Reference compound |
| HY-158480 | FA2[3]G1 & FA2[6]G1 glycan (G1F), procainamide labelled | | Biochemical Assay Reagents |
| HY-158481 | FA2[3]G1 & FA2[6]G1 glycan (G1F), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158482 | M3 glycan (Man3) | | Biochemical Assay Reagents |
| HY-158483 | M3 glycan (Man3), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158484 | M3 glycan (Man3), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158485 | M5 glycan (Man5) | | Biochemical Assay Reagents |
| HY-158486 | FA2G2S1 glycan (G2FS1), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158487 | A3G3 glycan (G3), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158488 | A3G3 glycan (G3), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158489 | A3G3 glycan (G3), procainamide labelled | | Biochemical Assay Reagents |
| HY-15849 | LP-533401 | 945976-43-2 | Reference compound |
| HY-158490 | A4G4 glycan | | Biochemical Assay Reagents |
| HY-158491 | A4G4 glycan, 2-AA labelled | | Biochemical Assay Reagents |
| HY-158492 | A4G4 glycan, 2-AB labelled | | Biochemical Assay Reagents |
| HY-158493 | A2 glycan (G0), procainamide labelled | | Biochemical Assay Reagents |
| HY-158494 | A2 glycan (G0) | | Biochemical Assay Reagents |
| HY-158495 | A2 glycan (G0), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158496 | A2 glycan (G0), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158497 | A2 glycan (G0), APTS labelled | | Biochemical Assay Reagents |
| HY-158498 | FA2 glycan (G0F) | | Biochemical Assay Reagents |
| HY-158499 | FA2 glycan (G0F), 2-AA labelled | | Biochemical Assay Reagents |
| HY-15849A | LP-533401 hydrochloride | 1040526-12-2 | Reference compound |
| HY-158500 | FA2 glycan (G0F), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158501 | M5 glycan (Man5), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158502 | FA2G2S1 glycan (G2FS1), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158503 | M5 glycan (Man5), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158504 | FA2G2S1 glycan (G2FS1), APTS labelled | | Biochemical Assay Reagents |
| HY-158505 | M5 glycan (Man5), APTS labelled | | Biochemical Assay Reagents |
| HY-158506 | A2G2S2 glycan (G2S2) | | Biochemical Assay Reagents |
| HY-158507 | M5 glycan (Man5), procainamide labelled | | Biochemical Assay Reagents |
| HY-158508 | A2G2S2 glycan (G2S2), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158509 | M6 glycan (Man6) | | Biochemical Assay Reagents |
| HY-15851 | Revefenacin | 864750-70-9 | Reference compound |
| HY-158510 | A2G2S2 glycan (G2S2), APTS labelled | | Biochemical Assay Reagents |
| HY-158511 | M6 glycan (Man6), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158512 | A2G2S2 glycan (G2S2), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158513 | FA2G2S2 glycan (G2FS2) | | Biochemical Assay Reagents |
| HY-158514 | M6 glycan (Man6), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158515 | FA2G2S2 glycan (G2FS2), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158516 | M6 glycan (Man6), procainamide labelled | | Biochemical Assay Reagents |
| HY-158517 | FA2G2S2 glycan (G2FS2), APTS labelled | | Biochemical Assay Reagents |
| HY-158518 | FA2G2S2 glycan (G2FS2), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158519 | M7 glycan (Man7) | | Biochemical Assay Reagents |
| HY-15851R | Revefenacin (Standard) | 864750-70-9 | Reference Standards |
| HY-15851S1 | Revefenacin-d9 | | Isotope-Labeled Compounds |
| HY-15851S2 | Revefenacin-d3 | | Isotope-Labeled Compounds |
| HY-15851S3 | Revefenacin-d4 | | Isotope-Labeled Compounds |
| HY-15852 | THRX-195518 | 909800-36-8 | Reference compound |
| HY-158520 | A2[3]G1 & A2[6]G1 glycan (G1), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158521 | M7 glycan (Man7), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158522 | A2[3]G1 & A2[6]G1 glycan (G1), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158523 | A2[3]G1 & A2[6]G1 glycan (G1) | | Biochemical Assay Reagents |
| HY-158524 | M7 glycan (Man7), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158525 | A3G3S3 glycan | | Biochemical Assay Reagents |
| HY-158526 | M7 glycan (Man7), procainamide labelled | | Biochemical Assay Reagents |
| HY-158527 | FA2 glycan (G0F), APTS labelled | | Biochemical Assay Reagents |
| HY-158528 | A3 glycan | | Biochemical Assay Reagents |
| HY-158529 | A3 glycan, 2-AA labelled | | Biochemical Assay Reagents |
| HY-15853 | MK-7246 | 1218918-62-7 | Reference compound |
| HY-158530 | A3 glycan, 2-AB labelled | | Biochemical Assay Reagents |
| HY-158531 | A3 glycan, procainamide labelled | | Biochemical Assay Reagents |
| HY-158532 | A4 glycan | | Biochemical Assay Reagents |
| HY-158533 | A3G3S3 glycan, 2-AA labelled | | Biochemical Assay Reagents |
| HY-158534 | M8 glycan (Man8) | | Biochemical Assay Reagents |
| HY-158535 | A3G3S3 glycan, 2-AB labelled | | Biochemical Assay Reagents |
| HY-158536 | M8 glycan (Man8), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158537 | A3G3S3 glycan, procainamide labelled | | Biochemical Assay Reagents |
| HY-158538 | M8 glycan (Man8), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158539 | M8 glycan (Man8), procainamide labelled | | Biochemical Assay Reagents |
| HY-15853A | MK-7246 S enantiomer | 2310135-53-4 | Reference compound |
| HY-158540 | A4 glycan, 2-AA labelled | | Biochemical Assay Reagents |
| HY-158541 | A4 glycan, 2-AB labelled | | Biochemical Assay Reagents |
| HY-158542 | A4 glycan, procainamide labelled | | Biochemical Assay Reagents |
| HY-158543 | M9 glycan (Man9) | | Biochemical Assay Reagents |
| HY-158544 | M9 glycan (Man9), 2-AA labelled | | Biochemical Assay Reagents |
| HY-158545 | M9 glycan (Man9), 2-AB labelled | | Biochemical Assay Reagents |
| HY-158546 | M9 glycan (Man9), procainamide labelled | | Biochemical Assay Reagents |
| HY-158547 | Etherolenic acid | 169217-39-4 | Natural Products |
| HY-15855 | Fosbretabulin (tromethamine) | 404886-32-4 | Reference compound |
| HY-158550 | 13(R),14(R)-epoxy Fluprostenol isopropyl ester | 2557329-36-7 | Reference compound |
| HY-158551 | PROTAC BcI-2/BcI-xI Degrader-1 | 3034200-49-9 | Reference compound |
| HY-158552 | 4-Ethylethcathinone hydrochloride | 2446466-62-0 | Reference compound |
| HY-158554 | 2-Ethylethcathinone (hydrochloride) | 2446466-59-5 | Reference compound |
| HY-158555 | 4-Ethyl-N,N-Dimethylcathinone (hydrochloride) | 2702382-98-5 | Reference compound |
| HY-158556 | 2,3-Dimethylethcathinone (hydrochloride) | 2705531-06-0 | Reference compound |
| HY-15856 | cis-(Z)-Flupentixol (dihydrochloride) | 51529-01-2 | Reference compound |
| HY-158569 | SAR114137 | 958853-11-7 | Reference compound |
| HY-15856A | Flupentixol | 2709-56-0 | Reference compound |
| HY-15856B | Flupentixol (dihydrochloride) | 2413-38-9 | Reference compound |
| HY-15856BR | Flupentixol (dihydrochloride) (Standard) | 2413-38-9 | Reference Standards |
| HY-15857 | CW-069 | 1594094-64-0 | Reference compound |
| HY-158570 | (2E)-Eicosenoic acid | 2127095-72-9 | Reference compound |
| HY-158571 | 17-Phenoxy trinor prostaglandin F2α | 2162157-41-5 | Reference compound |
| HY-158575 | all-cis-14,17,20,23,26,29-Dotriacontahexaenol | 2649103-52-4 | Natural Products |
| HY-15858 | AP-III-a4 | 1177827-73-4 | Reference compound |
| HY-158580 | 5-CF3-ddUTP (sodium) | 149208-43-5 | Biochemical Assay Reagents |
| HY-158583 | 13-POHSA | 2126038-97-7 | Reference compound |
| HY-158584 | 13-OAHSA | 1997286-67-5 | Reference compound |
| HY-158586 | 3'-Azido-ddATP sodium solution (100mM) | 1383937-03-8 | Biochemical Assay Reagents |
| HY-158587 | 3′-Azido-ddGTP (sodium) | | Biochemical Assay Reagents |
| HY-158588 | 3′-Azido-ddCTP (sodium) | | Biochemical Assay Reagents |
| HY-15858A | AP-III-a4 (hydrochloride) | 2070014-95-6 | Reference compound |
| HY-15859 | Atglistatin | 1469924-27-3 | Reference compound |
| HY-158594 | Docosahexaenoic acid alkyne | 2692622-57-2 | Reference compound |
| HY-158595 | 15(R),19(R)-Hydroxy prostaglandin F2α | 1224444-23-8 | Reference compound |
| HY-15860 | FLI-06 | 313967-18-9 | Reference compound |
| HY-15861 | Targapremir-210 | 1049722-30-6 | Reference compound |
| HY-158611 | 4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid methyl ester | 2055816-84-5 | Reference compound |
| HY-158612 | 3-Keto sphinganine (d8:0) (hydrochloride) | 1824382-78-6 | Reference compound |
| HY-158614 | 1-Palmitoyl-2-12-PAHSA-3-oleoyl-sn-glycerol | 2456348-64-2 | Reference compound |
| HY-158615 | STING18 | 2706536-26-5 | Reference compound |
| HY-158616 | 4-Methyl-7-(2-nitrophenoxy)-2H-chromen-2-one | 1286479-53-5 | Reference compound |
| HY-158617 | 4-Methyl-7-(4-nitrophenoxy)-2H-chromen-2-one | 1644277-00-8 | Reference compound |
| HY-158620 | Acyclo-5-Br-UTP (sodium) | | Biochemical Assay Reagents |
| HY-158621 | AcycloCTP (sodium) | | Biochemical Assay Reagents |
| HY-158622 | AcycloATP (sodium) | | Biochemical Assay Reagents |
| HY-158623 | (±)13(14)-DiHDPA | 1345275-24-2 | Natural Products |
| HY-158627 | JPC0323 Oleate | 1612785-68-8 | Reference compound |
| HY-158638 | NBD-FTY720 phenoxy (hydrochloride) | 2319882-09-0 | Dye Reagents |
| HY-158639 | 12-POHSA | 2042646-31-9 | Reference compound |
| HY-158649 | Fasnall (benzenesulfonate) | 2187367-11-7 | Reference compound |
| HY-15865 | FR901463 | 146478-74-2 | Reference compound |
| HY-158650 | 10-OAHSA | 2005487-34-1 | Reference compound |
| HY-158652 | (R)-CCG-1423 | 2309931-09-5 | Reference compound |
| HY-158655 | C17 3'-Sulfo galactosylceramide (d18:1/17:0) | 1071654-84-6 | Reference compound |
| HY-158656 | 3-Keto sphinganine (d6:0) (hydrochloride) | 1824544-52-6 | Reference compound |
| HY-158657 | 3-Keto-C12-dihydrosphingosine (hydrochloride) | 1823032-02-5 | Natural Products |
| HY-15866 | FR901465 | 146478-73-1 | Reference compound |
| HY-158661 | N-Methoxy mephedrone (hydrochloride) | 2703493-29-0 | Reference compound |
| HY-158662 | 3-Me-5-OMe-UTP (sodium) | | Biochemical Assay Reagents |
| HY-158663 | N,N-Dimethyl-ATP (sodium) | | Biochemical Assay Reagents |
| HY-158664 | 2-Amino-ATP (sodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-158665 | 3'-Deoxy-3'-amino-ATP (sodium) | | Biochemical Assay Reagents |
| HY-158666 | 3'-Amino-3'-dGTP (sodium) | | Biochemical Assay Reagents |
| HY-158667 | N4-Me-dCTP (sodium) | | Biochemical Assay Reagents |
| HY-158668 | 3'-Aminoacetyl-GTP (sodium) | | Biochemical Assay Reagents |
| HY-158669 | 3'-NH2-ddATP (sodium) | | Biochemical Assay Reagents |
| HY-158670 | 3'-NH2-ddGTP (sodium) | | Biochemical Assay Reagents |
| HY-158671 | 3'-NH2-ddCTP (sodium) | | Biochemical Assay Reagents |
| HY-158672 | 3′-O-Azidomethyl-dTTP (sodium) | | Biochemical Assay Reagents |
| HY-158673 | 3'-P-dATP (sodium) | | Biochemical Assay Reagents |
| HY-158674 | 3'-P-dGTP (sodium) | | Biochemical Assay Reagents |
| HY-158675 | 3'-P-dCTP (sodium) | | Biochemical Assay Reagents |
| HY-158676 | 3'-P-dTTP (sodium) | | Biochemical Assay Reagents |
| HY-158677 | BcI-2/BcI-xI ligand 1 | 3034202-16-6 | Reference compound |
| HY-158678 | E3 ligase Ligand 27 | 3034204-25-3 | Reference compound |
| HY-158679 | E3 Ligase Ligand-linker Conjugate 110 | | Reference compound |
| HY-15868 | HS-173 | 1276110-06-5 | Reference compound |
| HY-158680 | PARP1-IN-21 | 2855979-51-8 | Reference compound |
| HY-158681 | PARP1-IN-22 | 3033649-17-8 | Reference compound |
| HY-158682 | LpxC-IN-13 | 3033881-14-7 | Reference compound |
| HY-158683 | KIF18A-IN-11 | | Reference compound |
| HY-158684 | YX-02-030 | 3049076-98-1 | Reference compound |
| HY-158685 | RG7112D | 2360561-90-4 | Reference compound |
| HY-158687 | SARS-CoV-2 Mpro-IN-18 | | Reference compound |
| HY-158688 | PI3Kδ-IN-21 | | Reference compound |
| HY-15869 | Inauhzin | 309271-94-1 | Reference compound |
| HY-158690 | DDD00057570 | 338965-07-4 | Reference compound |
| HY-158692 | Tyk2-IN-18 | 3024860-29-2 | Reference compound |
| HY-158693 | WLB-87848 | 2839205-09-1 | Reference compound |
| HY-158694 | TLR7 agonist 20 | 3029695-00-6 | Reference compound |
| HY-158694A | TLR7 agonist 20 (hydrochloride) | | Reference compound |
| HY-158695 | Dual AChE-MAO B-IN-4 | | Reference compound |
| HY-158696 | BChE/MAO-B-IN-1 | | Reference compound |
| HY-158697 | α-Glucosidase-IN-65 | | Reference compound |
| HY-15870 | SR 11302 | 160162-42-5 | Reference compound |
| HY-158700 | DprE1-IN-10 | 1254782-81-4 | Reference compound |
| HY-158701 | KRAS G12D inhibitor 23 | | Reference compound |
| HY-158702 | 5-HTQ (chloride) | 40581-89-3 | Reference compound |
| HY-158703 | KRAS G12D inhibitor 24 | 3033701-29-7 | Reference compound |
| HY-158704 | 3'-NH2-ddTTP (sodium) | | Biochemical Assay Reagents |
| HY-158705 | SAINT-2 | 187587-97-9 | Reference compound |
| HY-158706 | SAE-IN-2 | | Reference compound |
| HY-158707 | dTTPαS (sodium) | 178603-75-3 | Biochemical Assay Reagents |
| HY-158709 | Cho-es-Lys | 1356250-80-0 | Biochemical Assay Reagents |
| HY-15870A | (6E)-SR 11302 | 1386982-70-2 | Reference compound |
| HY-15871 | GGTI298 (Trifluoroacetate) | 1217457-86-7 | Reference compound |
| HY-158711 | STING agonist-38 | 2850251-27-1 | Reference compound |
| HY-158712 | 3'-ONH2-dATP (sodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-158713 | 3'-ONH2-dGTP (sodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-158714 | 3'-ONH2-dCTP (sodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-158715 | 3'-ONH2-dTTP (sodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-158716 | 3'-O-Methylthiomethyl-dTTP (sodium) | | Biochemical Assay Reagents |
| HY-158717 | 3'-O-Methylthiomethyl-dATP (sodium) | | Biochemical Assay Reagents |
| HY-158718 | 3'-O-Methylthiomethyl-dGTP (sodium) | | Biochemical Assay Reagents |
| HY-158719 | 3′-O-Azidomethyl-dATP (sodium) solution (100mM) | | Biochemical Assay Reagents |
| HY-15872 | FTI-277 | 170006-73-2 | Reference compound |
| HY-158722 | Caerulein (acetate) | 2760881-68-1 | Peptides |
| HY-158724 | Calxgluk | 1820596-85-7 | Reference compound |
| HY-158725 | N-Octadecenoyl-(cis-9)-sulfatide | 1292769-40-4 | Natural Products |
| HY-158726 | Complex 3 | 2480150-28-3 | Reference compound |
| HY-158728 | 28-Deoxybetulin methyleneamine | 1025068-94-3 | Reference compound |
| HY-15872A | FTI-277 (hydrochloride) | 180977-34-8 | Reference compound |
| HY-15873 | FTI 276 | 170006-72-1 | Reference compound |
| HY-158730 | N-3-Hydroxybutyryl-L-homoserine lactone | 1325550-06-8 | Reference compound |
| HY-158732 | MAO-B-IN-33 | 2286257-25-6 | Reference compound |
| HY-158733 | HR68 | 2454582-64-8 | Reference compound |
| HY-158734 | Methyl γ-linolenyl fluorophosphonate | 1370451-91-4 | Reference compound |
| HY-158735 | Thioarginine (hydrobromide) | 2108196-23-0 | Reference compound |
| HY-158736 | Lyso-sulfatide (bovine) (ammonium) | 1246681-32-2 | Reference compound |
| HY-158738 | TCEP-biotin | 2227020-26-8 | Reference compound |
| HY-158739 | Rhodamine dithenoyl hydrazide | 2740257-94-5 | Dye Reagents |
| HY-15873A | FTI 276 (TFA) | 1217471-51-6 | Reference compound |
| HY-15874 | Fiboflapon | 936350-00-4 | Reference compound |
| HY-158740 | 1(R)-(Trifluoromethyl)oleyl alcohol | 2644636-20-2 | Reference compound |
| HY-158741 | IPG-2 AM | 1369302-24-8 | Dye Reagents |
| HY-158742 | SBB-Analogue (GL13) Biotin | 2171036-89-6 | Dye Reagents |
| HY-158743 | Indium (III) thiosemicarbazone 5b | 2345755-20-4 | Reference compound |
| HY-158746 | Fluo-2 AM | 1070771-36-6 | Dye Reagents |
| HY-158747 | CBDPA (CRM) | 2718149-62-1 | Reference compound |
| HY-158749 | 1-Oleoyl-2-lauroyl-3-palmitoyl-rac-glycerol | 1183882-29-2 | Natural Products |
| HY-15874A | Fiboflapon sodium | 1196070-26-4 | Reference compound |
| HY-158750 | 1-1(Z)-Octadecenyl-2-adrenoyl-sn-glycero-3-pe | 1390622-95-3 | Reference compound |
| HY-158751 | Jun9-72-2 | 2657659-42-0 | Reference compound |
| HY-158757 | KIF18A-IN-12 | 3033980-95-6 | Reference compound |
| HY-158758 | PROTAC IRAK4 degrader-10 | 3033829-95-4 | Reference compound |
| HY-158759 | Poly(vinyl acetate) | 9003-20-7 | Reference compound |
| HY-15876 | Clopidogrel thiolactone | 1147350-75-1 | Reference compound |
| HY-158760 | PROTAC IRAK4 degrader-11 | | Reference compound |
| HY-158761 | Polyaminopropyl biguanide | 133029-32-0 | Reference compound |
| HY-158762 | TK-642 | 2765183-10-4 | Reference compound |
| HY-158763 | MPI8 | 856242-63-2 | Reference compound |
| HY-158764 | PROTAC BET Degrader-12 | | Reference compound |
| HY-158765 | Leuco ethyl violet | 4865-00-3 | Reference compound |
| HY-158766 | 3-sucCA | 94159-47-4 | Reference compound |
| HY-158767 | Dehydro amlodipine (fumarate) | 2138811-33-1 | Reference compound |
| HY-158767R | Dehydro amlodipine (fumarate) (Standard) | 2138811-33-1 | Reference Standards |
| HY-158768 | Amino-PEG4-GGFG-Dxd | 2879227-88-8 | ADC Related |
| HY-15876R | Clopidogrel thiolactone (Standard) | 1147350-75-1 | Reference Standards |
| HY-15877 | BTB06584 | 219793-45-0 | Reference compound |
| HY-158771 | PRC1 ligand 1 | 2467965-59-7 | Reference compound |
| HY-158772 | m7G(5')ppp(5')(2'OMeA)pU (ammonium) | | Oligonucleotides |
| HY-158774 | TG2-179-1 | 1135023-19-6 | Reference compound |
| HY-158775 | Ferroptocide | 2505218-38-0 | Reference compound |
| HY-158776 | SLU-10482 | 2755451-45-5 | Reference compound |
| HY-158779 | Sulfane sulfur probe 4 | 1810731-98-6 | Dye Reagents |
| HY-15878 | LDC000067 | 1073485-20-7 | Reference compound |
| HY-158783 | SACLAC | 2248703-42-4 | Reference compound |
| HY-158784 | Arachidonoyl m-nitroaniline | 1175954-87-6 | Reference compound |
| HY-15879 | LB42708 | 226929-39-1 | Reference compound |
| HY-158790 | (R)-HTS-3 | 2771208-83-2 | Reference compound |
| HY-158791 | Enpp-1-IN-21 | 2803505-78-2 | Reference compound |
| HY-158792 | GK241 | 1899930-93-8 | Reference compound |
| HY-158793 | Lentztrehalose A | 1609356-99-1 | Reference compound |
| HY-158794 | Lentztrehalose B | 1808096-67-4 | Reference compound |
| HY-158795 | Fz25 | 2762498-70-2 | Reference compound |
| HY-158796 | L202 | 2170488-92-1 | Oligonucleotides |
| HY-158799 | Poly(ADP-ribose) Polymer/pADPr | | Reference compound |
| HY-15880 | CCT007093 | 176957-55-4 | Reference compound |
| HY-158800 | 1-NBD-decanoyl-2-decanoyl-sn-glycerol | 2309189-98-6 | Reference compound |
| HY-158803 | C6 Biotin glucosylceramide (d18:1/6:0) | 2692623-22-4 | Natural Products |
| HY-158805 | 4-Methoxy-α-pyrrolidinopropiophenone (tosylate) | 2748561-60-4 | Reference compound |
| HY-158806 | 3,4-DHMA (TFA) | 2704135-58-8 | Reference compound |
| HY-15881 | TCS JNK 5a | 312917-14-9 | Reference compound |
| HY-158812 | Eicosapentaenoyl-L-carnitine (chloride) | 2133456-02-5 | Reference compound |
| HY-158814 | 2-(2-Chlorophenyl)-1-(1H-indol-3-yl)ethanone | 1096914-22-5 | Reference compound |
| HY-158815 | SM-102 N-Oxide | 2824195-50-6 | Reference compound |
| HY-158818 | DXR-IN-2 | 2260608-07-7 | Reference compound |
| HY-158819 | m7(3'OMeG)(5')ppp(5')m6(2'OMeA)pG (trisodium) | 2956651-00-4 | Oligonucleotides |
| HY-15882 | GNE-783 | 1200127-66-7 | Reference compound |
| HY-158820 | Cosdosiran | 1834560-88-1 | Oligonucleotides |
| HY-158820A | Cosdosiran (sodium) | | Oligonucleotides |
| HY-158821 | ISTH0036 | 2179222-27-4 | Oligonucleotides |
| HY-158821A | ISTH0036 (sodium) | | Oligonucleotides |
| HY-158822 | IMT504 | 1075758-80-3 | Oligonucleotides |
| HY-158822A | IMT504 (sodium) | | Oligonucleotides |
| HY-158823 | GTI-2501 | 236391-67-6 | Oligonucleotides |
| HY-158823A | GTI-2501 (sodium) | | Oligonucleotides |
| HY-158824 | Asvasiran | 870094-26-1 | Oligonucleotides |
| HY-158824A | Asvasiran (sodium) | 1386946-83-3 | Oligonucleotides |
| HY-158825 | Cepadacursen (sodium) | 2252375-14-5 | Oligonucleotides |
| HY-158826 | EZN-2968 | 1098309-50-2 | Oligonucleotides |
| HY-158826A | EZN-2968 (sodium) | | Oligonucleotides |
| HY-158827 | AZD8233 | 2604215-74-7 | Oligonucleotides |
| HY-158827A | AZD8233 (sodium) | | Oligonucleotides |
| HY-158828 | SSO111 (sodium) | | Oligonucleotides |
| HY-158829 | SSOe26 (sodium) | | Oligonucleotides |
| HY-15883 | GNE-900 | 1200126-26-6 | Reference compound |
| HY-158830 | MDM4-targeting ASO (sodium) | | Oligonucleotides |
| HY-158836 | NAPIE | 2748289-69-0 | Reference compound |
| HY-158839 | 4-Ethyl pentedrone (hydrochloride) | 2748592-71-2 | Reference compound |
| HY-15884 | GSK2838232 | 1443460-91-0 | Reference compound |
| HY-158843 | 15(S)-Hete-biotin | 1217461-45-4 | Natural Products |
| HY-158845 | 8Br-HA | 2937864-01-0 | Reference compound |
| HY-15885 | LY2119620 | 886047-22-9 | Reference compound |
| HY-158857 | ortho-CBNQ | 2565592-49-4 | Reference compound |
| HY-15886 | Mdivi-1 | 338967-87-6 | Reference compound |
| HY-158861 | C3-K2-E14 | 2933215-86-0 | Biochemical Assay Reagents |
| HY-158867 | DOSPA (hydrochlorid) | 913194-16-8 | Oligonucleotides |
| HY-15887 | MG 149 | 1243583-85-8 | Reference compound |
| HY-158873 | N,N-Dihexyl sphingosine (d18:1/6:0/6:0) | 2377379-53-6 | Reference compound |
| HY-15888 | PTC-209 | 315704-66-6 | Reference compound |
| HY-158881 | DDG | 2350271-86-0 | Reference compound |
| HY-158882 | FLAC6 | 2820046-26-0 | Reference compound |
| HY-158883 | ODG | 2350271-85-9 | Reference compound |
| HY-158884 | CALXCHOL (sodium) | 2121543-66-4 | Reference compound |
| HY-15888A | PTC-209 (hydrobromide) | 1217022-63-3 | Reference compound |
| HY-15889 | AMG 925 | 1401033-86-0 | Reference compound |
| HY-158899 | 3,4-Ethylenedioxy U-51754 (hydrochloride) | 2748623-92-7 | Reference compound |
| HY-15889A | AMG 925 (HCl) | 1401034-19-2 | Reference compound |
| HY-15890 | C-7280948 | 587850-67-7 | Reference compound |
| HY-158905 | MTDB-Alkyne | 2923694-73-7 | Reference compound |
| HY-15891 | GW311616 | 198062-54-3 | Reference compound |
| HY-158912 | 1-Oleoyl-3-arachidoyl-rac-glycerol | 1427086-85-8 | Reference compound |
| HY-158913 | 4-Methylthio-N-benzylcathinone (hydrochloride) | 2706488-88-0 | Reference compound |
| HY-158918 | 4-CF3-TPP-DC | 2661108-93-4 | Reference compound |
| HY-15891A | GW311616 (hydrochloride) | 197890-44-1 | Reference compound |
| HY-15892 | CK-636 | 442632-72-6 | Reference compound |
| HY-158925 | Conglobatin C1 | 2673270-37-4 | Natural Products |
| HY-158927 | 5-Chloro-2-thiothinone (hydrochloride) | 2903386-66-1 | Reference compound |
| HY-15893 | DMOG | 89464-63-1 | Reference compound |
| HY-158934 | (±)-CBCQ | 2415352-36-0 | Reference compound |
| HY-158935 | Dihydro K22 | 2926907-58-4 | Reference compound |
| HY-158936 | Lumula | 511229-72-4 | Reference compound |
| HY-158937 | 15(R)-15-Methyl prostaglandin F2α methyl ester | 35700-22-2 | Reference compound |
| HY-158938 | 11(Z),14(Z),17(Z)-Eicosatrienoic acid methyl ester | 62472-96-2 | Reference compound |
| HY-158939 | (5Z,11Z,15R)-15-Hydroxyeicosa-5,11-dien-13-ynoic acid | 339534-01-9 | Reference compound |
| HY-15894 | BQ-788 (sodium salt) | 156161-89-6 | Reference compound |
| HY-158940 | N-Glycine 3'-sulfo galactosylsphingosine | 2620491-81-6 | Reference compound |
| HY-158943 | 2-Fluoro QMPSB | 2707165-48-6 | Reference compound |
| HY-158944 | 1,2-Dipalmitoleoyl-3-11(Z)-octadecenoyl-rac-glycerol | 2692623-04-2 | Reference compound |
| HY-158945 | 1,3-Dipalmitoleoyl-2-11(Z)-octadecenoyl glycerol | 2348469-98-5 | Reference compound |
| HY-158946 | 1,2-Dielaidoyl-3-linoleoyl-rac-glycerol | 2692623-11-1 | Reference compound |
| HY-158947 | 1-1(Z)-Hexadecenyl-2-palmitoyl-sn-glycero-3-PE | 1199257-33-4 | Reference compound |
| HY-158947S | 1-1(Z)-Hexadecenyl-2-Palmitoyl-d9-sn-glycero-3-PE | 2738509-20-9 | Isotope-Labeled Compounds |
| HY-158948 | 1-Palmitoyl-2-11(Z)-octadecenoyl-3-butyroyl-rac-glycerol | 2692623-15-5 | Reference compound |
| HY-158949 | 1-Palmitoyl-2-11(Z)-octadecenoyl-3-oleoyl-rac-glycerol | 2692623-16-6 | Reference compound |
| HY-15894A | BQ-788 | 173326-37-9 | Reference compound |
| HY-15895 | Aprocitentan | 1103522-45-7 | Reference compound |
| HY-158952 | C24 (2'(R)-Hydroxy) dihydro ceramide (d18:0/24:0) | 164989-36-0 | Reference compound |
| HY-158957 | 1,3-Diheptadecanoyl-2-oleoyl glycerol | 869990-15-8 | Reference compound |
| HY-158958 | 1,2-Dilinoleoyl-3-γ-linolenoyl-rac-glycerol | 852369-68-7 | Reference compound |
| HY-158959 | 1,3-Diarachidonoyl-2-oleoyl glycerol | 869990-37-4 | Reference compound |
| HY-15895R | Aprocitentan (Standard) | 1103522-45-7 | Reference Standards |
| HY-15895S | Aprocitentan-d4 | | Isotope-Labeled Compounds |
| HY-158960 | 1,2-Dioleoyl-3-arachidonoyl-rac-glycerol | 91539-55-8 | Reference compound |
| HY-158961 | 1,3-Dielaidoyl-2-oleoyl glycerol | 946577-28-2 | Reference compound |
| HY-158964 | 1-Palmitoyl-2-oleoyl-3-linolenoyl-rac-glycerol | 78144-20-4 | Reference compound |
| HY-158967 | 3,4-Difluoro-N-desmethyl U-47700 (hydrochloride) | 2740551-86-2 | Reference compound |
| HY-158968 | MMs02943764 | 708287-29-0 | Reference compound |
| HY-15897 | LDN-212854 | 1432597-26-6 | Reference compound |
| HY-158970 | Caf1-IN-1 | 1807775-88-7 | Reference compound |
| HY-158973 | bCSE-IN-1 | | Reference compound |
| HY-158974 | YTHDC1-IN-1 | 2995344-53-9 | Reference compound |
| HY-158975 | VRK1/CK1-IN-1 | 3050772-20-5 | Reference compound |
| HY-158976 | Sodium lactate ringer's solution | | Biochemical Assay Reagents |
| HY-158977 | β-Lactamase-IN-9 | | Reference compound |
| HY-158978 | Multitarget AD inhibitor-2 | | Reference compound |
| HY-158979 | Nav1.8-IN-14 | 2417373-18-1 | Reference compound |
| HY-15898 | Y-320 | 288250-47-5 | Reference compound |
| HY-158980 | Antifungal agent 103 | | Reference compound |
| HY-158981 | Herbicide safener-3 | 3029112-55-5 | Reference compound |
| HY-158985 | Amino-PEG3-2G degrader-1 | 2267315-06-8 | Reference compound |
| HY-158985A | Amino-PEG3-2G degrader-1 (hydrochloride) | | Reference compound |
| HY-158987 | Adenosine phosphonobutyric, 2'(3'), 5'-diposphate | 1050202-63-5 | Reference compound |
| HY-15899 | Des(benzylpyridyl) Atazanavir | 1192224-24-0 | Reference compound |
| HY-158990 | GE1111 | 2883669-12-1 | Reference compound |
| HY-158991 | I1421 | | Reference compound |
| HY-158992S | SP-(Val-13C5,15N)-EKNQ-(Leu-13C6,15N)-TIDFINIVKDPVPHNEYKT (TFA) | | Isotope-Labeled Compounds |
| HY-158994S | MEGDSRGG-(Ala-13C3,15N)-GGEA-(Leu-13C6,15N)-DPESAASSLSGAS (TFA) | | Isotope-Labeled Compounds |
| HY-158995S | 3-Epiglycyrrhetinic acid-d2 | | Isotope-Labeled Compounds |
| HY-158995S1 | 3-Epiglycyrrhetinic acid-d3 | | Isotope-Labeled Compounds |
| HY-158998 | ALKBH1-IN-2 | | Reference compound |
| HY-158999 | VCPIP1-IN-1 | 3025297-92-8 | Reference compound |
| HY-15900 | Voxtalisib | 934493-76-2 | Reference compound |
| HY-159000 | VCPIP1-IN-2 | 3025298-68-1 | Reference compound |
| HY-159001 | ZCDD083 | 2958659-59-9 | Reference compound |
| HY-159002S | Methyl-warfarin-d3 | | Isotope-Labeled Compounds |
| HY-159004 | Se-DOPE | | Reference compound |
| HY-159005 | TDTM | 1357270-50-8 | Reference compound |
| HY-159006 | CYP1B1 ligand 3 | 65823-65-6 | Reference compound |
| HY-159007 | BD-AcAc2 | 58213-75-5 | Oligonucleotides |
| HY-159008 | NHSF | 2292112-27-5 | Reference compound |
| HY-159009 | MS7 | 1593654-46-6 | Reference compound |
| HY-15901 | LGB321 | 1210417-75-6 | Reference compound |
| HY-159015 | SIAIS630120-NC | | Reference compound |
| HY-159016 | SIAIS630121-NC | | Reference compound |
| HY-159017 | EM-12-Alkyne-C6-OMs | 2570254-42-9 | Reference compound |
| HY-159018 | Alkyne-C6-OMs | 228403-45-0 | Reference compound |
| HY-15901A | LGB321 (monohydrochloride) | 1469925-36-7 | Reference compound |
| HY-15902 | ABTS (diammonium salt) | 30931-67-0 | Dye Reagents |
| HY-15903 | ADOS | 82692-96-4 | Dye Reagents |
| HY-15904 | N-Ethyl-N-(3-sulfopropyl)-m-anisidine (sodium) | 82611-88-9 | Biochemical Assay Reagents |
| HY-159045 | F-SAHA | 149648-08-8 | Reference compound |
| HY-159046S | ASGITFSNSGMHW(Val-13C5,15N)R (TFA) | | Isotope-Labeled Compounds |
| HY-15905 | ALPS | 82611-85-6 | Dye Reagents |
| HY-159051 | Dragendorff reagent | 39775-75-2 | Biochemical Assay Reagents |
| HY-159053 | 2,3,4,6-Tetra-O-acetyl-D-mannopyranose | 140147-37-1 | Biochemical Assay Reagents |
| HY-159057 | Biotin-BMCC | 188682-72-6 | Reference compound |
| HY-159058 | Hericium Erinaceus Extract | | Biochemical Assay Reagents |
| HY-159059 | Ganoderma Lucidum/Reishi Extract | | Biochemical Assay Reagents |
| HY-15906 | AMPPD | 122341-56-4 | Biochemical Assay Reagents |
| HY-159060 | Coriolus Versicolor Extract | | Biochemical Assay Reagents |
| HY-159061 | Antrodia Camphorata Extract | | Biochemical Assay Reagents |
| HY-159062 | Goji Extract | | Biochemical Assay Reagents |
| HY-159063 | Soy Polysaccharides | | Biochemical Assay Reagents |
| HY-159064S | DSPSAPVNVT(Val-13C5,15N)R (TFA) | | Isotope-Labeled Compounds |
| HY-159065S | FIQE(Val-13C5,15N)NTTTR (TFA) | | Isotope-Labeled Compounds |
| HY-159066 | Polysachoride of astragalus mongholicus | | Biochemical Assay Reagents |
| HY-159067 | DEAE-dextran, MW 500000 (hydrochloride) | 9064-91-9 | Biochemical Assay Reagents |
| HY-159068 | Coreopsis tinctoria polysacharide | | Biochemical Assay Reagents |
| HY-159069 | Zymosan (ZM), 95% | 9010-72-4 | Biochemical Assay Reagents |
| HY-15907 | BBD | 18378-20-6 | Dye Reagents |
| HY-159071 | Lichenan, 80% | 1402-10-4 | Biochemical Assay Reagents |
| HY-159072 | Mal-Val-Ala-PAB-N(SO2Me)-Exatecan | 2575682-08-3 | Reference compound |
| HY-159075 | N-Sulfosuccinimidyl iodoacetate (sodium) | | Reference compound |
| HY-159076 | E3 ligase Ligand 7 | 37630-54-9 | Reference compound |
| HY-159077 | H2N-C6-NH-CO-CH2-O-Ph-CH2-NH-Boc | | Reference compound |
| HY-159078 | PolQi1 | 2607139-80-8 | Reference compound |
| HY-15908 | BCA | 979-88-4 | Biochemical Assay Reagents |
| HY-159080 | HgCht2-IN-1 | | Reference compound |
| HY-159081 | AChE/BChE-IN-20 | | Reference compound |
| HY-159082 | E3 ligase Ligand 28 | | Reference compound |
| HY-159083 | DN5355 | 937012-09-4 | Reference compound |
| HY-159085 | P-gp inhibitor 24 | | Reference compound |
| HY-159086 | RGB097 | | Reference compound |
| HY-159087 | RGB110 | | Reference compound |
| HY-159088 | KOR agonist 2 | | Reference compound |
| HY-15909 | BCIP | 6578-06-9 | Dye Reagents |
| HY-159090 | AT1R antagonist 3 | 3053482-15-5 | Reference compound |
| HY-159091 | HIV-1 integrase inhibitor 12 | | Reference compound |
| HY-159092 | HIV-1 integrase inhibitor 13 | | Reference compound |
| HY-159093 | Antitumor agent-178 | | Reference compound |
| HY-159094 | Nav1.8-IN-15 | 524061-69-6 | Reference compound |
| HY-159095 | PKR activator 5 | 2761226-35-9 | Reference compound |
| HY-159096 | Apoptosis inducer 21 | | Reference compound |
| HY-159097 | T.cruzi-IN-4 | | Reference compound |
| HY-159098 | dWIZ-1 | | Reference compound |
| HY-159099 | HbF inducer 2 | 2654011-51-3 | Reference compound |
| HY-15910 | 5-BrdU | 59-14-3 | Oligonucleotides |
| HY-159100 | PVP-037 | 862810-50-2 | Reference compound |
| HY-159101 | EP26 | | Reference compound |
| HY-159102 | PVP-037.2 | | Reference compound |
| HY-159103 | LeuRS-IN-2 | | Reference compound |
| HY-159104 | Cinnamon bark oil, from Cinnamonum zeylanicum Blume | 8015-91-6 | Biochemical Assay Reagents |
| HY-159106 | MeSeI | 2901664-87-5 | Reference compound |
| HY-159107 | 2-MNG | 2101538-28-5 | Reference compound |
| HY-159108 | AZ683 | 953798-95-3 | Reference compound |
| HY-159109 | HDAC6-IN-46 | 3038789-39-5 | Reference compound |
| HY-15911 | CNP-AFU | 157843-41-9 | Biochemical Assay Reagents |
| HY-159110 | ABA-DMNB | 1947375-16-7 | Reference compound |
| HY-159111 | KS124 | | Reference compound |
| HY-159112 | AW01178 | 651293-70-8 | Reference compound |
| HY-159113 | PCC0105003 | | Reference compound |
| HY-159114 | Whole Glucan Particles | | Biochemical Assay Reagents |
| HY-159115 | ART26.12 | 2766800-24-0 | Reference compound |
| HY-159116 | AChE-IN-69 | 2755986-33-3 | Reference compound |
| HY-159118 | PC-Qz1 | | Reference compound |
| HY-159119 | hDHODH-IN-15 | | Reference compound |
| HY-159120 | ZG-2291 | 2962103-40-6 | Reference compound |
| HY-159121 | sEH inhibitor-17 | 2823295-37-8 | Reference compound |
| HY-159122 | CA IX-IN-2 | 3009842-92-3 | Reference compound |
| HY-159123 | KHK-6 | | Reference compound |
| HY-159124 | YZL-51N | 3031072-69-9 | Reference compound |
| HY-159125 | PD-1/PD-L1-IN-47 | 1137341-95-7 | Reference compound |
| HY-159126 | SIRT2-IN-15 | 312275-43-7 | Reference compound |
| HY-159127 | HRS-4642 | 2836263-09-1 | Reference compound |
| HY-159128 | hCAIX-IN-21 | | Reference compound |
| HY-159129 | hCAXII-IN-10 | | Reference compound |
| HY-15913 | DAOS | 83777-30-4 | Biochemical Assay Reagents |
| HY-159130 | AO-022 | | Reference compound |
| HY-159131 | PNSC928 | | Reference compound |
| HY-159132 | CAIX/CAXII-IN-2 | | Reference compound |
| HY-159133 | BuChE-IN-13 | | Reference compound |
| HY-159134 | TRPA1-IN-3 | 92585-24-5 | Reference compound |
| HY-159135 | Fmoc-Thr(OtBu)-OtBu | 129460-13-5 | Reference compound |
| HY-159136 | Fmoc-Ser(tBu)-OtBu | 129460-16-8 | Reference compound |
| HY-15914 | DHBS | 54970-72-8 | Dye Reagents |
| HY-159143 | BChE-IN-33 | | Reference compound |
| HY-159144 | Anti-inflammatory agent 91 | | Reference compound |
| HY-159145 | Lenalidomide-acetylene-C3-MsO | 2138441-31-1 | Reference compound |
| HY-159146 | PPARα agonist 4 | | Reference compound |
| HY-159147 | SIAIS039 | 2570251-69-1 | Reference compound |
| HY-159148 | AChE-IN-70 | | Reference compound |
| HY-159149 | Antitumor agent-182 | | Reference compound |
| HY-15915 | DTNB | 69-78-3 | Biochemical Assay Reagents |
| HY-159150 | HIV-1 inhibitor-71 | 2762922-66-5 | Reference compound |
| HY-159151 | AChE/Aβ-IN-6 | | Reference compound |
| HY-159152 | PQM-164 | 2226535-25-5 | Reference compound |
| HY-159153 | Photosensitizer-4 | | Reference compound |
| HY-159154 | PSS-II | | Reference compound |
| HY-159155 | CDK2/4-IN-1 | | Reference compound |
| HY-159156 | MAT2A inhibitor 6 | 2447686-21-5 | Dye Reagents |
| HY-159157 | Anti-inflammatory agent 92 | 1609387-77-0 | Reference compound |
| HY-159158 | COX-1/2-IN-8 | | Reference compound |
| HY-159159 | MS-II-124 | 3037332-85-4 | Reference compound |
| HY-15916 | DTE | 6892-68-8 | Biochemical Assay Reagents |
| HY-159160 | HBV-IN-46 | 3034992-40-7 | Reference compound |
| HY-159162 | 7-(2-Aminoethyl)camptothecin | 433284-40-3 | ADC Related |
| HY-159162A | 7-(2-Aminoethyl)camptothecin (TFA) | | Reference compound |
| HY-159163 | KRASG12C IN-12 | 2093328-45-9 | Reference compound |
| HY-159164 | PROTAC CRBN ligand-3 | | Reference compound |
| HY-159165 | Pomalidomide-cyclopentane-amide-Alkyne | | Reference compound |
| HY-159169 | 5-LOX/sEH-IN-1 | | Reference compound |
| HY-15917 | DL-dithiothreitol | 3483-12-3 | Biochemical Assay Reagents |
| HY-159170 | Quorum sensing-IN-7 | | Reference compound |
| HY-159171 | sEH/HDAC6-IN-2 | 3009011-58-6 | Reference compound |
| HY-159172 | HDAC3-IN-4 | 2988762-46-3 | Reference compound |
| HY-159173 | AChE-IN-71 | 1708114-58-2 | Reference compound |
| HY-159174 | EPHA2/A4/GAK-IN-1 | | Reference compound |
| HY-159175 | XM-U-14 | | Reference compound |
| HY-159176 | Antitumor agent-183 | 2775428-94-7 | Isotope-Labeled Compounds |
| HY-159177 | M4 mAChR Modulator-1 | | Reference compound |
| HY-159178 | m-AM-BBIQ | 1258457-58-7 | Reference compound |
| HY-159179 | α4 integrin receptor antagonist 3 | 863226-74-8 | Reference compound |
| HY-15917A | L-Dithiothreitol | 16096-97-2 | Biochemical Assay Reagents |
| HY-15917S | DL-dithiothreitol-d10 | 302912-05-6 | Isotope-Labeled Compounds |
| HY-15917S1 | DL-dithiothreitol-d10-1 | 203633-21-0 | Isotope-Labeled Compounds |
| HY-15917S2 | DL-dithiothreitol-d6 | 850153-85-4 | Isotope-Labeled Compounds |
| HY-15918 | HDAOS | 82692-88-4 | Biochemical Assay Reagents |
| HY-159180 | p-NCS-Bz-NODA-GA | 1660127-21-8 | Biochemical Assay Reagents |
| HY-159181 | p-NCS-Bz-DOTA-GA | 2194580-71-5 | Biochemical Assay Reagents |
| HY-159183 | THP-NCS | 1807847-98-8 | Biochemical Assay Reagents |
| HY-159184 | THP-Mal | 1314929-99-1 | Biochemical Assay Reagents |
| HY-15919 | HTBA | 53279-72-4 | Biochemical Assay Reagents |
| HY-159190 | HRX-0233 | 2409140-12-9 | Reference compound |
| HY-159191S | VQPGQN(Phe-13C9,15N)HMFTKEKLEEVIKDI (TFA) | | Isotope-Labeled Compounds |
| HY-159192S | SADDNIKTPAE(Arg-13C6,15N4)LLGPLPPSADDNLKT (TFA) | | Isotope-Labeled Compounds |
| HY-159193S | DHATS(Leu-13C6,15N)PVTIPSAVST(Gly-13C2,15N)HTTPLPVTDT (TFA) | | Isotope-Labeled Compounds |
| HY-159194 | DSPE-PEG2000-Cy5.5 | | Reference compound |
| HY-15920 | INT | 146-68-9 | Biochemical Assay Reagents |
| HY-159204 | 3'-Amino-Modifier C7 CPG 1000 | | Biochemical Assay Reagents |
| HY-15921 | IPTG | 367-93-1 | Biochemical Assay Reagents |
| HY-15921A | IPTG hemidioxane | 1330286-44-6 | Biochemical Assay Reagents |
| HY-15922 | Luminol | 521-31-3 | Dye Reagents |
| HY-15922A | Luminol (sodium salt) | 20666-12-0 | Dye Reagents |
| HY-15923 | MAOS | 82692-97-5 | Dye Reagents |
| HY-15924 | Thiazolyl Blue | 298-93-1 | Dye Reagents |
| HY-15925 | Nitro blue tetrazolium chloride | 298-83-9 | Dye Reagents |
| HY-15926 | ONPG | 369-07-3 | Biochemical Assay Reagents |
| HY-15926S | ONPG-13C | 864933-71-1 | Isotope-Labeled Compounds |
| HY-15927 | 4-Nitrophenyl β-D-glucopyranoside | 2492-87-7 | Biochemical Assay Reagents |
| HY-15928 | PNPP (disodium) | 4264-83-9 | Dye Reagents |
| HY-15929 | TBHBA | 14348-40-4 | Biochemical Assay Reagents |
| HY-15930 | TMB | 54827-17-7 | Dye Reagents |
| HY-15930A | TMB (dihydrochloride) | 64285-73-0 | Dye Reagents |
| HY-15930B | TMB (dihydrochloride x.hydrate) | 207738-08-7 | Biochemical Assay Reagents |
| HY-15930C | TMB (monosulfate) | 54827-18-8 | Dye Reagents |
| HY-15930R | TMB (Standard) | 54827-17-7 | Dye Reagents |
| HY-15931 | TMB-PS | 102062-36-2 | Dye Reagents |
| HY-15932 | TOOS | 82692-93-1 | Biochemical Assay Reagents |
| HY-15933 | TOPS | 40567-80-4 | Biochemical Assay Reagents |
| HY-15934 | X-GAL | 7240-90-6 | Dye Reagents |
| HY-15934A | 5-Bromo-4-chloro-3-indolyl-α-D-mannopyranoside, 93% | 125229-64-3 | Biochemical Assay Reagents |
| HY-15935 | X-Gluc (Dicyclohexylamine) | 18656-96-7 | Dye Reagents |
| HY-15935B | X-Gluc (cyclohexanamine) | 114162-64-0 | Dye Reagents |
| HY-15935C | X-Gluc (sodium) | 129541-41-9 | Dye Reagents |
| HY-15936 | γ-GT | 63699-78-5 | Biochemical Assay Reagents |
| HY-15937 | 5(6)-FAM SE | 117548-22-8 | Dye Reagents |
| HY-15938 | 5-FAM SE | 92557-80-7 | Dye Reagents |
| HY-15939 | 6-FAM SE | 92557-81-8 | Dye Reagents |
| HY-15940 | 5(6)-Carboxyfluorescein | 72088-94-9 | Dye Reagents |
| HY-15941 | 5(6)-FITC | 27072-45-3 | Dye Reagents |
| HY-15942 | 5-TAMRA | 91809-66-4 | Dye Reagents |
| HY-159422 | S-309309 | 2267352-04-3 | Reference compound |
| HY-15943 | 6-TAMRA | 91809-67-5 | Dye Reagents |
| HY-15944 | 5(6)-TAMRA | 98181-63-6 | Dye Reagents |
| HY-159449 | PROTAC SMARCA2 degrader-5 | 2568277-68-7 | Reference compound |
| HY-15945 | DBeQ | 177355-84-9 | Reference compound |
| HY-159450 | PROTAC SMARCA2 degrader-6 | 2568523-72-6 | Reference compound |
| HY-159451 | PROTAC SMARCA2 degrader-7 | 2568277-71-2 | Reference compound |
| HY-159452 | PROTAC SMARCA2/4-degrader-1 | 2568273-68-5 | Reference compound |
| HY-159453 | PROTAC SMARCA2/4-degrader-2 | 2568277-76-7 | Reference compound |
| HY-159454 | PROTAC SMARCA2/4-degrader-3 | 2568507-10-6 | Reference compound |
| HY-159455 | PROTAC SMARCA2/4-degrader-4 | 2568523-81-7 | Reference compound |
| HY-159456 | PROTAC SMARCA2/4-degrader-5 | 2568277-84-7 | Reference compound |
| HY-159457 | PROTAC SMARCA2/4-degrader-6 | 2568277-87-0 | Reference compound |
| HY-159458 | PROTAC SMARCA2/4-degrader-7 | 2568277-89-2 | Reference compound |
| HY-159459 | PROTAC SMARCA2/4-degrader-32 | 2568273-79-8 | Reference compound |
| HY-159460 | PROTAC SMARCA2/4-degrader-8 | 2568507-14-0 | Reference compound |
| HY-159461 | PROTAC SMARCA2/4-degrader-9 | 2568507-15-1 | Reference compound |
| HY-159462 | PROTAC SMARCA2 degrader-10 | 2568279-34-3 | Reference compound |
| HY-159465 | E3 ligase Ligand 30 | 2725913-42-6 | Reference compound |
| HY-159466 | E3 Ligase Ligand-linker Conjugate 113 | 2378054-01-2 | Reference compound |
| HY-15947 | Ravoxertinib | 1453848-26-4 | Reference compound |
| HY-159470 | Polyprenol (13~21) | 308068-00-0 | Biochemical Assay Reagents |
| HY-159471 | N6-[(6-Aminohexyl)carbamoylmethyl]-ADP | 100826-95-7 | Reference compound |
| HY-159472 | SMARCA2/4-ligand-1 | 2411651-36-8 | Reference compound |
| HY-159473 | K-Ras-IN-3 | 3024991-82-7 | Reference compound |
| HY-159474 | KRAS inhibitor-24 | 3030576-47-4 | Reference compound |
| HY-159475 | KRAS inhibitor-25 | 3030577-05-7 | Reference compound |
| HY-159476 | KRAS inhibitor-26 | 3030576-80-5 | Reference compound |
| HY-159477 | SARS-CoV-2-IN-92 | 2123489-12-1 | Reference compound |
| HY-159478 | CHO-Ph-spiro[3.3]heptane-COOEt | | Reference compound |
| HY-159479 | PfSUB1-IN-1 | | Reference compound |
| HY-15947A | Ravoxertinib hydrochloride | 2070009-58-2 | Reference compound |
| HY-15948 | Kif15-IN-1 | 672926-32-8 | Reference compound |
| HY-159480 | AD1058 | 2907782-78-7 | Reference compound |
| HY-159481 | SDH-IN-17 | | Reference compound |
| HY-159482 | SBN-284 | | Reference compound |
| HY-159483 | SelB-1 | 2674058-66-1 | Reference compound |
| HY-159484 | Hsp110/sGC-modulator-1 | | Reference compound |
| HY-159485 | NFh-ALP | | Reference compound |
| HY-159486 | SDH-IN-18 | 723748-50-3 | Reference compound |
| HY-159487 | (S,R,S)-AHPC-CO-spiro[3.3]heptane-Ph-CHO | | Reference compound |
| HY-159488 | PPO-IN-14 | | Reference compound |
| HY-159489 | SDUY038 | 2892720-11-3 | Reference compound |
| HY-15949 | Kif15-IN-2 | 672926-33-9 | Reference compound |
| HY-159490 | Thalidomide-5-piperazine-C-piperidine-CO-C8-NH2 | | Reference compound |
| HY-159491 | DPP-4-IN-11 | | Reference compound |
| HY-159492 | 5-HT7 receptor ligand 2 | | Reference compound |
| HY-159493 | BI2536-PEG2-Halo | | Reference compound |
| HY-159494 | PROTAC sEH-degrader-1 | | Reference compound |
| HY-159495 | Keap1-Nrf2-IN-21 | | Reference compound |
| HY-159496 | Dyrk1A-IN-10 | 2891824-14-7 | Reference compound |
| HY-15950 | AZD1981 | 802904-66-1 | Reference compound |
| HY-159500 | Zopocianine | 2206660-94-6 | Reference compound |
| HY-159500A | Zopocianine (sodium) | 2206660-95-7 | Reference compound |
| HY-159502 | Surlorian | 1467605-57-7 | Reference compound |
| HY-159503 | Segigratinib | 1882873-93-9 | Reference compound |
| HY-159503A | Segigratinib (hydrochloride) | 2847066-15-1 | Reference compound |
| HY-159504 | Pregabalinum naproxencarbilum | 1221072-91-8 | Reference compound |
| HY-159506 | Bimokalner | 2243284-19-5 | Reference compound |
| HY-159507 | Brezivaptan | 1370444-22-6 | Reference compound |
| HY-159508 | Brimarafenibum | 1643326-82-2 | Reference compound |
| HY-159509 | Claziprotamidum | 2361124-03-8 | Reference compound |
| HY-15951 | ML167 | 1285702-20-6 | Reference compound |
| HY-159510 | VEGFR-2-IN-51 | | Reference compound |
| HY-159511 | Hedgehog IN-7 | | Reference compound |
| HY-159512 | EGFR kinase inhibitor 7 | | Reference compound |
| HY-159513 | Bcl-2/Mcl-1-IN-4 | | Reference compound |
| HY-159514 | Graveolide | 72173-44-5 | Natural Products |
| HY-159515 | PBE-AMF | | Reference compound |
| HY-159516 | Sabialimon P | 2267333-96-8 | Reference compound |
| HY-159517 | PI3K/Akt/mTOR-IN-5 | | Reference compound |
| HY-159518 | ROS inducer 4 | 2959444-40-5 | Reference compound |
| HY-159519 | EGFR/HER2-IN-16 | | Reference compound |
| HY-159520 | Ofirnoflastum | 2731294-23-6 | Reference compound |
| HY-159521 | HN252 | | Reference compound |
| HY-159522 | Odentegravirum | 2495436-99-0 | Reference compound |
| HY-159523 | Nurandociguatum | 2781965-75-9 | Reference compound |
| HY-159524 | Matsupexolum | 1399442-97-7 | Reference compound |
| HY-159525 | Linustedastatum | 2254299-48-2 | Reference compound |
| HY-159526 | Adarulatide tetraxetan | 1246013-02-4 | Peptides |
| HY-159527 | Glovadalenum | 2576359-31-2 | Reference compound |
| HY-159528 | Girocitinibum | 2222137-79-1 | Reference compound |
| HY-159529 | DBCO-PEG4-Eosin 5-isothiocyanate | | Dye Reagents |
| HY-159530 | Darbinuradum | 1877347-38-0 | Reference compound |
| HY-159534 | Flezurafenibum | 2760321-00-2 | Reference compound |
| HY-159535 | Fovinaciclibum | 2146171-49-3 | Reference compound |
| HY-159536 | Frevecitinibum | 1299417-07-4 | Reference compound |
| HY-159537 | (S,R,S)-AHPC-CO-bicyclo[2.2.2]octane-CHO | | Reference compound |
| HY-159538 | COOEt-bicyclo[2.2.2]octane-CHO | 959958-67-9 | Reference compound |
| HY-159539 | COOEt-spiro[3.3]heptane-CHO | 2226571-47-5 | Reference compound |
| HY-15954 | NVP-CGM097 | 1313363-54-0 | Reference compound |
| HY-159540 | (S,R,S)-AHPC-CO-Spiro-CHO | | Reference compound |
| HY-159542 | SMARCA2 ligand-6 | 2408394-89-6 | Reference compound |
| HY-159543 | (S,R,S)-AHPC-CO-Ph-Ph-CHO | | Reference compound |
| HY-159544 | SMARCA2 ligand-7 | 2568281-41-2 | Reference compound |
| HY-159545 | SMARCA2/4-ligand-2 | 2568281-88-7 | Reference compound |
| HY-159546 | (S,R,S)-AHPC-Me-CO-cyclohexene-Bpin | | Reference compound |
| HY-159547 | Cyclopropane-(S,R,S)-AHPC | 2502205-74-3 | Reference compound |
| HY-159548 | Cyclopropane-(S,R,S)-AHPC-CO-cyclohexene-Bpin | | Reference compound |
| HY-159549 | (S,R,S)-AHPC-CO-C-Cyclohexene-Bpin | | Reference compound |
| HY-15954A | NVP-CGM097 (stereoisomer) | 2070009-54-8 | Reference compound |
| HY-15954B | NVP-CGM097 (sulfate) | 1313367-56-4 | Reference compound |
| HY-15954C | (R)-NVP-CGM097 | 2643938-26-3 | Reference compound |
| HY-159550 | (S,R,S)-AHPC-CO-cyclohexene-Bpin | | Reference compound |
| HY-159553 | Ac-NH-(S,R,S)-AHPC | | Reference compound |
| HY-159556 | Dimethylformamide-(S,R,S)-AHPC | | Reference compound |
| HY-159557 | Ethyl-trans-4-benzylcyclohexane-1-carboxylate | 1923826-92-9 | Reference compound |
| HY-159558 | (S,R,S)-AHPC-CO-cyclohexane-C-Ph-pyrimidine-diazabicyclo | | Reference compound |
| HY-159560 | PBA-AMF | | Reference compound |
| HY-159561 | COX-1-IN-2 | | Reference compound |
| HY-159562 | COX-2-IN-46 | | Reference compound |
| HY-159563 | Mal-va-mac-SN38 | 2778229-31-3 | Reference compound |
| HY-159564 | iNOS/COX-2-IN-3 | | Reference compound |
| HY-159565 | VEGFR-2/InhA-IN-1 | | Reference compound |
| HY-159567 | Ferroptosis-IN-11 | 1266755-01-4 | Reference compound |
| HY-159568 | hCAIX-IN-22 | | Reference compound |
| HY-159569 | TfR-1-IN-1 | 1643444-62-5 | Reference compound |
| HY-159570 | XD2-149 | 2710221-08-0 | Reference compound |
| HY-159571 | Thalidomide-NH-C5-azacyclohexane-N-Boc | 2710222-09-4 | Reference compound |
| HY-159572 | NH2-C5-Azacyclohexane-N-Boc | | Reference compound |
| HY-159573 | Napabucasin analogue | 1133287-34-9 | Reference compound |
| HY-159575 | COOEt-cyclohexane-C-Ph-pyrimidine-diazabicyclo | | Reference compound |
| HY-159576 | O-Me Eribulin | 2676196-81-7 | ADC Related |
| HY-159577 | Nic-15 | 2896739-91-4 | Reference compound |
| HY-159578S | VU6036864 | 2746406-36-8 | Isotope-Labeled Compounds |
| HY-159579 | CW-3308 | 3055592-99-6 | Reference compound |
| HY-15958 | VBY-825 | 1310340-58-9 | Reference compound |
| HY-159580 | STAT3-IN-31 | | Reference compound |
| HY-159581 | URAT1&XO inhibitor 3 | 2089040-93-5 | Reference compound |
| HY-159582 | ACKR3 agonist 1 | | Reference compound |
| HY-159583 | FPR2 agonist 4 | 2101188-49-0 | Reference compound |
| HY-159584 | LBG20304 | | Reference compound |
| HY-159585 | CYP51-IN-20 | | Reference compound |
| HY-159586 | Tyrosinase-IN-32 | | Reference compound |
| HY-159587 | P300-IN-4 | | Reference compound |
| HY-159588 | Mcl-1 inhibitor 20 | | Reference compound |
| HY-159589 | BTK-IN-37 | | Reference compound |
| HY-15958A | (S,R,R)-VBY-825 | | Reference compound |
| HY-15959 | Savolitinib | 1313725-88-0 | Reference compound |
| HY-159592 | Piperazine-Pyrimidine-Cyclohexane-COOEt | | Reference compound |
| HY-159593 | Ac-NH-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo | | Reference compound |
| HY-159594 | Dimethylformamide-(S,R,S)-AHPC-CO-cyclohexane-pyrimidine-diazabicyclo | | Reference compound |
| HY-159595 | PCSK9-IN-29 | 1233353-86-0 | Reference compound |
| HY-159596 | Naphthyridin-Me-dimethoxybenzene-COOH | | Reference compound |
| HY-159597 | Thalidomide-methylpyrrolidine | 2616540-84-0 | Reference compound |
| HY-159598 | 3-Azaspiro[5.5]undecane-9-methanol | 1784372-01-5 | Reference compound |
| HY-159599 | Thalidomide-pyrrolidine-C-azaspiro | 2832871-47-1 | Reference compound |
| HY-159601 | CSN5-IN-1 | | Reference compound |
| HY-159602 | BET BD2-IN-3 | 2677039-66-4 | Reference compound |
| HY-159603 | S-WJM992 | | Reference compound |
| HY-159604 | METTL3-IN-9 | 295348-36-6 | Reference compound |
| HY-159605 | Autophagy inducer 5 | | Reference compound |
| HY-159606 | MS182 | 3034773-62-8 | Reference compound |
| HY-159607 | PRT3789 | 2755761-78-3 | Reference compound |
| HY-159608 | PROTAC Cbl-b-IN-1 | 3035210-39-7 | Reference compound |
| HY-159609 | PROTAC GSPT1 degrader-1 | 3034310-17-0 | Reference compound |
| HY-15961 | Antitumor agent-3 | 420126-30-3 | Reference compound |
| HY-159610 | PROTAC GSPT1 degrader-2 | 3024909-61-0 | Reference compound |
| HY-159611 | KRAS G12C inhibitor 68 | 3034851-27-6 | Reference compound |
| HY-159612 | PARP1-IN-28 | 2855059-11-7 | Reference compound |
| HY-159613 | PELP1-IN-1 | 946262-80-2 | Reference compound |
| HY-159615 | Cbl-b-IN-21 | 2851878-87-8 | Reference compound |
| HY-159617 | Cbz-Pip-2C-Pip-C-Pip | 3035215-25-6 | Reference compound |
| HY-159618 | (3S)Lenalidomide-5-Pip-C-Pip-2C-Pip | | Reference compound |
| HY-159619 | Boc-azetidine-2C-oxotetrahydropyrimidin-bromophenyl | 3034310-18-1 | Reference compound |
| HY-159620 | Thalidomide 5-azetidine-2C-oxotetrahydropyrimidin-bromophenyl | 3034310-00-1 | Reference compound |
| HY-159621 | Endosidine 5 | 364361-68-2 | Reference compound |
| HY-159622 | Boc-Pip-C-oxotetrahydropyrimidin-bromophenyl | 3024909-51-8 | Reference compound |
| HY-159623 | Thalidomide 5-Pip-C-oxotetrahydropyrimidin-bromophenyl | 3024909-50-7 | Reference compound |
| HY-159624 | KK-92A | | Reference compound |
| HY-159625 | WX8 | 232935-92-1 | Reference compound |
| HY-159627A | Met-AMS (TEA) | 1122489-97-7 | Reference compound |
| HY-159628A | Glu-AMS (TEA) | 1810728-44-9 | Reference compound |
| HY-159632 | PAR4 antagonist 6 | | Reference compound |
| HY-159633 | PLpro-IN-5 | 3009839-42-0 | Reference compound |
| HY-159636 | Lactalbumin | 9013-90-5 | Biochemical Assay Reagents |
| HY-159637 | IWY357 | 3052672-51-9 | Reference compound |
| HY-159638 | Elunonavir | 2242428-57-3 | Reference compound |
| HY-159639 | BAY-2925976 | 2642235-06-9 | Reference compound |
| HY-15964 | Tirasemtiv | 1005491-05-3 | Reference compound |
| HY-159640 | NVP-FVP954 | | Reference compound |
| HY-159641 | VVD-130037 | 3034880-93-5 | Reference compound |
| HY-159642 | TYRA-300 | 2800223-30-5 | Reference compound |
| HY-159642G | TYRA-300 (GMP) | 2800223-30-5 | GMP Small Molecules |
| HY-159643 | NDI-101150 | 2628486-22-4 | Reference compound |
| HY-159644 | Casdatifan | 2709069-30-5 | Reference compound |
| HY-159646 | BMS-986397 | 2564486-44-6 | Reference compound |
| HY-159647 | PLX-4545 | 2892065-45-9 | Reference compound |
| HY-159648 | PF-07328948 | 2936625-34-0 | Reference compound |
| HY-159649 | BMS-986408 | 2618418-12-3 | Reference compound |
| HY-15965 | Uprosertib | 1047634-65-0 | Reference compound |
| HY-159650 | EOS-984 | 2724937-55-5 | Reference compound |
| HY-159651 | PTOTAC HSD17B13 degrader 1 | 3046195-01-8 | Reference compound |
| HY-159652 | KRAS inhibitor-31 | 2920695-77-6 | Reference compound |
| HY-159653 | MASTL-IN-5 | 3024916-78-4 | Reference compound |
| HY-159654 | PDE4-IN-19 | 3042879-82-0 | Reference compound |
| HY-159655 | PLpro-IN-6 | 3041046-04-9 | Reference compound |
| HY-159656 | PNPLA3 modifier 1 | 3036158-95-6 | Reference compound |
| HY-159657 | SIK-IN-4 | 3033846-10-2 | Reference compound |
| HY-159658 | TTR stabilizer 1 | 2778162-15-3 | Reference compound |
| HY-15965A | Uprosertib hydrochloride | 1047635-80-2 | Reference compound |
| HY-15966 | GSK2110183 analog 1 | 1047634-63-8 | Reference compound |
| HY-159660 | E3 ligase Ligand 31 | 2357114-13-5 | Reference compound |
| HY-159661 | E3 Ligase Ligand-linker Conjugate 114 | | Reference compound |
| HY-159662 | HSD17B13 degrader 2 | 3035000-69-9 | Reference compound |
| HY-159665 | CDLI-5 | 3047549-85-6 | Reference compound |
| HY-159666 | Nystatin A1 | 34786-70-4 | Reference compound |
| HY-159668 | DL002 | 3049680-91-0 | ADC Related |
| HY-159669 | Stercobilin hydrochloride (mixture of isomers) | 13129-80-1 | Biochemical Assay Reagents |
| HY-15966A | GSK2110183 analog 1 (hydrochloride) | 2070009-64-0 | Reference compound |
| HY-15967 | PS48 | 1180676-32-7 | Reference compound |
| HY-159670 | Monophosphoryl Lipid A-12 | 1332714-01-8 | Biochemical Assay Reagents |
| HY-159670B | Monophosphoryl Lipid A-12 (triethylamine) | | Reference compound |
| HY-159671 | 3D-Monophosphoryl Lipid (14) | 252042-59-4 | Biochemical Assay Reagents |
| HY-159671A | 3D-Monophosphoryl Lipid (14) (triethylamine) | 252042-60-7 | Reference compound |
| HY-159671B | 3D-Monophosphoryl Lipid (14) (ammonium) | | Reference compound |
| HY-159672 | 3D-Monophosphoryl Lipid (12,16) | | Biochemical Assay Reagents |
| HY-159672A | 3D-Monophosphoryl Lipid (12,16) (free acid) | 220048-49-7 | Reference compound |
| HY-159672B | 3D-Monophosphoryl Lipid (12,16) (triethylamine) | | Reference compound |
| HY-159674 | N-Tetamine-pSar45-Maleimide | | Biochemical Assay Reagents |
| HY-159675 | 1-A-N | | Oligonucleotides |
| HY-159677 | E3 Ligase Ligand-linker Conjugate 115 | 2375564-59-1 | Reference compound |
| HY-159678 | 4-(1,3-Dioxolan-2-yl)phenethyl methanesulfonate | 2369046-75-1 | Reference compound |
| HY-159679 | E3 Ligase Ligand-linker Conjugate 116 | 2409844-90-0 | Reference compound |
| HY-15968 | Entospletinib | 1229208-44-9 | Reference compound |
| HY-159680 | OMs-PEG2-NHAlloc-PEG2-Boc | 2376332-47-5 | Reference compound |
| HY-159681 | AASS-IN-1 | | Reference compound |
| HY-159682 | 3,8-Diazabicyclo[3.2.1]octane-4-pyrimidine-piperidine-cyclohexene-Bpin | | Reference compound |
| HY-159683 | E3 Ligase Ligand-linker Conjugate 117 | | Reference compound |
| HY-159683A | E3 Ligase Ligand-linker Conjugate 119 | | Reference compound |
| HY-159684 | 3,8-Diazabicyclo[3.2.1]octane-pyrimidine-piperidine-cyclohexene-Bpin | | Reference compound |
| HY-159685 | E3 Ligase Ligand-linker Conjugate 118 | | Reference compound |
| HY-159686 | Aclidinium | 727649-81-2 | Reference compound |
| HY-159687 | Nafithromycin | 1691240-78-4 | Reference compound |
| HY-159688 | Cefditoren | 104145-95-1 | Reference compound |
| HY-159689 | Cloroperone | 61764-61-2 | Reference compound |
| HY-15969 | Sal003 | 1164470-53-4 | Reference compound |
| HY-159691 | IONIS-FGFR4Rx | 1416376-17-4 | Oligonucleotides |
| HY-159691A | IONIS-FGFR4Rx (sodium) | | Oligonucleotides |
| HY-159692 | AZD8701 | 2603457-08-3 | Oligonucleotides |
| HY-159692A | AZD8701 (sodium) | | Oligonucleotides |
| HY-159693 | ISIS 626112 | 2091995-55-8 | Oligonucleotides |
| HY-159693A | ISIS 626112 (sodium) | | Oligonucleotides |
| HY-159694 | IONIS PTP1BRx | 1403406-29-0 | Oligonucleotides |
| HY-159694A | IONIS PTP1BRx (sodium) | | Oligonucleotides |
| HY-159695 | IONIS-GCCRRx | 1431900-72-9 | Oligonucleotides |
| HY-159695A | IONIS-GCCRRx (sodium) | | Oligonucleotides |
| HY-159696 | ISIS 449884 | 1428588-67-3 | Oligonucleotides |
| HY-159696A | ISIS 449884 (sodium) | | Oligonucleotides |
| HY-159697 | ISIS 532401 | 1644201-52-4 | Oligonucleotides |
| HY-159697A | ISIS 532401 (sodium) | | Oligonucleotides |
| HY-159698 | IONIS-DGAT 2Rx | 2091332-22-6 | Oligonucleotides |
| HY-159698A | IONIS-DGAT 2Rx (sodium) | | Oligonucleotides |
| HY-159699 | 80-O18 | | Oligonucleotides |
| HY-15970 | Verdinexor | 1392136-43-4 | Reference compound |
| HY-159700 | AA3-DLin | 3027565-91-6 | Oligonucleotides |
| HY-159704 | 9-Keto-latanoprost | 141074-06-8 | Reference compound |
| HY-159706 | S9-A13 | 1223771-84-3 | Reference compound |
| HY-159708 | Ionizable lipid Az1 | | Oligonucleotides |
| HY-159709 | VL-422 | 2765519-47-7 | Oligonucleotides |
| HY-15971 | AMD 3465 (hexahydrobromide) | 185991-07-5 | Reference compound |
| HY-159710 | TNT-b10 | 3037332-26-3 | Oligonucleotides |
| HY-159711 | PPPDA-O16B | | Oligonucleotides |
| HY-159713 | Lipid R6 | | Oligonucleotides |
| HY-159714 | Lipid HTO12 | 3047222-45-4 | Oligonucleotides |
| HY-159715 | Lipid DIM1 | 2820155-36-8 | Oligonucleotides |
| HY-159716 | Lipid 50 | 2440135-57-7 | Oligonucleotides |
| HY-159717 | Lipid 331 | | Oligonucleotides |
| HY-159718 | NLRP3-IN-46 | | Reference compound |
| HY-15971A | AMD 3465 | 185991-24-6 | Reference compound |
| HY-159725 | BAmP-O16B | | Oligonucleotides |
| HY-159726 | C10-200 | | Oligonucleotides |
| HY-159728 | PROTAC PRMT3 degrader 1 | | Reference compound |
| HY-15973 | BSF-466895 | 262442-90-0 | Reference compound |
| HY-159730 | ERG245 | | Reference compound |
| HY-159731 | OX2R agonist 1 | 2648347-78-6 | Reference compound |
| HY-159732 | PRMT3-IN-4 | | Reference compound |
| HY-159733 | E3 Ligase Ligand-linker Conjugate 120 | | Reference compound |
| HY-159734 | TPP-resveratrol | | Reference compound |
| HY-159735 | Lipid 23 | | Oligonucleotides |
| HY-159737 | Rociclovir | 108436-80-2 | Reference compound |
| HY-159738 | N-(2-(Diethylamino)ethyl)-2-iodobenzamide | 170794-62-4 | Reference compound |
| HY-159741 | Minamestane | 105051-87-4 | Reference compound |
| HY-159742 | GP130 modulator-1 | 2375779-31-8 | Reference compound |
| HY-159743 | M101 | | Reference compound |
| HY-159744 | M103 | | Reference compound |
| HY-159745 | M107 | | Reference compound |
| HY-159746 | HS801 | | Reference compound |
| HY-159747 | M401 | | Reference compound |
| HY-159748 | M402 | | Reference compound |
| HY-159749 | M902 | | Reference compound |
| HY-15975 | GNF179 | 1261114-01-5 | Reference compound |
| HY-159750 | M903 | | Reference compound |
| HY-159751 | HS101 | | Reference compound |
| HY-159752 | HS103 | | Reference compound |
| HY-159753 | HS105 | | Reference compound |
| HY-159754 | HS201 | | Reference compound |
| HY-15976 | P7C3 | 301353-96-8 | Reference compound |
| HY-159767A | (S)-DOTAGA.(SA.FAPi)2 | 2417089-06-4 | ADC Related |
| HY-159768A | DOTAGA.Glu.(FAPi)2 | 2882922-68-9 | Reference compound |
| HY-15977 | (S)-P7C3-OMe | 1235481-43-2 | Reference compound |
| HY-159770A | (S)-EB-FAPI-B2 | 2740747-99-1 | ADC Related |
| HY-159772 | 1-(4-(2-Aminoethyl)piperidin-1-yl)-2-azidoethan-1-one | | Reference compound |
| HY-159774 | ADC Control human IgG1-DM1 | | ADC Related |
| HY-159777 | CPI-203-PEG5-Alkyne | | Reference compound |
| HY-159779 | NR-V04 | 2766608-52-8 | Reference compound |
| HY-15978 | P7C3-A20 | 1235481-90-9 | Reference compound |
| HY-159780 | Amino-PEG4-(S,R,S)-AHPC-Me | 2458220-06-7 | Reference compound |
| HY-159783 | Mal-Exatecan | 3028213-52-4 | ADC Related |
| HY-159788 | PROTAC K-Ras Degrader-4 | 2938169-99-2 | Reference compound |
| HY-15979 | H-89 | 127243-85-0 | Reference compound |
| HY-159794 | Azido-methyltetrazine di-arm linker | 2861998-16-3 | ADC Related |
| HY-159795 | Claturafenib | 2754408-94-9 | Reference compound |
| HY-159798 | NR-11c | | Reference compound |
| HY-159799 | p38α inhibitor 5 | 2550397-96-9 | Reference compound |
| HY-15979A | H-89 (dihydrochloride) | 130964-39-5 | Reference compound |
| HY-15980 | GNF179 (Metabolite) | 1310455-86-7 | Reference compound |
| HY-159800 | 6-(4-Azidobutanamido)hexanoic acid | | Reference compound |
| HY-159801 | E3 Ligase Ligand-linker Conjugate 122 | 3033187-29-7 | Reference compound |
| HY-159802 | Tolamolol | 38103-61-6 | Reference compound |
| HY-159803 | IST-622 | 128201-92-3 | Reference compound |
| HY-159805 | CDK2-IN-31 | 2813260-27-2 | Reference compound |
| HY-159806 | UU | 2415-43-2 | Oligonucleotides |
| HY-159807 | UAU | 752-71-6 | Oligonucleotides |
| HY-159809 | Antibacterial agent 249 | 138801-72-6 | Reference compound |
| HY-15981 | Omarigliptin | 1226781-44-7 | Reference compound |
| HY-159811 | Antitumor agent-187 | 2879230-64-3 | Reference compound |
| HY-159817 | Asaretoclax | 2363074-01-3 | Reference compound |
| HY-159818 | Amogammadex | 1309580-40-2 | Reference compound |
| HY-159819 | Vormatrigine | 2392951-18-5 | Reference compound |
| HY-15981R | Omarigliptin (Standard) | 1226781-44-7 | Reference Standards |
| HY-15982 | APY0201 | 1232221-74-7 | Reference compound |
| HY-159820 | Veonetinib | 1210828-09-3 | Reference compound |
| HY-159821 | Ulacamten | 2830607-59-3 | Reference compound |
| HY-159822 | Teprosulvose | 1983131-47-0 | Reference compound |
| HY-159823 | Suricapavir | 2417270-21-2 | Reference compound |
| HY-159824 | Soxataltinib | 2546116-88-3 | Reference compound |
| HY-159825 | Branosotine | 2412849-26-2 | Reference compound |
| HY-159826 | Brexanolone caprilcerbate | 2681264-65-1 | Reference compound |
| HY-159827 | Cenacitinib | 2641636-52-2 | Reference compound |
| HY-159828 | Dezecapavir | 2570323-59-8 | Reference compound |
| HY-159829 | Direclidine | 1803346-98-6 | Reference compound |
| HY-159830 | Rivasterat | 2446590-96-9 | Reference compound |
| HY-159831 | Remlifanserin | 2289704-13-6 | Reference compound |
| HY-159832 | Relicpixant | 2445366-94-7 | Reference compound |
| HY-159833 | Ranosidenib | 2301974-60-5 | Reference compound |
| HY-159834 | Progerinin | 2249696-72-6 | Reference compound |
| HY-159835 | Oveporexton | 2460722-04-5 | Reference compound |
| HY-159836 | Nivegacetor | 2443487-67-8 | Reference compound |
| HY-159837 | Nispomeben | 1443133-41-2 | Reference compound |
| HY-159838 | Enrupatinib | 2222689-47-4 | Reference compound |
| HY-159839 | Evategrel | 2760609-74-1 | Reference compound |
| HY-15984 | VER-50589 | 747413-08-7 | Reference compound |
| HY-159840 | Fanregratinib | 1628537-44-9 | Reference compound |
| HY-159841 | Filricianine | 2140857-94-7 | Reference compound |
| HY-159841A | Filricianine (sodium) | 2140857-96-9 | Dye Reagents |
| HY-159842 | Fosrolapitant | 2573694-38-7 | Reference compound |
| HY-159843 | Glasmacinal | 2097822-02-9 | Reference compound |
| HY-159844 | Gridegalutamide | 2446929-86-6 | Reference compound |
| HY-159845 | Lecufexor | 2247972-61-6 | Reference compound |
| HY-159846 | Luvometinib | 2739690-43-6 | Reference compound |
| HY-159847 | Nacresertib | 2629977-59-7 | Reference compound |
| HY-159848 | Nedemelteon | 1000334-38-2 | Reference compound |
| HY-159849 | Cytidylyl-(3′,5′)-uridine | 2382-64-1 | Oligonucleotides |
| HY-15985 | CTX-0294885 | 1439934-41-4 | Reference compound |
| HY-159850 | CAU | 3022-32-0 | Oligonucleotides |
| HY-159852 | BBO-10203 | 2971769-60-3 | Reference compound |
| HY-159853 | C14-A1 | | Reference compound |
| HY-159854 | C14-O2 | 2639634-77-6 | Oligonucleotides |
| HY-159855 | CAP 2 (hydrochloride) | | Reference compound |
| HY-159856 | 16:0 Cardiolipin | 105380-95-8 | Reference compound |
| HY-159857 | Gp(2′-5′)Ap (sodium) | | Oligonucleotides |
| HY-159858 | Lipid 16 | | Oligonucleotides |
| HY-159859 | IZ-Chol | 191990-35-9 | Reference compound |
| HY-15985A | CTX-0294885 (hydrochloride) | 2319590-02-6 | Reference compound |
| HY-15986 | VER-49009 | 558640-51-0 | Reference compound |
| HY-159860 | IR-117-17 | 2940241-38-1 | Reference compound |
| HY-159861 | Ionizable Lipid 4 | 1799316-81-6 | Reference compound |
| HY-159862 | IM21.7c | 2416939-42-7 | Reference compound |
| HY-159863 | Cholesterol‑undecanoate‑glucose conjugate | | Reference compound |
| HY-159865 | CL15F6 | 2766493-40-5 | Reference compound |
| HY-159866 | mPEG2000-CLS | | Reference compound |
| HY-159868 | SORT1-IN-1 | 2806762-69-4 | Reference compound |
| HY-159869 | G0-C14 analog | 2935435-86-0 | Reference compound |
| HY-159870 | E12CA1A3 | 2778182-26-4 | Reference compound |
| HY-159874 | KRN7000 analog 2 | | Reference compound |
| HY-159875 | SORT1-IN-2 | 2854233-44-4 | Reference compound |
| HY-159876 | SORT1-IN-3 | 2915675-56-6 | Reference compound |
| HY-159877 | SORT1-IN-4 | 2915675-58-8 | Reference compound |
| HY-159878 | SORT1-IN-5 | 3031580-91-0 | Reference compound |
| HY-159879 | AAK1-IN-6 | 3061058-16-7 | Reference compound |
| HY-159880 | AChE/BChE-IN-24 | 3053509-06-8 | Reference compound |
| HY-159881 | SHS206 | | Reference compound |
| HY-159883 | DDHF20 | | Reference compound |
| HY-159884 | MG-T-19 | 328540-44-9 | Reference compound |
| HY-159885 | MG-B-28 | | Reference compound |
| HY-159886 | MG-C-30 | 877164-43-7 | Reference compound |
| HY-159888 | SON38 | 3034673-37-2 | Reference compound |
| HY-159889 | hA3AR agonist 2 | | Reference compound |
| HY-15989 | SM-164 | 957135-43-2 | Reference compound |
| HY-159890 | MTI013 | | Reference compound |
| HY-159891 | Microtubule destabilizing agent-2 | | Reference compound |
| HY-159892 | PD-1/PD-L1-IN-54 | 1393644-68-2 | Reference compound |
| HY-159893 | SMO-IN-5 | | Reference compound |
| HY-159894 | Autophagy-lysosome activator-1 | | Reference compound |
| HY-159895 | PAR4 antagonist 7 | | Reference compound |
| HY-159896 | PAR4 antagonist 8 | | Reference compound |
| HY-159897 | PAK4-IN-5 | | Reference compound |
| HY-159898 | AChE/BChE-IN-23 | | Reference compound |
| HY-159899 | DHFR-IN-22 | 2941327-87-1 | Reference compound |
| HY-15989A | SM-164 (hydrochloride) | 2734174-02-6 | Reference compound |
| HY-15990 | CH5164840 | 1052645-73-4 | Reference compound |
| HY-159900 | Antimalarial agent 46 | 2715225-19-5 | Reference compound |
| HY-159901 | LSD1-IN-37 | | Reference compound |
| HY-159902 | KRN7000 analog 3 | 1384423-78-2 | Reference compound |
| HY-159904 | ChAT IN-1 | | Reference compound |
| HY-159905 | HPK1-IN-54 | 3048537-48-7 | Reference compound |
| HY-159909 | ATMW-2 | | Reference compound |
| HY-15991 | Tenapanor | 1234423-95-0 | Reference compound |
| HY-159910 | LH1513 | | Reference compound |
| HY-159911 | SARS-CoV-2 Mpro-IN-29 | | Reference compound |
| HY-159912 | pan-TEAD-IN-1 | 3027484-09-6 | Reference compound |
| HY-159913 | AYK004-C1 | 3031612-92-4 | Reference compound |
| HY-159914 | AYK004-B1 | 3031612-91-3 | Reference compound |
| HY-159915 | Se2h | | Reference compound |
| HY-159916 | AYK004 | 3031612-90-2 | Reference compound |
| HY-159917 | PPL agonist-1 | 3040997-52-9 | Reference compound |
| HY-159918 | AYK005 | 3031612-93-5 | Reference compound |
| HY-159919 | UM-3006 | 1927013-87-3 | Reference compound |
| HY-15991A | Tenapanor (hydrochloride) | 1234365-97-9 | Reference compound |
| HY-15992 | BIBF 1202 | 894783-71-2 | Reference compound |
| HY-159920 | PSB-22269 | | Reference compound |
| HY-159921 | Tubulin Polymerization-IN-1 prodrug | 3033099-32-7 | Reference compound |
| HY-159922 | AR antagonist 9 | | Reference compound |
| HY-159923 | BPRMU191 | 2131199-52-3 | Reference compound |
| HY-159924 | DBPR116 | 2131200-75-2 | Reference compound |
| HY-159925 | QKY-613 | 2646682-38-2 | Reference compound |
| HY-159926 | Tixanox (sodium) | 40691-57-4 | Reference compound |
| HY-159927 | TAK-661 | 175215-34-6 | Reference compound |
| HY-159928 | Neuroprotective agent 8 | | Reference compound |
| HY-159929 | Antibiotic adjuvant 2 | | Reference compound |
| HY-15992S | BIBF 1202-13C,d3 | | Isotope-Labeled Compounds |
| HY-15993 | Posizolid | 252260-02-9 | Reference compound |
| HY-159930 | Antibiotic adjuvant 3 | 2972593-21-6 | Reference compound |
| HY-159931 | HW161023 | 2920698-73-1 | Reference compound |
| HY-159932 | SARS-CoV-2 Mpro-IN-30 | | Reference compound |
| HY-159933 | SARS-CoV-2-IN-105 | | Reference compound |
| HY-159934 | QI-18 | | Reference compound |
| HY-159935 | Top1-IN-2 | | Reference compound |
| HY-159936 | CS4 | | Reference compound |
| HY-159937 | PKMYT1-IN-7 | 2986404-30-0 | Reference compound |
| HY-159938 | p38α inhibitor 6 | | Reference compound |
| HY-15994 | Citarinostat | 1316215-12-9 | Reference compound |
| HY-159940 | Ferroptosis/apoptosis inducer-2 | 2869886-85-9 | Reference compound |
| HY-159941 | tau-0N4R-IN-1 | 2200453-71-8 | Reference compound |
| HY-159942 | 5-HT7R antagonist 3 | 1887043-58-4 | Reference compound |
| HY-159943 | ROS151 | | Reference compound |
| HY-159944 | PPARγ agonist 14 | 6951-57-1 | Reference compound |
| HY-159945 | tau Protein/α-synuclein-IN-2 | | Reference compound |
| HY-159947 | PROTAC BTK Degrader-11 | 2736508-94-2 | Reference compound |
| HY-159949 | YS10 | 3055427-13-6 | Reference compound |
| HY-15995 | Tubulysin A | 205304-86-5 | ADC Related |
| HY-159952 | ALK5-IN-84 | | Reference compound |
| HY-159953 | IRAK1/4/pan-FLT3 Kinase-IN-1 | 2760328-82-1 | Reference compound |
| HY-159955 | DC-159a | 931411-93-7 | Reference compound |
| HY-159956 | BTK-IN-39 | 2736510-62-4 | Reference compound |
| HY-159957 | BAY-184 | 2520347-03-7 | Reference compound |
| HY-159958 | KNa1.1-IN-2 | 3037315-44-6 | Reference compound |
| HY-159959 | cis-3-Indoleacrylic acid | 29953-72-8 | Reference compound |
| HY-15996 | Seviteronel | 1610537-15-9 | Reference compound |
| HY-159960 | Carbonic anhydrase inhibitor 28 | | Reference compound |
| HY-159961 | SARS-CoV-2 Mpro-IN-34 | | Reference compound |
| HY-159962 | TGase2-IN-1 | 2244702-64-3 | Reference compound |
| HY-159963 | PfCLK3-IN-1 | | Reference compound |
| HY-159964 | USP7-IN-16 | 2166587-77-3 | Reference compound |
| HY-159965 | NOD1-RIPK2-IN-1 | | Reference compound |
| HY-159966 | Top/HDAC-IN-3 | 3059615-90-3 | Reference compound |
| HY-159969 | MLEB-22043 | | Reference compound |
| HY-15996A | Seviteronel (R enantiomer) | 1375603-38-5 | Reference compound |
| HY-15996B | Seviteronel (racemate) | 1375603-36-3 | Reference compound |
| HY-15997 | (-)-U-50488 (hydrochloride) | 114528-79-9 | Reference compound |
| HY-159972 | PKR1 antagonist 1 | 910113-60-9 | Reference compound |
| HY-159973 | Me-SJ46411 | | Reference compound |
| HY-159974 | Me-SJ46411-PEG1-Piperazine-Boc | | Reference compound |
| HY-159977 | 1,2-Didehydrotanshinone IIA | 119963-50-7 | Reference compound |
| HY-15997A | (+)-U-50488 (hydrochloride) | 114528-81-3 | Reference compound |
| HY-15997B | (±)-U-50488 (hydrochloride) | 67197-96-0 | Reference compound |
| HY-15997C | (±)-U-50488 (hydrate hydrochloride) | | Reference compound |
| HY-159982 | SH7s | | Reference compound |
| HY-159983 | GS-2278 | 2750508-72-4 | Reference compound |
| HY-159984 | HIV-1 inhibitor-78 | | Reference compound |
| HY-159985 | Jun13728 | | Reference compound |
| HY-159986 | X-17 | | Reference compound |
| HY-159987 | AB-161 | 2848560-66-5 | Reference compound |
| HY-159989 | UNC10142 | | Reference compound |
| HY-15999 | Cerdulatinib | 1198300-79-6 | Reference compound |
| HY-159990 | GPX4-IN-15 | 3032966-42-7 | Reference compound |
| HY-159993 | MR44397 | | Reference compound |
| HY-159994 | AUPF02 | 904803-58-3 | Reference compound |
| HY-159996 | GRL093-22 | | Reference compound |
| HY-159997 | AD353 | | Reference compound |
| HY-15999A | Cerdulatinib (hydrochloride) | 1369761-01-2 | Reference compound |
| HY-160001 | ZH8659 | 885466-70-6 | Reference compound |
| HY-160002 | MAO-B-IN-27 | 788824-83-9 | Reference compound |
| HY-160003 | PPARγ agonist 9 | 474329-47-0 | Reference compound |
| HY-160004 | PXL770 | 1523493-53-9 | Reference compound |
| HY-160005 | LMP517 | 1883730-99-1 | Reference compound |
| HY-160006 | PIM-IN-2 | 1006699-45-1 | Reference compound |
| HY-160007 | DHX9-IN-3 | 2973401-57-7 | Reference compound |
| HY-160008 | DHX9-IN-4 | 2973401-45-3 | Reference compound |
| HY-160009 | DHX9-IN-5 | 2973398-17-1 | Reference compound |
| HY-160010 | DHX9-IN-6 | 2973401-56-6 | Reference compound |
| HY-160013 | FGFR-IN-12 | 943189-02-4 | Reference compound |
| HY-160015 | CB07-Exatecan | 2879247-31-9 | ADC Related |
| HY-160017 | Pomalidomide-5'-C8-acid | 2682112-09-8 | Reference compound |
| HY-160018 | BAY-155 | 2163769-52-4 | Reference compound |
| HY-160019 | MTX115325 | 2750895-97-5 | Reference compound |
| HY-160020 | ET516 | 2820120-95-2 | Reference compound |
| HY-160021 | RORγt agonist 4 | 2241769-59-3 | Reference compound |
| HY-160022 | XIAP BIR2/BIR2-3 inhibitor-1 | 1609384-59-9 | Reference compound |
| HY-160023 | Elisrasib | 2914919-85-8 | Reference compound |
| HY-160025 | IDO antagonist-1 | 2206797-88-6 | Reference compound |
| HY-160026 | IL-17 modulator 8 | 1608097-49-9 | Reference compound |
| HY-160027 | TNF-alpha-IN-1 | | Reference compound |
| HY-160028 | IL-17 modulator 9 | 1449211-26-0 | Reference compound |
| HY-160029 | PRMT5-IN-32 | 2918815-34-4 | Reference compound |
| HY-160030 | XIAP BIR2/BIR2-3 inhibitor-3 | 1434125-52-6 | Reference compound |
| HY-160031 | GLP-1R agonist 19 | 2765065-09-4 | Reference compound |
| HY-160036 | PCSK9-IN-22 | 2794203-47-5 | Reference compound |
| HY-160037 | SEW06622 | 261349-28-4 | Reference compound |
| HY-160038 | GAC0003A4 | 929492-71-7 | Reference compound |
| HY-160039 | GAC0001E5 | 927969-67-3 | Reference compound |
| HY-160040 | Cobitolimod | 1226822-98-5 | Oligonucleotides |
| HY-160040A | Cobitolimod (sodium) | 1527479-55-5 | Oligonucleotides |
| HY-160041 | Olaptesed pegol | 1390628-22-4 | Oligonucleotides |
| HY-160041A | Olaptesed pegol (sodium) | | Oligonucleotides |
| HY-160042 | AFP aptamer (sodium) | | Oligonucleotides |
| HY-160043 | AL6 aptamer (sodium) | | Oligonucleotides |
| HY-160044 | Apt-M13 aptamer (sodium) | | Oligonucleotides |
| HY-160045 | AP1153 aptamer (sodium) | | Oligonucleotides |
| HY-160046 | AS2 (sodium) | | Oligonucleotides |
| HY-160047 | AX102 (sodium) | | Oligonucleotides |
| HY-160048 | PEG40K unconjugated/naked AX102 (sodium) | | Oligonucleotides |
| HY-160049 | BC15 aptamer (sodium) | | Oligonucleotides |
| HY-160050 | CD63-1 aptamer (sodium) | | Oligonucleotides |
| HY-160051 | CD63-2 aptamer (sodium) | | Oligonucleotides |
| HY-160052 | IL-6 aptamer (sodium) | | Oligonucleotides |
| HY-160053 | Gint4.T aptamer (sodium) | | Oligonucleotides |
| HY-160054 | GMT 3 aptamer (sodium) | | Oligonucleotides |
| HY-160055 | GMT 4 aptamer (sodium) | | Oligonucleotides |
| HY-160056 | GMT 5 aptamer (sodium) | | Oligonucleotides |
| HY-160057 | GMT 8 aptamer (sodium) | | Oligonucleotides |
| HY-160058 | GMT 9 aptamer (sodium) | | Oligonucleotides |
| HY-160059 | JHIT2e aptamer (sodium) | | Oligonucleotides |
| HY-160060 | MA3 aptamer (sodium) | | Oligonucleotides |
| HY-160061 | P12FR2 aptamer (sodium) | | Oligonucleotides |
| HY-160062 | S2.2 aptamer (sodium) | | Oligonucleotides |
| HY-160063 | SW1 aptamer (sodium) | | Oligonucleotides |
| HY-160064 | SW1-A aptamer (sodium) | | Oligonucleotides |
| HY-160065 | sgc8c aptamer (sodium) | | Oligonucleotides |
| HY-160065F | FAM-sgc8c aptamer (sodium) | | Dye Reagents |
| HY-160066 | SYL3C aptamer (sodium) | | Oligonucleotides |
| HY-160067 | T18.3 aptamer (sodium) | | Oligonucleotides |
| HY-160068 | 2-2(t) aptamer (sodium) | | Oligonucleotides |
| HY-160069 | Fmoc-Gly-Gly-Gly-NH-PEG4-C2-COOH | 2922060-48-6 | Reference compound |
| HY-16007 | (-)-Hydroxycitric acid | 27750-10-3 | Natural Products |
| HY-160070 | Phorbol-12,13-didecanoate | 24928-17-4 | Reference compound |
| HY-160071 | Bis(2,5-dioxopyrrolidin-1-yl) octadecanedioate | 191091-33-5 | Reference compound |
| HY-160072 | Fmoc-NH-PEG2-NHS ester | 1194666-63-1 | Reference compound |
| HY-160073 | Florensocatib | 2762114-61-2 | Reference compound |
| HY-160073A | Florensocatib (hydrate) | 2971064-13-6 | Reference compound |
| HY-160076 | APJ receptor agonist 8 | 2049973-39-7 | Reference compound |
| HY-160077 | Pomalidomide-CO-C5-azide | 2227423-33-6 | Reference compound |
| HY-160078 | Deferiprone O-β-D-glucuronide | 141675-48-1 | Reference compound |
| HY-160079A | 3′-O-Azidomethyl-dCTP (sodium) | | Biochemical Assay Reagents |
| HY-160080 | Creatinol (hemisulfate) | 50648-53-8 | Reference compound |
| HY-160081 | KCC2 Modulator-1 | 2704531-36-0 | Reference compound |
| HY-160082 | KCC2 Modulator-2 | 2704531-37-1 | Reference compound |
| HY-160084 | 2′-Deoxy-4′-thiocytidine | 134111-30-1 | Reference compound |
| HY-16009 | Buntanetap | 116839-68-0 | Reference compound |
| HY-160092 | Martinostat | 1629052-58-9 | Reference compound |
| HY-160092A | Martinostat (hydrochloride) | | Reference compound |
| HY-160093 | SQLE-IN-1 | 1019169-83-5 | Reference compound |
| HY-160094 | BCN-sulfonamide-PEG2-sulfonamide-N-bis(ethanol) | 2126749-81-1 | Reference compound |
| HY-160096 | M3541 | 1360628-91-6 | Reference compound |
| HY-160097 | AXC-666 | 313350-30-0 | Reference compound |
| HY-160099 | 20-5,14-HEDE | 240427-86-5 | Reference compound |
| HY-16009B | Buntanetap (L-Tartrate) | 865795-23-9 | Reference compound |
| HY-160105 | GABAB receptor antagonist 3 | 160415-40-7 | Reference compound |
| HY-160107 | AZ1422 | | Reference compound |
| HY-160108 | Bcl-2-IN-17 | 1321801-22-2 | Reference compound |
| HY-160109 | Ac5GalNTGc | | Reference compound |
| HY-160109A | Ac5GalNTGc epimer | 1334320-77-2 | Reference compound |
| HY-16011 | NE 10790 | 152831-36-2 | Reference compound |
| HY-160111 | PDM-042 | 1404488-48-7 | Reference compound |
| HY-160113 | Sodium phosphate buffer (pH 6.9 0.02 mol/l) | | Biochemical Assay Reagents |
| HY-160114 | Potassium phosphate buffer (pH 6.9 0.1 mol/l) | | Biochemical Assay Reagents |
| HY-160115 | TDP-43 degrader-1 | 2902692-25-3 | Reference compound |
| HY-160116 | α-Synuclein aggregate binder 1 | 1565797-17-2 | Reference compound |
| HY-16012 | Domatinostat (tosylate) | 1186222-89-8 | Reference compound |
| HY-160120 | Disodium carbamyl phosphate | 72461-86-0 | Reference compound |
| HY-160123 | DGKζ-IN-5 | 2951002-04-1 | Reference compound |
| HY-160124 | Infigratinib-Boc | 2504949-83-9 | Reference compound |
| HY-160127 | SerSA | 299437-44-8 | Reference compound |
| HY-160129 | Centanamycin | 413577-16-9 | Reference compound |
| HY-16012A | Domatinostat | 910462-43-0 | Reference compound |
| HY-160131 | Macropa | 1128304-86-8 | Reference compound |
| HY-160132 | TG-2-IN-4 | 2410899-01-1 | Reference compound |
| HY-16014 | A-385358 | 406228-55-5 | Reference compound |
| HY-160141 | Catadegbrutinib | 2736508-60-2 | Reference compound |
| HY-160142 | UBX-382 | 2884554-45-2 | Reference compound |
| HY-160143 | G3-VC-PAB-DMEA-Duocarmycin DM | 2415664-00-3 | ADC Related |
| HY-160144S | Lomedeucitinib | 2328068-29-5 | Isotope-Labeled Compounds |
| HY-160144S1 | (S)-Lomedeucitinib | 2328068-38-6 | Isotope-Labeled Compounds |
| HY-160144S2 | (rac)-Lomedeucitinib | 2328064-33-9 | Isotope-Labeled Compounds |
| HY-160147 | (Z)-Hexadec-9-en-15-ynoicacid | 2231023-75-7 | Reference compound |
| HY-16015 | Opaganib | 915385-81-8 | Reference compound |
| HY-160150 | 2-Hydroxyphytanoyl-CoA | 172787-73-4 | Reference compound |
| HY-160151 | TP1L | | Reference compound |
| HY-160155 | Cholesteryl-Teg azide | 1391826-58-6 | Reference compound |
| HY-160157 | IM-2 | 2813269-89-3 | ADC Related |
| HY-160159 | PPARγ modulator-1 | 1415321-54-8 | Reference compound |
| HY-16015A | Opaganib (hydrochloride) | 1185157-59-8 | Reference compound |
| HY-160160 | BAY-5516 | 2891706-79-7 | Reference compound |
| HY-160161 | BAY-5094 | 2891706-78-6 | Reference compound |
| HY-160162 | SR 11023 | 1820602-13-8 | Reference compound |
| HY-160165 | TRK-IN-25 | 2412309-60-3 | Reference compound |
| HY-160166 | TRK-IN-26 | 2412309-52-3 | Reference compound |
| HY-160167 | Birelentinib | 2662512-15-2 | Reference compound |
| HY-160168 | BTK-IN-31 | 2662512-02-7 | Reference compound |
| HY-160169 | Necrosis inhibitor 2 | 2258671-03-1 | Reference compound |
| HY-160169A | Necrosis inhibitor 2 (hydrocholide) | | Reference compound |
| HY-160170 | Necrosis inhibitor 3 | 2258670-86-7 | Reference compound |
| HY-160171 | CDK9-IN-31 | 2991074-93-0 | Reference compound |
| HY-160171A | CDK9-IN-31 (dimaleate) | | Reference compound |
| HY-160172 | ALK/ROS1-IN-4 | 2649878-59-9 | Reference compound |
| HY-160172A | ALK/ROS1-IN-4 (hydrate) | | Reference compound |
| HY-160173 | LPA receptor antagonist-1 | 1614824-42-8 | Reference compound |
| HY-160174 | BCR-ABL kinase-IN-3 | 2699634-21-2 | Reference compound |
| HY-160174A | BCR-ABL kinase-IN-3 (dihydrocholide) | | Reference compound |
| HY-160176 | SSTR5 antagonist 6 | 1007836-12-5 | Reference compound |
| HY-160177 | Glucocorticoid receptor agonist-3 | 2842165-73-3 | ADC Related |
| HY-160178 | Glucocorticoid receptor agonist-3 Ala-Ala-Mal | 3014393-35-9 | ADC Related |
| HY-160179 | Glucocorticoid receptor agonist-4 | 2842165-72-2 | ADC Related |
| HY-16018 | Ilorasertib | 1227939-82-3 | Reference compound |
| HY-160180 | Glucocorticoid receptor agonist-4 Ala-Ala-Mal | 3014393-37-1 | Reference compound |
| HY-160181 | INX-SM-3 | 2734877-96-2 | ADC Related |
| HY-160182 | INX-P | 2734878-02-3 | ADC Related |
| HY-160183 | LSD1-IN-29 | 1496573-83-1 | Reference compound |
| HY-160186 | 20-SOLA | | Reference compound |
| HY-160187 | AAA | | Reference compound |
| HY-160188 | BAY-9683 | 2891706-83-3 | Reference compound |
| HY-160189 | 3-Ethyl-3-methylthiolan-2-one | 103620-92-4 | Reference compound |
| HY-16018A | Ilorasertib (hydrochloride) | 1847485-91-9 | Reference compound |
| HY-160191 | LSD1-IN-30 | 1289575-45-6 | Reference compound |
| HY-160196 | HC-7366 | 2803470-63-3 | Reference compound |
| HY-160197 | Aluminum phosphate adjuvant | | Reference compound |
| HY-160197G | Aluminum phosphate adjuvant (GMP) | | GMP Small Molecules |
| HY-160198 | Vaccine adjuvant-1 | | Reference compound |
| HY-160198G | Vaccine adjuvant-1 (GMP) | | GMP Small Molecules |
| HY-160199 | 3'-L-Histidyl-AMP | 213206-31-6 | Oligonucleotides |
| HY-160199A | 3'-L-histidyl-AMP (disodium) | | Oligonucleotides |
| HY-16020 | AC-430 (hydrobromide) | 1359828-49-1 | Reference compound |
| HY-160202 | 18:1 Cardiolipin (disodium) | 115404-77-8 | Reference compound |
| HY-160203 | 18:0 Cardiolipin | 64069-64-3 | Oligonucleotides |
| HY-160207 | Elunetirom | 2156649-32-8 | Reference compound |
| HY-160208 | BI-8668 | 2084059-97-0 | Reference compound |
| HY-160209 | KIO-301 | 1643463-61-9 | Reference compound |
| HY-160210 | BAY-6096 | 2313483-41-7 | Reference compound |
| HY-160211 | JA310 | 3022928-90-8 | Reference compound |
| HY-160212 | JP3000 | 3034097-74-7 | Reference compound |
| HY-160213 | JA397 | | Reference compound |
| HY-160214 | Perforin-IN-2 | 1567836-70-7 | Reference compound |
| HY-160215 | TGF-βRI inhibitor 1 | 2169299-67-4 | Reference compound |
| HY-160215A | TGF-βRI inhibitor 1 (methylbenzenesulfonate) | 2345717-52-2 | Reference compound |
| HY-160216 | RIPK1-IN-18 | 2682889-01-4 | Reference compound |
| HY-160216A | RIPK1-IN-18 (sulfate hydrate) | 2897618-64-1 | Reference compound |
| HY-160217 | HPK1-IN-41 | 2828455-23-6 | Reference compound |
| HY-160218 | HPK1-IN-42 | 2848684-50-2 | Reference compound |
| HY-160219S | BTK-IN-33 | 2765854-31-5 | Isotope-Labeled Compounds |
| HY-16022 | Acetyldigitoxin | 1111-39-3 | Natural Products |
| HY-160220S | KRAS inhibitor-23 | 2641747-55-7 | Isotope-Labeled Compounds |
| HY-160221 | PROTAC AR Degrader-7 | 2505495-83-8 | Reference compound |
| HY-160222 | HSV-60mer (sodium) | | Oligonucleotides |
| HY-160223 | ssVACV-70mer (sodium) | | Oligonucleotides |
| HY-160224 | dsVACV-70mer (sodium) | | Oligonucleotides |
| HY-160225 | ISD (sodium) | | Oligonucleotides |
| HY-160226 | ISD Control (sodium) | | Oligonucleotides |
| HY-160227 | ORN 06 | 1116698-32-8 | Oligonucleotides |
| HY-160227A | ORN 06 (sodium) | | Oligonucleotides |
| HY-160228 | ORN 02 | 937769-72-7 | Oligonucleotides |
| HY-160228A | ORN 02 (sodium) | | Oligonucleotides |
| HY-160229 | ssRNA40 (sodium) | | Oligonucleotides |
| HY-16023 | Acolbifene (hydrochloride) | 252555-01-4 | Reference compound |
| HY-160230 | ssRNA41 (sodium) | | Oligonucleotides |
| HY-160231 | ssRNA42 (sodium) | | Oligonucleotides |
| HY-160234 | mc-vc-PAB-PBD | 2088364-36-5 | ADC Related |
| HY-160235 | Pomalidomide-C2-amide-C5-azide | 2732859-29-7 | Reference compound |
| HY-160236 | 3-(3-Sulfooxyphenyl)propanoic acid | 86321-32-6 | Reference compound |
| HY-160237 | HYL001 | 2426547-83-1 | Reference compound |
| HY-160239 | HFI-437 | 1110650-74-2 | Reference compound |
| HY-16023A | Acolbifene | 182167-02-8 | Reference compound |
| HY-16023B | (Rac)-Acolbifene | 151533-34-5 | Reference compound |
| HY-160240 | HPI | 210541-64-3 | Reference compound |
| HY-160241 | Lenalidomide-C5-acid | 2338824-30-7 | Reference compound |
| HY-160244 | Pomalidomide 5'-piperazine-4-methylpiperidine (dihydrochloride) | 2758431-93-3 | Reference compound |
| HY-160245 | QL47R | 1579278-89-9 | Reference compound |
| HY-160246 | QL47B | 1579278-92-4 | Reference compound |
| HY-160246A | QL47B (TFA) | | Reference compound |
| HY-160247 | Boc-Lys-PEG8-N-bis(D-glucose) | 2892350-30-8 | ADC Related |
| HY-16025 | EOC317 | 939805-30-8 | Reference compound |
| HY-160250 | UGT1A1-IN-1 | 2097024-37-6 | Reference compound |
| HY-160251 | 3-HC-Gluc | 132929-88-5 | Reference compound |
| HY-160252 | PHGDH-IN-4 | 2132969-16-3 | Reference compound |
| HY-160255 | N-Cbz-L-Cysteine | 53907-29-2 | Reference compound |
| HY-160255A | N-Cbz-D-Cysteine | 156916-81-3 | Reference compound |
| HY-160256 | DSPE-PEG-BDP FL,MW 2000 | | Biochemical Assay Reagents |
| HY-160257 | DOPE-PEG-BDP FL,MW 5000 | | Biochemical Assay Reagents |
| HY-160258 | GDP-Fucose-Tz | 2762518-76-1 | Reference compound |
| HY-160259 | VEGFR-2-IN-39 | 2353417-86-2 | Reference compound |
| HY-16026 | Ricolinostat | 1316214-52-4 | Reference compound |
| HY-160260 | EP300/CBP-IN-1 | 2638507-71-6 | Reference compound |
| HY-160261S | EP300/CBP-IN-2 | 2379527-49-6 | Isotope-Labeled Compounds |
| HY-160262 | AR/BET protein degrader-1 | 2571123-81-2 | Reference compound |
| HY-160263S | Anticancer agent 186 | 2408740-75-8 | Isotope-Labeled Compounds |
| HY-160264 | PROTAC ER Degrader-12 | | Reference compound |
| HY-160265 | URAT1 inhibitor 9 | 2251727-90-7 | Reference compound |
| HY-160266 | THR-β agonist 7 | 2604229-32-3 | Isotope-Labeled Compounds |
| HY-160267 | iPAF1C | 950403-60-8 | Reference compound |
| HY-160269 | DSPE-PEG-Fluor 488,MW 2000 | | Biochemical Assay Reagents |
| HY-16027 | Acyline | 170157-13-8 | Peptides |
| HY-160270 | DSPE-PEG-Fluor 488,MW 5000 | | Biochemical Assay Reagents |
| HY-160271 | DSPE-CH2-PEG-Fluor 488,MW 2000 | | Biochemical Assay Reagents |
| HY-160272 | DOPE-PEG-Fluor 488,MW 2000 | | Biochemical Assay Reagents |
| HY-160273 | DOPE-PEG-Fluor 488,MW 5000 | | Biochemical Assay Reagents |
| HY-160274 | DSPE-PEG-Fluor 555,MW 2000 | | Biochemical Assay Reagents |
| HY-160275 | DOPE-PEG-Fluor 555,MW 2000 | | Biochemical Assay Reagents |
| HY-160276 | DOPE-PEG-Fluor 555,MW 5000 | | Biochemical Assay Reagents |
| HY-160277 | DSPE-PEG-Fluor 594,MW 2000 | | Biochemical Assay Reagents |
| HY-160278 | DSPE-PEG-Fluor 647,MW 2000 | | Biochemical Assay Reagents |
| HY-160279 | DSPE-PEG-Fluor 647,MW 5000 | | Biochemical Assay Reagents |
| HY-16027A | Acyline (TFA) | | Peptides |
| HY-160280 | DOPE-PEG-Fluor 647,MW 2000 | | Biochemical Assay Reagents |
| HY-160281 | CCD-2 | 2271351-19-8 | Reference compound |
| HY-160282 | PI3K-IN-49 | 2922415-69-6 | Reference compound |
| HY-160283 | PI3K-IN-50 | 3023536-43-5 | Reference compound |
| HY-160284 | CDK12/13-IN-1 | 2407774-31-4 | Reference compound |
| HY-160287 | NVS MLLT-1 | 2561471-13-2 | Reference compound |
| HY-160289 | ARI-3144 | 1426305-25-0 | Reference compound |
| HY-160291 | Trivalent GalNAc-DBCO | 2765060-22-6 | Reference compound |
| HY-160292 | Enoltasosartan | 159237-67-9 | Reference compound |
| HY-160296 | AN-988 | 340304-55-4 | Reference compound |
| HY-160297 | GDP-FAzP4Biotin | 2762518-71-6 | Reference compound |
| HY-16031 | AFP464 (free base) | 468719-52-0 | Reference compound |
| HY-16031B | AFP464 (dihydrochloride) | | Reference compound |
| HY-16032 | Akt1-IN-2 | 473382-39-7 | Reference compound |
| HY-16034 | AKT-IN-20 | 473382-50-2 | Reference compound |
| HY-16035 | Alatrofloxacin | 146961-76-4 | Reference compound |
| HY-16035A | Alatrofloxacin (mesylate) | 146961-77-5 | Reference compound |
| HY-16036A | ALB-109564 (hydrochloride) | 1300114-12-8 | Reference compound |
| HY-16039 | AM095 | 1345614-59-6 | Reference compound |
| HY-16040 | AM095 (free acid) | 1228690-36-5 | Reference compound |
| HY-160406 | SNX281 | 2332803-84-4 | Reference compound |
| HY-160408 | Mal-GGG-Bal-NHS ester | 1193111-65-7 | ADC Related |
| HY-160409 | TopBP1-IN-1 | 1212595-23-7 | Reference compound |
| HY-160410 | Ceramide 3B | 178436-06-1 | Natural Products |
| HY-160412 | Balinatunfib | 2248726-53-4 | Reference compound |
| HY-160414 | TRX-COBI | | Reference compound |
| HY-160415 | WD6305 | | Reference compound |
| HY-160415A | WD6305 (TFA) | | Reference compound |
| HY-160416 | THR-β modulator-2 | 2542029-56-9 | Reference compound |
| HY-160417 | PARP1-IN-19 | 2756337-27-4 | Reference compound |
| HY-160418 | PI3K-IN-51 | 2055765-77-8 | Reference compound |
| HY-160419 | Mps1-IN-8 | 2259843-95-1 | Reference compound |
| HY-160420 | Cinoxolone | 31581-02-9 | Reference compound |
| HY-160421 | TREM2-IN-1 | 2000236-36-0 | Reference compound |
| HY-160424 | DEANO (sodium) | 92382-74-6 | Reference compound |
| HY-160426 | Gcase activator 3 | 2270984-21-7 | Reference compound |
| HY-160428 | DMTr-5-fluoro-2'-deoxycytidine-phosphoramidite | 143774-48-5 | Reference compound |
| HY-160429 | PSAR18-COOH | 2313534-26-6 | Peptides |
| HY-160433 | TNF-α-IN-12 | 364039-56-5 | Reference compound |
| HY-160434 | TNF-α-IN-13 | 364039-48-5 | Reference compound |
| HY-160435 | TNF-α-IN-14 | 364039-54-3 | Reference compound |
| HY-160436 | TNF-α-IN-15 | 364039-58-7 | Reference compound |
| HY-160437 | TNF-α-IN-16 | 364039-60-1 | Reference compound |
| HY-160438 | PBX-7011 | 3003834-30-5 | Reference compound |
| HY-160438A | PBX-7011 (mesylate) | | ADC Related |
| HY-160438B | PBX-7011 (TFA) | | Reference compound |
| HY-160439 | Ionizable lipid-2 | 2763904-72-7 | Oligonucleotides |
| HY-160440 | rel-VU6021625 | 2307718-96-1 | Reference compound |
| HY-160440A | VU6021625 | 2803696-99-1 | Reference compound |
| HY-160441 | MC-Val-Cit-PAB-Ispinesib | 1629737-40-1 | ADC Related |
| HY-160444 | SJ3149 | 3026986-17-1 | Reference compound |
| HY-160445 | KRAS G12D inhibitor 19 | 2833695-47-7 | Reference compound |
| HY-160446 | BET-IN-24 | 2407658-21-1 | Reference compound |
| HY-160447 | FAK/Aurora kinase-IN-1 | 2178117-69-4 | Reference compound |
| HY-160448 | p53 Activator 9 | 2849345-37-3 | Reference compound |
| HY-160449 | p53 Activator 10 | 2849484-29-1 | Reference compound |
| HY-16045 | Hexaminolevulinate (hydrochloride) | 140898-91-5 | Dye Reagents |
| HY-160450 | p53 Activator 11 | 2850211-42-4 | Reference compound |
| HY-160453 | MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH | 2922606-39-9 | ADC Related |
| HY-160455 | GSTP1-1 inhibitor 1 | 3829-23-0 | Reference compound |
| HY-160456 | FABP4/5-IN-4 | 2862795-48-8 | Reference compound |
| HY-160457 | FABP4/5-IN-5 | 2862791-11-3 | Reference compound |
| HY-160458 | PI3Kα-IN-17 | 2935973-28-5 | Reference compound |
| HY-16046 | Rimiducid | 195514-63-7 | Reference compound |
| HY-160469 | INY-05-040 | 2503018-29-7 | Reference compound |
| HY-160471S | N-Nitrososertraline-d3 | | Isotope-Labeled Compounds |
| HY-160473 | TAM557 | 1802499-20-2 | ADC Related |
| HY-160473A | TAM557 (TFA) | | Reference compound |
| HY-160477 | DC-SX029 | 300713-88-6 | Reference compound |
| HY-160478 | GNF-6 | 839708-29-1 | Reference compound |
| HY-160481 | MG-1102 | 2567913-75-9 | Reference compound |
| HY-160485 | G-4'G-7S | 1630724-68-3 | Reference compound |
| HY-160487 | KME-2780 | 2968466-26-2 | Reference compound |
| HY-160488 | PTK7/β-catenin-IN-1 | 906147-24-8 | Reference compound |
| HY-160489 | PTK7/β-catenin-IN-2 | 902434-29-1 | Reference compound |
| HY-160493 | PTK7/β-catenin-IN-6 | 1219439-82-3 | Reference compound |
| HY-160496 | STAT3-IN-25 | 2591440-75-2 | Reference compound |
| HY-160497 | MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 | 2722697-86-9 | Reference compound |
| HY-160498 | Amoitone B | 1257228-26-4 | Reference compound |
| HY-160499 | BRD4 Inhibitor-30 | 1789731-20-9 | Reference compound |
| HY-16050 | Plitidepsin | 137219-37-5 | Natural Products |
| HY-160501 | DS17 | | Reference compound |
| HY-160502 | CST967 | | Reference compound |
| HY-160505 | RO-275 | 2648837-04-9 | Reference compound |
| HY-160506 | PRO-6E | 2353493-69-1 | Reference compound |
| HY-160508 | NCX1-IN-1 | 2754283-55-9 | Reference compound |
| HY-160509 | BTB 06061 | 652967-47-0 | Reference compound |
| HY-16050R | Plitidepsin (Standard) | 137219-37-5 | Reference Standards |
| HY-160512 | Lipid 9 | 2982842-90-8 | Oligonucleotides |
| HY-160514 | LXQ46 | 2097148-94-0 | Reference compound |
| HY-160515 | USP7-IN-13 | 2305046-93-7 | Reference compound |
| HY-160519 | Targocil-II | 955918-74-8 | Reference compound |
| HY-160520 | ALK-IN-28 | 1108743-80-1 | Reference compound |
| HY-160523 | DBCO Ir catayst | 2695594-15-9 | Reference compound |
| HY-160524 | NOX2-IN-3 | 921145-98-4 | Reference compound |
| HY-160525 | CDO1 degrader-1 | | Reference compound |
| HY-160527 | BRD4 degrader-4 | 2851986-83-7 | Reference compound |
| HY-160528 | IBG3 | | Reference compound |
| HY-160529 | α7 nAChR Modulator-2 | | Reference compound |
| HY-160530 | WEE1-IN-6 | 2928524-08-5 | Reference compound |
| HY-160531 | IKZF1-degrader-1 | 2915586-02-4 | Reference compound |
| HY-160532 | CK1α degrader-1 | 2881012-96-8 | Reference compound |
| HY-160533 | IKZF1-degrader-2 | 2915330-86-6 | Reference compound |
| HY-160540 | MRGPRX2 modulator-1 | 2781839-42-5 | Reference compound |
| HY-160542 | Clenhexyl (hydrochloride) | 37162-93-9 | Reference compound |
| HY-160543 | Exatecan-amide-CH2-O-CH2-CH2-OH | 2920907-39-5 | ADC Related |
| HY-160545 | NLRP3-IN-31 | 2769040-08-4 | Reference compound |
| HY-160546 | cGAS-IN-2 | 2765273-11-6 | Reference compound |
| HY-160547 | PROTAC AR Degrader-5 | 2703021-51-4 | Reference compound |
| HY-160548 | mTOR inhibitor-18 | 2170358-67-3 | Reference compound |
| HY-160549 | c-Myc inhibitor 14 | 2581994-88-7 | Reference compound |
| HY-16055 | Silatecan | 220913-32-6 | Reference compound |
| HY-160550 | DPM-1003 | 3018836-86-4 | Reference compound |
| HY-160552 | 244cis | 2956402-64-3 | Biochemical Assay Reagents |
| HY-160553 | 9322-O16B | 2909427-23-0 | Biochemical Assay Reagents |
| HY-160554 | C12-113 | 1220890-27-6 | Biochemical Assay Reagents |
| HY-160555 | (S,R,S)-AHPC-CO-C9-NH2 | 2349429-71-4 | Reference compound |
| HY-160555A | (S,R,S)-AHPC-CO-C9-NH2 (hydrochloride) | 2376139-50-1 | Reference compound |
| HY-160556 | CDK2-IN-26 | 2821777-43-7 | Reference compound |
| HY-160557 | PLK1/BRD4-IN-2 | 2251709-89-2 | Reference compound |
| HY-160558 | PLK1/BRD4-IN-3 | 2251709-91-6 | Reference compound |
| HY-16056 | Arbutamine | 128470-16-6 | Reference compound |
| HY-160562 | PROTAC ERα Degrader-7 | 3025781-93-2 | Reference compound |
| HY-160563 | PROTAC ERα Degrader-8 | 3025533-68-7 | Reference compound |
| HY-160564 | ZNL-0056 | 2767987-38-0 | Reference compound |
| HY-160569 | C14-SPM | 2241864-59-3 | Biochemical Assay Reagents |
| HY-16056A | Arbutamine (hydrochloride) | 125251-66-3 | Reference compound |
| HY-160573 | cKK-E15 | 1432494-71-7 | Biochemical Assay Reagents |
| HY-160576 | DNCA | 2226561-66-4 | Biochemical Assay Reagents |
| HY-160577 | DOG-IM4 | 2758097-38-8 | Biochemical Assay Reagents |
| HY-160578 | Glucosamine Cholesterol | 1257309-90-2 | Biochemical Assay Reagents |
| HY-160579 | MIC5 | 2349307-32-8 | Biochemical Assay Reagents |
| HY-160580 | G1-OC2-K3-E10 | 2933216-12-5 | Biochemical Assay Reagents |
| HY-160581 | OH-C-Chol | 496801-51-5 | Biochemical Assay Reagents |
| HY-160582 | MR-2-93-3 | 2941228-90-4 | Biochemical Assay Reagents |
| HY-160585 | PD-L1/PD-1-IN-1 | 2753642-49-6 | Reference compound |
| HY-160586 | Srpk1-IN-1 | 2408444-93-7 | Reference compound |
| HY-160587 | Antiangiogenic agent 5 | 2095397-52-5 | Reference compound |
| HY-160588 | Nav1.8-IN-7 | 2761181-58-0 | Reference compound |
| HY-160589 | Nav1.8-IN-8 | 2626945-23-9 | Reference compound |
| HY-16059 | Arglabin | 84692-91-1 | Natural Products |
| HY-160591 | Nav1.8-IN-10 | 2664047-95-2 | Reference compound |
| HY-160592 | Nav1.8-IN-11 | 2990578-70-4 | Reference compound |
| HY-160593 | Nav1.8-IN-12 | 3029020-84-3 | Reference compound |
| HY-160596 | 5-Formyl-dCTP | 2409156-19-8 | Reference compound |
| HY-160597 | Exatecan-amide-bicyclo[1.1.1]pentan-1-ol | 2866299-06-9 | ADC Related |
| HY-160598 | Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol | 2891774-71-1 | Reference compound |
| HY-16060 | Apalutamide | 956104-40-8 | Reference compound |
| HY-160602 | CPL207280 | 2361497-72-3 | Reference compound |
| HY-160603 | PF-05214030 | 1669444-50-1 | Reference compound |
| HY-160604 | Remacemide | 128298-28-2 | Reference compound |
| HY-160607 | MMA-NODAGA | 1440903-11-6 | Reference compound |
| HY-16060R | Apalutamide (Standard) | 956104-40-8 | Reference Standards |
| HY-16060S | Apalutamide-d4 | 1638885-65-0 | Isotope-Labeled Compounds |
| HY-16060S1 | Apalutamide-d3 | 1638885-61-6 | Isotope-Labeled Compounds |
| HY-16060S2 | Apalutamide-13C,d3 | | Isotope-Labeled Compounds |
| HY-16060S3 | Apalutamide-d7 | | Isotope-Labeled Compounds |
| HY-160610A | Carbamoyl phosphate (dilithium salt) | 1866-68-8 | Reference compound |
| HY-160611 | TgENR-IN-1 | 1428626-91-8 | Reference compound |
| HY-160612 | Transthyretin-IN-2 | 4664-62-4 | Reference compound |
| HY-160613 | EGFR/HER2-IN-11 | 1346176-20-2 | Reference compound |
| HY-160615 | TP receptor antagonist-1 | 1448452-21-8 | Reference compound |
| HY-160616 | LPA5 antagonist 3 | 1664336-44-0 | Reference compound |
| HY-160617 | SIRT2-IN-14 | 1884571-59-8 | Reference compound |
| HY-160618 | 11β-HSD2-IN-2 | 1834601-37-4 | Reference compound |
| HY-16062 | ARQ 621 | 1095253-39-6 | Reference compound |
| HY-160621 | CXF-009 | 2727084-00-4 | Reference compound |
| HY-160623 | INS018 055 | 2828567-39-9 | Reference compound |
| HY-160624 | CD 10899 | 1331770-20-7 | Reference compound |
| HY-160628 | GPR120 Agonist 4 | 1628641-89-3 | Reference compound |
| HY-16063 | ARQ-736 | 1228237-57-7 | Reference compound |
| HY-160633 | PfFAS-II inhibitor 1 | 1459704-68-7 | Reference compound |
| HY-160634 | BRD4 Inhibitor-31 | 1446233-35-7 | Reference compound |
| HY-160635 | Ack1 inhibitor 2 | 1196392-26-3 | Reference compound |
| HY-160636 | BRD4 Inhibitor-32 | 1445992-86-8 | Reference compound |
| HY-160637 | Lp-PLA2-IN-17 | 1818842-74-8 | Reference compound |
| HY-160638 | NSC-311068 | 73768-68-0 | Reference compound |
| HY-160641 | isoG Nucleoside-1 | 242816-13-3 | Oligonucleotides |
| HY-160642 | isoG Nucleoside-2 | 915098-24-7 | Reference compound |
| HY-160643 | CDK2-IN-27 | 2927473-94-5 | Reference compound |
| HY-160644 | 8PC | 952588-30-6 | Reference compound |
| HY-160645 | P2X4 antagonist-1 | 2055601-42-6 | Reference compound |
| HY-160646 | LTA4H-IN-3 | 2707473-09-2 | Reference compound |
| HY-160647 | CCR8 antagonist 3 | 912463-57-1 | Reference compound |
| HY-160648 | InhA-IN-6 | 1040406-33-4 | Reference compound |
| HY-160649 | MC-Gly-Gly-Phe-Gly-GABA-Exatecan | 1599439-52-7 | ADC Related |
| HY-160652 | 17-Azidoheptadecanoic acid | 1841512-95-5 | Reference compound |
| HY-160653 | JPL | 952588-18-0 | Reference compound |
| HY-160654 | IRAK4 modulator-1 | 1356014-97-5 | Reference compound |
| HY-160655 | SERT-IN-3 | 289717-03-9 | Reference compound |
| HY-160656 | 5-HT/NA Reuptake inhibitor-1 | 844882-78-6 | Reference compound |
| HY-160657 | DC-TEADin04 | 2380228-38-4 | Reference compound |
| HY-160658 | AZ760 | 912461-36-0 | Reference compound |
| HY-160659 | Androgen receptor antagonist 10 | 876759-87-4 | Reference compound |
| HY-160660 | BRD4 Inhibitor-33 | 1445993-17-8 | Reference compound |
| HY-160661 | LPAR1 antagonist 2 | 1664336-46-2 | Reference compound |
| HY-160662 | BRD4-IN-5 | 1445993-41-8 | Reference compound |
| HY-160663 | Nav1.7 blocker 1 | 1426336-36-8 | Reference compound |
| HY-160664 | TP receptor antagonist-2 | 1448452-22-9 | Reference compound |
| HY-160668 | Histamine H3 antagonist-1 | 1000392-25-5 | Reference compound |
| HY-160669 | Antibacterial agent 198 | 1649473-36-8 | Reference compound |
| HY-160670 | BRD4-IN-6 | 1446232-91-2 | Reference compound |
| HY-160671 | BRD4-IN-7 | 1446232-98-9 | Reference compound |
| HY-160672 | BRD4-IN-8 | 1445992-82-4 | Reference compound |
| HY-160675 | TCMDC-137332 | 165119-08-4 | Reference compound |
| HY-160676 | sEH-IN-1 | 1061377-99-8 | Reference compound |
| HY-160677 | P2X4 antagonist-2 | 2055601-24-4 | Reference compound |
| HY-160678 | InhA-IN-7 | 952588-17-9 | Reference compound |
| HY-160679 | BaENR-IN-1 | 1071966-17-0 | Reference compound |
| HY-160680 | AR antagonist 6 | 876760-08-6 | Reference compound |
| HY-160681 | OvCHT1-IN-1 | 1613336-69-8 | Reference compound |
| HY-160682 | EGFR/HER2-IN-12 | 2237230-21-4 | Reference compound |
| HY-160683 | MC-Gly-Gly-Phe-Gly-NH-CH2-O-amide-Eribulin | 2907719-55-3 | ADC Related |
| HY-160684 | GW701427A | 433224-56-7 | Reference compound |
| HY-160685 | GW809897X | 579515-94-9 | Reference compound |
| HY-160686 | GSK248233A | 850665-21-3 | Reference compound |
| HY-160687 | GW549390X | 135307-33-4 | Reference compound |
| HY-160688 | GW759710A | 944795-23-7 | Reference compound |
| HY-160689 | GW694590A | 948313-24-4 | Reference compound |
| HY-16069 | Tucatinib | 937263-43-9 | Reference compound |
| HY-160690 | GW632046X | 681002-67-5 | Reference compound |
| HY-160691 | GW814408X | 886599-05-9 | Reference compound |
| HY-160692 | AR antagonist 7 | 876759-97-6 | Reference compound |
| HY-160693 | 2′-O-Methylguanosine 5′-monophosphate | 24121-01-5 | Reference compound |
| HY-160694 | cBu-Cit-PROTAC BRD4 Degrader-5 | 2417369-73-2 | Reference compound |
| HY-160695 | PT-179 | 2924858-25-1 | Reference compound |
| HY-160696 | ORIC-533 | 2641306-62-7 | Reference compound |
| HY-160698 | SGR-1505 | 2661481-41-8 | Reference compound |
| HY-160699 | DCC-3116 | 2543673-19-2 | Reference compound |
| HY-16069A | Tucatinib (hemiethanolate) | 1429755-56-5 | Reference compound |
| HY-16069S | Tucatinib-d6 | | Isotope-Labeled Compounds |
| HY-160700 | TNG348 | 2839740-79-1 | Reference compound |
| HY-160701 | Cirtociclib | 2888704-84-3 | Reference compound |
| HY-160702 | DMBA-SIL-Mal-MMAE | 2923885-49-6 | ADC Related |
| HY-160703 | DMBA-SIL-PNP | 2923885-47-4 | Reference compound |
| HY-160704 | CMX-521 | 2077178-99-3 | Reference compound |
| HY-160705 | PNI 132 | 2568616-81-7 | Oligonucleotides |
| HY-160706 | HHQ16 | 2620471-66-9 | Oligonucleotides |
| HY-160708 | Tie2 kinase inhibitor 3 | 870225-11-9 | Reference compound |
| HY-160709 | Wnt/β-catenin-IN-2 | 1397006-01-7 | Reference compound |
| HY-16071 | AT13148 | 1056901-62-2 | Reference compound |
| HY-160714 | Fmoc-Ala-Ala-Ala-amide-C-O-C-COOH | 3002986-41-3 | ADC Related |
| HY-160715 | BNT411 | 2296821-50-4 | Reference compound |
| HY-160719 | NHS-activated 2-octynoic acid-BSA | | Reference compound |
| HY-160726 | Polymethacrylate Copolymer (N−C4−52−6.9) | 2315261-99-3 | Biochemical Assay Reagents |
| HY-160728 | 3′-O-N3-dATP | 1048021-78-8 | Oligonucleotides |
| HY-160728A | 3′-O-N3-dATP (trisodium) | | Reference compound |
| HY-160734 | Aleniglipron | 2685823-26-9 | Reference compound |
| HY-16074 | ATN-224 | 649749-10-0 | Reference compound |
| HY-160745 | 2'-O-methyladenosine 5'-phosphate | 24121-00-4 | Oligonucleotides |
| HY-160755 | UM-2 | 349484-08-8 | Oligonucleotides |
| HY-160756A | Val-Cit-Exatecan (TFA) | | ADC Related |
| HY-160758 | J9Z38 | 1414864-34-8 | Reference compound |
| HY-160761 | K-Opioid receptor agonist-1 | 1816990-29-0 | Reference compound |
| HY-160764 | N6-Carboxymethyl-ATP | 55860-25-8 | Reference compound |
| HY-160765 | WNTinib | 2770091-44-4 | Reference compound |
| HY-160768 | OTUB2-IN-1 | | Reference compound |
| HY-160769 | NIBR-LTSi | | Reference compound |
| HY-160773 | DBCO-PEG6-NHS ester | | Reference compound |
| HY-160773A | DBCO-C3-amide-PEG6-NHS ester | | Reference compound |
| HY-160774 | Val-Cit-PABC-DOX | 1022094-34-3 | ADC Related |
| HY-160776 | Diazido-methyltetrazine tri-arm | 2861998-18-5 | ADC Related |
| HY-160777 | VNPP433-3β | 1630820-51-7 | Reference compound |
| HY-160783 | SRI-43265 | 2727872-88-8 | Reference compound |
| HY-160785 | TREX1-IN-1 | 2756594-27-9 | Reference compound |
| HY-160786 | TREX1-IN-3 | 2588445-13-8 | Reference compound |
| HY-160786A | TREX1-IN-4 | 2588445-14-9 | Reference compound |
| HY-160787 | NCGC1481 | 2193085-94-6 | Reference compound |
| HY-160788 | DBCO-β-Glu-PEG12-Exatecan | 3025107-83-6 | Reference compound |
| HY-16079 | AZD3514 | 1240299-33-5 | Reference compound |
| HY-160790 | β-Glu-PNP | 3025520-67-3 | ADC Related |
| HY-160791 | Claramine | 1430194-56-1 | Reference compound |
| HY-160791A | Claramine (TFA) | 3030428-57-7 | Reference compound |
| HY-160793 | NSC80734 | 501950-47-6 | Reference compound |
| HY-160795 | Boc-NMeVal-Val-Dil-Dap | 1369426-99-2 | ADC Related |
| HY-160799 | HA-9104 | 2412367-83-8 | Reference compound |
| HY-160801 | HKYK-0030 | 2923054-94-6 | Reference compound |
| HY-160804 | Desmethyl nevanimibe | 2419904-59-7 | Reference compound |
| HY-160806 | (5-Cl)-Exatecan | 2813268-66-3 | Oligonucleotides |
| HY-160807 | DBM-GGFG-NH-O-CO-Exatecan | 2769152-95-4 | ADC Related |
| HY-160811 | hVEGF-IN-3 | 46739-60-0 | Reference compound |
| HY-160818 | MC3138 | 1844889-12-8 | Reference compound |
| HY-16082 | AZD7545 | 252017-04-2 | Reference compound |
| HY-160821A | N-Acetylmannosamine 6-phosphate (sodium salt) | 335275-62-2 | Reference compound |
| HY-160822 | AGG-523 | 920289-29-8 | Reference compound |
| HY-160831 | PQQ-trimethylester | 74447-88-4 | Reference compound |
| HY-160832 | GC373 | 1429218-54-1 | Reference compound |
| HY-160839 | SPB-PEG4-AAD | 3027246-94-9 | Reference compound |
| HY-160840 | SPB-AAD | 3027246-93-8 | Reference compound |
| HY-160841 | Biotin-16-dCTP | 2567941-52-8 | Reference compound |
| HY-160842 | CSF1R-IN-24 | 3024322-57-1 | Reference compound |
| HY-160843 | NCAO | 20584-81-0 | Reference compound |
| HY-160845 | HDAC6-IN-39 | 2653255-56-0 | Reference compound |
| HY-160846 | HDAC6-IN-40 | 2653254-34-1 | Reference compound |
| HY-160848 | FLT3/ITD-IN-5 | 3023632-62-1 | Reference compound |
| HY-160849 | N-Desmethyl Rilmazolam | 50330-93-3 | Reference compound |
| HY-160850 | C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) | 384835-48-7 | Reference compound |
| HY-160851 | GDC-3280 | 1590403-33-0 | Reference compound |
| HY-160852 | YSK 12C4 | 1829511-70-7 | Reference compound |
| HY-160853 | Tubulin inhibitor 42 | 2135713-96-9 | Reference compound |
| HY-160854 | Tubulin inhibitor 43 | 1541208-02-9 | Reference compound |
| HY-160856 | TOP5300 | 1848981-48-5 | Reference compound |
| HY-160857 | TOP5668 | 1850256-71-1 | Reference compound |
| HY-160859 | WRN inhibitor 8 | 3026502-95-1 | Reference compound |
| HY-16086 | Balaglitazone | 199113-98-9 | Reference compound |
| HY-160864 | Torbafylline | 105102-21-4 | Reference compound |
| HY-160865 | PRMT5-IN-35 | 1989620-03-2 | Reference compound |
| HY-160866 | (Rac)-D3S-001 | 2706637-43-4 | Reference compound |
| HY-160869 | Firefly luciferase-IN-2 | 796108-95-7 | Dye Reagents |
| HY-160870 | Firefly luciferase-IN-3 | 898155-17-4 | Dye Reagents |
| HY-160871 | Anticancer agent 208 | 894565-34-5 | Reference compound |
| HY-160873 | Firefly luciferase-IN-5 | 959557-37-0 | Dye Reagents |
| HY-160874 | GST-FH.4 | 1358386-87-4 | Reference compound |
| HY-160875 | GST-FH.1 | 920115-54-4 | Reference compound |
| HY-160876 | BC-1901S | 1358617-36-3 | Reference compound |
| HY-160877 | EBOV-IN-2 | | Reference compound |
| HY-160878 | EBOV-IN-3 | 2896193-40-9 | Reference compound |
| HY-160879 | EBOV-IN-4 | 2896193-43-2 | Reference compound |
| HY-160880 | EBOV-IN-5 | 68207-15-8 | Reference compound |
| HY-160881 | EBOV-IN-6 | | Reference compound |
| HY-160882 | EBOV-IN-7 | 68207-16-9 | Reference compound |
| HY-160883 | EBOV-IN-8 | 286854-12-4 | Reference compound |
| HY-160884 | DMT-2'-OMe-D-Ribitol phosphoramidite | 1470023-72-3 | Oligonucleotides |
| HY-160885 | NH2-Gly-PAB-Exatecan-D-glucuronic acid | 2763252-31-7 | Reference compound |
| HY-160885A | NH2-Gly-PAB-Exatecan-D-glucuronic acid (formic) | | Reference compound |
| HY-160887 | FPT | 2048491-06-9 | Reference compound |
| HY-160888 | ASP8302 | 1839583-42-4 | Reference compound |
| HY-160893 | PSMA-azide | 2374814-84-1 | ADC Related |
| HY-160896 | Autophagy-IN-5 | 1262888-20-9 | Reference compound |
| HY-160897 | Methoxy-PEG-C3-amide-C2-Mal | 883993-35-9 | Reference compound |
| HY-160899A | Thailanstatin A cyclohexane diamine (formic) | | Reference compound |
| HY-160900 | RN-1665 | 1803003-65-7 | Reference compound |
| HY-160901 | CP-289,503 | 1349637-14-4 | Reference compound |
| HY-160902 | 2G-HaloAUTAC | 2241668-58-4 | Reference compound |
| HY-160903 | Suzetrigine phenol | 2649467-91-2 | Reference compound |
| HY-160908 | Lipid 88 | 2982842-99-7 | Oligonucleotides |
| HY-160912 | ELOVL6-IN-5 | 1135000-36-0 | Reference compound |
| HY-160915 | WP836 | 266000-09-3 | Reference compound |
| HY-160917 | BAY-43-9695 | 233255-39-5 | Reference compound |
| HY-160920 | Sylsens B | 107595-44-8 | Dye Reagents |
| HY-160921 | Capeserod | 769901-96-4 | Reference compound |
| HY-160922 | BAY 249716 | 696628-24-7 | Reference compound |
| HY-160924 | MS147 | | Reference compound |
| HY-160926 | 16-Oxocafestol | 108664-98-8 | Natural Products |
| HY-160927 | Docosahexaenoyl Serinol | 1638355-62-0 | Reference compound |
| HY-160928 | Smurf1 modulator-1 | 1825371-51-4 | Reference compound |
| HY-160929 | Linafexor | 2765593-43-7 | Reference compound |
| HY-160930 | TOP1288 | 1630202-02-6 | Reference compound |
| HY-160931 | NMDA receptor modulator 8 | 1629853-49-1 | Reference compound |
| HY-160932 | RS-15385-198 | 121961-55-5 | Reference compound |
| HY-160937 | AZD-9574-acid | 2923687-90-3 | Reference compound |
| HY-160939 | ASK1-IN-6 | 2407451-82-3 | Reference compound |
| HY-16094 | Bethanidine (sulfate) | 114-85-2 | Reference compound |
| HY-160941 | CDK2-IN-29 | 247149-58-2 | Reference compound |
| HY-160943 | F594-1001 | 1215326-44-5 | Reference compound |
| HY-160943A | F594-1001 (hydrochloride) | | Reference compound |
| HY-160944 | hsa62 | 780822-35-7 | Reference compound |
| HY-160945 | NMT-IN-7 | 3032302-70-5 | ADC Related |
| HY-160956 | Nitto Phase HL UnyLinker 300 | | Reference compound |
| HY-160957 | Cap A (Acetonitrile/Acetic Anhydride, 80/20 v/v) | | Oligonucleotides |
| HY-160958 | Cap B (Acetonitrile/N-methylimidazole /pyridine, 50/20/30 v/v/v) | | Reference compound |
| HY-160959 | AN317 | 946074-35-7 | Reference compound |
| HY-160962 | SM1044 | 1331880-08-0 | Reference compound |
| HY-160966 | PROTAC BTK Degrader-10 | 2988804-46-0 | Reference compound |
| HY-160967 | MC-GGFG-PAB-Exatecan | 2928560-25-0 | ADC Related |
| HY-160971 | Ribonucleic Acid, Transfer from Brewing yeast | 9014-25-9 | Biochemical Assay Reagents |
| HY-160972 | MM0299 | 474255-10-2 | Reference compound |
| HY-160973 | ELF97 phosphate | 147394-94-3 | Biochemical Assay Reagents |
| HY-160978 | Timelotem | 96306-34-2 | Reference compound |
| HY-160979 | Bisfentidine | 96153-56-9 | Natural Products |
| HY-160980 | Sornidipine | 95105-77-4 | Reference compound |
| HY-160981 | Mal-PEG4-VCP-NB | 1345681-54-0 | ADC Related |
| HY-160982 | Mal-PEG3-VCP-NB | 1345681-77-7 | ADC Related |
| HY-160983 | PHYLPA-8 | 169736-88-3 | Reference compound |
| HY-160984 | Rotraxate | 92071-51-7 | Reference compound |
| HY-160985 | Lemidosul | 88041-40-1 | Reference compound |
| HY-160991 | Menabitan | 83784-21-8 | Reference compound |
| HY-160991A | Menabitan (dihydrochloride) | 58019-50-4 | Reference compound |
| HY-160992 | Vinepidine (sulfate) | 83200-11-7 | Reference compound |
| HY-160993 | Ciprostene | 81845-44-5 | Reference compound |
| HY-160994 | Pyrophendane | 7009-69-0 | Reference compound |
| HY-160995 | Crotoniazide | 7007-96-7 | Reference compound |
| HY-160996 | Glucosulfamide | 7007-76-3 | Reference compound |
| HY-160997 | Prosulpride | 68556-59-2 | Reference compound |
| HY-160998 | YM-344031 | 671204-98-1 | Reference compound |
| HY-16100 | BI 99179 | 1291779-76-4 | Reference compound |
| HY-161001 | AMOZ-CHPh-3-acid | 1393444-23-9 | Reference compound |
| HY-161002 | AMOZ-CHPh-4-O-C-acid | 1149378-54-0 | Reference compound |
| HY-161003 | AMOZ-CHPh-3-O-C-acid | 1416047-55-6 | Reference compound |
| HY-161004 | AMOZ-CH-acid | 1416047-56-7 | Reference compound |
| HY-161005 | TETS-Methyl benzoate | 2107375-54-0 | Reference compound |
| HY-161006 | TETS-C4-acid | | Reference compound |
| HY-161010 | DHFR-IN-13 | | Reference compound |
| HY-161011 | Spire2-FMN2 interaction-IN-1 | 1557337-03-7 | Reference compound |
| HY-161012 | RB-07-16 | | Reference compound |
| HY-161013 | Antiproliferative agent-44 | 3017217-08-9 | Reference compound |
| HY-161014 | DYRK2-IN-1 | | Reference compound |
| HY-161015 | JAK1-IN-13 | 2778330-90-6 | Reference compound |
| HY-161016 | TNF/IFN-γ-IN-1 | 876013-29-5 | Reference compound |
| HY-161017 | WDR91-IN-1 | 2759614-35-0 | Reference compound |
| HY-161018 | CF3–K11 | 3032121-66-4 | Reference compound |
| HY-161019 | JAK1/TYK2-IN-4 | 2734918-33-1 | Reference compound |
| HY-16102 | Bismuth subcitrate (potassium) | 880149-29-1 | Reference compound |
| HY-161020 | m-PEG12-OTs | 2103241-71-8 | Reference compound |
| HY-161021 | AC2 selective-IN-1 | | Reference compound |
| HY-161022 | FL118-C3-O-C-amide-C-NH2 | 2821769-41-7 | ADC Related |
| HY-161022A | FL118-C3-O-C-amide-C-NH2 (formate) | | ADC Related |
| HY-161022S | FL118-C3-O-C-amide-C-NH2-d5 | | Isotope-Labeled Compounds |
| HY-161022S1 | FL118-C3-O-C-amide-C-NH2-d5 (formate) | | Isotope-Labeled Compounds |
| HY-161024 | AC1Q3QWB | 46697-00-1 | Reference compound |
| HY-161025 | SYHA1813 | 1807466-30-3 | Reference compound |
| HY-161026 | JM-9 | | Reference compound |
| HY-161027 | DHP-B | | Reference compound |
| HY-161028 | Antibacterial agent 167 | 1940173-83-0 | Reference compound |
| HY-161029 | T14-A24 | | Reference compound |
| HY-16102R | Bismuth subcitrate (potassium) (Standard) | 880149-29-1 | Reference Standards |
| HY-16103 | Bitolterol (mesylate) | 30392-41-7 | Reference compound |
| HY-161030 | EGFR-IN-92 | | Reference compound |
| HY-161031 | EGFR-IN-93 | | Reference compound |
| HY-161039 | MDM2-p53-IN-18 | 1818291-95-0 | Reference compound |
| HY-16104 | BIX 02565 | 1311367-27-7 | Reference compound |
| HY-161040 | MDM2-p53-IN-19 | 1818292-01-1 | Reference compound |
| HY-161041 | MDM2-p53-IN-20 | 2095120-09-3 | Reference compound |
| HY-161042 | Neuroprotective agent 2 | 2996062-20-3 | Reference compound |
| HY-161043 | ECDD-S16 | | Reference compound |
| HY-161045 | T-1-DOCA | | Reference compound |
| HY-161046 | PLK1-IN-8 | | Reference compound |
| HY-161047 | Antiviral agent 45 | | Reference compound |
| HY-161048 | PDH E1-IN-1 | | Reference compound |
| HY-161049 | Antifungal agent 89 | | Reference compound |
| HY-161050 | YSR734 | 3032969-58-4 | Reference compound |
| HY-161051 | Anticancer agent 177 | | Reference compound |
| HY-161057 | HG-7-86-01 | 1258391-14-8 | Reference compound |
| HY-161058 | AChE-IN-49 | | Reference compound |
| HY-161059 | ZB-R-55 | 2416593-55-8 | Reference compound |
| HY-16106 | Talazoparib | 1207456-01-6 | Reference compound |
| HY-161060 | Zharp1-211 | 2258671-41-7 | Reference compound |
| HY-161061 | Arginase inhibitor 7 | 2377392-07-7 | Reference compound |
| HY-161062 | TAOA AM Ester trimethyl lock | | Reference compound |
| HY-161063 | DHFR-IN-14 | | Reference compound |
| HY-161064 | DHFR-IN-15 | | Reference compound |
| HY-161065 | HKI12134085 | 2102393-11-1 | Reference compound |
| HY-161066 | KRAS G13D-IN-1 | | Reference compound |
| HY-161067 | EGFR-IN-96 | | Reference compound |
| HY-161068 | hACE2/SP-IN-1 | | Reference compound |
| HY-161069 | Anti-infective agent 8 | | Reference compound |
| HY-16106A | (8R,9S)-Talazoparib | 1207456-00-5 | Reference compound |
| HY-16106S | Talazoparib-13C,d4 | | Isotope-Labeled Compounds |
| HY-16106S1 | Talazoparib-d4 | | Isotope-Labeled Compounds |
| HY-16107 | BMS-303141 | 943962-47-8 | Reference compound |
| HY-161070 | Antiviral agent 46 | 877660-90-7 | Reference compound |
| HY-161071 | Antioxidant/anticancer agent 1 | 1449470-38-5 | Reference compound |
| HY-161072 | CSC-6 | | Reference compound |
| HY-161074 | PNT6555 | 2715113-34-9 | Reference compound |
| HY-161075 | Microtubule inhibitor 8 | 2310293-81-1 | Reference compound |
| HY-161076 | KTt-45 | 2244987-60-6 | Reference compound |
| HY-161077 | QP5020 | 3027434-06-3 | Reference compound |
| HY-161078 | QP5038 | 3031429-88-3 | Reference compound |
| HY-161079 | TDI-8304 | 2307262-96-8 | Reference compound |
| HY-161080 | 4'-Ethynyl-2'-deoxycytidine | 232588-95-3 | Reference compound |
| HY-161082 | Topoisomerase I inhibitor 12 | | Reference compound |
| HY-161083 | PARP/EZH2-IN-2 | | Reference compound |
| HY-161084 | CSF1R-IN-18 | | Reference compound |
| HY-161085 | BI 1265162 | 3042822-44-3 | Reference compound |
| HY-161086 | Antibiofilm agent-4 | 3027083-73-1 | Reference compound |
| HY-161087 | β-catenin/BCL9 PPI-IN-1 | | Reference compound |
| HY-161088 | Anti-aging agent 1 | 1884611-28-2 | Reference compound |
| HY-161089 | Antiproliferative agent-45 | | Reference compound |
| HY-16108A | Squalene synthase-IN-3 (tripotassium) | 157126-15-3 | Reference compound |
| HY-16109 | BMS-188494 | 191866-32-7 | Reference compound |
| HY-161090 | AMPA receptor modulator-7 | | Reference compound |
| HY-161091 | AM-2-19 | 2761794-74-3 | Natural Products |
| HY-161092 | KIO-301 (chloride) | 1643463-59-5 | Reference compound |
| HY-161092A | KIO-301 (chloride) (hydrochloride) | | Reference compound |
| HY-161093 | PROTAC BRD4 Degrader-23 | | Reference compound |
| HY-161094 | Metallo-β-lactamase-IN-12 | 3028594-43-3 | Reference compound |
| HY-161095 | iRGD-CPT | | Reference compound |
| HY-161096 | Antitumor agent-127 | | Reference compound |
| HY-161097 | Antibacterial agent 171 | | Reference compound |
| HY-161098 | Apoptosis inducer 14 | 2750370-67-1 | Reference compound |
| HY-16110 | Tegafur-Uracil | 74578-38-4 | Reference compound |
| HY-161100 | BDM19 | 500273-31-4 | Reference compound |
| HY-161101 | MG degrader 1 | | Reference compound |
| HY-161102 | [Ru(phen)2(xant)] (hexafluorophosphate) | | Reference compound |
| HY-161103 | Angeloyl-CoA | 6247-64-9 | Enzyme |
| HY-161104 | Kv2.1-IN-1 | 2252448-93-2 | Reference compound |
| HY-161105 | FPIP | | Reference compound |
| HY-161106 | OX04528 | 3028055-45-7 | Reference compound |
| HY-161107 | OX04529 | | Reference compound |
| HY-161108 | PROTAC Chk1 degrader-1 | 2597167-34-3 | Reference compound |
| HY-161109 | Aβ42-IN-4 | 2387822-02-6 | Reference compound |
| HY-16111 | BMS-214662 | 195987-41-8 | Reference compound |
| HY-161110 | APP degrader-1 | | Reference compound |
| HY-161111 | KVS0001 | 3056394-59-0 | Reference compound |
| HY-161112 | LG157 | 2840558-89-4 | Reference compound |
| HY-161113 | Z8554052021 | | Reference compound |
| HY-161114 | MDOLL-0229 | 3036752-42-5 | Reference compound |
| HY-161115 | NR2E3 agonist 1 | 911211-69-3 | Reference compound |
| HY-161116 | AD-5584 | 2306525-79-9 | Reference compound |
| HY-161117 | AD-8007 | 1497439-74-3 | Reference compound |
| HY-161118 | MB327 | 61368-98-7 | Reference compound |
| HY-161119 | Drpitor1a | 73326-98-4 | Reference compound |
| HY-16111A | BMS-214662 (hydrochloride) | 195981-08-9 | Reference compound |
| HY-16111A1 | BMS-214662 (mesylate) | 474010-58-7 | Reference compound |
| HY-161120 | NLRP3-IN-27 | 2997864-57-8 | Reference compound |
| HY-161123 | WDR5-IN-8 | | Reference compound |
| HY-161124 | SrtA-IN-2 | | Reference compound |
| HY-161125 | (+)-JQ1-OH | | Reference compound |
| HY-161126 | EGFR-IN-98 | | Reference compound |
| HY-161127 | NT-B2R | | Reference compound |
| HY-161128 | Lenalidomide 4'-PEG1-amine (dihydrochloride) | 2624336-86-1 | Reference compound |
| HY-161129 | "Lenalidomide 4'-PEG2-amine (dihydrochloride)" | 2624336-88-3 | Reference compound |
| HY-161130 | "Lenalidomide 4'-PEG3-amine (dihydrochloride)" | 2624336-87-2 | Reference compound |
| HY-161131 | Lenalidomide 4'-alkyl-C3-azide | 2399455-71-9 | Reference compound |
| HY-161132 | Lenalidomide 4'-alkyl-C5-azide | 2399455-78-6 | Reference compound |
| HY-161133 | Lenalidomide 4'-PEG1-azide | 2399455-45-7 | Reference compound |
| HY-161134 | Lenalidomide 4'-PEG2-azide | 2399455-48-0 | Reference compound |
| HY-161135 | TBAJ-5307 | 2332831-92-0 | Reference compound |
| HY-161136 | EGFR/STAT3-IN-1 | | Reference compound |
| HY-161137 | LQFM215 | | Reference compound |
| HY-161138 | WK369 | | Reference compound |
| HY-161139 | JAK1-IN-14 | | Reference compound |
| HY-16114 | BNC105 | 945771-74-4 | Reference compound |
| HY-161140 | PI3Kα-IN-16 | 1448711-61-2 | Reference compound |
| HY-161141 | EGFR/c-Met-IN-2 | 2761180-01-0 | Reference compound |
| HY-161142 | Carbonic anhydrase/AChE-IN-1 | | Reference compound |
| HY-161143 | Carbonic anhydrase/AChE-IN-2 | | Reference compound |
| HY-161144 | AKT-IN-21 | | Reference compound |
| HY-161145 | EGFR/microtubule-IN-1 | 1970269-96-5 | Reference compound |
| HY-161146 | EGFR-IN-100 | | Reference compound |
| HY-161147 | COX-2-IN-37 | | Reference compound |
| HY-161148 | FtsZ-IN-9 | 1273524-44-9 | Reference compound |
| HY-161149 | CM-1758 | 2256079-39-5 | Reference compound |
| HY-16115 | BPH-652 | 157124-84-0 | Reference compound |
| HY-161150 | AChE/BChE-IN-17 | | Reference compound |
| HY-161151 | RecQ helicase-IN-1 | | Reference compound |
| HY-161152 | DNA relaxation-IN-1 | 2190506-29-5 | Reference compound |
| HY-161153 | Microtubule inhibitor 9 | | Reference compound |
| HY-161154 | HDAC3-IN-3 | 2170996-03-7 | Reference compound |
| HY-161155 | HDAC6-IN-31 | | Reference compound |
| HY-161156 | BChE-IN-26 | | Reference compound |
| HY-161157 | dTAG-13-NEG | 2451573-90-1 | Reference compound |
| HY-161157A | dTAG-13-NEG (TFA) | | Reference compound |
| HY-161158 | KCNK13-IN-1 | 361368-24-3 | Reference compound |
| HY-161159 | DMHBO+ | 2322286-81-5 | Dye Reagents |
| HY-161160 | Ac4ManNDAz | 1015698-39-1 | Reference compound |
| HY-161161 | aTAG 2139-NEG | 2758431-99-9 | Reference compound |
| HY-161162 | aTAG 2139 | 2387510-81-6 | Reference compound |
| HY-161163 | IND 1316 | 1888473-12-8 | Reference compound |
| HY-161164 | Tricyclic cytosine tC | 1174063-74-1 | Reference compound |
| HY-161166 | MM-02-57 | | Reference compound |
| HY-161167 | MM-02-08 | | Reference compound |
| HY-161168 | Cyclin K degrader 1 | | Reference compound |
| HY-161169 | TP0628103 | 2865102-08-3 | Reference compound |
| HY-161170 | Antimalarial agent 36 | 2982633-03-2 | Reference compound |
| HY-161171 | Antimalarial agent 37 | 2982633-16-7 | Reference compound |
| HY-161172 | Antibacterial agent 178 | | Reference compound |
| HY-161173 | PROTAC SOS1 degrader-5 | 2836273-61-9 | Reference compound |
| HY-161174 | Carbonic anhydrase inhibitor 17 | 3033849-05-4 | Reference compound |
| HY-161175 | IMP-1575 | 3026255-85-3 | Reference compound |
| HY-161176 | PROTAC KRAS G12D degrader 1 | 3033583-54-6 | Reference compound |
| HY-161177 | PROTAC KRAS G12D degrader 2 | | Reference compound |
| HY-161178 | LK-60 | | Reference compound |
| HY-161179 | TRK-IN-27 | | Reference compound |
| HY-16117A | Brostallicin | 203258-38-2 | Reference compound |
| HY-161180 | Antitumor agent-136 | 2484876-94-8 | Reference compound |
| HY-161181 | BTTES-acid | 2223032-74-2 | Reference compound |
| HY-161182 | uPSEM792 (hydrochloride) | 2341841-08-3 | Reference compound |
| HY-161183 | (S)-Thalidomide-O-(1S,3r)-C4H4-N(Me)-Pip-C2-O-C-boc | | Reference compound |
| HY-161184 | Deoxy-thalidomide-piperidine-C-piperazine-C2-OH | | Reference compound |
| HY-161185 | Thalidomide-piperidine-O-azetidine-boc | 2991611-55-1 | Reference compound |
| HY-161186 | Thalidomide-piperidine-C-azetidine-C2-O-C-boc | | Reference compound |
| HY-161187 | Thalidomide-piperidine-1,6-diazaspiro[3.3]heptane-boc | | Reference compound |
| HY-161188 | Thalidomide-O-C4H4-N(Me)-piperidine-C2-OH | | Reference compound |
| HY-161189 | Thalidomide-2,6-diazaspiro[3.4]octane-C-piperidine-C2-O-C-boc | | Reference compound |
| HY-161190 | Thalidomide-piperidine-C-2,6-diazaspiro[3.3]heptane-C2-OH | | Reference compound |
| HY-161191 | Thalidomide-azetidine-piperazine-C2-O-C2-OH | | Reference compound |
| HY-161192 | Thalidomide-O-C4H4-N(Me)-piperidine-C-boc | | Reference compound |
| HY-161193 | Thalidomide-piperazine-(R)-C-pyrrolidine-C-boc | | Reference compound |
| HY-161194 | (S,R,S)-AHPC-acetyl-azetidine-PIP-boc | | Reference compound |
| HY-161195 | Deoxy-thalidomide-piperidine-C-piperazine-C-boc | | Reference compound |
| HY-161196 | Thalidomide-2,6-diazaspiro[3.4]octane-C-piperidine-C-boc | | Reference compound |
| HY-161197 | Thalidomide-2,6-diazaspiro[3.4]octane-C-piperidine-C2-O-C2-OH | | Reference compound |
| HY-161198 | Thalidomide-azetidine-pyrrolidine-C-piperidine-C-boc | | Reference compound |
| HY-161199 | Thalidomide-azetidine-pyrrolidine-C-piperidine-C2-OH | | Reference compound |
| HY-161200 | Thalidomide-piperazine-C-azetidine-C2-OH | | Reference compound |
| HY-161201 | Thalidomide-piperazine-pyrimidine-piperazine-C-boc | | Reference compound |
| HY-161202 | Thalidomide-piperidine-O-piperidine-C2-OH | | Reference compound |
| HY-161203 | Thalidomide-azetidine-piperazine-C2-O-C-boc | | Reference compound |
| HY-161204 | Thalidomide-O-C4H4-N(Me)-piperidine-boc | | Reference compound |
| HY-161205 | Thalidomide-PIP-(R)C-pyrrolidine-boc | 2839668-87-8 | Reference compound |
| HY-161206 | Thalidomide-Pip-C-Pip-O-C-boc | | Reference compound |
| HY-161207 | (S,R,S)-AHPC-acetyl-Pip-O-azetidine-boc | | Reference compound |
| HY-161208 | Deoxy-thalidomide-Pip-C-PIP-boc | 2963655-14-1 | Reference compound |
| HY-161209 | Thalidomide-2,6-diazaspiro[3.4]octane-C-Pip-boc | | Reference compound |
| HY-16121 | CAA-0225 | 244072-26-2 | Reference compound |
| HY-161210 | Thalidomide-azetidine-C-PIP-C-boc | 2589699-87-4 | Reference compound |
| HY-161211 | HSD17B13-IN-7 | 863564-16-3 | Reference compound |
| HY-161212 | HSD17B13-IN-8 | 2758802-02-5 | Reference compound |
| HY-161213 | HSD17B13-IN-11 | 2758802-03-6 | Reference compound |
| HY-161214 | HSD17B13-IN-12 | 2758802-04-7 | Reference compound |
| HY-161215 | HSD17B13-IN-14 | 2758802-05-8 | Reference compound |
| HY-161216 | HSD17B13-IN-15 | 2758802-07-0 | Reference compound |
| HY-161217 | HSD17B13-IN-16 | 2758802-09-2 | Reference compound |
| HY-161218 | HSD17B13-IN-17 | 2758802-10-5 | Reference compound |
| HY-161219 | HSD17B13-IN-18 | 2758802-14-9 | Reference compound |
| HY-16122 | CAL-130 (Racemate) | 474012-90-3 | Reference compound |
| HY-161220 | HSD17B13-IN-19 | 2758802-17-2 | Reference compound |
| HY-161221 | HSD17B13-IN-21 | 2758802-18-3 | Reference compound |
| HY-161222 | HSD17B13-IN-23 | 2758802-19-4 | Reference compound |
| HY-161223 | HSD17B13-IN-27 | 2758802-31-0 | Reference compound |
| HY-161224 | HSD17B13-IN-31 | 2758802-33-2 | Reference compound |
| HY-161225 | HSD17B13-IN-40 | 2770246-06-3 | Reference compound |
| HY-161226 | HSD17B13-IN-42 | 2770246-10-9 | Reference compound |
| HY-161227 | HSD17B13-IN-43 | 2770246-11-0 | Reference compound |
| HY-161228 | HSD17B13-IN-48 | 2770246-12-1 | Reference compound |
| HY-161229 | HSD17B13-IN-69 | 2770246-16-5 | Reference compound |
| HY-16122A | CAL-130 | 1431697-74-3 | Reference compound |
| HY-16122B | CAL-130 (Hydrochloride) | 1431697-78-7 | Reference compound |
| HY-16123 | Canfosfamide (hydrochloride) | 439943-59-6 | Reference compound |
| HY-161230 | HSD17B13-IN-75 | 2770246-20-1 | Reference compound |
| HY-161231 | HSD17B13-IN-78 | 2770246-21-2 | Reference compound |
| HY-161232 | HSD17B13-IN-79 | 2770246-31-4 | Reference compound |
| HY-161233 | BTX-6654 | | Reference compound |
| HY-161234 | KRAS ligand 3 | 2654741-53-2 | Reference compound |
| HY-161235 | BTX-7312 | | Reference compound |
| HY-161236 | KRAS ligand 4 | | Reference compound |
| HY-161237 | Antitrypanosomal agent 20 | | Reference compound |
| HY-161238 | SARS-CoV-2-IN-79 | | Reference compound |
| HY-161239 | (S)-IB-96212 | | Reference compound |
| HY-161239A | IB-96212 | | Reference compound |
| HY-16124 | Canfosfamide | 158382-37-7 | Reference compound |
| HY-161240 | MAO-B-IN-30 | 82973-15-7 | Reference compound |
| HY-161241 | Tyrosinase-IN-23 | | Reference compound |
| HY-161242 | CBI1 | | Reference compound |
| HY-161242A | CBI1 (formic) | | Reference compound |
| HY-161243 | AChE-IN-56 | | Reference compound |
| HY-161244 | FGA145 | | Reference compound |
| HY-161245 | FGA146 | | Reference compound |
| HY-161246 | uPSEM792 | 2323525-19-3 | Reference compound |
| HY-161247 | 5-HT2A antagonist 2 | 2641482-08-6 | Reference compound |
| HY-161248 | E7130 | | Reference compound |
| HY-161249 | Vanin-1-IN-4 | 2173134-02-4 | Reference compound |
| HY-16125 | Carboxyamidotriazole (Orotate) | 187739-60-2 | Reference compound |
| HY-161250 | Pomalidomide-NH-PEG6-amide-C2-CPI-1612 | | Reference compound |
| HY-161251 | SPOP-IN-2 | 3031640-86-2 | Reference compound |
| HY-161252 | PBD-monoamide | 2093165-00-3 | ADC Related |
| HY-161253 | OSU-ERb-12 | 2088837-20-9 | Reference compound |
| HY-161254 | ATPase-IN-3 | 1134203-12-5 | Reference compound |
| HY-161255 | 3,4-DAA | 2117759-07-4 | Reference compound |
| HY-161256 | Tubulin inhibitor 41 | 2770273-12-4 | Reference compound |
| HY-161257 | CDC20-IN-1 | | Reference compound |
| HY-161258 | Antibacterial agent 181 | | Reference compound |
| HY-161259 | JAK-IN-36 | | Reference compound |
| HY-16126 | Carboxyamidotriazole | 99519-84-3 | Reference compound |
| HY-161260 | P-gp inhibitor 20 | | Reference compound |
| HY-161261 | SARS-CoV-2-IN-81 | | Reference compound |
| HY-161262 | SB03178 | 2952588-12-2 | Reference compound |
| HY-161263 | Antibacterial agent 182 | | Reference compound |
| HY-161264 | Antiviral agent 49 | | Reference compound |
| HY-161265 | HIF-2α agonist 3 | | Reference compound |
| HY-161266 | COX-2/NLRP3-IN-1 | | Reference compound |
| HY-161267 | Mitochondrial respiration-IN-4 | | Reference compound |
| HY-161268 | NAE-IN-1 | | Reference compound |
| HY-161269 | EGFR-IN-101 | 2982583-44-6 | Reference compound |
| HY-16126R | Carboxyamidotriazole (Standard) | 99519-84-3 | Reference Standards |
| HY-161270 | HIV-1 protease-IN-13 | | Reference compound |
| HY-161271 | MLK-IN-2 | 2614255-51-3 | Reference compound |
| HY-161272 | Nav1.8-IN-6 | | Reference compound |
| HY-161273 | TRPV1 antagonist 6 | | Reference compound |
| HY-161274 | Bfl-1-IN-1 | | Reference compound |
| HY-161275 | BI-4732 | 2769715-68-4 | Reference compound |
| HY-161276 | BFC1108 | 692774-37-1 | Reference compound |
| HY-161277 | HSD17B13-IN-100 | 2770246-33-6 | Reference compound |
| HY-161278 | HSD17B13-IN-102 | 2770246-34-7 | Reference compound |
| HY-161279 | Antibiofilm agent-5 | | Reference compound |
| HY-161280 | PROTAC FLT-3 degrader 3 | | Reference compound |
| HY-161281 | α-Glucosidase-IN-49 | | Reference compound |
| HY-161282 | hCAII-IN-10 | | Reference compound |
| HY-161283 | JT21-25 | 2996864-57-2 | Reference compound |
| HY-161284 | MMP-9/10-IN-1 | | Reference compound |
| HY-161285 | MMP-9/10-IN-2 | | Reference compound |
| HY-161286 | hCAXII-IN-8 | | Reference compound |
| HY-161287 | HDAC6-IN-32 | | Reference compound |
| HY-161288 | UKTT15 | 2468199-58-6 | Reference compound |
| HY-161289 | Tyrosinase-IN-24 | | Reference compound |
| HY-16129 | CBP-501 | 565434-85-7 | Peptides |
| HY-161290 | PDE5-IN-12 | | Reference compound |
| HY-161291 | CDK2-IN-25 | | Reference compound |
| HY-161292 | DHFR-IN-16 | | Reference compound |
| HY-161293 | p38-α MAPK-IN-6 | 29368-40-9 | Reference compound |
| HY-161294 | COX-2-IN-41 | | Reference compound |
| HY-161295 | hCAIX/XII-IN-10 | | Reference compound |
| HY-161296 | TH6342 | | Reference compound |
| HY-161297 | NT-0249 | 2763617-39-4 | Reference compound |
| HY-161297A | NT-0249 (free base) | | Reference compound |
| HY-161298 | MAT2A-IN-15 | | Reference compound |
| HY-161299 | LAPTc-IN-1 | 930898-33-2 | Reference compound |
| HY-161300 | Antibacterial agent 191 | | Reference compound |
| HY-161301 | PI3K-IN-52 | | Reference compound |
| HY-161302 | Polθ/PARP-IN-1 | | Reference compound |
| HY-161303 | ZNF207-IN-1 | 2923208-52-8 | Reference compound |
| HY-161304 | HDAC6-IN-33 | 2444302-23-0 | Reference compound |
| HY-161305 | SE-7552 | 2243575-79-1 | Reference compound |
| HY-161306 | ITF5924 | 2760854-72-4 | Reference compound |
| HY-161307 | T-518 | 2276680-91-0 | Reference compound |
| HY-161308 | HPPD-IN-3 | 3024245-46-0 | Reference compound |
| HY-161309 | PfPKG-IN-2 | | Reference compound |
| HY-161310 | Metallo-β-lactamase-IN-15 | 1804934-57-3 | Reference compound |
| HY-161311 | AChE/BChE-IN-18 | | Reference compound |
| HY-161312 | Antifungal agent 93 | | Reference compound |
| HY-161313 | DYB-03 | 2982792-85-6 | Reference compound |
| HY-161315 | 15-LOX-IN-1 | | Reference compound |
| HY-161316 | NNMT-IN-5 | | Reference compound |
| HY-161317 | Gαq/11 protein-IN-1 | | Reference compound |
| HY-161318 | α-Glucosidase-IN-52 | | Reference compound |
| HY-161319 | EGFR-IN-104 | 2758904-45-7 | Reference compound |
| HY-161320 | EGFR-IN-105 | 831244-98-5 | Reference compound |
| HY-161321 | PTP1B-IN-24 | 2221707-61-3 | Reference compound |
| HY-161322 | hCAXII-IN-9 | | Reference compound |
| HY-161323 | FLT3-ITD/D835Y-IN-1 | | Reference compound |
| HY-161324 | Tubulin degrader 1 | | Reference compound |
| HY-161325 | Antileishmanial agent-26 | | Reference compound |
| HY-161326 | CXF-007 | 2727083-99-8 | Reference compound |
| HY-161327 | HBV-IN-44 | | Reference compound |
| HY-161328 | MAO-B-IN-31 | | Reference compound |
| HY-161329 | NLRP3-IN-32 | | Reference compound |
| HY-161330 | Anti-MRSA agent 10 | | Reference compound |
| HY-161331 | S16–1029 | 2653349-51-8 | Reference compound |
| HY-161332 | Antitumor agent-143 | | Reference compound |
| HY-161333 | ADS031 | | Reference compound |
| HY-161334 | CARM1-IN-4 | 2878481-07-1 | Reference compound |
| HY-161335 | HPK1-IN-43 | | Reference compound |
| HY-161336 | Alendronate prodrug-1 | | Reference compound |
| HY-161337 | PKL-IN-1 | | Reference compound |
| HY-161338 | Tubulin polymerization-IN-61 | 2758114-60-0 | Reference compound |
| HY-161339 | SIRT2-IN-13 | | Reference compound |
| HY-16134 | Celgosivir | 121104-96-9 | Reference compound |
| HY-161340 | Anti-melanoma agent 2 | 2361522-62-3 | Reference compound |
| HY-161341 | β-Glucuronidase responsive conjugate 1 | | Reference compound |
| HY-161342 | CTSL/CAPN1-IN-2 | 2410075-64-6 | Reference compound |
| HY-161343 | HDL-16 | 2373280-36-3 | Reference compound |
| HY-161344 | Z36-MP5 | 2839660-03-4 | Reference compound |
| HY-161345 | Meriolin 16 | | Reference compound |
| HY-161346 | EBET-1055 | | Reference compound |
| HY-161348 | AT-0174 | | Reference compound |
| HY-161349 | LTA4H-IN-4 | | Reference compound |
| HY-16134A | Celgosivir (hydrochloride) | 141117-12-6 | Reference compound |
| HY-16135 | CEP-11981 | 856691-93-5 | Reference compound |
| HY-161350 | ALK/HDAC-IN-1 | | Reference compound |
| HY-161351 | STAT3/AKT-IN-1 | | Reference compound |
| HY-161352 | NPI52 | 1429218-68-7 | Reference compound |
| HY-161353 | c-Met-IN-23 | | Reference compound |
| HY-161354 | JAK3 covalent inhibitor-2 | 2664050-97-7 | Reference compound |
| HY-161355 | α-Amylase/α-Glucosidase-IN-9 | | Reference compound |
| HY-161356 | BPR3P0128 | 1345406-09-8 | Reference compound |
| HY-161357 | KR-27370 | | Reference compound |
| HY-161358 | FAK-IN-20 | 3004967-41-0 | Reference compound |
| HY-161359 | BACE1-IN-14 | | Reference compound |
| HY-16135A | CEP-11981 (tosylate) | 901128-79-8 | Reference compound |
| HY-161360 | LXQ-217 | 2524718-79-2 | Reference compound |
| HY-161361 | MLKL-IN-7 | | Reference compound |
| HY-161362 | SR-3-65 | | Reference compound |
| HY-161363 | ERK2 allosteric-IN-1 | 872591-16-7 | Reference compound |
| HY-161364 | Antibacterial agent 200 | | Reference compound |
| HY-161365 | PLpro-IN-2 | | Reference compound |
| HY-161366 | OMS14 | | Reference compound |
| HY-161367 | VHL-SF2 | 3050690-24-6 | Reference compound |
| HY-161368 | BRD-SF2 | 3050690-26-8 | Reference compound |
| HY-161369 | CBPD-268 | 2832961-58-5 | Reference compound |
| HY-16137 | Cefaloglycin | 3577-01-3 | Reference compound |
| HY-161370 | VD4162 | 2574390-19-3 | Reference compound |
| HY-161371 | VD5123 | | Reference compound |
| HY-161372 | PARP1/c-Met-IN-1 | 2944101-99-7 | Reference compound |
| HY-161373 | PI3Kα-IN-22 | 2925030-26-6 | Reference compound |
| HY-161374 | Carbonic anhydrase inhibitor 20 | | Reference compound |
| HY-161375 | SDH-IN-13 | 2975187-87-0 | Reference compound |
| HY-161376 | M4K2281 | | Reference compound |
| HY-161377 | M4K2306 | 3034840-25-7 | Reference compound |
| HY-161378 | UCHL1-IN-1 | | Reference compound |
| HY-161379 | CLZX-205 | 3033694-01-5 | Reference compound |
| HY-16138 | Ivaltinostat | 936221-33-9 | Reference compound |
| HY-161380 | Antifungal agent 96 | | Reference compound |
| HY-161381 | PDE4-IN-15 | 3034837-89-0 | Reference compound |
| HY-161382 | NPFF2-R ligand 1 | | Reference compound |
| HY-161383 | CHK1-IN-9 | | Reference compound |
| HY-161384 | WJM-715 | | Reference compound |
| HY-161385 | Topoisomerase I inhibitor 16 | | Reference compound |
| HY-161386 | WRN inhibitor 7 | 444780-45-4 | Reference compound |
| HY-161387 | EBET-590 | 3031540-40-3 | Reference compound |
| HY-161388 | NSCLC-IN-1 | | Reference compound |
| HY-161389 | SP-alkyne | | Reference compound |
| HY-16138A | Ivaltinostat (formic) | | Reference compound |
| HY-161390 | SPC-alkyne | | Reference compound |
| HY-161391 | CW0134 | 1076235-18-1 | Reference compound |
| HY-161392 | CW2158 | | Reference compound |
| HY-161393 | RB-CO-PEG5-C2-CO-VH032 | | Reference compound |
| HY-161394 | SPRT | | Reference compound |
| HY-161395 | IDD-8E | | Reference compound |
| HY-161396 | Anti-inflammatory agent 76 | | Reference compound |
| HY-161397 | NA-1-157 | | Reference compound |
| HY-161398 | TGFβRII-IN-3 | 2351149-20-5 | Reference compound |
| HY-161400 | TGFβRII-IN-2 | | Reference compound |
| HY-161401 | PAR4 antagonist 2 | | Reference compound |
| HY-161402 | METTL16-IN-1 | | Reference compound |
| HY-161403 | CYP1B1-IN-8 | | Reference compound |
| HY-161404 | Antibacterial agent 202 | 3035899-61-4 | Reference compound |
| HY-161405 | NPFF1-R antagonist 1 | 3057753-40-6 | Reference compound |
| HY-161406 | DXPS-IN-1 | | Reference compound |
| HY-161407 | AURKA-IN-1 | | Reference compound |
| HY-161408 | GePhos1 | | Reference compound |
| HY-161408A | iGePhos1 | | Reference compound |
| HY-161409 | SC912 | | Reference compound |
| HY-16141 | Cilengitide | 188968-51-6 | Reference compound |
| HY-161410 | WH244 | 2941088-96-4 | Reference compound |
| HY-161411 | α-Glucosidase-IN-60 | | Reference compound |
| HY-161412 | STR-V-53 | 2798954-66-0 | Reference compound |
| HY-161413 | Antibacterial agent 204 | 1211465-32-5 | Reference compound |
| HY-161414 | trans-VUF25471 | | Reference compound |
| HY-161415 | BCL-xL/BCL-2 ligand 1 | 2941091-91-2 | Reference compound |
| HY-161417 | LIMK-IN-2 | 2747216-27-7 | Reference compound |
| HY-161418 | 1-NBX | | Reference compound |
| HY-161419 | EZH2-IN-18 | 2826234-37-9 | Reference compound |
| HY-161420 | TRPV1 antagonist 7 | | Reference compound |
| HY-161421 | α-Glucosidase-IN-61 | | Reference compound |
| HY-161425 | Antitumor agent-149 | 2368983-54-2 | Reference compound |
| HY-161427 | HSP90-IN-30 | | Reference compound |
| HY-161428 | ZINC000003015356 | 872861-28-4 | Reference compound |
| HY-161429 | Antidiabetic agent 5 | 2152667-21-3 | Reference compound |
| HY-16143 | Cilengitide (TFA) | 199807-35-7 | Reference compound |
| HY-161430 | RTx-161 | | Reference compound |
| HY-161431 | RTx-152 | 3035072-48-8 | Reference compound |
| HY-161432 | Antimicrobial agent-29 | 731793-27-4 | Reference compound |
| HY-161433 | VMAT2-IN-3 | | Reference compound |
| HY-161434 | PCSK9-IN-26 | 3033361-09-7 | Reference compound |
| HY-161435 | PCSK9-IN-27 | | Reference compound |
| HY-161436 | TPA-dT | | Reference compound |
| HY-161438 | Akt1-IN-3 | 3033576-50-7 | Reference compound |
| HY-161439 | Akt1-IN-4 | 3033577-05-5 | Reference compound |
| HY-161440 | SIK-IN-1 | 3033846-29-3 | Reference compound |
| HY-161441 | SIK-IN-2 | 3033846-20-4 | Reference compound |
| HY-161442 | SIK-IN-3 | | Reference compound |
| HY-161443 | TEAD-IN-9 | | Reference compound |
| HY-161444 | Piperazine-acetyl-PIP-AcOH | | Reference compound |
| HY-161445 | (S,R,S)-AHPC-Me-piperazine-acetyl-PIP-AcOH | | Reference compound |
| HY-161446 | USP1-IN-7 | 3033480-42-8 | Reference compound |
| HY-161447 | USP1-IN-8 | 3033480-77-9 | Isotope-Labeled Compounds |
| HY-161448 | Tau-aggregation-IN-3 | 3032869-59-0 | Reference compound |
| HY-161449 | JTT-654 | 916828-66-5 | Reference compound |
| HY-161450 | LHF418 | | Reference compound |
| HY-161451 | Lenalidomide nonanedioic acid | | Reference compound |
| HY-161452 | SOS1 Ligand intermediate-3 | | Reference compound |
| HY-161453 | BChE-IN-32 | | Reference compound |
| HY-161454 | Antiviral agent 54 | | Reference compound |
| HY-161455 | Xanthine oxidase-IN-13 | | Reference compound |
| HY-161456 | PHGDH-IN-5 | 17402-86-7 | Reference compound |
| HY-161457 | (Gly0.8Nap0.2)20 | | Reference compound |
| HY-161458 | GSK-3β inhibitor 16 | | Reference compound |
| HY-161459 | GLI1-IN-1 | 2923907-92-8 | Reference compound |
| HY-16146 | Combretastatin A-1 phosphate (tetrasodium) | 288847-34-7 | Reference compound |
| HY-161460 | Ferroptosis-IN-7 | | Reference compound |
| HY-161461 | E234G HYPE-IN-1 | 1341007-95-1 | Reference compound |
| HY-161462 | ERK2/p38α MAPK-IN-1 | 1016427-72-7 | Reference compound |
| HY-161463 | CDK2-IN-28 | 3025006-64-5 | Reference compound |
| HY-161464 | Chlopynostat | | Reference compound |
| HY-161465 | HDAC8-IN-7 | | Reference compound |
| HY-161466 | AChE-IN-62 | | Reference compound |
| HY-161467 | Aster-A Ligand-3 | 2375541-28-7 | Reference compound |
| HY-161468 | Thalidomide-N-C3-O-C4-O-C3-OH | | Reference compound |
| HY-161469 | α-Amylase/α-Glucosidase-IN-13 | | Reference compound |
| HY-16147 | Combretastatin A1 phosphate | 288847-35-8 | Reference compound |
| HY-161470 | WS-384 | 2247544-03-0 | Reference compound |
| HY-161471 | DCLK1-IN-5 | 3028774-14-0 | Reference compound |
| HY-161472 | Aldose reductase-IN-7 | | Reference compound |
| HY-161473 | Apoptosis inducer 16 | | Reference compound |
| HY-161474 | Antiproliferative agent-50 | 301675-59-2 | Reference compound |
| HY-161475 | Luciferase-IN-4 | 1020413-85-7 | Reference compound |
| HY-161476 | Ir-ImNO | | Dye Reagents |
| HY-161477 | Histamine/BSA | | Biochemical Assay Reagents |
| HY-161478 | Phosphoserine/BSA | | Biochemical Assay Reagents |
| HY-161479 | Melamine/OVA | | Biochemical Assay Reagents |
| HY-161480 | Melamine/BSA | | Biochemical Assay Reagents |
| HY-161481 | Melamine/bov igG | | Biochemical Assay Reagents |
| HY-161482 | Alginic acid/BSA | | Biochemical Assay Reagents |
| HY-161483 | CBP/p300 ligand 3 | 1936425-34-1 | Reference compound |
| HY-161484 | Penicillin G/OVA | | Biochemical Assay Reagents |
| HY-161485 | Gentamicin/BSA | | Biochemical Assay Reagents |
| HY-161486 | AOZ/OVA | | Biochemical Assay Reagents |
| HY-161487 | AOZ/BSA | | Biochemical Assay Reagents |
| HY-161488 | Eugenol/BSA | | Biochemical Assay Reagents |
| HY-161489 | Enrofloxacin/BSA | | Biochemical Assay Reagents |
| HY-161490 | AMOZ/BSA | | Biochemical Assay Reagents |
| HY-161491 | 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid-linker/OVA | | Biochemical Assay Reagents |
| HY-161492 | Estradiol/OVA | | Biochemical Assay Reagents |
| HY-161493 | 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid/BSA | | Biochemical Assay Reagents |
| HY-161494 | XYD190 | | Reference compound |
| HY-161495 | CBP/p300 ligand 4 | | Reference compound |
| HY-161496 | Boc-NHCH2-Ph-Py-NH2 | 3040121-14-7 | Reference compound |
| HY-161497 | Thalidomide-benzylamine-Py-NH2 | | Reference compound |
| HY-161498 | XYD198 | | Reference compound |
| HY-161499 | Boc-NHCH2-Ph-pyrimidine-NH2 | 3040121-15-8 | Reference compound |
| HY-161500 | Thalidomide-NHCH2-Ph-pyrimidine-NH2 | | Reference compound |
| HY-161501 | 3-Fluoro-evodiamine glucose | | Reference compound |
| HY-161502 | DHX-SP | | Dye Reagents |
| HY-161503 | PPO-IN-10 | 3034607-58-1 | Reference compound |
| HY-161504 | SDH-IN-14 | | Reference compound |
| HY-161505 | Transthyretin-IN-3 | 3008535-20-1 | Reference compound |
| HY-161506 | PDE1-IN-7 | 3027833-49-1 | Reference compound |
| HY-161507 | hCAI/II-IN-8 | 3036136-18-9 | Reference compound |
| HY-161508 | AChE/BChE-IN-19 | 3036136-22-5 | Reference compound |
| HY-161509 | PT-88 | 2803307-04-0 | Reference compound |
| HY-161511 | LPH-5 | 2641630-97-7 | Reference compound |
| HY-161512 | hAChE/hBACE-1-IN-4 | 229476-71-5 | Reference compound |
| HY-161513 | iNOS/COX-2-IN-1 | | Reference compound |
| HY-161514 | Xanthine oxidase-IN-15 | 2982794-86-3 | Reference compound |
| HY-161515 | BRD4/NAMPT-IN-1 | 3049218-28-9 | Reference compound |
| HY-161516 | HDAC6-IN-42 | | Reference compound |
| HY-161517 | PARP1-IN-20 | 2659357-95-4 | Reference compound |
| HY-161518 | PD-1/PD-L1-IN-44 | 3043669-06-0 | Reference compound |
| HY-161519 | PKM2 activator 7 | | Reference compound |
| HY-16152 | Crilvastatin | 120551-59-9 | Reference compound |
| HY-161520 | Glucocorticoid receptor/NF-κB modulator-1 | | Reference compound |
| HY-161521 | PLK1-IN-10 | 2991469-21-5 | Reference compound |
| HY-161522 | α-Glucosidase-IN-63 | 2375866-82-1 | Reference compound |
| HY-161523 | XOR/URAT1-IN-1 | 2810137-86-9 | Reference compound |
| HY-161524 | HDAC6-IN-43 | 3037978-19-8 | Reference compound |
| HY-161525 | 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker/BSA | | Biochemical Assay Reagents |
| HY-161526 | T3/KLH | | Biochemical Assay Reagents |
| HY-161527 | 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid-OVA | | Biochemical Assay Reagents |
| HY-161528 | T3/OVA | | Biochemical Assay Reagents |
| HY-161529 | Angiotensin I/BSA | | Biochemical Assay Reagents |
| HY-161530 | Angiotensin II/BSA | | Biochemical Assay Reagents |
| HY-161531 | Diethylstilbestrol/BSA | | Biochemical Assay Reagents |
| HY-161532 | Eugenol/OVA | | Biochemical Assay Reagents |
| HY-161533 | Digoxin/BSA | | Biochemical Assay Reagents |
| HY-161534 | Sulfadiazine/BSA | | Biochemical Assay Reagents |
| HY-161535 | Oxytetracycline/BSA | | Biochemical Assay Reagents |
| HY-161536 | PROTAC EGFR degrader 9 | 2992670-33-2 | Reference compound |
| HY-161537 | EGFR ligand-9 | 2992670-44-5 | Reference compound |
| HY-161538 | Lenalidomide-C6-Br | 2580970-60-9 | Reference compound |
| HY-161539 | KOR agonist 1 | | Reference compound |
| HY-161540 | Oxytetracycline/OVA | | Biochemical Assay Reagents |
| HY-161541 | Estradiol/BSA | | Biochemical Assay Reagents |
| HY-161542 | Isoniazid/BSA | | Biochemical Assay Reagents |
| HY-161543 | DHT/KLH | | Biochemical Assay Reagents |
| HY-161544 | Cholyglycine/BSA | | Biochemical Assay Reagents |
| HY-161545 | Sudan I/BSA | | Biochemical Assay Reagents |
| HY-161546 | Melamine/KLH | | Biochemical Assay Reagents |
| HY-161547 | Tetracycline/BSA | | Biochemical Assay Reagents |
| HY-161548 | Metronidazole/KLH | | Biochemical Assay Reagents |
| HY-161549 | Phosphotyrosine/BSA | | Biochemical Assay Reagents |
| HY-161551 | 25-OH Vitamin D3/KLH | | Biochemical Assay Reagents |
| HY-161552 | T3/BSA | | Biochemical Assay Reagents |
| HY-161553 | Biotin/KLH | | Biochemical Assay Reagents |
| HY-161554 | Clenbuterol/BSA | | Biochemical Assay Reagents |
| HY-161555 | Clenbuterol/KLH | | Biochemical Assay Reagents |
| HY-161556 | Alginic acid/KLH | | Biochemical Assay Reagents |
| HY-161557 | Ractopamine/BSA | | Biochemical Assay Reagents |
| HY-161558 | Ractopamine/KLH | | Biochemical Assay Reagents |
| HY-161559 | Sudan I/OVA | | Biochemical Assay Reagents |
| HY-161560 | Tacrolimus/BSA | | Biochemical Assay Reagents |
| HY-161561 | PROMETON/OVA | | Biochemical Assay Reagents |
| HY-161562 | PROMETON/BSA | | Biochemical Assay Reagents |
| HY-161563 | 4,4'-Sulfonyldiphenol/BSA | | Biochemical Assay Reagents |
| HY-161564 | T4/OVA | | Biochemical Assay Reagents |
| HY-161565 | Gastrin(1-17)/BSA | | Biochemical Assay Reagents |
| HY-161566 | DHT/BSA | | Biochemical Assay Reagents |
| HY-161567 | OX2R-IN-3 | 2791360-37-5 | Reference compound |
| HY-161568 | TEAD-IN-10 | 3032196-65-6 | Reference compound |
| HY-161569 | TEAD-IN-11 | 3032196-88-3 | Reference compound |
| HY-161570 | LRRK2-IN-12 | 3032733-05-1 | Reference compound |
| HY-161571 | LRRK2-IN-13 | 3032733-17-5 | Reference compound |
| HY-161572 | Nav1.8-IN-13 | 2785391-79-7 | Reference compound |
| HY-161573 | BAY-593 | 2413020-56-9 | Reference compound |
| HY-161573A | (7S)-BAY-593 | 2413068-25-2 | Reference compound |
| HY-161573B | BAY-593 (hydrochloride) | 2413020-57-0 | Reference compound |
| HY-161574 | LLC0424 | | Reference compound |
| HY-161575 | NSD2 ligand 1 | | Reference compound |
| HY-161576 | Thalidomide-Pip-N-boc | 2636798-54-2 | Reference compound |
| HY-161577 | BFC1103 | 701231-39-2 | Reference compound |
| HY-161578 | Dithio-CN03 | | Reference compound |
| HY-16158 | Cyclacillin | 3485-14-1 | Reference compound |
| HY-161580 | 3-Nitrotyrosine/BSA | | Biochemical Assay Reagents |
| HY-161581 | Metronidazole/OVA | | Biochemical Assay Reagents |
| HY-161583 | Marijuana/BSA | | Biochemical Assay Reagents |
| HY-161584 | Sudan I/KLH | | Biochemical Assay Reagents |
| HY-161585 | Diethylstilbestrol/KLH | | Biochemical Assay Reagents |
| HY-161586 | Chloramphenicol/BSA | | Biochemical Assay Reagents |
| HY-161587 | Chloramphenicol/OVA | | Biochemical Assay Reagents |
| HY-161588 | GABA/BSA | | Biochemical Assay Reagents |
| HY-161589 | GABA/KLH | | Biochemical Assay Reagents |
| HY-16158R | Cyclacillin (Standard) | 3485-14-1 | Reference Standards |
| HY-161590 | AHD/BSA | | Biochemical Assay Reagents |
| HY-161591 | SEM/BSA | | Biochemical Assay Reagents |
| HY-161594 | Furazolidone/BSA | | Biochemical Assay Reagents |
| HY-161595 | CDK5-IN-4 | 1212711-91-5 | Reference compound |
| HY-161596 | SmCB1-IN-1 | | Reference compound |
| HY-161597 | PROTAC DYRK2 degrader 1 | | Reference compound |
| HY-161598 | DYRK2 ligand 1 | | Reference compound |
| HY-16160 | Cysmethynil | 851636-83-4 | Reference compound |
| HY-161601 | Ferroptosis inducer-2 | 28657-88-7 | Reference compound |
| HY-161602 | EGFR/HER2-IN-13 | 3034701-46-4 | Reference compound |
| HY-161603 | EGFR/HER2-IN-14 | 3034701-54-4 | Reference compound |
| HY-161604 | HBV/HDV-IN-1 | 3034161-55-9 | Reference compound |
| HY-161605 | HBV/HDV-IN-2 | 3034161-76-4 | Reference compound |
| HY-161606 | PARP-1/2/7-IN-1 | 3034665-49-8 | Reference compound |
| HY-161607 | PARP7-IN-21 | 3034666-02-6 | Reference compound |
| HY-161608 | Myosin modulator 1 | 3034189-56-2 | Reference compound |
| HY-161609 | Myosin modulator 2 | 3034189-87-9 | Reference compound |
| HY-161610 | FGFR4-IN-21 | | Reference compound |
| HY-161611 | Plant 14-3-3-IN-1 | | Reference compound |
| HY-161612 | Mycosporine 2 glycine | 149092-45-5 | Reference compound |
| HY-161613 | 7-Bromoheptanoyl chloride | 50733-91-0 | Reference compound |
| HY-161614 | Tubulin inhibitor 44 | 3025180-36-0 | Reference compound |
| HY-161615 | PROTAC ATR degrader-2 | 3010273-12-5 | Reference compound |
| HY-161616 | ATR-IN-30 | 3010273-13-6 | Reference compound |
| HY-161617 | LASSBio-2052 | 2549160-15-6 | Reference compound |
| HY-161618 | MJ04 | 2099014-23-8 | Reference compound |
| HY-161619 | RMC-113 | 2258606-34-5 | Reference compound |
| HY-16162 | D-3263 | 947257-66-1 | Reference compound |
| HY-161620 | DW18134 | 2626988-87-0 | Reference compound |
| HY-161621 | JAK-IN-37 | | Reference compound |
| HY-161622 | K1586 | | Reference compound |
| HY-161623 | ERCC1/XPA interaction inhibitor 1 | | Reference compound |
| HY-161624 | Kv7.2 modulator 1 | 3034884-49-3 | Reference compound |
| HY-161625 | Kv7.2 modulator 2 | 2950243-05-5 | Reference compound |
| HY-161626 | PSMA binder-3 | 3049900-51-5 | Reference compound |
| HY-161627 | Anemoside A3-methyl 6-aminohexanoate | 2919975-48-5 | Reference compound |
| HY-161628 | Tapcin | | Reference compound |
| HY-161629 | TLR8 agonist 7 | 3034750-26-7 | Reference compound |
| HY-16162A | D-3263 (hydrochloride) | 1008763-54-9 | Reference compound |
| HY-161630 | TLR8 agonist 8 | 3034750-58-5 | Reference compound |
| HY-161631 | TLR8 agonist 9 | 3034750-61-0 | Reference compound |
| HY-161632 | PROTAC EGFR degrader 10 | 3034244-56-6 | Reference compound |
| HY-161633 | PROTAC EGFR degrader 11 | 3034244-71-5 | Reference compound |
| HY-161634 | PROTAC SOS1 degrader-8 | 3036155-11-7 | Reference compound |
| HY-161635 | SOS1 Ligand intermediate-4 | 3036155-94-6 | Reference compound |
| HY-161636 | PROTAC SOS1 degrader-9 | 3036155-21-9 | Reference compound |
| HY-161637 | E3 ligase Ligand 25 | 2633633-39-1 | Reference compound |
| HY-161638 | E3 Ligase Ligand-linker Conjugate 108 | 2911613-56-2 | Reference compound |
| HY-161639 | E3 ligase Ligand 26 | 2911613-35-7 | Reference compound |
| HY-161640 | E3 Ligase Ligand-linker Conjugate 109 | 2911613-55-1 | Reference compound |
| HY-161641 | Tubulin polymerization-IN-62 | | Reference compound |
| HY-161642 | DENV-2/ZIKV-IN-1 | | Reference compound |
| HY-161643 | S21-1011 | 2671859-87-1 | Reference compound |
| HY-161644 | STAT3-IN-27 | | Reference compound |
| HY-161645 | P-gp modulator-4 | | Reference compound |
| HY-161646 | P-selectin antagonist 1 | 2099111-75-6 | Reference compound |
| HY-161647 | Antitumor agent-156 | | Reference compound |
| HY-161648 | Anticancer agent 222 | | Reference compound |
| HY-161649 | hCYP1B1-IN-2 | 3043683-33-3 | Reference compound |
| HY-161650 | PROTAC BRD4 Degrader-26 | 3050769-37-1 | Reference compound |
| HY-161651 | BRD4 ligand 6 | 1101702-80-0 | Reference compound |
| HY-161651A | BRD4 ligand 6 (TFA) | 2763548-61-2 | Reference compound |
| HY-161652 | Thalidomide-NH-C3-O-Ph(NO2)-methylester-O-pyrrolidine-2,5-dione | | Reference compound |
| HY-161653 | Boc-NH-C3-O-Ph(NO2)-methylester-O-pyrrolidine-2,5-dione | 3050769-33-7 | Reference compound |
| HY-161654 | PROTAC SOS1 degrader-10 | 3043923-74-3 | Reference compound |
| HY-161655 | SOS1 Ligand intermediate-5 | 3043923-70-9 | Reference compound |
| HY-161656 | PIP-C-3-Azaspiro[5.5]undecane-boc | 3027978-51-1 | Reference compound |
| HY-161657 | 2-Methoxyphenyl dihydrouracil-azaspiro[5.5]undecane-C-PIP | | Reference compound |
| HY-161658 | Aβ-IN-9 | | Reference compound |
| HY-161659 | Apoptosis inducer 19 | 3049296-75-2 | Reference compound |
| HY-16166 | Dalvastatin | 132100-55-1 | Reference compound |
| HY-161660 | DS44470011 | 1192586-35-8 | Reference compound |
| HY-161661 | Anticancer agent 223 | 1328150-75-9 | Reference compound |
| HY-161662 | ALK5-IN-80 | 3039952-63-8 | Reference compound |
| HY-161663 | Phosphodiesterase-IN-2 | 3047610-96-5 | Reference compound |
| HY-161664 | ZINC866533340 | | Reference compound |
| HY-161665 | BDZ-P7 | | Reference compound |
| HY-161666 | mCMY416 | | Reference compound |
| HY-161667 | GSK-3β/HDAC-IN-1 | | Reference compound |
| HY-161668 | Ru-Poma | | Reference compound |
| HY-161669 | NLRP3-IN-40 | | Reference compound |
| HY-161670 | NSD2-PWWP1 ligand 1 | | Reference compound |
| HY-161671 | GAT2711 | | Reference compound |
| HY-161672 | G-5758 | 2413455-99-7 | Reference compound |
| HY-161673 | CDC14A/B-IN-1 | 3048655-03-1 | Reference compound |
| HY-161674 | Monoamine Oxidase B inhibitor 4 | 424794-91-2 | Reference compound |
| HY-161675 | Lenalidomide-5-bromopentanamide | 2545963-24-2 | Reference compound |
| HY-161676 | DOTA-RBB-Ga | | Reference compound |
| HY-161677 | PD-L1/CD-73-IN-1 | 3048634-84-7 | Reference compound |
| HY-161679S | Pyruvate Carboxylase-IN-3 | | Isotope-Labeled Compounds |
| HY-16168 | Degarelix (acetate) | 934016-19-0 | Reference compound |
| HY-161680 | Pyruvate Carboxylase-IN-4 | 2369048-06-4 | Reference compound |
| HY-161681 | Formycin triphosphate | 16409-13-5 | Reference compound |
| HY-161682 | GPR84 antagonist 9 | 2654791-96-3 | Reference compound |
| HY-161683 | Tyk2-IN-19 | 2866415-98-5 | Reference compound |
| HY-161684 | JAK2-IN-10 | 3035735-18-0 | Isotope-Labeled Compounds |
| HY-161685 | Antibiofilm agent-8 | | Reference compound |
| HY-161686 | Carbonic anhydrase inhibitor 24 | | Reference compound |
| HY-161687 | Cisplatin/Dasatinib prodrug-1 | 3049801-09-1 | Reference compound |
| HY-161688 | HDAC-IN-73 | 2323571-16-8 | Reference compound |
| HY-161689 | Antibacterial agent 220 | | Reference compound |
| HY-16168A | Degarelix | 214766-78-6 | Reference compound |
| HY-16168AR | Degarelix (Standard) | 214766-78-6 | Reference Standards |
| HY-16168AS | Degarelix-d7 | | Isotope-Labeled Compounds |
| HY-16168B | Degarelix (acetate hydrate) | 934246-14-7 | Reference compound |
| HY-161690 | EF-4-177 | 2891574-93-7 | Reference compound |
| HY-161691 | EBOV-IN-9 | | Reference compound |
| HY-161692 | ERα degrader 8 | 2971837-95-1 | Reference compound |
| HY-161693 | Telomeric G4s ligand 1 | 3047091-81-3 | Reference compound |
| HY-161694 | DNMT1-IN-3 | 3025012-68-1 | Reference compound |
| HY-161695 | Angiogenesis inhibitor 6 | 2752466-36-5 | Reference compound |
| HY-161696 | AN5777 | 491586-42-6 | Reference compound |
| HY-161697 | hCAIX-IN-20 | 3047054-26-9 | Reference compound |
| HY-161699 | SDTWS01 | | Reference compound |
| HY-16170 | Desvenlafaxine (succinate) | 448904-47-0 | Reference compound |
| HY-161700 | BMS-737 | 1356053-63-8 | Reference compound |
| HY-161701 | (3β,4β,17β)-17-(2-Pyridinylmethyl)androst-5-ene-3,4,17-triol | 1393651-00-7 | Reference compound |
| HY-161702 | RO6806051 | 1433901-75-7 | Reference compound |
| HY-161703 | 2-Hydroxy-3′-O-methyladenosine | 157309-10-9 | Reference compound |
| HY-161704 | AKT-IN-23 | 1226801-23-5 | Reference compound |
| HY-161705 | Anti-apoptotic agent 1 | 2563616-64-6 | Reference compound |
| HY-161706 | c-Fms-IN-15 | 3047930-25-3 | Reference compound |
| HY-161707 | MMP2-IN-4 | 92535-43-8 | Reference compound |
| HY-161708 | PROTAC FLT3/CDKs degrader-1 | | Reference compound |
| HY-161709 | FLT3/CDKs ligand-1 | 2452019-67-7 | Reference compound |
| HY-16171 | Diphenmanil (methylsulfate) | 62-97-5 | Reference compound |
| HY-161710 | XYD129 | | Reference compound |
| HY-161711 | CBP/p300 ligand 5 | | Reference compound |
| HY-161712 | Nampt-IN-12 | 2427862-70-0 | Reference compound |
| HY-161713 | PD-1/PD-L1-IN-45 | | Reference compound |
| HY-161714 | HH0043 | 2922069-42-7 | Reference compound |
| HY-161715 | LH708 | 1616757-93-7 | Reference compound |
| HY-161716 | LH1753 | 2650492-10-5 | Reference compound |
| HY-161717 | MRS5663 | 1377272-66-6 | Reference compound |
| HY-161718 | MRS8028 | 1784714-67-5 | Reference compound |
| HY-161719 | NF764 | | Reference compound |
| HY-16171R | Diphenmanil (methylsulfate) (Standard) | 62-97-5 | Reference Standards |
| HY-16172 | DMAPT | 791595-09-0 | Reference compound |
| HY-161721 | Cathepsin Inhibitor 4 | | Reference compound |
| HY-161722 | SARS-CoV-2 Mpro-IN-21 | 3041099-79-7 | Reference compound |
| HY-161723 | LH2-051 | 2358754-22-8 | Reference compound |
| HY-161724 | TFEB activator 2 | 3027414-04-3 | Reference compound |
| HY-161725 | TFEB activator 3 | 3027413-48-2 | Reference compound |
| HY-161726 | TLR7 agonist 23 | 2408268-38-0 | Reference compound |
| HY-161727 | P2Y14R antagonist 1 | 2728291-29-8 | Reference compound |
| HY-161728 | Antibacterial agent 223 | 833432-18-1 | Reference compound |
| HY-161729 | PLpro-IN-3 | 3047093-72-8 | Reference compound |
| HY-16172A | (S)-DMAPT | 870677-05-7 | Reference compound |
| HY-161730 | αvβ1 integrin-IN-3 | | Reference compound |
| HY-161731 | DS08701581 | | Reference compound |
| HY-161732 | GQN-B37-E | 2982663-28-3 | Reference compound |
| HY-161733 | GQN-B37-Me | | Reference compound |
| HY-161734 | Microtubule inhibitor 11 | | Reference compound |
| HY-161735 | CXCR4-IN-3 | | Reference compound |
| HY-161736 | ARN25499 | | Reference compound |
| HY-161737 | YT-8-8 | 892572-23-5 | Reference compound |
| HY-161738 | YOK-2204 | 2409959-99-3 | Reference compound |
| HY-161739 | YOK-1304 | 2409960-03-6 | Reference compound |
| HY-161740 | PHTPP-1304 | 2410081-60-4 | Reference compound |
| HY-161741 | VinclozolinM2-2204 | | Reference compound |
| HY-161742 | Fumagilin-105 | 2410081-58-0 | Reference compound |
| HY-161743 | PBA-1105 | 2410081-56-8 | Reference compound |
| HY-161743A | PBA-1105 (TFA) | | Reference compound |
| HY-161744 | PBA-1106 | 2410081-55-7 | Reference compound |
| HY-161745 | PBA-1105b | 2941386-60-1 | Reference compound |
| HY-161746 | Anle138b-F105 | 2941386-44-1 | Reference compound |
| HY-161747 | Tubulin inhibitor 46 | | Reference compound |
| HY-161748 | PD-1/PD-L1-IN-46 | | Reference compound |
| HY-161749 | PROTAC ALK degrader-1 | 3049802-45-8 | Reference compound |
| HY-161750 | PROTAC ALK degrader-2 | | Reference compound |
| HY-161751 | MJ34 | 2099015-13-9 | Reference compound |
| HY-161752 | Antibacterial agent 224 | | Reference compound |
| HY-161753 | CFTR potentiator 1 | | Reference compound |
| HY-161755 | Anticancer agent 232 | | Reference compound |
| HY-161756 | DNA Gyrase-IN-10 | | Reference compound |
| HY-161757 | Anti-inflammatory agent 86 | | Reference compound |
| HY-161758 | F0045(S) | 2716077-17-5 | Reference compound |
| HY-161759 | MS152 | | Reference compound |
| HY-161760 | Ferroptosis inducer-3 | | Reference compound |
| HY-161761 | Urease-IN-15 | | Reference compound |
| HY-161762 | RA-0002034 | 3038542-51-4 | Reference compound |
| HY-161762A | (E/Z)-RA-0002034 | 2305572-22-7 | Reference compound |
| HY-161763 | Tubulin polymerization-IN-65 | | Reference compound |
| HY-161764 | α-Glucosidase-IN-67 | | Reference compound |
| HY-161765 | iHSP110-33 | | Reference compound |
| HY-161766 | L687 | 2776151-36-9 | Reference compound |
| HY-161767 | JWJ-01-306 | | Reference compound |
| HY-161768 | VCC972839:01 | | Reference compound |
| HY-161769 | HL435 | | Reference compound |
| HY-161770 | HL389 | | Reference compound |
| HY-161771 | JNJ-7184 | 2347368-51-6 | Reference compound |
| HY-161772 | (S)-Gebr32a | 3055162-32-5 | Reference compound |
| HY-161773 | HL389-NHC2-PEG3-C2NH | | Reference compound |
| HY-161774 | ST80 | | Reference compound |
| HY-161775 | RET/TRKA-IN-1 | 3048634-52-9 | Reference compound |
| HY-161776 | P-gp/CDK2-IN-1 | | Reference compound |
| HY-161777 | SARS-CoV-2 Mpro-IN-23 | | Reference compound |
| HY-161778 | ZG-126 | 3049802-32-3 | Reference compound |
| HY-161779 | PLX-3618 | 2851986-76-8 | Reference compound |
| HY-161780 | Maleimide-PEG8-Val-Ala-PAB-SNS032 | | ADC Related |
| HY-161781 | HVH-2930 | 3034605-72-3 | Reference compound |
| HY-161782 | α-Amylase-IN-7 | 3049575-16-5 | Reference compound |
| HY-161783 | HDAC6-IN-45 | 3048532-05-1 | Reference compound |
| HY-161784 | GABAA receptor modulator-5 | 3021554-08-2 | Reference compound |
| HY-161785 | EGFR-IN-117 | 3035639-05-2 | Reference compound |
| HY-161786 | Bcl-2-IN-20 | | Reference compound |
| HY-161787 | G9a-IN-2 | 2648853-26-1 | Reference compound |
| HY-161788 | DNA Gyrase-IN-11 | 2497486-58-3 | Reference compound |
| HY-161789 | PROTAC SARS-CoV-2 Mpro degrader-3 | | Reference compound |
| HY-161790 | Mpro ligand 1 | | Reference compound |
| HY-161791 | Mpro ligand 2 | 2816967-14-1 | Reference compound |
| HY-161792 | N3-C5-O-C-Boc | 2836521-02-7 | Reference compound |
| HY-161793 | (S,R,S)-AHPC-NHCO-C-O-C5-N3 | 2816967-28-7 | Reference compound |
| HY-161794 | SP3N | | Reference compound |
| HY-161794A | SP3N (hydrochloride) | | Reference compound |
| HY-161795 | SP3CHO | | Reference compound |
| HY-161796 | UNC8732 | 2929304-05-0 | Reference compound |
| HY-161796A | UNC8732 (TFA) | 2929304-06-1 | Reference compound |
| HY-161797 | Antibacterial agent 227 | 301304-67-6 | Reference compound |
| HY-161798 | Orpinolide | | Reference compound |
| HY-161800 | Aminoacyl tRNA synthetase-IN-3 | | Reference compound |
| HY-161801 | MMV006833 | 701253-55-6 | Reference compound |
| HY-161802 | Antibacterial agent 228 | | Reference compound |
| HY-161803 | Anti-MRSA agent 12 | 2314380-76-0 | Reference compound |
| HY-161804 | GNF-2-deg | | Reference compound |
| HY-161805 | GNF-2-acid | 714962-05-7 | Reference compound |
| HY-161806 | ZXH-8-004 | | Reference compound |
| HY-161807 | DENV ligand 1 | 1628758-48-4 | Reference compound |
| HY-161808 | DENV ligand 2 | | Reference compound |
| HY-161810 | MRS8247 | 2991693-72-0 | Reference compound |
| HY-161811 | FEACYP | | Reference compound |
| HY-161812 | MOR agonist-4 | 3050669-97-8 | Reference compound |
| HY-161813 | Antibacterial agent 229 | 3049500-54-8 | Reference compound |
| HY-161814 | Apoptosis inducer 20 | | Reference compound |
| HY-161815 | Anti-inflammatory agent 89 | | Reference compound |
| HY-161816 | PI3K/AKT-IN-3 | 2488891-30-9 | Reference compound |
| HY-161817 | TGR5 agonist 5 | | Reference compound |
| HY-161818 | LLW-018 | 3049369-11-8 | Reference compound |
| HY-161819 | TRK-IN-29 | | Reference compound |
| HY-16182 | Ecamsule | 92761-26-7 | Reference compound |
| HY-161820 | IAV-IN-3 | 3049492-11-4 | Reference compound |
| HY-161821 | Antitumor agent-173 | | Reference compound |
| HY-161822 | Antibacterial agent 230 | 3049368-26-2 | Reference compound |
| HY-161823 | Anti-MRSA agent 13 | | Reference compound |
| HY-161824 | Antiproliferative agent-52 | 2913194-20-2 | Reference compound |
| HY-161825 | Tubulin polymerization-IN-66 | | Reference compound |
| HY-161826 | Antitumor agent-174 | | Reference compound |
| HY-161827 | Anti-MRSA agent 14 | 3050586-22-3 | Reference compound |
| HY-161828 | JWZ-5-13 | | Reference compound |
| HY-161829 | CDK7 ligand 1 | | Reference compound |
| HY-16182A | Ecamsule (disodium) | 90458-75-6 | Reference compound |
| HY-16182R | Ecamsule (Standard) | 92761-26-7 | Reference Standards |
| HY-16183 | Echothiopate iodide | 513-10-0 | Reference compound |
| HY-161830 | CDK7 ligand 2 | 2603381-71-9 | Reference compound |
| HY-161831 | Antitumor agent-175 | | Reference compound |
| HY-161832 | (S,R,S)-Me-AHPC-amide-C3-alkyne | 3016512-69-6 | Reference compound |
| HY-161833 | HSP90-IN-31 | 2117645-10-8 | Reference compound |
| HY-161834 | RG100204 | 2140901-88-6 | Reference compound |
| HY-161835 | SR140333B | 155418-06-7 | Reference compound |
| HY-161836 | α2AR agonist 1 | | Reference compound |
| HY-161837 | SARS-CoV-2 Mpro-IN-24 | | Reference compound |
| HY-161838 | ICT10336 | | Reference compound |
| HY-161839 | AKR1C2/3-IN-1 | | Reference compound |
| HY-16183A | Echothiopate (chloride) | 120087-68-5 | Reference compound |
| HY-161840 | Antitumor agent-176 | | Reference compound |
| HY-161841 | Antitumor agent-177 | | Reference compound |
| HY-161842 | AChE-IN-67 | | Reference compound |
| HY-161843 | Necroptosis-IN-4 | | Reference compound |
| HY-161844 | Virapinib | 1794091-10-3 | Reference compound |
| HY-161845 | Anticancer agent 240 | 3039831-27-8 | Reference compound |
| HY-161846 | Tyrosinase-IN-31 | 903206-81-5 | Reference compound |
| HY-161847 | HZ1 | 3030492-40-8 | Reference compound |
| HY-161848 | TCP-MP-CA | | Reference compound |
| HY-161849 | LSD1-IN-31 | | Reference compound |
| HY-161850 | ULK1-IN-3 | | Reference compound |
| HY-161851 | MDL3 | | Reference compound |
| HY-161852 | PI3K-IN-55 | | Reference compound |
| HY-161853 | TX-2552 | 2446767-14-0 | Reference compound |
| HY-161854 | LASSBio-1911 | | Reference compound |
| HY-161855 | VEGFR-2-IN-50 | | Reference compound |
| HY-161856 | Antifungal agent 106 | | Reference compound |
| HY-161857 | Akt/mTOR-IN-1 | | Reference compound |
| HY-161858 | EpskA21 | | Reference compound |
| HY-161859 | VEGFR-2/STAT-3-IN-1 | | Reference compound |
| HY-161860 | Antibacterial agent 233 | | Reference compound |
| HY-161861 | VEGFR-2/AKT-IN-1 | | Reference compound |
| HY-161862 | COX-2-IN-44 | | Reference compound |
| HY-161863 | Tubulin polymerization-IN-67 | | Reference compound |
| HY-161864 | STAT3-IN-29 | 2256751-16-1 | Reference compound |
| HY-161865 | Antitumor agent-180 | | Reference compound |
| HY-161866 | EGFR-IN-118 | | Reference compound |
| HY-161867 | Platelet aggregation-IN-1 | | Reference compound |
| HY-161868 | DLC-50 | 2928537-98-6 | Reference compound |
| HY-161869 | LSD1-IN-32 | | Reference compound |
| HY-16187 | EL-102 | 1233948-61-2 | Reference compound |
| HY-161870 | Antibiotic adjuvant 1 | 2351883-15-1 | Reference compound |
| HY-161871 | WEE1-IN-8 | 2493422-74-3 | Reference compound |
| HY-161872 | LC3in-C42 | | Reference compound |
| HY-161873 | PW507 | 2573850-59-4 | Reference compound |
| HY-161874 | RPS6-IN-1 | | Reference compound |
| HY-161875 | NAT1-IN-1 | | Reference compound |
| HY-161876 | GSTO1-IN-2 | 3020776-77-3 | Reference compound |
| HY-161877 | GS-7682 | 2694736-39-3 | Reference compound |
| HY-161878 | USP1-IN-10 | 2857051-98-8 | Reference compound |
| HY-161879 | WEE1-IN-9 | 2510782-14-4 | Reference compound |
| HY-161880 | WEE1-IN-10 | 2226938-19-6 | Reference compound |
| HY-161881 | SMARCA2-IN-9 | | Reference compound |
| HY-161882 | PROTAC SMARCA2 degrader-8 | 2669027-50-1 | Reference compound |
| HY-161883 | JP-2-249 | 3036530-41-0 | Reference compound |
| HY-161884 | SMARCA2/4-IN-1 | 76947-79-0 | Reference compound |
| HY-161885 | SMARCA2-IN-6 | 2270875-79-9 | Reference compound |
| HY-161886 | SMARCA2-IN-7 | 2270879-43-9 | Reference compound |
| HY-161887 | SMARCA2-IN-8 | 2270875-93-7 | Reference compound |
| HY-161888 | DCSM06 | 924855-67-4 | Reference compound |
| HY-161889 | DCSM06-05 | 880811-10-9 | Reference compound |
| HY-16189 | Elliptinium (acetate) | 58337-35-2 | Reference compound |
| HY-161890 | Antimycobacterial agent-8 | | Reference compound |
| HY-161891 | EGFR/Akt-IN-1 | | Reference compound |
| HY-161892 | FABP4-IN-4 | | Reference compound |
| HY-161893 | Anti-MRSA agent 15 | | Reference compound |
| HY-161894 | CFTR corrector 13 | | Reference compound |
| HY-161895 | CFTR corrector 14 | | Reference compound |
| HY-161896 | Transcription factor-IN-1 | | Reference compound |
| HY-161897 | CENP-E-IN-2 | | Reference compound |
| HY-161898 | CENP-E-IN-3 | | Reference compound |
| HY-161899 | MCHR1 antagonist 4 | 1574538-43-4 | Reference compound |
| HY-161900 | Apoptosis inducer 22 | | Reference compound |
| HY-161901 | BC-1293 | 1219395-86-4 | Reference compound |
| HY-161902 | MI-1904 | 3033379-90-4 | Reference compound |
| HY-161903 | Progranulin modulator-3 | 371116-39-1 | Reference compound |
| HY-161904 | CDYL-IN-1 | 2378625-66-0 | Reference compound |
| HY-161905 | ML471 | 2226227-77-4 | Reference compound |
| HY-161906 | SD-066-4 | 64640-77-3 | Reference compound |
| HY-161907 | h15-LOX-2 inhibitor 2 | | Reference compound |
| HY-161908 | h15-LOX-2 inhibitor 3 | 1164515-84-7 | Reference compound |
| HY-161909 | USP30-I-1 | 2511541-78-7 | Reference compound |
| HY-16191 | ELR510444 | 1233948-35-0 | Reference compound |
| HY-161910 | SH-E4A-66 | | Reference compound |
| HY-161911 | Necroptosis-IN-5 | | Reference compound |
| HY-161912 | 5TTU | | Reference compound |
| HY-161913 | AC-4-248 | | Reference compound |
| HY-161914 | P2X3 antagonist 39 | | Reference compound |
| HY-161915 | GLP-1R agonist 23 | 2855245-46-2 | Reference compound |
| HY-161916 | Polθ-IN-4 | 3043810-73-4 | Reference compound |
| HY-161917 | HPK1-IN-49 | 2845144-97-8 | Reference compound |
| HY-161918 | SARM1-IN-3 | 3046146-15-7 | Reference compound |
| HY-161919 | SARS-CoV-2 3CLpro-IN-25 | | Reference compound |
| HY-161920 | SIRT3-IN-1 | | Reference compound |
| HY-161921 | Antifungal agent 108 | | Reference compound |
| HY-161922 | Antibacterial agent 235 | | Reference compound |
| HY-161923 | EGFR-IN-120 | | Reference compound |
| HY-161924 | HIV-1 inhibitor-73 | | Reference compound |
| HY-161925 | sTGFBR3 antagonist 1 | | Reference compound |
| HY-161926 | YGT-31 | 2835447-74-8 | Reference compound |
| HY-161927 | EGFR-TK-IN-4 | 3053485-72-3 | Reference compound |
| HY-161928 | GPX4 activator 1 | 1030098-18-0 | Reference compound |
| HY-161929 | GPX4 activator 2 | 950365-31-8 | Reference compound |
| HY-161930 | PROTAC GPX4 degrader-3 | | Reference compound |
| HY-161931 | Demethyl-RSL3-boc | 2375354-07-5 | Reference compound |
| HY-161933 | 1-Adamantane-amide-C7-NH2 | 2860813-92-7 | Reference compound |
| HY-161934 | PARP1-IN-27 | | Reference compound |
| HY-161935 | 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid | | Reference compound |
| HY-161936 | Z21115 | 2958668-54-5 | Reference compound |
| HY-161937 | Antibacterial agent 236 | 2364479-10-5 | Reference compound |
| HY-161938 | BRD8518 | 1565828-01-4 | Reference compound |
| HY-161939 | 7030B-C5 | 370871-42-4 | Reference compound |
| HY-16194 | Emiglitate | 80879-63-6 | Reference compound |
| HY-161940 | PCSK9-IN-30 | | Reference compound |
| HY-161941 | MeIm | 2043947-71-1 | Reference compound |
| HY-161942 | PCSK9-IN-31 | 2247649-76-7 | Reference compound |
| HY-161943 | NEU3-IN-1 | | Reference compound |
| HY-161944 | α-Amylase-IN-8 | 1503788-07-5 | Reference compound |
| HY-161945 | IN-RNA-IN-2 | | Reference compound |
| HY-161946 | GBM CSCs-IN-1 | | Reference compound |
| HY-161947 | TOFA-Plasmalogen | | Reference compound |
| HY-161948 | Ferroptosis inducer-4 | | Reference compound |
| HY-161949 | AP-6 | 1369963-51-8 | Reference compound |
| HY-161950 | Tyrosinase-IN-33 | 137058-21-0 | Reference compound |
| HY-161951 | PPO-IN-15 | 3029518-71-3 | Reference compound |
| HY-161952 | JAB-3312 | 2245082-05-5 | Reference compound |
| HY-161953 | O-GlcNAcase-IN-2 | | Reference compound |
| HY-161954 | HDAC8-IN-12 | 3028095-13-5 | Reference compound |
| HY-161955 | TMV-IN-11 | 2991481-09-3 | Reference compound |
| HY-161956 | Antiviral agent 59 | | Reference compound |
| HY-161957 | Top1/2-IN-1 | | Reference compound |
| HY-161958 | dCE-2 | | Reference compound |
| HY-161959 | EP300/CBP ligand 1 | | Reference compound |
| HY-16196 | ENMD-1198 | 864668-87-1 | Reference compound |
| HY-161960 | EP300/CBP ligand 2 | | Reference compound |
| HY-161961 | Thalidomide-NH-C10-Boc | 2428400-25-1 | Reference compound |
| HY-161962 | D-Glucoside, octyl | 54549-23-4 | Biochemical Assay Reagents |
| HY-161963 | Arlacel A | 9049-98-3 | Biochemical Assay Reagents |
| HY-161964 | (2-Decyloxy)ethanol | 23238-40-6 | Biochemical Assay Reagents |
| HY-161965 | MK-3168 (12C) | 1242441-26-4 | Reference compound |
| HY-161966 | VEGFR-2-IN-52 | 3046428-94-5 | Reference compound |
| HY-161967 | JAK2/FLT3-IN-3 | 3038183-53-5 | Reference compound |
| HY-161968 | EGFR/PI3Kα-IN-1 | | Reference compound |
| HY-161969 | Tyrosinase-IN-34 | | Reference compound |
| HY-16197 | Epicochlioquinone A | 147384-57-4 | Reference compound |
| HY-161970 | XSJ05 | 1461652-87-8 | Reference compound |
| HY-161971 | Tyrosinase-IN-35 | 1613467-47-2 | Reference compound |
| HY-161972 | ZX782 | | Reference compound |
| HY-161973 | Hydroxyl-ML-210 | | Reference compound |
| HY-161974 | Adamantan-C-amide-PEG2-C-Br | | Reference compound |
| HY-161975 | ROS1-IN-2 | 2120337-16-6 | Reference compound |
| HY-161976 | ACC1-IN-2 | 3027705-67-2 | Reference compound |
| HY-161977 | Cbl-b-IN-26 | 3035443-17-2 | Reference compound |
| HY-161978 | CDK4/6-IN-22 | 3036014-62-4 | Reference compound |
| HY-161979 | HSD17B13-IN-103 | 3035000-89-3 | Reference compound |
| HY-161980 | Topoisomerases/ribosomes-IN-1 | | Reference compound |
| HY-161981 | Antitumor photosensitizer-8 | | Reference compound |
| HY-161982 | JNU-0921 | | Reference compound |
| HY-161983 | Neuraminidase-IN-22 | | Reference compound |
| HY-161984 | HDAC-IN-76 | | Reference compound |
| HY-161985 | PPARγ-IN-3 | | Reference compound |
| HY-161986 | HIV-1 inhibitor-74 | | Reference compound |
| HY-161987 | LpxH-IN-2 | 2923230-41-3 | Reference compound |
| HY-161988 | Antimicrobial agent-34 | | Reference compound |
| HY-161989 | DZ-837 | | Reference compound |
| HY-161990 | BCL6 ligand-2 | | Reference compound |
| HY-161991 | Caspase-3 activator 4 | 1817874-62-6 | Reference compound |
| HY-161992 | Nrf2 activator-11 | | Reference compound |
| HY-161993 | BI-9787 | 3043939-18-7 | Reference compound |
| HY-161994 | COX-2-IN-47 | 2043670-02-4 | Reference compound |
| HY-161995 | FGFR1/VEGFR2-IN-2 | | Reference compound |
| HY-161996 | IDO1-IN-25 | 2841467-86-3 | Reference compound |
| HY-161997 | hTopo-II/tubulin-IN-1 | | Reference compound |
| HY-161998 | Urease-IN-16 | 1203704-26-0 | Reference compound |
| HY-161999 | α-Glucosidase-IN-73 | | Reference compound |
| HY-16200 | Ethynylcytidine | 180300-43-0 | Reference compound |
| HY-162000 | hCAIX/XII-IN-13 | | Reference compound |
| HY-162001 | INX-315 | 2745060-92-6 | Reference compound |
| HY-162002 | WSD0628 | 2765448-96-0 | Reference compound |
| HY-162002A | (S)-WSD0628 | 2765449-10-1 | Reference compound |
| HY-162003 | DCPT1061 | 2289726-31-2 | Reference compound |
| HY-162003A | DCPT1061 (hydrochloride) | | Reference compound |
| HY-162004 | NF-κB-IN-14 | 3019972-01-8 | Reference compound |
| HY-162005 | AChE-IN-48 | | Reference compound |
| HY-162006 | Pim-1 kinase inhibitor 8 | 916038-47-6 | Reference compound |
| HY-162007 | PYRA-2 | | Reference compound |
| HY-162008 | S1g-10 | 3032432-71-3 | Reference compound |
| HY-162009 | CaMKK2-IN-1 | 3032691-65-6 | Reference compound |
| HY-162010 | MAT2A-IN-13 | 2851449-24-4 | Reference compound |
| HY-162011 | GPR183 antagonist-2 | 2924063-98-7 | Reference compound |
| HY-162012 | HC-258 | 3056128-12-9 | Reference compound |
| HY-162013 | NLRP3-IN-26 | 2927413-30-5 | Reference compound |
| HY-162014 | WDR5 degrader-1 | 3032434-45-7 | Reference compound |
| HY-162015 | LTA4H-IN-2 | 2851480-52-7 | Reference compound |
| HY-162016 | IP6K-IN-1 | | Reference compound |
| HY-162020 | SB1617 | | Reference compound |
| HY-162021 | Methotrexate triglutamate | 41600-14-0 | Reference compound |
| HY-162022 | BTA-188 | 314062-80-1 | Reference compound |
| HY-162023 | mTOR inhibitor-10 | 1144075-36-4 | Reference compound |
| HY-162024 | mTOR inhibitor-16 | 1144075-42-2 | Reference compound |
| HY-162025 | mTOR inhibitor-17 | 1144075-40-0 | Reference compound |
| HY-162026 | 11β-HSD1-IN-14 | 946394-50-9 | Reference compound |
| HY-162027 | PB118 | | Reference compound |
| HY-162028 | GaMF1.39 | 2568607-82-7 | Reference compound |
| HY-162029 | Tyrosinase-IN-20 | 1024364-57-5 | Reference compound |
| HY-162030 | MMT3-72 | 2996158-39-3 | Reference compound |
| HY-162031 | MMT3-72-M2 | 936091-74-6 | Reference compound |
| HY-162032 | FLT3-IN-25 | | Reference compound |
| HY-162033 | PAT1inh-A0030 | 1030097-65-4 | Reference compound |
| HY-162034 | FAK-IN-17 | | Reference compound |
| HY-162035 | MDM2-IN-23 | | Reference compound |
| HY-162036 | α-Amylase/α-Glucosidase-IN-7 | 1038094-94-8 | Reference compound |
| HY-162037 | CDDD11-8 | 2241659-94-7 | Reference compound |
| HY-162038 | RXP03 | 284667-65-8 | Reference compound |
| HY-162039 | MMP-11-IN-1 | | Reference compound |
| HY-162040 | P-gp inhibitor 17 | 2556388-58-8 | Reference compound |
| HY-162041 | AQIM-I | 2247881-73-6 | Reference compound |
| HY-162042 | AMPK activator 14 | 1356632-18-2 | Reference compound |
| HY-162043 | CKR-49-17 | | Reference compound |
| HY-162044 | COX-1/2-IN-6 | 327024-84-0 | Reference compound |
| HY-162045 | Ru-4T | | Reference compound |
| HY-162046 | Anticancer agent 178 | | Reference compound |
| HY-162050 | 8AQ−Cu−5Iu | | Reference compound |
| HY-162051 | CYP1B1-IN-6 | 2952712-68-2 | Reference compound |
| HY-162059 | Pim-1 kinase inhibitor 10 | 2918764-57-3 | Reference compound |
| HY-162060 | YPX-C-05 | 2894823-79-9 | Reference compound |
| HY-162061 | ChEs/MAOs-IN-1 | | Reference compound |
| HY-162062 | EGFR WT/T790M/L858R-IN-1 | | Reference compound |
| HY-162063 | hCAIX/XII-IN-9 | | Reference compound |
| HY-162064 | T-1-MBHEPA | | Reference compound |
| HY-162065 | N6F11 | 851398-76-0 | Reference compound |
| HY-162066 | DNDI-6174 | 2868298-43-3 | Reference compound |
| HY-162068 | Auristatin23 | 2375388-36-4 | Reference compound |
| HY-162069 | Antiviral agent 47 | 89419-23-8 | Reference compound |
| HY-16207 | FGH10019 | 1046045-61-7 | Reference compound |
| HY-162070 | CCK antagonist 1 | 742116-45-6 | Reference compound |
| HY-162071 | PKM2-IN-5 | 904457-46-1 | Reference compound |
| HY-162072 | PfThrRS-IN-1 | | Reference compound |
| HY-162073 | ZIKV-IN-8 | 3022924-04-2 | Reference compound |
| HY-162074 | Nipamovir | 2651908-78-8 | Reference compound |
| HY-162075 | RF16 | | Reference compound |
| HY-162076 | AEP-IN-3 | 2978521-26-3 | Reference compound |
| HY-162077 | HIV-IN-10 | 2413866-14-3 | Reference compound |
| HY-162078 | Antiproliferative agent-46 | | Reference compound |
| HY-162079 | Anticancer agent 183 | 3018960-58-9 | Reference compound |
| HY-16208 | Fluorapacin | 869811-23-4 | Reference compound |
| HY-162080 | METTL1-WDR4-IN-1 | 374705-10-9 | Reference compound |
| HY-162081 | BTK-IN-32 | 1015441-29-8 | Reference compound |
| HY-162082 | METTL1-WDR4-IN-2 | 2919742-07-5 | Reference compound |
| HY-162083 | CB2R/5-HT1AR agonist 1 | 2821085-76-9 | Reference compound |
| HY-162084 | BKN-1 | 1607831-82-2 | Reference compound |
| HY-162085 | Axl-IN-17 | 3048409-80-6 | Reference compound |
| HY-162086 | HDAC-IN-68 | | Reference compound |
| HY-162086A | HDAC-IN-68 (hydrochloride) | | Reference compound |
| HY-162087 | FabH-IN-2 | 3040281-87-3 | Reference compound |
| HY-162088 | DW71177 | 2241311-72-6 | Reference compound |
| HY-162089 | MY-1442 | 3050871-87-6 | Reference compound |
| HY-16209 | Forodesine (hydrochloride) | 284490-13-7 | Reference compound |
| HY-162090 | TRPC antagonist 1 | 3027139-12-1 | Reference compound |
| HY-162091 | Topoisomerase I inhibitor 13 | | Reference compound |
| HY-162092 | Multi-target Pt | 3041997-77-4 | Reference compound |
| HY-162093 | Aβ1–42 aggregation inhibitor 2 | 3036099-60-9 | Reference compound |
| HY-162094 | Antitubercular agent-44 | 3027135-80-1 | Reference compound |
| HY-162096 | Keap1-Nrf2-IN-17 | 3042821-85-9 | Reference compound |
| HY-162097 | RIPK1-IN-20 | 3026543-19-8 | Reference compound |
| HY-162098 | PROTAC tubulin-Degrader-1 | | Reference compound |
| HY-162099 | VEGFR-IN-4 | 3000483-29-1 | Reference compound |
| HY-16210 | Forodesine | 209799-67-7 | Reference compound |
| HY-162100 | MR-2088 | 2922531-69-7 | Reference compound |
| HY-162101 | Topoisomerase inhibitor 3 | 3026832-96-9 | Reference compound |
| HY-162102 | DDR1-IN-8 | 3038810-92-0 | Reference compound |
| HY-162103 | Axl-IN-18 | 3040329-68-5 | Reference compound |
| HY-162104 | BRCA2-RAD51-IN-1 | 2830213-53-9 | Reference compound |
| HY-162105 | Aromatase-IN-3 | | Reference compound |
| HY-162106 | PROTAC GPX4 degrader-2 | | Reference compound |
| HY-162107 | Dyrk1A-IN-6 | | Reference compound |
| HY-162108 | Antitumor agent-128 | 1942910-49-7 | Reference compound |
| HY-162109 | Thrombin inhibitor 11 | | Reference compound |
| HY-162110 | AM-9022 | 2446872-46-2 | Reference compound |
| HY-162110A | (S)-AM-9022 | 2446872-47-3 | Reference compound |
| HY-162111 | SARS-CoV-2-IN-73 | | Reference compound |
| HY-162113 | Antibacterial agent 174 | 2896196-09-9 | Reference compound |
| HY-162114 | PARP1-IN-18 | 2958609-64-6 | Reference compound |
| HY-162115 | TLR7 agonist 17 | 2410517-32-5 | Reference compound |
| HY-162116 | TLR7 agonist 18 | | Reference compound |
| HY-162117 | LBG30300 | | Reference compound |
| HY-162118 | RGH-122 | 2355304-05-9 | Reference compound |
| HY-162119 | PRL-IN-1 | 331431-75-5 | Reference compound |
| HY-16212 | FR901464 | 146478-72-0 | Natural Products |
| HY-162120 | FZQ-21 | | Reference compound |
| HY-162121 | Antitumor agent-129 | | Reference compound |
| HY-162122 | PPARα/γ agonist 3 | | Reference compound |
| HY-162123 | PPARα/δ agonist 2 | | Reference compound |
| HY-162124 | HDAC/NAMPT-IN-1 | 2898381-63-8 | Reference compound |
| HY-162125 | AT2 receptor ligand-1 | | Reference compound |
| HY-162126 | Tubulin polymerization-IN-58 | | Reference compound |
| HY-162127 | hAChE/hBACE-1-IN-3 | | Reference compound |
| HY-162128 | Antitumor agent-130 | | Reference compound |
| HY-162129 | Antitumor agent-131 | | Reference compound |
| HY-16213 | FURNIDIPINE | 138661-03-7 | Reference compound |
| HY-162130 | Antibacterial agent 176 | | Reference compound |
| HY-162131 | Antitumor agent-132 | | Reference compound |
| HY-162132 | WZB117-PPG | | Reference compound |
| HY-162133 | MSA-2-Pt | | Reference compound |
| HY-162134 | Trypanothione synthetase-IN-5 | | Reference compound |
| HY-162135 | MAT2A-IN-14 | | Reference compound |
| HY-162136 | GPR40 agonist 7 | 1821647-46-4 | Reference compound |
| HY-162137 | Hepatoprotective agent-1 | 1225971-07-2 | Reference compound |
| HY-162138 | BChE-IN-23 | 2020357-32-6 | Reference compound |
| HY-162139 | Urease-IN-11 | 517906-12-6 | Reference compound |
| HY-16214 | FX-11 | 213971-34-7 | Reference compound |
| HY-162140 | Tyrosinase-IN-21 | | Reference compound |
| HY-162141 | MD102 | 2755794-94-4 | Reference compound |
| HY-162142 | BB2-50F | 2226086-65-1 | Reference compound |
| HY-162143 | SKI-349 | 727686-80-8 | Reference compound |
| HY-162144 | BDM91288 | 2892824-53-0 | Reference compound |
| HY-162145 | AChE-IN-54 | | Reference compound |
| HY-162146 | NS3-IN-1 | | Reference compound |
| HY-162147 | Nur77 modulator 3 | 2097787-75-0 | Reference compound |
| HY-162148 | HNPMI | 1980848-48-3 | Reference compound |
| HY-162149 | Urease-IN-12 | | Reference compound |
| HY-16215 | Mipsagargin | 1245732-48-2 | Peptides |
| HY-162150 | Azalamellarin N | 1809535-57-6 | Reference compound |
| HY-162151 | SARS-CoV-2-IN-74 | | Reference compound |
| HY-162152 | biKEAP1 | | Reference compound |
| HY-162153 | CYY292 | 2644673-04-9 | Reference compound |
| HY-162154 | SARS-CoV-2-IN-75 | 2738323-08-3 | Reference compound |
| HY-162155 | Diarctigenin | | Reference compound |
| HY-162156 | TTK inhibitor 4 | 2964520-80-5 | Reference compound |
| HY-162158 | DA ZP1 | 1816254-69-9 | Dye Reagents |
| HY-162159 | Ac-Cys-NHMe | 10061-65-1 | Reference compound |
| HY-16216 | Gabapentin enacarbil | 478296-72-9 | Reference compound |
| HY-162160 | NR12S | 1221739-85-0 | Dye Reagents |
| HY-162161 | Flutax-2 | 301844-13-3 | Dye Reagents |
| HY-162162 | RXR agonist 1 | | Reference compound |
| HY-162163 | TLR7 agonist 19 | 2682008-42-8 | Reference compound |
| HY-162164 | Neuroprotective agent 3 | 130995-63-0 | Reference compound |
| HY-162165 | Neuroprotective agent 4 | 161095-11-0 | Reference compound |
| HY-162166 | COX-2/15-LOX/mPGES1-IN-1 | | Reference compound |
| HY-162167 | COX-1-IN-1 | 1369503-03-6 | Reference compound |
| HY-162168 | Anti-inflammatory agent 71 | | Reference compound |
| HY-162169 | α-Amylase/α-Glucosidase-IN-8 | | Reference compound |
| HY-16217 | Gadobutrol | 770691-21-9 | Reference compound |
| HY-162170 | Anti-inflammatory agent 72 | | Reference compound |
| HY-162171 | Antibacterial agent 179 | | Reference compound |
| HY-162172 | PARP7-IN-18 | 2819999-00-1 | Reference compound |
| HY-162173 | WYZ90 | | Reference compound |
| HY-162174 | MBL-IN-2 | | Reference compound |
| HY-162175 | TAMRA-isoADPr | | Dye Reagents |
| HY-162176 | 5-HT2A agonist 2 | | Reference compound |
| HY-162177 | SARS-CoV-2-IN-78 | 38716-45-9 | Reference compound |
| HY-16217A | Gadobutrol (hydrate) | 198637-52-4 | Reference compound |
| HY-162180 | E3 Ligase Ligand-linker Conjugate 2 | | Reference compound |
| HY-162181 | E3 Ligase Ligand-linker Conjugate 5 | 2839670-45-8 | Reference compound |
| HY-162182 | E3 Ligase Ligand-linker Conjugate 7 | 2758531-47-2 | Reference compound |
| HY-162183 | E3 Ligase Ligand-linker Conjugate 9 | | Reference compound |
| HY-162184 | E3 ligase Ligand-Linker Conjugate 11 | | Reference compound |
| HY-162185 | E3 Ligase Ligand-linker Conjugate 12 | | Reference compound |
| HY-162186 | E3 Ligase Ligand-linker Conjugate 13 | | Reference compound |
| HY-162187 | E3 Ligase Ligand-linker Conjugate 14 | | Reference compound |
| HY-162188 | E3 Ligase Ligand-linker Conjugate 15 | 2716124-25-1 | Reference compound |
| HY-162189 | E3 Ligase Ligand-linker Conjugate 16 | | Reference compound |
| HY-16219 | Gadoxetate (disodium) | 135326-22-6 | Reference compound |
| HY-162190 | E3 Ligase Ligand-linker Conjugate 17 | | Reference compound |
| HY-162191 | E3 Ligase Ligand-linker Conjugate 18 | | Reference compound |
| HY-162192 | E3 Ligase Ligand-linker Conjugate 20 | | Reference compound |
| HY-162193 | E3 Ligase Ligand-linker Conjugate 27 | | Reference compound |
| HY-162194 | E3 Ligase Ligand-linker Conjugate 28 | 2229717-76-2 | Reference compound |
| HY-162195 | E3 ligase Ligand-Linker Conjugate 34 | 2682113-65-9 | Reference compound |
| HY-162196 | E3 ligase Ligand-Linker Conjugate 39 | 2632308-04-2 | Reference compound |
| HY-162197 | E3 ligase Ligand-Linker Conjugate 41 | | Reference compound |
| HY-162198 | E3 ligase Ligand-Linker Conjugate 43 | | Reference compound |
| HY-162199 | E3 Ligase Ligand-linker Conjugate 45 | 2871775-00-5 | Reference compound |
| HY-162200 | E3 Ligase Ligand-linker Conjugate 47 | | Reference compound |
| HY-162201 | E3 Ligase Ligand-linker Conjugate 48 | 2520105-41-1 | Reference compound |
| HY-162202 | E3 Ligase Ligand-linker Conjugate 50 | 2918813-56-4 | Reference compound |
| HY-162203 | E3 Ligase Ligand-linker Conjugate 51 | 2589706-80-7 | Reference compound |
| HY-162204 | E3 Ligase Ligand-linker Conjugate 54 | 2229725-33-9 | Reference compound |
| HY-162205 | E3 Ligase Ligand-linker Conjugate 55 | | Reference compound |
| HY-162206 | E3 Ligase Ligand-linker Conjugate 58 | 2229725-27-1 | Reference compound |
| HY-162207 | HSD17B13-IN-54 | 2770247-49-7 | Reference compound |
| HY-162208 | HSD17B13-IN-55 | 2770247-58-8 | Reference compound |
| HY-162209 | HSD17B13-IN-63 | 2770247-51-1 | Reference compound |
| HY-162210 | HSD17B13-IN-65 | 2770247-59-9 | Reference compound |
| HY-162211 | HSD17B13-IN-84 | 2770247-73-7 | Reference compound |
| HY-162212 | HSD17B13-IN-85 | 2770247-76-0 | Reference compound |
| HY-162213 | HSD17B13-IN-86 | 2770247-78-2 | Reference compound |
| HY-162214 | HSD17B13-IN-90 | 2848620-81-3 | Reference compound |
| HY-162215 | HSD17B13-IN-88 | 2770247-93-1 | Reference compound |
| HY-162216 | HSD17B13-IN-89 | 2770247-94-2 | Reference compound |
| HY-162217 | HSD17B13-IN-91 | 2848620-83-5 | Reference compound |
| HY-162219 | HSD17B13-IN-93 | 2848620-87-9 | Reference compound |
| HY-162220 | HSD17B13-IN-94 | 2848620-90-4 | Reference compound |
| HY-162221 | HSD17B13-IN-95 | 2849338-41-4 | Reference compound |
| HY-162222 | HSD17B13-IN-96 | 2849338-43-6 | Reference compound |
| HY-162223 | HSD17B13-IN-97 | 2849338-44-7 | Reference compound |
| HY-162224 | HSD17B13-IN-98 | 2849338-45-8 | Reference compound |
| HY-162225 | HSD17B13-IN-99 | 2849338-46-9 | Reference compound |
| HY-162226 | Carbonic anhydrase inhibitor 19 | 3033374-40-9 | Reference compound |
| HY-162227 | Antitumor agent-138 | 2975168-22-8 | Reference compound |
| HY-162228 | VI-60 | | Reference compound |
| HY-162229 | GRL-190-21 | 2755957-14-1 | Reference compound |
| HY-162230 | PRMT5-IN-33 | | Reference compound |
| HY-162231 | HY-078020 | 2756222-90-7 | Reference compound |
| HY-162232 | mGluR2 agonist 1 | | Reference compound |
| HY-162232A | mGluR2 agonist 1 (hydrochloride) | | Reference compound |
| HY-162233 | SHP2-IN-25 | | Reference compound |
| HY-162234 | PKCTheta-IN-1 | 2948289-20-9 | Reference compound |
| HY-162235 | CVN766 | 1803557-42-7 | Reference compound |
| HY-162236 | SARS-CoV-2-IN-80 | 57341-12-5 | Reference compound |
| HY-162237 | RIPK1-IN-22 | | Reference compound |
| HY-162238 | OSM-S-106 | 2650846-59-4 | Reference compound |
| HY-162239 | Anticancer agent 187 | | Reference compound |
| HY-162240 | SJH1-51B | | Reference compound |
| HY-162241 | SJH1-62B | | Reference compound |
| HY-162242 | Cap-dependent endonuclease-IN-27 | | Reference compound |
| HY-162244 | COX-2-IN-40 | 444790-64-1 | Reference compound |
| HY-162245 | PROTAC SMARCA2 degrader-3 | 3024266-69-8 | Reference compound |
| HY-162246 | Nav1.8-IN-5 | 3023247-79-9 | Reference compound |
| HY-162247 | MDM2-IN-26 | 1818393-11-1 | Reference compound |
| HY-162248 | JAK1/2-IN-1 | 3023876-01-6 | Reference compound |
| HY-162249 | ASP6918 | | Reference compound |
| HY-162250 | MS8847 | 3050872-59-5 | Reference compound |
| HY-162252 | SIRT2-IN-12 | | Reference compound |
| HY-162253 | HIV-1 inhibitor-64 | 2919019-36-4 | Reference compound |
| HY-162254 | EGFR/ACK1-IN-1 | | Reference compound |
| HY-162255 | CDK2-IN-23 | 2488073-20-5 | Reference compound |
| HY-162256 | Antibacterial agent 184 | | Reference compound |
| HY-162257 | BTK-IN-34 | 3016419-52-3 | Reference compound |
| HY-162258 | AChE-IN-57 | | Reference compound |
| HY-162259 | QC-182 | 3032646-96-8 | Reference compound |
| HY-162260 | MNK-IN-4 | | Reference compound |
| HY-162261 | Antibacterial agent 186 | | Reference compound |
| HY-162262 | α-Glucosidase-IN-48 | | Reference compound |
| HY-162264 | Tubulin polymerization/V-ATPase-IN-1 | | Reference compound |
| HY-162265 | UCM-13369 | 2921944-77-4 | Reference compound |
| HY-162265A | UCM-13369 (dihydrochloride) | | Reference compound |
| HY-162266 | C3TD879 | 2850259-33-3 | Reference compound |
| HY-162267 | LPAR1 antagonist 1 | 3032275-33-2 | Reference compound |
| HY-162268 | MALT1-IN-13 | | Reference compound |
| HY-162269 | Nampt activator-5 | | Reference compound |
| HY-162270 | CDK2-IN-24 | | Reference compound |
| HY-162271 | Antibacterial agent 187 | | Reference compound |
| HY-162273 | Antibacterial agent 189 | | Reference compound |
| HY-162274 | Oxazepine | | Reference compound |
| HY-162275 | JMJD1C-IN-1 | 861224-48-8 | Reference compound |
| HY-162276 | Anticancer agent 188 | 1207377-56-7 | Reference compound |
| HY-162277 | BuChE-IN-10 | | Reference compound |
| HY-162278 | HSD17B13-IN-101 | | Reference compound |
| HY-162279 | Insecticidal agent 8 | | Reference compound |
| HY-16228 | Genz-644282 | 529488-28-6 | Reference compound |
| HY-162280 | PROTAC BTK Degrader-9 | | Reference compound |
| HY-162281 | PROTAC SOS1 degrader-6 | 3032282-51-9 | Reference compound |
| HY-162282 | PROTAC METTL3-14 degrader 1 | | Reference compound |
| HY-162283 | FGFR4-IN-18 | | Reference compound |
| HY-162284 | BAY-9835 | 3032487-31-0 | Reference compound |
| HY-162285 | Anticancer agent 189 | | Reference compound |
| HY-162286 | α-Glucosidase-IN-50 | | Reference compound |
| HY-162287 | α-Glucosidase-IN-51 | | Reference compound |
| HY-162288 | FAZ-3532 | 3036029-72-5 | Reference compound |
| HY-162289 | FAZ-3780 | 3036029-78-1 | Reference compound |
| HY-16229 | GGTI-2154 | 251577-10-3 | Reference compound |
| HY-162290 | Z2206320703 | | Reference compound |
| HY-162291 | Lck-IN-3 | | Reference compound |
| HY-162292 | Anticancer agent 190 | | Reference compound |
| HY-162293 | CDK8-IN-14 | 2924193-12-2 | Reference compound |
| HY-162294 | c-Myc inhibitor 13 | | Reference compound |
| HY-162295 | SARS-CoV-2-IN-83 | | Reference compound |
| HY-162296 | Antibacterial agent 188 | 88312-54-3 | Reference compound |
| HY-162297 | 4-(Sulfooxy)benzoic acid | 3233-38-3 | Reference compound |
| HY-162298 | γ-Linolenoyl monoethanolamide | 150314-37-7 | Reference compound |
| HY-162299 | EGFR kinase inhibitor 3 | 2922402-03-5 | Reference compound |
| HY-16229A | GGTI-2154 (hydrochloride) | 478908-50-8 | Reference compound |
| HY-16230 | GGTI-2417 | 501010-05-5 | Reference compound |
| HY-162300 | EGFR kinase inhibitor 4 | 2922402-05-7 | Reference compound |
| HY-162301 | P3FI-63 | 931596-95-1 | Reference compound |
| HY-162302 | NMY1009 | | Reference compound |
| HY-162303 | C175-0062 | 686736-69-6 | Reference compound |
| HY-162304 | MAGL-IN-14 | 2770967-04-7 | Reference compound |
| HY-162305 | MAGL-IN-15 | 2770967-08-1 | Reference compound |
| HY-162306 | GLP-1R agonist 18 | 2855243-02-4 | Reference compound |
| HY-162307 | Nrf2 degrader 1 | 3025286-00-1 | Reference compound |
| HY-162308 | NSD-IN-3 | 744260-15-9 | Reference compound |
| HY-162309 | CSF1R-IN-20 | 2935479-57-3 | Reference compound |
| HY-16231 | GGTI-2418 | 501010-06-6 | Reference compound |
| HY-162310 | Anticancer agent 193 | | Reference compound |
| HY-162311 | Anticancer agent 194 | 2767204-90-8 | Reference compound |
| HY-162312 | LLK203 | 2758090-62-7 | Reference compound |
| HY-162313 | NIP-22c | 2309384-85-6 | Reference compound |
| HY-162314 | TNIK-IN-8 | | Reference compound |
| HY-162315 | MAGL-IN-16 | | Reference compound |
| HY-162316 | NF-κB-IN-15 | | Reference compound |
| HY-162317 | AMPK-IN-5 | | Reference compound |
| HY-162318 | MYC degrader 1 | 2946670-96-6 | Reference compound |
| HY-162318A | MYC degrader 1 (TFA) | | Reference compound |
| HY-162319 | Tubulin/HDAC-IN-4 | | Reference compound |
| HY-16232 | Glufosfamide | 132682-98-5 | Reference compound |
| HY-162320 | PPARγ agonist 12 | | Reference compound |
| HY-162321 | ZINC57632462 | 1286482-29-8 | Reference compound |
| HY-162322 | VU0542270 | 1396814-79-1 | Reference compound |
| HY-162323 | EGFR-IN-106 | | Reference compound |
| HY-162324 | MX106-4C | | Reference compound |
| HY-162325 | WJ-39 | 3009908-95-3 | Reference compound |
| HY-162326 | VEGFR-2-IN-41 | | Reference compound |
| HY-162327 | PROTAC PAPD5 degrader 1 | | Reference compound |
| HY-162328 | Antibacterial agent 194 | 2157356-88-0 | Reference compound |
| HY-162329 | Antibacterial agent 195 | | Reference compound |
| HY-162330 | HDAC6-IN-36 | | Reference compound |
| HY-162331 | STING Degrader-1 | | Reference compound |
| HY-162332 | EGFR-PK/JNK-2-IN-1 | | Reference compound |
| HY-162333 | BAL-0028 | 2842012-69-3 | Reference compound |
| HY-162334 | HYOU1-IN-1 | 2832155-52-7 | Reference compound |
| HY-162336 | Casein kinase 1δ-IN-15 | 2765264-27-3 | Reference compound |
| HY-162337 | PPO-IN-8 | | Reference compound |
| HY-162338 | BChE-IN-29 | | Reference compound |
| HY-162339 | BChE-IN-30 | | Reference compound |
| HY-162340 | Z32439948 | 920845-86-9 | Reference compound |
| HY-162341 | Topoisomerase I inhibitor 15 | | Reference compound |
| HY-162342 | Topoisomerase I inhibitor 14 | | Reference compound |
| HY-162343 | PD-1/PD-L1-IN-41 | | Reference compound |
| HY-162344 | Ir-CA | 2870682-93-0 | Reference compound |
| HY-162345 | CK-963 | 2851991-63-2 | Reference compound |
| HY-162346 | KN-17 | | Reference compound |
| HY-162347 | Nav1.7-IN-13 | 2776235-57-3 | Reference compound |
| HY-162348 | Antitumor agent-145 | 2983120-65-4 | Reference compound |
| HY-162349 | PARP7/HDACs-IN-1 | | Reference compound |
| HY-162350 | TDI-11055 | | Reference compound |
| HY-162351 | EBP-IN-1 | | Reference compound |
| HY-162352 | SDU-071 | 3036109-10-8 | Reference compound |
| HY-162353 | AZ'9567 | | Reference compound |
| HY-162355 | SHP2-IN-27 | 2376012-00-7 | Reference compound |
| HY-162356 | PD-L1-IN-4 | 2597056-86-3 | Reference compound |
| HY-162357 | PD-L1-IN-5 | 2597056-85-2 | Reference compound |
| HY-162358 | DHFR-IN-17 | | Reference compound |
| HY-162359 | BIO-7488 | 2573211-25-1 | Reference compound |
| HY-162360 | EGFR-IN-109 | 3019971-97-9 | Reference compound |
| HY-162361 | HDAC1-IN-7 | 794552-20-8 | Reference compound |
| HY-162362 | MS8709 | 3060730-06-2 | Reference compound |
| HY-162363 | MD6a | | Reference compound |
| HY-162364 | p38-α MAPK-IN-7 | | Reference compound |
| HY-162365 | JD-02 | | Reference compound |
| HY-162366 | KRAS G12D inhibitor 20 | | Reference compound |
| HY-162367 | FLT3/CHK1-IN-2 | | Reference compound |
| HY-162368 | cPLA2α-IN-2 | | Reference compound |
| HY-162369 | PID-9 | | Reference compound |
| HY-162370 | CYP51-IN-16 | | Reference compound |
| HY-162371 | NRPSs-IN-1 | | Reference compound |
| HY-162372 | Hedgehog IN-6 | 2916444-33-0 | Reference compound |
| HY-162373 | α-Amylase/α-Glucosidase-IN-10 | | Reference compound |
| HY-162374 | ANO61 | 940476-20-0 | Reference compound |
| HY-162375 | AF299 | 832685-79-7 | Reference compound |
| HY-162376 | T3SS-IN-4 | 2316760-41-3 | Reference compound |
| HY-162378 | LT-630 | | Reference compound |
| HY-162379 | Anticancer agent 200 | | Reference compound |
| HY-162380 | Topoisomerase II inhibitor 18 | 2382959-65-9 | Reference compound |
| HY-162381 | Topoisomerase II inhibitor 19 | | Reference compound |
| HY-162382 | KTC1101 | 2764833-47-6 | Reference compound |
| HY-162384 | EPIC-0628 | | Reference compound |
| HY-162385 | COX-2-IN-42 | | Reference compound |
| HY-162386 | UM4118 | 324530-92-9 | Reference compound |
| HY-162387 | UK4b | 2171000-87-4 | Reference compound |
| HY-162388 | TIM-098a | | Reference compound |
| HY-162389 | Anticancer agent 202 | | Reference compound |
| HY-162390 | α-Amylase/α-Glucosidase-IN-11 | | Reference compound |
| HY-162392 | Anticancer agent 203 | | Reference compound |
| HY-162393 | XL44 | 2637949-91-6 | Reference compound |
| HY-162394 | Vasopressin V2 receptor antagonist 2 | | Reference compound |
| HY-162395 | α-Glucosidase-IN-58 | | Reference compound |
| HY-162396 | P-gp inhibitor 21 | | Reference compound |
| HY-162397 | Neopetromin | | Natural Products |
| HY-162398 | LQ23 | 2997615-62-8 | Reference compound |
| HY-162399 | PD-L1-IN-6 | | Reference compound |
| HY-162400 | TMV-IN-8 | 3023856-56-3 | Reference compound |
| HY-162401 | AZ7976 | 2813866-27-0 | Reference compound |
| HY-162402 | NLRP3-IN-33 | | Reference compound |
| HY-162403 | Antiviral agent 53 | | Reference compound |
| HY-162404 | Smad2/3-IN-2 | | Reference compound |
| HY-162405 | Smad2/3-IN-1 | | Reference compound |
| HY-162406 | UNC8969 | 3036049-17-6 | Reference compound |
| HY-162407 | I-As-1 | | Reference compound |
| HY-162408 | PAR4 antagonist 3 | 3057206-40-0 | Reference compound |
| HY-162409 | PAR4 antagonist 4 | 3057206-41-1 | Reference compound |
| HY-162410 | Fluplatin | | Reference compound |
| HY-162411 | E3 ligase Ligand 24 | 3038773-47-3 | Reference compound |
| HY-162412 | PROTAC AR/AR-V7 degrader-1 | 2841308-96-9 | Reference compound |
| HY-162413 | (R)-LW-Srci-8 | | Reference compound |
| HY-162414 | SARS-CoV-2-IN-84 | 214221-82-6 | Reference compound |
| HY-162415 | CSF1R-IN-22 | 2760585-35-9 | Reference compound |
| HY-162416 | CDK7-IN-27 | | Reference compound |
| HY-162417 | PPO-IN-12 | | Reference compound |
| HY-162418 | Antibacterial agent 203 | | Reference compound |
| HY-162420 | PPO-IN-9 | | Reference compound |
| HY-162421 | SL antagonist 1 | | Reference compound |
| HY-162422 | Mito-DK | | Dye Reagents |
| HY-162423 | CYB210010 | 2762568-47-6 | Reference compound |
| HY-162424 | ZBP1/RIP3/MLKL activator 1 | | Reference compound |
| HY-162425 | Anti-inflammatory agent 78 | | Reference compound |
| HY-162426 | UNC-CA2-103 | | Reference compound |
| HY-162427 | NMS-0963 | 2765304-82-1 | Reference compound |
| HY-162428 | PTPN2/1-IN-3 | | Reference compound |
| HY-162429 | Antibacterial agent 205 | | Reference compound |
| HY-162430 | Antibacterial agent 206 | | Reference compound |
| HY-162431 | MK-1084 | 2641216-67-1 | Reference compound |
| HY-162432 | MDM2-IN-27 | | Reference compound |
| HY-162433 | I-070 | | Reference compound |
| HY-162434 | I-128 | | Reference compound |
| HY-162435 | GLP-1R agonist 20 | | Reference compound |
| HY-162436 | GLP-1R agonist 21 | | Reference compound |
| HY-162437 | GLP-1R agonist 22 | | Reference compound |
| HY-162438 | PHD2-IN-2 | | Reference compound |
| HY-162439 | pan-KRAS-IN-6 | 3033565-36-2 | Reference compound |
| HY-162440 | pan-KRAS-IN-7 | | Reference compound |
| HY-162441 | pan-KRAS-IN-8 | | Reference compound |
| HY-162442 | pan-KRAS-IN-9 | | Reference compound |
| HY-162443 | pan-KRAS-IN-10 | | Reference compound |
| HY-162444 | KRAS G12D inhibitor 22 | | Reference compound |
| HY-162445 | KRASG12D-IN-3 | 3033638-63-7 | Reference compound |
| HY-162445S | KRASG12D-IN-3-d3 | 3033638-69-3 | Isotope-Labeled Compounds |
| HY-162446 | pan-KRAS-IN-13 | 3033637-76-9 | Reference compound |
| HY-162447 | P-gp inhibitor 22 | 1226674-74-3 | Reference compound |
| HY-162448 | SerBut | 63321-66-4 | Reference compound |
| HY-162449 | GIC-20 | 2942242-60-4 | Reference compound |
| HY-162450 | Antitumor agent-150 | | Reference compound |
| HY-162451 | Antibacterial agent 207 | | Reference compound |
| HY-162452 | Prolyl endopeptidase inhibitor 2 | 2362592-81-0 | Reference compound |
| HY-162453 | Anticancer agent 204 | | Reference compound |
| HY-162454 | DA-023 | 2585643-97-4 | Reference compound |
| HY-162455 | NA-014 | | Reference compound |
| HY-162456 | Anticancer agent 205 | | Reference compound |
| HY-162457 | Mn007 | 1843236-92-9 | Reference compound |
| HY-162458 | Antifungal agent 100 | 2975157-18-5 | Reference compound |
| HY-162459 | cGAS-IN-3 | | Reference compound |
| HY-16246 | Haloprogin | 777-11-7 | Reference compound |
| HY-162460 | ERK1/2 inhibitor 10 | | Reference compound |
| HY-162461 | HIV-1 inhibitor-66 | | Reference compound |
| HY-162462 | Antitumor agent-151 | | Reference compound |
| HY-162463 | Ir-UA | 3033235-42-3 | Reference compound |
| HY-162464 | MPD2 | | Reference compound |
| HY-162465 | BDW568 | 335401-44-0 | Reference compound |
| HY-162466 | ABA receptor agonist 1 | 2981430-43-5 | Reference compound |
| HY-162467 | Opabactin | 2407423-32-7 | Reference compound |
| HY-162469 | 6K465 | 2702965-27-1 | Reference compound |
| HY-16247 | Apoptone | 183387-50-0 | Reference compound |
| HY-162470 | DBPR728 | 2702965-64-6 | Reference compound |
| HY-162471 | GSK_WRN3 | 2923009-50-9 | Reference compound |
| HY-162472 | XRD-0394 | 2595308-10-2 | Reference compound |
| HY-162473 | MLEB-1934 | | Reference compound |
| HY-162474 | BZG2 | | Reference compound |
| HY-162475 | Fluorofolin | 2757070-32-7 | Reference compound |
| HY-162476 | SHP2-IN-28 | | Reference compound |
| HY-162477 | TS-24 | 1563260-97-8 | Reference compound |
| HY-162478 | GR-28 | | Reference compound |
| HY-162479 | PTP1B-IN-26 | | Reference compound |
| HY-162480 | PTP1B-IN-27 | | Reference compound |
| HY-162481 | Anticancer agent 210 | | Reference compound |
| HY-162482 | EGFR kinase inhibitor 5 | | Reference compound |
| HY-162483 | EGFR kinase inhibitor 6 | | Reference compound |
| HY-162484 | GZNL-P36 | | Reference compound |
| HY-162485 | DV-B-120 | | Reference compound |
| HY-162487 | HDAC-IN-72 | 763066-77-9 | Reference compound |
| HY-162488 | Laccase-IN-3 | | Reference compound |
| HY-162489 | Tyrosine kinase-IN-8 | | Reference compound |
| HY-162490 | TF-S14 | 2425563-60-4 | Reference compound |
| HY-162491 | JR-6 | | Reference compound |
| HY-162492 | Influenza A virus-IN-14 | | Reference compound |
| HY-162493 | MBL-IN-3 | 1452395-68-4 | Reference compound |
| HY-162494 | PAD4-IN-4 | | Reference compound |
| HY-162495 | IDOR-1117-2520 | 2737274-49-4 | Reference compound |
| HY-162496 | L-NBDNJ | | Reference compound |
| HY-162497 | Insecticidal agent 12 | | Reference compound |
| HY-162498 | Antileishmanial agent-29 | | Reference compound |
| HY-162499 | MY17 | | Reference compound |
| HY-162500 | Antifungal agent 99 | | Reference compound |
| HY-162501 | Yaddle1 | | Reference compound |
| HY-162502 | WZU-13 | 304882-43-7 | Reference compound |
| HY-162503 | ST166 (free acid) | 50580-23-9 | Reference compound |
| HY-162504 | 2'-RIBOTAC-U | | Reference compound |
| HY-162505 | SQA1 | 1255915-27-5 | Reference compound |
| HY-162506 | IGF-1R inhibitor-3 | 1227753-12-9 | Reference compound |
| HY-162507 | 2'-RIBOTAC-U recruiter-linker | | Reference compound |
| HY-162508 | KSK-104 | | Reference compound |
| HY-162509 | YS07 | | Reference compound |
| HY-162510 | SPDZi1 | | Reference compound |
| HY-162511 | IP2015 | 1320346-14-2 | Reference compound |
| HY-162512 | CB-0821 | 81430-62-8 | Reference compound |
| HY-162513 | DPP-4-IN-10 | 1123219-12-4 | Reference compound |
| HY-162514 | BBC0403 | 2644662-83-7 | Reference compound |
| HY-162515 | 8-OAc | 2550395-87-2 | Reference compound |
| HY-162516 | DBI-2 | 2939087-00-8 | Reference compound |
| HY-162517 | UMM-766 | 443643-17-2 | Reference compound |
| HY-162518 | Eg5-IN-3 | | Reference compound |
| HY-162519 | LZFPN-90 | | Reference compound |
| HY-16251A | Hetacillin | 3511-16-8 | Reference compound |
| HY-16252 | Hexafluorenium (dibromide) | 317-52-2 | Reference compound |
| HY-162520 | DJ-1-IN-1 | 797780-71-3 | Reference compound |
| HY-162521 | Antibacterial agent 215 | | Reference compound |
| HY-162522 | SL-IN-1 | | Reference compound |
| HY-162523 | hMAO-B-IN-8 | | Reference compound |
| HY-162524 | Tyrosinase-IN-28 | | Reference compound |
| HY-162525 | GS-9770 | 2306328-43-6 | Reference compound |
| HY-162526 | HIV capsid modulator 2 | | Reference compound |
| HY-162527 | Antibacterial agent 216 | | Reference compound |
| HY-162528 | CDK12-IN-7 | 3033863-94-1 | Reference compound |
| HY-162529 | CDK4/6-IN-19 | 3033950-86-3 | Reference compound |
| HY-162530 | CDK4/6-IN-20 | 3033950-84-1 | Reference compound |
| HY-162531 | KIF18A-IN-9 | 3034541-82-4 | Reference compound |
| HY-162532 | KIF18A-IN-10 | 3034542-28-1 | Reference compound |
| HY-162533 | GSPT1 degrader-4 | 3034764-32-1 | Reference compound |
| HY-162534 | GSPT1 degrader-5 | 3034764-38-7 | Reference compound |
| HY-162535 | GSPT1 degrader-6 | 3034764-41-2 | Reference compound |
| HY-162536 | Pan-RAS-IN-5 | | Reference compound |
| HY-162537 | LYP-8 | | Reference compound |
| HY-162538 | LC-MI-3 | | Reference compound |
| HY-162539 | T2-BDP589 | | Dye Reagents |
| HY-162540 | LLC355 | | Reference compound |
| HY-162541 | α-Glucosidase-IN-64 | | Natural Products |
| HY-162543 | 18:1 Liss Rhod PE | 384833-00-5 | Dye Reagents |
| HY-162544 | PROTAC HPK1 Degrader-2 | 2893885-31-7 | Reference compound |
| HY-162545 | HPK1-IN-47 | 2893885-42-0 | Reference compound |
| HY-162546 | 3-Hydroxypropanoic acid-pip-hydroquinone-dihydrouracil | | Reference compound |
| HY-162547 | Oxogestone phenpropionate | 16915-80-3 | Reference compound |
| HY-162548 | Homprenorphine | 16549-56-7 | Reference compound |
| HY-162549 | CPK20 | 2397708-22-2 | Reference compound |
| HY-16255 | Imirestat | 89391-50-4 | Reference compound |
| HY-162550 | Jobosic acid | 223611-93-6 | Reference compound |
| HY-162551 | PPO-IN-13 | | Reference compound |
| HY-162552 | KOR/DOR agonist 1 | | Reference compound |
| HY-162553 | GNE7599 | 2771069-76-0 | Reference compound |
| HY-162554 | CD73-IN-15 | | Reference compound |
| HY-162555 | BMS-986308 | 2254333-97-4 | Reference compound |
| HY-162557 | VEGFR-2-IN-45 | | Reference compound |
| HY-162558 | NCGC00351170 | 886536-76-1 | Reference compound |
| HY-162559 | SDH-IN-16 | | Reference compound |
| HY-16256 | Amrinone (lactate) | 75898-90-7 | Reference compound |
| HY-162560 | Antitumor agent-162 | | Reference compound |
| HY-162561 | GB1908 | | Reference compound |
| HY-162562 | E28362 | 930017-01-9 | Reference compound |
| HY-162563 | AK59 | | Reference compound |
| HY-162564 | Antibacterial agent 221 | 3034402-33-7 | Reference compound |
| HY-162565 | CDD-2807 | | Reference compound |
| HY-162566 | REM127 | 1417823-67-6 | Reference compound |
| HY-162567 | AP-4-139B | 2716909-84-9 | Reference compound |
| HY-162568 | 7-tert-Butylfascaplysin | | Reference compound |
| HY-162569 | Ru-TRZ2 | | Reference compound |
| HY-162570 | Volazocine | 15686-68-7 | Reference compound |
| HY-162572 | Bitipazone | 13456-08-1 | Reference compound |
| HY-162573 | Monoamine Oxidase B inhibitor 5 | 2969160-15-2 | Reference compound |
| HY-162574 | CYP11B2-IN-2 | 2241573-22-6 | Reference compound |
| HY-162575 | Anticancer agent 231 | 128519-30-2 | Reference compound |
| HY-162577 | FGFR-IN-14 | | Reference compound |
| HY-162578 | PPARα/γ agonist 4 | | Reference compound |
| HY-162579 | TLR7 agonist 22 | 3036114-68-5 | Reference compound |
| HY-162580 | SphK2-IN-3 | | Reference compound |
| HY-162581 | FCPR16 | 1917347-71-7 | Reference compound |
| HY-162582 | Z19153 | 2600702-14-3 | Reference compound |
| HY-162583 | PDE4-IN-17 | | Reference compound |
| HY-162584 | TRPC4/5-IN-2 | | Reference compound |
| HY-162585 | 5-HT1AR agonist 1 | | Reference compound |
| HY-162586 | PDHK-IN-7 | 1220965-73-0 | Reference compound |
| HY-162587 | Fagopyrine | 72393-03-4 | Reference compound |
| HY-162588 | MC-ND-18 | | Reference compound |
| HY-162589 | Lw13 | | Reference compound |
| HY-16259 | Indecainide (hydrochloride) | 73681-12-6 | Reference compound |
| HY-162590 | ECIN | 66160-25-6 | Reference compound |
| HY-162591 | MR33317 | | Reference compound |
| HY-162592 | EYA2-IN-1 | | Reference compound |
| HY-162593 | Tubulin inhibitor 45 | | Reference compound |
| HY-162594 | Antitumor agent-164 | 2757188-21-7 | Reference compound |
| HY-162595 | BDM88855 | 2892824-25-6 | Reference compound |
| HY-162595A | BDM88855 (hydrochloride) | 2892824-26-7 | Reference compound |
| HY-162596 | NRL-1049 | 1973494-16-4 | Reference compound |
| HY-162597 | Dyrk1A-IN-9 | | Reference compound |
| HY-162598 | CET-1 | | Reference compound |
| HY-162599 | Spirohypertone B | | Natural Products |
| HY-162600 | CDK8-IN-15 | 2988020-03-5 | Reference compound |
| HY-162601 | D-01 | | Reference compound |
| HY-162602 | EGFR-IN-115 | | Reference compound |
| HY-162603 | HDAC-IN-74 | 1449310-17-1 | Reference compound |
| HY-162604 | SARS-CoV-2-IN-90 | | Reference compound |
| HY-162605 | CYD0682 | | Reference compound |
| HY-162606 | MAO-A/B-IN-3 | 315210-31-2 | Reference compound |
| HY-162607 | STAT3-IN-28 | | Reference compound |
| HY-162608 | PROTAC JAK1 degrader 1 | 3052553-20-2 | Reference compound |
| HY-162609 | ST-2560 | | Reference compound |
| HY-16261 | Aldoxorubicin | 1361644-26-9 | ADC Related |
| HY-162610 | Thalidomide-alkyne-C4-NHBoc | 2093387-85-8 | Reference compound |
| HY-162611 | 8-Hydroxyoctanoic acid-thalidomide | 2399454-65-8 | Reference compound |
| HY-162613 | ASM-IN-2 | 2305789-66-4 | Reference compound |
| HY-162614 | Rogersonin E | | Natural Products |
| HY-162615 | Antibacterial agent 225 | | Reference compound |
| HY-162616 | SelSA | 1225038-92-5 | Reference compound |
| HY-162617 | PSB-KK1415 | 885896-26-4 | Reference compound |
| HY-162618 | PSB-KK1445 | 885896-54-8 | Reference compound |
| HY-162619 | CDK9-IN-33 | | Reference compound |
| HY-16261A | MC-DOXHZN | 151038-96-9 | ADC Related |
| HY-16261B | MC-DOXHZN (hydrochloride) | 480998-12-7 | ADC Related |
| HY-16261C | Aldoxorubicin (hydrochloride) | 1361563-03-2 | Reference compound |
| HY-162620 | α2A-AR agonist 1 | 2971825-58-6 | Reference compound |
| HY-162621 | BET-IN-25 | | Reference compound |
| HY-162622 | BET-IN-26 | | Reference compound |
| HY-162623 | EGFR/HER2-IN-15 | | Reference compound |
| HY-162624 | Quorum sensing-IN-5 | | Reference compound |
| HY-162625 | Tubulin inhibitor 47 | | Reference compound |
| HY-162626 | FGFR2 degrader 1 | | Reference compound |
| HY-162627 | LDHA-IN-6 | 3043790-18-4 | Reference compound |
| HY-162629 | LDHA-IN-7 | 3043790-15-1 | Reference compound |
| HY-162630 | HDAC6-IN-44 | | Reference compound |
| HY-162631 | IDH1 Inhibitor 9 | 3037967-71-5 | Reference compound |
| HY-162632 | Hit 14 | 440338-68-1 | Reference compound |
| HY-162633 | USP1-IN-9 | 2925548-22-5 | Reference compound |
| HY-162634 | α-Amylase/α-Glucosidase-IN-15 | | Reference compound |
| HY-162635 | α-Amylase/α-Glucosidase-IN-14 | | Reference compound |
| HY-162636 | 5HT6-ligand-2 | | Reference compound |
| HY-162637 | CTL26 | | Reference compound |
| HY-162638 | GSK-3β inhibitor 18 | | Reference compound |
| HY-162639 | α-Glucosidase-IN-68 | 1624628-01-8 | Reference compound |
| HY-162640 | ROR1-IN-1 | 3053223-31-4 | Reference compound |
| HY-162641 | AF-45 | | Reference compound |
| HY-162642 | Bfl-1-IN-3 | | Reference compound |
| HY-162643 | Antitumor agent-169 | | Reference compound |
| HY-162644 | Antitumor agent-170 | | Reference compound |
| HY-162645 | BPR5K230 | 3029897-97-7 | Reference compound |
| HY-162646 | FXIIa-IN-5 | 3047411-80-0 | Reference compound |
| HY-162647 | PI3Kδ-IN-22 | | Reference compound |
| HY-162648 | Succinate dehydrogenase-IN-1 | 2969128-94-5 | Reference compound |
| HY-162649 | TIC10g | 754998-88-4 | Reference compound |
| HY-16265 | JI-101 | 900573-88-8 | Reference compound |
| HY-162650 | SL44 | | Reference compound |
| HY-162651 | PROTAC BRD9 Degrader-8 | | Reference compound |
| HY-162652 | HSR-IN-1 | | Reference compound |
| HY-162653 | CDKL2-IN-1 | 2471972-15-1 | Reference compound |
| HY-162654 | FXIIIa-IN-1 | 55909-92-7 | Reference compound |
| HY-162655 | SLF80821178 | 2764877-61-2 | Reference compound |
| HY-162655A | SLF80821178 (hydrochloride) | 2764877-62-3 | Reference compound |
| HY-162656 | DHFR-IN-19 | 41927-06-4 | Reference compound |
| HY-162657 | AChE-IN-74 | | Reference compound |
| HY-162658 | Leuxinostat | | Reference compound |
| HY-162659 | β2AR ligand 1 | 3051498-44-0 | Reference compound |
| HY-16266 | JNJ-DGAT1-A | 1092067-85-0 | Reference compound |
| HY-162660 | BI-9508 | | Reference compound |
| HY-162661 | P2Y14R antagonist 2 | 2989271-65-8 | Reference compound |
| HY-162662 | VU6008677 | 2170550-99-7 | Reference compound |
| HY-162663 | VU0448088 | 1417616-42-2 | Reference compound |
| HY-162664 | STING antagonist 1 | 3036981-21-9 | Reference compound |
| HY-162665 | WIZ degrader 1 | 2839552-68-8 | Reference compound |
| HY-162666 | TMEM175 modulator 1 | 3038770-25-8 | Reference compound |
| HY-162667 | EX05 | 2892307-20-7 | Reference compound |
| HY-162668 | N-Biotinyl-N'-Boc-1,4-butanediamine | 1001575-89-8 | Biochemical Assay Reagents |
| HY-162669 | Mu opioid receptor antagonist 8 | 3040171-60-3 | Reference compound |
| HY-162670 | Anticancer agent 238 | | Reference compound |
| HY-162671 | BuChE-IN-12 | 1363947-94-7 | Reference compound |
| HY-162672 | Antibacterial agent 231 | | Reference compound |
| HY-162673 | α-Amylase/α-Glucosidase-IN-16 | | Reference compound |
| HY-162674 | MERS-CoV-IN-2 | | Reference compound |
| HY-162675 | COB-187 | 1862177-86-3 | Reference compound |
| HY-162676 | SJ45566 | | Reference compound |
| HY-162677 | MT-1207 | 1610794-70-1 | Reference compound |
| HY-162678 | HDAC-IN-75 | | Reference compound |
| HY-162679 | c-Met degrader-1 | | Reference compound |
| HY-16268 | Kartogenin | 4727-31-5 | Reference compound |
| HY-162680 | OSC-GCDI(P) | | Reference compound |
| HY-162681 | eeAChE-IN-3 | | Reference compound |
| HY-162682 | 5-HT6R antagonist 4 | | Reference compound |
| HY-162683 | (S)-PHA533533 | 437982-89-3 | Reference compound |
| HY-162684 | Antitubercular agent-46 | | Reference compound |
| HY-162686 | MYC-IN-3 | 3042878-82-7 | Reference compound |
| HY-162687 | Antibacterial agent 232 | 2694805-94-0 | Reference compound |
| HY-162688 | Anticancer agent 239 | | Reference compound |
| HY-162689 | GprA | | Reference compound |
| HY-16268A | Kartogenin (sodium) | 1401168-39-5 | Reference compound |
| HY-162690 | DNA polymerase-IN-5 | | Reference compound |
| HY-162691 | DEP-5 | | Reference compound |
| HY-162692 | DNA-PK-IN-14 | 2766001-96-9 | Reference compound |
| HY-162693 | AChE-IN-68 | | Reference compound |
| HY-162694 | Ferroptosis-IN-10 | | Reference compound |
| HY-162695 | Antitumor agent-168 | | Reference compound |
| HY-162696 | mCMQ069 | 3025257-02-4 | Reference compound |
| HY-162697 | α-Glucosidase-IN-69 | | Reference compound |
| HY-162698 | JMF4073 | 1927930-61-7 | Reference compound |
| HY-162699 | LY2023-001 | 327031-30-1 | Reference compound |
| HY-162700 | MK2-IN-6 | | Reference compound |
| HY-162701 | Antiviral agent 58 | 939655-35-3 | Reference compound |
| HY-162702 | AZ'3137 | 2960179-55-7 | Reference compound |
| HY-162703 | Lipid-lowering agent-2 | | Reference compound |
| HY-162704 | JMV7048 | 2871774-88-6 | Reference compound |
| HY-162706 | BSJ-5-63 | 2519823-37-9 | Reference compound |
| HY-162707 | RA-0002323-01 | | Reference compound |
| HY-162708 | KHKI-01128 | | Reference compound |
| HY-162709 | KHKI-01215 | | Reference compound |
| HY-16271 | Kevetrin (hydrochloride) | 66592-89-0 | Reference compound |
| HY-162710 | LTA4H-IN-5 | | Reference compound |
| HY-162711 | Methylbiocin | 23370-12-9 | Reference compound |
| HY-162712 | OX-201 | 2460722-03-4 | Reference compound |
| HY-162713 | MTX-531 | 2791417-66-6 | Reference compound |
| HY-162714 | C3N-Dbn-Trp2 | 2631659-57-7 | Reference compound |
| HY-162715 | EV-A71-IN-2 | | Reference compound |
| HY-162716 | GPX4-IN-10 | | Reference compound |
| HY-162717 | GPX4-IN-11 | 951570-56-2 | Reference compound |
| HY-162718 | GPX4-IN-12 | 931704-14-2 | Reference compound |
| HY-162719 | RH12 | | Reference compound |
| HY-16271S | Kevetrin (hydrochloride)-13C2,15N3 | 2300178-72-5 | Isotope-Labeled Compounds |
| HY-162720 | NNRT-IN-4 | | Reference compound |
| HY-162721 | Anticancer agent 242 | | Reference compound |
| HY-162722 | GSK-3 inhibitor 6 | 1772823-37-6 | Reference compound |
| HY-162723 | FOSL1 degrader 1 | | Reference compound |
| HY-162725 | TLR7 agonist 24 | | Reference compound |
| HY-162726 | GCS-11 | | Reference compound |
| HY-162727 | GCS-12 | | Reference compound |
| HY-162728 | RO-76 | | Reference compound |
| HY-162729 | LSD1-IN-34 | | Reference compound |
| HY-16273 | L-778123 | 183499-57-2 | Reference compound |
| HY-162730 | OPB-171775 | 2131210-15-4 | Reference compound |
| HY-162731 | MASTL-IN-3 | 2883041-26-5 | Reference compound |
| HY-162732 | MASTL-IN-4 | 2883041-36-7 | Reference compound |
| HY-162733 | SVC-02 | 2911548-33-7 | Reference compound |
| HY-162734 | BRD5075 | | Reference compound |
| HY-162735 | BRD5080 | | Reference compound |
| HY-162736 | 1-Piperazinehexanoic acid | 17096-76-3 | Reference compound |
| HY-162737 | 1-Piperazinehexanoic acid-thalidomide | 2819682-33-0 | Reference compound |
| HY-162738 | JMV6944 | 2871774-93-3 | Reference compound |
| HY-162739 | SMARCA2-IN-1 | 2568055-21-8 | Reference compound |
| HY-16273A | L-778123 (hydrochloride) | 253863-00-2 | Reference compound |
| HY-16273B | L-778123 (dihydrochloride) | 183499-56-1 | Reference compound |
| HY-16274 | Lapaquistat acetate | 189060-13-7 | Reference compound |
| HY-162740 | SMARCA2-IN-2 | 2568055-24-1 | Reference compound |
| HY-162741 | PROTAC SMARCA2/4-degrader-33 | 2568276-36-6 | Reference compound |
| HY-162742 | PROTAC SMARCA2 degrader-16 | 2568276-37-7 | Reference compound |
| HY-162743 | PROTAC SMARCA2/4-degrader-29 | 2568273-82-3 | Reference compound |
| HY-162744 | PROTAC SMARCA2/4-degrader-31 | 2568273-83-4 | Reference compound |
| HY-162745 | SMARCA2 degrader-20 | 2568273-85-6 | Reference compound |
| HY-162746 | PROTAC SMARCA2 degrader-9 | 2568276-39-9 | Reference compound |
| HY-162747 | PROTAC SMARCA2 degrader-17 | 2568276-43-5 | Reference compound |
| HY-162748 | PROTAC SMARCA2/4-degrader-30 | 2568276-44-6 | Reference compound |
| HY-162749 | G9D-4 | | Reference compound |
| HY-162750 | ZJCK-6-46 | | Reference compound |
| HY-162751 | Anticancer agent 249 | | Reference compound |
| HY-162752 | Anticancer agent 250 | | Reference compound |
| HY-162753 | ZW-1226 | 2351940-23-1 | Reference compound |
| HY-162754 | LMP7/LMP2-IN-1 | 3053755-09-9 | Reference compound |
| HY-162755 | SHP2-IN-30 | | Reference compound |
| HY-162756 | CK1-IN-4 | | Reference compound |
| HY-162757 | Anticonvulsant agent 5 | | Reference compound |
| HY-162758 | ALR2-IN-5 | | Reference compound |
| HY-162759 | Sigma-1 receptor antagonist 6 | 1335032-28-4 | Reference compound |
| HY-16276 | Osilodrostat | 928134-65-0 | Reference compound |
| HY-162760 | COMT-IN-1 | 2987884-27-3 | Reference compound |
| HY-162761 | COX-1/2-IN-9 | | Reference compound |
| HY-162762 | PAR-2 antagonist 1 | 313957-41-4 | Reference compound |
| HY-162763 | FLQY2 | 794512-88-2 | Reference compound |
| HY-162764 | Androgen receptor degrader-5 | 2902679-11-0 | Reference compound |
| HY-162765 | TRPV4-IN-5 | 3046390-54-6 | Reference compound |
| HY-162766 | Antitumor agent-184 | 3040164-45-9 | Reference compound |
| HY-162767 | KUNG65 | 2144469-30-5 | Reference compound |
| HY-162768 | Grp94 Inhibitor-2 | | Reference compound |
| HY-162769 | HDAC3-IN-5 | | Reference compound |
| HY-16276A | Osilodrostat (phosphate) | 1315449-72-9 | Reference compound |
| HY-162770 | Antiproliferative agent-55 | | Reference compound |
| HY-162771 | Mu opioid receptor agonist 1 | | Reference compound |
| HY-162772 | IDH1/2-IN-1 | | Reference compound |
| HY-162773 | MET-IN-1 | | Reference compound |
| HY-162774A | GRP75-IN-1 (dihydrochloride) | | Reference compound |
| HY-162775 | TST1N-224 | 50566-97-7 | Reference compound |
| HY-162776 | Succinate dehydrogenase-IN-3 | | Reference compound |
| HY-162777 | SARS-CoV-2-IN-93 | | Reference compound |
| HY-162778 | FM-1088 | 2410561-64-5 | Reference compound |
| HY-162779 | CDD-3290 | | Reference compound |
| HY-16278 | Pradigastat | 956136-95-1 | Reference compound |
| HY-162780 | Mcl-1 inhibitor 19 | | Reference compound |
| HY-162781 | HDAC1/6-IN-2 | | Reference compound |
| HY-162782A | V–C6–Bg-PhCl (TFA) | | Reference compound |
| HY-162783 | AZ-PRMT5i-1 | 2918814-96-5 | Reference compound |
| HY-162784 | CYP51-IN-19 | 3006888-90-7 | Reference compound |
| HY-162785 | XC219 | | Reference compound |
| HY-162786 | Nurr1 agonist 11 | 1090335-04-8 | Reference compound |
| HY-162787 | Adenosine receptor antagonist 5 | | Reference compound |
| HY-162788 | EGFR-IN-121 | 418799-16-3 | Reference compound |
| HY-162789 | Galectin-3-IN-5 | | Reference compound |
| HY-16278A | Pradigastat (sodium) | 956136-98-4 | Reference compound |
| HY-162790 | SARS-CoV-2-IN-95 | 2817810-96-9 | Reference compound |
| HY-162791 | (1s,4s)-C1-Piperidine-C1-cyclohexane-C1 | | Reference compound |
| HY-162792 | E3 Ligase Ligand-linker Conjugate 112 | | Reference compound |
| HY-162793 | RdRP-IN-8 | | Reference compound |
| HY-162794 | YCH3124 | | Reference compound |
| HY-162795 | HBV-IN-47 | | Reference compound |
| HY-162796 | TS-2 | | Reference compound |
| HY-162797 | PDE4-IN-18 | | Reference compound |
| HY-162798 | ROCK2-IN-9 | | Reference compound |
| HY-162799 | ChoKα inhibitor-6 | | Reference compound |
| HY-162801 | Neuraminidase-IN-21 | | Reference compound |
| HY-162802 | PI3K/AKT-IN-4 | | Reference compound |
| HY-162803 | c-Met-IN-24 | | Reference compound |
| HY-162804 | ATP synthase inhibitor 3 | | Reference compound |
| HY-162805 | iNOS/TopoI-IN-1 | | Reference compound |
| HY-162807 | TMV-IN-10 | 443749-05-1 | Reference compound |
| HY-162808 | GTSE1-IN-1 | 3002034-34-3 | Reference compound |
| HY-162809 | XMU-MP-9 | 2251130-41-1 | Reference compound |
| HY-16281 | Lecimibide | 130804-35-2 | Reference compound |
| HY-162810 | ICOS-IN-1 | 1006002-58-9 | Reference compound |
| HY-162811 | LAG-3 biner 1 | 1830484-40-6 | Reference compound |
| HY-162812 | H3R antagonist 4 | | Reference compound |
| HY-162813 | PROTAC SMARCA2/4-degrader-25 | | Reference compound |
| HY-162814 | SMARCA2/4-ligand-3 | | Reference compound |
| HY-162815 | PROTAC SMARCA2/4-degrader-26 | | Reference compound |
| HY-162816 | PROTAC HPK1 Degrader-3 | | Reference compound |
| HY-162817 | N′-Nitrosonornicotine N-glucuronide | 864071-82-9 | Biochemical Assay Reagents |
| HY-162818 | Antibacterial agent 237 | | Reference compound |
| HY-162819 | Apoptosis inducer 26 | | Reference compound |
| HY-162820 | Bcl-2-IN-21 | | Reference compound |
| HY-162821 | LI-3948 | 3024591-38-3 | Reference compound |
| HY-162822 | P-gp modulator-5 | | Reference compound |
| HY-162824 | Antitumor photosensitizer-6 | 2938922-20-2 | Reference compound |
| HY-162825 | Antitumor photosensitizer-7 | | Reference compound |
| HY-162826 | Apoptosis inducer 27 | | Reference compound |
| HY-162827 | RAR/RXR agonist-1 | | Reference compound |
| HY-162828 | STAT3/HDAC-IN-2 | | Reference compound |
| HY-162829 | hURAT1 inhibitor 1 | | Reference compound |
| HY-162830 | 5-LOX/MAOs-IN-1 | 33865-93-9 | Reference compound |
| HY-162831 | MPC-IN-1 | | Reference compound |
| HY-162832 | Amyloid-β-IN-1 | | Reference compound |
| HY-162833 | Antileishmanial agent-30 | | Reference compound |
| HY-162834 | PROTAC SMARCA2/4-degrader-27 | 2375564-54-6 | Reference compound |
| HY-162835 | PROTAC SMARCA2/4-degrader-28 | 2409844-88-6 | Reference compound |
| HY-162836 | Rifamycin B | 13929-35-6 | Reference compound |
| HY-162837 | AURKA against 1 | | Reference compound |
| HY-162838 | TCF199 | | Reference compound |
| HY-162839 | Cerastecin D | 3018085-89-4 | Reference compound |
| HY-162840 | Thalidomide-azetidin-3-one | 2770869-33-3 | Reference compound |
| HY-162841 | HPK1 ligand 1 | | Reference compound |
| HY-162842 | HPK1-IN-51 | | Reference compound |
| HY-162845 | TLR7/8 agonist 11 | | Reference compound |
| HY-162846 | NLRP3-IN-44 | 3040298-34-5 | Reference compound |
| HY-162847 | S24–14 | 2348566-35-6 | Reference compound |
| HY-162848 | IHMT-PI3K-315 | | Reference compound |
| HY-162849 | PKMYT1-IN-3 | | Reference compound |
| HY-162850 | DOR agonist 2 | 1212540-02-7 | Reference compound |
| HY-162851 | Adenosine receptor agonist 1 | | Reference compound |
| HY-162852 | OAF89 | | Reference compound |
| HY-162853 | Mtb-IN-8 | 2549199-96-2 | Reference compound |
| HY-162854 | Diacylglycerol acyltransferase inhibitor-2 | 2186700-48-9 | Reference compound |
| HY-162855 | E3 ligase Ligand 33 | 3023410-43-4 | Reference compound |
| HY-162856 | TRPV1-IN-2 | | Reference compound |
| HY-162857 | Heme Oxygenase-1-IN-3 | 1043712-39-5 | Reference compound |
| HY-162858 | BRD-810 | 2329719-65-3 | Reference compound |
| HY-162859 | AB25583 | 2565637-94-5 | Reference compound |
| HY-162860 | FO-4-15 | 1030759-58-0 | Reference compound |
| HY-162861 | 3-Methyl-chuangxinmycin | | Reference compound |
| HY-162862 | JAK-IN-38 | | Reference compound |
| HY-162863 | ERK-MYD88 interaction inhibitor 1 | 2215927-89-0 | Reference compound |
| HY-162864 | JX237 | 1021125-90-5 | Reference compound |
| HY-162865 | FGFR2-IN-3 | 389629-38-3 | Reference compound |
| HY-162866 | CXM102 | | Reference compound |
| HY-162867 | Photosensitizer-5 | | Reference compound |
| HY-162868 | c-Met/HDAC-IN-4 | | Reference compound |
| HY-162872 | NBI-35965 | 268546-19-6 | Reference compound |
| HY-162873 | MEK/RAF-IN-1 | | Reference compound |
| HY-162874 | diABZI-V/C-DBCO | 3035557-60-6 | Reference compound |
| HY-162875 | PROTAC BRD4 Degrader-27 | 2407163-44-2 | Reference compound |
| HY-162876 | PROTAC BRD4 ligand-3 | 1445994-28-4 | Reference compound |
| HY-162877 | AZD4144 | 2890191-41-8 | Reference compound |
| HY-162878 | CHF-6523 | 2500579-21-3 | Reference compound |
| HY-162879 | FAK inhibitor 7 | 2890814-94-3 | Reference compound |
| HY-162880 | RIPK1-IN-24 | 1358585-26-8 | Reference compound |
| HY-162881 | DS06652923 | | Reference compound |
| HY-162882 | CC15009 | 2482713-67-5 | Reference compound |
| HY-162883 | SHMT-IN-4 | 3014814-72-0 | Reference compound |
| HY-162884 | β-Glucuronidase-IN-4 | 2208619-76-3 | Reference compound |
| HY-162885 | YSY01A | 1194235-46-5 | Reference compound |
| HY-162886 | BSO-07 | | Reference compound |
| HY-162887 | VEGFR-2-IN-53 | | Reference compound |
| HY-162888 | WQ-C-401 | 2376694-72-1 | Reference compound |
| HY-162889 | Tyrosinase-IN-36 | | Reference compound |
| HY-16289 | Lodoxamide (tromethamine) | 63610-09-3 | Reference compound |
| HY-162890 | EGFR-IN-122 | 1807453-44-6 | Reference compound |
| HY-162891 | EGFR-IN-123 | 2543763-00-2 | Reference compound |
| HY-162892 | BRD4-IN-9 | 2468959-08-0 | Reference compound |
| HY-162893 | SX29 | | Reference compound |
| HY-162894 | Tyrosinase-IN-37 | 1899025-43-4 | Reference compound |
| HY-162895 | NL13 | | Reference compound |
| HY-162896 | And1 degrader 1 | 3029132-46-2 | Reference compound |
| HY-162897 | BAY-2413555 | 2206665-50-9 | Reference compound |
| HY-162898 | Anti-virulence factor-IN-1 | 2983120-29-0 | Reference compound |
| HY-162899 | DXR-IN-3 | 1465907-72-5 | Reference compound |
| HY-16290 | Lonaprisan | 211254-73-8 | Reference compound |
| HY-162900 | HSP90-IN-32 | 2169279-38-1 | Reference compound |
| HY-162901 | NLRP3-IN-48 | | Reference compound |
| HY-162902 | ALK5-IN-82 | 3001361-04-9 | Reference compound |
| HY-162903 | LN002 | 321372-40-1 | Reference compound |
| HY-162904 | BPU17 | 2198977-68-1 | Reference compound |
| HY-162905 | Antimalarial agent 43 | | Reference compound |
| HY-162906 | FLT3/HDAC-IN-2 | | Reference compound |
| HY-162907 | HDAC-IN-78 | | Reference compound |
| HY-162908 | TRPV1/CB2 agonist 1 | | Reference compound |
| HY-162909 | Tyrosinase-IN-38 | | Reference compound |
| HY-16291 | APTO-253 | 916151-99-0 | Reference compound |
| HY-162910 | HDAC-IN-79 | | Reference compound |
| HY-162911 | Enpp-1-IN-22 | 2954111-09-0 | Reference compound |
| HY-162912 | Enpp-1-IN-23 | 2954111-03-4 | Reference compound |
| HY-162913 | GSK-3β inhibitor 20 | 3044109-48-7 | Reference compound |
| HY-162914 | SARS-CoV-2-IN-96 | | Reference compound |
| HY-162915 | AChE-IN-75 | | Reference compound |
| HY-162916 | AChE-IN-76 | | Reference compound |
| HY-162917 | CD73-IN-16 | | Reference compound |
| HY-162918 | CD73-IN-17 | | Reference compound |
| HY-162919 | YK-2168 | 2571068-74-9 | Reference compound |
| HY-16291A | APTO-253 (hydrochloride) | 1691221-67-6 | Reference compound |
| HY-162920 | QGC583 | 2417001-25-1 | Reference compound |
| HY-162921 | KAT6-IN-2 | | Reference compound |
| HY-162922 | MAP4K4-IN-6 | | Reference compound |
| HY-162923 | Antibacterial agent 244 | | Reference compound |
| HY-162924 | SARS-CoV-IN-6 | 2244671-47-2 | Reference compound |
| HY-162925 | CGRP antagonist 6 | | Reference compound |
| HY-162926 | Antituberculosis agent-12 | | Reference compound |
| HY-162927 | p53-MDM2-IN-6 | 1054506-59-0 | Reference compound |
| HY-162928 | RIPK1-IN-26 | 2252271-96-6 | Reference compound |
| HY-162929 | TP-DEA2 | | Reference compound |
| HY-16293 | Lurbinectedin | 497871-47-3 | Reference compound |
| HY-162930 | PROTAC METTL3 degrader 1 | | Reference compound |
| HY-162932 | ATG12-IN-1 | 2950162-68-0 | Reference compound |
| HY-162933 | AChE-IN-77 | | Reference compound |
| HY-162934 | TFCP2L1-IN-1 | 364621-46-5 | Reference compound |
| HY-162935 | V-ATPase-IN-1 | 1243603-61-3 | Reference compound |
| HY-162936 | SILA-123 | 2911585-37-8 | Reference compound |
| HY-162937 | KIF18A-IN-13 | 3029503-57-6 | Reference compound |
| HY-162938 | Skp2 inhibitor 3 | | Reference compound |
| HY-162939 | TB22 | | Reference compound |
| HY-16293S | Lurbinectedin-d3 | | Isotope-Labeled Compounds |
| HY-16294 | LY2090314 | 603288-22-8 | Reference compound |
| HY-162940 | MerTK/Axl-IN-1 | 3036009-40-9 | Reference compound |
| HY-162941 | SGD-9501-TFA | | ADC Related |
| HY-162942 | SLC7A11-IN-3 | | Reference compound |
| HY-162943 | P60-L3-VHL | | Reference compound |
| HY-162944 | NA-Ir | 3031762-97-4 | Reference compound |
| HY-162946 | Alkyne-P60 | | Peptides |
| HY-162947 | 2-(2-(2-(6-Azidohexanamido)ethoxy)ethoxy)acetic acid | 3036674-82-2 | Reference compound |
| HY-162948 | (S,R,S)-AHPC-PEG2-C5-N3 | | Reference compound |
| HY-162949 | Piperidin-4-amine-C5-O-C1 | 1098625-76-3 | Reference compound |
| HY-162950 | Piperidin-4-amine-C5-O-C1-Thalidomide | 3038591-71-5 | Reference compound |
| HY-162951 | P2X7 receptor antagonist-5 | 3046388-16-0 | Reference compound |
| HY-162952 | cSRC/BCR-ABL1-IN-1 | | Reference compound |
| HY-162953 | Laccase-IN-4 | | Reference compound |
| HY-162954 | PDE11A4-IN-2 | | Reference compound |
| HY-162955 | LSD1/HDAC-IN-1 | 3056145-98-0 | Reference compound |
| HY-162956 | SARS-CoV-2-IN-97 | 364338-71-6 | Reference compound |
| HY-162957 | LasR-IN-5 | | Reference compound |
| HY-162958 | Photosensitizer-6 | 3052251-17-6 | Reference compound |
| HY-162959 | BWC0977 | 2254567-00-3 | Reference compound |
| HY-162960 | pan-KRAS degrader 1 | 2937327-83-6 | Reference compound |
| HY-162961 | Xanthine oxidase-IN-16 | | Reference compound |
| HY-162962 | IDO1/TDO-IN-7 | | Reference compound |
| HY-162963 | PPARδ agonist 11 | 2982696-04-6 | Reference compound |
| HY-162964 | EGFR-IN-126 | 2890621-88-0 | Reference compound |
| HY-162965 | Immunoproteasome activator 1 | 901728-48-1 | Reference compound |
| HY-162966 | MS7829 | | Reference compound |
| HY-162967 | MS8588 | | Reference compound |
| HY-162968 | MRTF-A-IN-1 | | Reference compound |
| HY-162969 | MRTF-A-IN-2 | | Reference compound |
| HY-16297 | Abemaciclib (methanesulfonate) | 1231930-82-7 | Reference compound |
| HY-162970 | XD23 | 2806007-82-7 | Reference compound |
| HY-162971 | KRAS inhibitor-33 | | Reference compound |
| HY-162972 | PROTAC PD-L1 degrader-2 | 2995357-09-8 | Reference compound |
| HY-162973 | PD-L1 ligand 1 | | Reference compound |
| HY-162974 | KRAS inhibitor-34 | 3054800-66-4 | Reference compound |
| HY-162975 | NVP-EVS459 (175Lu) | | Reference compound |
| HY-162976 | KRAS inhibitor-35 | 3030078-96-4 | Reference compound |
| HY-162977 | Orexin receptor activator-1 | 3038645-77-8 | Reference compound |
| HY-162978 | DGAT2-IN-3 | 3037141-61-7 | Reference compound |
| HY-162979 | GLP-1R agonist 25 | | Reference compound |
| HY-16297A | Abemaciclib | 1231929-97-7 | Reference compound |
| HY-16297AR | Abemaciclib (Standard) | 1231929-97-7 | Reference Standards |
| HY-16297AS | Abemaciclib-d8 | 2088650-53-5 | Isotope-Labeled Compounds |
| HY-16297R | Abemaciclib (methanesulfonate) (Standard) | 1231930-82-7 | Reference Standards |
| HY-162980 | NLRP3-IN-52 | | Reference compound |
| HY-162981 | PLpro-IN-7 | 3046158-99-7 | Reference compound |
| HY-162982 | KHK-IN-6 | 3043939-56-3 | Reference compound |
| HY-162983 | KRAS inhibitor-36 | 332373-49-6 | Reference compound |
| HY-162984 | SARS-CoV-2-IN-99 | 2394839-81-5 | Reference compound |
| HY-162985 | JHD205 | | Reference compound |
| HY-162986 | PKMYT1-IN-4 | 3047617-07-9 | Reference compound |
| HY-162987 | PKMYT1-IN-6 | | Reference compound |
| HY-162988 | Myt1-IN-5 | | Reference compound |
| HY-162989 | PRMT5-MTA-IN-2 | | Reference compound |
| HY-162991 | TCO-PAL-PARP | | Dye Reagents |
| HY-162992 | NLRP3-IN-53 | 3044779-14-5 | Reference compound |
| HY-162993 | HN2210 | | Reference compound |
| HY-162994 | KAT6A-IN-1 | 2991087-72-8 | Reference compound |
| HY-162995 | KAT6A-IN-2 | 2991087-74-0 | Reference compound |
| HY-162996 | Spns2-IN-2 | | Reference compound |
| HY-162997 | KAT6-IN-3 | | Reference compound |
| HY-162998 | AT2R antagonist 2 | | Reference compound |
| HY-162999 | TRIP13-IN-1 | | Reference compound |
| HY-163000 | EGFR-IN-129 | | Reference compound |
| HY-163001 | Microcolin H | 2408008-21-7 | Natural Products |
| HY-163002 | viFSP1 | 951945-67-8 | Reference compound |
| HY-163003 | Antitrypanosomal agent 19 | | Reference compound |
| HY-163004 | Type II TRK inhibitor 2 | | Reference compound |
| HY-163005 | α-Glucosidase-IN-43 | 3018963-27-1 | Reference compound |
| HY-163006 | EGFR/c-Met-IN-1 | 3020728-68-8 | Reference compound |
| HY-163007 | Malonylurea-cyclopentene-butanoic acid | | Reference compound |
| HY-163008 | Dicamba-5-aminopentanoic acid | 2339488-53-6 | Reference compound |
| HY-163009 | Dicamba-butyric acid | 2892008-11-4 | Reference compound |
| HY-163010 | Dicamba-propionic acid | 2892008-18-1 | Reference compound |
| HY-163011 | Dicamba-hex-5-ynoic acid | 2892008-20-5 | Reference compound |
| HY-163012 | Dicamba-6-amino-6-oxohexanoic acid | | Reference compound |
| HY-163013 | Dicamba-5-hydroxypentanoic acid | 2892008-29-4 | Reference compound |
| HY-163014 | Dicamba 1-azidopropane | 2892008-32-9 | Reference compound |
| HY-163015 | RNA polymerase-IN-1 | 2447106-74-1 | Reference compound |
| HY-163016 | RNA polymerase-IN-2 | 2447106-79-6 | Reference compound |
| HY-163017 | NP-5497-KA | | Reference compound |
| HY-163018 | Kv3.1 modulator 2 | | Reference compound |
| HY-163019 | EN884 | 2189497-60-5 | Reference compound |
| HY-163020 | Ametryn-acetic acid | 2222775-68-8 | Reference compound |
| HY-163021 | Simeton-acetic acid | 2222775-69-9 | Reference compound |
| HY-163022 | Simazine-acetic acid | 125454-26-4 | Reference compound |
| HY-163023 | Atrazine-acetic acid | 193889-80-4 | Reference compound |
| HY-163024 | Atrazine-3-mercaptopropanoic acid | 125454-31-1 | Reference compound |
| HY-163025 | Cyanazine-3-mercaptopropanoic acid | | Reference compound |
| HY-163026 | Cyromazine-3-mercaptopropanoic acid | 2365353-26-8 | Reference compound |
| HY-163027 | R079 | 2115659-62-4 | Reference compound |
| HY-163028 | ML-T7 | 459789-75-4 | Reference compound |
| HY-163029 | CTSL/B-IN-1 | | Reference compound |
| HY-163030 | LasB-IN-1 | | Reference compound |
| HY-163031 | MAO-B-IN-28 | 3028096-72-9 | Reference compound |
| HY-163032 | FABP4-IN-3 | | Reference compound |
| HY-163033 | Antitubercular agent-42 | | Reference compound |
| HY-163034 | Antitumor photosensitizer-5 | | Reference compound |
| HY-163035 | EM-163 | 1206480-93-4 | Reference compound |
| HY-163036 | Glucosamine–biotin adduct | 1825360-98-2 | Reference compound |
| HY-163037 | Pseudo-β-D-mannopyranose | 90694-07-8 | Reference compound |
| HY-163038 | Sulfamethoxazole-NO (hydrate) | | Reference compound |
| HY-163039 | DOTA-biotin | 188428-79-7 | Reference compound |
| HY-16304 | Mannose 1-phosphate | 27251-84-9 | Natural Products |
| HY-163040 | DOTA-Tyr-Lys-DOTA | 2757339-62-9 | Reference compound |
| HY-163041 | PD-1/PD-L1-IN-36 | 2714327-65-6 | Reference compound |
| HY-163042 | HSGN-218 | 2519410-44-5 | Reference compound |
| HY-163044 | C12-SPM | 2055647-81-7 | Biochemical Assay Reagents |
| HY-163045 | 4-Azidophenylarsonic acid | 861605-27-8 | Reference compound |
| HY-16304A | Mannose 1-phosphate (sodium) | | Natural Products |
| HY-16305 | Maribavir | 176161-24-3 | Reference compound |
| HY-163052 | Ciproquazone | 33453-23-5 | Reference compound |
| HY-163057 | 2,2',2''-Nitrilotris(NH-EG8-Lys-2,4-dinitroaniline) | 929540-19-2 | Reference compound |
| HY-16305R | Maribavir (Standard) | 176161-24-3 | Reference Standards |
| HY-16305S | Maribavir-d6 | | Isotope-Labeled Compounds |
| HY-16305S1 | Maribavir-d6 (TFA) | | Isotope-Labeled Compounds |
| HY-163062 | Tubulin/NRP1-IN-1 | 2983719-82-8 | Reference compound |
| HY-163063 | Antimalarial agent 34 | | Reference compound |
| HY-163064 | CC-3240 | 2922675-91-8 | Reference compound |
| HY-163065 | σ1 Receptor/μ Opioid receptor modulator 2 | 3009018-61-2 | Reference compound |
| HY-163066 | α-Glucosidase-IN-44 | | Reference compound |
| HY-163067 | SARS-CoV-2-IN-71 | | Reference compound |
| HY-163068 | FLT3-IN-24 | | Reference compound |
| HY-163069 | Antitubercular agent-43 | | Reference compound |
| HY-16307 | MB05032 | 261365-11-1 | Reference compound |
| HY-163070 | Antimalarial agent 35 | | Reference compound |
| HY-163071 | V023-9340 | 1048304-96-6 | Reference compound |
| HY-163072 | FXR antagonist 3 | 3024652-96-5 | Reference compound |
| HY-163073 | Anti-MRSA agent 9 | | Reference compound |
| HY-163074 | Ferroptosis-IN-6 | 1517780-59-4 | Reference compound |
| HY-163075 | SYB4 | 2101953-60-8 | Reference compound |
| HY-163076 | Anticancer agent 174 | 2987820-29-9 | Reference compound |
| HY-163077 | Anticancer agent 175 | | Reference compound |
| HY-163078 | C2-Gal-Dox | | Reference compound |
| HY-163079 | AlF-PD-FAPI | | Reference compound |
| HY-16308 | FBPase-IN-5 | 882755-95-5 | Reference compound |
| HY-163080S | Selenium-77 | 14681-72-2 | Isotope-Labeled Compounds |
| HY-163081 | PARP7-IN-17 | 3024030-10-9 | Reference compound |
| HY-163082 | GB1490 | 2172866-22-5 | Reference compound |
| HY-163083 | JN122 | | Reference compound |
| HY-163084 | HJ445A | 3032441-59-8 | Reference compound |
| HY-163085 | HIV capsid modulator 1 | 3031547-95-9 | Reference compound |
| HY-163087 | PT-91 | 3037561-48-8 | Reference compound |
| HY-163088 | CHIKV-IN-4 | 1269363-88-3 | Reference compound |
| HY-163089 | Anticancer agent 176 | | Reference compound |
| HY-16309 | MB-07803 | 882757-24-6 | Reference compound |
| HY-163090 | HR488B | | Reference compound |
| HY-163091 | EP4 receptor antagonist 5 | | Reference compound |
| HY-163093 | ATX inhibitor 24 | | Reference compound |
| HY-163094 | EGFR-IN-95 | 3027135-04-9 | Reference compound |
| HY-163095 | RH1115 | | Reference compound |
| HY-163096 | GPR88 agonist 3 | 2963597-44-4 | Reference compound |
| HY-163097 | ZCAN262 | | Reference compound |
| HY-163098 | JJ-OX-007 | | Dye Reagents |
| HY-163099 | P5(PEG24)-VC-PAB-Exatecan | 2928571-43-9 | Reference compound |
| HY-163101 | CP-96021 | 139401-43-7 | Reference compound |
| HY-163102 | IA-14069 | 2271216-04-5 | Reference compound |
| HY-163103 | (S)-Isomyosmine | 67209-94-3 | Reference compound |
| HY-163104 | Antibacterial agent 169 | 2879255-03-3 | Reference compound |
| HY-163105 | Tubulin/NEDDylation-IN-1 | | Reference compound |
| HY-163106 | W000113414_I13 | 853598-55-7 | Reference compound |
| HY-163107 | Antimycobacterial agent-7 | | Reference compound |
| HY-163108 | ATAD2-IN-1 | 3004556-06-0 | Reference compound |
| HY-163109 | Carbonic anhydrase inhibitor 16 | 4479-70-3 | Reference compound |
| HY-16311 | MB-7133 | 685111-92-6 | Reference compound |
| HY-163110 | NNRT-IN-2 | 2999794-78-2 | Reference compound |
| HY-163111 | Antibacterial agent 170 | 2764797-36-4 | Reference compound |
| HY-163112 | Anticancer agent 179 | | Reference compound |
| HY-163113 | Anticancer agent 180 | | Natural Products |
| HY-163114 | 2-Stearoxyphenethyl phosphocholin | 2170888-39-6 | Reference compound |
| HY-163115 | 2-Oleoxyphenethyl phosphocholin | 2170888-41-0 | Reference compound |
| HY-163116 | Anti-inflammatory agent 67 | | Reference compound |
| HY-163117 | Anti-inflammatory agent 68 | | Reference compound |
| HY-163118 | Topoisomerase II inhibitor 17 | | Reference compound |
| HY-163119 | Pim-1 kinase inhibitor 9 | | Reference compound |
| HY-16312 | MDL-29951 | 130798-51-5 | Reference compound |
| HY-163120 | Myosin-IN-1 | 849011-39-8 | Reference compound |
| HY-163121 | PST3.1a | 1096144-06-7 | Reference compound |
| HY-163122 | 5-Formylsalicylic acid | 616-76-2 | Reference compound |
| HY-163124 | HBV-IN-43 | 2305897-05-4 | Reference compound |
| HY-163125 | BHEPN | | Reference compound |
| HY-163126 | AChE-IN-52 | 2214210-63-4 | Reference compound |
| HY-163127 | AUTAC2-2G | | Reference compound |
| HY-163128 | SPL-IN-1 | 353770-24-8 | Reference compound |
| HY-163129 | BPU | | Reference compound |
| HY-163131 | Glucosylceramide synthase-IN-4 | 2776965-41-2 | Reference compound |
| HY-163132 | DDABT1 | 2777045-35-7 | Reference compound |
| HY-163133 | PIKfyve-IN-3 | | Reference compound |
| HY-163134 | DNA-PK-IN-12 | 2792146-91-7 | Reference compound |
| HY-163136 | Autophagy/REV-ERB-IN-1 | | Reference compound |
| HY-163136A | Autophagy/REV-ERB-IN-1 (hydrochloride) | | Reference compound |
| HY-163137 | Telomerase-IN-6 | | Reference compound |
| HY-163138 | DAT-IN-1 | | Reference compound |
| HY-163139 | Physagulide Y | | Natural Products |
| HY-163140 | IL-33 probe-1 | | Reference compound |
| HY-163141 | PCSK9-IN-24 | 2974496-96-1 | Reference compound |
| HY-163142 | Antibacterial agent 172 | 3023114-93-1 | Reference compound |
| HY-163143 | HDAC8-IN-6 | | Reference compound |
| HY-163144 | DAS-5-oCRBN | | Reference compound |
| HY-163145 | α-Synuclein inhibitor 11 | | Reference compound |
| HY-163146 | TME-HYM (PH Probe) | | Dye Reagents |
| HY-163147 | PAN endonuclease-IN-1 | 2378640-67-4 | Reference compound |
| HY-163148 | PHD-IN-3 | 2924181-77-9 | Reference compound |
| HY-163149 | AB-452 | 2226178-35-2 | Reference compound |
| HY-163150 | 5-HT6R antagonist 3 | | Reference compound |
| HY-163151 | JE-133 | 2579171-69-8 | Reference compound |
| HY-163152 | PROTAC BRM degrader-1 | 2378051-80-8 | Reference compound |
| HY-163153 | Anticancer agent 184 | | Reference compound |
| HY-163154 | JJC8-091 | 1627576-76-4 | Reference compound |
| HY-163155 | RDS03-94 | 2324108-96-3 | Reference compound |
| HY-163156 | JJC12-009 | | Reference compound |
| HY-163157 | Insecticidal agent 7 | 2951079-77-7 | Reference compound |
| HY-163158 | DHODH-IN-24 | 418775-30-1 | Reference compound |
| HY-163159 | NP3-562 | 2409825-32-5 | Reference compound |
| HY-16316 | Metipranolol hydrochloride | 36592-77-5 | Reference compound |
| HY-163160 | BET-IN-23 | 2953287-57-3 | Reference compound |
| HY-163161 | HIV-1 inhibitor-62 | | Reference compound |
| HY-163162 | Anhydro-Ouabain | 3029806-33-2 | Reference compound |
| HY-163163S | 18:1-21:2-18:1 TG-d5 | 2342574-90-5 | Isotope-Labeled Compounds |
| HY-163164S | 18:1-17:1-18:1 TG-d5 | 2342574-91-6 | Isotope-Labeled Compounds |
| HY-163165S | 16:0-19:2-16:0 TG-d5 | 2342574-87-0 | Isotope-Labeled Compounds |
| HY-163166S | 18:1-19:2-18:1 TG-d5 | 2342574-89-2 | Isotope-Labeled Compounds |
| HY-163167 | VH 032 amide-alkylC5-azide | 2821804-11-7 | Reference compound |
| HY-163168 | aTAG 4531 | 2412985-00-1 | Reference compound |
| HY-163169 | Phenyl-glutarimide 4'-oxyacetic acid | 2782024-58-0 | Reference compound |
| HY-163170 | FMF-04-159-R | 2741262-15-5 | Reference compound |
| HY-163171 | ARN11391 | 1214569-31-9 | Reference compound |
| HY-163172 | Miro1 Reducer | 2624336-91-8 | Reference compound |
| HY-163173 | TEAD-IN-8 | 1008768-41-9 | Reference compound |
| HY-163174 | II399 | 2928480-72-0 | Reference compound |
| HY-163175 | BChE-IN-24 | | Reference compound |
| HY-163176 | WB518 | | Reference compound |
| HY-163177 | HIV-1 inhibitor-63 | | Reference compound |
| HY-163179 | NLRP3-IN-28 | 2922814-80-8 | Reference compound |
| HY-163180 | AKT-IN-22 | 1313880-28-2 | Reference compound |
| HY-163181 | MSU-43085 | 2810846-51-4 | Reference compound |
| HY-163182 | CSNK2A-IN-2 | | Reference compound |
| HY-163183 | JAK3/BTK-IN-7 | 2844387-16-0 | Reference compound |
| HY-163184 | DCLK1-IN-3 | | Reference compound |
| HY-163185 | DCLK1-IN-4 | | Reference compound |
| HY-163186 | SARS-CoV-2 Mpro-IN-13 | | Reference compound |
| HY-163187 | COX-2/LOX-IN-1 | | Reference compound |
| HY-163188 | COX-2/LOX-IN-2 | | Reference compound |
| HY-163189 | c-ABL-IN-6 | | Reference compound |
| HY-163190 | NDM-1 inhibitor-4 | 604811-49-6 | Reference compound |
| HY-163191 | NDM-1 inhibitor-5 | 1613045-02-5 | Reference compound |
| HY-163192 | W6134 | 2983540-55-0 | Reference compound |
| HY-163193 | MJO445 | 1968-56-5 | Reference compound |
| HY-163194 | Cbl-b-IN-16 | | Reference compound |
| HY-163195 | Tubulin inhibitor 40 | | Reference compound |
| HY-163196 | PSMA-IN-4 | 1561171-59-2 | Reference compound |
| HY-163197 | JSF-2827 | | Reference compound |
| HY-163198 | ASCT2-IN-1 | 3032651-18-3 | Reference compound |
| HY-163199 | ASCT2-IN-2 | | Reference compound |
| HY-163200 | Cu(I) chelator 1 | | Reference compound |
| HY-163201 | TMV-IN-7 | | Reference compound |
| HY-163202 | MAGL-IN-13 | | Reference compound |
| HY-163203 | DDC18-8A | | Reference compound |
| HY-163204 | RhQ-DMB | | Reference compound |
| HY-163205 | VU6067416 | 3027515-24-5 | Reference compound |
| HY-163206 | SARS-CoV-2-IN-77 | | Reference compound |
| HY-163207 | sEH/HDAC6-IN-1 | 2847838-67-7 | Reference compound |
| HY-163208 | VH 032 amide-alkylC9-amine (hydrochloride) | 2758364-04-2 | Reference compound |
| HY-163209 | VH 032 amide-PEG6-amine (hydrochloride) | 2763910-08-1 | Reference compound |
| HY-16321 | Micafungin (sodium) | 208538-73-2 | Reference compound |
| HY-163210 | Pomalidomide 5'-fluoro-6'-piperazine-4-methylpiperidine (hydrochloride) | 2758431-94-4 | Reference compound |
| HY-163211 | SARS-CoV-2 Mpro-IN-14 | 2679814-93-6 | Reference compound |
| HY-163212 | PreQ1-alkyne | 2771096-76-3 | Reference compound |
| HY-163213 | Psoralen-triethylene glycol azide | 1352815-11-2 | Reference compound |
| HY-163214 | (S)-PROTAC PTK6 ligand-1-(2S,4R)-O-CH2-O-hygric acid | | Reference compound |
| HY-163215 | (S)-PROTAC PTK6 ligand-O-4,4-dimethylpiperidine-Boc | | Reference compound |
| HY-163216 | PROTAC PTK6 ligand-O-4,4-dimethylpiperidine-Boc | | Reference compound |
| HY-163217 | PROTAC PTK6 ligand-2,7-diazaspiro[3.5]nonane-Boc | | Reference compound |
| HY-163218 | PROTAC PTK6 ligand-1-(2S,4R)-O-CH2-O-hygric acid | | Reference compound |
| HY-163219 | VHL Ligand 8-PEG2-O-piperidine-Boc | | Reference compound |
| HY-16321R | Micafungin (sodium) (Standard) | 208538-73-2 | Reference Standards |
| HY-16322 | Minodronic acid | 180064-38-4 | Reference compound |
| HY-163220 | (S,R,S)-AHPC-CO-CH2-O-CH2-piperidine-Boc | | Reference compound |
| HY-163221 | (S)-Thalidomide-piperazine-(1S,4r)-cyclohexane-N(Me)-Boc | | Reference compound |
| HY-163222 | 4-Methylanisole-dihydrouracil-imidazo[1,2-a]pyridine-piperidine-NH-Boc | | Reference compound |
| HY-163223 | (S,R,S)-AHPC-CO-CH2-piperazine-C3-piperazine-Boc | | Reference compound |
| HY-163224 | (S)-PROTAC PTK6 ligand-O-C2-O-piperidine-Boc | | Reference compound |
| HY-163225 | (S)-Thalidomide-piperazine-(1S,4r)-cyclohexane-NH-Boc | | Reference compound |
| HY-163226 | (1R,5S)-Thalidomide-3,8-diazabicyclo[3.2.1]octane-(1R,4r)-cyclohexane-NH-Boc | | Reference compound |
| HY-163227 | (1R,4R)-Thalidomide-2,5-diazabicyclo[2.2.1]heptane-(1R,4r)-cyclohexane-NH-Boc | | Reference compound |
| HY-163228 | PROTAC PTK6 ligand-O-C2-O-piperidine-Boc | | Reference compound |
| HY-163229 | (1r,4r)-Thalidomide-piperidine-N(Me)-CH-cyclohexane-NH-Boc | | Reference compound |
| HY-16322A | Minodronic acid (hydrate) | 155648-60-5 | Reference compound |
| HY-16322S | Minodronic acid-d4 | 1807367-80-1 | Isotope-Labeled Compounds |
| HY-163230 | (1R,5S)-Thalidomide-3,8-diazabicyclo[3.2.1]octane-Boc | | Reference compound |
| HY-163231 | (S,R,S)-AHPC-CO-CH2-azetidine-piperazine-CH2-COOH | | Reference compound |
| HY-163232 | Phthalimidinoglutarimide-piperidine-NH-Boc | 2229720-55-0 | Reference compound |
| HY-163233 | Phthalimidinoglutarimide-5-piperazine | | Reference compound |
| HY-163234 | Phthalimidinoglutarimide-piperidine-NH2 | 2591197-83-8 | Reference compound |
| HY-163235 | Phenyl phenylcarbamate-CH-5-methoxypicolinamide-CH-CH-Ph-CF3 | | Reference compound |
| HY-163236 | Thalidomide-piperidine-O-azetidine-acetic acid | | Reference compound |
| HY-163237 | Thalidomide-piperidine-O-azetidineethanol | | Reference compound |
| HY-163238 | Thalidomide-azetidine-CH-piperazineethanol | | Reference compound |
| HY-163239 | (R)-Thalidomide-piperazine-pyrrolidineethanol | | Reference compound |
| HY-163240 | HSD17B13-IN-24 | 2770246-37-0 | Reference compound |
| HY-163241 | HSD17B13-IN-25 | 2770246-39-2 | Reference compound |
| HY-163242 | HSD17B13-IN-28 | 2770246-42-7 | Reference compound |
| HY-163243 | HSD17B13-IN-29 | 2770246-48-3 | Reference compound |
| HY-163244 | HSD17B13-IN-30 | 2770246-58-5 | Reference compound |
| HY-163245 | HSD17B13-IN-32 | 2770246-61-0 | Reference compound |
| HY-163246 | HSD17B13-IN-34 | 2770246-68-7 | Reference compound |
| HY-163247 | HSD17B13-IN-35 | 2770246-69-8 | Reference compound |
| HY-163248 | HSD17B13-IN-37 | 2770246-71-2 | Reference compound |
| HY-163249 | HSD17B13-IN-49 | 2770246-74-5 | Reference compound |
| HY-16325 | Miriplatin (hydrate) | 250159-48-9 | Reference compound |
| HY-163250 | HSD17B13-IN-51 | 2770246-75-6 | Reference compound |
| HY-163251 | HSD17B13-IN-52 | 2770246-77-8 | Reference compound |
| HY-163252 | HSD17B13-IN-53 | 2770246-81-4 | Reference compound |
| HY-163253 | HSD17B13-IN-56 | 2770246-82-5 | Reference compound |
| HY-163253S | HSD17B13-IN-56-d3 | 2770247-60-2 | Isotope-Labeled Compounds |
| HY-163254 | HSD17B13-IN-57 | 2770246-86-9 | Reference compound |
| HY-163255 | HSD17B13-IN-58 | 2770246-89-2 | Reference compound |
| HY-163256 | HSD17B13-IN-59 | 2770247-11-3 | Reference compound |
| HY-163257 | HSD17B13-IN-60 | 2770247-20-4 | Reference compound |
| HY-163258 | HSD17B13-IN-61 | 2770247-26-0 | Reference compound |
| HY-163259 | HSD17B13-IN-62 | 2770247-32-8 | Reference compound |
| HY-163259S | HSD17B13-IN-62-d3 | 2770247-67-9 | Isotope-Labeled Compounds |
| HY-16325A | Miriplatin | 141977-79-9 | Reference compound |
| HY-163260 | HSD17B13-IN-64 | 2770247-34-0 | Reference compound |
| HY-163261 | HSD17B13-IN-66 | 2770247-37-3 | Reference compound |
| HY-163262 | HSD17B13-IN-71 | 2770247-40-8 | Reference compound |
| HY-163263 | HSD17B13-IN-80 | 2770247-42-0 | Reference compound |
| HY-163263S | HSD17B13-IN-80-d3 | 2770247-70-4 | Isotope-Labeled Compounds |
| HY-163263S1 | HSD17B13-IN-80-d2 | 2770247-90-8 | Isotope-Labeled Compounds |
| HY-163264 | HSD17B13-IN-81 | 2770247-45-3 | Reference compound |
| HY-163265 | HSD17B13-IN-82 | 2770247-47-5 | Reference compound |
| HY-163266 | HSD17B13-IN-83 | 2770247-41-9 | Reference compound |
| HY-163267 | ZNL0325 | | Reference compound |
| HY-163268 | Carbonic anhydrase inhibitor 18 | | Reference compound |
| HY-163269 | MPT | 2413282-48-9 | Reference compound |
| HY-163270 | PM534 | 2446376-25-4 | Reference compound |
| HY-163271 | XL-126 | 3033576-12-1 | Reference compound |
| HY-163272 | GPX4/CDK-IN-1 | | Reference compound |
| HY-163273 | FGFR4-IN-17 | 3011805-61-8 | Reference compound |
| HY-163274 | NOD1 antagonist-1 | | Reference compound |
| HY-163275 | MDM2-IN-24 | | Reference compound |
| HY-163276 | OX2R-IN-2 | | Reference compound |
| HY-163277 | PIPE-3297 | | Reference compound |
| HY-163278 | Lck-IN-2 | 2615173-24-3 | Reference compound |
| HY-163279 | Fluopipamine | 885902-66-9 | Reference compound |
| HY-163280 | JGB-1-155 | 3011930-28-9 | Reference compound |
| HY-163281 | FSY-OSO2F | 1839622-49-9 | Dye Reagents |
| HY-163282 | NB512 | | Reference compound |
| HY-163283 | 6′-Methyl paeonol | 6540-66-5 | Reference compound |
| HY-163284 | SDH-IN-12 | 3027210-28-9 | Reference compound |
| HY-163285 | PDE3B-IN-1 | 3032458-01-5 | Reference compound |
| HY-163286 | BODIQPy-TPA | 2738333-02-1 | Dye Reagents |
| HY-163287 | QPy-TPA | 2738332-94-8 | Dye Reagents |
| HY-163288 | EZH2/HSP90-IN-29 | | Reference compound |
| HY-163290 | HDAC-MB | | Dye Reagents |
| HY-163291 | AM4085 | | Reference compound |
| HY-163292 | Antibacterial agent 180 | | Reference compound |
| HY-163293 | Mcl-1 inhibitor 18 | | Reference compound |
| HY-163294 | PPARγ agonist 10 | 2445990-92-9 | Reference compound |
| HY-163295 | BTK degrader-1 | 2377645-56-0 | Reference compound |
| HY-163297 | Antifungal agent 90 | 3023095-87-3 | Reference compound |
| HY-163298 | Herbicidal agent 2 | 3024668-43-4 | Reference compound |
| HY-163299 | pan-KRAS-IN-5 | 3027172-23-9 | Reference compound |
| HY-163300 | NLRP3-IN-30 | | Reference compound |
| HY-163301 | Antitumor agent-139 | | Reference compound |
| HY-163303 | Tyk2-IN-15 | 3010873-44-3 | Reference compound |
| HY-163304 | Tyk2-IN-16 | 3010874-30-0 | Reference compound |
| HY-163305 | Tyk2-IN-17 | 3010874-31-1 | Reference compound |
| HY-163307 | PD-1/PD-L1-IN-39 | | Reference compound |
| HY-163308 | Bcl-2-IN-18 | | Reference compound |
| HY-163309 | Bcl-2-IN-19 | | Reference compound |
| HY-163310 | Transketolase-IN-5 | | Reference compound |
| HY-163311 | Transketolase-IN-6 | | Reference compound |
| HY-163312S | Tyk2-IN-18-d5 | 3018160-63-6 | Isotope-Labeled Compounds |
| HY-163313S | Tyk2-IN-19-d6 | 3018160-65-8 | Isotope-Labeled Compounds |
| HY-163314S | Tyk2-IN-18-d3 | 3018160-68-1 | Isotope-Labeled Compounds |
| HY-163315 | YPLP | 2414391-44-7 | Reference compound |
| HY-163316 | SIRT4-IN-1 | | Reference compound |
| HY-163317 | MMC(TMZ)-TOC | | Peptides |
| HY-163317A | MMC(TMZ)-TOC (TFA) | | Reference compound |
| HY-163318 | NS2B/NS3-IN-8 | 1021221-94-2 | Reference compound |
| HY-163319 | NCA029 | | Reference compound |
| HY-163320 | AChE/Aβ-IN-5 | 181114-32-9 | Reference compound |
| HY-163321 | DapE-IN-1 | | Reference compound |
| HY-163322 | MAO-A inhibitor 2 | | Reference compound |
| HY-163323 | AKR1C3-IN-12 | 891075-67-5 | Reference compound |
| HY-163324 | 2-Me PeER (chloride) | | Dye Reagents |
| HY-163324A | 2-Me PeER | | Reference compound |
| HY-163325 | Fli-1-IN-1 (fumarate) | | Reference compound |
| HY-163325A | Fli-1-IN-1 | 3027140-81-1 | Reference compound |
| HY-163326 | Tyrosinase-IN-25 | | Reference compound |
| HY-163327 | pFBC | | Reference compound |
| HY-163328 | DHODH-IN-25 | 2619531-95-0 | Reference compound |
| HY-163329 | BCH-HSP-C01 | | Reference compound |
| HY-163330 | 8-Azakinetin riboside | 2347524-00-7 | Reference compound |
| HY-163331 | Cresomycin | 2999743-51-8 | Reference compound |
| HY-163332 | MPO-IN-6 | | Reference compound |
| HY-163334 | GGDPS-IN-1 | | Reference compound |
| HY-163335 | MPO-IN-7 | | Reference compound |
| HY-163336 | 14,15-Leukotriene A4 methyl ester | 75290-58-3 | Reference compound |
| HY-163337 | Antifungal agent 92 | 3020687-94-6 | Reference compound |
| HY-163338 | Metallo-β-lactamase-IN-13 | 1802366-23-9 | Reference compound |
| HY-163339 | Metallo-β-lactamase-IN-14 | 1802367-43-6 | Reference compound |
| HY-163340 | GA32 | 1386811-71-7 | Reference compound |
| HY-163341 | PAR4 antagonist 1 | 2173201-65-3 | Reference compound |
| HY-163342 | Antibacterial agent 190 | | Reference compound |
| HY-163343 | Enpp-1-IN-20 | | Reference compound |
| HY-163345 | 5-HT7R antagonist 2 | 1448808-50-1 | Reference compound |
| HY-163346 | TPEG-P | | Reference compound |
| HY-163347 | FXIIa-IN-3 | | Reference compound |
| HY-163348 | FXIIa-IN-4 | | Reference compound |
| HY-163349 | TUG-2099 | | Reference compound |
| HY-163350 | TUG-2208 | | Reference compound |
| HY-163351 | PDI-IN-2 | | Reference compound |
| HY-163352 | Chitinase-IN-6 | | Reference compound |
| HY-163353 | Antibacterial agent 193 | | Reference compound |
| HY-163354 | EGFR-IN-103 | 2568506-66-9 | Reference compound |
| HY-163355 | COX-2/15-LOX-IN-5 | 443790-30-5 | Reference compound |
| HY-163356 | Tubulin polymerization-IN-60 | 2361303-91-3 | Reference compound |
| HY-163357 | CDK2/MDM2-IN-1 | | Reference compound |
| HY-163358 | SLC3037 | | Reference compound |
| HY-163359 | CYP17A1/HDAC6-IN-1 | 3047489-22-2 | Reference compound |
| HY-16336 | Motexafin gadolinium | 246252-06-2 | Reference compound |
| HY-163360 | PI3Kα-IN-19 | 885692-56-8 | Reference compound |
| HY-163361 | PI3Kα-IN-20 | 228999-57-3 | Reference compound |
| HY-163362 | HIV-1 inhibitor-65 | | Reference compound |
| HY-163363 | β-AR antagonist 2 | 2779507-62-7 | Reference compound |
| HY-163364 | DS-22-inf-021 | 945170-74-1 | Reference compound |
| HY-163365 | UTX-143 | | Reference compound |
| HY-163366 | TRK-IN-28 | 2991504-43-7 | Reference compound |
| HY-163367 | MATE-IN-1 | | Reference compound |
| HY-163368 | HDAC6-IN-34 | 1432508-73-0 | Reference compound |
| HY-163369 | HDAC6-IN-35 | 1394615-06-5 | Reference compound |
| HY-163370 | HIF-1α-IN-7 | 3026685-76-4 | Reference compound |
| HY-163371 | EGFR WT/T790M-IN-1 | | Reference compound |
| HY-163372 | PROTAC HPK1 Degrader-1 | 3034182-97-0 | Reference compound |
| HY-163373 | 13,14-Dihydro-15-keto prostaglandin D1 | 1392219-79-2 | Reference compound |
| HY-163374 | Cdc7-IN-20 | | Reference compound |
| HY-163375 | Methyl cis-12-octadecenoate | 2733-86-0 | Reference compound |
| HY-163376 | 17-Trifluoromethylphenyl trinor prostaglandin F2α ethyl amide | 1621369-73-0 | Reference compound |
| HY-163377 | AZ5385 | 848439-89-4 | Reference compound |
| HY-163378 | C5aR1 antagonist 1 | 2365325-67-1 | Reference compound |
| HY-163379 | C5aR1 antagonist 2 | 2365161-92-6 | Reference compound |
| HY-163380 | CA/MAO-B-IN-1 | | Reference compound |
| HY-163381 | Antiproliferative agent-48 | 1621594-62-4 | Reference compound |
| HY-163382 | Cbz-Gly-Pro-Ala-O-cinnamyl | | Reference compound |
| HY-163383 | L-Ent-oxPt(IV) | | Reference compound |
| HY-163384 | (S)-CE-123 | 2378384-49-5 | Reference compound |
| HY-163385 | ALKBH1-IN-1 | | Reference compound |
| HY-163386 | HFTC-HClO 1 | | Reference compound |
| HY-163387 | CHI3L1-IN-1 | 2982256-78-8 | Reference compound |
| HY-163388 | CHI3L1-IN-2 | 2982257-63-4 | Reference compound |
| HY-163389 | Mpro/Cathepsin L-IN-1 | | Reference compound |
| HY-16339 | N3PT | 13860-66-7 | Reference compound |
| HY-163390 | RIP1 kinase inhibitor 9 | | Reference compound |
| HY-163392 | Neuraminidase-IN-17 | 2935407-34-2 | Reference compound |
| HY-163393 | Neuraminidase-IN-18 | 2935407-32-0 | Reference compound |
| HY-163394 | CB2 receptor agonist 6 | | Reference compound |
| HY-163395 | 3-Tosylimidazolidine-2,4-dione | | Reference compound |
| HY-163396 | EGFR-IN-107 | | Reference compound |
| HY-163397 | Antibacterial agent 196 | | Reference compound |
| HY-163398 | TLR7-IN-1 | 3026308-79-9 | Reference compound |
| HY-163399 | Antibacterial agent 197 | 54387-80-3 | Reference compound |
| HY-163401 | Epoxykynin | 640263-95-2 | Reference compound |
| HY-163402 | "EGFR-IN-108 (chloride
)" | | Reference compound |
| HY-163403 | VEGFR-2-IN-43 | | Reference compound |
| HY-163404 | Urease-IN-13 | | Reference compound |
| HY-163405 | Galectin-3-IN-3 | 2491661-50-6 | Reference compound |
| HY-163406 | PDE1-IN-6 | 2877017-16-6 | Reference compound |
| HY-163407 | Galectin-3-IN-4 | 2496515-38-7 | Reference compound |
| HY-163408 | ALP-IN-1 | | Reference compound |
| HY-163409 | CGK012 | 2044497-76-7 | Reference compound |
| HY-163410 | AU-24118 | | Reference compound |
| HY-163411 | Neutrophil elastase inhibitor 6 | | Reference compound |
| HY-163412 | IKKβ-IN-3 | | Reference compound |
| HY-163413 | BRD4-BD1-IN-3 | | Reference compound |
| HY-163414 | hCAIX/XII-IN-11 | | Reference compound |
| HY-163415 | MAO-IN-5 | 906728-07-2 | Reference compound |
| HY-163417 | HER2-IN-15 | | Reference compound |
| HY-163418 | HER2-IN-17 | | Reference compound |
| HY-163419 | HER2-IN-18 | | Reference compound |
| HY-163420 | HER2-IN-16 | | Reference compound |
| HY-163421 | hERG-IN-2 | 2414055-95-9 | Reference compound |
| HY-163422S | PHSHPALTPEQK-(Lys-13C6,15N2) | | Isotope-Labeled Compounds |
| HY-163423S | TELAEPTSTR-(Arg-13C6,15N4) | | Isotope-Labeled Compounds |
| HY-163424S | SSVFVADPK-(Lys-13C6,15N2) | | Isotope-Labeled Compounds |
| HY-163425S | AILNYVANK-(Lys-13C6,15N2) | | Isotope-Labeled Compounds |
| HY-163426S | AFFGHYLYEVAR-(Arg-13C6,15N4) | | Isotope-Labeled Compounds |
| HY-163427S | FNLEALVTHTLPFEK-(Lys-13C6,15N2) | | Isotope-Labeled Compounds |
| HY-163428 | Perzebertinib | 2414056-31-6 | Reference compound |
| HY-163429 | J-1149 | 2883580-95-6 | Reference compound |
| HY-16343 | NB-598 | 131060-14-5 | Reference compound |
| HY-163430 | HDAC-IN-71 | 2995354-52-2 | Reference compound |
| HY-163431 | URAT1 inhibitor 10 | 3012586-38-5 | Reference compound |
| HY-163432 | YGL-12 | | Reference compound |
| HY-163433 | α-Glucosidase-IN-57 | | Reference compound |
| HY-163434 | PRMT5/EGFR-IN-1 | | Reference compound |
| HY-163435 | Anticancer agent 201 | | Reference compound |
| HY-163436 | F44-A13 | 1338190-14-9 | Reference compound |
| HY-163437 | Antitubercular agent-45 | | Reference compound |
| HY-163438 | BKIDC-1553 | 1951431-34-7 | Reference compound |
| HY-163439 | α-Amylase/α-Glucosidase-IN-12 | | Reference compound |
| HY-16343A | NB-598 (hydrochloride) | 136719-25-0 | Reference compound |
| HY-16343C | NB-598 (Maleate) | 155294-62-5 | Reference compound |
| HY-16344 | Nedocromil sodium | 69049-74-7 | Reference compound |
| HY-163440 | PROTAC NAMPT Degrader-1 | | Reference compound |
| HY-163441 | BChE-IN-31 | | Reference compound |
| HY-163442A | PIM3-IN-1 (hydrochloride) | | Reference compound |
| HY-163443 | PPAR agonist 4 | | Reference compound |
| HY-163444 | Apoptosis inducer 15 | | Reference compound |
| HY-163445 | NAMPT activator-6 | 2237267-86-4 | Reference compound |
| HY-163448 | NPP1-IN-2 | | Reference compound |
| HY-163449 | NPP3-IN-1 | | Reference compound |
| HY-163450 | Nimbiol | 561-95-5 | Natural Products |
| HY-163451 | Apoptosis inducer 17 | | Reference compound |
| HY-163452 | Squalene synthase-IN-2 | | Reference compound |
| HY-163453 | HER2-IN-19 | | Reference compound |
| HY-163454 | NorA-IN-2 | | Reference compound |
| HY-163455 | pan-HCN-IN-1 | 1334308-63-2 | Reference compound |
| HY-163456 | Chx-HT | | Reference compound |
| HY-163457 | Antileishmanial agent-27 | | Reference compound |
| HY-163458 | Anti-inflammatory agent 77 | | Reference compound |
| HY-163459 | HWY-289 | 908001-51-4 | Reference compound |
| HY-16346 | Netupitant | 290297-26-6 | Reference compound |
| HY-163460 | MS8535 | | Reference compound |
| HY-163461 | 4F-DDC | | Reference compound |
| HY-163462 | Poacic acid | 160097-32-5 | Reference compound |
| HY-163463 | PTP1B-IN-25 | | Reference compound |
| HY-163464 | Plasma kallikrein-IN-5 | | Reference compound |
| HY-163465 | DTNP | 3010266-66-4 | Dye Reagents |
| HY-163466 | FXR agonist 7 | | Reference compound |
| HY-163467 | CHEMBL4224880 | 2095850-54-5 | Reference compound |
| HY-163468 | SRC-3-IN-1 | | Reference compound |
| HY-163469 | SRC-3-IN-2 | 3074959-44-4 | Reference compound |
| HY-16346R | Netupitant (Standard) | 290297-26-6 | Reference Standards |
| HY-16346S | Netupitant-d6 | 2070015-31-3 | Isotope-Labeled Compounds |
| HY-163470 | Luciferase activator-1 | 315703-95-8 | Reference compound |
| HY-163471 | PDGFRα/β/VEGFR-2-IN-1 | | Reference compound |
| HY-163472 | PR280 | | Reference compound |
| HY-163473 | IITR08367 | | Reference compound |
| HY-163474 | MAO-B-IN-32 | | Reference compound |
| HY-163475 | CXCL-CXCR1/2-IN-1 | 2415653-55-1 | Reference compound |
| HY-163476 | PIP5K1C-IN-1 | 3060954-15-3 | Reference compound |
| HY-163477 | PIP5K1C-IN-2 | 3060954-34-6 | Reference compound |
| HY-163478 | TNIK-IN-9 | | Reference compound |
| HY-163479 | MNK1/2-IN-7 | 2548283-27-6 | Reference compound |
| HY-163480 | PF-06835375 | 2796997-12-9 | Inhibitory Antibodies |
| HY-163481 | Antibiofilm agent-6 | | Reference compound |
| HY-163482 | ELQ-596 | 3023709-98-7 | Reference compound |
| HY-163483 | ELQ-598 | 3023709-99-8 | Reference compound |
| HY-163484 | ELQ-650 | 3023710-00-8 | Reference compound |
| HY-163485 | AR antagonist 8 | | Reference compound |
| HY-163486 | Antituberculosis agent-10 | 2095636-19-2 | Reference compound |
| HY-163487 | Puxitatug samrotecan drug-linker | 3025787-81-6 | Reference compound |
| HY-163488 | pan-KRAS-IN-14 | | Reference compound |
| HY-163489 | pan-KRAS-IN-15 | 3034052-52-0 | Reference compound |
| HY-16349 | Nimorazole | 6506-37-2 | Reference compound |
| HY-163490 | PKMYT1-IN-1 | 3033609-83-2 | Reference compound |
| HY-163491 | PKMYT1-IN-2 | 3033609-84-3 | Reference compound |
| HY-163492 | PARP7-IN-19 | | Reference compound |
| HY-163493 | NLRP3-IN-35 | | Reference compound |
| HY-163494 | NLRP3-IN-36 | | Reference compound |
| HY-163495 | HPK1-IN-44 | | Reference compound |
| HY-163496 | HPK1-IN-45 | | Reference compound |
| HY-163497 | NLRP3-IN-38 | 3033054-46-2 | Reference compound |
| HY-163498 | NLRP3-IN-37 | 3033054-51-9 | Reference compound |
| HY-163499 | NAMPT activator-7 | | Reference compound |
| HY-16349R | Nimorazole (Standard) | 6506-37-2 | Reference Standards |
| HY-16350 | BOLD-100 | 197723-00-5 | Reference compound |
| HY-163500 | NAMPT activator-8 | 3034104-30-5 | Reference compound |
| HY-163501 | PI3Kα-IN-23 | | Reference compound |
| HY-163502 | PROTAC STAT3 degrader-3 | | Reference compound |
| HY-163503 | HDAC6-IN-38 | 3030872-95-5 | Reference compound |
| HY-163504 | PAR4 antagonist 5 | 3024653-17-3 | Reference compound |
| HY-163505 | Anti-MRSA agent 11 | 3029704-83-1 | Reference compound |
| HY-163506 | Ebselen derivative 1 | 3030492-59-9 | Reference compound |
| HY-163507 | ALK5-IN-79 | 2725056-38-0 | Reference compound |
| HY-163508 | Antibacterial agent 210 | | Reference compound |
| HY-163509 | COX-2-IN-43 | 1023524-40-4 | Reference compound |
| HY-163510 | AR/AR-V7-IN-1 | 2964558-54-9 | Reference compound |
| HY-163511 | PI3K/Akt/mTOR-IN-4 | | Reference compound |
| HY-163512 | Anti-inflammatory agent 79 | | Reference compound |
| HY-163513 | AACA | 2515609-54-6 | Reference compound |
| HY-163514 | hAChE-IN-8 | | Reference compound |
| HY-163515 | Anticancer agent 207 | | Reference compound |
| HY-163516 | HBV-IN-45 | | Reference compound |
| HY-163517 | Antibacterial agent 211 | | Reference compound |
| HY-163518 | Antitumor agent-153 | | Reference compound |
| HY-163519 | α-Synuclein inhibitor 13 | | Reference compound |
| HY-163520 | IDO1-IN-24 | | Reference compound |
| HY-163521 | Neuraminidase-IN-19 | 3040120-40-6 | Reference compound |
| HY-163522 | Neuraminidase-IN-20 | | Reference compound |
| HY-163523 | PYRIB-SO 2 | | Reference compound |
| HY-163524 | NAE-IN-2 | | Reference compound |
| HY-163526 | STAT3-IN-26 | 3033746-27-6 | Reference compound |
| HY-163527 | FGFR-IN-13 | 2962941-25-7 | Reference compound |
| HY-163528 | Antibacterial agent 213 | | Reference compound |
| HY-163529 | HN0037 | 2233566-79-3 | Reference compound |
| HY-163529A | (S)-HN0037 | 2233566-78-2 | Reference compound |
| HY-163530 | GPR41 modulator 1 | 3050768-93-6 | Reference compound |
| HY-163531 | GPR41 modulator 2 | 3050769-11-1 | Reference compound |
| HY-163532 | FLS-359 | 2309398-79-4 | Reference compound |
| HY-163533 | CPD-002 | 2617376-08-4 | Reference compound |
| HY-163534 | PD-1/PD-L1-IN-43 | | Reference compound |
| HY-163535 | J208 | 2116468-11-0 | Reference compound |
| HY-163536 | TGF-β1/Smad3-IN-1 | | Reference compound |
| HY-163537 | AChE/BuChE-IN-5 | | Reference compound |
| HY-163538 | TYM-3-98 | | Reference compound |
| HY-163540 | NP-BTA | 544420-99-7 | Reference compound |
| HY-163541 | SMS121 | | Reference compound |
| HY-163542 | Pneumolysin-IN-1 | 330842-49-4 | Reference compound |
| HY-163543 | Progranulin modulator-2 | | Reference compound |
| HY-163544 | δ-Tocotrienol prodrug-1 | 128254-90-0 | Reference compound |
| HY-163545 | Tc-Me2P | | Reference compound |
| HY-163546 | HSV-1-IN-1 | | Reference compound |
| HY-163547 | PPAR agonist 5 | | Reference compound |
| HY-163548 | SPP-002 | | Reference compound |
| HY-163549 | APN-PEG5-VC-PAB-MMAE | | Reference compound |
| HY-16355 | NVP-QAV-572 | 957209-68-6 | Reference compound |
| HY-163550 | 5-MethylCytosine/BSA | | Biochemical Assay Reagents |
| HY-163551 | BNP peptide/KLH | | Biochemical Assay Reagents |
| HY-163552 | Prostaglandin F2a/BSA | | Biochemical Assay Reagents |
| HY-163553 | Metronidazole/BSA | | Biochemical Assay Reagents |
| HY-163555 | BZO/BSA | | Biochemical Assay Reagents |
| HY-163556 | COT/BSA | | Biochemical Assay Reagents |
| HY-163558 | Anticancer agent 212 | | Reference compound |
| HY-163559 | HPPD-IN-4 | 3028731-23-6 | Reference compound |
| HY-163560 | Insecticidal agent 10 | 3026314-21-3 | Reference compound |
| HY-163561 | CARM1-IN-6 | 1269199-96-3 | Reference compound |
| HY-163562 | JYQ-164 | | Reference compound |
| HY-163563 | JYQ-173 | | Reference compound |
| HY-163564 | JYQ-194 | | Reference compound |
| HY-163565 | BIIB129 | 2770960-52-4 | Reference compound |
| HY-163566 | Apoptosis inducer 18 | | Reference compound |
| HY-163567 | RSV-IN-10 | | Reference compound |
| HY-163568 | RSV-IN-11 | | Reference compound |
| HY-163569 | FGFR4-IN-20 | | Reference compound |
| HY-16357 | Octimibate | 89838-96-0 | Reference compound |
| HY-163570 | PPO-IN-11 | | Reference compound |
| HY-163571 | CYP51-IN-17 | | Reference compound |
| HY-163572 | PIP5K1α-IN-1 | 3063813-76-0 | Reference compound |
| HY-163573 | FANCM-BTR PPI-IN-1 | 3033990-61-0 | Reference compound |
| HY-163574 | TDP-43-IN-1 | 3033951-71-9 | Reference compound |
| HY-163575 | TDP-43-IN-2 | 3033951-93-5 | Reference compound |
| HY-163576 | GID4-IN-1 | 3034834-45-9 | Reference compound |
| HY-163577 | Akt1-IN-5 | 3034252-53-1 | Reference compound |
| HY-163578 | Akt1-IN-6 | 3034254-12-8 | Reference compound |
| HY-163579 | Akt1-IN-7 | 3034255-09-6 | Reference compound |
| HY-163580 | HBV/HDV-IN-3 | 2883679-03-4 | Reference compound |
| HY-163581A | HBV/HDV-IN-4 (hydrochloride) | 3034059-40-7 | Reference compound |
| HY-163582 | PROTAC SOS1 degrader-7 | 3036155-26-4 | Reference compound |
| HY-163583 | SOS1 Ligand intermediate-6 | 3036156-01-8 | Reference compound |
| HY-163585 | PRMT5-IN-36 | 3034033-75-2 | Reference compound |
| HY-163586 | PRMT5-IN-37 | 3034033-98-9 | Reference compound |
| HY-163587 | PRMT5-IN-39-d3 | 3034033-85-4 | Isotope-Labeled Compounds |
| HY-163588 | PRMT5-IN-39 | 3030464-01-5 | Reference compound |
| HY-163589 | PRMT5-IN-40 | 3034034-95-9 | Reference compound |
| HY-163590 | PRMT5-IN-41 | 3034034-32-4 | Reference compound |
| HY-163591 | PRMT5-IN-36-d3 | 3034034-10-8 | Isotope-Labeled Compounds |
| HY-163592 | PRMT5-IN-43 | 3034746-11-4 | Reference compound |
| HY-163593 | PRMT5-IN-44 | 3034746-35-2 | Reference compound |
| HY-163594 | Pan-RAS-IN-3 | 3034588-80-9 | Reference compound |
| HY-163595 | Pan-RAS-IN-4 | 3024060-23-6 | Reference compound |
| HY-163596 | PTPN2-IN-1 | 3033936-66-9 | Reference compound |
| HY-163597 | HIF-2α-IN-10 | 3034532-74-3 | Reference compound |
| HY-163598 | HIF-2α-IN-11 | 3034589-50-6 | Reference compound |
| HY-163599 | HIF-2α-IN-12 | 3034488-33-7 | Reference compound |
| HY-163600 | HIF-2α-IN-13 | 3034488-42-8 | Reference compound |
| HY-163601 | HIF-2α-IN-14 | 3033981-37-9 | Reference compound |
| HY-163602 | HIF-2α-IN-15 | 3033981-70-0 | Reference compound |
| HY-163603 | HIF-2α-IN-16 | 3033981-97-1 | Reference compound |
| HY-163604 | PDE4B/D-IN-1 | 3034683-55-8 | Reference compound |
| HY-163605 | PDE4B/D-IN-2 | 3034683-66-1 | Reference compound |
| HY-163606 | PDE4B/D-IN-3 | 3034683-69-4 | Reference compound |
| HY-163607 | SpiD3 | 3033533-25-1 | Reference compound |
| HY-163608 | Ac-macropa | | Reference compound |
| HY-163609 | PROTAC AKR1C3 degrader-1 | | Reference compound |
| HY-163610 | AKR1C3-IN-13 | | Reference compound |
| HY-163611 | XY039 | | Reference compound |
| HY-163612 | XY077 | | Reference compound |
| HY-163613 | NS163 | | Reference compound |
| HY-163614 | SARS-CoV-2-IN-87 | | Reference compound |
| HY-163615 | Antimicrobial agent-32 | | Reference compound |
| HY-163616 | Anticancer agent 221 | | Reference compound |
| HY-163617 | c-PB2(OH)2 | | Reference compound |
| HY-163618 | DHMQ | | Dye Reagents |
| HY-163619 | Anticancer agent 227 | | Reference compound |
| HY-16361A | Omigapil (maleate) | 200189-97-5 | Reference compound |
| HY-163620 | LHQ490 | | Reference compound |
| HY-163621 | Cap-dependent endonuclease-IN-28 | | Reference compound |
| HY-163622 | USP10-IN-3 | 3059565-11-3 | Reference compound |
| HY-163623 | Phenolphthalein bisphosphate (sodium) | 68807-90-9 | Biochemical Assay Reagents |
| HY-163624 | Bfl-1-IN-2 | | Reference compound |
| HY-163625 | Mtb-IN-7 | | Reference compound |
| HY-163626 | STK17A/B-IN-1 | 3002038-21-0 | Reference compound |
| HY-163626A | STK17A/B-IN-1 (hydrochloride) | | Reference compound |
| HY-163627 | SARS-CoV-2 Mpro-IN-19 | | Reference compound |
| HY-163628 | SARS-CoV-2 Mpro-IN-20 | | Reference compound |
| HY-163629 | Anticancer agent 224 | | Reference compound |
| HY-16363 | Omtriptolide | 195883-06-8 | Reference compound |
| HY-163630 | Antibacterial agent 217 | | Reference compound |
| HY-163631 | Antibacterial agent 218 | | Reference compound |
| HY-163632 | EGFR-IN-112 | 2758436-98-3 | Reference compound |
| HY-163633 | CYP51-IN-18 | | Reference compound |
| HY-163634 | YZK-C22 | 1111646-44-6 | Reference compound |
| HY-163635 | Antifungal agent 102 | | Reference compound |
| HY-163636 | Deltaflexin3 | | Reference compound |
| HY-163637 | Sodium Channel inhibitor 5 | | Reference compound |
| HY-163638 | BRD4 degrader-1 | | Reference compound |
| HY-163639 | BRD4 degrader-2 | 3036530-43-2 | Reference compound |
| HY-163640 | CDK4 degrader 1 | | Reference compound |
| HY-163641 | AR Degrader-1 | | Reference compound |
| HY-163642 | TNF-α agonistic 1 | 2379727-88-3 | Reference compound |
| HY-163643 | STING modulator-7 | 702662-64-4 | Reference compound |
| HY-163644 | VT-105 | 2417718-38-6 | Reference compound |
| HY-163645 | P2Y12 antagonist 1 | 6222-65-7 | Reference compound |
| HY-163646 | (Rac)-TZ3O | 2218754-19-7 | Reference compound |
| HY-163647 | Lenalidomide-COCH-PEG2-azido | 2380273-88-9 | Reference compound |
| HY-163648 | Suloxifen | 25827-12-7 | Reference compound |
| HY-163649 | A17 | 2568186-47-8 | Reference compound |
| HY-163650 | DTPD-Q | 252950-56-4 | Reference compound |
| HY-163651 | (R)-Vorbipiprant | 2502965-92-4 | Reference compound |
| HY-163652 | Glicetanile | 24455-58-1 | Reference compound |
| HY-163653 | Zemprocitinib | 2417414-44-7 | Reference compound |
| HY-163654 | Ferroptosis-IN-8 | | Reference compound |
| HY-163655 | Glutaminyl Cyclase Inhibitor 6 | | Reference compound |
| HY-163656 | MAT2A inhibitor 5 | 2957874-18-7 | Reference compound |
| HY-163657 | HER2-IN-20 | | Reference compound |
| HY-163658 | PARP-1-IN-23 | 2976497-48-8 | Reference compound |
| HY-163659 | Anti-Influenza agent 6 | 2917502-08-8 | Reference compound |
| HY-16366 | Briciclib | 865783-99-9 | Reference compound |
| HY-163660 | Carbonic anhydrase inhibitor 23 | | Reference compound |
| HY-163661 | p53-MDM2-IN-5 | 2750075-06-8 | Reference compound |
| HY-163662 | AE027 | 1011351-65-7 | Reference compound |
| HY-163663 | AZ14133346 | | Reference compound |
| HY-163664 | Tubulin polymerization-IN-63 | 3040385-73-4 | Reference compound |
| HY-163665 | AHR antagonist 8 | | Reference compound |
| HY-163666 | HIV-1 inhibitor-68 | | Reference compound |
| HY-163667 | Atoxifent | | Reference compound |
| HY-163668 | MK-2118 | 2218504-06-2 | Reference compound |
| HY-163669 | ITI-333 | 2117619-00-6 | Reference compound |
| HY-163670 | TLR7 agonist 21 | | Reference compound |
| HY-163671 | PW0729 | 2767348-36-5 | Reference compound |
| HY-163672 | Glucocorticoid receptor modulator 3 | 2688785-13-7 | Reference compound |
| HY-163673 | Glucocorticoid receptor modulator 4 | 2688785-30-8 | Reference compound |
| HY-163674 | Mincle agonist 1 | | Reference compound |
| HY-163675 | Maleimide-PEG8-Val-Ala-PAB | | Reference compound |
| HY-163676 | MI-217 | | Reference compound |
| HY-163677 | ARM165 | | Reference compound |
| HY-163678 | Pomalidomide-CO-C7-NH-CO-C3-COOH | | Reference compound |
| HY-163679 | PROTAC ERα Degrader-9 | | Reference compound |
| HY-163680 | ERα degrader 9 | | Reference compound |
| HY-163681 | Zamzetoclax | 2388470-64-0 | Reference compound |
| HY-163683 | EB-PSMA-617 | 2375590-67-1 | ADC Related |
| HY-163684 | Zoracopan | 2243483-63-6 | Reference compound |
| HY-163685 | Bisobrin | 22407-74-5 | Reference compound |
| HY-163687 | Tropirine | 19410-02-7 | Reference compound |
| HY-163688 | Quindecamine (acetate) | 19146-62-4 | Reference compound |
| HY-163689 | Vicadrostat | 1868065-21-7 | Reference compound |
| HY-163690 | HTRA1-IN-1 | 3052552-04-9 | Reference compound |
| HY-163691 | Antitumor agent-163 | | Reference compound |
| HY-163692 | Tubulin polymerization-IN-64 | | Reference compound |
| HY-163693 | Antifungal agent 104 | | Reference compound |
| HY-163694 | ADRA2A antagonist 1 | | Reference compound |
| HY-163695 | NLRP3-IN-41 | 1209698-02-1 | Reference compound |
| HY-163696A | HV1-IN-1 (hydrochloride) | 1609461-57-5 | Reference compound |
| HY-163697 | WEE1-IN-7 | 2924006-98-2 | Reference compound |
| HY-163698 | SIRT-IN-4 | | Reference compound |
| HY-163699 | MUS81-IN-1 | | Reference compound |
| HY-163700 | Fabl inhibitor 1 | | Reference compound |
| HY-163701 | hA2AAR antagonist 1 | 2842150-81-4 | Reference compound |
| HY-163702 | CHF-6550 | 3052116-62-5 | Reference compound |
| HY-163703 | D4R antagonist-2 | | Reference compound |
| HY-163704 | KRN7000 analog 1 | | Reference compound |
| HY-163705 | BR-cpd7 | | Reference compound |
| HY-163706 | SARS-CoV-2-IN-88 | | Reference compound |
| HY-163707 | UR778Br | 866127-80-2 | Reference compound |
| HY-163708 | Antibacterial agent | | Reference compound |
| HY-163709 | PROTAC FAK degrader 2 | | Reference compound |
| HY-16371 | Ortataxel | 186348-23-2 | Reference compound |
| HY-163710 | hCA/VEGFR-2-IN-5 | | Reference compound |
| HY-163711 | trans-[Ru(2TU)(PPh3)2(bipy)]PF6 | 2407376-95-6 | Reference compound |
| HY-163712 | 17-Epiestriol | 1228-72-4 | Reference compound |
| HY-163713 | SARS-CoV-2-IN-89 | 1016762-41-6 | Reference compound |
| HY-163714 | IRAP-IN-1 | | Reference compound |
| HY-163715 | Antitumor agent-165 | | Reference compound |
| HY-163716 | Antibacterial agent 222 | | Reference compound |
| HY-163717 | HPK1-IN-48 | | Reference compound |
| HY-163718 | Ferroptosis-IN-9 | | Reference compound |
| HY-163719 | PARP7-IN-22 | 2946705-91-3 | Reference compound |
| HY-16372 | CP 461 | 227619-96-7 | Reference compound |
| HY-163720 | KRAS G12C inhibitor 63 | | Reference compound |
| HY-163721 | CDK7-IN-29 | 3024545-83-0 | Reference compound |
| HY-163722 | EGFR/DHFR-IN-1 | | Reference compound |
| HY-163723 | EGFR-IN-116 | | Reference compound |
| HY-163724 | LW-216 | 2146090-18-6 | Reference compound |
| HY-163725 | DHFR-IN-18 | | Reference compound |
| HY-163726 | GLUT1/EGFR-IN-1 | 2393787-80-7 | Reference compound |
| HY-163727 | MMV1557817 | 2065197-82-0 | Reference compound |
| HY-163728 | DSP-6745 | 2235409-96-6 | Reference compound |
| HY-163729 | I-BET787 | 2201082-98-4 | Reference compound |
| HY-16373 | CP-609754 | 1190094-64-4 | Reference compound |
| HY-163731 | EGR-1-IN-1 | | Reference compound |
| HY-163732 | TEAD-IN-16 | | Reference compound |
| HY-163733 | AKU-005 | 1515855-85-2 | Reference compound |
| HY-163734 | Tyrosinase-IN-30 | | Reference compound |
| HY-163735 | BA6b9 | 609335-29-7 | Reference compound |
| HY-163736 | mPGES-1/5-LOX-IN-1 | | Reference compound |
| HY-163737 | ST-401 | 2419942-78-0 | Reference compound |
| HY-163738 | Furin-IN-2 | | Reference compound |
| HY-163739 | LETC | 951131-13-8 | Reference compound |
| HY-163740 | VEGFR-2-IN-46 | | Reference compound |
| HY-163741 | EZH2-IN-19 | 3026848-13-2 | Reference compound |
| HY-163742 | SARS-CoV-2 Mpro-IN-22 | 1236310-35-2 | Natural Products |
| HY-163743 | SIC-19 | 713112-69-7 | Reference compound |
| HY-163744 | NLRP3-IN-42 | | Reference compound |
| HY-163746 | BuChE-IN-11 | | Reference compound |
| HY-163747 | VEGFR-2-IN-47 | | Reference compound |
| HY-163748 | GSK-3β inhibitor 17 | 2521624-67-7 | Reference compound |
| HY-163749 | STING-IN-8 | | Reference compound |
| HY-16375 | Ozarelix | 295350-45-7 | Peptides |
| HY-163750 | KMU-11342 | | Reference compound |
| HY-163751 | STING-IN-9 | | Reference compound |
| HY-163752 | CS17919 | 2379346-41-3 | Reference compound |
| HY-163753 | Carbonic anhydrase inhibitor 25 | | Reference compound |
| HY-163754 | TMV-IN-9 | 412315-55-0 | Reference compound |
| HY-163755 | GPER activator 1 | 2629960-35-4 | Reference compound |
| HY-163756 | NLRP3-IN-43 | 2769903-01-5 | Reference compound |
| HY-163757 | PROTAC PD-L1 degrader-1 | | Reference compound |
| HY-163758 | COOH-C3-CONH-C7-COOH | | Reference compound |
| HY-163759 | HuR degrader 2 | 3040301-46-7 | Reference compound |
| HY-163760 | ZM-32 | 2667585-44-4 | Reference compound |
| HY-163761 | LT166 | | Reference compound |
| HY-163762 | Antibacterial agent 226 | | Reference compound |
| HY-163763 | T-10418 | 1608784-68-4 | Reference compound |
| HY-163764 | Bfl-1-IN-4 | | Reference compound |
| HY-163765 | Antimalarial agent 41 | | Reference compound |
| HY-163766 | Antiproliferative agent-51 | | Reference compound |
| HY-163767 | Antitumor agent-171 | 3003004-76-7 | Reference compound |
| HY-163768 | Antitumor agent-172 | 3027905-74-1 | Reference compound |
| HY-163769 | DUB-IN-8 | | Reference compound |
| HY-163770 | Anticancer agent 233 | | Reference compound |
| HY-163771 | Pyruvate Carboxylase-IN-5 | | Reference compound |
| HY-163772 | Fraxinellone analog 1 | | Reference compound |
| HY-163773 | RSV-IN-13 | | Reference compound |
| HY-163774 | WDR5-MYC-IN-1 | | Reference compound |
| HY-163775 | Anti-inflammatory agent 88 | | Reference compound |
| HY-163776 | Insecticidal agent 13 | 3007662-84-9 | Reference compound |
| HY-163777 | Talaroterphenyl A | | Natural Products |
| HY-163778 | ZM600 | | Reference compound |
| HY-163779 | β-Glucocerebrosidase modulator 1 | | Reference compound |
| HY-163780 | AChE-IN-66 | | Reference compound |
| HY-163781 | Antifungal agent 105 | 3038220-10-6 | Reference compound |
| HY-163782 | SMIP-031 | | Reference compound |
| HY-163783 | CSNK2-IN-1 | | Reference compound |
| HY-163784 | AKR1C3-IN-14 | 1057882-82-2 | Reference compound |
| HY-163785 | 1"-α-Azido-RDPr | | Reference compound |
| HY-163786 | PROTAC CDK4/6 degrader 1 | 3025082-14-5 | Reference compound |
| HY-163787 | YY173 | 330550-51-1 | Reference compound |
| HY-163788 | C5-CONH-C2-N-CH3 | 1251346-48-1 | Reference compound |
| HY-163789 | Desthiobiotin-PEG3-triazole-DBCO-sulfo-Maleimide | | Biochemical Assay Reagents |
| HY-16379 | Pacritinib | 937272-79-2 | Reference compound |
| HY-163790 | Desthiobiotin-PEG3-sulfo-Maleimide | | Biochemical Assay Reagents |
| HY-163791 | Fluorescein Biotin Azide | | Biochemical Assay Reagents |
| HY-163793 | Biotin-2-sulfopropanoic acid (TEA) | | Biochemical Assay Reagents |
| HY-163794 | DC371739 | 2135765-21-6 | Reference compound |
| HY-163795 | GPR183-IN-1 | 2924063-70-5 | Reference compound |
| HY-163796 | GPR183-IN-2 | 2924064-10-6 | Reference compound |
| HY-163797 | WRN inhibitor 10 | | Reference compound |
| HY-163798 | Menin-MLL inhibitor 33 | | Reference compound |
| HY-163799 | PRMT5-MTA-IN-1 | 3048425-88-0 | Reference compound |
| HY-16379A | Pacritinib (hydrochloride) | 1228923-43-0 | Reference compound |
| HY-16379B | Pacritinib (citrate) | 1228923-42-9 | Reference compound |
| HY-16379R | Pacritinib (Standard) | 937272-79-2 | Reference Standards |
| HY-163801 | Nurr1 agonist 9 | | Reference compound |
| HY-163802 | Nurr1 agonist 10 | | Reference compound |
| HY-163803 | CM-444 | | Reference compound |
| HY-163804 | Cyprocide-B | 49809-25-8 | Reference compound |
| HY-163806 | NT376 | 2820208-97-5 | Reference compound |
| HY-163807 | 22-SLF | | Reference compound |
| HY-163808 | Anticancer agent 237 | 17822-61-6 | Reference compound |
| HY-163809 | BRD9 Degrader-2 | 3033018-68-4 | Reference compound |
| HY-16381 | Pasireotide | 396091-73-9 | Peptides |
| HY-163810 | BRD9 Degrader-3 | 3033018-77-5 | Reference compound |
| HY-163811 | BRD9 Degrader-4 | 3024541-39-4 | Reference compound |
| HY-163812 | ER degrader 9 | 3023359-75-0 | Reference compound |
| HY-163813 | AR Degrader-2 | 3023359-76-1 | Reference compound |
| HY-163814 | CDK2 degrader 1 | 3036604-59-5 | Reference compound |
| HY-163815 | CDK2 degrader 2 | 3030271-16-7 | Reference compound |
| HY-163816 | Antiproliferative agent-53-d3 | 2923508-77-2 | Isotope-Labeled Compounds |
| HY-163817 | PARP1/2-IN-3 | 3032451-58-1 | Reference compound |
| HY-163818 | WIZ degrader 2 | 2839552-69-9 | Reference compound |
| HY-163819 | WIZ degrader 3 | 2839637-72-6 | Reference compound |
| HY-16381A | Pasireotide (acetate) | 396091-76-2 | Peptides |
| HY-16381B | Pasireotide (diaspartate) | 1421446-02-7 | Peptides |
| HY-16381C | (2R)-Pasireotide (diaspartate) | 820232-50-6 | Reference compound |
| HY-16382 | PCI-27483 | 871266-63-6 | Reference compound |
| HY-163820 | WIZ degrader 4 | 2879250-22-1 | Reference compound |
| HY-163821 | HO-CONH-C3-PEG3-NH2 | 2136574-39-3 | Reference compound |
| HY-163822 | WIZ degrader 5 | 2879250-73-2 | Reference compound |
| HY-163823 | WIZ degrader 6 | 3036553-87-1 | Reference compound |
| HY-163824 | WIZ degrader 7 | 3036553-83-7 | Reference compound |
| HY-163825 | RNB-61 | | Reference compound |
| HY-163826 | Benzothiazole-CH2(NH-CO-CH2Cl)-CONH-CH2-Ph | | Reference compound |
| HY-163827 | ABBV-992 | 2792171-84-5 | Reference compound |
| HY-163828 | PPA24 | 3035032-77-7 | Reference compound |
| HY-163829 | TLR2 agonist 1 | | Reference compound |
| HY-163830 | Pegasus | | Reference compound |
| HY-163831 | AZ12559322 | 947184-66-9 | Reference compound |
| HY-163832 | FPPS-IN-2 | | Reference compound |
| HY-163833 | MMV1634566 | | Reference compound |
| HY-163834 | HDAC6-IN-47 | | Reference compound |
| HY-163835 | UniPR1454 | | Reference compound |
| HY-163836 | HMBPP analog 1 | | Reference compound |
| HY-163837 | PD-1/PD-L1-IN-48 | | Reference compound |
| HY-163838 | Quorum sensing-IN-6 | | Reference compound |
| HY-163839 | DS-1093a | | Reference compound |
| HY-16384 | L-156602 | 125228-51-5 | Reference compound |
| HY-163840 | GFRα2/3-IN-1 | | Reference compound |
| HY-163841 | Antitumor agent-181 | | Reference compound |
| HY-163842 | Cathepsin K inhibitor 7 | | Reference compound |
| HY-163843 | Antibacterial agent 234 | | Reference compound |
| HY-163844 | PD-1/PD-L1-IN-49 | | Reference compound |
| HY-163845 | YX862 | | Reference compound |
| HY-163846 | HDAC8-IN-10 | | Reference compound |
| HY-163847 | Anti-osteoporosis agent-9 | | Reference compound |
| HY-163848 | Anti-inflammatory agent 90 | | Reference compound |
| HY-163849 | Mizoribine prodrug-1 | 2237237-22-6 | Reference compound |
| HY-163850 | Mizoribine prodrug-2 (trifluoroacetate) | 2237237-32-8 | Reference compound |
| HY-163851 | PROTAC Vif degrader-1 | | Reference compound |
| HY-163852 | HIV-1 inhibitor-72 | 2801703-79-5 | Reference compound |
| HY-163853 | Antidiabetic agent 6 | | Reference compound |
| HY-163854 | HSP70-IN-6 | 3048341-44-9 | Reference compound |
| HY-163855 | KGP-25 | | Reference compound |
| HY-163856 | CDK7-IN-30 | 3040999-70-7 | Reference compound |
| HY-163857 | SARS-CoV-2-IN-91 | | Reference compound |
| HY-163858 | Haspin-IN-4 | | Reference compound |
| HY-163859 | LSD1-IN-33 | | Reference compound |
| HY-163860 | EGFR-TK-IN-3 | | Reference compound |
| HY-163861 | Tl45b | | Reference compound |
| HY-163862 | PPARα agonist 3 | | Reference compound |
| HY-163863 | Fast Red RC salt, 97% | 85252-22-8 | Biochemical Assay Reagents |
| HY-163864 | PROTAC SMARCA2/4-degrader-11 | 2568276-71-9 | Reference compound |
| HY-163865 | PROTAC SMARCA2 degrader-13 | 2568276-72-0 | Reference compound |
| HY-163866 | PROTAC SMARCA2 degrader-14 | 2568276-73-1 | Reference compound |
| HY-163867 | PROTAC SMARCA2 degrader-15 | 2568276-78-6 | Reference compound |
| HY-163868 | PROTAC SMARCA2/4-degrader-15 | 2568276-81-1 | Reference compound |
| HY-163869 | PROTAC SMARCA2/4-degrader-16 | 2568273-64-1 | Reference compound |
| HY-16387 | PF 00337210 | 854514-88-8 | Reference compound |
| HY-163870 | PROTAC SMARCA2/4-degrader-17 | 2568276-88-8 | Reference compound |
| HY-163871 | PROTAC SMARCA2/4-degrader-18 | 2568276-91-3 | Reference compound |
| HY-163872 | PROTAC SMARCA2/4-degrader-10 | 2568277-33-6 | Reference compound |
| HY-163873 | PROTAC SMARCA2/4-degrader-20 | 2568277-38-1 | Reference compound |
| HY-163874 | PROTAC SMARCA2 degrader-12 | 2568277-42-7 | Reference compound |
| HY-163875 | PROTAC SMARCA2/4-degrader-22 | 2568277-48-3 | Reference compound |
| HY-163876 | PROTAC SMARCA2/4-degrader-23 | 2568277-50-7 | Reference compound |
| HY-163877 | PROTAC SMARCA2/4-degrader-19 | 2568277-57-4 | Reference compound |
| HY-163879 | hMAO-B-IN-9 | | Reference compound |
| HY-163880 | EGFR-IN-119 | | Reference compound |
| HY-163881 | VEGFR-IN-5 | | Reference compound |
| HY-163882 | CUHK242 | 2408055-05-8 | Reference compound |
| HY-163883 | BChE-IN-34 | 2215768-12-8 | Reference compound |
| HY-163884 | BDE33872639 | | Reference compound |
| HY-163885 | SSZ | 1262287-23-9 | Reference compound |
| HY-163886 | KHK-IN-5 | 3043939-40-5 | Reference compound |
| HY-163887 | PBZ1038 | 2043687-46-1 | Reference compound |
| HY-163888 | NO-IN-1 | | Reference compound |
| HY-163889 | Ferroptosis/apoptosis inducer-1 | | Reference compound |
| HY-163890 | Succinate dehydrogenase-IN-2 | 3023681-83-3 | Reference compound |
| HY-163891 | Antifungal agent 107 | 2684411-12-7 | Reference compound |
| HY-163892 | POLRMT-IN-1 | | Reference compound |
| HY-163893 | Apoptosis inducer 23 | | Reference compound |
| HY-163894 | HDAC6-IN-48 | | Reference compound |
| HY-163895 | δ opioid receptor antagonist 1 | | Dye Reagents |
| HY-163896 | β-Catenin modulator-7 | 2892294-93-6 | Reference compound |
| HY-163897 | PROTAC NCOA4 degrader-1 | | Reference compound |
| HY-163899 | (+)-Crinatusin A1 | | Reference compound |
| HY-163900 | Galectin-8N-IN-2 | 3055149-84-0 | Reference compound |
| HY-163901 | E6-272 | 945142-65-4 | Reference compound |
| HY-163902 | SP100030 analogue 1 | 154934-68-6 | Reference compound |
| HY-163903 | OH-C2-PEG3-NHCO-C3-COOH | | Reference compound |
| HY-163904 | (S,R,R)-VH032-CO-C3-CONH-C2-PEG3-OH | | Reference compound |
| HY-163905 | EG-2184 | 2770297-66-8 | Reference compound |
| HY-163906 | Anti-MRSA agent 16 | | Reference compound |
| HY-163907 | α-Glucosidase-IN-71 | | Reference compound |
| HY-163908 | SARS-CoV-2-IN-94 | | Reference compound |
| HY-163909 | AChE-IN-72 | | Reference compound |
| HY-16391 | Glasdegib | 1095173-27-5 | Reference compound |
| HY-163910 | Herbicidal agent 5 | | Reference compound |
| HY-163911 | SDH-IN-19 | | Reference compound |
| HY-163912 | JZD-07 | 2917528-98-2 | Reference compound |
| HY-163913 | SARS-CoV-IN-5 | | Reference compound |
| HY-163914 | Telomerase-IN-7 | 444320-44-9 | Reference compound |
| HY-163915 | 8-(4-(Trifluoromethyl)anilino)quercetin | | Reference compound |
| HY-163916 | SalA-VS-07 | 2445895-33-8 | Reference compound |
| HY-163917 | SalA-VS-08 | 2439152-14-2 | Reference compound |
| HY-163918 | N,N-Dimethyl-idarubicin | 3033865-16-3 | Reference compound |
| HY-163919 | N,N-Dimethyl-idarubicin-trisaccharide | 3033865-28-7 | Reference compound |
| HY-16391A | Glasdegib (maleate) | 2030410-25-2 | Reference compound |
| HY-16391B | Glasdegib (hydrochloride) | 1095173-64-0 | Reference compound |
| HY-16391S1 | Glasdegib-d4 | | Isotope-Labeled Compounds |
| HY-163920 | PROTAC HDAC8 Degrader-1 | | Reference compound |
| HY-163921 | HDAC8-IN-11 | 3035977-24-0 | Reference compound |
| HY-163922 | CRBN ligand-1-piperidine-Me | | Reference compound |
| HY-163923 | Apoptosis inducer 24 | 2763063-09-6 | Reference compound |
| HY-163924 | Apoptosis inducer 25 | 2763063-15-4 | Reference compound |
| HY-163925 | Lu-AAZTA-NI-PSMA-093 | | Reference compound |
| HY-163926 | SMARCA2/4-IN-2 | 1339378-93-6 | Reference compound |
| HY-163927 | E3 ligase Ligand 29 | 2154341-52-1 | Reference compound |
| HY-163928 | Pomalidomide-cyclohexane | 2924858-40-0 | Reference compound |
| HY-163929 | 5-Aminothalidomide-cyclohexane | 2924858-26-2 | Reference compound |
| HY-163930 | (S,R,S)-AHPC-CO-cyclohexane-C2 | | Reference compound |
| HY-163931 | E3 Ligase Ligand-linker Conjugate 111 | | Reference compound |
| HY-163932 | (S,R,S)-AHPC-O-CF3 | 2641373-92-2 | Reference compound |
| HY-163933 | (S,R,S)-AHPC-CO-C-cyclohexane | 2010985-17-6 | Reference compound |
| HY-163934 | (S,R,S)-AHPC-phenylacetic acid | 2010985-19-8 | Reference compound |
| HY-163935 | (S,R,S)-AHPC-m-Tolylacetic acid | | Reference compound |
| HY-163936 | (S,R,S)-AHPC-p-toluic acid | | Reference compound |
| HY-163937 | "(S,R,S)-AHPC-O-CF3
-CO-cyclohexane" | | Reference compound |
| HY-163938 | PROTAC erf3a Degrader-1 | 3033871-19-8 | Reference compound |
| HY-163938A | PROTAC erf3a Degrader-2 | 3033871-15-4 | Reference compound |
| HY-163939 | RGT-018 | 2794934-49-7 | Reference compound |
| HY-16394 | PG-11047 (tetrahydrochloride) | 206991-64-2 | Reference compound |
| HY-163940 | LX1 | 2647877-84-5 | Reference compound |
| HY-163941 | GSK_WRN2 | | Reference compound |
| HY-163942 | GSK_WRN4 | 2923008-66-4 | Reference compound |
| HY-163943 | UNI418 | 1802068-51-4 | Reference compound |
| HY-163944 | LL-K12-18 | | Reference compound |
| HY-163945 | ZTA-261 | 3049368-51-3 | Reference compound |
| HY-163947 | UG-480 | | Reference compound |
| HY-163949 | SMARCA2/4-IN-3 | | Reference compound |
| HY-16395 | PG-11047 | 308145-19-9 | Reference compound |
| HY-163950 | (S,R,S)-AHPC-O-CF3-CO-cyclohexene-Bpin | | Reference compound |
| HY-163951 | (S,R,S)-AHPC-Ac | 2361116-63-2 | Reference compound |
| HY-163952 | (S,R,S)-AHPC-Ac-CO-cyclohexene-Bpin | | Reference compound |
| HY-163953 | (S,R,S)-AHPC-Ala | 2641319-58-4 | Reference compound |
| HY-163954 | (S,R,S)-AHPC-Ala-CO-cyclohexene-Bpin | | Reference compound |
| HY-163957 | Tambjamine LY2 | | Reference compound |
| HY-163958 | PD-L1-IN-7 | 3024733-03-4 | Reference compound |
| HY-163959 | PF-07853578 | 3036158-98-9 | Reference compound |
| HY-163960 | NH2-Ph-NH-cyclohexane-NH-Boc | 3033871-69-8 | Reference compound |
| HY-163961 | (S)-Thalidomide-NH-cyclohexane-NH-Ph-NH2 | | Reference compound |
| HY-163961A | Thalidomide-NH-cyclohexane-NH-Ph-NH2 | | Reference compound |
| HY-163962 | L18I | 2451070-32-7 | Reference compound |
| HY-163963 | IBT6A-CO-ethyne | 1970122-88-3 | Reference compound |
| HY-163964 | Lenalidomide-C3-PEG3-N3 | | Reference compound |
| HY-163965 | Antitumor agent-185 | | Reference compound |
| HY-163966 | Decarboxyl ofloxacin | 123155-82-8 | Biochemical Assay Reagents |
| HY-163966R | Decarboxyl ofloxacin (Standard) | 123155-82-8 | Reference Standards |
| HY-163967 | Clindamycin 2,4-diphosphate | 1309048-48-3 | Biochemical Assay Reagents |
| HY-163968 | Elmycin B | 128233-09-0 | Biochemical Assay Reagents |
| HY-163969 | (±)-myo-Inositol-1-phosphate | 573-35-3 | Biochemical Assay Reagents |
| HY-16397 | Phenformin | 114-86-3 | Reference compound |
| HY-163970 | Heparin disaccharide I-A (sodium) | 136098-00-5 | Biochemical Assay Reagents |
| HY-163971 | Granulocyte-macrophage colony-stimulating factor | 83869-56-1 | Biochemical Assay Reagents |
| HY-163972 | Cocamidopropyl betaine | 86438-79-1 | Biochemical Assay Reagents |
| HY-163973 | α-D-Glucopyranosyl β-D-arabino-2-hexulofuranosidonic acid | 150787-99-8 | Biochemical Assay Reagents |
| HY-163974 | MRS7292 | 2092913-97-6 | Reference compound |
| HY-163975 | α-Glucosidase-IN-72 | | Reference compound |
| HY-163976 | 3-Indoxyl phosphate (bis(2-amino-2-methyl-1,3-propanediol)) | 107475-12-7 | Biochemical Assay Reagents |
| HY-163977 | Silyl-ether based ROMP Monomer | 1621108-00-6 | Biochemical Assay Reagents |
| HY-163978 | YGZ-331 | 1350113-04-0 | Reference compound |
| HY-163979 | Antifungal agent 109 | | Reference compound |
| HY-16397A | Phenformin (hydrochloride) | 834-28-6 | Reference compound |
| HY-16397AR | Phenformin (hydrochloride) (Standard) | 834-28-6 | Reference Standards |
| HY-16397AS | Phenformin-d5 (hydrochloride) | | Isotope-Labeled Compounds |
| HY-16398 | Pipobroman | 54-91-1 | Reference compound |
| HY-163980 | AChE-IN-73 | | Reference compound |
| HY-163981 | ABCB1-IN-2 | | Reference compound |
| HY-163982 | FOXJ1 agonist 1 | | Reference compound |
| HY-163983 | Tubulin polymerization-IN-68 | 2924156-96-5 | Reference compound |
| HY-163984 | Antibacterial agent 240 | 2899202-97-0 | Reference compound |
| HY-163985 | PROTAC FGFR2 degrader 1 | | Reference compound |
| HY-163986 | Pomalidomide-C2-NHCO-C6 | | Reference compound |
| HY-163987 | SIRT3 activator 2 | 3061491-60-6 | Reference compound |
| HY-163988 | Amylose azure | 71501-06-9 | Biochemical Assay Reagents |
| HY-163989 | N-Ethylheptanamide | 54007-34-0 | Reference compound |
| HY-16399 | Pladienolide B | 445493-23-2 | Reference compound |
| HY-163990 | Poly(ethylene glycol) diacrylamide (MW 2000) | 160556-48-9 | Biochemical Assay Reagents |
| HY-163990A | Poly(ethylene glycol) diacrylamide (MW 3400) | 160556-48-9 | Biochemical Assay Reagents |
| HY-163990B | Poly(ethylene glycol) diacrylamide (MW 3700) | 160556-48-9 | Biochemical Assay Reagents |
| HY-163990C | Poly(ethylene glycol) diacrylamide (MW 4000) | 160556-48-9 | Biochemical Assay Reagents |
| HY-163990D | Poly(ethylene glycol) diacrylamide (MW 6000) | 160556-48-9 | Biochemical Assay Reagents |
| HY-163990E | Poly(ethylene glycol) diacrylamide (MW 10000) | 160556-48-9 | Biochemical Assay Reagents |
| HY-163991 | (Z-Asp-Glu-Val-Asp)2-Rh110 | 220846-75-3 | Biochemical Assay Reagents |
| HY-163992S | VTMTRDTSISTAYMELSR-(Ile-13C6,15N) | | Isotope-Labeled Compounds |
| HY-163993S | GMDRWGQGTLVTVSS-(Leu-13C6,15N) | | Isotope-Labeled Compounds |
| HY-163994 | Ibuterol (hydrochloride) | 57576-17-7 | Reference compound |
| HY-163995 | GPX4-IN-13 | 2644044-43-7 | Oligonucleotides |
| HY-163996 | DD202-114 | 2886728-09-0 | Reference compound |
| HY-163997 | Antimalarial agent 42 | | Reference compound |
| HY-163998 | TLR4-IN-1 | 2617578-93-3 | Reference compound |
| HY-163999 | TMV-IN-12 | 2861919-00-6 | Reference compound |
| HY-164000 | CFTR corrector 15 | 1170387-92-4 | Reference compound |
| HY-164002 | PF-303 | 1609465-78-2 | Reference compound |
| HY-164003 | Dapabutan | 6582-31-6 | Reference compound |
| HY-164004 | Stevaladil | 6535-03-1 | Reference compound |
| HY-164005 | CBP/EP300 bromodomain receptor-IN-1 | 1190262-14-6 | Reference compound |
| HY-164009 | Teniloxazine | 62473-79-4 | Reference compound |
| HY-16401 | Zalypsis | 308359-57-1 | Reference compound |
| HY-164010 | SUN-1334H (free base) | 607737-00-8 | Reference compound |
| HY-164011 | Alaproclate | 60719-82-6 | Reference compound |
| HY-164012 | Proxicromil | 60400-92-2 | Reference compound |
| HY-164013 | Brazergoline | 60019-20-7 | Reference compound |
| HY-164014 | 9-CCN | 596592-83-5 | Reference compound |
| HY-164018A | PMEG-DP (disodium) | | Reference compound |
| HY-164021 | Brovanexine (hydrochloride) | 54340-60-2 | Reference compound |
| HY-164022 | Acridorex | 47487-22-9 | Reference compound |
| HY-164025 | DB775 | 475976-08-0 | Reference compound |
| HY-164026 | ISR modulator-1 | 2842928-87-2 | Reference compound |
| HY-164027 | MyoMed 205 | 2614161-13-4 | Reference compound |
| HY-16403 | Polythiazide | 346-18-9 | Reference compound |
| HY-164031 | Cloperidone | 4052-13-5 | Oligonucleotides |
| HY-164032 | Dimethandrolone undecanoate | 366472-45-9 | Reference compound |
| HY-164033 | HOE 689 | 33156-28-4 | Reference compound |
| HY-164034 | Ganglefene | 299-61-6 | Reference compound |
| HY-164035 | DOPE-PEG-DBCO (MW 2000) | | Biochemical Assay Reagents |
| HY-164036 | Lolamicin | 2930690-12-1 | Reference compound |
| HY-164036R | Lolamicin (Standard) | 2930690-12-1 | Reference Standards |
| HY-164037 | Riselcaftor | 2799652-36-9 | Reference compound |
| HY-164039 | Talorasib | 2648584-48-7 | Reference compound |
| HY-164040 | Zavolosotine | 2604416-66-0 | Reference compound |
| HY-164041 | Staurosporine-Boc | 120685-17-8 | Reference compound |
| HY-164043 | (S,R,S)-AHPC(Me)-amido-C2-acid | 2365173-01-7 | Reference compound |
| HY-164049 | TG8-260 | 2490544-50-6 | Reference compound |
| HY-16405 | PR-104 | 851627-62-8 | Reference compound |
| HY-164050 | HDAC2-IN-2 | 332169-78-5 | Reference compound |
| HY-164051 | 1650-M15 | 850935-88-5 | Reference compound |
| HY-164052 | Antiparasitic agent-23 | 556055-08-4 | Reference compound |
| HY-164053 | MicroRNA modulator-1 | 756865-61-9 | Reference compound |
| HY-164054 | MicroRNA modulator-2 | 438599-31-6 | Reference compound |
| HY-164055 | HL1 | 202828-10-2 | Reference compound |
| HY-164056 | EGFR T790M/L858R-IN-8 | 333419-97-9 | Reference compound |
| HY-164058 | LZCap AG(3'Acm) RFP mRNA | | Oligonucleotides |
| HY-164059 | LZCap AG(3'Acm) mCherry mRNA | | Oligonucleotides |
| HY-16406 | PR-104 (sodium) | 851627-80-0 | Reference compound |
| HY-164060 | LZCap AG(3'Acm) RLuc mRNA | | Oligonucleotides |
| HY-164061 | LZCap AG(3'Acm) GLuc mRNA | | Oligonucleotides |
| HY-164062 | LZCap AG(3'Acm) Cas9 mRNA | | Oligonucleotides |
| HY-164064 | Anticancer agent 230 | 2485052-87-5 | Reference compound |
| HY-164065 | Sodium Hyaluronate Hydroxypropyltrimonium Chloride | 1714127-68-0 | Natural Products |
| HY-164066 | Sodium Acetylated Hyaluronate | 287390-12-9 | Natural Products |
| HY-164067 | Silylanization hyaluronate ester | 135507-00-5 | Natural Products |
| HY-164068 | Cross-linked sodium hyaluronate gel | | Natural Products |
| HY-164069 | Aldehyde Sodium Hyaluronate | | Natural Products |
| HY-164070 | Dextran Hydroxypropyltrimonium Chloride | 83855-79-2 | Reference compound |
| HY-164071 | Carboxymethyl Dextran (CM-Dextran) | 9044-05-7 | Natural Products |
| HY-164072 | DBCO-Dextran | | Reference compound |
| HY-164073 | Allylate Dextran | | Reference compound |
| HY-164076 | mPEG-Epoxide | | Reference compound |
| HY-164077 | mPEG-PLGA | 743423-15-6 | Natural Products |
| HY-164082 | Methyl clofenapate | 21340-68-1 | Reference compound |
| HY-164083 | GR65630 | 113140-33-3 | Reference compound |
| HY-164084 | DBCO-NHCO-C5-O-phenylethenesulfonyl fluoride | 2849417-34-9 | Reference compound |
| HY-164085 | Azide-C3-NHCO-C3-NHS ester | 920748-93-2 | Reference compound |
| HY-164088 | DBM-C5-VC-PAB-MMAE | 1644228-55-6 | ADC Related |
| HY-164090 | Adenosine 3'-phosphate 5'-phosphosulfate | 482-67-7 | Reference compound |
| HY-164091 | Mevalonate 5-phosphate | 73566-35-5 | Reference compound |
| HY-164092 | Eicosanoyl-CoA | 15895-27-9 | Reference compound |
| HY-164093 | Isovaleryl-CoA | 6244-91-3 | Reference compound |
| HY-164094 | Isobutyryl-CoA | 15621-60-0 | Natural Products |
| HY-164094A | Isobutyryl-CoA (trisodium) | | Enzyme |
| HY-164098 | JWZ-7-7-Neg1 | 3008612-30-1 | Reference compound |
| HY-164099 | LSD1/HDAC6-IN-2 | 2982787-50-6 | Reference compound |
| HY-164102 | TNF-α-IN-18 | 1272322-42-5 | Reference compound |
| HY-164105 | S-Lactylglutathione | 25138-66-3 | Reference compound |
| HY-164112 | 1,2-Dioleoyl-sn-glycero-3-(cytidine diphosphate) (ammonium) | 799812-77-4 | Biochemical Assay Reagents |
| HY-164117 | BNN6 | 106476-75-9 | Reference compound |
| HY-164122 | Antiviral agent 56 | 524055-95-6 | Reference compound |
| HY-164123 | Antibiofilm agent-9 | 2001602-07-7 | Reference compound |
| HY-164125 | 6-O-Bis[1-(2-nitrophenyl)-ethoxyphosphoryl]-D-trehalose | 1404341-61-2 | Reference compound |
| HY-164126 | 6-O-Bis-(4,5-dimethoxy-2-nitrobenzyloxyphosphoryl)-D-trehalose | 1404341-58-7 | Reference compound |
| HY-164128 | AHL modulator-1 | 942296-18-6 | Reference compound |
| HY-16413 | Protokylol (hydrochloride) | 136-69-6 | Reference compound |
| HY-164130 | AChE-IN-65 | 98704-22-4 | Reference compound |
| HY-164136 | 17β-HSD5 inhibitor 1 | 243638-37-1 | Reference compound |
| HY-164137 | 17β-HSD5 inhibitor 2 | 1106941-19-8 | Reference compound |
| HY-164138 | 17β-HSD5 inhibitor 3 | 948581-46-2 | Reference compound |
| HY-164139 | Antiviral agent 57 | 3027227-86-4 | Reference compound |
| HY-164140 | EM 1404 | 243836-37-5 | Reference compound |
| HY-164142 | ETB | 634589-47-2 | Reference compound |
| HY-164143 | T638 | 2770585-67-4 | Reference compound |
| HY-164144 | EPZ033294 | 1887195-17-6 | Reference compound |
| HY-164145 | CDD-1653 | 3034216-44-6 | Reference compound |
| HY-164146 | BCN-HS-PEG2(vcPABC-MMAE)2 | 2126083-82-5 | ADC Related |
| HY-164151 | ERK-IN-8 | 2226293-75-8 | Reference compound |
| HY-164152 | ADC Control Human IgG1-Deruxtecan (DAR 4) | | ADC Related |
| HY-164152A | ADC Control Human IgG1-Deruxtecan (DAR 8) | | ADC Related |
| HY-164153 | ADC Control Human IgG1-vcMMAE | | ADC Related |
| HY-164154 | ADC Control Human IgG1-vcMMAF | | ADC Related |
| HY-164159 | α-Glucosylrutin | 130603-71-3 | Reference compound |
| HY-164160 | 1,2-Dipalmitoyl-rac-glycero-3-phospho-L-serine | 3036-82-6 | Biochemical Assay Reagents |
| HY-164165 | Paclitaxel-2′-succinate NHS ester | 245110-80-9 | Reference compound |
| HY-164166 | Fmoc-Sar-Sar-Sar-OH | 2749824-37-9 | Peptides |
| HY-164170 | Photocaged DAP | 2321346-88-5 | Reference compound |
| HY-164179 | dGpdG | 15180-30-0 | Reference compound |
| HY-164181 | Fmoc-protected DMT-Dt PEG2 NH2 amidite | 2416858-32-5 | Reference compound |
| HY-164182S | Myristoleyl carnitine-d3 | 1803252-79-0 | Isotope-Labeled Compounds |
| HY-164183 | Trimethaphan (bromide) | 21035-85-8 | Reference compound |
| HY-164185 | P12FR2 sodium | | Oligonucleotides |
| HY-164186 | M9-5 sodium | | Oligonucleotides |
| HY-164187 | "m7(3'Ma-Cy7)Gppp(2'OMe)ApG ammonium
" | | Oligonucleotides |
| HY-164188 | m7(3'Ma-Cy5)Gppp(2'OMe)ApG (triammonium) | | Oligonucleotides |
| HY-164189 | m7(3'Ma-Cy3)Gppp(2'OMe)ApG ammonium | | Oligonucleotides |
| HY-164190 | "m7(3'Ma-Biotin)Gppp(2'OMe)ApG ammonium
" | | Oligonucleotides |
| HY-164191 | "m7(3'Ma-Peg5-FAM)Gppp(2'OMe)ApG ammonium
" | | Oligonucleotides |
| HY-164192 | m7(3'AcmG)(5')ppp(5')(2'OMeA)pG ammonium | | Oligonucleotides |
| HY-164193 | m7(3'AcmG)(5')ppp(5')(2'OMeA)pU (ammonium) | | Oligonucleotides |
| HY-16420 | R112 | 575474-82-7 | Reference compound |
| HY-164201 | HIV-1 inhibitor-69 | 257891-65-9 | Reference compound |
| HY-164202 | ORM-5029 | | Reference compound |
| HY-164207 | VLPA-GlcNAc | 474644-34-3 | Reference compound |
| HY-164209 | DBCO-PEG3-C1-acid | 2249926-65-4 | Reference compound |
| HY-16421 | Ragaglitazar | 222834-30-2 | Reference compound |
| HY-164210 | DBCO-PEG2-C2-acid | 2305845-07-0 | Reference compound |
| HY-164211 | DBCO-PEG2-OH | 2181837-96-5 | Reference compound |
| HY-164212 | DBCO-PEG1-OH | 2754384-62-6 | Reference compound |
| HY-164220 | PPM1A-IN-1 | 2919466-30-9 | Reference compound |
| HY-164226 | Rosuvastatin impurity-1 | | Reference compound |
| HY-164227 | Vericiguat impurity-2 | | Reference compound |
| HY-164228 | Vericiguat impurity-3 | | Reference compound |
| HY-164229 | Mianserin impurity-1 | 73771-03-6 | Reference compound |
| HY-16423 | Rapacuronium bromide | 156137-99-4 | Reference compound |
| HY-164233 | YX968 | 2742732-92-7 | Reference compound |
| HY-164236 | C22 Glucosylceramide (d18:1/22:0) | 119242-44-3 | Natural Products |
| HY-164236S | C22 Glucosylceramide (d18:1/22:0)-d4 | 2738376-81-1 | Isotope-Labeled Compounds |
| HY-164238 | LysoPC(18:3) | 62512-91-8 | Natural Products |
| HY-164239 | NH2-PEG3-VC-PAB-MMAE | 2641442-97-7 | ADC Related |
| HY-164247 | UnyLinker 12 | 852684-08-3 | Oligonucleotides |
| HY-164248 | Ac-rG | 21967-06-6 | Oligonucleotides |
| HY-164249 | DMT-rG(Ac) | 231957-27-0 | Oligonucleotides |
| HY-16425 | RG2833 | 1215493-56-3 | Reference compound |
| HY-164252 | DMT-2'-F-U | 2923-90-2 | Oligonucleotides |
| HY-164253 | TBS-rG(Ac) | 1256468-15-1 | Oligonucleotides |
| HY-164259 | AJM 290 | 840474-95-5 | Reference compound |
| HY-164263 | N-Acetylphytosphingosine | 21830-28-4 | Reference compound |
| HY-164264 | Caged MK801 | 217176-91-5 | Reference compound |
| HY-164267 | Sphingomyelin (d18:1,C14:0) | 121999-55-1 | Reference compound |
| HY-164271 | 10-Boc-SN-38 | 362497-15-2 | ADC Related |
| HY-164272 | 2'-O-TBDMS-Paclitaxel | 114655-02-6 | ADC Related |
| HY-164273 | Azidoacetyl-Val-Cit-PAB-OH | 2285375-34-8 | ADC Related |
| HY-164275 | Alkyne-Val-Cit-PAB-OH | 2748039-76-9 | ADC Related |
| HY-164278 | diABZI-V/C-Mal | 3035557-55-9 | Reference compound |
| HY-164279 | YTR107 | 1207615-74-4 | Reference compound |
| HY-164283 | DOCP | 1360461-57-9 | Oligonucleotides |
| HY-164284 | LK-2 | 2649762-09-2 | Reference compound |
| HY-164285 | MYX1715 | 2445448-66-6 | Reference compound |
| HY-164288 | TDI-6570 | 2287331-29-5 | Reference compound |
| HY-164290 | Rhodady C10 | 1367579-04-1 | Reference compound |
| HY-164293 | Methyl (5α,7α)-7-hydroxy-3-oxocholan-24-oate | 14772-96-4 | Reference compound |
| HY-164294 | Aluminum phthalocyanine disulfonate | 68637-19-4 | Reference compound |
| HY-164295 | U-78517 | 122003-11-6 | Reference compound |
| HY-164296 | SMP-96745 | 2760408-63-5 | ADC Related |
| HY-164303 | Val-Cit-PAB-DEA-Duo-DM | 1698870-53-9 | ADC Related |
| HY-164304 | INF 195 | 1211379-56-4 | Reference compound |
| HY-164306 | PROTAC PARP1 degrader-2 | 2923686-62-6 | Reference compound |
| HY-164307 | Pebezertinib | 2769954-39-2 | Reference compound |
| HY-164308 | SA-15-P | 852846-00-5 | Reference compound |
| HY-164309 | DBCO-PEG3-Glu-Val-Cit-PABC-MMAE | 2861998-23-2 | ADC Related |
| HY-164310 | TCO-PEG3-Glu-Val-Cit-PABC-MMAF | 2862795-63-7 | ADC Related |
| HY-164311 | GPR17 modulator-1 | 3039853-91-0 | Reference compound |
| HY-164315 | KRAS G12C inhibitor 67 | 2649788-46-3 | Re |